<SEC-DOCUMENT>0001104659-24-124782.txt : 20241203
<SEC-HEADER>0001104659-24-124782.hdr.sgml : 20241203
<ACCEPTANCE-DATETIME>20241203062758
ACCESSION NUMBER:		0001104659-24-124782
CONFORMED SUBMISSION TYPE:	S-4
PUBLIC DOCUMENT COUNT:		148
FILED AS OF DATE:		20241203
DATE AS OF CHANGE:		20241203

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aerovate Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001798749
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				831377888
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-283562
		FILM NUMBER:		241521004

	BUSINESS ADDRESS:	
		STREET 1:		930 WINTER STREET
		STREET 2:		SUITE M-500
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		617-443-2400

	MAIL ADDRESS:	
		STREET 1:		930 WINTER STREET
		STREET 2:		SUITE M-500
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4
<SEQUENCE>1
<FILENAME>avte-20240930xs4.htm
<DESCRIPTION>FORM S-4
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.8.0.95 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 12/3/2024 12:41:38 AM -->
<!-- iXBRL Library version: 1.0.9027.2259 -->
<!-- iXBRL Service Job ID: cc37ea54-74ab-4853-b8f6-19de45bd518b -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:avte="http://aerovatetx.com/20240930" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" xs:nil="true" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_D8P5g644MEqYiCcOi5fx2g"/><ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" xs:nil="true" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_KQ43XTa71UGoOuPuvoxvkQ"/><ix:nonNumeric contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList" id="Hidden_UTi9VdCHy0yvkZrI7rz-4A">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList" id="Hidden_ki9xJbPqnEiOMq8YpIJHoQ">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" xs:nil="true" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" name="us-gaap:CommitmentsAndContingencies" id="Hidden_9AOUSbiMT0-FAEyAzmzKuA"/><ix:nonNumeric contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_5-ruO4LtJES2K1msXUwd4g">http://fasb.org/us-gaap/2023#ShortTermInvestments</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_hQmR02kie0SHXecfenEnnA">http://fasb.org/us-gaap/2023#ShortTermInvestments</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="dei:EntityCentralIndexKey" id="Tc_uPlj5sCms0OGS1TNNkDgng_0_1">0001798749</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="dei:AmendmentFlag" id="Tc_ZaGaVv1mSEad3KsvZxbdcA_1_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" xs:nil="true" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" name="us-gaap:PreferredStockValue" id="Hidden_ocCBIaD8DUywIpPD-inl4w"/><ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" xs:nil="true" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" name="us-gaap:PreferredStockValue" id="Hidden_uqoQ-VLEfEKQOnE0P46H4A"/><ix:nonNumeric contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_W6CC4s96t0iIo9WxVs7plA" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_n34-iiJT30mFenREfVs5IQ">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_nBfMkaz2rkyUUeyEAYEfkw" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_g3-e0FT-IE2Xj7oAU60QZg">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_x6W-38r_4UO4O_0NkamyBg" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_VYoFbHUwRE-bLITQC63xcQ">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YD6uCjdaok-GlOfcPMgZfg" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_eUKRKJ4iNkSfQy8r2Vg3Mg">P1Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" xs:nil="true" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" id="Hidden_LfTcQM9iZEGlLfhH4tvpYg"/><ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" xs:nil="true" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" name="us-gaap:PreferredStockValue" id="Hidden_BTUAgG66VkC8uiBG5TgIww"/><ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" xs:nil="true" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" name="us-gaap:PreferredStockValue" id="Hidden_g-F-zaysXU2M6cBzvAutMw"/><ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" xs:nil="true" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" id="Hidden_4JwO-qU5RkW6VPbwSIIzwQ"/><ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" xs:nil="true" contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_qTxFaY50VUaWw7Jr5uMTQQ" name="us-gaap:CashEquivalentsAtCarryingValue" id="Hidden_NvvtqfTNDUi3pAQbMuV3Iw"/><ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" xs:nil="true" contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_eQIO1TPDN0uO88FWDH85mA" name="us-gaap:CashEquivalentsAtCarryingValue" id="Hidden_W5lZ48FLCEy_u2gCz_QeZg"/><ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" xs:nil="true" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_sWDh72OE6kSOPCSLEhKjBQ" name="us-gaap:CashEquivalentsAtCarryingValue" id="Hidden_EIT7Ft-M4U2oTXvtr5qvPQ"/><ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" xs:nil="true" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_d-MHPg2o6kmGhmn8RSNWEQ" name="us-gaap:CashEquivalentsAtCarryingValue" id="Hidden_XpL8HTw1KUeUXBHbhjlt2w"/><ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" xs:nil="true" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_Qsv0Icq8UEm3CaReRWRLpw" name="us-gaap:ShortTermInvestments" id="Hidden_lN0AgyYwBUGSBPvHUXVvCA"/><ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" xs:nil="true" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_zGfui5LVXkSMPfb_dUdAhA" name="us-gaap:ShortTermInvestments" id="Hidden_ATiC6JEvSUm2xAjs-Qle-w"/><ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" xs:nil="true" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_ZI4VzLqXf0WVcsu5oJ_P-A" name="us-gaap:ShortTermInvestments" id="Hidden_FAR9X24s2UOjJM_mFfQemw"/><ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" xs:nil="true" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_r9QjcP-Lg0ePFAB0AX5tPg" name="us-gaap:ShortTermInvestments" id="Hidden__tPLOVORX06K05WNcJNPHQ"/><ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" xs:nil="true" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_DbsTo893-0aN2-ZX2BZP2w" name="us-gaap:ShortTermInvestments" id="Hidden_hGln6qJd7kWjTm5e4HDgWA"/><ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" xs:nil="true" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_cYlSXcLKKkmR--QmXRet5g" name="us-gaap:ShortTermInvestments" id="Hidden_sBbWTO6GDUu9JQZjdyFFlw"/><ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" xs:nil="true" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_878tdSddu02PyGWA-g7TfA" name="us-gaap:ShortTermInvestments" id="Hidden_Ib6YuqwgvUOu1jkJDvoCZQ"/><ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" xs:nil="true" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_r3JexBQzmEy8wd3QhtRFlg" name="us-gaap:ShortTermInvestments" id="Hidden_HN51f_bDUkShpzdYGLsCOw"/><ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" xs:nil="true" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_d-MHPg2o6kmGhmn8RSNWEQ" name="us-gaap:ShortTermInvestments" id="Hidden_sNomPq10ZESk15LyPnEosQ"/><ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" xs:nil="true" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_d-MHPg2o6kmGhmn8RSNWEQ" name="us-gaap:AssetsFairValueDisclosure" id="Hidden_YNU4YHIeWEuPQ_VjMX_kCQ"/><ix:nonNumeric contextRef="As_Of_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_psQydqKoEkSDWEV9UfDtig" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Hidden_QkmZslh310SYGgzTas8QSQ">P39M</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_sGvwx0X7s0WPUgXlH8FQrg" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Hidden_5dOxBlntyUCTd-8nElVMiw">P39M</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_sGvwx0X7s0WPUgXlH8FQrg" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Hidden_mWsXBWWQvkivgmOrUGyQhg">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_cbrxP5-YikuDmBVJrOS3Sw" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_OXhRKVDiBU-X90wrZ-v3BA">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_KBzCYJ3aOkiZwx3mZ7SYTQ" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_Sk9GO9o6hE2czOoGU9-uIA">P3Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="avte-20240930.xsd"/></ix:references><ix:resources><xbrli:context id="As_Of_8_3_2020_us-gaap_StatementEquityComponentsAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_c5TH3GCKvEGQuOxOnb7Lrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_3_2020_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_lrXI44Ykp02VlKaxJ3Nieg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1mDefc7T6EyF8Qo5feNffg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mK0glKtp20-JMUhi6bQzgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SOdnYt1ZJUmGZUp4nkZ_Dg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eIQAEotTfU2ghqhEOp-9tQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_GUQQrLL2E0uGyzx6Fyxj_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2018_To_8_31_2018_srt_CounterpartyNameAxis_avte_RaCapitalHealthcareFundL.pMember_f26Wjuj0S0u8Hw2V4pgTMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avte:RaCapitalHealthcareFundL.pMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gOVZr7JYNEKGhCeqwxOmnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K4s3v6nxgU-obbx2d9aSOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OqpE3l_LB0G_beKE0PBP5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uXs3dXPjTUaFIqn7C-QEEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_70YqRRSkWEWlj8cmh1CBtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2AicAM6JCEOlEUXMi5ktng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_vPXXIZakVEKr1VLr1ptsQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_FsIjL_FCA0ypY_AxEKEtOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Y6cZV9QIL0C4SojMpiXIJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_lCewvdNJxkWfBMMcTCfUEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_V-lvpQAYG0u0LVvYzwbGTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CPH6za25g0uUfCifzsYkkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vnVV5804C0ScsiBOSJ6srg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Y99KaUn2oUW0_Rr118_mxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_qUiBx0SpzUGr9LR_aNTQUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_QLbiEq19A02perNXBXbTKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_r3UKbN8hp0mfWhezRkf1lQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_UqfaQqRd1U-rmSnO35M5GQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UCLAdEOov0OXILzRhTTw3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZE61xkcRkUCNaq4gU5yrWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FJ3Ctxrxc0CDo2XUQUe3QA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KPy_Azxvr0mBNfoqRZD5Ew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VpGpQUz2xki0YzMNgZlDQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_afA-gfdpa02BAMGQN_YZBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_HPAMtIcY9Eq1U2SHfyr_uw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_M2y81zs0L0Oc7hgVHJlBTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HWbpxkODu0WkRFHnGDEkSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_HyF9ifdj0Ui9zRFDa7dqYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_Ju0lA-npTUKKlfj1h0_hIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_a5ipJvXbekyb6Q7U_qk5JA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dcFzNA8x9Ui_AjpnWINDyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QECF8CV7f0Kgvhlc6flPyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZtSEQpTQBEWAhx3kbiC17g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_m_AT2h9P5EyXiFBYKZDj7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_VEufXZsdzEu6C4BySyFyBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_wvATQii3UU6_fDF_T6RfnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_s7LhYqe820KPsrH32hrUXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_gxzbNSquREapCV0wgG6K_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_9J-eqG0s9EqtvXrgFV1g6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_HTNjaqHx1UmoE5boQ95RMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_VbGf1ULGCUm2eW5RKvPgKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_B2h8T12AhEy09dFKjhebjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_Z4bGGvwZkEKAnVLtaP7k4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_RToG1KKrEU2I3goa1SB0fQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_cYlSXcLKKkmR--QmXRet5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_zGfui5LVXkSMPfb_dUdAhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_r3JexBQzmEy8wd3QhtRFlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_r9QjcP-Lg0ePFAB0AX5tPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_DbsTo893-0aN2-ZX2BZP2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_tzNK_fGEakm5HbGQ9zPcaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_PbzReIi7W0qZtcZBeUxt9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_xuDF7JacqEyVD_8bE4KGbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_paK6hjSIN0utjCqZ6uTFBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_Qsv0Icq8UEm3CaReRWRLpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_878tdSddu02PyGWA-g7TfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_ZI4VzLqXf0WVcsu5oJ_P-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_GLAldi10KUCn9sv4BDXzvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8Ja-oIvtvEOUSt1VbId_rw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_YfltLULy-Euim90Lqzh2Iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_23DxYpsziUKkF0FV76-EIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_2EbSprzX4UmWm8yxfF94Hw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_dAN4ZtziuEiP3QwWp9yKPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_ywomA-WM5EmdfslLNmeoUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_NYTb6k4rLkCljLkmM_mSYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_14Q4SyHhfEip0yfmjiQBjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_SnzjzhUup0auURpf_CvbCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_8pnWeqBIpESIlttN4ujbaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__iWQPWvZwkOiM4XiYpOJ7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_geY3vwOu-UyPu9NwOyIAkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hMDvqIPNTkyi3vwRMi3AWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iFYHzpsOAk6upQL9o0JHJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HmDl-Xe2CkiW7tLgrbq_Fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uKGL0eef7kyr6Ltc79lK9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vWNBs-3fkEi8yguhaSbYeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bPKy-329i0a269T7iYdlfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8NQImWg4J0qy7AIOsD5XtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2018_srt_CounterpartyNameAxis_avte_RaCapitalHealthcareFundL.pMember_MybYzQoXkkeq-kvOFSYqcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avte:RaCapitalHealthcareFundL.pMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_wlI-MiSjLkiqAu8-lbQ9Sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyEighteenStockOptionAndIncentivePlanMember_5jF5V5Er3Eu8MevJLE47ZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_12_31_2023_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_xUfhDItNQkiJKYFlFdOMwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_i_a9v0UQS0KpP37FqkD36Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_s-aYJQaQfEO0AGSWXOYO6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_oV0DwhFiqUeSjADTrzXG4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyEighteenStockOptionAndIncentivePlanMember_J-NqcxMgNUSJ7I39_xVsUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_rO2RmIvkokKdeJv-xbshfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2024_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_Heb8BZ5jAUughxoa-nLBgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_p7xQ831-8k-rQnNZukmxqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_jOQSNYFMiE2CvUhNjVDLEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_ePMqutmojUyuoaStQiHwbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_1_1_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_7n9TuWQvlEKuoOSnaqxmoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_73e_CZGNZEyHg-KoZi_SKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_Ftq0AHVniEWCeuEfN5x_ZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_KY3AqSzTb0OwCTsNTj4W_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_7qar8kvNhkGFswXJGPAVXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_AM4SWxu1AEWvAgiUoTpxpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_gcSTyLkkmk2V2zzgD-_vtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_g2GESSwZAUiWFez9AGcUtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_ZBG0wBshS02tcTB4D_om6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_cbrxP5-YikuDmBVJrOS3Sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_teg0ACtMzkG-j6fB92sMEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_KBzCYJ3aOkiZwx3mZ7SYTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2flsdvnZxUqHPV0GQoL5Gw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_x6W-38r_4UO4O_0NkamyBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_kdwiV7iJm0yXiFQVoEPDqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YD6uCjdaok-GlOfcPMgZfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember__SKGl6wkOE-Kjnfpn0KZcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_R7ajYhISp021nisBN9RonQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tKrwYaxnJk285FLx0psBsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_wbLsz84n5UemDXpr6FCylA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mQCZMz_2oEWLJpuw7OHgvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_uPFIHMkymk27XMLFjHO_1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_dh_QB-NHhUST-PrSPEqJ1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_8Cexqi34OkyeCy4KU0ckUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_WbyCz7z-OUWYQdDXhY6H5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MM86-nEOIUC1fgZNk-MY1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_mxwv-vX1-EKBfodK731-kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mCr7TNm_z0awNKcONlrnIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nOSs2A7SvUChDUg7Gvgu0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_t77TAzlnOUGgpyEM6N3T8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_GhxOUzzS90-GzmvIc16b8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_8aHt_5B77EiYc-jzE1Txdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_5_2023_To_4_5_2023_srt_CounterpartyNameAxis_avte_BofaSecuritiesInc.Member_eXGnRQpI10OVMaKnBBIqeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avte:BofaSecuritiesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-05</xbrli:startDate><xbrli:endDate>2023-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_W6CC4s96t0iIo9WxVs7plA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_nBfMkaz2rkyUUeyEAYEfkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_srt_CounterpartyNameAxis_avte_BofaSecuritiesInc.Member_fT8d84SKjEiyXJr9wvIUUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avte:BofaSecuritiesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_avte_BofaSecuritiesInc.Member_LeFPgJGk10aB82UXVdtuHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avte:BofaSecuritiesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_Omgdwr0yakip4mYX2MbLqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_LI5YHiUWtUqb-dWGgEgt2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_pWvY-k6LJEyAy3X_g6pRyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_WDqRejYbEUSzCLXwlEWRhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_hsfYMw1YQUiRxCSpEvhLOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_4mWrWAlR1U2qPGLn2vS_fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_PLHhQPxnDkGS0X1B4pdMdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">avte:FosterCityLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_Db-jvbls9U2OcKGqstWiEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avte:ServicesAgreementWithCarnotLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_GK_CqlKS30Gm2NvMdNBc3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avte:ServicesAgreementWithCarnotLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_j8k9mWHPuUaAW-sNf4hesg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nyimchTjV0KbghS9hcjUig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UlG_BWompUqeXJDTFYDksw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pv40wdBMdU2Z1HGOA_ocaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fB9Oej3iHEuLzftkJpBxOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Rr0GlkP2XEun1mQJs3HD0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aXw1Zj8XYkqQuwDSYY4ipw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KuqcIl38qk-Am_HOfAm4Iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2024_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_zn19noNKY029l5Ec-T6CTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">avte:WalthamLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_b5ksvgJaa02KO-43SndRnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_6Bs2-neN-U2EmecB-QIl0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_JDWj8X9B5Eu8UjEOpYq-Pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_8CT_KtQnWUiGek0hhT0EXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_SfcoGV5hFkuKGuO_rvH3RA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_wy5Ete1m60Gp0JfLF-sD_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_g1st23sQ50KGJ_c8e9kcQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yYm-QanqNEuE0_c7yIDEKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_s-ZbaqOFEkqsqlAtFTXFQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_R1aNdniYp0yg5IJCGgDujA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_y1zASwVL00OvpCxcnCK7Yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rSCB_jEoQUWrJ9udMpqr1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2021_To_7_2_2021_zM4kB7thfEaK38J25p-KHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_2_2021_w8fg7T9i30-Tb8oR9Nn9Ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_WBdMq-xE_k6SSkWqaFUxDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_7LIRbHXsBEeM6CKDpiodeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_CommonStockMember_euLPHJw1sEmiJdRRSszShQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_4YcJ4RjRj0GB-mGnU1wJUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Gy-ZvYruXkinoI8nJEgktA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_aLb1VNRswEiUg0bp5BxGmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_CommonStockMember_YflOQXijzkee839-W5_-ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vFkjMAci2kCM1_635tV-aQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_n9o8wjs2y0evFtOumxNmtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_eQIO1TPDN0uO88FWDH85mA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_qTxFaY50VUaWw7Jr5uMTQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_C-UwaOvYgEmhc5KbjSNoaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_jXLEnvJsuU2DjT7WrX1onA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_F964c7FBf0qgpnkWSEYhwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AyHw9eprTkCuYHbb4OSTdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_e-zMRu88YEulFM6FDn839A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_3SZLVaYF3Uaoxk9Z6taH9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8yGurj7uGke-WnYhN4sOug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YzIcvZaeZUu6LSDu8bymCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_HnxnO2kja0uIhwuJkAHhcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_fyLg3XbfjUyiu8CJN34Bjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_PE43wqGHWU6QaYBuVIux_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_cMFhMcP0AE2-6VZ7iiNWxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_GL6agAj25k-cPwtptPUzow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_xThuN_5MDkqYF87Q3NeYSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__yohEd5oXkm5sOjdtwzPqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_dKc-asA1AkOzmsiFfkV83w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_d-MHPg2o6kmGhmn8RSNWEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_sWDh72OE6kSOPCSLEhKjBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Uy_OzIg220WOoPfwtTN9Cg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_alE2cQWlWUmYEMSvxQfOpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Lk-ps-R70EiQI3935QJvXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kHkV564Q4kqYbVZPXq-xpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Kcx7c1ohMECfaPSrYxC0Nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_sGvwx0X7s0WPUgXlH8FQrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">avte:FosterCityLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_psQydqKoEkSDWEV9UfDtig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">avte:WalthamLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ZpDGpfQ1TkilwLHCKcIxnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_3UmwRa-EAE-11acDMKDuHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_KH1NXBTyjkur0ov9ZtwkMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_shfv-0j6hE2RH9wjzcjK0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_VNugwlI_n0evghUr12SqYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_QNvV2K_cRECh_I59hVJgKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ChUwiv23hEy7LMz7LGvpuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_LZBhq8TBukyCmnM6XHK1BQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_pLhOme55706_ApNfgYI-eA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_z3LyNn-sk0-txThcBPD1Yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Cxy8Whj0fkC98fl4coAgEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_vfttyrGb-EW4_y-k4IU1OA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_h9FVlzwiVkmij0mSQNLnEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_SpjyK1AxVEqPXklSW5dc7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_DdnUA-mndEmQoBFn-wT6ng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_8Qb64bPhgUq_qlFXMzlYzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_tQTCT3FErESwh4_H6D13eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_eKXqES4MhEC5wSlAU18O1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_W3X1hUg8vke6Gh4fxUQQlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FLsOS9KJZUm-Ldlf9yt1hQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tfvBCfSvrEinR9S17WhtYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_gnY1UC1Lf0eSFvl6XWqbGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pzSeRKqRmUWfGQi3u9vQfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_FUDixdV2nkO01qprXRWNww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ImI5-uZhs02-PHLXTrl4zw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3YNubJsuwUyt1b4HmIVa7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_0RTLeeNjREWrXNlRldBizg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_RQUeGZjabU2LSVSR_5lP_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_G7iErj3me0qVgh1ge_DiqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_tdpGz56jqk6Dn9XNb5jQVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LKCmt_IMoEm2kACXc_PCig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_fjXbQ_EYZ0OduVaJ4JsVzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avte:ServicesAgreementWithCarnotLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_0tBp6f6PUUW7kvis6j685w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avte:ServicesAgreementWithCarnotLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_srt_CounterpartyNameAxis_avte_BofaSecuritiesInc.Member_IwOYf_4k8kOpNBRHvM5Rxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avte:BofaSecuritiesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_avte_BofaSecuritiesInc.Member_t15u6BZEqkaKnYEH9TOQCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avte:BofaSecuritiesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_l2cNv6JCfkyvIREeesp36w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_WvqE0K12M0iiC1AH3k88Tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_7_31_2019_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_n2CK4UQgq0-A1CPzs_pKqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avte:ServicesAgreementWithCarnotLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_30_2024_To_10_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_RPVQa3dXU0OggwPnCBtwgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-30</xbrli:startDate><xbrli:endDate>2024-10-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_UR7pUGE3y0avsGAAh5HJFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_30_2024_dei_LegalEntityAxis_avte_JadeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7tb7W4BvUUu3IUTHi97FXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">avte:JadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2018_To_8_31_2018_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_-N_0UjeZlUm9GQWNR1RVdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avte:ServicesAgreementWithCarnotLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_m3e0XkrsxkWOCq0GHEPF6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">avte:FosterCityLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_DaiW5HZ95E-5aglfFdRpPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">avte:WalthamLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_1_31_2024_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_PodE97lmJkSHEwoc1aClWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">avte:WalthamLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_0Iv5XCHgWUyuS-1MyqMPSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_SYM7muK7eU6UOC8tcjKjzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_BlyAQCATVkGjKh-kOfQdJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_O8QXwFu-kEqrEQwa9rKRJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_eZcGsEFbHEW38q44Yr6mVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_OlIabHctWUyzxlnqkr4bCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_rsRxqqwUvEm2inEelixs4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_zaDLiCFPqUqEufSLy6NbzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_qYrKRTeZrkCEoPKcnJyr4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_YQFimAiCRUGyikQapBgwVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_kql4M0ph3Umd2bhh5TV1nA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_3_2020_EcWWeWov-0O5egWgb1IO4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Vote_68Fy5nhdn0WonvfwhauHwA"><xbrli:measure>avte:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_5xtOY_aM_0eoVegCdMhIVQ"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_segment_bCa297tYP0mkIHafmd-9BQ"><xbrli:measure>avte:segment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_individual_HQaf273bdUKcqMGv_RJZsw"><xbrli:measure>avte:individual</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:10.35pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_c4aac6cf_7cd7_4c7e_aee1_117a5e5c86c1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="color:#231f20;font-weight:bold;">As filed with the Securities and Exchange Commission on December&#160;2, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 3pt 0pt;"><b style="color:#231f20;font-weight:bold;">Registration No.&#160;333-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-size:13pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">WASHINGTON, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="color:#231f20;font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="dei:DocumentType" id="Narr_3KYIRfLgmk-7CbIjnUNFmQ"><b style="color:#231f20;font-weight:bold;">S-4</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">REGISTRATION STATEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">UNDER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">THE SECURITIES ACT OF 1933</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="dei:EntityRegistrantName" id="Narr_OVtRYY3e2E2B1suk5YAvfg"><b style="color:#231f20;font-weight:bold;">AEROVATE THERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">(Exact Name of Registrant as Specified in Its Charter)</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Delaware</b></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2834</b></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">83-1377888</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">(State or Other Jurisdiction of</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">(Primary Standard Industrial</span></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">(I.R.S. Employer</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">Incorporation or Organization)</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">Classification Code Number)</span></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">Identification Number)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">930 Winter Street, Suite&#160;M-500</b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">Waltham, MA 02451</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="color:#231f20;font-weight:bold;">(617) 443-2400</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#8217;s Principal Executive Offices)</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Timothy P. Noyes</b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">Chief Executive Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Aerovate Therapeutics,&#160;Inc.</b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">930 Winter Street, Suite&#160;M-500</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Waltham, MA 02451</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="color:#231f20;font-weight:bold;">(617) 443-2400</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="color:#231f20;font-weight:bold;">Copies to:</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Edwin M. O&#8217;Connor, Esq.</b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">Tevia K. Pollard, Esq.</b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">Alicia M. Tschirhart, Esq.</b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">Goodwin Procter LLP</b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">620 Eighth Avenue</b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">New York, NY 10018</b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">(212) 813-8800</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ryan Murr, Esq.</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Branden Berns, Esq.</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Chris Trester, Esq.</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Gibson Dunn &amp; Crutcher LLP</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">One Embarcadero Center, Suite 2600</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">San Francisco, CA 94111</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(415) 393-8373</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;">Approximate date of commencement of proposed sale of the securities to the public: As soon as practicable after the effective date of this registration statement and the satisfaction or waiver of all other conditions under the Merger Agreement described herein.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;">If the securities being registered on this Form&#160;are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following box </span><span style="color:#231f20;font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;">If this Form&#160;is filed to register additional securities for an offering pursuant to Rule&#160;462(b)&#160;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. </span><span style="color:#231f20;font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;">If this Form&#160;is a post-effective amendment filed pursuant to Rule&#160;462(d)&#160;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. </span><span style="color:#231f20;font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></p><a id="_c956e62e_6194_4420_b7bc_c91e46ddd6c8"></a><a id="Tc_zTTpxTS-aUKjVPrwN7tzYA_0_0"></a><a id="Tc_PmfJbm7szkGQYDFkId897g_0_1"></a><a id="Tc_v9MlIsKAgkKu-xqI7ecM3Q_0_3"></a><a id="Tc_x66B1o_bkEak5Z5oZkGrdA_0_4"></a><a id="Tc_EYFbEvKjR0eOveJkc-b6eg_1_1"></a><a id="Tc_F9rjGxZZ_ES0cOh5r8OsLw_1_3"></a><a id="Tc_rKsw5TBtGUCEBK6_OMOtQQ_2_3"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.07870102%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:11.55pt;"><td style="vertical-align:top;width:19.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 3pt 18pt;"><span style="color:#231f20;">Large accelerated filer</span></p></td><td style="vertical-align:top;width:32.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:top;width:18.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;">Accelerated filer</span></p></td><td style="vertical-align:top;width:27.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr style="height:11.9pt;"><td style="vertical-align:top;width:19.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 18pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="dei:EntityFilerCategory" id="Tc_LizwkTAaCEWmu4PvpR-TDQ_1_0"><span style="color:#231f20;font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:32.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:top;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;">Smaller reporting company</span></p></td><td style="vertical-align:top;width:27.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="dei:EntitySmallBusiness" id="Tc_8reE8S0-r0C8lyPF64GguQ_1_4"><span style="color:#231f20;font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr style="height:11.55pt;"><td style="vertical-align:top;width:19.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="color:#231f20;">Emerging growth company</span></p></td><td style="vertical-align:top;width:27.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="dei:EntityEmergingGrowthCompany" id="Tc_VBLyJ8t71UGrkboJOx3WBg_2_4"><span style="color:#231f20;font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B)&#160;of the Securities Act. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="dei:EntityExTransitionPeriod" id="Narr_iSFW0TBvkkW2QUA-JRG49Q"><span style="color:#231f20;font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;">If applicable, place an X in the box to designate the appropriate rule&#160;provision relied upon in conducting this transaction:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;">Exchange Act Rule&#160;13e-4(i)&#160;(Cross-Border Issuer Tender Offer)&#160;</span><span style="color:#231f20;font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;">Exchange Act Rule&#160;14d-1(d)&#160;(Cross-Border Third-Party Tender Offer) </span><span style="color:#231f20;font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a)&#160;of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:3pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><div style="height:0pt;position:relative;width:100%;"><div style="left:0pt;position:absolute;top:18.09pt;width:34.29pt;z-index:251658240;"><div style="left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:33.84pt;"><div style="align-items:center;display:flex;left:0pt;position:relative;text-indent:0pt;top:0pt;transform:rotate(180.1deg);width:33.84pt;writing-mode:vertical-rl;-ms-writing-mode:tb-rl;"><div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;width:100%;margin:0pt;"><b style="color:#ff0000;font-weight:bold;">The information in this proxy statement/prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This proxy statement/prospectus is not an offer to sell and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</b></p></div></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:685.72pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_cbec61f5_5cd8_4098_999f_b8ca52abb9dc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:43.2pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#ff0000;font-weight:bold;">SUBJECT TO COMPLETION, DATED DECEMBER&#160;2, 2024</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:middle;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="avte-20240930xs4007.jpg" alt="Graphic" style="display:inline-block;height:40.7pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:180.95pt;"/></p></td><td style="vertical-align:middle;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="avte-20240930xs4008.jpg" alt="Graphic" style="display:inline-block;height:50.1pt;width:134pt;"/></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:43.2pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:43.2pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PROPOSED MERGER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:43.2pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">YOUR VOTE IS VERY IMPORTANT</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:6pt;margin-left:21.6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:43.2pt;margin:0pt 0pt 12pt 0pt;">To the Stockholders of Aerovate Therapeutics,&#160;Inc. and Jade Biosciences,&#160;Inc.,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 43.2pt;">Aerovate Therapeutics,&#160;Inc., a Delaware corporation (&#8220;Aerovate&#8221;) and Jade Biosciences,&#160;Inc., a Delaware corporation (&#8220;Jade&#8221;) entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) on October&#160;30, 2024, pursuant to which, among other matters, (i)&#160;Caribbean Merger Sub I,&#160;Inc., a direct, wholly owned subsidiary of Aerovate (&#8220;Merger Sub I&#8221;), will merge with and into Jade, with Jade surviving as a wholly owned subsidiary of Aerovate and the surviving corporation of the merger (the &#8220;First Merger&#8221;), and (ii)&#160;Jade will merge with and into Caribbean Merger Sub II, LLC, a direct, wholly owned subsidiary of Aerovate (&#8220;Merger Sub II&#8221;), with Merger Sub II being the surviving entity of the merger (the &#8220;Second Merger&#8221; and collectively with the First Merger, the &#8220;Merger&#8221;). Aerovate following the Merger is referred to herein as the &#8220;Combined Company.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 43.2pt;">At the effective time of the First Merger (the &#8220;First Effective Time&#8221;), (i)&#160;each share of Jade common stock (including shares of Jade common stock issued in the Jade Pre-Closing Financing described below) will be converted into the right to receive a number of shares of Aerovate common stock equal to the exchange ratio described in more detail in the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#160;&#8212; Exchange Ratio</i>&#8221; beginning on page&#160;138 of the accompanying proxy statement/prospectus, referred to herein as the &#8220;Exchange Ratio,&#8221; and <span style="color:#231f20;">(ii)&#160;each share of Jade Series&#160;Seed Convertible Preferred Stock, par value $0.0001 per share, will be converted into the right to receive a number of shares of Aerovate Series&#160;A Non-Voting Convertible Preferred Stock (the &#8220;Aerovate Series&#160;A Preferred Stock&#8221;) equal to the Exchange Ratio divided by 1,000. If any shares of Jade common stock are unvested or subject to a repurchase option or risk of forfeiture at the First Effective Time (the &#8220;Jade Restricted Stock&#8221;), then the shares of Aerovate common stock issued in exchange for such shares will to the same extent be unvested and subject to the same repurchase option or risk of forfeiture.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 43.2pt;">In connection with the Merger, each outstanding and unexercised option to purchase shares of Jade common stock will be assumed by Aerovate and will be converted into an option to purchase shares of Aerovate&#8217;s common stock, with necessary adjustments to reflect the Exchange Ratio. See the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#160;&#8212; Treatment of Jade Options</i>&#8221; beginning on page&#160;140 of the accompanying proxy statement/ prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 43.2pt;">Each share of Aerovate common stock that is issued and outstanding at the effective time of the Merger will remain issued and outstanding and such shares, subject to the proposed reverse stock split, will be unaffected by the Merger. Each option to acquire shares of Aerovate&#8217;s common stock with an exercise price less than or equal to the Aerovate Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (A)&#160;the excess of the Aerovate Closing Price over the exercise price per share of Aerovate common stock underlying such Aerovate option by (B)&#160;the number of shares of Aerovate common stock underlying such Aerovate option, and each option with an exercise price greater than the Aerovate Closing Price, as adjusted for the proposed special Cash Dividend (as defined below), to acquire shares of Aerovate&#8217;s common stock (the &#8220;Aerovate OTM Options&#8221;) will be cancelled for no consideration. As used herein, the &#8220;Aerovate Closing Price&#8221; means the volume weighted average closing trading price of a share of Aerovate common stock on The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;), for the five (5)&#160;consecutive trading&#160;days ending three (3)&#160;days immediately prior to the anticipated date for the special meeting of Aerovate stockholders. Each unvested Aerovate restricted stock unit (&#8220;Aerovate RSU&#8221;) shall be accelerated in full.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_57b12284_19cc_40c6_a0b7_f6670707a70c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Based on Aerovate&#8217;s and Jade&#8217;s capitalization as of October&#160;30, 2024 and taking into account Aerovate&#8217;s current cash position, each share of Jade common stock is currently estimated to be entitled to receive approximately 21.4388 shares of Aerovate common stock and each share of Jade Preferred Stock is currently estimated to be entitled to receive approximately 0.0214388 shares of Aerovate Series A Preferred Stock. This estimated Exchange Ratio does not give effect to the proposed Aerovate reverse stock split and is subject to adjustment based on Aerovate&#8217;s estimated Net Cash (as defined herein) at the closing of the First Merger as described in more detail in the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#160;&#8212; Exchange Ratio</i>&#8221; beginning on page&#160;138 of the accompanying proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Prior to the closing of the Merger (the &#8220;Closing&#8221;), certain investors have agreed to purchase shares of Jade common stock or pre-funded warrants for an aggregate purchase price of approximately $300 million, including the conversion of Jade&#8217;s previously issued $95 million convertible notes, referred to herein as the &#8220;Jade Pre-Closing Financing.&#8221; The closing of the Jade Pre-Closing Financing is conditioned upon the satisfaction or waiver of the conditions to the Closing as well as certain other conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Immediately after the Merger, Aerovate securityholders as of immediately prior to the Merger are expected to own approximately 1.6% of the outstanding shares of the Combined Company on a fully- diluted basis, former Jade securityholders, excluding shares purchased in the Jade Pre-Closing Financing, are expected to own approximately 34.0% of the outstanding shares of the Combined Company on a fully- diluted basis, and shares and pre-funded warrants issued in the Jade Pre-Closing Financing are expected to represent approximately 64.4% of the outstanding shares of capital stock of the Combined Company on a fully-diluted basis, subject to certain assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Shares of Aerovate common stock are currently listed on Nasdaq under the symbol &#8220;AVTE.&#8221; Aerovate intends to file an initial listing application for the Combined Company with Nasdaq. After completion of the Merger, Aerovate will be renamed &#8220;Jade Biosciences,&#160;Inc.&#8221; and it is expected that the common stock of the Combined Company will trade on Nasdaq under the symbol &#8220;JBIO.&#8221; On November&#160;29, 2024, the last trading day before the date of the accompanying proxy statement/prospectus, the closing sale price of Aerovate common stock was $2.63 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Jade Pre-Closing Financing is more fully described in the accompanying proxy statement/ prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Aerovate stockholders are cordially invited to attend the special meeting of Aerovate stockholders. Aerovate is holding its special meeting of stockholders (the &#8220;Aerovate Special Meeting&#8221;), on&#160;&#160;&#160;&#160;&#160;, 2025, at&#160;&#160;&#160;&#160;&#160; Eastern Time, unless postponed or adjourned to a later date, in order to obtain the stockholder approvals necessary to complete the Merger and related matters. The Aerovate Special Meeting will be held at&#160;&#160;&#160;&#160;&#160;. Aerovate stockholders will be able to attend and participate in the Aerovate Special Meeting in person where they will be able to ask questions and vote. At the Aerovate Special Meeting, Aerovate will ask its stockholders to:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">Approve (i)&#160;the issuance of shares of common stock of Aerovate (including the shares of Aerovate common stock issuable upon conversion of the Aerovate Series&#160;A Preferred Stock), which will represent more than 20% of the shares of Aerovate common stock outstanding immediately prior to the Merger, to stockholders of Jade, pursuant to the terms of the Merger Agreement, a copy </span>of which is attached as <i style="font-style:italic;">Annex A </i>to the accompanying proxy statement/prospectus, and (ii)&#160;the change of control resulting from the Merger, pursuant to Nasdaq Listing Rules&#160;5635(a)&#160;and 5635(b), respectively (the &#8220;Nasdaq Stock Issuance Proposal&#8221; or &#8220;Proposal No.&#160;1&#8221;);</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">2.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">Approve an amendment to the amended and restated certificate of incorporation of Aerovate to effect a reverse stock split of Aerovate&#8217;s issued and outstanding common stock at a ratio determined by the Aerovate board of directors and agreed to by Jade, of one new share of Aerovate common stock for every&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;shares (or any number in between) of outstanding Aerovate common stock in the form attached as </span><i style="color:#231f20;font-style:italic;">Annex B </i><span style="color:#231f20;">to the accompanying proxy statement/prospectus (the &#8220;Reverse Stock Split Proposal&#8221; or &#8220;Proposal No.&#160;2&#8221;);</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">3.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">Approve an amendment to the amended and restated certificate of incorporation of Aerovate to increase the number of shares of Aerovate common stock that Aerovate is authorized to issue from 150,000,000 to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, in the form attached as </span><i style="color:#231f20;font-style:italic;">Annex C </i><span style="color:#231f20;">(the &#8220;Authorized Share Increase Proposal&#8221; or &#8220;Proposal No.&#160;3&#8221;);</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">4.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">Approve the redomestication of Aerovate from the State of Delaware to the State of Nevada by conversion (the &#8220;Redomestication Proposal&#8221; or &#8220;Proposal No.&#160;4&#8221;);</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">5.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Approve the Jade Biosciences,&#160;Inc. 2025 Stock Incentive Plan (the &#8220;Stock Plan Proposal&#8221; or &#8220;Proposal No.&#160;5&#8221;);</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">6.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Approve the Jade Biosciences,&#160;Inc. 2025 Employee Stock Purchase Plan (the &#8220;ESPP Proposal&#8221; or &#8220;Proposal No.&#160;6&#8221;);</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">7.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Approve an adjournment of the Aerovate Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 1, 2 and 3 (the &#8220;Adjournment Proposal&#8221; or &#8220;Proposal No.&#160;7&#8221;); and</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">8.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Transact such other business as may properly come before the stockholders at the Aerovate Special Meeting or any adjournment or postponement thereof.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As described in the accompanying proxy statement/prospectus, certain Aerovate stockholders who in the aggregate owned approximately 38.1% of the outstanding shares of Aerovate as of October&#160;30, 2024, and certain Jade stockholders who in the aggregate owned approximately 99.0% of the outstanding shares of Jade capital stock as of October&#160;30, 2024, are parties to stockholder support agreements with Aerovate and Jade, respectively, whereby such stockholders have agreed to vote in favor of the approval of the transactions contemplated therein, including, with respect to Jade stockholders, adoption of the Merger Agreement and approval of the Merger and, with respect to such Aerovate stockholders, Proposal Nos. 1&#160;&#8211; 7, subject to the terms of the support agreements. Following the effectiveness of the registration statement on Form&#160;S-4 of which the accompanying proxy statement/prospectus is a part and pursuant to the Merger Agreement, Jade stockholders holding a sufficient number of shares of Jade capital stock to adopt the Merger Agreement and approve the Merger and related transactions will be asked to execute written consents providing for such adoption and approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, prior to the First Effective Time, the Aerovate board of directors will declare and set aside the aggregate cash amount to be paid in accordance with a pre-Closing special cash dividend (the &#8220;Cash Dividend&#8221;) to holders of record of outstanding shares of Aerovate common stock as of a record date prior to the First Effective Time, to be set by the Aerovate board of directors as close as reasonably practicable to (but not later than) the anticipated Closing. The ex-dividend date in respect of such Cash Dividend will be determined by Nasdaq. Aerovate stockholders of record who continue to hold their eligible shares of Aerovate common stock until market open on the ex-dividend date will be entitled to payment of the Cash Dividend. The Cash Dividend will be equal in the aggregate to Aerovate&#8217;s reasonable, good faith approximation of the amount by which Aerovate&#8217;s Net Cash (as determined pursuant to the Merger Agreement) is expected to exceed $0 as of the closing of the Merger. The aggregate amount of the Cash Dividend is expected to be approximately $65.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After careful consideration, each of the Aerovate and Jade boards of directors have approved the Merger Agreement and have determined that it is advisable to consummate the Merger. Aerovate&#8217;s board of directors has approved the proposals described in the accompanying proxy statement/prospectus and recommends that its stockholders vote &#8220;FOR&#8221; the proposals described in the accompanying proxy statement/ prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">More information about Aerovate, Jade, the Merger Agreement and transactions contemplated thereby and the foregoing proposals is contained in the accompanying proxy statement/prospectus. Aerovate urges you to read the accompanying proxy statement/prospectus carefully and in its entirety. IN PARTICULAR, YOU SHOULD CAREFULLY CONSIDER THE MATTERS DISCUSSED UNDER &#8220;RISK FACTORS&#8221; BEGINNING ON PAGE&#160;</b><span style="font-weight:bold;">24</span> <b style="font-weight:bold;">OF THE ACCOMPANYING PROXY STATEMENT/PROSPECTUS.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate and Jade are excited about the opportunities the Merger brings to Aerovate&#8217;s and Jade&#8217;s stockholders and thank you for your consideration and continued support. Sincerely,</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:14.4pt;"><td style="vertical-align:middle;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Timothy Noyes</p></td><td style="vertical-align:middle;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Tom Frohlich</p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:middle;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Chief Executive Officer</i></p></td><td style="vertical-align:middle;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Chief Executive Officer</i></p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:middle;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Aerovate Therapeutics, Inc.</p></td><td style="vertical-align:middle;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Jade Biosciences, Inc.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the accompanying proxy statement/ prospectus. Any representation to the contrary is a criminal offense.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">The accompanying proxy statement/prospectus is dated&#160;&#160;&#160;&#160;&#160;, 2025, and is first being mailed to Aerovate&#8217;s stockholders on or about&#160;&#160;&#160;&#160;&#160;, 2025.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_3c734fe7_d44a_42c3_9095_5d54df19d0d0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AEROVATE THERAPEUTICS,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">930 Winter Street, Suite&#160;M-500</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Waltham, MA 02451</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(617) 443-2400</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTICE OF SPECIAL MEETING OF STOCKHOLDERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To the stockholders of Aerovate Therapeutics,&#160;Inc.:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTICE IS HEREBY GIVEN </b>that a special meeting of stockholders (the &#8220;Aerovate Special Meeting&#8221;), will be held on&#160;&#160;&#160;&#160;&#160;, 2025, at&#160;&#160;&#160;&#160;Eastern Time, unless postponed or adjourned to a later date. The Aerovate Special Meeting will be held at&#160;&#160;&#160;&#160;&#160;. You will be able to attend and participate in the Aerovate Special Meeting in person where you will be able to ask questions and vote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The Aerovate Special Meeting will be held for the following purposes:</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">To approve (i)&#160;the issuance of shares of common stock of Aerovate Therapeutics,&#160;Inc. (&#8220;Aerovate&#8221;) (including the shares of Aerovate common stock issuable upon conversion of the Aerovate </span>Series&#160;A Non-Voting Convertible Preferred Stock), which will represent more than 20% of the shares of Aerovate common stock outstanding immediately prior to the Merger (as defined herein), to stockholders of Jade Biosciences,&#160;Inc. (&#8220;Jade&#8221;) pursuant to the terms of the Agreement and Plan of Merger among Aerovate, Jade and Caribbean Merger Sub I,&#160;Inc. (&#8220;Merger Sub I&#8221;) and Caribbean Merger Sub II, LLC (&#8220;Merger Sub II&#8221;), dated as of October&#160;30, 2024, a copy of which is attached as <i style="font-style:italic;">Annex A </i>to the accompanying proxy statement/prospectus, which is referred to in this notice as the &#8220;Merger Agreement,&#8221; and (ii)&#160;the change of control resulting from the Merger, pursuant to Nasdaq Listing Rules&#160;5635(a)&#160;and 5635(b), respectively (the &#8220;Nasdaq Stock Issuance Proposal&#8221; or &#8220;Proposal No.&#160;1&#8221;);</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">2.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">To approve an amendment to the amended and restated certificate of incorporation of Aerovate to effect a reverse stock split of Aerovate&#8217;s issued and outstanding common stock at a ratio determined by the Aerovate board of directors and agreed to by Jade, of one new share of Aerovate common stock for </span>every&#160;&#160;&#160;&#160;&#160;shares<span style="color:#231f20;"> (or any number in between) of outstanding Aerovate common stock in the form attached as </span><i style="color:#231f20;font-style:italic;">Annex B </i><span style="color:#231f20;">to the accompanying proxy statement/prospectus (the &#8220;Reverse Stock Split Proposal&#8221; or &#8220;Proposal No.&#160;2&#8221;);</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">3.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">To approve an amendment to the amended and restated certificate of incorporation of Aerovate to increase the number of shares of Aerovate common stock that Aerovate is authorized to issue from 150,000,000 to&#160;&#160;&#160;&#160;&#160;, in the form attached as </span><i style="color:#231f20;font-style:italic;">Annex C </i><span style="color:#231f20;">(the &#8220;Authorized Share Increase Proposal&#8221; or &#8220;Proposal No.&#160;3&#8221;);</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">4.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">To approve the redomestication of Aerovate from the State of Delaware to the State of Nevada by conversion (the &#8220;Redomestication Proposal&#8221; or &#8220;Proposal No.&#160;4&#8221;);</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">5.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">To approve the Jade Biosciences,&#160;Inc. 2025 Stock Incentive Plan (the &#8220;Stock Plan Proposal&#8221; or &#8220;Proposal No.&#160;5&#8221;);</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">6.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">To approve the Jade Biosciences,&#160;Inc. 2025 Employee Stock Purchase Plan (the &#8220;ESPP Proposal&#8221; or &#8220;Proposal No.&#160;6&#8221;);</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">7.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">To approve an adjournment of the Aerovate Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 1, 2 and 3 (the &#8220;Adjournment Proposal&#8221; or &#8220;Proposal No.&#160;7&#8221;); and</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">8.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">To transact such other business as may properly come before the stockholders at the Aerovate Special Meeting or any adjournment or postponement thereof.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Record Date: </b>Aerovate&#8217;s board of directors has fixed&#160;&#160;&#160;&#160;, 2025 as the record date for the determination of stockholders entitled to notice of, and to vote at, the Aerovate Special Meeting and any adjournment or postponement thereof. Only holders of record of shares of Aerovate common stock at the close of business on the record date are entitled to notice of, and to vote at, the Aerovate Special Meeting. At the close of business on the record date, Aerovate had&#160;&#160;&#160;&#160;&#160;shares of common stock outstanding and entitled to vote.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Your vote is important. The affirmative vote of a majority of the votes properly cast at the Aerovate Special Meeting, assuming a quorum is present, is required for approval of Proposal Nos. 1, 5, 6, 7 and 8. The affirmative vote of a majority of the outstanding shares of Aerovate common stock entitled to vote thereon is required for approval of Proposal Nos. 2, 3 and 4. Approval of each of Proposal No.&#160;1, Proposal No.&#160;2 and Proposal No.&#160;3 is a condition to the completion of the Merger. Therefore, the Merger cannot be consummated without the approval of Proposal Nos. 1, 2 and 3.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Even if you plan to attend the Aerovate Special Meeting, Aerovate requests that you sign and return the enclosed proxy or vote by mail or online to ensure that your shares will be represented at the Aerovate Special Meeting if you are unable to attend. You may change or revoke your proxy at any time before it is voted at the Aerovate Special Meeting.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AEROVATE&#8217;S BOARD OF DIRECTORS HAS DETERMINED AND BELIEVES THAT EACH OF THE PROPOSALS OUTLINED ABOVE IS FAIR TO, IN THE BEST INTERESTS OF, AND ADVISABLE TO AEROVATE AND ITS STOCKHOLDERS AND HAS APPROVED EACH SUCH PROPOSAL. AEROVATE&#8217;S BOARD OF DIRECTORS RECOMMENDS THAT AEROVATE STOCKHOLDERS VOTE &#8220;FOR&#8221; EACH SUCH PROPOSAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Important Notice Regarding the Availability of Proxy Materials for the Stockholders&#8217; Meeting</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">to Be Held on&#160;&#160;&#160;&#160;&#160;, 2025 at&#160;&#160;&#160;&#160;&#160;Eastern Time at&#160;&#160;&#160;&#160;&#160;.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The proxy statement/prospectus and annual report to stockholders are available at www.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">By Order of Aerovate&#8217;s Board of Directors,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Timothy Noyes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e3266da6_87b1_4296_ae42_4afe709c5841"></a><a id="REFERENCESTOADDITIONALINFORMATION_764607"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REFERENCES TO ADDITIONAL INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This proxy statement/prospectus incorporates important business and financial information about Aerovate Therapeutics,&#160;Inc. that is not included in or delivered with this document. You may obtain this information without charge through the Securities and Exchange Commission website (<i style="font-style:italic;">www.sec.gov</i>) or upon your written or oral request by contacting the Corporate Secretary of Aerovate Therapeutics,&#160;Inc. by calling (617) 443-2400 or via email to Legal@AerovateTx.com.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">To ensure timely delivery of these documents, any request should be made no later than&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025 to receive them before the Aerovate Special Meeting</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For additional details about where you can find information about Aerovate, please see the section titled &#8220;<i style="font-style:italic;">Where You Can Find More Information</i>&#8221; beginning on page&#160;336 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">i</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e78ac2aa_ef7f_4cf7_be94_5f8980868aa2"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:93.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 2.9pt 0pt 0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#REFERENCESTOADDITIONALINFORMATION_764607"><span style="font-style:normal;font-weight:normal;">References To Additional Information</span></a></p></td><td style="vertical-align:bottom;width:6.63%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">i</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#QUESTIONSANDANSWERSABOUTTHEMERGER_259040"><span style="font-style:normal;font-weight:normal;">Questions and Answers About the Merger</span></a></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">1</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#PROSPECTUSSUMMARY_216069"><span style="font-style:normal;font-weight:normal;">Prospectus Summary</span></a></p></td><td style="vertical-align:bottom;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">10</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#MARKETPRICEANDDIVIDENDINFORMATION_402401"><span style="font-style:normal;font-weight:normal;">Market Price and Dividend Information</span></a></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">23</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#RISKFACTORS_64429"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">24</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#CAUTIONARYNOTEREGARDINGFORWARDLOOKINGSTA"><span style="font-style:normal;font-weight:normal;">Cautionary Note Regarding Forward-Looking Statements</span></a></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">93</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#THESPECIALMEETINGOFAEROVATESTOCKHOLDERS_"><span style="font-style:normal;font-weight:normal;">The Special Meeting of Aerovate Stockholders</span></a></p></td><td style="vertical-align:bottom;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">95</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#THEMERGER_864508"><span style="font-style:normal;font-weight:normal;">The Merger</span></a></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">99</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#THEMERGERAGREEMENT_24528"><span style="font-style:normal;font-weight:normal;">The Merger Agreement</span></a></p></td><td style="vertical-align:bottom;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">137</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#AGREEMENTSRELATEDTOTHEMERGER_818530"><span style="font-style:normal;font-weight:normal;">Agreements Related to the Merger</span></a></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">153</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#EQUITYCOMPENSATIONPLANINFORMATION_273176"><span style="font-style:normal;font-weight:normal;">Equity Compensation Plan Information</span></a></p></td><td style="vertical-align:bottom;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">156</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#JADEEXECUTIVECOMPENSATION_402680"><span style="font-style:normal;font-weight:normal;">Jade Executive Compensation</span></a></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">157</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#JADEDIRECTORCOMPENSATION_571938"><span style="font-style:normal;font-weight:normal;">Jade Director Compensation</span></a></p></td><td style="vertical-align:bottom;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">159</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#MATTERSBEINGSUBMITTEDTOAVOTEOFAEROVATEST"><span style="font-style:normal;font-weight:normal;">Matters Being Submitted to a Vote of Aerovate Stockholders</span></a></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">160</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#PROPOSALNO1THENASDAQSTOCKISSUANCEPROPOSA"><span style="font-style:normal;font-weight:normal;">PROPOSAL NO. 1 &#8211; THE NASDAQ STOCK ISSUANCE PROPOSAL</span></a></p></td><td style="vertical-align:bottom;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">160</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#PROPOSALNO2THEREVERSESTOCKSPLITPROPOSAL_"><span style="font-style:normal;font-weight:normal;">PROPOSAL NO. 2 &#8211; THE REVERSE STOCK SPLIT PROPOSAL</span></a></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">162</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#PROPOSALNO3THEAUTHORIZEDSHAREINCREASEPRO"><span style="font-style:normal;font-weight:normal;">PROPOSAL NO. 3 &#8211; THE AUTHORIZED SHARE INCREASE PROPOSAL</span></a></p></td><td style="vertical-align:bottom;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">168</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#PROPOSALNO4THEREDOMESTICATIONPROPOSAL_92"><span style="font-style:normal;font-weight:normal;">PROPOSAL NO. 4 &#8211; THE REDOMESTICATION PROPOSAL</span></a></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">170</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#PROPOSALNO5THESTOCKPLANPROPOSAL_567099"><span style="font-style:normal;font-weight:normal;">PROPOSAL NO. 5 &#8211; THE STOCK PLAN PROPOSAL</span></a></p></td><td style="vertical-align:bottom;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">193</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#PROPOSALNO6THEESPPPROPOSAL_545692"><span style="font-style:normal;font-weight:normal;">PROPOSAL NO. 6 &#8211; THE ESPP PROPOSAL</span></a></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">197</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#PROPOSALNO7THEADJOURNMENTPROPOSAL_509679"><span style="font-style:normal;font-weight:normal;">PROPOSAL NO. 7 &#8211; THE ADJOURNMENT PROPOSAL</span></a></p></td><td style="vertical-align:bottom;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">201</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#AEROVATESBUSINESS_579799"><span style="font-style:normal;font-weight:normal;">Aerovate&#8217;s Business</span></a></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">202</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#JADESBUSINESS_86053"><span style="font-style:normal;font-weight:normal;">Jade&#8217;s Business</span></a></p></td><td style="vertical-align:bottom;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">225</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#AEROVATEMANAGEMENTSDISCUSSIONANDANALYSIS"><span style="font-style:normal;font-weight:normal;">Aerovate Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">269</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#QUANTITATIVEANDQUALITATIVEDISCLOSURESABO"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About the Market Risk of Ae</span><span style="font-style:normal;font-weight:normal;">rovate</span></a></p></td><td style="vertical-align:bottom;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">278</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#JADESMANAGEMENTSDISCUSSIONANDANALYSISOFF"><span style="font-style:normal;font-weight:normal;">Jade Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">279</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#MANAGEMENTFOLLOWINGTHEMERGER_152663"><span style="font-style:normal;font-weight:normal;">Management Following the Merger</span></a></p></td><td style="vertical-align:bottom;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">294</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#CERTAINRELATIONSHIPSANDRELATEDPARTYTRANS"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Party Transactions of the Combined Company</span></a></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">300</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#UNAUDITEDPROFORMACONDENSEDCOMBINEDFINANC"><span style="font-style:normal;font-weight:normal;">Unaudited Pro Forma Condensed Combined Financial Information</span></a></p></td><td style="vertical-align:bottom;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">305</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#NOTESTOUNAUDITEDPROFORMACONDENSEDCOMBINE"><span style="font-style:normal;font-weight:normal;">Notes to Unaudited Pro Forma Condensed Combined Financial Information</span></a></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">310</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#DESCRIPTIONOFAEROVATECAPITALSTOCK_252931"><span style="font-style:normal;font-weight:normal;">Description of Aerovate Capital Stock</span></a></p></td><td style="vertical-align:bottom;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">317</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#COMPARISONOFRIGHTSOFHOLDERSOFAEROVATECAP"><span style="font-style:normal;font-weight:normal;">Comparison of Rights of Holders of Aerovate Capital Stock and Jade Capital Stock</span></a></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">321</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#PRINCIPALSTOCKHOLDERSOFAEROVATE_338001"><span style="font-style:normal;font-weight:normal;">Principal Stockholders of Aerovate</span></a></p></td><td style="vertical-align:bottom;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">330</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#PRINCIPALSTOCKHOLDERSOFJADE_445448"><span style="font-style:normal;font-weight:normal;">Principal Stockholders of Jade</span></a></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">332</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#PRINCIPALSTOCKHOLDERSOFTHECOMBINEDCOMPAN"><span style="font-style:normal;font-weight:normal;">Principal Stockholders of the Combined Company</span></a></p></td><td style="vertical-align:bottom;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">334</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#LEGALMATTERS_385782"><span style="font-style:normal;font-weight:normal;">Legal Matters</span></a></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">336</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#EXPERTS_704648"><span style="font-style:normal;font-weight:normal;">Experts</span></a></p></td><td style="vertical-align:bottom;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">336</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#WHEREYOUCANFINDMOREINFORMATION_104067"><span style="font-style:normal;font-weight:normal;">Where You Can Find More Information</span></a></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">336</p></td></tr><tr><td style="vertical-align:bottom;width:93.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#OTHERMATTERS_255176"><span style="font-style:normal;font-weight:normal;">Other Matters</span></a></p></td><td style="vertical-align:bottom;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 2pt 0pt;">337</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">ii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:10.35pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#INDEXTOFINANCIALSTATEMENTS_141952"><span style="font-style:normal;font-weight:normal;">Index to Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-1</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ANNEXA"><span style="font-style:normal;font-weight:normal;">Annex A: Agreement and Plan of Merger</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-1</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ANNEXB_419735"><span style="font-style:normal;font-weight:normal;">Annex B: Form of Amendment for the Aerovate Charter (Reverse Stock Split)</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">B-1</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ANNEXC_115424"><span style="font-style:normal;font-weight:normal;">Annex C: Form of Amendment for the Aerovate Charter (Authorized Share Increase)</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">C-1</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ANNEXD_143895"><span style="font-style:normal;font-weight:normal;">Annex D: Plan of Conversion*</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">D-1</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ANNEXE_874079"><span style="font-style:normal;font-weight:normal;">Annex E: Resolutions of the Board of Directors of Jade for the Nevada Redomesication*</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">E-1</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ANNEXF_328548"><span style="font-style:normal;font-weight:normal;">Annex F: Lucid Capital Markets LLC Fairness Opinion</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-1</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ANNEXG_706122"><span style="font-style:normal;font-weight:normal;">Annex G: Appraisal Rights (Section 262 of the Delaware General Corporate Law)</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">G-1</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ANNEXH_655067"><span style="font-style:normal;font-weight:normal;">Annex H: Form of Lock-Up Agreement</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">H-1</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ANNEXI_908298"><span style="font-style:normal;font-weight:normal;">Annex I: Form of Jade Biosciences, Inc. 2025 Stock Incentive Plan*</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">I-1</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ANNEXJ_562775"><span style="font-style:normal;font-weight:normal;">Annex J: Form of Jade Biosciences, Inc. 2025 Employee Stock Purchase Plan*</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">J-1</p></td></tr><tr style="height:9pt;"><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ANNEXK_308832"><span style="font-style:normal;font-weight:normal;">Annex K: Delaware Certificate of Designation</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">K-1</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ANNEXL_412267"><span style="font-style:normal;font-weight:normal;">Annex L: Nevada Certificate of Designation*</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">L-1</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ANNEXM_944480"><span style="font-style:normal;font-weight:normal;">Annex M: Securities Purchase Agreement</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">M-1</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ANNEXN_545330"><span style="font-style:normal;font-weight:normal;">Annex N: Form of Aerovate Stockholder Support Agreement</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">N-1</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ANNEXO_872350"><span style="font-style:normal;font-weight:normal;">Annex O: Form of Jade Stockholder Support Agreement</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">O-1</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ANNEXP_209392"><span style="font-style:normal;font-weight:normal;">Annex P: Form of Aerovate Therapeutics, Inc. Proxy Card*</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">P-1</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.27em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">*&#160;&#160;&#160;&#160;&#160;To be filed by amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">iii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_d7508df4_d931_4a2d_b59d_f7a276970563"></a><a id="QUESTIONSANDANSWERSABOUTTHEMERGER_259040"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">QUESTIONS AND ANSWERS ABOUT THE MERGER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split described in Proposal No.&#160;2 of this proxy statement/prospectus.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following section provides answers to frequently asked questions about the Merger. This section, however, provides only summary information. For a more complete response to these questions and for additional information, please refer to the cross-referenced sections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">What is the Merger?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">On October&#160;30, 2024, Aerovate, Jade, Merger Sub I and Merger Sub II entered into the Merger Agreement, a copy of which is attached to this proxy statement/prospectus as </span><i style="color:#231f20;font-style:italic;">Annex A</i><span style="color:#231f20;">. The Merger Agreement contains the terms and conditions of the proposed Merger. Pursuant to the Merger Agreement, Merger Sub I will merge with and into Jade, with Jade continuing as a wholly owned subsidiary of Aerovate and the surviving corporation of the First Merger. Jade will then merge with and into Merger Sub II, with Merger Sub II being the surviving entity of the Second Merger. This entire transaction is referred to in this proxy statement/prospectus as the &#8220;Merger.&#8221; In connection with the Merger, Aerovate will change its corporate name to &#8220;Jade Biosciences,&#160;Inc.&#8221;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="color:#231f20;font-weight:bold;">What will Jade securityholders receive in the Merger?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, (i)&#160;each then-outstanding share of Jade common stock (including shares of Jade common stock issued in the Jade Pre-Closing Financing) (excluding shares to be cancelled pursuant to the Merger Agreement and excluding dissenting shares) will be converted into the right to receive a number of shares of Aerovate common stock equal to the Exchange Ratio (described in more detail in the section titled &#8220;</span><i style="color:#231f20;font-style:italic;">The Merger Agreement&#160;&#8212; Exchange Ratio</i><span style="color:#231f20;">&#8221; beginning on page&#160;</span><span style="color:#231f20;">138</span><span style="color:#231f20;"> of this proxy statement/ prospectus), (ii)&#160;each then-outstanding share of Jade Series&#160;Seed Convertible Preferred Stock, par value </span>$0.0001 per share (&#8220;Jade Preferred Stock&#8221;), will be converted into the right to receive a number of shares of Aerovate Series&#160;A Non-Voting Convertible Preferred Stock (the &#8220;Aerovate Series&#160;A Preferred Stock&#8221;), which are each convertible into 1,000 shares of Aerovate common stock, equal to the Exchange Ratio divided by 1,000, in accordance with the terms of the Merger Agreement, (iii)&#160;each then- outstanding option to purchase Jade common stock will be assumed by Aerovate and converted into an option to purchase shares of Aerovate common stock, subject to adjustment as set forth in the Merger Agreement, and (iv)&#160;each then-outstanding pre-funded warrant to purchase shares of Jade common stock will be converted into a pre-funded warrant to purchase shares of Aerovate common stock, subject to adjustment as set forth in the Merger Agreement and the form of pre-funded warrant.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">For a more complete description of the treatment of Jade securities in the Merger, please see the sections titled &#8220;<i style="font-style:italic;">The Merger Agreement&#160;&#8212; Merger Consideration</i>,&#8221; and &#8220;<i style="font-style:italic;">The Merger Agreement&#160;&#8212; Exchange Ratio</i>&#8221; beginning on pages&#160;137 and 138, respectively, of this proxy statement/prospectus. For a description of the effect of the Jade Pre-Closing Financing on Jade&#8217;s current securityholders, please see the section titled &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#160;&#8212; Subscription Agreement</i>&#8221; beginning on page&#160;153 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">What will Aerovate securityholders receive in the Merger?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Each share of Aerovate common stock that is issued and outstanding at the effective time of the Merger will remain issued and outstanding and such shares, subject to the proposed reverse stock split, will be unaffected by the Merger. Each option to acquire shares of Aerovate&#8217;s common stock with an exercise price less than or equal to the Aerovate Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (A)&#160;the excess of the Aerovate Closing Price over the exercise price per share of Aerovate common stock underlying such Aerovate option by (B)&#160;the number of shares of Aerovate common stock underlying such Aerovate option, and each other option to acquire shares of Aerovate&#8217;s common stock will be cancelled for no consideration. Immediately after the Merger, </span>Aerovate securityholders as of immediately prior to the Merger are expected to own approximately 1.6% of the outstanding shares of the Combined Company on a fully-diluted basis, former Jade securityholders, excluding shares purchased in the Jade Pre-Closing Financing, are expected to own approximately 34.0% of the outstanding shares of the Combined Company on a fully-diluted basis, and shares and pre-funded warrants issued in the Jade Pre-Closing Financing are expected to represent approximately 64.4% of the outstanding shares of capital stock of the Combined Company on a fully- diluted basis, subject to certain assumptions, including, but not limited to, Aerovate&#8217;s Net Cash as of Closing being approximately $0.</p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">In addition, prior to the First Effective Time, Aerovate&#8217;s board of directors expects to declare the Cash Dividend to stockholders of record of outstanding shares of Aerovate common stock as of the record date prior to the First Effective Time, to be set by Aerovate&#8217;s board of directors as close as reasonably practicable to (but not later than) the First Effective Time. The ex-dividend date in respect of such Cash Dividend will be determined by Nasdaq. Aerovate stockholders of record who continue to hold their eligible shares of Aerovate common stock until market open on the ex-dividend date will be entitled to payment of the Cash Dividend. The Cash Dividend will be equal in the aggregate to Aerovate&#8217;s reasonable, good faith approximation of the amount by which Aerovate&#8217;s Net Cash (as determined pursuant to the Merger Agreement) is expected to exceed $0. Aerovate currently estimates that the aggregate amount of cash to be distributed to stockholders of record as of the record date for the Cash Dividend will be approximately $65.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">For a more complete description of the treatment of Aerovate securities in the Merger, please see the sections titled &#8220;<i style="font-style:italic;">The Merger Agreement&#160;&#8212; Merger Consideration</i>,&#8221; &#8220;<i style="font-style:italic;">The Merger Agreement&#160;&#8212; Exchange Ratio</i>,&#8221; and &#8220;<i style="font-style:italic;">Market Price and Dividend Information</i>&#8221; beginning on pages&#160;137, 138 and 23, respectively, of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">Why are the two companies proposing to merge?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Aerovate and Jade believe that combining the two companies will result in a company focused on developing biologics designed to optimize the treatment of autoimmune diseases with a strong leadership team and substantial capital resources. For a more complete description of the reasons for the Merger, please see the sections titled &#8220;</span><i style="color:#231f20;font-style:italic;">The Merger&#160;&#8212; Aerovate&#8217;s Reasons for the Merger</i><span style="color:#231f20;">&#8221; and &#8220;</span><i style="color:#231f20;font-style:italic;">The Merger&#160;&#8212; Jade&#8217;s Reasons for the Merger</i><span style="color:#231f20;">&#8221; beginning on pages&#160;</span><span style="color:#231f20;">108</span><span style="color:#231f20;"> and </span><span style="color:#231f20;">112</span><span style="color:#231f20;">, respectively, of this proxy statement/ prospectus.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="color:#231f20;font-weight:bold;">What will happen to Aerovate if, for any reason, the Merger with Jade does not close?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Aerovate has invested significant time and incurred, and expects to continue to incur, significant expenses related to the proposed Merger with Jade. In the event the Merger does not close, Aerovate will have a limited ability to continue its current operations indefinitely. Although Aerovate&#8217;s board of directors may elect, among other things, to attempt to complete another strategic transaction if the Merger with Jade does not close, Aerovate&#8217;s board of directors may instead take steps necessary to liquidate or dissolve Aerovate&#8217;s business and assets if a viable alternative strategic transaction is not available. If Aerovate decides to dissolve and liquidate its assets, Aerovate would be required to pay all of its contractual obligations, and to set aside certain reserves for potential future claims, and there can be no assurance as to the amount of and the timing of such liquidation and distribution of available </span>cash left to distribute to stockholders after paying the obligations of Aerovate and setting aside funds for reserves.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">Why am I receiving this proxy statement/prospectus?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">You are receiving this proxy statement/prospectus because you have been identified as a stockholder of Aerovate and/or Jade as of the applicable record date, and you are entitled to vote to approve the matters set forth herein. This document serves as:</span></p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a proxy statement of Aerovate used to solicit proxies for the Aerovate Special Meeting to vote on the matters set forth herein; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a prospectus of Aerovate used to offer (i)&#160;shares of Aerovate common stock issued in exchange for shares of Jade common stock (including shares of Jade common stock issued in the Jade Pre-Closing Financing), (ii)&#160;shares of Aerovate common stock issuable upon exercise of pre-funded warrants issued in exchange for pre-funded warrants to purchase shares of Jade common stock sold in the Jade Pre-Closing Financing, and (iii)&#160;shares of Aerovate common stock issuable upon conversion of Aerovate Series&#160;A Preferred Stock issued in exchange for shares of Jade Preferred Stock in the Merger.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="color:#231f20;font-weight:bold;">What is the Jade Pre-Closing Financing?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="color:#231f20;">On October&#160;30, 2024, concurrently with the execution and delivery of the Merger Agreement, Jade entered into the Securities Purchase Agreement with certain investors named therein, including, among others, Fairmount, Venrock Healthcare Capital Partners, and a large investment firm, with participation from Deep Track Capital, Braidwell LP, Driehaus Capital Management, Frazier Life Sciences, RA Capital Management, Great Point Partners, Soleus Capital, Avidity Partners, Blackstone Multi-Asset Investing, Logos Capital, Deerfield Management, OrbiMed, and Samsara BioCapital, pursuant to which such investors agreed to purchase shares of Jade common stock and pre-funded warrants to purchase shares of </span>Jade common stock for an aggregate purchase price of approximately $300.0 million (which reflects the conversion of the previously issued $95 million of convertible </p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">notes). Shares of Jade common stock and pre-funded warrants issued pursuant to this financing transaction will be converted into shares of Aerovate common stock and pre-funded warrants to acquire shares of Aerovate common stock, in accordance with the Exchange Ratio and the Merger Agreement. Aerovate shareholders should not consider investments made by Jade&#8217;s existing investors as a factor when making a decision on how to vote on the proposals in this proxy statement/prospectus, since Jade&#8217;s existing investors may have had different risk tolerances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Immediately after the Merger, the shares of Jade common stock and Jade pre-funded warrants issued in the Jade Pre-Closing Financing are expected to represent approximately 64.4% of the outstanding shares of common stock of the Combined Company. Aerovate, Jade and the investors participating in the Jade Pre-Closing Financing have also agreed to enter into a registration rights agreement at the closing of the Jade Pre-Closing Financing, pursuant to which, among other things, the Combined Company will agree to provide for the registration and resale of certain shares of Aerovate common stock that are held by the investors participating in the Jade Pre-Closing Financing from time to time pursuant to Rule&#160;415. The closing of the Jade Pre-Closing Financing is conditioned upon the satisfaction or waiver of the conditions to the Closing as well as certain other conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">For a more complete description of the Jade Pre-Closing Financing, please see the sections titled &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#160;&#8212; Subscription Agreement</i>&#8221; and &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#160;&#8212; Registration Rights Agreement</i>&#8221; beginning on pages&#160;153 and 155 of this proxy statement/ prospectus, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="color:#231f20;font-weight:bold;">What proposals will be voted on at the Aerovate Special Meeting in connection with the Merger?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Pursuant to the terms of the Merger Agreement, the following proposals must be approved by the requisite stockholder vote at the Aerovate Special Meeting in order for the Merger to close (the &#8220;Merger Proposals&#8221;):</span></p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Proposal No.&#160;1&#160;&#8212; The Nasdaq Stock Issuance Proposal </b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to approve (i)&#160;the issuance of shares of common stock of Aerovate (including the shares of Aerovate common stock issuable upon conversion of the Aerovate Series&#160;A Preferred Stock), which will represent more than 20% of the shares of Aerovate common stock outstanding immediately prior to the Merger, to stockholders of Jade, pursuant to the terms of the Merger Agreement, a copy of which is attached as </span><i style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Annex A </i><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to the accompanying proxy statement/prospectus, and (ii)&#160;the change of control resulting from the Merger, pursuant to Nasdaq Listing Rules&#160;5635(a)&#160;and 5635(b), respectively;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Proposal No.&#160;2&#160;&#8212; The Reverse Stock Split Proposal </b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to approve an amendment to the amended and restated certificate of incorporation of Aerovate to effect a reverse stock split of Aerovate&#8217;s issued and outstanding common stock at a ratio determined by the Aerovate board of directors and agreed to by Jade, of one new share of Aerovate common stock for every&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;shares (or any number </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in between) of outstanding Aerovate common stock in the form attached as </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Annex B </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to the accompanying proxy statement/prospectus; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Proposal No.&#160;3&#160;&#8212;</b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">The Authorized Share Increase Proposal </b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to approve an amendment to the amended and restated certificate of incorporation of Aerovate to increase the number of shares of Aerovate common stock that Aerovate is authorized to issue from 150,000,000 to , in the form attached as </span><i style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Annex C </i><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to this proxy statement/prospectus.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Approval of each of Proposal Nos. 1, 2 and 3 is a condition to completion of the Merger. The issuance of Aerovate common stock, including shares of common stock issuable upon conversion of Aerovate Series&#160;A Preferred Stock, in connection with the Merger and the change of control resulting from the Merger will not take place unless Proposal No.&#160;1 is approved by Aerovate stockholders and the Merger is consummated. The amendment to the amended and restated certificate of incorporation of Aerovate to effect a reverse stock split of Aerovate&#8217;s issued and outstanding common stock will not take place unless Proposal No.&#160;2 is approved by the requisite Aerovate stockholders and the Merger is consummated. The amendment to the amended and restated certificate of incorporation of Aerovate to increase the number of authorized shares of Aerovate common stock will not take place unless Proposal No.&#160;3 is approved by the requisite Aerovate stockholders and the Merger is consummated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">In addition to the requirement of obtaining Aerovate stockholder approval, the Closing is subject to the satisfaction or waiver of each of the other closing conditions set forth in the Merger Agreement. For a more complete description of the closing conditions under the Merger Agreement, please see the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#160;&#8212; Conditions to the Completion of the Merger</i>&#8221; beginning on page&#160;149 of this proxy statement/prospectus.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">The presence, in person or being represented by proxy, at the Aerovate Special Meeting of the holders of a majority of the shares of Aerovate common stock outstanding and entitled to vote at the Aerovate Special Meeting is necessary to constitute a quorum at the meeting for the purpose of approving the Merger Proposals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="color:#231f20;font-weight:bold;">What proposals are to be voted on at the Aerovate Special Meeting, other than the Merger Proposals?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">At the Aerovate Special Meeting, the holders of Aerovate common stock will also be asked to consider the following proposals:</span></p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Proposal No.&#160;4&#160;&#8212; The Redomestication Proposal </b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to approve the redomestication of Aerovate from the State of Delaware to the State of Nevada by conversion (the &#8220;Nevada Redomestication&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Proposal No.&#160;5&#160;&#8212; The Stock Plan Proposal </b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to approve the Jade Biosciences,&#160;Inc. 2025 Stock Incentive Plan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Proposal No.&#160;6&#160;&#8212; The ESPP Proposal </b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to approve the Jade Biosciences,&#160;Inc. 2025 Employee Stock Purchase Plan; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Proposal No.&#160;7&#160;&#8212; The Adjournment Proposal </b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to approve an adjournment of the Aerovate Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 1, 2 and 3.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">The approvals of Proposal Nos. 4, 5, 6 and 7 are not conditions to the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">The presence, in person or being represented by proxy, at the Aerovate Special Meeting of the holders of a majority of the shares of Aerovate common stock outstanding and entitled to vote at the Aerovate Special Meeting is necessary to constitute a quorum at the meeting for the purpose of approving the proposals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="color:#231f20;font-weight:bold;">What stockholder votes are required to approve the proposals at the Aerovate Special Meeting?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">The affirmative vote of a majority of votes properly cast at the Aerovate Special Meeting, assuming a quorum is present, is required for approval of Proposal Nos. 1, 5, 6, and 7. The affirmative vote of the </span>holders of a majority of the outstanding shares of Aerovate common stock entitled to vote thereon is required for approval of Proposal Nos. 2, 3 and 4.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Votes will be counted by the inspector of election appointed for the meeting, who will separately count &#8220;FOR&#8221; and &#8220;AGAINST&#8221; votes, abstentions and broker non-votes. Abstentions and broker non-votes, if any, will not be treated as shares present for the purpose of determining the presence of a quorum for the transaction of business at the special meeting. Abstentions and broker non-votes, if any, will have no effect on Proposal Nos. 1, 5, 6 and 7 and will have the effect of a vote &#8220;AGAINST&#8221; Proposal Nos. 2, 3 and 4.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="color:#231f20;font-weight:bold;">Why is Aerovate seeking stockholder approval to issue shares of Aerovate common stock to existing stockholders of Jade in the Merger?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="color:#231f20;">Because the Aerovate common stock is listed on Nasdaq, Aerovate is subject to the Nasdaq rules. Nasdaq Listing Rule&#160;5635(a)&#160;requires stockholder approval with respect to the issuance of Aerovate common stock when, among other instances, (i)&#160;the shares to be issued are being issued in connection with the acquisition of the stock or assets of another company and are equal to 20% or more of the outstanding shares of Aerovate common stock before the issuance and (ii)&#160;any director, officer or &#8220;Substantial Shareholder&#8221; (as defined by Nasdaq Listing Rule&#160;5635(e)(3)) of such company has a 5% or greater interest (or such persons collectively have a 10% or greater interest), directly or indirectly, in the company to be acquired or in the consideration to be paid in the transaction and the issuance of common stock could result in an increase in outstanding common shares or voting power of 5% or more. Nasdaq Listing Rule&#160;5635(b)&#160;also requires stockholder approval when any issuance or potential issuance will result in a &#8220;change of control&#8221; of the issuer. Although Nasdaq has not adopted any rule&#160;on what constitutes a &#8220;change of control&#8221; for purposes of Rule&#160;5635(b), Nasdaq has previously indicated that the acquisition of, or right to acquire, by a single investor or affiliated investor group, as little as 20% of the common stock (or securities convertible into or exercisable for common stock) or voting power of an issuer could constitute a change of control. Nasdaq will consider all facts and circumstances concerning a transaction, including whether there are any other relationships or agreements between the company and the investor or group. Nasdaq Listing Rule&#160;5635(d)&#160;also requires stockholder approval for a transaction other than a public offering involving the sale, issuance or potential issuance by an issuer of common equity securities (or securities convertible into or exercisable for </span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="color:#231f20;">common equity securities) at a price that is less than market value of the stock if the number of equity securities to be issued is or may equal to 20% or more of the common equity securities, or 20% or more of the voting power, outstanding before the issuance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">In the case of the Merger, Aerovate expects to issue approximately 1.06 million shares of Aerovate common stock, excluding shares of Aerovate common stock underlying the Jade pre-funded warrants and shares of Jade Preferred Stock to be exchanged for Aerovate pre-funded warrants and shares of Aerovate Series&#160;A Preferred Stock, respectively, and Aerovate common stock to be issued pursuant to the Merger Agreement (including the shares issued to investors in the Jade Pre-Closing Financing) will represent greater than 20% of its voting stock outstanding before the issuance. Accordingly, Aerovate is seeking stockholder approval of the issuance pursuant to the Merger Agreement and the Jade Pre- Closing Financing under the Nasdaq rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">Will the common stock of the Combined Company trade on an exchange?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Shares of Aerovate common stock are currently listed on Nasdaq under the symbol &#8220;AVTE.&#8221; Aerovate intends to file an initial listing application for the common stock of the Combined Company with Nasdaq. After completion of the Merger, Aerovate will be renamed &#8220;Jade Biosciences,&#160;Inc.&#8221; and it is expected that the common stock of the Combined Company will trade on Nasdaq under the symbol &#8220;JBIO.&#8221; It is a condition to the consummation of the Merger that Aerovate will receive confirmation from Nasdaq that the Combined Company has been approved for listing on Nasdaq, but there can be no assurance such listing condition will be met or that Aerovate will obtain such confirmation from Nasdaq. If such listing condition is not met or if such confirmation is not obtained, the Merger will not be consummated unless the condition is waived. The Nasdaq condition set forth in the Merger Agreement is not expected to be waived by the applicable parties.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">On November&#160;29, 2024 the last trading day before the date of this proxy statement/prospectus, the closing sale price of Aerovate common stock was $2.63 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">Who will be the directors of the Combined Company following the Merger?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Immediately following the Merger, the Combined Company&#8217;s board of directors will be composed of six (6)&#160;members, all of whom have been designated by Jade. Effective as of the First Effective Time, Aerovate&#8217;s board of directors will appoint the following Jade designees: Tom Frohlich, Chris Cain, Eric Dobmeier, Lawrence Klein, Tomas Kiselak and Erin Lavelle, to the board of directors of the Combined Company and concurrently therewith, all of Aerovate&#8217;s current directors will resign from their positions as directors of Aerovate&#8217;s board of directors. Mr.&#160;Dobmeier is expected to be appointed as Chair of </span>the board of directors of the Combined Company. The staggered structure of the Aerovate board of directors will remain in place for the Combined Company following the completion of the Merger. For additional information, please see the section titled &#8220;<i style="font-style:italic;">Management Following the Merger</i>&#8221; beginning on page&#160;294 of this proxy statement/prospectus.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="color:#231f20;font-weight:bold;">Who will be the executive officers of the Combined Company immediately following the Merger?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Immediately following the Merger, the executive management team of the Combined Company is expected to consist of members of the Jade executive management team prior to the Merger, including:</span></p></td></tr></table><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr><td style="vertical-align:bottom;width:46.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:50.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tom Frohlich</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer and Director</p></td></tr><tr><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jonathan Quick</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President, Finance and Treasurer</p></td></tr><tr><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Andrew King, BVMS, Ph.D.</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Scientific Officer &amp; Head of Research and Development</p></td></tr><tr><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hetal Kocinsky, M.D.</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Medical Officer</p></td></tr><tr><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Elizabeth Balta, J.D.</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General Counsel and Corporate Secretary</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">As an Aerovate stockholder, how does Aerovate&#8217;s board of directors recommend that I vote?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Aerovate&#8217;s board of directors, in consultation with financial and legal advisors and management, evaluated the terms of the Merger Agreement and the related transactions contemplated thereby and: (i)&#160;determined that the Merger and the related transactions contemplated by the Merger Agreement are fair to, advisable and in the best interests of Aerovate and its stockholders; (ii)&#160;approved and declared advisable the Merger Agreement and the related transactions contemplated by the Merger Agreement and the Subscription Agreement, including the issuance of shares of Aerovate common stock, including shares of Aerovate common stock issuable upon conversion of Aerovate Series&#160;A Preferred Stock, in connection with the Merger and the Jade Pre-Closing Financing, respectively; and (iii) recommends that Aerovate&#8217;s stockholders vote &#8220;FOR&#8221; each of the Proposals.</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="color:#231f20;font-weight:bold;">What risks should I consider in deciding whether to vote in favor of the Merger?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">You should carefully review the section titled &#8220;</span><i style="color:#231f20;font-style:italic;">Risk Factors</i><span style="color:#231f20;">&#8221; beginning on page&#160;</span><span style="color:#231f20;">24</span><span style="color:#231f20;"> of this proxy statement/ prospectus and the documents incorporated by reference herein, which set forth certain risks and uncertainties related to the Merger, risks and uncertainties to which the Combined Company&#8217;s business will be subject, and risks and uncertainties to which each of Aerovate and Jade, as independent companies, are subject.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="color:#231f20;font-weight:bold;">When do you expect the Merger to be consummated?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">The Merger is anticipated to close in the first half of 2025, but the exact timing cannot be predicted. </span>For more information, please see the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#160;&#8212; Conditions to the Completion of the Merger</i>&#8221; beginning on page&#160;149 of this proxy statement/prospectus.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">Why is Aerovate seeking approval for the Nevada Redomestication?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A</b><span style="color:#231f20;">:</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">The Aerovate and Jade boards of directors believe that there are several reasons why the Nevada Redomestication is in the best interests of Aerovate and Aerovate&#8217;s stockholders. First, the Nevada Redomestication will eliminate the Combined Company&#8217;s obligation to pay the annual Delaware franchise tax, which Aerovate and Jade expect will result in substantial savings to the Combined Company over the long term. In addition, the Nevada Redomestication may help the Combined Company attract and retain qualified management by reducing the risk of lawsuits being filed against the Combined Company and its directors and officers. Aerovate and Jade believe that for the reasons described in this proxy statement/prospectus, in general, Nevada law will provide greater protection to the Combined Company and its directors and officers than Delaware law. The Aerovate board of directors believes that the Nevada Redomestication will give the Combined Company more flexibility and predictability in various corporation transactions. The Nevada Redomestication must receive a &#8220;FOR&#8221; vote from a majority of the outstanding shares of Aerovate common stock entitled to vote thereon in order to pass.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">How will the Nevada Redomestication affect the rights of Combined Company stockholders?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Your rights as a stockholder currently are governed by Delaware law and the provisions of the amended and restated certificate of incorporation of Aerovate, and Aerovate&#8217;s amended and restated bylaws. As a result of the Nevada Redomestication, you will become a stockholder of the Combined Company with rights governed by Nevada law and the provisions of the articles of incorporation and the bylaws of the Combined Company, which differ in certain respects from your current rights. These important differences are discussed and summarized in this proxy statement/prospectus under &#8220;</span><i style="color:#231f20;font-style:italic;">Proposal No. 4 &#8212; The Redomestication Proposal &#8212; Effects of the Nevada Redomestication &#8212; Comparison of Rights of Holders of the Delaware Corporation Capital Stock and the Nevada Corporation Capital Stock&#8221;</i><span style="color:#231f20;"> beginning on page </span><span style="color:#231f20;">172</span><span style="color:#231f20;"> of this proxy statement/prospectus. Forms of the Combined Company&#8217;s articles of association and bylaws are available as exhibits to this proxy statement/ prospectus.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="color:#231f20;font-weight:bold;">What are the U.S. federal income tax considerations of the Nevada Redomestication to the Combined Company stockholders?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Subject to the limitations and qualifications described in the section titled &#8220;</span><i style="color:#231f20;font-style:italic;">Proposal No. 4 &#8212; The Redomestication Proposal &#8212; U.S. Federal Income Tax Considerations of the Nevada Redomestication</i><span style="color:#231f20;">&#8221; beginning on page </span><span style="color:#231f20;">189</span><span style="color:#231f20;"> of this proxy statement/prospectus, Aerovate intends that the Nevada Redomestication qualify as a &#8220;reorganization&#8221; within the meaning of Section 368(a) of the Code. Assuming the Nevada Redomestication so qualifies, a U.S. Holder (as defined therein) of Aerovate stock (as defined therein) will not recognize gain or loss upon the Nevada Redomestication. For a more detailed discussion of the U.S. federal income tax considerations of the Nevada Redomestication, see the section titled &#8220;</span><i style="color:#231f20;font-style:italic;">Proposal No. 4 &#8212; The Redomestication Proposal &#8212; U.S. Federal Income Tax Considerations of the Nevada Redomestication</i><span style="color:#231f20;">&#8221; beginning on page </span><span style="color:#231f20;">189</span><span style="color:#231f20;"> of this proxy statement/prospectus.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">What</b><b style="color:#231f20;font-weight:bold;"> do I need to do now?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Aerovate urges you to read this proxy statement/prospectus carefully, including the annexes and the documents incorporated by reference, and to consider how the Merger affects you.</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Stockholder of Record: Shares Registered in Your Name</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">If you are a stockholder of record, you may vote in person at the Aerovate Special Meeting, vote by proxy over the telephone, vote by proxy through the Internet or vote by proxy using a proxy card, the form of which is attached as <i style="font-style:italic;">Annex P</i>. Whether or not you plan to attend the meeting, we urge you to vote by proxy to ensure your vote is counted. You may still attend the meeting and vote in person even if you have already voted by proxy.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To vote in person, come to the special meeting and we will give you a ballot when you arrive.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To vote using the proxy card, simply complete, sign and date the proxy card that you may request or that we may elect to deliver at a later time and return it promptly in the envelope provided. If you return your signed proxy card to us before the special meeting, we will vote your shares as you direct.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To vote over the telephone, dial toll-free&#160;&#160;&#160;&#160;using a touch-tone phone and follow the recorded instructions. You will be asked to provide the company number and control number found on the proxy card. Your vote must be received by 11:59&#160;p.m. Eastern Time on&#160;&#160;&#160;&#160;&#160;to be counted.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To vote through the Internet, go to&#160;&#160;&#160;&#160;&#160;to complete an electronic proxy card. You will be asked to provide the company number and control number from the proxy card. Your vote must be received by 11:59&#160;p.m. Eastern Time on&#160;&#160;&#160;&#160;&#160;, 2025 to be counted.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Beneficial Owner: Shares Registered in the Name of Broker, Bank or Other Agent</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">If you are a beneficial owner of shares registered in the name of your broker, bank, or other agent, you should have received voting instructions from that organization rather than from Aerovate. Simply follow the voting instructions provided to ensure that your vote is counted. You may vote by telephone or over the Internet as instructed by your broker, bank or other agent. To vote in person at the Aerovate Special Meeting, you must contact your broker, bank, or other agent and obtain a valid legal proxy in order to attend, participate in and vote at the Aerovate Special Meeting. Follow the voting instructions from your broker, bank or other agent, or contact your broker, bank or other agent for instructions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="color:#231f20;font-weight:bold;">What happens if I do not return a proxy card or otherwise vote or provide proxy instructions, as applicable?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">If you are an Aerovate stockholder, the failure to return your proxy card or otherwise vote or provide proxy instructions will reduce the aggregate number of votes required to approve Proposal Nos. 1, 5, 6 and 7 and will have the effect of a vote &#8220;AGAINST&#8221; Proposal Nos. 2, 3 and 4.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="color:#231f20;font-weight:bold;">May&#160;I attend the Aerovate Special Meeting and vote in person?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Stockholders of record as of&#160;&#160;&#160;&#160;&#160;will be able to attend and participate in the Aerovate Special Meeting in person.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="color:#231f20;font-weight:bold;">Who counts the votes?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Computershare has been engaged as Aerovate&#8217;s independent agent to tabulate stockholder votes, which Aerovate refers to as the inspector of election. If you are a stockholder of record, your executed </span>proxy card is returned directly to Computershare for tabulation. If you hold your shares through a broker, your broker returns one proxy card to Computershare on behalf of all its clients.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="color:#231f20;font-weight:bold;">If my Aerovate shares are held in &#8220;street name&#8221; by my broker, will my broker vote my shares for me?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A</b><span style="color:#231f20;">:</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">If you hold shares beneficially in street name and you do not instruct your broker, bank or other agent how to vote your shares, your broker, bank or other agent will only be able to vote your shares with respect to proposals considered to be &#8220;routine.&#8221; Your broker, bank or other agent is not entitled to vote your shares with respect to &#8220;non-routine&#8221; proposals, resulting in a &#8220;broker non-vote&#8221; with respect to such proposals. Accordingly, if you hold your shares beneficially in street name please be sure to instruct your broker, bank or other agent how to vote to ensure that your vote is counted on each of the proposals, following the procedures provided by your broker, bank or other agent.</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="color:#231f20;font-weight:bold;">What are broker non-votes and do they count for determining a quorum?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Generally, a &#8220;broker non-vote&#8221; occurs when shares held by a broker are not voted with respect to a particular proposal because the broker has not received voting instructions from its clients with respect to such shares on how to vote and does not have or did not exercise discretionary authority to vote </span>on the matter.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Broker non-votes, if any, will not be treated as shares present for the purpose of determining the presence of a quorum for the transaction of business at the Aerovate Special Meeting. Broker non- votes, if any, will not be counted as &#8220;votes properly cast&#8221; or &#8220;shares entitled to vote&#8221; and will therefore have no effect on Proposal Nos. 1, 5, 6 and 7 and will have the effect of a vote &#8220;AGAINST&#8221; Proposal Nos. 2, 3 and 4.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="color:#231f20;font-weight:bold;">May&#160;I revoke and/or change my vote after I have submitted a proxy or provided proxy instructions?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Aerovate stockholders of record, unless such stockholder&#8217;s vote is subject to a support agreement, may revoke and/or change their vote at any time before their proxy is voted at the Aerovate Special Meeting in one of four ways:</span></p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">You may submit another properly completed proxy with a later date by mail or via the internet.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">You can provide your proxy instructions via telephone at a later date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">You may send an instrument in writing revoking the proxy or another duly executed proxy bearing a later date to Aerovate&#8217;s corporate secretary. Any written notice of revocation or subsequent proxy card must be received by Aerovate&#8217;s corporate secretary prior to the taking of the vote at the Aerovate Special Meeting. Such written notice of revocation or subsequent proxy card should be sent to Aerovate&#8217;s principal executive offices at Aerovate Therapeutics,&#160;Inc., 930 Winter Street, Suite&#160;M-500, Waltham, Massachusetts 02451, Attention: Corporate Secretary.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">You may attend the Aerovate Special Meeting and vote in person, although attendance at the Aerovate Special Meeting will not, by itself, revoke and/or change your proxy.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Your signed proxy card, telephonic proxy instructions, internet proxy instructions, or written notice must be received by&#160;&#160;&#160;&#160;&#160;, 2025, 11:59&#160;p.m. Eastern Time to be counted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">If an Aerovate stockholder who owns Aerovate shares in &#8220;street name&#8221; has instructed a broker to vote its shares of Aerovate common stock, the stockholder must follow directions received from its broker to change and/or revoke those instructions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">Who is paying for this proxy solicitation?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Aerovate and Jade will share equally the cost of printing and filing of this proxy statement/prospectus and the proxy card. Arrangements will also be made with brokerage firms and other custodians, nominees and fiduciaries who are record holders of Aerovate common stock for the forwarding of solicitation materials to the beneficial owners of Aerovate common stock. Aerovate will reimburse these brokers, custodians, nominees and fiduciaries for the reasonable out-of-pocket expenses they incur in connection with the forwarding of solicitation materials.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="color:#231f20;font-weight:bold;">What are the material U.S. federal income tax considerations of the Merger to U.S. Holders of Aerovate capital stock?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Aerovate stockholders will not sell, exchange or dispose of any shares of Aerovate common stock as a result of the Merger. Thus, there will be no U.S. federal income tax considerations to Aerovate stockholders as a result of the Merger.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="color:#231f20;font-weight:bold;">What are the U.S. federal income tax considerations of the Merger to U.S. Holders of Jade capital stock?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="color:#231f20;">Subject to the limitations and qualifications described in the section titled &#8220;</span><i style="color:#231f20;font-style:italic;">The Merger&#160;&#8212; U.S. Federal Income Tax Considerations of the Merger</i><span style="color:#231f20;">&#8221; beginning on page&#160;</span><span style="color:#231f20;">130</span><span style="color:#231f20;"> of this proxy statement/prospectus, each of Jade and Aerovate intend that the Merger qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Code. Assuming the Merger so qualifies, a U.S. Holder of Jade stock (as defined therein) will not recognize gain or loss upon the exchange of its Jade stock for Aerovate stock. For a more detailed discussion of the U.S. federal income tax considerations of the Merger, please see the section titled </span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="color:#231f20;">&#8220;</span><i style="color:#231f20;font-style:italic;">The Merger&#160;&#8212; U.S. Federal Income Tax Considerations of the Merger</i><span style="color:#231f20;">&#8221; beginning on page&#160;</span><span style="color:#231f20;">130</span><span style="color:#231f20;"> of this proxy statement/prospectus.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="color:#231f20;font-weight:bold;">What are the U.S. federal income tax considerations of the reverse stock split to holders of Aerovate common stock?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">A holder of Aerovate common stock should not recognize gain or loss upon the reverse stock split, except to the extent such holder receives cash in lieu of a fractional share of Aerovate common stock, and subject to the discussion in the section titled &#8220;</span><i style="color:#231f20;font-style:italic;">Proposal No.&#160;2&#160;&#8212; The Reverse Stock Split Proposal &#8212; U.S. Federal Income Tax Considerations of the Reverse Stock Split</i><span style="color:#231f20;">&#8221; beginning on page&#160;</span><span style="color:#231f20;">165</span><span style="color:#231f20;"> of this proxy statement/prospectus. Please review the information in the section titled &#8220;</span><i style="color:#231f20;font-style:italic;">Proposal No.&#160;2&#160;&#8212; The Reverse Stock Split Proposal &#8212; U.S. Federal Income Tax Considerations of the Reverse Stock Split</i><span style="color:#231f20;">&#8221; beginning on page&#160;</span><span style="color:#231f20;">165</span><span style="color:#231f20;"> of this proxy statement/ prospectus for a more complete description of the U.S. federal income tax considerations of the reverse stock split to holders of Aerovate common stock.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="color:#231f20;font-weight:bold;">What are the U.S. federal income tax considerations of the Cash Dividend that Aerovate will declare and pay to holders of Aerovate common stock?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A</b><span style="color:#231f20;">:</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">The U.S. federal income tax considerations of a holder&#8217;s receipt of the Cash Dividend generally should be treated first as a dividend to the extent of Aerovate&#8217;s current and accumulated earnings and </span>profits, then as a non-taxable return of capital to the extent of the holder&#8217;s basis in Aerovate common stock, and then as capital gain from the sale or exchange of Aerovate common stock with respect to any remaining amount. However, there can be no assurance that it will be so treated. Please review the information in the section titled &#8220;<i style="font-style:italic;">The Merger&#160;&#8212;</i> <i style="font-style:italic;">U.S. Federal Income Tax Considerations of the Cash Dividend</i>&#8221; beginning on page&#160;132 of this proxy statement/prospectus for a discussion of the U.S. federal income tax considerations of the Cash Dividend to holders of Aerovate common stock.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">Who can help answer my questions?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-weight:bold;">A:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">If you are an Aerovate stockholder and would like additional copies of this proxy statement/prospectus without charge or if you have questions about the Merger or related matters, including the procedures for voting your shares, you should contact:</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Aerovate Therapeutics,&#160;Inc.<br/>930 Winter Street, Suite&#160;M-500<br/>Waltham, MA 02451<br/>Attn: Investor Relations<br/>Telephone: (617) 443-2400<br/>Email: Legal@AerovateTx.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_c40a2be5_ba93_4a90_b8e5_87aaa130c27a"></a><a id="PROSPECTUSSUMMARY_216069"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PROSPECTUS SUMMARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">This summary highlights selected information from this proxy statement/prospectus and may not contain all of the information that is important to you. To better understand the Merger and the proposals being considered at the Aerovate Special Meeting, you should read this entire proxy statement/prospectus carefully, including the Merger Agreement and the other annexes to which you are referred in this proxy statement/ prospectus, and the documents incorporated by reference therein. For more information, please see the section titled &#8220;Where You Can Find More Information&#8221; beginning on page&#160;</i><span style="font-style:italic;">336</span><i style="font-style:italic;"> of this proxy statement/prospectus. Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split described in Proposal No.&#160;2 of this proxy statement/prospectus.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The Companies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Aerovate Therapeutics,&#160;Inc.<br/>930 Winter Street, Suite&#160;M-500<br/>Waltham, MA 02451<br/>(617) 443-2400</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate is a biopharmaceutical company. Aerovate&#8217;s initial focus was on advancing AV 101, its dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (&#8220;PAH&#8221;), a devastating disease impacting approximately 70,000 people in the United States and Europe. On June&#160;17, 2024, Aerovate announced topline results from the Phase 2b portion of our Phase 2b/Phase 3 Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial of AV-101 (&#8220;IMPAHCT&#8221;). Topline data showed that, while AV-101 was generally well tolerated across all dose groups, the study did not meet its primary endpoint for improvement in pulmonary vascular resistance compared to placebo for any of the studied doses or show meaningful improvements in the secondary endpoint of change in six minute walk distance. Aerovate also reviewed data from several additional secondary endpoints of the Phase 2b portion of IMPAHCT, which also failed to show meaningful improvements. Based upon these results and in agreement with the independent study advisory committee, Aerovate halted enrollment and shut down the Phase 3 portion of IMPAHCT as well as the long-term extension study. AV-101 for the treatment of PAH was Aerovate&#8217;s only product candidate in development. At this time, Aerovate does not intend to resume development of AV- 101 or any other product candidates. In July&#160;2024, Aerovate announced the decision to conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value. Aerovate also engaged Wedbush Securities&#160;Inc. (Wedbush PacGrow) as its exclusive strategic financial advisor to assist in the process of exploring strategic alternatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since inception in 2018, Aerovate had devoted substantially all its efforts and financial resources to organizing and staffing its company, business planning, raising capital, discovering product candidates and securing related intellectual property rights and conducting research and development activities for AV-101. Aerovate does not have any products approved for sale, and has not generated any revenue from product sales. Aerovate may never be able to develop or commercialize a marketable product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Jade Biosciences,&#160;Inc.<br/>221 Crescent Street, Building 23, Suite&#160;105<br/>Waltham, MA 02453<br/>(781) 312-3013</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Jade is a biopharmaceutical company developing potentially differentiated biologic therapies for patients living with autoimmune diseases with the goal of improving upon the existing treatment paradigm through the delivery of improved dosing and convenience, a comparable safety profile, and potentially increased clinical activity. Jade&#8217;s approach is to discover and efficiently develop biologics that address emerging targets supported by third-party clinical data and that overcome shortcomings of existing product candidates in development, such as potency, bioavailability, formulation, and pharmacokinetic properties. JADE-001, its initial product candidate, is a monoclonal antibody targeting a cytokine called &#8220;A PRoliferation Inducing Ligand&#8221; (&#8220;APRIL&#8221;) that modulates plasma cell survival and immunoglobulin production, which Jade plans to initially develop for the treatment of IgA nephropathy (&#8220;IgAN&#8221;). IgAN is an autoimmune disease typically diagnosed in young adults with an estimated incidence of at least 2.5 cases in every 100,000 adults in studies spanning multiple countries, an estimate that likely underestimates the true prevalence since confirmatory diagnosis requires a kidney biopsy. While there are three small molecule drugs that have been approved for the treatment of IgAN, Tarpeyo, Filspari and Fabhalta, there are not yet any disease-modifying therapies approved for the treatment of IgAN that directly target the excess production of a pathogenic form of IgA and stabilize kidney function. Emerging third-party clinical data has highlighted the critical importance of APRIL. JADE-001 has been engineered to address two key limitations of anti-APRIL&#160;monoclonal antibody candidates currently in clinical development: potency and pharmacokinetic half-life. Increased APRIL&#160;binding affinity, improved potency in in </p></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">vitro functional assays and an extended pharmacokinetic half-life in non-human primates (&#8220;NHPs&#8221;) have been observed in head- to-head preclinical studies of JADE-001 lead clones conducted by Paragon, compared to product candidates currently in clinical development that were manufactured based on public data. Jade does not yet have clinical data regarding patients with IgAN that have been treated with JADE-001 and there can be no assurance that its clinical trials will have similar or comparable results. Jade believes that JADE-001 has the potential to capture a sizable portion of what it estimates to be the $10 billion IgAN market, calculated based on the U.S. prevalence multiplied by the proportion of patients with proteinuria (a condition where there is too much protein in the urine) &gt; 0.5g/day. Jade intends to initiate a Phase 1 clinical trial of JADE-001 in healthy volunteers in Australia or New Zealand, pending regulatory authorization, in the second half of 2025 with the aim of generating mechanistic biomarker data by the first half of 2026. Pending positive data from this trial, Jade expects to file an Investigational New Drug Application (&#8220;IND&#8221;) or foreign equivalent prior to the initiation of additional clinical trials. In addition to JADE-001, Jade is advancing pre-clinical discovery with respect to two additional product candidate programs, JADE-002 and JADE-003, in inflammation and immunology indications with high unmet need. Jade is focused on opportunities with the potential for a product profile to be best-in-class and best-in-indication, the ability to efficiently demonstrate clinical proof-of-concept in indications with high unmet need, and which fit Jade&#8217;s team&#8217;s discovery and development expertise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Caribbean Merger Sub I,&#160;Inc.<br/>930 Winter Street, Suite&#160;M-500 <br/>Waltham, MA 02451<br/>(617) 443-2400</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Merger Sub I is a direct, wholly owned subsidiary of Aerovate and was formed solely for the purpose of carrying out the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Caribbean Merger Sub II, LLC<br/>930 Winter Street, Suite&#160;M-500<br/>Waltham, MA 02451<br/>(617) 443-2400</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Merger Sub II is a direct, wholly owned subsidiary of Aerovate and was formed solely for the purpose of carrying out the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The Merger </b>(see page&#160;99)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the satisfaction or waiver of the closing conditions set forth in the Merger Agreement, at the Closing, Merger Sub I will merge with and into Jade, with Jade continuing as a wholly owned subsidiary of Aerovate and the surviving corporation of the First Merger and, as part of the same overall transaction, Jade will merge with and into Merger Sub II, with Merger Sub II being the surviving entity of the Second Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Aerovate&#8217;s Reasons for the Merger </b>(see page&#160;108)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After consideration and consultation with its management, consultants and advisors, outside legal counsel and financial advisor, the Aerovate board of directors determined that the Merger Agreement, the Merger and other transactions contemplated thereby are advisable and in the best interests of Aerovate and its stockholders. The Aerovate board of directors considered various reasons to reach its determination. For example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the financial condition and prospects of Aerovate and the risks associated with continuing to operate Aerovate on a stand-alone basis, particularly in light of Aerovate's June 2024 decision to discontinue the Phase 2b/Phase 3 clinical trial of AV-101, initiate a process to explore strategic alternatives and reduce its workforce;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that the Aerovate board of directors and its financial advisor undertook a comprehensive and thorough process of reviewing and analyzing potential strategic alternatives and merger partner candidates and the Aerovate board of directors' view that no alternatives to the Merger (including remaining a standalone company, a liquidation and dissolution of Aerovate and the distribution of any available cash, a cash tender offer at a discount to net cash value, and alternative strategic transactions) were reasonably likely to create greater value to Aerovate's stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Aerovate board of directors' conclusion that the Merger would provide Aerovate's existing stockholders a significant opportunity to participate in the potential growth of the Combined Company following the merger, which will focus on Jade's </span></td></tr></table></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product candidates, while also receiving a cash payment following the closing of the Merger on account of the special Cash Dividend;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Aerovate board of directors' belief, after thorough review of strategic alternatives and discussions with Aerovate's management, outside legal counsel and financial advisor, that the Merger is more favorable to Aerovate's stockholders than the potential value that might have resulted from other strategic alternatives available to Aerovate, including a liquidation and dissolution of Aerovate and the distribution of any available cash or a cash tender offer at a discount to net cash value;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Aerovate board of directors' belief that the $8 million enterprise value ascribed to Aerovate would provide the existing Aerovate stockholders significant value for Aerovate's public listing, and afford the Aerovate stockholders a significant opportunity to participate in the potential growth of the Combined Company following the Merger at the negotiated Exchange Ratio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Aerovate board of directors' belief, after a thorough review of strategic alternatives, such as attempting to further advance the development of its internal programs, entering into a licensing, sale or other strategic agreement related to certain assets sufficient to fund operations, combining with other potential strategic transaction candidates, and discussions with Aerovate's management, financial advisors and legal counsel, that the Merger is more favorable to Aerovate stockholders than the potential value that might have resulted from other strategic alternatives available to Aerovate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Aerovate board of directors' belief that, as a result of arm's length negotiations with Jade, Aerovate and its representatives negotiated the highest Exchange Ratio to which Jade was willing to agree and that the other terms of the Merger Agreement include the most favorable terms to Aerovate in the aggregate to which Jade was willing to agree; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Aerovate board of directors' view, following a review with Aerovate's management and advisors of Jade's current development and clinical trial plans, of the likelihood that the Combined Company would possess sufficient cash resources at the closing of the Merger, or have access to sufficient resources, to fund continued development of Jade's product candidates through upcoming value inflection points.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Jade&#8217;s Reasons for the Merger </b>(see page&#160;112)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the course of reaching its decision to approve the Merger and the Jade Pre-Closing Financing, Jade&#8217;s board of directors held several meetings, consulted with Jade&#8217;s senior management, legal counsel and financial advisors, and considered a wide variety of factors. Ultimately, Jade&#8217;s board of directors concluded that a merger with Aerovate, together with the additional financing committed from the Jade Pre-Closing Financing, was the best option to generate capital resources to support the advancement of Jade&#8217;s pipeline and fund the combined organization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additional factors Jade&#8217;s board of directors considered included the following (which factors are not necessarily presented in any order of relative importance):</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Merger will potentially expand the access to capital and the range of investors available as a public company to support the clinical development of Jade&#8217;s pipeline, compared to the capital and investors Jade could otherwise gain access to if it continued to operate as a privately-held company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential benefits from increased public market awareness of Jade and its pipeline;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the historical and current information concerning Jade&#8217;s business, including its financial performance and condition, operations, management and preclinical data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade&#8217;s board of directors&#8217; belief that no alternatives to the Merger, together with the additional financing committed from the Jade Pre-Closing Financing, were reasonably likely to create greater value for Jade stockholders, after considering the various financing and other strategic options to enhance stockholder value that were considered by the Jade board of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade&#8217;s board of directors&#8217; expectation that the Merger, together with the additional financing committed from the Jade Pre-Closing Financing, would be a higher probability and more cost-effective means to access capital than other options considered, including an initial public offering;</span></td></tr></table></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expected operations, management structure and operating plans of the Combined Company (including the ability to support the Combined Company&#8217;s current and planned preclinical studies and planned clinical trials);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the business, history, operations, financial resources, assets, technology and credibility of Aerovate; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and conditions of the Merger Agreement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s board of directors also considered a number of uncertainties and risks in its deliberations concerning the Merger and the other transactions contemplated by the Merger Agreement, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possibility that the Merger or the Jade Pre-Closing Financing might not be completed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Exchange Ratio used to establish the number of shares of Aerovate&#8217;s common stock to be issued to Jade stockholders in the Merger is fixed, except for adjustments due to Aerovate&#8217;s Net Cash balances, the amount of proceeds from the Jade Pre-Closing Financing and outstanding capital stock at Closing, and thus the relative&#160;percentage ownership of Aerovate stockholders and Jade stockholders in the combined organization immediately following the completion of the Merger is similarly fixed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential reduction of Aerovate&#8217;s Net Cash prior to the Closing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possibility that Aerovate could, under certain circumstances, consider unsolicited acquisition proposals if superior to the Merger or change its recommendation to approve the Merger upon certain events;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in connection with completing the Merger, the time and effort of Jade senior management required to complete the Merger, the related disruptions or potential disruptions to Jade&#8217;s business operations and future prospects, including its relationships with its employees, suppliers and partners and others that do business or may do business in the future with Jade, and related administrative challenges associated with combining the companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the additional expenses and obligations to which Jade&#8217;s business will be subject to following the Merger that Jade has not previously been subject to, and the operational changes to Jade&#8217;s business, in each case that may result from being a public company; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">various other risks associated with the combined organization and the Merger, including the risks described in the section titled &#8220;</span><i style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Risk Factors</i><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; beginning on page&#160;</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">24</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of this proxy statement/prospectus.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Interests of Aerovate Directors and Executive Officers in the Merger </b>(see page&#160;124)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In considering the recommendation of the Aerovate board of directors with respect to issuing shares of Aerovate common stock and Aerovate Series&#160;A Preferred Stock in the Merger and the other matters to be acted upon by the Aerovate stockholders at the Aerovate Special Meeting, Aerovate stockholders should be aware that Aerovate&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of Aerovate&#8217;s stockholders generally. Interests of the directors and executive officers may be different from or in addition to the interests of the stockholders for the following reasons, among others:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Under the Merger Agreement, Aerovate&#8217;s directors and executive officers are entitled to continued indemnification, expense reimbursement and insurance coverage.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In connection with the Merger, options to purchase Aerovate&#8217;s common stock, with an exercise price lower than the Aerovate Closing Price, prior to giving effect to Aerovate&#8217;s Cash Dividend and the reverse stock split (the &#8220;Aerovate ITM Options&#8221;), (including those held by Aerovate&#8217;s executive officers and directors) will vest in full upon the Closing and, once vested, such options shall be cancelled in exchange for the cash difference between the Aerovate Closing Price and such option&#8217;s exercise price.</span></td></tr></table></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In connection with the Merger, the vesting of each outstanding and unvested Aerovate RSU (including those held by Aerovate&#8217;s executive officers and directors), if any are outstanding, will accelerate in full and each outstanding and unsettled Aerovate RSU will be settled in shares of Aerovate common stock. As of the date of this proxy statement/prospectus, there are no Aerovate RSUs outstanding.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In connection with his anticipated termination of employment following the effective time of the Merger, Timothy Noyes, Aerovate&#8217;s Chief Executive Officer and George Eldridge, Aerovate&#8217;s Chief Financial Officer, would be entitled to receive certain enhanced severance payments and benefits under the terms of their respective employment agreements with Aerovate.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These interests are discussed in more detail in the section titled &#8220;<i style="font-style:italic;">The Merger&#160;&#8212; Interests of Aerovate Directors and Executive Officers in the Merger</i>&#8221; beginning on page&#160;124 of this proxy statement/prospectus. The members of Aerovate&#8217;s board of directors were aware of and considered these interests, among other matters, in evaluating and negotiating the Merger Agreement and the Merger, and in recommending to the stockholders that the Merger Proposals be approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain Aerovate stockholders have also entered into support agreements in connection with the Merger. For a more detailed discussion of the support agreements, please see the section titled &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#160;&#8212; Support Agreements</i>&#8221; beginning on page&#160;153 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Interests of Jade Directors and Executive Officers in the Merger </b>(see page&#160;126)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In considering the recommendation of Jade&#8217;s board of directors with respect to approving the Merger, stockholders should be aware that Jade&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of Jade stockholders generally. These interests may present them with actual or potential conflicts of interest. These interests include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">as of October&#160;30, 2024, Jade&#8217;s current non-employee directors and executive officers beneficially owned, in the aggregate, approximately 80.1% of the shares of Jade capital stock, which for purposes of this subsection excludes any Jade shares issuable upon exercise or settlement of Jade options </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">held by such individual;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Fairmount Healthcare Fund II&#160;L.P. (&#8220;Fairmount Fund II&#8221;), an affiliate of Tomas Kiselak and Chris Cain, Jade directors, currently holds shares of capital stock and an unsecured convertible promissory note with an initial principal amount of $20.0 million at an interest rate of 12% per annum of Jade and has agreed to purchase shares and pre-funded warrants in the Jade Pre-Closing Financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in connection with the Merger, each option to purchase shares of Jade common stock held by Jade&#8217;s executive officers and directors, whether or not vested, will be converted into an option to purchase </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">shares of the Combined Company&#8217;s common stock, on the same terms and conditions (including any vesting and acceleration provisions);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade&#8217;s directors and executive officers are expected to become directors and executive officers of the Combined Company upon completion of the Merger; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade&#8217;s directors and executive officers are entitled to certain indemnification and liability insurance coverage pursuant to the terms of the Merger Agreement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s board of directors was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Jade stockholders approve the Merger as contemplated by this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Opinion of Aerovate&#8217;s Financial Advisor </b>(see page&#160;114)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Aerovate retained Lucid Capital Markets, LLC (&#8220;Lucid&#8221;) to render an opinion to Aerovate&#8217;s board of directors as to the fairness of the Exchange Ratio, from a financial point of view, to the holders of the common stock of Aerovate in connection with the Merger and the other transactions contemplated by the Merger Agreement. On October&#160;30, 2024, Lucid rendered to the Aerovate board of directors its oral opinion, which was subsequently confirmed by delivery of a written opinion to the Aerovate board of directors dated </p></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">October&#160;30, 2024, that, as of such date and based upon and subject to the various assumptions made, and the qualifications and limitations upon the review undertaken by Lucid in preparing its opinion, the Exchange Ratio proposed to be paid by Aerovate pursuant to the Merger Agreement was fair, from a financial point of view, to Aerovate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The full text of the written opinion of Lucid, dated October&#160;30, 2024, which describes the assumptions made and the qualifications and limitations upon the review undertaken by Lucid in preparing its opinion, is attached as <i style="font-style:italic;">Annex F </i>to this proxy statement/prospectus and is incorporated herein by reference<b style="font-weight:bold;">. Lucid&#8217;s financial advisory services and opinion were provided for the information and assistance of Aerovate&#8217;s board of directors (in their capacity as directors and not in any other capacity) in connection with and for purposes of the Aerovate board of directors&#8217; consideration of the Merger and the opinion of Lucid addressed only the fairness, from a financial point of view, as of the date thereof, to Aerovate of the Exchange Ratio proposed to be paid by Aerovate pursuant to the terms of the Merger Agreement. The opinion of Lucid did not address any other term or aspect of the Merger Agreement or the Merger and does not constitute a recommendation to any stockholder of Aerovate as to whether or how such holder should vote with respect to the Merger or otherwise act with respect to the Merger or any other matter.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The full text of the written opinion of Lucid should be read carefully in its entirety for a description of the assumptions made and limitations upon the review undertaken by Lucid in preparing its opinion.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview of the Merger Agreement and Agreements Related to the Merger Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Merger Consideration </span>(see page&#160;137)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, (i)&#160;each then-outstanding share of Jade common stock (including shares of Jade common stock issued in the Jade Pre-Closing Financing) (excluding shares to be cancelled pursuant to the Merger Agreement and excluding dissenting shares) will be converted into the right to receive a number of shares of Aerovate common stock equal to the Exchange Ratio (described in more detail in the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#160;&#8212; Exchange Ratio</i>&#8221; beginning on page&#160;138 of this proxy statement/prospectus), (ii)&#160;each then-outstanding share of Jade Preferred Stock will be converted into the right to receive a number of shares of Aerovate Series&#160;A Preferred Stock, which are each convertible into 1,000 shares of Aerovate common stock, equal to the Exchange Ratio divided by 1,000, in accordance with the terms of the Merger Agreement, <span style="color:#231f20;">(iii)&#160;each then-outstanding option to purchase Jade common stock will be assumed by Aerovate, subject to adjustment as set forth in the Merger Agreement, and (iv)&#160;each then-outstanding pre-funded warrant to purchase shares of Jade common stock will be converted into a pre-funded warrant to purchase shares of Aerovate common stock, subject to adjustment as set forth in the Merger Agreement and the form of pre- funded warrant.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Immediately after the Merger, Aerovate securityholders as of immediately prior to the Merger are expected to own approximately 1.6% of the outstanding shares of capital stock of the Combined Company on a fully-diluted basis and former holders of Jade securities are expected to own approximately 98.4% of the outstanding shares of capital stock of the Combined Company on a fully-diluted basis. Under certain circumstances further described in the Merger Agreement, the ownership&#160;percentages may be adjusted up or down including, but not limited to, if Aerovate&#8217;s Net Cash as of Closing is lower than $0.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, prior to the First Effective Time, Aerovate expects to declare the Cash Dividend to the pre- First Merger Aerovate stockholders equal in the aggregate to Aerovate&#8217;s reasonable, good faith approximation of the amount by which Aerovate&#8217;s Net Cash (as determined pursuant to the Merger Agreement) will exceed $0. Aerovate management currently anticipates that Aerovate&#8217;s Net Cash as of Closing to be approximately $0, after giving effect to the Cash Dividend, which is expected to be approximately $65.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade Options and Jade&#8217;s Amended and Restated 2024 Equity Incentive Plan </span>(see page&#160;140)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Merger Agreement, Aerovate will assume Jade&#8217;s Amended&#160;&amp; Restated 2024 Equity Incentive Plan and each option to purchase shares of Jade common stock that is outstanding and unexercised immediately prior to the First Effective Time, whether or not vested, will be assumed and converted into an option to purchase shares of Aerovate common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Accordingly, from and after the First Effective Time: (i)&#160;each outstanding Jade stock option assumed by Aerovate may be exercised solely for shares of Aerovate common stock; (ii)&#160;the number of shares of Aerovate common stock subject to each outstanding Jade stock option assumed by Aerovate will be determined by multiplying (A)&#160;the number of shares of Jade common stock that were subject to such Jade stock option assumed by Aerovate, as in effect immediately prior to the First Effective Time, by </p></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(B)&#160;the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of Aerovate common stock; and (iii)&#160;the per share exercise price of each Jade stock option assumed by Aerovate will be determined by dividing (A)&#160;the per share exercise price of such Jade stock option, as in effect immediately prior to the First Effective Time, by (B)&#160;the Exchange Ratio, and rounding the resulting exercise price up to the nearest whole cent. Each Jade stock option assumed by Aerovate will otherwise continue in full force and effect and the term, exercisability, vesting schedule, acceleration rights and other terms and conditions of such Jade stock option will otherwise remain unchanged.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each Jade stock option shall, in accordance with its terms, continue to be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of Aerovate common stock subsequent to the First Effective Time. In addition, the Combined Company&#8217;s compensation committee will succeed to the authority and responsibility of Jade&#8217;s board of directors as administrator of Jade&#8217;s Amended and Restated 2024 Equity Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade Pre-Funded Warrants </span>(see page&#160;140)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Merger Agreement, each pre-funded Jade warrant to purchase shares of Jade common stock issued pursuant to the Jade Pre-Closing Financing that is outstanding and unexercised immediately prior to the First Effective Time, whether or not vested, will be converted into a pre-funded warrant to purchase shares of Aerovate common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accordingly, from and after the First Effective Time: (i)&#160;each outstanding Jade pre-funded warrant assumed by Aerovate may be exercised solely for shares of Aerovate common stock; (ii)&#160;the number of shares of Aerovate common stock subject to each outstanding Jade pre-funded warrant assumed by Aerovate will be determined by multiplying (A)&#160;the number of shares of Jade common stock issuable upon exercise of the Jade pre-funded warrant that were subject to such Jade pre-funded warrant, as in effect immediately prior to the First Effective Time, by (B)&#160;the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of Aerovate common stock; and (iii)&#160;the per share exercise price for the Aerovate common stock issuable upon exercise of each Jade pre-funded warrant assumed by Aerovate will be determined by dividing (A)&#160;the per share exercise price of Aerovate common stock subject to such Jade pre- funded warrant as in effect immediately prior to the First Effective Time, by (B)&#160;the Exchange Ratio, and rounding the resulting exercise price up to the nearest whole cent. Each Jade pre-funded warrant assumed by Aerovate will otherwise continue in full force and effect and the term, any restriction on the exercise and other provisions of such Jade pre-funded warrant will otherwise remain unchanged.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each Jade pre-funded warrant shall, in accordance with its terms, continue to be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of Aerovate common stock subsequent to the First Effective Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate Common Stock and Aerovate Options </span>(see page&#160;141)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as contemplated by the proposed increase in the number of authorized shares of Aerovate common stock described in Proposal No.&#160;3 of this proxy statement/prospectus and the proposed reverse stock split of issued and outstanding Aerovate common stock described in Proposal No.&#160;2 of this proxy statement/prospectus, Aerovate common stock will remain unaffected by the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Merger Agreement, prior to the Closing, Aerovate&#8217;s board of directors will accelerate the vesting of all equity awards of Aerovate then outstanding but not then vested or exercisable, and cancel each Aerovate ITM Option, in each case, in accordance with the terms of the Merger Agreement. At the First Effective Time, (i)&#160;each Aerovate ITM Option will be cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (A)&#160;the excess of the Aerovate Closing Price over the exercise price per share of Aerovate common stock underlying such Aerovate ITM Option by (B)&#160;the number of shares of Aerovate common stock underlying such Aerovate ITM Option and (ii)&#160;each Aerovate OTM Option will be cancelled for no consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Conditions to the Completion of the Merger </span>(see page&#160;149)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To complete the Merger, Aerovate stockholders must approve Proposal No.&#160;1, Proposal No.&#160;2 and Proposal No.&#160;3 and Jade stockholders must adopt the Merger Agreement and approve the Merger and the related transactions contemplated by the Merger Agreement. Additionally, each of the other closing conditions set forth in the Merger Agreement must be satisfied or waived.</p></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Non-Solicitation </span>(see page&#160;145)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement contains non-solicitation provisions prohibiting Aerovate and Jade from soliciting a competing transaction. Each of Aerovate and Jade have agreed that, subject to certain exceptions, Aerovate and Jade and any of their respective subsidiaries will not, nor will either party or any of its subsidiaries authorize any of the directors, officers, employees, investment bankers, financial advisors, attorneys, accountants or other advisors, agents or representatives retained by it or any of its subsidiaries to, directly or indirectly:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of, any Acquisition Proposal or Acquisition Inquiry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">furnish any non-public information with respect to it to any person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">engage in discussions or negotiations with any person with respect to any Acquisition Proposal or Acquisition Inquiry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subject to certain exceptions set forth in the Merger Agreement, approve, endorse or recommend any Acquisition Proposal;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">execute or enter into any letter of intent or any contract contemplating or otherwise relating to any Acquisition Transaction;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publicly propose to do any of the foregoing.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Board Recommendation Change </span>(see page&#160;147)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Neither Jade&#8217;s board of directors nor Aerovate&#8217;s board of directors may change its recommendation in favor of the Merger, except that prior to receipt by such party of its stockholder approval, such party&#8217;s board of directors may effect a change in recommendation as a result of a material development or change in circumstances (&#8220;Intervening Event&#8221;), or with respect to a superior offer that did not result from a material breach of the Merger Agreement if:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such party&#8217;s board of directors shall have determined in good faith, based on the advice of its outside legal counsel, that the failure to effect such change in recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such party has provided at least four business&#160;days&#8217; prior written notice to the other party that it intends to effect a change in recommendation, and during such period has, and has caused its lead financial advisor and outside legal counsel to, negotiate with the other party in good faith to make such adjustments to the terms and conditions so that the acquisition proposal ceases to constitute a superior offer; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if, after the other party shall have delivered to such party a written offer to alter the terms or conditions of the Merger Agreement during the four-business day period referred to above, such party&#8217;s board of directors shall have determined in good faith (based on the advice of its outside legal counsel), that the failure to effect a change in recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In the event of any material amendment to any superior offer, the party considering the superior offer would be required to provide the other party with notice of such material amendment and there would be a new two-business day period following such notification during which the parties would be obligated to comply again with the requirements described above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In the case of an Intervening Event, the party suffering such event shall promptly notify the other party before effecting a change in recommendation. The written notice is required to state the material facts and circumstances related to the applicable Intervening Event and that such party&#8217;s board of directors intends to make a change in recommendation.</p></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Termination of the Merger Agreement </span>(see page&#160;150)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Either Aerovate or Jade may terminate the Merger Agreement under certain circumstances, which would prevent the Merger from being consummated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Termination Fee </span>(see page&#160;152)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Merger Agreement is terminated under certain circumstances, Aerovate could be required to pay Jade a termination fee of $2,340,000 or Jade could be required to pay Aerovate a termination fee of $5,250,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Support Agreements </span>(see page&#160;153)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain stockholders of Jade (solely in their respective capacities as Jade stockholders) holding approximately 99% of the outstanding shares of Jade capital stock have entered into support agreements with Aerovate and Jade to vote all of their shares of Jade capital stock in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby (the &#8220;Jade Support Agreements&#8221;). Certain stockholders of Aerovate holding approximately 38.1% of the outstanding shares of Aerovate common stock have entered into support agreements with Aerovate and Jade to vote all of their shares of Aerovate common stock in favor of Proposal Nos.1&#8211; 7.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Lock-Up Agreements </span>(see page&#160;153)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain of Jade&#8217;s executive officers, directors and stockholders have entered into lock-up agreements, pursuant to which such parties have agreed not to, except in limited circumstances, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Aerovate&#8217;s common stock or any securities convertible into or exercisable or exchangeable for Aerovate common stock, currently or thereafter owned, including shares of Aerovate common stock issuable upon conversion of Aerovate Series&#160;A Preferred Stock issued in exchange for shares of Jade preferred stock in the Merger, but excluding, as applicable, shares purchased by existing Jade stockholders in the Jade Pre-Closing Financing (including any shares of Aerovate common stock issuable upon exercise of pre-funded warrants issued in exchange for pre-funded warrants to purchase shares of Jade common stock sold in the Jade Pre-Closing Financing), until 180&#160;days after the effective time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Subscription Agreement and Registration Rights Agreement </span>(see page&#160;153 and 155)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Concurrently with the execution and delivery of the Merger Agreement, certain new and existing investors of Jade entered into the Subscription Agreement with Jade, pursuant to which such investors have agreed to purchase, immediately prior to the Merger, shares of Jade common stock or, in lieu thereof, Jade pre-funded warrants, representing an aggregate commitment of approximately $300 million, which includes the conversion of the previously issued $95 million aggregate principal amount of Jade convertible notes, in the Jade Pre-Closing Financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The shares of Jade common stock and Jade pre-funded warrants that are issued in the Jade Pre- Closing Financing will be or will have the right to be, respectively, converted into shares of Aerovate common stock in the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Subscription Agreement contains customary representations and warranties of Jade and also contains customary representations and warranties of the purchaser parties thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Subscription Agreement also contemplates Jade and the investors participating in the Jade Pre- Closing Financing entering into a registration rights agreement at the closing of the Jade Pre-Closing Financing, pursuant to which, among other things, the Combined Company will agree to provide for the registration and resale of certain shares of Aerovate common stock that are held by the investors participating in the Jade Pre-Closing Financing from time to time pursuant to Rule&#160;415.</p></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Management Following the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the name, age as of November&#160;15, 2024 and position of each of the individuals who are expected to serve as executives and directors of the Combined Company following completion of the Merger:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:31.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Age</b></p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:48.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Executive Officers</span></p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.17%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Tom Frohlich</p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">49</p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer and Director</p></td></tr><tr><td style="vertical-align:bottom;width:31.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Jonathan Quick</p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">36</p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President, Finance and Treasurer</p></td></tr><tr><td style="vertical-align:bottom;width:31.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Andrew King, BVMS, Ph.D.</p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">45</p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Scientific Officer &amp; Head of Research and Development</p></td></tr><tr><td style="vertical-align:bottom;width:31.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Hetal Kocinsky, M.D.</p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">51</p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Medical Officer</p></td></tr><tr><td style="vertical-align:bottom;width:31.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Elizabeth Balta, J.D.</p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">54</p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General Counsel and Corporate Secretary</p></td></tr><tr><td style="vertical-align:bottom;width:31.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Non-Employee Directors</span></p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Eric Dobmeier, J.D.</p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">56</p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chair and Director</p></td></tr><tr><td style="vertical-align:bottom;width:31.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Christopher Cain, Ph.D.</p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">40</p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:31.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Tomas Kiselak</p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">38</p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:31.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Lawrence Klein, Ph.D.</p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">42</p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:31.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Erin Lavelle</p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">47</p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">U.S. Federal Income Tax Considerations of the Merger </b>(see page&#160;130)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As discussed in detail in the section titled &#8220;<i style="font-style:italic;">The Merger&#160;&#8212; U.S. Federal Income Tax Considerations of the Merge</i>r&#8221; beginning on page&#160;130 of this proxy statement/prospectus and subject to the limitations and qualifications described therein, Aerovate and Jade intend the Merger to qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Code. Assuming the Merger so qualifies, a U.S. Holder of Jade stock will not recognize gain or loss upon the exchange of its Jade stock for Aerovate stock. Since the Aerovate stockholders will not sell, exchange or dispose of any shares of Aerovate stock as a result of the Merger, there will be no material U.S. federal income tax considerations to Aerovate stockholders as a result of the Merger. For a more detailed discussion of the U.S. federal income tax considerations of the Merger, see the section titled &#8220;<i style="font-style:italic;">The Merger&#160;&#8212; U.S. Federal Income Tax Considerations of the Merger</i>,&#8221; beginning on page 130 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">U.S. Federal Income Tax Considerations of the Nevada Redomestication </b>(see page&#160;189)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the limitations and qualifications described in the section titled &#8220;<i style="font-style:italic;">Proposal No.&#160;4 &#8212; The Redomestication Proposal&#160;&#8212; U.S. Federal Income Tax Considerations of the Nevada Redomestication</i>,&#8221; Aerovate intends that the Nevada Redomestication qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Code. Assuming the Nevada Redomestication so qualifies, a U.S. Holder of Aerovate stock will not recognize gain or loss upon the Nevada Redomestication. For a more detailed discussion of the U.S. federal income tax considerations of the Nevada Redomestication, please see the section titled &#8220;<i style="font-style:italic;">Proposal No.&#160;4 &#8212; The Redomestication Proposal&#160;&#8212; U.S. Federal Income Tax Considerations of the Nevada Redomestication</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risk Factors </b>(see page&#160;24)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Both Aerovate and Jade are subject to various risks associated with their businesses and their industries. In addition, the Merger, including the possibility that the Merger may not be completed, poses a number of risks to each company and its respective securityholders, including the following risks:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to the Merger:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Failure to complete, or delays in completing, the potential Merger with Jade, announced on October&#160;31, 2024, could materially and adversely affect Aerovate&#8217;s or Jade&#8217;s results of operations, business, financial results and may cause a decline in the market price of Aerovate common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Exchange Ratio will not change or otherwise be adjusted based on the market price of Aerovate common stock as the Exchange Ratio depends on Aerovate&#8217;s Net Cash at the Closing and not the market price of Aerovate&#8217;s common stock, so the Merger consideration at the Closing may have a greater or lesser value than at the time the Merger Agreement was signed;</span></td></tr></table></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The issuance of Aerovate common stock to Jade stockholders pursuant to the Merger Agreement and the resulting change in control from the Merger must be approved by Aerovate stockholders, and the Merger Agreement and transactions contemplated thereby must be approved by the Jade stockholders. Failure to obtain these approvals would prevent the Closing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Failure to complete the Merger may result in Aerovate or Jade paying a termination fee to the other party and could harm the common stock price of Aerovate and the future business and operations of each company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Some Aerovate and Jade executive officers and directors have interests in the Merger that are different from yours;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aerovate stockholders and Jade stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If the Merger is not completed, Aerovate&#8217;s stock price may decline significantly.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to the Proposed Reverse Stock Split:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The reverse stock split may not increase the Combined Company&#8217;s stock price over the long-term;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The reverse stock split may decrease the liquidity of the Combined Company&#8217;s common stock; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The reverse stock split may lead to a decrease in the Combined Company&#8217;s overall market capitalization.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to Aerovate:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aerovate may not be successful in consummating the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If the Merger is not completed, Aerovate&#8217;s board of directors may decide to pursue a dissolution and liquidation. In such an event, the amount of cash available for distribution to Aerovate&#8217;s stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aerovate has incurred significant operating losses since its inception and anticipates that it will continue to incur losses for the foreseeable future. Aerovate may never achieve or maintain profitability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aerovate has no products approved for commercial sale and has not generated any revenue from product sales; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aerovate may require additional capital to finance its operations, which may not be available on acceptable terms, or at all.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to Jade:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Even if the Merger and the Jade Pre-Closing Financing are successful, Jade will require substantial additional capital to finance its operations in the future, which raises substantial doubt about its ability to continue as a going concern. If Jade is unable to raise such capital when needed, or on acceptable terms, Jade may be forced to delay, reduce and/or eliminate one or more </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of its development programs or future commercialization efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade is a preclinical stage biotechnology company with a limited operating history on which to assess its business; Jade has not initiated, conducted or completed any clinical trials, and Jade has no products approved for commercial sale, which may make it difficult for you to evaluate its current business and likelihood of success and viability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade is substantially dependent on the success of JADE-001, and Jade&#8217;s anticipated clinical trials of such program may not be successful;</span></td></tr></table><div style="margin-top:12pt;"></div></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade relies on collaborations and licensing arrangements with third parties, including its collaboration with Paragon pursuant to the Option Agreement with Paragon and Parade (as amended, the &#8220;Paragon Option Agreement&#8221;) and the JADE-001 License Agreement. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If Jade is unable to maintain these collaborations or licensing arrangements, or if these collaborations or licensing arrangements are not successful, its business could be negatively impacted;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In order to successfully implement its plans and strategies, Jade will need to grow the size of its organization and it may experience difficulties in managing this growth; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Preclinical and clinical development involves a lengthy and expensive process that is subject to delays and with uncertain outcomes, and results of earlier studies and trials may not be predictive of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future clinical trial results. If Jade&#8217;s preclinical studies and clinical trials are not sufficient to support regulatory approval of any of its product candidates, Jade may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidate.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to the Nevada Redomestication:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Currently, Aerovate is governed by Delaware law, but upon effectiveness of the Nevada Redomestication the Combined Company will be governed by Nevada law and the Combined Company&#8217;s articles of incorporation and bylaws, provisions of which have anti-takeover implications; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Because the Combined Company&#8217;s articles of incorporation and bylaws limit the court in which you may bring an action against the Combined Company, you may have difficulty obtaining a favorable judicial forum or you may incur more expense enforcing any rights which you may claim as compared to prior to the Nevada Redomestication.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to the Ownership of the Common Stock of the Combined Company:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The market price of the Combined Company&#8217;s common stock is expected to be volatile, and the market price of the common stock may drop following the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Combined Company may incur losses for the foreseeable future and may never achieve profitability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Combined Company will need to raise additional financing in the future to fund its operations, which may not be available to it on favorable terms or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">After completion of the Merger, the Combined Company&#8217;s executive officers, directors and principal stockholders will have the ability to control or significantly influence all matters submitted to the Combined Company&#8217;s stockholders for approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Conflicts of interest may arise between the Combined Company and Paragon or the Combined Company and Fairmount; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Combined Company will have broad discretion in the use of the cash and cash equivalents of the Combined Company and the proceeds from the Jade Pre-Closing Financing and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These risks and other risks are discussed in greater detail under the section titled &#8220;<i style="font-style:italic;">Risk Factors</i>&#8221; beginning on page&#160;24 of this proxy statement/prospectus. Aerovate and Jade both encourage you to read and consider all of these risks carefully.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Regulatory Approvals </b>(see page&#160;148)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each of Aerovate and Jade will use commercially reasonable efforts to file or otherwise submit, as soon as practicable after the date of the Merger Agreement, all applications, notices, reports and other documents reasonably required to be filed by such party with or otherwise submitted by such party to any governmental authority with respect to the transactions contemplated by the Merger Agreement, if any, and to submit promptly any additional information requested by any such governmental authority.</p></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:17.6pt 5.22% 0pt 5.22%;padding:4pt 0.65% 4pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Nasdaq Stock Market Listing </b>(see page&#160;133)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Aerovate intends to file an initial listing application for the Combined Company common stock with Nasdaq. If such application is accepted, Aerovate anticipates that the common stock of the Combined Company will be listed on Nasdaq following the Closing under the trading symbol &#8220;JBIO.&#8221; It is a condition to the consummation of the Merger that Aerovate will receive confirmation from Nasdaq that the Combined Company has been approved for listing on Nasdaq, but there can be no assurance such listing condition will be met or that Aerovate will obtain such confirmation from Nasdaq. If such listing condition is not met or if such confirmation is not obtained, the Merger will not be consummated unless the condition is waived. The Nasdaq condition set forth in the Merger Agreement is not expected to be waived by the applicable parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Anticipated Accounting Treatment </b>(see page&#160;133)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The Merger is expected to be treated by Aerovate as a reverse merger and will be accounted for as a reverse recapitalization of Aerovate by Jade in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as, at close, the transaction is, in essence, the issuance of equity for Aerovate&#8217;s net assets, which primarily consist of nominal non-operating assets and liabilities. For accounting purposes, Jade is considered to be acquiring the assets and liabilities of Aerovate in this transaction based on the terms of the Merger Agreement and other factors, including: (i)&#160;Jade&#8217;s equity holders will own a substantial majority of the voting rights in the Combined Company; (ii)&#160;Jade&#8217;s largest stockholder will retain the largest interest in the Combined Company; (iii)&#160;Jade will designate all of the initial members of the board of directors of the Combined Company; and (iv)&#160;Jade&#8217;s executive management team will become the management of the Combined Company. The Combined Company will be named Jade Biosciences,&#160;Inc. Accordingly, the Merger is expected to be treated as the equivalent of Jade issuing stock to acquire the net assets of Aerovate. As a result of the Merger, the net assets of Aerovate will be stated at fair value, which approximates carrying value, with no goodwill or other intangible assets recorded, and the historical results of operations prior to the Merger will be those of Jade. The direct and incremental costs related to the Merger will be treated as a reduction of the net proceeds received within additional paid-in-capital. Please see the section titled &#8220;<i style="font-style:italic;">Unaudited Pro Forma Condensed Combined Financial Information</i>&#8221; beginning on page&#160;305 of this proxy statement/prospectus for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Appraisal Rights and Dissenters&#8217; Rights </b>(see page&#160;134)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Holders of Aerovate common stock are not entitled to appraisal rights in connection with the Merger under Delaware law. Holders of Jade capital stock are entitled to appraisal rights in connection with the Merger under Delaware law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Comparison of Stockholder Rights </b>(see page&#160;321)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Aerovate and Jade are incorporated under the laws of the State of Delaware and, accordingly, the rights of the stockholders of each are currently, and will continue to be, governed by the Delaware General Corporation Law (&#8220;DGCL&#8221;). If the Merger is completed, Jade stockholders will become Aerovate stockholders, and their rights will be governed by the DGCL, the amended and restated bylaws of Aerovate and the second amended and restated certificate of incorporation of Aerovate (the &#8220;Aerovate Charter&#8221;), as may be further amended by Proposal Nos. 2 and 3 if approved by the Aerovate stockholders at the Aerovate Special Meeting. The rights of Aerovate stockholders contained in the Aerovate Charter and Aerovate&#8217;s amended and restated bylaws differ from the rights of Jade stockholders under Jade&#8217;s certificate of incorporation and Jade&#8217;s bylaws, as more fully described under the section titled &#8220;<i style="font-style:italic;">Comparison of Rights of Holders of Aerovate Capital Stock and Jade Capital Stock</i>&#8221; beginning on page 321 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If Proposal No. 4 is approved by Aerovate stockholders and the Merger is completed, the Combined Company will effect the Nevada Redomestication pursuant to the Plan of Conversion as set forth in the form attached as <i style="font-style:italic;">Annex D</i> to this proxy statement/prospectus, and, upon completion of the Nevada Redomestication, the rights of Aerovate stockholders and the rights of Jade stockholders who become Aerovate stockholders pursuant to the Merger will no longer be governed by the Aerovate Charter, Aerovate&#8217;s amended and restated bylaws and the DGCL and instead will be governed by a Nevada articles of incorporation, Nevada bylaws and the Nevada Revised Statutes. For a comparison of rights of holders of the Combined Company capital stock as a Delaware corporation and the Combined Company capital stock as a Nevada corporation assuming the completion of the Nevada Redomestication, see the section titled &#8220;<i style="font-style:italic;">Proposal No. 4 &#8211; The Redomestication Proposal &#8211; Effects of the Nevada Redomestication &#8211; Comparison of Rights of Holders of the Delaware Corporation Capital Stock and the Nevada Corporation Capital Stock</i>&#8221; beginning on page 172 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e7fb1da8_4b92_455d_81eb_3c08a2967623"></a><a id="MARKETPRICEANDDIVIDENDINFORMATION_402401"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MARKET PRICE AND DIVIDEND INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Aerovate common stock is currently listed on The Nasdaq Global Market under the symbol &#8220;AVTE.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The closing price of the Aerovate common stock on October&#160;30, 2024, the last day of trading prior to the announcement of the Merger, as reported on The Nasdaq Global Market, was $2.19 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because the market price of the Aerovate common stock is subject to fluctuation, the market value of the shares of the Jade common stock that the Aerovate stockholders will be entitled to receive in the Merger may increase or decrease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Assuming approval of Proposal Nos. 1, 2 and 3 and successful application for initial listing with The Nasdaq Global Market, following the consummation of the Merger, the Aerovate common stock will trade on The Nasdaq Global Market under Aerovate&#8217;s new name, &#8220;Jade Biosciences,&#160;Inc.,&#8221; and new trading symbol &#8220;JBIO&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of&#160;&#160;&#160;&#160;&#160;, 2025, the Record Date for the Special Meeting, there were approximately registered holders of record of the Aerovate common stock. As of&#160;&#160;&#160;&#160;&#160;, 2025, Jade had&#160;&#160;&#160;&#160;holders of record of Jade common stock and&#160;&#160;&#160;&#160;holders of record of Jade Preferred Stock. For detailed information regarding the beneficial ownership of certain Aerovate and Jade stockholders, see the sections of this proxy statement/prospectus titled &#8220;<i style="font-style:italic;">Principal Stockholders of Aerovate</i>&#8221; and &#8220;<i style="font-style:italic;">Principal Stockholders of Jade</i>&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Dividends</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate has never declared or paid any cash dividends on the Aerovate common stock and does not anticipate paying cash dividends on the Aerovate common stock for the foreseeable future, except the Cash Dividend that Aerovate will declare and pay to the holders of record of outstanding shares of Aerovate common stock as of a record date prior to the effective time of the Merger, to be set by the Aerovate board of directors as close as reasonably practicable to (but not later than) the anticipated date of Closing (the &#8220;Closing Date&#8221;). The aggregate amount of the Cash Dividend is expected to equal approximately $65.0 million, subject to certain adjustments depending on Aerovate&#8217;s Net Cash. Notwithstanding the foregoing, any determination to pay cash dividends subsequent to the Merger will be at the discretion of the Combined Company&#8217;s then-current board of directors and will depend upon a number of factors, including the Combined Company&#8217;s results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors the then-current board of directors deems relevant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade has never paid or declared any cash dividends on the Jade capital stock. If the Merger does not occur, Jade does not anticipate paying any cash dividends on the Jade capital stock in the foreseeable future, and Jade intends to retain all available funds and any future earnings to fund the development and expansion of its business. Any future determination to pay dividends will be at the discretion of the Jade board of directors and will depend upon a number of factors, including its results of operations, financial condition, future prospects, contractual restrictions, and restrictions imposed by applicable laws and other factors the Jade board of directors deems relevant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_dda22153_cc8f_49bf_b4d3_fe761f033f85"></a><a id="RISKFACTORS_64429"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RISK FACTORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The Combined Company will be faced with a market environment that cannot be predicted and that involves significant risks, many of which will be beyond its control. In addition to the other information contained or incorporated by reference in this proxy statement/prospectus, you should carefully consider the material risks described below before deciding how to vote your shares of Aerovate common stock. You should also read and consider the other information in this proxy statement/prospectus and additional information about Aerovate set forth in its Annual Report on Form&#160;10-K for the fiscal&#160;year ended December&#160;31, 2023, which is filed with the Securities and Exchange Commission (&#8220;SEC&#8221;), as updated by its Quarterly Reports on Form&#160;10-Q, in each case incorporated by reference into this proxy statement/prospectus. Please see the section titled &#8220;Where You Can Find More Information&#8221; beginning on page&#160;</i><span style="font-style:italic;">336</span><i style="font-style:italic;"> of this proxy statement/prospectus for further information regarding the documents incorporated by reference into this proxy statement/prospectus.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Failure to complete, or delays in completing, the potential Merger with Jade, announced on October&#160;31, 2024, could materially and adversely affect Aerovate&#8217;s or Jade&#8217;s results of operations, business, financial results and may cause a decline in the market price of Aerovate common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October&#160;30, 2024, Aerovate entered into the Merger Agreement with Jade, pursuant to which, if all the closing conditions are satisfied or waived, Merger Sub I, a direct, wholly owned subsidiary of Aerovate, will merge with and into Jade, with Jade surviving as a wholly owned subsidiary of Aerovate and the surviving corporation of the First Merger, following which Jade will merge with and into Merger Sub II, with Merger Sub II being the surviving entity of the Second Merger. Consummation of the Merger is subject to certain closing conditions, a number of which are not within Aerovate&#8217;s control. Any failure to satisfy or, to the extent permitted by applicable law, waive these required closing conditions may prevent, delay or otherwise materially adversely affect the consummation of the Merger. Aerovate cannot predict with certainty whether or when any of the required conditions will be satisfied or, to the extent permitted by applicable law, waived, or if another uncertainty may arise and cannot assure you that Aerovate will be able to successfully consummate the Merger as currently contemplated under the Merger Agreement or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate&#8217;s efforts to complete the Merger could cause substantial disruptions in, and create uncertainty surrounding, Aerovate&#8217;s business, which may materially adversely affect Aerovate&#8217;s results of operation and Aerovate&#8217;s business. Uncertainty as to whether the Merger will be completed may affect Aerovate&#8217;s ability to recruit prospective employees or to retain and motivate existing employees. Employee retention may be particularly challenging while the transaction is pending because employees may experience uncertainty about their roles following the transaction. Uncertainty as to whether the Merger will be completed could adversely affect Aerovate&#8217;s business and Aerovate&#8217;s relationship with collaborators, suppliers, vendors, regulators and other business partners. For example, vendors, collaborators and other counterparties may defer their decisions to work with Aerovate or seek to change their existing business relationships with Aerovate. Changes to, or termination of, existing business relationships could adversely affect Aerovate&#8217;s results of operations and financial condition, as well as the market price of Aerovate common stock. The adverse effects of the pendency of the transaction could be exacerbated by any delays in completion of the transaction or termination of the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Exchange Ratio will not be adjusted based on the market price of Aerovate common stock as the Exchange Ratio depends on the Aerovate Net Cash at the Closing and not the market price of Aerovate common stock, so the Merger consideration at the Closing may have a greater or lesser value than at the time the Merger Agreement was signed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the First Effective Time, as described in the Merger Agreement, outstanding shares of Jade capital stock will be converted into shares of Aerovate common stock. Based on Aerovate&#8217;s and Jade&#8217;s capitalization as of October&#160;30, 2024, the Exchange Ratio is estimated to be equal to approximately 21.4388 shares of Aerovate common stock for each share of Jade common stock and 0.0214388 shares of Aerovate Series A Preferred Stock for each share of Jade Preferred Stock. After applying the Exchange Ratio, the former Jade securityholders immediately before the Merger, excluding shares purchased in the Jade Pre-Closing Financing, are expected to own approximately 34.0% of the aggregate number of shares of Aerovate common stock on a fully-diluted basis, shares issued in the Jade Pre-Closing Financing are expected to represent approximately 64.4% of the outstanding shares of Aerovate common stock on a fully-diluted basis and Aerovate securityholders immediately before the Merger are expected to own approximately 1.6% of the aggregate number of shares of Aerovate common stock on a fully-diluted basis, subject to certain assumptions, including, but not limited to, Aerovate&#8217;s Net Cash as of Closing being no less than $0. In the event Aerovate&#8217;s Net Cash is below $0, the Exchange Ratio will be adjusted such that the number of shares issued to Jade&#8217;s pre-Closing securityholders will be increased, and Aerovate stockholders will own a smaller&#160;percentage of the Combined Company.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any changes in the market price of Aerovate common stock before the completion of the Merger will not affect the Exchange Ratio or the number of shares Jade stockholders will be entitled to receive pursuant to the Merger Agreement. Therefore, if before the completion of the Merger, the market price of Aerovate common stock increases from the market price on the date of the Merger Agreement, then Jade stockholders could receive Merger consideration with substantially more value for their shares of Jade capital stock than the parties had negotiated when they established the Exchange Ratio. Similarly, if before the completion of the Merger the market price of Aerovate common stock declines from the market price on the date of the Merger Agreement, then Jade stockholders could receive Merger consideration with substantially lower value than the parties negotiated when they established the Exchange Ratio. The Merger Agreement does not include a price-based termination right.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The issuance of Aerovate common stock to Jade stockholders pursuant to the Merger Agreement and the resulting change in control from the Merger must be approved by Aerovate stockholders, and the Merger Agreement and transactions contemplated thereby must be approved by the Jade stockholders. Failure to obtain these approvals would prevent the Closing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Before the Merger can be completed, Aerovate stockholders must approve, among other things, the issuance of Aerovate common stock to Jade stockholders pursuant to the Merger Agreement and the resulting change in control from the Merger, and Jade stockholders must adopt the Merger Agreement and approve the Merger and the related transactions. Failure to obtain the required stockholder approvals may result in a material delay in, or the abandonment of, the Merger. Any delay in completing the Merger may materially adversely affect the timing and benefits that are expected to be achieved from the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Failure to complete the Merger may result in either Aerovate or Jade paying a termination fee to the other party, and could harm the common stock price of Aerovate and future business and operations of each company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">If the Merger is not completed, Aerovate and Jade are subject to the following risks:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if the Merger Agreement is terminated under specified circumstances, Aerovate could be required to pay Jade a termination fee of $2.34 million, or Jade could be required to pay Aerovate a termination fee of $5.25 million;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the price of Aerovate common stock may decline and could fluctuate significantly; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial costs related to the Merger may be incurred by either party, such as financial advisor, legal and accounting fees, a majority of which must be paid even if the Merger is not completed.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Merger Agreement is terminated and the board of directors of Aerovate or Jade determines to seek another business combination, there can be no assurance that either Aerovate or Jade will be able to find another third party to transact a business combination with, yielding comparable or greater benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the conditions to the Merger are not satisfied or waived, the Merger may not occur.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if the Merger is approved by the stockholders of Jade and Proposal Nos. 1, 2 and 3 as described in this proxy statement/prospectus are approved by the Aerovate stockholders, specified conditions must be satisfied or, to the extent permitted by applicable law, waived to complete the Merger. These conditions are set forth in the Merger Agreement and each material condition to the completion of the Merger is described in the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#160;&#8212; Conditions to the Completion of the Merger</i>&#8221; beginning on page&#160;149 of this proxy statement/prospectus. Aerovate and Jade cannot assure you that all of the conditions to the consummation of the Merger will be satisfied or waived. If the conditions are not satisfied or waived, the Merger may not occur or the Closing may be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Merger may be completed even though a material adverse effect may result from the announcement of the Merger, industry-wide changes or other causes.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In general, neither Aerovate nor Jade is obligated to complete the Merger if there is a material adverse effect affecting the other party between October&#160;30, 2024, the date of the Merger Agreement, and the Closing. However, certain types of events and/or causes are excluded from the concept of a &#8220;material adverse effect.&#8221; Such exclusions include, but are not limited to, changes in general economic or political conditions, industry wide changes, changes resulting from the announcement of the Merger, natural disasters, pandemics (including the COVID-19 pandemic), other public health events, other force majeure events, acts or threat of terrorism or war and changes in U.S. GAAP. Therefore, if any of these events were to occur and adversely affect Aerovate or Jade, the other party would still be obligated to consummate the Closing notwithstanding such material adverse effects. If any such adverse effects occur </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and Aerovate and Jade consummates the Closing, the stock price of the Combined Company may suffer. This, in turn, may reduce the value of the Merger to the stockholders of Aerovate, Jade or both. For a more complete discussion of what constitutes a material adverse effect on Aerovate or Jade, please see the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#160;&#8212; Representations and Warranties</i>&#8221; beginning on page&#160;142 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If Aerovate and Jade complete the Merger, the Combined Company will need to raise additional capital by issuing equity securities or additional debt or through licensing arrangements, which may cause significant dilution to the Combined Company&#8217;s stockholders or restrict the Combined Company&#8217;s operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October&#160;30, 2024, Jade entered into a securities purchase agreement with certain investors, including existing investors of Jade, pursuant to which Jade agreed to sell, and the investors agreed to purchase, immediately prior to the consummation of the Merger, shares of Jade common stock and pre-funded warrants for an aggregate purchase price of approximately $300.0 million in the Jade Pre-Closing Financing. The closing of the Jade Pre-Closing Financing is conditioned upon the satisfaction or waiver of the conditions to the Closing as well as certain other conditions. The shares of Jade common stock issued in the Jade Pre- Closing Financing will result in dilution to all securityholders of the Combined Company (i.e., both the pre- Merger Aerovate securityholders and former pre-Merger Jade securityholders). The Jade Pre-Closing Financing is more fully described under the section titled &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#160;&#8212; Subscription Agreement</i>&#8221; beginning on page&#160;153 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additional financing may not be available to the Combined Company when it is needed or may not be available on favorable terms. To the extent that the Combined Company raises additional capital by issuing equity securities, such financing will cause additional dilution to all securityholders of the Combined Company, including Aerovate&#8217;s pre-Merger securityholders and Jade&#8217;s former securityholders. It is also possible that the terms of any new equity securities may have preferences over the Combined Company&#8217;s common stock. Any debt financing the Combined Company enters into may involve covenants that restrict its operations. These restrictive covenants may include limitations on additional borrowing and specific restrictions on the use of the Combined Company&#8217;s assets, as well as prohibitions on its ability to create liens, pay dividends, redeem its stock or make investments. In addition, if the Combined Company raises additional funds through licensing arrangements, it may be necessary to grant licenses on terms that are not favorable to the Combined Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Some Aerovate and Jade directors and executive officers have interests in the Merger that are different from yours.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Directors and executive officers of Aerovate and Jade may have interests in the Merger that are different from, or in addition to, the interests of other Aerovate stockholders generally. These interests with respect to Aerovate&#8217;s directors and executive officers may include, among others, acceleration of stock option or restricted stock unit vesting, retention bonus payments, extension of exercisability periods of previously issued stock option grants, severance payments if employment is terminated in a qualifying termination in connection with the Merger and rights to continued indemnification, expense advancement and insurance coverage. These interests with respect to Jade&#8217;s directors and executive officers may include, among others, certain of Jade&#8217;s directors and executive officers have options, subject to vesting, to purchase shares of Jade common stock which, after the effective time of the Merger, will be converted into and become options to purchase shares of the common stock of the Combined Company; Jade&#8217;s executive officers are expected to continue as executive officers of the Combined Company after the effective time of the Merger; and all of Jade&#8217;s directors and executive officers are entitled to certain indemnification and liability insurance coverage pursuant to the terms of the Merger Agreement. In addition, certain of Aerovate&#8217;s directors and Jade&#8217;s directors are affiliated with investment funds which hold an interest in the other party, and are participating in the Jade Pre-Closing Financing. Further, current members of Jade&#8217;s board of directors will continue as directors of the Combined Company after the effective time of the Merger, and, following the Closing, will be eligible to be compensated as non-employee directors of the Combined Company pursuant to the Aerovate non-employee director compensation policy that is expected to remain in place following the effective time of the Merger. The directors and executive officers own options and/or, with respect to Aerovate, restricted stock units, to purchase the shares of their respective companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Aerovate and Jade boards considered the interests in the Merger that the respective directors and officers may have that are different than yours, among other matters, in reaching their decisions to approve and adopt the Merger Agreement, approve the Merger, and recommend the approval of the Merger Agreement to Aerovate and Jade stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For more information regarding the interests of Aerovate and Jade directors and executive officers in the Merger, please see the sections titled &#8220;<i style="font-style:italic;">The Merger&#160;&#8212; Interests of Aerovate Directors and Executive Officers in the Merger</i>&#8221; and &#8220;<i style="font-style:italic;">The Merger&#160;&#8212; Interests of Jade Directors and Executive Officers in the Merger</i>&#8221; beginning on pages&#160;124 and 126, respectively, of this proxy statement/prospectus.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate stockholders and Jade stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger, including the conversion of Jade common stock issued in the Jade Pre-Closing Financing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Combined Company is unable to realize the full strategic and financial benefits currently anticipated from the Merger, Aerovate stockholders and Jade stockholders will have experienced substantial dilution of their ownership interests without receiving any commensurate benefit, or only receiving part of the commensurate benefit to the extent the Combined Company is able to realize only part of the strategic and financial benefits currently anticipated from the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the Merger is not completed, Aerovate&#8217;s stock price may decline significantly.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The market price of Aerovate common stock is subject to significant fluctuations. Market prices for securities of pharmaceutical, biotechnology and other life science companies have historically been particularly volatile. In addition, the market price of Aerovate common stock will likely be volatile based on whether stockholders and other investors believe that Aerovate can complete the Merger or otherwise raise additional capital to support Aerovate&#8217;s operations if the Merger is not consummated and another strategic transaction cannot be identified, negotiated and consummated in a timely manner, if at all. The volatility of the market price of Aerovate common stock is exacerbated by low trading volume. Additional factors that may cause the market price of Aerovate common stock to fluctuate include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the entry into, or termination of, key agreements, including commercial partner agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements by commercial partners or competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the loss of key employees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future sales of its common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general and industry-specific economic conditions that may affect its research and development expenditures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the failure to meet industry analyst expectations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">period-to-period fluctuations in financial results.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of Aerovate common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate and Jade securityholders will generally have a reduced ownership and voting interest in, and will exercise less influence over the management of, the Combined Company following the completion of the Merger as compared to their current ownership and voting interests in the respective companies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After the completion of the Merger, the current stockholders of Aerovate and Jade will generally own a smaller&#160;percentage of the Combined Company than their ownership of their respective companies prior to the Merger. Immediately after the Merger, Aerovate stockholders as of immediately prior to the Merger are expected to own approximately 1.6% of the outstanding shares of the Combined Company on a fully- diluted basis, former Jade securityholders, excluding shares purchased in the Jade Pre-Closing Financing, are expected to own approximately 34.0% of the outstanding shares of the Combined Company on a fully- diluted basis and shares issued in the Jade Pre-Closing Financing are expected to represent approximately 64.4% of the outstanding shares of capital stock of the Combined Company on a fully-diluted basis, subject to certain assumptions, including, but not limited to, Aerovate&#8217;s Net Cash as of Closing being $0. The Chief Executive Officer of Jade will serve as the Chief Executive Officer of the Combined Company following the completion of the Merger.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">During the pendency of the Merger, Aerovate and Jade may not be able to enter into a business combination with another party on more favorable terms because of restrictions in the Merger Agreement, which could adversely affect their respective business prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Covenants in the Merger Agreement impede the ability of Aerovate and Jade to make acquisitions during the pendency of the Merger, subject to specified exceptions. As a result, if the Merger is not completed, the parties may be at a disadvantage to their competitors during that period. In addition, while the Merger Agreement is in effect, each party is generally prohibited from soliciting, seeking, initiating or knowingly encouraging, inducing or facilitating the communication, making, submission or announcement of any acquisition proposal or acquisition inquiry or taking any action that could reasonably be expected to lead to certain transactions involving a third party, including a merger, sale of assets or other business combination, subject to specified exceptions. Any such transactions could be favorable to such party&#8217;s stockholders, but the parties may be unable to pursue them. For more information, please see the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#160;&#8212; Non-Solicitation</i>&#8221; beginning on page&#160;145 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Certain provisions of the Merger Agreement may discourage third parties from submitting competing proposals, including proposals that may be superior to the transactions contemplated by the Merger Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The terms of the Merger Agreement prohibit each of Aerovate and Jade from soliciting competing proposals or cooperating with persons making unsolicited takeover proposals, except in limited circumstances as described in further detail in the sections titled &#8220;<i style="font-style:italic;">The Merger Agreement&#160;&#8212; Non-Solicitation</i>&#8221; beginning on page&#160;145 of this proxy statement/prospectus. In addition, if Aerovate terminates the Merger Agreement under specified circumstances, Aerovate could be required to pay Jade a termination fee of $2.34 million, or Jade could be required to pay Aerovate a termination fee of $5.25 million. This termination fee may discourage third parties from submitting competing proposals to Aerovate, Jade or their respective stockholders, and may cause the Aerovate or Jade board of directors to be less inclined to recommend a competing proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Because the lack of a public market for Jade&#8217;s capital stock makes it difficult to evaluate the fair market value of Jade&#8217;s capital stock, the value of the Aerovate common stock to be issued to Jade stockholders may be more or less than the fair market value of Jade&#8217;s capital stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The outstanding capital stock of Jade is privately held and is not traded in any public market. The lack of a public market makes it difficult to determine the fair market value of Jade&#8217;s capital stock. Because the&#160;percentage of Aerovate equity to be issued to Jade stockholders was determined based on negotiations between the parties, it is possible that the value of the Aerovate common stock and Aerovate Series&#160;A Non- Voting Convertible Preferred Stock (the &#8220;Aerovate Series&#160;A Preferred Stock&#8221;) to be issued to Jade stockholders will be more or less than the fair market value of Jade&#8217;s capital stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Lawsuits may be filed against Aerovate, Jade, or any of the members of their respective boards of directors arising out of the Merger, which may delay or prevent the Merger.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Putative stockholder complaints, including stockholder class action complaints, and other complaints may be filed against Aerovate, the Aerovate board of directors, Jade, the Jade board of directors and others in connection with the transactions contemplated by the Merger Agreement. The outcome of litigation is uncertain, and Aerovate or Jade may not be successful in defending against any such future claims. Lawsuits that may be filed against Aerovate, the Aerovate board of directors, Jade, or the Jade board of directors could delay or prevent the Merger, divert the attention of Aerovate&#8217;s or Jade&#8217;s management and employees from their day-to-day business and otherwise adversely affect Aerovate and Jade financially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate is substantially dependent on Aerovate&#8217;s remaining employees to facilitate the consummation of the Merger.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of November&#160;15, 2024, Aerovate had only four full-time employees. Aerovate&#8217;s ability to successfully complete the Merger depends in large part on Aerovate&#8217;s ability to retain certain remaining personnel. Despite Aerovate&#8217;s efforts to retain these employees, one or more employees may terminate their employment with Aerovate on short notice. The loss of the service of certain employees could potentially harm Aerovate&#8217;s ability to consummate the Merger and run Aerovate&#8217;s day-to-day business operations, as well as fulfill Aerovate&#8217;s reporting obligations as a public company.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to the Proposed Reverse Stock Split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The reverse stock split may not increase the Combined Company&#8217;s stock price over the long-term.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The principal purpose of the reverse stock split is to increase the per-share market price of Aerovate&#8217;s common stock above the minimum bid price requirement under the Nasdaq rules&#160;so that the listing of Aerovate and the shares of Aerovate common stock being issued in the Merger on Nasdaq will be approved. It cannot be assured, however, that the reverse stock split will accomplish this objective for any meaningful period of time. While it is expected that the reduction in the number of outstanding shares of common stock will proportionally increase the market price of Aerovate&#8217;s common stock, it cannot be assured that the reverse stock split will increase the market price of its common stock by a multiple of the reverse stock split ratio mutually agreed by Aerovate and Jade, or result in any permanent or sustained increase in the market price of Aerovate&#8217;s common stock, which is dependent upon many factors, including Aerovate&#8217;s business and financial performance, general market conditions and prospects for future success. Thus, while the stock price of Aerovate might meet the listing requirements for Nasdaq initially, it cannot be assured that it will continue to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The reverse stock split may decrease the liquidity of the Combined Company&#8217;s common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although the Aerovate board believes that the anticipated increase in the market price of the Combined Company&#8217;s common stock resulting from the proposed reverse stock split could encourage interest in its common stock and possibly promote greater liquidity for its stockholders, such liquidity could also be adversely affected by the reduced number of shares outstanding after the reverse stock split. The reduction in the number of outstanding shares may lead to reduced trading and a smaller number of market makers for the Combined Company&#8217;s common stock. In addition, the reverse stock split may not result in an increase in the Combined Company&#8217;s stock price necessary to satisfy Nasdaq&#8217;s initial listing requirements for the Combined Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The reverse stock split may lead to a decrease in the Combined Company&#8217;s overall market capitalization.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Should the market price of the Combined Company&#8217;s common stock decline after the reverse stock split, the&#160;percentage decline may be greater, due to the smaller number of shares outstanding, than it would have been prior to the reverse stock split. A reverse stock split is often viewed negatively by the market and, consequently, can lead to a decrease in the Combined Company&#8217;s overall market capitalization. If the per share market price does not increase in proportion to the reverse stock split ratio, then the value of the Combined Company, as measured by its stock capitalization, will be reduced. In some cases, the per-share stock price of companies that have effected reverse stock splits subsequently declined back to pre-reverse split levels, and accordingly, it cannot be assured that the total market value of the Combined Company&#8217;s common stock will remain the same after the reverse stock split is effected, or that the reverse stock split will not have an adverse effect on the Combined Company&#8217;s stock price due to the reduced number of shares outstanding after the reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Aerovate</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate may not be successful in consummating the Merger.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2024, based upon 24-week topline results from the Phase 2b portion of Aerovate&#8217;s clinical trial evaluating AV-101 for the treatment of PAH, Aerovate announced its decision to halt enrollment and shut down the Phase 3 portion of the trial as well as the long-term extension study. In July&#160;2024, Aerovate announced that it was undertaking a comprehensive review of strategic alternatives focused on maximizing shareholder value, which may include but are not limited to, the Merger or an alternative transaction or liquidation. Aerovate has and expects to continue to devote substantial time and resources to exploring strategic alternatives that its board of directors believes will maximize stockholder value. There can be no assurances that the Merger will be successfully consummated or lead to increased stockholder value or that Aerovate will make any additional cash distributions to its stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The process of completing the Merger may be very costly, time-consuming and complex and Aerovate has incurred, and may in the future incur, significant costs related to the Merger, including legal and accounting fees and expenses and other related charges. Aerovate may also incur additional unanticipated expenses in connection with the Merger, which will be incurred regardless of whether the Merger is completed. These expenses will decrease the remaining cash available for use in Aerovate&#8217;s business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Aerovate is not currently pursuing further clinical development of AV-101. Resuming the development of AV-101 and any potential commercialization would require substantial additional cash to fund the costs associated with conducting the necessary preclinical and clinical testing and obtaining regulatory approval. Consequently, if the Merger is completed, Jade may choose not to spend additional resources to continue development of AV-101 and may attribute little or no value, in the Merger to AV-101. The </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Merger could have a variety of negative consequences, or yield unexpected results that adversely affects Aerovate&#8217;s business and decreases the remaining cash available for use in Aerovate&#8217;s business or the execution of its strategic plan. The completion of the Merger is dependent on a number of factors that may be beyond Aerovate&#8217;s control, including, among other things, market conditions, industry trends and obtaining stockholder approval. Any failure of the Merger could significantly impair Aerovate&#8217;s ability to enter into any future strategic transactions and may significantly diminish or delay any future distributions to Aerovate&#8217;s stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Merger is not completed in a timely fashion, this may cause reputational harm with Aerovate&#8217;s stockholders and the value of Aerovate&#8217;s securities may be adversely impacted. In addition, speculation regarding the completion of the Merger and perceived uncertainties related to the future of Aerovate could cause Aerovate&#8217;s stock price to fluctuate significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If Aerovate is successful in completing a strategic transaction, Aerovate may be exposed to other operational and financial risks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although there can be no assurance that the Merger will be completed, the negotiation and consummation of the Merger will require significant time on the part of Aerovate&#8217;s management, and the diversion of management&#8217;s attention may disrupt Aerovate&#8217;s business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The negotiation and consummation of the Merger may also require more time or greater cash resources than Aerovate anticipates and expose Aerovate to other operational and financial risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased near-term and long-term expenditures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exposure to unknown liabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">higher than expected acquisition or integration costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incurrence of substantial debt or dilutive issuances of equity securities to fund future operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">write-downs of assets or goodwill or incurrence of non-recurring, impairment or other charges;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased amortization expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to retain key employees of Aerovate to complete the Merger; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">possibility of future litigation.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any of the foregoing risks could have a material adverse effect on Aerovate&#8217;s business, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the Merger is not completed, Aerovate&#8217;s board of directors may decide to pursue a dissolution and liquidation. In such an event, the amount of cash available for distribution to Aerovate&#8217;s stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Merger is not completed, Aerovate&#8217;s board of directors may decide to pursue a dissolution and liquidation. In such an event, the amount of cash available for distribution to Aerovate&#8217;s stockholders will depend heavily on the timing of such decision and, with the passage of time the amount of cash available for distribution will be reduced as Aerovate continues to fund its operations. In addition, if Aerovate&#8217;s board of directors were to approve and recommend, and Aerovate&#8217;s stockholders were to approve, a dissolution and liquidation, Aerovate would be required under Delaware corporate law to pay its outstanding obligations, as well as to make reasonable provision for contingent and unknown obligations, prior to making any distributions in liquidation to Aerovate&#8217;s stockholders. As a result of this requirement, a portion of Aerovate&#8217;s assets may need to be reserved pending the resolution of such obligations and the timing of any such resolution is uncertain. In addition, Aerovate may be subject to litigation or other claims related to a dissolution and liquidation. If a dissolution and liquidation were pursued, Aerovate&#8217;s board of directors, in consultation with its advisors, would need to evaluate these matters and make a determination about a reasonable amount to reserve. Accordingly, holders of Aerovate&#8217;s common stock could lose all or a significant portion of their investment in the event of a liquidation, dissolution or winding up.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate&#8217;s ability to consummate the Merger depends on its ability to retain its employees required to consummate such transaction.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate&#8217;s ability to consummate the Merger depends upon Aerovate&#8217;s ability to retain its employees required to consummate such a transaction, the loss of whose services may adversely impact the ability to consummate such transaction. In connection with the evaluation of strategic alternatives and in order to extend resources, Aerovate implemented workforce reduction plan, which resulted in the termination of nearly all of Aerovate&#8217;s workforce (the &#8220;Workforce Reduction Plan&#8221;). Under the Workforce Reduction Plan, approximately 90% of Aerovate&#8217;s workforce was terminated as of September&#160;30, 2024. The Merger process is supported by Aerovate&#8217;s deep and broad experience at the board of directors, executive management and supporting staff levels. Aerovate&#8217;s cash conservation activities may yield unintended consequences, such as attrition beyond Aerovate&#8217;s Workforce Reduction Plan and reduced employee morale, which may cause remaining employees to seek alternative employment. Aerovate&#8217;s ability to successfully complete the Merger depends in large part on its ability to retain certain of its remaining personnel. If Aerovate is unable to successfully retain its remaining personnel, Aerovate is at risk of a disruption to the Merger process as well as business operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate&#8217;s cash preservation activities, including the Workforce Reduction Plan, may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt Aerovate&#8217;s business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2024, Aerovate implemented its Workforce Reduction Plan. In connection with the Workforce Reduction Plan, Aerovate incurred costs of approximately $6.4 million, which are primarily one-time severance benefits. Aerovate may not realize, in full or in part, the anticipated benefits, savings and improvements in its cost structure from its restructuring efforts due to unforeseen difficulties, delays or unexpected costs. If Aerovate is unable to realize the expected operational efficiencies and cost savings from the restructuring, its operating results and financial condition would be adversely affected. Furthermore, Aerovate&#8217;s Workforce Reduction Plan may be disruptive to its operations. For example, headcount reductions could yield unanticipated consequences, such as increased difficulties in implementing Aerovate&#8217;s business strategy, including retention of remaining employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Due to Aerovate&#8217;s limited resources, Aerovate may not be able to effectively manage its operations, which may result in weaknesses in Aerovate&#8217;s infrastructure, risks that Aerovate may not be able to comply with legal and regulatory requirements, and loss of employees and reduced productivity among remaining employees. For example, Aerovate&#8217;s limited resources and workforce reduction may negatively impact efforts to winddown Aerovate&#8217;s clinical trial activities or expose Aerovate to cybersecurity risks, which could result in unexpected costs and expenses and have a material adverse effect on Aerovate&#8217;s business, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate may become involved in litigation, including securities class action litigation, that could divert management&#8217;s attention and harm Aerovate&#8217;s business, and insurance coverage may not be sufficient to cover all costs and damages.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the past, litigation, including securities class action litigation, has often followed certain significant business transactions, such as a merger, or the announcement of negative events, such as negative results from clinical trials. These events may also result in investigations by the SEC. Aerovate may be exposed to such litigation in connection with the Merger even if no wrongdoing occurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, the stock market in general, and Nasdaq and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. The market price of Aerovate&#8217;s common stock may be volatile, and Aerovate may be the target of this type of litigation in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Litigation is usually expensive and diverts management&#8217;s attention and resources from other business concerns, which could adversely affect Aerovate&#8217;s business and cash resources and its ability to consummate the Merger or the ultimate value Aerovate&#8217;s stockholders receive in any such transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Aerovate&#8217;s Limited Operating History, Financial Position and Capital Requirements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate is a biopharmaceutical company with a limited operating history.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Aerovate is a biopharmaceutical company established in July&#160;2018 with a limited operating history. Since its inception, Aerovate had devoted substantially all of its efforts to organizing and staffing Aerovate, research and development of AV-101, Aerovate&#8217;s only product candidate, business planning, raising capital, and providing general and administrative support for these operations. Aerovate </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">has limited experience and has not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the pharmaceutical industry. In June&#160;2024, Aerovate announced its decision to halt enrollment and shut down the Phase 3 portion of its IMPAHCT clinical trial for AV-101 in adults with PAH as well as the long-term extension study. Aerovate does not intend to resume development of AV-101 or conduct research on additional product candidates at this time. Aerovate has no products approved for commercial sale and therefore has never generated any revenue from product sales, and does not expect to in the foreseeable future. Aerovate has no other experience as a company conducting clinical trials, submitting applications for regulatory approvals, such as a New Drug Application (&#8220;NDA&#8221;), or commercializing any products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate has incurred significant operating losses since its inception and anticipates that it will continue to incur losses for the foreseeable future. Aerovate may never achieve or maintain profitability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate has incurred significant operating losses in each&#160;year since its incorporation in July&#160;2018, does not expect to become profitable in the near future, and may never achieve profitability. Aerovate&#8217;s net losses were $64.2 million and $55.1 million for the nine&#160;months ended September&#160;30, 2024 and 2023, respectively. As of September&#160;30, 2024, Aerovate had an accumulated deficit of $227.6 million. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. Aerovate has no products approved for commercial sale, has not generated any revenue from product sales and has incurred losses in each&#160;year since its inception in July&#160;2018. Substantially all of its operating losses have resulted from costs incurred in connection with its research and development program of AV-101 and from general and administrative costs associated with its operations. Aerovate does not intend to resume development of AV-101 or conduct research on additional product candidates at this time. As a public company, Aerovate continues to incur additional costs associated with operating that it did not incur as a private company. In addition, Aerovate expects to continue to incur costs and expenditures in connection with the process of winding down its clinical trial of AV-101 and the Merger. As a result, Aerovate expects to continue to incur significant expenses and operating losses for the foreseeable future. Because of the numerous risks and uncertainties associated with the Merger process, Aerovate is unable to predict the extent of any future losses. Aerovate&#8217;s prior losses, combined with expected future losses, have had and will continue to have an adverse effect on its stockholders&#8217; deficit and working capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The amount of Aerovate&#8217;s future losses is uncertain and its quarterly and annual operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause its stock price to fluctuate or decline. Aerovate&#8217;s quarterly and annual operating results may fluctuate significantly in the future due to a variety of factors, many of which are outside of Aerovate&#8217;s control and may be difficult to predict, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and outcome of the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the experience of any delays or any issues with winding down Aerovate&#8217;s clinical trial activities for AV-101;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aerovate&#8217;s ability to retain necessary personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential litigation, including securities class action litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the changing and volatile United States and global economic conditions; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future accounting pronouncements or changes in Aerovate&#8217;s accounting policies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The cumulative effects of these factors could result in large fluctuations and unpredictability in Aerovate&#8217;s quarterly and annual operating results. As a result, comparing Aerovate&#8217;s operating results on a period-to-period basis may not be meaningful. This variability and unpredictability could also result in Aerovate failing to meet the expectations of industry or financial analysts or investors for any period. If Aerovate&#8217;s revenue or operating results fall below the expectations of analysts or investors or below any forecasts Aerovate may provide to the market, or if the forecasts Aerovate provides to the market are below the expectations of analysts or investors, the price of Aerovate&#8217;s common stock could decline substantially. Such a stock price decline could occur even when Aerovate has met any previously publicly stated guidance it may provide.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:20pt;text-indent:-20pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate has no products approved for commercial sale and has not generated any revenue from product sales.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate&#8217;s ability to become profitable depends upon its ability to generate revenue. To date, Aerovate has not generated revenue, and does not expect to generate any revenue in the near future. Aerovate does not intend to resume development of AV-101 or conduct research on additional product candidates at this time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate may require additional capital to finance its operations, which may not be available on acceptable terms, or at all. If Aerovate is unable to raise capital when needed, Aerovate would be forced to delay, reduce or terminate its product development or commercialization efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since its inception, Aerovate had invested substantially all of its efforts and financial resources in the development of AV-101 to address the core disease processes of PAH. Aerovate does not intend to resume development of AV-101 or conduct research on additional product candidates at this time. As of September&#160;30, 2024, Aerovate had cash and cash equivalents and short-term investments of $88.7 million. Aerovate expects its existing cash and cash equivalents and short-term investments will be sufficient to fund its planned operations for at least twelve&#160;months from the date of filing this proxy statement/ prospectus based upon its current operating plans. However, Aerovate&#8217;s operating plans may change as a result of many factors currently unknown to Aerovate, and Aerovate may need to seek additional funds sooner than planned. In addition, Aerovate may seek additional capital due to favorable market conditions or strategic considerations even if it believes it has sufficient funds for its current or future operating plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To date, Aerovate has funded its operations through private placements of convertible preferred stock, convertible notes and proceeds from its initial public offering (&#8220;Aerovate&#8217;s IPO&#8221;). Aerovate will be required to seek additional funding in the future and currently intends to do so through public or private equity offerings or debt financings, credit or loan facilities or a combination of one or more of these funding sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Aerovate raises additional funds by issuing equity securities, its stockholders will suffer dilution and the terms of any financing may adversely affect the rights of its stockholders. In addition, as a condition to providing additional funds to Aerovate, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, is likely to involve restrictive covenants limiting Aerovate&#8217;s flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of Aerovate&#8217;s equity securities would receive any distribution of Aerovate&#8217;s corporate assets. Additionally, global economic instability, higher interest rates and diminished credit availability may limit Aerovate&#8217;s ability to obtain debt financing on favorable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate&#8217;s ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond Aerovate&#8217;s control. Fundraising efforts may divert Aerovate&#8217;s management from their day-to-day activities, which may adversely affect Aerovate&#8217;s ability to develop and commercialize such product candidates. Disruptions in the financial markets in general, and due to public health crises, geopolitical conflicts and economic instability, may make equity and debt financing more difficult to obtain, and may have a material adverse effect on Aerovate&#8217;s ability to meet its fundraising needs. Aerovate cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to Aerovate, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Aerovate&#8217;s Research and Development Activities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The results of earlier studies and trials may not be predictive of future trial results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Product candidates in later stages of clinical trials may fail to show the desired pharmacological properties or safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. For example, in June&#160;2024, Aerovate announced the discontinuation of the Phase 3 portion of IMPAHCT as well as the long-term extension study, despite prior positive results in preclinical studies and initial clinical trials of AV-101.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interim, topline and preliminary results from preclinical studies and clinical trials that Aerovate may announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">From time to time, Aerovate has publicly disclosed preliminary, interim or topline data from its preclinical studies and clinical trials. These interim updates are based on a preliminary analysis of then- available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. Aerovate also makes assumptions, estimations, calculations and conclusions as part of its analyses of data, and Aerovate may not have received </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that Aerovate reports may differ from future results of the same studies or trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data Aerovate previously published. As a result, topline data should be viewed with caution until the final data are available. In addition, Aerovate may report interim analyses of only certain endpoints rather than all endpoints. Interim data from clinical trials that Aerovate may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse changes between interim data and final data could significantly harm Aerovate&#8217;s business and prospects. Further, additional disclosure of interim data by Aerovate or by its competitors in the future could result in volatility in the price of Aerovate&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the information Aerovate chooses to publicly disclose regarding a particular study or trial is typically selected from a more extensive amount of available information. Investors may not agree with what Aerovate determines is the material or otherwise appropriate information to include in Aerovate&#8217;s disclosure, and any information Aerovate determines not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or Aerovate&#8217;s business. If the preliminary or topline data that Aerovate reports differ from late, final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, Aerovate&#8217;s ability to obtain approval for, and commercialize, any of its product candidates may be harmed, which could harm Aerovate&#8217;s business, financial condition, results of operations and prospects.</p><a id="RiskFactor_Risk_Aerovate_Intel_Prop"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Aerovate&#8217;s Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate has six issued U.S. patents, and many pending patent applications with respect to AV-101. Aerovate can provide no assurance that any of its other current or future patent applications will result in issued patents. If Aerovate cannot protect its patent rights or its other proprietary rights, others may develop products similar or identical to Aerovate&#8217;s, and Aerovate may not be able to compete effectively in its market or successfully commercialize any product candidates Aerovate may develop.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate&#8217;s success has depended to a significant degree upon Aerovate continuing to secure, enforce and defend intellectual property rights that protect its AV-101 product candidate, and to operate Aerovate&#8217;s business without infringing, misappropriating or otherwise violating the intellectual property rights of others. If Aerovate is unable to obtain and maintain sufficient intellectual property protection for AV-101, or if the scope of the intellectual property protection obtained is not sufficiently broad, Aerovate&#8217;s competitors and other third parties could develop and commercialize product candidates similar or identical to Aerovate&#8217;s, and Aerovate&#8217;s ability to successfully commercialize AV-101 may be impaired. In June&#160;2024, Aerovate announced its decision to halt enrollment and shut down the Phase 3 portion of IMPAHCT as well as the long-term extension study of AV-101 in PAH, and Aerovate does not intend to continue to seek or maintain intellectual property protection on the technology underlying AV-101.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate owns six issued U.S. patents with respect to AV-101, and can provide no assurance that any of its other current or future patent applications will result in issued patents or that any issued patents will provide Aerovate with any competitive advantage. Failure to obtain additional issued patents could have a material adverse effect on Aerovate&#8217;s ability to develop and commercialize its product candidates. Furthermore, other parties may successfully challenge, invalidate or circumvent Aerovate&#8217;s issued patents so that Aerovate&#8217;s patent rights do not create an effective competitive barrier or revenue source.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate has sought to protect its proprietary position by, among other things, filing patent applications in the United States and abroad related to Aerovate&#8217;s proprietary technologies, development programs and product candidates. The patent prosecution process is expensive and time-consuming, and Aerovate may not be able to file and prosecute all necessary or desirable patent applications or to maintain, defend and enforce any patents that may issue from such patent applications at a reasonable cost or in a timely manner. It is also possible that Aerovate will fail to identify patentable aspects of its research and development output before it is too late to obtain patent protection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, any of Aerovate&#8217;s non-provisional patent applications may fail to result in issued patents with claims that cover its proprietary products and technology, including its AV-101 product candidate or any other product candidate in the United States or in other foreign countries, in whole or in part. Although Aerovate enters into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of its research and development output, such as its employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach these agreement and disclose such results before a patent application is filed, thereby jeopardizing Aerovate&#8217;s ability to seek patent protection.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal, technological and factual questions and has, in recent&#160;years, been the subject of much debate and litigation throughout the world. In addition, the laws of foreign countries may not protect Aerovate&#8217;s rights to the same extent as the laws of the United States, or vice versa. As a result, the issuance, scope, validity, enforceability, and commercial value of Aerovate&#8217;s patent rights are highly uncertain. The subject matter claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Therefore, Aerovate&#8217;s pending and future patent applications may not result in patents being issued in relevant jurisdictions that protect Aerovate&#8217;s product candidates, in whole or in part, or which effectively prevent others from commercializing competitive product candidates, and even if Aerovate&#8217;s patent applications issue as patents in relevant jurisdictions, they may not issue in a form that will provide Aerovate with any meaningful protection for its product candidates or technology, prevent competitors from competing with Aerovate or otherwise provide Aerovate with any competitive advantage. Additionally, Aerovate&#8217;s competitors may be able to circumvent Aerovate&#8217;s patents by developing similar or alternative product candidates or technologies in a non-infringing manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, the natural expiration of a patent is generally 20&#160;years after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Without patent protection for Aerovate&#8217;s current or future product candidates, Aerovate may be open to competition from generic versions of such products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, Aerovate&#8217;s patent portfolio may not provide Aerovate with sufficient rights to exclude others from commercializing products similar or identical to Aerovate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and Aerovate&#8217;s patents may be challenged in the courts or patent offices in the United States and abroad. Aerovate may be subject to a third-party pre-issuance submission of prior art to the United States Patent and Trademark Office (&#8220;USPTO&#8221;), or become involved in opposition, derivation, revocation, reexamination, <i style="font-style:italic;">inter partes </i>review, post-grant review or interference proceedings challenging Aerovate&#8217;s patent rights or the patent rights of others, or other proceedings in the USPTO or applicable foreign offices that challenge priority of invention or other features of patentability. An adverse determination in any such submission, proceeding or litigation could result in loss of exclusivity or freedom to operate, patent claims being narrowed, invalidated or held unenforceable, in whole or in part, limit the scope or duration of the patent protection of AV-101 or any other product candidates that Aerovate may identify, all of which could limit Aerovate&#8217;s ability to stop others from using or commercializing similar or identical product candidates or technology to compete directly with Aerovate, without payment to Aerovate, or result in Aerovate&#8217;s inability to manufacture or commercialize product candidates or approved products (if any) without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by Aerovate&#8217;s patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with Aerovate to license, develop or commercialize current or future product candidates, or could have a material adverse effect on Aerovate&#8217;s ability to raise funds necessary to continue its research programs or clinical trials. Such proceedings also may result in substantial cost and require significant time from Aerovate&#8217;s scientists and management, even if the eventual outcome is favorable to Aerovate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate cannot be certain that the USPTO and courts in the United States or the patent offices and courts in foreign countries will consider the claims in Aerovate&#8217;s patents and applications covering its AV-101 product candidate and possible future product candidates as patentable. Method-of-use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to Aerovate&#8217;s product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for Aerovate&#8217;s targeted indications, physicians may prescribe these products off-label. Although off-label prescriptions may infringe or contribute to the infringement of method-of-use patents, the practice is common and such infringement is difficult to prevent, including through legal action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual property litigation could cause Aerovate to spend substantial resources and prevent Aerovate from pursuing its programs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">From time to time Aerovate may have to defend its intellectual property rights. If Aerovate is involved in an intellectual property dispute, Aerovate may need to litigate to defend its rights or assert them against others. Disputes can involve arbitration, litigation or proceedings declared by the USPTO or the International Trade Commission or foreign patent authorities. Even if resolved in Aerovate&#8217;s favor, litigation or other legal proceedings relating to intellectual property claims may cause Aerovate to incur significant expenses, and could distract Aerovate&#8217;s technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of Aerovate&#8217;s common stock. Such litigation or proceedings could substantially increase Aerovate&#8217;s operating losses and reduce the resources available for </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">development activities or any future sales, marketing or distribution activities. Aerovate may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of Aerovate&#8217;s competitors may be able to sustain the costs of such litigation or proceedings more effectively than Aerovate can because of their greater financial resources and more mature and developed intellectual property portfolios.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Aerovate were to initiate legal proceedings against a third party to enforce a patent covering Aerovate&#8217;s product candidate, the defendant could counterclaim that Aerovate&#8217;s patent is invalid or unenforceable. In patent litigation in the United States and in Europe, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non- enablement. Third parties might allege unenforceability of Aerovate&#8217;s patents because during prosecution of the patent an individual connected with such prosecution withheld relevant information or made a misleading statement. The outcome of proceedings involving assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity of patents, for example, Aerovate cannot be certain that there is no invalidating prior art of which Aerovate&#8217;s and the patent examiner were unaware during prosecution, but that an adverse third party may identify and submit in support of such assertions of invalidity. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, Aerovate would lose at least part, and perhaps all, of the patent protection on its product candidate. Aerovate&#8217;s patents and other intellectual property rights also will not protect Aerovate&#8217;s technology if competitors design around Aerovate&#8217;s protected technology without infringing Aerovate&#8217;s patents or other intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Because of the expense and uncertainty of litigation, Aerovate may not be in a position to enforce its intellectual property rights against third parties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because of the expense and uncertainty of litigation, Aerovate may conclude that even if a third party is infringing Aerovate&#8217;s issued patent, any patents that may be issued as a result of Aerovate&#8217;s pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of Aerovate or its stockholders. In such cases, Aerovate may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Third parties may initiate or threaten legal proceedings alleging that Aerovate is infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of Aerovate&#8217;s business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate&#8217;s commercial success depends upon its ability and the ability of its strategic partners to develop, manufacture, market and sell its drugs and use its proprietary technologies without infringing the proprietary rights and intellectual property of third parties. Extensive litigation regarding patents and other intellectual property rights is common in the biotechnology and pharmaceutical industries. Aerovate may in the future become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to Aerovate&#8217;s drugs and technology, including interference, derivation, reexamination, post-grant review, opposition, cancellation or similar proceedings before the USPTO or its foreign counterparts. Third parties may assert infringement claims against Aerovate based on existing patents or patents that may be granted in the future, resulting in payment of damages. These damages potentially include increased damages and attorneys&#8217; fees if Aerovate is found to have infringed such rights willfully. Parties making claims against Aerovate may seek and obtain injunctive or other equitable relief, which could effectively block Aerovate&#8217;s ability to further develop and commercialize its product candidates. Aerovate may not be aware of all such intellectual property rights potentially relating to its drugs and their uses. If a third party claims that Aerovate&#8217;s AV-101 product candidate, any other product candidates that Aerovate may identify, or Aerovate&#8217;s technology infringes its patents or other intellectual property rights, Aerovate or its partners may have to discontinue an important product or product line, alter products and processes, pay license fees or cease certain activities. Aerovate could be required to obtain a license from such third party in order to continue developing and commercializing AV-101 or other product candidates. However, Aerovate may not be able to obtain a license to needed intellectual property on commercially reasonable terms, if at all. Even if a license can be obtained on reasonable terms, the rights may be nonexclusive, which would give Aerovate&#8217;s competitors access to the same intellectual property rights. Aerovate might also be forced to redesign or modify its product candidates so that Aerovate no longer infringes the third-party intellectual property rights, which may result in significant cost or delay to Aerovate, or which redesign or modification could be impossible or technically infeasible. There are many patents issued or applied for in the biotechnology industry, and Aerovate may not be aware of patents or patent applications held by others that relate to its business. This is especially true since patent applications in the United States are filed confidentially for the first 18&#160;months. Moreover, the validity and breadth of biotechnology patents involve complex legal and factual questions for which important legal issues remain. Thus, Aerovate does not know with certainty that its drugs or the intended commercialization thereof, does and will not infringe or otherwise violate any third party&#8217;s intellectual property.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If Aerovate does not obtain additional protection under the Hatch-Waxman Amendments and similar foreign legislation cannot be obtained to extend the patent protection for a product candidate, business operations may be materially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Depending upon the timing, duration and specifics of the first FDA marketing authorization of a product candidate, a United States patent may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments allow the owner of an approved product to extend patent protection for up to five&#160;years as compensation for patent term lost during product development and the FDA regulatory review process. During this period of extension, the scope of protection is limited to the approved product and approved uses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Patent term restoration for products may not succeed if, for example, there is a failure to apply within applicable deadlines, failure to apply prior to expiration of relevant patents or otherwise a failure to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than requested. Failure to obtain patent term restoration, or if the term of any such patent restoration is less than requested, competitors may enter the market and compete sooner than anticipated, and the ability to generate revenue could be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent which might adversely affect Aerovate&#8217;s ability to develop, manufacture and market its product candidate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate cannot guarantee that any of its patent searches or analyses, including but not limited to the identification of relevant patents, analysis of the scope of relevant patent claims or determination of the expiration of relevant patents, are complete or thorough, nor can Aerovate be certain that it has identified each and every third-party patent and pending application in the United States, Europe and elsewhere that is relevant to or necessary for the commercialization of AV-101 or any other product candidates that Aerovate may identify in any jurisdiction. For example, in the United States, applications filed before November&#160;29, 2000 and certain applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States, EU and elsewhere are published approximately 18&#160;months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering Aerovate&#8217;s product candidates could be filed by others without Aerovate&#8217;s knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover AV-101 or any other product candidates that Aerovate may identify or the use of AV-101 or any other product candidates that Aerovate may identify. After issuance, the scope of patent claims remains subject to construction as determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Aerovate&#8217;s interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact Aerovate&#8217;s ability to market its product candidates. Aerovate may incorrectly determine that AV-101 or any other product candidates that Aerovate may identify is not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Aerovate&#8217;s determination of the expiration date of any patent in the United States, the EU or elsewhere that Aerovate considers relevant may be incorrect, which may negatively impact Aerovate&#8217;s ability to develop and market AV-101 or any other product candidates that Aerovate may identify. Aerovate&#8217;s failure to identify and correctly interpret relevant patents may negatively impact Aerovate&#8217;s ability to develop and market AV-101 or any other product candidates that Aerovate may identify.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Aerovate fails to correctly identify or interpret relevant patents, Aerovate may be subject to infringement claims. Aerovate cannot guarantee that it will be able to successfully settle or otherwise resolve such infringement claims. If Aerovate fails in any such dispute, in addition to being forced to pay monetary damages, Aerovate may be temporarily or permanently prohibited from commercializing AV-101 or any other product candidates that Aerovate may identify. Aerovate might, if possible, also be forced to redesign AV-101 or any other product candidates that Aerovate may identify in a manner that no longer infringes third-party intellectual property rights. Any of these events, even if Aerovate were ultimately to prevail, could require Aerovate to divert substantial financial and management resources that would otherwise be able to be devoted to Aerovate&#8217;s business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in patent law could diminish the value of patents in general, thereby impairing the ability to protect product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Recent court rulings, including rules&#160;from the United States Supreme Court, have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to the ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken the ability to obtain new patents or to enforce existing patents and patents that might be obtained in the future.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the America Invents Act (&#8220;AIA&#8221;), which was passed in September&#160;2011, resulted in significant changes to the U.S. patent system. An important change introduced by the AIA is that, as of March&#160;16, 2013, the United States transitioned from a &#8220;first-to-invent&#8221; to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. Under a &#8220;first-to-file&#8221; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the USPTO. This applies to all U.S. patents, even those issued before March&#160;16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accordingly, a third party may attempt to use the USPTO procedures to invalidate patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. It is not clear what, if any, impact the AIA will have on the operation of Aerovate&#8217;s business. However, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate may become involved in opposition, interference, derivation, inter partes review or other proceedings challenging Aerovate&#8217;s patent rights, and the outcome of any proceedings are highly uncertain. An adverse determination in any such proceeding could reduce the scope of, or invalidate, Aerovate&#8217;s patent rights, allow third parties to commercialize Aerovate&#8217;s technology or products and compete directly with Aerovate, without payment to Aerovate, or result in Aerovate&#8217;s inability to manufacture or commercialize products without infringing third-party patent rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, a new court system recently became operational in the European Union. The Unified Patent Court (&#8220;UPC&#8221;) began accepting patent cases on June&#160;1, 2023. The UPC is a common patent court with jurisdiction over patent infringement and revocation proceedings effective for multiple member states of the European Union. The broad geographic reach of the UPC could enable third parties to seek revocation of any of Aerovate&#8217;s European patents in a single proceeding at the UPC rather than through multiple proceedings in each of the individual European Union member states in which the European patent is validated. Under the UPC, a successful revocation proceeding for a European patent under the UPC would result in loss of patent protection in those European Union countries. Accordingly, a single proceeding under the UPC could result in the partial or complete loss of patent protection in numerous European Union countries. Such a loss of patent protection could have a material adverse impact on Aerovate&#8217;s business and ability to commercialize its technology and product candidates and, resultantly, on Aerovate&#8217;s business, financial condition, prospects and results of operations. Moreover, the controlling laws and regulations of the UPC will develop over time and Aerovate cannot predict what the outcomes of cases tried before the UPC will be. The case law of the UPC may adversely affect Aerovate&#8217;s ability to enforce or defend the validity of its European patents. Patent owners have the option to opt-out their European patents from the jurisdiction of the UPC, defaulting to pre-UPC enforcement mechanisms. Aerovate decided to opt out certain European patents and patent applications from the UPC. However, if certain formalities and requirements are not met, Aerovate&#8217;s European patents and patent applications could be subject to the jurisdiction of the UPC. Aerovate cannot be certain that its European patents and patent applications will avoid falling under the jurisdiction of the UPC, if Aerovate decides to opt out of the UPC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and Aerovate&#8217;s patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The USPTO and European and other patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and European and other patent agencies over the lifetime of a patent. While an inadvertent failure to make payment of such fees or to comply with such provisions can in many cases be cured by additional payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance with such provisions will result in the abandonment or lapse of the patent or patent application, and the partial or complete loss of patent rights in the relevant </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents within prescribed time limits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2024, Aerovate announced its decision to halt enrollment and shut down the Phase 3 portion of IMPAHCT as well as the long-term extension study of AV-101 in PAH, and Aerovate does not intend to continue to seek or maintain intellectual property protection on the technology underlying AV-101. If Aerovate fails to maintain the patents and patent applications covering AV-101 or if Aerovate otherwise allows its patents or patent applications to be abandoned or lapse, it will result in partial or complete loss of patent rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate may be subject to claims challenging the inventorship or ownership of its patents and other intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate generally enters into confidentiality and intellectual property assignment agreements with its employees, consultants, and contractors. These agreements generally provide that inventions conceived by the party in the course of rendering services to Aerovate will be Aerovate&#8217;s exclusive property. However, those agreements may not be honored and may not effectively assign intellectual property rights to Aerovate. Moreover, there may be some circumstances, where Aerovate is unable to negotiate for such ownership rights. Disputes regarding ownership or inventorship of intellectual property can also arise in other contexts, such as collaborations and sponsored research. If Aerovate is subject to a dispute challenging its rights in or to patents or other intellectual property, such a dispute could be expensive and time consuming. If Aerovate were unsuccessful, Aerovate could lose valuable rights in intellectual property that it regards as its own. The issuance of a patent is not conclusive as to its inventorship.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate may be subject to claims that its employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate could in the future be subject to claims that Aerovate or its employees have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of former employers or competitors. Although Aerovate tries to ensure that its employees and consultants do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for Aerovate, Aerovate may become subject to claims that it caused an employee to breach the terms of his or her non- competition or non-solicitation agreement, or that Aerovate or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While Aerovate may litigate to defend itself against these claims, even if Aerovate is successful, litigation could result in substantial costs and could be a distraction to management. If Aerovate&#8217;s defenses to these claims fail, in addition to requiring Aerovate to pay monetary damages, a court could prohibit Aerovate from using technologies or features that are essential to its product candidates, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect Aerovate&#8217;s reputation, its ability to form strategic alliances or sublicense its rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on Aerovate&#8217;s business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If Aerovate is unable to protect the confidentiality of its trade secrets, Aerovate&#8217;s business and competitive position would be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate relies on trade secrets and confidentiality agreements to protect its unpatented know-how, technology and other proprietary information and to maintain its competitive position. Trade secrets and know-how can be difficult to protect. Aerovate seeks to protect these trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as Aerovate&#8217;s employees, collaborators consultants, advisors and other third parties. Aerovate also enters into confidentiality and invention or patent assignment agreements with its employees and consultants. Aerovate cannot guarantee that it has entered into such agreements with each party that may have or has had access to Aerovate&#8217;s trade secrets or proprietary technology and processes. Despite these efforts, any of these parties may breach the agreements and disclose Aerovate&#8217;s proprietary information, including its trade secrets, and Aerovate may not be able to obtain adequate remedies for such breaches. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of Aerovate&#8217;s product candidates that Aerovate considers proprietary. Monitoring unauthorized uses and disclosures is difficult, and Aerovate does not know whether the steps it has taken to protect its proprietary information will be effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Aerovate also seeks to preserve the integrity and confidentiality of its confidential proprietary information by maintaining physical security of its premises and physical and electronic security of its information technology systems, but it is possible that these </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">security measures could be breached. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time- consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of Aerovate&#8217;s trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, Aerovate would have no right to prevent them from using that technology or information to compete with Aerovate. If any of Aerovate&#8217;s trade secrets were to be disclosed to or independently developed by a competitor or other third party, Aerovate&#8217;s competitive position would be materially and adversely harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If Aerovate and its partners do not adequately protect the trademarks and trade names for Aerovate&#8217;s products, then Aerovate and its partners may not be able to build name recognition in Aerovate&#8217;s markets of interest and Aerovate&#8217;s business may be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate&#8217;s competitors or other third parties may challenge, infringe or circumvent the trademarks or trade names for its products. Aerovate and its partners may not be able to protect these trademarks and trade names. In addition, if the trademarks or trade names for one of Aerovate&#8217;s products infringe the rights of others, Aerovate or its partners may be forced to stop using the trademarks or trade names, which Aerovate needs for name recognition in its markets of interest. If Aerovate cannot establish name recognition based on its trademarks and trade names, Aerovate and its partners may not be able to compete effectively and Aerovate&#8217;s business may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Government Regulation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate may be unable to obtain regulatory approval under applicable regulatory requirements. The denial or delay of any such approval would delay commercialization of any product candidates and adversely impact Aerovate&#8217;s potential to generate revenue, its business and its results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate has not previously submitted an NDA or any other marketing application to the FDA or similar filings to comparable foreign regulatory authorities. An NDA or other similar regulatory filing requesting approval to market a product candidate must include extensive preclinical and clinical data and supporting information to establish that the product candidate is safe, effective, pure and potent for each desired indication. The NDA or other similar regulatory filing must also include significant information regarding the chemistry, manufacturing and controls for the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of pharmaceutical products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, and such regulations differ from country to country. Product candidates cannot be marketed in the United States or in any foreign countries until receiving the requisite approval from the applicable regulatory authorities of such jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA or any foreign regulatory bodies can delay, limit or deny approval of product candidates for many reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to demonstrate to the satisfaction of the FDA or the applicable foreign regulatory body that a product candidate is safe and effective for the requested indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA&#8217;s or the applicable foreign regulatory agency&#8217;s disagreement with trial protocol or the interpretation of data from preclinical studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to demonstrate that the clinical and other benefits of a product candidate outweigh any safety or other perceived risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA&#8217;s or the applicable foreign regulatory agency&#8217;s requirement for additional preclinical studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA&#8217;s or the applicable foreign regulatory agency&#8217;s non-approval of the formulation, labeling or specifications for a product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA&#8217;s or the applicable foreign regulatory agency&#8217;s failure to approve manufacturing processes and facilities or the facilities of third-party manufacturers relied upon; or</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential for approval policies or regulations of the FDA or the applicable foreign regulatory agencies to significantly change in a manner rendering clinical data insufficient for approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Of the large number of pharmaceutical products in development, only a small&#160;percentage successfully complete the FDA or other regulatory bodies&#8217; approval processes and are commercialized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if Aerovate eventually completes clinical testing and receives approval from the FDA or applicable foreign agencies for any product candidates, the FDA or the applicable foreign regulatory agency may grant approval contingent on the performance of costly additional clinical trials which may be required after approval. The FDA or the applicable foreign regulatory agency also may approve a product candidate for a more limited indication or a narrower patient population than originally requested, and the FDA, or applicable foreign regulatory agency, may not approve it with the labeling that is necessary or desirable for the successful commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Should Aerovate in the future conduct clinical trials outside the United States, the FDA, EMA and applicable foreign regulatory authorities may not accept data from such trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The acceptance of trial data from clinical trials conducted outside the United States by the FDA, EMA, or applicable foreign regulatory authority may be subject to certain conditions. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i)&#160;the data are applicable to the United States population and United States medical practice; (ii)&#160;the trials were performed by clinical investigators of recognized competence and pursuant to good clinical practice (&#8220;GCP&#8221;) regulations; and (iii)&#160;the data may be considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies have similar approval requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, such foreign trials will be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, EMA, or any applicable foreign regulatory authority will accept data from trials conducted outside of the United States. If the FDA, EMA, or any applicable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay the business plan, and which may result in a product candidate not receiving approval or clearance for commercialization in the applicable jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if Aerovate obtains regulatory approval for a product candidate, Aerovate will be subject to ongoing regulatory requirements, which may result in significant additional expenses. If approved, Aerovate&#8217;s product candidates could be subject to labeling and other restrictions, and Aerovate may be subject to penalties if it fails to comply with regulatory requirements or experience unanticipated problems with any product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate does not intend to resume development of AV-101 or commence development of any other product candidates. However, if Aerovate has a product candidate approved by the FDA or a comparable foreign regulatory authority, it will be subject to extensive and ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and listing, as well as continued compliance with current Good Manufacturing Practices (&#8220;current GMPs&#8221;) and Good Manufacturing Practices for any clinical trials that Aerovate conducts post-approval. Any regulatory approvals that Aerovate receives for its product candidates may also be subject to limitations on the approved indicated uses, including the duration of use, for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing studies, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product. The FDA may also require a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;), in order to approve a product candidate, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to current GMP regulations and implementing tracking and tracing requirements for certain prescription pharmaceutical products. As such, Aerovate and its contract manufacturers will be subject to continual review and inspections to assess compliance with current GMP and adherence to </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">commitments made in any approved marketing application. Accordingly, Aerovate and others with whom Aerovate works must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event any future product candidates are approved, Aerovate would have to comply with requirements concerning advertising and promotion. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved label. As such, Aerovate may not promote a product candidate for indications or uses for which it does not have approval. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. Aerovate also must submit new or supplemental applications and obtain approval for certain changes to product labeling, or manufacturing process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Aerovate discovers previously unknown problems with any product candidate, such as adverse events of unanticipated severity or frequency, or problems with the facility where a product candidate is manufactured, or if the FDA disagrees with the promotion, marketing or labeling, the FDA may impose restrictions on such product candidate or Aerovate, including requiring withdrawal of it from the market. If Aerovate fails to comply with applicable regulatory requirements, the FDA and other regulatory authorities may, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issue warning letters or other regulatory enforcement action;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impose injunctions, fines or civil or criminal penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspend or withdraw regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspend any clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refuse to approve pending applications or supplements to approved applications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require revisions to the labeling, including limitations on approved uses or the addition of additional warnings, contraindications or other safety information, including boxed warnings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impose a REMS which may include distribution or use restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require the conduct of an additional post-market clinical trial or trials to assess the safety of the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impose restrictions on Aerovate&#8217;s operations, including closing its contract manufacturers&#8217; facilities where regulatory inspections identify observations of noncompliance requiring remediation; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrict the marketing of the product, require a product recall, seizure or detention, or refuse to permit the import or export of the product.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any government action or investigation of alleged violations of law could require Aerovate to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect Aerovate&#8217;s ability to commercialize and generate revenue. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of Aerovate and its operating results will be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, the policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of any product candidates. Aerovate cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. In addition, if Aerovate is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if Aerovate is not able to maintain regulatory compliance, Aerovate may be subject to enforcement action and may not achieve or sustain profitability.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate has received orphan drug designation from the FDA and EMA for AV-101 for treatment of PAH, but Aerovate may be unable to obtain additional designations or to maintain the benefits associated with orphan drug status, including the potential for non-patent market exclusivity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug or biologic as an orphan drug if it is a product intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population of 200,000 or more in the United States where there is no reasonable expectation that the cost of developing the product will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Similarly, in the European Union, the European Commission, upon the recommendation of the EMA&#8217;s Committee for Orphan Medicinal Products, may grant orphan designation in respect of products that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions and either (i)&#160;such condition affects not more than five in 10,000 persons in the European Union when the application is made or (ii)&#160;without incentives, it is unlikely that the marketing of the product would generate sufficient return in the European Union to justify the necessary investment in its development, and, in each case, for which no satisfactory method of diagnosis, prevention, or treatment has been authorized (or the product would be a significant benefit to those affected). In the European Union, orphan designation entitles a party to financial incentives such as reduction of fees or fee waivers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Generally, if a product with an orphan drug designation subsequently receives the first regulatory approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same product and indication for that time period, except in limited circumstances. Any competitor developing imatinib in the same indication with orphan drug designation may block Aerovate&#8217;s ability to obtain orphan drug exclusivity in the future if the competitor receives marketing approval before Aerovate does. The applicable exclusivity period is seven&#160;years in the United States and ten&#160;years in the European Union. The European Union exclusivity period can be reduced to six&#160;years if, at the end of the fifth&#160;year, it is established that a product no longer meets the criteria for orphan drug designation, including if the product is sufficiently profitable so that market exclusivity is no longer justified. Legislation has been proposed by the European Commission that, if implemented, has the potential in some cases to shorten the ten-year period of orphan drug exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate previously obtained orphan drug designation for AV-101 in the United States from the FDA and in the European Union from the EMA for the treatment of PAH. Even with orphan drug exclusivity, that exclusivity may not effectively protect a product from competition because different products can be approved for the same condition. Even after an orphan drug is approved, the FDA or EMA can subsequently approve the same product for the same condition if the FDA or EMA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition or if another product with the same active moiety is determined to be safer, more effective, or represents a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a product nor gives the product any advantage in the regulatory review or approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if FDA approval in the United States is obtained, it does not guarantee approval for or successful commercialization of a product candidate outside of the United States, which would limit the ability to realize its full market potential.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To market product candidates outside of the United States requires obtaining marketing authorizations and comply with numerous and varying regulatory requirements of other countries regarding quality, safety and efficacy. Clinical trials conducted in one country may not be accepted by foreign regulatory authorities, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and costs and require additional non-clinical studies or clinical trials, which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of a product candidate in those countries. Aerovate, as a company, does not have experience in obtaining regulatory approval in international markets. Failing to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approval in international markets is delayed, the target market will be reduced and the full market potential of such product candidate could not be realized.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate&#8217;s business operations and relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers have been subject to applicable healthcare regulatory laws, which could expose Aerovate to penalties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate&#8217;s business operations and arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers, may expose Aerovate to broadly applicable fraud and abuse and other healthcare laws, including, without limitation, the federal Anti- Kickback Statute, the federal civil and criminal False Claims Act and Physician Payments Sunshine Act and regulations. These laws may constrain the business or financial arrangements and relationships through which Aerovate conducts its operations, including how Aerovate researches, markets, sells and distributes product candidates, if approved. For more information, please see the section titled &#8220;<i style="font-style:italic;">Aerovate&#8217;s Business&#160;&#8212; Government Regulation&#160;&#8212; Healthcare Laws and Regulation&#8221; </i>beginning on page&#160;221 of this proxy statement/ prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ensuring that any internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations involves substantial costs. It is possible that governmental authorities will conclude that business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws. If operations are found to be in violation of any of the laws described above or any other governmental laws that may apply, it may result in significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of operations. If any of the physicians or other providers or entities with business is done are found to not be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect the ability to operate its business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Healthcare legislative reform measures may have a material adverse effect on Aerovate&#8217;s business and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay regulatory approval of product candidates, restrict or regulate post-approval activities and affect the ability to profitably sell a product for which regulatory approval is obtained. Changes in regulations, statutes or the interpretation of existing regulations could impact manufacturing arrangements, require additions or modifications to product labeling, result in the recall or discontinuation of products or result in additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect business operations. For more information, please see the section titled &#8220;<i style="font-style:italic;">Aerovate&#8217;s Business&#160;&#8212; Government Regulation&#160;&#8212; Pricing and Reimbursement&#8221; </i>beginning on page&#160;220 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Revenue prospects could be affected by changes in healthcare spending and policy in the United States and abroad. Healthcare is a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery or payment for healthcare products and services could negatively impact business, operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. Aerovate cannot predict the initiatives that may be adopted in the future, including repeal, replacement or significant revisions to the Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Reconciliation Act (&#8220;ACA&#8221;). Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect future profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inadequate funding for the FDA, the SEC and other government agencies, including from government- shutdowns, or other disruptions to these agencies&#8217; operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of Aerovate&#8217;s business may rely, which could negatively impact Aerovate&#8217;s business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent&#160;years as a result. Disruptions at the FDA and other agencies </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect business operations of regulated entities. In addition, government funding of the SEC and other government agencies on which Aerovate&#8217;s operations may rely is subject to the political process, which is inherently fluid and unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies. For example, over the last several&#160;years the United States government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. Future government shutdowns could impact the ability to access the public markets and obtain necessary capital in order to properly capitalize and continue Aerovate&#8217;s operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Aerovate&#8217;s Employee Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate&#8217;s insurance policies may be inadequate and potentially expose Aerovate to unrecoverable risks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate has limited director and officer insurance and product liability insurance policies. Any significant insurance claims would have a material adverse effect on Aerovate&#8217;s business, financial condition and results of operations. Insurance availability, coverage terms, including deductibles and pricing, continue to vary with market conditions. Aerovate endeavors to obtain appropriate insurance coverage for insurable risks that it identifies; however, Aerovate may fail to correctly anticipate or quantify insurable risks, Aerovate may not be able to obtain appropriate insurance coverage, and insurers may not respond as Aerovate intends to cover insurable events that may occur. Aerovate has observed rapidly changing conditions in the insurance markets relating to nearly all areas of traditional corporate insurance. Such conditions have resulted in higher premium costs, higher policy deductibles and lower coverage limits. For some risks, Aerovate may not have or maintain insurance coverage because of cost or availability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate may be unable to adequately protect its information systems and infrastructure from cyberattacks and other cybersecurity incidents, which could result in the disclosure or compromise of confidential or proprietary information, including personal data, damage to Aerovate&#8217;s reputation, and subject Aerovate to significant financial and legal exposure.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate relies on information technology systems that Aerovate or its third-party providers operate to process, transmit and store electronic information in its day-to-day operations. In connection with Aerovate&#8217;s product discovery efforts, Aerovate may collect and use a variety of personal data, such as names, mailing addresses, email addresses, phone numbers and clinical trial information. A successful cyberattack or other cybersecurity incident could result in the theft or destruction of this personal data, intellectual property, other data, or other misappropriation of assets, or otherwise compromise Aerovate&#8217;s confidential or proprietary information and disrupt Aerovate&#8217;s operations. Cybersecurity incidents are increasing in their frequency, sophistication, level of persistence and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Cyberattacks could include wrongful conduct by hostile foreign governments, industrial espionage, wire fraud and other forms of cyber fraud, the deployment of harmful malware, denial-of-service, ransomware, social engineering fraud or other means to threaten data security, confidentiality, integrity and availability. Aerovate may also face increased cybersecurity risks due to its reliance on internet technology and the number of Aerovate&#8217;s employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, Aerovate may be unable to anticipate these techniques or implement adequate preventative measures. Aerovate may also experience cybersecurity incidents that may remain undetected for an extended period. A successful cyberattack could cause serious negative consequences for Aerovate, including, without limitation, the disruption of operations, the misappropriation of confidential business information, including financial information, trade secrets, financial loss and the disclosure of corporate strategic plans. Although Aerovate devotes resources to protect its information systems, Aerovate realizes that cybersecurity incidents are a threat, and there can be no assurance that its efforts will prevent cybersecurity incidents that would result in business, legal, financial or reputational harm to Aerovate, or would have a material adverse effect on Aerovate&#8217;s results of operations and financial condition. Aerovate maintains cybersecurity insurance in the event of a cybersecurity incident; however, the coverage may not be sufficient to cover all financial losses. Any failure to prevent or mitigate cybersecurity incidents or improper access to, use of, or disclosure or compromise of Aerovate&#8217;s clinical data or patients&#8217; personal data could result in significant liability under state (e.g., state breach notification laws), federal, and international law and may cause a material adverse impact to Aerovate&#8217;s reputation, affect Aerovate&#8217;s ability to conduct new studies and potentially disrupt Aerovate&#8217;s business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Aerovate relies on its third-party providers to implement effective security measures and identify and correct for any such failures, deficiencies or breaches. If Aerovate or its third-party providers fail to maintain or protect Aerovate&#8217;s information technology </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">systems and data integrity effectively or fail to anticipate, plan for or manage significant disruptions to Aerovate&#8217;s information technology systems, Aerovate or its third-party providers could have difficulty preventing, detecting and controlling such cyber-attacks and any such incidents could result in the losses described above as well as disputes with physicians, patients and partners, regulatory sanctions or penalties, increases in operating expenses, other expenses or lost revenues or other adverse consequences, any of which could have a material adverse effect on Aerovate&#8217;s business, results of operations, financial condition, prospects and cash flows. Any failure by such third parties to prevent or mitigate cybersecurity incidents or improper access to or disclosure or compromise of such information could have similarly adverse consequences for Aerovate. If Aerovate is unable to prevent or mitigate the impact of such cybersecurity incidents, Aerovate could be exposed to litigation and governmental investigations, which could lead to a potential disruption to Aerovate&#8217;s business. By way of example, the California Consumer Privacy Act as amended by the California Privacy Rights Act (&#8220;CCPA&#8221;), provides a private right of action for data breaches impacting California residents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Ownership of Aerovate&#8217;s Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate&#8217;s ability to utilize its net operating loss carryforwards and certain other tax attributes may be limited.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under Section&#160;382 of the Code, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50&#160;percentage point change (by value) in the ownership of its equity over a three&#160;year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and certain other pre-change tax attributes to offset its post-change income may be limited. Aerovate may have experienced such ownership changes in the past, and Aerovate may experience ownership changes in the future or subsequent shifts in Aerovate&#8217;s stock ownership, some of which are outside Aerovate&#8217;s control. As of December&#160;31, 2023, Aerovate had federal net operating loss (&#8220;NOL&#8221;) carryforwards of approximately $64.8 million and are accruing additional net operating losses in calendar&#160;year 2024, which will be added to the net operating loss carryover balance once the current&#160;year is completed. Aerovate&#8217;s ability to utilize its net operating loss carryforwards could be limited by an &#8220;ownership change&#8221; as described above, which could result in increased tax liability to Aerovate. Furthermore, Aerovate&#8217;s ability to utilize its NOLs or credits is conditioned upon Aerovate&#8217;s attaining profitability and generating U.S. federal and state taxable income. As a result, the amount of the net operating loss and tax credit carryforwards presented in Aerovate&#8217;s financial statements could be limited and may expire unutilized. Federal net operating loss carryforwards generated since Aerovate&#8217;s incorporation in July&#160;2018 will not be subject to expiration. However, any such net operating loss carryforwards may only offset 80% of Aerovate&#8217;s annual taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in tax law may adversely affect Aerovate or its investors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The rules&#160;dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the U.S. Internal Revenue Service (&#8220;IRS&#8221;) and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect Aerovate or holders of its common stock. In recent&#160;years, many changes have been made and changes are likely to continue to occur in the future. For example, under Section&#160;174 of the Code, in taxable&#160;years beginning after December&#160;31, 2021, expenses that are incurred for research and development in the U.S. are capitalized and amortized, which may have an adverse effect on Aerovate&#8217;s cash flow. In addition, it is unclear how these U.S. federal income tax changes will affect state and local taxation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It cannot be predicted whether, when, in what form, or with what effective dates, new tax laws may be enacted, or regulations and rulings may be enacted, promulgated or issued under existing or new tax laws, which could result in an increase in Aerovate&#8217;s or its stockholders&#8217; tax liability or require changes in the manner in which Aerovate operates in order to minimize or mitigate any adverse effects of changes in tax law or in the interpretation thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Anti-takeover provisions in the Aerovate Charter and under Delaware law could make an acquisition of Aerovate, which may be beneficial to Aerovate&#8217;s stockholders, more difficult and may prevent attempts by Aerovate&#8217;s stockholders to replace or remove Aerovate&#8217;s current management.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Aerovate Charter and amended and Aerovate&#8217;s restated bylaws contain provisions that could delay or prevent a change of control of Aerovate or changes in Aerovate&#8217;s board of directors that Aerovate&#8217;s stockholders might consider favorable. Some of these provisions include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board of directors will be elected at one time;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of Aerovate&#8217;s stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a requirement that special meetings of the stockholders may be called only by the board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">then in office, and special meetings of stockholders may not be called by any other person or persons;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advance notice requirements for stockholder proposals and nominations for election to Aerovate&#8217;s board of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a requirement that no member of Aerovate&#8217;s board of directors may be removed from office by Aerovate&#8217;s stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds (2/3) of all outstanding shares of Aerovate&#8217;s voting stock then entitled to vote in the election of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a requirement of approval of not less than a majority of all outstanding shares of Aerovate&#8217;s voting stock to amend any bylaws by stockholder action and not less than two-thirds (2/3) of all outstanding shares of Aerovate&#8217;s voting stock to amend specific provisions of the Aerovate Charter; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval, which preferred stock may include rights superior to the rights of the holders of common stock.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, because Aerovate is incorporated in Delaware, Aerovate is governed by the provisions of Section&#160;203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of Aerovate&#8217;s outstanding voting stock. These anti-takeover provisions and other provisions in the Aerovate Charter and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of Aerovate&#8217;s board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving Aerovate. These provisions could also discourage proxy contests and make it more difficult for Aerovate&#8217;s stockholders to elect directors of their choosing or cause Aerovate to take other corporate actions that Aerovate&#8217;s stockholders desire. Any delay or prevention of a change of control transaction or changes in Aerovate&#8217;s board of directors could cause the market price of Aerovate&#8217;s common stock to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate&#8217;s amended and restated bylaws designate certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by Aerovate&#8217;s stockholders, which could limit Aerovate&#8217;s stockholders&#8217; ability to obtain a favorable judicial forum for disputes with Aerovate or its directors, officers, or employees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate&#8217;s amended and restated bylaws provide that, unless Aerovate consents in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claim for (i)&#160;any derivative action or proceeding brought on Aerovate&#8217;s behalf, (ii)&#160;any action asserting a claim of breach of fiduciary duty owed by any of Aerovate&#8217;s directors, officers, and employees to Aerovate&#8217;s or its stockholders, (iii)&#160;any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, the Aerovate Charter or Aerovate&#8217;s amended and restated bylaws (including the interpretation, validity or enforceability thereof) or <span style="color:#231f20;">(iv)&#160;any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants </span>therein (the &#8220;Delaware Forum Provision&#8221;). The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Aerovate&#8217;s amended and restated bylaws further provide that, unless Aerovate consents in writing to the selection of an alternative forum, the federal district courts of the United States shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act (the &#8220;Federal Forum Provision&#8221;). In addition, Aerovate&#8217;s bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of Aerovate&#8217;s common stock is deemed to have notice of and consented to the foregoing provisions; provided, however, that stockholders cannot and will not be deemed to have waived Aerovate&#8217;s compliance with the federal securities laws and the rules&#160;and regulations thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Aerovate recognizes that the Delaware Forum Provision in Aerovate&#8217;s amended and restated bylaws may impose additional litigation costs on stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware. Additionally, the forum selection clauses in Aerovate&#8217;s amended and restated bylaws may limit Aerovate&#8217;s stockholders&#8217; ability to bring a claim in a forum that they find favorable for disputes with Aerovate or its directors, officers or employees, which may discourage such lawsuits against Aerovate and its directors, officers and employees even though an action, if successful, might </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">benefit Aerovate&#8217;s stockholders. In addition, while the Delaware Supreme Court ruled in March&#160;2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court were &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other courts will enforce Aerovate&#8217;s Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, Aerovate may incur additional costs associated with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the federal district courts of the United States may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to Aerovate than Aerovate&#8217;s stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Aerovate&#8217;s General Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Unfavorable global economic or political conditions could adversely affect Aerovate&#8217;s business, financial condition or results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate&#8217;s results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A global financial crisis or a global or regional political disruption could cause extreme volatility in the capital markets and lead to diminished liquidity and credit availability, higher interest rates, declines in consumer confidence and economic growth, increases in unemployment rates and uncertainty about economic stability. For instance, the COVID-19 pandemic led to a period of considerable uncertainty and volatility and interest rates in the United States have recently increased to levels not seen in decades. In addition, the impact of geopolitical tension, such as a deterioration in the bilateral relationship between the United States and China or the ongoing war in Ukraine and the conflict in the Middle East, including any resulting sanctions, export controls or other restrictive actions, also could lead to disruption, instability, and volatility in the global markets, as well as disruptions to Aerovate&#8217;s business. A severe or prolonged economic downturn or political disruption could result in a variety of risks to Aerovate&#8217;s business, strategic prospects and ability to raise additional capital as needed on acceptable terms, if at all. Any of the foregoing could harm Aerovate&#8217;s business and Aerovate cannot anticipate all of the ways in which the political or economic climate and financial market conditions could adversely impact Aerovate&#8217;s business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect Aerovate&#8217;s current and projected business operations and its financial condition and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, on March&#160;10, 2023, Silicon Valley Bank (&#8220;SVB&#8221;), was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) as receiver. Similarly, on March&#160;12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership; since then, additional financial institutions have experienced similar failures and have been placed into receivership. It is possible that other banks will face similar difficulty in the future. Aerovate had no exposure to the SVB closure and did not experience any adverse impact to its liquidity or to its current and projected business operations, financial condition or results of operations. However, uncertainty remains over liquidity concerns in the broader financial services industry, and there may be additional impacts to Aerovate&#8217;s business and industry that Aerovate cannot predict at this time. Similar impacts have occurred in the past, such as during the 2008-2010 financial crisis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although Aerovate assesses its banking and customer relationships as it believes necessary or appropriate, Aerovate&#8217;s access to funding sources and other credit arrangements in amounts adequate to finance or capitalize Aerovate&#8217;s current and projected future business operations could be significantly impaired by factors that affect Aerovate, the financial institutions with which Aerovate has credit agreements or arrangements directly, or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could involve financial institutions or financial services industry companies with which Aerovate has financial or business relationships, but could also include factors involving financial markets or the financial services industry generally.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The results of events or concerns that involve one or more of these factors could include a variety of material and adverse impacts on Aerovate&#8217;s current and projected business operations and Aerovate&#8217;s financial condition and results of operations. These could include, but may not be limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delayed or lost access to, or reductions in borrowings available under revolving existing credit facilities or other working capital sources and/or delays, inability or reductions in Aerovate&#8217;s ability to refund, roll over or extend the maturity of, or enter into new credit facilities or other working capital resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential or actual breach of contractual obligations that require Aerovate to maintain letters of credit or other credit support arrangements; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash management arrangements.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any decline in available funding or access to Aerovate&#8217;s cash and liquidity resources could, among other risks, adversely impact Aerovate&#8217;s ability to meet Aerovate&#8217;s operating expenses, financial obligations or fulfill Aerovate&#8217;s other obligations, result in breaches of Aerovate&#8217;s financial and/or contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on Aerovate&#8217;s liquidity and current and/or projected business operations and financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, any further deterioration in the macroeconomic economy or financial services industry could lead to losses or defaults by Aerovate&#8217;s suppliers, which in turn, could have a material adverse effect on Aerovate&#8217;s current and/or projected business operations and results of operations and financial condition. For example, a supplier may determine that it will no longer deal with Aerovate as a customer or a supplier could be adversely affected by any of the liquidity or other risks that are described above as factors that could result in material adverse impacts on Aerovate, including but not limited to delayed access or loss of access to uninsured deposits or loss of the ability to draw on existing credit facilities involving a troubled or failed financial institution. Any supplier bankruptcy or insolvency, or the failure of any customer to make payments when due, or any breach or default by a supplier, or the loss of any significant supplier relationships, could result in material losses to Aerovate and may have a material adverse impact on Aerovate&#8217;s business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate&#8217;s business is affected by macroeconomic conditions, including rising inflation, interest rates and supply chain constraints.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Various macroeconomic factors could adversely affect Aerovate&#8217;s business and results of operations and financial condition, including changes in inflation, interest rates and overall economic conditions and uncertainties such as those resulting from the current and future conditions in the global financial markets. For instance, recent supply chain constraints have led to higher inflation, which if sustained could have a negative impact on Aerovate&#8217;s development of future product candidates, as well as Aerovate&#8217;s business and results of operations. If inflation or other factors were to significantly increase Aerovate&#8217;s business costs, ability to develop its current pipeline and new therapeutic products may be negatively affected. Interest rates, the liquidity of the credit markets and the volatility of the capital markets could also affect the operation of Aerovate&#8217;s business and ability to raise capital on favorable terms, or at all, in order to fund its operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate&#8217;s employees and independent contractors, including principal investigators, consultants, commercial collaborators, service providers and other vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on Aerovate&#8217;s results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Aerovate is exposed to the risk that its employees and independent contractors, including principal investigators, consultants, any future commercial collaborators, service providers and other vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or other unauthorized activities that violate the laws and regulations of the FDA and other similar regulatory bodies, including those laws that require the reporting of true, complete and accurate information to such regulatory bodies; manufacturing standards; United States federal and state fraud and abuse laws, data privacy and security laws and other similar non-United States laws; or laws that require the true, complete and accurate reporting of </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in Aerovate&#8217;s preclinical studies or clinical trials, or illegal misappropriation of product, which could result in regulatory sanctions and cause serious harm to Aerovate&#8217;s reputation. It is not always possible to identify and deter misconduct by employees and other third-parties, and the precautions Aerovate takes to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting Aerovate from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, Aerovate is subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against Aerovate, and Aerovate is not successful in defending itself or asserting its rights, those actions could have a significant impact on Aerovate&#8217;s business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other United States federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings and curtailment of Aerovate&#8217;s operations, any of which could adversely affect Aerovate&#8217;s ability to operate its business and its results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Actual or perceived failures to comply with United States and foreign privacy and data protection laws, regulations and standards may adversely affect Aerovate&#8217;s business, operations and financial performance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate is subject to or affected by numerous federal, state and foreign laws and regulations, as well as regulatory guidance, governing the collection, use, disclosure, retention, and security of personal information, such as information that Aerovate collects about patients and healthcare providers in connection with clinical trials in the United States and abroad. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. This evolution may create uncertainty in Aerovate&#8217;s business, affect Aerovate&#8217;s or any service providers&#8217;, contractors&#8217; or future collaborators&#8217; ability to operate in certain jurisdictions or to collect, store, transfer, use and share personal information, necessitate the acceptance of more onerous obligations in Aerovate&#8217;s contracts, result in liability or impose additional costs on Aerovate. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by Aerovate or its collaborators, service providers and contractors to comply with federal, state or foreign laws or regulations, Aerovate&#8217;s internal policies and procedures or Aerovate&#8217;s contracts governing processing of personal information could result in negative publicity, diversion of management time and effort and proceedings against Aerovate by governmental entities or others. In many jurisdictions, enforcement actions and consequences for noncompliance are rising.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As Aerovate&#8217;s operations and business grow, Aerovate may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the United States, HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for Aerovate and its future customers and strategic partners. For example, the CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches. The CCPA may increase Aerovate&#8217;s compliance costs and potential liability. Following the amendment of the CCPA by the California Privacy Rights Act (&#8220;CPRA&#8221;), the CCPA is implemented and enforced by a new California data protection agency, which may result in increased regulatory scrutiny of California businesses in the areas of data protection and security. The effects of the CCPA, as amended by the CPRA, are potentially significant and may require Aerovate to modify its data collection or processing practices and policies and to incur substantial costs and expenses in an effort to comply and increase Aerovate&#8217;s potential exposure to regulatory enforcement and/or litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain other state laws impose similar privacy obligations and Aerovate also anticipates that more states will increasingly enact legislation similar to the CCPA. Already, laws similar to the CCPA have been passed in numerous other states. While these laws incorporate many similar concepts of the CCPA, there are also several key differences in the scope, application, and enforcement of the laws that will change the operational practices of regulated entities. In addition, Washington state recently passed a comprehensive health information privacy law. Proposed and newly enacted legislation may add additional complexity, variation in requirements, restrictions and potential legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Aerovate&#8217;s operations abroad may also be subject to increased scrutiny or attention from data protection authorities. Many countries in these regions have established or are in the process of establishing privacy and data security legal frameworks with which </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Aerovate, its collaborators, service providers, including its contract research organizations (&#8220;CROs&#8221;), and contractors must comply. For example, the European Union General Data Protection Regulation (with regards to the European Economic Area (&#8220;EEA&#8221;)) and the UK GDPR (with regards to the UK), as well as applicable national data protection legislation and requirements. In this document, GDPR refers to both EU GDPR and the UK GDPR, unless specified otherwise. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal information, including requirements relating to having a legal basis for processing personal data, stricter requirements relating to the processing of sensitive data (such as health sensitive data), where required by GDPR obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, requirements to conduct data protection impact assessments for high risk processing and taking certain measures when engaging third-party processors. Failure to comply with the requirements of the GDPR may result in warning letters, mandatory audits, orders to cease/change the use of data, and financial penalties, including fines of up to 4% of global revenues, or 20,000,000 Euro (&#163;17.5 million for the UK), whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GDPR provides that EEA member states may make their own further laws and regulations in relation to the processing of genetic, biometric or health data, which could result in differences between member states, limit Aerovate&#8217;s ability to use and share personal data or could cause Aerovate&#8217;s costs to increase, and harm Aerovate&#8217;s business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GDPR also includes restrictions on cross-border transfers of personal data to countries outside the EEA and UK that are not considered by the European Commission or UK government as providing adequate protection to personal data, including the United States, unless a valid GDPR mechanism (for example, the European Commission approved Standard Contractual Clauses (&#8220;SCCs&#8221;), and the UK International Data Transfer Agreement/Addendum (&#8220;UK IDTA&#8221;)) has been put in place. Where relying on the SCCs or UK IDTA for data transfers, Aerovate may also be required to carry out transfer impact assessments to assess whether the recipient is subject to local laws which allow public authority access to personal data. Further, the EU and United States have adopted its adequacy decision for the EU-U.S. Data Privacy Framework (the &#8220;Framework&#8221;), which entered into force on July&#160;11, 2023. This Framework provides that the protection of personal data transferred between the EU and the United States is comparable to that offered in the EEA. This provides a further avenue to ensuring transfers to the United States are carried out in line with GDPR. There has been an extension to the Framework to cover UK transfers to the United States. The Framework could be challenged like its predecessor frameworks. The international transfer obligations under the EEA and UK data protection regimes will require significant effort and cost, and may result in Aerovate needing to make strategic considerations around where EEA and UK personal data is transferred and which service providers Aerovate can utilize for the processing of EEA and UK personal data. Although the UK is regarded as a third country under the EU GDPR, the European Commission has issued a decision recognizing the UK as providing adequate protection under the EU GDPR (&#8220;UK Adequacy Decision&#8221;) and, therefore, transfers of personal data originating in the EEA to the UK remain unrestricted. The UK government has confirmed that personal data transfers from the UK to the EEA remain free flowing. The UK government has also now introduced a Data Protection and Digital Information Bill (&#8220;UK Bill&#8221;) into the UK legislative process. The aim of the UK Bill is to reform the UK&#8217;s data protection regime following Brexit. If passed, the final version of the UK Bill will have the effect of further altering the similarities between the UK and EEA data protection regime and threaten the UK Adequacy Decision from the European Commission. This may lead to additional compliance costs and could increase Aerovate&#8217;s overall risk. The respective provisions and enforcement of the EU GDPR and UK GDPR may further diverge in the future and create additional regulatory challenges and uncertainties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, many jurisdictions outside of Europe are also considering and/or enacting comprehensive data protection legislation. For example, as of August&#160;2020, the Brazilian General Data Protection Law imposes stringent requirements similar to GDPR with respect to personal information collected from individuals in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In China, there have also been recent significant developments concerning privacy and data security. On June&#160;10, 2021, the Standing Committee of the PRC National People&#8217;s Congress published the Data Security Law of the People&#8217;s Republic of China (the &#8220;Data Security Law&#8221;) which took effect on September&#160;1, 2021. The Data Security Law requires data processing (which includes the collection, storage, use, processing, transmission, provision and publication of data), to be conducted in a legitimate and proper manner. The Data Security Law imposes data security and privacy obligations on entities and individuals carrying out data processing activities and also introduces a data classification and hierarchical protection system based on the importance of data in economic and social development and the degree of harm it may cause to national security, public interests, or legitimate rights and interests of individuals or organizations if such data are tampered with, destroyed, leaked, illegally acquired or illegally used. The appropriate level of protection measures is required to be taken for each respective category of data.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Also in China, on August&#160;20, 2021, the Standing Committee of the National People&#8217;s Congress of the PRC promulgated the Personal Information Protection Law (&#8220;PIPL&#8221;), which took effect on November&#160;1, 2021. PIPL raises the protection requirements for processing personal information, and many specific requirements of the PIPL remain to be clarified. Fines for PIPL violations range from $7.7 million to up to 5% of the infringing company&#8217;s previous&#160;year&#8217;s revenues. Aerovate may be required to make further significant adjustments to Aerovate&#8217;s business practices to comply with the personal information protection laws and regulations in China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although Aerovate works to comply with applicable laws, regulations and standards, Aerovate&#8217;s contractual obligations and other legal obligations, because the interpretation and application of many privacy and data protection laws (including the GDPR), commercial frameworks, and standards are uncertain, it is possible that these laws, frameworks, and standards may be interpreted and applied in a manner that is inconsistent with Aerovate&#8217;s existing data management practices and policies. If so, in addition to the possibility of fines, lawsuits, breach of contract claims, and other claims and penalties, Aerovate could be required to fundamentally change its business activities and practices or modify Aerovate&#8217;s solutions, which could have an adverse effect on Aerovate&#8217;s business. Any inability to adequately address privacy and security concerns, even if unfounded, or comply with applicable privacy and security or data security laws, regulations, and policies, could result in additional cost and liability to Aerovate, damage Aerovate&#8217;s reputation, inhibit Aerovate&#8217;s ability to conduct trials, and adversely affect Aerovate&#8217;s business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate is an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) and a &#8220;smaller reporting company&#8221; as defined in the Exchange Act, and will be able to avail itself of reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies, which could make Aerovate&#8217;s common stock less attractive to investors and adversely affect the market price of Aerovate&#8217;s common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:19.95pt;margin:0pt 0pt 12pt 0pt;">Aerovate is an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. Aerovate will remain an emerging growth company until the earlier of (i)&#160;the last day of the fiscal&#160;year in which Aerovate has total annual gross revenues of $1.235 billion or more; (ii)&#160;the last day of the fiscal&#160;year following the fifth anniversary of the date of the completion of Aerovate&#8217;s IPO; (iii)&#160;the date on which Aerovate has issued more than $1 billion in nonconvertible debt during the previous three&#160;years; or (iv)&#160;the date on which Aerovate is deemed to be a large accelerated filer under the rules&#160;of the SEC, which means the market value of Aerovate&#8217;s common stock that is held by non-affiliates exceeds $700 million as of June&#160;30th. For so long as Aerovate remains an emerging growth company, Aerovate is permitted and intends to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes- Oxley Act of 2002, or Section&#160;404;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">providing only two&#160;years of audited financial statements in addition to any required unaudited interim financial statements and a correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the requirement to provide detailed compensation discussion and analysis in proxy statements and reports filed under the Exchange Act and instead provide a reduced level of disclosure regarding executive compensation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved and some of the disclosure requirements of the Dodd-Frank Act relating to compensation of executive officers.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Although Aerovate is still evaluating the JOBS Act, Aerovate currently intends to take advantage of some, but not all, of the available exemptions available to Aerovate so long as Aerovate qualifies as an &#8220;emerging growth company.&#8221; Aerovate has taken advantage of reduced reporting burdens in this proxy statement/prospectus. In particular, Aerovate has provided only two&#160;years of audited financial statements and has not included all of the executive compensation information that would be required if Aerovate were not an emerging growth company. Aerovate cannot predict whether investors will find its common stock less attractive if </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Aerovate relies on these exemptions. If some investors find Aerovate&#8217;s common stock less attractive as a result, there may be a less active trading market for Aerovate&#8217;s common stock and Aerovate&#8217;s stock price may be more volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. Aerovate has elected to &#8220;opt out&#8221; of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, Aerovate will adopt the new or revised standard at the time public companies adopt the new or revised standard.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result, changes in rules&#160;of United States generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in Aerovate&#8217;s business could significantly affect Aerovate&#8217;s financial position and results of operations. In addition, Aerovate&#8217;s independent registered public accounting firm will not be required to provide an attestation report on the effectiveness of Aerovate&#8217;s internal control over financial reporting so long as Aerovate qualifies as an &#8220;emerging growth company,&#8221; which may increase the risk that material weaknesses in Aerovate&#8217;s internal control over financial reporting go undetected. Likewise, so long as Aerovate qualifies as an &#8220;emerging growth company,&#8221; Aerovate may elect not to provide Aerovate&#8217;s stockholders with certain information, including certain financial information and certain information regarding compensation of Aerovate&#8217;s executive officers, that Aerovate would otherwise have been required to provide in filings Aerovate makes with the SEC, which may make it more difficult for investors and securities analysts to evaluate Aerovate. Aerovate cannot predict if investors will find its common stock less attractive because Aerovate may rely on these exemptions. If some investors find Aerovate&#8217;s common stock less attractive as a result, there may be a less active trading market for Aerovate&#8217;s common stock, and Aerovate&#8217;s stock price may be more volatile and may decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even after Aerovate no longer qualifies as an emerging growth company, Aerovate may still qualify as a &#8220;smaller reporting company,&#8221; which would allow Aerovate to continue to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in Aerovate&#8217;s periodic reports and proxy statements. Aerovate cannot predict if investors will find its common stock less attractive because Aerovate may rely on these exemptions. If some investors find Aerovate&#8217;s common stock less attractive as a result, there may be a less active trading market for Aerovate&#8217;s common stock and Aerovate&#8217;s stock price may be more volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate may not pay any cash dividends on its capital stock in the foreseeable future, other than the Cash Dividend in connection with the Merger, and capital appreciation, if any, will be Aerovate&#8217;s stockholders&#8217; sole source of gain.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate has never declared or paid cash dividends on its capital stock. Aerovate intends to declare and pay to the holders of record of outstanding shares of Aerovate common stock as of a record date prior to the Effective Time of the Merger, to be set by the Aerovate board of directors as close as reasonably practicable to (but not later than) the anticipated Closing Date. Otherwise, Aerovate may retain all of its future earnings, if any, to finance the growth and development of Aerovate&#8217;s business. In addition, the terms of any future debt agreements may preclude Aerovate from paying dividends. As a result, capital appreciation, if any, of Aerovate&#8217;s common stock will be Aerovate&#8217;s stockholders&#8217; sole source of gain for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate incurs increased costs as a result of operating as a public company, and Aerovate&#8217;s management is required to devote substantial time to new compliance initiatives.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a public company, and particularly after Aerovate is no longer an &#8220;emerging growth company,&#8221; Aerovate will continue to incur significant legal, accounting and other expenses that Aerovate did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002 and rules&#160;subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Aerovate&#8217;s management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules&#160;and regulations will increase Aerovate&#8217;s legal and financial compliance costs and will make some activities more time-consuming and costly. For example, Aerovate expects that these rules&#160;and regulations may make it more difficult and more expensive for Aerovate to maintain director and officer liability insurance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Pursuant to Section&#160;404, Aerovate is required to furnish a report by Aerovate&#8217;s management on its internal control over financial reporting. Management&#8217;s initial certification under Section&#160;404 of the Sarbanes- Oxley Act was provided with Aerovate&#8217;s annual report on Form&#160;10-K for the fiscal&#160;year ended December&#160;31, 2023, filed with the SEC on March&#160;25, 2024. However, while Aerovate remains an emerging growth company, it will not be required to include an attestation report on internal control over financial </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">reporting issued by Aerovate&#8217;s independent registered public accounting firm. To achieve compliance with Section&#160;404 within the prescribed period, Aerovate has engaged in a process to document and evaluate Aerovate&#8217;s internal control over financial reporting, which is both costly and challenging. In this regard, Aerovate has been and will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite Aerovate&#8217;s efforts, there is a risk that neither Aerovate nor its independent registered public accounting firm will be able to conclude within the prescribed timeframe that Aerovate&#8217;s internal control over financial reporting is effective as required by Section&#160;404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of Aerovate&#8217;s financial statements. In addition, if Aerovate is not able to continue to meet these requirements, Aerovate may not be able to remain listed on Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If Aerovate fails to establish and maintain proper and effective internal control over financial reporting, Aerovate&#8217;s operating results and ability to operate its business could be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ensuring that Aerovate has adequate internal financial and accounting controls and procedures in place so that Aerovate can produce accurate financial statements on a timely basis is a costly and time- consuming effort that needs to be re-evaluated frequently. Aerovate&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. In connection with Aerovate&#8217;s IPO, Aerovate began the process of documenting, reviewing and improving its internal controls and procedures for compliance with Section&#160;404 of the Sarbanes-Oxley Act, which will require annual management assessment of the effectiveness of Aerovate&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Implementing any appropriate changes to Aerovate&#8217;s internal controls may distract Aerovate&#8217;s officers and employees, entail substantial costs to modify Aerovate&#8217;s existing processes, and take significant time to complete. These changes may not, however, be effective in maintaining the adequacy of Aerovate&#8217;s internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase Aerovate&#8217;s operating costs and harm its business. In addition, investors&#8217; perceptions that Aerovate&#8217;s internal controls are inadequate or that Aerovate is unable to produce accurate financial statements on a timely basis may harm Aerovate&#8217;s stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate&#8217;s disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate is subject to the periodic reporting requirements of the Exchange Act. Aerovate designed its disclosure controls and procedures to reasonably assure that information Aerovate must disclose in reports it files or submits under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules&#160;and forms of the SEC. Aerovate believes that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision- making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in Aerovate&#8217;s control system, misstatements due to error or fraud may occur and not be detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If securities analysts do not publish research or reports about Aerovate&#8217;s business or if they publish negative evaluations of Aerovate&#8217;s stock, the price of Aerovate&#8217;s stock could decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The trading market for Aerovate&#8217;s common stock will rely in part on the research and reports that industry or financial analysts publish about Aerovate or its business. Aerovate does not have control over these analysts. There can be no assurance that existing analysts will continue to provide research coverage or that new analysts will begin to provide research coverage. Although Aerovate has obtained analyst coverage, if one or more of the analysts covering Aerovate&#8217;s business downgrade their evaluations of Aerovate&#8217;s stock, the price of Aerovate&#8217;s stock could decline. If one or more of these analysts cease to cover Aerovate&#8217;s stock, Aerovate&#8217;s could lose visibility in the market for its stock, which in turn could cause Aerovate&#8217;s stock price to decline.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Jade</b></p><a id="RiskFactor_Jade_LimitedOperatingHistory"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Jade&#8217;s Limited Operating History, Financial Position and Capital Requirements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade is a preclinical stage biotechnology company with a limited operating history on which to assess its business; Jade has not initiated, conducted or completed any clinical trials, and Jade has no products approved for commercial sale, which may make it difficult for you to evaluate its current business and likelihood of success and viability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade is a preclinical stage biotechnology company with limited operating history. Since its inception in June&#160;2024, Jade has incurred operating losses with no corresponding revenue and has utilized substantially all of its resources to identify, license and develop JADE-001, initiate discovery efforts with respect to its JADE-002 and JADE-003 programs, organize and staff its company and provide other general and administrative support for its operations. Jade has no significant experience as a company in initiating, conducting or completing preclinical studies or clinical trials. In part because of this lack of experience, Jade cannot be certain that its preclinical studies or clinical trials will begin or be completed on time, if at all. In addition, Jade has not yet demonstrated an ability to obtain regulatory approvals, manufacture a clinical or commercial-scale product or arrange for a third party to do so on its behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any predictions you make about Jade&#8217;s future success or viability may not be as accurate as they could be if Jade had a longer operating history.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, as Jade&#8217;s business grows, it may encounter unforeseen expenses, restrictions, difficulties, complications, delays and other known and unknown factors. Jade will need to transition at some point from a company with an early research and development focus to a company capable of supporting larger scale clinical trials and eventually commercial activities. Jade may not be successful in such a transition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if the Merger and the Jade Pre-Closing Financing are successful, Jade will require substantial additional capital to finance its operations in the future, which raises substantial doubt about its ability to continue as a going concern. If Jade is unable to raise such capital when needed, or on acceptable terms, Jade may be forced to delay, reduce and/or eliminate one or more of its development programs or future commercialization efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Developing biotechnology products is a very long, time-consuming, expensive and uncertain process that takes&#160;years to complete. Jade expects its expenses to increase in connection with its ongoing activities, particularly as Jade conducts preclinical studies, clinical trials of, and seeks regulatory approval for JADE-001, advances discovery efforts with respect to its JADE-002 and JADE-003 programs, and advances any future programs and product candidates that it may license. Even if one or more of the programs that Jade develops is approved for commercial sale, Jade anticipates incurring significant costs associated with sales, marketing, manufacturing and distribution activities to launch any such product. Jade&#8217;s expenses could increase beyond expectations if it is required by the FDA or other regulatory agencies to perform preclinical studies or clinical trials in addition to or more expansive than those that Jade currently anticipates. Because the design and outcome of Jade&#8217;s planned and anticipated clinical trials are highly uncertain, it cannot reasonably estimate the actual amount of funding that will be necessary to successfully complete the development and commercialization of any program Jade develops. Jade&#8217;s future capital requirements depend on many factors, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, results and costs of discovery, preclinical and clinical development for Jade&#8217;s product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost and timing of completion of clinical and commercial-scale manufacturing activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining, defending and enforcing Jade&#8217;s intellectual property and proprietary rights, and defending intellectual property- related claims, including claims of infringement, misappropriation or other violations of third-party intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing and outcome of the regulatory review of Jade&#8217;s product candidates and obtaining the requisite regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of Jade&#8217;s future commercialization activities, either by itself or in collaboration with others, including product sales, marketing, manufacturing, and distribution for any product candidate for which Jade receives regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the revenue, if any, received from commercial sales of product candidates for which Jade receives regulatory approval;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of Jade&#8217;s current or future collaborations, including its collaboration with Paragon pursuant to the Paragon Option Agreement and any future license agreements Jade enters into with Paragon;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade&#8217;s ability to establish and maintain additional collaborations on favorable terms, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which Jade acquires or in-licenses products, intellectual property and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of operational, financial and management information systems and associated personnel; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of operating as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accordingly, Jade will require substantial additional funding to continue its operations. As of September&#160;30, 2024, Jade had $88.0 million of cash. Even if the Merger and the Jade Pre-Closing Financing be successful, Jade will still need to raise additional capital to continue to fund its operations in the future. If Jade is unable to raise additional capital when needed, that could raise substantial doubt about Jade&#8217;s ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade has concluded there is substantial doubt about its ability to continue as a going concern for at least 12&#160;months from the date its financial statements as of September&#160;30, 2024 were issued. In light of these concerns, Jade&#8217;s independent registered public accounting firm included in its opinion on the financial statements an explanatory paragraph expressing substantial doubt about Jade&#8217;s ability to continue as a going concern beyond 12&#160;months from the date its financial statements were issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade may be required to seek additional funds sooner than planned through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources, and adequate additional financing may not be available to it on acceptable terms, or at all. Such financing may dilute Jade&#8217;s stockholders or the failure to obtain such financing may restrict its operating activities. Any additional fundraising efforts may divert Jade&#8217;s management from their day-to-day activities, which may adversely affect its business. To the extent that Jade raises additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences and anti-dilution protections that adversely affect your rights as a stockholder. Debt financing may result in the imposition of debt covenants, increased fixed payment obligations or other restrictions that may affect Jade&#8217;s business. If Jade raises additional funds through upfront payments or milestone payments pursuant to current or future collaborations with third parties, Jade may have to relinquish valuable rights to its product candidates, or grant licenses on terms that are not favorable to it. Jade&#8217;s ability to raise additional capital may be adversely impacted by global macroeconomic conditions and volatility in the credit and financial markets in the United States and worldwide. Jade&#8217;s failure to raise capital as and when needed or on acceptable terms would have a negative impact on its financial condition and its ability to pursue its business strategy, and Jade may have to delay, reduce the scope of, suspend or eliminate one or more of its product candidates, clinical trials or future commercialization efforts or cease its operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade has incurred losses since inception, and Jade expects to incur losses for the foreseeable future and may not be able to achieve or sustain profitability in the future. Jade has no products approved for sale, has not generated any revenue from its product candidates and may never generate revenue or become profitable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Investment in biotechnology product development is a highly speculative undertaking and entails substantial upfront capital expenditures and significant risks that any product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially viable. Jade has no products approved for commercial sale, has not generated any revenue from product sales to date, and continues to incur significant research and development and other expenses related to its ongoing operations. Jade does not expect to generate product revenue unless or until it successfully completes preclinical and clinical development and obtains regulatory approval of, and then successfully commercializes, at least one of its product candidates. Jade may never succeed in these activities and, even if it does, may never generate revenues that are significant or large enough to achieve profitability. If Jade is unable to raise sufficient additional capital to advance a product candidate to commercialization or generate sufficient revenue through the sale of any approved products, Jade may be unable to continue operations without additional funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Jade has incurred significant net losses in each period since it commenced operations in June&#160;2024. Jade generated net losses of $16.9 million for the period from June&#160;18, 2024 (inception) to September&#160;30, 2024. As of September&#160;30, 2024, Jade had an accumulated deficit of $16.9 million, and Jade has concluded that there is substantial doubt about its ability to continue as a going concern for at least 12&#160;months from the date its financial statements for the period June&#160;18, 2024 (inception) to September&#160;30, 2024 </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">were issued. Jade expects to continue to incur losses for the foreseeable future. Jade&#8217;s operating expenses and net losses may fluctuate significantly from quarter to quarter and&#160;year to&#160;year. Jade anticipates that its expenses will increase substantially if and as it:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advances its existing and future product candidates through preclinical and clinical development, including potential expansion into additional indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeks to identify additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintains, expands, enforces, defends and protects its intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeks, obtains and maintains regulatory and regulatory approvals for its product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeks to identify, establish and maintain additional collaborations and license agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">makes milestone payments to Paragon under the Paragon Option Agreement and JADE-001 License Agreement, and under any additional future collaboration or license agreements that Jade enters into;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ultimately establishes a sales, marketing and distribution infrastructure to commercialize any drug products for which Jade may obtain regulatory approval, either by itself or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">generates revenue from commercial sales of product candidates for which Jade receives regulatory approval, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hires additional personnel including research and development, clinical and commercial personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adds operational, financial and management information systems and personnel, including personnel to support its product development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquires or in-licenses products, intellectual property and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishes clinical and commercial-scale current good manufacturing practices (&#8220;cGMP&#8221;) capabilities through a third-party or its own manufacturing facility; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">operates as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, Jade&#8217;s expenses will increase if, among other things, it is required by the FDA or other regulatory authorities to perform clinical trials or studies in addition to, or different than, those that Jade currently anticipates, there are any delays in completing its clinical trials or the development of any of its product candidates, or there are any third-party challenges to Jade&#8217;s intellectual property or Jade needs to defend against any intellectual property-related claim.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if Jade obtains regulatory approval for, and is successful in commercializing, one or more of its product candidates, Jade expects to incur substantial additional research and development and other expenditures to develop and market additional product candidates and/or to expand the approved indications of any marketed product. Jade may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect its business. The size of Jade&#8217;s future net losses will depend, in part, on the rate of future growth of its expenses and its ability to generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s failure to become profitable would decrease Jade&#8217;s value and could impair its ability to raise capital, maintain its research and development efforts, expand its business and/or continue its operations. A decline in Jade&#8217;s value of could also cause you to lose all or part of your investment.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Jade&#8217;s Discovery, Development and Commercialization</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade faces competition from entities that have developed or may develop product candidates for the diseases addressed by its product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The development and commercialization of drugs is highly competitive. Jade&#8217;s product candidates, if approved, will face significant competition and Jade&#8217;s failure to effectively compete may prevent it from achieving significant market penetration. Jade competes with a variety of multinational biopharmaceutical companies, specialized biotechnology companies and emerging biotechnology companies, including Calliditas Therapeutics, AB, Novartis AG, Otsuka Pharmaceutical Co.,&#160;Ltd., Travere Therapeutics, Vera Therapeutics,&#160;Inc., and Vertex Pharmaceuticals Incorporated, as well as academic institutions, governmental agencies, and public and private research institutions, among others. Many of the companies with which Jade is currently competing or will compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and regulatory approved products than Jade does, and are further along in the clinical development and/or commercialization process. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller number of Jade&#8217;s competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with Jade in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, raising capital, patient registration for clinical trials, establishing and defending rights to intellectual property, as well as in acquiring technologies complementary to, or necessary for, Jade&#8217;s product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s competitors have developed or are developing, and may in the future develop, product candidates or products competitive with Jade&#8217;s product candidates. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any potential new treatments, including those currently under clinical development. Jade&#8217;s success will depend partially on its ability to develop and commercialize products that have a competitive safety, efficacy, dosing and/or presentation profile. Jade&#8217;s commercial opportunity and success will be reduced or eliminated if competing products are safer, more effective, have a more attractive dosing profile or presentation or are less expensive than the products Jade develops, or if Jade&#8217;s competitors develop competing products or biosimilars that enter the market more quickly than Jade does and are able to gain market acceptance. Conversely, the lack of commercial success of other competing therapies may raise concerns about the financial viability of Jade&#8217;s product candidates. Please see the section titled &#8220;<i style="font-style:italic;">Jade&#8217;s Business&#160;&#8212; Competition</i>&#8221; beginning on page&#160;246 of this proxy statement/prospectus for a more detailed description of Jade&#8217;s competitors and the factors that may affect the success of Jade&#8217;s product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, because of the competitive landscape for autoimmune indications, including IgA nephropathy (&#8220;IgAN&#8221;), Jade may also face competition for establishing trial sites and clinical trial enrollment. Patient enrollment will depend on many factors, including if potential clinical trial patients choose to undergo treatment with approved products or enroll in competitors&#8217; ongoing clinical trials for product candidates that are under development for the same indications as Jade&#8217;s product candidates. An increase in the number of approved products for the indications Jade is targeting with its product candidates will likely further exacerbate this competition. Jade&#8217;s inability to enroll a sufficient number of patients could, among other impacts, delay its development timeline, which may further harm Jade&#8217;s competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">JADE-001 is in the preclinical stage of development and may fail in development or suffer delays that materially and adversely affect its viability. If Jade or its current or future collaborators are unable to complete development of or commercialize Jade&#8217;s product candidates, or experience significant delays in doing so, Jade&#8217;s business will be materially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade has no commercially approved products, and JADE-001 and Jade&#8217;s additional programs are in the preclinical stage of development and have not been tested in humans. As a result, Jade expects it will be many&#160;years before it commercializes any product candidate, if ever. Jade&#8217;s ability to achieve and sustain profitability depends on obtaining regulatory approvals for, and successfully commercializing, Jade&#8217;s product candidates, either alone or with third parties, and Jade cannot guarantee you that it will ever obtain regulatory approval for any of its product candidates. Jade has not yet demonstrated its ability to initiate or complete any clinical trials, obtain regulatory approvals, manufacture a clinical development or commercial scale product or arrange for a third party to do so on its behalf, or conduct sales and marketing activities necessary for successful product commercialization. Before obtaining regulatory approval for the commercial distribution of any product candidate, Jade or an existing or future collaborator must conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of the product candidate.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade or its collaborators may experience delays in initiating or completing preclinical studies or clinical trials. Jade or its collaborators also may experience numerous unforeseen events during, or as a result of, any future preclinical studies or clinical trials that Jade could conduct that could delay or prevent its ability to receive regulatory approval or commercialize its product candidates, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators, such as the FDA, institutional review boards (&#8220;IRBs&#8221;) or comparable foreign regulatory authorities may not authorize, Jade or its investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trial sites may deviate from the trial protocol, fail to conduct trials in a compliant manner or drop out of a trial, which may require that Jade add new clinical trial sites or investigators or otherwise negatively impact the timing or integrity of Jade&#8217;s clinical trial(s);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials of any product candidates may fail to show safety or efficacy, produce negative or inconclusive results and Jade may decide, or regulators may require it, to conduct additional preclinical studies or clinical trials or Jade may decide to abandon a product development program;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of subjects required for clinical trials of any product candidates may be larger than Jade anticipates, especially if regulatory bodies require completion of non-inferiority or superiority </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trials, enrollment in these clinical trials may be slower than Jade anticipates or subjects may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than Jade anticipates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade&#8217;s third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to Jade in a timely manner, or at all, or may deviate from the clinical trial protocol or suffer other quality or performance issues that negatively impact the timing or integrity of Jade&#8217;s clinical trial(s);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade may elect to, or regulators, IRBs or ethics committees may require that Jade or its investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants in Jade&#8217;s clinical trials are being exposed to unacceptable health risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of clinical trials of any of Jade&#8217;s product candidates may be greater than Jade anticipates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the quality of Jade&#8217;s product candidates or other materials necessary to conduct clinical trials of its product candidates may be inadequate to initiate or successfully complete a given clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade may be unable to manufacture sufficient quantities of its product candidates for use in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reports from clinical testing of other therapies may raise safety or efficacy concerns about Jade&#8217;s product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade may fail to establish an appropriate safety profile for a product candidate based on clinical or preclinical data for such product candidates as well as data emerging from other therapies in the same class as its product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or other regulatory authorities may require Jade to submit additional data such as long-term toxicology studies, or impose other requirements before permitting Jade to initiate a clinical trial.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Commencing clinical trials in the United States is subject to acceptance by the FDA of an IND and finalizing the trial design based on discussions with the FDA. Commencing clinical trials in jurisdictions outside of the United States, such as Australia or New Zealand, is similarly subject to acceptance by the applicable regulatory authority of clinical trial documentation following discussions with such authority. In the event that the FDA or other applicable regulatory authority requires Jade to complete additional preclinical studies or Jade is required to satisfy other FDA or foreign regulatory authority requests, respectively, prior to commencing clinical </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">trials, the start of Jade&#8217;s first clinical trials may be delayed. Even after Jade receives and incorporates guidance from these regulatory authorities, the FDA or other regulatory authorities could disagree as to whether Jade has satisfied their requirements to commence any clinical trial or change their position on the acceptability of Jade&#8217;s trial design or the clinical endpoints selected, which may require Jade to complete additional preclinical studies or clinical trials, delay the enrollment of Jade&#8217;s clinical trials or impose stricter approval conditions than Jade currently expects. There are analogous processes and risks applicable to clinical trial applications in other countries, including countries in the EU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade may not have the financial resources to continue development of its product candidates if Jade experiences any issues that delay or prevent regulatory approval of, or Jade&#8217;s ability to commercialize, its product candidates. Jade or its current or future collaborators&#8217; inability to complete development of, or commercialize Jade&#8217;s product candidates, or significant delays in doing so, could have a material and adverse effect on Jade&#8217;s business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade is substantially dependent on the success of JADE-001, and Jade&#8217;s anticipated clinical trials of such program may not be successful.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s future success is substantially dependent on its ability to timely obtain regulatory approval for, and then successfully commercialize, JADE-001. Jade is initially investing a majority of its efforts and financial resources into the research and development of this program. Jade anticipates initiating a Phase 1 clinical trial of JADE-001 in healthy volunteers in Australia or New Zealand in the second half of 2025. The success of JADE-001 is dependent on observing suppression of IgA levels and improved pharmacokinetic properties compared to other anti-APRIL&#160;monoclonal antibody product candidates in clinical development. This is based in part on the assumption that the increased <i style="font-style:italic;">in vitro </i>potency and improved pharmacokinetics observed in non-human primates (&#8220;NHPs&#8221;) will translate into a suppression of IgA levels and improved pharmacokinetic properties of JADE-001 in humans, resulting in a more convenient dosing regimen. To the extent Jade does not observe this suppression of IgA levels or improved pharmacokinetic properties when Jade doses humans with its product candidates, it would significantly and adversely affect the clinical and commercial potential of JADE-001.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s product candidates will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, regulatory approval in multiple jurisdictions, substantial investment and significant marketing efforts before Jade generates any revenues from product sales. Jade is not permitted to market or promote these product candidates, or any other product candidates, before it receives regulatory approval from the FDA and comparable foreign regulatory authorities, and Jade may never receive such regulatory approvals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The success of Jade&#8217;s product candidates will depend on a variety of factors. Jade does not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to Jade&#8217;s intellectual property rights, potential threats from the intellectual property rights of third parties and the manufacturing, marketing, distribution and sales efforts of any current or future collaborator. Accordingly, Jade cannot assure you that Jade will ever be able to generate revenue through the sale of these product candidates, even if approved. If Jade is not successful in obtaining regulatory approval and commercializing JADE-001 or other future product candidates, or is significantly delayed in doing so, Jade&#8217;s business will be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If Jade does not achieve its projected development goals in the time frames it announces and expects, the commercialization of Jade&#8217;s product candidates may be delayed and its expenses may increase and, as a result, its stock price may decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, Jade estimates the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product development goals, which Jade sometimes refers to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials, such as the expected timing for the initiation of Jade&#8217;s Phase 1 clinical trial of JADE-001 in healthy volunteers and generation of mechanistic clinical proof-of-concept data, as well as the timing for receipt of clinical data and submission of regulatory filings. From time to time, Jade may publicly announce the expected timing of some of these milestones. All of these milestones are and will be based on numerous assumptions. The actual timing of these milestones can vary dramatically compared to Jade&#8217;s estimates, in many cases for reasons beyond its control. If Jade does not meet these milestones as publicly announced, or at all, Jade&#8217;s prospects and reputation may be adversely affected and Jade&#8217;s stock price may decline. Additionally, delays relative to Jade&#8217;s projected timelines are likely to cause overall expenses to increase, which may require Jade to raise additional capital sooner than expected and prior to achieving targeted development milestones.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The target patient population for the treatment of IgAN is small and has not been definitively determined, and if Jade&#8217;s estimates of the number of treatable patients is lower than expected, Jade&#8217;s potential revenues from sales of its product candidates, if approved, and Jade&#8217;s ability to achieve profitability would be compromised.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s estimates of both the number of patients who have IgAN, as well as the subset of patients with these diseases in a position to receive treatment from JADE-001 (i.e., those with proteinuria &gt; 0.5g/day), if approved, are based on Jade&#8217;s beliefs, and these estimates may prove to be incorrect. These estimates have been derived from a variety of sources, including scientific literature, input from physicians that treat patients with the diseases Jade is targeting, patient foundations and secondary market research databases. For example, Jade&#8217;s estimates of the prevalence of IgAN in certain geographies are based in part on the published prevalence of IgAN among patient populations in the United States split across ethnicities, and Jade&#8217;s own analyses of prevalence in Europe, and on published disease incidence rates for certain geographies and estimated for the populations of such geographies. Further, new studies may change the estimated incidence or prevalence of IgAN, and any regulatory approvals that Jade may receive for JADE-001 may include limitations for use or contraindications that decrease the addressable patient population. Accordingly, Jade&#8217;s target patient populations may turn out to be lower than expected, in which case the potential revenues from sales of its product candidates, if approved, would be lower than expected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade&#8217;s approach to the discovery and development of its product candidates is unproven, and Jade may not be successful in its efforts to build a pipeline of product candidates with commercial value.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s approach to the discovery and development of its product candidates leverages well-established mechanisms of action and incorporates advanced antibody engineering to optimize half-life and other properties designed to overcome limitations of existing therapies, including increased binding affinity. Jade&#8217;s product candidates are purposefully designed to improve upon existing product candidates and products while maintaining the same, well-established mechanisms of action. However, the scientific research that forms the basis of Jade&#8217;s efforts to develop product candidates using half-life extension technologies and to enhance efficacy through improved binding affinity, including monoclonal antibodies, is ongoing and may not result in viable product candidates. Jade has limited clinical data on product candidates utilizing monoclonal antibody half-life extension technologies, especially in autoimmune indications, demonstrating whether they are safe or effective for long-term treatment in humans. Jade also has no clinical data to indicate whether its modifications to enhance binding affinity translate into improved efficacy in humans. The long-term safety and efficacy of Jade&#8217;s product candidates compared to currently approved products is unknown.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade may ultimately discover that utilizing half-life extension technologies for Jade&#8217;s specific targets and indications and any product candidates resulting therefrom do not possess certain properties required for therapeutic effectiveness. Jade currently has only preclinical data regarding the increased half-life properties of Jade&#8217;s product candidates and the same results may not be seen in humans. In addition, product candidates using half-life extension technologies may demonstrate different chemical and pharmacological properties in patients than they do in laboratory studies. This technology and any product candidates resulting therefrom may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways. Many product candidates that appeared highly promising in preclinical studies or in early stage clinical trials have failed when advanced into, or further in, clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, other companies are developing drug products that utilize half-life extension technology in other targets and indications. The failure of those companies to demonstrate the safety and efficacy of their product candidates may be harmful to Jade&#8217;s business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, Jade may in the future seek to discover and develop product candidates that are based on novel targets and technologies that are unproven. If Jade&#8217;s discovery or business development activities fail to identify novel targets or technologies for drug development, or such targets or technologies prove to be unsuitable for treating human disease, Jade may not be able to develop viable additional product candidates. Jade and its existing or future collaborators may never receive approval to market and commercialize any product candidate. Even if Jade or an existing or future collaborator obtains regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as Jade intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. If the products resulting from Jade&#8217;s product candidates prove to be ineffective, unsafe or commercially unviable, its product candidates and pipeline would have little, if any, value, which would have a material and adverse effect on Jade&#8217;s business, financial condition, results of operations and prospects.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preclinical and clinical development involves a lengthy and expensive process that is subject to delays and with uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results. If Jade&#8217;s preclinical studies and clinical trials are not sufficient to support regulatory approval of any of its product candidates, Jade may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Before obtaining regulatory approval from regulatory authorities for the sale of any product candidate, Jade must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of its product candidate in humans. Jade&#8217;s clinical trials may not be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process. For example, Jade depends on the availability of NHPs to conduct certain preclinical studies that Jade is required to complete prior to submitting an IND and initiating clinical development. There is currently a global shortage of NHPs available for drug development. While Jade currently does not anticipate that this shortage will materially impact its costs or timelines, a continuing or future shortage could cause the cost of obtaining NHPs for Jade&#8217;s future preclinical studies to increase significantly or result in delays to its development timelines. Furthermore, a failure of one or more clinical trials can occur at any clinical trial phase. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain regulatory approval of their product candidates. In addition, Jade expects to rely on patients to provide feedback on measures such as measures of disease and quality of life, which are subjective and inherently difficult to evaluate. These measures can be influenced by factors outside of Jade&#8217;s control, and can vary widely from day to day for a particular patient, and from patient to patient and from site to site within a clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade cannot be sure that the FDA or comparable foreign regulatory authorities will agree with its clinical development plan. Jade plans to use the data from its planned Phase 1 trial of JADE-001 in healthy volunteers to support Phase 2 trials in other indications. However, there is no guarantee the data from such Phase 1 trial will support a Phase 2 trial in any indication. If the FDA or comparable foreign regulatory authorities require Jade to conduct additional trials or enroll additional patients, Jade&#8217;s development timelines may be delayed. Jade cannot be sure that submission of an IND or similar foreign application will result in the FDA or comparable foreign regulatory authorities, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could cause regulatory authorities to suspend or terminate such clinical trials. Events that may prevent successful or timely initiation or completion of clinical trials include: inability to generate sufficient preclinical, toxicology or other <i style="font-style:italic;">in vivo </i>or <i style="font-style:italic;">in vitro </i>data to support the initiation or continuation of clinical trials; delays in reaching a consensus with regulatory authorities on study design or implementation of the clinical trials; delays or failure in obtaining regulatory authorization to commence a trial; delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; delays in identifying, recruiting and training suitable clinical investigators; delays in obtaining required IRB approval or positive ethics committee opinions at each clinical trial site; delays in manufacturing, testing, releasing, validating or importing/ exporting sufficient stable quantities of Jade&#8217;s product candidates for use in clinical trials or the inability to do any of the foregoing; failure by Jade&#8217;s CROs, other third parties or Jade to adhere to clinical trial protocols; failure to perform in accordance with the FDA&#8217;s or any other regulatory authority&#8217;s GCP requirements or regulatory guidelines; changes to the clinical trial protocols; clinical sites deviating from trial protocol or dropping out of a trial; changes in regulatory requirements, guidance or clinical trial plans that require amending or submitting new clinical protocols; selection of clinical endpoints that require prolonged periods of observation or analyses of resulting data; transfer of manufacturing processes to larger-scale facilities and delays or failure by Jade&#8217;s contract manufacturing organizations (&#8220;CMOs&#8221;) or Jade to make any necessary changes to such manufacturing process; and third parties being unwilling or unable to satisfy their contractual obligations to Jade.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade could also encounter delays if a clinical trial is suspended or terminated by Jade, by the IRBs or ethics committees of the institutions in which such clinical trials are being conducted, by the Data Safety Monitoring Board, if any, for such clinical trial or by the FDA or comparable foreign regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or Jade&#8217;s clinical trial protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from the product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If Jade is required to conduct additional clinical trials or other testing of Jade&#8217;s product candidates beyond those that it currently contemplates, if Jade is unable to successfully complete clinical trials of its product candidates, if the results of these trials are not positive or are only moderately positive or if there are safety concerns, Jade&#8217;s business and results of operations would be adversely affected.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade may find it difficult to enroll patients in its clinical trials given the relatively small patient population and significant competition for patients who have the diseases for which JADE-001 is being developed. If Jade encounters difficulties enrolling patients in its JADE-001 clinical trials or future clinical trials, Jade&#8217;s clinical development activities could be delayed or otherwise adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade may experience difficulties in patient enrollment in its future clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on Jade&#8217;s ability to enroll a sufficient number of patients who remain in the trial until its conclusion. In particular, as a result of the inherent difficulties in diagnosing IgAN, an indication with relatively small patient populations, and the significant competition for recruiting patients with IgAN in clinical trials, there may be delays in enrolling the patients Jade needs to complete clinical trials on a timely basis, or at all. In addition, because Jade is initially focused on developing product candidates for indications for which there is significant competition for recruiting patients, Jade may encounter similar challenges for patient enrollment when it commences clinical programs for additional product candidates in the future. Further, there are three recently approved products for the treatment of IgAN, and patients may decide, or physicians may recommend, to use such approved treatments instead of enrolling in clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The enrollment of patients in future trials for any of Jade&#8217;s product candidates will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">size and nature of the patient population; severity of the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability and efficacy of approved drugs for the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patient eligibility and exclusion criteria for the trial in question;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patients&#8217; and clinicians&#8217; perceived risks and benefits of the product candidate under study;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if patients choose to enroll in clinical trials, rather than using approved products, or if Jade&#8217;s competitors have ongoing clinical trials for product candidates that are under development for the same indications as Jade&#8217;s product candidates, and patients instead enroll in such clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efforts to facilitate timely enrollment in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patient referral practices of physicians;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to monitor patients adequately during and after treatment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">proximity and availability of clinical trial sites for prospective patients; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continued enrollment of prospective patients by clinical trial sites.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, the number of patients required for clinical trials of Jade&#8217;s product candidates may be larger than Jade anticipates, especially if regulatory bodies require the completion of non-inferiority or superiority trials. Even if Jade is able to enroll a sufficient number of patients for its future clinical trials, Jade may have difficulty maintaining patients in its clinical trials. Jade&#8217;s inability to enroll or maintain a sufficient number of patients would result in significant delays in completing clinical trials or receipt of regulatory approvals and increased development costs or may require Jade to abandon one or more clinical trials altogether, which could cause Jade&#8217;s value to decline, limit its ability to obtain additional financing and otherwise harm its prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preliminary, &#8220;topline&#8221; or interim data from Jade&#8217;s clinical trials that it announces or publishes from time to time may change as more patient data become available and are subject to audit and verification procedures.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, Jade may publicly disclose preliminary or topline data from its preclinical studies and clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data. Jade also makes assumptions, estimations, calculations and conclusions as part of its analyses of these data without the opportunity to fully and carefully evaluate complete data. As a result, the preliminary or topline results that Jade reports may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated or subsequently made subject to audit and verification procedures.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any preliminary or topline data should be viewed with caution until the final data are available. From time to time, Jade may also disclose interim data from its preclinical studies and clinical trials. Interim data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from Jade&#8217;s clinical trials continue other treatments. Further, others, including regulatory authorities, may not accept or agree with Jade&#8217;s assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular product candidate, the approvability or commercialization of the particular product candidate and of Jade as a company. In addition, the information Jade chooses to publicly disclose regarding a particular preclinical study or clinical trial is based on what is typically extensive information, and you or others may not agree with what Jade determines is material or otherwise appropriate information to include in its disclosure. As a result, you or others may have reached different conclusions based on such extensive information in comparison to Jade&#8217;s publicly disclosed conclusion regarding a particular preclinical study or clinical trial. If the preliminary, topline or interim data that Jade reports differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, Jade&#8217;s ability to obtain approval for, and commercialize, its product candidates may be harmed, which could harm Jade&#8217;s business, operating results, prospects or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade&#8217;s future clinical trials or those of its current or future collaborators may reveal significant adverse events or undesirable side effects not seen in Jade&#8217;s preclinical studies and may result in a safety profile that could halt clinical development, inhibit regulatory approval or limit commercial potential or market acceptance of any of Jade&#8217;s product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Results of Jade&#8217;s clinical trials could reveal a high or unacceptable severity and prevalence of side effects, adverse events or unexpected characteristics. Jade has not yet initiated any clinical trials in humans. If significant adverse events or other side effects are observed in any of its future clinical trials, Jade may have difficulty recruiting patients to such trials, patients may drop out of its trials, or Jade may be required to abandon the trials or its development efforts of one or more product candidates altogether. For example, although anti-APRIL&#160;monoclonal antibodies have been generally well tolerated in clinical trials to date, two cases of decreased Immunoglobulin G (&#8220;IgG&#8221;) levels to a threshold requiring dosing interruption mandated by the protocol were reported by Chinook Therapeutics in the ADU-CL-19 study, an ongoing phase 1/2 trial investigating BION-1301 (zigakibart) in patients with IgAN (NCT03945318). Infections were not reported in the patients with low IgG levels; however, low IgG levels are a known risk factor for increased infection risk. Because JADE-001 will have a similar mechanism of action, it is possible that patients in Jade&#8217;s future clinical trials could exhibit decreased IgG levels, which could lead to infections. Jade, the FDA or other applicable regulatory authorities, or an IRB or ethics committee, may suspend any clinical trials of any product candidate at any time for various reasons, including a belief that subjects or patients in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential products developed in the biotechnology industry that initially showed therapeutic promise in early-stage studies and trials have later been found to cause side effects that prevented their further development. Other potential products have shown side effects in preclinical studies, which side effects do not present themselves in clinical trials in humans. Even if the side effects do not preclude the product candidate from obtaining or maintaining regulatory approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. In addition, an extended half-life could prolong the duration of undesirable side effects, which could also inhibit market acceptance. Treatment-emergent adverse events could also affect patient recruitment or the ability of enrolled subjects to complete Jade&#8217;s clinical trials or could result in potential product liability claims. Potential side effects associated with Jade&#8217;s product candidates may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from Jade&#8217;s product candidates may not be normally encountered in the general patient population and by medical personnel. Any of these occurrences could harm Jade&#8217;s business, financial condition, results of operations and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, even if Jade successfully advances its product candidates or any future product candidate through clinical trials, such trials will only include a limited number of patients and limited duration of exposure to Jade&#8217;s product candidates. As a result, Jade cannot be assured that adverse effects of its product candidates will not be uncovered when a significantly larger number of patients are exposed to the product candidate after approval. Further, any clinical trials may not be sufficient to determine the effect and safety consequences of using Jade&#8217;s product candidates over a multi-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If any of the foregoing events occur or if one or more of Jade&#8217;s product candidates prove to be unsafe, its entire pipeline could be affected, any of which would have a material adverse effect on Jade&#8217;s business, financial condition, results of operations and prospects.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade may expend its limited resources to pursue a particular program and fail to capitalize on programs that may be more profitable or for which there is a greater likelihood of success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because Jade has limited financial and managerial resources, it focuses its research and development efforts on certain selected programs. For example, Jade is initially focused primarily on its initial program, JADE-001. As a result, Jade may forgo or delay pursuit of opportunities with other programs that later prove to have greater commercial potential. Jade&#8217;s resource allocation decisions may cause Jade to fail to capitalize on viable commercial products or profitable market opportunities. Jade&#8217;s spending on current and future research and development product candidates for specific indications may not yield any commercially viable product candidates. If Jade does not accurately evaluate the commercial potential or target market for a particular product candidate, Jade may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for Jade to retain sole development and commercialization rights to such product candidate. In addition, Jade selects product candidates amongst a variety of potential product candidates from Paragon, and the product candidates it selects may fail to be viable commercial products or the product candidates it does not select may have a greater likelihood of success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any approved products resulting from Jade&#8217;s current programs or any future program may not achieve adequate market acceptance among clinicians, patients, healthcare third-party payors and others in the medical community necessary for commercial success and Jade may not generate any future revenue from the sale or licensing of such products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if regulatory approval is obtained for a product candidate resulting from one of Jade&#8217;s current or future programs, it may not gain market acceptance among physicians, healthcare professionals, patients, healthcare payors or the medical community. Jade may not generate or sustain revenue from sales of the product due to factors such as whether the product can be sold at a competitive cost and whether it will otherwise be accepted in the market. There are three recently approved products and product candidates in later stages of development for the treatment of IgAN, including Tarpeyo<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and Filspari<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, both of which lead to modest benefits on kidney function. Similarly, results from Fabhalta<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> provide support for the ability of anti-inflammatory drugs to reduce the rate of IgAN kidney damage. However, JADE-001 is designed to block the activity of APRIL&#160;and incorporate advanced antibody engineering to optimize half-life of antibodies targeting IgAN; to date, no such disease-modifying therapy that depletes pathogenic IgA and stabilizes kidney function has been approved by the FDA for the treatment of IgAN, though several such agents are in advanced clinical development. Market participants with significant influence over acceptance of new treatments, such as clinicians and third-party payors, may not adopt a biologic that incorporates anti-APRIL&#160;antibodies and half-life extension for Jade&#8217;s targeted indications, and Jade may not be able to convince the medical community and third-party payors to accept and use, or to provide favorable reimbursement for, any programs developed by Jade or Jade&#8217;s existing or future collaborators. An extended half-life may make it more difficult for patients to change treatments and there is a perception that half-life extension could exacerbate side effects, each of which may adversely affect Jade&#8217;s ability to gain market acceptance. Market acceptance of Jade&#8217;s product candidates may be negatively impacted by potential poor performance of its competitors, including the occurrence of serious adverse events in such competitors&#8217; clinical trials or failure by such competitors to obtain and maintain regulatory approval for their product candidates. Additionally, although Jade believes that the improved dosing and convenience it expects its product candidates to provide will improve market acceptance of such product candidates and that its candidates will have a competitive efficacy profile, Jade&#8217;s predictions may not be accurate and other competitive products may instead gain and hold the applicable market. Sales of medical products also depend on the willingness of clinicians to prescribe the treatment. Jade cannot predict whether clinicians, clinicians&#8217; organizations, hospitals, other healthcare providers, government agencies or private insurers will determine that Jade&#8217;s product is safe, therapeutically effective, cost effective or less burdensome as compared with competing treatments. If any current or future product candidate is approved but does not achieve an adequate level of acceptance by such parties, Jade may not generate or derive sufficient revenue from that product candidate and may not become or remain profitable. Market acceptance of Jade&#8217;s product candidates will depend on many factors, including factors that are not within its control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Certain of Jade&#8217;s programs may compete with its other programs, which could negatively impact Jade&#8217;s business and reduce its future revenue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade is developing JADE-001 for the treatment of IgAN and intends to develop its JADE-002 and JADE-003 programs for other autoimmune indications, and may in the future develop programs for additional autoimmune indications. However, developing multiple product candidates for autoimmune indications may negatively impact Jade&#8217;s business if the product candidates compete with each other. For example, if multiple product candidates are conducting clinical trials at the same time, they could compete for the enrollment of patients. In addition, if multiple product candidates are approved for the same indication, they may compete for market share, which could limit Jade&#8217;s future revenue.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade plans to conduct clinical trials for product candidates at sites outside the United States, and the FDA may not accept data from trials conducted in such locations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade currently intends to conduct its Phase 1 clinical trial of JADE-001 in Australia or New Zealand, and Jade may choose to conduct one or more of its future clinical trials outside the United States in whole or in part. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will depend on its determination that the trials also complied with all applicable U.S. laws and regulations. Many foreign regulatory authorities have similar requirements for clinical data gathered outside of their respective jurisdictions. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States, Australia, New Zealand or the relevant jurisdiction, as applicable. If the FDA or any comparable foreign regulatory authority does not accept such data, it would likely result in the need for additional trials, which would be costly and time-consuming and would delay or permanently halt Jade&#8217;s development of the applicable product candidates or delay or prevent regulatory approval for commercialization in the applicable jurisdiction. Even if the FDA or any comparable foreign regulatory authority accepted such data, it could require Jade to modify Jade&#8217;s planned clinical trials to receive clearance to initiate such trials in the United States, Australia, New Zealand or the relevant jurisdiction, as applicable, or to continue such trials once initiated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, conducting international clinical trials presents additional risks that may delay completion of Jade&#8217;s clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs that could restrict or limit Jade&#8217;s ability to conduct its clinical trials, the administrative burdens of conducting clinical trials under multiple sets of foreign regulations, foreign exchange fluctuations, diminished protection of intellectual property in some countries, as well as political and economic risks relevant to foreign countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Jade&#8217;s Reliance on Third Parties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade relies on collaborations and licensing arrangements with third parties, including its collaboration with Paragon pursuant to the Paragon Option Agreement and the JADE-001 License Agreement. If Jade is unable to maintain these collaborations or licensing arrangements, or if these collaborations or licensing arrangements are not successful, its business could be negatively impacted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade relies on its collaboration with a third party, Paragon, for a substantial portion of its discovery capabilities and for the rights necessary to develop and commercialize Jade&#8217;s product candidates. In the future, Jade could also rely on additional licensing arrangements with third parties. For example, on October&#160;30, 2024, Jade entered into a license agreement for JADE-001 with Paragon. However, Paragon could terminate the agreement under certain circumstances, including Jade&#8217;s failure to make any payments owed to Paragon under the agreement or any uncured material breach of the JADE-001 License Agreement by Jade, in which event Jade may lose intellectual property rights and may not be able to develop or commercialize the products covered by that agreement, including JADE-001.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade considers Paragon to be a related party because, prior to the Merger and Jade Pre-Closing Financing, Paragon beneficially owned approximately 9.7% of Jade&#8217;s outstanding common stock. Fairmount Funds Management LLC (&#8220;Fairmount&#8221;), which beneficially owns more than 5% of Paragon, beneficially owns more than 5% of Jade&#8217;s capital stock. Please see the section titled &#8220;<i style="font-style:italic;">Certain Relationships and Related Party Transactions of the Combined Company &#8212; Jade Transactions&#160;&#8212; Jade&#8217;s Relationships with Paragon, Parade and Fairmount</i>&#8221; beginning on page&#160;301 of this proxy statement/prospectus for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Collaborations or licensing arrangements that Jade enters into may not be successful, and any success will depend heavily on the efforts and activities of such collaborators or licensors. If any of Jade&#8217;s collaborators or licensors experiences delays in performance of, or fails to perform, its obligations under its agreement with Jade, disagrees with Jade&#8217;s interpretation of the terms of such agreement or terminates their agreement with Jade, Jade&#8217;s pipeline and product candidates and development timeline could be adversely affected. If Jade fails to comply with any of the obligations under its collaborations or license agreements, including payment terms and diligence terms, Jade&#8217;s collaborators or licensors may have the right to terminate such agreements, in which event Jade may lose intellectual property rights and may not be able to develop, manufacture, market or sell the products covered by its agreements or may face other penalties under its agreements. Jade&#8217;s collaborators and licensors may also fail to properly maintain or </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">defend the intellectual property Jade has licensed from them, if required by Jade&#8217;s agreement with them, leading to the potential invalidation of Jade&#8217;s intellectual property, or they may even infringe upon Jade&#8217;s intellectual property rights, any of which could subject Jade to litigation or arbitration, which would be time-consuming and expensive and could harm Jade&#8217;s ability to commercialize its product candidates. In addition, collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with Jade&#8217;s product candidates and products if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As part of its strategy, Jade plans to evaluate additional opportunities to enhance its capabilities and expand its development pipeline or add development or commercialization capabilities. Jade may not realize the benefits of such collaborations, alliances or licensing arrangements. Any of these relationships may require Jade to incur non-recurring and other charges, increase Jade&#8217;s near and long-term expenditures, issue securities that dilute Jade&#8217;s existing stockholders or disrupt Jade&#8217;s management and business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade may face significant competition in attracting appropriate collaborators, and more established companies may also be pursuing strategies to license or acquire third-party intellectual property rights that Jade considers attractive. These companies may have a competitive advantage over Jade due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies may be unwilling to assign or license rights to Jade, whether they perceive Jade to be a competitor or for other reasons. Whether Jade reaches a definitive agreement for a collaboration will depend, among other things, upon Jade&#8217;s assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Collaborations are complex and time-consuming to negotiate, document and execute. In addition, consolidation among large pharmaceutical and biotechnology companies has reduced the number of potential future collaborators. Jade may not be able to negotiate additional collaborations on a timely basis, on acceptable terms or at all. If Jade fails to enter into collaborations and does not have sufficient funds or expertise to undertake the necessary development and commercialization activities, it may not be able to further develop Jade&#8217;s product candidates or bring them to market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks associated with the in-licensing or acquisition of product candidates could cause substantial delays in the preclinical and clinical development of Jade&#8217;s product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade has relied and continues to rely on Paragon, and expects to rely on Jade&#8217;s future licensing partners, to (i)&#160;conduct research and development in accordance with the applicable protocol, legal, regulatory and scientific standards, (ii)&#160;accurately report the results of all preclinical trials conducted prior to Jade&#8217;s licensing or acquisition of the relevant product candidates and (iii)&#160;correctly collect and interpret the data from these trials. If the research and development processes or the results of the development programs prior to Jade&#8217;s licensing or acquisition of its product candidates prove to be unreliable, this could result in increased costs and delays in the development of Jade&#8217;s product candidates, which could adversely affect any future revenue from such product candidates, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade may also acquire or in-license additional product candidates for preclinical or clinical development in the future as it continues to build its pipeline. The risks associated with acquiring or in-licensing product candidates could result in delays in the commencement or completion of Jade&#8217;s preclinical studies and clinical trials, if ever, and Jade&#8217;s ability to generate revenues from its product candidates may be delayed. Please see the section titled &#8220;<i style="font-style:italic;">Risk Factors&#160;&#8212; Risks Related to Jade&#8217;s Intellectual Property&#160;&#8212; If Jade is unable to obtain or maintain necessary rights to its programs through acquisitions and in-licenses, its business may be materially harmed</i>&#8221; beginning on page&#160;74 of this proxy statement/prospectus for additional information regarding such risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade currently relies, and plans to rely in the future, on third parties to conduct and support its preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, Jade may not be able to obtain regulatory approval of or commercialize its product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Jade has utilized and plans to continue to utilize and depend upon independent investigators and collaborators, such as medical institutions, CROs, contract testing labs and strategic partners, to conduct and support its preclinical studies and clinical trials under agreements with Jade. Jade will rely heavily on these third parties over the course of its preclinical studies and clinical trials, and Jade controls only certain aspects of their activities. As a result, Jade will have less direct control over the conduct, timing and completion of these preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials than would be the case if Jade were relying entirely upon its own staff. Nevertheless, Jade is responsible for ensuring that each of its studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and its reliance on these third parties does not relieve Jade of its regulatory responsibilities. Jade and Jade&#8217;s third-party contractors and CROs are required to comply with GCP, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of Jade&#8217;s product candidates in clinical development. If Jade or any of these third parties fail to comply with applicable GCP regulations, </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the clinical data generated in Jade&#8217;s clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require Jade to perform additional clinical trials before approving Jade&#8217;s marketing applications. Jade cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of its clinical trials comply with GCP. In addition, Jade&#8217;s clinical trials must be conducted with products manufactured in accordance with cGMP. Jade&#8217;s failure to comply with these requirements may require Jade to repeat clinical trials, which would delay the regulatory approval process. Moreover, Jade&#8217;s business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws, and foreign equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any third parties conducting Jade&#8217;s clinical trials will not be Jade&#8217;s employees and, except for remedies available to Jade under its agreements with such third parties, Jade cannot control whether they devote sufficient time and resources to its programs. These third parties may encounter challenges hiring and retaining sufficient qualified personnel or they may be involved in mergers, acquisitions or similar transactions and may have relationships with other commercial entities, including Jade&#8217;s competitors, for whom they may also be conducting clinical trials or other product development activities, which could negatively affect their performance on Jade&#8217;s behalf and the timing thereof and could lead to products that compete directly or indirectly with Jade&#8217;s current or future product candidates. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to Jade&#8217;s clinical protocols or regulatory requirements or for other reasons, Jade&#8217;s clinical trials may be extended, delayed or terminated and Jade may not be able to complete development of, obtain regulatory approval of or successfully commercialize Jade&#8217;s product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, Jade plans to rely on foreign CROs and CMOs, including WuXi Biologics (Hong Kong) Limited (&#8220;WuXi Biologics (Hong Kong)&#8221;), for formulation and manufacturing of Jade&#8217;s Phase 1 clinical trial materials, and will likely continue to rely on foreign CROs and CMOs in the future. WuXi Biologics (Hong Kong) is a subsidiary or affiliate of WuXi Biologics, which is identified in the proposed U.S. legislation known as the BIOSECURE Act as a biotechnology &#8220;company of concern.&#8221; The current version of the BIOSECURE Act introduced in the House of Representatives would prohibit federal agencies from entering into procurement contracts with, as well as providing grants and loans to, an entity that uses biotechnology equipment or services from a biotechnology company of concern, and includes a grandfathering provision allowing biotechnology equipment and services provided or produced by named &#8220;biotechnology companies of concern&#8221; under a contract or agreement entered into before the effective date until January&#160;1, 2032. The pathway and timing for the BIOSECURE Act or its provisions to become law are uncertain, although the bill was passed in the House of Representatives on September&#160;9, 2024. Depending on whether the BIOSECURE Act becomes law, what the final language of the BIOSECURE Act includes, and how the law is interpreted by U.S. federal agencies, Jade could be potentially restricted from pursuing U.S. federal government business or grants in the future if Jade continues to use WuXi Biologics (Hong Kong) or other parties identified as &#8220;biotechnology companies of concern&#8221; beyond the grandfathering period. Foreign CMOs may be the target of U.S. legislation, including the proposed BIOSECURE Act, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to Jade, delay the procurement or supply of such material, restrict or even prohibit Jade&#8217;s ability to work with such CMOs, or have an adverse effect on Jade&#8217;s ability to secure significant commitments from governments to purchase potential therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For example, the biopharmaceutical industry in China is strictly regulated by the Chinese government. Changes to Chinese regulations or government policies affecting biopharmaceutical companies are unpredictable and may have a material adverse effect on Jade&#8217;s collaborators in China which could have an adverse effect on Jade&#8217;s business, financial condition, results of operations and prospects. Evolving changes in China&#8217;s public health, economic, political, and social conditions and the uncertainty around China&#8217;s relationship with other governments, such as the United States and the UK, could also negatively impact Jade&#8217;s ability to manufacture its product candidates for its planned clinical trials or have an adverse effect on its ability to secure government funding, which could adversely affect Jade&#8217;s financial condition and cause it to delay its clinical development programs. Furthermore, if the BIOSECURE Act is passed and one or more of Jade&#8217;s collaborators or vendors in China, including WuXi Biologics (Hong Kong), is deemed to be a biotechnology company of concern, Jade&#8217;s operations and financial condition may be negatively impacted as a result of any delays or increased costs arising from the trade restrictions and other foreign regulatory requirements affecting such collaborators. In addition, while Jade has established relationships with CROs and CMOs outside of China, moving to those suppliers in the event of a geopolitical instability affecting Jade&#8217;s collaborators in China could introduce delays into the development program.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade relies on the use of third-party CMOs to manufacture Jade&#8217;s product candidates, and Jade expects to continue to rely on third-party CMOs to produce its products, if approved. Jade&#8217;s business could be adversely affected if it is unable to use third-party manufacturing suites or if the third-party manufacturers encounter difficulties in production.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade does not currently own any facility that may be used as its clinical-scale manufacturing and processing facility and must rely on CMOs to manufacture its product candidates. Jade has not yet caused its product candidates to be manufactured on a commercial scale and may not be able to do so for any of its product candidates, if approved. Jade expects to have a sole source relationship for its supply of JADE-001. If there should be any disruption in such supply arrangement, including any adverse events affecting its sole supplier, it could have a negative effect on the clinical development of Jade&#8217;s product candidates and other operations while Jade works to identify and qualify an alternate supply source. Jade has limited control over the manufacturing process of, and may be dependent on, its contract manufacturing partners for compliance with cGMP requirements and any other regulatory requirements of the FDA or comparable foreign regulatory authorities for the manufacture of Jade&#8217;s product candidates. Beyond periodic audits, Jade has limited control over the ability of its CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or another applicable regulatory authority does not approve these facilities for the manufacture of Jade&#8217;s product candidates or withdraws any approval in the future, Jade may need to find alternative manufacturing facilities, which would require the incurrence of significant additional costs and delays and materially adversely affect Jade&#8217;s ability to develop, obtain regulatory approval for or market its product candidates, if approved. Jade, or its future contract manufacturers, any current or future collaborators and their contract manufacturers could be subject to periodic unannounced inspections by the FDA, competent authorities of member states of the European Union (&#8220;EU Member States&#8221;) or other comparable foreign regulatory authorities, to monitor and ensure compliance with cGMP. Despite Jade&#8217;s efforts to audit and verify regulatory compliance, one or more of its third-party manufacturing vendors may be found on regulatory inspection by the FDA, competent authorities of EU Member States or other comparable foreign regulatory authorities to be noncompliant with cGMP regulations. Jade&#8217;s failure, or the failure of its CMOs, to comply with applicable regulations could result in sanctions being imposed on Jade, including fines, injunctions, civil penalties, delays, suspension, variation or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of Jade&#8217;s product candidates or products, if approved, and harm its business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, Jade&#8217;s CMOs may experience manufacturing difficulties due to resource constraints, supply chain issues, intellectual property disputes or as a result of labor disputes or unstable political environments. If any CMOs on which Jade will rely fail to manufacture quantities of its product candidates at quality levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated demand at a commercially reasonable cost, Jade&#8217;s business, financial condition and prospects could be materially and adversely affected. In addition, Jade&#8217;s CMOs are responsible for transporting temperature controlled materials that can be inadvertently degraded during transport due to several factors, rendering certain batches unsuitable for trial use for failure to meet, among others, Jade&#8217;s integrity and purity specifications. Jade and any of its CMOs may also face product seizure or detention or refusal to permit the import or export of products. Jade&#8217;s business could be materially adversely affected by business disruptions to its third-party providers that could materially adversely affect Jade&#8217;s anticipated timelines, potential future revenue and financial condition and increase Jade&#8217;s costs and expenses. Each of these risks could delay or prevent the completion of Jade&#8217;s preclinical studies and clinical trials or the approval of any of its product candidates by the FDA or comparable foreign regulatory authorities, result in higher costs or adversely impact commercialization of Jade&#8217;s product candidates. Please see the section titled &#8220;<i style="font-style:italic;">Jade&#8217;s Business&#160;&#8212; Manufacturing and Supply</i>&#8221; beginning on page&#160;247 of this proxy statement/prospectus for a more detailed description of Jade&#8217;s manufacturing plans and assumptions and the factors that may affect the success of Jade&#8217;s programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Jade&#8217;s Business and Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">In order to successfully implement its plans and strategies, Jade will need to grow the size of its organization and it may experience difficulties in managing this growth.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade expects to experience significant growth in the number of its employees and the scope of its operations, particularly in the areas of preclinical and clinical drug development, technical operations, clinical operations and regulatory affairs. To manage its anticipated future growth, Jade must continue to implement and improve its managerial, operational and financial personnel and systems, expand its facilities and continue to recruit and train additional qualified personnel. Due to Jade&#8217;s limited financial resources and the limited experience of its management team working together in managing a company with such anticipated growth, Jade may not be able to effectively manage the expansion of its operations or recruit and train additional qualified personnel.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade is highly dependent on its key personnel and anticipate hiring new key personnel. If Jade is not successful in attracting and retaining highly qualified personnel, it may not be able to successfully implement its business strategy.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon its ability to attract and retain highly qualified managerial, scientific and medical personnel. Jade is highly dependent on its managerial, scientific and medical personnel, including its Chief Executive Officer, Chief Scientific Officer and other key members of its leadership team. Although Jade has entered into employment agreements with its executive officers, each of them may terminate their employment with Jade at any time. Jade does not maintain &#8220;key person&#8221; insurance for any of its executives or other employees. The loss of the services of Jade&#8217;s executive officers or other key employees could impede the achievement of its research, development and commercialization objectives and seriously harm its ability to successfully implement its business strategy. Furthermore, replacing executive officers and key personnel may be difficult and may take an extended period of time. If Jade does not succeed in attracting and retaining qualified personnel, it could materially adversely affect Jade&#8217;s business, financial condition and results of operations. Jade could in the future have difficulty attracting and retaining experienced personnel and may be required to expend significant financial resources in Jade&#8217;s employee recruitment and retention efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade&#8217;s future growth may depend, in part, on its ability to operate in foreign markets, where Jade would be subject to additional regulatory burdens and other risks and uncertainties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s future growth may depend, in part, on its ability to develop and commercialize its product candidates, if approved, in foreign markets for which Jade may rely on collaboration with third parties. Jade is not permitted to market or promote any of its product candidates before Jade receives regulatory approval from the applicable foreign regulatory authority, and may never receive such regulatory approval for any of its product candidates. To obtain separate regulatory approval in many other countries, Jade must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of Jade&#8217;s product candidates, if approved, and Jade cannot predict success in these jurisdictions. If Jade fails to comply with the regulatory requirements in international markets and receive applicable regulatory approvals, Jade&#8217;s target market will be reduced and its ability to realize the full market potential of its product candidates will be harmed and its business will be adversely affected. Moreover, even if Jade obtains approval of its product candidates and ultimately commercializes its product candidates in foreign markets, Jade would be subject to the risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and reduced protection of intellectual property rights in some foreign countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade&#8217;s estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which Jade competes achieve the forecasted growth, its business may not grow at similar rates, or at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. Jade&#8217;s estimates and forecasts relating to size and expected growth of its target market may prove to be inaccurate. Even if the markets in which Jade competes meet Jade&#8217;s size estimates and growth forecasts, Jade&#8217;s business may not grow at similar rates, or at all. Jade&#8217;s growth is subject to many factors, including its success in implementing its business strategy, which is subject to many risks and uncertainties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s revenue will be dependent, in part, upon the size of the markets in the territories for which it gains regulatory approval, the accepted price for the product, the ability to obtain coverage and reimbursement and whether Jade owns the commercial rights for that territory. If the number of Jade&#8217;s addressable patients is not as significant as it estimates, the indication approved by regulatory authorities is narrower than it expects or the treatment population is narrowed by competition, physician choice or treatment guidelines, Jade may not generate significant revenue from sales of such products, even if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade&#8217;s employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Jade is exposed to the risk that its employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors acting for or on Jade&#8217;s behalf may engage in misconduct or other improper activities. Misconduct by these parties could include intentional, reckless or negligent conduct or disclosure of unauthorized activities to Jade that violates FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA, manufacturing standards, federal and state healthcare laws and regulations, and laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and business arrangements in the healthcare industry are </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to Jade&#8217;s reputation. Jade will adopt a code of conduct, which will become effective as of the Closing, but it is not always possible to identify and deter misconduct by these parties and the precautions Jade takes to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting Jade from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade&#8217;s internal information technology systems, or those of any of Jade&#8217;s CROs, manufacturers, other contractors or consultants, third party service providers, or existing or future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of Jade&#8217;s proprietary or confidential data, employee data or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to Jade&#8217;s brand and material disruption of its operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of its business, Jade and the third parties upon which Jade relies collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, &#8220;Process&#8221;) proprietary, confidential, and sensitive data, including personal data, intellectual property, trade secrets, and other sensitive data (collectively, &#8220;Sensitive Information&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Despite the implementation of security measures in an effort to protect systems that store Jade&#8217;s information, given their size and complexity and the increasing amounts of information maintained on Jade&#8217;s internal information technology systems and those of Jade&#8217;s third-party CROs, other contractors (including sites performing Jade&#8217;s clinical trials), third party service providers and supply chain companies, and consultants, these systems are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by Jade&#8217;s employees, contractors, consultants, business partners and/or other third parties, or from cyber-attacks by malicious third parties, which may compromise Jade&#8217;s system infrastructure or lead to the loss, destruction, alteration or dissemination of, or damage to, Jade&#8217;s data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, Jade, and the third parties upon which Jade relies, may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt Jade&#8217;s systems and operations. In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in Jade&#8217;s operations, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but Jade may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent that any disruption or security breach were to result in loss, destruction, unavailability, alteration or dissemination of, or damage to, Jade&#8217;s data or applications, or for it to be believed or reported that any of these occurred, Jade could incur liability and reputational damage and the development and commercialization of Jade&#8217;s product candidates could be delayed. Further, Jade&#8217;s insurance policies may not be adequate to compensate Jade for the potential losses arising from any such disruption in, or failure or security breach of, Jade&#8217;s systems or third-party systems where information important to Jade&#8217;s business operations or commercial development is stored.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s remote workforce may create additional risks for its information technology systems and data because its employees work remotely and utilize network connections, computers, and devices working at home, while in transit and in public locations. Additionally, business transactions (such as acquisitions or integrations) could expose Jade to additional cybersecurity risks and vulnerabilities, as Jade&#8217;s systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">While Jade has implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. Jade may be unable in the future to detect vulnerabilities in its information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Further, Jade may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. Applicable data privacy and security obligations may require Jade to notify relevant stakeholders of security </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade relies on third-party service providers and technologies to operate critical business systems to Process Sensitive Information in a variety of contexts. Jade&#8217;s ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If Jade&#8217;s third-party service providers experience a security incident or other interruption, Jade could experience adverse consequences. While Jade may be entitled to damages if its third-party service providers fail to satisfy their privacy or security-related obligations to Jade, any award may be insufficient to cover its damages, or Jade may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and Jade cannot guarantee that third parties&#8217; infrastructure in its supply chain or its third-party partners&#8217; supply chains have not been compromised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Jade (or a third party upon whom Jade relies) experiences a security incident or are perceived to have experienced a security incident, Jade may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on Processing Sensitive Information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in Jade&#8217;s operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may cause stakeholders (including investors and potential customers) to stop supporting Jade&#8217;s platform, deter new customers from products, and negatively impact Jade&#8217;s ability to grow and operate its business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in Jade&#8217;s contracts are sufficient to protect Jade from liabilities, damages, or claims related to its data privacy and security obligations. Jade cannot be sure that its insurance coverage will be adequate or sufficient to protect Jade from or to mitigate liabilities arising out of its privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade is subject to stringent and changing laws, regulations and standards, and contractual obligations relating to privacy, data protection, and data security. The actual or perceived failure to comply with such obligations could lead to government enforcement actions (which could include civil or criminal penalties), fines and sanctions, private litigation and/or adverse publicity and could negatively affect Jade&#8217;s operating results and business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade, and third parties who Jade works with are or may become subject to numerous domestic and foreign laws, regulations, and standards relating to privacy, data protection, and data security, the scope of which is changing, subject to differing applications and interpretations, and may be inconsistent among countries, or conflict with other rules. In addition, Jade is or may become subject to the terms of contractual obligations related to privacy, data protection, and data security. Jade&#8217;s obligations may also change or expand as its business grows. The actual or perceived failure by Jade or third parties related to Jade to comply with such laws, regulations and obligations could increase Jade&#8217;s compliance and operational costs, expose Jade to regulatory scrutiny, actions, fines and penalties, result in reputational harm, lead to a loss of customers, result in litigation and liability, and otherwise cause a material adverse effect on Jade&#8217;s business, financial condition, and results of operations. Please see the section titled &#8220;<i style="font-style:italic;">Jade&#8217;s Business&#160;&#8212; Government Regulation&#160;&#8212; Data Privacy and Security</i>&#8221; beginning on page&#160;255 of this proxy statement/prospectus for a more detailed description of the laws that may affect Jade&#8217;s ability to operate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If Jade fails to comply with environmental, health and safety laws and regulations, it could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of Jade&#8217;s business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade is subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Jade&#8217;s operations may involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. In addition, Jade may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair Jade&#8217;s research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade may be subject to adverse legislative or regulatory tax changes that could negatively impact its financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The rules&#160;governing U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect Jade&#8217;s stockholders or Jade. Jade assesses the impact of various tax reform </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">proposals and modifications to existing tax treaties in all jurisdictions where Jade has operations to determine the potential effect on Jade&#8217;s business and any assumptions it has made about Jade&#8217;s future taxable income. Jade cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on Jade&#8217;s business if they were to be enacted. For example, the United States enacted the Inflation Reduction Act of 2022, which implements, among other changes, a 1% excise tax on certain stock buybacks. In addition, beginning in 2022, the Tax Cuts and JOBS Act eliminated the previously available option to deduct research and development expenditures and requires taxpayers to amortize them generally over five&#160;years for research activities conducted in the United States and over 15&#160;years for research activities conducted outside the United States. The U.S. Congress is considering legislation that would restore the current deductibility of research and development expenditures; however, Jade has no assurance that the provision will be repealed or otherwise modified. Such changes, among others, may adversely affect Jade&#8217;s effective tax rate, results of operation and general business condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade may acquire businesses, product candidates or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade may acquire additional businesses or products, form strategic alliances, or create joint ventures with third parties that Jade believes will complement or augment its existing business. If Jade acquires businesses with promising markets or technologies, it may not be able to realize the benefit of acquiring such businesses if Jade is unable to successfully integrate them with its existing operations and company culture. Jade may encounter numerous difficulties in developing, manufacturing and marketing any new product candidates or products resulting from a strategic alliance or acquisition that delay or prevent Jade from realizing their expected benefits or enhancing Jade&#8217;s business. There is no assurance that, following any such acquisition, Jade will achieve the synergies expected in order to justify the transaction, which could result in a material adverse effect on Jade&#8217;s business and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade maintains its cash at financial institutions, often in balances that exceed federally-insured limits. The failure of financial institutions could adversely affect Jade&#8217;s ability to pay its operational expenses or make other payments.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s cash held in non-interest-bearing and interest-bearing accounts exceeds the FDIC insurance limits. If such banking institutions were to fail, Jade could lose all or a portion of those amounts held in excess of such insurance limitations. For example, the FDIC took control of Silicon Valley Bank on March&#160;10, 2023. The Federal Reserve subsequently announced that account holders would be made whole. However, the FDIC may not make all account holders whole in the event of future bank failures. In addition, even if account holders are ultimately made whole with respect to a future bank failure, account holders&#8217; access to their accounts and assets held in their accounts may be substantially delayed. Any material loss that Jade may experience in the future or inability for a material time period to access Jade&#8217;s cash and cash equivalents could have an adverse effect on its ability to pay its operational expenses or make other payments, which could adversely affect Jade&#8217;s business.</p><a id="RiskFactor_Risk_Jade_Intel_Prop"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Jade&#8217;s Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade does not currently own any issued patents or pending patent applications, and, as of October&#160;30, 2024, it in- licenses its rights to JADE-001. Therefore, Jade&#8217;s ability to obtain and protect its patent rights, and protect other proprietary rights, is uncertain, exposing Jade to the possible loss of competitive advantage.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade will rely upon a combination of patents, trademarks, trade secret protection, copyrights and confidentiality agreements and the Paragon Option Agreement to protect the intellectual property related to Jade&#8217;s programs and technologies and to prevent third parties from competing unfairly with Jade. Jade&#8217;s success depends in large part on its ability to obtain and maintain patent protection for its product candidates and their uses, as well as Jade&#8217;s ability to operate without infringing on or violating the proprietary rights of others. Jade does not currently own any patents, but has licensed certain patent rights from Paragon under the JADE-001 License Agreement, and expects to in the future prosecute underlying intellectual property for some or all of the in-licensed or owned product candidates that it develops. Paragon has filed provisional patent applications and intends to file one or more additional provisional patent applications directed to anti- APRIL&#160;monoclonal antibodies, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including JADE-001. However, Jade may not be able to obtain or protect its intellectual property rights throughout the world and the legal systems in certain countries may not favor enforcement or protection of at least certain patents, trade secrets or other intellectual property. Filing, prosecuting, maintaining and defending patents on product candidates and other related inventions worldwide would be expensive and Jade&#8217;s intellectual property rights in some foreign jurisdictions can be less extensive than those in the United States; the reverse may also occur. As such, Jade may not have patents in all countries or all major markets and may not be able to obtain patents in all jurisdictions even if Jade or its licensor files patent applications to obtain such rights. Jade&#8217;s competitors may operate in countries where Jade does not have patent protection and may be able to freely use Jade&#8217;s technologies and discoveries in such countries, at least to the extent not forbidden by law.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s intellectual property portfolio is at an early stage. Jade does not currently own any issued patents or pending patent applications, and in-licenses its rights to JADE-001. Jade&#8217;s currently licensed or future optioned in-licensed or owned patent applications may not result in patents being issued. Any issued patents may not afford sufficient protection of Jade&#8217;s product candidates or their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed, designed around, invalidated by third parties, or effectively prevent others from commercializing competitive technologies, products or product candidates. Even if these patents are granted, they may be difficult to enforce. Further, any issued patents that Jade may license or own covering its product candidates could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad, including the USPTO. If Jade does not obtain patent coverage for the work it is conducting, or if Jade obtains such rights but they are invalidated or rendered unenforceable, it may be unable to exclude competitors from pursuing and marketing the same or similar product candidates. Other risks Jade faces if it is not able to obtain and maintain patent coverage for its product candidates are the reduction in valuation of Jade&#8217;s product candidates, and ultimately of Jade as a company, by potential investors, and Jade&#8217;s inability to assert claims for infringement against third parties or counterclaim against such third parties or negotiate more advantageous settlement parameters. Further, if Jade encounters delays in its clinical trials or delays in obtaining regulatory approval, the period of time during which Jade could market its product candidates under patent protection would be reduced. Thus, the patents that Jade may own or license may not afford Jade any meaningful exclusivity period or competitive advantage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to seeking patents for some of its technology and product candidates, Jade may also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain its competitive position. Any disclosure, either intentional or unintentional, by Jade&#8217;s employees, the employees of third parties with whom Jade shares its facilities or third-party consultants and vendors that Jade engages to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of its trade secrets or proprietary information could enable competitors to duplicate or surpass its technological achievements, thus eroding Jade&#8217;s competitive position in its market. In order to protect its proprietary technology and processes, Jade relies in part on confidentiality agreements with its collaborators, employees, consultants, outside scientific collaborators and sponsored researchers and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Jade may need to share its proprietary information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or state actors and those affiliated with or controlled by state actors. In addition, while Jade undertakes reasonable efforts to protect its trade secrets and other confidential information from disclosure, others may independently discover trade secrets and proprietary information, and in such cases, Jade may not be able to assert any trade secret rights against such party. Costly and time-consuming litigation could be necessary to enforce and determine the scope of Jade&#8217;s proprietary rights and failure to obtain or maintain trade secret protection could adversely affect its competitive business position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lastly, if Jade&#8217;s trademarks and trade names are not registered or adequately protected, then Jade may not be able to build name recognition in its markets of interest and its business may be adversely affected.</p><a id="RiskFactor_If_JadeUnable"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If Jade is unable to obtain or maintain necessary rights to its programs through acquisitions and in-licenses, its business may be materially harmed</span><span style="font-style:italic;font-weight:bold;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because Jade&#8217;s development programs currently do and may in the future require the use of proprietary rights held by third parties, the growth of its business will depend in part on its ability to acquire, in-license, or use these third-party proprietary rights. Jade may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that Jade identifies as necessary for its programs. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that Jade may consider attractive or necessary. These established companies may have a competitive advantage over Jade due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive Jade to be a competitor may be unwilling to assign or license rights to Jade. Jade also may be unable to license or acquire third-party intellectual property rights on terms that would allow Jade to make an appropriate return on its investment or at all. If Jade is unable to successfully obtain rights to required third-party intellectual property rights or maintain intellectual property rights it obtains in the future, Jade may have to abandon development of the relevant program, which could have a material adverse effect on Jade&#8217;s business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">While Jade has the right to control prosecution, defense, maintenance and enforcement of patents in- licensed under the JADE-001 License Agreement, once the trigger for transfer of prosecution control is met, there may be times when rights for patents and patent applications relating to Jade&#8217;s product candidates are controlled by its future licensors or collaboration partners. For </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">example, Paragon currently has the right to file patent applications and control prosecution with respect to any inventions that may fall within the Paragon Option Agreement, including those that may apply to JADE-002 and JADE-003. If Jade, Paragon or any of its future licensors or collaboration partners fail to prosecute, defend, maintain and enforce such patents and patent applications in a manner consistent with the best interests of Jade, including by payment of all applicable fees for patents covering its product candidates, Jade could lose its rights to the intellectual property or its exclusivity with respect to those rights, its ability to develop and commercialize those product candidates may be adversely affected and Jade may not be able to prevent competitors from making, using and selling competing products. In addition, even if Jade has the right to control patent prosecution of patents and patent applications Jade has licensed to and from third parties, including under the JADE-001 License Agreement following the point at which such control is assumed, Jade may still be adversely affected or prejudiced by actions or inactions of Paragon, additional licensees, or licensors and their counsel prior to the date upon which Jade assumes control over patent prosecution. For example, prior to entering into the JADE-001 License Agreement, Paragon was responsible for the prosecution, defense, maintenance and enforcement of patents related to JADE-001. Subsequent to entering into such license agreement, Jade will control patent prosecution over JADE-001 following the trigger for transfer of prosecution control to Jade.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s future licensors may not be the sole and exclusive owners of all rights in the patents Jade may in- license. If other third parties have rights to Jade&#8217;s future in-licensed patents, they may be able to license such patents to its competitors, and its competitors could market competing products and technology. This could have a material adverse effect on Jade&#8217;s competitive position, business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is possible that Jade may be unable to obtain licenses at a reasonable cost or on reasonable terms, if at all. Even if Jade is able to obtain a license, it may be non-exclusive, thereby giving its competitors access to the same technologies licensed to Jade. In that event, Jade may be required to expend significant time and resources to redesign its product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If Jade is unable to do so, it may be unable to develop or commercialize the affected product candidates, which could harm Jade&#8217;s business, financial condition, results of operations, and prospects significantly. Jade cannot provide any assurances that third-party patents do not exist which might be enforced against Jade&#8217;s product candidates, manufacturing methods or future products or methods resulting in either an injunction prohibiting Jade&#8217;s manufacture or future sales, or, with respect to Jade&#8217;s future sales, an obligation on Jade&#8217;s part to pay royalties and/or other forms of compensation to third parties, which could be significant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Disputes may arise between Jade and Jade&#8217;s future licensors regarding intellectual property subject to a license agreement, including (but not limited to): the scope of rights granted under the license agreement and other interpretation-related issues; whether and the extent to which Jade&#8217;s technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; Jade&#8217;s right to sublicense patents and other rights to third parties; Jade&#8217;s right to transfer or assign the license; the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by Jade&#8217;s future licensors and Jade and its partners; and the priority of invention of patented technology. If Jade or its future licensors breach the terms of its license agreements, such breach may have a material adverse effect on Jade&#8217;s business and the commercialization efforts for Jade&#8217;s programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade may be subject to patent infringement claims or may need to file claims to protect Jade&#8217;s intellectual property, which could result in substantial costs and liability and prevent Jade from commercializing Jade&#8217;s potential products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because the intellectual property landscape in the biotechnology industry is rapidly evolving and interdisciplinary, it is difficult to conclusively assess Jade&#8217;s freedom to operate and guarantee that Jade can operate without infringing on or violating third party rights. If certain of Jade&#8217;s product candidates are ultimately granted regulatory approval, patent rights held by third parties could be alleged to render one or more of Jade&#8217;s product candidates infringing. If a third party successfully brings a claim against Jade, and its rights are not held invalid or unenforceable, Jade may be required to pay substantial damages, be forced to abandon any affected product candidate and/or seek a license from the patent holder. In addition, any intellectual property claims (e.g., patent infringement or trade secret misappropriation) brought against Jade, whether or not successful, may cause Jade to incur significant legal expenses and divert the attention of Jade&#8217;s management and key personnel from other business concerns. Jade cannot be certain that future patents, if filed and issued, owned or licensed by Jade will not be challenged by others, whether in the course of litigation or in agencies like the USPTO. Some of Jade&#8217;s competitors may be able to sustain the costs of complex intellectual property litigation more effectively than Jade can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on Jade&#8217;s ability to raise funds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Competitors may infringe or otherwise violate Jade&#8217;s future patents, trademarks, copyrights or other intellectual property. To counter infringement or other violations, Jade may be required to file claims, which can be expensive and time-consuming. Any such </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">claims could provoke these parties to assert counterclaims against Jade, including claims alleging that Jade infringes their patents or other intellectual property rights. In addition, in a patent infringement proceeding, a court or administrative body may decide that one or more of the patents Jade asserts is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to prevent the other party from using the technology at issue on the grounds that Jade&#8217;s patents do not cover the technology. Similarly, if Jade asserts trademark infringement claims, a court or administrative body may determine that the marks Jade has asserted are invalid or unenforceable or that the party against whom Jade has asserted trademark infringement has superior rights to the marks in question. In such a case, Jade could ultimately be forced to cease use of such marks. In any intellectual property litigation, even if Jade is successful, any award of monetary damages or other remedy it receives may not be commercially valuable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, Jade may be required to protect its future patents, if filed and issued, through procedures created to attack the validity of a patent at the USPTO. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, Jade&#8217;s patent rights, which could adversely affect its competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, if Jade&#8217;s product candidates are found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims against Jade&#8217;s future licensees or customers and other parties with whom Jade has business relationships and Jade may be required to indemnify those parties for any damages they suffer as a result of these claims, which may require Jade to initiate or defend protracted and costly litigation on behalf of licensees or other parties regardless of the merits of such claims. If any of these claims succeed, Jade may be forced to pay damages on behalf of those parties or may be required to obtain licenses for the products they use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to Jade&#8217;s intellectual property rights, there is a risk that some of its confidential information could be compromised by disclosure during this type of litigation or other proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade&#8217;s success will depend in part on its and its future licensors&#8217; ability to obtain, maintain and enforce patent protection for its licensed intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s success will depend in part on its and its future licensors&#8217; (including Paragon&#8217;s) ability to obtain, maintain and enforce patent protection for its licensed intellectual property. After entry into the JADE-001 License Agreement and once the trigger for transfer of prosecution control is met, Jade will control the prosecution, maintenance, enforcement and defense of JADE-001. Prior to entering into the license agreement, Paragon held such rights. Jade, Paragon and Jade&#8217;s future licensors may not successfully prosecute the patent applications that cover Jade&#8217;s product candidates. Even if patents are issued in respect of these patent applications, Jade and its future licensors (including Paragon) may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue such litigation less aggressively than Jade would. Without protection for any in-licensed intellectual property, other companies might be able to offer substantially identical products for sale, which could adversely affect Jade&#8217;s competitive business position and harm its business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade may be subject to claims that it has wrongfully hired an employee from a competitor or that its employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As is common in the biotechnology industry, in addition to its employees, Jade engages the services of consultants to assist Jade in the development of its product candidates. Many of these consultants, and many of Jade&#8217;s employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or pharmaceutical companies including Jade&#8217;s competitors or potential competitors. Jade could in the future be subject to claims that Jade or its employees have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of former employers or competitors. Although Jade tries to ensure that its employees and consultants do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for Jade, Jade may become subject to claims that it caused an employee to breach the terms of his or her non- competition or non-solicitation agreement, or that Jade or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">While Jade may litigate to defend itself against these claims, even if Jade is successful, litigation could result in substantial costs and could be a distraction to management and other employees. If Jade&#8217;s defenses to these claims fail, in addition to requiring Jade to </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">pay monetary damages, a court could prohibit Jade from using technologies or features that are essential to Jade&#8217;s product candidates, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect Jade&#8217;s reputation, Jade&#8217;s ability to form strategic alliances or sublicense Jade&#8217;s rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on Jade&#8217;s business, results of operations and financial condition. Even if Jade is successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing Jade&#8217;s ability to protect its products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Changes in either the patent laws or interpretation of patent laws in the United States, including patent reform legislation such as the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;) could increase the uncertainties and costs surrounding the prosecution of Jade&#8217;s owned and in-licensed patent applications and the maintenance, enforcement or defense of Jade&#8217;s owned and in-licensed issued patents. The Leahy- Smith Act includes a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Assuming that other requirements for patentability are met, prior to March&#160;2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March&#160;2013, under the Leahy-Smith Act, the United States transitioned to a first-to-file system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation increased the uncertainties and costs surrounding the prosecution of Jade&#8217;s patent applications and the enforcement or defense of Jade&#8217;s issued patents, all of which could have a material adverse effect on Jade&#8217;s business, financial condition, results of operations and prospects. Additionally, there have been proposals for additional changes to the patent laws of the United States and other countries that, if adopted, could impact Jade&#8217;s ability to enforce its proprietary technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. U.S. Supreme Court and U.S. Court of Appeals for the Federal Circuit rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations, including in the antibody arts. For example, the United States Supreme Court in <i style="font-style:italic;">Amgen,&#160;Inc. v. Sanofi </i>(&#8220;<i style="font-style:italic;">Amgen</i>&#8221;) recently held that Amgen&#8217;s patent claims to a class of antibodies functionally defined by their ability to bind a particular antigen were invalid for lack of enablement where the patent specification provided 26 exemplary antibodies, but the claimed class of antibodies covered a &#8220;vast number&#8221; of additional antibodies not disclosed in the specification. The Court stated that if patent claims are directed to an entire class of compositions of matter, then the patent specification must enable a person skilled in the art to make and use the entire class of compositions. This decision makes it unlikely that Jade will be granted U.S. patents with composition of matter claims as broad as Amgen&#8217;s directed to antibodies functionally defined by their ability to bind a particular antigen. Even if Jade is granted claims directed to functionally defined antibodies, it is possible that a third party may challenge Jade&#8217;s patents, when issued, relying on the reasoning in <i style="font-style:italic;">Amgen </i>or other precedential court decisions. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on Jade&#8217;s patent rights and its ability to protect, defend and enforce Jade&#8217;s patent rights in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the U.S. Supreme Court&#8217;s July&#160;2024 decision to overturn established case law giving deference to regulatory agencies&#8217; interpretations of ambiguous statutory language has introduced uncertainty regarding the extent to which the FDA&#8217;s regulations, policies and decisions may become subject to increasing legal challenges, delays, and/or changes. Jade cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. Geopolitical instability in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of patent applications and the maintenance, enforcement or defense of issued patents. In addition, the UPC entered into force on June&#160;1, 2023. The UPC is a common patent court that hears patent infringement and revocation proceedings effective for EU Member States. This could enable third parties to seek revocation of a European patent in a single proceeding at the UPC rather than through multiple proceedings in each of the jurisdictions in which the European patent is validated.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although Jade does not currently own any European patents or applications, if Jade obtains or licenses such patents and applications in the future, any such revocation and loss of patent protection could have a material adverse impact on Jade&#8217;s business and its ability to commercialize or license its technology and products. Moreover, the controlling laws and regulations of the UPC will develop over time, and may adversely affect Jade&#8217;s ability to enforce or defend the validity of any European patents Jade may obtain. Jade may decide to opt out from the UPC any future European patent applications that Jade may file and any patents it may obtain. If certain formalities and requirements are not met, however, such European patents and patent applications could be challenged for non-compliance and brought under the jurisdiction of the UPC. Jade cannot be certain that future European patents and patent applications will avoid falling under the jurisdiction of the UPC, if it decides to opt out of the UPC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and Jade&#8217;s patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Periodic maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If Jade fails to maintain any future patents and patent applications, if filed and issued, covering Jade&#8217;s product candidates, Jade&#8217;s competitive position would be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect Jade&#8217;s ability to develop and market its products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade cannot guarantee that any of its patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can Jade be certain that it has identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of Jade&#8217;s product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent, the patent&#8217;s prosecution history and in some cases certain extrinsic evidence of the meaning of terms in a claim. Jade&#8217;s interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, Jade may incorrectly determine that its products are not covered by a third-party patent or may incorrectly predict whether a third-party&#8217;s pending application will issue with claims of relevant scope. Jade&#8217;s determination of the expiration date of any patent in the United States or abroad that Jade considers relevant may be incorrect. Jade&#8217;s failure to identify and correctly interpret relevant patents may negatively impact its ability to develop and market its products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18&#160;months after filing, and publications in the scientific literature often lag behind actual discoveries, Jade cannot be certain that others have not filed patent applications for technology covered by Jade&#8217;s future issued patents or Jade&#8217;s pending applications, if filed, or that Jade was the first to invent the technology. Jade&#8217;s competitors may have filed, and may in the future file, patent applications covering Jade&#8217;s products or technology similar to ours. Any such patent application may have priority over Jade&#8217;s future patent applications or patents, if filed and issued, which could require Jade to obtain rights to issued patents covering such technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade may become subject to claims challenging the inventorship or ownership of Jade&#8217;s patents, if issued, and other intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Jade may be subject to claims that former employees, collaborators or other third parties have an interest in Jade&#8217;s future patents, if filed and issued, or other intellectual property as an inventor or co- inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being invalid or unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing Jade&#8217;s programs or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, Jade may enter into agreements to clarify </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the scope of Jade&#8217;s rights in such intellectual property. If Jade fails in defending any such claims, in addition to paying monetary damages, it may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on Jade&#8217;s business. Even if Jade is successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s current or future licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the U.S. government, such that Jade&#8217;s licensors are not the sole and exclusive owners of the patents Jade in-licensed. If other third parties have ownership rights or other rights to Jade&#8217;s in-licensed patents, they may be able to license such patents to Jade&#8217;s competitors, and its competitors could market competing products and technology. This could have a material adverse effect on Jade&#8217;s competitive position, business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Patent terms may be inadequate to protect Jade&#8217;s competitive position of its product candidates for an adequate amount of time.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering Jade&#8217;s product candidates are obtained, once the patent life has expired, Jade may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, Jade&#8217;s owned and licensed patent portfolio may not provide Jade with sufficient rights to exclude others from commercializing products similar or identical to ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade&#8217;s technology licensed from various third parties may be subject to retained rights.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s future licensors may retain certain rights under the relevant agreements with Jade, including the right to use or license the licensed technology outside of the scope of Jade&#8217;s license, use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether Jade&#8217;s licensors limit their use of the technology to these uses, and Jade could incur substantial expenses to enforce its rights to its licensed technology in the event of misuse. In addition, while there are certain restrictions on Paragon&#8217;s ability to develop products that could be competitive with Jade&#8217;s as more fully described in the section titled &#8220;<i style="font-style:italic;">Jade&#8217;s Business&#160;&#8212; Jade&#8217;s Collaboration, License and Services Agreements&#160;&#8212; JADE-001 License Agreement</i>&#8221; beginning on page&#160;245 of this proxy statement/prospectus, these restrictions may not prevent the possible future license or development by Paragon of certain technology that could lead to product candidates competitive with Jade&#8217;s. This could have a material adverse effect on Jade&#8217;s competitive position, business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Government Regulation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. If Jade is not able to obtain, or if there are delays in obtaining, required regulatory approvals for its product candidates, Jade will not be able to commercialize, or will be delayed in commercializing, its product candidates, and its ability to generate revenue will be materially impaired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The process of obtaining regulatory approvals, both in the United States and abroad, is unpredictable, expensive and typically takes many&#160;years following commencement of clinical trials, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Jade cannot commercialize product candidates in the United States without first obtaining regulatory approval from the FDA. Similarly, Jade cannot commercialize product candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of Jade&#8217;s product candidates, including JADE-001, Jade must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that Jade&#8217;s product candidates are both safe and effective for each targeted indication. Securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Further, Jade&#8217;s product candidates may not be effective, may be only moderately effective, may prove to have undesirable or unintended side effects, toxicities or other characteristics, or may fail to improve on the applicable standard of care, any of which may preclude Jade&#8217;s obtaining regulatory approval. The FDA and comparable foreign regulatory authorities have discretion in the approval process and may refuse to accept any application or may decide that Jade&#8217;s data are insufficient for approval and require additional preclinical, clinical or other data. Jade&#8217;s product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including: the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of Jade&#8217;s clinical </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">trials; Jade may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication; the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; serious and unexpected drug- related side effects may be experienced by participants in Jade&#8217;s clinical trials or by individuals using drugs similar to its product candidates; Jade may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; the FDA or comparable foreign regulatory authorities may disagree with Jade&#8217;s interpretation of data from preclinical studies or clinical trials; the data collected from clinical trials of Jade&#8217;s product candidates may not be acceptable or sufficient to support the submission of a BLA or other submission or to obtain regulatory approval in the United States or elsewhere, and Jade may be required to conduct additional clinical trials; the FDA or the applicable foreign regulatory authority may disagree regarding the formulation, labeling and/or the specifications of Jade&#8217;s product candidates; the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which Jade contracts for clinical and commercial supplies; and the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering Jade&#8217;s clinical data insufficient for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Of the large number of drugs in development, only a small&#160;percentage successfully complete the FDA or applicable foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in Jade&#8217;s failing to obtain regulatory approval to market Jade&#8217;s product candidates, which would significantly harm Jade&#8217;s business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Jade were to obtain approval, regulatory authorities may approve any of Jade&#8217;s product candidates for fewer or more limited indications than Jade requests, including failing to approve the most commercially promising indications, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. If Jade is not able to obtain, or if there are delays in obtaining, required regulatory approvals for Jade&#8217;s product candidates, it will not be able to commercialize, or will be delayed in commercializing, this could have a material adverse effect on Jade&#8217;s competitive position, business, financial condition, results of operations, and prospects. .</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade may not be able to meet requirements for the chemistry, manufacturing and control of its product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to receive approval of Jade&#8217;s products by the FDA and comparable foreign regulatory authorities, Jade must show that Jade and its contract manufacturing partners are able to characterize, control and manufacture Jade&#8217;s drug products safely and in accordance with regulatory requirements. This includes manufacturing the active ingredient, developing an acceptable formulation, manufacturing the drug product, performing tests to adequately characterize the formulated product, documenting a repeatable manufacturing process, and demonstrating that Jade&#8217;s drug products meet stability requirements. Meeting these chemistry, manufacturing and control requirements is a complex task that requires specialized expertise. If Jade is not able to meet the chemistry, manufacturing and control requirements, it may not be successful in getting Jade&#8217;s products approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade&#8217;s product candidates for which Jade intends to seek approval as biologics may face competition from biosimilars sooner than anticipated.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a highly similar or &#8220;biosimilar&#8221; product may not be submitted to the FDA until four&#160;years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12&#160;years from the date on which the reference product was first approved. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade believes that any of its product candidates approved as biologics under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider Jade&#8217;s product candidates to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference products in a way that is similar to traditional generic substitution for non- biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if Jade receives regulatory approval of its product candidates, Jade will be subject to extensive ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and Jade may be subject to penalties if it fails to comply with regulatory requirements or experiences unanticipated problems with Jade&#8217;s product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Any regulatory approvals that Jade may receive for its product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a REMS in order to approve Jade&#8217;s product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Comparable foreign regulatory authorities may impose similar requirements. In addition, if the FDA or comparable foreign regulatory authorities approve Jade&#8217;s product candidates, Jade&#8217;s product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export will be subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable foreign regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as on-going compliance with current cGMPs and GCPs for any clinical trials that Jade conducts following approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMPs. If Jade or a regulatory authority discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory authority may impose restrictions on that product, the manufacturing facility or Jade, including requiring recall or withdrawal of the product from the market or suspension of manufacturing, delays or restrictions on Jade&#8217;s ability to conduct clinical trials or delays or refusal to grant a marketing authorization, including full or partial clinical holds on ongoing or planned trials, restrictions on the manufacturing process, warning or untitled letters, civil and criminal penalties, injunctions, product seizures, detentions or import bans, suspension, withdrawal or variation of any marketing authorization that has been granted, voluntary or mandatory publicity requirements and imposition of restrictions on operations, including costly new manufacturing requirements. Similar penalties may apply in case of failure by Jade or by any of Jade&#8217;s third-party partners, including suppliers, manufacturers and distributors to comply with FDA, EU laws and the related national laws of individual EU Member States and other applicable regulatory authorities governing the conduct of clinical trials, manufacturing approval, marketing authorization of medicinal products and marketing of such products, both before and after grant of a marketing authorization, statutory health insurance, bribery and anti-corruption or other applicable regulatory requirements may result in administrative, civil or criminal penalties. The occurrence of any event or penalty described above may inhibit Jade&#8217;s ability to commercialize its product candidates and generate revenue and could require Jade to expend significant time and resources in response and could generate negative publicity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Disruptions at the FDA, the SEC and other government agencies and regulatory authorities caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of Jade&#8217;s business may rely, which could negatively impact Jade&#8217;s business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The ability of the FDA to review regulatory filings and Jade&#8217;s ability to commence human clinical trials can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent&#160;years as a result. In addition, government funding of the SEC, and other government agencies on which Jade&#8217;s operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Disruptions at the FDA and other agencies or comparable foreign regulatory authorities, may also slow the time necessary for the review and approval of applications for clinical trial or marketing authorization, which would adversely affect Jade&#8217;s business. For example, in recent&#160;years, including in 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process Jade&#8217;s regulatory submissions, which could have a material adverse effect on Jade&#8217;s business. Further, future government shutdowns could impact Jade&#8217;s ability to access the public markets and obtain necessary capital in order to properly capitalize and continue Jade&#8217;s operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process Jade&#8217;s regulatory submissions, which could have a material adverse effect on its business.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade may face difficulties from healthcare and regulatory legislative reform measures.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of Jade&#8217;s product candidates. Jade cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If Jade is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if Jade is not able to maintain regulatory compliance, it may lose any regulatory approval that Jade may have obtained and Jade may not achieve or sustain profitability. Please see the section titled &#8220;<i style="font-style:italic;">Jade&#8217;s Business&#160;&#8212; Government Regulation&#160;&#8212; Healthcare Reform</i>&#8221; beginning on page&#160;256 of this proxy statement/prospectus for a more detailed description of healthcare reforms measures that may prevent or limit Jade&#8217;s ability to generate revenue, attain profitability, or commercialize Jade&#8217;s product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade&#8217;s business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose Jade to penalties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Jade&#8217;s business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers may expose Jade to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which Jade conducts its operations, including how Jade researches, markets, sells and distributes its product candidates, if approved. See the sections titled &#8220;<i style="font-style:italic;">Jade&#8217;</i>s <i style="font-style:italic;">Business&#160;&#8212; Government Regulation&#160;&#8212; Other Healthcare Laws and Compliance Requirements</i>&#8221; and &#8220;<i style="font-style:italic;">Jade&#8217;s Business&#160;&#8212; Government Regulation&#160;&#8212; Regulation in the European Union</i>&#8221; beginning on pages&#160;254 and 258, respectively, of this proxy statement/prospectus for a more detailed description of the laws that may affect Jade&#8217;s ability to operate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Ensuring that Jade&#8217;s internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. If Jade&#8217;s operations are found to be in violation of any of these laws or any other governmental laws and regulations that may apply to Jade, Jade may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of Jade&#8217;s operations. Further, defending against any such actions can be costly and time-consuming and may require significant personnel resources. Therefore, even if Jade is successful in defending against any such actions that may be brought against Jade, Jade&#8217;s business may be impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if Jade is able to commercialize any product candidates, due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, Jade may not be able to offer such product candidates at competitive prices which would seriously harm Jade&#8217;s business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Jade intends to seek approval to market its product candidates in both the United States and in selected foreign jurisdictions. If Jade obtains approval in one or more foreign jurisdictions for its product candidates, Jade will be subject to rules&#160;and regulations in those jurisdictions. Jade&#8217;s ability to successfully commercialize any product candidates that Jade may develop will depend in part on the extent to which reimbursement for these product candidates and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. These entities may create preferential access policies for a competitor&#8217;s product, including a branded or generic/biosimilar product, over Jade&#8217;s products in an attempt to reduce their costs, which may reduce Jade&#8217;s commercial opportunity. See the sections titled &#8220;<i style="font-style:italic;">Jade&#8217;s</i> <i style="font-style:italic;">Business&#160;&#8212; Government Regulation&#160;&#8212; Coverage and Reimbursement</i>&#8221; and &#8220;<i style="font-style:italic;">Jade&#8217;s</i> <i style="font-style:italic;">Business&#160;&#8212; Other Government Regulation Outside of the United States</i>&#8221; beginning on pages&#160;256 and 257, respectively, of this proxy statement/prospectus for a more detailed description of the government regulations and third-party payor practices that may affect Jade&#8217;s ability to commercialize its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade is subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Jade can face criminal liability and other serious consequences for violations, which can harm Jade&#8217;s business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Jade is subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">laws in the countries in which Jade conducts activities. Governmental regulation of the import or export of Jade&#8217;s drug candidates, or Jade&#8217;s failure to obtain any required import or export authorization for Jade&#8217;s candidates, when applicable, could harm international operations. Furthermore, export control laws and economic sanctions prohibit the provision of certain items, technology, and services to countries, governments, and persons targeted by sanctions programs. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to or from recipients in the public or private sector. Jade may engage third parties to sell its products outside the United States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. Jade has direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. Jade can be held liable for the corrupt or other illegal activities of Jade&#8217;s employees, agents, contractors, and other collaborators, even if Jade does not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Governments outside the United States tend to impose strict price controls, which may adversely affect Jade&#8217;s revenue, if any.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In some countries, particularly EU Member States, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of regulatory approval for a therapeutic. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States and parallel distribution, or arbitrage between low-priced and high- priced EU Member States, can further reduce prices. To obtain coverage and reimbursement or pricing approvals in some countries, Jade or future collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of Jade&#8217;s product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, Jade&#8217;s business, financial condition, results of operations or prospects could be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade may attempt to obtain accelerated approval of its product candidates. If Jade is unable to obtain accelerated approval, Jade may be required to conduct clinical trials beyond those that it contemplates, or the size and duration of Jade&#8217;s pivotal clinical trials could be greater than currently planned, which could increase the expense of obtaining, reduce the likelihood of obtaining, and/or delay the timing of obtaining necessary regulatory approvals. Even if Jade receives accelerated approval from the FDA or comparable foreign regulatory authorities, the FDA or comparable foreign regulatory authorities may require that Jade conducts confirmatory trials to verify clinical benefit. If Jade&#8217;s confirmatory trials do not verify clinical benefit, or if Jade does not comply with rigorous post-approval requirements, the FDA may seek to withdraw accelerated approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Jade may seek accelerated approval for Jade&#8217;s product candidates. The FDA may grant accelerated approval to a product designed to treat a serious or life-threatening condition that provides meaningful therapeutic advantage over available therapies and demonstrates an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease. If granted, accelerated approval may be contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s predicted effect on irreversible morbidity or mortality or other clinical benefit. Under the Food and Drug Omnibus Reform Act of 2022, the FDA may require, as appropriate, that such studies be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. The FDA may require that any such confirmatory study be initiated or substantially underway prior to the submission of an application for accelerated approval. If such post-approval studies fail to confirm the drug&#8217;s clinical benefits relative to its risks, the FDA may withdraw its approval of the drug. If Jade chooses to pursue accelerated approval, there can be no assurance that the FDA will agree that Jade&#8217;s proposed primary endpoint is an appropriate surrogate endpoint. Similarly, there can be no assurance that after subsequent FDA feedback that Jade will continue to pursue accelerated approval or any other form of expedited development, review, or approval, even if Jade initially decides to do so. Furthermore, if Jade submits an application for accelerated approval, there can be no assurance that such application will be accepted or that approval will be granted on a timely basis, or at all. The FDA also could require Jade to conduct further studies or trials prior to considering Jade&#8217;s application or granting approval of any type. Jade might not be able to fulfill the FDA&#8217;s requirements in a timely manner, which would cause delays, or approval might not be granted because Jade&#8217;s submission is deemed incomplete by the FDA. Comparable considerations apply outside of the United States.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Even if Jade receives accelerated approval from the FDA, Jade will be subject to rigorous post-approval requirements, including submission to the FDA of all promotional materials prior to their dissemination. The FDA will require Jade to conduct a confirmatory study to verify the predicted clinical benefit. The FDA could withdraw accelerated approval for multiple reasons, including Jade&#8217;s failure to conduct any required post-approval study with due diligence, or the inability of such study to confirm the predicted clinical benefit. A failure to obtain accelerated approval or any other form of expedited review or approval for a product candidate could result in a longer time period prior to commercializing such product candidate, increase the cost of development of such product candidate, and harm Jade&#8217;s competitive position in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Jade&#8217;s General Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade may become exposed to costly and damaging liability claims, either when testing a product candidate in the clinical or at the commercial stage, and Jade&#8217;s product liability insurance may not cover all damages from such claims.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Jade is exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of pharmaceutical products. While Jade currently has no products that have been approved for commercial sale, the future use of a product candidate in clinical trials, and the sale of any approved products in the future, may expose Jade to liability claims. These claims may be made by patients that use the product, healthcare providers, pharmaceutical companies, or others selling such product. Any claims against Jade, regardless of their merit, could be difficult and costly to defend and could materially and adversely affect the market for Jade&#8217;s products or any prospects for commercialization of its products. Although Jade intends to obtain product liability insurance for its future clinical trials, it is possible that its liabilities could exceed Jade&#8217;s insurance coverage or that in the future Jade may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against Jade for uninsured liabilities or in excess of insured liabilities, Jade&#8217;s assets may not be sufficient to cover such claims and Jade&#8217;s business operations could be impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Litigation costs and the outcome of litigation could have a material adverse effect on Jade&#8217;s business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:19.95pt;margin:0pt 0pt 10pt 0pt;">From time to time, Jade may be subject to litigation claims through the ordinary course of Jade&#8217;s business operations regarding, but not limited to, securities litigation, employment matters, security of patient and employee personal information, contractual relations with collaborators and licensors and intellectual property rights. Litigation to defend ourselves against claims by third parties, or to enforce any rights that Jade may have against third parties, could result in substantial costs and diversion of Jade&#8217;s resources, causing a material adverse effect on Jade&#8217;s business, financial condition, results of operations or cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade&#8217;s business could be adversely affected by economic downturns, inflation, increases in interest rates, natural disasters, public health crises, political crises, geopolitical events, or other macroeconomic conditions, which could have a material and adverse effect on Jade&#8217;s results of operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including, among other things, diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, increases in inflation rates, higher interest rates, and uncertainty about economic stability. Adverse macroeconomic conditions, including inflation, slower growth or recession, new or increased tariffs and other barriers to trade, changes to fiscal and monetary policy or government budget dynamics (particularly in the pharmaceutical and biotech areas), tighter credit, higher interest rates, volatility in financial markets, high unemployment, labor availability constraints, currency fluctuations and other challenges in the global economy have in the past adversely affected, and may in the future adversely affect, Jade and Jade&#8217;s business partners and suppliers. For example, the COVID-19 pandemic resulted in widespread unemployment, economic slowdown and extreme volatility in the capital markets. The Federal Reserve has raised interest rates multiple times in recent&#160;years in response to concerns about inflation and it may raise them again. High interest rates, coupled with reduced government spending and volatility in financial markets, may increase economic uncertainty and affect consumer spending. Similarly, the ongoing military conflict between Russia and Ukraine and in the Middle East and rising tensions with China have created extreme volatility in the global capital markets and may have further global economic consequences, including disruptions of the global supply chain. Any such volatility and disruptions may adversely affect Jade&#8217;s business or the third parties on whom Jade relies. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more costly, more dilutive, or more difficult to obtain in a timely manner or on favorable terms, if at all. Increased inflation rates can adversely affect Jade by increasing Jade&#8217;s costs, including labor and employee benefit costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Jade may in the future experience disruptions as a result of such macroeconomic conditions, including delays or difficulties in initiating or expanding clinical trials and manufacturing sufficient quantities of materials. Any one or a combination of these events could have a material and adverse effect on Jade&#8217;s results of operations and financial condition.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Risks Related to the Nevada Redomestication</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Currently, Aerovate is governed by Delaware law, but upon effectiveness of the Nevada Redomestication the Combined Company will be governed by Nevada law and the Combined Company&#8217;s articles of incorporation and bylaws, provisions of which have anti-takeover implications.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Upon effectiveness of the Nevada Redomestication, the Combined Company&#8217;s organizational documents will change and the Combined Company and its organizational documents will be governed by Nevada law rather than Delaware law. Chapter 78 of the Nevada Revised Statutes also contains provisions that may enable the Combined Company&#8217;s board of directors to discourage, delay or prevent a change in the Combined Company&#8217;s ownership or in its management. The combinations with interested stockholders provisions of the Nevada Revised Statutes, subject to certain exceptions, restrict the Combined Company&#8217;s ability to engage in any combination with an interested stockholder for two years after the date a stockholder becomes an interested stockholder, unless, prior to the stockholder becoming an interested stockholder, the Combined Company board of directors approved the combination or transaction by which stockholder first became an interested stockholder. If the combination or acquisition was not so approved prior to the stockholder becoming an interested stockholder, the interested stockholder may effect a combination after the two-year period only if either the stockholder receives approval from at least 60% of the outstanding voting power, excluding shares beneficially owned by the interested stockholder or its affiliates or associates, or the consideration to be paid by the interested stockholder exceeds certain thresholds set forth in the statute. For purposes of the foregoing provisions, &#8220;interested stockholder&#8221; means either a person, other than the Combined Company or its subsidiaries, who directly or indirectly beneficially owns 10% or more of the voting power of the Combined Company&#8217;s outstanding voting shares, or one of the Combined Company&#8217;s affiliates or associates which at any time within two years immediately before the date in question directly or indirectly beneficially owned 10% or more of the voting power of our outstanding shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Because the Combined Company&#8217;s articles of incorporation and bylaws limit the court in which you may bring an action against the Combined Company, you may have difficulty obtaining a more favorable judicial forum or you may incur more expense enforcing any rights which you may claim as compared to prior to the Nevada Redomestication.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Combined Company&#8217;s charter and its bylaws provide that, to the extent permitted by law, any person who acquires equity in the Combined Company shall be deemed to have notice and consented to the forum selection provision of the Combined Company&#8217;s bylaws, which require actions to be brought only in state court in Clark County, Nevada, which may inhibit or deter stockholders&#8217; actions (i)&#160;brought in the name of the Combined Company or on its behalf; (ii)&#160;asserting a claim for breach of any fiduciary duty owed by any director, officer, employee or agent of the Combined Company to the Combined Company or the Combined Company&#8217;s stockholders; (iii)&#160;arising or asserting a claim arising pursuant to any provision of NRS Chapters 78 or 92A or any provision of the articles of incorporation or bylaws of the Combined Company; (iv)&#160;to interpret, apply, enforce or determine the validity of any provision of the Combined Company&#8217;s articles of incorporation or bylaws; or (v)&#160;asserting a claim governed by the internal affairs doctrine. This exclusive forum provision may limit the Combined Company&#8217;s stockholders&#8217; ability to obtain what they believe to be a favorable judicial forum for disputes with us and our officers and directors. This provision does not apply to claims brought under the Securities Act or the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Any person or entity purchasing or otherwise acquiring any interest in any of the Combined Company&#8217;s securities shall be deemed to have notice of and consented to this provision. These exclusive-forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum of its choosing for disputes with the Combined Company or its directors, officers, or other employees, which may discourage lawsuits against the Combined Company and its directors, officers, and other employees. If a court were to find either exclusive- forum provision in the Combined Company&#8217;s bylaws to be inapplicable or unenforceable in an action, the Combined Company may incur additional costs associated with resolving the dispute in other jurisdictions, which could harm its results of operations.</p><a id="RiskFactor_Risk_CombinedCompany"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Risks Related to the Combined Company</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">If any of the events described in &#8220;Risks Related to Aerovate&#8221; or &#8220;Risks Related to Jade&#8221; occur, those events could cause potential benefits of the Merger not to be realized.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Following completion of the Merger, the Combined Company will be susceptible to many of the risks described in the sections herein entitled &#8220;<i style="font-style:italic;">Risks Related to Aerovate</i>&#8221; and &#8220;<i style="font-style:italic;">Risks Related to Jade.</i>&#8221; To the extent any of the events in the risks described in those sections occur, the potential benefits of the Merger may not be realized and the results of operations and financial condition of the Combined Company could be adversely affected in a material way. This could cause the market price of the Combined Company&#8217;s common stock to decline.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">The market price of the Combined Company&#8217;s common stock is expected to be volatile, and the market price of the common stock may drop following the Merger.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The market price of the Combined Company&#8217;s common stock following the Merger could be subject to significant fluctuations. Some of the factors that may cause the market price of the Combined Company&#8217;s common stock to fluctuate include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results of clinical trials and preclinical studies of the Combined Company&#8217;s product candidates, or those of the Combined Company&#8217;s competitors or the Combined Company&#8217;s existing or future collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to meet or exceed financial and development projections the Combined Company may provide to the public;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to meet or exceed the financial and development projections of the investment community;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if the Combined Company does not achieve the perceived benefits of the Merger as rapidly or to the extent anticipated by financial or industry analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by the Combined Company or its competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actions taken by regulatory agencies with respect to the Combined Company&#8217;s product candidates, clinical studies, manufacturing process or sales and marketing terms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes or other developments relating to proprietary rights, including patents, litigation matters, and the Combined Company&#8217;s ability to obtain patent protection for its technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additions or departures of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant lawsuits, including patent or stockholder litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if securities or industry analysts do not publish research or reports about the Combined Company&#8217;s business, or if they issue adverse or misleading opinions regarding its business and stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the market valuations of similar companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general market or macroeconomic conditions or market conditions in the pharmaceutical and biotechnology sectors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of securities by the Combined Company or its securityholders in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if the Combined Company fails to raise an adequate amount of capital to fund its operations or continued development of its product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading volume of the Combined Company&#8217;s common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements by competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse publicity relating to precision medicine product candidates, including with respect to other products in such markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the introduction of technological innovations or new therapies that compete with the products and services of the Combined Company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">period-to-period fluctuations in the Combined Company&#8217;s financial results.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of the Combined Company&#8217;s common stock. In addition, a recession, depression or other sustained adverse market event could materially and adversely </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">affect the Combined Company&#8217;s business and the value of its common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies. Furthermore, market volatility may lead to increased shareholder activism if the Combined Company experiences a market valuation that activists believe is not reflective of its intrinsic value. Activist campaigns that contest or conflict with the Combined Company&#8217;s strategic direction or seek changes in the composition of its board of directors could have an adverse effect on its operating results, financial condition and cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Combined Company may incur losses for the foreseeable future and may never achieve profitability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Combined Company may never become profitable, even if it is able to complete clinical development for one or more product candidates and eventually commercialize such product candidates. The Combined Company will need to successfully complete significant research, development, testing and regulatory compliance activities that, together with projected general and administrative expenses, is expected to result in substantial increased operating losses for at least the next several&#160;years. Even if the Combined Company does achieve profitability, it may not be able to sustain or increase profitability on a quarterly or annual basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the Combined Company fails to attract and retain management and other key personnel, it may be unable to continue to successfully develop or commercialize its product candidates or otherwise implement its business plan.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Combined Company&#8217;s ability to compete in the highly competitive pharmaceuticals industry depends on its ability to attract and retain highly qualified managerial, scientific, medical, legal, sales and marketing and other personnel. The Combined Company will be highly dependent on its management and scientific personnel. The loss of the services of any of these individuals could impede, delay, or prevent the successful development of the Combined Company&#8217;s product pipeline, completion of its planned clinical trials, commercialization of its product candidates or in-licensing or acquisition of new assets and could impact negatively its ability to implement successfully its business plan. If the Combined Company loses the services of any of these individuals, it might not be able to find suitable replacements on a timely basis or at all, and its business could be harmed as a result. The Combined Company might not be able to attract or retain qualified management and other key personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Combined Company will need to raise additional financing in the future to fund its operations, which may not be available to it on favorable terms or at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Combined Company will require substantial additional funds to conduct the costly and time- consuming clinical efficacy trials necessary to pursue regulatory approval of each potential product candidate and to continue the development of JADE-001, JADE-002, JADE-003 and Jade&#8217;s future product candidates. The Combined Company&#8217;s future capital requirements will depend upon a number of factors, including: the number and timing of future product candidates in the pipeline; progress with and results from preclinical testing and clinical trials; the ability to manufacture sufficient drug supplies to complete preclinical and clinical trials; the costs involved in preparing, filing, acquiring, prosecuting, maintaining and enforcing patent and other intellectual property claims; and the time and costs involved in obtaining regulatory approvals and favorable reimbursement or formulary acceptance. Raising additional capital may be costly or difficult to obtain and could, for example, through the sale of common stock or securities convertible or exchangeable into common stock, significantly dilute the Combined Company&#8217;s stockholders&#8217; ownership interests or inhibit the Combined Company&#8217;s ability to achieve its business objectives. If the Combined Company raises additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely the rights of its common stockholders. In addition, any debt financing may subject the Combined Company to fixed payment obligations and covenants limiting or restricting its ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If the Combined Company raises additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, the Combined Company may have to relinquish certain valuable intellectual property or other rights to its product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to it. Even if the Combined Company were to obtain sufficient funding, there can be no assurance that it will be available on terms acceptable to the Combined Company or its stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Combined Company will incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Combined Company will incur significant legal, accounting and other expenses as a public company that Jade did not incur as a private company, including costs associated with public company reporting obligations under the Exchange Act. The Combined Company&#8217;s management team will consist of the executive officers of Jade prior to the Merger. These executive officers and other personnel will need to devote substantial time to gaining expertise related to public company reporting requirements and compliance with applicable laws and regulations to ensure that the Combined Company complies with all of these requirements. Any changes the </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Combined Company makes to comply with these obligations may not be sufficient to allow it to satisfy its obligations as a public company on a timely basis, or at all. These reporting requirements, rules&#160;and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for the Combined Company to attract and retain qualified persons to serve on the board of directors or on board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Upon completion of the Merger, failure by the Combined Company to comply with the initial listing standards of Nasdaq will prevent its stock from being listed on Nasdaq.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Upon completion of the Merger, Aerovate, under the new name &#8220;Jade Biosciences,&#160;Inc.&#8221; will be required to meet the initial listing requirements to maintain the listing and continued trading of its shares on Nasdaq. These initial listing requirements are more difficult to achieve than the continued listing requirements. Pursuant to the Merger Agreement, Aerovate agreed to use its commercially reasonable efforts to cause the shares of Aerovate common stock being issued in the Merger (including any common stock issuable upon conversion of the Aerovate Series&#160;A Preferred Stock and the exercise of pre-funded warrants) to be approved for listing on Nasdaq at or prior to the effective time of the Merger. Based on information currently available to Aerovate, Aerovate anticipates that its stock will be unable to meet the $4.00 minimum bid price initial listing requirement at the Closing unless it effects a reverse stock split. Aerovate&#8217;s board of directors intends to effect a reverse stock split of the shares of Aerovate common stock at a ratio of between&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. In addition, often a reverse stock split will not result in a trading price for the affected common stock that is proportional to the ratio of the split. Following the Merger, if the Combined Company is unable to satisfy Nasdaq listing requirements, Nasdaq may notify the Combined Company that its shares of common stock will not be listed on Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Upon a potential delisting from Nasdaq, if the common stock of the Combined Company is not then eligible for quotation on another market or exchange, trading of the shares could be conducted in the over- the-counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it is likely that there would be significantly less liquidity in the trading of the common stock of the Combined Company; decreases in institutional and other investor demand for the shares, coverage by securities analysts, market making activity and information available concerning trading prices and volume; and fewer broker dealers willing to execute trades in the common stock of the Combined Company. Also, it may be difficult for the Combined Company to raise additional capital if the Combined Company&#8217;s common stock is not listed on a major exchange. The occurrence of any of these events could result in a further decline in the market price of the common stock of the Combined Company and could have a material adverse effect on the Combined Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Once the Combined Company is no longer a smaller reporting company or otherwise no longer qualifies for applicable exemptions, the Combined Company will be subject to additional laws and regulations affecting public companies that will increase the Combined Company&#8217;s costs and the demands on management and could harm the Combined Company&#8217;s operating results and cash flows.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Combined Company will be subject to the reporting requirements of the Exchange Act, which requires, among other things, that the Combined Company file with the SEC, annual, quarterly and current reports with respect to the Combined Company&#8217;s business and financial condition as well as other disclosure and corporate governance requirements. However, as a &#8220;smaller reporting company,&#8221; as such term is defined in Rule&#160;12b-2 under the Exchange Act, in at least the near term, the Combined Company may take advantage of exemptions from disclosure requirements and reduced disclosure obligations regarding executive compensation in this proxy statement/prospectus and in the Combined Company&#8217;s periodic reports and proxy statements. In addition, if the Combined Company is a smaller reporting company with less than $100.0 million in annual revenue, it would not be required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act. Once the Combined Company is no longer a smaller reporting company or otherwise no longer qualifies for these exemptions, the Combined Company will be required to comply with these additional legal and regulatory requirements applicable to public companies and will incur significant legal, accounting and other expenses to do so. If the Combined Company is not able to comply with the requirements in a timely manner or at all, the Combined Company&#8217;s financial condition or the market price of the Combined Company&#8217;s common stock may be harmed. For example, if the Combined Company or its independent auditor identifies deficiencies in the Combined Company&#8217;s internal control over financial reporting that are deemed to be material weaknesses the Combined Company could face additional costs to remedy those deficiencies, the market price of the Combined Company&#8217;s stock could decline or the Combined Company could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the Combined Company fails to maintain proper and effective internal controls, its ability to produce accurate financial statements on a timely basis could be impaired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Provided the Combined Company continues to be listed on Nasdaq, the Combined Company will be subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules&#160;and regulations of Nasdaq. The Sarbanes-Oxley Act requires, among other things, that the Combined Company maintain effective disclosure controls and procedures and internal control over financial reporting. The Combined Company must perform system and process evaluation and testing of its internal control over financial reporting to allow management to report on the effectiveness of its internal controls over financial reporting in its Annual Report on Form&#160;10-K filing for that&#160;year, as required by Section&#160;404 of the Sarbanes- Oxley Act. As a private company, Jade has not been required to document and test its internal controls over financial reporting nor has its management been required to certify the effectiveness of its internal controls and its auditors have not been required to opine on the effectiveness of its internal control over financial reporting. Following the Merger, the Combined Company will be required to incur substantial professional fees and internal costs to expand its accounting and finance functions and expend significant management efforts. The Combined Company may experience difficulty in meeting these reporting requirements in a timely manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Combined Company may discover weaknesses in its system of internal financial and accounting controls and procedures that could result in a material misstatement of its financial statements. The Combined Company&#8217;s internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If the Combined Company is not able to comply with the requirements of Section&#160;404 of the Sarbanes- Oxley Act, or if it is unable to maintain proper and effective internal controls, the Combined Company may not be able to produce timely and accurate financial statements. If that were to happen, the market price of its common stock could decline and it could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">The unaudited pro forma condensed combined financial information for Aerovate and Jade included in this proxy statement/prospectus are preliminary, and the Combined Company&#8217;s actual financial position and operations after the Merger may differ materially from the unaudited pro forma financial information included in this proxy statement/prospectus.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The unaudited pro forma financial information for Aerovate and Jade included in this proxy statement/ prospectus are presented for illustrative purposes only and is not necessarily indicative of the Combined Company&#8217;s actual financial condition or results of operations of future periods, or the financial condition or results of operations that would have been realized had the entities been combined during the period presented. The Combined Company&#8217;s actual results and financial position after the Merger may differ materially and adversely from the unaudited pro forma financial information included in this proxy statement/ prospectus. The Exchange Ratio reflected in this proxy statement/prospectus is preliminary. The final Exchange Ratio could differ from the preliminary Exchange Ratio used to prepare the pro forma adjustments. For more information, please see the section titled &#8220;<i style="font-style:italic;">Unaudited Pro Forma Condensed Combined Financial Information</i>&#8221; beginning on page&#160;305 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate and Jade do not anticipate that the Combined Company will pay any cash dividends in the foreseeable future other than the Cash Dividend that Aerovate will declare and pay to the holders of record of outstanding shares of Aerovate common stock as of a record date prior to the effective time of the Merger, to be set by the Aerovate board of directors as close as reasonably practicable to (but not later than) the anticipated Closing Date.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Other than the Cash Dividend, the current expectation is that the Combined Company will retain its future earnings, if any, to fund the growth of the Combined Company&#8217;s business as opposed to paying dividends. As a result, capital appreciation, if any, of the common stock of the Combined Company will be your sole source of gain, if any, for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">An active trading market for the Combined Company&#8217;s common stock may not develop and its stockholders may not be able to resell their shares of common stock for a profit, if at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Prior to the Merger, there had been no public market for shares of Jade capital stock. An active trading market for the Combined Company&#8217;s shares of common stock may never develop or be sustained. If an active market for the Combined Company&#8217;s common stock does not develop or is not sustained, it may be difficult for the Combined Company&#8217;s stockholders to sell their shares at an attractive price or at all.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Future sales of shares by existing stockholders could cause the Combined Company&#8217;s stock price to decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If existing securityholders of Aerovate and Jade sell, or indicate an intention to sell, substantial amounts of the Combined Company&#8217;s common stock in the public market after legal restrictions on resale discussed in this proxy statement/prospectus lapse, the trading price of the common stock of the Combined Company could decline. Based on shares outstanding as of September 30, 2024, after giving effect to the estimated Exchange Ratio and the shares of Jade common stock to be issued in the Jade Pre-Closing Financing and shares expected to be issued upon completion of the Merger and prior to giving effect to the anticipated Aerovate reverse stock split, the Combined Company is expected to have outstanding a total of approximately 1,086,166,382 shares of common stock immediately following the completion of the Merger (or approximately 1,777,841,130 shares of common stock after giving effect to the conversion of the Aerovate Series&#160;A Preferred Stock and the exercise of the Jade pre-funded warrants to be issued in the Jade Pre-Closing Financing). Approximately &#160;&#160;&#160;&#160; million shares will be freely tradeable upon completion of the Merger and approximately &#160;&#160;&#160;&#160; million shares (or approximately &#160;&#160;&#160;&#160; million, if the Aerovate Series&#160;A Preferred Stock is converted and the Jade pre-funded warrants are exercised) will become available for sale in the public market beginning 180&#160;days after the Closing as a result of the expiration of lock-up agreements between Aerovate on the one hand and certain securityholders of Jade on the other hand (and without giving effect to any restrictions on resale under securities laws). In addition, shares of common stock that are subject to outstanding options of Jade will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements and Rules&#160;144 and 701 under the Securities Act. If these shares are sold, the trading price of the Combined Company&#8217;s common stock could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">After completion of the Merger, the Combined Company&#8217;s executive officers, directors and principal stockholders will have the ability to control or significantly influence all matters submitted to the Combined Company&#8217;s stockholders for approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Upon the completion of the Merger, and giving effect to the issuance of the shares of Jade common stock and the Jade pre-funded warrants prior to the Closing pursuant to the Jade Pre-Closing Financing, it is anticipated that the Combined Company&#8217;s executive officers, directors and principal stockholders will, in the aggregate, beneficially own approximately &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of the Combined Company&#8217;s outstanding shares of common stock (on a fully-diluted basis), subject to certain assumptions, including, but not limited to, Aerovate&#8217;s Net Cash as of Closing being $0. Aerovate management currently anticipates Aerovate&#8217;s Net Cash as of Closing will be approximately $0, after giving effect to the Cash Dividend, which is expected to be approximately $65.0 million, and the currently estimated ownership&#160;percentages reflect this projection. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to the Combined Company&#8217;s stockholders for approval, as well as the Combined Company&#8217;s management and affairs. For example, these stockholders, if they choose to act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of the Combined Company&#8217;s assets. This concentration of voting power could delay or prevent an acquisition of the Combined Company on terms that other stockholders may desire.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Conflicts of interest may arise between the Combined Company and Paragon or the Combined Company and Fairmount.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Paragon is a biotechnology company that performs research and development activities to discover and engineer novel antibody candidates for various therapeutic targets. Prior to the Merger and the Jade Pre- Closing Financing, Paragon beneficially owned 9.7% of Jade&#8217;s capital stock and following the Merger and the Jade Pre-Closing Financing is expected to beneficially own&#160;&#160;&#160;% of the Combined Company&#8217;s common stock (based on the number of shares of common stock outstanding as of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, assuming no exercise of outstanding options). In addition, Paragon is the licensor of Jade&#8217;s lead product candidate JADE-001 and has granted Jade an exclusive option to an exclusive license to JADE-002 and JADE-003. Specifically, Jade and Paragon have entered into the JADE-001 License Agreement and Jade, Paragon and Parade, an entity formed by Paragon to hold equity in Jade and share profits with certain employees of Paragon, have entered into the Paragon Option Agreement, pursuant to which Jade has the option to acquire exclusive rights to certain antibody candidates discovered and developed by Paragon with respect to its JADE-002 and JADE-003 programs. Although Jade will have the right to control the prosecution, defense, maintenance and enforcement of the patents underlying the licenses it may obtain from Paragon after entry into the applicable license agreement and the trigger for transfer of prosecution control is met, Jade relies on Paragon to obtain, maintain and enforce such patents prior to Jade&#8217;s exercise of the option and entry into a license agreement. Jade also reimburses Paragon for certain development costs related to Jade&#8217;s selected targets and will grant Parade warrants to purchase Jade&#8217;s common stock as part of the Paragon Option Agreement. Fairmount, an investment firm that has launched and funded several biotechnology companies, including Jade, beneficially owned 77.5% of Jade&#8217;s capital stock prior to the Jade Pre-Closing Financing and the Merger, and following the Jade Pre-Closing Financing and the Merger is expected to beneficially own &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of the Combined Company&#8217;s common stock assuming no conversion of the Aerovate Series&#160;A Preferred Stock, which is non-voting, into common stock, and &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% assuming conversion of the Aerovate Series&#160;A Preferred Stock into common stock (in each case, based on the number of shares of common stock outstanding as of &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024, and assuming no exercise of outstanding options). In addition, Fairmount owns approximately 95% of Paragon.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Two of the Combined Company&#8217;s non-employee directors, Tomas Kiselak and Chris Cain, are affiliated with Fairmount. The Combined Company&#8217;s third non-employee director, Lawrence Klein, is an executive officer at Oruka Therapeutics,&#160;Inc., another entity affiliated with Fairmount and Paragon. The remaining members of the Combined Company&#8217;s board of directors are not affiliated with Fairmount or Paragon. The Combined Company&#8217;s relationship with Paragon, Parade, Fairmount and Jade&#8217;s non- employee directors may create, or may create the appearance of, conflicts of interest when the Combined Company is faced with decisions that could have different implications for Paragon or Parade than the decisions have for the Combined Company. For example, such conflicts may arise in connection with the selection of additional targets, the exercise of the remaining options under the Paragon Option Agreement, the negotiation of the terms of any future license agreements, the allocation of resources and expenses, the enforcement or defense of intellectual property rights, the pursuit of strategic partnerships or transactions, or the resolution of any disputes that may arise between the Combined Company and Paragon or Parade. Furthermore, because Paragon and Fairmount have interests in other biotechnology companies that may compete with the Combined Company or pursue similar or complementary product candidates or technologies, they may have an incentive to favor or support such other companies over the Combined Company. These potential conflicts of interest may make it more difficult for the Combined Company to favorably advance the Combined Company&#8217;s business interests and may adversely affect the Combined Company&#8217;s competitive position, business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about the Combined Company, its business or its market, its stock price and trading volume could decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The trading market for the Combined Company&#8217;s common stock will be influenced by the research and reports that equity research analysts publish about it and its business. Equity research analysts may elect to not provide research coverage of the Combined Company&#8217;s common stock after the completion of the Merger, and such lack of research coverage may adversely affect the market price of its common stock. In the event it does have equity research analyst coverage, the Combined Company will not have any control over the analysts or the content and opinions included in their reports. The price of the Combined Company&#8217;s common stock could decline if one or more equity research analysts downgrade its stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of the Combined Company or fails to publish reports on it regularly, demand for its common stock could decrease, which in turn could cause its stock price or trading volume to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Combined Company will have broad discretion in the use of the cash and cash equivalents of the Combined Company and the proceeds from the Jade Pre-Closing Financing and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Combined Company will have broad discretion over the use of the cash and cash equivalents of the Combined Company and the proceeds from the Jade Pre-Closing Financing. You may not agree with the Combined Company&#8217;s decisions, and its use of the proceeds may not yield any return on your investment. The Combined Company&#8217;s failure to apply these resources effectively could compromise its ability to pursue its growth strategy and the Combined Company might not be able to yield a significant return, if any, on its investment of these net proceeds. You will not have the opportunity to influence its decisions on how to use the Combined Company&#8217;s cash resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Combined Company&#8217;s ability to use NOL carryforwards and other tax attributes may be limited, including as a result of the Merger.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As discussed above, Aerovate has incurred losses during its history, and the Combined Company does not expect to become profitable in the near future and may never achieve profitability. As of December&#160;31, 2023, Aerovate had federal and state NOL carryforwards of approximately $64.8 million and $44.1 million, respectively. Aerovate had approximately $6.0 million and $1.3 million of federal and state research and development credits, respectively, that may be used to offset future taxable income. Under current law, Aerovate&#8217;s U.S. federal NOLs of $64.8 million incurred in tax&#160;years beginning after December&#160;31, 2017 may be carried forward indefinitely, but the deductibility of such net operating loss carryforwards is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to federal law. In addition, under Sections 382 and 383 of the Code, U.S. federal net operating loss carryforwards and other tax attributes may become subject to an annual limitation in the event of certain cumulative changes in ownership. An &#8220;ownership change&#8221; pursuant to Section&#160;382 of the Code generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a company&#8217;s stock increase their ownership by more than 50&#160;percentage points over their lowest ownership&#160;percentage within a rolling three-year period. The Combined Company&#8217;s ability to utilize its net operating loss carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including, as discussed above, in connection with the Merger or other transactions. Similar rules&#160;may apply under state tax laws. If the Combined Company earns taxable income, such limitations could result in increased future income tax liability to the Combined Company, and the Combined Company&#8217;s future cash flows could be adversely affected.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Unfavorable global economic conditions could adversely affect the Combined Company&#8217;s business, financial condition, results of operations or cash flows.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Combined Company&#8217;s results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn could result in a variety of risks to the Combined Company&#8217;s business, including, weakened demand for the Combined Company&#8217;s product candidates and the Combined Company&#8217;s ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain the Combined Company&#8217;s suppliers, possibly resulting in supply disruption, or cause the Combined Company&#8217;s customers to delay making payments for its services. Any of the foregoing could harm the Combined Company&#8217;s business and the Combined Company cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact its business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">The class structure of the Combined Company&#8217;s capital stock may limit your ability to influence corporate matters and may limit your visibility with respect to certain transactions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The class structure of the Combined Company&#8217;s capital stock may limit your ability to influence corporate matters. Holders of the Combined Company&#8217;s common stock are entitled to one vote per share, while holders of the Aerovate Series&#160;A Preferred Stock are not entitled to any votes. Nonetheless, each share of the Aerovate Series&#160;A Preferred Stock may be converted at any time into 1,000 shares of the Combined Company&#8217;s common stock at the option of its holder by providing written notice to the Combined Company, subject to the limitations provided for in the Combined Company&#8217;s amended and restated certificate of incorporation and to requisite stockholder approval. Consequently, if holders of the Aerovate Series&#160;A Preferred Stock exercise their option to make this conversion, this will have the effect of increasing the relative voting power of those prior holders of the Aerovate Series&#160;A Preferred Stock, and correspondingly decreasing the voting power of the holders of the Combined Company&#8217;s common stock, which may limit your ability to influence corporate matters. Additionally, stockholders who hold, in the aggregate, more than 10% of the Combined Company&#8217;s common stock and Aerovate Series&#160;A Preferred Stock, but 10% or less of the Combined Company&#8217;s common stock, and are not otherwise an insider, may not be required to report changes in their ownership due to transactions in the Aerovate Series&#160;A Preferred Stock pursuant to Section&#160;16(a)&#160;of the Exchange Act, and may not be subject to the short-swing profit provisions of Section&#160;16(b)&#160;of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Combined Company will be an &#8220;emerging growth company&#8221; and it cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make the Combined Company&#8217;s common stock less attractive to investors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Combined Company will be an &#8220;emerging growth company&#8221; as defined in the JOBS Act. As an emerging growth company, the Combined Company will only be required to provide two&#160;years of audited financial statements and management discussion and analysis of financial condition and results of operations disclosure. In addition, the Combined Company will not be required to obtain auditor attestation of reporting on internal control over financial reporting, will have reduced disclosure obligations regarding executive compensation and will not be required to hold non-binding advisory votes on executive compensation. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. These provisions allow an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. The Combined Company cannot predict whether investors will find the Combined Company&#8217;s common stock to be less attractive as a result of its reliance on these exemptions. If some investors find the Combined Company&#8217;s common stock to be less attractive as a result, there may be a less active trading market for the Combined Company&#8217;s common stock and the price of the common stock may be more volatile than the current trading market and price of Aerovate common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Combined Company will remain an emerging growth company until the earliest of: (i)&#160;the end of the fiscal&#160;year in which the Combined Company has total annual gross revenue of $1.235 billion; <span style="color:#231f20;">(ii)&#160;December&#160;31, 2026; (iii)&#160;the date on which the Combined Company issues more than $1.0 billion in non- convertible debt during the preceding three-year period; or (iv)&#160;the end of the fiscal&#160;year in which the market value of the Combined Company common stock held by non-affiliates exceeds $700 million as of the last business day of the Combined Company&#8217;s most recently completed second fiscal quarter.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, there is no guarantee that the exemptions available under the JOBS Act will result in significant savings. To the extent that the Combined Company chooses not to use exemptions from various reporting requirements under the JOBS Act, it will incur additional compliance costs, which may impact its financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_972f6490_0b28_443f_b9d7_064d7ce39595"></a><a id="CAUTIONARYNOTEREGARDINGFORWARDLOOKINGSTA"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CAUTIONARY NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This proxy statement/prospectus and the documents incorporated by reference into this proxy statement/ prospectus contain forward-looking statements relating to Aerovate, Jade, the Merger and the other proposed transactions contemplated thereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These forward-looking statements include express or implied statements relating to Aerovate&#8217;s and Jade&#8217;s management team&#8217;s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward- looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Aerovate, Jade or the proposed transaction will be those that have been anticipated. These forward- looking statements involve a number of risks, uncertainties (some of which are beyond Aerovate&#8217;s or Jade&#8217;s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the conditions to the Closing are not satisfied, including the failure to obtain stockholder approval for the Merger; the risk that the Jade Pre-Closing Financing is not completed in a timely manner or at all; uncertainties as to the timing of the consummation of the transaction and the ability of each of Aerovate and Jade to consummate the transaction, including the Jade Pre-Closing Financing; risks related to Aerovate&#8217;s continued listing on the Nasdaq Stock Market until Closing; risks related to Aerovate&#8217;s and Jade&#8217;s ability to correctly estimate their respective operating expenses and expenses associated with the transaction, as well as uncertainties regarding the impact any delay in the Closing would have on the anticipated cash resources of the Combined Company upon Closing and other events and unanticipated spending and costs that could reduce the Combined Company&#8217;s cash resources; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Merger Agreement; statements regarding the Cash Dividend that Aerovate may pay the Aerovate stockholders in connection with the completion of the Merger; the effect of the announcement or pendency of the Merger on Aerovate&#8217;s or Jade&#8217;s business relationships, operating results and business generally; costs related to the Merger; the outcome of any legal proceedings that may be instituted against Aerovate, Jade or any of their respective directors or officers related to the Merger Agreement or the transactions contemplated thereby; the ability of Jade to protect its intellectual property rights; competitive responses to the transaction; unexpected costs, charges or expenses resulting from the transaction; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction; adverse legislative, regulatory, political and economic developments; the risk of setbacks in Jade&#8217;s plans to develop and commercialize product candidates for the treatment of autoimmune diseases; Jade&#8217;s ability to maintain the JADE-001 License Agreement and the Paragon Option Agreement and enter into new license and collaboration agreements; delays or challenges in Jade&#8217;s ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials; the risk that the efficacy, safety and extended half-life of Jade&#8217;s product candidates will be disappointing compared with expectations; Jade&#8217;s plans relating to the further development of its programs, including additional indications Jade may pursue; the risk that the size of the market opportunity for Jade&#8217;s programs, including Jade&#8217;s estimates of the number of patients who suffer from the diseases it is targeting may be lower than expected; Jade&#8217;s reliance on third parties to conduct additional preclinical studies and clinical trials of its programs and for the manufacture of Jade&#8217;s programs for preclinical studies and clinical trials; the risk of negative developments in the cost, timing and results of Jade&#8217;s preclinical and clinical development activities and planned clinical trials; Jade&#8217;s plans regarding, and its ability to maintain, obtain, and negotiate favorable terms of, any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize its programs; the timing of and Jade&#8217;s ability to obtain and maintain regulatory approvals for its product candidates, as well as future product candidates. Should one or more of these risks or uncertainties materialize, or should any of Aerovate&#8217;s or Jade&#8217;s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. There may be additional risks that Aerovate considers immaterial or which are unknown. It is not possible to predict or identify all such risks. Aerovate&#8217;s and Jade&#8217;s forward-looking statements only speak as of the date they are made, and Aerovate and Jade do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For a discussion of the factors that may cause Aerovate, Jade or the Combined Company&#8217;s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied in such forward-looking statements, or for a discussion of risk associated with the ability of Aerovate and Jade to complete the Merger and the effect of the Merger on the business of Aerovate, Jade and the Combined Company, please see the section titled &#8220;<i style="font-style:italic;">Risk Factors</i>&#8221; beginning on page&#160;24 of this proxy statement/prospectus. Additional factors that could cause actual results to differ materially from those expressed in the forward-looking statements are discussed in reports filed with the SEC by Aerovate and incorporated by reference herein. Please see the section titled &#8220;<i style="font-style:italic;">Where You Can Find More Information</i>&#8221; beginning on page&#160;336 of this proxy statement/prospectus. There can be no assurance that the Merger will be completed, or if it is completed, that it will be completed within the anticipated time period or that the expected benefits of the Merger will be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If any of these risks or uncertainties materialize or any of these assumptions prove incorrect, the results of Aerovate, Jade or the Combined Company could differ materially from the forward-looking statements. All forward-looking statements in this proxy statement/prospectus are current only as of the date on which the statements were made. Aerovate and Jade do not undertake any obligation to (and expressly disclaim any such obligation to) publicly update any forward-looking statement to reflect events or circumstances after the date on which any statement is made or to reflect the occurrence of unanticipated events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_5b235a79_6d19_439a_9345_26216aa1eecc"></a><a id="THESPECIALMEETINGOFAEROVATESTOCKHOLDERS_"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE SPECIAL MEETING OF AEROVATE STOCKHOLDERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Date, Time and Place</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Aerovate Special Meeting will be held on &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, commencing at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Eastern Time, unless postponed or adjourned to a later date. The Aerovate Special Meeting will be held at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. You will be able to attend and participate in the Aerovate Special Meeting in person where you will be able to ask questions and vote. Aerovate is sending this proxy statement/prospectus to its stockholders in connection with the solicitation of proxies by Aerovate&#8217;s board of directors for use at the Aerovate Special Meeting and any adjournments or postponements of the Aerovate Special Meeting. This proxy statement/prospectus is first being furnished to Aerovate stockholders on or about &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Purposes of the Aerovate Special Meeting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The purposes of the Aerovate Special Meeting are:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">1.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">To approve (i)&#160;the issuance of shares of common stock of Aerovate (including the shares of Aerovate common stock issuable upon conversion of the Aerovate Series&#160;A Preferred Stock), which will represent more than 20% of the shares of Aerovate common stock outstanding immediately prior to the Merger, to stockholders of Jade pursuant to the terms of the Agreement and Plan of Merger among Aerovate, Jade, Merger Sub I and Merger Sub II, dated as of October&#160;30, 2024, a copy of which is attached as </span><i style="color:#231f20;font-style:italic;">Annex A </i><span style="color:#231f20;">to the accompanying proxy statement/prospectus, and (ii)&#160;the change of control resulting from the Merger, pursuant to Nasdaq Listing Rules&#160;5635(a)&#160;and 5635(b), respectively (the &#8220;Nasdaq Stock Issuance Proposal&#8221; or &#8220;Proposal No.&#160;1&#8221;);</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">2.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">To approve an amendment to the amended and restated certificate of incorporation of Aerovate to effect a reverse stock split of Aerovate&#8217;s issued and outstanding common stock at a ratio determined by the Aerovate board of directors and agreed to by Jade, of one new share of Aerovate common stock for every shares (or any number in between) of outstanding Aerovate common stock in the form attached as </span><i style="color:#231f20;font-style:italic;">Annex B</i><span style="color:#231f20;">; to the accompanying proxy statement/prospectus (the &#8220;Reverse Stock Split Proposal&#8221; or &#8220;Proposal No.&#160;2&#8221;);</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">3.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Approve an amendment to the amended and restated certificate of incorporation of Aerovate to increase the number of shares of Aerovate common stock that Aerovate is authorized to issue from 150,000,000 to , in the form attached as </span><i style="color:#231f20;font-style:italic;">Annex C </i><span style="color:#231f20;">(the &#8220;Authorized Share Increase Proposal&#8221; or &#8220;Proposal No.&#160;3&#8221;);</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">4.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Approve the redomestication of Aerovate from the State of Delaware to the State of Nevada by conversion (the &#8220;Redomestication Proposal&#8221; or &#8220;Proposal No.&#160;4&#8221;);</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">5.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Approve the Jade Biosciences,&#160;Inc. 2025 Stock Incentive Plan (the &#8220;Stock Plan Proposal&#8221; or &#8220;Proposal No.&#160;5&#8221;);</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">6.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Approve the Jade Biosciences,&#160;Inc. 2025 Employee Stock Purchase Plan (the &#8220;ESPP Proposal&#8221; or &#8220;Proposal No.&#160;6&#8221;);</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">7.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">To approve an adjournment of the Aerovate Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 1, 2 and 3 (the &#8220;Adjournment Proposal&#8221; or &#8220;Proposal No.&#160;7&#8221;); and</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">8.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">To transact such other business as may properly come before the stockholders at the Aerovate Special Meeting or any adjournment or postponement thereof.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each of Proposal Nos. 1, 2 and 3 is a condition to completion of the Merger. The issuance of Aerovate common stock in connection with the Merger, the amendment to the amended and restated certificate of incorporation of Aerovate to effect a reverse stock split of Aerovate&#8217;s issued and outstanding common stock and the amendment to the amended and restated certificate of incorporation to increase the number of shares of Aerovate common stock that Aerovate is authorized to issue will not take place unless approved by the requisite Aerovate stockholders and the Merger is consummated. Therefore, the Merger cannot be consummated without the approval of Proposal Nos. 1, 2 and 3.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recommendation of Aerovate&#8217;s Board of Directors</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aerovate&#8217;s board of directors has determined and believes that the issuance of shares of Aerovate&#8217;s common stock, including shares of common stock issuable upon conversion of Aerovate Series&#160;A Preferred Stock, pursuant to the Merger Agreement is fair to, in the best interests of, and advisable to, Aerovate and its stockholders and has approved such issuance. Aerovate&#8217;s board of directors unanimously recommends that Aerovate stockholders vote &#8220;FOR&#8221; Proposal No.&#160;1 to approve the issuance of shares of Aerovate common stock pursuant to the Merger Agreement and the change of control resulting from the Merger.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aerovate&#8217;s board of directors has determined and believes that it is fair to, in the best interests of, and advisable to, Aerovate and its stockholders to approve the amendment to the amended and restated certificate of incorporation of Aerovate to effect the reverse stock split, as described in this proxy statement/prospectus. Aerovate&#8217;s board of directors unanimously recommends that Aerovate stockholders vote &#8220;FOR&#8221; Proposal No.&#160;2 to approve the reverse stock split.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aerovate&#8217;s board of directors has determined and believes that it is fair to, in the best interests of, and advisable to, Aerovate and its stockholders to approve the amendment to the amended and restated certificate of incorporation of Aerovate to increase the number of shares of Aerovate common stock that Aerovate is authorized to issue from 150,000,000 to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, as described in this proxy statement/prospectus. Aerovate&#8217;s board of directors unanimously recommends that Aerovate stockholders vote &#8220;FOR&#8221; Proposal No.&#160;3 to approve the increase of authorized shares of Aerovate common stock.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aerovate&#8217;s board of directors has determined and believes that it is fair to, in the best interests of, and advisable to, Aerovate and its stockholders to approve the redomestication of Aerovate from the State of Delaware to the State of Nevada by conversion (the &#8220;Nevada Redomestication&#8221;), as described in this proxy statement/ prospectus. Aerovate&#8217;s board of directors unanimously recommends that Aerovate stockholders vote &#8220;FOR&#8221; Proposal No.&#160;4 to approve the Nevada Redomestication.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aerovate&#8217;s board of directors has determined and believes that it is fair to, in the best interests of, and advisable to, Aerovate and its stockholders to approve the Jade Biosciences,&#160;Inc. 2025 Stock Incentive Plan, as described in this proxy statement/prospectus. Aerovate&#8217;s board of directors unanimously recommends that Aerovate stockholders vote &#8220;FOR&#8221; Proposal No.&#160;5 to approve the Jade Biosciences,&#160;Inc. 2025 Stock Incentive Plan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aerovate&#8217;s board of directors has determined and believes that it is fair to, in the best interests of, and advisable to, Aerovate and its stockholders to approve the Jade Biosciences,&#160;Inc. 2025 Employee Stock Purchase Plan, as described in this proxy statement/prospectus. Aerovate&#8217;s board of directors unanimously recommends that Aerovate stockholders vote &#8220;FOR&#8221; Proposal No.&#160;6 to approve the Jade Biosciences,&#160;Inc. 2025 Employee Stock Purchase Plan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aerovate&#8217;s board of directors has determined and believes that adjourning the Aerovate Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 1, 2 and 3 is fair to, in the best interests of, and advisable to, Aerovate and its stockholders and has approved and adopted the proposal. Aerovate&#8217;s board of directors unanimously recommends that Aerovate stockholders vote &#8220;FOR&#8221; Proposal No.&#160;7 to adjourn the Aerovate Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 1, 2 and 3.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Record Date and Voting Power</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Only holders of record of Aerovate common stock at the close of business on the record date &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, are entitled to notice of, and to vote at, the Aerovate Special Meeting. At the close of business on the record date, there were &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; holders of record of Aerovate common stock and there were shares of Aerovate common stock issued and outstanding. Each share of Aerovate common stock entitles the holder thereof to one vote on each matter submitted for stockholder approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Voting and Revocation of Proxies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This proxy statement/prospectus is solicited on behalf of Aerovate&#8217;s board of directors for use at the Aerovate Special Meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If, as of the record date referred to above, your shares were registered directly in your name with the transfer agent for Aerovate common stock, Computershare Trust Company, N.A., then you are a stockholder of record. Whether or not you plan to attend the </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Aerovate Special Meeting in person, Aerovate urges you to fill out and return the proxy card or vote by proxy over the telephone or on the internet as instructed below to ensure your vote is counted, the form of which is attached hereto as <i style="font-style:italic;">Annex E</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The procedures for voting are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If you are a stockholder of record, you may vote at the Aerovate Special Meeting. Alternatively, you may vote by proxy by using the accompanying proxy card, over the internet or by telephone. Whether or not you plan to attend the Aerovate Special Meeting, Aerovate encourages you to vote by proxy to ensure your vote is counted. Even if you have submitted a proxy before the Aerovate Special Meeting, you may still attend the Aerovate Special Meeting and vote. In such case, your previously submitted proxy will be disregarded.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To vote at the Aerovate Special Meeting, attend the Aerovate Special Meeting and vote in person.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To vote using the proxy card, simply complete, sign and date the accompanying proxy card and return it promptly in the envelope provided. If you return your signed proxy card before the Aerovate Special Meeting, Aerovate will vote your shares in accordance with the proxy card.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To vote by proxy over the internet, follow the instructions provided on the proxy card.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To vote by telephone, you may vote by proxy by calling the toll free number found on the proxy card.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If you are a beneficial owner of shares registered in the name of your broker, bank or other agent, you should have received voting instructions with these proxy materials from that organization rather than from Aerovate. Simply follow the voting instructions provided to ensure that your vote is counted. You may vote by telephone or over the Internet as instructed by your broker, bank or other agent. To vote in person at the Aerovate Special Meeting, you must contact your broker, bank or other agent and obtain a valid legal proxy in order to attend, participate in and vote at the Aerovate Special Meeting. Follow the voting instructions from your broker, bank or other agent, or contact your broker, bank or other agent for instructions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate provides internet proxy voting to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers and telephone companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If you hold shares beneficially in street name and you do not instruct your broker, bank or other agent how to vote your shares, your broker, bank or other agent will only be able to vote your shares with respect to proposals considered to be &#8220;routine.&#8221; Your broker, bank or other agent is not entitled to vote your shares with respect to &#8220;non-routine&#8221; proposals, resulting in a &#8220;broker non-vote&#8221; with respect to such proposals. Accordingly, if you hold your shares beneficially in street name, please be sure to instruct your broker, bank or other agent how to vote to ensure that your vote is counted on each of the proposals, following the procedures provided by your broker, bank or other agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All properly executed proxies that are not revoked will be voted at the Aerovate Special Meeting and at any adjournments or postponements of the Aerovate Special Meeting in accordance with the instructions contained in the proxy. <b style="font-weight:bold;">If a holder of Aerovate common stock executes and returns a proxy and does not specify otherwise, the shares represented by that proxy will be voted &#8220;FOR&#8221; all of the proposals in accordance with the recommendation of Aerovate&#8217;s board of directors.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If you are a stockholder of record of Aerovate and you have not executed a support agreement, you may change your vote at any time before your proxy is voted at the Aerovate Special Meeting in any one of the following ways:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">You may submit another properly completed proxy with a later date by mail or via the internet.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">You can provide your proxy instructions via telephone at a later date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">You may send an instrument in writing revoking the proxy or another duly executed proxy bearing a later date to Aerovate&#8217;s corporate secretary. Any written notice of revocation or subsequent proxy card must be received by Aerovate&#8217;s corporate secretary prior to the taking of the vote at the Aerovate Special Meeting. Such written notice of revocation or subsequent proxy card should be sent to Aerovate&#8217;s principal executive offices at Aerovate Therapeutics,&#160;Inc., 930 Winter Street, Suite&#160;M-500, Waltham, Massachusetts 02451, Attention: Corporate Secretary.</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">You may attend the Aerovate Special Meeting and vote in person, although attendance at the Aerovate Special Meeting will not, by itself, revoke and/or change your proxy.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If your shares are held by your broker, bank or other agent, you should follow the instructions provided by them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Required Vote</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The presence at the Aerovate Special Meeting of the holders of a majority of the shares of Aerovate common stock outstanding and entitled to vote at the Aerovate Special Meeting is necessary to constitute a quorum at the meeting. Abstentions and broker non-votes will be counted towards a quorum. The affirmative vote of a majority of votes cast at the Aerovate Special Meeting, assuming a quorum is present, is required for approval of Proposal Nos. 1, 5, 6, and 7. The affirmative vote of the holders of a majority of the outstanding shares of Aerovate capital stock entitled to vote thereon is required for approval of Proposal Nos. 2, 3 and 4. Each of Proposal Nos. 1, 2 and 3 is a condition to the completion of the Merger. Therefore, the Merger cannot be consummated without the approval of Proposal Nos. 1, 2 and 3. The issuance of Aerovate common stock in connection with the Merger and the change of control resulting from the Merger, the amendment to the amended and restated certificate of incorporation of Aerovate to effect a reverse stock split of Aerovate&#8217;s issued and outstanding common stock and the amendment to the amended and restated certificate of incorporation of Aerovate to increase the number of shares of Aerovate common stock that Aerovate is authorized to issue will not take place unless approved by the requisite Aerovate stockholders and the Merger is consummated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Votes will be counted by the inspector of election appointed for the meeting, who will separately count &#8220;FOR&#8221; and &#8220;AGAINST&#8221; votes, abstentions and broker non-votes. Abstentions and broker non-votes, if any, will not be treated as shares present for the purpose of determining the presence of a quorum for the transaction of business at the special meeting. Abstentions and broker non-votes, if any, will have no effect on Proposal Nos. 1, 5, 6 and 7 and will have the effect of a vote &#8220;AGAINST&#8221; Proposal Nos. 2, 3 and 4.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of October&#160;30, 2024, the Aerovate stockholders that are party to a support agreement, including the directors and certain executive officers of Aerovate, owned an aggregate number of shares of Aerovate common stock representing approximately 38.1% of the outstanding shares of Aerovate common stock. Each stockholder that entered into a support agreement, including the directors and certain executive officers of Aerovate, has agreed to vote all shares of Aerovate common stock owned by him or her as of the record date in favor of Proposal Nos. 1&#160;&#8211; 7 and against any competing &#8220;Acquisition Proposal&#8221; (as defined in the Merger Agreement).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Solicitation of Proxies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to solicitation by mail, the directors, officers, employees and agents of Aerovate may solicit proxies from Aerovate stockholders by personal interview, telephone, email, fax or otherwise. Aerovate and Jade will share equally the costs of printing and filing this proxy statement/prospectus and proxy card. Arrangements will also be made with brokerage firms and other custodians, nominees and fiduciaries who are record holders of Aerovate common stock for the forwarding of solicitation materials to the beneficial owners of Aerovate common stock. Aerovate will reimburse these brokers, custodians, nominees and fiduciaries for the reasonable out of pocket expenses they incur in connection with the forwarding of solicitation materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of the date of this proxy statement/prospectus, Aerovate&#8217;s board of directors does not know of any business to be presented at the Aerovate Special Meeting other than as set forth in the notice accompanying this proxy statement/prospectus. If any other matters should properly come before the Aerovate Special Meeting, it is intended that the shares represented by proxies will be voted with respect to such matters in accordance with the judgment of the persons voting the proxies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_b36a9538_88e9_438a_aeaf_3d1e73a07ba8"></a><a id="THEMERGER_864508"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE MERGER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">This section and the section titled &#8220;The Merger Agreement&#8221; beginning on page&#160;</i><span style="font-style:italic;">137</span><i style="font-style:italic;"> of this proxy statement/ prospectus describe the material aspects of the Merger and the Merger Agreement. While Aerovate and Jade believe that this description covers the material terms of the Merger and the Merger Agreement, it may not contain all of the information that is important to you. You should read carefully this entire proxy statement/ prospectus for a more complete understanding of the Merger and the Merger Agreement and the other documents to which you are referred in this proxy statement/prospectus. Please see the section titled &#8220;Where You Can Find More Information&#8221; beginning on page&#160;</i><span style="font-style:italic;">336</span><i style="font-style:italic;"> of this proxy statement/prospectus.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Background of the Transaction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following chronology summarizes the key meetings and events that led to the signing of the Merger Agreement. The following chronology does not purport to catalogue every conversation among the Aerovate board of directors or committees thereof or the representatives of Aerovate and other parties.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to June 2024, Aerovate was a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate&#8217;s initial focus was on advancing AV-101, its proprietary dry powder inhaled formulation of the drug imatinib for the treatment of patients with PAH. Aerovate&#8217;s lead clinical trial was its Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (&#8220;IMPAHCT&#8221;) trial, which was a randomized, double-blind, placebo-controlled, multi-national Phase 2b / Phase 3 trial of AV-101 in adults with pulmonary arterial hypertension. During this period, and in furtherance of this strategy, the Aerovate board of directors and Aerovate&#8217;s management would, from time to time, review and discuss Aerovate&#8217;s business, financial condition, operations and strategic priorities and consider various strategic business initiatives intended to strengthen Aerovate&#8217;s business and enhance stockholder value. In particular, these discussions included the exploration of strategic relationships, collaborations and partnering opportunities with respect to the advancement and development of&#160;AV-101. Aerovate&#8217;s management provided periodic updates regarding these discussions, including the discussions described below, to the Aerovate board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 17, 2024, following a decision by the Aerovate board of directors, Aerovate announced that the Phase 2b portion of IMPAHCT did not meet its primary endpoint for improvement in PVR compared to placebo for any of the studied doses or show meaningful improvements in the secondary endpoint of change in six minute walk distance. Aerovate also announced that, in light of the Phase 2b data and in agreement with the independent study advisor committee, it was instituting a voluntary halt to enrollment and shutting down the Phase 3 and long-term extension trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 21, 2024, the Aerovate board of directors held a meeting at which members of Aerovate&#8217;s management and representatives of Goodwin Procter LLP (&#8220;Goodwin&#8221;), Aerovate&#8217;s outside legal counsel, were present. The Aerovate board of directors and management discussed, among other things, the factors contributing to the voluntary halting of enrollment and the closing down of the Phase 3 and long-term extension trials and the strategic, financial and operational challenges associated with these decisions. The Aerovate board of directors and management also discussed potential research alternatives to the Phase 3 trial and the amount of time it would take before Aerovate could generate sufficient data with AV-101 to raise additional capital, Aerovate&#8217;s cash runway and potential financing needs and the likelihood of success in a clinical trial with AV-101 given the results of the Phase 2b trial. Following discussion, the Aerovate board of directors directed Aerovate&#8217;s management to review Aerovate&#8217;s business, including the status of its programs, resources and capabilities and prepare a recommendation for the Aerovate board of directors to consider. The Aerovate board of directors determined that, in connection with these efforts, Aerovate&#8217;s management should commence a process to evaluate business development, strategic or other transactions regarding&#160;AV-101, related assets and intellectual property (including potential partnerships, licensing transactions and asset sales) and authorized Aerovate&#8217;s management to identify and engage in discussions with various third parties. The Aerovate board of directors and management also determined that a significant reduction in force would be required as a result of the Phase 2b clinical data and the decision to shut down the Phase 3 and long-term extension trials. Following discussion, the Aerovate board of directors authorized Aerovate&#8217;s management to proceed with implementing various actions to preserve cash available, including by implementing a reduction in force intended to reduce Aerovate&#8217;s operational cash burn in an effort to maximize its strategic optionality and enhance stockholder value, on such timeline as Aerovate&#8217;s management deemed to be in Aerovate&#8217;s best interest. Following further discussion, the Aerovate board of directors determined that Aerovate should publicly announce the results of its business review and that Aerovate was reviewing strategic alternatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Also at the Aerovate board of directors meeting held on June 21, 2024, the Aerovate board of directors established a Strategic Transaction Committee of the Aerovate board of directors (the &#8220;Transaction Committee&#8221;), for convenience (and not because of any actual or perceived conflicts of interests), in order to assist the Aerovate board of directors, as needed, in exploring strategic </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">alternatives, including without limitation, a sale or other divestiture, including a&#160;spin-out&#160;of all, substantially all or a material portion of Aerovate&#8217;s business or assets, a &#8220;reverse merger,&#8221; &#8220;merger of equals&#8221; or similar transaction, or a sale of control of Aerovate. The initial members of the Transaction Committee were the following independent directors, who were selected because they have significant experience with merger and acquisition transactions and/or clinical development: Allison Dorval, Joshua Resnick, M.D., David Grayzel, M.D. and Habib Dable. The Aerovate board of directors delegated authority to the Transaction Committee to, among other things: direct the process for the review and evaluation of any potential strategic transaction; provide guidance regarding a proposed strategic transaction to (a) consider and evaluate all proposals that might be received by Aerovate in connection with a possible sale or other business transaction or series of transactions involving all or substantially all of Aerovate&#8217;s equity or assets on a consolidated basis, through any form of transaction, including, without limitation, merger, stock purchase, asset purchase, recapitalization, reorganization, going-private transaction, consolidation, amalgamation, spin-out of assets, licensing, collaboration of all or certain assets, dividends or distribution of assets or rights to assets or future payments, debt or equity financing, liquidation, dissolution or other transaction, (b) participate in and direct the negotiation of the material terms and conditions of any such transaction, (c) consider any alternatives to any such transaction, including without limitation, Aerovate continuing to operate as an independent company, and (d) recommend to the Aerovate board of directors the advisability of entering into a definitive agreement (and any ancillary agreements relating thereto) with respect to any such transaction, or the advisability of pursuing any other alternative, in each case subject to applicable law. In connection with the exploration of strategic alternatives, Aerovate&#8217;s management, at the direction of the Transaction Committee, initiated a process to select a financial advisor to assist management in its review of strategic alternatives, including identifying counterparties for a possible strategic transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 24 and 26, 2024, the Transaction Committee held meetings at which members of Aerovate&#8217;s board of directors, Aerovate management and representatives of Goodwin were present. During these meetings, representatives of Wedbush Securities Inc.&#160;(&#8220;Wedbush&#8221;)&#160;and one other financial advisory firm presented to the Transaction Committee, which presentations included reviews of their respective strategic and financial advisory expertise and experience, as well as their thoughts on potential business combination timelines, related activities, potential transaction structures and relevant precedents. The discussions covered a variety of topics, including the potential relevance of Aerovate&#8217;s net cash position, market conditions for certain business combinations, the potential criteria to be considered in selecting a potential business combination partner, certain considerations regarding asset sales in connection with or in advance of such transactions, and the role of the Transaction Committee in such process. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 28, 2024, the Aerovate board of directors held a meeting at which members of Aerovate&#8217;s management and representatives of Goodwin were present. At this meeting, the Aerovate board of directors considered various strategic alternatives and, with management and Goodwin, weighed the potential value that Aerovate could deliver to stockholders in the event of a possible reverse merger compared to a liquidation scenario. Following such discussion, the Aerovate board of directors determined that management should focus its efforts on pursuing a possible reverse merger and, as a parallel contingency plan, a liquidation or dissolution of Aerovate. A reverse merger, which is a transaction in which a wholly owned Aerovate subsidiary would merge with and into a privately held company with Aerovate surviving as the parent company and the privately held company continuing as a wholly owned Aerovate subsidiary, was considered to be the most desirable transaction structure to enhance stockholder value, given Aerovate&#8217;s cash position, its status as a public company, similar transactions recently completed with attractive merger partners and the termination of Aerovate&#8217;s clinical development program. The Aerovate board of directors considered the value that Aerovate&#8217;s public listing and access to public capital markets and cash might provide to a high-quality private company seeking to advance its own clinical programs or business by becoming a public company. Further, a reverse merger could provide Aerovate stockholders with a stake in a combined organization possessing both promising clinical or commercial prospects and the means to pursue them, and provide an opportunity for long-term value creation for Aerovate stockholders. Following further discussion, the Aerovate board of directors determined that Aerovate should publicly announce the results of its business review and that Aerovate was reviewing strategic alternatives. Aerovate&#8217;s management then discussed the formal engagement of Wedbush, including the terms of a proposed engagement letter between Aerovate and Wedbush, and noted Wedbush&#8217;s qualifications, professional reputation, experience and expertise as a transaction advisor for reverse mergers in the biopharmaceutical industry. The Aerovate board of directors also took into account Wedbush&#8217;s status as an internationally recognized investment banking firm that has substantial experience in transactions similar to those that the Aerovate board of directors would potentially be considering. The Aerovate board of directors reviewed and discussed the terms of the engagement letter and subsequently approved the entry into an engagement letter, dated July 4, 2024, between Aerovate and Wedbush. The engagement letter provided for a 3.0% success fee based on the valuation attributed to Aerovate in the definitive documentation related to a strategic transaction, with a minimum fee of $1,750,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Also on June 28, 2024, Aerovate publicly announced the implementation of its reduction in workforce plan to terminate nearly all of its workforce in the following months, beginning with notifying 39 individuals, or 78% of the Company&#8217;s workforce, of their termination.&#160;</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 8, 2024, Aerovate announced that it would conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value. Aerovate announced that, as part of the review process, Aerovate had engaged Wedbush as the company&#8217;s exclusive strategic financial advisor to assist in the process of exploring strategic alternatives, which may include but are not limited to, an acquisition, merger, reverse merger, business combination, liquidation or other transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the July 8, 2024 announcement through October 9, 2024, as authorized by the Aerovate board of directors and the Transaction Committee, representatives of Wedbush and Aerovate&#8217;s management contacted, or were contacted by, 245 potential counterparties regarding their interest in a potential strategic transaction with Aerovate. The companies were primarily privately-held biotechnology companies that were identified, or identified themselves, based on their need to obtain financing and/or their interest in becoming a public company with access to the public capital markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Of these 245 companies (including Jade), representatives of Wedbush distributed 109 process letters requesting that such potential counterparties&#160;submit&#160;non-binding&#160;indications&#160;of interest with respect to a strategic transaction with Aerovate. At the direction of the Aerovate board of directors and the Transaction Committee, members of Aerovate&#8217;s management, members of the Transaction Committee, and Aerovate&#8217;s financial and legal advisors, conducted due diligence on multiple potential counterparties, focusing on strategic, scientific and clinical diligence, as well as competitive and other business factors. Of the 109 process letters sent by Wedbush to potential counterparties, 56 counterparties submitted non-binding indications of interest, and 18 of these counterparties (including Party A, Party B, Party C, Party D, Party E, Party F and Party G) executed customary mutual confidentiality agreements with Aerovate (each of which included customary standstill provisions that automatically terminated upon Aerovate&#8217;s announcement of the transaction with Jade), and 11 of these companies held management presentations and due diligence sessions for Aerovate management, representatives of Wedbush, representatives of Goodwin, members of the Aerovate board of directors and technical expert representatives from certain of the investment funds affiliated with certain members of the Aerovate board of directors. </p><a id="_Hlk183440660"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 29, 2024, the Aerovate board of directors held a meeting at which members of Aerovate&#8217;s management, representatives of Wedbush and Goodwin were present. Representatives of Wedbush reviewed the status of outreach to potential counterparties and indications of interest received thus far. The Aerovate board of directors and Aerovate&#8217;s management, together with input from Wedbush, discussed and agreed upon the proposed criteria that, along with other factors, would be used as a guide to evaluate any potential indications of interest, consisting of the following factors: the stage of development of the counterparty&#8217;s product candidates and the likelihood of success in clinical trials; the therapeutic focus of the counterparty&#8217;s product candidates; the quality of management, board and investor base; potential value inflection milestones in the relative near term, including within the anticipated cash runway period following the closing of a transaction; readiness to be a U.S. publicly traded company, including the availability of audited financial statements; commercial opportunity, including competitive differentiation, pricing, reimbursement and potential market share; intellectual property position; insider support for capitalizing the Combined Company in a concurrent financing; the Combined Company&#8217;s financing needs following the completion of a transaction with Aerovate; and the proposed relative valuations and pro forma ownership splits of the Combined Company&#8217;s equity (collectively, the &#8220;Criteria&#8221;). The Aerovate board of directors and members of Aerovate&#8217;s management, together with input from Wedbush, also discussed the status of their review of the indications of interest, both when compared to the Criteria and in light of information learned about the counterparties not included in the Criteria. After reviewing all of the submitted indications of interest, the Transaction Committee selected eight indications of interest to prioritize, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The indication of interest from &#8220;Party A&#8221;, a privately held biotechnology company developing therapies to treat autoimmune and oncology diseases, which was received on July 19, 2024, and which proposed a reverse merger transaction with an ascribed valuation of Aerovate of $80 million (assuming closing net cash of $70 million) and an ascribed valuation of Party A of $200 million, with an implied ownership interest in the Combined Company of approximately 24% for existing Aerovate stockholders. Party A&#8217;s proposal also contemplated a concurrent financing of $50 million, with participation from current Party A investors.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The indication of interest from &#8220;Party B&#8221;, a privately held biotechnology company developing therapies to treat cardiovascular diseases, which was received on July 22, 2024, and which proposed a reverse merger transaction with an ascribed valuation of Aerovate of $80 million (assuming closing net cash of $70 million) and an ascribed valuation of Party B of $122.5 million, with an implied ownership interest in the Combined Company of approximately 30% for existing Aerovate stockholders. Party B&#8217;s proposal also contemplated a concurrent financing of $65 million, with participation from current Party B investors and new investors.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The indication of interest from &#8220;Party C&#8221;, a privately held biotechnology company developing therapies to treat fibrotic diseases, which was received on July 23, 2024, and which proposed a reverse merger transaction with an ascribed valuation </span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of Aerovate of $80 million (assuming closing net cash of $70 million) and an ascribed valuation of Party C of $163 million, with an implied ownership interest in the Combined Company of approximately 27% for existing Aerovate stockholders. Party C&#8217;s proposal also contemplated a concurrent financing of $50 million from current Party C investors.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The indication of interest from &#8220;Party D&#8221;, a privately held biotechnology company developing medicines to treat oncology diseases, which was received on July 23, 2024, and which proposed a reverse merger transaction with an ascribed valuation of Aerovate of $80 million (assuming closing net cash of $70 million) and an ascribed valuation of Party D of $190 million, with an implied ownership interest in the Combined Company of approximately 19% for existing Aerovate stockholders. Party D&#8217;s proposal also contemplated a concurrent financing of $150 million from current Party D investors and new investors.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The indication of interest from &#8220;Party E&#8221;, a privately held biotechnology company developing therapies to treat inflammatory and autoimmune diseases, which was received on July 23, 2024, and which proposed a reverse merger transaction with an ascribed valuation of Aerovate of $82 million (assuming closing net cash of $70 million) and an ascribed valuation of Party E of $230 million, with an implied ownership interest in the Combined Company of approximately 23% for existing Aerovate stockholders. Party E&#8217;s proposal also contemplated a concurrent financing of $40 million from current Party E investors and new investors.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The indication of interest from &#8220;Party F&#8221;, a privately held biotechnology company developing therapies to treat autoimmune and oncology diseases, which was received on July 23, 2024, and which proposed a reverse merger transaction with an ascribed valuation of Aerovate of $85 million (assuming closing net cash of $70 million) and an ascribed valuation of Party F of $525 million, with an implied ownership interest in the Combined Company of approximately 13% for existing Aerovate stockholders. Party F&#8217;s proposal also contemplated a concurrent financing of $70 million from current Party F investors.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The indication of interest from &#8220;Party G&#8221;, a privately held biotechnology company developing medicines for oncology diseases, which was received on July 24, 2024, and which proposed a reverse merger transaction with an ascribed valuation of Aerovate of $85 million (assuming closing net cash of $70 million) and an ascribed valuation of Party G of $590 million, with an implied ownership interest in the Combined Company of approximately 11% for existing Aerovate stockholders. Party G&#8217;s proposal also contemplated a concurrent financing of $100 million from current Party G investors and new investors.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The indication of interest from &#8220;Party H&#8221;, a privately held biotechnology company developing therapies to treat autoimmune and inflammatory diseases, which was received on July 24, 2024, and which proposed a reverse merger transaction with an ascribed valuation of Aerovate of $80 million (assuming closing net cash of $70 million) and an ascribed valuation of Party H of $160 million, with an implied ownership interest in the Combined Company of approximately 24% for existing Aerovate stockholders. Party H&#8217;s proposal also contemplated a concurrent financing of $100 million from current Party H investors and new investors.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Of these eight indications of interest the Transaction Committee selected to prioritize, the Transaction Committee further selected four potential counterparties &#8211; Party A, Party C, Party F and Party G &#8211; to invite to make corporate presentations based on the likelihood of such counterparties&#8217; ability to meet the most number of the Criteria. </p><a id="_Hlk182338072"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Beginning on July 29, 2024, at the direction of the Aerovate board of directors, representatives of Wedbush requested each of the four counterparties identified by the Transaction Committee to make corporate presentations to the Aerovate management, representatives of Wedbush, representatives of Goodwin, members of the Aerovate board of directors and technical expert representatives from certain of the investment funds affiliated with certain members of the Aerovate board of directors, and to otherwise be available for due diligence sessions with Wedbush, the Transaction Committee, Aerovate&#8217;s management and its legal advisors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From July 30, 2024 through August 1, 2024, each of the four potential counterparties identified by the Aerovate board of directors (Party A, Party C, Party F and Party G) met with and presented their corporate presentation to the Aerovate board of directors, Aerovate&#8217;s management and representatives of Wedbush.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On August 1, 2024, the Aerovate board of directors held a meeting at which members of Aerovate&#8217;s management and representatives of Wedbush and Goodwin were present. During this meeting, representatives of Wedbush provided the Aerovate board of directors with customary disclosures regarding any material relationships that Wedbush had with the proposed counterparties. </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Representatives of Goodwin reviewed the fiduciary duties of the members of the Aerovate board of directors and the process by which any conflicted board members or advisors would be recused from certain discussions and decisions to approve a final strategic transaction in the event that a material conflict was determined to exist. Also during this meeting, the Transaction Committee and Aerovate&#8217;s management reviewed their diligence of the four prioritized counterparties, Party A, Party C, Party F and Party G, including feedback following their corporate presentations. At the direction of the Aerovate board of directors, Aerovate&#8217;s management continued to diligence and evaluate Party C, Party F and Party G following these meetings. Aerovate&#8217;s management also discussed a preliminary liquidation model with the Aerovate board of directors, noting that the estimated timing for any distributions to stockholders in a dissolution scenario would be two to three months for an initial distribution and two to three years for the final distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 5, 2024, the Aerovate Board of directors, via unanimous written consent, for convenience (and not because of any conflicts of interest) approved the reconstitution of the Transaction Committee to be comprised of disinterested directors Ms. Dorval, Maha Katabi, Ph.D. and Mr. Noyes, who were selected because they have significant experience with merger and acquisition transactions and/or clinical development and were likely to be able to attend additional meetings throughout the remainder of the process. The delegated authority of the Transaction Committee remained the same and the members of the Transaction Committee did not receive fees for their service on the Transaction Committee. Throughout the Transaction Committee&#8217;s evaluation of a potential strategic transaction described below, the Transaction Committee conducted formal meetings, and its members were also in regular informal discussions with Aerovate&#8217;s management and legal and financial advisors and with each other.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 12, 2024, the Transaction Committee, additional members of the Aerovate board of directors, Aerovate&#8217;s management and representatives of Wedbush conducted additional due diligence on Party C and Party G. This additional due diligence included holding videoconferences with counterparty management, evaluating answers to submitted questions and reviewing the contents of counterparty virtual data rooms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Also on August 12, 2024, the Aerovate board of directors held a meeting at which members of Aerovate&#8217;s management and representatives of Wedbush and Goodwin were present. During this meeting and from the beginning and throughout the strategic review processes conducted by Aerovate, the Aerovate board of directors and representatives of Goodwin reviewed potential conflicts between certain members of the Aerovate board of directors and certain of the potential counterparties to a potential strategic transaction, noting that certain of Aerovate&#8217;s directors were affiliated with various investment funds that were investors in, and in some cases had board representation on, certain of the potential counterparties. The attendees discussed that while there were not actual or existing conflicts at this time, where appropriate to avoid potential conflicts or the appearance of potential conflicts, a particular director would recuse himself or herself from meetings (or relevant portions thereof) relating to, and any deliberations or discussions regarding, a possible transaction with that potential counterparty. Further, it was noted that certain attorneys from Goodwin (although not those advising Aerovate or the Transaction Committee) had provided legal services to certain of the potential counterparties and were outside legal counsel to Party A and Party F.&#160;Also during this meeting, representatives of Wedbush reviewed the status of discussions with each of the potential counterparties that the Transaction Committee, with input from Aerovate&#8217;s management, had identified Party C, Party F and Party G as priority candidates based on the Criteria. The discussion focused on the potential counterparties&#8217; strengths and weaknesses with respect to fundraising ability, valuations, product candidate viability, potential data readouts, competition and other Criteria. In the course of the discussion, the Transaction Committee eliminated Party F as a potential counterparty, based on the Criteria and a determination that Party F&#8217;s indication of interest was not viable. The Aerovate board of directors directed representatives of Wedbush to provide guidance to Party G that its proposed valuation of Party G, based on the Aerovate board of directors&#8217; assessment of Party G, was not competitive and that it should consider revising its proposal. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 14, 2024, Dr. Katabi and Dr. Grayzel had calls with the chief executive officer of Party C to discuss diligence questions and information regarding Party C&#8217;s valuation of its business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 15, 2024, the Aerovate board of directors held a meeting at which members of Aerovate&#8217;s management and representatives of Wedbush and Goodwin were present. Representatives of Wedbush provided an update on the status of discussions with each of the potential counterparties that the Transaction Committee, with input from Aerovate&#8217;s management, had identified as a priority based on the Criteria, including Party C and Party G, and the due diligence conducted on Party C and Party G. Dr. Katabi and Dr. Grayzel provided an update on the August 14 discussion she and Dr. Grayzel had with the chief executive officer of Party C. Following these discussions, the Transaction Committee directed Aerovate&#8217;s management and representatives of Wedbush and Goodwin to negotiate term sheets with each of Party C and Party G. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On August 15, 2024, at the direction of the Transaction Committee, representatives of Wedbush sent a&#160;non-binding&#160;term sheet to Party C. The term sheet proposed a reverse merger transaction that provided an ascribed value of Party C of $145&#160;million, with an </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">implied ownership interest in the Combined Company of approximately 61.7% for Party C equityholders and an ascribed value of Aerovate of $90&#160;million (assuming closing net cash of $70 million) with an implied ownership interest in the Combined Company of approximately 38.3% for existing Aerovate equityholders, in each case, prior to any concurrent financing. The Aerovate valuation was based on (i) $70&#160;million of net cash at closing, plus (ii)&#160;a&#160;non-cash&#160;enterprise value of $20&#160;million. The term sheet also provided for a concurrent financing at closing of no less than $90&#160;million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From August 15 through August 23, 2024, representatives of Aerovate and representatives of Party C discussed and negotiated the term sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 23, 2024, the Transaction Committee held a meeting at which members of Aerovate&#8217;s management and representatives of Goodwin were present. Aerovate&#8217;s management and representatives of Goodwin provided an update on the term sheet negotiations with Party C and the anticipated timeline for a potential transaction with Party C. The Transaction Committee provided feedback and direction to Aerovate&#8217;s management and Aerovate&#8217;s advisors on these matters, and authorized Aerovate&#8217;s management to continue to negotiate and to execute the non-binding term sheet based on such feedback.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 23, 2024, Aerovate and Party C executed the&#160;non-binding&#160;term sheet. The executed non-binding term sheet proposed a reverse merger transaction that provided an ascribed value of Party C of $145&#160;million, with an implied ownership interest in the Combined Company of approximately 61.7% for Party C equityholders and an ascribed value of Aerovate of $90&#160;million (assuming closing net cash of $70 million) with an implied ownership interest in the Combined Company of approximately 38.3% for existing Aerovate equityholders, in each case, prior to any concurrent financing. The Aerovate valuation was based on (i) $70&#160;million of net cash at closing, plus (ii)&#160;a&#160;non-cash&#160;enterprise value of $20&#160;million. The term sheet also provided for a concurrent financing at closing of no less than $90&#160;million. The executed term sheet also provided for an exclusive negotiation period through 11:59 p.m., Eastern Time, on September 22, 2024, which would be automatically extended through 11:59 p.m., Eastern Time, on September 29, 2024 if the parties were continuing to negotiate in good faith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 26, 2024, Party G provided a revised indication of interest, which proposed a reverse merger transaction with an ascribed valuation of Aerovate of $85 million (assuming closing net cash of $70 million) and an ascribed valuation of Party G of $295 million, with an implied ownership interest in the Combined Company of approximately 22% for existing Aerovate stockholders, prior to any concurrent financing. Party G&#8217;s proposal also contemplated a concurrent financing of $100 million, 40% of which would be provided by existing Aerovate investors, with the remaining 60% to be provided by existing investors in Party G and new investors. As Aerovate had entered into a mutual exclusivity period with Party C, neither Aerovate nor its advisors engaged with Party G regarding such revised indication of interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From August 28 through September 30, 2024, representatives of Aerovate and representatives of Party C completed confirmatory due diligence on each other and negotiated the terms of a merger agreement and the other documents contemplated by the proposed transaction. Also during this period, Party C engaged in discussions with potential investors for a concurrent financing that would close concurrently with the closing of Aerovate&#8217;s reverse merger transaction with Party C.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 30, 2024, Party C was provided access to an online data room containing nonpublic information regarding Aerovate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On September 19, 2024, the Aerovate board of directors held a meeting at which members of Aerovate&#8217;s management and representatives of Wedbush and Goodwin were present. Representatives from Goodwin provided a summary of the negotiations of the merger agreement. The meeting participants discussed the status of the proposed reverse merger with Party C and its concurrent financing, noting that Party C had not yet been able to secure the proposed concurrent financing commitments from potential investors. The meeting participants discussed strategic options available to Aerovate in the event Party C was unable to complete a concurrent financing in an amount or otherwise on terms that would enable Aerovate to proceed with the proposed transaction with Party C and generate sufficient value to Aerovate stockholders. The meeting participants noted the upcoming expiration of exclusivity with Party C on September 22, 2024 or, if extended, on September 29, 2024. In anticipation of the expiration of exclusivity with Party C, the meeting participants discussed potential strategic alternatives to the transaction with Party C, including other potential reverse merger candidates, a strategic transaction with another public company for the redeployment of Aerovate&#8217;s net cash and a potential liquidation of Aerovate. Aerovate&#8217;s management presented the Aerovate board of directors with an updated analysis prepared by Aerovate&#8217;s management regarding a potential liquidation of Aerovate, including the potential timeline for liquidation and an estimate of the amount that would be distributable to Aerovate stockholders in such liquidation scenario. Aerovate&#8217;s management did not update the potential liquidation scenario or prepare any other liquidation analysis after September 19, 2024, as described in the section titled &#8220;<i style="font-style:italic;">The Merger </i>&#8212; <i style="font-style:italic;">Aerovate Liquidation Analysis</i>&#8221; beginning on page&#160;111 of this proxy statement/prospectus. The Aerovate board </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">of directors also reviewed a customary relationship disclosure letter made available by Wedbush prior to the meeting, indicating that Wedbush had not been engaged by Party C during the&#160;two-year&#160;period prior to such disclosure. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 23, 2024 the chief executive officer of Party C informed Mr. Noyes and representatives of Wedbush that several leading healthcare investors that Party C had expected to participate in the concurrent financing had declined interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 29, 2024, the chief executive officer of Party C informed Mr. Noyes that it was unlikely that Party C would be able to raise the required $90 million for a concurrent financing. Mr. Noyes informed the Aerovate board of directors regarding these discussions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 29, 2024, at 11:59 p.m., Eastern Time, the mutual exclusivity period with Party C expired pursuant to the terms of the non-binding term sheet between Aerovate and Party C.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 30, 2024, at the direction of the Transaction Committee and due to Party C&#8217;s inability to raise the required concurrent financing, Aerovate&#8217;s management and its advisors terminated diligence activities and discussions with Party C. No further discussions regarding a strategic transaction between Aerovate and Party&#160;C occurred after this time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Also on September 30, 2024, Aerovate received an inbound phone call from Party B, which included information regarding Party B&#8217;s new clinical data and a revised development plan. Aerovate&#8217;s management shared this information with the Aerovate board of directors and the Aerovate board of directors provided support, via email, for Aerovate&#8217;s management and advisors to conduct additional diligence on Party B to determine whether Party B was likely to meet a sufficient number of the Criteria. Following such additional diligence, the Aerovate board of directors determined that Party B was not likely to meet a sufficient number of the Criteria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 6, 2024, Dr. Katabi resigned from the Aerovate board of directors and from the Audit Committee, Compensation Committee and Transaction Committee. This departure was not the result of any disagreement with Aerovate, the Aerovate board of directors or any committee thereof on any matter relating to Aerovate&#8217;s operations, practices or policies, or strategic process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 9, 2024, representatives of Wedbush introduced Mr. Noyes to Tom Frohlich, Chief Executive Officer of Jade via email.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 10, 2024, Mr. Noyes had an introductory call with Mr. Frohlich, during which the parties discussed Jade&#8217;s interest in a potential reverse merger transaction with Aerovate, as well as an overview of Jade&#8217;s operating strategy. During this call, the parties also discussed aspects of a potential reverse merger transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 11, 2024, the Aerovate board of directors held a meeting at which members of Aerovate&#8217;s management and representatives of Goodwin were present. The parties discussed an upcoming meeting between the parties&#8217; respective advisors to discuss Jade&#8217;s readiness to prepare financial statements required in a registration statement filed in connection with a potential reverse merger and inviting Jade to present their corporate presentation to the Aerovate board of directors. The Aerovate board of directors provided feedback and direction to Aerovate&#8217;s management and Aerovate&#8217;s advisors. Following discussion, the Aerovate board of directors directed Aerovate&#8217;s management and advisors to continue to diligence Jade and invite Jade to present its corporate presentation to the Aerovate board of directors, and to begin negotiations with Jade on a non-binding term sheet. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Later on October 11, 2024, as directed by the Aerovate board of directors, Wedbush informed Mr. Frohlich that the Aerovate board of directors would like to have Aerovate&#8217;s advisors talk to Jade&#8217;s advisors to understand Jade&#8217;s plan for preparing audited financial statements and to have Jade present its corporate presentation to the Aerovate board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 14, 2024, members of Aerovate&#8217;s management, including Mr. Noyes, had a call with members of Jade&#8217;s management, including Mr. Frohlich, at which representatives of Goodwin and Gibson, Dunn &amp; Crutcher LLP (&#8220;Gibson&#8221;), counsel to Jade, were present. During this call, the participants discussed the proposed transaction structure and Jade&#8217;s plan for preparing the financial statements required in a registration statement filed in connection with a potential reverse merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On October 15, 2024, at the direction of the Aerovate board of directors, representatives of Wedbush sent a non-binding term sheet to Jade. The term sheet provided for a reverse merger transaction an ascribed value of Aerovate of $10 million, in each case, prior to any concurrent financing. The Aerovate valuation was based on (i) $0 of net cash at closing plus (ii) a non-cash enterprise value of $10 million. The term sheet also provided for a special cash dividend of 100% of Aerovate&#8217;s net cash to Aerovate </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">stockholders prior to the closing. The term sheet also provided for a concurrent financing at closing of no less than $175 million, and a post-closing board of directors to be mutually agreed upon by Aerovate and Jade. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 15, 2024, Mr. Noyes and Mr. Frohlich had a call during which the parties discussed Jade&#8217;s upcoming corporate presentation to the Aerovate board of directors and details regarding Jade&#8217;s operating strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 16, 2024, Jade sent a revised draft of the non-binding term sheet to Aerovate, which provided for an ascribed value of Jade of $175&#160;million and an ascribed value of Aerovate of $7&#160;million (assuming closing net cash of $0), in each case, prior to any concurrent financing. The Aerovate valuation was based on (i) $0 of net cash at closing plus (ii)&#160;a&#160;non-cash&#160;enterprise value of $7&#160;million. The term sheet also provided for a cash dividend of 100% of Aerovate&#8217;s net cash to Aerovate stockholders prior to the closing, a concurrent financing at closing of no less than $150&#160;million, and a post-closing board of directors designated by Jade in its sole discretion. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 17, 2024, representatives of Jade made a corporate presentation to the Aerovate board of directors and members of Aerovate&#8217;s management. Representatives of Wedbush and Goodwin and technical expert representatives from certain of the investment funds affiliated with certain members of the Aerovate board of directors were present.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Also on October 17, 2024, following the Jade corporate presentation, the Aerovate board of directors held a meeting at which members of Aerovate&#8217;s management, representatives of Wedbush and Goodwin, and technical expert representatives from certain of the investment funds affiliated with certain members of the Aerovate board of directors were present. The participants provided feedback regarding the Jade corporate presentation and the economic terms proposed by Jade, including the potential cash dividend paid to Aerovate stockholders prior to the closing of a proposed reverse merger transaction. Representatives from Goodwin provided a summary of the terms of the October 16 draft of the non-binding term sheet. Following discussion, the Aerovate board of directors directed Aerovate&#8217;s management to provide guidance to Jade that the value ascribed to Aerovate in Jade&#8217;s proposed economic terms should be increased from $7 million to $8 million in order to be acceptable to the Aerovate board of directors, and, if such change to the proposed economic terms was accepted by Jade, directed Aerovate&#8217;s management and advisors to enter into the non-binding term sheet with Jade.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Later on October 17, 2024, Aerovate sent a revised draft of the non-binding term sheet to Jade, which provided for an ascribed value of Jade of $175&#160;million and an ascribed value of Aerovate of $8&#160;million (assuming closing net cash of $0), in each case, prior to any concurrent financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 18, 2024, Aerovate and Jade executed the&#160;non-binding&#160;term sheet. The executed term sheet was substantially identical to the draft term sheet Aerovate provided on October 17, 2024. The executed term sheet also provided for an exclusive negotiation period through November 8, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October&#160;21, 2024, Goodwin sent a first draft of the Merger Agreement to Gibson.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 22, 2024, Jade was provided access to an online data room containing nonpublic information regarding Aerovate. From this date through October 30, 2024, Jade and Gibson shared nonpublic information regarding Jade via e-mail with representatives of Goodwin and Aerovate&#8217;s management team.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 22, 2024, Mr. Noyes and Mr. Frohlich had a call, during which the parties discussed Jade&#8217;s recent research results as well as the timing for completing a potential transaction between Aerovate and Jade.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October&#160;25, 2024, Gibson sent a revised draft of the Merger Agreement to Goodwin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">From October&#160;25 through October 30, 2024, representatives of Goodwin, with input from the Aerovate board of directors (including through the Transaction Committee) and Aerovate&#8217;s management, and Jade&#8217;s representatives and Gibson exchanged drafts and participated in discussions regarding the terms of the Merger Agreement and related documents. The items negotiated with respect to the Merger Agreement and related documents included, among other things: the representations and warranties to be made by the parties; the restrictions on the conduct of the parties&#8217; businesses until completion of the transaction; the definitions of material adverse effect; the conditions to completion of the Merger; the determination of Aerovate&#8217;s net cash balance at closing; the allocation of transaction expenses; the terms of the subscription agreement for the Jade private placement and the aggregate amount of the Jade private placement proceeds to be committed concurrently with the execution of the Merger Agreement, as discussed below; potential adjustments to the amount of the special cash dividend to Aerovate&#160;pre-Merger&#160;stockholders; the provisions regarding Aerovate&#8217;s </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">employee benefit plans, severance and other compensation matters; the remedies available to each party under the Merger Agreement, including the triggers of the termination fee payable to each of the parties and the outside date for the proposed transaction; the amounts of the termination fees; and the terms of the support agreements&#160;and&#160;lock-up&#160;agreements&#160;entered into concurrent with the execution of the Merger Agreement. In addition, during this period, Jade engaged in discussions with potential investors for the Jade concurrent investment that would close concurrently with the closing of Aerovate&#8217;s transaction with Jade.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 25 and 30, 2024, representatives of Jade provided Aerovate&#8217;s management with an update on the status of the Jade concurrent investment. In particular, Jade informed Aerovate that Jade anticipated receiving subscriptions concurrent with the execution of the Merger Agreement to invest more than $175&#160;million, from new and existing Jade investors, and that the size of the concurrent financing would not be finalized until immediately prior to signing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 27, 2024, the Aerovate board of directors discussed via email the formal engagement of Lucid Capital Markets, LLC (&#8220;Lucid&#8221;) to provide a fairness opinion to the Aerovate board of directors in the context of a reverse merger with Jade. Aerovate management noted Wedbush&#8217;s prior discussions with Aerovate&#8217;s management, during which Wedbush indicated that they were unable to provide a fairness opinion to the Aerovate board of directors due to Wedbush &amp; Co., LLC serving as a placement agent on Jade&#8217;s concurrent financing. Aerovate&#8217;s management noted Lucid&#8217;s qualifications, professional reputation and experience, including that Lucid has been engaged by other companies to render financial opinions in connection with mergers, acquisitions, and for other purposes. Based on these factors, on October 30, 2024, the Transaction Committee authorized and ratified the engagement of Lucid to provide a fairness opinion in connection with the reverse merger with Jade. Such engagement letter was entered into between Aerovate and Lucid, effective October 29, 2024. Following the execution of the engagement letter with Lucid, the Aerovate board of directors was provided a customary relationship disclosure letter made available by Lucid prior to the meeting, indicating that Lucid had not been engaged by Jade during the&#160;two-year&#160;period prior to such disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 30, 2024, the Transaction Committee and Aerovate board of directors held a joint meeting at which members of Aerovate&#8217;s management and representatives of Wedbush, Lucid and Goodwin were present. Aerovate&#8217;s management and representatives of Goodwin and Wedbush provided an update on the status of negotiations with Jade and the status of the transaction documents. The meeting participants also discussed Jade&#8217;s plan for preparing the audited financial statements required to be filed with a registration filed in connection with a reverse merger transaction with Aerovate. Aerovate&#8217;s management and representatives from Goodwin provided an update that, based on previous discussions with representatives from Jade, Jade&#8217;s preparation of the required financial statements may be delayed, and noted that the draft Merger Agreement contemplated that the outside date by which the proposed transaction must be consummated was six months from the signing date, subject to a two-month automatic extension if the reason the transaction was not consummated was due to the registration statement filed in connection with the transaction not being effective. In light of such potential delay, the Aerovate board of directors directed Aerovate management and representatives of Goodwin to convey to representatives of Jade and Gibson that the outside date should be six months from signing without such two-month automatic extension. Based on the liquidation scenario previously provided by Aerovate&#8217;s management and the discussions at prior meetings of the Aerovate board of directors, it was Aerovate&#8217;s board of directors&#8217; view that a liquidation and dissolution of Aerovate was not reasonably likely to create greater value for Aerovate stockholders than the anticipated transaction, even with a potential delay in the preparation of the required Jade financial statements, noting that the timing of a portion of the distribution to stockholders in a dissolution scenario would be over a year.&#160;</p><a id="_Hlk183440099"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The participants discussed the status of the Jade private placement, noting that the size of the financing at the time of execution of the Merger Agreement was now projected to be approximately $300 million (including the conversion of the $95 million convertible note) rather than the $175&#160;million minimum required in the term sheet. Representatives of Goodwin reviewed the fiduciary duties under Delaware law of the Aerovate board of directors in connection with the proposed Merger with Jade, the terms of the Merger Agreement and the forms of subscription agreement, support agreement&#160;and&#160;lock-up&#160;agreement.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The meeting participants reviewed the due diligence process that Aerovate and its representatives undertook to evaluate Jade, including its technology, pipeline, commercial prospects, regulatory interactions, clinical plans and data, intellectual property, legal and compliance matters, financial position and other matters. Wedbush then reminded the Aerovate board of directors of material features of the strategic process to date and discussed with the Aerovate board of directors that the Exchange Ratio in the Merger Agreement, which provided for a 98.4% and 1.6% ownership split for the Jade and Aerovate equityholders in the post-closing company, respectively, was based on an assumed $8&#160;million valuation of Aerovate (assuming net cash of $0 and an enterprise value of Aerovate of $8 million) and an assumed $175&#160;million valuation for Jade. Representatives of Wedbush and Goodwin also discussed with the Aerovate board of directors that Jade had secured approximately $300&#160;million (including the $95 million convertible note) for the Jade concurrent financing. Representatives of Lucid then reviewed and discussed with the Aerovate board of directors Lucid&#8217;s preliminary financial analysis with respect to Aerovate, Jade and the proposed terms of the Merger. In addition, the Aerovate board of </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">directors reviewed and discussed the cash dividend of approximately $65 million that would be declared and paid to Aerovate stockholder prior to the consummation of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Later on October 30, 2024, the parties finalized the Merger Agreement and the securities purchase agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Later on October 30, 2024, the Transaction Committee and Aerovate board of directors held a joint meeting at which members of Aerovate&#8217;s management and representatives of Wedbush, Lucid and Goodwin were present, to consider approval of the proposed transaction with Jade. Members of Aerovate&#8217;s management and representatives of Goodwin indicated that the shortening of the outside date to six months from the signing date of the Merger Agreement was accepted by Jade and that the Merger Agreement was finalized. Representatives of Lucid confirmed that Lucid&#8217;s financial analysis with respect to Aerovate, Jade and the proposed terms of the Merger was unchanged since the earlier October 30 meeting. Thereafter, at the request of the Aerovate board of directors, Lucid rendered to the Aerovate board of directors its oral opinion, which was subsequently confirmed by delivery of a written opinion dated October 30, 2024, that, as of such date and based upon and subject to the various assumptions made, and the qualifications and limitations upon the review undertaken by Lucid in preparing its opinion, the Exchange Ratio proposed to be paid by Aerovate pursuant to the terms of the Merger Agreement was fair, from a financial point of view, to Aerovate. For a detailed discussion of Lucid&#8217;s opinion, please see heading titled &#8220;<i style="font-style:italic;">The Merger</i>&#8212;<i style="font-style:italic;">Opinion of Aerovate&#8217;s Financial Advisor</i>&#8221; beginning on page&#160;114 of this proxy statement/prospectus. After discussion, the Transaction Committee unanimously recommended that the Aerovate board of directors approve Aerovate&#8217;s entry into the Merger Agreement for the transaction with Jade on the terms presented at this meeting. After further discussion, based on the factors cited in &#8220;<i style="font-style:italic;">The Merger</i>&#8212;<i style="font-style:italic;">Aerovate&#8217;s Reasons for the Merger</i>&#8221; beginning on page&#160;108 of this proxy statement/prospectus, the Aerovate board of directors (excluding Mr. Dable, who was not present): (a)&#160;determined that the transactions contemplated by the Merger Agreement are fair to, advisable and in the best interests of Aerovate and its stockholders, (b) approved and declared advisable the Merger Agreement and the transactions contemplated by the Merger Agreement, including the issuance of shares of Aerovate common stock to the stockholders of Jade pursuant to the Merger Agreement, the support agreement and the constructive issuance, (c) determined that the reverse stock split proposal, among other things, is advisable and in the best interests of Aerovate and its stockholders, (d) determined to recommend, upon the terms and subject to the conditions set forth in the Merger Agreement, that the stockholders of Aerovate vote to authorize the issuance proposal, that the stockholders of Aerovate vote to approve the reverse stock split proposal and the other Aerovate stockholder proposals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Later on October 30, 2024, the parties executed the Merger Agreement and the securities purchase agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;">On the morning of October 31, 2024, prior to the opening of trading on the Nasdaq market, Aerovate and Jade issued a joint press release announcing entry into the Merger Agreement and the Jade concurrent investment. Aerovate also filed a current report on Form&#160;8-K&#160;with the SEC announcing, among other things, the execution of the Merger Agreement.</p><a id="TheMerger_Aerovate_Reason"></a><a id="_Hlk183785237"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Aerovate&#8217;s Reasons for the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the course of its evaluation of the Merger Agreement and the transactions contemplated by the Merger Agreement, the Aerovate board of directors held numerous meetings, consulted with Aerovate&#8217;s management, Aerovate&#8217;s consultants and advisors, outside legal counsel and financial advisor, and reviewed and assessed a significant amount of information. In reaching its decision to approve the Merger Agreement and the transactions contemplated by the Merger Agreement, the Aerovate board of directors considered a number of factors that it viewed as supporting its decision to approve the Merger Agreement, including: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the financial condition and prospects of Aerovate and the risks associated with continuing to operate Aerovate on a stand-alone basis, particularly in light of Aerovate&#8217;s June 2024 decision to discontinue the Phase 2b/Phase 3 clinical trial of AV-101, initiate a process to explore strategic alternatives and reduce its workforce;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that the Aerovate board of directors and its financial advisor undertook a comprehensive and thorough process of reviewing and analyzing potential strategic alternatives and merger partner candidates and the Aerovate board of directors&#8217; view that no alternatives to the Merger (including remaining a standalone company, a liquidation and dissolution of Aerovate and the distribution of any available cash, a cash tender offer at a discount to net cash value, and alternative strategic transactions) were reasonably likely to create greater value to Aerovate&#8217;s stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Aerovate board of directors&#8217; conclusion that the Merger would provide Aerovate&#8217;s existing stockholders a significant opportunity to participate in the potential growth of the Combined Company following the Merger, which will focus on Jade&#8217;s product candidates, while also receiving a cash payment following the closing of the Merger on account of the special cash dividend;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Aerovate board of directors&#8217; belief, after thorough review of strategic alternatives and discussions with Aerovate&#8217;s management, outside legal counsel and financial advisor, that the Merger is more favorable to Aerovate&#8217;s stockholders than the potential value that might have resulted from other strategic alternatives available to Aerovate, including a liquidation and dissolution of Aerovate and the distribution of any available cash or a cash tender offer at a discount to net cash value;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Aerovate board of directors&#8217; belief, after thorough discussions with Aerovate&#8217;s management and Aerovate&#8217;s consultants and advisors, that a potential liquidation and dissolution was not reasonably likely to create greater value for Aerovate&#8217;s stockholders than a strategic alternative transaction based on, among other things, the need to hold back a meaningful amount of Aerovate&#8217;s current cash balance for over a year to cover current and potential future liabilities, including those triggered by a liquidation strategy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Aerovate board of directors&#8217; belief that the $8 million enterprise value ascribed to Aerovate would provide the existing Aerovate stockholders significant value for Aerovate&#8217;s public listing, and afford the Aerovate stockholders a significant opportunity to participate in the potential growth of the Combined Company following the Merger at the negotiated exchange ratio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Aerovate board of directors&#8217; belief, after a thorough review of strategic alternatives, such as attempting to further advance the development of its internal programs, entering into a licensing, sale or other strategic agreement related to certain assets sufficient to fund operations, combining with other potential strategic transaction candidates, and discussions with Aerovate&#8217;s management, financial advisors and legal counsel, that the Merger is more favorable to Aerovate stockholders than the potential value that might have resulted from other strategic alternatives available to Aerovate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Aerovate board of directors&#8217; belief that, as a result of arm&#8217;s length negotiations with Jade, Aerovate and its representatives negotiated the highest exchange ratio to which Jade was willing to agree and that the other terms of the Merger Agreement include the most favorable terms to Aerovate in the aggregate to which Jade was willing to agree;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Aerovate board of directors&#8217; positive view, based on the scientific, regulatory and technical due diligence conducted by Aerovate&#8217;s management and advisors, of the regulatory pathway for, and potential significant market opportunity of, Jade&#8217;s product candidates, which will be the focus of the Combined Company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Aerovate board of directors&#8217; consideration of the expected cash balances of the Combined Company as of the closing of the Merger resulting from the cash Jade currently holds and the expected gross proceeds of no less than approximately $300.0 million from the Concurrent Investment (which includes the $95.0 million of Jade convertible notes previously issued and $1.7 million of accrued interest from the convertible notes, both converting at a 20% discount), which will precede the closing of the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Aerovate board of directors&#8217; view, following a review with Aerovate&#8217;s management and advisors of Jade&#8217;s current development and clinical trial plans, of the likelihood that the Combined Company would possess sufficient cash resources at the closing of the Merger, or have access to sufficient resources, to fund continued development of Jade&#8217;s product candidates through upcoming value inflection points;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prospects of and risks associated with the other strategic candidates that had made proposals for a strategic transaction with Aerovate based on the scientific, technical and other due diligence conducted by Aerovate&#8217;s management and advisors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Aerovate board of directors&#8217; view that the Combined Company will be led by an experienced board of directors and senior management team from Jade;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the current financial market conditions and historical market prices, volatility and trading information with respect to Aerovate common stock; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the opinion of Lucid, rendered orally to the Aerovate board of directors on October 30, 2024 (and subsequently confirmed in writing by delivery of Lucid&#8217;s written opinion, dated October 30, 2024) that, as of such date and based upon and subject to the various assumptions made, and the qualifications and limitations upon the review undertaken by Lucid in preparing its opinion, the Exchange Ratio proposed to be paid by Aerovate pursuant to the terms of the Merger Agreement was fair, from a financial point of view, as of October 30, 2024, to the holders of Aerovate common stock, as more fully described below in </span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the section titled &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The Merger&#8212;Opinion of Aerovate&#8217;s Financial Advisor</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">,&#8221; beginning on page </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">114</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of this proxy statement/prospectus.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Aerovate board of directors also reviewed the terms of the Merger Agreement and related transaction documents, including those described below, and concluded that the terms of the Merger Agreement and related transaction documents, in the aggregate, were reasonable under the circumstances:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the calculation of the Exchange Ratio, closing net cash and the estimated number of shares of Aerovate common stock to be issued in the Merger, including that the valuation of Aerovate under the Merger Agreement would be reduced to the extent that Aerovate&#8217;s closing net cash is less than $0, which would result in a decrease in the ownership of the pre-Merger Aerovate stockholders in the Combined Company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and nature of the conditions to Aerovate&#8217;s and Jade&#8217;s respective obligations to complete the Merger and the likelihood that the Merger will be completed on a timely basis, as more fully described below in the caption &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The Merger Agreement&#8211;Conditions to the Completion of the Merger</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">,&#8221; beginning on page </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">149</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of this proxy statement/prospectus;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the respective rights of, and limitations on, Aerovate and Jade under the Merger Agreement to consider and engage in discussions regarding unsolicited acquisition proposals under certain circumstances, and the limitations on the board of directors of each party to change its recommendation in favor of the Merger, as more fully described below under the caption &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The Merger Agreement&#8211;Non-solicitation</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">,&#8221; beginning on page </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">145</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of this proxy statement/prospectus;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential termination fee of $2.34 million, which would become payable by Aerovate to Jade, or the potential termination fee of $5.25 million, which would become payable by Jade to Aerovate, if the Merger Agreement is terminated in certain circumstances, as more fully described below under the caption &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The Merger Agreement</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8211;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Termination and Termination Fee</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">,&#8221; beginning on page </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">150</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of this proxy statement/prospectus;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the lock-up agreements, pursuant to which certain stockholders of Jade have, subject to certain exceptions, agreed not to transfer their shares of the Combined Company common stock during the period of 180 days following the completion of the Merger, as more fully described below under the caption &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Agreements Related to the Merger&#8211;Lock-Up Agreements</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">,&#8221; beginning on page </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">153</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of this proxy statement/prospectus; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the support agreements, pursuant to which certain stockholders of Jade and Aerovate, respectively, have agreed, solely in their capacities as stockholders, to vote their shares of Jade common stock or Aerovate common stock, respectively, in favor of the proposals submitted to them in connection with the Merger, as more fully described in &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Agreements Related to the Merger&#8211;Support Agreements</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">,&#8221; beginning on page </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">153</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of this proxy statement/prospectus.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the course of its deliberations, the Aerovate board of directors and also considered a variety of risks and other countervailing factors related to entering into the Merger, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the $2.34 million termination fee payable by Aerovate upon the occurrence of certain events and the potential effect of such termination fee in deterring other potential acquirors from proposing an alternative acquisition that may be more advantageous of Aerovate&#8217;s stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the substantial expenses to be incurred by Aerovate in connection with the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prohibition on Aerovate to solicit alternative acquisition proposals during the pendency of the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible volatility of the trading price of Aerovate common stock resulting from the announcement, pendency or completion of the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that the Merger might not be consummated in a timely manner or at all and the potential effect of the public announcement of the Merger or the failure to complete the Merger on the reputation of Aerovate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scientific, technical, regulatory and other risks and uncertainties associated with development and commercialization of Jade&#8217;s product candidates; and</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the various other risks associated with the Combined Company and the proposed transaction, including those described in the sections titled &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Risk Factors</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Cautionary Note Regarding Forward-Looking Statements</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; beginning on pages </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">24</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">93</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, respectively, of this proxy statement/prospectus.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The foregoing information and factors considered by the Aerovate board of directors are not intended to be exhaustive but are believed to include all of the material factors considered by the Aerovate board of directors. In view of the wide variety of factors considered in connection with its evaluation of the Merger and the complexity of these matters, the Aerovate board of directors did not find it useful to attempt, and did not attempt, to quantify, rank or otherwise assign relative weights to these factors. In considering the factors described above, individual members of the Aerovate board of directors may have given different weight to different factors. The Aerovate board of directors conducted an overall analysis of the factors described above, including thorough discussions with, and questioning of, Aerovate&#8217;s management, outside legal counsel and financial advisor, and considered the factors overall to be favorable to, and to support, its determination<span style="color:#212529;">.</span></p><a id="TheMerger_Aerovate_Liquidation_Analysis"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Aerovate Liquidation Analysis</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the evaluation of the Merger by Aerovate&#8217;s board of directors, Aerovate management prepared an analysis with respect to the estimated value of the liquidation or dissolution of Aerovate as a potential alternative to the Merger, including for such purposes Aerovate&#8217;s estimated cash position at the time of the potential dissolution or liquidation, Aerovate&#8217;s estimated expenses in connection with any such liquidation or dissolution, and the amount of cash available to be distributed to Aerovate&#8217;s stockholders in connection with any such proposed future dissolution or liquidation (the &#8220;Liquidation Analysis&#8221;). Although the Liquidation Analysis assumes that the entirety of the Aerovate cash balance at the time of the dissolution or liquidation would be available for distribution to Aerovate &#8217;s stockholders, it is unlikely that the entirety of such cash balance would be available at the time of an actual dissolution or liquidation due to the requirements of applicable law. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The inclusion of the Liquidation Analysis should not be deemed an admission or representation by Aerovate or any of its officers, directors, affiliates, advisors, or other representatives with respect to the accuracy of the Liquidation Analysis. The Liquidation Analysis is not included to influence your views on the Merger, the Merger Agreement and the transactions contemplated thereby and is summarized in this proxy statement/prospectus solely to provide stockholders access to certain information considered by Aerovate&#8217;s board of directors in connection with its evaluation of the Merger, the Merger Agreement and the transactions contemplated thereby and was provided to its financial advisor. Any estimates contained in these analyses are not necessarily indicative of actual values or predictive of future results or values, which may be significantly more or less favorable than as set forth below. In addition, analyses relating to the value of Aerovate do not purport to be appraisals or reflect the prices at which shares of Aerovate common stock may actually be valued or trade, either before or after the consummation of the Merger. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The prospective financial information included in this proxy statement/prospectus has been prepared by, and is the responsibility of, Aerovate management. PricewaterhouseCoopers LLP has not audited, reviewed, examined, compiled nor applied agreed-upon procedures with respect to the accompanying prospective financial information and, accordingly, PricewaterhouseCoopers LLP does not express an opinion or any other form of assurance with respect thereto. The PricewaterhouseCoopers LLP report included in this proxy statement/prospectus relates to Jade Biosciences, Inc.&#8217;s previously issued financial statements. It does not extend to the prospective financial information and should not be read to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Liquidation Analysis was not prepared with a view toward public disclosure, nor was it prepared with a view toward compliance with published guidelines of the SEC, the guidelines established by the American Institute of Certified Public Accountants for preparation and presentation of prospective financial information, or GAAP. Neither the independent registered public accounting firm of Aerovate nor any other independent accountant has audited, reviewed, compiled, examined or performed any procedures with respect to the accompanying unaudited prospective financial information for the purpose of its inclusion herein, and accordingly, neither the independent registered public accounting firm of Aerovate nor any other independent accountant expresses an opinion or provides any form of assurance with respect thereto for the purpose of this proxy statement/prospectus. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Liquidation Analysis includes estimates of cash and of certain expenditures, which for the purpose of the Liquidation Analysis were not calculated in accordance with GAAP. Non-GAAP financial measures should not be viewed as a substitute for GAAP financial measures and may be different from non-GAAP financial measures used by other companies. Furthermore, there are limitations inherent in non-GAAP financial measures because they exclude charges and credits that are required to be included in a GAAP presentation. Accordingly, non-GAAP financial measures should be considered together with, and not as an alternative to, financial measures prepared in accordance with GAAP. The SEC rules, which otherwise would require a reconciliation of a non-GAAP financial measure to a GAAP financial measure, do not apply to non-GAAP financial measures provided to a board of </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">directors or financial advisors in connection with a proposed reverse merger transaction such as the Merger if the disclosure is included in a document such as this proxy statement/prospectus to comply with requirements under state laws, including case law. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">In light of the foregoing factors and the uncertainties inherent in estimated cash balances, stockholders are cautioned not to place undue reliance, if any, on the Liquidation Analysis. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The below summary of the Liquidation Analysis is subject to the statements above, and it represents Aerovate management&#8217;s estimates of Aerovate&#8217;s cash which may be distributed to stockholders as permitted under applicable law pursuant to a plan of dissolution. </p><a id="_Hlk182898979"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Key assumptions underlying the Liquidation Analysis included: (i) that the Aerovate board of directors began the path to dissolution in mid-September 2024; (ii) that the initial distribution of Aerovate&#8217;s net cash would be made in late November 2024; (iii) that Aerovate would have approximately $76.7 million in cash, after deducting costs and expenses, including legal fees, the fees payable to Aerovate&#8217;s strategic financial advisor, accounting fees, employee retention bonuses, severance and benefits, insurance expenses and other transaction-related costs, with no adjustments for taxes; (iv) that these costs and expenses were forecasted to total approximately $8.2 million assuming the completion of a dissolution and liquidation is finalized two to three years later; and (v) approximately 28.9 million total shares of Aerovate common stock outstanding as of November 2024. The analysis resulted in an estimated cash distribution per share in total of $2.66 per share with a portion of cash distributed to stockholders in November 2024 and the final cash distribution to stockholders approximately two to three years later.</p><a id="TheMerger_Jade_Reason"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Jade&#8217;s Reasons for the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the course of reaching its decision to approve the Merger and the Jade Pre-Closing Financing, Jade&#8217;s board of directors held numerous meetings, consulted with Jade&#8217;s senior management, legal counsel and financial advisors, and considered a wide variety of factors. Ultimately, Jade&#8217;s board of directors concluded that a merger with Aerovate, together with the additional financing committed from the Jade Pre-Closing Financing, was the best option to generate capital resources to support the advancement of Jade&#8217;s pipeline and fund the combined organization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additional factors Jade&#8217;s board of directors considered included the following (which factors are not necessarily presented in any order of relative importance):</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Merger will potentially expand the access to capital and the range of investors available as a public company to support the clinical development of Jade&#8217;s pipeline, compared to the capital and investors Jade could otherwise gain access to if it continued to operate as a privately-held company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Jade Pre-Closing Financing will generate capital resources to fund the Combined Company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential benefits from increased public market awareness of Jade and its pipeline;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the historical and current information concerning Jade&#8217;s business, including its financial performance and condition, operations, management and preclinical data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the competitive nature of the industry in which Jade operates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade&#8217;s board of directors&#8217; fiduciary duties to Jade stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade&#8217;s board of directors&#8217; belief that no alternatives to the Merger, together with the additional financing committed from the Jade Pre-Closing Financing, were reasonably likely to create greater value for Jade stockholders, after considering the various financing and other strategic options to enhance stockholder value that were considered by the Jade board of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade&#8217;s board of directors&#8217; expectation that the Merger, together with the additional financing committed from the Jade Pre-Closing Financing, would be a higher probability and more cost-effective means to access capital than other options considered, including an IPO;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expected operations, management structure and operating plans of the Combined Company (including the ability to support the Combined Company&#8217;s current and planned preclinical studies and planned clinical trials);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the business, history, operations, financial resources, assets, technology and credibility of Aerovate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of appraisal rights under the Delaware General Corporation Law (&#8220;DGCL&#8221;) to holders of Jade capital stock who comply with the required procedures under the DGCL, which </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">allow such holders to seek appraisal of the fair value of their shares of Jade capital stock as determined by the Delaware Court of Chancery;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and conditions of the Merger Agreement, including the following:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the determination that the expected relative&#160;percentage ownership of Aerovate stockholders and Jade stockholders in the combined organization was appropriate, based on Jade&#8217;s board of directors&#8217; judgment and assessment of the approximate valuations of Aerovate (including the value of the Net Cash Aerovate is expected to provide to the combined organization) and Jade (including the value of the amount of proceeds from the Jade Pre-Closing Financing);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expectation that the Merger will be treated as a reorganization for U.S. federal income tax purposes, with the result that the Jade stockholders will generally not recognize taxable gain or loss for U.S. federal income tax purposes with respect to the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the limited number and nature of the conditions of the obligation of Aerovate to consummate the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rights of Jade under the Merger Agreement to consider certain unsolicited acquisition proposals under certain circumstances should Jade receive a superior offer;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rights of Jade under the Merger Agreement to effect a change in recommendation in favor of the Merger as a result of a material development or change in circumstances (i.e., applicable Intervening Events);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the conclusion of Jade&#8217;s board of directors that the potential termination fees payable by Aerovate or Jade to the other party, and the circumstances when such fee may be payable, were reasonable; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the belief that the other terms of the Merger Agreement, including the parties&#8217; representations, warranties and covenants, and the conditions to their respective obligations, were reasonable in light of the entire transaction;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the shares of Aerovate&#8217;s common stock issued to Jade stockholders, including shares of Aerovate common stock issued in exchange for shares of Jade common stock sold in the Jade Pre-Closing Financing, will be registered on a Form&#160;S-4 registration statement and will become freely tradable for Jade stockholders who are not affiliates of Jade and who are not parties to lock-up agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the support agreements, pursuant to which certain directors, officers and stockholders of Jade and Aerovate, respectively, have agreed, solely in their capacity as stockholders of Jade and Aerovate, respectively, to vote all of their shares of Jade capital stock or Aerovate common stock in favor of the adoption or approval, respectively, of the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to obtain a Nasdaq listing and the change of the combined organization&#8217;s name to Jade Biosciences,&#160;Inc. prior to or upon the Closing; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the likelihood that the Merger will be consummated on a timely basis.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s board of directors also considered a number of uncertainties and risks in its deliberations concerning the Merger and the other transactions contemplated by the Merger Agreement, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possibility that the Merger might not be completed and the potential adverse effect of the public announcement of the Merger on the reputation of Jade and the ability of Jade to obtain financing in the future in the event the Merger is not completed;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possibility that the Jade Pre-Closing Financing might not be completed or completed in accordance with the terms of the Subscription Agreement and the potential adverse effect of the public announcement of the Jade Pre-Closing Financing on the reputation of Jade and the ability of Jade to obtain financing in the future in the event the Jade Pre-Closing Financing is not completed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Exchange Ratio used to establish the number of shares of Aerovate&#8217;s common stock to be issued to Jade stockholders in the Merger is fixed, except for adjustments due to Aerovate&#8217;s Net Cash balances, the amount of proceeds from the Jade Pre-Closing Financing and outstanding capital stock </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at Closing, and thus the relative&#160;percentage ownership of Aerovate stockholders and Jade stockholders in the combined organization immediately following the completion of the Merger is similarly fixed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential reduction of Aerovate&#8217;s Net Cash prior to the Closing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possibility that Aerovate could, under certain circumstances, consider unsolicited acquisition proposals if superior to the Merger or change its recommendation to approve the Merger upon certain events;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that the Merger might not be consummated in a timely manner or at all, for a variety of reasons, such as the failure of Aerovate to obtain the required stockholder vote or the failure of Jade to close the Jade Pre-Closing Financing, and the potential adverse effect on the reputation of Jade and the ability of Jade to obtain financing in the future in the event the Merger is not completed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in connection with completing the Merger, the time and effort of Jade senior management required to complete the Merger, the related disruptions or potential disruptions to Jade&#8217;s business operations and future prospects, including its relationships with its employees, suppliers and partners and others that do business or may do business in the future with Jade, and related administrative challenges associated with combining the companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the additional expenses and obligations to which Jade&#8217;s business will be subject to following the Merger that Jade has not previously been subject to, and the operational changes to Jade&#8217;s business, in each case that may result from being a public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the fact that the representations and warranties in the Merger Agreement do not survive the Closing and the potential risk of liabilities that may arise post-Closing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that future sales of common stock by existing Aerovate stockholders may cause the price of Aerovate common stock to fall, thus reducing the potential value of Aerovate common stock received by Jade stockholders following the Merger; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">various other risks associated with the combined organization and the Merger, including the risks described in the section titled &#8220;</span><i style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Risk Factors</i><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; beginning on page&#160;</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">24</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of this proxy statement/prospectus.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The foregoing information is not intended to be exhaustive, but is believed to include a summary of all of the material factors considered by Jade&#8217;s board of directors in its consideration of the Merger Agreement, the Jade Pre-Closing Financing, and the transactions contemplated thereby. After conducting an overall analysis of these and other factors, including thorough discussions with, and questioning of, Jade&#8217;s senior management and legal counsel, Jade&#8217;s board of directors concluded that the benefits, advantages and opportunities of a potential transaction outweighed the uncertainties and risks described above. Based on this overall analysis of the factors described above, Jade&#8217;s board of directors unanimously approved the Merger Agreement, the Merger, the Jade Pre-Closing Financing and the other transactions contemplated by the Merger Agreement.</p><a id="TheMerger_OpinionAerovate_FinanAdvisor"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Opinion of Aerovate&#8217;s Financial Advisor</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As stated above, pursuant to an engagement letter dated October&#160;29, 2024 (the &#8220;Engagement Letter&#8221;), Aerovate retained Lucid to render an opinion to Aerovate&#8217;s board of directors as to the fairness of the Exchange Ratio, from a financial point of view, to the holders of common stock of Aerovate (the &#8220;Lucid Opinion&#8221;). On October&#160;30, 2024, at the request of Aerovate&#8217;s board of directors, Lucid rendered an oral opinion, subsequently confirmed by delivery of the Lucid Opinion dated October&#160;30, 2024, to Aerovate&#8217;s board of directors, that the Exchange Ratio was fair, from a financial point of view, to the holders of common stock of Aerovate as of the date of the Lucid Opinion and based upon the various assumptions, qualifications and limitations set forth therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">The full text of the Lucid Opinion is attached as </b><span style="font-style:italic;font-weight:bold;">Annex F </span><b style="font-weight:bold;">to this proxy statement/prospectus and is incorporated by reference. Aerovate encourages its stockholders to read the Lucid Opinion in its entirety for the assumptions made, </b></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">procedures followed, other matters considered and limits of the review by Lucid. The summary of the Lucid Opinion set forth herein is qualified by reference to the full text of the Lucid Opinion. Lucid provided the Lucid Opinion for the sole benefit and use by Aerovate&#8217;s board of directors in its consideration of the Merger. The Lucid Opinion is not a recommendation to Aerovate&#8217;s board of directors or to any stockholder as to how to vote with respect to the proposed Merger or to take any other action in connection with the Merger or otherwise.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Lucid Opinion, Lucid took into account an assessment of general economic, market and financial conditions as well as its experience in connection with similar transactions and securities valuations generally and, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed a draft of the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed and analyzed certain publicly available financial and other information for each of Aerovate and Jade;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Discussed with certain members of the management of Aerovate the historical and current business operations, financial condition and prospects of Aerovate and Jade;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed and analyzed certain operating results of Jade as compared to operating results and the reported price and trading histories of certain publicly traded companies that Lucid deemed relevant;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed and analyzed certain financial terms of the Agreement as compared to the publicly available financial terms of certain selected business combinations that Lucid deemed relevant;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed and analyzed certain financial terms of completed initial public offerings for certain companies that Lucid deemed relevant;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed certain pro forma financial effects of the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed and analyzed certain internal financial analyses, including the cash burn model over the next&#160;year and whether concurrent capital raised would sufficiently cover select programs, reports, and other information concerning Jade prepared by Jade; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed and analyzed such other information and such other factors, and conducted such other financial studies, analyses and investigations, as Lucid deemed relevant for the purposes of the Lucid Opinion.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In conducting Lucid&#8217;s review and arriving at the Lucid Opinion, Lucid has, with Aerovate&#8217;s consent, assumed and relied upon the accuracy and completeness of all financial and other information provided to or discussed with Lucid by Aerovate and Jade, respectively (or their respective employees, representatives or affiliates), or which is publicly available or was otherwise reviewed by Lucid. Lucid has not undertaken any responsibility for the accuracy, completeness or reasonableness of, or independent verification of, such information. Furthermore, Lucid has assumed, with Aerovate&#8217;s consent, that the Exchange Ratio will be 21.4388 shares of Aerovate common stock for each share of Jade common stock (and 0.0214388 shares of Aerovate Series A Preferred Stock for each share of Jade Preferred Stock). Lucid has, with Aerovate&#8217;s consent, relied upon the assumption that all information provided to Lucid by Aerovate and Jade is accurate and complete in all material respects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Lucid expressly disclaimed any undertaking or obligation to advise any person of any change in any fact or matter affecting the Lucid Opinion of which Lucid has become aware after the date of the Lucid Opinion. Lucid assumed there were no material changes in the assets, liabilities, financial condition, results of operations, business or prospects of Aerovate or Jade since the date of the last financial statements made available to Lucid. Lucid has not obtained any independent evaluations, valuations or appraisals of the assets or liabilities of Aerovate or Jade, nor has Lucid been furnished with such materials. In addition, Lucid has not evaluated the solvency or fair value of Aerovate or Jade under any state or federal laws relating to bankruptcy, insolvency or similar matters. The Lucid Opinion does not address any legal, tax or accounting matters related to the Merger, as to which Lucid has assumed that Aerovate and Aerovate&#8217;s board of directors have received such advice from legal, regulatory, tax and accounting advisors as each has determined appropriate. The Lucid Opinion addresses only the fairness of the Exchange Ratio, from a financial point of view, to the holders of common stock of Aerovate. Lucid expresses no view as to any other aspect or implication of the Merger or any other agreement or arrangement entered into in connection with the Merger. The Lucid Opinion is necessarily based upon economic and market conditions and other circumstances as they existed and could be evaluated by Lucid on the date of the Lucid Opinion. It should </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">be understood that although subsequent developments may affect the Lucid Opinion, Lucid does not have any obligation to update, revise or reaffirm the Lucid Opinion and Lucid expressly disclaims any responsibility to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lucid did not consider any potential legislative or regulatory changes currently being considered or recently enacted by the United States or any foreign government, or any domestic or foreign regulatory body, or any changes in accounting methods or generally accepted accounting principles that may be adopted by the U.S. Securities and Exchange Commission, the Financial Accounting Standards Board, or any similar foreign regulatory body or board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of rendering the Lucid Opinion, Lucid assumed in all respects material to Lucid&#8217;s analysis, that the representations and warranties of each party contained in the Merger Agreement were true and correct, that each party will perform all of the covenants and agreements required to be performed by it under the Merger Agreement and that all conditions to the consummation of the Merger will be satisfied without waiver or amendment of any term or condition thereof. Lucid has assumed that the final form of the Merger Agreement will be substantially similar to the last draft reviewed by Lucid. Lucid has also assumed that all governmental, regulatory and other consents and approvals contemplated by the Merger Agreement or otherwise required for the transactions contemplated thereby will be obtained and that in the course of obtaining any of those consents no restrictions will be imposed or waivers made that would have an adverse effect on Aerovate, Jade or the contemplated benefits of the Merger. Lucid has assumed that the Merger will be consummated in a manner that complies with the applicable provisions of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and all other applicable federal and state statutes, rules&#160;and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of rendering the Lucid Opinion, Lucid, with Aerovate&#8217;s consent, assumed that (i)&#160;prior to the Closing, Aerovate&#8217;s Cash Dividend has occurred, (ii)&#160;prior to Closing, Jade will receive approximately $331.3 million in proceeds from the Jade Pre-Closing Financing (including the $95 million Jade convertible notes previously issued plus approximately $6 million of accrued interest from the Convertible Notes, both converting at a 20% discount), (iii)&#160;the Exchange Ratio will be 21.4388 shares of Aerovate common stock for each share of Jade common stock (and 0.0214388 shares of Aerovate Series A Preferred Stock for each share of Jade Preferred Stock), and (iv)&#160;upon Closing, the holders of Jade common stock, Jade Preferred Stock, Jade options and Jade pre-funded warrants will in the aggregate hold approximately 98.4% of the fully-diluted shares of Aerovate common stock (excluding certain Aerovate options) and the holders of Aerovate common stock will in the aggregate hold approximately 1.6% of the fully-diluted shares of Aerovate common stock (excluding certain Aerovate options) immediately following the Merger, after giving effect to Aerovate&#8217;s Cash Dividend and the Jade Pre-Closing Financing, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is understood that the Lucid Opinion is intended for the benefit and use of Aerovate&#8217;s board of directors in its consideration of the financial terms of the Merger and, except as set forth in the Engagement Letter, may not be used for any other purpose or reproduced, disseminated, quoted or referred to at any time, in any manner or for any purpose without Lucid&#8217;s prior written consent, unless pursuant to applicable law or regulations or required by other regulatory authority by the order or ruling of a court or administrative body, except that the Lucid Opinion may be included in its entirety in any filing related to the Merger to be filed with the U.S. Securities and Exchange Commission and the proxy statement/prospectus to be mailed to the Aerovate stockholders. The Lucid Opinion does not constitute a recommendation to Aerovate&#8217;s board of directors of whether or not to approve the Merger or to any Aerovate stockholder or any other person as to how to vote with respect to the Merger or to take any other action in connection with the Merger or otherwise. The Lucid Opinion does not address Aerovate&#8217;s underlying business decision to proceed with the Merger or the relative merits of the Merger compared to other alternatives available to Aerovate. Lucid expressed no opinion as to the prices or ranges of prices at which shares or the securities of any person, including Aerovate, will trade at any time, including following the announcement or consummation of the Merger. Lucid has not been requested to opine as to, and the Lucid Opinion does not in any manner address, the amount or nature of compensation to any of the officers, directors or employees of any party to the Merger, or any class of such persons, relative to the compensation to be paid to the Aerovate stockholders in connection with the Merger or with respect to the fairness of any such compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Lucid Opinion may not be published or otherwise used or referred to, nor shall any public reference to Lucid be made, without Lucid&#8217;s prior written consent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Principal Financial Analyses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following is a summary of the principal financial analyses performed by Lucid to arrive at the Lucid Opinion. Some of the summaries of financial analyses include information presented in tabular format. In order to fully understand the financial analyses, the tables must be read together with the text of each summary. The tables alone do not constitute a complete description of the financial analyses. Considering the data set forth in the tables without considering the full narrative description of the financial analyses, including the methodologies and assumptions underlying the analyses, could create a misleading or incomplete view of the </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">financial analyses. Lucid performed certain procedures, including each of the financial analyses described below and reviewed with Aerovate&#8217;s board of directors the assumptions on which such analyses were based and other factors, including the historical and projected financial results of Aerovate and Jade.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Transaction Overview as of the Date of the Lucid Opinion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based upon the Exchange Ratio of 21.4388 shares of Aerovate common stock for each share of Jade common stock (and 0.0214388 shares of Aerovate Series A Preferred Stock for each share of Jade Preferred Stock) at the time of the signing of the Merger Agreement, it was estimated that at the Closing: (a)&#160;Jade equity holders as of immediately prior to the Merger (including the shares issued in the approximately $331.3 million Jade Pre-Closing Financing) will own approximately 98.4% of the fully-diluted shares of Aerovate common stock at the Closing, and (b)&#160;the Aerovate equity holders as of immediately prior to the Merger (excluding for this purpose the Aerovate OTM Options) will own approximately 1.6% of the fully-diluted shares of Aerovate common stock at the Closing, in each case, subject to adjustment of the Exchange Ratio as set forth in the Merger Agreement and described herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade Valuation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the purpose of the Lucid Opinion, Lucid utilized a Jade Valuation of $506.3 million, which is calculated by adding the negotiated Jade Equity Value of $175.0 million plus the total proceeds contemplated by the Jade Pre-Closing Financing ($205.0 million) plus proceeds of the Jade convertible notes contributed to the Jade Pre-Closing Financing ($95.0 million, or $118.8 million on an as converted basis) plus accrued interest ($6.0 million, or $7.5 million on an as converted basis).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Analysis of Selected Initial Public Offering Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lucid reviewed certain publicly available information for the initial public offerings (&#8220;IPOs&#8221;) of 18 inflammation/autoimmune-focused biopharmaceutical companies that have completed an IPO since May&#160;2018 and whose lead product at the time of IPO was in early-stage of clinical development. Although the companies referred to below were used for comparison purposes, none of these companies are directly comparable to Jade. Accordingly, an analysis of the results of such a comparison is not purely mathematical but instead involves complex considerations and judgments concerning differences in historical and projected financial and operating characteristics of the selected companies below. These companies, which are referred to as the &#8220;Selected Precedent IPO Companies,&#8221; were:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Apogee Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Applied Molecular Transport</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Avidity Biosciences</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Azitra</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Biora Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Cabaletta Bio</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Contineum Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">DICE Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dyne Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evelo Biosciences</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Hoth Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Kezar Life Sciences</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Kymera Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Morphic Holding</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Prometheus Biosciences</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Third Harmonic Bio</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Ventyx Biosciences</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Virpax Pharmaceuticals</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The total enterprise value at IPO is defined as the pre-money equity value plus indebtedness, liquidation value of preferred stock and non-controlling interest, minus cash and cash equivalents at the time of its IPO. The Selected Precedent IPO Companies had total enterprise values between $33.0 million and $637.6 million. Lucid derived a median total enterprise value of $309.1 million for the Selected Precedent IPO Companies. Using the 25<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>&#160;percentile and the 75<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>&#160;percentile of the implied total enterprise values, Lucid then calculated a range of implied total equity values for Jade (by adding an estimated $300.0 million in net cash at Closing), which was approximately $456.5 million to $749.4 million. This compares to the Jade Valuation as per the Merger Agreement of $506.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Selected Precedent IPO Companies</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:top;width:53.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:24.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Filing Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.11%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Issuer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Enterprise</b><b style="color:#231f20;font-weight:bold;">&#160;</b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">Value&#160;($M)</b></p></td></tr><tr><td style="vertical-align:top;width:53.54%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">4/5/24 </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:24.11%;background:#cceeff;border-top:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Contineum Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18%;background:#cceeff;border-top:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">174.2</span></p></td></tr><tr><td style="vertical-align:top;width:53.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">7/13/23</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:24.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Apogee Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">384.3</span></p></td></tr><tr><td style="vertical-align:top;width:53.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">6/15/23</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:24.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Azitra</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">58.6</span></p></td></tr><tr><td style="vertical-align:top;width:53.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">9/14/22</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:24.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Third Harmonic Bio</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">359.8</span></p></td></tr><tr><td style="vertical-align:top;width:53.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">10/20/21</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:24.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Ventyx Biosciences</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">466.6</span></p></td></tr><tr><td style="vertical-align:top;width:53.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">9/14/21</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:24.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">DICE Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">343.5</span></p></td></tr><tr><td style="vertical-align:top;width:53.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">3/11/21</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:24.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Prometheus Biosciences</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">442.5</span></p></td></tr><tr><td style="vertical-align:top;width:53.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">2/16/21</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:24.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Virpax Pharmaceuticals</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">33.0</span></p></td></tr><tr><td style="vertical-align:top;width:53.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">9/17/20</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:24.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Dyne Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">460.4</span></p></td></tr><tr><td style="vertical-align:top;width:53.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">8/20/20</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:24.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Kymera Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">526.2</span></p></td></tr><tr><td style="vertical-align:top;width:53.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">6/19/20</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:24.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Biora Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">638.5</span></p></td></tr><tr><td style="vertical-align:top;width:53.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">6/12/20</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:24.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Avidity Biosciences</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">292.2</span></p></td></tr><tr><td style="vertical-align:top;width:53.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">6/4/20</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:24.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Applied Molecular Transport</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">260.5</span></p></td></tr><tr><td style="vertical-align:top;width:53.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">10/24/19</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:24.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Cabaletta Bio</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">108.0</span></p></td></tr><tr><td style="vertical-align:top;width:53.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">6/26/19</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:24.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Morphic Holding</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">154.4</span></p></td></tr><tr><td style="vertical-align:top;width:53.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">2/15/19</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:24.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Hoth Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">45.0</span></p></td></tr><tr><td style="vertical-align:top;width:53.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">6/20/18</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:24.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Kezar Life Sciences</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">141.5</span></p></td></tr><tr><td style="vertical-align:top;width:53.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">5/8/18</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:24.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Evelo Biosciences</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">315.2</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Analysis of Selected Publicly Traded Companies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on its experience and professional judgment and using financial screening sources and databases to find companies that share similar business characteristics to Jade within the biopharmaceutical industry, Lucid selected financial data of 12 publicly traded companies (referred to as the &#8220;Selected Publicly Traded Companies&#8221;). Each of the Selected Publicly Traded Companies had a lead candidate in the early stages of clinical development and focused on the inflammation/autoimmune space. Furthermore, Lucid concentrated its analysis on comparable companies reporting cash balances exceeding $50 million, aligning with Jade&#8217;s anticipated cash balance of over $300 million at the time of Closing. Although the companies referred to below were used for comparison purposes, none of those companies is directly comparable to Jade.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Accordingly, an analysis of the results of such a comparison is not purely mathematical but instead involves complex considerations and judgments concerning differences in historical and projected financial and operating characteristics of the selected </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">companies below. The total enterprise values are based on closing stock prices on October&#160;30, 2024. The Selected Publicly Traded Companies were:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AbCellera Biologics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Absci</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Adicet Bio</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Climb Bio</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Contineum Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">IGM Biosciences</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Oruka Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ProQR Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Regulus Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Spyre Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Third Harmonic Bio</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Zura bio</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Selected Publicly Traded Companies had implied total enterprise values between negative $112.0 million and $1.3 billion. Lucid derived a median implied total enterprise value of $212.9 million for the Selected Publicly Traded Companies. Using the 25<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>&#160;percentile and the 75<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th&#160;</sup>percentile of the implied total enterprise values, Lucid then calculated a range of implied total equity values for Jade (by adding an estimated $300.0 million in net cash at Closing), which was approximately $390.1 million to $745.7 million. This compares to the Jade Valuation as per the Merger Agreement of $506.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Selected Publicly Traded Companies</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:top;width:82.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Company Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Enterprise</b><b style="color:#231f20;font-weight:bold;">&#160;</b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">Value&#160;($M)</b></p></td></tr><tr><td style="vertical-align:top;width:82.17%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Spyre Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.8%;background:#cceeff;border-top:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">1,325.8</span></p></td></tr><tr><td style="vertical-align:top;width:82.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Oruka Therapeutics </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">1,111.9</span></p></td></tr><tr><td style="vertical-align:top;width:82.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">IGM Biosciences</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">789.4</span></p></td></tr><tr><td style="vertical-align:top;width:82.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Absci</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">331.1</span></p></td></tr><tr><td style="vertical-align:top;width:82.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Third Harmonic Bio</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">327.9</span></p></td></tr><tr><td style="vertical-align:top;width:82.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Contineum Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">221.7</span></p></td></tr><tr><td style="vertical-align:top;width:82.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">ProQR Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">204.1</span></p></td></tr><tr><td style="vertical-align:top;width:82.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">AbCellera Biologics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">148.8</span></p></td></tr><tr><td style="vertical-align:top;width:82.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Zura Bio</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">107.0</span></p></td></tr><tr><td style="vertical-align:top;width:82.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Climb Bio</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">39.7</span></p></td></tr><tr><td style="vertical-align:top;width:82.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Regulus Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">6.2</span></p></td></tr><tr><td style="vertical-align:top;width:82.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Adicet Bio</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">112.0</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Analysis of Selected Fairmount-Backed Publicly Traded Companies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Based on its experience and professional judgment and using financial screening sources and databases to find companies that share similar business characteristics to Jade within the biopharmaceutical industry, Lucid selected financial data of six publicly traded companies previously backed by the Fairmount team or connected to Paragon Therapeutics (referred to as the &#8220;Selected Fairmount-</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Backed Publicly Traded Companies&#8221;). Although the companies referred to below were used for comparison purposes, none of those companies is directly comparable to Jade. Accordingly, an analysis of the results of such a comparison is not purely mathematical but instead involves complex considerations and judgments concerning differences in historical and projected financial and operating characteristics of the selected companies below. The total enterprise values are based on closing stock prices on October&#160;30, 2024. The Selected Publicly Traded Companies were:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Apogee Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Astria Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Cogent Biosciences</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Oruka Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Spyre Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Viridian Therapeutics</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Selected Fairmount-Backed Publicly Traded Companies had implied total enterprise values between $325.8 million and $2.4 billion. Lucid derived a median implied total enterprise value of $1.0 billion for the Selected Fairmount-Backed Publicly Traded Companies. Using the 25<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>&#160;percentile and the 75<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>&#160;percentile of the implied total enterprise values, Lucid then calculated a range of implied total equity values for Jade (by adding an estimated $300.0 million in net cash at Closing), which was approximately $1.2 billion to $1.6 billion. This compares to the Jade Valuation as per the Merger Agreement of $506.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Selected Publicly Traded Companies</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:81.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Company Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Enterprise</b><b style="color:#231f20;font-weight:bold;">&#160;</b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">Value&#160;($M)</b></p></td></tr><tr><td style="vertical-align:top;width:81.94%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Apogee Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.94%;background:#cceeff;border-top:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">2,422.1</span></p></td></tr><tr><td style="vertical-align:top;width:81.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Spyre Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">1,325.8</span></p></td></tr><tr><td style="vertical-align:top;width:81.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Oruka Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">1,111.9</span></p></td></tr><tr><td style="vertical-align:top;width:81.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Cogent Biosciences</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">924.6</span></p></td></tr><tr><td style="vertical-align:top;width:81.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Viridian Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">916.7</span></p></td></tr><tr><td style="vertical-align:top;width:81.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Astria Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">325.8</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Selected Precedent M&amp;A Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lucid reviewed the financial terms, to the extent the information was publicly available, of the 13 most recent qualifying merger transactions of companies in the biopharmaceutical industry which had a lead candidate in the early-stage of clinical development and focused on the inflammation/autoimmune space (referred to as the &#8220;Selected Precedent M&amp;A Transactions&#8221;). Although the precedent transactions referred to below were used for comparison purposes, none of the target companies is directly comparable to Jade. Accordingly, an analysis of the results of such a comparison is not purely mathematical, but instead involves complex considerations and judgments concerning differences in historical and projected financial and operating characteristics of the companies involved and other factors that could affect the merger value of such companies and Jade to which they are being compared. Lucid reviewed the total enterprise values of the target companies (including future milestone payments). These transactions, including the date each was closed, were as follows below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Selected Precedent M&amp;A Transactions had total implied enterprise values between $20.0 million and $2.4 billion. Lucid derived a median total enterprise value of $300.0 million for the Selected Precedent M&amp;A Transactions. Using the 25<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>&#160;percentile and the 75<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>&#160;percentile of the implied total enterprise values, Lucid then calculated a range of implied total enterprise values for Jade (by adding an estimated $300.0 million in net cash at Closing), which was approximately $362.3 million to $1.2 billion. This compares to Jade&#8217;s Valuation as per the Merger Agreement of $506.3 million.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Selected Precedent M&amp;A Transactions</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Closed Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Target</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Acquirer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Implied&#160;Enterprise</b><b style="font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">Value&#160;($M)</b></p></td></tr><tr><td style="vertical-align:top;width:31%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">6/21/24</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:21%;background:#cceeff;border-top:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Proteologix</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:21%;background:#cceeff;border-top:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Johnson&#160;&amp; Johnson</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:top;white-space:nowrap;width:20%;background:#cceeff;border-top:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">850.0</span></p></td></tr><tr><td style="vertical-align:top;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">4/11/24</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Clade Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Century Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">35.0</span></p></td></tr><tr><td style="vertical-align:top;width:31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">3/13/24</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">IFM Due</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Novartis AG</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:20%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">90.0</span></p></td></tr><tr><td style="vertical-align:top;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">2/15/24</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Aiolos Bio</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">GSK</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">1,000.0</span></p></td></tr><tr><td style="vertical-align:top;width:31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">1/18/24</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Calypso Biotech</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Novartis AG</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:20%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">250.0</span></p></td></tr><tr><td style="vertical-align:top;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">8/9/23</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">DICE Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Eli Lilly</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">2,400.0</span></p></td></tr><tr><td style="vertical-align:top;width:31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">8/4/22</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">MiroBio</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Gilead</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:20%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">405.0</span></p></td></tr><tr><td style="vertical-align:top;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">12/1/21</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">ORIGIMM Biotechnology</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Sanofi</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">62.3</span></p></td></tr><tr><td style="vertical-align:top;width:31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">3/20/21</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Rodeo Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Amgen</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:20%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">55.0</span></p></td></tr><tr><td style="vertical-align:top;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">2/25/21</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Pandion Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Merck</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">1,850.0</span></p></td></tr><tr><td style="vertical-align:top;width:31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">5/7/19</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">IFM Tre</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Novartis</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:20%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">310.0</span></p></td></tr><tr><td style="vertical-align:top;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">8/8/17</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Confluence Life Sciences</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Aclaris Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">20.0</span></p></td></tr><tr><td style="vertical-align:top;width:31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">1/26/17</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Delinia,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Celegene Corporation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:20%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">300.0</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aerovate Valuation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Analysis of Precedent Reverse Merger Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lucid reviewed the financial terms, to the extent the information was publicly available, of life sciences reverse merger transactions dating back to January&#160;2018 (referred to as the &#8220;Selected Precedent Reverse Merger Transactions&#8221;). Lucid reviewed the total premium to cash delivered to each target, along with other quantitative metrics. These transactions, including the date each was closed, are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Selected Precedent Reverse Merger Transactions</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Closed Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Surviving&#160;Company</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Public&#160;Company</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value&#160;Delivered&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">for&#160;Public&#160;Vehicle&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Net&#160;of&#160;Cash</b><b style="color:#231f20;font-weight:bold;">&#160;</b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">($&#160;mm&#8217;s)</b></p></td></tr><tr><td style="vertical-align:top;width:15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">10/17/2024</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:28%;background:#cceeff;border-top:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">TuHURA Biosciences</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:35%;background:#cceeff;border-top:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Kintara Therapeutics (Nasdaq: KTRA)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18.95pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;background:#cceeff;border-top:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 18.95pt;"><span style="color:#231f20;">11</span></p></td></tr><tr><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">10/9/2024</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Wex Pharmaceuticals</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Virios Therapeutics (Nasdaq: VIRI)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">6</span></p></td></tr><tr><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">9/3/2024</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Oruka Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">ARCA Biopharma (Nasdaq: ABIO)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">6</span></p></td></tr><tr><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">8/12/24</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Firefly Neurosciences</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">WaveDancer (Nasdaq: WAVD)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 29.65pt;"><span style="color:#231f20;">14</span></p></td></tr><tr><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">6/20/24</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Tetonic Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AVROBIO (Nasdaq: AVRO)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 29.65pt;"><span style="color:#231f20;">13</span></p></td></tr><tr><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">4/1/2024</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Tawsfynydd Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Onconova Therapeutics (Nasdaq: ONTX)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 29.65pt;"><span style="color:#231f20;">11</span></p></td></tr><tr><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">3/26/2024</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Serina Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AgeX Therapeutics (Nasdaq: AGE)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">6</span></p></td></tr><tr><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">3/25/2024</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Q32 Bio</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Homology Medicines (Nasdaq: FIXX)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 29.65pt;"><span style="color:#231f20;">20</span></p></td></tr><tr><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">3/21/2024</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">LENZ Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Graphite Bio (Nasdaq: GRPH)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 29.65pt;"><span style="color:#231f20;">12</span></p></td></tr><tr><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">3/14/2024</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Immunogenx</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">First Wave BioPharma (FWBI)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 29.65pt;"><span style="color:#231f20;">15</span></p></td></tr><tr><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">3/6/2024</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Adaptive Phage Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Biomx (NYSEAM: PHGE)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 23.95pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 23.95pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 23.95pt;"><span style="color:#231f20;">NA</span></p></td></tr><tr><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">12/27/2023</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Cyclo Therapeutics (Nasdaq: CYTH)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Applied Molecular Transport (Nasdaq: AMTI)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">1</span></p></td></tr><tr><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">12/18/2023</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Neurogene</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Neoleukin Therapeutics (Nasdaq: NLTX)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 29.65pt;"><span style="color:#231f20;">14</span></p></td></tr><tr><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">11/13/2023</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Cartesian Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Selecta Biosciences (Nasdaq: RNAC)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 29.65pt;"><span style="color:#231f20;">13</span></p></td></tr><tr><td style="vertical-align:top;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">11/3/2023</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Korro Bio</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Frequency Therapeutics (Nasdaq: FREQ)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 29.65pt;"><span style="color:#231f20;">15</span></p></td></tr><tr><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">10/31/2023</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Lung Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Aileron Therapeutics (Nasdaq: ALRN)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 29.65pt;"><span style="color:#231f20;">10</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:37.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Closed Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 52pt;"><b style="color:#231f20;font-weight:bold;">Surviving&#160;Company</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.74%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Public&#160;Company</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value&#160;Delivered&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">for&#160;Public&#160;Vehicle&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Net&#160;of&#160;Cash</b><b style="color:#231f20;font-weight:bold;">&#160;</b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">($&#160;mm&#8217;s)</b></p></td></tr><tr><td style="vertical-align:top;width:12%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">10/16/2023</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;background:#cceeff;border-top:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Notable Labs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;background:#cceeff;border-top:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Vascular Biogenics&#160;Ltd. (Nasdaq: VBLT)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;background:#cceeff;border-top:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">20</span></p></td></tr><tr><td style="vertical-align:top;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">9/11/2023 </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Dianthus Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Magenta Therapeutics (Nasdaq: MGTA)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">20</span></p></td></tr><tr><td style="vertical-align:top;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">8/16/2023</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">EIP Pharma (CervoMed)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Diffusion Pharmaceuticals (Nasdaq: DFFN)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">10</span></p></td></tr><tr><td style="vertical-align:top;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">6/29/2023 </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">TeraImmune</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Baudax Bio (Nasdaq: BXRX)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">3</span></p></td></tr><tr><td style="vertical-align:top;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">6/22/2023 </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Spyre Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Aeglea BioTherapeutics (Nasdaq: AGLE)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">25</span></p></td></tr><tr><td style="vertical-align:top;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">6/1/2023 </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Elicio Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Angion Biomedica (Nasdaq: ANGN)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">7</span></p></td></tr><tr><td style="vertical-align:top;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">4/22/2023 </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">GRI Bio</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Vallon Pharmaceuticals (Nasdaq: VLON)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">29</span></p></td></tr><tr><td style="vertical-align:top;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">3/20/2023 </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">CalciMedica</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Graybug Vision (Nasdaq: GRAY)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">15</span></p></td></tr><tr><td style="vertical-align:top;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">3/7/2023 </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Carisma Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Sesen Bio (Nasdaq: SESN)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">15</span></p></td></tr><tr><td style="vertical-align:top;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">2/23/2023 </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Enliven Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Imara (Nasdaq: IMRA)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">10</span></p></td></tr><tr><td style="vertical-align:top;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">1/9/2023 </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Catheter Precision,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Ra Medical Systems (NYSE: RMED)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">4</span></p></td></tr><tr><td style="vertical-align:top;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">12/29/2022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Disc Medicine</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Gemini Therapeutics (Nasdaq: GMTX)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">10</span></p></td></tr><tr><td style="vertical-align:top;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">12/27/2022 </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">GNI Group (Gyre Therapeutics)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Catalyst Biosciences (Nasdaq: CBIO)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">9</span></p></td></tr><tr><td style="vertical-align:top;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">12/19/2022 </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Kineta,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Yumanity Therapeutics (Nasdaq: YMTX)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">26</span></p></td></tr><tr><td style="vertical-align:top;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">11/8/2022 </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">ARS Pharmaceuticals</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Silverback Therapeutics (Nasdaq: SBTX)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">5</span></p></td></tr><tr><td style="vertical-align:top;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">9/28/2022 </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Aceragen,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Idera Pharmaceuticals (Nasdaq: IDRA)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">7</span></p></td></tr><tr><td style="vertical-align:top;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">9/15/2022 </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Lisata Therapeutics (Cend)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Caladrius Biosciences (Nasdaq: CLBS)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">25</span></p></td></tr><tr><td style="vertical-align:top;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">8/30/2022 </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Vivani Medical (Nano Precision)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Second Sight Medical (Nasdaq: EYES)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 23.95pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">NA</span></p></td></tr><tr><td style="vertical-align:top;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">7/5/2022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Syros Pharmaceuticals (Nasdaq: SYRS)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Tyme Technologies (Nasdaq: TYME)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">8</span></p></td></tr><tr><td style="vertical-align:top;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">5/16/2022 </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Aprea Therapeutics,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Atrin Pharmaceuticals (NasdaqGS: APRE)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">15</span></p></td></tr><tr><td style="vertical-align:top;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">10/24/2021 </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Quoin Pharmaceuticals,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Cellect Biotechnology&#160;Ltd. (Nasdaq: APOP)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">13</span></p></td></tr><tr><td style="vertical-align:top;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">8/26/2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Aadi Bioscience,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Aerpio Pharmaceuticals,&#160;Inc. (Nasdaq: ARPO)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">15</span></p></td></tr><tr><td style="vertical-align:top;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">8/3/2021 </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Decoy Biosystems,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Indaptus Therapeutics (Intec) (Nasdaq: INDP)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">10</span></p></td></tr><tr><td style="vertical-align:top;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">7/27/2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Cytocom,&#160;Inc. (Statera)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Cleveland BioLabs,&#160;Inc. (Nasdaq: CBLI)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 23.95pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">NA</span></p></td></tr><tr><td style="vertical-align:top;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">6/28/2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Tempest Therapeutics&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Millendo Therapeutics,&#160;Inc. (Nasdaq: MLND)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">19</span></p></td></tr><tr><td style="vertical-align:top;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">6/15/2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">ReShape Lifesciences&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Obalon Therapeutics,&#160;Inc. (Nasdaq: OBLN)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">15</span></p></td></tr><tr><td style="vertical-align:top;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">4/27/2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Leading BioSciences,&#160;Inc. (Palisade)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Seneca Biopharma,&#160;Inc. (Nasdaq: SNCA)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">30</span></p></td></tr><tr><td style="vertical-align:top;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">4/16/2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">MyMD Pharmaceuticals,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Akers Biosciences,&#160;Inc. (Nasdaq: AKER)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">5</span></p></td></tr><tr><td style="vertical-align:top;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">3/31/2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">StemoniX&#160;Inc. (Vyant Bio)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Cancer Genetics,&#160;Inc. (Nasdaq: CGIX)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">15</span></p></td></tr><tr><td style="vertical-align:top;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">3/16/2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">ChemomAb&#160;Ltd.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Anchiano Therapeutics&#160;Ltd. (Nasdaq: ANCN)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">15</span></p></td></tr><tr><td style="vertical-align:top;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">2/24/2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Viracta Therapeutics,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Sunesis Pharmaceuticals (Nasdaq: SNSS)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">16</span></p></td></tr><tr><td style="vertical-align:top;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">1/28/2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Quellis Biosciences,&#160;Inc. (Astria)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Catabasis Pharmaceuticals (Nasdaq: CATB)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">25</span></p></td></tr><tr><td style="vertical-align:top;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">12/22/2020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Yumanity Therapeutics&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Proteostasis Therapeutics (Nasdaq: PTI)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">34</span></p></td></tr><tr><td style="vertical-align:top;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">12/1/2020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Petros Pharmaceuticals,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Neurotrope,&#160;Inc. (NasdaqCM: NTRP)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">4</span></p></td></tr><tr><td style="vertical-align:top;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">11/23/2020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">F-star Therapeutics, Limited</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Spring Bank Pharmaceuticals,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">23</span></p></td></tr><tr><td style="vertical-align:top;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">11/5/2020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Ocuphire Pharma,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Rexahn Pharmaceuticals (Nasdaq: REXN)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">16</span></p></td></tr><tr><td style="vertical-align:top;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">10/27/2020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Viridian Therapeutics,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Miragen Therapeutics,&#160;Inc. (NasdaqCM: MGEN)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">15</span></p></td></tr><tr><td style="vertical-align:top;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">9/15/2020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Adicet Bio,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">resTORbio,&#160;Inc. (NasdaqGS: TORC)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">8</span></p></td></tr><tr><td style="vertical-align:top;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">9/14/2020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Anelixis Therapeutics (Eledon)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Novus Therapeutics,&#160;Inc. (NasdaqCM: NVUS)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">5</span></p></td></tr><tr><td style="vertical-align:top;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">7/6/2020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Kiq Bio (Cogent)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Unum Therapeutics,&#160;Inc. (NASDAQ: UMRX)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">17</span></p></td></tr><tr><td style="vertical-align:top;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">6/15/2020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Forte Biosciences,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Tocagen&#160;Inc. (NasdaqGS: TOCA)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">8</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:11.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:29.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:36.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Closed Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.36%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 52pt;"><b style="color:#231f20;font-weight:bold;">Surviving&#160;Company</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.96%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Public&#160;Company</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value&#160;Delivered&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">for&#160;Public&#160;Vehicle&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Net&#160;of&#160;Cash</b><b style="color:#231f20;font-weight:bold;">&#160;</b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">($&#160;mm&#8217;s)</b></p></td></tr><tr><td style="vertical-align:top;width:11.66%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">5/28/2020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;background:#cceeff;border-top:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Larimar Therapeutics,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;background:#cceeff;border-top:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Zafgen,&#160;Inc. (NasdaqGS: ZFGN)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;background:#cceeff;border-top:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">5</span></p></td></tr><tr><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">5/26/2020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Histogen,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Conatus Pharmaceuticals (Nasdaq: CNAT)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">23</span></p></td></tr><tr><td style="vertical-align:top;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">5/22/2020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Qualigen,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Ritter Pharmaceuticals (Nasdaq: RTTR)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 23.95pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">NA</span></p></td></tr><tr><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">5/18/2020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Timber Pharmaceuticals,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">BioPharmX Corporation (AMEX: BPMX)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">16</span></p></td></tr><tr><td style="vertical-align:top;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">4/1/2020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Curetis NV (Euronext: CURE)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">OpGen,&#160;Inc. (NasdaqCM: OPGN)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">7</span></p></td></tr><tr><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">1/9/2020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Protara Therapeutics,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Proteon Therapeutics,&#160;Inc. (NASDAQ: PRTO)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">5</span></p></td></tr><tr><td style="vertical-align:top;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">12/30/2019</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">NeuroBo Pharmaceuticals,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Gemphire Therapeutics&#160;Inc. (NASDAQ: GEMP)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">8</span></p></td></tr><tr><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">11/7/2019</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Venus Concept&#160;Ltd.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Restoration Robotics,&#160;Inc. (NASDAQ: HAIR)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">20</span></p></td></tr><tr><td style="vertical-align:top;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">9/27/2019</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Ocugen,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Histogenics Corporation (NASDAQ: HSGX)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 23.95pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">NA</span></p></td></tr><tr><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">8/31/2019</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Brickell Biotech,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Vical Incorporated (NASDAQ: VICL)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">4</span></p></td></tr><tr><td style="vertical-align:top;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">7/31/2019</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">ESSA Pharma (NASDAQ: EPIX)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Realm Therapeutics plc (NASDAQ: RLM)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">1</span></p></td></tr><tr><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">7/22/2019</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Salarius Pharmaceuticals, LLC</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Flex Pharma,&#160;Inc. (NASDAQ: FLKS)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">4</span></p></td></tr><tr><td style="vertical-align:top;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">7/15/2019</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">NeuBase Therapeutics</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Ohr Pharmaceutical (NASDAQ: OHRP)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">7</span></p></td></tr><tr><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">6/10/2019</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Oncternal Therapeutics,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">GTx,&#160;Inc. (NASDAQ: GTXI)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">9</span></p></td></tr><tr><td style="vertical-align:top;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">6/9/2019</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Edesa Biotech&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Stellar Biotechnologies,&#160;Inc. (NASDAQ: SBOT)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">2</span></p></td></tr><tr><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">5/9/2019</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Armata Pharmaceuticals (f.k.a. C3J)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Ampliphi Biosciences (NYSE: APHB)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">10</span></p></td></tr><tr><td style="vertical-align:top;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">5/6/2019</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Adynxx,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Alliqua BioMedical,&#160;Inc. (NASDAQ: ALQA)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">3</span></p></td></tr><tr><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">4/23/2019</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Mereo BioPharma (AIM: MPH)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Oncomed Pharmaceuticals (NASDAQ: OMED)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">20</span></p></td></tr><tr><td style="vertical-align:top;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">4/12/2019</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Immunic AG</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Vital Therapies,&#160;Inc. (NASDAQ: VTL)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">10</span></p></td></tr><tr><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">3/26/2019</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Enlivex Therapeutics&#160;Ltd.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Bioblast Pharma&#160;Ltd. (NASDAQ: ORPN)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">5</span></p></td></tr><tr><td style="vertical-align:top;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">3/18/2019</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">PDS Biotechnology Corporation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Edge Therapeutics,&#160;Inc. (NASDAQ: EDGE)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">5</span></p></td></tr><tr><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">3/13/2019</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">X4 Pharmaceuticals,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Arsanis,&#160;Inc. (NASDAQ: ASNS)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">29</span></p></td></tr><tr><td style="vertical-align:top;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">1/24/2019</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Seelos Therapeutics,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Apricus Biosciences,&#160;Inc. (NASDAQ: APRI)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">8</span></p></td></tr><tr><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">12/7/2018</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Millendo Therapeutics,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">OvaScience,&#160;Inc. (NASDAQ: OVAS)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">5</span></p></td></tr><tr><td style="vertical-align:top;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">10/12/2018</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Aravive Biologics,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Versartis,&#160;Inc. (NASDAQ: VSAR)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">0</span></p></td></tr><tr><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">2/13/2018</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Vaxart,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Aviragen Therapeutics,&#160;Inc. (NASDAQ: AVIR)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">44</span></p></td></tr><tr><td style="vertical-align:top;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">1/30/2018</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Innovate Biopharmaceuticals,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Monster Digital,&#160;Inc. (NASDAQ: MSDI)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">6</span></p></td></tr><tr><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">1/17/2018</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Evofem Biosciences,&#160;Inc.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Neothetics,&#160;Inc. (NASDAQ: NEOT)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.65pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">29</span></p></td></tr><tr><td style="vertical-align:top;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">1/4/2018</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:29.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Rocket Pharmaceuticals, Ltd</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:36.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Inotek Pharmaceuticals Corp (NASDAQ: ITEK)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">5</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lucid reviewed the value delivered for the public vehicle (net of cash) from the Selected Precedent Reverse Merger Transactions, which ranged from $0.0 million to $44.0 million. Lucid derived the median for the value delivered for the public vehicle (net of cash) to be $10.0 million. The 25<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>&#160;percentile and the 75<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th&#160;</sup>percentile for the value delivered for the public vehicle (net of cash) was $6.0 million and $16.0 million respectively. This compares to the Aerovate Valuation as per the Merger Agreement of $8 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The summary set forth above does not purport to be a complete description of all the analyses performed by Lucid. The preparation of a fairness opinion involves various determinations as to the most appropriate and relevant methods of financial analysis and the application of these methods to the particular circumstances. Therefore, such an opinion is not readily susceptible to partial analysis or summary description. Lucid did not attribute any particular weight to any analysis or factor considered by it, but rather made qualitative judgments as to the significance and relevance of each analysis and factor. Accordingly, notwithstanding the separate factors summarized above, Lucid believes, and advised Aerovate&#8217;s board of directors, that its analyses must be considered as a whole. Selecting portions of its analyses and the factors considered by it without considering all analyses and factors could create an incomplete view of the process underlying the Lucid Opinion. In performing its analyses, Lucid made numerous assumptions with respect to industry performance, business and economic conditions and other matters, many of which are beyond the control of Aerovate and Jade. These analyses performed by Lucid are not necessarily indicative of actual values or future results, which may be significantly more or less favorable than suggested by such analyses. In addition, analyses relating to the value of businesses do not purport to be appraisals or to reflect the prices at which businesses or securities may actually be sold. Accordingly, such analyses and estimates are inherently subject to uncertainty, being based upon numerous factors or events beyond the control of the parties or their respective advisors. None of Aerovate, Jade, Lucid or any other person assumes responsibility if future results are materially different from those projected. The analyses supplied by Lucid and the Lucid Opinion were among several factors taken into consideration by Aerovate&#8217;s board of directors in making its decision to enter into the Merger Agreement and should not be considered as determinative of such a decision.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lucid was selected by Aerovate&#8217;s board of directors to render an opinion to Aerovate&#8217;s board of directors because Lucid is a nationally recognized investment banking firm and as part of its investment banking business, Lucid is continually engaged in the valuation of businesses and their securities in connection with mergers, negotiated underwritings, secondary distributions of listed and unlisted securities, private placements and valuations for corporate and other purposes. In addition, in the ordinary course of its business, Lucid and its affiliates may trade the equity securities of Aerovate for its own account and for the accounts of their customers, and, accordingly, may at any time hold a long or short position in such securities. In the two&#160;years preceding the date hereof, Lucid has not received any fees from Aerovate. In the two&#160;years preceding the date hereof, Lucid has not had a relationship with Jade and has not received any fees from Jade. Lucid and its affiliates may in the future seek to provide investment banking or financial advisory services to Aerovate and Jade and/or certain of their respective affiliates and expect to receive fees for the rendering of these services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Engagement Letter between Lucid and Aerovate, Lucid received a fee for the Lucid Opinion of $500,000 upon delivery of the Lucid Opinion. Additionally, Aerovate has agreed to reimburse Lucid for its out-of-pocket expenses and has agreed to indemnify Lucid against certain liabilities, including liabilities under the federal securities laws. The terms of the fee arrangement with Lucid, which are customary in transactions of this nature, were negotiated at arm&#8217;s length between Aerovate and Lucid, and Aerovate&#8217;s board of directors was aware of the arrangement.</p><a id="TheMerger_AerovateAndExecutive"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Interests of Aerovate Directors and Executive Officers in the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In considering the recommendation of the Aerovate board of directors with respect to approving the Merger, stockholders should be aware that Aerovate&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of Aerovate stockholders generally. These interests may present them with actual or perceived conflicts of interest, and these interests, to the extent material, are described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The board of directors of Aerovate was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Aerovate stockholders approve the Merger as contemplated by this proxy statement/ prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Treatment of Aerovate Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Merger Agreement, each Aerovate ITM Option will vest in full upon the Closing and, once vested, the holder of such Aerovate ITM Option will be entitled to receive (i)&#160;an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (A)&#160;the excess of the Aerovate Closing Price over the exercise price per share of Aerovate common stock underlying such option by (B)&#160;the number of shares of Aerovate common stock underlying such option. All outstanding Aerovate OTM Options will be cancelled for no consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The table below sets forth information regarding the Aerovate ITM Options and Aerovate OTM Options held as of November&#160;15, 2024, before giving effect to any vesting acceleration provided for in the applicable option award agreement or the Merger Agreement, by each of the individuals who are or were an executive officer or non-employee directors of Aerovate since the beginning of Aerovate&#8217;s last fiscal&#160;year. The number of shares of Aerovate common stock underlying such options will be adjusted appropriately to reflect the proposed reverse stock split and Cash Dividend.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:29.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Aerovate</b><b style="color:#231f20;font-weight:bold;">&#160;</b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="font-weight:bold;">ITM&#160;Options&#160;Held</b><b style="color:#231f20;font-weight:bold;">&#160;(#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Exercise&#160;Price&#160;of&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Aerovate&#160;ITM&#160;Options</b><b style="color:#231f20;font-weight:bold;">&#160;($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Aerovate</b><b style="color:#231f20;font-weight:bold;">&#160;</b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="font-weight:bold;">OTM&#160;Options&#160;Held</b><b style="color:#231f20;font-weight:bold;">&#160;(#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Exercise&#160;Price&#160;of&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Aerovate&#160;OTM&#160;Options</b><b style="color:#231f20;font-weight:bold;">&#160;($)</b></p></td></tr><tr><td style="vertical-align:top;width:29.74%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Executive Officers</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;border-top:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;"><span style="color:#231f20;">Timothy P. Noyes </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">597,634</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">2.14</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">814,768</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.85pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">15.70</span></p></td></tr><tr><td style="vertical-align:top;width:29.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;">Benjamin Dake, PhD<span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">182,434</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.85pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">15.68</p></td></tr><tr><td style="vertical-align:top;width:29.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;"><span style="color:#231f20;">George Eldridge</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">44,531</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">2.14</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">293,919</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.85pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">17.95</p></td></tr><tr><td style="vertical-align:top;width:29.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;">Hunter Gillies, MBChB </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">74,949</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2.12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">125,610</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.85pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">15.55</p></td></tr><tr><td style="vertical-align:top;width:29.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;">Ralph Niven, PhD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.85pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:29.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;">Timothy J. Pigot </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.85pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td></tr><tr><td style="vertical-align:top;width:29.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;">Marinus Verwijs, Ph.D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.85pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Aerovate</b><b style="color:#231f20;font-weight:bold;">&#160;</b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="font-weight:bold;">ITM&#160;Options&#160;Held</b><b style="color:#231f20;font-weight:bold;">&#160;</b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">(#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Exercise&#160;Price&#160;of&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Aerovate&#160;ITM&#160;Options</b><b style="color:#231f20;font-weight:bold;">&#160;</b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Aerovate</b><b style="color:#231f20;font-weight:bold;">&#160;</b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="font-weight:bold;">OTM&#160;Options&#160;Held</b><b style="color:#231f20;font-weight:bold;">&#160;</b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">(#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Exercise&#160;Price&#160;of&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Aerovate&#160;OTM&#160;Options</b><b style="color:#231f20;font-weight:bold;">&#160;</b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">($)</b></p></td></tr><tr><td style="vertical-align:top;width:30%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-Employee Directors</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;border-top:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;">Habib J. Dable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">41,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.85pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">18.78</p></td></tr><tr><td style="vertical-align:top;width:30%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;">Allison Dorval</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">62,500</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.85pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">15.42</p></td></tr><tr><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;">David Grayzel, M.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">77,810</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.85pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">15.50</p></td></tr><tr><td style="vertical-align:top;width:30%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;">Mark Iwicki</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">116,297</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">79,700</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.85pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">14.86</p></td></tr><tr><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;">Joshua Resnick, M.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">62,500</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.85pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">15.09</p></td></tr><tr><td style="vertical-align:top;width:30%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;">Donald Santel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">52,889</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.85pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">20.59</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Treatment of Aerovate RSUs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Merger Agreement, each outstanding and unvested Aerovate RSU will accelerate in full effective as of immediately prior to the effective time and each outstanding and unsettled Aerovate RSU shall be settled in a number of shares of Aerovate common stock equal to the number of vested and unsettled shares of Aerovate common stock underlying such Aerovate RSUs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No executive officer or non-employee director of Aerovate held unvested Aerovate RSUs as of November&#160;15, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Executive Employment and Retention Arrangements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Employment Agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate is party to an employment agreement with Mr.&#160;Noyes, pursuant to which he is eligible to receive the following severance payments and benefits in the event of a termination without Cause or resignation for Good Reason (each, as defined in Mr.&#160;Noyes&#8217; employment agreement) one&#160;month prior to or within 12&#160;months following a change in control (a &#8220;Qualifying Termination&#8221;), subject to the execution and nonrevocation of a release in favor of Aerovate: (i)&#160;18&#160;months of base salary and 1.5x the target annual bonus for the&#160;year of termination, payable in lump sum, (ii)&#160;18&#160;months of continued Company-paid COBRA continuation benefits, and (iii)&#160;full accelerated vesting of all equity awards subject to time-based vesting conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate is also party to an employment agreement with Mr.&#160;Eldridge, entered into in June&#160;2021 in connection with his employment as Aerovate&#8217;s Chief Financial Officer, pursuant to which he is eligible to receive the following severance payments and benefits in the event of a Qualifying Termination, subject to the execution and nonrevocation of a release in favor of Aerovate: (i)&#160;12&#160;months of base salary and the target annual bonus for the&#160;year of termination, payable in lump sum, (ii)&#160;12&#160;months of continued Company-paid COBRA continuation benefits, and (iii)&#160;full accelerated vesting of all equity awards subject to time-based vesting conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the employment agreements, if any payments would be subject to the excise tax imposed by Section&#160;4999 of the Code, then such payments shall be reduced to avoid the imposition of such excise tax, provided, however, that such reduction shall only occur if the executive&#8217;s reduced payments, in the aggregate, are greater than the aggregate payments to be received by the executive absent such reduction but with the imposition of the excise tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash Dividend</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the First Effective Time, Aerovate expects to declare the Cash Dividend to the Aerovate stockholders as of a record date prior to the First Effective Time equal in the aggregate to Aerovate&#8217;s reasonable, good faith approximation of the amount by which Aerovate&#8217;s Net Cash will exceed $0, and any of Aerovate&#8217;s directors and executive officers that are also Aerovate stockholders will share in any such Cash Dividend proportionally to their ownership of Aerovate common stock as of that record date (please see the section titled &#8220;<i style="font-style:italic;">Principal Stockholders of Aerovate</i>&#8221; beginning on page&#160;330 of this proxy statement/prospectus for additional information regarding Aerovate&#8217;s directors&#8217; and officers&#8217; holdings of Aerovate common stock; notably, as of November&#160;15, 2024, entities affiliated with RA Capital Management,&#160;L.P. together hold 9,242,092 shares of Aerovate common stock, representing approximately 32% of outstanding shares of Aerovate common stock).</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Limitations of Liability and Indemnification</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition to the indemnification obligations required by the amended and restated certificate of incorporation and the amended and restated by-laws of Aerovate, Aerovate has entered into indemnification agreements with each of its directors and officers. These agreements provide for the indemnification of Aerovate&#8217;s directors and executive officers and, at times, their affiliates to the fullest extent permitted by Delaware law. Aerovate will advance expenses, including attorney&#8217;s fees, incurred in connection with any action or proceeding brought against Aerovate&#8217;s directors and executive officers arising from that person&#8217;s services as a director or officer brought on behalf of Aerovate or in furtherance of Aerovate&#8217;s rights, and certain of Aerovate&#8217;s directors or officers may have certain rights to advancement of expenses or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director&#8217;s or executive officer&#8217;s services to Aerovate. Aerovate believes that these restated certificate of incorporation provisions, amended and restated by-laws provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers.</p><a id="TheMerger_Jade_DirectorExecutive"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Interests of Jade Directors and Executive Officers in the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In considering the recommendation of Jade&#8217;s board of directors with respect to approving the Merger, stockholders should be aware that Jade&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of Jade stockholders generally. These interests may present them with actual or potential conflicts of interest, and these interests, to the extent material, are described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Jade&#8217;s board of directors was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Jade stockholders approve the Merger as contemplated by this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Ownership Interests</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of November&#160;15, 2024, Jade&#8217;s current non-employee directors and executive officers beneficially owned, in the aggregate, approximately 80.1% of the shares of Jade capital stock, which for purposes of this subsection excludes any Jade shares issuable upon exercise or settlement of Jade options held by such individual. Each of Jade&#8217;s officers, directors and affiliated stockholders have also entered into a support agreement in connection with the Merger. For a more detailed discussion of the support agreements, please see the section titled &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#160;&#8212; Support Agreements</i>&#8221; beginning on page&#160;153 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Fairmount Fund II, an affiliate of Tomas Kiselak and Chris Cain, directors of Jade, Lawrence Klein, a director of Jade, and Andrew King, Chief Scientific Officer&#160;&amp; Head of Research and Development of Jade, also currently hold shares of Jade capital stock. The table below sets forth the ownership of Jade capital stock by Fairmount Fund II, Lawrence Klein and Andrew King as of November&#160;15, 2024. Fairmount Fund II also holds a Convertible Note&#160;and has agreed to purchase shares and pre-funded warrants in the Jade Pre- Closing Financing. For a more detailed discussion of these relationships, please see the section titled &#8220;<i style="font-style:italic;">Certain Relationships and Related Party Transactions of the Combined Company&#160;&#8212; Jade Transactions</i>&#8221; beginning on page&#160;300 of this proxy statement/prospectus.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Stockholder</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Shares&#160;of&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Capital&#160;Stock&#160;held</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.01%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Fairmount Healthcare Fund II L.P.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">20,000,000<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:79.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Lawrence Klein</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">136,612<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:79.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Andrew King, BVMS, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">546,448<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(1)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">Consists of 20,000,000 shares of Jade common stock issuable upon conversion of 20,000,000 shares of Jade Preferred Stock held directly by Fairmount Fund II. Fairmount Funds Management LLC (&#8220;Fairmount&#8221;) serves as the investment manager for Fairmount Fund II. Fairmount Fund II has delegated to Fairmount the sole power to vote and the sole power to dispose of all securities held in Fairmount Fund II&#8217;s portfolio. The general partner of Fairmount is Fairmount Funds Management GP LLC (&#8220;Fairmount GP&#8221;). As a managing member of Fairmount GP, Tomas Kiselak may be deemed to have voting and investment power over the shares held by Fairmount Fund II. Fairmount, Fairmount GP, and Mr. Kiselak disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(2)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">Consists of 136,612 shares of Jade common stock held by Lawrence Klein. Such shares were purchased by Dr.&#160;Klein, in anticipation of his service as a director of Jade, at the fair market value on the purchase date. The purchased shares are subject to vesting as to 25% on July&#160;23, 2025 and in equal&#160;monthly installments for the 36&#160;months thereafter.</span></p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(3)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">Consists of 546,448 shares of Jade common stock held by Andrew King. Such shares were purchased by Dr.&#160;King, in anticipation of his service as Jade&#8217;s Chief Scientific Officer&#160;&amp; Head of Research and Development, at the fair market value on the purchase date. The purchased shares are subject to vesting as to 25% on August&#160;1, 2025 and in equal&#160;monthly installments for the 36&#160;months thereafter.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Frohlich and King Anti-Dilution Provisions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the offer letter agreements between Jade and each of Mr.&#160;Frohlich and Dr.&#160;King, Jade is obligated to issue additional options to purchase shares of Jade common stock in order to maintain (i) <span style="color:#231f20;">Mr.&#160;Frohlich&#8217;s ownership in Jade at approximately 5% on a fully-diluted basis, and (ii)&#160;Dr.&#160;King&#8217;s ownership in Jade at approximately 2% on a fully-diluted basis, in each case, until Jade has raised an aggregate of </span>$200 million in financing. As a result, Jade expects to issue Mr.&#160;Frohlich and Dr.&#160;King options to purchase shares of Jade common stock in full satisfaction of such obligations to maintain their ownership in Jade at the applicable ownership&#160;percentage, up to the applicable financing limit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the Merger, each outstanding and unexercised option to purchase shares of Jade common stock will be converted into an option to purchase shares of Aerovate&#8217;s common stock, with necessary adjustments to reflect the Exchange Ratio. Aerovate will assume Jade&#8217;s Amended and Restated 2024 Equity Incentive Plan and each such outstanding option to purchase shares of Jade common stock in accordance with the terms (as in effect as of the date of the Merger Agreement) of Jade&#8217;s Amended and Restated 2024 Equity Incentive Plan and the terms of the stock option agreement by which such option to purchase shares of Jade common stock is evidenced. In connection with the Merger, Aerovate will change its corporate name to &#8220;Jade Biosciences,&#160;Inc.&#8221; and all Jade options it assumed in the Merger will be options to purchase Combined Company common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The table below sets forth information regarding the Jade stock options held as of November&#160;15, 2024 by each of Jade&#8217;s current executive officers and non-employee directors. The number of shares of common stock underlying such options and the exercise price will be adjusted appropriately to reflect the Exchange Ratio.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Vested&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Options&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Held&#160;(#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Exercise&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Price&#160;of&#160;Vested&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Options&#160;($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Unvested&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Options&#160;Held&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Average&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Exercise&#160;Price&#160;of&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Unvested&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Options&#160;($)</b></p></td></tr><tr><td style="vertical-align:top;width:45.99%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Executive Officers</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Tom Frohlich</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">1,475,410</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.96</p></td></tr><tr><td style="vertical-align:top;width:45.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Jonathan Quick </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">132,786</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">0.96</span></p></td></tr><tr><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Andrew King, BVMS, Ph.D.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">1,821</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">0.31</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">335,666</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">1.32</span></p></td></tr><tr><td style="vertical-align:top;width:45.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Hetal Kocinsky, M.D.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">295,081</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">0.96</span></p></td></tr><tr><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Elizabeth Balta, J.D.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">221,311</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.46</p></td></tr><tr><td style="vertical-align:top;width:45.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Non-Employee Directors</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Eric Dobmeier</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">147,541</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">1.46</span></p></td></tr><tr><td style="vertical-align:top;width:45.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Tomas Kiselak</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td></tr><tr><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Chris Cain</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td></tr><tr><td style="vertical-align:top;width:45.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Lawrence Klein </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td></tr><tr><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Erin Lavelle</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">73,770</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.96</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Management Following the Merger</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As described in the section captioned &#8220;<i style="font-style:italic;">Management Following the Merger</i>&#8221; beginning on page&#160;294 of this proxy statement/prospectus, all of Jade&#8217;s directors and executive officers are expected to become the directors and executive officers of the Combined Company upon the Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Limitations of Liability, Indemnification and Insurance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition to the indemnification obligations required by the certificate of incorporation and bylaws of Jade, Jade has entered into indemnification agreements with each of its directors and officers. These agreements provide for the indemnification of Jade&#8217;s directors and executive officers for reasonable expenses and liabilities incurred in connection with any action or proceeding brought against them by reason of the fact that they are or were agents of Jade. Jade believes that the certificate of incorporation provisions, bylaws provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For a discussion of the indemnification and insurance provisions related to the Jade directors and officers under the Merger Agreement, please see the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#160;&#8212; Indemnification and Insurance for Directors and Officers</i>&#8221; beginning on page&#160;148 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Form&#160;of the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Subject to the terms and conditions of the Merger Agreement, and in accordance with the DGCL, (i) <span style="color:#231f20;">at the First Effective Time, Merger Sub I will merge with and into Jade, with Jade continuing as a wholly </span>owned subsidiary of Aerovate and the surviving corporation of the First Merger and (ii)&#160;as part of the same overall transaction at the completion of the Second Merger, Jade will merge with and into Merger Sub II, with Merger Sub II being the surviving entity of the Second Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Merger Consideration and Adjustment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, (i)&#160;each then-outstanding share of Jade common stock (including shares of Jade common stock issued in the Jade Pre-Closing Financing) (excluding shares to be cancelled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of Aerovate common stock equal to the Exchange Ratio (described in more detail in the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#160;&#8212; Exchange Ratio</i>&#8221; beginning on page&#160;138 of this proxy statement/ prospectus), (ii)&#160;each then-outstanding share of Jade Preferred Stock (excluding shares to be cancelled pursuant to the Merger Agreement and excluding dissenting shares) will be converted into the right to receive a number of shares of Aerovate Series&#160;A Preferred Stock, which are each convertible into 1,000 shares of Aerovate common stock, equal to the Exchange Ratio divided by 1,000, in accordance with the terms of the Merger Agreement, (iii)&#160;each then-outstanding option to purchase Jade common stock will be assumed by Aerovate, subject to adjustment based on the Exchange Ratio as set forth in the Merger Agreement, and <span style="color:#231f20;">(iv)&#160;each then-outstanding pre-funded warrant to purchase shares of Jade common stock will be converted into a pre-funded warrant to purchase shares of Aerovate common stock, subject to adjustment based on the Exchange Ratio as set forth in the Merger Agreement and the form of pre-funded warrant.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">No fractional shares of Aerovate common stock or Aerovate Series&#160;A Preferred Stock shall be issued in connection with the Merger, and no certificates or scrip for any such fractional shares shall be issued. Each holder of shares of Jade common stock or Jade Preferred Stock converted pursuant to the Merger who would otherwise have been entitled to receive a fraction of a share of Aerovate common stock or Aerovate Series&#160;A Preferred Stock (after taking into account all certificates delivered by such holder and the aggregate number of shares of Aerovate common stock or Aerovate preferred stock represented thereby) will receive, in lieu thereof, cash (without interest and subject to applicable tax withholding) in an amount equal to such fractional part of a share of Aerovate common stock or Series&#160;A Preferred Stock multiplied by the last reported sale price of Aerovate common stock at 4:00&#160;p.m. (New York City time), end of regular trading hours on Nasdaq on the last trading day prior to the effective time of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Determination of Aerovate&#8217;s Net Cash</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the terms of the Merger Agreement, Aerovate&#8217;s &#8220;Net Cash&#8221; means, as of the close of business on the Closing Date (the &#8220;Net Cash Determination Time&#8221;), the sum (without duplication) of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aerovate&#8217;s unrestricted cash, cash equivalents and short-term investments determined; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Certain Aerovate prepaid expenses, deposits, restricted cash and short-term receivables set forth in Aerovate&#8217;s disclosure letter, to the extent capable of use by the Combined Company after the Closing.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">minus</i> the sum (without duplication) of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aerovate&#8217;s short-term and long-term liabilities, including all accounts payable, indebtedness, lease termination costs, all actual and reasonably projected costs and expenses relating to the winding down of the Aerovate&#8217;s legacy business and any related prepayment penalties and premiums, and any unpaid transaction expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any and all change in control payments, severance payments and any payroll or similar taxes owed in connection with the foregoing or any of Aerovate&#8217;s equity plans, in each case to the extent payable to Aerovate&#8217;s employees solely as a result of the consummation of the transactions under the Merger Agreement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Cash Dividend.</span></td></tr></table><div style="margin-top:10pt;"></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">No less than ten business&#160;days prior to the anticipated Closing Date, (i)&#160;Aerovate will deliver to Jade a net cash schedule setting forth, in reasonable detail, Aerovate&#8217;s good faith estimated calculation of its Net Cash as of the close of business on the anticipated Closing Date, prepared and certified by Aerovate&#8217;s chief financial officer (or if there is no chief financial officer, the principal financial and accounting officer), as the case may be, and, if requested, the relevant work papers and back-up materials used or useful in preparing the net cash schedule. No later than five business&#160;days after delivery of such net cash schedule (the last day of such period referred to as the response date), Jade will have the right to dispute any part of the net cash schedule by delivering a written notice to that effect to Aerovate (referred to herein as a &#8220;dispute notice&#8221;). Any dispute notice will identify, in reasonable detail and, to the extent known, the nature and amounts of any proposed revisions to Aerovate&#8217;s Net Cash calculation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If Jade disputes the net cash schedule, the parties shall attempt in good faith to resolve the disputed items and negotiate an agreed-upon determination of Net Cash. If the parties are unable to negotiate an agreed-upon determination of the disputed items or component thereof within three&#160;days after the delivery of the dispute notice, any remaining disagreements will be referred to an independent auditor of recognized national standing mutually agreed upon by Aerovate and Jade. The determination of the amount of Net Cash made by such auditor shall be final and binding on Aerovate and Jade.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Aerovate&#8217;s Net Cash balance is subject to numerous factors, some of which are outside of Aerovate&#8217;s control. The actual amount of Net Cash will depend significantly on the timing of the Closing. In addition, the Closing could be delayed if Aerovate and Jade are not able to agree upon the amount of Aerovate&#8217;s Net Cash as of the Net Cash Determination Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Procedures for Exchanging Company Stock Certificates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On or prior to the Closing Date, Aerovate will select an exchange agent and, immediately prior to the First Effective Time, Aerovate will deposit with the exchange agent evidence of book-entry shares representing the shares of Aerovate common stock issuable pursuant to the terms of the Merger Agreement in exchange for shares of Jade common stock (including shares of Jade common stock issued in the Jade Pre-Closing Financing) (excluding shares to be cancelled pursuant to the Merger Agreement and excluding dissenting shares) and the shares of Aerovate Series&#160;A Preferred Stock issuable pursuant to the terms of the Merger Agreement in exchange for shares of Jade Preferred Stock calculated in accordance with the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As soon as reasonably practicable after the First Effective Time and in any event not later than the tenth (10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>) business day prior to the anticipated Closing Date, Aerovate and Jade shall cause the exchange agent to mail to each record holder of Jade common stock (including shares of Jade common stock issued in the Jade Pre-Closing Financing) (excluding shares to be cancelled pursuant to the Merger Agreement and excluding dissenting shares) and each record holder of Jade Preferred Stock who will receive Aerovate Series&#160;A Preferred Stock issuable in exchange for such Jade Preferred Stock pursuant to the terms, and calculated in accordance with, the Merger Agreement (i)&#160;a letter of transmittal and (ii)&#160;instructions for surrendering the record holder&#8217;s stock certificates and identifying the record holder&#8217;s book-entry shares in exchange for the Merger consideration. Upon delivery to the exchange agent of a duly executed letter of transmittal in accordance with the exchange agent&#8217;s instructions, the surrender of the record holder&#8217;s stock certificates and identification of book-entry shares, if applicable, and delivery to the exchange agent of such other documents as may be reasonably required by the exchange agent, the record holder of such stock certificates or book-entry shares, as applicable, will be entitled to receive in exchange therefor book-entry shares (unless a physical certificate is requested) representing the number of whole shares of Aerovate common stock or Aerovate Series&#160;A Preferred Stock issuable to such holder pursuant to the Merger Agreement and any dividends or other distributions payable pursuant to the Merger Agreement. The surrendered certificates representing shares of Jade common stock or Jade Preferred Stock will be canceled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">After the First Effective Time, each certificate or book-entry share representing Jade common stock or Jade Preferred Stock that has not been surrendered will represent only the right to receive the Merger consideration payable in respect thereof pursuant to the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">HOLDERS OF JADE COMMON STOCK OR JADE PREFERRED STOCK SHOULD NOT SEND IN THEIR JADE STOCK CERTIFICATES UNTIL THEY RECEIVE A LETTER OF TRANSMITTAL FROM THE EXCHANGE AGENT WITH INSTRUCTIONS FOR THE SURRENDER OF JADE STOCK CERTIFICATES.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Effective Time of the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Merger Agreement requires the parties to consummate the Merger as promptly as practicable (and in any event within two business&#160;days) after all of the conditions to the consummation of the Merger contained in the Merger Agreement are satisfied or waived, including the adoption of the Merger Agreement by the Jade stockholders and the approval by the Aerovate stockholders of the issuance of Aerovate common stock, including shares of Aerovate common stock issuable upon conversion of the Aerovate </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Series&#160;A Preferred Stock, and the other transactions proposed under the Merger Agreement, other than those conditions that by their nature are to be satisfied at the Closing. The First Merger will become effective upon the filing of a certificate of Merger (the &#8220;First Certificate of Merger&#8221;), with the Secretary of State of the State of Delaware or at such later time as is agreed by Aerovate and Jade and specified in the First Certificate of Merger. The Second Merger will become effective upon the filing of a certificate of Merger (the &#8220;Second Certificate of Merger&#8221;), with the Secretary of State of the State of Delaware or at such later time as is agreed by Aerovate and Jade and specified in the Second Certificate of Merger. Neither Aerovate nor Jade can predict the exact timing of the consummation of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Regulatory Approvals</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, Aerovate must comply with applicable federal and state securities laws and the rules&#160;and regulations of Nasdaq in connection with the issuance of shares of Aerovate common stock, including shares of Aerovate common stock issuable upon conversion of Aerovate Series&#160;A Preferred Stock, to Jade&#8217;s stockholders in connection with the transactions contemplated by the Merger Agreement and the filing of this proxy statement/prospectus with the SEC. Aerovate and Jade do not intend to seek any regulatory approval from antitrust authorities to consummate the transactions.</p><a id="TheMerger_USFederal_Merger"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">U.S. Federal Income Tax Considerations of the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following discussion is a summary of U.S. federal income tax considerations to U.S. Holders (as defined below) of Jade common stock or Jade Preferred Stock (collectively, &#8220;Jade stock&#8221;) of the Merger. The discussion does not purport to be a complete analysis of all potential tax considerations. The considerations of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or non-U.S. tax laws, are not discussed. This discussion is based on the Code, Treasury Regulations promulgated under the Code, judicial decisions and published rulings and administrative pronouncements of the IRS, in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a U.S. Holder. Jade has not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax considerations of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This discussion is limited to a U.S. Holder that holds Jade stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax considerations relevant to a U.S. Holder&#8217;s particular circumstances, including, without limitation. the effect of the Medicare contribution tax on net investment income, the alternative minimum tax, or the special tax accounting rules&#160;under Section&#160;451(b)&#160;of the Code. In addition, it does not address considerations relevant to U.S. Holders subject to special rules, such as:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. expatriates and former citizens or long-term residents of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. Holders whose functional currency is not the U.S. dollar;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons holding Jade stock as part of a hedge, straddle or other risk-reduction strategy or as part of a conversion transaction or other integrated investment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">banks, insurance companies and other financial institutions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">real estate investment trusts or regulated investment companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">brokers, dealers or traders in securities or other persons that elect to use a mark-to-market method of accounting for their holdings in Jade stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">partnerships or other entities or arrangements classified as partnerships, passthroughs, or disregarded entities for U.S. federal income tax purposes (and investors therein), S corporations or other passthrough entities (including hybrid entities);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax-exempt organizations or governmental organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons deemed to sell Jade stock under the constructive sale provisions of the Code;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons who hold or receive Jade stock pursuant to the exercise of any employee stock option or otherwise as compensation;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax-qualified retirement plans; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons that own, or have owned, actually or constructively, more than 5% of Jade stock;</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If an entity or arrangement classified as a partnership for U.S. federal income tax purposes holds Jade stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership, and certain determinations made at the partner level. Accordingly, a partnership holding Jade stock and each partner in such partnership is urged to consult its tax advisor regarding the U.S. federal income tax considerations to it of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">This discussion is for informational purposes only and is not tax advice. Each prospective investor is urged to consult its tax advisor with respect to the application of the U.S. federal income tax laws to its particular situation as well as any tax considerations of the Merger arising under U.S. federal estate or gift tax laws, the laws of any state, local or non-U.S. taxing jurisdiction or any applicable income tax treaty.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purpose of this discussion, a &#8220;U.S. Holder&#8221; is any beneficial owner of Jade stock that, for U.S. federal income tax purposes, is or is treated as any of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an individual who is a citizen or resident of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a corporation created or organized under the laws of the United States, any state thereof or the District of Columbia;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a trust that: (i)&#160;is subject to the primary supervision of a U.S. court and the control of one or more &#8220;United States persons&#8221; (within the meaning of Section&#160;7701(a)(30) of the Code); or (ii)&#160;has a valid election in effect to be treated as a U.S. person for U.S. federal income tax purposes.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each of Jade and Aerovate intends that the Merger qualifies as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Code. Assuming the Merger so qualifies, a U.S. Holder will not recognize gain or loss upon the exchange of its Jade stock for Aerovate common stock or Aerovate Series&#160;A Preferred Stock (collectively, &#8220;Aerovate stock&#8221;). A U.S. Holder will have the same aggregate basis in its Aerovate stock after the Merger as such U.S. Holder had in the corresponding Jade stock immediately prior to the Merger. A U.S. Holder&#8217;s holding period in the Aerovate stock immediately following the Merger will include such U.S. Holder&#8217;s holding period in the corresponding Jade stock immediately prior to the Merger. If a U.S. Holder holds different blocks of Jade stock (generally, Jade stock acquired on different dates or at different prices), such U.S. Holder is urged to consult its tax advisor with respect to the determination of the tax bases and/or holding periods of the shares of Aerovate stock received in the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each U.S. Holder is urged to consult its tax advisor regarding the U.S. federal income tax considerations of the Merger in light of its personal circumstances and the considerations to them under state, local and non-U.S. tax laws and other federal tax laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Information Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each U.S. Holder who receives Aerovate stock in the Merger is required to retain permanent records pertaining to the Merger and make such records available to any authorized IRS officers and employees. Such records should specifically include information regarding the amount, basis, and fair market value of all transferred property, and relevant facts regarding any liabilities assumed or extinguished as part of such reorganization. Each U.S. Holder who owned immediately before the Merger at least one&#160;percent (by vote or value) of the total outstanding stock of Jade is required to attach a statement to its tax return for the&#160;year in which the Merger is consummated that contains the information listed in Treasury Regulation Section&#160;1.368-3(b). Such statement must include the U.S. Holder&#8217;s tax basis in such U.S. Holder&#8217;s Jade stock surrendered in the Merger, the fair market value of such Jade stock, the date of the Merger, and the name and employer identification number of each of Jade and Aerovate. Each U.S. Holder is urged to consult with its tax advisor to comply with these rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">131</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="TheMerger_USFederal_CashDividend"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">U.S. Federal Income Tax Considerations of the Cash Dividend</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following discussion is a summary of U.S. federal income tax considerations to a U.S. Holder (as defined below) of Aerovate common stock of the receipt of the Cash Dividend. The discussion does not purport to be a complete analysis of all potential tax considerations. The considerations of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or non-U.S. tax laws, are not discussed. This discussion is based on the Code, Treasury Regulations promulgated under the Code, judicial decisions and published rulings and administrative pronouncements of the IRS, in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a U.S. Holder. Aerovate has not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax considerations of the receipt of the Cash Dividend.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This discussion is limited to a U.S. Holder that holds Aerovate common stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax considerations relevant to a U.S. Holder&#8217;s particular circumstances, including without limitation the effect of the Medicare contribution tax on net investment income, the alternative minimum tax, or the special tax accounting rules&#160;under Section&#160;451(b)&#160;of the Code. In addition, it does not address considerations relevant to U.S. Holders subject to special rules, such as:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. expatriates and former citizens or long-term residents of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. Holders whose functional currency is not the U.S. dollar;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons holding Aerovate common stock as part of a hedge, straddle or other risk-reduction strategy or as part of a conversion transaction or other integrated investment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">banks, insurance companies and other financial institutions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">real estate investment trusts or regulated investment companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">brokers, dealers or traders in securities or other persons that elect to use a mark-to-market method of accounting for their holdings in Aerovate common stock ;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">partnerships or other entities or arrangements classified as partnerships, passthroughs, or disregarded entities for U.S. federal income tax purposes (and investors therein), S corporations or other passthrough entities (including hybrid entities);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax-exempt organizations or governmental organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons deemed to sell Aerovate common stock under the constructive sale provisions of the Code;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons who hold or receive Aerovate common stock pursuant to the exercise of any employee stock option or otherwise as compensation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax-qualified retirement plans; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons that own, or have owned, actually or constructively, more than 5% of Aerovate common stock.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If an entity or arrangement classified as a partnership for U.S. federal income tax purposes holds Aerovate common stock , the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership, and certain determinations made at the partner level. Accordingly, a partnership holding Aerovate common stock and each partner in such partnership is urged to consult its tax advisor regarding the U.S. federal income tax considerations to it of the receipt of the Cash Dividend.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purpose of this discussion, a &#8220;U.S. Holder&#8221; is any beneficial owner of Aerovate common stock that, for U.S. federal income tax purposes, is or is treated as any of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an individual who is a citizen or resident of the United States;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">132</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a corporation created or organized under the laws of the United States, any state thereof or the District of Columbia;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a trust that: (i)&#160;is subject to the primary supervision of a U.S. court and the control of one or more &#8220;United States persons&#8221; (within the meaning of Section&#160;7701(a)(30) of the Code); or (ii)&#160;has a valid election in effect to be treated as a U.S. person for U.S. federal income tax purposes.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">This discussion is for informational purposes only and is not tax advice. Each prospective investor is urged to consult its tax advisor with respect to the application of the U.S. federal income tax laws to its particular situation as well as any tax considerations of the Cash Dividend arising under U.S. federal estate or gift tax laws, the laws of any state, local or non-U.S. taxing jurisdiction or any applicable income tax treaty.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The distribution of the Cash Dividend generally will be included in a U.S. Holder&#8217;s income as ordinary dividend income to the extent of the Aerovate&#8217;s current or accumulated earnings and profits. Distributions in excess of Aerovate&#8217;s current or accumulated earnings and profits will be treated as a tax-free return of capital to the extent of a U.S. Holder&#8217;s tax basis in Aerovate common stock and thereafter as capital gain from the sale or exchange of such common stock. Dividends received by a corporate U.S. Holder may be eligible for a dividends-received deduction, subject to applicable limitations. Dividends received by certain individuals and other non-corporate U.S. Holders generally are subject to a reduced rate of U.S. federal income tax, provided certain holding period and other requirements are satisfied. Each U.S. Holder is urged to consult its tax advisor with respect to the U.S. federal income tax considerations to it of the receipt of the Cash Dividend.</p><a id="TheMerger_NasdaqStock"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Nasdaq Stock Market Listing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Shares of Aerovate common stock are currently listed on Nasdaq under the symbol &#8220;AVTE.&#8221; Aerovate has agreed to use commercially reasonable efforts to (a)&#160;maintain its listing on Nasdaq until the First Effective Time and to obtain approval of the listing of the combined corporation on Nasdaq; (b)&#160;to the extent required by the rules&#160;and regulations of Nasdaq, prepare and submit to Nasdaq a notification form for the listing of the shares of Aerovate common stock to be issued in connection with the Merger and transactions contemplated thereunder, and to cause such shares to be approved for listing (subject to official notice of issuance); (c)&#160;prepare and timely submit to Nasdaq a notification form for the proposed reverse stock split (if required) and to submit a copy of the amendment to the Aerovate Charter effecting the proposed reverse stock split, certified by the Secretary of State of the State of Delaware, to Nasdaq on the Closing Date; and (d)&#160;to the extent required by Nasdaq Marketplace Rule&#160;5110, assist Jade in preparing and filing an initial listing application for the Aerovate common stock issued to Jade stockholders (including any common stock issuable upon conversion of the Aerovate Series&#160;A Preferred Stock) (the &#8220;Nasdaq Listing Application&#8221;) and to cause such Nasdaq Listing Application to be conditionally approved prior to the First Effective Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, under the Merger Agreement, each of Aerovate&#8217;s and Jade&#8217;s obligation to complete the Merger is subject to the satisfaction or waiver by each of the parties, at or prior to the Closing, of various conditions, including that the Nasdaq Listing Application shall have been approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Nasdaq Listing Application is approved, Aerovate anticipates that the common stock of the Combined Company will be listed on Nasdaq following the Closing under the trading symbol &#8220;JBIO.&#8221; In order for the Nasdaq Listing Application to be accepted, among other requirements, the Combined Company must maintain a bid price of $4.00 or higher for a certain period of time following the proposed reverse stock split.</p><a id="TheMerger_AnticipatedAccount"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Anticipated Accounting Treatment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Merger is expected to be treated by Aerovate as a reverse merger and will be accounted for as an in- substance reverse recapitalization of Aerovate by Jade in accordance with U.S. GAAP as, at close, the transaction is, in essence, the issuance of equity for Aerovate&#8217;s net assets, which primarily consist of nominal non-operating assets and liabilities. For accounting purposes, Jade is considered to be acquiring the assets and liabilities of Aerovate in this transaction based on the terms of the Merger Agreement and other factors, including: (i)&#160;Jade&#8217;s equity holders will own a substantial majority of the voting rights in the Combined Company; (ii)&#160;Jade&#8217;s largest stockholder will retain the largest interest in the Combined Company; (iii)&#160;Jade will designate all of the initial members of the board of directors of the Combined Company; and (iv)&#160;Jade&#8217;s executive management team will become the management of the Combined Company. The Combined Company will be named Jade Biosciences,&#160;Inc. Accordingly, the Merger is expected to be treated as the equivalent of Jade issuing stock to acquire the net assets of Aerovate. As a result of the Merger, the net </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">133</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">assets of Aerovate will be stated at fair value, which approximates carrying value, with no goodwill or other intangible assets recorded, and the historical results of operations prior to the Merger will be those of Jade. The direct and incremental costs related to the Merger will be treated as a reduction of the net proceeds received within additional paid-in-capital. Please see the section titled &#8220;<i style="font-style:italic;">Unaudited Pro Forma Condensed Combined Financial Information</i>&#8221; beginning on page&#160;305 of this proxy statement/prospectus for additional information.</p><a id="TheMerger_Appraisal_DissenterRight"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Appraisal Rights and Dissenters&#8217; Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the DGCL, Aerovate stockholders are not entitled to appraisal rights in connection with the Merger. Jade stockholders are entitled to appraisal rights in connection with the Merger under Section&#160;262 of the DGCL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The discussion below is not a complete summary regarding Jade&#8217;s stockholders&#8217; appraisal rights under Delaware law and is qualified in its entirety by reference to the text of the relevant provisions of Delaware law, which are attached as <i style="font-style:italic;">Annex G </i>in this proxy statement/prospectus. Stockholders intending to exercise appraisal rights should carefully review <i style="font-style:italic;">Annex G</i>. Failure to follow precisely any of the statutory procedures set forth in <i style="font-style:italic;">Annex G </i>may result in a termination or waiver of these rights. This summary does not constitute legal or other advice, nor does it constitute a recommendation that Jade stockholders exercise their appraisal rights under Delaware law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under Section&#160;262, where a Merger is adopted by stockholders by written consent in lieu of a meeting of stockholders pursuant to Section&#160;228 of the DGCL, either the constituent corporation before the effective date of such Merger or the surviving corporation, within ten&#160;days after the effective date of such Merger, must notify each stockholder of the constituent corporation entitled to appraisal rights of the approval of such Merger, the effective date of such Merger and that appraisal rights are available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Merger is completed, within ten&#160;days after the effective date of the Merger, Jade will notify its stockholders that the Merger has been approved, the effective date of the Merger and that appraisal rights are available to any stockholder who has not approved the Merger. Holders of shares of Jade capital stock who desire to exercise their appraisal rights must deliver a written demand for appraisal to Jade within 20&#160;days after the date of mailing of that notice, and that stockholder must not have delivered a written consent approving the Merger. A demand for appraisal must reasonably inform Jade of the identity of the stockholder and that such stockholder intends thereby to demand appraisal of the shares of Jade capital stock held by such stockholder. Failure to deliver a written consent approving the Merger will not in and of itself constitute a written demand for appraisal satisfying the requirements of Section&#160;262. All demands for appraisal should be addressed to c/o Jade Biosciences,&#160;Inc., 221 Crescent St., Building 23, Suite&#160;105, Waltham, MA 02453, and should be executed by, or on behalf of, the record holder of shares of Jade capital stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ALL DEMANDS MUST BE RECEIVED BY JADE WITHIN 20&#160;DAYS AFTER THE DATE JADE MAILS A NOTICE TO ITS STOCKHOLDERS NOTIFYING THEM THAT THE MERGER HAS BEEN APPROVED, THE EFFECTIVE DATE OF THE MERGER AND THAT APPRAISAL RIGHTS ARE AVAILABLE TO ANY STOCKHOLDER WHO HAS NOT APPROVED THE MERGER.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If you fail to deliver a written demand for appraisal within the time period specified above, you will be entitled to receive the Merger consideration for your shares of Jade capital stock as provided for in the Merger Agreement, but you will have no appraisal rights with respect to your shares of Jade capital stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To be effective, a demand for appraisal by a holder of shares of Jade capital stock must be made by, or in the name of, the registered stockholder, fully and correctly, as the stockholder&#8217;s name appears on the stockholder&#8217;s stock certificate(s). Beneficial owners who do not also hold the shares of record may not directly make appraisal demands to Jade. The beneficial owner must, in these cases, have the registered owner, such as a broker, bank or other custodian, submit the required demand in respect of those shares. If shares are owned of record in a fiduciary capacity, such as by a trustee, guardian or custodian, execution of a demand for appraisal should be made by or for the fiduciary; and if the shares are owned of record by more than one person, as in a joint tenancy or tenancy in common, the demand should be executed by or for all joint owners. An authorized agent, including an authorized agent for two or more joint owners, may execute the demand for appraisal for a stockholder of record; however, the agent must identify the record owner or owners and expressly disclose the fact that, in executing the demand, he or she is acting as agent for the record owner. A record owner, such as a broker, who holds shares as a custodian for others, may exercise the record owner&#8217;s right of appraisal with respect to the shares held for one or more beneficial owners, while not exercising this right for other beneficial owners. In that case, the written demand should state the number of shares as to which appraisal is sought. Where no number of shares is expressly mentioned, the demand will be presumed to cover all shares held in the name of the record owner. In addition, the stockholder must continuously hold the shares of record from the date of making the demand through the effective time.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">134</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If you hold your shares of Jade capital stock in a brokerage account or in other custodian form and you wish to exercise appraisal rights, you should consult with your bank, broker or other custodian to determine the appropriate procedures for the making of a demand for appraisal by the custodian.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At any time within 60&#160;days after the effective time, any stockholder who has demanded an appraisal, but has neither commenced an appraisal proceeding or joined an appraisal proceeding as a named party, has the right to withdraw such stockholder&#8217;s demand and accept the terms of the Merger by delivering a written withdrawal to Jade. If, following a demand for appraisal, you have withdrawn your demand for appraisal in accordance with Section&#160;262, you will have the right to receive the Merger consideration for your shares of Jade capital stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Within 120&#160;days after the effective date of the Merger, any stockholder who has delivered a demand for appraisal in accordance with Section&#160;262 will, upon written request to the surviving corporation, be entitled to receive a written statement setting forth the aggregate number of shares not voted in favor of the Merger Agreement and with respect to which demands for appraisal rights have been received and the aggregate number of holders of these shares. This written statement will be mailed to the requesting stockholder within 10&#160;days after the stockholder&#8217;s written request is received by the surviving corporation or within 10&#160;days after expiration of the period for delivery of demands for appraisal, whichever is later. Within 120&#160;days after the effective date of the Merger, either the surviving corporation or any stockholder who has delivered a demand for appraisal in accordance with Section&#160;262 may file a petition in the Delaware Court of Chancery demanding a determination of the fair value of the shares held by all such stockholders. Upon the filing of the petition by a stockholder, service of a copy of the petition must be made upon the surviving corporation. The surviving corporation has no obligation to file a petition in the Delaware Court of Chancery in the event there are dissenting stockholders, and Aerovate, which is expected to be the surviving corporation, has no present intent to file a petition in the Delaware Court of Chancery. Accordingly, the failure of a stockholder to file a petition within the period specified could nullify the stockholder&#8217;s previously written demand for appraisal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a petition for appraisal is duly filed by a stockholder and a copy of the petition is delivered to the surviving corporation, the surviving corporation will then be obligated, within 20&#160;days after receiving service of a copy of the petition, to provide the Delaware Court of Chancery with a duly verified list containing the names and addresses of all stockholders who have demanded an appraisal of their shares and with whom agreements as to the value of their shares have not been reached by the surviving corporation. After notice to dissenting stockholders who demanded appraisal of their shares, the Delaware Court of Chancery is empowered to conduct a hearing upon the petition, and to determine those stockholders who have complied with Section&#160;262 and who have become entitled to the appraisal rights provided thereby. The Delaware Court of Chancery may require the stockholders who have demanded appraisal for their shares to submit their stock certificates to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any stockholder fails to comply with that direction, the Delaware Court of Chancery may dismiss the proceedings as to that stockholder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After determination of the stockholders entitled to appraisal of their shares, the Delaware Court of Chancery will appraise the &#8220;fair value&#8221; of the shares owned by those stockholders. This value will be exclusive of any element of value arising from the accomplishment or expectation of the Merger, but may include a fair rate of interest, if any, upon the amount determined to be the fair value. When the value is determined, the Delaware Court of Chancery will direct the payment of the value, with interest thereon accrued during the pendency of the proceeding, if the Delaware Court of Chancery so determines, to the stockholders entitled to receive the same, upon surrender by the holders of the certificates representing those shares. At any time before the entry of judgment in the proceedings, the surviving corporation may pay to each stockholder entitled to appraisal an amount in cash, in which case interest shall accrue thereafter only upon the sum of (i)&#160;the difference, if any, between the amount so paid and the fair value of the shares subject to appraisal as determined by the Delaware Court of Chancery and (ii)&#160;interest theretofore accrued, unless paid at that time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In determining fair value and, if applicable, a fair rate of interest, the Delaware Court of Chancery is required to take into account all relevant factors. In Weinberger v. UOP,&#160;Inc., the Delaware Supreme Court discussed the factors that could be considered in determining fair value in an appraisal proceeding, stating that &#8220;proof of value by any techniques or methods which are generally considered acceptable in the financial community and otherwise admissible in court&#8221; should be considered, and that &#8220;fair price obviously requires consideration of all relevant factors involving the value of a company.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Section&#160;262 provides that fair value is to be &#8220;exclusive of any element of value arising from the accomplishment or expectation of the merger.&#8221; In Cede&#160;&amp; Co. v. Technicolor,&#160;Inc., the Delaware Supreme Court stated that this exclusion is a &#8220;narrow exclusion [that] does not encompass known elements of value,&#8221; but which rather applies only to the speculative elements of value arising from such accomplishment or expectation. In Weinberger, the Delaware Supreme Court construed Section&#160;262 to mean that &#8220;elements of future </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">135</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">value, including the nature of the enterprise, which are known or susceptible of proof as of the date of the merger and not the product of speculation, may be considered.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">You should be aware that the fair value of your shares as determined under Section&#160;262 could be more than, the same as, or less than the value that you are entitled to receive under the terms of the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Costs of the appraisal proceeding may be imposed upon the surviving corporation and the stockholders participating in the appraisal proceeding by the Delaware Court of Chancery as the Court deems equitable in the circumstances. Upon the application of a stockholder, the Delaware Court of Chancery may order all or a portion of the expenses incurred by any stockholder in connection with the appraisal proceeding, including, without limitation, reasonable attorneys&#8217; fees and the fees and expenses of experts, to be charged pro rata against the value of all shares entitled to appraisal. In the absence of such a determination of assessment, each party bears its own expenses. Any stockholder who had demanded appraisal rights will not, after the effective time, be entitled to vote shares subject to that demand for any purpose or to receive payments of dividends or any other distribution with respect to those shares, other than with respect to payment as of a record date prior to the effective time; however, if no petition for appraisal is filed within 120&#160;days after the effective time, or if the stockholder delivers a written withdrawal of his or her demand for appraisal and an acceptance of the terms of the Merger within 60&#160;days after the effective time, then the right of that stockholder to appraisal will cease and that stockholder will be entitled to receive the Merger consideration for shares of his or her Jade capital stock pursuant to the Merger Agreement. Any withdrawal of a demand for appraisal made more than 60&#160;days after the effective time may only be made with the written approval of the surviving corporation. No appraisal proceeding in the Delaware Court of Chancery will be dismissed as to any stockholder without the approval of the court.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Failure to follow the steps required by Section&#160;262 for perfecting appraisal rights may result in the loss of appraisal rights. In view of the complexity of Section&#160;262, stockholders who may wish to dissent from the Merger and pursue appraisal rights should consult their legal advisors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">136</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_45cf07ba_0d36_44b2_b100_2fa7cf3df10d"></a><a id="THEMERGERAGREEMENT_24528"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE MERGER AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following is a summary of the material terms of the Merger Agreement. A copy of the Merger Agreement is attached to this proxy statement/prospectus as Annex A and is incorporated by reference into this proxy statement/prospectus. The Merger Agreement has been attached to this proxy statement/prospectus to provide you with information regarding its terms. It is not intended to provide any other factual information about Aerovate, Jade, Merger Sub I or Merger Sub II. The following description does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement. You should refer to the full text of the Merger Agreement for details of the Merger and the terms and conditions of the Merger Agreement.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The Merger Agreement contains representations and warranties that Aerovate, Merger Sub I and Merger Sub II, on the one hand, and Jade, on the other hand, have made to one another as of specific dates. These representations and warranties have been made for the benefit of the other parties to the Merger Agreement and may be intended not as statements of fact but rather as a way of allocating the risk to one of the parties if those statements prove to be incorrect. In addition, the assertions embodied in the representations and warranties are qualified by information in confidential disclosure schedules exchanged by the parties in connection with signing the Merger Agreement. While Aerovate and Jade do not believe that these disclosure schedules contain information required to be publicly disclosed under the applicable securities laws, other than information that has already been so disclosed, the disclosure schedules do contain information that modifies, qualifies and creates exceptions to the representations and warranties set forth in the attached Merger Agreement. Accordingly, you should not rely on the representations and warranties as current characterizations of factual information about Aerovate or Jade, because they were made as of specific dates, may be intended merely as a risk allocation mechanism between Aerovate, Merger Sub I, Merger Sub II and Jade and are modified by the disclosure schedules.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Structure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the terms and conditions of the Merger Agreement, and in accordance with Delaware law, at the Closing, Merger Sub I, a wholly owned subsidiary of Aerovate formed by Aerovate in connection with the Merger, will merge with and into Jade, with Jade surviving as a wholly owned subsidiary of Aerovate, and immediately following such Merger, and as part of the same overall transaction, Jade will merge with and into Merger Sub II with Merger Sub II being the surviving entity of such Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Completion and Effectiveness of the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement requires the parties to consummate the Merger as promptly as practicable (and in any event within two business&#160;days) after all of the conditions to the consummation of the Merger contained in the Merger Agreement are satisfied or waived, including the adoption of the Merger Agreement by the Jade stockholders and the approval by the Aerovate stockholders of the issuance of Aerovate common stock, including shares of Aerovate common stock issuable upon conversion of Aerovate Series&#160;A Preferred Stock, and the other transactions proposed under the Merger Agreement, other than those conditions that by their nature are to be satisfied at the Closing. The Merger will become effective upon the filing of certificates of Merger with the Secretary of State of the State of Delaware or at such later time as is agreed by Aerovate and Jade and specified in the certificates of Merger. Neither Aerovate nor Jade can predict the exact timing of the consummation of the Merger.</p><a id="MergerAgreement_MergerConsideration"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Merger Consideration</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, each then-outstanding share of Jade common stock (including shares of Jade common stock issued in the Jade Pre-Closing Financing) (excluding shares to be cancelled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of Aerovate common stock equal to the Exchange Ratio (described in more detail below) and each then-outstanding share of Jade Preferred Stock (excluding shares to be cancelled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of Aerovate Series&#160;A Preferred Stock, which are each convertible into 1,000 shares of Aerovate common stock, equal to the Exchange Ratio divided by 1,000, in accordance with the terms of the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">No fractional shares of Aerovate common stock will be issued in connection with the Merger, and no certificates or scrip for any such fractional shares will be issued. Any fractional shares of Aerovate common stock resulting from the conversion of shares of Jade common stock (including shares of Jade common stock issued in the Jade Pre-Closing Financing) shall converted into the right to receive cash equal to such fractional part of a share of Aerovate common stock multiplied by the last reported sale price of Aerovate </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">137</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">common stock at 4:00&#160;p.m. (New York City time), end of regular trading hours on Nasdaq on the last trading day prior to the Effective Time.</p><a id="MERGER_AGREEMENT_ExchangeRatio"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exchange Ratio</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Exchange Ratio is calculated using a formula intended to allocate existing Aerovate and Jade securityholders a&#160;percentage of the Combined Company. Based on Aerovate&#8217;s and Jade&#8217;s capitalization as of October&#160;30, 2024, the Exchange Ratio was estimated to be equal to approximately 21.4388 shares of Aerovate common stock for each share of Jade common stock. This estimate is subject to adjustment prior to the closing of the First Merger for Net Cash as of the Net Cash Determination Time (and as a result, Aerovate securityholders could own less, and Jade securityholders (including, for this purpose, investors in the Jade Pre-Closing Financing) could own more, or vice versa, of the Combined Company). Aerovate management currently anticipates that Aerovate&#8217;s Net Cash as of Closing will be approximately $0, after giving effect to the Cash Dividend, which is expected to be approximately $65.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on the estimates set forth above, after giving effect to the Jade Pre-Closing Financing, and certain other assumptions, immediately following the completion of the Merger, Aerovate securityholders would own approximately 1.6% of the capital stock of the Combined Company post-Merger on a fully- diluted basis, and Jade securityholders, including shares of Jade common stock and Jade pre-funded warrants purchased in the Jade Pre-Closing Financing, would own approximately 98.4% of the capital stock of the Combined Company post-Merger on a fully-diluted basis. Under certain circumstances further described in the Merger Agreement, the ownership&#160;percentages may be adjusted up or down including, but not limited to, if Jade&#8217;s net cash as of Closing is lower than $0. Aerovate management currently anticipates Aerovate&#8217;s Net Cash as of Closing will be approximately $0, after giving effect to the Cash Dividend, which is expected to be approximately $65.0 million, and the currently estimated ownership&#160;percentages reflect this projection. There can be no assurance that any of these assumptions will be accurate at Closing when the final Exchange Ratio is determined. For more information on the Jade Pre-Closing Financing, please see the section titled &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#160;&#8212; Subscription Agreement</i>&#8221; beginning on page&#160;153 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Exchange Ratio formula is the quotient obtained (rounded to four decimal places) by dividing the Jade Value Per Share by the Aerovate Value Per Share, in which:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Jade Equity Value&#8221; means $175,000,000.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Jade Outstanding Shares&#8221; means the total number of shares of Jade capital stock outstanding immediately prior to the First Effective Time (including any shares of Jade common stock that are issued in, or issuable upon the exercise or conversion of securities issued in, the Jade Pre-Closing Financing), expressed on a fully diluted and as-converted-to-Jade common stock basis assuming, without limitation or duplication the exercise of all Jade options, Jade warrants or other rights or commitments to receive shares of Jade common stock or Jade Preferred Stock (or securities convertible or exercisable into shares of Jade common stock or Jade Preferred Stock, including the Jade convertible notes), whether conditional or unconditional, that are outstanding as of immediately prior to the First Effective Time; provided, that for the avoidance of doubt, Jade Outstanding Shares shall (1)&#160;exclude, to avoid the double-counting of, any shares of Jade capital stock underlying the Jade convertible notes that are to be contributed as consideration in the Jade Pre-Closing Financing, and (2)&#160;exclude any shares of Jade capital stock underlying any Jade options, Jade warrants and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any other equity awards issued under Jade&#8217;s Amended and Restated 2024 Equity Incentive Plan (including any shares of Jade common stock issuable upon the exercise of such Jade options, Jade warrants or other equity awards) issued to directors, employees, consultants or other service providers following the date of the Merger Agreement but prior to the Closing.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Jade Valuation&#8221; means the Jade Equity Value, plus an amount equal to the total proceeds contemplated by the Jade Pre-Closing Financing received (including in the total proceeds any Jade </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">convertible note contributed in the Jade Pre-Closing Financing, and any interest, premium and other amounts thereon) by Jade prior to the First Effective Time.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Jade Value Per Share&#8221; equals the Jade Valuation divided by the number of Jade Outstanding Shares (rounded to four decimal places).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Aerovate Outstanding Shares&#8221; means the total number of shares of Aerovate capital stock outstanding immediately prior to the First Effective Time (after giving effect, to the extent completed prior to the First Effective Time, to the reverse stock split), assuming (i)&#160;the exercise, conversion or exchange of all options, warrants, conversion rights, exchange rights or any other rights to receive shares of Aerovate capital stock which exist immediately prior to the First Effective Time (excluding any Aerovate Series&#160;A Preferred Stock issuable following the Closing in accordance with the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Merger Agreement), (ii)&#160;the </span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">138</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">settlement in shares of Aerovate common stock of Aerovate options outstanding as of immediately prior to the First Effective Time on a net settlement basis as provided in Section&#160;6.6 of the Merger Agreement and (iii)&#160;the settlement in shares of Aerovate common stock of Aerovate RSUs outstanding as of immediately prior to the First Effective Time on a net settlement basis as provided in Section&#160;6.7 of the Merger Agreement. Notwithstanding the foregoing, Aerovate options with an exercise price greater than the Aerovate Closing Price (in each case, as adjusted to take into account the Cash Dividend in accordance with Aerovate&#8217;s equity plans, as applicable), shall not be included in the total number of shares of Aerovate capital stock for purposes of determining the Aerovate Outstanding Shares to the extent cancelled at or prior to Closing under Section&#160;6.6 of the Merger Agreement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Aerovate Valuation&#8221; means (i)&#160;$8,000,000, minus (ii)&#160;the amount by which Net Cash is less than $0 (if any).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Aerovate Value Per Share&#8221; equals the Aerovate Valuation divided by the number of Aerovate Outstanding Shares (rounded to four decimal places).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Calculation of Aerovate&#8217;s Final Net Cash</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Merger Agreement, Aerovate&#8217;s &#8220;Net Cash&#8221; means, as of close of business on the Closing Date, the sum (without duplication) of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aerovate&#8217;s unrestricted cash, cash equivalents and short-term investments; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Certain Aerovate prepaid expenses, deposits, restricted cash and short-term receivables set forth in Aerovate&#8217;s disclosure letter;</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">in each case, to the extent capable of use by the Combined Company after the Closing, <i style="font-style:italic;">minus </i>the sum of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aerovate&#8217;s short-term and long-term liabilities, including all accounts payable, indebtedness, lease termination costs, all actual and reasonably projected costs and expenses relating to the winding down of the Aerovate&#8217;s legacy business and any related prepayment penalties and premiums, and any unpaid transaction expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any and all change in control payments, severance payments and any payroll or similar taxes owed in connection with the foregoing or any of Aerovate&#8217;s equity plans, in each case to the extent payable to Aerovate&#8217;s employees solely as a result of the consummation of the transactions under the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any and all change in control payments, severance payments and any payroll or similar taxes owed in connection with the foregoing or any of Aerovate&#8217;s equity plans, in each case to the extent payable to Aerovate&#8217;s employees solely as a result of the consummation of the transactions contemplated </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by the Merger Agreement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Cash Dividend.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No less than ten business&#160;days prior to the anticipated Closing Date, (i)&#160;Aerovate will deliver to Jade a net cash schedule setting forth, in reasonable detail, Aerovate&#8217;s good faith estimated calculation of its Net Cash as of the close of business on the anticipated Closing Date, prepared and certified by Aerovate&#8217;s chief financial officer (or if there is no chief financial officer, the principal financial and accounting officer), as the case may be, and, if requested, the relevant work papers and back-up materials used or useful in preparing the net cash schedule. No later than five business&#160;<span style="white-space:pre-wrap;">days after delivery of such net cash schedule (the last day of such period referred to as the response date), Jade will have the right to dispute any part of the net cash schedule by delivering a written notice to that effect to Aerovate (referred to herein as a &#8220;dispute notice&#8221;). Any dispute notice  will identify, in reasonable detail and, to the extent known, the nature and amounts of any proposed revisions to Aerovate&#8217;s Net Cash calculation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Jade disputes the net cash schedule, the parties shall attempt in good faith to resolve the disputed items and negotiate an agreed-upon determination of Net Cash. If the parties are unable to negotiate an agreed-upon determination of the disputed items or component thereof within three&#160;days after the delivery of the dispute notice, any remaining disagreements will be referred to an independent auditor of recognized national standing mutually agreed upon by Aerovate and Jade. The determination of the amount of Net Cash made by such auditor shall be final and binding on Aerovate and Jade.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">139</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate&#8217;s Net Cash balance is subject to numerous factors, some of which are outside of Aerovate&#8217;s control. The actual amount of Net Cash will depend significantly on the timing of the Closing. In addition, the Closing could be delayed if Aerovate and Jade are not able to agree upon the amount of Aerovate&#8217;s Net Cash as of the Net Cash Determination Time.</p><a id="MergerAgreement_TrtmtJade_Option"></a><a id="TreatmentofJadeOptions_910274"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Treatment of Jade Options</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Merger Agreement, each option to purchase shares of Jade common stock that is outstanding and unexercised immediately prior to the First Effective Time, whether or not vested, will be assumed and converted into an option to purchase shares of Aerovate common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accordingly, from and after the First Effective Time: (i)&#160;each outstanding Jade stock option assumed by Aerovate may be exercised solely for shares of Aerovate common stock; (ii)&#160;the number of shares of Aerovate common stock subject to each outstanding Jade stock option assumed by Aerovate will be determined by multiplying (A)&#160;the number of shares of Jade common stock that were subject to such Jade stock option assumed by Aerovate, as in effect immediately prior to the First Effective Time, by (B)&#160;the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of Aerovate common stock; and (iii)&#160;the per share exercise price of each Jade stock option assumed by Aerovate will be determined by dividing (A)&#160;the per share exercise price of such Jade stock option, as in effect immediately prior to the First Effective Time, by (B)&#160;the Exchange Ratio, and rounding the resulting exercise price up to the nearest whole cent. Each Jade stock option assumed by Aerovate will otherwise continue in full force and effect and the term, exercisability, vesting schedule, acceleration rights and other terms and conditions of such Jade stock option will otherwise remain unchanged.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent provided under the terms of a Jade stock option assumed by Aerovate in accordance with the terms of the Merger Agreement, such Jade stock option shall, in accordance with its terms, be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of Jade common stock subsequent to the First Effective Time. Following the completion of the Merger, the Combined Company&#8217;s board of directors or a committee thereof will succeed to the authority and responsibility of Jade&#8217;s board of directors or any committee thereof with respect to each Jade option assumed by Aerovate in accordance with the terms of the Merger Agreement.</p><a id="MergerAgreement_TrtmtJade_PreFunded"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Treatment of Jade Pre-Funded Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Merger Agreement, each pre-funded warrant to purchase shares of Jade common stock that is outstanding and unexercised immediately prior to the First Effective Time, whether or not vested, will be converted into a pre-funded warrant to purchase shares of Aerovate common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accordingly, from and after the First Effective Time: (i)&#160;each outstanding Jade pre-funded warrant assumed by Aerovate may be exercised solely for shares of Aerovate common stock; (ii)&#160;the number of shares of Aerovate common stock subject to each outstanding Jade pre-funded warrant assumed by Aerovate will be determined by multiplying (A)&#160;the number of shares of Jade common stock issuable upon exercise of the Jade pre-funded warrant that were subject to such Jade pre-funded warrant, as in effect immediately prior to the First Effective Time, by (B)&#160;the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of Aerovate common stock; and (iii)&#160;the per share exercise price for the Aerovate common stock issuable upon exercise of each Jade pre-funded warrant assumed by Aerovate will be determined by dividing (A)&#160;the per share exercise price of Aerovate common stock subject to such Jade pre- funded warrant as in effect immediately prior to the First Effective Time, by (B)&#160;the Exchange Ratio, and rounding the resulting exercise price up to the nearest whole cent. Each Jade pre-funded warrant assumed by Aerovate will otherwise continue in full force and effect and the term, any restriction on the exercise and other provisions of such Jade pre-funded warrant will otherwise remain unchanged.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent provided under the terms of a Jade pre-funded warrant assumed by Aerovate in accordance with the terms of the Merger Agreement, such Jade pre-funded warrant shall, in accordance with its terms, be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of Aerovate common stock subsequent to the First Effective Time. In addition, Aerovate&#8217;s board of directors or a committee thereof will succeed to the authority and responsibility of Jade&#8217;s board of directors or any committee thereof with respect to each Jade pre-funded warrant assumed by Aerovate in accordance with the terms of the Merger Agreement.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">140</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="MergerAgreement_TrtmtAero_CommonStock"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Treatment of Aerovate Common Stock and Aerovate Options</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as contemplated by the proposed increase in the number of authorized shares of Aerovate common stock described in Proposal No.&#160;3 of this proxy statement/prospectus and the proposed reverse stock split of issued and outstanding Aerovate common stock described in Proposal No.&#160;2 of this proxy statement/prospectus, Aerovate common stock will remain unaffected by the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Merger Agreement, prior to the Closing, Aerovate&#8217;s board of directors will accelerate the vesting of all equity awards of Aerovate then outstanding but not then vested or exercisable, and cancel each option to acquire shares of Aerovate common stock with an exercise price per share greater than the Aerovate Closing Price, in each case, in accordance with the terms of the Merger Agreement. At the First Effective Time, (i)&#160;each option to acquire shares of Aerovate&#8217;s common stock with an exercise price less than or equal to the Aerovate Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (A)&#160;the excess of the Aerovate Closing Price over the exercise price per share of Aerovate common stock underlying such Aerovate option by (B)&#160;the number of shares of Aerovate common stock underlying such Aerovate option and (ii)&#160;each other option to acquire shares of Aerovate&#8217;s common stock will be cancelled for no consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Procedures for Exchanging Jade Stock Certificates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the closing date of the First Merger, Aerovate will select an exchange agent and, at the First Effective Time, Aerovate will deposit with the exchange agent evidence of book-entry shares representing the shares of Aerovate common stock and Aerovate Series&#160;A Preferred Stock issuable pursuant to the terms of the Merger Agreement in exchange for shares of Jade common stock or Jade Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Promptly after the First Effective Time, the exchange agent will mail to each record holder of Jade common stock or Jade Preferred Stock (i)&#160;a letter of transmittal and (ii)&#160;instructions for surrendering the record holder&#8217;s stock certificates in exchange for the Merger consideration. Upon delivery to the exchange agent of a duly executed letter of transmittal in accordance with the exchange agent&#8217;s instructions and the declaration for tax withholding purposes, the surrender of the record holder&#8217;s stock certificates, if applicable, and delivery to the exchange agent of such other documents as may be reasonably required by the exchange agent or Aerovate, the record holder of such stock certificates or book-entry shares, as applicable, will be entitled to receive in exchange therefor book-entry shares representing the number of whole shares of Aerovate common stock issuable to such holder pursuant to the Merger Agreement. The surrendered certificates representing shares of Jade common stock or Jade Preferred Stock will be canceled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After the First Effective Time, each certificate representing Jade common stock or Jade Preferred Stock that has not been surrendered will represent only the right to receive shares of Aerovate common stock or Aerovate Series&#160;A Preferred Stock (as applicable) issuable pursuant to the Merger Agreement to which the holder of any such certificate is entitled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">HOLDERS OF JADE COMMON STOCK OR JADE PREFERRED STOCK SHOULD NOT SEND IN THEIR JADE STOCK CERTIFICATES UNTIL THEY RECEIVE A LETTER OF TRANSMITTAL FROM THE EXCHANGE AGENT WITH INSTRUCTIONS FOR THE SURRENDER OF JADE STOCK CERTIFICATES.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Directors and Officers of Aerovate Following the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Merger Agreement, each of the directors and officers of Aerovate will resign effective as of the First Effective Time and Aerovate&#8217;s board of directors will thereafter consist of a total of six new directors designated by Jade. Jade has designated Tom Frohlich, Chris Cain, Eric Dobmeier, Tomas Kiselak, Lawrence Klein and Erin Lavelle to serve as members of Aerovate&#8217;s board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, upon the Closing, Tom Frohlich will serve as Chief Executive Officer, Jonathan Quick will serve as Senior Vice President, Finance and Treasurer, Andrew King will serve as Chief Scientific Officer&#160;&amp; Head of Research and Development, Hetal Kocinsky will serve as Chief Medical Officer and Elizabeth Balta will serve as General Counsel and Corporate Secretary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Amendment of the Amended and Restated Certificate of Incorporation of Aerovate</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Aerovate agreed to amend its certificate of incorporation to (i)&#160;change Aerovate&#8217;s name to &#8220;Jade Biosciences,&#160;Inc.&#8221;, (ii)&#160;effect the proposed reverse stock split, if needed, (iii)&#160;authorize a sufficient number of shares of common stock to issue the Merger </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">141</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">consideration, (iv)&#160;increase the number of shares of Aerovate common stock that Aerovate is authorized to issue to the amount proposed in this Proxy Statement and <span style="color:#231f20;">(v)&#160;redomicile Aerovate from Delaware to such jurisdiction as may be determined by Jade.</span></p><a id="RepresentationsandWarranties_378089"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Representations and Warranties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement contains customary representations and warranties of Aerovate, Merger Sub I and Merger Sub II, on one hand, and Jade, on the other hand, for a transaction of this type relating to, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">corporate organization and power, and similar corporate matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">due organization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subsidiaries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">organizational documents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authority to enter into the Merger Agreement and the related agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">votes required for completion of the Merger and approval of the proposals that will come before the Aerovate Special Meeting of stockholders and that will be the subject of the Jade stockholder approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">except as otherwise specifically disclosed in the Merger Agreement, the fact that the consummation of the Merger would not contravene the organizational documents, certain laws, governmental authorizations or certain contracts of the parties; result in any encumbrances on the parties&#8217; assets or require the consent of any third party;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the parties&#8217; efforts with respect to ensuring the inapplicability of Section&#160;203 of the DGCL and other similar takeover laws;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">capitalization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial statements and, with respect to Aerovate, documents filed with the SEC and the accuracy of information contained in those documents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">material changes or events;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">liabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">title to assets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">real property and leaseholds;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">material contracts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the validity of material contracts to which the parties or their subsidiaries are a party and any default of such contracts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory compliance, permits and restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">legal proceedings and orders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employee and labor matters and benefit plans;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">environmental matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">with respect to Jade, the subscription agreement;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">142</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">insurance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial advisors and similar fees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">certain transactions or relationships with affiliates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">privacy and data security; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">with respect to Aerovate, the valid issuance in the Merger of Aerovate common stock.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The representations and warranties are, in many respects, qualified by materiality and knowledge, and will not survive the Merger. The accuracy of the representations and warranties of each of Aerovate and Jade form the basis of certain of the conditions to the obligations of Aerovate and Jade to complete the Merger, subject to materiality thresholds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Covenants; Conduct of Business Pending the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate has agreed that, except as contemplated or permitted by the Merger Agreement, as required by law, or unless Jade has provided written consent, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the First Effective Time and the termination of the Merger Agreement, Aerovate will, and will cause its subsidiaries to, use commercially reasonable efforts to conduct their business and operations in the ordinary course consistent with past practices and in material compliance with all applicable laws, regulations and certain material contracts. Aerovate has also agreed that, subject to certain limited exceptions and except as contemplated or permitted by the Merger Agreement, as required by law, or unless Jade has provided written consent, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the First Effective Time and the termination of the Merger Agreement, it will not, and will not cause or permit any of its subsidiaries to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock; or repurchase, redeem or otherwise reacquire any shares of capital stock or other securities (except for shares of Aerovate common stock from terminated employees, directors or consultants of Aerovate);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sell, issue, grant, pledge or otherwise dispose of or encumber or authorize the issuance of any capital stock or other security (except for Aerovate common stock issued upon the valid exercise of outstanding Aerovate options or Aerovate RSU awards, as applicable), any option, warrant or right to acquire any capital stock or any other security or any instrument convertible into or exchangeable for any capital stock or other security;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">except as required to give effect to anything in contemplation of the Closing, amend the certificate of incorporation, bylaws or other similar organizational documents of Aerovate, or effect or be a </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except as related to the transactions contemplated in the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">form any subsidiary or acquire any equity interest or other interest in any other entity or enter into any joint venture with any other entity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lend money to any person or entity; incur or guarantee any indebtedness for borrowed money; guarantee any debt securities of others; or make any capital expenditure or commitment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other than as expressly required by applicable law or the terms of any Aerovate employee benefit plan in effect as of the date of the Merger Agreement, adopt, establish or enter into certain agreements, plans or arrangements relating to employment or benefits matters; cause or permit any such agreement, plan or arrangement to be amended other than as required by law or in order to make amendments for purposes of Section&#160;409A of the Code; pay any bonus or make any profit-sharing or similar payment to, or increase the amount of the wages, salary, commissions, fringe benefits or other compensation or remuneration payable to, any of its employees, directors or consultants; increase the severance or change of control benefits offered to any current or new employees, directors or consultants; or hire or terminate (other than for cause, or absent such a definition of cause, for conduct that Aerovate or such subsidiary determines in good faith constitutes material misconduct) any officer, employee or consultant;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">143</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enter into any material transaction outside the ordinary course of business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquire any material asset or sell, lease, license or otherwise irrevocably dispose of any of its assets or properties, or grant any lien with respect to such assets or properties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">make, change or revoke any material tax election; file any amended income or other material amendment to any tax return; settle or compromise any material tax claim; waive or extend any statute of limitations in respect of a period within which an assessment or reassessment of material taxes may be issued (other than any extension pursuant to an extension to file any tax return); enter into any &#8220;closing agreement&#8221; as described in Section&#160;7121 of the Code (or any similar law) with </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any governmental entity; surrender any material claim for refund; or adopt or change any material accounting method in respect of taxes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">waive, settle or compromise any pending or threatened legal proceeding against Aerovate or any of its subsidiaries, other than waivers, settlements or agreements for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">thereof) and that do not impose any material restrictions on the operations or businesses of Aerovate or its subsidiaries, taken as a whole, or any equitable relief on, or the admission of wrongdoing by Aerovate or any of its subsidiaries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay or fail to repay when due any material obligation, including accounts payable and accrued expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">forgive any loans to any person, including its employees, officers, directors or affiliate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sell, assign, transfer, license, sublicense or otherwise dispose of any intellectual property of Aerovate (other than in the ordinary course of business);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">terminate or modify in any material respect, or fail to exercise renewal rights to, any material insurance policy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enter into, amend, terminate, or waive any material option or right under, any of Aerovate&#8217;s material contracts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enter into any agreement to purchase or sell any interest in real property, grant any security interest in any real property, enter into any lease, sublease, license or other occupancy agreement with respect to any real property or alter, amend, modify, exercise any extension or expansion right under or violate or terminate any of the terms of any real property leases of Aerovate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other than as expressly required by law or generally accepted accounting principles, take any action to change accounting policies or procedures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">materially change pricing or royalties or other payments set or charged by Aerovate or any of subsidiaries to its customers or licensees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">agree to materially change pricing or royalties or other payments set or charged by persons who have licensed intellectual property to Aerovate or any of subsidiaries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">agree, resolve or commit to do any of the foregoing.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing restrictions, Aerovate is expressly permitted to engage in the sale, license, transfer, disposition, divestiture or other monetization transaction (i.e., a royalty transaction) and/or winding down of its legacy business (including terminating its real estate leases and other contracts) and is expressly permitted to declare and pay a dividend on the shares of Aerovate common stock outstanding prior to the First Effective Time (excluding for the avoidance of doubt any shares of Aerovate common stock issuable pursuant to the Merger), up to an amount equal in the aggregate to Aerovate&#8217;s reasonable, good faith approximation of the amount by which Aerovate&#8217;s Net Cash at the First Effective Time will exceed $0.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Jade has agreed that, except as contemplated or permitted by the Merger Agreement or the Subscription Agreement, as required by law, or unless Aerovate shall have provided its written consent, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the First Effective Time and the termination of the Merger Agreement, Jade </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">144</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">will, and will cause its subsidiaries to, use commercially reasonable efforts to conduct its business and operations in the ordinary course consistent with past practices and in material compliance with all applicable laws, regulations and certain contracts. Jade has also agreed that, subject to certain limited exceptions and except as contemplated or permitted by the Merger Agreement or the Subscription Agreement, as required by law, or unless Jade has provided written consent, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the First Effective Time and the termination of the Merger Agreement, it will not, and will not cause or permit its subsidiary to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock; or repurchase, redeem or otherwise reacquire any shares of its capital stock or other securities (except for shares of common stock from terminated employees, directors or consultants of Jade);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">except as required to give effect to anything in contemplation of the Closing, amend the certificate of incorporation, bylaws or other organizational documents of Jade, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except as related to the transactions contemplated in the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other than in the ordinary course of its business, sell, issue, grant, pledge or otherwise dispose of or encumber or authorize the issuance of any of the foregoing actions with respect to more than 25% of the shares of Jade capital stock outstanding as of the date the Merger Agreement was signed: any capital stock or other security of Jade or its subsidiaries (except for shares of outstanding Jade common stock issued upon the valid exercise or settlement of Jade options in accordance with their terms as in effect as of the date of the Merger Agreement); any option, warrant or right to acquire any capital stock or any other security; or any instrument convertible into or exchangeable for any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">capital stock or other security of Jade or its subsidiaries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other than in the ordinary course of its business, form any subsidiary or acquire any equity interest or other interest in any other entity or enter into a joint venture with any other entity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lend money to any person or entity; incur or guarantee any indebtedness for borrowed money; guarantee any debt securities of others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sell, lease, license or otherwise irrevocably dispose of any of its assets or properties, or grant any lien with respect to such assets or properties, except in the ordinary course of business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">waive, settle or compromise any pending or threatened legal proceeding against Jade or its subsidiaries, other than waivers, settlements or agreements (A)&#160;for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B)&#160;that do not impose any material restrictions on the operations or businesses of Jade or its </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subsidiaries, taken as a whole, or any equitable relief on, or the admission of wrongdoing by Jade or any of its subsidiaries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay or fail to repay when due any material obligation, including accounts payable and accrued expenses, other than in the ordinary course of business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sell, assign, transfer, license, sublicense or otherwise dispose of any material intellectual property of Jade, other than in the ordinary course of business; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">agree, resolve or commit to do any of the foregoing.</span></td></tr></table><div style="margin-top:10pt;"><a id="MergerAgreement_NonSolicitation"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Non-Solicitation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each of Aerovate and Jade have agreed that, except as described below, Aerovate and Jade and any of their respective subsidiaries will not, nor will either party or any of its subsidiaries authorize any of the directors, officers, employees, investment bankers, financial advisors, attorneys, accountants or other advisors, agents or representatives retained by it or any of its subsidiaries to, directly or indirectly:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of, any Acquisition Proposal or Acquisition Inquiry;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">145</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">furnish any non-public information with respect to it to any person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">engage in discussions or negotiations with any person with respect to any Acquisition Proposal or Acquisition Inquiry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approve, endorse or recommend any Acquisition Proposal, subject to the terms of the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">execute or enter into any letter of intent or any contract contemplating or otherwise relating to an Acquisition Transaction;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publicly propose to do any of the foregoing.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An &#8220;Acquisition Inquiry&#8221; means, with respect to a party, an inquiry, indication of interest or request for information (other than an inquiry, indication of interest or request for information made or submitted by Jade, on the one hand, or Aerovate on the other hand, to the other party) that could reasonably be expected to lead to an Acquisition Proposal, other than the Jade Pre-Closing Financing or the issuance of any Jade convertible notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An &#8220;Acquisition Proposal&#8221; means, with respect to either party, any proposal or offer, whether written or oral from any person (other than an offer or proposal made or submitted by or on behalf of Jade or any of its affiliates, on the one hand, or by or on behalf of Aerovate or any of its affiliates, on the other hand, to the other party) contemplating or otherwise relating to an Acquisition Transaction with such party (other than in connection with the Jade Pre-Closing Financing, Aerovate&#8217;s leases, the sale by Aerovate of its legacy assets or the exercise or repurchase of existing equity interests).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An &#8220;Acquisition Transaction&#8221; means any transaction or series of related transactions (other than a sale by Aerovate of its legacy assets, the issuance of convertible notes by Jade or the Jade Pre-Closing Financing) involving:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of securities, reorganization, recapitalization, tender offer, exchange offer or similar transaction: (i)&#160;in which any individual, entity, governmental entity, or &#8220;group,&#8221; as defined under applicable securities laws, directly or indirectly acquires beneficial or record ownership of securities representing more than 20% of the outstanding securities of any class of voting securities of Aerovate or Jade or any of their respective subsidiaries or (ii)&#160;in which Aerovate, Jade or Merger Subs or any of their respective subsidiaries issues securities representing more than 20% of the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding securities of any class of voting securities of such party or any of its subsidiaries or issues securities convertible into more than 20% of the outstanding securities of any class of voting securities; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or account for 20% or more of the consolidated book value or the fair market value of the assets of Aerovate or Jade and their respective subsidiaries, as applicable, taken as a whole.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing, before obtaining the applicable approvals of the Aerovate stockholders or Jade stockholders required to consummate the Merger, each party may furnish non-public information regarding such party and its subsidiaries to, and may enter into discussions or negotiations with, any third party in response to a bona fide written Acquisition Proposal, which such party&#8217;s board of directors determines in good faith, after consultation with such party&#8217;s financial advisors and outside legal counsel, constitutes or is reasonably likely to result in a Superior Offer (and is not withdrawn), if:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such Acquisition Proposal was not obtained or made as a direct or indirect result of a breach of the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such party&#8217;s board of directors concludes in good faith, based on the advice of outside legal counsel, that the failure to take such action would reasonably be expected to be inconsistent with the fiduciary duties of such board of directors under applicable law;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at least two business&#160;days prior to furnishing any non-public information or entering into discussions with a third party, such party gives the other party written notice of the identity of the third party and of that party&#8217;s intention to furnish non-public information to, or enter into discussions with, such third party;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">146</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such party receives from the third party an executed confidentiality agreement containing provisions at least as favorable to such party as those contained in the confidentiality agreement between Aerovate and Jade; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at least two business&#160;days prior to furnishing any non-public information to a third party, such party furnishes the same non-public information to the other party to the extent not previously furnished.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A &#8220;Superior Offer&#8221; means an unsolicited <i style="font-style:italic;">bona fide </i>written Acquisition Proposal (with all references to 20% in the definition of Acquisition Transaction being treated as references to 50% for these purposes) that (a) <span style="color:#231f20;">was not obtained or made as a direct or indirect result of a breach of (or in violation of) the Merger Agreement and (b)&#160;is on terms and conditions that the board of directors of the party receiving the offer determines in good faith, based on such matters that it deems relevant (including the likelihood of consummation thereof and the financing terms thereof), as well as any written offer by the other party to the Merger Agreement to amend the terms of the Merger Agreement, and following consultation with its outside legal counsel and financial advisors, if any, are more favorable, from a financial point of view, to that party&#8217;s stockholders than the terms of the transactions contemplated by the Merger Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement also provides that each party will promptly (and in no event later than one business day after such party receives any such Acquisition Proposal or Acquisition Inquiry) advise the other party of the status and terms of, and keep the other party reasonably informed with respect to, any Acquisition Proposal or Acquisition Inquiry and any material modification or material proposed modification thereto.</p><a id="MergerAgreement_BoardRecommendation"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Board Recommendation Change</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Merger Agreement, subject to certain exceptions described below, both Jade and Aerovate agreed that their respective board of directors may not withhold, amend, withdraw or modify (or publicly propose to withhold, amend, withdraw or modify) the recommendation of such party&#8217;s board of directors in a manner adverse to the other party except for in limited circumstances described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At any time prior to the approval of the Merger by each party&#8217;s respective stockholders, if (i)&#160;such party has received a bona fide written Acquisition Proposal that the such party&#8217;s board of directors determines, following consultation with its outside legal counsel and financial advisor, to be a Superior Offer, or (ii)&#160;a material development or change in circumstances (other than any such event, development or change to the extent related to any Acquisition Proposal, Acquisition Inquiry, Acquisition Transaction or the consequences thereof, or the fact, in and of itself, that such party meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations) that affects the business, assets or operations of such party and occurs or arises after the date the Merger Agreement was executed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the case of a change recommendation due to a material development or change in circumstance, such party&#8217;s board of directors must first promptly notify the other party, in writing, at least four business&#160;days before making a change in its recommendation, stating the material facts and circumstances related to the applicable material development or change in circumstance and that such party&#8217;s board of directors intends to make a change in its recommendation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the case of a change its recommendation due to a Superior Offer, such party&#8217;s board of directors must first:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determine in good faith, based on the advice of its outside legal counsel, that the failure to make a change in its recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">negotiate with the other party in good faith to make such adjustments to the terms and conditions of the Merger Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer, during the required four business day notice period and provide the other party with certain information regarding such Superior Offer.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the other party delivers a written offer to alter the terms or conditions of the Merger Agreement during the required four business day notice period, the party considering a change in the recommendation of its board of directors must redetermine in good faith, based on the advice of its outside legal counsel, that the failure to make a change in its recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law (after taking into account such alterations of the terms and conditions of the Merger Agreement).</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">147</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Meeting of Aerovate&#8217;s Stockholders and Written Consent of Jade&#8217;s Stockholders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate is obligated under the Merger Agreement to take all action necessary under applicable law to call, give notice of and hold a meeting of the holders of Aerovate common stock for the purpose of considering and voting to approve the Merger Agreement and the transactions contemplated thereby (including the Merger) and amendments to the Aerovate Charter as further described herein. The Aerovate Special Meeting will be held as promptly as practicable after this registration statement on Form&#160;S-4 is declared effective under the Securities Act, and in any event no later than 45&#160;days after the effective date of this registration statement on Form&#160;S-4.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Promptly after this registration statement on Form&#160;S-4 has been declared effective, and no later than two business&#160;days thereafter, Jade is required to obtain the approval by written consent from the holders of a majority of the outstanding shares of Jade&#8217;s common stock and preferred stock, voting together as a single class on an as-converted basis and the holders of a majority of the outstanding shares of Jade Preferred Stock, voting as a separate class, to (x)&#160;adopt and approve the Merger Agreement and the Merger or the transactions contemplated thereby (including the Merger), (y)&#160;acknowledge that the approval given thereby is irrevocable and that such stockholders are aware of their rights to demand appraisal for their shares pursuant to Section&#160;262 of the DGCL, and that such stockholder has received and read a copy of Section&#160;262 of the DGCL and (z)&#160;acknowledge that by their approval of the Merger, they are not entitled to appraisal rights with respect to their shares in connection with the Merger and thereby waive any rights to receive payment of the fair value of their capital stock under the DGCL. Reasonably promptly following receipt of such consents, Jade will prepare, and cause to be mailed to its stockholders who did not execute such consents, a notice in accordance with the DGCL.</p><a id="MergerAgreement_RegulatoryApproval"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Regulatory Approvals</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each party agreed to use commercially reasonable efforts to file or otherwise submit, as soon as practicable after the date of the Merger Agreement, all applications, notices, reports and other documents reasonably required to be filed by such party with or otherwise submitted by such party to any governmental authority with respect to the transactions contemplated by the Merger Agreement, and to submit promptly any additional information requested by any such governmental authority. Aerovate and Jade do not intend to seek any regulatory approval from antitrust or other regulatory authorities to consummate the transactions.</p><a id="MergerAgreement_Indemnification_Insuranc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Indemnification and Insurance for Directors and Officers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Merger Agreement, from the First Effective Time through the sixth anniversary of the date on which the First Effective Time occurs, Aerovate and the surviving entity in the Second Merger agreed to indemnify and hold harmless each person who is now, or has been at any time prior to the date of the Merger Agreement, or who becomes prior to the First Effective Time, a director or officer of Aerovate or Jade, respectively, against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements, incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the indemnified officer or director is or was a director or officer of Aerovate or of Jade, whether asserted or claimed prior to, at or after the First Effective Time, in each case, to the fullest extent permitted under the DGCL. From and after the First Effective Time, Aerovate and the surviving corporation in the Merger will also fulfill Aerovate&#8217;s and Jade&#8217;s indemnity obligations, respectively, to each person who is, has been, or who becomes prior to the First Effective Time, a director or officer of Aerovate or Jade.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The certificate of formation and limited liability company agreement of the surviving entity will contain provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those presently set forth in Aerovate&#8217;s certificate of incorporation and Aerovate&#8217;s amended and restated bylaws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From and after the First Effective Time, Aerovate will maintain director and officers&#8217; liability insurance policies, with an effective date as of the Closing Date, on commercially available terms and conditions and with coverage limits customary for U.S. public companies similarly situated to Aerovate. In addition, Aerovate will secure and purchase a six&#160;year &#8220;tail policy&#8221; on Aerovate&#8217;s existing directors&#8217; and officers&#8217; liability insurance policy with an effective date as of the date of the closing of the First Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Closing Cash Dividend</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Aerovate shall declare the Cash Dividend to the holders of record of outstanding shares of Aerovate common stock as of a record date prior to the first effective time, to be determined by the Aerovate board of directors, which shall be implemented and performed such that Aerovate&#8217;s Net Cash, after taking into account such Cash Dividend, shall be no less than $0 as of the Closing. Subject to such adjustment, and as set forth in the Merger Agreement, the Cash Dividend shall be approximately $65.0 million in the aggregate. </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">148</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The ex-dividend date in respect of such Cash Dividend (i.e. the date on which shares of Aerovate common stock shall trade without the right to receive the Cash Dividend) will be determined by Nasdaq. Aerovate stockholders of record who continue to hold their eligible shares of Aerovate common stock until market open on the ex-dividend date will be entitled to payment of the Cash Dividend. Aerovate expects the Cash Dividend to be paid to Aerovate stockholders of record entitled to receive the Cash Dividend prior to the Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Additional Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each of Aerovate and Jade has agreed to use its reasonable best efforts to cause to be taken all actions necessary to consummate the Merger and the other transactions contemplated by the Merger Agreement. In connection therewith, each party has agreed to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">make all filings and other submissions (if any) and give all notices (if any) required to be made and given by such party in connection with the transactions contemplated by the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">use commercially reasonable efforts to obtain each consent (if any) reasonably required to be obtained (pursuant to any applicable law or contract, or otherwise) in connection with the Merger and the other transactions contemplated by the Merger Agreement or for such contract to remain in full force and effect;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">use commercially reasonable efforts to lift any injunction prohibiting, or any other legal bar to, the transactions contemplated by the Merger Agreement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">use commercially reasonable efforts to satisfy the conditions precedent to the consummation of the Merger Agreement.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Merger Agreement, Aerovate and Jade have further agreed that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aerovate will use its commercially reasonable efforts to maintain its listing on Nasdaq and cause the shares of Aerovate common stock (including any shares of Aerovate common stock issuable upon conversion of the Aerovate Series&#160;A Preferred Stock) being issued in the Merger to be approved for listing on Nasdaq at or prior to the First Effective Time.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aerovate will keep Jade reasonably informed regarding any stockholder litigation against Aerovate or any of its directors relating to the Merger Agreement or the transactions contemplated thereby. Aerovate will (i)&#160;give Jade the opportunity to participate in the defense, settlement or prosecution of any such litigation (ii)&#160;consult with Jade with respect to the defense, settlement and prosecution of any such litigation and (iii)&#160;consider in good faith Jade&#8217;s advice with respect to such litigation.</span></td></tr></table><div style="margin-top:10pt;"><a id="ConditionstotheCompletionoftheMerger_982"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Conditions to the Completion of the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following contains a description of all material conditions to the completion of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each party&#8217;s obligation to complete the Merger is subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by each of the parties, at or prior to the Closing, of various conditions, which include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the registration statement on Form&#160;S-4, of which this proxy statement/prospectus is a part, must have been declared effective by the SEC in accordance with the Securities Act and must not be subject to any stop order or any proceeding seeking a stop order that has not been withdrawn; and any material state securities laws applicable to the issuance of the shares of Aerovate&#8217;s capital stock in connection with the Merger or any of the other transactions contemplated by the Merger Agreement shall have been complied with and no stop order (or similar order) shall have been issued or threatened in writing in respect of such shares of Aerovate&#8217;s capital stock by any applicable state securities commissioner or court of competent jurisdiction;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">there must not have been issued, and remain in effect, any order preventing the consummation of the Merger or any of the other transactions contemplated by the Merger Agreement by any governmental authority of competent jurisdiction, and there must not be any law, statute, ordinance, rule, code, regulation, order, judgment, injunction, decree or other legally enforceable requirement in effect which has the effect of making the consummation of the Merger or any of the other transactions contemplated by the Merger Agreement illegal;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the holders of a majority of the outstanding shares of Jade&#8217;s common stock and preferred stock, voting together as a single class on an as-converted basis and the holders of a majority of the outstanding shares of Jade Preferred Stock, voting as a </span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">149</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">separate class, must have adopted and approved the Merger Agreement and the transactions contemplated thereby by written consent, or the Jade stockholder approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the holders of the shares of Aerovate common stock constituting a majority of the votes properly cast at the Aerovate Special Meeting must have approved the Merger Agreement and the transactions contemplated thereby;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the initial listing application for Aerovate&#8217;s common stock on Nasdaq (including any shares of Aerovate&#8217;s common stock issuable upon conversion of the shares of Aerovate Series&#160;A Preferred Stock) shall have been approved by Nasdaq;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the lock-up agreements executed by certain stockholders of Jade will continue to be in full force and effect as of immediately following the First Effective Time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Aerovate Charter amendment shall have been duly filed with the Secretary of State of the State of Delaware, containing such amendments as are necessary to consummate the transactions contemplated by the Merger Agreement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aerovate shall have filed a Certificate of Designation with the Secretary of State of the State of Delaware designating the Aerovate Series&#160;A Preferred Stock.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, each party&#8217;s obligation to complete the Merger is further subject to the satisfaction or waiver by that party of the following additional conditions:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the other party&#8217;s representations and warranties being true and correct as of the Closing Date, subject to applicable materiality qualifiers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the other party to the Merger Agreement must have performed or complied with in all material respects all of such party&#8217;s agreements and covenants required to be performed or complied with by it under the Merger Agreement at or prior to the First Effective Time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the lack of a material adverse effect that is continuing with respect to the other party; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the other party having delivered certain certificates and other documents required under the Merger Agreement for the Closing.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the obligation of Aerovate and Merger Subs to complete the Merger is further subject to the Subscription Agreement being in full force and effect and cash proceeds of not less than $175 million having been received by Jade, substantially simultaneously with the Closing.</p><a id="MergerAgreement_Termination_TermFees"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Termination and Termination Fee</b></p><a id="MergerAgreement_Termination"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Termination of the Merger Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement may be terminated at any time before the First Effective Time, whether before or after the required stockholder approvals to complete the Merger have been obtained, as set forth below:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">by mutual written consent of Aerovate and Jade;</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">by either Aerovate or Jade, if the Merger has not been consummated by April&#160;30, 2025 (subject to possible extension as provided in the Merger Agreement); </span><i style="color:#231f20;font-style:italic;">provided, however</i><span style="color:#231f20;">, that this right to terminate the Merger Agreement will not be available to any party whose action or failure to act has been a principal cause of the failure of the Merger to occur on or before April&#160;30, 2025 and such action or failure to act constitutes a breach of the Merger Agreement;</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">by either Aerovate or Jade, if a court of competent jurisdiction or governmental entity has issued a final and non-appealable order, or has taken any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting the Merger or any of the transactions contemplated by the Merger Agreement;</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="color:#231f20;">(d)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="color:#231f20;">by either Aerovate or Jade, if the Jade stockholder approval has not been obtained within two business&#160;days of the registration statement on Form&#160;S-4, of which this proxy statement/prospectus is a part, becoming effective; </span><i style="color:#231f20;font-style:italic;">provided </i><span style="color:#231f20;">that this right to terminate the Merger Agreement will not be available to Aerovate or Jade once Jade obtains such stockholder </span></p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">150</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="color:#231f20;">approval; and </span><i style="color:#231f20;font-style:italic;">provided, further</i><span style="color:#231f20;">, that this right to terminate the Merger Agreement will not be available to any party whose action or failure to act has been a principal cause of the failure to obtain the Jade stockholder approval and such action or failure to act constitutes a breach of the Merger Agreement;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">(e)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">by either Aerovate or Jade, if the Aerovate Special Meeting has been held and completed and Aerovate stockholders have taken a final vote on the Merger Proposals set forth herein to be considered at the Aerovate Special Meeting, and the Merger Proposals have not been approved by the Aerovate stockholders; </span><i style="color:#231f20;font-style:italic;">provided </i><span style="color:#231f20;">that this right to terminate the Merger Agreement will not </span>be available to any party whose action or failure to act has been a principal cause of the failure to obtain the Aerovate stockholder approval at the Aerovate Special Meeting and such action or failure to act constitutes a breach of the Merger Agreement;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(f)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">by Jade, at any time prior to obtaining the approval by Aerovate stockholders of the Merger Proposals set forth herein to be considered at the Aerovate Special Meeting, if any of the following circumstances shall occur:</span></p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aerovate fails to include in this proxy statement/prospectus Aerovate&#8217;s board of directors&#8217; recommendation that Aerovate stockholders vote to approve the Merger Proposals set forth herein to be considered at the Aerovate Special Meeting;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aerovate&#8217;s board of directors, or any committee thereof, makes an Aerovate board recommendation change in a manner adverse to Jade (or publicly proposes to do so), or adopts, approves or recommends any Acquisition Proposal (or publicly proposes to do so);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aerovate enters into any letter of intent or similar document or any contract relating to any Acquisition Proposal, other than a confidentiality agreement permitted pursuant to the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a tender offer or exchange offer for outstanding shares of Aerovate common stock commences, and Aerovate&#8217;s board of directors (or any committee thereof) recommends that the Aerovate stockholders tender their shares in such tender or exchange offer or, within ten business&#160;days after the commencement of such tender offer or exchange offer, Aerovate&#8217;s board of directors fails </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to recommend against acceptance of such offer; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aerovate fails to issue a press release confirming Aerovate&#8217;s board of directors&#8217; recommendation that Aerovate stockholders vote to approve the Merger Proposals set forth herein to be considered at the Aerovate Special Meeting within ten business&#160;days following Jade&#8217;s written request to Aerovate to issue such press release in response to any other publicly announced Acquisition Proposal with respect to Aerovate.</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(g)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">by Aerovate, at any time prior to obtaining the Jade stockholder approval, if any of the following circumstances shall occur:</span></p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade&#8217;s board of directors publicly approves, endorses or recommends any Acquisition Proposal; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade enters into any letter of intent or similar document or any contract relating to any Acquisition Proposal, other than a confidentiality agreement permitted pursuant to the Merger Agreement;</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(h)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">by Jade, if Aerovate or Merger Subs have breached any of their representations, warranties, covenants or agreements contained in the Merger Agreement or if any representation or warranty of Aerovate has become inaccurate, in either case such that the conditions to the Closing would not be satisfied as of time of such breach or inaccuracy; </span><i style="color:#231f20;font-style:italic;">provided </i><span style="color:#231f20;">that Jade is not then in material breach of any representation, warranty covenant or agreement under the Merger Agreement; </span><i style="color:#231f20;font-style:italic;">provided, further</i><span style="color:#231f20;">, if such breach or inaccuracy is curable, then Jade shall not be permitted to terminate the Merger Agreement pursuant to this paragraph as a result of a particular breach or inaccuracy until the earlier of (i)&#160;the expiration of a 30-day period after delivery of written notice of such breach or inaccuracy from Jade to Aerovate or Merger Subs and Jade&#8217;s intention to terminate pursuant to this paragraph and (ii)&#160;Aerovate and Merger Subs (as applicable) ceasing to exercise commercially reasonable efforts to cure such breach following delivery of such written notice (it being understood that Jade shall not be permitted to terminate the Merger Agreement pursuant to this paragraph as a result of such particular breach or inaccuracy if such breach by Aerovate or Merger Subs is cured prior to such termination becoming effective);</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="color:#231f20;">by Aerovate, if Jade has breached any of its representations, warranties, covenants or agreements contained in the Merger Agreement or if any representation or warranty of Jade has become inaccurate, in either case such that the conditions to the Closing would not be satisfied as of time of such breach or inaccuracy; </span><i style="color:#231f20;font-style:italic;">provided </i><span style="color:#231f20;">that Aerovate is not then in material breach of any representation, warranty covenant or agreement under the Merger Agreement; </span><i style="color:#231f20;font-style:italic;">provided, further</i><span style="color:#231f20;">, if such breach or </span></p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">151</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="color:#231f20;">inaccuracy is curable, then Aerovate shall not be permitted to terminate the Merger Agreement pursuant to this paragraph as a result of a particular breach or inaccuracy until the earlier of (i)&#160;the expiration of a 30-day period after delivery of written notice of such breach or inaccuracy from Aerovate to Jade and Aerovate&#8217;s intention to terminate pursuant to this paragraph and (ii)&#160;Jade ceasing to exercise commercially reasonable efforts to cure such breach following delivery of such written notice (it being understood that the Merger Agreement will not </span>terminate pursuant to this paragraph as a result of such particular breach or inaccuracy if such breach by Jade is cured prior to such termination becoming effective); or</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(j)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">by Aerovate (at any time prior to obtaining the Aerovate stockholder approval), concurrently with Aerovate&#8217;s entering into a definitive agreement for a superior offer, subject to certain conditions.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Termination Fees Payable by Aerovate</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate must pay Jade a termination fee of $2,340,000 if (i)&#160;the Merger Agreement is terminated by Aerovate or Jade pursuant to clause (e)&#160;above or by Jade pursuant to clause (f)&#160;above, (ii)&#160;at any time after the date of the Merger Agreement and prior to the Aerovate Special Meeting, an Acquisition Proposal with respect to Aerovate will have been publicly announced, disclosed or otherwise communicated to Aerovate&#8217;s board of directors (and will not have been withdrawn), and (iii)&#160;within 12&#160;months after the date of such termination, Aerovate enters into a definitive agreement with respect to a subsequent transaction or consummates a subsequent transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Termination Fees Payable by Jade</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade must pay Aerovate a termination fee of $5,250,000 if (i)&#160;the Merger Agreement is terminated by Aerovate or Jade pursuant to clause (d)&#160;above or by Aerovate pursuant to clause (g)&#160;above, (ii)&#160;at any time after the date of the Merger Agreement and before obtaining the Jade stockholder approval, an Acquisition Proposal with respect to Jade will have been publicly announced, disclosed or otherwise communicated to Jade&#8217;s board of directors (and will not have been withdrawn), and (iii)&#160;within six&#160;months after the date of such termination, Jade enters into a definitive agreement with respect to a subsequent transaction or consummates a subsequent transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Amendment and Waiver</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement may be amended by the parties to the Merger Agreement by action taken or authorized by their respective boards of directors at any time, whether before or after the approval of the Merger Agreement by either party&#8217;s stockholders has been obtained; <i style="font-style:italic;">provided</i>, that after approval of the Merger Agreement has been obtained by either party&#8217;s stockholders, no amendment may be made that pursuant to applicable law requires further approval or adoption by the stockholders of either party, without such further approval or adoption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any provision of the Merger Agreement may be waived by any party solely on that party&#8217;s behalf, without the consent of any other party, to the extent permitted by applicable law; <i style="font-style:italic;">provided</i>, that after approval of the Merger Agreement has been obtained by either party&#8217;s stockholders, no waiver may be made that pursuant to applicable law requires further approval or adoption by the stockholders of either party, without such further approval or adoption. The waiver must be expressly set forth in a written instrument duly executed and delivered on behalf of such party, which will only be valid in the specific instance in which it is given. No failure or delay on the part of any party with respect to the exercise of any right or power under the Merger Agreement will operate as a waiver of such right or power. Furthermore, no single or partial exercise of any such right or power will preclude any other or further exercise thereof or of any other right or power.</p><a id="MergerAgreement_Termination_Fees"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Fees and Expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Merger Agreement provides all fees and expenses incurred in connection with the Merger Agreement and the transactions contemplated thereby shall be paid by the party incurring such expenses, except as described above in the section titled &#8220;<i style="font-style:italic;">The Merger Agreement &#8212; Termination and Termination Fees</i>&#8221; beginning on page&#160;150 of this proxy statement/prospectus, and except that Aerovate and Jade will share equally in any fees and expenses incurred in relation to the filings with the SEC of the registration statement on Form&#160;S-4 (including any financial statements and exhibits) and any related amendments or supplements and paid to a financial printer or the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">152</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_4037d27d_b2c7_4ad0_9323_b19e48dd1c72"></a><a id="AGREEMENTSRELATEDTOTHEMERGER_818530"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AGREEMENTS RELATED TO THE MERGER</b></p><a id="Agreement_Related_SupportAgreement"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Support Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain Jade stockholders holding approximately 99.0% of the outstanding shares of Jade capital stock have entered into Jade Support Agreements with Aerovate and Jade to vote all of their shares of Jade capital stock in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby and against any alternative Acquisition Proposals. Certain Aerovate stockholders holding approximately 38.1% of the outstanding shares of Aerovate common stock have entered into Aerovate Support Agreements with Aerovate and Jade to vote all of their shares of Aerovate common stock in favor of, among others, the proposals presented herein.</p><a id="Agreement_Related_LockUp"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Lock-Up Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain of Jade&#8217;s executive officers, directors and stockholders have entered into lock-up agreements, pursuant to which such parties have agreed not to, except in limited circumstances, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Aerovate&#8217;s common stock or any securities convertible into or exercisable or exchangeable for Aerovate common stock, currently or thereafter owned, including shares of Aerovate common stock issuable upon conversion of Aerovate Series&#160;A Preferred Stock issued in exchange for shares of Jade Preferred Stock in the Merger, but excluding, as applicable, shares purchased by existing Jade stockholders in the Jade Pre-Closing Financing (including any shares of Aerovate common stock issuable upon exercise of pre-funded warrants issued in exchange for pre-funded warrants to purchase shares of Jade common stock sold in the Jade Pre-Closing Financing), until 180&#160;days after the effective time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Jade stockholders who have executed lock-up agreements as of October&#160;30, 2024 owned, in the aggregate, approximately 99.0% of the shares of Jade&#8217;s outstanding capital stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The foregoing description of the lock-up agreements does not purport to be complete and is qualified in its entirety by the full text of the form of lock-up agreement, which is attached hereto as <i style="font-style:italic;">Annex H</i>.</p><a id="Agreement_Related_SubscriptionAgreement"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Subscription Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Concurrently with the execution and delivery of the Merger Agreement, certain new and existing investors of Jade entered into the Subscription Agreement with Jade, pursuant to which such investors have agreed to purchase immediately prior to the Merger, shares of Jade common stock or, in lieu thereof, Jade pre-funded warrants, representing an aggregate commitment of approximately $300.0 million (which reflects the conversion of the previously issued $95 million of convertible notes), in the Jade Pre-Closing Financing. The convertible notes convert into shares of Jade common stock equal to the principal plus accrued and unpaid interest divided by the applicable conversion price thereunder. For purposes of the Jade Pre-Closing Financing, the conversion price is equal to the price per share sold in the Jade Pre-Closing Financing multiplied by 0.80. Accordingly, the aggregate value of shares of Jade common stock or Jade pre-funded warrants received by holders of convertible notes in the Jade Pre-Closing Financing is approximately $126.3 million and the value of the remaining shares of Jade common stock or pre-funded warrants issued in the Jade Pre-Closing Financing is $205 million, for a total value of securities issued of approximately $331.3 million. Under the Subscription Agreement, the number of shares of Jade common stock or pre- funded warrants, as applicable, shall be determined at a purchase price per share or pre-funded warrant equal to (i)&#160;a valuation for Jade equal to approximately $175 million, (ii)&#160;divided by the number of shares of Jade common stock outstanding immediately prior to the First Effective Time (including the securities being issued under the Subscription Agreement).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The shares of Jade common stock and Jade pre-funded warrants that are issued in the Jade Pre- Closing Financing will be or will have the right to be, respectively, converted into shares of Aerovate common stock in the Merger. Accordingly, by approving Proposal No.&#160;1 relating to the Merger, Aerovate stockholders will also be approving the issuance of shares of Aerovate common stock to be issued in exchange for all shares of Jade common stock and pre-funded warrants that are sold in the Jade Pre-Closing Financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Subscription Agreement contains customary representations and warranties of Jade and also contains customary representations and warranties of the purchaser parties thereto.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">153</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each purchaser&#8217;s obligation to purchase shares of Jade common stock and/or Jade pre-funded warrants from Jade pursuant to the Subscription Agreement is subject to the satisfaction or waiver of certain conditions, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade&#8217;s representations and warranties in the Subscription Agreement being true and correct in all respects as of the effective date of the Subscription Agreement and true and correct in all material respects as of the closing date for the Jade Pre-Closing Financing, subject to certain exceptions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade having performed and complied in all material respects with the obligations and conditions required to be performed or complied with by it;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the issuance of a compliance certificate by an authorized officer of Jade;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all consents, permits, approvals, registrations and waivers necessary for the consummation of the purchase and sale of the securities under the Subscription Agreement having been obtained and in full force and effect;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the issuance of a secretary&#8217;s certificate by the secretary of Jade;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the satisfaction or waiver of all conditions to the Closing set forth in the Merger Agreement (other than the condition regarding the Jade Pre-Closing Financing and other than those conditions which, by their nature, are to be satisfied at the Closing of the transactions contemplated by the Merger) and the Closing being set to occur substantially concurrently with the closing of the Jade Pre-Closing Financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no injunction having been issued prohibiting the consummation of the Jade Pre-Closing Financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade having delivered the registration rights agreement required by the Subscription Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">this registration statement on Form&#160;S-4 shall have been become effective under the Securities Act, no stop order shall be suspending the effectiveness of this registration statement and no proceeding for that purpose shall have been initiated or threatened in writing by the SEC;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Nasdaq Listing Application shall have been approved by Nasdaq;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no material adverse effect shall have occurred that is continuing, since the date of the Subscription Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade having received at Closing aggregate proceeds from the purchase of securities pursuant to the Subscription Agreement of not less than $175 million (including in the proceeds any convertible securities contributed as consideration in accordance with the Subscription Agreement); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an opinion from Company counsel, dated as of the Closing.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s obligation to sell shares of Jade common stock to each purchaser pursuant to the Subscription Agreement is subject to the satisfaction or waiver of certain conditions, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the representations and warranties made by the purchasers being true and correct as of the closing date of the Jade Pre-Closing Financing, subject to certain exceptions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each purchaser having performed and complied with all obligations and conditions required to be performed or complied with by each purchaser;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no injunction having been issued prohibiting the consummation of the Jade Pre-Closing Financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each investor having delivered the registration rights agreement required by the Subscription Agreement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade having received payment in full from each investor as required by the Subscription Agreement, subject to certain exceptions.</span></td></tr></table><div style="margin-top:10pt;"></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">154</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Agreement_Related_RegisRightsAgreement"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Registration Rights Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Subscription Agreement contemplates Aerovate, Jade and the investors participating in the Jade Pre-Closing Financing entering into a registration rights agreement at the closing of the Jade Pre-Closing Financing, pursuant to which, among other things, the Combined Company will agree to provide for the registration and resale of certain shares of Jade common stock that are held by the investors participating in the Jade Pre-Closing Financing from time to time, including the shares of Aerovate common stock issued in exchange for shares of Jade common stock sold in the Jade Pre-Closing Financing and Jade pre-funded warrants assumed upon conversion of the Jade pre-funded warrants sold in the Jade Pre-Closing Financing (including shares issuable upon exercise of such pre-funded warrants).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the registration rights agreement, the Combined Company will agree to prepare and file a resale registration statement covering the resale of the Aerovate common stock within 30 business&#160;days of the Closing pursuant to Rule&#160;415 and to use its commercially reasonable efforts to keep such registration statement continuously effective under the Securities Act until the earlier of (a)&#160;the date that all registrable securities covered by such registration statement (i)&#160;have been sold thereunder or pursuant to Rule&#160;144 of the Securities Act (&#8220;Rule&#160;144&#8221;), or (ii)&#160;may be sold without volume or manner-of-sale restrictions pursuant to Rule&#160;144 and without the requirement for the Combined Company to be in compliance with the current public information requirement under Rule&#160;144, and (b)&#160;five&#160;years after the date of the registration rights agreement.</p><a id="RRA_Endpara"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The registration rights agreement also provides that the Combined Company will pay certain expenses relating to such registrations and indemnify the applicable securityholders against certain liabilities. The form of registration rights agreement is filed as Exhibit&#160;10.5 to this registration statement on Form&#160;S-4 of which this proxy statement/prospectus is a part, and the foregoing description of the registration rights agreement is qualified in its entirety by reference thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">155</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_ee5c2f98_45cd_40f3_8490_bca67af00333"></a><a id="EQUITYCOMPENSATIONPLANINFORMATION_273176"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EQUITY COMPENSATION PLAN INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table provides information as of December&#160;31, 2023, with respect to the securities authorized for issuance under Aerovate&#8217;s equity compensation plans, consisting of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2018 Equity Incentive Plan</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2021 Stock Option and Incentive Plan</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2021 Employee Stock Purchase Plan</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:17.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:18.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Plan Category</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Securities&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">to&#160;be&#160;Issued&#160;Upon&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Exercise&#160;of&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Outstanding&#160;Options,&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Warrants&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">and&#160;Rights</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Exercise&#160;Price&#160;of&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Outstanding&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Options,&#160;Warrants</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">and&#160;Rights</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Securities&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Available&#160;for&#160;Future&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Issuance&#160;Under&#160;Equity&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Compensation&#160;Plans</b></p></td></tr><tr><td style="vertical-align:top;width:43.2%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Equity compensation plans approved by security holders<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.55%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5,252,312<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.53%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1,039,615<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)(4)</sup></p></td></tr><tr><td style="vertical-align:top;width:43.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Equity compensation plans not approved by security holders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:17.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:17.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">5,252,312</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">13.66</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">1,039,615</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">Consists of Aerovate&#8217;s 2021 Plan, 2018 Plan, and 2021 Employee Stock Purchase Plan (&#8220;ESPP&#8221;). Following Aerovate&#8217;s IPO, Aerovate has not and will not grant any awards under its 2018 Plan, but all outstanding awards under the 2018 Plan will continue to be governed by their existing terms. The shares of common stock underlying any awards granted under the 2018 Plan or 2021 Plan that are forfeited, canceled, reacquired by Aerovate prior to vesting, satisfied without the issuance of stock, or otherwise terminated (other than by exercise) and the shares of common stock that are withheld upon exercise </span>of a stock option or settlement of such award to cover the exercise price or tax withholding will be added to the shares of common stock available for issuance under the 2021 Plan.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(2)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">Includes 5,230,344 shares of common stock issuable upon the exercise of outstanding options and 21,968 shares of common stock issuable upon the settlement of outstanding restricted stock unit awards. Does not include shares of restricted stock as they have been reflected in our total shares outstanding.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(3)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">As of December&#160;31, 2023, there were 604,363 shares available for future issuance under the 2021 Plan and 435,252 shares available for future issuance under the ESPP.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(4)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">The 2021 Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January&#160;1, beginning on January&#160;1, 2022, by an amount equal to the lesser of (i)&#160;4% of the total number of outstanding shares of our common stock on the last trading day in December&#160;in the prior&#160;year or (ii)&#160;such lesser number as determined by Aerovate&#8217;s board of directors. On January&#160;1, 2024, the number of shares available for issuance under the 2021 Plan increased automatically by 1,110,508 shares pursuant to this provision. This increase is not reflected in the table above. The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January&#160;1, beginning on January&#160;1, 2022, by an amount equal to the lesser of (i)&#160;1% of the total number of outstanding shares of our common stock on the last trading day in December&#160;in the prior&#160;year, or (ii)&#160;such lesser number as determined by Aerovate&#8217;s board of directors. On January&#160;1, 2024, the number of shares available for issuance under the ESPP was not increased pursuant to this provision.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">156</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_bdc2445c_4324_4a1e_a3e8_8ffca6b86724"></a><a id="JADEEXECUTIVECOMPENSATION_402680"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">JADE EXECUTIVE COMPENSATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following completion of the Merger, the executive officers of Jade will become executive officers of the Combined Company. Because Jade was not formed until 2024, there were no executive officers during 2023. This section sets forth the current compensatory arrangements for the following executive officers of Jade as of November&#160;15, 2024, each of whom is expected to become an executive officer of the Combined Company.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:46.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:30.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NAME</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">POSITION</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">APPOINTMENT&#160;DATE</b></p></td></tr><tr><td style="vertical-align:top;width:30.2%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Tom Frohlich</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:46.59%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">October 3, 2024</p></td></tr><tr><td style="vertical-align:top;width:30.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Jonathan Quick</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:46.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President, Finance and Treasurer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">September 23, 2024</p></td></tr><tr><td style="vertical-align:top;width:30.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Andrew King, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:46.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Scientific Officer &amp; Head of Research and Development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">August 1, 2024</p></td></tr><tr><td style="vertical-align:top;width:30.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Hetal Kocinsky, M.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:46.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 0pt 0pt;">Chief Medical Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 0pt 0pt;">September 9, 2024</p></td></tr><tr><td style="vertical-align:top;width:30.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Elizabeth Balta, J.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:46.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 0pt 0pt;">General Counsel and Corporate Secretary</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 0pt 0pt;">October 22, 2024</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Offer Letters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the commencement of their employment with Jade, Jade entered into offer letters with each of Jade&#8217;s executive officers, as described below. For purposes of the following descriptions, &#8220;cause,&#8221; &#8220;change in control,&#8221; and &#8220;good reason&#8221; have the meanings provided under the respective offer letter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Offer Letter with Mr.&#160;Frohlich</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Mr.&#160;Frohlich&#8217;s offer letter provides for an annual base salary of $600,000 and an annual target bonus equal to 50% of his base salary, pro-rated for 2024. The offer letter also provides for (i)&#160;an initial grant of stock options to purchase 5% of Jade&#8217;s fully-diluted equity, which will vest 25% on October&#160;3, 2025 and in equal&#160;monthly installments for the 36&#160;months thereafter, and (ii)&#160;periodic grants of stock options sufficient to maintain Mr.&#160;Frohlich&#8217;s ownership at approximately 5% on a fully-diluted basis until Jade has raised an aggregate of $200 million in financing, to vest in equal&#160;monthly installments for the 48&#160;months after the applicable date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under Mr.&#160;Frohlich&#8217;s offer letter, in the event of Mr.&#160;Frohlich&#8217;s termination by Jade without cause prior to (or more than 12&#160;months following) a change in control of Jade, he is eligible for the following severance benefits, subject to his execution and non-revocation of a release of claims: (i)&#160;severance payments equal to 12&#160;months of his base salary (which payment will be inclusive of his Canadian statutory entitlements), plus an additional 15% to account for lost benefits, (ii)&#160;any earned but unpaid bonus for the&#160;year prior to the&#160;year of termination, and (iii)&#160;accelerated vesting with respect to 30% of the unvested portion of his outstanding time-based equity awards if such termination occurs after October&#160;3, 2025. Upon a termination by Jade without cause or his resignation for good reason within 12&#160;months following a change in control, he will be eligible to receive the foregoing severance benefits; however, 100% of his outstanding time-based equity awards will accelerate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Offer Letters with Mr.&#160;Quick, Dr.&#160;Kocinsky and Ms.&#160;Balta</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to Mr.&#160;Quick&#8217;s offer letter, Mr.&#160;Quick is eligible to receive an annual base salary of $320,000 and an annual target bonus equal to 35% of his base salary, pro-rated for 2024. Dr.&#160;Kocinsky&#8217;s offer letter provides for an annual base salary of $450,000 and an annual target bonus equal to 40% of her base salary, pro-rated for 2024. Ms.&#160;Balta&#8217;s offer letter provides for an annual base salary of $400,000 and an annual target bonus equal to 35% of her base salary, pro-rated for 2024. The offer letters also provide for initial grants of stock options to purchase 132,786 shares for Mr.&#160;Quick, 295,081 shares for Dr.&#160;Kocinsky and 221,311 shares for Ms.&#160;Balta, in each case, which will vest 25% on the first anniversary of their respective appointment dates and in equal&#160;monthly installments for the 36&#160;months thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Mr.&#160;Quick, Dr.&#160;Kocinsky and Ms.&#160;Balta are also eligible to receive the same severance benefits as described below for Dr.&#160;King under their respective offer letters, except that for Mr.&#160;Quick and Ms.&#160;Balta, the cash severance payments will be equal to six&#160;months of their respective base salaries and the Jade- subsidized continued health coverage will continue for up to six&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Offer Letter with Dr.&#160;King</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Under Dr.&#160;King&#8217;s offer letter, he is eligible to receive an annual base salary of $470,000 and an annual target bonus equal to 35% of his base salary, pro-rated for 2024. In connection with his employment, Dr.&#160;King purchased 546,448 shares of Jade&#8217;s common stock </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">157</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">at a nominal amount on the purchase date, which will vest as to 25% on August&#160;1, 2025 and in equal&#160;monthly installments for the 36&#160;months thereafter. The offer letter also provides that Dr.&#160;King will receive periodic grants of stock options, subject to approval by Jade&#8217;s board of directors, sufficient to maintain Dr.&#160;King&#8217;s ownership at approximately 2% on a fully- diluted basis until Jade has raised an aggregate of $200 million in financing. Such options, if granted, will be subject to&#160;monthly vesting over 48&#160;months from the applicable date of grant. In accordance with such provision, on September&#160;4, 2024, Jade&#8217;s board of directors approved the grant of 43,716 options to Dr.&#160;King under the Amended and Restated Jade Biosciences,&#160;Inc. 2024 Equity Incentive Plan, which vest&#160;monthly over the 48&#160;months following the grant date. Separately, on October&#160;29, 2024, Jade&#8217;s board of directors approved the grant of 293,771 options to Dr.&#160;King, which will vest as to 25% on August&#160;1, 2025 and in equal&#160;monthly installments for the 36&#160;months thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under Dr.&#160;King&#8217;s offer letter, in the event of Dr.&#160;King&#8217;s termination by Jade without cause prior to (or more than 12&#160;months following) a change in control of Jade, he is eligible for the following severance benefits, subject to his execution and non-revocation of a release of claims: (i)&#160;severance payments equal to 12&#160;months of his base salary, (ii)&#160;any earned but unpaid bonus for the&#160;year prior to the&#160;year of termination, and (iii) <span style="color:#231f20;">Jade-subsidized continued health coverage for up to 12&#160;months. Upon a termination by Jade without cause or his resignation for good reason within 12&#160;months following a change in control, he will be eligible to receive the foregoing severance benefits as well as the full acceleration of his outstanding time-based equity awards.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary Description of the Amended and Restated Jade Biosciences,&#160;Inc. 2024 Equity Incentive Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade maintains an Amended and Restated 2024 Equity Incentive Plan (the &#8220;Jade 2024 EIP&#8221;), the purpose of which is to advance the interests of Jade&#8217;s stockholders by enhancing Jade&#8217;s ability to attract, retain and motivate persons who are expected to make important contributions to Jade and by providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align the interests of such persons with those of Jade&#8217;s stockholders. The Jade 2024 EIP provides for the issuance of up to 12,783,696 shares of Jade common stock, which may be granted as stock options, restricted stock, restricted stock units and other stock-based awards to eligible employees, officers, directors, consultants and advisors of Jade on such terms and conditions as approved by Jade&#8217;s board of directors or any committee appointed by Jade&#8217;s board of directors to administer the Jade 2024 EIP. No grants will be made under the Jade 2024 EIP following consummation of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">158</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_476da5f6_8ed2_4ed1_a463_96f5f9f4df47"></a><a id="JADEDIRECTORCOMPENSATION_571938"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">JADE DIRECTOR COMPENSATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because Jade was not formed until 2024, there were no directors during 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with his appointment as a member of Jade&#8217;s board of directors, Lawrence Klein purchased 136,612 shares of Jade common stock at a nominal amount on the purchase date. The purchased shares are subject to vesting as to 25% on the first anniversary of his commencement of services with Jade and in equal&#160;monthly installments for the 36&#160;months thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with their appointment to Jade&#8217;s board of directors, Erin Lavelle received a grant of stock options to purchase 73,770 shares of Jade common stock, and Eric Dobmeier received a grant of stock options to purchase 147,541 shares of Jade common stock. These stock options vest as to 25% on the first anniversary of the vesting commencement date (September&#160;26, 2024 for Ms.&#160;Lavelle and October&#160;23, 2024 for Mr.&#160;Dobmeier) and in equal&#160;monthly installments thereafter through the fourth anniversary of the vesting commencement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is expected that Jade will implement a non-employee director compensation program that is expected to include an annual cash retainer and annual equity grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">159</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_861b5028_dfe8_4f18_b7c3_2238a600d1ae"></a><a id="MATTERSBEINGSUBMITTEDTOAVOTEOFAEROVATEST"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">MATTERS BEING SUBMITTED TO A VOTE OF AEROVATE STOCKHOLDERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="PROPOSALNO1THENASDAQSTOCKISSUANCEPROPOSA"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PROPOSAL NO.&#160;1&#160;&#8212; THE NASDAQ STOCK ISSUANCE PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Aerovate Special Meeting, Aerovate stockholders will be asked to approve (i)&#160;the issuance of shares of Aerovate common stock (including the shares of Aerovate common stock issuable upon conversion of the Aerovate Series&#160;A Preferred Stock) to the stockholders of Jade pursuant to the Merger Agreement, which shares of Aerovate common stock will represent more than 20% of the shares of Aerovate common stock outstanding immediately prior to the Merger, and (ii)&#160;the change of control resulting from the Merger, pursuant to Nasdaq Listing Rules&#160;5635(a)&#160;and 5635(b), respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Immediately after the Merger, Aerovate securityholders as of immediately prior to the Merger are expected to own approximately 1.6% of the outstanding shares of capital stock of the Combined Company on a fully-diluted basis and former holders of Jade securities are expected to own approximately 98.4% of the outstanding shares of capital stock of the Combined Company on a fully-diluted basis, subject to certain assumptions, including, but not limited to, Aerovate&#8217;s Net Cash at Closing being $0.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate will assume outstanding and unexercised options and pre-funded warrants to purchase shares of Jade common stock, and such securities will be converted into options and pre-funded warrants, as applicable, to purchase shares of Aerovate common stock, subject to certain adjustments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, prior to the First Effective Time, Aerovate expects to declare the Cash Dividend to the pre- First Merger Aerovate stockholders equal in the aggregate to Aerovate&#8217;s reasonable, good faith approximation of the amount by which Aerovate&#8217;s Net Cash (as determined pursuant to the Merger Agreement) will exceed $0.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The terms of, reasons for and other aspects of the Merger Agreement, the Merger and the issuance of Aerovate common stock in the Merger are described in detail in the section of this proxy statement/ prospectus titled &#8220;<i style="font-style:italic;">The Merger Agreement</i>.&#8221; A copy of the Merger Agreement is attached as <i style="font-style:italic;">Annex A </i>to this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Reason for the Proposal</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under Nasdaq Listing Rule&#160;5635(a)(1), a company listed on Nasdaq is required to obtain stockholder approval prior to the issuance of common stock, among other things, in connection with the acquisition of another company&#8217;s stock, if the number of shares of common stock to be issued is in excess of 20% of the number of shares of common stock then outstanding. The potential issuance of the shares of Aerovate common stock in the Merger exceeds the 20% under the Nasdaq Listing Rules&#160;and is expected to represent approximately 98.4% of Aerovate&#8217;s common stock on a fully diluted basis immediately following the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accordingly, in order to ensure compliance with Nasdaq Listing Rule&#160;5635(a)(1), Aerovate must obtain the approval of Aerovate stockholders for the issuance of these shares of common stock in the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under Nasdaq Listing Rule&#160;5635(b), a company listed on Nasdaq is required to obtain stockholder approval prior to an issuance of stock that will result in a &#8220;change of control&#8221; of the listed company. It is expected that Nasdaq will determine that the Merger constitutes a &#8220;change of control&#8221; of the listed company. Accordingly, in order to ensure compliance with Nasdaq Listing Rule&#160;5635(b), Aerovate must obtain the approval of Aerovate stockholders of the change of control resulting from the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Required Vote</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The affirmative vote of a majority of the votes properly cast by the holders of Aerovate common stock at the Aerovate Special Meeting is required to approve the Nasdaq Stock Issuance Proposal. Abstentions and broker-non votes, if any, will have no effect on the Nasdaq Stock Issuance Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger is conditioned upon the approval of the Nasdaq Stock Issuance Proposal. Notwithstanding the approval of the Nasdaq Stock Issuance Proposal, if the Merger is not consummated for any reason, the actions contemplated by the Nasdaq Stock Issuance Proposal will not be effected.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">160</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Nasdaq Stock Issuance Proposal is conditioned on the approval of the Reverse Stock Split Proposal and the Authorized Share Increase Proposal. Notwithstanding the approval of the Nasdaq Stock Issuance Proposal, if the Reverse Stock Split Proposal and the Authorized Share Increase Proposal are not approved, the actions contemplated by the Nasdaq Stock Issuance Proposal will not be effected and the Merger will not be consummated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain Aerovate stockholders have agreed to vote any shares of Aerovate common stock owned by them in favor of the Nasdaq Stock Issuance Proposal. Please see the section titled &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#160;&#8212; Support Agreements</i>&#8221; beginning on page&#160;153 of this proxy statement/prospectus for more information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;FOR&#8221; the approval of the Nasdaq Stock Issuance Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE AEROVATE BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE NASDAQ STOCK ISSUANCE PROPOSAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">161</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_54167bcc_f4b6_4338_a686_d8e4affedd53"></a><a id="PROPOSALNO2THEREVERSESTOCKSPLITPROPOSAL_"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROPOSAL NO.&#160;2&#160;&#8212; THE REVERSE STOCK SPLIT PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">At the Aerovate Special Meeting, Aerovate stockholders will be asked to approve an amendment to the Aerovate Charter to effect a reverse stock split of the issued and outstanding shares of Aerovate common stock at a ratio in the range of one new share for every &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares and one new share for every&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares outstanding (or any number in between), to be determined mutually by the Aerovate board of directors and the Jade board of directors (the &#8220;Split Ratio&#8221;). The final Split Ratio and effectiveness of such amendment will be mutually agreed by the Aerovate board of directors and the Jade board of directors, assuming this proposal is approved by Aerovate&#8217;s stockholders. On&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024, the Aerovate board of directors adopted resolutions approving the proposed certificate of amendment to the Aerovate Charter in the form attached as <i style="font-style:italic;">Annex B </i>to this proxy statement/prospectus. If this certificate is filed with the Secretary of State of the State of Delaware, upon the effectiveness of such amendment (the &#8220;Reverse Stock Split Effective Time&#8221;), the issued and outstanding shares of Aerovate common stock immediately prior to the Reverse Stock Split Effective Time will automatically without further action on the part of Aerovate by combined into a smaller number of shares in accordance with the final Split Ratio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Aerovate board of directors may determine to effect the reverse stock split, if it is approved by the Aerovate stockholders, even if the other proposals to be acted upon at the meeting are not approved, including the issuance of Aerovate common stock pursuant to the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">By approving this Proposal No.&#160;2, Aerovate stockholders will: approve an amendment to the Aerovate Charter pursuant to which any whole number of issued and outstanding shares of Aerovate common stock, between and including to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, would be combined into one share of Aerovate common stock and will authorize the Aerovate board of directors to file such certificate of amendment, as mutually agreed by the Aerovate board of directors and Jade board of directors. As of the record date, 150,000,000 shares of Aerovate common stock were authorized&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, shares of Aerovate common stock were outstanding and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of Aerovate common stock were held in treasury.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">All holders of Aerovate common stock will be affected proportionately by the reverse stock split. No fractional shares of Aerovate common stock will be issued as a result of the reverse stock split. Instead, Aerovate stockholders who otherwise would be entitled to receive fractional shares will be entitled to receive cash as set forth below under the caption &#8220;No Fractional Shares.&#8221; Each Aerovate stockholder will hold the same&#160;percentage of the outstanding Aerovate common stock immediately following the reverse stock split as that Aerovate stockholder did immediately prior to the reverse stock split, except to the extent that the reverse stock split results in Aerovate stockholders receiving cash in lieu of fractional shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Should Aerovate receive the required stockholder approval for this Proposal No.&#160;2, and following such stockholder approval, the Aerovate board of directors, subject to agreement by Jade, determines that effecting the reverse stock split is in the best interests of Aerovate and its stockholders, the reverse stock split will become effective as specified in the amendment filed with the Secretary of State of the State of Delaware.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The amendment filed thereby will contain the number of shares selected by the Aerovate board of directors and Jade board of directors within the limits set forth in this Proposal No.&#160;2 to be combined into one share of Aerovate common stock. Accordingly, upon the effectiveness of the amendment to the Aerovate Charter, at the Reverse Stock Split Effective Time, every&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares (or any number in between) of Aerovate common stock outstanding immediately prior to the split effective time will be combined and reclassified into one share of Aerovate common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The proposed form of certificate of amendment to the Aerovate Charter to effect the reverse stock split, as more fully described below, will affect the reverse stock split but <span style="font-style:italic;font-weight:bold;">will not </span>change the number of authorized shares of Aerovate common stock or preferred stock, or the par value of Aerovate common stock or preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A copy of the proposed form of certificate of amendment to the Aerovate Charter to effect the reverse stock split is attached as <i style="font-style:italic;">Anne B </i>to this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Notwithstanding approval of this Proposal No.&#160;2 by Aerovate stockholders, the Aerovate board of directors may, in its sole discretion, abandon the proposed amendments and determine prior to the effectiveness of any filing with the Secretary of State of the State of Delaware not to effect the reverse stock split, as permitted under Section&#160;242(c)&#160;of the Delaware General Corporation Law.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">162</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Reasons for the Reverse Stock Split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Aerovate board of directors approved the proposal approving the amendment to the Aerovate Charter effecting the reverse stock split for the following reasons:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Aerovate board of directors believes effecting the reverse stock split will result in an increase in the minimum bid price of Aerovate common stock and reduce the risk of a delisting of Aerovate common stock from Nasdaq in the future; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Aerovate board of directors believes a higher stock price may help generate investor interest in Aerovate and ultimately the Combined Company and help Aerovate attract and retain employees.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If the reverse stock split successfully increases the per share price of Aerovate common stock, the Aerovate board of directors also believes this increase may increase trading volume in Aerovate common stock and facilitate future financings by Aerovate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Requirements for Listing on Nasdaq</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Aerovate common stock is listed on The Nasdaq Global Market under the symbol &#8220;AVTE.&#8221; Aerovate intends to file an initial listing application pursuant to the terms of the Merger Agreement for the Combined Company to list the securities of the Combined Company on Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">According to the Nasdaq rules, an issuer must, in a case such as this, apply for initial inclusion following a transaction whereby the issuer combines with a non-Nasdaq entity, resulting in a change of control of the issuer and potentially allowing the non-Nasdaq entity to obtain a Nasdaq listing. Accordingly, the listing standards of Nasdaq will require Aerovate to have, among other things, a $4.00 per share minimum bid price for a certain number of trading&#160;days preceding the Closing, unless it effects a reverse stock split . Therefore, the reverse stock split may be necessary in order to satisfy Nasdaq requirements and consummate the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, it is a condition to the Closing that the shares of Aerovate common stock to be issued in the Merger pursuant to the Merger Agreement having been approved for listing on Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">One of the effects of the reverse stock split will be to effectively increase the proportion of authorized shares which are unissued relative to those which are issued. This could result in Aerovate&#8217;s management being able to issue more shares without further stockholder approval. The reverse stock split will not affect the number of authorized shares of Aerovate capital stock, which will continue to be authorized pursuant to the Aerovate Charter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Potential Increased Investor Interest</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On November&#160;29, 2024, Aerovate common stock closed at $2.63 per share. An investment in Aerovate common stock may not appeal to brokerage firms that are reluctant to recommend lower priced securities to their clients. Investors may also be dissuaded from purchasing lower priced stocks because the brokerage commissions, as a&#160;percentage of the total transaction, tend to be higher for such stocks. Moreover, the analysts at many brokerage firms do not monitor the trading activity or otherwise provide research coverage of lower priced stocks. Also, the Aerovate board of directors believes that most investment funds are reluctant to invest in lower priced stocks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">There are risks associated with the reverse stock split, including that the reverse stock split may not result in an increase in the per share price of Aerovate common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Aerovate cannot predict whether the reverse stock split will increase the market price for Aerovate common stock. The history of similar stock split combinations for companies in like circumstances is varied. There is no assurance that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the market price per share of Aerovate common stock after the reverse stock split will rise in proportion to the reduction in the number of shares of Aerovate common stock outstanding before the reverse stock split;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the reverse stock split will result in a per share price that will attract brokers and investors who do not trade in lower priced stocks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the reverse stock split will result in a per share price that will increase the ability of Aerovate to attract and retain employees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the market price per share will either exceed or remain in excess of the $1.00 minimum bid price as required by Nasdaq for continued listing; or</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">163</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the market price per share will achieve and maintain the $4.00 minimum bid price requirement, unless it effects a reverse stock split, for a sufficient period of time for the Combined Company&#8217;s common stock to be approved for listing by Nasdaq.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The market price of Aerovate common stock will also be based on the performance of Aerovate, and after the Merger, on the performance of the Combined Company, and other factors, some of which are unrelated to the number of shares outstanding. If the reverse stock split is effected and the market price of Aerovate common stock declines, the&#160;percentage decline as an absolute number and as a&#160;percentage of the overall market capitalization of Aerovate may be greater than would occur in the absence of a reverse stock split. Furthermore, the liquidity of Aerovate common stock could be adversely affected by the reduced number of shares that would be outstanding after the reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Principal Effects of the Reverse Stock Split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The reverse stock split will be realized simultaneously for all shares of Aerovate common stock and options to purchase shares of Aerovate common stock outstanding immediately prior to the Reverse Stock Split Effective Time. The reverse stock split will affect all holders of shares of Aerovate common stock outstanding immediately prior to the Reverse Stock Split Effective Time uniformly and each such stockholder will hold the same&#160;percentage of Aerovate common stock outstanding immediately following the reverse stock split as that stockholder held immediately prior to the reverse stock split, except for immaterial adjustments that may result from the treatment of fractional shares as described below. The reverse stock split will not change the par value of Aerovate common stock or preferred stock and will not reduce the number of authorized shares of Aerovate common stock or preferred stock. Aerovate common stock issued pursuant to the reverse stock split will remain fully paid and nonassessable. Proportionate adjustments will be made to the per share exercise price, the number of shares issuable upon the exercise, vesting or settlement of all outstanding options to purchase shares of Aerovate common stock, and the number of shares reserved for issuance pursuant to Aerovate&#8217;s existing equity incentive and employee stock purchase plans will be reduced proportionately based on the Split Ratio. The reverse stock split will not affect Aerovate continuing to be subject to the periodic reporting requirements of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Procedure for Effecting Reverse Stock Split and Exchange of Stock Certificates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If the Aerovate stockholders approve the amendment to the Aerovate Charter effecting the reverse stock split, the Aerovate board of directors and Jade board of directors mutually agree that a reverse stock split is necessary, and the Aerovate board of directors still believes that a reverse stock split is in the best interests of Aerovate and its stockholders, Aerovate will file the amendment to the Aerovate Charter with the Secretary of State of the State of Delaware at such time as the Aerovate board of directors has determined to be the appropriate Reverse Stock Split Effective Time. The Aerovate board of directors and Jade board of directors may mutually agree to delay effecting the reverse stock split without resoliciting stockholder approval. Beginning at the Reverse Stock Split Effective Time, each stock certificate representing pre-split shares will be deemed for all corporate purposes to evidence ownership of post-split shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As soon as practicable after the Reverse Stock Split Effective Time, the Aerovate stockholders will be notified that the reverse stock split has been effected. Aerovate expects that the Aerovate transfer agent will act as exchange agent for purposes of implementing the exchange of stock certificates. Holders of pre- split shares will be asked to surrender to the exchange agent stock certificates representing pre-split shares in exchange for stock certificates (or book-entry positions) representing post-split shares in accordance with the procedures to be set forth in a letter of transmittal to be sent by Aerovate. No new certificates (or book- entry positions) will be issued to a stockholder until such stockholder has surrendered such stockholder&#8217;s outstanding certificate(s)&#160;together with the properly completed and executed letter of transmittal to the exchange agent. Shares held in book-entry form will be automatically exchanged. Any pre-split shares submitted for transfer, whether pursuant to a sale or other disposition, or otherwise, will automatically be exchanged for post-split shares. <b style="font-weight:bold;">Stockholders should not destroy any stock certificate(s)&#160;and should not submit any certificate(s)&#160;unless and until requested to do so.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">No Fractional Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">No fractional shares will be issued in connection with the reverse stock split. Stockholders of record who otherwise would be entitled to receive fractional shares because they hold a number of pre-split shares not evenly divisible by the number of pre-split shares for which each post-split share is to be reclassified, will be entitled, upon surrender to the exchange agent of certificates representing such shares, to a cash payment in lieu thereof at a price equal to the fraction of a share to which the stockholder would otherwise be entitled multiplied by the closing price of the common stock on Nasdaq on the date of the filing of the amendment to the Aerovate Charter effecting the reverse stock split. For the foregoing purposes, all shares of common stock held by a holder will be aggregated (thus resulting in no more than one fractional share per holder). The ownership of a fractional interest will not give the holder thereof any voting, dividend or other rights except to receive payment therefor as described herein.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">164</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Stockholders should be aware that, under the escheat laws of the various jurisdictions where stockholders reside, where Aerovate is domiciled and where the funds will be deposited, sums due for fractional interests that are not timely claimed after the effective date of the split may be required to be paid to the designated agent for each such jurisdiction, unless correspondence has been received by Aerovate or the exchange agent concerning ownership of such funds within the time permitted in such jurisdiction. Thereafter, stockholders otherwise entitled to receive such funds will have to seek to obtain them directly from the state to which they were paid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Potential Anti-Takeover Effect</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Although the increased proportion of unissued authorized shares to issued shares could, under certain circumstances, have an anti-takeover effect, for example, by permitting issuances that would dilute the stock ownership of a person seeking to effect a change in the composition of the Aerovate board of directors or contemplating a tender offer or other transaction for the combination of Aerovate with another company, the Reverse Stock Split Proposal is not being proposed in response to any effort of which Aerovate is aware to accumulate shares of Aerovate common stock or obtain control of Aerovate, other than in connection with the Merger, nor is it part of a plan by management to recommend a series of similar amendments to the Aerovate board of directors and stockholders. Other than the proposals being submitted to the Aerovate stockholders for their consideration at the Aerovate Special Meeting, the Aerovate board of directors does not currently contemplate recommending the adoption of any other actions that could be construed to affect the ability of third parties to take over or change control of Aerovate. For more information, please see the section titled &#8220;<i style="font-style:italic;">Risk Factors&#160;&#8212; Risks Related to the Combined Company</i>&#8221; beginning on page&#160;85 of this proxy statement/prospectus.</p><a id="Proposal2_USFederal_ReverseStock"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">U.S. Federal Income Tax Considerations of the Reverse Stock Split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following discussion is a summary of U.S. federal income tax considerations to U.S. Holders (as defined below) of Aerovate common stock of the reverse stock split. The discussion does not purport to be a complete analysis of all potential tax considerations. The considerations of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or non-U.S. tax laws, are not discussed. This discussion is based on the Code, Treasury Regulations promulgated under the Code, judicial decisions and published rulings and administrative pronouncements of the IRS, in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a U.S. Holder. Aerovate have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax considerations of the reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">This discussion is limited to a U.S. Holder that holds Aerovate common stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax considerations relevant to a U.S. Holder&#8217;s particular circumstances, including without limitation the effect of the Medicare contribution tax on net investment income, the alternative minimum tax, or the special tax accounting rules&#160;under Section&#160;451(b)&#160;of the Code. In addition, it does not address considerations relevant to U.S. Holders subject to special rules, such as:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. expatriates and former citizens or long-term residents of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. Holders whose functional currency is not the U.S. dollar;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons holding Aerovate common stock as part of a hedge, straddle or other risk-reduction strategy or as part of a conversion transaction or other integrated investment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">banks, insurance companies and other financial institutions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">real estate investment trusts or regulated investment companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">brokers, dealers or traders in securities or other persons that elect to use a mark-to-market method of accounting for their holdings in Aerovate common stock ;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">partnerships or other entities or arrangements classified as partnerships, passthroughs, or disregarded entities for U.S. federal income tax purposes (and investors therein), S corporations or other passthrough entities (including hybrid entities);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax-exempt organizations or governmental organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons deemed to sell Aerovate common stock under the constructive sale provisions of the Code;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">165</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons who hold or receive Aerovate common stock pursuant to the exercise of any employee stock option or otherwise as compensation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax-qualified retirement plans; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons that own, or have owned, actually or constructively, more than 5% of Aerovate common stock.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If an entity or arrangement classified as a partnership for U.S. federal income tax purposes holds Aerovate common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership, and certain determinations made at the partner level. Accordingly, a partnership holding Aerovate common stock and each partner in such partnership is urged to consult its tax advisor regarding the U.S. federal income tax considerations to it of the reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For purpose of this discussion, a &#8220;U.S. Holder&#8221; is any beneficial owner of Aerovate common stock that, for U.S. federal income tax purposes, is or is treated as any of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an individual who is a citizen or resident of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a corporation created or organized under the laws of the United States, any state thereof or the District of Columbia;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a trust that: (i)&#160;is subject to the primary supervision of a U.S. court and the control of one or more &#8220;United States persons&#8221; (within the meaning of Section&#160;7701(a)(30) of the Code); or (ii)&#160;has a valid election in effect to be treated as a U.S. person for U.S. federal income tax purposes.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">This discussion is for informational purposes only and is not tax advice. Each prospective investor is urged to consult its tax advisor with respect to the application of the U.S. federal income tax laws to its particular situation as well as any tax considerations of the reverse stock split arising under U.S. federal estate or gift tax laws, the laws of any state, local or non-U.S. taxing jurisdiction or any applicable income tax treaty.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Tax Consequences of the Reverse Stock Split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The proposed reverse stock split is intended to qualify as a &#8220;recapitalization&#8221; for U.S. federal income tax purposes pursuant to Section&#160;368(a)(1)(E)&#160;of the Code. As a result, a U.S. Holder generally should not recognize gain or loss upon the proposed reverse stock split, except with respect to cash received in lieu of a fractional share of Aerovate common stock, as discussed below. A U.S. Holder&#8217;s aggregate adjusted tax basis in the shares of Aerovate common stock received pursuant to the proposed reverse stock split should equal the aggregate adjusted tax basis of the shares of the Aerovate common stock surrendered (excluding any portion of such basis that is allocated to any fractional share of Aerovate common stock), and such U.S. Holder&#8217;s holding period in the shares of Aerovate common stock received should include the holding period in the shares of Aerovate common stock surrendered. U.S. Treasury Regulations provide detailed rules&#160;for allocating the tax basis and holding period of the shares of Aerovate common stock surrendered to the shares of Aerovate common stock received in a recapitalization pursuant to the proposed reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Each U.S. Holder of shares of Aerovate common stock acquired on different dates and at different prices is urged to consult its tax advisor regarding the allocation of the tax basis and holding period of such shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Cash in Lieu of Fractional Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A U.S. Holder that receives cash in lieu of a fractional share of Aerovate common stock pursuant to the proposed reverse stock split should recognize capital gain or loss in an amount equal to the difference between the amount of cash received and the U.S. Holder&#8217;s tax basis in the shares of Aerovate common stock surrendered that is allocated to such fractional share of Aerovate common stock. Such capital gain or loss should be long-term capital gain or loss if the U.S. Holder&#8217;s holding period for Aerovate common stock surrendered exceeded one&#160;year at the effective time of the reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Tax Reporting Regarding the Reverse Stock Split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Assuming the reverse stock split qualifies as a recapitalization within the meaning of Section&#160;368(a)&#160;of the Code, each U.S. Holder who receives shares of Aerovate common stock in the reverse stock split is required to retain permanent records pertaining to the reverse stock split and make such records available to any authorized IRS officers and employees. Such records should specifically </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">166</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">include information regarding the amount, basis, and fair market value of all transferred property and relevant facts regarding any liabilities assumed or extinguished as part of such reorganization. Each U.S. Holder who owned at least five&#160;percent (by vote or value) of the total outstanding stock of Aerovate or who owned securities in Aerovate with a basis of $1,000,000 or more are required to attach a statement to their tax returns for the&#160;year in which the reverse stock split is consummated that contains the information listed in Treasury Regulations Section&#160;1.368-3(b). Such statement must include the holder&#8217;s tax basis in the U.S. Holder&#8217;s Aerovate common stock and the fair market value of such stock. Each U.S. Holder is urged to consult with its tax advisor to comply with these rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">This discussion of U.S. federal income tax considerations of the reverse stock split is for general information purposes only and is not intended to be, and should not be construed as, tax advice. Determining the actual tax consequences of the reverse stock split to you may be complex and will depend on your specific situation and on factors that are not within Aerovate&#8217;s knowledge or control. Each prospective investor is urged to consult its tax advisor with respect to the application of U.S. federal income tax laws to its specific situation as well as any tax considerations arising under the U.S. federal estate or gift tax rules&#160;or under the laws of any state, local, non-U.S. or other taxing jurisdiction.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Information Reporting and Backup Withholding</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Payments of cash made in lieu of a fractional share of Aerovate common stock may, under certain circumstances, be subject to information reporting and backup withholding. To avoid backup withholding, each holder of Aerovate common stock that does not otherwise establish an exemption should furnish its taxpayer identification number and comply with the applicable certification procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Backup withholding is not an additional tax. Any amounts withheld will be allowed as a credit against the holder&#8217;s U.S. federal income tax liability and may entitle such holder to a refund, provided the required information is timely furnished to the IRS. Holders of Aerovate common stock should consult their tax advisors regarding their qualification for an exemption from backup withholding and the procedures for obtaining such an exemption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Required Vote</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The affirmative vote of the holders of a majority of the outstanding shares of Aerovate capital stock is required to approve the Reverse Stock Split Proposal. Abstentions and broker non-votes, if any, will have the effect of a vote &#8220;AGAINST&#8221; the Reverse Stock Split Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Merger is conditioned upon the approval of the Reverse Stock Split Proposal. Notwithstanding the approval of the Reverse Stock Split Proposal, if the Merger is not consummated for any reason, the actions contemplated by the Reverse Stock Split Proposal will not be effected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Reverse Stock Split Proposal is conditioned on the approval of the Nasdaq Stock Issuance Proposal and the Authorized Share Increase Proposal. Notwithstanding the approval of the Reverse Stock Split Proposal, if the Nasdaq Stock Issuance Proposal and the Authorized Share Increase Proposal are not approved, the actions contemplated by the Reverse Stock Split Proposal will not be effected and the Merger will not be consummated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Certain Aerovate stockholders have agreed to vote any shares of Aerovate common stock owned by them in favor of the Reverse Stock Split Proposal. Please see the section titled &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#160;&#8212; Support Agreements</i>&#8221; beginning on page&#160;153 of this proxy statement/prospectus for more information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;FOR&#8221; the approval of the Reverse Stock Split Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">THE AEROVATE BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE REVERSE STOCK SPLIT PROPOSAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">167</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_f1a0b98c_5a1b_4032_9ca6_ea83b34900a7"></a><a id="PROPOSALNO3THEAUTHORIZEDSHAREINCREASEPRO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PROPOSAL NO.&#160;3&#160;&#8212; THE AUTHORIZED SHARE INCREASE PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Aerovate Special Meeting, Aerovate will ask its stockholders to approve an amendment to the Aerovate Charter to increase the number of authorized shares of Aerovate common stock (the &#8220;Aerovate Share Increase Amendment&#8221;). On&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024, Aerovate&#8217;s board of directors approved a proposal to amend the Aerovate Charter to increase the number of authorized shares of Aerovate common stock from 150,000,000 shares to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, which would also have the effect of increasing the total number of authorized shares from 160,000,000, including Aerovate preferred stock, to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(the &#8220;Aerovate Share Increase&#8221;), in the form attached as <i style="font-style:italic;">Annex C </i>to this proxy statement/prospectus. As of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, there were shares of Aerovate common stock issued and outstanding, and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of Aerovate common stock reserved for issuance. Accordingly, approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of the total number of Aerovate common stock currently authorized remain available for issuance or may be reserved for issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Form&#160;of the Aerovate Share Increase Amendment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Aerovate Share Increase Amendment would amend and restate the first paragraph of Article&#160;IV of the Aerovate Charter in its entirety as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;The total number of shares of capital stock which the Corporation shall have authority to issue is , of which (i) shares shall be a class designated as common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;), and (ii)&#160;10,000,000 shares shall be a class designated as undesignated preferred stock, par value $0.0001 per share (the &#8220;Undesignated Preferred Stock&#8221;).&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Background and Reasons for the Aerovate Share Increase Amendment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Aerovate Charter currently authorizes the issuance of up to 150,000,000 shares of Aerovate common stock and 10,000,000 shares of preferred stock. As of the close of business as of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, there were&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of Aerovate common stock issued and outstanding, and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of Aerovate common stock reserved for issuance. Accordingly,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of the total number of Aerovate common stock currently authorized remain available for issuance or may be reserved for issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As described in greater detail in the section of this proxy statement/prospectus titled &#8220;<i style="font-style:italic;">The Merger Agreement</i>,&#8221; pursuant to the Merger Agreement, Aerovate will be required to issue shares of Aerovate common stock, including shares of Aerovate common stock issuable upon conversion of Aerovate Series&#160;A Preferred Stock, to Jade stockholders and to assume Jade&#8217;s Amended and Restated 2024 Equity Incentive Plan and outstanding options and pre-funded warrants to purchase Jade common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The number of shares of Aerovate common stock currently authorized and unissued and not reserved for issuance is not sufficient for (i)&#160;the issuance of Aerovate common stock, including shares of Aerovate common stock issuable upon conversion of Aerovate Series&#160;A Preferred Stock, pursuant to the Merger Agreement and (ii)&#160;the assumption of Jade&#8217;s Amended and Restated 2024 Equity Incentive Plan and outstanding options and pre-funded warrants to purchase Jade common stock. In addition, there will not be sufficient shares of Aerovate common stock available for issuance in connection with possible future acquisitions, equity and equity-based financings, possible future awards under employee benefit plans and other corporate purposes that Aerovate&#8217;s board of directors may determine to be desirable. Therefore, Aerovate&#8217;s board of directors has determined that the Aerovate Share Increase Amendment is in the best interests of Aerovate and its stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Aerovate Share Increase Amendment is approved by stockholders, upon its effectiveness, and without giving effect to the proposed reverse stock split described in Proposal No.&#160;2 of this proxy statement/ prospectus, Aerovate will have a total of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;authorized shares of Aerovate common stock, with shares of Aerovate common stock issued and outstanding (as of the Record Date), and shares reserved for issuance (as of the Record Date), leaving a balance of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of Aerovate common stock authorized and unissued and not reserved for any specific purpose. Such outstanding share amounts will be correspondingly adjusted to the extent the proposed reverse stock split is effected prior to effectiveness of the Aerovate Share Increase Amendment, but the reverse stock split will not change the number of authorized shares of common or preferred stock. The Aerovate Share Increase Amendment will have no effect on the authorized shares of Aerovate preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Except for (i)&#160;the issuance of shares of Aerovate common stock, including shares of Aerovate common stock issuable upon conversion of Aerovate Series&#160;A Preferred Stock, and (ii)&#160;the issuance of shares of Aerovate common stock that may result from the assumption of Jade&#8217;s Amended and Restated 2024 Equity Incentive Plan and outstanding options and pre-funded warrants to purchase </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">168</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">Jade common stock, each pursuant to the terms of the Merger Agreement, Aerovate does not currently have any plans, proposals or arrangement to issue any of its authorized but unissued shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Possible Effects of the Aerovate Share Increase Amendment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">If the Aerovate Share Increase Amendment is approved and becomes effective, the additional authorized shares would be available for issuance at the discretion of Aerovate&#8217;s board of directors and without further stockholder approval, except as may be required by law or Nasdaq rules. The additional shares of authorized Aerovate common stock would have the same rights and privileges as the shares of Aerovate common stock currently issued and outstanding. Holders of Aerovate common stock have no preemptive rights. The Aerovate Share Increase would not change the number of shares of common stock outstanding, nor will it have any immediate dilutive effect; however, the issuance of additional shares of Aerovate common stock authorized by the Aerovate Share Increase may, among other things, have a dilutive effect on earnings per share and on stockholders&#8217; equity and voting rights. Furthermore, future sales of substantial amounts of Aerovate common stock, or the perception that these sales might occur, could adversely affect the prevailing market price of Aerovate common stock or limit Aerovate&#8217;s ability to raise additional capital. Aerovate stockholders should recognize that, as a result of this proposal, they will own a smaller&#160;percentage of shares relative to the total authorized shares of Aerovate than they presently own.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Appraisal or Dissenters&#8217; Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Pursuant to the DGCL, stockholders are not entitled to appraisal rights or dissenter&#8217;s rights with respect to the Aerovate Share Increase Amendment or the Aerovate Share Increase.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Effectiveness of Amendment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">If the Aerovate Share Increase Amendment is approved by the stockholders at the Aerovate Special Meeting, it will become effective upon the filing of a certificate of amendment, a copy of which is attached as <i style="font-style:italic;">Annex C </i>to this proxy statement/prospectus, with the Delaware Secretary of State or such later effective date and time as specified in the certificate of amendment in accordance with Delaware law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Copies of the Aerovate Charter and the certificates of amendment to the Aerovate Charter are available as exhibits to this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Required Vote</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The affirmative vote of the holders of a majority of the outstanding shares of Aerovate capital stock is required to approve the Authorized Share Increase Proposal. Abstentions and broker non-votes, if any, will have the same effect of a vote &#8220;AGAINST&#8221; the Authorized Share Increase Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The Merger is conditioned upon the approval of the Authorized Share Increase Proposal. Notwithstanding the approval of the Authorized Share Increase Proposal, if the Merger is not consummated for any reason, the actions contemplated by the Authorized Share Increase Proposal will not be effected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The Authorized Share Increase Proposal is conditioned on the approval of the Nasdaq Stock Issuance Proposal and the Reverse Stock Split Proposal. Notwithstanding the approval of the Authorized Share Increase Proposal, if the Nasdaq Stock Issuance Proposal and the Reverse Stock Split Proposal are not approved, the actions contemplated by the Authorized Share Increase Proposal will not be effected and the Merger will not be consummated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Certain Aerovate stockholders have agreed to vote any shares of Aerovate common stock owned by them in favor of the Authorized Share Increase Proposal. Please see the section titled &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#160;&#8212; Support Agreements</i>&#8221; beginning on page&#160;153 of this proxy statement/prospectus for more information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;FOR&#8221; the Authorized Share Increase Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">THE AEROVATE BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE AUTHORIZED SHARE INCREASE PROPOSAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">169</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_d97d8cf9_d9ef_4b20_bed9_cddf14d46f28"></a><a id="PROPOSALNO4THEREDOMESTICATIONPROPOSAL_92"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PROPOSAL NO.&#160;4&#160;&#8212; THE REDOMESTICATION PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Aerovate special meeting, Aerovate stockholders will be asked to approve the conversion of Aerovate from a corporation organized under the laws of the State of Delaware (the &#8220;Delaware Corporation&#8221;) to a corporation organized under the laws of the State of Nevada (the &#8220;Nevada Corporation&#8221;) and to adopt the resolutions of Aerovate&#8217;s board of directors approving the redomestication (the &#8220;Nevada Redomestication Resolution&#8221;) included as <i style="font-style:italic;">Annex E</i> to this proxy statement/prospectus, as more fully described in this Proposal No. 4. The proposed redomestication of the Delaware Corporation by a conversion into the Nevada Corporation is referred to herein as the &#8220;Nevada Redomestication.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Principal Terms of the Nevada Redomestication</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Nevada Redomestication is approved by Aerovate stockholders and the Merger is completed, the Nevada Redomestication will be effected by the Combined Company through a conversion pursuant to Section 266 of the DGCL, and Sections 92A.195 and 92A.205 of the Nevada Revised Statutes (as may be amended from time to time, &#8220;NRS&#8221;), as set forth in the plan of conversion (the &#8220;Plan of Conversion&#8221;), included as <i style="font-style:italic;">Annex D</i> to this proxy statement/prospectus. Approval of the Redomestication Proposal will constitute approval of the Plan of Conversion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Through the adoption of the Plan of Conversion, upon the effectuation of the Nevada Redomestication:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Combined Company will continue in existence as a Nevada corporation and will continue to operate its business under the name &#8220;Jade Biosciences, Inc.&#8221;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The internal affairs of the Combined Company will cease to be governed by Delaware law and will instead be governed by Nevada law. See &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Effects of the Nevada Redomestication&#8212;Comparison of Stockholder Rights under Delaware and Nevada Law</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; below.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Combined Company will cease to be governed by Aerovate&#8217;s second amended and restated certificate of incorporation (the &#8220;Delaware Charter&#8221; or the &#8220;Aerovate Charter&#8221;) and Aerovate&#8217;s amended and restated bylaws (the &#8220;Delaware Bylaws&#8221;) and will instead be governed by the provisions of the proposed Nevada articles of incorporation (the &#8220;Nevada Charter&#8221;) and the proposed Nevada bylaws (the &#8220;Nevada Bylaws&#8221;), forms of which are included as </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Exhibit 3.2</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Exhibit 3.4</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, respectively, to this proxy statement/prospectus. See &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Effects of the Nevada Redomestication&#8212;Comparison of Rights of Holders of the Delaware Corporation Capital Stock and the Nevada Corporation Capital Stock</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; below.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Nevada Redomestication will not result in any change in the Combined Company&#8217;s business, management, obligations, assets or liabilities (other than as a result of the transaction costs related to the Nevada Redomestication).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Each outstanding share of common stock of the Delaware Corporation will be automatically converted into one outstanding share of common stock of the Nevada Corporation.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Each outstanding share of any series of the preferred stock of the Delaware Corporation will be automatically converted into one outstanding share of the corresponding series of the preferred stock of the Nevada Corporation.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Stockholders of the Combined Company will not be required to exchange their existing stock certificates for new stock certificates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Each outstanding option or right to acquire shares of common stock of the Delaware Corporation will continue in existence in the form of and will automatically become an option or right to acquire an equal number of shares of common stock of the Nevada Corporation under the same terms and conditions.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The common stock of the Nevada Corporation resulting from the conversion will continue to be traded on Nasdaq under the symbol &#8220;JBIO.&#8221; The Nevada Redomestication is not expected to cause any interruption in the trading of such common stock.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">170</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Aerovate stockholders approve the Nevada Redomestication and the Merger is completed, Aerovate and Jade anticipate that the Nevada Redomestication will become effective as soon as practicable following the Merger (the &#8220;Nevada Redomestication Effective Time&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Nevada Redomestication may be delayed by Aerovate&#8217;s board of directors or the Combined Company&#8217;s board of directors, or the Plan of Conversion may be terminated and abandoned by action of Aerovate&#8217;s board of directors or the Combined Company&#8217;s board of directors, at any time prior to the Nevada Redomestication Effective Time, whether before or after the approval by Aerovate&#8217;s stockholders, if Aerovate&#8217;s board of directors or the Combined Company&#8217;s board of directors determines for any reason that such delay or abandonment would be in the best interests of Aerovate and its stockholders or the Combined Company and its stockholders, as the case may be, including if the Merger is not completed for any reason. In addition, Aerovate or the Combined Company may face legal challenges to the Nevada Redomestication, including, among others, stockholder challenges under Delaware law, seeking to delay or prevent the Nevada Redomestication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Reasons for the Nevada Redomestication</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate&#8217;s board of directors and Jade&#8217;s board of directors believe that there are several reasons the Nevada Redomestication is in the best interests of the Combined Company and its stockholders. In particular, Aerovate&#8217;s board of directors and Jade&#8217;s board of directors believe that the Nevada Redomestication will allow the Combined Company to take advantage of certain provisions of the corporate and tax laws of Nevada.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Nevada Redomestication will eliminate the Combined Company&#8217;s obligation to pay the annual Delaware franchise tax, which Aerovate and Jade expect will result in substantial savings to the Combined Company over the long term. For fiscal year 2023, Aerovate paid approximately $200,000 in Delaware franchise taxes. Jade anticipates that, if the Combined Company remains a Delaware Corporation, for fiscal &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, the Combined Company&#8217;s Delaware franchise taxes will be approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (based on the expected capital structure and assets of the combined company). If the Combined Company redomesticates in Nevada, the Combined Company&#8217;s current annual fees will consist of an annual Nevada state business license fee of $500, and the current fee for filing the Combined Company&#8217;s annual list of directors and officers, based on the number of authorized shares of capital stock and their par value, would equal to $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Nevada Redomestication will potentially reduce the risk of opportunistic stockholder demands and litigation for the Combined Company and its directors and officers, which may allow the Combined Company&#8217;s directors and officers to focus on the Combined Company&#8217;s business and save it the cost of such demands and litigation. Within recent years, the increasing frequency and cost of claims directed towards directors and officers of Delaware corporations has expanded the risk facing directors and officers of public companies in exercising their duties. For example, from time to time, public companies respond to stockholder books and records inspection demands pursuant to Section 220 of the DGCL, purportedly seeking to investigate alleged mismanagement and wrongdoing, which, in turn, causes public companies to expend substantial legal fees and costs in responding to such demands, in addition to the time and distraction for the management team in gathering records and providing information to the company&#8217;s lawyers. Such stockholder demands and litigation can be time-consuming and burdensome, both for the directors and officers involved and other members of management and employees. If the Combined Company were to be targeted by opportunistic stockholder demands or lawsuits, the costs or other consequences of responding to or defending such claims could potentially be borne by the Combined Company&#8217;s stockholders through, among other things, indemnification obligations, distraction to the Combined Company&#8217;s management and employees, and increased insurance premiums. Aerovate&#8217;s board of directors believes Nevada&#8217;s statute-focused approach will better balance the benefits and costs of litigation to the Combined Company and its stockholders since it depends less upon judicial supplementation and revision, and is intended to be stable, predictable and efficient, whereas Delaware law&#8217;s dependence on judicial interpretation may lend itself to greater uncertainty and instability over time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Nevada Redomestication will potentially provide the Combined Company&#8217;s directors and officers with greater protection, which may help the Combined Company attract and retain highly qualified management personnel. Delaware law permits a corporation to adopt provisions limiting or eliminating the liability of a director or an officer to a company and its stockholders for monetary damages for breach of fiduciary duty, provided that the liability does not arise from certain proscribed conduct, including breach of the duty of loyalty, acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law. In contrast, Nevada law provides for a broader exclusion of individual liability of both officers and directors to a Nevada corporation and its stockholders, allowing for the exclusion of damages as a result of any director&#8217;s or officer&#8217;s act or failure to act, unless the presumption that the director or officer acted in good faith, on an informed basis, and with a view to the interests of the corporation has been rebutted and it is proven that the director or officer breached their fiduciary duty and such breach involved intentional misconduct, fraud, or a knowing violation of the law. Accordingly, the Nevada Redomestication will allow the Combined </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">171</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Company to eliminate any liability of directors or officers for a breach of the duty of loyalty unless the breach involves intentional misconduct, fraud, or a knowing violation of law. There is currently no known pending claim or litigation against any of Aerovate&#8217;s directors or officers for breach of fiduciary duty related to their service as directors or officers of Aerovate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Certain Risks Associated with the Nevada Redomestication</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that the Nevada Redomestication will result in all or any of the benefits described in this proxy statement/prospectus, including the benefits of or resulting from incorporation under Nevada or the application of Nevada law to the internal affairs of the Combined Company. See &#8220;<i style="font-style:italic;">Risk Factors&#8212;Risks Related to the Nevada Redomestication.</i>&#8221;</p><a id="Proposal4_Effect_NevadaRedom"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Effects of the Nevada Redomestication</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Nevada Redomestication will effect a change in the legal domicile of the Combined Company and other changes, the most significant of which are described below. Following the Nevada Redomestication, the Combined Company will be governed by the NRS instead of the DGCL, and the Combined Company will be governed by the Nevada Charter and the Nevada Bylaws. Approval of this Proposal No. 4 will constitute approval of the Nevada Charter and Nevada Bylaws. The Delaware Charter and the Delaware Bylaws will no longer be applicable following completion of the Nevada Redomestication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The summaries below do not purport to be complete and are subject to, and qualified in its entirety by reference to, the NRS, the Nevada Charter, Nevada Bylaws, the DGCL, the Delaware Charter and Delaware Bylaws, which you should carefully read, together with this entire document and the other referenced documents for a more complete understanding of the differences between being a stockholder of the Delaware Corporation before the Nevada Redomestication and being a stockholder of the Nevada Corporation following the completion of the Nevada Redomestication. Copies of the Nevada Charter, the Nevada Bylaws, the Delaware Charter, the Delaware Bylaws, the form of certificate of amendment to effect the proposed reverse stock split described in Proposal No. 2 and the form of certificate of amendment to effect the increase in the number of authorized shares of Aerovate common stock described in Proposal No. 3 are included as <i style="font-style:italic;">Exhibit 3.2, Exhibit 3.4, Exhibit 3.1,</i> Exhibit 3.3, <i style="font-style:italic;">Annex B</i> and <i style="font-style:italic;">Annex C</i> respectively, to this proxy statement/prospectus.</p><a id="Proposal4_Comparison_DelawareNevada"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of Rights of Holders of the Delaware Corporation Capital Stock and the Nevada Corporation Capital Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Nevada Charter and Nevada Bylaws differ in several respects from the Delaware Charter and Delaware Bylaws, respectively. The differences between the rights of stockholders of the Delaware Corporation under the Delaware Charter and Delaware Bylaws and their rights as stockholders of the Nevada Corporation after the Nevada Redomestication, under the Nevada Charter and Nevada Bylaws, both as will be in effect immediately following the Nevada Redomestication, are summarized below. The following summary gives effect to the proposed reverse stock split described in Proposal No. 2 and the proposed increase in the number of authorized shares of Aerovate common stock described in Proposal No. 3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The Delaware Corporation</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The Nevada Corporation</b></p></th></tr><tr><td style="vertical-align:top;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">Organizational Documents</i></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The rights of the Delaware Corporation&#8217;s stockholders are governed by the Delaware Charter, Delaware Bylaws and the DGCL.</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The rights of the Nevada Corporation&#8217;s stockholders are governed by the Nevada Charter, Nevada Bylaws and the NRS.</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">Authorized Capital Stock</i></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Delaware Corporation is authorized to issue two classes of capital stock which are designated, respectively, &#8220;common stock&#8221; and &#8220;undesignated preferred stock.&#8221; The total number of shares that the Delaware Corporation  will be authorized to issue is&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, of which&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares are common stock, par value $0.0001 per share, and 10,000,000 shares are undesignated preferred stock, par value $0.0001 per share. The number of authorized shares of Delaware Corporation common stock or undesignated preferred stock may be increased or decreased (but not below the number of shares of such class then outstanding) by the affirmative vote of the holders of a majority of the voting power of the outstanding shares of capital stock of Aerovate </span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Nevada Corporation is authorized to issue two classes of capital stock which are designated, respectively, &#8220;common stock&#8221; and &#8220;undesignated preferred stock.&#8221; The total number of shares that the Nevada Corporation is authorized to issue is &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, of which &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares are common stock, par value $0.0001 per share, and 10,000,000 shares are undesignated preferred stock, par value $0.0001 per share. The number of authorized shares of Nevada Corporation common stock or undesignated preferred stock may be increased or decreased by an amendment to the Nevada Charter adopted by resolution of the Nevada Corporation&#8217;s board of directors and approved by the stockholders holding shares representing at least a majority of the </p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">172</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The Delaware Corporation</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The Nevada Corporation</b></p></th></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">entitled to vote thereon, irrespective of the provisions of Section 242(b)(2) of the DGCL.</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"/><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">voting power, as long as the proposed amendment does not adversely alter or change any preference or relative or other right given to any class or series of outstanding shares (in which event, unless the articles specifically deny the right to vote on such an amendment, the amendment must be approved by the holders of shares representing a majority of the voting power of each class or series adversely affected by the amendment regardless of limitations or restrictions on the voting power thereof). The number of authorized shares of Nevada Corporation common stock or undesignated preferred stock may also be increased or decreased by resolution of the Nevada Corporation&#8217;s board of directors, without a vote of the stockholders, as long as the corporation simultaneously and correspondingly increases or decreases the number of issued and outstanding shares of common stock or undesignated preferred stock held by each stockholder of record and the action taken (i) does not adversely alter or change any preference or relative or other right given to any other class or series of outstanding shares and (ii) does not include any provisions pursuant to which only money will be paid or scrip issued to stockholders who hold 10% or more of the outstanding shares of the affected class and series, and who would otherwise be entitled to receive a fraction of a share in exchange for the cancellation of all of their outstanding shares.  </span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">Common Stock</i></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Delaware Corporation&#8217;s authorized common stock will consist of &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Each holder of a share of Delaware Corporation common stock is entitled to one vote for each such share held of record on the applicable record date on each matter voted on at a meeting of stockholders.</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Nevada Corporation&#8217;s authorized common stock consists of &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Each holder of a share of Nevada Corporation common stock is entitled to one vote for each such share held of record on the applicable record date on each matter voted on at a meeting of stockholders.</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">Preferred Stock</i></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Delaware Corporation&#8217;s authorized preferred stock consists of 10,000,000 shares of undesignated preferred stock. No shares of the Delaware Corporation&#8217;s undesignated preferred stock are currently outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the Merger, the Delaware Corporation&#8217;s board of directors will designate approximately &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of the Delaware Corporation&#8217;s undesignated preferred stock as Series A Non-Voting Convertible Preferred Stock (the &#8220;Delaware Corporation Series A Preferred Stock&#8221;) through a certificate of designation in the form attached as <i style="font-style:italic;">Annex K</i> (the &#8220;Delaware Certificate of Designation&#8221;). No shares of the Delaware Corporation Series A Preferred Stock are currently authorized or outstanding. As long as any shares of the Delaware Corporation Series A Preferred Stock are outstanding, the Delaware Corporation will not, without the affirmative vote or written waiver of the holders of a majority of the then outstanding shares of the Delaware Corporation Series A Preferred Stock: (i) alter or change adversely the powers, preferences or rights given to the Delaware Corporation Series A Preferred Stock or alter or amend the Delaware Certificate of Designation, amend or repeal any </p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Nevada Corporation&#8217;s authorized preferred stock consists of 10,000,000 shares of undesignated preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Assuming the Delaware Corporation&#8217;s board of directors designates approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of the Delaware Corporation&#8217;s undesignated preferred stock as the Delaware Corporation Series A Preferred Stock through the Delaware Certificate of Designation, the Nevada Corporation will have approximately &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of the Series A Non-Voting Convertible Preferred Stock (the &#8220;Nevada Corporation Series A Preferred Stock&#8221;) through a certificate of designation in the form attached as <i style="font-style:italic;">Annex L</i> (the &#8220;Nevada Certificate of Designation&#8221;). As long as any shares of the Nevada Corporation Series A Preferred Stock are outstanding, the Nevada Corporation will not, without the affirmative vote or written waiver of the holders of a majority of the then outstanding shares of the Nevada Corporation Series A Preferred Stock: (i) alter or change adversely the powers, preferences or rights given to the Nevada Corporation Series A Preferred Stock or alter or amend the Nevada Certificate of Designation, amend or repeal any provision of, or add any provision to, the Nevada Charter or Nevada </p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">173</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The Delaware Corporation</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The Nevada Corporation</b></p></th></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">provision of, or add any provision to, the Delaware Charter or Delaware Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of the Delaware Corporation&#8217;s preferred stock, in each case if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Delaware Corporation Series A Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the Delaware Charter or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (ii) issue further shares of the Delaware Corporation Series A Preferred Stock beyond those contemplated for issuance in the Merger Agreement or increase or decrease (other than by conversion) the number of authorized shares of the Delaware Corporation Series A Preferred Stock, (iii) at any time while at least &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of the originally issued Delaware Corporation Series A Preferred Stock remains issued and outstanding, consummate either: (A) any Fundamental Transaction (as defined in the Delaware Certificate of Designation) or (B) any merger or consolidation of Aerovate with or into another entity or any stock sale to, or other business combination in which the stockholders of the Delaware Corporation immediately before such transaction do not hold at least a majority on an as-converted-to-Delaware Corporation common stock basis of the capital stock of the Delaware Corporation, immediately after such transaction or (iv) enter into any agreement with respect to any of the foregoing that does not explicitly require the approval contemplated herein to consummate such transaction.</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"/><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of the Nevada Corporation&#8217;s preferred stock, in each case if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Nevada Corporation Series A Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the Nevada Charter or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (ii) issue further shares of the Nevada Corporation Series A Preferred Stock beyond those contemplated for issuance in the Merger Agreement or increase or decrease (other than by conversion) the number of authorized shares of the Nevada Corporation Series A Preferred Stock, (iii) at any time while at least &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of the originally issued Nevada Corporation Series A Preferred Stock remains issued and outstanding, consummate either: (A) any Fundamental Transaction (as defined in the Nevada Certificate of Designation) or (B) any merger or consolidation of the Nevada Corporation with or into another entity or any stock sale to, or other business combination in which the stockholders of the Nevada Corporation immediately before such transaction do not hold at least a majority on an as-converted-to-Nevada Corporation common stock basis of the capital stock of the Nevada Corporation, immediately after such transaction or (iv) enter into any agreement with respect to any of the foregoing that does not explicitly require the approval contemplated herein to consummate such transaction.</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">Number and Qualification of Directors</i></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The number of Delaware Corporation directors is fixed from time to time by resolution of the Delaware Corporation&#8217;s board of directors. Following the completion of the Merger, the Delaware Corporation&#8217;s board of directors is expected to consist of six members. No decrease in the authorized number of directors constituting the Delaware Corporation&#8217;s board of directors will shorten the term of any incumbent director. Directors need not be stockholders of the Delaware Corporation.</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The number of Nevada Corporation directors is fixed from time to time by resolution of the Nevada Corporation&#8217;s board of directors. The Nevada Corporation&#8217;s board of directors is expected to consist of six members at the Nevada Redomestication Effective Time. No decrease in the authorized number of directors constituting the Nevada Corporation&#8217;s board of directors will shorten the term of any incumbent director. Directors need not be stockholders of the Nevada Corporation.</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">Structure of Board of Directors; Term of Directors; Election of Directors</i></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Other than any directors elected by the separate vote of the holders of any series of the Delaware Corporation&#8217;s undesignated preferred stock, the Delaware Corporation&#8217;s board of directors is divided into three classes, designated as Class I, Class II and Class III, respectively. Directors are assigned to each class in accordance with a resolution or resolutions adopted by the Delaware Corporation&#8217;s board of directors. At each annual meeting of stockholders, directors are elected for a full term of three years to succeed the directors of the class whose terms expire at such annual meeting. Notwithstanding the foregoing, directors elected to each class hold office until their successors are duly elected and qualified or until their earlier resignation, death or removal. Directors are elected by a plurality of the votes properly cast.</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Other than any directors elected by the separate vote of the holders of any series of the Nevada Corporation&#8217;s undesignated preferred stock, the Nevada Corporation&#8217;s board of directors will be divided into three classes, designated as Class I, Class II and Class III, respectively, with directors assigned to each class in accordance with a resolution or resolutions adopted by the Nevada Corporation&#8217;s board of directors. At each annual meeting of stockholders, directors are elected for a full term of three years to succeed the directors of the class whose terms expire at such annual meeting. Notwithstanding the foregoing, directors elected to each class hold office until their successors are duly elected and qualified or until their earlier resignation, death or removal. Directors are elected by a plurality of the votes properly cast.</p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">174</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The Delaware Corporation</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The Nevada Corporation</b></p></th></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">Removal of Directors</i></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Subject to the rights of the holders of any series of the Delaware Corporation&#8217;s undesignated preferred stock to elect directors, or except as otherwise provided by the DGCL or the Delaware Charter, any director may be removed from office at any time, but only with cause and only by the affirmative vote of the holders of not less than two-thirds (66<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2/3</sup>%) of the outstanding shares of capital stock of the Delaware Corporation then entitled to vote at an election of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Subject to the rights of the holders of any series of the Nevada Corporation&#8217;s undesignated preferred stock to elect directors, or except as otherwise provided by the NRS or the Nevada Charter, any director may be removed from office at any time, only by the affirmative vote of the holders of not less than two-thirds (66<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2/3</sup>%) of the outstanding shares of capital stock of the Nevada Corporation then entitled to vote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">Vacancies on the Board of Directors</i></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any director may resign at any time upon notice in writing or electronic transmission to Delaware Corporation&#8217;s Chairman of the board of directors, President or Secretary. Such resignation shall be effective upon receipt, unless the resignation otherwise provides. Subject to any limitations imposed by applicable law and subject to the rights of the holders of any series of the Delaware Corporation&#8217;s undesignated preferred stock, all vacancies, however occurring, including, without limitation, by reason of an increase in the size of the board of directors, shall be filled solely and exclusively by the affirmative vote of a majority of the remaining directors then in office, even if less than a quorum of the board of directors, and not by the stockholders. Any director elected in accordance with the preceding sentence will hold office for the remainder of the full term of the class of the directors for which the vacancy was created or occurred and until such director&#8217;s successor is elected and qualified or until his or her earlier resignation, death or removal.</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any director may resign at any time upon notice in writing or electronic transmission to Nevada Corporation&#8217;s Chair of the board of directors, President or Secretary. Such resignation shall be effective upon receipt, unless the resignation otherwise provides. Subject to any limitations imposed by applicable law and the rights of the holders of any series of the Nevada Corporation&#8217;s undesignated preferred stock, all vacancies, however occurring, including, without limitation, by reason of an increase in the size of the board of directors, shall be filled solely and exclusively by the affirmative vote of a majority of the remaining directors then in office, even if less than a quorum, and not by the stockholders. Any director appointed in accordance with the preceding sentence will hold office for the remainder of the full term of the class of directors in which the vacancy was created or occurred and until such director&#8217;s successor is elected and qualified or until his or her earlier resignation, death or removal.</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">Stockholder Action by Written Consent</i></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">No action may be taken by the stockholders except at an annual or special meeting of stockholders called in accordance with the Delaware Corporation&#8217;s Bylaws, and no action may be taken by the stockholders by written consent.</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">No action may be taken by the stockholders except at an annual or special meeting of stockholders called in accordance with the Nevada Bylaws, and no action may be taken by the stockholders by written consent.</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">Quorum</i></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise provided by law, the Delaware Charter or the Delaware Bylaws, at each meeting of stockholders the holders of a majority of the outstanding shares of stock entitled to vote at the meeting, present in person or represented by proxy, will constitute a quorum for the transaction of business. If less than a quorum is present at a meeting, the holders of voting stock representing a majority of the voting power present at the meeting or the presiding officer may adjourn the meeting from time to time, and the meeting may be held as adjourned without further notice.</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Except as otherwise required by law, the Nevada Charter or the Nevada Bylaws, at any meeting of stockholders, the holders of a majority of the voting power of the stock outstanding and entitled to vote at the meeting, present in person or represented by proxy, shall constitute a quorum for the transaction of business. If a quorum is not present or represented at any meeting, then the chair of the meeting, or the holders of a majority of the voting power of the stock present in person or represented by proxy at the meeting and entitled to vote thereon, shall have power to adjourn the meeting from time to time, until a quorum is present or represented.</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">Special Meetings of Stockholders</i></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Except as otherwise required by statute and subject to the rights, if any, of the holders of any series of undesignated preferred stock, special meetings of stockholders may be called only by the </p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Except as otherwise required by statute and subject to the rights, if any, of the holders of any series of undesignated preferred stock, special meetings of stockholders may be called only by the </p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">175</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The Delaware Corporation</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The Nevada Corporation</b></p></th></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Delaware Corporation&#8217;s board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office. Special meetings may not be called by any other person or persons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Only those matters set forth in the notice of the special meeting may be considered or acted upon at such special meeting. Nominations of persons for election to the Delaware Corporation&#8217;s board of directors and stockholder proposals of other business shall not be brought before a special meeting of stockholders to be considered by the stockholders unless such special meeting is held in lieu of an annual meeting of stockholders in accordance with the Delaware Bylaws.</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"/><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Nevada Corporation&#8217;s board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office. Special meetings may not be called by any other person or persons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Only those matters set forth in the notice of the special meeting may be considered or acted upon at such special meeting. Nominations of persons for election to the Nevada Corporation&#8217;s board of directors and stockholder proposals of other business shall not be brought before a special meeting of stockholders to be considered by the stockholders unless such special meeting is held in lieu of an annual meeting of stockholders in accordance with the Nevada Bylaws.</p></td></tr><tr style="height:29.25pt;"><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">Notice of Stockholder Meetings</i></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Notice of each meeting of stockholders stating the hour, date and place, if any, of such meeting and the means of remote communication, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting shall be given not less than ten (10) days nor more than sixty (60) days before the meeting, to each stockholder entitled to vote thereat by delivering such notice to such stockholder or by mailing it to the stockholder&#8217;s address of record. Without limiting the manner by which notice may otherwise be given to stockholders, any notice to stockholders may be given by electronic transmission in the manner provided in Section 232 of the DGCL. Notice of special meetings must also state the purpose(s) for which the meeting has been called.</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Notice of each meeting of stockholders stating the date, time and place, if any, of such meeting and the means of remote communication, if any, by which stockholders and proxies may be deemed to be present in person and vote at such meeting shall be given not less than ten (10) days nor more than sixty (60) days before the meeting, to each stockholder entitled to vote thereat by delivering such notice to such stockholder, by mailing it to the stockholder&#8217;s address of record or by timely filing a proxy statement or an amendment thereto with the SEC, containing the notice, pursuant to Section 14(a) of the Exchange Act. Notice of special meetings must also state the purpose(s) for which the meeting has been called.</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">Advance Notice Requirements for Stockholder Proposals</i></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Nominations of persons for election to the Delaware Corporation&#8217;s board of directors and the proposal of business other than nominations to be considered by the stockholders may be made at an annual meeting of stockholders only (i) by or at the direction of the Delaware Corporation&#8217;s board of directors or (ii) by any stockholder of the Delaware Corporation who is a stockholder of record at the time of giving notice provided for in the Delaware Bylaws, who is entitled to vote at the meeting, who is present (in person or by proxy) at the meeting and who complies with the notice procedures set forth in the Delaware Bylaws. For the avoidance of doubt, the foregoing clause (ii) is the exclusive means for a stockholder to make director nominations and submit other business (other than matters properly included in the corporation&#8217;s notice of meeting of stockholders and proxy statement under Rule 14a-8 under the Exchange Act) before an annual meeting of stockholders.</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Nominations of persons for election to the Nevada Corporation&#8217;s board of directors and the proposal of business other than nominations to be considered by the stockholders may be made at an annual meeting of stockholders only (i) by or at the direction of the Nevada Corporation&#8217;s board of directors or (ii) by any stockholder of the Nevada Corporation who is a stockholder of record at the time of giving notice provided for in the Nevada Bylaws, who is entitled to vote at the meeting, who is present (in person or by proxy) at the meeting and who complies with the notice procedures set forth in the Nevada Bylaws. For the avoidance of doubt, the foregoing clause (ii) is the exclusive means for a stockholder to make director nominations and submit other business (other than matters properly included in the corporation&#8217;s notice of meeting of stockholders and proxy statement under Rule 14a-8 under the Exchange Act) before an annual meeting of stockholders.</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">Amendment of Certificate or Articles of Incorporation</i></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The affirmative vote of the majority of the outstanding shares of capital stock entitled to vote, and the affirmative vote of the majority of the outstanding shares of each class entitled to vote thereon as a class, at a duly constituted meeting of stockholders called expressly for such purpose, is required to amend or repeal </p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The affirmative vote of the majority of the outstanding shares of capital stock entitled to vote, and the affirmative vote of the majority of the outstanding shares of each class or series of capital stock entitled to vote thereon as a separate class, at a duly constituted meeting of stockholders called expressly for such </p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">176</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The Delaware Corporation</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The Nevada Corporation</b></p></th></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">provisions of the Delaware Charter; provided, however, that the affirmative vote of not less than two-thirds (2/3) of the outstanding shares of capital stock entitled to vote on such amendment or repeal, and the affirmative vote of not less than two-thirds (2/3) of the outstanding shares of each class entitled to vote thereon as a class, shall be required to amend or repeal any provision of Article V (Shareholder Action), Article VI (Directors), Article VII (Limitations of Liability), Article VIII (Amendment of By-Laws) or Article IX (Amendment of Certificate of Incorporation) of the Delaware Charter. </p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"/><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">purpose, is required to amend or repeal provisions of the Nevada Charter; provided, however, that the affirmative vote of not less than two-thirds (2/3) of the outstanding shares of capital stock entitled to vote on such amendment or repeal, and the affirmative vote of not less than two-thirds (2/3) of the outstanding shares of each class or series of capital stock entitled to vote thereon as a separate class, shall be required to amend or repeal any provision of &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; or &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; of the Nevada Charter. </p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">Amendment of Bylaws</i></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The affirmative vote of not less than two-thirds (2/3) of the outstanding shares of capital stock entitled to vote on such amendment or repeal, voting together as a single class, is required to amend or repeal the Delaware Bylaws; provided, however, that if the Delaware Corporation&#8217;s board of directors recommends that stockholders approve such amendment or repeal, such amendment or repeal shall only require the affirmative vote of the majority of the outstanding shares of capital stock entitled to vote on such amendment or repeal at such meeting of stockholders, voting together as a single class. Except as otherwise provided by law, the Delaware Bylaws may be amended or repealed by the Delaware Corporation&#8217;s board of directors by the affirmative vote of a majority of the directors then in office.</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The affirmative vote of not less than two-thirds (2/3) of the outstanding shares of capital stock entitled to vote on such amendment or repeal, voting together as a single class, is required to amend or repeal the Nevada Bylaws; provided, however, that if the Nevada Corporation&#8217;s board of directors recommends that stockholders approve such amendment or repeal, such amendment or repeal shall only require the affirmative vote of the majority of the outstanding shares of capital stock entitled to vote on such amendment or repeal at such meeting of stockholders, voting together as a single class. Except as otherwise provided by law, the Nevada Bylaws may be amended or repealed by the Nevada Corporation&#8217;s board of directors by the affirmative vote of a majority of the directors then in office.</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">Limitation on Director and Officer Liability</i></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Delaware Charter provides that a director of the Delaware Corporation will not be personally liable to the Delaware Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (a)&#160;for any breach of the director&#8217;s duty of loyalty to Aerovate or its stockholders, (b)&#160;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (c)&#160;under Section&#160;174 of the DGCL or (d)&#160;for any transaction from which the director derived an improper personal benefit. If the DGCL is amended after the effective date of the Delaware Charter to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director to the Delaware Corporation shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended.</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Nevada Charter will not contain comparable provisions to the Delaware Charter, as limitation on liability is provided by statute in Nevada. Under the NRS, the Nevada Corporation&#8217;s directors and officers will not be personally liable to the Nevada Corporation or its stockholders or creditors for any damages for breach of fiduciary duty as a director or officer as a result of any act or failure to act in their capacity as a director or officer, unless the presumption of Nevada&#8217;s codified business judgment rule has been rebutted and it is be proven that the director&#8217;s or officer&#8217;s act or failure to act constituted a breach of their fiduciary duties as a director or officer, and that the breach of those duties involved intentional misconduct, fraud or a knowing violation of law. </p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">Indemnification</i></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To the fullest extent permitted by the DGCL, the Delaware Corporation is authorized to provide indemnification of (and advancement of expenses to) directors, officers and non-officer employees of the Delaware Corporation (and any other persons to which applicable law permits the Delaware Corporation to provide indemnification) through provisions of the Delaware Bylaws, agreements with such persons, vote of stockholders or disinterested directors or otherwise in excess of the </p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To the fullest extent permitted by the NRS, the Nevada Corporation is authorized to provide indemnification of (and advancement of expenses to) directors, officers and non-officer employees of the Nevada Corporation (and any other persons to which applicable law permits the Nevada Corporation to provide indemnification) through provisions of the Nevada Bylaws, agreements with such persons, vote of stockholders or disinterested directors or otherwise in excess of the </p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">177</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The Delaware Corporation</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The Nevada Corporation</b></p></th></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">indemnification and advancement otherwise permitted by the DGCL.</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"/><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">indemnification and advancement otherwise permitted by the NRS.</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">Conversion Rights</i></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Delaware Corporation does not currently have any outstanding shares of undesignated preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In connection with the Merger, the Delaware Corporation&#8217;s board of directors will designate approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of the Delaware Corporation Series A Preferred Stock through the Delaware Certificate of Designation. Following the First Effective Time, each share of the Delaware Corporation Series A Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the holder of the Delaware Corporation Series A Preferred Stock, into a number of shares equal to 1,000 shares of the Delaware Corporation common stock, subject to certain limitations, including that a holder of the Delaware Corporation Series A Preferred Stock is prohibited from converting shares of the Delaware Corporation Series A Preferred Stock into shares of the Delaware Corporation common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;%) of the total number of shares of the Delaware Corporation common stock issued and outstanding immediately after giving effect to such conversion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Assuming the Delaware Corporation&#8217;s board of directors designates approximately &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of the Delaware Corporation&#8217;s undesignated preferred stock as the Delaware Corporation Series A Preferred Stock through the Delaware Certificate of Designation, the Nevada Corporation will designate a comparable number of shares of the Nevada Corporation Series A Preferred Stock through the Nevada Certificate of Designation. Each share of the Nevada Corporation Series A Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of each holder of the Nevada Corporation Series A Preferred Stock, into a number of shares equal to 1,000 shares of the Nevada Corporation common stock, subject to certain limitations, including that a holder of the Nevada Corporation Series A Preferred Stock is prohibited from converting shares of the Nevada Corporation Series A Preferred Stock into shares of the Nevada Corporation common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;%) of the total number of shares of the Nevada Corporation common stock issued and outstanding immediately after giving effect to such conversion.</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">Preemptive Rights</i></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Delaware Corporation stockholders do not have preemptive rights. Thus, if additional shares of the Delaware Corporation common stock are issued, the current holders of the Delaware Corporation common stock will own a proportionately smaller interest in a larger number of outstanding shares of common stock to the extent that they do not participate in the additional issuance.</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Nevada Corporation stockholders will not have preemptive rights. Thus, if additional shares of the Nevada Corporation common stock are issued, the then current holders of the Nevada Corporation common stock will own, after such issuance, a proportionately smaller interest in a larger number of outstanding shares of common stock to the extent that they do not participate in the additional issuance.</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">Distributions to Stockholders</i></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Subject to any preferential dividend rights of any outstanding preferred stock and subject to the provisions of the Delaware Charter and applicable law, dividends may be declared and paid or set apart for payment upon the Delaware Corporation common stock out of any assets or funds of the Delaware Corporation legally available for the payment of dividends, but only when and as declared by the board of directors or any authorized committee thereof. </p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Subject to any preferential rights to distributions of any outstanding shares of preferred stock and subject to the provisions of applicable law, distributions may be made to or for the benefit of all holders of shares of any one or more classes or series of capital stock, with respect to such shares, out of any money or property of the Nevada Corporation legally available for the payment of distributions, but only when and as declared by the board of directors or any authorized committee thereof.</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">Exclusive Forum</i></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Delaware Bylaws provide that unless the Delaware Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for any state law claims for (i) any derivative action or proceeding brought on behalf of the Delaware Corporation, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other </p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Nevada Bylaws will provide that, unless the Nevada Corporation consents in writing to the selection of an alternative forum, the Eighth Judicial District Court of Clark County, Nevada (or, if such state court lacks jurisdiction, then any other state district court located in the State of Nevada), shall be the sole and exclusive forum for any action, suit, proceeding or claim (i) brought in the name or right or on behalf of the Nevada </p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">178</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The Delaware Corporation</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The Nevada Corporation</b></p></th></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">employee of the Delaware Corporation to the Delaware Corporation or its stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL or the Delaware Charter or the Delaware Bylaws (including the interpretation, validity or enforceability thereof), or (iv) any action asserting a claim governed by the internal affairs doctrine. Unless the Delaware Corporation consents in writing to the selection of an alternative forum, the federal district courts of the United States shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, as amended. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Delaware Corporation shall be deemed to have notice of and consented to the forum selection provision of the Delaware Bylaws.</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"/><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Corporation, (ii) for or based upon a breach of any fiduciary duty owed by any director, officer, employee or agent of the Nevada Corporation in such capacity, (iii) arising pursuant to, or to interpret, apply, enforce or determine the validity of, any provision of NRS Title 7 (including without limitation NRS Chapters 78 and 92A), the Nevada Charter or the Nevada Bylaws, or as to which the NRS confers jurisdiction on the courts of the State of Nevada, or (iv) asserting a claim governed by the internal affairs doctrine; provided that a federal district court of the United States located in the State of Nevada shall be the sole and exclusive forum for the resolution of any action, suit or proceeding against the Nevada Corporation or any of its directors or officers arising under the Securities Act or any claim for which the federal courts have exclusive jurisdiction. Any person or entity purchasing or otherwise acquiring any interest in any shares of capital stock of the Nevada Corporation shall be deemed to have notice of and consented to the forum selection provision of the Nevada Bylaws.</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">Registration Rights</i></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Certain holders of the Delaware Corporation&#8217;s common stock are party to an investors&#8217; rights agreement with Delaware Corporation and have demand registration rights, short-form registration rights and piggyback registration rights. In accordance with the terms of the investors&#8217; rights agreement, the demand registration rights, short-form and piggyback registration rights will terminate upon the closing of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the Merger, the Delaware Corporation will enter into a registration rights agreement with the investors participating in the Jade Pre-Closing Financing, pursuant to which, among other things, the Delaware Corporation will agree to prepare and file a resale registration statement covering the resale of certain shares of Delaware Corporation common stock within 30 business days of the Closing pursuant to Rule 415 and to use its commercially reasonable efforts to keep such registration statement continuously effective under the Securities Act. The registration rights agreement also provides that the Delaware Corporation will pay certain expenses relating to such registrations and indemnify the applicable securityholders against certain liabilities.</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Assuming the Delaware Corporation enters into a registration rights agreement with the investors participating in the Jade Pre-Closing Financing, the Nevada Corporation will have comparable obligations pursuant to the registration rights agreement. </p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">Stock Transfer Restrictions Applicable to Stockholders</i></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares of the Delaware Corporation are transferable in the manner prescribed by the DGCL.</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares of the Nevada Corporation are transferable in the manner prescribed by the NRS.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of Stockholder Rights under Delaware and Nevada Law</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The statutory corporate laws of Nevada, as governed by the NRS, are similar in many respects to those of Delaware, as governed by the DGCL. However, there are certain differences that may affect the rights of a stockholder of the Combined Company, as well as the corporate governance of the Combined Company. The following are brief summaries of material differences between the current rights of stockholders of the Delaware Corporation under the DGCL and the rights of stockholders of the Nevada Corporation following completion of the Nevada Redomestication under the NRS.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">179</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Increasing or Decreasing Authorized Capital Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under both Delaware and Nevada law, stockholders must approve an amendment to the corporation&#8217;s charter to increase or decrease in the number of authorized shares in accordance with the provisions of the applicable statutes. The NRS also allows the board of directors of a Nevada corporation, unless otherwise provided in the articles of incorporation (and the Nevada Charter does not otherwise provide), to increase or decrease the number of authorized shares of a class or series of the corporation&#8217;s shares and correspondingly effect a proportional forward or reverse split of the same class or series of the corporation&#8217;s shares (and change the par value thereof) without a vote of the stockholders. However, if the action taken (i) adversely changes or alters any right or preference of the stockholders and (ii) includes any provisions pursuant to which only money will be paid or scrip issued to stockholders who hold 10% or more of the outstanding shares of the affected class and series, and who would otherwise be entitled to receive a fraction of a share in exchange for the cancellation of all of their outstanding shares, then the proposed increase or decrease must be approved by the stockholders holding a majority of the voting power of the affected class or series. Delaware law has no similar provision to these Nevada statutes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Classified Board of Directors</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The DGCL permits any Delaware corporation to classify its board of directors into as many as three classes with staggered terms of office. If this is done, the stockholders elect only one class each year and each class would have a term of office of three years. The Delaware Charter also provides for a classified board of directors, with only one class elected each year, each to serve a term of three years in office. The NRS also permits any Nevada corporation to classify its board of directors into classes with staggered terms of office, as long as at least one-fourth of the total number of directors is elected annually. The Nevada Charter provides for a board of directors classified into three classes, and thus our stockholders will continue to elect one class of directors each year for a three-year term following the consummation of the Nevada Redomestication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cumulative Voting</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cumulative voting for directors entitles each stockholder to cast a number of votes that is equal to the number of voting shares held by such stockholder, multiplied by the number of directors to be elected, and to cast all such votes for one nominee or distribute such votes among up to as many candidates as there are positions to be filled. Cumulative voting may enable a minority stockholder or group of stockholders to elect at least one representative to the board of directors where such stockholders would not be able to elect any directors without cumulative voting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although the DGCL does not generally grant stockholders cumulative voting rights, a Delaware corporation may provide in its certificate of incorporation for cumulative voting in the election of directors. The NRS also permits any Nevada corporation to provide in its articles of incorporation the right to cumulative voting in the election of directors if certain procedures are followed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Delaware Charter does not provide for cumulative voting in the election of directors. Similarly, the Nevada Charter does not provide for cumulative voting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Vacancies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under both the DGCL and the NRS, subject to the certificate or articles of incorporation and bylaws, vacancies on the board of directors, including those resulting from any increase in the authorized number of directors, may be filled by the affirmative vote of a majority of the remaining directors then in office, even if less than a quorum. Any director so appointed will hold office for the remainder of the term of the director no longer on the board. Both the Delaware Charter and Nevada Charter provide that only the board of directors, and not the stockholders, may fill vacancies on the board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Removal of Directors</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Under the DGCL, the holders of a majority of shares of each class entitled to vote at an election of directors may vote to remove any director or the entire board without cause unless (i) the board is a classified board, in which case directors may be removed only for cause, or (ii) the corporation has cumulative voting, in which case, if less than the entire board is to be removed, no director may be removed without cause if the votes cast against their removal would be sufficient to elect him or her. Currently, as permitted by the DGCL when a company&#8217;s board of directors is classified, the Delaware Charter provides that directors may be removed only for cause and only by the affirmative vote of the holders of not less than two-thirds (2/3) of the outstanding shares of capital stock of the Delaware Corporation then entitled to vote at an election of directors. The NRS does not make a distinction between removal for or </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">180</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">without cause, and, therefore, the Nevada Corporation will permit removal with or without cause. The NRS requires the vote of the holders representing not less than two-thirds of the voting power of the issued and outstanding stock entitled to vote in order to remove a director or all of the directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fiduciary Duties and Business Judgment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Nevada, like most jurisdictions, requires that directors and officers of Nevada corporations exercise their powers in good faith and with a view to the interests of the corporation but, unlike some other jurisdictions (such as Delaware), fiduciary duties of directors and officers are codified. As a matter of statute, directors and officers, in exercising their respective powers, are presumed to act in good faith, on an informed basis and with a view to the interests of the corporation. In performing such duties, directors and officers may exercise their business judgment through reliance on information, opinions, reports, financial statements and other financial data prepared or presented by corporate directors, officers or employees who are reasonably believed to be reliable and competent. Reliance may also be based upon: (i) advice or information provided by legal counsel, public accountants, advisers, bankers or other persons reasonably believed to be competent; and (ii) the work of a committee (on which the particular director or officer does not serve) if the committee was established and empowered by the corporation&#8217;s board of directors, and if the committee&#8217;s work was within its designated authority and relates to matters on which the committee was reasonably believed to merit confidence. However, directors and officers may not rely on such information, opinions, reports, books of account or similar statements if they have knowledge concerning the matter in question that would make such reliance unwarranted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under Delaware law, members of the board of directors or any committee designated by the board of directors are similarly entitled to rely in good faith upon the records of the corporation and upon such information, opinions, reports and statements presented to the corporation by corporate officers, employees, committees of the board of directors or other persons as to matters such member reasonably believes are within such other person&#8217;s professional or expert competence, provided that such other person has been selected with reasonable care by or on behalf of the corporation. Such appropriate reliance on records and other information protects directors from liability related to decisions made based on such records and other information. Both Delaware and Nevada law extend the statutory protection for reliance on such persons to corporate officers. The Nevada Corporation&#8217;s directors and officers will, therefore, be subject to their statutory duties and protections as set forth above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Flexibility for Decisions, Including Takeovers</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Nevada provides directors with more discretion than Delaware in making corporate decisions, including decisions made in takeover situations. Under Nevada law, director and officer actions taken in response to a change or potential change in control are generally protected by the statutory business judgment rule.  In exercising their powers, including in response to a change or potential change of control, directors and officers of Nevada corporations may consider all relevant facts, circumstances, contingencies or constituencies, which may include, without limitation, the effect of the decision on several corporate constituencies in addition to the stockholders, including the corporation&#8217;s employees, suppliers, creditors and customers, the economy of the state and nation, the interests of the community and society in general, and the long-term as well as short-term interests of the corporation and its stockholders, including the possibility that these interests may be best served by the continued independence of the corporation. The NRS specifically states that such directors and officers are not required to consider the effect of a proposed corporate action upon any constituent as a dominant factor. Further, a director may resist a change or potential change in control of the corporation if the board of directors determines that the change or potential change of control is opposed to or not in the best interest of the corporation, upon consideration of any relevant facts, circumstances, contingencies or constituencies, including that there are reasonable grounds to believe that, within a reasonable time the corporation or any successor would be or become insolvent and subjected to bankruptcy proceedings.  However, in the case of an action to resist a change or potential change in control that impedes the rights of stockholders to vote for or remove directors, directors will only be given the benefit of the presumption of the business judgment rule if the directors have reasonable grounds to believe a threat to corporate policy and effectiveness exists, and if the action taken that impedes the exercise of the stockholders&#8217; rights is reasonable in relation to such threat.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significantly, the DGCL does not provide a similar list of statutory factors that corporate directors and officers may consider in making decisions. Instead, in a number of cases and in certain situations, Delaware law has been interpreted to provide that fiduciary duties require directors to accept an offer from the highest bidder regardless of the effect of such sale on the corporate constituencies other than the stockholders. Thus, the flexibility granted to directors of Nevada corporations when making business decisions, including in the context of a hostile takeover, are significantly greater than those granted to directors of Delaware corporations. In light of the Nevada constituency statute, the Combined Company&#8217;s board of directors will have greater discretion in determining the appropriate factors to take into consideration when making corporate decisions under Nevada law than under Delaware law.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">181</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Limitation on Personal Liability of Directors and Officers</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The NRS and the DGCL each, by way of statutory provisions or permitted provisions in corporate charter documents, eliminate or limit the personal liability of directors and officers to the corporation and their stockholders for monetary damages for breach of a director&#8217;s fiduciary duty, subject to the differences discussed below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The DGCL permits corporations to adopt charter provisions exculpating directors from monetary liability to the corporation and its stockholders for breaches of the directors&#8217; duty of care, but the statute precludes liability limitation for breach of the duty of loyalty, acts or omissions not in good faith or involving intentional misconduct and for paying dividends or repurchasing stock out of other than lawfully available funds. With respect to a corporation&#8217;s most senior officers namely, the chief executive officer, president, chief financial officer, chief operating officer, chief legal officer, controller, treasurer and chief accounting officer, as well as any other persons identified as &#8220;named executive officers&#8221; in a public company&#8217;s most recent SEC filings or who otherwise consent to jurisdiction under Delaware&#8217;s long-arm statute applicable to directors and officers of Delaware corporations the DGCL authorizes similar limitations of liability, but only in connection with direct claims brought by stockholders, including class actions. The DGCL does not, however, authorize a limitation on liability of officers for breach of fiduciary duty arising out of claims brought by the corporation itself or for derivative claims brought by stockholders in the name of the corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the NRS, in order for a director or officer to be individually liable to the corporation or its stockholders or creditors for damages as a result of any act or failure to act, the presumption of the codified business judgment rule must be rebutted and it must be proven that the director&#8217;s or officer&#8217;s act or failure to act constituted a breach of their fiduciary duties as a director or officer, and that the breach of those duties involved intentional misconduct, fraud or a knowing violation of law. Unlike the DGCL, however, the limitation on director and officer liability under the NRS does not distinguish the duty of loyalty or transactions from which a director derives an improper personal benefit, but it does, pursuant to NRS 78.300, impose limited personal liability on directors for distributions made in violation of NRS 78.288. Further, the NRS permits a corporation to renounce in its articles of incorporation any interest or expectancy to participate in specific or specified classes or categories of business opportunities. Both the DGCL and the NRS permit limitation of liability which applies to both directors and officers, though the NRS also expressly applies this limitation to individual liabilities of directors or officers to creditors of the corporation. Furthermore, under the NRS, it is not necessary for a corporation to adopt provisions in its articles of incorporation limiting personal liability of directors or officers, as this limitation is provided by statute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As described above, the NRS provides broader protection from personal liability for directors and officers than the DGCL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Indemnification</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The NRS and the DGCL each have statutory mechanisms that permit corporations to indemnify directors, officers, employees and agents in similar circumstances, subject to the differences discussed below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In suits that are not brought by or in the right of the corporation, both jurisdictions&#8217; statutory indemnification mechanisms permit a corporation to indemnify current and former directors, officers, employees and agents for attorneys&#8217; fees and other expenses, judgments and amounts paid in settlement that the person actually and reasonably incurred in connection with the action, suit or proceeding. The person seeking indemnity may recover under these statutory provisions as long as they acted in good faith and believed their actions were either in the best interests of or not opposed to the best interests of the corporation. Under the indemnification mechanism provided under the NRS, the person seeking indemnity may also be indemnified if they are not held liable for breach of their fiduciary duties. Similarly, with respect to a criminal proceeding, the person seeking indemnification must not have had any reasonable cause to believe their conduct was unlawful. The articles of incorporation may provide for further indemnification than that described in the statutory mechanism provided under the NRS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In derivative suits, a corporation in either jurisdiction may indemnify its directors, officers, employees or agents for expenses that the person actually and reasonably incurred. A corporation may not indemnify a person if the person was adjudged to be liable to the corporation unless a court otherwise orders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the statutory indemnification mechanism in either jurisdiction, no corporation may indemnify a party unless it decides that indemnification is proper. Under the DGCL, the corporation through its stockholders, directors or independent legal counsel will determine whether the conduct of the person seeking indemnity conformed to the statutory provisions governing indemnity. Similarly, under the statutory indemnification mechanisms under the NRS, the corporation through its stockholders, directors or independent counsel must determine that the indemnification is proper.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">182</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The indemnification pursuant to the statutory mechanisms available under the NRS, as described above, does not exclude any other rights to which a person seeking indemnification or advancement of expenses may be entitled under the articles of incorporation or any bylaw, agreement, vote of stockholders or disinterested directors or otherwise. However, unless otherwise ordered by a court, indemnification may not be made to or on behalf of any director or officer finally adjudged by a court of competent jurisdiction, after exhaustion of any appeals taken therefrom, to be liable for intentional misconduct, fraud or a knowing violation of law, and such misconduct, fraud or violation was material to the cause of action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Advancement of Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The DGCL and NRS have substantially similar provisions regarding indemnification by a corporation of its officers, directors, employees and agents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The DGCL provides that expenses incurred by an officer or director in defending any civil, criminal, administrative or investigative action, suit or proceeding may be paid by the corporation in advance of the final disposition of such action, suit or proceeding, upon receipt of an undertaking by or on behalf of such director or officer to repay the amount if it is ultimately determined that they are not entitled to be indemnified by the corporation as authorized under the DGCL. A Delaware corporation has the discretion to decide whether or not to advance such defense expenses, unless its certificate of incorporation or bylaws provide for mandatory advancement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The NRS similarly provides that unless otherwise restricted by the articles of incorporation, the bylaws or an agreement made by the corporation, the corporation may pay defense expenses of a director or officer in advance of the final disposition of the action, suit or proceeding, upon receipt of an undertaking by or on behalf of the director or officer to repay the amount if it is ultimately determined by a court of competent jurisdiction that they are not entitled to be indemnified by the corporation. Similar to Delaware, such advancement of expenses would be discretionary unless the articles of incorporation, the bylaws, or an agreement made by the corporation require the corporation to pay such expenses upon receipt of such an undertaking.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Director Compensation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The DGCL does not have a specific statute governing either the establishment of director compensation, or the fairness of director compensation. In contrast, the NRS provides that, unless otherwise provided in the articles of incorporation or bylaws, the board of directors, without regard to personal interest, may establish the compensation of directors for services in any capacity, and, if the board of directors so establishes the compensation of directors, such compensation is presumed to be fair to the corporation unless proven unfair by a preponderance of the evidence. The Combined Company&#8217;s board of directors after the Nevada Redomestication will establish the compensation of its directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Action by Written Consent of Directors</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Both the DGCL and NRS provide that, unless the certificate or articles of incorporation or the bylaws provide otherwise, any action required or permitted to be taken at a meeting of the directors or a committee thereof may be taken without a meeting if all members of the board or committee, as the case may be, consent to the action in writing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Neither the Delaware Charter or Delaware Bylaws, nor the Nevada Charter or Nevada Bylaws, limit the type or nature of a board action taken by written consent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Actions by Written Consent of Stockholders</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The DGCL provides that, unless the certificate of incorporation provides otherwise, any action required or permitted to be taken at a meeting of the stockholders may be taken without a meeting if the holders of outstanding stock having at least the minimum number of votes that would be necessary to authorize or take the action at a meeting of stockholders at which all shares entitled to vote thereon were present and voted, consent to the action in writing. The NRS provides that, unless the articles of incorporation provides otherwise, any action required or permitted to be taken at a meeting of the stockholders may be taken without a meeting if, before or after the action, a written consent to such action is signed by stockholders holding at least a majority of the voting power, except that if a different proportion of voting power is required for such an action at a meeting, then that proportion of written consents is required.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">183</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the DGCL requires the corporation to give prompt notice of the taking of corporate action without a meeting by less than unanimous written consent to those stockholders who did not consent in writing. There is no equivalent notice requirement under the NRS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The NRS also permits a corporation to prohibit stockholder action by written consent in lieu of a meeting of stockholders by including such prohibition in its articles of incorporation or bylaws. Both the Delaware Charter and the Nevada Charter prohibit action by written consent of the stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dividends and Distributions</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Delaware law is more restrictive than Nevada law with respect to dividend payments. Unless further restricted in the certificate of incorporation, the DGCL permits a corporation to declare and pay dividends out of either (i) surplus, or (ii) if no surplus exists, out of net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year (provided that the amount of capital of the corporation is not less than the aggregate amount of the capital represented by the issued and outstanding stock of all classes having a preference upon the distribution of assets). The DGCL defines surplus as the excess, at any time, of the net assets of a corporation over its stated capital. In addition, the DGCL provides that a corporation may redeem or repurchase its shares only when the capital of the corporation is not impaired and only if such redemption or repurchase would not cause any impairment of the capital of the corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The NRS provides that no distribution (including, without limitation, dividends, redemptions or purchases of shares of capital stock or distributions of indebtedness, in each case to or for the benefit of all holders of shares of any one or more classes or series of the capital stock of the corporation with respect to such shares) may be made if, after giving effect to such distribution, (i) the corporation would not be able to pay its debts as they become due in the usual course of business, or, (ii) except as otherwise specifically permitted by the articles of incorporation, the corporation&#8217;s total assets would be less than the sum of its total liabilities plus the amount that would be needed at the time of a dissolution to satisfy the preferential rights of preferred stockholders. Directors may consider financial statements prepared on the basis of accounting practices that are reasonable under the circumstances, a fair valuation, including but not limited to unrealized appreciation and depreciation, and any other method that is reasonable under the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Restrictions on Business Combinations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Both Delaware and Nevada law provide certain protections to stockholders in connection with certain business combinations. These protections can be found in Section 203 of the DGCL and NRS 78.411 through 78.444, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under Section 203 of the DGCL, certain &#8220;business combinations&#8221; with &#8220;interested stockholders&#8221; of the Delaware Corporation are subject to a three-year moratorium unless specified conditions are met. For purposes of Section 203, the term &#8220;interested stockholders&#8221; generally is defined as any person (including its affiliates and associates) that beneficially owns 15% or more of the outstanding voting stock of the corporation or is an affiliate or associate of the corporation and was the beneficial owner of 15% or more of the outstanding voting stock of the corporation at any time in the last 3-year period, and the term &#8220;business combination&#8221; is defined broadly to include (i) mergers with or caused by the interested stockholder; (ii) sales or other dispositions to the interested stockholder (except proportionately with the corporation&#8217;s other stockholders) of assets of the corporation or a subsidiary equal to 10% or more of the aggregate market value of either the corporation&#8217;s consolidated assets or its outstanding stock; (iii) the issuance or transfer by the corporation or a subsidiary of stock of the corporation or such subsidiary to the interested stockholder (except for transfers in a conversion or exchange or a pro rata distribution or certain other transactions, none of which increase the interested stockholder&#8217;s proportionate ownership of any class or series of the corporation&#8217;s or such subsidiary&#8217;s stock); or (iv) receipt by the interested stockholder (except proportionately as a stockholder), directly or indirectly, of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation or a subsidiary. The three-year moratorium imposed on business combinations by Section 203 of the DGCL does not apply if: (i) prior to the time on which such stockholder becomes an interested stockholder the board of directors approves either the business combination or the transaction which resulted in the person becoming an interested stockholder; (ii) the interested stockholder owns 85% of the corporation&#8217;s voting stock upon consummation of the transaction that made him or her an interested stockholder (excluding from the 85% calculation shares owned by directors who are also officers of the target corporation and shares held by employee stock plans that do not permit employees to decide confidentially whether to accept a tender or exchange offer); or (iii) at or after the time on which such stockholder becomes an interested stockholder, the board approves the business combination and it is also approved at a stockholder meeting by at least two-thirds (66-2/3%) of the outstanding voting stock not owned by the interested stockholder.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">184</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In contrast, the NRS imposes a maximum moratorium of two years versus Delaware&#8217;s three-year moratorium on business combinations. However, NRS 78.411 through 78.444 regulate business combinations more stringently. First, an interested stockholder is defined as a beneficial owner of 10% or more of the voting power. Second (as opposed to Delaware&#8217;s provision that allows interested stockholder combinations with stockholder approval at the time of such combination), the two-year moratorium under Nevada law can be lifted only by the approval by the corporation&#8217;s board of directors, in advance, of the combination or the transaction by which such person first becomes an interested stockholder, or if the combination is approved by the board and 60% of the corporation&#8217;s voting power not beneficially owned by the interested stockholder, its affiliates and associates. Finally, after the two-year period, a combination remains prohibited unless (i) it is approved by the board of directors, the disinterested stockholders or a majority of the outstanding voting power not beneficially owned by the interested stockholder and its affiliates and associates or (ii) the terms of the combination satisfy certain fair value requirements. However, these statutes do not apply to any combination of a corporation and an interested stockholder after the expiration of four years after the person first became an interested stockholder. These combinations statutes in Nevada apply only to Nevada corporations with 200 or more stockholders of record.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Companies are entitled to opt out of the business combination provisions of the DGCL and NRS. The Delaware Corporation has not opted out of the business combination provisions of Section 203 of the DGCL, and the Nevada Corporation has not opted out of the business combination provisions of NRS 78.411 through 78.444. Any opt-out of the business combinations provisions of the NRS must be contained in an amendment to the Nevada Charter approved by a majority of the outstanding voting power not then owned by interested stockholders, but the amendment would not be effective until 18 months after the vote of the stockholders to approve the amendment and would not apply to any combination with a person who first became an interested stockholder on or before the effective date of the amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Acquisition of Controlling Interests</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the restrictions on business combinations with interested stockholders, Nevada law also protects the corporation and its stockholders from persons acquiring a &#8220;controlling interest&#8221; in a corporation. The provisions can be found in NRS 78.378 through 78.3793. Delaware law does not have similar provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to NRS 78.379, any person who acquires a controlling interest in a corporation may not exercise voting rights on any control shares unless such voting rights are conferred by a majority vote of the disinterested stockholders of the issuing corporation at a special meeting of such stockholders held upon the request and at the expense of the acquiring person. NRS 78.3785 provides that a &#8220;controlling interest&#8221; means the ownership of outstanding voting shares of an issuing corporation sufficient to enable the acquiring person, individually or in association with others, directly or indirectly, to exercise (i) one fifth or more but less than one third, (ii) one third or more but less than a majority or (iii) a majority or more of the voting power of the issuing corporation in the election of directors, and once an acquirer crosses one of these thresholds, shares which it acquired in the transaction taking it over the threshold and within the 90 days immediately preceding the date when the acquiring person acquired or offered to acquire a controlling interest become &#8220;control shares&#8221; to which the voting restrictions described above apply. In the event that the control shares are accorded full voting rights and the acquiring person acquires control shares with a majority or more of all the voting power, any stockholder, other than the acquiring person, who does not vote in favor of authorizing voting rights for the control shares is entitled to dissenter&#8217;s rights under NRS Chapter 92A.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">NRS 78.378(1) provides that the control share statutes of the NRS do not apply to any acquisition of a controlling interest in an issuing corporation if the articles of incorporation or bylaws of the corporation in effect on the 10th day following the acquisition of a controlling interest by the acquiring person provide that the provisions of those sections do not apply to the corporation or to an acquisition of a controlling interest specifically by types of existing or future stockholders, whether or not identified. In addition, NRS 78.3788 provides that the controlling interest statutes apply as of a particular date only to a corporation that has 200 or more stockholders of record, at least 100 of whom have addresses in Nevada appearing on the corporation&#8217;s stock ledger at all times during the 90 days immediately preceding that date, and which does business in Nevada directly or indirectly or through an affiliated corporation. NRS 78.378(2) provides that the corporation, by virtue of its articles of incorporation, bylaws or resolutions adopted by directors, may impose stricter requirements if it so desires.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Corporations are entitled to opt out of the above controlling interest provisions of the NRS. The Nevada Corporation has &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; of these provisions in the &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">185</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Stockholder Vote for Mergers and Other Corporate Reorganizations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the DGCL, unless the certificate of incorporation specifies a higher percentage, the stockholders of a corporation that is being acquired in a merger or sale involving substantially all of its assets must authorize such merger or sale of assets by vote of an absolute majority of outstanding shares entitled to vote. The corporation&#8217;s board of directors must also approve such transaction. Similarly, under the NRS, a merger or sale of all assets requires authorization by stockholders of the corporation being acquired or selling its assets by at least a majority of the voting power of the outstanding shares entitled to vote, as well as approval of such corporation&#8217;s board of directors. Although a substantial body of case law has been developed in Delaware as to what constitutes the &#8220;sale of substantially all of the assets&#8221; of a corporation, it is difficult to determine the point at which a sale of virtually all, but less than all, of a corporation&#8217;s assets would be considered a &#8220;sale of all of the assets&#8221; of the corporation for purposes of Nevada law. It is possible that some sales of less than all of the assets of a corporation requiring stockholder authorization under Delaware law would be judicially determined to not require stockholder authorization under Nevada law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The DGCL and NRS have substantially similar provisions with respect to approval by stockholders of a surviving corporation in a merger. The DGCL does not require a stockholder vote of a constituent corporation in a merger (unless the corporation provides otherwise in its certificate of incorporation) if (i) the plan of merger does not amend the existing certificate of incorporation, (ii) each share of stock of such constituent corporation outstanding immediately before the effective date of the merger is an identical outstanding share after the effective date of merger and (iii) either no shares of the common stock of the surviving corporation and no shares, securities or obligations convertible into such stock are to be issued or delivered under the plan of merger, or the authorized unissued shares or treasury shares of the common stock of the surviving corporation to be issued or delivered under the plan of merger, plus those initially issuable upon conversion of any other shares, securities or obligations to be issued or delivered under such plan, do not exceed 20% of the shares of common stock of such constituent corporation outstanding immediately prior to the effective date of the merger. The NRS does not require a stockholder vote of the surviving corporation in a merger under substantially similar circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Appraisal or Dissenter&#8217;s Rights</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In both jurisdictions, dissenting stockholders of a corporation engaged in certain major corporate transactions are entitled to appraisal rights. Appraisal or dissenter&#8217;s rights permit a stockholder to receive cash generally equal to the fair value of the stockholder&#8217;s shares (as determined by agreement of the parties or by a court) in lieu of the consideration such stockholder would otherwise receive in any such transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under Section 262 of the DGCL, appraisal rights are generally available for the shares of any class or series of stock of a Delaware corporation in a merger, consolidation or conversion, provided that no appraisal rights are available with respect to shares of any class or series of stock if, at the record date for the meeting held to approve such transaction, such shares of stock, or depositary receipts in respect thereof, are either (i) listed on a national securities exchange or (ii) held of record by more than 2,000 holders, unless the stockholders receive in exchange for their shares anything other than shares of stock of the surviving or resulting corporation (or depositary receipts in respect thereof), or of any other corporation that is listed on a national securities exchange or held by more than 2,000 holders of record, cash in lieu of fractional shares or fractional depositary receipts described above or any combination of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, Section 262 of the DGCL allows beneficial owners of shares to file a petition for appraisal without the need to name a nominee holding such shares on behalf of such owner as a nominal plaintiff and makes it easier than under Nevada law to withdraw from the appraisal process and accept the terms offered in the merger, consolidation or conversion. Under the DGCL, no appraisal rights are available to stockholders of the surviving or resulting corporation if the merger did not require their approval. The Delaware Charter and Delaware Bylaws do not provide for appraisal rights in addition to those provided by the DGCL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Under the NRS, a stockholder is entitled to dissent from, and obtain payment for, the fair value of the stockholder&#8217;s shares in the event of (i) certain acquisitions of a controlling interest in the corporation, (ii) consummation of a plan of merger, if approval by the stockholders is required for the merger, regardless of whether the stockholder is entitled to vote on the merger or if the domestic corporation is a subsidiary and is merged with its parent, or if the domestic corporation is a constituent entity in a merger pursuant to NRS 92A.133, (iii) consummation of a plan of conversion to which the corporation is a party, (iv) consummation of a plan of exchange in which the corporation is a party, (iv) any corporate action taken pursuant to a vote of the stockholders, if the articles of incorporation, bylaws or a resolution of the board of directors provides that voting or nonvoting stockholders are entitled to dissent and obtain payment for their shares, or (v) any corporate action to which the stockholder would be obligated, as a result of the corporate action, to accept money or scrip rather than receive a fraction of a share in exchange for the cancellation of all the </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">186</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">stockholder&#8217;s outstanding shares, except where the stockholder would not be entitled to receive such payment pursuant to NRS 78.205, 78.2055 or 78.207.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Also under the NRS, holders of covered securities (generally those that are listed on a national securities exchange), any shares traded in an organized market and held by at least 2,000 stockholders of record with a market value of at least $20,000,000, and any shares issued by an open-end management investment company registered under the Investment Company Act of 1940 and which may be redeemed at the option of the holder at net asset value, are generally not entitled to dissenter&#8217;s rights. However, this exception is not available in connection with accordance of full voting rights to &#8220;control shares&#8221; under Nevada&#8217;s acquisitions of a controlling interest statutes, or if (i) the articles of incorporation of the corporation issuing the shares provide that such exception is not available, (ii) the resolution of the board of directors approving the plan of merger, conversion or exchange expressly provides otherwise or (iii) the holders of the class or series of stock are required by the terms of the corporate action to accept for the shares anything except cash, shares of stock or other securities as described in NRS 92A.390(3) or any combination thereof. The NRS prohibits a dissenting stockholder from voting their shares or receiving certain dividends or distributions after their dissent. As with the Delaware Charter and the Delaware Bylaws, the Nevada Charter and Nevada Bylaws do not provide for dissenter&#8217;s rights in addition to those provided by the NRS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The mechanics and timing procedures vary somewhat between Delaware and Nevada, but both require technical compliance with specific notice and payment protocols.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Special Meetings of Stockholders</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The DGCL permits special meetings of stockholders to be called by the board of directors or by any other person authorized in the certificate of incorporation or bylaws to call a special stockholder meeting. The NRS permits special meetings of stockholders to be called by the entire board of directors, any two directors or the President, unless the articles of incorporation or bylaws provide otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Delaware and Nevada Charter provide that special meetings of stockholders may be called only by the corporation&#8217;s board of directors. Special meetings may not be called by any other person or persons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Meetings Pursuant to Petition of Stockholders</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The DGCL provides that a director or a stockholder of a corporation may apply to the Delaware Court of Chancery if the corporation fails to hold an annual meeting for the election of directors or there is no written consent to elect directors in lieu of an annual meeting for a period of 30 days after the date designated for the annual meeting or, if there is no date designated, within 13 months after the last annual meeting or the last action by written consent to elect directors in lieu of an annual meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the NRS, stockholders having not less than 15% of the voting power may petition the district court to order a stockholder meeting for the election of directors if a corporation fails to call a meeting for that purpose within 18 months after the last meeting at which directors were elected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Adjournment of Stockholder Meetings</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the DGCL, if a meeting of stockholders is adjourned due to lack of a quorum and the adjournment is for more than 30 days, or if after the adjournment a new record date is fixed for the adjourned meeting, notice of the adjourned meeting must be given to each stockholder of record entitled to vote at the meeting. At the adjourned meeting the corporation may transact any business that might have been transacted at the original meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In contrast, under the NRS, a corporation is not required to give any notice of an adjourned meeting or of the business to be transacted at an adjourned meeting, other than by announcement at the meeting at which the adjournment is taken, unless the board of directors of the corporation fixes a new record date for the adjourned meeting or the meeting date is adjourned to a date more than 60 days later than the date set for the original meeting, in which case a new record date must be fixed and notice given.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Duration of Proxies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the DGCL, a proxy executed by a stockholder will remain valid for a period of three years, unless the proxy provides for a longer period.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">187</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the NRS, a proxy is effective only for a period of six months, unless it is coupled with an interest or unless otherwise provided in the proxy, which duration may not exceed seven years. The NRS also provides for irrevocable proxies, without limitation on duration, in limited circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Quorum and Voting</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The DGCL provides that the certificate of incorporation and bylaws may establish quorum and voting requirements, but in no event shall a quorum consist of less than one-third of the shares entitled to vote. If the certificate of incorporation and bylaws are silent as to specific quorum and voting requirements: (a) a majority of the shares entitled to vote shall constitute a quorum at a meeting of stockholders; (b) in all matters other than the election of directors, the affirmative vote of the majority of shares present at the meeting and entitled to vote on the subject matter shall be the act of the stockholders; (c) directors shall be elected by a plurality of the votes of the shares present at the meeting and entitled to vote on the election of directors; and (d) where a separate vote by a class or series is required, a majority of the outstanding shares of such class or series shall constitute a quorum entitled to take action with respect to that vote on that matter and, in all matters other than the election of directors, the affirmative vote of the majority of shares of such class or series present at the meeting shall be the act of such class or series, or classes or series. A bylaw amendment adopted by stockholders which specifies the votes that shall be necessary for the election of directors shall not be further amended or repealed by the board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The NRS provides that, unless the articles of incorporation or bylaws provide otherwise, a majority of the voting power of the corporation, present in person or by proxy at a meeting of stockholders (regardless of whether the proxy has authority to vote on any matter), constitutes a quorum for the transaction of business. Under the NRS, unless the articles of incorporation or bylaws provide for different proportions, action by the stockholders on a matter other than the election of directors is approved if the number of votes cast in favor of the action exceeds the number of votes cast in opposition to the action. Unless provided otherwise in the corporation&#8217;s articles of incorporation or bylaws, directors are elected at the annual meeting of stockholders by plurality vote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Stockholder Inspection Rights</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The DGCL grants any stockholder or beneficial owner of shares the right, upon written demand under oath stating the proper purpose thereof, either in person or by attorney or other agent, to inspect and make copies and extracts from a corporation&#8217;s stock ledger, list of stockholders and its other books and records for any proper purpose. A proper purpose is one reasonably related to such person&#8217;s interest as a stockholder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Inspection rights under Nevada law are more limited. The NRS grants any person who has been a stockholder of record of a corporation for at least six months immediately preceding the demand, or any person holding, or thereunto authorized in writing by the holders of, at least 5% of all of its outstanding shares, upon at least five days&#8217; written demand the right to inspect in person or by agent or attorney, during usual business hours (i) the articles of incorporation and all amendments thereto, (ii) the bylaws and all amendments thereto and (iii) a stock ledger or a duplicate stock ledger, revised annually, containing the names, alphabetically arranged, of all persons who are record stockholders of the corporation, showing their places of residence, if known, and the number of shares held by them respectively. A Nevada corporation may require a stockholder to furnish the corporation with an affidavit that such inspection is not desired for a purpose which is in the interest of a business or object other than the business of the corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the NRS grants certain stockholders the right to inspect the books of account and financial statements of a corporation, provided that an affidavit from the stockholders making such demand is provided to the corporation stating that the inspection is not desired for any purpose not related to his or her interest as a stockholder. The right to inspect the books of account and financial statements of a corporation, to make copies of records and to conduct an audit of such records is available only to a stockholder who owns at least 15% of the issued and outstanding shares of a Nevada corporation, or who has been authorized in writing by the holders of at least 15% of such shares. In addition, the board of directors may condition such inspection on the stockholders exercising such rights to enter into and comply with a confidentiality agreement having such terms and scope as reasonably related to protecting the legitimate interests of the corporation. However, these requirements do not apply to any corporation that furnishes to its stockholders a detailed annual financial statement or any corporation that has filed during the preceding 12 months all reports required to be filed pursuant to Section 13 or Section 15(d) of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Business Opportunities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Under Delaware law, the corporate opportunity doctrine holds that a corporate officer or director may not generally and unilaterally take a business opportunity for their own if: (i) the corporation is financially able to exploit the opportunity; (ii) the </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">188</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">opportunity is within the corporation&#8217;s line of business; (iii) the corporation has an interest or expectancy in the opportunity; and (iv) by taking the opportunity for their own, the corporate fiduciary will thereby be placed in a position inimical to his duties to the corporation. The DGCL permits a Delaware corporation to renounce, in its certificate of incorporation or by action of the board of directors, any interest or expectancy of the corporation in, or being offered an opportunity to participate in, specified business opportunities or specified classes or categories of business opportunities that are presented to the corporation or one or more of its officers, directors or stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Similar to the DGCL, the NRS permits a Nevada corporation to renounce, in its articles of incorporation or by action of the board of directors, any interest or expectancy to participate in specified business opportunities or specified classes or categories of business opportunities that are presented to the corporation or one or more of its officers, directors or stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">What Doesn&#8217;t Change After Nevada Redomestication?</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Apart from being governed by the Nevada Charter, the Nevada Bylaws and the NRS, following completion of the Nevada Redomestication, the Combined Company will continue to exist in the form of a Nevada corporation. By virtue of the Nevada Redomestication, all of the rights, privileges and powers of the Delaware Corporation, and all property, real, personal and mixed, and all debts due to the Delaware Corporation, as well as all other things and causes of action belonging to the Delaware Corporation, will remain vested in the Nevada Corporation and will be the property of the Nevada Corporation. In addition, all debts, liabilities and duties of the Delaware Corporation will remain attached to the Nevada Corporation and may be enforced against the Nevada Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">No Change in the Business</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Nevada Redomestication will not result in any change in the Combined Company&#8217;s business, management, obligations, assets or liabilities (other than as a result of the transaction costs related to the Nevada Redomestication).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Combined Company&#8217;s management, including all directors and officers, will remain the same in connection with the Nevada Redomestication and will have the same positions with the Nevada Corporation. To the extent that the Nevada Redomestication will require the consent or waiver of a third party, the Combined Company will use commercially reasonable effects to obtain such consent or waiver before completing the Nevada Redomestication. Aerovate and Jade do not expect that any such required consent will impede the Combined Company&#8217;s ability to reincorporate in Nevada. The Nevada Redomestication will not otherwise adversely affect any of the Combined Company&#8217;s material contracts with any third parties, and the Combined Company&#8217;s rights and obligations under such material contractual arrangements will continue as rights and obligations of the Nevada Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">No Securities Act Consequences</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Combined Company will continue to be a publicly held company following completion of the Nevada Redomestication, and the Nevada Corporation&#8217;s common stock will continue to be listed on Nasdaq and traded under the symbol &#8220;JBIO&#8221;. The Combined Company will continue to file required periodic reports and other documents with the SEC. There is not expected to be any interruption in the trading of the Nevada Corporation common stock as a result of the Nevada Redomestication. The Combined Company and its stockholders will be in the same respective positions under the federal securities laws after the Nevada Redomestication as the Combined Company and its stockholders were prior to the Nevada Redomestication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">No Material Accounting Implications</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Effecting the Nevada Redomestication will not have any material accounting implications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">No Exchange of Stock Certificates Required</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Stockholders will not be required to exchange their existing stock certificates for new stock certificates.</p><a id="Proposal4_USFederal_NevadaRedom"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">U.S. Federal Income Tax Considerations of the Nevada Redomestication</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following discussion is a summary of U.S. federal income tax considerations to U.S. Holders (as defined below) of the Combined Company common stock and the Combined Company convertible preferred stock (the &#8220;Combined Company stock&#8221;) of the Nevada Redomestication. The discussion does not purport to be a complete analysis of all potential tax considerations. The </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">189</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">considerations of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or non-U.S. tax laws, are not discussed. This discussion is based on the Code, Treasury Regulations promulgated under the Code, judicial decisions and published rulings and administrative pronouncements of the IRS, in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a U.S. Holder. The Combined Company has not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax considerations of the Nevada Redomestication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This discussion is limited to a U.S. Holder that holds the Combined Company stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax considerations relevant to a U.S. Holder&#8217;s particular circumstances, including without limitation the effect of the Medicare contribution tax on net investment income, the alternative minimum tax, or the special tax accounting rules under Section 451(b) of the Code. In addition, it does not address considerations relevant to U.S. Holders subject to special rules, such as:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. expatriates and former citizens or long-term residents of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. Holders whose functional currency is not the U.S. dollar;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons holding the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Combined Company</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> stock as part of a hedge, straddle or other risk-reduction strategy or as part of a conversion transaction or other integrated investment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">banks, insurance companies and other financial institutions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">real estate investment trusts or regulated investment companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">brokers, dealers or traders in securities or other persons that elect to use a mark-to-market method of accounting for their holdings in the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Combined Company</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">partnerships or other entities or arrangements classified as partnerships, passthroughs, or disregarded entities for U.S. federal income tax purposes (and investors therein), S corporations or other passthrough entities (including hybrid entities);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax-exempt organizations or governmental organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons deemed to sell the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Combined Company</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> stock under the constructive sale provisions of the Code;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons who hold or receive the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Combined Company</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> stock pursuant to the exercise of any employee stock option or otherwise as compensation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax-qualified retirement plans; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons that own, or have owned, actually or constructively, more than 5% of the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Combined Company </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stock.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If an entity or arrangement classified as a partnership for U.S. federal income tax purposes holds the Combined Company stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership, and certain determinations made at the partner level. Accordingly, a partnership holding Combined Company stock and each partner in such partnership is urged to consult its tax advisor regarding the U.S. federal income tax considerations to it of the Nevada Redomestication<b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purpose of this discussion, a &#8220;U.S. Holder&#8221; is any beneficial owner of the Combined Company stock that, for U.S. federal income tax purposes, is or is treated as any of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an individual who is a citizen or resident of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a corporation created or organized under the laws of the United States, any state thereof or the District of Columbia;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">190</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a trust that: (i) is subject to the primary supervision of a U.S. court and the control of one or more &#8220;United States persons&#8221; (within</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> the meaning of Section 7701(a)(30) of the Code); or (ii) has a valid election in effect to be treated as a U.S. person for U.S. federal income tax purposes.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">This discussion is for informational purposes only and is not tax advice. Each prospective investor is urged to consult its tax advisor with respect to the application of the U.S. federal income tax laws to its particular situation as well as any tax considerations of the Nevada Redomestication arising under U.S. federal estate or gift tax laws, the laws of any state, local or non-U.S. taxing jurisdiction or any applicable income tax treaty.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Nevada Redomestication is intended to qualify as a &#8220;reorganization&#8221; for U.S. federal income tax purposes pursuant to Section 368(a)(1)(F) of the Code. As a result, a U.S. Holder generally should not recognize gain or loss upon the proposed Nevada Redomestication. A U.S. Holder will have the same aggregate basis in its the Combined Company stock after the Nevada Redomestication as such U.S. Holder had in the corresponding the Combined Company stock immediately prior to the Nevada Redomestication. A U.S. Holder&#8217;s holding period in the Combined Company stock immediately following the Nevada Redomestication will include such U.S. Holder&#8217;s holding period in the corresponding the Combined Company stock immediately prior to the Nevada Redomestication. Each U.S. Holder of shares of the Combined Company stock acquired on different dates and at different prices is urged to consult its tax advisor regarding the allocation of the tax basis and holding period of such shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Tax Reporting Regarding the Nevada Redomestication</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Assuming the Nevada Redomestication qualifies as a &#8220;reorganization&#8221; within the meaning of Section 368(a) of the Code, each U.S. Holder that receives shares of the Combined Company stock<span style="white-space:pre-wrap;"> in the Nevada Redomestication is required to retain permanent records pertaining to the reverse stock split and make such records available to any authorized IRS officers and employees. Such records should specifically include information regarding the amount, basis, and fair market value of all transferred property and relevant facts regarding any liabilities assumed or extinguished as part of such reorganization.  Each U.S. Holder who owned at least five percent (by vote or value) of the total outstanding stock of </span>the Combined Company stock or who owned securities in the Combined Company stock with a basis of $1,000,000 or more are required to attach a statement to their tax returns for the year in which the reverse stock split is consummated that contains the information listed in Treasury Regulations Section 1.368-3(b). Such statement must include the U.S. Holder&#8217;s tax basis in the holder&#8217;s the Combined Company stock<span style="white-space:pre-wrap;"> and the fair market value of such stock.  </span>Each U.S.<span style="font-family:'Times New Roman PS Std';">&#160;</span>Holder is urged to consult with its tax advisor to comply with these rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">This discussion of U.S.</b><b style="font-family:'Times New Roman PS Std';font-weight:bold;">&#160;</b><b style="font-weight:bold;">federal income tax considerations of the Nevada Redomestication is for general information purposes only and is not intended to be, and should not be construed as, tax advice. Determining the actual tax considerations of the Nevada Redomestication to a holder may be complex and will depend on such holder</b><b style="font-family:'Times New Roman PS Std';font-weight:bold;">&#8217;</b><b style="font-weight:bold;">s specific situation and on factors that are not within Aerovate</b><b style="font-family:'Times New Roman PS Std';font-weight:bold;">&#8217;</b><b style="font-weight:bold;">s knowledge or control. Each holder is urged to consult its tax advisor with respect to the application of U.S.</b><b style="font-family:'Times New Roman PS Std';font-weight:bold;">&#160;</b><b style="font-weight:bold;">federal income tax laws to its specific situation as well as any tax considerations arising under the U.S.</b><b style="font-family:'Times New Roman PS Std';font-weight:bold;">&#160;</b><b style="font-weight:bold;">federal estate or gift tax rules or under the laws of any state, local, non-U.S.</b><b style="font-family:'Times New Roman PS Std';font-weight:bold;">&#160;</b><b style="font-weight:bold;">or other taxing jurisdiction.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Additional Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Regulatory Matters</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consummation of the Nevada Redomestication requires the filing of the Articles of Conversion and the Nevada Charter with the office of the Nevada Secretary of State and the Certificate of Conversion with the Office of the Secretary of State in Delaware. No regulatory or governmental approvals or consents will be required in connection with the Nevada Redomestication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Appraisal Rights</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Holders of our Delaware Corporation Common Stock are not entitled to appraisal rights with respect to the Nevada Redomestication described in this proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Legal Proceedings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">From time to time, Aerovate may become subject to various legal proceedings and claims that arise in the ordinary course of its business activities. As of the date of this proxy statement/prospectus, Aerovate is not currently a party to any claim or litigation, the </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">191</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">outcome of which, if determined adversely to it, would individually or in the aggregate be reasonably expected to have a material adverse effect on its business. Regardless of the outcome, litigation can have an adverse impact on Aerovate because of defense and settlement costs, diversion of management resources and other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Interest of Certain Persons</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate&#8217;s board of directors believes that the corporate laws of the state of Delaware and the State of Nevada are substantially comparable as to the rights of stockholders, at least on balance of the relevant considerations against one another and as relevant to the combined company. As part of its process, Aerovate&#8217;s board of directors considered if redomestication to Nevada would convey any non-ratable benefits on any of the combined company&#8217;s directors or officers and did not identify any such non-ratable benefits. However, others may allege, and stockholders should be aware in voting on the Redomestication Proposal and the Nevada Redomestication Resolution, that the combined company&#8217;s directors and executive officers may be considered to have interests in the Nevada Redomestication that are different from, or in addition to, the interests of the stockholders generally. Aerovate&#8217;s board of directors has considered these potential interests, among other matters, in reaching the decision to approve the Nevada Redomestication and to recommend that Aerovate&#8217;s stockholders vote in favor of this proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Vote Required</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The affirmative vote of a majority of the shares of Aerovate common stock outstanding is required to approve the Nevada Redomestication and adopt the Nevada Redomestication Resolution. Abstentions and broker non-votes, if any, will have the same effect as a vote &#8220;AGAINST&#8221; the matter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;FOR&#8221; the approval of the Nevada Redomestication and the adoption of the Nevada Redomestication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">THE AEROVATE BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE REDOMESTICATION PROPOSAL AND THE ADOPTION OF THE NEVADA REDOMESTICATION RESOLUTION.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">192</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_056743c9_140b_4f3b_99a3_5038dc33073a"></a><a id="PROPOSALNO5THESTOCKPLANPROPOSAL_567099"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PROPOSAL NO.&#160;5&#160;&#8212; THE STOCK PLAN PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Aerovate Special Meeting, Aerovate will ask its stockholders to approve the Jade Biosciences,&#160;Inc. 2025 Stock Incentive Plan (the &#8220;2025 Stock Plan&#8221;) to be effective on the Closing Date. The 2025 Stock Plan was approved by Aerovate&#8217;s board of directors on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, subject to stockholder approval and the consummation of the Merger. If the 2025 Stock Plan is approved by stockholders and the Merger is consummated, no further awards will be granted under the Aerovate 2021 Stock Option and Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The purpose of the 2025 Stock Plan is to promote and closely align the interests of employees, officers, non-employee directors and other individual service providers of the Combined Company and its stockholders by providing stock-based compensation and other performance-based compensation. The objectives of the 2025 Stock Plan are to attract and retain the best available employees, officers, non-employee directors and other individual service providers for positions of substantial responsibility and to motivate participants to optimize the profitability and growth of the Combined Company through incentives that are consistent with the Combined Company&#8217;s goals and that link the personal interests of participants to those of the Combined Company&#8217;s stockholders. The 2025 Stock Plan allows for the grant of stock options, stock appreciation rights (&#8220;SARs&#8221;), restricted stock, restricted stock units (&#8220;RSUs&#8221;), other stock-based awards and incentive bonuses, collectively referred to herein as &#8220;Awards.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary of the 2025 Stock Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following description of the 2025 Stock Plan is not intended to be complete and is qualified in its entirety by the complete text of the 2025 Stock Plan, a copy of which is attached as <i style="font-style:italic;">Annex I </i>to this proxy statement. Stockholders are urged to read the 2025 Stock Plan in its entirety.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Administration</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2025 Stock Plan will be administered by the compensation committee of the Combined Company board of directors (the &#8220;Board&#8221;), or another committee designated by the Board to administer the 2025 Stock Plan, which is referred to herein as the &#8220;Administrator.&#8221; The Administrator will have broad authority, subject to the provisions of the 2025 Stock Plan, to administer and interpret the 2025 Stock Plan and Awards granted thereunder. All decisions and actions of the Administrator will be final.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Subject to 2025 Stock Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The initial share pool under the 2025 Stock Plan will be&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of the total number of shares of outstanding capital stock immediately following the consummation of the Merger, subject to certain adjustments in the event of a change in the Combined Company&#8217;s capitalization. The shares that may be issued under the 2025 Stock Plan will be automatically increased on January&#160;1 of each&#160;year beginning in and ending with a final increase on January&#160;1,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;in an amount equal to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of the diluted stock (including Combined Company common stock, preferred stock and unexercised pre-funded warrants) on the preceding December&#160;31, unless a lower, or no, increase is determined by the Administrator. Only shares of Combined Company common stock may be issued under the 2025 Stock Plan as incentive stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Shares of Combined Company common stock issued under the 2025 Stock Plan may be either authorized and unissued shares or previously issued shares acquired by the Combined Company. On termination or expiration of an Award under the 2025 Stock Plan, in whole or in part, the number of shares of Combined Company common stock subject to such Award but not issued thereunder or that are otherwise forfeited back to the Combined Company will again become available for grant under the 2025 Stock Plan. Additionally, shares retained or withheld in payment of any exercise price, purchase price, or tax withholding obligation of an Award will again become available for grant under the 2025 Stock Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Eligibility</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Current or prospective employees, officers, non-employee directors, and other independent service providers of the Combined Company and its subsidiaries will be eligible to participate in the 2025 Stock Plan. Following the Merger, it is expected that approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;employees (including five executive officers),&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;non-employee directors and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;other individual service providers of the Combined Company will be eligible to participate in the 2025 Stock Plan.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">193</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Types of Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Options</span>. All stock options granted under the 2025 Stock Plan will be evidenced by a written agreement with the participant, which provides, among other things, whether the option is intended to be an incentive stock option or a non-qualified stock option, the number of shares subject to the option, the exercise price, exercisability (or vesting), the term of the option, which may not generally exceed ten&#160;years, and other terms and conditions. Subject to the express provisions of the 2025 Stock Plan, options generally may be exercised over such period, in installments or otherwise, as the Administrator may determine. The exercise price for any stock option granted may not generally be less than the fair market value of the Combined Company common stock subject to that option on the grant date. The exercise price may be paid in cash or such other method as determined by the Administrator, including an irrevocable commitment by a broker to pay over such amount from a sale of the shares issuable under an option, the delivery of previously owned shares, or withholding of shares deliverable upon exercise. The 2025 Stock Plan permits, without stockholder approval, the Administrator to reduce the exercise price of a previously awarded option or cancel and re-grant or exchange such option for cash or a new Award with a lower (or no) exercise price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Appreciation Rights</span>. SARs may be granted alone or in conjunction with all or part of a stock option. Upon exercising a SAR, the participant is entitled to receive the amount by which the fair market value of the Combined Company common stock at the time of exercise exceeds the exercise price of the SAR. This amount is payable in Combined Company common stock, cash, restricted stock, or a combination thereof, at the Administrator&#8217;s discretion. The 2025 Stock Plan permits, without stockholder approval, the Administrator to reduce the exercise price of a previously awarded SAR or cancel and re-grant or exchange such SAR for cash or a new Award with a lower (or no) exercise price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restricted Stock and RSUs</span>. Awards of restricted stock consist of shares of stock that are transferred to the participant subject to restrictions that may result in forfeiture if specified conditions are not satisfied. RSUs result in the transfer of shares of cash or stock to the participant only after specified conditions are satisfied. The Administrator will determine the restrictions and conditions applicable to each award of restricted stock or RSUs, which may include performance vesting conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Stock-Based Awards</span>. Other stock-based awards are Awards denominated in or payable in, valued in whole or in part by reference to, or otherwise based on or related to, the value of Combined Company common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Incentive Bonuses</span>. Each incentive bonus will confer upon the participant the opportunity to earn a payment, which may be subject to vesting or performance criteria established by the Administrator. Payment of the amount due under an incentive bonus may be made in cash or shares, as determined by the Administrator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Performance Criteria</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Administrator may specify certain performance criteria which must be satisfied before Awards will be granted or will vest. The performance goals may vary from participant to participant, group to group, and period to period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Transferability</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Awards generally may not be sold, transferred for value, pledged, assigned, or otherwise alienated or hypothecated by a participant other than by will or the laws of descent and distribution, and each option or SAR may be exercisable only by the participant during his or her lifetime.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clawback</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Awards will be subject to recoupment in accordance with any clawback policy adopted by the Combined Company, including Aerovate&#8217;s Compensation Recovery Policy (or any successor clawback policy adopted by the Combined Company).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Adjustments Upon a Change in Capitalization</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of a change in capitalization of the Combined Company, including any reorganization, reclassification, combination of shares, stock split, reverse stock split, spin-off, dividend or distribution (other than quarterly cash dividends), the share pool and outstanding Awards will be equitably adjusted by the Administrator.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">194</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Change in Control</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of a change in control of the Combined Company, the Administrator may (i)&#160;provide for the assumption of outstanding Awards, (ii)&#160;issue substitute awards, (iii)&#160;accelerate vesting or waiver any forfeiture conditions, (iv)&#160;accelerate the exercisability of the award, (v)&#160;make any other adjustments to outstanding Awards as deemed to be appropriate or (vi)&#160;provide for the cancellation and cash-out of outstanding Awards; however, if Awards are not assumed, continued or substituted for, then all outstanding Awards will become fully vested and exercisable (with performance based on target or actual achievement as determined by the Administrator).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Amendment and Termination</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Combined Company board of directors will have the right to amend, alter, suspend, or terminate the 2025 Stock Plan at any time, provided certain enumerated material amendments may not be made without stockholder approval. No amendment or alteration to the 2025 Stock Plan or an Award or Award agreement will be made that would materially impair the rights of the holder, without such holder&#8217;s consent; however, no consent will be required if the Administrator determines in its sole discretion and prior to the date of any change in control that such amendment or alteration either is required or advisable in order for us, the 2025 Stock Plan, or such Award to satisfy any law or regulation or to meet the requirements of or avoid adverse financial accounting consequences under any accounting standard, or is not reasonably likely to significantly diminish the benefits provided under such Award, or that any such diminishment has been adequately compensated. The 2025 Stock Plan will automatically terminate as to the grant of future awards, unless earlier terminated by the Combined Company board of directors, on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2035.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Federal Income Tax Consequences</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of the U.S. federal income tax treatment applicable to the Combined Company and the participants who receive Awards under the 2025 Stock Plan based on the federal income tax laws in effect on the date of this proxy statement/prospectus. This summary is not intended to be exhaustive and does not address all matters relevant to a particular participant based on their specific circumstances. The summary expressly does not discuss the income tax laws of any state, municipality, or non-U.S. taxing jurisdiction, or the gift, estate, excise (including the rules&#160;applicable to deferred compensation under Section&#160;409A of the Code), or tax laws other than U.S. federal income tax law. Because individual circumstances may vary, each participant is urged to consult their own tax advisor concerning the tax implications of Awards granted under the 2025 Stock Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Incentive Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Options granted under the 2025 Stock Plan may be either incentive stock options, which are intended to satisfy the requirements of Section&#160;422 of the Code, or non-qualified stock options, which are not intended to meet such requirements. No taxable income is recognized by the optionee at the time of the option grant, and no taxable income is recognized for ordinary income tax purposes at the time the option is exercised, although taxable income may arise at that time for alternative minimum tax purposes. Unless there is a &#8220;disqualifying disposition&#8221;, as described below, the optionee will recognize long-term capital gain in an amount equal to the excess of (i)&#160;the amount realized upon the sale or other disposition of the purchased shares over (ii)&#160;the exercise price paid for the shares. A disqualifying disposition occurs if the disposition is less than two&#160;years after the date of grant or less than one&#160;year after the exercise date. If there is a disqualifying disposition of the shares, then the excess of (i)&#160;the fair market value of those shares on the exercise date or (if less) the amount realized upon such sale or disposition over (ii)&#160;the exercise price paid for the shares will be taxable as ordinary income to the optionee. Any additional gain or loss recognized upon the disposition will be a capital gain or loss. If the optionee makes a disqualifying disposition of the purchased shares, then the Combined Company will be entitled to an income tax deduction for the taxable&#160;year in which such disposition occurs equal to the amount of ordinary income recognized by the optionee as a result of the disposition. The Combined Company will not be entitled to any income tax deduction if the optionee makes a qualifying disposition of the shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Nonqualified Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No taxable income is recognized by an optionee upon the grant of a non-qualified stock option. The optionee in general will recognize ordinary income, in the&#160;year in which the option is exercised, equal to the excess of the fair market value of the purchased shares on the exercise date over the exercise price paid for the shares, and the optionee will be required to satisfy the tax withholding requirements applicable to such income. The Combined Company will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the optionee with respect to the exercised non-qualified stock option.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">195</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Appreciation Rights</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No taxable income is recognized upon receipt of a SAR. The participant will recognize ordinary income in the&#160;year in which the SAR is exercised, in an amount equal to the excess of the fair market value of the underlying shares of common stock on the exercise date over the base price in effect for the exercised right, and the participant will be required to satisfy the tax withholding requirements applicable to such income. The Combined Company will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant in connection with the exercise of the SAR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Stock Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A participant who receives unvested shares of Combined Company common stock will not recognize any taxable income at the time those shares are granted but will have to report as ordinary income, as and when those shares subsequently vest, an amount equal to the excess of (i)&#160;the fair market value of the shares on the vesting date over (ii)&#160;the cash consideration (if any) paid for the shares. The participant may, however, elect under Section&#160;83(b)&#160;of the Code to include as ordinary income in the&#160;year the unvested shares are issued an amount equal to the excess of (a)&#160;the fair market value of those shares on the issue date over (b)&#160;the cash consideration (if any) paid for such shares. If the Section&#160;83(b)&#160;election is made, the participant will not recognize any additional income as and when the shares subsequently vest. The Combined Company will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant at the time such ordinary income is recognized by the participant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Stock Units, Other Stock-Based Awards, Incentive Bonuses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Generally, no taxable income is recognized upon the grant of RSUs, other stock-based awards or incentive bonuses. The participant will recognize ordinary income in the&#160;year in which the award is settled in shares or cash. The amount of that income will be equal to the fair market value of the shares on the date of issuance or the amount of the cash paid in settlement of the award, and the participant will be required to satisfy the tax withholding requirements applicable to the income. The Combined Company will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant at the time the shares are issued or the cash amount is paid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Deductibility of Executive Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;162(m)&#160;of the Code limits the deductibility for federal income tax purposes of certain compensation paid to any &#8220;covered employee&#8221; in excess of $1 million. It is expected that compensation deductions for any covered employee with respect to awards granted under the 2025 Stock Plan will be subject to the $1 million annual deduction limitation. The administrator of the 2025 Stock Plan may grant Awards under the 2025 Stock Plan or otherwise that are or may become non-deductible when it believes doing so is in the best interests of the Combined Company and its stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">New Plan Benefits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate cannot currently determine the benefits or number of shares subject to Awards that may be granted in the future to eligible participants under the 2025 Stock Plan because the grant of Awards and terms of such Awards are to be determined in the sole discretion of the administrator of the 2025 Stock Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Required Vote</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The affirmative vote of a majority of votes properly cast by the holders of Aerovate common stock at the Aerovate Special Meeting is required to approve the Stock Plan Proposal. Abstentions and broker non-votes, if any, will have no effect on the Stock Plan Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Merger is not conditioned upon the approval of the Stock Plan Proposal.<br/><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain Aerovate stockholders have agreed to vote any shares of Aerovate common stock owned by them in favor of the Stock Plan Proposal. Please see the section titled &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#160;&#8212; Support Agreements</i>&#8221; beginning on page&#160;153 of this proxy statement/prospectus for more information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">THE AEROVATE BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE STOCK PLAN PROPOSAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">196</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_b206f8ca_7e97_47b2_a6f1_40cb4cb394b5"></a><a id="PROPOSALNO6THEESPPPROPOSAL_545692"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PROPOSAL NO.&#160;6&#160;&#8212; THE ESPP PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Aerovate Special Meeting, Aerovate will ask its stockholders to approve the Jade Biosciences,&#160;Inc. 2025 Employee Stock Purchase Plan (the &#8220;2025 ESPP&#8221;) to be effective on the Closing Date. The 2025 ESPP was approved by Aerovate&#8217;s board of directors on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, subject to stockholder approval and the consummation of the Merger. If the 2025 ESPP is approved by stockholders and the Merger is consummated, the Aerovate 2021 Employee Stock Purchase Plan will be terminated and no further shares will be issued thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The purpose of the 2025 ESPP is to provide employees of the Combined Company and its designated subsidiaries with an opportunity to purchase shares of the Combined Company common stock through accumulated contributions. The 2025 ESPP, and the rights of participants to make purchases thereunder, is intended to qualify under Section&#160;423 of the Code; however, sub-plans that do not meet the requirements of Section&#160;423 of the Code may be established for the benefit of eligible employees of non-U.S. subsidiaries of the Combined Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary of the ESPP</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following description of the 2025 ESPP is not intended to be complete and is qualified in its entirety by the complete text of the 2025 ESPP, a copy of which is attached as <i style="font-style:italic;">Annex J </i>to this proxy statement. Stockholders are urged to read the 2025 ESPP in its entirety.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Administration</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ESPP will be administered by the compensation committee of the Board or another committee designated by the Board to administer, which we refer to herein as the &#8220;ESPP Administrator.&#8221; All questions of interpretation of the 2025 ESPP are determined by the ESPP Administrator, whose decisions are final and binding upon all participants. The ESPP Administrator may delegate, subject to applicable law, its responsibilities under the 2025 ESPP to one or more other persons. The ESPP Administrator may adopt rules&#160;or procedures relating to the operation and administration of the 2025 ESPP to accommodate the specific requirements of local laws and procedures, including to adopt sub-plans for participants outside of the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Subject to ESPP</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The initial share pool under the 2025 ESPP will be the lesser of (i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of the total number of shares of outstanding capital stock immediately following the consummation of the Merger or (ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, subject to certain adjustments in the event of a change in the Combined Company&#8217;s capitalization. The shares that may be issued under the 2025 ESPP will be automatically increased on January&#160;1 of each&#160;year beginning in&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and ending with a final increase on January&#160;1, 2035 in an amount equal to the lesser of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of the diluted stock (including Combined Company common stock, preferred stock and unexercised pre-funded warrants) on the preceding December&#160;31 or&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, unless a lower, or no, increase is determined by the ESPP Administrator. Shares of Combined Company common stock issued under the 2025 ESPP may either be shares of authorized but unissued Combined Company common stock, Combined Company common stock held as treasury shares, or Combined Company common stock acquired in an open-market transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the total number of shares to be purchased by all participants on any exercise date (as defined below) exceeds the number of shares remaining available for issuance under the 2025 ESPP, the ESPP Administrator may make a pro rata allocation of the remaining available number of shares in as uniform a manner as possible and as the ESPP Administrator determines to be equitable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Eligibility</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All employees of the Combined Company or a designated subsidiary of the Combined Company (as defined in the 2025 ESPP) who customarily work for more than 20 hours per week and more than five&#160;months in any calendar&#160;year and satisfy the requirements set forth in the 2025 ESPP will be eligible to participate in the 2025 ESPP. However, any employee who would own (or pursuant to Section&#160;424(d)&#160;of the Code would be deemed to own) more than 5% of the voting power or value of the Combined Company common stock immediately after a grant under the 2025 ESPP is not eligible to participate and no participant may purchase more than $25,000 of Combined Company common stock in any one calendar&#160;year. Following the Merger, it is expected that approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;employees will be eligible to participate in the 2025 ESPP.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">197</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Offering Periods</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2025 ESPP is generally implemented by a series of &#8220;offering periods&#8221;. Unless otherwise specified by the ESPP Administrator, the first offering period and the first purchase period will begin on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and end on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, with subsequent offering periods and purchase periods lasting for&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and ending every.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Payroll Deductions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To participate in an offering period, an eligible employee must execute and submit a properly completed subscription agreement on or before a date determined by the ESPP Administrator prior to the applicable enrollment date. Once enrolled in the 2025 ESPP, a participant can purchase shares of our common stock with payroll deductions at the end of the applicable offering period. Once an offering period is over, a participant is automatically enrolled in the next offering period unless the participant chooses to withdraw from the 2025 ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each subscription agreement will request a deduction in an amount expressed as a whole&#160;percentage between 1% and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% and all payroll deductions will be credited to the eligible employee&#8217;s account. No interest will be paid on any amount held in the account of any eligible employee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Option Grant</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On the first trading day of each offering period, each eligible employee automatically will be granted an option to acquire shares of Combined Company common stock on the exercise date. All participants granted options under the 2025 ESPP will have the same rights and privileges consistent with the requirements set forth in Section&#160;423 of the Code. No eligible employee will be permitted to purchase more than shares of Combined Company common stock during each purchase period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Purchase Price</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The price per share at which shares are purchased under the 2025 ESPP is determined by the ESPP Administrator, but in no event will be less than 85% of the fair market value of the Combined Company common stock on the first or the last day of the offering period, whichever is lower.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Exercise of Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the end of each offering period, unless the participant has withdrawn from the 2025 ESPP, payroll deductions are applied automatically to purchase shares of common stock at the price described above. The number of shares purchased is determined by dividing the payroll deductions by the applicable purchase price, rounded down to the nearest whole share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any payroll deductions accumulated in a participant&#8217;s account that are not sufficient to purchase a full share will be retained in the participant&#8217;s account for the subsequent option period (subject to earlier withdrawal in accordance with the terms of the 2025 ESPP). Any other amounts of payroll deductions in a participant&#8217;s account that are not used for the purchase of shares of Combined Company common stock, whether because of the participant&#8217;s withdrawal, because the amount would enable the participant to purchase more than the maximum number of shares, or for any other reason, will be returned to the participant, without interest, as soon as administratively practicable after such withdrawal, exercise date or other event, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cancellation and Withdrawal</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Participants may cancel all (but not less than all) of their option and terminate their subscription agreement by delivering a written notice revoking their subscription to the Combined Company or by following an electronic or other withdrawal procedure determined by the ESPP Administrator. Upon such termination and cancellation, the balance in the participant&#8217;s account will be returned to the participant, without interest, as soon as administratively practicable thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Termination of Employment or Eligibility</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Upon the termination of a participant&#8217;s employment with the Combined Company (or a designated subsidiary, as applicable) for any reason or if a participant loses eligibility to participate in the 2025 ESPP, the participant&#8217;s option will be deemed cancelled, the balance in the participant&#8217;s account will be returned to the participant (or his or her estate or designated beneficiary in the event of the </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">198</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">participant&#8217;s death), without interest, as soon as administratively practicable, and the participant will have no other rights under the 2025 ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Transferability</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Rights to purchase Combined Company common stock under the 2025 ESPP may not be transferred by a participant and may be exercised during a participant&#8217;s lifetime only by the participant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Adjustments Upon a Change in Capitalization</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of any reorganizations, recapitalizations, stock splits, reverse stock splits, stock dividends, extraordinary dividends or distributions, or similar events, the ESPP Administrator will appropriately adjust the number and class of shares available under the 2025 ESPP and the applicable purchase price of such shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Merger or Other Corporate Transaction</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of a merger, sale, or other similar corporate transaction involving the Combined Company, each outstanding option will be assumed or an equivalent option substituted by the successor corporation or a parent or subsidiary of the successor corporation. If the successor corporation refuses to assume or substitute for the option, the offering period with respect to which such option relates will be shortened by setting a new exercise date on which such offering period shall end. The new exercise date will occur before the date of the Combined Company&#8217;s proposed merger, sale, or other similar corporate transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Amendment and Termination</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ESPP Administrator may amend, suspend or terminate the 2025 ESPP at any time and, in the event of a termination of the 2025 ESPP, may terminate all outstanding offering periods (and return each participant&#8217;s account balance to the participant) or allow outstanding offering periods to expire in accordance with their terms. The 2025 ESPP will continue in effect until terminated by the ESPP Administrator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Federal Income Tax Consequences</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a brief description of the federal income tax treatment that will generally apply to the grant and exercise of rights under the 2025 ESPP, based on federal income tax laws in effect on the date of this proxy statement/prospectus. The exact federal income tax treatment of options under the 2025 ESPP will depend on the specific nature of any such option and the individual tax attributes of the participant. The following summary is not intended to be exhaustive and, among other considerations, does not describe gift, estate, social security, state, local or international tax consequences. In addition, if one or more sub-plans are established for employees of non-U.S. subsidiaries, the tax rules&#160;may be different than discussed below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2025 ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section&#160;423 of the Code and, as a result, employees who participate in the 2025 ESPP will be afforded favorable tax treatment subject to meeting certain requirements specified by the Code. In general, there are no federal income tax consequences to a participant upon the grant of the option to purchase shares under the 2025 ESPP at the beginning of an option period or upon its exercise on the exercise date at the end of an option period. Upon the disposition of shares of common stock acquired upon exercise of an option, the participant will generally be subject to tax and the nature and amount of the tax will depend on whether the employee has satisfied the statutory holding period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the employee holds shares acquired under the 2025 ESPP for at least two&#160;years from the grant date of his or her option and at least one&#160;year from the date he or she acquired the shares (referred to as the &#8220;statutory holding period&#8221;), any gain on the sale of the shares will be taxed as ordinary income to the extent of the lesser of (i)&#160;the amount by which the fair market value of the shares on the grant date (i.e., the first day of the option period) exceeded the exercise price for the option, or (ii)&#160;the amount by which the fair market value of the shares on the date of sale exceeds the exercise price of the option. Any additional gain or loss will be taxed as long-term capital gain or loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the participant sells or otherwise disposes of the shares before the expiration of the statutory holding period, then in the&#160;year of such &#8220;disqualifying&#8221; disposition, the participant will be required to recognize ordinary income equal to the difference between the fair market value of the shares on the date of the exercise of the option and the exercise price of the option. Any additional gain or loss will be short-term or long-term capital gain or loss depending on the length of time the employee has held the shares.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">199</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Combined Company is not entitled to any deduction with respect to the difference between the fair market value of the common stock and the option exercise price if the participant satisfies the statutory holding period described above. If shares are sold before the statutory holding period is satisfied, the Combined Company receives a tax deduction for any ordinary income recognized by the participant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">New Plan Benefits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The benefits that will be received by or allocated to eligible employees under the 2025 ESPP cannot be determined at this time because the amount of payroll deductions contributed to purchase shares of Combined Company common stock under the 2025 ESPP is entirely within the discretion of each participant (subject to the limitations discussed above).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Required Vote</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The affirmative vote of a majority of votes properly cast by holders of Aerovate common stock at the Aerovate Special Meeting is required to approve the ESPP Proposal. Abstentions and broker non-votes, if any, will have no effect on the ESPP Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger is not conditioned upon the approval of the ESPP Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain Aerovate stockholders have agreed to vote any shares of Aerovate common stock owned by them in favor of the ESPP Proposal. Please see the section titled &#8220;<i style="font-style:italic;">Agreements Related to the Merger &#8212; Support Agreements</i>&#8221; beginning on page 153 of this proxy statement/prospectus for more information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">THE AEROVATE BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE ESPP PROPOSAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">200</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_4c3150c9_874a_4cb7_9a3a_f8dca405ed9e"></a><a id="PROPOSALNO7THEADJOURNMENTPROPOSAL_509679"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PROPOSAL NO.&#160;7&#160;&#8212; THE ADJOURNMENT PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Aerovate fails to receive a sufficient number of votes to approve Proposal Nos. 1, 2 and 3, Aerovate may propose to adjourn the Aerovate Special Meeting, for a period of not more than 60&#160;days, for the purpose of soliciting additional proxies to approve Proposal Nos. 1, 2 and 3. Aerovate currently does not intend to propose adjournment at the Aerovate Special Meeting if there are sufficient votes to approve Proposal Nos. 1, 2 and 3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a quorum is not present at the Aerovate Special Meeting, under Aerovate&#8217;s amended and restated bylaws, the holders of voting stock representing a majority of the voting power present at the meeting or the presiding officer may adjourn the special meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Required Vote</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The affirmative vote of a majority of votes properly cast by the holders of Aerovate common stock at the Aerovate Special Meeting is required to approve the Adjournment Proposal. Abstentions and broker non- votes, if any, will have no effect on the Adjournment Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger is not conditioned upon the approval of the Adjournment Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain Aerovate stockholders have agreed to vote any shares of Aerovate common stock owned by them in favor of the Adjournment Proposal. Please see the section titled &#8220;<i style="font-style:italic;">Agreements Related to the Merger &#8212; Support Agreements</i>&#8221; beginning on page 153 of this proxy statement/prospectus for more information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares &#8220;FOR&#8221; the Adjournment Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE AEROVATE BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE ADJOURNMENT PROPOSAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">201</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_c84e3fe5_946f_4c96_bae5_22cb24cf2c10"></a><a id="AEROVATESBUSINESS_579799"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AEROVATE&#8217;S BUSINESS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate is a biopharmaceutical company. Aerovate&#8217;s historical focus was on advancing AV-101, Aerovate&#8217;s dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (&#8220;PAH&#8221;) a devastating disease impacting approximately 70,000 people in the United States and Europe. On June&#160;17, 2024, Aerovate announced topline results from the Phase 2b portion of its Phase 2b/Phase 3 Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial of AV-101 (&#8220;IMPAHCT&#8221;). Topline data showed that, while AV-101 was generally well tolerated across all dose groups, the study did not meet its primary endpoint for improvement in pulmonary vascular resistance compared to placebo for any of the studied doses or show meaningful improvements in the secondary endpoint of change in six-minute walk distance (&#8220;6MWD&#8221;). Aerovate also reviewed data from several additional secondary endpoints of the Phase 2b portion of IMPAHCT, which also failed to show meaningful improvements. Based upon these results and in agreement with the independent study advisory committee, Aerovate halted enrollment and shut down the Phase 3 portion of IMPAHCT as well as the long-term extension study. AV-101 for the treatment of PAH was Aerovate&#8217;s only product candidate in development. Aerovate does not intend to resume development of AV-101 or any other product candidates. In July&#160;2024, Aerovate announced the decision to conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value. Aerovate also engaged Wedbush Securities&#160;Inc. as its exclusive strategic financial advisor to assist in the process of exploring strategic alternatives, which includes the Merger with Jade.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2024, following Aerovate&#8217;s decision to halt further development of AV-101, Aerovate announced its plan to terminate nearly all of its workforce (the &#8220;Workforce Reduction Plan&#8221;). As of September&#160;30, 2024, 46 individuals, or approximately 90% of Aerovate&#8217;s workforce, have been terminated. The affected individuals have been and will be provided severance benefits, including cash severance payments. Each affected individual&#8217;s eligibility for severance benefits is contingent upon entering into a separation agreement, which includes a general release of claims against Aerovate. In connection with the Workforce Reduction Plan, Aerovate incurred costs (in consideration of releases) of approximately $6.4 million, which are primarily one-time severance benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Aerovate&#8217;s Strategy to Date</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">PAH is an orphan disease with unmet medical need and is characterized by high pressure in the vessels transporting blood from the right side of the heart to the lungs. This high pressure is caused by abnormal cellular hyperproliferation and resistance to apoptosis, driven by improper signaling in cells of the distal pulmonary arteries, which over time results in narrowing of the pulmonary vessels and forces the heart to work harder to pump blood through the lungs. The severe blood flow restriction and strain on the heart becomes increasingly severe over time and ultimately leads to heart failure that is often fatal. Aerovate estimates there are between 30,000&#160;&#8211; 40,000 patients treated with approved PAH therapies in the U.S. alone, many of whom are on two or more approved PAH therapies. It is estimated that the combined global sales for PAH products in 2023 was $6.2 billion. Despite the availability of multiple approved therapies, PAH has a five-year survival rate for newly diagnosed and prevalent patients between 61% and 65%. None of the approved therapies directly address the abnormal cellular hyperproliferation of the pulmonary vasculature that causes the increased resistance to blood flow. Aerovate believes that novel treatments that primarily address abnormal cellular hyperproliferation may provide therapeutic benefit to PAH patients and lead to improved quality of life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate&#8217;s focus on developing AV-101 had been driven by historical results from the Phase 3 IMPRES clinical trial of oral imatinib for the treatment of PAH patients. Oral imatinib is a well-characterized targeted kinase inhibitor and approved oncology treatment, but clinical trials had also supported its potential for the treatment of PAH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June&#160;17, 2024, Aerovate announced topline results from the Phase 2b portion of the Phase 2b/ Phase 3 IMPAHCT trial. Results showed that, while AV-101 was well tolerated across all dose groups, the study did not meet its primary endpoint for improvement in pulmonary vascular resistance (&#8220;PVR&#8221;), compared to placebo for any of the studied doses or show meaningful improvements in the secondary endpoint of change in 6MWD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Primary Endpoint &#8212; ITT analysis of PVR (</b><span style="font-style:italic;font-weight:bold;">dynes*sec/cm</span><sup style="font-size:7.5pt;font-style:italic;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#708;</sup><span style="font-style:italic;font-weight:bold;">5</span><b style="font-weight:bold;">)</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:28.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Dose</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Least-squares&#160;mean&#160;difference&#160;as&#160;compared&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">with&#160;placebo&#160;(95%&#160;CI)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">P&#160;value</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.21%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10mg BID (N=50)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">42.8 <i style="font-style:italic;">(-80.57 to 166.09)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.4968</p></td></tr><tr><td style="vertical-align:bottom;width:60.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">35mg BID (N=49)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">-5.5 <i style="font-style:italic;">(-129.16 to 118.18)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.9306</p></td></tr><tr><td style="vertical-align:bottom;width:60.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">70mg BID (N=51)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">-57.0 <i style="font-style:italic;">(-181.14 to 67.20)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.3685</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">202</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Secondary Endpoint&#160;&#8212; ITT analysis of 6MWD (meters)</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Dose</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Least-squares&#160;mean&#160;difference&#160;as</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">compared&#160;with&#160;placebo&#160;(95%&#160;CI)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10mg BID (N=50)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">-11.7 (-34.75 to 11.26)</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">35mg BID (N=49)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">-4.2 (-27.74 to 19.37)</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">70mg BID (N=51)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">+1.3 (-22.09 to 24.60)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate also reviewed data from several additional secondary endpoints of the Phase 2b portion of IMPAHCT, which also failed to show meaningful improvements. Based upon these results, Aerovate, in agreement with the independent study advisory committee, halted enrollment and shut down the Phase 3 portion of IMPAHCT as well as the long-term extension study. Aerovate plans to release full data from the Phase 2b portion of IMPAHCT at a later date, the timing of which is to be determined.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Properties and Facilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate&#8217;s headquarters is located in Waltham, Massachusetts, where it leases approximately 5,000 square feet of office space. The Waltham lease expires in December&#160;2025. Aerovate also leases approximately 3,500 square feet of office space located in Foster City, California which expires in October&#160;2025. Aerovate believes that its existing facilities, as well as facilities available for rent, are sufficient for its current needs and its needs for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, Aerovate may become subject to various legal proceedings and claims that arise in the ordinary course of its business activities. As of the date of this proxy statement/prospectus, Aerovate is not currently a party to any claim or litigation, the outcome of which, if determined adversely to it, would individually or in the aggregate be reasonably expected to have a material adverse effect on its business. Regardless of the outcome, litigation can have an adverse impact on Aerovate because of defense and settlement costs, diversion of management resources and other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Manufacturing and Supply</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate has historically used third-party contract manufacturers for the production of its combination product, AV-101. Aerovate&#8217;s active pharmaceutical ingredient (&#8220;API&#8221;) is generic and can be purchased from multiple commercial vendors in compliance with the FDA&#8217;s current Good Manufacturing Practice (&#8220;cGMP&#8221;) regulations and European Pharmacopoeia standards. To be used in Aerovate&#8217;s inhaled product, the API required an additional manufacturing step, which was completed at Aerovate&#8217;s contract manufacturing organization that complies with the FDA&#8217;s cGMP regulations. The API was converted into drug product for aerosol use by one of Aerovate&#8217;s two contract fill/finish providers in the United States. As AV-101 is a drug- device combination product, Aerovate has historically contracted with a third-party to manufacture the single- dose inhaler device that Aerovate used for delivering inhaled AV-101 to patients in its Phase 2b/Phase 3 clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Release and stability testing to date supports stability of at least 36&#160;months for API under ambient conditions and supports stability of at least 36&#160;months for drug product also under ambient conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate&#8217;s API, finished product, and single-dose inhaler producers are accepted by the health authorities in all countries that were included in its global Phase 2b/Phase 3 clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate has paused manufacturing of AV-101 as Aerovate engages in its process to evaluate strategic alternatives, including the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Sales and Marketing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate&#8217;s commercialization strategy was previously to develop AV-101 into a leading therapy worldwide for the treatment of PAH. Should Aerovate resume product development activities and obtain approval for any products, Aerovate would need to establish a sales and marketing organization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate cannot guarantee that AV-101 or any future product candidate will receive coverage and reimbursement by public and commercial payors.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">203</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate&#8217;s commercial success has depended in part on its ability to obtain and maintain proprietary protection for its products, novel discoveries, drug development technologies and know-how; to operate without infringing on or otherwise violating the proprietary rights of others; and to prevent others from infringing or otherwise violating Aerovate&#8217;s proprietary rights. Aerovate&#8217;s policy has been to seek to protect its proprietary position by, among other methods, filing or in-licensing U.S. and foreign patents and patent applications related to its products and other proprietary technology, inventions and improvements that are important to the development and implementation of Aerovate&#8217;s business. Aerovate also has relied on trademarks, trade secrets, know-how, continuing technological innovation and potential in-licensing opportunities to develop and maintain its proprietary position. In June&#160;2024, Aerovate announced its decision to halt enrollment and shut down the Phase 3 portion of IMPAHCT as well as the long-term extension study of AV-101 in PAH, and Aerovate does not intend to continue to seek or maintain intellectual property protection on the technology underlying AV-101.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate&#8217;s intellectual property portfolio includes issued patents in the United States, pending patent applications in the United States, under the Patent Cooperation Treaty (&#8220;PCT international applications&#8221;), and in commercially relevant foreign jurisdictions for Aerovate&#8217;s products. The PCT international applications preserve all of Aerovate&#8217;s rights to file patent applications in commercially relevant foreign jurisdictions for its products. As of September&#160;30, 2024, Aerovate owns six U.S. patents, 11 U.S. patent applications, no pending PCT international applications, and 30 foreign patent applications. Aerovate&#8217;s U.S. patent portfolio is expected to expire between May&#160;14, 2040 and February&#160;15, 2042, excluding any extension of patent term that may be available and assuming that the filed patent applications will issue as patents. Aerovate&#8217;s foreign patent portfolio is expected to expire between May&#160;14, 2040 and February&#160;15, 2042, excluding any extension of patent terms that may be available and assuming that filed applications will issue as patents and that the foreign patent terms are calculated similarly to the calculation of U.S. patent terms for the corresponding U.S. portion of the patent portfolio. Aerovate&#8217;s patent portfolio is summarized in the following table.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:16%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 2.45pt;"><b style="font-weight:bold;">APPLICATION/</b><b style="font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">PATENT NO.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">RELATED</b><b style="color:#231f20;font-weight:bold;"> </b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">PRODUCT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">PROTECTION&#160;SOUGHT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 0.05pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 0.05pt;"><b style="font-weight:bold;">PROJECTED </b><b style="font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">EXPIRATION*</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">JURISDICTION</b></p></td></tr><tr><td style="vertical-align:top;width:16%;background:#cceeff;border-top:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.44pt;"><span style="color:#231f20;">62/849,054</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:40%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Composition of Matter; Use</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;">N/A</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;">US</span></p></td></tr><tr><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.44pt;"><span style="color:#231f20;">11,229,650</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Composition of Matter; Use</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;">5/14/2040</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;">US</span></p></td></tr><tr><td style="vertical-align:top;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.44pt;"><span style="color:#231f20;">11,806,349</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:40%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Composition of Matter; Use</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;">5/14/2040</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;">US</span></p></td></tr><tr><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;"><span style="color:#231f20;">18/377,561</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Composition of Matter; Use</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;">5/14/2040</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;">US</span></p></td></tr><tr><td style="vertical-align:top;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;"><span style="color:#231f20;">20806383.4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:40%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Composition of Matter; Use; Process</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;">5/14/2040</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;">Europe</span></p></td></tr><tr><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;"><span style="color:#231f20;">202080051359.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Composition of Matter; Use; Process</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;">5/14/2040</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;">China</span></p></td></tr><tr><td style="vertical-align:top;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;"><span style="color:#231f20;">2021-568694</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:40%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Composition of Matter; Use; Process</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;">5/14/2040</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;">Japan</span></p></td></tr><tr><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;"><span style="color:#231f20;">2020274521</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Composition of Matter; Use; Process</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;">5/14/2040</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;">Australia</span></p></td></tr><tr><td style="vertical-align:top;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;"><span style="color:#231f20;">3140641</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:40%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Composition of Matter; Use; Process</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;">5/14/2040</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;">Canada</span></p></td></tr><tr><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;"><span style="color:#231f20;">288111</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Composition of Matter; Use; Process</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;">5/14/2040</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;">Israel</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">204</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:16.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:38.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:16.57%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2.45pt;"><b style="font-weight:bold;">APPLICATION/</b><b style="font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">PATENT NO.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RELATED</b><b style="color:#231f20;font-weight:bold;"> </b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">PRODUCT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">PROTECTION&#160;SOUGHT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.05pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 0.05pt;"><b style="font-weight:bold;">PROJECTED </b><b style="font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">EXPIRATION*</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.05pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">JURISDICTION</b></p></td></tr><tr><td style="vertical-align:top;width:16.57%;background:#cceeff;border-top:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.44pt;"><span style="color:#231f20;">202117055928 </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;background:#cceeff;border-top:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Composition of Matter; Use; Process</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;">5/14/2040</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;">India</span></p></td></tr><tr><td style="vertical-align:top;width:16.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.44pt;"><span style="color:#231f20;">11202112719X</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Composition of Matter; Use; Process</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;">5/14/2040</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;">Singapore</span></p></td></tr><tr><td style="vertical-align:top;width:16.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.44pt;"><span style="color:#231f20;">10-2021-7041312</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Composition of Matter; Use; Process</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;">5/14/2040</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;">Republic of Korea</span></p></td></tr><tr><td style="vertical-align:top;width:16.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;"><span style="color:#231f20;">MX/A/2021/104029</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Composition of Matter; Use; Process</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;">5/14/2040</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;">Mexico</span></p></td></tr><tr><td style="vertical-align:top;width:16.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;"><span style="color:#231f20;">BR1120210230149</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Composition of Matter; Use; Process</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;">5/14/2040</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;">Brazil</span></p></td></tr><tr><td style="vertical-align:top;width:16.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;"><span style="color:#231f20;">2021/09070</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Composition of Matter; Use; Process</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;">5/14/2040</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;">South Africa</span></p></td></tr><tr><td style="vertical-align:top;width:16.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;"><span style="color:#231f20;">20210285</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Composition of Matter; Use; Process</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;">5/14/2040</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;">Bahrain</span></p></td></tr><tr><td style="vertical-align:top;width:16.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;"><span style="color:#231f20;">305/2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Composition of Matter; Use; Process</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;">5/14/2040</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;">Jordan</span></p></td></tr><tr><td style="vertical-align:top;width:16.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;"><span style="color:#231f20;">KW/P/2021/466</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Composition of Matter; Use; Process</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;">5/14/2040</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;">Kuwait</span></p></td></tr><tr><td style="vertical-align:top;width:16.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;"><span style="color:#231f20;">OM/P/2021/00467</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Composition of Matter; Use; Process</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;">5/14/2040</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;">Oman</span></p></td></tr><tr><td style="vertical-align:top;width:16.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;"><span style="color:#231f20;">QA/202111/000655</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Composition of Matter; Use; Process</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;">5/14/2040</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;">Qatar</span></p></td></tr><tr><td style="vertical-align:top;width:16.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;"><span style="color:#231f20;">521430873</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Composition of Matter; Use; Process</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;">5/14/2040</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;">Saudi Arabia</span></p></td></tr><tr><td style="vertical-align:top;width:16.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;"><span style="color:#231f20;">P6002085/2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Composition of Matter; Use; Process</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;">5/14/2040</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;">UAE</span></p></td></tr><tr><td style="vertical-align:top;width:16.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;"><span style="color:#231f20;">PCT/US20/32872</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Composition of Matter; Use; Process</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;">N/A</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;"><span style="color:#231f20;">International PCT</span></p></td></tr><tr><td style="vertical-align:top;width:16.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">62/849,056</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Composition of Matter; Use</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">US</p></td></tr><tr><td style="vertical-align:top;width:16.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">11,298,355</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Composition of Matter; Use</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">5/14/2040</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">US</p></td></tr><tr><td style="vertical-align:top;width:16.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">62/849,058</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">US</p></td></tr><tr><td style="vertical-align:top;width:16.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">11,413,289</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">5/14/2040</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">US</p></td></tr><tr><td style="vertical-align:top;width:16.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">11,813,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">5/14/2040</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">US</p></td></tr><tr><td style="vertical-align:top;width:16.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">18/378,949</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">5/14/2040</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">US</p></td></tr><tr><td style="vertical-align:top;width:16.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">62/849,059</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Composition of Matter; Use</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">US</p></td></tr><tr><td style="vertical-align:top;width:16.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">16/874,128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Composition of Matter; Use</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">5/14/2040</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">US</p></td></tr><tr><td style="vertical-align:top;width:16.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">62/877,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Composition of Matter; Process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">US</p></td></tr><tr><td style="vertical-align:top;width:16.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">16/874,143</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Composition of Matter; Process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">5/14/2040</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">US</p></td></tr><tr><td style="vertical-align:top;width:16.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">62/942,408</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Composition of Matter; Use</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">US</p></td></tr><tr><td style="vertical-align:top;width:16.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">11,464,776</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Composition of Matter; Use</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">5/14/2040</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">US</p></td></tr><tr><td style="vertical-align:top;width:16.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">17/963,607</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Composition of Matter; Use</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">5/14/2040</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">US</p></td></tr><tr><td style="vertical-align:top;width:16.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">62/984,037</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Use; Kit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">US</p></td></tr><tr><td style="vertical-align:top;width:16.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">16/874,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Use; Kit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">5/14/2040</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">US</p></td></tr><tr><td style="vertical-align:top;width:16.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">17/685,704</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Use; Kit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">5/14/2040</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">US</p></td></tr><tr><td style="vertical-align:top;width:16.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">62/958,481</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Use</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">US</p></td></tr><tr><td style="vertical-align:top;width:16.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">16/874,190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Use</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">5/14/2040</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">US</p></td></tr><tr><td style="vertical-align:top;width:16.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">PCT/US20/32874</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Use</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">International PCT</p></td></tr><tr><td style="vertical-align:top;width:16.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">20806763.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Use</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">Europe</p></td></tr><tr><td style="vertical-align:top;width:16.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">63/117,258</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Composition of Matter; Combination Products; Use</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">US</p></td></tr><tr><td style="vertical-align:top;width:16.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">63/150,731</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Composition of Matter; Combination Products; Use</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">US</p></td></tr><tr><td style="vertical-align:top;width:16.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">18/034,558</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Composition of Matter; Combination Products; Use</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">11/23/2041</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">US</p></td></tr><tr><td style="vertical-align:top;width:16.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">2021382051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Composition of Matter; Combination Products; Use</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">11/23/2041</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">Australia</p></td></tr><tr><td style="vertical-align:top;width:16.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">3199091</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Composition of Matter; Combination Products; Use</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">11/23/2041</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">Canada</p></td></tr><tr><td style="vertical-align:top;width:16.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">202180076594.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Composition of Matter; Combination Products; Use</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">11/23/2041</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">China</p></td></tr><tr><td style="vertical-align:top;width:16.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">21895804.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Composition of Matter; Combination Products; Use</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">11/23/2041</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">Europe</p></td></tr><tr><td style="vertical-align:top;width:16.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">202317028210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Composition of Matter; Combination Products; Use</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">11/23/2041</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">India</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">205</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:16.57%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2.45pt;"><b style="font-weight:bold;">APPLICATION/</b><b style="font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">PATENT NO.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RELATED</b><b style="color:#231f20;font-weight:bold;"> </b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">PRODUCT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">PROTECTION&#160;SOUGHT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.05pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 0.05pt;"><b style="font-weight:bold;">PROJECTED </b><b style="font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">EXPIRATION*</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.05pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">JURISDICTION</b></p></td></tr><tr><td style="vertical-align:top;width:16.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">2023-530592</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Composition of Matter; Combination Products; Use</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">11/23/2041</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">Japan</p></td></tr><tr><td style="vertical-align:top;width:16.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">PCT/US21/60526</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Composition of Matter; Combination Products; Use</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">International PCT</p></td></tr><tr><td style="vertical-align:top;width:16.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">63/149,446</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Process; Composition of Matter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">US</p></td></tr><tr><td style="vertical-align:top;width:16.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">18/276,396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Process; Composition of Matter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">2/15/2042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">US</p></td></tr><tr><td style="vertical-align:top;width:16.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">2022220017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Process; Composition of Matter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">2/15/2042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">Australia</p></td></tr><tr><td style="vertical-align:top;width:16.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">3211077</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Process; Composition of Matter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">2/15/2042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">Canada</p></td></tr><tr><td style="vertical-align:top;width:16.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">202280024931.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Process; Composition of Matter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">2/15/2042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">China</p></td></tr><tr><td style="vertical-align:top;width:16.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">22753517.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Process; Composition of Matter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">2/15/2042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">Europe</p></td></tr><tr><td style="vertical-align:top;width:16.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">2023-548863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Process; Composition of Matter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">2/15/2042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">Japan</p></td></tr><tr><td style="vertical-align:top;width:16.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">PCT/US22/16422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Process; Composition of Matter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">International PCT</p></td></tr><tr><td style="vertical-align:top;width:16.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;">63/619,079</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">AV-101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:38.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Use</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.7pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.75pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.15pt;">US</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Projected patent expiration dates were calculated for pending U.S. Nonprovisional Applications and Foreign Applications based on filing date. These calculations do not take into account any terminal disclaimers or patent term adjustments that may occur during prosecution or for pharmaceutical patents in Australia. U.S. Provisional and International PCT filings will not issue as patents and therefore do not have a projected expiration date. European filings will issue only in validated European countries and the projected expiration date will apply to those individual country patents.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Aerovate&#8217;s intellectual property estate strategy is designed to provide multiple layers of protection, including: (1)&#160;proprietary patent rights with claims directed to Aerovate&#8217;s drug product; (2)&#160;proprietary patent rights covering methods of treatment using Aerovate&#8217;s drug product; and (3)&#160;proprietary patent rights covering innovative manufacturing processes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">While Aerovate seeks broad coverage under its pending patent applications, there is always a risk that a modification of the product or manufacturing process may allow a competitor to avoid infringement claims. In addition, patents, if granted, expire, and Aerovate cannot provide any assurance that any patents will be issued from Aerovate&#8217;s pending or any future applications or that any issued patents will adequately protect Aerovate&#8217;s products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Aerovate has conducted freedom to operate analyses of the current patent landscape with respect to its lead product candidates. In doing so, Aerovate has strived to ensure its ability to operate freely within the complex patent landscape of inhalable kinase inhibitors and the use of such products in the field of PAH. Developing new formulations of drug products and new uses for such products would require seeking patent protection on its own to expand the layers of protection provided by its intellectual property estate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Patent Protection and Terms</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Individual patents extend for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, patents issued from regularly filed applications in the United States are granted a term of 20&#160;years from the earliest effective filing date. In addition, in certain instances, a patent term can be adjusted to recapture a portion of the United States Patent and Trademark Office(the &#8220;USPTO&#8221;) delay in issuing the patent, and extended to recapture a portion of the patent term effectively lost as a result of the FDA regulatory review period of the drug covered by the patent. However, as to the FDA component, the restoration period cannot be longer than five&#160;years, the total patent term including the restoration period must not exceed 14&#160;years following FDA approval of the drug, and the extension may only apply to one patent that covers the approved drug (and to only those patent claims covering the approved drug, a method for using it, or a method for manufacturing it). There can be no assurance that any such patent term adjustment or extension will be obtained. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20&#160;years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a product-by-product basis, from country to country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Furthermore, the patent positions of biotechnology and pharmaceutical products and processes are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the breadth of claims allowed in such patents has emerged to date in the United States. The patent situation outside the United States is even more uncertain. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries can diminish the ability to protect inventions and enforce intellectual property rights, can make it easier to challenge the validity, enforceability or scope of any patents that may issue, and, more generally, could affect the value of intellectual property. Accordingly, the breadth of claims that may be allowed or enforced in patents or in third-party patents cannot be predicted.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">206</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Third-Party Patent Filings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Numerous U.S. and foreign issued patents and patent applications owned by third parties exist in the fields in which Aerovate may resume developing products. In addition, because patent applications can take many&#160;years to issue, there may be applications unknown to Aerovate, which may later result in issued patents that Aerovate&#8217;s products or proprietary technologies may infringe. Moreover, Aerovate may be aware of patent applications, but incorrectly predict the likelihood of those applications issuing with claims of relevance to Aerovate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under U.S. law, a person may be able to patent a discovery of a new way to use a previously known compound, even if such compound itself is patented, provided the newly discovered use is novel and non- obvious. Such a method-of-use patent, however, if valid, only protects the use of a claimed compound for the specified methods claimed in the patent. This type of patent does not prevent persons from using the compound for any previously known use of the compound. Further, this type of patent does not prevent persons from making and marketing the compound for an indication that is outside the scope of the patented method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Trade Secrets and Other Protections</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition to the protections afforded by patents and other regulatory protections, Aerovate may rely, in some circumstances, on trade secrets to protect its technology. Trade secrets may be useful to protect proprietary know-how that is not patentable or which Aerovate elects not to patent. Trade secrets may also be useful for processes or improvements for which patents are difficult to enforce.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Aerovate also protects its products and proprietary technology through confidentiality agreements with employees, consultants, advisors, contractors and collaborators. These agreements are designed to protect Aerovate&#8217;s proprietary information and, in the case of the invention assignment agreements, to grant Aerovate ownership of technologies that are developed through a relationship with a third party. These agreements may be breached, and Aerovate may not have adequate remedies for any such breach. In addition, Aerovate&#8217;s trade secrets may otherwise become known or be independently discovered by competitors. To the extent that Aerovate&#8217;s commercial partners, collaborators, employees and consultants use intellectual property owned by others in their work for Aerovate, disputes may arise as to the rights in related or resulting know- how and inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Aerovate also seeks to preserve the integrity and confidentiality of its data and trade secrets by maintaining physical security of Aerovate&#8217;s premises and physical and electronic security of Aerovate&#8217;s information technology systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Infringement of Third-Party Proprietary Rights</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Commercial success depends in part on not infringing upon or otherwise violating the intellectual property and proprietary rights of third parties. If Aerovate is found to infringe a third party&#8217;s intellectual property rights, Aerovate could be required to obtain a license from such third party to continue developing and marketing a products and technology. However, Aerovate may not be able to obtain any required license on commercially reasonable terms or at all. Even if Aerovate were able to obtain a license, it could be non-exclusive, thereby giving Aerovate&#8217;s competitors access to the same technologies licensed to Aerovate. Aerovate could also be forced, including by court order, to cease commercializing the infringing product or technology. In addition, Aerovate could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if Aerovate is found to have willfully infringed a patent. A finding of infringement could prevent Aerovate from commercializing its products or force Aerovate to cease some of its business operations. For more information regarding these risks, please see the section titled &#8220;<i style="font-style:italic;">Risk Factors&#160;&#8212; Risks Related to Aerovate&#8217;s Intellectual Property</i>&#8221; beginning on page&#160;34 of this proxy statement/ prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Competition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. Aerovate has faced potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions. In June&#160;2024, Aerovate announced its decision to halt enrollment and shut down the Phase 3 portion of IMPAHCT as well as the long-term extension study of AV-101 in PAH and will not advance development of AV-101 in PAH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Some of Aerovate&#8217;s historical competitors have had significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than Aerovate did. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">207</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The key competitive factors that differentiate products, if approved, are likely to be efficacy, safety, convenience, price, and the availability of reimbursement from commercial, government and other third-party payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Government Regulation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">United States-FDA Process</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The FDCA and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Aerovate, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory authorities of the countries in which Aerovate wishes to conduct studies or seek approval of its product candidates. Failure to comply with applicable United States requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending New Drug Applications (&#8220;NDAs&#8221;), withdrawal of an approval, warning or untitled letters, clinical holds, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, civil penalties, and criminal prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">FDA approval is required before any new unapproved product or a product with certain changes to a previously approved product, including a new use of a previously approved drug, can be marketed in the United States. The steps required to be completed by the FDA before a drug may be marketed in the United States generally includes the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of preclinical laboratory tests, animal studies, and formulation studies performed in accordance with the FDA&#8217;s Good Laboratory Practice (&#8220;GLP&#8221;) regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an investigational new drug (&#8220;IND&#8221;) application for human clinical testing, which must become effective before human clinical trials may begin and must be updated annually or when significant changes are made;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an independent institutional review board (&#8220;IRB&#8221;) or ethics committee at each clinical site before the clinical trial is commenced;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, good clinical practice (&#8220;GCP&#8221;) requirements and other clinical-trial related regulations to establish the safety and efficacy of the proposed drug for each indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preparation and submission to the FDA of a NDA after completion of all pivotal clinical trials, which includes not only the results of the clinical trials, but also, detailed information on the chemistry, manufacture and quality controls for the product candidate and proposed labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a determination by the FDA within 60&#160;days of its receipt of an NDA to file the application for review;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed drug is produced to assess compliance with cGMP regulations and of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">selected clinical trial sites to assess compliance with GCPs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the United States.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Satisfaction of FDA pre-market approval requirements typically takes many&#160;years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Preclinical and Clinical Development</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Preclinical tests include laboratory evaluation of product chemistry, formulation, and toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the product candidate. The conduct of the preclinical tests must comply with federal regulations and requirements, including GLPs. The results of preclinical testing are submitted to the FDA as part of an IND </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">208</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">application along with other information, including information about the product candidate, chemistry, manufacturing and controls, any available human data or literature to support the use of the product candidate and a proposed clinical trial protocol. Long term preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">An IND application must become effective before human clinical trials may begin. The IND application automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA, within the 30-day period, raises safety concerns or questions relating to one or more proposed clinical trials and places the clinical trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. The FDA may also impose clinical holds on a product candidate at any time before or during clinical trials due to safety concerns, non-compliance or other issues affecting the integrity of the trial. Accordingly, submission of an IND application may or may not result in the FDA allowing clinical trials to commence and, once begun, issues may arise that could cause the trial to be suspended or terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Clinical trials involve the administration of the investigational drug product to human subjects under the supervision of a qualified investigator. Clinical trials must be conducted: (i)&#160;in compliance with federal regulations; (ii)&#160;in compliance with GCP, an international standard meant to protect the rights and health of clinical research participants and to define the roles of clinical trial sponsors, administrators, and monitors; as well as (iii)&#160;under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing on United States patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. Furthermore, an independent IRB or ethics committee for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objects. The FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA requirements. Further, an IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#8217;s requirements, or may impose other conditions. Some trials also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may recommend a clinical trial to be halted if it determines that there is an unacceptable safety risk for subjects or other grounds, such as futility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trials to support an NDA for marketing approval are typically conducted in three sequential phases, but the phases may overlap or be combined. In Phase 1 clinical trials, the investigational product is typically introduced into a limited population of healthy human subjects or patients with the target disease or condition. These trials are designed to test the safety, dosage tolerance, pharmacokinetics and pharmacological actions of the investigational product, to identify side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. Phase 2 clinical trials usually involve administering the investigational product to a limited patient population with the specified disease or condition to evaluate the preliminarily efficacy, dosage tolerance, and optimum dosage, and to identify possible adverse effects and safety risks. Phase 3 clinical trials are typically undertaken in a larger number of patients, typically at geographically dispersed clinical trial sites, to provide substantial evidence of clinical efficacy and to further test for safety in an expanded and diverse patient population. These clinical trials are intended to permit the FDA to evaluate the overall benefit-risk relationship of the investigational product and to provide adequate information for the labeling of the product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In reviewing an NDA, the FDA will consider all information submitted in the NDA, including the results of all clinical trials conducted. In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may be made a condition to approval of the NDA. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication and further document clinical benefit in the case of drugs approved under accelerated approval regulations. Failure to exhibit due diligence with regard to conducting Phase 4 clinical trials could result in the withdrawal of approval for products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">209</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical study investigators. Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the product candidate, findings from animal or in vitro testing that suggest a significant risk for human subjects, and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">NDA Submission and Review</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Assuming successful completion of the required clinical testing in accordance with all applicable regulatory requirements, an NDA application which includes, among other information, the results of product development, preclinical studies and clinical trials are submitted to the FDA. FDA approval of the NDA is required before marketing of the product may begin in the United States. The NDA must include, among other things, the results of all trials and preclinical testing, and other testing and a compilation of data relating to the product&#8217;s pharmacology, chemistry, manufacture, controls and proposed labeling. The cost of preparing and submitting an NDA is substantial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA has 60&#160;days from its receipt of an NDA to either issue a Refuse to File Letter or accept the NDA for filing, indicating that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of NDAs. Under the Prescription Drug User Fee Act, the FDA has a goal of responding to standard review NDAs within ten&#160;months after it accepts the application for filing, or, if the application qualifies for priority review, six&#160;months after the FDA accepts the application for filing, but this timeframe can be extended such as by the submission of major amendments by applicants during the review period. The FDA reviews an NDA to determine, among other things, whether the product is safe and effective and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA may refer applications for novel drug products, or drug products that present difficult questions of safety or efficacy, to an advisory committee-typically a panel that includes clinicians and other experts-for review, evaluation, and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. Additionally, the FDA will inspect the facility or the facilities at which the proposed product is manufactured. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After the FDA evaluates the NDA and conducts inspections of the manufacturing facilities where the investigational product and/or its drug substance will be produced, it issues either an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the drug with approved prescribing information for specific indications. A Complete Response letter indicates that the review cycle of the application is complete and the application is not ready for approval. A Complete Response letter generally outlines the deficiencies in the submission, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting required inspections or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may require substantial additional clinical data and/or other significant, expensive, and time-consuming requirements related to clinical trials, preclinical studies and/or manufacturing. If a Complete Response letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, withdraw the application or request a hearing. The FDA has committed to reviewing resubmissions of the NDA addressing such deficiencies in two or six&#160;months depending on the type of information included. Even if such data are submitted, however, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If regulatory approval of a product is granted, such approval will be granted for a particular indication(s)&#160;and may include limitations on the indicated use(s)&#160;for which such product may be marketed. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling or may condition the approval of the NDA on other changes to the proposed labeling, development of adequate controls and specifications, or a commitment to conduct post-market testing or clinical trials and surveillance to monitor the effects of approved products. As a condition of NDA approval, the FDA may </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">210</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">require a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) to help ensure that the benefits of the drug outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use (&#8220;ETASU&#8221;). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for REMS can materially affect the potential market and profitability of the product. Moreover, product approval may also be conditioned on substantial post-approval testing, such as Phase 4 post-market studies, and surveillance to monitor the product&#8217;s safety or efficacy, and FDA may limit further marketing of the product based on the results of these post-approval studies. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing NDA supplements as it does in reviewing NDAs. As with new NDAs, the review process is often significantly extended by the FDA requests for additional information or clarification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">505(b)(2)&#160;NDA Approval Process</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;505(b)(2)&#160;of the FDCA provides an alternate regulatory pathway for the FDA to approve a new product and permits reliance for such approval on published literature or an FDA finding of safety and effectiveness for a previously approved drug product. Specifically, section 505(b)(2)&#160;permits the filing of an NDA where one or more of the investigations relied upon by the applicant for approval were not conducted by or for the applicant and for which the applicant has not obtained a right of reference. Typically, 505(b)(2)&#160;applicants must perform additional trials to support the change from the previously approved drug and to further demonstrate the new product&#8217;s safety and effectiveness. The FDA may then approve the new product candidate for all or some of the labeled indications for which the referenced product has been approved, as well as for any new indication sought by the section 505(b)(2)&#160;applicant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Regulation of Combination Products in the United States</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain products may be comprised of components, such as drug components and device components, that would normally be regulated under different types of regulatory authorities, and frequently by different centers at the FDA. These products are known as combination products. Specifically, under regulations issued by the FDA, a combination product may be:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a product comprised of two or more regulated components that are physically, chemically, or otherwise combined or mixed and produced as a single entity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two or more separate products packaged together in a single package or as a unit and comprised of drug and device products, device and biological products, or biological and drug products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a drug, or device, or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, or </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">device, or biological product where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any investigational drug, or device, or biological product packaged separately that according to its proposed labeling is for use only with another individually specified investigational drug, device, or biological product where both are required to achieve the intended use, indication, or effect.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Under the FDCA and its implementing regulations, the FDA is charged with assigning a center with primary jurisdiction (the &#8220;lead center&#8221;) for review of a combination product. The designation of a lead center generally eliminates the need to receive approvals from more than one FDA component for combination products, although it does not preclude consultations by the lead center with other components of FDA. The determination of which center will be the lead center is based on the &#8220;primary mode of action&#8221; of the combination product. Thus, if the primary mode of action of a drug-device combination product is attributable to the drug product, the FDA center responsible for premarket review of the drug product would have primary jurisdiction for the combination product. The FDA has also established an Office of Combination Products to address issues surrounding combination products and provide more certainty to the regulatory review process. That office serves as a focal point for combination product issues for agency reviewers and industry. It is also responsible for developing guidance and regulations to clarify the regulation of combination products, and for </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">211</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">assignment of the FDA center that has primary jurisdiction for review of combination products where the jurisdiction is unclear or in dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A combination product with a drug primary mode of action generally would be reviewed and approved pursuant to the drug approval processes under the FDCA. In reviewing the NDA application for such a product, however, FDA reviewers in the drug center could consult with their counterparts in the device center to ensure that the device component of the combination product met applicable requirements regarding safety, effectiveness, durability and performance. In addition, under FDA regulations, combination products are subject to cGMP requirements applicable to both drugs and devices, including the Quality System regulations applicable to medical devices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Post-Approval Requirements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Once an NDA is approved, a product will be subject to pervasive and continuing regulation by the FDA including, among other things, requirements relating to cGMPs, quality controls, record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. For instance, the FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet. Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Failure to comply with these requirements can result in adverse publicity, warning letters, corrective advertising, and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by Aerovate and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the practice of medicine by physicians or their choice of treatments. The FDA does, however, regulate manufacturer&#8217;s communications on the subject of off-label use of their products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, quality control, drug manufacture, packaging, and labeling procedures must continue to conform to cGMPs after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA, and certain state agencies for compliance with cGMPs, which impose certain organizational, procedural and documentation requirements with respect to manufacturing and quality assurance activities. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon Aerovate and any third-party manufacturers that Aerovate may decide to use. NDA holders using contract manufacturers, laboratories or packagers are responsible for the selection and monitoring of qualified firms, and, in certain circumstances, qualified suppliers to these firms. Drug manufacturers and other parties involved in the drug supply chain for prescription drug products must also comply with product tracking and tracing requirements and for notifying the FDA of counterfeit, diverted, stolen and intentionally adulterated products or products that are otherwise unfit for distribution in the United States. The discovery of violative conditions, including failure to conform to cGMP, could result in enforcement actions that interrupt the operation of any such facilities or the ability to distribute products manufactured, processed or tested by them. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality-control to maintain compliance with cGMPs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards or is not maintained, if problems occur following initial marketing, or if previously unrecognized problems are subsequently discovered. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters or holds on post-approval clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal of the FDA to permit the import or export of products;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">212</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mandated modification of promotional materials and labeling and the issuance of corrective information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">U.S. Patent Term Restoration</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Depending upon the timing, duration and specifics of the potential FDA approval of AV-101 and any future product candidates, some of Aerovate&#8217;s U.S. patents may be eligible for limited patent term extension. The Hatch-Waxman Amendments permit a patent restoration term, often referred to as patent term extension, of up to five&#160;years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14&#160;years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA plus the time between the submission date of an NDA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves or denies the application for any patent term extension or restoration. In the future, Aerovate intends to apply for extension of patent term for one of its patents covering AV-101 to add patent life beyond its current expected expiration date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">U.S. Marketing Exclusivity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Market exclusivity provisions under the FDCA can also delay the submission or the approval of certain marketing applications, including 505(b)(2)&#160;applications. The FDA provides three&#160;years of marketing exclusivity for an NDA (including a 505(b)(2)&#160;application), or supplement to an existing NDA, if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application. Three-year exclusivity is typically awarded to innovative changes to a previously-approved drug product, such as new indications, dosage forms or strengths. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving applications for drugs that do not have the innovative change, such as generic copies of the original, unmodified drug product. Three-year exclusivity blocks approval of 505(b)(2)&#160;applications and Abbreviated New Drug Applications but will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the nonclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. Orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances. Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six&#160;months to existing exclusivity periods, including exclusivity attaching to certain patent certifications. This six-month exclusivity, which runs from the end of other exclusivity protection and patent terms, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#8220;Written Request&#8221; for such a trial, provided that at the time pediatric exclusivity is granted there is not less than nine&#160;months of term remaining.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Orphan Drug Designation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition-generally a disease or condition with either a patient population that affects fewer than 200,000 individuals in the United States or a patient population greater than 200,000 individuals in the United States and there is no reasonable expectation that the cost of developing and making available the drug will be recovered from sales of the drug in the United States. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the generic identity of the product and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The first NDA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with FDA orphan drug designation is entitled to a seven-year exclusive marketing period in the United States for that product, for that indication. During the seven-year exclusivity period, the FDA may not approve any other applications to market the same product for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of the patients with the disease or condition for which the product was designated. Orphan drug </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">213</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">exclusivity does not prevent the FDA from approving a different product for the same disease or condition, or the same product for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA or BLA application user fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan drug designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fast Track Designation, Breakthrough Therapy Designation and Accelerated Approval</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA is required to facilitate the development, and expedite the review, of drugs that are intended for the treatment of a serious or life-threatening disease or condition which demonstrate the potential to address unmet medical needs for the condition. These programs include fast track designation, priority review and accelerated approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A product candidate is eligible for fast track designation if it is intended to treat a serious or life- threatening disease or condition and demonstrates the potential to address unmet medical needs for such disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. Under the fast track program, the sponsor of a drug candidate may request that the FDA designate the candidate for a specific indication as a fast track product concurrent with, or after, the filing of the IND for the candidate. The FDA must determine if the product candidate qualifies for fast track designation within 60&#160;days of receipt of the sponsor&#8217;s request. Fast track designation provides increased opportunities for sponsor interactions with the FDA during preclinical and clinical development, in addition to the potential for rolling review of sections of a the applicant&#8217;s NDA before the application is complete. This rolling review is available if the applicant provides, and the FDA approves, a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, the FDA&#8217;s time period goal for reviewing an application does not begin until the last section of the NDA is submitted. Additionally, the fast track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the FDA&#8217;s breakthrough therapy program, a sponsor may seek FDA designation of its product candidate as a breakthrough therapy if the product candidate is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that it may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough therapy designation comes with all of the benefits of fast track designation. The FDA may take other actions appropriate to expedite the development and review of the product candidate, including intensive guidance on an efficient product development program beginning as early as Phase 1, and FDA organizational commitment to expedited development, including involvement of senior managers and experienced review staff in a cross-disciplinary review, where appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any product submitted to the FDA for marketing, including under the fast track or breakthrough designation program, may also be eligible for other types of FDA programs intended to expedite development and review, such as accelerated approval. Products are eligible for accelerated approval if they can be shown to have an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions, or survives. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. A product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the conduct of Phase 4, or post-approval, clinical trials to confirm the effect on the clinical endpoint which must be conducted with due diligence and, under the Food and Drug Omnibus Reform Act of 2022 (&#8220;FDORA&#8221;), the FDA may require, as appropriate, that such trials be underway prior to approval or within a specific time period after the date accelerated approval is granted. Additionally, under FDORA, the FDA has increased authority for expedited procedures to withdraw a product or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA unless otherwise informed by the FDA.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">214</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Priority Review</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A product is eligible for priority review if it has the potential to provide a significant improvement in safety or effectiveness in the treatment, diagnosis or prevention of a serious disease or condition. A priority review means that the goal for the FDA to review an application is six&#160;months, rather than the standard review of ten&#160;months under current Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) guidelines. Under the current PDUFA agreement, these six and ten&#160;month review periods are measured from the &#8220;filing&#8221; date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two&#160;months to the timeline for review and decision from the date of submission. Most products that are eligible for fast track designation are also likely to be considered appropriate to receive a priority review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Pediatric Information</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Pediatric Research Equity Act (&#8220;PREA&#8221;), NDAs or supplements to NDAs must contain data to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. The FDA may grant full or partial waivers, or deferrals, for submission of data. Unless otherwise required by regulation, PREA does not apply to any drug for an indication for which orphan designation has been granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Disclosure of Clinical Trial Information</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Sponsors of clinical trials of FDA-regulated products, including drugs and combination products, are required to register and disclose certain clinical trial information. Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after completion. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved. Failure to timely register a covered clinical study or to submit study results as provided for in the law can give rise to civil monetary penalties and also prevent the non- compliant party from receiving future grant funds from the federal government. The Final Rule&#160;on ClinicalTrials.gov registration and reporting requirements became effective in 2017, and both the National Institutes of Health and the FDA have signaled the government&#8217;s willingness to begin enforcing those requirements against non-compliant clinical trial sponsors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">European Union-Process</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the European Union (&#8220;EU&#8221;), Aerovate&#8217;s product candidate(s)&#160;may also be subject to extensive regulatory requirements governing, among other things, clinical trials and any commercial sales and distribution of Aerovate&#8217;s product candidate(s).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Whether or not Aerovate obtains FDA approval for a product candidate, Aerovate must obtain the requisite approvals from regulatory authorities located in the member states of the EU (&#8220;EU Member States&#8221;) prior to the commencement of clinical trials as well as EU or national regulatory approvals prior to marketing the product candidate(s).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Non-Clinical Studies and Clinical Trials</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Similar to the United States, the various phases of non-clinical studies and clinical trials in the EU are subject to significant regulatory controls.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Non-clinical studies are performed to demonstrate the health or environmental safety of new chemical substances. Non-clinical studies must be conducted in compliance with the principles of GLP, as set forth in EU Directive 2004/10/EC. In particular, non-clinical studies, both in vitro and in vivo, must be planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules&#160;and criteria for a quality system for the organizational process and the conditions for non- clinical studies. These GLP standards reflect the Organization for Economic Co-operation and Development requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Clinical trials of medicinal products in the EU must be conducted in accordance with the EU Clinical Trials Regulation (EU) No 536/2014 (&#8220;CTR&#8221;) (which was adopted in April&#160;2014, and repealed the EU Clinical Trials Directive 2001/20/EC on January&#160;31, 2022), and the International Conference on Harmonization guidelines on GCP, as well as the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. If the sponsor of the clinical trial is not established within the EU, it must appoint an EU entity to act as its legal representative (unless all EU Member States in which the trial is being </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">215</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">conducted have chosen not to apply such rule, in which case it may be that only a contact person in the EU is required), who shall be responsible for ensuring compliance with the sponsor&#8217;s obligations under the CTR and be the addressee for all communications provided for under the CTR. The sponsor must take out a clinical trial insurance policy, and in most EU Member States, the sponsor is liable to provide &#8216;no fault&#8217; compensation to any study subject injured in the clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The CTR is directly applicable in all EU Member States (meaning that no national implementing legislation in each EU Member State is required). Under the CTR, there is a centralized application procedure where one national authority takes the lead in reviewing the application and the other national authorities have only limited involvement (instead of submitting applications separately to each national competent authority and ethics committee in the EU Member States in which the trial will be conducted, as was the case under the previous EU Clinical Trials Directive). The CTR also makes it more efficient for EU Member States to evaluate and authorize applications together, via the Clinical Trials Information System. Medicines used in clinical trials must be manufactured in accordance with GMP. Other national and EU-wide regulatory requirements may also apply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Disclosure of Clinical Trial Information</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The CTR significantly enlarges the publication and transparency obligations for clinical trial sponsors from the previous position under the Clinical Trials Directive. Additionally, the CTR requires that EU Member States adopt specific measures, including penalties, to adequately sanction infringements of the relevant transparency obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Marketing Authorisations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the EU, medicinal products can only be placed on the market after obtaining a marketing authorisation (&#8220;MA&#8221;). To obtain regulatory approval of a product in the EU, Aerovate must submit a Marketing Authorization Application (&#8220;MAA&#8221;). The process for doing this depends, among other things, on the nature of the medicinal product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Centralized Procedure</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the centralized procedure, the European Commission issues a single MA, based on the opinion of the European Medicines Agency&#8217;s (&#8220;EMA&#8221;), Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;), which is valid across the entire territory of the EU, as well as Iceland, Liechtenstein and Norway (i.e., the European Economic Area (&#8220;EEA&#8221;)). The centralized procedure is compulsory for human medicines that are: (i)&#160;derived from biotechnology processes; (ii)&#160;advanced-therapy medicinal products (i.e. gene therapy, somatic cell-therapy or tissue-engineered medicines); (iii)&#160;contain a new active substance indicated for the treatment of certain diseases, such as HIV, AIDS, cancer, diabetes, neurodegenerative diseases, viral diseases or autoimmune diseases and other immune dysfunctions; and (iv)&#160;officially designated orphan medicines. For medicines that do not fall within these categories, an applicant has the option of submitting an application for a centralized MA to the EMA if the product contains a new active substance not yet authorized in the EU, or the medicine concerned is a significant therapeutic, scientific or technical innovation, or that the granting of a centralized authorization would be in the interest of public health at the EU-level.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the centralized procedure the maximum timeframe for the evaluation of an MAA by the EMA is 210&#160;days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP. Clock stops may extend the timeframe of evaluation of an MAA considerably beyond 210&#160;days. Where the CHMP gives a positive opinion, the EMA provides the opinion together with supporting documentation to the European Commission, who makes the final decision to grant an MA, which is issued within 67&#160;days of receipt of the EMA&#8217;s recommendations. Accelerated assessment may be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and, in particular, from the point of view of therapeutic innovation. Accelerated assessment of an MAA will be performed by the CHMP in no more than 150&#160;days (excluding clock stops) but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that the application is no longer appropriate to conduct an accelerated assessment. Innovative products that target an unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the EU or, if there is, the new medicine will bring a major therapeutic advantage) may be eligible for a number of expedited development and review programs, such as the PRIME scheme, which provides incentives similar to the breakthrough therapy designation in the United States. PRIME is a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicines that target unmet medical needs. It is based on increased interaction and early dialogue with companies developing promising medicines, to optimize their product development plans and speed up their evaluation to help them reach patients earlier. Product developers that benefit from PRIME designation can expect to be eligible for accelerated assessment but this is not guaranteed. The benefits of a PRIME designation include the appointment of a CHMP rapporteur before submission of an MAA, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review earlier in the application process.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">216</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">National Authorisation Procedures</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There are also two other possible routes to authorize medicinal products in several EU Member States. National MAs are issued by the national competent authorities of the EU Member States and only cover their respective territory. They are available for products that fall outside the scope of the centralized procedure:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Decentralized procedure. If the product has not received a national MA in any EU Member State at the time of application, an applicant may apply for simultaneous MAs in more than one EU Member State. Under the decentralized procedure an identical dossier is submitted to the national competent authority of each of the Member States in which an MA is sought, one of which is selected by the applicant as the Reference Member State.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Mutual recognition procedure. Under the mutual recognition procedure, a medicine that has already been authorized in one EU Member State in accordance with the national procedures of that EU Member State, can be recognized in another EU Member State.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">MAs have an initial duration of five&#160;years. After these five&#160;years, the authorization may be renewed for an unlimited period on the basis of a reevaluation of the risk-benefit balance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Similar to the United States, there is a process for authorization of generic/biosimilar versions of innovator medicinal products authorized in the EU. Abridged applications for the authorization of generic/ biosimilar versions of medicinal products authorized via the EU centralized procedure can be submitted to the EMA through the centralized procedure referencing the innovator&#8217;s data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Data and Market Exclusivity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the EU, innovative medicinal products approved on the basis of a complete and independent data package qualify for eight&#160;years of data exclusivity upon the grant of an MA and an additional two&#160;years of market exclusivity. Data exclusivity prevents generic and biosimilar applicants from referencing the innovator&#8217;s preclinical and clinical trial data contained in the dossier of the reference product when applying for an MA for a period of eight&#160;years from the date on which the reference product was first authorized in the EU. During the additional two-year period of market exclusivity, a generic or biosimilar MAA can be submitted and authorized, and the innovator&#8217;s data may be referenced, but no generic or biosimilar medicinal product can be marketed until the expiration of the market exclusivity period. The overall 10&#160;year period will be extended to a maximum of 11&#160;years if, during the first eight&#160;years of those 10&#160;years, the MA holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to authorization, is held to bring a significant clinical benefit in comparison with existing therapies. There is no guarantee that a product will be considered by the EMA to be an innovative medicinal product, and products may not qualify for data exclusivity. Even if a product is considered to be an innovative medicinal product so that the innovator gains the prescribed period of data exclusivity, another company may market another version of the product if such company obtained an MA based on an MAA with a complete and independent data package of pharmaceutical tests, preclinical tests and clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Orphan Medicinal Products</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The criteria for designating an &#8220;orphan medicinal product&#8221; in the EU are similar in principle to those in the United States. A medicinal product may be designated as orphan if (1)&#160;it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (2)&#160;either (a)&#160;such condition affects no more than 5 in 10,000 persons in the EU when the application is made, or (b)&#160;it is unlikely that the marketing of the product, without the benefits derived from orphan status, would generate sufficient return in the EU to justify the necessary investment in its development; and (3)&#160;there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU or, if such a method exists, the product in question would be of significant benefit compared to products available for that condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the EU, orphan designation entitles a party to financial incentives such as reduction of fees or fee waivers, regulatory assistance and the possibility to apply for a centralized MA. The application for orphan designation must be submitted before the application for an MA. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The grant of an MA for an orphan medicinal product leads to ten&#160;years of market exclusivity. During the ten-year market exclusivity period, the EMA cannot accept an MAA, or grant an MA, or accept an application to extend an MA, for the same therapeutic indication, in respect of a &#8220;similar medicinal product&#8221;. A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. An orphan medicinal product can also obtain an additional two&#160;years of market exclusivity in the EU for </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">217</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">pediatric studies conducted in compliance with an agreed pediatric investigation plan (&#8220;PIP&#8221;). No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 10-year market exclusivity may be reduced to six&#160;years if, at the end of the fifth&#160;year, it is established that the orphan designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. At any time, an MA may be granted to a similar medicinal product for the same therapeutic indication if: (i)&#160;a second applicant can establish that its product, although similar to the authorized product, is safer, more effective or otherwise clinically superior; (ii)&#160;the MA holder for the authorized orphan product consents to a second orphan medicinal product application; or (iii)&#160;the MA holder for the authorized orphan product cannot supply enough orphan medicinal product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Pediatric Development</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the EU, MAAs for new medicinal products have to include the results of trials conducted in the pediatric population, in compliance with a PIP agreed with the EMA&#8217;s Pediatric Committee (&#8220;PDCO&#8221;). The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the product for which an MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data are not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the MA is obtained in all EU Member States and study results are included in the product information, even when negative, the product is eligible for a six-months supplementary protection certificate (&#8220;SPC&#8221;) extension (provided an application for such extension is made at the same time as filing the SPC application for the product, or at any point up to two&#160;years before the SPC expires) or, in the case of orphan medicinal products, a two-year extension of the orphan market exclusivity is granted. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Failure to comply with EU and EU Member State laws that apply to the conduct of clinical trials, manufacturing approval, marketing of such products, both before and after grant of the MA, manufacturing of pharmaceutical products, statutory health insurance, bribery and anti-corruption or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials, or to grant an MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Reform of the Regulatory Framework in the European Union</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The European Commission introduced legislative proposals in April&#160;2023 that, if implemented, will replace the current regulatory framework in the EU for all medicines (including those for rare diseases and for children). The European Commission has provided the legislative proposals to the European Parliament and the European Council for their review and approval. In October&#160;2023, the European Parliament published draft reports proposing amendments to the legislative proposals, which will be debated by the European Parliament. Once the European Commission&#8217;s legislative proposals are approved (with or without amendment), they will be adopted into EU law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Regulation of Combination Products</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The EU regulates medical devices and medicinal products separately, through different legislative instruments, and the applicable requirements will vary depending on the type of drug-device combination product. EU guidance has been published to help manufacturers select the right regulatory framework. In the case of drug-delivery products intended to administer a medicinal product where the device and the medicinal product do not form a single integral product (i.e. where the medicinal product and the device do not form a single product which is intended exclusively for use in the given combination and which is not reusable), the medicinal product is regulated in accordance with the aforementioned rules&#160;while the device part is regulated as a medical device and will have to comply with all the requirements set forth by Regulation 2017/745 (the &#8220;Medical Devices Regulation&#8221;) (which became applicable on May&#160;26, 2021 and repealed the EU Council Directive 93/42/EEC (the &#8220;Medical Devices Directive&#8221;)). The dry powder delivery device used with AV-101 is classed as a class IIa device under the Medical Devices Regulation and this will need to be certified under the Medical Devices Regulation in due course as described below. The current</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">218</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CE mark for the delivery device is in accordance with the Medical Devices Directive as a class I device. Under the transitional provisions of the Medical Devices Regulation, medical devices for which the conformity assessment procedure pursuant to the Medical Devices Directive did not require the involvement of a notified body, for which the declaration of conformity was drawn up prior to May&#160;26, 2021 and for which the conformity assessment procedure pursuant to the Medical Device Regulation requires the involvement of a notified body, may be placed on the market or put into service until December&#160;31, 2028, after which they must be re-certified under the Medical Devices Regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The characteristics of non-integral devices used for the administration of medicinal products may impact the quality, safety and efficacy profile of the medicinal products. To the extent that administration devices are co-packaged with the medicinal product or, in exceptional cases, where the use of a specific type of administration device is specifically provided for in the product information of the medicinal product, additional information may need to be provided in the MAA for the medicinal product on the characteristics of the medical device(s)&#160;that may impact on the quality, safety and/or efficacy of the medicinal product. The requirements regarding quality aspects for integral drug-device combination products, including devices that are co-packaged with medicinal products, are outlined in an EMA guideline which came into effect on January&#160;1, 2022. For a medical device to obtain a CE mark under the Medical Devices Regulation, the device must meet the relevant general safety and performance requirements laid down in Annex I of the Medical Devices Regulation. The most fundamental requirement is that a medical device must be designed and manufactured in such a way that it will not compromise the clinical condition or safety of patients, or the safety and health of users and others. In addition, the device must achieve the performances intended by the manufacturer and be designed, manufactured, and packaged in a suitable manner. To demonstrate compliance with the general safety and performance requirements laid down in Annex I to the Medical Devices Regulation, medical device manufacturers must undergo a conformity assessment procedure, which varies according to the type of medical device and its (risk) classification. Conformity assessment procedures require an assessment of available clinical evidence, literature data for the product, and post-market experience in respect of similar products already marketed. For class IIa medical devices, a conformity assessment procedure requires the intervention of a notified body. Notified bodies are independent organizations designated by EU countries to assess the conformity of devices before being placed on the market. If satisfied that the relevant product conforms to the relevant general safety and performance requirements, the notified body issues a certificate of conformity, which the manufacturer uses as a basis for its own declaration of conformity. The manufacturer may then apply the CE mark to the device, which allows the device to be placed on the market throughout the EU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a general rule, demonstration of conformity of medical devices and their manufacturers with the general safety and performance requirements must be based, among other things, on the evaluation of clinical data supporting the safety and performance of the products during normal conditions of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use, that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended performance, and that any claims made about the performance and safety of the device are supported by suitable evidence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The aforementioned EU rules&#160;are generally applicable in the EEA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Brexit and the Regulatory Framework in the United Kingdom</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The United Kingdom (&#8220;UK&#8221;) formally left the EU (commonly referred to as &#8220;Brexit&#8221;) on January&#160;31, 2020, and the EU and the UK have concluded a trade and cooperation agreement (&#8220;TCA&#8221;), which was provisionally applicable since January&#160;1, 2021 and has been formally applicable since May&#160;1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not provide for wholesale mutual recognition of UK and EU pharmaceutical or medical devices regulations. At present, Great Britain has implemented EU legislation on the marketing, promotion and sale of medicinal products through the Human Medicines Regulations 2012 (as amended) (under the Northern Ireland Protocol, the EU regulatory framework currently continues to apply in Northern Ireland). The medicinal products regulatory regime in Great Britain therefore largely aligns with EU regulations, however it is possible that these regimes will diverge more significantly in future now that Great Britain&#8217;s regulatory system is independent from the EU and the TCA does not provide for mutual recognition of UK and EU pharmaceutical legislation. The new Medical Devices Regulation is not applicable in Great Britain following Brexit and the current legislation is based on the previous Medical Devices Directive. However, notwithstanding that there is no wholesale recognition of EU pharmaceutical legislation under the TCA, under a new framework which was put in place by the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;), the UK medicines and medical devices regulator, on January&#160;1, 2024, the MHRA may take into account decisions on the approval of MAs from the EMA (and certain other regulators) when considering an application for a Great Britain or UK MA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On February&#160;27, 2023, the UK government and the European Commission announced a political agreement in principle to replace the Northern Ireland Protocol with a new set of arrangements, known as the &#8220;Windsor Framework&#8221;. This new framework </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">219</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">fundamentally changes the existing system under the Northern Ireland Protocol, including with respect to the regulation of medicinal products in the UK. In particular, the MHRA will be responsible for approving all medicinal products destined for the UK market (i.e., Great Britain and Northern Ireland), and the EMA will no longer have any role in approving medicinal products destined for Northern Ireland. A single UK-wide MA will be granted by the MHRA for all medicinal products to be sold in the UK, enabling products to be sold in a single pack and under a single authorization throughout the UK. The Windsor Framework was approved by the EU-UK Joint Committee on March&#160;24, 2023, so the UK government and the EU will enact legislative measures to bring it into law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On June&#160;9, 2023, the MHRA announced that the medicines aspects of the Windsor Framework will apply from January&#160;1, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other International Markets-Drug Approval Process</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In some international markets (<i style="font-style:italic;">e.g.</i>, China or Japan), although data generated in United States or EU trials may be submitted in support of an MAA, additional clinical trials conducted in the host territory, or studying people of the ethnicity of the host territory, may be required prior to the filing or approval of MA within the country.</p><a id="AerovateBusiness_Pricing_Reimburse"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pricing and Reimbursement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In the United States and internationally, sales of products that Aerovate markets in the future, and its ability to generate revenues on such sales, are dependent, in significant part, on the availability and level of reimbursement from third-party payors such as state and federal governments, managed care providers and private insurance plans. Substantial uncertainty exists as to the reimbursement status of newly approved healthcare products by third-party payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In the United States no uniform policy of coverage and reimbursement for drug products exists. Accordingly, decisions regarding the extent of coverage and amount of reimbursement to be provided for any products will be made on a payor by payor basis. Private third-party payors tend to follow Medicare coverage policies and payment limitations in setting their own reimbursement rate to a substantial degree, but also have their own methods and approval process apart from Medicare determinations. As a result, coverage determination process is often a time-consuming and costly process that will require providing scientific and clinical support for the use of product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. Factors payors consider in determining reimbursement are based on whether the product is:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a covered benefit under its health plan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safe, effective and medically necessary;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">appropriate for the specific patient;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cost-effective; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">neither experimental nor investigational.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Increasingly, third party payors are implementing cost-cutting and reimbursement initiatives and likely will continue to do so in the future. These include establishing formularies that govern the drugs and biologics that will be offered and also the out-of-pocket obligations of member patients for such products. In addition, net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. It is possible that future legislation in the United States and other jurisdictions could be enacted which could potentially impact the reimbursement rates for products in development and that may be developed in the future and also could further impact the levels of discounts and rebates paid to federal and state government entities. Any legislation that impacts these areas could impact, in a significant way, the ability to generate revenues from sales of products that, if successfully developed, are brought to market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. In the EU, governments influence the price of medicinal products through their pricing and reimbursement rules&#160;and control of national healthcare systems that fund a large part of the cost of those products to consumers. EU Member States are free to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed to by the government. EU Member States may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market, including volume-based </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">220</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">arrangements, caps and reference pricing mechanisms. To obtain reimbursement or pricing approval, some of the EU Member States may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies that are considered the local standard of care. Other EU Member States allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on healthcare costs in general, particularly prescription medicines, has become very intense. It is increasingly common in many EU Member States for MA holders to be required to demonstrate the pharmaco-economic superiority of their products as compared to products already subject to pricing and reimbursement in specific countries. In order for drugs to be evaluated positively under such criteria, pharmaceutical companies may need to re-examine, and consider altering, a number of traditional functions relating to the selection, study, and management of drugs, whether currently marketed, under development, or being evaluated as candidates for research and/or development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sales and Marketing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Sales, promotion and other activities following product approval are subject to regulation by numerous regulatory authorities in addition to the FDA, including, in the United States, the Centers for Medicare&#160;&amp; Medicaid Services, other divisions of the Department of Health and Human Services, the U.S. Department of Justice, and similar foreign, state, and local government authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As described above, the FDA regulates all advertising and promotion activities for products under its jurisdiction both prior to and after approval. A company can make only those claims relating to safety and efficacy that are approved by the FDA in labeling. Physicians may prescribe legally available drugs for uses that are not described in the drug&#8217;s labeling and that differ from those tested uses and uses approved by the FDA. Such off-label uses are common across medical specialties, and often reflect a physician&#8217;s belief that the off-label use is the best treatment for the patients. The FDA does not regulate the behavior of physicians in their choice of treatments, but FDA regulations do impose stringent restrictions on manufacturers&#8217; communications regarding off-label uses. Failure to comply with applicable FDA requirements may subject a company to adverse publicity, enforcement action by the FDA, corrective advertising, consent decrees and the full range of civil and criminal penalties available to the FDA.</p><a id="AerovateBusiness_HealthLaws"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Healthcare Laws and Regulations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Pharmaceutical companies are also subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business that may constrain the financial arrangements and relationships through which products are researched, sold, marketed and distributed, when marketing authorization is obtained. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, and transparency laws and regulations related to drug pricing and payments and other transfers of value made to physicians and other healthcare providers. If operations are found to be in violation of any of such laws or any other governmental regulations that apply, there may be penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting obligations, exclusion from participation in federal and state healthcare programs and responsible individuals may be subject to imprisonment. Such laws include, but are not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the United States federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under any United States federal healthcare program, such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act or federal civil money penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the United States federal civil monetary penalty and civil and criminal false claims laws, including the civil federal False Claims Act, which can be enforced through civil whistleblower or qui tam actions, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the United States federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the United States federal government. Manufacturers can be held liable under the federal False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. Pharmaceutical manufacturers can cause false claims to be presented to the United States federal government by engaging in impermissible marketing practices, such as the off-label promotion of a product for an </span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">221</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">indication for which it has not received FDA approval. In addition, the government may assert that a claim including items and services resulting from a violation of the United States federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act. The federal False Claims Act also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the federal False Claims Act and to share in any monetary recovery; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which created new federal criminal statutes that prohibit a person from knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious, or fraudulent statements or representations in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), and their respective implementing regulations, including the Final Omnibus Rule&#160;published in January&#160;2013, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates, independent contractors or agents of covered entities, that perform services for them that involve the creation, maintenance, receipt, use, or disclosure of, individually identifiable health information relating to the privacy, security and transmission of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, there may be additional federal, state and non-U.S. laws which govern the privacy and security of health and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the United States Physician Payments Sunshine Act and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the government information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other licensed health care professionals, and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal government price reporting laws, which require Aerovate to calculate and report complex pricing metrics in an accurate and timely manner to government programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analogous United States state laws, including: state anti-kickback and false claims laws, which may apply to Aerovate&#8217;s business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the United States federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws requiring the registration of pharmaceutical sales representatives;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the United States Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, United States companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international </span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">222</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">organizations and foreign government owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">similar healthcare laws in the European Union and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers and laws governing privacy and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Similar rigid restrictions are imposed on the promotion and marketing of medicinal products in the EU and other countries. Laws (including those governing promotion, marketing and anti-kickback provisions), industry regulations and professional codes of conduct often are strictly enforced. Even in those countries where Aerovate is not directly responsible for the promotion and marketing of Aerovate&#8217;s products, inappropriate activity by Aerovate&#8217;s international distribution partners can have adverse implications for Aerovate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Healthcare Reform and Legislation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Payors, whether domestic or foreign, or governmental or private, are developing increasingly sophisticated methods of controlling healthcare costs and those methods are not always specifically adapted for new technologies such as gene therapy and therapies addressing rare diseases. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact the ability to sell products profitably. In particular, in 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the &#8220;ACA&#8221;), was enacted, which, among other things, subjected biologic products to potential competition by lower-cost biosimilars; increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations; subjected manufacturers to new annual fees and taxes for certain branded prescription drugs; created a Medicare Part&#160;D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part&#160;D; and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. The Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers up to 2% per fiscal&#160;year. Subsequent legislation extended the 2% payment reduction which remains in effect through 2031. In addition, the American Taxpayer Relief Act of 2012 further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years. On March&#160;11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January&#160;1, 2024. Due to the Statutory Pay-As-You-Go Act of 2010, estimated budget deficit increases resulting from the American Rescue Plan Act of 2021, and subsequent legislation, Medicare payments to providers will be further reduced starting in 2025 absent further legislation. These laws and regulations may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices Aerovate may obtain for any of its product candidates for which Aerovate may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. Additionally, in May&#160;2019, CMS issued a final rule&#160;to allow Medicare Advantage Plans the option of using step therapy for Part&#160;B drugs beginning January&#160;1, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;) includes several provisions that may impact the healthcare industry to varying degrees, including provisions that reduce the out-of-pocket cap for Medicare Part&#160;D beneficiaries to $2,000 starting in 2025; impose new manufacturer financial liability on certain drugs under Medicare Part&#160;D, allow the U.S. government to negotiate Medicare Part&#160;B and Part&#160;D price caps for certain high-cost drugs and biologics without generic or biosimilar competition, require companies to pay rebates to Medicare for certain drug prices that increase faster than inflation, and delay the rebate rule&#160;that would limit the fees that pharmacy benefit managers can charge. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one orphan designation and for which the only approved indication is for that disease or condition. If a product receives multiple orphan designations or has multiple approved indications, it may not qualify for the orphan drug exemption. The implementation of the IRA is currently subject to ongoing litigation challenging the constitutionality of the IRA&#8217;s Medicare drug price negotiation program. The effects of the IRA on the healthcare industry is not yet known.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent United States Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">223</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. President Biden has issued multiple executive orders that have sought to reduce prescription drug costs. In February&#160;2023, HHS also issued a proposal in response to an October&#160;2022 executive order from President Biden that includes a proposed prescription drug pricing model that will test whether targeted Medicare payment adjustments will sufficiently incentivize manufacturers to complete confirmatory trials for drugs approved through FDA&#8217;s accelerated approval pathway. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that it will continue to seek new legislative measures to control drug costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Further, on May&#160;30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">At the state level, individual states are increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for products or put pressure on product pricing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Data Privacy and Security Laws</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Numerous state, federal and foreign laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access to, confidentiality, and security of personal information, including health-related information. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws, including HIPAA and federal and state consumer protection laws and regulations (e.g., Section&#160;5 of the Federal Trade Commission Act) govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, certain state and non-U.S. laws, such as the CCPA, and GDPR, govern the privacy and security of personal information, including health-related information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to make compliance efforts more challenging, and can result in investigations, proceedings, or actions that lead to significant penalties and restrictions on data processing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Laws and Regulatory Processes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Aerovate is subject to a variety of financial disclosure and securities trading regulations as a public company in the United States, including laws relating to the oversight activities of the SEC and the regulations of The Nasdaq Global Market. In addition, the Financial Accounting Standards Board, the SEC and other bodies that have jurisdiction over the form and content of Aerovate&#8217;s accounts, Aerovate&#8217;s financial statements and other public disclosure are constantly discussing and interpreting proposals and existing pronouncements designed to ensure that companies best display relevant and transparent information relating to their respective businesses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Aerovate&#8217;s international operations are subject to compliance with the Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;), which prohibits corporations and individuals from paying, offering to pay, or authorizing the payment of anything of value to any foreign government official, government staff member, political party, or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. Aerovate also may be implicated under the FCPA for activities by its partners, collaborators, contract research organizations, vendors or other agents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Aerovate&#8217;s present and future business has been and will continue to be subject to various other laws and regulations. The extent of government regulation, which might result from future legislation or administrative action, cannot accurately be predicted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">224</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_7cd8763f_9424_4b24_978a_d9e6e8ca9eab"></a><a id="JADESBUSINESS_86053"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">JADE&#8217;S BUSINESS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade is a biopharmaceutical company developing potentially differentiated biologic therapies for patients living with autoimmune diseases with the goal of improving upon the existing treatment paradigm through the delivery of improved dosing and convenience, a comparable safety profile, and potentially increased clinical activity. Jade&#8217;s approach is to discover and efficiently develop biologics that address emerging targets supported by third-party clinical data and that overcome shortcomings of existing product candidates in development, such as potency, bioavailability, formulation, and pharmacokinetic properties. JADE-001, Jade&#8217;s initial product candidate, is a monoclonal antibody targeting a cytokine called &#8220;A PRoliferation Inducing Ligand&#8221; (&#8220;APRIL&#8221;) that modulates plasma cell survival and immunoglobulin production, which Jade plans to initially develop for the treatment of IgA nephropathy (&#8220;IgAN&#8221;). IgAN is an autoimmune disease typically diagnosed in young adults with an estimated incidence of at least 2.5 cases in every 100,000 adults in studies spanning multiple countries, an estimate that likely underestimates the true prevalence since confirmatory diagnosis requires a kidney biopsy. While there are three small molecule drugs that have been approved for the treatment of IgAN, Tarpeyo, Filspari and Fabhalta, there are not yet any disease-modifying therapies currently approved for the treatment of IgAN that directly target the excess production of a pathogenic form of IgA and stabilize kidney function. Emerging third-party clinical data has highlighted the critical importance of APRIL. JADE-001 has been engineered to address two key limitations of anti-APRIL&#160;monoclonal antibody candidates in clinical development: potency and pharmacokinetic half-life. Increased APRIL&#160;binding affinity, improved potency in <i style="font-style:italic;">in vitro </i>functional assays and an extended pharmacokinetic half-life in non-human primates (&#8220;NHPs&#8221;) have been observed in head-to-head preclinical studies of JADE-001 lead clones conducted by Paragon Therapeutics,&#160;Inc. (&#8220;Paragon&#8221;), compared to product candidates currently in clinical development that were manufactured based on public data. Jade does not yet have clinical data regarding patients with IgAN that have been treated with JADE-001 and there can be no assurance that its clinical trials will have similar or comparable results. Jade believes that JADE-001 has the potential to capture a sizable portion of what it estimates to be the $10 billion IgAN market, calculated based on the U.S. prevalence multiplied by the proportion of patients with proteinuria &gt; 0.5g/day. Jade intends to initiate a Phase 1 clinical trial of JADE-001 in healthy volunteers in Australia or New Zealand, pending regulatory authority approval, in the second half of 2025 with the aim of generating mechanistic biomarker data by the first half of 2026. Pending positive data from this trial, Jade expects to file an Investigational New Drug Application (&#8220;IND&#8221;) or foreign equivalent prior to the initiation of additional clinical trials. In addition to JADE-001, Jade is conducting pre-clinical research with respect to two other programs in serious, systemic autoimmune indications with high unmet need, JADE-002 and JADE-003. Jade is focused on opportunities with the potential for a product profile to be best-in-class and best-in- indication, the ability to efficiently demonstrate clinical proof-of-concept in indications with high unmet need, and which fits its team&#8217;s discovery and development expertise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s initial approach is to identify opportunities for which it believes there is strong clinical validation for a therapeutic mechanism to provide transformative benefit to patients, but where the existing solutions have shortcomings that may limit their impact. Jade&#8217;s focus is on biologics, where it believes its team&#8217;s extensive experience in optimizing the properties of monoclonal antibodies, such as potency, bioavailability, formulation, and half-life, has the potential for the greatest differentiation across dosing, convenience, and therapeutic benefit. Biologics are a well-established class of drugs representing over 30% of the total new drug approvals by the FDA in 2023, and 28% over the past five&#160;years. In 2023, biologics represented seven of the top 10 selling therapies globally, including the top two. The ability of biologics to deliver therapeutic benefits that have eluded small molecule drugs and their associated clinical and commercial success has sparked robust interest in discovery of potential new drugs in this class. It has been estimated that there are over 1,500 biologics in clinical trials. As with many drugs, first-in-class biologic product candidates provide valuable clinical proof-of-concept, but they do not necessarily represent the best-in-class solutions. There are often opportunities for follow-on drugs to deliver higher efficacy, improved safety, and/or more convenient dosing regimens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade believes that its approach offers several advantages:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Moderates development risks associated with novel mechanisms or modalities, as Jade&#8217;s product candidates target well-established mechanisms of action (i.e., existing anti-APRIL&#160;monoclonal antibodies in development for IgAN).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Facilitates efficient development of Jade&#8217;s product candidates by leveraging development and regulatory paths previously navigated by others.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Focuses Jade&#8217;s product development efforts to address unmet medical needs through improvement and differentiation as compared to precedent product candidates and existing standards of care.</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">225</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Leverages decades of broadly applicable industry experience in the field of biologics and a rich knowledge base of methods such as affinity maturation and YTE half-life extension technology to optimize the properties of Jade&#8217;s product candidates, such as affinity and pharmacokinetics.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade also benefits from the availability of researchers, drug developers, and manufacturers with experience in monoclonal antibodies that it can access to support its efforts, subject to any restrictions related to intellectual property, resulting in lower technical challenges than other treatment modalities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">IgAN is an autoimmune disease in which pathological immune complexes containing a class of immunoglobulins known as IgA deposit in the kidney. Together, the immune complexes and associated inflammation lead to kidney damage. IgAN is a progressive disease. Within 20&#160;years of diagnosis, 20&#160;&#8211; 50% of IgAN patients go on to suffer from end stage kidney disease (&#8220;ESKD&#8221;), requiring dialysis or kidney transplant for survival. IgAN is typically diagnosed in young adults and is the most common primary glomerular disease in the world. The U.S. Food and Drug Administration (&#8220;FDA&#8221;) estimates a U.S. prevalence for IgAN of 169,000, with approximately 60&#160;&#8211; 75% of patients with persistent proteinuria requiring treatment per international guidelines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While there are three small molecule drugs that have been approved for the treatment of IgAN, there are no currently approved therapies that stop the decline of kidney function in IgAN. Currently, the disease is typically treated either with small molecule therapies directed at reducing pressure in the kidney or with general immune-modulating therapies such as glucocorticoids, neither of which possess disease modifying properties. However, emerging data from third-party clinical trials of two classes of biologics has provided evidence of the potential for disease modification through reducing the ability of specialized B cells, called plasma cells, to produce IgA. These biologics bind to APRIL&#160;and block it from activating its receptors through two distinct mechanisms of action: APRIL-targeting monoclonal antibodies and ligand-binding fusion proteins. Product candidates, such as sibeprenlimab, originally discovered by Visterra&#160;Inc. (&#8220;Visterra&#8221;) and now in development by Otsuka Pharmaceutical Co.,&#160;Ltd. (&#8220;Otsuka&#8221;), are monoclonal antibodies directed against APRIL. Other product candidates are fusion proteins that contain the ligand binding domain of a receptor called transmembrane activator and calcium modulator and cyclophilin ligand interactor (&#8220;TACI&#8221;) that binds both APRIL&#160;and another B-cell activation and proliferation factor called BAFF, also known as Blys. An example of this class of product candidate is povetacicept, originally discovered by Alpine Immune Sciences, a company recently acquired by Vertex Pharmaceuticals Incorporated (&#8220;Vertex&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although both classes of product candidates lead to inhibition of IgA production and significant clinical benefit in IgAN patients, there is considerable scientific and clinical evidence that the beneficial effect in IgAN of blocking APRIL&#160;signaling on plasma cells is independent of their ability to block BAFF. Notably, the ability of the TACI fusion proteins to also block BAFF has not been shown to improve efficacy in IgAN and may result in general immunosuppression through reduced B-cell production. In clinical results from belimumab, a BAFF-specific antibody approved in systemic lupus erythematosus and lupus nephritis marketed by GSK as Benlysta<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, it has been observed that such reductions in B cells persist for&#160;years while on treatment. Jade believes that this additional immunosuppressive activity of TACI fusion proteins represents a potential liability for treatment of IgAN, a disease that presents in young adults who may require decades of therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">JADE-001 is an APRIL-directed monoclonal antibody that has been designed to address two key limitations of anti-APRIL&#160;monoclonal antibody candidates in clinical development: potency and pharmacokinetic half-life. JADE-001 has been engineered to improve the ability to deliver the therapeutic benefits of anti-APRIL&#160;therapy by leveraging YTE pharmacokinetic half-life extension technology, and to do so with an antibody that is a more potent inhibitor of APRIL&#160;signaling. While JADE-001 has not yet been evaluated in any clinical trials, Jade believes that JADE-001 has the potential to at least match the clinical activity of sibeprenlimab with a more convenient, less frequent dosing schedule, potentially administered at intervals of several&#160;months as compared to product candidates in development with dosing frequencies of two to four weeks, which would provide considerable benefit to IgAN patients who are often diagnosed as young adults and require chronic, often decades-long, treatment. In addition, Jade believes JADE-001 has the potential to provide improved clinical benefit by more completely suppressing APRIL, thereby maximizing clinical remission rates, as was observed with intravenous administration of the high dose of sibeprenlimab in a Phase 2 clinical trial. The Phase 2 clinical data suggests that the subcutaneous dose of sibeprenlimab being explored in an ongoing Phase 3 clinical trial may not achieve efficacy levels demonstrated in the highest intravenous dose. Consequently, Jade believes that JADE-001 has the potential to capture a sizable portion of what it estimates to be the $10 billion IgAN market, calculated based on the U.S. prevalence multiplied by the proportion of patients with proteinuria &gt; 0.5g/day.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In clinical trials of other anti-APRIL&#160;candidates and TACI fusion proteins a strong correlation between the ability to suppress IgA levels in healthy volunteers and IgA in IgAN patients has been observed. Furthermore, the degree of IgA reduction achieved by anti-APRIL&#160;monoclonal antibodies and TACI fusion proteins in IgAN patients has been found to be correlated with reduction of </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">226</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">proteinuria, a key kidney disease biomarker that is recognized by the FDA as a surrogate endpoint to support accelerated approval in IgAN. In multiple studies a strong association between proteinuria reduction and long-term kidney function preservation has been observed, which is necessary to support full approval of JADE-001 in IgAN. Jade intends to initiate a Phase 1 clinical trial of JADE-001 in healthy volunteers in Australia or New Zealand, pending regulatory authority approval, in the second half of 2025 to assess its safety, tolerability, and pharmacokinetics and its ability to reduce levels of IgA. Results of this trial, expected by the first half of 2026, will provide critical data on the safety and tolerability of JADE-001, the impact of YTE half-life extension technology on its pharmacokinetics, and its effect on the IgA biomarker. This data could support acceleration of the clinical development of JADE-001 through qualification for an accelerated approval pathway with the FDA. Pending positive data from this trial, Jade expects to file an IND or foreign equivalent prior to the initiation of additional clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade&#8217;s History and Team</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade was founded by leading healthcare investor Fairmount Funds Management LLC(&#8220;Fairmount&#8221;) and launched to research and develop antibody candidates licensed from Paragon Therapeutics,&#160;Inc. (&#8220;Paragon&#8221;), an antibody discovery engine founded by Fairmount and led by industry veterans with extensive experience in drug discovery. Paragon is specifically focused on the discovery of biologics for patients with high unmet needs that can potentially overcome limitations of existing therapies. In July&#160;2024, Jade entered into the Paragon Option Agreement with Paragon and Parade Biosciences Holding LLC (&#8220;Parade&#8221;) pursuant to which Paragon agreed to perform certain research activities to discover, generate, identify, and characterize monospecific antibody candidates directed to certain mutually agreed therapeutic targets of interest to Jade. The Paragon Option Agreement initially included one selected target for JADE-001: APRIL. The Paragon Option Agreement was amended on September&#160;27, 2024 to, among other things, include a target for each of JADE-002 and JADE-003. Under the Paragon Option Agreement, Jade has the exclusive option to, on a research program-by-research program basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture, and commercialize the antibodies and products directed to the selected target(s)&#160;(an &#8220;Option&#8221;). Jade exercised the Option to acquire the intellectual property rights to JADE-001 on October&#160;7, 2024, and Jade entered into a license agreement for JADE-001 with Paragon on October&#160;30, 2024. Jade&#8217;s Options to acquire the intellectual property rights to certain other research programs under the Paragon Option Agreement, including JADE-002 and JADE-003, remain currently unexercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Fairmount has launched a series of companies based on assets licensed from Paragon, including: Apogee Therapeutics, a company developing potential best-in-class biologics addressing clinically validated targets in immunological and inflammatory disorders; Spyre Therapeutics, a company advancing a pipeline of product candidates that seek to maximize the efficacy, safety, and convenience of treatments for inflammatory bowel disease; and Oruka Therapeutics, a company developing biologics that aim to redefine the standard of care for patients with chronic skin diseases, including plaque psoriasis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade is led by an experienced management team. Jade&#8217;s Chief Executive Officer, Tom Frohlich, brings deep experience in company building, business strategy, and product development. Before joining Jade, he co-founded and served as Chief Operating Officer of Chinook Therapeutics, where he guided the company&#8217;s growth to its acquisition by Novartis AG (&#8220;Novartis&#8221;) in 2023. Jade&#8217;s drug discovery and development efforts are led by Andrew King, BVMS, Ph.D., its Chief Scientific Officer &amp; Head of Research and Development, who has extensive experience in autoimmune drug development, including IgAN, having previously served in a similar role at Chinook Therapeutics. Jade&#8217;s remaining management team includes Hetal Kocinsky, M.D., Chief Medical Officer, Jonathan Quick, Senior Vice President, Finance and Elizabeth Balta, General Counsel &amp; Corporate Secretary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade has secured financing commitments that, upon closing of the Jade pre-closing financing, are expected to result in total gross proceeds of approximately $300 million from a syndicate of healthcare investors led by Fairmount, Venrock Healthcare Capital Partners, and a large investment firm, with participation from Deep Track Capital, Braidwell LP, Driehaus Capital Management, Frazier Life Sciences, RA Capital Management, Great Point Partners, Soleus Capital, Avidity Partners, Blackstone Multi-Asset Investing, Logos Capital, Deerfield Management, OrbiMed, and Samsara BioCapital, among other leading investment management firms. The financing includes common stock and pre-funded warrants to purchase additional shares of common stock and reflects the conversion of previously issued $95 million convertible notes, and is expected to close immediately prior to the Closing.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">227</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Jade&#8217;s strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s goal is to discover and develop differentiated biologic therapies for patients living with autoimmune diseases. Jade&#8217;s strategy to accomplish this goal includes:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Advance JADE-001 into clinical development in IgAN. Preclinical studies conducted by Paragon indicate that JADE-001 may have increased in vitro potency compared to other anti-APRIL&#160;product candidates in clinical development and improved pharmacokinetics in NHPs compared to sibeprenlimab. Jade intends to advance JADE-001 into a Phase 1 clinical trial in healthy volunteers in Australia and New Zealand, pending regulatory authority approval, in the second half of 2025 and anticipate mechanistic biomarker results confirming its anti-APRIL&#160;activity and pharmacokinetic properties by the first half of 2026. Pending positive data from this trial, Jade expects to file an </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">IND or foreign equivalent prior to the initiation of additional clinical trials. Jade believes that successful demonstration of anti-APRIL&#160;activity with IgA reductions in healthy volunteers, along with an extended half-life, has the potential to translate into clinical activity in IgAN patients in subsequent clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Advance its JADE-002 and JADE-003 programs in preclinical development towards clinical studies. Pursuant to the Paragon Option Agreement, Jade has exclusive options to license each of the JADE-002 and JADE-003 targets and Jade has commenced preclinical discovery with respect to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">these programs. Jade anticipates initiating Phase 1 clinical trials in healthy volunteers in the first half of 2026 and the first half of 2027 for JADE-002 and JADE-003, respectively, subject to relevant regulatory approvals. While Jade&#8217;s initial and primary focus is to in-license product candidates from Paragon, it may also from time to time explore the acquisition or in-licensing of product candidates from other third parties or identify and develop its own product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">JADE-001, a product candidate for the treatment of IgAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade is developing JADE-001, an anti-APRIL&#160;product candidate, for the treatment of autoimmune diseases, focusing initially on IgAN. Emerging clinical data from product candidates such as sibeprenlimab, in development by Otsuka, and zigakibart, in development by Novartis, have provided clinical validation of the disease-modifying potential of anti-APRIL&#160;therapy in the treatment of IgAN. JADE-001 incorporates both increased potency and improved pharmacokinetic properties as compared to existing product candidates. Preclinical studies performed by Paragon have confirmed the improved pharmacokinetics of JADE-001 in non-human primates, and Jade intends to advance JADE-001 into a Phase 1 clinical trial in healthy volunteers in Australia, pending regulatory authority approval, in the second half of 2025. Pending positive data from this trial, Jade expects to file an IND or foreign equivalent prior to the initiation of additional clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">IgAN disease background</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">IgAN is the most common primary glomerular disease in the world. IgAN is a progressive disease that is most often diagnosed before age 40 and can result in kidney failure. IgAN has an estimated incidence of at least 2.5 cases in every 100,000 adults, in studies spanning multiple countries, an estimate that likely underestimates the true prevalence since confirmatory diagnosis requires a kidney biopsy. The FDA estimates a U.S. prevalence for IgAN of 169,000, and the European Medicines Agency (&#8220;EMA&#8221;) estimates a European Union prevalence of 205,000, and Novartis estimates a Japan prevalence of 103,000 and China prevalence of 783,000, totaling a prevalence of over 1,000,000 globally. The prevalence of IgAN varies geographically with the highest prevalence in the Asia Pacific region.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">228</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:214.75pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Within 20&#160;years of diagnosis, between 20&#160;&#8211; 50% of patients with IgAN progress to ESKD a disease state requiring dialysis or kidney transplant for survival due to insufficient kidney function.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="avte-20240930xs4014.jpg" alt="Graphic" style="display:inline-block;height:214.75pt;width:365pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 1. IgAN is a progressive disease that results in kidney failure in the majority of patients.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the morbidity and mortality associated with ESKD, treatment of patients with ESKD has a significant economic burden. The costs of dialysis for a patient in the United States are typically between $100,000 and $275,000 annually and the cost of a kidney transplant can be over $450,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Underlying molecular cause</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">IgAN is an autoimmune kidney disease that is caused by the deposition of immune complexes containing IgA in the glomerular mesangium, the cellular structures supporting the tiny blood vessels of the glomeruli of the kidney that filter waste from the blood, leading to kidney injury. IgAN is commonly diagnosed following a respiratory tract infection, and the initiating pathogenic event is considered to be an aberrant mucosal immune response that leads to the excess production of an abnormal form of IgA that is deficient in sugar residues, called galactose-deficient IgA1 (&#8220;Gd-IgA1&#8221;). APRIL&#160;is thought to be a key driver of Gd-IgA1 overproduction in IgAN. Gd-IgA1 acts as an autoantigen and is recognized by circulating autoantibodies resulting in the formation of immune complexes which deposit in the glomerular mesangium of the kidney and trigger complement activation and an inflammatory response, leading to kidney injury. This injury results in leakage of protein across the filtration barrier of the kidney, leading to increased protein levels in the urine (proteinuria), an important measure of disease severity and predictor of risk of progression in IgAN. Over time, progressive injury can lead to a loss in the number of functional filtration units in the kidney, impairing the kidney&#8217;s ability to effectively filter the blood to clear waste products from the body, which can result in dialysis and/or kidney transplant in a subset of patients. Serum levels of creatinine are an important marker of this loss of filtration function and are used to calculate the estimated glomerular filtration rate (&#8220;eGFR&#8221;), a parameter that is used to assess the loss of kidney function over time in IgAN and other kidney diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Current treatment options for IgAN</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Current treatment guidelines recommend optimizing supportive therapy, including blood pressure control, a low-sodium diet, and smoking cessation. However, these measures are not disease-modifying in the vast majority of patients. Renin&#8211;angiotensin&#8211;aldosterone system (&#8220;RAAS&#8221;) inhibitors are recommended for IgAN patients with a proteinuria level of more than 0.5 g/day. International treatment guidelines currently recommend that patients who remain at high risk of progression with proteinuria &gt;0.75-1 g/day, despite &gt;90&#160;days of optimized supportive care including RAAS inhibitors, should be offered the opportunity to participate in a clinical trial. A six-month course of systemic steroids can be considered for high-risk patients, although the significant risk of treatment-emergent toxicity must be discussed with patients, and systemic steroids should be used with extreme caution or avoided in certain high-risk patient groups. Because most patients with IgAN are diagnosed before age 40 and IgAN is a disease that progresses over decades, the toxicity risks associated with long-term use of steroid therapies limit their overall impact.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">229</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:211.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Sodium-glucose cotransporter 2 inhibitors are approved for chronic kidney disease and can provide an additional option for conservative therapy to treat patients with IgAN. Importantly, they do not eliminate the risk of developing kidney failure or stabilize kidney function.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Proposed updates to current treatment guidelines have been published for public comment, including an emphasis on the importance of early diagnosis, recommending kidney biopsies for all adults with proteinuria levels of 0.5 g/d or higher when IgAN is suspected. The proposed updates to the guidelines also establish more rigorous proteinuria targets for IgAN patient management since patients exhibiting proteinuria of 0.5 g/d or higher are considered at risk for progressive kidney function decline. The proposed updates to the guidelines also direct the incorporation of treatments that have been proven to reduce pathogenic forms of IgA in the management of IgAN patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA has recently approved three drugs to treat IgAN: Tarpeyo<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, Filspari<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, and Fabhalta<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>. Tarpeyo, marketed by Calliditas Therapeutics, is a delayed release formulation of budesonide, a corticosteroid. Filspari, or sparsentan, is a dual endothelin and angiotensin II receptor antagonist marketed by Travere Therapeutics. Neither Tarpeyo nor Filspari are disease modifying. As a result, each provides only relatively modest reductions in proteinuria relative to control and neither has been shown to stabilize kidney function as eGFR has been observed to continue to decline while on treatment. Tarpeyo is only approved for a 9-month treatment course, due to the risk of significant adverse effects associated with long-term steroid use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In August&#160;2024, iptacopan, marketed as Fabhalta by Novartis, received accelerated approval for the treatment of IgAN based on interim results in high risk IgAN patients for whom iptacopan treatment was associated with a 38% decrease in urine protein creatinine ratio (&#8220;UPCR&#8221;) compared to placebo. Iptacopan is an inhibitor of the immune complement system and is approved to treat paroxysmal nocturnal hemoglobinuria, a rare disease of red blood cell destruction or hemolysis. Results from iptacopan provide support for the ability of anti-inflammatory drugs to reduce the kidney damage in IgAN, as anti-inflammatory drugs do not target overproduction of pathologic IgA, the primary cause of the disease. The long-term effect on kidney function stabilization has not yet been reported.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="avte-20240930xs4015.jpg" alt="Graphic" style="display:inline-block;height:211pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:442pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 2. Current treatments for IgAN.</i></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">230</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:211.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Emerging therapeutic approaches</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Multiple emerging approaches attempt to address the underlying autoimmune nature of IgAN by targeting antibody-producing B cells. Therapies approved for other autoimmune indications that target B cells, such as rituximab, an anti-CD20 drug which depletes B cells, have been observed to have a minimal impact in IgAN. Specifically, B-cell depletion with rituximab failed to reduce Gd-IgA1, anti-Gd-IgA1 autoantibody or proteinuria and did not preserve eGFR. This lack of activity is believed to be due to the loss of CD20 expression as B cells mature into antibody-producing plasma cells, which are thought to be the pathogenic cell type in IgAN. Furthermore, blisibimod, a BAFF-targeted peptibody, a type of fusion protein, was tested in IgAN and also observed to have a minimal impact in reducing either IgA or proteinuria from baseline through the first&#160;year of treatment in IgAN, which is directly comparable to the treatment duration available for other programs. Promising clinical results have been obtained, however, with therapies targeting plasma cell function and survival. Most notable are inhibitors of APRIL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="avte-20240930xs4016.jpg" alt="Graphic" style="display:inline-block;height:211pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:442.65pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 3. Antibody-producing plasma cells are dependent on APRIL.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">231</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:270pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Potential of APRIL&#160;inhibitors to treat IgAN</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">APRIL&#160;has been shown to regulate the development of plasma cells, which are specialized B cells that secrete large amounts of immunoglobulins. APRIL&#160;is produced by various immune cells, including macrophages, dendritic cells, and activated T cells. APRIL&#160;exerts its effects through binding to its two receptors: B-cell maturation antigen (&#8220;BCMA&#8221;), and TACI. These two receptors also bind to a related ligand called B cell activating factor from the tumor necrosis factor family, also known as &#8220;BAFF&#8221; or &#8220;BlyS.&#8221; In addition to these two receptors, BAFF also binds to the BAFF receptor, a binding event that is essential for both survival and maturation of immature B cells. Although BAFF and APRIL&#160;are structurally related, they bind to their receptors with different affinities and have distinct biological roles in regulating B cell function.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="avte-20240930xs4017.jpg" alt="Graphic" style="display:inline-block;height:269.85pt;left:0%;padding-bottom:0.15pt;position:relative;top:0pt;width:376.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 4. BAFF and APRIL&#160;stimulate overlapping but non-identical B cell pathways.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Multiple product candidates that block the activity of BAFF and APRIL&#160;are in clinical development for the treatment of IgAN. Atacicept, in development by Vera Therapeutics,&#160;Inc. (&#8220;Vera Therapeutics&#8221;), and telitacicept, a product from RemeGen approved in China for the treatment of systemic lupus erythematosus (&#8220;SLE&#8221;), are biologics called fusion proteins that fuse the cytokine binding domain of the TACI receptor to the fragment crystallizable portion of an antibody. These fusion proteins bind to both BAFF and APRIL&#160;to prevent B-cell activation via BAFF and block pathological antibody production via APRIL. In IgAN patients in a Phase 2 trial treated with telitacicept, circulating levels of IgA antibodies were observed to decrease by approximately 50% and had reductions in certain IgA immune complexes of over 60%. In a double-blind Phase 2b trial, once weekly subcutaneous doses of 150 mg or 75 mg of atacicept led to a combined reduction in the UPCR of 31% at week 24, which was a significantly greater reduction than the 8% observed with patients that received placebo. In patients on atacicept, stabilization of eGFR at week 36 was observed compared to a decline observed with placebo.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Povetacicept is a more potent TACI receptor fusion protein in development by Alpine Immune Sciences. In an ongoing open-label Phase 2 trial, subcutaneous doses of 80 mg administered every four weeks were observed to reduce UPCR from baseline by approximately 58.5% at 36 weeks in nine treated patients in which stable kidney function was also observed as assessed by eGFR. Alpine Immune Sciences was acquired by Vertex in May&#160;2024 for $4.9 billion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">These clinical trial results are part of a large body of scientific and third-party clinical evidence that points to the inhibition of APRIL&#160;and not BAFF as the primary mechanism of action of TACI fusion proteins in the treatment of IgAN, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">An association of a genetic variant of APRIL&#160;with increased risk of developing IgAN has been identified by genome-wide association studies;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">232</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:253.55pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Elevated levels of APRIL&#160;are found in IgAN patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Elevated levels of APRIL&#160;are correlated with disease severity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">APRIL&#160;promotes secretion of pathologic IgA from IgAN patient lymphocytes in ex vivo experiments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">IgA class switching can be driven by APRIL&#160;in vivo;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Knockout of the gene for APRIL&#160;decreases IgA levels in mice;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Overexpression of APRIL&#160;is sufficient to cause glomerular IgA deposition in mice;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Selective inhibitors of APRIL&#160;demonstrate activity in preclinical IgAN murine models and in IgAN patients; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Selective inhibition of BAFF demonstrated minimal clinical activity in IgAN.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Anti-APRIL&#160;products in development for the treatment of IgAN provide proof-of-concept data</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Two selective anti-APRIL&#160;monoclonal antibodies have been investigated in Phase 2 trials in IgAN patients. Zigakibart, under development by Chinook Therapeutics, a Novartis company, was well-tolerated in IgAN patients in an open-label Phase 2 trial in which rapid and sustained reductions in APRIL&#160;levels were observed. Zigakibart treatment resulted in lower levels of pathologic IgA levels and reduced proteinuria that continued to decline through one&#160;year of treatment. Stabilization of eGFR was observed through 72 weeks of treatment. No treatment-related serious adverse events were observed. A Phase 3 trial is now enrolling patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Similarly, sibeprenlimab, under development by Visterra, an Otsuka company, led to significant reductions in pathogenic IgA and proteinuria in IgAN patients in a Phase 2 double-blind placebo controlled study. Initial UPCR reductions from baseline of over 60% in the 4 mg/kg and 8 mg/kg groups were observed following a 12-month treatment period with sibeprenlimab and were sustained for an additional four&#160;months following treatment discontinuation. No treatment-related serious adverse events were observed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="avte-20240930xs4018.jpg" alt="Graphic" style="display:inline-block;height:253.55pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:363.75pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:162.1pt;text-indent:-162.1pt;margin:0pt 0pt 12pt 71.59pt;"><i style="font-style:italic;">Figure 5. Intravenous doses of sibeprenlimab led to significant and sustained reductions in UPCR in a Phase 2 trial in IgAN.</i></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">233</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:193.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At 12&#160;months of treatment with 4 mg/kg or 8 mg/kg sibeprenlimab, eGFR was observed to stabilize, providing strong clinical validation of the potential for an anti-APRIL&#160;monoclonal antibody to stabilize kidney function as measured by eGFR. In an ongoing Phase 3 clinical trial, Otsuka reported in October&#160;2024 that an interim analysis found that the trial primary endpoint had been met with a statistically and clinically significant reduction in 24-hour UPCR compared to placebo after nine&#160;months of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="avte-20240930xs4019.jpg" alt="Graphic" style="display:inline-block;height:193.45pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:261.1pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 6. Sibeprenlimab led to eGFR stabilization at 4 and 8 mg/kg IV.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Rapid and sustained reduction in serum levels of APRIL&#160;in healthy volunteers treated with sibeprenlimab were observed, but it had no effect on the serum levels of BAFF, highlighting the ability of an APRIL-selective antibody to distinguish between these two related cytokines. The ability to specifically target APRIL&#160;also differentiates anti-APRIL&#160;antibody approaches from TACI fusion proteins which block both APRIL&#160;and BAFF activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">234</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:285pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Evidence from belimumab, an anti-BAFF monoclonal antibody marketed as Benlysta<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> by GSK for the treatment of SLE, highlights the potential disadvantages of targeting BAFF for the treatment of IgAN. Substantial decreases in B cells across their developmental lineage were observed in patients with SLE on long-term treatment with belimumab. Based on the multiple lines of evidence supporting the role of APRIL&#160;in IgAN and the lack of any additional reported clinical benefit of anti-BAFF activity, Jade believes that potential therapies, such as TACI fusion proteins, that also target BAFF, may have pharmacologic effects on B cells that not only lack additional benefits in IgAN patients, but may in fact lead to an increased risk of broader immunosuppressive effects than necessary to combat IgAN disease progression.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="avte-20240930xs4020.jpg" alt="Graphic" style="display:inline-block;height:284.85pt;left:0%;padding-bottom:0.15pt;position:relative;top:0pt;width:450.15pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 62.45pt;"><i style="font-style:italic;">Figure 7. Belimumab treatment over seven-year period results in broad reductions in all B cell populations.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">235</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:211.6pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although cross-trial comparisons may not be reliable predictors of the relative clinical activity of product candidates that may be approved or that are in development, a cross-trial analysis of the effects of anti- APRIL&#160;antibodies, TACI fusion proteins, and an anti-BAFF fusion protein provides support for the finding that targeting BAFF is not effective or additive in the treatment of IgAN. Blisibimod, an anti- BAFF peptibody, a type of fusion protein, was observed to have minimal effects on UPCR and on IgA levels after one&#160;year of dosing in IgAN patients. By contrast, other product candidates that target APRIL&#160;have been observed to have substantial and comparable reductions in UPCR and suppression of IgA, regardless of whether they also targeted BAFF.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="avte-20240930xs4021.jpg" alt="Graphic" style="display:inline-block;height:211.6pt;width:435.15pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 8. Reductions in UPCR and IgA are driven by product candidates that target APRIL&#160;with no additional activity derived from targeting BAFF. No head-to-head trials of JADE-001 and product candidates presented above have been conducted.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">236</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:283.6pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical data from the most advanced anti-APRIL&#160;antibodies and TACI fusion proteins reveal that they have similar profiles with regard to pharmacodynamic biomarker responses, efficacy, tolerability, and dosing schedules. Jade believes that there is potential for a differentiated anti-APRIL&#160;product candidate without potentially unnecessary immunosuppression (via BAFF inhibition) to capture a sizable portion of the highly competitive emerging IgAN market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="avte-20240930xs4022.jpg" alt="Graphic" style="display:inline-block;height:283.6pt;width:450.15pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 9. The most advanced anti-APRIL&#160;antibodies and TACI fusion proteins have similar activity in clinical trials. Pbo = placebo; SC = subcutaneous; QW = once-weekly dosing; Q2W = once every other week</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">dosing; Q4W = once-monthly dosing.</i></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">237</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:209.1pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Jade&#8217;s solution: JADE-001</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">JADE-001 is a selective humanized anti-APRIL&#160;monoclonal antibody designed to build on the proof-of- concept validating data generated in clinical trials of sibeprenlimab and zigakibart in IgAN while addressing shortcomings which Jade believes will limit those antibodies&#8217; clinical and commercial impact. Jade believes that JADE-001 has the potential to deliver improved dosing and convenience, a comparable safety profile and potentially increased clinical activity through antibody modifications that improve potency and extend its half-life, as compared to the existing product candidates in development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="avte-20240930xs4023.jpg" alt="Graphic" style="display:inline-block;height:209.1pt;width:447.65pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 10. Design of JADE-001</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Increased potency</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Through a series of <i style="font-style:italic;">in vitro </i>selection and protein engineering steps, JADE-001 was designed by targeting a series of antibodies with an affinity for APRIL&#160;that were at least five-fold higher in the same assay than other anti-APRIL&#160;product candidates manufactured based on published data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The binding affinity to APRIL&#160;of potential JADE-001 candidates, referred to as lead clones, was measured using surface plasmon resonance. Serial dilutions of test antibodies were flowed over APRIL&#160;immobilized on sensor chips to assess binding kinetics and affinity. Binding at various concentrations was measured by an increase in resonance units and the dependence of the rate of binding with the concentration allowed the equilibrium dissociation constant (&#8220;K<sub style="font-size:7.5pt;vertical-align:sub;">D</sub>&#8221;) to be determined. The smaller the K<sub style="font-size:7.5pt;vertical-align:sub;">D</sub> value, the greater the binding affinity of the antibody for APRIL. JADE-001 lead clones had K<sub style="font-size:7.5pt;vertical-align:sub;">D </sub>values of at least five- fold lower than that observed for sibeprenlimab, indicating higher binding affinity to APRIL&#160;for JADE-001 lead clones compared to sibeprenlimab.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The increased affinity of JADE-001 for APRIL&#160;was observed to increase potency in a series of <i style="font-style:italic;">in vitro </i>competition binding and reporter cell assays. Multiple lead clones for JADE-001 have been observed to be more potent inhibitors of APRIL&#160;binding to BCMA and TACI receptors, as assessed in BCMA and TACI competition ELISA assays, than sibeprenlimab, zigakibart and povetacicept (manufactured based on published data). JADE-001 lead clones were also observed to be more potent in blocking APRIL&#160;signaling in BCMA and TACI cellular reporter assays than these comparators. Jade believes that this increased potency as a result of the greater binding affinity will facilitate the ability to maximally suppress APRIL&#160;signaling in IgAN patients as JADE-001 is advanced into a Phase 1 clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Improved pharmacokinetics in preclinical studies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">High molecular weight biologics, such as antibodies, are routinely dosed via intravenous or subcutaneous administration. Subcutaneous administration enables the potential for convenient self-administration at home. Jade believes that the disease-modifying impact and tolerability profile observed with anti-APRIL&#160;product candidates under clinical development provides the </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">238</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:217.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">opportunity for an anti-APRIL&#160;product, such as JADE-001, to gain a competitive advantage based on a less frequent and more convenient subcutaneous dosing regimen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">JADE-001 has been engineered to have an extended half-life in the body based on specific modifications that have been shown to be effective in other therapies. One of these modifications, YTE substitution, significantly extends the half-life of antibodies by increasing their ability to be recycled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="avte-20240930xs4024.jpg" alt="Graphic" style="display:inline-block;height:217.25pt;left:0%;padding-bottom:0.25pt;position:relative;top:0pt;width:454.55pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Figure 11. Illustration of a monoclonal antibody without YTE half-life extension technology compared to Jade antibodies that employ YTE half-life extension technology.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">While the half-life of an immunoglobulin G antibody is typically a few weeks, antibodies that are engineered with YTE half-life extension amino acid substitutions have half-lives that have been observed to be up to four-fold longer. Nirsevimab<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, a YTE-modified anti-RSV antibody marketed as Beyfortus<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> by Sanofi, has a half-life of 59&#160;days in infants. Evusheld<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, a combination of two half-life extended antibodies that target the SARS-CoV-2 virus, has been shown to protect against infection for six&#160;months after a single dose. APG777, a YTE-modified anti-IL-13 antibody in development for atopic dermatitis, has shown a half- life of approximately 75&#160;days in a phase 1 clinical trial in healthy volunteers, compared to an approximately 25-day half-life shown by lebrikizumab in an earlier trial in healthy volunteers, a non-half-life extended anti-IL-13 antibody.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In a single-dose study in NHPs dosed with JADE-001 lead clones with half-life extension modification, a two- to three-fold increase in half-life was observed when compared to sibeprenlimab (manufactured based on published data).</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">239</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:169.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Jade believes that the extended half-life observed in NHPs with JADE-001 has the potential to carry over into clinical development, as the half-life of other antibodies in NHPs, including those engineered to have extended half-lives, correlates with that observed in humans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="avte-20240930xs4025.jpg" alt="Graphic" style="display:inline-block;height:169.05pt;left:0%;padding-bottom:0.45pt;position:relative;top:0pt;width:200.95pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 12. Clinical stage YTE monoclonal antibodies and non-YTE monoclonal antibodies demonstrate half-life extension in both NHPs and humans.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Opportunity for JADE-001 to have differentiated clinical activity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Compared to existing monoclonal anti-APRIL&#160;antibodies in clinical development, two features of JADE-001, its increased potency and half-life extension, have the potential to deliver improved dosing and convenience, a comparable safety profile and potentially increased clinical activity in IgAN. In a third-party Phase 2 trial, a clear increase in clinical remission with higher doses of intravenously administered sibeprenlimab was observed. At the highest dose of 8 mg/kg, 26% of patients were observed to be in clinical remission at 12&#160;months, defined as proteinuria of less than 0.3 g/day.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="avte-20240930xs4026.jpg" alt="Graphic" style="display:inline-block;height:132.75pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:338.1pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 84.45pt;"><i style="font-style:italic;">Figure 13. A dose-response in IgAN remission was observed in a Phase 2 trial of sibeprenlimab.</i></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">240</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:171pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, the highest rates of clinical remission at the highest 8 mg/kg intravenous dose were accompanied by the deepest levels of APRIL&#160;suppression.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="avte-20240930xs4027.jpg" alt="Graphic" style="display:inline-block;height:170.9pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:447.65pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:176.5pt;text-indent:-176.5pt;margin:0pt 0pt 12pt 51.44pt;"><i style="font-style:italic;">Figure 14. The 8 mg/kg dose of sibeprenlimab demonstrated the deepest level of APRIL&#160;suppression in a third-party Phase 2 trial.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the ongoing Phase 3 clinical trial of sibeprenlimab, a trial known as VISIONARY, the dosing regimen was changed from weight-based intravenous administration to a fixed subcutaneous dose of 400 mg administered every four weeks. Based on a single ascending dose study with subcutaneous administration, the bioavailability of sibeprenlimab was reported to be approximately 75% of that observed in intravenous administration. Based on the average adult IgAN weight of approximately 85 kg reported in third-party global Phase 3 IgAN trials, Jade estimates that a subcutaneous dose of 400 mg would roughly correspond to an intravenous dose of less than 4 mg/kg in an average IgAN patient, a dose that did not maximally suppress APRIL&#160;or provide the highest levels of clinical activity. A body weight range of approximately 45 to 125 kg (95% confidence interval) has been reported in global third-party Phase 3 IgAN trials. For the higher body weight patients, the Phase 3 dosing regimen for sibeprenlimab would correspond to well below 4 mg/kg. JADE-001&#8217;s increased potency, improved exposure through half-life extension and femtomolar affinity may provide an opportunity for patients to obtain incremental clinical benefit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade believes that the longer half-life of JADE-001 has the potential to require less frequent dosing and lead to potentially higher clinical activity as therapeutic levels of the antibody are expected to be maintained in a patient&#8217;s body for longer periods of time, as compared to existing product candidates. Delivering improved clinical benefit with less frequent dosing would be less burdensome for IgAN patients and may also ultimately result in improved outcomes through better adherence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">241</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:220.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Potential mechanism of action validation in a Phase 1 trial in healthy volunteers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Third-party clinical data generated with both anti-APRIL&#160;antibodies and TACI fusion proteins provides strong support for the value of Phase 1 clinical data to signal the clinical activity of these product candidates in IgAN patients. The ability to suppress IgA production in healthy volunteers has been shown to closely correlate with the ability to reduce IgA levels in IgAN patients. Furthermore, the level of reduction in IgA levels in IgAN patients correlates with improvements in kidney function, as measured by parameters such as UPCR. Based on these observations, reduction in IgA levels in healthy volunteers may serve as an early surrogate for IgAN clinical efficacy; in addition, such reduction serves as a critical validation for clinical development of candidates in IgAN. UPCR in IgAN patients was the basis for accelerated approval of iptacopan. In addition, Phase 1 clinical data may also characterize other pharmacokinetic properties such as half-life extension, subcutaneous bioavailability and immunogenicity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="avte-20240930xs4028.jpg" alt="Graphic" style="display:inline-block;height:220.4pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:458.9pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 58.85pt;"><i style="font-style:italic;">Figure 15. IgA reduction in healthy volunteers is a critical de-risking event for clinical development in IgAN.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade intends to initiate a Phase 1 clinical trial of JADE-001 in healthy volunteers in Australia or New Zealand in the second half of 2025. Jade expects results to be available in the first half of 2026 on both the ability of JADE-001 to suppress IgA levels in healthy volunteers as well as pharmacokinetic and safety data. Pending positive data from this trial, Jade expects to file an IND or foreign equivalent prior to the initiation of additional clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">IgAN market opportunity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Current therapies for IgAN lack the efficacy needed to adequately treat the disease. A retrospective study of over 2,200 biopsy-confirmed IgAN patients in the United Kingdom found that, in over 70% of cases, decline in kidney function was not well-controlled, putting patients at risk for developing ESKD. Given the number of supportive care therapies prescribed to patients off-label, and the commercial success of only recently launched, non-disease modifying branded agents Tarpeyo and Filspari that have yet to achieve full market penetration (2023 sales of $101 million and approximately $29 million, respectively), Jade believes that there is a meaningful market opportunity for a safe and effective therapeutic in IgAN in the United States. Much like other autoimmune markets, the IgAN market is expected to grow rapidly as new, more effective, potentially disease-modifying products are approved. Jade estimates a U.S. total addressable market opportunity of approximately $10 billion based on the current estimated number of IgAN patients, 60 &#8722; 75% of which have persistent proteinuria and would be eligible for new, disease-modifying therapies, and pricing that is comparable to existing therapies. As a reference, Tarpeyo is estimated to cost $170,000 annually and Filspari is estimated to cost $119,000 annually.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">242</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Successful case studies of superior later entrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pharmaceutical markets across indications, such as plaque psoriasis and eosinophilic asthma, have evidenced that greater convenience is a key factor in sales outperformance. Convenience of administration has been shown to differentiate products and overcome first-to-market advantages, even among therapies with identical mechanisms of action. For example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In plaque psoriasis, two anti-IL-23p19 antibodies, guselkumab (marketed by Johnson&#160;&amp; Johnson as TREMFYA) and risankizumab (marketed by AbbVie as SKYRIZI), have demonstrated similar efficacy as measured by PASI response rates. Guselkumab and risankizumab were first approved in this indication by the FDA in 2017 and 2019, respectively. The key differentiating factor between the two therapies is that risankizumab is dosed every 12 weeks while guselkumab is dosed every 8 weeks. Despite being two&#160;years later to market, risankizumab posted 2023 sales of approximately $8 billion, while guselkumab posted 2023 sales of approximately $3 billion.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In eosinophilic asthma, two antibodies that target the IL-5 pathway, mepolizumab (marketed by GSK as NUCALA) and benralizumab (marketed by AstraZeneca as FASENRA), have demonstrated similar efficacy as measured by asthma exacerbation rates. Mepolizumab and benralizumab were first approved by the FDA in this indication in 2015 and 2017, respectively. The key differentiating factor between the two therapies is that benralizumab is dosed every 8 weeks while mepolizumab is dosed every 4 weeks. Despite mepolizumab being approved in more indications than benralizumab, and benralizumab being approved two&#160;years later, cumulative sales of benralizumab in its first </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">six&#160;years on the market (2018 to 2023) totaled approximately $6 billion, while cumulative sales of mepolizumab in its first six&#160;years on the market (2016 to 2021) totaled approximately $5 billion, according to GlobalData.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Therefore, Jade believes that the favorable pharmacokinetic profile observed in Jade-001, and associated potential for a more convenient dosing regimen, will serve as a potentially differentiating element of its therapeutic profile, which has the potential for positive commercial impact notwithstanding the broader landscape of competitive therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade&#8217;s pipeline beyond JADE-001</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In selecting programs to add to its pipeline, Jade is focused on:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The potential for a product profile to be best-in-class and best-in-indication.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The potential for the product to rapidly demonstrate clinical proof-of-concept.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">High unmet need within the indications of interest.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Paragon Option Agreement, Jade has an option to exclusively license certain Paragon intellectual property with respect to JADE-002 and JADE-003. Jade has commenced preclinical development of each of these programs and anticipates initiating Phase 1 clinical trials in healthy volunteers in the first half of 2026 and the first half of 2027, respectively. While Jade&#8217;s initial and primary focus is to in-license product candidates from Paragon, it may also from time to time explore the acquisition or in-licensing of product candidates from other third parties or identify and develop its own product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Jade&#8217;s Collaboration, License and Services Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Paragon Option Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July&#160;24, 2024, Jade entered into the Paragon Option Agreement with Paragon and Parade. Under the terms of the agreement, Paragon agreed to perform certain research activities to discover, generate, identify, and characterize one or more antibody candidates directed to certain mutually agreed therapeutic targets of interest to Jade (each, a &#8220;Research Program&#8221;). The Paragon Option Agreement initially included one selected target for JADE-001: APRIL. From time to time, Jade can choose to add additional targets by mutual agreement with Paragon and Parade. The Paragon Option Agreement was amended on September&#160;27, 2024 to, among other things, include a target for each of JADE-002 and JADE-003.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Paragon Option Agreement requires Jade, Paragon, and Parade to develop a research plan for each target that includes design, modeling, synthesis, evaluation, and other mutually agreed activities (each, a &#8220;Research Plan&#8221;), which activities may include </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">243</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">performing preclinical studies. Paragon will perform the activities set forth in each Research Plan on the timelines set forth in such Research Plan and in compliance with a mutually agreed budget. Each Research Program will be overseen and coordinated by a joint development committee consisting of two employees from Jade and two employees from Paragon, with Jade and Paragon each having one vote with respect to decisions of the committee. When Paragon and Parade have produced an antibody against a selected target, and upon the completion of each Research Program, Paragon and Parade will deliver to Jade a data package that includes sequence information for all then- existing antibodies and information directed to such target. Jade, Paragon, and Parade have developed a Research Plan for JADE-001 consistent with the foregoing, and Paragon and Parade have delivered an antibody against APRIL&#160;in accordance with such Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Paragon Option Agreement, Jade has an Option, on a Research Program-by-Research Program basis, to enter into a separate agreement with Paragon consistent with a set of pre-negotiated terms (a &#8220;License Agreement&#8221;). Each License Agreement will include (a)&#160;an exclusive, worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable Research Program to develop, manufacture, and commercialize the monospecific antibodies and products directed to the selected target(s), (b)&#160;a non-exclusive, worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable Research Program to develop, manufacture, and commercialize multispecific antibodies and products direct to the selected target(s), and (c) <span style="color:#231f20;">a right of first negotiation for a set period of time after the execution of the License Agreement with regard to any multispecific antibodies or products that are developed by Paragon. The Option with respect to </span>each Research Program is exercisable at Jade&#8217;s sole discretion at any time during the period beginning on the initiation of activities under the associated Research Program and ending a specified number of&#160;days following the delivery of the data package from Paragon related to the results of the Research Program (an &#8220;Option Period&#8221;). There is no payment due upon exercise of an Option pursuant to the Paragon Option Agreement. Activities under a Research Plan may continue past the exercise of an Option or entry into a License Agreement. Jade exercised the Option to acquire the intellectual property rights to JADE-001 on October&#160;7, 2024, and Jade entered into a License Agreement for JADE-001 with Paragon on October&#160;30, 2024. Jade&#8217;s Options to acquire the intellectual property rights to certain other Research Programs under the Paragon Option Agreement, including JADE-002 and JADE-003, currently remain unexercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon exercise of an Option with respect to a Research Program, the parties are obligated to use reasonable efforts to finalize and execute a License Agreement within 30&#160;days. Under the terms of a License Agreement, Jade expects that it will have sole authority over and control of the development, regulatory approval, manufacturing and commercialization of such in-licensed intellectual property worldwide. In addition, Jade expects to have sole authority over and control of the application for and issuance of all regulatory approvals related to such in-licensed intellectual property. Prior to entry into a License Agreement, Paragon is responsible for the prosecution, defense, maintenance and enforcement of patents related to the Research Program. Following entry into a License Agreement, Jade expects to control prosecution, defense, maintenance and enforcement of patents in-licensed under such License Agreement. However, there is no assurance that Jade will successfully negotiate future License Agreements with Paragon or that the terms will not differ from those described in this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless terminated earlier, the Paragon Option Agreement shall continue in force on a Research Program- by-Research Program basis until the later of: (i)&#160;the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by Jade; (ii)&#160;if Jade exercises its Option with respect to a Research Program, but the parties are unable to finalize and execute a License Agreement within 30&#160;days, the expiration of such 30-day period (subject to any mutually agreed extension of such period); and (iii)&#160;the expiration of the applicable Research Term (as defined under the Paragon Option Agreement). Jade may terminate the Paragon Option Agreement or any Research Program at any time for any or no reason upon 30&#160;days&#8217; prior written notice to Paragon; provided, that Jade must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate the Paragon Option Agreement or a Research Program immediately upon written notice to Jade if, as a result of any action or failure to act by Jade or its affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number of&#160;months. Each party has the right to terminate the Paragon Option Agreement or any Research Program upon (i)&#160;30&#160;days&#8217; prior written notice of the other party&#8217;s material breach that remains uncured for the 30-day period and (ii) <span style="color:#231f20;">the other party&#8217;s bankruptcy.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Upon signing of the Paragon Option Agreement, Jade was required to reimburse Paragon $5.6 million for development costs related to APRIL&#160;incurred by Paragon through June&#160;30, 2024 and certain other development costs incurred by Paragon between July&#160;1, 2024 and July&#160;24, 2024. This amount was recognized as research and development expense during the period from June&#160;18, 2024 (inception) to September&#160;30, 2024. Jade paid $5.6 million to Paragon in August&#160;2024. Jade is also required to pay Paragon for certain development fees and costs on a Research Program-by-Research Program basis. Under the Paragon Option Agreement, Jade is required to pay Paragon a one-time, non-refundable research initiation fee within 30&#160;days following finalization of a Research Plan in </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">244</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the amount of $1.3 million for JADE-001 and $1.0 million for each of JADE-002 and JADE-003. Under the Paragon Option Agreement, on a Research Program-by- Research Program basis, Jade is required to make one-time non-refundable milestone payments to Paragon of up to a total of $22.0 million upon the achievement of certain clinical development and regulatory milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon exercise of the Option with respect to a Research Program, the parties are obligated to use reasonable efforts to finalize and execute a License Agreement within 30&#160;days. Any License Agreement entered into with respect to a given Research Program shall contain the same milestone payment obligations as the Paragon Option Agreement, provided that any milestone set in the Paragon Option Agreement that has not yet been achieved and is duplicated in such License Agreement shall no longer be achievable and payable under the terms of the Paragon Option Agreement and shall only be achievable under the terms of the License Agreement. For the avoidance of doubt, if a milestone is achieved and paid by Jade pursuant to the Paragon Option Agreement for a certain Research Program, then there shall be no milestone payment due for the achievement of such milestone under a subsequently executed License Agreement for such Research Program. Further, under a License Agreement, Jade would also be required to make royalty payments to Paragon in the low single-digit&#160;percentage range based on net sales of products, subject to certain reductions. The royalty term will terminate on a product-by-product and country-by-country basis upon the later of the expiration of the last-to-expire valid claim within the relevant patent rights or the twelfth anniversary of the first commercial sale of such product in such country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, as part of the Paragon Option Agreement, on each of December&#160;31, 2025 and December&#160;31, 2026, Jade will grant Parade warrants to purchase a number of shares equal to 1.00% of its outstanding capital stock as of the date of the grant on a fully-diluted basis, with an exercise price equal to the fair market value of the underlying shares of Jade common stock on each respective grant date. Parade is an entity formed by Paragon as a vehicle to hold equity in Jade in order to share profits with certain employees of Paragon and will not perform any substantive role under the Paragon Option Agreement other than to receive such warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of the date of this proxy statement/prospectus, Jade has paid Paragon $14.0 million under the Paragon Option Agreement for development costs related to APRIL&#160;incurred by Paragon through the effective date of the agreement. Jade considers Paragon and Fairmount to be related parties. Please see the section titled &#8220;<i style="font-style:italic;">Certain Relationships and Related Party Transactions&#160;&#8212; Jade&#8217;s Relationships with Paragon, Parade and Fairmount</i>&#8221; beginning on page&#160;301 of this proxy statement/prospectus.</p><a id="JadeBusiness_Jade001_License"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">JADE-001 License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October&#160;30, 2024, Jade entered into a License Agreement for JADE-001 with Paragon (the &#8220;JADE-001 License Agreement&#8221;), pursuant to which Paragon granted Jade a royalty-bearing, worldwide, exclusive and sublicensable license with respect to certain inventions, patent rights, sequence information and other intellectual property rights related to antibodies directed at the APRIL&#160;target (the &#8220;Licensed Antibody Technology&#8221;) to use, make, sell, import, export and otherwise exploit certain antibodies and products targeting APRIL in the field of prophylaxis, palliation, treatment and diagnosis of human disease and disorders in all therapeutic areas (the &#8220;field&#8221;). Under the terms of the JADE-001 License Agreement, Jade is obligated to pay Paragon up to $22.0 million based on specific development and regulatory milestones, including a $1.5 million fee for nomination of a development candidate and a further milestone payment of $2.5 million upon the first dosing of a human patient in a Phase 1 trial. In addition, the following summarizes other key terms of the JADE-001 License Agreement:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Paragon also granted Jade a royalty-bearing, worldwide, non-exclusive, sublicensable right and license under the Licensed Antibody Technology to use, make, sell, import, export or otherwise exploit certain multispecific antibodies and products targeting APRIL.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Paragon will not conduct any new campaigns that generate APRIL&#160;monospecific antibodies in the field for at least five&#160;years.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Paragon may pursue the development and commercialization of multispecific antibodies and products directed at the APRIL&#160;target in the field and in the territory, and Jade has a right of first negotiation for any such multispecific antibodies and products proposed by Paragon for a period of five&#160;years from the execution of the JADE-001 License Agreement. If Jade does not exercise its right of first negotiation, or if the parties are unable to agree on a definitive agreement, Paragon may proceed without any obligations to Jade with respect to the right of first negotiation, and Jade&#8217;s </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">non-exclusive license will exclude any multispecific antibodies and products that were the subject of the right of first negotiation.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade will pay Paragon a low-to-mid single-digit&#160;percentage royalty based on annual net sales of the products in the field and in the territory, and a mid single-digit&#160;percentage royalty based on annual net sales of the multispecific products in the field and in the territory, subject to a 30% reduction if </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">there is no valid patent covering the product in the country.</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">245</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The royalty term ends on the later of (i)&#160;the twelfth anniversary of such date or (ii)&#160;the expiration of the last-to- expire valid patent covering the product or the multispecific product in the country at issue.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The JADE-001 License Agreement may be terminated on 60&#160;days&#8217; notice by Jade; on material breach without cure; and to the extent permitted by law, on a party&#8217;s insolvency or bankruptcy.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">With respect to patents licensed to Jade under the JADE-001 License Agreement that have been filed as of the effective date of the JADE-001 License Agreement, Jade will control the preparing, filing, prosecuting and maintenance of such patents. With respect to patents filed after the effective date of the JADE-001 License Agreement, Paragon will control the preparing, filing, prosecuting and maintaining of such patents until the final deliverable for the relevant research program is delivered to Jade, after which Jade will control the preparing, filing, prosecuting and maintain of such patents.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Biologics Master Services Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July&#160;10 2024, Jade entered into a biologics master services agreement (the &#8220;WuXi Biologics MSA&#8221;) with WuXi Biologics (Hong Kong). The WuXi Biologics MSA governs certain development activities and good manufacturing practice (&#8220;GMP&#8221;) manufacturing and testing for the JADE-001 program, as well as future programs, on a work order basis. Under the WuXi Biologics MSA, Jade is obligated to pay WuXi Biologics (Hong Kong) a service fee and all non-cancellable obligations in the amount specified in each work order associated with the agreement for the provision of services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The WuXi Biologics MSA terminates on the later of (i)&#160;July&#160;3, 2029 or (ii)&#160;the completion of services under all work orders executed by the parties prior to July&#160;3, 2029, unless terminated earlier. The term of each work order terminates upon completion of the services under such work order, unless terminated earlier. Jade can terminate the WuXi Biologics MSA or any work order at any time upon 30&#160;days&#8217; prior written notice and immediately upon written notice if WuXi Biologics (Hong Kong) fails to obtain or maintain required material governmental licenses or approvals. Either party may terminate a work order (i)&#160;at any time upon six&#160;months&#8217; prior notice with reasonable cause, provided however that if WuXi Biologics (Hong Kong) terminates a work order in such manner, no termination or cancellation fees shall be paid by Jade and (ii)&#160;immediately for cause upon (a)&#160;the other party&#8217;s material breach that remains uncured for 30&#160;days after notice of such breach, (b)&#160;the other party&#8217;s bankruptcy or (c)&#160;a force majeure event that prevents performance for a period of at least 90&#160;days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cell Line License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October&#160;22, 2024, Jade entered into a cell line license agreement (the &#8220;Cell Line License Agreement&#8221;) with WuXi Biologics Ireland Limited (&#8220;WuXi Ireland&#8221;). Under the Cell Line License Agreement, Jade received a non-exclusive, worldwide, sublicensable license to certain of WuXi Ireland&#8217;s know-how, cell line, biological materials and media and feeds to make, have made, use, sell and import certain therapeutic products produced through the use of the cell line licensed by WuXi Ireland under the Cell Line License Agreement (the &#8220;WuXi Ireland Licensed Products&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In consideration for the license, Jade paid WuXi Ireland a non-refundable license fee of $150,000. Additionally, if Jade manufactures all of its commercial supplies of bulk drug product with a manufacturer other than WuXi Ireland or its affiliates, it is required to make royalty payments to WuXi Ireland in an amount equal to a fraction of a single digit&#160;percentage of global net sales of the WuXi Ireland Licensed Products manufactured by a third-party manufacturer (the &#8220;Royalty&#8221;). If Jade manufactures part of its commercial supplies of the WuXi Ireland Licensed Products with WuXi Ireland or its affiliates, then the Royalty will be reduced accordingly on a pro rata basis. Jade has the option, at any time, to pay WuXi Ireland a non-refundable lump-sum royalty buyout payment on a drug product-by-drug product basis to extinguish future Royalty obligations with respect to such drug product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Cell Line License Agreement will continue indefinitely unless terminated (i)&#160;by Jade upon six&#160;months&#8217; prior written notice and its payment of all undisputed amounts due to WuXi Ireland through the effective date of termination, (ii)&#160;by WuXi Ireland for a material breach by Jade that remains uncured for 60&#160;days after written notice, (iii)&#160;by WuXi Ireland if Jade fails to make a payment and such failure continues for 30&#160;days after receiving notice of such failure, or (iv)&#160;by either party upon the other party&#8217;s bankruptcy.</p><a id="JadeBusiness_Competition"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Competition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The biotechnology and biopharmaceutical industries are characterized by continuing technological advancement and significant competition. While Jade believes that its programs, technology, development experience and scientific knowledge provide it with competitive advantages, Jade faces competition from major pharmaceutical and biotechnology companies, academic institutions, </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">246</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">governmental agencies and public and private research institutions, among others. Any product candidates that Jade successfully develops and commercializes will compete with existing therapies and new therapies currently in clinical development or that may become available in the future. Many of the companies with which Jade is currently competing or will complete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than Jade does. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller number of Jade&#8217;s competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with Jade in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, patient enrollment for clinical trials as well as in acquiring technologies complementary to, or necessary for, Jade&#8217;s programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Key competitive factors affecting the success of all Jade&#8217;s product candidates that it will develop, if approved, are likely to be efficacy, safety, convenience, dosing frequency, presentation, price, the level of competition and generic competition and the availability of reimbursement from government and other third-party payors. Some competitors have obtained regulatory approval for products and they or others may in the future also obtain regulatory approvals for products with similar or different mechanisms of action as compared with Jade&#8217;s product candidates more rapidly than Jade may obtain approval for its product candidates, which may result in Jade&#8217;s competitors establishing a strong market position before Jade is able to enter the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Specifically, there are several companies developing or marketing treatments that may be approved for the same indications and/or disease as Jade&#8217;s most advanced program, JADE-001, including major pharmaceutical companies, some of which use the same mechanism of action as JADE-001. Jade does not yet have clinical data for any of its programs and there can be no assurance that its programs will have similar or superior results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While there are no biologics currently approved for the treatment of IgAN, there are three small molecule drugs that have been approved: Tarpeyo, Filspari and Fabhalta. Neither Tarpeyo nor Filspari are disease modifying. As a result, each provides only relatively modest reductions in proteinuria relative to control and neither has been shown to stabilize kidney function as eGFR continues to decline while on treatment. Tarpeyo is approved for a 9-month treatment course, due to the risk of significant adverse effects associated with long-term steroid use. While results from Fabhalta provide support for the ability of anti- inflammatory drugs to reduce the rate of IgAN kidney damage, anti-inflammatory drugs do not target overproduction of pathologic IgA, the primary cause of the disease. The treatment paradigm in IgAN is rapidly evolving and several companies, including Otsuka, Novartis, Vera Therapeutics and Vertex, are developing therapeutics for IgAN currently in late stage clinical development that are expected to be disease modifying in IgAN and direct competitors with JADE-001.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade does not yet have clinical data for its JADE-001 program for the treatment of IgAN and there can be no assurance that its programs will have similar or superior results to those offered by the existing and evolving treatment landscape.</p><a id="JadeBusiness_ManufacturingSupply"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Manufacturing and Supply</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade does not own or operate, and currently has no plans to establish, any manufacturing facilities. All of Jade&#8217;s preclinical and clinical drug supply development, manufacturing, storage, distribution and testing are outsourced to third-party manufacturers and facilities. Jade&#8217;s manufacturing strategy enables it to more efficiently direct financial resources to the research, development and commercialization of programs rather than diverting resources to internally develop and maintain manufacturing facilities. As its programs advance through development, Jade expects to enter into longer-term commercial supply agreements with key suppliers and manufacturers to fulfill and secure its supply needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Overview</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade strives to protect the proprietary programs and technologies that it believes are important to its business, including seeking and maintaining patent protection intended to cover the composition of matter of its programs, its methods of use and manufacture, and other inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Paragon has filed provisional patent applications, directed to anti-APRIL&#160;antibodies, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies. A provisional patent application is an application filed in the USPTO for the purpose of securing an early date of priority for the applicant&#8217;s invention. The provisional application must </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">247</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">include a written description of what the inventor has discovered, along with a drawing of the invention, but need not include patent claims, statements concerning or disclosing the prior art, or certain other formalities. A provisional patent application allows for an effective filing date to be established with regard to an invention, but once a provisional patent application is filed, either a corresponding non-provisional patent application or a petition to convert the provisional patent application into a non-provisional patent application must be filed within 12&#160;months or such effective filing date will be lost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The maximum term of a U.S. patent, excluding extensions and adjustments, begins on the effective filing date of the first non-provisional application claiming the patented invention and ending 20&#160;years from that date. In essence, a provisional patent application provides a patent applicant two principal advantages over filing a non-provisional application. First, it allows the applicant to secure an earlier priority date for its invention than that of an equivalent non-provisional application&#160;&#8212; up to one&#160;year earlier than the filing date of a related non-provisional application. Second, since the term of a patent runs from the effective filing date of the first non-provisional application but does not begin upon filing a provisional application, filing a provisional application provides the applicant an additional&#160;year&#8217;s time to refine that invention before filing a related non-provisional application without surrendering the earlier priority date. Securing an earlier priority date both ensures that later inventors cannot obtain a patent to the same invention and provides protection against certain arguments that developments in the field arising after the priority date should prevent or invalidate the applicant&#8217;s invention.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Jade or Paragon timely file non-provisional patent applications in the United States and in countries outside of the United States with regard to Paragon&#8217;s JADE-001 provisional patent applications and these non- provisional patent applications result in issued patents, such patents are expected to expire in 2045, without taking potential patent term adjustment or patent term extension into consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other IP Rights</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to patents, Jade relies upon unpatented trade secrets, know-how and continuing technological innovation to develop and maintain its competitive position. However, trade secrets and know-how can be difficult to protect. Jade seeks to protect its proprietary information, in part by executing confidentiality agreements with its collaborators and scientific advisors, and non-competition, non-solicitation, confidentiality and invention assignment agreements with its employees and consultants. Jade has also executed agreements requiring assignment of inventions with selected scientific advisors and collaborators. The confidentiality agreements Jade enters into are designed to protect its proprietary information and the agreements or clauses requiring assignment of inventions to Jade are designed to grant Jade ownership of technologies that are developed through its relationship with the respective counterparty. Jade cannot guarantee, however, that it has executed such agreements with all applicable counterparties, that such agreements will not be breached, or that these agreements will afford it adequate protection of its intellectual property and proprietary rights. For more information, please see the section titled &#8220;<i style="font-style:italic;">Risk Factors&#160;&#8212; Risks Related to Jade&#8217;s Intellectual Property</i>&#8221; beginning on page&#160;73 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Employees and Human Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of November&#160;15, 2024, Jade had 24 full-time employees, nine of whom have Ph.D. or M.D. degrees and are engaged in research and development. Jade also retains independent contractors, as needed, to support its organization&#8217;s needs. None of Jade&#8217;s employees are represented by labor unions or covered under collective bargaining agreements. Jade considers its relationship with its employees to be good.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade believes its employees are critical to its success and ability to achieve its business objectives. To that end, Jade is focused on retaining, developing and engaging its existing employees, and attracting high performing talent to join its team. Jade&#8217;s rewards package (cash and equity-based compensation and 401(k)&#160;and health and welfare benefits plans) is a key tool in retaining, engaging and rewarding its team. Jade is also committed to the continued learning and development of its employees, which Jade believes will enable it to do its best work for patients. Jade encourages its team members to attend conferences and seminars and take continuing education courses to further their development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade expects to continue to build its team to ensure it can effectively execute against its business plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Government Regulation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">248</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of biologics such as those Jade is developing. Jade, along with its third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory authorities of the countries in which Jade wishes to conduct studies or seek approval or licensure of its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">U.S. Biologics Regulation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, biological products (or &#8220;biologics&#8221;) are subject to regulation under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;), the Public Health Service Act (&#8220;PHSA&#8221;) and other federal, state, local, and foreign statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or following approval may subject an applicant to administrative action and judicial sanctions. The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s current Good Laboratory Practices (&#8220;GLP&#8221;) regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an independent institutional review board (&#8220;IRB&#8221;), or ethics committee at each clinical site before the trial is commenced;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacture of the proposed biologic candidate in accordance with current good manufacturing practices (&#8220;cGMPs&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice (&#8220;GCP&#8221;) requirements to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preparation of and submission to the FDA of a biologics license application (&#8220;BLA&#8221;), after completion of all pivotal clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a determination by the FDA within 60&#160;days of its receipt of a BLA to file the application for review;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMPs, and to assure that </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the facilities, methods and controls are adequate to preserve the </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">biological</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> product&#8217;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with GCPs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of a BLA to permit commercial marketing of the product for particular indications for use in the United States.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preclinical and Clinical Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Prior to beginning the first clinical trial with a product candidate, in the United States, Jade must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol or protocols for preclinical studies and clinical trials. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls information, and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA, within the 30-day period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on partial or full clinical hold and the IND sponsor, </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">249</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB representing each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing preclinical studies and clinical trials and clinical study results to public registries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1. The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 2. The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 3. The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain FDA regulatory requirements in order to use the study as support for an IND or application for marketing approval or licensure, including that the study was conducted in accordance with GCP, including review and approval by an independent ethics committee and use of proper procedures for obtaining informed consent from subjects, and the FDA is able to validate the data from the study through an onsite inspection if the FDA deems such inspection necessary. The GCP requirements encompass both ethical and data integrity standards for clinical studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">BLA Submission and Review</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">250</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of the product, or from a number of alternative sources, including studies initiated and sponsored by investigators. The submission of a BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Within 60&#160;days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. Once a BLA has been accepted for filing, the FDA&#8217;s goal is to review standard applications within 10&#160;months after the filing date, or, if the application qualifies for priority review, six&#160;months after the FDA accepts the application for filing. In both standard and priority reviews, the review process may also be extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a REMS to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Post-Approval Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Any products manufactured or distributed by Jade pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record- keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state authorities, and are subject to periodic unannounced inspections by the FDA and certain state authorities for compliance with cGMPs, </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">251</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">which impose certain procedural and documentation requirements upon Jade and its third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon Jade and any third-party manufacturers that it may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters or holds on post-approval clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal of the FDA to permit the import or export of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mandated modification of promotional materials and labeling and the issuance of corrective information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other governmental regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by Jade and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Biosimilars and Reference Product Exclusivity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The BPCIA created an abbreviated approval pathway for biological products that are highly similar, or &#8220;biosimilar,&#8221; to or interchangeable with an FDA-approved reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, is generally shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. A product shown to be biosimilar or interchangeable with an FDA- approved reference biological product may rely in part on the FDA&#8217;s </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">252</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">previous determination of safety and effectiveness for the reference product for approval, which can potentially reduce the cost and time required to obtain approval to market the product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA. In September&#160;2021, the FDA issued two guidance documents intended to inform prospective applicants and facilitate the development of proposed biosimilars and interchangeable biosimilars, as well as to describe the FDA&#8217;s interpretation of certain statutory requirements added by the BPCIA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four&#160;years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12&#160;years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A reference biologic is granted 12&#160;years of exclusivity from the time of first licensure of the reference product. The first biologic product submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against other biologics submitted under the abbreviated approval pathway for the lesser of (i)&#160;one&#160;year after the first commercial marketing, (ii)&#160;18&#160;months after approval if there is no legal challenge, (iii)&#160;18&#160;months after the resolution in the applicant&#8217;s favor of a lawsuit challenging the biologics&#8217; patents if an application has been submitted, or (iv)&#160;42&#160;months after the application has been approved if a lawsuit is ongoing within the 42-month period. The FDA&#8217;s thinking on interchangeability determinations continues to evolve. In June&#160;2024, the FDA issued a draft guidance document proposing to update its 2019 final interchangeability guidance to reflect the agency&#8217;s expectations of the data and assessments required to demonstrate interchangeability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six&#160;months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In July&#160;2018, the FDA announced an action plan to encourage the development and efficient review of biosimilars, including the establishment of a new office within the agency that will focus on therapeutic biologics and biosimilars. On December&#160;20, 2020, Congress amended the PHSA as part of the COVID-19 relief bill to further simplify the biosimilar review process by making it optional to show that conditions of use proposed in labeling have been previously approved for the reference product, which used to be a requirement of the application. In addition, government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As discussed below, the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) is a significant new law that intends to foster generic and biosimilar competition and to lower drug and biologic costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Patent Term Extension</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the United States, after a BLA is approved, owners of relevant drug patents may apply for up to a five-&#160;year patent extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory process. The allowable patent term extension is typically calculated as one-half the time between (1)&#160;the later of (a)&#160;the effective date of an IND and (b)&#160;issue date of the patent for which extension is sought, and (2)&#160;the submission date of a BLA, plus the time between BLA submission date and the BLA approval date, up to a maximum of five&#160;years. The time can be shortened if the FDA determines that the applicant did not pursue licensure with due diligence. The total patent term after the extension may not exceed 14&#160;years from the date of product licensure. Only one patent applicable to a licensed biological product is eligible for extension and only those claims covering the product, a method for using it, or a method for manufacturing it may be extended, and the application for the extension must be submitted prior to the expiration of the patent in question. However, Jade may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Some, but not all, foreign </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">253</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">jurisdictions possess patent term extension or other additional patent exclusivity mechanisms that may be more or less stringent and comprehensive than those of the United States.</p><a id="JadeBusiness_OtherHealth_Compliance"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Healthcare Laws and Compliance Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business that may restrict certain general business and marketing practices. Such laws include, without limitation: the federal Anti-Kickback Statute (&#8220;AKS&#8221;); the federal False Claims Act (&#8220;FCA&#8221;); the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) and similar foreign, federal and state fraud, abuse and transparency laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The AKS prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under any federal healthcare program. The term remuneration has been interpreted broadly to include anything of value. The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand, and prescribers and purchasers on the other. The government often takes the position that to violate the AKS, only one purpose of the remuneration need be to induce referrals, even if there are other legitimate purposes for the remuneration. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from AKS prosecution, but they are drawn narrowly and practices that involve remuneration, such as consulting agreements, that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Jade&#8217;s practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the AKS. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Civil and criminal false claims laws, including the FCA, and civil monetary penalty laws, which can be enforced through civil whistleblower or qui tam actions, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment of federal government funds, including in federal healthcare programs, that are false or fraudulent. Pharmaceutical and other healthcare companies have been prosecuted under these laws for engaging in a variety of different types of conduct that caused the submission of false claims to federal healthcare programs. Under the AKS, for example, a claim resulting from a violation of the AKS is deemed to be a false or fraudulent claim for purposes of the FCA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">HIPAA created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program, including private third-party payors, and making false statements relating to healthcare matters. A person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate the statute in order to have committed a violation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDCA addresses, among other things, the design, production, labeling, promotion, manufacturing, and testing of drugs, biologics and medical devices, and prohibits such acts as the introduction into interstate commerce of adulterated or misbranded drugs or devices. The PHSA also prohibits the introduction into interstate commerce of unlicensed or mislabeled biological products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to the Centers for Medicaid&#160;&amp; Medicare Services (&#8220;CMS&#8221;) information related to payments or other transfers of value to various healthcare professionals including physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, certified nurse-midwives, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Beginning on January&#160;1, 2023, California Assembly Bill 1278 requires California physicians and surgeons to notify patients of the Open Payments database established under the federal Physician Payments Sunshine Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Jade is also subject to additional similar U.S. state and foreign law equivalents of each of the above federal laws, which, in some cases, differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. If Jade&#8217;s operations are found to be in violation of any of such laws or any other governmental regulations that apply, Jade may be subject to penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">254</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of its operations.</p><a id="JadeBusiness_DataPrivacy_Security"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Data Privacy and Security</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Numerous state, federal, and foreign laws govern the collection, dissemination, use, access to, confidentiality, and security of personal information, including health-related information. In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations, govern the collection, use, disclosure, and protection of health-related and other personal information could apply to Jade&#8217;s operations or the operations of its partners. For example, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health, and their respective implementing regulations imposes privacy, security, and breach notification obligations on certain health care providers, health plans, and health care clearinghouses, known as covered entities, as well as their business associates and their covered subcontractors that perform certain services that involve using, disclosing, creating, receiving, maintaining, or transmitting individually identifiable protected health information for or on behalf of such covered entities. Entities that are found to be in violation of HIPAA may be subject to significant civil, criminal, and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) to settle allegations of HIPAA non-compliance. Further, entities that knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA covered entity in a manner that is not authorized or permitted by HIPAA may be subject to criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even when HIPAA does not apply, according to the FTC, violating consumers&#8217; privacy rights or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section&#160;5(a)&#160;of the Federal Trade Commission Act. In addition, certain states, such as California, have additional laws imposing obligations that may apply even when HIPAA does not, such as the Confidentiality of Medical Information Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, certain comprehensive state privacy laws, such as the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;), as amended by the California Privacy Rights Act of 2020 (&#8220;CPRA&#8221;), govern the privacy and security of personal information, including health-related information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. The CCPA/CPRA applies to personal data of consumers, business representatives, and employees, and imposes obligations on certain businesses that do business in California, including to provide specific disclosures in privacy notices and honor requests of California residents to exercise certain privacy rights, including the right to opt out of certain disclosures of their personal information. Health information falls under the CCPA/CPRA&#8217;s definition of personal information where it identifies, relates to, describes, or is reasonably capable of being associated with or could reasonably be linked with a particular consumer or household&#160;&#8212; unless it is subject to HIPAA&#160;&#8212; and is included under a new category of personal information, &#8220;sensitive personal information,&#8221; which is offered greater protection. The CCPA provides for civil penalties of up to $7,500 per violation and allows private litigants affected by certain data breaches to recover significant statutory damages, and the CPRA established a new regulatory agency to implement and enforce the law. Although the CCPA exempts some data processed in the context of clinical trials in addition to exempting information subject to HIPAA, the CCPA increases compliance costs and potential liability with respect to other personal data Jade maintains about California residents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other states have also enacted comprehensive privacy laws, and similar laws have been passed or are being considered in several other states, as well as at the federal and local levels. While the laws in these states, like the CCPA, also exempt some data processed in the context of clinical trials, such developments further complicate compliance efforts, and increase legal risk and compliance costs for Jade and the third parties upon whom Jade relies. The scope and enforcement of these laws is uncertain and subject to rapid change. For example, increasing concerns about health information privacy have recently prompted the federal government to take a newly expansive view of the scope of existing privacy laws and regulations. Congress and some states are considering new laws and regulations that further and more broadly protect the privacy and security of personal health information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">There are also an increasing number of, and continuous change within, foreign laws regulating data privacy and security, such as Canada&#8217;s Personal Information Protection and Electronic Documents Act, Australia&#8217;s Privacy Act 1988, New Zealand&#8217;s Privacy Act 2020 and South Korea&#8217;s Personal Information Protection Act. In particular, when Jade conducts clinical trials, including in Australia or New Zealand, it will need to comply with the applicable country data privacy and security laws with respect to the processing of clinical data, which impose obligations similar to those described below in the section titled &#8220;<i style="font-style:italic;">&#8212; Other Government Regulation Outside of the United States&#160;&#8212; Regulation in the European Union&#160;&#8212; European Data Laws</i>&#8221; beginning on page&#160;258 of this proxy </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">255</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">statement/prospectus. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to government activity, privacy advocacy groups and technology and other industries are considering various new, additional or different self-regulatory standards that may place additional burden on Jade.</p><a id="JadeBusiness_CoverageReimburse"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Coverage and Reimbursement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which Jade obtains regulatory approval. Sales of any product, if approved, depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement, if any, for such product by third-party payors. Decisions regarding whether to cover any of Jade&#8217;s product candidates, if approved, the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time-consuming and costly process that will require Jade to provide scientific and clinical support for the use of its product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Decreases in third-party reimbursement for any product or a decision by a third-party not to cover a product could reduce physician usage and patient demand for the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. The IRA provides CMS with significant new authorities intended to curb drug costs and to encourage market competition. For the first time, CMS will be able to directly negotiate prescription drug prices and to cap out-of-pocket costs. Each&#160;year, CMS will select and negotiate a preset number of high-spend drugs and biologics that are covered under Medicare Part&#160;B and Part&#160;D that do not have generic or biosimilar competition and have been on the market for many&#160;years (i.e., at least seven&#160;years for drugs and 11&#160;years for biologics). On August&#160;15, 2024, CMS announced the agreed-upon reimbursement prices of the first 10 drugs that were subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. CMS will select up to 15 additional drugs covered under Part&#160;D for price negotiation in 2025. The IRA also provides a new &#8220;inflation rebate&#8221; covering Medicare patients that took effect in 2023 and is intended to counter certain price increases in prescriptions drugs. The inflation rebate provision will require drug manufacturers to pay a rebate to the federal government if the price for a drug or biologic under Medicare Part&#160;B and Part&#160;D increases faster than the rate of inflation. To support biosimilar competition, beginning in October&#160;2022, qualifying biosimilars may receive a Medicare Part&#160;B payment increase for a period of five&#160;years. Separately, if a biologic drug for which no biosimilar exists delays a biosimilar&#8217;s market entry beyond two&#160;years, CMS will be authorized to subject the biologics manufacturer to price negotiations intended to ensure fair competition. Notwithstanding these provisions, the IRA&#8217;s impact on commercialization and competition remains largely uncertain.</p><a id="JadeBusiness_HealthcareReform"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Healthcare Reform</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">256</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For example, the ACA, which was enacted in March&#160;2010, substantially changed the way healthcare is financed by both governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular import to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and Jade expects there will be additional challenges and amendments to the ACA in the future. For example, the IRA, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan&#160;year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part&#160;D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other legislative changes have been proposed and adopted since the ACA was enacted, including automatic aggregate reductions of Medicare payments to providers of on average 2% per fiscal&#160;year as part of the federal budget sequestration under the Budget Control Act of 2011. These reductions went into effect in April&#160;2013 and, due to subsequent legislative amendments, will remain in effect until 2032 unless additional action is taken by Congress. In addition, the Bipartisan Budget Act of 2018, among other things, amended the Medicare Act (as amended by the ACA) to increase the point-of-sale discounts that manufacturers must agree to offer under the Medicare Part&#160;D coverage discount program from 50% to 70% off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs being covered under Medicare Part&#160;D.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state measures designed to, among other things, reduce the cost of prescription drugs, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, in May&#160;2019, CMS adopted a final rule&#160;allowing Medicare Advantage Plans the option to use step therapy for Part&#160;B drugs, permitting Medicare Part&#160;D plans to apply certain utilization controls to new starts of five of the six protected class drugs, and requiring the Explanation of Benefits for Part&#160;D beneficiaries to disclose drug price increases and lower cost therapeutic alternatives, which went into effect on January&#160;1, 2021. In response to the Biden administration&#8217;s October&#160;2022 executive order, on February&#160;14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December&#160;7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December&#160;8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the IRA, continued legislative and enforcement interest exists in the United States with respect to specialty drug pricing practices. Jade expects regulators to continue pushing for transparency to drug pricing, reducing the cost of prescription drugs under Medicare, reviewing the relationship between pricing and manufacturer patient programs, and reforming government program reimbursement methodologies for drugs.</p><a id="JadeBusiness_GovernRegu_Outside_US"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Other Government Regulation Outside of the United States</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to regulations in the United States, Jade is subject to a variety of regulations in other jurisdictions governing, among other things, research and development, clinical trials, testing, manufacturing, safety, efficacy, quality control, labeling, packaging, storage, record keeping, distribution, reporting, export and import, advertising, marketing and other promotional practices involving biological products as well as authorization, approval as well as post-approval monitoring and reporting of its products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Whether or not Jade obtains FDA approval for a product, it must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">257</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The requirements and process governing the conduct of clinical trials, including requirements to conduct additional clinical trials, product licensing, safety reporting, post-authorization requirements, marketing and promotion, interactions with healthcare professionals, pricing and reimbursement may vary widely from country to country. No action can be taken to market any product in a country until an appropriate approval application has been approved by the regulatory authorities in that country. The current approval process varies from country to country, and the time spent in gaining approval varies from that required for FDA approval. In certain countries, the sales price of a product must also be approved. The pricing review period often begins after market approval is granted. Even if a product is approved by a regulatory authority, satisfactory prices may not be approved for such product, which would make launch of such products commercially unfeasible in such countries.</p><a id="JadeBusiness_Regulation_European"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Regulation in the European Union</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">European Data Laws</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The collection and use of personal health data and other personal data in the EU is governed by the provisions of the European General Data Protection Regulation (EU) 2016/679 (GDPR), which came into force in May&#160;2018, and related data protection laws in individual member states of the EU (&#8220;EU Member States&#8221;). The GDPR imposes a number of strict obligations and restrictions on the ability to process, including collecting, analyzing and transferring, personal data of individuals, in particular with respect to health data from clinical trials and adverse event reporting. The GDPR includes requirements relating to the legal basis of the processing (such as consent of the individuals to whom the personal data relates), the information provided to the individuals prior to processing their personal data, the notification obligations to the national data protection authorities, and the security and confidentiality of the personal data. EU Member States may also impose additional requirements in relation to health, genetic and biometric data through their national legislation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the GDPR imposes specific restrictions on the transfer of personal data to countries outside of the EU and in Iceland, Norway and Liechtenstein (together the European Economic Area (&#8220;EEA&#8221;)) that are not considered by the European Commission (&#8220;EC&#8221;) to provide an adequate level of data protection (including the United States). Appropriate safeguards are required to enable such transfers. Among the appropriate safeguards that can be used, the data exporter may use the standard contractual clauses (&#8220;SCCs&#8221;). With regard to the transfer of data from the EEA to the United States, on July&#160;10, 2023, the EC adopted its adequacy decision for the EU-US Data Privacy Framework. On the basis of the new adequacy decision, personal data can flow from the EEA to U.S. companies participating in the framework.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU Member States may result in significant monetary fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater, other administrative penalties and a number of criminal offenses (punishable by uncapped fines) for organizations and, in certain cases, their directors and officers, as well as civil liability claims from individuals whose personal data was processed. Data protection authorities from the different EU Member States may still implement certain variations, enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing personal data in the EU. Guidance developed at both the EU level and at the national level in individual EU Member States concerning implementation and compliance practices are often updated or otherwise revised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, there is a growing trend towards the required public disclosure of clinical trial data in the EU, which adds to the complexity of obligations relating to processing health data from clinical trials. Such public disclosure obligations are provided in the new EU Clinical Trial Regulation (&#8220;CTR&#8221;), EMA disclosure initiatives and voluntary commitments by industry. Failure to comply with these obligations could lead to government enforcement actions and significant penalties against Jade, harm to Jade&#8217;s reputation, and adversely impact its business and operating results. The uncertainty regarding the interplay between different regulatory frameworks, such as the CTR and the GDPR, further adds to the complexity that Jade faces with regard to data protection regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">With regard to the transfer of data from the EU to the United Kingdom (&#8220;UK&#8221;), personal data may freely flow from the EU to the UK since the UK is deemed to have an adequate data protection level. However, the adequacy decisions include a &#8216;sunset clause&#8217; which entails that the decisions will automatically expire in 2025 (four&#160;years after their entry into force). Additionally, following the UK&#8217;s withdrawal from the EU and the EEA, companies also have to comply with the UK&#8217;s data protection laws (including the GDPR, as incorporated into UK national law), the latter regime having the ability to separately fine up to the greater of &#163;17.5 million or 4% of global turnover.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">258</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the UK&#8217;s withdrawal from the EU and the EEA, companies are subject to specific transfer rules&#160;under the UK regime; personal data may flow freely from the UK to the EEA, since the EEA is deemed to have an adequate data protection level for purposes of the UK regime. These UK international transfer rules&#160;broadly mirror the GDPR rules. On February&#160;2, 2022, the UK Secretary of State laid before the UK Parliament the international data transfer agreement (&#8220;IDTA&#8221;) and the international data transfer addendum to the EC&#8217;s standard contractual clauses for international data transfers (the &#8220;IDTA Addendum&#8221;) and a document setting out transitional provisions. The IDTA and IDTA Addendum came into force on March&#160;21, 2022 and replaced the old SCCs for the purposes of the UK regime.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">With regard to the transfer of personal data from the UK to the United States, the UK government has adopted an adequacy decision for the United States (the &#8220;UK-US Data Bridge&#8221;), which came into force on October&#160;12, 2023. The UK-US Data Bridge recognizes the United States as offering an adequate level of data protection where the transfer is to a U.S. company participating in the EU-US Data Privacy Framework and the UK Extension to the EU-US Data Privacy Framework.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Drug and Biologic Development Process</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Regardless of where they are conducted, all clinical trials included in applications for marketing authorization for human medicines in the EU/EEA must have been carried out in accordance with EU regulations. This means that clinical trials conducted in the EU/EEA have to comply with EU clinical trial legislation but also that clinical trials conducted outside the EU/EEA have to comply with ethical principles equivalent to those set out in the EEA, including adhering to international good clinical practice and the Declaration of Helsinki. The conduct of clinical trials in the EU is governed by the EU CTR (EU) No.&#160;536/2014, which entered into force on January&#160;31, 2022. The CTR replaced the Clinical Trials Directive 2001/20/EC (&#8220;Clinical Trials Directive&#8221;) and introduced a complete overhaul of the existing regulation of clinical trials for medicinal products in the EU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the former regime, which will expire after a transition period of three&#160;years, as outlined below in more detail, before a clinical trial can be initiated it must be approved in each EU member state where there is a site at which the clinical trial is to be conducted. The approval must be obtained from two separate entities: the National Competent Authority (&#8220;NCA&#8221;) and one or more Ethics Committees. The NCA of the EU Member States in which the clinical trial will be conducted must authorize the conduct of the trial, and the independent Ethics Committee must grant a positive opinion in relation to the conduct of the clinical trial in the relevant EU member state before the commencement of the trial. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be submitted to or approved by the relevant NCA and Ethics Committees. Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial must be reported to the NCA and to the Ethics Committees of the EU member state where they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A more unified procedure will apply under the new CTR. A sponsor will be able to submit a single application for approval of a clinical trial through a centralized EU clinical trials portal. One national regulatory authority (the reporting EU member state proposed by the applicant) will take the lead in validating and evaluating the application and consult and coordinate with the other concerned EU Member States. If an application is rejected, it may be amended and resubmitted through the EU clinical trials portal. If an approval is issued, the sponsor may start the clinical trial in all concerned EU Member States. However, a concerned EU member state may in limited circumstances declare an &#8220;opt-out&#8221; from an approval and prevent the clinical trial from being conducted in such member state. The CTR also aims to streamline and simplify the rules&#160;on safety reporting, and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU Database. The CTR foresees a three-&#160;year transition period. EU Member States will work in CTIS immediately after the system has gone live. Since January&#160;31, 2023, submission of initial clinical trial applications via CTIS is mandatory, and by January&#160;31, 2025, all ongoing trials approved under the former Clinical Trials Directive will need to comply with the CTR and have to be transitioned to CTIS. On July&#160;19, 2023, the EC published guidance concerning the steps to be taken in this transition. This guidance provides, among other things, that (i)&#160;documentation which was previously assessed will not be reassessed, (ii)&#160;templates that were developed and endorsed by the EU Clinical Trials Expert Group to provide compliance with the CTR do not need to be updated and (iii) <span style="color:#231f20;">there is no need to retrospectively create a site suitability form, which are only necessary for new trial sites.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under both the former regime and the new CTR, national laws, regulations, and the applicable GCP and GLP standards must also be respected during the conduct of the trials, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use guidelines on GCP and the ethical principles that have their origin in the Declaration of Helsinki.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">During the development of a medicinal product, the EMA and national regulators within the EU provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) on the recommendation of the Scientific Advice Working </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">259</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Party. A fee is incurred with each scientific advice procedure, but is significantly reduced for designated orphan medicines. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk-management programs. Advice is not legally binding with regard to any future Marketing Authorization Application (&#8220;MAA&#8221;) of the product concerned.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Drug Marketing Authorization</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the European Union, medicinal products, including advanced therapy medicinal products (&#8220;ATMPs&#8221;) are subject to extensive pre- and post-market regulation by regulatory authorities at both the European Union and national levels. ATMPs comprise gene therapy products, somatic cell therapy products and tissue engineered products, which are genes, cells or tissues that have undergone substantial manipulation and that are administered to human beings in order to cure, diagnose or prevent diseases or regenerate, repair or replace a human tissue. Pursuant to the ATMP regulation, the Committee on Advanced Therapies (&#8220;CAT&#8221;) is responsible in conjunction with the CHMP for the evaluation of ATMPs. The CHMP and CAT are also responsible for providing guidelines on ATMPs. These guidelines provide additional guidance on the factors that the EMA will consider in relation to the development and evaluation of ATMPs and include, among other things, the preclinical studies required to characterize ATMPs manufacturing and control information that should be submitted in the EU/EEA, after completion of all required clinical testing, pharmaceutical products may only be placed on the market after obtaining a Marketing Authorization (&#8220;MA&#8221;). To obtain an MA of a drug under European Union regulatory systems, an applicant can submit a MAA through, amongst others, a centralized or decentralized procedure. Although such guidelines are not legally binding, compliance with them is often necessary to gain and maintain approval for product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the mandatory Risk Management Plan (&#8220;RMP&#8221;), the holder of a MA for an ATMP must put in place and maintain a system to ensure that each individual product and its starting and raw materials, including all substances coming into contact with the cells or tissues it may contain, can be traced through the sourcing, manufacturing, packaging, storage, transport and delivery to the relevant healthcare institution where the product is used.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To be used or sold in the UK, a drug must have an effective MA obtained by a centralized application through EMA or a national application. National applications are governed by the Human Medicines Regulations (SI 2012/1916). Applications are made electronically through the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) Submissions Portal. The process from application to authorizations generally takes up to 210&#160;days, excluding time taken to provide any additional information or data required by the MHRA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August&#160;30, 2023, the MHRA published detailed guidance on its recently announced new International Reliance Procedure (&#8220;IRP&#8221;) for MAAs. The IRP applies since January&#160;1, 2024 and replaces existing EU reliance procedures to apply for authorizations from seven international regulators (e.g., Health Canada, Swissmedic, FDA, EMA, among others). The IRP allows medicinal products approved in other jurisdictions that meet certain criteria to undergo a fast-tracked MHRA review to obtain and/or update a MA in the UK or Great Britain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Applicants can submit initial MAAs to the IRP but the procedure can also be used throughout the lifecycle of a product for post-authorization procedures including line extensions, variations and renewals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Centralized Authorization Procedure</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The centralized procedure provides for the grant of a single MA that is issued by the EC following the scientific assessment of the application by the EMA that is valid for all EU Member States as well as in the three additional EEA member states. The centralized procedure is compulsory for certain types of medicinal products, including for medicines developed by means of certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products (&#8220;ATMP&#8221;) and medicinal products with a new active substance indicated for the treatment of certain diseases (AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases). For medicinal products containing a new active substance not yet authorized in the EEA before May&#160;20, 2004 and indicated for the treatment of other diseases, medicinal products that constitute significant therapeutic, scientific or technical innovations or for which the grant of a MA through the centralized procedure would be in the interest of public health at EU level, an applicant may voluntarily submit an application for a marketing authorization through the centralized procedure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Under the centralized procedure, the CHMP established at the EMA, is responsible for conducting the initial assessment of a drug. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">260</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">or extensions to an existing marketing authorization. Under the centralized procedure, the timeframe for the evaluation of an MAA by the EMA&#8217;s CHMP is, in principle, 210&#160;days from receipt of a valid MAA. However, this timeline excludes clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP, so the overall process typically takes a&#160;year or more, unless the application is eligible for an accelerated assessment. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. Upon request, the CHMP can reduce the time frame to 150&#160;days if the applicant provides sufficient justification for an accelerated assessment. The CHMP will provide a positive opinion regarding the application only if it meets certain quality, safety and efficacy requirements. This opinion is then transmitted to the EC, which has the ultimate authority for granting MA within 67&#160;days after receipt of the CHMP opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Decentralized Authorization Procedure</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Medicines that fall outside the mandatory scope of the centralized procedure have three routes to authorization: (i)&#160;they can be authorized under the centralized procedure if they concern a significant therapeutic, scientific or technical innovation, or if their authorization would be in the interest of public health; (ii)&#160;they can be authorized under a decentralized procedure where an applicant applies for simultaneous authorization in more than one EU member state; or (iii)&#160;they can be authorized in an EU member state in accordance with that state&#8217;s national procedures and then be authorized in other EU countries by a procedure whereby the countries concerned agree to recognize the validity of the original, national marketing authorization (mutual recognition procedure).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The decentralized procedure permits companies to file identical MA applications for a medicinal product to the competent authorities in various EU Member States simultaneously if such medicinal product has not received marketing approval in any EU Member State before. This procedure is available for pharmaceutical products not falling within the mandatory scope of the centralized procedure. The competent authority of a single EU Member State, the reference member state, is appointed to review the application and provide an assessment report. The competent authorities of the other EU Member States, the concerned member states, are subsequently required to grant a marketing authorization for their territories on the basis of this assessment. The only exception to this is where the competent authority of an EU Member State considers that there are concerns of potential serious risk to public health, the disputed points are subject to a dispute resolution mechanism and may eventually be referred to the EC, whose decision is binding for all EU Member States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk Management Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All new MAAs must include a RMP describing the risk management system that a company will put in place and documenting measures to prevent or minimize the risks associated with the product. RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available. An updated RMP must be submitted: (i)&#160;at the request of EMA or a national competent authority, or (ii)&#160;whenever the risk-management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit-risk profile or as a result of an important pharmacovigilance or risk-minimization milestone being reached. The regulatory authorities may also impose specific obligations as a condition of the MA. Since October&#160;20, 2023, all RMPs for centrally authorized products are published by the EMA, subject only to limited redactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">MA Validity Period</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Marketing Authorizations have an initial duration of five&#160;years. After these five&#160;years, the authorization may subsequently be renewed on the basis of a reevaluation of the risk-benefit balance. Once renewed, the MA is valid for an unlimited period unless the EC or the national competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with only one additional five-year renewal. Applications for renewal must be made to the EMA at least nine&#160;months before the five-year period expires.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, the holder of a MA for an ATMP must put in place and maintain a system to ensure that each individual product and its starting and raw materials, including all substances coming into contact with the cells or tissues it may contain, can be traced through the sourcing, manufacturing, packaging, storage, transport and delivery to the relevant healthcare institution where the product is used.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any authorization which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market of the authorizing member state within three&#160;years after authorization ceases to be valid.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">261</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the UK, the period of three&#160;years during which the drug has not been marketed in Great Britain will be restarted from the date of conversion to a Great Britain MA. Conversion refers to the procedure by which, as of January&#160;1, 2021, MAs granted on the basis of a centralized procedure in the EU are only valid in Northern Ireland but not in Great Britain, whereas, prior EU authorizations have all been automatically converted into UK MAs effective in Great Britain only.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On the other hand, for the EU, in the case the drug has been marketed in the UK, the placing on the UK market before the end of the period starting when the UK left the EU on January&#160;31, 2020 and ending on December&#160;31, 2020 (the &#8220;Brexit Transition Period&#8221;) will be taken into account. If, after the end of the Brexit Transition Period, the drug is not placed on any other market of the remaining EU Member States, the three-year period will start running from the last date the drug was placed on the UK market before the end of the Brexit Transition Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Exceptional Circumstances/Conditional Approval</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Similar to accelerated approval regulations in the United States, conditional MAs can be granted in the EU in exceptional circumstances. A conditional MA can be granted for medicinal products where, although comprehensive clinical data referring to the safety and efficacy of the medicinal product have not been supplied, a number of criteria are fulfilled: (i)&#160;the benefit/risk balance of the product is positive, (ii)&#160;it is likely that the applicant will be in a position to provide the comprehensive clinical data, (iii)&#160;unmet medical needs will be fulfilled by the grant of the MA and (iv)&#160;the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional MA must be renewed annually.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Data and Market Exclusivity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As in the United States, it may be possible to obtain a period of market and / or data exclusivity in the EU that would have the effect of postponing the entry into the marketplace of a competitor&#8217;s generic, hybrid or biosimilar product (even if the pharmaceutical product has already received a MA) and prohibiting another applicant from relying on the MA holder&#8217;s pharmacological, toxicological and clinical data in support of another MA for the purposes of submitting an application, obtaining MA or placing the product on the market. New Chemical Entities (&#8220;NCEs&#8221;) approved in the EU qualify for eight&#160;years of data exclusivity and 10&#160;years of marketing exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An additional non-cumulative one-year period of marketing exclusivity is possible if during the data exclusivity period (the first eight&#160;years of the 10-year marketing exclusivity period), the MA holder obtains an authorization for one or more new therapeutic indications that are deemed to bring a significant clinical benefit compared to existing therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The data exclusivity period begins on the date of the product&#8217;s first MA in the EU. After eight&#160;years, a generic product application may be submitted and generic companies may rely on the MA holder&#8217;s data. However, a generic product cannot launch until two&#160;years later (or a total of 10&#160;years after the first MA in the EU of the innovator product), or three&#160;years later (or a total of 11&#160;years after the first MA in the EU of the innovator product) if the MA holder obtains MA for a new indication with significant clinical benefit within the eight-year data exclusivity period. Additionally, another noncumulative one-year period of data exclusivity can be added to the eight&#160;years of data exclusivity where an application is made for a new indication for a well-established substance, provided that significant preclinical or clinical studies were carried out in relation to the new indication. Another&#160;year of data exclusivity may be added to the eight&#160;years, where a change of classification of a pharmaceutical product has been authorized on the basis of significant pre- trial tests or clinical trials (when examining an application by another applicant for or holder of market authorization for a change of classification of the same substance the competent authority will not refer to the results of those tests or trials for one&#160;year after the initial change was authorized).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Products may not be granted data exclusivity since there is no guarantee that a product will be considered by the European Union&#8217;s regulatory authorities to include an NCE. Even if a compound is considered to be a NCE and the MA applicant is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the medicinal product if such company can complete a full MAA with their own complete database of pharmaceutical tests, preclinical studies and clinical trials and obtain MA of its product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April&#160;26, 2023, the EC submitted a proposal for the reform of the European pharmaceutical legislation. The current draft envisages, e.g., a shortening of the periods of data exclusivity; however, there is currently neither a final version of this draft nor a date for its entry into force.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">262</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Pediatric Development</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the EU, companies developing a new medicinal product are obligated to study their product in children and must therefore submit a pediatric improvement plan (&#8220;PIP&#8221;) together with a request for agreement to the EMA. The EMA issues a decision on the PIP based on an opinion of the EMA&#8217;s Pediatric Committee. Companies must conduct pediatric clinical trials in accordance with the PIP approved by the EMA, unless a deferral (e.g., until enough information to demonstrate its effectiveness and safety in adults is available) or waiver (e.g., because the relevant disease or condition occurs only in adults) has been granted by the EMA. The MAA for the medicinal product must include the results of all pediatric clinical trials performed and details of all information collected in compliance with the approved PIP, unless a waiver or a deferral has been granted, in which case the pediatric clinical trials may be completed at a later date. Medicinal products that are granted an MA on the basis of the pediatric clinical trials conducted in accordance with the approved PIP are eligible for a six-month extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval) or, in the case of orphan medicinal products, a two-&#160;year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the approved PIP are developed and submitted. An approved PIP is also required when a MA holder wants to add a new indication, medicinal form or route of administration for a medicine that is already authorized and covered by intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the UK, the MHRA has published guidance on the procedures for UK PIPs which, where possible, mirror the submission format and requirements of the EU system. EU PIPs remain applicable for Northern Ireland and EU PIPs agreed by the EMA prior to January&#160;1, 2021 have been adopted as UK PIPs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">PRIME Designation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The Priority Medicines (&#8220;PRIME&#8221;) scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small- and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies on the basis of compelling non-clinical data and tolerability data from initial clinical trials. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, once a candidate medicine has been selected for the PRIME scheme, a dedicated contact point and rapporteur from the CHMP or from CAT are appointed facilitating increased understanding of the product at EMA&#8217;s Committee level. A kick-off meeting with the CHMP/CAT rapporteur initiates these relationships and includes a team of multidisciplinary experts to provide guidance on the overall development plan and regulatory strategy. PRIME eligibility does not change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Post-Approval Regulation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the EC and/or the competent regulatory authorities of the EU Member States. This oversight applies both before and after grant of manufacturing licenses and marketing authorizations. It includes control of compliance with EU good manufacturing practices rules, manufacturing authorizations, pharmacovigilance rules&#160;and requirements governing advertising, promotion, sale, and distribution, recordkeeping, importing and exporting of medicinal products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Failure by Jade or by any of its third-party partners, including suppliers, manufacturers and distributors to comply with EU laws and the related national laws of individual EU Member States governing the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of MA, statutory health insurance, bribery and anti-corruption or other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The holder of MA for a medicinal product must also comply with EU pharmacovigilance legislation and its related regulations and guidelines, which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of medicinal products.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">263</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These pharmacovigilance rules&#160;can impose on holders of MAs the obligation to conduct a labor intensive collection of data regarding the risks and benefits of marketed medicinal products and to engage in ongoing assessments of those risks and benefits, including the possible requirement to conduct additional clinical studies or post-authorization safety studies to obtain further information on a medicine&#8217;s safety, or to measure the effectiveness of risk-management measures, which may be time consuming and expensive and could impact Jade&#8217;s profitability. MA holders must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of Periodic Safety Update Reports (&#8220;PSURs&#8221;) in relation to medicinal products for which they hold MAs. The EMA reviews PSURs for medicinal products authorized through the centralized procedure. If the EMA has concerns that the risk benefit profile of a product has varied, it can adopt an opinion advising that the existing MA for the product be suspended, withdrawn or varied. The agency can advise that the MA holder be obliged to conduct post-authorization Phase 4 safety studies. If the EC agrees with the opinion, it can adopt a decision varying the existing MA. Failure by the MA holder to fulfill the obligations for which the EC&#8217;s decision provides can undermine the ongoing validity of the MA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">More generally, non-compliance with pharmacovigilance obligations can lead to the variation, suspension or withdrawal of the MA for the product or imposition of financial penalties or other enforcement measures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The manufacturing process for pharmaceutical products in the European Union is highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice. These requirements include compliance with EU GMP standards when manufacturing pharmaceutical products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the European Union with the intention to import the active pharmaceutical ingredients into the European Union. Similarly, the distribution of pharmaceutical products into and within the European Union is subject to compliance with the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of the EU Member States. The manufacturer or importer must have a qualified person who is responsible for certifying that each batch of product has been manufactured in accordance with GMP, before releasing the product for commercial distribution in the European Union or for use in a clinical trial. Manufacturing facilities are subject to periodic inspections by the competent authorities for compliance with GMP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Sales and Marketing Regulations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The advertising and promotion of Jade&#8217;s products is also subject to EU laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. In addition, other national legislation of individual EU Member States may apply to the advertising and promotion of medicinal products and may differ from one country to another. These laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s summary of product characteristics (&#8220;SmPC&#8221;) as approved by the competent regulatory authorities. The SmPC is the document that provides information to physicians concerning the safe and effective use of the medicinal product. It forms an intrinsic and integral part of the marketing authorization granted for the medicinal product. Promotion of a medicinal product that does not comply with the SmPC is considered to constitute off-label promotion. All advertising and promotional activities for the product must be consistent with the approved SmPC and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription-only medicines is also prohibited in the EU. Violations of the rules&#160;governing the promotion of medicinal products in the European Union could be penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising and promotion of Jade&#8217;s products to the general public and may also impose limitations on its promotional activities with healthcare professionals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">EU regulation with regards to dispensing, sale and purchase of medicines has generally been preserved in the UK following Brexit, through the Human Medicines Regulations 2012. However, organizations wishing to sell medicines online need to register with the MHRA. Following Brexit, the requirements to display the common logo no longer apply to UK-based online sellers, except for those established in Northern Ireland.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Anti-Corruption Legislation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the EU, interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct both at EU level and in the individual EU Member States. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">264</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">purchase, supply, order or use of medicinal products is prohibited in the European Union. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of the EU Member States. Violation of these laws could result in substantial fines and imprisonment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Payments made to physicians in certain EU Member States also must be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician&#8217;s employer, his/her regulatory professional organization, and/or the competent authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the individual EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the UK, the pharmaceutical sector is recognized as being particularly vulnerable to corrupt practices, some of which fall within the scope of the Bribery Act 2010. Due to the Bribery Act 2010&#8217;s far-reaching territorial application, the potential penalized act does not have to occur in the UK to become within its scope. If the act or omission does not take place in the UK, but the person&#8217;s act or omission would constitute an offense if carried out there and the person has a close connection with the UK, an offense will still have been committed. The Bribery Act 2010 is comprised of four offenses that cover (i)&#160;individuals, companies and partnerships that give, promise or offer bribes, (ii)&#160;individuals, companies and partnerships that request, agree to receive or accept bribes, (iii)&#160;individuals, companies and partnerships that bribe foreign public officials, and (iv)&#160;companies and partnerships that fail to prevent persons acting on their behalf from paying bribes. The penalties imposed under the Bribery Act 2010 depend on the offence committed, harm and culpability and penalties range from unlimited fines to imprisonment for a maximum term of 10&#160;years and in some cases both.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Regulations in the UK and Other Markets</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The UK formally left the EU on January&#160;31, 2020 and the transition period, during which EU laws continued to apply to the UK, expired on December&#160;31, 2020. This means EU laws now only apply to the UK in respect of Northern Ireland as laid out in the Protocol on Ireland and Northern Ireland. Following the end of the transition period, the EU and the UK concluded the TCA, which applied provisionally from January&#160;1, 2021 and entered into force on May&#160;1, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The TCA includes provisions affecting the life sciences sector (including on customs and tariffs) but areas for further discussion between the EU and the UK remain. Some specific provisions concerning pharmaceuticals are in place, including the mutual recognition of GMP and issued GMP documents. The TCA does not, however, contain wholesale mutual recognition of UK and EU pharmaceutical regulations and product standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since January&#160;1, 2021, the EU laws which have been transposed into UK law through secondary legislation continue to be applicable in the UK as &#8220;retained EU law.&#8221; As there is no general power to amend these regulations, the UK government has enacted the Medicines and Medical Devices Act 2021. The purpose of the act is to enable the existing regulatory frameworks in relation to human medicines, clinical trials of human medicines, veterinary medicines and medical devices to be updated. The powers under the act may only be exercised in relation to specified matters and must safeguard public health.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Specified provisions of the Medicines and Medical Devices Act 2021 entered into force on February&#160;11, 2021. The remaining provisions came into effect within two&#160;months of February&#160;11, 2021 or will otherwise come into effect as stipulated in subsequent statutory instruments. The Medicines and Medical Devices Act 2021 supplements the UK Medical Devices Regulations 2002 (the &#8220;UK Regulations&#8221;), which are based on the EU Medical Devices Directive as amended to reflect the UK&#8217;s post-Brexit regulatory regime. Notably, the UK Regulations do not include any of the revisions that have been made by the EU Medical Devices Regulation (EU) 2017/745, which, since May&#160;26, 2021, now applies in all EU Member States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For other countries outside of the European Union, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Jade fails to comply with applicable foreign regulatory requirements, it may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">265</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Regulation of Medicinal Products in Australia</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Australian Therapeutic Goods Administration (&#8220;TGA&#8221;) and the National Health and Medical Research Council (&#8220;NHMRC&#8221;) set the GCP requirements for clinical research in Australia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Compliance with the regulations, standards and codes set by the TGA and NHMRC is mandatory. Under the Therapeutic Goods Act 1989 (Cth) and the Therapeutic Goods Regulations 1990 (Cth), it is a condition (amongst other conditions) of all clinical trials involving investigational medicinal products to comply with the National Statement on Ethical Conduct in Research Involving Humans, published by the NHMRC (the &#8220;National Statement&#8221;), and the Guideline for Good Clinical Practice published by the International Council for Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (&#8220;ICH Guidelines&#8221;). The ICH Guidelines have been adopted in Australia and must be complied with across all fields of clinical research involving therapeutic goods, including those related to pharmaceutical quality, nonclinical and clinical data requirements and trial designs. The basic requirements for preclinical data to support a first-in-human trial under ICH Guidelines are applicable in Australia. Requirements related to adverse event reporting in Australia are generally similar to those required in other major jurisdictions, although reporting timeframes may differ to other jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trials conducted using &#8220;unapproved therapeutic goods&#8221; in Australia, being those which have not yet been evaluated by the TGA for quality, safety and efficacy (and including unapproved indications of therapeutic goods which have otherwise been approved for use in Australia) must occur pursuant to either the Clinical Trial Notification Scheme (&#8220;CTN Scheme&#8221;) or the Clinical Trial Approval Scheme (&#8220;CTA Scheme&#8221;). In each case, the trial is supervised by a Human Research Ethics Committee (&#8220;HREC&#8221;), an independent review committee constituted in accordance with the National Statement that ensures the protection of rights, safety and well-being of human subjects involved in a clinical trial. An HREC reviews, approves and provides continuing oversight of trial protocols (including any amendments), methods and materials intended to be used in obtaining and documenting informed consent of the clinical trial subjects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The CTN Scheme broadly involves:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to an HREC, of all material relating to the proposed clinical trial, including the trial protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the HREC reviews the scientific validity of the trial design, the balance of risk versus harm of the therapeutic good, the ethical acceptability of the trial process, and approves the trial protocol. The HREC is also responsible for monitoring the conduct of the trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the institution or organization at which the trial will be conducted (the &#8220;Approving Authority&#8221;) giving final approval for the conduct of the trial at the site, in terms no less restrictive to those advised by the HREC; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the investigator submitting a &#8216;Notification of Intent to Conduct a Clinical Trial&#8217; form (&#8220;CTN Form&#8221;) to the TGA. The CTN Form&#160;must be signed by the sponsor, the principal investigator, the chairman of the HREC and a person responsible from the Approving Authority. The TGA does not review any data relating to the clinical trial however CTN trials cannot commence until the trial </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">has been notified to the TGA. It is the responsibility of the sponsor to ensure that all relevant </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approvals</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> are in place before supplying the &#8220;unapproved&#8221; therapeutic goods in clinical trials in Australia.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the CTA Scheme:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a sponsor submits an application to conduct a clinical trial to the TGA for evaluation and comment, which includes payment of relevant fees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the TGA will undertake a preliminary assessment to ensure that there is sufficient data to begin evaluation. If critical data is missing, the TGA may request further information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a sponsor must forward any comments made by the TGA delegate to the HREC(s)&#160;at the sites where the trial will be conducted;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the HREC is responsible for considering the scientific and ethical issues of the proposed trial protocol.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">266</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A sponsor cannot commence a trial under the CTA Scheme until written advice has been received from the TGA regarding the application and approval for the conduct of the trial has been obtained from an ethics committee and the institution at which the trial will be conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Approval for inclusion in the Australian Register of Therapeutic Goods (&#8220;ARTG&#8221;) is required before a therapeutic good (including pharmaceutical product) may be marketed (or supplied, imported, exported or manufactured) in Australia. Exceptions apply to therapeutic goods/pharmaceutical products that are supplied, imported, and exported to and from Australia for the purposes of a clinical trial, on the basis that certain conditions are met (e.g., the trial is conducted in accordance with the CTN or CTA Scheme).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Once a sponsor decides to register a therapeutic good/pharmaceutical product in Australia, in order to obtain registration of the product on the ARTG, it is required that (amongst others):</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sponsor submits appropriate documentation, including the outcomes of clinical trials and studies, to allow the TGA to assess the quality, safety and efficacy of the therapeutic product/ pharmaceutical product; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sponsor submits evidence which demonstrates that the manufacture of the therapeutic product/ pharmaceutical product complies with the applicable GMP requirements.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The TGA has the ultimate discretion to decide whether to include the therapeutic product/ pharmaceutical product in the ARTG.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Regulation of Medical Products in New Zealand</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trials in New Zealand are regulated under the Medicines Act 1981 (&#8220;Medicines Act&#8221;) and Medicines Regulations 1984.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical trial requirements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The New Zealand Medicines and Medical Devices Safety Authority (&#8220;Medsafe&#8221;) is the regulatory authority that administers the application and approval process for medicines and clinical trials in New Zealand (under delegation from the Director-General of Health). Approval from Medsafe is required in the following two circumstances:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">before a medicine can be distributed in New Zealand&#8201;&#8212;&#8201;see &#8220;Approval for distribution&#8221; below; however, there is an exemption from this approval requirement for medicines that are imported or manufactured for the sole purpose of use in a clinical trial (including pharmacokinetic, bioequivalence and first-in-human studies); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for all clinical trials involving unapproved medicines carried out in New Zealand; however, if a medicine is already approved by Medsafe for distribution in New Zealand, then there is no separate requirement to obtain approval for clinical trials with that medicine (including if the medicine is being tested for a use not provided for under its existing authorization).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Medsafe also expects all clinical trials to be carried out in accordance with internationally accepted standards for good clinical practice as published by the EMA in its Guideline for Good Clinical Practice, to the extent that these standards are compatible with the Medicines Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical trial approval process</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The clinical trial approval process requires submission of an online application to Medsafe. The application must include information about the nature of the medicine, the purpose of the trial, details of the investigators conducting the trial, written consent to nomination from each investigator, copies of information supplied to the investigators, a protocol of the trial, and details of the sites and facilities used. The application must be made by the actual or intended importer, manufacturer, packer, or supplier of the medicine in New Zealand. Once approved, the applicant becomes the &#8220;sponsor&#8221; and assumes responsibility and legal liability for the trial in New Zealand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Once an application is received, Medsafe provides it to the Health Research Council of New Zealand (&#8220;HRC&#8221;). One of two HRC standing committees will consider the application and make a recommendation to Medsafe as to whether the clinical trial should be approved (with or without conditions) or declined. The Standing Committee on Therapeutic Trials considers pharmaceutical medicine trial applications, while the Gene Technology Advisory Committee considers applications for trials involving gene and other biotechnology therapies. Both standing committees undertake a similar scientific assessment process, and consider factors such as trial </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">267</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">protocol and design, data collection, and general compliance with the Guideline for Good Practice before making a recommendation to Medsafe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Ethical requirements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Medsafe expects all clinical trials to be approved by the Health and Disability Ethics Committee (&#8220;HDEC&#8221;), regardless of whether Medicines Act approval is required. HDEC reviews and approves applications and provides ongoing oversight of clinical trials to ensure alignment with good ethical practice. HDEC approval can be sought before, during, or after Medicines Act approval is sought from Medsafe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Registration</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A clinical trial&#8217;s sponsor may register a trial with the Australian New Zealand Clinical Trials Registry (&#8220;ANZCTR&#8221;), an online public registry of clinical trials undertaken in New Zealand, Australia, and elsewhere. While not mandatory, the ANZCTR is a recognized part of the World Health Organisation Registry Network and registration is encouraged by the World Health Organisation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Approval for distribution</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a sponsor decides to distribute the new medicine product in New Zealand after the clinical trial, the sponsor must apply for distribution approval. This is separate to the approval process for clinical trials and involves submitting an application to Medsafe for consideration. Medsafe assesses the safety, efficacy, quality and risk profile of the medicine, and makes a recommendation to the Minister of Health as to whether the medicine should be approved for distribution (in practice, the Minister follows Medsafe&#8217;s recommendation).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Properties and Facilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade is a fully remote company and does not maintain physical corporate offices. Jade believes this arrangement supports its current and near-term future anticipated needs. For administrative purposes, Jade maintains a mailing address at 221 Crescent St., Building 23, Suite&#160;105, Waltham, MA. As Jade expands, it believes that suitable additional alternative spaces will be available in the future on commercially reasonable terms, if required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">From time to time, Jade may be involved in legal proceedings arising in the ordinary course of its business. Jade is not presently a party to or aware of any legal proceedings that, in the opinion of management, would have, individually or in the aggregate, a material adverse effect on its business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on Jade due to defense and settlement costs, diversion of management resources, negative publicity and reputational harm, and other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">268</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_22de474d_7f24_4bd1_ae80_5a9ec9afe227"></a><a id="AEROVATEMANAGEMENTSDISCUSSIONANDANALYSIS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AEROVATE MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following discussion and analysis of Aerovate&#8217;s financial condition and results of operations should be read in conjunction with Aerovate&#8217;s unaudited condensed consolidated financial statements and related notes appearing elsewhere in this proxy statement/prospectus and with the audited consolidated financial statements and related notes included in Aerovate&#8217;s Annual Report on Form&#160;10-K for the fiscal&#160;year ended December&#160;31, 2023, filed with the Securities and Exchange Commission on March&#160;25, 2024. This discussion contains forward- looking statements that reflect Aerovate&#8217;s plans, estimates and beliefs, and involve risks and uncertainties. Aerovate&#8217;s actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those discussed in the section titled &#8220;Risk Factors&#8221; beginning on page&#160;</i><span style="font-style:italic;">24</span><i style="font-style:italic;"> of this proxy statement/prospectus and elsewhere in this proxy statement/ prospectus. Please see the section titled &#8220;Cautionary Note&#160;Regarding Forward-Looking Statements&#8221; beginning on page&#160;</i><span style="font-style:italic;">93</span><i style="font-style:italic;"> of this proxy statement/prospectus.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate is a biopharmaceutical company. Aerovate&#8217;s initial focus was on advancing AV-101, Aerovate&#8217;s dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (&#8220;PAH&#8221;), a devastating disease impacting approximately 70,000 people in the United States and Europe. On June&#160;17, 2024, Aerovate announced topline results from the Phase 2b portion of its Phase 2b/Phase 3 Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial of AV-101 (&#8220;IMPAHCT&#8221;). Topline data showed that, while AV-101 was generally well tolerated across all dose groups, the study did not meet its primary endpoint for improvement in pulmonary vascular resistance compared to placebo for any of the studied doses or show meaningful improvements in the secondary endpoint of change in six-minute walk distance. Aerovate also reviewed data from several additional secondary endpoints of the Phase 2b portion of IMPAHCT, which also failed to show meaningful improvements. Based upon these results and in agreement with the independent study advisory committee, Aerovate halted enrollment and shut down the Phase 3 portion of IMPAHCT as well as the long-term extension study. AV-101 for the treatment of PAH was Aerovate&#8217;s only product candidate in development. Aerovate does not intend to resume development of AV-101 or any other product candidates. In July&#160;2024, Aerovate announced the decision to conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value. Aerovate also engaged Wedbush Securities&#160;Inc. as its exclusive strategic financial advisor to assist in the process of exploring strategic alternatives, which may include but are not limited to, an acquisition, merger, reverse merger, business combination, liquidation or other transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Developments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2024, following Aerovate&#8217;s decision to halt further development of AV-101, Aerovate announced its plan to terminate nearly all of its workforce in the coming&#160;months (the &#8220;Workforce Reduction Plan&#8221;). As of September&#160;30, 2024, 46 individuals, or approximately 90% of Aerovate&#8217;s workforce, have been terminated. The affected individuals have been and will be provided severance benefits, including cash severance payments. Each affected individual&#8217;s eligibility for severance benefits is contingent upon entering into a separation agreement, which includes a general release of claims against Aerovate. In connection with the Workforce Reduction Plan, Aerovate incurred costs (in consideration of releases) of approximately $6.4 million, which are primarily one-time severance benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October&#160;30, 2024, Aerovate entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), by and among Aerovate, Caribbean Merger Sub I,&#160;Inc., a Delaware corporation and Aerovate&#8217;s wholly owned subsidiary (&#8220;Merger Sub I&#8221;), Caribbean Merger Sub II, LLC, a Delaware limited liability company and Aerovate&#8217;s wholly owned subsidiary (&#8220;Merger Sub II,&#8221; and together with Merger Sub I, &#8220;Merger Subs&#8221;), and Jade Biosciences,&#160;Inc., a Delaware corporation (&#8220;Jade&#8221;), pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, among other things, Merger Sub I will merge with and into Jade, with Jade surviving as a wholly owned subsidiary of Aerovate and the surviving corporation of the merger (the &#8220;First Merger&#8221;), and as part of the same overall transaction, Jade will merge with and into Merger Sub II, with Merger Sub II continuing as Aerovate&#8217;s wholly owned subsidiary and the surviving entity of the merger (the &#8220;Second Merger,&#8221; and together with the First Merger, the &#8220;Merger&#8221;). The Merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, in connection with the closing of the Merger (the &#8220;Closing&#8221;), Aerovate expects to declare a pre-Closing special cash dividend (the &#8220;Cash Dividend&#8221;) to its pre-Merger stockholders of approximately $65.0 million in the aggregate, provided such amount is subject to adjustment as set forth in the Merger Agreement.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">269</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger (the &#8220;Effective Time&#8221;), (a)&#160;each then-outstanding share of Jade common stock, par value $0.0001 per share (including shares of Jade common stock issued in the Jade Pre-Closing Financing), will be converted into the right to receive a number of shares of Aerovate common stock, par value $0.0001 per share, based on a ratio calculated in accordance with the Merger Agreement (the &#8220;Exchange Ratio&#8221;), provided that any unvested restricted shares of Jade common stock will be subject to the same terms and conditions (including, without limitation, vesting and repurchase provisions) that are otherwise applicable to such unvested shares as of immediately prior to the Effective Time, (b)&#160;each then-outstanding share of Jade preferred stock, par value $0.0001 per share (&#8220;Jade Preferred Stock&#8221;) will be converted into the right to receive a number of shares of Aerovate&#8217;s newly authorized convertible preferred stock, par value $0.0001 per share, equal to (x)&#160;the Exchange Ratio divided by (y)&#160;1,000, (c)&#160;each then-outstanding option to purchase Jade common stock will be assumed by Aerovate, subject to adjustment based on the Exchange Ratio as set forth in the Merger Agreement and (d)&#160;each then-outstanding pre-funded warrant to purchase shares of Jade common stock will be converted into a warrant to purchase shares of Aerovate common stock, subject to adjustment based on the Exchange Ratio as set forth in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate and Jade have each agreed to customary representations, warranties and covenants in the Merger Agreement, including, among others, covenants relating to (1)&#160;obtaining the requisite approval of their respective stockholders, (2)&#160;non-solicitation of alternative acquisition proposals and (3)&#160;the conduct of their respective businesses during the period between the date of signing the Merger Agreement and the Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October&#160;30, 2024, Jade entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain existing Jade stockholders and new investors (the &#8220;Investors&#8221;). Pursuant to the Purchase Agreement, and subject to the terms and conditions thereof, Jade agreed to sell, and the Investors agreed to purchase, immediately prior to the consummation of the Merger, shares of Jade common stock and pre- funded warrants for an aggregate purchase price of approximately $300.0 million in the Jade Pre-Closing Financing, which reflects the conversion of the previously issued $95 million of convertible notes. The consummation of the Jade Pre-Closing Financing is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement and in the Purchase Agreement. Shares of Jade common stock and pre-funded warrants issued pursuant to this financing transaction will be converted into shares of Aerovate common stock and pre-funded warrants to acquire shares of Aerovate common stock, in accordance with the Exchange Ratio and the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Consummation of the Merger is subject to certain closing conditions, including, among other things, (1) <span style="color:#231f20;">requisite approval by Aerovate&#8217;s stockholders, (2)&#160;approval by the requisite Jade stockholders of the adoption and approval of the Merger Agreement and the transactions contemplated thereby, (3)&#160;Nasdaq&#8217;s approval of the listing of the shares of Aerovate common stock to be issued in connection with the Merger, and (4)&#160;an executed Purchase Agreement for the Jade Pre-Closing Financing in full force and effect evidencing cash proceeds of not less than $80.0 million to be received by the Combined Company immediately prior to or following the Closing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement contains certain termination rights of each of Aerovate and Jade. Upon termination of the Merger Agreement under specified circumstances, Aerovate may be required to pay Jade a termination fee of $2,340,000, and in certain other circumstances, Jade may be required to pay Aerovate a termination fee of $5,250,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Pursuant to a Certificate of Designation of Preferences, Rights and Limitations of the Series&#160;A Non- Voting Convertible Preferred Stock to be filed by Aerovate with the Secretary of State of the State of Delaware (the &#8220;Certificate of Designation&#8221;) in connection with the Merger Agreement and the transactions thereunder, Aerovate will establish the terms of a new series of preferred stock of Aerovate designated as Series&#160;A Non-Voting Convertible Preferred Stock, par value $0.001 per share (the &#8220;Aerovate Series&#160;A Preferred Stock&#8221;). Holders of the Aerovate Series&#160;A Preferred Stock will be entitled to receive dividends on shares of Aerovate Series&#160;A Preferred Stock equal to, on an as-if-converted-to-Aerovate common stock basis, and in the same form as dividends actually paid on shares of Aerovate common stock. Except as otherwise required by the Certificate of Designation or law, the Aerovate Series&#160;A Preferred Stock will not have voting rights. However, as long as any shares of Aerovate Series&#160;A Preferred Stock are outstanding, Aerovate will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Aerovate Series&#160;A Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to the Aerovate Series&#160;A Preferred Stock, (b)&#160;alter or amend the Certificate of Designation, (c)&#160;amend Aerovate&#8217;s certificate of incorporation, bylaws or other charter documents in any manner that adversely affects any rights of the holders of the Aerovate Series&#160;A Preferred Stock, (d)&#160;file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock (as defined in the Certificate of Designation), if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Aerovate Series&#160;A Preferred Stock, (e)&#160;issue further shares of the Aerovate Series&#160;A Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of the Aerovate Series&#160;A Preferred Stock, (f)&#160;at any time while at least &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of the originally issued Aerovate Series&#160;A Preferred Stock remains issued and </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">270</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">outstanding, consummate either (A)&#160;a Fundamental Transaction (as defined in the Certificate of Designation) or (B)&#160;any merger or consolidation of Aerovate or other business combination in which Aerovate&#8217;s stockholders immediately before such transaction do not hold at least a majority of the capital stock of Aerovate immediately after such transaction, or (f)&#160;enter into any agreement with respect to any of the foregoing. The Aerovate Series&#160;A Preferred Stock does not have a preference upon any liquidation, dissolution or winding-up of Aerovate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the closing of the First Merger, each share of Aerovate Series&#160;A Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the holder of the Aerovate Series&#160;A Preferred Stock, into a number of shares equal to 1,000 shares of Aerovate common stock, subject to certain limitations, including that a holder of Aerovate Series&#160;A Preferred Stock is prohibited from converting shares of Aerovate Series&#160;A Preferred Stock into shares of Aerovate common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified&#160;percentage (initially set at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; %) of the total number of shares of Aerovate common stock issued and outstanding immediately after giving effect to such conversion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Effective Time, Aerovate&#8217;s board of directors of is expected to consist of six members, all of whom will be designated by Jade.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Concurrently and in connection with the execution of the Merger Agreement, (i)&#160;certain stockholders of Jade (solely in their respective capacities as Jade stockholders) holding approximately 99% of the outstanding shares of Jade capital stock have entered into support agreements with Aerovate and Jade to vote all of their shares of Jade capital stock in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby and (ii)&#160;certain of Aerovate&#8217;s stockholders holding approximately 38.1% of the outstanding shares of Aerovate common stock have entered into support agreements with Aerovate and Jade to vote all of their shares of Aerovate common stock in favor of, among other things, the adoption and approval of the Merger Agreement and the transactions contemplated thereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">At-The-Market Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April&#160;5, 2023, Aerovate entered into an ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM </sup>Sales Agreement (the &#8220;Sales Agreement&#8221;), with BofA Securities,&#160;Inc. (the &#8220;Agent&#8221;), pursuant to which Aerovate established an &#8220;at-the-market&#8221; offering program, to sell, from time to time, at Aerovate&#8217;s option, up to an aggregate of $75.0 million of shares of Aerovate common stock, through the Agent, as sales agent. As of September&#160;30, 2024, 3,462,721 shares have been sold under the Sales Agreement, generating $67.9 million of net proceeds after deducting commissions to the Agent and other offering costs. As of the date of this proxy statement/ prospectus, up to $6.0 million of shares of Aerovate common stock remain available for sale from time to time under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Components of Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate currently has no products approved for sale, and has not generated any revenue to date. At this time, Aerovate does not intend to resume development of AV-101 or any other product candidates, and as a result, Aerovate currently does not anticipate generating revenue. Aerovate&#8217;s ability to generate product revenue will depend on the successful development and eventual commercialization of any future drug candidates Aerovate may pursue. If Aerovate does not resume development activities or if Aerovate resumes development but fails to obtain regulatory approval for any future drug candidates, Aerovate&#8217;s ability to generate future revenue and its results of operations and financial position would be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Operating Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to mid-June, Aerovate&#8217;s research and development expenses have related to the development of AV-101. Since Aerovate&#8217;s decision to halt further development of AV-101, Aerovate has also incurred costs related to shutting down its clinical trials and research and development operations. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">271</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">external research and development expenses incurred under agreements with contract research organizations (&#8220;CROs&#8221;) and consultants to conduct and support clinical trials of AV-101 and Aerovate&#8217;s preclinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs related to manufacturing AV-101 for use in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">personnel-related costs, including salaries, payroll taxes, employee benefits, stock-based compensation charges and severance, for those individuals involved in research and development efforts; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs related to shutting down clinical trials of AV-101.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate&#8217;s research and development expenses consist principally of direct costs, such as fees paid to CROs, investigative sites and consultants in connection with Aerovate&#8217;s clinical trials, preclinical and non- clinical studies, and costs related to manufacturing clinical trial materials. Aerovate deploys its personnel related resources across all of its research and development activities. Aerovate tracks direct expenses on a clinical and non-clinical basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The successful development of any future product candidates is highly uncertain. Therefore, Aerovate cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that would be necessary to complete the potential development and commercialization of any future product candidates. Aerovate is also unable to predict when, if ever, material net cash inflows will commence from the sale of potential future product candidates, if approved. This is due to the numerous risks and uncertainties associated with developing product candidates, including the uncertainty of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">per patient trial costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of trials required for approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of sites included in the trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the countries in which the trials are conducted;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the length of time required to enroll eligible patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of patients that participate in the trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of doses evaluated in the trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the drop-out or discontinuation rates of patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential additional safety monitoring requested by regulatory agencies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the duration of patient participation in the trials and follow-up; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy and safety profile of the product candidate.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General and Administrative</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of personnel-related costs, including salaries, payroll taxes, employee benefits, stock-based compensation and severance charges for those individuals in executive, finance and other administrative functions. Other significant costs include legal fees relating to intellectual property and corporate matters, professional fees for accounting and consulting services, and insurance costs. Aerovate anticipates that its general and administrative expenses will decrease for the second half of 2024 as Aerovate decreases the size of its organization in connection with the Workforce Reduction Plan. Aerovate&#8217;s future general and administrative expenses will be significantly dependent on Aerovate&#8217;s ability to successfully consummate the Merger, related audit and legal expenses and whether Aerovate decides to pursue any future product development efforts.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">272</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest Income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Interest income consists of interest earned on cash and cash equivalents and short-term investments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of the three&#160;months ended September&#160;30, 2024 and 2023 (Unaudited)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes Aerovate&#8217;s results of operations for the three&#160;months ended September&#160;30, 2024 and 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:54.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">September&#160;30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="11" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:54.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12.45pt;"><span style="color:#231f20;">Research and development</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">10,328</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">16,884</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(6,556)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12.45pt;"><span style="color:#231f20;">General and administrative</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">7,082</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">4,484</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">2,598</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><span style="color:#231f20;">Total operating expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">17,410</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">21,368</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.51%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(3,958)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;"><span style="color:#231f20;">Loss from operations</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(17,410)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(21,368)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.51%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">3,958</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Other income:</span> <span style="color:#231f20;">Interest income</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">1,183</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">1,804</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(621)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12.45pt;"><span style="color:#231f20;">Other income (expense)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(10)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(11)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;"><span style="color:#231f20;">Total other income</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">1,173</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">1,805</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.51%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(632)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;"><span style="color:#231f20;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(16,237)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(19,563)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.51%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">3,326</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses for the three&#160;months ended September&#160;30, 2024 were $10.3 million compared to $16.9 million for the three&#160;months ended September&#160;30, 2023. The decrease of $6.6 million was primarily due to a $4.3 million decrease in contract manufacturing costs, a $2.0 million decrease in clinical trial costs, a $2.0 million decrease in base wages and bonus expense, and a $1.4 million decrease in stock based compensation expense, partially offset by a $2.6 million increase in severance expense, a $0.4 million increase in regulatory and other expenses, and a $0.1 million increase in payroll taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses for the three&#160;months ended September&#160;30, 2024 were $7.1 million compared to $4.5 million for the three&#160;months ended September&#160;30, 2023. The increase of $2.6 million was primarily due to a $1.6 million increase in legal and consulting expenses, $1.1 million in severance expense, $0.1 million in stock based compensation expense, and $0.1 million in insurance and other costs, partially offset by a decrease of $0.4 million in base wages and bonus expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Total Other Income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other income for the three&#160;months ended September&#160;30, 2024 was $1.2 million compared to $1.8 million for the three&#160;months ended September&#160;30, 2023. The decrease of $0.6 million was due to interest earned on cash and cash equivalents and short-term investments for the three&#160;months ended September&#160;30, 2024.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">273</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of the nine&#160;months ended September&#160;30, 2024 and 2023 (Unaudited)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes Aerovate&#8217;s results of operations for the nine&#160;months ended September&#160;30, 2024 and 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine&#160;Months&#160;Ended&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">September&#160;30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.03%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="11" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12.45pt;"><span style="color:#231f20;">Research and development</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">51,656</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">46,406</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">5,250</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12.45pt;"><span style="color:#231f20;">General and administrative</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">16,537</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">12,937</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">3,600</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><span style="color:#231f20;">Total operating expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">68,193</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.13%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">59,343</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">8,850</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;"><span style="color:#231f20;">Loss from operations</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(68,193)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(59,343)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">(8,850)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Other income (expense):</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.13%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12.45pt;"><span style="color:#231f20;">Interest income</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">4,014</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">4,236</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(222)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12.45pt;"><span style="color:#231f20;">Other expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(19)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">(1)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(18)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;"><span style="color:#231f20;">Total other income</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">3,995</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">4,235</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(240)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;"><span style="color:#231f20;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(64,198)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.13%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(55,108)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.44%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">(9,090)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Research and development expenses for the nine&#160;months ended September&#160;30, 2024 were $51.7 million compared to $46.4 million for the nine&#160;months ended September&#160;30, 2023. The increase of $5.3 million was primarily due to a $5.0 million increase in severance expense, $1.6 million in travel and other miscellaneous expense, $0.7 million in contract manufacturing costs, $0.6 million in regulatory and preclinical costs, $0.2 million in stock based compensation, and $0.2 million in benefits, partially offset by a $1.5 million decrease in base wages and bonus expense, and a $1.6 million decrease in clinical trial costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">General and administrative expenses for the nine&#160;months ended September&#160;30, 2024 were $16.5 million compared to $12.9 million for the nine&#160;months ended September&#160;30, 2023. The increase of $3.6 million was primarily due to a $1.3 million increase in severance expense, $1.2 million in stock compensation expense, $1.4 million in legal and consulting expenses, $0.1 million in rent allocation, and $0.2 million in insurance and other costs, partially offset by a decrease of $0.6 million in base wages and bonus expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Total Other Income (Expense)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Other income for the nine&#160;months ended September&#160;30, 2024, was $4.0 million compared to $4.2 million for the nine&#160;months ended September&#160;30, 2023. The decrease of $0.2 million was due to interest earned on cash and cash equivalents and short-term investments for the nine&#160;months ended September&#160;30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">From Aerovate&#8217;s inception through September&#160;30, 2024, Aerovate has received aggregate net proceeds of $79.8 million from the sale of shares of its convertible preferred stock and $5.0 million from convertible promissory notes to related parties. In July&#160;2021, Aerovate completed its initial public offering with aggregate net proceeds from the offering of $126.9 million, after deducting underwriting discounts, commissions and offering costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On October&#160;30. 2024, Aerovate entered into the Merger Agreement pursuant to which, subject to the satisfaction or waiver of the conditions therein, Merger Sub I will merge with and into Jade, with Jade surviving as a wholly owned subsidiary of Aerovate and the surviving corporation of the First Merger and, as part of the same overall transaction, Jade will merge with and into Merger Sub II, with Merger Sub II continuing as Aerovate&#8217;s wholly owned subsidiary and the surviving entity of the Second Merger. The Closing is subject to approval by Aerovate&#8217;s stockholders and the stockholders of Jade and other customary closing conditions. Aerovate&#8217;s future operations are highly dependent on the success of the proposed Merger with Jade.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">274</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">At-the-Market Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On April&#160;5, 2023, Aerovate entered into the Sales Agreement with the Agent, pursuant to which Aerovate can sell, from time to time, up to an aggregate of $75.0 million of shares of Aerovate common stock, through the Agent, as sales agent. As of September&#160;30, 2024, 3,462,721 shares have been sold under the Sales Agreement, generating $67.9 million of net proceeds after deducting commissions to the Agent and other offering costs. As of the date of this proxy statement/prospectus, up to $6.0 million of shares of Aerovate common stock remain available for sale from time to time under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Future Funding Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of September&#160;30, 2024, Aerovate had cash and cash equivalents and short-term investments of $88.7 million. Aerovate expects its existing cash and cash equivalents and short-term investments will be sufficient to fund its operations for at least twelve&#160;months from the date of filing this proxy statement/ prospectus. However, Aerovate&#8217;s forecast of the period of time through which Aerovate&#8217;s financial resources will be adequate to support its operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. Aerovate has based this estimate on assumptions that may prove to be wrong, and Aerovate could deplete its capital resources sooner than expected. Additionally, the process of conducting clinical trials is costly, and the timing of progress and expenses in these trials is uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Aerovate&#8217;s future capital requirements will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aerovate&#8217;s ability to successfully consummate the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of any future product development efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with retaining key personnel and consultants, and hiring additional personnel should Aerovate decide to resume development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and amount of the milestone or other payments Aerovate must make to any future licensors, if Aerovate enters into any license agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of establishing or securing sales and marketing capabilities if a product candidate is approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aerovate&#8217;s ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third- party payors and adequate market share and revenue for any approved products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patients&#8217; ability and willingness to pay out-of-pocket costs for any approved products in the absence of coverage and/or adequate reimbursement from third-party payors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs associated with any products or technologies that Aerovate may in-license or acquire.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Aerovate expects to finance its cash needs through its existing cash, cash equivalents and short-term investments. However, Aerovate may be unable to enter into arrangements when needed on favorable terms or at all. To the extent that Aerovate raises additional capital through the sale of equity or convertible debt securities, the ownership interest of Aerovate&#8217;s stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of Aerovate&#8217;s common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting Aerovate&#8217;s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If Aerovate raises funds through collaborations, or other similar arrangements with third parties, Aerovate may have to relinquish valuable rights to its technologies, future revenue streams, research programs or drug candidates or grant licenses on terms that may not be favorable to Aerovate and/or may reduce the value of Aerovate common stock. Aerovate&#8217;s failure to raise capital or enter into such other arrangements when needed could have a negative impact on Aerovate&#8217;s financial condition and on its ability to pursue its business plans and strategies. If Aerovate is unable to raise additional funds through equity or debt financings when needed, Aerovate may be required to delay, limit, reduce or terminate its product development or future commercialization efforts or grant rights to develop and market its drug candidates even if Aerovate would otherwise prefer to develop and market such drug candidates itself.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">275</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Lease Obligations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In August&#160;2021, Aerovate entered into a lease agreement (the &#8220;Waltham Lease&#8221;) for approximately 5,000 square feet of office space in Waltham, Massachusetts. The base rent under the Waltham Lease is $43.00 per rentable square foot, or approximately $18,000 per&#160;month and is subject to scheduled annual increases of $1.00 per rentable square foot during the lease term. In January&#160;2024, Aerovate entered into the First Amendment to the Waltham Lease resulting in the lease expiring on December&#160;31, 2025, and an increase of $1.00 per rentable square foot during the additional lease term. In obtaining this lease extension, Aerovate no longer has the option to extend the Waltham Lease for one additional period of three&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In April&#160;2022, Aerovate entered into a lease agreement (the &#8220;Foster City Lease&#8221;) for approximately 3,500 square feet of office space in Foster City, California. The base rent under the Foster City Lease is $76.80 per rentable square foot, or approximately $22,600 per&#160;month and is subject to scheduled annual increases of 3% on each annual anniversary during the lease term. The term of the Foster City Lease is thirty- nine&#160;months, unless extended or earlier terminated pursuant to the terms of the Foster City Lease. Aerovate has the option to extend the Foster City Lease for one additional period of one&#160;year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of September&#160;30, 2024, Aerovate does not have any other operating lease obligations, long-term debt obligations, capital lease obligations, purchase obligations or long-term liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Aerovate enters into contracts in the normal course of business for contract research services, contract manufacturing services, professional services and other services and products for operating purposes. These contracts generally provide for termination after a notice period, and, therefore, are cancelable contracts and not included above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of the nine&#160;months ended September&#160;30, 2024 and 2023 (Unaudited)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following table sets forth a summary of the net cash flow activity for the nine&#160;months ended September&#160;30, 2024 and 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:95%;"><tr><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine&#160;Months&#160;Ended</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">September&#160;30,</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.39%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Net cash used in operating activities</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(60,149)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(41,978)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Net cash provided by investing activities</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">42,900</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">6,228</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Net cash provided by financing activities</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">24,873</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">45,533</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.39%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Net increase in cash and cash equivalents</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="border-bottom-style:solid;border-bottom-width:0.5pt;color:#231f20;text-decoration-line:underline;text-decoration-style:double;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.98%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">7,624</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.95%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">9,783</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.39%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="border-bottom-style:solid;border-bottom-width:0.5pt;color:#231f20;text-decoration-line:underline;text-decoration-style:double;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Operating Activities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Net cash used in operating activities for the nine&#160;months ended September&#160;30, 2024 was $60.1 million, consisting primarily of Aerovate&#8217;s net loss incurred during the period of $64.2 million adjusted for non-cash charges of $10.1 million for stock-based compensation expense, $1.9 million of accretion on investments, $0.3 million of depreciation expense, and $4.4 million for net changes in operating assets and liabilities. The net change in operating assets and liabilities primarily related to a $0.1 million increase in prepaid expenses, a $0.8 million decrease in other assets, a $5.6 million decrease in accounts payable and accrued and other current liabilities, and a $0.5 million decrease in other liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Net cash used in operating activities for the nine&#160;months ended September&#160;30, 2023 was $42.0 million, consisting primarily of Aerovate&#8217;s net loss incurred during the period of $55.1 million adjusted for non-cash charges of $8.7 million for stock-based compensation expense, $2.1 million of accretion on investments, and $6.5 million for net changes in operating assets and liabilities. The net change in operating assets and liabilities primarily related to a $6.8 million increase in accounts payable and accrued and other current liabilities, a $0.1 million decrease in other assets, a $0.1 million decrease in other liabilities and a $0.1 million decrease in prepaid expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Investing Activities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Net cash provided by investing activities for the nine&#160;months ended September&#160;30, 2024 of $42.9 million was comprised of purchases of short-term investments of $19.7 million, offset by maturities of short-term investments of $62.6 million.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">276</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Net cash provided by investing activities for the nine&#160;months ended September&#160;30, 2023 of $6.2 million was comprised of purchases of short-term investments of $96.2 million, $0.1 million for purchases of property and equipment, offset by maturities of short-term investments of $102.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Financing Activities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Net cash provided by financing activities for the nine&#160;months ended September&#160;30, 2024 of $24.9 million was comprised of $23.6 million in net proceeds received from sales of Aerovate common stock under the Sales Agreement, after deducting Agent commissions, $0.3 million of payments made for offering costs, and $1.5 million of proceeds from stock option exercises and issuances of Aerovate common stock under Aerovate&#8217;s employee stock purchase plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Net cash provided by financing activities for the nine&#160;months ended September&#160;30, 2023 of $45.5 million was comprised of $44.9 million in net proceeds received from sales of Aerovate common stock under the Sales Agreement, after deducting Agent commissions, $0.2 million of payments made for offering costs, and $0.8 million of proceeds from stock option exercises and issuances of Aerovate common stock under Aerovate&#8217;s employee stock purchase plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Critical Accounting Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Aerovate&#8217;s consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of Aerovate&#8217;s consolidated financial statements requires Aerovate to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the related disclosures of contingent liabilities in Aerovate&#8217;s consolidated financial statements and accompanying notes. Aerovate bases its estimates and assumptions on historical experience and other factors that Aerovate believes to be reasonable under the circumstances. Aerovate evaluates its estimates and judgments on an ongoing basis. Actual results may differ significantly from these estimates under different assumptions, judgments or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">There have been no significant changes in Aerovate&#8217;s critical accounting policies and estimates during the nine&#160;months ended September&#160;30, 2024, as compared to the critical accounting policies and estimates disclosed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in Aerovate&#8217;s Annual Report on Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Aerovate is required to estimate its expenses resulting from obligations under contracts with vendors, consultants and CROs, in connection with conducting research and development activities. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. Aerovate reflects research and development expenses in its consolidated financial statements by matching those expenses with the period in which services and efforts are expended. Aerovate accounts for these expenses according to the progress of the preclinical or clinical study as measured by the timing of various aspects of the study or related activities. Aerovate determines clinical trial cost estimates through review of the underlying contracts along with preparation of financial models taking into account discussions with research and other key personnel and outsider service providers as to the progress of studies or other services being conducted. During the course of a study, Aerovate adjusts its rate of expense recognition if actual results differ from its estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Emerging Growth Company Status</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), Aerovate can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. Aerovate has elected to &#8220;opt out&#8221; of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, Aerovate will adopt the new or revised standard at the time public companies adopt the new or revised standard. The decision to opt out of the extended transition period under the JOBS Act is irrevocable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Recently Issued Accounting Pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Aerovate has reviewed all recently issued accounting pronouncements by the Financial Accounting Standards Board and other standard-setting bodies and have determined that such standards that do not require adoption until a future date are not expected to have a material impact on Aerovate&#8217;s consolidated financial statements, if adopted, or do not otherwise apply to Aerovate&#8217;s operations.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">277</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_b182986c_3766_4db8_92ea_3d1145fdbb67"></a><a id="QUANTITATIVEANDQUALITATIVEDISCLOSURESABO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT THE MARKET RISK OF AEROVATE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate is a smaller reporting company as defined by Rule&#160;12b-2 of the Exchange Act and is not required to provide the information otherwise required under this section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">278</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_b82fbb3f_7e8f_4b67_9443_37a6e0749f76"></a><a id="JADESMANAGEMENTSDISCUSSIONANDANALYSISOFF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">JADE MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">AND RESULTS OF OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should read the following discussion of Jade&#8217;s financial condition and results of operations in conjunction with the financial statements and the related notes thereto and other financial information included elsewhere in this proxy statement/prospectus. The following discussion contains forward-looking statements that reflect Jade&#8217;s current plans, estimates and beliefs. Jade&#8217;s historical results are not necessarily indicative of the results that may be expected for any period in the future. Jade&#8217;s actual results and the timing of events could differ materially from those discussed in these forward- looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this proxy statement/prospectus, particularly in the section titled &#8220;Risk Factors.&#8221; Please also see the section titled &#8220;Cautionary Note&#160;Regarding Forward-Looking Statements.&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade is a biopharmaceutical company developing potentially differentiated biologic therapies for patients living with autoimmune diseases with the goal of improving upon the existing treatment paradigm through the delivery of improved dosing and convenience, a comparable safety profile, and potentially increased clinical activity. Jade&#8217;s approach is to discover and efficiently develop biologics that address emerging targets supported by third-party clinical data and that overcome shortcomings of existing product candidates in development, such as potency, bioavailability, formulation, and pharmacokinetic properties. JADE-001, Jade&#8217;s initial product candidate, is a monoclonal antibody targeting a cytokine called &#8220;A PRoliferation Inducing Ligand&#8221; (&#8220;APRIL&#8221;) that modulates plasma cell survival and immunoglobulin production, which Jade plans to initially develop for the treatment of IgA nephropathy (&#8220;IgAN&#8221;). In addition to JADE-001, Jade is conducting pre-clinical research with respect to two other programs in serious, systemic autoimmune indications with high unmet need, JADE-002 and JADE-003.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since its inception in June&#160;2024, Jade has devoted substantially all of its resources to raising capital, organizing and staffing Jade, business and scientific planning, conducting discovery and research activities, establishing arrangements with third parties, and providing general and administrative support for these operations. Jade does not have any programs approved for sale and has not generated any revenue from product sales. To date, Jade has funded its operations primarily with proceeds from the issuance of its convertible notes, from which Jade received gross proceeds of $80.0 million in July&#160;2024 and $15.0 million in September&#160;2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade has incurred operating losses since inception. Jade&#8217;s ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of any programs Jade may develop. Jade generated net losses of $16.9 million for the period from June&#160;18, 2024 (inception) to September&#160;30, 2024. As of September&#160;30, 2024, Jade had an accumulated deficit of $16.9 million. Jade expects to continue to incur significantly increased expenses for the foreseeable future if and as it:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advances its existing and future research and development and discovery-related development of its JADE-001, JADE-002 and JADE-003 programs, including potential expansion into additional indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeks and identifies additional research programs and product candidates and initiates discovery- related activities and preclinical studies for those programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completes future preclinical studies for Jade&#8217;s pipeline;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pursues investigational new drug applications or comparable foreign applications that allow commencement of Jade&#8217;s planned clinical trials or future clinical trials for any programs Jade may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiates enrollment and successfully completes clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pursues positive results from Jade&#8217;s future clinical trials that support a finding of safety and effectiveness, an acceptable risk-benefit profile in the intended populations and a competitive efficacy, safety and half-life profile;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hires research and development, clinical, manufacturing and commercial personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adds operational, financial and management information systems and personnel;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">279</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">experiences any delays, challenges, or other issues associated with the preclinical and clinical development of Jade&#8217;s programs, including with respect to its regulatory strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develops, maintains and enhances a sustainable, scalable, reproducible and transferable clinical and commercial-scale current good manufacturing practices (&#8220;cGMP&#8221;) capabilities through a third-party or Jade&#8217;s own manufacturing facility for the programs Jade may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeks, obtains and maintains regulatory approvals for any product candidates for which Jade successfully completes clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ultimately establishes a sales, marketing and distribution infrastructure to commercialize any programs for which Jade may obtain regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">generates revenue from commercial sales of product candidates for which Jade receives regulatory approval, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintains safety, tolerability and efficacy profile of any product Jade may develop in additional indications following approval in one indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintains, expands, enforces, defends and protects Jade&#8217;s intellectual property portfolio and other intellectual property protection or regulatory exclusivity for any products Jade may develop and defends any intellectual property-related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">further acquires or in-licenses product candidates or programs, intellectual property and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintains Jade&#8217;s current collaboration and establishes and maintains any future collaborations, including making milestone, royalty or other payments thereunder; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incurs additional costs of operating as a public company, including increased costs of audit, legal, regulatory and tax-related services associated with maintaining compliance with an exchange listing and U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) requirements, director and officer insurance premiums and investor and public relations costs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any changes in the outcome of any of these variables with respect to the development of programs that Jade may identify could mean a significant change in the costs and timing associated with the development of such programs. For example, if the U.S. Food and Drug Administration or another comparable regulatory authority were to require Jade to conduct clinical trials beyond those that Jade currently anticipates will be required to complete clinical development and obtain regulatory approval of one or more product candidates, or if Jade experiences significant delays in Jade&#8217;s preclinical studies or clinical trials, Jade would be required to expend significant additional financial resources and time to advance and complete clinical development. Jade may never obtain regulatory approval for any of its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade will not generate revenue from product sales unless and until it successfully initiates and completes clinical development and obtains regulatory approval for any product candidates. If Jade obtains regulatory approval for any of its product candidates and does not enter into a commercialization partnership, it expects to incur significant expenses related to developing Jade&#8217;s commercialization capability to support product sales, manufacturing, marketing, and distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result of all the foregoing, Jade expects to need substantial additional funding to support its continued operations and growth strategy. Until such a time as Jade can generate significant revenue from product sales, if ever, it expects to finance its operations through the sale of equity, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. Jade may be unable to raise additional funds or enter into such other agreements on favorable terms, or at all. If Jade fails to raise capital or enters into such agreements as, and when, needed, Jade may have to significantly delay, scale back or discontinue the development and commercialization of one or more of its programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because of the numerous risks associated with product development, Jade is unable to accurately predict the timing or amount of increased expenses or when or if Jade will be able to achieve or maintain profitability. Even if Jade is able to generate product sales, Jade may not become profitable. If Jade fails to become profitable or is unable to sustain profitability on a continuing basis, then Jade may be unable to continue its operations at planned levels and be forced to reduce or terminate its operations.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">280</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30, 2024, Jade had cash of $88.0 million. Based on its current operating plan, Jade has concluded that there is substantial doubt about its ability to continue as a going concern within the 12&#160;months after the date Jade&#8217;s financial statements for the period from June&#160;18, 2024 (inception) to September&#160;30, 2024 were issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate Therapeutics,&#160;Inc., a Delaware corporation (&#8220;Aerovate&#8221;), and Jade entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) on October&#160;30, 2024, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Caribbean Merger Sub I, a Delaware corporation and a wholly owned subsidiary of Aerovate (&#8220;First Merger Sub&#8221;), will merge with and into Jade, with Jade continuing as a wholly owned subsidiary of Aerovate and the surviving corporation of the merger (the &#8220;First Merger&#8221;), and Jade will merge with and into Caribbean Merger Sub II, LLC, a Delaware limited liability company (&#8220;Second Merger Sub&#8221; and together with First Merger Sub, &#8220;Merger Subs&#8221;), with Second Merger Sub being the surviving entity of the merger continuing as a wholly owned subsidiary of Aerovate (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;). In connection with the Merger, Aerovate will change its name to &#8220;Jade Biosciences,&#160;Inc.&#8221; Aerovate following the Merger is referred to herein as the &#8220;Combined Company.&#8221; The Combined Company will be led by Jade&#8217;s management team and will focus on developing differentiated biologic therapies for patients living with autoimmune diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Concurrent with the execution of the Merger Agreement, Jade entered into a Subscription Agreement with certain investors to which Jade agreed to issue and sell to investors in a private placement financing (the &#8220;Jade Pre-Closing Financing&#8221;) shares and pre-funded warrants of the Jade common stock at an estimated purchase price of $5.9407 per share and $5.9046 per pre-funded warrant for an aggregate purchase price of $300.0 million (which includes $95.0 million of proceeds previously received from the issuance of convertible notes), which is expected to close immediately prior to the closing of the Merger (the &#8220;Closing&#8221;). At the effective time of the Merger, (i)&#160;shares of the Jade&#8217;s common stock issued in the Jade Pre-Closing Financing will be converted into shares of Aerovate common stock in accordance with the Exchange Ratio and (ii)&#160;pre- funded warrants to purchase shares of Jade&#8217;s common stock will be converted into a pre-funded warrant to purchase shares of Aerovate common stock, subject to adjustment as set forth in the Merger Agreement and the form of pre-funded warrant. The proceeds from the Jade Pre-Closing Financing are expected to advance the Combined Company&#8217;s pipeline and will be used for research and development, business development, working capital, and other general corporate purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade estimates that the net proceeds from the Merger and the Jade Pre-Closing Financing, together with Jade&#8217;s existing cash as of the date of this proxy statement/prospectus, will be sufficient to enable Jade to fund its operating expenses and capital expenditure requirements through 2027. Jade has based this estimate on assumptions that may prove to be wrong, Jade&#8217;s operating plan may change as a result of many factors currently unknown to Jade and Jade could exhaust its available capital resources sooner than Jade expects. See the sections titled &#8220;&#8212; <i style="font-style:italic;">Liquidity and Capital Resources</i>&#8221; below and &#8220;<i style="font-style:italic;">Risk Factors&#160;&#8212; Risks Related to Jade&#8217;s Limited Operating History, Financial Position and Capital Requirements</i>&#8221; beginning on page&#160;55 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Impact of General Economic Risk Factors on Jade&#8217;s Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Uncertainty in the global economy presents significant risks to Jade&#8217;s business. Jade is subject to continuing risks and uncertainties in connection with the current macroeconomic environment, including increases in inflation, fluctuating interest rates, new or increased tariffs and other barriers to trade, changes to fiscal and monetary policy or government budget dynamics (particularly in the pharmaceutical and biotech areas), recent bank failures, geopolitical factors, including the ongoing conflicts between Russia and Ukraine and in the Middle East and the responses thereto, and supply chain disruptions. While Jade is closely monitoring the impact of the current macroeconomic and geopolitical conditions on all aspects of Jade&#8217;s business, including the impacts on participants in any future clinical trials and its employees, suppliers, vendors and business partners and Jade&#8217;s future access to capital, the ultimate extent of the impact on Jade&#8217;s business remains highly uncertain and will depend on future developments and factors that continue to evolve. Most of these developments and factors are outside Jade&#8217;s control and could exist for an extended period of time. Jade will continue to evaluate the nature and extent of the potential impacts to its business, results of operations, liquidity and capital resources. For additional information, see the section titled &#8220;Risk Factors&#160;&#8212; Risks Related to Jade&#8217;s Business and Operations.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Components of Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">To date, Jade has not generated revenue from any sources, including product sales, and does not expect to generate any revenue from the sale of products in the foreseeable future. If Jade&#8217;s development efforts for its product candidates are successful and result in regulatory approval, Jade may generate revenue in the future from product sales or payments from future collaboration or license agreements that Jade may enter into with third parties, or any combination thereof. Jade cannot predict if, when, or to what extent it </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">281</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">will generate revenue from the commercialization and sale of Jade&#8217;s product candidates. Jade may never succeed in obtaining regulatory approval for any of its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Operating Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s operating expenses consist of (i)&#160;research and development expenses and (ii)&#160;general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist primarily of costs incurred in connection with the research and development of Jade&#8217;s programs. These expenses include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs of funding research performed by third parties, including Paragon, that conduct research and development activities on Jade&#8217;s behalf and services rendered under the Paragon Option Agreement (as defined below) for JADE-001, and Jade&#8217;s JADE-002 and JADE-003 programs, which have currently undisclosed targets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred in connection with continuing Jade&#8217;s current research programs and discovery- phase development of any programs Jade may identify, including under future agreements with third parties, such as consultants and contractors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">personnel-related expenses, including recruiting costs, salaries, bonuses, benefits and equity-based compensation expense.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade expenses research and development costs as incurred. For the period from June&#160;18, 2024 (inception) to September&#160;30, 2024, Jade recognized $13.2 million of expenses in connection with services provided by Paragon under the Paragon Option Agreement in Jade&#8217;s statement of operations and comprehensive loss. See the section titled &#8220;Contractual Obligations and Commitments&#8221; below for further details on Jade&#8217;s research plans.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General and Administrative</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of personnel-related expenses, including recruiting costs, salaries, bonuses, benefits, and equity-based compensation, for individuals in Jade&#8217;s executive, finance, operations, human resources, business development and other administrative functions. Other significant general and administrative expenses include legal fees relating to corporate matters and patent-related activities, insurance costs, information technology, and professional and consulting fees associated with accounting, audit, tax and investor and public relations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade expects that its general and administrative expenses will increase substantially for the foreseeable future as Jade increases its headcount and establishes office space to support its expected growth. Jade also expects to incur increased expenses associated with the Merger and Jade Pre-Closing Financing transactions and becoming a public company, including transactional costs and increased costs of accounting, audit, legal, regulatory and tax related services associated with maintaining compliance with SEC requirements, additional director and officer insurance costs, and investor and public relations costs. Jade also expects to incur additional intellectual property-related expenses as Jade files patent applications to protect innovations arising from its research and development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Expense, Net</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other expense, net primarily relates to the fair value adjustment related to Jade&#8217;s convertible notes and interest income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No provision for income taxes was recorded for the period from June&#160;18, 2024 (inception) through September&#160;30, 2024. Jade has recorded a full valuation allowance against its net deferred tax assets at each balance sheet date, as Jade believes it is not more likely than not that the benefit will be realized due to its cumulative losses generated to date and expectation of future losses.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">282</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Results of Operations for the Period from June&#160;18, 2024 (Inception) to September&#160;30, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes Jade&#8217;s statement of operations and comprehensive loss for the period presented (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:75.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Period from</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">June 18, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">(Inception) to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">September 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12.45pt;"><span style="color:#231f20;">Research and development</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">13,659</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12.45pt;"><span style="color:#231f20;">General and administrative</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">1,896</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><span style="color:#231f20;">Total operating expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.46%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">15,555</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><span style="color:#231f20;">Loss from operations</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.44%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(15,555)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Other expense, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.46%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12.45pt;"><span style="color:#231f20;">Other expense, net</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(1,312)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 11.5pt;"><span style="color:#231f20;">Total other expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.46%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">(1,312)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2.5pt;"><span style="color:#231f20;">Net loss and comprehensive loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.46%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.44%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(16,867)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">(1)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Includes related party amount of $13,224 for the period from June&#160;18, 2024 (inception) to September&#160;30, 2024.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">(2)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Includes related party amount of $889 for the period from June&#160;18, 2024 (inception) to September&#160;30, 2024.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">(3)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Includes related party amount of $425 for the period from June&#160;18, 2024 (inception) to September&#160;30, 2024.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes Jade&#8217;s research and development expenses incurred for the period presented (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:75.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Period from</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">June 18, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">(Inception) to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">September 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-family:'TimesNRMTPro';">External research and development costs:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12.45pt;"><span style="color:#231f20;">Product candidate expenses</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">13,269</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-family:'TimesNRMTPro';">Other research and development costs:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12.45pt;"><span style="font-family:'TimesNRMTPro';">Personnel-related (including stock-based compensation)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">380</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12.25pt;"><span style="font-family:'TimesNRMTPro';">Other</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">10</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><span style="font-family:'TimesNRMTPro';">Total research and development expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.46%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.44%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">13,659</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">(1)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Includes related party amount of $13,224 for the period from June 18, 2024 (inception) to September 30, 2024.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses were $13.7 million for the period from June&#160;18, 2024 (inception) to September&#160;30, 2024 and consisted primarily of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$13.2 million of research and development expense due to Paragon for services rendered under the Paragon Option Agreement for the Company&#8217;s selected product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.1 million of external research and development costs related to the Company&#8217;s product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.4 million of personnel-related costs related to recruiting costs, salaries, benefits and other compensation-related costs, including stock-based compensation expense of less than $0.1 million; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">less than $0.1 million of other research and development expense.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">283</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes Jade&#8217;s total general and administrative expenses for the period presented (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:75.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Period from</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">June 18, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">(Inception) to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">September 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-family:'TimesNRMTPro';">Professional and consulting fees</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> (1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">1,616</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-family:'TimesNRMTPro';">Legal fees related to patent filings</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> (2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">229</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-family:'TimesNRMTPro';">Personnel-related (including stock-based compensation)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-family:'TimesNRMTPro';">Other</span><sup style="font-family:'TimesNRMTPro';font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">37</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;"><span style="font-family:'TimesNRMTPro';">Total general and administrative expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.46%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.44%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">1,896</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(1)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">Includes related party amount of $632 for the period from June 18, 2024 (inception) to September 30, 2024.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(2)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">Includes related party amount of $229 for the period from June 18, 2024 (inception) to September 30, 2024.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(3)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">Includes related party amount of $28 for the period from June 18, 2024 (inception) to September 30, 2024.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses were $1.9 million for the period from June&#160;18, 2024 (inception) to September&#160;30, 2024 and consisted primarily of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.6 million of professional and consulting fees associated with accounting, audit, investor and public relations, and legal fees due to an increase in Jade&#8217;s business activity and as Jade began preparing to become a public company, including reimbursement to Paragon for such services provided;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.2 million of legal fees due to Paragon associated with patent-related activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Less than $0.1 million of personnel-related costs related to recruiting costs, salaries, benefits and other compensation-related costs, including stock-based compensation of less than $0.1 million; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Less than $0.1 million of other business expenses.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sources of Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since its inception, Jade has incurred significant operating losses. Jade expects to incur significant expenses and operating losses for the foreseeable future as Jade continues the preclinical development of its programs and commences clinical development of JADE-001. Jade has not yet commercialized any products and Jade does not expect to generate revenue from sales of products for several&#160;years, if at all. To date, Jade has funded its operations primarily with proceeds from the sale of Jade&#8217;s convertible notes. In July&#160;2024, Jade received $80.0 million in gross proceeds from the issuance of its convertible notes and in September&#160;2024 Jade received $15.0 million in gross proceeds for the issuance of additional convertible notes. As of September&#160;30, 2024, Jade had cash of $ 88.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flows</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes Jade&#8217;s cash flows for the period presented (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:75.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Period from</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">June 18, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">(Inception) to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">September 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-family:'TimesNRMTPro';">Net cash used in operating activities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">(6,802)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-family:'TimesNRMTPro';">Net cash provided by financing activities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">94,772</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12.25pt;"><span style="font-family:'TimesNRMTPro';">Net increase in cash</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.46%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.44%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">87,970</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">284</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Cash Used in Operating Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From June&#160;18, 2024 (inception) to September&#160;30, 2024, net cash used in operating activities was $6.8 million, which was primarily attributable to a net loss of $16.9 million, offset by non-cash charges of $10.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Cash Provided by Financing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From June&#160;18, 2024 (inception) to September&#160;30, 2024, net cash provided by financing activities was $94.8 million, consisting of $95.0 million of net proceeds from the issuance of the convertible notes, partially offset by $0.2 million of payments in deferred offering costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Future Funding Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To date, Jade has not generated any revenue from product sales. Jade does not expect to generate revenue from product sales unless and until Jade successfully completes preclinical and clinical development of, receives regulatory approval for, and commercializes a product candidate. Jade does not know when, or if, that will occur. Jade expects its expenses to increase substantially in connection with its ongoing activities, particularly as Jade advances the preclinical activities and studies and initiates clinical trials. In addition, if Jade obtains regulatory approval for any programs, Jade expects to incur significant expenses related to product sales, marketing, and distribution to the extent that such sales, marketing and distribution are not the responsibility of potential collaborators. Further, upon the completion of the Merger, Jade expects to incur additional costs associated with operating as a public company. The timing and amount of Jade&#8217;s operating expenditures will depend largely on the factors set out above. For more information, see the section titled &#8220;<i style="font-style:italic;">Risk Factors&#160;&#8212; Risks Related To Jade&#8217;s Limited Operating History, Financial Position and Capital Requirements</i>&#8221; beginning on page&#160;55 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s funding requirements and timing and amount of its operating expenditures will depend on many factors, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rate of progress in the development of Jade&#8217;s existing and future research and development and discovery-related development of its JADE-001, JADE-002 and JADE-003 programs, including potential expansion into additional indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, results and costs of additional research programs and product candidates and discovery-related activities and preclinical studies for those programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability of Jade to successfully file investigational new drug applications or comparable foreign applications and obtain authorization to commence of Jade&#8217;s planned clinical trials or future clinical trials for any programs Jade may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of enrollment and successful completion of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs necessary to pursue positive results from Jade&#8217;s future clinical trials that support a finding of safety and effectiveness, an acceptable risk-benefit profile in the intended populations and a competitive efficacy, safety and half-life profile;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of hiring research and development, clinical, manufacturing and commercial personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of adding operational, financial and management information systems and personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs necessary to obtain regulatory approvals, if any, for any approved products in the United States and other jurisdictions, and the costs of post-marketing studies that could be required by regulatory authorities in jurisdictions where approval is obtained;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of developing, maintaining and enhancing sustainable, scalable, reproducible and transferable clinical and commercial-scale cGMP capabilities through a third-party or Jade&#8217;s own manufacturing facility for the programs Jade may develop;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">285</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of future commercialization activities, including establishing sales, marketing and distribution infrastructure to commercialize any programs, for any of Jade&#8217;s product candidates for which Jade receives regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the revenue, if any, received from commercial sales of Jade&#8217;s product candidates for which Jade receives marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of preparing, maintaining, expanding, enforcing, defending and protecting Jade&#8217;s intellectual property rights and protection or regulatory exclusivity for any products Jade may develop and defending any intellectual property-related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and payment of milestone, royalty or other payments Jade must make pursuant to its existing and potential future collaborations and licensing arrangements with third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs Jade incurs in maintaining business operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with being a public company, including costs of audit, legal, regulatory and tax- related services associated with maintaining compliance with an exchange listing and SEC requirements, director and officer insurance premiums and investor and public relations costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effect of competing technological and market developments; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which Jade acquires or invests in businesses, products and technologies, including entering into licensing or collaboration arrangements for programs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Identifying potential programs and product candidates and conducting preclinical studies and clinical trials is a time consuming, expensive and uncertain process that takes&#160;years to complete, and Jade may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, Jade&#8217;s programs, if approved, may not achieve commercial success. Jade&#8217;s commercial revenues, if any, will be derived from sales of products that Jade does not expect to be commercially available for many&#160;years, if ever. Accordingly, Jade will need to obtain substantial additional funds to achieve its business objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Adequate additional funds may not be available to Jade on acceptable terms, or at all. Jade does not currently have any committed external source of funds. To the extent that Jade raises additional capital through the sale of equity or convertible debt securities, ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of Jade&#8217;s existing stockholders. Additional debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting Jade&#8217;s ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially dilute ownership interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Jade raises additional funds through strategic collaborations or licensing arrangements with third parties, Jade may have to relinquish valuable rights to its technologies, future revenue streams, research programs, or product candidates or grant licenses on terms that may not be favorable to Jade. If Jade is unable to raise additional funds through equity or debt financings when needed, Jade may be required to delay, limit or terminate its product development programs or any future commercialization efforts or grant rights to develop and market product candidates to third parties that Jade would otherwise prefer to develop and market itself.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30, 2024, Jade had cash of $ 88.0 million. Based on its current operating plan, Jade has concluded that there is substantial doubt about its ability to continue as a going concern for at least 12&#160;months from the date Jade&#8217;s financial statements for the period June&#160;18, 2024 (inception) to September&#160;30, 2024 were issued. Jade estimates that the net proceeds from the Merger and the Jade Pre-Closing Financing, together with Jade&#8217;s existing cash as of the date of this proxy statement/prospectus, will be sufficient to enable Jade to fund Jade&#8217;s operating expenses and capital expenditure obligations requirements through 2027. Jade has based this estimate on assumptions that may prove to be wrong, Jade&#8217;s operating plan may change as a result of many factors currently unknown to Jade and Jade could exhaust its available capital resources sooner than Jade expects.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">286</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Contractual Obligations and Other Commitments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Paragon Option Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July&#160;24, 2024, Jade entered into the Option Agreement with Paragon and Parade (as amended, the &#8220;Paragon Option Agreement&#8221;). Under the terms of the agreement, Paragon agreed to perform certain research activities to discover, generate, identify, and characterize one or more antibody candidates directed to certain mutually agreed therapeutic targets of interest to Jade (each, a &#8220;Research Program&#8221;). The Paragon Option Agreement initially included one selected target, APRIL, and the corresponding program is called JADE-001. From time to time, Jade can choose to add additional targets to the Paragon Option Agreement by mutual agreement with Paragon and Parade. The Paragon Option Agreement was amended on September&#160;27, 2024 to, among other things, include a target for each of JADE-002 and JADE-003.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Paragon Option Agreement requires Jade, Paragon, and Parade to develop a research plan for each target that includes design, modeling, synthesis, evaluation, and other mutually agreed activities (each, a &#8220;Research Plan&#8221;), which activities may include performing preclinical studies. Paragon will perform the activities set forth in each Research Plan on the timelines set forth in such Research Plan and in compliance with a mutually agreed budget. Each Research Program will be overseen and coordinated by a joint development committee consisting of two employees from Jade and two employees from Paragon, with Jade and Paragon each having one vote with respect to decisions of the committee. When Paragon and Parade have produced an antibody against a selected target, and upon the completion of each Research Program, Paragon and Parade will deliver to Jade a data package that includes sequence information for all then- existing antibodies and information directed to such target. Jade, Paragon, and Parade have developed a Research Plan for JADE-001 consistent with the foregoing, and Paragon and Parade have delivered an antibody against APRIL&#160;in accordance with such Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Paragon Option Agreement, Jade has the exclusive option (an &#8220;Option&#8221;), on a Research Program-by-Research Program basis, to finalize and execute a separate agreement with Paragon consistent with a set of pre-negotiated terms (a &#8220;License Agreement&#8221;). Each License Agreement will include (a)&#160;an exclusive, worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable Research Program to develop, manufacture, and commercialize the monospecific antibodies and products directed to the selected target(s), (b)&#160;a non-exclusive, worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable Research Program to develop, manufacture, and commercialize multispecific antibodies and products direct to the selected target(s), and (c)&#160;a right of first negotiation for a set period of time after the execution of the License Agreement with regard to any multispecific antibodies or products that are developed by Paragon. The Option with respect to each Research Program is exercisable at Jade&#8217;s sole discretion at any time during the period beginning on the initiation of activities under the associated Research Program and ending a specified number of&#160;days following the delivery of the data package from Paragon related to the results of the Research Program (an &#8220;Option Period&#8221;). There is no payment due upon exercise of an Option pursuant to the Paragon Option Agreement. Activities under a Research Plan may continue past the exercise of an Option or entry into a License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade exercised the Option to acquire the intellectual property rights to JADE-001 on October&#160;7, 2024, and Jade entered into a License Agreement for JADE-001 with Paragon on October&#160;30, 2024. Jade&#8217;s Options to acquire the intellectual property rights to certain other Research Programs under the Paragon Option Agreement, including JADE-002 and JADE-003, currently remain unexercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon exercise of an Option with respect to a Research Program, the parties are obligated to use reasonable efforts to finalize and execute a License Agreement within 30&#160;days. Under the terms of a License Agreement, Jade expects that it will have sole authority over and control of the development, regulatory approval, manufacturing and commercialization of such in-licensed intellectual property worldwide. In addition, Jade expects to have sole authority over and control of the application for and issuance of all regulatory approvals related to such in-licensed intellectual property. Prior to entry into a License Agreement, Paragon is responsible for the prosecution, defense, maintenance and enforcement of patents related to the Research Program. Following entry into a License Agreement, Jade expects to control prosecution, defense, maintenance and enforcement of patents licensed under such License Agreement. However, there is no assurance that Jade will successfully negotiate future License Agreements with Paragon or that the terms will not differ from those described in this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Unless terminated earlier, the Paragon Option Agreement shall continue in force on a Research Program- by-Research Program basis until the later of: (i)&#160;the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by Jade; (ii)&#160;if Jade exercises its Option with respect to a Research Program, but the parties are unable to finalize and execute a License Agreement within 30&#160;days, the expiration of such 30-day period (subject to any mutually agreed extension of such period); and </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">287</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(iii)&#160;the expiration of the applicable Research Term (as defined under the Paragon Option Agreement). Jade may terminate the Paragon Option Agreement or any Research Program at any time for any or no reason upon 30&#160;days&#8217; prior written notice to Paragon; provided, that Jade must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate the Paragon Option Agreement or a Research Program immediately upon written notice to Jade if, as a result of any action or failure to act by Jade or its affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number of&#160;months. Each party has the right to terminate the Paragon Option Agreement or any Research Program upon (i)&#160;30&#160;days&#8217; prior written notice of the other party&#8217;s material breach that remains uncured for the 30-day period and (ii) <span style="color:#231f20;">the other party&#8217;s bankruptcy.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon signing of the Paragon Option Agreement, Jade was required to reimburse Paragon $5.6 million for research and development costs related to APRIL&#160;and other costs incurred by Paragon to support Jade&#8217;s activities through June&#160;30, 2024 and certain other development costs incurred by Paragon between July&#160;1, 2024 and July&#160;24, 2024. Of this upfront research and development costs related to APRIL, a total of $5.5 million was recognized as research and development expense during the period from June&#160;18, 2024 (inception) to September&#160;30, 2024. Jade paid $5.6 million to Paragon in August&#160;2024. Jade is also required to pay Paragon for certain development fees and costs on a Research Program-by-Research Program basis. Under the Paragon Option Agreement, Jade is also responsible for any additional development costs incurred by Paragon, which from July&#160;1, 2024 to September&#160;30, 2024 totaled $7.2 million which was recognized as research and development expense. An amount of $7.0 million is included in related party accrued expenses and other current liabilities within Jade&#8217;s balance sheet as of September&#160;30, 2024. Under the Paragon Option Agreement, Jade is required to pay Paragon a one- time, non-refundable research initiation fee within 30&#160;days following finalization of a Research Plan in the amount of $1.3 million for JADE-001.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade will reimburse Paragon $0.3 million for costs related to JADE-002 incurred by Paragon through September&#160;30, 2024 of which $0.2 million was recognized as research and development expense and $0.1 million was recognized in general and administrative expense during the period from June&#160;18, 2024 (inception) to September&#160;30, 2024. An amount of $0.3 million is included in related party accrued expenses and other current liabilities within Jade&#8217;s balance sheet as of September&#160;30, 2024. In addition, Jade is required to pay Paragon $1.0 million following the finalization of the Research Plan, which has not yet occurred as of September&#160;30, 2024, as well as for subsequent development costs related to JADE-002.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade will reimburse Paragon $0.3 million for costs related to JADE-003 incurred by Paragon through September&#160;30, 2024. This amount was recognized as research and development expense during the period from June&#160;18, 2024 (inception) to September&#160;30, 2024. An amount of $0.3 million is included in related party accrued expenses and other current liabilities within Jade&#8217;s balance sheet as of September&#160;30, 2024. In addition, Jade is required to pay Paragon $1.0 million following the finalization of the research plan, which has not yet occurred as of September&#160;30, 2024, as well as for subsequent development costs related to JADE-003.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any License Agreement entered into with respect to a given Research Program shall contain the same milestone payment obligations as the Paragon Option Agreement, provided that any milestone set in the Paragon Option Agreement that has not yet been achieved and is duplicated in such License Agreement shall no longer be achievable and payable under the terms of the Paragon Option Agreement and shall only be achievable under the terms of the License Agreement. For the avoidance of doubt, if a milestone is achieved and paid by Jade pursuant to the Paragon Option Agreement for a certain Research Program, then there shall be no milestone payment due for the achievement of such milestone under a subsequently executed License Agreement for such Research Program. Further, under a License Agreement, Jade would also be required to make royalty payments to Paragon in the low single-digit&#160;percentage range based on net sales of products, subject to certain reductions. The royalty term will terminate on a product-by-product and country- by-country basis upon the later of the expiration of the last-to-expire valid claim within the relevant patent rights or the twelfth anniversary of the first commercial sale of such product in such country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, as part of the Paragon Option Agreement, on each of December&#160;31, 2025 and December&#160;31, 2026, Jade will grant Parade warrants to purchase a number of shares equal to 1.00% of Jade&#8217;s outstanding capital stock as of the date of the grant on a fully-diluted basis, with an exercise price equal to the fair market value of the underlying shares of Jade common stock on each respective grant date. Parade is an entity formed by Paragon as a vehicle to hold equity in Jade in order to share profits with certain employees of Paragon and will not perform any substantive role under the Paragon Option Agreement other than to receive such warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade considers Paragon and Fairmount to be related parties. See the section titled &#8220;<i style="font-style:italic;">Certain Relationships and Related Party Transactions of the Combined Company &#8212; Jade&#8217;s Relationships with Paragon, Parade and Fairmount</i>.&#8221;</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">288</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">JADE-001 License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 30, 2024, Jade entered into a License Agreement for JADE-001 with Paragon (the &#8220;JADE-001 License Agreement&#8221;), pursuant to which Paragon granted Jade a royalty-bearing, worldwide, exclusive and sublicensable license with respect to certain inventions, patent rights, sequence information and other intellectual property rights related to antibodies directed at the APRIL target (the &#8220;Licensed Antibody Technology&#8221;) to use, make, sell, import, export and otherwise exploit certain antibodies and products targeting APRIL in the field of prophylaxis, palliation, treatment and diagnosis of human disease and disorders in all therapeutic areas (the &#8220;field&#8221;). Under the terms of the JADE-001 License Agreement, Jade is obligated to pay Paragon up to $22.0 million based on specific development and regulatory milestones, including a $1.5 million fee for nomination of a development candidate and a further milestone payment of $2.5 million upon the first dosing of a human patient in a Phase 1 trial. In addition, the following summarizes other key terms of the JADE-001 License Agreement:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Paragon also granted Jade a royalty-bearing, worldwide, non-exclusive, sublicensable right and license under the Licensed Antibody Technology to use, make, sell, import, export or otherwise exploit certain multispecific antibodies and products targeting APRIL target.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Paragon will not conduct any new campaigns that generate APRIL&#160;monospecific antibodies in the field for at least five&#160;years.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Paragon may pursue the development and commercialization of multispecific antibodies and products directed at the APRIL&#160;target in the field and in the territory, and Jade has a right of first negotiation for any such multispecific antibodies and products proposed by Paragon for a period of five&#160;years from the execution of the JADE-001 License Agreement. If Jade does not exercise its right of first negotiation, or if the parties are unable to agree on a definitive agreement, Paragon may proceed without any obligations to Jade with respect to the right of first negotiation, and Jade&#8217;s </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">non-exclusive license will exclude any multispecific antibodies and products that were the subject of the right of first negotiation.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade will pay Paragon a low-to-mid single-digit&#160;percentage royalty based on annual net sales of the products in the field and in the territory, and a mid single-digit&#160;percentage royalty based on annual net sales of the multispecific products in the field and in the territory, subject to a 30% reduction if </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">there is no valid patent covering the product in the country.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The royalty term ends on the later of (i) the twelfth anniversary of such date or (ii) the expiration of the last-to- expire valid patent covering the product or the multispecific product in the country at issue.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The JADE-001 License Agreement may be terminated on 60&#160;days&#8217; notice by Jade; on material breach without cure; and to the extent permitted by law, on a party&#8217;s insolvency or bankruptcy.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">With respect to patents licensed to Jade under the JADE-001 License Agreement that have been filed as of the effective date of the JADE-001 License Agreement, Jade will control the preparing, filing, prosecuting and maintenance of such patents. With respect to patents filed after the effective date of the JADE-001 License Agreement, Paragon will control the preparing, filing, prosecuting and maintaining of such patents until the final deliverable for the relevant research program is delivered to Jade, after which Jade will control the preparing, filing, prosecuting and maintain of such patents.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Biologics Master Services Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July&#160;10, 2024, Jade entered into a biologics master services agreement (the &#8220;WuXi Biologics MSA&#8221;) with WuXi Biologics (Hong Kong). The WuXi Biologics MSA governs certain development activities and GMP manufacturing and testing for the JADE-001 program, as well as future programs, on a work order basis. Under the WuXi Biologics MSA, Jade is obligated to pay WuXi Biologics (Hong Kong) a service fee and all non-cancellable obligations in the amount specified in each work order associated with the agreement for the provision of services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The WuXi Biologics MSA terminates on the later of (i)&#160;July&#160;3, 2029 or (ii)&#160;the completion of services under all work orders executed by the parties prior to July&#160;3, 2029, unless terminated earlier. The term of each work order terminates upon completion of the services under such work order, unless terminated earlier. Jade can terminate the WuXi Biologics MSA or any work order at any time upon 30&#160;days&#8217; prior written notice and immediately upon written notice if WuXi Biologics (Hong Kong) fails to obtain or maintain required material governmental licenses or approvals. Either party may terminate a work order (i)&#160;at any time upon six&#160;months&#8217; prior notice with reasonable cause, provided however that if WuXi Biologics (Hong Kong) terminates a work order in such manner, no termination or cancellation fees shall be paid by Jade and (ii)&#160;immediately for cause upon (a)&#160;the other party&#8217;s material breach that </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">289</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">remains uncured for 30&#160;days after notice of such breach, (b)&#160;the other party&#8217;s bankruptcy or (c)&#160;a force majeure event that prevents performance for a period of at least 90&#160;days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cell Line License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October&#160;22, 2024, Jade entered into a cell line license agreement (the &#8220;Cell Line License Agreement&#8221;) with WuXi Biologics Ireland Limited (&#8220;WuXi Ireland&#8221;). Under the Cell Line License Agreement, Jade received a non-exclusive, worldwide, sublicensable license to certain of WuXi Ireland&#8217;s know-how, cell line, biological materials and media and feeds to make, have made, use, sell and import certain therapeutic products produced through the use of the cell line licensed by WuXi Ireland under the Cell Line License Agreement (the &#8220;WuXi Ireland Licensed Products&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In consideration for the license, Jade paid WuXi Ireland a non-refundable license fee of $150,000. Additionally, if Jade manufactures all of its commercial supplies of bulk drug product with a manufacturer other than WuXi Ireland or its affiliates, it is required to make royalty payments to WuXi Ireland in an amount equal to a fraction of a single digit&#160;percentage of global net sales of the WuXi Ireland Licensed Products manufactured by a third-party manufacturer (the &#8220;Royalty&#8221;). If Jade manufactures part of its commercial supplies of the WuXi Ireland Licensed Products with WuXi Ireland or its affiliates, then the Royalty will be reduced accordingly on a pro rata basis. Jade has the option, at any time, to pay WuXi Ireland a non-refundable lump sum royalty buyout payment on a drug product-by-drug product basis to extinguish future Royalty obligations with respect to such drug product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Cell Line License Agreement will continue indefinitely unless terminated (i)&#160;by Jade upon six&#160;months&#8217; prior written notice and its payment of all undisputed amounts due to WuXi Ireland through the effective date of termination, (ii)&#160;by WuXi Ireland for a material breach by Jade that remains uncured for 60&#160;days after written notice, (iii)&#160;by WuXi Ireland if Jade fails to make a payment and such failure continues for 30&#160;days after receiving notice of such failure, or (iv)&#160;by either party upon the other party&#8217;s bankruptcy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Convertible Notes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July&#160;and September&#160;2024, Jade completed convertible note financings in which Jade issued and sold to certain investors an aggregate principal amount of $80 million and $15 million, respectively, in convertible notes at an interest rate of 12% per annum. Upon a &#8220;Next Equity Financing&#8221; under the terms of the convertible notes, the principal amount and all accrued interest under each convertible note will convert into a number of shares of Jade common stock equal to the quotient obtained by dividing the purchase price by the conversion price in connection with the Next Equity Financing. In a conversion pursuant to a Next Equity Financing, the conversion price of the convertible notes is the product resulting from multiplying the price per share in the financing transaction by 80%. All unpaid interest and principal is scheduled to mature on December&#160;31, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies and Significant Judgments and Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s management&#8217;s discussion and analysis of its financial condition and results of operations is based on Jade&#8217;s financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires Jade to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues recognized and expenses incurred during the reporting periods. Jade&#8217;s estimates are based on its historical experience and on various other factors that Jade believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While Jade&#8217;s significant accounting policies are described in more detail in Note&#160;2 to its financial statements for the period from June&#160;18, 2024 (inception) to September&#160;30, 2024 included elsewhere in this proxy statement/prospectus, Jade believes the following accounting policies used in the preparation of Jade&#8217;s financial statements require the most significant judgments and estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Contract Costs Accruals</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade records the costs associated with research studies and manufacturing development as incurred. These costs are a significant component of Jade&#8217;s research and development expenses, with a substantial portion of Jade&#8217;s ongoing research and development activities conducted by third-party service providers, including contract research organizations and contract manufacturing organizations, and Jade&#8217;s related party Paragon.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">290</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade accrues for expenses resulting from obligations under Paragon Option Agreement between Paragon, Parade, and Jade and agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials or services are provided to Jade. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. Jade makes significant judgments and estimates in determining the accrual balance in each reporting period. In the event advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be expensed as the contracted services are performed. Changes in these estimates that result in material changes to Jade&#8217;s accruals could materially affect its results of operations. As of September&#160;30, 2024, Jade has not experienced any material deviations between accrued and actual research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade measures stock-based awards granted to employees, directors, and non-employees in the form of stock options to purchase shares of Jade&#8217;s common stock, based on their fair value on the date of the grant using the Black-Scholes model. Jade measures restricted common stock awards using the difference, if any, between the purchase price per share of the award and the fair value of Jade&#8217;s common stock at the date of grant. Compensation expense for those awards is recognized using the straight-line method over the requisite service period, which is generally the vesting period of the respective award for employees. Compensation expense for awards to non-employees with service-based vesting conditions is recognized in the same manner as if Jade had paid cash in exchange for the goods or services, which is generally over the vesting period of the award. Jade accounts for forfeitures as they occur. Jade classifies its stock-based compensation expenses in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Black-Scholes model uses inputs that are determined by the board of directors on the date of grant and assumptions Jade makes for the volatility of stock-based awards, the expected term of stock- based awards, the risk-free interest rate for a period that approximates the expected term of Jade&#8217;s stock- based awards and its expected dividend yield. Jade has historically been a private company and lacks company- specific historical and implied volatility information of Jade&#8217;s stock. Therefore, Jade estimates its expected stock volatility based on the historical volatility of a representative group of public companies in the biotechnology industry for a term equal to the remaining time of the expected term. The expected term of Jade&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain- vanilla&#8221; stock options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the remaining contractual term of the options on the date of measurement. Jade has estimated a 0% dividend yield based on the expected dividend yield and the fact that Jade has never paid, and does not expect to pay, any cash dividends in the foreseeable future. See Note&#160;2 to Jade&#8217;s financial statements included elsewhere in this proxy statement/prospectus for information concerning certain of the specific assumptions Jade used in applying the Black-Scholes model to determine the estimated fair value of its stock options granted in the periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Determination of Fair Value of Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As there has been no public market for Jade&#8217;s common stock from June&#160;18, 2024 (inception) to September&#160;30, 2024, the estimated fair value of stock-based awards has been determined by Jade&#8217;s board of directors as of the date of grant, with input from management, and with consideration of additional objective and subjective factors that Jade believed were relevant. In addition, the board of directors considered various objective and subjective factors to determine the fair value of Jade&#8217;s share-based awards as of each grant date, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prices at which Jade sold shares of Jade Preferred Stock and preferences of the Jade Preferred Stock relative to its stock-based awards at the time of each grant;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade&#8217;s common stock valuations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress of Jade&#8217;s research and development programs, including the status of discovery-phase studies for Jade&#8217;s product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade&#8217;s stage of development and business strategy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">external market conditions affecting the biotechnology industry and trends within the biotechnology industry;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">291</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade&#8217;s financial position, including cash on hand, and its historical and forecasted performance and operating results; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The lack of an active public market for Jade&#8217;s common stock and Jade Preferred Stock at the grant dates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s common stock valuations were prepared using a hybrid method, including an option pricing method (&#8220;OPM&#8221;). The OPM treats common stock and preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#8217;s securities changes. Under this method, the common stock has value only if the funds available for distribution to stockholders exceed the value of the preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. The hybrid method is a probability-weighted expected return method (&#8220;PWERM&#8221;), where the equity value in one or more of the scenarios is calculated using an OPM. The PWERM is a scenario-based methodology that estimates the fair value of common stock based upon an analysis of future values for a company, assuming various outcomes. The common stock value is based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of stock. The future value of the common stock under each outcome is discounted back to the valuation date at an appropriate risk- adjusted discount rate and probability weighted to arrive at an indication of value for the common stock. A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The assumptions underlying these valuations represented management&#8217;s best estimate, which involved inherent uncertainties and the application of management&#8217;s judgment. As a result, if Jade had used significantly different assumptions or estimates, the fair value of Jade&#8217;s incentive shares and its stock-based compensation expense could have been materially different.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Once a public trading market for Jade&#8217;s common stock has been established in connection with the completion of the Merger, it is no longer necessary for the board of directors to estimate the fair value of Jade&#8217;s stock-based awards in connection with its accounting for granted stock-based awards or other such awards Jade may grant, as the fair value of its common stock and share-based awards is determined based on the quoted market price of Jade&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Convertible Notes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30, 2024, Jade has issued $95.0 million in convertible notes to certain investors. Jade accounts for its convertible notes under Accounting Standard Codification (&#8220;ASC&#8221;) No.&#160;815, Derivatives and Hedging (&#8220;ASC 815&#8221;). Under ASC 815-15-25, the election can be at the inception of a financial instrument to account for the instrument under ASC No.&#160;825, Fair Value Measurements and Disclosures (Including the Fair Value Option) (&#8220;ASC 825&#8221; and the &#8220;Fair Value Option&#8221;). Jade performed an analysis of all of the terms and features of the convertible notes and has elected to address simplification and cost-benefit considerations to use the Fair Value Option to account for the convertible notes as Jade has identified embedded derivatives, such as automatic conversion upon closing of the Next Equity Financing (as defined in the convertible notes) and automatic conversion upon the event of a Corporate Transaction, both of which would require bifurcation and separate accounting. The convertible notes are and will be remeasured at fair value at each balance sheet date until repayment or conversion. Changes to the fair value of the convertible notes will be recorded in other expense in the statement of operations and comprehensive loss. Any changes in fair value caused by instrument-specific credit risk, if any, are presented separately in other comprehensive loss. The analysis of the fair value of the convertible notes contains inherent assumptions related to the market interest rate, instrument-specific credit risk, the probability of alternate financing, change of control, initial public offering, maturity extension, and payment at original maturity. Due to the use of significant unobservable inputs, the overall fair value measurement of the convertible notes is classified as Level 3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recently Issued Accounting Pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A description of recently issued accounting pronouncements that may potentially impact Jade&#8217;s financial position, results of operations or cash flows is disclosed in Note&#160;2 to Jade&#8217;s financial statements as of September&#160;30, 2024 included elsewhere in this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the periods presented Jade did not have, nor does Jade currently have, any off-balance sheet arrangements as defined in the rules&#160;and regulations of the SEC.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">292</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Quantitative and Qualitative Disclosures About Market Risks</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest Rate Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The convertible notes bear interest until December&#160;2026 at a fixed rate per annum equal to 12%. An immediate 10% change in the prime rate would not have a material impact on Jade&#8217;s debt-related obligations, financial position or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inflation Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s results of operations and financial condition are presented based on historical cost. While it is difficult to accurately measure the impact of inflation due to the imprecise nature of the estimates required, Jade believes the effects of inflation, if any, on its business, results of operations, financial condition or financial statements included elsewhere in this proxy statement/prospectus have been immaterial. Jade cannot assure you its business will not be affected in the future by inflation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">293</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_38ee66e5_ec78_4227_a9a0_4cad28301f53"></a><a id="MANAGEMENTFOLLOWINGTHEMERGER_152663"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MANAGEMENT FOLLOWING THE MERGER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Executive Officers and Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the completion of the Merger, the business and affairs of the Combined Company will be managed under the direction of the Combined Company&#8217;s board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Combined Company&#8217;s board of directors will initially be fixed at six members, consisting of six current Jade board members, namely Tom Frohlich, Chris Cain, Eric Dobmeier, Tomas Kiselak, Lawrence Klein and Erin Lavelle. The staggered structure of the current Aerovate board of directors will remain in place for the Combined Company following the completion of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each executive officer of the Combined Company will serve at the discretion of the Combined Company&#8217;s board of directors and holds office until his or her successor is duly elected and qualified or until his or her earlier resignation or removal. There are no family relationships among any of the proposed Combined Company&#8217;s directors or executive officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All of Aerovate&#8217;s current directors are expected to resign from their positions as directors of Aerovate, effective as of the Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the name, age as of November&#160;15, 2024 and position of each of the individuals who are expected to serve as executives and directors of the Combined Company following completion of the Merger:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:34.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Age</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.55%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">Executive Officers:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Tom Frohlich</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer and Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Jonathan Quick</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President, Finance and Treasurer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Andrew King, BVMS, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Scientific Officer &amp; Head of Research and Development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Hetal Kocinsky, M.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Medical Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Elizabeth Balta, J.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General Counsel and Corporate Secretary</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">Non-Employee Directors:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Chris Cain, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Eric Dobmeier, J.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Tomas Kiselak</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Lawrence Klein, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Erin Lavelle</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">47</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Executive Officers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Tom Frohlich. </span>Mr.&#160;Frohlich has served as Jade&#8217;s Chief Executive Officer and as a member of its board of directors since October&#160;2024. From June&#160;2021 to October&#160;2023, Mr.&#160;Frohlich served as Chief Operating Officer and, from January&#160;2019 to June&#160;2021, as Chief Business Officer at Chinook Therapeutics,&#160;Inc., a Nasdaq-listed biopharmaceutical company that was acquired by Novartis AG in August&#160;2023, where he was responsible for strategy, business development, commercial planning, chemistry, manufacturing and controls, quality and program management. From April&#160;2018 to October&#160;2023, Mr.&#160;Frohlich also served as an Operating Principal and subsequently as an Entrepreneur in Residence at Versant Ventures, a healthcare investment firm, where he was responsible for company creation and due diligence. From April&#160;2018 to December&#160;2018, Mr.&#160;Frohlich served as the Senior Vice President of Business Development at Inception Sciences,&#160;Inc., a drug discovery engine co-founded with Versant Ventures. Prior to joining Inception Sciences, from 2014 to 2018, Mr.&#160;Frohlich held positions of increasing responsibility at Arbutus Biopharma (formerly Tekmira Pharmaceuticals) (Nasdaq: ABUS), a biopharmaceutical company, most recently as Vice President of Business Development from 2016 through 2018. Prior to joining Arbutus Biopharma, Mr.&#160;Frohlich worked internationally at Johnson&#160;&amp; Johnson (NYSE: JNJ), a pharmaceutical and medical technology company, from 2007 through 2014, and at Merck&#160;&amp; Co.,&#160;Inc. (NYSE: MRK), a pharmaceutical company, from 1998 through 2006, in various roles leading commercial strategy across all stages of product development. Mr.&#160;Frohlich serves on the board of directors of Nested Therapeutics and Borealis Biosciences. Mr.&#160;Frohlich received a B.Sc. in Biochemistry from the University of Victoria and an M.B.A. from the University of Oxford.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade believes Mr.&#160;Frohlich is qualified to serve as a member of the Combined Company&#8217;s board of directors because of his business development, operational and senior management experience in the biotechnology industry.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">294</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jonathan Quick. </span>Mr.&#160;Quick has served as Jade&#8217;s Senior Vice President, Finance and Treasurer since September&#160;2024. From January&#160;2023 to September&#160;2024, Mr.&#160;Quick served as the Senior Vice President of Finance at Myeloid Therapeutics,&#160;Inc., a private biotechnology company, where he was responsible for overseeing the company&#8217;s finance, accounting and treasury functions. Prior to Myeloid, Mr.&#160;Quick served as Vice President of Finance at Alexion Pharmaceuticals,&#160;Inc., a biopharmaceutical company and subsidiary of AstraZeneca PLC (Nasdaq: AZN), from November&#160;2022 to March&#160;2023, where he led the finance and accounting functions for Alexion&#8217;s genomic medicines division. From April&#160;2019 to November&#160;2022, Mr.&#160;Quick served as the Vice President of Finance at LogicBio Therapeutics,&#160;Inc., a Nasdaq-listed biotechnology company that was acquired by Alexion in November&#160;2022, where he was responsible for overseeing the company&#8217;s financial operations, including the controllership function, public company reporting and financial planning and analysis. Prior to LogicBio, Mr.&#160;Quick served in various roles of increasing responsibility at Karyopharm Therapeutics&#160;Inc. (Nasdaq: KPTI) and Celldex Therapeutics,&#160;Inc. (Nasdaq: CLDX). Mr.&#160;Quick began his career at PricewaterhouseCoopers LLP, where he was part of the Deals Advisory practice. Mr.&#160;Quick received a B.S. in Accountancy from Providence College and is a Certified Public Accountant in Massachusetts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Andrew King, BVMS, Ph.D. </span>Dr.&#160;King has served as Jade&#8217;s Chief Scientific Officer&#160;&amp; Head of Research and Development since August&#160;2024 and previously served as a consultant to Paragon from May&#160;2024 to August&#160;2024. From June&#160;2021 to October&#160;2023, Dr.&#160;King served as Chief Scientific Officer and, from May&#160;2019 to June&#160;2021, as Head of Renal Discovery and Translational Medicine at Chinook Therapeutics,&#160;Inc., a Nasdaq-listed biopharmaceutical company that was acquired by Novartis AG in August&#160;2023, where he was responsible for overseeing the discovery research, non-clinical development, translational medicine and early clinical development teams, and led late-stage clinical development strategy as chair or co-chair of the development review committee and as a sponsor representative on the company&#8217;s global Phase 3 clinical trial steering committees. From August&#160;2018 through May&#160;2019, Dr.&#160;King served as the Executive Vice President of Discovery at BIOAGE Labs, a private biotechnology company. From 2015 through August&#160;2018, Dr.&#160;King served as the Senior Director of Discovery and Translational Biology at Ardelyx,&#160;Inc. (Nasdaq: ARDX), a biotechnology company, where he focused on delivering small molecule candidates for the treatment of cardio-renal diseases. Prior to Ardelyx,&#160;Inc., Dr.&#160;King was a Principal Research Scientist at AbbVie&#160;Inc. (NYSE: ABBV), a biopharmaceutical company, from 2013 through 2015, where he led the Renal Discovery scientific strategy to treat chronic kidney disease. From 2008 to 2012, Dr.&#160;King held positions of increasing responsibility at Abbott Laboratories (NYSE: ABT), a biotechnology company. Dr.&#160;King received a B.Sc. in Veterinary Biology from Murdoch University in Australia, a BVMS from Murdoch University in Australia and a Ph.D. in Pharmacology and Toxicology from Michigan State University.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Hetal Kocinsky, M.D. </span>Dr.&#160;Kocinsky has served as Jade&#8217;s Chief Medical Officer since September&#160;2024. From December&#160;2022 to August&#160;2024, Dr.&#160;Kocinsky served as Vice President of Translational Medicine at Chinook Therapeutics,&#160;Inc., a Nasdaq-listed biopharmaceutical company that was acquired by Novartis AG in August&#160;2023, where she was responsible for overseeing the clinical elements of an NDA submission, as well as leading early clinical development, clinical pharmacology, toxicology and biomarker functions. From February&#160;2022 to December&#160;2022, Dr.&#160;Kocinsky served as Executive Medical Director and, from September&#160;2018 to February&#160;2022, as Senior Medical Director at Apellis Pharmaceuticals,&#160;Inc. (Nasdaq: APLS), a biopharmaceutical company, where she was responsible for leading clinical development teams for neurology, hematology and nephrology in various stages of development, ranging from Phase 2 to post- marketing. Prior to Apellis, from 2012 to 2018, Dr.&#160;Kocinsky served in various roles of increasing responsibility at Achillion Pharmaceuticals,&#160;Inc., a Nasdaq-listed biopharmaceutical company that was acquired by Alexion Pharmaceuticals,&#160;Inc. in 2020, most recently serving as Executive Medical Director. Prior to Achillion, Dr.&#160;Kocinsky was on faculty at Yale University School of Medicine in the Department of Pediatric Nephrology. Dr.&#160;Kocinsky received a B.A. from Columbia College, Columbia University and an M.D. from UT Southwestern Medical Center. She completed her residency in Pediatrics at St. Christopher&#8217;s Hospital for Children and her fellowship in Pediatric Nephrology at Yale University School of Medicine. She is board-certified in Pediatrics and Pediatric Nephrology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Elizabeth Balta, J.D</span><b style="font-weight:bold;">. </b>Ms.&#160;Balta has served as Jade&#8217;s General Counsel and Corporate Secretary since October&#160;2024. From September&#160;2021 to March&#160;2024, Ms.&#160;Balta served as General Counsel of Icosavax,&#160;Inc., a Nasdaq-listed biotechnology company that was acquired by AstraZeneca plc in February&#160;2024, where she led the Legal Affairs function overseeing corporate, transactional, intellectual property and compliance matters. From March&#160;2016 to September&#160;2021, Ms.&#160;Balta served as Associate General Counsel of Seagen,&#160;Inc., a Nasdaq-listed biotechnology company that was acquired by Pfizer,&#160;Inc. in 2023, where she led the Corporate Law function with responsibility for corporate governance, securities law compliance, corporate financings and support of Seagen&#8217;s commercial expansion in Europe. Prior to Seagen, Ms.&#160;Balta served in various legal roles of increasing responsibility at Oncothyreon (Nasdaq: ONTY), which subsequently was renamed Cascadian Therapeutics and was acquired by Seagen in 2018, Emergent Biosolutions (NYSE: EBS) and Trubion Pharmaceuticals (Nasdaq: TRBN), which was acquired by Emergent Biosolutions in October&#160;2010. Ms.&#160;Balta received her B.A. in Human Biology from Stanford University and her J.D. from Harvard Law School.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">295</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Non-employee Directors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Chris Cain, Ph.D. </span>Dr.&#160;Cain has served as a member of Jade&#8217;s board of directors since July&#160;2024. Dr.&#160;Cain has served as Director of Research at Fairmount Funds Management LLC, a healthcare investment firm, since April&#160;2020. Prior to Fairmount, Dr.&#160;Cain served in various positions, his most recent being Vice President, at healthcare funds, including Samsara BioCapital, LP, a biotherapeutics-focused venture capital fund, from February&#160;2019 to February&#160;2020, Apple Tree Partners, a life sciences-focused venture capital fund, from 2016 to January&#160;2019, and, before that, RA Capital Management, an investment management company, where he invested in both public and emerging private biotechnology companies. Previously, Dr.&#160;Cain was a writer and editor at BioCentury Publications. He currently serves as a member of the board of directors of Cogent Biosciences,&#160;Inc. (Nasdaq: COGT). He received a B.A. from the University of California, Santa Barbara and a Ph.D. in Biochemistry and Molecular Biology from the University of California, San Francisco.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade believes Dr.&#160;Cain is qualified to serve as a member of the Combined Company&#8217;s board of directors because of his leadership, scientific, business and managerial experience in the biotechnology industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Eric Dobmeier, J.D. </span>Mr.&#160;Dobmeier has served as a member of Jade&#8217;s board of directors since October&#160;2024. Mr.&#160;Dobmeier has served as a Venture Partner at Samsara BioCapital, LP, a biotherapeutics- focused venture capital fund, since May&#160;2024. From April&#160;2019 to September&#160;2023, Mr.&#160;Dobmeier served as President and Chief Executive Officer at Chinook Therapeutics,&#160;Inc., a Nasdaq-listed biopharmaceutical company that was acquired by Novartis AG in August&#160;2023. Prior to that role, during 2018, Mr.&#160;Dobmeier served as President and Chief Executive Officer at Silverback Therapeutics,&#160;Inc., a Nasdaq-listed biopharmaceutical company that merged with ARS Pharmaceuticals,&#160;Inc. in 2022. From 2002 to 2017, Mr.&#160;Dobmeier held positions of increasing responsibility at Seagen,&#160;Inc., a Nasdaq-listed biotechnology company that was acquired by Pfizer,&#160;Inc. in 2023, most recently serving as Chief Operating Officer. Mr.&#160;Dobmeier currently serves as a member of the board of directors of Janux Therapeutics,&#160;Inc. (Nasdaq: JANX) and Structure Therapeutics,&#160;Inc. (Nasdaq: GPCR), and previously served as a member of the board of directors of Atara Biotherapeutics,&#160;Inc. (Nasdaq: ATRA) from March&#160;2015 to June&#160;2024 and Adaptive Biotechnologies (Nasdaq: ADPT) from September&#160;2016 to March&#160;2021. Mr.&#160;Dobmeier received his A.B. in History from Princeton University and his J.D. from the University of California, Berkeley School of Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade believes Mr.&#160;Dobmeier is qualified to serve as a member of the Combined Company&#8217;s board of directors because of his leadership, business and managerial experience in the biotechnology industry and experience advising, investing in and serving as a director of biotechnology companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Tomas Kiselak. </span>Mr.&#160;Kiselak has served as a member of Jade&#8217;s board of directors since July&#160;2024. Mr.&#160;Kiselak is a Managing Member at Fairmount Funds Management LLC, a healthcare investment firm he co-founded in April&#160;2016. Prior to Fairmount, Mr.&#160;Kiselak was a managing director at RA Capital Management, LLC, a healthcare and life science investment firm. Mr.&#160;Kiselak currently serves as the chairman of the board of directors of Viridian Therapeutics,&#160;Inc. (Nasdaq: VRDN) and as a member of the board of directors of Apogee Therapeutics,&#160;Inc. (Nasdaq: APGE), Dianthus Therapeutics,&#160;Inc. (Nasdaq: DNTH) and Spyre Therapeutics,&#160;Inc. (Nasdaq: SYRE). Mr.&#160;Kiselak also serves as a director for several private companies. He received a B.S. in Neuroscience and Economics from Amherst College.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade believes Mr.&#160;Kiselak is qualified to serve as a member of the Combined Company&#8217;s board of directors because of his experience advising and serving as a director of biotechnology companies and as a manager of funds specializing in the area of life sciences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Lawrence Klein, Ph.D. </span>Dr.&#160;Klein has served as a member of Jade&#8217;s board of directors since July&#160;2024. Dr.&#160;Klein has served as Chief Executive Officer and as a member of the board of directors of Oruka Therapeutics,&#160;Inc. (formerly known as ARCA biopharma,&#160;Inc.) (Nasdaq: ORKA) (&#8220;Oruka&#8221;), a biotechnology company, since August&#160;2024, and served as Chief Executive Officer and as a member of the board of directors of a private biotechnology company formerly known as Oruka Therapeutics,&#160;Inc. from February&#160;2024 through the completion of the company&#8217;s business combination with Oruka in August&#160;2024. From January&#160;2023 to February&#160;2024, Dr.&#160;Klein was a Partner at Versant Venture Management, LLC (&#8220;Versant&#8221;), a healthcare and biotechnology venture capital firm. Prior to Versant, Dr.&#160;Klein served in various positions at CRISPR Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical company, including Chief Operating Officer from January&#160;2020 to October&#160;2022, Chief Business Officer from January&#160;2019 to January&#160;2020, Senior Vice President, Business Development and Strategy from November&#160;2017 to December&#160;2018 and as Vice President, Strategy from February&#160;2016 to November&#160;2017. Before joining CRISPR, Dr.&#160;Klein was an Associate Partner at McKinsey&#160;&amp; Company, a global management consulting firm, from October&#160;2014 to February&#160;2016. Dr.&#160;Klein served as a member of the board of directors of Dyne Therapeutics,&#160;Inc. (Nasdaq: DYN) from September&#160;2019 to May&#160;2023 and of Jasper Therapeutics,&#160;Inc. </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">296</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(Nasdaq: JSPR) from September&#160;2021 to June&#160;2023. Dr.&#160;Klein received his B.S. in Biochemistry and Physics from the University of Wisconsin-Madison and his Ph.D. in Biophysics from Stanford University.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade believes Dr.&#160;Klein is qualified to serve as a member of the Combined Company&#8217;s board of directors because of his business development, operational and senior management experience in the biotechnology industry and his academic expertise and accomplishments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Erin Lavelle. </span>Ms.&#160;Lavelle has served as a member of Jade&#8217;s board of directors since September&#160;2024. From October&#160;2023 until July&#160;2024, Ms.&#160;Lavelle served as the Chief Operating Officer and Chief Financial Officer at ProfoundBio,&#160;Inc., a private biotechnology company that was acquired by Genmab A/S in May&#160;2024. Prior to ProfoundBio, Ms.&#160;Lavelle served as Chief Operating Officer and Chief Financial Officer at Climb Bio,&#160;Inc. (formerly Eliem Therapeutics,&#160;Inc.) (Nasdaq: CLYM), a biotechnology company, from October&#160;2020 to March&#160;2023. From April&#160;2018 to February&#160;2020, Ms.&#160;Lavelle served as the Chief Operating Officer at Alder BioPharmaceuticals,&#160;Inc., a Nasdaq-listed biotechnology company that was acquired by H. Lundbeck A/S in October&#160;2019. In addition to that role, she served as Alder&#8217;s appointed director for Vitaeris&#160;Inc., a privately held biotechnology company based in Vancouver, British Columbia, Canada. Prior to that, Ms.&#160;Lavelle served in various roles at Amgen&#160;Inc. (Nasdaq: AMGN) from 2003 to 2018, most recently serving as General Manager Taiwan from September&#160;2017 to April&#160;2018, as Executive Director, Japan Asia Pacific (Hong Kong) from May&#160;2016 to September&#160;2017, and Executive Director, Global Marketing Business Analytics and Insights from June&#160;2014 to May&#160;2016. She started her career as an investment banker in the healthcare group at Merrill Lynch&#160;&amp; Co. Ms.&#160;Lavelle currently serves as a member of the board of directors of Avalyn Pharma&#160;Inc., Aviceda Therapeutics,&#160;Inc. and Rivus Pharmaceuticals,&#160;Inc., including audit chair of Avalyn and Rivus, and served as a member of the board of directors of Neoleukin Therapeutics,&#160;Inc., a Nasdaq-listed biopharmaceutical company, which later became Neurogene&#160;Inc. (Nasdaq: NGNE), from May&#160;2020 to December&#160;2023. Ms.&#160;Lavelle holds a Bachelor of Arts in Economics from Yale University.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade believes Ms.&#160;Lavelle is qualified to serve as a member of the Combined Company&#8217;s board of directors because of her experience as an executive officer and director of life sciences companies, her expertise in finance and her background in business development and operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Composition of the Board of Directors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate&#8217;s board of directors currently consists of seven members, divided into three staggered classes, with one class to be elected at each annual meeting to serve for a three-year term. The staggered structure of the board of directors will remain in place for the Combined Company following the completion of the Merger, with Class&#160;I directors holding terms expiring at the 2025 annual meeting of stockholders, Class&#160;II directors holding terms expiring at the 2026 annual meeting of stockholders and Class&#160;III directors holding terms expiring at the 2027 annual meeting of stockholders. It is anticipated that the incoming directors will be appointed to classes of the Combined Company board of directors following the completion of the Merger as follows:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;are expected to be Class&#160;I directors;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;are expected to be Class&#160;II directors; and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;are expected to be Class&#160;III directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Director Independence</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Nasdaq listing rules&#160;have objective tests and a subjective test for determining who is an &#8220;independent director.&#8221; The subjective test states that an independent director must be a person who lacks a relationship that, in the opinion of the board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. Subject to specified exceptions, each member of a listed company&#8217;s audit, compensation and nominating committees must be independent, and audit and compensation committee members must satisfy additional independence criteria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on information provided by each proposed director concerning her or his background, employment and affiliations, Aerovate and Jade expect that the Combined Company&#8217;s board of directors will determine that Chris Cain, Eric Dobmeier, Tomas Kiselak, Dr.&#160;Lawrence Klein and Erin Lavell qualify as &#8220;independent directors&#8221; as defined under Nasdaq listing rules. In making these determinations, the Combined Company&#8217;s board of directors will consider the current and prior relationships that each director has with Aerovate and Jade and all other facts and circumstances that the Combined Company&#8217;s board of directors deems relevant in determining the independence of each proposed director, including the interests of each Combined Company director in the Merger, any relevant related party transactions and the beneficial ownership of securities of Aerovate, Jade or the Combined Company by each Combined Company director. See also the sections titled &#8220;<i style="font-style:italic;">The Merger&#160;&#8212; Interests of Jade Directors and Executive Officers in the Merger</i>,&#8221; &#8220;<i style="font-style:italic;">Certain Relationships and Related Party Transactions of the Combined Company</i>&#8221; and &#8220;<i style="font-style:italic;">Principal Stockholders of Jade</i>&#8221; beginning on pages&#160;126, 300 and 332, respectively, of this proxy statement/prospectus for additional information.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">297</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Board Leadership Structure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the completion of the Merger, Eric Dobmeier is expected to serve as Chair of the Combined Company&#8217;s board of directors (&#8220;Chair&#8221;). Although the Combined Company&#8217;s governance documents will not require that the Combined Company separate the Chief Executive Officer and Chair positions, Jade believes that having the positions be separate is the appropriate leadership structure for the Combined Company at this time as it helps facilitate independent board oversight of management and allows the Chief Executive Officer to focus on strategy execution and managing the business while the Chair focuses on corporate governance and managing the Combined Company&#8217;s board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade&#8217;s board of directors recognizes that, depending on future circumstances, other leadership models, such as combining the roles of Chief Executive Officer and Chair, might be appropriate. Accordingly, the Combined Company&#8217;s board may periodically review its leadership structure. At any time when a non- independent director is serving as Chair, Jade anticipates that the independent directors of the Combined Company will designate a lead independent director to preside at all meetings of the board of directors of the Combined Company at which the Chair is not present, preside over executive sessions of the independent directors, which will occur regularly throughout each&#160;year, serve as a liaison between the Chair and independent directors, and perform such additional duties as the Combined Company&#8217;s board of directors may otherwise determine and delegate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Board Committees</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the completion of the Merger, Aerovate and Jade anticipate that the Combined Company&#8217;s board of directors of the Combined Company will establish an audit committee, a compensation committee and a nominating and governance committee (&#8220;governance committee&#8221;), each of which will operate pursuant to a charter adopted by the board of directors of the Combined Company. Aerovate and Jade believe that following the completion of the Merger the functioning and composition of these committees of the Combined Company will comply with the requirements of Nasdaq listing rules&#160;and SEC rules&#160;and regulations. The board of directors of the Combined Company may also establish other committees from time to time to assist the Combined Company and its board of directors. Each of the audit committee, compensation committee and the governance committee is expected to have the responsibilities described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Audit Committee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the completion of the merger, the members of the Combined Company&#8217;s audit committee are expected to be Erin Lavelle, Eric Dobmeier, and Lawrence Klein, each of whom qualifies as an independent director for audit committee purposes, as defined under the rules of the SEC and the applicable Nasdaq listing rules and has sufficient knowledge in financial and auditing matters to serve on the Combined Company&#8217;s audit committee. Erin Lavelle is expected to chair the audit committee. In addition, Jade&#8217;s board of directors has determined that Ms. Lavelle is an &#8220;audit committee financial expert&#8221; as defined under the rules of the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The primary responsibilities of the Combined Company&#8217;s audit committee will be to oversee the Combined Company&#8217;s accounting and financial reporting processes, including the audits of the financial statements, and the internal and external audit processes. The audit committee will oversee the system of internal controls established by management and the Combined Company&#8217;s compliance with legal and regulatory requirements. The audit committee will also be responsible for the review, consideration and approval or ratification of related party transactions. The audit committee will oversee the independent auditors, including their independence and objectivity. The audit committee will be empowered to retain outside legal counsel and other advisors as it deems necessary or appropriate to assist it in fulfilling its responsibilities and to approve the fees and other retention terms of the advisors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Compensation Committee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the consummation of the Merger, the members of the Combined Company&#8217;s compensation committee are expected to be Tomas Kiselak, Chris Cain and Erin Lavelle, each of whom qualifies as an independent director for compensation committee purposes, as defined under the rules of the SEC and the applicable Nasdaq listing rules. Tomas Kiselak is expected to chair the compensation committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The primary responsibilities of the Combined Company&#8217;s compensation committee will be to periodically review and approve the compensation and other benefits for the Combined Company&#8217;s senior officers and directors. This will include reviewing and approving corporate goals and objectives relevant to the compensation of the Combined Company&#8217;s executive officers, evaluating the performance of these officers in light of the goals and objectives and setting the officers&#8217; compensation. The compensation committee </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">298</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">will also administer and make recommendations to the Combined Company&#8217;s board of directors regarding equity incentive plans that are subject to the board of directors&#8217; approval and approve the grant of equity awards under the plans to executive officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Governance Committee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the consummation of the Merger, the members of the Combined Company&#8217;s governance committee are expected to be Lawrence Klein, Chris Cain and Eric Dobmeier, each of whom qualifies as an independent director, as defined under applicable Nasdaq listing rules. Lawrence Klein is expected to chair the governance committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Combined Company&#8217;s governance committee will be responsible for engaging in succession planning for the Combined Company&#8217;s board of directors, developing and recommending to the Combined Company&#8217;s board of directors criteria for identifying and evaluating qualified director candidates and making recommendations to the Combined Company&#8217;s board of directors regarding candidates for election or reelection to the Combined Company&#8217;s board of directors at each annual stockholders&#8217; meeting. In addition, the governance committee will be responsible for overseeing corporate governance matters. The governance committee will also be responsible for overseeing the structure, composition and functioning of the Combined Company&#8217;s board of directors and its committees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Compensation Committee Interlocks and Insider Participation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None of the expected members of the Combined Company&#8217;s compensation committee has at any time been one of the officers or employees of the Combined Company. None of the Combined Company&#8217;s expected executive officers currently serves, or in the past fiscal&#160;year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers that is or are expected to serve on the Combined Company&#8217;s board of directors or compensation committee following the completion of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Code of Conduct and Ethics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the completion of the Merger, the Combined Company will adopt a Code of Conduct and Ethics that establishes the standards of ethical conduct applicable to all of the Combined Company&#8217;s directors, officers and employees. The full text of the Combined Company&#8217;s Code of Conduct and Ethics will be posted on the Combined Company&#8217;s website at&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. It is expected to address, among other matters, compliance with laws and policies, conflicts of interest, corporate opportunities, regulatory reporting, external communications, confidentiality requirements, insider trading, proper use of assets and how to report compliance concerns. The Combined Company intends to disclose any amendments to the Code of Conduct and Ethics, or any waivers of its requirements, on its website to the extent required by applicable rules. The Combined Company&#8217;s audit committee will be responsible for applying and interpreting the Code of Conduct and Ethics in situations where questions are presented to it. Information contained on, or that can be accessed through, the Combined Company&#8217;s website is not incorporated by reference into this proxy statement/prospectus, and you should not consider information on the Combined Company&#8217;s website to be part of this proxy statement/prospectus. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">299</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_cfa3b13c_e987_414e_970a_b6f232493ef2"></a><a id="CERTAINRELATIONSHIPSANDRELATEDPARTYTRANS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">OF THE COMBINED COMPANY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition to the compensation arrangements, including employment, termination of employment and change in control arrangements, with Aerovate&#8217;s and Jade&#8217;s directors and executive officers, including those discussed in the sections titled &#8220;<i style="font-style:italic;">Management Following the Merger</i>&#8221; and &#8220;<i style="font-style:italic;">Jade Executive Compensation</i>&#8221; beginning on pages&#160;294 and 157, respectively, of this proxy statement/prospectus, the following is a description of each transaction involving Aerovate since January&#160;1, 2022, each transaction involving Jade since June&#160;18, 2024 (inception) and each currently proposed transaction in which:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the amounts involved exceeded or will exceed the lesser of $120,000 and 1% of the average of Jade&#8217;s or Aerovate&#8217;s total assets at&#160;year-end for the last two completed fiscal&#160;years, as applicable; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any of Jade&#8217;s or Aerovate&#8217;s directors, executive officers or holders of more than 5% of Jade&#8217;s or Aerovate&#8217;s capital stock, or an affiliate or immediate family member of the foregoing persons, had or will have a direct or indirect material interest.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Aerovate Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Since January&#160;1, 2022, there has not been and there is not currently proposed, any transaction or series of similar transactions to which Aerovate is, or will be, a party in which the amount involved exceeded, or will exceed, $120,000 (or, if less, 1% of the average of our total assets amounts at December&#160;31, 2023 and 2022) and in which any director, executive officer, holder of 5% or more of any class of our capital stock or any member of the immediate family of, or entities affiliated with, any of the foregoing persons, had, or will have, a direct or indirect material interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Indemnification Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Aerovate has entered into agreements to indemnify its directors and executive officers. These agreements, among other things, require Aerovate to indemnify these individuals for certain expenses (including attorneys&#8217; fees), judgments, fines and settlement amounts reasonably incurred by such person in any action or proceeding, including any action by or in our right, on account of any services undertaken by such person on behalf of our company or that person&#8217;s status as a member of Aerovate&#8217;s board of directors to the maximum extent allowed under Delaware law.</p><a id="CertainRelationship_Jade_Transaction"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Jade Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following is a summary of each transaction or series of similar transactions since June&#160;18, 2024 (inception) or any currently proposed transaction, to which Jade was or is a party in which:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the amounts involved exceeded or will exceed the lesser of $120,000 and 1% of Jade&#8217;s total assets; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any of Jade&#8217;s directors or executive officers, any holder of 5% of any class of Jade&#8217;s voting securities or any member of his or her immediate family had or will have a direct or indirect material interest.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Private Placements of Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Initial Financing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In June&#160;2024, Jade completed a financing of Jade Preferred Stock and common stock and issued and sold (i)&#160;an aggregate of 20,000,000 shares of Jade Preferred Stock to Fairmount at a purchase price of $0.0001 per share per share and (ii)&#160;an aggregate of 5,000,000 shares of Jade common stock to Paragon at a purchase price of $0.0001 per share, 2,500,000 of which Paragon subsequently contributed to Parade. Paragon beneficially owns more than 5% of a class of Jade&#8217;s voting securities through its holdings of Jade common stock. Fairmount beneficially owns more than 5% of a class of Jade voting securities, has two seats on Jade&#8217;s board of directors and beneficially owns more than 5% of Paragon. Fairmount appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment of any executive officers of Paragon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Convertible Note&#160;Financing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In July&#160;and September&#160;2024, Jade completed convertible note financings in which it issued and sold to certain investors an aggregate principal amount of $80 million and $15 million, respectively, in convertible notes at an interest rate of 12% per annum. The principal amount and all accrued interest under each convertible note will convert into a number of shares of Jade common stock </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">300</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">equal to the quotient obtained by dividing the purchase price by the conversion price in connection with the Jade Pre-Closing Financing, which constitutes a &#8220;Next Equity Financing&#8221; under the convertible notes. In a conversion pursuant to a Next Equity Financing, the conversion price of the convertible notes is the product resulting from multiplying the price per share in the Next Equity Financing by 80%. The following table summarizes the purchases of Jade convertible notes by related persons:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:bottom;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PRINCIPAL</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INTEREST RATE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">PURCHASER</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AMOUNT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(PER ANNUM)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.39%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Entities affiliated with Fairmount</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">20,000,000.00</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:17%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">12</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">%</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jade Pre-Closing Financing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On October&#160;30, 2024, in connection with the execution of the Merger Agreement, Jade entered into the Subscription Agreement with certain investors to consummate the Jade Pre-Closing Financing. Pursuant to the Subscription Agreement, the investors agreed to purchase an estimated aggregate of 43,497,393 shares of Jade common stock and 12,262,755 Jade pre-funded warrants, at an estimated price of $5.9407 per share of common stock and $5.9046 per pre-funded warrant, assuming the Exchange Ratio is 21.4388 shares of Aerovate common stock for each share of Jade common stock (and 0.0214388 shares of Aerovate Series A Preferred Stock for each share of Jade Preferred Stock), for an aggregate purchase price of approximately $300.0 million (which includes $95.0 million of proceeds previously received from the issuance of convertible notes). The aggregate purchase price of $300.0 million is fixed, while the purchase price per share or pre- funded warrant and the aggregate number of shares and pre-funded warrants to be purchased is subject to change pursuant to the terms of the Subscription Agreement. Please see the section titled &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#160;&#8212; Subscription Agreement</i>&#8221; beginning on page&#160;153 of this proxy statement/prospectus. The closing of the Jade Pre-Closing Financing is conditioned upon the satisfaction or waiver of the conditions to the Merger as well as certain other conditions. Four of the investors in the Jade Pre-Closing Financing or their affiliates are, or are expected to be as of immediately following the Jade Pre-Closing Financing, beneficial holders of more than 5% of Jade&#8217;s capital stock, and the table below sets forth the number of shares of Jade common stock and Jade pre-funded warrants expected to be purchased by such holders at the closing of the Jade Pre-Closing Financing (based on the currently estimated purchase price per share or pre-funded warrant, as applicable). The share and dollar amounts in this section do not give effect to the proposed reverse stock split or the Merger.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pre-funded</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Jade</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Purchase</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Participant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Common Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Jade</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Entities affiliated with Fairmount</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">5,061,290</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">7,844,273</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">70,000,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Entities affiliated with Venrock Healthcare Capital Partners</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">5,061,289</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">3,804,367</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">46,000,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Entities affiliated with FMR LLC</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">4,713,224</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">28,000,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Entities affiliated with Deep Track Capital</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">4,629,289</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">22,500,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(1)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">Includes $20.0 million of proceeds previously received by Jade from the issuance of a convertible note and accrued interest on such note, with the remainder of the purchase price to be paid in cash.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">Includes $20.0 million of proceeds previously received by Jade from the issuance of a convertible note and accrued interest on such note, with the remainder of the purchase price to be paid in cash.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(3)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">Includes $15.0 million of proceeds previously received by Jade from the issuance of a convertible note and accrued interest on such note, with the remainder of the purchase price to be paid in cash.</span></p></td></tr></table><a id="JadeWith_ParagonParadeFairmount"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Jade&#8217;s Relationships with Paragon, Parade and Fairmount</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Jade is party to the Paragon Option Agreement with Paragon and Parade. Paragon and Parade each beneficially own more than 5% of a class of Jade&#8217;s voting securities through their respective holdings of Jade common stock. Fairmount beneficially owns more than 5% of a class of Jade&#8217;s voting securities, two of Jade&#8217;s directors are affiliated with Fairmount (Tomas Kiselak and Chris Cain) and Fairmount beneficially owns more than 5% of Paragon. Fairmount appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment of any executive officers of Paragon. Parade is an entity formed by Paragon as a vehicle to hold equity in Jade in order to share profits with certain employees of Paragon and will not perform any substantive role under the Paragon Option Agreement other than to receive warrants granted to Parade under the Paragon Option Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On July&#160;24, 2024, Jade entered into the Paragon Option Agreement with Paragon and Parade. Under the terms of the agreement, Paragon agreed to perform certain research activities to discover, generate, identify, and characterize one or more antibody candidates directed to certain mutually agreed therapeutic targets of interest to Jade (each, a &#8220;Research Program&#8221;). The Paragon Option </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">301</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Agreement initially included one selected target for JADE-001: APRIL. From time to time, Jade can choose to add additional targets by mutual agreement with Paragon and Parade. The Paragon Option Agreement was amended on September&#160;27, 2024 to, among other things, include a target for each of JADE-002 and JADE-003.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Paragon Option Agreement requires Jade, Paragon, and Parade to develop a research plan for each target that includes design, modeling, synthesis, evaluation, and other mutually agreed activities (each, a &#8220;Research Plan&#8221;), which activities may include performing preclinical studies. Paragon will perform the activities set forth in each Research Plan on the timelines set forth in such Research Plan and in compliance with a mutually agreed budget. Each Research Program will be overseen and coordinated by a joint development committee consisting of two employees from Jade and two employees from Paragon, with Jade and Paragon each having one vote with respect to decisions of the committee. When Paragon and Parade have produced an antibody against a selected target, and upon the completion of each Research Program, Paragon and Parade will deliver to Jade a data package that includes sequence information for all then- existing antibodies and information directed to such target. Jade, Paragon, and Parade have developed a Research Plan for JADE-001 consistent with the foregoing, and Paragon and Parade have delivered an antibody against APRIL&#160;in accordance with such Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the Paragon Option Agreement, Jade has the exclusive option (an &#8220;Option&#8221;), on a Research Program-by-Research Program basis, to enter into a separate agreement with Paragon consistent with a set of pre-negotiated terms (a &#8220;License Agreement&#8221;). Each License Agreement will include (a)&#160;an exclusive, worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable Research Program to develop, manufacture, and commercialize the monospecific antibodies and products directed to the selected target(s), (b)&#160;a non-exclusive, worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable Research Program to develop, manufacture, and commercialize multispecific antibodies and products direct to the selected target(s), and (c)&#160;a right of first negotiation for a set period of time after the execution of the License Agreement with regard to any multispecific antibodies or products that are developed by Paragon. The Option with respect to each Research Program is exercisable at Jade&#8217;s sole discretion at any time during the period beginning on the initiation of activities under the associated Research Program and ending a specified number of&#160;days following the delivery of the data package from Paragon related to the results of the Research Program (an &#8220;Option Period&#8221;). There is no payment due upon exercise of an Option pursuant to the Paragon Option Agreement. Activities under a Research Plan may continue past the exercise of an Option or entry into a License Agreement. Jade exercised the Option to acquire the intellectual property rights to JADE-001 on October&#160;7, 2024, and Jade entered into a License Agreement for JADE-001 with Paragon on October&#160;30, 2024. Jade&#8217;s Options to acquire the intellectual property rights to certain other Research Programs under the Paragon Option Agreement, including JADE-002 and JADE-003, currently remain unexercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Upon exercise of an Option with respect to a Research Program, the parties are obligated to use reasonable efforts to finalize and execute a License Agreement within 30&#160;days. Under the terms of a License Agreement, Jade expects that it will have sole authority over and control of the development, regulatory approval, manufacturing and commercialization of such in-licensed intellectual property worldwide. In addition, Jade expects to have sole authority over and control of the application for and issuance of all regulatory approvals related to such in-licensed intellectual property. Prior to entry into a License Agreement, Paragon is responsible for the prosecution, defense, maintenance and enforcement of patents related to the Research Program. Following entry into a License Agreement, Jade expects to control prosecution, defense, maintenance and enforcement of patents in-licensed under such License Agreement. However, there is no assurance that Jade will successfully negotiate future License Agreements with Paragon or that the terms will not differ from those described in this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Unless terminated earlier, the Paragon Option Agreement shall continue in force on a Research Program- by-Research Program basis until the later of: (i)&#160;the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by Jade; (ii)&#160;if Jade exercises its Option with respect to a Research Program, but the parties are unable to finalize and execute a License Agreement within 30&#160;days, the expiration of such 30-day period (subject to any mutually agreed extension of such period); and (iii)&#160;the expiration of the applicable Research Term (as defined under the Paragon Option Agreement). Jade may terminate the Paragon Option Agreement or any Research Program at any time for any or no reason upon 30&#160;days&#8217; prior written notice to Paragon; provided, that Jade must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate the Paragon Option Agreement or a Research Program immediately upon written notice to Jade if, as a result of any action or failure to act by Jade or its affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number of&#160;months. Each party has the right to terminate the Paragon Option Agreement or any Research Program upon (i)&#160;30&#160;days&#8217; prior written notice of the other party&#8217;s material breach that remains uncured for the 30-day period and (ii) <span style="color:#231f20;">the other party&#8217;s bankruptcy.</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">302</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Upon signing of the Paragon Option Agreement, Jade was required to reimburse Paragon $5.6 million for development costs related to APRIL&#160;incurred by Paragon through June&#160;30, 2024 and certain other development costs incurred by Paragon between July&#160;1, 2024 and July&#160;24, 2024. This amount was recognized as research and development expense during the period from June&#160;18, 2024 (inception) to September&#160;30, 2024. Jade paid $5.6 million to Paragon in August&#160;2024. Jade is also required to pay Paragon for certain development fees and costs on a Research Program-by-Research Program basis. Under the Paragon Option Agreement, Jade is required to pay Paragon a one-time, non-refundable research initiation fee within 30&#160;days following finalization of a Research Plan in the amount of $1.3 million for JADE-001 and $1.0 million for each of JADE-002 and JADE-003. Under the Paragon Option Agreement, on a Research Program-by- Research Program basis, Jade is required to make one-time non-refundable milestone payments to Paragon of up to a total of $22.0 million upon the achievement of certain clinical development and regulatory milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Upon exercise of the Option with respect to a Research Program, the parties are obligated to use reasonable efforts to finalize and execute a License Agreement within 30&#160;days. Any License Agreement entered into with respect to a given Research Program shall contain the same milestone payment obligations as the Paragon Option Agreement, provided that any milestone set in the Paragon Option Agreement that has not yet been achieved and is duplicated in such License Agreement shall no longer be achievable and payable under the terms of the Paragon Option Agreement and shall only be achievable under the terms of the License Agreement. For the avoidance of doubt, if a milestone is achieved and paid by Jade pursuant to the Paragon Option Agreement for a certain Research Program, then there shall be no milestone payment due for the achievement of such milestone under a subsequently executed License Agreement for such Research Program. Further, under a License Agreement, Jade would also be required to make royalty payments to Paragon in the low single-digit&#160;percentage range based on net sales of products, subject to certain reductions. The royalty term will terminate on a product-by-product and country-by-country basis upon the later of the expiration of the last-to-expire valid claim within the relevant patent rights or the twelfth anniversary of the first commercial sale of such product in such country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Additionally, as part of the Paragon Option Agreement, on each of December&#160;31, 2025 and December&#160;31, 2026, Jade will grant Parade warrants to purchase a number of shares equal to 1.00% of Jade&#8217;s outstanding capital stock as of the date of the grant on a fully-diluted basis, with an exercise price equal to the fair market value of the underlying shares of Jade common stock on each respective grant date. Parade is an entity formed by Paragon as a vehicle to hold equity in Jade in order to share profits with certain employees of Paragon and will not perform any substantive role under the Paragon Option Agreement other than to receive such warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of the date of this proxy statement/prospectus, Jade has paid Paragon $14.0 million under the Paragon Option Agreement for development costs related to APRIL&#160;incurred by Paragon through the effective date of the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">JADE-001 License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On October 30, 2024, Jade entered into a License Agreement for JADE-001 with Paragon (the &#8220;JADE-001 License Agreement&#8221;), pursuant to which Paragon granted Jade a royalty-bearing, worldwide, exclusive and sublicensable license with respect to certain inventions, patent rights, sequence information and other intellectual property rights related to antibodies directed at the APRIL target (the &#8220;Licensed Antibody Technology&#8221;) to use, make, sell, import, export and otherwise exploit certain antibodies and products targeting APRIL in the field of prophylaxis, palliation, treatment and diagnosis of human disease and disorders in all therapeutic areas (the &#8220;field&#8221;). Under the terms of the JADE-001 License Agreement, Jade is obligated to pay Paragon up to $22.0 million based on specific development and regulatory milestones, including a $1.5 million fee for nomination of a development candidate and a further milestone payment of $2.5 million upon the first dosing of a human patient in a Phase 1 trial. In addition, the following summarizes other key terms of the JADE-001 License Agreement:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Paragon also granted Jade a royalty-bearing, worldwide, non-exclusive, sublicensable right and license under the Licensed Antibody Technology to use, make, sell, import, export or otherwise exploit certain multispecific antibodies and products targeting APRIL.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Paragon will not conduct any new campaigns that generate APRIL&#160;monospecific antibodies in the field for at least five&#160;years.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Paragon may pursue the development and commercialization of multispecific antibodies and products directed at the APRIL&#160;target in the field and in the territory, and Jade has a right of first negotiation for any such multispecific antibodies and products proposed by Paragon for a period of five&#160;years from the execution of the JADE-001 License Agreement. If Jade does not exercise its right of first negotiation, or if the parties are unable to agree on a definitive agreement, Paragon may proceed without any obligations to Jade with respect to the right of first negotiation, and Jade&#8217;s </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">non-exclusive license will exclude any multispecific antibodies and products that were the subject of the right of first negotiation.</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">303</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade will pay Paragon a low-to-mid single-digit&#160;percentage royalty based on annual net sales of the products in the field and in the territory, and a mid single-digit&#160;percentage royalty based on annual net sales of the multispecific products in the field and in the territory, subject to a 30% reduction if </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">there is no valid patent covering the product in the country.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The royalty term ends on the later of (i)&#160;the twelfth anniversary of such date or (ii)&#160;the expiration of the last-to- expire valid patent covering the product or the multispecific product in the country at issue.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The JADE-001 License Agreement may be terminated on 60&#160;days&#8217; notice by Jade; on material breach without cure; and to the extent permitted by law, on a party&#8217;s insolvency or bankruptcy.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">With respect to patents licensed to Jade under the JADE-001 License Agreement that have been filed as of the effective date of the JADE-001 License Agreement, Jade will control the preparing, filing, prosecuting and maintenance of such patents. With respect to patents filed after the effective date of the JADE-001 License Agreement, Paragon will control the preparing, filing, prosecuting and maintaining of such patents until the final deliverable for the relevant research program is delivered to Jade, after which Jade will control the preparing, filing, prosecuting and maintain of such patents.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Indemnification Agreements and Insurance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Jade has entered into an indemnification agreement with each of its directors and officers and Jade has purchased directors&#8217; and officers&#8217; liability insurance. The indemnification agreements require Jade to indemnify its directors and officers to the fullest extent permitted under Delaware law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Restricted Stock Grants to Directors and Executive Officers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade has entered into restricted stock purchase agreements with certain of its executive officers and directors, as more fully described in the sections titled &#8220;<i style="font-style:italic;">Jade Executive Compensation</i>&#8221; and &#8220;<i style="font-style:italic;">Jade Director Compensation</i>&#8221; beginning on pages&#160;157 and 159, respectively, of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Policies for Approval of Related Party Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Jade does not have a formal policy regarding approval of transactions with related parties. To date, all disclosable transactions with related parties have been approved by the directors not interested in such transaction pursuant to Section&#160;144(a)(1)&#160;of the DGCL. Following the completion of the Merger, Jade anticipates that the Combined Company will adopt a related party transaction approval policy and the Combined Company&#8217;s audit committee will be responsible for the review, consideration and approval or ratification of related party transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">304</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_75bbd78d_f734_42ec_bb5e_be58a009b4af"></a><a id="UNAUDITEDPROFORMACONDENSEDCOMBINEDFINANC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Defined terms included below shall have the same meaning as terms defined and included elsewhere in this proxy statement/prospectus.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 30, 2024, Jade entered into the Merger Agreement with Aerovate and the Merger Subs, pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub I will merge with and into Jade, with Jade surviving as a wholly owned subsidiary of Aerovate and the surviving corporation of the First Merger, and, immediately following the First Merger and as part of the same overall transaction, Jade will merge with and into Merger Sub II, with Merger Sub II being the surviving entity of the Second Merger. The Merger is expected to close in the first half of 2025 following the effectiveness of this registration statement and receipt of approval by the stockholders of each of Jade and Aerovate, in the latter case pursuant to the Aerovate Special Meeting. In connection with the Merger, Merger Sub II will change its corporate name to &#8220;Jade Biosciences, LLC&#8221; and Aerovate will change its name to &#8220;Jade Biosciences, Inc.&#8221; Aerovate following the Merger is referred to herein as the &#8220;Combined Company.&#8221; The Combined Company will be led by Jade&#8217;s management team and will focus on developing differentiated biologic therapies for patients living with autoimmune diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, (i) each then-outstanding share of Jade common stock (including shares of Jade common stock issued in connection with the Jade Pre-Closing Financing) will be converted into the right to receive a number of shares of Aerovate common stock equal to the Exchange Ratio, (ii) each then-outstanding share of Jade Preferred Stock will be converted into the right to receive a number of shares of Aerovate Series A Preferred Stock, which are each convertible into 1,000 shares of Aerovate common stock, equal to the Exchange Ratio divided by 1,000, (iii) each then-outstanding option to purchase Jade common stock will be assumed by Aerovate and will be converted into an option to purchase shares of Aerovate common stock, and (iv) each then-outstanding pre-funded warrant to purchase shares of Jade common stock will be converted into a pre-funded warrant to purchase shares of Aerovate common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Exchange Ratio is currently estimated to be approximately 21.4388 shares of Aerovate common stock for each share of Jade common stock (and 0.0214388 shares of Aerovate Series A Preferred Stock for each share of Jade Preferred Stock) on the Closing Date. Under the Exchange Ratio formula, the former Jade stockholders immediately before the effective time, including those purchasing shares and pre-funded warrants in the Jade Pre-Closing Financing, are estimated to own approximately 98.4% of the outstanding common stock of the Combined Company, and the stockholders of Aerovate immediately before the effective time are estimated to own approximately 1.6% of the outstanding common stock of the Combined Company, which give effect to (a) Aerovate&#8217;s Net Cash (as defined in the Merger Agreement) as of the Closing being approximately $0, (b) Jade closing the Jade Pre-Closing Financing for an aggregate purchase price of approximately $300.0 million, which reflects the conversion of the previously issued $95.0 million of convertible notes, (c) a valuation for Aerovate equal to its Net Cash as of the business day immediately prior to the Closing Date, plus $8.0 million, and (d) a valuation for Jade equal to $175.0 million, in each case as further described in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following unaudited pro forma condensed combined financial information gives effect to the Merger, which is expected to be accounted for as a reverse recapitalization under U.S. GAAP. For further details related to the accounting for the Merger, please see Notes&#160;1 and 3 below. All share amounts have been adjusted to reflect the estimated Exchange Ratio of 21.4388 shares of Aerovate common stock for each share of Jade common stock, unless otherwise stated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unaudited pro forma condensed combined balance sheet combines the historical balance sheets of Aerovate and Jade as of September&#160;30, 2024 and depicts the accounting of the transactions prepared pursuant to Article&#160;11 of Regulation S-X (the &#8220;pro forma balance sheet transaction accounting adjustments&#8221;). The unaudited pro forma condensed combined statements of operations for the nine&#160;months ended September&#160;30, 2024 for Aerovate, the period from June&#160;18, 2024 (inception) to September&#160;30, 2024 for Jade, and the&#160;year ended December&#160;31, 2023 for Aerovate combine the historical results of Aerovate and Jade for those periods and depict the pro forma transaction accounting adjustments assuming that those adjustments were made as of January&#160;1, 2023 (the &#8220;pro forma statements of operations transaction accounting adjustments&#8221;). Collectively, the pro forma balance sheet transaction accounting adjustments and the pro forma statements of operations transaction accounting adjustments are referred to as the &#8220;transaction accounting adjustments&#8221; or &#8220;pro forma adjustments.&#8221;</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">305</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These unaudited pro forma condensed combined financial information and related notes have been derived from and should be read in conjunction with:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the historical audited financial statements of Jade as of September&#160;30, 2024 and for the period from June&#160;18, 2024 (inception) to September&#160;30, 2024, and the related notes included elsewhere in this proxy statement/prospectus;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the historical unaudited condensed consolidated financial statements of Aerovate as of and for the nine&#160;months ended September&#160;30, 2024, and the related notes included elsewhere in this proxy statement/prospectus;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the historical audited consolidated financial statements of Aerovate for the&#160;year ended December&#160;31, 2023, and the related notes included elsewhere in this proxy statement/prospectus; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sections titled &#8220;Aerovate&#8217;s Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; &#8220;Jade&#8217;s Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation,&#8221; and other financial information relating to Aerovate and Jade included elsewhere in this proxy statement/prospectus.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unaudited pro forma condensed combined financial information is based on the assumptions and pro forma adjustments that are described in the accompanying notes. The pro forma adjustments are preliminary, subject to further revision as additional information becomes available and additional analyses are performed including but not limited to additional financing, additional direct and incremental offering costs and a reverse stock split. Adjustments have been made solely for the purpose of providing unaudited pro forma condensed combined financial information. Differences between these preliminary estimates and the final accounting, expected to be completed after the Closing, may occur and these differences could have a material impact on the accompanying unaudited pro forma condensed combined financial information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unaudited pro forma condensed combined financial information does not give effect to the potential impact of current financial conditions, regulatory matters, operating efficiencies or other savings or expenses that may be associated with the integration of the two companies. The unaudited pro forma condensed combined financial information is not necessarily indicative of the financial position or results of operations in the future periods or the result that actually would have been realized had Aerovate and Jade been a combined organization during the specified periods. The actual results reported in periods following the Merger may differ significantly from those reflected in the unaudited condensed combined pro forma financial information presented herein for a number of reasons, including, but not limited to, differences in the assumptions used to prepare this unaudited pro forma condensed combined financial information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">306</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_dc851d16_4f86_4f60_93c2_51e2fdf19214"></a><a id="UNAUDITEDPROFORMACONDENSEDCOMBINEDBALANC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">AS OF SEPTEMBER&#160;30, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(In thousands, except share amounts)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:39.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:28.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">Historical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">5(A)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.55%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">5(B)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">Aerovate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">Jade</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accounting</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">Pro&#160;Forma</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">Therapeutics,&#160;Inc.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">Biosciences,&#160;Inc.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Adjustments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">Combined</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">31,115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">87,970</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(5,144)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(a)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">276,820</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">205,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(c)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(23,128)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(d)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(6,775)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(e)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(129)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(h)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(65,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(i)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(4,704)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(j)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">57,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(k)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">57,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(57,615)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(k)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,875</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(992)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(f)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,101</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">90,605</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">88,188</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">99,128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">277,921</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">259</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(259)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(g)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(g)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,159</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(1,159)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(d)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">90,959</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">89,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">97,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">278,002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Liabilities, Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">908</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">923</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">1,831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;">Accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,948</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(3,951)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(a)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">843</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(4,704)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(j)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;">Related party accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,011</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">8,011</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;">Operating lease liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">459</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(459)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(g)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,315</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,484</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(9,114)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">10,685</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Long term liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;">Operating lease liabilities &#8211; net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(81)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(g)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;">Other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;">Warrant liability, related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;">Notes payable to related parties, noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">96,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">24,286</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(c)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(120,986)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(c)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,466</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">106,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(105,895)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">10,779</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Jade convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(b)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Stockholders&#8217; equity (deficit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Aerovate Series A non-voting convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(b)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Aerovate common stock, $0.0001 par value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">(3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(l)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Jade common stock, $0.0001 par value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(c)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(c)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">307,888</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">120,984</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(c)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">308,368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">204,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(c)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">(24,287)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(d)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,283</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(h)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">(65,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(i)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">(245,500)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(l)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-family:'TimesNRMTPro';">Accumulated other comprehensive (loss) income</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">(224)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(l)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-family:'TimesNRMTPro';">Accumulated deficit</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">(227,622)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">(16,867)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">(1,193)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(a)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">(41,153)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">(6,775)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(e)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">(992)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(f)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">(24,286)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(c)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">267</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(g)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">(9,412)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(h)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">245,727</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(l)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-family:'TimesNRMTPro';">Total stockholders&#8217; equity (deficit)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#ffffff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">80,493</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#ffffff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#ffffff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#ffffff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">(16,863)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#ffffff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#ffffff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#ffffff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">203,593</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#ffffff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#ffffff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#ffffff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#ffffff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#ffffff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">267,223</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-family:'TimesNRMTPro';">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">90,959</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.53%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">89,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">97,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">278,002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">See accompanying notes to the unaudited pro forma condensed combined financial information.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">307</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_41028ca4_be9f_4b51_a286_ed6caeb22b42"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS FOR THE NINE&#160;MONTHS ENDED SEPTEMBER&#160;30, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(In thousands, except share and per share amounts)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk183641395"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:36.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:27.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">Historical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">6(A)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.4%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">6(B)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">Aerovate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">Jade</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accounting</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">Pro&#160;Forma</b></p></td><td style="vertical-align:top;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">Therapeutics,&#160;Inc.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">Biosciences,&#160;Inc.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Adjustments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">Combined</b></p></td><td style="vertical-align:top;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.58%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.44%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6.5pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">51,656</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13,659</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">6(f)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">65,405</p></td><td style="vertical-align:top;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6.5pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">16,537</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,896</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">6(f)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">18,832</p></td><td style="vertical-align:top;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12.95pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.58%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">68,193</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,555</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">489</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">84,237</p></td><td style="vertical-align:top;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Income (loss) from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.58%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(68,193)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.44%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(15,555)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(489)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(84,237)</p></td><td style="vertical-align:top;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6.5pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">388</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,402</p></td><td style="vertical-align:top;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6.5pt;">Change in fair value of convertible note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(1,700)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(1,700)</p></td><td style="vertical-align:top;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6.5pt;">Other (expense) income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(19)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(19)</p></td><td style="vertical-align:top;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12.95pt;">Total other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.58%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(1,312)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(2,683)</p></td><td style="vertical-align:top;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.58%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(64,198)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.44%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(16,867)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(489)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(81,554)</p></td><td style="vertical-align:top;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Weighted average shares used in computing net loss per share attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.58%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">28,572,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.44%;border-bottom:3px double transparent;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double transparent;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;border-bottom:3px double transparent;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double transparent;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 2.9pt 0pt 0pt;">1,312,176,666</p></td><td style="vertical-align:top;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">6(g)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Weighted average shares used in computing net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.58%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.44%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">428,776</p></td><td style="vertical-align:top;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;">6(g)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss per share attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.58%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(2.25)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.44%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(0.05)</p></td><td style="vertical-align:top;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.58%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.44%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(46.84)</p></td><td style="vertical-align:top;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">See accompanying notes to the unaudited pro forma condensed combined financial information.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">308</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_5c28e7c3_dd01_465b_8793_25c1afce497c"></a><a id="UNAUDITEDPROFORMACONDENSEDCOMBINEDSTATEM"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS FOR THE TWELVE&#160;MONTHS ENDED DECEMBER&#160;31, 2023</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(In thousands, except share and per share amounts)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk183641937"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:bottom;width:42.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 1.8pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Historical</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.24%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.01%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.01%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.98%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 1.8pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">6(C)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 1.8pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aerovate</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 1.8pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Therapeutics,</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accounting</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pro&#160;Forma</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 1.8pt;"><span style="color:#231f20;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inc.</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.24%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Adjustments</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Combined</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:center;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:normal;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 1.8pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 1.8pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.79%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.2pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.2pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.2pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 3.2pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.2pt;"><span style="color:#231f20;font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#231f20;">Research and development</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 1.8pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 1.8pt;"><span style="color:#231f20;">64,219</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">119</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">6(f)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.2pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 3.2pt;"><span style="color:#231f20;">64,338</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.2pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 3.2pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.2pt;"><span style="color:#231f20;font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#231f20;">General and administrative</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 24.45pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 24.45pt;"><span style="color:#231f20;">17,190</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">1,193</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">6(a)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">29,051</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">993</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">6(b)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(267)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">6(c)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">9,412</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">6(d)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 14.4pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 1.75pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 1.75pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">530</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">6(f)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.2pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 3.2pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.2pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 3.2pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.2pt;"><span style="color:#231f20;font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 14.4pt;"><span style="color:#231f20;">Total operating expenses</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 1.75pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 1.75pt;"><span style="color:#231f20;">81,409</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.24%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">11,980</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.2pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 3.2pt;"><span style="color:#231f20;">93,389</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.2pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.98%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 3.2pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.2pt;"><span style="color:#231f20;font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Income (loss) from operations</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(81,409)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(11,980)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(93,389)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Other income (expense), net</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#231f20;">Interest income</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">5,945</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">5,945</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#231f20;">Change in fair value of convertible note</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(24,286)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">6(e)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(24,286)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#231f20;">Other expense</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(1)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.24%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.79%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(1)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.98%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 14.4pt;"><span style="color:#231f20;">Total other income (expense), net</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 1.75pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 1.75pt;"><span style="color:#231f20;">5,944</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.24%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.2pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 2.9pt;"><span style="color:#231f20;">5,944</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.2pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.98%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 3.2pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.2pt;"><span style="color:#231f20;font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Net loss before income taxes</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 1.8pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0pt 1.8pt;"><span style="color:#231f20;">(75,465)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.24%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(36,266)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.79%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(111,731)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.98%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Provision for income taxes</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 1.75pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 1.75pt;"><span style="color:#231f20;">56</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.24%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:normal;width:10.84%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 1.75pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.2pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:normal;width:10.84%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 3.2pt;"><span style="color:#231f20;">56</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.2pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.98%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 3.2pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.2pt;"><span style="color:#231f20;font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 1.8pt;"><span style="color:#231f20;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0pt 1.8pt;"><span style="color:#231f20;">(75,521)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.24%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(36,266)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.79%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="color:#231f20;">(111,787)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.98%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Weighted average shares used in </span>computing net loss per share attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:normal;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">26,331,630</p></td><td style="vertical-align:bottom;white-space:normal;width:2.24%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;border-bottom:3px double transparent;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;border-bottom:3px double transparent;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.79%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,309,935,958</p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.98%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">6(g)</p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Weighted average shares used in computing net loss per share attributable to Series&#160;A non-voting convertible preferred stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:normal;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.24%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.79%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">428,776</p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.98%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">6(g)</p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss per share attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:normal;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(2.87)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.24%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.79%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(0.06)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.98%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss per share attributable to Series&#160;A non-voting convertible preferred stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:normal;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.24%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.79%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:10.84%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(64.29)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.39%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.98%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">See accompanying notes to the unaudited pro forma condensed combined financial information.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">309</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_4b9bad8e_b3ad_4115_8eb8_879862bae7af"></a><a id="NOTESTOUNAUDITEDPROFORMACONDENSEDCOMBINE"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES&#160;TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></span><b style="font-weight:bold;">Description of the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October&#160;30, 2024, Jade entered into the Merger Agreement with Aerovate and the Merger Subs, pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub I will merge with and into Jade, with Jade surviving as a wholly owned subsidiary of Aerovate and the surviving corporation of the First Merger, and, immediately following the First Merger and as part of the same overall transaction, Jade will merge with and into Merger Sub II, with Merger Sub II being the surviving entity of the Second Merger. The Merger is expected to close in the first half of 2025 following the effectiveness of this registration statement and receipt of approval by the stockholders of each of Jade and Aerovate, in the latter case pursuant to the Aerovate Special Meeting. In connection with the Merger, Merger Sub II will change its corporate name to &#8220;Jade Biosciences, LLC&#8221; and Aerovate will change its name to &#8220;Jade Biosciences,&#160;Inc.&#8221; Aerovate following the Merger is referred to herein as the &#8220;Combined Company.&#8221; Subject to the terms and conditions of the Merger Agreement, at closing of the Merger (the &#8220;Closing&#8221;):</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">each then-outstanding share of Jade common stock (including shares of Jade common stock issued in connection with the Jade Pre-Closing Financing) will be converted into the right to receive a number of shares of Aerovate common stock equal to the Exchange Ratio;</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">each then-outstanding share of Jade Preferred Stock will be converted into the right to receive a number of shares of Aerovate Series&#160;A Preferred Stock, which are each convertible into 1,000 shares of Aerovate common stock, equal to the Exchange Ratio divided by 1,000;</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">c)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">each then-outstanding option to purchase Jade common stock will be assumed by Aerovate and will be converted into an option to purchase shares of Aerovate common stock; and</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">d)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">each then-outstanding pre-funded warrant to purchase shares of Jade common stock will be converted into a pre-funded warrant to purchase shares of Aerovate common stock, subject to adjustment as set forth in the form of pre-funded warrant.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The shares of Aerovate common stock issued in exchange for shares of Jade Restricted Stock will to the same extent be unvested and subject to the same repurchase option or risk of forfeiture.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each option to acquire shares of Aerovate&#8217;s common stock with an exercise price less than or equal to the Aerovate Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (A)&#160;the excess of the Aerovate Closing Price over the exercise price per share of Aerovate common stock underlying such Aerovate option by (B)&#160;the number of shares of Aerovate common stock underlying such Aerovate option, and each option with an exercise price greater than the Aerovate Closing Price, as adjusted for the proposed special Cash Dividend, to acquire shares of Aerovate&#8217;s common stock will be cancelled for no consideration. The incremental fair value of Aerovate&#8217;s options associated with the modification to accelerate vesting and the acceleration of grant date fair value associated with the cancelation of certain stock options for no consideration has been included as an adjustment to the unaudited pro forma condensed combined financial information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Immediately following the Merger, Aerovate securityholders as of immediately prior to the Merger are expected to own approximately 1.6% of the outstanding capital stock of the Combined Company on a fully diluted basis, former Jade securityholders, excluding shares purchased in the Jade Pre-Closing Financing, are expected to own approximately 34.4% of the outstanding capital stock of the Combined Company on a fully diluted basis, and shares and pre-funded warrants issued in the Jade Pre-Closing Financing are expected to own approximately 64.0% of the outstanding capital stock of the Combined Company on a fully diluted basis. Jade stockholders are expected to receive approximately 1,807,946,994 shares on a fully diluted basis in connection with the Merger, including (i)&#160;95,566,666 shares of Aerovate common stock and stock options subject to vesting terms, based on the number of shares of Jade common stock outstanding immediately prior to the Merger, including Jade Restricted Stock, (ii)&#160;the shares of common stock and pre- funded warrants issued in the Jade Pre-Closing Financing, and (iii)&#160;Jade Preferred Stock outstanding as of September&#160;30, 2024, which will be exchanged into shares of newly created Aerovate Series&#160;A Preferred Stock which are each convertible into 1,000 shares of Aerovate common stock, equal to the Exchange Ratio divided by 1,000. These estimates are subject to certain inputs, which include, but are not limited to, (a)&#160;Aerovate&#8217;s Net Cash (as defined in the Merger Agreement) as of the Closing being approximately $0, (b)&#160;Jade closing the Jade Pre-Closing Financing for an aggregate purchase price of approximately $300.0 million, which reflects the conversion of the previously issued $95.0 million of convertible notes, (c)&#160;a valuation for Aerovate equal to $8.0 million (d)&#160;a valuation for Jade equal to $175.0 million, in each case as further described in the Merger Agreement. The following table </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">310</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">summarizes the pro forma number of shares of common stock of the Combined Company outstanding following the consummation of the Transactions:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:59.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Pro Forma</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">(Assuming Aerovate Net Cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:36.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">at Closing of $0)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Equity Capitalization Summary (fully diluted basis)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.43%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">%</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Upon Consummation of the Merger</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Shares Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Ownership</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Jade stockholders</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.43%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">631,536,666</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">34.4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Aerovate stockholders</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">28,867,711</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">1.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Investors participating in the Subscription Agreement</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">1,176,410,328</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">64.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Total common stock of the Combined Company</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.43%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">1,836,814,705</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">100.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">%</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span><span style="color:#231f20;">Includes 257,220,707 pre-funded warrants issued in the Jade Pre-Closing Financing after reflecting the estimated Exchange Ratio.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Consummation of the Merger is subject to certain closing conditions, including, among other things, (1) <span style="color:#231f20;">approval by Aerovate stockholders of the issuance of Aerovate common stock, including shares of Aerovate common stock issuable upon conversion of the Aerovate Series&#160;A Preferred Stock, and the other transactions proposed under the Merger Agreement, (2)&#160;adoption of the Merger Agreement by the Jade stockholders, (3)&#160;Nasdaq&#8217;s approval of the listing of the shares of Aerovate common stock to be issued in connection with the Merger and (4)&#160;the effectiveness of this registration statement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The employment agreements for Aerovate employees include entitlement to change in control payments for certain executives, and severance for certain non-executives, the aggregate of which will be treated as pre- Merger compensation expense of Aerovate and will be reflected as an increase to accrued expenses of Aerovate, which will be assumed by the Combined Company at Closing to the extent they are not yet settled in cash beforehand by Aerovate. Prior to the Closing, Aerovate also has or expects to (i)&#160;discontinue its research and development activities, (ii)&#160;close out of all contracts related to Aerovate&#8217;s worldwide clinical trial, and (iii) <span style="color:#231f20;">terminate its office space leases. Additionally, Aerovate&#8217;s current Directors&#160;&amp; Officers (&#8220;D&amp;O&#8221;) policy will be fully utilized at Closing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Private Financing Transaction&#160;&#8212; Subscription Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Concurrently with the execution of the Merger Agreement, certain parties have entered into the Subscription Agreement with Jade to purchase, prior to the consummation of the Merger, approximately 42,875,050 shares of Jade common stock and 11,997,906 pre-funded warrants before giving effect to the Exchange Ratio, at an estimated purchase price of $5.9407 and $5.9406 per share, respectively, for aggregate purchase price, assuming the financing transaction had happened on September 30, 2024, of approximately $326.0 million, which includes the $95.0 million of Jade convertible notes previously issued and $1.7 million of accrued interest as of September 30, 2024 from the convertible notes, both converting at a 20% discount. Shares of Jade common stock and pre-funded warrants to purchase shares of Jade common stock issued pursuant to the Subscription Agreement will be converted into shares of Aerovate common stock and pre-funded warrants to purchase shares of Aerovate common stock at Closing per the Merger Agreement.</p><a id="_7420f473_108c_4456_aebd_67a95ce66476"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></span><b style="font-weight:bold;">Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unaudited pro forma condensed combined financial information has been prepared in accordance with Article&#160;11 of Regulation S-X. The adjustments presented in the unaudited pro forma condensed combined financial information have been identified and presented to provide relevant information necessary for an understanding of the Combined Company upon consummation of the Merger. The unaudited pro forma condensed combined statement of operations data for the nine&#160;months ended September&#160;30, 2024 and the unaudited pro forma condensed combined statement of operations data for the&#160;year ended December&#160;31, 2023 give effect to the Merger as if it had been consummated on January&#160;1, 2023. The unaudited pro forma condensed combined balance sheet as of September&#160;30, 2024 gives effect to the Merger and combines the historical balance sheets of Aerovate and Jade as if the Merger had been consumated on September 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The unaudited pro forma condensed combined financial information is based on the assumptions and adjustments that are described in the accompanying notes. Accordingly, the pro forma adjustments are preliminary, subject to further revision as additional information becomes available and additional analyses are performed and have been made solely for the purpose of providing unaudited pro forma condensed combined financial information. Differences between these preliminary accounting conclusions and estimates and the final accounting conclusions and amounts may occur as a result of, among other reasons: (i)&#160;changes in initial assumptions in the determination of the accounting acquirer and related accounting, (ii)&#160;changes in the amount of Aerovate&#8217;s Net Cash </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">311</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">to be assumed at the Closing Date, and (iii)&#160;other changes in Aerovate&#8217;s assets and liabilities, which are expected to be completed after the Closing, and these differences could have a material impact on the accompanying unaudited pro forma condensed combined financial information and the Combined Company&#8217;s future results of operations and financial position.</p><a id="_2998116d_dddf_4184_b878_7cc7d2a9b527"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></span><b style="font-weight:bold;">Accounting for the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The unaudited pro forma condensed combined financial information gives effect to the Merger, which will be accounted for under U.S. GAAP as a reverse recapitalization of Aerovate by Jade, as the transaction is, in essence, the issuance of equity for Aerovate&#8217;s net assets, which will primarily consist of nominal non-operating assets and liabilities. Under this method of accounting, Jade will be considered the accounting acquirer for financial reporting purposes. This determination is based on the expectations that, immediately following the Merger:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Immediately prior to the Merger, Jade is not a variable interest entity as it has sufficient equity at risk in order to fund its next development milestones;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade stockholders will own a substantial majority of the voting rights in the Combined Company through existing ownership and additional interest through the Subscription Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade&#8217;s largest stockholder will retain the largest interest in the Combined Company (38.2%);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade will designate the initial members of the board of directors of the Combined Company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jade&#8217;s executive management team will become the management of the Combined Company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Combined Company will be renamed &#8220;Jade Biosciences,&#160;Inc.&#8221;</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As a result of Jade being the accounting acquirer, Jade&#8217;s assets and liabilities will be recorded at their pre- combination carrying amounts. Aerovate&#8217;s assets and liabilities will be measured and recognized at their fair values as of the effective time of the Merger, which are expected to approximate the carrying value of the acquired other non-operating assets and liabilities, with no goodwill or other intangible assets recorded. Any difference between the consideration transferred and the fair value of the net assets of Aerovate following the determination of the actual consideration transferred for Aerovate will be reflected as an adjustment to additional paid-in capital. For periods prior to Closing, the historical financial statements of Jade shall become the historical financial statements of the Combined Company.</p><a id="_3ef06dda_74f0_4bc8_8413_2fab32504b23"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></span><b style="font-weight:bold;">Shares of Aerovate Common Stock, Convertible Preferred Stock, Options, and Warrants Issued to Jade Stockholders upon Closing of the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">At Closing, all outstanding shares of Jade common stock, on a fully-diluted basis, will be exchanged for shares of Aerovate common stock based on the preliminary estimated Exchange Ratio of 21.4388 shares of Aerovate common stock for each share of Jade common stock, determined in accordance with the terms of the Merger Agreement. The estimated number of shares of Aerovate common stock that Aerovate expects to issue to Jade&#8217;s stockholders assumes Aerovate&#8217;s Net Cash at Closing is $0 and is determined as follows:</p><a id="_Hlk183450670"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Shares of Jade common stock outstanding as of September 30, 2024<sup style="font-size:7.5pt;letter-spacing:0.15pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:12.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,819,672</p></td><td style="vertical-align:bottom;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Shares of Jade common stock to be issued upon conversion of Jade convertible preferred stock</p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20,000,000</p></td><td style="vertical-align:bottom;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Shares of Jade common stock issued upon exercise of Jade stock options<sup style="font-size:7.5pt;letter-spacing:0.15pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,637,978</p></td><td style="vertical-align:bottom;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Estimated shares of Jade common stock to be issued in connection with the Subscription Agreement, see Note&#160;5(c)</p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">42,875,050</p></td><td style="vertical-align:bottom;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Estimated Jade prefunded warrants to be issued in connection with the Subscription Agreement, see Note 5(c)</p></td><td style="vertical-align:bottom;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11,997,906</p></td><td style="vertical-align:bottom;width:0.46%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total Jade fully diluted shares prior to the Closing</p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.85%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">84,330,606</p></td><td style="vertical-align:bottom;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Estimated Exchange Ratio</p></td><td style="vertical-align:bottom;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">21.4388</p></td><td style="vertical-align:bottom;width:0.46%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Estimated fully diluted shares to be issued to existing Jade stockholders and investors participating in Jade Pre-Closing Financing upon the Closing</p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.85%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,807,946,994</p></td><td style="vertical-align:bottom;width:0.46%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(1)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">Represents shares of Jade common stock outstanding as of September&#160;30, 2024, including 819,672 shares of unvested Jade Restricted Stock.</span></p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">312</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(2)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">Represents the outstanding options as of September&#160;30, 2024 to acquire Jade common stock and stock options granted in October&#160;2024 to acquire Jade common stock.</span></p></td></tr></table><a id="_8de23637_c353_484e_afe6_359a86678f57"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.</b></span><b style="color:#231f20;font-weight:bold;">Adjustments to </b><b style="font-weight:bold;">Unaudited</b><b style="color:#231f20;font-weight:bold;"> Pro Forma Condensed Combined Balance Sheet as of September&#160;30, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The pro forma notes and adjustments, based on preliminary estimates that could change materially as additional information is obtained, are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pro forma notes:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">5(A)&#160;Derived from the unaudited condensed consolidated balance sheet of Aerovate as of September&#160;30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">5(B)&#160;Derived from the audited balance sheet of Jade as of September&#160;30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pro forma Balance Sheet Transaction Accounting Adjustments:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">5(a)&#160;To reflect preliminary estimated incremental compensation expense of $1.2 million related to severance payments and change in control bonus resulting from pre-existing employment agreements or from approval from Aerovate&#8217;s board of directors that is expected to be incurred upon the Closing. This amount is in addition to existing severance payments of $3.9 million owed and unpaid by Aerovate at September&#160;30, 2024. The pro forma adjustment is reflected as a decrease in cash of $5.1 million for the severance payments made subsequent to September&#160;30, 2024, a decrease to accrued expenses of $3.9 million and an increase to accumulated deficit of $1.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">5(b)&#160;To reflect the exchange of all outstanding shares of Jade Preferred Stock, with a carrying amount of less than $0.1 million, into new created Aerovate Series&#160;A Preferred Stock at Closing, with the terms of Aerovate Series&#160;A Preferred Stock expected to result in classification within stockholders&#8217; equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">5(c)&#160;To reflect an incremental fair value adjustment of $24.3 million of convertible notes, reflecting the 20% discount on convertible notes and accrued interest immediately prior to the conversion, as well as the issuance of 42,875,050 shares of Jade common stock and 11,997,906 pre-funded warrants, prior to giving effect to the Exchange Ratio, pursuant to the Subscription Agreement, which includes the $95.0 million Jade convertible notes previously issued. The incremental change in fair value of the convertible notes of $24.3 million is adjusted for pro forma purposes through accumulated deficit at September 30, 2024 and as an expense in the earliest income statement period presented, i.e., the statement of operations for the year ended December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The net cash proceeds received prior to direct and incremental transaction costs from the Subscription Agreement and corresponding adjustment to additional paid-in-capital upon close of the Merger is determined as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:90%;"><tr><td style="vertical-align:bottom;width:66.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Subscription</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Convertible</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Agreement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Proceeds received from the Subscription Agreement and convertible notes, prior to direct and incremental costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">205,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">95,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">300,000</p></td></tr><tr><td style="vertical-align:bottom;width:66.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Fair value adjustment previously accured as of September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,700</p></td></tr><tr><td style="vertical-align:bottom;width:66.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Fair value adjustment related to the conversion of the convertible notes (see note 6(e))</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">24,286</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">24,286</p></td></tr><tr><td style="vertical-align:bottom;width:66.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Aggregate purchase price of the Subscription Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">205,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">120,986</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">325,986</p></td></tr><tr><td style="vertical-align:bottom;width:66.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Issuance of Jade common stock and pre-funded warrants at par value upon Closing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(5)</p></td></tr><tr><td style="vertical-align:bottom;width:66.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Additional paid-in capital related to the issuance of Jade common stock and pre-funded warrants upon Closing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">204,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">120,984</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">325,981</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">5(d)&#160;To reflect preliminary estimated transaction costs of $23.1 million, not yet reflected in the historical financial statements, that are expected to be incurred by Jade in connection with the Merger, and $1.2 million reflected in the historical financial statements as deferred offering costs, such as advisory, legal and auditor fees, as a reduction in cash and a reduction in other assets in the unaudited pro forma condensed combined balance sheet. As the Merger will be accounted for as a reverse </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">313</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">recapitalization equivalent to the issuance of equity for the net assets, primarily cash, of Aerovate, these direct and incremental costs are treated as a reduction of the net proceeds received within additional paid-in capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">5(e)&#160;To reflect preliminary estimated transaction costs of $6.8 million, not yet reflected in the historical financial statements, which are expected to be incurred by Aerovate in connection with the Merger, such as advisory, legal and auditor fees and including the estimated $1.2 million cost of a D&amp;O tail policy, as a reduction in cash of $6.8 million, and a reduction in accumulated deficit of $6.8 million in the unaudited pro forma condensed combined balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">5(f)&#160;To derecognize $1.0 million of Aerovate&#8217;s prepaid expenses consisting of $0.1 million of prepaid expenses related to software that will not be utilized and $0.9 million of prepaid insurance primarily related to the current Aerovate&#8217;s D&amp;O insurance policy that will be fully utilized at Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">5(g)&#160;To reflect the derecognition of Aerovate&#8217;s operating leases that will expire prior to the Closing and the derecognition of property and equipment that will be fully depreciated prior to the Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">5(h)&#160;To reflect the one-time stock compensation expense of $9.4 million in general and administrative expense related to the cancellation of out-of-the-money stock options for no consideration, acceleration of stock options pursuant to pre-existing grant agreements, which provide for such acceleration upon a change in control provision, which will be triggered by the Merger, and to reflect the one-time cash payment of $0.1 million to settle in-the-money stock options per the terms of the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">5(i)&#160;To reflect an estimate of the one-time dividend of $65.0 million declared and paid on the shares of Aerovate&#8217;s common stock outstanding prior to the Merger. The dividend will be treated as a decrease in additional paid-in capital in the unaudited pro forma condensed combined balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">5(j)&#160;To reflect a one-time payment for $4.7 million for the close out of all contracts related to Aerovate&#8217;s worldwide clinical trial that were recorded as accrued research and development expense in the historical financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">5(k)&#160;To reflect the liquidation of Aerovate&#8217;s short-term investments of $57.6 million into cash prior to the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">5(l)&#160;To reflect the recapitalization of Jade and the derecognition of accumulated other comprehensive income and the accumulated deficit of Aerovate, which is reversed to additional paid-in capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The derecognition of accumulated deficit of Aerovate of $245.7 million is determined as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:88.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Accumulated deficit of Aerovate as of September 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">227,622</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Compensation expense related to Aerovate severance payments and change in control bonus, see</span> <span style="letter-spacing:0.2pt;">Note 5(a)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,193</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Preliminary estimated transaction costs of Aerovate, see Note 5(e)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,775</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Derecognition of Aerovate prepaid software expenses and prepaid insurance, see Note 5(f)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">992</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Derecognition of Aerovate operating leases, see Note 5(g)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(267)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Pre-Merger stock-based compensation expense for Aerovate&#8217;s cancelled and accelerated awards,</span> <span style="letter-spacing:0.2pt;">see Note 5(h)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,412</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Total adjustment to derecognize the accumulated deficit of Aerovate</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">245,727</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_0da40ba2_f913_46f4_b877_e7b81a6142aa"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.</b></span><b style="font-weight:bold;">Adjustments to Unaudited Pro Forma Condensed Combined Statement of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The pro forma notes and adjustments, based on preliminary estimates that could change materially as additional information is obtained, are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pro forma notes:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">6(A)&#160;Derived from the unaudited condensed consolidated statement of operations and comprehensive loss of Aerovate for the nine&#160;months ended September&#160;30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">6(B)&#160;Derived from the audited statement of operations and comprehensive loss of Jade for the period June&#160;18, 2024 (inception) to September&#160;30, 2024.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">314</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">6(C)&#160;Derived from the audited consolidated statement of operations and comprehensive loss of Aerovate for the&#160;year ended December&#160;31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade and Aerovate did not record any provision or benefit for income taxes during the nine&#160;months ended September&#160;30, 2024 because each company expects to incur a pre-tax loss in 2024 and each company maintains a full valuation allowance on its deferred tax assets. Accordingly, no pro forma adjustments have an impact on associated income tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pro forma Statements of Operations Transaction Accounting Adjustments:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">6(a)&#160;To reflect preliminary estimated incremental compensation expense related to severance and change in control payments recorded in general and administrative expenses of $1.2 million, resulting from pre-existing employment agreements or from approval from Aerovate&#8217;s board of directors that will be incurred upon Closing, assuming that the adjustment described in Note&#160;5(a)&#160;was made on January&#160;1, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">6(b)&#160;To reflect the derecognition of Aerovate&#8217;s prepaid expenses of $0.1 million related to software that will not be utilized, and prepaid insurance of $0.9 million primarily related to the current Aerovate D&amp;O policy that will be fully utilized at Closing, assuming the adjustment made in Note&#160;5(f)&#160;was made on January&#160;1, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">6(c)&#160;To reflect the derecognition of Aerovate&#8217;s operating leases that will expire prior to the Closing and the derecognition of property and equipment that will be fully depreciated prior to the Closing. The operating lease right-of-use assets and property and equipment of $0.3 million will be derecognized, assuming the adjustment made in Note&#160;5(g)&#160;was made on January&#160;1, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">6(d)&#160;To reflect the one-time stock compensation expense of $9.4 million in general and administrative expense related to the cancellation of out-of-the-money stock options for no consideration, acceleration of stock options pursuant to pre-existing grant agreements which provide for such acceleration upon a change in control provision, which will be triggered by the Merger, assuming the adjustment made in Note&#160;5(h)&#160;was made on January&#160;1, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">6(e)&#160;To reflect the incremental change in fair value related to Jade&#8217;s convertible notes including interest expense that is recorded in its historical financial statements, to be recorded in the unaudited pro forma condensed combined statement of operations for the twelve months ended December 31, 2023, assuming that the adjustment described in Note&#160;5(c)&#160;was made on January&#160;1, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">6(f)&#160;To reflect stock compensation expenses of $0.5 million and $0.4 million for the year ended December 31, 2023 and the nine months ended September 30, 2024, respectively, in general and administrative expense and to reflect stock compensation expenses of $0.1 million and $0.1 million for the year ended December 31, 2023 and the nine months ended September 30, 2024, respectively in research and development, related to stock options expected to be issued to Jade&#8217;s Chief Executive Officer and Chief Scientific Officer to maintain 5.0% and 2.0% ownership, respectively, pursuant to their employment agreements, assuming the adjustment was made on January 1, 2023. These stock options vest over 48 months from the date of issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">6(g)&#160;The pro forma combined basic and diluted net loss per share has been adjusted to reflect the pro forma net loss for the nine months ended September 30, 2024 and the year ended December 31, 2023. In addition, the number of shares used in calculating the pro forma combined basic and diluted net loss per share has been adjusted to reflect the estimated total number of shares of common stock of the Combined Company for the respective periods. Pro forma weighted average shares outstanding includes the pre-funded warrants related to the Subscription Agreement as the exercise price is negligible and they are fully vested and exercisable. Shares of Aerovate Series A Preferred Stock share the same characteristics as common stock and have no substantive preference attributed to them and, accordingly, have been considered a class of common stock in the computation of net loss per share regardless of their legal form. Net loss is allocated to common stock based on its </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">315</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">proportional ownership on an as-converted basis. Net loss is not allocated to participating securities as they do not have an obligation to fund losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">The pro forma weighted average shares have been calculated as follows:</p><a id="_Hlk183945134"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:68.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:top;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:top;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:13.78%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Basic&#160;and&#160;Diluted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:13.7%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Basic&#160;and&#160;Diluted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Net loss attributable to common stockholders</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.56%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(61,468)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.48%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(84,220)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Net loss attributable to Series non-voting convertible preferred stockholders</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(20,086)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(27,567)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Historical weighted average number of Aerovate common shares outstanding</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">28,572,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">26,331,630</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Shares of Aerovate common stock issued to Jade stockholders upon close</span> <span style="letter-spacing:0.2pt;">of Merger, assuming consummation of the Merger as of January 1,</span> <span style="letter-spacing:0.2pt;">2023 </span><sup style="font-size:7.5pt;letter-spacing:0.15pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,283,604,328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,283,604,328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Pro forma combined weighted average number of common shares outstanding</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.56%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,312,176,666</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.48%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,309,935,958</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Pro forma combined weighted average number of shares of Series A Preferred Stock outstanding</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.56%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">428,776</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">428,776</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Net loss per share attributable to common stockholders, basic and diluted</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.56%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.05)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.48%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.06)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(46.84)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(64.29)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">(1)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Represents the shares of Aerovate common stock issued to Jade stockholders at Closing, excluding (i) the outstanding and unvested Jade Restricted Stock and options to purchase Jade common stock at Closing that were converted to the right to receive 17,572,784 shares of the Aerovate common stock and 77,993,882 options to purchase shares of Aerovate common stock, respectively, after reflecting the estimated Exchange Ratio and (ii) the outstanding shares of Jade Preferred Stock that were exchanged for 428,776 shares of Aerovate Series A Preferred Stock. The 17,572,784 shares of Aerovate common stock issued in exchange for shares of Jade Restricted Stock and 77,993,882 options to purchase shares of Aerovate common stock issued in exchange for options to purchase shares of Jade common stock are subject to the same vesting and forfeiture conditions, applicable, as they were prior to the Merger.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">316</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_474747fd_12b4_4b63_90e6_20ad31bd0123"></a><a id="DESCRIPTIONOFAEROVATECAPITALSTOCK_252931"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DESCRIPTION OF AEROVATE CAPITAL STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="white-space:pre-wrap;">The following description of Aerovate&#8217;s capital stock and provisions of the Aerovate Charter and Aerovate&#8217;s amended and restated bylaws are summaries and are qualified by reference to such amended and restated certificate of incorporation and bylaws and applicable provisions of Delaware corporate law. Aerovate has filed copies of these documents  as exhibits to the registration statement of which this proxy statement/prospectus forms a part.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Aerovate&#8217;s authorized capital stock consists of 150,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share, all of which shares of preferred stock are undesignated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">As of November&#160;15, 2024, 28,910,070 shares of Aerovate common stock were outstanding and held by 14 stockholders of record.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The holders of Aerovate common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of Aerovate common stock do not have any cumulative voting rights. Holders of Aerovate common stock are entitled to receive ratably any dividends declared by Aerovate&#8217;s board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Aerovate&#8217;s common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">In the event of Aerovate&#8217;s liquidation, dissolution or winding up, holders of Aerovate common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">When Aerovate issues shares of common stock under this proxy statement/prospectus, the shares will fully be paid and nonassessable and will not have, or be subject to, any preemptive or similar rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Preferred Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Aerovate&#8217;s certificate of incorporation provides for 10,000,000 authorized shares of preferred stock. Aerovate&#8217;s board of directors may determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The purpose of authorizing Aerovate&#8217;s board of directors to issue preferred stock in one or more series and determine the number of shares in the series and its rights and preferences is to eliminate delays associated with stockholder votes on specific issuances. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of Aerovate or other corporate action. As of the date of this proxy statement/prospectus, there are no shares of preferred stock outstanding, and Aerovate has no present plans to issue any shares of preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Series&#160;A Non-Voting Convertible Preferred Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Aerovate&#8217;s board of directors will designate approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of Aerovate preferred stock as Series&#160;A Non-Voting Convertible Preferred Stock (&#8220;Aerovate Series&#160;A Preferred Stock&#8221;) through a certificate of designation in the form attached as <i style="font-style:italic;">Annex K </i>(the &#8220;Certificate of Designation&#8221;), after giving effect to the estimated Exchange Ratio of 21,4388. Holders of the Aerovate Series&#160;A Preferred Stock will be entitled to receive dividends on shares of Aerovate Series&#160;A Preferred Stock equal to, on an as-if-converted-to- Aerovate common stock basis, and in the same form as dividends actually paid on shares of Aerovate common stock. Except as otherwise required by the Certificate of Designation or law, the Aerovate Series&#160;A Preferred Stock will not have voting rights. However, as long as any shares of Aerovate Series&#160;A Preferred Stock are outstanding, Aerovate will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Aerovate Series&#160;A Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to the Aerovate Series&#160;A Preferred Stock, (b)&#160;alter or amend the Certificate of Designation, (c)&#160;amend the Aerovate Charter or Aerovate&#8217;s amended and restated bylaws in any manner that adversely affects any rights of the holders of the Aerovate Series&#160;A Preferred Stock, (d)&#160;file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock (as defined in the Certificate of Designation), if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Aerovate Series&#160;A Preferred Stock, (e)&#160;issue further shares of the Aerovate Series&#160;A Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of the Aerovate Series&#160;A Preferred Stock, (f)&#160;at any time while at least&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of the originally issued Aerovate Series&#160;A Preferred Stock remains issued and outstanding, consummate either (A)&#160;a Fundamental </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">317</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">Transaction (as defined in the Certificate of Designation) or (B)&#160;any merger or consolidation of Aerovate or other business combination in which the stockholders of Aerovate immediately before such transaction do not hold at least a majority of the capital stock of Aerovate immediately after such transaction, or (f)&#160;enter into any agreement with respect to any of the foregoing. The Aerovate Series&#160;A Preferred Stock does not have a preference upon any liquidation, dissolution or winding-up of Aerovate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Following the First Effective Time, each share of Aerovate Series&#160;A Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the holder of the Aerovate Series&#160;A Preferred Stock, into a number of shares equal to 1,000 shares of Aerovate common stock, subject to certain limitations, including that a holder of Aerovate Series&#160;A Preferred Stock is prohibited from converting shares of Aerovate Series&#160;A Preferred Stock into shares of Aerovate common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified&#160;percentage (initially set at&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;%) of the total number of shares of Aerovate common stock issued and outstanding immediately after giving effect to such conversion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Registration Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The holders of 11,041,324 shares of Aerovate common stock are entitled to rights with respect to the registration of such shares under the Securities Act (such shares are referred to herein as the &#8220;Registrable Securities&#8221;). These rights are provided under the terms of an investors&#8217; rights agreement among Aerovate and certain holders of its common stock. The investors&#8217; rights agreement includes demand registration rights, short-form registration rights and piggyback registration rights. All fees, costs and expenses of underwritten registrations under this agreement will be borne by Aerovate and all selling expenses, including underwriting discounts and selling commissions, will be borne by the holders of the shares being registered. The investors&#8217; rights agreement contains customary cross-indemnification provisions, under which Aerovate is obligated to indemnify holders of Registrable Securities in the event of material misstatements or omissions in the registration statement attributable to Aerovate, and they are obligated to indemnify Aerovate for material misstatements or omissions attributable to them. In accordance with the terms of the investors&#8217; rights agreement, the demand registration rights, short-form and piggyback registration rights will terminate upon the Closing. In addition, in connection with the Closing, Aerovate anticipates that the investors&#8217; rights agreement will be terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Anti-Takeover Effects of the Aerovate Charter and Amended and Restated Bylaws and Delaware Law</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Certain provisions of the DGCL and of the Aerovate Charter and amended and restated bylaws could have the effect of delaying, deferring or discouraging another party from acquiring control of Aerovate. These provisions, which are summarized below, are expected to discourage certain types of coercive takeover practices and inadequate takeover bids and, as a consequence, they might also inhibit temporary fluctuations in the market price of Aerovate&#8217;s common stock that often result from actual or rumored hostile takeover attempts. These provisions are also designed in part to encourage anyone seeking to acquire control of Aerovate to first negotiate with Aerovate&#8217;s board of directors. These provisions might also have the effect of preventing changes in Aerovate&#8217;s management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders might otherwise deem to be in their best interests. However, Aerovate believes that the advantages gained by protecting Aerovate&#8217;s ability to negotiate with any unsolicited and potentially unfriendly acquirer outweigh the disadvantages of discouraging such proposals, including those priced above the then-current market value of Aerovate&#8217;s common stock, because, among other reasons, the negotiation of such proposals could improve their terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Board Composition and Filling Vacancies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The Aerovate Charter provides for the division of Aerovate&#8217;s board of directors into three classes serving staggered three-year terms, with one class being elected each year. Aerovate&#8217;s certificate of incorporation also provides that directors may be removed only for cause and then only by the affirmative vote of the holders of two-thirds or more of the shares then entitled to vote at an election of directors. Furthermore, any vacancy on Aerovate&#8217;s board of directors, however occurring, including a vacancy resulting from an increase in the size of Aerovate&#8217;s board of directors, may only be filled by the affirmative vote of a majority of Aerovate&#8217;s directors then in office even if less than a quorum. The classification of directors, together with the limitations on removal of directors and treatment of vacancies, has the effect of making it more difficult for stockholders to change the composition of Aerovate&#8217;s board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">No Written Consent of Stockholders</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The Aerovate Charter provides that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special meeting and that stockholders may not take any action by written consent in lieu of a meeting. This may lengthen the amount of time required to take stockholder actions and would prevent the amendment of Aerovate&#8217;s amended and restated bylaws or removal of directors by Aerovate&#8217;s stockholders without holding a meeting of stockholders.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">318</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Meetings of Stockholders</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The Aerovate Charter and Aerovate&#8217;s amended and restated bylaws provide that only a majority of the members of Aerovate&#8217;s board of directors then in office may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Aerovate&#8217;s amended and restated bylaws limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Advance Notice Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Aerovate&#8217;s amended and restated bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of Aerovate&#8217;s stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to Aerovate&#8217;s corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at Aerovate&#8217;s principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual meeting for the preceding year. Aerovate&#8217;s amended and restated bylaws specify the requirements as to form and content of all stockholders&#8217; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Amendment to Certificate of Incorporation and Bylaws</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Any amendment of Aerovate&#8217;s amended and restated certificate of incorporation must first be approved by a majority of Aerovate&#8217;s board of directors, and if required by law or the Aerovate Charter, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of the provisions relating to stockholder action, board of directors composition, and limitation of liability must be approved by not less than two-thirds of the outstanding shares entitled to vote on the amendment, and not less than two-thirds of the outstanding shares of each class entitled to vote thereon as a class. Aerovate&#8217;s amended and restated bylaws may be amended by the affirmative vote of a majority of the directors then in office, subject to any limitations set forth in the amended and restated bylaws; and may also be amended by the affirmative vote of a majority of the outstanding shares entitled to vote on the amendment, voting together as a single class, except that the amendment of the provisions relating to notice of stockholder business and nominations and special meetings must be approved by not less than two-thirds of the outstanding shares entitled to vote on the amendment, and not less than two-thirds of the outstanding shares of each class entitled to vote thereon as a class, or, if Aerovate&#8217;s board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Undesignated Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The Aerovate Charter provides for 10,000,000 authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable Aerovate&#8217;s board of directors to discourage an attempt to obtain control of Aerovate by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, Aerovate&#8217;s board of directors were to determine that a takeover proposal is not in the best interests of Aerovate&#8217;s stockholders, Aerovate&#8217;s board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, the Aerovate Charter grants Aerovate&#8217;s board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of Aerovate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Choice of Forum</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Aerovate&#8217;s amended and restated bylaws provide that, unless Aerovate consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Chancery Court does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) will be the sole and exclusive forum for: (1) any derivative action or proceeding brought on Aerovate&#8217;s behalf; (2) any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of Aerovate&#8217;s directors, officers, employees or agents to Aerovate or its stockholders; (3) any action asserting a claim against Aerovate arising pursuant to any provision of the DGCL or the Aerovate Charter or Aerovate&#8217;s amended and restated bylaws (including the interpretation, validity or enforceability thereof) or (4) any action asserting a claim governed by the internal affairs doctrine. The choice of forum provision does not apply to any actions arising under the Securities Act or the Securities Exchange Act of 1934, as amended. In addition, Aerovate&#8217;s amended and restated bylaws provide that, unless Aerovate consents in writing to the selection of an alternative forum, the federal district courts of the United States shall be the sole and exclusive forum for resolving any complaint asserting a cause or causes of action arising under the Securities Act, including all causes of action asserted against any </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">319</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">defendants to such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by Aerovate, its officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. Any person or entity purchasing or otherwise acquiring any interest in Aerovate&#8217;s securities shall be deemed to have notice of and consented to these forum provisions. These forum provisions may impose additional costs on stockholders, may limit Aerovate&#8217;s stockholders&#8217; ability to bring a claim in a forum they find favorable, and the designated courts may reach different judgments or results than other courts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Delaware Anti-Takeover Statute</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Aerovate is subject to the provisions of Section 203 of the DGCL. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section 203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">before the stockholder became interested, Aerovate&#8217;s board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at or after the time the stockholder became interested, the business combination was approved by Aerovate&#8217;s board of directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">Section 203 defines a business combination to include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any merger or consolidation involving the corporation and the interested stockholder;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges, or other financial benefits provided by or through the corporation.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">320</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_0ef04609_5f92_4714_8b30_3520130b160e"></a><a id="COMPARISONOFRIGHTSOFHOLDERSOFAEROVATECAP"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">COMPARISON OF RIGHTS OF HOLDERS OF AEROVATE CAPITAL STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AND JADE CAPITAL STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Merger is completed, Jade stockholders will receive shares of Aerovate common stock and shares of Aerovate Series A Preferred Stock pursuant to the terms of the Merger Agreement. Prior to or in connection with the Closing, assuming that Proposal Nos. 2 and 3 are approved by Aerovate stockholders, the Aerovate Charter will be amended to effect the reverse stock split and increase the number of shares of Aerovate common stock that Aerovate is authorized to issue from 150,000,000 to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, as set forth in the forms of certificate of amendment attached as <i style="font-style:italic;">Annex B</i> and <i style="font-style:italic;">Annex C</i> to this proxy statement/prospectus, respectively. In addition, after the completion of the Merger, the Aerovate Charter will be amended to change its corporate name to &#8220;Jade Biosciences, Inc.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate and Jade are both incorporated under the laws of the State of Delaware. The rights of Aerovate stockholders and Jade stockholders are generally governed by the DGCL. Upon completion of the Merger, Jade stockholders will become Aerovate stockholders, and their rights will be governed by the DGCL, the amended and restated bylaws of Aerovate and the Aerovate Charter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The material differences between the current rights of Jade stockholders under the Jade certificate of incorporation and bylaws and their rights as Aerovate stockholders, after the Merger, under the Aerovate Charter and Aerovate&#8217;s amended and restated bylaws, both as will be in effect immediately following the completion of the Merger, are summarized below. The summary below does not purport to be complete and is subject to, and qualified in its entirety by reference to, the DGCL and the governing corporate instruments that are subject to amendment in accordance with their terms. You should carefully read this entire document and the other referenced documents, including the governing corporate instruments, for a more complete understanding of the differences between being a stockholder of Aerovate or Jade before the Merger and being a stockholder of the Combined Company following the completion of the Merger. For more information on how to obtain these documents, please see the section titled &#8220;<i style="font-style:italic;">Where You Can Find More Information</i>&#8221; beginning on page&#160;336 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Proposal No. 4 is approved by Aerovate stockholders and the Merger is completed, the Combined Company will effect the Nevada Redomestication pursuant to the Plan of Conversion as set forth in the form attached as <i style="font-style:italic;">Annex D</i> to this proxy statement/prospectus, and, upon completion of the Nevada Redomestication, the rights of Aerovate stockholders and the rights of Jade stockholders who become Combined Company stockholders pursuant to the Merger will no longer be governed by the Aerovate Charter, Aerovate&#8217;s amended and restated bylaws and the DGCL and instead will be governed by a Nevada articles of incorporation, Nevada bylaws and the Nevada Revised Statutes. For a comparison of rights of holders of the Combined Company capital stock as a Delaware corporation and the Combined Company capital stock as a Nevada corporation, assuming the completion of the Nevada Redomestication, see the section titled &#8220;<i style="font-style:italic;">Proposal No. 4 &#8212; The Redomestication Proposal &#8212; Effects of the Nevada Redomestication &#8212; Comparison of Rights of Holders of the Delaware Corporation Capital Stock and the Nevada Corporation Capital Stock</i>&#8221; beginning on page 172 of this proxy statement/prospectus.</p><a id="_Hlk183600445"></a><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:49.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Aerovate</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Jade</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Organizational Documents</i></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The rights of Aerovate&#8217;s stockholders are governed by the Aerovate Charter, Aerovate&#8217;s amended and restated bylaws and the DGCL.</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The rights of Jade&#8217;s stockholders are governed by Jade&#8217;s certificate of incorporation (the &#8220;Jade Charter&#8221;), Jade&#8217;s bylaws (the &#8220;Jade Bylaws&#8221;) and the DGCL.</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Authorized Capital Stock</i></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Aerovate is authorized to issue two classes of capital stock which are designated, respectively, &#8220;common stock&#8221; and &#8220;undesignated preferred stock.&#8221; The total number of shares that Aerovate will be authorized to issue is &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, of which &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares are common stock, par value $0.0001 per share, and 10,000,000 shares are undesignated preferred stock, par value $0.0001 per share. The number of authorized shares of Aerovate common stock or undesignated preferred stock may be increased or decreased (but not below the number of shares of such class then outstanding) by the affirmative vote of the holders of a majority of the voting power of the outstanding shares of capital stock of Aerovate entitled to vote thereon, irrespective of the provisions of Section&#160;242(b)(2)&#160;of the DGCL.</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Jade is authorized to issue two classes of capital stock which are designated, respectively, &#8220;common stock&#8221; and &#8220;preferred stock.&#8221; The total number of shares that Jade is authorized to issue is 60,000,000, of which 40,000,000 shares are common stock, par value $0.0001 per share, and 20,000,000 shares are preferred stock, par value $0.0001 per share. The number of authorized shares of Jade common stock may be increased or decreased (but not below the number of shares thereof then outstanding) by (in addition to any vote of the holders of one or more series of Jade preferred stock that may be required under the Jade Charter) the affirmative vote of the holders of shares of Jade capital stock representing a majority of the votes represented by all </span></p></td></tr></table></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">321</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:49.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Aerovate</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Jade</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">outstanding shares of Jade capital stock entitled to vote, irrespective of the provisions of Section&#160;242(b)(2)&#160;of the DGCL.</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Common Stock</i></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Aerovate&#8217;s authorized common stock will consist of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of common stock.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Each holder of a share of Aerovate common stock is entitled to one vote for each such share held of record on the applicable record date on each matter voted on at a meeting of stockholders.</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Jade&#8217;s authorized common stock consists of 40,000,000 shares of common stock, par value $0.0001 per share.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Each holder of a share of Jade common stock is entitled to one vote for each such share held of record on the applicable record date on each matter voted on at a meeting of stockholders (and written actions in lieu of meetings).</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Preferred Stock</i></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Aerovate&#8217;s authorized preferred stock consists of 10,000,000 shares of undesignated preferred stock. No shares of Aerovate undesignated preferred stock are currently outstanding.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">In connection with the Merger, Aerovate&#8217;s board of directors will designate shares of undesignated preferred stock as Aerovate Series&#160;A Preferred Stock through the Certificate of Designation. No shares of Aerovate Series&#160;A Preferred Stock are currently authorized or outstanding. As long as any shares of Aerovate Series&#160;A Preferred Stock are outstanding, Aerovate will not, without the affirmative vote or written waiver of the holders of a majority of the then outstanding shares of the Aerovate Series&#160;A Preferred Stock: (i)&#160;alter or change adversely the powers, preferences or rights given to the Aerovate Series&#160;A Preferred Stock or alter or amend the Certificate of Designation, amend or repeal any provision of, or add any provision to, the Aerovate Charter or Aerovate&#8217;s amended and restated bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Aerovate preferred stock, in each case if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Aerovate Series&#160;A Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the Aerovate Charter or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (ii)&#160;issue further shares of Aerovate Series&#160;A Preferred Stock beyond those contemplated for issuance in the Merger Agreement or increase or decrease (other than by conversion) the number of authorized shares of Aerovate Series&#160;A Preferred Stock, (iii)&#160;at any time while at least % of the originally issued Aerovate Series&#160;A Preferred Stock remains issued and outstanding, consummate either: (A)&#160;any Fundamental Transaction (as defined in the Certificate of Designation) or (B)&#160;any merger or consolidation of Aerovate with or into another entity or any stock sale to, or other business combination in which the stockholders of Aerovate immediately before such transaction do not hold at least a majority on an as-converted-to-Aerovate common stock basis of the capital stock of Aerovate, immediately after such transaction or (iv) </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">enter into any agreement with respect to any of the foregoing that does not explicitly require the approval contemplated herein to consummate such transaction.</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">All of Jade&#8217;s 20,000,000 shares of preferred stock are designated as shares of &#8220;Series&#160;Seed Preferred Stock,&#8221; of which 20,000,000 are issued and outstanding. On each matter voted on at a meeting of stockholders (and written actions in lieu of meetings), each holder of a share of Jade preferred stock is entitled to cast the number of votes equal to the number of whole shares of Jade common stock into which the shares of preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter.</span> <span style="font-family:'Times New Roman','Times','serif';">Holders of Jade preferred stock vote together with holders of Jade common stock as a single class and on an as-converted to common stock basis.</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">322</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><div style="margin-left:0pt;"><a id="_Hlk183633048"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:49.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Aerovate</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Jade</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Number and Qualification of Directors</i></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The number of Aerovate directors is fixed from time to time by resolution of the Aerovate board of directors. Following the completion of the Merger, Aerovate&#8217;s board of directors is expected to consist of six members. No decrease in the authorized number of directors constituting the Aerovate board of directors will shorten the term of any incumbent director. Directors need not be stockholders of Aerovate.</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The number of directors of Jade is established from time to time by the board of directors. Jade&#8217;s board of directors currently consists of six members. Any decrease in the authorized number of directors shall not become effective until the expiration of the term of the directors then in office, unless, at the time of such decrease, there are vacancies on the board which are eliminated by the decrease.</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Structure of Board of Directors; Term of Directors; Election of Directors</i></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Other than any directors elected by the separate vote of the holders of any series of Aerovate undesignated preferred stock, the Aerovate board of directors is divided into three classes, designated as Class&#160;I, Class&#160;II and Class&#160;III, respectively. Directors are assigned to each class in accordance with a resolution or resolutions adopted by the Aerovate board of directors. At each succeeding annual meeting of stockholders, directors are elected for a full term of three&#160;years to succeed the directors of the class whose terms expire at such annual meeting.</span> <span style="font-family:'Times New Roman','Times','serif';">Notwithstanding the foregoing, directors elected to each class hold office until their successors are duly elected and qualified or until their earlier resignation, death or removal. Directors are elected by a plurality of the votes properly cast.</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Jade directors shall be elected at the annual meeting of stockholders by such stockholders as have the right to vote on such election. Election of directors need not be by written ballot. Each director shall hold office for a term of one&#160;year and until his or her successor is elected and qualified, or until such director&#8217;s earlier resignation or removal. All elections shall be determined by a plurality of the votes cast, except as otherwise required by law.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The holders of record of the shares of Jade Preferred Stock, voting together exclusively and as a separate class, are entitled to elect one director of Jade. The holders of record of the shares of common stock and of any other class or series of voting stock (including the Jade Preferred Stock), exclusively and voting together as a single class on an as-converted to common stock basis, shall be entitled to elect the balance of the total number of directors.</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Removal of Directors</i></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Subject to the rights of the holders of any series of Aerovate undesignated preferred stock to elect directors, or except as otherwise provided by the DGCL or the Aerovate Charter, any director may be removed from office at any time, but only with cause and only by the affirmative vote of the holders of not less than two-thirds (66</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2/3</sup><span style="font-family:'Times New Roman','Times','serif';">%) of the outstanding shares of capital stock of Aerovate then entitled to vote at an election of directors.</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Any director may be removed, with or without cause, by the holders of a majority of shares of the class or series of capital stock entitled to elect such director, voting together as a single class on an as-converted to common stock basis, given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders.</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Vacancies on the Board of Directors</i></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Any director may resign at any time upon notice in writing or electronic transmission to Aerovate&#8217;s Chairman of the board of directors, President or Secretary. Such resignation shall be effective upon receipt, unless the resignation otherwise provides. Subject to any limitations imposed by applicable law and subject to the rights of the holders of any series of Aerovate undesignated preferred stock, all vacancies, however occurring, including, without limitation, by reason of an increase in the size of the board of directors, shall be filled solely and exclusively by the affirmative vote of a majority of the remaining directors then in office, even if less than a quorum of the board of directors, and not by the stockholders. Any director elected in accordance with the preceding sentence will hold office for the remainder of the full term of the class of the directors for which the vacancy was created or occurred and until such director&#8217;s successor is elected and qualified or until his or her earlier resignation, death or removal.</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Any director may resign at any time upon notice given in writing or by electronic transmission to Jade. Such resignation shall be effective upon receipt unless it is specified to be effective at some other time or upon the happening of some other event. A vacancy in any director seat not reserved for holders of Jade Preferred Stock can be filled by either (A) the vote or written consent in lieu of a meeting of the stockholders entitled to elect the director, or (B) the vote or written consent in lieu of a meeting of a majority of the remaining director(s), although less than a quorum. Vacancies and newly created directorships resulting from any increase in the authorized number of directors may be filled by a majority of the directors then in office, though less than a quorum, or by a sole remaining director, and the directors so chosen shall hold office until the next annual election and until their successors are duly elected and shall qualify, unless sooner </span></p></td></tr></table></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">323</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:49.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Aerovate</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Jade</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">displaced. If there are no directors in office, then an election of directors may be held in the manner provided by statute.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">If the holders of shares of Jade Preferred Stock fail to elect a sufficient number of directors to fill all directorships for which they are entitled to elect directors, then any directorship not so filled shall remain vacant until such time as the holders of the Jade Preferred Stock elect a person to fill such directorship.</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Stockholder Action by Written Consent</i></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">No action may be taken by the stockholders except at an annual or special meeting of stockholders called in accordance with Aerovate&#8217;s amended and restated bylaws, and no action may be taken by the stockholders by written consent.</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Any action required or permitted to be taken at any annual or special meeting of stockholders may be taken without a meeting, without prior notice and without a vote, if a consent in writing, setting forth the action so taken, is signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. Every written consent shall bear the date of signature of each stockholder who signs the consent, and no written consent shall be effective to take the corporate action referred to therein unless, within 60&#160;days of the earliest dated consent delivered to Jade, a written consent signed by a sufficient number of stockholders to take action are delivered to Jade.</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Quorum</i></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Unless otherwise provided by law, the Aerovate Charter, or Aerovate&#8217;s amended and restated bylaws, at each meeting of stockholders the holders of a majority of the outstanding shares of stock entitled to vote at the meeting, present in person or represented by proxy, will constitute a quorum for the transaction of business. If less than a quorum is present at a meeting, the holders of voting stock representing a majority of the voting power present at the meeting or the presiding office may adjourn the meeting from time to time, and the meeting may be held as adjourned without further notice.</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Except as otherwise provided by the DGCL or the Jade Charter, the holders of a majority of the voting power of all of the shares of stock entitled to vote at the meeting, present in person or by proxy, shall constitute a quorum for all purposes. Where a separate vote by a class or series is required, a majority of the voting power of the shares of such class or series present in person or represented by proxy shall constitute a quorum entitled to take action with respect to that vote on that matter. The stockholders present at a duly constituted meeting may continue to transact business until adjournment notwithstanding the withdrawal of enough stockholders to reduce the voting shares below a quorum. If a quorum shall fail to attend any meeting, the chairman of the meeting or the holders of a majority of the shares of stock entitled to vote who are present, in person or by proxy, may adjourn the meeting to another place, if any, date, or time.</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Special Meetings of Stockholders</i></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Except as otherwise required by statute and subject to the rights, if any, of the holders of any series of undesignated preferred stock, special meetings of stockholders may be called only by the Aerovate board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office. Special meetings may not be called by any other person or persons.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Only those matters set forth in the notice of the special meeting may be considered or acted upon at such special meeting. Nominations of persons for election to Aerovate&#8217;s board of directors and stockholder proposals of other business shall not be brought before a special meeting of stockholders to be considered by the stockholders unless such special meeting is held in lieu of </span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Special meetings of the stockholders, for any purpose or purposes prescribed in the notice of the meeting, may be called by Jade&#8217;s board of directors or the Chief Executive Officer if one is elected, or the President, and shall be held at such place, date, and time as they or he or she shall fix.</span></p></td></tr></table></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">324</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:49.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Aerovate</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Jade</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">an annual meeting of stockholders in accordance with the Aerovate&#8217;s bylaws.</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Notice of Stockholder Meetings</i></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Notice of each meeting of stockholders stating the hour, date and place, if any, of such meeting and the means of remote communication, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting shall be given not less than ten (10)&#160;days nor more than sixty (60)&#160;days before the meeting, to each stockholder entitled to vote thereat by delivering such notice to such stockholder or by mailing it to the stockholder&#8217;s address of record. Without limiting the manner by which notice may otherwise be given to stockholders, any notice to stockholders may be given by electronic transmission in the manner provided in Section&#160;232 of the DGCL. Notice of special meetings must also state the purpose(s)&#160;for which the meeting has been called.</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Except as otherwise provided by the DGCL or the Jade Charter, notice of the place, if any, date, and time of all meetings of the stockholders, the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, and the record date for determining the stockholders entitled to vote at the meeting, shall be given not less than 10&#160;days nor more than 60&#160;days before the date of the meeting to each stockholder entitled to vote at such meeting as of the record date for determining the stockholders entitled to notice of the meeting.</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Advance Notice Requirements for Stockholder Proposals</i></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Nominations of persons for election to the Aerovate board of directors and the proposal of business other than nominations to be considered by the stockholders may be made at an annual meeting of stockholders only (i)&#160;by or at the direction of the Aerovate board of directors or (ii)&#160;by any stockholder of Aerovate who is a stockholder of record at the time of giving notice provided for in Aerovate&#8217;s amended and restated bylaws, who is entitled to vote at the meeting, who is present (in person or by proxy) at the meeting and who complies with the notice procedures set forth in Aerovate&#8217;s amended and restated bylaws. For the avoidance of doubt, the foregoing clause (ii)&#160;is the exclusive means for a stockholder to make director nominations and submit other business (other than matters properly included in the corporation&#8217;s notice of meeting of stockholders and proxy statement under Rule&#160;14a-8 under the Exchange Act) before an annual meeting of stockholders.</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Neither the Jade Charter nor the Jade Bylaws contain advance notice requirements for stockholder proposals.</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Amendment of Certificate of Incorporation</i></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The affirmative vote of the majority of the outstanding shares of capital stock entitled to vote, and the affirmative vote of the majority of the outstanding shares of each class entitled to vote thereon as a class, at a duly constituted meeting of stockholders called expressly for such purpose, is required to amend or repeal provisions of the Aerovate Charter; provided, however, that the affirmative vote of not less than two-thirds (2/3) of the outstanding shares of capital stock entitled to vote</span> <span style="font-family:'Times New Roman','Times','serif';"> on such amendment or repeal, and the affirmative vote of not less than two-thirds (2/3) of the outstanding shares of each class entitled to vote thereon as a class, shall be required to amend or repeal any provision of Article V (Shareholder Action), Article VI (Directors), Article VII (Limitations of Liability), Article VIII (Amendment of By-Laws) or Article IX (Amendment of Certificate of Incorporation) of the Aerovate Charter.</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Jade Charter may be amended pursuant to Section&#160;242 of the DGCL; provided that, at any time when shares of preferred stock are outstanding, the written consent or affirmative vote of the holders of at least a majority of the outstanding shares of preferred stock, voting together as a single class on an as-converted to common stock basis (the &#8220;Requisite Holders&#8221;), is required to (i)&#160;amend, alter or repeal of any provision of the Jade Charter in a manner that adversely affects the special rights, powers, and preferences of the preferred stock or any series thereof, (ii)&#160;create or issue any capital stock unless the same ranks junior to the preferred stock with respect to its special rights, powers and preferences or (iii)&#160;increase the authorized number of shares of preferred stock or any additional class or series of capital stock of Jade unless the same ranks junior to the preferred stock with respect to its special rights, powers and preferences.</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Amendment of Bylaws</i></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The affirmative vote of not less than two-thirds (2/3) of the outstanding shares of capital stock entitled to vote on such </span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Jade Bylaws may be amended or repealed by Jade&#8217;s board of directors or by the stockholders; provided that, at any time when </span></p></td></tr></table></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">325</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><div style="margin-left:0pt;"><a id="_Hlk183933169"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:49.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Aerovate</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Jade</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">amendment or repeal, voting together as a single class, is required to amend or repeal Aerovate&#8217;s amended and restated bylaws; provided, however, that if the Aerovate board of directors recommends that stockholders approve such amendment or repeal, such amendment or repeal shall only require the affirmative vote of the majority of the outstanding shares of capital stock entitled to vote on such amendment or repeal at such meeting of stockholders, voting together as a single class. Except as otherwise provided by law, Aerovate&#8217;s bylaws may be amended or repealed by the Aerovate board of directors by the affirmative vote of a majority of the directors then in office.</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">shares of preferred stock are outstanding, the written consent or affirmative vote of the Requisite Holders is required to amend, alter or repeal of any provision of the Jade Bylaws in a manner that adversely affects the special rights, powers, and preferences of the preferred stock or any series thereof.</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Limitation on Director or Officer Liability</i></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Aerovate Charter provides that a director of Aerovate will not be personally liable to Aerovate or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (a) for any breach of the director&#8217;s duty of loyalty to Aerovate or its stockholders, (b) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (c) under Section 174 of the DGCL or (d) for any transaction from which the director derived an improper personal benefit. If the DGCL is amended after the effective date of the Aerovate Charter to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director to Aerovate will be eliminated or limited to the fullest extent permitted by the DGCL as so amended.</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Jade Charter provides that, to the fullest extent permitted by law, a director or officer of Jade shall not be personally liable to Jade or its stockholders for monetary damages for breach of fiduciary duty as a director or officer. If the DGCL or any other law of the State of Delaware is amended to authorize corporate action further eliminating or limiting the personal liability of directors or officers, then the liability of a director or officer of Jade shall be eliminated or limited to the fullest extent permitted by the DGCL as so amended.</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Indemnification</i></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">To the fullest extent permitted by the DGCL, Aerovate is authorized to provide indemnification of (and advancement of expenses to) directors, officers and non-officer employees of Aerovate (and any other persons to which applicable law permits Aerovate to provide indemnification) through provisions of Aerovate&#8217;s amended and restated bylaws, agreements with such persons, vote of stockholders or disinterested directors or otherwise in excess of the indemnification and advancement otherwise permitted by the DGCL. </span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Jade Charter (i) requires Jade to indemnify, to the fullest extent permitted by applicable law, any director or officer of Jade, and (ii) authorizes jade to indemnify, to the extent permitted by the DGCL, any employee or agent of Jade, who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (for purposes of this paragrpah, a &#8220;proceeding&#8221;) by reason of the fact that he or she is or was a director, officer, employee or agent of Jade or is or was serving at the request of Jade as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any such proceeding. Jade is required to indemnify a director or officer in connection with a proceeding initiated by such person only if the proceeding was authorized by Jade&#8217;s board of directors.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Jade Bylaws require Jade to indemnify, to the fullest extent permitted by Delaware law, except in certain circumstances, each person who was or is made a party to or is threatened to be made a party to or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (for purpose of this paragraph, a &#8220;proceeding&#8221;), by reason of the fact that he or she is or was a director or an officer of Jade or is or was serving at the request of Jade as a director, </span></p></td></tr></table></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">326</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:49.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Aerovate</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Jade</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">officer, or trustee of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to an employee benefit plan (for purpose of this paragraph, an &#8220;indemnitee&#8221;), whether the basis of such proceeding is alleged action in an official capacity as a director, officer or trustee, or in any other capacity while serving as a director, officer or trustee. The Jade Bylaws also provide that an indemnitee will have the right to be paid by Jade expenses (including attorney&#8217;s fees) incurred in defending any such proceeding in advance of its final disposition, provided, however, that, if the DGCL requires, an advancement of expenses incurred by an indemnitee in his or her capacity as a director or officer shall be made only upon delivery to Jade of an undertaking, by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal that such indemnitee is not entitled to be indemnified for such expenses. The Jade Bylaws also provide that the rights to indemnification and advance of expenses shall not be exclusive of any other right which any person may have or hereafter acquire under any statute, the Jade Charter, the Jade Bylaws, agreement, vote of stockholders or disinterested directors or otherwise.</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Conversion Rights</i></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Aerovate does not currently have any outstanding shares of undesignated preferred stock.</span> <span style="font-family:'Times New Roman','Times','serif';">In connection with the Merger, Aerovate&#8217;s board of directors will designate approximately &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of Aerovate Series A Preferred Stock through the Certificate of Designation. Following the First Effective Time, each share of Aerovate Series A Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the holder of Aerovate Series A Preferred Stock, into a number of shares equal to 1,000 shares of Aerovate common stock, subject to certain limitations, including that a holder of Aerovate Series A Preferred Stock is prohibited from converting shares of Aerovate Series A Preferred Stock into shares of Aerovate common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">%) of the total number of shares of Aerovate common stock issued and outstanding immediately after giving effect to such conversion.</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Jade Charter provides that holders of preferred stock have the right to convert such shares into shares of common stock, at the option of the holder, at any time, at a conversion rate in accordance with the terms set forth in the Jade Charter. In addition, upon the earliest to occur of (i) immediately prior to the closing of the sale of shares of common stock to the public at a price of at least $1.00 per share (subject to appropriate adjustment for any stock dividend, stock split, combination or other similar recapitalization with respect to the common stock), in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act, resulting in at least $50,000,000 of gross proceeds, net of the underwriting discount and commissions, to Jade and in connection with such offering the shares of Jade common stock are listed for trading on the Nasdaq Stock Market&#8217;s National Market, the New York Stock Exchange or another exchange or marketplace approved by Jade&#8217;s board of directors; and (ii) the date and time, or the occurrence of an event, specified by vote or written consent of the Requisite Holders, (A) all outstanding shares of preferred stock other than the Jade Preferred Stock will automatically be converted into shares of common stock and (B) all outstanding shares of Jade Preferred Stock will automatically be converted into shares of non-voting preferred stock with the rights, privileges, duties and obligations to be determined, at the then effective conversion rate as calculated in accordance with the Jade Charter.</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Preemptive Rights</i></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Aerovate stockholders do not have preemptive rights. Thus, if additional shares of Aerovate common stock are issued, the current holders of Aerovate common stock will own a proportionately smaller interest in a larger number of outstanding </span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Jade stockholders do not have preemptive rights. Thus, if additional shares of Jade common stock are issued, the current holders of Jade common stock will own a proportionately smaller interest in a larger number of outstanding shares of common </span></p></td></tr></table></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">327</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:49.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Aerovate</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Jade</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">shares of common stock to the extent that they do not participate in the additional issuance.</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">stock to the extent that they do not participate in the additional issuance.</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Distributions to Stockholders</i></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Subject to any preferential dividend rights of any outstanding preferred stock and the provisions of the Aerovate Charter and applicable law, dividends may be declared and paid or set apart for payment upon Aerovate&#8217;s common stock out of any assets or funds of Aerovate legally available for the payment of dividends, but only when and as declared by the board of directors or any authorized committee thereof. </span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Jade shall not declare, pay or set aside any dividends (other than dividends on shares of common stock payable in shares of common stock) unless holders of preferred stock first receive, or simultaneously receive, a dividend on each outstanding share of preferred stock in an amount calculated in accordance with the Jade Charter.</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Exclusive Forum</i></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Aerovate&#8217;s amended and restated bylaws provide that unless Aerovate consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claims for (i)&#160;any derivative action or proceeding brought on behalf of Aerovate, (ii) </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">any action asserting a claim of breach of a </span><span style="font-family:'Times New Roman','Times','serif';">fiduciary duty owed by any director, officer or other employee of Aerovate to Aerovate or Aerovate&#8217;s stockholders, (iii)&#160;any action asserting a claim arising pursuant to any provision of the DGCL or the Aerovate Charter or Aerovate&#8217;s amended and restated bylaws (including the interpretation, validity or enforceability thereof), or (iv)&#160;any action asserting a claim governed by the internal affairs doctrine. Unless Aerovate consents in writing to the selection of an alternative forum, the federal district courts of the United States shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of Aerovate shall be deemed to have notice of and consented to the forum selection provision of the Aerovate Charter.</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Jade Charter provides that, unless Jade consents in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i)&#160;any derivative action or proceeding brought on behalf of Jade, (ii)&#160;any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of Jade to Jade or Jade&#8217;s stockholders, (iii)&#160;any action asserting a claim against Jade, its directors, officers or employees arising pursuant to any provision of the DGCL, the Jade Charter or the Jade Bylaws or (iv)&#160;any action asserting a claim against Jade, its directors, officers or employees governed by the internal affairs doctrine or that otherwise relates to the internal affairs of Jade, except for, as to each of (i)&#160;through (iv)&#160;</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">above, any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten&#160;days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. These provisions may impose additional costs on Jade&#8217;s stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or were permitted to select another jurisdiction. Additionally, these provisions may limit Jade&#8217;s stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with Jade or its directors, officers or other employees, which may discourage such lawsuits against Jade and its directors, officers and other employees even though an action, if successful, might benefit its stockholders.</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Registration Rights</i></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Certain holders of Aerovate&#8217;s common stock are party to an investors&#8217; rights agreement with Aerovate and have demand registration rights, short-form registration rights and piggyback registration rights. In accordance with the terms of the investors&#8217; rights agreement, the demand registration rights, short-form and piggyback registration rights will terminate upon the closing of the Merger.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">In connection with the Merger, Aerovate will enter into a registration rights agreement with the investors participating in </span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Jade stockholders do not have any registration rights.</span></p></td></tr></table></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">328</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:49.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Aerovate</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Jade</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">the Jade Pre-Closing Financing, pursuant to which, among other things, the Combined Company will agree to prepare and file a resale registration statement covering the resale of certain shares of Aerovate&#8217;s common stock within 30 business days of the Closing pursuant to Rule 415 and to use its commercially reasonable efforts to keep such registration statement continuously effective under the Securities Act. The registration rights agreement also provides that the Combined Company will pay certain expenses relating to such</span> <span style="font-family:'Times New Roman','Times','serif';">registrations and indemnify the applicable securityholders against certain liabilities.</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Stock Transfer Restrictions Applicable to Stockholders</i></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Shares of Aerovate are transferable in the manner prescribed by the DGCL.</span></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Shares of Jade are transferable in the manner prescribed by the DGCL.</span></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">329</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_badb2446_427e_4775_b1fd_9a898033c296"></a><a id="PRINCIPALSTOCKHOLDERSOFAEROVATE_338001"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PRINCIPAL STOCKHOLDERS OF AEROVATE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following table sets forth information, to the extent known by Aerovate or ascertainable from public filings, with respect to the beneficial ownership of Aerovate common stock as of November&#160;15, 2024 by:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each of Aerovate&#8217;s directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each of Aerovate&#8217;s named executive officers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all of Aerovate&#8217;s directors and executive officers as a group; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each person, or group of affiliated persons, who is known by Aerovate to beneficially own greater than 5.0% of Aerovate&#8217;s common stock.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The column entitled &#8220;Shares Beneficially Owned&#8221; is based on a total of 28,910,070 shares of Aerovate common stock outstanding as of November&#160;15, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Beneficial ownership is determined in accordance with the rules&#160;and regulations of the SEC and includes voting or investment power with respect to Aerovate common stock. Shares of Aerovate common stock subject to options that are currently exercisable or exercisable within 60&#160;days of November&#160;15, 2024 are considered outstanding and beneficially owned by the person holding the options for the purpose of calculating the&#160;percentage ownership of that person but not for the purpose of calculating the&#160;percentage ownership of any other person. Except as otherwise noted, the persons and entities in this table have sole voting and investing power with respect to all of the shares of Aerovate common stock beneficially owned by them, subject to community property laws, where applicable. Except as otherwise indicated in the table below, addresses of named beneficial owners are in care of Aerovate Therapeutics,&#160;Inc., 930 Winter Street, Suite&#160;M-500, Waltham, Massachusetts 02451.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PERCENTAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NUMBER&#160;OF</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OF&#160;SHARES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SHARES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OUTSTANDING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BENEFICIALLY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BENEFICIALLY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">NAME OF BENEFICIAL OWNER</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">OWNED</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">OWNED</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Entities affiliated with RA Capital Management,&#160;L.P.</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">9,242,092</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">31.9</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Sofinnova Venture Partners X,&#160;L.P.</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">3,758,686</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">13.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Entities affiliated with TCG Crossover</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">2,240,809</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">7.8</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Entities affiliated with Atlas Venture</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">1,799,232</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">6.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Directors and Named Executive Officers:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#231f20;">Timothy P. Noyes</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">1,040,153</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">3.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#231f20;">Habib J. Dable</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">16,612</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">*</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#231f20;">Allison Dorval</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(7)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">50,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">*</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#231f20;">David Grayzel, M.D.</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)(8)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">1,864,542</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">6.4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#231f20;">Mark Iwicki</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(9)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">169,402</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">*</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#231f20;">Joshua Resnick, M.D.</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(10)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">50,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">*</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#231f20;">Donald J. Santel</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(11)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">31,361</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">*</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#231f20;">George A. Eldridge</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(12)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">209,807</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">*</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#231f20;">All executive officers and directors as a group (8 persons)</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(13)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">3,431,877</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">11.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">%</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Represents beneficial ownership of less than one&#160;percent.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="color:#231f20;">(1)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="color:#231f20;">Based on information provided in a Schedule 13D/A filed on June&#160;20, 2024, by RA Capital Management, </span>L.P. (&#8220;RA Capital&#8221;), Peter Kolchinsky, Rajeev Shah and RA Capital Healthcare Fund,&#160;L.P. (&#8220;RA Healthcare&#8221;). Consists of (i)&#160;7,893,678 shares of common stock held by RA Healthcare, (ii)&#160;987,244 shares of common stock held by RA Capital Nexus Fund,&#160;L.P. (&#8220;RA Nexus&#8221;), and (iii)&#160;311,170 shares of common stock held in a separately managed account (the &#8220;Account&#8221;). In addition, RA Capital, Dr.&#160;Kolchinsky and Mr.&#160;Shah are the beneficial owners of 62,500 shares subject to options held by Dr.&#160;Resnick, a member of our board of directors, 50,000 of which are vested and exercisable within 60&#160;days of November&#160;15, 2024. RA Capital is the investment manager for RA Healthcare, RA Nexus and the Account. The general partner of RA Capital is RA Capital </p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">330</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 19.5pt;">Management GP, LLC (&#8220;RA Capital GP&#8221;), of which Peter Kolchinsky and Rajeev Shah are the managing members. RA Capital, RA Capital GP, Peter Kolchinsky and Rajeev Shah may be deemed to have voting and investment power over the shares held of record by RA Healthcare, RA Nexus and the Account. RA Capital, RA Capital GP, Peter Kolchinsky, and Rajeev Shah disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The address of RA Capital is 200 Berkeley Street, 18th Floor, Boston, Massachusetts 02116.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(2)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">Based on information provided in a Schedule 13D/A filed on February&#160;20, 2024, by Sofinnova Venture Partners X,&#160;L.P. and Sofinnova Management X, L.L.C. Consists of 3,758,686 shares of common stock held by Sofinnova Venture Partners X,&#160;L.P. (&#8220;Sofinnova X&#8221;). Sofinnova Management X, L.L.C. (&#8220;Sofinnova Management&#8221;), is the general partner of Sofinnova X. Maha Katabi, Ph.D., together with James I. Healy, are the managing members of Sofinnova Management. Such individuals and Sofinnova Management may be deemed to beneficially own the shares owned by Sofinnova X. Such </span>individuals and Sofinnova Management expressly disclaim beneficial ownership over all shares except to the extent of any pecuniary interest therein. The address for Sofinnova X and Sofinnova Management is 3000 Sand Hill Road, Building 4, Suite&#160;250, Menlo Park, California 94025.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(3)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">Based on information contained in a Form&#160;13F Holdings Report filed by TCG Crossover Management, LLC on November&#160;14, 2024 and other filings with the SEC. Consists of 2,240,809 shares of common stock held by TCG Crossover I,&#160;L.P. TCG Crossover GP I, LLC is the general partner of TCG Crossover I,&#160;L.P. and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP I, LLC and may be deemed to share voting, investment and dispositive power with respect to these securities. The address for TCG Crossover GP I, LLC and TCG Crossover I,&#160;L.P. is 705 High Street, Palo Alto, CA 94301.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(4)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">Based on information provided in a Form&#160;4 filed on April&#160;11, 2024, by David Grayzel, M.D. Consists of (i)&#160;1,784,730 shares of common stock held by Atlas Venture Fund XII,&#160;L.P. (&#8220;Atlas XII&#8221;) and (ii) 14,502 shares of common stock held by Atlas Venture Associates XII,&#160;L.P. (&#8220;AVA XII LP&#8221;). The general partner of Atlas Fund XII is AVA XII&#160;LP. Atlas Venture Associates XII, LLC (&#8220;AVA XII LLC&#8221;), is the general partner of AVA XII&#160;LP. David Grayzel, M.D. is a member of AVA XII&#160;LLC. Each of AVA XII LP, AVA XII LLC and Dr.&#160;Grayzel may be deemed to beneficially own the shares held by Atlas Fund XII. Each of AVA XII LP, AVA XII LLC and Dr.&#160;Grayzel expressly disclaim beneficial ownership of the securities owned by Atlas Fund XII, except to the extent of its pecuniary interest therein, if </span>any. The address for AVA XII LP, AVA XII LLC and Atlas Fund XII is 300 Technology Sq., 8th Floor, Cambridge, MA 02139.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(5)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">Consists of 1,412,402 shares subject to options held by Mr.&#160;Noyes, 1,040,153 of which are vested and exercisable within 60&#160;days of November&#160;15, 2024.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(6)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">Consists of 41,995 shares subject to options held by Mr.&#160;Dable, 16,612 of which are vested and exercisable within 60&#160;days of November&#160;15, 2024.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(7)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">Consists of 62,500 shares subject to options held by Ms.&#160;Dorval, 50,000 of which are vested and exercisable within 60&#160;days of November&#160;15, 2024.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(8)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">Consists of 77,810 shares subject to options held by Dr.&#160;Grayzel, 65,310 of which are vested and exercisable within 60&#160;days of November&#160;15, 2024, together with 1,784,730 shares of common stock held by Atlas XII and 14,502 shares of common stock held by AVA XII&#160;LP.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(9)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">Consists of 195,997 shares subject to options held by Mr.&#160;Iwicki, 169,402 of which are vested and exercisable within 60&#160;days of November&#160;15, 2024.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(10)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">Consists of 62,500 shares subject to options held by Dr.&#160;Resnick, 50,000 of which are vested and exercisable within 60&#160;days of November&#160;15, 2024.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(11)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">Consists of 52,889 shares subject to options held by Mr.&#160;Santel, 31,361 of which are vested and exercisable within 60&#160;days of November&#160;15, 2024.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(12)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">Consists of (i)&#160;5,022 shares of common stock and (ii)&#160;338,450 shares subject to options held by Mr.&#160;Eldridge, 204,785 of which are vested and exercisable within 60&#160;days of November&#160;15, 2024.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="color:#231f20;">(13)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="color:#231f20;">Includes the shares described in notes (4)&#160;through (12) above.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">331</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_378ca35f_49c2_4d72_bbb3_e39e22321132"></a><a id="PRINCIPALSTOCKHOLDERSOFJADE_445448"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PRINCIPAL STOCKHOLDERS OF JADE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth information known to Jade regarding beneficial ownership of Jade capital stock on an as-converted to Jade common stock basis as of November&#160;15, 2024 for:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each of Jade&#8217;s directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each of Jade&#8217;s executive officers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all of Jade&#8217;s directors and executive officers as a group; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each person, or group of affiliated persons, who is known by Jade to beneficially own greater than 5.0% of Jade&#8217;s common stock.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Beneficial ownership is determined in accordance with the rules&#160;of the SEC and thus represents voting or investment power with respect to Jade&#8217;s securities. Under such rules, beneficial ownership includes any shares over which the individual has sole or shared voting power or investment power as well as any shares that the individual has the right to acquire within 60&#160;days of November&#160;15, 2024. Shares of Jade common stock that an individual has the right to acquire within 60&#160;days of November&#160;15, 2024 are deemed to be outstanding and beneficially owned by the individual for the purpose of computing the&#160;percentage ownership of that individual, but they are not treated as outstanding for the purpose of computing the&#160;percentage ownership of any other person. To Jade&#8217;s knowledge and subject to applicable community property rules, and except as otherwise indicated below, the persons and entities named in the table have sole voting and sole investment power with respect to all shares beneficially owned. The&#160;percentage of beneficial ownership shown prior to the Merger and Jade Pre-Closing Financing in the table below is based on 25,819,672 shares of Jade common stock deemed to be outstanding as of November&#160;15, 2024, assuming the conversion of all outstanding shares of Jade Preferred Stock into shares of Jade common stock. The following table does not reflect any shares of Jade common stock or Jade pre-funded warrants that such holders have agreed to purchase in the Jade Pre-Closing Financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise indicated, the address for each beneficial owner is c/o Jade Biosciences,&#160;Inc., 221 Crescent Street, Building 23, Suite&#160;105, Waltham, MA 02453.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PERCENTAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NUMBER&#160;OF</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OF&#160;SHARES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SHARES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OUTSTANDING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BENEFICIALLY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BENEFICIALLY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">NAME OF BENEFICIAL OWNER</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OWNED</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OWNED</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">5% or Greater Stockholders</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Fairmount Healthcare Fund II,&#160;L.P.</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">20,000,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">77.46</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Paragon Therapeutics,&#160;Inc.</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2) </sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">2,500,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">9.68</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;">Parade Biosciences Holding LLC</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3) </sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">2,500,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">9.68</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Directors and Executive Officers:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#231f20;">Tom Frohlich </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 32pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 32pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 32pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#231f20;">Jonathan Quick</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 32pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 32pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 32pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#231f20;">Andrew King, BVMS, Ph.D.</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4) </sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#231f20;">550,091</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">2.13</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#231f20;">Hetal Kocinsky, M.D.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 32pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 32pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 32pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#231f20;">Elizabeth Balta, J.D.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 32pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 32pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 32pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#231f20;">Eric Dobmeier, J.D.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 32pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 32pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 32pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#231f20;">Christopher Cain, Ph.D.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 32pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 32pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 32pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#231f20;">Tomas Kiselak</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">20,000,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">77.46</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#231f20;">Lawrence Klein, Ph.D.</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">136,612</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 37pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 37pt;"><span style="color:#231f20;">*</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 37pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#231f20;">Erin Lavelle</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 32pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 32pt;"><span style="color:#231f20;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 32pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">All executive officers and directors as a group (10 persons)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20,686,703</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 32pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 32pt;">80.12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Less than 1%.</p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">332</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">(1)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Consists of 20,000,000 shares of Jade common stock issuable upon conversion of 20,000,000 shares of Jade Preferred Stock held directly by Fairmount Fund II. Fairmount serves as investment manager for Fairmount Fund II. Fairmount Fund II has delegated to Fairmount the sole power to vote and the sole power to dispose of all securities held in Fairmount Fund II&#8217;s portfolio. Because Fairmount Fund II has divested itself of voting and investment power over the securities it holds and may not revoke that delegation on less than 61 days&#8217; notice, Fairmount Fund II disclaims beneficial ownership of the securities it holds. The general partner of Fairmount is Fairmount Funds Management GP LLC (&#8220;Fairmount GP&#8221;). As managing members of Fairmount GP, Peter Harwin and Tomas Kiselak may be deemed to have voting and investment power over the shares held by Fairmount Fund II. Fairmount, Fairmount GP, Peter Harwin and Tomas Kiselak disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The address of each of the entities and individuals listed is 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA 19428.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">(2)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Consists of 2,500,000 shares of Jade common stock held by Paragon. Paragon is managed by its board of directors, consisting of Peter Harwin, Tomas Kiselak and Evan Thompson.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">(3)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Consists of 2,500,000 shares of Jade common stock held by Parade. Parade is managed by its sole manager, Evan Thompson.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">(4)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Consists of 546,448 shares of restricted voting common stock and of 3,643 shares of common stock issuable upon the exercise of options that will vest within 60&#160;days after the date of this table.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">(5)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Consists of 136,612 shares of restricted voting common stock.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="color:#231f20;">(6)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="color:#231f20;">Consists of (i)&#160;20,000,000 shares of Jade common stock issuable upon the conversion of 20,000,000 shares of Jade Preferred Stock, (ii)&#160;683,060 shares of restricted voting common stock and (iii)&#160;3,643 shares of common stock issuable upon the exercise of options that will vest within 60&#160;days after the day of this table.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">333</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_88c21421_e5ee_4b27_b401_92b61f69c553"></a><a id="PRINCIPALSTOCKHOLDERSOFTHECOMBINEDCOMPAN"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PRINCIPAL STOCKHOLDERS OF THE COMBINED COMPANY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth certain information regarding beneficial ownership of the Combined Company&#8217;s common stock immediately after consummation of the Merger, assuming the consummation of the Merger occurred on , 2025 for:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each person or group of affiliated persons who is expected by Aerovate and Jade to be the beneficial owner or more than 5% of the Combined Company&#8217;s common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each person expected to be a director of the Combined Company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each person expected to be a named executive officer of the Combined Company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all of the Combined Company&#8217;s expected directors and executive officers as a group.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Beneficial ownership is determined in accordance with the rules&#160;of the SEC and thus represents voting or investment power with respect to the Combined Company&#8217;s securities. Under such rules, beneficial ownership includes any shares over which the individual or entity has sole or shared voting power or investment power as well as any shares that the individual has the right to acquire within 60&#160;days of , 2025. Shares of the Combined Company&#8217;s common stock that an individual or entity has the right to acquire within 60&#160;days of , 2025 are deemed to be outstanding and beneficially owned by the individual or entity for the purpose of computing the&#160;percentage ownership of that individual, but they are not treated as outstanding for the purpose of computing the&#160;percentage ownership of any other person. To Aerovate&#8217;s and Jade&#8217;s knowledge and subject to applicable community property rules, and except as otherwise indicated below, the persons and entities named in the table have sole voting and sole investment power with respect to all shares beneficially owned.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The table lists applicable&#160;percentage ownership based on shares of common stock expected to be outstanding upon consummation of the Merger, after giving effect to the anticipated Aerovate reverse stock split and the Jade Pre-Closing Financing. The number of shares beneficially owned includes shares of common stock that each person has the right to acquire within 60&#160;days, including upon the exercise of stock options and pre-funded warrants. These stock options and pre-funded warrants shall be deemed to be outstanding for the purpose of computing the&#160;percentage of outstanding shares of the Combined Company&#8217;s common stock expected to be owned by such person but shall not be deemed to be outstanding for the purpose of computing the&#160;percentage of outstanding shares of the combined organization&#8217;s common stock expected to be owned by any other person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Immediately after the Merger, Aerovate securityholders as of immediately prior to the Merger are expected to own approximately 1.6% of the outstanding shares of capital stock of the Combined Company (on a fully-diluted basis), and former holders of Jade securities are expected to own approximately 98.4% of the outstanding shares of capital stock of the Combined Company (on a fully-diluted basis), subject to certain assumptions, including, but not limited to, Aerovate&#8217;s Net Cash as of Closing being equal to $0. Aerovate management currently anticipates Aerovate&#8217;s Net Cash as of Closing will be approximately $0, after giving effect to the special Cash Dividend, which is expected to be approximately $65.0 million, and the currently estimated ownership&#160;percentages reflect this projection. There can be no assurances any of these assumptions will be accurate at Closing when the final Exchange Ratio is determined. The table below assumes that, based on Aerovate&#8217;s and Jade&#8217;s capitalization as of October&#160;30, 2024, the date the Merger Agreement was executed, the Exchange Ratio is estimated to be equal to approximately 21.4388 shares of Aerovate common stock for each share of Jade common stock (and 0.0214388 shares of Aerovate Series A Preferred Stock for each share of Jade Preferred Stock), prior to giving effect to the anticipated Aerovate reverse stock split. The estimated Exchange Ratio was derived on a fully-diluted basis as of October&#160;30, 2024, using a stipulated value of Jade of approximately $175.0 million and of Aerovate of approximately $8.0 million, assuming Net Cash of $0 as of Closing. The final Exchange Ratio is subject to adjustment prior to Closing based upon Aerovate&#8217;s Net Cash at Closing and the aggregate proceeds from the sale of Jade common stock and Jade pre- funded warrants in the Jade Pre-Closing Financing.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">334</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise indicated, the address for each beneficial owner is c/o Jade Biosciences,&#160;Inc., 221 Crescent Street, Building 23, Suite&#160;105, Waltham, MA 02453.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PERCENTAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NUMBER&#160;OF</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OF&#160;SHARES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SHARES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OUTSTANDING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BENEFICIALLY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BENEFICIALLY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">NAME OF BENEFICIAL OWNER</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OWNED</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OWNED</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">5% or Greater Stockholders</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Directors and Executive Officers:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 32pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 32pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 32pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 32pt;"><span style="color:#231f20;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 32pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 32pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 32pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 32pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 32pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 32pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 32pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 32pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 37pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 37pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 32pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 32pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">All executive officers and directors as a group ( persons)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 32pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 32pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Less than 1%.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">335</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_665874b4_5cda_413d_a892_edb696f84672"></a><a id="LEGALMATTERS_385782"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">LEGAL MATTERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Goodwin Procter LLP will pass upon the validity of Aerovate&#8217;s common stock offered by this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2b907a80_be35_4049_804d_96d9124953bf"></a><a id="EXPERTS_704648"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXPERTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements of Aerovate Therapeutics,&#160;Inc. as of December&#160;31, 2023 and 2022, and for each of the&#160;years in the two-year period ended December&#160;31, 2023, have been included herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The financial statements of Jade Biosciences, Inc. as of September&#160;30, 2024 and June 18, 2024 and for the period from June 18, 2024 (inception) to September 30, 2024 included in this proxy statement/ prospectus have been so included in reliance on the report (which contains an explanatory paragraph relating to Jade Biosciences, Inc.&#8217;s ability to continue as a going concern as described in Note&#160;1 to the financial statements) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2cb078f9_ef51_44b6_88ed_c863d87b05a3"></a><a id="WHEREYOUCANFINDMOREINFORMATION_104067"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHERE YOU CAN FIND MORE INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate is subject to the informational requirements of the Exchange Act and in accordance therewith, files annual, quarterly and current reports, proxy statements and other information with the SEC electronically, and the SEC maintains a website that contains Aerovate&#8217;s filings as well as reports, proxy and information statements, and other information issuers file electronically with the SEC at <i style="font-style:italic;">www.sec.gov</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate also makes available free of charge on or through its website at <i style="font-style:italic;">https://ir.aerovatetx.com/ financials/sec-filings</i>, its Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K and amendments to those reports filed or furnished pursuant to Section&#160;13(a)&#160;or 15(d)&#160;of the Exchange Act as soon as reasonably practicable after Aerovate electronically files such material with or otherwise furnishes it to the SEC. The website addresses for the SEC and Aerovate are inactive textual references and except as specifically incorporated by reference into this proxy statement/prospectus, information on those websites is not part of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate has filed with the SEC a registration statement on Form&#160;S-4, of which this proxy statement/ prospectus is a part, under the Securities Act to register the shares of Aerovate common stock (including the shares of Aerovate common stock issuable upon conversion of the Aerovate Series&#160;A Preferred Stock) to be issued to Jade stockholders in the Merger. The registration statement, including the attached annexes, exhibits and schedules, contains additional relevant information about Aerovate and Aerovate common stock. This proxy statement/prospectus does not contain all of the information set forth in the registration statement because certain parts of the registration statement are omitted in accordance with the rules&#160;and regulations of the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate has supplied all the information contained in or incorporated by reference into this proxy statement/prospectus relating to Aerovate, and Jade has supplied all information contained in this proxy statement/prospectus relating to Jade.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">You can obtain any of the documents incorporated by reference into this proxy statement/prospectus from Aerovate or from the SEC through the SEC&#8217;s website at <i style="font-style:italic;">www.sec.gov</i>. Documents incorporated by reference are available from Aerovate without charge, excluding any exhibits to those documents, unless the exhibit is specifically incorporated by reference as an exhibit into this proxy statement/prospectus. If you would like to request documents from Aerovate or Jade, please send a request in writing or by telephone to either Aerovate or Jade at the following addresses:</p><a id="_Hlk183825621"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Aerovate Therapeutics, Inc.</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Jade Biosciences, Inc.</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">930 Winter Street, Suite M-500</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">221 Crescent Street, Building 23, Suite 105</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Waltham, MA 02451</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Waltham, MA 02453</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Attn: Investor Relations</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Attn: Investor Relations</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Tel: (617) 443-2400</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Tel: (781) 312-3013</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Email: Legal@AerovateTx.com</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Email: IR@JadeBiosciences.com</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">336</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_60c9c9ce_0735_4e44_81b7_da7112857698"></a><a id="OTHERMATTERS_255176"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OTHER MATTERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stockholder Proposals</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An Aerovate stockholder who would like to have a proposal considered for inclusion in Aerovate&#8217;s 2025 proxy statement must submit the proposal in accordance with the procedures outlined in Rule&#160;14a-8 of the Exchange Act so that it is received by Aerovate no later than December&#160;27, 2024. However, if the date of the 2025 Annual Meeting of Stockholders is changed by more than 30&#160;days from the date of the previous year&#8217;s meeting, then the deadline is a reasonable time before Aerovate begins to print and send its proxy statement for the 2025 Annual Meeting of Stockholders. SEC rules&#160;set standards for eligibility and specify the types of stockholder proposals that may be excluded from a proxy statement. Stockholder proposals should be addressed to Aerovate Therapeutics,&#160;Inc., 930 Winter Street, Suite&#160;M-500, Waltham, Massachusetts 02451, Attention: Corporate Secretary. Aerovate also encourages you to submit any such proposals via email to Legal@AerovateTx.com.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a stockholder wishes to propose a nomination of persons for election to Aerovate&#8217;s board of directors or present a proposal at an annual meeting but does not wish to have the proposal considered for inclusion in Aerovate&#8217;s proxy statement and proxy card, Aerovate&#8217;s bylaws establish an advance notice procedure for such nominations and proposals. Stockholders at an annual meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the board of directors or by a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has delivered timely notice in proper form to Aerovate&#8217;s corporate secretary of the stockholder&#8217;s intention to bring such business before the meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The required notice must be in writing and received by Aerovate&#8217;s corporate secretary at Aerovate&#8217;s principal executive offices not less than 90&#160;days nor more than 120&#160;days prior to the first anniversary of the preceding&#160;year&#8217;s annual meeting. However, in the event that the date of the annual meeting is advanced by more than 30&#160;days, or delayed by more than 60&#160;days, from the first anniversary of the preceding&#160;year&#8217;s annual meeting, a stockholder&#8217;s notice must be so received no earlier than the 120th day prior to such annual meeting and not later than the close of business on the later of (A)&#160;the 90th day prior to such annual meeting and (B)&#160;the tenth day following the day on which notice of the date of such annual meeting was mailed or public disclosure of the date of such annual meeting was made, whichever first occurs. For stockholder proposals to be brought before the 2025 Annual Meeting of Stockholders, the required notice must be received by Aerovate&#8217;s corporate secretary at Aerovate&#8217;s principal executive offices no earlier than February&#160;5, 2025 and no later than March&#160;7, 2025. In addition, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than Aerovate&#8217;s nominees must provide notice by the same deadline noted herein to submit a notice of nomination for consideration at the 2025 Annual Meeting of Stockholders. Such notice must comply with the additional requirements of Rule&#160;14a-19(b). Stockholder proposals and the required notice should be addressed to Aerovate Therapeutics,&#160;Inc., 930 Winter Street, Suite&#160;M-500, Waltham, Massachusetts 02451, Attention: Corporate Secretary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stockholder Communication with the Aerovate Board</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any interested party with concerns about Aerovate may report such concerns to the board of directors or the chairman of Aerovate&#8217;s board of directors or the chairman of Aerovate&#8217;s nominating and corporate governance committee, by submitting a written communication to the attention of such director at the following address:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">c/o Aerovate Therapeutics,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">930 Winter Street, Suite&#160;M-500</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Waltham, MA 02451</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">United States</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">You may submit your concern anonymously or confidentially by postal mail. You may also indicate whether you are a stockholder, customer, supplier, or other interested party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A copy of any such written communication may also be forwarded to Aerovate&#8217;s legal counsel and a copy of such communication may be retained for a reasonable period of time. The director may discuss the matter with Aerovate&#8217;s legal counsel, with independent advisors, with non-management directors, or with management, or may take other action or no action as the director determines in good faith, using reasonable judgment, and applying his or her own discretion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Communications may be forwarded to other directors if they relate to important substantive matters and include suggestions or comments that may be important for other directors to know. In general, communications relating to corporate governance and long-</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">337</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">term corporate strategy are more likely to be forwarded than communications relating to ordinary business affairs, personal grievances, and matters as to which we tend to receive repetitive or duplicative communications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The audit committee oversees the procedures for the receipt, retention, and treatment of complaints received by Aerovate regarding accounting, internal accounting controls, or audit matters, and the confidential, anonymous submission by employees of concerns regarding questionable accounting, internal accounting controls or auditing matters. Aerovate has also established a toll-free telephone number for the reporting of such activity, which is (844) 517-1122.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Householding of Proxy Statement/Prospectus</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The SEC has adopted rules&#160;that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for proxy materials with respect to two or more stockholders sharing the same address by delivering a single set of the proxy materials addressed to those stockholders. This process, which is commonly referred to as &#8220;householding,&#8221; potentially means extra convenience for stockholders and cost savings for companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In connection with the Aerovate Special Meeting, a number of brokers with account holders who are Aerovate stockholders will be &#8220;householding&#8221; Aerovate&#8217;s proxy materials. A single set of proxy materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once a stockholder has received notice from his or her broker that the broker will be &#8220;householding&#8221; communications to such stockholder&#8217;s address, &#8220;householding&#8221; will continue until the stockholder is notified otherwise or until the stockholder revokes his or her consent. If, at any time, a stockholder no longer wishes to participate in &#8220;householding&#8221; and would prefer to receive a separate set of proxy materials, such stockholder should notify his or her broker or Aerovate. Direct the written request to Aerovate Therapeutics,&#160;Inc., 930 Winter Street, Suite&#160;M-500, Waltham, Massachusetts 02451, Attention: Corporate Secretary, telephone: (617) 443-2400. Stockholders who currently receive multiple copies of the proxy materials at their addresses and would like to request &#8220;householding&#8221; of their communications should contact their brokers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">338</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_64bd0e82_282d_4113_a078_d84f0b7849b8"></a><a id="INDEXTOFINANCIALSTATEMENTS_141952"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INDEX TO FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INDEX TO AEROVATE&#8217;S CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Audited Consolidated Financial Statements as of and for the&#160;Years ended December&#160;31, 2023 and 2022:</p><a id="_Hlk183933347"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ReportofIndependenntRegistered"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Accounting Firm</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-2</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#BALANCESHEETS_90827"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-3</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#COMPREHENSIVELOSS_41676"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-4</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#STOCKHOLDERSEQUITY_810711"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CASHFLOWS_844977"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_7"><span style="font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-7</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unaudited Interim Condensed Financial Statements for the Nine&#160;Months ended September&#160;30, 2024 and 2023:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financial Statements (Unaudited)</p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CondensedConsolidatedBalanceSheets_97473"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-20</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CondensedConsolidatedStatementsofOperati"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-21</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CondensedConsolidatedStatementsofRedeema"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-22</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CondensedConsolidatedStatementsofCashFlo"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-24</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTESTOUNAUDITEDINTERIMCONDENSEDCONSOLID"><span style="font-style:normal;font-weight:normal;">Notes to Unaudited Condensed Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-25</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INDEX TO JADE&#8217;S FINANCIAL STATEMENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ReportOfIndependentRegistered1"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Accounting Firm</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-35</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#BALANCESHEETS"><span style="font-style:normal;font-weight:normal;">Balance Sheets</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-36</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#COMPREHENSIVELOSS"><span style="font-style:normal;font-weight:normal;">Statement of Operations and Comprehensive Loss</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-37</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#STOCKHOLDERSDEFICIT"><span style="font-style:normal;font-weight:normal;">Statement of Convertible Preferred Stock and Stockholders&#8217; Deficit</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-38</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CASHFLOWS"><span style="font-style:normal;font-weight:normal;">Statement of Cash Flows</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-39</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NatureoftheBusinessandBasisofP"><span style="font-style:normal;font-weight:normal;">Notes to Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-40</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_99b4c519_0a89_4d7f_aa35_53a7661da908"></a><a id="ReportofIndependenntRegistered"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To the Stockholders and Board of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Aerovate Therapeutics,&#160;Inc.:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Opinion on the Consolidated Financial Statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have audited the accompanying consolidated balance sheets of Aerovate Therapeutics,&#160;Inc. and subsidiary (the Company) as of December&#160;31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for the&#160;years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2023 and 2022, and the results of its operations and its cash flows for the&#160;years then ended, in conformity with U.S. generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Basis for Opinion</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules&#160;and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">/s/ KPMG LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have served as the Company&#8217;s auditor since 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">San Diego, California</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;25, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_97372eb2_6aea_4674_b5a3_e6ba83a8921c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">AEROVATE THERAPEUTICS,&#160;INC.</p><a id="BALANCESHEETS_90827"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">(IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)</p><a id="_dff33fd4_e673_4dd5_8c32_f9d70e0f242c"></a><a id="Tc_Dr5-t2uJTUmFkMHHqB3i3A_1_2"></a><a id="Tc_aBhlaaaZCEyXX0q-iMBlxw_1_5"></a><a id="Tc_mf62Ul-s4k6kFeK-RsfFHw_2_2"></a><a id="Tc_Bf5acysvvUaSDm6Zdj_muA_2_5"></a><a id="Tc_RU0aB4eEHUqHUdivj6MfOg_3_0"></a><a id="Tc_La-vKQEklk62qpzfucabKQ_4_0"></a><a id="Tc_bOvX3xNS4kmTCNDzgEI4HA_5_0"></a><a id="Tc_7gQm2iX1mUuQOGWy6FSdjw_5_2"></a><a id="Tc_Vcy-f7zqKkS3AzTDuy1kug_5_5"></a><a id="Tc_c7MUO2f7X0KKpeR-rGrUhA_6_0"></a><a id="Tc_Nj8kLyjPRUuzm3ntEzoL_A_7_0"></a><a id="Tc_S27yxE2ur02cEf0b-dprTg_8_0"></a><a id="Tc_O6w30vfvn0yXNF5xIgOZuA_9_0"></a><a id="Tc_Xy3ENdcSi0mHLx96BKuqyw_10_0"></a><a id="Tc_-q6psDy3B0-dazD_ZiDJig_11_0"></a><a id="Tc_T1pCkhYiAEOjbeqOZjFqKQ_12_0"></a><a id="Tc_e_F84vYUcUibpffPi_l8_Q_12_2"></a><a id="Tc_5_Gh88bdkk6G_pvqtkCE-A_12_5"></a><a id="Tc_1kzwwwGwgUqX01OxJnX3yw_14_0"></a><a id="Tc_-kksC8YPZEOdAy_eqUkQmA_16_0"></a><a id="Tc_PpzbZEO93UCIASv2zoKFgg_17_0"></a><a id="Tc_etSqAb8S80-D28W6xgCTgw_17_2"></a><a id="Tc_0Tu_Ki5gTkKXbuH556B4pQ_17_5"></a><a id="Tc_ZsHdKZyvSk-pp-LGwGXBHQ_18_0"></a><a id="Tc_15ciarp1g0KsXxWLvxotXg_19_0"></a><a id="Tc_IvkKMihDe0eHRkfEwSIDvQ_20_0"></a><a id="Tc_ScN42zlDcUumhg5rBIQIUQ_21_0"></a><a id="Tc_J_NEABwPqEyUO0bs1211GA_22_0"></a><a id="Tc_6BrEOETBAkawoJVETxgS0g_23_0"></a><a id="Tc_yAhygV1ipEaB1IupFLS96Q_25_0"></a><a id="Tc_HPUqWP-AT0SpUk0uBZw6oQ_26_0"></a><a id="Tc_2M78IbEJ6kSkwTqqU9bTAQ_27_0"></a><a id="Tc_vZq7ILUhU0Ko_CnKI_UNhg_28_0"></a><a id="Tc_3u-Wq6pxPkiLTUNjjefqkA_29_0"></a><a id="Tc_PsqnTg3JkkWt0n-Q8XC3HQ_30_0"></a><a id="Tc_eTjS8OwyF0iMtAtOSk3tAg_31_0"></a><a id="Tc_z2zpj1MdxU-gOvrbsEJJuA_32_0"></a><a id="Tc_RpswJ-_SN0CeEjU9G2V7ww_33_0"></a><a id="Tc_n6AuURwPDEuIIkEyJTxzPw_33_2"></a><a id="Tc_QLFPQI5_SE2qsqAatsjsAQ_33_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:68.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_RBvDLJARpkyVI629bT_O3w_5_3">23,491</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_w_M0NlG0qkqUWSHNs7lolw_5_6">22,397</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_2I6dbzCp1E28FQ2CXHWbIQ_6_3">98,948</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_SNbXbFRofE-etw4ACbY0gw_6_6">106,823</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_G5rHKPs8KEaXQbRYvw7emA_7_3">1,793</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_26pd06G7pUyQu42gHsuTWA_7_6">2,276</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_SZew7qlDTE21pr9CS6diBA_8_3">124,232</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_GOqgEJbDtEKGokmIhijQfw_8_6">131,496</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_AqKKDY-0Tky3iNM_jFWsaQ_9_3">288</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_4JZYNfiv3k6AJfPOttuMNQ_9_6">242</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_h8soSiCkUUWJhyfe3820Dw_10_3">614</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_9KQ8y2z-RkuQD7SnkJYWIg_10_6">1,003</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Other long-term assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_NMPq4t4vAU-b1ZHtR_4Ghw_11_3">2,284</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_HLNeZdJB3k6gFYMpeB51TA_11_6">2,560</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_MV0AK4Dk7ky5K3oIz2baYA_12_3">127,418</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_U6XIiiZHdEObLWOlWs6ogg_12_6">135,301</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_e3IdSMaBh0iJDDemRmg5Sw_17_3">2,396</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_qcOKE13jT02CekzznRqqvw_17_6">2,575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accrued and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent" scale="3" id="Tc_1K2KV7v5rkmwRfi7cpPDXg_18_3">14,821</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent" scale="3" id="Tc_K95hKUGRAkiMXz8cqxGrTA_18_6">4,822</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_Gs-xXUD7iEaKHCkQ1ckWOQ_19_3">420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_6b0IrQReC0K1ew3IwO5GqA_19_6">385</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_w2v-8mJ16kWJ1fyKqhzOVA_20_3">17,637</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_h8ahAS1PdkuJY8_KxpnlRw_20_6">7,782</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating lease liabilities, net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_SAbXAi-kA0iYUk8Ie8anaw_21_3">255</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_20BMFTm-EkmmDiz2Y9mqWg_21_6">705</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilities" scale="3" id="Tc_RBuh7EPNBU6aQMgVjmq0cA_22_3">70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilities" scale="3" id="Tc_qFsMFBRn4U-9CTfJPc8q9w_22_6">71</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_zjvLiHkakUSRLYJjWXvvdQ_23_3">17,962</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_Dx52aToRvk6yZMNALkKs7A_23_6">8,558</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Commitments and contingencies (Note 5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_szf5J-nRaUiQ7t8URD_uQA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_DMQn_d65nUqSk8UH02_9vw">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_0i4tRXuaG0iJpqgrQvrrAg"><ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_c2_1D6PxeU23E4H55I7ocA">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of December&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively; <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_hWRwdFxw8kC_orvD4O8xlg"><ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_Ld1x0AtFjkKwSXWvKn4UQg"><ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_g2e4IoSuW06sC8pj90RY0w"><ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_NkZRpGpGFUixSsL_fmNS5w">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_ocCBIaD8DUywIpPD-inl4w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_uqoQ-VLEfEKQOnE0P46H4A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_BgwSDfALt0mhQn2buc2wyw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_IQgLvzABWE24tfKZQBv28w">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_9DicjN_tp0CAB6y3o7DJ0w"><ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_UGCpdin1m0idpDxWLqd6bA">150,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively; <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_RsTUsZqqoUK7Ze1HQIQehg"><ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_idlN_PQOc0WoQFXIyyPp7g">27,762,703</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_Yzsyis-9_UiIadiKW4jYBg"><ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_WO-semx4sEO9ebCV5aYDQQ">24,722,974</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_yPrt11I0T0GsYdE35vG8uw_28_3">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_tGdrcV1JmUGZk4r4uGP4EQ_28_6">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_9RPFJlHX_0-F7gieNtKPYw_29_3">272,640</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_LqsXhT5__0eZpgeKlUrSxg_29_6">215,110</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accumulated other comprehensive income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_1QkhxlNxDkqopSyhAIhQzg_30_3">237</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_6k3rBlreR0O1SInhsyvaYA_30_6">466</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_zJJWFDXAmEmwiLxmRZxb8A_31_3">163,424</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_fcURjK3t2k2BaNj-_yU3WQ_31_6">87,903</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total stockholders&#8217; equity </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_X4yPXGV_rUuQDT761fXvxA_32_3">109,456</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Jv4dKwVRb0uGOHlhPjKC0w_32_6">126,743</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_5hA0bfnWeEC1ix2_jr_PTA_33_3">127,418</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_JV1yxVnPhE2HsAJ7q8q9VA_33_6">135,301</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">See accompanying notes to consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_4b548e17_1564_473e_91ac_822a43806736"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">AEROVATE THERAPEUTICS,&#160;INC.</p><a id="COMPREHENSIVELOSS_41676"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">(IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)</p><a id="_20f89532_1d2a_4180_a8bb_2d6957ed46e3"></a><a id="_89dbaea2_1b18_4846_954f_26b70e2a71f9"></a><a id="Tc_0s5VTXb90UGdMqiJjF75eQ_1_2"></a><a id="Tc_IZ5NBAQbQUeiTQSB_RiABw_2_2"></a><a id="Tc_t1RO3gk1REaMIMAQalUhiA_2_5"></a><a id="Tc_HRGpgK4FKkCWdkQ0EZ_b8A_3_0"></a><a id="Tc_9CDMYE7tcUqpLhS-s3X67A_4_0"></a><a id="Tc_F-EGRhhLqkSfA65iLlzAEA_4_2"></a><a id="Tc_F8kB_AUN8EGiy-KfWU1D3Q_4_5"></a><a id="Tc_9Elwi4CSykOtCgDtLBgeSg_5_0"></a><a id="Tc_6GYHK6S2M0eIoc1RyPWV8w_6_0"></a><a id="Tc_SoTfb-dYyUGdY8W4U5fatg_7_0"></a><a id="Tc_hxUFEsMv80KPsbEVGs-9Dw_8_0"></a><a id="Tc_G57XrpDI3kqflXxGFDfIaA_9_0"></a><a id="Tc_Xc8wT7mj0UqY-sfxz8fZAA_10_0"></a><a id="Tc_c8YLvjXSf0qvpNFh50rYjg_11_0"></a><a id="Tc_ZsJf1ATTNUGVTgCq9yUX_w_12_0"></a><a id="Tc_pRCn7BwjD02zkoMV6zTs5A_13_0"></a><a id="Tc_cVBEvfLKA0uhwtHWWwMK-Q_14_0"></a><a id="Tc_WvSvAK9ilESybGM2xcJXrg_14_2"></a><a id="Tc_WDr-8kX1R0ylnRisUb1uzQ_14_5"></a><a id="Tc_LX9sNKVPZEWsRBjLPV_p4A_15_0"></a><a id="Tc_BC4xoRcve0KP62rBLACSiw_16_0"></a><a id="Tc_L8yWwxNv7EmOC6E9xIFrLw_16_2"></a><a id="Tc_uXi57yGKVUSrsiHPSz3jwA_16_5"></a><a id="Tc_Ce2x-KPl9EijLIK4Sp_3ow_17_0"></a><a id="Tc_XOTPzBF_20CWoYYgurgx7g_18_0"></a><a id="Tc_M0sOdSE7XkmQg0TzB6q9Bg_19_0"></a><a id="Tc_U-zZOZUg0U2qppiEbow4Eg_19_2"></a><a id="Tc_g68MGXPaK0eMQxCdvbq5wg_19_5"></a><a id="Tc_-2CkP5OZAEaMASK7ZGFAtQ_20_0"></a><a id="Tc_gEvF6O9iCkmMZCLqNbZSNg_20_2"></a><a id="Tc_BCVhlDi09EKhfxeMLjQUzg_20_5"></a><a id="Tc_Co0sg8VJDkSh1mX6pVzcHQ_21_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:63.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:63.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_Ujvm-tCR0UCKiZoSNQV6Qw_4_3">64,219</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_-CB0Wjvrz0qjB21vBzk96A_4_6">38,622</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_O1xySUlqREmXvEeuoQV1ng_5_3">17,190</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_gt_JkRbPE021ahzzZBTtpw_5_6">14,615</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_2hi58gNk3E6rIsnipS0eSA_6_3">81,409</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_XXOAoKu9DEmWzyK0PKhNKA_6_6">53,237</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_ojOfg7KOw0igdxqIdwgGCw_7_3">81,409</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_yBDAw3-4wk6kgD68w5mWJA_7_6">53,237</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="Tc_xwh4BI6lVkGNb2zDdSr0-w_9_3">5,945</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="Tc_sChcVcmLrU6b_FudgpMI7Q_9_6">1,830</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other expense:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_qqdrdxtZhUOtNBICcWs93g_10_3">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_4TVCClLNB02mLkwnRZnsdg_10_6">79</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_mgEb8Zt3VkmQ0r-RpjrW4A_11_3">5,944</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_KaJlC7MdGkqEiaVrrhllHg_11_6">1,751</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_A6rk2WNWbkWYIrd8u9gFQA_12_3">75,465</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_POFjsgs9lEql51QSasdLVQ_12_6">51,486</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_wMyGAkbx-0mOz3EEwiCS6w_13_3">56</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_0xJpqFa-90OLayQ0C8zmDw_13_6">25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_OcbVeE9vV0qHoHlFqD-s2g_14_3">75,521</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_poDjjiKd5EabCP3QVfQlgA_14_6">51,511</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Comprehensive loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Fu1FM9TQJ0KfQGxCD9VClw_16_3">75,521</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_d6_J7L87AEKwhX_7q53zXw_16_6">51,511</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other comprehensive loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Unrealized gain (loss) on securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesTradingUnrealizedGainLoss" scale="3" id="Tc_8IPzhIg12USMibxVnfOikg_18_3">703</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesTradingUnrealizedGainLoss" sign="-" scale="3" id="Tc_8F5uaYj96kGrhI9k2YTJlw_18_6">407</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_gk0EhE6nr0-HCC8wX52CKQ_19_3">74,818</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_GNgyQpybzkm_mwfPgRxovg_19_6">51,918</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_S6k5mG-R20KpoYR_htN5yw_20_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_S6k5mG-R20KpoYR_htN5yw_20_3_2">2.87</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_FfeoVXijgEevX1DjuvuvMA_20_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_FfeoVXijgEevX1DjuvuvMA_20_6_2">2.10</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average shares of common stock outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_VHOxdwU8x06_40T9HRVecQ_21_3"><ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_VHOxdwU8x06_40T9HRVecQ_21_3_2">26,331,630</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_GYvMaFgeqEOsybpvZYLLTQ_21_6"><ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_GYvMaFgeqEOsybpvZYLLTQ_21_6_2">24,472,104</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">See accompanying notes to consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-style:italic;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_3f21aaf1_bced_4af3_a442_7bbd80625e43"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">AEROVATE THERAPEUTICS,&#160;INC.</p><a id="STOCKHOLDERSEQUITY_810711"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">(IN THOUSANDS, EXCEPT SHARE AMOUNTS)</p><a id="_85613309_7d01_4a20_b9d8_f4d0a9c9007e"></a><a id="Tc_NZsSJNE_Pk2-CgyHj3dWtA_2_10"></a><a id="Tc_2OpR2I2NQE23vdreaN23Bg_3_7"></a><a id="Tc_LKA_3goI1Ua0lmnIXObKnQ_3_10"></a><a id="Tc_IJyxGuoaOkeUU--m5EMzAw_3_16"></a><a id="Tc_gFCpwwARekaylbxf-L9kgg_4_2"></a><a id="Tc_ofPEfca8Ukmli_bcUd-U2A_4_7"></a><a id="Tc__hjXegaAEkaoRr-UKV7Whg_4_10"></a><a id="Tc_WokPDZmIz0ixWsYzMnIJlQ_4_13"></a><a id="Tc_R9xCG365g0OxPxAzxkupiQ_4_16"></a><a id="Tc_I_tjnOu8NkOqJ0zx5z8ETg_5_2"></a><a id="Tc_Ov7_x_4Dy0eTUDLA3LNxLw_5_4"></a><a id="Tc_fE4ldgomD0KAaets4esgxA_5_7"></a><a id="Tc_LsZYqJFojEW-iSdRVIm4pg_5_10"></a><a id="Tc_7IfhLzDeWUqRT4Hcmk4fTQ_5_13"></a><a id="Tc_oaPR-tN7aUWNQ6y3n2E9ow_5_16"></a><a id="Tc_q2f2uNHVZkeBvWsIhKGA6w_6_0"></a><a id="Tc_uod5JkSk10KtAd2pUoaRKw_6_4"></a><a id="Tc_hksu7BRkV0CwW8WtcDk57g_6_7"></a><a id="Tc_3_D-6PtkJkqDy0L1nycQNg_6_10"></a><a id="Tc_5enFkKzfOkWT5DBTzVUO2w_6_13"></a><a id="Tc_Ifd9F2yqukafImfQyQG4KQ_6_16"></a><a id="Tc_h9ngKGiIH0-QOzbIfYBxTQ_7_0"></a><a id="Tc_MH-_ZzJvA0OONuKO4gdVCw_7_2"></a><a id="Tc_pIspoCNjckqUbrTgW7xL1g_7_5"></a><a id="Tc_e3evQWmezkarYfYDWml6iw_7_8"></a><a id="Tc_cCnAm6sF8UWClTSnx2uXgg_7_14"></a><a id="Tc_tLoEWsRXiU6VA0VgvIXwwg_8_0"></a><a id="Tc_ttQmx4sH5EGo4K81ZTKC_w_8_2"></a><a id="Tc_X1cZnxhbDUSbNv1Y5bsBBQ_8_5"></a><a id="Tc_YYyuYwhyDEOhimL5SwjdJA_8_11"></a><a id="Tc_SOTbKuu0lEqSEMJTgJrdKw_8_14"></a><a id="Tc_czMpYKDwXEer3wO7h7ZSoQ_9_0"></a><a id="Tc_c86qJNnhDUy50hzPe5etxg_9_5"></a><a id="Tc_3kRB968U_ESpXbTtbsanWw_9_11"></a><a id="Tc_b-flTlcLPUWAfSwFOv_9rQ_9_14"></a><a id="Tc_kswe9rR6dU6BVxwwcsY3kQ_10_0"></a><a id="Tc_Z581_INNrEmmTx_4rO7qEg_10_5"></a><a id="Tc_4Mpek-ksC0K99hqCH-nqSQ_10_11"></a><a id="Tc_tXEeki4sGkWE96-l70HmOw_10_14"></a><a id="Tc_0mc_zbtn-UavN_VAMIyP_Q_11_0"></a><a id="Tc_n5Q7Zt4kJU2dQ5R3d1impg_11_2"></a><a id="Tc_RhBMnfyQUE6CFmLTq6jSow_11_5"></a><a id="Tc_qhA6uMEScEWX8VsBvD45xw_11_8"></a><a id="Tc_TSd_GIhyo0q6wc_QVKRCLg_11_11"></a><a id="Tc_5UoIdyHz50u9-1rOpaeVSA_12_0"></a><a id="Tc_lbLHow4ovUqn-Ms1QHO8gw_12_4"></a><a id="Tc__mH_JdEtuEm5UYNGX-Crrw_12_7"></a><a id="Tc_1JgHW74bvkuWPVLZ4ghspg_12_10"></a><a id="Tc_8wvoEcsZqkKJie_cg9Jekg_12_13"></a><a id="Tc_fA0t-oHEK0u3I0UR7uPXxQ_12_16"></a><a id="Tc_6AW-TQE7Sk2d64x7hCDrlA_13_0"></a><a id="Tc_O0toBKouKEq42lJXgNy_MQ_13_2"></a><a id="Tc_dW1vtQx5XkyEQ134Gt59iA_13_5"></a><a id="Tc_8ShfwUPXZUiTRUQWn5thbg_13_8"></a><a id="Tc_IFXsOgh5nUu6CZN8yzE9lg_13_14"></a><a id="Tc_j2J5pfByn0-YntjkgoJxLw_14_0"></a><a id="Tc_Zn_EBE2dS0Ww3k4r1Lnzaw_14_2"></a><a id="Tc_DPSK6O-plkepDWl01cQepQ_14_5"></a><a id="Tc_xlUQP4dfVUySPnl6wWYc7A_14_11"></a><a id="Tc_vtMwG4WX-UCDdmH8MKwitg_14_14"></a><a id="Tc_YbJAe9CbQE-S3WxUdtqXqQ_15_0"></a><a id="Tc_gSKQgevvZUe_fmvUGUGysA_15_11"></a><a id="Tc_QHPIWcWbE0GxjARHdy6MEQ_15_14"></a><a id="Tc_uG_gBbHnLUSTnnKA1n3bdw_16_0"></a><a id="Tc_rtrpYRstpku8-DGOa6rF1w_16_5"></a><a id="Tc_Ns6vBpTz9ki4U-k7jlJ4hw_16_8"></a><a id="Tc_s0G72wOprUq3Jy65iWFp6g_16_11"></a><a id="Tc__rGbMrEF8U6PNrlP1BGUTw_16_14"></a><a id="Tc_Oi8hagSXb0Wm-QArkn-b7A_16_17"></a><a id="Tc_KKl8GyXNVE-CerdsqmgAcQ_17_0"></a><a id="Tc_z4FRCYzWFUidZnGUW5XXvA_17_5"></a><a id="Tc_Keb23aLp1k2LF9OE-TSu0A_17_11"></a><a id="Tc_Us6XBdfHbEu03yNOuYCF7w_17_14"></a><a id="Tc_lAE9_TNi6UaKI_SSuXNZhg_18_0"></a><a id="Tc_f2mJTTFUfE2hVaffIZuNGQ_18_5"></a><a id="Tc_Uv78ooMrCEOS3ZCsfoHo1Q_18_11"></a><a id="Tc_yEOYQmejMEGnsah0ShcErg_18_14"></a><a id="Tc_ecWi0ZKsbkGv1vXn6SSXmg_19_0"></a><a id="Tc_NvVcRpfJJEOy1F5Gfgvqvw_19_2"></a><a id="Tc_chq4HiKTNUyCtk-5NL-qMA_19_5"></a><a id="Tc_UGa3pbfZok-NRNmLtqEdnw_19_8"></a><a id="Tc_f6kUUaHT-kq66cAobiUpSQ_19_11"></a><a id="Tc_HcXASdY3kkuEQyOf5Es2UQ_20_0"></a><a id="Tc_KqJGHYlhOUWmprKasXoFiQ_20_4"></a><a id="Tc_gbJiWL7EhUWyOBRD14AsAA_20_7"></a><a id="Tc_jDo4poSoXEaO-HVikK589A_20_10"></a><a id="Tc_pe6r-V0rc06ATWBR785tPg_20_13"></a><a id="Tc_vuqJ5RMSlEe7KcMhZesqIQ_20_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Loss) Income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:top;width:33.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8NQImWg4J0qy7AIOsD5XtA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_wXMOhDjbqUmA6yhiKYSpiQ_6_2">24,410,393</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8NQImWg4J0qy7AIOsD5XtA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_dlxKmqFeP0mDrB3YYgTMlg_6_5">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_m_AT2h9P5EyXiFBYKZDj7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_LbrtTlv5f0CSZrQhRFn0MQ_6_8">208,867</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_VEufXZsdzEu6C4BySyFyBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_AQWpD3FB-EWrVr0CCdSv7Q_6_11">59</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZtSEQpTQBEWAhx3kbiC17g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_g0Xyup21qUG3nnUtM2aP8Q_6_14">36,392</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2021_3SZLVaYF3Uaoxk9Z6taH9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_UtoNkt5fUk29EoyeLZtRkQ_6_17">172,418</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:33.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Unrealized loss on investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yYm-QanqNEuE0_c7yIDEKg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesTradingUnrealizedLoss" scale="3" id="Tc_DKqv2XF_Ukuv8dWcgvQ0UA_7_11">407</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesTradingUnrealizedLoss" scale="3" id="Tc_mRp81Oz_kE2K6kcwN2l4bw_7_17">407</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:33.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LKCmt_IMoEm2kACXc_PCig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_jFOtTpec90qPPDShqJQSOQ_8_8">5,476</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_a8kRPxNnxUynoYIeCEyirg_8_17">5,476</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:33.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Issuance of common stock upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uXs3dXPjTUaFIqn7C-QEEg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_zz289nzbzU-lfdLytpyfZA_9_2">298,712</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LKCmt_IMoEm2kACXc_PCig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_bqSZtXIqFUqSNV-79q4wEg_9_8">617</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_Ed-8lNVtckeLz3v2LLR9Ug_9_17">617</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:33.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Issuance of common stock under ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uXs3dXPjTUaFIqn7C-QEEg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_-qosxU9nLkOKmTECry6ppA_10_2">13,869</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LKCmt_IMoEm2kACXc_PCig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_wDexsXU3rUC0k-inrpWv8g_10_8">150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_9dDa45UobU-Y66ac2R1fHw_10_17">150</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:33.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KuqcIl38qk-Am_HOfAm4Iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_YcwHFZMTq0a4QXbWOGF01A_11_14">51,511</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_axUC36_LJ0WQ88d8FwOnIQ_11_17">51,511</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:33.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bPKy-329i0a269T7iYdlfQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_l1SqB7wdM0ah7ziebxIbkQ_12_2">24,722,974</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bPKy-329i0a269T7iYdlfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_cGwaW2v6M0SVIyKXU86_Wg_12_5">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dcFzNA8x9Ui_AjpnWINDyw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_b6iJwNp-LUm2oWrrUPPKEg_12_8">215,110</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QECF8CV7f0Kgvhlc6flPyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_FQQWFSixYECMA24trtmQng_12_11">466</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_a5ipJvXbekyb6Q7U_qk5JA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_fZjd7LDgfUq-kn1cA5y4lg_12_14">87,903</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_MNyO7QULU0m9tW8lG-cMzw_12_17">126,743</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:33.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Unrealized gain on investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_y1zASwVL00OvpCxcnCK7Yw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesTradingUnrealizedGain" scale="3" id="Tc_3jjz3N2hBkC-su3eOtbG-w_13_11">703</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesTradingUnrealizedGain" scale="3" id="Tc_oNU0or-pWUm7mH44RDJQfg_13_17">703</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:33.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_RQUeGZjabU2LSVSR_5lP_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Szz2Flodg0GsaxW35vZn5w_14_8">11,906</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_yjPYSCDsNEagYzMh7H-t_w_14_17">11,906</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:33.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Issuance of common stock in connection with ATM, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OqpE3l_LB0G_beKE0PBP5g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_isj_reVGGU-qMdZzC9m0OA_15_2">2,662,721</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OqpE3l_LB0G_beKE0PBP5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_DfVZWzpvpUCArw7IV_EQIw_15_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_RQUeGZjabU2LSVSR_5lP_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_tcVx5Lp2V0ertTlTINlUYg_15_8">44,282</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_2_VeaVDchUqLvc-2DYmaKg_15_17">44,283</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:33.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OqpE3l_LB0G_beKE0PBP5g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_-luRyUhS4UeIfKjlHKmrgw_16_2">9,913</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:33.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Issuance of common stock upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OqpE3l_LB0G_beKE0PBP5g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_qsD3TVc360WQcxYw9fBytQ_17_2">338,987</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_RQUeGZjabU2LSVSR_5lP_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_4akXlDREm0az1kz07ovtoQ_17_8">986</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_UT_JNGYTtESp5K6cFoLX6Q_17_17">986</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:33.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Issuance of common stock under ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OqpE3l_LB0G_beKE0PBP5g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_xrUtHzWSz0SSVu2olV9xhw_18_2">28,108</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_RQUeGZjabU2LSVSR_5lP_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_bOdSOQdirEm0pCTNetGAbQ_18_8">356</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_RTTqMPhE7UihoW1wfrC6zQ_18_17">356</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:33.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Rr0GlkP2XEun1mQJs3HD0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_lZTNN_Iz6k6dAGODO1SvXQ_19_14">75,521</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_OkQR4FTOLEOIA9MLtF5YKw_19_17">75,521</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:33.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iFYHzpsOAk6upQL9o0JHJA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_bOhnFABIWESODoshFWttzQ_20_2">27,762,703</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iFYHzpsOAk6upQL9o0JHJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_lIkUh-oDHkeHMFCDaKSFkw_20_5">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_r3UKbN8hp0mfWhezRkf1lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_kxngZ8SmJEKOXFIqywkjqA_20_8">272,640</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_UqfaQqRd1U-rmSnO35M5GQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_LcmWbDkrTk2dLMfHFxqqWg_20_11">237</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_QLbiEq19A02perNXBXbTKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_tPJTCbK7SkqBPRi8qNf7mA_20_14">163,424</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Ayei7e0vUEmDNcjULGn5VQ_20_17">109,456</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:33.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">See accompanying notes to consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_1fe254de_1f29_4301_b3d4_0fe5d19209ef"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">AEROVATE THERAPEUTICS,&#160;INC.</p><a id="CASHFLOWS_844977"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(IN THOUSANDS)</b></p><a id="_31f85d5e_0e15_4433_ae1a_730793fad939"></a><a id="Tc_oE4UZQ9tzUKLTO51BNd2zQ_1_2"></a><a id="Tc_vEiDHB_YMECcJLQYEeriwg_2_2"></a><a id="Tc_NExWnQ6T0UiaajUj314dcQ_2_5"></a><a id="Tc_flErGYSHM0i-R9zlB7bFdg_3_0"></a><a id="Tc_ulnRcBO4nke832ijVACLIw_4_0"></a><a id="Tc_L0RSGWTKWUmtRyPBOholaw_4_2"></a><a id="Tc_1gbt-9HLb02TFYpI4vRSMQ_4_5"></a><a id="Tc_PNDmvyYoW0y9NqW7pPyMsg_5_0"></a><a id="Tc_MuimpB0H0UmCaXB_Ej2KzA_6_0"></a><a id="Tc_Bec4RsI2vEmpdOm0Csbm4A_7_0"></a><a id="Tc_WeiaEGznzEmI4SVrm21geA_8_0"></a><a id="Tc_KKA3x7GadU-u4_XFPhBrQg_9_0"></a><a id="Tc_9OxkCkImeECzPjkUQLQa4Q_10_0"></a><a id="Tc_7ZbCjUao2Um3lJWri7AUHw_11_0"></a><a id="Tc_cC8fbtlfHEy5eDcWnsUMRw_12_0"></a><a id="Tc_D1GT9QVv90uUwcPJNHQRDA_13_0"></a><a id="Tc_Lky6MoZmgUqGXG-v7T0RrQ_14_0"></a><a id="Tc_eK_HRd4TNEKkqm4-JI2aPg_15_0"></a><a id="Tc_XXyjxoLDa0yw3L_nKxeCwA_16_0"></a><a id="Tc_0Qk6sawgi0Kij2LJZtxLpg_16_2"></a><a id="Tc_uwFEmwkry0u3xphgbrgXlA_16_5"></a><a id="Tc_VewbGRQ1CkyJY0R9_1Qh-w_18_0"></a><a id="Tc_nqeKjiB5SE6luAGs-YcsXw_19_0"></a><a id="Tc_1KJh6SVrrEKD_G8LGEvDNw_20_0"></a><a id="Tc_GlAq5GpcFkORMhivaHK__A_21_0"></a><a id="Tc_CflnageWXUiSNCVSejuSdQ_22_0"></a><a id="Tc_zkGbGWddhUin5Wdmvop_DQ_22_2"></a><a id="Tc_zTuGZKMP1EGJgAyqhippmg_22_5"></a><a id="Tc_WpxkZh8xP0KAUe1ThiE2lg_24_0"></a><a id="Tc_6uFT6GmCGEyTksWQ6_Xz8Q_25_0"></a><a id="Tc_c3gKIeePOEK3ZOEgV7jAKg_25_6"></a><a id="Tc_DpQlDfSWpkyc6MB1KP6dmQ_26_0"></a><a id="Tc_BR-NrXEA20iW60OPNiT8fw_27_0"></a><a id="Tc_nWJ1ubDCDEqUFc0tfZ7KPg_28_0"></a><a id="Tc_4UrLIlKnMkG1ELreq_k7tg_29_0"></a><a id="Tc__y0NC9OevE2goXH5qd4s3w_29_2"></a><a id="Tc_D55RNa74U0-467jEX6YWSQ_29_5"></a><a id="Tc_WCXDpHwc0EeUGV9bnudUrA_31_0"></a><a id="Tc_nYrfLwxJm0-dWMow-Ir8xg_32_0"></a><a id="Tc_9Pnx1aIKf022NHFz82wsGg_33_0"></a><a id="Tc_Ypgo-ci2WEGEthcL97OYmg_33_2"></a><a id="Tc_y0kvInMIYUuB-aG02e6Iiw_33_5"></a><a id="Tc_0WkoNu5iEkalf_T8q3LZZg_35_0"></a><a id="Tc_oAeqrbCm2kGf3r9nKwn6GA_36_0"></a><a id="Tc_RJwu5_OaGU2X_VC5I99nHA_36_2"></a><a id="Tc_RNXpXhRqMkCk4FtqWSjyBA_36_3"></a><a id="Tc_mcugfDjYLkiX0NmKegyYqw_36_5"></a><a id="Tc_Wx0vbTJJrk--INZoDy41MQ_37_0"></a><a id="Tc_PAI-D55h2k23JpNBAzJYhA_37_2"></a><a id="Tc__LZSvLGj7ECNB92rq4dFRQ_37_3"></a><a id="Tc_lbh14p4ZwUOzeQfkn3ij7A_37_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flow from operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_oKA9eRZaj06waHDKtho40w_4_3">75,521</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_-NAW2LSZEEKPFbT6vHg5Dg_4_6">51,511</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_jZ_8F9AXQUS7w29A3pKHUw_6_3">11,906</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_nDe2Swl3WUiGtuV48FOwDA_6_6">5,476</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Depreciation and amortization expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_gpwzc4NyBUa4nx2ntnjKaA_7_3">96</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_vqjyNWtfzkCaLgRnDKAf9g_7_6">68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accretion of discounts and amortization of premiums on investments, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="avte:AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet" sign="-" scale="3" id="Tc_jgM1H2xLskytLOKGT4ASBA_8_3">3,057</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="avte:AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet" sign="-" scale="3" id="Tc_ip2UiANFeECNvdM3P3aikw_8_6">910</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_IaqSE2_O_kCGgih5787X3A_10_3">483</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_J_2Q10vKRE-r6XIa1WW58g_10_6">4,677</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Other long-term assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="Tc_u3lt-Yk-VUaloUpzyVoFbQ_11_3">110</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="Tc_fSQ89zwqZ0abEx5Qa31sXw_11_6">1,872</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_bQOogcGGRU2pY15U4AG3ww_12_3">164</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_nA_oD7UHd0q--pAh4a3wJg_12_6">1,368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Accrued and other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="Tc_NtvJ_tF8ZEmxz4vTMz88qQ_13_3">9,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="Tc_BpwObMfbFEKVRgmYCOaFgA_13_6">3,672</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease assets and liabilities, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="avte:IncreaseDecreaseInOperatingLeaseAssetAndLiability" sign="-" scale="3" id="Tc_08iEXMoToUGbksdpqPwKfQ_14_3">26</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="avte:IncreaseDecreaseInOperatingLeaseAssetAndLiability" scale="3" id="Tc_0VoaMjTBgkufsMInPLBFAQ_14_6">43</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" sign="-" scale="3" id="Tc_mMDJi89_eUixqOtjAq-SCA_15_3">384</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" sign="-" scale="3" id="Tc_YOKcp3JtbkC1zRPSXupnNA_15_6">133</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_7_-MzsDwmU2EifSsC2Z85A_16_3">56,778</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_fiin2ydNskO1UtJXyQ67hQ_16_6">39,122</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flow from investing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Purchases of short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="3" id="Tc_Vq9MbN85sEyZWhKFSok5Xg_19_3">123,982</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="3" id="Tc_LxNofLzLU0W4d6ZVuuYNRw_19_6">147,623</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Maturities of short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" scale="3" id="Tc_0chSRODKQUOj0DIyhog5Tg_20_3">136,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" scale="3" id="Tc_-3WPVxbGtE6Gf4xq8-8t9w_20_6">154,744</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_PewIcroWp0GCx_6m1uc74A_21_3">142</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_57yKWTPpf0Onxiokba4drQ_21_6">195</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_xe8Rqa-6DEWseA9WNbIQLA_22_3">11,876</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc__gjDcmPBKEue38VT97myYA_22_6">6,926</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flow from financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from sale of common stock in connection with ATM, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_DWKVdqWdikGstGl2rVa-OQ_25_3">44,888</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Payments for offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_Qta4hWJmwkGEZGYnYsD8ag_26_3">234</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_6Rku8GydRU67Sz0CO83_EQ_26_6">371</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from issuance of common stock under ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="Tc_VSaEfrPIlESeI0_L5Kin4Q_27_3">356</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="Tc_xU0Gi6Q3zUa4GnfZCvBW6A_27_6">150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from issuance of common stock upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_8sZbyod3EUqiAWs27F-Icw_28_3">986</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_3KF3xrFHKUyDJwtBAjnclg_28_6">617</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_VcIV3sEYN0O_HON0Fq-zTQ_29_3">45,996</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_e0z01__Cl0Sye8RxQ7OUrQ_29_6">396</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net increase (decrease) in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_w5AQKLUjTE2ZHMuCcLqKhA_31_3">1,094</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_4tGmTCuH70-QWFkISYNvZw_31_6">31,800</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents at the beginning of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="Tc_UEPfRz1480Kvpn7ZwWNo2g_32_3">22,397</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2021_3SZLVaYF3Uaoxk9Z6taH9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="Tc_skgz0J6XVUKUL5MUcNTwYw_32_6">54,197</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents at the end of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="Tc_lZlDDBY78EePUUasZdzDMg_33_3">23,491</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="Tc_T4mc7VFECUiEaFvuJzh9hg_33_6">22,397</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Supplemental disclosure of noncash investing and financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Right-of-use asset obtained in exchange for operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_5TojZhOP0Ey4s5MC6v7X4g_36_6">765</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Deferred offering costs included in accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="avte:DeferredOfferingCostsIncludedInAccountsPayable" scale="3" id="Tc_EzIcsk1aO0y94f9JvSnb7g_37_6">15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">See accompanying notes to consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">AEROVATE THERAPEUTICS,&#160;INC.</p><a id="NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p><a id="_Hlk129215296"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_-fZQaktVdkKXsv2FNUJr5g" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Organization and Nature of Operations</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate Therapeutics&#160;Inc. (&#8220;Aerovate&#8221; or the &#8220;Company&#8221;) was incorporated in the state of Delaware in July&#160;2018, and is headquartered in Waltham, Massachusetts. The Company has a wholly owned subsidiary, Aerovate Securities Corporation. The Company is a clinical-stage biopharmaceutical company that is focused on the development of drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. The Company&#8217;s initial focus is on advancing AV-101, the Company&#8217;s dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (&#8220;PAH&#8221;). The Company initiated a global Phase 2b/Phase 3 trial of AV-101 in adults with PAH in December&#160;2021 and announced in November 2023 completion of enrollment of the Phase 2b portion of this trial and enrollment of the first patient in the Phase 3 portion of this trial. </p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">At-the-Market Offering</span><span style="font-style:italic;"> </span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 5, 2023, the Company entered into an ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement, or the Sales Agreement, with BofA Securities, Inc., or the Agent, pursuant to which the Company can sell, from time to time, at its option, up to an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_5_2023_To_4_5_2023_srt_CounterpartyNameAxis_avte_BofaSecuritiesInc.Member_eXGnRQpI10OVMaKnBBIqeg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_25Q5FtFHPEqmqTTmswPRxw">75.0</ix:nonFraction> million of shares of its common stock, through the Agent, as its sales agent. As of December 31, 2023, <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_avte_BofaSecuritiesInc.Member_LeFPgJGk10aB82UXVdtuHQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_RHRszG05fEqU9YZAEBZqJQ">2,662,721</ix:nonFraction> shares have been sold under the Sales Agreement, generating approximately $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_avte_BofaSecuritiesInc.Member_LeFPgJGk10aB82UXVdtuHQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_tzsPsTwzAEuxmox9ypi9_Q">44.3</ix:nonFraction> million of net proceeds after deducting commissions to the sales agent and other offering costs, and up to $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_avte_BofaSecuritiesInc.Member_t15u6BZEqkaKnYEH9TOQCA" decimals="-5" format="ixt:numdotdecimal" name="avte:ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram" scale="6" id="Narr_yLtp3n5qwUCL0cXd4Wp5Dg">30.0</ix:nonFraction> million of shares of the Company&#8217;s common stock remain available for sale from time to time under the Sales Agreement. </p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Liquidity and Management Plans</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since inception, the Company has devoted substantially all of its resources to research and development activities, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations and has not realized revenues from its planned principal operations. The Company has incurred losses and negative cash flows from operations since inception. In addition, the Company expects to incur substantial operating losses for the next several&#160;years as it continues its research and development activities. As of December&#160;31, 2023, the Company had cash and cash equivalents and short-term investments of $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="Narr_lhWJH51eekyZtmg3vteQ7A">122.4</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management plans to continue to incur substantial costs in order to conduct research and development activities and additional capital will be needed to undertake these activities. The Company intends to raise such capital through debt or equity financings or other arrangements to fund operations. Management believes that the Company&#8217;s current cash and cash equivalents and short-term investments will provide sufficient funds to enable the Company to meet its obligations for at least twelve&#160;months from the filing date of this report.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_38vfvHgio0Oc-Pa-9c0bqw" continuedAt="Tb_38vfvHgio0Oc-Pa-9c0bqw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(2)</b></span>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_LkkjwaXQY0K7Jvl3XBGdGg" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Basis of Presentation</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include the Company&#8217;s wholly owned subsidiary, Aerovate Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:UseOfEstimates" id="Tb_RLufNvdm7UiSEnCEv7pPFQ" continuedAt="Tb_RLufNvdm7UiSEnCEv7pPFQ_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Use of Estimates</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The preparation of the Company&#8217;s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. Accounting estimates and management judgements reflected in the consolidated financial statements include: normal recurring accruals, including the accrual for research and </p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_38vfvHgio0Oc-Pa-9c0bqw_cont1" continuedAt="Tb_38vfvHgio0Oc-Pa-9c0bqw_cont2"><ix:continuation id="Tb_RLufNvdm7UiSEnCEv7pPFQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">development expenses, stock-based compensation, fair value of investments, and operating lease right-of-use assets and lease liabilities. Estimates and assumptions are reviewed quarterly. Any revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_Qv8OtQUJnkmnhi7PRwoNaw" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Cash and Cash Equivalents</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents include cash in readily available checking accounts, money market funds and commercial paper. The Company considers all highly liquid investments with an original maturity of three&#160;months or less from the date of purchase to be cash equivalents.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="avte:ShortTermInvestmentPolicyTextBlock" id="Tb_cLkEP-GitEGuXVPS3Ommqg" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(d)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Short-term Investments</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Short-term investments consist of corporate debt securities, commercial paper and U.S. Treasury bills, classified as available-for-sale securities and have maturities of greater than three&#160;months. The Company has classified all of its available-for-sale investment securities as current assets on the consolidated balance sheets because these are considered highly liquid securities and are available for use in current operations. The Company carries these securities at fair value and reports unrealized gains and losses as a separate component of accumulated other comprehensive loss. The cost of debt securities is adjusted for amortization of purchase premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income in the consolidated statements of operations and comprehensive loss. Realized gains and losses on sales of securities are determined using the specific identification method and recorded in other income (expense), net in the consolidated statement of operations and comprehensive loss.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_XyZQoenz3UKKeo8ljk0Nbg" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(e)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Concentration of Credit Risk</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains cash, cash equivalents and short-term investments with various high credit quality banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has not experienced any losses on deposits since inception.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_XCq1Z7SBQ0Ohr8NtAYsNtg" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(f)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Comprehensive Loss</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Comprehensive loss consists of net loss and unrealized gains or losses on available-for-sale investments. The Company displays comprehensive loss and its components as part of the consolidated statements of operations and comprehensive loss.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Tb_1cAWJ0Hz1kyIhDgXy5Aw7w" continuedAt="Tb_1cAWJ0Hz1kyIhDgXy5Aw7w_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(g)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Fair Value Measurements</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">Level 1: Observable inputs such as quoted prices in active markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying amounts of prepaid expenses and other current assets, accounts payable, accrued liabilities and other current liabilities are reasonable estimates of their fair value due to the short-term nature of these accounts.</p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_38vfvHgio0Oc-Pa-9c0bqw_cont2" continuedAt="Tb_38vfvHgio0Oc-Pa-9c0bqw_cont3"><ix:continuation id="Tb_1cAWJ0Hz1kyIhDgXy5Aw7w_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="avte:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" id="Tb_Ut94TTsm-kKkjO3uqFmw-g" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(h)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Prepaid Expenses and Other Current Assets</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any expenses paid prior to the related services rendered are recorded as prepaid expenses. Such prepaid expenses are expensed in the period the expense is incurred. If the expense is for a service covering multiple periods, it is expensed from the date the services begin and over the period of the service rendered (or contract service period if services rendered dates are not defined).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_TQzxAUqQzUK5pbXB0i0i2A" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(i)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Property and Equipment, Net</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property and equipment, which consist of leasehold improvements, furniture and fixtures, research equipment, computers and construction-in-progress are stated at cost less accumulated depreciation or accumulated amortization. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets, which ranges from <span style="-sec-ix-hidden:Hidden_n34-iiJT30mFenREfVs5IQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to <span style="-sec-ix-hidden:Hidden_g3-e0FT-IE2Xj7oAU60QZg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five&#160;years</span></span>. Leasehold improvements are amortized over the remaining life of the lease for leasehold improvements at the time the asset is placed into service.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_JKgXm5uZVEKvePH409ajSQ" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(j)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Impairment of Long-lived Assets</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying value of long-lived assets, including property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. Through December&#160;31, 2023, there has been <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="Narr_Zd8-4msL_UmJnqM_bBUd7g">no</ix:nonFraction> such impairment losses recorded by the Company.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_S8ro-uPMeUGET7Ef9Z-kXQ" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(k)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Leases</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the commencement date of a lease, the Company recognizes lease liabilities which represent its obligation to make lease payments, and right-of-use assets (&#8220;ROU assets&#8221;) which represent its right to use the underlying asset during the lease term. The lease liability is measured at the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the lease commencement date. The ROU asset is measured at cost, which includes the initial measurement of the lease liability and initial direct costs incurred by the Company and excludes lease incentives. ROU assets are recorded in operating lease ROU assets and lease liabilities are recorded in operating lease liabilities, current and noncurrent in the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected not to separate lease and non-lease components and not recognize lease liabilities and ROU assets for short-term leases with terms of twelve&#160;months or less.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="avte:ConvertiblePreferredStockPolicyTextBlock" id="Tb_jfzrSjarw0i4TFw72amGuw" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(l)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Convertible Preferred Stock</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company records convertible preferred stock at fair value on the dates of issuance, net of issuance costs. Upon the occurrence of certain events that are outside the Company&#8217;s control, including a deemed liquidation event, holders of the convertible preferred stock can cause redemption for cash. Therefore, convertible preferred stock is classified outside of stockholders&#8217; deficit on the balance sheets as events triggering the liquidation preferences are not solely within the Company&#8217;s control. The carrying values of the convertible preferred stock are adjusted to their liquidation preferences if and when it becomes probable that such a liquidation event will occur.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb__UWTolqHr0KcgPvPV5IzVg" continuedAt="Tb__UWTolqHr0KcgPvPV5IzVg_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(m)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Research and Development Expenses</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and other benefits of research and development personnel, including associated share-based compensation, costs related to research activities, preclinical studies, clinical trial, drug manufacturing and allocated overhead and facility-related expenses. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, as they are incurred, based </p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_38vfvHgio0Oc-Pa-9c0bqw_cont3" continuedAt="Tb_38vfvHgio0Oc-Pa-9c0bqw_cont4"><ix:continuation id="Tb__UWTolqHr0KcgPvPV5IzVg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="Tb_gBtrwPrSMkKmfHX8YlxoNw" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(n)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Stock-Based Compensation</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Stock-based compensation expense represents the cost of the grant-date fair value of employee, officer, director, and non-employee stock option grants and restricted stock units, estimated in accordance with the applicable accounting guidance, recognized using the straight-line method over the vesting period for service-based options and using the graded vesting method for performance-based options. The vesting period generally approximates the expected service period of the awards. Forfeitures are recognized and accounted for as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The fair value of stock options is estimated using a Black-Scholes option pricing model on the date of grant. This method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#8217;s common stock, expected dividend yield, and a risk-free interest rate. Options and awards granted during the&#160;year have a maximum contractual term of <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_AM4SWxu1AEWvAgiUoTpxpw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_qSgp_R6M2kabgRb9jrw80g">ten&#160;years</ix:nonNumeric>. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the average of the contractual term of the stock option and its weighted-average vesting period. The expected volatility of stock options is based upon the historical volatility of a number of publicly traded companies in similar stages of clinical development. The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future. The risk-free interest rates used are based on the U.S. Department of Treasury (&#8220;U.S. Treasury&#8221;) yield in effect at the time of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term of the stock options.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_5Mkyw_rJuEqxP98Z3wigbQ" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(o)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Income Taxes</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Income taxes are accounted for using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss ("NOL") and tax credit carryforwards. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="white-space:pre-wrap;">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.  The company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.  The company recognizes interest and penalties related to unrecognized tax benefits within income tax expense.  Any accrued interest and penalties are included within the related tax liability.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_-bGaCrGrJEC6sYW3cKVRng" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(p)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Segment Reporting</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as <ix:nonFraction unitRef="Unit_Standard_segment_bCa297tYP0mkIHafmd-9BQ" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_R8oOol6R-kmHu6mMywB5-w">one</ix:nonFraction> operating segment.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_btwWhBe4lkeZrcsDqjA8ug" continuedAt="Tb_btwWhBe4lkeZrcsDqjA8ug_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(q)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Net Loss Per Share</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company&#8217;s potentially dilutive securities, which include convertible preferred stock prior to the conversion of such shares to common stock and outstanding stock options under the Company&#8217;s equity incentive plan, have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_52c8d707_1030_4d90_81cb_8ca7d4581404"></a><a id="_35379541_9ada_4baf_afb8_2a655507e385"></a><a id="Tc_pcKL-Jh_ikKwDheaAR8VtQ_1_2"></a><a id="Tc_59MCVn3dwU-GfeFR6ZN83g_2_2"></a><a id="Tc_eHHriKBJaE2DuzhvE-6ssA_2_5"></a><a id="Tc_4UOdQcdmK0er-Xw9C1_KSg_3_0"></a><a id="Tc_4rq4ru95TU-j5aTvKF6gRQ_4_0"></a><a id="Tc_Kyml_iws4Emc00K8L9K3ng_4_2"></a><a id="Tc_QcFfefd66UONFICrmaMxmA_4_5"></a><a id="Tc_lSWQWNeKt0W9OpL0f5Q8Ng_5_0"></a><a id="Tc_iNfJR300TUysb6v247QY_Q_5_2"></a><a id="Tc_F1lzOoFNukadh4P9WgssFg_5_5"></a><a id="Tc_dsYdaE0uCkS5JB9Jy4lxVw_7_0"></a><a id="Tc_HdxvVQ5IfEe7XJSuUojUZw_8_0"></a><a id="Tc_MrIbJJb40UaRw7FZn-t4pg_9_0"></a><a id="Tc_tbyG_DvM_UC2r2OUHjIybg_9_2"></a><a id="Tc_uEo_-TV5lUCGRYaDPZbhtg_9_5"></a><a id="_48dfdb1b_9ef8_4ba8_b4fa_a34e5b5e95f9"></a><a id="Tc_60-Vr6F2DEGegMmU9dsOxQ_1_2"></a><a id="Tc_82_UHrjdHECGkA9h-oTKEQ_2_2"></a><a id="Tc_77XuyPueNEWwWO3ygjg1cw_2_4"></a><a id="Tc_eyU9qXTdFEWh3A9eXEf5dQ_3_0"></a><a id="Tc_zF1zxrCnWkS6d7ZfafgcaQ_4_0"></a><ix:continuation id="Tb_38vfvHgio0Oc-Pa-9c0bqw_cont4"><ix:continuation id="Tb_btwWhBe4lkeZrcsDqjA8ug_cont1"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_UbUKyOWLRUWGCsMT_MIV0g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The following table summarizes the Company&#8217;s net loss per share:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_f9YcFDCA8UKu3tQxjjzVVg_4_3">75,521</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_yBYUWljb-0iS1QgIN-udVw_4_6">51,511</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_qTDNrl4R6Umise87CpglyA_5_3">75,521</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_wzPX4u1Km0uUH0pyFdIvog_5_6">51,511</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Weighted-average common stock outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_yKuShD-dGE6gPJGwS6B9Rg_8_3"><ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_yKuShD-dGE6gPJGwS6B9Rg_8_3_2">26,331,630</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_6TKnpAN-KkOu1sMvHkl-WA_8_6"><ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_6TKnpAN-KkOu1sMvHkl-WA_8_6_2">24,472,104</ix:nonFraction></ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_VoGYsGfdnk2Fsa0MJu-m4w_9_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_VoGYsGfdnk2Fsa0MJu-m4w_9_3_2">2.87</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_rzNPZ4biW0qwGGogK42-pA_9_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_rzNPZ4biW0qwGGogK42-pA_9_6_2">2.10</ix:nonFraction></ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_cW-v2ZSPjUqsYJY_hOlIwQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:61.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_KH1NXBTyjkur0ov9ZtwkMA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_WoHXhZASU0WNPEMT-zD67w_3_2">5,230,344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ChUwiv23hEy7LMz7LGvpuQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_j9NE5irV-EWU_r_jeOygRw_3_4">4,110,219</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:61.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_3UmwRa-EAE-11acDMKDuHQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_mgEuD1n-ykS97sKtineEVA_4_2">21,968</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_QNvV2K_cRECh_I59hVJgKg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_0et2HXJqyEmI6LbA3cK-nw_4_4">28,881</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ds3uzUzxnE-8H6aX9MxltQ_5_2">5,252,312</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_sjR7SWsW5UCUgcd1DgMacg_5_4">4,139,100</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_v-LPkOBQT0OMt8L-c2AAqA" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(r)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Recently Issued Accounting Pronouncements</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In December 2023, the FASB issued ASU No. 2023-09, "Improvements to Income Tax Disclosures." ASU 2023-09 requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024 and for private businesses for annual periods beginning after December 15, 2025, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its financial statement disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In June 2022, the FASB issued ASU No. 2022-03, Fair Value Measurement (Topic 820) - Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard will be effective for the Company on January 1, 2024, and is not expected to have an impact on the Company&#8217;s financial position or results of operations upon adoption.</p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_2b58cb24_8f33_4c77_863e_6aca81a88fa7"></a><a id="Tc_QneJcnJkz0awcHNDw5Tzww_1_5"></a><a id="Tc__8L8JiE8WUWBb4Vg1StTOw_2_5"></a><a id="Tc_ckZaPH8HUEmx4GLvbzHhMg_3_5"></a><a id="Tc_qg7iYCbyok2Vkbvrjwcepw_3_8"></a><a id="Tc_H6pZpMRJs0m6qUI32jwgcg_3_11"></a><a id="Tc_uY5RzYbZOEmUCVaaHxleCg_4_5"></a><a id="Tc_9iUguw5CGki7UNa_5PJZ5A_4_8"></a><a id="Tc_eUy6iDQ7c022sCHXqlSkjQ_4_11"></a><a id="Tc_y-2GW8dFI0WsZZxUIabrnQ_5_2"></a><a id="Tc_5X4HTxjH9k2w49zXcC97Dg_5_5"></a><a id="Tc_hNimHw6EGkutQEwIEWcupQ_5_8"></a><a id="Tc_vg0L3dAxrkeh-8jMVu6N6w_5_11"></a><a id="Tc_e63c2J5_4kmWeyUkwM7LTg_6_2"></a><a id="Tc_3xoqsYSryEK1eyfsPzC4hQ_6_5"></a><a id="Tc_5aiX9Yc6uESeCmBQxupemQ_6_8"></a><a id="Tc_LQFTI6ZoJkeT4po5ebgO6w_6_11"></a><a id="Tc_RY0O5cFLWUSv7UAy7nOdfw_7_0"></a><a id="Tc_zYBOxKul_E-EjeBZ6pKpFg_8_0"></a><a id="Tc_BanKVeaoPESmhYNpfStzZA_9_0"></a><a id="Tc_XWtZsGpqYkGm8xUdq1FAkQ_9_2"></a><a id="Tc_cMwNfelFu0-tzw7rY_6nZA_9_5"></a><a id="Tc_b2x-DCRpLEu9dzqZ10GEWQ_9_8"></a><a id="Tc_5HXy6i1EcUG1PBWlY4vuhQ_9_9"></a><a id="Tc_OhYLmBSwg0afqiUR2o_fgA_9_11"></a><a id="Tc_qraSiRGkR0WHV27fWFrTdg_9_12"></a><a id="Tc_BRNlmwyJ0Uevhsv_nfJxiQ_10_0"></a><a id="Tc_iBtZx0ehHU6KVCgcLSPqJQ_10_9"></a><a id="Tc_Tt3oavIZ-0KTe0pGYv9cLQ_10_12"></a><a id="Tc_K1DdVD_2P0mQzWHZqrwqWg_12_0"></a><a id="Tc__cYCXMTJIkOVq4UnMhJ7wQ_13_0"></a><a id="Tc_xXptYD79EUSZ8raDtKdHjA_13_6"></a><a id="Tc_zNSUa3a7hECmCTvvVaU8Aw_13_12"></a><a id="Tc_IA9cT7PPNE2MBTUo6KS1MQ_14_0"></a><a id="Tc_1WApkINUNE-stvb05BvSgg_14_6"></a><a id="Tc_PhkSrcAEDE2pIgOluhcP9Q_14_12"></a><a id="Tc_zQWJ1jcujki_uwQueudQ5Q_15_0"></a><a id="Tc_O1-GytYBHEmWhEKxbtI9Dw_15_9"></a><a id="Tc_oD40NuoiIEq0E_IZCthUbw_15_12"></a><a id="Tc_vZWhZt1h8EyI9o3t1V9PMQ_16_0"></a><a id="Tc_wWi1DcV76kWai6cRaY7sSw_16_6"></a><a id="Tc_APpiop1b50KvZ5OtZj8ZRA_16_12"></a><a id="Tc_hodvCtJ_e0uDfsytQMgb4A_17_0"></a><a id="Tc_hiadKHmeGUqFpEmE9L0Bcg_17_12"></a><a id="Tc_bejRiPV0rUOMMCJgv5xWhw_19_0"></a><a id="Tc_WO3tzmt3sUS8116IuYiMlw_19_2"></a><a id="Tc_msQpmHPgvUOW7_d4zQcoXw_19_5"></a><a id="Tc_fmHTchjJC0yVuakx2dooHQ_19_8"></a><a id="Tc_qHavMCFSlkCxj2NQ-nZweg_19_11"></a><a id="Tc_rn7LM3IeRUKOmas1jqWtgA_19_12"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_1X4MxkgG9EuvqB5vQGp4Xg" continuedAt="Tb_1X4MxkgG9EuvqB5vQGp4Xg_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">(3)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">FAIR VALUE OF FINANCIAL INSTRUMENTS</p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_BmsCG8PFvUONZaPfiA1MDA" continuedAt="Tb_BmsCG8PFvUONZaPfiA1MDA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The following tables summarize the Company&#8217;s financial assets measured at fair value on a recurring basis and their respective input levels based on the fair value hierarchy (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:normal;width:41.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for&#160;Identical</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level&#160;3)</b></p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_jXLEnvJsuU2DjT7WrX1onA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_DxrMaF0580OYzeJsXL_UQA_9_3">19,787</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_C-UwaOvYgEmhc5KbjSNoaA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_KEG1dv2KQEKCEwB6t3Y94w_9_6">19,787</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_alE2cQWlWUmYEMSvxQfOpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_Yb3621cLpkKHcwtI3LH7tw_10_3">19,787</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Uy_OzIg220WOoPfwtTN9Cg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_O7A29qrBA0-iBSyUz4-I7A_10_6">19,787</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_GLAldi10KUCn9sv4BDXzvw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_-L6Jd0UCNUWsmhrfc9Ti0g_13_3">42,255</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_RToG1KKrEU2I3goa1SB0fQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_7qEomVAd50qDKjA_SdxIvA_13_9">42,255</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Commercial Paper</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_2EbSprzX4UmWm8yxfF94Hw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_JXnIJ4F9V064BlxDchrEOQ_14_3">38,386</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_xuDF7JacqEyVD_8bE4KGbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_zLXAZzqc0EemxpKmv5BM9Q_14_9">38,386</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8Ja-oIvtvEOUSt1VbId_rw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_G_bdccPzY022dsv3sbwaCQ_15_3">10,362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_paK6hjSIN0utjCqZ6uTFBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_2yr8ziPWlUKOt6jrQjYGuA_15_6">10,362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_23DxYpsziUKkF0FV76-EIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc__IEGBw1hVUO_T4zvS71Zhw_16_3">7,945</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_PbzReIi7W0qZtcZBeUxt9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_pkAa9s5oUUOrJQJ9qPtgMQ_16_9">7,945</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_alE2cQWlWUmYEMSvxQfOpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_TMe69xbKYkq2qAKN53XGWQ_17_3">98,948</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Uy_OzIg220WOoPfwtTN9Cg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_cCdI3QgCWU2VQA3_FqSbQw_17_6">10,362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_sWDh72OE6kSOPCSLEhKjBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_OBSorDHXNU66-KZN7TD1Rg_17_9">88,586</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total fair value of assets</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_alE2cQWlWUmYEMSvxQfOpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_-cgE9VrXdEO19QTquLI3NA_19_3">118,735</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Uy_OzIg220WOoPfwtTN9Cg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_sbxpcvwoWEiF1EudZa3nwQ_19_6">30,149</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_sWDh72OE6kSOPCSLEhKjBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_AL8Z8PI6C0WCSUJawLkuxQ_19_9">88,586</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_3803d005_f48f_41e6_9a8e_5938637562e8"></a><a id="Tc_j6Yve_O5iEqB7SRvHO05Fg_1_5"></a><a id="Tc_OJWeAgjM0EW4GFjERX1SNA_2_5"></a><a id="Tc_sfuznRTrxkCcg6WIF78Fyw_3_5"></a><a id="Tc_9oIWM4sUVEiJ90Y14GEUEQ_3_8"></a><a id="Tc_Bg1zLCtxZ0GoZOiHFnOWYg_3_11"></a><a id="Tc_Z0AqIfRtKku5_cpFSw6UZA_4_5"></a><a id="Tc_fE7pHcaWXk2dlQzd3oMctg_4_8"></a><a id="Tc_ba6Xga6-skCkUZLZ9fFELg_4_11"></a><a id="Tc_d5yamdOfN0KMkd0kDANY2Q_5_2"></a><a id="Tc_QUqwdGv-NkWxk3WjCD80bQ_5_5"></a><a id="Tc_Qn4pMYjj1UCaeGwoJUVQkw_5_8"></a><a id="Tc_xNMtE6-rx0y6KUIFvo9HkA_5_11"></a><a id="Tc_Ev26OU5OFUKmDu5kzqTAhQ_6_2"></a><a id="Tc_x76qRqLYZke1-bZp5wQYpQ_6_5"></a><a id="Tc_NjMUMWcL4kKEgebUFqOzSw_6_8"></a><a id="Tc_9swiMfAZVUqoYFc3ypDBSg_6_11"></a><a id="Tc_UofrVoUKyE2d8fp7n0CrOA_7_0"></a><a id="Tc_1X7rV2EnHkCPe0ibXoMPpg_8_0"></a><a id="Tc_OVPj0M0rgkSNBoanTgB8oA_9_0"></a><a id="Tc_iqQvpm0xGU6GICP8gF1buA_9_2"></a><a id="Tc_v-ogvqnSNka4f_k0mvJA2g_9_5"></a><a id="Tc_rLqR-C1I4Ey_7PqwmpZNAw_9_8"></a><a id="Tc_kT0hCTI6vUmXOZyJ8JKNHA_9_9"></a><a id="Tc_ak9M4bSOyESBJCg6QL5XJw_9_11"></a><a id="Tc_gYgOUjGfdUqjcd8pFOYNfQ_9_12"></a><a id="Tc_6ylIQ_6DCEGYlVK-N-9SJA_10_0"></a><a id="Tc_B4b_xOkIMkKNQC66AmmF4w_10_9"></a><a id="Tc_XoYHF-z64UaiUDgZjmfG3Q_10_12"></a><a id="Tc_EzsacT5pcEC-kSQi-Msa0w_12_0"></a><a id="Tc_relxnpVkwkWYlF8syCq4rA_13_0"></a><a id="Tc_NMp0SG_zAUyN1sxE5mSD-g_13_6"></a><a id="Tc_Xs_CMiCWoU6SyRDJMgbZlA_13_12"></a><a id="Tc_n2gqNfr24UiZkyk2Qg_uAQ_14_0"></a><a id="Tc_v_TdzMb3MkyJohkbVjf6wQ_14_9"></a><a id="Tc_buvfBNYiQE6Vly2odtQxww_14_12"></a><a id="Tc_BPM2cKIVfUepAmK1MYlEOA_15_0"></a><a id="Tc_lgvjLkp4c0WgRL6_n-VPfg_15_6"></a><a id="Tc_0zcXM9o_ykS3KLMf9tR1sw_15_12"></a><a id="Tc_3Kjhv9BMgkOxz_ogTufLrQ_16_0"></a><a id="Tc_iG4jqtaDc0OMJYFq8q4q_w_16_12"></a><a id="Tc_X58B6YWOy0K9aN2U5dCgqg_18_0"></a><a id="Tc_Yhf6sUHqn0G7kR2D4Qa1Kw_18_2"></a><a id="Tc_8kijYN_wAEatJWbc9SmuNg_18_5"></a><a id="Tc_dvCadtA_oUyH-fU8Tzo_fA_18_8"></a><a id="Tc_eCYMeG9gPkuw1yl6ROVdNg_18_11"></a><a id="Tc_oN8qNiVCnke64PdD-q6HGw_18_12"></a><a id="_80dc96d6_438b_4c4f_b10e_eb03ab42ee7b"></a><a id="Tc_mrttwQdrLkedPyx5Q0Os7w_1_4"></a><a id="Tc_6i4Ditlp9EK4jqfLZtiw6g_2_7"></a><a id="Tc_3wRlfrPvD0ydWttygDlZCQ_2_10"></a><a id="Tc_ND-12UC1o0mdhltuMFVdCg_3_4"></a><a id="Tc_4PvoQb-slEC9mbewx8CjRw_3_7"></a><a id="Tc_51B-rm_atEuXnplVj8MUBw_3_10"></a><a id="Tc_ZNmS3DCayUWgpNnd72S0fw_3_13"></a><a id="Tc_SABEPrHHPkCf0WvDzx6HEA_4_2"></a><a id="Tc_9MUa4kuF50S4adBNQncvoA_4_4"></a><a id="Tc_yznJrqRZG0eNwXVipQkPNg_4_7"></a><a id="Tc_9igrrHfhgUa96gNF8LvuOw_4_10"></a><a id="Tc_G9gLdm_8JkCTOE-tZutjrg_4_13"></a><a id="Tc_A8YvW7q52k2lM1ap8EwIHw_5_0"></a><a id="Tc_LnV8ydWP5k6CAbENWFN_HQ_5_2"></a><a id="Tc_Txb9NeB3SkycfWJlefZFbw_6_0"></a><a id="Tc_yExdKLVKbUyq5CfNI3rhYw_6_2"></a><a id="Tc_wKHGfPURa0-TnK9PI77lAw_7_0"></a><a id="Tc_puGOB2GDhESzODUUDsjDYA_7_2"></a><a id="Tc_sVRnBHwCe0WOtYfHeYJ19g_8_0"></a><a id="Tc_SU77PCI27EyvdlNkavFw1g_8_2"></a><a id="Tc_BHygqzgge0qUVnBmGwaqMA_9_4"></a><a id="Tc_XzzMVzJi2kCYWJyWORrbHQ_9_7"></a><a id="Tc_3sm4jxsoxUCTkJ99fM-kCQ_9_10"></a><a id="Tc_cZ-NSWQuP028MP-IHKP4Zg_9_13"></a><a id="_142b5cf7_8e5b_404b_b984_f575aebc3726"></a><a id="Tc_OsrT7bVkdkOg6FbDq0Pyyg_1_4"></a><a id="Tc__vgnaf8_50W_s9R8O3iQcQ_2_7"></a><a id="Tc_AQRP9t6xb0CL2eymhIyfmQ_2_10"></a><a id="Tc_eelBrimWBEmUVJd4oYXlxw_3_4"></a><a id="Tc_126LiIJITE6bPbVESAyhJA_3_7"></a><a id="Tc_2sLJMtEgaUaoX-cZyi238Q_3_10"></a><a id="Tc_Qi8NIBAynE2bYGniLntXEQ_3_13"></a><a id="Tc_gjRvLwlGL0WXg8-vwUKIRQ_4_2"></a><a id="Tc_JCWudY1mI0yn8X2R1zWi9g_4_4"></a><a id="Tc_LSJ3JLlY8UiSH8LeL1UpaQ_4_7"></a><a id="Tc_medDPjx45Emh2qGoinssRg_4_10"></a><a id="Tc_sWFD9GqgFU2J3NEN2Ro_4Q_4_13"></a><a id="Tc_Mhb3W0sw1kKAcUdDh2vbFw_5_0"></a><a id="Tc_vBr9rznZc0mE6AaF0dyRuQ_5_2"></a><a id="Tc_IyM_3seHZki58ZR9S9e2FA_5_4"></a><a id="Tc_SHn4STbfU0a9Yyrq1mE80Q_5_7"></a><a id="Tc_KbiMEHqQMUmx3XwSsEqMsg_5_10"></a><a id="Tc_TEzRD7VnMUq2J78Yqg1OhQ_5_13"></a><a id="Tc_3shlncc9yEaBELTLjcNeZg_6_0"></a><a id="Tc_e7CXfNMwYE2nmuA563kBBQ_6_2"></a><a id="Tc_QnvevTypk0GgMGJvioQnzw_6_8"></a><a id="Tc_4DXJydX6gU2ge96yRZy1lQ_7_0"></a><a id="Tc_1SYfW7GWskq5TazihZSEww_7_2"></a><a id="Tc_bu5CwRYa_06l8WeM0JGmcQ_8_4"></a><a id="Tc_M2PvC_96yUG114kAAU3xbA_8_7"></a><a id="Tc_fU-SHrKvRkOUAe4EHmD7EQ_8_10"></a><a id="Tc_JNabRfCHLUCXwsWAHyaMdw_8_13"></a><ix:continuation id="Tb_1X4MxkgG9EuvqB5vQGp4Xg_cont1" continuedAt="Tb_1X4MxkgG9EuvqB5vQGp4Xg_cont2"><ix:continuation id="Tb_BmsCG8PFvUONZaPfiA1MDA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:41.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">for&#160;Identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(level&#160;3)</b></p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AyHw9eprTkCuYHbb4OSTdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_CqPJ8G_PMESPKWikpzm9Bw_9_3">18,436</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_F964c7FBf0qgpnkWSEYhwg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_M_YIIzwiC0KGC49lMH6yww_9_6">18,436</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Kcx7c1ohMECfaPSrYxC0Nw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_X4S3hHNVvEuOC79yOULZDQ_10_3">18,436</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kHkV564Q4kqYbVZPXq-xpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_TaQT90JxHE6aIrnHegbXfg_10_6">18,436</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_8pnWeqBIpESIlttN4ujbaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_VU8AFepDbkiYHZbMa-vp_Q_13_3">55,577</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_ywomA-WM5EmdfslLNmeoUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_wfIHz9-hsEuOrZ_CKvYjhA_13_9">55,577</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_SnzjzhUup0auURpf_CvbCQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_waVSP0GywUul6u12b8TeOw_14_3">26,841</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_NYTb6k4rLkCljLkmM_mSYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_pA_d1jpQCE2XafBo_7IF1g_14_6">26,841</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Agency Bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_14Q4SyHhfEip0yfmjiQBjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_li-kUJ6ADkq6dwNri2RtGA_15_3">24,405</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_dAN4ZtziuEiP3QwWp9yKPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_P8bN7nLNQUWdcExR9zMypQ_15_9">24,405</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Kcx7c1ohMECfaPSrYxC0Nw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_mwfIdN0IGU2z0P1nVUnucQ_16_3">106,823</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kHkV564Q4kqYbVZPXq-xpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_kyfwgVpB7UiiTMSTp0p88w_16_6">26,841</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Lk-ps-R70EiQI3935QJvXw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_JDZ33o79lkKPRF87lvcRMg_16_9">79,982</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total fair value of assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Kcx7c1ohMECfaPSrYxC0Nw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_Lw0uqm-zu0qWHMe3m4MMtA_18_3">125,259</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kHkV564Q4kqYbVZPXq-xpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_5ilFJ5rzeUepb3KrQJGc6Q_18_6">45,277</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Lk-ps-R70EiQI3935QJvXw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_4dlGXXmGHUqhJJj5cad8Jw_18_9">79,982</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash Equivalents and Short-Term Investments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial assets measured at fair value on a recurring basis consist of the Company&#8217;s cash equivalents and short-term investments. Cash equivalents consisted of cash, money market funds and commercial paper, and short-term investments consisted of U.S. Treasury bills, agency bonds, corporate debt securities and commercial paper. The Company obtains pricing information from its investment manager and generally determines the fair value of investment securities using standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="Tb_7zmf5Rc5iUWqMgowzPXv_Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following tables summarize the Company&#8217;s short-term investments (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maturity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_OlIabHctWUyzxlnqkr4bCg" format="ixt-sec:durwordsen" name="avte:DebtSecuritiesAvailableForSaleMaturityTerm" id="Narr_qWh5wPBlzUqE6U-KrqGOUA">2&#160;years</ix:nonNumeric>&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="3" id="Tc_qb6SxEx5cUe7r_K1FGOSiQ_5_5">42,090</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_qEdGyfxvEUmDnTBJkRq9GA_5_8">179</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_KILFzGl-s0u9Zrj0ThTpJQ_5_11">14</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_99I-vZIk_E-cha0yjCS6pQ_5_14">42,255</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_zaDLiCFPqUqEufSLy6NbzQ" format="ixt-sec:durwordsen" name="avte:DebtSecuritiesAvailableForSaleMaturityTerm" id="Narr_ErP_oa1v-0i0y8GffgCQGA">2&#160;years</ix:nonNumeric>&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="3" id="Tc_EfS6sLc4aEyjDjePAFZqOA_6_5">38,362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_sBFymzb0zkeFoiTp-RvNIQ_6_8">29</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_p8AM9_u4g0Oh_ox52iLxgQ_6_11">5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_9Dlb-2fLwkutcr9w4-tTsA_6_14">38,386</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_eZcGsEFbHEW38q44Yr6mVw" format="ixt-sec:durwordsen" name="avte:DebtSecuritiesAvailableForSaleMaturityTerm" id="Narr_7Od7ttfk5kqmvt_28wB3Mg">2&#160;years</ix:nonNumeric>&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="3" id="Tc_LKI4AAprjkGYatD95TqWng_7_5">10,334</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_lGxrp_1nokSKEAmQD8hxOw_7_8">31</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_LSDIa5QddkeSHpy5MCx3Jw_7_11">3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_zMyr3EjJCUqTuI2D2WChGw_7_14">10,362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_rsRxqqwUvEm2inEelixs4Q" format="ixt-sec:durwordsen" name="avte:DebtSecuritiesAvailableForSaleMaturityTerm" id="Narr_44smtp7kaEGISHjAO6t_gA">2&#160;years</ix:nonNumeric>&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="3" id="Tc_jLqXUti2_0e0qHf3km_4CA_8_5">7,925</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_LFUmRjfrjEijuzVVBahlaA_8_8">21</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_NOBTNIlWCk6fyyCwrNZWwg_8_11">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_YZNCXB47g06G6E5lwbJEEg_8_14">7,945</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="3" id="Tc_FpEd-FRj4U2ayjsxfYX5vQ_9_5">98,711</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_qTIiNbt9y0ez5q0bScJtsQ_9_8">260</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_JOvyiMgAUk6l_NSM5GgkVw_9_11">23</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_ebQxFMV3mEy1_zsPG43dfg_9_14">98,948</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maturity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_kql4M0ph3Umd2bhh5TV1nA" format="ixt-sec:durwordsen" name="avte:DebtSecuritiesAvailableForSaleMaturityTerm" id="Narr_P5DnjcqfJkabUjJtgVBh9g">1&#160;year</ix:nonNumeric>&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_GL6agAj25k-cPwtptPUzow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="3" id="Tc_Wfw4-3C78EuhNgA54cGhpQ_5_5">55,645</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_GL6agAj25k-cPwtptPUzow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_83WQD_MKx0KtxVTuw7UXHg_5_8">16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_GL6agAj25k-cPwtptPUzow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_4rQ5CBlWLE-A2BYjKv6XEw_5_11">84</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_GL6agAj25k-cPwtptPUzow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_OYPgV-HZWUisr3vEb7WG3Q_5_14">55,577</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_qYrKRTeZrkCEoPKcnJyr4Q" format="ixt-sec:durwordsen" name="avte:DebtSecuritiesAvailableForSaleMaturityTerm" id="Narr_502dxCHwZ0SJ434xdHbSmg">1&#160;year</ix:nonNumeric>&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8yGurj7uGke-WnYhN4sOug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="3" id="Tc_B9j5tx_RrU-Yf6X5I0ZxXQ_6_5">27,108</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8yGurj7uGke-WnYhN4sOug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_ymDdXfohkUqOC1OEE_9XCQ_6_11">267</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8yGurj7uGke-WnYhN4sOug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_jQfoAKkfd0eLC05iIeAr1g_6_14">26,841</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_YQFimAiCRUGyikQapBgwVA" format="ixt-sec:durwordsen" name="avte:DebtSecuritiesAvailableForSaleMaturityTerm" id="Narr_uynXua4cekeuBfbcmVyFAA">2&#160;years</ix:nonNumeric>&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_cMFhMcP0AE2-6VZ7iiNWxQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="3" id="Tc_fYZb0xqcv06OwADJwosCwQ_7_5">24,536</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_cMFhMcP0AE2-6VZ7iiNWxQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_glOINKHGtkCsqn5yCGtjpg_7_8">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_cMFhMcP0AE2-6VZ7iiNWxQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_crBZpP90uU-mycrpXdB3Ig_7_11">133</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_cMFhMcP0AE2-6VZ7iiNWxQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_6nzCZ07wjUmBvO5Nf4dAGg_7_14">24,405</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="3" id="Tc_M3pQF0Aa9USfESjrA7IGAg_8_5">107,289</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_Dc0n61eD0EmOaa4JYWmy6w_8_8">18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_abAHTp6je06yRmhi7InSdA_8_11">484</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_QXPxXlyng0CQ6wvUff43xw_8_14">106,823</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_104f8999_db84_4f52_a270_4ada19573448"></a><a id="Tc_sGN8Gpr_SkyhmSkuwTok_w_1_1"></a><a id="Tc_oWIWUYHtU0Ckp3HTTiL5WQ_2_1"></a><a id="Tc_tymyC0mH4U2bMdHDTY3fQg_2_7"></a><a id="Tc_9d5J64quREadDcS9YtYYVQ_3_4"></a><a id="Tc_6Sk1crhMckiQyU5jUzdP-g_3_10"></a><a id="Tc_sDgHAnk9c0mJSh8xBY9Pcg_3_13"></a><a id="Tc_b5zh40Y8IkiFiHW5hIZy7g_3_16"></a><a id="Tc_eo2H0ubaZ0Ck-37mTKfrMg_4_1"></a><a id="Tc_Orhg_W_SP0uP5VyR0hBlKA_4_4"></a><a id="Tc_k5wYIErR4UuNc2Po7jNYzw_4_7"></a><a id="Tc_cD5jFAWMUkuJ6q4OYHIbcA_4_10"></a><a id="Tc_4Z7E4vUfBk2YUOmHFHa-nA_4_13"></a><a id="Tc_ynujgEPr-ES6yggPILSKpQ_4_16"></a><a id="Tc_pNBgwLkcY0Sse4M6VPwWTg_5_0"></a><a id="Tc_ObUFmxTFaU6KStKk5kXuxQ_5_1"></a><a id="Tc_XZ6Ns8rD5ES73Mi9AExOcg_5_4"></a><a id="Tc_OHTVC4-JNUKzvOUFkaLswA_5_7"></a><a id="Tc_vJmmJRrKZUGNtpl_mnjjPQ_5_8"></a><a id="Tc_Y3Q98TuKnkOGfZVuOaGJ-w_5_10"></a><a id="Tc_-33QMC1QuUGfnQy5-Bz5gw_5_11"></a><a id="Tc_xbunv2IRAkmy4-lKOD5o_g_5_13"></a><a id="Tc_nwhKZiRrWEmDCR6hxVpYjw_5_16"></a><a id="Tc_yGHiraaCdUSgDCtMHy4NgA_6_0"></a><a id="Tc_Lk7RvPY7SUCQoNpYK8gmOw_7_0"></a><a id="Tc_PHghbqIyM0aP3sVtyeQfYQ_8_0"></a><a id="Tc_adSTv8gTxUWGRAmwi_4QBQ_8_8"></a><a id="Tc_8exs7KWXkUW1MVfKNzJPpQ_8_11"></a><a id="Tc_n90MGRIeMkerhRajmfOrpA_9_1"></a><a id="Tc_RNAwjbUfi02_yHZ8ajh0QA_9_4"></a><a id="Tc_deugU9f86EivT6OE02EHLw_9_7"></a><a id="Tc_b72QHwyT4ESOFMPE20oWiQ_9_10"></a><a id="Tc_lBVjABDvd02UJ5MmdUEPtw_9_13"></a><a id="Tc_72GS90isAUC_Or0C00VopQ_9_16"></a><a id="_6d31ede3_c53c_45f5_802f_fd44a99f9db6"></a><a id="Tc_0KQQsVq85ECvF9rincR0Xw_1_1"></a><a id="Tc_5Bq65yvwt0y5HYWT1lj0zQ_2_1"></a><a id="Tc_T4gZccJtbEeagr2FC5KZFg_2_7"></a><a id="Tc_zLVhW6iM40iVlxVhDscC6A_3_4"></a><a id="Tc_RP9KfbDCW0-MhQ6GStlXsQ_3_10"></a><a id="Tc_wP87ZvJRd02a3wjjZchqHA_3_13"></a><a id="Tc_ht8a7hE1202yRkU4RaasCg_3_16"></a><a id="Tc_9ssSS0AaxE2O2k51qsXgHw_4_1"></a><a id="Tc_HtI8NTJxWkSulWck_I3u_g_4_4"></a><a id="Tc_8dEEasr3pE2HPy1e6b-_3A_4_7"></a><a id="Tc_edEMciG4fUWLnF-YKbtFRg_4_10"></a><a id="Tc_uFrHaCT2QUezRXWQqbR71Q_4_13"></a><a id="Tc_eOr7IXPBukuJEzFeDT-eUQ_4_16"></a><a id="Tc_mtSTax-4WkmHtYGgAq8lUg_5_0"></a><a id="Tc_otBAkHVMGUSJ7ZxPH57vBg_5_1"></a><a id="Tc_K1cYNbaWFkaZTucu6_Yhgw_5_4"></a><a id="Tc_POsJ1Jl4tEyQn4gM5o8CZw_5_7"></a><a id="Tc_Q0xNRvnzzEGAnuftHFl0CA_5_8"></a><a id="Tc_nToY3zVqwUSBMA38hT1Klg_5_10"></a><a id="Tc_NafUfCA0vUuUbsIRAFkOyA_5_11"></a><a id="Tc_uUCUuPsAK0WuPralToH9Jg_5_13"></a><a id="Tc_W13wjswirEKW9X8p-9RTwQ_5_16"></a><a id="Tc_ujzJOpz3i0WX5VibH-b4YA_6_0"></a><a id="Tc_hDOaycW3Z0KuA-KAPL3ORg_7_0"></a><a id="Tc_kOnD7DZwoUy-uHzjLfJ9kA_7_8"></a><a id="Tc_tmGqHdP78kGf3yCNAsy24A_7_11"></a><a id="Tc_E29KTOW9C0uO0eHfB-Hxzw_8_1"></a><a id="Tc_JcofbTvFTkKoo1yX75voPQ_8_4"></a><a id="Tc_whOMpsTFzkmC6NeTXKp_vA_8_7"></a><a id="Tc_uCxXar7dS0y97GUFFVoXQQ_8_10"></a><a id="Tc_e3X5vtXbVUqLPpXzT8H-sA_8_13"></a><a id="Tc_3xU9KFpfOEu1bYr4GVHFhQ_8_16"></a><a id="_790dca4d_e49a_42d5_b7c9_74ae40a5b827"></a><a id="_790dca4d_e49a_42d5_b7c9_74ae40a5b827_2"></a><a id="_790dca4d_e49a_42d5_b7c9_74ae40a5b827_3"></a><ix:continuation id="Tb_1X4MxkgG9EuvqB5vQGp4Xg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following tables summarize the Company&#8217;s short-term investments with unrealized losses for less than 12 months and 12 months or greater:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="Tb_7B4GRys0v0O5HbCct40i3g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:65.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.56%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.58%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">12 months or Greater</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.03%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Unrealized</b></p></td></tr><tr><td style="vertical-align:bottom;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="Tc_srC84Z44IEmbY5Ns0AlKVg_5_2">6,042</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="Tc_mzoprdBmAkOgDFkkhRuuPw_5_5">5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="Tc_3Q1MNZQqN0q64IkrvsmlDQ_5_14">6,042</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="Tc_5WmhI20KKkSlSOXmFPww4g_5_17">5</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="Tc_ka4wTUKJt0KG9Y02NxieZg_6_2">3,760</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="Tc_YPNPCfmvrUySFvny6U_kFw_6_5">6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="Tc_vXkUBUBFmk2_keCTO2HcyA_6_8">6,579</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="Tc_z3gK1a5Xd0SKC6bKwUd2Hg_6_11">8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="Tc_mk5zchBz30-D5yLiJz5TJA_6_14">10,339</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="Tc_2gvKjt8Ofki1C_2El0_Q9Q_6_17">14</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="Tc_nC0juwXiUUOsdQnEfgLsXw_7_2">488</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="Tc_83waXynraEmKiKqrFBL5vA_7_5">2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="Tc_z0SCzPUxDkaMjWQI8Ud5Fg_7_8">1,007</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="Tc_n6ekbLVzuU6D7eI_S9YrRg_7_11">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="Tc_2NvxHcy430KYEt9gWcNbcA_7_14">1,495</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="Tc_Fd9-ZHr2yEGFXWZRocyDHA_7_17">3</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="Tc_Q7Lv6hL13kuKuRtYyZcHyQ_8_2">3,110</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="Tc_AL4HjntIPkaoLFnD7pc-Fg_8_5">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="Tc_M9qA3ccbbUGovJLsQ7Q7LA_8_14">3,110</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="Tc_mIcWi7wqJ069aTY_UUWYXw_8_17">1</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="Tc_rx6ZnarNxEyV5MdGM5w8tg_9_2">13,400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="Tc_n1p6f4QxLEm1nxKC6q4OsQ_9_5">14</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="Tc_FzyZts9eD0W3FXaO_XewCA_9_8">7,586</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="Tc_rArUMrNjRUaYUiTrSdznKQ_9_11">9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="Tc_pRPI_A2l6UKPJ-ehFiwjXw_9_14">20,986</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="Tc_IrZ62k-900KyCAj4HuUJBg_9_17">23</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:32.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:67.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.01%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.32%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">12 months or Greater</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Unrealized</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:32.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_GL6agAj25k-cPwtptPUzow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="Tc_EcVXHIRdGUulbX8gms1mCg_5_2">34,928</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_GL6agAj25k-cPwtptPUzow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="Tc_JfcRaSQ60kWROX96kvANmA_5_5">84</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_GL6agAj25k-cPwtptPUzow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="Tc_gDVzS4LD_kiVN8hRLkeYfg_5_14">34,928</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_GL6agAj25k-cPwtptPUzow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="Tc_p0M5t44f30ejMu6BibsskA_5_17">84</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8yGurj7uGke-WnYhN4sOug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="Tc_nmL-gk-M_km13YAqMQyPCw_6_2">1,971</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8yGurj7uGke-WnYhN4sOug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="Tc_3rGW-3iPYEWTs5V9bbRWFQ_6_5">6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8yGurj7uGke-WnYhN4sOug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="Tc_ptbw2Mo_CU6TcCGF3kzX-Q_6_8">24,833</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8yGurj7uGke-WnYhN4sOug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="Tc_2N-KdxUsF0SezvPltcs3vQ_6_11">261</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8yGurj7uGke-WnYhN4sOug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="Tc_reSunN2_Pk6tYg2DNx95VQ_6_14">26,804</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8yGurj7uGke-WnYhN4sOug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="Tc_u52Pil6NgEquQ31QByHHYA_6_17">267</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:32.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_cMFhMcP0AE2-6VZ7iiNWxQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="Tc_-pmZXF3J_EW2W6Ku24nkZQ_7_2">22,964</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_cMFhMcP0AE2-6VZ7iiNWxQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="Tc_bjpSDVUsS024STJVdj6EHg_7_5">133</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_cMFhMcP0AE2-6VZ7iiNWxQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="Tc_Eu9Wx3VR_UO27KAPCq6rNA_7_14">22,964</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_cMFhMcP0AE2-6VZ7iiNWxQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="Tc_HqKAXnd9fUKVlFa0YKFgpQ_7_17">133</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="Tc_8LdkeUzoGkmJZ0PaQi_VKQ_8_2">59,863</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="Tc_mnY-0hTXn0Oqmd_CyhtI1Q_8_5">223</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="Tc_NdQJf3hfGkOby1wRvMkA_w_8_8">24,833</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="Tc_LcXc55BxD0OgpBsqxws3lw_8_11">261</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="Tc_nqTkxAKNfkG1eMayLV_Iuw_8_14">84,696</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="Tc_cUCKEwx0r0Gi72R3syeabg_8_17">484</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company considers whether unrealized losses have resulted from a credit loss or other factors. The unrealized losses on the Company&#8217;s available-for-sale securities as of December&#160;31, 2023 were caused by fluctuations in market value and interest rates as a result of the economic environment and not credit risk. The Company concluded that an allowance for credit losses was unnecessary as of December&#160;31, 2023. It is neither management&#8217;s intention to sell nor is it more likely than not that the Company will be required to sell these investments prior to recovery of their cost basis or recovery of fair value. Unrealized gains and losses are included in accumulated other comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Accrued interest receivable is written off through net realized investment gains (losses) at the time the issuer of the bond defaults or is expected to default on payment. Accrued interest receivable related to short-term investments was $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent" scale="6" id="Narr_xCXiuQbpEEWCn-usoY6mJg">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent" scale="6" id="Narr_aK3NSYkEfUSczntRY5Irvw">0.3</ix:nonFraction> million as of December&#160;31, 2023 and December 31, 2022, respectively.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_4b502ce2_2c98_4d6f_8319_8c327bfcd50d"></a><a id="Tc_cVRqbmGNFUypfmkP1MdU4Q_1_2"></a><a id="Tc_4_xoVq3o00yoHQitcx41KQ_1_5"></a><a id="Tc_W1ufzipmEE-TvL6kSh2G7A_2_2"></a><a id="Tc_q5UjBWDmaU63ud6F2OucRQ_2_5"></a><a id="Tc_yAvmiyM6AE2e5IWxjro3TA_3_0"></a><a id="Tc_6yBEtDvSrECrTqtcwNCt6g_3_2"></a><a id="Tc_Aw4KoGVgtUu333Puqb8WVQ_3_5"></a><a id="Tc_nsCSX1TDrEGuFyk4PTiv1Q_4_0"></a><a id="Tc_zn9_vIUr2k-M5oRPPo8WCQ_5_0"></a><a id="Tc_ZvbqcJIyW0WRO5igFwpD_A_6_0"></a><a id="Tc_hHboJaT440K9pshyvpl8ow_6_2"></a><a id="Tc_9-55Xyrqrk-MINqE6vRGzg_6_5"></a><a id="_8a0c3d9c_721f_4be2_aa79_9fa2188951d5"></a><a id="Tc_Ina7CPUiTEesORG9sIhZbg_1_2"></a><a id="Tc_pU5EWaOcekmgvv1zU74P8Q_1_5"></a><a id="Tc_POOhvh7IokSnbpj1t84-oA_2_2"></a><a id="Tc_n63_VRZcE0e-HoKvfkc4cQ_2_5"></a><a id="Tc_I6l0X17DvUCNhyz5f8KZ5w_3_0"></a><a id="Tc_7FQXsVsNUEart8UP818Q1Q_3_2"></a><a id="Tc_MNpQu_wraEW_txpD0iASWQ_3_5"></a><a id="Tc_0w-GU-MOB0udUGU4Lha3vw_4_0"></a><a id="Tc_H-DQZ2bHLE68XORnU1r8DA_5_0"></a><a id="Tc_AEHJnDjLeUuYKk-_yvTdMg_6_0"></a><a id="Tc_Gx4Zh2hUpE6Zvn-KYcul_w_6_2"></a><a id="Tc_dx_GdYXIK0GNSzPlj7aI5A_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="Tb_xmgvBO9E70SAUJ14BU1qag" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">(4)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">BALANCE SHEET COMPONENTS</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Prepaid Expenses and Other Current Assets</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="avte:ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock" id="Tb_45sf72ZinUCDY-HuX3oTuQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Prepaid expenses and other current assets consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:62.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_5X7PVJJWxUuU8uZsOP19Qw_3_3">1,168</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_PkpEc8wEXEWGpjtZ86_xuw_3_6">1,503</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Prepaid research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="avte:PrepaidResearchAndDevelopment" scale="3" id="Tc_F39G850fB0uI0iJfOcPz-A_4_3">375</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="avte:PrepaidResearchAndDevelopment" scale="3" id="Tc_3zQTqyczdkGiihpuWxH8fQ_4_6">478</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="Tc_bhoHQgEEu0WvOiyf3o-4yg_5_3">250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="Tc_vQa68Q_fJkCzbDQuEja6yw_5_6">295</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Total prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_EYwHHgUxoEyTGyO25FOT7g_6_3">1,793</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_jKxSj6Ytnk22f27vXqtx6g_6_6">2,276</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accrued and Other Current Liabilities</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_y8-E6XKi8E-nnJls74u4Kw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Accrued and other current liabilities consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued research and development</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="avte:AccruedResearchAndDevelopmentCurrent" scale="3" id="Tc_tPafr-ZE6k2aGV8VM8bsIg_3_3">9,363</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="avte:AccruedResearchAndDevelopmentCurrent" scale="3" id="Tc_PaKtwfybzk66xeRH4EYBqw_3_6">2,751</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued payroll and other employee benefits</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_Tn3KqzxXKkOtt5re_0YD-w_4_3">4,368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_LleTmr5UuUyp1cqMMc7QvA_4_6">1,691</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_k3hGgFiRDUCTiGfBLXN_Aw_5_3">1,090</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_q6IsHJwjkEy_ljba-HSzXw_5_6">380</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total accrued and other current liabilities</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent" scale="3" id="Tc_Gepji09HgkS1W41cbjA0HA_6_3">14,821</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent" scale="3" id="Tc_sos84JO200aUEsI21HbYUQ_6_6">4,822</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_30e0e9ff_edc7_42ff_b734_f93e205b2879"></a><a id="Tc_ijbW34vHiUiQuz6k99tBaQ_1_1"></a><a id="Tc_ssJFHWLdI0GcJMazfTbMtQ_2_1"></a><a id="Tc_oRMkHDzkyk6uZhrNXo9u_w_3_0"></a><a id="Tc_AUCzDmUl_0GnLzf1ah1V8g_3_2"></a><a id="Tc_vVTCLoCJckaihxv8T3PggA_4_0"></a><a id="Tc_dHBvQ5VxkkWoKwYqFMb62Q_5_0"></a><a id="Tc_-1os32eVs0mJ4ZCwoy1qMQ_6_0"></a><a id="Tc_Ubw8Ahwq60O7trUDrrk79g_7_0"></a><a id="Tc_OeDRERKmWE-VFycwPuzjEg_7_2"></a><a id="_b557be19_1216_432e_b78b_2054a880d4d9"></a><a id="Tc_-56hQcuJPUqVr5lLJh0gGg_1_2"></a><a id="Tc_R5Zf7h3TekK8VIEcyrulaw_1_5"></a><a id="Tc_uK05jWGOc0SCnlOzrlGsgA_2_0"></a><a id="Tc_JZMvLECWeUKqjsiTYSTv4g_2_2"></a><a id="Tc_aRoQ_ONuJE-dE6dECbAfEw_2_5"></a><a id="Tc_lco2mdH3nUeqev5iMlLlgw_3_0"></a><a id="Tc_PqnM6tAPHkeuhjSs_raGcA_4_0"></a><a id="Tc_Nx5eGD69Xk6N5OZRO5V04Q_5_0"></a><a id="Tc_MLLr1iUXdUWe0PPXRmDWWg_5_2"></a><a id="Tc_1Kzg5D33akCMNxP1taKDBg_5_5"></a><a id="Tc_-GjMYK6fbUK8fJQjYi7eYg_6_0"></a><a id="Tc_ITZIH4XcXUSZEQL3YEyiug_7_0"></a><a id="Tc_xYX_fitAkUaU0HwcpfPEQg_7_4"></a><a id="Tc_EHlOgszjQU6dwc3XijIOeg_7_7"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_igd0bUuW9Uqx0esf-CNSGA" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">(5)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">COMMITMENTS AND CONTINGENCIES</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2021, the Company entered into a lease agreement (the &#8220;Waltham Lease&#8221;) for approximately <ix:nonFraction unitRef="Unit_Standard_sqft_5xtOY_aM_0eoVegCdMhIVQ" contextRef="As_Of_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_psQydqKoEkSDWEV9UfDtig" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfLand" scale="0" id="Narr_RKmWDrShzUK-Ndwu3j3xkw">5,000</ix:nonFraction> square feet of office space in Waltham, Massachusetts for the Company&#8217;s corporate headquarters. The Waltham Lease has a term of <ix:nonNumeric contextRef="As_Of_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_psQydqKoEkSDWEV9UfDtig" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_EcSVj2xasUKUbXaAA15LaA">thirty-nine months</ix:nonNumeric> (&#8220;Lease Term&#8221;), unless extended or earlier terminated. The Company has the option to extend the Waltham Lease for <ix:nonNumeric contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_DaiW5HZ95E-5aglfFdRpPw" format="ixt:booleantrue" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Narr_nmdZMFJLJkeU64Cxtswmig">one</ix:nonNumeric> additional period of <ix:nonNumeric contextRef="As_Of_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_psQydqKoEkSDWEV9UfDtig" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_Z8QgiPSNn0O83DMyW6KLBA">three&#160;years</ix:nonNumeric>. The Lease Term had an initial abatement period, and the initial base rent payable is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_DaiW5HZ95E-5aglfFdRpPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRent" scale="0" id="Narr_eUjpJiwUpk6Ykok3jHvFnQ">18,000</ix:nonFraction> per&#160;month following the abatement period. The initial base rent payable will increase by approximately <ix:nonFraction unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA" contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_DaiW5HZ95E-5aglfFdRpPw" decimals="INF" format="ixt:numdotdecimal" name="avte:LeaseIncreaseInRentPercentage" scale="-2" id="Narr_Zz6VztXlBEii7brwuxEjTw">2</ix:nonFraction>% per&#160;year over the Lease Term. The Waltham Lease commencement date was September&#160;1, 2021. In January 2024, the Company entered into the First Amendment to the Waltham Lease resulting in the lease expiring on December 31, 2025, and an increase of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2024_To_1_31_2024_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_PodE97lmJkSHEwoc1aClWg" decimals="2" format="ixt:numdotdecimal" name="avte:IncreaseRentalAmount" scale="0" id="Narr_FVnJBkJzjkmWWP6jZ25j-A">1.00</ix:nonFraction> per rentable square foot during the additional lease term. In obtaining this lease extension, the Company no longer has the option to extend the Waltham Lease for <ix:nonNumeric contextRef="Duration_1_1_2024_To_1_31_2024_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_PodE97lmJkSHEwoc1aClWg" format="ixt:booleanfalse" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Narr_u00xX1y5ZUSb-l5YI1qDcQ">one</ix:nonNumeric> additional period of <ix:nonNumeric contextRef="As_Of_1_31_2024_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_zn19noNKY029l5Ec-T6CTg" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_lf3S1LpY4EOh_-0wjlhbeg">three years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April 2022, the Company entered into a lease agreement (the &#8220;Foster City Lease&#8221;) for approximately <ix:nonFraction unitRef="Unit_Standard_sqft_5xtOY_aM_0eoVegCdMhIVQ" contextRef="As_Of_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_sGvwx0X7s0WPUgXlH8FQrg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfLand" scale="0" id="Narr_Qu4uOLSJtUmGBl8cLf2xJQ">3,500</ix:nonFraction> square feet of office space in Foster City, California. The Foster City Lease has a term of <ix:nonNumeric contextRef="As_Of_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_sGvwx0X7s0WPUgXlH8FQrg" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_6P2z4CMdNUaanc4XoJCfdw">thirty-nine months</ix:nonNumeric>, unless extended or earlier terminated. The Company has the option to extend the Foster City Lease for on additional period of <ix:nonNumeric contextRef="As_Of_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_sGvwx0X7s0WPUgXlH8FQrg" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_4CRIVku6jEy9qv5jdsgvxQ">one year</ix:nonNumeric>. The base rent payable under the Lease Term will be $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_1_2022_To_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_m3e0XkrsxkWOCq0GHEPF6A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRent" scale="0" id="Narr_ozvFD5YgFEytwMF7R3lKsg">22,600</ix:nonFraction> per month and will be subject to annual increase of <ix:nonFraction unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA" contextRef="Duration_4_1_2022_To_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_m3e0XkrsxkWOCq0GHEPF6A" decimals="INF" format="ixt:numdotdecimal" name="avte:LeaseIncreaseInRentPercentage" scale="-2" id="Narr_MlDAXE9HdUi18-eFLhxURQ">3</ix:nonFraction>% on each anniversary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the consolidated balance sheet includes an operating lease right-of-use asset of $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_c0D3hoXug0S2GySc_eFfjg">0.6</ix:nonFraction> million and operating lease liability of $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_Ns-Kc47YvUCEFMiNPPJjmA">0.7</ix:nonFraction> million. The total operating lease expense was $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr_hj4lTuHDQ02hSmQhH7ySgw"><ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr_I4NmVPJT7k2ItewSm395vw">0.4</ix:nonFraction></ix:nonFraction> million for both of the years ended December 31, 2023 and 2022. </p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_udZFqz6MaUibo3VdXDSxDw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the future minimum annual lease payments under the operating leases were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:24.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 12.25pt;"><b style="font-weight:bold;">Total Minimum</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:24.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 12.25pt;"><b style="font-weight:bold;">Lease Payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_cPVElBsSPkqVyD0TPyv3Yw_3_3">466</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_FSsUzcsmMUihadiTXD8fjg_4_3">242</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total operating lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_gsYUxuasdk6Jh9a4zxp7xA_5_3">708</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Amount representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_UnV7jy89c06zCREPulETCQ_6_3">33</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Present value of net minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_d7e24gdUTkKUeOG2g-V7jw_7_3">675</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="avte:ScheduleOfComponentsOfOperatingLeasesTableTextBlock" id="Group_FNYtDpzYCkmqwlPDXCWnOA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The components of operating leases for the years ended December 31, 2023 and December 31, 2022 were as follows (in thousands except lease term and discount rate):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Operating lease liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_ZZhgEI34IUWHeDCxZMh6Zw_3_3">420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_6eB55Br9mEO7keU0tfM5pw_3_6">385</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_NpBDCpoMh0yb48r06MwALg_4_3">255</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_zww7-Hh4zk6oU0EnVNVCHA_4_6">705</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_uFGsbFEsR0GC7CQvbwDLUQ_5_3">675</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_do-0keK96k6jBOW6n-ff-A_5_6">1,090</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_bcsRlyvxE0WwL-sy7MQ1_Q_6_3"> 1.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_b6vpDc6N-kmVKAw7mzCh0Q_6_6"> 2.4</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average incremental borrowing rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_n8TMGfsEKEW3GqvSVDDwZQ_7_3">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_jTvq0CJtlkW2ovicUndl9Q_7_6">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Legal Proceedings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company may from time to time be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings during the years ended December 31, 2023 and 2022, and no material legal proceedings are currently pending or, to the best of its knowledge, threatened.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_s3kWcgW5V0iSKSrPz2R-Ng" continuedAt="Tb_s3kWcgW5V0iSKSrPz2R-Ng_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">(6)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">STOCKHOLDERS&#8217; EQUITY</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Company&#8217;s Amended and Restated Certificates of Incorporation dated August&#160;3, 2020, the Company had a total of <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_8_3_2020_EcWWeWov-0O5egWgb1IO4Q" decimals="INF" format="ixt:numdotdecimal" name="avte:CapitalStockSharesAuthorized" scale="0" id="Narr_R8HfmHMhy0C1jCIGkMetPA">94,052,154</ix:nonFraction> shares of capital stock authorized for issuance, consisting of <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_8_3_2020_EcWWeWov-0O5egWgb1IO4Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_nMeAl9w0sUCtvhVIRJIU7g">50,000,000</ix:nonFraction> shares of common stock, par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="As_Of_8_3_2020_EcWWeWov-0O5egWgb1IO4Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_o8VAbgA1aE-Fd3d_SvsWig">0.0001</ix:nonFraction> per share, and <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_8_3_2020_EcWWeWov-0O5egWgb1IO4Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_BFL9Z_WK_UKZatFI7nr_MQ">44,052,154</ix:nonFraction> shares of convertible preferred stock, par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="As_Of_8_3_2020_EcWWeWov-0O5egWgb1IO4Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_w3jN_xJ-ckm1Paw5pYxhcw">0.0001</ix:nonFraction> per share. Shares of authorized convertible preferred stock were designated as <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_8_3_2020_us-gaap_StatementEquityComponentsAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_c5TH3GCKvEGQuOxOnb7Lrg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_tLR6HyjAXUimEequXNixyQ">4,000,000</ix:nonFraction> shares of Series&#160;Seed redeemable convertible preferred stock and <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_8_3_2020_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_lrXI44Ykp02VlKaxJ3Nieg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_ohKL_LsTzEOcQ_d-brMBMw">40,052,154</ix:nonFraction> shares of Series&#160;A redeemable convertible preferred stock.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_efe76d0a_9f15_4e8c_8be7_41e9879dad0e"></a><a id="Tc_-jmQrlL3Z06LaNapcL7Ehg_1_2"></a><a id="Tc_eJGQcdWHBU6Xd6Ep-9PByQ_2_0"></a><a id="Tc_46ywvYho8UGmBEI5eZxHkw_3_0"></a><a id="Tc_ZOdxOuewuEevJ_FcZvnVFg_4_0"></a><a id="Tc_wxRZznws_EmL7AX_jFB39g_5_0"></a><a id="Tc_cU0_Y0-4rUumPwXQUBx8KA_6_0"></a><ix:continuation id="Tb_s3kWcgW5V0iSKSrPz2R-Ng_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July&#160;2, 2021, the Company&#8217;s certificate of amendment to its certificate of incorporation became effective, which provided <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_7_2_2021_w8fg7T9i30-Tb8oR9Nn9Ag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_jEfBSHdSOUyQC201oTWFgA">150,000,000</ix:nonFraction> authorized shares of common stock with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="As_Of_7_2_2021_w8fg7T9i30-Tb8oR9Nn9Ag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_EyJwlFpSH0aiLEkQNoQV4Q">0.0001</ix:nonFraction> per share and <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_7_2_2021_w8fg7T9i30-Tb8oR9Nn9Ag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_AV1XlKCzTUa9HwEKZyzz6w">10,000,000</ix:nonFraction> authorized shares of undesignated preferred stock with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="As_Of_7_2_2021_w8fg7T9i30-Tb8oR9Nn9Ag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_orpQZTmOVk2F810F-uWDqA">0.0001</ix:nonFraction> per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2018, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_8_1_2018_To_8_31_2018_srt_CounterpartyNameAxis_avte_RaCapitalHealthcareFundL.pMember_f26Wjuj0S0u8Hw2V4pgTMA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_xVUU7_5xWUydgKTxa6V2mw">241,467</ix:nonFraction> shares of common stock to RA Capital Healthcare Fund,&#160;L.P. at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="As_Of_8_31_2018_srt_CounterpartyNameAxis_avte_RaCapitalHealthcareFundL.pMember_MybYzQoXkkeq-kvOFSYqcw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_eZb1iwicPUOAxBYoHKZ9RQ">0.0012</ix:nonFraction> per share. On July&#160;2, 2021, in conjunction with the Company&#8217;s initial public offering, or IPO, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_GUQQrLL2E0uGyzx6Fyxj_A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_q9MioMtRcE69n1n0j-Wdsg">9,984,463</ix:nonFraction> shares of its common stock and all outstanding shares of the Company&#8217;s redeemable convertible preferred stock were converted into <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_7_2_2021_To_7_2_2021_zM4kB7thfEaK38J25p-KHg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="Narr_epj0ilCDJkGUJfw7StfKdg">14,182,854</ix:nonFraction> shares of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The holders of the common stock are entitled to <ix:nonFraction unitRef="Unit_Standard_Vote_68Fy5nhdn0WonvfwhauHwA" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="INF" format="ixt-sec:numwordsen" name="avte:NumberOfVotesForEachShareOfCommonStock" scale="0" id="Narr_9WyjPO-s6EmTdJAhEKpY_A">one</ix:nonFraction> vote for each share of common stock held at all meetings of stockholders.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="avte:ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock" id="Tb_2LYnHAg15EeqUomqvlivTg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the Company had reserved the following shares of common stock for future issuance:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options granted and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_CommonStockMember_YflOQXijzkee839-W5_-ag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_rTEzvjsgqEyKuuTNgQ0q9w_2_2">5,230,344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Shares reserved for issuance under the 2021 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_aLb1VNRswEiUg0bp5BxGmQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_Xxo9bFkDZUa8XA626QVMDA_3_2">604,363</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Reserved for vesting of outstanding restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Gy-ZvYruXkinoI8nJEgktA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_7AKQ9P244kKvolr2WOZxZA_4_2">21,968</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Reserved for future ESPP issuances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_4YcJ4RjRj0GB-mGnU1wJUA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_1o-D9-ovLEWBBY7ka8gYtg_5_2">435,252</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_nJjgTFhBZEefgXp4GZXh2g_6_2">6,291,927</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_D0OoZfwvGkO9Y7oSr4Gnqw" continuedAt="Tb_D0OoZfwvGkO9Y7oSr4Gnqw_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">(7)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">SHARE-BASED COMPENSATION</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Stock Option Plan</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s 2021 Stock Option and Incentive Plan (the &#8220;2021 Plan&#8221;) was adopted by the Company&#8217;s board of directors and approved by the Company&#8217;s stockholders in June&#160;2021 and became effective as of June&#160;29, 2021. Upon the effectiveness of the 2021 Plan, the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) was terminated and no further grants may be made thereunder. The Company&#8217;s 2021 Plan allows for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, stock bonuses, restricted stock, stock units and other forms of awards including cash awards to its officers, directors, employees, consultants and advisors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, a total of <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_jOQSNYFMiE2CvUhNjVDLEg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_XmSDkM79D0K_GXNTtg_0Wg">4,565,333</ix:nonFraction> shares of the Company&#8217;s common stock were authorized for issuance with respect to awards granted under the 2021 Plan. The share limit will automatically increase on the first trading day in January&#160;of each&#160;year (commencing with 2022) by an amount equal to the lesser of (1)&#160;<ix:nonFraction unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_s-aYJQaQfEO0AGSWXOYO6A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="Narr_Nvmw1JsolUmnobgWGnMrGQ">4</ix:nonFraction>% of the total number of outstanding shares of the Company&#8217;s common stock on the last trading day in December&#160;in the prior&#160;year, or (2)&#160;such lesser number as determined by the Company&#8217;s board of directors. Since adoption, the annual increases have accumulated to a total of <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_7_1_2021_To_12_31_2023_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_xUfhDItNQkiJKYFlFdOMwQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="Narr_UGA8m4z1_EyDLgpr-kV6tQ">3,075,841</ix:nonFraction> shares through January 1, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any shares subject to awards granted under the 2021 Plan or the 2018 Plan that are not paid, delivered or exercised before they expire or are canceled or terminated, or otherwise fail to vest, as well as shares used to pay the purchase or exercise price of such awards or related tax withholding obligations, will become available for new award grants under the 2021 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_oV0DwhFiqUeSjADTrzXG4A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_U57znnm9n06ZjNPODjfrvw">3,931,887</ix:nonFraction> options had been granted under the 2021 Plan, with <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_p7xQ831-8k-rQnNZukmxqQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_TDuWn3R78U6WqwPhgGOzkQ">604,363</ix:nonFraction> shares authorized under the 2021 Plan available for future issuance. As of December 31, 2023, a total of <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyEighteenStockOptionAndIncentivePlanMember_J-NqcxMgNUSJ7I39_xVsUw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr__9Gy__PfbEyYT0et6qrNmA">1,298,457</ix:nonFraction> options had been granted and were outstanding under the 2018 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The options that are granted under the 2021 Plan and the 2018 Plan are exercisable at various dates as determined upon grant and terminate within <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_7qar8kvNhkGFswXJGPAVXQ" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_Tcs87ZG3tU6BJEokUPzyVA">10&#160;years</ix:nonNumeric> of the date of grant. The vesting period generally occurs over <span style="-sec-ix-hidden:Hidden_VYoFbHUwRE-bLITQC63xcQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_kdwiV7iJm0yXiFQVoEPDqQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_c4ec9vV_JkuRNfzsaOyMYg">four&#160;years</ix:nonNumeric>.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_ccffe4a5_a6a4_4834_b99c_87e9f92cb846"></a><a id="Tc_50nVgGcvYk67FDKWGQT0rQ_1_7"></a><a id="Tc_PFjr5N-uDE2yvIas8cRWrQ_2_7"></a><a id="Tc_jqe707spv0yAh-ap-HXpmw_3_7"></a><a id="Tc_y79Ky-FDZkiA4rr-oAZoIQ_3_9"></a><a id="Tc_yssLlNsNZEiRHlFpE8cqqg_4_4"></a><a id="Tc_ZZA0niZ-M0ulz0QnOaJGVg_4_7"></a><a id="Tc_b3-T9LxTMUSZ0s9Y4CiG-A_4_9"></a><a id="Tc_FNxMQpgGHkKJZ5Ikwa7Xtg_5_2"></a><a id="Tc_b6txK4kgBkWaQeMVn_AjSA_5_4"></a><a id="Tc_NvPrbs1EEkKd-YVIYDWyjA_5_7"></a><a id="Tc_mEJBI2X-XEO5Ve83IuZQ5A_5_9"></a><a id="Tc_jzH6SUpHckqWQYCUr3V8pQ_6_0"></a><a id="Tc_HuC43C5Rik62NH2gTfhf0Q_6_4"></a><a id="Tc_PVcsCyoD9kyutfUuiNLwAQ_6_9"></a><a id="Tc_GqJecGgepkCVFsbpgJRW0w_7_0"></a><a id="Tc_CQannz0dD0GeKA2gZXjGtg_8_0"></a><a id="Tc_hqdyx6sCAESCHWFjLB5YwA_9_0"></a><a id="Tc_0tYf0yOVQ0O3cB0zkC1N8A_10_0"></a><a id="Tc_pounMDKw_k28JvZKJzu3iQ_10_4"></a><a id="Tc_2MxfNFXwZUexAuXG91X4YQ_10_9"></a><a id="Tc_6oo-OL4hqk2omkgveYTrvA_11_0"></a><a id="Tc_M0-H_jZ_qUenGHnDGtxDUA_12_0"></a><a id="Tc_cYpIGXRLx0WsuXABBuXvUA_12_4"></a><a id="Tc_LGg5XQvEKUqcoBnsHCIlLg_12_9"></a><a id="Tc_yTGOX3d34kiIJp0kx3_b_w_1_4"></a><a id="Tc_TFoAS_2kbkilfnAlrd93dw_2_4"></a><a id="Tc_Af-39j1iGkWqb1K1Fsy4XQ_3_4"></a><a id="Tc_SZg7V_DNM0qc7-y0ty9GYg_4_2"></a><a id="Tc_vuZOmIvBPUijt8NEiUM-yA_4_4"></a><a id="Tc_6Q9bRmq1lEiSYnm1egHi_g_5_0"></a><a id="Tc_CljMaaSCV0ag12t5TBOwKA_5_4"></a><a id="Tc_ou1k5QyfRkGAWe13MtSd2A_6_0"></a><a id="Tc_R5A_rZeEBUWPYrIqSuZ7fQ_7_0"></a><a id="Tc_K31bDFZ1bkihjbbTaD8Q2g_8_0"></a><a id="Tc_wa2vKEhVck6WMd50keWi8w_8_2"></a><a id="Tc_Kmtmm6NbGUKt_gmF2-kSng_8_5"></a><a id="Tc_t1FCv5_Roket3C4wGU7HWA_9_0"></a><a id="Tc_yk-6k4kqUUWXSZUHRzpi4w_9_4"></a><ix:continuation id="Tb_D0OoZfwvGkO9Y7oSr4Gnqw_cont1" continuedAt="Tb_D0OoZfwvGkO9Y7oSr4Gnqw_cont2"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_ZMa4aQ6DX0qT2GWUrYueVQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the option activity under the 2021 Plan and 2018 Plan for the&#160;year ended December&#160;31, 2023:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual&#160;Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and expected to vest at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_XP2aXFPZRkCbuA4_q5QTLg_6_2">4,110,219</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_ADHR1d5IwEK_dEPxvfBQig_6_5">9.23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_63VHaRkvp0qeXSg4w54YBg_6_7"> 8.46</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_OPWvITxza0eaCzzsdymVHw_6_10">82,490</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_nNznQThn2USeMMsgXw3N5A_7_2">1,546,001</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_IibEuLDBIkygjQq6N9bUGw_7_5">22.85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_025LnL7-GkKnHFNFl-6-6w_8_2">338,987</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_iCq9fivA906LY2iGS0g-2A_8_5">2.91</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cancelled/Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="Tc_U5IQmqczdki0dVtguZgTrg_9_2">86,889</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_mReBYi0ipUq-LrtD8aOeTQ_9_5">9.62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_vEfpxL-XPkCr7wfzjAIjMQ_10_2">5,230,344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_yVoT92rddEmvwliyrgU6_w_10_5">13.66</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_DP8R30CBjUaJLHM1clJheQ_10_7"> 8.16</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_LMSr_i63b0KRmLB_3qUobQ_10_10">49,728</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and exercisable at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="Tc_M2SaQSHiLkGPVEnODtW9vw_11_2">2,157,378</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="Tc_6BmZHdxpr02q6c74LEOBLQ_11_5">11.24</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="Tc_KFEaKkYK_0KHai7S1SBeRQ_11_7"> 7.81</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="Tc_UPM19WqSvEawWxpZ8zRcvg_11_10">25,152</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and expected to vest at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_nbdVPCdPfUeWHVS2tIpx3Q_12_2">5,230,344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_0OK0QhrwNUajnUqv5qdHlw_12_5">13.66</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Tc_R8P3rSdTkUuP7Mko1RpHCw_12_7"> 8.16</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="Tc_uLuqbLB1jkSmyrBxBcxPNg_12_10">49,728</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant date fair value of stock option grants was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_BG6OxbHhQE-Jha056enx2g">15.69</ix:nonFraction>&#160;and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_PrtSEfI2rUiHhjH4RJ_5hQ">10.48</ix:nonFraction> per share for the years ended December 31,&#160;2023 and December 31, 2022, respectively. All exercisable options are vested and all outstanding options are vested or expected to vest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023 there was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_WEjhd3Pw2E2yWcmGpQ_tWg">29.1</ix:nonFraction> million of unrecognized stock-based compensation expense related to nonvested stock-based compensation arrangements granted under the 2021 Plan and 2018 Plan, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_gEy_E2_z1Eio4GntjIlhZQ">2.3</ix:nonNumeric>&#160;years.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Employee Stock Purchase Plan</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) was adopted by the Company&#8217;s board of directors and stockholders in June&#160;2021 and became effective upon the consummation of the IPO. A total of <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_ePMqutmojUyuoaStQiHwbg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_ZIwwHdH3nUSxgdtLmTtZ9A">230,000</ix:nonFraction> shares of the Company&#8217;s common stock is initially available for issuance under the ESPP. The share limit will automatically increase on the first trading day in January&#160;of each&#160;year (commencing with 2022) by an amount equal to the lesser of (1)&#160;<ix:nonFraction unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_l2cNv6JCfkyvIREeesp36w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="Narr_aPaYGlWKQ02-0BTxH6BG6Q">1</ix:nonFraction>% of the total number of outstanding shares of the Company&#8217;s common stock on the last trading day in December&#160;in the prior&#160;year, or (2)&#160;such lesser number as determined by the Company&#8217;s board of directors. The number of shares available under the 2021 Plan increased by <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_1_1_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_7n9TuWQvlEKuoOSnaqxmoQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_oeZg1Q77jkqKlX-bwHqeew">247,229</ix:nonFraction> shares effective January 1, 2023 as determined by the Company&#8217;s board of directors. The ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA" contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_WvqE0K12M0iiC1AH3k88Tw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="Narr_8JsNlO6ac0-7W_JDN817oA">15</ix:nonFraction>% of their eligible compensation, subject to any plan limitations. The ESPP provides for <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_l2cNv6JCfkyvIREeesp36w" format="ixt-sec:durwordsen" name="avte:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" id="Narr_QKN5FQlm_U-kl2OjkIwWyg">six-month</ix:nonNumeric> offering periods, and at the end of each offering period, employees are able to purchase shares at <ix:nonFraction unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA" contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_WvqE0K12M0iiC1AH3k88Tw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" scale="-2" id="Narr_0bu4m5E_SU6m50xzfGYymg">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last trading day of the offering period. As of December&#160;31, 2023, <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_l2cNv6JCfkyvIREeesp36w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Narr__J-DmZA960ibPMjmMLJUtA">41,977</ix:nonFraction> shares had been issued under the ESPP, and <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_4YcJ4RjRj0GB-mGnU1wJUA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_kixCkuxRmUuIboxPUIlkHA">435,252</ix:nonFraction> shares authorized under the ESPP Plan were available for issuance.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Restricted Stock Units</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_ZBG0wBshS02tcTB4D_om6g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_HgZxHn9NUkaktWlCY7xTVw">31,881</ix:nonFraction> restricted stock units had been awarded under the 2021 Plan. A summary of the status of and changes in unvested restricted stock unit activity under the Company&#8217;s equity award plans for the year ended December 31, 2023, was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="Tb_s3yQZVnwyEiI8be6QWlPYA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:65.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average&#160;Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date&#160;Fair&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per&#160;Unit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_gcSTyLkkmk2V2zzgD-_vtQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_Tar4PfUJQESZ2xkGVmyjmg_5_2">28,881</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_gcSTyLkkmk2V2zzgD-_vtQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_OWV6VDY8qk2zwgZK63Es4g_5_5">21.62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_6Bs2-neN-U2EmecB-QIl0w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_qJF-YHg9xEm2eu775LObHg_6_2">3,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_6Bs2-neN-U2EmecB-QIl0w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_vrhk5qEQe02Hw5pu44wMJg_6_5">24.58</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_6Bs2-neN-U2EmecB-QIl0w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_2SWOWm-Ss0CzxN4VgtzCcA_7_2">9,913</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_6Bs2-neN-U2EmecB-QIl0w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_HB0LX0TzaUaUa7fOVsbCSQ_7_5">21.10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Gy-ZvYruXkinoI8nJEgktA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_sPgWRCfRvkq5W5NvhJP66w_9_2">21,968</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Gy-ZvYruXkinoI8nJEgktA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_L6WNRrObkEynBI0gd7YTwA_9_5">22.26</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation of restricted stock units is based on the fair value of the Company&#8217;s common stock on the date of grant and recognized over the vesting period. The vesting period generally occurs over <span style="-sec-ix-hidden:Hidden_eUKRKJ4iNkSfQy8r2Vg3Mg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember__SKGl6wkOE-Kjnfpn0KZcQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_ukVu46uvnU6dWhTCrbHXEw">four years</ix:nonNumeric>.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_ALZy91XgJU-JoYYY5e_mtQ_1_2"></a><a id="Tc_3h2R7cwYU067BJh1Wdigbw_2_2"></a><a id="Tc_P6_IP7YILECrNfHI0_qF3Q_2_4"></a><a id="Tc_8w0pP2hx30eNel-FCJY2_w_3_0"></a><a id="Tc_hHKFTpdVm0G8j_VSsG4GAg_3_2"></a><a id="Tc_ocT79TuLtUCkDvs57OfYqA_3_4"></a><a id="Tc_4ev4sKfZR0aHbmrkmxSPjA_4_0"></a><a id="Tc_bSzEJVmcrkesj6J9aC0pig_4_2"></a><a id="Tc_k6hTVFy-ukmiZk3setugvA_4_3"></a><a id="Tc_rsYyTtjzQUqGz3C-ZC_KMw_4_4"></a><a id="Tc_fRY95sEH2k-DgtPTCcgcVA_4_5"></a><a id="Tc_61Iim87rJUOlhY5us6-YYg_5_0"></a><a id="Tc_SqkLyIAwfUKGYVThWzGo-Q_5_2"></a><a id="Tc_hW4nRO46SEiUELIcZrSlOA_5_3"></a><a id="Tc_528rGYcf8Emc_MehR5MYeA_5_4"></a><a id="Tc_QlN99moyFkCo4Fem9NtmQw_5_5"></a><a id="Tc_2FcA_zFL3kG1x_-0cm-Rxg_6_0"></a><a id="Tc_uftlQx32LEGb0-eN3EVoFw_6_2"></a><a id="Tc_1LL9UKFDx0WJHC5_AJpdyA_6_4"></a><a id="_8689229c_b254_4a74_a046_8b5f72b935bf"></a><a id="Tc_2Mmfj9Ss8EqxvsQ5iFMSvQ_1_2"></a><a id="Tc_3Kx96aTezUCigIAZEoEDzA_2_2"></a><a id="Tc_wHBaVhR6ykqpEQfriwdO_A_2_5"></a><a id="Tc_lCC_OVmk7kuxXlHRaIcXMw_3_0"></a><a id="Tc_vFzvaKzYRUeIm2rDcV2K7w_3_2"></a><a id="Tc_k5mNoCmvd06OWmp1pqkeng_3_5"></a><a id="Tc_iASN_-XkfUSe7t9dSGxs5g_4_0"></a><a id="Tc__y6h2P6SMEumg07K3XmTaQ_5_0"></a><a id="Tc_cuvNrbHsZ0ueRU1pskKJ5A_5_2"></a><a id="Tc_MKrVp0edeEuRz0uQ8dCj4A_5_5"></a><a id="_a80dd96e_e517_4b97_8cda_e62e30d7dcab"></a><a id="Tc_yB2lcEUE7Emqse4EJeYWcg_1_2"></a><a id="Tc_TSx_0IfuaEeN7OZ5bwuQeA_2_2"></a><a id="Tc_LjF6fXtBLkKwzmijGMLejg_2_5"></a><a id="Tc_MROL3__-40uqYWSSwsuHaA_3_0"></a><a id="Tc_7bSGw8kp5kKlDBg6PYAPig_3_2"></a><a id="Tc_HWLqE11MwUuyUfEeua0TjA_3_5"></a><a id="Tc_nnrn_i1dX0CeU60SgK_huQ_4_0"></a><a id="Tc_RtkEAUd0WEKhrb2YGBuaWA_5_0"></a><a id="Tc_vwCSRkSAGEytr2vLtwnZrg_6_0"></a><a id="Tc_OXS76gJxik2iM0iqmBf2WA_6_2"></a><a id="Tc_3Q6adQe9gkKpGpQPyrzmew_6_5"></a><ix:continuation id="Tb_D0OoZfwvGkO9Y7oSr4Gnqw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31,&#160;2023, the Company had unrecognized stock-based compensation expense related to its unvested restricted stock units of $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Gy-ZvYruXkinoI8nJEgktA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_YCu7wgn0akqzx4r2pGFrzA">0.9</ix:nonFraction> million, which is expected to be recognized over the remaining weighted-average vesting period of&#160;<ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_6Bs2-neN-U2EmecB-QIl0w" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr__tN6jsIJN021mZXu2RmlAA">2.4</ix:nonNumeric>&#160;years. </p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(d)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Stock-Based Compensation Expense</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company estimated the fair value of stock options using the Black-Scholes valuation model. The Company accounts for any forfeitures of options when they occur. Previously recognized compensation expense for an award is reversed in the period that the award is forfeited. The fair value of stock options was estimated using the following assumptions:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_EPjzkmTE60O9Jmc6RjpZ0Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:26.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_73e_CZGNZEyHg-KoZi_SKw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_j8XsE1Npo0WOr28-2zXPhw">5.3</ix:nonNumeric> - <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_AM4SWxu1AEWvAgiUoTpxpw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_L6VRPmqud0GFZLuY66Fxgw">6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_Ftq0AHVniEWCeuEfN5x_ZQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_eMPtYSDydkaHIUrW7ttyhA">5.5</ix:nonNumeric> - <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_KY3AqSzTb0OwCTsNTj4W_Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_kPKH3bRyskGjkp4ydAFAHw">6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_7EWlQiMX00SZQZa87h2MJQ">73.9</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_ljhtmS9JI0a8mmB0YCodFA">91.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_ZElrqEbVK0mQsrgr2JKOqQ">73.5</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_M_uIDH3Vk0a2C-Ke6ZzbVg">76.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_ZnVR20eX3EOA-CB8nHJdLw">3.5</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_J1Z5PUCdB0KYIa2LTLUljw">4.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_IHfOOm8z0kG7zsU5m0vlhQ">1.6</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_2DQCyEWDDE-pZOUxBIOzrQ">4.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Expected dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_3WIBzCnin0Kyjrce05KlqQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense recognized for stock option grants has been reported in the statements of operations and comprehensive loss as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_SpjyK1AxVEqPXklSW5dc7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_BBtyt0JVEEa6NhVnWjTA4A_3_3">6,621</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_eKXqES4MhEC5wSlAU18O1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_PA-SIoALQUWZ512nKwlUxw_3_6">2,129</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_DdnUA-mndEmQoBFn-wT6ng" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_-MJd4ad96k6X37gORpjMVg_4_3">5,285</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_W3X1hUg8vke6Gh4fxUQQlQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_aT1gq91-1E-Z_o5Btrd6uA_4_6">3,347</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_mK6An4mZPEKdwtSiEO6F3g_5_3">11,906</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_0shW0IbKw0Kvuy86fMptuA_5_6">5,476</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense by type of award included within the consolidated statements of operations and comprehensive (loss) income was as follows: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:11.7pt;"><td style="vertical-align:bottom;width:61.03%;margin:0pt;padding:0pt;"><div style="height:11.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:11.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></div></div></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:11.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:11.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.5pt;"><td style="vertical-align:bottom;width:61.03%;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:61.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MM86-nEOIUC1fgZNk-MY1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_7M2OqttB0kWZ381dfA9O3Q_3_3">11,494</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_8aHt_5B77EiYc-jzE1Txdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_pW-kYIx7rUiK_XGUXb7wpA_3_6">5,316</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Employee stock purchase plan awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_l2cNv6JCfkyvIREeesp36w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_gPRbVGsSPU21BciBtoyfYA_4_3">211</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_t77TAzlnOUGgpyEM6N3T8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_qE8j2X2LzkazEgDS8XF-WQ_4_6">62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock awards and units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_6Bs2-neN-U2EmecB-QIl0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_pkOFBAMwTUK0c3xsTWuwxg_5_3">201</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_GhxOUzzS90-GzmvIc16b8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_DFadl7nCdkK5ZuiM4nxOsA_5_6">98</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_STD4afZKAEai-MsLu141Kg_6_3">11,906</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_0us3wO33skSeHlJOoKsfMA_6_6">5,476</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 33.1pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_stzsSI5-EEmAFuqirPwJ0w" continuedAt="Tb_stzsSI5-EEmAFuqirPwJ0w_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">(8)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">RELATED PARTY TRANSACTIONS</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Services Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2018, the Company entered into a services agreement (&#8220;Services Agreement&#8221;) with Carnot, LLC (&#8220;Carnot&#8221;), an entity owned and controlled by RA Capital Management,&#160;L.P. under which Carnot provides research and other services to the Company. RA Capital Management,&#160;L.P. is a related party due to its equity ownership of the Company. The Company pays Carnot for services performed and costs incurred. The Services Agreement is for a term of <ix:nonNumeric contextRef="Duration_8_1_2018_To_8_31_2018_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_-N_0UjeZlUm9GQWNR1RVdQ" format="ixt-sec:durwordsen" name="avte:RelatedPartyTransactionTerm" id="Narr_U0g5r8deXEeTc7dIMKnnWA">two years</ix:nonNumeric>. The Company may terminate the Services Agreement by giving <ix:nonNumeric contextRef="Duration_8_1_2018_To_8_31_2018_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_-N_0UjeZlUm9GQWNR1RVdQ" format="ixt-sec:durwordsen" name="avte:NoticeToTerminateAgreementPeriod" id="Narr_2TskPhSK20OK0JjzVfIhdg">30&#160;days</ix:nonNumeric>&#8217; prior notice and either party can terminate the services agreement for a material breach, if not cured within <ix:nonNumeric contextRef="Duration_8_1_2018_To_8_31_2018_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_-N_0UjeZlUm9GQWNR1RVdQ" format="ixt-sec:durwordsen" name="avte:MaterialBreachCorrectionPeriod" id="Narr_5255-t5O4Ea76eDwOkfL4g">30&#160;days</ix:nonNumeric> following notice by the nonbreaching party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July&#160;2019, the Services Agreement with Carnot was amended whereby research and other services are now performed by Carnot Pharma, LLC (&#8220;Carnot Pharma&#8221;), an entity owned and controlled by RA Capital Management,&#160;L.P., and the term was updated to the later of (i)&#160;<ix:nonNumeric contextRef="Duration_7_1_2019_To_7_31_2019_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_n2CK4UQgq0-A1CPzs_pKqg" format="ixt-sec:durwordsen" name="avte:RelatedPartyTransactionTerm" id="Narr_rMiX0g8yvUCZpGVPqPfWbw">two&#160;years</ix:nonNumeric> from July&#160;15, 2019 and (ii)&#160;completion of services under the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Expenses incurred by the Company under the Services Agreement with Carnot Pharma totaled $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_Db-jvbls9U2OcKGqstWiEQ" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="6" id="Narr_gGEIGJH3DU2nEoi0E0A0Iw">0</ix:nonFraction> and less than $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_GK_CqlKS30Gm2NvMdNBc3A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="6" id="Narr_p06OEJLlPkaAKOiheuH6WA">0.1</ix:nonFraction> million for the&#160;years ended December&#160;31, 2023 and December&#160;31, 2022, respectively, and are presented in the statement of operations and comprehensive loss as research and development and general and administrative expenses. <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_0tBp6f6PUUW7kvis6j685w" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="0" id="Narr_CQIRRyg_XEWwI2nVSRbZVA"><ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_fjXbQ_EYZ0OduVaJ4JsVzw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="0" id="Narr_XLRmCI5TjkK4EToM2vRAVg">No</ix:nonFraction></ix:nonFraction> amount was due to Carnot Pharma, LLC as of December 31, 2023 and December 31, 2022.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_stzsSI5-EEmAFuqirPwJ0w_cont1"></ix:continuation><a id="_63f8240f_6d6f_4768_930b_d09a31d23b16"></a><a id="Tc_K2o2vrxHxkWhdWhn2y_Syg_1_2"></a><a id="Tc_MR0KPXIzpkaJLZnlNrU2Vg_2_2"></a><a id="Tc_Aqr7p1A49UCYa1YordKjcg_2_5"></a><a id="Tc_RLoRCpUINE-DNF3afKgt6g_3_0"></a><a id="Tc_pcYjhvwOb0-65vItbbg5OA_4_0"></a><a id="Tc_E_ZW4ZjX6kewhUFA3Mnb3w_4_2"></a><a id="Tc_hjQKanFRV022frAqdpvdvA_4_5"></a><a id="Tc_0YD9k8Bws06tdKNoJ8GRlQ_5_0"></a><a id="Tc_Ft2KZt2oBUWSDcU7L24-JQ_6_0"></a><a id="Tc_X8_JO2hRoEOFCbFT2J07Aw_7_0"></a><a id="Tc_v6le-9My90q6G3LFt3RRBw_8_0"></a><a id="Tc_vK_ZDf-ex0mmjjV6iFSxqw_9_0"></a><a id="Tc_3P4jQOw6u0aGlCKP0tUrJw_10_0"></a><a id="Tc_RfkpOA_3tkSLUHAszQRXJg_11_0"></a><a id="Tc_GreMDtsR1EunTbNUwXp4JQ_12_0"></a><a id="Tc_NKnRqtMtJ0Wm-KlE_JL0Hg_13_0"></a><a id="Tc_-IPZ0BixEUOwtq8vQ0FqcA_14_0"></a><a id="Tc_I2bXvBWQjEaniF7d45LSww_15_0"></a><a id="Tc_1r7wWmUKWUS3imBYVl84MQ_15_2"></a><a id="Tc_puwvcQFuo0yQEddEriwfWg_15_3"></a><a id="Tc_fCGYwEMgDEWYjs8x97XKVg_15_5"></a><a id="_f7080a3b_e5dc_4fb9_a3f4_5eba55621427"></a><a id="Tc_9FusN0hpXUupFCs8Fl51xQ_1_2"></a><a id="Tc_On1jM3fS3Uuj4CcVmTX_gQ_2_2"></a><a id="Tc_tbiWzDy3jEuTapQuxt8Qzw_2_5"></a><a id="Tc_YQ8iCG6mYUSYyvK9YBxcsQ_3_0"></a><a id="Tc_s2YYfkIdJECOFb1E3u3Rjg_3_2"></a><a id="Tc_aHGQE784NUK_7LO3r0sfPw_3_5"></a><a id="Tc_N5_qc_UiTkKGxH9zJedvPg_4_0"></a><a id="Tc_dwvpgCqPwEOu0NWJnRQ6Gg_5_0"></a><a id="Tc_ef1KCFMj9kWthHMnEdxcFg_6_0"></a><a id="Tc_3gAaYVRL5kGWd7zVQmWBXw_7_0"></a><a id="Tc_RzaO21wcl0Cp0srDpPiV7w_8_0"></a><a id="Tc_oCrwbwTu6EmRS-zdG669eg_9_0"></a><a id="Tc_KaGH7g9yuUmuZ25M8ip4Qw_9_2"></a><a id="Tc_4qiyxulzPUCk4uZJgnlu_w_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_d_sS68pwv0-eIs1omF9KJA" continuedAt="Tb_d_sS68pwv0-eIs1omF9KJA_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">(9)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">INCOME TAXES</p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_r3CAOUC9Y026gWYOFgDmHQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant components of the Company&#8217;s net deferred tax assets are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred income tax assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">NOL carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_g6MS-ePq90Cc80JE0WauzA_4_3">16,199</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_CYjNdTLxkE2_jtxhz5tfPw_4_6">11,781</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_TBSWKr0kLEK5w7msrfqkVQ_5_3">5,153</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_9v-OGtGWeEOnJHgjmvy9wg_5_6">1,601</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized R&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="avte:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" scale="3" id="Tc_8sNVWof4h0meP1fl6OaXrg_6_3">19,404</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="avte:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" scale="3" id="Tc_xX7fEm_zJEKkyS0mK0XeTQ_6_6">8,490</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_XwuYkX0cJEiC7Y5fJq5Z-Q_7_3">1,929</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_YfEfD-qaIEWxmzc16dHrDg_7_6">923</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_v5JQFsG7RkWKo3GaJmSTqA_8_3">1,117</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_CI8hEyHXskeeX0Yb0XHUcA_8_6">790</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_UUZ6o_mCI0WvXxKv23glKQ_9_3">43,802</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_9vlC9KuPCkSZf5_xPQHxCw_9_6">23,585</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_-otI0kuSpUyhUj_H9wrMZg_10_3">43,596</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_BDMVpDuBQUSKkzjvrdi3jQ_10_6">23,283</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_pitMDR_uj0O1VBXQTyBkYA_11_3">206</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_GJqif0C5NkqNwxHWoih0Ug_11_6">302</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred income tax liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="Tc_hxrT_LhbSEW_BPCgWB1eew_13_3">206</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="Tc_lGiEp3oIYUKqXjhiQPHy8A_13_6">302</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="3" id="Tc_pmgg1Gcnx0uRJsPiDuFF6A_14_3">206</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="3" id="Tc_ECcGEtEd6UeOqw286pmlhw_14_6">302</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net deferred tax assets (liabilities)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_LfTcQM9iZEGlLfhH4tvpYg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_N3ZC0VnDvE2ZJbmbzTFsIA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years&#160;ended&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Federal statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="3" id="Tc_syZQVvzyJ0q7SbUG-npsLg_3_3">15,831</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="3" id="Tc_84ywc5-X1Uac1m5v1QYhXA_3_6">10,829</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" sign="-" scale="3" id="Tc_IrYdWzBpIUGGa9Uqtc8lXA_4_3">3,389</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" sign="-" scale="3" id="Tc_6-pFL5sozEi1eEVnllujUQ_4_6">2,828</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent and other differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="Tc_ruq5jlq3DkuJQIinRqrpjQ_5_3">416</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="Tc_UKS7jlqfeUScaRCtPpvEhQ_5_6">563</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="3" id="Tc_I1rZ-wpSgEqNljkMfRONOg_6_3">1,049</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" sign="-" scale="3" id="Tc_L3Mvx26pz0WCZgxhvQtHbg_6_6">787</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="avte:EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" sign="-" scale="3" id="Tc_8oqx6j6Zu0anchSMEAcoGg_7_3">2,676</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="avte:EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" sign="-" scale="3" id="Tc_K3p4q_SU3U-jxUIA5GONKw_7_6">757</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="Tc_Oc_vbgoavkW8unmMhiu7BA_8_3">20,487</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="Tc_Kg0lKWN1Wkm2Dn_kWuYoAQ_8_6">14,663</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_CwV-lPB__USqVlM0kiCgUQ_9_3">56</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_C_JOX5-wBUCpoXab6yjp6w_9_6">25</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company had federal NOL carryforwards available of $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_LI5YHiUWtUqb-dWGgEgt2Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_bszgC6BgRESokf5-X2h7PQ">64.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_4mWrWAlR1U2qPGLn2vS_fw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_Pym4galJ5kGNPL14vdj_iw">46.9</ix:nonFraction> million as of December&#160;31, 2023 and December&#160;31, 2022, respectively, before consideration of limitations under Section&#160;382 of the Internal Revenue Code or Section&#160;382, as further described below. The NOL generated from 2018 onwards of $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_LI5YHiUWtUqb-dWGgEgt2Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_nvKdOYKpCEu3VXaJha3tnA">64.8</ix:nonFraction> million will carryforward indefinitely and be available to offset up to 80% of future taxable income each&#160;year. Additionally, the Company had state NOL carryforwards available of $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_Omgdwr0yakip4mYX2MbLqw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_Zy43YNnXUEKw0OWZ7laJyw">44.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_hsfYMw1YQUiRxCSpEvhLOA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_ezjtCCQY_0WUOpm87qP4bA">30.5</ix:nonFraction> million as of December&#160;31, 2023 and December&#160;31, 2022, respectively. The state NOLs may be used to offset future taxable income and will begin to expire in 2038. At December 31, 2023 the Company had federal and state research and development credit carryforwards available of $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_WDqRejYbEUSzCLXwlEWRhA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_TV1oDXWvtEiZaVcHN0Wctg">6.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_pWvY-k6LJEyAy3X_g6pRyA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_LijB9pr5g0qITL3mU8s83w">1.3</ix:nonFraction> million, respectively. The federal credit carryforwards will begin to expire in 2038, unless previously utilized. The Massachusetts credit carryforwards will begin expiring in 2036, unless previously utilized. The California credits carry forward indefinitely. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has established a full valuation allowance for its deferred tax assets due to uncertainties that preclude it from determining that it is more likely than not that the Company will be able to generate sufficient taxable income to realize such assets. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred since inception. Such objective evidence limits the ability to consider other subjective evidence such as the Company&#8217;s projections for future growth. Based on this evaluation, as of December&#160;31, 2023 and December&#160;31, 2022, a valuation allowance of $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="Narr_qVzz_382-ECOM0oJVooSYg">43.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="Narr_b-0S_U1LW0-xo3a7piqnLw">23.3</ix:nonFraction> million, respectively, has been recorded against all of the Company&#8217;s net deferred tax assets, as the Company has determined that none of the Company&#8217;s balance of net deferred tax assets is more likely than not to be realized. The amount of the deferred tax assets considered realizable, however, could be adjusted in the future if objective negative evidence in the form of cumulative losses is no longer present and additional weight may be given to subjective evidence, such as estimates of future taxable income during carryforward periods and the Company&#8217;s projections for growth.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_0e4b565f_9ef7_47a6_8586_465eaadc8021"></a><a id="Tc_jgT0vvJehU2cbZfDeEyKbA_1_2"></a><a id="Tc_kpWKsi8JTESIGqi5Taxwfw_2_2"></a><a id="Tc_eNS5vOc7bkupbBr4M0MEmQ_2_5"></a><a id="Tc_zW9Nb_rcP0q8RjxwrUx7nA_3_0"></a><a id="Tc_wworDbthwEayOkTwjEMXLQ_3_2"></a><a id="Tc_piQdxG40iUyAMDHt0oWH0g_3_5"></a><a id="Tc_89h013g4YEGFga3YKC5s8Q_4_0"></a><a id="Tc_uLIWejBQVUOjuCBbWd1aoA_5_0"></a><a id="Tc_k1xSYTF6X0iRq9QbwhmotQ_6_0"></a><a id="Tc_Objr90iMAUeY2Aryw6Arzg_6_2"></a><a id="Tc_2E0ryFwHCE2riButVlLwmg_6_5"></a><ix:continuation id="Tb_d_sS68pwv0-eIs1omF9KJA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The future utilization of the Company&#8217;s NOL and tax credit carryforwards to offset future taxable income may be subject to a substantial annual limitation as a result of changes in ownership by stockholders that hold 5% or more of the Company&#8217;s common stock. An assessment of such ownership changes under Section&#160;382 and 383 was not completed through December&#160;31, 2023. Utilization of our net operating loss and income tax credit carryforwards may be subject to a substantial annual limitation due to ownership changes that may have occurred or that could occur in the future. These ownership changes may limit the amount of the net operating loss and income tax credit carryover that can be utilized annually to offset future taxable income. The Company will examine the impact of any potential ownership changes in the future.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="Tb_4f4EYDXRt0GvLYUss4UTBA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the activity related to the Company&#8217;s gross unrecognized tax benefits at the beginning and end of the&#160;years ended December&#160;31, 2023 and December&#160;31, 2022 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years&#160;ended&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance of unrecognized tax benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_ZyA9PdR2OUmc55f8WbDNrA_3_3">993</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2021_3SZLVaYF3Uaoxk9Z6taH9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_r0oPjESInUWFrwfAKPs1Rw_3_6">529</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additions based on tax positions related to the current year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_mcZV1vrvZ06lmdJ92DOdIw_4_3">1,127</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_pq84eKESTEuxoM9EkDg4hg_4_6">461</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additions based on tax positions related to the prior year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="Tc_3kpvSMaK9Uy-ZHWi9dJNQA_5_3">94</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="Tc_6i0tR0UooEyKunfFGO_MMg_5_6">3</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance of unrecognized tax benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_Hfz-nUCHAE6nw8atST7vzw_6_3">2,214</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_33SKx5N780mZRqQ0FMmATw_6_6">993</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unrecognized tax benefit amounts are reflected in the determination of the Company&#8217;s deferred tax assets. If recognized, none of these amounts would affect the Company&#8217;s effective tax rate, since it would be offset by an equal corresponding adjustment in the deferred tax asset valuation allowance. The Company does not foresee material changes to its liability for uncertain tax benefits within the next twelve&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to taxation in the United States and various states. The Company&#8217;s Federal and state returns are subject to examination, due to the carryforward of unutilized net operating losses and research and development credits.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_22f83fcf_e157_499d_982a_afa3f573f2e8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Aerovate Therapeutics, Inc.</b></p><a id="CondensedConsolidatedBalanceSheets_97473"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(in thousands, except share and per share amounts)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_ccdaeece_d1f3_4c35_9fdd_b60aec85bfb2"></a><a id="Tc_vyu6Xxrdok-K9dDPmeyL8w_1_2"></a><a id="Tc_qAf0zZawUUim_GR3oucAPA_1_5"></a><a id="Tc_BNbufB3F30a9oVijGtcBYA_2_2"></a><a id="Tc_K6gEGvXCuEmkS3-aV7FX5w_2_5"></a><a id="Tc_ROvMvkNFiUenCFer8rx8Zg_3_0"></a><a id="Tc_vKkWJuZHdUi15cAKPwMI1w_4_0"></a><a id="Tc_rymKyAMrM0CoWILDLh70Sw_5_0"></a><a id="Tc_i-a7POeQbUqlkK0Jv9bkIA_5_2"></a><a id="Tc_D87_KpGfVUagpVcICoMZ2g_5_5"></a><a id="Tc_r3i22AlN806cGpIMEgZRlQ_6_0"></a><a id="Tc_pCeBcRoE6k2Yw6AmtjQRfA_7_0"></a><a id="Tc_38AFoXaoeUGfqCC7p4zZRA_8_0"></a><a id="Tc_fglS7Z8z30qYfuAxJdhosQ_9_0"></a><a id="Tc_hB4HEvDjsEGCwRjar9UqBw_10_0"></a><a id="Tc_yeO2MdrOZUWU2sx698jiWA_11_0"></a><a id="Tc_6r71zLDxQ0eu4Q9ta5t-ug_12_0"></a><a id="Tc_yLwp4i-WQUWZZ9rIFIZgAQ_12_2"></a><a id="Tc_Ep7KTnaD3kyEpw7gbBNc4w_12_5"></a><a id="Tc_UfBQuwYQZkuAuN7vqj3VyQ_14_0"></a><a id="Tc_Ldls_YLbbUikkiCPnjgBOw_16_0"></a><a id="Tc_0m2jW5ssn0G3_zE5_7qqMA_17_0"></a><a id="Tc_Yq64zS4rZEea0w_hWSecwg_17_2"></a><a id="Tc_9ASSGHAP402Z20g966aRww_17_5"></a><a id="Tc_CgQei1r8yUur4RaOURZ7kQ_18_0"></a><a id="Tc_NntAUu6-eEKNutKBXgrRfQ_19_0"></a><a id="Tc_v6eqI4ys2U2d6OoQBroc9w_20_0"></a><a id="Tc_rf0xssOPaEivvCvlo8n_jQ_21_0"></a><a id="Tc_OuCFhBjxt0uniur5S3yFbg_22_0"></a><a id="Tc_eJc3FRTas06xon44iOdofw_23_0"></a><a id="Tc_8VnmTdGKoka_e_c2rJ6YpA_25_0"></a><a id="Tc_Qs_xoFr6-UiDEPodUkdFWA_26_0"></a><a id="Tc_N0SpIvKDNEyBNA3jUbKm5A_27_0"></a><a id="Tc_idZnSnuw50OCkxzlPJKzjw_28_0"></a><a id="Tc_4lu_gQOOVUeBpq4yU571rw_29_0"></a><a id="Tc_i2eHrrTVcEG4Wu4vJcGErw_30_0"></a><a id="Tc_X0YpAdrWtUC6nmRxFMpWGA_31_0"></a><a id="Tc_kQH9-b8Iw0GzKmkzL7zI9g_32_0"></a><a id="Tc_tpuzygcdPkCUX2oEKb4sPQ_33_0"></a><a id="Tc_6Lv7qqrNrU20yFZQPfGNww_33_2"></a><a id="Tc_MfcuTrjo-EOC9USC7S433Q_33_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_U1-xkhovVUiT4imA2mQsOw_5_3">31,115</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_PniCWoxBi0y1TB5twaR_Ew_5_6">23,491</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_gA6BdfNBmUON9qcBnzk_uA_6_3">57,615</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_1-te3jFzb02YiiGNk0f1Ow_6_6">98,948</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_YXsxTsvsh0O8Sn3Jutg6iw_7_3">1,875</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_L-D7NvmAPkSP2PxnFoCPzw_7_6">1,793</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_lZxwmobZv06ot9M0IWwGmw_8_3">90,605</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_niP3S0UiPU-j0EnxqGuNjw_8_6">124,232</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_nku0_SMr6EK_lZAWDn8NyA_9_3">14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_olyTnucztkCAfSKE9_CASA_9_6">288</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_nsZZLSd3V0-nj8g0cVW-rw_10_3">259</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_ox3V_Xz0MkCZ5jyMRDoIMw_10_6">614</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other long-term assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_3zfS43y2xketxKnNPXx-zw_11_3">81</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_30_uSnBNi0yqpUwpxctKhA_11_6">2,284</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_O38qPEbWoUa3XZ5was4OHQ_12_3">90,959</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_Vm9FCHBCn0uejJRNrDboZg_12_6">127,418</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_dHGczeoc-EOGK81Mbs9bHQ_17_3">908</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_C2nLYYUofkuMnAtt9MtJnQ_17_6">2,396</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accrued and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent" scale="3" id="Tc_5GJ26KBqOU6FSXoFM1sLrg_18_3">8,948</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent" scale="3" id="Tc_WGKPjlJ2uk6QzlVLwVi7_w_18_6">14,821</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_71UBes5y8kSJYKT8t2QVXg_19_3">459</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_XgncqNkbZUagc15qTZ2nEw_19_6">420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_EZ2ECcN040ax9cT6QtbtZw_20_3">10,315</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_tWcYEExZCEKFuXXY7QyNdQ_20_6">17,637</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities, net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_tBx7rWaR40-oft8Pg-38lw_21_3">81</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_N8VRLAZfBkWVGEbtZLfh7A_21_6">255</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilities" scale="3" id="Tc_dNHCC4tuUUq9mzf5ew2IlA_22_3">70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilities" scale="3" id="Tc_eAL9YfX0f0G3KhAa-lQ7UA_22_6">70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_IbpLETYvwEq6R1NgNPEKfg_23_3">10,466</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_ywIU3a6vCkKinHMqycUpJw_23_6">17,962</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Commitments and contingencies (Note 5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_jY_nI_26nkSysj0V3HAECw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_HLtqTZR9HE6oeUTXYXEVzQ">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_yo_jgxCoOEuMnEAzbkDdiQ"><ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_E2bolh-Ud0GNPsZlpqagCw">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of September&#160;30,&#160;2024 and December&#160;31,&#160;2023, respectively; <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_FwaNMmkAi0ioO8NP7s7q6g"><ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_wHGaboHMaU-0HOpAVSecMA"><ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_InL7bflLlkWc9zas7hS6NQ"><ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_y9p4l7Punke8wv6gHWKjEg">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at September&#160;30,&#160;2024 and December&#160;31,&#160;2023, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_BTUAgG66VkC8uiBG5TgIww;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_g-F-zaysXU2M6cBzvAutMw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_hJEurFtKvkO4iLxY6cKrqA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_zj-0kxLOt0mvHKhWavXswQ">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_WFtiQQzsC0a8qxHiHV1Hiw"><ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_Mi3KKEmvDkC7JV4i1hcrrA">150,000,000</ix:nonFraction></ix:nonFraction> shares authorized at September&#160;30,&#160;2024 and December&#160;31,&#160;2023, respectively; <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_h3-4XNp3_EaK6Dfl5RmRgw"><ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_uf6ZHvgXokmZj4nYHP4O2w">28,867,711</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_Km4geJ7FWUaHqQTmyRhNdg"><ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_5xcTZvP8TUisa2iwKEq2Lg">27,762,703</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September&#160;30,&#160;2024 and December&#160;31,&#160;2023, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_B1c45jSg_UiEO2cd2uzr0g_28_3">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_QcmHjubxe0GnlAV5IQYOAQ_28_6">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_Kk1PCKuIdEOB6qotd4p2eA_29_3">307,888</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_PX1HI6FuMkmPT8KxlbmKew_29_6">272,640</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated other comprehensive gain</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_qVfrv0L7tE-oYtP82kkc5g_30_3">224</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_MG5aA7LnpUeeW65s3-WBbg_30_6">237</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_Gy01mKKxS0S0M5qaVhGamg_31_3">227,622</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_EowEm8DZ70GH_pWRlZBWQQ_31_6">163,424</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total stockholders&#8217; equity </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_LHXN0J3_2U6qCMk-WNIbsg_32_3">80,493</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_gYNm0tlq7ESb5Hv7fmiwMA_32_6">109,456</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_DeyMipcQ4UO9yvsFt55u3w_33_3">90,959</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_M3bj7kSPMkmQwtn6-ylXxg_33_6">127,418</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">See accompanying notes to unaudited interim condensed consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_8f837447_5a09_4d1b_bea7_b4146782a895"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Aerovate Therapeutics,&#160;Inc.</b></p><a id="CondensedConsolidatedStatementsofOperati"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Operations and Comprehensive Loss</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(in thousands, except share and per share amounts)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_ecafe439_5b5d_4f61_aa68_576a988b7dc4"></a><a id="_8f6bea48_26f0_4ee1_b8c3_51aa2db8a902"></a><a id="Tc_Q2G2HKZU0UKvxndMsGKOsg_1_2"></a><a id="Tc_xFzY_oW5eUODf7r8vEVH7w_1_8"></a><a id="Tc_3nJzOYOkM02XdKwfYtEaug_2_2"></a><a id="Tc_ykBU6lS3I0eX6HnYiCl5Ww_2_5"></a><a id="Tc_8rAkE0M_eUemyMGwxdvGLg_2_8"></a><a id="Tc_g5BI-xqPck-9aZYKV27xbw_2_11"></a><a id="Tc_ov12nchogUmh0GUjJb-3Kg_3_0"></a><a id="Tc_aIgkdN6MIkSW0TxaQo24Vw_4_0"></a><a id="Tc_AqY5tmPKskqsoGULGEAlDQ_4_2"></a><a id="Tc_PibqXFrOBkWR-A-WNUkmqQ_4_5"></a><a id="Tc_Fi04CC2VzESnNg386k02pA_4_8"></a><a id="Tc_OWXla_gCyk6Gsxsb76RFvA_4_11"></a><a id="Tc_JdLRr6jpF0SpcpJucNa4uw_5_0"></a><a id="Tc_wWcAoZaD1keUZ3wiYbDS-g_6_0"></a><a id="Tc_AhOGUT-pYUObaqg2sNYNug_7_0"></a><a id="Tc_kCiNW_5Nn0iguT95Pe4GNg_8_0"></a><a id="Tc_e0Z6S1RchkuJa8D0aggvcQ_9_0"></a><a id="Tc_yW6FnLGjXkabNQ_v3Iu4QA_10_0"></a><a id="Tc_hdA4HZv8FkaAHHAhAO15SA_11_0"></a><a id="Tc_BxfH0lKKMUaMHc9V6UuecA_12_0"></a><a id="Tc_kfa0uEgSVU6WfPENjWKzXA_12_2"></a><a id="Tc_PMKJ4iJEw02k2vAkLxtTxA_12_5"></a><a id="Tc__TBpsFBga0-4B26NwJA4YQ_12_8"></a><a id="Tc_ZPcQXZJ5cUa4t5-C_FeczA_12_11"></a><a id="Tc_WKWTAv6yIE2P5ILLAD17UQ_13_0"></a><a id="Tc_hylAuKjw_0i-7PIB8naXzA_14_0"></a><a id="Tc_zsx5s9DAvkK62fj0M9IOHw_14_2"></a><a id="Tc_AeoB3ZrsfEaDX6nGjzfP4g_14_5"></a><a id="Tc_mBlFsBuNTUyPuqkf2R3Q2w_14_8"></a><a id="Tc_q6BCTrmoUUCj3CaYt6vUPg_14_11"></a><a id="Tc_IniNsLKq8E6wy63X7N_NIA_15_0"></a><a id="Tc_BG51BVNWZEW8HoGfqPLlow_16_0"></a><a id="Tc_lIw3msSaGU-T7ctWlKADEQ_17_0"></a><a id="Tc_Qv_clUjO20u_qJ9GiL1hXg_17_2"></a><a id="Tc_q-3zQlpIm0yYPmIjsVk4jw_17_5"></a><a id="Tc_dpyNujwn2km07U9onVtJ-Q_17_8"></a><a id="Tc_pvMhZCTPa0qUXuJGapBZKA_17_11"></a><a id="Tc_kHNf3nIVyEyGgeHRnUzNEQ_18_0"></a><a id="Tc_KNbWIrgRZEqEO5WdySJiDQ_18_2"></a><a id="Tc_sAhqRm5x70q3jP8WfrR2Tw_18_5"></a><a id="Tc_IkCBRXRs5kqjP2vgB7ZIag_18_8"></a><a id="Tc_670fCR2ED0-tIf8hCFEEuQ_18_11"></a><a id="Tc_1xXaMUS59EufbsYoglD8Ng_19_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:45.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_2rorMzQOEEGZb0f0hAjQFA_4_3">10,328</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_YecPPD4sIEG6VNGDygS7wA_4_6">16,884</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_XyxBWoqYJkWlD6P7R_z5zw_4_9">51,656</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_WHfNg1MjAkWvJBj1UOvYQA_4_12">46,406</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_5lm23t4uuECKig3z6YNhVA_5_3">7,082</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_OCcJ5HQyeUGMDTwlKB47og_5_6">4,484</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_dQKyrj4Y-keH2VWeLzNDxw_5_9">16,537</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_rVaRHHrtkUeHhpoUbLkQ-g_5_12">12,937</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_QeGK5ozf1Uag0YWvN9lRfA_6_3">17,410</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_6Yz8sLnk2ka1gnyVCYr9VQ_6_6">21,368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_qXXBq5PB1kulHRPHTFTXtw_6_9">68,193</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_RKKjcO_Bt0Wxk9wZWkK5ig_6_12">59,343</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_7h6UPOpSkU66H24UV1dvAQ_7_3">17,410</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_rJr6GdlHFkOPmVXtnW167A_7_6">21,368</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_0yimzPqUk0akMBiBLAMBAg_7_9">68,193</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_8g1cddnlIUODEIeF2-lRuA_7_12">59,343</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="Tc_CD1kvMBum0qukXtr_jbiAg_9_3">1,183</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="Tc_W5xWWvJzD0CLN398H0KpOQ_9_6">1,804</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="Tc_TM5j8T5qx0yqE62XDQM3NQ_9_9">4,014</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="Tc_mGckEaz5d0G--tOMcfSAWA_9_12">4,236</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other expense:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_BluXY8Aw4UuO7zcaP6cADw_10_3">10</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_D8ztsjaGhUmUhMQ7Q1lczQ_10_6">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_0LC5QH5atUaZWI5UxapUfg_10_9">19</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_2nr7bmOuMEuwvI2rux3iTQ_10_12">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_Cnp0p5kR8k61u5ibV2IQHg_11_3">1,173</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_W46jL5g86EWBXyf8ewXB2w_11_6">1,805</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_k6A8yVT4SUqwIOFVxdS-eA_11_9">3,995</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_-U2fOaXnqkOH-4TZM4_tSw_11_12">4,235</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_mwl4pFy9oU2nbbQkanSX_g_12_3">16,237</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_8QMyekEzhE2BASY5Kd6XFQ_12_6">19,563</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_bPjHmkr1IUawZC6ebEAwVQ_12_9">64,198</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_0FI8niRdlUGELOnfsi0nUQ_12_12">55,108</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Comprehensive loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_XcYnNIY7rUqtUmTDrgv3Iw_14_3">16,237</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_SKStvn5dR0GYMB94XRXj2w_14_6">19,563</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_xb9GSfedp0S8UYjFcJ5epA_14_9">64,198</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_ZXTRTgbfIU-Wp3HBcO0_WQ_14_12">55,108</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other comprehensive loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Unrealized (loss) gain on securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesTradingUnrealizedGainLoss" scale="3" id="Tc_7miHMgjU-k24UaLe77eBnQ_16_3">307</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesTradingUnrealizedGainLoss" sign="-" scale="3" id="Tc_WkfhWugla0KcxyRy3Ly4FQ_16_6">22</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesTradingUnrealizedGainLoss" sign="-" scale="3" id="Tc_oOyLjXbjMEuT5umM1Ea2gg_16_9">13</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesTradingUnrealizedGainLoss" scale="3" id="Tc_r-fnKc5NKki9yvpA1CYYCw_16_12">243</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_kyJPJIv5t06rreJ-glFCuw_17_3">15,930</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_Wld9y8CiJ0yYxHOFDnIjsw_17_6">19,585</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_Xy-RVB_Z7U61CBMrrcC9Zg_17_9">64,211</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_0YylNwhUd0-T7nhjEBN5yQ_17_12">54,865</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_PFbFWPzYikSBSkZdruwqIQ_18_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_PFbFWPzYikSBSkZdruwqIQ_18_3_2">0.56</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_rCSeA2R470G-KXfNnuKozQ_18_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_rCSeA2R470G-KXfNnuKozQ_18_6_2">0.71</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_kfxwKBRW_EykPSwLGPgrkw_18_9"><ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_kfxwKBRW_EykPSwLGPgrkw_18_9_2">2.25</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_FiIrSZkB9kSHdxpExq0o1g_18_12"><ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_FiIrSZkB9kSHdxpExq0o1g_18_12_2">2.13</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average shares of common stock outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc__p6-Zd-DS0iXfny0SoxqFA_19_3"><ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc__p6-Zd-DS0iXfny0SoxqFA_19_3_2">28,863,327</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_wdxSKWrz-0Cb-9j0MNLI2g_19_6"><ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_wdxSKWrz-0Cb-9j0MNLI2g_19_6_2">27,640,542</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_ijGoW_mB5kqmXovF9-DBuQ_19_9"><ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_ijGoW_mB5kqmXovF9-DBuQ_19_9_2">28,572,338</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_6H1mc0DYtkSwf8fd_nvOhg_19_12"><ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_6H1mc0DYtkSwf8fd_nvOhg_19_12_2">25,872,118</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">See accompanying notes to unaudited interim condensed consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_8695747b_d099_4dfd_8b1c_8f6c069fd5b3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Aerovate Therapeutics,&#160;Inc.</b></p><a id="CondensedConsolidatedStatementsofRedeema"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(in thousands, except share amounts)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b6d745c1_9e62_47c3_8f43_f28f086b238b"></a><a id="Tc_4YyjIo3iTUmn6efAkbhKNQ_2_10"></a><a id="Tc_1MyB7K0rUUaOTx0PRpYdjQ_3_7"></a><a id="Tc_bdTFe4GKtUCaaXtMJwoUeQ_3_10"></a><a id="Tc_XtnYJSBT_0uxF_0vpECEMQ_3_16"></a><a id="Tc_OfIfh45RQkmpiIsgwvaXsA_4_2"></a><a id="Tc_0FMOnITx1UeGw0d3MMhQxA_4_7"></a><a id="Tc_SYDJyaJUb0iRc7qJdbZR5g_4_10"></a><a id="Tc_6bZmo-rYukmpgU8qOBXAXg_4_13"></a><a id="Tc_lbFqpvKTQU2opI05xs7OHw_4_16"></a><a id="Tc_htM598k_EkSflGjvzQNPzw_5_2"></a><a id="Tc_NKutAcZrCEu7KJxXlFiPAQ_5_4"></a><a id="Tc_JXBrix-zBEuGcnX2VsXngw_5_7"></a><a id="Tc_B6X7EWzpnES88AXAmLCQsg_5_10"></a><a id="Tc_dcb444V39UCjqFUAQ0Aa7w_5_13"></a><a id="Tc_LMQe9Lik6EaUm6KDBZ-Gdw_5_16"></a><a id="Tc_EKx1Cee5o0CVQfRvOX4JFA_6_0"></a><a id="Tc_NGoI5ocnvEWecDIpuipCsQ_6_4"></a><a id="Tc_6LM-w5_SA0ebG4SxzI28Dw_6_7"></a><a id="Tc_47ylsVn1y0eowZf4QCJ0Yg_6_10"></a><a id="Tc_3rWWCbK8YUOam3wGcvkYkg_6_13"></a><a id="Tc_Sxfo5vY94ka-WZzgLmKQnw_6_16"></a><a id="Tc_ZoAWmjLvak21-jgVkeEiNA_7_0"></a><a id="Tc_PCCbtWD7AkaHKhQy5lqkxQ_7_2"></a><a id="Tc_NVK1mVJNaUak8F4zfq6vnw_7_5"></a><a id="Tc_9t_GoSdwJ0KcQtICbJjT2Q_7_8"></a><a id="Tc_rraIzFQdeUqr_pVN6Ekz-A_7_14"></a><a id="Tc_WwrHWExSL0S63VOt2MUjpQ_8_0"></a><a id="Tc_57FQz4mgikmd6LkFGprMRQ_8_5"></a><a id="Tc_J9MYdElSp0y9dBVdK0Mw5Q_8_11"></a><a id="Tc_1NOCNawEj0qxYzzniuqfWA_8_14"></a><a id="Tc_mg1q9dlQo0-m640Ia3oWgw_9_0"></a><a id="Tc_9Y_S4pnL50KlUP4nXvgl6w_9_5"></a><a id="Tc_vCO7sIeeSECaMhgCCeOW5w_9_8"></a><a id="Tc_FP64d5l-wk-csW5S5Eno3w_9_11"></a><a id="Tc_nZmEvlQwU0Gj8Rr-FRHW3A_9_14"></a><a id="Tc_jMP0zT1PUEKXftePUwFmJA_9_17"></a><a id="Tc_lKFw8IfRmkyO1VCSNqfMqQ_10_0"></a><a id="Tc_UdcA4qMP5ka8-RRDz83e_g_10_2"></a><a id="Tc_Ca_11VVdbk2JRxmK0zDyFA_10_5"></a><a id="Tc_zMykBz3jt0upyTRSDzMLwA_10_11"></a><a id="Tc_Dy1K5wtfOUWIoeLeRkzu5w_10_14"></a><a id="Tc_vsxAteg26U2WxJyFjCq7Iw_11_0"></a><a id="Tc_aQaEvhVD4kSoZFdeqNQkdw_11_2"></a><a id="Tc_tGtgnI9q9Em_76v-ze_azQ_11_5"></a><a id="Tc_ea9GfF6L5Uq_pB4XtMCoIw_11_8"></a><a id="Tc_lb6XvBTJJku-wvGcibJpDw_11_11"></a><a id="Tc_LEUyGrRzTEuxPRc6nQjPWA_12_0"></a><a id="Tc_2nPLRVBHp0-swRWZztNbNg_12_4"></a><a id="Tc_sZ0bCSVsK0mb1RSGMNKluA_12_7"></a><a id="Tc_l-gskCT75E2xrBWugrO5SQ_12_10"></a><a id="Tc_NEBycrYPRkOf3hLTwUB_pw_12_13"></a><a id="Tc_eStNyOlho0i5SJqngV4-2g_12_16"></a><a id="Tc_-CH1a-4ZWUew1C5N1gsK_Q_13_0"></a><a id="Tc_xV9ZP_P72kq1ZGeYcgebTg_13_2"></a><a id="Tc_Fx0Y_rRGCEmBfIrgHP7cXw_13_5"></a><a id="Tc_1uTXGlNpbEe51LNJthZpCQ_13_8"></a><a id="Tc_-zu-c76Y-EitVIE7QIoP2g_13_14"></a><a id="Tc_ZgRFlDy_00-gMBdT2Phnzw_14_0"></a><a id="Tc_ngVXV_tUzkqjVxGu4i-jFg_14_5"></a><a id="Tc_gF0AqARSq0mhJOaaIkob_g_14_11"></a><a id="Tc_zO2MVhHowUaMWjEEluUU7g_14_14"></a><a id="Tc_gYkOUZXw106vY48g2gSYuA_15_0"></a><a id="Tc_fLqZeiIBX0CepK466mhZxQ_15_5"></a><a id="Tc_9u1Lxu8uqEqhuIQXanZUDw_15_11"></a><a id="Tc_LjYgCkdxRE2QCmZQh6XeuA_15_14"></a><a id="Tc_10twKkZaiEabVn-45wdpjw_16_0"></a><a id="Tc_dJD05BIf4kOxnjk-cQF78w_16_5"></a><a id="Tc_IpsV5Q7BWUu2ZO7zsP5r2w_16_11"></a><a id="Tc_XLC8Hke9KkWW54JA23RK0g_16_14"></a><a id="Tc_tJxLNCIzzkCVKjY0pPIrsw_17_0"></a><a id="Tc_q2QwHz0w90WlkqdYZRyFFw_17_5"></a><a id="Tc_LJiRE2-RGkCWYBwZQojz4A_17_8"></a><a id="Tc_ZnfZAicGyEabQte886jzNg_17_11"></a><a id="Tc_7Q5Ax3fxYkqs2Z6xLNBJPA_17_14"></a><a id="Tc_yPjEOJhOvEKWpbUriFHxvg_17_17"></a><a id="Tc_azgW2AT5bEa0N2qDwtR91w_18_0"></a><a id="Tc_VSLXKRjSPEKSSeH9IHbSPg_18_2"></a><a id="Tc_NTqHUT9Kx0WJGwv8skEozw_18_5"></a><a id="Tc_ksYGmsLf_UGmdZWcXBCOBg_18_11"></a><a id="Tc_cvJeEb99-UaW3oBhTqOvlw_18_14"></a><a id="Tc_b-G1YLJIj0uGQEGYnzOHpw_19_0"></a><a id="Tc_6TWIE0FneUm48pgLSpoOLA_19_2"></a><a id="Tc_AoL1vxj0ZEmBBJ_qeCR4fQ_19_5"></a><a id="Tc_NqT5zDeTXEuUw8F0DzUisg_19_8"></a><a id="Tc_gH2_LpIWRU2JiS1Q-17c7A_19_11"></a><a id="Tc_jK9OFF6CzU-AaP8gLv3jyQ_20_0"></a><a id="Tc_rCSNsUs-t0Cm4GqB1Pk-kQ_20_4"></a><a id="Tc_qINgY7yhU0eqH6b-qWx9Pg_20_7"></a><a id="Tc_8Frk8jcZn0CHgmtk1_oXCQ_20_10"></a><a id="Tc_ZZ3sb-J8aEqRRTEgzoWfAQ_20_13"></a><a id="Tc_L0fUzWxXnEaPXUeHVAGCqA_20_16"></a><a id="Tc_cMrvS8VKtEOxEqMh2yWSSQ_21_0"></a><a id="Tc_tCBEvsaJ9kGoUOnyGHhrbg_21_2"></a><a id="Tc_EHfUMIL81U-7noI8U1DhCg_21_5"></a><a id="Tc_YH0gj-rz8kClU47nzyEaXg_21_8"></a><a id="Tc_RYjWCu2VP06-xoSSTJ0FSA_21_14"></a><a id="Tc_5WUXNFHT00iquFWorfqZtA_22_0"></a><a id="Tc_WxFA28zKXUertkn23ef4IA_22_5"></a><a id="Tc_MdKu2BFLjkeHptSwo5h9DA_22_11"></a><a id="Tc_djqf8yGRxkGBGX_YLQ3Q9g_22_14"></a><a id="Tc_Xu7GkScvLU-vW5g26gY6sA_23_0"></a><a id="Tc_pLlCGPSznUSbX9Ti5P4ImQ_23_2"></a><a id="Tc_OaN1EoBvgUiMGHJgCusvMg_23_5"></a><a id="Tc_wBj01mWzHUeFf8nOYI7lKw_23_11"></a><a id="Tc_1hf_ToD5b0KOt1SUdfgYYg_23_14"></a><a id="Tc_qSD6JROPaUKZSVcb33o39w_24_0"></a><a id="Tc_Wx96WPMFVUuFCbP5Z5YTiA_24_2"></a><a id="Tc_J3mudMnn4ECXHRJ_5tnICg_24_5"></a><a id="Tc_ybtz5V0ONE6bIEs9d3H1vA_24_8"></a><a id="Tc_BBkI4IjKCEqTvZWlX1YvwA_24_11"></a><a id="Tc_s2rt1Up1mUu48u1PflnITA_25_0"></a><a id="Tc_5mJGRavY9ECqwXUAFp0U1Q_25_4"></a><a id="Tc_nv43NWD3Xku3Inb4lMCkqQ_25_7"></a><a id="Tc_5joUTU2hcU2knU4xkf3rVA_25_10"></a><a id="Tc_I5TxGJFc806jbxtP9l5WCQ_25_13"></a><a id="Tc_ad078XwfkUm0uTELElMp1Q_25_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gain/(Loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iFYHzpsOAk6upQL9o0JHJA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_lgZUzVFwPka6Fh-eB6StLg_6_2">27,762,703</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iFYHzpsOAk6upQL9o0JHJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_cQ3pRhm33UGFRLUZPSxvRw_6_5">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_r3UKbN8hp0mfWhezRkf1lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_NDRbrvtVSUiOV-eyuilepA_6_8">272,640</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_UqfaQqRd1U-rmSnO35M5GQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_0jd_3DmtAUGsfjSZhW_CSQ_6_11">237</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_QLbiEq19A02perNXBXbTKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_-cWrWzSxTUGuKc3Tielrng_6_14">163,424</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_FAf8CRMgaUisICnAUnrSZQ_6_17">109,456</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Unrealized loss on investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_wy5Ete1m60Gp0JfLF-sD_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesTradingUnrealizedLoss" scale="3" id="Tc_x__rLLcLdECfUC8rFl93iw_7_11">270</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_3_31_2024_FUDixdV2nkO01qprXRWNww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesTradingUnrealizedLoss" scale="3" id="Tc_fWuMFRu_h0GGTtTN39c6DQ_7_17">270</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SOdnYt1ZJUmGZUp4nkZ_Dg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_w4KkMJkTIEWbp3Ke08YGgg_8_2">133,282</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pzSeRKqRmUWfGQi3u9vQfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_FVVP5ujeqUWHn8MqD6JSgg_8_8">704</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_3_31_2024_FUDixdV2nkO01qprXRWNww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_oD1ftKiaCkmEsewelFW56g_8_17">704</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SOdnYt1ZJUmGZUp4nkZ_Dg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc__sYvtQeFgkK9W-Lszw9XEQ_9_2">2,776</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pzSeRKqRmUWfGQi3u9vQfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Zt6bQxrQkkesUqC_f0ZI4w_10_8">4,200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_3_31_2024_FUDixdV2nkO01qprXRWNww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_azMg8rnUd0OmapXTTfg7jg_10_17">4,200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UlG_BWompUqeXJDTFYDksw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_q04W7aIuykeqPfKyMQJ8Xw_11_14">23,186</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_3_31_2024_FUDixdV2nkO01qprXRWNww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_szFxPg70M0ytsDPRaw0jNg_11_17">23,186</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hMDvqIPNTkyi3vwRMi3AWA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_CmelX3uT7Em7t7mvIi4tTQ_12_2">27,898,761</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hMDvqIPNTkyi3vwRMi3AWA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_AIVOqguwPES3iWQEZDRwyw_12_5">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vnVV5804C0ScsiBOSJ6srg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_yUpgQKE2CkClMnh_KXbw1Q_12_8">277,544</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Y99KaUn2oUW0_Rr118_mxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_w2TrMzUPTEuReLUglhNQHA_12_11">33</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CPH6za25g0uUfCifzsYkkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc__kWVVU5JQkiowvCk8I7S0Q_12_14">186,610</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_3_31_2024_qUiBx0SpzUGr9LR_aNTQUg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_-B7xH1I8akWHF_vyqbw6YQ_12_17">90,904</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Unrealized loss on investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_SfcoGV5hFkuKGuO_rvH3RA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesTradingUnrealizedLoss" scale="3" id="Tc_QO1rG9cp3kyOtxGmIQ3C4Q_13_11">50</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_1_2024_To_6_30_2024_gnY1UC1Lf0eSFvl6XWqbGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesTradingUnrealizedLoss" scale="3" id="Tc__5l8x85JlUaRnoLxiOZVjw_13_17">50</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock in connection with ATM, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gOVZr7JYNEKGhCeqwxOmnQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_qLOfWVZOr0Oc7IWZ3ZDW4w_14_2">800,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tfvBCfSvrEinR9S17WhtYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_02SdIrRfS02h18NvEdS9pA_14_8">23,635</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_1_2024_To_6_30_2024_gnY1UC1Lf0eSFvl6XWqbGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_rtrCEiy3F0Gpo8HJ3i9vZg_14_17">23,635</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gOVZr7JYNEKGhCeqwxOmnQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_bCH06vlDOE6rICSJapUFGw_15_2">119,239</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tfvBCfSvrEinR9S17WhtYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_C80A3kF-RUmVLnmXMy0vrw_15_8">511</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_1_2024_To_6_30_2024_gnY1UC1Lf0eSFvl6XWqbGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_5vtlkb9CRkKnMUo-mfmkNg_15_17">511</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock under ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gOVZr7JYNEKGhCeqwxOmnQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_OjmE5BqsQ0CSEvBBWG__-g_16_2">34,034</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tfvBCfSvrEinR9S17WhtYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_NdkJcl6Y2Ea-kkfxFZrLPA_16_8">308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_1_2024_To_6_30_2024_gnY1UC1Lf0eSFvl6XWqbGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_cj8oZVc73UKjzD2gE6eMjg_16_17">308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gOVZr7JYNEKGhCeqwxOmnQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_iamRJV1_vkujNHSOowgqqA_17_2">2,716</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tfvBCfSvrEinR9S17WhtYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_MHBb7UmS60qXq19e3ESzQw_18_8">3,865</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_1_2024_To_6_30_2024_gnY1UC1Lf0eSFvl6XWqbGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_wbwCGyztGkCzGlgwnNE3Vw_18_17">3,865</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nyimchTjV0KbghS9hcjUig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_4Bc8721pAEW5AYDETvA7QA_19_14">24,775</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_1_2024_To_6_30_2024_gnY1UC1Lf0eSFvl6XWqbGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_GqxTNvx0TkKYuGRmvG741w_19_17">24,775</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_geY3vwOu-UyPu9NwOyIAkw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_G8Go8_usqkKYCdXxw4W-VA_20_2">28,854,750</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_geY3vwOu-UyPu9NwOyIAkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_N7kFbsoq_kK4SDNCGnnLNg_20_5">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Y6cZV9QIL0C4SojMpiXIJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_uMCRDQBE8kKGbJVP00ibWQ_20_8">305,863</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_lCewvdNJxkWfBMMcTCfUEA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_6lkQ9-v95EOBsjEsPkRUbA_20_11">83</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_FsIjL_FCA0ypY_AxEKEtOA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_EO7m3lGTFUmunGHJe-AYqw_20_14">211,385</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_6_30_2024_V-lvpQAYG0u0LVvYzwbGTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_uqkaEq62MEecPNvHb1x5Zg_20_17">94,398</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Unrealized gain on investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_s-ZbaqOFEkqsqlAtFTXFQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesTradingUnrealizedGain" scale="3" id="Tc_wV0a0MhSFECDk16nfcKF6w_21_11">307</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesTradingUnrealizedGain" scale="3" id="Tc_wQ7KEi79VkOrHzXjoefRaA_21_17">307</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1mDefc7T6EyF8Qo5feNffg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_l2ZzUrwUukKAgR530ycMbw_22_2">12,961</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FLsOS9KJZUm-Ldlf9yt1hQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_YvxgOxflxEmq6CvGHPMKDQ_22_8">22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc__0g7WRAvjEqKTAVJCwIeng_22_17">22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FLsOS9KJZUm-Ldlf9yt1hQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_pa77q3qIJ0CHhvozHokvdw_23_8">2,003</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_XWLm4faWykSeZto8nLlgPw_23_17">2,003</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_j8k9mWHPuUaAW-sNf4hesg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_SsEr_uDqM0-hfw0MD9SZ0Q_24_14">16,237</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_u5uyPPqZJEOybvSor04g1w_24_17">16,237</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__iWQPWvZwkOiM4XiYpOJ7Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_KuE6JWb4c0KvMhrpS1NAkw_25_2">28,867,711</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__iWQPWvZwkOiM4XiYpOJ7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_5s53vdM3YUWN-cOrArEdxA_25_5">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2AicAM6JCEOlEUXMi5ktng" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc__CjIxsKujU6gjh6CAJcQ7g_25_8">307,888</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_vPXXIZakVEKr1VLr1ptsQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Cexm2fNI_0aMqktasJwN7w_25_11">224</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_70YqRRSkWEWlj8cmh1CBtA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_i73oVoa40Eue_64zzv5qjw_25_14">227,622</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_L4J3edCl7kiV7kxG9o1bcw_25_17">80,493</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">See accompanying notes to unaudited interim condensed consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Aerovate Therapeutics,&#160;Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(in thousands, except share amounts)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><a id="_b1111512_a93f_4ff9_8335_d03840d64b87"></a><a id="Tc_RePR-wGHDUayG4sORJvdxQ_2_10"></a><a id="Tc_Q_572i5loUi-zNQMhG6Fwg_3_7"></a><a id="Tc_AyeTgpjr-UuJ4jJqQH8Tfw_3_10"></a><a id="Tc_AYvrMh_Bz0S1o2JxFZQ00w_3_16"></a><a id="Tc_-csuK6OS90248ykOSD_kxg_4_2"></a><a id="Tc_lH2DHCbZokewfsfAOzaEQQ_4_7"></a><a id="Tc_pxco1WDF8k20mJThqnM0WA_4_10"></a><a id="Tc_6Hnrg34zpUWnzB8J4DRJNQ_4_13"></a><a id="Tc_TyRxZ9_NQkipv-wAFq2l9g_4_16"></a><a id="Tc_zZ20FoQC0kGGs2XI3tIOZA_5_2"></a><a id="Tc_GyL24NXLcUqF4AaL9DKtLQ_5_4"></a><a id="Tc_0IzzwlBzeUyrXInOgOLOYQ_5_7"></a><a id="Tc_Vi_JVUmmB0WRuXIDlE4qEA_5_10"></a><a id="Tc_dY6g7buZJUKZ-olqYJMKyA_5_13"></a><a id="Tc_xXCkX2YUWUuxfkLffFfHjg_5_16"></a><a id="Tc_BZ3jP6YB8Ue4rWvWh7_p-w_6_0"></a><a id="Tc_HZ-5oCEcokCOSmTGI0C-WQ_6_4"></a><a id="Tc_F0oEQudFwUWC2fTkvsQanQ_6_7"></a><a id="Tc_EsdQP9D97ES5n048_7IADg_6_10"></a><a id="Tc_riJ-ulzj60S1FuAQCigDtg_6_13"></a><a id="Tc_XoVxD7XLOUGj6HiP0qlgqQ_6_16"></a><a id="Tc_rrErHkBTHUKqjnDGXztCYw_7_0"></a><a id="Tc_tw7rQzkTA0SVP-nKknM7EA_7_2"></a><a id="Tc_ZdBgmzKtRUiH4-O9zJvi1A_7_5"></a><a id="Tc_RXFHhVat9EaxPcZyOLO18A_7_8"></a><a id="Tc_Syuz6Ecwm0edY4ky5YzFrg_7_14"></a><a id="Tc_QE0LGFPT60OE7v63AVHz5g_8_0"></a><a id="Tc_unKRadptLEyJXlGq_v6Tdw_8_5"></a><a id="Tc_GvxG4btZlkS9iiY9lOrsLw_8_11"></a><a id="Tc_368e6-sedEWTBH75BSTeFQ_8_14"></a><a id="Tc_WY_N3eLEvUaEAw4fQU0s-Q_9_0"></a><a id="Tc_vi37d2hEwkq5FtNvHjuiMA_9_2"></a><a id="Tc_ExxyL-T44UCuVncggDWXHA_9_5"></a><a id="Tc_wngML_gnSUaZ_gMd81N3KA_9_11"></a><a id="Tc_rs4xSfAN7U6KzXdbA70l5Q_9_14"></a><a id="Tc__zMRv1gfBUCAdJsoebLN8g_10_0"></a><a id="Tc_FFPC3YwpuUqzGrXKfilmZA_10_2"></a><a id="Tc_vVxP3v_F4UCFaviloEW4qQ_10_5"></a><a id="Tc_vpPWqyXSSkabNKWbLhchxw_10_8"></a><a id="Tc_xevbkSCZiEafkO2hwUjdZQ_10_11"></a><a id="Tc_sjOmlQtJJkSK6JHyXtjUpg_11_0"></a><a id="Tc_D2VyOCSYw0Wu9UI1XguRjQ_11_4"></a><a id="Tc_jkBEvKEt30Kn7z3WVPdQ1A_11_7"></a><a id="Tc_xE-OoORL-UWrFwlKY-MafA_11_10"></a><a id="Tc_b2lfyez-70avquNLkOVmAQ_11_13"></a><a id="Tc_ELYqma0ISUSwLpCVTm5BdQ_11_16"></a><a id="Tc_WzSCJl758E2VStczS2HtBQ_12_0"></a><a id="Tc_BFNTJ9hBf0mxe6secaZzhw_12_2"></a><a id="Tc_fmFi3AXpnUyfbo-1NOFbdg_12_5"></a><a id="Tc_YHrnFIIJD0Oye1qO7ncWPw_12_8"></a><a id="Tc_WgyWoiHubUGXirllPnrFHQ_12_14"></a><a id="Tc_Dpy4xz4s4Ua8VB5MZEv6ag_13_0"></a><a id="Tc_jqmwxmV4YEqX4LLIW9QZ2g_13_11"></a><a id="Tc_4_gp2YK59kWPX5R0KWqQ6A_13_14"></a><a id="Tc_UJHMSS-_skSXaZUT5m0IAQ_14_0"></a><a id="Tc_vrq4dmGHi0KMD-aRPHvBzA_14_5"></a><a id="Tc_EZItVG76w0GQI6YDnfdv5w_14_11"></a><a id="Tc_eHEbUxGzk0yMz3IKyzoAEQ_14_14"></a><a id="Tc_RufzbCaJWE2djiyTCxbDlQ_15_0"></a><a id="Tc_9G5SCzLXHEyX4BrFhVaK7g_15_5"></a><a id="Tc_K4kgDoETc0iLolQyV-nIJA_15_11"></a><a id="Tc_SeTyJl7s2kW8TDJL5MGs3g_15_14"></a><a id="Tc_omKeMRXNLkeVdJk3tKl5WQ_16_0"></a><a id="Tc_CGWdcm7Sf0OAqXulzT011g_16_5"></a><a id="Tc_QauvjGQcDEqJ3gB85p4gGQ_16_11"></a><a id="Tc_GsysE4lQV02OV7qtRs7jtQ_16_14"></a><a id="Tc_prs_llsrjUarSIIle9G31Q_16_17"></a><a id="Tc_D265An0JP0uiY01scSvhKg_17_0"></a><a id="Tc_LN-kPC8Ny0OST_-OG9oiGQ_17_2"></a><a id="Tc_gTLxwqwg1kunN0o-dqR3dA_17_5"></a><a id="Tc_H0mIEVefv0CYvzVuUuhGTA_17_11"></a><a id="Tc_LsPLDsvz-0GwW3BvXZom2A_17_14"></a><a id="Tc_-OquxnJhH020Hezav3PnAA_18_0"></a><a id="Tc_RUP3SVn8vkmKIRPN_kTbzg_18_2"></a><a id="Tc_8Gbc3LSszUmWocGrUzSzpQ_18_5"></a><a id="Tc_hYaq_xTshkOo4qdlzKBkaQ_18_8"></a><a id="Tc_B4j8lPXX10Kbd0UVn4y3-g_18_11"></a><a id="Tc_tIE-ZqnqH0ywB4_PPsc0mA_19_0"></a><a id="Tc_bXk0lkJ2zUKGDjHKHZchPA_19_4"></a><a id="Tc_l7SIQrtoi0iORcwqF0R20w_19_7"></a><a id="Tc__rCXWjWZWEu6whGHqbOb2Q_19_10"></a><a id="Tc_DeFSSJDqPEKfABBwjQew4Q_19_13"></a><a id="Tc_zfaDt91kZ0i3VQfPAWpV5A_19_16"></a><a id="Tc_BgXm2z4PVkyhIkZlDIH4ew_20_0"></a><a id="Tc_1VYEe2iyRUWofGBeAFBsng_20_2"></a><a id="Tc_XAUALucjmE6OBnFgM8n1qQ_20_5"></a><a id="Tc_Wp6hz704yU-dZQNKWn8sQQ_20_8"></a><a id="Tc_Zp9-e2RmWEGDTlG9uXBlsQ_20_14"></a><a id="Tc_55P7eTpn1UiIuI1S7hz_zQ_21_0"></a><a id="Tc_O3nR353_KkeQv5eKigS3iQ_21_5"></a><a id="Tc_ChV79KPokk6Y_RfHIWhfdQ_21_11"></a><a id="Tc_af3PXiotC0OQMK6ggLuRmA_21_14"></a><a id="Tc_B8b8btNssUmy3driTL99Hw_22_0"></a><a id="Tc_Z21a78FVOkOYw53wTE9wTg_22_5"></a><a id="Tc_p7TMMqIC_Ua-bq4NBcBvQA_22_8"></a><a id="Tc_0bNnhb5mYU-gpsL8Lyiqmg_22_11"></a><a id="Tc_jf2vZTCeCkC3KaMqJ9AwkQ_22_14"></a><a id="Tc_S3nrUMAJdU6uy4FYDI0xKw_22_17"></a><a id="Tc_U441QObOp0SpMT56RREsiQ_23_0"></a><a id="Tc_MVTX1NLXJ0OvNanZR1Xfmw_23_2"></a><a id="Tc_8WulzR0Al0-KxbwJBUsH0Q_23_5"></a><a id="Tc_SYjE-RRUSE2J-gZaWwnXgg_23_11"></a><a id="Tc_0xiJFnnYUkey00kY5LN4kQ_23_14"></a><a id="Tc_X9zCOukHKEal5bOxeHov9Q_24_0"></a><a id="Tc_f0kpp15rK0uUX0GehThyrg_24_2"></a><a id="Tc_GTSITmO1oUqDy35qOagfGg_24_5"></a><a id="Tc_gxKUsH02yEyUE3rn8bO2qw_24_8"></a><a id="Tc_vFy8giwlKEOotfHlMfrw_A_24_11"></a><a id="Tc_D3enamq92UeQLFFdSe7bAA_25_0"></a><a id="Tc_xZTewgAOA0OionrfzsuNLQ_25_4"></a><a id="Tc__5OaQP66LUmP1w1HB_YoLg_25_7"></a><a id="Tc_OkBR_I_BpEuFjBoe3YlHXg_25_10"></a><a id="Tc_DWnleYH4z0Ci26yMPVVNJg_25_13"></a><a id="Tc_l6uYNgBWhUmqXIW19jUwRA_25_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gain/(Loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bPKy-329i0a269T7iYdlfQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_26CjU_r46U-ywbx_uOnwJQ_6_2">24,722,974</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bPKy-329i0a269T7iYdlfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_KD4RPcTdw0qFF1agC3DU9g_6_5">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dcFzNA8x9Ui_AjpnWINDyw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_A7wgAM2f606C774lXHH_Zg_6_8">215,110</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QECF8CV7f0Kgvhlc6flPyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_QteWIGgzwUi5EBosZUS3iA_6_11">466</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_a5ipJvXbekyb6Q7U_qk5JA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_c9RShHStj0Oz_tcc4f6MsA_6_14">87,903</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_AunStqKsvEaUaZXPyK_CUw_6_17">126,743</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Unrealized gain on investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rSCB_jEoQUWrJ9udMpqr1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesTradingUnrealizedGain" scale="3" id="Tc_ppChjoJ7hkqSXUF3PyqGqQ_7_11">265</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_3_31_2023_tdpGz56jqk6Dn9XNb5jQVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesTradingUnrealizedGain" scale="3" id="Tc__lzlGv3YD0yGN_pxlO5SKg_7_17">265</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mK0glKtp20-JMUhi6bQzgA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_2RqRIQ4cmkSv1-2m5hUgdw_8_2">93,966</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_G7iErj3me0qVgh1ge_DiqA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_z6KPfaCfv0WfJSM6csDK-Q_8_8">223</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_3_31_2023_tdpGz56jqk6Dn9XNb5jQVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_ZiDe5JGFTE-xxeUmlKvlVQ_8_17">223</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_G7iErj3me0qVgh1ge_DiqA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_lQAlM8Q7T0qOtVeBDctsOg_9_8">2,384</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_3_31_2023_tdpGz56jqk6Dn9XNb5jQVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_uXYtah8rjE23yTD1ExKqEw_9_17">2,384</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aXw1Zj8XYkqQuwDSYY4ipw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_zwAOPORKN0yaMafLK9ktqg_10_14">16,520</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_3_31_2023_tdpGz56jqk6Dn9XNb5jQVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_cD0X646oVkOJzm_z_JSNJQ_10_17">16,520</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vWNBs-3fkEi8yguhaSbYeg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_WWVAVP2ifk2PX3y9Cv3-Jw_11_2">24,816,940</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vWNBs-3fkEi8yguhaSbYeg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_-RaB64vP4EWOkboen83GzQ_11_5">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HWbpxkODu0WkRFHnGDEkSA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_1o0gi8VSxk2I6hvjKcNw-g_11_8">217,717</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_HyF9ifdj0Ui9zRFDa7dqYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_dH1F0mLtaUCop_imy5pRng_11_11">201</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_M2y81zs0L0Oc7hgVHJlBTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_RKliB1m5JU6PX1e6_fXgkg_11_14">104,423</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_3_31_2023_Ju0lA-npTUKKlfj1h0_hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_UNYjWk10nk21q8Wt_VfUVg_11_17">113,095</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Unrealized loss on investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_g1st23sQ50KGJ_c8e9kcQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesTradingUnrealizedLoss" scale="3" id="Tc_mL8QO2cguEyCdVCjeuOY9w_12_11">22</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_1_2023_To_6_30_2023_0RTLeeNjREWrXNlRldBizg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesTradingUnrealizedLoss" scale="3" id="Tc_Y4i81sf9_U6-9vmHSs5Xhg_12_17">22</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock in connection with ATM, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K4s3v6nxgU-obbx2d9aSOQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_y_lLILLFREOSqjAmp1L2GA_13_2">2,662,721</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K4s3v6nxgU-obbx2d9aSOQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_r1ywNZufPEuhvyaSJt9QsA_13_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3YNubJsuwUyt1b4HmIVa7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_VyXls7xKe0Ceaa2c_pX_zw_13_8">44,282</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_1_2023_To_6_30_2023_0RTLeeNjREWrXNlRldBizg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_kXyF5rL0Fk225FCvcZzhCg_13_17">44,283</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K4s3v6nxgU-obbx2d9aSOQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_Mk3DH5W180mzHcbazrpIMQ_14_2">106,756</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3YNubJsuwUyt1b4HmIVa7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_pLDlRnZ0c0KNy5mEOuJZFg_14_8">333</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_1_2023_To_6_30_2023_0RTLeeNjREWrXNlRldBizg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_AdCPnLOgXkmaJOaRzLqjCg_14_17">333</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock under ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K4s3v6nxgU-obbx2d9aSOQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_IXot23xYX0OPXvHQZH-82w_15_2">13,866</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3YNubJsuwUyt1b4HmIVa7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_zuGIY3fCEkibCObjrkMnBQ_15_8">228</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_1_2023_To_6_30_2023_0RTLeeNjREWrXNlRldBizg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_MyvhA47FB0yduYPNqfGg-A_15_17">228</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K4s3v6nxgU-obbx2d9aSOQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_TE3nbg3WQ02k0d3Ltm-mJQ_16_2">815</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3YNubJsuwUyt1b4HmIVa7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Y3l19lKGgESZyezKRUNPxw_17_8">3,034</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_1_2023_To_6_30_2023_0RTLeeNjREWrXNlRldBizg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Fa3Xf_e7T0yqycbie9OECg_17_17">3,034</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fB9Oej3iHEuLzftkJpBxOA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_XClkJSvLsEyXZiR_aULDgQ_18_14">19,025</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_1_2023_To_6_30_2023_0RTLeeNjREWrXNlRldBizg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_qVyXMPEkG0eY-z6fMYXRTw_18_17">19,025</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uKGL0eef7kyr6Ltc79lK9A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_5J78XPTUA0KKbGxL_obWxQ_19_2">27,601,098</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uKGL0eef7kyr6Ltc79lK9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_SHgleWoQmUuPuSjuoTPrLA_19_5">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VpGpQUz2xki0YzMNgZlDQw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ClsL4e0EAk207zUqCsTYhw_19_8">265,594</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_afA-gfdpa02BAMGQN_YZBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_zMGIiR7JO0KEL6KEyek_NA_19_11">223</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KPy_Azxvr0mBNfoqRZD5Ew" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_VjUg43PmK02IWo-_I3oZqA_19_14">123,448</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_6_30_2023_HPAMtIcY9Eq1U2SHfyr_uw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_kiO17TBk00qbExTcYniB_w_19_17">141,926</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Unrealized gain on investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_R1aNdniYp0yg5IJCGgDujA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesTradingUnrealizedGain" scale="3" id="Tc_mDdRxX8TDk-M7B-clRFqXA_20_11">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesTradingUnrealizedGain" scale="3" id="Tc_Xaq8q4KfgEmFjg3G5ShEcA_20_17">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eIQAEotTfU2ghqhEOp-9tQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_Dl1F9TYhxUSGtuqz1922YQ_21_2">46,777</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ImI5-uZhs02-PHLXTrl4zw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_FLt95P4Ho0WROvs4RXAqBQ_21_8">95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_QKc09OVYNUmbKHKMrhVsgw_21_17">95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eIQAEotTfU2ghqhEOp-9tQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_JscBdlx1kUK1GIX09MfbsQ_22_2">5,312</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ImI5-uZhs02-PHLXTrl4zw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_1-zJZk_ukUqLkAtCVzXyhw_23_8">3,237</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_oa7Ks0PNU0SGvP_uzdGfaw_23_17">3,237</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pv40wdBMdU2Z1HGOA_ocaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_B8xt0uovM0iaEuYBDFUh_Q_24_14">19,563</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_oP2KlMRgYUmR8XQqRjtzQQ_24_17">19,563</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HmDl-Xe2CkiW7tLgrbq_Fg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_hcRKka8sRUSOEgYxSp_fCA_25_2">27,653,187</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HmDl-Xe2CkiW7tLgrbq_Fg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_dA6N0Nv6oUuRXASKlrkTbQ_25_5">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZE61xkcRkUCNaq4gU5yrWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_S2gT69xcr0-UzpbVWkuVIg_25_8">268,926</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FJ3Ctxrxc0CDo2XUQUe3QA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_0jMWORoAyUuhupNCyuOS2Q_25_11">195</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UCLAdEOov0OXILzRhTTw3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_gI4qR04LpES7C0MfkOXKtw_25_14">143,011</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2023_e-zMRu88YEulFM6FDn839A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_j76AhuuuKUeSX2PnNPVt3Q_25_17">125,723</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">See accompanying notes to unaudited interim condensed consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_74a6e4b6_0f4c_46df_878c_a3fc838d3671"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Aerovate Therapeutics,&#160;Inc.</b></p><a id="CondensedConsolidatedStatementsofCashFlo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_87ebcd24_de68_4849_aa78_f8dd5dc877ce"></a><a id="Tc_MOB1SVP7PkiZ-5xxMq-IRw_1_2"></a><a id="Tc_dlkj1Nk2aUWmRtHqDv1ydg_2_2"></a><a id="Tc_zWdGxG0MBUab_gDLUIRv1A_2_5"></a><a id="Tc__icNAeisDkyDIgkM3o0QJQ_3_0"></a><a id="Tc_nx8fSoOgxEKoYkm1_7RM9A_4_0"></a><a id="Tc_ySeIKBe8SUKHif42mi9IMQ_4_2"></a><a id="Tc_z3mxGDPGFkiSUFjmpXxKyw_4_5"></a><a id="Tc_BhTSelr-aEiEB8Doy74Z6A_5_0"></a><a id="Tc_o5kGaQ27BEKbkjJ8VHPezg_6_0"></a><a id="Tc_h6-fOJGaek2wjIHQRAIaPQ_7_0"></a><a id="Tc_cYZzLq0M40qYi_w9GGsevA_8_0"></a><a id="Tc_S3gtj80hSU-XQ8wtOJuRrA_9_0"></a><a id="Tc_jj18tmXFrECm-TGEtEL_wQ_10_0"></a><a id="Tc_zBHUC8MOq0mNNLyWUdIhRg_11_0"></a><a id="Tc_SwRXVAppS0KKef3BlDG78Q_12_0"></a><a id="Tc_z4UW0zloVkOLuh555jnp1g_13_0"></a><a id="Tc_qghyBAPx50m-JnDCdSGytA_14_0"></a><a id="Tc_A5Cx7zjo0US55LXFsxmsRA_15_0"></a><a id="Tc_oCdvtYp8p0uk9dvhrA1h-A_16_0"></a><a id="Tc_S1ZamCh6_UWZPHjjlgnKaA_16_2"></a><a id="Tc_4C6CEAUVrUa7KAr54L1I9A_16_5"></a><a id="Tc_zREfKvyLqkiJiScx8ogUdg_18_0"></a><a id="Tc_1BlU18oHbEmGgyQSWfFatQ_19_0"></a><a id="Tc_TMjSvtyA30-AwfZlhRVacQ_20_0"></a><a id="Tc_0BkRDewkYUCPq9kv5NIXEw_21_0"></a><a id="Tc_2Uqg-HVQqEOIwEYb4Pmzpg_21_3"></a><a id="Tc_w_QrRF-EakiHnYZJXeNDNw_22_0"></a><a id="Tc_-wKtAzWQxku3mkW6rAqwuw_22_2"></a><a id="Tc_DZpEdjo8r0CWzN2h9RxlHQ_22_5"></a><a id="Tc_Uc50serFi0Wu5CFoNLT1sQ_24_0"></a><a id="Tc_nYlA_rEqYUC31fZb9n7C5w_25_0"></a><a id="Tc_FBtJD8t73U-oil9Wl_eJOw_26_0"></a><a id="Tc_UZ_GNeGbIkag9Dba5MRIzw_27_0"></a><a id="Tc_Bi23YJD8GUq2HMPzHi4IQA_28_0"></a><a id="Tc_4MwtmAEjnUmkD3WbFbCicQ_29_0"></a><a id="Tc_ILYCvqsz5U-vjT56gZYneg_29_2"></a><a id="Tc_1qgGeLuxhk2Qlfk7EXBuRg_29_5"></a><a id="Tc_KZIxyhxJQkSOG2yr75oNig_31_0"></a><a id="Tc__SYC5FnJj0GicwYq2zQhOA_32_0"></a><a id="Tc_ebM_Or37skiiloApzx21Qw_33_0"></a><a id="Tc_uH09nnJbqkmZSJ-yk6VnYg_33_2"></a><a id="Tc_gUOVbjMPZUKu1uVUl9TMoA_33_5"></a><a id="Tc_GG5pD6LSA0STSAHOYTdpZA_35_0"></a><a id="Tc_XlEuHaN4F0ejHSw1tJOibA_36_0"></a><a id="Tc_M9er0PF81EmFMqPABO-5kg_36_2"></a><a id="Tc_o6gJePkroEunG-4kuNMS7g_36_5"></a><a id="Tc_RCywB6O8DkqHOZoaZKtfpA_37_0"></a><a id="Tc_tj3SoCaJSkeT_SzyI8DtsQ_37_2"></a><a id="Tc_YDP2ykydS0eZAYjGJ_8Rqg_37_3"></a><a id="Tc_64lhWEzo00yFwxErc1606g_37_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine months ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flow from operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_SqqLDplXQEWR1kM3RiscRg_4_3">64,198</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_XoFSDrCfS0K2gS3iUa8BXg_4_6">55,108</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_b3_DWWHz70OmlXxOBM6DFw_6_3">10,068</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_b2ug1va7Kk6FOqW1bzsICg_6_6">8,655</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Depreciation and amortization expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_UZupSwxS1ki2rNaGcB6TNg_7_3">274</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_6u56ZWMoCUuZcDnMTjEfEg_7_6">68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accretion of discounts and amortization of premiums on investments, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="avte:AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet" sign="-" scale="3" id="Tc_lny9i8EMM0u84tSnMcwBPQ_8_3">1,912</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="avte:AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet" sign="-" scale="3" id="Tc_wXLFxkB0M0mYxastdf3nxg_8_6">2,118</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_c_06Pps3z025bQ7uFY7rjQ_10_3">82</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_UwIHUIvkT02H0XhVdzOhBQ_10_6">128</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other long-term assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" sign="-" scale="3" id="Tc_8U4vKg-XwkOAUaQXFYDHXw_11_3">789</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="Tc_-jrMh1p9fUqcmqmr_9iQuQ_11_6">70</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_8oDgq9-_8kGnwxc2NvUtVQ_12_3">1,488</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_5NUeBzCDH0iygBkhuOghpA_12_6">880</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accrued and other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" sign="-" scale="3" id="Tc_q69qn_pL30SPYBBsZDMl3w_13_3">4,152</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="Tc_bMrANz53iky5ciq8yf45cQ_13_6">5,948</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease assets and liabilities, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="avte:IncreaseDecreaseInOperatingLeaseAssetAndLiability" scale="3" id="Tc_LhjVMartlEmOXjtb31f_Gw_14_3">220</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="avte:IncreaseDecreaseInOperatingLeaseAssetAndLiability" scale="3" id="Tc_IuRW7OtQAEW5fonMW0mTRA_14_6">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="Tc_7_IbIVcMekGZ7cpUEzlvjw_15_3">332</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" sign="-" scale="3" id="Tc_3Hxr-sIeJkaEZmU6eZOpJg_15_6">114</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_Ld9tr6tYJUeklHVFdqqAmw_16_3">60,149</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_jXby8AlJNEa-TgpT6mfR3Q_16_6">41,978</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flow from investing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Purchases of short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="3" id="Tc_ohogI6p1o0OumIj4m9Xqbw_19_3">19,683</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="3" id="Tc_A6KdyiVqZ0OL-FsT-AMhVw_19_6">96,194</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Maturities of short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" scale="3" id="Tc_6ZomomRwaEa2KvFrDjW_cA_20_3">62,583</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" scale="3" id="Tc_5PTQS7364Eu5WmyL8-P7tA_20_6">102,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_Egi13x0AqUmSqdls2ihuYw_21_6">78</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_MOIxRA3KcECVc1nSW_hzBg_22_3">42,900</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_-KWpu_mMMEyjaznduh3gPQ_22_6">6,228</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flow from financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from sale of common stock in connection with ATM, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc__-BYFJ_g2UOkUesRfphulQ_25_3">23,635</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_WONyAUeypkqrNCQZ5CamDQ_25_6">44,888</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Payments for offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_8MtlZvkkG0qSc2ZOMfNRBA_26_3">307</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_PF_H_6afvU-q8uTsSLvlYA_26_6">234</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from issuance of common stock under ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="Tc_P2l_M3R-nUelPpnk83lfkA_27_3">308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="Tc__Y6K9NB0nUieaeVqJ8FVjw_27_6">228</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from issuance of common stock upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_OSsSnvOY3kC2RNrjdsF-0A_28_3">1,237</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_vNbLyUUPakWroclQIU0Lew_28_6">651</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_mzMtoAoPUEytk4YLMSEtKg_29_3">24,873</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_2w-14Kc4sUSwfLcrToMn3A_29_6">45,533</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_mFdLP53gvUWJILIh8MfiPg_31_3">7,624</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_uQG0L2E5PkSYSgW3yA1LOA_31_6">9,783</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents at the beginning of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="Tc_oVtGMxCOt0Od-0M5oKNwAA_32_3">23,491</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="Tc_5pBLSG8H1ES3fTHD6PtJ9Q_32_6">22,397</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents at the end of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="Tc_cFK9n2Frs0yJONQQ4P2l9Q_33_3">31,115</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2023_e-zMRu88YEulFM6FDn839A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="Tc_N2sLNBY7tke8BydLdy5B6g_33_6">32,180</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Supplemental disclosure of noncash investing and financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Right-of-use asset obtained in exchange for operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_dbT5RexU3kWKVKEUmPld0w_36_3">206</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_4JwO-qU5RkW6VPbwSIIzwQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Purchases of property and equipment in accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_lBTrZfa0rEuijq81Gr4tUw_37_6">64</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">See accompanying notes to unaudited interim condensed consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_Hlk181793979"></a><a id="_759518ea_2eda_4877_8b5e_6d5704e32a04"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">AEROVATE THERAPEUTICS,&#160;INC.</b></p><a id="NOTESTOUNAUDITEDINTERIMCONDENSEDCONSOLID"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES&#160;TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_zujOrBdYI06EOELAYaoyRg" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">(1)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">ORGANIZATION AND NATURE OF OPERATIONS</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Organization and Nature of Operations</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate Therapeutics Inc. (&#8220;Aerovate&#8221; or the &#8220;Company&#8221;) was incorporated in the state of Delaware in July 2018, and is headquartered in Waltham, Massachusetts. The Company has a wholly owned subsidiary, Aerovate Securities Corporation. The Company is a biopharmaceutical company. The Company&#8217;s initial focus was on advancing AV-101, the Company&#8217;s dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (&#8220;PAH&#8221;). However, in June 2024, the Company announced negative results from the Phase 2b portion of its global Phase 2b/Phase 3 trial of AV-101 in adults with PAH, and, as a result, the Company decided to halt enrollment and shut down the Phase 3 portion of the Phase 2b/Phase 3 trial as well as the long-term extension study. In June 2024, the Company announced a corporate restructuring and in July 2024, the Company engaged Wedbush PacGrow as the Company&#8217;s exclusive strategic financial advisor to assist in the process of exploring strategic alternatives, including but not limited to an acquisition, merger, reverse merger, business combination, liquidation or other transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 30, 2024, the Company entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), by and among the Company, Caribbean Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (&#8220;Merger Sub I&#8221;), Caribbean Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of the Company (&#8220;Merger Sub II&#8221; and together with Merger Sub I, the &#8220;Merger Subs&#8221;), and Jade Biosciences, Inc., a Delaware corporation (&#8220;Jade&#8221;), pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, among other things, Merger Sub I will merge with and into Jade, with Jade surviving the merger as the surviving corporation (the &#8220;First Merger&#8221;), and as part of the same overall transaction, Jade will merge with and into Merger Sub II, with Merger Sub II continuing as a wholly owned subsidiary of the Company and the surviving corporation of the merger (the &#8220;Second Merger&#8221; and together with the First Merger, the &#8220;Merger&#8221;). In addition, in connection with the closing of the Merger (the &#8220;Closing&#8221;), the Company expects to declare a cash dividend to its pre-Merger stockholders of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_10_30_2024_To_10_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_RPVQa3dXU0OggwPnCBtwgg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="Narr_Lzx7Rhe5BUSSm3uxGQh6Jw">65.0</ix:nonFraction> million in the aggregate (the &#8220;Cash Dividend&#8221;), provided such amount is subject to adjustment as set forth in the Merger Agreement. The Merger was approved by the Company&#8217;s board of directors (the &#8220;Board&#8221;), and the Board resolved to recommend approval of the Merger Agreement to the Company&#8217;s stockholders. The Closing is subject to approval by the stockholders of the Company and Jade as well as other customary closing conditions, including the effectiveness of a registration statement filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) in connection with the transaction. If the Merger is completed, the business of Jade will continue as the business of the combined company.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">At-the-Market Offering </span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 5, 2023, the Company entered into an ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement (the &#8220;Sales Agreement&#8221;) with BofA Securities, Inc., or the Agent, pursuant to which the Company can sell, from time to time, at its option, up to an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_5_2023_To_4_5_2023_srt_CounterpartyNameAxis_avte_BofaSecuritiesInc.Member_eXGnRQpI10OVMaKnBBIqeg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_I5iiZJLdS0CqIBelce0_2g">75.0</ix:nonFraction> million of shares of its common stock, through the Agent, as its sales agent. As of September 30,&#160;2024, <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2024_To_9_30_2024_srt_CounterpartyNameAxis_avte_BofaSecuritiesInc.Member_fT8d84SKjEiyXJr9wvIUUw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_GbxUO2U9akavOoe8RGXiLw">3,462,721</ix:nonFraction> shares have been sold under the Sales Agreement, generating $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_srt_CounterpartyNameAxis_avte_BofaSecuritiesInc.Member_fT8d84SKjEiyXJr9wvIUUw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_BumIMhUE30SjA2Z31dH-Lg">67.9</ix:nonFraction> million of net proceeds after deducting commissions to the Agent and other offering costs. As of the date of this Quarterly Report on Form 10-Q, up to $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_srt_CounterpartyNameAxis_avte_BofaSecuritiesInc.Member_IwOYf_4k8kOpNBRHvM5Rxg" decimals="-5" format="ixt:numdotdecimal" name="avte:ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram" scale="6" id="Narr_Xn4X9U0ImEupPF_e0hf6qQ">6.0</ix:nonFraction> million of shares of the Company&#8217;s common stock remain available for sale from time to time under the Sales Agreement. </p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity and Management Plans</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since inception, the Company has devoted substantially all of its resources to research and development activities, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations and has not realized revenues from its planned principal operations. The Company has incurred losses and negative cash flows from operations since inception. As of September&#160;30,&#160;2024, the Company had cash and cash equivalents and short-term investments of $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="Narr_GsFQW6bRskmzApzgg-tEbw">88.7</ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management believes that the Company&#8217;s current cash and cash equivalents and short-term investments will provide sufficient funds to enable the Company to meet its obligations for at least twelve&#160;months from the filing date of this report while it explores strategic alternatives.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_wV-NldgiKUy_eUUZnqXDqw" continuedAt="Tb_wV-NldgiKUy_eUUZnqXDqw_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">(2)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</b></p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_BCR_htwfwkmfmtb2HHvgzg" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements as of September&#160;30,&#160;2024 and for the three and nine months ended September&#160;30,&#160;2024 and 2023 have been prepared in conformity with generally accepted accounting principles (&#8220;GAAP&#8221;) in the United States of America for interim financial information and pursuant to Article&#160;10 of Regulation S-X of the Securities Act of 1933, as amended (the Securities Act). Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include only normal and recurring adjustments that the Company believes are necessary to fairly state the Company&#8217;s financial position and the results of its operations and cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The results for the three and nine months ended September&#160;30,&#160;2024 are not necessarily indicative of the results expected for the full fiscal&#160;year or any subsequent interim period. The condensed consolidated balance sheet as of December&#160;31,&#160;2023 has been derived from the audited financial statements at that date but does not include all disclosures required by GAAP for complete financial statements. Because all of the disclosures required by GAAP for complete financial statements are not included herein, these unaudited condensed consolidated financial statements and the notes accompanying them should be read in conjunction with the Company&#8217;s audited financial statements for the&#160;year ended December&#160;31,&#160;2023. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="us-gaap:UseOfEstimates" id="Tb__8b-AM4p10Gouw7MNRlYdg" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the Company&#8217;s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. Accounting estimates and management judgements reflected in the consolidated financial statements include: normal recurring accruals, including the accrual for research and development expenses, stock-based compensation, fair value of investments, and operating lease right-of-use assets and lease liabilities. Estimates and assumptions are reviewed quarterly. Any revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_C9pY79J1rECAk5mO9zgOrA" continuedAt="Tb_C9pY79J1rECAk5mO9zgOrA_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Net Loss Per Share</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company&#8217;s potentially dilutive securities have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_a29392f9_f492_40e9_8587_4be9ca8d2fc5"></a><a id="_1fb6ace7_44d3_4806_8308_c6b14b6f4823"></a><a id="Tc_UsVq5ZpEZE2CxP56iB9Hvg_1_2"></a><a id="Tc_NdrecrQ-NkKBuyBNVnMPXA_1_8"></a><a id="Tc_Gb1N5pepW0mk3E9vdsbFTg_2_2"></a><a id="Tc_7eLwNTScCUG8JuFTRL7yhA_2_5"></a><a id="Tc_afFEWIsnHEq4UQpQp2SPTw_2_8"></a><a id="Tc_ADC_pz3dIkCfed6-ROW1rg_2_11"></a><a id="Tc_h50U-nnix0uIc8wEvok2TQ_3_0"></a><a id="Tc_f4J3gz0plEOKDv6sm9vgPg_4_0"></a><a id="Tc_DOCA_AXOsUaawAhBjfwuFA_4_2"></a><a id="Tc_bwdxlEffNUGMJOeySdZhHA_4_5"></a><a id="Tc_WMO-EUIGKUi2JK5fYrsdcw_4_8"></a><a id="Tc_ha5Ypa-KJkK5kYLSBwmu4Q_4_11"></a><a id="Tc_lIG-Vsw_EkuC31VpezB15A_5_0"></a><a id="Tc_ASRpmd5u40SlLtz6qPPKXg_5_2"></a><a id="Tc_WpCfSdQ2qEebXTa3cJo7Xw_5_5"></a><a id="Tc_YWWcwYwrY0Gf560nOXZAuA_5_8"></a><a id="Tc_U8F3jDhEm0m3dzGU4vS3Dw_5_11"></a><a id="Tc_GyGXjaYvvEufQZESosUU3g_7_0"></a><a id="Tc_Pga0lCrYY0KSskvOXfBm6A_8_0"></a><a id="Tc_kGaRi6fLpUSQfJA3FSocmw_9_0"></a><a id="Tc_us9GOW9FmEW0VGoPxiCSow_9_2"></a><a id="Tc_rgI_dqHGp027DDP-QnQj5g_9_5"></a><a id="Tc_zF1SHrM810-rqQmZ9JvNBA_9_8"></a><a id="Tc_EM_wp5kiNUiVLO1z114piw_9_11"></a><a id="_00181180_da5b_46b3_8e98_48baaeea5499"></a><a id="Tc_cdoZnFfC4EuEENAIEHMK0w_1_2"></a><a id="Tc_9AG4Fs81Ek2xELZNwHpeUQ_2_2"></a><a id="Tc_k89ID0TXpUOlEEOnkIqM6A_2_4"></a><a id="Tc_WgxBHNmNgk2gDx7NKkxBXQ_3_0"></a><a id="Tc_yRntO8x-SUSFsurXcdPB8g_4_0"></a><a id="Tc_idUMt-5ciEaDz-W7o7Jvmw_4_2"></a><ix:continuation id="Tb_wV-NldgiKUy_eUUZnqXDqw_cont1"><ix:continuation id="Tb_C9pY79J1rECAk5mO9zgOrA_cont1"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_CKYVPL39J0yWu-xvaAkjbA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes the Company&#8217;s net loss per share (in thousands, except share and per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_-83OVHfMIkSwb-tdy1JqFQ_4_3">16,237</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_qixUwQnv-02L5rDwU7UoGw_4_6">19,563</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_aN99tfUU-UOrspO3lVIKTQ_4_9">64,198</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_bD_ZL9mbjUeheuxnf6VU5Q_4_12">55,108</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_mwgzOFmLx0uQXLw8_btDrQ_5_3">16,237</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_eDLW03SnZEaWnejqeRLr0w_5_6">19,563</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_KsPFpfBlLUCTnzAjb7pVug_5_9">64,198</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_jYu9KqWJWUqiisFa_f0RIQ_5_12">55,108</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Weighted-average common stock outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_Ibmunrc0ok2QIc7oFSZMmA_8_3"><ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_Ibmunrc0ok2QIc7oFSZMmA_8_3_2">28,863,327</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_lH_9GLLK0kWZfKq_eqiTFA_8_6"><ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_lH_9GLLK0kWZfKq_eqiTFA_8_6_2">27,640,542</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_sdFdOGJK2kilWqDWQgfnVQ_8_9"><ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_sdFdOGJK2kilWqDWQgfnVQ_8_9_2">28,572,338</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_lQgneF1lqkiWExX25ervXw_8_12"><ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_lQgneF1lqkiWExX25ervXw_8_12_2">25,872,118</ix:nonFraction></ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_70wLo5FSgUqSrC4lvGn84A_9_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_70wLo5FSgUqSrC4lvGn84A_9_3_2">0.56</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_mEjpmUOTv06joGt5hl9E-g_9_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_mEjpmUOTv06joGt5hl9E-g_9_6_2">0.71</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_rmOxV2zIKkeKaveib3fHHg_9_9"><ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_rmOxV2zIKkeKaveib3fHHg_9_9_2">2.25</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_b_R4Mz4450W5Q0OMVqw8Ng_9_12"><ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_b_R4Mz4450W5Q0OMVqw8Ng_9_12_2">2.13</ix:nonFraction></ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_Gc6r7TT1REmScK7ALpx_pQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:61.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ZpDGpfQ1TkilwLHCKcIxnw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_clkRSW2KE0aPeJGXW1W0nw_3_2">3,714,104</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_VNugwlI_n0evghUr12SqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_tEUfQ6MuHEyNS-BD-BGtdw_3_4">5,236,832</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:61.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_shfv-0j6hE2RH9wjzcjK0Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_4QgYzic0t0KJYMghZHKcpA_4_4">25,754</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_UqQnY7D960KbdOTqv8F4nQ_5_2">3,714,104</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_aWIVjmOFsUyIiV83ac1zxA_5_4">5,262,586</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_oUY-DeqcN0exZqb8kk5Z2w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(d)</span></span><span style="font-style:italic;font-weight:bold;">Recently Issued and Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In November 2023, the FASB issued ASU 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280)</i>: Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments&#8217; significant expenses on an interim and annual basis. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Entities must adopt the changes to the segment reporting guidance on a retrospective basis, and early adoption is permitted. The Company does not anticipate this ASU to materially impact our consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In December 2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740)</i>: Improvements to Income Tax Disclosures, which expands disclosures in an entity&#8217;s income tax rate reconciliation table and regarding cash taxes paid both in the U.S. and foreign jurisdictions. The standard is effective for fiscal years beginning after December 15, 2024, and interim periods in fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact the adoption of this standard may have on its consolidated financial statements and related disclosures, and does not anticipate this ASU to materially impact our consolidated financial statements and related disclosures.</p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_02681e32_95dc_47c1_9021_95086328ea10"></a><a id="Tc_9Azqh8HRY0iLxHaHCP4Qaw_1_5"></a><a id="Tc_FI70KO5HYkuVUvQ1QZMFOg_2_5"></a><a id="Tc_9jQe7ko-fkiD_uRzhKV81g_3_5"></a><a id="Tc_PBXe4OFSaUyzs2xfCH8DFA_3_8"></a><a id="Tc_3N0DFj81vUSJXDJ25_RqRg_3_11"></a><a id="Tc_F129rpG4PU67o_f3I9Onkg_4_5"></a><a id="Tc_CFhUWmcLmkuZqOruagc9UA_4_8"></a><a id="Tc_hRdgapQIekee5n0kpIu2tg_4_11"></a><a id="Tc_EdpTHQ5Vik2wZ8FAJSLS5Q_5_2"></a><a id="Tc_HMkRPEkpiECxJJtNG9WtIw_5_5"></a><a id="Tc_ZB0_QcSjukyNVWaunETzHg_5_8"></a><a id="Tc_SRatWQcIBkuOpSHO0qREyw_5_11"></a><a id="Tc_zLj_kuCXskGFSOdi9IOx7w_6_2"></a><a id="Tc_mw4K_D88JkKvUqtXWyTneg_6_5"></a><a id="Tc_tpGN6fQ0l0GD51Pk9PhIpQ_6_8"></a><a id="Tc_2oxgAPUXOUifVLxaAbALog_6_11"></a><a id="Tc_THyR35WoJU-SM4w6a2MsUQ_7_0"></a><a id="Tc_B4bkRqgpxE2-EgToM-l4DQ_8_0"></a><a id="Tc_983SiYZ9PE-bUUjb3wBymQ_9_0"></a><a id="Tc_pAl4T5rQ5kWp0rEaDEOKzQ_9_2"></a><a id="Tc_61UEzm_r3U-4vxcZAGc5FA_9_5"></a><a id="Tc_gAwgzVLt8UKz6s3hsklzWw_9_8"></a><a id="Tc_EnF3Na1UUUSHhcNRBP6bPw_9_9"></a><a id="Tc_CqKn0Pz2yUiHBErSe2mfLQ_9_11"></a><a id="Tc_jOLby3s7pUWwS9d54MWYJA_9_12"></a><a id="Tc_QIlIHiykZkyZnLKDU8J3nw_10_0"></a><a id="Tc_HSQuYWFePEmdJyMa2aHmAw_10_9"></a><a id="Tc_N3kLpNVqok-3MdocliQrEQ_10_12"></a><a id="Tc_5YFw6E4qH0aI3SUntplmVA_12_0"></a><a id="Tc_Pl3GgCLuEECt2FctLTT-kA_13_0"></a><a id="Tc_YvXT-THoL0WQMMgDaxI6kg_13_6"></a><a id="Tc_7cwYzjddLUuEoA0A5iW5yA_13_12"></a><a id="Tc_GfGF9s1QEEatWzrU_Aiyyw_14_0"></a><a id="Tc_B0V9z9zSlUKZZzzU2KCsfA_14_6"></a><a id="Tc_XuaFQsL2uUOtyi3Y0BKLPw_14_12"></a><a id="Tc_Jgoi5KvUEEe065KRowP7-g_15_0"></a><a id="Tc_fw99h-XqZ0mbljkcLDhqzg_15_6"></a><a id="Tc_nrhthRZ3Nk-RblMDVfs3Fg_15_12"></a><a id="Tc_5EMGEpcnRUKYTmA1vvkgVA_16_0"></a><a id="Tc_pOugAzLUdU2pqjHEz5tD6g_16_9"></a><a id="Tc_h2l-SCbcN0O4562nDCb-ig_16_12"></a><a id="Tc_4aSrHo-jDU-f02C_nnwT1w_17_0"></a><a id="Tc_SWiDOLBInEG_R-kJ-YJwbA_17_12"></a><a id="Tc_yALf2VE4cEehD51denXFSQ_19_0"></a><a id="Tc__uCzcpKOgkmoSvtHyD3fHA_19_2"></a><a id="Tc_XwR0BqHAiUSduyvHrCxJnA_19_5"></a><a id="Tc_Cn-Nz2gLukSTPi4fBlyBkQ_19_8"></a><a id="Tc_Lsav86kSdUG-mtd-9jNLHg_19_11"></a><a id="Tc_hlWtnqKwz0utm4pMtlOuVA_19_12"></a><a id="_8cd27c24_d98f_462b_93e3_5ce7bf484e60"></a><a id="Tc_ymBmu7UQ1EujTyNTPgWkKA_1_5"></a><a id="Tc_ZwXy8nYblE-U_GI77BqlkQ_2_5"></a><a id="Tc_ZvOFyBYch06ph1S6MF0row_3_5"></a><a id="Tc_nLa_m2_zwk6zTNAlLgGzCQ_3_8"></a><a id="Tc_PSNshXM9pki80uI9dQ6f9w_3_11"></a><a id="Tc_W3YoR9XYBE6xx0yLB4HIVA_4_5"></a><a id="Tc_nAJT9RcPf0at22sMu8vQTA_4_8"></a><a id="Tc_r7d74cDiL0CuZB5gvvo4eQ_4_11"></a><a id="Tc_j12wqT29Wk-ciy0PgzWYow_5_2"></a><a id="Tc_GD17ydz-3kmeynsVfuYtJg_5_5"></a><a id="Tc_-TzBzRtg-k2Ay8X-GgI-TA_5_8"></a><a id="Tc_LujBPLgF8EG2fh1Y4kBb4A_5_11"></a><a id="Tc_UQjQv12VgUyl9VflHucc4Q_6_2"></a><a id="Tc_QKiTApMKBkeaXRd2pBRobQ_6_5"></a><a id="Tc_h9ganijrcEKhAsrC4PkVlg_6_8"></a><a id="Tc_mDFMig3RZUColYxEYNKoAQ_6_11"></a><a id="Tc_Ae2cbgLRz0W6VkORpVWaTA_7_0"></a><a id="Tc_1yNiBO2u4U2OLcsLE2ZpRA_8_0"></a><a id="Tc_TMCuM6ZMzUOIoyJ8DqcqDw_9_0"></a><a id="Tc_Xd0noTrg5k6jA487_2_vYQ_9_2"></a><a id="Tc_ATQ6KnXtjEKGkP6gDv0PZw_9_5"></a><a id="Tc_0kdoLHO6UECYzG11fD0zOA_9_8"></a><a id="Tc_SUlyzWsXy0KHeiGyBrfymw_9_11"></a><a id="Tc_RcCG5w1u8UyjvLUjJSLKug_10_0"></a><a id="Tc_yCT2TkP66kSrheQ2yFUE_w_12_0"></a><a id="Tc_tI2w0wHLoUaWYZOAT2NydQ_13_0"></a><a id="Tc__q9CEH0rS0qqxNuqC793wg_14_0"></a><a id="Tc_d25Igy_LsUyQfYPNTbbiYg_15_0"></a><a id="Tc_3YZ77we-yUW7Pe1Pk_meFg_16_0"></a><a id="Tc_2ZXXaAZ2D0eyphet8UU9eg_17_0"></a><a id="Tc_zG0hADB3lk2_Y5iw7eB0aQ_19_0"></a><a id="Tc_7joJWRr6tECcSs2vTwYTXw_19_2"></a><a id="Tc_FLq2bxwmr0uCVYa_5VEVww_19_5"></a><a id="Tc_ViDV1LIxgUaFFl6-5aMsRg_19_8"></a><a id="Tc_m_duoKMNxEaaWcQG4Sp6Sg_19_11"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_QNEn0CbvC06PKqvZk-WZig" continuedAt="Tb_QNEn0CbvC06PKqvZk-WZig_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">(3)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">FAIR VALUE OF FINANCIAL INSTRUMENTS</b></p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_2iA16SK0Q0eJ6WbEbDA_pQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following tables summarize the Company&#8217;s financial assets measured at fair value on a recurring basis and their respective input levels based on the fair value hierarchy (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for&#160;Identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level&#160;3)</b></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_n9o8wjs2y0evFtOumxNmtQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_XJ7cW8Ews0G0BBNCB7sO-Q_9_3">28,265</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vFkjMAci2kCM1_635tV-aQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_UHLKNa_NLkmlQ2iSeqy7JQ_9_6">28,265</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_dKc-asA1AkOzmsiFfkV83w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_P58JTbvshUaT7wmix8OqvQ_10_3">28,265</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__yohEd5oXkm5sOjdtwzPqg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_DbOGJndPlUi3AnLK01D8AQ_10_6">28,265</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_VbGf1ULGCUm2eW5RKvPgKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_4VgjJJl5i0GS1G0Ra2k57g_13_3">27,168</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_wvATQii3UU6_fDF_T6RfnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_i0rY_QDKnUi6Jt_VIABbSg_13_9">27,168</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_B2h8T12AhEy09dFKjhebjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_PkXtU2Ppd0-QieGfV2fHgg_14_3">11,926</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_s7LhYqe820KPsrH32hrUXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_frxwcmNj6U6r5hnPfV-LUg_14_9">11,926</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_Z4bGGvwZkEKAnVLtaP7k4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc__2OvlpBhsEGGX1KZWgbEoQ_15_3">9,443</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_gxzbNSquREapCV0wgG6K_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_5606CG4fK0G2JGP7BgLF6w_15_9">9,443</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_HTNjaqHx1UmoE5boQ95RMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_C7CDfLJNrUWB2mJSZLSkCg_16_3">9,078</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_9J-eqG0s9EqtvXrgFV1g6Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_5AQe5K5Vv0a6R-8lbcbhXg_16_6">9,078</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_dKc-asA1AkOzmsiFfkV83w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_dwChbX1On0-Q2FSOGqI4NA_17_3">57,615</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__yohEd5oXkm5sOjdtwzPqg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_JTnpHQlQrk6-LO1PpT2jig_17_6">9,078</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_xThuN_5MDkqYF87Q3NeYSw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_VxpMNzx0f02taNfQRyGfOQ_17_9">48,537</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total fair value of assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_dKc-asA1AkOzmsiFfkV83w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_-GMPtnK_q0KIMRkRaZAiGg_19_3">85,880</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__yohEd5oXkm5sOjdtwzPqg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_su7AaOMYmEuh33FFU0vkfQ_19_6">37,343</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_xThuN_5MDkqYF87Q3NeYSw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_9IDE2KQaTUSm4U_KGBlcig_19_9">48,537</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for&#160;Identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level&#160;3)</b></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_jXLEnvJsuU2DjT7WrX1onA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_jPe93QG4xk2YeASIMgTP3g_9_3">19,787</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_C-UwaOvYgEmhc5KbjSNoaA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_maZMp6bDYEW2IJC6TAQ7bg_9_6">19,787</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_NvvtqfTNDUi3pAQbMuV3Iw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_W5lZ48FLCEy_u2gCz_QeZg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_alE2cQWlWUmYEMSvxQfOpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_qUbcDrI3vEyXxS2spMBIEQ_10_3">19,787</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Uy_OzIg220WOoPfwtTN9Cg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_UNlbpAhgwku2XHPCKeM8FA_10_6">19,787</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_EIT7Ft-M4U2oTXvtr5qvPQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_XpL8HTw1KUeUXBHbhjlt2w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_YfltLULy-Euim90Lqzh2Iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_J2yhFxF0qEOgq74I-JeEuw_13_3">42,255</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_lN0AgyYwBUGSBPvHUXVvCA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_tzNK_fGEakm5HbGQ9zPcaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_Y3PMVCJSCkqxtZOblKEcfA_13_9">42,255</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_ATiC6JEvSUm2xAjs-Qle-w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_2EbSprzX4UmWm8yxfF94Hw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_vl_ZW3ZkJUqlt3NA8N_vQg_14_3">38,386</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_FAR9X24s2UOjJM_mFfQemw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_xuDF7JacqEyVD_8bE4KGbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_Yf7qbNmaHkKaAKyP-2fXYA_14_9">38,386</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden__tPLOVORX06K05WNcJNPHQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8Ja-oIvtvEOUSt1VbId_rw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_NP51hai4IECUJaM2RDcFsQ_15_3">10,362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_paK6hjSIN0utjCqZ6uTFBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_0jUKAJNhL0y1ZB2ZdMaKdg_15_6">10,362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_hGln6qJd7kWjTm5e4HDgWA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_sBbWTO6GDUu9JQZjdyFFlw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_23DxYpsziUKkF0FV76-EIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_XkjdmcR_W0Wwqj69Mn9IFA_16_3">7,945</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_Ib6YuqwgvUOu1jkJDvoCZQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_PbzReIi7W0qZtcZBeUxt9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_F6K02D_9IUChiytFK5ut5A_16_9">7,945</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_HN51f_bDUkShpzdYGLsCOw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_alE2cQWlWUmYEMSvxQfOpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_GCNhMaEkXUW6RtOSkvYOvA_17_3">98,948</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Uy_OzIg220WOoPfwtTN9Cg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_bfHRKCBrgU-X9npEQBdn-Q_17_6">10,362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_sWDh72OE6kSOPCSLEhKjBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_Fa1gbTqeokqn6Xj81dekbA_17_9">88,586</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_sNomPq10ZESk15LyPnEosQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total fair value of assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_alE2cQWlWUmYEMSvxQfOpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_kWNFG8GnU0WOa1VXKK3I8Q_19_3">118,735</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Uy_OzIg220WOoPfwtTN9Cg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_wwPK17YWEEmnKQgqUjK_MQ_19_6">30,149</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_sWDh72OE6kSOPCSLEhKjBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc__ESpP0RyLUejCyP-BSY9gA_19_9">88,586</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_YNU4YHIeWEuPQ_VjMX_kCQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash Equivalents and Short-Term Investments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial assets measured at fair value on a recurring basis consist of the Company&#8217;s cash equivalents and short-term investments. Cash equivalents consisted of money market funds and commercial paper, and short-term investments consisted of U.S. Treasury bills, agency bonds, corporate debt securities, and commercial paper. The Company obtains pricing information from its investment manager and generally determines the fair value of investment securities using standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_08c1b9bb_9d5b_4ad7_bb23_52049cff1077"></a><a id="Tc_HEZJtN_HE0eNKnvqfrmqRw_1_4"></a><a id="Tc_nMc_y0zS3UeZ8zKoDOoD4g_2_7"></a><a id="Tc_Z8Ms7o2kRUmhknDKY_6TSg_2_10"></a><a id="Tc_LDLDlhgep02q_cVSM9ksyw_3_4"></a><a id="Tc_IlrOXwA4_EiYhl4z57MyOA_3_7"></a><a id="Tc_sPL2R3_Pt0KD9sB1StZtBg_3_10"></a><a id="Tc_d4z096T6nUSY_xix52AeBg_3_13"></a><a id="Tc_lZHyH2S-50qiUtDs9ewDlQ_4_2"></a><a id="Tc_y20hmR3x8UO6AU0GYLMvqQ_4_4"></a><a id="Tc_NIGBOJX6d0mVDtShK5gnEA_4_7"></a><a id="Tc_RRoeF5UZ40KVrxW4OxFJsA_4_10"></a><a id="Tc_NuoNnlvdEkGw_2of8wACHw_4_13"></a><a id="Tc_wA-6LWlGVEqlIASDWtYacQ_5_0"></a><a id="Tc_CnD7EYOr1kOoc6eB6ExyIQ_5_2"></a><a id="Tc_FHr_QgcGikG8Wz4yqjQQmg_5_11"></a><a id="Tc_8bhsTrRzKkiuoKrGLrHtmg_6_0"></a><a id="Tc_srqWepJgJkOPE9TSb-XD0A_6_2"></a><a id="Tc_5UgHY_2OAEy-PrPoJvuQLg_6_11"></a><a id="Tc_q05jJ8q5X0WbTJpzjdXuag_7_0"></a><a id="Tc_8ycXzmemdUqzndDurTgtXA_7_2"></a><a id="Tc_xm-LkFlqBkqe4r2zjQuE6A_7_11"></a><a id="Tc_CQwZhsTzaU2EK0L-GxFV6Q_8_0"></a><a id="Tc_kuHu3O4LgEyBJLo6TEX7bQ_8_2"></a><a id="Tc_mcRgGGg9e0yZKy279bpuwA_8_11"></a><a id="Tc_x6sYm9RUW0m546WUz0m5dA_9_4"></a><a id="Tc_fC-gr6m4EUOfi7vYsb-5CA_9_7"></a><a id="Tc_3Olreiv4o0yE7toBnItBMA_9_10"></a><a id="Tc_5dL11BcfA06fXhik_df19w_9_11"></a><a id="Tc_73uw5N06W0meg4NiZw3fng_9_13"></a><a id="_9fdbd756_919b_4769_9ecc_9346d7ead65a"></a><a id="Tc_SsGUhYm46UaY9AdF3jPkww_1_4"></a><a id="Tc_t2clI2sURECMxrpE97FW-A_2_7"></a><a id="Tc_1xpHe6tl2kyh29bSkb5yqA_2_10"></a><a id="Tc_oMS0_tgROkOxbaCuzAPLBg_3_4"></a><a id="Tc_1VQiolO6JkCTNaIXSbcxyw_3_7"></a><a id="Tc_mDpYtSmqXkS_QY5Rbpju_A_3_10"></a><a id="Tc_p57Zk1q2A06Q2Hk8HCUvpA_3_13"></a><a id="Tc_va0KCXSDHUaBatp0ylEi-w_4_2"></a><a id="Tc_ZW9D6gcVBkS_SqVKI8LbXw_4_4"></a><a id="Tc_cVNXwe_HnEuT_cqyhjIimg_4_7"></a><a id="Tc_OR6WOEVrek2qiYorAY_YsQ_4_10"></a><a id="Tc_4gFNC_C2FEGe6q8MP3yDhw_4_13"></a><a id="Tc_yYgY6r1B90iIYmMVjvPnWQ_5_0"></a><a id="Tc_9Bqg9VHxXE675E5wbIvURg_5_2"></a><a id="Tc_jVkO1c-hQk-BMXC9jrjxDQ_5_4"></a><a id="Tc_KrTo2D7GV0m_sAGYZjHZRw_5_13"></a><a id="Tc_CTCv0F7RuUWkookJK8iFgQ_6_0"></a><a id="Tc_oIPmGLrqUkq4R6DKoT_MMg_6_2"></a><a id="Tc_c5pbSURNGU-dbLI9Pj0ddw_7_0"></a><a id="Tc_lmxx314Yk06p2pyn6KNQ5A_7_2"></a><a id="Tc_u-cAKj5D4kCmDTbNIYq45w_8_0"></a><a id="Tc_uheTx4vKBE6i925cFRrAng_8_2"></a><a id="Tc_M0AQZfT4cUG62glFMYB-sQ_9_4"></a><a id="Tc_3JjkfkfU1U6fXGmg--GK0A_9_7"></a><a id="Tc_a34CcKKMnEyozPDoZJnC3Q_9_10"></a><a id="Tc_MUvuxNtnkUq9ToKbC5_efQ_9_13"></a><a id="_6338e7d4_5bfe_40d1_86dd_72c3495d5891"></a><a id="Tc_JQ2xZP9maEmMQeYa-ASEhg_1_2"></a><a id="Tc_9zYi8mN9sUWnYWLqPd7leg_2_2"></a><a id="Tc_WRYGusLhbU24I8GTGeEFZg_2_7"></a><a id="Tc_IUlDgt29z0K-yvcVYlN8Ag_3_4"></a><a id="Tc_DXSnjEAut06lhGiYQWG8Iw_3_10"></a><a id="Tc_fysdgLgEoEiMeuQdAol7yg_3_13"></a><a id="Tc_4H93OqAEu02DpITtfXDFJQ_3_16"></a><a id="Tc_9BMYFbL1oUqGqhkcZFkwWg_4_2"></a><a id="Tc_qouknFGuY02U7PnuqrLHWg_4_4"></a><a id="Tc_wTAFTkEVZECHFj0j-kluPg_4_7"></a><a id="Tc_KsSLzhaQI0-3NLBA4zTVsA_4_10"></a><a id="Tc_b9tYbGj5t0SRHvwT2MQ3bw_4_13"></a><a id="Tc_Wj9YhiPhD0OES6YUHpl5aQ_4_16"></a><a id="Tc_Nt77Vp2hKk-AdSXUqUUIAw_5_0"></a><a id="Tc_QnOsIX2tXUqi-GAMqAfTDw_5_1"></a><a id="Tc_X_E_dFMqbUGnjZGunRcbzw_5_4"></a><a id="Tc_oAE-Obyok0CJOvnBriA-FA_5_7"></a><a id="Tc_jn9M5jj6EkKypeJjXHklbw_5_8"></a><a id="Tc_9kwnK0GWb06ItmJmgsF1LA_5_10"></a><a id="Tc_vJdm8v8Z706gaMdKA7jY-g_5_11"></a><a id="Tc_oFMWCbhC6EuT1hrt3JUB_g_5_13"></a><a id="Tc_x2KS7Rz6SEiG6pv6vhpPrw_5_16"></a><a id="Tc_6Nm2-niEFE67gadCC6ZQ4w_6_0"></a><a id="Tc_pvA68SLVOEidYzcqB_pGNQ_7_0"></a><a id="Tc_pT168bOAcE-erzFmv_jtog_8_0"></a><a id="Tc_kifZJ5jMakWcfstok59OnA_8_8"></a><a id="Tc_HSBG_s7rLEmLQXHhpofJrg_8_11"></a><a id="Tc_sEHJwDawE0auQQWGTth7VA_9_1"></a><a id="Tc_2ME-wa9ywki6c0y-Hrlh7Q_9_4"></a><a id="Tc_E26NHfucMUyNc3XdErV1EA_9_7"></a><a id="Tc_OHfot8lTTEKBwF-lObcKsw_9_10"></a><a id="Tc_4mJLZiQViUSTPu8GSjYqtg_9_13"></a><a id="Tc_xNVmqIfy40OOqC2S9B1xYQ_9_16"></a><a id="_c366680a_dd4c_49a2_9a24_61de72783ab8"></a><a id="_c366680a_dd4c_49a2_9a24_61de72783ab8_2"></a><a id="_c366680a_dd4c_49a2_9a24_61de72783ab8_3"></a><ix:continuation id="Tb_QNEn0CbvC06PKqvZk-WZig_cont1"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="Tb_lqR8tqQis027ANr7IzdWcA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following tables summarize the Company&#8217;s short-term investments (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Maturity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_SYM7muK7eU6UOC8tcjKjzQ" format="ixt-sec:durwordsen" name="avte:DebtSecuritiesAvailableForSaleMaturityTerm" id="Narr_n1OW6Jlmmk-NghNqgYzOuw">1&#160;year</ix:nonNumeric>&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_HnxnO2kja0uIhwuJkAHhcQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="3" id="Tc_bCLtyLoY90WyHiZnDKN_5w_5_5">27,029</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_HnxnO2kja0uIhwuJkAHhcQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_jwUZChgA-0SIeQqT1_xG9Q_5_8">139</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_HnxnO2kja0uIhwuJkAHhcQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_ApfLPC0oQ06oPbkAKsdjiQ_5_14">27,168</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_BlyAQCATVkGjKh-kOfQdJA" format="ixt-sec:durwordsen" name="avte:DebtSecuritiesAvailableForSaleMaturityTerm" id="Narr_6CyMu72eJUudOf5Q0MI56Q">1&#160;year</ix:nonNumeric>&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_fyLg3XbfjUyiu8CJN34Bjw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="3" id="Tc_9KY6ayS2j0CjeNrM9cR20Q_6_5">11,866</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_fyLg3XbfjUyiu8CJN34Bjw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_DMslFoYA30mEz4dwqGOShw_6_8">60</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_fyLg3XbfjUyiu8CJN34Bjw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_k6iI8bFbR0e80IU-PP_3aQ_6_14">11,926</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_O8QXwFu-kEqrEQwa9rKRJA" format="ixt-sec:durwordsen" name="avte:DebtSecuritiesAvailableForSaleMaturityTerm" id="Narr_smUX_9rMAkSkoyCrE4Fo_A">1&#160;year</ix:nonNumeric>&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_PE43wqGHWU6QaYBuVIux_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="3" id="Tc_Zdqbq7F74U2YIyjTCNehcA_7_5">9,438</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_PE43wqGHWU6QaYBuVIux_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_LBBsWI5HbUWDDgoOQ32f1g_7_8">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_PE43wqGHWU6QaYBuVIux_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_ychviAjcQ0-OpcOXREyGMw_7_14">9,443</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_0Iv5XCHgWUyuS-1MyqMPSg" format="ixt-sec:durwordsen" name="avte:DebtSecuritiesAvailableForSaleMaturityTerm" id="Narr_7LnQILbJQUCtN2TlZrtRlg">1&#160;year</ix:nonNumeric>&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YzIcvZaeZUu6LSDu8bymCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="3" id="Tc_uWKeuH7ozU-UcmQ-U2nMng_8_5">9,058</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YzIcvZaeZUu6LSDu8bymCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_lM-d2guyPUGPQbAw5AfJ7A_8_8">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YzIcvZaeZUu6LSDu8bymCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_4P5Rh-SS0kyYJKvoUpOjPg_8_14">9,078</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="3" id="Tc_jUGRV-0OWUCMIQzZi9lyxQ_9_5">57,391</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_PAsnbmTRFUuaPVRGbUwBLQ_9_8">224</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_A-7X70JI60imJ9dBGfefYw_9_14">57,615</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Maturity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_OlIabHctWUyzxlnqkr4bCg" format="ixt-sec:durwordsen" name="avte:DebtSecuritiesAvailableForSaleMaturityTerm" id="Narr_iNbeKoUuqkqw8Cwqr48bzQ">2&#160;years</ix:nonNumeric>&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="3" id="Tc_rNW-LiD5BEqt8ZVCEGykXQ_5_5">42,090</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_mcbuFVwaUUqHk-BsO5pCOg_5_8">179</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_oCq22AKR70iMo7joDKkLeQ_5_11">14</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_9MluHGanXU2027nqKtOclw_5_14">42,255</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_zaDLiCFPqUqEufSLy6NbzQ" format="ixt-sec:durwordsen" name="avte:DebtSecuritiesAvailableForSaleMaturityTerm" id="Narr_rZ8alhcEo02xwV2NVPOZFw">2&#160;years</ix:nonNumeric>&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="3" id="Tc_BN1SEA-P4E-_u4C58pOIFQ_6_5">38,362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_Fz69FDWz6UWgNNIuq7yECg_6_8">29</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_tL9m1ri700C47euDSnJ9tQ_6_11">5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_kQDY6nVZrUaEkyh6vkhkaA_6_14">38,386</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_eZcGsEFbHEW38q44Yr6mVw" format="ixt-sec:durwordsen" name="avte:DebtSecuritiesAvailableForSaleMaturityTerm" id="Narr_5ABepR0m0UuGA2fUUzUZdg">2&#160;years</ix:nonNumeric>&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="3" id="Tc_1BYhyvL6PUKInFRmUQzhmQ_7_5">10,334</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_H7nYcl0WDEaFP6_SmecSqA_7_8">31</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_xkSYqmel8US30oxMC-p29g_7_11">3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_SwcekCmsckeIWEdkloqqxA_7_14">10,362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_rsRxqqwUvEm2inEelixs4Q" format="ixt-sec:durwordsen" name="avte:DebtSecuritiesAvailableForSaleMaturityTerm" id="Narr_Z-6eQiK_vk2CZ6veKe-0yQ">2&#160;years</ix:nonNumeric>&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="3" id="Tc_ec7haCMKkU2G06-eayk3Zg_8_5">7,925</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_eQZWSzcdS0eEqz26_785tw_8_8">21</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_oTeyw4i1tkWn-vTIEZ3PIA_8_11">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_yhoX6WYsykeE8NzqFO7Dww_8_14">7,945</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="3" id="Tc_RHM1rPcSGk6hgV0mas10SQ_9_5">98,711</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_XdG5aFsbKkmTqlkUGhgpOw_9_8">260</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_UyO1pZN1zkKFzbJptNVN3A_9_11">23</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_VoFfgUpy-UqIBzE64L1WJA_9_14">98,948</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="Tb_-o5rfZk1XkuWDF2IHpE-Ag" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following tables summarize the Company&#8217;s short-term investments with unrealized losses for less than 12 months and 12 months or greater (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:35.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="16" style="vertical-align:bottom;white-space:nowrap;width:62.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">12 months or Greater</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Unrealized</b></p></td></tr><tr style="height:10.35pt;"><td style="vertical-align:bottom;width:35.88%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></div></div></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:35.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="Tc_4VjRe4U8I0GSEqQXPnvl7Q_5_2">6,042</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="Tc_BRX6dmrBGkihrkDR6ttegQ_5_5">5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="Tc_m1LgcfIlRUSX9n9OD2uEEw_5_14">6,042</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="Tc_mu5giqyuukibek5wrD3cZA_5_17">5</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:35.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="Tc_nNEcy53bP0yz0EeGx8xwtQ_6_2">3,760</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="Tc_pDHS4a7Ea0Gf3sOTbiyABQ_6_5">6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="Tc_uXmOOrfFqEG87N7MsQzV2Q_6_8">6,579</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="Tc_QtNrtK-zn0KuiGh0huSetw_6_11">8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="Tc_lzkw6hR7oEaiyk_2OOf6ow_6_14">10,339</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="Tc_1jvegWfTlE-JQJjbSp3G1w_6_17">14</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:35.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="Tc_FCs4wo0FlUu_sx9OOcZnpA_7_2">488</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="Tc_ompod8u86EOEVCJqtfS-Ag_7_5">2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="Tc_nrayLFYH60iFpIRyI_iuNw_7_8">1,007</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="Tc_u7HeWfQrukG78VS8y_Toaw_7_11">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="Tc_V550A5cw9EWiRXRdux1Wag_7_14">1,495</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="Tc_a-y35pfnD0ujtC1dB8F0cA_7_17">3</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:35.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="Tc_zHV6g1WacUasnKOFzAPvYA_8_2">3,110</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="Tc_O04xRo15LEKkyxM5Wd4CbA_8_5">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="Tc_Qk9tpraYjkit3VyIAUKtSg_8_14">3,110</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="Tc_kGRMniySO0uPGcX5oyRQtg_8_17">1</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="Tc_KxK4hZvgFE2MdV1UWnh30Q_9_2">13,400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="Tc_GKdQr_BQ2k6SmcUEJjDK0w_9_5">14</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="Tc_sjZy20PohkGUU0oPzSL_fQ_9_8">7,586</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="Tc_op8Kpv9vmUqeetedTiM6Kw_9_11">9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="Tc_W3nhR8jUX0W80wMqdJrWEg_9_14">20,986</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="Tc_Lj0IiH6jpUuRnPGas2uGIg_9_17">23</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company did not hold any short-term investments in a loss position as of September 30, 2024. The Company considers whether unrealized losses have resulted from a credit loss or other factors. The unrealized losses on the Company&#8217;s short-term investments as of December&#160;31,&#160;2023, were caused by fluctuations in market value and interest rates as a result of the economic environment and not credit risk. As of September&#160;30,&#160;2024 and December&#160;31,&#160;2023, <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="Narr_HdAtuSyXPEudnGGnz8FWtg"><ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="Narr_tsWu0jnHI0C9dWZpDHCzZw">no</ix:nonFraction></ix:nonFraction> allowance for credit losses was recorded. During the nine months ended September&#160;30,&#160;2024, the Company did not recognize any impairment losses related to its short-term investments. It is neither management&#8217;s intention to sell nor is it more likely than not that the Company will be required to sell these investments prior to recovery of their cost basis or recovery of fair value. Unrealized gains and losses are included in accumulated other comprehensive gain (loss). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Accrued interest receivable is written off through net realized investment gains (losses) at the time the issuer of the bond defaults or is expected to default on payment. Accrued interest receivable related to short-term investments was $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" scale="6" id="Narr_cSjKq_PDHkG1QMS4heRCDA">0.3</ix:nonFraction> million as of September&#160;30,&#160;2024 and $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" scale="6" id="Narr_VD2nP5PHDU-nIieVP1daQw">0.6</ix:nonFraction> million as of December&#160;31,&#160;2023. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_1a844369_d26b_4c4d_a43e_79578d0ef362"></a><a id="Tc_RtUynsL0vkiEXz824Nd6JA_1_2"></a><a id="Tc_zmi_T3F77kaCMcsXr2LohQ_1_5"></a><a id="Tc_IWWnXsxRAEe_7eurRnPV3Q_2_2"></a><a id="Tc_J8rAw3A28UGSAgnJZr7EEg_2_5"></a><a id="Tc_NqxAyFOeMEOL_i6YjCIYLA_3_0"></a><a id="Tc_xqZkFNfhm0KF75zhZubA-A_3_2"></a><a id="Tc_INf0zEv_4EmG2DR5aK_5kA_3_5"></a><a id="Tc_DgSrVPsXNka3_DWh9vE0Mg_4_0"></a><a id="Tc_gKfxg_SfyEiNUPJ7pdH_Sg_5_0"></a><a id="Tc_itUo2lIEwkiQXiyCFkvNTQ_5_3"></a><a id="Tc_SbfhnXVlgUyxqN_EVkdHRA_6_0"></a><a id="Tc_xfhJzQPr_UKHKAFBjekDxg_6_2"></a><a id="Tc_-gKLpOGso0-Qu4Hg2aXU7A_6_5"></a><a id="_b8cd80c0_bf24_4dfe_bc69_77e6288d29a3"></a><a id="Tc_XS_Obsu4C0muh_-fSIB2jg_1_2"></a><a id="Tc_Ovlefl1y-0iXwlCYTut4hA_1_5"></a><a id="Tc_TD0X9uu9kU-S-zViXhyzYA_2_2"></a><a id="Tc_chGjw6m56U-ybI-TFObi5w_2_5"></a><a id="Tc_KTPqHvoaY0uc1tZok7sa9g_3_0"></a><a id="Tc_sG-H8tJa2EacO-_Qq9no2Q_3_2"></a><a id="Tc_g6oGMWPrtEqJN4QripgORA_3_5"></a><a id="Tc_loUcOnkopEW4ghZAjiM1Mw_4_0"></a><a id="Tc_pxaYrOpCkU-PxiB4gYUs_Q_5_0"></a><a id="Tc_PVKaDTgaXkWpj6xVIJhEug_6_0"></a><a id="Tc_CTuaC7xuD0qA8x5eY62yLQ_6_2"></a><a id="Tc_CmW3kBmtTUmtQ_sIWncKAw_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="Tb_XHkF6_CyIEyG4VLrg_-09g" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">(4)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">BALANCE SHEET COMPONENTS</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Prepaid Expenses and Other Current Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="avte:ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock" id="Tb_yvhU98QzrUKFpcsED47RjQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Prepaid expenses and other current assets consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_WtdNOssFL0eMwpS8D5RbcQ_3_3">993</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_XMHYlloyAEGDjfsu3LYqLg_3_6">1,168</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="Tc_siSTafRR8UO5cJTa2Hn8Fw_4_3">882</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="Tc_N4DgDKNLA0ySqqBuO3Gv2Q_4_6">250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="avte:PrepaidResearchAndDevelopment" scale="3" id="Tc_ZZJ6fWCpJ0-zB346UppGtA_5_6">375</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_XMhswNrdS06HpqFGc-9gsw_6_3">1,875</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_2viuBaXVw06s1ru0fi0gig_6_6">1,793</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Accrued and Other Current Liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In June 2024, following the Company&#8217;s decision to halt further development of AV-101, the Company announced its plan to terminate nearly all of its workforce in the coming months (the &#8220;Workforce Reduction Plan&#8221;). As of September 30, 2024, <ix:nonFraction unitRef="Unit_Standard_individual_HQaf273bdUKcqMGv_RJZsw" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" scale="0" id="Narr_DeTW55_NFUeF5AxNT9F8Vw">46</ix:nonFraction> individuals, or approximately <ix:nonFraction unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" scale="-2" id="Narr_x1WEb4nYj0yLyvUM2zAWqw">90</ix:nonFraction>% of the Company&#8217;s workforce, have been terminated. The affected individuals have been and will be provided severance benefits, including cash severance payments. Each affected individual&#8217;s eligibility for severance benefits is contingent upon entering into a separation agreement, which includes a general release of claims against the Company. In connection with the Workforce Reduction Plan, the Company incurred costs (in consideration of releases) of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="Narr_--VigptL9kerjiuDsWiZuw">6.4</ix:nonFraction> million, which are primarily one-time severance benefits, during the nine months ended September 30, 2024. The Company has paid approximately $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRestructuring" scale="6" id="Narr_zIZSkbhkI0KWYXMthNzKZA">2.4</ix:nonFraction> million of severance benefits, and liabilities associated with the Workforce Reduction Plan were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" scale="6" id="Narr_889EKeIOHES4kDUIOOaQtg">4.0</ix:nonFraction> million as of September 30, 2024. The Company estimates that the remaining liabilities will be paid in the fourth quarter of 2024 and first quarter of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_kfdcwHJbeE-Uug9FJiLf7g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Accrued and other current liabilities consisted of the following (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="avte:AccruedResearchAndDevelopmentCurrent" scale="3" id="Tc_ldSRX8Bu2UWyoWq1iGN1pA_3_3">4,704</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="avte:AccruedResearchAndDevelopmentCurrent" scale="3" id="Tc_cqD18dqrz0yL0FpkAqkUhQ_3_6">9,363</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued payroll and other employee benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_Eg3lgKCYcUyadTC02JrCVg_4_3">3,952</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_4Z2Bo3mGqUKG2fJzoJfsFg_4_6">4,368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_yvM1kZuMwEGf0FoCdWV-gQ_5_3">292</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_LwXVgy00ZEmRYWBuW1b0kA_5_6">1,090</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total accrued and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent" scale="3" id="Tc_WI97hcC79kCjzPTmDrnHRQ_6_3">8,948</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent" scale="3" id="Tc_WybrY_gamkydfB9sqYEeKQ_6_6">14,821</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_ObPN7_DoHE-MwiHdgwsiaw" continuedAt="Tb_ObPN7_DoHE-MwiHdgwsiaw_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">(5)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">COMMITMENTS AND CONTINGENCIES</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2021, the Company entered into a lease agreement (the &#8220;Waltham Lease&#8221;) for approximately <ix:nonFraction unitRef="Unit_Standard_sqft_5xtOY_aM_0eoVegCdMhIVQ" contextRef="As_Of_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_psQydqKoEkSDWEV9UfDtig" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfLand" scale="0" id="Narr_gI2toN_BXUezoarh3wgOwA">5,000</ix:nonFraction> square feet of office space in Waltham, Massachusetts for the Company&#8217;s corporate headquarters. The Waltham Lease has a term of <span style="-sec-ix-hidden:Hidden_QkmZslh310SYGgzTas8QSQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">thirty-nine&#160;months</span></span> (&#8220;Lease Term&#8221;), unless extended or earlier terminated. The Company had the option to extend the Waltham Lease for <ix:nonNumeric contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_DaiW5HZ95E-5aglfFdRpPw" format="ixt:booleantrue" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Narr_TooBIjLKL0qdIv3zN1rVAQ">one</ix:nonNumeric> additional period of <ix:nonNumeric contextRef="As_Of_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_psQydqKoEkSDWEV9UfDtig" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_3tPJjY3F7ECF3pTovKx_og">three&#160;years</ix:nonNumeric>. The Lease Term has an initial abatement period, and the initial base rent payable is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_DaiW5HZ95E-5aglfFdRpPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRent" scale="0" id="Narr_Cjq0W23PnkuRVKoSgpYeAw">18,000</ix:nonFraction> per&#160;month following the abatement period. The initial base rent payable will increase by approximately <ix:nonFraction unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA" contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_DaiW5HZ95E-5aglfFdRpPw" decimals="2" format="ixt:numdotdecimal" name="avte:LeaseIncreaseInRentPercentage" scale="-2" id="Narr_8QG2uUOb6Umg3XobpzWGFQ">2</ix:nonFraction>% per&#160;year over the Lease Term. The Waltham Lease commencement date was September&#160;1, 2021. In January 2024, the Company entered into the First Amendment to the Waltham Lease resulting in the lease expiring on December 31, 2025, and an increase of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2024_To_1_31_2024_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_PodE97lmJkSHEwoc1aClWg" decimals="2" format="ixt:numdotdecimal" name="avte:IncreaseRentalAmount" scale="0" id="Narr_eTX9joGoWUSKVvPaBHsrdA">1.00</ix:nonFraction> per rentable square foot during the additional lease term. In obtaining this lease extension, the Company no longer has the option to extend the Waltham Lease for <ix:nonNumeric contextRef="Duration_1_1_2024_To_1_31_2024_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_PodE97lmJkSHEwoc1aClWg" format="ixt:booleanfalse" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Narr_wBajvji9bkexXX57BDuKzg">one</ix:nonNumeric> additional period of <ix:nonNumeric contextRef="As_Of_1_31_2024_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_zn19noNKY029l5Ec-T6CTg" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_wlXKgd69q0eWA9-hF9CzZg">three years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2022, the Company entered into a lease agreement (the &#8220;Foster City Lease&#8221;) for approximately <ix:nonFraction unitRef="Unit_Standard_sqft_5xtOY_aM_0eoVegCdMhIVQ" contextRef="As_Of_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_sGvwx0X7s0WPUgXlH8FQrg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfLand" scale="0" id="Narr_Ipc9MaYMPEC7zxDGQk6oMg">3,500</ix:nonFraction> square feet of office space in Foster City, California. The Foster City Lease has a term of <span style="-sec-ix-hidden:Hidden_5dOxBlntyUCTd-8nElVMiw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">thirty-nine&#160;months</span></span>, unless extended or earlier terminated. The Company has the option to extend the Foster City Lease for an additional period of <span style="-sec-ix-hidden:Hidden_mWsXBWWQvkivgmOrUGyQhg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one&#160;year</span></span>. The base rent payable under the Foster City Lease is $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_4_1_2022_To_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_m3e0XkrsxkWOCq0GHEPF6A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRent" scale="0" id="Narr_Ot5tCFESrUqe68287PafJQ">22,600</ix:nonFraction> per&#160;month and will be subject to annual increase of <ix:nonFraction unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA" contextRef="Duration_4_1_2022_To_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_m3e0XkrsxkWOCq0GHEPF6A" decimals="2" format="ixt:numdotdecimal" name="avte:LeaseIncreaseInRentPercentage" scale="-2" id="Narr_8pfEfzKFVU--mmBpddH22g">3</ix:nonFraction>% on each anniversary. Following the Company&#8217;s Workforce Reduction Plan, the Company terminated all employees in the Foster City office and vacated the premises in September 2024. As a result, the Company impaired the related right-of-use asset of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_PLHhQPxnDkGS0X1B4pdMdQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseImpairmentLoss" scale="6" id="Narr_UXQW6xSsZkOuLUrxcyi7ew">0.3</ix:nonFraction> million, and recognized a loss on impairment in its general and administrative operating expenses during the three months ended September 30, 2024.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_270785a8_eba8_4278_a6d4_f82f0d3d4eec"></a><a id="Tc_YLTdjlQTJE6ftXZELDb2hw_1_1"></a><a id="Tc_3CJsC8wPg02Tlcay3H2LtQ_2_1"></a><a id="Tc_N22BCGxnJkC2Ikrz7ahSbQ_3_0"></a><a id="Tc_0jqbQmGqRkCGsXyKKpEkWg_3_2"></a><a id="Tc_IK1MGtnWukW7UwuW7krlUw_4_0"></a><a id="Tc_m6YGKdcoBkC8qokbsBIlKA_5_0"></a><a id="Tc_g5-RlaiWrUutIJHQNC3LCw_6_0"></a><a id="Tc_CXgCdYqVXkuHsMlBnIvzoQ_7_0"></a><a id="Tc_07iHpq2lZEqN_26XBeeaIg_7_2"></a><a id="_f66de848_9574_4077_9ec8_fb02dd4d8a6d"></a><a id="Tc_gnkVZ9zARU2sOnmAda4KGQ_1_2"></a><a id="Tc_DiG4IHk-80-0OdmhRRV4EA_1_5"></a><a id="Tc_Ni2_QlDZoESaX_5vKOYfhA_2_2"></a><a id="Tc_Nz8p-tb6P02-KBalMqKnqQ_2_5"></a><a id="Tc_MpF0XIFD4kKR_J8I-Ed2Jw_3_0"></a><a id="Tc_Z7FJy6iecUm_EgBm7nZ0KA_4_0"></a><a id="Tc_iUK5pKKJUUOhv7KsLD9LSA_5_0"></a><a id="Tc_CHhDcuQ-dEiWbbOQHF2V5A_6_0"></a><a id="Tc_2Rnbw6Zn8kKB-6lWW0Y1tA_6_2"></a><a id="Tc_Uj9nFLzXz0iymGyMVIzw7g_6_5"></a><a id="Tc_fnJXJ1RgvUKFqgr3-0uOhw_7_0"></a><a id="Tc_53rvaHQI0U-tZIUjyzc9-w_8_0"></a><a id="Tc_suZPPxN9gUirCmevGMATRg_8_4"></a><a id="Tc_9sQ_ffYsmE2-SiKsV0EbXQ_8_7"></a><a id="_e9d5fc25_ce5c_4240_8d7c_e9b06551d18c"></a><a id="Tc_nxqcgXqqokGTZNXgaO247Q_1_2"></a><a id="Tc_cOLGaAg2L0yK_bJHPcxwGQ_2_2"></a><a id="Tc_5C6IUyJ5AUi4qfkzJjLPxQ_2_5"></a><a id="Tc_DmhIYJffuka_qC5BwQ6sOQ_3_0"></a><a id="Tc_DzSo82PHCUaXz1kpVrHQgg_3_2"></a><a id="Tc_itHgM1qFg0ezZmqDpo4VDg_3_5"></a><a id="_5b0df0b0_010d_4cd0_a0d8_19604643cedd"></a><a id="Tc_BaPXeTbBYkWTcMHSikdz1w_1_2"></a><a id="Tc_4cUjrgoJT06qJLrt4RFeag_1_8"></a><a id="Tc_fUew13fQ7EyxTAKiwE46Aw_2_2"></a><a id="Tc_12NULQrmW0CYsQSxFSszyw_2_5"></a><a id="Tc_RYtpv02krESYCAQI9nlRrw_2_8"></a><a id="Tc_z97CEtgqi0OGZIATvs-B4g_2_11"></a><a id="Tc_T_NXLSEtjEOWWC8voOx2oQ_3_0"></a><a id="Tc_-B_MXBDpfEStVH3D-UXovA_3_2"></a><a id="Tc_9IkrBpGHJ0u1shIBlSE9_A_3_5"></a><a id="Tc_GhAWSZ216EGgZH7QBOmV2g_3_8"></a><a id="Tc_VSdLHEDufkGYsycEU55o9g_3_11"></a><a id="Tc_oaTto9fGpUOEUXvOtK51CQ_4_0"></a><a id="Tc_KcRsBpwlQUShahlLQPuL1A_4_3"></a><a id="Tc_gm-hbeoYg0eg8JN20tr_1Q_4_6"></a><a id="Tc_dljs0CamJ0-Maa2q884eTg_4_12"></a><a id="Tc_6baWa23UgUSftUpxaEtyaw_5_0"></a><a id="Tc_PC3I4NP87Eqz8DfdYIbREw_5_2"></a><a id="Tc_MYxD7jVBsEOsISO79MiL0g_5_5"></a><a id="Tc_IMj5qLBenU20LKjgYLs2zw_5_8"></a><a id="Tc_KFbWFNtkYEmGCzHkICYGug_5_11"></a><ix:continuation id="Tb_ObPN7_DoHE-MwiHdgwsiaw_cont1"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_7jV8Yg3X9kuTjKeLN8RXWA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of September&#160;30,&#160;2024, the future minimum annual lease payments under the operating leases were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:74.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:25.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 12.25pt;"><b style="font-weight:bold;">Total Minimum</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:25.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 12.25pt;"><b style="font-weight:bold;">Lease Payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="Tc_D6JHIuqFQUa2lJhIklwKjw_3_3">316</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_Eg-aw6w5mkmDk49DQetLsg_4_3">242</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total operating lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_tds2CG4r_0-hty-BSaKpBQ_5_3">558</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less: Amount representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_QSPJWaVSgES-ZjytZcZJiQ_6_3">18</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Present value of net minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_-mywYTOxJ0GAgXXXmSr0Qg_7_3">540</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="avte:ScheduleOfComponentsOfOperatingLeasesTableTextBlock" id="Tb_kk0-GeL1UEycfbZI278dvQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Company&#8217;s leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the lease commencement date. The components of operating leases as of September&#160;30,&#160;2024 and as of December&#160;31,&#160;2023 were as follows (in thousands except lease term and discount rate):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_kfzj4RVjMEOsUowcN25Pow_4_3">459</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_anoosM82ukmM_K3C1L6eJg_4_6">420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_Q6_dvMMbF02DVqYHxh667g_5_3">81</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_O3138Ff7pUaQnVU2X4khCQ_5_6">255</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_6vf7zm_7J0eX60BPNFvpMA_6_3">540</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_7MzmJEdVx06xF_l68PnG6w_6_6">675</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_B0G_vPnFc0euHCv7jNnBaw_7_3"> 1.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_FzmkPMcdLkeqEJML_qV-2A_7_6"> 1.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average incremental borrowing rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_uoXxb0CaikWPwFCkpoiPeg_8_3">6.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_H65-VT3ErU-v3HO8XY8xAw_8_6">6.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="Tb_Z6DXDOgDCkaE_zkuNwM5Ug" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Supplemental cash flow information related to cash paid for amounts included in the measurement of operating lease liabilities was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:75.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine months </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">ended </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:75.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid included in operating cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_fwfbKfqkg0yV2_D-jJpv3w_3_3">380</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_a3xfqkvOm0yoEwetSM_cdA_3_6">323</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="us-gaap:LeaseCostTableTextBlock" id="Tb_vqK3-j7uUE25tnG8kEAfGQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Rent expense was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:40.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_4LbKVKGRoUyWdKRYGxyBZQ_3_3">115</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_vVV6jjMkIEKHtymUQkCnFQ_3_6">111</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_hUpoY7eyW0Wb5b07Hok6Dg_3_9">343</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_bhVnzCddhkCiktD7VzOCJQ_3_12">332</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:40.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermLeaseCost" scale="3" id="Tc_w-oQjDcf9UGebKRJ2Xtl7g_4_9">165</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:40.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total rent expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_odLQYUFhGkOyyWFZMXrn7A_5_3">115</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_PxquMY6HzEiMK45c0mnbvQ_5_6">111</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc__1ewlWoNPkOw91Ac3yL0HQ_5_9">508</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_Pg3hsvtLGEyvOLhQ3lRz4Q_5_12">332</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_be6ea4d4_3ecb_47b7_9910_4e12e6c844cc"></a><a id="Tc_IrMjTdWbSk6BdBKimJPbkg_1_2"></a><a id="Tc_O_aprPsgdUmp_OAi5nTpzA_2_0"></a><a id="Tc_kQ65B4MNU0uWpRZFwR2yXA_3_0"></a><a id="Tc_vVRlmMKXDEiiX92nZ4-s2w_4_0"></a><a id="Tc_jUP__TvknU2LmfaJjp_UEw_5_0"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_Sxkp51P1sUSql_O5r4KSMw" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">(6)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">STOCKHOLDERS&#8217; EQUITY</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July&#160;2, 2021, the Company&#8217;s certificate of amendment to its certificate of incorporation became effective, which provided <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_7_2_2021_w8fg7T9i30-Tb8oR9Nn9Ag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_ugdv3_MgAU6xHaqOx6nKuA">150,000,000</ix:nonFraction> authorized shares of common stock with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="As_Of_7_2_2021_w8fg7T9i30-Tb8oR9Nn9Ag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_6WjWALa19k6u1enAmkHFmA">0.0001</ix:nonFraction> per share and <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_7_2_2021_w8fg7T9i30-Tb8oR9Nn9Ag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_xmKmnrQV506Tt1wEHa-rAA">10,000,000</ix:nonFraction> authorized shares of undesignated preferred stock with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="As_Of_7_2_2021_w8fg7T9i30-Tb8oR9Nn9Ag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_uJJClbgXH0CsyGRtH-SWzA">0.0001</ix:nonFraction> per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The holders of the common stock are entitled to <ix:nonFraction unitRef="Unit_Standard_Vote_68Fy5nhdn0WonvfwhauHwA" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="INF" format="ixt-sec:numwordsen" name="avte:NumberOfVotesForEachShareOfCommonStock" scale="0" id="Narr_qRurA_robUiQJ77HKg3vxg">one</ix:nonFraction> vote for each share of common stock held at all meetings of stockholders.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="avte:ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock" id="Tb_v5_gFjN-gEmjk5fnbn5Fxg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of September&#160;30,&#160;2024, the Company had reserved the following shares of common stock for future issuance:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:72.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common stock options granted and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_CommonStockMember_euLPHJw1sEmiJdRRSszShQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_J6gkSh4JuUmCzCVc7jLFrQ_2_2">3,714,104</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:72.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares reserved for issuance under the 2021 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_7LIRbHXsBEeM6CKDpiodeA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_xfh-GVciY0-eTKIcQ_F-yQ_3_2">2,982,105</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:72.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reserved for future ESPP issuances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_WBdMq-xE_k6SSkWqaFUxDA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_iFD26ANvX0SfHfyY0le1MQ_4_2">401,218</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_XhnbpqeAoUmA6lHD5TkgeA_5_2">7,097,427</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_dvG-A92_aEqVf-i7ZQU-gA_1_7"></a><a id="Tc_Z0cUI-wqc0SVE0JQKzMuhg_2_7"></a><a id="Tc_tM17BSgxU0Opb4tco6FOTg_3_7"></a><a id="Tc_F3BV6-OikEKUAGuybMW0GA_3_9"></a><a id="Tc_0gioC2TR_kynnqKsHvcSoA_4_4"></a><a id="Tc_XeXo7JZqiUSNlFozmg7aGg_4_7"></a><a id="Tc_LLh75JSKR0KwNxD6cYG7yw_4_9"></a><a id="Tc_DA9Tg2rsS02sfNhkA09tlw_5_2"></a><a id="Tc_BIP3xmNlUkStdBuW9jrfUg_5_4"></a><a id="Tc_OsH93DsL8EaNbsceIRtjLw_5_7"></a><a id="Tc_RnMhIX9vXEKyQqfd48WzuA_5_9"></a><a id="Tc_FHmjxhDp6USKjXEsjlEoyg_6_0"></a><a id="Tc_1XbyufR6-EKG0m0rV7_ICA_6_4"></a><a id="Tc_pS76Ippf5k-XGg2t5SyDwQ_6_9"></a><a id="Tc_qoMFaX1P9Um3SFQmUC4jrg_7_0"></a><a id="Tc_r1Q6d5fZv0WIW0dG8SMw2Q_8_0"></a><a id="Tc_YmqQQQvQJk-NH1WAZACGSQ_9_0"></a><a id="Tc_qbjvdOzvN0uTXPI4M5EycQ_10_0"></a><a id="Tc_boJC5VsMFkmKWKsqzlyQHQ_10_4"></a><a id="Tc_s21vmQo7Wk6KzG8bL3Rj0g_10_9"></a><a id="Tc_8N702LENrESkucNwlDZIfA_11_0"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_m18c7GVNZ0mgL-hlavwMpA" continuedAt="Tb_m18c7GVNZ0mgL-hlavwMpA_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">(7)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">STOCK-BASED COMPENSATION</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Stock Option Plan</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s 2021 Stock Option and Incentive Plan (the &#8220;2021 Plan&#8221;) was adopted by the Company&#8217;s board of directors and approved by the Company&#8217;s stockholders in June&#160;2021 and became effective as of June&#160;29, 2021. Upon the effectiveness of the 2021 Plan, the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) was terminated and no further grants may be made thereunder. The Company&#8217;s 2021 Plan allows for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, stock bonuses, restricted stock, stock units and other forms of awards including cash awards to its officers, directors, employees, consultants and advisors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30,&#160;2024, a total of <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_9_30_2024_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_rO2RmIvkokKdeJv-xbshfQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_JCwH5uClcUeFDfs2kSRguA">5,675,841</ix:nonFraction> shares of the Company&#8217;s common stock were authorized for issuance with respect to awards granted under the 2021 Plan, of which <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_9_30_2024_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_rO2RmIvkokKdeJv-xbshfQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_k2O_xyxbD0iRL1IUIizYxw">2,982,105</ix:nonFraction> shares remain available for issuance. The share limit will automatically increase on the first trading day in January&#160;of each&#160;year (commencing with 2022) by an amount equal to the lesser of (1)&#160;<ix:nonFraction unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_i_a9v0UQS0KpP37FqkD36Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="Narr_JAWTmf4Qp06owiRzcrV8-g">4</ix:nonFraction>% of the total number of outstanding shares of the Company&#8217;s common stock on the last trading day in December&#160;in the prior&#160;year, or (2)&#160;such lesser number as determined by the Company&#8217;s board of directors. Since adoption, the number of shares available under the 2021 Plan pursuant to the annual increases totaled <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_1_1_2024_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_Heb8BZ5jAUughxoa-nLBgw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_Fzz9JyWKjkGQVf-Y_brwzw">3,075,841</ix:nonFraction> shares through January 1, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any shares subject to awards granted under the 2021 Plan or the 2018 Plan that are not paid, delivered or exercised before they expire or are canceled or terminated, or otherwise fail to vest, as well as shares used to pay the purchase or exercise price of such awards or related tax withholding obligations, will become available for new award grants under the 2021 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30,&#160;2024, <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_wlI-MiSjLkiqAu8-lbQ9Sw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="Narr_gxY1oU3lrky1kDDqM2tPLw">2,753,788</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyEighteenStockOptionAndIncentivePlanMember_5jF5V5Er3Eu8MevJLE47ZQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="Narr_y1eGm46D60S8-zIW0SNNHg">960,316</ix:nonFraction> options had been granted under the 2021 Plan and 2018 Plan, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The options that are granted under the 2021 Plan and the 2018 Plan are exercisable at various dates as determined upon grant and terminate within <ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_b5ksvgJaa02KO-43SndRnw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_18Rqhml9Z0KZ4IQKaU5J2Q">10</ix:nonNumeric>&#160;years of the date of grant. The vesting period generally occurs over <span style="-sec-ix-hidden:Hidden_OXhRKVDiBU-X90wrZ-v3BA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to <ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_teg0ACtMzkG-j6fB92sMEQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_8GwmBr2gPEqkj7EtmH3U2Q">four&#160;years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes the option activity under the 2021 Plan and 2018 Plan for the nine months ended September&#160;30,&#160;2024:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_hfsHRPMZDkeezoRHeKKieg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual&#160;Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_Tjtv4rvBf067c01LnlSbjA_6_2">5,230,344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_w5mSZCMVNEW1ZMdwHuHbTw_6_5">13.66</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_uB_rBUzvSkabhpZy_6DbCg_6_7"> 8.16</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_GUrmtsTD40uVpv2Gh9mY8w_6_10">49,728</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_culh4LlooUSe0f6imFDOhw_7_2">1,489,191</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_EPGdqDOx9EW1eMeiszxm6g_7_5">19.70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_wO4EhHADx0SchscfJJzROA_8_2">265,482</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_7s9FN4JRXkWKD34Ceu1mBA_8_5">4.67</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cancelled/Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="Tc_ec4ytAn26EeCDo5VTwshJA_9_2">2,739,949</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_9HXkxNg2Q0CRNV60o5Mthg_9_5">18.84</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_uW80le0u30iE8GcIe1Hx6w_10_2">3,714,104</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_zu7FIFXX7EuaXA-exNCz2A_10_5">12.91</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_-WlEVE1MrUWpACE0I_SCtQ_10_7"> 4.98</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_Q7ZnstyUNEG5ndoVbJNmhg_10_10">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and exercisable at September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="Tc_vpBN1dG5WUaKJV8SD3uAJw_11_2">2,791,181</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="Tc_WJsUK9pNCU-NbuTofkeeKA_11_5">12.06</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="Tc_H8PudXhcHE6cKGwvueSvpA_11_7"> 3.95</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="Tc_OmzmxRI6iUy7eZQwdHeYwQ_11_10">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant date fair value of stock option grants was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_xf_QmrG82Uer7be98shqPQ">14.92</ix:nonFraction> per share for the nine months ended September&#160;30,&#160;2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30,&#160;2024, there was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_JDWj8X9B5Eu8UjEOpYq-Pg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_3pt1KrrenkWZIu-KGVbm-g">9.4</ix:nonFraction> million of total unrecognized stock-based compensation expense related to unvested stock options granted under the 2021 Plan and 2018 Plan, which is expected to be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_b5ksvgJaa02KO-43SndRnw" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_DNDsmhIMr02iLf_eNj-yNw">1.9</ix:nonNumeric>&#160;years.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) was adopted by the Company&#8217;s board of directors and stockholders in June 2021 and became effective upon the consummation of the IPO. A total of <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_ePMqutmojUyuoaStQiHwbg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_AYRrD__d-kinIZ1qK04trQ">230,000</ix:nonFraction> shares of the Company&#8217;s common stock was initially available for issuance under the ESPP. The share limit will automatically increase on the first trading day in January of each year (commencing with 2022) by an amount equal to the lesser of (1) <ix:nonFraction unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA" contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_WvqE0K12M0iiC1AH3k88Tw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="Narr_9pPksjJnI0Ok7v4ljX6DFg">1</ix:nonFraction>% of the total number of outstanding shares of the Company&#8217;s common stock on the last trading day in December in the prior year, or (2) such lesser number as determined by the Company&#8217;s board of directors. The number of shares available under the 2021 Plan increased by <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2023_To_1_1_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_7n9TuWQvlEKuoOSnaqxmoQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_fJVs27PJHUC8RZt8JG9y7g">247,229</ix:nonFraction> shares effective January 1, </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_VWcuDWoo00KFtfjbxas03g_1_4"></a><a id="Tc_IvWnPSnDnEedykobFOA88Q_2_4"></a><a id="Tc_aFiW7P7MdkGBWAxnjy8jew_3_4"></a><a id="Tc_Pi4EPByQ_EmX-VBp1XY5iA_4_2"></a><a id="Tc_FIbXVwtZtUqGgBc8ZdQiMw_4_4"></a><a id="Tc_-1Gz1kLkiESzXhnZ3q3p4A_5_0"></a><a id="Tc_ata9Lc7ujUuMUdOtP0W38Q_5_4"></a><a id="Tc_g4IRsxR3F0SLTHD-t0ggbA_6_0"></a><a id="Tc_oPaIiH5C0Uy4Q53PNZib1w_6_2"></a><a id="Tc_LBMRXz5Z4UWWsjiXN4-n5A_6_5"></a><a id="Tc__uR-wv1nUUKkOu1KlKTOtA_7_0"></a><a id="Tc_aF5K71xN4EqNO9UBmx-2BQ_8_0"></a><a id="Tc_UlGMZVvDdUu7BC9RGPAyEw_9_0"></a><a id="Tc_Vhp_Ie-wakqiYbDvgjqqLQ_9_2"></a><a id="Tc_GK0WfkqlLUK521GWogoPvQ_9_4"></a><a id="Tc_K4st3VXlckSefui7NHd4ew_9_5"></a><a id="_33c69b19_d685_4bcb_99c6_4782a36160f3"></a><a id="Tc_TZsTg25KVk-_KvFL61A9Dg_1_2"></a><a id="Tc_ZXZHG73XX0uj2UmIjfEu8g_1_8"></a><a id="Tc_8iymUcLQzkWv9hs-hTEMGw_2_2"></a><a id="Tc_fI4CbVt-xUu0ilsagrzXVw_2_5"></a><a id="Tc_7Li_JJCBNEGC7VIg0RHQFg_2_8"></a><a id="Tc_ezId31AkD0m0G_dkUxmzXw_2_11"></a><a id="Tc_h1_p89lSu0edrabKYS7ELA_3_0"></a><a id="Tc_I9XvddbXYEusQ1bZlmk0vA_3_2"></a><a id="Tc_zEfEr7fYKUSEje3XO-9rzw_3_5"></a><a id="Tc_ul2nXtn3qEGUcCMFFU50VQ_3_8"></a><a id="Tc_BjKcw-hJPU6PKa01hfvYUw_3_11"></a><a id="Tc_psq7CQS7T0a4j1sfNNC6aA_4_0"></a><a id="Tc_zlqDpFs9uU-ZrHP7C3ZNWw_5_0"></a><a id="Tc_0iaTw7on40G1Hqmm6H5seQ_5_2"></a><a id="Tc_fLTHMg6-ckyPJYehKbYUdA_5_5"></a><a id="Tc_D4VE7vUjJECUl47BdXHZFA_5_8"></a><a id="Tc_bEW8a440KkSLvpFxuRmG1Q_5_11"></a><a id="_96135d32_7a6b_484e_871b_357683fece3a"></a><a id="Tc_rZwE7ASe60qWbYTJRcjMSA_1_2"></a><a id="Tc_RIA7lmQZ80q24UCHu4JGTA_1_8"></a><a id="Tc_mMe1Iz89DUSzN9wHxm_Jfw_2_2"></a><a id="Tc_CCVicJtELkCOABm9zSnSVw_2_5"></a><a id="Tc_P_PGQQctGES32HiDSB3Z4w_2_8"></a><a id="Tc_RuSaWxULC0WoFNeh6DPC6Q_2_11"></a><a id="Tc_1UR9Pfmc00WIfZGTjQz7KQ_3_0"></a><a id="Tc_3okjcmZoOk-j8FoE91C7zg_3_2"></a><a id="Tc_7hOQwKYhLUSWcpedYa2Mmg_3_5"></a><a id="Tc_m1K10p83YUm2BgeXY_Nrfg_3_8"></a><a id="Tc_BKnnnaJxyEidoPG-WTAPUw_3_11"></a><a id="Tc_wEsvfOUzzk2pur_1brcEjA_4_0"></a><a id="Tc_F_cgPYlD70qhXzRL6kfu1A_4_3"></a><a id="Tc_Rqo12yEz8kyMLLO7H-4iZw_5_0"></a><a id="Tc_yrJxIZb7hEyCovr2tpDbUQ_6_0"></a><a id="Tc_rxhVBmrkBke6xBen9fuLOA_6_2"></a><a id="Tc_pzuxG_fe-kuFF4a1VPSm0w_6_5"></a><a id="Tc_gSgms2GNoESyK35bdgrS7w_6_8"></a><a id="Tc_1ew8aVJ5TkeeYBZmeRVwgQ_6_11"></a><ix:continuation id="Tb_m18c7GVNZ0mgL-hlavwMpA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">2023 as determined by the Company&#8217;s board of directors. The ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA" contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_WvqE0K12M0iiC1AH3k88Tw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="Narr_hHBG__D2Zk2VA4Qim58yIg">15</ix:nonFraction>% of their eligible compensation, subject to any plan limitations. The ESPP provides for <ix:nonNumeric contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_WvqE0K12M0iiC1AH3k88Tw" format="ixt-sec:durwordsen" name="avte:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" id="Narr_cz4CqsBpAEOlcHTDghFY2A">six-month</ix:nonNumeric> offering periods, and at the end of each offering period, employees are able to purchase shares at <ix:nonFraction unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA" contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_WvqE0K12M0iiC1AH3k88Tw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" scale="-2" id="Narr_SkyhFnZlSEuSXNgTmxIzOg">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last trading day of the offering period. As of September&#160;30,&#160;2024, <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_wbLsz84n5UemDXpr6FCylA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Narr_Ms-dPeFYP0aSeUT6EvkDWg">76,011</ix:nonFraction> shares had been issued under the ESPP, and <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_WBdMq-xE_k6SSkWqaFUxDA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_N3MnwCRyD0e3lR-rUVOFCg">401,218</ix:nonFraction> shares authorized under the ESPP Plan were available for issuance.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Stock Units</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of September&#160;30,&#160;2024, <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_g2GESSwZAUiWFez9AGcUtA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_EONAFbn0IEmcJUgm-ViksA">31,881</ix:nonFraction> restricted stock units had been awarded under the 2021 Plan. A summary of the status of and changes in unvested restricted stock unit activity under the Company&#8217;s equity award plans for the nine months ended September&#160;30,&#160;2024 was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="Tb_qmyxEJQJ2U-sdNpidxJGsg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:59.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average&#160;Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date&#160;Fair&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per&#160;Unit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Gy-ZvYruXkinoI8nJEgktA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_SnvS8WMM6UiLZWnkQ9W7Nw_5_2">21,968</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Gy-ZvYruXkinoI8nJEgktA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_PbU3lNPL8UqLlpb4HMO93w_5_5">22.26</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mQCZMz_2oEWLJpuw7OHgvw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_AMHS9H1yJ0OwlmR6jiv3_A_7_2">5,492</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mQCZMz_2oEWLJpuw7OHgvw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_txqkyPN4F02kqiS44zTH1g_7_5">21.30</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mQCZMz_2oEWLJpuw7OHgvw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_YmWAbSDW20OCSWknLe3O0g_8_2">16,476</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mQCZMz_2oEWLJpuw7OHgvw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_t7AEdE0wqEGhR4C42aRDRw_8_5">22.58</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units as of September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation of restricted stock units is based on the fair value of the Company&#8217;s common stock on the date of grant and recognized over the vesting period. The vesting period generally occurs over <span style="-sec-ix-hidden:Hidden_Sk9GO9o6hE2czOoGU9-uIA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to <ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2flsdvnZxUqHPV0GQoL5Gw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_fTUpH81mRESUBDnZGzBLUA">four&#160;years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30,&#160;2024, the Company had <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_8CT_KtQnWUiGek0hhT0EXw" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="Narr_Grcs81SeYkqrq4xQ0yAp9w">no</ix:nonFraction> unrecognized stock-based compensation expense related to its unvested restricted stock units.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(d)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation Expense</span></p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_TjrgxOnufEqVoZOm-TQJXQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations and comprehensive loss as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_LZBhq8TBukyCmnM6XHK1BQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_mWzYjHP77k6l_3vASF1TsA_3_3">458</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_vfttyrGb-EW4_y-k4IU1OA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_bbZOPDkx0UW1QEUhiaYNdQ_3_6">1,817</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_z3LyNn-sk0-txThcBPD1Yw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_0jN-qgSlmk65IfIvZsNGnA_3_9">4,987</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_8Qb64bPhgUq_qlFXMzlYzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_0E1sHSo34Uqf7S2wcCaQ0A_3_12">4,798</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_pLhOme55706_ApNfgYI-eA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_qCDV9ohnwEK3T9X3FFWniQ_4_3">1,545</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_h9FVlzwiVkmij0mSQNLnEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_-nZwG0ApXkuZnd97ElPuGw_4_6">1,420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Cxy8Whj0fkC98fl4coAgEw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_VHXjou-Ap0enm9sY9u3Ung_4_9">5,081</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_tQTCT3FErESwh4_H6D13eg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_LkvC_7xYVUG3oaFu41Hfdg_4_12">3,857</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc__NYcB_ImrkCgCu7ZeNP7qg_5_3">2,003</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_XGPyzea6okWdD9QCnsWZCg_5_6">3,237</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_P1doux7B90OzKuUG-aHp5Q_5_9">10,068</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_mL-jPvhuZEW0xDO2I4UPPw_5_12">8,655</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Stock-based compensation expense by type of award included within the consolidated statements of operations and comprehensive income (loss) was as follows: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tKrwYaxnJk285FLx0psBsA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_LyC1_nuxQU2h2h5VtZtXtA_3_3">2,014</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_WbyCz7z-OUWYQdDXhY6H5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_D7JQ6wQlf0io_8dLJGnE0A_3_6">3,140</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_uPFIHMkymk27XMLFjHO_1A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_HllyPygRiEKv0uSXlXYhEQ_3_9">9,890</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nOSs2A7SvUChDUg7Gvgu0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_kRCw3eMvYEaeYjRGTDjvhg_3_12">8,369</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock awards and units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_8Cexqi34OkyeCy4KU0ckUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_hgp71p7A50S6M9O6cmJZMw_4_6">52</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mQCZMz_2oEWLJpuw7OHgvw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_sV6IKC8yCUiTwLPnIntjVg_4_9">116</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mCr7TNm_z0awNKcONlrnIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_bsnof25z5kGLF7M4lSxB6g_4_12">151</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee stock purchase plan awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_R7ajYhISp021nisBN9RonQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" sign="-" scale="3" id="Tc_a_JX-zR5TUSL8hLrmvuezg_5_3">11</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_dh_QB-NHhUST-PrSPEqJ1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_s-Xy5jXhQU6iHiPILvYQKw_5_6">45</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_wbLsz84n5UemDXpr6FCylA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_amtAZ4r4sk6NPYlqnuRdxg_5_9">62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_mxwv-vX1-EKBfodK731-kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_Oq4IivmSika1tERLhfwdqA_5_12">135</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_uGCtqx4usECun1P-HXjCUg_6_3">2,003</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_2JJb3uJxC0WH98qZg2SuIw_6_6">3,237</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_zzi3jusWtkSaFmScINhbTg_6_9">10,068</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_Bl-lP-XLnE6jaE-pCB4KpQ_6_12">8,655</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA" name="us-gaap:SubsequentEventsTextBlock" id="Tb_9cob3qmGoE6Z0jbCQcT8zA" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">(8)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">SUBSEQUENT EVENT</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 30, 2024, the Company formed wholly-owned subsidiaries, Merger Sub I, a Delaware shell corporation, and Merger Sub II, a Delaware limited liability company, each formed solely for the purpose of merging with Jade in connection with the proposed Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June 2024, the Company announced a corporate restructuring, and in July 2024, announced that it initiated a process to evaluate strategic alternatives. After a comprehensive review of strategic alternatives, including identifying and reviewing potential candidates for a strategic transaction, on October 30, 2024, the Company entered into the Merger Agreement, by and among the Company, Merger Sub I, Merger Sub II, and Jade, pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, among other things, Merger Sub I will merge with and into Jade, with Jade surviving the first merger as the surviving corporation, and as part of the same overall transaction, Jade will merge with and into Merger Sub II, with Merger Sub II continuing as a wholly owned subsidiary of the Company and the surviving corporation of the second merger. In addition, in connection with the Closing, the Company expects to declare the Cash Dividend to its pre-Merger stockholders of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_10_30_2024_To_10_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_RPVQa3dXU0OggwPnCBtwgg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="Narr_CPG_v-TcBUy5TwEzVUKo0w">65.0</ix:nonFraction> million in the aggregate, provided such amount is subject to adjustment as set forth in the Merger Agreement. The Merger was approved by the Board, and the Board resolved to recommend approval of the Merger Agreement to the Company&#8217;s stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger is expected to close in the first half of 2025. The Closing is subject to approval by the stockholders of the Company and Jade as well as other customary closing conditions, including the effectiveness of a registration statement filed with the SEC in connection with the Merger and the approval of The Nasdaq Stock Market LLC of the listing of shares of the Company&#8217;s common stock to be issued in connection with the Merger and (4) an executed Purchase Agreement for the Concurrent Investment (each as defined below) in full force and effect evidencing cash proceeds of not less than $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="Duration_10_30_2024_To_10_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_RPVQa3dXU0OggwPnCBtwgg" decimals="-5" format="ixt:numdotdecimal" name="avte:PurchaseAgreementCashProceedsToBeReceivedUponClosingOfMerger" scale="6" id="Narr_ASes0PTmykm9dX8UD0JUaQ">80.0</ix:nonFraction> million to be received by the combined company immediately prior to or following the Closing. If the Company is unable to satisfy certain closing conditions or if other mutual closing conditions are not satisfied, Jade will not be obligated to complete the Merger. The Merger Agreement contains certain termination rights of each of the Company and Jade. Upon termination of the Merger Agreement under specified circumstances, the Company may be required to pay Jade a termination fee of $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_10_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_UR7pUGE3y0avsGAAh5HJFA" decimals="0" format="ixt:numdotdecimal" name="avte:MergerAgreementTerminationFeesPayable" scale="0" id="Narr__0WfeEVkrU23R9d2bE5lPQ">2,340,000</ix:nonFraction>, and in certain other circumstances, Jade may be required to pay the Company a termination fee of $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_10_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_UR7pUGE3y0avsGAAh5HJFA" decimals="0" format="ixt:numdotdecimal" name="avte:MergerAgreementTerminationFeesReceivable" scale="0" id="Narr_45K0p33lgE-sLgbVh-JG_w">5,250,000</ix:nonFraction>. If the Merger is completed, the business of Jade will continue as the business of the combined company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger (the &#8220;Effective Time&#8221;), (a) each then-outstanding share of Jade&#8217;s common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="As_Of_10_30_2024_dei_LegalEntityAxis_avte_JadeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7tb7W4BvUUu3IUTHi97FXg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_dLu2AFnFDky1Wcx4p5yk3Q">0.0001</ix:nonFraction> per share, will be converted into the right to receive a number of shares of the Company&#8217;s common stock, based on a ratio calculated in accordance with the Merger Agreement (the &#8220;Exchange Ratio&#8221;), provided that any unvested restricted shares of Jade common stock will be subject to the same terms and conditions (including, without limitation, vesting and repurchase provisions) that are otherwise applicable to such unvested shares as of immediately prior to the Effective Time, (b) each then-outstanding share of Jade&#8217;s preferred stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="As_Of_10_30_2024_dei_LegalEntityAxis_avte_JadeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7tb7W4BvUUu3IUTHi97FXg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_VujdjkSaA0CmNCY50NgZFQ">0.0001</ix:nonFraction> per share, will be converted into the right to receive a number of shares of the Company&#8217;s newly authorized convertible preferred stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A" contextRef="As_Of_10_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_UR7pUGE3y0avsGAAh5HJFA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_q68j6fOcckGhxnlzjp8Sjg">0.0001</ix:nonFraction> per share, equal to (x) the Exchange Ratio divided by (y) <ix:nonFraction unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w" contextRef="As_Of_10_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_UR7pUGE3y0avsGAAh5HJFA" decimals="INF" format="ixt:numdotdecimal" name="avte:MergerAgreementSharesToBeIssuedDenominatorForCalculation" scale="0" id="Narr_TdNWh4San0C3kxs1__1Gvg">1,000</ix:nonFraction>, (c) each then-outstanding option to purchase Jade common stock will be assumed by the Company, subject to adjustment as set forth in the Merger Agreement and (d) each then-outstanding warrant to purchase shares of Jade common stock or Jade preferred stock will be assumed by the Company, subject to adjust as set forth in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 30, 2024, Jade entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain existing Jade stockholders and new investors (the &#8220;Investors&#8221;). Pursuant to the Purchase Agreement, and subject to the terms and conditions thereof, Jade agreed to sell, and the Investors agreed to purchase, immediately prior to the consummation of the Merger, shares of Jade common stock and pre-funded warrants (together, the &#8220;Securities&#8221;) for an aggregate purchase price of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_10_30_2024_dei_LegalEntityAxis_avte_JadeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7tb7W4BvUUu3IUTHi97FXg" decimals="-5" format="ixt:numdotdecimal" name="avte:MergerAgreementSecuritiesCapitalAmountReservedForFutureIssuance" scale="6" id="Narr_HTbyhNV9DkK_Vx4-RdSejA">300.0</ix:nonFraction> million (collectively, the &#8220;Concurrent Investment&#8221;), which reflects the conversion of the previously issued $<ix:nonFraction unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg" contextRef="As_Of_10_30_2024_dei_LegalEntityAxis_avte_JadeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7tb7W4BvUUu3IUTHi97FXg" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ConvertibleNotesPayable" scale="6" id="Narr_JDMpf4wrJUCeGpm6mA1afQ">95</ix:nonFraction> million of convertible notes. The consummation of the transactions contemplated by such agreements is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement and in the Purchase Agreement. Shares of Jade Common Stock and pre-funded warrants issued pursuant to this financing transaction will be converted into shares of common stock of the Company and pre-funded warrants to acquire shares of common stock of the Company, in accordance with the Exchange Ratio and the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that the Company does not complete the transaction with Jade, the Company may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of the Company.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_248b0ba5_edc0_449d_9065_102e23f55464"></a><a id="ReportOfIndependentRegistered1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To the Board of Directors and Stockholders of Jade Biosciences, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Opinion on the Financial Statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have audited the accompanying balance sheets of Jade Biosciences, Inc. (the <span style="font-family:'Georgia';">&#8220;</span>Company<span style="font-family:'Georgia';">&#8221;</span>) as of September 30, 2024 and June 18, 2024, and the related statements of operations and comprehensive loss, convertible preferred stock and stockholders<span style="font-family:'Georgia';">&#8217;</span> deficit and cash flows for the period from June 18, 2024 (inception) to September 30, 2024, including the related notes (collectively referred to as the <span style="font-family:'Georgia';">&#8220;</span>financial statements<span style="font-family:'Georgia';">&#8221;</span>). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of September 30, 2024 and June 18, 2024, and the results of its operations and its cash flows for the period from June 18, 2024 (inception) to September 30, 2024 in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Substantial Doubt about the Company</i><i style="font-family:'Georgia';font-style:italic;">&#8217;</i><i style="font-style:italic;">s Ability to Continue as a Going Concern</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has incurred significant operating losses and negative cash flows from operations since inception that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Basis for Opinion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">These financial statements are the responsibility of the Company<span style="font-family:'Georgia';">&#8217;</span>s management. Our responsibility is to express an opinion on the Company<span style="font-family:'Georgia';">&#8217;</span>s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We conducted our audits of these financial statements in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ PricewaterhouseCoopers LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Boston, Massachusetts</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 2, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have served as the Company's auditor since 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_0fce0390_756d_4d8b_a928_8f22ce99880d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES,&#160;INC.</b></p><a id="BALANCESHEETS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BALANCE SHEETS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share and per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;18,</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 87,970</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;">&#8199;&#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Related party subscription receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 218</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 88,188</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,159</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 89,347</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 923</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 550</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Related party accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,011</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,484</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Long-term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Warrant liability, related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Convertible notes payable<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 96,700</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 106,208</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Commitments and contingencies (Note 11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series Seed convertible preferred stock, $0.0001 par value; 20,000,000 shares authorized as of each of September 30, 2024 and June 18, 2024; 20,000,000 shares issued and outstanding as of each of September 30, 2024 and June 18, 2024; liquidation preference of $2 as of each of September 30, 2024 and June 18, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Stockholders&#8217; deficit:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Common stock, $0.0001 par value; 40,000,000 shares authorized, 5,819,672 shares issued and outstanding as of each of September 30, 2024 and June 18, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (16,867)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Total stockholders&#8217; deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (16,863)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total liabilities, convertible preferred stock and stockholders&#8217; deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 89,347</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;">Includes related party amount of $20.4&#160;million</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_4ebe678b_cf3f_4a50_a4b1_f7b58657486e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES,&#160;INC.</b></p><a id="COMPREHENSIVELOSS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share and per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Period&#160;from</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;18,</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Inception)&#160;to</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 5.75pt;">Research and development<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13,659</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 5.75pt;">General and administrative<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,896</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 11.5pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,555</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (15,555)</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other income / (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 5.75pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 388</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 5.75pt;">Change in fair value of convertible notes payable<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,700)</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 11.5pt;">Total other expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,312)</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss and comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (16,867)</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3.37)</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,000,000</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;">Includes related party amount of $13.2&#160;million for the period from June&#160;18, 2024 (inception) to September&#160;30, 2024 (see Note&#160;13).</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;">Includes related party amount of $0.9&#160;million for the period from June&#160;18, 2024 (inception) to September&#160;30, 2024 (see Note&#160;13).</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;">(3)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;">Includes related party amount of $0.4&#160;million for the period from June&#160;18, 2024 (inception) to September&#160;30, 2024 (see Note&#160;13).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_db6e86f1_a44b_458b_9d95_e3c8ace4db12"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES,&#160;INC.</b></p><a id="STOCKHOLDERSDEFICIT"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">STATEMENT OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; DEFICIT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Convertible</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances as of June 18, 2024 (inception)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,000,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,819,672</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">&#8199;&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (16,867)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (16,867)</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances as of September 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,000,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,819,672</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (16,867)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (16,863)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_3a09baa8_ddea_486a_b7ab_b88be11e253d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES,&#160;INC.</b></p><a id="CASHFLOWS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">STATEMENT OF CASH FLOWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Period&#160;from</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;18,</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Inception)&#160;to</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flows from operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (16,867)</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Change in fair value of convertible notes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,700</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 27</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (215)</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 298</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 244</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Related party accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,011</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (6,802)</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flows from financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from issuance of convertible notes payable<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 95,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Payment of deferred offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (228)</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 94,772</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><b style="font-weight:bold;">Net increase in cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 87,970</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash at beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 87,970</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Supplemental disclosure of non-cash financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred offering costs in accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 306</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred offering costs in accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 625</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;">Includes related party amount of $20.0&#160;million for the period from June&#160;18, 2024 (inception) to September&#160;30, 2024.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e81f9846_9ecc_4637_b1e2_151b73e505f3"></a><a id="NatureoftheBusinessandBasisofP"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Nature of the Business and Basis of Presentation</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Background and Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jade Biosciences,&#160;Inc. (&#8220;Jade&#8221; or the &#8220;Company&#8221;) was established and incorporated under the laws of the state of Delaware on June&#160;18, 2024. Jade was founded by healthcare investor Fairmount Funds Management LLC (&#8220;Fairmount&#8221;) and launched to research and develop antibody candidates licensed from Paragon Therapeutics,&#160;Inc. (&#8220;Paragon&#8221;), an antibody discovery engine founded by Fairmount. The Company currently operates as a virtual company, and thus, does not maintain a corporate headquarters or other significant facilities. Jade was formed to develop biologics to optimize the treatment of autoimmune diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, the ability to complete preclinical and clinical trials, the ability to obtain regulatory approval for product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, reliance on third-party organizations, protection of proprietary technology, compliance with government regulations, product liability, uncertainty of market acceptance of products and the ability to raise additional capital to fund operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s potential product candidates will require approval from the U.S. Federal Food and Drug Administration or comparable foreign authorities prior to the commencement of commercial sales. There can be no assurance that the Company&#8217;s potential product candidates will receive all the required approvals. In addition, there can be no assurance that the Company&#8217;s potential product candidates, if approved, will be accepted in the marketplace, that any future product candidates can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such product candidates will be successfully marketed, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate Therapeutics, Inc., a Delaware corporation (&#8220;Aerovate&#8221;), and the Company entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) on October 30, 2024, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Caribbean Merger Sub I, Inc., a Delaware corporation, will merge with and into Jade, with Jade continuing as a wholly owned subsidiary of Aerovate and the surviving corporation of the merger (the &#8220;First Merger&#8221;), and Jade will merge with and into Caribbean Merger Sub II, LLC, a Delaware limited liability company (&#8220;Second Merger Sub&#8221;), with Second Merger Sub being the surviving entity of the merger (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;). In connection with the Merger, Second Merger Sub will change its corporate name to &#8220;Jade Biosciences, LLC&#8221; and Aerovate will change its name to &#8220;Jade Biosciences, Inc.&#8221; Aerovate following the Merger is referred to herein as the &#8220;combined company.&#8221; The combined company will be led by Jade&#8217;s management team and will focus on developing differentiated biologic therapies for patients living with autoimmune diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the effective time of the First Merger (the &#8220;First Effective Time&#8221;), (i)&#160;each share of Jade common stock (including shares of Jade common stock issued in the Jade pre-closing financing described below) will be converted into the right to receive a number of shares of Aerovate common stock equal to the exchange ratio set forth in the Merger Agreement and (ii)&#160;each share of Jade Series&#160;Seed Convertible Preferred Stock, par value $0.0001 per share, will be converted into the right to receive a number of shares of Aerovate Series&#160;A Non-Voting Convertible Preferred Stock (the &#8220;Aerovate Series&#160;A Preferred Stock&#8221;) equal to the exchange ratio divided by 1,000. If any shares of Jade common stock are unvested or subject to a repurchase option or risk of forfeiture at the First Effective Time (the &#8220;Jade restricted common stock&#8221;), then the shares of Aerovate common stock issued in exchange for such shares will to the same extent be unvested and subject to the same repurchase option or risk of forfeiture.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 30, 2024, concurrent with the execution of the Merger Agreement, the Company entered into a Subscription Agreement with certain investors pursuant to which the Company agreed to issue and sell to such investors in a private placement financing (the &#8220;Private Placement&#8221;) shares of the Company&#8217;s common stock and pre-funded warrants to purchase shares of the Company&#8217;s common stock at an estimated purchase price of $5.9407 per share of common stock and $5.9046 per pre-funded warrant, for gross proceeds of approximately $300.0&#160;million (which includes $95.0&#160;million of proceeds previously received from the issuance of convertible notes (the &#8220;Convertible Notes&#8221;)), which will precede the closing of the Merger. Shares of the Company&#8217;s common stock issued pursuant to the Private Placement will be converted into shares of Aerovate common stock in accordance with the exchange ratio at the effective time of the close of the transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The financial statement and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Going Concern</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within twelve months of the date that the financial statements are issued. As of September&#160;30, 2024, the Company had $88.0&#160;million in cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will devote substantially all of its resources to advancing the development of its programs, organizing and staffing the Company, business planning, raising capital, and providing general and administrative support for these operations. Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and regulatory approvals to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. If the Company obtains regulatory approval for any of its potential product candidates and starts to generate revenue, it expects to incur significant expenses related to developing its internal commercialization capability to support product sales, marketing, and distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result, the Company will need substantial additional funding to support its operating activities as it advances its potential product candidates through development, seeks regulatory approval and prepares for and, if any of its potential product candidates are approved, proceeds to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination of equity offerings and debt financings. Adequate funding may not be available to the Company on acceptable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Company is unable to obtain additional funding, the Company will assess its capital resources and may be required to delay, reduce the scope of or eliminate some or all of its planned operations, which may have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and ability to operate as a going concern. The financial statements do not include any adjustments that may result if the Company is not able to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception. The Company has incurred a net loss of $16.9&#160;million during the period from June&#160;18, 2024 (inception) to September&#160;30, 2024. As of September&#160;30, 2024, the Company had an accumulated deficit of $16.9&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July&#160;2024, the Company received $80.0&#160;million in gross proceeds from a Convertible Note&#160;Agreement with several investors, of which Fairmount, through an affiliate fund, holds a convertible note with an initial principal amount of $20.0&#160;million, which qualifies as a related party transaction (see Note&#160;13). In September&#160;2024, the Company received an additional $15.0&#160;million in gross proceeds from issuing convertible notes&#160;to other investors under the Convertible Note&#160;Agreement (see Note&#160;5).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Concurrent with the execution of the Merger Agreement, certain parties have entered into the Subscription Agreement with Jade to purchase, prior to the consummation of the Merger, shares of Jade common stock and pre-funded warrants at an estimated purchase price of $5.9407 and $5.9406 per share, respectively, for aggregate gross cash proceeds of approximately $300.0 million, which includes the $95.0 million of Jade convertible notes previously issued. Shares of Jade common stock and pre-funded warrants to purchase shares of Jade common stock issued pursuant to the Subscription Agreement will be converted into shares of Aerovate common stock and pre-funded warrants to purchase shares of Aerovate common stock at Closing per the Merger Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">However, the completion of the transactions is subject to the satisfaction of customary closing conditions, and there are no assurances that such conditions will be achieved nor that such financing or other strategic transactions will be available on acceptable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on its expectations of continuing operating losses and negative cash flows from operations for the foreseeable future, as of December&#160;2, 2024, the date the Company&#8217;s financial statements are available to be issued, the Company has concluded that there is substantial doubt about its ability to continue as a going concern for at least 12&#160;months from the date the financial statements are available to be issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The accompanying financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accordingly, the financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</p><a id="_7a4a1a9d_9643_4428_849f_91d3247d95b6"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Summary of Significant Accounting Policies</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the Company&#8217;s financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions, and judgements that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected within these financial statements include but are not limited to research and development expenses and related prepaid or accrued costs, the valuation of stock-based compensation awards and related expenses, and the valuation of outstanding convertible notes. The Company bases its estimates on known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Actual results may differ materially from those estimates or assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segment Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company operates and manages its business as a single segment for the purposes of assessing performance and making operating decisions. The Company&#8217;s chief executive officer, who is the chief operating decision maker (the &#8220;CODM&#8221;), reviews the Company&#8217;s financial information for purposes of evaluating financial performance and allocating resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash. The Company maintains its cash balances at an accredited financial institution in amounts that, at times, may exceed federally insured limits. However, the Company has not experienced any losses on its deposits of cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is dependent on third-party organizations to research, develop, manufacture, and process its potential product candidates for its development programs. The Company expects to continue to be dependent on a small number of manufacturers to supply it with its requirements for all products. The Company&#8217;s research and development programs could be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company&#8217;s research and development activities are performed under its agreements with Paragon (see Note&#160;10).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Deferred Offering Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain legal, professional, accounting, and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After the consummation of an equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of the preferred stock or in stockholders&#8217; deficit as a reduction of additional paid-in capital generated as a result of the offering. Should the in-process equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statement of operations and comprehensive loss. As of September&#160;30, 2024, deferred offering costs of $1.2&#160;million were recorded as Other assets in the balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Subscription receivable</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for any notes received in exchange for common stock, including those with related parties as a subscription receivable, provided the note underlying the receivable is paid prior to the date the financial statements are available to be issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value Measurements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1&#8201;&#8212;&#8201;Quoted prices in active markets that are identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2&#8201;&#8212;&#8201;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3&#8201;&#8212;&#8201;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies, and similar techniques.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying values of the Company&#8217;s prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their relatively short maturity periods. The Company has elected the fair value option (&#8220;FVO&#8221;) for its convertible notes. The analysis of the fair value of the convertible notes contains inherent assumptions related to the market interest rate, instrument-specific credit risk, the probability of alternate financing, change of control, initial public offering, maturity extension, and payment at original maturity. Due to the use of significant unobservable inputs, the overall fair value measurement of the convertible notes is classified as Level&#160;3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Classification of Convertible Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has classified the Series&#160;Seed convertible preferred stock (the &#8220;Convertible Preferred Stock&#8221;) outside of stockholders&#8217; equity on the Company&#8217;s balance sheet because the holders of such stock have certain liquidation rights in the event of a deemed liquidation event that, in certain situations, is not solely within the control of the Company and would require the redemption of the then-outstanding Convertible Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Convertible Preferred Stock is not redeemable, except in the event of deemed liquidation (see Note&#160;6). Because the occurrence of a deemed liquidation event is not currently probable, the carrying values of the Convertible Preferred Stock are not being accreted to their redemption values. Subsequent adjustments to the carrying values of the Convertible Preferred Stock would be made only when a deemed liquidation event becomes probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Convertible Notes&#160;Payable</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company performed an analysis of all of the terms and features of the Convertible Notes and has elected the FVO to account for the Convertible Notes&#160;to address simplification as the Company has identified embedded derivatives, such as automatic conversion upon the closing of a $25.0&#160;million or greater financing event, including an initial public offering (a &#8220;Next Equity Financing&#8221;), and automatic conversion upon certain events (e.g., a sale of substantially all Company assets, a merger, etc.), both of which would require bifurcation and separate accounting. The Convertible Notes&#160;will be remeasured at fair value at each balance sheet date until repayment or conversion. Changes to the fair value of the Convertible Notes&#160;will be recorded in other income (expense), net in the Company&#8217;s statement of operations and comprehensive loss. The Company has also elected the option of combining interest expense and the change in fair value as a single line item within the Company&#8217;s statement of operations and comprehensive loss. Changes in fair value resulting from changes in instrument-specific credit risk, if any, will be recognized separately in other comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Contract Costs Accruals</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company records the costs associated with research studies and manufacturing development as incurred. These costs are a significant component of the Company&#8217;s research and development expenses, with a substantial portion of the Company&#8217;s ongoing research and development activities conducted by third-party service providers, including contract research organizations (&#8220;CROs&#8221;) and contract manufacturing organizations (&#8220;CMOs&#8221;), and the Company&#8217;s related party Paragon (see Note&#160;10).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company accrues for expenses resulting from obligations under its antibody discovery and option agreement (as amended, the &#8220;Paragon Option Agreement&#8221;) by and among the Company, Paragon and Parade Biosciences Holding LLC (&#8220;Parade&#8221;), an entity </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">formed by Paragon as a vehicle to hold equity in the Company, and agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrual balance in each reporting period. In the event advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be expensed as the contracted services are performed. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect the Company&#8217;s results of operations. As of September&#160;30, 2024, the Company has not experienced any material deviations between accrued and actual research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Research and development costs include amounts reimbursed to Paragon under the option agreement (see Note&#160;10), salaries and bonuses, stock-based compensation, employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses on the accompanying balance sheet. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable advance payments represent a one-time cost for obtaining goods or services, with anticipated benefits to be utilized within a&#160;year of period end, the payment is expensed immediately.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of salaries and bonuses, stock-based compensation, employee benefits, finance and administration costs, and professional fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Commitments and Contingencies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company may be subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities. The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but not probable; however, it discloses the range of reasonably possible losses. As of September&#160;30, 2024, no liabilities were recorded for loss contingencies (see Note&#160;11).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company classifies stock-based compensation expense in its statement of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company grants stock options and restricted stock awards that are subject to service-based vesting conditions. Compensation expense for awards to employees and directors with service-based vesting conditions is recognized using the straight-line method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards to non-employees with service-based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. As of each reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation expense until it is probable that the performance-based vesting condition will be achieved. The Company has issued stock options and restricted common stock awards (&#8220;RSAs&#8221;) with service-based vesting conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company measures all stock-based awards granted to employees, directors, and non-employees in the form of stock options to purchase shares of its common stock, based on the fair value of the awards on the date of grant using the Black-Scholes option-</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">pricing model. The Company measures RSAs using the difference, if any, between the purchase price per share of the award and the fair value of the Company&#8217;s common stock at the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s common stock valuations were prepared using a hybrid method, including an option pricing method (&#8220;OPM&#8221;). The OPM treats common stock and preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#8217;s securities changes. Under this method, the common stock has value only if the funds available for distribution to stockholders exceed the value of the preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. The hybrid method is a probability-weighted expected return method (&#8220;PWERM&#8221;), where the equity value in one or more of the scenarios is calculated using an OPM. The PWERM is a scenario-based methodology that estimates the fair value of common stock based upon an analysis of future values for the company, assuming various outcomes. The common stock value is based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of stock. The future value of the common stock under each outcome is discounted back to the valuation date at an appropriate risk- adjusted discount rate and probability weighted to arrive at an indication of value for the common stock. A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The assumptions underlying these valuations represented management&#8217;s best estimate, which involved inherent uncertainties and the application of management&#8217;s judgment. As a result, if the Company had used significantly different assumptions or estimates, the fair value of incentive shares and stock-based compensation expense could have been materially different.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net Loss per Share Attributable to Common Stockholders</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company applies the two-class method when computing net loss per share attributable to the Company&#8217;s common stockholders as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires loss available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the undistributed earnings as if all loss for the period had been distributed. The Company considers its Convertible Preferred Stock to be participating securities as, in the event a dividend is paid on common stock, the holders of Convertible Preferred Stock would be entitled to receive dividends on a basis consistent with the Company&#8217;s common stockholders. There is no allocation required under the two-class method during periods of loss since the participating securities do not have a contractual obligation to share in the losses of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to the Company&#8217;s common stockholders by the weighted average number of common shares outstanding for the period, excluding potentially dilutive common shares. Diluted net loss per share attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss by the weighted average number of common shares outstanding for the period, including potentially dilutive securities. For purposes of this calculation, the Company&#8217;s outstanding Convertible Preferred Stock, Convertible Notes, stock options to purchase common stock and unvested RSAs are considered potentially dilutive common shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company generated a net loss for the period presented. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis of assets and liabilities using enacted tax rates in effect for the&#160;years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">allowance is established through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or penalties related to uncertain tax positions as of both June&#160;18, 2024 and September&#160;30, 2024. The Company did not have any uncertain tax positions as of both June 18, 2024 and September 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2023-07,&#160;<i style="font-style:italic;">Segment Reporting</i>&#160;(<i style="font-style:italic;">Topic 280</i>) (&#8220;ASU 2023-07&#8221;), which enhances the segment disclosure requirements for public entities on an annual and interim basis. Under this proposal, public entities will be required to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss. Additionally, current annual disclosures about a reportable segment&#8217;s profit or loss and assets will be required on an interim basis. Entities will also be required to disclose information about the CODM&#8217;s title and position at the Company along with an explanation of how the CODM uses the reported measures of segment profit or loss in their assessment of segment performance and deciding how to allocate resources. Finally, ASU 2023-07 requires all segment disclosures for public entities that have only a single reportable segment. The amendments in ASU 2023-07 are effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2023, the FASB issued ASU 2023-09,&#160;<i style="font-style:italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>. This ASU expands disclosures in an entity&#8217;s income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S. and foreign jurisdictions. This update is effective beginning with the Company&#8217;s 2025 fiscal&#160;year annual reporting period. The Company is currently evaluating the impact of this standard on its financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;). The amendments in ASU 2024-03 require public entities to disclose specified information about certain costs and expenses. ASU 2024-03 is effective for the Company&#8217;s annual reporting period beginning after December 15, 2026 and interim reporting periods beginning after December 27, 2027, with early adoption permitted. The Company is currently evaluating the impact of this standard on its financial statements.</p><a id="_9b03d4f5_1c70_42a7_b56f_9260a1122496"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Fair Value Measurements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table presents information about the Company&#8217;s liabilities that are measured at fair value on a recurring basis as of September&#160;30, 2024 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine the fair value (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:42.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Convertible notes payable, noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 96,700</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 96,700</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 96,700</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 96,700</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Convertible notes&#160;payable are revalued at each remeasurement date using inputs that are generally unobservable and reflect management&#8217;s estimates of assumptions that market participants would use in pricing the liability, which represent a Level&#160;3 measurement within the fair value hierarchy. For the period from June&#160;18, 2024 (inception) to September&#160;30, 2024, there were no transfers between Level&#160;1, Level&#160;2 and Level&#160;3. There were no financial assets and liabilities that were measured at fair value at a </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">recurring basis as of June 18, 2024 (inception).<br/><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table presents the changes in the fair value of the Level&#160;<span style="white-space:pre-wrap;">3  Convertible notes&#160;payable (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amounts</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of June 18, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Convertible notes payable issuance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 95,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Change in fair value of Convertible notes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,700</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 96,700</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Convertible notes&#160;payable in the table above consists of the fair value of an aggregate principal amount of $95.0&#160;million, and accrued interest of $1.7 million, in Convertible Notes&#160;which the Company issued and sold to certain investors. Each holder of Convertible Notes&#160;is expected to contribute the principal amount and all accrued interest under the applicable convertible note in exchange for the Company&#8217;s common stock or non-voting preferred stock in connection with a financing event under the Convertible Notes&#160;(see Note&#160;5). The Company&#8217;s valuation of the Convertible notes&#160;payable utilizes a scenario-based valuation analysis, which incorporated assumptions and estimates to value the Convertible Notes&#160;and a probability assessment of the achievement of the Next Equity Financing. The Company assesses these assumptions and estimates on a quarterly basis as additional information impacting the assumptions is obtained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table presents the assumptions and estimates incorporated into the Convertible notes&#160;payable at the initial issuance date of July&#160;24, 2024 and as of September&#160;30, 2024. The change in fair value is attributable to the impact of accrued interest:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:84.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Time to Next Equity Financing (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.22&#8201;&#8211;&#8201;0.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Probability of Next Equity Financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">15-35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Time to Next Equity Financing / prior to Trade Sale (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.75&#8201;&#8211;&#8201;0.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Probability of Next Equity Financing / prior to Trade Sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 65</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 67.9</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_9d65020b_55b6_4e6b_b14a_a68de1990156"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Accrued Expenses and Other Current Liabilities</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued employee compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 80</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional and consulting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 443</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued research and development contract costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 27</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 550</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_ef9b0629_5f29_4875_a46d_37226327f876"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Convertible Notes&#160;Payable</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July&#160;2024, the Company entered into a Convertible Note&#160;Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with a series of investors, pursuant to which the Company issued convertible notes with an initial principal amount of $80.0&#160;million (of which $20.0&#160;million is from a related party). In September&#160;2024, the Company received an additional $15.0&#160;million in gross proceeds from issuing additional convertible notes to additional investors. The principal amount and all accrued interest of the Convertible Notes&#160;will automatically convert into the Company&#8217;s common stock or preferred stock in connection with the closing of a Next Equity Financing or other events (e.g., a sale of substantially all Company assets, a merger, etc.). The Convertible Notes&#160;accrue interest at a rate of 12.0% per annum, compounded annually. All unpaid interest and principal are scheduled to mature on December&#160;31, 2026 (the &#8220;Maturity Date&#8221;). Prepayment is not permitted without prior written consent of the majority of the holders of the Convertible Notes. The principal payment along with the accrued interest on each Convertible Note&#160;is due in full on the Maturity Date. As of September&#160;30, 2024, the Company had outstanding borrowings of $95.0&#160;million under its Convertible Notes.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the automatic conversions described above, the Convertible Notes&#160;will convert into a number of shares of common stock equal to the quotient obtained by dividing the initial purchase price plus accrued and unpaid interest by the conversion price of the Convertible Notes, which is the product resulting from multiplying the price per share in the Next Equity Financing by 80%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Convertible Notes&#160;were recorded at the fair value of $95.0&#160;million on the respective issuance dates and were remeasured to the fair value of $96.7&#160;million as of September&#160;30, 2024. The change in the fair value of the Convertible Notes&#160;of $1.7&#160;million was recorded within Other income (expense), net on the Company&#8217;s statement of operations and comprehensive loss for the period from June&#160;18, 2024 (inception) to September&#160;30, 2024. There was less than $0.1&#160;million of debt issuance cost incurred in connection with the Convertible Notes. This amount was recognized as general and administrative expense in the Company&#8217;s statement of operations and comprehensive loss during the period from June 18, 2024 (inception) to September 30, 2024.</p><a id="_e9bd304f_4e9a_4694_837b_ac970820c6cb"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Convertible Preferred Stock</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June&#160;18, 2024, the Company issued 20,000,000 shares of the Series&#160;Seed Convertible Preferred Stock to a related party, Fairmount Healthcare Fund&#160;II&#160;L.P., an affiliate fund of Fairmount, at a purchase price of $0.0001 per share for gross proceeds of less than $0.1&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the issuance of the Convertible Preferred Stock, the Company assessed the embedded conversion and liquidation features of the securities as described below and determined that such features did not require the Company to separately account for these features as embedded derivatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30, 2024 and June&#160;18, 2024, Convertible Preferred Stock consisted of the following (in thousands, except share amounts):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2024&#160;and&#160;June&#160;18,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liquidation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuable&#160;Upon</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Authorized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preference</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Conversion</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series Seed Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,000,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,000,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,000,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,000,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,000,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,000,000</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The holders of the Convertible Preferred Stock have the following rights and preferences:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Voting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The holders of Convertible Preferred Stock are entitled to vote, together with the holders of the Company&#8217;s common stock, on all matters submitted to stockholders for a vote. Each holder of outstanding shares of Convertible Preferred Stock is entitled to the number of votes equal to the number of shares of common stock into which the shares of preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. A majority vote of the holders of Convertible Preferred Stock is required to liquidate or dissolve the Company, amend the certificate of incorporation or bylaws in a manner that adversely affects the rights of the Convertible Preferred Stock, reclassify common stock or establish another class of capital stock (unless the same ranks junior to the Convertible Preferred Stock with respect to its rights), create shares that would rank senior to or authorize additional shares of Convertible Preferred Stock, declare a dividend or make a distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the holders of shares of Convertible Preferred Stock are entitled to elect one director of the Company. The holders of shares of common stock and any other class or series of voting stock (including Convertible Preferred Stock), exclusively and voting together as a single class, are entitled to elect the balance of the total number of directors of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Conversion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Each share of Convertible Preferred Stock is convertible into common shares at the option of the holder, at any time, and without the payment of additional consideration by the holder. Additionally, in the event of a Mandatory Conversion, such as the Merger, each share of Convertible Preferred Stock will be automatically converted into shares of newly created non-voting preferred stock at the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">applicable conversion ratio then in effect upon (i)&#160;the closing of a firm-commitment underwritten public offering of the Company&#8217;s common stock at a price of at least $1.00 per share resulting in at least $50.0&#160;million of gross proceeds to the Company, net of the underwriting discount and commissions, and (ii)&#160;the vote or written consent of the holders of a majority of the outstanding shares of preferred stock, voting as a single class. The rights, privileges, duties and obligations relating to the non-voting preferred stock are to be determined at the time of a Mandatory Conversion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The conversion ratio of Convertible Preferred Stock is determined by dividing the original issue price by the conversion price in effect at the time of conversion. The original issue price is $0.0001 per share for Convertible Preferred Stock (in each case subject to appropriate adjustment in the event of any stock split, stock dividend, combination or other similar recapitalization and other adjustments as set forth in the Company&#8217;s certificate of incorporation, as amended and restated). The conversion price is $0.0001 per share for Series&#160;Seed Convertible Preferred Stock. As of September&#160;30, 2024, each outstanding share of Convertible Preferred Stock was convertible into common stock on a one-for-one basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dividends</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company may not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company (other than dividends on shares of common stock payable in shares of common stock) unless the holders of the Convertible Preferred Stock then outstanding first receive, or simultaneously receive, a dividend on each outstanding share of Convertible Preferred Stock in an amount at least equal to (i)&#160;in the case of a dividend being distributed to common stock or any class or series that is convertible into common stock, the equivalent dividend on an as-converted basis or (ii)&#160;in the case of a dividend on any class or series that is not convertible into common stock, a dividend equal to a dividend rate on Convertible Preferred Stock calculated based on the respective original issue price of Convertible Preferred Stock of $0.0001 per share. Dividends are non-cumulative. As of September&#160;30, 2024, no cash dividends had been declared or paid by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, or upon the occurrence of a Deemed Liquidation Event (as defined below), the holders of shares of Convertible Preferred Stock then outstanding are entitled to be paid out of the assets or funds of the Company available for distribution to stockholders before any payment is made to the holders of common stock. The holders of Convertible Preferred Stock are entitled to an amount equal to the greater of (i)&#160;the applicable original issue price per share of the Convertible Preferred Stock, plus any declared but unpaid dividends thereon, or (ii)&#160;the amount per share that would have been payable had all shares of Convertible Preferred Stock been converted into common stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event. If upon any such liquidation event, the assets or funds of the Company available for distribution to stockholders are insufficient to pay the full amount to which they are entitled, then the holders of shares of Convertible Preferred Stock in preference to any distributions to common stock will share ratably in any distribution of the assets or funds available for distribution in proportion to the respective amounts which would otherwise be payable if it were paid in full.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless the holders of a majority in voting power of the then outstanding shares of Convertible Preferred Stock elect otherwise, a Deemed Liquidation Event shall include a merger or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares of the surviving or acquiring corporation) or sale, lease, transfer, exclusive license or other disposition of all or substantially all of the Company&#8217;s assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Redemption</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Convertible Preferred Stock does not have redemption rights, except for the contingent redemption upon the occurrence of a Deemed Liquidation Event.</p><a id="_1ecc6889_814b_45eb_a118_e3c3a0915a61"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Common Stock</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of September&#160;30, 2024, the Company has the authority to issue a total of 40,000,000 shares of common stock at a par value of $0.0001 per share. As of September&#160;30, 2024, 5,000,000 shares of common stock were issued and outstanding and 819,672 RSAs were issued and outstanding. Both the shares of common stock and RSAs were issued at par value in exchange for nominal cash. Each share of common stock entitles the holder to one vote, together with the holders of Convertible Preferred Stock, on all matters </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">submitted to the stockholders for a vote. The holders of common stock are entitled to receive dividends, if any, as declared by the Company&#8217;s board of directors (the &#8220;Board of Directors&#8221;), subject to the preferential dividend rights of the holders of Convertible Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30, 2024, there are 20,198,633 shares of common stock reserved for issuance for the potential conversion of shares of Convertible Preferred Stock into common stock and the exercise of outstanding stock options for common stock under the 2024 Plan (as defined below).</p><a id="_dc89ca18_602a_42ae_aa7b_9cbd818cf6d3"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">8.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Stock-Based Compensation</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2024 Equity Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June&#160;18, 2024, the Board of Directors approved the 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;), under which the Company may grant stock options, restricted stock awards, restricted stock&#160;units, or other stock-based awards to its employees, officers, directors, consultants, and advisors. The 2024 Plan is administered by the Board of Directors, or, at the discretion of the Board of Directors, by a committee of the Board of Directors. The exercise prices, vesting and other restrictions are determined at the discretion of the Board of Directors, or its committee, if so delegated. Stock options granted under the 2024 Plan generally vest over four&#160;years, subject to the participant&#8217;s continued service, and expire after ten&#160;years. Upon adoption, the 2024 Plan authorized 136,612 shares of common stock reserved for issuance under the plan. On July&#160;24, 2024, the Board of Directors approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the 2024 Plan from 136,612 to 3,644,808. As of September&#160;30, 2024, the total number of shares of common stock reserved for issuance under the 2024 Plan was 198,633, with 3,446,175 shares of common stock available for future grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Option Valuation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value of each stock option grant is estimated on the grant date using the Black-Scholes option-pricing model. The Company is a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For stock options with service-based vesting conditions, the expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; stock options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the weighted-average assumptions used in calculating the fair value of the awards for the period June&#160;18, 2024 (inception) to September&#160;30, 2024:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Period&#160;from</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;18,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Inception)&#160;to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 96.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6.1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the stock option activity for the period from June&#160;18, 2024 (inception) to September&#160;30, 2024:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term&#160;(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of June 18, 2024 (inception)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 198,633</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.31</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 198,633</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.31</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9.9</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Vested and expected to vest, September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 198,633</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.31</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9.9</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable, September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The weighted average grant-date fair value of stock options granted for the period June&#160;18, 2024 (inception) to September&#160;30, 2024 was $0.24. For the period from June&#160;18, 2024 (inception) to September&#160;30, 2024, there was $0.1 million in intrinsic value related to outstanding options. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had an exercise price lower than the fair value of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Stock Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June&#160;18, 2024, the Board of Directors issued a total of 819,672 RSAs outside of the 2024 Plan to an employee, a director, and a consultant at a price of $0.0001 per share, the par value of the common stock. Of the 819,672 RSAs issued on June&#160;18, 2024, 136,612 RSAs were issued to a consultant in exchange for regulatory and strategic services provided to the Company and the issuance was determined to be a related party transaction (see Note&#160;13). Such RSAs have service-based vesting conditions only and vest over a four-year period, during which time all unvested shares are subject to forfeiture by the Company in the event the holder&#8217;s service with the Company voluntarily or involuntarily terminates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September 2024, the Company cancelled 136,612 RSAs previously granted to a board member and concurrently regranted 136,612 RSAs to the board member at a nominal purchase price and a fair value of $0.31 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the RSA activity for the period from June&#160;18, 2024 (inception) to September&#160;30, 2024:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant&#160;Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">RSAs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance as of June 18, 2024 (inception)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 819,672</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance as of September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 819,672</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Parade Warrant Obligation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In July&#160;2024, the Company entered into the Paragon Option Agreement with Paragon and Parade. Under the terms of the Paragon Option Agreement, Parade will be entitled to grants of warrants to purchase a number of shares equal to 1.00% of the then outstanding shares of the Company&#8217;s stock, on a fully diluted basis, on December&#160;31, 2025 and December&#160;31, 2026, at the fair market value determined by the Board of Directors (the &#8220;Parade Warrant Obligation&#8221;). The grant dates for the issuance of warrants are expected to be December&#160;31, 2025 and December&#160;31, 2026 as all terms of the award, including number of shares and exercise price, will be known by all parties. Parade&#8217;s research and discover related activities has a service inception period for the grant preceding the grant date, with the full award being vested as of the grant date with no post-grant date service requirement. As of September&#160;30, 2024, the pro-rated estimated fair value of warrants to be granted on December&#160;31, 2025 was $0.2&#160;million. For the period from June&#160;18, 2024 </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(inception) to September&#160;30, 2024, less than $0.1&#160;million was recognized as stock-based compensation expense related to the Parade Warrant Obligation. The warrants expected to be granted to Parade are liability-classified and after the initial recognition, the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the statement of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the assumptions used in calculating the fair value of the awards for the period June 18, 2024 (inception) to September 30, 2024:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:bottom;width:80.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period&#160;from</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:80.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;18,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Inception)&#160;to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">94.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">10.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">3.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the classification of the Company&#8217;s stock-based compensation expense in the statement of operations and comprehensive loss (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Period&#160;from</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;18,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Inception)&#160;to</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 25</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 27</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30, 2024, total unrecognized compensation cost related to the unvested stock options was $0.1&#160;million, which is expected to be recognized over a weighted average period of approximately 3.9&#160;years. As of September&#160;30, 2024, total unrecognized compensation cost related to the unvested RSAs was less than $0.1&#160;million, which is expected to be recognized over a weighted average period of 3.9&#160;years. As of September&#160;30, 2024, the unrecognized compensation cost related to the Parade Warrant Obligation was $0.2&#160;million, which is expected to be recognized over a weighted average period of 1.3&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the award types of the Company&#8217;s stock-based compensation expense in the statement of operations and comprehensive loss (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Period&#160;from</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;18,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Inception)&#160;to</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Parade warrant obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 24</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 27</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_36149edf_06a7_482e_9980_c521046094f6"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">9.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Income Taxes</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A reconciliation of the Company&#8217;s statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Period&#160;from</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;18,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Inception)&#160;to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Federal statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 21.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:83.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Change in deferred tax asset valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (18.9)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:83.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Fair market adjustments related to convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2.1)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:83.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net deferred tax assets consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Period&#160;from</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;18,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Inception)&#160;to</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized start-up expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 396</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accruals and reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,751</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,185</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3,185)</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company had a federal net operating loss carryforward of $0.1&#160;million for the period from June&#160;18, 2024 (inception) to September&#160;30, 2024. The Company had state net operating loss carryforwards of less than $0.1&#160;million for the period from June&#160;18, 2024 (inception) to September&#160;30, 2024. The federal net operating loss carryforwards may be carried forward indefinitely. The state net operating loss carryforwards begin to expire in 2044.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Future realization of the tax benefits of existing temporary differences and net operating loss carryforwards ultimately depends on the existence of sufficient taxable income within the carryforward period. As of September&#160;30, 2024, the Company performed an evaluation to determine whether a valuation allowance was needed. The Company considered all available evidence, both positive and negative, which included the results of operations for the current&#160;year. The Company determined that it was not possible to reasonably quantify future taxable income and determined that it is more likely than not that all of the deferred tax assets will not be realized. Accordingly, the Company maintained a full valuation allowance as of September&#160;30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the period from June&#160;18, 2024 (inception) to September&#160;30, 2024, the valuation allowance increased primarily due to the increases in net operating loss carryforwards and research and development tax credit carryforwards. The changes in the valuation allowance were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Period&#160;from</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;18,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Inception)&#160;to</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance as of June 18, 2024 (inception)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Increases recorded to income tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,185</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance as of September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,185</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Tax Cuts and Jobs Act of 2017 resulted in significant changes to the treatment of research and development expenditures under Section&#160;174. For tax&#160;years beginning after the&#160;year ended December&#160;31, 2021, taxpayers are required to capitalize and amortize all research and development expenditures that are paid or incurred in connection with its trade or business. Specifically, costs for U.S. based research and development activities must be amortized over five&#160;years using a midyear convention. For the period from June&#160;18, 2024 (inception) to September&#160;30, 2024, the Company capitalized $13.6&#160;million of research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has also not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company became a loss corporation as defined in Section&#160;382. Future changes in the Company&#8217;s capital ownership, which may be outside of the Company&#8217;s control, may trigger an ownership change. In addition, future equity offerings or acquisitions that have equity as a component of the purchase price could result in an ownership change. If an ownership change has occurred or does occur in the future, utilization of the net operating loss carryforwards or other tax attributes may be limited, which could potentially result in increased future tax liability for the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations for both federal taxes and the many states in which the Company operates or does business in. ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company records uncertain tax positions as liabilities in accordance with ASC 740 and adjusts these liabilities when the Company&#8217;s judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the Company&#8217;s current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. For the period from June&#160;18, 2024 (inception) to September&#160;30, 2024, the Company has not recorded any uncertain tax positions in the Company&#8217;s financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying statement of operations. For the period from June&#160;18, 2024 (inception) to September&#160;30, 2024, no accrued interest or penalties are included on the related tax liability line in the balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company&#8217;s tax&#160;years are still open under statute from inception.</p><a id="_89a54a1e_be8a_4a43_b038_1a429136cc72"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">10.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Paragon Option Agreement</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July&#160;2024, the Company entered into an Antibody Discovery and Option Agreement with Paragon and Parade for the selected target, APRIL, for the Company&#8217;s initial research program, JADE-001, which was amended in September&#160;2024 to add two additional undisclosed targets for additional research programs named JADE-002 and JADE-003. Under the Paragon Option Agreement, Jade has the exclusive option (an &#8220;Option&#8221;), on a Research Program-by-Research Program basis, to enter into a separate agreement with Paragon consistent with a set of pre-negotiated terms (a &#8220;License Agreement&#8221;). If the Company exercises its options and finalizes the related license agreement, it will be required to make non-refundable milestone payments to Paragon of up to $12.0&#160;million under each respective agreement upon the achievement of certain clinical development milestones, up to $10.0&#160;million under each respective agreement upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the low-to-mid single-digits beginning on the first commercial sale of each developed product. From time to time, the Company can choose to add additional targets by mutual agreement with Paragon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Under the terms of the agreement, Paragon agreed to perform certain research activities to discover, generate, identify, and characterize one or more antibody candidates directed to certain mutually agreed therapeutic targets of interest to Jade (each, a &#8220;Research Program&#8221;). The Paragon Option Agreement requires Jade, Paragon, and Parade to develop a research plan for each target that includes design, modeling, synthesis, evaluation, and other mutually agreed activities (each, a &#8220;Research Plan&#8221;), which activities may include performing preclinical studies. Paragon will perform the activities set forth in each Research Plan on the timelines set forth in such Research Plan and in compliance with a mutually agreed budget. Each Research Program will be overseen and coordinated by a joint development committee consisting of two employees from Jade and two employees from Paragon, with Jade and Paragon each having one vote with respect to decisions of the committee. When Paragon and Parade have produced an antibody </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">against a selected target, and upon the completion of each Research Program, Paragon and Parade will deliver to Jade a data package that includes sequence information for all then-existing antibodies and information directed to such target. Jade, Paragon and Parade have developed a Research Plan for JADE-001 consistent with the foregoing, and Paragon and Parade have delivered an antibody against APRIL&#160;in accordance with such Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless terminated earlier, the Paragon Option Agreement shall continue in force on a Research Program-by-Research Program basis until the later of: (i)&#160;the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by the Company; (ii)&#160;if the Company exercises its Option with respect to a Research Program, but the parties are unable to finalize and execute a License Agreement within 30&#160;days, the expiration of such 30-day period (subject to any mutually agreed extension of such period); and (iii)&#160;the expiration of the applicable Research Term (as defined under the Paragon Option Agreement). The Company may terminate the Paragon Option Agreement or any Research Program at any time for any or no reason upon 30&#160;days&#8217; prior written notice to Paragon, provided that the Company must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate the Paragon Option Agreement or a Research Program immediately upon written notice to the Company if, as a result of any action or failure to act by the Company or its affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number of&#160;months. Each party has the right to terminate the Paragon Option Agreement or any Research Program upon (i)&#160;30&#160;days&#8217; prior written notice of the other party&#8217;s material breach that remains uncured for the 30-day period and (ii)&#160;the other party&#8217;s bankruptcy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Paragon Option Agreement, the Company reimbursed Paragon $5.6&#160;million for research and development costs that per the agreement were incurred by Paragon related to APRIL&#160;prior to entering into the Paragon Option Agreement and other costs incurred by Paragon to support the Company&#8217;s activities through June&#160;30, 2024. Of this upfront research and development costs related to APRIL, a total of $5.5&#160;million was recognized as research and development expense in the Company&#8217;s statement of operations and comprehensive loss during the period from June&#160;18, 2024 (inception) to September&#160;30, 2024. The Company paid $5.6&#160;million to Paragon in August&#160;2024. The Company is also required to pay Paragon for certain development fees and costs on a Research Program-by-Research Program basis. Under the Paragon Option Agreement, the Company is also responsible for any additional development costs incurred by Paragon, which from July&#160;1, 2024 to September&#160;30, 2024 totaled $7.2&#160;million which, was recognized as research and development expense in the Company&#8217;s statement of operation and comprehensive loss during the period from June&#160;18, 2024 (inception) to September&#160;30, 2024. An amount of $7.0&#160;million is included in related party accrued expenses and other current liabilities within the Company&#8217;s balance sheet as of September&#160;30, 2024. In addition, the Company is obligated to pay Paragon $1.3&#160;million following finalization of the research plan for APRIL, which has not yet occurred as of September&#160;30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will reimburse Paragon $0.3&#160;million for development costs related to JADE-002 incurred by Paragon through September&#160;30, 2024 of which $0.2&#160;million was recognized as research and development expense and $0.1&#160;million was recognized in general and administrative expense in the Company&#8217;s statement of operations and comprehensive loss during the period from June&#160;18, 2024 (inception) to September&#160;30, 2024. An amount of $0.3&#160;million is included in related party accrued expenses and other current liabilities as of September&#160;30, 2024. In addition, the Company will pay Paragon $1.0&#160;million following the finalization of the research plan, which has not yet occurred as of September&#160;30, 2024, as well as for subsequent development costs related to JADE-002.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will reimburse Paragon $0.3&#160;million for development costs related to JADE-003 incurred by Paragon through September&#160;30, 2024. This amount was recognized as research and development expense in the Company&#8217;s statement of operations and comprehensive loss during the period from June&#160;18, 2024 (inception) to September&#160;30, 2024. An amount of $0.3&#160;million is included in related party accrued expenses and other current liabilities as of September&#160;30, 2024. In addition, the Company will pay Paragon $1.0&#160;million following the finalization of the research plan, which has not yet occurred as of September&#160;30, 2024, as well as for subsequent development costs related to JADE-003.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Any License Agreement entered into with respect to a given Research Program shall contain the same milestone payment obligations as the Paragon Option Agreement, provided that any milestone set in the Paragon Option Agreement that has not yet been achieved and is duplicated in such License Agreement shall no longer be achievable and payable under the terms of the Paragon Option Agreement and shall only be achievable under the terms of the License Agreement. For the avoidance of doubt, if a milestone is achieved and paid by Jade pursuant to the Paragon Option Agreement for a certain Research Program, then there shall be no milestone payment due for the achievement of such milestone under a subsequently executed License Agreement for such Research Program. Further, under a License Agreement, Jade would also be required to make royalty payments to Paragon in the low single-digit&#160;percentage range based on net sales of products, subject to certain reductions. The royalty term will terminate on a product-by-</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">product and country-by-country basis upon the later of the expiration of the last-to-expire valid claim within the relevant patent rights or the twelfth anniversary of the first commercial sale of such product in such country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, as part of the Paragon Option Agreement, on each of December&#160;31, 2025 and December&#160;31, 2026, Jade will grant Parade warrants to purchase a number of shares equal to 1.00% of Jade&#8217;s outstanding capital stock as of the date of the grant on a fully-diluted basis, with an exercise price equal to the fair market value of the underlying shares of Jade common stock on each respective grant date. Parade is an entity formed by Paragon as a vehicle to hold equity in Jade in order to share profits with certain employees of Paragon and will not perform any substantive role under the Paragon Option Agreement other than to receive such warrants. The warrants are liability-classified and after the initial recognition, the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the statement of operations and comprehensive loss (see Note&#160;8).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company expenses the fees incurred under the Paragon Option Agreement as the associated costs are incurred when the underlying services are rendered. Such amounts are classified within research and development expenses in the accompanying statement of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the rights obtained under the Paragon Option Agreement represent an asset acquisition whereby the underlying assets comprise in-process research and development assets with no alternative future use. The Paragon Option Agreement did not qualify as a business combination because substantially all of the fair value of the assets acquired was concentrated in the exclusive license options, which represent a group of similar identifiable assets. The research initiation fees represent a one-time cost on a research program-by research program basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of on-going development cost,&#160;monthly development cost fee and additional development expenses incurred by Paragon due to work completed for selected targets prior to the effective date of the Paragon Option Agreement and Amendment to the Paragon Option Agreement that associated with services being rendered under the related Research Programs is recognized as research and development expense when incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the period from June&#160;18, 2024 (inception) to September&#160;30, 2024 the Company recognized $13.2&#160;million of research and development expenses in connection with services provided by Paragon under the Paragon Option Agreement.</p><a id="_11e5faca_5cb2_4412_9bcf_849394c13958"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">11.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Commitments and Contingencies</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">401(k)&#160;Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company maintains a defined-contribution plan under Section&#160;401(k)&#160;of the Internal Revenue Code of 1986 (the &#8220;401(k)&#160;Plan&#8221;). The 401(k)&#160;Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Matching contributions to the 401(k)&#160;Plan may be made at the discretion of management. For the period from June&#160;18, 2024 (inception) to September&#160;30, 2024, the Company has not recorded any expense related to 401(k)&#160;Plan match contributions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Indemnification Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with each of its directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or executive officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its financial statements as of September&#160;30, 2024.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Legal Proceedings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, the Company may become involved in legal proceedings or other litigation relating to claims arising in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and estimated exposure amount. Legal fees and other costs associated with such proceedings are expensed as incurred. As of September&#160;30, 2024, the Company was not a party to any material legal proceedings or claims.</p><a id="_48c2f856_2774_4296_8760_f6333e09d7dd"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">12.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Net Loss per Share</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Period&#160;from</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;18,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Inception)&#160;to</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (16,867)</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,000,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3.37)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the computation of basic net loss per share attributable to common stockholders, the amount of weighted-average common shares outstanding excludes all shares of unvested restricted common stock as such shares are not considered outstanding for accounting purposes until vested.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded potential common shares from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have had an anti-dilutive effect:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Period&#160;from</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;18,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Inception)&#160;to</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Convertible preferred stock (as converted to common stock)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,000,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 819,672</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Stock options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 198,633</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 21,018,305</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_ef389716_a4ab_48e9_a716_b075e342d777"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">13.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Related Party Transactions</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June&#160;18, 2024, the Board of Directors issued 136,612 RSAs to a consultant in exchange for regulatory and strategic services provided to the Company. The consultant is an employee of Fairmount, who is a related party of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Paragon and Parade each currently beneficially own more than 5% of the Company&#8217;s capital stock through their respective common stock holdings. For the period from June&#160;18, 2024 (inception) to September&#160;30, 2024, the Company recognized $13.2&#160;million of expenses, recognized as research and development expense in the Company&#8217;s statement of operations and comprehensive loss, in connection with services provided by Paragon and Parade under the Paragon Option Agreement. For the period from June&#160;18, 2024 (inception) to September&#160;30, 2024, the Company recognized $0.9&#160;million of expenses, recognized as general and administrative expense in the Company&#8217;s statement of operations and comprehensive loss, in connection with services provided by Paragon and </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Parade under the Paragon Option Agreement. As of September&#160;30, 2024, the Company had $8.0&#160;million in related party accrued expenses pertaining to services provided by Paragon and Parade under the Paragon Option Agreement and reimbursements of recruiting and start-up fees on its balance sheet. In addition, under the terms of the Paragon Option Agreement, Parade will be entitled to grants of warrants to purchase a number of shares equal to 1.00% of outstanding shares of the Company&#8217;s common stock, on a fully diluted basis, as of the date of the grants (see Note&#160;8). If the Company exercises its options, it will be required to make non-refundable milestone payments to Paragon of up to $12.0&#160;million under each respective agreement upon the achievement of certain clinical development milestones, up to $10.0&#160;million under each respective agreement upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the low-to-mid single-digits beginning on the first commercial sale of each product developed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Fairmount beneficially owns more than 5% of the Company&#8217;s capital, currently has two representatives appointed to the Board of Directors, and beneficially owns more than 5% of Paragon. In June&#160;2024, the Company issued and sold an aggregate of 20,000,000 shares of Series&#160;Seed Preferred Stock to Fairmount, at a purchase price of $0.0001 per share, for gross proceeds of less than $0.1&#160;million (see Note&#160;6). In July&#160;2024, Fairmount entered into the Purchase Agreement with the Company and holds a convertible note with an initial principal amount of $20.0&#160;million (see Note&#160;5).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of related party accrued expenses and other current liabilities (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Reimbursable fees under the terms of the Paragon Option Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,761</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Paragon reimbursable recruiting and start-up fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 250</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,011</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_fee28b52_d361_41fa_9ce4_ccdb6ef2179f"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">14.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Subsequent Events</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has evaluated events and transactions occurring subsequent to September&#160;30, 2024 through December&#160;2, 2024, the date at which the financial statements were available to be issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October&#160;7, 2024, the Company exercised the Option to acquire the intellectual property rights to JADE-001, and the Company entered into a License Agreement for JADE-001 with Paragon on October&#160;30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 22, 2024, the Company entered into a cell line license agreement (the &#8220;Cell Line License Agreement&#8221;) with Wuxi Biologics Ireland Limited (&#8220;WuXi Ireland&#8221;). Under the Cell Line License Agreement, the Company received a non-exclusive, worldwide, sublicensable license to certain of WuXi Ireland&#8217;s know-how, cell line, biological materials and media and feeds to make, have made, use, sell and import certain therapeutic products produced through the use of the cell line licensed by WuXi Ireland. In consideration for the license, the Company paid WuXi Ireland a non-refundable license of $0.2 million. The Company has the option, at any time, to pay WuXi Ireland a non-refundable lump-sum royalty buyout payment on a drug product-by-drug product basis to extinguish future Royalty obligations with respect to such drug product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2024, the Company granted options for the purchase of an aggregate of 3,439,345 shares of common stock to employees and directors, at a weighted average exercise price of $1.07 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_9973ca08_b43b_4c11_a54a_0414142cf365"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ANNEX A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AGREEMENT AND PLAN OF MERGER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">by and among</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AEROVATE THERAPEUTICS,&#160;INC.,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARIBBEAN MERGER SUB I,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARIBBEAN MERGER SUB II, LLC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">and</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dated as of October&#160;30, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_edf1d4a1_1571_4e94_bc92_4bf999283df4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:middle;width:12.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:middle;width:80.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:middle;width:6.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></th></tr><tr><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td colspan="2" style="vertical-align:middle;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#ARTICLEI_534557"><span style="font-style:normal;font-weight:normal;">ARTICLE I DEFINITIONS &amp; INTERPRETATIONS</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-3</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section11"><span style="font-style:normal;font-weight:normal;">Section 1.1</span></a></p></td><td style="vertical-align:middle;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section11"><span style="font-style:normal;font-weight:normal;">Certain Definitions</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-3</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section12"><span style="font-style:normal;font-weight:normal;">Section 1.2</span></a></p></td><td style="vertical-align:middle;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section12"><span style="font-style:normal;font-weight:normal;">Interpretation</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-7</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section13"><span style="font-style:normal;font-weight:normal;">Section 1.3</span></a></p></td><td style="vertical-align:middle;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section13"><span style="font-style:normal;font-weight:normal;">Currency</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-8</p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#ARTICLEII"><span style="font-style:normal;font-weight:normal;">ARTICLE II THE MERGER</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-8</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section21"><span style="font-style:normal;font-weight:normal;">Section 2.1</span></a></p></td><td style="vertical-align:middle;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section21"><span style="font-style:normal;font-weight:normal;">Formation of Merger Subs</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-8</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section22"><span style="font-style:normal;font-weight:normal;">Section 2.2</span></a></p></td><td style="vertical-align:middle;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section22"><span style="font-style:normal;font-weight:normal;">The Mergers</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-8</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section23"><span style="font-style:normal;font-weight:normal;">Section 2.3</span></a></p></td><td style="vertical-align:middle;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section23"><span style="font-style:normal;font-weight:normal;">Closing</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-8</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section24"><span style="font-style:normal;font-weight:normal;">Section 2.4</span></a></p></td><td style="vertical-align:middle;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section24"><span style="font-style:normal;font-weight:normal;">Certificate of Designation; First Effective Time; Second Effective Time</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-8</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section25"><span style="font-style:normal;font-weight:normal;">Section 2.5</span></a></p></td><td style="vertical-align:middle;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section25"><span style="font-style:normal;font-weight:normal;">Effects of the Merger</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-8</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section26"><span style="font-style:normal;font-weight:normal;">Section&#160;2.6</span></a></p></td><td style="vertical-align:middle;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section26"><span style="font-style:normal;font-weight:normal;">Parent Governance</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-9</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section27"><span style="font-style:normal;font-weight:normal;">Section&#160;2.7</span></a></p></td><td style="vertical-align:middle;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section27"><span style="font-style:normal;font-weight:normal;">First Step Surviving Company and Surviving Entity Governance</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-9</p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#ARTICLEIII"><span style="font-style:normal;font-weight:normal;">ARTICLE&#160;III EFFECT ON THE CAPITAL STOCK OF THE CONSTITUENT COMPANIES; EXCHANGE OF CERTIFICATES</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;"><span style="color:#231f20;">A-</span><span style="color:#231f20;">10</span></p></td></tr><tr><td style="vertical-align:middle;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section31"><span style="font-style:normal;font-weight:normal;">Section&#160;3.1</span></a></p></td><td style="vertical-align:middle;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section31"><span style="font-style:normal;font-weight:normal;">Conversion of Capital Stock</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-10</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section32"><span style="font-style:normal;font-weight:normal;">Section&#160;3.2</span></a></p></td><td style="vertical-align:middle;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section32"><span style="font-style:normal;font-weight:normal;">Company Options; Company Warrants</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-12</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section33"><span style="font-style:normal;font-weight:normal;">Section&#160;3.3</span></a></p></td><td style="vertical-align:middle;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section33"><span style="font-style:normal;font-weight:normal;">Exchange and Payment</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-12</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section34"><span style="font-style:normal;font-weight:normal;">Section&#160;3.4</span></a></p></td><td style="vertical-align:middle;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section34"><span style="font-style:normal;font-weight:normal;">Withholding Rights</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-14</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section35"><span style="font-style:normal;font-weight:normal;">Section&#160;3.5</span></a></p></td><td style="vertical-align:middle;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section35"><span style="font-style:normal;font-weight:normal;">Dissenters Rights</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-15</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section36"><span style="font-style:normal;font-weight:normal;">Section&#160;3.6</span></a></p></td><td style="vertical-align:middle;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section36"><span style="font-style:normal;font-weight:normal;">Calculation of Net Cash</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-15</p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#ARTICLEIV"><span style="font-style:normal;font-weight:normal;">ARTICLE&#160;IV REPRESENTATIONS AND WARRANTIES OF THE COMPANY</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;"><span style="color:#231f20;">A-</span><span style="color:#231f20;">16</span></p></td></tr><tr><td style="vertical-align:middle;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section41"><span style="font-style:normal;font-weight:normal;">Section&#160;4.1</span></a></p></td><td style="vertical-align:middle;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section41"><span style="font-style:normal;font-weight:normal;">Organization, Standing and Power</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-16</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section42"><span style="font-style:normal;font-weight:normal;">Section&#160;4.2</span></a></p></td><td style="vertical-align:middle;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section42"><span style="font-style:normal;font-weight:normal;">Capital Stock</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-17</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section43"><span style="font-style:normal;font-weight:normal;">Section&#160;4.3</span></a></p></td><td style="vertical-align:middle;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section43"><span style="font-style:normal;font-weight:normal;">Subsidiaries</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-17</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section44"><span style="font-style:normal;font-weight:normal;">Section&#160;4.4</span></a></p></td><td style="vertical-align:middle;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section44"><span style="font-style:normal;font-weight:normal;">Authority</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-18</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section45"><span style="font-style:normal;font-weight:normal;">Section&#160;4.5</span></a></p></td><td style="vertical-align:middle;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section45"><span style="font-style:normal;font-weight:normal;">No Conflict; Consents and Approvals</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-18</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section46"><span style="font-style:normal;font-weight:normal;">Section&#160;4.6</span></a></p></td><td style="vertical-align:middle;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section46"><span style="font-style:normal;font-weight:normal;">Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-19</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section47"><span style="font-style:normal;font-weight:normal;">Section&#160;4.7</span></a></p></td><td style="vertical-align:middle;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section47"><span style="font-style:normal;font-weight:normal;">No Undisclosed Liabilities</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-19</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section48"><span style="font-style:normal;font-weight:normal;">Section&#160;4.8</span></a></p></td><td style="vertical-align:middle;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section48"><span style="font-style:normal;font-weight:normal;">Absence of Certain Changes or Events</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-20</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section49"><span style="font-style:normal;font-weight:normal;">Section&#160;4.9</span></a></p></td><td style="vertical-align:middle;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section49"><span style="font-style:normal;font-weight:normal;">Litigation</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-20</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section410"><span style="font-style:normal;font-weight:normal;">Section&#160;4.10</span></a></p></td><td style="vertical-align:middle;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section410"><span style="font-style:normal;font-weight:normal;">Compliance with Laws</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-20</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section411"><span style="font-style:normal;font-weight:normal;">Section&#160;4.11</span></a></p></td><td style="vertical-align:middle;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section411"><span style="font-style:normal;font-weight:normal;">Health Care Regulatory Matters</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-20</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section412"><span style="font-style:normal;font-weight:normal;">Section&#160;4.12</span></a></p></td><td style="vertical-align:middle;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section412"><span style="font-style:normal;font-weight:normal;">Benefit Plans</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-22</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section413"><span style="font-style:normal;font-weight:normal;">Section&#160;4.13</span></a></p></td><td style="vertical-align:middle;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section413"><span style="font-style:normal;font-weight:normal;">Labor and Employment Matters</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-24</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section414"><span style="font-style:normal;font-weight:normal;">Section&#160;4.14</span></a></p></td><td style="vertical-align:middle;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section414"><span style="font-style:normal;font-weight:normal;">Environmental Matters</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-25</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section415"><span style="font-style:normal;font-weight:normal;">Section&#160;4.15</span></a></p></td><td style="vertical-align:middle;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section415"><span style="font-style:normal;font-weight:normal;">Taxes</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-26</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section416"><span style="font-style:normal;font-weight:normal;">Section&#160;4.16</span></a></p></td><td style="vertical-align:middle;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section416"><span style="font-style:normal;font-weight:normal;">Contracts</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-27</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section417"><span style="font-style:normal;font-weight:normal;">Section&#160;4.17</span></a></p></td><td style="vertical-align:middle;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section417"><span style="font-style:normal;font-weight:normal;">Insurance</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-28</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section418"><span style="font-style:normal;font-weight:normal;">Section&#160;4.18</span></a></p></td><td style="vertical-align:middle;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section418"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-28</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section419"><span style="font-style:normal;font-weight:normal;">Section&#160;4.19</span></a></p></td><td style="vertical-align:middle;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section419"><span style="font-style:normal;font-weight:normal;">Intellectual Property</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-29</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section420"><span style="font-style:normal;font-weight:normal;">Section&#160;4.20</span></a></p></td><td style="vertical-align:middle;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section420"><span style="font-style:normal;font-weight:normal;">State Takeover Statutes</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-30</p></td></tr><tr><td style="vertical-align:middle;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section421"><span style="font-style:normal;font-weight:normal;">Section&#160;4.21</span></a></p></td><td style="vertical-align:middle;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section421"><span style="font-style:normal;font-weight:normal;">No Rights Plan</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-<span style="color:#231f20;">30</span></p></td></tr><tr><td style="vertical-align:middle;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section422"><span style="font-style:normal;font-weight:normal;">Section&#160;4.22</span></a></p></td><td style="vertical-align:middle;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section422"><span style="font-style:normal;font-weight:normal;">Related Party Transactions</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-<span style="color:#231f20;">31</span></p></td></tr><tr><td style="vertical-align:middle;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section423"><span style="font-style:normal;font-weight:normal;">Section&#160;4.23</span></a></p></td><td style="vertical-align:middle;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section423"><span style="font-style:normal;font-weight:normal;">Certain Payments</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-<span style="color:#231f20;">31</span></p></td></tr><tr><td style="vertical-align:middle;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section424"><span style="font-style:normal;font-weight:normal;">Section&#160;4.24</span></a></p></td><td style="vertical-align:middle;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section424"><span style="font-style:normal;font-weight:normal;">Trade Control Laws</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-<span style="color:#231f20;">31</span></p></td></tr><tr><td style="vertical-align:middle;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section425"><span style="font-style:normal;font-weight:normal;">Section&#160;4.25</span></a></p></td><td style="vertical-align:middle;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section425"><span style="font-style:normal;font-weight:normal;">Brokers</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-<span style="color:#231f20;">31</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-i</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:middle;width:12.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:middle;width:80.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:middle;width:6.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></th></tr><tr><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:middle;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section426"><span style="font-style:normal;font-weight:normal;">Section&#160;4.26</span></a></p></td><td style="vertical-align:middle;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section426"><span style="font-style:normal;font-weight:normal;">Securities Purchase Agreement</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-<span style="color:#231f20;">31</span></p></td></tr><tr><td style="vertical-align:middle;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section427"><span style="font-style:normal;font-weight:normal;">Section&#160;4.27</span></a></p></td><td style="vertical-align:middle;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section427"><span style="font-style:normal;font-weight:normal;">No Other Representations and Warranties</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-<span style="color:#231f20;">31</span></p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#ARTICLEV"><span style="font-style:normal;font-weight:normal;">ARTICLE&#160;V REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUBS</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-<span style="color:#231f20;">32</span></p></td></tr><tr><td style="vertical-align:middle;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section51"><span style="font-style:normal;font-weight:normal;">Section&#160;5.1</span></a></p></td><td style="vertical-align:middle;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section51"><span style="font-style:normal;font-weight:normal;">Organization, Standing and Power</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-<span style="color:#231f20;">32</span></p></td></tr><tr><td style="vertical-align:middle;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section52"><span style="font-style:normal;font-weight:normal;">Section&#160;5.2</span></a></p></td><td style="vertical-align:middle;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section52"><span style="font-style:normal;font-weight:normal;">Capital Stock</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-<span style="color:#231f20;">32</span></p></td></tr><tr><td style="vertical-align:middle;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section53"><span style="font-style:normal;font-weight:normal;">Section&#160;5.3</span></a></p></td><td style="vertical-align:middle;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section53"><span style="font-style:normal;font-weight:normal;">Subsidiaries</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-<span style="color:#231f20;">33</span></p></td></tr><tr><td style="vertical-align:middle;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section54"><span style="font-style:normal;font-weight:normal;">Section&#160;5.4</span></a></p></td><td style="vertical-align:middle;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section54"><span style="font-style:normal;font-weight:normal;">Authority</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-<span style="color:#231f20;">33</span></p></td></tr><tr><td style="vertical-align:middle;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section55"><span style="font-style:normal;font-weight:normal;">Section&#160;5.5</span></a></p></td><td style="vertical-align:middle;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section55"><span style="font-style:normal;font-weight:normal;">No Conflict; Consents and Approvals</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-<span style="color:#231f20;">34</span></p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section56"><span style="font-style:normal;font-weight:normal;">Section 5.6</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section56"><span style="font-style:normal;font-weight:normal;">SEC Reports; Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-35</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section57"><span style="font-style:normal;font-weight:normal;">Section 5.7</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section57"><span style="font-style:normal;font-weight:normal;">No Undisclosed Liabilities</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-36</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section58"><span style="font-style:normal;font-weight:normal;">Section 5.8</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section58"><span style="font-style:normal;font-weight:normal;">Absence of Certain Changes or Events</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-36</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section59"><span style="font-style:normal;font-weight:normal;">Section 5.9</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section59"><span style="font-style:normal;font-weight:normal;">Litigation</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-36</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section510"><span style="font-style:normal;font-weight:normal;">Section 5.10</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section510"><span style="font-style:normal;font-weight:normal;">Compliance with Law</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-37</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section511"><span style="font-style:normal;font-weight:normal;">Section 5.11</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section511"><span style="font-style:normal;font-weight:normal;">Health Care Regulatory Matters</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-37</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section512"><span style="font-style:normal;font-weight:normal;">Section 5.12</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section512"><span style="font-style:normal;font-weight:normal;">Benefit Plans</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-38</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section513"><span style="font-style:normal;font-weight:normal;">Section 5.13</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section513"><span style="font-style:normal;font-weight:normal;">Labor and Employment Matters</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-40</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section514"><span style="font-style:normal;font-weight:normal;">Section 5.14</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section514"><span style="font-style:normal;font-weight:normal;">Environmental Matters</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-41</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section515"><span style="font-style:normal;font-weight:normal;">Section 5.15</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section515"><span style="font-style:normal;font-weight:normal;">Taxes</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-41</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section516"><span style="font-style:normal;font-weight:normal;">Section 5.16</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section516"><span style="font-style:normal;font-weight:normal;">Contracts</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-43</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section517"><span style="font-style:normal;font-weight:normal;">Section 5.17</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section517"><span style="font-style:normal;font-weight:normal;">Insurance</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-44</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section518"><span style="font-style:normal;font-weight:normal;">Section 5.18</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section518"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-44</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section519"><span style="font-style:normal;font-weight:normal;">Section 5.19</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section519"><span style="font-style:normal;font-weight:normal;">Intellectual Property</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-45</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section520"><span style="font-style:normal;font-weight:normal;">Section 5.20</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section520"><span style="font-style:normal;font-weight:normal;">Related Party Transactions</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-46</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section521"><span style="font-style:normal;font-weight:normal;">Section 5.21</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section521"><span style="font-style:normal;font-weight:normal;">Certain Payments</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-46</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section522"><span style="font-style:normal;font-weight:normal;">Section 5.22</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section522"><span style="font-style:normal;font-weight:normal;">Trade Control Laws</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-46</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section523"><span style="font-style:normal;font-weight:normal;">Section 5.23</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section523"><span style="font-style:normal;font-weight:normal;">Brokers</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-46</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section524"><span style="font-style:normal;font-weight:normal;">Section 5.24</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section524"><span style="font-style:normal;font-weight:normal;">Opinion of Financial Advisor</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-46</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section525"><span style="font-style:normal;font-weight:normal;">Section 5.25</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section525"><span style="font-style:normal;font-weight:normal;">State Takeover Statutes</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-46</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section526"><span style="font-style:normal;font-weight:normal;">Section 5.26</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section526"><span style="font-style:normal;font-weight:normal;">No Other Representations or Warranties</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-46</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#ARTICLEVI"><span style="font-style:normal;font-weight:normal;">ARTICLE VI COVENANTS</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-47</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section61"><span style="font-style:normal;font-weight:normal;">Section 6.1</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section61"><span style="font-style:normal;font-weight:normal;">Operation of Parent&#8217;s Business</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-47</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section62"><span style="font-style:normal;font-weight:normal;">Section 6.2</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section62"><span style="font-style:normal;font-weight:normal;">Operation of Company&#8217;s Business</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-49</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section63"><span style="font-style:normal;font-weight:normal;">Section 6.3</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section63"><span style="font-style:normal;font-weight:normal;">Access and Investigation</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-50</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section64"><span style="font-style:normal;font-weight:normal;">Section 6.4</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section64"><span style="font-style:normal;font-weight:normal;">No Solicitation</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-50</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section65"><span style="font-style:normal;font-weight:normal;">Section 6.5</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section65"><span style="font-style:normal;font-weight:normal;">Notification of Certain Matters</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-51</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section66"><span style="font-style:normal;font-weight:normal;">Section 6.6</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section66"><span style="font-style:normal;font-weight:normal;">Parent Options</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-51</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section67"><span style="font-style:normal;font-weight:normal;">Section 6.7</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section67"><span style="font-style:normal;font-weight:normal;">Parent Restricted Stock Unit Awards</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-52</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section68"><span style="font-style:normal;font-weight:normal;">Section 6.8</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section68"><span style="font-style:normal;font-weight:normal;">Parent ESPP</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-52</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section69"><span style="font-style:normal;font-weight:normal;">Section 6.9</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section69"><span style="font-style:normal;font-weight:normal;">Parent 401(K) Plan</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-52</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#ARTICLEVII"><span style="font-style:normal;font-weight:normal;">ARTICLE VII ADDITIONAL AGREEMENTS</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-52</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section71"><span style="font-style:normal;font-weight:normal;">Section 7.1</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section71"><span style="font-style:normal;font-weight:normal;">Registration Statement; Proxy Statement</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-52</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section72"><span style="font-style:normal;font-weight:normal;">Section 7.2</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section72"><span style="font-style:normal;font-weight:normal;">Company Stockholder Approval</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-54</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section73"><span style="font-style:normal;font-weight:normal;">Section 7.3</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section73"><span style="font-style:normal;font-weight:normal;">Parent Stockholders&#8217; Meeting</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-55</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section74"><span style="font-style:normal;font-weight:normal;">Section 7.4</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section74"><span style="font-style:normal;font-weight:normal;">Efforts; Regulatory Approvals; Transaction Litigation</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-56</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section75"><span style="font-style:normal;font-weight:normal;">Section 7.5</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section75"><span style="font-style:normal;font-weight:normal;">Indemnification, Exculpation and Insurance</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-57</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section76"><span style="font-style:normal;font-weight:normal;">Section 7.6</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section76"><span style="font-style:normal;font-weight:normal;">Section 16 Matters</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-58</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section77"><span style="font-style:normal;font-weight:normal;">Section 7.7</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section77"><span style="font-style:normal;font-weight:normal;">Disclosure</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-58</p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-ii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:middle;width:12.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:middle;width:80.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:middle;width:6.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></th></tr><tr><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section78"><span style="font-style:normal;font-weight:normal;">Section 7.8</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section78"><span style="font-style:normal;font-weight:normal;">Listing</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-58</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section79"><span style="font-style:normal;font-weight:normal;">Section 7.9</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section79"><span style="font-style:normal;font-weight:normal;">Tax Matters</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-59</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section710"><span style="font-style:normal;font-weight:normal;">Section 7.10</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section710"><span style="font-style:normal;font-weight:normal;">Directors and Officers</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-59</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section711"><span style="font-style:normal;font-weight:normal;">Section 7.11</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section711"><span style="font-style:normal;font-weight:normal;">Termination of Certain Agreements and Rights</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-59</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section712"><span style="font-style:normal;font-weight:normal;">Section 7.12</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section712"><span style="font-style:normal;font-weight:normal;">Obligations of Merger Subs</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-60</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section713"><span style="font-style:normal;font-weight:normal;">Section 7.13</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section713"><span style="font-style:normal;font-weight:normal;">Allocation Certificate</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-60</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section714"><span style="font-style:normal;font-weight:normal;">Section 7.14</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section714"><span style="font-style:normal;font-weight:normal;">Pre-Closing Cash Dividend</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-60</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section715"><span style="font-style:normal;font-weight:normal;">Section 7.15</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section715"><span style="font-style:normal;font-weight:normal;">Concurrent Investment</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-60</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section716"><span style="font-style:normal;font-weight:normal;">Section 7.16</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section716"><span style="font-style:normal;font-weight:normal;">Parent Equity Plans</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-61</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section717"><span style="font-style:normal;font-weight:normal;">Section 7.17</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section717"><span style="font-style:normal;font-weight:normal;">Wind-Down Activities</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-61</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section718"><span style="font-style:normal;font-weight:normal;">Section 7.18</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section718"><span style="font-style:normal;font-weight:normal;">Parent SEC Documents</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-61</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#ARTICLEVIII"><span style="font-style:normal;font-weight:normal;">ARTICLE&#160;VIII CLOSING CONDITIONS</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-61</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section81"><span style="font-style:normal;font-weight:normal;">Section 8.1</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section81"><span style="font-style:normal;font-weight:normal;">Conditions Precedent of each Party</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-61</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section82"><span style="font-style:normal;font-weight:normal;">Section 8.2</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section82"><span style="font-style:normal;font-weight:normal;">Conditions Precedent to Obligation of the Company</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-62</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section83"><span style="font-style:normal;font-weight:normal;">Section 8.3</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section83"><span style="font-style:normal;font-weight:normal;">Conditions Precedent of Parent and Merger Subs</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-63</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#ARTICLEIX"><span style="font-style:normal;font-weight:normal;">ARTICLE IX TERMINATION</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-63</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section91"><span style="font-style:normal;font-weight:normal;">Section 9.1</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section91"><span style="font-style:normal;font-weight:normal;">Termination</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-63</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section92"><span style="font-style:normal;font-weight:normal;">Section 9.2</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section92"><span style="font-style:normal;font-weight:normal;">Effect of Termination</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-65</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section93"><span style="font-style:normal;font-weight:normal;">Section 9.3</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section93"><span style="font-style:normal;font-weight:normal;">Expenses; Termination Fees</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-65</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#ARTICLEX"><span style="font-style:normal;font-weight:normal;">ARTICLE X GENERAL PROVISIONS</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-66</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section101"><span style="font-style:normal;font-weight:normal;">Section 10.1</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section101"><span style="font-style:normal;font-weight:normal;">Non-survival of Representations and Warranties</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-66</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section102"><span style="font-style:normal;font-weight:normal;">Section 10.2</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section102"><span style="font-style:normal;font-weight:normal;">Amendment or Supplement</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-66</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section103"><span style="font-style:normal;font-weight:normal;">Section 10.3</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section103"><span style="font-style:normal;font-weight:normal;">Waiver</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-66</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section104"><span style="font-style:normal;font-weight:normal;">Section 10.4</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section104"><span style="font-style:normal;font-weight:normal;">Fees and Expenses</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-67</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section105"><span style="font-style:normal;font-weight:normal;">Section 10.5</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section105"><span style="font-style:normal;font-weight:normal;">Notices</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-67</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section106"><span style="font-style:normal;font-weight:normal;">Section 10.6</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section106"><span style="font-style:normal;font-weight:normal;">Entire Agreement</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-67</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section107"><span style="font-style:normal;font-weight:normal;">Section 10.7</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section107"><span style="font-style:normal;font-weight:normal;">No Third Party Beneficiaries</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-68</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section108"><span style="font-style:normal;font-weight:normal;">Section 10.8</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section108"><span style="font-style:normal;font-weight:normal;">Governing Law</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-68</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section109"><span style="font-style:normal;font-weight:normal;">Section 10.9</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section109"><span style="font-style:normal;font-weight:normal;">Submission to Jurisdiction</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-68</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section1010"><span style="font-style:normal;font-weight:normal;">Section 10.10</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section1010"><span style="font-style:normal;font-weight:normal;">Assignment; Successors</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-68</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section1011"><span style="font-style:normal;font-weight:normal;">Section 10.11</span></a></p></td><td style="vertical-align:bottom;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section1011"><span style="font-style:normal;font-weight:normal;">Specific Performance</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-68</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section1012"><span style="font-style:normal;font-weight:normal;">Section 10.12</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section1012"><span style="font-style:normal;font-weight:normal;">Severability</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-69</p></td></tr><tr><td style="vertical-align:top;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section1013"><span style="font-style:normal;font-weight:normal;">Section&#160;10.13</span></a></p></td><td style="vertical-align:top;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section1013"><span style="font-style:normal;font-weight:normal;">Waiver of Jury Trial</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-69</p></td></tr><tr><td style="vertical-align:top;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section1014"><span style="font-style:normal;font-weight:normal;">Section&#160;10.14</span></a></p></td><td style="vertical-align:top;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section1014"><span style="font-style:normal;font-weight:normal;">Counterparts</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-69</p></td></tr><tr><td style="vertical-align:top;width:12.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section1015"><span style="font-style:normal;font-weight:normal;">Section&#160;10.15</span></a></p></td><td style="vertical-align:top;width:80.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section1015"><span style="font-style:normal;font-weight:normal;">Facsimile or .pdf Signature</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-69</p></td></tr><tr><td style="vertical-align:top;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 7.2pt;"><a href="#Section1016"><span style="font-style:normal;font-weight:normal;">Section&#160;10.16</span></a></p></td><td style="vertical-align:top;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#Section1016"><span style="font-style:normal;font-weight:normal;">No Presumption Against Drafting Party</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">A-69</p></td></tr><tr><td style="vertical-align:top;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">Exhibit&#160;A</p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">Form&#160;of Parent Support Agreement</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">Exhibit&#160;B</p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">Form&#160;of Company Support Agreement</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">Exhibit&#160;C</p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">Form&#160;of Lock-Up Agreement</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">Exhibit&#160;D</p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">Form&#160;of Securities Purchase Agreement</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">Exhibit&#160;E-1</p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">First Certificate of Merger, including certificate of incorporation of the First Step Surviving Corporation attached as Exhibit&#160;A thereto, incorporated by reference into this Agreement</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">Exhibit&#160;E-2</p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">Second Certificate of Merger, incorporated by reference into this Agreement</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit F</p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Certificate of Designation</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-iii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INDEX OF DEFINED TERMS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Definition</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Location</b></p></th></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024 Equity Incentive Plan</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024 ESPP</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024 Plans</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AAA</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.6(e)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acceptable Confidentiality Agreement</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounting Firm</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.6(e)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquisition Inquiry</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquisition Proposal</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquisition Transaction</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Action</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.9</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Affiliate</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agreement</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preamble</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Allocation Certificate</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 7.13</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Anticipated Meeting Date</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.6(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assumed Option</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.2(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assumed Warrant</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.2(b)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Book-Entry Shares</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.3(b)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Business Day</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash Determination Time</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.6(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Certificate of Designation</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Certificate of Merger</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 2.4</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Certificates</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.3(b)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Closing Section 2.3</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Code</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preamble</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Audited Financial Statements</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 7.1(g)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Balance Sheet</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.6(b)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Board</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Board Adverse Recommendation Change</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 7.2(c) </p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Board Recommendation</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 7.2(c)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Bylaws</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.1(b)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Capital Stock</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Charter</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.1(b)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Common Stock</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Disclosure Letter</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Article IV</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Equity Plan</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Equity Value</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.1(i)(A))</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Financial Statements</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.6(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Fundamental Representations</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Interim Financial Statements</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 7.1(g)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Intervening Event</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 7.2(d)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Notes</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Notice Period</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 7.2(d)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Options</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Outstanding Shares</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.1(i)(B))</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Owned IP</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Plan</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Preferred Stock</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Products</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.11(c)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Registered IP</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.19(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Restricted Shares</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.1(b)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Stock Awards</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.2(b)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Stockholder Approval</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Support Agreements</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-iv</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Definition</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Location</b></p></th></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Termination Fee</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">9.3(b)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Triggering Event</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Valuation</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.1(i)(C))</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Value Per Share</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.1(i)(D))</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Warrant</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Concurrent Investment</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Concurrent Investment Amount</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Concurrent Investment Investor</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Concurrent Investment Investors</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Confidentiality Agreement</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Constructive Issuance</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contemplated Transactions</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">control</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Controlled Group</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.12(c)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current Offering Period</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 6.8</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">D&amp;O Indemnified Parties</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 7.5(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Data Processors</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.19(h)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Delaware Secretary of State</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 2.4</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Delivery Date</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.6(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">DGCL</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dispute Notice</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.6(b)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dissenting Shares</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.5</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend Record Date</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 7.14</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">DLLCA</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee Plan</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">End Date</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 9.1(b)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Environmental Law</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.14(b)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ERISA</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exchange Act</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.5(b)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exchange Agent</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.3(a))</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exchange Fund</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.3(a))</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exchange Ratio</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.1(a)(i)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Excluded Shares</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.1(a)(iii))</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FDA</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.11(c)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FDA Ethics Policy</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.11(i)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FDCA</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.11(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Final Parent Net Cash</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.6(c)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">First Certificate of Merger</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 2.4</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">First Effective Time</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 2.4</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">First Merger</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">First Merger Sub</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preamble</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">First Step Surviving Company</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 2.2</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Form S-4</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 7.1(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GAAP</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.6(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hazardous Substance</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.11(c)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Care Laws</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.11(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">HSR Act</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intellectual Property</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intended Tax Treatment</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Investor Agreements</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 7.11(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">IRS</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.12(b)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">IT Systems</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.19(g)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">knowledge</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lock-Up Agreement</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Material Adverse Effect</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.1(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Material Contracts</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.16(a)</p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-v</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Definition</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Location</b></p></th></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Measurement Date</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 5.2(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Merger</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Merger Consideration</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.1(a)(i)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Merger Subs</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preamble</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Multiemployer Plan</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nasdaq</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nasdaq Fees</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nasdaq Issuance Proposal</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nasdaq Listing Application</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 7.8</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nasdaq Reverse Stock Split</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net Cash</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ordinary Course</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ordinary Course Agreement</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.15(g)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preamble</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent 401(k) Plan</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 6.9</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Board</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Board Adverse Recommendation Change</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 7.3(b)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Board Recommendation</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 7.3(b)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Capital Stock</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Charter Amendment</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 2.6(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Closing Price</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Common Stock</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Common Stock Issuance</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 5.4(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Convertible Preferred Stock</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Disclosure Letter</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Article V</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Equity Plans</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent ESPP</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Fundamental Representations</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Intervening Event</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 7.3(c)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent IT Systems</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 5.19(d)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent ITM Option</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Legacy Assets</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Legacy Business</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1 (hh)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Legacy Transaction</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 6.1(c)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Material Adverse Effect</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 5.1(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Material Contracts</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 5.16(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Net Cash Calculation</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.6(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Net Cash Schedule</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.6(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Notice Period</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 7.3(c)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Options</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent OTM Options</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Outstanding Shares</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.1(i)(E))</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Owned IP</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Plan</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Preferred Stock</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Products</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 5.11(c)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Registered IP</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 5.19(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Restricted Stock Unit Awards</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent SEC Documents</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 5.6(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Stock Option Cash Consideration</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 6.6</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Stockholder Approval</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 5.4(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Stockholder Meeting</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 7.3(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Stockholder Proposals</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 7.3(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Support Agreements</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Termination Fee</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">9.3(d)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Triggering Event</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-vi</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Definition</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Location</b></p></th></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Valuation</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.1(i)(F))</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Value Per Share</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.1(i)(G))</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PBGC</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.12(d)(iv)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permits</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.10</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permitted Alternative Agreement</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 9.1(j)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permitted Liens</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.18(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Person</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personal Information</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.19(h)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pre-Closing Cash Dividend</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pre-Closing Cash Dividend Amount</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 7.14</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pre-Closing Period</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 6.1(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Privacy Laws</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.19(h)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proxy Statement</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 7.1(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Registration Statement</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 7.1(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Representative</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Response Date</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.6(b)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reverse Stock Split Proposal</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 2.6(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Safety Notices</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.11(g)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sarbanes-Oxley Act</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 5.6(a)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SEC</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Second Certificate of Merger</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 2.4</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Second Effective Time</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 2.4</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Second Merger</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Second Merger Sub</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preamble</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Securities Act</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.5(b)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Service Provider Grants</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.1(a)(i)(A)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholder Notice</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 7.2(b)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Securities Purchase Agreement</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Subsequent Transaction</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Subsidiary</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Superior Offer</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Surviving Entity</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 2.2</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Takeover laws</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.20</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax Action</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.15(d)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax Certificates</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 7.9(c)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax Return</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Taxes</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade Approvals</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.24</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade Laws</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.24</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Transaction Expenses</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Transaction Litigation</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 7.4(c)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">WARN Act</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 4.13(d)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Withholding Agent</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 3.4</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-vii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="ANNEXA"></a><a id="_d7d7a491_5613_434c_b941_dd0f7a3fceef"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AGREEMENT AND PLAN OF MERGER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">THIS AGREEMENT AND PLAN OF MERGER (this &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</span>&#8221;), dated as of October&#160;30, 2024, by and among Aerovate Therapeutics,&#160;Inc., a Delaware corporation (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent</span>&#8221;), Caribbean Merger Sub I,&#160;Inc., a Delaware corporation (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">First Merger Sub</span>&#8221;) and wholly owned subsidiary of Parent, Caribbean Merger Sub II, LLC, a Delaware limited liability company (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Second Merger Sub</span>&#8221; and, together with First Merger Sub, &#8220;Merger Subs&#8221;) and wholly owned subsidiary of Parent, and Jade Biosciences,&#160;Inc., a Delaware corporation (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, Parent and the Company intend to effect a merger of First Merger Sub with and into the Company (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">First Merger</span>&#8221;) in accordance with this Agreement and the General Corporation Law of the State of Delaware (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DGCL</span>&#8221;). Upon consummation of the First Merger, First Merger Sub will cease to exist and the Company will become a wholly-owned subsidiary of Parent;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, immediately following the First Merger and as part of the same overall transaction as the First Merger, the Company will merge with and into Second Merger Sub (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;) in accordance with this Agreement, the DGCL and the Delaware Limited Liability Company Act (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DLLCA&#8221;</span>), with Second Merger Sub being the surviving entity of the Second Merger;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the parties hereto intend that the First Merger and the Second Merger, taken together, qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Code</span>&#8221;) and the Treasury Regulations promulgated thereunder, and that this Agreement be, and hereby is, adopted as a &#8220;plan of reorganization&#8221; for the purposes of Section&#160;368 of the Code and Treasury Regulations Section&#160;1.368-2(g)&#160;and 1.368-3 (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intended Tax Treatment</span>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the Board of Directors of the Company (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Board</span>&#8221;) has (i)&#160;determined that the Contemplated Transactions are fair to, advisable and in the best interests of the Company and its stockholders, (ii)&#160;approved and declared advisable this Agreement and the Contemplated Transactions and (iii) <span style="color:#231f20;">determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of the Company vote to adopt this Agreement and thereby approve the Contemplated Transactions;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the Company Board has unanimously approved this Agreement and the Merger, with the Company continuing as the First Step Surviving Company (as defined below), after the First Effective Time (as defined below), pursuant to which, among other things, (i)&#160;each share of common stock, par value $0.0001 per share, of the Company (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Common Stock</span>&#8221;) (other than any Excluded Shares, Dissenting Shares) shall be converted into the right to receive a number of shares of common stock, par value $0.0001 per share, of Parent (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Common Stock</span>&#8221;) equal to the Exchange Ratio and (ii)&#160;each share of Company Preferred Stock outstanding immediately prior to the First Effective Time (other than any Excluded Shares, Dissenting Shares) shall be converted solely into the right to receive a number of shares of Parent Convertible Preferred Stock equal to (x)&#160;the Exchange Ratio divided by (y)&#160;1,000, in each case, upon the terms and subject to the conditions set forth in this Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, First Merger Sub is a newly incorporated Delaware corporation that is wholly-owned by Parent, and has been formed for the sole purpose of effecting the First Merger;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, Second Merger Sub is a newly incorporated Delaware limited liability company that is wholly-owned by Parent, and has been formed for the sole purpose of effecting the Second Merger;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the Board of Directors of Parent (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Board</span>&#8221;) has (i)&#160;determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders, (ii) <span style="color:#231f20;">approved and declared advisable this Agreement and the Contemplated Transactions, including the issuance of shares of Parent Capital Stock to the stockholders of the Company pursuant to this Agreement and the Parent Support Agreements and the constructive issuance by the Company of shares of Company Common Stock to stockholders of Parent (as reflected in Rule&#160;145(a)&#160;of the Securities Act) (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Constructive Issuance</span><span style="color:#231f20;">&#8221;), (iii)&#160;determined that the Reverse Stock Split Proposal (as defined below), among other things, </span>is advisable and in the best interests of Parent and its stockholders, (iv)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of Parent vote to authorize the issuance of the Parent Common Stock in accordance with Nasdaq Listing Rule&#160;5635 (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nasdaq Issuance Proposal</span>&#8221;), the Reverse Stock Split Proposal and the other Parent Stockholder Proposals;</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the board of directors of First Merger Sub has (i)&#160;determined that the Contemplated Transactions are fair to, advisable and in the best interests of First Merger Sub and its sole stockholder, (ii) <span style="color:#231f20;">approved and declared advisable this Agreement and the Contemplated Transactions and (iii)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder of First Merger Sub votes to adopt this Agreement and thereby approve the Contemplated Transactions;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the sole member of the Second Merger Sub has (i)&#160;determined that the Contemplated Transactions are fair to, advisable, and in the best interests of Second Merger Sub and its sole member, and (ii) approved and declared advisable this Agreement and the Contemplated<span style="color:#231f20;"> Transactions;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, Parent, Merger Subs and the Company each desire to make certain representations, warranties, covenants and agreements in connection with the Merger and also to prescribe certain conditions to the Merger as specified herein;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, concurrently with the execution and delivery of this Agreement and as a condition and inducement to the Company&#8217;s willingness to enter into this Agreement, the officers, directors and stockholders of Parent listed on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;A</span> of the Parent Disclosure Letter have entered into Parent Support Agreements, dated as of the date of this Agreement, in the form attached hereto as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</span> (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Support Agreements</span>&#8221;), pursuant to which such officers, directors and stockholders have, subject to the terms and conditions set forth therein, agreed to vote all of their shares of Parent Common Stock in favor of the approval of this Agreement and thereby approve the Contemplated Transactions, including, but not limited to the Parent Stockholder Proposals;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, concurrently with the execution and delivery of this Agreement and as a condition and inducement of Parent&#8217;s willingness to enter into this Agreement, the officers, directors and stockholders of the Company listed on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;A</span> of the Company Disclosure Letter have entered into Company Support Agreements, dated as of the date of this Agreement, in the form attached hereto as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;B</span> (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Support Agreements</span>&#8221;), pursuant to which such officers, directors and stockholders have, subject to the terms and conditions set forth therein, agreed to vote all of their shares of Company Common Stock in favor of the adoption of this Agreement and thereby approve the Contemplated Transactions;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, concurrently with the execution and delivery of this Agreement and as a condition and inducement to Parent&#8217;s willingness to enter into this Agreement, certain stockholders of the Company listed on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;B</span> of the Company Disclosure Letter are executing lock-up agreements in the form attached hereto as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;C</span> (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lock-Up Agreement</span>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, it is expected that within two (2)&#160;Business Days after the Registration Statement is declared effective under the Securities Act, the stockholders of the Company will execute an action by written consent by the holders of (i)&#160;at least a majority of the outstanding shares of Company Common Stock and Company Preferred Stock, voting together as a single class, and (ii)&#160;at least a majority of the outstanding shares of and Company Preferred Stock, voting as a single class, in form and substance reasonably acceptable to Parent, approving and adopting this Agreement (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Stockholder Approval</span>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the stockholders of Parent as of the Dividend Record Date (which for clarity shall exclude holders of Parent Capital Stock issued as part of the Merger Consideration) shall be entitled to receive from Parent a cash dividend in an expected aggregate amount of $70,000,000, subject to certain adjustments as set forth herein (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pre-Closing Cash Dividend</span>&#8221;); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, concurrently with the execution of this Agreement, certain investors (each a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Concurrent Investment Investor</span>&#8221; and collectively the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Concurrent Investment Investors</span>&#8221;) have entered into a securities purchase agreement representing an aggregate commitment of not less than $80,000,000 (which, for the avoidance of doubt, excludes any Company Notes&#160;issued on or prior to the date hereof and expected to be contributed in connection with the Concurrent Investment) (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Concurrent Investment Amount</span>&#8221;) in the form attached hereto as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;D</span> (collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Securities Purchase Agreement</span>&#8221;), pursuant to which such Persons will have agreed, subject to the terms and conditions set forth therein, to subscribe and purchase a number of shares of the Company Common Stock immediately prior to the Closing (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Concurrent Investment</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">NOW, THEREFORE, in consideration of the premises, and of the representations, warranties, covenants and agreements contained herein, and intending to be legally bound hereby, Parent, Merger Subs and the Company hereby agree as follows:</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="ARTICLEI_534557"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DEFINITIONS&#160;&amp; INTERPRETATIONS</b></p><a id="Section11"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;1.1 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certain Definitions</span>. For purposes of this Agreement:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">2024 Equity Incentive Plan</span><span style="color:#231f20;">&#8221; shall mean an equity incentive plan of Parent in form and substance as designated by the Company, reserving for issuance a number of shares of Parent Common Stock to be designated by the Company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">2024 ESPP</span><span style="color:#231f20;">&#8221; shall mean an &#8220;employee stock purchase plan&#8221; of Parent in form and substance as designated by Company, reserving for issuance a number of shares of Parent Common Stock to be designated by the Company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">2024 Plans</span><span style="color:#231f20;">&#8221; shall mean both the 2024 Equity Incentive Plan and 2024 ESPP.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Acceptable Confidentiality Agreement</span><span style="color:#231f20;">&#8221; means a confidentiality agreement containing terms not materially less restrictive in the aggregate to the counterparty thereto than the terms of the Confidentiality Agreement, except such confidentiality agreement need not contain any standstill, non-solicitation or no hire provisions. Notwithstanding the foregoing, a Person who has previously entered into a confidentiality agreement with Parent relating to a potential Acquisition Proposal on terms that are not materially less restrictive than the Confidentiality Agreement with respect to the scope of coverage and restrictions on disclosure and use shall not be required to enter into a new or revised confidentiality agreement, and such existing confidentiality agreement shall be deemed to be an Acceptable Confidentiality Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="color:#231f20;">&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Acquisition Inquiry</span><span style="color:#231f20;">&#8221; means, with respect to a party, an inquiry, indication of interest or request for information (other than an inquiry, indication of interest or request for information made or submitted by the Company, on the one hand, or Parent, on the other hand, to the other party) that could reasonably be expected to lead to an Acquisition Proposal, other than the Concurrent Investment or the issuance of any Company Notes.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span><span style="color:#231f20;">&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Acquisition Proposal</span><span style="color:#231f20;">&#8221; means, with respect to either party hereto, any proposal or offer (whether written or oral) from any Person (other than the other party or any of its Representatives) contemplating or otherwise relating to an Acquisition Transaction (other than in connection with the Concurrent Investment, Parent&#8217;s leases, a Parent Legacy Transaction or the exercise or repurchase of existing equity interests).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span><span style="color:#231f20;">&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Acquisition Transaction</span><span style="color:#231f20;">&#8221; means any transaction or series of related transactions (other than the Concurrent Investment or the issuance of any Company Notes) involving:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="color:#231f20;">any merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of securities, reorganization, recapitalization, tender offer, exchange offer or other similar transaction: (i)&#160;in which a party is a constituent entity, (ii)&#160;in which a Person or &#8220;group&#8221; (as defined in the Exchange Act and the rules&#160;promulgated thereunder) of Persons directly or indirectly acquires beneficial or record ownership of securities representing more than 20% of the outstanding securities of any class of voting securities of a party or any of its Subsidiaries or (iii)&#160;in which a party or any of its Subsidiaries issues securities representing more than 20% of the outstanding securities of </span>any class of voting securities of such party or any of its Subsidiaries; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span><span style="color:#231f20;">any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or account for 20% or more of the consolidated book value of the fair market value of the assets of a party and its Subsidiaries taken as a whole.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span><span style="color:#231f20;">&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Affiliate</span><span style="color:#231f20;">&#8221; of any Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such first Person.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="color:#231f20;">&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Business Day</span><span style="color:#231f20;">&#8221; means any day other than a Saturday, a Sunday or a day on which banks in New York, New York are authorized or required by applicable Law to be closed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span><span style="color:#231f20;">&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Certificate of Designation</span><span style="color:#231f20;">&#8221; means the Certificate of Designation of Preferences, Rights and Limitations of Parent Convertible Preferred Stock in the form attached hereto as </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;F</span><span style="color:#231f20;">.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(k)</span></span><span style="color:#231f20;">&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Capital Stock</span><span style="color:#231f20;">&#8221; means, collectively, the Company Common Stock and Company Preferred Stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(l)</span></span><span style="color:#231f20;">&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Equity Plan</span><span style="color:#231f20;">&#8221; means the Company&#8217;s 2024 Equity Incentive Plan, as amended from time to time.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(m)</span></span><span style="color:#231f20;">&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Fundamental Representations</span><span style="color:#231f20;">&#8221; means each of the representations and warranties of the Company set forth in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.1</span><span style="color:#231f20;">, </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.2</span><span style="color:#231f20;">, </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.2(a)</span><span style="color:#231f20;">. </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.4</span><span style="color:#231f20;"> and </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.25</span><span style="color:#231f20;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(n)</span></span><span style="color:#231f20;">&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Notes</span><span style="color:#231f20;">&#8221; means the convertible notes issued pursuant to (i)&#160;that certain Convertible Note&#160;Purchase Agreement, dated as of July&#160;24, 2024, between the Company and the purchasers party thereto, and (ii)&#160;that certain Convertible Note&#160;Purchase Agreement, dated as of September&#160;30, 2024, between the Company and the purchasers party thereto, or any additional convertible promissory notes that may </span>be issued from time to time prior to the Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(o)</span></span><span style="color:#231f20;">&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Options</span><span style="color:#231f20;">&#8221; means options to purchase shares of Company Common Stock granted by the Company under the Company Equity Plan.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(p)</span></span><span style="color:#231f20;">&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Owned IP</span><span style="color:#231f20;">&#8221; means all Intellectual Property owned by the Company or any of its Subsidiaries in whole or in part.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(q)</span></span><span style="color:#231f20;">&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Plan</span><span style="color:#231f20;">&#8221; means each Employee Plan that is sponsored, maintained, or contributed (or required to be contributed) to by the Company or any of its Subsidiaries for the benefit of one or more current or former employees, officers, directors or other service providers of the Company or any of its Subsidiaries and with respect to which the Company or any of its Subsidiaries has any liability, contingent or otherwise, other than any plan, program, arrangement, agreement or policy mandated by applicable Laws.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(r)</span></span><span style="color:#231f20;">&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Preferred Stock</span><span style="color:#231f20;">&#8221; means the shares of the Company&#8217;s capital stock designated as Series&#160;Seed Preferred Stock par value $0.0001 per share.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(s)</span></span><span style="color:#231f20;">&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Triggering Event</span><span style="color:#231f20;">&#8221; shall be deemed to have occurred if, at any time prior to the adoption of this Agreement and the approval of the Contemplated Transactions by the Company Stockholder Approval: (a)&#160;the Company Board shall have publicly approved, endorsed or recommended any Acquisition Proposal or (b)&#160;the Company shall have entered into any letter of intent or similar document or any Contract relating to any Acquisition Proposal (other than an Acceptable Confidentiality Agreement) permitted pursuant to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.4</span><span style="color:#231f20;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(t)</span></span><span style="color:#231f20;">&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Warrant</span><span style="color:#231f20;">&#8221; means warrants to purchase shares of Company Capital Stock issued by the Company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(u)</span></span><span style="color:#231f20;">&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality Agreement</span><span style="color:#231f20;">&#8221; means that certain non-disclosure agreement, dated as of July&#160;24, 2024, between the Company and Parent.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</span></span><span style="color:#231f20;">&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Contemplated Transactions</span><span style="color:#231f20;">&#8221; means the Merger, the Constructive Issuance and the other transactions contemplated by this Agreement (other than the Parent Legacy Transaction and Parent Charter Amendment), the Concurrent Investment and the Nasdaq Reverse Stock Split (to the extent applicable and deemed necessary by Parent and the Company).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(w)</span></span><span style="color:#231f20;">&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">control</span><span style="color:#231f20;">&#8221; (including the terms &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">controlled</span><span style="color:#231f20;">,&#8221; &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">controlled by</span><span style="color:#231f20;">&#8221; and &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">under common control with</span><span style="color:#231f20;">&#8221;) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(x)</span></span><span style="color:#231f20;">&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Employee Plan</span><span style="color:#231f20;">&#8221; means each &#8220;employee benefit plan&#8221; (within the meaning of section 3(3)&#160;of ERISA, whether or not subject to ERISA), Multiemployer Plans, and all stock purchase, stock option, phantom stock or other equity-based plan, severance, employment, change-in-control, fringe benefit, bonus, incentive, deferred compensation, compensation, supplemental retirement, health, life, or disability insurance, dependent care, vacation and all other employee benefit and compensation plans, agreements, programs, policies or other arrangements, whether or not subject to ERISA (including any funding mechanism therefor now in effect or required in the future as a result of the Contemplated Transactions or otherwise), whether formal or informal, written or oral.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(y)</span></span><span style="color:#231f20;">&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">ERISA</span><span style="color:#231f20;">&#8221; means the U.S. Employee Retirement Income Security Act of 1974, as amended.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(z)</span></span><span style="color:#231f20;">&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">HSR Act</span><span style="color:#231f20;">&#8221; means the U.S. Har Scott-Rodino Antitrust Improvements Act of 1976, as amended.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(aa)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Intellectual Property</span><span style="color:#231f20;">&#8221; means all intellectual property rights of any kind, including all of the </span>following: (i)&#160;trademarks or service marks (whether registered or unregistered), trade names, domain names, social media user names, social media addresses, logos, slogans, and trade dress, including applications to register any of the foregoing, together with the goodwill symbolized by any of the foregoing; (ii)&#160;patents, utility models and any similar or equivalent statutory rights with respect to the protection of inventions, and all applications for any of the foregoing, together with all re-issuances, continuations, continuations-in- part, divisionals, revisions, extensions and reexaminations thereof; (iii)&#160;copyrights (registered and unregistered) and applications for registration; (iv)&#160;trade secrets and customer lists, in each case to the extent any of the foregoing derives economic value (actual or potential) from not being generally known to other Persons who can obtain economic value from its disclosure or use, and other confidential information (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trade Secrets</span>&#8221;); and (v)&#160;any other proprietary or intellectual property rights of any kind or nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(bb)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">knowledge</span><span style="color:#231f20;">&#8221; of any party means (i)&#160;the actual knowledge of any executive officer of such party or other officer having primary responsibility for the relevant matter or any employee consultant or interim officer serving similar roles (ii)&#160;any fact or matter which any such Person would be expected to discover or otherwise become aware of in the course of conducting due inquiry, consistent with such Person&#8217;s title and responsibilities, concerning the existence of the relevant matter.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(cc)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Multiemployer Plan</span><span style="color:#231f20;">&#8221; shall have the meaning set forth in Section&#160;3(37) of ERISA. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(dd)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Nasdaq</span><span style="color:#231f20;">&#8221; means the Nasdaq Stock Market,&#160;LLC.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(ee)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Nasdaq Fees</span><span style="color:#231f20;">&#8221; means all Nasdaq fees associated with any action contemplated by </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.8</span><span style="color:#231f20;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(ff)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Nasdaq Reverse Stock Split</span><span style="color:#231f20;">&#8221; means a reverse stock split of all outstanding shares of Parent Common Stock at a reverse stock split ratio as mutually agreed to by Parent and the Company that is effectuated by Parent for the purpose of maintaining compliance with Nasdaq listing standards.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(gg)&#160;&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Net Cash</span><span style="color:#231f20;">&#8221; means (i)&#160;Parent&#8217;s unrestricted cash, cash equivalents and short-term investments, </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">plus</span><span style="color:#231f20;"> (ii)&#160;all prepaid expenses, deposits, restricted cash and short-term receivables set forth on Schedule 1.1(a), in each case, to the extent capable of use by the combined company after the Closing, </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">minus</span><span style="color:#231f20;"> (iii)&#160;the sum </span>of Parent&#8217;s short-term and long-term liabilities, including all accounts payable, indebtedness, lease termination costs, all actual and reasonably projected costs and expenses relating to the winding down of the <span style="color:#231f20;">Parent</span> Legacy Business and any related prepayment penalties and premiums, and any unpaid Transaction Expenses (including any costs, fees or other liabilities, including Taxes, related to the premiums, commissions and other fees paid or payable in connection with obtaining Parent&#8217;s D&amp;O tail policy as set forth in Section&#160;7.5(d)), <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">minus</span> (iv)&#160;any and all change in control payments, severance payments and any payroll or similar Taxes owed in connection with the foregoing or any of Parent&#8217;s equity plans, including, for the avoidance of doubt, any employer-side portion of any payroll or similar Taxes owed in connection with the vesting and settlement of the Parent Restricted Stock Unit Awards pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.7</span> hereof), in each case to the extent payable to Parent&#8217;s employees solely as a result of the consummation of the Contemplated Transactions, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">minus</span> (v)&#160;the Pre-Closing Cash Dividend Amount. Set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.1(a)</span>&#160;of the Parent Disclosure Letter is an illustrative example of the calculation of Net Cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(hh)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Ordinary Course</span><span style="color:#231f20;">&#8221; means, in the case of each of the Company and Parent, such actions taken in the ordinary course of its business and consistent with its past practice or, with respect to the Company, the customary practices of a recently formed company at a similar stage of development.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 18pt;"><span style="color:#231f20;">(ii)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Capital Stock</span><span style="color:#231f20;">&#8221; means the Parent Common Stock and the Parent Preferred Stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(jj)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Closing Price</span><span style="color:#231f20;">&#8221; means the volume weighted average closing trading price of a share of Parent Common Stock on Nasdaq for the five (5)&#160;consecutive trading&#160;days ending three (3)&#160;trading&#160;days immediately prior to the Anticipated Meeting Date as reported by Bloomberg&#160;L.P.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(kk)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Convertible Preferred Stock</span><span style="color:#231f20;">&#8221; means Parent&#8217;s non-voting convertible preferred stock, par value $0.001 per share, with the rights, preferences, powers and privileges specified in the Certificate of Designation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(ll)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Equity Plans</span><span style="color:#231f20;">&#8221; means each of Parent&#8217;s 2018 Equity Incentive Plan and 2021 Stock Option and Incentive Plan, in each case, as amended from time to time.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(mm)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent ESPP</span><span style="color:#231f20;">&#8221; means Parent&#8217;s 2021 Employee Stock Purchase Plan.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(nn)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Fundamental Representations</span><span style="color:#231f20;">&#8221; means each of the representations and warranties of Parent and Merger Subs set forth in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.1</span><span style="color:#231f20;">, </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.2</span><span style="color:#231f20;">, </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.3</span><span style="color:#231f20;">, </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.4</span><span style="color:#231f20;"> and </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.25</span><span style="color:#231f20;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(oo)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent ITM Option</span><span style="color:#231f20;">&#8221; means each Parent Option that is not a Parent OTM Option.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(pp)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Legacy Assets</span><span style="color:#231f20;">&#8221; means all assets, technology and Intellectual Property of Parent as they existed at any time prior to the date of this Agreement, including for purposes of clarity, and the tangible and intangible assets, in each case to the extent primarily used in or primarily related to AV-101 (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Legacy Business</span><span style="color:#231f20;">&#8221;).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(qq)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Options</span><span style="color:#231f20;">&#8221; means options to purchase shares of Parent Common Stock issued pursuant to a Parent Equity Plan or otherwise including, for the avoidance of doubt, the Parent ESPP.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(rr)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent OTM Option</span><span style="color:#231f20;">&#8221; means Parent Options with an exercise price greater than the Parent Closing Price, in each case, as adjusted to take into account the Pre-Closing Cash Dividend in accordance with the Parent Equity Plans, as applicable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(ss)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Owned IP</span><span style="color:#231f20;">&#8221; means all Intellectual Property owned by Parent in whole or in part.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(tt)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Plan</span><span style="color:#231f20;">&#8221; means each Employee Plan that is sponsored, maintained, or contributed (or </span>required to be contributed) to by Parent or any of its Subsidiaries for the benefit of current or former employees, officers, directors or other service providers of Parent or any of its Subsidiaries or with respect to which Parent or any of its Subsidiaries has any liability, contingent or otherwise, other than any plan, program, arrangement, agreement or policy mandated by applicable Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(uu)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Preferred Stock</span><span style="color:#231f20;">&#8221; means the shares of Parent&#8217;s capital stock designated as preferred stock, par value $0.0001 per share of Parent, including the Parent Convertible Preferred Stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(vv)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Restricted Stock Unit Awards</span><span style="color:#231f20;">&#8221; means each award of restricted stock unit awards with respect to shares of Parent Common Stock issued pursuant to a Parent Equity Plan or otherwise.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(ww)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Triggering Event</span><span style="color:#231f20;">&#8221; shall be deemed to have occurred if: (a)&#160;Parent shall have failed to include in the Proxy Statement the Parent Board Recommendation (as defined below), (b)&#160;the Parent Board or any committee thereof shall have made a Parent Board Adverse Recommendation Change or approved, endorsed or recommended any Acquisition Proposal, (c)&#160;Parent shall have entered into any letter of intent or similar document or any Contract relating to any Acquisition Proposal (other than an Acceptable Confidentiality Agreement permitted pursuant to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.4</span><span style="color:#231f20;">), (d)&#160;a tender offer or exchange offer for outstanding shares of Parent Common Stock is commenced, and the Parent Board (or any committee thereof) recommends that the stockholders of Parent tender their shares in such tender or exchange offer or, within ten (10)&#160;Business Days after the commencement of such tender offer or exchange offer, the Parent Board fails to recommend against acceptance of such offer, or (e)&#160;Parent shall have failed to issue a press release confirming the Parent Board Recommendation within ten (10)&#160;Business Days following the Company&#8217;s written request to Parent to issue such press release in response to any other publicly announced Acquisition Proposal with respect to Parent.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(xx)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Person</span><span style="color:#231f20;">&#8221; means an individual, corporation, partnership, limited liability company, association, trust or other entity or organization, including any Governmental Entity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(yy)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Representative</span><span style="color:#231f20;">&#8221; means a party&#8217;s directors, officers, employees, investment bankers, financial advisors, attorneys, accountants or other advisors, agents or representatives.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(zz)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">SEC</span><span style="color:#231f20;">&#8221; means the Securities and Exchange Commission.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(aaa)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Subsequent Transaction</span><span style="color:#231f20;">&#8221; means any Acquisition Transaction (with all references to 20% in the definition of Acquisition Transaction being treated as references to 50% for these purposes).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(bbb)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Subsidiary</span><span style="color:#231f20;">&#8221; means, with respect to any Person, any other Person of which stock or other equity interests having ordinary voting power to elect more than 50% of the board of directors or other governing body are owned, directly or indirectly, by such first Person.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_Hlk183616316"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;"><span style="color:#231f20;">(ccc)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Superior Offer</span><span style="color:#231f20;">&#8221; means an unsolicited bona fide written Acquisition Proposal (with all references to 20% in the definition of Acquisition Transaction being treated as references to 50% for these purposes) that: (a) was not obtained or made as a direct or indirect result of a breach of (or in violation of) the Agreement and (b) is on terms and conditions that the Parent Board or the Company Board, as applicable, determines in good faith, based on such matters that it deems relevant (including the likelihood of consummation thereof and the financing terms thereof), as well as any written offer by the other party to the Agreement to amend the terms of the Agreement, and following consultation with its outside legal counsel and financial advisors, if any, are more favorable, from a financial point of view, to the Parent&#8217;s stockholders or the Company&#8217;s stockholders, as applicable, than the terms of the Contemplated Transactions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;"><span style="color:#231f20;">(ddd)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Tax Return</span><span style="color:#231f20;">&#8221; means any return, declaration, report, certificate, bill, election, claim for refund, information return, statement or other written information and any other document filed or supplied or required to be filed or supplied to any Governmental Entity with respect to Taxes, including any schedule, attachment or supplement thereto, and including any amendment thereof.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;"><span style="color:#231f20;">(eee)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Taxes</span><span style="color:#231f20;">&#8221; means all U.S. federal, state and local and non-U.S. net income, gross income, gross receipts, sales, use, stock, ad valorem, transfer, transaction, franchise, profits, gains, registration, license, wages, lease, service, service use, employee and other withholding, imputed underpayment, social security, unemployment, welfare, disability, payroll, employment, excise, severance, stamp, occupation, workers&#8217; compensation, premium, real property, personal property, windfall profits, net worth, capital, value-added, alternative or add-on minimum, customs duties, estimated and other taxes, fees, assessments, charges or levies in the nature of a tax (whether imposed, assessed, determined, administered, enforced or collected directly or through withholding and including any amounts resulting from the failure to file any Tax Return), whether disputed or not, together with any interest and any penalties, additions to tax or additional amounts with respect thereto (or attributable to the nonpayment thereof).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;"><span style="color:#231f20;">(fff)&#160;&#160;&#160;&#160;&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Transaction Expenses</span><span style="color:#231f20;">&#8221; means the aggregate amount (without duplication) of all costs, fees, Taxes and expenses incurred by Parent and Merger Subs, or for which Parent or Merger Subs are or may become liable in connection with the Contemplated Transactions and the negotiation, preparation and execution of this Agreement or any other agreement, document, instrument, filing, certificate, schedule, exhibit, letter or other document prepared or executed in connection with the Contemplated Transactions, including (i) the maximum amount of fees and expenses payable to financial advisors, investment bankers, legal counsel, accountants, brokers, consultants, Tax advisors, transfer agents, proxy solicitor and other advisors of Parent, including the employer portion of any payroll or similar Taxes incurred or to be incurred by Parent or Merger Subs with respect to the payment of any item listed in this definition of Transaction Expenses; (ii) 50% of the fees paid to the SEC in connection with filing the Registration Statement, the Proxy Statement, and any amendments and supplements thereto, with the SEC; (iii) 50% of the fees and expenses incurred in connection with the printing, mailing and distribution of the Registration Statement and any amendments and supplements thereto; (iv) 50% of the filing fees of Parent in connection with the HSR Act; (v) 50% of the fees and expenses incurred in connection with the Exchange Agent; and (vi) any bonus, retention payments, severance, change-in-control payments or similar payment obligations (including payments with &#8220;single-trigger&#8221; provisions triggered at and as of the consummation of the transactions contemplated hereby) that become due or payable to any director, officer, employee or consultant in connection with the consummation of the Contemplated Transactions, together with any payroll Taxes associated therewith; provided, however, that Transaction Expenses shall specifically exclude (A) any fees and expenses incurred by the Company in connection with the Concurrent Investment, (B) the value or anticipated value of any settlement or judgment that is entered into or awarded post-Closing relating to stockholder litigation or threatened litigation arising out of or in connection with the Contemplated Transactions, (C) 50% of any Nasdaq Fees, and (D) 50% of the filing fees of Parent in connection with the HSR Act.</span></p><a id="Section12"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interpretation</span>. When a reference is made in this Agreement to a Section, Article, Exhibit or Schedule such reference shall be to a Section, Article, Exhibit or Schedule of this Agreement unless otherwise indicated. The table of contents and headings contained in this Agreement or in any Exhibit or Schedule are for convenience of reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. All words used in this Agreement will be construed to be of such gender or number as the circumstances require. Any capitalized terms used in any Exhibit or Schedule but not otherwise defined therein shall have the meaning as defined in this Agreement. All Exhibits and Schedules annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as if set forth herein. The word &#8220;including&#8221; and words of similar import when used in this Agreement will mean &#8220;including, without limitation,&#8221; unless otherwise specified. The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of similar import when used in this Agreement shall refer to the Agreement as a whole and not to any particular provision in this Agreement. The term &#8220;or&#8221; is not exclusive. The word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall.&#8221; References to days mean calendar days unless otherwise specified.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Section13"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Currency</span>. All references to &#8220;dollars&#8221; or &#8220;$&#8221; or &#8220;US$&#8221; in this Agreement refer to United States dollars, which is the currency used for all purposes in this Agreement.</p><a id="ARTICLEII"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE MERGER</b></p><a id="Section21"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Formation of Merger Subs</span>. Parent has caused each of First Merger Sub and Second Merger Sub to be organized under the laws of the State of Delaware.</p><a id="Section22"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Mergers</span>. Upon the terms and subject to the conditions set forth in this Agreement and in accordance with the DGCL, at the First Effective Time, First Merger Sub shall be merged with and into the Company. Following the First Merger, the separate corporate existence of First Merger Sub shall cease, and the Company shall continue as the surviving company of the Merger (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">First Step Surviving Company</span>&#8221;) and a wholly-owned subsidiary of Parent. Upon the terms and subject to the conditions set forth in this Agreement and in accordance with the DGCL and the DLLCA, at the Second Effective Time, the First Step Surviving Corporation will merge with and into Second Merger Sub, and the separate existence of the First Step Surviving Corporation shall cease. As a result of the Second Merger, Second Merger Sub will continue as the surviving entity in the Second Merger (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surviving Entity</span>&#8221;).</p><a id="Section23"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing</span>. Unless this Agreement is earlier terminated pursuant to the provisions of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IX</span>, and subject to the satisfaction or waiver of the conditions set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VIII</span>, the consummation of the Merger (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing</span>&#8221;) shall take place remotely by the electronic exchange of documents, as promptly as practicable (but in no event later than the second Business Day following the satisfaction or waiver of the last to be satisfied or waived of the conditions set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VIII</span>, other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or waiver of each of such conditions), unless another time, date and place is mutually agreed upon by Parent and the Company in writing. The date on which the Closing actually takes place is referred to as the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing Date</span>.&#8221;</p><a id="Section24"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certificate of Designation; First Effective Time; Second Effective Time</span>. Prior to the Closing, Parent shall file the Certificate of Designation with the office of the Secretary of State of the State of Delaware. Upon the terms and subject to the provisions of this Agreement, at the Closing, the parties (i) <span style="color:#231f20;">shall cause the First Merger to be consummated by executing and filing a certificate of merger with respect to the First Merger in the form attached hereto as Exhibit&#160;E-1 hereto (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">First Certificate of Merger</span><span style="color:#231f20;">&#8221; ) and (ii)&#160;shall cause the Second Merger to be consummated by executing and filing a certificate of merger with respect to the Second Merger in the form attached hereto as Exhibit&#160;E-2 hereto (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Second Certificate of </span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger</span>&#8221; and together with the First Certificate of Merger, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certificate of Merger</span>&#8221; ), in each case, with the Secretary of State of the State of Delaware (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delaware Secretary of State</span>&#8221; ), in such form as is required by, and executed in accordance with the relevant provisions of the DGCL and the DLLCA, as the case may be. The First Merger shall become effective at such time as the First Certificate of Merger is duly filed with the Delaware Secretary of State or at such other time as Parent and the Company shall agree in writing and shall specify in the Certificate of Merger (the time the First Merger becomes effective being the &#8220;First <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Time</span>&#8221; ). The Second Merger shall become effective at the time of the filing of such Second Certificate of Merger with the Secretary of State of the State of Delaware or at such later time as may be specified in such Second Certificate of Merger with the consent of Parent and the Company (the time as of which the Second Merger becomes effective being the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Second Effective Time</span>&#8221; ).</p><a id="Section25"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effects of the Merger</span>. At and after the First Effective Time, the First Merger shall have the effects set forth in this Agreement and in the relevant provisions of the DGCL. At and after the Second Effective Time, the Second Merger shall have the effects set forth in this Agreement and in the relevant provisions of the DGCL and the DLLCA. Without limiting the generality of the foregoing, and subject thereto, (i)&#160;at the First Effective Time, all the property, rights, privileges, powers and franchises of the Company and First Merger Sub shall vest in the First Step Surviving Company, and all debts, liabilities and duties of the Company and First Merger Sub shall become the debts, liabilities and duties of the First Step Surviving Company, and (ii)&#160;at the Second Effective Time, all the property, rights, privileges, powers and franchises of the First Step Surviving Company shall vest in the Surviving Entity, and all debts, liabilities and duties of the First Step Surviving Company shall become the debts, liabilities and duties of the Surviving Entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Section26"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;2.6 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Governance</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Certificate of Incorporation</span><span style="color:#231f20;">. As of the Second Effective Time, the certificate of incorporation of Parent shall be identical to the certificate of incorporation of Parent immediately prior to the First Effective Time, until thereafter amended in accordance with its terms and as provided by applicable Law; </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">provided</span><i style="color:#231f20;font-style:italic;">, </i><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">however</span><span style="color:#231f20;">, that, at the Second Effective Time or at such other time as Parent and the Company shall agree in writing, Parent shall file an amendment to the certificate of incorporation to (i)&#160;effect the Nasdaq Reverse Stock Split (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Reverse Stock Split Proposal</span><span style="color:#231f20;">&#8221;), (ii)&#160;change the name of Parent to &#8220;Jade Biosciences,&#160;Inc.&#8221; (iii)&#160;increase the number of shares of Parent Capital Stock that Parent is authorized to issue to a number mutually agreed between Parent and the Company, such amount to be sufficient to allow for consummation of the Contemplated Transactions, (iv)&#160;redomicile Parent from Delaware to such jurisdiction as may be determined by the Company (being either the Cayman Islands or Bermuda) and (v)&#160;make such other changes as mutually agreeable to Parent and the Company (such amendment, the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Charter Amendment</span><span style="color:#231f20;">&#8221;).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Bylaws</span><span style="color:#231f20;">. As of the Second Effective Time, the bylaws of Parent shall be identical to the bylaws of Parent immediately prior to the First Effective Time, until thereafter amended in accordance with their terms and as provided by applicable Law; provided, however, that, at the Second Effective Time or at such other time as Parent and the Company shall agree in writing, Parent shall file an amendment to the bylaws as necessary to redomicile Parent from Delaware to such jurisdiction as may be determined by the Company (being either the Cayman Islands or Bermuda).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Board of Directors</span><span style="color:#231f20;">. The parties shall take all action necessary (including, to the extent necessary, procuring the resignation of any directors on the Parent Board immediately prior to the First Effective Time) so that, as of the First Effective Time, the Board of Directors shall upon the First Effective Time initially consist of the Persons set forth in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.6(c)</span><span style="color:#231f20;">&#160;of the Company Disclosure Letter.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Officers</span><span style="color:#231f20;">. The parties shall take all action necessary (including, to the extent necessary, procuring the resignation or removal of any officers of Parent immediately prior to the Second Effective Time) so that, as of the First Effective Time and the First Effective Time, the Parent officers shall initially consist of the Persons set forth in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.6(d)</span><span style="color:#231f20;">&#160;of the Company Disclosure Letter.</span></p><a id="Section27"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Section&#160;2.7 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">First Step Surviving Company and Surviving Entity Governance</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">At the First Effective Time:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="color:#231f20;">The Certificate of Incorporation of the First Step Surviving Company shall, by virtue of the Merger and without any further action, be amended and restated to read in its entirety as set forth on Exhibit&#160;A to the Certificate of Merger, and, as so amended and restated, shall be the Certificate of Incorporation of the First Step Surviving Company until thereafter amended in accordance with applicable Law;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span><span style="color:#231f20;">The bylaws of the First Step Surviving Company shall be amended and restated to read in their entirety as the bylaws of First Merger Sub as in effect immediately prior to the First Effective Time (except that references to the name of First Merger Sub shall be replaced with references to the name of the First Step Surviving Company), and, as so amended and restated, shall be the bylaws of the First Step Surviving Company until thereafter amended in accordance with applicable Law;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span><span style="color:#231f20;">The directors of the First Step Surviving Company shall be such persons as are designated by the Company prior to the First Effective Time, each to hold office in accordance with the certificate of incorporation and bylaws of the First Step Surviving Company until the earlier of their resignation or removal or until their respective successors are duly elected and qualified; and</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</span></span><span style="color:#231f20;">The officers of the First Step Surviving Company shall be such persons as are designated by the Company prior to the First Effective Time, each to hold office in accordance with the certificate of incorporation and bylaws of the First Step Surviving Company until the earlier of their resignation </span>or removal or until their respective successors are duly elected and qualified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">At the Second Effective Time</span><span style="color:#231f20;">:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="color:#231f20;">The certificate of formation of the Surviving Entity shall be the certificate of formation of Second Merger Sub as in effect immediately prior to the Second Effective Time, until thereafter amended as provided by the DLLCA and such certificate of formation; provided, however, that at the Second Effective Time (as part of the Second Certificate of Merger), the certificate of </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 10pt 0pt;"><span style="color:#231f20;">formation shall be amended to (A)&#160;change the name of the Surviving Entity to &#8220;Jade Biosciences Operating Company, </span>LLC,&#8221; and (B)&#160;make such other changes as are mutually agreed to by Parent and the Company; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span><span style="color:#231f20;">The limited liability company agreement of the Surviving Entity shall be amended and restated in its entirety to read identically to the limited liability company agreement of Second Merger Sub as in effect immediately prior to the Second Effective Time, until thereafter amended as provided by the DLLCA and such limited liability company agreement; provided, however, that following the Second Effective Time (as soon thereafter as practicable), the limited liability company agreement shall be amended to change the name of the Surviving Entity to &#8220;Jade Biosciences Operating Company, LLC&#8221;.</span></p><a id="ARTICLEIII"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;III</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EFFECT ON THE CAPITAL STOCK OF THE CONSTITUENT COMPANIES; EXCHANGE OF CERTIFICATES</b></p><a id="Section31"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;3.1 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conversion of Capital Stock</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">At the First Effective Time, by virtue of the Merger and without any action on the part of Parent, Merger Subs, the Company or the holders of any shares of capital stock of the Parent, Merger Subs or the Company:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="color:#231f20;">Subject to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(g)</span><span style="color:#231f20;">, (i)&#160;each share of Company Common Stock issued and outstanding immediately prior to the First Effective Time (other than any Excluded Shares, Dissenting Shares, but including any Company Restricted Shares which shall be subject to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1(b)</span><span style="color:#231f20;">&#160;below) shall be converted into and become exchangeable for the right to receive, a number of shares of Parent Common Stock equal to the Exchange Ratio and (ii)&#160;each share of Company Preferred Stock outstanding immediately prior to the First Effective Time (other than any Excluded Shares, Dissenting Shares) shall be converted solely into the right to receive a number of shares of Parent Convertible Preferred Stock </span>equal to (x)&#160;the Exchange Ratio divided by (y)&#160;1,000 (collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger Consideration</span>&#8221; ). As of the First Effective Time, all such shares of Company Capital Stock shall no longer be outstanding and shall automatically be cancelled and shall cease to exist, and shall thereafter only represent the right to receive the Merger Consideration. For purposes of this Agreement, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exchange Ratio</span>&#8221; shall mean the ratio (rounded to four decimal places) equal to (a)&#160;the Company Value Per Share divided by (b) <span style="color:#231f20;">the Parent Value Per Share, in which:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(A)</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Equity Value</span><span style="color:#231f20;">&#8221; means $175,000,000.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(B)</span></span><span style="color:#231f20;">&#8221;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Outstanding Shares</span><span style="color:#231f20;">&#8221; means the total number of shares of Company Capital Stock outstanding immediately prior to the First Effective Time (including any shares of Company Common Stock that are issued in, or issuable upon the exercise or conversion of securities issued in, the Concurrent Investment), expressed on a fully diluted and as-converted-to-Company Common Stock basis assuming, without limitation or duplication the exercise of all Company Options, Company Warrants or other rights or commitments to receive shares of Company Common Stock or Company Preferred Stock (or securities convertible or exercisable into shares of Company Common Stock or Company Preferred Stock, including the Company Notes), whether conditional or unconditional, that are outstanding as of immediately prior to the First Effective Time; provided, that for the avoidance of doubt, Company Outstanding Shares shall (1)&#160;exclude, to avoid the double-counting of, any shares of Company Capital Stock underlying Company Notes&#160;that are to be contributed as consideration in the Concurrent Investment, and (2)&#160;exclude any shares of Company Capital Stock underlying any Company Options, Company Warrants and any other equity awards issued under the Company Equity Plan (including any shares of Company Common Stock issuable upon the exercise of such Company Options, Company Warrants or other equity awards) issued to directors, employees, consultants or other service providers following the date hereof but prior to the Closing (collectively, the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Service Provider Grants</span><span style="color:#231f20;">&#8221;).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(C)</span></span><span style="color:#231f20;">&#8221;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Valuation</span><span style="color:#231f20;">&#8221; means the Company Equity Value, plus an amount equal to the total proceeds contemplated by the Concurrent Investment received (including in the total proceeds any Company Notes&#160;contributed in the Concurrent Investment, and any interest, premium and other amounts thereon) by the Company prior to the First Effective Time.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(D)</span></span><span style="color:#231f20;">&#8221;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Value Per Share</span><span style="color:#231f20;">&#8221; equals the Company Valuation divided by the number of Company Outstanding Shares (rounded to four decimal places).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(E)</span></span><span style="color:#231f20;">&#8221;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Outstanding Shares</span><span style="color:#231f20;">&#8221; means the total number of shares of Parent Capital Stock outstanding immediately prior to the First Effective Time (after giving effect, to the extent completed prior to the First Effective Time, to the Nasdaq </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 36pt;"><span style="color:#231f20;">Reverse Stock Split), assuming (i)&#160;the exercise, conversion or exchange of all options, warrants, conversion rights, exchange rights or any other rights to receive shares of Parent Capital Stock which exist immediately prior to the First Effective Time (excluding any Parent Convertible Preferred Stock issuable following the Closing in accordance herewith), (ii)&#160;the settlement in shares of Parent Common Stock of Parent Options outstanding as of immediately prior to the First Effective Time on a net settlement basis as provided in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.6</span><span style="color:#231f20;"> and (iii)&#160;the settlement in shares of Parent Common Stock of Parent Restricted Stock Units outstanding as of immediately prior to the First Effective Time on a net settlement basis as provided in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.7</span><span style="color:#231f20;">. Notwithstanding the foregoing, Parent OTM Options, shall not be included in the total number of shares of Parent Capital Stock for purposes of determining the Parent Outstanding Shares to the extent cancelled at or prior to Closing under </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.6</span><span style="color:#231f20;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(F)</span></span><span style="color:#231f20;">&#8221;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Valuation</span><span style="color:#231f20;">&#8221; means (i)&#160;$8,000,000, minus (ii)&#160;the amount by which Net Cash is less than $0 (if any).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(G)</span></span><span style="color:#231f20;">&#8221;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Value Per Share</span><span style="color:#231f20;">&#8221; equals the Parent Valuation divided by the number of Parent Outstanding Shares (rounded to four decimal places).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">For the avoidance of doubt and for illustrative purposes only, sample &#8220;Exchange Ratio&#8221; and &#8220;Parent Valuation&#8221; calculations are set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1(a)(i)(F)</span>&#160;of the Parent Disclosure Letter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span><span style="color:#231f20;">At the First Effective Time, each share of Parent Capital Stock issued and outstanding immediately prior to the First Effective Time shall remain outstanding.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span><span style="color:#231f20;">Each share of Company Capital Stock held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Subs immediately prior to the First Effective Time (collectively, &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Excluded Shares</span><span style="color:#231f20;">&#8221;) shall automatically be cancelled and shall cease to exist, and no consideration </span>shall be delivered in exchange therefor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</span></span><span style="color:#231f20;">Each share of common stock, par value $0.001 per share, of First Merger Sub issued and outstanding immediately prior to the First Effective Time shall be converted into and become one validly issued, fully paid and non-assessable share of common stock, par value $0.001 per share, of the First Step Surviving Company. Each book entry share of First Merger Sub evidencing ownership of any such shares shall, as of the First Effective Time, evidence ownership of such shares of common stock of the First Step Surviving Company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">If any shares of Company Capital Stock outstanding immediately prior to the First Effective Time are unvested or are subject to a repurchase option or a risk of forfeiture under any applicable restricted stock purchase agreement or other similar agreement with the Company (such shares, collectively, the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Restricted Shares</span><span style="color:#231f20;">&#8221;, shall automatically and without any action on the part of the holder thereof, become converted into a number of Parent Common Stock (rounded down to the nearest whole share) equal to the product of (x)&#160;the number of Company Restricted Shares and (y)&#160;the Exchange Ratio in accordance with </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1(a)(i)</span><span style="color:#231f20;">; provided that such converted shares of Parent Common Stock issued in exchange for such shares of Company Restricted Shares will, to the same extent be unvested and subject to the same repurchase option or risk of forfeiture, and such shares of Parent Common Stock shall accordingly </span>be marked with appropriate legends. The Company shall take all actions that may be necessary to ensure that, from and after the First Effective Time, Parent is entitled to exercise any such repurchase option or other right set forth in any such restricted stock purchase agreement or other agreement. For clarity, the provisions of this Section&#160;3.1(b)&#160;shall not result in a duplication of the issuance of the Merger Consideration in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1(a)(i)</span>, and each share of Company Restricted Shares shall only be entitled to receive a number of shares of Parent Common Stock equal to the Exchange Ratio. For the avoidance of doubt, stockholders and equityholders of the Company, in their capacity as such, shall not receive any Cash Dividend pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.14</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">If, between the date of this Agreement and the First Effective Time, the outstanding Company Capital Stock or Parent Capital Stock shall have been changed into, or exchanged for, a different number of shares or a different class, by reason of any stock dividend, subdivision, reclassification, recapitalization, split (including the Nasdaq Reverse Stock Split to the extent such split has not previously been taken into account in calculating the Exchange Ratio), combination or exchange of shares or other like change, the Exchange Ratio shall, to the extent necessary, be equitably adjusted to reflect such change to the extent necessary to provide the holders of Company Capital Stock, Company Options, Company Warrants and Parent Capital Stock with the same economic effect as contemplated by this Agreement prior to such stock dividend, subdivision, reclassification, recapitalization, split, combination or exchange of shares or other like change; provided, however, that nothing herein will be construed to permit the Company or Parent to </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">take any action with respect to Company Capital Stock or Parent Capital Stock, respectively, that is prohibited or not expressly permitted by the terms of this Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">At the Second Effective Time, by virtue of the Second Merger and without any action on the part of Parent, the First Step Surviving Corporation, Second Merger Sub or their respective stockholders, each share of the First Step Surviving Corporation issued and outstanding immediately prior to the Second Effective Time shall be canceled and extinguished without any conversion thereof and no payment or distribution shall be made with respect thereto.</span></p><a id="Section32"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Options; Company Warrants</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">At the First Effective Time, Parent shall assume each Company Equity Plan and each Company Option outstanding immediately prior to the First Effective Time (including any Service Provider Grants) shall automatically without any further action on the part of Parent, Merger Subs, Company or any holder of a Company Option, be converted, at the First Effective Time, into an option (an &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Assumed Option</span><span style="color:#231f20;">&#8221;) to </span>acquire, on the same terms and conditions (including the same vesting and exercisability terms and conditions) as were applicable under the Company Equity Plan and option agreement applicable to such Company Option immediately prior to the First Effective Time, except for administrative or ministerial changes as determined by the Company Board (or, following the First Effective Time, the Parent Board or compensation committee). The number of shares of Parent Common Stock subject to each such Assumed Option shall be determined by multiplying the number of shares of Company Common Stock subject to such Company Option immediately prior to the First Effective Time by the Exchange Ratio, rounding down to the nearest whole number of shares, at a per share exercise price determined by dividing the per share exercise price of such Company Option immediately prior to the First Effective Time by the Exchange Ratio, rounding up to the nearest whole cent; provided, that in the case of any Company Option to which Section&#160;421 of the Code applies as of immediately prior to the First Effective Time (taking into account the effect of any accelerated vesting thereof, if applicable) by reason of its qualification under Section&#160;422 of the Code, the exercise price, the number of shares of Parent Common Stock subject to such option and the terms and conditions of exercise of such option shall be determined in a manner consistent with the requirements of Section&#160;424(a)&#160;of the Code; provided further, that for any other Assumed Option, the exercise price, the number of shares of Parent Common Stock subject to such option and the terms and conditions of exercise of such option shall, in all events, be determined in a manner consistent with the requirements of Section&#160;409A of the Code in order to avoid the imposition of any additional taxes thereunder. As of the First Effective Time, Parent will assume each Company Equity Plan, with the number of shares available for issuance thereunder being determined by multiplying the number of shares of Company Common Stock available for issuance thereunder prior to the First Effective Time by the Exchange Ratio. For the avoidance of doubt, stockholders and equityholders of the Company, in their capacities as such, shall not receive any Pre-Closing Cash Dividend pursuant to Section&#160;7.14.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">At the First Effective Time, each Company Warrant (including any pre-funded Company Warrant issued pursuant to the Concurrent Investment), whether vested or unvested, that is outstanding immediately prior to the First Effective Time shall, at the First Effective Time, cease to represent a right to acquire shares of Company Capital Stock and shall be converted, at the First Effective Time, into a warrant to purchase shares of Parent Common Stock (an &#8220;Assumed Warrant&#8221;), on the same terms and conditions (including any vesting provisions and any provisions providing for accelerated vesting upon certain events) as were applicable under such Assumed Warrant as of immediately prior to the First Effective Time. The number of shares of Parent Common Stock subject to each such Assumed Warrant shall be equal to (i)&#160;the number of shares of the Company Common Stock subject to each Assumed Warrant immediately prior to the First Effective Time multiplied by (ii)&#160;the Exchange Ratio, rounded down, if necessary, to the nearest </span>whole share of Parent Common Stock, and such Assumed Warrant shall have an exercise price per share (rounded up to the nearest whole cent) equal to (A)&#160;the exercise price per share of the Company Common Stock otherwise purchasable pursuant to such Assumed Warrant immediately prior to the First Effective Time divided by (B)&#160;the Exchange Ratio.</p><a id="Section33"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exchange and Payment</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">Parent shall issue and deposit (or cause to be deposited) with a bank or trust company designated by Parent (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Exchange Agent</span><span style="color:#231f20;">&#8221;), in trust for the benefit of holders of shares of Company Capital Stock immediately prior to the First Effective Time (other than holders to the extent they hold Excluded Shares or Dissenting Shares), book-entry shares (or certificates if requested) representing the shares of Parent </span>Capital Stock issuable pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1(a)(i)</span>. In addition, Parent shall make available by depositing with the Exchange Agent, as necessary from time to time after the First Effective Time any dividends or other distributions payable pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(e)</span>&#160;(which for clarity shall not include the Pre-Closing Cash Dividend). All certificates representing </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;">shares of Parent Capital Stock, and any dividends, distributions and cash deposited with the Exchange Agent are hereinafter referred to as the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exchange Fund</span>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">As soon as reasonably practicable after the First Effective Time and in any event not later than the tenth (10</span><sup style="color:#231f20;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="color:#231f20;">) Business Day prior to the anticipated Closing Date, the parties shall cause the Exchange Agent to mail to each holder of record of a certificate that immediately prior to the First Effective Time represented outstanding shares of Company Capital Stock (collectively, the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Certificates</span><span style="color:#231f20;">&#8221;) and to each holder of record of uncertificated shares of Company Capital Stock represented by book entry (&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Book-Entry Shares</span><span style="color:#231f20;">&#8221;) that were converted into the right to receive the Merger Consideration (together with any dividends </span>or other distributions payable pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(e)</span>, but not the Pre-Closing Cash Dividend), (i)&#160;a form of letter of transmittal (which shall specify that delivery shall be effected, and risk of loss and title to any Certificates held by such Person shall pass, only upon proper delivery of such Certificates, if any, and identification of the Book-Entry Shares, if any, to the Exchange Agent, and which letter shall be in customary form and contain such other provisions as Parent or the Exchange Agent may reasonably specify) and (ii)&#160;instructions for use in effecting the surrender of any such Certificates and identifying such Book-Entry Shares in exchange for the Merger Consideration (together with any dividends or other distributions payable pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(e)</span>, but not the Pre-Closing Cash Dividend). Upon surrender of a Certificate and identification of the Book-Entry Shares, as applicable, to the Exchange Agent, together with such letter of transmittal, duly completed and validly executed in accordance with the instructions thereto, and such other documents as the Exchange Agent may reasonably require, the holder of such Certificate or Book-Entry Share shall be entitled to receive in exchange for the shares of Company Capital Stock formerly represented by such Certificate or Book-Entry Share (other than Excluded Shares or Dissenting Shares) (A)&#160;that number of whole shares of Parent Capital Stock (after taking into account all shares of Company Capital Stock then held by such holder under all Certificates so surrendered and Book- Entry Shares so identified) to which such holder of Company Capital Stock shall have become entitled pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1(a)(i)</span>&#160;(which shall be in uncertificated book-entry form unless a physical certificate is requested), and (B)&#160;any dividends or other distributions payable pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(e)</span>&#160;(but not the Pre- Closing Cash Dividend), and any Certificate so surrendered, together with any Book-Entry Shares, shall forthwith be cancelled. No interest will be paid or accrued on any unpaid dividends and distributions, if any, payable to holders of Certificates or Book-Entry Shares. Until surrendered as contemplated by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3</span>, each Certificate or Book-Entry Share shall be deemed after the First Effective Time to represent only the right to receive the Merger Consideration payable in respect thereof (together with any dividends or other distributions payable pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(e)</span>, but not the Pre-Closing Cash Dividend).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">If payment of the Merger Consideration is to be made to a Person other than the Person in whose name the surrendered Certificate or Book-Entry Share is registered, it shall be a condition of payment that such Certificate so surrendered shall be properly endorsed or shall be otherwise in proper form for transfer or such Book-Entry Share shall be properly transferred and that the Person requesting such payment shall have paid any transfer and other Taxes required by reason of the payment of the Merger Consideration to a Person other than the registered holder of such Certificate or Book-Entry Share or shall have established </span>to the satisfaction of Parent that such Tax is not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">Holders of Company Capital Stock, in their capacities as such, shall not be entitled to any portion of the Pre-Closing Cash Dividend, and the Certificates and Book-Entry Shares shall not represent any right to any portion of the Pre-Closing Cash Dividend.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="color:#231f20;">(i)&#160;No dividends or other distributions with respect to Parent Capital Stock with a record date after the First Effective Time shall be paid to the holder of any unsurrendered Certificate with respect to the shares of Parent Capital Stock that the holder thereof has the right to receive upon the surrender thereof until the holder thereof shall surrender such Certificate in accordance with this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;III</span><span style="color:#231f20;">. Following the surrender of a Certificate in accordance with this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;III</span><span style="color:#231f20;">, there shall be paid to the record holder thereof, without interest, (A)&#160;promptly after such surrender, the amount of any dividends or other distributions </span>with a record date after the First Effective Time theretofore paid with respect to such whole shares of Parent Capital Stock, and (B)&#160;at the appropriate payment date, the amount of dividends or other distributions with a record date after the First Effective Time but prior to such surrender and a payment date subsequent to such surrender payable with respect to such whole shares of Parent Capital Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span><span style="color:#231f20;">Holders of Book-Entry Shares who are entitled to receive shares of Parent Capital Stock under this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;III</span><span style="color:#231f20;"> shall be paid (A)&#160;at the time of payment of such Parent Capital Stock by the Exchange Agent under </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(b)</span><span style="color:#231f20;">, the amount of dividends or other distributions (other than the Pre- Closing Cash Dividend) with a record date after the First Effective Time theretofore paid with respect to such whole shares of Parent Capital Stock, and (B)&#160;at the appropriate payment date, the amount of dividends or other distributions with a record date after the First Effective Time but prior to the time of such payment by the </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="color:#231f20;">Exchange Agent under </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(b)</span><span style="color:#231f20;">&#160;and a payment date subsequent to the time of such payment by the Exchange Agent under </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(b)</span><span style="color:#231f20;">&#160;payable with respect to such whole shares of Parent Capital Stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span><span style="color:#231f20;">The Merger Consideration (together with any dividends or other distributions payable pursuant to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(e)</span><span style="color:#231f20;">, but not the Pre-Closing Cash Dividend) shall be deemed to have been issued and paid in full satisfaction of all rights pertaining to the shares of Company Capital Stock formerly represented by such Certificates or Book-Entry Shares. At the First Effective Time, the stock transfer books of the Company shall be closed and there shall be no further registration of transfers of the shares of Company Capital Stock that were outstanding immediately prior to the First Effective Time. If, after the First Effective Time, Certificates are presented to the Surviving Entity or the Exchange Agent for transfer or transfer is sought for Book-Entry Shares, such Certificates or Book-Entry Shares shall be cancelled and exchanged as provided </span>in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;III</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span><span style="color:#231f20;">No fractional shares of Parent Capital Stock shall be issued in connection with the Merger, and no certificates or scrip for any such fractional shares shall be issued. Notwithstanding any other provision of this Agreement, each holder of shares of Company Capital Stock converted pursuant to the Merger who would otherwise have been entitled to receive a fraction of a share of Parent Capital Stock (after taking into account all Certificates delivered by such holder and the aggregate number of shares of Parent Capital </span>Stock represented thereby) shall receive, in lieu thereof, cash (without interest and subject to applicable Tax withholding) in an amount equal to such fractional part of a share of Parent Common Stock multiplied by the last reported sale price of Parent Common Stock at 4:00&#160;p.m. (New York City time), end of regular trading hours on Nasdaq on the last trading day prior to the Effective Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span><span style="color:#231f20;">Any portion of the Exchange Fund that remains undistributed to the holders of Certificates or Book-Entry Shares six&#160;months after the First Effective Time shall be delivered to the Surviving Entity, upon demand, and any remaining holders of Certificates or Book-Entry Shares (except to the extent representing Excluded Shares or Dissenting Shares) shall thereafter look only to the Surviving Entity, as general creditors thereof, for payment of the Merger Consideration (together with any dividends or other distributions payable pursuant to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(e)</span><span style="color:#231f20;">&#160;but not the Pre-Closing Cash Dividend) (subject to abandoned property, escheat or other similar laws), without interest.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="color:#231f20;">None of Parent, the Surviving Entity, the Exchange Agent or any other Person shall be liable to any Person in respect of shares of Parent Capital Stock, dividends or other distributions with respect thereto properly delivered to a public official pursuant to any applicable abandoned property, escheat or similar Law. If any Certificates or Book-Entry Shares shall not have been exchanged prior to two&#160;years after the First Effective Time (or immediately prior to such earlier date on which the related Merger Consideration (and all dividends or other distributions with respect to shares of Parent Capital Stock) would otherwise escheat to or become the property of any Governmental Entity), any such Merger Consideration (and such dividends, distributions and cash) in respect thereof shall, to the extent permitted by applicable Law, become the property of the Surviving Entity, free and clear of all claims or interest of any Person previously entitled thereto.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span><span style="color:#231f20;">If any Certificate shall have been lost, stolen or destroyed, upon the making of an affidavit, in form and substance reasonably acceptable to Parent, of that fact by the Person claiming such Certificate to be lost, stolen or destroyed and, if required by Parent or the Exchange Agent, the posting by such Person of a bond in such amount as Parent or the Exchange Agent may determine is reasonably necessary as indemnity against any claim that may be made against it or the Surviving Entity with respect to such Certificate, then the Exchange Agent will deliver in exchange for such lost, stolen or destroyed Certificate the Merger Consideration payable in respect thereof (together with any dividends or other distributions payable pursuant to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(e)</span><span style="color:#231f20;">&#160;but not the Pre-Closing Cash Dividend).</span></p><a id="Section34"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Withholding Rights</span>. Parent, the Surviving Entity and the Exchange Agent (each, a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Withholding Agent</span>&#8221;) shall each be entitled to deduct and withhold, or cause to be deducted and withheld, from the consideration otherwise payable pursuant to this Agreement such amounts as any Withholding Agent is required to deduct and withhold under applicable Law. To the extent that amounts are so deducted and withheld by a Withholding Agent and remitted to the appropriate Governmental Entity, such amounts shall be treated for all purposes of this Agreement as having been paid to the Person in respect of whom such deduction and withholding was made. Except in connection with a failure of the Company to comply with payments under this Agreement in respect of Company Restricted Shares for which an election under Section&#160;83(b)&#160;of the Code has not been filed, the Withholding Agent shall use commercially reasonable efforts to (i)&#160;notify each holder of Company Capital Stock at least five (5)&#160;Business Days prior to deducting or withholding any amounts of its intent to deduct and withhold and (ii)&#160;cooperate with such holder to minimize any such deductions and withholding.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Section35"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dissenters Rights</span>. Notwithstanding anything in this Agreement to the contrary, each share of the Company Capital Stock (other than Excluded Shares) outstanding immediately prior to the First Effective Time and held by a holder who is entitled to demand and has properly demanded appraisal for such shares of the Company Capital Stock in accordance with Section&#160;262 of the DGCL and, as of the First Effective Time, have neither effectively withdrawn nor lost their rights to such appraisal and payment under the DGCL (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dissenting Shares</span>&#8221;), shall not be converted into or be exchangeable for the right to receive a portion of the Merger Consideration but shall be entitled only to such rights as are granted by Section&#160;262 of the DGCL, unless and until such holder fails to perfect or withdraws or otherwise loses such holder&#8217;s right to appraisal and payment under the DGCL. If, after the First Effective Time, any such holder fails to perfect or withdraws or loses such holder&#8217;s right to appraisal, such Dissenting Shares shall thereupon be treated as if they had been converted as of the First Effective Time into the right to receive the portion of the Merger Consideration, if any, to which such holder is entitled pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1(a)(i)</span>, without interest. The Company shall give Parent (a)&#160;prompt notice of any demands received by the Company for appraisal of any shares of the Company Capital Stock issued and outstanding immediately prior to the First Effective Time, attempted written withdrawals of such demands, and any other instruments served pursuant to the DGCL and received by the Company relating to stockholders&#8217; rights to appraisal with respect to the Merger and (b)&#160;the opportunity to participate in all negotiations and proceedings with respect to any exercise of such appraisal rights under the DGCL. The Company shall not, except with the prior written consent of Parent, which shall not be unreasonably withheld, conditioned or delayed, voluntarily make any payment with respect to any demands for payment of fair value for capital stock of the Company, offer to settle or settle any such demands or approve any withdrawal of any such demands.</p><a id="Section36"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Calculation of Net Cash</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">Not less than ten (10)&#160;Business Days prior to the anticipated date for the Parent Stockholder Meeting as mutually agreed in good faith by Parent and the Company (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Anticipated Meeting Date</span><span style="color:#231f20;">&#8221;), Parent will deliver to the Company a certificate signed by an officer of Parent in the form reasonably acceptable to the Company setting forth a schedule (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Net Cash Schedule</span><span style="color:#231f20;">&#8221; , and the date of delivery of the Parent Net Cash Schedule, the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Delivery Date</span><span style="color:#231f20;">&#8221;) setting forth, in reasonable detail, Parent&#8217;s good faith, estimated calculation of Net Cash (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Net Cash Calculation</span><span style="color:#231f20;">&#8221;) as of the close of business on the Closing Date (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Cash Determination Time</span><span style="color:#231f20;">&#8221;) prepared and certified by Parent&#8217;s chief financial officer (or if there is no chief financial officer at such time, the principal financial and accounting officer for Parent). Parent shall make available to the Company (electronically to the greatest extent possible), as reasonably requested by the Company, the work papers and back-up materials (including all relevant invoices and similar evidence of outstanding obligations) used or useful in preparing the Parent Net Cash Schedule and, if reasonably requested by the Company, Parent&#8217;s internal finance personnel, accountants and counsel at reasonable times and upon reasonable notice.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">Within five (5)&#160;Business Days after the Delivery Date (the last day of such period, the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Response Date</span><span style="color:#231f20;">&#8221;), the Company shall have the right to dispute any part of the Parent Net Cash Calculation by delivering a written notice to that effect to Parent (a &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Dispute Notice</span><span style="color:#231f20;">&#8221;). Any Dispute Notice shall identify in reasonable detail and, to the extent known, the nature and amounts of any proposed revisions to the Parent Net </span>Cash Calculation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">If, on or prior to the Response Date, the Company notifies Parent in writing that it has no objections to the Parent Net Cash Calculation or, if prior to 11:59&#160;p.m. (Pacific time) on the Response Date, the Company fails to deliver a Dispute Notice as provided in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.6(b)</span><span style="color:#231f20;">, then the Parent Net Cash Calculation as set forth in the Parent Net Cash Schedule shall be deemed to have been finally determined for purposes of this Agreement and to represent the Net Cash at the Cash Determination Time (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Final Parent Net Cash</span><span style="color:#231f20;">&#8221;) for purposes of this Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">If the Company delivers a Dispute Notice on or prior to 11:59&#160;p.m. (Pacific time) on the Response Date, then Representatives of Parent and the Company shall promptly, and in no event later than one calendar day after the Response Date, communicate and attempt in good faith to resolve the disputed item(s)&#160;and negotiate an agreed-upon determination of Net Cash, which agreed upon Net Cash amount (if so resolved) </span>shall be deemed to have been finally determined for purposes of this Agreement and to represent the Final Parent Net Cash for purposes of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="color:#231f20;">If Representatives of Parent and the Company are unable to resolve the disputed items pursuant to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.6(d)</span><span style="color:#231f20;">&#160;within three calendar&#160;days after delivery of the Dispute Notice (or such other period as Parent and the Company may mutually agree upon), then any remaining disagreements as to the calculation of Net Cash shall be referred to an independent auditor of recognized national standing jointly selected by Parent and the Company (provided that if the parties are unable to select an independent auditor within five (5) days, then either Parent or the Company may thereafter request that the Boston, Massachusetts Office of the American Arbitration Association (&#8220;AAA&#8221;) make such selection (either the independent auditor jointly selected by both parties or such </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">independent auditor selected by the AAA, the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Accounting Firm</span><span style="color:#231f20;">&#8221;). Parent shall promptly deliver to the Accounting Firm all work papers and back-up materials used in preparing the Parent Net Cash Schedule, and Parent and the Company shall use commercially reasonable efforts to </span>cause the Accounting Firm to make its determination within five calendar&#160;days of accepting its selection. Parent and the Company shall be afforded the opportunity to present to the Accounting Firm any material related to the unresolved disputes and to discuss the issues with the Accounting Firm; provided, however, that no such presentation or discussion shall occur without the presence of a Representative of each of Parent and the Company. The determination of the Accounting Firm shall be limited to the disagreements submitted to the Accounting Firm. The determination of the amount of Net Cash made by the Accounting Firm shall be made in writing delivered to each of Parent and the Company, shall be final and binding on Parent and the Company and shall (absent manifest error) be deemed to have been finally determined for purposes of this Agreement and to represent the Final Parent Net Cash for purposes of this Agreement. The parties shall delay the Closing until the resolution of the matters described in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.6(e)</span>. The fees and expenses of the Accounting Firm shall be allocated between Parent and the Company in the same proportion that the disputed amount of the Net Cash that was unsuccessfully disputed amount by such party (as finally determined by the Accounting Firm) bears to the total disputed amount of the Net Cash amount and such portion of the costs and expenses of the Accounting Firm borne by the Company and any other fees, costs or expenses incurred by the Company following the Anticipated Meeting Date in connection with the procedures set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.6(e)</span>&#160;shall be deducted from the final determination of the amount of Net Cash, to the extent of available amounts. If this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.6(e)</span>&#160;applies as to the determination of the Final Parent Net Cash described in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.6(a)</span>, upon resolution of the matter in accordance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.6(e)</span>, the parties shall not be required to determine the Net Cash again even though the Closing Date may occur later than the Anticipated Meeting Date. Notwithstanding anything else in this Agreement, Parent shall redetermine the Final Parent Net Cash if the Closing Date is more than ten calendar&#160;days after the Anticipated Meeting Date.</p><a id="ARTICLEIV"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;IV</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REPRESENTATIONS AND WARRANTIES OF THE COMPANY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as set forth in the corresponding section or subsection of the disclosure letter delivered by the Company to Parent (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Disclosure Letter</span>&#8221;) (it being agreed that the disclosure of any information in a particular section or subsection of the Company Disclosure Letter shall be deemed disclosure of such information with respect to any other section or subsection of this Agreement to which the relevance of such information is readily apparent on its face), the Company represents and warrants to Parent and Merger Subs as follows:</p><a id="Section41"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Organization, Standing and Power</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">The Company (i)&#160;is an entity duly organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation, (ii)&#160;has all requisite corporate or similar power and authority to own, lease and operate its properties and to carry on its business as now being conducted and (iii)&#160;is duly qualified or licensed to do business and is in good standing in each jurisdiction in which the nature of its </span>business or the ownership, leasing or operation of its properties makes such qualification or licensing necessary, except in the case of clause (iii), where the failure to be so qualified or licensed or in good standing, individually or in the aggregate, has not had and would not reasonably be expected to have a Material Adverse Effect. For purposes of this Agreement, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Material Adverse Effect</span>&#8221; means any event, change, circumstance, occurrence, effect or state of facts that (A)&#160;is or would reasonably be expected to be materially adverse to the business, assets, liabilities, financial condition, or results of operations of the Company and its Subsidiaries, taken as a whole, or (B)&#160;materially impairs the ability of the Company to consummate the Merger or any of the other Contemplated Transactions; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that in the case of clause (A) <span style="color:#231f20;">only, Material Adverse Effect shall not include any event, change, circumstance, occurrence, effect or state of facts to the extent resulting from (1)&#160;changes or conditions generally affecting the industries in which the Company and its Subsidiaries operate, or the economy or the financial, debt, banking, capital, credit </span>or securities markets, in the United States, including effects on such industries, economy or markets resulting from any regulatory and political conditions or developments in general, (2)&#160;the outbreak or escalation of war or acts of terrorism or any natural disasters, acts of God or comparable events, epidemic, pandemic or disease outbreak (including the COVID-19 virus) or any worsening of the foregoing, or any declaration of martial law, quarantine or similar directive, policy or guidance or Law or other action by any Governmental Entity in response thereto, (3)&#160;changes in Law or GAAP, or the interpretation or enforcement thereof, (4)&#160;the public announcement or pendency of this Agreement, or (5)&#160;any specific action taken (or omitted to be taken) by the Company at or with the express written consent of Parent; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that, with respect to clauses (1), (2)&#160;and (3), the impact of such event, change, circumstance, occurrence, effect or state of facts is not disproportionately adverse to the Company and its Subsidiaries as compared to other participants in the industries in which the Company and its Subsidiaries operate.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">The Company has previously made available to Parent true and complete copies of the Company&#8217;s Certificate of Incorporation (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Charter</span><span style="color:#231f20;">&#8221;) and bylaws (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Bylaws</span><span style="color:#231f20;">&#8221;) and the Certificate of Incorporation and bylaws of each other Subsidiary of the Company, in each case as amended to the date of this Agreement, and each as so delivered is in full force and effect. None of the Company or any of its Subsidiaries is in violation of any provision of its Certificate of Incorporation or bylaws.</span></p><a id="Section42"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Capital Stock</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">The authorized capital stock of the Company consists of 60,000,000 shares of Company Capital Stock. As of the date hereof, (i)&#160;5,819,672 shares of Company Common Stock (excluding treasury shares) were issued and outstanding (of which 819,672 shares are the Company Restricted Shares), (ii)&#160;zero shares of Company Common Stock were held by the Company in its treasury, (iii)&#160;20,000,000 shares of Company Preferred Stock were issued and outstanding, (iv)&#160;3,637,978 Company Options were issued and outstanding and (v)&#160;zero shares of Company Common Stock subject to the exercise of Company Warrants. All outstanding shares of capital stock of the Company and any of its Subsidiaries are duly authorized, validly issued, fully paid and nonassessable and not subject to any preemptive rights. Neither the Company nor </span>any of its Subsidiaries has any outstanding bonds, debentures, notes or other obligations having the right to vote (or convertible into, or exchangeable or exercisable for, securities having the right to vote) with the stockholders of the Company or any of its Subsidiaries on any matter. Except as set forth above in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.2(a)</span>, neither the Company nor any of its Subsidiaries has any outstanding (A)&#160;shares of capital stock or other voting securities or equity interests of the Company or any of its Subsidiaries, (B)&#160;securities of the Company or any of its Subsidiaries convertible into or exchangeable or exercisable for shares of capital stock of the Company or any of its Subsidiaries or other voting securities or equity interests of the Company or any of its Subsidiaries, (C)&#160;stock appreciation rights, &#8220;phantom&#8221; stock rights, performance units, interests in or rights to the ownership or earnings of the Company or any of its Subsidiaries or other equity equivalent or equity-based awards or rights, (D)&#160;subscriptions, options, warrants, calls, commitments, Contracts or other rights to acquire from the Company or any of its Subsidiaries, or obligations of the Company or any of its Subsidiaries to issue, any shares of capital stock of the Company or any of its Subsidiaries, voting securities, equity interests or securities convertible into or exchangeable or exercisable for capital stock or other voting securities or equity interests of the Company or any of its Subsidiaries or rights or interests described in the preceding clause (C), or (E)&#160;obligations of the Company or any of its Subsidiaries to repurchase, redeem or otherwise acquire any such securities or to issue, grant, deliver or sell, or cause to be issued, granted, delivered or sold, any such securities. There are no stockholder agreements, voting trusts or other agreements or understandings to which the Company or any of its Subsidiaries is a party or of which the Company has knowledge with respect to the holding, voting, registration, redemption, repurchase or disposition of, or that restricts the transfer of, any capital stock or other voting securities or equity interests of the Company or any of its Subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.2(b)</span><span style="color:#231f20;">&#160;of the Company Disclosure Letter sets forth a true and complete list of all holders, as of the date hereof, of outstanding Company Restricted Shares, Company Options and other similar rights </span>to purchase or receive shares of Company Common Stock or similar rights granted under the Company Equity Plan or otherwise (collectively, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Stock Awards</span>&#8221;), indicating as applicable, with respect to each Company Stock Award then outstanding, the type of award granted, the number of shares of Company Common Stock subject to such Company Stock Award, the name of the agreement under which such Company Stock Award was granted, the date of grant, exercise or purchase price, vesting schedule, payment schedule (if different from the vesting schedule) and expiration thereof, whether the Company Stock Award is a non-statutory stock option or qualifies as an &#8220;incentive stock option&#8221; as defined in Section&#160;422 of the Code, whether an 83(b)&#160;election was timely filed, and whether (and to what extent) the vesting of such Company Stock Award will be accelerated or otherwise adjusted in any way or any other terms will be triggered or otherwise adjusted in a way by the consummation of the Merger and the other Contemplated Transactions or by the termination of employment or engagement or change in position of any holder thereof following or in connection with the Merger. The Company has made available to Parent true and complete copies of all forms of award agreements evidencing outstanding Company Stock Awards. Neither the Company nor any of its Subsidiaries is under any obligation to issue shares of Company Common Stock or any capital stock of any of its Subsidiaries pursuant to any employee or director stock option, stock purchase or equity compensation plan or arrangement other than the ones issued under the Company Equity Plan.</p><a id="Section43"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subsidiaries</span>. Section&#160;4.3 of the Company Disclosure Letter sets forth a true and complete list of each Subsidiary of the Company, including its jurisdiction of incorporation or formation. Each of the Company&#8217;s Subsidiaries (i)&#160;is an entity duly organized, validly existing and in good standing under the Laws of the jurisdiction of its organization, (ii)&#160;has all requisite corporate or similar power and authority to own, lease and operate its properties and to carry on its business as now being conducted and (iii) <span style="color:#231f20;">is duly qualified or licensed to do business and is in good standing in each jurisdiction in which the nature of its business or the ownership, leasing or operations of its properties makes such qualification or licensing necessary, except in the case of clause (iii), where the failure to be so qualified or licensed or in good standing, individually or in the aggregate, has not had and would not </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">reasonably be expected to have a Material Adverse Effect. All outstanding shares of capital stock and other voting securities or equity interests of each such Subsidiary are owned directly by the Company, free and clear of all Liens. Except for the capital stock of, or other equity or voting interests in, its Subsidiaries, the Company does not own, directly or indirectly, any equity, membership interest, partnership interest, joint venture interest, or other equity or voting interest in, or any interest convertible into, exercisable or exchangeable for any of the foregoing, </span>nor is it under any current or prospective obligation to form or participate in, provide funds to, make any loan, capital contribution, guarantee, credit enhancement or other investment in, or assume any liability or obligation of, any Person.</p><a id="Section44"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authority</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">The Company has all necessary corporate power and authority to execute, deliver and perform its obligations under this Agreement and to consummate the Contemplated Transactions. The execution, delivery and performance of this Agreement by the Company and the consummation by the Company of the Contemplated Transactions have been duly authorized by all necessary corporate action on the part of the Company and no other corporate proceedings on the part of the Company are necessary to approve this Agreement or to consummate the Merger and the other Contemplated Transactions, subject, in the case of the consummation of the Merger, to receipt of the Company Stockholder Approval. This Agreement has been duly executed and delivered by the Company and, assuming the due authorization, execution and delivery by Parent and Merger Subs, constitutes a valid and binding obligation of the Company, enforceable against the Company in accordance with its terms (except to the extent that enforceability may be limited by applicable bankruptcy, insolvency, moratorium, reorganization or similar Laws affecting the enforcement of creditors&#8217; rights generally or by general principles of equity).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">The Company Board, at a meeting duly called and held at which all directors of the Company were present, duly and unanimously adopted resolutions (i)&#160;determining that the terms of this Agreement, the Company Support Agreements, the Merger, the Concurrent Investment and the other Contemplated Transactions are fair to, advisable and in the best interests of the Company&#8217;s stockholders, (ii)&#160;approving and declaring advisable this Agreement and the Contemplated Transactions, including the Merger, (iii) directing that this Agreement be submitted to the stockholders of the Company for adoption, and (iv) resolving to recommend that the Company&#8217;s stockholders vote in favor of the adoption of this Agreement and the Contemplated Transactions, including the Merger, which resolutions have not been subsequently rescinded, modified or withdrawn in any way.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">The Company Stockholder Approval is the only vote of the holders of any class or series of the Company Capital Stock or other securities required in connection with the consummation of the Merger. Other than the Company Stockholder Approval (and except with respect to the Concurrent Investment), no vote of the holders of any class or series of the Company&#8217;s capital stock or other securities is required in connection with the consummation of any of the Contemplated Transactions to be consummated by the Company.</span></p><a id="Section45"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Conflict; Consents and Approvals</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">Except as set forth in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.5(a)</span><span style="color:#231f20;">&#160;of the Company Disclosure Letter, the execution, delivery and performance of this Agreement by the Company does not, and the consummation of the Merger and the other Contemplated Transactions and compliance by the Company with the provisions hereof will not, conflict with, or result in any violation or breach of, or default (with or without notice or lapse of time, or both) under, or give rise to a right of, or result in, termination, cancellation, modification or acceleration </span>of any obligation or to the loss of a benefit under, or result in the creation of any pledge, claim, lien, charge, option, right of first refusal, encumbrance or security interest of any kind or nature whatsoever (including any limitation on voting, sale, transfer or other disposition or exercise of any other attribute of ownership) (collectively, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Liens</span>&#8221;) in or upon any of the properties, assets or rights of the Company under, or give rise to any increased, additional, accelerated or guaranteed rights or entitlements under, or require any consent, waiver or approval of any Person pursuant to, any provision of (i)&#160;the Company Charter or Company Bylaws, (ii)&#160;any material bond, debenture, note, mortgage, indenture, guarantee, license, lease, purchase or sale order or other contract, commitment, agreement, instrument, obligation, arrangement, understanding, undertaking, permit, concession or franchise, whether oral or written (each, including all amendments thereto, a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contract</span>&#8221;) to which the Company is a party or by which the Company or any of its properties or assets may be bound or (iii)&#160;subject to the governmental filings and other matters referred to in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.5(b)</span>, any federal, state, local or foreign law (including common law), statute, ordinance, rule, code, regulation, order, judgment, injunction, decree or other legally enforceable requirement (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Law</span>&#8221;) applicable to the Company or by which the Company or any of its properties or assets may be bound, except as, in the case of clauses (ii)&#160;and (iii), as individually or in the aggregate, has not had and would not reasonably be expected to have a Material Adverse Effect.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">No consent, approval, order or authorization of, or registration, declaration, filing with or notice to, any federal, state, local or foreign government or subdivision thereof or any other governmental, administrative, judicial, arbitral, legislative, executive, regulatory or self-regulatory authority, instrumentality, agency, commission or body (each, a &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Governmental Entity</span><span style="color:#231f20;">&#8221;) is required by or with respect to the Company in connection with the execution, delivery and performance of this Agreement by the Company or the consummation by the Company of the Merger and the other Contemplated Transactions or compliance with the provisions hereof, except for (i)&#160;the filing of the pre-merger notification report under the HSR Act, (ii) the filing with the SEC of such reports under Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934, as amended (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Exchange Act</span><span style="color:#231f20;">&#8221;), as may be required in connection with this Agreement and the Contemplated Transactions, (iii)&#160;such other filings and reports as may be required pursuant to the applicable requirements of the Securities Act of 1933, as amended (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Securities Act</span><span style="color:#231f20;">&#8221;), the Exchange Act and any other applicable state or federal securities, takeover and &#8220;blue sky&#8221; laws, (iv)&#160;the filing of the Certificate of Merger with the Delaware Secretary of State as required by the DGCL, and (v)&#160;such other consents, approvals, orders, authorizations, registrations, declarations, filings or notices the failure of which to be obtained or made, individually or in the aggregate, have not had and would not reasonably be expected to have a Material Adverse Effect.</span></p><a id="Section46"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financial Statements</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">True and complete copies of the audited balance sheet of the Company as at September&#160;30, 2024 and June&#160;18, 2024, and the related audited statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; deficit and cash flows, together with all related notes and schedules thereto (collectively referred to as the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Financial Statements</span><span style="color:#231f20;">&#8221;). The Company Financial Statements (i) are correct and complete in all material respects and have been prepared in accordance with the books and records of the Company; (ii)&#160;have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">GAAP</span><span style="color:#231f20;">&#8221;) applied on a consistent basis throughout the periods indicated (except as may be indicated in the notes thereto); and (iii)&#160;fairly present, in all material respects, the financial position, results of operations and cash flows of the Company as at the respective dates thereof and for the respective periods indicated therein, except as otherwise noted therein and subject, in the case of any unaudited financial statements, to normal and recurring&#160;year-end adjustments that will not, individually or in the aggregate, be material.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;"> Except as and to the extent adequately accrued or reserved against in the audited consolidated balance sheet of the Company as at December&#160;31, 2023 (such balance sheet, together with all related notes and schedules thereto, the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Balance Sheet</span><span style="color:#231f20;">&#8221;), the Company does not have any liability or obligation of any nature, whether accrued, absolute, contingent or otherwise, whether known or unknown and whether or not required by GAAP to be reflected in a balance sheet of the Company or disclosed in the notes thereto, except for liabilities and obligations, incurred in the ordinary course of business consistent with past practice since the date of the Company Balance Sheet, that are not, individually or in the aggregate, material to the Company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">The books of account and financial records of the Company and its Subsidiaries are true and correct and have been prepared and are maintained in accordance with sound accounting practice.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">The Company maintains a system of internal accounting controls designed to provide reasonable assurance that: (i)&#160;transactions are executed in accordance with management&#8217;s general or specific authorizations, (ii)&#160;transactions are recorded as necessary to permit preparation of the financial statements of the Company in conformity with GAAP and to maintain accountability of the Company&#8217;s assets, (iii)&#160;access to the Company&#8217;s assets is permitted only in accordance with management&#8217;s general or specific authorization, and (iv)&#160;the recorded accountability for the Company&#8217;s assets is compared with the existing assets at </span>regular intervals and appropriate action is taken with respect to any differences. The Company maintains internal control over financial reporting that provides reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="color:#231f20;">Since January&#160;1, 2023, neither the Company nor its independent auditors have identified (i)&#160;any significant deficiency or material weakness in the design or operation of the system of internal accounting controls utilized by the Company, (ii)&#160;any fraud, whether or not material, that involves the Company, the Company&#8217;s management or other employees who have a role in the preparation of financial statements or the internal accounting controls utilized by the Company or (iii)&#160;any claim or allegation regarding any of the foregoing.</span></p><a id="Section47"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Undisclosed Liabilities</span>. Neither the Company nor any of its Subsidiaries has any liabilities or obligations of any nature, whether accrued, absolute, contingent or otherwise, known or unknown, whether due or to become due and whether or not required to be recorded or reflected on a balance sheet under GAAP, except (a)&#160;to the extent specifically and adequately accrued or </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">reserved against in the Company Balance Sheet and (b)&#160;for liabilities and obligations incurred in the ordinary course of business consistent with past practice (none of which is a liability for a breach or default under any contract, breach of warranty, tort, infringement, misappropriation or violation of law) since the date of the Company Balance Sheet that are not individually or in the aggregate material to the Company.</p><a id="Section48"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Absence of Certain Changes or Events</span>. Except as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.8</span> of the Company Disclosure Letter, since the date of the Company Balance Sheet: (i)&#160;except in connection with the execution of this Agreement and the consummation of the Contemplated Transactions, the Company and its Subsidiaries have conducted their business only in the ordinary course consistent with past practice; (ii) <span style="color:#231f20;">there has not been any change, event or development or prospective change, event or development that, individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect; and (iii)&#160;neither the Company nor any of its Subsidiaries has:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;"> (i)&#160;declared, set aside or paid any dividends on, or made any other distributions (whether in cash, stock or property) in respect of, any of its capital stock or other equity interests, (ii)&#160;purchased, redeemed or otherwise acquired shares of capital stock or other equity interests of the Company or any of its Subsidiaries </span>or any options, warrants, or rights to acquire any such shares or other equity interests, or (iii)&#160;split, combined, reclassified or otherwise amended the terms of any of its capital stock or other equity interests or issued or authorized the issuance of any other securities in respect of, in lieu of or in substitution for shares of its capital stock or other equity interests;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">amended or otherwise changed, or authorized or proposed to amend or otherwise change, its certificate of incorporation or by-laws (or similar organizational documents);</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">adopted or entered into a plan of complete or partial liquidation, dissolution, restructuring, recapitalization or reorganization; or</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">changed its financial or Tax accounting methods, principles or practices, except insofar as may have been required by a change in GAAP or applicable Law, or revalued any of its material assets.</span></p><a id="Section49"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;4.9 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Litigation</span>. There is no action, suit, claim, arbitration, investigation, inquiry, grievance or other proceeding (each, an &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Action</span>&#8221;) (or basis therefor) pending or, to the knowledge of the Company, threatened against or affecting the Company or any of its Subsidiaries, its properties or assets, or any present or former officer, director or employee of the Company or any of its Subsidiaries in such individual&#8217;s capacity as such, other than any Action that (a)&#160;does not involve an amount in controversy in excess of $100,000 and (b)&#160;does not seek injunctive or other non-monetary relief. Neither the Company nor any of its Subsidiaries nor any of their respective properties or assets is subject to any outstanding judgment, order, injunction, rule&#160;or decree of any Governmental Entity. There is no Action pending or, to the knowledge of the Company, threatened seeking to prevent, hinder, modify, delay or challenge the Merger or any of the other Contemplated Transactions.</p><a id="Section410"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;4.10 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Laws</span>. The Company and each of its Subsidiaries are and have been in compliance in all material respects with all Laws applicable to their businesses, operations, properties or assets. Neither the Company nor any of its Subsidiaries has received, since January&#160;1, 2021, a notice or other written communication alleging or relating to a possible material violation of any Law applicable to their businesses, operations, properties, assets or Company Products (as defined below). The Company and each of its Subsidiaries have in effect all material permits, licenses, variances, exemptions, applications, approvals, clearances, authorizations, registrations, formulary listings, consents, operating certificates, franchises, orders and approvals (collectively, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Permits</span>&#8221;) of all Governmental Entities necessary or advisable for them to own, lease or operate its properties and assets and to carry on its businesses and operations as now conducted, and there has occurred no violation of, default (with or without notice or lapse of time or both) under or event giving to others any right of revocation, non-renewal, adverse modification or cancellation of, with or without notice or lapse of time or both, any such Permit, nor would any such revocation, non-renewal, adverse modification or cancellation result from the consummation of the Contemplated Transactions.</p><a id="Section411"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;4.11 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Health Care Regulatory Matters</span>. Except as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.11</span> of the Company Disclosure Letter:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">The Company, and to the knowledge of the Company, each of its directors, officers, management employees, agents (while acting in such capacity), contract manufacturers, suppliers, and distributors are, and for the past six (6)&#160;years have been, in material compliance with all health care laws to the extent applicable to the Company or any of its products or activities, including, but not limited to the following: the Federal Food, Drug&#160;&amp; Cosmetic Act (&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">FDCA</span><span style="color:#231f20;">&#8221;); the Public Health Service Act (42 U.S.C. &#167; 201 et seq.), </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">including the Clinical Laboratory Improvement Amendments of 1988 (42 U.S.C. &#167; 263a); the Federal Trade Commission Act (15 U.S.C. &#167; 41 et seq.); the Controlled Substances Act (21 U.S.C. &#167; 801 et seq.); the federal Anti-Kickback Statute (42 U.S.C. &#167; 1320a-7b(b)); the civil monetary penalties law (42 U.S.C. &#167; 1320a-7a); the civil False Claims Act (31 U.S.C. &#167; 3729 et seq.); the administrative False Claims Law (42 U.S.C. &#167; 1320a-7b(a)); the Stark law (42 U.S.C. &#167; 1395nn); the Criminal Health Care Fraud Statute (18 U.S.C. &#167; 1347); the exclusion laws </span>(42 U.S.C. &#167; 1320a-7); Medicare (Title XVIII of the Social Security Act); Medicaid (Title XIX of the Social Security Act); any regulations promulgated pursuant to such laws; and any other state, federal or ex-U.S. laws or regulations governing the manufacturing, development, testing, labeling, advertising, marketing or distribution of drug, biologic and medical device products, kickbacks, patient or program charges, recordkeeping, claims process, documentation requirements, medical necessity, referrals, the hiring of employees or acquisition of services or supplies from those who have been excluded from government health care programs, quality, safety, privacy, security, licensure, accreditation or any other aspect of providing health care, clinical laboratory or diagnostic products or services, to the extent applicable to the Company (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Health Care Laws</span>&#8221;). To the knowledge of the Company, there are no facts or circumstances that reasonably would be expected to give rise to any material liability under any Health Care Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">Neither the Company nor any of its Subsidiaries is a party to any material corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any Governmental Entity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">All applications, notifications, submissions, information, claims, reports and statistical analyses, and other data and conclusions derived therefrom, utilized as the basis for or submitted in connection with any and all requests for a Permit from the U.S. Food and Drug Administration (&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">FDA</span><span style="color:#231f20;">&#8221;) or other Governmental Entity relating to products that are regulated as drugs, medical devices, or other healthcare products under Health Care Laws, including drugs or medical devices, compounds or products being researched, tested, stored, developed, labeled, manufactured, packed, imported, exported and/or distributed by the Company or any of its Subsidiaries (&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Products</span><span style="color:#231f20;">&#8221;), including, without limitation, investigational new drug applications and investigational device exemptions, when submitted to the FDA or other Governmental Entity were true, complete and correct in all material respects as of the date of submission and any necessary or required updates, changes, corrections or modification to such applications, submissions, information and data have been submitted to the FDA or other Governmental Entity. The Company does not have knowledge of any facts or circumstances that would be reasonably likely to lead the revocation, suspension, limitation, or cancellation of a Permit required under Health Care Laws or of any application for marketing approval currently pending before the FA or such other Governmental Entity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">All preclinical studies and clinical trials conducted by or, to the knowledge of the Company, on behalf of the Company have been, and if still pending are being, conducted in compliance with research protocols and all applicable Health Care Laws, including, but not limited to, the FDCA and its applicable implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58, 312, 314, 320 and 812. No clinical trial conducted by or on behalf of the Company has been conducted using any clinical investigators who have been disqualified. No clinical trial conducted by or on behalf of the Company has been terminated or suspended prior to completion, and no clinical investigator that has participated or is participating in, or institutional review board that has or has had jurisdiction over, a clinical trial conducted by or on behalf of the Company has placed a clinical hold order on, or otherwise terminated, delayed or suspended, such a Company </span>clinical trial at a clinical research site based on an actual or alleged lack of safety or efficacy of any Company Product or a failure to conduct such clinical trial in compliance with applicable Health Care Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="color:#231f20;">All manufacturing operations conducted by or, to the knowledge of the Company, for the benefit of the Company have been and are being conducted in material compliance with all Permits under applicable Health Care Laws, all applicable provisions of the FDA&#8217;s current good manufacturing practice (cGMP) regulations for drug products at 21 C.F.R. Parts 210 and 211, the Quality System (QS) regulations at 21 C.F.R. Part&#160;820 and all comparable foreign regulatory requirements of any Governmental Entity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span><span style="color:#231f20;">The Company has not received any written communication that relates to an alleged violation or non-compliance with any Health Care Laws, including any notification of any pending or threatened claim, suit, proceeding, hearing, enforcement, investigation, arbitration, import detention or refusal, FDA Warning Letter or Untitled Letter, or any action by a Governmental Entity relating to any Health Care Laws. All Warning Letters, Form-483 observations, or comparable findings from other Governmental Entities listed in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.11(f)</span><span style="color:#231f20;">&#160;of the Company Disclosure Letter have been resolved to the satisfaction of the applicable Governmental Entity.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span><span style="color:#231f20;">There have been no seizures, withdrawals, recalls, detentions, or suspensions of manufacturing, testing, or distribution relating to the Company Products required or requested by a Governmental Entity, or other notice of action relating to an alleged lack of safety, efficacy, or regulatory compliance of the Company Products, or any adverse experiences relating to the Company Products that have been reported to FDA or other Governmental Entity (&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Safety Notices</span><span style="color:#231f20;">&#8221;). All Safety Notices listed in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.11(g)</span><span style="color:#231f20;">&#160;of the Company Disclosure Letter have been resolved to the satisfaction of the applicable Governmental Entity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span><span style="color:#231f20;">Except as set forth in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.11(h)</span><span style="color:#231f20;">&#160;of the Company Disclosure Letter, there are no unresolved Safety Notices, and to the knowledge the Company, there are no facts or circumstances that would be reasonably likely to result in a Safety Notice with respect to the Company Products or a termination or suspension of developing and testing of any of the Company Products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="color:#231f20;">Neither the Company, nor, to the knowledge of the Company, any officer, employee, agent, or distributor of the Company has made an untrue statement of a material fact or fraudulent or misleading statement to a Governmental Entity, failed to disclose a material fact required to be disclosed to a Governmental Entity, or committed an act, made a statement, or failed to make a statement that would reasonably be expected to provide a basis for the FDA to invoke its policy respecting &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy set forth in 56 Fed. Reg. 46191 (September&#160;10, 1991) and any amendments thereto (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">FDA Ethics Policy</span><span style="color:#231f20;">&#8221;). None of the aforementioned is or has been under investigation resulting from any allegedly untrue, fraudulent, misleading, or false statement or omission, including data fraud, or had any action pending or threatened relating to the FDA Ethics Policy.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span><span style="color:#231f20;">All reports, documents, claims, Permits and notices required to be filed, maintained or furnished to the FDA or any Governmental Entity by the Company have been so filed, maintained or furnished, except where failure to file, maintain or furnish such reports, documents, claims, Permits or notices have not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. All such reports, documents, claims, Permits and notices were true and complete in all material respects on the date filed (or were corrected in or supplemented by a subsequent filing).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(k)</span></span><span style="color:#231f20;">Neither the Company nor, to the knowledge of the Company, any officer, employee, agent, or distributor of the Company has been convicted of any crime or engaged in any conduct that has resulted, or would reasonably be expected to result, in debarment under applicable Law, including, without limitation, 21 U.S.C. &#167; 335a, or exclusion under 42 U.S.C. &#167; 1320a-7, or any other statutory provision or similar law applicable in other jurisdictions in which the Company Products are sold or intended to be sold. Neither the Company nor, to the knowledge of the Company, any officer, employee, agent or distributor of the Company, has been excluded from participation in any federal health care program or convicted of any crime or engaged in any conduct for which such Person could be excluded from participating in any federal health care program under Section&#160;1128 of the Social Security Act of 1935, as amended, or any similar Health Care Law or program.</span></p><a id="Section412"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.12</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Benefit Plans</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.12(a)</span><span style="color:#231f20;">&#160;of the Company Disclosure Letter contains a true, correct and complete list of each material Company Plan.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">The Company has provided or made available to Parent a current, accurate and complete copy of each material Company Plan, or if such Company Plan is not in written form, a written summary of all of the material terms of such Company Plan. With respect to each Company Plan, the Company has furnished or made available to Parent a current, accurate and complete copy of, to the extent applicable: (i)&#160;all documents embodying or governing such Company Plan and any related trust agreement or other funding instrument, (ii)&#160;the most recent determination letter of the Internal Revenue Service (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">IRS</span><span style="color:#231f20;">&#8221;), (iii)&#160;any summary plan description, summary of material modifications, and other similar material written communications (or a written description of any material oral communications) to the employees of the Company or its Subsidiaries concerning the extent of the benefits provided under a Company Plan, (iv)&#160;all non-routine correspondence to and from any governmental agency, and (v)&#160;for the three most recent&#160;years and as applicable (A)&#160;the Form&#160;5500 and attached schedules, (B)&#160;audited financial statements, (C) nondiscrimination testing results and (D)&#160;actuarial valuation reports.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">Neither the Company, its Subsidiaries or any member of their &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Controlled Group</span><span style="color:#231f20;">&#8221; (defined as any organization which is a member of a controlled, affiliated or otherwise related group of entities within the meaning of Sections 414(b), (c), (m)&#160;or (o)&#160;of the Code) has ever sponsored, maintained, contributed to or been required to contribute to or incurred any liability (contingent or otherwise) with respect to: (i)&#160;a Multiemployer Plan, (ii)&#160;an &#8220;employee pension benefit plan&#8221; (within the meaning of Section&#160;3(2)&#160;of </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">ERISA) that is subject to Title IV of ERISA or Section&#160;412 of the Code or Section&#160;302 of ERISA, (iii)&#160;any &#8220;multiple </span>employer plan&#8221; as defined in Section&#160;413 of the Code or Section&#160;210 of ERISA, (iv)&#160;a &#8220;funded welfare benefit plan&#8221; within the meaning of Section&#160;419 of the Code or (v)&#160;any &#8220;multiple employer welfare arrangement&#8221; (as such term is defined in Section&#160;3(40) of ERISA).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">With respect to the Company Plans:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="color:#231f20;">each Company Plan is and has been established, operated, and administered in all material respects with its terms and materially complies in form and in operation with the applicable provisions of ERISA and the Code and all other applicable legal requirements;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span><span style="color:#231f20;">no Company Plan is, or within the past six&#160;years has been, the subject of an application or filing under a government sponsored amnesty, voluntary compliance, or similar program, or been the subject of any self-correction under any such program;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span><span style="color:#231f20;">each Company Plan intended to be qualified under Section&#160;401(a)&#160;of the Code has received a favorable determination, advisory and/or opinion letter, as applicable, from the IRS that it is so qualified and nothing has occurred to the knowledge of the Company since the date of such letter that would reasonably be expected to cause the loss of the sponsor&#8217;s ability to rely upon such letter, and nothing has occurred to the knowledge of the Company that would reasonably be expected to result in the loss of the qualified status of such Company Plan;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</span></span><span style="color:#231f20;">there is no material Action (including any investigation, audit or other administrative proceeding) by the Department of Labor, the Pension Benefit Guaranty Corporation (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">PBGC</span><span style="color:#231f20;">&#8221;), the IRS or any other Governmental Entity or by any plan participant or beneficiary pending, or to the knowledge of the Company, threatened, relating to the Company Plans, any fiduciaries thereof with respect to their duties to the Company Plans or the assets of any of the trusts under any of the Company Plans (other than routine claims for benefits);</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</span></span><span style="color:#231f20;">none of the Company Plans currently provides, or reflects or represents any liability to provide post-termination or retiree welfare benefits to any person for any reason, except as may be required by Section&#160;601, </span><i style="color:#231f20;font-style:italic;">et seq. </i><span style="color:#231f20;">of ERISA and Section&#160;4980B(b)&#160;of the Code or other applicable similar law regarding health care coverage continuation (collectively &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">COBRA</span><span style="color:#231f20;">&#8221;), and none of the Company, its Subsidiaries or any members of their Controlled Group has any liability to provide post-termination or retiree welfare benefits to any person or ever represented, promised or contracted to any employee or former employee of the Company (either individually or to Company employees as a group) or any other person that such employee(s)&#160;or other person would be provided with post-termination or retiree welfare benefits, except to the extent required by statute or except with respect to a contractual obligation to reimburse any premiums such person may pay in order to obtain health coverage under COBRA;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vi)</span></span><span style="color:#231f20;">all payments and/or contributions required to have been timely made with respect to all Company Plans either have been made or have been accrued in accordance with the terms of the applicable Company Plan and applicable law;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vii)</span></span><span style="color:#231f20;">each Company Plan is subject exclusively to United States Law; and</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(viii)</span></span><span style="color:#231f20;">the execution and delivery of this Agreement, the Company Stockholder Approval, and the consummation of the Merger will not, either alone or in combination with any other event, (A)&#160;entitle any current or former employee, officer, director or consultant of the Company or any Subsidiary to severance pay, unemployment compensation or any other similar termination payment, or (B)&#160;accelerate the time of payment or vesting, or increase the amount of or otherwise enhance any benefit due any such employee, officer, director or consultant.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="color:#231f20;">Neither the Company nor any of its Subsidiaries is a party to any agreement, contract, arrangement or plan (including any Company Plan) that may reasonably be expected to result, separately or in the aggregate, in connection with the Contemplated Transactions (either alone or in combination with any other events), in the payment of any &#8220;parachute payments&#8221; within the meaning of Section&#160;280G of the Code. There is no agreement, plan or other arrangement to which the Company or any Subsidiary is a party or by </span>which the Company or any Subsidiary is otherwise bound to compensate any person in respect of Taxes or other liabilities incurred with respect to Section&#160;409A or 4999 of the Code.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span><span style="color:#231f20;">Each Company Plan that is a &#8220;nonqualified deferred compensation plan&#8221; within the meaning of Section&#160;409A of the Code (or any comparable or similar provision of state, local, or foreign Law) complies in both form and operation in all material respects with the requirements of Section&#160;409A of the Code (or any comparable or similar provision of state, local, or foreign Law) and all applicable IRS guidance issued with respect thereto (and has so complied for the entire period during which Section&#160;409A of the Code has applied to such Company Plan) so that no amount paid or payable pursuant to any such Company Plan is subject to any additional Tax or interest under Section&#160;409A of the Code (or any comparable or similar provision of state, local, or foreign Law).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span><span style="color:#231f20;">No Company Plan provides major medical health or long-term disability benefits that are not fully insured through an insurance contract.</span></p><a id="Section413"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.13</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Labor and Employment Matters</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">The Company and its Subsidiaries are and since January&#160;1, 2021, have been in compliance in all material respects with all applicable Laws relating to labor or employment matters, including those relating to employment practices, terms and conditions of employment, collective bargaining, disability, immigration, health and safety, wages, hours and benefits, non-discrimination in employment, workers&#8217; compensation, the collection and payment of withholding and/or payroll Taxes and similar Taxes, unemployment compensation, equal employment opportunity, discrimination, harassment, employee and contractor classification, restrictive covenants, pay equity, information privacy and security, and continuation coverage with respect to group health plans. Since January&#160;1, 2021, there has not been, and as of the date of this Agreement there is not pending or, to the knowledge of the Company, threatened, any labor dispute, work stoppage, labor strike or lockout against the Company or any of its Subsidiaries by employees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">No employee of the Company or any of its Subsidiaries, or since January&#160;1, 2021 has been, is covered by an effective or pending collective bargaining agreement or similar labor agreement. To the knowledge of the Company, there has not been any activity on behalf of any labor union, labor organization or similar employee group to organize any employees of the Company or any of its Subsidiaries. There are no, and since January&#160;1, 2021 there has not been any: (i)&#160;unfair labor practice charges or complaints against the Company or any of its Subsidiaries pending before the National Labor Relations Board or any other labor relations tribunal or authority and to the knowledge of the Company no such representations, claims or petitions are threatened, (ii)&#160;representations, claims or petitions pending before the National Labor Relations Board or any other labor relations tribunal or authority or (iii)&#160;grievances or pending arbitration proceedings against the Company or any of its Subsidiaries that arose out of or under any collective bargaining agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">To the knowledge of the Company, no current officer of the Company or any of its Subsidiaries intends, or is expected, to terminate such individual&#8217;s employment relationship with such entity in connection with or as a result of the Contemplated Transactions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">Since January&#160;1, 2021, (i)&#160;neither the Company nor any of its Subsidiaries has effectuated a &#8220;plant closing&#8221; (as defined in the Worker Adjustment Retraining and Notification Act of 1988, as amended (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">WARN Act</span><span style="color:#231f20;">&#8221;)) affecting any site of employment or one or more facilities or operating units within any site of employment or facility, (ii)&#160;there has not occurred a &#8220;mass layoff&#8221; (as defined in the WARN Act) in connection with the Company or any of its Subsidiaries affecting any site of employment or one or more facilities or operating units within any site of employment or facility and (iii)&#160;neither the Company nor any of its Subsidiaries has engaged in layoffs or employment terminations sufficient in number to trigger application of any similar state, local or foreign law. The Company and its Subsidiaries properly classify and for the three (3)&#160;years immediately preceding the date hereof have properly classified its and their (i) employees as exempt or non-exempt in accordance with applicable overtime laws, (ii)&#160;contingent workers in accordance with applicable law and (iii)&#160;workers as employees or non-employees (e.g., consultants, independent contractors), in accordance with applicable law.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="color:#231f20;">Except as set forth on </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.13(e)</span><span style="color:#231f20;">&#160;of the Company Disclosure Letter, with respect to any current or former employee, officer, consultant or other service provider of the Company, there have not </span>been Actions against or involving the Company or any of its Subsidiaries pending, or to the knowledge of the Company, threatened to be brought or filed, in connection with the employment or engagement of any current or former employee, officer, consultant or other service provider of the Company, including, without limitation, any claim relating to employment discrimination, harassment, retaliation, equal pay, employment classification, contractor </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;">classification, wages, hours, and benefits, or any other employment related matter arising under applicable Laws, except where such action would not, individually or in the aggregate, result in the Company incurring a material liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span><span style="color:#231f20;">Except as set forth on </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.13(f)</span><span style="color:#231f20;">&#160;of the Company Disclosure Letter or with respect to any Company Plan (which subject is addressed in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.12</span><span style="color:#231f20;"> above), the execution of this Agreement and the consummation of the transactions set forth in or contemplated by this Agreement will not result in any breach or violation of, or cause any payment to be made under, any applicable Laws respecting labor and employment or any collective bargaining agreement to which the Company or any of its Subsidiaries is a party.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span><span style="color:#231f20;">Since January&#160;1, 2021, (i)&#160;no allegations of harassment or discrimination (with respect to any category protected by applicable law, including, without limitation, sexual harassment), retaliation on the basis of protected activity (including as a whistleblower) or protected class status in accordance with applicable law, or other misconduct relating to the workplace have been made, initiated, filed or, to the knowledge of the Company, threatened against the Company or any of its Subsidiaries or any of their respective current or former directors, officers or senior level management employees, (ii)&#160;to the knowledge of the Company, no incidents of any such workplace-related harassment, discrimination, retaliation or other misconduct have occurred, and (iii)&#160;the Company has not entered into any settlement agreement related to allegations of </span>such harassment, discrimination, retaliation or other workplace-related misconduct by any of their directors, officers or employees described in clause (i)&#160;hereof or any independent contractor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span><span style="color:#231f20;">No employee or other worker of the Company is subject to any service relationship that is not &#8220;at- will&#8221; or that is terminable on more than 30&#160;days&#8217; notice.</span></p><a id="Section414"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.14</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Environmental Matters</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Material Adverse Effect, (i)&#160;the Company and its Subsidiaries have conducted their respective businesses in compliance with all, and have not violated any, applicable Environmental Laws; (ii)&#160;the Company and its Subsidiaries have obtained all Permits of all Governmental Entities and any other Person that are required under any Environmental Law; (iii)&#160;there has been no release of any Hazardous Substance by the Company or any of its Subsidiaries or any other Person in any manner that has given or would reasonably be expected to give rise to any remedial or investigative obligation, corrective action requirement or liability of the Company or any its Subsidiaries under applicable Environmental Laws; (iv)&#160;the Company and its Subsidiaries have not received any claims, notices, demand letters or requests for information (except for such claims, notices, demand letters or requests for information the subject matter of which has been resolved prior to the date of this Agreement) from any federal, state, local, foreign or provincial Governmental Entity or any other Person asserting that the Company or any of its Subsidiaries is in violation of, or liable under, any Environmental Law; (v)&#160;no Hazardous Substance has been disposed of, arranged to be disposed of, released or transported in violation of any applicable Environmental Law, or in a manner that has given </span>rise to, or that would reasonably be expected to give rise to, any liability under any Environmental Law, in each case, on, at, under or from any current or former properties or facilities owned or operated by the Company or any of its Subsidiaries or as a result of any operations or activities of the Company or any of its Subsidiaries at any location and, to the knowledge of the Company, Hazardous Substances are not otherwise present at or about any such properties or facilities in amount or condition that has resulted in or would reasonably be expected to result in liability to the Company or any of its Subsidiaries under any Environmental Law; and (vi)&#160;neither the Company nor any of its Subsidiaries nor any of their respective properties or facilities are subject to, or are threatened to become subject to, any liabilities relating to any suit, settlement, court order, administrative order, regulatory requirement, judgment or claim asserted or arising under any Environmental Law or any agreement relating to environmental liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">As used herein, &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Environmental Law</span><span style="color:#231f20;">&#8221; means any Law relating to (i)&#160;the protection, preservation or restoration of the environment (including air, surface water, groundwater, drinking water supply, surface </span>and subsurface soils and strata, wetlands, plant and animal life or any other natural resource) or (ii)&#160;the exposure to, or the use, storage, recycling, treatment, generation, transportation, processing, handling, labeling, production, release or disposal of Hazardous Substances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">As used herein, &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Hazardous Substance</span><span style="color:#231f20;">&#8221; means any substance listed, defined, designated, classified or regulated as a waste, pollutant or contaminant or as hazardous, toxic, radioactive or dangerous or any other term of similar import under any Environmental Law, including but not limited to petroleum.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Section415"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.15</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Taxes</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">The Company and its Subsidiaries have (i)&#160;filed all income and other material Tax Returns required to be filed by or on behalf of it (taking into account any applicable extensions thereof) and all such Tax Returns are true, accurate and complete in all material respects; and (ii)&#160;paid in full (or caused to be timely paid in full) all material Taxes that are required to be paid by or with respect to it, whether or not such Taxes were shown as due on such Tax Returns.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">All material Taxes not yet due and payable by the Company as of the date of the Company Balance Sheet have been, in all respects, properly accrued in accordance with GAAP on the Company Financial Statements, and such Company Financial Statements reflect an adequate reserve (in accordance with GAAP) for all material Taxes accrued but unpaid by the Company through the date of such financial statements. Since the date of the Company Financial Statements, neither the Company nor any of its Subsidiaries has incurred, individually or in the aggregate, any liability for Taxes outside the ordinary course of business consistent with past practice.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">Neither the Company nor any of its Subsidiaries has executed any waiver of any statute of limitations on, or extended the period for the assessment or collection of, any amount of Tax, in each case that has not since expired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">No material audits or other investigations, proceedings, claims, assessments or examinations by any Governmental Entity (each, a &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Tax Action</span><span style="color:#231f20;">&#8221;) with respect to Taxes or any Tax Return of the Company or any of its Subsidiaries are presently in progress or have been asserted, threatened or proposed in writing and to the knowledge of the Company, no such Tax Action is being contemplated. No deficiencies or claims for a material amount of Taxes have been claimed, proposed, assessed or asserted in writing against the Company or any of its Subsidiaries by a Governmental Entity, other than any such claim, proposal, assessment or assertion that has been satisfied by payment in full, settled or withdrawn.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="color:#231f20;">Subject to exceptions as would not be material, the Company and its Subsidiaries have timely withheld all Taxes required to have been withheld from payments made (or deemed made) to its employees, independent contractors, creditors, shareholders and other third parties and, to the extent required, such Taxes have been timely paid to the relevant Governmental Entity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span><span style="color:#231f20;">Neither the Company nor any of its Subsidiaries has engaged in a &#8220;listed transaction&#8221; as set forth in Treasury Regulations &#167; 1.6011-4(b)(2).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span><span style="color:#231f20;">Neither the Company nor any of its Subsidiaries (i)&#160;is a party to or bound by, or has any liability pursuant to, any Tax sharing, allocation, indemnification or similar agreement or obligation, other than any such agreement or obligation which is a customary commercial agreement obligation entered into in the ordinary course of business with vendors, lessors, lenders or the like the primary purpose of which is unrelated to Taxes (each, an &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Ordinary Course Agreement</span><span style="color:#231f20;">&#8221;); (ii)&#160;is or has been a member of a group (other than a group the common parent of which is the Company) filing a consolidated, combined, affiliated, unitary or similar income Tax Return; (iii)&#160;has any liability for the Taxes of any Person (other than the Company or its Subsidiaries) pursuant to Treasury Regulations &#167; 1.1502-6 (or any similar provision of state, local or non-United States Law) as a transferee or successor, by Contract or otherwise by operation of </span>Law; or (iv)&#160;is or has been treated as a resident for any income Tax purpose, or as subject to Tax by virtue of having a permanent establishment, an office or fixed place of business, in any country other than the country in which it was or is organized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span><span style="color:#231f20;">No private letter rulings, technical advice memoranda, or similar material agreements or rulings have been requested, entered into or issued by any Governmental Entity with respect to the Company or any of its Subsidiaries which rulings remain in effect.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="color:#231f20;">Neither the Company nor any of its Subsidiaries will be required to include any item of income in, or exclude any item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of (i)&#160;a change in, or use of improper, method of accounting requested or initiated on or prior to the Closing Date, (ii)&#160;a &#8220;closing agreement&#8221; as described in Section&#160;7121 of the Code (or any similar provision of Law) executed on or prior to the Closing Date, (iii)&#160;an installment sale or open transaction disposition made on or prior to the Closing Date, (iv)&#160;any prepaid amount received or deferred revenue accrued on or prior to the Closing Date, other than in respect of such amounts received </span>in the ordinary course of business or (v)&#160;to the knowledge of the Company, an intercompany transaction or excess loss amount described in Treasury Regulations under Section&#160;1502 of the Code (or any corresponding or similar provision of state, local or foreign income Tax Law).</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span><span style="color:#231f20;">There are no liens for Taxes upon any of the assets of the Company or any of its Subsidiaries other than Liens described in clause (i)&#160;of the definition of Permitted Liens.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(k)</span></span><span style="color:#231f20;">Neither the Company nor any of its Subsidiaries has distributed stock of another Person or has had its stock distributed by another Person, in a transaction (or series of transactions) that was purported or intended to be governed in whole or in part by Sections 355 or 361 of the Code.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(l)</span></span><span style="color:#231f20;">Neither the Company nor any of its Subsidiaries has been a United States real property holding corporation, as defined in Section&#160;897(c)(2)&#160;of the Code during the applicable period specified in Section&#160;897(c)(1)(A)(ii)&#160;of the Code.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(m)</span></span><span style="color:#231f20;">No material claim has been made in writing by any Governmental Entity in a jurisdiction where the Company or any of its Subsidiaries does not currently file a Tax Return of a certain type or pay Taxes of a certain type that the Company is or may be subject to taxation by such jurisdiction of such type.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(n)</span></span><span style="color:#231f20;">There are no outstanding shares of Company stock issued in connection with the performance of services (within the meaning of Section&#160;83 of the Code) that immediately prior to the First Effective Time are subject to a substantial risk of forfeiture (as such terms are defined in Section&#160;83 of the Code) for which a valid election under Section&#160;83(b)&#160;of the Code has not been made.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(o)</span></span><span style="color:#231f20;">To the knowledge of the Company, neither the Company nor any of its Subsidiaries has been, is, or immediately prior to the First Effective Time will be, treated as an &#8220;investment company&#8221; within the meaning of Section&#160;368(a)(2)(F)&#160;of the Code.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(p)</span></span><span style="color:#231f20;">Neither the Company nor any of its Subsidiaries has taken, or failed to take, any action nor knows of any fact or circumstance that, in each case, could reasonably be expected to prevent or impede the Merger from qualifying as a transaction qualifying for the Intended Tax Treatment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.15</span>, where the context permits, each reference to the Company shall include a reference to any person for whose Taxes the Company is liable under applicable Law.</p><a id="Section416"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.16</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contracts</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.16(a)</span><span style="color:#231f20;">&#160;of the Company Disclosure Letter sets forth each contract that, as of the date of this Agreement, that would constitute a &#8220;material contract&#8221; (as such term is defined in Item&#160;601(b)(10)&#160;of Regulation S-K under the Securities Act), with respect to the Company (assuming the Company were subject to the requirements of the Exchange Act) (all such contracts, in addition to those set forth in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.16(b)</span><span style="color:#231f20;">&#160;of the Company Disclosure Letter, but excluding any Company Plans, &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Material Contracts</span><span style="color:#231f20;">&#8221;).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.16(b)</span><span style="color:#231f20;">&#160;of the Company Disclosure Letter lists the following contracts, in effect as of the date of this Agreement, which involve payment or receipt by the Company in excess of $250,000 in the aggregate, which for the purposes of this Agreement shall be considered Material Contracts:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="color:#231f20;">each Contract relating to any agreement for indemnification or guaranty not entered into in the ordinary course of business;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span><span style="color:#231f20;">each Contract containing (A)&#160;any covenant prohibiting the Company or the Surviving Entity from engaging in any line of business or competing with any Person, or limiting the development, manufacture or distribution of the Surviving Entity&#8217;s products or services, (B)&#160;any most-favored pricing </span>arrangement, (C)&#160;any exclusivity provision in favor of a third party, or (D)&#160;any non-solicitation provision applicable to the Company, in the case of the foregoing clause (D), which are material to the Company, taken as a whole;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span><span style="color:#231f20;">each Contract relating to capital expenditures and requiring payments after the date of this Agreement pursuant to its express terms and not cancelable without penalty;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</span></span><span style="color:#231f20;">each Contract relating to the disposition or acquisition of material assets or any ownership interest in any Person;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</span></span><span style="color:#231f20;">each Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit or creating any material Liens with respect to any assets of the Company or any loans or debt obligations with officers or directors of the Company;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vi)</span></span><span style="color:#231f20;">(A)&#160;any Contract involving supply or distribution (identifying any that contain exclusivity provisions), (B)&#160;any Contract involving provision of services or products with respect to any pre- clinical or clinical development activities of the Company, (C)&#160;any Contract involving a dealer, distributor, joint marketing, alliance, joint venture, cooperation, development or other Contract currently in force under which the Company has continuing obligations to develop or market any product, technology or service, or any Contract pursuant to which the Company has continuing obligations to develop any Intellectual Property that will not be owned, in whole or in part, by the Company or (D)&#160;any Contract to license any patent, trademark registration, service mark registration, trade name or copyright registration to or from any third party to manufacture or produce any product, service or technology of the Company or any Contract to sell, distribute or commercialize any products or service of the Company, in each case, except for Contracts entered into in the ordinary course of business;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vii)</span></span><span style="color:#231f20;">each Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services to the Company in connection with the Contemplated Transactions; and</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(viii)</span></span><span style="color:#231f20;">each Contract relating to leases of real properties with respect to which the Company directly or indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of or leased by the Company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">(i)&#160;Each Material Contract is valid and binding on the Company, and to the knowledge of the Company, each other party thereto, and is in full force and effect and enforceable in accordance with its terms; and (ii)&#160;as of the date of this Agreement, the Company has not receive any written notice of any material default under any Material Contract by the Company or of any event or condition that has occurred that constitutes, or, after notice or lapse of time or both, would constitute, a material default on the part of the Company. The Company has made available to Parent true and complete copies of all Material Contracts, including all amendments thereto. Except as set forth in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.16(c)</span><span style="color:#231f20;">&#160;of the Company Disclosure Letter, there are no Material Contracts that are not in written form.</span></p><a id="Section417"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.17</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Insurance</span>. Each of the Company and its Subsidiaries is covered by valid and currently effective insurance policies issued in favor of the Company or its Subsidiaries that are customary and adequate for companies of similar size in the industries and locations in which the Company and its Subsidiaries operate. <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.17</span> of the Company Disclosure Letter sets forth, as of the date hereof, a true and complete list of all material insurance policies issued in favor of the Company or any of its Subsidiaries, or pursuant to which the Company or any of its Subsidiaries is a named insured or otherwise a beneficiary, as well as any historic incurrence-based policies still in force. With respect to each such insurance policy, (a) <span style="color:#231f20;">such policy is in full force and effect and all premiums due thereon have been paid, (b)&#160;neither the Company nor any of its Subsidiaries is in breach or default, and has not taken any action or failed to take any action which (with or without notice or lapse of time, or both) would constitute such a breach or default, or would permit termination or modification of, any such policy and (c)&#160;to the knowledge of the Company, no insurer issuing any such policy has been declared insolvent or placed in receivership, conservatorship or liquidation. No notice of cancellation or termination has been received with respect to any such policy, nor will any such cancellation or termination result from the consummation of the Contemplated Transactions.</span></p><a id="Section418"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.18</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Properties</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">The Company or one of its Subsidiaries has good and valid title to, or in the case of leased property and leased tangible assets, a valid leasehold interest in, all of its real properties and tangible assets that are necessary for the Company and its Subsidiaries to conduct their respective businesses as currently conducted, free and clear of all Liens other than (i)&#160;Liens for Taxes and assessments not yet due and payable or the amount or validity of which is being contested in good faith by appropriate proceedings, (ii) mechanics&#8217;, workmen&#8217;s, repairmen&#8217;s, warehousemen&#8217;s and carriers&#8217; Liens arising in the ordinary course of business of the Company and its Subsidiaries consistent with past practice and (iii)&#160;any such matters of record, Liens and other imperfections of title that do not, individually or in the aggregate, materially impair the continued ownership, use and operation of the assets to which they relate in the business of the Company and its Subsidiaries as currently conducted (&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Permitted Liens</span><span style="color:#231f20;">&#8221;). Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, the tangible personal property currently used in the operation of the business of the Company and its Subsidiaries is in good working order (reasonable wear and tear excepted).</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">Each of the Company and its Subsidiaries has complied with the terms of all leases to which it is a party, and all such leases are in full force and effect, except for any such noncompliance or failure to be in full force and effect that, individually or in the aggregate, has not had and would not reasonably be expected to have a Material Adverse Effect. Each of the Company and its Subsidiaries enjoys peaceful and undisturbed possession under all such leases, except for any such failure to do so that, individually or in the aggregate, has not had and would not reasonably be expected to have a Material Adverse Effect.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.18(c)</span><span style="color:#231f20;">&#160;of the Company Disclosure Letter sets forth a true and complete list of (i)&#160;all real property owned by the Company or any of its Subsidiaries and (ii)&#160;all real property leased for the benefit of the Company or any of its Subsidiaries.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">This </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.18</span><span style="color:#231f20;"> does not relate to intellectual property, which is the subject of </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.19</span><span style="color:#231f20;">.</span></p><a id="Section419"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.19</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Intellectual Property</span><span style="color:#231f20;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> Section&#160;4.19(a)</span><span style="color:#231f20;">&#160;of the Company Disclosure Letter sets forth a true and complete list of all (i) patents and patent applications; (ii)&#160;trademark registrations and applications; and (iii)&#160;material copyright registrations and applications, in each case owned or licensed by the Company and its Subsidiaries (collectively, &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Registered IP</span><span style="color:#231f20;">&#8221;) and a true and complete list of all domain names owned or exclusively licensed by the Company and its Subsidiaries. Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Material Adverse Effect (A)&#160;all of the Company Registered IP is subsisting and, solely in the case of any Company Registered IP that is registered or issued and to the knowledge of the Company, valid and enforceable, (B)&#160;no Company Registered IP is involved in any interference, reissue, derivation, reexamination, opposition, cancellation or similar proceeding and, to the knowledge of the Company, no such action is threatened with respect to any of the Company Registered IP and (C)&#160;the Company and its Subsidiaries own exclusively, free and clear of any and all Liens (other than Permitted Liens), all Company Owned IP, including all Intellectual Property created on behalf of the Company or its Subsidiaries by employees or independent contractors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.19(b)</span><span style="color:#231f20;">&#160;of the Company Disclosure Letter accurately identifies (i)&#160;all contracts pursuant to which any Intellectual Property is licensed to the Company or any of its Subsidiaries (other than (A)&#160;any non-customized software that (1)&#160;is so licensed solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (2) is not incorporated into, or material to the development, manufacturing, or distribution of, any of the products and services of the Company or any of its Subsidiaries, (B)&#160;any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of equipment, reagents or other materials, (C)&#160;any confidential information provided under confidentiality agreements and (D)&#160;agreements between the Company or any of its Subsidiaries and its employees in the Company&#8217;s standard form thereof), (ii)&#160;whether such contract involves the Company Registered IP licensed to the Company or any of its Subsidiaries and (iii) whether the license or licenses granted to the Company or any of its Subsidiaries are exclusive or nonexclusive.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> Section&#160;4.19(c)</span><span style="color:#231f20;">&#160;if the Company Disclosure Letter accurately identifies each of the Company&#8217;s contracts pursuant to which any Person has been granted any license or covenant not sue under, or otherwise has received or acquired any right (whether or not currently exercisable) or interest in, any Company Registered IP (other than (i)&#160;any confidential information provided under confidentiality agreements and (ii) any Company Registered IP nonexclusively licensed to academic collaborators, suppliers, manufacturers or service providers for the sole purpose of enabling such academic collaborator, supplier, manufacturer </span>or service provider to provide services for the Company&#8217;s benefit).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;"> To the knowledge of the Company, the Company Registered IP constitutes all Intellectual Property necessary for the Company to conduct its business as currently conducted; provided, however, that the foregoing representation is not a representation with respect to non-infringement of Intellectual Property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="color:#231f20;"> The Company and its Subsidiaries have taken commercially reasonable measures to maintain the confidentiality of all information that constitutes or constituted a material Trade Secret of the Company and its Subsidiaries, including requiring all Persons having access thereto to execute written non-disclosure agreements or other binding obligations to maintain confidentiality of such information.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span><span style="color:#231f20;"> Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Material Adverse Effect, (i)&#160;to the knowledge of the Company, the conduct of the businesses of the Company and its Subsidiaries, including the manufacture, marketing, offering for sale, sale, importation, use or intended use or other disposal of any product as currently sold or </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">under development by Company or any of its Subsidiaries, has not infringed, misappropriated or diluted, and does not infringe, misappropriate or dilute, any Intellectual Property of any Person, (ii)&#160;neither the Company nor any of its Subsidiaries </span>have received any written notice or claim asserting or suggesting that any such infringement, misappropriation, or dilution is or may be occurring or has or may have occurred and (iii)&#160;to the knowledge of the Company, no Person is infringing, misappropriating, or diluting in any material respect any Company Registered IP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span><span style="color:#231f20;"> Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Material Adverse Effect, (i)&#160;the Company and its Subsidiaries have taken commercially reasonable steps to protect the confidentiality and security of the computer and information technology systems used by the Company or any of its Subsidiaries (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">IT Systems</span><span style="color:#231f20;">&#8221;) and the information and transactions stored or contained therein or transmitted thereby, (ii)&#160;to the knowledge of the Company, during the past two (2) years, there has been no unauthorized or improper use, loss, access, transmittal, modification or corruption of any such information or data and (iii)&#160;since January&#160;1, 2021, there have been no material failures, crashes, viruses, security breaches (including any unauthorized access to any personally identifiable information), affecting the IT Systems.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span><span style="color:#231f20;"> The Company and its Subsidiaries have at all times complied in all material respects with all: (i) applicable Laws, published privacy policies and contractual obligations relating to privacy, data protection, and the collection, retention, protection, and use of information that alone or in combination with other information can be used to identify an individual, household or device (&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Personal Information</span><span style="color:#231f20;">&#8221;) collected, used, or held for use by the Company or any of its Subsidiaries (collectively, &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Privacy Laws</span><span style="color:#231f20;">&#8221;), (ii)&#160;since January&#160;1, 2021, no claims have been asserted or, to the knowledge of the Company, threatened in writing against the Company or any of its Subsidiaries alleging a violation of any Person&#8217;s privacy or Personal Information, (iii)&#160;neither this Agreement nor the consummation of the Contemplated Transactions will breach or otherwise violate any Privacy Laws and (iv)&#160;the Company and its Subsidiaries have taken commercially reasonable steps to protect the Personal Information collected, used or held for use by the Company or any of its Subsidiaries against loss and unauthorized access, use, modification or disclosure, or other misuse. The Company and its Subsidiaries have contractually obligated all vendors, processors, service providers and other Persons collecting, using or otherwise processing Personal Information by or for the Company or any of its Subsidiaries (&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Data Processors</span><span style="color:#231f20;">&#8221;) to comply with applicable Privacy Laws and to take reasonable measures to protect Personal Information from unauthorized, access, use or disclosure. To the knowledge of the Company, no Data Processors have failed to comply with Privacy Laws with respect to the Personal Information processed on behalf of the Company or its Subsidiaries.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="color:#231f20;"> To the knowledge of the Company, no government funding, facilities or resources of a university, college, other educational institution or research center or funding from third parties was used in the </span>development of Company Owned IP or any Intellectual Property, exclusively licensed to the Company or any of its Subsidiaries, and no Governmental Entity, university, college, other educational institution or research center has, to the knowledge of the Company, any claim or right in or to such Intellectual Property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span><span style="color:#231f20;"> Except as set forth on </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.19(j)</span><span style="color:#231f20;">&#160;of the Company Disclosure Letter, the execution, delivery and performance by the Company of this Agreement, and the consummation of the Contemplated Transactions, will not result in the loss of, or give rise to any right of any third party to terminate or modify any of the rights or obligations of the Company or any of its Subsidiaries under any agreement under which the Company or any of its Subsidiaries grants to any Person, or any Person grants to the Company or any of its Subsidiaries, a license or right under or with respect to any Intellectual Property that is material to any of the businesses of the Company or any of its Subsidiaries.</span></p><a id="Section420"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.20</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">State Takeover Statutes</span>. As of the date hereof and at all times on or prior to the First Effective Time, the Company Board has taken all actions so that the restrictions applicable to business combinations contained in Section&#160;203 of the DGCL are, and will be, inapplicable to the execution, delivery and performance of this Agreement and the timely consummation of the Merger and the other Contemplated Transactions and will not restrict, impair or delay the ability of Parent or Merger Subs, after the First Effective Time, to vote or otherwise exercise all rights as a stockholder of the Company. No other &#8220;moratorium,&#8221; &#8220;fair price,&#8221; &#8220;business combination,&#8221; &#8220;control share acquisition&#8221; or similar provision of any state anti-takeover Law (collectively, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Takeover Laws</span>&#8221;) or any similar anti-takeover provision in the Company Charter or Company Bylaws is, or at the First Effective Time will be, applicable to this Agreement, the Merger or any of the other Contemplated Transactions.</p><a id="Section421"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.21</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Rights Plan</span>. There is no stockholder rights plan, &#8220;poison pill&#8221; anti-takeover plan or other similar device in effect to which the Company or any of its Subsidiaries is a party or is otherwise bound.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Section422"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.22</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Related Party Transactions</span>. Except as set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.22</span> of the Company Disclosure Letter, since January&#160;1, 2022 through the date of this Agreement, there have been no transactions, agreements, arrangements or understandings between the Company or any of its Subsidiaries, on the one hand, and the Affiliates of the Company or any of its Subsidiaries, on the other hand that would be required to be disclosed under Item&#160;404 of Regulation S-K under the Securities Act (assuming the Company and its Subsidiaries were subject to the requirements of the Exchange Act).</p><a id="Section423"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.23</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certain Payments</span>. For the five (5)&#160;years immediately preceding the date hereof, neither the Company nor any of its Subsidiaries nor, to the knowledge of the Company, any of their respective directors, executives, representatives, agents or employees (a)&#160;has used or is using any corporate funds for any illegal contributions, gifts, entertainment or other unlawful expenses relating to political activity, (b)&#160;has used or is using any corporate funds for any direct or indirect unlawful payments to any foreign or domestic governmental officials or employees, (c)&#160;has violated or is violating any provision of the Foreign Corrupt Practices Act of 1977, as amended, (d)&#160;has established or maintained, or is maintaining, any unlawful fund of corporate monies or other properties, or (e)&#160;has made any bribe, unlawful rebate, payoff, influence payment, kickback or other unlawful payment of any nature.</p><a id="Section424"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.24</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trade Control Laws</span>. Since April&#160;24, 2019, the Company and its Subsidiaries have been in material compliance with all applicable import, export control, and economic and trade sanctions laws, regulations, statutes, and orders, including the Export Administration Regulations, the International Traffic in Arms Regulations, and the regulations administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trade Laws</span>&#8221;) and have obtained, or are otherwise qualified to rely upon, all material import and export licenses, consents, notices, waivers, approvals, orders, authorizations, registrations, declarations or other authorizations from, and made any filings with, any governmental authority required for (i)&#160;the import, export, and reexport of products, services, software and technologies and (ii)&#160;releases of technologies and software to foreign nationals (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trade Approvals</span>&#8221;). There are no pending or threatened claims against the Company or its Subsidiaries, nor any actions, conditions, facts, or circumstances that would reasonably be expected to give rise to any material future claims with respect to the Trade Laws or Trade Approvals.</p><a id="Section425"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.25</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Brokers</span>. No broker, investment banker, financial advisor or other Person, other than as set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.25</span> of the Company Disclosure Letter, the fees and expenses of which will be paid by the Company or any of its Subsidiaries, or following the First Effective Time, Parent is entitled to any broker&#8217;s, finder&#8217;s, financial advisor&#8217;s or other similar fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of the Company, any of its Subsidiaries or any of its Affiliates. The Company has furnished to Parent a true and complete copy of any Contract between the Company or any of its Subsidiaries and any Person identified on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.25</span> of the Company Disclosure Letter.</p><a id="Section426"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.26</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Securities Purchase Agreement</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">The Company has delivered to Parent and Merger Subs, correct and complete copies of all definitive agreements related to the Concurrent Investment, including the Securities Purchase Agreement. The Securities Purchase Agreement has not been amended or modified prior to the date of this Agreement and as of the date hereof, the respective obligations and commitments contained in the Securities Purchase Agreement have not been withdrawn or rescinded in any respect.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">As of the date hereof, the Securities Purchase Agreement is in full force and effect and is the legal, valid, binding and enforceable obligation of the Company, and, to the knowledge of the Company, each of the Concurrent Investment Investors. There are no conditions precedent or other contingencies related to the funding of the full amount of the Concurrent Investment, other than as expressly set forth in the Securities Purchase Agreement. As of the date hereof, no event has occurred which, with or without notice, lapse of time or both, would reasonably be expected to constitute a default or breach on the part of the Company or, to the knowledge of the Company, any Concurrent Investment Investor under the Securities Purchase Agreement.</span></p><a id="Section427"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.27</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Other Representations and Warranties</span>. Except for the representations and warranties contained in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;V</span>, the Company acknowledges and agrees that none of Parent, Merger Subs or any other Person on behalf of Parent or Merger Subs makes any other express or implied representation or warranty whatsoever, and specifically (but without limiting the generality of the foregoing) that none of Parent, its Subsidiaries or any other Person on behalf of Parent or Merger Subs makes any representation or warranty with respect to any projections or forecasts delivered or made available to the Company or any of its Representatives of future revenues, results of operations (or any component thereof), cash flows or financial condition (or any component thereof) of Parent (including any such projections or forecasts made available to the Company and Representatives in certain &#8220;data rooms&#8221; or management presentations in expectation of the Contemplated Transactions), and the Company has not relied on any such information or any representation or warranty not set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;V</span>.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="ARTICLEV"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;V</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUBS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except (a)&#160;as disclosed in the Parent SEC Documents at least three Business Days prior to the date of this Agreement and that is reasonably apparent on the face of such disclosure to be applicable to the representation and warranty set forth herein (other than any disclosures contained or referenced therein under the captions &#8220;Risk Factors,&#8221; &#8220;Forward-Looking Statements,&#8221; &#8220;Quantitative and Qualitative Disclosures About Market Risk,&#8221; and any other disclosures contained or referenced therein of information, factors, or risks that are predictive, cautionary, or forward-looking in nature); or (b)&#160;as set forth in the corresponding section or subsection of the disclosure letter delivered by Parent to the Company (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Disclosure Letter</span>&#8221;) (it being agreed that the disclosure of any information in a particular section or subsection of the Parent Disclosure Letter shall be deemed disclosure of such information with respect to any other section or subsection of this Agreement to which the relevance of such information is readily apparent on its face), each of Parent and Merger Subs represent and warrant to the Company as follows:</p><a id="Section51"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Organization, Standing and Power</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">Each of Parent and Merger Subs is a corporation duly organized or other entity duly formed, validly existing and in good standing under the Laws of the jurisdiction of its incorporation. Each of Parent and Merger Subs (x)&#160;has all requisite corporate or similar power and authority to own, lease and </span>operate its properties and to carry on its business as now being conducted and (y)&#160;is duly qualified or licensed to do business and is in good standing in each jurisdiction in which the nature of its business or the ownership, leasing or operation of its properties makes such qualification or licensing necessary, except in the case of clause (y), where the failure to be so qualified or licensed or in good standing, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect. For purposes of this Agreement, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Material Adverse Effect</span>&#8221; means any event, change, circumstance, occurrence, effect or state of facts that (A)&#160;is or would reasonably be expected to be materially adverse to the business, assets, liabilities, financial condition, or results of operations of Parent and its Subsidiaries, taken as a whole, or (B)&#160;materially impairs the ability of Parent or Merger Subs to consummate the Merger or any of the other Contemplated Transactions; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that in the case of clause (A)&#160;only, Parent Material Adverse Effect shall not include any event, change, circumstance, occurrence, effect or state of facts to the extent resulting from (1)&#160;changes or conditions generally affecting the industries in which Parent and its Subsidiaries operate, or the economy or the financial, debt, banking, capital, credit or securities markets, in the United States, including effects on such industries, economy or markets resulting from any regulatory and political conditions or developments in general, (2)&#160;the outbreak or escalation of war or acts of terrorism or any natural disasters, acts of God or comparable events, epidemic, pandemic or disease outbreak (including the COVID-19 virus) or any worsening of the foregoing, or any declaration of martial law, quarantine or similar directive, policy or guidance or Law or other action by any Governmental Entity in response thereto, (3)&#160;changes in Law or GAAP, or the interpretation or enforcement thereof, (4)&#160;the public announcement or pendency of this Agreement, or (5)&#160;any specific action taken (or omitted to be taken) by Parent at or with the express written consent of the Company; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that, with respect to clauses (1), (2) <span style="color:#231f20;">and (3), the impact of such event, change, circumstance, occurrence, effect or state of facts is not disproportionately adverse to Parent and its Subsidiaries, as compared to other participants in the industries in which Parent and its Subsidiaries operate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">Parent has previously made available to the Company true and complete copies of the Certificate of Incorporation and bylaws of each of Parent, each of its Subsidiaries, and Merger Subs, in each case, as amended to the date of this Agreement, and each as so delivered is in full force and effect. None of Parent, its Subsidiaries, or Merger Subs is in violation of any provision of their respective Certificate of Incorporation or bylaws or equivalent governing documents.</span></p><a id="Section52"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Capital Stock</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">The authorized capital stock of Parent consists of 150,000,000 shares of Parent Common Stock and 10,000,000 shares of Parent Preferred Stock. As of the close of business on October&#160;29, 2024 (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Measurement Date</span><span style="color:#231f20;">&#8221;), (i)&#160;28,867,711 shares of Parent Common Stock (excluding treasury shares) were issued and outstanding, all of which were validly issued, fully paid and nonassessable (which term means that no further sums are required to be paid by the holders thereof in connection with the issue of such shares) and were free of preemptive rights, (ii)&#160;no shares of Parent Common Stock were held in treasury, (iii)&#160;an aggregate of 3,266,711 shares of Parent Common Stock were subject to the exercise of outstanding Parent Options, (iv)&#160;no shares of Parent Common Stock were subject to outstanding Parent Restricted Stock Unit Awards, and (v)&#160;no shares of Parent Preferred Stock were issued and outstanding or held in treasury. </span>Except as set forth above in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.2(a)</span>, Parent does not have any outstanding bonds, debentures, notes or other obligations having the right to vote (or convertible into, or exchangeable or exercisable for, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;">securities having the right to vote) with the stockholders of Parent or any of its Subsidiaries on any matter. Except as set forth above in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.2(a)</span>&#160;and except for changes since the close of business on the Measurement Date resulting from the exercise of any options as described above, as of the Measurement Date, there are no outstanding (A)&#160;shares of capital stock or other voting securities or equity interests of Parent or any of its Subsidiaries, (B)&#160;securities of Parent or any of its Subsidiaries convertible into or exchangeable or exercisable for shares of capital stock of Parent or any of its Subsidiaries or other voting securities or equity interests of Parent or any of its Subsidiaries, (C)&#160;stock appreciation rights, &#8220;phantom&#8221; stock rights, performance units, interests in or rights to the ownership or earnings of Parent or any of its Subsidiaries or other equity equivalent or equity-based awards or rights, (D)&#160;subscriptions, options, warrants, calls, commitments, Contracts or other rights to acquire from Parent or any of its Subsidiaries, or obligations of Parent or any of its Subsidiaries to issue, any shares of capital stock of Parent or any of its Subsidiaries, voting securities, equity interests or securities convertible into or exchangeable or exercisable for capital stock or other voting securities or equity interests of Parent or any of its Subsidiaries or rights or interests described in the preceding clause (C), or (E)&#160;obligations of Parent or any of its Subsidiaries to repurchase, redeem or otherwise acquire any such securities or to issue, grant, deliver or sell, or cause to be issued, granted, delivered or sold, any such securities. There are no stockholder agreements, voting trusts or other agreements or understandings to which Parent or any of its Subsidiaries is a party or of which Parent has knowledge with respect to the holding, voting, registration, redemption, repurchase or disposition of, or that restricts the transfer of, any capital stock or other voting securities or equity interests of Parent or any of its Subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">The authorized capital stock of First Merger Sub consists of 1,000 shares of common stock, par value $0.001 per share, of which 1,000 shares are issued and outstanding, all of which shares are beneficially owned by Parent.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">The shares of Parent Common Stock to be issued pursuant to the Merger will be duly authorized, validly issued, fully paid and nonassessable and not subject to any preemptive rights.</span></p><a id="Section53"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subsidiaries</span>. <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.3</span> of the Parent Disclosure Letter sets forth a true and complete list of each Subsidiary of Parent, including its jurisdiction of incorporation or formation. Each of Parent&#8217;s Subsidiaries (i)&#160;is an entity duly organized, validly existing and in good standing under the Laws of the jurisdiction of its organization, (ii)&#160;has all requisite corporate or similar power and authority to own, lease and operate its properties and to carry on its business as now being conducted and (iii)&#160;is duly qualified or licensed to do business and is in good standing in each jurisdiction in which the nature of its business or the ownership, leasing or operations of its properties makes such qualification or licensing necessary, except in the case of clause (iii), where the failure to be so qualified or licensed or in good standing, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect. All outstanding shares of capital stock and other voting securities or equity interests of each such Subsidiary are owned directly by Parent, free and clear of all Liens. Except for the capital stock of, or other equity or voting interests in, its Subsidiaries, Parent does not own, directly or indirectly, any equity, membership interest, partnership interest, joint venture interest, or other equity or voting interest in, or any interest convertible into, exercisable or exchangeable for any of the foregoing, nor is it under any current or prospective obligation to form or participate in, provide funds to, make any loan, capital contribution, guarantee, credit enhancement or other investment in, or assume any liability or obligation of, any Person. Each Merger Sub was formed solely for the purpose of engaging in the Merger and the other Contemplated Transactions and has engaged in no business other than in connection with the Contemplated Transactions.</p><a id="Section54"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authority</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">Each of Parent and Merger Subs has all necessary corporate power and authority to execute, deliver and perform its obligations under this Agreement and to consummate the Merger and the other Contemplated Transactions, including the issuance of the shares of Parent Common Stock to the holders of Company capital stock as Merger Consideration (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Common Stock Issuance</span><span style="color:#231f20;">&#8221;). The execution, delivery and performance of this Agreement by Parent and Merger Subs and the consummation by Parent and Merger Subs of the Merger and the other Contemplated Transactions have been duly authorized by all necessary corporate action on the part of Parent and Merger Subs and no other corporate proceedings on the part of Parent or Merger Subs are necessary to approve this Agreement or to consummate the Merger and the other Contemplated Transactions, subject to (i)&#160;obtaining the approval of the Nasdaq Issuance Proposal and the Reverse Stock Split Proposal by the holders of a majority of the votes cast for such proposals (collectively, the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Stockholder Approval</span><span style="color:#231f20;">&#8221;) and (ii)&#160;the approval of this Agreement by Parent as the sole stockholder of Merger Subs. This Agreement has been duly executed and delivered by Parent and Merger Subs and, assuming the due authorization, execution and delivery by the Company, constitutes a valid and binding obligation of each of Parent and Merger Subs, enforceable against each of Parent and Merger Subs in accordance with its terms (except to the extent that enforceability may be limited by </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">applicable bankruptcy, insolvency, moratorium, reorganization or similar Laws affecting the enforcement of creditors&#8217; rights generally or by general principles of equity).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">The Parent Board, at a meeting duly called and held at which all directors of Parent were present, duly adopted resolutions (i)&#160;determining that the terms of this Agreement, the Merger and the other Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders, (ii) approving and declaring advisable this Agreement and the Contemplated Transactions, including the Merger, the issuance of shares of Parent Common Stock to the stockholders of the Company pursuant to the terms of this Agreement, the Concurrent Investment, the Pre-Closing Cash Dividend and the Parent </span>Support Agreements, (iii)&#160;determining to submit the Parent Board Recommendation to the stockholders of Parent, and (iv)&#160;determining to approve and recommend the Parent Stockholder Proposal to the stockholders of Parent as promptly as practicable after the form of the Reverse Stock Split Proposal is mutually agreed to by Parent and the Company. The board of directors of Merger Subs (by unanimous written consent) has: (x)&#160;determined that the Contemplated Transactions are fair to, advisable, and in the best interests of Merger Subs and its sole stockholder, (y)&#160;deemed advisable and approved this Agreement and the Contemplated Transactions and (z)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder of Merger Subs vote to adopt this Agreement and thereby the Contemplated Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;"> The Parent Stockholder Approval is the only vote of the holders of any class or series of the Parent Common Stock or other securities required in connection with the consummation of the Merger and the other Contemplated Transactions, including the Parent Common Stock Issuance. Other than the Parent Stockholder Approval, no vote of the holders of any class or series of the Parent Common Stock or other securities is required in connection with the consummation of any of the Contemplated Transactions to be consummated by Parent.</span></p><a id="Section55"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Conflict; Consents and Approvals</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">Except as set forth in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.5(a)</span><span style="color:#231f20;">&#160;of the Parent Disclosure Letter, the execution, delivery and performance of this Agreement by each of Parent and Merger Subs does not, and the consummation of the Merger and the other Contemplated Transactions and compliance by each of Parent and Merger Subs </span>with the provisions hereof will not, conflict with, or result in any violation or breach of, or default (with or without notice or lapse of time, or both) under, or give rise to a right of, or result in, termination, cancellation, modification or acceleration of any obligation or to the loss of a benefit under, or result in the creation of any Lien in or upon any of the properties, assets or rights of Parent or Merger Subs under, or give rise to any increased, additional, accelerated or guaranteed rights or entitlements under, or require any consent, waiver or approval of any Person pursuant to, any provision of (i)&#160;the Certificate of Incorporation or bylaws of Parent or Merger Subs, (ii)&#160;any Parent Material Contract to which Parent or Merger Subs is a party by which Parent, Merger Subs or any of their respective properties or assets may be bound, or (iii)&#160;subject to the governmental filings and other matters referred to in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.5(b)</span>, any material Law or any rule&#160;or regulation of Nasdaq applicable to Parent or Merger Subs or by which Parent, Merger Subs or any of their respective properties or assets may be bound, except as, in the case of clauses (ii)&#160;and (iii), as individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">No consent, approval, order or authorization of, or registration, declaration, filing with or notice to, any Governmental Entity is required by or with respect to Parent or Merger Subs in connection with the execution, delivery and performance of this Agreement by Parent or Merger Subs or the consummation </span>by Parent or Merger Subs of the Merger and the other Contemplated Transactions or compliance with the provisions hereof, except for (i)&#160;the filing of the pre-merger notification report under the HSR Act, (ii)&#160;the filing with the SEC of such reports under Section&#160;13(a)&#160;or 15(d)&#160;of the Exchange Act, as may be required in connection with this Agreement and the Contemplated Transactions, (iii)&#160;such other filings and reports as may be required pursuant to the applicable requirements of the Securities Act, the Exchange Act and any other applicable state or federal securities, takeover and &#8220;blue sky&#8221; laws, (iv)&#160;the filing of the Certificate of Merger with the Delaware Secretary of State as required by the DGCL, (v)&#160;any filings required under the rules&#160;and regulations of Nasdaq and (vi)&#160;such consents, approvals, orders, authorizations, registrations, declarations, filings or notices the failure of which to be obtained or made, individually or in the aggregate, have not had and would not reasonably be expected to have a Parent Material Adverse Effect.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Section56"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SEC Reports; Financial Statements</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">Parent has filed with or furnished to the SEC on a timely basis true and complete copies of all forms, reports, schedules, statements and other documents required to be filed with or furnished to the SEC by Parent since January&#160;1, 2024 (all such documents, together with all exhibits and schedules to the foregoing materials and all information incorporated therein by reference, the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent SEC Documents</span><span style="color:#231f20;">&#8221;). As of their respective filing dates (or, if amended or superseded by a filing prior to the date of this Agreement, then </span>on the date of such filing), the Parent SEC Documents complied in all material respects with the applicable requirements of the Securities Act, the Exchange Act and the Sarbanes-Oxley Act of 2002 (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sarbanes- Oxley Act</span>&#8221;), as the case may be, including, in each case, the rules&#160;and regulations promulgated thereunder, and none of the Parent SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">The financial statements (including the related notes and schedules thereto) included (or incorporated by reference) in the Parent SEC Documents (i)&#160;have been prepared in a manner consistent with the books and records of Parent, (ii)&#160;have been prepared in accordance with GAAP (except, in the case of unaudited statements, as permitted by Form&#160;10-Q of the SEC) applied on a consistent basis during the periods involved (except as may be indicated in the notes thereto), (iii)&#160;comply as to form in all material respects with applicable accounting requirements and the published rules&#160;and regulations of the SEC with respect thereto and (iv)&#160;fairly present in all material respects the consolidated financial position of Parent</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">as of the dates thereof and their respective consolidated results of operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal and recurring&#160;year-end audit adjustments that were not, or are not expected to be, material in amount), all in accordance with GAAP and the applicable rules&#160;and regulations promulgated by the SEC. Since January&#160;1, 2024, Parent has not made any change in the accounting practices or policies applied in the preparation of its financial statements, except as required by GAAP, SEC rule&#160;or policy or applicable Law. The books and records of Parent have been, and are being, maintained in all material respects in accordance with GAAP (to the extent applicable) and any other applicable legal and accounting requirements and reflect only actual transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">Parent has established and maintains disclosure controls and procedures (as defined in Rules&#160;13a- 15(e)&#160;and 15d-15(e)&#160;under the Exchange Act). Such disclosure controls and procedures are designed to ensure that information relating to Parent required to be disclosed in Parent&#8217;s periodic and current reports under the Exchange Act, is made known to Parent&#8217;s principal executive officer and principal financial officer by others within those entities to allow timely decisions regarding required disclosures as required under the Exchange Act. The chief executive officer and chief financial officer of Parent have evaluated the effectiveness of Parent&#8217;s disclosure controls and procedures and, to the extent required by applicable Law, presented in any applicable Parent SEC Document that is a report on Form&#160;10-K or Form&#160;10-Q, or any amendment thereto, its conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by such report or amendment based on such evaluation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">Parent has established and maintains a system of internal control over financial reporting (as defined in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;under the Exchange Act) which is effective in providing reasonable assurance regarding the reliability of Parent&#8217;s financial reporting and the preparation of Parent&#8217;s financial statements for external purposes in accordance with GAAP. Parent has disclosed, based on its most recent evaluation of Parent&#8217;s internal control over financial reporting prior to the date hereof, to Parent&#8217;s auditors and audit committee (i)&#160;any significant deficiencies and material weaknesses in the design or operation of Parent&#8217;s internal control over financial reporting which are reasonably likely to adversely affect Parent&#8217;s ability to record, process, summarize and report financial information and (ii)&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in Parent&#8217;s internal control over financial reporting. A true, correct and complete summary of any such disclosures made by management </span>to Parent&#8217;s auditors and audit committee is set forth as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.6(d)</span>&#160;of Parent Disclosure Letter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="color:#231f20;">Since January&#160;1, 2024, (i)&#160;neither Parent nor, to the knowledge of Parent, any of its directors, officers, employees, auditors, accountants or representatives has received or otherwise had or obtained knowledge of any material complaint, allegation, assertion or claim, whether written or oral, regarding the accounting or auditing practices, procedures, methodologies or methods of Parent or its internal accounting controls, including any material complaint, allegation, assertion or claim that Parent has engaged in questionable accounting or auditing practices and (ii)&#160;no attorney representing Parent, whether or not employed by Parent, has reported evidence of a material violation of securities Laws, breach of fiduciary duty or similar violation by Parent or any of its officers, directors, employees or agents to the Parent Board or any committee thereof or to any director or officer of Parent.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span><span style="color:#231f20;">As of the date of this Agreement, there are no outstanding or unresolved comments in the comment letters received from the SEC staff with respect to the Parent SEC Documents. To the knowledge of Parent, none of the Parent SEC Documents is subject to ongoing review or outstanding SEC comment or investigation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span><span style="color:#231f20;">Parent is not a party to, or has any commitment to become a party to, any joint venture, off balance sheet partnership or any similar Contract (including any Contract or arrangement relating to any transaction or relationship between or among Parent, on the one hand, and any unconsolidated Affiliate, including any structured finance, special purpose or limited purpose entity or Person, on the other hand, or any &#8220;off balance sheet arrangements&#8221; (as defined in Item&#160;303(a)&#160;of Regulation S K under the Exchange Act)), where the result, purpose or intended effect of such Contract is to avoid disclosure of any material transaction involving, or material liabilities of, Parent in Parent&#8217;s published financial statements or other Parent SEC Documents.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span><span style="color:#231f20;">Parent is in compliance in all material respects with (i)&#160;the provisions of the Sarbanes-Oxley Act and (ii)&#160;the rules&#160;and regulations of Nasdaq, in each case, that are applicable to Parent.</span></p><a id="Section57"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Undisclosed Liabilities</span>. Neither Parent nor any of its Subsidiaries has any liabilities or obligations of any nature, whether accrued, absolute, contingent or otherwise, known or unknown, whether due or to become due and whether or not required to be recorded or reflected on a balance sheet under GAAP, except (a)&#160;to the extent specifically and adequately accrued or reserved against in the audited balance sheet of Parent as at December&#160;31, 2023 included in the Annual Report on Form&#160;10-K filed by Parent with the SEC on March&#160;25, 2024 (without giving effect to any amendment thereto filed on or after the date hereof) and (b)&#160;for liabilities and obligations incurred in the ordinary course of business consistent with past practice (none of which is a liability for a breach or default under any contract, breach of warranty, tort, infringement, misappropriation or violation of law) since December&#160;31, 2023 that are not individually or in the aggregate material to Parent.</p><a id="Section58"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Absence of Certain Changes or Events</span>. Except as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.8</span> of the Parent Disclosure Letter, since December&#160;31, 2023, (i)&#160;except in connection with the execution of this Agreement and the consummation of the Contemplated Transactions, Parent and its Subsidiaries have conducted their business only in the ordinary course consistent with past practice; (ii)&#160;there has not been any change, event or development or prospective change, event or development that, individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect; and (iii)&#160;neither Parent nor any of its Subsidiaries has:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">(i)&#160;declared, set aside or paid any dividends on, or made any other distributions (whether in cash, stock or property) in respect of, any of its capital stock or other equity interests, other than the Pre-Closing Cash Dividend, (ii)&#160;purchased, redeemed or otherwise acquired shares of capital stock or other equity interests of Parent or any of its Subsidiaries or any options, warrants, or rights to acquire any such shares or other equity interests, or (iii)&#160;split, combined, reclassified or otherwise amended the terms of any of its capital stock or other equity interests or issued or authorized the issuance of any other securities in respect of, in lieu of or in substitution for shares of its capital stock or other equity interests;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">amended or otherwise changed, or authorized or proposed to amend or otherwise change, its certificate of incorporation or by-laws (or similar organizational documents);</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">adopted or entered into a plan of complete or partial liquidation, dissolution, restructuring, recapitalization or reorganization; or</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">changed its financial or Tax accounting methods, principles or practices, except insofar as may have been required by a change in GAAP or applicable Law, or revalued any of its material assets.</span></p><a id="Section59"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.9</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Litigation</span>. There is no Action (or basis therefor) pending or, to the knowledge of Parent, threatened against or affecting Parent or any of its Subsidiaries, any of its properties or assets, or any present or former officer, director or employee of Parent or any of its Subsidiaries in such individual&#8217;s capacity as such, other than any Action that (a)&#160;does not involve an amount in controversy in excess of $100,000 and (b) <span style="color:#231f20;">does not seek injunctive or other non-monetary relief. Neither Parent nor any of its Subsidiaries nor any of their respective properties or assets is subject to any outstanding judgment, order, injunction, rule&#160;or </span>decree of any Governmental Entity. There is no Action pending or, to the knowledge of Parent, threatened seeking to prevent, hinder, modify, delay or challenge the Merger or any of the other Contemplated Transactions.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Section510"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.10</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Law</span>. Parent and each of its Subsidiaries are and have been in compliance in all material respects with all Laws applicable to its businesses, operations, properties or assets. Neither Parent nor any of its Subsidiaries has received, since January&#160;1, 2021, a notice or other written communication alleging or relating to a possible material violation of any Law applicable to its business, operations, properties, assets or Parent Products (as defined below). Parent and each of its Subsidiaries have in effect all material Permits of all Governmental Entities necessary or advisable for it to own, lease or operate its properties and assets and to carry on its business and operations as now conducted, and there has occurred no violation of, default (with or without notice or lapse of time or both) under or event giving to others any right of revocation, non-renewal, adverse modification or cancellation of, with or without notice or lapse of time or both, any such Permit, nor would any such revocation, non-renewal, adverse modification or cancellation result from the consummation of the Contemplated Transactions.</p><a id="Section511"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.11</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Health Care Regulatory Matters</span>. Except as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.11</span> of the Parent Disclosure Letter:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">Parent, and to the knowledge of Parent, each of its directors, officers, management employees, agents (while acting in such capacity), contract manufacturers, suppliers, and distributors are, and at all times prior hereto were, in material compliance with all health care laws to the extent applicable to Parent or any of its products or activities, including, but not limited to the Health Care Laws, to the extent applicable to Parent. To the knowledge of Parent, there are no facts or circumstances that reasonably would be expected to give rise to any material liability under any Health Care Laws.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">Neither Parent nor any of its Subsidiaries is not party to any material corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any Governmental Entity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">All applications, notifications, submissions, information, claims, reports and statistical analyses, and other data and conclusions derived therefrom, utilized as the basis for or submitted in connection with any and all requests for a Permit from the FDA or other Governmental Entity relating to products that are regulated as biologics under Health Care Laws, including biological candidates, compounds or products being researched, tested, stored, developed, labeled, manufactured, packed, imported, exported and/or distributed by Parent or any of its Subsidiaries (&#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Products</span><span style="color:#231f20;">&#8221;), including, without limitation, investigational new drug applications, when submitted to the FDA or other Governmental Entity were true, complete and correct in all material respects as of the date of submission and any necessary or required updates, changes, corrections or modification to such applications, submissions, information and data have been submitted to the FDA or other Governmental Entity. Parent does not have knowledge of any facts </span>or circumstances that would be reasonably likely to lead the revocation, suspension, limitation, or cancellation of a Permit required under Health Care Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">All preclinical studies and clinical trials conducted by or, to the knowledge of Parent, on behalf of Parent in respect of a Parent Product for submission to the FDA or other Governmental Entity have been since January&#160;1, 2018, and if still pending are being, conducted in compliance with research protocols and all applicable Health Care Laws, including, but not limited to, the FDCA and its applicable implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58, 312, 314 and 812. No clinical trial conducted by or on behalf of Parent has been conducted using any clinical investigators who have been disqualified. Except as set forth on </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.11(d)</span><span style="color:#231f20;">&#160;of the Parent Disclosure Letter, no clinical trial conducted by or on behalf of the Company has been terminated or suspended prior to completion, and no clinical investigator that has participated or is participating in, or institutional review board that has or has had jurisdiction over, a clinical trial conducted by or on behalf of Parent has placed a clinical hold order on, or otherwise terminated, delayed or suspended, such a clinical trial at a clinical research site based on an actual or alleged lack of safety or efficacy of any Parent Product or a failure to conduct such clinical trial in compliance with applicable Health Care Laws.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="color:#231f20;">All manufacturing operations conducted by or, to the knowledge of Parent, for the benefit of Parent have been and are being conducted in material compliance with all Permits under applicable Health Care Laws, all applicable provisions of the FDA&#8217;s current good manufacturing practice (cGMP) regulations at 21 C.F.R. Parts 210-211 and Parts 600 and 610 and FDA&#8217;s Quality System (QS) regulations at 21 C.F.R. Part&#160;820, and all comparable foreign regulatory requirements of any Governmental Entity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span><span style="color:#231f20;">Parent has not received any written communication that relates to an alleged violation or </span>non-compliance with any Health Care Laws, including any notification of any pending or threatened claim, suit, proceeding, hearing, enforcement, investigation, arbitration, import detention or refusal, FDA Warning Letter or Untitled Letter, or any action by a Governmental Entity relating to any Health Care Laws. All Warning Letters, Form-483 observations, or comparable findings from other Governmental Entities listed in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.11(f)</span>&#160;of the Parent Disclosure Letter have been resolved to the satisfaction of the applicable Governmental Entity.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span><span style="color:#231f20;">There have been no seizures, withdrawals, recalls, detentions, or suspensions of manufacturing, testing, or distribution relating to the Parent Products required or requested by a Governmental Entity, or other Safety Notices. All Safety Notices listed in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.11(g)</span><span style="color:#231f20;">&#160;of the Parent Disclosure Letter have been resolved to the satisfaction of the applicable Governmental Entity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span><span style="color:#231f20;">Except as set forth in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.11(h)</span><span style="color:#231f20;">&#160;of the Parent Disclosure Letter, there are no unresolved Safety Notices, and to the knowledge Parent, there are no facts or circumstances that would be reasonably likely to result in a Safety Notice with respect to the Parent Products or a termination or suspension of developing and testing of any of the Parent Products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="color:#231f20;">Neither Parent, nor, to the knowledge of Parent, any officer, employee, agent, or distributor of Parent has made an untrue statement of a material fact or fraudulent or misleading statement to a Governmental Entity, failed to disclose a material fact required to be disclosed to a Governmental Entity, or committed an act, made a statement, or failed to make a statement that would reasonably be expected to provide a basis for the FDA to invoke its FDA Ethics Policy. None of the aforementioned is or has been under investigation resulting from any allegedly untrue, fraudulent, misleading, or false statement or omission, including data fraud, or had any action pending or threatened relating to the FDA Ethics Policy.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span><span style="color:#231f20;">All reports, documents, claims, Permits and notices required to be filed, maintained or furnished to the FDA or any Governmental Entity by Parent have been so filed, maintained or furnished, except where failure to file, maintain or furnish such reports, documents, claims, Permits or notices have not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. All such reports, documents, claims, Permits and notices were true and complete in all material respects on the date filed (or were corrected in or supplemented by a subsequent filing).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(k)</span></span><span style="color:#231f20;">Neither Parent nor, to the knowledge of Parent, any officer, employee, agent, or distributor of Parent has committed any act, made any statement or failed to make any statement that violates the Federal Anti-Kickback Statute, 28 U.S.C. &#167; 1320a-7b, the Federal False Claims Act, 31 U.S.C. &#167; 3729, other Health Care Laws, or any other similar federal, state, or ex-U.S. law applicable in the jurisdictions in which the Parent Products are sold or intended to be sold.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(l)</span></span><span style="color:#231f20;">Neither Parent nor, to the knowledge of Parent, any officer, employee, agent, or distributor of Parent has been convicted of any crime or engaged in any conduct that has resulted, or would reasonably be expected to result, in debarment under applicable Law, including, without limitation, 21 U.S.C. &#167; 335a, or exclusion under 42 U.S.C. &#167; 1320a-7, or any other statutory provision or similar law applicable in other jurisdictions in which the Parent Products are sold or intended to be sold. Neither Parent nor, to the knowledge of Parent, any officer, employee, agent or distributor of Parent, has been excluded from participation in </span>any federal health care program or convicted of any crime or engaged in any conduct for which such Person could be excluded from participating in any federal health care program under Section&#160;1128 of the Social Security Act of 1935, as amended, or any similar Health Care Law or program.</p><a id="Section512"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.12</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Benefit Plans</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.12(a)</span><span style="color:#231f20;">&#160;of the Parent Disclosure Letter contains a true, correct, and complete list of each material Parent Plan.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">Parent has provided or made available to the Company a current, accurate and complete copy of each material Parent Plan, or if such Parent Plan is not in written form, a written summary of all of the material terms of such Parent Plan. With respect to each Parent Plan, Parent has furnished or made available to the Company a current, accurate and complete copy of, to the extent applicable: (i)&#160;all documents embodying or governing such Parent Plan and any related trust agreement or other funding instrument, (ii) the most recent determination letter of the IRS, (iii)&#160;any summary plan description, summary of material modifications, and other similar material written communications (or a written description of any material oral communications) to the employees of Parent or any of its Subsidiaries concerning the extent of the benefits provided under a Parent Plan, (iv)&#160;all non-routine correspondence to and from any governmental agency, and (v)&#160;for the three most recent&#160;years and as applicable (A)&#160;the Form&#160;5500 and attached schedules, (B)&#160;audited financial statements, (C)&#160;nondiscrimination testing results and (D)&#160;actuarial valuation reports.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">Neither Parent, its Subsidiaries or any member of their Controlled Group has ever sponsored, maintained, contributed to, or been required to contribute to or incurred any liability (contingent or otherwise) with respect to: (i)&#160;a Multiemployer Plan, (ii)&#160;an &#8220;employee pension benefit plan&#8221; (within the meaning of Section&#160;3(2)&#160;of ERISA) that is subject to Title IV of ERISA or Section&#160;412 of the Code or Section&#160;302 of ERISA, (iii)&#160;any &#8220;multiple employer plan&#8221; as defined in Section&#160;413 of the Code or Section&#160;210 of ERISA, </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(iv)&#160;a &#8220;funded welfare benefit plan&#8221; within the meaning of Section&#160;419 of the Code or (v)&#160;any &#8220;multiple employer welfare arrangement&#8221; (as such term is defined in Section&#160;3(40) of ERISA).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">With respect to the Parent Plans:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="color:#231f20;">each Parent Plan is and has been established, operated and administered in all material respects with its terms and materially complies in form and in operation with the applicable provisions of ERISA and the Code and all other applicable legal requirements;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span><span style="color:#231f20;"> no Parent Plan is, or within the past six&#160;years has been, the subject of an application or filing under a government sponsored amnesty, voluntary compliance, or similar program, or been the subject of any self-correction under any such program;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span><span style="color:#231f20;"> each Parent Plan intended to be qualified under Section&#160;401(a)&#160;of the Code has received a favorable determination, advisory and/or opinion letter, as applicable, from the IRS that it is so qualified and nothing has occurred to the knowledge of Parent since the date of such letter that would reasonably be expected to cause the loss of the sponsor&#8217;s ability to rely upon such letter, and nothing has occurred to the knowledge of Parent that would reasonably be expected to result in the loss of the qualified status of such Parent Plan;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</span></span><span style="color:#231f20;"> there is no material Action (including any investigation, audit or other administrative proceeding) by the Department of Labor, the PBGC, the IRS or any other Governmental Entity or by any plan participant or beneficiary pending, or to the knowledge of Parent, threatened, relating to the Parent Plans, any fiduciaries thereof with respect to their duties to Parent Plans or the assets of any </span>of the trusts under any of Parent Plans (other than routine claims for benefits);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</span></span><span style="color:#231f20;"> none of the Parent Plans currently provides, or reflects or represents any liability to provide post-termination or retiree welfare benefits to any person for any reason, except as may be required by COBRA, and neither Parent nor any members of its Controlled Group has any liability to provide post- termination or retiree welfare benefits to any person or ever represented, promised or contracted to </span>any employee or former employee of Parent (either individually or to Parent employees as a group) or any other person that such employee(s)&#160;or other person would be provided with post-termination or retiree welfare benefits, except to the extent required by statute or except with respect to a contractual obligation to reimburse any premiums such person may pay in order to obtain health coverage under COBRA;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vi)</span></span><span style="color:#231f20;">all payments and/or contributions required to have been timely made with respect to all Parent Plans either have been made or have been accrued in accordance with the terms of the applicable Parent Plan and applicable law;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vii)</span></span><span style="color:#231f20;">each Parent Plan is subject exclusively to United States Law; and</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(viii)</span></span><span style="color:#231f20;">the execution and delivery of this Agreement, the Parent Stockholder Approval, and the consummation of the Merger will not, either alone or in combination with any other event, (A)&#160;entitle any current or former employee, officer, director or consultant of Parent or any of its Subsidiaries to severance pay, unemployment compensation or any other similar termination payment, or (B)&#160;accelerate </span>the time of payment or vesting, or increase the amount of or otherwise enhance any benefit due any such employee, officer, director or consultant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="color:#231f20;">Neither Parent nor any of its Subsidiaries is a party to any agreement, contract, arrangement or plan (including any Parent Plan) that may reasonably be expected to result, separately or in the aggregate, in connection with the Contemplated Transactions (either alone or in combination with any other events), in the payment of any &#8220;parachute payments&#8221; within the meaning of Section&#160;280G of the Code. There is no agreement, plan or other arrangement to which Parent or any of its Subsidiaries is a party or by which Parent or any of its Subsidiaries is otherwise bound to compensate any person in respect of Taxes or other liabilities incurred with respect to Section&#160;409A or 4999 of the Code.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span><span style="color:#231f20;">Each Parent Plan that is a &#8220;nonqualified deferred compensation plan&#8221; within the meaning of Section&#160;409A of the Code (or any comparable or similar provision of state, local, or foreign Law) complies in both form and operation in all material respects with the requirements of Section&#160;409A of the Code (or any comparable or similar provision of state, local, or foreign Law) and all applicable IRS guidance issued with respect thereto (and has so complied for the entire period during which Section&#160;409A of the Code </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">has applied to such Parent Plan) so that no amount paid or payable pursuant to any such Parent Plan is subject to any additional Tax or interest under Section&#160;409A of the Code (or any comparable or similar provision of state, local, or foreign Law).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span><span style="color:#231f20;">No Parent Plan provides major medical health or long-term disability benefits that are not fully insured through an insurance contract.</span></p><a id="Section513"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.13</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Labor and Employment Matters</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">Parent and each of its Subsidiaries are and, since January&#160;1, 2021, have been in compliance in all material respects with all applicable Laws relating to labor or employment matters, including those relating to employment practices, terms and conditions of employment, collective bargaining, disability, immigration, health and safety, wages, hours and benefits, non-discrimination in employment, workers&#8217; compensation, the collection and payment of withholding and/or payroll Taxes and similar Taxes, unemployment compensation, equal employment opportunity, discrimination, harassment, employee and contractor classification, restrictive covenants, pay equity, information privacy and security, and continuation coverage with respect to group health plans. Since January&#160;1, 2021, there has not been, and as of the date of this Agreement there is not pending or, to the knowledge of Parent, threatened, any labor dispute, work stoppage, labor strike or lockout against Parent or any of its Subsidiaries by employees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">No employee of Parent or any of its Subsidiaries is, or since January&#160;1, 2021 has been, covered by an effective or pending collective bargaining agreement or similar labor agreement. To the knowledge of Parent, there has not been any activity on behalf of any labor union, labor organization or similar employee group to organize any employees of Parent or any of its Subsidiaries. There are no and since January&#160;1, 2021 there has not been any: (i)&#160;unfair labor practice charges or complaints against Parent or any of its Subsidiaries pending before the National Labor Relations Board or any other labor relations tribunal or authority and to the knowledge of Parent no such representations, claims or petitions are threatened, (ii) representations, claims or petitions pending before the National Labor Relations Board or any other labor relations tribunal or authority or (iii)&#160;grievances or pending arbitration proceedings against Parent or any of its Subsidiaries that arose out of or under any collective bargaining agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">To the knowledge of Parent, no current officer of Parent or any of its Subsidiaries intends, or is expected, to terminate such individual&#8217;s employment relationship with Parent in connection with or as a result of the Contemplated Transactions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">Since January&#160;1, 2021, (i)&#160;neither Parent nor any of its Subsidiaries has not effectuated a &#8220;plant closing&#8221; (as defined in the WARN Act) affecting any site of employment or one or more facilities or operating units within any site of employment or facility, (ii)&#160;there has not occurred a &#8220;mass layoff&#8221; (as defined in the WARN Act) in connection with Parent or any of its Subsidiaries affecting any site of employment or one or more facilities or operating units within any site of employment or facility and (iii) neither Parent nor any of its Subsidiaries has not engaged in layoffs or employment terminations sufficient in number to trigger application of any similar state, local or foreign law. Parent and its Subsidiaries properly classify and for the three (3)&#160;years immediately preceding the date hereof have properly classified </span>its and their (i)&#160;employees as exempt or non-exempt in accordance with applicable overtime laws, (ii) <span style="color:#231f20;">contingent workers in accordance with applicable law and (iii)&#160;workers as employees or non-employees (e.g., consultants, independent contractors), in accordance with applicable law.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="color:#231f20;">Except as set forth on </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.13(e)</span><span style="color:#231f20;">&#160;of the Parent Disclosure Letter, with respect to any current or former employee, officer, consultant or other service provider of Parent, there are no Actions against Parent or any of its Subsidiaries pending, or to the knowledge of Parent, threatened to be brought or filed, in connection with the employment or engagement of any current or former employee, officer, consultant or other service provider of Parent, including, without limitation, any claim relating to employment discrimination, harassment, retaliation, equal pay, employment classification, contractor classification, wages, hours, and benefits or any other employment related matter arising under applicable Laws, except where such action would not, individually or in the aggregate, result in Parent incurring a material liability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span><span style="color:#231f20;">Except as set forth on </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.13(f)</span><span style="color:#231f20;">&#160;of the Parent Disclosure Letter or with respect to any Parent Plan (which subject is addressed in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.12</span><span style="color:#231f20;"> above), the execution of this Agreement and the consummation of the transactions set forth in or contemplated by this Agreement will not result in any breach or violation of, or cause any payment to be made under, any applicable Laws respecting labor and employment or any collective bargaining agreement to which Parent or any of its Subsidiaries is a party.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span><span style="color:#231f20;">Since January&#160;1, 2021, (i)&#160;no allegations of harassment or discrimination (with respect to any category protected by applicable law, including, without limitation, sexual harassment), retaliation on the basis of protected activity (including as a whistleblower) or protected class status in accordance with applicable law, or other misconduct relating to the workplace have been </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">made, initiated, filed or, to the knowledge of Parent, threatened against or involving Parent or any of its Subsidiaries or any of their respective current or former directors, officers or senior level management employees, (ii)&#160;to the knowledge of Parent, no incidents of any such workplace harassment, discrimination, retaliation, or other misconduct have occurred, and (iii)&#160;Parent has not entered into any settlement agreement related to allegations of such harassment, discrimination, retaliation or other workplace-related misconduct by any of their directors, officers or employees described in clause (i)&#160;hereof or any independent contractor.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span><span style="color:#231f20;">No employee or other worker of Parent is subject to any service relationship that is not &#8220;at-will&#8221; or that is terminable on more than 30&#160;days&#8217; notice.</span></p><a id="Section514"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.14</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Environmental Matters</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect, (i)&#160;Parent and its Subsidiaries have conducted its businesses in compliance with all, and have not violated any, applicable Environmental Laws; (ii)&#160;Parent and its Subsidiaries have obtained all Permits of all Governmental Entities and any other Person that are required under any Environmental Law; (iii)&#160;there has been no release of any Hazardous Substance by Parent or any of its Subsidiaries or any other Person in any manner that has given or would reasonably be expected to give rise to any remedial or investigative obligation, corrective action requirement or liability of Parent or any of its Subsidiaries under applicable Environmental Laws; (iv)&#160;Parent and its Subsidiaries have not received any claims, notices, demand letters or requests for information (except for such claims, notices, demand letters or requests for information the subject matter of which has been resolved prior to the date of this Agreement) from any federal, state, local, foreign or provincial Governmental Entity or any other Person asserting </span>that Parent or any of its Subsidiaries is in violation of, or liable under, any Environmental Law; (v)&#160;no Hazardous Substance has been disposed of, arranged to be disposed of, released or transported in violation of any applicable Environmental Law, or in a manner that has given rise to, or that would reasonably be expected to give rise to, any liability under any Environmental Law, in each case, on, at, under or from any current or former properties or facilities owned or operated by Parent or any of its Subsidiaries or as a result of any operations or activities of Parent or any of its Subsidiaries at any location and, to the knowledge of Parent, Hazardous Substances are not otherwise present at or about any such properties or facilities in amount or condition that has resulted in or would reasonably be expected to result in liability to Parent or any of its Subsidiaries under any Environmental Law; and (vi)&#160;neither Parent or any of its Subsidiaries nor any of their properties or facilities are subject to, or are threatened to become subject to, any liabilities relating to any suit, settlement, court order, administrative order, regulatory requirement, judgment or claim asserted or arising under any Environmental Law or any agreement relating to environmental liabilities.</p><a id="Section515"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.15</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Taxes</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">Parent and its Subsidiaries have (i)&#160;filed all income and other material Tax Returns required to be filed by or on behalf of it (taking into account any applicable extensions thereof) and all such Tax Returns are true, accurate and complete in all material respects; and (ii)&#160;paid in full (or caused to be timely paid in full) all material Taxes that are required to be paid by or with respect to it, whether or not such Taxes were shown as due on such Tax Returns.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">All material Taxes not yet due and payable by Parent as of the date of the balance sheet included in the financial statements (including the related notes and schedules thereto) included (or incorporated by reference) in the Parent SEC Documents have been, in all respects, properly accrued in accordance with GAAP on the financial statements (including the related notes and schedules thereto) included (or incorporated by reference) in the Parent SEC Documents, and such financial statements (including the related notes and schedules thereto) included (or incorporated by reference) in the Parent SEC Documents reflect an adequate reserve (in accordance with GAAP) for all material Taxes accrued but unpaid by Parent through the date of such financial statements. Since the date of financial statements (including the related notes and schedules thereto) included (or incorporated by reference) in the Parent SEC Documents, neither Parent nor any of its Subsidiaries has incurred, individually or in the aggregate, any liability for Taxes outside the ordinary course of business consistent with past practice.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">Neither Parent nor any of its Subsidiaries has executed any waiver of any statute of limitations on, or extended the period for the assessment or collection of, any amount of Tax, in each case that has not since expired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">No material Tax Action with respect to Taxes or any Tax Return of Parent or any of its Subsidiaries are presently in progress or have been asserted, threatened or proposed in writing and to the knowledge of Parent, no such Tax Action is being contemplated. No deficiencies or claims for a material amount of Taxes have been claimed, proposed, assessed or asserted in writing against Parent </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">or any of its Subsidiaries by a Governmental Entity, other than any such claim, proposal, assessment or assertion that has been satisfied by payment in full, settled or withdrawn.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="color:#231f20;">Subject to exceptions as would not be material, Parent and its Subsidiaries have timely withheld all Taxes required to have been withheld from payments made (or deemed made) to its employees, independent contractors, creditors, shareholders and other third parties and, to the extent required, such Taxes have been timely paid to the relevant Governmental Entity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span><span style="color:#231f20;">Neither Parent nor any of its Subsidiaries has engaged in a &#8220;listed transaction&#8221; as set forth in Treasury Regulations &#167; 1.6011-4(b)(2).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span><span style="color:#231f20;">Neither Parent nor any of its Subsidiaries (i)&#160;is a party to or bound by, or has any liability pursuant to, any Tax sharing, allocation, indemnification or similar agreement or obligation other than any Ordinary Course Agreement; (ii)&#160;is or has been a member of a group (other than a group the common parent of which is Parent) filing a consolidated, combined, affiliated, unitary or similar income Tax Return; (iii) has liability for the Taxes of any Person (other than Parent or its Subsidiaries) pursuant to Treasury Regulations &#167; 1.1502-6 (or any similar provision of state, local or non-United States Law) as a transferee or successor, by Contract, or otherwise by operation of Law; or (iv)&#160;is or has been treated as a resident for any income Tax purpose, or as subject to Tax by virtue of having a permanent establishment, an office or fixed place of business, in any country other than the country in which it was or is organized.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span><span style="color:#231f20;">No private letter rulings, technical advice memoranda, or similar material agreements or rulings have been requested, entered into or issued by any Governmental Entity with respect to Parent or any of its Subsidiaries which rulings remain in effect.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="color:#231f20;">Neither Parent nor any of its Subsidiaries will be required to include any item of income in, or exclude any item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of (i)&#160;a change in, or use of improper, method of accounting requested or initiated on or prior to the Closing Date, (ii)&#160;a &#8220;closing agreement&#8221; as described in Section&#160;7121 of the Code (or any similar provision of Law) executed on or prior to the Closing Date, (iii)&#160;an installment sale or open transaction disposition made on or prior to the Closing Date, (iv)&#160;any prepaid amount received or deferred </span>revenue accrued on or prior to the Closing Date, other than in respect of such amounts received in the ordinary course of business, or (v)&#160;to the knowledge of Parent, an intercompany transaction or excess loss amount described in Treasury Regulations under Section&#160;1502 of the Code (or any corresponding or similar provision of state, local or foreign income Tax Law).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span><span style="color:#231f20;">There are no liens for Taxes upon any of the assets of Parent or any of its Subsidiaries other than Liens described in clause (i)&#160;of the definition of Permitted Liens.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(k)</span></span><span style="color:#231f20;">Neither Parent nor any of its Subsidiaries has distributed stock of another Person or has had its stock distributed by another Person, in a transaction (or series of transactions) that was purported or intended to be governed in whole or in part by Sections 355 or 361 of the Code.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(l)</span></span><span style="color:#231f20;">Neither Parent nor any of its Subsidiaries has been a United States real property holding corporation, as defined in Section&#160;897(c)(2)&#160;of the Code during the applicable period specified in Section&#160;897(c)(1)(A)(ii)&#160;of the Code.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(m)</span></span><span style="color:#231f20;">No material claim has been made in writing by any Governmental Entity in a jurisdiction where Parent or any of its Subsidiaries does not currently file a Tax Return of a certain type or pay Taxes of a certain type that Parent is or may be subject to taxation by such jurisdiction of such type.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(n)</span></span><span style="color:#231f20;">There are no outstanding shares of Parent stock issued in connection with the performance of services (within the meaning of Section&#160;83 of the Code) that immediately prior to the First Effective Time are subject to a substantial risk of forfeiture (as such terms are defined in Section&#160;83 of the Code) for which a valid election under Section&#160;83(b)&#160;of the Code has not been made.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(o)</span></span><span style="color:#231f20;">To the knowledge of Parent, neither Parent nor any of its Subsidiaries has been, is, or immediately prior to the First Effective Time will be, treated as an &#8220;investment company&#8221; within the meaning of </span>Section&#160;368(a)(2)(F)&#160;of the Code.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(p)</span></span><span style="color:#231f20;">Neither Parent nor any of its Subsidiaries has taken, or failed to take, any action nor knows of any fact or circumstance that, in each case, could reasonably be expected to prevent or impede the Merger from qualifying as a transaction qualifying for the Intended Tax Treatment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.15</span>, where the context permits, each reference to Parent shall include a reference to any person for whose Taxes Parent is liable under applicable law.</p><a id="Section516"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.16</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contracts</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">Except for any Parent Plans (which are the subject of </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.12</span><span style="color:#231f20;">) and except as set forth in the Parent SEC Documents publicly available prior to the date of this Agreement, Parent is not a party to or bound by any &#8220;material contract&#8221; (as such term is defined in Item&#160;601(b)(10)&#160;of Regulation S-K under the Securities Act) (all such contracts including those set forth in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.16(b)</span><span style="color:#231f20;">&#160;of the Parent Disclosure Letter, &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Material Contracts</span><span style="color:#231f20;">&#8221;).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">(b)</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"><span style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:6.34pt;">&#8203; &#8203;<span style="display:inline-block;height:0pt;width:100%;"></span></span>Section&#160;5.16(b)</span><span style="color:#231f20;">&#160;of the Parent Disclosure Letter lists the following contracts, which for the purposes of this Agreement shall be considered Parent Material Contracts:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="color:#231f20;">each Contract relating to any agreement of indemnification or guaranty not entered into in the ordinary course of business;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span><span style="color:#231f20;">each Contract containing (A)&#160;any covenant prohibiting Parent, its Subsidiaries or the Surviving Entity from engaging in any line of business or competing with any Person, or limiting the development, manufacture or distribution of the Surviving Entity&#8217;s products or services (B)&#160;any most- favored pricing arrangement, (C)&#160;any exclusivity provision in favor of a third party or (D)&#160;any non- solicitation provision applicable to Parent or its Subsidiaries, in the case of the foregoing clause (D)&#160;which are material to Parent or its Subsidiaries, as applicable, taken as a whole;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#c0c0c0;">(iii)</span></span><span style="color:#231f20;">each Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $100,000 pursuant to its express terms and not cancelable without penalty;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#c0c0c0;">(iv)</span></span><span style="color:#231f20;">each Contract relating to the disposition or acquisition of material assets or any ownership interest in any Person;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#c0c0c0;">(v)</span></span><span style="color:#231f20;">each Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit in excess of $100,000 or creating any material Liens with respect to any assets of the Parent or any of its Subsidiaries or any loans or debt obligations with officers or directors of the Parent;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vi)</span></span><span style="color:#231f20;">each Contract requiring payment by or to the Parent after the date of this Agreement in excess of $100,000 pursuant to its express terms relating to: (A)&#160;any Contract involving a dealer, distributor, joint marketing, alliance, joint venture, cooperation, research and/or development (including pre-clinical and clinical research and/or development), material transfer, services (including technical writing and consulting), manufacturing, supply, distribution or other agreement relating to the research, development, testing, labeling, manufacturing, marketing, commercialization, or distribution of any product, technology or service, or any Contract pursuant to which any Intellectual Property is developed by or for Parent or (B)&#160;any Contract to license any patent, trademark registration, service mark registration, trade name or copyright registration to or from any third party to research, develop, test, label, manufacture, market, or produce any product, service or technology of the Parent or any Contract to sell, distribute or commercialize any products or services of the Parent;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vii)</span></span><span style="color:#231f20;">each Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services to the Parent in connection with the Contemplated Transactions;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(viii)</span></span><span style="color:#231f20;">each Contract relating to leases of real properties with respect to which the Parent directly or indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of or leased by Parent or any of its Subsidiaries;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ix)</span></span><span style="color:#231f20;">each Contract to which the Parent is a party or by which any of its assets and properties is currently bound, which involves annual obligations of payment by, or annual payments to, the Parent in excess of $100,000; and</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(x)</span></span><span style="color:#231f20;">any other Contract that is not terminable at will (with no penalty or payment) by the Parent, and that is material to the business or operations of the Parent.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">Each Parent Material Contract is valid and binding on Parent, and to the knowledge of Parent, each other party thereto, and is in full force and effect and enforceable in accordance with its terms; (ii)&#160;Parent, and, to the knowledge of Parent, each other party thereto, has performed all material obligations required to be performed by it under each Parent Material Contract; and (iii)&#160;there is no material default under any Parent Material Contract by Parent or, to the knowledge of Parent, any other party thereto, and no event </span>or condition has occurred that constitutes, or, after notice or lapse of time or both, would constitute, a material default on the part of Parent or, to the knowledge of Parent, any other party thereto under any such Parent Material Contract, nor has Parent received any notice of any such material default, event or condition. Parent has made available to the Company true and complete copies of all Parent Material Contracts, including all amendments thereto. Except as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.16(c)</span>&#160;of the Parent Disclosure Letter, there are no Parent Material Contracts that are not in written form. No Person is renegotiating, or has a right pursuant to the terms of any Parent Material Contract to change, any material amount paid or payable to the Parent under any Parent Material Contract or any other material term or provision of any Parent Material Contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">Parent will terminate all Parent Material Contracts (including all statements of work, work orders, change orders, purchase orders, and any other Contract thereunder) effective no later than the Closing Date. As of such termination: (i)&#160;other than those Contracts identified in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.16(d)(i)</span><span style="color:#231f20;">&#160;of the Parent Disclosure Letter, no party thereto or third party beneficiary thereof has or will have any right, title, or interest (including under any license grants or by exercise of any options or technology transfer rights) </span>in or to any part of Parent Registered IP or material Company Registered IP; (ii)&#160;other than those Contracts identified in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.16(d)(ii)</span>&#160;of the Parent Disclosure Letter, no payment under any such Parent Material Contract is or will be due or payable by Parent to any party thereto or third party beneficiary thereof (including in connection with any completed work or work-in-progress; severance costs; non-cancellable expenses or commitments; early termination penalties; termination costs; wind-down costs; royalties; or milestones); (iii)&#160;other than those Contracts identified in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.16(d)(iii)</span>&#160;of the Parent Disclosure Letter, Parent is under no obligation under such Parent Material Contracts, on its own or with any other party thereto or third party beneficiary thereof, to: (A)&#160;research, develop, manufacture, or commercialize any product or service thereunder; (B)&#160;make any regulatory filing with respect thereto or seek or obtain regulatory approval therefor; or (C)&#160;fund or commit any funding or resources, make any efforts, or prepare or submit any reports (including information reports and progress reports), with respect to any of the foregoing; and (iv) <span style="color:#231f20;">other than those Contracts identified in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.16(d)(iv)</span><span style="color:#231f20;">&#160;of the Parent Disclosure Letter, no party thereto or third party beneficiary thereof has or will have any outstanding subscriptions, options, warrants, calls, commitments, Contracts or other rights under such Parent Material Contract to acquire or be issued, granted, delivered, sold, or cause to be issued, granted, delivered or sold, any shares of capital stock of the Parent or any of its Subsidiaries, voting securities, stock appreciation rights, &#8220;phantom&#8221; stock rights, performance units, interests in or rights to the ownership or earnings of the Parent or any of its Subsidiaries or other equity equivalent or equity-based awards or rights, or equity interests or securities convertible into or exchangeable or exercisable for capital stock or other voting securities or equity interests of the Parent or any of its Subsidiaries.</span></p><a id="Section517"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;5.17 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Insurance</span>. Each of Parent and its Subsidiaries is covered by valid and currently effective insurance policies issued in favor of Parent or its Subsidiaries that are customary and adequate for companies of similar size in the industries and locations in which Parent and its Subsidiaries operate. <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.17</span> of the Parent Disclosure Letter sets forth, as of the date hereof, a true and complete list of all material insurance policies issued in favor of Parent or any of its Subsidiaries, or pursuant to which Parent or any of its Subsidiaries is a named insured or otherwise a beneficiary, as well as any historic incurrence- based policies still in force. With respect to each such insurance policy, (a)&#160;such policy is in full force and effect and all premiums due thereon have been paid, (b)&#160;neither Parent nor any of its Subsidiaries is in breach or default, and has not taken any action or failed to take any action which (with or without notice or lapse of time, or both) would constitute such a breach or default, or would permit termination or modification of, any such policy and (c)&#160;to the knowledge of Parent, no insurer issuing any such policy has been declared insolvent or placed in receivership, conservatorship or liquidation. No notice of cancellation or termination has been received with respect to any such policy, nor will any such cancellation or termination result from the consummation of the Contemplated Transactions.</p><a id="Section518"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.18</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Properties</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">Parent and its Subsidiaries has good and valid title to, or in the case of leased property and leased tangible assets, a valid leasehold interest in, all of its real properties and tangible assets that are necessary for Parent and its Subsidiaries to conduct its businesses as currently conducted, free and clear of all Liens other than Permitted Liens. Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect, the tangible personal property currently used in the operation of the business of Parent and its Subsidiaries is in good working order (reasonable wear and tear excepted).</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">Each of Parent and its Subsidiaries has complied with the terms of all leases to which it is a party, and all such leases are in full force and effect, except for any such noncompliance or failure to be in full force and effect that, individually or in the aggregate, has not had and would not reasonably be expected to have </span>a Parent Material Adverse Effect. Each of Parent and its Subsidiaries enjoys peaceful and undisturbed possession under all such leases, except for any such failure to do so that, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.18(c)</span><span style="color:#231f20;">&#160;of the Parent Disclosure Letter sets forth a true and complete list of (i)&#160;all real property owned by Parent or any of its Subsidiaries and (ii)&#160;all real property leased for the benefit of Parent or any of its Subsidiaries.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">This </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.18</span><span style="color:#231f20;"> does not relate to intellectual property, which is the subject of </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.19</span><span style="color:#231f20;">.</span></p><a id="Section519"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.19</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intellectual Property</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.19(a)</span><span style="color:#231f20;">&#160;of the Parent Disclosure Letter sets forth a true and complete list of all (i)&#160;patents and patent applications; (ii)&#160;trademark registrations and applications; and (iii)&#160;material copyright registrations and applications, in each case owned or licensed by Parent and its Subsidiaries (collectively, &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Registered IP</span><span style="color:#231f20;">&#8221;) and a true and complete list of all domain names owned or exclusively licensed by Parent and its Subsidiaries. Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect (i)&#160;all of the Parent Registered IP is subsisting and, solely in the case of any Parent Registered IP that is registered or issued and to the knowledge of Parent, valid </span>and enforceable, (ii)&#160;no Parent Registered IP, is involved in any interference, reissue, derivation, reexamination, opposition, cancellation or similar proceeding and, to the knowledge of Parent, no such action is threatened with respect to any of the Parent Registered IP and (iii)&#160;Parent and its Subsidiaries own exclusively, free and clear of any and all Liens (other than Permitted Liens), all Parent Owned IP, including all Intellectual Property created on behalf of Parent or its Subsidiaries by employees or independent contractors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">Parent and its Subsidiaries have taken commercially reasonable measures to maintain the confidentiality of all information that constitutes or constituted a material Trade Secret of Parent and its Subsidiaries, including requiring all Persons having access thereto to execute written non-disclosure agreements or other binding obligations to maintain confidentiality of such information.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect, (i)&#160;to the knowledge of Parent, the conduct of the businesses of Parent and its Subsidiaries, including the manufacture, marketing, offering for sale, sale, importation, use or intended use or other disposal of any product as currently sold or under development by Parent or any of its Subsidiaries, has not infringed, misappropriated or diluted, and does not infringe, misappropriate or dilute, any Intellectual Property of any Person, (ii)&#160;neither Parent nor any of its Subsidiaries have received any written notice or claim asserting or suggesting that any such infringement, misappropriation, or dilution is or may be occurring or has or may have occurred and (iii)&#160;to the knowledge of Parent, no Person is infringing, misappropriating, or diluting in any material respect any Parent Registered IP.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect, (i)&#160;Parent and its Subsidiaries have taken commercially reasonable steps to protect the confidentiality and security of the computer and information technology systems used by Parent or any of its Subsidiaries (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent IT Systems</span><span style="color:#231f20;">&#8221;) and the information and transactions stored or contained therein or transmitted thereby, (ii)&#160;to the knowledge of Parent, during the past two (2)&#160;years, there has been no unauthorized or improper use, loss, access, transmittal, modification or corruption of any </span>such information or data, and (iii)&#160;during the past two (2)&#160;years, there have been no material failures, crashes, viruses, security breaches (including any unauthorized access to any personally identifiable information), affecting the Parent IT Systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="color:#231f20;">Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect, (i)&#160;to the knowledge of Parent, Parent and its Subsidiaries have at all times complied in all material respects with all applicable Privacy Laws, (ii)&#160;during the past two (2)&#160;years since the First Effective Time, no claims have been asserted or, to the knowledge of Parent, threatened in writing against Parent or any of its Subsidiaries alleging a violation of any Person&#8217;s privacy or Personal Information, (iii)&#160;neither this Agreement nor the consummation of the Contemplated Transactions will breach or otherwise violate any Privacy Laws and (iv)&#160;Parent and its Subsidiaries have taken commercially reasonable steps to protect the Personal Information collected, used or held for use by Parent or any of its Subsidiaries against loss and unauthorized access, use, modification or disclosure, or other misuse.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span><span style="color:#231f20;">To the knowledge of Parent, no government funding, facilities or resources of a university, college, other educational institution or research center or funding from third parties was used in the development of the Parent Owned IP or any Intellectual Property exclusively licensed to Parent or any of its Subsidiaries, and no Governmental Entity, university, college, other educational institution or research center has, to </span>the knowledge of Parent, any claim or right in or to such Intellectual Property. Except as set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.19(f)</span>&#160;of the Parent Disclosure Letter, the execution, delivery and performance by Parent of this Agreement, and the consummation of the Contemplated Transactions, will not result in the loss of, or give rise to any right of any third party to terminate or modify any of the rights or obligations of Parent or any of its Subsidiaries under any agreement under which Parent or any of its Subsidiaries grants to any Person, or any Person grants to Parent or any of its Subsidiaries, a license or right under or with respect to any Intellectual Property that is material to any of the businesses of Parent or any of its Subsidiaries.</p><a id="Section520"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.20</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Related Party Transactions</span>. Since January&#160;1, 2022 through the date of this Agreement, there have been no transactions, agreements, arrangements or understandings between Parent or any of its Subsidiaries, on the one hand, and the Affiliates of Parent or any of its Subsidiaries, on the other hand that would be required to be disclosed under Item&#160;404 of Regulation S-K under the Securities Act and that have not been so disclosed in the Parent SEC Documents.</p><a id="Section521"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.21</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certain Payments</span>. For the five (5)&#160;years immediately preceding the date hereof, neither Parent nor any of its Subsidiaries nor, to the knowledge of Parent, any of their directors, executives, representatives, agents or employees (a)&#160;has used or is using any corporate funds for any illegal contributions, gifts, entertainment or other unlawful expenses relating to political activity, (b)&#160;has used or is using any corporate funds for any direct or indirect unlawful payments to any foreign or domestic governmental officials or employees, (c)&#160;has violated or is violating any provision of the Foreign Corrupt Practices Act of 1977, as amended, (d)&#160;has established or maintained, or is maintaining, any unlawful fund of corporate monies or other properties, or (e)&#160;has made any bribe, unlawful rebate, payoff, influence payment, kickback or other unlawful payment of any nature.</p><a id="Section522"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.22</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trade Control Laws</span>. Since April&#160;24, 2019, Parent and its Subsidiaries have been in material compliance with all applicable Trade Laws and have obtained, or are otherwise qualified to rely upon, all material Trade Approvals. There are no pending or threatened claims against the Parent or its Subsidiaries, nor any actions, conditions, facts or circumstances that would reasonably be expected to give rise to any material future claims with respect to the Trade Laws or Trade Approvals.</p><a id="Section523"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.23</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Brokers</span>. No broker, investment banker, financial advisor or other Person, other than Wedbush Securities&#160;Inc. and Lucid Capital Markets, LLC, the fees and expenses of which will be paid by Parent or any of its Subsidiaries, is entitled to any broker&#8217;s, finder&#8217;s, financial advisor&#8217;s or other similar fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of Parent, any of its Subsidiaries or any of its Affiliates. Parent has furnished to Company a true and complete copy of any Contract between Parent and each of Wedbush Securities&#160;Inc. and Lucid Capital Markets, LLC pursuant to which Wedbush Securities&#160;Inc. and Lucid Capital Markets, LLC, as applicable, could be entitled to any payment from Parent relating to the Contemplated Transactions.</p><a id="Section524"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.24</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Opinion of Financial Advisor</span>. Parent Board has received the opinion of Lucid Capital Markets, LLC, dated the date of this Agreement, to the effect that, as of such date and based upon and subject to the qualifications, limitations, assumptions and other matters set forth therein, the Exchange Ratio is fair, from a financial point of view, to the stockholders of Parent, a signed true and complete copy of which opinion has been or will promptly be provided on a non-reliance basis to the Company.</p><a id="Section525"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.25</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">State Takeover Statutes</span>. No Takeover Laws or any similar anti-takeover provision in the Certificate of Incorporation or bylaws of Parent applicable to Parent is, or at the First Effective Time will be, applicable to this Agreement, the Merger, the Parent Common Stock Issuance, or any of the other Contemplated Transactions. The Parent Board and the Merger Subs board have taken and will take all actions necessary to ensure that the restrictions applicable to business combinations contained in Section&#160;203 of the DGCL are, and will be, inapplicable to the execution, delivery and performance of this Agreement, the Parent Support Agreements and to the consummation of the Contemplated Transactions or the Parent Support Agreements.</p><a id="Section526"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.26</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Other Representations or Warranties</span>. Except for the representations and warranties contained in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IV</span>, each of Parent and Merger Subs acknowledges and agrees that none of the Company or any other Person on behalf of the Company makes any other express or implied representation or warranty whatsoever, and specifically (but without limiting the generality of the foregoing) that none of the Company, its Subsidiaries, or any other Person on behalf of the Company or any of its Subsidiaries makes any representation or warranty with respect to any projections or forecasts delivered or made available to Parent, Merger Subs or any of their respective Representatives of future revenues, results of operations (or any component thereof), cash flows or financial condition (or any component thereof) of the Company (including any such projections or forecasts made available to Parent, Merger Subs or any of their respective Representatives in certain &#8220;data rooms&#8221; or management presentations in expectation of the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Contemplated Transactions), and none of Parent or Merger Subs has relied on any such information or any representation or warranty not set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IV</span>.</p><a id="ARTICLEVI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;VI</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COVENANTS</b></p><a id="Section61"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Operation of Parent&#8217;s Business</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">Except as expressly contemplated or permitted by this Agreement, as expressly required by applicable Law or unless the Company shall otherwise consent in writing (email being sufficient), during the period commencing on the date of this Agreement and continuing until the earlier to occur of the termination of this Agreement pursuant to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IX</span><span style="color:#231f20;"> and the First Effective Time (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Pre-Closing Period</span><span style="color:#231f20;">&#8221;), Parent shall, and shall cause its Subsidiaries to, use commercially reasonable efforts to (x)&#160;conduct its business and operations in the Ordinary Course and in material compliance with the applicable Law </span>and the requirements of all Contracts that constitute Parent Material Contracts and (y)&#160;continue to pay material outstanding accounts payable and other material current liabilities (including payroll) when due and payable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">Except (i)&#160;as expressly contemplated or permitted by this Agreement, (ii)&#160;as set forth in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.1(b)</span><span style="color:#231f20;">&#160;of the Parent Disclosure Letter, (iii)&#160;as required by applicable Law or (iv)&#160;with the prior </span>written consent of the Company (which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the Pre-Closing Period, Parent shall not, nor shall it cause or permit any of its Subsidiaries to, do any of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="color:#231f20;">declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock or repurchase, redeem or otherwise reacquire any shares of its capital stock or other securities (except for shares of Parent Common Stock from terminated employees, directors or consultants of Parent in accordance with agreements in effect on the date of this Agreement providing for the repurchase of shares at no more than the purchase price thereof in connection with any termination of services to Parent or any of its Subsidiaries);</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span><span style="color:#231f20;">sell, issue, grant, pledge or otherwise dispose of or encumber or authorize the issuance of: (A) any capital stock or other security (except for Parent Common Stock issued upon the valid exercise or settlement of outstanding Parent Options or Parent Restricted Stock Unit Awards as applicable), (B) any option, warrant or right to acquire any capital stock or any other security or (C)&#160;any instrument convertible into or exchangeable for any capital stock or other security;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 8pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span><span style="color:#231f20;">except as required to give effect to anything in contemplation of the Closing, amend any of its organizational documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</span></span><span style="color:#231f20;">form any Subsidiary or acquire any equity interest or other interest in any other entity or enter into a joint venture with any other entity;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</span></span><span style="color:#231f20;">(A)&#160;lend money to any Person, (B)&#160;incur or guarantee any indebtedness for borrowed money, (C) guarantee any debt securities or others or (D)&#160;make any capital expenditure or commitment;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vi)</span></span><span style="color:#231f20;">other than as expressly required by applicable Law or the terms of any Parent Plan in effect as of the date of this Agreement: (A)&#160;adopt, establish or enter into any Parent Plan, including, for the avoidance of doubt, any equity award plans, (B)&#160;cause or permit any Parent Plan to be amended other than as required by Law or in order to make amendments for the purposes of Section&#160;409A of the Code, (C)&#160;pay any bonus or make any profit-sharing or similar payment to (except with respect to obligations in place on the date of this Agreement pursuant to any Parent Plan), or increase the amount of the wages, salary, commissions, fringe benefits or other compensation or remuneration payable to, any of its employees, directors or consultants, (D)&#160;increase the severance or change of control benefits offered to any current or new employees, directors or consultants, or (E)&#160;hire or terminate (other than for </span>cause, or absent such a definition of cause, for conduct that the Parent or such Subsidiary determines in good faith constitutes material misconduct) any officer, employee or consultant;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vii)</span></span><span style="color:#231f20;">enter into any material transaction outside the Ordinary Course ;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="color:#231f20;">(viii) acquire any material asset or sell, lease, license or otherwise irrevocably dispose of any of its assets or properties, or grant any Lien with respect to such assets or properties;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ix)</span></span><span style="color:#231f20;">make, change or revoke any material Tax election; file any amended income or other material amendment to any Tax Return; settle or compromise any material Tax claim; waive or extend any statute of limitations in respect of a period within which an assessment or reassessment of material Taxes may be issued (other than any extension pursuant to an extension to file any Tax Return); enter into any &#8220;closing agreement&#8221; as described in Section&#160;7121 of the Code (or any similar Law) with any Governmental Entity; surrender any material claim for refund; or adopt or change any material accounting method in respect of Taxes;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(x)</span></span><span style="color:#231f20;">waive, settle or compromise any pending or threatened Action against Parent or any of its Subsidiaries, other than waivers, settlements or agreements (A)&#160;for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B)&#160;that do not impose any material restrictions on the operations or businesses of Parent or its Subsidiaries, taken as a whole, or any equitable relief on, or the admission of wrongdoing by Parent or any of its Subsidiaries;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xi)</span></span><span style="color:#231f20;">delay or fail to repay when due any material obligation, including accounts payable and accrued expenses;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xii)</span></span><span style="color:#231f20;">forgive any loans to any Person, including its employees, officers, directors or Affiliate;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xiii)</span></span><span style="color:#231f20;">sell, assign, transfer, license, sublicense or otherwise dispose of any Intellectual Property of the Parent (other than in the Ordinary Course);</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xiv)</span></span><span style="color:#231f20;">terminate or modify in any material respect, or fail to exercise renewal rights with respect to, any material insurance policy;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">(xv)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">enter into, amend, terminate, or waive any material option or right under, any Parent Material Contract;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xvi)</span></span><span style="color:#231f20;">enter into any agreement to purchase or sell any interest in real property, grant any security interest in any real property, enter into any lease, sublease, license or other occupancy agreement with respect to any real property or alter, amend, modify, exercise any extension or expansion right under or violate or terminate any of the terms of any real property leases of Parent;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xvii)</span></span><span style="color:#231f20;">other than as expressly required by Law or GAAP, take any action to change accounting policies or procedures;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="color:#231f20;">(xviii) (A)&#160;materially change pricing or royalties or other payments set or charged by Parent or any of Subsidiaries to its customers or licensees or (B)&#160;agree to materially change pricing or royalties or other payments set or charged by Persons who have licensed Intellectual Property to Parent or any of its Subsidiaries; or</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="color:#231f20;">(xix) agree, resolve or commit to do any of the foregoing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Nothing contained in this Agreement shall give the Company, directly or indirectly, the right to control or direct the operations of Parent prior to the First Effective Time. Prior to the First Effective Time, Parent shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">Notwithstanding any provision herein to the contrary (including the foregoing provisions of this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.1</span><span style="color:#231f20;">), Parent may engage in the sale, license, transfer, disposition, divestiture or other monetization transaction (i.e., a royalty transaction) and/or winding down of, and/or the sale, license, transfer, disposition, divestiture or other monetization transaction (i.e., a royalty transaction) or other disposition of any Parent </span>Legacy Assets (each, an &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Legacy Transaction</span>&#8221;); provided, however, that to the extent any Parent Legacy Transaction results in any obligations of or adverse consequences to Parent or its Subsidiaries that could extend beyond Closing, or contemplates that any consideration paid in respect thereof is in anything other than immediately available cash, or otherwise interferes with or delays in any manner the ability of Parent to perform its obligations under this Agreement or timely consummate the transaction contemplated hereby, Parent shall procure prior written consent of the Company prior to entering into any Parent Legacy Transaction and any such post-Closing obligations shall be treated as a reduction to Net Cash hereunder. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;">Notwithstanding anything to the contrary herein, Parent (i)&#160;shall permit the Company and its counsel to review and comment on the transaction documents related to the Parent Legacy Transaction; (ii) <span style="color:#231f20;">shall consider any such comments in good faith and shall accept all reasonable additions, deletions or changes suggested by the Company and its counsel in connection therewith; and (iii)&#160;shall not sign any agreements, contracts or other definitive documents (not including term sheets or letters of intent) related to Parent Legacy Transaction without first providing the Company and its counsel the opportunity to exercise their rights under clauses (i)&#160;and (ii)&#160;above. Any consideration actually received by Parent prior to the Closing in any such sale or license of any Parent Legacy Assets, net of all liability and obligations relating to such transaction, would be added to Net Cash.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">Notwithstanding any provision herein to the contrary (including the foregoing provisions of this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.1</span><span style="color:#231f20;">), Parent may declare the Pre-Closing Cash Dividend.</span></p><a id="Section62"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Operation of Company&#8217;s Business</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">Except (i)&#160;as expressly contemplated or permitted by this Agreement or the Securities Purchase Agreement (including actions in connection with the Concurrent Investment), (ii)&#160;as set forth in Section&#160;6.2(a)&#160;of the Company Disclosure Letter, (iii)&#160;with respect to the issuance of any Company Notes, which is expressly permitted, (iv)&#160;as expressly required by applicable Law or (v)&#160;unless Parent shall otherwise consent in writing (email being sufficient), during the Pre-Closing Period, the Company shall, and shall cause its Subsidiaries to, use commercially reasonable efforts to conduct its business and operations in the Ordinary Course and in material compliance with the applicable Law and the requirements of all Contracts that constitute Material Contracts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">Except (i)&#160;as expressly contemplated or permitted by this Agreement, including the Securities Purchase Agreement, (ii)&#160;as set forth in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.2(b)</span><span style="color:#231f20;">&#160;of the Company Disclosure Letter, (iii)&#160;with respect to the issuance of any Company Notes, which is expressly permitted, (iv)&#160;as expressly required by applicable Law or (v)&#160;with the prior written consent of Parent (which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the Pre-Closing Period, the Company shall not, nor shall it cause or permit any of its Subsidiaries to, do any of the following:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="color:#231f20;">declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock or repurchase, redeem or otherwise reacquire any shares of its capital stock or other securities (except for shares of Company Common Stock from terminated employees, directors or consultants of the Company);</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span><span style="color:#231f20;">other than in the Ordinary Course (including grants of Company Options under the Company Equity Plan), sell, issue, grant, pledge or otherwise dispose of or encumber or authorize the issuance of any of the foregoing actions with respect to more than 25% of the shares of Company Capital Stock outstanding as of the date of this Agreement: (A)&#160;any capital stock or other security (except for Company Common Stock issued upon the valid exercise or settlement of outstanding Company Options), (B)&#160;any option, warrant or right to acquire any capital stock or any other security or (C)&#160;any instrument convertible into or exchangeable for any capital stock or other security;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span><span style="color:#231f20;">except as required to give effect to anything in contemplation of the Closing, amend any of its organizational documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</span></span><span style="color:#231f20;">other than in the Ordinary Course, form any Subsidiary or acquire any equity interest or other interest in any other entity or enter into a joint venture with any other entity;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</span></span><span style="color:#231f20;">(A)&#160;lend money to any Person, (B)&#160;incur or guarantee any indebtedness for borrowed money, or (C)&#160;guarantee any debt securities;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vi)</span></span><span style="color:#231f20;">sell, lease, license or otherwise irrevocably dispose of any of its assets or properties, or grant any Lien with respect to such assets or properties, except in the Ordinary Course;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vii)</span></span><span style="color:#231f20;">waive, settle or compromise any pending or threatened Action against the Company or any of its Subsidiaries, other than waivers, settlements or agreements (A)&#160;for an amount not in excess of </span>$100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B)&#160;that do not impose any material restrictions on the operations </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 18pt;">or businesses of the Company or its Subsidiaries, taken as a whole, or any equitable relief on, or the admission of wrongdoing by the Company or any of its Subsidiaries;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(viii) </span></span><span style="color:#231f20;">delay or fail to repay when due any material obligation, including accounts payable and accrued expenses, other than in the Ordinary Course;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ix)</span></span><span style="color:#231f20;">sell, assign, transfer, license, sublicense or otherwise dispose of any material Intellectual Property of the Company (other than in the Ordinary Couse); or</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(x)</span></span><span style="color:#231f20;">agree, resolve or commit to do any of the foregoing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Nothing contained in this Agreement shall give Parent, directly or indirectly, the right to control or direct the operations of the Company prior to the First Effective Time. Prior to the First Effective Time, the Company shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations.</p><a id="Section63"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Access and Investigation</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">Subject to the terms of the Confidentiality Agreement, which the parties agree will continue in full force following the date of this Agreement, during the Pre-Closing Period, upon reasonable advance written notice, Parent, on the one hand, and the Company, on the other hand, shall and shall use commercially reasonable efforts to cause such party&#8217;s Representatives to: (a)&#160;provide the other party and such other party&#8217;s Representatives with reasonable access during normal business hours to such party&#8217;s Representatives, personnel, property and assets and to all existing books, records, Tax Returns, work papers and other documents and information relating to such party and its Subsidiaries, (b)&#160;provide the other party and such other party&#8217;s Representatives with such copies of the existing books, records, Tax Returns, work papers, product data and other documents and information relating to such party and its Subsidiaries, and with such additional financial, operating and other data and information regarding such party and its Subsidiaries as the other party may reasonably request, (c)&#160;permit the other party&#8217;s officers and other employees to meet, upon reasonable notice and during normal business hours, with the chief financial officer and other </span>officers and managers of such party responsible for such party&#8217;s financial statements and the internal controls of such party to discuss such matters as the other party may deem necessary and (d)&#160;make available to the other party copies of any material notice, report or other document filed with or sent to or received from any Governmental Entity in connection with the Contemplated Transactions. Any investigation conducted by either Parent or the Company pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.3(a)</span>&#160;shall be conducted in such manner as not to interfere unreasonably with the conduct of the business of the other party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">Notwithstanding anything herein to the contrary in this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.3(b)</span><span style="color:#231f20;">, no access or examination contemplated by this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.3(b)</span><span style="color:#231f20;">&#160;shall be permitted to the extent that it would require any party or its Subsidiaries (i)&#160;to waive the attorney-client privilege or attorney work product privilege, (ii)&#160;violate any applicable Law or (iii)&#160;breach such party&#8217;s confidentiality obligations to a third party; provided, that such party or its Subsidiary (A)&#160;shall be entitled to withhold only such information that may not be provided without causing such violation or waiver, (B)&#160;shall provide to the other party all related information that may be provided without causing such violation or waiver (including, to the extent permitted, redacted versions of any such information), (C)&#160;shall enter into such effective and appropriate joint-defense agreements or other protective arrangements as may be reasonably requested by the other party in order that all such information may be provide to the other party without causing such violation or waiver, and (D)&#160;in the case of subsection (iii)&#160;above, upon the other party&#8217;s reasonable request, such party shall use its reasonable efforts to obtain such third party&#8217;s consent to permit such other party access to such information, subject to </span>appropriate confidentiality protections. In addition, no access or examination contemplated by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.3</span> shall be permitted to the extent that it would require any party or its Subsidiaries, except as otherwise expressly required by this Agreement, to provide information to the other party that relates to (1) <span style="color:#231f20;">the negotiation of this Agreement, or (2)&#160;the valuation of the other party in connection with this Agreement or the Contemplated Transactions.</span></p><a id="Section64"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Solicitation</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">Each of Parent and the Company agrees that, during the Pre-Closing Period, neither it nor any of its Subsidiaries shall, nor shall it or any of its Subsidiaries authorize any of its Representatives to, directly or indirectly: (i)&#160;solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry, (ii)&#160;furnish any </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">nonpublic information regarding such party to any Person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry, (iii)&#160;engage in discussions or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry, (iv)&#160;approve, endorse or recommend any Acquisition Proposal (subject to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.2</span><span style="color:#231f20;"> and </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.3</span><span style="color:#231f20;">), (v)&#160;execute or enter into any letter of intent or any Contract contemplating or otherwise relating to any Acquisition Transaction, (vi)&#160;take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry or (vii)&#160;publicly propose to do any of the following; provided, however, that, notwithstanding anything contained in this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.4</span><span style="color:#231f20;"> and subject to compliance with this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.4</span><span style="color:#231f20;">, prior to obtaining the Parent Stockholder Approval, </span>Parent may furnish nonpublic information regarding Parent and its Subsidiaries to, and enter into discussions or negotiations with, any Person in response to a bona fide written Acquisition Proposal by such Person which the Parent Board determines in good faith, after consultation with its financial advisors and outside legal counsel, constitutes, or is reasonably likely to result in, a Superior Offer (and is not withdrawn) if: (A) <span style="color:#231f20;">such Acquisition Proposal was not obtained or made as a direct or indirect result of any breach of this Agreement, (B)&#160;the Parent Board concludes in good faith, after consulting with outside counsel, that </span>the failure to take such action would reasonably be expected to constitute a violation of the Parent Board&#8217;s fiduciary duties under applicable Law, (C)&#160;at least two (2)&#160;Business Days prior to initially furnishing any such nonpublic information to, or enter into discussions with, such Person, (D)&#160;Parent receives from such Person an executed Acceptable Confidentiality Agreement and (E)&#160;at least two (2)&#160;Business Days prior to furnishing any such nonpublic information to such Person, Parent furnishes such nonpublic information to the Company (to the extent such information has not been previously furnished by Parent to the Company). Without limiting the generality of the foregoing, each party acknowledges and agrees that, in the event any Representative of such party takes any action that, if taken by such party, would constitute a breach of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.4</span> by such party, the taking of such action by such Representative shall be deemed to constitute a breach of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.4</span> by such party for purposes of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">If any party or any Representative of such party receives an Acquisition Proposal or Acquisition Inquiry at any time during the Pre-Closing Period, then such party shall promptly (and in no event later than one (1)&#160;Business Day after such party becomes aware of such Acquisition Proposal or Acquisition Inquiry (including the identity of the Person making or submitting such Acquisition Proposal or Acquisition Inquiry, and the terms thereof). Such party shall keep the other party reasonably informed with respect to the status and terms of any such Acquisition Proposal or Acquisition Inquiry and any material modification or material proposed modification thereto.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">Each party shall immediately cease and cause to be terminated any existing discussions, negotiations and communications with any Person that relate to any Acquisition Proposal or Acquisition Inquiry as of the date of this Agreement and request the destruction or return of any nonpublic information provided to such Person.</span></p><a id="Section65"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notification of Certain Matters</span>. During the Pre-Closing Period, each of the Company, on the one hand, and Parent, on the other hand, shall promptly notify the other (and, if in writing, furnish copies of) if any of the following occurs: (a)&#160;any notice or other communication is received from any Person alleging that the consent of such Person is or may be required in connection with any of the Contemplated Transactions, (b)&#160;any Action against or involving or otherwise affecting such party or its Subsidiaries is commenced, or, to the knowledge of such party, threatened against such party or, to the knowledge of such party, any director, officer or employee of such party, (c)&#160;such party becomes aware of any inaccuracy in any representation or warranty made by such party in this Agreement or (d)&#160;the failure of such party to comply with any covenant or obligation of such party; in each case that could reasonably be expected to make the timely satisfaction of any of the conditions set forth in Article&#160;VII or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VIII</span>, as applicable, impossible or materially less likely. No such notice shall be deemed to supplement or amend the Company Disclosure Letter or the Parent Disclosure Letter for the purpose of (x)&#160;determining the accuracy of any of the representations and warranties made by the Company or Parent in this Agreement or (y)&#160;determining whether any condition set forth in Article&#160;VII or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VIII</span> has been satisfied. Any failure by either party to provide notice pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.5</span> shall not be deemed to be a breach for purposes of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.2(b)</span>&#160;and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.3(b)</span>, as applicable, unless such failure to provide such notice was knowing and intentional.</p><a id="Section66"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Options</span>. Prior to the Closing Date, the Parent Board shall have adopted appropriate resolutions and taken all other actions necessary and appropriate to provide that (a)&#160;each outstanding Parent OTM Option will be cancelled for no consideration and (b)&#160;the vesting and exercisability of each unexpired, unexercised and unvested Parent ITM Option shall be accelerated in full, in each case, effective as of immediately prior to the First Effective Time, contingent on the occurrence of the Closing Date. At the First Effective Time, each Parent ITM Option that is then outstanding shall be canceled and the holder thereof shall be entitled to receive (i)&#160;an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (A)&#160;the excess of the Parent Closing Price over the exercise price per share of the Parent Common Stock underlying such Parent Option by (B)&#160;the number of shares of the Parent Common Stock underlying such Parent Option (such amount, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Stock Option Cash Consideration</span>&#8221;). Parent shall cause the Surviving Entity to pay the Parent Stock Option Cash Consideration, less applicable withholdings, at or within ten (10)&#160;business&#160;days after the First Effective Time.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Section67"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Restricted Stock Unit Awards</span>. Prior to the Closing Date, the Parent Board shall have adopted appropriate resolutions and taken all other actions necessary and appropriate to provide that (a) <span style="color:#231f20;">the vesting of each outstanding and unvested Parent Restricted Stock Unit Award shall be accelerated in full effective as of immediately prior to the First Effective Time, contingent on the occurrence of the Closing and (b)&#160;for each outstanding and unsettled Parent Restricted Stock Unit Award, the holder thereof shall receive, immediately prior to the First Effective Time, a number of shares of Parent Common Stock equal to the number of vested and unsettled shares of Parent Common Stock underlying such Parent Restricted Stock Unit Award. Notwithstanding anything herein to the contrary, the Tax withholding obligations for each holder receiving shares of Parent Common Stock in accordance with the preceding sentence shall be satisfied by Parent withholding from issuance that number of shares of Parent Common Stock calculated by multiplying the maximum statutory withholding rate for such holder in connection with such issuance by the number of shares of Parent Common Stock to be issued in accordance with the preceding sentence, and rounding up to the nearest whole share and remitting such withholding in cash to the appropriate taxing authorities.</span></p><a id="Section68"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent ESPP</span>. As soon as reasonably practicable following the date of this Agreement, the Parent Board shall adopt appropriate resolutions to provide that (a)&#160;no offering periods or purchase periods shall be commenced following or in addition to the offering period underway as of the date hereof under the Parent ESPP (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Current Offering Period</span>&#8221;), (b)&#160;no payroll deductions or other contributions shall be made or effected after the Current Offering Period with respect to the Parent ESPP after the date of such resolutions, and (c)&#160;the Current Offering Period shall be terminated and each Parent ESPP participant&#8217;s accumulated contributions under the Parent ESPP shall be returned to the participant in accordance with the terms of the Parent ESPP.</p><a id="Section69"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6.9</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent 401(K)&#160;Plan</span>. Unless otherwise requested by the Company in writing at least ten <span style="color:#231f20;">(10)&#160;Business Days prior to the Closing Date, the Parent Board or an authorized committee thereof shall take (or cause to be taken) all actions to adopt such resolutions as may be necessary or appropriate to terminate, effective no later than the day prior to the Closing Date but subject to the Closing, any Parent Plan that contains a cash or deferred arrangement intended to qualify under Section&#160;401(k)&#160;of the Code (a &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent 401(k)&#160;Plan</span><span style="color:#231f20;">&#8221;). If Parent is required to terminate any Parent 401(k)&#160;Plan, then Parent shall provide to the Company prior to the Closing Date written evidence of the adoption by the Parent Board or an authorized committee thereof of resolutions authorizing the termination of such Parent 401(k)&#160;Plan (the form and substance of which shall be subject to the reasonable prior review and approval of the Company, not to be unreasonably withheld, conditioned or delayed).</span></p><a id="ARTICLEVII"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;VII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ADDITIONAL AGREEMENTS</b></p><a id="Section71"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Registration Statement; Proxy Statement</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">As promptly as practicable (but in any event, no later than seven (7)&#160;Business Days after the date of this Agreement), (i)&#160;Parent shall prepare, and file with the SEC a proxy statement relating to the Parent Stockholders Meeting to be held in connection with the Merger (together with any amendments thereof or supplements thereto, the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Proxy Statement</span><span style="color:#231f20;">&#8221;) and (ii)&#160;Parent, in cooperation with the Company, shall prepare and file with the SEC a registration statement on Form&#160;S-4 (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Form&#160;S-4</span><span style="color:#231f20;">&#8221;), in which the Proxy Statement shall be included as a part (the Proxy Statement and the Form&#160;S-4, collectively, the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Registration Statement</span><span style="color:#231f20;">&#8221;), in connection with the registration under the Securities Act of the shares of Parent Common Stock (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock and exercise of the Assumed Warrants) to be issued by virtue of the Contemplated Transactions, other than any shares of Parent Capital Stock which are not permitted to be registered on Form&#160;S-4 pursuant to applicable Law. Parent shall use its reasonable best efforts to (i)&#160;cause the Registration Statement to comply with the applicable rules&#160;and regulations promulgated by the SEC, (ii)&#160;cause the Registration Statement to become effective as promptly as practicable, and (iii)&#160;respond promptly to any comments or requests of the SEC or its staff relating to the Registration Statement. Parent shall take all or any action required under any applicable federal, state, securities and other Laws in connection with the issuance of shares of Parent Capital Stock pursuant to the Contemplated Transactions (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock and exercise of the Assumed Warrants). Each of the parties shall reasonably cooperate with the other party and furnish all information concerning itself and their Affiliates, as applicable, to the other parties that is required by law to be included in the Registration Statement as the other parties may reasonably request in connection with such actions and the preparation of the Registration Statement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">Parent covenants and agrees that the Registration Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith) will (i)&#160;comply as to form in all material respects with the requirements of applicable U.S. federal securities laws and the DGCL, and (ii)&#160;will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">not misleading. The Company covenants and agrees that the information supplied by or on behalf of the Company, concerning itself, to Parent for inclusion in the Registration Statement (including the Company Interim Financial Statements) will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make such information, in </span>light of the circumstances under which they were made, not misleading. Notwithstanding the foregoing, neither party makes any covenant, representation or warranty with respect to statements made in the Registration Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith), if any, based on information provided by the other party or any of their Representatives regarding such other party or its Affiliates for inclusion therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">Parent shall use commercially reasonable efforts to cause the Proxy Statement to be mailed to Parent&#8217;s stockholders as promptly as practicable after the Registration Statement is declared effective under the Securities Act.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">If at any time before the First Effective Time (i)&#160;any party (A)&#160;becomes aware of any event or information that, pursuant to the Securities Act or the Exchange Act, should be disclosed in an amendment or supplement to the Registration Statement, (B)&#160;receives notice of any SEC request for an amendment or supplement to the Registration Statement or for additional information related thereto, or (C)&#160;receives SEC comments on the Registration Statement, or (ii)&#160;the information provided in the Registration Statement </span>has become &#8220;stale&#8221; and new information should be disclosed in an amendment or supplement to the Registration Statement; then, in each case such party, as the case may be, shall promptly inform the other parties thereof and shall cooperate with such other parties in filing such amendment or supplement with the SEC (and, if appropriate, in mailing such amendment or supplement to the Parent stockholders) or otherwise addressing such SEC request or comments and each party shall use their commercially reasonable efforts to cause any such amendment to become effective, if required. Parent shall promptly notify the Company if it becomes aware (1)&#160;that the Registration Statement has become effective, (2)&#160;of the issuance of any stop order or suspension of the qualification or registration of the Parent Capital Stock issuance in connection with the Contemplated Transactions (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock and exercise of the Assumed Warrants) for offering or sale in any jurisdiction, or (3)&#160;any order of the SEC related to the Registration Statement, and shall promptly provide to the Company copies of all written correspondence between it or any of its Representatives, on the one hand, and the SEC or staff of the SEC, on the other hand, with respect to the Registration Statement and all orders of the SEC relating to the Registration Statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="color:#231f20;">The Company shall reasonably cooperate with Parent and provide, and cause its Representatives to provide, Parent and its Representatives, with all true, correct and complete information regarding the Company and its Subsidiaries that is required by law to be included in the Registration Statement or reasonably requested by Parent to be included in the Registration Statement. Without limiting the Company&#8217;s obligations in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.1(a)</span><span style="color:#231f20;">, the Company will use commercially reasonable efforts to cause to be delivered to Parent a letter of the Company&#8217;s independent accounting firm, dated no more than two (2)&#160;Business Days before the date on which the Registration Statement becomes effective (and reasonably satisfactory in form and substance to Parent), that is customary in scope and substance for letters delivered by independent public accountants in connection with registration statements similar to the Registration Statement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span><span style="color:#231f20;">The Company and its legal counsel shall be given reasonable opportunity to review and comment on the Registration Statement, including all amendments and supplements thereto, prior to the filing thereof with the SEC, and on the response to any comments of the SEC on the Registration Statement, prior to </span>the filing thereof with the SEC. No filing of, or amendment or supplement to, the Registration Statement will be made by Parent, and no filing of, or amendment or supplement to, the Registration Statement will be made by Parent, in each case, without the prior consent of the Company, which shall not be unreasonably withheld, conditioned or delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span><span style="color:#231f20;">As promptly as reasonably practicable following the date of this Agreement (but in any event, no later than seven (7)&#160;Business Days after the date of the Agreement), the Company will use commercially reasonable efforts to furnish to Parent (i)&#160;audited financial statements for each of its fiscal&#160;years required to be included in the Registration Statement (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Audited Financial Statements</span><span style="color:#231f20;">&#8221;) and (ii)&#160;unaudited interim financial statements for each interim period completed prior to Closing that would be required to be included in the Registration Statement or any periodic report due prior to the Closing if the Company </span>were subject to the periodic reporting requirements under the Securities Act or the Exchange Act (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Interim Financial Statements</span>&#8221;). Each of the Company Audited Financial Statements and the Company Interim Financial Statements will be prepared in accordance with GAAP as applied on a consistent basis during the periods involved (except in each case as described in the notes thereto and except, in the case of any unaudited financial statements, to normal&#160;year-end audit adjustments) and on that basis will present fairly, in all material respects, the financial position and the results of operations, changes in stockholders&#8217; equity, and cash </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;">flows of the Company as of the dates of and for the periods referred to in the Company Audited Financial Statements or the Company Interim Financial Statements, as the case may be.</p><a id="Section72"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Stockholder Approval</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">Promptly after the Registration Statement has been declared effective under the Securities Act, and in any event no later than two (2)&#160;Business Days thereafter, the Company shall solicit for approval the Company Stockholder Approval. Under no circumstances shall the Company assert that any other approval or consent is necessary by its stockholders to approve this Agreement and the Contemplated Transactions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">Reasonably promptly following receipt of the Company Stockholder Approval, the Company shall prepare and mail the Registration Statement (or a portion thereof constituting a notice of the Contemplated Transactions and of the Company Stockholder Approval) to every stockholder of the Company that did not execute the Company Stockholder Approval, if any (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Stockholder Notice</span><span style="color:#231f20;">&#8221;). The Stockholder Notice shall (i)&#160;be a statement to the effect that the Company Board determined that the Merger is advisable in accordance with Section&#160;251(b)&#160;of the DGCL and in the best interests of the stockholders of the Company and approved and adopted this Agreement, the Merger and the other Contemplated Transactions and (ii)&#160;provide the stockholders of the Company to whom it is sent with notice </span>of the availability of appraisal rights and notice of the actions taken in the Company Stockholder Approval, including the adoption and approval of this Agreement, the Merger and the other Contemplated Transactions in accordance with Sections 228(e)&#160;and 262 of the DGCL and the organizational documents of the Company. All materials (including any amendments thereto) submitted to the stockholders of the Company in accordance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.2(b)</span>&#160;shall be subject to Parent&#8217;s advanced review and reasonable approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">The Company agrees that: (i)&#160;the Company Board shall recommend that the Company&#8217;s stockholders vote to adopt and approve this Agreement and the Contemplated Transactions and shall use commercially reasonable efforts to solicit such approval within the time set forth in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.2(a)</span><span style="color:#231f20;">&#160;(the recommendation of the Company Board that the Company&#8217;s stockholders vote to adopt and approve this Agreement being referred to as the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Board Recommendation</span><span style="color:#231f20;">&#8221;) and (ii)&#160;the Company Board Recommendation shall not be withdrawn or modified (and the Company Board shall not publicly propose to withdraw or modify the Company Board Recommendation) in a manner adverse to Parent, and no resolution by the Company Board or any committee thereof to withdraw or modify the Company Board Recommendation in a manner adverse to Parent or to adopt, approve or recommend (or publicly adopt, approve or recommend) any Acquisition Proposal shall be adopted or proposed (the actions set forth in the foregoing clause (ii), collectively, a &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Board Adverse Recommendation Change</span><span style="color:#231f20;">&#8221;).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">Notwithstanding anything to the contrary contained in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.2(c)</span><span style="color:#231f20;">, and subject to compliance with </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.4</span><span style="color:#231f20;"> and </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.2</span><span style="color:#231f20;">, if at any time prior to approval and adoption of this Agreement by the Company Stockholder Approval, (i)&#160;the Company receives a bona fide written Superior Offer, or (ii)&#160;as a result of a material development or change in circumstances (other than any such event, development or change to the extent related to (A)&#160;any Acquisition Proposal, Acquisition Inquiry, Acquisition Transaction or the consequences thereof or (B)&#160;the fact, in and of itself, that the Company meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations) that affects the business, assets or operations of the Company that occurs or arises after the date of this Agreement (a &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Intervening Event</span><span style="color:#231f20;">&#8221;), the Company Board may make a Company Board Adverse Recommendation Change if, but only if, in the case of a Superior Offer, following the receipt of and on account of such Superior Offer, (1)&#160;the Company Board determines in good faith, after consulting with outside legal counsel, that the failure to withhold, amend, withdraw or modify such recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law, (2)&#160;the Company has, and has caused its financial advisors and outside legal counsel to, during the Company Notice Period, negotiate with Parent in good faith to make such adjustments to the terms and conditions of this Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer (to the extent Parent desires to negotiate) and (3)&#160;if after Parent shall have delivered to the Company an irrevocable written offer to alter the terms or conditions of this Agreement during the Company Notice Period, the Company Board shall have determined in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Company Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law (after taking into account such alterations of the terms and conditions of this Agreement); provided that (x)&#160;Parent receives written notice from the Company confirming that the Company Board has determined to change its recommendation at least four (4) Business Days in advance of the Company Board Adverse Recommendation Change (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Notice Period</span><span style="color:#231f20;">&#8221;), which notice shall include a description in reasonable detail of the reasons for such Company Board Adverse Recommendation Change, and written copies of any relevant proposed transaction agreements with </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">any party making a potential Superior Offer, (y)&#160;during any Company Notice Period, Parent shall be entitled to deliver to the Company one or more counterproposals to such Acquisition Proposal and the Company will, and cause its Representatives to, negotiate with Parent in good faith (to the extent Parent desires to negotiate) to make such adjustments in the terms and conditions of this Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer and (z)&#160;in the event of any material amendment to any Superior Offer (including any revision in the amount, form or mix of consideration or&#160;percentage of the combined company that the Company&#8217;s stockholders would receive as a result of such potential Superior Offer), the Company shall be required to provide Parent with notice of such material amendment and the Company Notice Period shall be extended, if applicable, to ensure that at </span>least two (2)&#160;Business Days remain in the Company Notice Period following such notification during which the parties shall comply again with the requirements of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.2(d)</span>&#160;and the Company Board shall not make a Company Board Adverse Recommendation Change prior to the end of such Company Notice Period as so extended (it being understood that there may be multiple extensions) or (ii)&#160;in the case of a Company Intervening Event, the Company promptly notifies Parent, in writing, within the Company Notice Period before making a Company Board Adverse Recommendation Change, which notice shall state expressly the material facts and circumstances related to the applicable Company Intervening Event and that the Company Board intends to make a Company Board Adverse Recommendation Change.</p><a id="Section73"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Stockholders&#8217; Meeting</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">Parent shall take all action necessary under applicable Law to call, give notice of and hold a meeting of the holders of Parent Common Stock (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Stockholder Meeting</span><span style="color:#231f20;">&#8221;) to consider and obtain the Parent Stockholder Approval and thereby approve the Contemplated Transactions and the Parent Charter Amendment and, if deemed necessary by Parent, any the Parent Legacy Transaction (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Stockholder Proposals</span><span style="color:#231f20;">&#8221;). The Parent Stockholder Meeting shall be held as promptly as practicable after the Registration Statement is declared effective under the Securities Act, and in any event no later than forty- five (45)&#160;days after the effective date of the Registration Statement. Parent shall take reasonable measures to ensure that all proxies solicited in connection with the Parent Stockholder Meeting are solicited in compliance with all applicable Law. Notwithstanding anything to the contrary contained herein, if on the date of the Parent Stockholder Meeting, or a date preceding the date on which the Parent Stockholder Meeting is scheduled, Parent reasonably believes that (i)&#160;it will not receive proxies sufficient to obtain the Parent Stockholder Approval, whether or not a quorum would be present or (ii)&#160;it will not have sufficient shares of Parent Common Stock represented (whether in person or by proxy) to constitute a quorum necessary to conduct the business of the Parent Stockholder Meeting, Parent may postpone or adjourn, or make one or more successive postponements or adjournments of, the Parent Stockholder Meeting as long as the date of the Parent Stockholder Meeting is not postponed or adjourned by more than an aggregate of thirty (30)&#160;days in connection with any postponements or adjournments.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">Parent agrees that, subject to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.3(c)</span><span style="color:#231f20;">, (i)&#160;the Parent Board shall recommend that the holders of Parent Common Stock vote to approve the Parent Stockholder Proposals and shall use commercially reasonable efforts to solicit such approval within the timeframe set forth in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.3(a)</span><span style="color:#231f20;">&#160;above and (ii)&#160;the Proxy Statement shall include a statement to the effect that the Parent Board recommends that Parent&#8217;s stockholders vote to approve the Parent Stockholder Proposal (the recommendation of the Parent Board being referred to as the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Board Recommendation</span><span style="color:#231f20;">&#8221;) and (iii)&#160;the Parent Board Recommendation shall not be withheld, amended, withdrawn or modified (and the Parent Board shall not publicly propose to withhold, amend, withdraw or modify the Parent Board Recommendation) in a manner adverse to the Company, and no resolution by the Parent Board or any committee thereof to withdraw or modify the Parent Board Recommendation in a manner adverse to the Company or to adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal shall be adopted or proposed (the actions set forth in the foregoing clause (iii), collectively, a &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Board Adverse Recommendation Change</span><span style="color:#231f20;">&#8221;).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">Notwithstanding anything to the contrary contained in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.3(b)</span><span style="color:#231f20;">, and subject to compliance with </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.4</span><span style="color:#231f20;"> and </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.3</span><span style="color:#231f20;">, at any time prior to the approval of the Parent Stockholder Proposal by the Parent Stockholder Approval, (i)&#160;if Parent receives a bona fide written Superior Offer or (ii)&#160;as a result of a material development or change in circumstances (other than any such event, development or change to the extent related to (A)&#160;any Acquisition Proposal, Acquisition Inquiry, Acquisition Transaction or the consequences thereof or (B)&#160;the fact, in and of itself, that Parent meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations) that affects the business, assets or operations of Parent that occurs or arises after the date of this Agreement (a &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Intervening Event</span><span style="color:#231f20;">&#8221;), the Parent Board may make a Parent Board Adverse Recommendation Change if, but only if in the case of a Superior Offer, following the receipt of and on account of such Superior Offer, (1) the Parent Board determines in good faith, after consulting with outside legal counsel, that the failure to withhold, amend, withdraw or modify such recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">Law, (2)&#160;Parent has, and has caused its financial advisors and outside legal counsel to, during the Parent Notice Period, negotiate with the Company in good faith to make such adjustments to the terms and conditions of this Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer (to the extent the Company desires to negotiate) and (3)&#160;if after the Company shall have delivered to Parent an irrevocable written offer to alter the terms or conditions of </span>this Agreement during the Parent Notice Period, the Parent Board shall have determined in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Parent Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law (after taking into account such alterations of the terms and conditions of this Agreement); provided that (x)&#160;the Company receives written notice from Parent confirming that the Parent Board has determined to change its recommendation at least four (4)&#160;Business Days in advance of the Parent Board Adverse Recommendation Change (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Notice Period</span>&#8221; ), which notice shall include a description in reasonable detail of the reasons for such Parent Board Adverse Recommendation Change, and written copies of any relevant proposed transaction agreements with any party making a potential Superior Offer, (y)&#160;during any Parent Notice Period, the Company shall be entitled to deliver to Parent one or more counterproposals to such Acquisition Proposal and Parent will, and cause its Representatives to, negotiate with the Company in good faith (to the extent the Company desires to negotiate) to make such adjustments in the terms and conditions of this Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer and (z)&#160;in the event of any material amendment to any Superior Offer (including any revision in the amount, form or mix of consideration or&#160;percentage of the combined company that Parent&#8217;s stockholders would receive as a result of such potential Superior Offer), Parent shall be required to provide the Company with notice of such material amendment and the Parent Notice Period shall be extended, if applicable, to ensure that at least two (2)&#160;Business Days remain in the Parent Notice Period following such notification during which the parties shall comply again with the requirements of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.3(c)</span>&#160;and the Parent Board shall not make a Parent Board Adverse Recommendation Change prior to the end of such Parent Notice Period as so extended (it being understood that there may be multiple extensions) or (ii)&#160;in the case of a Parent Intervening Event, Parent promptly notifies the Company, in writing, within the Parent Notice Period before making a Parent Board Adverse Recommendation Change, which notice shall state expressly the material facts and circumstances related to the applicable Parent Intervening Event and that the Parent Board intends to make a Parent Board Adverse Recommendation Change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">Unless this Agreement is validly terminated pursuant to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(j)</span><span style="color:#231f20;">, Parent&#8217;s obligation to call, give notice of and hold the Parent Stockholder Meeting in accordance with </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.3(a)</span><span style="color:#231f20;">&#160;shall not be limited to or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer or Acquisition Proposal, or by any withdrawal or modification of the Parent Board Recommendation or any Parent Board Adverse Recommendation Change.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="color:#231f20;">Nothing contained in this Agreement shall prohibit Parent or the Parent Board from complying with Rules&#160;14d-9 and 14e-2(a)&#160;promulgated under the Exchange Act; provided however, that any disclosure made by Parent or the Parent Board pursuant to Rules&#160;14d-9 and 14e-2(a)&#160;shall be limited to a statement that Parent is unable to take a position with respect to the bidder&#8217;s tender offer unless the Parent Board determines in good faith, after consultation with its outside legal counsel, that such statement would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law.</span></p><a id="Section74"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Efforts; Regulatory Approvals; Transaction Litigation</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">The parties shall use commercially reasonable efforts to consummate the Contemplated Transactions. Without limiting the generality of the foregoing, each party: (i)&#160;shall promptly as practicable and in any event no more than five (5)&#160;Business Days after the date of this Agreement, make or cause to be made any filings required by each of them or any of their respective Affiliates under the HSR Act, (ii)&#160;shall make all filings and other submissions (if any) and give all notices (if any) required to be made and given by such party in connection with the Contemplated Transactions, (iii)&#160;shall use commercially reasonable </span>efforts to obtain each consent (if any) reasonably required to be obtained (pursuant to any applicable law or Contract, or otherwise) by such party in connection with the Contemplated Transactions or for such Contract to remain in full force and effect, (iv)&#160;shall use commercially reasonable efforts to lift any injunction prohibiting, or any other legal bar to, the Contemplated Transactions and (v)&#160;shall use commercially reasonable efforts to satisfy the conditions precedent to the consummations of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">Notwithstanding the generality of the foregoing, each party shall use commercially reasonable efforts to file or otherwise submit, as soon as practicable after the date of this Agreement, all applications, notices, reports and other documents reasonably required to be filed by such party with or otherwise submitted </span>by such party to any Governmental Entity with respect to the Contemplated Transactions, and to submit promptly any additional information requested by any such Governmental Entity.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">Without limiting the generality of the foregoing, Parent shall give the Company prompt (but not later than within two (2)&#160;Business Days) written notice of any &#8220;demand letter&#8221; or any litigation initiated, or threatened or in writing against Parent and/or its directors relating to this Agreement or the Contemplated Transactions (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Transaction Litigation</span><span style="color:#231f20;">&#8221;) (including by providing copies of all pleadings with respect thereto) and keep the Company reasonably informed with respect to the status thereof. Parent will (i)&#160;give the Company the opportunity to participate in the defense, settlement or prosecution of any Transaction Litigation, (ii)&#160;consult with the Company with respect to the defense, settlement and prosecution of any Transaction Litigation, (iii)&#160;consider in good faith the Company&#8217;s advice with respect to such Transaction Litigation and (iv)&#160;will not settle or consent or agree to settle or compromise any Transaction Litigation without the Company&#8217;s prior written consent (which such consent shall not be unreasonably withheld or delayed). Without otherwise limiting the rights of current or former directors and officers of Parent with regard to the right to counsel, following the First Effective Time, current or former directors and officers of Parent with rights to indemnification as described in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.5</span><span style="color:#231f20;"> shall be entitled to retain any counsel selected by such indemnified parties to defend any Transaction Litigation as it relates to such indemnified parties in accordance with </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.5</span><span style="color:#231f20;">.</span></p><a id="Section75"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification, Exculpation and Insurance</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">From the First Effective Time through the sixth (6th) anniversary of the date on which the First Effective Time occurs, each of Parent and the Surviving Entity shall indemnify and hold harmless each Person who is now, or has been at any time prior to the date hereof, or who becomes prior to the First Effective Time, a director or officer of Parent or the Company, respectively (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">D&amp;O Indemnified Parties</span><span style="color:#231f20;">&#8221;), against all demands, claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements, incurred in connection with any claim, Action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the D&amp;O Indemnified Party is or was a director or officer of Parent or of the Company, whether asserted or claimed prior to, at or after the First Effective Time, in each case, to the fullest extent permitted under the DGCL. Each D&amp;O Indemnified Party will be entitled to advancement of fees, costs and expenses incurred in the defense of any such demand, claim, Action, suit, proceeding or investigation from each of Parent and the Surviving Entity, jointly and severally, upon receipt by Parent or the Surviving Entity from the D&amp;O Indemnified Party of a request therefor; </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">provided</span><span style="color:#231f20;">, that any such D&amp;O Indemnified Party </span>to whom expenses are advanced provides an undertaking to Parent, to the extent then required by the DGCL, to repay such advances if it is ultimately determined that such D&amp;O Indemnified Party is not entitled to indemnification. Such undertaking, if required, shall be unsecured and made without reference to the D&amp;O Indemnified Party&#8217;s ability to repay such advances or, except as may be limited by applicable Law, ultimate entitlement to indemnification. No other form of undertaking shall be required. All rights to indemnification, exculpation and advancement of expenses or other protection in respect of any claim asserted or made, and for which a D&amp;O Indemnified Party delivers a written notice to Parent or the Surviving Entity prior to the sixth (6<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>) anniversary of the First Effective Time asserting a claim for such protections pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.5</span>, shall continue until the final disposition of such claim.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">The certificate of incorporation and bylaws of the Surviving Entity shall contain, and Parent shall cause the certificate of incorporation and bylaws of the Surviving Entity to so contain, provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those presently set forth in the certificate of incorporation and bylaws of Parent.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">From and after the First Effective Time, (i)&#160;the Surviving Entity shall fulfill and honor in all respects the obligations of the Company to its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under the Company&#8217;s organizational documents and pursuant to any indemnification agreements between the Company and such D&amp;O Indemnified Parties, with respect to demands, claims, Actions, suits, proceedings or investigations whether asserted or claimed prior to, at or after the First Effective Time, arising out of matters occurring at or prior to the First Effective Time and (ii)&#160;Parent shall fulfill and honor in all respects the obligations of Parent to its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under Parent&#8217;s organizational documents and pursuant to any indemnification agreements between Parent and such D&amp;O </span>Indemnified Parties, with respect to demands, claims, Actions, suits, proceedings or investigations whether asserted or claimed prior to, at or after the First Effective Time, arising out of matters occurring at or prior to the First Effective Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">From and after the First Effective Time, Parent shall maintain directors&#8217; and officers&#8217; liability insurance policies, with an effective date as of the Closing Date, on commercially reasonable terms and conditions and with coverage limits customary for U.S. public companies similarly situated to Parent. In addition, Parent shall purchase, prior to the First Effective Time, a six-year prepaid &#8220;D&amp;O tail policy&#8221; for the non-cancellable extension of the directors&#8217; and officers&#8217; liability coverage of Parent&#8217;s existing directors&#8217; and </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">officers&#8217; insurance policies for a claims reporting or discovery period of at least six&#160;years from and after the First Effective Time with respect to any claim related to any period of time at or prior to the First </span>Effective Time with terms, conditions, exclusions, retentions and limits of liability that are no less favorable than the coverage provided under Parent&#8217;s existing policies as of the date of this Agreement with respect to any actual or alleged error, misstatement, misleading statement, act, omission, neglect, breach of duty or any matter claimed against a director or officer of Parent by reason of him or her serving in such capacity that existed or occurred at or prior to the First Effective Time (including in connection with this Agreement or the Contemplated Transactions or in connection with Parent&#8217;s initial public offering of shares of Parent Common Stock).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="color:#231f20;">From and after the First Effective Time, Parent shall pay all expenses, including reasonable attorneys&#8217; fees, including in advance (subject to the advancement requirements set forth in Section&#160;7.5(a)), that are incurred by the persons referred to in this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.5</span><span style="color:#231f20;"> in connection with their enforcement of the rights provided to such persons in this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.5</span><span style="color:#231f20;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span><span style="color:#231f20;">The provisions of this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.5</span><span style="color:#231f20;"> are intended to be in addition to the rights otherwise available to the current and former officers and directors of Parent and the Company by Law, charter, statute, bylaw or agreement, and shall operate for the benefit of, and shall be enforceable by, each of the D&amp;O Indemnified Parties, their heirs and their Representatives.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span><span style="color:#231f20;">In the event Parent or the Surviving Entity or any of their respective successors or assigns</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="color:#231f20;">consolidates with or merges into any other Person and shall not be the continuing or surviving company or entity of such consolidation or merger or (ii)&#160;transfers all or substantially all of its properties and assets to any Person, then, and in each such case, proper provision shall be made so that the successors and assigns of Parent or the Surviving Entity, as the case may be, shall succeed to the obligations set forth in this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.5</span><span style="color:#231f20;">. Parent shall cause the Surviving Entity to perform all of the obligations of the Surviving Entity under this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.5</span><span style="color:#231f20;">.</span></p><a id="Section76"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;16 Matters</span>. Prior to the First Effective Time, each of Parent and the Company shall take all such steps as may be necessary or appropriate to cause the acquisitions of Parent Capital Stock (including derivative securities with respect to such Parent Common Stock) resulting from the Contemplated Transactions by each individual who will become subject to the reporting requirements of Section&#160;16(a) of the Exchange Act with respect to Parent to be exempt under Rule&#160;16b promulgated under the Exchange Act.</p><a id="Section77"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosure</span>. The parties shall use their commercially reasonable efforts to agree to the text of any initial press release and Parent&#8217;s Form&#160;8-K announcing the execution and delivery of this Agreement. Without limiting any party&#8217;s obligations under the Confidentiality Agreement, no party shall, and no party shall permit any of its Subsidiaries or any of its Representatives to, issue any press release or make any disclosure (to any customers or employees of such party, to the public or otherwise) regarding the Contemplated Transactions unless (a)&#160;the other party shall have approved such press release or disclosure in writing, such approval not to be unreasonably conditioned, withheld or delayed; or (b)&#160;such party shall have determined in good faith, upon the advice of outside legal counsel, that such disclosure is requited by applicable Law and, to the extent practicable, before such press release or disclosure is issued or made, such party advises the other party of, and consults with the other party regarding, the text of such press release or disclosure; provided, however, that each of the Company and Parent may make any public statement in response to specific questions by the press, analysts, investors or those attending industry conferences or financial analyst conference calls, so long as any such statements made by the Company or Parent in compliance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.7</span>. Notwithstanding the foregoing, a party need not consult with any other parties in connection with such portion of any press release, public statement or filing to be issued or made pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.3(d)</span>&#160;or with respect to any Acquisition Proposal, Company Board Adverse Recommendation Change, Parent Board Adverse Recommendation Change, or pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.3(e)</span>.</p><a id="Section78"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Listing</span>. From the date hereof until the First Effective Time, Parent shall maintain its existing listing on Nasdaq until the First Effective Time. At or prior to the First Effective Time, (a)&#160;Parent shall obtain approval of the listing of the combined corporation on Nasdaq, (b)&#160;to the extent required by the rules&#160;and regulations of Nasdaq, prepare for the Company&#8217;s review and submit (with the prior approval of the Company) to Nasdaq a notification form for the listing of shares of Parent Common Stock to be issued in connection with the Contemplated Transactions, and to cause such shares to be approved for listing (subject to official notice of issuance), and (c)&#160;prepare and timely submit to Nasdaq a notification form for the Nasdaq Reverse Stock Split (if required) and submit a copy of the amendment to Parent&#8217;s certificate of incorporation effecting the Nasdaq Reverse Stock Split, certified by the Secretary of State of the State of Delaware, to Nasdaq on the Closing Date. To the extent required by Nasdaq Marketplace Rule&#160;5110, the Company shall prepare and file an initial listing application for the Parent Common Stock on Nasdaq (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock) (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nasdaq Listing Application</span>&#8221;), and from the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">date hereof until the First Effective Time, Parent shall assist the Company in preparing and filing such Nasdaq Listing Application and to cause such Nasdaq Listing Application to be conditionally approved prior to the First Effective Time. Each party will reasonably promptly inform the other party of all verbal or written communications between Nasdaq and such party or its Representatives. The parties will use commercially reasonable efforts to coordinate with respect to compliance with Nasdaq rules&#160;and regulations. Parent will cooperate with the Company as reasonably requested by the Company with respect to the Nasdaq Listing Application and promptly furnish to the Company all information concerning Parent that may be required or reasonably requested in connection with any action contemplated by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.8</span>. All of the Nasdaq Fees associated with any action contemplated by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.8</span> shall be shared equally by the Company and Parent.</p><a id="Section79"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.9</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Matters</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">Each of Parent and the Company will (and will cause its respective Affiliates to) (i)&#160;use reasonable best efforts to cause the Merger to qualify for the Intended Tax Treatment and (ii)&#160;not take any action, or fail to take any action, that could reasonably be expected to prevent or impede the Merger from qualifying for the Intended Tax Treatment. Parent shall file (or cause its Affiliates, including the Company, to file) all </span>U.S. federal, state or local Tax Return after the Closing Date in a manner that is consistent with the treatment of the Merger as a transaction qualifying for the Intended Tax Treatment, and shall not take any inconsistent position during the course of any audit, litigation or other proceeding with respect to Taxes, in each case, unless otherwise required by a &#8220;determination&#8221; that is final within the meaning of Section&#160;1313(a)&#160;of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">All transfer, documentary, sales, use, stamp, registration, excise, recording, registration value added and other such similar Taxes and fees (including any penalties and interest) that become payable in connection with or by reason of the execution of this Agreement and the Contemplated Transactions shall be borne and paid equally by the Parent and the Company. Unless otherwise required by applicable Law, the Company shall timely file any Tax Return or other document with respect to such Taxes or fees (and </span>Parent shall reasonably cooperate with respect thereto as necessary).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">If the SEC requires that an opinion with respect to the Intended Tax Treatment be prepared and submitted in connection with the Registration Statement, (i)&#160;the Company and Parent shall each use its reasonable best efforts to cause Gibson, Dunn and Crutcher LLP (or such other nationally recognized law or accounting firm reasonably satisfactory to the Company) and Goodwin Procter LLP (or such other nationally recognized law or accounting firm reasonably satisfactory to Parent), respectively, to furnish such opinion (as so required and subject to customary assumptions and limitations) and (ii)&#160;Parent and the Company shall each deliver to Gibson, Dunn and Crutcher LLP (or such other nationally recognized law or accounting firm reasonably satisfactory to the Company) and Goodwin Procter LLP (or such other nationally recognized law or accounting firm reasonably satisfactory to the Parent) a Tax certificate, signed by an officer of Parent or the Company, as applicable, containing customary representations and covenants reasonably acceptable to the Company and Parent, as applicable, in each case, as reasonably necessary and appropriate to enable each such tax advisor to render such opinion (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Tax Certificates</span><span style="color:#231f20;">&#8221;). Each of Parent </span>and the Company shall use its reasonable best efforts not to take or cause to be taken any action that would cause to be untrue (or fail to take or cause not to be taken any action which would cause to be untrue) any of the certifications, covenants or representations included in the Tax Certificates.</p><a id="Section710"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.10</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Directors and Officers</span>. Until successors are duly elected or appointed and qualified in accordance with applicable Law, the parties shall use commercially reasonable efforts to take all necessary actions so that the Persons listed on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 2.6(c)</span>&#160;and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.6(d)</span>&#160;of the Company Disclosure Letter are elected or appointed, as applicable, to the positions of officers and directors of Parent and the Surviving Entity, as set forth therein, to serve in such positions effective as of the First Effective Time. If any Person listed on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.6(c)</span>&#160;and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.6(d)</span>&#160;of the Company Disclosure Letter is unable or unwilling to serve as officer or director of Parent or the Surviving Entity, as set forth therein, the party appointing such Person (as set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 2.6(c)</span>&#160;and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.6(d)</span>&#160;of the Company Disclosure Letter) shall designate a successor. The parties shall use reasonable best efforts to have each of the Persons that will serve as directors and officers of the Parent following the Closing to execute and deliver a Lock-Up Agreement prior to Closing.</p><a id="Section711"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.11</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Certain Agreements and Rights</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">Except as set forth on </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.11(a)</span><span style="color:#231f20;">&#160;of the Parent Disclosure Letter or Company Disclosure Letter, as applicable, each of Parent and the Company shall use commercially reasonable efforts to cause any stockholder agreements, voting agreements, registration rights agreements, co-sale agreements and any other similar Contracts between either Parent or the Company and any holders of Parent Common Stock or Company Common Stock, respectively, including any such Contract granting any Person investor rights, rights of first refusal, registration rights or director registration rights (collectively, the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Investor Agreements</span><span style="color:#231f20;">&#8221;), to be </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">terminated immediately prior to the First Effective Time, without any liability being imposed on the party of Parent or the Surviving Entity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">Parent shall use commercially reasonable efforts to cause all Contracts set forth in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.11(b)</span><span style="color:#231f20;">&#160;of the Parent Disclosure Letter to be terminated effective no later than the First Effective Time (or, to the extent specified on such </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.11(b)</span><span style="color:#231f20;">&#160;of the Parent Disclosure Letter, any applicable rights thereunder waived).</span></p><a id="Section712"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.12</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Obligations of Merger Subs</span>. Parent will take all action necessary to cause Merger Subs to perform their respective obligations under this Agreement and to consummate the Merger on the terms and conditions set forth in this Agreement.</p><a id="Section713"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.13</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Allocation Certificate</span>. The Company will prepare and deliver to Parent at least two (2) <span style="color:#231f20;">Business Days prior to the Closing Date a spreadsheet setting forth (as of immediately prior to the First Effective Time) (a)&#160;each holder of the Company Capital Stock, (b)&#160;such holder&#8217;s name and physical address, (c)&#160;the number or&#160;percentage and type of the Company Capital Stock held as of the Closing Date for each such holder and (d)&#160;the number of shares of Parent Capital Stock to be issued to such holder pursuant to this Agreement in respect of the Company Capital Stock held by such holder as of immediately prior to the First Effective Time (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Allocation Certificate</span><span style="color:#231f20;">&#8221;).</span></p><a id="Section714"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.14</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pre-Closing Cash Dividend</span>. Prior to the First Effective Time, the Parent Board shall set a record date for the Pre-Closing Cash Dividend (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dividend Record Date</span>&#8221;), which date shall be as close as reasonably practicable to (but not later than) the anticipated Closing Date. Parent shall ensure that the declaration of the Dividend Record Date and the payment of the Pre-Closing Cash Dividend shall be implemented and performed such the Pre-Closing Cash Dividend be up to an amount equal in the aggregate to Parent&#8217;s reasonable, good faith approximation of the amount by which the Final Parent Net Cash will exceed $0 (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pre-Closing Cash Dividend Amount</span>&#8221;), subject to any adjustments as may be mutually agreed between Parent and the Company. The Parent Board shall cause to be paid the Pre-Closing Cash Dividend as soon as practicable after the Dividend Record Date, but in any case, not prior to the date upon which the Final Parent Net Cash has been finally determined in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.6</span> and not later than sixty (60)&#160;days after the Dividend Record Date. Parent shall announce, declare and pay (or cause to be paid) the Pre-Closing Cash Dividend in compliance with all applicable Law, including, without limitation, any rule&#160;or regulation of Nasdaq applicable to Parent. The amount of the Pre-Closing Cash Dividend shall be reduced by any Taxes required to be withheld from such payment (including, for the avoidance of doubt, because at the time of payment it is not known whether Parent will have current or accumulated earnings and profits for U.S. federal income tax purposes in the&#160;year in which the Pre-Closing Cash Dividend is paid), and any amounts that are deducted or withheld shall be treated as having been paid to the stockholder of Parent in respect of whom such payment was made.</p><a id="Section715"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.15</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Concurrent Investment</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">Subject to the terms and conditions of this Agreement, the Company shall use commercially reasonable efforts to obtain the Concurrent Investment on the terms and conditions described in the Securities Purchase Agreement and satisfy the conditions to the Concurrent Investment as described in the Securities Purchase Agreement and shall not permit any termination, amendment or modification to be made to, or any waiver of any provision under, or any replacement of, the Securities Purchase Agreement if such termination, amendment, modification, waiver or replacement (i)&#160;reduces the aggregate amount of the Concurrent Investment Amount or (ii)&#160;adversely impact the ability of the Company to enforce its rights against other parties to the Securities Purchase Agreement. The Company shall promptly deliver to Parent copies of any such termination, amendment, modification, waiver or replacement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">The Company shall use commercially reasonable efforts (i)&#160;to maintain in effect the Securities Purchase Agreement, (ii)&#160;to enforce its rights under the Securities Purchase Agreement and (iii)&#160;to comply with its obligations under the Securities Purchase Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">The Company shall use commercially reasonable efforts to give Parent prompt notice (i)&#160;of any material breach or default by any party to the Securities Purchase Agreement or definitive agreements related to the Concurrent Investment of which the Company becomes aware, (ii)&#160;of the receipt of any written notice or other written communication from any Concurrent Investment Investor with respect to any (x) actual material breach, default, termination or repudiation by any party to the Securities Purchase Agreement or definitive agreements related to the Concurrent Investment of any provisions of the Securities Purchase Agreement or definitive agreements related to the Concurrent Investment or (y)&#160;material dispute or disagreement relating to the Concurrent Investment with respect to the obligation to fund the Concurrent Investment at or substantially simultaneously with the Closing, and (iii)&#160;if at any time for any reason the Company believes in good faith that it will not be able to obtain all or any portion of the Concurrent Investment on the terms and conditions, in the manner or from the sources contemplated by the Securities Purchase Agreement or definitive </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">agreements related to the Concurrent Investment. The Company shall promptly provide information reasonably requested by Parent relating to the circumstances referred to in clauses (i), (ii)&#160;or (iii)&#160;of the immediately preceding sentence.</span></p><a id="Section716"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.16</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Equity Plans</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">Prior to the First Effective Time, the Parent Board will adopt the 2024 Equity Incentive Plan, subject to the Closing and effective as of the First Effective Time, and will include provisions in the Proxy Statement for the stockholders of Parent to approve the 2024 Equity Incentive Plan. Subject to the approval of the 2024 Equity Incentive Plan by the stockholders of Parent prior to the First Effective Time, Parent shall file with the SEC, promptly after the First Effective Time and at the Company&#8217;s expense, a registration statement on Form&#160;S-8 (or any successor form), if available for use by Parent, relating to the shares of Parent Common Stock issuable with respect to the 2024 Equity Incentive Plan.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">Prior to the First Effective Time, the Parent Board will adopt the 2024 ESPP, subject to the Closing and effective as of the First Effective Time, and will include provisions in the Proxy Statement for the stockholders of Parent to approve the 2024 ESPP. Subject to the approval of the 2024 ESPP by the stockholders of Parent prior to the First Effective Time, Parent shall file with the SEC, promptly after the First Effective Time and the Company&#8217;s expense, a registration statement on Form&#160;S-8 (or any successor form), if available for use by Parent, relating to the shares of Parent Common Stock issuable with respect to the 2024 ESPP.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">For the avoidance of doubt, approval of the 2024 Plans by the stockholders of Parent shall not be a condition to Closing.</span></p><a id="Section717"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.17</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Wind-Down Activities</span>. From the date hereof through the Closing, Parent shall use its commercially reasonable efforts to continue the wind-down activities of Parent set forth on Section&#160;7.17 of the Parent Disclosure Letter.</p><a id="Section718"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.18</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent SEC Documents</span>. From the date of this Agreement to the First Effective Time, Parent shall timely file with the SEC all Parent SEC Documents. As of its filing date, or if amended after the date of this Agreement, as of the date of the last such amendment, each Parent SEC Document filed by Parent with the SEC (a)&#160;shall comply in all material respects with the applicable requirements of the Exchange Act and the Securities Act, and (b)&#160;shall not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.</p><a id="ARTICLEVIII"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;VIII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CLOSING CONDITIONS</b></p><a id="Section81"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;8.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conditions Precedent of each Party</span>. The obligations of each party to effect the Merger and otherwise consummate the Contemplated Transactions to be consummated at the Closing are subject to the satisfaction or, to the extent permitted by applicable Law, the written waiver by each of the parties, at or prior to the Closing, of each of the following conditions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">The Registration Statement shall have become effective in accordance with the provisions of the Securities Act, and shall not be subject to any stop order or proceeding seeking a stop order with respect to the Registration Statement and has not been withdrawn. Any material state securities Laws applicable to </span>the issuance of the shares of Parent Common Stock in connection with the Contemplated Transactions shall have been complied with and no stop order (or similar order) shall have been issued or threatened in writing in respect of such shares of Parent Common Stock by any applicable state securities commissioner or court of competent jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">Any applicable waiting periods (or extensions thereof) under the HSR Act shall have expired or otherwise been terminated.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">No temporary restraining order, preliminary or permanent injunction or other order preventing the consummation of the Contemplated Transactions shall have been issued by any court of competent jurisdiction or other Governmental Entity of competent jurisdiction and remain in effect and there shall not be any Law which has the effect of making the consummation of the Contemplated Transactions illegal.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">(i)&#160;Parent shall have obtained the Parent Stockholder Approval and (ii)&#160;the Company shall have obtained the Company Stockholder Approval.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="color:#231f20;">The Lock-Up Agreements will continue to be in full force and effect as of immediately following the First Effective Time.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span><span style="color:#231f20;">The Parent Charter Amendment shall have been duly filed with the Secretary of State of the State of Delaware, containing such amendments as are necessary to consummate the transactions contemplated by this Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span><span style="color:#231f20;">Parent shall have filed the Certificate of Designation with the Secretary of State of the State of Delaware.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span><span style="color:#231f20;">The Securities Purchase Agreement shall be in full force and effect and cash proceeds of not less than the Concurrent Investment Amount shall have been received by the Company, or will be received by the Company substantially simultaneously with the Closing, in connection with the consummation of the transactions contemplated by the Securities Purchase Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="color:#231f20;">(i)&#160;The approval of the listing of the additional shares pursuant to the Nasdaq Listing Application shall have been approved for listing (subject to official notice of issuance) on Nasdaq and (ii)&#160;Parent has maintained its existing listing on Nasdaq and obtained approval of the listing of the combined corporation on Nasdaq.</span></p><a id="Section82"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;8.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conditions Precedent to Obligation of the Company</span>. The obligations of the Company to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the satisfaction or the written waiver by the Company, at or prior to the Closing, of each of the following conditions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Accuracy of Representations</span><span style="color:#231f20;">. The representations and warranties of Parent and Merger Subs made in this Agreement (other than the Parent Fundamental Representations) shall have been true and correct in all respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of the Closing Date except (a)&#160;in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a Parent Material Adverse Effect (without giving effect to any references therein to any Parent Material Adverse Effect or other materiality qualifications) or (b)&#160;for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause (a), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Parent Disclosure Letter made or purported to have been made after the date of this Agreement </span>shall be disregarded). The Parent Fundamental Representations shall have been true and correct except in de minimis respects as of the date of this Agreement and shall be true and correct except in de minimis respects on and as of the Closing Date with the same force and effect as if made on and as of such date, except, in each case, (x)&#160;in respect of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.2</span> for such inaccuracies which are de minimis, individually or in the aggregate or (y)&#160;for those representations and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct, subject to the qualifications as set forth in the preceding clause (x), as of such particular date).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Performance of Covenants</span><span style="color:#231f20;">. Parent shall have performed or complied with in all material respects all agreements and covenants required to be performed or complied with by it under this Agreement at or prior to the First Effective Time.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">No Parent Material Adverse Effect</span><span style="color:#231f20;">. Since the date of this Agreement, there shall not have occurred any Parent Material Adverse Effect.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Termination of the Investor Agreements</span><span style="color:#231f20;">. The Investor Agreements shall have been terminated.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Documents</span><span style="color:#231f20;">. The Company shall have received the following documents, each of which shall be in full force and effect:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="color:#231f20;">a certificate executed by an officer of Parent certifying that the conditions set forth in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.2(a)</span><span style="color:#231f20;">, </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">(b), (c)</span><span style="color:#231f20;">&#160;and (d)&#160;have been duly satisfied;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span><span style="color:#231f20;">written resignations in forms reasonably satisfactory to the Company, dated as of the Closing Date and effective as of the Closing executed by the officers and directors of Parent who are not to continue as officers or directors of Parent pursuant to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.10</span><span style="color:#231f20;">; and</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span><span style="color:#231f20;">the Parent Net Cash Schedule.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span><span style="color:#231f20;">If Parent declares the Pre-Closing Cash Dividend, then the Pre-Closing Cash Dividend Amount shall have been deposited by Parent with Parent&#8217;s transfer agent for further distribution to the holders of the shares of Parent Capital Stock outstanding as of the record date of the Pre-Closing Cash Dividend.</span></p><a id="Section83"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;8.3 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conditions Precedent of Parent and Merger Subs</span>. The obligations of Parent and Merger Subs to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the satisfaction or the written waiver by Parent, at or prior to the Closing, of each of the following conditions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Accuracy of Representations</span><span style="color:#231f20;">. The representations and warranties of the Company made in this Agreement (other than the Company Fundamental Representations) shall have been true and correct in all respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of the Closing Date except (a)&#160;in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a Material Adverse Effect (without giving effect to any references therein to any Material Adverse Effect or other materiality qualifications) or (b)&#160;for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in </span>the preceding clause (a), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Company Disclosure Letter made or purported to have been made after the date of this Agreement shall be disregarded). The Company Fundamental Representations shall have been true and correct except in de minimis respects as of the date of this Agreement and shall be true and correct except in de minimis respects on and as of the Closing Date with the same force and effect as if made on and as of such date, except, in each case, (x)&#160;in respect of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.2</span> for such inaccuracies which are de minimis, individually or in the aggregate, (y)&#160;for those representations and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct, subject to the qualifications as set forth in the preceding clause (x), as of such particular date), or (z)&#160;variances arising solely due to the transactions contemplated under the Securities Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Performance of Covenants</span><span style="color:#231f20;">. The Company shall have performed or complied with in all material respects all agreements and covenants required to be performed or complied with by it under this Agreement at or prior to the First Effective Time.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">No Material Adverse Effect</span><span style="color:#231f20;">. Since the date of this Agreement, there shall not have occurred any Material Adverse Effect.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Closing Certificate</span><span style="color:#231f20;">. Parent shall have received a certificate executed by an officer of the Company certifying (i)that the conditions set forth in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.3(a)</span><span style="color:#231f20;">, </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">(b)</span><span style="color:#231f20;">, and </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">(c)</span><span style="color:#231f20;">&#160;have been duly satisfied and (ii)&#160;that the information set forth in the Allocation Certificate delivered by the Company in accordance with </span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.13</span> is true and accurate in all respects as of the Closing Date.</p><a id="ARTICLEIX"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;IX</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TERMINATION</b></p><a id="Section91"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;9.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</span>. This Agreement may be terminated prior to the First Effective Time (whether before or after the adoption of this Agreement by the Company&#8217;s stockholders and whether before or after approval of the Parent Stockholder Proposal by Parent&#8217;s stockholders, unless otherwise specified below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">by mutual consent of Parent and the Company;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">by either Parent or the Company if the Merger shall not have been consummated by April&#160;30, 2025 (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">End Date</span><span style="color:#231f20;">&#8221;); provided, however, that the right to terminate this Agreement under this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(b)</span><span style="color:#231f20;">&#160;shall not be available to the Company or Parent if such party&#8217;s (or in the case of Parent, Merger Subs&#8217;) breach of this Agreement has been a principal cause of the failure of the Merger to occur on or before the End Date;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">by either Parent or the Company if a court of competent jurisdiction or other Governmental Entity shall have issued a final and nonappealable order, or shall have taken any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting the Contemplated Transactions, provided, however, that the right to terminate this Agreement under this Section&#160;9.1(c)&#160;shall not be available to a party if such party&#8217;s (or in the case of Parent, Merger Subs&#8217;) breach of this Agreement is a principal cause of any such Governmental Entity issuing any such order or taking any such other action;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">by either Parent or the Company if the Company Stockholder Approval shall not have been obtained by written consent of the Company&#8217;s stockholders in lieu of a meeting within two (2)&#160;Business Days of the Registration Statement becoming effective in accordance with the provisions of the Securities Act; provided, however, that once the Company Stockholder Approval has been obtained, neither party may terminate this Agreement pursuant to this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(d)</span><span style="color:#231f20;">&#160;and (ii)&#160;the right to terminate this Agreement under this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(d)</span><span style="color:#231f20;">&#160;shall not be available to a party if such party&#8217;s (or in the case of Parent or Merger Subs&#8217;) breach of this Agreement is a principal cause of the failure of the Company Stockholder Approval to have been obtained on or before such second (2nd) Business Day;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="color:#231f20;">by either Parent or the Company if (i)&#160;the Parent Stockholder Meeting (including any adjournments and postponements thereof) shall have been held and completed and Parent&#8217;s stockholders shall have taken a final vote on the Parent Stockholder Proposal and (ii)&#160;the Parent Stockholder Approval shall not have been obtained at the Parent Stockholder Meeting (or any adjournment or postponement thereof); provided, however, that the right to terminate this Agreement under this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(e)</span><span style="color:#231f20;">&#160;shall not be available to a party </span>if such party&#8217;s (or in the case of Parent, Merger Subs&#8217;) breach of this Agreement is a principal cause of the failure of the Parent Stockholder Approval to have been obtained at the Parent Stockholder Meeting;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span><span style="color:#231f20;">by the Company (at any time prior to obtaining the Parent Stockholder Approval) if any Parent Triggering Event shall have occurred;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span><span style="color:#231f20;">by Parent (at any time prior to obtaining the Company Stockholder Approval) if any Company Triggering Event shall have occurred;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span><span style="color:#231f20;">by the Company, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by Parent or Merger Subs or if any representation or warranty of Parent or Merger Subs shall have become inaccurate, in either case, such that the conditions set forth in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.2(a)</span><span style="color:#231f20;">&#160;or </span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.2(b)</span>&#160;would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become inaccurate; provided that the Company is not then in material breach of any representation, warranty, covenant or agreement under this Agreement; provided, further that if such inaccuracy in Parent&#8217;s or Merger Subs&#8217; representations and warranties or breach by Parent or Merger Subs is curable by Parent or Merger Subs, then this Agreement shall not terminate pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(h)</span>&#160;as a result of such particular breach or inaccuracy until the earlier of (i)&#160;the expiration of a 30-day period commencing upon delivery of written notice from the Company to Parent or Merger Subs of such breach or inaccuracy and its intention to terminate pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(h)</span>&#160;and (ii)&#160;Parent or Merger Subs (as applicable) ceasing to exercise commercially reasonable efforts to cure such breach following delivery of written notice from the Company to Parent or Merger Subs of such breach or inaccuracy and its intention to terminate pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(h)</span>&#160;(it being understood that this Agreement shall not terminate pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(h)</span>&#160;as a result of such particular breach or inaccuracy if such breach by Parent or Merger Subs is cured prior to such termination becoming effective);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="color:#231f20;">by the Parent, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by the Company or if any representation or warranty of Parent or Merger Subs shall have become inaccurate, in either case, such that the conditions set forth in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.3(a)</span><span style="color:#231f20;">&#160;or </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.3(b)</span><span style="color:#231f20;">&#160;would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become inaccurate; provided that Parent is not then in material breach of any representation, warranty, covenant or agreement under this Agreement; provided, further that if such inaccuracy in the Company&#8217;s representations and warranties or breach by the Company is curable by the Company, then this Agreement shall not terminate pursuant to this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(i)</span><span style="color:#231f20;">&#160;as a result of such particular breach or inaccuracy until the earlier of (i)&#160;the expiration of a 30-day period commencing upon delivery of written notice from the </span>Parent to the Company of such breach or inaccuracy and its intention to terminate pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(i)</span>&#160;and (ii)&#160;the Company ceasing to exercise commercially reasonable efforts to cure such breach following delivery of written notice from Parent to the Company of such breach or inaccuracy and its intention to terminate pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(i)</span>&#160;(it being understood that this Agreement shall not terminate pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(i)</span>&#160;as a result of such particular breach or inaccuracy if such breach by the Company is cured prior to such termination becoming effective); or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span><span style="color:#231f20;">by Parent (at any time prior to obtaining the Parent Stockholder Approval) and following compliance with all of the requirements set forth in the proviso to this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(j)</span><span style="color:#231f20;">, concurrently with Parent&#8217;s entering into a definitive agreement for a Superior Offer (a &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Permitted Alternative Agreement</span><span style="color:#231f20;">&#8221;) and after having paid to the Company the Company Termination Fee pursuant to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.3(c)</span><span style="color:#231f20;">; provided, however, that Parent shall not enter into any Permitted Alternative Agreement unless: (i)&#160;the Company shall have received written notice from Parent of Parent&#8217;s intention to enter into such Permitted Alternative Agreement at least four </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">(4)&#160;Business Days in advance, with such notice describing in reasonable detail the reasons for such intention as well as the material terms and conditions of such Permitted Alternative </span>Agreement, including the identity of the counterparty together with copies of the then current draft of such Permitted Alternative Agreement and any other related principal transaction documents, (ii)&#160;Parent shall have complied in all material respects with its obligations under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.4</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.3</span>, and (iii)&#160;the Parent Board shall have determined in good faith, after consultation with its outside legal counsel, that the failure to enter into such Permitted Alternative Agreement would reasonably be expected to be inconsistent with its fiduciary obligations under applicable Law. The party desiring to terminate this Agreement pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1</span> (other than pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(a)</span>) shall give a notice of such termination to the other party specifying the provisions hereof pursuant to which such termination is made and the basis therefor described in reasonable detail.</p><a id="Section92"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;9.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effect of Termination</span>. In the event of the termination of this Agreement as provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1</span>, this Agreement shall be of no further force or effect; provided, however, that (a)&#160;this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.2</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.3</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;X</span> (and the related definitions of the defined terms in such section) shall survive the termination of this Agreement and shall remain in full force and effect and (b)&#160;the termination of this Agreement and the provisions of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.3</span> shall not relieve any party of any liability for fraud or for any willful and material breach of any representation, warranty, covenant, obligation or other provision contained in this Agreement.</p><a id="Section93"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;9.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expenses; Termination Fees</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">Except as set forth in this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.3</span><span style="color:#231f20;"> and </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.9</span><span style="color:#231f20;"> all fees and expenses incurred in connection with this Agreement and the Contemplated Transactions shall be paid by the party incurring such expenses, whether or not the Merger is consummated provided, however, that Parent and the Company shall share equally all fees and expenses incurred in relation to the printing and filing with the SEC of the Registration Statement (including any financial statements and exhibits) and any amendments or supplements thereto and paid to a financial printer or the SEC.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">If (i)&#160;this Agreement is terminated by Parent or the Company pursuant to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(e)</span><span style="color:#231f20;">&#160;or by the Company pursuant to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(f)</span><span style="color:#231f20;">, (ii)&#160;at any time after the date of this Agreement and prior to the Parent Stockholder Meeting an Acquisition Proposal with respect to Parent shall have been publicly announced, disclosed or otherwise communicated to the Parent Board (and shall not have been withdrawn) and (iii)&#160;within twelve (12)&#160;months after the date of such termination, Parent enters into a definitive agreement with </span>respect to a Subsequent Transaction or consummates a Subsequent Transaction, then Parent shall pay the Company, within ten (10)&#160;Business Days after termination (or, if applicable, upon such entry into a definitive agreement and/or consummation of a Subsequent Transaction), a nonrefundable fee in an amount equal to $2,340,000 (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Termination Fee</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">If this Agreement is terminated (i)&#160;by the Company pursuant to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(b)</span><span style="color:#231f20;">&#160;or </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(e)</span><span style="color:#231f20;">&#160;(in which the Company has the right to terminate this Agreement pursuant </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(f)</span><span style="color:#231f20;">) or (ii)&#160;by Parent pursuant to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(j)</span><span style="color:#231f20;">, then Parent shall pay to the Company the Company Termination Fee, by wire transfer of same day funds to an account designated by the Company, (x)&#160;in the case of a termination by Parent referred to in the foregoing clause (i)&#160;or (ii), prior (and as a condition) to such termination or (y)&#160;in the case of a termination by the Company described in the foregoing clause (i), within two (2)&#160;Business Days after such termination.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">If (i)&#160;this Agreement is terminated by Parent or the Company pursuant to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(d)</span><span style="color:#231f20;">&#160;or by Parent pursuant to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(g),</span><span style="color:#231f20;"> (ii)&#160;at any time after the date of this Agreement and prior to obtaining the Company Stockholder Approval, an Acquisition Proposal with respect to the Company shall have been publicly announced, disclosed or otherwise communicated to the Company Board (and shall not have been withdrawn) and (iii)&#160;within six (6)&#160;months after the date of such termination, the Company enters into a definitive agreement with respect to a Subsequent Transaction or consummates a Subsequent Transaction, then the Company shall pay to Parent, within ten (10)&#160;Business Days after termination (or, if applicable, upon the earlier of such entry into a definitive agreement and/or the consummation of a Subsequent Transaction), a nonrefundable fee in an amount equal to $5,250,000 (the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Parent Termination Fee</span><span style="color:#231f20;">&#8221;), by wire transfer of same-day funds to an account designated by Parent.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="color:#231f20;">If this Agreement is terminated by Parent pursuant to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(g)</span><span style="color:#231f20;">&#160;(or by the Company in circumstances in which Parent has the right to terminate this Agreement pursuant to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1(g)</span><span style="color:#231f20;">), then the Company shall pay to Parent the Parent Termination Fee, by wire transfer of same day funds to an account designated by Parent, (x)&#160;in the case of a termination by the Company referred to in the foregoing clause, prior (and as a condition) to such termination or (y)&#160;in the case of a termination by Parent described in the foregoing clause, within two (2)&#160;Business Days after such termination.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span><span style="color:#231f20;">If either party fails to pay when due any amount payable by it under this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.3</span><span style="color:#231f20;">, then (i)&#160;such party shall reimburse the other party for reasonable costs and expenses (including reasonable fees and </span>disbursements of counsel) incurred in connection with the collection of such overdue amount and the enforcement by the other party of its rights under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.3</span> and (ii)&#160;such party shall pay to the other party interest on such overdue amount (for the period commencing as of the date such overdue amount was originally required to be paid and ending on the date such overdue amount is actually paid to the other party in full) at a rate per annum equal to the &#8220;prime rate&#8221; (as announced by Bank of America or any successor thereto) in effect on the date such overdue amount was originally required to be paid plus three&#160;percent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span><span style="color:#231f20;">The parties agree that, subject to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.2</span><span style="color:#231f20;">, the payment of fees and expenses set forth in this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.3</span><span style="color:#231f20;"> shall be the sole and exclusive remedy of each party following a termination of this Agreement under the circumstances described in this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.3</span><span style="color:#231f20;">, it being understood that in no event shall either Parent or the Company be required to pay the individual fees, damages payable pursuant to this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.3</span><span style="color:#231f20;"> on more than one occasion. Subject to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.2</span><span style="color:#231f20;">, following the payment of the fees and expenses set forth in this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.3</span><span style="color:#231f20;"> by a party, (i)&#160;such party shall have no further liability to the other party in connection with or arising out of this Agreement or the termination thereof, any breach of this Agreement by the other party giving rise to such termination, or the failure of the Contemplated Transactions to be consummated, (ii)&#160;no other party or their respective Affiliates shall be entitled to bring or maintain any other claim, action or proceeding against such party or seek to obtain any recovery, judgment or damages of any kind against such party (or any partner, member, stockholder, director, officer, employee, Subsidiary, Affiliate, agent or other Representative of such party) in connection with or arising out of this Agreement or the termination thereof, any breach by such party giving rise to such termination or the failure of the Contemplated Transactions </span>to be consummated and (iii)&#160;all other parties and their respective Affiliates shall be precluded from any other remedy against such party and its Affiliates, at law or in equity or otherwise, in connection with or arising out of this Agreement or the termination thereof, any breach by such party giving rise to such termination or the failure of the Contemplated Transactions to be consummated. Each of the parties acknowledges that (x) <span style="color:#231f20;">the agreements contained in this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.3</span><span style="color:#231f20;"> are an integral part of the Contemplated Transactions, (y) without these agreements, the parties would not enter into this Agreement and (z)&#160;any amount payable pursuant to this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.3</span><span style="color:#231f20;"> is not a penalty, but rather is liquidated damages in a reasonable amount that will compensate the parties in the circumstances in which such amount is payable; provided, however, that nothing in this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.3(g)</span><span style="color:#231f20;">&#160;shall limit the rights of the parties under </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;10.3</span><span style="color:#231f20;">.</span></p><a id="ARTICLEX"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;X</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">GENERAL PROVISIONS</b></p><a id="Section101"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-survival of Representations and Warranties</span>. None of the representations, warranties, covenants or agreements in this Agreement or in any instrument delivered pursuant to this Agreement shall survive the First Effective Time, other than this Article&#160;X and those covenants or agreements of the parties which by their terms apply, or are to be performed in whole or in part, after the First Effective Time.</p><a id="Section102"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment or Supplement</span>. This Agreement may be amended, modified or supplemented by the parties by action taken or authorized by their respective Boards of Directors at any time, whether before or after Company Stockholder Approval or the Parent Stockholder Approval has been obtained; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that after the Company Stockholder Approval or the Parent Stockholder Approval has been obtained, no amendment shall be made that pursuant to applicable Law requires further approval or adoption by the stockholders of the Company or Parent, as applicable, without such further approval or adoption. This Agreement may not be amended, modified or supplemented in any manner, whether by course of conduct or otherwise, except by an instrument in writing specifically designated as an amendment hereto, signed on behalf of each of the parties in interest at the time of the amendment.</p><a id="Section103"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver</span>. The parties may, by action taken or authorized by their respective Boards of Directors, to the extent permitted by applicable Law, waive compliance with any of the agreements or conditions of the other parties contained herein; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that after the Company Stockholder Approval or the Parent Stockholder Approval has been obtained, no waiver may be made that pursuant to applicable Law requires further approval or adoption by the stockholders of the Company or Parent, as applicable, without such further approval or adoption. Any agreement on the part of a party to any such waiver shall be valid only if set forth in a written instrument executed and delivered by a duly authorized officer on behalf of such party. No failure or delay of any party in exercising any right or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such right or power, or any course of conduct, preclude any other or further exercise thereof or the exercise of any other right or power. No party shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such party and any </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">such waiver shall not be applicable or have any effect except in the specific instance in which it is given. The rights and remedies of the parties hereunder are cumulative and are not exclusive of any rights or remedies which they would otherwise have hereunder.</p><a id="Section104"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fees and Expenses</span>. Except as otherwise set forth in this Agreement, all fees and expenses incurred in connection with this Agreement, the Merger and the other Contemplated Transactions shall be paid by the party incurring such fees or expenses.</p><a id="Section105"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</span>. All notices and other communications hereunder shall be in writing and shall be deemed duly given (a)&#160;on the date of delivery if delivered personally, or if by e-mail, upon written confirmation of receipt by e-mail or otherwise, (b)&#160;on the first (1st) Business Day following the date of dispatch if delivered utilizing a next-day service by a recognized next-day courier or (c)&#160;on the earlier of confirmed receipt or the fifth (5th) Business Day following the date of mailing if delivered by registered or certified mail, return receipt requested, postage prepaid. All notices hereunder shall be delivered to the addresses set forth below, or pursuant to such other instructions as may be designated in writing by the party to receive such notice:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="color:#231f20;">if to Parent, Merger Subs, to:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;">Aerovate Therapeutics,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;">930 Winter Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;">Waltham, MA 02451</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;">Attention: Timothy P. Noyes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">E-mail:</span></span>[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;">with a copy (which shall not constitute notice) to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;">Goodwin Procter LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;">The New York Times Building</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;">620 Eighth Avenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;">New York, NY 10018</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;">Attention: Edwin O&#8217;Connor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;">Tevia K. Pollard</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Email:</span></span>[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span><span style="color:#231f20;">if to Company, to:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;">Jade Biosciences,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;">221 Crescent Street, Building 23, Suite&#160;105 Waltham, MA 02453</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;">Attention: Tom Frohlich</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">E-mail:</span></span>[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">with a copy (which shall not constitute notice) to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;">Gibson, Dunn&#160;&amp; Crutcher LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;">One Embarcadero Center, Suite&#160;2600</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;">San Francisco, CA 94111</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;">Attention: Ryan Murr, Branden Berns, Chris Trester</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Email:</span></span>[***],</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 54pt;">[***],</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">[***]</p><a id="Section106"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</span>. This Agreement (including the Exhibits hereto), the Company Disclosure Letter, the Parent Disclosure Letter, the Securities Purchase Agreements, and the Confidentiality Agreement constitute the entire agreement, and supersede all prior written agreements, arrangements, communications and understandings and all prior and contemporaneous oral agreements, arrangements, communications and understandings among the parties with respect to the subject matter hereof and thereof; provided, however, that the Confidentiality Agreement shall not be superseded and shall remain in full force and effect in </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">accordance with its terms; provided, further, that only Exhibit&#160;E (including Exhibit&#160;A to such Exhibit) is incorporated by reference and made a part hereof for purposes of Section&#160;251 of the DGCL.</p><a id="Section107"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Third Party Beneficiaries</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person other than the parties and their respective successors and permitted assigns any legal or equitable right, benefit or remedy of any nature under or by reason of this Agreement, except as provided in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.5</span><span style="color:#231f20;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">Except as set forth in the Securities Purchase Agreement, the representations and warranties in this Agreement are the product of negotiations among the parties hereto and are for the sole benefit of the parties hereto. Any inaccuracies in such representations and warranties are subject to waiver </span>by the parties hereto in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;10.3</span> without notice or liability to any other Person. In some instances, the representations and warranties in this Agreement may represent an allocation among the parties hereto of risks associated with particular matters regardless of the knowledge of any of the parties hereto. Consequently, except as set forth in the Securities Purchase Agreement, Persons other than the parties hereto may not rely upon the representations and warranties in this Agreement as characterizations of actual facts or circumstances as of the date of this Agreement or as of any other date.</p><a id="Section108"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 10.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</span>. This Agreement and all disputes or controversies arising out of or relating to this Agreement or the Contemplated Transactions shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to the laws of any other jurisdiction that might be applied because of the conflicts of laws principles of the State of Delaware.</p><a id="Section109"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.9</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Submission to Jurisdiction</span>. Each of the parties irrevocably agrees that any legal action or proceeding arising out of or relating to this Agreement brought by any party or its Affiliates against any other party or its Affiliates shall be brought and determined in the Court of Chancery of the State of Delaware; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that if jurisdiction is not then available in the Court of Chancery of the State of Delaware, then any such legal action or proceeding may be brought in any federal court located in the State of Delaware or any other Delaware state court. Each of the parties hereby irrevocably submits to the jurisdiction of the aforesaid courts for itself and with respect to its property, generally and unconditionally, with regard to any such action or proceeding arising out of or relating to this Agreement and the Contemplated Transactions. Each of the parties agrees not to commence any action, suit or proceeding relating thereto except in the courts described above in Delaware, other than actions in any court of competent jurisdiction to enforce any judgment, decree or award rendered by any such court in Delaware as described herein. Each of the parties further agrees that notice as provided herein shall constitute sufficient service of process and the parties further waive any argument that such service is insufficient. Each of the parties hereby irrevocably and unconditionally waives, and agrees not to assert, by way of motion or as a defense, counterclaim or otherwise, in any action or proceeding arising out of or relating to this Agreement or the Contemplated Transactions, (a)&#160;any claim that it is not personally subject to the jurisdiction of the courts in Delaware as described herein for any reason, (b)&#160;that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (c)&#160;that (i)&#160;the suit, action or proceeding in any such court is brought in an inconvenient forum, (ii)&#160;the venue of such suit, action or proceeding is improper or (iii)&#160;this Agreement, or the subject matter hereof, may not be enforced in or by such courts.</p><a id="Section1010"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:90pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.10</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment; Successors</span>. Neither this Agreement nor any of the rights, interests or obligations under this Agreement may be assigned or delegated, in whole or in part, by operation of law or otherwise, by any party without the prior written consent of the other parties, and any such assignment without such prior written consent shall be null and void. Subject to the preceding sentence, this Agreement will be binding upon, inure to the benefit of, and be enforceable by, the parties and their respective successors and assigns.</p><a id="Section1011"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:90pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.11</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Specific Performance</span>. The parties agree that irreparable damage would occur in the event that the parties hereto do not perform the provisions of this Agreement in accordance with its terms or otherwise breach such provisions. Accordingly, the parties acknowledge and agree that each party shall be entitled to seek an injunction, specific performance and other equitable relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in the Court of Chancery of the State of Delaware, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that if jurisdiction is not then available in the Court of Chancery of the State of Delaware, then in any federal court located in the State of Delaware or any other Delaware state court, this being in addition to any other remedy to which such party is entitled at law or in equity. Each of the parties hereby further waives and will not oppose the granting of an injunction, specific performance or other equitable relief on the basis of (a)&#160;any defense in any action for specific performance that a remedy at </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">law would be adequate and (b)&#160;any requirement under any law to post any bond, surety or other security as a prerequisite to obtaining equitable relief.</p><a id="Section1012"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:90pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.12</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</span>. Whenever possible, each provision or portion of any provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable Law, but if any provision or portion of any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable Law or rule&#160;in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or portion of any provision in such jurisdiction, and this Agreement shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision or portion of any provision had never been contained herein.</p><a id="Section1013"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:90pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.13</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver of Jury Trial</span>. EACH OF THE PARTIES TO THIS AGREEMENT HEREBY IRREVOCABLY WAIVES ALL RIGHT TO A TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE CONTEMPLATED TRANSACTIONS.</p><a id="Section1014"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:90pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.14</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</span>. This Agreement may be executed in two or more counterparts, all of which shall be considered one and the same instrument and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other party.</p><a id="Section1015"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:90pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.15</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Facsimile or .pdf Signature</span>. This Agreement may be executed by facsimile or .pdf signature and a facsimile or .pdf signature shall constitute an original for all purposes.</p><a id="Section1016"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:90pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.16</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Presumption Against Drafting Party</span>. Each of Parent, Merger Subs and the Company acknowledges that each party to this Agreement has been represented by counsel in connection with this Agreement and the Contemplated Transactions. Accordingly, any rule&#160;of law or any legal decision that would require interpretation of any claimed ambiguities in this Agreement against the drafting party has no application and is expressly waived.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">[<i style="font-style:italic;">The remainder of this page&#160;is intentionally left blank</i>.]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_9a2aa976_840c_40c6_ab80_b1f165756412"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">AEROVATE THERAPEUTICS, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:46.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Timothy P. Noyes</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Timothy P. Noyes</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CARIBBEAN MERGER SUB I, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:bottom;width:46.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Timothy P. Noyes</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Timothy P. Noyes</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: President</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CARIBBEAN MERGER SUB II, LLC</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: Aerovate Therapeutics, Inc., its Manager</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:46.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Timothy P. Noyes</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Timothy P. Noyes</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:46.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Tom Frolich</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Tom Frolich</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_2936e2c8_ce4a_4935_8348_3daab1c24d09"></a><a id="ANNEXB_419735"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ANNEX B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTIFICATE OF AMENDMENT TO THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AEROVATE THERAPEUTICS,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate Therapeutics,&#160;Inc., a corporation organized and existing under the laws of the State of Delaware (the &#8220;Corporation&#8221;), certifies that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</span></span><span style="color:#231f20;">The current name of the Corporation is Aerovate Therapeutics,&#160;Inc.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</span></span><span style="color:#231f20;">The amendments set forth in this Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of the Corporation (this &#8220;Certificate of Amendment&#8221;) have been duly adopted in accordance with Section&#160;242 of the Delaware General Corporation Law by the board of directors of </span>the Corporation and by the stockholders of the Corporation. This Certificate of Amendment hereby amends the Corporation&#8217;s Second Amended and Restated Certificate of Incorporation, as currently in effect (the &#8220;Certificate of Incorporation&#8221;) as set forth below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</span></span><span style="color:#231f20;">Article&#160;IV of the Certificate of Incorporation is hereby amended to add the following new Section&#160;C immediately following the existing Section&#160;B thereof:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">&#8220;C. <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">REVERSE STOCK SPLIT</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Effective as of [<span style="font-family:'Symbol';">&#183;</span>]&#160;p.m. (Eastern Time) on [<span style="font-family:'Symbol';">&#183;</span>], 2025 (such time, the &#8220;<b style="font-weight:bold;">Effective Time</b>&#8221;), a one-for-[<span style="font-family:'Symbol';">&#183;</span>] reverse stock split of the shares of Common Stock, pursuant to which every [<span style="font-family:'Symbol';">&#183;</span>] shares of the Common Stock issued and held of record by each stockholder of the Corporation (including treasury shares) immediately prior to the Effective Time shall be reclassified and combined into one validly issued, fully paid and non-assessable share of Common Stock from and after the Effective Time, without any action on the part of the Corporation or the respective stockholders thereof (such reclassification and combination of shares, the &#8220;<b style="font-weight:bold;">Reverse Stock Split</b>&#8221;). The par value of the Common Stock following the Reverse Stock Split shall remain at $0.0001 per share. No fractional shares of Common Stock shall be issued as a result of the Reverse Stock Split. In lieu of any fractional shares, if upon aggregating all of the shares of Common Stock held by a record holder immediately following the Reverse Stock Split such holder would otherwise be entitled to a fractional share of Common Stock as a result of the Reverse Stock Split, the Corporation shall pay in cash (without interest) to each such holder an amount equal to the product of such resulting fractional interest in one share of Common Stock multiplied by the closing trading price on The Nasdaq Stock Market LLC of a share of Common Stock on the last trading day immediately prior to the date on which the Effective Time occurs (with such price proportionately adjusted to give effect to the Reverse Stock Split).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each stock certificate or book entry share that, immediately prior to the Effective Time, represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall, from and after the Effective Time, automatically and without the necessity of presenting the same for exchange, represent that number of whole shares of Common Stock after the Effective Time into which the shares formerly represented by such certificate or book entry share have been combined (as well as the right to receive cash in lieu of fractional shares of Common Stock after the Effective Time); provided, however, that each stockholder of record holding a certificate that represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall receive, upon surrender of such certificate, a new certificate evidencing and representing the number of whole shares of Common Stock after the Effective Time into which the shares of Common Stock formerly represented by such certificate shall have been combined.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</span></span><span style="color:#231f20;">Except as amended hereby, the provisions of the Certificate of Incorporation shall remain in full force and effect.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</span></span><span style="color:#231f20;">This Certificate of Amendment shall be effective at [</span><span style="color:#231f20;font-family:'Symbol';">&#183;</span><span style="color:#231f20;">] (Eastern Time) as of [</span><span style="color:#231f20;font-family:'Symbol';">&#183;</span><span style="color:#231f20;">], 2025.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">B-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, this Certificate of Amendment has been signed by an authorized officer of the Corporation on &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">AEROVATE THERAPEUTICS,&#160;INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Timothy P. Noyes</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">B-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_1f576c5d_578f_45ea_8982_3e49429466f0"></a><a id="ANNEXC_115424"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ANNEX C</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTIFICATE OF AMENDMENT TO THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AEROVATE THERAPEUTICS,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate Therapeutics,&#160;Inc., a corporation organized and existing under the laws of the State of Delaware (the &#8220;Corporation&#8221;), certifies that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</span></span><span style="color:#231f20;">The current name of the Corporation is Aerovate Therapeutics,&#160;Inc.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</span></span><span style="color:#231f20;">The amendments set forth in this Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of the Corporation (this &#8220;Certificate of Amendment&#8221;) have been duly adopted in accordance with Section&#160;242 of the Delaware General Corporation Law by the board of directors of </span>the Corporation and by the stockholders of the Corporation. This Certificate of Amendment hereby amends the Corporation&#8217;s Second Amended and Restated Certificate of Incorporation, as currently in effect (the &#8220;Certificate of Incorporation&#8221;) as set forth below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</span></span><span style="color:#231f20;">The first paragraph of Article&#160;IV of the Certificate of Incorporation is hereby amended and restated in its entirety as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8220;CAPITAL STOCK</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The total number of shares of capital stock which the Corporation shall have authority to issue is [<span style="font-family:'Symbol';">&#183;</span>], of which (i)&#160;[<span style="font-family:'Symbol';">&#183;</span>] shares shall be a class designated as common stock, par value $0.0001 per share (the &#8220;<b style="font-weight:bold;">Common Stock</b>&#8221;), and (ii)&#160;10,000,000 shares shall be a class designated as undesignated preferred stock, par value $0.0001 per share (the &#8220;<b style="font-weight:bold;">Undesignated Preferred Stock</b>&#8221;).&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</span></span><span style="color:#231f20;">Except as amended hereby, the provisions of the Certificate of Incorporation shall remain in full force and effect.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</span></span><span style="color:#231f20;">This Certificate of Amendment shall be effective at [</span><span style="color:#231f20;font-family:'Symbol';">&#183;</span><span style="color:#231f20;">] (Eastern Time) as of [</span><span style="color:#231f20;font-family:'Symbol';">&#183;</span><span style="color:#231f20;">], 2025.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">C-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, this Certificate of Amendment has been signed by an authorized officer of the Corporation on &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">AEROVATE THERAPEUTICS,&#160;INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Timothy P. Noyes</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">C-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_1c260204_3045_4d62_b649_443c89e402bf"></a><a id="ANNEXD_143895"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ANNEX D</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">D-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_a62a998c_c480_4249_8b8d_6eb29d45e6ca"></a><a id="ANNEXE_874079"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ANNEX E</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">E-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:37.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_30a351f2_52e2_433b_9479_a2887e7280a6"></a><a id="ANNEXF_328548"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ANNEX F</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="avte-20240930xs4042.jpg" alt="Graphic" style="display:inline-block;height:32.55pt;left:0%;padding-bottom:0.45pt;position:relative;top:0pt;width:164.05pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Strictly Confidential</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">October&#160;30, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Aerovate Therapeutics&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">930 Winter Street, Suite&#160;M-500</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Waltham, MA 02451</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attention: Habib Dable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Chairman of the Board of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Members of the Board of Directors:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have been advised that Aerovate Therapeutics&#160;Inc., a Delaware corporation (&#8220;Aerovate&#8221; or &#8220;Parent&#8221;), proposes to enter into an Agreement and Plan of Merger (the &#8220;Agreement&#8221;), by and among Aerovate, Caribbean Merger Sub,&#160;Inc. a Delaware corporation (&#8220;First Merger Sub&#8221;) and wholly owned subsidiary of Parent, Caribbean Merger Sub II, LLC, a Delaware limited liability company (&#8220;Second Merger Sub&#8221; and, together with First Merger Sub, &#8220;Merger Subs&#8221;) and wholly owned subsidiary of Parent, and Jade Biosciences,&#160;Inc. a Delaware corporation (&#8220;Jade&#8221; or the &#8220;Company&#8221;). Upon the terms and subject to the conditions set forth in the Agreement, at the First Effective Time, First Merger Sub will be merged with and into the Company (the &#8220;First Merger&#8221;), and the separate existence of First Merger Sub will cease. The Company will continue as the surviving corporation in the First Merger (the &#8220;First Step Surviving Corporation&#8221;). Upon the terms and subject to the conditions set forth in the Agreement, at the Second Effective Time, the First Step Surviving Corporation will merge with and into Second Merger Sub (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;), and the separate existence of the First Step Surviving Corporation shall cease. As a result of the Second Merger, Second Merger Sub will continue as the surviving entity in the Second Merger (the &#8220;Surviving Entity&#8221;). Pursuant to the terms and subject to the conditions set forth in the Agreement, upon consummation of the Merger, (i)&#160;each outstanding share of Company Common Stock (excluding shares of Company Capital Stock held as treasury stock immediately prior to the First Effective Time which shall be canceled and excluding Dissenting Shares) will be converted solely into the right to receive a number of shares of Parent Common Stock equal to the Exchange Ratio, and (ii)&#160;each outstanding share of Company Preferred Stock (excluding shares of Company Capital Stock held as treasury stock immediately prior to the First Effective Time which shall be canceled and excluding Dissenting Shares) will be converted solely into the right to receive a number of shares of Parent Convertible Preferred Stock equal to (x)&#160;the Exchange Ratio divided by (y)&#160;1,000 (collectively, the &#8220;Merger Consideration&#8221;). The terms and conditions of the Merger are more fully set forth in the Agreement. Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Agreement contemplates that Parent may declare and pay a cash dividend on the shares of Parent Common Stock outstanding prior to the First Effective Time (excluding for the avoidance of doubt any shares of Parent Capital Stock issued as part of the Merger Consideration) up to an amount equal to the aggregate to Parent&#8217;s reasonable good faith approximation of the amount by which Parent&#8217;s net cash (as calculated pursuant to the Merger Agreement) will exceed $0 (the &#8220;Pre-Closing Cash Dividend&#8221;) after effecting the Parent Pre-Closing Cash Dividend. We have assumed, with your consent, that Parent&#8217;s net cash (as calculated pursuant to the Merger Agreement) is expected to be approximately zero at Closing after effecting the Parent Pre-Closing Cash Dividend.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><img src="avte-20240930xs4043.jpg" alt="Graphic" style="display:inline-block;height:37.5pt;width:222pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Agreement also contemplates that concurrently with the execution and delivery of the Agreement, certain investors will execute a Subscription Agreement representing an aggregate commitment of $205.0 (but not less than $80 million) (which, for the avoidance of doubt, excludes the $95 million Convertible Notes&#160;previously issued plus approximately $6 million of accrued interest from the Convertible Notes, both converting at a 20% discount) pursuant to which such Persons will agree to purchase shares of Company Common Stock immediately prior to the Closing (the &#8220;Concurrent Investment&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of rendering our Opinion we have, with your consent, assumed that (i)&#160;prior to the closing of the Merger, the Parent Pre-Closing Cash Dividend has occurred, (ii)&#160;prior to closing the Merger, the Company will receive approximately $331.3 million in proceeds from the Concurrent Investment (including the $95 million Convertible Notes&#160;previously issued plus approximately $6 million of accrued interest from the Convertible Notes, both converting at a 20% discount), (iii)&#160;the Exchange Ratio will be 21.4388, and (iv) <span style="color:#231f20;">upon closing of the Merger, the holders of Company Common Stock, Company Preferred Stock, Company Options and Company Warrants will in the aggregate hold approximately 98.4% of the fully- diluted shares of Parent Common Stock (excluding certain Parent Options) and the holders of Parent Common Stock will in the aggregate hold approximately 1.6% of the fully-diluted shares of Parent Common Stock (excluding certain Parent Options) immediately following the Merger, after giving effect to the </span>Parent Pre-Closing Cash Dividend and the Concurrent Financing, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have, with your consent, relied upon the assumption that all information provided to us by Aerovate and Jade is accurate and complete in all material respects. We expressly disclaim any undertaking or obligation to advise any person of any change in any fact or matter affecting our Opinion of which we become aware after the date hereof. We have assumed there were no material changes in the assets, liabilities, financial condition, results of operations, business or prospects of Aerovate or Jade since the date of the last financial statements made available to us. We have not obtained any independent evaluations, valuations or appraisals of the assets or liabilities of Aerovate or Jade, nor have we been furnished with such materials. In addition, we have not evaluated the solvency or fair value of Aerovate or Jade under any state or federal laws relating to bankruptcy, insolvency or similar matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Opinion does not address any legal, regulatory, tax or accounting matters related to the Merger, as to which we have assumed that Aerovate and the Board of Directors have received such advice from legal, tax and accounting advisors as each has determined appropriate. Our Opinion addresses only the fairness from a financial point of view of the Exchange Ratio as set forth in the Agreement to the holders of Parent Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We express no view as to any other aspect or implication of the Merger or any other agreement or arrangement entered into in connection with the Merger. Our Opinion is necessarily based upon economic and market conditions and other circumstances as they exist and can be evaluated by us on the date hereof. It should be understood that although subsequent developments may affect our Opinion, we do not have any obligation to update, revise or reaffirm our Opinion and we expressly disclaim any responsibility to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have not considered any potential legislative or regulatory changes currently being considered or recently enacted by the United States or any foreign government, or any domestic or foreign regulatory body, or any changes in accounting methods or generally accepted accounting principles that may be adopted by the Securities and Exchange Commission (the &#8220;SEC&#8221;), the Financial Accounting Standards Board, or any similar foreign regulatory body or board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In your capacity as members of the Board of Directors of Aerovate (the &#8220;Board of Directors&#8221;), you have requested our opinion (our &#8220;Opinion&#8221;) as to the fairness, from a financial point of view and as of the date hereof, of the Exchange Ratio as set forth in the Agreement to the holders of Parent Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with our Opinion, we took into account an assessment of general economic, market and financial conditions as well as our experience in connection with similar transactions and securities valuations generally and, among other things:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Reviewed a draft of the Merger Agreement;</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Reviewed and analyzed certain publicly available financial and other information for each of Aerovate and Jade;</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Discussed with certain members of the management of Aerovate the historical and current business operations, financial condition and prospects of Aerovate and Jade;</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Reviewed and analyzed certain operating results of Jade as compared to operating results and the reported price and trading histories of certain publicly traded companies that Lucid deemed relevant;</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Reviewed and analyzed certain financial terms of the Agreement as compared to the publicly available financial terms of certain selected business combinations that Lucid deemed relevant;</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Reviewed and analyzed certain financial terms of completed initial public offerings for certain companies that Lucid deemed relevant;</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Reviewed certain pro forma financial effects of the Merger;</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Reviewed and analyzed certain internal financial analyses, including the cash burn model over the next&#160;year and whether the concurrent capital raised would sufficiently cover select programs, reports and other information concerning Jade prepared by Jade; and</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">Reviewed and analyzed such other information and such other factors, and conducted such other financial studies, analyses and investigations, as Lucid deemed relevant for purposes of this Opinion.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of rendering our Opinion we have assumed, with your consent, that except as would not be in any way meaningful to our analysis: (i)&#160;the final form of the Agreement will not differ from the draft Agreement that we have reviewed; (ii)&#160;the representations and warranties of each party contained in the Agreement are true and correct in all respects; (iii)&#160;each party will perform all of the covenants and agreements required to be performed by such party under the Agreement; and (iv)&#160;the transactions contemplated by the Agreement will be consummated in accordance with the terms of the Agreement, without any waiver or amendment of any term or condition thereof. We have also assumed that all governmental, regulatory and other consents and approvals contemplated by the Agreement or otherwise required for the transactions contemplated by the Agreement will be obtained and that in the course of obtaining any of those consents no restrictions will be imposed, or waivers made that would have an adverse effect on Aerovate, Jade, or the contemplated benefits of the Merger. We have assumed that the Merger will be consummated in a manner that complies with the applicable provisions of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and all other applicable federal and state statutes and the rules&#160;and regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is understood that this letter is intended for the benefit and use of the Board of Directors (in its capacity as such) in its consideration of the financial terms of the Merger and, except as set forth in our engagement letter with Aerovate, dated as of October&#160;29, 2024 (the &#8220;Engagement Letter&#8221;), may not be used for any other purpose or reproduced, disseminated, quoted or referred to at any time, in any manner or for any purpose without our prior written consent, except that this Opinion may be included in its entirety in any filing related to the Merger required to be filed with the SEC and any proxy statement to be mailed to holders of Parent Common Stock. This letter does not constitute a recommendation to the Board of Directors of whether to approve the Merger or to any stockholder of Aerovate or any other person as to how to vote or act with respect to the transactions contemplated by the Agreement (including the Merger) or any other matter. Our Opinion does not address Aerovate&#8217;s underlying business decision to proceed with the Merger or the relative merits of the Merger compared to other alternatives available to Aerovate. We express no opinion as to the prices or ranges of prices at which shares or the securities of any person, including Aerovate, will trade at any time, including following the announcement or consummation of the Merger, or as to the potential effects of volatility in the credit, financial, and stock markets on Aerovate, Jade or the transactions contemplated by the Agreement. We have not been requested to opine as to, and our Opinion does not in any manner address, the amount or nature of compensation to any of the officers, directors or employees of any party to the Merger, or any class of such persons, relative to the compensation to be paid to the holders of Parent Common Stock in connection with the Merger or with respect to the fairness of any such compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lucid is an investment bank providing investment banking, brokerage, equity research, institutional sales and trading services. As part of our investment banking services, we are regularly engaged in the valuation of businesses and their securities in connection with mergers, negotiated underwritings, secondary distributions of listed and unlisted securities, private placements and valuations for corporate and other purposes. Lucid will receive a fee for rendering our Opinion set forth below pursuant to the Engagement Letter, which is not contingent upon consummation of the Merger. In addition, Aerovate has agreed to reimburse our expenses and indemnify us for certain liabilities that may arise out of our engagement. In the two&#160;years preceding the date hereof, Lucid has not had a relationship with Aerovate or its affiliates and has not received any fees from Aerovate or any of its affiliates. In the two&#160;years preceding the date hereof, Lucid has not had a relationship with Jade or any of its affiliates and has not received any fees from Jade or any of its affiliates. Lucid and its affiliates may in the future seek to provide investment banking or financial advisory services to Aerovate and Jade and/or their respective affiliates and expect to receive fees for the rendering of these services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the ordinary course of business, Lucid or certain of our affiliates, as well as investment funds in which we or our affiliates may have financial interests, may acquire, hold or sell long or short positions, or trade or otherwise effect transactions in debt, equity, and </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:16.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">other securities and financial instruments (including bank loans and other obligations) of, or investments in, Aerovate, Jade or any other party that may be involved in the Merger and/or their respective affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Consistent with applicable legal and regulatory requirements, Lucid has adopted policies and procedures to establish and maintain the independence of our research department and personnel. As a result, our research analysts may hold views, make statements or investment recommendations and/or publish research reports with respect to Aerovate and the proposed Merger that may differ from the views of Lucid&#8217;s investment banking personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Opinion set forth below was reviewed and approved by a fairness opinion committee of Lucid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based upon and subject to the foregoing, including the various assumptions and limitations set forth herein and such other factors that we deem relevant, it is our opinion that, as of the date hereof, the Exchange Ratio is fair, from a financial point of view, to the holders of Parent Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Very truly yours,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><img src="avte-20240930xs4044.jpg" alt="Graphic" style="display:inline-block;height:16.3pt;left:0%;padding-bottom:0.2pt;position:relative;top:0pt;width:139.6pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Lucid Capital Markets, LLC</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_b47cdb4b_6f85_4e61_b9ca_bc858e71376f"></a><a id="ANNEXG_706122"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">ANNEX G</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Section&#160;262 of the Delaware General Corporation Law</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#167; 262. Appraisal rights</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">Any stockholder of a corporation of this State who holds shares of stock on the date of the making of a demand pursuant to subsection (d)&#160;of this section with respect to such shares, who continuously holds such shares through the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, who has otherwise complied with subsection (d)&#160;of this section and who has neither </span>voted in favor of the merger, consolidation, conversion, transfer, domestication or continuance nor consented thereto in writing pursuant to &#167; 228 of this title shall be entitled to an appraisal by the Court of Chancery of the fair value of the stockholder&#8217;s shares of stock under the circumstances described in subsections (b)&#160;and (c) <span style="color:#231f20;">of this section. As used in this section, the word &#8220;stockholder&#8221; means a holder of record of stock in a corporation; the words &#8220;stock&#8221; and &#8220;share&#8221; mean and include what is ordinarily meant by those words; the words &#8220;depository receipt&#8221; mean a receipt or other instrument issued by a depository representing an interest in 1 or more shares, or fractions thereof, solely of stock of a corporation, which stock is deposited with the depository; the words &#8220;beneficial owner&#8221; mean a person who is the beneficial owner of shares of stock held either in voting trust or by a nominee on behalf of such person; and the word &#8220;person&#8221; means any individual, corporation, partnership, unincorporated association or other entity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">Appraisal rights shall be available for the shares of any class or series of stock of a constituent, converting, transferring, domesticating or continuing corporation in a merger, consolidation, conversion, transfer, domestication or continuance to be effected pursuant to &#167; 251 (other than a merger effected pursuant to &#167; 251(g)&#160;of this title), &#167; 252, &#167; 254, &#167; 255, &#167; 256, &#167; 257, &#167; 258, &#167; 263, &#167; 264, &#167; 266 or &#167; 390 of this title (other than, in each case and solely with respect to a converted or domesticated corporation, a merger, consolidation, conversion, transfer, domestication or continuance authorized pursuant to and in accordance with the provisions of &#167; 265 or &#167; 388 of this title):</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span><i style="color:#231f20;font-style:italic;">Provided, however</i><span style="color:#231f20;">, that no appraisal rights under this section shall be available for the shares of any class or series of stock, which stock, or depository receipts in respect thereof, at the record date fixed to determine the stockholders entitled to receive notice of the meeting of stockholders, or at </span>the record date fixed to determine the stockholders entitled to consent pursuant to &#167; 228 of this title, to act upon the agreement of merger or consolidation or the resolution providing for the conversion, transfer, domestication or continuance (or, in the case of a merger pursuant to &#167; 251(h)&#160;of this title, as of immediately prior to the execution of the agreement of merger), were either: (i)&#160;listed on a national securities exchange or (ii)&#160;held of record by more than 2,000 holders; and further provided that no appraisal rights shall be available for any shares of stock of the constituent corporation surviving a merger if the merger did not require for its approval the vote of the stockholders of the surviving corporation as provided in &#167; 251(f)&#160;of this title.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(2)</span></span><span style="color:#231f20;">Notwithstanding paragraph (b)(1)&#160;of this section, appraisal rights under this section shall be available for the shares of any class or series of stock of a constituent, converting, transferring, domesticating or continuing corporation if the holders thereof are required by the terms of an agreement of merger or consolidation, or by the terms of a resolution providing for conversion, transfer, domestication or continuance, pursuant to &#167; 251, &#167; 252, &#167; 254, &#167; 255, &#167; 256, &#167; 257, &#167; 258, &#167; 263, &#167; 264, </span>&#167; 266 or &#167; 390 of this title to accept for such stock anything except:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a.</span></span><span style="color:#231f20;">Shares of stock of the corporation surviving or resulting from such merger or consolidation, or of the converted entity or the entity resulting from a transfer, domestication or continuance if such entity is a corporation as a result of the conversion, transfer, domestication or continuance, or depository receipts in respect thereof;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b.</span></span><span style="color:#231f20;">Shares of stock of any other corporation, or depository receipts in respect thereof, which shares of stock (or depository receipts in respect thereof) or depository receipts at the effective date of the merger, consolidation, conversion, transfer, domestication or continuance will be either listed on a national securities exchange or held of record by more than 2,000 holders;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">c.</span></span><span style="color:#231f20;">Cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a. and b. of this section; or</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">d.</span></span><span style="color:#231f20;">Any combination of the shares of stock, depository receipts and cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a., b. and c. of this section.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">G-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(3)</span></span><span style="color:#231f20;">In the event all of the stock of a subsidiary Delaware corporation party to a merger effected under &#167; 253 or &#167; 267 of this title is not owned by the parent immediately prior to the merger, appraisal rights shall be available for the shares of the subsidiary Delaware corporation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(4)</span></span><span style="color:#231f20;">[Repealed.]</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">Any corporation may provide in its certificate of incorporation that appraisal rights under this section shall be available for the shares of any class or series of its stock as a result of an amendment to its certificate of incorporation, any merger or consolidation in which the corporation is a constituent corporation, the sale of all or substantially all of the assets of the corporation or a conversion effected pursuant to &#167; 266 of this title or a transfer, domestication or continuance effected pursuant to &#167; 390 of this title. If the certificate of incorporation contains such a provision, the provisions of this section, including those set forth in subsections (d), (e), and (g)&#160;of this section, shall apply as nearly as is practicable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">Appraisal rights shall be perfected as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span><span style="color:#231f20;">If a proposed merger, consolidation, conversion, transfer, domestication or continuance for which appraisal rights are provided under this section is to be submitted for approval at a meeting of stockholders, the corporation, not less than 20&#160;days prior to the meeting, shall notify each of its stockholders who was such on the record date for notice of such meeting (or such members who received notice in accordance with &#167; 255(c)&#160;of this title) with respect to shares for which appraisal rights are available pursuant to subsection (b)&#160;or (c)&#160;of this section that appraisal rights are available for any or all of the shares of the constituent corporations or the converting, transferring, domesticating or continuing corporation, and shall include in such notice either a copy of this section (and, if 1 of the constituent corporations or the converting corporation is a nonstock corporation, a copy of &#167; 114 of this title) or information directing the stockholders to a publicly available electronic resource at which this section (and, &#167; 114 of this title, if applicable) may be accessed without subscription or cost. Each stockholder electing to demand the appraisal of such stockholder&#8217;s shares shall deliver to the corporation, before the taking of the vote on the merger, consolidation, conversion, transfer, domestication or continuance, a written demand for appraisal of such stockholder&#8217;s shares; provided that a demand may be delivered to the corporation by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs the corporation of the identity of the stockholder and that the stockholder </span>intends thereby to demand the appraisal of such stockholder&#8217;s shares. A proxy or vote against the merger, consolidation, conversion, transfer, domestication or continuance shall not constitute such a demand. A stockholder electing to take such action must do so by a separate written demand as herein provided. Within 10&#160;days after the effective date of such merger, consolidation, conversion, transfer, domestication or continuance, the surviving, resulting or converted entity shall notify each stockholder of each constituent or converting, transferring, domesticating or continuing corporation who has complied with this subsection and has not voted in favor of or consented to the merger, consolidation, conversion, transfer, domestication or continuance, and any beneficial owner who has demanded appraisal under paragraph (d)(3)&#160;of this section, of the date that the merger, consolidation or conversion has become effective; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(2)</span></span><span style="color:#231f20;">If the merger, consolidation, conversion, transfer, domestication or continuance was approved pursuant to &#167; 228, &#167; 251(h), &#167; 253, or &#167; 267 of this title, then either a constituent, converting, transferring, domesticating or continuing corporation before the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, or the surviving, resulting or converted entity within 10&#160;days after such effective date, shall notify each stockholder of any class or series of stock of such constituent, converting, transferring, domesticating or continuing corporation who is entitled to appraisal rights of the approval of the merger, consolidation, conversion, transfer, </span>domestication or continuance and that appraisal rights are available for any or all shares of such class or series of stock of such constituent, converting, transferring, domesticating or continuing corporation, and shall include in such notice either a copy of this section (and, if 1 of the constituent corporations or the converting, transferring, domesticating or continuing corporation is a nonstock corporation, a copy of &#167; 114 of this title) or information directing the stockholders to a publicly available electronic resource at which this section (and &#167; 114 of this title, if applicable) may be accessed without subscription or cost. Such notice may, and, if given on or after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, shall, also notify such stockholders of the effective date of the merger, consolidation, conversion, transfer, domestication or continuance. Any stockholder entitled to appraisal rights may, within 20&#160;days after the date of giving such notice or, in the case of a merger approved pursuant to &#167; 251(h)&#160;of this title, within the later of the consummation of the offer contemplated by &#167; 251(h)&#160;of this title and 20&#160;days after the date of giving such notice, demand in writing from the surviving, resulting or converted entity the appraisal of such holder&#8217;s shares; provided that a demand may be delivered to such entity by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs such entity of the identity of </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">G-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">the stockholder and that the stockholder intends thereby to demand the appraisal of such holder&#8217;s shares. If such notice did not notify stockholders of the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, either (i) <span style="color:#231f20;">each such constituent corporation or the converting, transferring, domesticating or continuing corporation shall send a second notice before the effective date of the merger, consolidation, conversion, transfer, domestication or continuance notifying each of the holders of any class or series of stock of such constituent, converting, transferring, domesticating or continuing corporation that are entitled to appraisal rights of the effective date of the merger, consolidation, conversion, transfer, domestication or continuance or (ii)&#160;the surviving, resulting or converted entity shall send such a second notice to all such holders on or within 10&#160;days after such effective date; provided, however, that if such second notice is sent more than 20&#160;days following the sending of the first notice or, in the case of a merger approved pursuant to &#167; 251(h)&#160;of this title, later than the later of the consummation of the offer contemplated by </span>&#167; 251(h)&#160;of this title and 20&#160;days following the sending of the first notice, such second notice need only be sent to each stockholder who is entitled to appraisal rights and who has demanded appraisal of such holder&#8217;s shares in accordance with this subsection and any beneficial owner who has demanded appraisal under paragraph (d)(3)&#160;of this section. An affidavit of the secretary or assistant secretary or of the transfer agent of the corporation or entity that is required to give either notice that such notice has been given shall, in the absence of fraud, be prima facie evidence of the facts stated therein. For purposes of determining the stockholders entitled to receive either notice, each constituent corporation or the converting, transferring, domesticating or continuing corporation may fix, in advance, a record date that shall be not more than 10&#160;days prior to the date the notice is given, provided, that if the notice is given on or after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, the record date shall be such effective date. If no record date is fixed and the notice is given prior to the effective date, the record date shall be the close of business on the day next preceding the day on which the notice is given.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(3)</span></span><span style="color:#231f20;">Notwithstanding subsection (a)&#160;of this section (but subject to this paragraph (d)(3)), a beneficial owner may, in such person&#8217;s name, demand in writing an appraisal of such beneficial owner&#8217;s shares in accordance with either paragraph (d)(1)&#160;or (2)&#160;of this section, as applicable; provided that (i) such beneficial owner continuously owns such shares through the effective date of the merger, consolidation, conversion, transfer, domestication or continuance and otherwise satisfies the requirements applicable to a stockholder under the first sentence of subsection (a)&#160;of this section and (ii) the demand made by such beneficial owner reasonably identifies the holder of record of the shares for which the demand is made, is accompanied by documentary evidence of such beneficial owner&#8217;s beneficial ownership of stock and a statement that such documentary evidence is a true and correct copy of what it purports to be, and provides an address at which such beneficial owner consents to receive notices given by the surviving, resulting or converted entity hereunder and to be set forth on the verified list required by subsection (f)&#160;of this section.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="color:#231f20;">Within 120&#160;days after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, the surviving, resulting or converted entity, or any person who has complied with subsections (a)&#160;and (d)&#160;of this section and who is otherwise entitled to appraisal rights, may commence an </span>appraisal proceeding by filing a petition in the Court of Chancery demanding a determination of the value of the stock of all such stockholders. Notwithstanding the foregoing, at any time within 60&#160;days after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, any person entitled to appraisal rights who has not commenced an appraisal proceeding or joined that proceeding as a named party shall have the right to withdraw such person&#8217;s demand for appraisal and to accept the terms offered upon the merger, consolidation, conversion, transfer, domestication or continuance. Within 120&#160;days after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, any person who has complied with the requirements of subsections (a)&#160;and (d)&#160;of this section, upon request given in writing (or by electronic transmission directed to an information processing system (if any) expressly designated for that purpose in the notice of appraisal), shall be entitled to receive from the surviving, resulting or converted entity a statement setting forth the aggregate number of shares not voted in favor of the merger, consolidation, conversion, transfer, domestication or continuance (or, in the case of a merger approved pursuant to &#167; 251(h)&#160;of this title, the aggregate number of shares (other than any excluded stock (as defined in &#167; 251(h)(6)d. of this title)) that were the subject of, and were not tendered into, and accepted for purchase or exchange in, the offer referred to in &#167; 251(h)(2)&#160;of this title)), and, in either case, with respect to which demands for appraisal have been received and the aggregate number of stockholders or beneficial owners holding or owning such shares (provided that, where a beneficial owner makes a demand pursuant to paragraph (d)(3)&#160;of this section, the record holder of such shares shall not be considered a separate stockholder holding such shares for purposes of such aggregate number). Such statement shall be given to the person within 10&#160;days after such person&#8217;s request for such a statement is received by the surviving, resulting or converted entity or within 10&#160;days after expiration of the period for delivery of demands for appraisal under subsection (d)&#160;of this section, whichever is later.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span><span style="color:#231f20;">Upon the filing of any such petition by any person other than the surviving, resulting or converted entity, service of a copy thereof shall be made upon such entity, which shall within 20&#160;days after such service file in the office of the Register in Chancery in which the petition was filed a duly verified list containing </span>the names and addresses of all persons who have demanded appraisal for their shares and with whom agreements as to the value of their shares have not been reached by such entity. If the petition shall be </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">G-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">filed by the surviving, resulting or converted entity, the petition shall be accompanied by such a duly verified list. The Register in Chancery, if so ordered by the Court, shall give notice of the time and place fixed for the hearing of such petition by registered or certified mail to the surviving, resulting or converted entity and to the persons shown on the list at the addresses therein stated. The forms of the notices by mail and by publication shall be approved by the Court, and the costs thereof shall be borne by the surviving, resulting or converted entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span><span style="color:#231f20;">At the hearing on such petition, the Court shall determine the persons who have complied with this section and who have become entitled to appraisal rights. The Court may require the persons who have demanded an appraisal for their shares and who hold stock represented by certificates to submit their certificates of stock to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any person fails to comply with such direction, the Court may dismiss the proceedings as to such person. If immediately before the merger, consolidation, conversion, transfer, domestication or continuance the shares of the class or series of stock of the constituent, converting, transferring, domesticating or continuing corporation as to which appraisal rights are available were listed on a national securities exchange, the Court shall dismiss the proceedings as to all holders of such shares who are otherwise entitled to appraisal rights unless (1)&#160;the total number of shares entitled to appraisal exceeds 1% of the outstanding shares of the class or series eligible for appraisal, (2)&#160;the value of the consideration provided in the merger, consolidation, conversion, transfer, domestication or continuance for such total number of shares exceeds $1 million, or (3)&#160;the merger was approved pursuant to &#167; 253 or &#167; 267 of this title.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span><span style="color:#231f20;">After the Court determines the persons entitled to an appraisal, the appraisal proceeding shall be conducted in accordance with the rules&#160;of the Court of Chancery, including any rules&#160;specifically governing appraisal proceedings. Through such proceeding the Court shall determine the fair value of the shares exclusive of any element of value arising from the accomplishment or expectation of the merger, consolidation, conversion, transfer, domestication or continuance, together with interest, if any, to be paid upon the amount determined to be the fair value. In determining such fair value, the Court shall take into account all relevant factors. Unless the Court in its discretion determines otherwise for good cause shown, and except as provided in this subsection, interest from the effective date of the merger, consolidation, conversion, transfer, </span>domestication or continuance through the date of payment of the judgment shall be compounded quarterly and shall accrue at 5% over the Federal Reserve discount rate (including any surcharge) as established from time to time during the period between the effective date of the merger, consolidation or conversion and the date of payment of the judgment. At any time before the entry of judgment in the proceedings, the surviving, resulting or converted entity may pay to each person entitled to appraisal an amount in cash, in which case interest shall accrue thereafter as provided herein only upon the sum of (1)&#160;the difference, if any, between the amount so paid and the fair value of the shares as determined by the Court, and (2)&#160;interest theretofore accrued, unless paid at that time. Upon application by the surviving, resulting or converted entity or by any person entitled to participate in the appraisal proceeding, the Court may, in its discretion, proceed to trial upon the appraisal prior to the final determination of the persons entitled to an appraisal. Any person whose name appears on the list filed by the surviving, resulting or converted entity pursuant to subsection (f)&#160;of this section may participate fully in all proceedings until it is finally determined that such person is not entitled to appraisal rights under this section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="color:#231f20;">The Court shall direct the payment of the fair value of the shares, together with interest, if any, by the surviving, resulting or converted entity to the persons entitled thereto. Payment shall be so made to each such person upon such terms and conditions as the Court may order. The Court&#8217;s decree may be enforced as other decrees in the Court of Chancery may be enforced, whether such surviving, resulting or converted entity be an entity of this State or of any state.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span><span style="color:#231f20;">The costs of the proceeding may be determined by the Court and taxed upon the parties as the Court deems equitable in the circumstances. Upon application of a person whose name appears on the list filed by the surviving, resulting or converted entity pursuant to subsection (f)&#160;of this section who participated in the proceeding and incurred expenses in connection therewith, the Court may order all or a portion of such expenses, including, without limitation, reasonable attorney&#8217;s fees and the fees and expenses of experts, to be charged pro rata against the value of all the shares entitled to an appraisal not dismissed pursuant to subsection (k)&#160;of this section or subject to such an award pursuant to a reservation of jurisdiction under subsection (k)&#160;of this section.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(k)</span></span><span style="color:#231f20;">Subject to the remainder of this subsection, from and after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, no person who has demanded appraisal rights with respect to some or all of such person&#8217;s shares as provided in subsection (d)&#160;of this section shall be entitled to vote such shares for any purpose or to receive payment of dividends or other distributions on such shares (except dividends or other distributions payable to stockholders of record at a date which is prior to the effective date of the merger, consolidation, conversion, transfer, domestication or continuance). If a person who has made a demand for an appraisal in accordance with this section shall deliver to the surviving, resulting or converted entity a written withdrawal of such person&#8217;s demand for an appraisal in respect of some or all of such person&#8217;s shares in accordance with subsection (e)&#160;of this section, either within 60&#160;days after such effective date or thereafter with the written approval of the corporation, </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">G-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">then the right of such person to an appraisal of the shares subject to the withdrawal shall cease. Notwithstanding the foregoing, an appraisal proceeding in the Court of Chancery shall not be dismissed as to any person without the approval of the Court, and such approval may be conditioned upon such terms as the Court deems just, including without limitation, a reservation of jurisdiction for any application to the Court made under subsection (j)&#160;of this section; provided, however that this provision shall not affect the right of any person who has not commenced an appraisal proceeding or joined that proceeding as a named party to withdraw such person&#8217;s demand for appraisal and to accept the terms offered upon the merger, consolidation, conversion, transfer, domestication or continuance within 60&#160;days after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, as set forth in subsection (e)&#160;of this section. If a petition for an appraisal is not filed within the time provided in subsection (e)&#160;of this section, the right to appraisal with respect to all shares shall cease.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(l)</span></span><span style="color:#231f20;">The shares or other equity interests of the surviving, resulting or converted entity to which the shares of stock subject to appraisal under this section would have otherwise converted but for an appraisal demand made in accordance with this section shall have the status of authorized but not outstanding shares of stock or other equity interests of the surviving, resulting or converted entity, unless and until the </span>person that has demanded appraisal is no longer entitled to appraisal pursuant to this section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">G-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_Hlk183363221"></a><a id="_8d78037c_3437_4921_b649_9bab5955aabd"></a><a id="ANNEXH_655067"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ANNEX H</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FORM&#160;OF LOCK-UP AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;">October&#160;30, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Aerovate Therapeutics,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">930 Winter Street,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Suite&#160;M-500</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Waltham, MA 02451</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Ladies and Gentlemen:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The undersigned signatory of this lock-up agreement (this &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lock-Up Agreement</span>&#8221;) understands that Aerovate Therapeutics,&#160;Inc., a Delaware corporation (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent</span>&#8221;), is entering into an Agreement and Plan of Merger, dated as of October&#160;30, 2024 (as the same may be amended from time to time, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger Agreement</span>&#8221;) with Caribbean Merger Sub I,&#160;Inc., a Delaware corporation and a wholly owned subsidiary of Parent, Caribbean Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of Parent, and Jade Biosciences,&#160;Inc., a Delaware corporation (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</span>&#8221;). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a condition and inducement to each of the parties to enter into the Merger Agreement and to consummate the transactions contemplated thereby, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned hereby irrevocably agrees that, subject to the exceptions set forth herein, without the prior written consent of Parent, the undersigned will not, during the period commencing upon the Closing and ending on the date that is 180&#160;days after the Closing Date (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restricted Period</span>&#8221;); provided, that if a registration statement covering the shares of Company Common Stock and pre-funded Company Warrants issued and sold in connection with the Company Pre-Closing Financing (other than any shares or pre-funded Company Warrants held by affiliates of the Company) has not been declared effective by the SEC prior to the end of such 180-day period, then the Restricted Period shall end on such later date upon which such registration statement is first declared effective:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span><span style="color:#231f20;">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Parent Common Stock or any securities convertible into or exercisable or exchangeable for shares of Parent Common Stock (including without limitation, shares of Parent Common Stock or such other securities of Parent which may be deemed to be beneficially owned by the undersigned in accordance with the rules&#160;and regulations of the SEC and securities of Parent which may be issued upon exercise or vesting, as applicable, of a stock option or warrant or settlement of a restricted stock unit or restricted stock award and Parent Common Stock or such other securities to be issued to the undersigned in connection with the Merger, in each case, that are currently or hereafter owned of record or beneficially (including holding as a custodian)) by the undersigned, except as set forth below (collectively, the &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Undersigned&#8217;s Shares</span><span style="color:#231f20;">&#8221;);</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(2)</span></span><span style="color:#231f20;">enter into any swap, short sale, hedge or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Undersigned&#8217;s Shares regardless of whether any such transaction described in clause (1)&#160;above or this clause (2)&#160;is to be settled by delivery of shares of Parent Common Stock or other securities, in cash or otherwise;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(3)</span></span><span style="color:#231f20;">make any demand for, or exercise any right with respect to, the registration of any shares of Parent Common Stock or any security convertible into or exercisable or exchangeable for shares of Parent Common Stock (other than such rights set forth in the Merger Agreement and that certain registration rights agreement entered into by the Company and certain signatories therein in connection with the Concurrent Investment); or</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(4)</span></span><span style="color:#231f20;">except for any support agreement entered into as of the date hereof by the undersigned with Parent and the Company, grant any proxies or powers of attorney with respect to any Parent Common </span>Stock, deposit any Parent Common Stock into a voting trust or enter into a voting agreement or similar arrangement or commitment with respect to any Parent Common Stock; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(5)</span></span><span style="color:#231f20;">publicly disclose the intention to do any of the foregoing.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">H-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The restrictions and obligations contemplated by this Lock-Up Agreement shall not apply to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">transfers of the Undersigned&#8217;s Shares:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span><span style="color:#231f20;">(A)&#160;to any person related to the undersigned (or to an ultimate beneficial owner of the undersigned) by blood or adoption who is an immediate family member of the undersigned, or by marriage or domestic partnership (a &#8220;</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Family Member</span><span style="color:#231f20;">&#8221;), or to a trust formed for the benefit of the undersigned or any of the undersigned&#8217;s Family Members, (B)&#160;to the undersigned&#8217;s estate, following the death of the undersigned, by will, intestacy or other operation of Law, (C)&#160;as a bona fide gift or a charitable contribution, as such term is described in Section&#160;501(c)(3)&#160;of the Code, or otherwise to a trust or other entity for the direct or indirect benefit of an immediate family </span>member of a beneficial owner (as defined in Rule&#160;13d-3 of the Exchange Act) of the Undersigned&#8217;s Shares (D)&#160;by operation of Law, such as pursuant to a qualified domestic order or in connection with a divorce settlement or (E)&#160;to any partnership, corporation, limited liability company or other entity, in each case, all of which the beneficial ownership interests of which are held by or otherwise under common control (via beneficial ownership, contract or otherwise) with the undersigned or a Family Member of the undersigned;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(2)</span></span><span style="color:#231f20;">if the undersigned is a </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">corporation</span><span style="color:#231f20;">, </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">partnership</span><span style="color:#231f20;">, </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">limited liability company</span><span style="color:#231f20;"> or </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">other entit</span><span style="color:#231f20;">y, (A)&#160;to another corporation, partnership, limited liability company or other entity that is a direct or indirect affiliate (as defined under Rule&#160;12b-2 of the Exchange Act) of the undersigned, including investment funds or other entities that controls or manages, is under common control </span>or management with, or is controlled or managed by, the undersigned (including, for the avoidance of doubt, where the undersigned is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), (B)&#160;as a distribution or dividend to equity holders, current or former partners, members, stockholders or managers (or to the estates of any of the foregoing), as applicable, of the undersigned (including upon the liquidation and dissolution of the undersigned pursuant to a plan of liquidation approved by the undersigned&#8217;s equity holders), (C)&#160;as a bona fide gift or a charitable contribution, as such term is described in Section&#160;501(c)(3)&#160;of the Code, or otherwise to a trust or other entity for the direct or indirect benefit of an immediate family member of a beneficial owner (as defined in Rule&#160;13d-3 of the Exchange Act) of the Undersigned&#8217;s Shares, (D)&#160;transfers or dispositions not involving a change in beneficial ownership or (E)&#160;with prior written consent of Parent (as constituted following the Closing); or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(3)</span></span><span style="color:#231f20;">if the undersigned is a </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">trust</span><span style="color:#231f20;">, to any grantors or beneficiaries of the trust;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that, in the case of any transfer or distribution pursuant to this clause (a), such transfer is not for value (other than transfers pursuant to 1(A), 1(E)&#160;or 2(A)) and each donee, heir, beneficiary or other transferee or distributee shall sign and deliver to Parent a lock-up agreement in the form of this Lock-Up Agreement with respect to the shares of Parent Common Stock or such other securities that have been so transferred or distributed and if a filing pursuant to Section&#160;16(a)&#160;of the Exchange Act is required, such filing shall describe the nature of the transfer or distribution;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">the exercise of an option to purchase shares of Parent Common Stock (including a net or cashless exercise of an option to purchase shares of Parent Common Stock ), and any related transfer of shares of Parent Common Stock to Parent for the purpose of paying the exercise price of such options or for paying taxes (including estimated taxes) due as a result of the exercise of such options or for paying taxes (including estimated taxes) due as a result of the exercise of such options; </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">provided</span><span style="color:#231f20;"> that, for the avoidance of doubt, the underlying shares of Parent Common Stock shall continue to be subject to the restrictions on transfer set forth in this Lock-Up Agreement;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="color:#231f20;">transfers to Parent in connection with the net settlement of any other equity award that represents the right to receive in the future shares of Parent Common Stock, settled in shares of Parent Common Stock, to pay any tax withholding obligations; provided that, for the avoidance of doubt, the underlying shares of Parent Common Stock shall continue to be subject to the restrictions on transfer set forth in this Lock-Up Agreement;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="color:#231f20;">the establishment of a trading plan pursuant to Rule&#160;10b5-l under the Exchange Act for the transfer of shares of Parent Common Stock; provided that such plan does not provide for any transfers of shares of Parent Common Stock during the Restricted Period;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="color:#231f20;">the disposition (including a forfeiture or repurchase) to Parent of any shares of restricted stock granted pursuant to the terms of any employee benefit plan or restricted stock purchase agreement;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">H-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span><span style="color:#231f20;">transfers, distributions, sales or other transactions by the undersigned of shares of Parent Common Stock purchased by the undersigned on the open market or in a public offering by Parent, in each case following the date of the Closing;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span><span style="color:#231f20;">transfers pursuant to a bona-fide third party tender offer, merger, consolidation or other similar transaction made to all holders of Parent&#8217;s capital stock involving a change of control of Parent, provided that in the event that such tender offer, merger, consolidation or other such transaction is not completed, the Undersigned&#8217;s Shares shall remain subject to the restrictions contained in this Lock-Up Agreement;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span><span style="color:#231f20;">transfers pursuant to an order of a court or regulatory agency;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="color:#231f20;">transfers by the undersigned of shares of Parent Common Stock issued pursuant to the Merger Agreement in respect of shares of the Company, if any, purchased from the Company on or about the Closing Date but prior to the Closing; or</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span><span style="color:#231f20;">transfers, distributions, sales or other transactions with the prior written consent of Parent (as constituted following the Closing).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, further, that, with respect to each of (b), (c), and (d)&#160;above, no filing by any party (including any donor, donee, transferor, transferee, distributor or distributee) under Section&#160;16 of the Exchange Act or other public announcement shall be made voluntarily reporting a reduction in beneficial ownership of shares of Parent Common Stock or any securities convertible into or exercisable or exchangeable for Parent Common Stock in connection with such transfer or disposition during the Restricted Period (other than any exit filings) and if any filings under Section&#160;16(a)&#160;of the Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of shares of Parent Common Stock in connection with such transfer or distribution, shall be legally required during the Restricted Period, such filing, report or announcement shall clearly indicate in the footnotes therein, in reasonable detail, a description of the circumstances of the transfer and that the shares remain subject to the Lock-Up Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of this Lock-Up Agreement, &#8220;change of control&#8221; shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions to a person or group of affiliated persons, of the Parent&#8217;s voting securities if, after such transfer, the Parent&#8217;s stockholders as of immediately prior to such transfer do not hold a majority of the outstanding voting securities of the Parent (or the surviving entity).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any attempted transfer in violation of this Lock-Up Agreement will be of no effect and null and void, regardless of whether the purported transferee has any actual or constructive knowledge of the transfer restrictions set forth in this Lock-Up Agreement, and will not be recorded on the share register of Parent. In furtherance of the foregoing, the undersigned agrees that Parent and any duly appointed transfer agent for the registration or transfer of the securities described herein are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Lock-Up Agreement. Parent may cause the legend set forth below, or a legend substantially equivalent thereto, to be placed upon any certificate(s)&#160;or other documents, ledgers or instruments evidencing the undersigned&#8217;s ownership of Parent Common Stock:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO AND MAY&#160;ONLY BE TRANSFERRED IN COMPLIANCE WITH A LOCK-UP AGREEMENT, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Lock-Up Agreement, and that upon request, the undersigned will execute any additional documents reasonably necessary to ensure the validity or enforcement of this Lock-Up Agreement. All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The undersigned understands that if the Merger Agreement is terminated for any reason, the undersigned shall be released from all obligations under this Lock-Up Agreement. The undersigned understands that Parent and the Company are proceeding with the transactions contemplated by the Merger Agreement in reliance upon this Lock-Up Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Any and all remedies herein expressly conferred upon Parent or the Company will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by Law or equity, and the exercise by Parent or the Company of any one remedy will not preclude the exercise of any other remedy. The undersigned agrees that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur to Parent and/or the Company in the event that any provision of this Lock-Up Agreement was not performed in accordance with its specific terms or were otherwise breached. It is accordingly agreed that </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">H-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Parent and/or the Company shall be entitled to an injunction or injunctions to prevent breaches of this Lock-Up Agreement and to enforce specifically the terms and provisions hereof in any court of the United States or any state having jurisdiction, this being in addition to any other remedy to which Parent or the Company is entitled at Law or in equity, and the undersigned waives any bond, surety or other security that might be required of Parent or the Company with respect thereto. Each of the parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event that any holder of Parent&#8217;s securities that are subject to a substantially similar agreement entered into by such holder, other than the undersigned, is permitted by Parent to sell or otherwise transfer or dispose of shares of Parent Common Stock for value other than as permitted by this or a substantially similar agreement entered into by such holder (whether in one or multiple releases or waivers), the same&#160;percentage of shares of Parent Common Stock held by the undersigned on the date of such release or waiver as the&#160;percentage of the total number of outstanding shares of Parent Common Stock held by such holder on the date of such release or waiver that are the subject of such release or waiver shall be immediately and fully released on the same terms from any remaining restrictions set forth herein (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pro-Rata Release</span>&#8221;); <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that such Pro-Rata Release shall not be applied unless and until permission has been granted by Parent to an equity holder or equity holders to sell or otherwise transfer or dispose of all or a portion of such equity holders shares of Parent Common Stock in an aggregate amount in excess of 1% of the number of shares of Parent Common Stock subject to a substantially similar agreement. In the event of any Pro-Rata Release, the Company shall promptly (and in any event within two (2)&#160;business&#160;days of such release) inform each relevant holder of Parent Common Stock or warrants of the terms of such Pro-Rata Release.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the release of any of the Undersigned&#8217;s Shares from this Lock-Up Agreement, Parent will facilitate the timely preparation and delivery of certificates or the establishment of book-entry positions at Parent&#8217;s transfer agent representing the Undersigned&#8217;s Shares without the restrictive legend above or the withdrawal of any stop transfer instructions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Lock-Up Agreement and any claim, controversy or dispute arising under or related to this Lock-Up Agreement shall be governed by and construed in accordance with the Laws of the state of Delaware, without regard to the conflict of Laws principles thereof. In any action or proceeding between any of the parties arising out of or relating to this Lock-Up Agreement, each of the parties: (i)&#160;irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (ii)&#160;agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with foregoing clause (i)&#160;of this paragraph, (iii)&#160;waives any objection to laying venue in any such action or proceeding in such courts, (iv)&#160;waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any party and (v)&#160;irrevocably and unconditionally waives the right to trial by jury. This Lock-Up Agreement constitutes the entire agreement between the parties to this Lock-Up Agreement and supersedes all other prior agreements, arrangements and understandings, both written and oral, among the parties with respect to the subject matter hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Lock-Up Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Lock-Up Agreement (in counterparts or otherwise) by Parent, the Company and the undersigned by electronic transmission in .pdf format shall be sufficient to bind such parties to the terms and conditions of this Lock-Up Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">[SIGNATURE PAGE&#160;FOLLOWS]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">H-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_fe649e45_1ba5_4414_a505_29b375984a88"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The undersigned understands that this Lock-Up Agreement is irrevocable and shall be binding upon the undersigned and the heirs, personal representatives, successors and assigns of the undersigned.</p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Very truly yours,</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Print Name of Stockholder:</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:52.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:52.49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Signature (for individuals):</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:52.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:52.49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Signature (for entities):</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">By:</span></p></td><td style="vertical-align:bottom;width:49.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49.81%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Name:</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Title:</span></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">[Signature Page to Lock-Up Agreement]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">H-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:bottom;width:50.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Accepted and Agreed</span></p></td><td style="vertical-align:top;width:49.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">By Aerovate Therapeutics,&#160;Inc.:</span></p></td><td style="vertical-align:top;width:49.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">By:</span></p></td><td style="vertical-align:bottom;width:47.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Name:</span></p></td><td style="vertical-align:top;width:49.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Title:</span></p></td><td style="vertical-align:top;width:49.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Accepted and Agreed</span></p></td><td style="vertical-align:top;width:49.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">by Jade Biosciences,&#160;Inc.:</span></p></td><td style="vertical-align:top;width:49.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">By:</span></p></td><td style="vertical-align:bottom;width:47.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Name:</span></p></td><td style="vertical-align:top;width:49.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Title:</span></p></td><td style="vertical-align:top;width:49.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">[Signature Page to Lock-Up Agreement]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">H-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_dddb25f5_9d94_4738_a96c_1419d76a4ac1"></a><a id="ANNEXI_908298"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ANNEX I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">I-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_82c773ae_beae_4723_a7fa_71a5211d5c70"></a><a id="ANNEXJ_562775"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ANNEX J</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">J-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_3fb2cd21_7789_40af_a9e5_b13210b45fcf"></a><a id="ANNEXK_308832"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ANNEX K</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AEROVATE THERAPEUTICS,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATE OF DESIGNATION OF PREFERENCES,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RIGHTS AND LIMITATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SERIES&#160;A NON-VOTING CONVERTIBLE PREFERRED STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Pursuant to Section&#160;151 of the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">General Corporation Law of the State of Delaware</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Aerovate Therapeutics&#160;Inc., a Delaware corporation (the &#8220;<span style="font-style:italic;font-weight:bold;">Corporation</span>&#8221;), that the following resolution was duly adopted by the Board of Directors of the Corporation (the &#8220;<span style="font-style:italic;font-weight:bold;">Board of Directors</span>&#8221;), in accordance with the provisions of Section&#160;151 of the General Corporation Law of the State of Delaware (the &#8220;<span style="font-style:italic;font-weight:bold;">DGCL</span>&#8221;), at a meeting duly called and held on [<span style="font-family:'Symbol';">&#183;</span>], which resolution provides for the creation of a series of the Corporation&#8217;s Preferred Stock, par value $0.001 per share, which is designated as &#8220;Series&#160;A Non-Voting Convertible Preferred Stock,&#8221; with the preferences, rights and limitations set forth therein relating to dividends, conversion, redemption, dissolution and distribution of assets of the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>: the Second Amended and Restated Certificate of Incorporation of the Corporation (as amended from time to time, the &#8220;<span style="font-style:italic;font-weight:bold;">Certificate of Incorporation</span>&#8221;), provides for a class of its authorized stock known as Preferred Stock, consisting of 10,000,000 shares, $0.0001 par value per share (the &#8220;<span style="font-style:italic;font-weight:bold;">Preferred Stock</span>&#8221;), issuable from time to time in one or more series.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RESOLVED</b><span style="white-space:pre-wrap;">:  that, pursuant to authority conferred upon the Board of Directors by the Certificate of Incorporation, (i)&#160;a series of Preferred Stock of the Corporation be, and hereby is, authorized by the Board of Directors, (ii)&#160;the Board of Directors hereby authorizes the issuance of [</span><span style="font-family:'Symbol';">&#183;</span>] shares of &#8220;Series&#160;A Non- Voting Convertible Preferred Stock&#8221; pursuant to the terms of the Agreement and Plan of Merger, dated October&#160;[<span style="font-family:'Symbol';">&#183;</span>], 2024, by and among the Corporation, Caribbean Merger Sub I,&#160;Inc., a Delaware corporation and wholly owned subsidiary of the Corporation, Caribbean Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Corporation, and Jade Biosciences,&#160;Inc., a Delaware corporation (the &#8220;<span style="font-style:italic;font-weight:bold;">Merger Agreement</span>&#8221;), and (iii)&#160;the Board of Directors hereby fixes the designations, powers, preferences and relative, participating, optional or other special rights, and the qualifications, limitations or restrictions thereof, of such shares of Preferred Stock, in addition to any provisions set forth in the Certificate of Incorporation that are applicable to the Preferred Stock of all classes and series, as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TERMS OF SERIES&#160;A NON-VOTING CONVERTIBLE PREFERRED STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Definitions</span><span style="color:#231f20;">. For the purposes hereof, the following terms shall have the following meanings:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="color:#231f20;">&#8220;</span><span style="color:#231f20;font-style:italic;font-weight:bold;">Buy-In</span><span style="color:#231f20;">&#8221; shall have the meaning set forth in </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.4.3</span><span style="color:#231f20;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">&#8220;<span style="font-style:italic;font-weight:bold;">Closing Sale Price</span>&#8221; means, for any security as of any date, the last closing trade price for such security immediately prior to 4:00&#160;p.m., New York City time, on the principal Trading Market where such security is listed or traded, as reported by Bloomberg,&#160;L.P. (or an equivalent, reliable reporting service), or if the foregoing do not apply, the last trade price of such security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg,&#160;L.P., or, if no last trade price is reported for such security by Bloomberg,&#160;L.P., the average of the bid prices of any market makers for such security as reported on the OTC Pink Market by OTC Markets Group,&#160;Inc. If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as determined in good faith by the Board of Directors of the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">&#8220;<span style="font-style:italic;font-weight:bold;">Commission</span>&#8221; means the United States Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">&#8220;<span style="font-style:italic;font-weight:bold;">Common Stock</span>&#8221; means the Corporation&#8217;s common stock, par value $0.001 per share, and stock of any other class of securities into which such securities may hereafter be reclassified or changed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">&#8220;<span style="font-style:italic;font-weight:bold;">Conversion Shares</span>&#8221; means, collectively, the shares of Common Stock issuable upon conversion of the shares of Series&#160;A Non-Voting Preferred Stock in accordance with the terms hereof.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">K-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">&#8220;<span style="font-style:italic;font-weight:bold;">Exchange Act</span>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules&#160;and regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">&#8220;<span style="font-style:italic;font-weight:bold;">Holder</span>&#8221; means a holder of shares of Series&#160;A Non-Voting Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">&#8220;<span style="font-style:italic;font-weight:bold;">Person</span>&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">&#8220;<span style="font-style:italic;font-weight:bold;">Trading Day</span>&#8221; means a day on which the principal Trading Market is open for business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">&#8220;<span style="font-style:italic;font-weight:bold;">Trading Market</span>&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Designation, Amount and Par Value</span><span style="color:#231f20;">. The series of Preferred Stock shall be designated as the Corporation&#8217;s Series&#160;A Non-Voting Convertible Preferred Stock (the &#8220;</span><span style="color:#231f20;font-style:italic;font-weight:bold;">Series&#160;A Non-Voting Preferred Stock</span><span style="color:#231f20;">&#8221;) and the number of shares so designated shall be [</span><span style="color:#231f20;font-family:'Symbol';">&#183;</span><span style="color:#231f20;">]. Each share of Series&#160;A Non-Voting Preferred Stock shall have a par value of $0.001 per share.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Dividends</span><span style="color:#231f20;">. Holders shall be entitled to receive, and the Corporation shall pay, dividends on shares of the Series&#160;A Non-Voting Preferred Stock (on an as-if-converted-to-Common-Stock basis, without regard to the Beneficial Ownership Limitation (as defined below)) equal to and in the same form, and in the same manner, as dividends (other than dividends on shares of the Common Stock payable in the form of Common Stock) actually paid on shares of the Common Stock when, as and if such dividends (other than dividends payable in the form of Common Stock) are paid on shares of the Common Stock. Other than as set forth in the previous sentence, no other dividends shall be paid on shares of Series&#160;A Non-Voting Preferred Stock, and the Corporation shall pay no dividends (other than dividends payable in the form of Common Stock) on shares of the Common Stock unless it simultaneously complies with the previous sentence.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Voting Rights</span><span style="color:#231f20;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.1</span></span><span style="color:#231f20;">Except as otherwise provided herein or as otherwise required by the DGCL, the </span>Series&#160;A Non-Voting Preferred Stock shall have no voting rights. However, as long as any shares of Series&#160;A Non-Voting Preferred Stock are outstanding, the Corporation shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series&#160;A Non- Voting Preferred Stock: (i)&#160;alter or change adversely the powers, preferences or rights given to the Series&#160;A Non-Voting Preferred Stock or alter or amend this Certificate of Designation of Preferences, Rights and Limitations of Series&#160;A Non-Voting Convertible Preferred Stock (the &#8220;<span style="font-style:italic;font-weight:bold;">Certificate of Designation</span>&#8221;), amend or repeal any provision of, or add any provision to, the Certificate of Incorporation or Amended and Restated Bylaws of the Corporation, as amended, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series&#160;A Non-Voting Preferred Stock, regardless of whether any of the foregoing actions shall be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (ii)&#160;issue further shares of Series&#160;A Non-Voting Preferred Stock beyond those contemplated for issuance in the Merger Agreement or increase or decrease (other than by conversion) the number of authorized shares of Series&#160;A Non-Voting Preferred Stock, (iii)&#160;at any time while at least [<span style="font-family:'Symbol';">&#183;</span>] shares of Series&#160;A Non-Voting Preferred Stock remains issued and outstanding, consummate either: (A)&#160;any Fundamental Transaction (as defined below) or (B)&#160;any merger or consolidation of the Corporation with or into another entity or any stock sale to, or other business combination in which the stockholders of the Corporation immediately before such transaction do not hold at least a majority on an as-converted-to- Common Stock basis of the capital stock of the Corporation immediately after such transaction or (iv)&#160;enter into any agreement with respect to any of the foregoing that does not explicitly require the approval contemplated herein to consummate such transaction. Holders of shares of Common Stock acquired upon the conversion of shares of Series&#160;A Non-Voting Preferred Stock shall be entitled to the same voting rights as each other holder of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.2</span></span><span style="color:#231f20;">Any vote required or permitted under </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.1</span><span style="color:#231f20;"> may be taken at a meeting of the Holders or through the execution of an action by written consent in lieu of such meeting or other written waiver by such stockholders, provided that the consent or waiver is executed by Holders representing a majority of the outstanding shares of Series&#160;A Non-Voting Preferred Stock.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">K-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Rank; Liquidation</span><span style="color:#231f20;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.1</span></span><span style="color:#231f20;">The Series&#160;A Non-Voting Preferred Stock shall rank on parity with the Common Stock as to distributions of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntarily or involuntarily (a &#8220;</span><span style="color:#231f20;font-style:italic;font-weight:bold;">Liquidation</span><span style="color:#231f20;">&#8221;).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.2</span></span><span style="color:#231f20;">Upon any Liquidation, each Holder shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation the same amount that a holder of Common Stock would receive if the Series&#160;A Non-Voting Preferred Stock were fully converted (disregarding for such purpose any Beneficial Ownership Limitations) to Common Stock which amounts shall be paid </span><i style="color:#231f20;font-style:italic;">pari passu </i><span style="color:#231f20;">with all holders of Common Stock, plus an additional amount equal to any dividends declared on but unpaid to such shares. If, upon any such Liquidation, the assets of the Corporation shall be insufficient to pay the Holders of shares of the Series&#160;A Non-Voting Preferred Stock the amount required under the preceding sentence, then all remaining assets of the Corporation shall be distributed ratably to the Holders and the holders of Common Stock in accordance with the respective amounts that would be payable on all such securities if all amounts payable thereon were paid in full. For the avoidance of any doubt, a Fundamental Transaction shall not be deemed a Liquidation unless the Corporation expressly declares that such Fundamental Transaction shall be treated as if it were a Liquidation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Conversion</span><span style="color:#231f20;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.1</span></span><span style="color:#231f20;">C</span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">onversion at Option of Holder</span><span style="color:#231f20;">. Subject to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.3</span><span style="color:#231f20;">, each share of Series&#160;A Non- Voting Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the Holder thereof, into a number of shares of Common Stock equal to the Conversion Ratio, subject to the Beneficial Ownership Limitation (as defined below) (each, an &#8220;</span><span style="color:#231f20;font-style:italic;font-weight:bold;">Optional Conversion</span><span style="color:#231f20;">&#8221;). Holders shall effect conversions by providing the Corporation with the form of conversion notice attached hereto as </span><b style="color:#231f20;font-weight:bold;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Annex A</b><span style="color:#231f20;"> (a &#8220;</span><span style="color:#231f20;font-style:italic;font-weight:bold;">Notice of Conversion</span><span style="color:#231f20;">&#8221;), duly completed and executed. Provided the Corporation&#8217;s transfer agent is participating in the Depository Trust Company (&#8220;</span><span style="color:#231f20;font-style:italic;font-weight:bold;">DTC</span><span style="color:#231f20;">&#8221;) Fast Automated Securities Transfer program, the Notice of Conversion may specify, at the Holder&#8217;s election, whether the applicable Conversion Shares shall be credited to the account of the Holder&#8217;s prime broker with DTC through its Deposit Withdrawal Agent Commission system (a &#8220;</span><span style="color:#231f20;font-style:italic;font-weight:bold;">DWAC Delivery</span><span style="color:#231f20;">&#8221;). The date on which an Optional Conversion shall be deemed effective (the &#8220;</span><span style="color:#231f20;font-style:italic;font-weight:bold;">Conversion Date</span><span style="color:#231f20;">&#8221;) shall be the Trading Day that the Notice of Conversion, completed and executed, is sent via email to, and received during regular business hours by, the Corporation; provided, that the original certificate(s)&#160;(if any) representing such shares of Series&#160;A Non-Voting Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation within two (2)&#160;Trading Days thereafter. In all other cases, the Conversion Date shall be defined as the Trading Day on which the original certificate(s)&#160;(if any) representing such shares of Series&#160;A Non-Voting Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation. The calculations set forth in the Notice of Conversion shall control in the absence of manifest or mathematical error.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.2</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Conversion Ratio</span><span style="color:#231f20;">. The &#8220;</span><span style="color:#231f20;font-style:italic;font-weight:bold;">Conversion Ratio</span><span style="color:#231f20;">&#8221; for each share of Series&#160;A Non-Voting Preferred Stock shall be 1,000 shares of Common Stock issuable upon the conversion (the &#8220;</span><span style="color:#231f20;font-style:italic;font-weight:bold;">Conversion</span><span style="color:#231f20;">&#8221;) of each share of Series&#160;A Non-Voting Preferred Stock (corresponding to a ratio of 1,000:1), subject to adjustment as provided herein.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.3</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Beneficial Ownership Limitation</span><span style="color:#231f20;">. Notwithstanding anything herein to the contrary, the Corporation shall not effect any conversion of any share of Series&#160;A Non-Voting Preferred Stock, and a Holder shall not have the right to convert any portion of the Series&#160;A Non-Voting Preferred Stock pursuant to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.1</span><span style="color:#231f20;">, to the extent that, after giving effect to such attempted conversion set forth on an applicable Notice of Conversion (as defined in the Certificate of Designation) with respect to the Series&#160;A Non-Voting Preferred Stock, such Holder (or any of such Holder&#8217;s affiliates or any other Person who would be a beneficial owner of Common Stock beneficially owned by the Holder for purposes of Section&#160;13(d)&#160;or Section&#160;16 of the Exchange Act and the applicable rules&#160;and regulations of the Commission, including any &#8220;group&#8221; of which the Holder is a member (the foregoing, &#8220;</span><span style="color:#231f20;font-style:italic;font-weight:bold;">Attribution Parties</span><span style="color:#231f20;">&#8221;)) would beneficially own a number of shares of Common Stock in excess of the Beneficial Ownership Limitation. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such Holder and its Attribution Parties shall include the number of shares of Common Stock issuable upon conversion of the Series&#160;A Non-Voting Preferred Stock subject to the Notice of Conversion with respect to which such determination is being made, but shall exclude the number of shares </span>of Common Stock which are issuable upon (A)&#160;conversion of the remaining, unconverted Series&#160;A Non-Voting Preferred Stock beneficially owned by such Holder or any of its Attribution Parties, and (B)&#160;exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) beneficially owned by such Holder or any of its Attribution Parties that are subject to and would exceed a limitation on conversion or exercise similar to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.3</span>, beneficial ownership shall be calculated in accordance with </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">K-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Section&#160;13(d)&#160;of the Exchange Act and the applicable rules&#160;and regulations of the Commission, and the terms &#8220;beneficial ownership&#8221; and &#8220;beneficially own&#8221; have the meanings ascribed to such terms therein. In addition, for purposes hereof, &#8220;group&#8221; has the meaning set forth in Section&#160;13(d)&#160;of the Exchange Act and the applicable rules&#160;and regulations of the Commission. For purposes of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.3</span>, in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as stated in the most recent of the following: (A) <span style="color:#231f20;">the Corporation&#8217;s most recent periodic or annual filing with the Commission, as the case may be, (B)&#160;a more recent public announcement by the Corporation that is filed with the Commission, or (C) a more recent notice by the Corporation or the Corporation&#8217;s transfer agent to the Holder setting forth the number of shares of Common Stock then outstanding. Upon the written request of a Holder (which may be by email), the Corporation shall, within two (2)&#160;Trading Days thereof, confirm in writing to such Holder (which may be via email) the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to any actual conversion or exercise of securities of the Corporation, including shares of Series&#160;A Non-Voting Preferred Stock, by such Holder or its Attribution Parties since the date as of which such number of outstanding shares of Common Stock was last publicly reported or confirmed to the Holder. The &#8220;</span><span style="color:#231f20;font-style:italic;font-weight:bold;">Beneficial Ownership Limitation</span><span style="color:#231f20;">&#8221; shall initially be 19.99% of the number of shares of Common Stock outstanding or deemed to be outstanding as of the applicable measurement date. The Corporation shall be entitled to rely on representations made to it by the Holder in any Notice of Conversion regarding its Beneficial Ownership Limitation. Notwithstanding the foregoing, by written notice to the Corporation (which may be via email), (i)&#160;the Holder may reset the Beneficial Ownership Limitation&#160;percentage to a </span>higher&#160;percentage, not to exceed 19.99%, which increase will not be effective until the sixty-first (61st) day after such written notice is delivered to the Corporation, and (ii)&#160;the Holder may reset the Beneficial Ownership Limitation&#160;percentage to a lower&#160;percentage effective immediately after the delivery of such notice to the Corporation. Upon such an increase by a Holder of the Beneficial Ownership Limitation pursuant to clause (i), not to exceed 19.99%, the Beneficial Ownership Limitation may not be further amended by such Holder without first providing the minimum notice required by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.3</span>. Notwithstanding the foregoing, (x)&#160;at any time following notice of a Fundamental Transaction, the Holder may waive and/or change the Beneficial Ownership Limitation effective immediately upon written notice to the Corporation and may reinstitute a Beneficial Ownership Limitation at any time thereafter effective immediately upon written notice to the Corporation (y)&#160;at any time that the beneficial ownership of shares of Common Stock of a Holder (together with any of such Holder&#8217;s Attribution Parties) is equal to or less than 9.00% of the number of shares of Common Stock outstanding as of any given date, then such Holder&#8217;s Beneficial Ownership Limitation shall automatically be set to 9.99%. The provisions of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.3</span> shall be construed, corrected and implemented in a manner so as to effectuate the intended Beneficial Ownership Limitation herein contained and the shares of Common Stock underlying the Series&#160;A Non-Voting Preferred Stock in excess of the Beneficial Ownership Limitation shall not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section&#160;13(d)&#160;or Rule&#160;16a-1(a)(1)&#160;of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.4</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Mechanics of Conversion</span><span style="color:#231f20;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.4.1</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Delivery of Certificate or Electronic Issuance</span><span style="color:#231f20;">. Upon Conversion not later than two (2)&#160;Trading Days after the applicable Conversion Date, or if the Holder requests the issuance of physical certificate(s), two (2)&#160;Trading Days after receipt by the Corporation of the original certificate(s)&#160;representing such shares of Series&#160;A Non-Voting Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion (the &#8220;</span><span style="color:#231f20;font-style:italic;font-weight:bold;">Share Delivery Date</span><span style="color:#231f20;">&#8221;), the Corporation shall either: (a)&#160;deliver, or cause to be delivered, to the converting Holder a physical certificate or certificates representing the number of Conversion Shares being acquired upon the conversion of shares of Series&#160;A Non-Voting Preferred Stock, or (b)&#160;in the case of a DWAC Delivery (if so requested by the Holder), electronically transfer such Conversion Shares by crediting the account of the Holder&#8217;s prime broker with DTC through its DWAC system. If in the case of any Notice of Conversion such certificate or certificates for the Conversion Shares are not delivered to or as directed by or, in the case of </span>a DWAC Delivery, such shares are not electronically delivered to or as directed by, the applicable Holder by the Share Delivery Date, the applicable Holder shall be entitled to elect to rescind such Notice of Conversion by written notice to the Corporation at any time on or before its receipt of such certificate or certificates for Conversion Shares or electronic receipt of such shares, as applicable, in which event the Corporation shall promptly return to such Holder any original Series&#160;A Non-Voting Preferred Stock certificate delivered to the Corporation and such Holder shall promptly return to the Corporation any Common Stock certificates or otherwise direct the return of any shares of Common Stock delivered to the Holder through the DWAC system, representing the shares of Series&#160;A Non-Voting Preferred Stock unsuccessfully tendered for conversion to the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 54pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.4.2</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Obligation Absolute</span><span style="color:#231f20;">. Subject to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.3</span><span style="color:#231f20;"> and subject to Holder&#8217;s right to rescind a Notice of Conversion pursuant to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.4.1</span><span style="color:#231f20;">, the Corporation&#8217;s obligation to issue and deliver the Conversion Shares upon conversion of Series&#160;A Non-</span>Voting<span style="color:#231f20;"> Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">K-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"><span style="color:#231f20;">any action or inaction by a Holder to enforce the same, any waiver or consent with respect to </span>any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by such Holder or any other Person of any obligation to the Corporation or any violation or alleged violation of law by such Holder or any other Person, and irrespective of any other circumstance which might otherwise limit such obligation of the Corporation to such Holder in connection with the issuance of such Conversion Shares. Subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.3</span> and subject to Holder&#8217;s right to rescind a Notice of Conversion pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.4.1</span>, in the event a Holder shall elect to convert any or all of its Series&#160;A Non-Voting Preferred Stock, the Corporation may not refuse conversion based on any claim that such Holder or anyone associated or affiliated with such Holder has been engaged in any violation of law, agreement or for any other reason, unless an injunction from a court, on notice to Holder, restraining and/or enjoining conversion of all or part of the Series&#160;A Non-Voting Preferred Stock of such Holder shall have been sought and obtained by the Corporation, and the Corporation posts a surety bond for the benefit of such Holder in the amount of 150% of the value of the Conversion Shares into which would be converted the Series&#160;A Non-Voting Preferred Stock which is subject to such injunction, which bond shall remain in effect until the completion of arbitration/litigation of the underlying dispute and the proceeds of which shall be payable to such Holder to the extent it obtains judgment. In the absence of such injunction, the Corporation shall, subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.3</span> and subject to Holder&#8217;s right to rescind a Notice of Conversion pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.4.1</span>, issue Conversion Shares upon a properly noticed conversion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.4.3</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Buy-In on Failure to Timely Deliver Certificates</span><span style="color:#231f20;">. If the Corporation fails to deliver to a Holder the applicable certificate or certificates or to effect a DWAC Delivery, as applicable, by the Share Delivery Date pursuant to </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.4.1</span><span style="color:#231f20;"> (other than a failure caused by materially incorrect or incomplete information provided by Holder to the Corporation or </span>the application of the Beneficial Ownership Limitation), and if after such Share Delivery Date such Holder is required by its brokerage firm to purchase (in an open market transaction or otherwise), or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by such Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion relating to such Share Delivery Date (a &#8220;<span style="font-style:italic;font-weight:bold;">Buy-In</span>&#8221;), then the Corporation shall (A)&#160;pay in cash to such Holder (in addition to any other remedies available to or elected by such Holder) the amount by which (x)&#160;such Holder&#8217;s total purchase price (including any brokerage commissions) for the shares of Common Stock so purchased exceeds (y)&#160;the product of (1)&#160;the aggregate number of shares of Common Stock that such Holder was entitled to receive from the conversion at issue multiplied by (2)&#160;the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B)&#160;at the option of such Holder, either reissue (if surrendered) the shares of Series&#160;A Non-Voting Preferred Stock equal to the number of shares of Series&#160;A Non-Voting Preferred Stock submitted for conversion or deliver to such Holder the number of shares of Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.4.1</span>. For example, if a Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted conversion of shares of Series&#160;A Non-Voting Preferred Stock with respect to which the actual sale price (including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under clause (A)&#160;of the immediately preceding sentence, the Corporation shall be required to pay such Holder $1,000. The Holder shall provide the Corporation written notice, within three (3)&#160;Trading Days after the occurrence of a Buy-In, indicating the amounts payable to such Holder in respect of such Buy-In together with applicable confirmations and other evidence reasonably requested by the Corporation. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Corporation&#8217;s failure to timely deliver certificates representing shares of Common Stock upon conversion of the shares of Series&#160;A Non-Voting Preferred Stock as required pursuant to the terms hereof; provided, however, that the Holder shall not be entitled to both (i)&#160;require the reissuance of the shares of Series&#160;A Non-Voting Preferred Stock submitted for conversion for which such conversion was not timely honored and (ii)&#160;receive the number of shares of Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.4.1</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.4.4</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Reservation of Shares Issuable Upon Conversion</span><span style="color:#231f20;">. The Corporation covenants that at all times it will reserve and keep available out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Series&#160;A Non-Voting Preferred Stock, free from preemptive rights or any other actual contingent purchase rights </span>of Persons other than the Holders of the Series&#160;A Non-Voting Preferred Stock, not less than such aggregate number of shares of the Common Stock as shall be issuable (taking into account the adjustments of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7</span>) upon the conversion of all outstanding shares of Series&#160;A Non- Voting Preferred Stock. The Corporation covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid and non- assessable.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">K-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.4.5</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Fractional Shares</span><span style="color:#231f20;">. No fractional shares of Common Stock shall be issued upon conversion of the Series&#160;A Non-Voting Preferred Stock, no certificates or scrip for any such fractional shares shall be issued and no cash shall be paid for any such </span>fractional<span style="color:#231f20;"> shares. Any fractional shares of Common Stock that a Holder of Series&#160;A Non-Voting Preferred Stock would otherwise be entitled to receive shall be aggregated with all fractional shares of Common Stock issuable to such Holder and any remaining fractional shares shall be rounded up to </span>the nearest whole share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.4.6</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Transfer Taxes</span><span style="color:#231f20;">. The issuance of certificates for shares of the Common Stock upon conversion of the Series&#160;A Non-Voting Preferred Stock shall be made without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of </span>the issue or delivery of such certificates, provided that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such certificate upon <span style="color:#231f20;">conversion</span> in a name other than that of the registered Holder(s)&#160;of such shares of Series&#160;A Non-Voting Preferred Stock and the Corporation shall not be required to issue or deliver such certificates unless or until the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.5</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Status as Stockholder</span><span style="color:#231f20;">. Upon each Conversion Date, (i)&#160;the shares of Series&#160;A Non- Voting Preferred Stock being converted shall be deemed converted into shares of Common Stock and (ii)&#160;the Holder&#8217;s rights as a holder of such converted shares of Series&#160;A Non-Voting Preferred Stock shall cease and terminate, excepting only the right to receive certificates for such shares of Common Stock and to any remedies provided herein or otherwise available at law or in equity to such Holder because of a failure by the Corporation to comply with the terms of this Certificate of Designation. In all cases, the Holder shall retain all of its rights and remedies for the Corporation&#8217;s failure to convert Series&#160;A Non-Voting Preferred Stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Certain Adjustments</span><span style="color:#231f20;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.1</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Stock Dividends and Stock Splits</span><span style="color:#231f20;">. If the Corporation, at any time while this Series&#160;A Non-Voting Preferred Stock is outstanding: (A)&#160;pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation upon conversion of this Series&#160;A Non-Voting Preferred Stock) with respect to the then outstanding shares of Common Stock; (B)&#160;subdivides outstanding shares of Common Stock into a larger number of shares; or (C) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares, then the Conversion Ratio shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Corporation) outstanding immediately after such event and of which the denominator shall be </span>the number of shares of Common Stock outstanding immediately before such event (excluding any treasury shares of the Corporation). Any adjustment made pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.1</span> shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision or combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.2</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Fundamental Transaction</span><span style="color:#231f20;">. If, at any time while this Series&#160;A Non-Voting Preferred Stock is outstanding, (A)&#160;the Corporation effects any merger or consolidation of the Corporation with or into another Person or any stock sale to, or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, share exchange or scheme of arrangement) with or into another Person (other than such a transaction in which the Corporation is the surviving or continuing entity and its Common Stock is not exchanged for or converted </span>into other securities, cash or property), (B)&#160;the Corporation effects any sale, lease, transfer or exclusive license of all or substantially all of its assets in one transaction or a series of related transactions, (C)&#160;any tender offer or exchange offer (whether by the Corporation or another Person) is completed pursuant to which more than 50% of the Common Stock not held by the Corporation or such Person is exchanged for or converted into other securities, cash or property, or (D)&#160;the Corporation effects any reclassification of the Common Stock or any compulsory share exchange pursuant (other than as a result of a dividend, subdivision or combination covered by <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.1</span>) to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (in any such case, a &#8220;<span style="font-style:italic;font-weight:bold;">Fundamental Transaction</span>&#8221;), then, upon any subsequent conversion of this Series&#160;A Non-Voting Preferred Stock the Holders shall have the right to receive, in lieu of the right to receive Conversion Shares, for each Conversion Share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction, the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had, immediately prior to such Fundamental Transaction, converted the Series&#160;A Non-Voting Preferred Stock (the &#8220;<span style="font-style:italic;font-weight:bold;">Alternate Consideration</span>&#8221;). For purposes of any such subsequent conversion, the determination of the Conversion Ratio shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">K-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Fundamental Transaction, and the Corporation shall adjust the Conversion Ratio in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holders shall be given the same choice as to the Alternate Consideration it receives upon any conversion of this Series&#160;A Non- Voting Preferred Stock following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the Corporation or surviving entity in such Fundamental Transaction shall file a new certificate of designations with the same terms and conditions and issue to the Holders new preferred stock consistent with the foregoing provisions and evidencing the Holders&#8217; right to convert such preferred stock into Alternate Consideration. The terms of any agreement to which the Corporation is a party and pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.2</span> and insuring that this Series&#160;A Non-Voting Preferred Stock (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental Transaction. The Corporation shall cause to be delivered to each Holder, at its last address as it shall appear upon the stock books of the Corporation, written notice of any Fundamental Transaction at least 20 calendar&#160;days prior to the date on which such Fundamental Transaction is expected to become effective or close. Notwithstanding anything to the contrary herein, any Parent Legacy Transaction (as defined in the Merger Agreement) shall not constitute a Fundamental Transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.3</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Calculations</span><span style="color:#231f20;">. All calculations under this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7</span><span style="color:#231f20;"> shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7</span><span style="color:#231f20;">, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Redemption</span><span style="color:#231f20;">. The shares of Series&#160;A Non-Voting Preferred Stock shall not be redeemable; provided, however, that the foregoing shall not limit the ability of the Corporation to purchase or otherwise deal in such shares to the extent otherwise permitted hereby and by law.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Transfer</span><span style="color:#231f20;">. A Holder may transfer any shares of Series&#160;A Non-Voting Preferred Stock together with the accompanying rights set forth herein, held by such holder without the consent of the Corporation; provided that such transfer is in compliance with applicable securities laws. The Corporation shall in good faith (i)&#160;do and perform, or cause to be done and performed, all </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">such</span><span style="color:#231f20;"> further acts and things, and (ii)&#160;execute and deliver all such other agreements, certificates, instruments and documents, in each case, as any holder of Series&#160;A Non-Voting Preferred Stock may reasonably request in order to carry out the intent and accomplish the purposes of this </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9</span><span style="color:#231f20;">. The transferee of any shares of Series&#160;A Non-Voting Preferred Stock shall be subject to the Beneficial Ownership Limitation applicable to the transferor as of the time of such transfer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Series&#160;A Non-Voting Preferred Stock Register</span><span style="color:#231f20;">. The Corporation shall maintain at its principal executive offices (or such other office or agency of the Corporation as it may designate by notice to the Holders in accordance with </span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;11</span><span style="color:#231f20;">), a register for the Series&#160;A Non-Voting Preferred Stock, in which the Corporation shall record (i)&#160;the name, address, and electronic mail address of each </span>holder in whose name the <span style="color:#231f20;">shares</span> of Series&#160;A Non-Voting Preferred Stock have been issued and (ii)&#160;the name, address, and electronic mail address of each transferee of any shares of Series&#160;A Non-Voting Preferred Stock. The Corporation may deem and treat the registered Holder of shares of Series&#160;A Non- Voting Preferred Stock as the absolute owner thereof for the purpose of any conversion thereof and for all other purposes. The Corporation shall keep the register open and available at all times during business hours for inspection by any holder of Series&#160;A Non-Voting Preferred Stock or his, her or its legal representatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Notices</span><span style="color:#231f20;">. Any notice required or permitted by the provisions of this Certificate of Designation to be given to a Holder of shares of Series&#160;A Non-Voting Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic communication in compliance with the provisions of the Delaware General Corporation Law, and shall be deemed sent upon such mailing or electronic transmission.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12.</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Book-Entry; Certificates</span><span style="color:#231f20;">. The Series&#160;A Non-Voting Preferred Stock will be issued in book- entry form; provided that, if a Holder requests that such Holder&#8217;s shares of Series&#160;A Non-Voting Preferred Stock be issued in certificated form, the Corporation will instead issue a stock certificate to such Holder representing such Holder&#8217;s shares of Series&#160;A Non-Voting Preferred Stock. To the extent that any shares of Series&#160;A Non-Voting Preferred Stock are issued in book-entry form, references herein to &#8220;certificates&#8221; shall instead refer to the book-entry notation relating to such shares.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">K-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Lost or Mutilated Series&#160;A Non-Voting Preferred Stock Certificate</span><span style="color:#231f20;">. If a Holder&#8217;s Series&#160;A Non-Voting Preferred Stock certificate shall be mutilated, lost, stolen or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the shares of Series&#160;A Non-Voting Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of such certificate, and of the ownership hereof reasonably satisfactory to the Corporation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Waiver</span><span style="color:#231f20;">. Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of Designation or a waiver by any other Holders. The failure of the Corporation or a Holder to insist upon strict adherence to any term of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder) of the right thereafter to insist upon strict adherence to that term or any other term of this Certificate of Designation. Any waiver by the Corporation or a Holder must be in writing. Notwithstanding any provision in this Certificate of Designation to the contrary, any provision contained herein and any right of the Holders of Series&#160;A Non-Voting Preferred Stock granted hereunder may be waived as to all shares of Series&#160;A Non-Voting Preferred Stock (and the Holders thereof) upon the written consent of the Holders of not less than a majority of the shares of Series&#160;A Non-Voting Preferred Stock then outstanding, provided, however, that the Beneficial Ownership Limitation applicable to a Holder, and any provisions contained herein that are related to such Beneficial Ownership Limitation, cannot be modified, waived or terminated without the consent of such Holder, provided further, that any proposed waiver that would, by its terms, have a disproportionate and materially adverse effect on any Holder shall require the consent of such Holder(s).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15.</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Severability</span><span style="color:#231f20;">. Whenever possible, each provision hereof shall be interpreted in a manner as to be effective and valid under applicable law, but if any provision hereof is held to be prohibited by or invalid under applicable law, then such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating or otherwise adversely affecting the remaining provisions hereof.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.</span></span><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Status of Converted Series&#160;A Non-Voting Preferred Stock</span><span style="color:#231f20;">. If any shares of Series&#160;A Non- Voting Preferred Stock shall be converted or redeemed by the Corporation, such shares shall, to the fullest extent permitted by applicable law, be retired and cancelled upon such acquisition, and shall not be reissued as a share of Series&#160;A Non-Voting Preferred Stock. Any share of Series&#160;A Non-Voting Preferred Stock so acquired shall, upon its retirement and cancellation, and upon the taking of any </span>action required by applicable law, resume the status of authorized but unissued shares of preferred stock and shall no longer be designated as Series&#160;A Non-Voting Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[<i style="font-style:italic;">Remainder of Page&#160;Intentionally Left Blank</i>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">K-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, Aerovate Therapeutics&#160;Inc. has caused this Certificate of Designation of Preferences, Rights and Limitations of Series&#160;A Non-Voting Convertible Preferred Stock to be duly executed by its [<span style="font-family:'Symbol';">&#183;</span>] on [<span style="font-family:'Symbol';">&#183;</span>], 202[5].</p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">AEROVATE THERAPEUTICS,&#160;INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">By:</span></p></td><td style="vertical-align:bottom;width:46.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Name:</span></p></td><td style="vertical-align:bottom;width:46.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Title:</span></p></td><td style="vertical-align:bottom;width:46.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">K-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_8c170e60_ca92_4793_91a1_cd43c907d72b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ANNEX A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTICE OF CONVERSION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(TO BE EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SHARES OF</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">SERIES&#160;A NON-VOTING CONVERTIBLE PREFERRED STOCK)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The undersigned Holder hereby irrevocably elects to convert the number of shares of Series&#160;A Non- Voting Preferred Stock indicated below, represented in book-entry form, into shares of common stock, par value $0.001 per share (the &#8220;<span style="font-style:italic;font-weight:bold;">Common Stock</span>&#8221;), of Aerovate Therapeutics,&#160;Inc., a Delaware corporation (the &#8220;<span style="font-style:italic;font-weight:bold;">Corporation</span>&#8221;), as of the date written below. If securities are to be issued in the name of a Person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto. Capitalized terms utilized but not defined herein shall have the meaning ascribed to such terms in that certain Certificate of Designation of Preferences, Rights and Limitations of Series&#160;A Non-Voting Convertible Preferred Stock (the &#8220;<span style="font-style:italic;font-weight:bold;">Certificate of Designation</span>&#8221;) filed by the Corporation with the Secretary of State of the State of Delaware on [<span style="font-family:'Symbol';">&#183;</span>], 202[5].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of the date hereof, the number of shares of Common Stock beneficially owned by the undersigned Holder (together with such Holder&#8217;s Attribution Parties), including the number of shares of Common Stock issuable upon conversion of the Series&#160;A Non-Voting Preferred Stock subject to this Notice of Conversion, but excluding the number of shares of Common Stock which are issuable upon (A)&#160;conversion of the remaining, unconverted Series&#160;A Non-Voting Preferred Stock beneficially owned by such Holder or any of its Attribution Parties, and (B)&#160;exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) beneficially owned by such Holder or any of its Attribution Parties that are subject to a limitation on conversion or exercise similar to the limitation contained in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.3</span> of the Certificate of Designation, is<span style="display:inline-block;width:2.67pt;"></span>. For purposes hereof, beneficial ownership shall be calculated in accordance with Section&#160;13(d)&#160;of the Exchange Act and the applicable regulations of the Commission. In addition, for purposes hereof, &#8220;group&#8221; has the meaning set forth in Section&#160;13(d)&#160;of the Exchange Act and the applicable regulations of the Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">CONVERSION CALCULATIONS:</p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Date to Effect Conversion:</span></p></td><td style="vertical-align:bottom;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Number of shares of Series&#160;A Non-Voting Preferred Stock owned prior to Conversion:</span></p></td><td style="vertical-align:bottom;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Number of shares of Series&#160;A Non-Voting Preferred Stock to be Converted:</span></p></td><td style="vertical-align:bottom;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Number of shares of Common Stock to be Issued:</span></p></td><td style="vertical-align:bottom;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Address for delivery of physical certificates:</span></p></td><td style="vertical-align:bottom;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For DWAC Delivery, please provide the following:</p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-family:'Times New Roman','Times','serif';">Broker No.:</span></p></td><td style="vertical-align:bottom;width:35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-family:'Times New Roman','Times','serif';">Account No.:</span></p></td><td style="vertical-align:bottom;width:35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:49.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">[HOLDER]</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:49.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">By:</span></p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Name:</span></p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Title:</span></p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">K-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e6b318be_98c3_45cc_a570_ad37d46b3003"></a><a id="ANNEXL_412267"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ANNEX L</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">L-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_c6dabf8f_9c52_4948_94de_54209607ef60"></a><a id="ANNEXM_944480"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ANNEX M</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECURITIES PURCHASE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This <b style="font-weight:bold;">SECURITIES PURCHASE AGREEMENT </b>(this &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;) is dated as of October&#160;30, 2024, by and among Jade Biosciences,&#160;Inc., a Delaware corporation (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;), and each of the Persons listed on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</span> attached to this Agreement (each, an &#8220;<b style="font-weight:bold;">Investor</b>&#8221; and together, the &#8220;<b style="font-weight:bold;">Investors</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, the Company and the Investors are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section&#160;4(a)(2)&#160;of the U.S. Securities Act of 1933, as amended (the &#8220;<b style="font-weight:bold;">Securities Act</b>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, the Company desires to sell to the Investors, and each Investor desires to purchase from the Company, severally and not jointly, upon the terms and subject to the conditions stated in this Agreement, (A)&#160;shares (the &#8220;<b style="font-weight:bold;">Initial Shares</b>&#8221;) of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;<b style="font-weight:bold;">Common Stock</b>&#8221;), including Common Stock being issued pursuant to any cancellation or conversion of Convertible Securities (as defined below) at a per share purchase price equal to the Share Price, and/or (B)&#160;the pre-funded warrants to purchase shares of Common Stock (the &#8220;<b style="font-weight:bold;">Pre-Funded Warrants</b>&#8221;) substantially in the form attached hereto as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;B</span> at a per warrant price equal to the Pre-Funded Warrant Price (as defined below);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, contemporaneously with the sale of the Initial Shares and/or the Pre-Funded Warrants, the parties hereto will execute and deliver a Registration Rights Agreement, in the form attached hereto as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;C</span>, pursuant to which the Company will agree to provide certain registration rights in respect of the Shares (as defined below) under the Securities Act and applicable state securities laws; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, the Company is party to that certain Agreement and Plan of Merger by and among the Company, Aerovate Therapeutics,&#160;Inc., a Delaware Corporation (&#8220;<b style="font-weight:bold;">Parent</b>&#8221;), Caribbean Merger Sub I,&#160;Inc., a Delaware corporation and wholly-owned subsidiary of the Parent (&#8220;<b style="font-weight:bold;">First Merger Sub</b>&#8221;), and Caribbean Merger Sub II, LLC, a Delaware limited liability company and wholly-owned subsidiary of the Parent (&#8220;<b style="font-weight:bold;">Second Merger Sub</b>&#8221;), dated on or about the date hereof (the &#8220;<b style="font-weight:bold;">Merger Agreement</b>&#8221;), pursuant to which (i)&#160;First Merger Sub will merge with and into the Company, with the Company surviving and becoming a wholly-owned subsidiary of Parent, and (ii)&#160;the Company will merge with and into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly-owned subsidiary of Parent (together, the &#8220;<b style="font-weight:bold;">Merger</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW THEREFORE</b>, in consideration of the mutual agreements, representations, warranties and covenants herein contained, the Company and each Investor, severally and not jointly, agree as follows:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</span>. As used in this Agreement, the following terms shall have the following respective meanings:</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Additional Securities</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.15</span> hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Affiliate</b>&#8221; means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Person. &#8220;<b style="font-weight:bold;">Aggregate Purchase Amount</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.2</span> hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Agreement</b>&#8221; has the meaning set forth in the recitals hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Amended and Restated Bylaws</b>&#8221; means the bylaws of the Company, as currently in effect and as in effect on the Closing Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Amended and Restated Certificate of Incorporation</b>&#8221; means the Certificate of Incorporation of the Company, as currently in effect and as in effect on the Closing Date. &#8220;<b style="font-weight:bold;">Beneficial Ownership Limitation</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1</span> hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Benefit Plan</b>&#8221; or &#8220;<b style="font-weight:bold;">Benefit Plans</b>&#8221; means employee benefit plans as defined in Section&#160;3(3)&#160;of ERISA and all other employee benefit practices or arrangements, including, without limitation, any such practices or arrangements providing severance pay, sick leave, vacation pay, salary continuation for disability, retirement benefits, deferred compensation, bonus pay, incentive pay, stock options or other stock-based compensation, hospitalization insurance, medical insurance, life insurance, scholarships or tuition </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">reimbursements, maintained by the Company or to which the Company or any of its Subsidiaries is obligated to contribute for employees or former employees of the Company and its Subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Board of Directors</b>&#8221; means the board of directors of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Business Day</b>&#8221; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Closing</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.2</span> hereof. &#8220;<b style="font-weight:bold;">Closing Date</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.2</span> hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Code</b>&#8221; means the U.S. Internal Revenue Code of 1986, as amended. &#8220;<b style="font-weight:bold;">Commitment Amount</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1</span> hereof. &#8220;<b style="font-weight:bold;">Common Stock</b>&#8221; has the meaning set forth in the recitals hereof. &#8220;<b style="font-weight:bold;">Company</b>&#8221; has the meaning set forth in the recitals hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Company Presentation</b>&#8221; means that certain Investor Presentation, dated October&#160;2024, as provided to the Investors prior to the date hereof and filed by Parent on Form&#160;8-K on or around the date hereof. &#8220;<b style="font-weight:bold;">Confidential Data</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.28</span> hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Contribution</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.2</span> hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Convertible Security</b>&#8221; means a convertible note issued by the Company or any of its Subsidiaries. &#8220;<b style="font-weight:bold;">Disclosure Document</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.3</span> hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Disclosure Time</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.3</span> hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Drug Regulatory Agency</b>&#8221; means the U.S. Food and Drug Administration (&#8220;<b style="font-weight:bold;">FDA</b>&#8221;) or other foreign, state, local or comparable governmental authority responsible for regulation of the research, development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of drug or biological products and drug or biological product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Environmental Laws</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.15</span> hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">ERISA</b>&#8221; means the U.S. Employee Retirement Income Security Act of 1974, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Exchange Act</b>&#8221; means the U.S. Securities Exchange Act of 1934, as amended, and all of the rules&#160;and regulations promulgated thereunder. &#8220;<b style="font-weight:bold;">Financial Statements</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.8</span>(b)&#160;hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">GAAP</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.8</span>(b)&#160;hereof. &#8220;<b style="font-weight:bold;">GDPR</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.29</span> hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Governmental Authorizations</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.11</span> hereof. &#8220;<b style="font-weight:bold;">Health Care Laws</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.19</span> hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">HIPAA</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.28</span> hereof. &#8220;<b style="font-weight:bold;">Indemnified Persons</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.10</span>(a). &#8220;<b style="font-weight:bold;">Initial Shares</b>&#8221; has the meaning set forth in the recitals hereof. &#8220;<b style="font-weight:bold;">Intellectual Property</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.12</span> hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Investor</b>&#8221; and &#8220;<b style="font-weight:bold;">Investors</b>&#8221; have the meanings set forth in the recitals hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Investor Majority</b>&#8221; means, (i)&#160;prior to the Closing, the Investors committed to purchase at least a majority of the Securities (provided that such majority shall include each Investor that committed an Aggregate Purchase Amount of no less than $27.5 million (including the Aggregate Purchase Amount of such Investor&#8217;s affiliates and related funds)) and (ii)&#160;following the Closing, the Investors who hold at least a majority of the Securities (including any Pre-Funded Warrant Shares) still held by the Investors.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">IT Systems</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.28</span> hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Material Adverse Effect</b>&#8221; means any change, event, circumstance, development, condition, occurrence or effect that, individually or in the aggregate, (a)&#160;was, is, or would reasonably be expected to be, materially adverse to the business, financial condition, properties, assets, liabilities, stockholders&#8217; equity or results of operations of the Company and its Subsidiaries, taken as a whole, or (b)&#160;materially delays or materially impairs the ability of the Company to timely comply, or prevents the Company from complying, with its obligations under this Agreement, the other Transaction Agreements, or with respect to the Closing, or would reasonably be expected to do so; provided, however, that none of the following will be deemed in themselves, either alone or in combination, to constitute, and that none of the following will be taken into account in determining whether there has been or will be, a Material Adverse Effect under subclause (a)&#160;of this definition:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:46.8pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:25.2pt;text-indent:0pt;white-space:nowrap;">(i)</span>any change generally affecting the economy, financial markets or political, economic or regulatory conditions in the United States or any other geographic region in which the Company conducts business, provided that the Company is not disproportionately affected thereby;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:46.8pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:25.2pt;text-indent:0pt;white-space:nowrap;">(ii)</span>general financial, credit or capital market conditions, including interest rates or exchange rates, or any changes therein, provided that the Company is not disproportionately affected thereby;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:46.8pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:25.2pt;text-indent:0pt;white-space:nowrap;">(iii)</span>any change that generally affects industries in which the Company and its Subsidiaries conduct business, provided that the Company is not disproportionately affected thereby;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:46.8pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:25.2pt;text-indent:0pt;white-space:nowrap;">(iv)</span>earthquakes, hurricanes, tsunamis, tornadoes, floods, mudslides, fires or other natural disasters, weather conditions, global pandemics, including the COVID-19 pandemic and related strains, epidemic or similar health emergency, and other force majeure events in the United States or any other location, provided that the Company is not disproportionately affected thereby;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:46.8pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:25.2pt;text-indent:0pt;white-space:nowrap;">(v)</span>national or international political or social conditions (or changes in such conditions), whether or not pursuant to the declaration of a national emergency or war, or the occurrence of any military or terrorist attack, provided that the Company is not disproportionately affected thereby;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:46.8pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:25.2pt;text-indent:0pt;white-space:nowrap;">(vi)</span>material changes in laws after the date of this Agreement; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-left:46.8pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:25.2pt;text-indent:0pt;white-space:nowrap;">(vii)</span>in and of itself, any material failure by the Company to meet any published or internally prepared estimates of drug development timelines (it being understood that the facts and circumstances giving rise to such failure may be deemed to constitute, and may be taken into account in determining whether there has been, a Material Adverse Effect to the extent that such facts and circumstances are not otherwise described in clauses (i)- (v)&#160;of this definition).</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Nasdaq</b>&#8221; means the Nasdaq Stock Market&#160;LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">National Exchange</b>&#8221; means (i)&#160;on and prior to the Closing Date, the Nasdaq Global Market, and (ii)&#160;following the Closing Date, any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question, together with any successor thereto: the NYSE American, The New York Stock Exchange, the Nasdaq Global Market, the Nasdaq Global Select Market and the Nasdaq Capital Market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;Parent</b>&#8221; has the meaning set forth in the recitals hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Person</b>&#8221; means an individual, partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or any other entity or organization. &#8220;<b style="font-weight:bold;">Personal Data</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.28</span> hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Placement Agent</b>&#8221; means each of Jefferies LLC, TD Securities (USA) LLC, Stifel, Nicolaus&#160;&amp; Company, Incorporated and Wedbush&#160;&amp; Co.,&#160;LLC. &#8220;<b style="font-weight:bold;">Pre-Funded Warrant Price</b>&#8221; means an amount equal to (i)&#160;the Share Price minus (ii)&#160;$0.001.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Pre-Funded Warrant Shares</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1</span> hereof. &#8220;<b style="font-weight:bold;">Pre-Funded Warrants</b>&#8221; has the meaning set forth in the recitals hereof. &#8220;<b style="font-weight:bold;">Privacy Laws</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.29</span> hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Privacy Statements</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.29</span> hereof. &#8220;<b style="font-weight:bold;">Process</b>&#8221; or &#8220;<b style="font-weight:bold;">Processing</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.29</span> hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Registration Rights Agreement</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.1</span>(j)&#160;hereof. &#8220;<b style="font-weight:bold;">Regulatory Agencies</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.18</span> hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Rule&#160;144</b>&#8221; means Rule&#160;144 promulgated by the SEC pursuant to the Securities Act, as such rule&#160;may be amended from time to time, or any similar rule&#160;or regulation hereafter adopted by the SEC having substantially the same effect as such rule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">SEC</b>&#8221; means the U.S. Securities and Exchange Commission. &#8220;<b style="font-weight:bold;">Securities</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1</span> hereof. &#8220;<b style="font-weight:bold;">Securities Act</b>&#8221; has the meaning set forth in the recitals hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Share Price</b>&#8221; means an amount equal to (i)&#160;the Company Equity Value (as defined in the Merger Agreement), (ii)&#160;divided by the number of Company Outstanding Shares (as defined in the Merger Agreement but excluding the Securities being issued hereunder) as of immediately prior to the closing of offering of the Securities hereunder; provided, that Company Outstanding Shares shall exclude (i)&#160;any Company Options (as defined in the Merger Agreement), Company Warrants (as defined in the Merger Agreement) and any other equity awards issued under the Company Stock Plans (as defined in the Merger Agreement), including any shares of Company Common Stock issuable upon the exercise of such Company Options, Company Warrants or other equity awards, issued to directors, employees, consultants or other service providers following the date hereof but prior to the Closing and (ii)&#160;any shares of Company Common Stock underlying Company Notes&#160;(as defined in the Merger Agreement) that are to be contributed as consideration pursuant to Section&#160;2.2 of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Shares</b>&#8221; means the Initial Shares and the Pre-Funded Warrant Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Short Sales</b>&#8221; include, without limitation, (i)&#160;all &#8220;short sales&#8221; as defined in Rule&#160;200 promulgated under Regulation SHO under the Exchange Act, whether or not against the box, and all types of direct and indirect stock pledges, forward sale contracts, options, puts, calls, short sales, swaps, &#8220;put equivalent positions&#8221; (as defined in Rule&#160;16a-1(h)&#160;under the Exchange Act) and similar arrangements (including on a total return basis), and (ii)&#160;sales and other transactions through non-U.S. broker dealers or non-U.S. regulated brokers (but shall not be deemed to include the location and/or reservation of borrowable shares of Common Stock), in each case, solely to the extent it has the same economic effect as a &#8220;short sale&#8221; (as defined in Rule&#160;200 promulgated under Regulation SHO under the Exchange Act).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Subsidiaries</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1</span> hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Tax</b>&#8221; or &#8220;<b style="font-weight:bold;">Taxes</b>&#8221; means any and all federal, state, local, foreign and other taxes, levies, fees, imposts, duties and charges of whatever kind (including any interest, penalties or additions to the tax imposed in connection therewith or with respect thereto), whether or not imposed on the Company, including, without limitation, taxes imposed on, or measured by, income, franchise, profits or gross receipts, and also ad valorem, value added, sales, use, service, real or personal property, capital stock, license, payroll, withholding, employment, social security, workers&#8217; compensation, unemployment compensation, utility, severance, production, excise, stamp, occupation, premium, windfall profits, transfer and gains taxes and customs duties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Tax Returns</b>&#8221; means returns, reports, information statements and other documentation (including any additional or supporting material) filed or maintained, or required to be filed or maintained, in connection with the calculation, determination, assessment or collection of any Tax and shall include any amended returns required as a result of examination adjustments made by the Internal Revenue Service or other Tax authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Transaction Agreements</b>&#8221; means this Agreement, the Merger Agreement, the Pre-Funded Warrants, the Registration Rights Agreement and any other documents or agreements explicitly contemplated hereunder or thereunder. &#8220;<b style="font-weight:bold;">Transfer Agent</b>&#8221; means, with respect to the Common Stock, Computershare Trust Company, N.A., or such other financial institution that provides transfer agent services as the Company may engage from time to time. &#8220;<b style="font-weight:bold;">Transfer Taxes</b>&#8221; means all real property transfer, sales, use, value added, stamp, documentary, recording, registration, conveyance, stock transfer, intangible property transfer, personal property transfer, gross receipts,</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">registration, duty, securities transactions or similar fees or Taxes (together with any interest, penalty, or addition thereto) incurred in connection with the transactions contemplated by this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:61.2pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Wire</b>&#8221; has the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.2</span> hereof.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchase and Sale of Securities</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchase and Sale</span>. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Investors, severally and not jointly, agree to purchase, the number of Initial Shares equal to (rounded down to the nearest whole Initial Share) (i)&#160;the aggregate commitment amount set forth under the heading &#8220;Commitment Amount&#8221; and opposite such Investor&#8217;s name on the <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</span> (the &#8220;<b style="font-weight:bold;">Commitment Amount</b>&#8221;) divided by (ii)&#160;the Share Price; p<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">rovided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, for any Investor that has provided notice to the Company at least ten (10)&#160;Business Days prior to the Closing that such Investor would beneficially own (when aggregated with all Securities then beneficially owned by the Investor and its affiliates (as calculated pursuant to Section&#160;13(d)&#160;of the Exchange Act and Rule&#160;13d-3 promulgated thereunder)) in excess of the Beneficial Ownership Limitation, or as such Investor may otherwise choose, in lieu of purchasing Initial Shares such Investor may elect to purchase Pre-Funded Warrants to purchase a number of shares of Common Stock issuable upon exercise of the Pre-Funded Warrants (the &#8220;<b style="font-weight:bold;">Pre- Funded Warrant Shares</b>&#8221;) equal to (rounded down to the nearest whole Pre-Funded Warrant Share) (i)&#160;the Commitment Amount (or any remainder thereof) divided by (ii)&#160;the Pre-Funded Warrant Price in lieu of Initial Shares in such manner to result in the same Aggregate Purchase Amount being paid by such Investor in the aggregate (including upon exercise of such Pre-Funded Warrants). The &#8220;<b style="font-weight:bold;">Beneficial Ownership Limitation</b>&#8221; shall initially be set at the discretion of each Investor to a&#160;percentage designated by such Investor on its signature page&#160;hereto between 0% and 9.9999% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of the Initial Shares and Pre-Funded Warrants on the Closing Date (collectively, the &#8220;<b style="font-weight:bold;">Securities</b>&#8221;); p<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">rovided</span> that such&#160;percentage shall be set at 9.9999% for any Investor that does not make such designation on its signature page&#160;hereto. Notwithstanding the foregoing, by written notice to the Company, any Investor may reset the Beneficial Ownership Limitation&#160;percentage to a higher or lower&#160;percentage, not to exceed 9.9999%; p<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">rovided</span> that any increase will not be effective until the sixty-first (61st) day after such written notice is delivered to the Company. Upon such a change by an Investor of the Beneficial Ownership Limitation, the Beneficial Ownership Limitation may not be further amended by such Investor without first providing the minimum notice required by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1</span>. Notwithstanding anything to the contrary set forth in this Agreement, for any Investor that has provided notice to the Company that this sentence shall apply to it, (i)&#160;the Investor shall not be required to purchase Pre-Funded Warrants and (ii)&#160;the Company shall not issue or sell, and the Investor shall not purchase or acquire, any Initial Shares which, when aggregated with all shares of Common Stock then beneficially owned by the Investor and its affiliates (as calculated pursuant to Section&#160;13(d)&#160;of the Exchange Act and Rule&#160;13d-3 promulgated thereunder), would result in the beneficial ownership by the Investor of more than 9.99% of the outstanding shares of Common Stock immediately after giving effect to the Closing and the consummation of the transactions contemplated hereby, and the number of Initial Shares and the Aggregate Purchase Amount for such Investor shall be reduced accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing</span>. Subject to the satisfaction or waiver of the conditions set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.13</span>, the closing of the purchase and sale of the Securities (the &#8220;<b style="font-weight:bold;">Closing</b>&#8221; and the date on which the Closing occurs, the &#8220;<b style="font-weight:bold;">Closing Date</b>&#8221;) shall occur remotely via the exchange of documents and signatures immediately prior to the First Effective Time (as defined in the Merger Agreement), or at such other time as agreed to by the Company and the Investor Majority. Not less than three (3)&#160;Business Days prior to the anticipated Closing Date, the Company shall provide written notice to the Investors (the &#8220;<b style="font-weight:bold;">Closing Notice</b>&#8221;) of the anticipated Closing Date and the wire instructions for delivery of the Aggregate Purchase Amount. At the Closing, the Securities shall be issued and registered in the name of such Investor, or in such nominee name(s)&#160;as designated by such Investor, representing the number of Securities to be purchased by such Investor at such Closing as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</span>, in each case against payment to the Company of the purchase price therefor (the &#8220;<b style="font-weight:bold;">Aggregate Purchase Amount</b>&#8221;) in full, either by (x)&#160;wire transfer to the Company of immediately available funds (a &#8220;<b style="font-weight:bold;">Wire</b>&#8221;), at or prior to the Closing, in accordance with wire instructions provided by the Company in the Closing Notice; (y)&#160;the cancellation of Convertible Securities or other debt of the Company or its Subsidiaries (including any outstanding principal, premium, interest or any other amounts due thereon) set forth under the heading &#8220;Convertible Securities Amount&#8221; and opposite such Investor&#8217;s name in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</span> (any such cancellation, a &#8220;<b style="font-weight:bold;">Contribution</b>&#8221;); or (z)&#160;a combination of such methods. On the Closing Date, the Company will (A)&#160;cause the Transfer Agent to issue the Initial Shares in book-entry form, free and clear of all restrictive and other legends (except as expressly provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.10</span> hereof) and the Company shall provide evidence of such issuance from the Company&#8217;s Transfer Agent as soon as reasonably practical following the Closing Date to each Investor and (B)&#160;deliver to such Investor (or such Investor&#8217;s designated custodian per its delivery instructions), or in such nominee name(s)&#160;as designated by such Investor, a Pre-Funded Warrant exercisable for a number of shares of Common Stock as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</span> with respect to such Investor. If the Closing has not occurred within two (2)&#160;Business Days after the expected Closing Date, unless otherwise agreed by the Company and such Investor, the Company shall promptly (but no later than one (1)&#160;Business Day thereafter) return the previously wired Aggregate Purchase </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Amount to each respective Investor by wire transfer of United States dollars in immediately available funds to the account specified by each Investor, and any book entries for the Securities shall be deemed cancelled; p<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">rovided</span> that, unless this Agreement has been terminated pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7</span>, such return of funds shall not terminate this Agreement or relieve such Investor of its obligation to purchase, or the Company of its obligation to issue and sell, the Securities at the Closing. Notwithstanding the foregoing and anything in this Agreement to the contrary, (i)&#160;the Company may amend <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</span> up to three (3)&#160;Business Days prior to the Closing, without the consent of the other parties hereto, to reflect the number of Securities purchased, the Aggregate Purchase Amount to be paid and the Convertible Securities Amount to be Contributed, in each case, by each applicable Investor, and shall provide such updated Exhibit&#160;A to an Investor upon request, and (ii), as may be agreed to among the Company and one or more Investors, if an Investor is (a)&#160;an investment company registered under the Investment Company Act of 1940, as amended, (b)&#160;advised by an investment adviser subject to regulation under the Investment Advisers Act of 1940, as amended, or (c)&#160;otherwise subject to internal policies and/or procedures relating to the timing of funding and issuance of securities, such Investor shall not be required to wire its Aggregate Purchase Amount until it confirms receipt of evidence of the issuance of such Investor&#8217;s Initial Shares from the Transfer Agent in form and substance reasonably acceptable to the Investor (and the Company shall use reasonable best efforts to cause the Transfer Agent to deliver such evidence) and, if applicable, copies of such Investor&#8217;s Pre- Funded Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conversion and Termination of Convertible Securities</span>. Notwithstanding anything in this Agreement to the contrary, by executing and delivering this Agreement, each Investor holding one or more Convertible Securities prior to the Closing hereby irrevocably agrees that:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:18pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</span>the aggregate amount of all such Convertible Securities (including any outstanding principal, premium, interest or any other amounts) held by such Investor is set forth under the heading &#8220;Convertible Securities Amount&#8221; and opposite such Investor&#8217;s name in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</span>;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:18pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</span>such Investor is the sole owner of all right, title and interest in and to the Convertible Securities corresponding to the amounts set forth under the heading &#8220;Convertible Securities Amount&#8221; and opposite such Investor&#8217;s name in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</span>;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:18pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</span>at the Closing, (i)&#160;all of such Investor&#8217;s Convertible Securities will automatically and without any action on the part of such Investor convert into that number of Securities as is calculated in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1</span> based on such Investor&#8217;s Aggregate Purchase Amount (whether paid via Wire or Contribution), regardless of whether any such Convertible Securities or an affidavit of loss therefor is actually delivered in original or other form to the Company, and (ii)&#160;any original Convertible Securities held by (or delivered, electronically or otherwise, to) the Company or any Subsidiary, as applicable, shall be cancelled (and marked cancelled) by the Company or any Subsidiary, as applicable, upon or following the Closing;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:18pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</span>with respect to any Contribution by such Investor, (i)&#160;such Investor (on behalf of itself and all beneficial owners of such Investor&#8217;s Convertible Securities) and Company (on behalf of itself and its Subsidiaries) hereby agree that any Convertible Securities that are Contributed hereby are and will be deemed for all purposes to have been amended and modified by virtue hereof to the full extent necessary to permit and facilitate their conversion as provided in this Agreement into Securities and (ii)&#160;such Investor&#8217;s Securities are issued in full and complete discharge and satisfaction of all obligations of the Company or its Subsidiaries, as applicable, (including any outstanding principal, premium, interest or any other amounts) under such Investor&#8217;s Convertible Securities, and such Convertible Securities will be terminated in full and will be null, void and of no further force or effect automatically immediately upon the Closing, p<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">rovided</span> that the foregoing will not impair the right of such Investor to receive the applicable number of Securities calculated in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1</span> above; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</span>the Company and its Subsidiaries, affiliates, and agents shall be entitled to deduct and withhold from the amounts deliverable in satisfaction of such Investor&#8217;s Convertible Securities (including any Securities otherwise issuable with respect thereto) such amounts, if any, as are required to be deducted and withheld under the Code or any other applicable tax law. To the extent that amounts are so deducted and withheld and duly paid over to the appropriate tax authority, such withheld amounts shall be treated for all purposes of this Agreement as having been delivered to the person in respect of whom such deduction and withholding was made. Each person holding Convertible Securities shall, upon request, use its commercially reasonable efforts to provide the applicable withholding agent with all necessary tax forms, including a duly executed IRS Form&#160;W-9 or appropriate version of IRS Form&#160;W- 8, as applicable. Prior to withholding any amounts pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.3</span>(e), the Company (and its Subsidiaries, affiliates, and agents) shall use commercially reasonable efforts to notify such Investor, and the Company and such Investor shall cooperate in good faith to reduce or eliminate any such withholding.</div><div style="margin-top:12pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">3.</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties of the Company</span>. The <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</span> hereby represents and warrants to each of the Investors and the Placement Agents that the statements contained in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3</span> are true and correct as of the date hereof and as of the Closing Date (except for the representations and warranties that speak as of a specific date, which shall be made as of such date):</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Organization and Power</span>. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware, has the requisite power and authority to own, lease and operate its properties and to carry on its business as now conducted and is qualified to do business in each jurisdiction in which the character of its properties or the nature of its business requires such qualification, except where such failure to be in good standing or to have such power and authority or to so qualify would not reasonably be expected to have a Material Adverse Effect. The Company does not have any subsidiaries and does not otherwise own any shares of capital stock or any interest in any other Person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.2</span></span>Capitalization. The authorized capital stock of the Company consists of 40,000,000 shares of Common Stock and 20,000,000 shares of preferred stock, par value $0.001 per share. All of the issued and outstanding shares of Common Stock have been duly authorized and validly issued and are fully paid and non-assessable. None of the outstanding shares of capital stock of the Company were issued in violation of any preemptive or other similar rights of any securityholder of the Company which have not been waived, and such shares were issued in compliance in all material respects with applicable state and federal securities law and any rights of third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.3</span></span>Registration Rights. Except as set forth in or contemplated by the Transaction Agreements (including in Section&#160;3.7), the Company is presently not under any obligation, and has not granted any rights, to register under the Securities Act any of the Company&#8217;s presently outstanding securities or any of its securities that may hereafter be issued that have not expired or been satisfied or waived.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.4</span></span>Authorization. The Company has all requisite corporate power and authority to enter into the Transaction Agreements and to carry out and perform its obligations under the terms of the Transaction Agreements, including the issuance and sale of the Securities and the issuance of the Pre-Funded Warrant Shares and the reservation of the Pre-Funded Warrant Shares. Except as contemplated by the Merger Agreement, all corporate action on the part of the Company, its officers, directors and stockholders necessary for the authorization of the Securities and the Pre-Funded Warrant Shares, the authorization, execution, delivery and performance of the Transaction Agreements and the consummation of the transactions contemplated herein, including the issuance and sale of the Securities and the Pre-Funded Warrant Shares, has been taken. This Agreement has been duly executed and delivered by the Company and assuming the due authorization, execution and delivery by each Investor and that this Agreement constitutes the legal, valid and binding agreement of each Investor, this Agreement and each of the Pre-Funded Warrants constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and similar laws relating to or affecting creditors generally or by general equity principles (regardless of whether such enforceability is considered in a proceeding in equity or at law). Upon its execution by the Company and the other parties thereto and assuming that it constitutes legal, valid and binding agreements of the other parties thereto, the Registration Rights Agreement and each Pre-Funded Warrant will constitute a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and similar laws relating to or affecting creditors generally or by general equity principles (regardless of whether such enforceability is considered in a proceeding in equity or at law).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.5</span></span>Valid Issuance. The Initial Shares being purchased by the Investors hereunder have been duly and validly authorized and, upon issuance pursuant to the terms hereof, against full payment therefor in accordance with the terms of this Agreement, will be duly and validly issued, fully paid and non-assessable and will be issued free and clear of any liens or other restrictions (other than those as provided in the Transaction Agreements or restrictions on transfer under applicable state and federal securities laws) and the holder of the Initial Shares shall be entitled to all rights accorded to a holder of Common Stock. The Pre-Funded Warrant Shares have been duly and validly authorized and reserved for issuance and, upon issuance pursuant to the terms of the Pre-Funded Warrants, against full payment therefor in accordance with the terms of the Pre-Funded Warrants, will be duly and validly issued, fully paid and non- assessable and will be issued free and clear of any liens or other restrictions (other than those as provided in the Transaction Agreements or restrictions on transfer under applicable state and federal securities laws) and the holder of the Pre-Funded Warrant Shares shall be entitled to all rights accorded to a holder of Common Stock. Subject to the accuracy of the representations and warranties made by the Investors in Section&#160;4 hereof, the offer and sale of the Securities to the Investors is and will be in compliance with applicable exemptions from (i)&#160;the registration and prospectus delivery requirements of the Securities Act and (ii)&#160;the registration and qualification requirements of applicable securities laws of the states of the United States.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.6</span></span>No Conflict. The execution, delivery and performance of the Transaction Agreements by the Company, the issuance and sale of the Securities and the consummation of the other transactions contemplated by the Transaction Agreements will not (i)&#160;violate any provision of the Amended and Restated Certificate of Incorporation or Amended and Restated Bylaws, (ii)&#160;conflict with or result in a violation of or default (with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancellation or acceleration of any obligation, a change of control right or to a loss of a benefit under any agreement or instrument, credit facility, franchise, license, judgment, order, statute, law, ordinance, rule&#160;or regulations, applicable to the Company or any Subsidiary or their respective properties or assets, or (iii)&#160;result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or any Subsidiary is subject (including federal and state securities laws and regulations) and the rules&#160;and regulations of any self-regulatory organization to which the Company or its securities are subject, or by which any property or asset of the Company or any Subsidiary is bound or affected, except, in the case of clauses (ii)&#160;and (iii), as would not, individually or in the aggregate, be reasonably expected to have a Material Adverse Effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.7</span></span>Consents. Assuming the accuracy of the representations and warranties of the Investors in Section&#160;4 and except as set forth in the Merger Agreement, no consent, approval, authorization, filing with or order of or registration with, any court or governmental agency or body is required in connection with the authorization, execution or delivery by the Company of the Transaction Agreements, the issuance and sale of the Securities and the performance by the Company of its other obligations under the Transaction Agreements, except such as (a)&#160;have been or will be obtained or made under the Securities Act or the Exchange Act, (b)&#160;the filing of any requisite notices and/or application(s)&#160;to the National Exchange for the issuance and sale of the Shares and the listing of the Shares for trading or quotation, as the case may be, thereon in the time and manner required thereby, (c)&#160;customary post-closing filings with the SEC or pursuant to state securities laws in connection with the offer and sale of the Shares by the Company in the manner contemplated herein, which will be filed on a timely basis, (d)&#160;the filing of the registration statement required to be filed by the Registration Rights Agreement, or (e)&#160;such that the failure of which to obtain would not have a Material Adverse Effect. All notices, consents, authorizations, orders, filings and registrations which the Company is required to deliver or obtain prior to the Closing pursuant to the preceding sentence have been obtained or made or will be delivered or obtained or effected, and shall remain in full force and effect, on or prior to the Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.8</span></span>Financial Statements. The statement of operations and comprehensive loss data for the period from June&#160;18, 2024 (inception) to September&#160;30, 2024 and summary balance sheet data as of September&#160;30, 2024 of the Company (collectively, the &#8220;<b style="font-weight:bold;">Financial Statements</b>&#8221;) comply in all material respects with applicable accounting requirements with respect thereto as in effect at the time of filing or public distribution (or to the extent corrected by a subsequent restatement) and fairly present in all material respects the financial position of the Company as of the dates indicated, and the results of its operations and cash flows for the periods therein specified, all in accordance with United States generally accepted accounting principles (&#8220;<b style="font-weight:bold;">GAAP</b>&#8221;) (except as otherwise noted therein and except that the unaudited financial statements may not contain footnotes and other presentation items required by GAAP and are subject to normal and recurring&#160;year-end adjustments) applied on a consistent basis unless otherwise noted therein throughout the periods therein specified. Except as set forth in the Financial Statements filed prior to the date hereof, the Company has not incurred any liabilities, contingent or otherwise, except (i)&#160;those incurred in the ordinary course of business, consistent with past practices since the date of such Financial Statements or (ii)&#160;liabilities not required under GAAP to be reflected in the Financial Statements, in either case, none of which, individually or in the aggregate, have had or would reasonably be expected to have a Material Adverse Effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.9</span></span>Absence of Changes. Except for the execution and performance of the Transaction Agreements, and the discussions, negotiations, and transactions preceding or related thereto, since the Company&#8217;s inception: (a) the Company has conducted its business only in the ordinary course of business and there have been no material transactions entered into by the Company; (b)&#160;no material change to any material contract or arrangement by which the Company is bound or to which any of its assets or properties is subject has been entered into that has not been disclosed to the Investors; and (c)&#160;there has not been any other event or condition of any character that has had or would reasonably be expected to have a Material Adverse Effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.10</span></span>&#160;&#160;Absence of Litigation. There is no action, suit, proceeding, arbitration, claim, investigation, charge, complaint or inquiry pending or, to the Company&#8217;s knowledge, threatened against the Company or any Subsidiary which, individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect, nor are there any orders, writs, injunctions, judgments or decrees outstanding of any court or government agency or instrumentality and binding upon the Company or any Subsidiary that have had or would reasonably be expected to have a Material Adverse Effect. Neither the Company nor any Subsidiary, nor to the knowledge of the Company, any director or officer of the Company or any Subsidiary, is, or within the last ten (10)&#160;years has been, the subject of any action involving a claim of violation of or liability under federal or </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">state securities laws relating to the Company or such Subsidiary or a claim of breach of fiduciary duty relating to the Company or such Subsidiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.11</span></span>&#160;&#160;Compliance with Law; Permits. None of the Company or any Subsidiary is in violation of, or has received any notices of violations with respect to, any laws, statutes, ordinances, rules&#160;or regulations of any governmental body, court or government agency or instrumentality, except for violations which, individually or in the aggregate, have not had and would not reasonably be expected to have a Material Adverse Effect. The Company and its Subsidiaries have all required licenses, permits, certificates and other authorizations (collectively, &#8220;<b style="font-weight:bold;">Governmental Authorizations</b>&#8221;) from such federal, state or local government or governmental agency, department or body that are currently necessary for the operation of the business of the Company and its Subsidiaries as currently conducted, except where the failure to possess currently such Governmental Authorizations has not had and is not reasonably expected to have a Material Adverse Effect. None of the Company or any Subsidiary has received any written (or, to the Company&#8217;s knowledge, oral) notice regarding any revocation or material modification of any such Governmental Authorization, which, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, has or would reasonably be expected to result in a Material Adverse Effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.12</span></span>&#160;&#160;Intellectual Property. The Company and its Subsidiaries own, or have rights to use, all material inventions, patent applications, patents, trademarks, trade names, service names, service marks, copyrights, trade secrets, know how (including unpatented and/or unpatentable proprietary of confidential information, systems or procedures) and other intellectual property as described in the Company Presentation necessary for, or used in the conduct of their respective businesses (collectively, &#8220;<b style="font-weight:bold;">Intellectual Property</b>&#8221;), except where any failure to own, possess or acquire such Intellectual Property has not had, and would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Intellectual Property of the Company and its Subsidiaries has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part. To the Company&#8217;s knowledge: (i) there are no third parties who have rights to any Intellectual Property, including no liens, security interests, or other encumbrances; and (ii)&#160;there is no infringement by third parties of any Intellectual Property. No action, suit, or other proceeding is pending, or, to the Company&#8217;s knowledge, is threatened: (A)&#160;challenging the Company&#8217;s or its Subsidiaries&#8217; rights in or to any Intellectual Property; (B)&#160;challenging the validity, enforceability or scope of any Intellectual Property; or (C)&#160;alleging that the Company or any of its Subsidiaries infringes, misappropriates, or otherwise violates any patent, trademark, trade name, service name, copyright, trade secret or other proprietary rights of others, except, in each case, which, individually or in the aggregate, have not had and would not reasonably be expected to have a Material Adverse Effect. The Company and its Subsidiaries have complied in all material respects with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or any of its Subsidiaries in all material respects, and to the Company&#8217;s knowledge all such agreements are in full force and effect. To the Company&#8217;s knowledge, there are no material defects in any of the patents or patent applications included in the Intellectual Property. The Company and its Subsidiaries have taken all reasonable steps to protect, maintain and safeguard their Intellectual Property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.13</span></span>&#160;&#160;Employee Benefits. Except as would not be reasonably likely to result in a Material Adverse Effect, each Benefit Plan has been established and administered in accordance with its terms and in compliance with the applicable provisions of ERISA, the Code, the Patient Protection and Affordable Care Act of 2010, as amended, and other applicable laws, rules&#160;and regulations. The Company and its Subsidiaries are in compliance with all applicable federal, state and local laws, rules&#160;and regulations regarding employment, except for any failures to comply that are not reasonably likely, individually or in the aggregate, to have a Material Adverse Effect. There is no labor dispute, strike or work stoppage&#160;against the Company or its Subsidiaries pending or, to the knowledge of the Company, threatened which may interfere with the business activities of the Company, except where such dispute, strike or work stoppage&#160;is not reasonably likely, individually or in the aggregate, to have a Material Adverse Effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.14</span></span>&#160;&#160;Taxes. The Company and its Subsidiaries have filed all federal, state and foreign income Tax Returns and other Tax Returns required to have been filed under applicable law (or extensions have been duly obtained) and have paid all Taxes required to have been paid by them, except for those which are being contested in good faith and except where failure to file such Tax Returns or pay such Taxes would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. No assessment in connection with United States federal tax returns has been made against the Company. The charges, accruals and reserves on the books of the Company in respect of any income and corporation tax liability for any&#160;years not finally determined are adequate to meet any assessments or reassessments for additional income tax for any&#160;years not finally determined, except to the extent of any inadequacy that would not result in a Material Adverse Effect. No audits, examinations, or other proceedings with respect to any material amounts of Taxes of the Company and its Subsidiaries are presently in progress or have been asserted or proposed in writing without subsequently being paid, settled or withdrawn. There are no liens on any of the assets of the Company. The Company, at all times since inception, has been and continues to be each classified as a corporation </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">for U.S. federal income tax purposes. Neither the Company nor any of its Subsidiaries has been a United States real property holding corporation within the meaning of Code Section&#160;897(c)(2)&#160;during the period specified in Code Section&#160;897(c)(1)(A)(ii).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">3.15&#160;&#160;Environmental Laws. The Company and its Subsidiaries (i)&#160;are in compliance with any and all applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (&#8220;<b style="font-weight:bold;">Environmental Laws</b>&#8221;), (ii)&#160;have received all permits and other Governmental Authorizations required under applicable Environmental Laws to conduct its business and (iii)&#160;are in compliance with all terms and conditions of any such permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. None of the Company or any Subsidiary has received since the Company&#8217;s inception, any written notice or other communication (in writing or otherwise), whether from a governmental authority or other Person, that alleges that the Company or any Subsidiary is not in compliance with any Environmental Law and, to the knowledge of the Company, there are no circumstances that may prevent or interfere with the Company&#8217;s or any Subsidiary&#8217;s compliance with any Environmental Law in the future, except where such failure to comply would not reasonably be expected to have a Material Adverse Effect. To the knowledge of the Company: (i)&#160;no current or (during the time a prior property was leased or controlled by the Company) prior property leased or controlled by the Company or any Subsidiary has received since the Company&#8217;s inception, any written notice or other communication relating to property owned or leased at any time by the Company, whether from a governmental authority, or other Person, that alleges that such current or prior owner or the Company or any Subsidiary is not in compliance with or violated any Environmental Law relating to such property and (ii)&#160;the Company has no material liability under any Environmental Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">3.16&#160;&#160;Title. Each of the Company and its Subsidiaries has good and marketable title to all personal property owned by it that is material to the business of the Company, free and clear of all liens, encumbrances and defects except such as do not materially affect the value of such property and do not materially and adversely interfere with the use made and proposed to be made of such property by the Company or its Subsidiaries, as the case may be. Any real property and buildings held under lease by the Company or its Subsidiaries is held under valid, subsisting and enforceable leases with such exceptions as are not material and do not materially and adversely interfere with the use made and proposed to be made of such property and buildings by the Company or its Subsidiaries, as the case may be. The Company does not own any real property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">3.17&#160;&#160;Insurance. The Company carries or is entitled to the benefits of insurance in such amounts and covering such risks that is customary for comparably situated companies and is adequate for the conduct of its business and the value of its properties (owned or leased) and assets, and each of such insurance policies is in full force and effect and the Company is in compliance in all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, since the Company&#8217;s inception, the Company has not received any notice or other communication regarding any actual or possible: (i)&#160;cancellation or invalidation of any insurance policy or (ii) refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">3.18&#160;&#160;Clinical Data and Regulatory Compliance. Except as would not reasonably be expected to result in a Material Adverse Effect: (i)&#160;the preclinical tests and clinical trials, and other studies used to support regulatory approval (collectively, &#8220;<b style="font-weight:bold;">studies</b>&#8221;) being conducted by the Company that are described in, or the results of which are referred to in, the Company Presentation were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; (ii)&#160;each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its Subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Company Presentation; (iii)&#160;the Company and its Subsidiaries have made or will make all such filings and obtained all such approvals as may be required by the FDA or from any other U.S. federal, state or local government or foreign government or Drug Regulatory Agency, or Institutional Review Board, each having jurisdiction over biopharmaceutical products (collectively, the &#8220;<b style="font-weight:bold;">Regulatory Agencies</b>&#8221;) for the conduct of its business as described in the Company Presentation; (iv)&#160;neither the Company nor any of its Subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination or suspension of or imposing any clinical hold on any clinical trials that are described or referred to in the Company Presentation; and (v)&#160;the Company and its Subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.19</span></span>&#160;&#160;Compliance with Health Care Laws. The Company and its Subsidiaries are in compliance in all material respects with all Health Care Laws to the extent applicable to the Company&#8217;s current business and research use only products. For purposes of this Agreement, &#8220;<b style="font-weight:bold;">Health Care Laws</b>&#8221; means: (i)&#160;the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section&#160;301 et seq.) and the Public Health Service Act (42 U.S.C. Section&#160;201 et seq.), and the regulations promulgated thereunder; (ii)&#160;all applicable federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the Anti-Kickback Statute (42 U.S.C. Section&#160;1320a-7b(b)); (iii)&#160;HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section&#160;17921 et seq.); (iv)&#160;the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010; (v)&#160;the European Union (&#8220;<b style="font-weight:bold;">EU</b>&#8221;) Clinical Trials Regulation (Regulation (EU) No.&#160;536/2014); (vi)&#160;the EU Regulation regarding community procedures for authorization and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (Regulation (EC) No.&#160;726/2004); (vii)&#160;licensure, quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or regulatory bodies; (viii)&#160;all other local, state, federal, national, supranational and foreign laws, relating to the regulation of the Company or its Subsidiaries, and (ix)&#160;the regulations promulgated pursuant to such statutes and any state or non-U.S. counterpart thereof. Neither the Company nor any of its Subsidiaries has received written or, to the Company&#8217;s knowledge, oral notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in material violation of any Health Care Laws nor, to the Company&#8217;s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened. The Company and its Subsidiaries have filed, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent submission). Neither the Company nor any of its Subsidiaries is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority. Additionally, neither the Company, any of its Subsidiaries nor any of their respective employees, officers, directors, or, to the knowledge of the Company, agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">3.20&#160;&#160;<span style="white-space:pre-wrap;">Accounting  Controls and Disclosure Controls and Procedures. The Company maintains a system of internal control over financial reporting (as defined in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;of the Exchange Act) that is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including policies and procedures sufficient to provide reasonable assurance (i)&#160;that the Company maintains records that in reasonable detail accurately and fairly reflect the Company&#8217;s transactions and dispositions of assets, (ii)&#160;that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (iii)&#160;that receipts and expenditures are made only in accordance with authorizations of management and the Board of Directors and (iv)&#160;regarding prevention or timely detection of the unauthorized acquisition, use or disposition of the Company&#8217;s assets that could have a material effect on the Company&#8217;s financial statements. Since the inception of the Company, there has been (a)&#160;no material weaknesses in the design or operation of the Company&#8217;s internal control over financial reporting (whether or not remediated) and (b)&#160;no change in the Company&#8217;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. The Company&#8217;s &#8220;disclosure controls and procedures&#8221; (as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;of the Exchange Act) are designed to provide reasonable assurance that all information (both financial and non-financial) required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules&#160;and forms of the SEC, and that all such information is accumulated and communicated to the Company&#8217;s management as appropriate to allow timely decisions regarding required disclosure.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.95pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.21</span></span>Price Stabilization of Common Stock. The Company has not taken, nor will it take, directly or indirectly, any action designed to stabilize or manipulate the price of the Common Stock to facilitate the sale or resale of the Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.95pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.22</span></span>Investment Company Act. The Company is not, and immediately after receipt of payment for the Securities will not be, an &#8220;investment company&#8221; within the meaning of the U.S. Investment Company Act of 1940, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.95pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.23</span></span>General Solicitation; No Integration or Aggregation. Neither the Company nor any other person or entity authorized by the Company to act on its behalf has engaged in a general solicitation or general advertising (within the meaning of Regulation D of the Securities Act) of investors with respect to offers or sales of the Securities pursuant to this Agreement. The Company has </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">not, directly or indirectly, sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of, any security (as defined in the Securities Act) which, to its knowledge, is or will be (i)&#160;integrated with the Securities sold pursuant to this Agreement for purposes of the Securities Act or (ii) aggregated with prior offerings by the Company for the purposes of the rules&#160;and regulations of the Nasdaq Global Market. Assuming the accuracy of the representations and warranties of the Investors set forth in Section&#160;4, neither the Company nor any of its Affiliates, its subsidiaries nor any Person acting on their behalf has, directly or indirectly, made any offers or sales of any Company security or solicited any offers to buy any Company security, under circumstances that would adversely affect reliance by the Company on Section&#160;4(a)(2)&#160;of the Securities Act for the exemption from registration for the transactions contemplated hereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.95pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.24</span></span>Brokers and Finders. Other than the Placement Agents, neither the Company nor any other Person authorized by the Company to act on its behalf has retained, utilized or been represented by any broker or finder in connection with the transactions contemplated by this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.95pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.25</span></span>Reliance by the Investors. The Company has a reasonable basis for making each of the representations set forth in this Section&#160;3. The Company acknowledges that each of the Investors will rely upon the truth and accuracy of, and the Company&#8217;s compliance with, the representations, warranties, agreements, acknowledgements and understandings of the Company set forth herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.95pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.26</span></span>No Additional Agreements. There are no agreements or understandings between the Company, on one hand, and any Investor, on the other hand, with respect to the transactions contemplated by the Transaction Agreements other than as specified in the Transaction Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.95pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.27</span></span><span style="white-space:pre-wrap;">Anti-Bribery and Anti-Money Laundering  Laws; Sanctions. Each of the Company, its Subsidiaries and, to the knowledge of the Company, any of their respective officers, directors, supervisors, managers, agents, or employees are and have at all times been in compliance with and its participation in the offering will not violate: (A)&#160;anti-bribery laws, including but not limited to, any applicable law, rule, or regulation of any locality, including but not limited to any law, rule, or regulation promulgated to implement the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, signed December&#160;17, 1997, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.K. Bribery Act 2010, or any other law, rule&#160;or regulation of similar purposes and scope, (B)&#160;anti-money laundering laws, including, but not limited to, applicable federal, state, international, foreign or other laws, regulations or government guidance regarding anti-money laundering, including, without limitation, Title 18 US. Code sections 1956 and 1957, the Patriot Act, the Bank Secrecy Act, and international anti-money laundering principles or procedures by an intergovernmental group or organization, such as the Financial Action Task Force on Money Laundering, of which the United States is a member and with which designation the United States representative to the group or organization continues to concur, all as amended, and any executive order, directive, or regulation pursuant to the authority of any of the foregoing, or any orders or licenses issued thereunder, or (C)&#160;except as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect, any laws with respect to import and export control and economic sanctions, including the U.S. Export Administration Regulations, the U.S. International Traffic in Arms Regulations, and economic sanctions regulations and executive orders administered by the U.S. Department of the Treasury Office of Foreign Asset Control.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.95pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.28</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cybersecurity</span>. The Company and its Subsidiaries&#8217; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#8220;<b style="font-weight:bold;">IT Systems</b>&#8221;) are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company and its Subsidiaries as currently conducted, and are free and clear of all material Trojan horses, time bombs, malware and other malicious code. The Company and its Subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls designed to maintain and protect the confidentiality, integrity, availability, privacy and security of all sensitive, confidential or regulated data (&#8220;<b style="font-weight:bold;">Confidential Data</b>&#8221;) used or maintained in connection with their businesses and Personal Data (defined below), and the integrity, availability continuous operation, redundancy and security of all IT Systems. &#8220;<b style="font-weight:bold;">Personal Data</b>&#8221; means the following data used in connection with the Company&#8217;s and its Subsidiaries&#8217; businesses and in their possession or control:(i) a natural person&#8217;s name, street address, telephone number, e-mail address, photograph, social security number or other tax identification number, driver&#8217;s license number, passport number, credit card number or bank information; (ii) information that identifies or may reasonably be used to identify an individual; (iii)&#160;any information that would qualify as &#8220;protected health information&#8221; under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, &#8220;<b style="font-weight:bold;">HIPAA</b>&#8221;); and (iv)&#160;any information that would qualify as &#8220;personal data,&#8221; &#8220;personal information&#8221; (or similar term) under the Privacy Laws. To the Company&#8217;s knowledge, there </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">have been no breaches, outages or unauthorized uses of or accesses to the Company&#8217;s IT Systems, Confidential Data, or Personal Data that would require notification under Privacy Laws (as defined below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.95pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.29</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Data Privacy Laws</span>. The Company and its Subsidiaries are, and at all prior times were, in material compliance with all applicable state, federal and foreign data privacy and security laws and regulations regarding the collection, use, storage, retention, disclosure, transfer, disposal, or any other processing (collectively &#8220;<b style="font-weight:bold;">Process</b>&#8221; or &#8220;<b style="font-weight:bold;">Processing</b>&#8221;) of Personal Data, including without limitation HIPAA, the EU General Data Protection Regulation (&#8220;<b style="font-weight:bold;">GDPR</b>&#8221;) (Regulation (EU) No.&#160;2016/679), all other local, state, federal, national, supranational and foreign laws relating to the regulation of the Company or its Subsidiaries, and the regulations promulgated pursuant to such statutes and any state or non-U.S. counterpart thereof (collectively, the &#8220;<b style="font-weight:bold;">Privacy Laws</b>&#8221;). To ensure material compliance with the Privacy Laws, the Company and its Subsidiaries have in place, comply with, and take all appropriate steps necessary to ensure compliance in all material respects with their policies and procedures relating to data privacy and security, and the Processing of Personal Data and Confidential Data (the &#8220;<b style="font-weight:bold;">Privacy Statements</b>&#8221;). The Company and its Subsidiaries have, except as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect, at all times since inception provided accurate notice of its Privacy Statements then in effect to its customers, employees, third party vendors and representatives. None of such disclosures made or contained in any Privacy Statements have been materially inaccurate, misleading, incomplete, or in material violation of any Privacy Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.95pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.30</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transactions with Affiliates and Employees</span>. No relationship, direct or indirect, exists between or among the Company, on the one hand, and any director, officer, stockholder, customer or supplier of the Company, on the other hand, that is required to be described in any forms, statements, certifications, reports and documents required to be filed or furnished with the SEC under the Exchange Act or the Securities Act that will not be so described in accordance with the Exchange Act following the Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.95pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.31</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Information Provided</span>. The information to be supplied by or on behalf of the Company for inclusion or incorporation by reference in the Registration Statement (as defined in the Merger Agreement), or supplied by or on behalf of the Company for inclusion in any filing pursuant to Rule&#160;165 and Rule&#160;425 under the Securities Act or Rule&#160;14a-12 under the 1934 Act (each a &#8220;<b style="font-weight:bold;">Regulation M-A Filing</b>&#8221;), shall not, at the time the Registration Statement or any such Regulation M-A Filing is filed with the Commission, at any time it is amended or supplemented or at the time the Registration Statement is declared effective by the Commission, as applicable, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein not misleading. The information to be supplied by or on behalf of the Company for inclusion in the Registration Statement to be sent to the stockholders of Parent in connection with the meeting of Parent&#8217;s stockholders (the &#8220;<b style="font-weight:bold;">Public Company Meeting</b>&#8221;), shall not, on the date the proxy statement/prospectus included in the Registration Statement is first mailed to stockholders of Parent, at the time of the Public Company Meeting or at the First Effective Time, contain any statement that, at such time and in light of the circumstances under which it shall be made, is false or misleading with respect to any material fact, or omit to state any material fact necessary in order to make the statements made in the Registration Statement not false or misleading; or omit to state any material fact necessary to correct any statement in any earlier communication with respect to the solicitation of proxies for the Public Company Meeting that has become false or misleading.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:33pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.32</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Representations and Warranties</span>.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</span>The Company&#8217;s representations and warranties set forth in the Merger Agreement in Section&#160;4.2 (Capital Stock), Section&#160;4.6 (Financial Statements), Section&#160;4.9 (Litigation), Section&#160;4.10 (Compliance with Laws), Section&#160;4.11 (Health Care Regulatory Matters), Section&#160;4.13 (Labor and Employment Matters), Section&#160;4.14 (Environmental Matters), Section&#160;4.16 Contracts), Section&#160;4.19 (Intellectual Property) and 4.22 (Related Party Transactions) are hereby incorporated by reference and made by the Company, as qualified by the disclosures in the Company Disclosure Schedule (as defined in the Merger Agreement).</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</span>As of the date hereof and as of the Closing Date, the representations and warranties of the Company contained in Section&#160;4 of the Merger Agreement and in any certificate or other writing delivered by the Company pursuant thereto are true and correct as though given in accordance with Section&#160;8.3(a)&#160;of the Merger Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</span>As of the date hereof and as of the Closing Date, to the knowledge of the Company, the representations and warranties of Parent contained in Section&#160;5 of the Merger Agreement and in any certificate or other writing delivered by Parent pursuant thereto are true and correct as though given in accordance with Section&#160;8.2(a)&#160;of the Merger Agreement.</div><div style="margin-top:12pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">4.</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties of Each Investor</span>. Each Investor, severally for itself and not jointly with any other Investor, represents and warrants to the Company and the Placement Agents that the statements contained in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4</span> are true and correct as of the date hereof and the Closing Date (except for the representations and warranties that speak as of a specific date, which shall be made as of such date):</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.35pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Organization</span>. Such Investor is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization and has the requisite power and authority to own, lease and operate its properties and to carry on its business as now conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.35pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authorization</span>. Such Investor has all requisite corporate or similar power and authority to enter into this Agreement and the other Transaction Agreements to which it will be a party and to carry out and perform its obligations hereunder and thereunder. All corporate, member or partnership action on the part of such Investor or its stockholders, members or partners necessary for the authorization, execution, delivery and performance of this Agreement and the other Transaction Agreements to which it will be a party and the consummation of the other transactions contemplated herein has been taken. The signature of the Investor on this Agreement is genuine and the signatory to this Agreement, if the Investor is an individual, has the legal competence and capacity to execute the same or, if the Investor is not an individual, the signatory has been duly authorized to execute the same on behalf of the Investor. Assuming this Agreement constitutes the legal and binding agreement of the Company, this Agreement constitutes a legal, valid and binding obligation of such Investor, enforceable against such Investor in accordance with its respective terms, except as such enforceability may be limited or otherwise affected by bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and/or similar laws relating to or affecting the rights of creditors generally or by general equity principles (regardless of whether such enforceability is considered in a proceeding in equity or at law).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.35pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Conflicts</span>. The execution, delivery and performance of the applicable Transaction Agreements by such Investor, the purchase of the Securities in accordance with their terms and the consummation by such Investor of the other transactions contemplated hereby will not conflict with or result in any violation of, breach or default by such Investor (with or without notice or lapse of time, or both) under, conflict with, or give rise to a right of termination, cancellation or acceleration of any obligation, a change of control right or to a loss of a material benefit under (i)&#160;any provision of the organizational documents of such Investor, including, without limitation, its incorporation or formation papers, bylaws, indenture of trust or partnership or operating agreement, as may be applicable or (ii)&#160;any agreement or instrument, undertaking, credit facility, franchise, license, judgment, order, ruling, statute, law, ordinance, rule&#160;or regulations, applicable to such Investor or its respective properties or assets, except, in the case of clause (ii), as would not, individually or in the aggregate, be reasonably expected to materially delay or materially hinder the ability of such Investor to perform its obligations under the Transaction Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.35pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Residency</span>. Such Investor&#8217;s residence (if an individual) or offices in which its investment decision with respect to the Securities was made (if an entity) are located at the address immediately below such Investor&#8217;s name on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</span>, except as otherwise communicated by such Investor to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.4pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Brokers and Finders</span>. Such Investor has not retained, utilized or been represented by any broker or finder in connection with the transactions contemplated by this Agreement whose fees the Company would be required to pay.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.35pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Investment Representations and Warranties</span>. Each Investor hereby represents and warrants that, it (i)&#160;as of the date hereof is, if an entity, a &#8220;qualified institutional buyer&#8221; (as defined in Rule&#160;144A under the Securities Act) or an &#8220;accredited investor&#8221; as that term is defined in Rule&#160;501(a)&#160;under Regulation D promulgated pursuant to the Securities Act; or (ii)&#160;if an individual, is an &#8220;accredited investor&#8221; as that term is defined in Rule&#160;501(a)&#160;of Regulation D of the Securities Act and has such knowledge and experience in financial and business matters as to be able to protect its own interests in connection with an investment in the Securities. Each Investor further represents and warrants that (x)&#160;it is capable of evaluating the merits and risk of such investment, and (y)&#160;that it has not been organized for the purpose of acquiring the Securities and is an &#8220;institutional account&#8221; as defined by FINRA Rule&#160;4512(c). Such Investor understands and agrees that the offering and sale of the Securities has not been registered under the Securities Act or any applicable state securities laws and is being made in reliance upon federal and state exemptions for transactions not involving a public offering which depend upon, among other things, the bona fide nature of the investment intent and the accuracy of such Investor&#8217;s representations as expressed herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.35pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intent</span>. Each Investor is purchasing the Securities solely for investment purposes, for such Investor&#8217;s own account and not for the account of others, and not with a view to the resale or distribution of any part thereof in violation of the Securities Act, and the Investor has no present intention of selling, granting any participation in, or otherwise distributing the same in violation of </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">the Securities Act without prejudice, however, to the Investor&#8217;s right at all times to sell or otherwise dispose of all or any part of such Securities in compliance with applicable federal and state securities laws. Notwithstanding the foregoing, if such Investor is purchasing the Securities as a fiduciary or agent for one or more investor accounts, such Investor has full investment discretion with respect to each such account, and the full power and authority to make the acknowledgements, representations and agreements herein on behalf of each owner of each such account. Each Investor has no present arrangement to sell the Securities to or through any person or entity. Each Investor understands that the Securities must be held indefinitely unless such Securities are resold pursuant to a registration statement under the Securities Act or an exemption from registration is available. Nothing contained herein shall be deemed a representation or warranty by such Investor to hold the Securities for any period of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.35pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Investment Experience</span>; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ability to Protect Its Own Interests and Bear Economic Risks</span>. Each Investor acknowledges that it can bear the economic risk and complete loss of its investment in the Securities and has knowledge and experience in finance, securities, taxation, investments and other business matters as to be capable of evaluating the merits and risks of investments of the kind described in this Agreement and contemplated hereby, and the Investor has had an opportunity to seek, and has sought, such accounting, legal, business and tax advice as such Investor has considered necessary to make an informed investment decision. Each Investor acknowledges that such Investor (i)&#160;is a sophisticated investor, experienced in investing in private placements of equity securities and capable of evaluating investment risks independently, both in general and with regard to all transactions and investment strategies involving a security or securities and (ii)&#160;has exercised independent judgment in evaluating its participation in the purchase of the Securities. Each Investor acknowledges that such Investor is aware that there are substantial risks incident to the purchase and ownership of the Securities, including those set forth in the Company&#8217;s filings with the SEC. Alone, or together with any professional advisor(s), such Investor has adequately analyzed and fully considered the risks of an investment in the Securities and determined that the Securities are a suitable investment for the Investor. Each Investor is, at this time and in the foreseeable future, able to afford the loss of such Investor&#8217;s entire investment in the Securities and such Investor acknowledges specifically that a possibility of total loss exists.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.35pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.9</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Independent Investment Decision</span>. Such Investor understands that nothing in the Transaction Agreements or any other materials presented by or on behalf of the Company to such Investor in connection with the purchase of the Securities constitutes legal, tax or investment advice. Such Investor has consulted such legal, tax and investment advisors as it, in their sole discretion, has deemed necessary or appropriate in connection with its purchase of the Securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.95pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.10</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Securities Not Registered</span>; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Legends</span>. Such Investor acknowledges and agrees that the Securities are being offered in a transaction not involving any public offering within the meaning of the Securities Act, and such Investor understands that the Securities have not been registered under the Securities Act, by reason of their issuance by the Company in a transaction exempt from the registration requirements of the Securities Act, and that the Securities must continue to be held and may not be offered, resold, transferred, pledged or otherwise disposed of by such Investor unless a subsequent disposition thereof is registered under the Securities Act or is exempt from such registration and in each case in accordance with any applicable securities laws of any state of the United States. Such Investor understands that the exemptions from registration afforded by Rule&#160;144 (the provisions of which are known to it) promulgated under the Securities Act depend on the satisfaction of various conditions including, but not limited to, the time and manner of sale, the holding period and on requirements relating to the Company which are outside of such Investor&#8217;s control and which the Company may not be able to satisfy, and that, if applicable, Rule&#160;144 may afford the basis for sales only in limited amounts. Such Investor acknowledges and agrees that it has been advised to consult legal counsel prior to making any offer, resale, transfer, pledge or disposition of any of the Securities. Such Investor acknowledges that no federal or state agency has passed upon or endorsed the merits of the offering of the Securities or made any findings or determination as to the fairness of this investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each Investor understands that any certificates or book entry notations evidencing the Securities may bear one or more legends in substantially the following form and substance:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">&#8220;THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY&#160;NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I)&#160;SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II)&#160;SUCH SECURITIES MAY&#160;BE SOLD PURSUANT TO RULE&#160;144, (III)&#160;THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSFER MAY&#160;LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES ACT, OR (IV)&#160;THE SECURITIES ARE TRANSFERRED WITHOUT CONSIDERATION TO AN AFFILIATE OF SUCH HOLDER OR A CUSTODIAL NOMINEE (WHICH FOR THE AVOIDANCE OF DOUBT SHALL REQUIRE NEITHER CONSENT NOR THE DELIVERY OF AN OPINION). NOTWITHSTANDING THE </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">FOREGOING, THE SECURITIES MAY&#160;BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the Securities may contain a legend regarding affiliate status of the Investor, if applicable, provided that the Company will notify the Investor in advance of Closing if such legend is to be placed on its Securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.7pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.11</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Placement Agents</span>. Each Investor hereby acknowledges and agrees that (a)&#160;each Placement Agent is acting solely as placement agent in connection with the execution, delivery and performance of the Transaction Agreements and the issuance of the Securities to the Investor and neither any Placement Agent nor any of its affiliates have acted as an underwriter or in any other capacity and is not and shall not be construed as a fiduciary or financial advisor for such Investor, the Company or any other person or entity in connection with the execution, delivery and performance of the Transaction Agreements and the issuance and purchase of the Securities, (b)&#160;no Placement Agent has made and does not make any representation or warranty, whether express or implied, of any kind or character, or has not provided any advice or recommendation in connection with the execution, delivery and performance of the Transaction Agreements or with respect to the Securities, nor is such information or advice necessary or desired, (c)&#160;no Placement Agent will have any responsibility with respect to (i)&#160;any representations, warranties or agreements made by any person or entity under or in connection with the execution, delivery and performance of the Transaction Agreements, or the execution, legality, validity or enforceability (with respect to any person) thereof, or (ii)&#160;the business, affairs, financial condition, operations, properties or prospects of, or any other matter concerning the Company, and (d)&#160;no Placement Agent will have any liability or obligation (including without limitation, for or with respect to any losses, claims, damages, obligations, penalties, judgments, awards, liabilities, costs, expenses or disbursements incurred by such Investor, the Company or any other person or entity), whether in contract, tort or otherwise, to such Investor, or to any person claiming through it, in respect of the execution, delivery and performance of the Transaction Agreements, except in each case for such party&#8217;s own gross negligence, willful misconduct or bad faith. No disclosure or offering document has been prepared by any Placement Agent or any of its affiliates in connection with the offer and sale of the Securities. Neither the Placement Agents nor any of their respective affiliates have made or make any representation as to the quality or value of the Securities and the Placement Agents and any their respective affiliates may have acquired non-public information with respect to the Company which the Investor agrees need not be provided to it.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.95pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.12</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No General Solicitation</span>. Each Investor acknowledges and agrees that the Investor is purchasing the Securities directly from the Company. Such Investor became aware of this offering of the Securities solely by means of direct contact from the Placement Agents or directly from the Company as a result of a pre-existing, substantive relationship with the Company or the Placement Agents, and/or their respective advisors (including, without limitation, attorneys, accountants, bankers, consultants and financial advisors), agents, control persons, representatives, affiliates, directors, officers, managers, members, and/or employees, and/or the representatives of such persons. The Securities were offered to such Investor solely by direct contact between such Investor and the Company, the Placement Agents and/or their respective representatives. Such Investor did not become aware of this offering of the Securities, nor were the Securities offered to such Investor, by any other means, and none of the Company, the Placement Agents and/or their respective representatives acted as investment advisor, broker or dealer to such Investor. Such Investor is not purchasing the Securities as a result of any general or public solicitation or general advertising, or publicly disseminated advertisement, article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television, radio or the internet or presented at any seminar or any other general solicitation or general advertisement, including any of the methods described in Section&#160;502(c)&#160;of Regulation D under the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.95pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.13</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Access to Information</span>. In making its decision to purchase the Securities, each Investor has relied solely upon independent investigation made by such Investor and upon the representations, warranties and covenants set forth herein. Such Investor acknowledges and agrees that such Investor has received such information as such Investor deems necessary in order to make an investment decision with respect to the Securities, including, with respect to the Company. Each Investor acknowledges and agrees that such Investor and such Investor&#8217;s professional advisor(s), if any, have had the opportunity to ask such questions, receive such answers and obtain such information from the Company regarding the Company, its business and the terms and conditions of the offering of the Securities as such Investor and such Investor&#8217;s professional advisor(s), if any, have deemed necessary to make an investment decision with respect to the Securities and that such Investor has independently made its own analysis and decision to invest in the Company. Neither such inquiries nor any other due diligence investigation conducted by such Investor shall modify, limit or otherwise affect such Investor&#8217;s right to rely on the Company&#8217;s representations and warranties contained in this Agreement.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.95pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.14</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">Certain Trading  Activities</span>. Other than consummating the transaction contemplated hereby, the Investor has not, nor has any Person acting on behalf of or pursuant to any understanding with such Investor, directly or indirectly executed any purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Investor was first contacted by the Company or any other Person regarding the transaction contemplated hereby and ending immediately prior to the date hereof. Notwithstanding the foregoing, (i)&#160;in the case of an Investor that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Investor&#8217;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Investor&#8217;s assets, the representation set forth above shall only apply with respect to the portion of the assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement and (ii)&#160;in the case of an Investor whose investment adviser utilized an information barrier with respect to the information regarding the transactions contemplated hereunder after first being contacted by the Company or such other Person representing the Company, the representation set forth above shall only apply after the point in time when the portfolio manager who manages such Investor&#8217;s assets was informed of the information regarding the transactions contemplated hereunder and, with respect to the Investor&#8217;s investment adviser, the representation set forth above shall only apply with respect to any purchases or sales, including Short Sales, of the securities of the Company on behalf of other funds or investment vehicles for which the Investor&#8217;s investment adviser is also an investment adviser or subadviser after the point in time when the portfolio manager who manages the assets of such other funds or investment vehicles for which the Investor&#8217;s investment adviser is also an investment adviser or sub-adviser was informed of the information regarding the transactions contemplated hereunder. Other than to other Persons party to this Agreement and to its advisors and agents who had a need to know such information, such Investor has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to the identification of the availability of, or securing of, available shares to borrow in order to effect Short Sales or similar transactions in the future.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">5.</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Covenants</span>.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.35pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.1</span></span>Further Assurances. Prior to the Closing, each party agrees to cooperate with each other and their respective officers, employees, attorneys, accountants and other agents, and, generally, do such other reasonable acts and things in good faith as may be necessary to effectuate the intents and purposes of this Agreement, subject to the terms and conditions hereof and compliance with applicable law, including taking reasonable action to facilitate the filing of any document or the taking of reasonable action to assist the other parties hereto in complying with the terms hereof. Each Investor acknowledges that the Company and the Placement Agents will rely on the acknowledgments, understandings, agreements, representations and warranties contained in this Agreement. Prior to the Closing, the Investor agrees to promptly notify the Company if any of the acknowledgments, understandings, agreements, representations and warranties set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4</span> are no longer accurate and the Company agrees to promptly notify each Investor if any of the acknowledgments, understandings, agreements, representations and warranties set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3</span> are no longer accurate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.35pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Listing</span>. The Company shall use commercially reasonable efforts (a)&#160;to cause Parent to maintain the listing and trading of Parent&#8217;s common stock on the Nasdaq Global Market and, in accordance therewith, will use reasonable best efforts to cause Parent to comply in all material respects with the Parent&#8217;s reporting, filing and other obligations under the rules&#160;and regulations of Nasdaq and (b)&#160;to obtain approval of the listing of the Shares on Nasdaq following the closing of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.35pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosure of Transactions</span>. The Company shall, by 9:00&#160;a.m., New York City time, on the first (1st) Business Day immediately following the date hereof (p<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">rovided</span> that, if this Agreement is executed between midnight and 9:00&#160;a.m., New York City time on any Business Day, no later than 9:01&#160;a.m. on the date hereof), issue a press release and ensure that Parent shall substantially contemporaneously file with the SEC a Current Report on Form&#160;8-K (including all exhibits thereto, the &#8220;<b style="font-weight:bold;">Disclosure Document</b>&#8221; and the actual filing of such press release and/or Current Report on Form&#160;8-K, the &#8220;<b style="font-weight:bold;">Disclosure Time</b>&#8221;) disclosing (i)&#160;all material terms of the transactions contemplated hereby and by the other Transaction Agreements and attaching this Agreement and the other Transaction Agreements as exhibits to such Disclosure Document, and (ii)&#160;all material non-public information concerning the Company, the transactions contemplated hereby or the transactions contemplated by the Merger Agreement disclosed to the Investors prior to the Disclosure Time. Following the Disclosure Time, no Investor shall be in possession of any material non-public information received from the Company, its subsidiaries or any of their respective officers, directors, employees or agents (including the Placement Agents). Notwithstanding anything in this Agreement, the Company shall not provide any of the Investors or their respective affiliates, attorneys, agents or representatives with any material non-public information regarding the Company or Parent or their respective securities from and after the Disclosure Time except as otherwise agreed by such Investor. The Company understands and confirms that the Investors will rely on the foregoing </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">representations, covenants and agreements in effecting securities transactions. Notwithstanding anything in this Agreement to the contrary, the Company shall not disclose the name of any Investor or any of its affiliates or advisers, or include the name of any Investor or any of its affiliates or advisers in any marketing materials (whether or not made publicly available), press release, public announcement or filing with the SEC (other than any registration statement contemplated by the Registration Rights Agreement, which shall be subject to review of the Investors in accordance with the terms of the Registration Rights Agreement) or any regulatory agency, without the prior written consent of such Investor, except (i)&#160;as required by the federal securities law in connection with (A)&#160;any registration statement contemplated by the Registration Rights Agreement and (B)&#160;the filing of final Transaction Agreements with the SEC or pursuant to other routine proceedings of regulatory authorities, or (ii)&#160;to the extent such disclosure is required by law, at the request of the staff of the SEC or regulatory agency or under the regulations of the Nasdaq Global Market, provided that the Company shall use commercially reasonable efforts to provide the Investors with prior written notice of and a reasonable opportunity to review such disclosure permitted under foregoing clauses (i)&#160;and (ii).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:32.35pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Integration</span>. The Company shall not, and shall use its commercially reasonable efforts to ensure that no Affiliate of the Company shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section&#160;2 of the Securities Act) that will be integrated with the offer or sale of the Securities in a manner that would require the registration under the Securities Act of the sale of the Securities to the Investors, or that will be integrated with the offer or sale of the Securities for purposes of the rules&#160;and regulations of any National Exchange such that it would require stockholder approval prior to the closing of such other transaction unless stockholder approval is obtained before the closing of such subsequent transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.4pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Removal of Legends</span>.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</span>In connection with any sale, assignment, transfer or other disposition of the Shares by an Investor pursuant to Rule&#160;144 or pursuant to any other exemption under the Securities Act such that the purchaser acquires freely tradable shares and upon compliance by the Investor with the requirements of this Agreement, if requested by the Investor by notice to the Company, the Company shall instruct the Transfer Agent to remove any restrictive legends related to the book entry account holding such Shares and make a new, unlegended entry for such book entry Shares sold or disposed of without restrictive legends as soon as reasonably practicable (expected to be three (3)&#160;Business Days) following any such request therefor from such Investor, provided that the Company has timely received from the Investor a completed Investor representation letter in substantially the form attached hereto as Exhibit&#160;D and such other customary representations as may be reasonably required, in accordance with applicable law in connection therewith. Any shares subject to legend removal under this Section&#160;5.5 may be transmitted by the Transfer Agent to the Investor by crediting the account of the Investor&#8217;s prime broker with the DTC System as directed by such Investor. The Company shall be responsible for the fees of its Transfer Agent, DTC and its legal counsel associated with such legend removal.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</span>In addition, without limiting Section&#160;5.5(a), and subject to receipt from the Investor by the Company and the Transfer Agent of customary representations and other documentation reasonably acceptable to the Company and the Transfer Agent in connection therewith, upon the earliest of such time as the Initial Shares or any other Shares (i)&#160;have been registered under the Securities Act pursuant to an effective registration statement, (ii) have been sold pursuant to Rule&#160;144 (in which case the provisions of Section&#160;5.5(a)&#160;shall apply), or (iii)&#160;are eligible for resale under Rule&#160;144(b)(1)&#160;without the requirement for the Company to be in compliance with the current public information requirements under Rule&#160;144(c)(1)&#160;(or any successor provision), the Company shall, in accordance with the provisions of this Section&#160;5.5(b)&#160;(A)&#160;upon effectiveness of the registration statement registering the resale of such Initial Shares or Other Shares as set forth in clause (i), provide a &#8220;blanket&#8221; opinion to the Transfer Agent for the removal of legends in connection with any sale pursuant to the effective registration statement, and (B)&#160;with respect to clauses (i), (ii)&#160;and (iii), as soon as reasonably practicable and no later than three (3)&#160;Business Days following any request therefor from an Investor accompanied by a completed Investor representation letter in substantially the form attached hereto as Exhibit&#160;E, deliver to the Transfer Agent irrevocable instructions that the Transfer Agent shall make a new, unlegended entry for such book entry shares. If, as a condition to the removal of any legends of any of the Securities, the Transfer Agent requires that the request for removal be accompanied by a certificate and/or an opinion of counsel reasonably satisfactory to the Transfer Agent, to the effect that the proposed transfer does not result in a violation of the Securities Act, the Company and/or its legal counsel shall provide such certificate or opinion with respect to any such transfer. The Company shall be responsible for the fees of its Transfer Agent, DTC and its legal counsel associated with such legend removal.</div><div style="margin-top:12pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:32.4pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Withholding &#160;Taxes</span>. Each Investor agrees to furnish the Company with any information, representations and forms as shall reasonably be requested by the Company from time to time to assist the Company in complying with any applicable tax law (including any withholding obligations).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:32.4pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fees and Taxes</span>. The Company shall be solely responsible for the payment of any placement agent&#8217;s fees, financial advisory fees, or broker&#8217;s commissions (other than for Persons engaged by an Investor) relating to or arising out of the transactions contemplated hereby, including, without limitation, any fees or commissions payable to the Placement Agents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:32.4pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Conflicting &#160;Agreements</span>. The Company will not take any action, enter into any agreement or make any commitment that would conflict or interfere in any material respect with the Company&#8217;s obligations to the Investors under the Transaction Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:32.4pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.9</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reporting &#160;Status</span>. The Company shall timely file all reports required to be filed with the SEC pursuant to the Exchange Act, and the Company shall not terminate its status as an issuer required to file reports under the Exchange Act even if the Exchange Act or the rules&#160;and regulations thereunder would otherwise permit such termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:33pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.10</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification.</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</span>The Company agrees to indemnify and hold harmless each Investor and its Affiliates, and their respective directors, officers, trustees, members, managers, employees, investment advisers and agents (collectively, the &#8220;<b style="font-weight:bold;">Indemnified Persons</b>&#8221;), from and against any and all losses, claims, damages, liabilities and expenses (including without limitation reasonable and documented attorney fees and disbursements and other documented out-of-pocket expenses reasonably incurred in connection with investigating, preparing or defending any action, claim or proceeding, pending or threatened and the costs of enforcement thereof) to which such Indemnified Person may become subject (i)&#160;as a result of any breach of representation, warranty, covenant or agreement made by or to be performed on the part of the Company under the Transaction Agreements or (ii)&#160;as a result of or arising out of any action, claim or proceeding, pending or threatened, against an Indemnified Person in any capacity by any stockholder of the Company (whether directly or in a derivative capacity) who is not an Affiliate of the Indemnified Person with respect to the transactions contemplated by the Transaction Agreements, and in each case will reimburse any such Indemnified Person for all such amounts as they are incurred by such Indemnified Person.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</span>Any person entitled to indemnification hereunder shall (i)&#160;give prompt written notice to the indemnifying party of any claim with respect to which it seeks indemnification and (ii)&#160;permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party; provided that any person entitled to indemnification hereunder shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such person unless (a)&#160;the indemnifying party has agreed in writing to pay such fees or expenses, (b)&#160;the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such person or (c)&#160;in the reasonable judgment of any such person, based upon written advice of its counsel, a conflict of interest exists between such person and the indemnifying party with respect to such claims (in which case, if the person notifies the indemnifying party in writing that such person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf of such person); and provided, further, that the failure of any indemnified party to give written notice as provided herein shall not relieve the indemnifying party of its obligations hereunder, except to the extent that such failure to give notice shall materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys at any time for all such indemnified parties. No indemnifying party will, except with the consent of the indemnified party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement unless such judgment or settlement (i)&#160;imposes no liability or obligation on, (ii)&#160;includes as an unconditional term thereof the giving of a complete, explicit and unconditional release from the party bringing such indemnified claims of all liability of the indemnified party in respect of such claim or litigation in favor of, and (iii)&#160;does not include any admission of fault, culpability, wrongdoing, or wrongdoing or malfeasance by or on behalf of, the indemnified party. No indemnified party will, except with the consent of the indemnifying party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement.</div><div style="margin-top:12pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:32.7pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.11</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pre-Closing &#160;Financing &#160;Restructuring</span>. In the event the structure of the Company Pre-Closing Financing (as defined in the Merger Agreement) either violates applicable Law (as defined in the Merger Agreement) or materially and adversely effects Parent&#8217;s ability to cause the Registration Statement (as defined in the Merger Agreement) to become effective in a timely manner, and in any event 60&#160;days prior to the End Date (as defined in, and as may be extended in accordance with, the Merger Agreement), then the Company and the Investors shall cooperate and use commercially reasonable efforts to cause the Company Pre-Closing Financing to be amended, modified and/or restructured such that such investment occurs as a direct acquisition of shares of Parent Common Stock (as defined in the Merger Agreement) substantially contemporaneously with the Closing in a manner which preserves to the extent possible, the amount of funds ultimately received by Parent and its subsidiaries, and preserves the number of Parent shares ultimately held by each Investor in respect of such amounts as though the Company Pre-Closing Financing has been consummated by its terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:32.95pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.12</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reservation of Common Stock</span>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue the Pre-Funded Warrant Shares that are issuable upon the exercise of the Pre-Funded Warrants, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:32.95pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.13</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Form&#160;S-4</span>. From the date hereof until the Closing Date, the Company shall use commercially reasonable efforts to ensure the Registration Statement will register the issuance of the shares of Parent Common Stock to be issued, subject to and in accordance with the terms of the Merger Agreement, by virtue of the Contemplated Transactions (as defined in the Merger Agreement), including shares of Parent Common Stock issued in exchange for the Initial Shares and Pre-Funded Warrant Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:32.5pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.14</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Amendment or Waiver of Merger Agreement Terms</span>. The Company shall not amend or modify any provision of the Merger Agreement in a manner that would reasonably be expected to materially and adversely affect the benefits that the Investors would reasonably expect to receive pursuant to this Agreement without the consent of the Investor Majority, it being agreed that any amendment or modification to the definitions of &#8220;Company Equity Value&#8221; and &#8220;Company Outstanding Shares&#8221; shall be deemed materially adverse to the Investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:32.95pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.15</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Legend Removal</span>. The Company shall use commercially reasonable efforts to ensure the restrictive legends described in Section&#160;4.10 shall promptly be removed in accordance with applicable securities laws following the closing of the Merger. The Company shall use commercially reasonable efforts to ensure the shares of Parent Common Stock to be received in the Merger in exchange for the Initial Shares or Pre-Funded Warrant Shares will be issued in book-entry form, free and clear of any liens or other restrictions whatsoever and without restrictive legends in accordance with applicable securities laws.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">6.</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conditions of Closing</span>.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:32.35pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conditions to the Obligation of the Investors</span>. The several obligations of each Investor to consummate the transactions to be consummated at the Closing, and to purchase and pay for the Securities being purchased by it at the Closing pursuant to this Agreement, are subject to the satisfaction or waiver in writing of the following conditions precedent:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties</span>. The representations and warranties of the Company contained herein shall be true and correct in all respects as of the date hereof except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct in all respects as of such earlier date, and the representations and warranties of the Company contained herein shall be true and correct in all material respects as of the Closing Date, as though made on and as of such date, except for those representations and warranties qualified by materiality or Material Adverse Effect, which shall be true and correct in all respects and except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct in all material respects as of such earlier date.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Performance</span>. The Company shall have performed in all material respects the obligations and conditions herein required to be performed or observed by the Company on or prior to the Closing Date.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No In</span>j<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">unction</span>. The purchase of and payment for the Securities by each Investor shall not be prohibited or enjoined by any law or governmental or court order or regulation and no such prohibition shall have been threatened in writing.</div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consents</span>. The Company shall have obtained any and all consents, permits, approvals, registrations and waivers necessary for the consummation of the purchase and sale of the Securities, all of which shall be in full force and effect.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer Agent</span>. The Company shall have furnished all required materials to the Transfer Agent to reflect the issuance of the Initial Shares at the Closing.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adverse Changes</span>. Since the date hereof, no event or series of events shall have occurred that has had or would reasonably be expected to have a Material Adverse Effect or a Parent Material Adverse Effect (as defined in the Merger Agreement).</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Opinion of Company Counsel</span>. The Company shall have delivered to the Investors and the Placement Agents the opinion of Gibson, Dunn&#160;&amp; Crutcher LLP, dated as of the Closing Date, in customary form and substance to be reasonably agreed upon with the Placement Agents and addressing such legal matters as the Placement Agents and the Company reasonably agree.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance Certificate</span>. An authorized officer of the Company shall have delivered to the Investors at the Closing Date a certificate in form and substance reasonably acceptable to the Investor Majority certifying that the conditions specified in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 6.1</span>(a)&#160;(Representations and Warranties), <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.1</span>(b)&#160;(Performance), <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.1</span>(c)&#160;(No Injunction), <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.1</span>(d)&#160;(Consents), <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.1</span>(f) (Adverse Changes), <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.1</span>(k)&#160;(Registration Statement), <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.1</span>(l) (Nasdaq), <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.1</span>(m)&#160;(Minimum Financing Amount), and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.1</span>(n)&#160;(Merger) of this Agreement have been fulfilled.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Secretary &#8216;s Certificate</span>. The Secretary of the Company shall have delivered to the Investors at the Closing Date a certificate certifying (i)&#160;the Amended and Restated Certificate of Incorporation, (ii)&#160;the Amended and Restated Bylaws, and (iii)&#160;resolutions of the Company&#8217;s Board of Directors (or an authorized committee thereof) approving this Agreement, the other Transaction Agreements, the transactions contemplated by this Agreement and the issuance of the Securities and the Pre-Funded Warrant Shares.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(j)</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Registration Rights Agreement</span>. The Company shall have executed and delivered the Registration Rights Agreement in the form attached hereto as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;C</span> (the &#8220;<b style="font-weight:bold;">Registration Rights Agreement</b>&#8221;) to the Investors.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(k)</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Registration Statement</span>. The Registration Statement shall have become effective under the 1933 Act and no stop order suspending the effectiveness of the Registration Statement shall have been issued and no proceeding for that purpose, and no similar proceeding with respect to the Registration Statement shall have been initiated or threatened in writing by the Commission or its staff.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(l)</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nasdaq</span>. Parent shall have submitted with Nasdaq an Initial Listing Application in respect of the Parent Common Stock to be issued in the Contemplated Transactions, which shall have been approved by Nasdaq.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(m)</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">Minimum Financing  Amount</span>. The Company shall receive at Closing aggregate proceeds from the purchase of Securities pursuant to this Agreement of not less than $175,000,000 (including in such proceeds any Convertible Securities Contributed as consideration in accordance with this Agreement).</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(n)</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger</span>. All conditions to the closing of the Merger shall have been satisfied or waived (other than the Closing hereunder and other than those conditions which, by their nature, are to be satisfied at the closing of the transactions contemplated by the Merger Agreement), and the closing of the Merger shall be set to occur substantially concurrently with the Closing hereunder. The Company shall not have amended, modified, or waived any provision under the Merger Agreement in a manner that would reasonably be expected to materially and adversely affect the benefits that the Investors would reasonably expect to receive under this Agreement without having received the Investor Majority&#8217;s prior written consent, it being agreed that any amendment or modification to the definitions of &#8220;Company Equity Value&#8221; and &#8220;Company Outstanding Shares&#8221; shall be deemed materially adverse to the Investors.</div><div style="margin-top:12pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:32.4pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conditions to the Obligation of the Company</span>. The obligation of the Company to consummate the transactions to be consummated at the Closing, and to issue and sell to each Investor the Securities to be purchased by it at the Closing pursuant to this Agreement, is subject to the satisfaction or waiver in writing of the following conditions precedent:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties</span>. The representations and warranties of each Investor in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4</span> hereto shall be true and correct on and as of the Closing Date, with the same force and effect as though made on and as of the Closing Date, except to the extent that any such representation or warranty expressly speaks as of an earlier date, in which case such representation and warranty shall be true and correct in all respects as of such earlier date, and consummation of the Closing shall constitute a reaffirmation by the Investor of each of the representations, warranties, covenants and agreements of the Investor contained in this Agreement as of the Closing Date.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Performance</span>. Each Investor shall have performed or complied with in all material respects all obligations and conditions herein required to be performed or observed by such Investor on or prior to the Closing Date.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">In</span>j<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">unction</span>. The purchase of and payment for the Securities by each Investor shall not be prohibited or enjoined by any law or governmental or court order or regulation.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Registration Rights Agreement</span>. Each Investor shall have executed and delivered the Registration Rights Agreement to the Company in the form attached as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;C</span>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment</span>. Except as may be agreed to among the Company and one or more Investors in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.2</span>, the Company shall have received payment, by wire transfer of immediately available funds, in the full amount of the purchase price for the number of Securities being purchased by each Investor at the Closing as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</span>.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:32.4pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</span>. The obligations of the Company, on the one hand, and each Investor, on the other hand, to effect the Closing shall terminate as follows:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</span>Upon the mutual written consent of the Company and the Investor Majority prior to the Closing;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</span>By the Company, if any of the conditions set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.2</span> shall have become incapable of fulfillment and shall not have been waived by the Company;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</span>By an Investor, solely as to itself, if any of the conditions set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.1</span> shall have become incapable of fulfillment and shall not have been waived by such Investor; or</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</span>By either the Company or an Investor, solely as to itself, if the Closing has not occurred on or before April&#160;30, 2025;</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that, except in the case of clauses (ii)&#160;through (iv)&#160;above, the party seeking to terminate its obligation to effect the Closing shall not then be in breach of any of its representations, warranties, covenants or agreements contained in the Transaction Agreements if such breach has resulted in the circumstances giving rise to such party&#8217;s seeking to terminate its obligation to effect the Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.35pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice</span>. In the event of termination pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.1</span>, written notice thereof shall be given to each other Investor. Nothing in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7</span> shall be deemed to release any party from any liability for any breach by such party of the other terms and provisions of the Transaction Agreements or to impair the right of any party to compel specific performance by any other party of its other obligations under the Transaction Agreements.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">8.</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous Provisions</span>.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.35pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Public Statements or Releases</span>. Except as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.3</span>, neither the Company nor any Investor shall make any public announcement with respect to the existence or terms of this Agreement or the transactions provided for herein without </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">the prior consent of the other party (which consent shall not be unreasonably withheld) other than filings pursuant to Section&#160;13 and/or Section&#160;16 of the Exchange Act, which, for avoidance of doubt, shall not require the Company&#8217;s consent; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that, the Company shall not publicly disclose the name of any Investor or any affiliate or investment adviser of any Investor without such Investor&#8217;s prior written consent (email being sufficient).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.35pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interpretation</span>. The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of similar import when used in this Agreement will refer to this Agreement as a whole and not to any particular provision of this Agreement, and section and subsection references are to this Agreement unless otherwise specified. The headings in this Agreement are included for convenience of reference only and will not limit or otherwise affect the meaning or interpretation of this Agreement. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they will be deemed to be followed by the words &#8220;without limitation.&#8221; The phrases &#8220;the date of this Agreement,&#8221; &#8220;the date hereof&#8221; and terms of similar import, unless the context otherwise requires, will be deemed to refer to the date set forth in the first paragraph of this Agreement. The meanings given to terms defined herein will be equally applicable to both the singular and plural forms of such terms. All matters to be agreed to by any party hereto must be agreed to in writing by such party unless otherwise indicated herein. References to agreements, policies, standards, guidelines or instruments, or to statutes or regulations, are to such agreements, policies, standards, guidelines or instruments, or statutes or regulations, as amended or supplemented from time to time (or to successors thereto).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.35pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</span>. Any notices or other communications required or permitted to be given hereunder shall be in writing and shall be deemed to be given (a)&#160;when delivered if personally delivered to the party for whom it is intended, (b)&#160;when delivered, if sent by electronic mail during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient&#8217;s next Business Day, provided no rejection or undeliverable notice is received, (c)&#160;three (3)&#160;days after having been sent by certified or registered mail, return-receipt requested and postage prepaid, or (d)&#160;one (1)&#160;Business Day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:68.1pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If to the Company, addressed as follows:</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:90pt;margin:0pt;">Jade Biosciences,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:90pt;margin:0pt;">221 Crescent Street, Building 23, Suite&#160;105</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:90pt;margin:0pt;">Waltham, MA 02453</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:90pt;margin:0pt;">Attention: Tom Frohlich</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:90pt;margin:0pt;">Email: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:20.15pt;text-indent:-20.15pt;margin:0pt 0pt 12pt 68.4pt;">with a copy to (which shall not constitute notice):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:90pt;margin:0pt;">Gibson, Dunn&#160;&amp; Crutcher LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:90pt;margin:0pt;">One Embarcadero Center, Suite&#160;2600</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:90pt;margin:0pt;">San Francisco, CA 94111</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:90pt;margin:0pt;">Attention: Ryan Murr, Branden Berns, Chris Trester</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:90pt;margin:0pt 0pt 12pt 0pt;">Email: [***]; [***]; [***]</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:68.1pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">(b)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If to any Investor, at its address set forth on </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> or to such e-mail address or address as subsequently modified by written notice given in accordance with this </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.3</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any Person may change the address to which notices and communications to it are to be addressed by notification as provided for herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.35pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</span>. If any part or provision of this Agreement is held unenforceable or in conflict with the applicable laws or regulations of any jurisdiction, the invalid or unenforceable part or provisions shall be replaced with a provision which accomplishes, to the extent possible, the original business purpose of such part or provision in a valid and enforceable manner, and the remainder of this Agreement shall remain binding upon the parties hereto.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.4pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">Governing  Law</span>; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Submission to Jurisdiction</span>; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Venue</span>; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver of Trial by Jury</span>.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</span>This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware without regard to choice of laws or conflicts of laws provisions thereof that would require the application of the laws of any other jurisdiction, except to the extent that mandatory principles of Delaware law may apply.</div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:68.4pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">(b)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company and each of the Investors hereby irrevocably and unconditionally:</span></td></tr></table><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:72pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(i)</span>submits for itself and its property in any legal action or proceeding relating solely to this Agreement or the transactions contemplated hereby, to the general jurisdiction of the any state court or United States Federal court sitting in the City of Wilmington in the State of Delaware;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:72pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(ii)</span>consents that any such action or proceeding may be brought in such courts, and waives any objection that it may now or hereafter have to the venue of any such action or proceeding in any such court or that such action or proceeding was brought in an inconvenient court and agrees not to plead or claim the same to the extent permitted by applicable law;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:72pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(iii)</span>agrees that service of process in any such action or proceeding may be effected by mailing a copy thereof by registered or certified mail (or any substantially similar form of mail), postage prepaid, to the party, as the case may be, at its address set forth in Section&#160;8.3 or at such other address of which the other party shall have been notified pursuant thereto;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:72pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(iv)</span>agrees that nothing herein shall affect the right to effect service of process in any other manner permitted by law or shall limit the right to sue in any other jurisdiction for recognition and enforcement of any judgment or if jurisdiction in the courts referenced in the foregoing clause (i)&#160;are not available despite the intentions of the parties hereto;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:72pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(v)</span>agrees that final judgment in any such suit, action or proceeding brought in such a court may be enforced in the courts of any jurisdiction to which such party is subject by a suit upon such judgment, provided that service of process is effected upon such party in the manner specified herein or as otherwise permitted by law;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:72pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(vi)</span>agrees that to the extent that such party has or hereafter may acquire any immunity from jurisdiction of any court or from any legal process with respect to itself or its property, such party hereby irrevocably waives such immunity in respect of its obligations under this Agreement, to the extent permitted by law; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-left:72pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(vii)</span>irrevocably and unconditionally waives trial by jury in any legal action or proceeding in relation to this Agreement.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.35pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver</span>. No waiver of any term, provision or condition of this Agreement, whether by conduct or otherwise, in any one or more instances, shall be deemed to be, or be construed as, a further or continuing waiver of any such term, provision or condition or as a waiver of any other term, provision or condition of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.35pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expenses</span>. Except as expressly set forth in the Transaction Agreements to the contrary, each party shall pay its own out-of-pocket fees and expenses, including the fees and expenses of attorneys, accountants and consultants employed by such party, incurred in connection with the proposed investment in the Securities and the consummation of the transactions contemplated thereby; provided, however, that the Company shall pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company), Transfer Taxes, stamp taxes and other taxes (other than income taxes) and duties levied in connection with the delivery of any Securities to the Investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.35pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment</span>. None of the parties may assign its rights or obligations under this Agreement or designate another person (i)&#160;to perform all or part of its obligations under this Agreement or (ii)&#160;to have all or part of its rights and benefits under this Agreement, in each case without the prior written consent of (x)&#160;the Company, in the case of an Investor, and (y)&#160;the Investors, in the case of the Company, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that an Investor may, without the prior consent of the Company, assign its rights to purchase the Securities hereunder to any of its affiliates or to any other investment funds or accounts managed or advised by </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">the investment manager who acts on behalf of such Investor (<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> each such assignee agrees to be bound by the terms of this Agreement and makes the same representations and warranties set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4</span> hereof). In the event of any assignment in accordance with the terms of this Agreement, the assignee shall specifically assume and be bound by the provisions of this Agreement by executing a writing agreeing to be bound by and subject to the provisions of this Agreement and shall deliver an executed counterpart signature page&#160;to this Agreement and, notwithstanding such assumption or agreement to be bound hereby by an assignee, no such assignment shall relieve any party assigning any interest hereunder from its obligations or liability pursuant to this Agreement unless expressly consented to by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.4pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.9</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidential Information</span>.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</span>Each Investor covenants that until such time as the transactions contemplated by this Agreement and any material non-public information provided to such Investor are publicly disclosed by the Company in accordance with Section&#160;5.3, such Investor will maintain the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction), other than to such Investor&#8217;s outside attorney, accountant, auditor or investment advisor only to the extent necessary to permit evaluation of the investment, and the performance of the necessary or required tax, accounting, financial, legal, or administrative tasks and services and other than as may be required by law.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</span>The Company may request from the Investors such reasonable and customary additional information as the Company may deem necessary to evaluate the eligibility of the Investor to acquire the Securities, and the Investor shall promptly provide such information as may reasonably be requested to the extent readily available; provided, that the Company agrees to keep any such information provided by the Investor confidential, except (i)&#160;as required by the federal securities laws, rules&#160;or regulations, (ii)&#160;to the extent such disclosure is required by other laws, rules&#160;or regulations, and (iii)&#160;at the request of the staff of the SEC or regulatory agency or under the regulations of Nasdaq, in which case of clause (ii)&#160;or (iii), the Company will use commercially reasonable efforts to notify the Investor and provide the Investor the opportunity to review such disclosure. The Investor acknowledges that the Company may file a form of this Agreement and the Registration Rights Agreement with the SEC as exhibits to a periodic report or a registration statement of the Company.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:33pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.10</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reliance by and Exculpation of Placement Agents</span>.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</span>Each Investor agrees for the express benefit of the Placement Agents and their respective affiliates and representatives that (i)&#160;the Placement Agents and their respective affiliates and representatives have not made, and will not make any representations or warranties with respect to the Company or the offer and sale of the Securities, and such Investor will not rely on any statements made by any Placement Agent, orally or in writing, to the contrary, (ii)&#160;such Investor will be responsible for conducting its own due diligence investigation with respect to the Company and the offer and sale of the Securities, (iii)&#160;such Investor will be purchasing Securities based on the results of its own due diligence investigation of the Company and the Placement Agents and each of their respective directors, officers, employees, representatives, and controlling persons have made no independent investigation with respect to the Company, the Securities, or the accuracy, completeness, or adequacy of any information supplied to the Investor by the Company, (iv)&#160;such Investor has negotiated the offer and sale of the Securities directly with the Company, and the Placement Agents will not be responsible for the ultimate success of any such investment and (v)&#160;the decision to invest in the Company will involve a significant degree of risk, including a risk of total loss of such investment. This <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.10</span> shall survive any termination of this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</span>The Company agrees and acknowledges that the Placement Agents may rely on its representations, warranties, agreements and covenants contained in this Agreement and each Investor agrees that the Placement Agents may rely on such Investor&#8217;s representations and warranties contained in this Agreement as if such representations and warranties, as applicable, were made directly to the Placement Agents.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</span>Neither the Placement Agents nor any of their respective affiliates or representatives (1)&#160;shall be liable for any improper payment made in accordance with the information provided by the Company; (2) makes any representation or warranty, or has any responsibilities as to the validity, accuracy, value or genuineness of any information, certificates or documentation delivered by or on behalf of the Company pursuant to the Transaction Agreements or in connection with any of the transactions contemplated therein; or (3)&#160;shall be liable (x)&#160;for any action taken, suffered or omitted by any of them in good faith and reasonably believed to be authorized or within the discretion or rights or powers conferred upon it by the </div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:0pt;">Transaction Agreements or (y)&#160;for anything which any of them may do or refrain from doing in connection with the Transaction Agreements, except in each case for such party&#8217;s own gross negligence, willful misconduct or bad faith.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</span>The Company agrees that the Placement Agents and their respective affiliates and representatives shall be entitled to (1)&#160;rely on, and shall be protected in acting upon, any certificate, instrument, notice, letter or any other document or security delivered to any of them by or on behalf of the Company, and (2)&#160;be indemnified by the Company for acting as the Placement Agents hereunder pursuant to the indemnification provisions set forth in the applicable letter agreement between the Company and the Placement Agents.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.7pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.11</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Parties</span>. Nothing in this Agreement, express or implied, is intended to confer on any Person other than the parties to this Agreement any rights, remedies, claims, benefits, obligations or liabilities under or by reason of this Agreement, and no Person that is not a party to this Agreement (including, without limitation, any partner, member, shareholder, director, officer, employee or other beneficial owner of any party to this Agreement, in its own capacity as such or in bringing a derivative action on behalf of a party to this Agreement) shall have any standing as a third party beneficiary with respect to this Agreement or the transactions contemplated hereby, except as expressly set forth in this Agreement. Notwithstanding the foregoing, each Placement Agent is an intended third-party beneficiary of the representations and warranties of the Company set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3</span>, the representations and warranties of each Investor set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.1</span>(g)&#160;and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.10</span> of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.95pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.12</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Independent Nature of Investors&#8217; Obligations and Right.</span> The obligations of each Investor under this Agreement are several and not joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance obligations of any other Investor under this Agreement. Nothing contained herein, and no action taken by any Investor pursuant hereto, shall be deemed to constitute the Investors as, and the Company acknowledges that the Investors do not so constitute, a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Investors are in any way acting in concert or as a group (including a &#8220;group&#8221; within the meaning of Section&#160;13(d)(3)&#160;of the 1934 Act), and the Company will not assert any such claim with respect to such obligations or the transactions contemplated by this Agreement and the Company acknowledges that the Investors are not acting in concert or as a group with respect to such obligations or the transaction contemplated by this Agreement. It is expressly understood that each provision contained in this Agreement is between the Company and an Investor, solely, and not between the Company and the Investors collectively and not between and among the Investors. The Company acknowledges and each Investor confirms that it has independently participated in the negotiation of the transaction contemplated hereby with the advice of its own counsel and advisors. Each Investor also acknowledges that Gibson, Dunn&#160;&amp; Crutcher LLP has not rendered legal advice to such Investor. Each Investor shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement, and it shall not be necessary for any other Investor to be joined as an additional party in any proceeding for such purpose. The Company has elected to provide all Investors with the same terms and Transaction Agreements for the convenience of the Company and not because it was required or requested to do so by any Investor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:33pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.13</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Headin</span>gs. The titles, subtitles and headings in this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.95pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.14</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</span>. This Agreement may be executed in two (2)&#160;or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile or pdf signature including any electronic signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original, not a facsimile or pdf (or other electronic reproduction of a) signature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.95pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.15</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</span>;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> Amendments</span>. This Agreement and the other Transaction Agreements (including all schedules and exhibits hereto and thereto) constitute the entire agreement between the parties hereto respecting the subject matter hereof and thereof and supersede all prior agreements, negotiations, understandings, representations and statements respecting the subject matter hereof and thereof, whether written or oral. No amendment, modification, alteration, or change in any of the terms of this Agreement shall be valid or binding upon the parties hereto unless made in writing and duly executed by the Company and the Investor Majority. Notwithstanding the foregoing, (i)&#160;this Agreement may not be directly or indirectly amended with respect to any Investor without the written consent of such Investor unless such amendment applies to all Investors in the same fashion and (ii)&#160;any direct or indirect amendment to the definition of &#8220;Share Price&#8221; (or of any of the other terms included in such definition) or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.5</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.10</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.1</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.1</span> or this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.15</span> shall require the consent of each Investor. The Company, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">on the one hand, and each Investor, on the other hand, may by an instrument signed in writing by such parties waive the performance, compliance or satisfaction by such Investor or the Company, respectively, with any term or provision hereof or any condition hereto to be performed, complied with or satisfied by such Investor or the Company, respectively. For the avoidance of doubt, an amendment to this Agreement after the date hereof allowing for the sale of additional Securities (&#8220;<b style="font-weight:bold;">Additional Securities</b>&#8221;) to one or more Persons (whether or not an existing Investor) shall only require the approval of the Company and the Investor Majority; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that the price paid for such Additional Securities is equal to or greater than the Share Price and Pre-Funded Warrant Price, as applicable. Notwithstanding the foregoing or anything else herein to the contrary, no amendment, modification, alteration, change or waiver of the last sentence of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.11</span> shall be valid without the prior written consent of each Placement Agent, which consent may be granted or withheld in the sole discretion of each Placement Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.95pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.16</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Survival</span>. The covenants, representations and warranties made by each party hereto contained in this Agreement shall survive the Closing and the delivery of the Securities in accordance with their respective terms. Each Investor shall be responsible only for its own representations, warranties, agreements and covenants hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.95pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.17</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mutual Drafting</span>. This Agreement is the joint product of each Investor and the Company and each provision hereof has been subject to the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:33pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.18</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Arm&#8217;s Length Negotiations</span>. For the avoidance of doubt, the parties acknowledge and confirm that the terms and conditions of the Securities were determined as a result of arm&#8217;s-length negotiations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:32.95pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.19</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Further Assurances</span>. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">[Remainder of Page&#160;Intentionally Left Blank.]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_211ea722_e4aa_4226_bd1f_22ade0f6c243"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the parties hereto have executed this Agreement as of the day and&#160;year first above written.</p><a id="_Hlk183651132"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">COMPANY:</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:47.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.31%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: </p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the parties hereto have executed this Agreement as of the day and&#160;year first above written.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">INVESTOR:</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">[NAME]</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:43.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:43.32%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:43.32%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beneficial Ownership Limitation: [&#9679;]</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_ed9caa10_c1fb_41d2_a877_e64dbf09c4b1"></a><a id="ANNEXN_545330"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:right;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">ANNEX N</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">FORM OF PARENT STOCKHOLDER SUPPORT AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">This Support Agreement (this &#8220;Agreement&#8221;) is made and entered into as of October&#160;30, 2024, by and among Jade Biosciences, Inc., a Delaware corporation (the &#8220;Company&#8221;), Aerovate Therapeutics, Inc., a Delaware corporation (&#8220;Parent&#8221;), and the undersigned holder (the &#8220;Stockholder&#8221;) of Shares (as defined below) of Parent. Capitalized terms used herein but not otherwise defined shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">WHEREAS, concurrently with the execution and delivery hereof, Parent, the Company, Caribbean Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (the &#8220;First Merger Sub&#8221;) and Caribbean Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of Parent (&#8220;Second Merger Sub,&#8221; and together with First Merger Sub, &#8220;Merger Sub&#8221;), have entered into an Agreement and Plan of Merger, dated of even date herewith (as such agreement may be amended or supplemented from time to time pursuant to the terms thereof, the &#8220;Merger Agreement&#8221;), pursuant to which (i)&#160;First Merger Sub will merge with and into the Company (the &#8220;First Merger&#8221;), with the Company surviving the First Merger as the surviving corporation and a wholly owned subsidiary of Parent, and (ii)&#160;the Company will merge with and into Second Merger Sub (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;), with the Company surviving the Second Merger as the surviving corporation, in each case, upon the terms and subject to the conditions set forth in the Merger Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">WHEREAS, as of the date hereof, the Stockholder is the beneficial owner (as defined in Rule&#160;13d-3 under the Exchange Act) and has sole or shared voting power with respect to such number of Shares, and holds Parent Options or Parent Restricted Stock Units to acquire the number of Shares, as indicated in&#160;Appendix A.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">WHEREAS, as an inducement and a condition to the willingness of the Company to enter into the Merger Agreement, each Stockholder has agreed to enter into and perform this Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">NOW, THEREFORE, in consideration of, and as a condition to, the Company&#8217;s entering into the Merger Agreement, each Stockholder, Parent and the Company agree as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">1.&#160;&#160;&#160;Certain Definitions.&#160;&#160;&#160;Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Merger Agreement. For all purposes of this Agreement, the following terms shall have the following respective meanings:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(a)&#160;&#160;&#160;&#8220;Constructive Sale&#8221; means, with respect to any security, a short sale with respect to such security, entering into or acquiring a derivative contract with respect to such security, entering into or acquiring a futures or forward contract to deliver such security or entering into any other hedging or other derivative transaction that has the effect of either directly or indirectly materially changing the economic benefits or risks of ownership of such security.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(b)&#160;&#160;&#160;&#8220;Shares&#8221; means (i)&#160;all shares of Parent Common Stock owned, beneficially or of record, by the Stockholder as of the date hereof, (ii)&#160;all additional shares of Parent Common Stock acquired by the Stockholder, beneficially or of record, during the period commencing with the execution and delivery of this Agreement and expiring on the Expiration Date (as defined below) and (iii)&#160;any shares of capital stock or other equity securities of Parent that such Stockholder acquires or with respect to which such Stockholder otherwise acquires sole or shared voting power (including any proxy) after the execution and delivery of this Agreement and expiring on the Expiration Date, whether by exercise of any Parent Options or otherwise, including, without limitation, by gift, succession, in the event of a stock split or as a dividend or distribution of any Shares.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(c)&#160;&#160;&#160;&#8220;Transfer&#8221; or &#8220;Transferred&#8221; means, with respect to any security, the direct or indirect assignment, sale, transfer, tender, exchange, pledge or hypothecation, or the grant, creation or suffrage of a lien, security interest or encumbrance in or upon, or the gift, grant or placement in trust, or the Constructive Sale or other disposition of such security (including transfers by testamentary or intestate succession, by domestic relations order or other court order, or otherwise by operation of law) or any right, title or interest therein (including any right or power to vote to which the holder thereof may be entitled, whether such right or power is granted by proxy or otherwise), or the record or beneficial ownership thereof, the offer to make such a sale, transfer, Constructive Sale or other disposition, and each agreement, arrangement or understanding, whether or not in writing, to effect any of the foregoing.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">N-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">2.&#160;&#160;&#160;Transfer and Voting Restrictions.&#160;&#160;&#160;The Stockholder covenants to Parent and the Company as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(a)&#160;&#160;&#160;Except as otherwise permitted by Section&#160;2(c), during the period commencing with the execution and delivery of this Agreement and expiring on the Expiration Date, the Stockholder shall not Transfer any of the Stockholder&#8217;s Shares, or publicly announce its intention to Transfer any of its Shares.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(b)&#160;&#160;&#160;Except as otherwise permitted by this Agreement or otherwise permitted or required or by order of a court of competent jurisdiction or a Governmental Entity, the Stockholder will not commit any act that would restrict the Stockholder&#8217;s legal power, authority and right to vote all of the Shares held by the Stockholder or otherwise prevent or disable the Stockholder from performing any of his, her or its obligations under this Agreement. Without limiting the generality of the foregoing, except for this Agreement and as otherwise permitted by this Agreement, the Stockholder shall not enter into any voting agreement with any person or entity with respect to any of the Stockholder&#8217;s Shares, grant any person or entity any proxy (revocable or irrevocable) or power of attorney with respect to any of the Shares, deposit any Shares in a voting trust or otherwise enter into any agreement or arrangement with any person or entity limiting or affecting the Stockholder&#8217;s legal power, authority or right to vote the Stockholder&#8217;s Shares in favor of the Parent Stockholder Proposals and against any other Acquisition Proposals.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(c)&#160;&#160;&#160;Except as otherwise permitted by this Agreement or otherwise permitted or required by order of a court of competent jurisdiction or a Governmental Entity, the Stockholder will not enter into any Contract, option, commitment or other arrangement or understanding with respect to the direct or indirect Transfer of any right, title or interest (including any right or power to vote to which the holder thereof may be entitled whether such right or power is granted by proxy or otherwise) to any Shares or take any action that would reasonably be expected to make any representation or warranty of such Stockholder contained herein untrue or incorrect or have the effect of restricting the Stockholder&#8217;s legal power, authority and right to vote all of the Shares or would otherwise prevent or disable such Stockholder from performing any of such Stockholder&#8217;s obligations under this Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(d)&#160;&#160;&#160;Notwithstanding anything else herein to the contrary, the Stockholder may, at any time, Transfer Shares (i)&#160;by will or other testamentary document or by intestacy, (ii)&#160;to any investment fund or other entity controlled or managed by the Stockholder or the investment adviser or general partner of the Stockholder, or an entity under common control or management with the Stockholders (in each case, directly or indirectly), (iii)&#160;to any member of the Stockholder&#8217;s immediate family (or, if the Stockholder is a corporation, partnership or other entity, to an immediate family member of a beneficial owner of the Shares held by the Stockholder), (iv)&#160;to any trust or other entity for the direct or indirect benefit of the Stockholder or the immediate family of the Stockholder (or, if the Stockholder is a corporation, partnership or other entity, for the direct or indirect benefit of an immediate family member of a beneficial owner of the Shares held by the Stockholder) or otherwise for estate tax or estate planning purposes, (v)&#160;in the case of a Stockholder who is not a natural person, by pro&#160;rata distributions from the Stockholder to its members, partners, or shareholders pursuant to the Stockholder&#8217;s organizational documents, (vi)&#160;with respect to such Stockholder&#8217;s Parent Options (and any Shares underlying such Parent Options) which expire on or prior to the Expiration Date, Transfers of Shares to Parent (or effecting a &#8220;net exercise&#8221; of a Parent Option) as payment for the (a)&#160;exercise price of such Stockholder&#8217;s Parent Options and (b)&#160;taxes applicable to the exercise of such Stockholder&#8217;s Parent Options, (vii)&#160;with respect to such Stockholder&#8217;s Parent Restricted Stock Units, (a)&#160;transfers for the net settlement of Stockholder&#8217;s Parent Restricted Stock Units settled in Shares (to pay any tax withholding obligations) or (b)&#160;transfers for receipt upon settlement of such Stockholder&#8217;s Parent Restricted Stock Units, and the sale of a sufficient number of such Shares acquired upon settlement of such securities as would generate sales proceeds sufficient to pay the aggregate taxes payable by such Stockholder as a result of the settlement, (viii)&#160;transfers to another holder of capital stock of Parent that has signed a support agreement that is reasonably acceptable to the Company, (ix)&#160;transfers, sales or other dispositions as the Company may otherwise agree in writing in its sole discretion; p&#160;rovided, that in the cases of clauses (i)-(ix), (1)&#160;such Transferred Shares shall continue to be bound by this Agreement and () the applicable direct transferee (if any) of such Transferred Shares shall have executed and delivered to Parent and the Company a support agreement substantially identical to this Agreement upon consummation of the Transfer, (x)&#160;purchased from the Company on or about the Closing Date but prior to the Closing (including any shares of the Company issued upon conversion of any pre-funded Company Warrants), or (xi)&#160;to the extent required by applicable Law.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(e)&#160;&#160;&#160;Notwithstanding anything to the contrary herein, nothing in this Agreement shall obligate the Stockholder to exercise any option or any other right to acquire any shares of Parent Common Stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">3.&#160;&#160;&#160;Agreement to Vote Shares.&#160;&#160;&#160;The Stockholder covenants to Parent and the Company as follows:</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">N-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(a)&#160;&#160;&#160;Until the Expiration Date, at any meeting of the stockholders of Parent, however called, and at every adjournment or postponement thereof, and on every action or approval by written consent of the stockholders of Parent, the Stockholder shall be (i)&#160;appear at such meeting as present (in person or by proxy) for purposes of calculating a quorum and (ii)&#160;vote, or exercise its right to consent with respect to, all Shares held by the Stockholder (1)(A) in favor of the Parent Stockholder Proposals, (B)&#160;in favor of any matter that could reasonably be expected to facilitate the Merger, the Concurrent Investment and the transactions contemplated by the Merger Agreement, and (C)&#160;against any Acquisition Proposals, or any agreement, transaction or other matter that is intended to, or would reasonably be expected to impede, interfere with, delay, postpone or materially and adversely affect the consummation of the Merger, the Concurrent Investment and the transactions contemplated in the Merger Agreement and (2)&#160;to approve any proposal to adjourn or postpone the meeting to a later date, if there are not sufficient votes for the issuance of the shares of Parent Common Stock by virtue of the Merger on the date on which such meeting is held. Stockholder shall not take or commit or agree to take any action inconsistent with the foregoing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(b)&#160;&#160;&#160;If the Stockholder is the beneficial owner, but not the record holder, of Shares, the Stockholder agrees to take all actions necessary to cause the record holder and any nominees to be present (in person or by proxy) and vote all the Stockholder&#8217;s Shares in accordance with this&#160;Section&#160;3.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(c)&#160;&#160;&#160;In the event of a stock split, stock dividend or distribution, or any change in the capital stock of Parent by reason of any split-up, reverse stock split, recapitalization, combination, reclassification, reincorporation, exchange of shares or the like, the term &#8220;Shares&#8221; shall be deemed to refer to and include such shares as well as all such stock dividends and distributions and any securities into which or for which any or all of such shares may be changed or exchanged or which are received in such transaction.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">4.&#160;&#160;&#160;Action in Stockholder Capacity Only.&#160;&#160;&#160;The Stockholder is entering into this Agreement solely in the Stockholder&#8217;s capacity as a record holder and/or beneficial owner, as applicable, of its Shares and not in the Stockholder&#8217;s capacity as a director or officer of Parent. Nothing herein shall limit or affect the Stockholder&#8217;s ability to act as an officer or director of Parent.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">5.&#160;&#160;&#160;Irrevocable Proxy.&#160;&#160;&#160;The Stockholder hereby revokes (or agrees to cause to be revoked) any proxies that the Stockholder has heretofore granted with respect to its Shares. In the event and to the extent that the Stockholder fails to vote the Shares in accordance with&#160;Section&#160;3&#160;at any applicable meeting of the stockholders of Parent or pursuant to any applicable written consent of the stockholders of Parent, the Stockholder shall be deemed to have irrevocably granted to, and appointed, Parent, and any individual designated in writing by it, and each of them individually, as his, her or its proxy and attorney-in-fact (with full power of substitution), for and in its name, place and stead, to vote his, her or its Shares in any action by written consent of Parent stockholders or at any meeting of Parent&#8217;s stockholders called with respect to any of the matters specified in, and in accordance and consistent with,&#160;Section&#160;3&#160;of this Agreement. Parent agrees not to exercise the proxy granted herein for any purpose other than the purposes described in this Agreement and the Stockholder affirms that the proxy set forth in this&#160;Section&#160;5&#160;is given in connection with, and granted in consideration of, and as an inducement to the Company, Parent and Merger Sub to enter into the Merger Agreement and that such proxy is given to secure the obligations of the Stockholder under&#160;Section&#160;3. Except as otherwise provided for herein, the Stockholder hereby affirms that the irrevocable proxy is coupled with an interest and may under no circumstances be revoked and that such irrevocable proxy is executed and intended to be irrevocable. The irrevocable proxy and power of attorney granted herein shall survive the death or incapacity of such Stockholder and the obligations of such Stockholder shall be binding on such Stockholder&#8217;s heirs, personal representatives, successors, transferees and assigns. Notwithstanding any other provisions of this Agreement, the irrevocable proxy granted hereunder shall automatically terminate upon the termination of this Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">6.&#160;&#160;&#160;No Solicitation.&#160;&#160;&#160;Subject to&#160;Section&#160;4, the Stockholder agrees not to, directly or indirectly, including through any of its officers, directors or agents, take any action that Parent is prohibited from taking pursuant to Section&#160;6.4 of the Merger Agreement and Section&#160;6.4 of the Merger Agreement is hereby incorporated by reference&#160;</span><i style="font-style:italic;letter-spacing:0.2pt;">mutatis mutandis</i><span style="letter-spacing:0.2pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt;"><span style="letter-spacing:0.2pt;">7.&#160;&#160;&#160;No Exercise of Appraisal Rights;&#160;Waivers.&#160;&#160;&#160;The Stockholder hereby irrevocably and unconditionally (a)&#160;waives, and agrees to cause to be waived and to prevent the exercise of, any rights of appraisal, any dissenters&#8217; rights and any similar rights (including any notice requirements related thereto) relating to the Merger that Stockholder may have by virtue of, or with respect to, any Shares (including all rights under Section&#160;262 of the DGCL) and (b)&#160;agrees that the Stockholder will not bring, commence, institute, maintain, prosecute or voluntarily aid or participate in any action, claim, suit or cause of action, in law or in equity, in any court or before any Governmental Entity, which (i)&#160;challenges the validity of or seeks to enjoin the operation of </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">N-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">any provision of this Agreement or (ii)&#160;alleges that the execution and delivery of this Agreement by the Stockholder, or the approval of the Merger Agreement by the Parent Board, breaches any fiduciary duty of the Parent Board or any member thereof; provided, that the Stockholder may defend against, contest or settle any such action, claim, suit or cause of action brought against the Stockholder that relates solely to the Stockholder&#8217;s capacity as a director, officer or securityholder of Parent.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">8.&#160;&#160;&#160;Representations and Warranties of the Stockholder.&#160;&#160;&#160;The Stockholder hereby represents and warrants to Parent and the Company as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(a)&#160;&#160;&#160;(i) The Stockholder is the beneficial or record owner of the shares of Parent Common Stock, Parent Options and/or Parent Restricted Stock Units indicated in&#160;Appendix A&#160;(each of which shall be deemed to be &#8220;held&#8221; by the Stockholder for purposes of&#160;Section&#160;3&#160;unless otherwise expressly stated with respect to any shares in&#160;Appendix A), free and clear of any and all Liens; and (ii)&#160;the Stockholder does not beneficially own any securities of Parent other than the shares of Parent Common Stock and rights to purchase shares Parent Common Stock set forth in&#160;Appendix A.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(b)&#160;&#160;&#160;With respect to any Stockholder that is an entity, the Stockholder is duly organized, validly existing and in good standing under the laws of the jurisdiction of its formation and is qualified to conduct its business in those jurisdictions necessary to perform this Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(c)&#160;&#160;&#160;Except as otherwise provided in this Agreement, the Stockholder has full power, legal capacity and authority to (i)&#160;make, enter into and carry out the terms of this Agreement and (ii)&#160;vote all of its Shares in the manner set forth in this Agreement without the consent or approval of, or any other action on the part of, any other person or entity (including any Governmental Entity). Without limiting the generality of the foregoing, the Stockholder has not entered into any voting agreement (other than this Agreement) with any person with respect to any of the Stockholder&#8217;s Shares, granted any person any proxy (revocable or irrevocable) or power of attorney with respect to any of the Stockholder&#8217;s Shares, deposited any of the Stockholder&#8217;s Shares in a voting trust or entered into any arrangement or agreement with any person limiting or affecting the Stockholder&#8217;s legal power, authority or right to vote the Stockholder&#8217;s Shares on any matter contemplated by this Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(d)&#160;&#160;&#160;This Agreement has been duly and validly executed and delivered by the Stockholder and (assuming the due authorization, execution and delivery by the other parties hereto) constitutes a valid and binding agreement of the Stockholder enforceable against the Stockholder in accordance with its terms, subject to (a)&#160;Laws of general application relating to bankruptcy, insolvency and the relief of debtors and (b)&#160;rules of law governing specific performance, injunctive relief and other equitable remedies. The execution and delivery of this Agreement by the Stockholder and the performance by the Stockholder of the agreements and obligations hereunder will not result in any breach or violation of or be in conflict with or constitute a default under any term of any Contract or if applicable any provision of an organizational document (including a certificate of incorporation) to or by which the Stockholder is a party or bound, or any applicable law to which the Stockholder (or any of the Stockholder&#8217;s assets) is subject or bound, except for any such breach, violation, conflict or default which, individually or in the aggregate, would not reasonably be expected to materially impair or adversely affect the Stockholder&#8217;s ability to perform its obligations under this Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(e)&#160;&#160;&#160;The execution, delivery and performance of this Agreement by the Stockholder do not and will not require any consent, approval, authorization or permit of, action by, filing with or notification to, any Governmental Entity, except for any such consent, approval, authorization, permit, action, filing or notification the failure of which to make or obtain, individually or in the aggregate, has not and would not materially impair the Stockholder&#8217;s ability to perform its obligations under this Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(f)&#160;&#160;&#160;The Stockholder has had the opportunity to review the Merger Agreement and this Agreement with counsel of the Stockholder&#8217;s own choosing. The Stockholder has had an opportunity to review with its own tax advisors the tax consequences of the Merger and the transactions contemplated thereby. The Stockholder understands that it must rely solely on its advisors and not on any statements or representations made by Parent, the Company or any of their respective agents or representatives with respect to the tax consequences of the Merger and the transactions contemplated thereby. The Stockholder understands that such Stockholder (and not Parent, the Company or the Surviving Corporation) shall be responsible for such Stockholder&#8217;s tax liability that may arise as a result of the Merger or the transactions contemplated thereby. The Stockholder understands and acknowledges that the Company, Parent and Merger Sub are entering into the Merger Agreement in reliance upon the Stockholder&#8217;s execution, delivery and performance of this Agreement.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">N-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(g)&#160;&#160;&#160;With respect to the Stockholder, as of the date hereof, there is no action, suit, investigation or proceeding pending against, or, to the knowledge of the Stockholder, threatened against, the Stockholder or any of the Stockholder&#8217;s properties or assets (including the Shares) that would reasonably be expected to prevent or materially delay or impair the ability of the Stockholder to perform its obligations hereunder or to consummate the transactions contemplated hereby.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">9.&#160;&#160;&#160;Termination.&#160;&#160;&#160;This Agreement shall terminate and shall cease to be of any further force or effect as of the earliest of (a)&#160;such date and time as the Merger Agreement shall have been terminated pursuant to the terms thereof, (b)&#160;the Effective Time or (c)&#160;the mutual written agreement of the parties to terminate this Agreement (clauses (a)-(c), the &#8220;</span><span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Expiration Date</span><span style="letter-spacing:0.2pt;">&#8221;);&#160;provided,&#160;however, that (i)&#160;Section&#160;10&#160;shall survive the termination of this Agreement, and (ii)&#160;the termination of this Agreement shall not relieve any party hereto from any liability for any material and willful breach of this Agreement prior to the Effective Time.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">10.&#160;&#160;&#160;Miscellaneous Provisions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(a)&#160;&#160;&#160;Amendments.&#160;&#160;&#160;No amendment of this Agreement shall be effective against any party unless it shall be in writing and signed by each of the parties hereto.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(b)&#160;&#160;&#160;Entire Agreement.&#160;&#160;&#160;This Agreement constitutes the entire agreement between the parties to this Agreement and supersedes all other prior agreements, arrangements and understandings, both written and oral, among the parties with respect to the subject matter hereof.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(c)&#160;&#160;&#160;Governing Law.&#160;&#160;&#160;All matters arising out of or relating to this Agreement and the transactions contemplated hereby (including its interpretation, construction, performance and enforcement) shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of laws of any jurisdictions other than those of the State of Delaware.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(d)&#160;&#160;&#160;Jurisdiction.&#160;&#160;&#160;Each of the parties to this Agreement (i)&#160;consents to submit itself to the exclusive personal jurisdiction of the Court of Chancery of the State of Delaware, New Castle County, or, if that court does not have jurisdiction, a federal court sitting in Wilmington, Delaware in any action or proceeding arising out of or relating to this Agreement or any of the transactions contemplated by this Agreement, (ii)&#160;agrees that all claims in respect of such action or proceeding shall be heard and determined in any such court, (iii)&#160;agrees that it shall not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such court and (iv)&#160;agrees not to bring any action or proceeding arising out of or relating to this Agreement or any of the transactions contemplated by this Agreement in any other court. Each of the parties hereto waives any defense of inconvenient forum to the maintenance of any action or proceeding so brought and waives any bond, surety or other security that might be required of any other party with respect thereto. Any party may make service on another party by sending or delivering a copy of the process to the party to be served at the address and in the manner provided for the giving of notices in&#160;Section&#160;10(j). Nothing in this&#160;Section&#160;10(d), however, shall affect the right of any party to serve legal process in any other manner permitted by law.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(e)&#160;&#160;&#160;WAIVER OF JURY TRIAL.&#160;&#160;&#160;EACH OF THE PARTIES TO THIS AGREEMENT HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THE ACTIONS OF ANY PARTY TO THIS AGREEMENT IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT OF THIS AGREEMENT.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(f)&#160;&#160;&#160;Assignment.&#160;&#160;&#160;Except as otherwise provided in&#160;Section&#160;2(d) hereof, no party may assign any of its rights or delegate any of its performance obligations under this Agreement, in whole or in part, by operation of law or otherwise, without the prior written consent of the other parties hereto, and any such assignment without such prior written consent shall be null and void. Subject to the preceding sentence, this Agreement shall be binding upon, inure to the benefit of, and be enforceable by, the parties hereto and their respective successors and permitted assigns. Any purported assignment of rights or delegation of performance obligations in violation of this&#160;Section&#160;10(f)&#160;is void.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(g)&#160;&#160;&#160;No Third Party Rights.&#160;&#160;&#160;This Agreement is not intended to, and shall not, confer upon any other person any rights or remedies hereunder other than the parties hereto to the extent expressly set forth herein.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">N-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(h)&#160;&#160;&#160;Severability.&#160;&#160;&#160;Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If the final judgment of a court of competent jurisdiction declares that any term or provision hereof is invalid or unenforceable, the parties hereto agree that the court making such determination shall have the power to limit the term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(i)&#160;&#160;&#160;Specific Performance.&#160;&#160;&#160;Except as otherwise provided herein, any and all remedies herein expressly conferred upon a party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise of any other remedy. The parties hereto agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the parties waives any bond, surety or other security that might be required of any other party with respect thereto. Each of the parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(j)&#160;&#160;&#160;Notices.&#160;&#160;&#160;All notices and other communications hereunder shall be in writing and shall be deemed given if delivered personally or sent by overnight courier (providing proof of delivery), by facsimile transmission (providing confirmation of transmission) or by electronic transmission (upon confirmation of receipt of transmission) to the Company or Parent, as the case may be, in accordance with Section&#160;10.5 of the Merger Agreement and to each Stockholder at his, her or its address or email address (upon confirmation of receipt of transmission) set forth on&#160;Appendix&#160;A&#160;attached hereto (or at such other address for a party as shall be specified by like notice).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(k)&#160;&#160;&#160;Counterparts.&#160;&#160;&#160;This Agreement may be executed in two or more counterparts (including by facsimile, by an electronic scan delivered by electronic mail or any electronic signature), each of which shall be deemed an original but all of which together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each of the parties hereto and delivered to the other parties, it being understood that all parties need not sign the same counterpart. This Agreement may be executed and delivered by facsimile, by an electronic scan delivered by electronic mail or by delivery of any electronic signature.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(l)&#160;&#160;&#160;Confidentiality.&#160;&#160;&#160;Except to the extent required by applicable Law or regulation, the Stockholder shall hold any non-public information regarding this Agreement, the Merger Agreement and the Merger in strict confidence and shall not divulge any such information to any third person until Parent has publicly disclosed its entry into the Merger Agreement and this Agreement; provided, however, that the Stockholder may disclose such information to its Affiliates, partners, members, stockholders, parents, subsidiaries, attorneys, accountants, consultants, trustees, beneficiaries and other representatives (provided that such Persons are subject to confidentiality obligations at least as restrictive as those contained herein). Neither the Stockholder nor any of its Affiliates (other than Parent, whose actions shall be governed by the Merger Agreement), shall issue or cause the publication of any press release or other public announcement with respect to this Agreement, the Merger, the Merger Agreement or the other transactions contemplated hereby or thereby without the prior written consent of the Company and Parent, except as may be required by applicable Law in which circumstance such announcing party shall make reasonable efforts to consult with the Company and Parent to the extent practicable. The Company is an intended third-party beneficiary of this&#160;Section&#160;10(l).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(m)&#160;&#160;&#160;Further Assurances.&#160;&#160;&#160;Each Stockholder shall, from time to time, execute and deliver, or cause to be executed and delivered, such additional or further consents, documents and other instruments as the Company or Parent may reasonably request for the purpose of effectively carrying out the transactions contemplated by this Agreement and the transactions contemplated by the Merger Agreement.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">N-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(n)&#160;&#160;&#160;Disclosure.&#160;&#160;&#160;Each Stockholder hereby agrees that Parent and the Company may publish and disclose in the Registration Statement, any prospectus or registration statement filed with any regulatory authority in connection with the transactions contemplated by the Merger Agreement and any related documents filed with such regulatory authority and as otherwise required by Law, such Stockholder&#8217;s identity and ownership of the Shares and the nature of such Stockholder&#8217;s commitments, arrangements and understandings under this Agreement and may further file this Agreement as an exhibit to the Registration Statement, prospectus or registration statement or in any other filing made by Parent or the Company as required by Law or the terms of the Merger Agreement, including with the SEC or other regulatory authority, relating to the transactions contemplated by the Merger Agreement. In the event of any such required disclosure, Parent or Company shall use commercially reasonable efforts to provide the Stockholder advance written notice of, and an opportunity to review, any such disclosure that identifies the Stockholder. Prior to the Closing, each Stockholder shall not, and shall use its reasonable best efforts to cause its representatives not to, directly or indirectly, make any press release, public announcement or other public communication with respect to this Agreement, the Merger, the Merger Agreement or the transactions contemplated thereby without the prior written consent of Parent and the Company, provided that the foregoing shall not limit or affect any actions taken by such Stockholder (or any affiliated officer or director of such Stockholder) that would be permitted to be taken by such Stockholder, Parent or the Company pursuant to the Merger Agreement; provided, further, that the foregoing shall not affect any actions of Stockholder the prohibition of which would be prohibited under applicable Law and shall not prohibit Stockholder or its Affiliates from making any publicly-available filings required by applicable law, regulation or legal process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(o)&#160;&#160;&#160;Fees and Expenses.&#160;&#160;&#160;Except as otherwise specifically provided herein, the Merger Agreement or any other agreement contemplated by the Merger Agreement to which a party hereto is a party, each party hereto shall bear its own expenses in connection with this Agreement and the transactions contemplated hereby.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(p)&#160;&#160;&#160;No Ownership Interest.&#160;&#160;&#160;Nothing contained in this Agreement shall be deemed to vest in the Company or Parent any direct or indirect ownership or incidence of ownership of or with respect to any Shares. All rights, ownership and economic benefits of and relating to the Shares shall remain vested in and belong to such Stockholder, and neither the Company nor Parent has authority to manage, direct, superintend, restrict, regulate, govern, or administer any of the policies or operations of Parent or exercise any power or authority to direct such Stockholder in the voting of any of the Shares, except as otherwise provided herein.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">(q)&#160;&#160;&#160;Interpretation.&#160;&#160;&#160;When reference is made in this Agreement to a Section or Appendix, such reference shall be to a Section of or Appendix to this Agreement, unless otherwise indicated. The headings contained in this Agreement are for convenience of reference only and shall not affect in any way the meaning or interpretation of this Agreement. The language used in this Agreement shall be deemed to be the language chosen by the parties hereto to express their mutual intent, and no rule of strict construction shall be applied against any party. Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular form of nouns and pronouns shall include the plural, and vice versa. Any reference to any federal, state, local or foreign statute or law shall be deemed also to refer to all rules and regulations promulgated thereunder, unless the context requires otherwise. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation.&#8221; The word &#8220;or&#8221; is not exclusive. &#8220;Writing,&#8221; &#8220;written&#8221; and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any agreement or Contract are to that agreement or Contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof. References to any Person include the successors and permitted assigns of that Person. References to any statute are to that statute and to the rules and regulations promulgated thereunder, in each case as amended, modified, re-enacted thereof, substituted, from time to time. References to &#8220;$&#8221; and &#8220;dollars&#8221; are to the currency of the United States. All accounting terms used herein will be interpreted, and all accounting determinations hereunder will be made, in accordance with GAAP unless otherwise expressly specified.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="letter-spacing:0.2pt;">References from or through any date shall mean, unless otherwise specified, from and including or through and including, respectively. All references to &#8220;days&#8221; shall be to calendar days unless otherwise indicated as a &#8220;Business Day.&#8221; Except as otherwise specifically indicated, for purposes of measuring the beginning and ending of time periods in this Agreement (including for purposes of &#8220;Business Day&#8221; and for hours in a day or Business Day), the time at which a thing, occurrence or event shall begin or end shall be deemed to occur in the Eastern time zone of the United States. The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">[Remainder of Page Left Intentionally Blank]</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.95pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt 0pt 0pt 5.95pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">N-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_4af1916d_b068_4b19_80be_d1e4733c75b7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 1.2pt 0pt;">IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed as of the date first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk183654586"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COMPANY:</p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jade Biosciences, Inc.</p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PARENT:</p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Aerovate Therapeutics, Inc.</p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[STOCKHOLDER],</p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">in his/her capacity as the Stockholder:</p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Signature:</p></td><td style="vertical-align:bottom;width:48.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address:</p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5.75pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 2.5pt 0pt;">[Signature Page to Company Support Agreement]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">N-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.2pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk183654582"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:25.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Name, Address and Email</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Address of Stockholder</b></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:23.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares of Parent</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Common Stock</b></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:22.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Parent Options</b></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:22.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Parent Restricted</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Stock Units</b></p></td></tr><tr><td style="vertical-align:bottom;width:25.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-weight:bold;margin-left:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.21%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.95pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.95pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt 0pt 0pt 5.95pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">N-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.95pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="_fc2a4d50_49ed_493f_ab50_c7931720f9d6"></a><a id="ANNEXO_872350"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ANNEX O</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">This Support Agreement (this &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</span>&#8221;) is made and entered into as of October 30, 2024, by and among Jade Biosciences, Inc., a Delaware corporation (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</span>&#8221;), Aerovate Therapeutics, Inc., a Delaware corporation (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent</span>&#8221;), and the undersigned holder (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stockholder</span>&#8221;) of Shares (as defined below) of the Company. Capitalized terms used herein but not otherwise defined shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">WHEREAS, concurrently with the execution and delivery hereof, Parent, the Company, Caribbean Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">First Merger Sub</span>&#8221;) and Caribbean Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of Parent (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Second Merger Sub</span>,&#8221; and together with First Merger Sub, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger Sub</span>&#8221;), have entered into an Agreement and Plan of Merger, dated of even date herewith (as such agreement may be amended or supplemented from time to time pursuant to the terms thereof, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger Agreement</span>&#8221;), pursuant to which (i) First Merger Sub will merge with and into the Company (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">First Merger</span>&#8221;), with the Company surviving the First Merger as the surviving corporation and a wholly owned subsidiary of Parent, and (ii) the Company will merge with and into Second Merger Sub (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Second Merger</span>&#8221; and, together with the First Merger, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger</span>&#8221;), with the Company surviving the Second Merger as the surviving corporation, in each case, upon the terms and subject to the conditions set forth in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">WHEREAS, as of the date hereof, the Stockholder is the beneficial owner (as defined in Rule 13d-3 under the Exchange Act) and has sole or shared voting power with respect to such number of Shares, and holds Company Options to acquire the number of Shares, as indicated in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">WHEREAS, as an inducement and a condition to the willingness of Parent to enter into the Merger Agreement, each Stockholder has agreed to enter into and perform this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">NOW, THEREFORE, in consideration of, and as a condition to, Parent entering into the Merger Agreement, each Stockholder, Parent and the Company agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certain Definitions</span>. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Merger Agreement. For all purposes of this Agreement, the following terms shall have the following respective meanings:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 9pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Constructive Sale</span>&#8221; means, with respect to any security, a short sale with respect to such security, entering into or acquiring a derivative contract with respect to such security, entering into or acquiring a futures or forward contract to deliver such security or entering into any other hedging or other derivative transaction that has the effect of either directly or indirectly materially changing the economic benefits or risks of ownership of such security.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 9pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shares</span>&#8221; means (i) all shares of Company Common Stock owned, beneficially or of record, by the Stockholder as of the date hereof, (ii) all additional shares of Company Common Stock acquired by the Stockholder, beneficially or of record, during the period commencing with the execution and delivery of this Agreement and expiring on the Expiration Date (as defined below) and (iii) any shares of capital stock or other equity securities of the Company that such Stockholder acquires or with respect to which such Stockholder otherwise acquires sole or shared voting power (including any proxy) after the execution and delivery of this Agreement and expiring on the Expiration Date, whether by exercise of any Company Options or otherwise, including, without limitation, by gift, succession, in the event of a stock split or as a dividend or distribution of any Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 9pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer</span>&#8221; or &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transferred</span>&#8221; means, with respect to any security, the direct or indirect assignment, sale, transfer, tender, exchange, pledge or hypothecation, or the grant, creation or suffrage of a lien, security interest or encumbrance in or upon, or the gift, grant or placement in trust, or the Constructive Sale or other disposition of such security (including transfers by testamentary or intestate succession, by domestic relations order or other court order, or otherwise by operation of law) or any right, title or interest therein (including any right or power to vote to which the holder thereof may be entitled, whether such right or power is granted by proxy or otherwise), or the record or beneficial ownership thereof, the offer to make such a sale, transfer, Constructive Sale or other disposition, and each agreement, arrangement or understanding, whether or not in writing, to effect any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">O-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_0b86b791_666f_442d_b1a7_6259f7622b1e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer and Voting Restrictions</span>. The Stockholder covenants to the Company and Parent as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Except as otherwise permitted by Section 2(c), during the period commencing with the execution and delivery of this Agreement and expiring on the Expiration Date, the Stockholder shall not Transfer any of the Stockholder&#8217;s Shares, or publicly announce its intention to Transfer any of its Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Except as otherwise permitted by this Agreement or otherwise permitted or required or by order of a court of competent jurisdiction or a Governmental Entity, the Stockholder will not commit any act that would restrict the Stockholder&#8217;s legal power, authority and right to vote all of the Shares held by the Stockholder or otherwise prevent or disable the Stockholder from performing any of his, her or its obligations under this Agreement. Without limiting the generality of the foregoing, except for this Agreement and as otherwise permitted by this Agreement, the Stockholder shall not enter into any voting agreement with any person or entity with respect to any of the Stockholder&#8217;s Shares, grant any person or entity any proxy (revocable or irrevocable) or power of attorney with respect to any of the Shares, deposit any Shares in a voting trust or otherwise enter into any agreement or arrangement with any person or entity limiting or affecting the Stockholder&#8217;s legal power, authority or right to execute and deliver the Company Stockholder Approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Except as otherwise permitted by this Agreement or otherwise permitted or required by order of a court of competent jurisdiction or a Governmental Entity, the Stockholder will not enter into any Contract, option, commitment or other arrangement or understanding with respect to the direct or indirect Transfer of any right, title or interest (including any right or power to vote to which the holder thereof may be entitled whether such right or power is granted by proxy or otherwise) to any Shares or take any action that would reasonably be expected to make any representation or warranty of such Stockholder contained herein untrue or incorrect or have the effect of restricting the Stockholder&#8217;s legal power, authority and right to vote all of the Shares or would otherwise prevent or disable such Stockholder from performing any of such Stockholder&#8217;s obligations under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Notwithstanding anything else herein to the contrary, the Stockholder may, at any time, Transfer Shares (i) by will or other testamentary document or by intestacy, (ii) to any investment fund or other entity controlled or managed by the Stockholder or the investment adviser or general partner of the Stockholder, or an entity under common control or management with the Stockholders (in each case, directly or indirectly), (iii) to any member of the Stockholder&#8217;s immediate family (or, if the Stockholder is a corporation, partnership or other entity, to an immediate family member of a beneficial owner of the Shares held by the Stockholder), (iv) to any trust or other entity for the direct or indirect benefit of the Stockholder or the immediate family of the Stockholder (or, if the Stockholder is a corporation, partnership or other entity, for the direct or indirect benefit of an immediate family member of a beneficial owner of the Shares held by the Stockholder) or otherwise for estate tax or estate planning purposes, (v) in the case of a Stockholder who is not a natural person, by pro rata distributions from the Stockholder to its members, partners, or shareholders pursuant to the Stockholder&#8217;s organizational documents, (vi) with respect to such Stockholder&#8217;s Company Options (and any Shares underlying such Company Options) which expire on or prior to the Expiration Date, Transfers of Shares to the Company (or effecting a &#8220;net exercise&#8221; of a Company Option) as payment for the (a) exercise price of such Stockholder&#8217;s Company Options and (b) taxes applicable to the exercise of such Stockholder&#8217;s Company Options, (vii) transfers to another holder of capital stock of the Company that has signed a support agreement that is reasonably acceptable to Parent, (viii) transfers, sales or other dispositions as Parent may otherwise agree in writing in its sole discretion; p <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">rovided</span>, that in the cases of clauses (i)-(viii), (1) such Transferred Shares shall continue to be bound by this Agreement and (2) the applicable direct transferee (if any) of such Transferred Shares shall have executed and delivered to Parent and the Company a support agreement substantially identical to this Agreement upon consummation of the Transfer, (x) purchased from the Company on or about the Closing Date but prior to the Closing (including any shares of the Company issued upon conversion of any pre-funded Company Warrants), or (xi) to the extent required by applicable Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>Notwithstanding anything to the contrary herein, nothing in this Agreement shall obligate the Stockholder to exercise any option or any other right to acquire any shares of Company Capital Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement to Vote Shares</span>. The Stockholder covenants to the Company and Parent as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Until the Expiration Date, at any meeting of the stockholders of the Company, however called, and at every adjournment or postponement thereof, and on every action or approval by written consent of the stockholders of the Company, the Stockholder shall (i) appear at such meeting as present (in person or by proxy) for purposes of calculating a quorum and (ii) vote, or exercise its right to consent with respect to, all Shares held by the Stockholder (A) in favor of the adoption and approval of the Merger Agreement, (B) in favor of the Contemplated Transactions, including any matter that could reasonably be expected to facilitate the Contemplated Transactions, and (C) against any Acquisition Proposals, or any agreement, transaction or other matter that is intended </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">O-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">to, or would reasonably be expected to impede, interfere with, delay, postpone or materially and adversely affect the consummation of the Merger and the other Contemplated Transactions. Stockholder shall not take or commit or agree to take any action inconsistent with the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>If the Stockholder is the beneficial owner, but not the record holder, of Shares, the Stockholder agrees to take all actions necessary to cause the record holder and any nominees to be present (in person or by proxy) and vote all the Stockholder&#8217;s Shares in accordance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>In the event of a stock split, stock dividend or distribution, or any change in the capital stock of the Company by reason of any split-up, reverse stock split, recapitalization, combination, reclassification, reincorporation, exchange of shares or the like, the term &#8220;Shares&#8221; shall be deemed to refer to and include such shares as well as all such stock dividends and distributions and any securities into which or for which any or all of such shares may be changed or exchanged or which are received in such transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Action in Stockholder Capacity Only</span>. The Stockholder is entering into this Agreement solely in the Stockholder&#8217;s capacity as a record holder and/or beneficial owner, as applicable, of its Shares and not in the Stockholder&#8217;s capacity as a director or officer of the Company. Nothing herein shall limit or affect the Stockholder&#8217;s ability to act as an officer or director of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Irrevocable Proxy</span>. The Stockholder hereby revokes (or agrees to cause to be revoked) any proxies that the Stockholder has heretofore granted with respect to its Shares. In the event and to the extent that the Stockholder fails to vote the Shares in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3</span> at any applicable meeting of the stockholders of the Company or pursuant to any applicable written consent of the stockholders of the Company, the Stockholder shall be deemed to have irrevocably granted to, and appointed, the Company, and any individual designated in writing by it, and each of them individually, as his, her or its proxy and attorney-in-fact (with full power of substitution), for and in its name, place and stead, to vote his, her or its Shares in any action by written consent of Company stockholders or at any meeting of the Company&#8217;s stockholders called with respect to any of the matters specified in, and in accordance and consistent with, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3</span> of this Agreement. The Company agrees not to exercise the proxy granted herein for any purpose other than the purposes described in this Agreement and the Stockholder affirms that the proxy set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5</span> is given in connection with, and granted in consideration of, and as an inducement to the Company, Parent and Merger Sub to enter into the Merger Agreement and that such proxy is given to secure the obligations of the Stockholder under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3</span>. Except as otherwise provided for herein, the Stockholder hereby affirms that the irrevocable proxy is coupled with an interest and may under no circumstances be revoked and that such irrevocable proxy is executed and intended to be irrevocable. The irrevocable proxy and power of attorney granted herein shall survive the death or incapacity of such Stockholder and the obligations of such Stockholder shall be binding on such Stockholder&#8217;s heirs, personal representatives, successors, transferees and assigns. Notwithstanding any other provisions of this Agreement, the irrevocable proxy granted hereunder shall automatically terminate upon the termination of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Solicitation</span>. Subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4</span>, the Stockholder agrees not to, directly or indirectly, including through any of its officers, directors or agents, take any action that the Company is prohibited from taking pursuant to Section 6.4 of the Merger Agreement and Section 6.4 of the Merger Agreement is hereby incorporated by reference <i style="font-style:italic;">mutatis mutandis</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Exercise of Appraisal Rights; Waivers</span>. The Stockholder hereby irrevocably and unconditionally (a) waives, and agrees to cause to be waived and to prevent the exercise of, any rights of appraisal, any dissenters&#8217; rights and any similar rights (including any notice requirements related thereto) relating to the Merger that Stockholder may have by virtue of, or with respect to, any Shares (including all rights under Section 262 of the DGCL) and (b) agrees that the Stockholder will not bring, commence, institute, maintain, prosecute or voluntarily aid or participate in any action, claim, suit or cause of action, in law or in equity, in any court or before any Governmental Entity, which (i) challenges the validity of or seeks to enjoin the operation of any provision of this Agreement or (ii) alleges that the execution and delivery of this Agreement by the Stockholder, or the approval of the Merger Agreement by the Company Board, breaches any fiduciary duty of the Company Board or any member thereof; provided, that the Stockholder may defend against, contest or settle any such action, claim, suit or cause of action brought against the Stockholder that relates solely to the Stockholder&#8217;s capacity as a director, officer or securityholder of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties of the Stockholder</span>. The Stockholder hereby represents and warrants to Parent and the Company as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>(i) The Stockholder is the beneficial or record owner of the shares of Company Common Stock and/or Company Options indicated in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</span> (each of which shall be deemed to be &#8220;held&#8221; by the Stockholder for purposes of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3</span> unless </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">O-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">otherwise expressly stated with respect to any shares in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</span>), free and clear of any and all Liens; and (ii) the Stockholder does not beneficially own any securities of the Company other than the shares of Company Common Stock and rights to purchase shares Company Common Stock set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>With respect to any Stockholder that is an entity, the Stockholder is duly organized, validly existing and in good standing under the laws of the jurisdiction of its formation and is qualified to conduct its business in those jurisdictions necessary to perform this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Except as otherwise provided in this Agreement, the Stockholder has full power, legal capacity and authority to (i) make, enter into and carry out the terms of this Agreement and (ii) vote all of its Shares in the manner set forth in this Agreement without the consent or approval of, or any other action on the part of, any other person or entity (including any Governmental Entity). Without limiting the generality of the foregoing, the Stockholder has not entered into any voting agreement (other than this Agreement) with any person with respect to any of the Stockholder&#8217;s Shares, granted any person any proxy (revocable or irrevocable) or power of attorney with respect to any of the Stockholder&#8217;s Shares, deposited any of the Stockholder&#8217;s Shares in a voting trust or entered into any arrangement or agreement with any person limiting or affecting the Stockholder&#8217;s legal power, authority or right to vote the Stockholder&#8217;s Shares on any matter contemplated by this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>This Agreement has been duly and validly executed and delivered by the Stockholder and (assuming the due authorization, execution and delivery by the other parties hereto) constitutes a valid and binding agreement of the Stockholder enforceable against the Stockholder in accordance with its terms, subject to (a) Laws of general application relating to bankruptcy, insolvency and the relief of debtors and (b) rules of law governing specific performance, injunctive relief and other equitable remedies. The execution and delivery of this Agreement by the Stockholder and the performance by the Stockholder of the agreements and obligations hereunder will not result in any breach or violation of or be in conflict with or constitute a default under any term of any Contract or if applicable any provision of an organizational document (including a certificate of incorporation) to or by which the Stockholder is a party or bound, or any applicable law to which the Stockholder (or any of the Stockholder&#8217;s assets) is subject or bound, except for any such breach, violation, conflict or default which, individually or in the aggregate, would not reasonably be expected to materially impair or adversely affect the Stockholder&#8217;s ability to perform its obligations under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>The execution, delivery and performance of this Agreement by the Stockholder do not and will not require any consent, approval, authorization or permit of, action by, filing with or notification to, any Governmental Entity, except for any such consent, approval, authorization, permit, action, filing or notification the failure of which to make or obtain, individually or in the aggregate, has not and would not materially impair the Stockholder&#8217;s ability to perform its obligations under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>The Stockholder has had the opportunity to review the Merger Agreement and this Agreement with counsel of the Stockholder&#8217;s own choosing. The Stockholder has had an opportunity to review with its own tax advisors the tax consequences of the Merger and the other Contemplated Transactions. The Stockholder understands that it must rely solely on its advisors and not on any statements or representations made by Parent, the Company or any of their respective agents or representatives with respect to the tax consequences of the Merger and the other Contemplated Transactions. The Stockholder understands that such Stockholder (and not Parent, the Company or the Surviving Corporation) shall be responsible for such Stockholder&#8217;s tax liability that may arise as a result of the Merger or the other Contemplated Transactions. The Stockholder understands and acknowledges that the Company, Parent and Merger Sub are entering into the Merger Agreement in reliance upon the Stockholder&#8217;s execution, delivery and performance of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>With respect to the Stockholder, as of the date hereof, there is no action, suit, investigation or proceeding pending against, or, to the knowledge of the Stockholder, threatened against, the Stockholder or any of the Stockholder&#8217;s properties or assets (including the Shares) that would reasonably be expected to prevent or materially delay or impair the ability of the Stockholder to perform its obligations hereunder or to consummate the transactions contemplated hereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</span>. This Agreement shall terminate and shall cease to be of any further force or effect as of the earliest of (a) such date and time as the Merger Agreement shall have been terminated pursuant to the terms thereof, (b) the Effective Time or (c) the mutual written agreement of the parties to terminate this Agreement (clauses (a)-(c), the &#8220;<span style="font-style:italic;font-weight:bold;">Expiration Date</span>&#8221;); <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that (i) <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</span> shall survive the termination of this Agreement, and (ii) the termination of this Agreement shall not relieve any party hereto from any liability for any material and willful breach of this Agreement prior to the Effective Time.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">O-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous </span>Provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendments</span>. No amendment of this Agreement shall be effective against any party unless it shall be in writing and signed by each of the parties hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</span>. This Agreement constitutes the entire agreement between the parties to this Agreement and supersedes all other prior agreements, arrangements and understandings, both written and oral, among the parties with respect to the subject matter hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</span>. All matters arising out of or relating to this Agreement and the transactions contemplated hereby (including its interpretation, construction, performance and enforcement) shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of laws of any jurisdictions other than those of the State of Delaware.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Jurisdiction</span>. Each of the parties to this Agreement (i) consents to submit itself to the exclusive personal jurisdiction of the Court of Chancery of the State of Delaware, New Castle County, or, if that court does not have jurisdiction, a federal court sitting in Wilmington, Delaware in any action or proceeding arising out of or relating to this Agreement or any of the transactions contemplated by this Agreement, (ii) agrees that all claims in respect of such action or proceeding shall be heard and determined in any such court, (iii) agrees that it shall not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such court and (iv) agrees not to bring any action or proceeding arising out of or relating to this Agreement or any of the transactions contemplated by this Agreement in any other court. Each of the parties hereto waives any defense of inconvenient forum to the maintenance of any action or proceeding so brought and waives any bond, surety or other security that might be required of any other party with respect thereto. Any party may make service on another party by sending or delivering a copy of the process to the party to be served at the address and in the manner provided for the giving of notices in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</span>(j). Nothing in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</span>(<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">d</span>), however, shall affect the right of any party to serve legal process in any other manner permitted by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">WAIVER OF JURY TRIAL</span>. EACH OF THE PARTIES TO THIS AGREEMENT HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THE ACTIONS OF ANY PARTY TO THIS AGREEMENT IN THE NEGOTIATION, ADMINISTRATION,PERFORMANCE AND ENFORCEMENT OF THIS AGREEMENT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment</span>. Except as otherwise provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2</span>(<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">d</span>) hereof, no party may assign any of its rights or delegate any of its performance obligations under this Agreement, in whole or in part, by operation of law or otherwise, without the prior written consent of the other parties hereto, and any such assignment without such prior written consent shall be null and void. Subject to the preceding sentence, this Agreement shall be binding upon, inure to the benefit of, and be enforceable by, the parties hereto and their respective successors and permitted assigns. Any purported assignment of rights or delegation of performance obligations in violation of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</span>(f<img src="avte-20240930xs4045.jpg" alt="Graphic" style="display:inline-block;height:0.55pt;width:3.75pt;"/>) is void.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Third Party Rights</span>. This Agreement is not intended to, and shall not, confer upon any other person any rights or remedies hereunder other than the parties hereto to the extent expressly set forth herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</span>. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If the final judgment of a court of competent jurisdiction declares that any term or provision hereof is invalid or unenforceable, the parties hereto agree that the court making such determination shall have the power to limit the term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Specific Performance</span>. Except as otherwise provided herein, any and all remedies herein expressly conferred upon a party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such party, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">O-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and the exercise by a party of any one remedy will not preclude the exercise of any other remedy. The parties hereto agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the parties waives any bond, surety or other security that might be required of any other party with respect thereto. Each of the parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</span>. All notices and other communications hereunder shall be in writing and shall be deemed given if delivered personally or sent by overnight courier (providing proof of delivery), by facsimile transmission (providing confirmation of transmission) or by electronic transmission (upon confirmation of receipt of transmission) to the Company or Parent, as the case may be, in accordance with Section 10.5 of the Merger Agreement and to each Stockholder at his, her or its address or email address (upon confirmation of receipt of transmission) set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</span> attached hereto (or at such other address for a party as shall be specified by like notice).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(k)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</span>. This Agreement may be executed in two or more counterparts (including by facsimile, by an electronic scan delivered by electronic mail or any electronic signature), each of which shall be deemed an original but all of which together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each of the parties hereto and delivered to the other parties, it being understood that all parties need not sign the same counterpart. This Agreement may be executed and delivered by facsimile, by an electronic scan delivered by electronic mail or by delivery of any electronic signature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(l)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality</span>. Except to the extent required by applicable Law or regulation, the Stockholder shall hold any non-public information regarding this Agreement, the Merger Agreement and the Merger in strict confidence and shall not divulge any such information to any third person until the Company and Parent have publicly disclosed their entry into the Merger Agreement and this Agreement; provided, however, that the Stockholder may disclose such information to its Affiliates, partners, members, stockholders, parents, subsidiaries, attorneys, accountants, consultants, trustees, beneficiaries and other representatives (provided that such Persons are subject to confidentiality obligations at least as restrictive as those contained herein). Neither the Stockholder nor any of its Affiliates (other than the Company, whose actions shall be governed by the Merger Agreement), shall issue or cause the publication of any press release or other public announcement with respect to this Agreement, the Merger, the Merger Agreement or the other transactions contemplated hereby or thereby without the prior written consent of the Company and Parent, except as may be required by applicable Law in which circumstance such announcing party shall make reasonable efforts to consult with the Company and Parent to the extent practicable. Parent is an intended third-party beneficiary of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</span>(l<img src="avte-20240930xs4046.jpg" alt="Graphic" style="display:inline-block;height:0.55pt;width:3.2pt;"/>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(m)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Further Assurances</span>. Each Stockholder shall, from time to time, execute and deliver, or cause to be executed and delivered, such additional or further consents, documents and other instruments as the Company or Parent may reasonably request for the purpose of effectively carrying out the transactions contemplated by this Agreement and the transactions contemplated by the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(n)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosure</span>. Each Stockholder hereby agrees that Parent and the Company may publish and disclose in the Registration Statement, any prospectus or registration statement filed with any regulatory authority in connection with the transactions contemplated by the Merger Agreement and any related documents filed with such regulatory authority and as otherwise required by Law, such Stockholder&#8217;s identity and ownership of the Shares and the nature of such Stockholder&#8217;s commitments, arrangements and understandings under this Agreement and may further file this Agreement as an exhibit to the Registration Statement, prospectus or registration statement or in any other filing made by Parent or the Company as required by Law or the terms of the Merger Agreement, including with the SEC or other regulatory authority, relating to the transactions contemplated by the Merger Agreement. In the event of any such required disclosure, Parent or Company shall use commercially reasonable efforts to provide the Stockholder advance written notice of, and an opportunity to review, any such disclosure that identifies the Stockholder. Prior to the Closing, each Stockholder shall not, and shall use its reasonable best efforts to cause its representatives not to, directly or indirectly, make any press release, public announcement or other public communication with respect to this Agreement, the Merger, the Merger Agreement or the other Contemplated Transactions without the prior written consent of Parent and the Company, provided that the foregoing shall not limit or affect any actions taken by such Stockholder (or any affiliated officer or director of such Stockholder) that would be permitted to be taken by such Stockholder, Parent or the Company pursuant to the Merger Agreement; provided, further, that the foregoing shall not affect any actions of Stockholder the prohibition of which would be prohibited under applicable Law and shall not </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">O-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">prohibit Stockholder or its Affiliates from making any publicly-available filings required by applicable law, regulation or legal process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(o)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fees and Expenses</span>. Except as otherwise specifically provided herein, the Merger Agreement or any other agreement contemplated by the Merger Agreement to which a party hereto is a party, each party hereto shall bear its own expenses in connection with this Agreement and the transactions contemplated hereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(p)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Ownership Interest</span>. Nothing contained in this Agreement shall be deemed to vest in the Company or Parent any direct or indirect ownership or incidence of ownership of or with respect to any Shares. All rights, ownership and economic benefits of and relating to the Shares shall remain vested in and belong to such Stockholder, and neither the Company nor Parent has authority to manage, direct, superintend, restrict, regulate, govern, or administer any of the policies or operations of the Company or exercise any power or authority to direct such Stockholder in the voting of any of the Shares, except as otherwise provided herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(q)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interpretation</span>. When reference is made in this Agreement to a Section or Appendix, such reference shall be to a Section of or Appendix to this Agreement, unless otherwise indicated. The headings contained in this Agreement are for convenience of reference only and shall not affect in any way the meaning or interpretation of this Agreement. The language used in this Agreement shall be deemed to be the language chosen by the parties hereto to express their mutual intent, and no rule of strict construction shall be applied against any party. Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular form of nouns and pronouns shall include the plural, and vice versa. Any reference to any federal, state, local or foreign statute or law shall be deemed also to refer to all rules and regulations promulgated thereunder, unless the context requires otherwise. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation.&#8221; The word &#8220;or&#8221; is not exclusive. &#8220;Writing,&#8221; &#8220;written&#8221; and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any agreement or Contract are to that agreement or Contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof. References to any Person include the successors and permitted assigns of that Person. References to any statute are to that statute and to the rules and regulations promulgated thereunder, in each case as amended, modified, re-enacted thereof, substituted, from time to time. References to &#8220;$&#8221; and &#8220;dollars&#8221; are to the currency of the United States. All accounting terms used herein will be interpreted, and all accounting determinations hereunder will be made, in accordance with GAAP unless otherwise expressly specified. References from or through any date shall mean, unless otherwise specified, from and including or through and including, respectively. All references to &#8220;days&#8221; shall be to calendar days unless otherwise indicated as a &#8220;Business Day.&#8221; Except as otherwise specifically indicated, for purposes of measuring the beginning and ending of time periods in this Agreement (including for purposes of &#8220;Business Day&#8221; and for hours in a day or Business Day), the time at which a thing, occurrence or event shall begin or end shall be deemed to occur in the Eastern time zone of the United States. The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[Remainder of Page Left Intentionally Blank]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">O-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_3ed69ffe_b2fc_46c8_8423_fcd458131a7d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 1.14pt 0pt;">IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed as of the date first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk183656263"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COMPANY:</p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jade Biosciences, Inc.</p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PARENT:</p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Aerovate Therapeutics, Inc.</p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[STOCKHOLDER],</p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">in his/her capacity as the Stockholder:</p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Signature:</p></td><td style="vertical-align:bottom;width:48.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address:</p></td><td style="vertical-align:bottom;width:42.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:57.7%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.5pt 5.95pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 2.5pt 0pt;">[Signature Page to Company Support Agreement]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">O-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.2pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:44.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Name, Address and Email Address of Stockholder</b></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:15.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares of Parent</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Common Stock</b></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;  </p></td><td style="vertical-align:bottom;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Parent Options</b></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:19.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Parent Restricted</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Stock Units</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.12%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.47%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.74%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">O-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_d9de1854_15e7_4d7a_8adc_d7e61e37caad"></a><a id="ANNEXP_209392"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">ANNEX P</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">P-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_62a9ca9c_0c86_4e09_bc3c_f1744d216d14"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART&#160;II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INFORMATION NOT REQUIRED IN PROXY STATEMENT/PROSPECTUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;20. Indemnification of Directors and Officers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;145 of the Delaware General Corporation Law (&#8220;DGCL&#8221;), authorizes a corporation to indemnify its directors and officers against liabilities arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses (including attorneys&#8217; fees) judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding. Section&#160;145 permits corporations to pay expenses (including attorneys&#8217; fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section&#160;145 provides that a corporation has the power to purchase and maintain insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the corporation would have the power to indemnify the director or officer against such liability under Section&#160;145.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate has adopted provisions in its certificate of incorporation and bylaws that limit or eliminate the personal liability of its directors to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. Consequently, a director will not be personally liable to Aerovate or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any breach of the director&#8217;s duty of loyalty to Aerovate or its stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any unlawful payments related to dividends or unlawful stock purchases, redemptions or other distributions; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any transaction from which the director derived an improper personal benefit.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, Aerovate&#8217;s bylaws provide that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aerovate will indemnify its directors, officers and, in the discretion of Aerovate&#8217;s board of directors, certain employees to the fullest extent permitted by the DGCL, as it now exists or may in the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future be amended; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aerovate will advance all expenses, including attorneys&#8217; fees, to its directors and, in the discretion of Aerovate&#8217;s board of directors, any or all expenses to its officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of Aerovate, subject to certain limitations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate has entered into indemnification agreements with each of its directors and executive officers. These agreements provide that Aerovate will indemnify each of its directors, executive officers and, at times, their affiliates to the fullest extent permitted by Delaware law. Aerovate will advance expenses, including attorneys&#8217; fees (but excluding judgments, fines and settlement amounts), to each indemnified director, executive officer or affiliate in connection with any proceeding in which indemnification is available and Aerovate will indemnify its directors and officers for any action or proceeding arising out of that person&#8217;s services as a director or officer brought on behalf of Aerovate or in furtherance of Aerovate&#8217;s rights. Additionally, certain of Aerovate&#8217;s directors or officers may have certain rights to indemnification, advancement of expenses or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director&#8217;s or officer&#8217;s services as a director referenced herein. Nonetheless, Aerovate has agreed in the indemnification agreements that Aerovate&#8217;s obligations to those same directors or officers are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the expenses or liabilities incurred by those directors are secondary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate also maintain general liability insurance which covers certain liabilities of its directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Merger Agreement, from the effective time of the Merger through the sixth (6th) anniversary of the date of the effective time, Aerovate and the surviving corporation agree to indemnify and hold harmless each person who was, as of October&#160;30, 2024, the signing date of the Merger Agreement, or had been at any time prior, or who becomes prior to the effective time of the Merger, a director or officer of Aerovate or Jade, against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses pertaining to claims arising out of the fact that such person was a director or officer of Aerovate or Jade, at or prior to the effective time of the Merger, to the fullest extent permitted under the DGCL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Merger Agreement, the certificate of incorporation and bylaws of the surviving corporation in the Merger with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers of Aerovate that are set forth in the certificate of incorporation and bylaws of Aerovate in effect as of October&#160;30, 2024, the date of the Merger Agreement, shall not be amended, modified or repealed for a period of six (6)&#160;years from the effective time of the Merger in a manner that would adversely affect the rights of such individuals who at the effective time of the Merger were officers or directors of Aerovate, unless required by applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement also provides that Aerovate shall purchase an insurance policy in effect for six (6) <span style="color:#231f20;">years from the effective time of the Merger, providing no less favorable coverage as the current directors&#8217; and officers&#8217; liability insurance policies maintained by Aerovate with respect to any actual or alleged error, misstatement, misleading statement, act, omission, neglect, breach of duty or any m atter claimed against the current and former officers and directors of Aerovate.</span></p><a id="_510b5ef0_6e82_49eb_a023_243f4448cf51"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;21. Exhibits and Financial Statement Schedules</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><i style="color:#231f20;font-style:italic;">Exhibit&#160;Index</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A list of exhibits filed with this registration statement on Form&#160;S-4 is set forth on the Exhibit&#160;Index and is incorporated herein by reference.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;"><span style="color:#231f20;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;"><i style="color:#231f20;font-style:italic;">Financial Statements</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The financial statements filed with this registration statement on Form&#160;S-4 are set forth on the Financial Statement Index and is incorporated herein by reference.</p><a id="_a8cafe94_cf30_4740_90ee_28f3a7611ba4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;22. Undertakings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 10pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">The registrant hereby undertakes:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 10pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span><span style="color:#231f20;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 10pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="color:#231f20;">To include any prospectus required by Section&#160;10(a)(3)&#160;of the Securities Act;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 10pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span><span style="color:#231f20;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule&#160;424(b)&#160;if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Filing Fee Table&#8221; table in the effective registration statement; and</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 10pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span><span style="color:#231f20;">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Provided, however</i>, that paragraphs (a)(1)(i)&#160;and (a)(1)(ii)&#160;herein do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Exchange Act (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the registration statement.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 10pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(2)</span></span><span style="color:#231f20;">That, for the purpose of determining any liability under the Securities Act, each such post- effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 10pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(3)</span></span><span style="color:#231f20;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="color:#231f20;">The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant&#8217;s annual report pursuant to Section&#160;13(a)&#160;or Section&#160;15(d)&#160;of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#8217;s annual </span>report pursuant to Section&#160;15(d)&#160;of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span><span style="color:#231f20;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</span></p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:7.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Description</b></p></th></tr><tr><td style="vertical-align:top;width:7.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">2.1</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;">&#8224;</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#ANNEXA"><span style="font-style:normal;font-weight:normal;">Agreement and Plan of Merger, dated as of October&#160;30, 2024, by and among Aerovate Therapeutics,&#160;Inc., Caribbean Merger Sub I,&#160;Inc., Caribbean Merger Sub II, LLC and Jade Biosciences, Inc. (included as </span><i style="font-style:italic;font-weight:normal;">Annex A </i><span style="font-style:normal;font-weight:normal;">to this proxy statement/prospectus and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">3.1</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="avte-20240930xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation of Jade Biosciences,&#160;Inc., as currently in effect.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">3.2*</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">Form&#160;of Articles of Incorporation of Jade Biosciences,&#160;Inc., a Nevada corporation, to be in effect upon completion of the redomestication.</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">3.3</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="avte-20240930xex3d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Bylaws of Jade Biosciences,&#160;Inc., as currently in effect.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">3.4*</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">Form&#160;of Bylaws of Jade Biosciences,&#160;Inc., a Nevada corporation, to be in effect upon completion of the redomestication.</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">3.5</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000110465921088918/tm2121331d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amended and Restated Certificate of Incorporation of Aerovate Therapeutics,&#160;Inc. (incorporated by reference to Exhibit&#160;3.1 to Aerovate Therapeutics,&#160;Inc.&#8217;s Current Report on Form&#160;8-K (File No.&#160;001-40544) filed with the SEC on July&#160;2, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">3.6</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000110465921088918/tm2121331d1_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws of Aerovate Therapeutics,&#160;Inc. (incorporated by reference to Exhibit&#160;3.2 to the Registrant&#8217;s Current Report on Form&#160;8-K (File No.&#160;001-40544) filed with the SEC on July&#160;2, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">4.1</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000110465921078871/tm2114556d4_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Investors&#8217; Rights Agreement among Aerovate Therapeutics,&#160;Inc. and certain of its stockholders, dated August&#160;5, 2020 (incorporated by reference to Exhibit&#160;4.2 to Aerovate Therapeutics,&#160;Inc.&#8217;s Registration Statement on Form&#160;S-1 (File No.&#160;333-256949) filed with the SEC on June&#160;9, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">4.2</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000110465921082643/tm2114556d8_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Specimen Common Stock Certificate of Aerovate Therapeutics,&#160;Inc. (incorporated by reference to Exhibit&#160;4.1 to Aerovate Therapeutics,&#160;Inc.&#8217;s Registration Statement on Form&#160;S-1A (File No.&#160;333-256949) filed with the SEC on June&#160;17, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">4.3</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000149315222008189/ex4-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Securities of Aerovate Therapeutics,&#160;Inc. (incorporated by reference to Exhibit&#160;4.3 to Aerovate Therapeutics,&#160;Inc.&#8217;s Annual Report on Form&#160;10-K (File No.&#160;001-40544) filed with the SEC on March&#160;30, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">5.1</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;">*</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">Opinion of Goodwin Procter LLP, counsel of Aerovate Therapeutics,&#160;Inc.</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">5.2</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;">*</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">Opinion of Gibson Dunn&#160;&amp; Crutcher LLP, counsel of Jade Biosciences,&#160;Inc.</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.1</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 3pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#ANNEXN_545330"><span style="font-style:normal;font-weight:normal;">Form&#160;of Aerovate Support Agreement (included as </span><i style="font-style:italic;font-weight:normal;">Annex N</i><span style="font-style:normal;font-weight:normal;"> to this proxy statement/prospectus and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.2</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#ANNEXO_872350"><span style="font-style:normal;font-weight:normal;">Form&#160;of Jade Support Agreement (included as </span><i style="font-style:italic;font-weight:normal;">Annex O</i><span style="font-style:normal;font-weight:normal;"> to this proxy statement/prospectus and incorporated herein by reference).</span></a></p></td></tr></table></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:7.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Description</b></p></th></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.3</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#ANNEXH_655067"><span style="font-style:normal;font-weight:normal;">Form&#160;of Lock-Up Agreement (included as </span><i style="font-style:italic;font-weight:normal;">Annex H</i><span style="font-style:normal;font-weight:normal;"> to this proxy statement/prospectus and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.4</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#ANNEXM_944480"><span style="font-style:normal;font-weight:normal;">Form&#160;of Securities Purchase Agreement (included as </span><i style="font-style:italic;font-weight:normal;">Annex M</i><span style="font-style:normal;font-weight:normal;"> to this proxy statement/prospectus and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.5</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000110465924112896/tm2427147d1_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Registration Rights Agreement (incorporated by reference to Exhibit&#160;10.5 to Aerovate Therapeutics,&#160;Inc.&#8217;s Current Report on Form&#160;8-K (File No.&#160;001-40544) filed with the SEC on October&#160;31, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.6#*</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">Form&#160;of Indemnification Agreement for directors and executive officers.</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.7#</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="avte-20240930xex10d7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Jade Biosciences,&#160;Inc. Amended and Restated 2024 Equity Incentive Plan and the Form&#160;of Stock Option Agreement thereunder.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.8#*</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">Jade Biosciences,&#160;Inc. 2025 Stock Incentive Plan.</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.9#*</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">Jade Biosciences,&#160;Inc. 2025 Employee Stock Purchase Plan.</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.10</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="avte-20240930xex10d10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Restricted Stock Purchase Agreement.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.11#</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="avte-20240930xex10d11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Offer Letter between Jade Biosciences,&#160;Inc. and Tom Frohlich, dated as of August&#160;20, 2024.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.12#</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="avte-20240930xex10d12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Offer Letter between Jade Biosciences,&#160;Inc. and Jonathan Quick, dated as of August&#160;29, 2024.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.13#</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="avte-20240930xex10d13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Offer Letter between Jade Biosciences,&#160;Inc. and Andrew King, dated as of July&#160;31, 2024.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">10.14#</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="avte-20240930xex10d14.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Offer Letter between Jade Biosciences,&#160;Inc. and Hetal Kocinsky, dated as of September&#160;3, 2024.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">10.15#</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="avte-20240930xex10d15.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Offer Letter between Jade Biosciences,&#160;Inc. and Elizabeth Balta, dated as of October&#160;21, 2024.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">10.16&#8224;&#8224;</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="avte-20240930xex10d16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Antibody Discovery and Option agreement, dated July&#160;24, 2024, by and between Paragon Therapeutics,&#160;Inc., Parade Biosciences Holding, LLC and Jade Biosciences,&#160;Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.17</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;">&#8224;&#8224;</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="avte-20240930xex10d17.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No.&#160;1 to Antibody Discovery and Option Agreement, dated as of September&#160;27, 2024.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.18</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;">&#8224;&#8224;</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="avte-20240930xex10d18.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Biologics Master Services Agreement, effective July&#160;10, 2024, by and between WuXi Biologics (Hong Kong) Limited) and Jade Biosciences,&#160;Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.19</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;">&#8224;&#8224;</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="avte-20240930xex10d19.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">APRIL&#160;License Agreement, dated October&#160;30, 2024, by and between Paragon Therapeutics,&#160;Inc. and Jade Biosciences,&#160;Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.20</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;">&#8224;&#8224;</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="avte-20240930xex10d20.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Cell Line License Agreement, effective October&#160;22, 2024, by and between WuXi Biologics Ireland Limited and Jade Biosciences,&#160;Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.21</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;">#</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000110465921078871/tm2114556d4_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Aerovate Therapeutics,&#160;Inc. 2018 Equity Incentive Plan, and form of award agreements thereunder (incorporated by reference to Exhibit&#160;10.1 to Aerovate Therapeutics,&#160;Inc.&#8217;s Registration Statement on Form&#160;S-1 (File No.&#160;333-256949) filed with the SEC on June&#160;9, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.22</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;">#</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000110465921082643/tm2114556d8_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Aerovate Therapeutics,&#160;Inc. 2021 Stock Option and Incentive Plan, and form of award agreements thereunder (incorporated by reference to Exhibit&#160;10.2 to Aerovate Therapeutics,&#160;Inc.&#8217;s Registration Statement on Form&#160;S-1A (File No.&#160;333-256949) filed with the SEC on June&#160;17, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.23</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;">#</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000110465921082643/tm2114556d8_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Aerovate Therapeutics,&#160;Inc. 2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit&#160;10.3 to Aerovate Therapeutics,&#160;Inc.&#8217;s Registration Statement on Form&#160;S-1A (File No.&#160;333-256949) filed with the SEC on June&#160;17, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.24</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;">#</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000110465921082643/tm2114556d8_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Aerovate Therapeutics,&#160;Inc. Non-Employee Director Compensation Policy (incorporated by reference to Exhibit&#160;10.4 to Aerovate Therapeutics&#160;Inc.&#8217;s Registration Statement on Form&#160;S-1A (File No.&#160;333-256949) filed with the SEC on June&#160;17, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.25</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;">#</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000110465921082643/tm2114556d8_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Indemnification Agreement between Aerovate Therapeutics,&#160;Inc. and each of its directors and executive officers (incorporated by reference to Exhibit&#160;10.5 to Aerovate Therapeutics&#160;Inc.&#8217;s Registration Statement on Form&#160;S-1A (File No.&#160;333-256949) filed with the SEC on June&#160;17, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.26</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;">#</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000110465921082643/tm2114556d8_ex10-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Aerovate Therapeutics,&#160;Inc. Form&#160;of Employment Agreement (incorporated by reference to Exhibit&#160;10.6 to Aerovate Therapeutics,&#160;Inc.&#8217;s Registration Statement on Form&#160;S-1A (File No.&#160;333-256949) filed with the SEC on June&#160;17, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.27</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;">#</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000110465921082643/tm2114556d8_ex10-10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Senior Executive Cash Incentive Bonus Plan (incorporated by reference to Exhibit&#160;10.10 to Aerovate Therapeutics,&#160;Inc.&#8217;s Registration Statement on Form&#160;S-1A (File No.&#160;333-256949) filed with the SEC on June&#160;17, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.28</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000110465921104289/tm2125007d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease, dated August&#160;6, 2021, by and between Aerovate Therapeutics,&#160;Inc. and PDM 930 Unit, LLC (incorporated by reference to Exhibit&#160;10.1 to Aerovate Therapeutics,&#160;Inc.&#8217;s Current Report on Form&#160;8-K (File No.&#160;001-40544) filed with the SEC on August&#160;12, 2021).</span></a></p></td></tr></table></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:7.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Description</b></p></th></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.29</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000155837024007985/tmb-20240331xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease Amendment, dated January&#160;2, 2024, by and between Aerovate Therapeutics,&#160;Inc. and PDM 930 Unit,&#160;LLC. (incorporated by reference to Exhibit&#160;10.1 to Aerovate Therapeutics,&#160;Inc.&#8217;s Quarterly Report on Form&#160;10-Q (File No.&#160;001-40544) filed with the SEC on May&#160;13, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.30</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000149315222011470/ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease, dated April&#160;26, 2022, by and between Aerovate Therapeutics,&#160;Inc. and Hudson Metro Center, LLC (incorporated by reference to Exhibit&#160;10.1 to Aerovate Therapeutics,&#160;Inc.&#8217;s Current Report on Form&#160;8-K (File No.&#160;001-40544) filed with the SEC on April&#160;29, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.31</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000179874923000023/tmb-20230405xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">ATM Equity Offering</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">SM </sup><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Sales Agreement, dated as of April&#160;5, 2023, by and between Aerovate Therapeutics,&#160;Inc. and BofA Securities,&#160;Inc. (incorporated by reference to Exhibit&#160;10.1 to Aerovate Therapeutics,&#160;Inc.&#8217;s Current Report on Form&#160;8-K (File No.&#160;001-40544) filed with the SEC on April&#160;5, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">10.32</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000179874924000059/tmb-20240930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Separation and Release Agreement, dated as of August&#160;15, 2024, by and between Aerovate Therapeutics,&#160;Inc. and Timothy Pigot (incorporated by reference to Exhibit&#160;10.1 to Aerovate Therapeutics,&#160;Inc.&#8217;s Quarterly Report on Form&#160;10-Q (File No.&#160;001-40544) filed with the SEC on November&#160;12, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">21.1</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1798749/000149315222008189/ex21-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">List of Subsidiaries of Aerovate Therapeutics,&#160;Inc. (incorporated by reference to Exhibit&#160;21.1 to Aerovate Therapeutics,&#160;Inc.&#8217;s Annual Report on Form&#160;10-K (File No.&#160;001-40544) filed with the SEC on March&#160;30, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">23.1</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="avte-20240930xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm of Jade Biosciences,&#160;Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">23.2</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="avte-20240930xex23d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of KPMG LLP, independent registered public accounting firm of Aerovate Therapeutics,&#160;Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">23.3</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="avte-20240930xex23d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Lucid Capital Markets LLC.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">23.4*</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">Consent of Goodwin Procter LLP (included in Exhibit&#160;5.1).</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">23.5*</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">Consent of Gibson Dunn&#160;&amp; Crutcher LLP (included in Exhibit&#160;5.2).</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">24.1</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#SIGNATURES_155921"><span style="font-style:normal;font-weight:normal;">Power of Attorney (included on signature page).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">99.1</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="avte-20240930xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Eric Dobmeier to serve as a director of Aerovate Therapeutics,&#160;Inc., to be renamed Jade Biosciences,&#160;Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">99.2</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="avte-20240930xex99d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Tomas Kiselak to serve as a director of Aerovate Therapeutics,&#160;Inc., to be renamed Jade Biosciences,&#160;Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">99.3</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="avte-20240930xex99d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Chris Cain to serve as a director of Aerovate Therapeutics,&#160;Inc., to be renamed Jade Biosciences,&#160;Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">99.4</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="avte-20240930xex99d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Lawrence Klein to serve as a director of Aerovate Therapeutics,&#160;Inc., to be renamed Jade Biosciences,&#160;Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">99.5</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="avte-20240930xex99d5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Tom Frohlich to serve as a director of Aerovate Therapeutics,&#160;Inc., to be renamed Jade Biosciences,&#160;Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">99.6</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="avte-20240930xex99d6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Erin Lavelle to serve as a director of Aerovate Therapeutics,&#160;Inc., to be renamed Jade Biosciences,&#160;Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">101.INS</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Inline XBRL Instance Document</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">101.SCH</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Inline XBRL Taxonomy Extension Schema Document</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">101.CAL</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;">Inline  XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">101.DEF</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">101.LAB</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">101.PRE</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Inline XBRL Taxonomy Presentation Linkbase Document</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">104</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Cover Page Interactive Data File. Formatted in Inline XBRL and contained in exhibit 101.</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">107</span></p></td><td style="vertical-align:top;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="avte-20240930xexfees.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Filing Fee Table.</span></a></p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;">&#8224;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;">The annexes, schedules, and certain exhibits to the Merger Agreement have been omitted pursuant to Item&#160;601(b)(2)&#160;of Regulation S-K. Aerovate hereby agrees to furnish supplementally a copy of any omitted annex, schedule or exhibit to the Commission upon request.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;">&#8224;&#8224;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;">Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules&#160;of the Securities and Exchange Commission.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;">#</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;">Indicates a management contract or compensatory plan.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">To be filed by amendment.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_8b1c5517_9371_4f2b_b7bc_d047330c0877"></a><a id="SIGNATURES_155921"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized on this second day of December, 2024.</p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">AEROVATE THERAPEUTICS,&#160;INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">By:</span></p></td><td style="vertical-align:bottom;width:46.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">/s/ Timothy P. Noyes</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:46.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Name: Timothy P. Noyes</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Title: Chief Executive Officer</span></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Timothy P. Noyes and George A. Eldridge, and each or any one of them, as his or her true and lawful attorney-in-fact and agent, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Act, this report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:25.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Signature</b></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:41.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Title</b></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:27.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.27%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">/s/ Timothy P. Noyes</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Chief Executive Officer and Director</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">December&#160;2, 2024</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Timothy P. Noyes</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">(</span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Principal Executive Officer</i><span style="font-family:'Times New Roman','Times','serif';">)</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">/s/ George A. Eldridge</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Chief Financial Officer</span><span style="font-family:'Times New Roman','Times','serif';"><br/></span><span style="font-family:'Times New Roman','Times','serif';">(</span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Principal Financial Officer</i><span style="font-family:'Times New Roman','Times','serif';"> </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">and</i></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">December&#160;2, 2024</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">George A. Eldridge</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Principal Accounting Officer</i><span style="font-family:'Times New Roman','Times','serif';">)</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">/s/ Habib Dable</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Director</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">December&#160;2, 2024</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Habib Dable</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">/s/ Allison Dorval</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Director</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">December&#160;2, 2024</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Allison Dorval</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">/s/ David Grayzel, M.D.</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Director</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">December&#160;2, 2024</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">David Grayzel, M.D.</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">/s/ Mark Iwicki</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Director</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">December&#160;2, 2024</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Mark Iwicki</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">/s/ Joshua Resnick, M.D.</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Director</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">December&#160;2, 2024</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Joshua Resnick, M.D.</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">/s/ Donald J. Santel</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Director</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">December&#160;2, 2024</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Donald J. Santel</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>avte-20240930xex3d1.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 12/3/2024 12:41:34 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 3.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATE OF INCORPORATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES,&#8239;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#8239;I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NAME OF CORPORATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>The name of this corporation (the &#8220;<b style="font-weight:bold;">Corporation</b>&#8221;) is Jade Biosciences,&#8239;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">&#8239;ARTICLE&#8239;II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REGISTERED OFFICE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>The address of the registered office of the Corporation in the State of Delaware is Corporation Trust Company, 1209 Orange Street, in the city of Wilmington, New Castle County, Delaware 19801. The name of its registered agent at such address is The Corporation Trust Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">&#8239;ARTICLE&#8239;III</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PURPOSE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware (the &#8220;<b style="font-weight:bold;">DGCL</b>&#8221;), as the same exists or as may hereafter be amended from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#8239;<b style="font-weight:bold;">ARTICLE&#8239;IV</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AUTHORIZED CAPITAL STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>The total number of shares of all classes of stock which the Corporation shall have the authority to issue is 60,000,000. The Corporation has two classes of stock, referred to as Common Stock and Preferred Stock. There are 40,000,000 shares of authorized Common Stock, $0.0001 par value per share (&#8220;<b style="font-weight:bold;">Common Stock</b>&#8221;), and 20,000,000 shares of authorized Preferred Stock, $0.0001 par value per share (&#8220;<b style="font-weight:bold;">Preferred Stock</b>&#8221;), all of which are hereby designated as &#8220;<b style="font-weight:bold;">Series&#8239;Seed Preferred Stock</b>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>The following is a statement of the designations and the powers, preferences and special rights, and the qualifications, limitations or restrictions thereof in respect of each class of capital stock of the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">A.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">COMMON STOCK</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise indicated, references to &#8220;Sections&#8221; in this Part&#8239;A of this Article&#8239;IV refer to sections of Part&#8239;A of this Article&#8239;IV.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General</u>. The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by the rights, powers, preferences and special rights of the holders of the Preferred Stock set forth herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8239;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Voting</u>. Except as otherwise provided herein or by applicable law, the holders of the Common Stock are entitled to one (1)&#8239;vote for each share of Common Stock held as of the applicable record date for each meeting of stockholders (and written actions in lieu of meetings). The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by (in addition to any vote of the holders of one (1)&#8239;or more series of Preferred Stock that may be required by the terms of this Certificate of Incorporation) the affirmative vote of the holders of shares of capital stock of the Corporation representing a majority of the votes represented by all outstanding shares of capital stock of the Corporation entitled to vote, irrespective of the provisions of Section&#8239;242(b)(2)&#8239;of the DGCL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8239;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dilution Events</u>. Upon each Dilution Event, the Corporation shall, for no additional consideration, grant shares of Common Stock to each of Paragon Therapeutics,&#8239;Inc. and Parade Biosciences Holding LLC (collectively, the &#8220;<b style="font-weight:bold;">Paragon Entities</b>&#8221;) pursuant to a Subscription Agreement with the same terms and conditions as set forth in such Paragon Entity&#8217;s initial Subscription Agreement or Contribution Agreement, as applicable, such that the aggregate Common Stock owned by each such Paragon Entity after such Dilution Event is equal to 10.00% of the sum of (A)&#8239;the Preferred Stock issued and outstanding (on an as-converted to Common Stock basis) and (B)&#8239;the Common Stock issued and outstanding; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u> that such sum shall exclude (X)&#8239;any shares of Common Stock underlying any options issued pursuant to the Corporation&#8217;s 2024 Equity Incentive Plan, as amended from time to time (the &#8220;<b style="font-weight:bold;">EIP</b>&#8221;), (Y)&#8239;any shares of Common Stock reserved by the Corporation for issuance under the EIP and (Z)&#8239;any shares of Common Stock issued to individuals (or entities designated by such individuals) in contemplation of employment, advisory, consulting or director services to be provided by such individuals. For purposes of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;3</u>, &#8220;<b style="font-weight:bold;">Dilution Event</b>&#8221; means any sale of the Corporation&#8217;s equity securities made after the date hereof solely to Fairmount Healthcare Fund II, L.P. and/or its affiliates, up to an aggregate sale amount of $20,000,000. For the avoidance of doubt, the issuance of equity securities pursuant to the Corporation&#8217;s EIP, shall not be considered a Dilution Event.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="white-space:pre-wrap;">&#8239;B.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">PREFERRED STOCK</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>The shares of the Preferred Stock shall have the powers, preferences and special rights set forth in this Part&#8239;B of this Article&#8239;IV. Unless otherwise indicated, references to &#8220;Sections&#8221; in this Part&#8239;B of this Article&#8239;IV refer to sections of Part&#8239;B of this Article&#8239;IV. References to &#8220;Preferred Stock&#8221; mean the Series&#8239;Seed Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dividends</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>The Corporation shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Corporation (other than dividends on shares of Common Stock payable in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere in this Certificate of Incorporation) the holders of the Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Preferred Stock in an amount at least equal to (i)&#8239;in the case of a dividend on Common Stock or any class or series that is convertible into Common Stock, that dividend per share of Preferred Stock as would equal the product of (A)&#8239;the dividend payable on each share of such class or series determined, if applicable, as if all shares of such class or series had been converted into Common Stock and (B)&#8239;the number of shares of Common Stock issuable upon conversion of a share of such Preferred Stock, in each case calculated on the record date for determination of holders entitled to receive such dividend or (ii)&#8239;in the case of a dividend on any class or series that is not convertible into Common Stock, at a rate per share of Preferred Stock determined by (A)&#8239;dividing the amount of the dividend payable on each share of such class or series of capital stock by the original issuance price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to such class or series) and (B)&#8239;multiplying such fraction by an amount equal to the applicable Original Issue Price (as defined below); <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u> that, if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than one (1)&#8239;class or series of capital stock of the Corporation, the dividend payable to the holders of a series of Preferred Stock pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;1</u> shall be calculated based upon the dividend on the class or series of capital stock that would result in the highest dividend for such series of Preferred Stock. The &#8220;<b style="font-weight:bold;">Original Issue Price</b>&#8221; shall mean, with respect to the Series&#8239;Seed Preferred Stock, $0.0001 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the applicable Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8239;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Liquidation, Dissolution or Winding Up; Certain Mergers, Consolidations and Asset Sales</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Preferential Payments to Holders of Preferred Stock</u>. In the event of (a)&#8239;any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of shares of Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders or (b)&#8239;a Deemed Liquidation Event (as defined below), out of the consideration payable to stockholders in such Deemed Liquidation Event or the Available Proceeds (as defined below), before any payment shall be made to the holders of Common Stock by reason of their ownership thereof, an amount per share equal to the greater of (i)&#8239;one (1)&#8239;times the Original Issue Price, plus any dividends declared but unpaid thereon, or (ii)&#8239;such amount per share as would have been payable had all shares of Preferred Stock been converted into Common Stock pursuant to Section&#8239;&#8206;4 immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event (the amount payable pursuant to this sentence is hereinafter referred to as the &#8220;<b style="font-weight:bold;">Liquidation Amount</b>&#8221;). If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of shares of Preferred Stock the full amount to which they shall be entitled under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;2.1</u>, the holders of shares of Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payments to Holders of Common Stock</u>. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, after the payment in full of all Liquidation Amounts required to be paid to the holders of shares of Preferred Stock, the remaining assets of the Corporation available for distribution to its stockholders or, in the case of a Deemed Liquidation Event, the consideration not payable to the holders of shares of Preferred Stock pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;2.1</u> or the remaining Available Proceeds, as the case may be, shall be distributed among the holders of shares of Common Stock, pro rata based on the number of shares held by each such holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Deemed Liquidation Events</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">2.3.1<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definition</u>. Each of the following events shall be considered a &#8220;<b style="font-weight:bold;">Deemed Liquidation Event</b>&#8221; unless the holders of at least a majority of the outstanding shares of Preferred Stock, voting together as a single class on an as-converted to Common Stock basis (the &#8220;<b style="font-weight:bold;">Requisite Holders</b>&#8221;), elect otherwise by affirmative vote or written notice:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(a)<font style="display:inline-block;width:24.9pt;"></font>a merger, consolidation, statutory conversion, transfer, domestication or continuance, in each case with a person or persons other than those that, directly or indirectly, control, are controlled by or under common control with the Corporation (each an &#8220;<b style="font-weight:bold;">Affiliate</b>&#8221;), and in which</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the Corporation is a constituent party or</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital stock pursuant to such merger, consolidation, statutory conversion, transfer, domestication or continuance,</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>except any such merger, consolidation, statutory conversion, transfer, domestication or continuance involving the Corporation or a subsidiary in which the shares of capital stock of the Corporation outstanding immediately prior to such merger, consolidation, statutory conversion, transfer, domestication, or continuance continue to represent, or are converted into or exchanged for shares of capital stock or other equity interests that represent, immediately following such merger, consolidation, statutory conversion, transfer, domestication or continuance, at least a majority, by voting power, of the capital stock of (1)&#8239;the surviving or resulting corporation or entity; or (2)&#8239;if the surviving or resulting corporation or entity is a wholly owned subsidiary of another corporation immediately following such merger, consolidation, statutory conversion, transfer, domestication or continuance, the parent corporation or entity of such surviving or resulting corporation or entity; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(b)<font style="display:inline-block;width:24.34pt;"></font>(1)&#8239;the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Corporation or any subsidiary of the Corporation of all or substantially all the assets or intellectual property (other than a license in a field of use not central to the Corporation&#8217;s business) of the Corporation and its subsidiaries taken as a whole to persons that are not directly or indirectly Affiliates of the Corporation or (2)&#8239;the sale, lease, transfer, exclusive license or other disposition (whether by merger, consolidation, statutory conversion, transfer, domestication or continuance or otherwise, and whether in a single transaction or a series of related transactions) of one (1)&#8239;or more subsidiaries of the Corporation if substantially all of the assets of the Corporation and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries to persons that are not directly or indirectly Affiliates of the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">2.3.2<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effecting a Deemed Liquidation Event</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(a)<font style="display:inline-block;width:24.9pt;"></font>The Corporation shall not have the power to effect a Deemed Liquidation Event referred to in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;2.3.1(a)(i)</u>&#8239;unless the agreement or plan with respect to such transaction, or terms of such transaction (any such agreement, plan or terms, the &#8220;<b style="font-weight:bold;">Transaction Document</b>&#8221;), provides that the consideration payable to the stockholders of the Corporation in such Deemed Liquidation Event shall be allocated to the holders of capital stock of the Corporation in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections &#8206;2.1</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;2.2.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(b)<font style="display:inline-block;width:24.34pt;"></font>In the event of a Deemed Liquidation Event referred to in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;2.3.1(a)(ii)</u>&#8239;or &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.3.1(b)</u>, if the Corporation does not effect a dissolution of the Corporation under the General Corporation Law within ninety (90) days after such Deemed Liquidation Event, then (i)&#8239;the Corporation shall send a written notice to each holder of Preferred Stock no later than the ninetieth (90<sup style="font-size:7.5pt;vertical-align:top;">th</sup>) day after the Deemed Liquidation Event advising such holders of their right (and the requirements to be met to secure such right) pursuant to the terms of the following clause (ii)&#8239;to require the redemption of such shares of Preferred Stock, and (ii)&#8239;if the Requisite Holders so request in a written instrument delivered to the Corporation not later than one hundred twenty (120) days after such Deemed Liquidation Event, the Corporation shall use the consideration received by the Corporation for such Deemed Liquidation Event (net of any retained liabilities associated with the assets sold or technology licensed, any other expenses reasonably related to such Deemed Liquidation Event or any other expenses incident to the dissolution of the Corporation as provided herein, in each case as determined in good faith by the Board of Directors of the Corporation (the &#8220;<b style="font-weight:bold;">Board of Directors</b>&#8221;))<b style="font-weight:bold;">, </b>together with any other assets of the Corporation available for distribution to its stockholders, all to the extent permitted by Delaware law governing distributions to stockholders (the &#8220;<b style="font-weight:bold;">Available Proceeds</b>&#8221;), on the one hundred fiftieth (150<sup style="font-size:7.5pt;vertical-align:top;">th</sup>) day after such Deemed Liquidation Event (the &#8220;<b style="font-weight:bold;">DLE Redemption Date</b>&#8221;), to redeem all outstanding shares of Preferred Stock at a price per share equal to the applicable Liquidation Amount; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, that if the definitive agreements governing such Deemed Liquidation Event contain contingent indemnification obligations on the part of the Corporation and prohibit the Corporation from distributing all or a portion of the Available Proceeds while such indemnification obligations remain outstanding, then the DLE Redemption Date shall automatically be extended to the date that is ten (10)&#8239;business days following the date on which such prohibition expires. Notwithstanding the foregoing, in the event of a redemption pursuant to the preceding sentence, if the Available Proceeds are not sufficient to redeem all outstanding shares of Preferred Stock, the Corporation shall redeem a pro rata portion of each holder&#8217;s shares of Preferred Stock to the fullest extent of such Available Proceeds, based on the respective amounts which would otherwise be payable in respect of the shares to be redeemed if the Available Proceeds were sufficient to redeem all such shares, and shall redeem the remaining shares as soon as it may lawfully do so under Delaware law governing distributions to stockholders. Prior to the distribution or redemption provided for in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;2.3.2&#8206;(b)</u>, the Corporation shall not expend or dissipate the Available Proceeds for any purpose, except to discharge expenses incurred in connection with such Deemed Liquidation Event. In connection with a distribution or redemption provided for in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;2.3.2</u>, the Corporation shall send written notice of the redemption (the &#8220;<b style="font-weight:bold;">Redemption Notice</b>&#8221;) to each holder of record of Preferred Stock. Each Redemption Notice shall state:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:216pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the number of shares of Preferred Stock held by the holder that the Corporation shall redeem on the date specified in the Redemption Notice;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:216pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the redemption date and the price per share at which the shares of Preferred Stock are being redeemed; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:216pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">for holders of shares in certificated form, that the holder is to surrender to the Corporation, in the manner and at the place designated, his, her or its certificate or certificates representing the shares of Preferred Stock to be redeemed.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>If the Redemption Notice shall have been duly given, and if payment is tendered or deposited with an independent payment agent so as to be available therefor in a timely manner, then notwithstanding that any certificates evidencing any of the shares of Preferred Stock so called for redemption shall not have been surrendered, all rights with respect to such shares shall forthwith after the date terminate, except only the right of the holders to receive the payment without interest upon surrender of any such certificate or certificates therefor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">2.3.3<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amount Deemed Paid or Distributed</u>. The amount deemed paid or distributed to the holders of capital stock of the Corporation upon any such merger, consolidation, sale, transfer, exclusive license, other disposition or redemption shall be the cash or the value of the property, rights or securities to be paid or distributed to such holders pursuant to such Deemed Liquidation Event. The value of such property, rights or securities shall be determined in good faith by the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">2.3.4<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Allocation of Escrow and Contingent Consideration</u>. In the event of a Deemed Liquidation Event pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;2.3.1&#8206;(a)&#8206;(i)</u>, if any portion of the consideration payable to the stockholders of the Corporation is payable only upon satisfaction of contingencies (the &#8220;<b style="font-weight:bold;">Additional Consideration</b>&#8221;), the Transaction Document shall provide that (a)&#8239;the portion of such consideration that is not Additional Consideration (such portion, the &#8220;<b style="font-weight:bold;">Initial Consideration</b>&#8221;) shall be allocated among the holders of capital stock of the Corporation in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections &#8206;2.1</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;2.2</u> as if the Initial Consideration were the only consideration payable in connection with such Deemed Liquidation Event; and (b)&#8239;any Additional Consideration which becomes payable to the stockholders of the Corporation upon satisfaction of such contingencies shall be allocated among the holders of capital stock of the Corporation in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections &#8206;2.1</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;2.2</u> after taking into account the previous payment of the Initial Consideration as part of the same transaction. For the purposes of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;2.3.4</u>, consideration placed into escrow or retained as a holdback to be available for satisfaction of indemnification or similar obligations in connection with such Deemed Liquidation Event shall be deemed to be Additional Consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Voting</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General</u>. On any matter presented to the stockholders of the Corporation for their action or consideration at any meeting of stockholders of the Corporation (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Preferred Stock held by such holder are convertible (as provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;4</u> below) as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of this Certificate of Incorporation, holders of Preferred Stock shall vote together with the holders of Common Stock as a single class and on an as-converted to Common Stock basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Election of Directors</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">3.2.1<font style="display:inline-block;width:16pt;"></font>The holders of record of the shares of Preferred Stock, voting together exclusively and as a separate class on an as-converted to Common Stock basis, shall be entitled to elect one (1)&#8239;director of the Corporation (the &#8220;<b style="font-weight:bold;">Preferred Director</b>&#8221;) and the holders of record of the shares of Common Stock and of any other class or series of voting stock (including the Preferred Stock), exclusively and voting together as a single class on an as-converted to Common Stock basis, shall be entitled to elect the balance of the total number of directors of the Corporation (the &#8220;<b style="font-weight:bold;">At-Large Directors</b>&#8221;); <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, for administrative convenience, the initial Preferred Director may also be appointed by the Board of Directors in connection with the approval of the initial issuance of Preferred Stock without a separate action by the holders of Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">3.2.2<font style="display:inline-block;width:16pt;"></font>Any director elected as provided in the <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;3.2.1</u> may be removed without cause by, and only by, the affirmative vote of the holders of a majority of the shares of the class or series of capital stock entitled to elect such director or directors, voting together as a single class on an as-converted to Common Stock basis, given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">3.2.3</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(a)<font style="display:inline-block;width:24.9pt;"></font>If the holders of shares of Preferred Stock fail to elect a sufficient number of directors to fill all directorships for which they are entitled to elect directors, pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;3.2.1</u> (and to the extent any of such directorships is not otherwise filled by a director appointed in accordance with the proviso in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;3.2.1)</u>, then any directorship not so filled shall remain vacant until such time as the holders of the Preferred Stock fill such directorship in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;3.2.1</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(b)<font style="display:inline-block;width:24.34pt;"></font>A vacancy in any At-Large Director seat can be filled by either (A)&#8239;the vote or written consent in lieu of a meeting of the stockholders entitled elect the At-Large Directors, or (B)&#8239;the vote or written consent in lieu of a meeting of a majority of the remaining director(s).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">3.2.4<font style="display:inline-block;width:16pt;"></font>At any meeting held for the purpose of electing a director, the presence in person or by proxy of the holders of a majority of the outstanding shares of the Common Stock and of any other class or series of capital stock entitled to elect such director shall constitute a quorum for the purpose of electing such director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Preferred Stock Protective Provisions</u>. At any time when shares of Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Preferred Stock) are outstanding, the Corporation shall not, either directly or indirectly by amendment, merger, consolidation, domestication, transfer, continuance, recapitalization, reclassification, waiver, statutory conversion, or otherwise, effect any of the following acts or transactions without (in addition to any other vote required by law or this Certificate of Incorporation) the written consent or affirmative vote of the Requisite Holders and any such&#8239;act or transaction that has not been approved by such consent or vote prior to such act or transaction being effected shall be null and void <i style="font-style:italic;">ab initio</i>, and of no force or effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">3.3.1<font style="display:inline-block;width:16pt;"></font>liquidate, dissolve or wind-up the business and affairs of the Corporation or effect any Deemed Liquidation Event or any other merger, consolidation, statutory conversion, transfer, domestication or continuance or consent to any of the foregoing;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">3.3.2<font style="display:inline-block;width:16pt;"></font>amend, alter or repeal any provision of this Certificate of Incorporation or Bylaws of the Corporation (the &#8220;<b style="font-weight:bold;">Bylaws</b>&#8221;) in a manner that adversely affects the special rights, powers and preferences of the Preferred Stock (or any series thereof);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">3.3.3<font style="display:inline-block;width:16pt;"></font>create, or authorize the creation of, or issue or obligate itself to issue shares of, or reclassify, any capital stock unless the same ranks junior to the Preferred Stock with respect to its special rights, powers and preferences;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">3.3.4<font style="display:inline-block;width:16pt;"></font>increase the authorized number of shares of Preferred Stock or any additional class or series of capital stock of the Corporation unless the same ranks junior to the Preferred Stock with respect to its rights, preferences and privileges;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">3.3.5<font style="display:inline-block;width:16pt;"></font>purchase or redeem (or permit any subsidiary to purchase or redeem) or pay or declare any dividend or make any distribution on, any shares of capital stock of the Corporation other than (i)&#8239;redemptions of or dividends or distributions on the Preferred Stock as expressly authorized herein, (ii)&#8239;dividends or other distributions payable on the Common Stock solely in the form of additional shares of Common Stock and (iii)&#8239;repurchases of stock from former employees, officers, directors, consultants or other persons who performed services for the Corporation or any subsidiary in connection with the cessation of such employment or service at no greater than the original purchase price thereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">3.3.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;create, or hold capital stock in, any subsidiary that is not wholly owned (either directly or through one (1)&#8239;or more other subsidiaries) by the Corporation, or permit any subsidiary to create, or authorize the creation of, or issue or obligate itself to issue, any shares of any class or series of capital stock, or sell, transfer or otherwise dispose of any capital stock of any direct or indirect subsidiary of the Corporation, or permit any direct or indirect subsidiary to sell, lease, transfer, exclusively license or otherwise dispose (in a single transaction or series of related transactions) of all or substantially all of the assets of such subsidiary, in each case without the approval of the Board of Directors; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">3.3.7<font style="display:inline-block;width:16pt;"></font>enter into any agreement or otherwise obligate the Corporation or any subsidiary to do any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Optional Conversion</u>. The holders of the Preferred Stock shall have conversion rights as follows (the &#8220;<b style="font-weight:bold;">Conversion Rights</b>&#8221;):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right to Convert</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.1.1<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conversion Ratio</u>. Each share of Preferred Stock shall be convertible, at the option of the holder thereof, at any time, and without the payment of additional consideration by the holder thereof, into such whole number of fully paid and non-assessable shares of Common Stock (calculated as provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;4.2</u> below) as is determined by dividing the applicable Original Issue Price by the applicable Conversion Price (as defined below) in effect at the time of conversion. The &#8220;<b style="font-weight:bold;">Conversion Price</b>&#8221; applicable to the Series&#8239;Seed Preferred Stock as of the Original Issue Date shall be equal to $0.0001 per share. Such initial Conversion Price for a series of Preferred Stock, and the rate at which shares of Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment as provided in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;4</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.1.2<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Conversion Rights</u>. In the event of a liquidation, dissolution or winding up of the Corporation or a Deemed Liquidation Event, the Conversion Rights shall terminate at the close of business on the last full day preceding the date fixed for the payment of any such amounts distributable on such event to the holders of Preferred Stock; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u> that the foregoing termination of Conversion Rights shall not affect the amount(s)&#8239;otherwise paid or payable in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;2.1</u> to the holders of Preferred Stock pursuant to such liquidation, dissolution or winding up of the Corporation or a Deemed Liquidation Event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Number of Shares Issuable Upon Conversion</u>. The number of shares of Common Stock issuable to a holder of Preferred Stock upon conversion of such Preferred Stock shall be rounded to the nearest whole share. For the avoidance of doubt, no fractional interests in shares of Common Stock shall be created or issuable as a result of the conversion of the Preferred Stock pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;4.1.1</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mechanics of Conversion</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.3.1<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Conversion</u>. In order for a holder of Preferred Stock to voluntarily convert shares of Preferred Stock into shares of Common Stock, such holder shall (a)&#8239;provide written notice to the Corporation&#8217;s transfer agent at the office of the transfer agent for the Preferred Stock (or at the principal office of the Corporation if the Corporation serves as its own transfer agent) that such holder elects to convert all or any number of such holder&#8217;s shares of Preferred Stock and, if applicable, any event on which such conversion is contingent and (b), if such holder&#8217;s shares are certificated, surrender the certificate or certificates for such shares of Preferred Stock (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate), at the office of the transfer agent for the Preferred Stock (or at the principal office of the Corporation if the Corporation serves as its own transfer agent). Such notice shall state such holder&#8217;s name or the names of the nominees in which such holder wishes the shares of Common Stock to be issued. If required by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by a written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or his, her or its attorney duly authorized in writing. The close of business on the date of receipt by the transfer agent (or by the Corporation if the Corporation serves as its own transfer agent) of such notice and, if applicable, certificates (or lost certificate affidavit and agreement) shall be the time of conversion (the &#8220;<b style="font-weight:bold;">Conversion Time</b>&#8221;), and the shares of Common Stock issuable upon conversion of the specified shares shall be deemed to be outstanding of record as of such date. The Corporation shall, as soon as practicable after the Conversion Time (i)&#8239;issue and deliver to such holder of Series&#8239;Seed Preferred Stock, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable upon such conversion in accordance with the provisions hereof and a certificate for the number (if any) of the shares of Series&#8239;Seed Preferred Stock represented by any surrendered certificate that were not converted into Common Stock, and (ii)&#8239;pay all declared but unpaid dividends on the shares of Preferred Stock converted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.3.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reservation of Shares</u>. The Corporation shall at all times when the Preferred Stock shall be outstanding, reserve and keep available out of its authorized but unissued capital stock, for the purpose of effecting the conversion of the Preferred Stock, such number of its duly authorized shares of Common Stock as shall from time to time be sufficient to effect the conversion of all outstanding Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding shares of the Preferred Stock, the Corporation shall take such corporate action as may be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes, including, without limitation, engaging in best efforts to obtain the requisite stockholder approval of any necessary amendment to this Certificate of Incorporation. Before taking any action that would cause an adjustment reducing the Conversion Price for any series of Preferred Stock below the then par value of the shares of Common Stock issuable upon conversion of such series of Preferred Stock, the Corporation will take any corporate action which may, in the opinion of its counsel, be necessary in order that the Corporation may validly and legally issue fully paid and non-assessable shares of Common Stock at such adjusted Conversion Price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.3.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effect of Conversion</u>. All shares of Preferred Stock which shall have been surrendered for conversion as herein provided shall no longer be deemed to be outstanding and all rights with respect to such shares shall immediately cease and terminate at the Conversion Time, except only the right of the holders thereof to receive shares of Common Stock in exchange therefor and to receive payment of any dividends declared but unpaid thereon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.3.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Further Adjustment</u>. Upon any such conversion, no adjustment to the Conversion Price shall be made for any declared but unpaid dividends on the Preferred Stock surrendered for conversion or on the Common Stock delivered upon conversion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.3.5<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Taxes</u>. The Corporation shall pay any and all issue and other similar taxes that may be payable in respect of any issuance or delivery of shares of Common Stock upon conversion of shares of Preferred Stock pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;4</u>. The Corporation shall not, however, be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of shares of Common Stock in a name other than that in which the shares of Preferred Stock so converted were registered, and no such issuance or delivery shall be made unless and until the person or entity requesting such issuance has paid to the Corporation the amount of any such tax or has established, to the satisfaction of the Corporation, that such tax has been paid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.4</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjustments to Preferred Stock Conversion Price for Diluting Issues</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.4.1<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Special Definitions</u>. For purposes of this Article&#8239;IV, the following definitions shall apply:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(a)<font style="display:inline-block;width:24.9pt;"></font>&#8220;<b style="font-weight:bold;">Additional Shares of Common Stock</b>&#8221; means all shares of Common Stock issued (or, pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;4.4.3</u> below, deemed to be issued) by the Corporation after the Original Issue Date (as defined below), other than (1)&#8239;the following shares of Common Stock and (2)&#8239;shares of Common Stock deemed issued pursuant to the following Options and Convertible Securities (clauses (1)&#8239;and (2), collectively, &#8220;<b style="font-weight:bold;">Exempted Securities</b>&#8221;):</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">as to any series of Preferred Stock shares of Common Stock, Options or Convertible Securities issued as a dividend or distribution on such series of Preferred Stock (including dividends payable in connection with dividends on other classes or series of stock);</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">shares of Common Stock, Options or Convertible Securities issued by reason of a dividend, stock split, split-up or other distribution on shares of Common Stock that is covered by <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;4.5</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;4.6</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;4.7</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;4.8</u><b style="font-weight:bold;">;</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">shares of Common Stock or Options issued to employees or directors of, or consultants or advisors to, the Corporation or any of its subsidiaries pursuant to a plan, agreement or arrangement approved (i)&#8239;prior to the Original Issue Date or (ii)&#8239;by the Board of Directors;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(iv)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">shares of Common Stock or Convertible Securities actually issued upon the exercise of Options or shares of Common Stock actually issued upon the conversion or exchange of Convertible Securities, in each case provided such issuance is pursuant to the terms of such Option or Convertible Security;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(v)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">shares of Common Stock, Options or Convertible Securities issued to banks, equipment lessors or other financial institutions, or to real property lessors, pursuant to a debt financing, equipment leasing or real property leasing transaction approved by the Board of Directors;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(vi)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">shares of Common Stock, Options or Convertible Securities issued to suppliers or third-party service providers in connection with the provision of goods or services pursuant to transactions approved by the Board of Directors;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(vii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">shares of Common Stock, Options or Convertible Securities issued as acquisition consideration pursuant to the acquisition of another corporation by the Corporation by merger, purchase of substantially all of the assets or other reorganization or to a joint venture agreement, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u> that such issuances are approved by the Board of Directors; or</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(viii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">shares of Common Stock, Options or Convertible Securities issued in connection with sponsored research, collaboration, technology license, development, OEM, marketing or other similar agreements or strategic partnerships approved by the Board of Directors.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(b)<font style="display:inline-block;width:24.34pt;"></font>&#8220;<b style="font-weight:bold;">Convertible Securities</b>&#8221; means any evidences of indebtedness, shares or other securities directly or indirectly convertible into or exchangeable for Common Stock, but excluding Options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(c)<font style="display:inline-block;width:24.9pt;"></font>&#8220;<b style="font-weight:bold;">Option</b>&#8221; means rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock or Convertible Securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(d)<font style="display:inline-block;width:24.34pt;"></font>&#8220;<b style="font-weight:bold;">Original Issue Date</b>&#8221; means the date the first share of Series&#8239;Seed Preferred Stock is issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.4.2<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Adjustment of Preferred Stock Conversion Price</u>. No adjustment in the Conversion Price of any series of Preferred Stock shall be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the Requisite Holders agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.4.3<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Deemed Issue of Additional Shares of Common Stock</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(a)<font style="display:inline-block;width:24.9pt;"></font>If the Corporation at any time or from time to time after the Original Issue Date shall issue any Options or Convertible Securities (excluding Options or Convertible Securities which are themselves Exempted Securities) or shall fix a record date for the determination of holders of any class of securities entitled to receive any such Options or Convertible Securities, then the maximum number of shares of Common Stock (as set forth in the instrument relating thereto, assuming the satisfaction of any conditions to exercisability, convertibility or exchangeability but without regard to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or, in the case of Convertible Securities and Options therefor, the conversion or exchange of such Convertible Securities, shall be deemed to be Additional Shares of Common Stock issued as of the time of such issue or, in case such a record date shall have been fixed, as of the close of business on such record date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(b)<font style="display:inline-block;width:24.34pt;"></font>If the terms of any Option or Convertible Security, the issuance of which resulted in an adjustment to the Conversion Price of any series of Preferred Stock pursuant to the terms of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;4.4.4</u>, are revised as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1)&#8239;any increase or decrease in the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any such Option or Convertible Security or (2)&#8239;any increase or decrease in the consideration payable to the Corporation upon such exercise, conversion and/or exchange, then, effective upon such increase or decrease becoming effective, the Conversion Price of such series of Preferred Stock computed upon the original issue of such Option or Convertible Security (or upon the occurrence of a record date with respect thereto) shall be readjusted to such Conversion Price of such series of Preferred Stock as would have obtained had such revised terms been in effect upon the original date of issuance of such Option or Convertible Security. Notwithstanding the foregoing, no readjustment pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;4.4.3(b)</u>&#8239;shall have the effect of increasing the Conversion Price applicable to a series of Preferred Stock to an amount which exceeds the lower of (i)&#8239;the Conversion Price for such series of Preferred Stock in effect immediately prior to the original adjustment made as a result of the issuance of such Option or Convertible Security, or (ii)&#8239;the Conversion Price for such series of Preferred Stock that would have resulted from any issuances of Additional Shares of Common Stock (other than deemed issuances of Additional Shares of Common Stock as a result of the issuance of such Option or Convertible Security) between the original adjustment date and such readjustment date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(c)<font style="display:inline-block;width:24.9pt;"></font>If the terms of any Option or Convertible Security (excluding Options or Convertible Securities which are themselves Exempted Securities), the issuance of which did not result in an adjustment to the Conversion Price of a series of Preferred Stock pursuant to the terms of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;4.4.4</u> (either because the consideration per share (determined pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;4.4.5</u>) of the Additional Shares of Common Stock subject thereto was equal to or greater than the applicable Conversion Price then in effect, or because such Option or Convertible Security was issued before the Original Issue Date), are revised after the Original Issue Date as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1)&#8239;any increase in the number of shares of Common Stock issuable upon the exercise, conversion or exchange of any such Option or Convertible Security or (2)&#8239;any decrease in the consideration payable to the Corporation upon such exercise, conversion or exchange, then such Option or Convertible Security, as so amended or adjusted, and the Additional Shares of Common Stock subject thereto (determined in the manner provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;4.4.3&#8206;(a))</u> shall be deemed to have been issued effective upon such increase or decrease becoming effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(d)<font style="display:inline-block;width:24.34pt;"></font>Upon the expiration or termination of any unexercised Option or unconverted or unexchanged Convertible Security (or portion thereof) which resulted (either upon its original issuance or upon a revision of its terms) in an adjustment to the Conversion Price of any series of Preferred Stock pursuant to the terms of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;4.4.4</u>, the Conversion Price of such series of Preferred Stock shall be readjusted to such Conversion Price for such series of Preferred Stock as would have obtained had such Option or Convertible Security (or portion thereof) never been issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(e)<font style="display:inline-block;width:24.9pt;"></font>If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, is calculable at the time such Option or Convertible Security is issued or amended but is potentially subject to adjustment based upon subsequent events, any adjustment to the Conversion Price of a series of Preferred Stock provided for in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;4.4.3</u> shall be effected at the time of such issuance or amendment based on such number of shares or amount of consideration without regard to any provisions for subsequent adjustments (and any subsequent adjustments shall be treated as provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">clauses &#8206;(b)</u>&#8239;and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;(c)</u>&#8239;of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;4.4.3</u>). If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, cannot be calculated at all at the time such Option or Convertible Security is issued or amended, any adjustment to the Conversion Price of a series of Preferred Stock that would result under the terms of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;4.4.3</u> at the time of such issuance or amendment shall instead be effected at the time such number of shares and/or amount of consideration is first calculable (even if subject to subsequent adjustments), assuming for purposes of calculating such adjustment to the Conversion Price for such series of Preferred Stock that such issuance or amendment took place at the time such calculation can first be made. In the event an Option or Convertible Security contains alternative conversion terms, such as a cap on the valuation of the Corporation at which such conversion will be effected, or circumstances where the Option or Convertible Security may be repaid in lieu of conversion, then the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of such Option or Convertible Security shall be deemed not calculable until such time as the applicable conversion terms are determined.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.4.4<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjustment of Conversion Price Upon Issuance of Additional Shares of Common Stock</u>. In the event the Corporation shall at any time after the Original Issue Date issue Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;4.4.3</u>), without consideration or for a consideration per share less than the Conversion Price of a series of Preferred Stock in effect immediately prior to such issuance or deemed issuance, then the Conversion Price for such series of Preferred Stock shall be reduced, concurrently with such issue, to a price (calculated to the nearest one-hundredth of a cent) determined in accordance with the following formula:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">CP<sub style="font-size:7.5pt;vertical-align:sub;">2</sub> = CP<sub style="font-size:7.5pt;vertical-align:sub;">1</sub>* (A + B) &#247; (A + C).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For purposes of the foregoing formula, the following definitions shall apply:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(a)<font style="display:inline-block;width:24.9pt;"></font>&#8220;CP<sub style="font-size:7.5pt;vertical-align:sub;">2</sub>&#8221; shall mean the Conversion Price of such series of Preferred Stock in effect immediately after such issuance or deemed issuance of Additional Shares of Common Stock;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(b)<font style="display:inline-block;width:24.34pt;"></font>&#8220;CP<sub style="font-size:7.5pt;vertical-align:sub;">1</sub>&#8221; shall mean the Conversion Price of such series of Preferred Stock in effect immediately prior to such issuance or deemed issuance of Additional Shares of Common Stock;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(c)<font style="display:inline-block;width:24.9pt;"></font>&#8220;A&#8221; shall mean the number of shares of Common Stock outstanding immediately prior to such issuance or deemed issuance of Additional Shares of Common Stock (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of Options outstanding immediately prior to such issuance or deemed issuance or upon conversion or exchange of Convertible Securities (including the Preferred Stock) outstanding (assuming exercise of any outstanding Options therefor) immediately prior to such issue);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(d)<font style="display:inline-block;width:24.34pt;"></font>&#8220;B&#8221; shall mean the number of shares of Common Stock that would have been issued if such Additional Shares of Common Stock had been issued or deemed issued at a price per share equal to CP<sub style="font-size:7.5pt;vertical-align:sub;">1</sub> (determined by dividing the aggregate consideration received by the Corporation in respect of such issue by CP<sub style="font-size:7.5pt;vertical-align:sub;">1</sub>); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(e)<font style="display:inline-block;width:24.9pt;"></font>&#8220;C&#8221; shall mean the number of such Additional Shares of Common Stock issued in such transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.4.5<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Determination of Consideration</u>. For purposes of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;4.4</u>, the consideration received by the Corporation for the issuance or deemed issuance of any Additional Shares of Common Stock shall be computed as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(a)<font style="display:inline-block;width:24.9pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash and Property</u>. Such consideration shall:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">insofar as it consists of cash, be computed at the aggregate amount of cash received by the Corporation, excluding amounts paid or payable for accrued interest;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">insofar as it consists of property other than cash, be computed at the fair market value thereof at the time of such issue, as determined in good faith by the Board of Directors; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">in the event Additional Shares of Common Stock are issued together with other shares or securities or other assets of the Corporation for consideration which covers both, be the proportion of such consideration so received, computed as provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">clauses &#8206;(i)</u>&#8239;and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;(ii</u>)&#8239;above, as determined in good faith by the Board of Directors.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(b)<font style="display:inline-block;width:24.34pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Options and Convertible Securities</u>. The consideration per share received by the Corporation for Additional Shares of Common Stock deemed to have been issued pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;4.4.3</u>, relating to Options and Convertible Securities, shall be determined by dividing:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The total amount, if any, received or receivable by the Corporation as consideration for the issue of such Options or Convertible Securities, plus the minimum aggregate amount of additional consideration (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such consideration) payable to the Corporation upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities, by</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the maximum number of shares of Common Stock (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.4.6<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Multiple Closing Dates</u>. In the event the Corporation shall issue on more than one date Additional Shares of Common Stock that are a part of one transaction or a series of related transactions and that would result in an adjustment to the Conversion Price of a series of Preferred Stock pursuant to the terms of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;4.4.4</u>, then, upon the final such issuance, the Conversion Price for such series of Preferred Stock shall be readjusted to give effect to all such issuances as if they occurred on the date of the first such issuance (and without giving effect to any additional adjustments as a result of any such subsequent issuances within such period).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.5</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjustment for Stock Splits and Combinations</u>. If the Corporation shall at any time or from time to time after the Original Issue Date effect a subdivision of the outstanding Common Stock, the Conversion Price of each series of Preferred Stock in effect immediately before that subdivision shall be proportionately decreased so that the number of shares of Common Stock issuable on conversion of each share of such series shall be increased in proportion to such increase in the aggregate number of shares of Common Stock outstanding. If the Corporation shall at any time or from time to time after the Original Issue Date combine the outstanding shares of Common Stock, the Conversion Price of each series of Preferred Stock in effect immediately before the combination shall be proportionately increased so that the number of shares of Common Stock issuable on conversion of each share of such series shall be decreased in proportion to such decrease in the aggregate number of shares of Common Stock outstanding. Any adjustment under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;4.5</u> shall become effective at the close of business on the date the subdivision or combination becomes effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.6</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjustment for Certain Dividends and Distributions</u>. In the event the Corporation at any time or from time to time after the Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable on the Common Stock in additional shares of Common Stock, then and in each such event the Conversion Price of each series of Preferred Stock in effect immediately before such event shall be decreased as of the time of such issuance or, in the event such a record date shall have been fixed, as of the close of business on such record date, by multiplying the Conversion Price of each such series of Preferred Stock then in effect by a fraction:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(1)<font style="display:inline-block;width:24.34pt;"></font>the numerator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date, and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(2)<font style="display:inline-block;width:24.34pt;"></font>the denominator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such dividend or distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing, (a)&#8239;if such record date shall have been fixed and such dividend is not fully paid or if such distribution is not fully made on the date fixed therefor, the Conversion Price of each series of Preferred Stock shall be recomputed accordingly as of the close of business on such record date and thereafter the Conversion Price of each series of Preferred Stock shall be adjusted pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;4.6</u> as of the time of actual payment of such dividends or distributions; and (b)&#8239;that no such adjustment shall be made if the holders of such series of Preferred Stock simultaneously receive a dividend or other distribution of shares of Common Stock in a number equal to the number of shares of Common Stock as they would have received if all outstanding shares of such series of Preferred Stock had been converted into Common Stock on the date of such event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.7</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjustments for Other Dividends and Distributions</u>. In the event the Corporation at any time or from time to time after the Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in securities of the Corporation (other than a distribution of shares of Common Stock in respect of outstanding shares of Common Stock) or in other property and the provisions of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;1</u> do not apply to such dividend or distribution, then and in each such event the holders of Preferred Stock shall receive, simultaneously with the distribution to the holders of Common Stock, a dividend or other distribution of such securities or other property in an amount equal to the amount of such securities or other property as they would have received if all outstanding shares of Preferred Stock had been converted into Common Stock on the date of such event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.8</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjustment for Merger or Reorganization,&#8239;etc</u>. Subject to the provisions of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;2.3</u>, if there shall occur any reorganization, recapitalization, reclassification, consolidation or merger involving the Corporation in which the Common Stock (but not the Preferred Stock) is converted into or exchanged for securities, cash or other property (other than a transaction covered by <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections &#8206;4.4</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;4.6</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;4.7</u>), then, following any such reorganization, recapitalization, reclassification, consolidation or merger, each share of Preferred Stock shall thereafter be convertible in lieu of the Common Stock into which it was convertible prior to such event into the kind and amount of securities, cash or other property which a holder of the number of shares of Common Stock of the Corporation issuable upon conversion of one (1)&#8239;share of such Preferred Stock immediately prior to such reorganization, recapitalization, reclassification, consolidation or merger would have been entitled to receive pursuant to such transaction; and, in such case, appropriate adjustment (as determined in good faith by the Board of Directors) shall be made in the application of the provisions in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;4</u> with respect to the rights and interests thereafter of the holders of the Preferred Stock, to the end that the provisions set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;4</u> (including provisions with respect to changes in and other adjustments of the Conversion Price of each series of Preferred Stock) shall thereafter be applicable, as nearly as reasonably may be, in relation to any securities or other property thereafter deliverable upon the conversion of the Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.9</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certificate as to Adjustments</u>. Upon the occurrence of each adjustment or readjustment of the Conversion Price of a series of Preferred Stock pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;4</u>, the Corporation at its expense shall, as promptly as reasonably practicable but in any event not later than ten (10)&#8239;days thereafter, compute such adjustment or readjustment in accordance with the terms hereof and furnish to each holder of each series of Preferred Stock a certificate setting forth such adjustment or readjustment (including the kind and amount of securities, cash or other property into which such series of Preferred Stock is convertible) and showing in detail the facts upon which such adjustment or readjustment is based. The Corporation shall, as promptly as reasonably practicable after the written request at any time of any holder of Preferred Stock (but in any event not later than ten (10)&#8239;days thereafter), furnish or cause to be furnished to such holder a certificate setting forth (i)&#8239;the Conversion Price then in effect for each series of Preferred Stock held by such holder, and (ii)&#8239;the number of shares of Common Stock and the amount, if any, of other securities, cash or property which then would be received upon the conversion of each such series of Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.10</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Record Date</u>. In the event:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(a)<font style="display:inline-block;width:24.9pt;"></font>the Corporation shall take a record of the holders of its Common Stock (or other capital stock or securities at the time issuable upon conversion of the Preferred Stock) for the purpose of entitling or enabling them to receive any dividend or other distribution, or to receive any right to subscribe for or purchase any shares of capital stock of any class or series or any other securities, or to receive any other security; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(b)<font style="display:inline-block;width:24.34pt;"></font>of any capital reorganization of the Corporation, any reclassification of the Common Stock of the Corporation, or any Deemed Liquidation Event; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(c)<font style="display:inline-block;width:24.9pt;"></font>of the voluntary or involuntary dissolution, liquidation or winding-up of the Corporation,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">then, and in each such case, the Corporation will send or cause to be sent to the holders of the Preferred Stock a notice specifying, as the case may be, (i)&#8239;the record date for such dividend, distribution or right, and the amount and character of such dividend, distribution or right, or (ii)&#8239;the effective date on which such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or winding-up is proposed to take place, and the time, if any is to be fixed, as of which the holders of record of Common Stock (or such other capital stock or securities at the time issuable upon the conversion of the Preferred Stock) shall be entitled to exchange their shares of Common Stock (or such other capital stock or securities) for securities or other property deliverable upon such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or winding-up, and the amount per share and character of such exchange applicable to the Preferred Stock and the Common Stock. Such notice shall be sent at least ten (10)&#8239;days prior to the record date or effective date for the event specified in such notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mandatory Conversion</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trigger Events</u>. Upon the earliest to occur of any of the following events (the time of such conversion is referred to herein as the &#8220;<b style="font-weight:bold;">Mandatory Conversion Time</b>&#8221;), (A)&#8239;all outstanding shares of Preferred Stock other than the Series&#8239;Seed Preferred Stock shall automatically be converted into shares of Common Stock, at the then effective conversion rate as calculated pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections&#8239;4.1.1</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;4.2</u> and (B)&#8239;all outstanding shares of Series&#8239;Seed Preferred Stock shall be automatically converted into shares of non-voting Preferred Stock with the rights, privileges, duties and obligations to be determined, at the then effective conversion rate as calculated pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections&#8239;4.1.1</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;4.2</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">5.1.1<font style="display:inline-block;width:16pt;"></font>Immediately prior to the closing of the sale of shares of Common Stock to the public at a price of at least $1.00 per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Common Stock), in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $50,000,000 of gross proceeds, net of the underwriting discount and commissions, to the Corporation and in connection with such offering the shares of Common Stock are listed for trading on the Nasdaq Stock Market&#8217;s National Market, the New York Stock Exchange or another exchange or marketplace approved by the Board of Directors; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">5.1.2<font style="display:inline-block;width:16pt;"></font>The date and time, or the occurrence of an event, specified by vote or written consent of the Requisite Holders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Procedural Requirements</u>. All holders of record of shares of Preferred Stock (or the applicable series thereof) shall be sent written notice of the Mandatory Conversion Time and the place designated for mandatory conversion of all such shares of Preferred Stock pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;5</u>. Such notice need not be sent in advance of the occurrence of the Mandatory Conversion Time. Upon receipt of such notice, each holder of shares of Preferred Stock being converted that holds such shares of Preferred Stock in certificated form shall surrender his, her or its certificate or certificates for all such shares (or, if such holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation at the place designated in such notice. If so required by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or by his, her or its attorney duly authorized in writing. All rights with respect to the Preferred Stock converted pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;5.1</u>, including the rights, if any, to receive notices and vote (other than as a holder of Common Stock), will terminate at the Mandatory Conversion Time (notwithstanding the failure of the holder or holders thereof to surrender any certificates at or prior to such time), except only the rights of the holders thereof, upon surrender of any certificate or certificates of such holders (or lost certificate affidavit and agreement) therefor, to receive the items provided for in the next sentence of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;&#8206;5.2</u>. As soon as practicable after the Mandatory Conversion Time and, if applicable, the surrender of any certificate or certificates (or lost certificate affidavit and agreement) for Preferred Stock, the Corporation shall (a)&#8239;issue and deliver to such holder, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock or Preferred Stock, as applicable, issuable upon such conversion in accordance with the provisions hereof, and (b)&#8239;pay any declared but unpaid dividends on the shares of Preferred Stock converted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Redeemed or Otherwise Acquired Shares</u>. Unless approved by the Board of Directors and the Requisite Holders, any shares of Preferred Stock that are redeemed, converted or otherwise acquired by the Corporation or any of its subsidiaries shall be automatically and immediately cancelled and retired and shall not be reissued, sold or transferred. Neither the Corporation nor any of its subsidiaries may exercise any voting or other rights granted to the holders of Preferred Stock following redemption, conversion or acquisition. The Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver</u>. Except as otherwise set forth herein, (a)&#8239;any of the rights, powers, preferences and other terms of the Preferred Stock set forth herein may be waived on behalf of all holders of Preferred Stock by the affirmative written consent or vote of the holders that would otherwise be required to amend such right, powers, preferences and other terms and (b)&#8239;at any time more than one (1)&#8239;series of Preferred Stock is issued and outstanding, any of the rights, powers, preferences and other terms of any series of Preferred Stock set forth herein may be waived on behalf of all holders of such series of Preferred Stock by the affirmative written consent or vote of the holders of such series of Preferred Stock that would otherwise be required to amend such right, power, preference, or other term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u>. Any notice required or permitted by the provisions of this Article&#8239;IV to be given to a holder of shares of Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic transmission in compliance with the provisions of the DGCL, and shall be deemed sent upon such mailing or electronic transmission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#8239;V</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BOARD POWER REGARDING BYLAWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to any additional vote required by this Certificate of Incorporation or the Bylaws, in furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to make, repeal, alter, amend and rescind any or all of the Bylaws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#8239;VI</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BOARD OF DIRECTORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to any additional vote required by this Certificate of Incorporation, the number of directors of the Corporation shall be determined in the manner set forth in the Bylaws of the Corporation. Each director shall be entitled to one (1)&#8239;vote on each matter presented to the Board of Directors; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that, so long as the holders of Preferred Stock are entitled to elect one or more Preferred Directors, the affirmative vote of such Preferred Directors shall be required for the authorization by the Board of Directors of any of the matters set forth in the Investors&#8217; Rights Agreement, dated on or about the Original Issue Date, by and among the Corporation and the other parties thereto, as such agreement may be amended from time to time, to the extent required by such provision and if such Preferred Directors are then serving.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#8239;VII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ELECTION OF DIRECTORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Elections of directors need not be by written ballot unless the Bylaws shall so provide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#8239;VIII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MEETINGS OF STOCKHOLDERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Meetings of stockholders may be held within or outside of the State of Delaware, as the Bylaws of the Corporation may provide. The books of the Corporation may be kept (subject to any provision of applicable law) outside of the State of Delaware at such place or places or in such manner or manners as may be designated from time to time by the Board of Directors or in the Bylaws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#8239;IX</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">LIABILITY OF DIRECTORS AND OFFICERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the fullest extent permitted by law, a director or officer of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer. If the DGCL or any other law of the State of Delaware is amended after approval by the stockholders of this Article&#8239;IX to authorize corporate action further eliminating or limiting the personal liability of directors or officers, then the liability of a director or officer of the Corporation shall be eliminated or limited to the fullest extent permitted by the DGCL as so amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Corporation shall indemnify, to the fullest extent permitted by applicable law, any director or officer of the Corporation who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative ( a &#8220;<b style="font-weight:bold;">Proceeding</b>&#8221;) by reason of the fact that he or she is or was a director, officer, employee or agent of the Corporation or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any such Proceeding. The Corporation shall be required to indemnify a person in connection with a Proceeding initiated by such person only if the Proceeding was authorized by the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Corporation shall have the power to indemnify, to the extent permitted by the DGCL, as it presently exists or may hereafter be amended from time to time, any employee or agent of the Corporation who was or is a party or is threatened to be made a party to any Proceeding by reason of the fact that he or she is or was a director, officer, employee or agent of the Corporation or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any such Proceeding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Neither any amendment nor repeal of this Article, nor the adoption of any provision of this Certificate of Incorporation inconsistent with this Article, shall eliminate or reduce the effect of this Article&#8239;in respect of any matter occurring, or any cause of action, suit or claim accruing or arising or that, but for this Article, would accrue or arise, prior to such amendment, repeal or adoption of an inconsistent provision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#8239;X</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CORPORATE POWER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Except as provided in Article&#8239;IX above, the Corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in the manner now or hereafter prescribed by statute, and all rights conferred on stockholders herein are granted subject to this reservation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#8239;XI</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXCLUDED OPPORTUNITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Corporation renounces, to the fullest extent permitted by law, any interest or expectancy of the Corporation in, or in being offered an opportunity to participate in, any Excluded Opportunity. An &#8220;<b style="font-weight:bold;">Excluded Opportunity</b>&#8221; is any matter, transaction or interest that is presented to, or acquired, created or developed by, or which otherwise comes into the possession of (i)&#8239;any director of the Corporation who is not an employee of the Corporation or any of its subsidiaries, or (ii)&#8239;any holder of Preferred Stock or any partner, member, director, stockholder, employee, affiliate or agent of any such holder, other than someone who is an employee of the Corporation or any of its subsidiaries (collectively, the persons referred to in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">clauses (</u>i)&#8239;and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(ii)</u>&#8239;are &#8220;<b style="font-weight:bold;">Covered Persons</b>&#8221;), unless such matter, transaction or interest is presented to, or acquired, created or developed by, or otherwise comes into the possession of, a Covered Person expressly and solely in such Covered Person&#8217;s capacity as a director of the Corporation while such Covered Person is performing services in such capacity. Any repeal or modification of this Article&#8239;XI will only be prospective and will not affect the rights under this Article&#8239;XI in effect at the time of the occurrence of any actions or omissions to act giving rise to liability. Notwithstanding anything to the contrary contained elsewhere in this Certificate of Incorporation, in addition to any other vote required by law or this Certificate of Incorporation, the affirmative vote of the Requisite Holders, will be required to amend or repeal, or to adopt any provisions inconsistent with this Article&#8239;XI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#8239;XII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXCLUSIVE FORUM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i)&#8239;any derivative action or proceeding brought on behalf of the Corporation, (ii)&#8239;any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of the Corporation to the Corporation or the Corporation&#8217;s stockholders, (iii)&#8239;any action asserting a claim against the Corporation, its directors, officers or employees arising pursuant to any provision of the DGCL or the Corporation&#8217;s Certificate of Incorporation or Bylaws or (iv)&#8239;any action asserting a claim against the Corporation, its directors, officers or employees governed by the internal affairs doctrine or that otherwise relates to the internal affairs of the Corporation, except for, as to each of (i)&#8239;through (iv)&#8239;above, any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten (10)&#8239;days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#8239;XIII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SEVERABILITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If any provision or provisions of this Certificate of Incorporation shall be held to be invalid, illegal or unenforceable as applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Certificate of Incorporation (including, without limitation, each portion of any sentence of this Certificate of Incorporation containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#8239;XIV</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INCORPORATOR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The name and mailing address of the incorporator of the Corporation is:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">Abby Quinio</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">Gibson, Dunn&#8239;&amp; Crutcher LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">3161 Michelson Drive</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">Irvine, CA 92612</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">THE UNDERSIGNED, being the incorporator hereinbefore named, for the purpose of incorporating and organizing a corporation under the DGCL, does make and file this Certificate of Incorporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Dated: June&#8239;18, 2024</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">/s/ Abby Quinio</i></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Abby Quinio,&#8239;Incorporator</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">* * *</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.3
<SEQUENCE>3
<FILENAME>avte-20240930xex3d3.htm
<DESCRIPTION>EXHIBIT 3.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 12/3/2024 12:41:33 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 3.3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Final</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BYLAWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Adopted June&#160;18, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#010000;font-weight:bold;">ARTICLE&#160;I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">STOCKHOLDERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#160;1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annual Meeting</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on such date, and at such time as the Board of Directors shall each year fix, which date shall be within 13 months of the last annual meeting of stockholders or, if no such meeting has been held, the date of incorporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Special Meetings</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Special meetings of the stockholders, for any purpose or purposes prescribed in the notice of the meeting, may be called by the Board of Directors or the Chief Executive Officer, if one is elected, or the President, and shall be held at such place, on such date, and at such time as they or he or she shall fix.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Meetings</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Notice of the place, if any, date, and time of all meetings of the stockholders, the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, and the record date for determining the stockholders entitled to vote at the meeting, if such date is different from the record date for determining stockholders entitled to notice of the meeting, shall be given, not less than 10 nor more than 60 days before the date on which the meeting is to be held, to each stockholder entitled to vote at such meeting as of the record date for determining the stockholders entitled to notice of the meeting, except as otherwise provided herein or required by law (meaning, here and hereinafter, as required from time to time by the Delaware General Corporation Law or the Certificate of Incorporation of the Corporation).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>When a meeting is adjourned to another time or place, notice need not be given of the adjourned meeting if the time and place, if any, thereof, and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting are announced at the meeting at which the adjournment is taken; <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that if the date of any adjourned meeting is more than 30 days after the date for which the meeting was originally noticed, notice of the place, if any, date, and time of the adjourned meeting and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting, shall be given to each stockholder in conformity herewith. If after the adjournment a new record date for stockholders entitled to vote is fixed for the adjourned meeting, the Board of Directors shall fix a new record date for notice of such adjourned meeting, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors and, except as otherwise required by law, shall not be more than 60 nor less than 10 days before the date of such adjourned meeting, and shall give notice of the adjourned meeting to each stockholder of record entitled to vote at such adjourned meeting as of the record date fixed for notice of such adjourned meeting. At any adjourned meeting, any business may be transacted which might have been transacted at the original meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#8239;4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Quorum</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>At any meeting of the stockholders, the holders of a majority of the voting power of all of the shares of stock entitled to vote at the meeting, present in person or by proxy, shall constitute a quorum for all purposes, unless or except to the extent that the presence of a larger number may be required by law. Where a separate vote by a class or classes or series is required, a majority of the voting power of the shares of such class or classes or series present in person or represented by proxy shall constitute a quorum entitled to take action with respect to that vote on that matter. The stockholders present at a duly constituted meeting may continue to transact business until adjournment notwithstanding the withdrawal of enough stockholders to reduce the voting shares below a quorum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>If a quorum shall fail to attend any meeting, the chairman of the meeting or the holders of a majority of the shares of stock entitled to vote who are present, in person or by proxy, may adjourn the meeting to another place, if any, date, or time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Organization</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Such person as the Board of Directors may have designated or, in the absence of such a person, the President of the Corporation or, in his or her absence, such person as may be chosen by the holders of a majority of the voting power of the shares entitled to vote who are present, in person or by proxy, shall call to order any meeting of the stockholders and act as chairman of the meeting. In the absence of the Secretary of the Corporation, the secretary of the meeting shall be such person as the chairman of the meeting appoints.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conduct of Business</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>The chairman of any meeting of stockholders shall determine the order of business and the procedure at the meeting, including such regulation of the manner of voting and the conduct of discussion as seem to him or her in order. The date and time of the opening and closing of the polls for each matter upon which the stockholders will vote at the meeting shall be announced at the meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proxies and Voting</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At any meeting of the stockholders, every stockholder entitled to vote may vote in person or by proxy authorized by an instrument in writing or by a transmission permitted by law filed in accordance with the procedure established for the meeting. Any copy, facsimile telecommunication or other reliable reproduction of the writing or transmission created pursuant to this paragraph may be substituted or used in lieu of the original writing or transmission for any and all purposes for which the original writing or transmission could be used; <i style="font-style:italic;">provided</i>, that such copy, facsimile telecommunication or other reproduction shall be a complete reproduction of the entire original writing or transmission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Corporation may, and to the extent required by law, shall, in advance of any meeting of stockholders, appoint one or more inspectors to act at the meeting and make a written report thereof. The Corporation may designate one or more alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders, the person presiding at the meeting may, and to the extent required by law, shall, appoint one or more inspectors to act at the meeting. Each inspector, before entering upon the discharge of his or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of his or her ability. Every vote taken by ballots shall be counted by an inspector or inspectors appointed by the chairman of the meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>All elections shall be determined by a plurality of the votes cast, and except as otherwise required by law, all other matters shall be determined by a majority of the votes cast affirmatively or negatively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock List</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>The officer who has charge of the stock ledger of the Corporation shall, at least 10 days before every meeting of stockholders, prepare and make a complete list of stockholders entitled to vote at any meeting of stockholders; <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that if the record date for determining the stockholders entitled to vote is less than 10 days before the meeting date, the list shall reflect the stockholders entitled to vote as of the 10th day before the meeting date, arranged in alphabetical order and showing the address of each such stockholder and the number of shares registered in his or her name. Such list shall be open to the examination of any stockholder for a period of at least 10 days prior to the meeting in the manner provided by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>A stock list shall also be open to the examination of any stockholder during the whole time of the meeting as provided by law. This list shall presumptively determine (a)&#8239;the identity of the stockholders entitled to examine such stock list and to vote at the meeting and (b)&#8239;the number of shares held by each of them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consent of Stockholders in Lieu of Meeting</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Any action required to be taken at any annual or special meeting of stockholders of the Corporation, or any action which may be taken at any annual or special meeting of the stockholders, may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the Corporation by delivery to its registered office in Delaware, its principal place of business, or an officer or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Delivery made to the Corporation&#8217;s registered office shall be made by hand or by certified or registered mail, return receipt requested.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Every written consent shall bear the date of signature of each stockholder who signs the consent, and no written consent shall be effective to take the corporate action referred to therein unless, within 60 days of the earliest dated consent delivered to the Corporation, a written consent or consents signed by a sufficient number of holders to take action are delivered to the Corporation in the manner prescribed in the first paragraph of this Section. A telegram, cablegram or other electronic transmission consenting to an action to be taken and transmitted by a stockholder or proxyholder, or by a person or persons authorized to act for a stockholder or proxyholder, shall be deemed to be written, signed and dated for the purposes of this Section&#8239;to the extent permitted by law. Any such consent shall be delivered in accordance with Section&#8239;228(d)(1)&#8239;of the Delaware General Corporation Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Any copy, facsimile or other reliable reproduction of a consent in writing may be substituted or used in lieu of the original writing for any and all purposes for which the original writing could be used; <i style="font-style:italic;">provided</i>, that such copy, facsimile or other reproduction shall be a complete reproduction of the entire original writing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#8239;<b style="color:#010000;font-weight:bold;">ARTICLE&#8239;II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BOARD OF DIRECTORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Number and Term of Office</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>The number of directors who shall constitute the whole Board of Directors shall be such number as the Board of Directors shall from time to time have designated. Each director shall be elected for a term of one year and until his or her successor is elected and qualified, except as otherwise provided herein or required by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Whenever the authorized number of directors is increased between annual meetings of the stockholders, a majority of the directors then in office shall have the power to elect such new directors for the balance of a term and until their successors are elected and qualified. Any decrease in the authorized number of directors shall not become effective until the expiration of the term of the directors then in office unless, at the time of such decrease, there shall be vacancies on the board which are being eliminated by the decrease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Removal of Directors; Resignation</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Unless otherwise provided by the Certificate of Incorporation or these bylaws, any director or the entire Board of Directors may be removed, with or without cause, by the holders of a majority of shares entitled to vote at an election of directors. Any director may resign at any time upon notice given in writing or by electronic transmission to the Corporation. Such resignation shall be effective upon receipt unless it is specified to be effective at some other time or upon the happening of some other event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vacancies</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Unless otherwise provided in the Corporation&#8217;s Certificate of Incorporation, as it may be amended, if the office of any director becomes vacant by reason of death, resignation, disqualification, removal or other cause, a majority of the directors remaining in office, although less than a quorum, may elect a successor for the unexpired term and until his or her successor is elected and qualified. Unless otherwise provided in the Corporation&#8217;s Certificate of Incorporation, as it may be amended, vacancies and newly created directorships resulting from any increase in the authorized number of directors may be filled by a majority of the directors then in office, though less than a quorum, or by a sole remaining director, and the directors so chosen shall hold office until the next annual election and until their successors are duly elected and shall qualify, unless sooner displaced. If there are no directors in office, then an election of directors may be held in the manner provided by statute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#8239;4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regular Meetings</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Regular meetings of the Board of Directors shall be held at such place or places, on such date or dates, and at such time or times as shall have been established by the Board of Directors and publicized among all directors. A notice of each regular meeting shall not be required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Special Meetings</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Special meetings of the Board of Directors may be called by one-third of the directors then in office (rounded up to the nearest whole number) or by the Chief Executive Officer, if one is elected, or, if there is no Chief Executive Officer, the President, and shall be held at such place, on such date, and at such time as they or he or she shall fix. Notice of the place, date, and time of each such special meeting shall be given to each director by whom it is not waived by mailing written notice not less than five days before the meeting or by telegraphing or telexing or by facsimile or electronic transmission of the same not less than 24 hours before the meeting. Unless otherwise indicated in the notice thereof, any and all business may be transacted at a special meeting. A meeting may be held at any time without notice if all the directors are present (except as otherwise provided by law) or if those not present waive notice of the meeting in writing, either before or after such meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Quorum</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>At any meeting of the Board of Directors, the greater of (a)&#8239;a majority of the directors then in office at the time quorum is to be determined and (b)&#8239;one-third of the total number of directors fixed pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section&#8239;1</u> of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Article&#8239;II</u> of these Bylaws shall constitute a quorum for the transaction of business. Less than a quorum may adjourn any meeting from time to time, and the meeting may be held as adjourned without further notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Participation in Meetings By Conference Telephone</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Members of the Board of Directors, or of any committee thereof, may participate in a meeting of such Board of Directors or committee by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and such participation shall constitute presence in person at such meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conduct of Business</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>At any meeting of the Board of Directors, business shall be transacted in such order and manner as the Board of Directors may from time to time determine, and all matters shall be determined by the vote of a majority of the directors present, except as otherwise provided herein or required by law. Action may be taken by the Board of Directors without a meeting if all members thereof consent thereto in writing or by electronic transmission, and the writing or writings or electronic transmission or transmissions are filed with the minutes of proceedings of the Board of Directors. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;&#8239;<font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#8239;9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compensation of Directors</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Directors, as such, may receive, pursuant to resolution of the Board of Directors, fixed fees and other compensation for their services as directors, including, without limitation, their services as members of committees of the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#8239;<b style="color:#010000;font-weight:bold;">ARTICLE&#8239;III</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMMITTEES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Committees of the Board of Directors</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>The Board of Directors may from time to time designate committees of the Board of Directors, with such lawfully delegable powers and duties as it thereby confers, to serve at the pleasure of the Board of Directors and shall, for those committees and any others provided for herein, elect a director or directors to serve as the member or members, designating, if it desires, other directors as alternate members who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of any member of any committee and any alternate member in his or her place, the member or members of the committee present at the meeting and not disqualified from voting, whether or not he or she or they constitute a quorum, may by unanimous vote appoint another member of the Board of Directors to act at the meeting in the place of the absent or disqualified member.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conduct of Business</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Each committee may determine the procedural rules&#8239;for meeting and conducting its business and shall act in accordance therewith, except as otherwise provided herein or required by law. Adequate provision shall be made for notice to members of all meetings; one-third of the members shall constitute a quorum unless the committee shall consist of one or two members, in which event one member shall constitute a quorum; and all matters shall be determined by a majority vote of the members present. Action may be taken by any committee without a meeting if all members thereof consent thereto in writing or by electronic transmission, and the writing or writings or electronic transmission or transmissions are filed with the minutes of the proceedings of such committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#010000;font-weight:bold;">ARTICLE&#8239;IV</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OFFICERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Generally</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>The officers of the Corporation will be chosen by the Board of Directors and will consist of a President, a Secretary, a Treasurer and such other officers, including, without limitation, a Chief Executive Officer and one or more Vice Presidents, as may from time to time be appointed by the Board of Directors. Officers shall be elected by the Board of Directors, which shall consider that subject at its first meeting after every annual meeting of stockholders. Each officer shall hold office until his or her successor is elected and qualified or until his or her earlier resignation or removal. Any number of offices may be held by the same person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Subject to any limitations which may be set forth in a resolution of the Board of Directors, all deeds, leases, transfers, contracts, bonds, notes and other obligations to be entered into by the Corporation in the ordinary course of its business without director action may be executed on behalf of the Corporation by a President or by any other officer, employee or agent of the Corporation as the Board of Directors may authorize.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Chief Executive Officer.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>The Chief Executive Officer, if one is elected, shall have such powers and shall perform such duties as the Board of Directors may from time to time designate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">President</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Subject to the provisions of these Bylaws and to the direction of the Board of Directors, the President shall have the responsibility for the general management and control of the business and affairs of the Corporation and shall perform all duties and have all powers which are commonly incident to the office of President or which are delegated to him or her by the Board of Directors. He or she shall have power to sign all stock certificates, contracts and other instruments of the Corporation which are authorized and shall have general supervision and direction of all of the other officers, employees and agents of the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vice President</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Each Vice President shall have such powers and duties as may be delegated to him or her by the Board of Directors. One Vice President shall be designated by the Board of Directors to perform the duties and exercise the powers of the President in the event of the President&#8217;s absence or disability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Treasurer</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>The Treasurer shall have the responsibility for maintaining the financial records of the Corporation. He or she shall make such disbursements of the funds of the Corporation as are authorized and shall render from time to time an account of all such transactions and of the financial condition of the Corporation. The Treasurer shall also perform such other duties as the Board of Directors may from time to time prescribe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">&#8239;&#8239;<font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#8239;6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Secretary</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>The Secretary shall issue all authorized notices for, and shall keep minutes of, all meetings of the stockholders and the Board of Directors. He or she shall have charge of the corporate books and shall perform such other duties as the Board of Directors may from time to time prescribe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Chairman of the Board</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Unless otherwise provided by the Board of Directors, the Chairman of the Board of Directors, if one is elected, shall preside, when present, at all meetings of the stockholders and the Board of Directors. The Chairman of the Board shall have such other powers and shall perform such duties as the Board of Directors may from time to time designate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delegation of Authority</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>The Board of Directors may from time to time delegate the powers or duties of any officer to any other officers or agents, notwithstanding any provision hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Removal</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Any officer of the Corporation may be removed at any time, with or without cause, by the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Action with Respect to Securities of Other Corporations</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise directed by the Board of Directors, the President or any officer of the Corporation authorized by the President shall have power to vote and otherwise act on behalf of the Corporation, in person or by proxy, at any meeting of stockholders of or with respect to any action of stockholders of any other corporation in which this Corporation may hold securities and otherwise to exercise any and all rights and powers which this Corporation may possess by reason of its ownership of securities in such other corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#8239;<b style="color:#010000;font-weight:bold;">ARTICLE&#8239;V</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#8239;1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certificates of Stock</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The shares of the Corporation shall be represented by certificates; <i style="font-style:italic;">provided</i>, that the Board may provide by resolution or resolutions that some or all of any or all classes or series of its stock shall be uncertificated shares. Any such resolution shall not apply to shares represented by a certificate until such certificate is surrendered to the Corporation. Each holder of stock represented by certificates shall be entitled to a certificate signed by, or in the name of the Corporation, by any two of the President, a Vice President, the Secretary, an Assistant Secretary, the Treasurer, an Assistant Treasurer or any other authorized officers of the Corporation, certifying the number of shares owned by him or her. Any or all of the signatures on the certificate may be by facsimile or electronic means.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#8239;2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfers of Stock</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Transfers of stock shall be made only upon the transfer books of the Corporation kept at an office of the Corporation or by transfer agents designated to transfer shares of the stock of the Corporation. Except where a certificate is issued in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section&#8239;4</u> of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Article&#8239;V</u> of these Bylaws, an outstanding certificate, if one has been issued, for the number of shares involved shall be surrendered for cancellation before a new certificate, if any, is issued therefor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Record Date</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>In order that the Corporation may determine the stockholders entitled to notice of any meeting of stockholders or any adjournment thereof, the Board of Directors may, except as otherwise required by law, fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than 60 nor less than 10 days before the date of such meeting. If the Board of Directors so fixes a date, such date shall also be the record date for determining the stockholders entitled to vote at such meeting unless the Board of Directors determines, at the time it fixes such record date, that a later date on or before the date of the meeting shall be the date for making such determination. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of and to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that the Board of Directors may fix a new record date for determination of stockholders entitled to vote at the adjourned meeting, and in such case shall also fix as the record date for stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of stockholders entitled to vote in accordance with the foregoing provisions of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section&#8239;3</u> at the adjourned meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than 60 days prior to such action. If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>In order that the Corporation may determine the stockholders entitled to consent to corporate action without a meeting, (including by telegram, cablegram or other electronic transmission as permitted by law), the Board of Directors may fix a record date, which shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall be not more than ten days after the date upon which the resolution fixing the record date is adopted. If no record date has been fixed by the Board of Directors and no prior action by the Board of Directors is required by the Delaware General Corporation Law, the record date shall be the first date on which a consent setting forth the action taken or proposed to be taken is delivered to the Corporation in the manner prescribed by <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section&#8239;9</u> of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#8239;I</u> hereof. If no record date has been fixed by the Board of Directors and prior action by the Board of Directors is required by the Delaware General Corporation Law with respect to the proposed action by consent of the stockholders without a meeting, the record date for determining stockholders entitled to consent to corporate action without a meeting shall be at the close of business on the day on which the Board of Directors adopts the resolution taking such prior action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#8239;4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lost, Stolen or Destroyed Certificates</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>In the event of the loss, theft or destruction of any certificate of stock, another may be issued in its place pursuant to such regulations as the Board of Directors may establish concerning proof of such loss, theft or destruction and concerning the giving of a satisfactory bond or bonds of indemnity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulations</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>The issue, transfer, conversion and registration of certificates of stock shall be governed by such other regulations as the Board of Directors may establish.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#8239;<b style="color:#010000;font-weight:bold;">ARTICLE&#8239;VI</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTICES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>If mailed, notice to stockholders shall be deemed given when deposited in the mail, postage prepaid, directed to the stockholder at such stockholder&#8217;s address as it appears on the records of the Corporation. Without limiting the manner by which notice otherwise may be given effectively to stockholders, any notice to stockholders may be given by electronic transmission in the manner provided in Section&#8239;232 of the Delaware General Corporation Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waivers</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>A written waiver of any notice, signed by a stockholder or director, or waiver by electronic transmission by such person, whether given before or after the time of the event for which notice is to be given, shall be deemed equivalent to the notice required to be given to such person. Neither the business nor the purpose of any meeting need be specified in such a waiver. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the beginning of the meeting to the transaction of any business because the meeting is not lawfully called or convened.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#010000;font-weight:bold;">ARTICLE&#8239;VII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MISCELLANEOUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Facsimile or Electronic Signatures</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>In addition to the provisions for use of facsimile or electronic signatures elsewhere specifically authorized in these Bylaws, facsimile or electronic signatures of any officer or officers of the Corporation may be used whenever and as authorized by the Board of Directors or a committee thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Corporate Seal</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>The Board of Directors may provide a suitable seal, containing the name of the Corporation, which seal shall be in the charge of the Secretary. If and when so directed by the Board of Directors or a committee thereof, duplicates of the seal may be kept and used by the Treasurer or by an Assistant Secretary or Assistant Treasurer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reliance upon Books, Reports and Records</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Each director, each member of any committee designated by the Board of Directors, and each officer of the Corporation shall, in the performance of his or her duties, be fully protected in relying in good faith upon the books of account or other records of the Corporation and upon such information, opinions, reports or statements presented to the Corporation by any of its officers or employees, or committees of the Board of Directors so designated, or by any other person as to matters which such director or committee member reasonably believes are within such other person&#8217;s professional or expert competence and who has been selected with reasonable care by or on behalf of the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fiscal Year</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>The fiscal year of the Corporation shall be as fixed by the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Offices</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>The Corporation may also have offices at such other places both within and without the State of Delaware as the Board of Directors may from time to time determine or the business of the Corporation may require.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Records and Reports</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>The application and requirements of Section&#8239;1501 of the California General Corporation Law are hereby expressly waived to the fullest extent permitted thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Time Periods</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>In applying any provision of these Bylaws which requires that an act be done or not be done a specified number of days prior to an event or that an act be done during a period of a specified number of days prior to an event, calendar days shall be used, the day of the doing of the act shall be excluded, and the day of the event shall be included.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#010000;font-weight:bold;">ARTICLE&#8239;VIII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INDEMNIFICATION OF DIRECTORS AND OFFICERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right to Indemnification</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Each person who was or is made a party to or is threatened to be made a party to or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (hereinafter a &#8220;<b style="font-weight:bold;">proceeding</b>&#8221;), by reason of the fact that he or she is or was a director or an officer of the Corporation or is or was serving at the request of the Corporation as a director, officer, or trustee of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to an employee benefit plan (hereinafter an &#8220;<b style="font-weight:bold;">indemnitee</b>&#8221;), whether the basis of such proceeding is alleged action in an official capacity as a director, officer or trustee, or in any other capacity while serving as a director, officer or trustee, shall be indemnified and held harmless by the Corporation to the fullest extent permitted by Delaware law, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than such law permitted the Corporation to provide prior to such amendment) against all expense, liability and loss (including attorneys&#8217; fees, judgments, fines, ERISA excise taxes or penalties and amounts paid in settlement) reasonably incurred or suffered by such indemnitee in connection therewith; <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that, except as provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section&#8239;3</u> of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Article&#8239;VIII</u> with respect to proceedings to enforce rights to indemnification, the Corporation shall indemnify any such indemnitee in connection with a proceeding (or part thereof) initiated by such indemnitee only if such proceeding (or part thereof) was authorized by the Board of Directors of the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right to Advancement of Expenses</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>In addition to the right to indemnification conferred in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section&#8239;1</u> of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Article&#8239;VIII</u>, an indemnitee shall also have the right to be paid by the Corporation the expenses (including attorney&#8217;s fees) incurred in defending any such proceeding in advance of its final disposition (hereinafter an &#8220;<b style="font-weight:bold;">advancement of expenses</b>&#8221;); <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that, if the Delaware General Corporation Law requires, an advancement of expenses incurred by an indemnitee in his or her capacity as a director or officer (and not in any other capacity in which service was or is rendered by such indemnitee, including, without limitation, service to an employee benefit plan) shall be made only upon delivery to the Corporation of an undertaking (hereinafter an &#8220;<b style="font-weight:bold;">undertaking</b>&#8221;), by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal (hereinafter a &#8220;<b style="font-weight:bold;">final adjudication</b>&#8221;) that such indemnitee is not entitled to be indemnified for such expenses under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section&#8239;2</u> or otherwise.&#8239;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#8239;3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right of Indemnitee to Bring Suit</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>If a claim under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section&#8239;1</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;2</u> of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Article&#8239;VIII</u> is not paid in full by the Corporation within 60 days after a written claim has been received by the Corporation, except in the case of a claim for an advancement of expenses, in which case the applicable period shall be 20 days, the indemnitee may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim. To the fullest extent permitted by law, if successful in whole or in part in any such suit, or in a suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the indemnitee shall be entitled to be paid also the expense of prosecuting or defending such suit. In (i)&#8239;any suit brought by the indemnitee to enforce a right to indemnification hereunder (but not in a suit brought by the indemnitee to enforce a right to an advancement of expenses) it shall be a defense that, and (ii)&#8239;in any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that, the indemnitee has not met any applicable standard for indemnification set forth in the Delaware General Corporation Law. Neither the failure of the Corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel, or its stockholders) to have made a determination prior to the commencement of such suit that indemnification of the indemnitee is proper in the circumstances because the indemnitee has met the applicable standard of conduct set forth in the Delaware General Corporation Law, nor an actual determination by the Corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel, or its stockholders) that the indemnitee has not met such applicable standard of conduct, shall create a presumption that the indemnitee has not met the applicable standard of conduct or, in the case of such a suit brought by the indemnitee, be a defense to such suit. In any suit brought by the indemnitee to enforce a right to indemnification or to an advancement of expenses hereunder, or brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the burden of proving that the indemnitee is not entitled to be indemnified, or to such advancement of expenses, under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Article&#8239;VIII</u> or otherwise, shall be on the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Exclusivity of Rights</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>The rights to indemnification and to the advancement of expenses conferred in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Article&#8239;VIII</u> shall not be exclusive of any other right which any person may have or hereafter acquire under any statute, the Corporation&#8217;s Certificate of Incorporation, Bylaws, agreement, vote of stockholders or disinterested directors or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Insurance</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>The Corporation may maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise against any expense, liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the Delaware General Corporation Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="color:#010000;">Section&#8239;6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification of Employees and Agents of the Corporation</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>The Corporation may, to the extent authorized from time to time by the Board of Directors, grant rights to indemnification and to the advancement of expenses to any employee or agent of the Corporation to the fullest extent of the provisions of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Article&#8239;VIII</u> with respect to the indemnification and advancement of expenses of directors and officers of the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">&#8239;&#8239;<font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#8239;7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nature of Rights</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>The rights conferred upon indemnitees in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Article&#8239;VIII</u> shall be contract rights and such rights shall continue as to an indemnitee who has ceased to be a director, officer or trustee and shall inure to the benefit of the indemnitee&#8217;s heirs, executors and administrators. Any amendment, alteration or repeal of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Article&#8239;VIII</u> that adversely affects any right of an indemnitee or its successors shall be prospective only and shall not limit, eliminate, or impair any such right with respect to any proceeding involving any occurrence or alleged occurrence of any action or omission to act that took place prior to such amendment, alteration or repeal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#8239;<b style="color:#010000;font-weight:bold;">ARTICLE&#8239;IX</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AMENDMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="white-space:pre-wrap;">&#8239;</font>These Bylaws may be amended or repealed by the Board of Directors at any meeting or by the stockholders at any meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATE OF SECRETARY OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES,&#8239;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>The undersigned, K. Evan Thompson, hereby certifies that he is the duly elected and acting Secretary of Jade Biosciences,&#8239;Inc., a Delaware corporation (the &#8220;<b style="font-weight:bold;">Corporation</b>&#8221;), and that the Bylaws attached hereto constitute the Bylaws of said Corporation as duly adopted by Action by Written Consent of the Sole Director in Lieu of the Organizational Meeting of the Board of Directors on June&#8239;18, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the undersigned has hereunto subscribed his or her name on June&#8239;18, 2024.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ K. Evan Thompson</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">K. Evan Thompson, Secretary</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURE PAGE TO JADE BIOSCIENCES, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BYLAWS</b></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>4
<FILENAME>avte-20240930xex10d7.htm
<DESCRIPTION>EXHIBIT 10.7
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 12/3/2024 12:41:34 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.7</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2024 EQUITY INCENTIVE PLAN</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purpose</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The purpose of this 2024 Equity Incentive Plan (the &#8220;<b style="font-weight:bold;">Plan</b>&#8221;) of Jade Biosciences,&#160;Inc., a Delaware corporation (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;), is to advance the interests of the Company&#8217;s stockholders by enhancing the Company&#8217;s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align the interests of such persons with those of the Company&#8217;s stockholders. Except where the context otherwise requires, the term &#8220;Company&#8221; shall include any of the Company&#8217;s present or future parent or subsidiary corporations as defined in Sections&#160;424(e)&#160;or (f)&#160;of the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the &#8220;<b style="font-weight:bold;">Code</b>&#8221;) and any other business venture (including, without limitation, joint venture or limited liability company) in which the Company has a controlling interest, as determined by the Board of Directors of the Company (the &#8220;<b style="font-weight:bold;">Board</b>&#8221;).</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Eligibility</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All of the Company&#8217;s employees, officers, directors, consultants and advisors are eligible to be granted options, restricted stock, restricted stock units, and other stock-based awards (each, an &#8220;<b style="font-weight:bold;">Award</b>&#8221;) under the Plan. Each person who receives an Award under the Plan is deemed a &#8220;<b style="font-weight:bold;">Participant</b>&#8221;.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administration and Delegation</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administration by Board of Directors</u>. The Plan will be administered by the Board. The Board shall have authority to grant Awards and to adopt, amend and repeal such administrative rules, guidelines and practices relating to the Plan as it shall deem advisable. The Board may construe and interpret the terms of the Plan and any Award agreements entered into under the Plan. The Board may correct any defect, supply any omission or reconcile any inconsistency in the Plan or any Award in the manner and to the extent it shall deem expedient to carry the Plan into effect and it shall be the sole and final judge of such expediency. All decisions by the Board shall be made in the Board&#8217;s sole discretion and shall be final and binding on all persons having or claiming any interest in the Plan or in any Award. No director or person acting pursuant to the authority delegated by the Board shall be liable for any action or determination relating to or under the Plan made in good faith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appointment of Committees</u>. To the extent permitted by applicable law, the Board may delegate any or all of its powers under the Plan to one or more committees or subcommittees of the Board (a &#8220;<b style="font-weight:bold;">Committee</b>&#8221;). All references in the Plan to the &#8220;<b style="font-weight:bold;">Board</b>&#8221; shall mean the Board or a Committee of the Board or the officers referred to in Section&#160;<b style="font-weight:bold;">&#8206;</b>3(c)&#160;to the extent that the Board&#8217;s powers or authority under the Plan have been delegated to such Committee or officers. The Board may abolish any Committee at any time, and notwithstanding any delegation of authority, the Board will always retain full authority to take any action permitted under the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delegation to Officers</u>. To the extent permitted by applicable law, the Board may delegate to one or more officers of the Company the power to grant Awards (subject to any limitations under the Plan) to employees or officers of the Company and to exercise such other powers under the Plan as the Board may determine, <i style="font-style:italic;">provided that</i> the Board shall fix the terms of the Awards to be granted by such officers (including the exercise price of such Awards, which may include a formula by which the exercise price will be determined) and the maximum number of shares subject to Awards that the officers may grant; <i style="font-style:italic;">provided further, however</i>, that no officer shall be authorized to grant Awards to any &#8220;executive officer&#8221; of the Company (as defined by Rule&#160;3b-7 under the Securities Exchange Act of 1934, as amended (the &#8220;<b style="font-weight:bold;">Exchange Act</b>&#8221;)) or to any &#8220;officer&#8221; of the Company (as defined by Rule&#160;16a-1 under the Exchange Act). The Board may rescind any such delegation at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Available for Awards</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Number of Shares</u>. Subject to adjustment under Section&#160;<b style="font-weight:bold;">&#8206;</b>8 hereof, Awards may be made under the Plan covering up to 3,644,808 shares of common stock of the Company (the &#8220;<b style="font-weight:bold;">Common Stock</b>&#8221;), all of which may be granted as Incentive Stock Options (as defined below). If any Award expires, lapses, or is terminated, surrendered or canceled without having been fully exercised or is forfeited in whole or in part (including as the result of shares of Common Stock subject to such Award being repurchased by the Company at or below the original issuance price), in any case in a manner that results in any shares of Common Stock covered by such Award not being issued or being so reacquired by the Company, the unused Common Stock covered by such Award shall again be available for the grant of Awards under the Plan. Further, shares of Common Stock delivered (whether by actual delivery or attestation) or tendered to the Company by a Participant to satisfy the applicable exercise or purchase price of an Award and/or to satisfy any applicable tax withholding obligation (including shares retained by the Company from the Award being exercised or purchased and/or creating the tax obligation) shall again be available for the grant of Awards under the Plan. However, in the case of Incentive Stock Options, the foregoing provisions shall be subject to any limitations under the Code. Shares of Common Stock issued under the Plan may consist in whole or in part of authorized but unissued shares, shares purchased on the open market, or treasury shares. At no time while there is any Option (as defined below) outstanding and held by a Participant who was a resident of the State of California on the date of grant of such Option, shall the total number of shares of Common Stock issuable upon exercise of all outstanding options and the total number of shares provided for under any stock bonus or similar plan or agreement of the Company exceed the applicable percentage as calculated in accordance with the conditions and exclusions of Section&#160;260.140.45 of the California Code of Regulations (the &#8220;<b style="font-weight:bold;">California Regulations</b>&#8221;), to the extent applicable, based on the shares of the Company which are outstanding at the time the calculation is made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Substitute Awards</u>. In connection with a merger or consolidation of an entity with the Company or the acquisition by the Company of property or stock of an entity, the Board may grant Awards in substitution for any options or other stock or stock-based awards granted prior to such merger or consolidation by such entity or an affiliate thereof. Substitute Awards may be granted on such terms as the Board deems appropriate in the circumstances, notwithstanding any limitations on Awards contained in the Plan. Substitute Awards shall not count against the overall share limit set forth in Section&#160;<b style="font-weight:bold;">&#8206;</b>4(a)&#160;hereof, except as may be required by reason of Section&#160;422 and related provisions of the Code.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Options</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General</u>. The Board may grant options to purchase Common Stock (each, an &#8220;<b style="font-weight:bold;">Option</b>&#8221;) and determine the number of shares of Common Stock to be covered by each Option, the exercise price of each Option and the conditions and limitations applicable to the exercise of each Option, including conditions relating to applicable federal or state securities laws, as it considers necessary or advisable. An Option that is not intended to be an Incentive Stock Option shall be designated a &#8220;<b style="font-weight:bold;">Nonstatutory Stock Option</b>&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Incentive Stock Options</u>. An Option that the Board intends to be an &#8220;incentive stock option&#8221; as defined in Section&#160;422 of the Code (an &#8220;<b style="font-weight:bold;">Incentive Stock Option</b>&#8221;) shall only be granted to employees of the Company (including any of the Company&#8217;s present or future parent or subsidiary corporations as defined in Sections 424(e)&#160;or (f)&#160;of the Code but excluding any other business venture (including, without limitation, joint venture or limited liability company) in which the Company has a controlling interest). All Options intended to qualify as Incentive Stock Options shall be subject to and shall be construed consistently with the requirements of Section&#160;422 of the Code, and without limiting generality of the foregoing, such Options shall be deemed to include terms that comply with the eligibility standards described Section&#160;422(b)&#160;of the Code. Subject to the remaining provisions of this Section&#160;<b style="font-weight:bold;">&#8206;</b>5(b), if an Option intended to qualify as an Incentive Stock Option does not so qualify, the Board may, at its discretion, amend the Plan and Award with respect to such Option so that such Option qualifies as an Incentive Stock Option. To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Participant during any calendar year (under all plans of the Company and any affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not comply with the rules&#160;governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with the rules&#160;will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Award. Neither the Company nor the Board shall have any liability to a Participant, or any other party, (i)&#160;if an Option (or any part thereof) which is intended to qualify as an Incentive Stock Option fails to qualify as such or (ii)&#160;for any action or omission by the Company or Board that causes an Option not to qualify as an Incentive Stock Option, including without limitation the conversion of an Incentive Stock Option to a Nonstatutory Stock Option or the grant of an Option intended as an Incentive Stock Option that fails to satisfy the requirements under the Code applicable to an Incentive Stock Option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise Price</u>. The Board shall establish the exercise price of each Option and specify the exercise price in the applicable option agreement. The exercise price shall be not less than 100% of the Fair Market Value on the date the Option is granted. In the case of an Incentive Stock Option granted to an employee who, at the time of grant of the Option, owns (or is treated as owning under Section&#160;424 of the Code) stock representing more than 10% of the voting power of all classes of stock of the Company (or a &#8220;parent corporation&#8221; or &#8220;subsidiary corporation&#8221; thereof within the meaning of Sections 424(e)&#160;or 424(f)&#160;of the Code, respectively) (such employee, a &#8220;<b style="font-weight:bold;">10% Holder</b>&#8221;), the per share exercise price shall be no less than 110% of the Fair Market Value on the date the Option is granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Duration of Options</u>. Each Option shall be exercisable at such times and subject to such terms and conditions as the Board may specify in the applicable option agreement, <i style="font-style:italic;">provided that</i> the term of any Option shall not exceed 10 years. In the case of an Incentive Stock Option granted to a 10% Holder, the term of the Option shall not exceed five years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise of Option; Notification of Disposition</u>. Options may be exercised by delivery to the Company of a written notice of exercise signed by the proper person or by any other form of notice (including electronic notice) approved by the Board together with payment in full as specified in Section&#160;<b style="font-weight:bold;">&#8206;</b>5(f)&#160;for the number of shares for which the Option is exercised. Unless otherwise determined by the Board, an Option may not be exercised for a fraction of a share of Common Stock. Shares of Common Stock subject to the Option will be delivered by the Company as soon as practicable following exercise. If an Option is designated as an Incentive Stock Option, the Participant shall give prompt notice to the Company of any disposition or other transfer of any shares of Common Stock acquired from the Option if such disposition or transfer is made (i)&#160;within two years from the grant date with respect to such Option or (ii)&#160;within one year after the transfer of such shares to the Participant (other than any such disposition made in connection with a Reorganization Event). Such notice shall specify the date of such disposition or other transfer and the amount realized, in cash, other property, assumption of indebtedness or other consideration, by the Participant in such disposition or other transfer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment Upon Exercise.</u> Common Stock purchased upon the exercise of an Option granted under the Plan shall be paid for as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font>in cash or by check, payable to the order of the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</font></font>when the Common Stock is registered under the Exchange Act, except as may otherwise be provided in the applicable option agreement, by (A)&#160;delivery of an irrevocable and unconditional undertaking by a creditworthy broker acceptable to the Company to deliver promptly to the Company sufficient funds to pay the exercise price and any required tax withholding or (B)&#160;delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a creditworthy broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to pay the exercise price and any required tax withholding;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</font></font>when the Common Stock is registered under the Exchange Act and to the extent provided for in the applicable option agreement or approved by the Board, in its sole discretion, by delivery (either by actual delivery or attestation) of shares of Common Stock owned by the Participant valued at their fair market value as determined by (or in a manner approved by) the Board (&#8220;<b style="font-weight:bold;">Fair Market Value</b>&#8221;), <i style="font-style:italic;">provided </i>(A)&#160;such method of payment is then permitted under applicable law, (B)&#160;such Common Stock, if acquired directly from the Company, was owned by the Participant for such minimum period of time, if any, as may be established by the Board in its discretion and (C)&#160;such Common Stock is not subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</font></font>to the extent permitted by applicable law and provided for in the applicable option agreement or approved by the Board, in its sole discretion, by (A)&#160;delivery of a promissory note of the Participant to the Company on terms determined by the Board, or (B)&#160;payment of such other lawful consideration as the Board may determine;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</font></font>to the extent provided for in the applicable option agreement or approved by the Board, in its sole discretion, by having the Company retain from the shares of Common Stock otherwise issuable upon the exercise of such Option a number of shares valued at their Fair Market Value; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vi)</font></font>by any combination of the above permitted forms of payment or any other lawful consideration as approved by the Board in its sole discretion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Early Exercise of Options</u>. The Board may provide in the terms of an option agreement that the Participant may exercise an Option in whole or in part prior to the full vesting of the Option in exchange for unvested shares of Restricted Stock (as defined below) with respect to any unvested portion of the Option so exercised. Shares of Restricted Stock acquired upon the exercise of any unvested portion of an Option shall be subject to such terms and conditions as the Board shall determine.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restricted Stock; Restricted Stock Units</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General</u>. The Board may grant Awards entitling recipients to acquire shares of Common Stock (&#8220;<b style="font-weight:bold;">Restricted Stock</b>&#8221;), subject to the right of the Company to repurchase all or part of such shares at their issue price or other stated or formula price (or to require forfeiture of such shares if issued at no cost) from the recipient in the event that conditions specified by the Board in the applicable Award are not satisfied prior to the end of the applicable restriction period or periods established by the Board for such Award. The Board may also grant Awards entitling the recipient to receive shares of Common Stock or cash to be delivered at or following the time such Award vests (&#8220;<b style="font-weight:bold;">Restricted Stock Units</b>&#8221; or &#8220;<b style="font-weight:bold;">RSUs</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Terms and Conditions</u>. The Board shall determine and set forth in the applicable award agreement the terms and conditions of Restricted Stock or RSUs, including the conditions for vesting and repurchase (or forfeiture) and the issue price, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Provisions Relating to Restricted Stock</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dividends</u>. Participants holding shares of Restricted Stock will be entitled to all ordinary cash dividends paid with respect to such shares to the extent such dividends have a record date that is on or after the date on which the Participant to whom such Restricted Stock is granted becomes the record holder of such Restricted Stock, unless otherwise provided by the Board. Unless otherwise provided by the Board, if any dividends or distributions are paid in shares, or consist of a dividend or distribution to holders of Common Stock other than an ordinary cash dividend, the shares or other property will be subject to the same restrictions on transferability and forfeitability as the shares of Restricted Stock with respect to which they were paid. Each dividend payment will be made as provided in the applicable award agreement, but no later than the end of the calendar year in which the dividends are paid to shareholders of that class of stock or, if later, the 15th day of the third month following the later of (A)&#160;the date the dividends are paid to shareholders of that class of stock and (B)&#160;the date the dividends are no longer subject to forfeiture.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Certificates</u>. The Company may require that any stock certificates issued in respect of shares of Restricted Stock shall be deposited in escrow by the Participant, together with a stock power endorsed in blank, with the Company (or its designee). At the expiration of the applicable restriction periods, the Company (or such designee) shall deliver the certificates no longer subject to such restrictions to the Participant or if the Participant has died, to the beneficiary designated, in a manner determined by the Board, by a Participant to receive amounts due or exercise rights of the Participant in the event of the Participant&#8217;s death (the &#8220;<b style="font-weight:bold;">Designated Beneficiary</b>&#8221;). In the absence of an effective designation by a Participant, &#8220;Designated Beneficiary&#8221; shall mean the Participant&#8217;s estate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Provisions Relating to Restricted Stock Units</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Settlement</u>. Upon or following the vesting of a Restricted Stock Unit, the Participant shall be entitled to receive from the Company one share of Common Stock or an amount of cash or other property equal to the Fair Market Value of one share of Common Stock on the settlement date (or such other date), as the Board shall determine and as provided in the applicable award agreement. The Board may provide that settlement of Restricted Stock Units shall occur upon or as soon as reasonably practicable after the vesting of the Restricted Stock Units or shall instead be deferred, on a mandatory basis or at the election of the Participant, in a manner that complies with Section&#160;409A of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Voting Rights</u>. A Participant shall have no voting rights with respect to any Restricted Stock Units unless and until shares are delivered in settlement thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dividend Equivalents</u>. To the extent provided by the Board, a grant of Restricted Stock Units may provide a Participant with the right to receive Dividend Equivalents. Dividend Equivalents may be paid currently or credited to an account for the Participant, may be settled in cash and/or shares of Common Stock and may be subject to the same restrictions on transfer and forfeitability as the Restricted Stock Units with respect to which the Dividend Equivalents are paid, as determined by the Board, subject, in each case, to such terms and conditions as the Board shall establish and set forth in the applicable award agreement. &#8220;<b style="font-weight:bold;">Dividend Equivalents</b>&#8221; means a right granted to a Participant to receive the equivalent value (in cash or shares of Common Stock) of dividends paid on shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Stock-Based Awards</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other Awards of shares of Common Stock, and other Awards that are valued in whole or in part by reference to, or are otherwise based on, shares of Common Stock or other property, may be granted hereunder to Participants (&#8220;<b style="font-weight:bold;">Other Stock-Based Awards</b>&#8221;), including without limitation stock appreciation rights (which shall be subject to the same limitations applicable to awards of Nonstatutory Stock Options) and Awards entitling recipients to receive shares of Common Stock to be delivered in the future. Such Other Stock-Based Awards shall also be available as a form of payment in the settlement of other Awards granted under the Plan or as payment in lieu of compensation to which a Participant is otherwise entitled. Other Stock-Based Awards may be paid in shares of Common Stock or cash, as the Board shall determine. Subject to the provisions of the Plan, the Board shall determine the terms and conditions of each Other Stock-Based Award, including any purchase price, transfer restrictions, vesting conditions and other terms and conditions applicable thereto.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">8.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjustments for Changes in Common Stock and Certain Other Events</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, spin-off, merger, consolidation, liquidation, reorganization, or other similar change in capitalization or event, or any dividend or distribution to holders of Common Stock other than an ordinary cash dividend, (i)&#160;the number and class of securities available under this Plan, (ii)&#160;the number and class of securities and exercise price per share of each outstanding Option, (iii)&#160;the number of shares subject to and the repurchase price per share subject to each other outstanding Award, and (iv)&#160;the terms of each other outstanding Award shall be equitably adjusted by the Company (or substituted Awards may be made, if applicable) in the manner determined by the Board; <i style="font-style:italic;">provided that</i>, unless otherwise determined by the Board, such changes to the Options shall comply with Section&#160;1.424-1 of the Treasury Regulations and Section&#160;409A of the Code. Without limiting the generality of the foregoing, in the event the Company effects a split of the Common Stock by means of a stock dividend and the exercise price of and the number of shares subject to an outstanding Option are adjusted as of the date of the distribution of the dividend (rather than as of the record date for such dividend), then a Participant who exercises an Option between the record date and the distribution date for such stock dividend shall be entitled to receive, on the distribution date, the stock dividend with respect to the shares of Common Stock acquired upon such Option exercise, notwithstanding the fact that such shares were not outstanding as of the close of business on the record date for such stock dividend.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reorganization Events and Change in Control</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(A)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<b style="font-weight:bold;">Beneficial Owner</b>&#8221; shall have the meaning set forth in Rule&#160;13d-3 under the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(B)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;A &#8220;<b style="font-weight:bold;">Change in Control</b>&#8221; means, except as otherwise provided in an Award agreement, the occurrence of any one of the following events:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(I)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any Person (as defined below) (other than any Designated Affiliate (as defined below)) is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company (not including the securities beneficially owned by such Person or any securities acquired directly from the Company or any entity in which the Company has a substantial direct or indirect equity interest, as determined by the Board from time to time (an &#8220;<b style="font-weight:bold;">Affiliate</b>&#8221;)) representing 50% or more of the combined voting power of the Company&#8217;s then outstanding securities, excluding any Person who becomes such a Beneficial Owner in connection with a transaction described in clause (III)(1)&#160;or (2)&#160;below;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(II)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the following individuals cease for any reason to constitute a majority of the number of directors then serving: (1)&#160;individuals who, on the Effective Date (as defined below), constitute the Board and (2)&#160;any new director (other than a director whose initial assumption of office is in connection with an actual or threatened election contest, including a consent solicitation, relating to the election of directors of the Company) whose appointment or election by the Board or nomination for election by the Company&#8217;s stockholders was approved or recommended by a vote of at least a majority of the directors then still in office who were either directors on the Effective Date or whose appointment, election or nomination for election was previously so approved or recommended;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(III)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;there is consummated a merger or consolidation of the Company or any direct or indirect subsidiary of the Company with any other entity (other than with any Designated Affiliate), other than (1)&#160;a merger or consolidation which would result in the holders of the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof) at least 50% of the combined voting power of the securities of the Company or such surviving entity or any parent thereof outstanding immediately after such merger or consolidation, or (2)&#160;a reverse merger or similar transaction;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(IV)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the implementation of a plan of complete liquidation or dissolution of the Company; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(V)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;there is consummated a sale or disposition by the Company of all or substantially all of the Company&#8217;s assets, other than a sale or disposition by the Company of all or substantially all of the Company&#8217;s assets to (1)&#160;an entity, at least 50% of the combined voting power of the voting securities of which is owned by stockholders of the Company in substantially the same proportions as their ownership of the Company immediately prior to such sale or (2)&#160;any Designated Affiliate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(C)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<b style="font-weight:bold;">Designated Affiliates</b>&#8221; means Fairmount Healthcare Fund II, L.P., its respective Controlled Affiliates, and any entity in which any such entity has a substantial direct or indirect equity interest, as determined by the Board from time to time; provided, however, that Fairmount Healthcare Fund II, L.P., its Controlled Affiliates, and any entity in which any such entity has a substantial direct or indirect equity interest, as determined by the Board from time to time, will cease to be Designated Affiliates at the time they no longer are the Beneficial Owner of securities of the Company represents at least 10% of the combined voting power of the Company&#8217;s then outstanding securities. For purposes of this definition, &#8220;<b style="font-weight:bold;">Controlled Affiliates</b>&#8221; means any Person referred to in the preceding sentence that, directly or indirectly, through one or more intermediaries, is controlling, controlled by, or under common control with, such other Person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(D)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<b style="font-weight:bold;">Person</b>&#8221; shall have the meaning given in Section&#160;3(a)(9)&#160;of the Exchange Act, as modified and used in Sections 14(d)&#160;and 15(d)&#160;thereof, except that such term shall not include (I)&#160;the Company or any of its Affiliates, (II)&#160;a trustee or other fiduciary holding securities under an employee benefit plan of the Company or any of its subsidiaries, (III)&#160;an underwriter temporarily holding securities pursuant to an offering of such securities or (IV)&#160;a corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(E)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;A &#8220;<b style="font-weight:bold;">Reorganization Event</b>&#8221; means the consummation of: (I)&#160;the dissolution or liquidation of the Company, (II)&#160;the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated Person, (III)&#160;a merger, reorganization or consolidation pursuant to which all or substantially all of the Persons who were Beneficial Owners of the Company&#8217;s outstanding voting power immediately prior to such transaction do not own, directly or indirectly, a majority (determined on an as-converted basis) of the outstanding voting power of the surviving or resulting entity (or its ultimate parent, if applicable), (IV)&#160;the acquisition of all or a majority of the outstanding voting stock of the Company in a single transaction or a series of a related transactions by a Person or group of Persons, or (V)&#160;any other acquisition of the business of the Company, as determined by the Board; <i style="font-style:italic;">provided, however</i>, that the first firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, covering the offer and sale by the Company of its equity securities, as a result of or following which the Common Stock shall be public, any subsequent public offering or another capital raising event, or a merger effected solely to change the Company&#8217;s domicile shall not constitute a &#8220;Reorganization Event.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consequences of a Reorganization Event or Change in Control on Awards</u>. In connection with a Reorganization Event and/or a Change in Control, the Board may take any one or more of the following actions as to all or any (or any portion of) outstanding Awards on such terms as the Board determines: (A)&#160;provide that Awards shall be assumed, or substantially equivalent Awards shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof); <i style="font-style:italic;">provided that</i>, unless otherwise determined by the Board, such assumption or substitution of the Options shall comply with Section&#160;1.424-1 of the Treasury Regulations and Section&#160;409A of the Code, (B)&#160;upon written notice to a Participant, provide that the Participant&#8217;s unexercised Awards will terminate immediately prior to the consummation of such Reorganization Event unless exercised by the Participant within a specified period following the date of such notice, (C)&#160;provide that outstanding Awards shall become vested, exercisable, realizable, or deliverable, or restrictions applicable to an Award shall lapse, in whole or in part prior to or upon such Reorganization Event, (D)&#160;in the event of a Reorganization Event under the terms of which holders of Common Stock will receive upon consummation thereof a cash payment for each share surrendered in the Reorganization Event (the &#8220;<b style="font-weight:bold;">Acquisition Price</b>&#8221;), make or provide for a cash payment to a Participant equal to the excess, if any, of (I)&#160;the Acquisition Price times the number of shares of Common Stock subject to the Participant&#8217;s Awards (to the extent the exercise price does not equal or exceed the Acquisition Price) over (II)&#160;the aggregate exercise price of all such outstanding Awards and any applicable tax withholdings, in exchange for the termination of such Awards (and the Board may cancel and terminate without payment or consideration any Award with an exercise price equal to or in excess of the Acquisition Price), (E)&#160;provide that, in connection with a liquidation or dissolution of the Company, Awards shall convert into the right to receive liquidation proceeds (if applicable, net of the exercise price thereof and any applicable tax withholdings) and (F)&#160;any combination of the foregoing. In taking any of the actions permitted under this Section&#160;<b style="font-weight:bold;">&#8206;</b>8(b), the Board shall not be obligated by the Plan to treat all Awards, all Awards held by a Participant, or all Awards of the same type, identically.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">For purposes of clause (A)&#160;above, an Option shall be considered assumed if, following consummation of the Reorganization Event or Change in Control, the Option confers the right to purchase, for each share of Common Stock subject to the Option immediately prior to the consummation of the Reorganization Event or Change in Control, the consideration (whether cash, securities or other property) received as a result of the Reorganization Event or Change in Control by holders of Common Stock for each share of Common Stock held immediately prior to the consummation of the Reorganization Event or Change in Control (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding shares of Common Stock); <i style="font-style:italic;">provided, however</i>, that if the consideration received as a result of the Reorganization Event or Change in Control is not solely common stock of the acquiring or succeeding corporation (or an affiliate thereof), the Company may, with the consent of the acquiring or succeeding corporation, provide for the consideration to be received upon the exercise of Options to consist solely of common stock of the acquiring or succeeding corporation (or an affiliate thereof) equivalent in value (as determined by the Board) to the per share consideration received by holders of outstanding shares of Common Stock as a result of the Reorganization Event or Change in Control.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">9.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General Provisions Applicable to Awards</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transferability of Awards</u>. Except as the Board may otherwise determine or provide in an Award, Awards shall not be sold, assigned, transferred, pledged or otherwise encumbered by the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution or, other than in the case of an Incentive Stock Option, pursuant to a qualified domestic relations order, and, during the life of the Participant, shall be exercisable only by the Participant. References to a Participant, to the extent relevant in the context, shall include references to authorized transferees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Documentation</u>. Each Award shall be evidenced in such form (written, electronic or otherwise) as the Board shall determine. Each Award may contain terms and conditions in addition to those set forth in the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board Discretion</u>. Except as otherwise provided by the Plan, each Award may be made alone or in addition or in relation to any other Award. The terms of each Award need not be identical, and the Board need not treat Participants uniformly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Status</u>. The Board shall determine the effect on an Award of the disability, death, retirement, termination or other cessation of employment, authorized leave of absence or other change in the employment or other status of a Participant and the extent to which, and the period during which, the Participant, or the Participant&#8217;s legal representative, conservator, guardian or Designated Beneficiary, may exercise rights under the Award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Withholding</u>. The Company shall not be obligated to deliver certificates, release from forfeiture, otherwise recognize a Participant&#8217;s unrestricted ownership in an Award or the cash or property proceeds therefrom, until the Company satisfies all applicable federal, state, and local or other income and employment tax withholding obligations. In its sole discretion, the Company may satisfy such withholding obligations by any of the following means or by a combination of such means: (i)&#160;causing the Participant to tender to the Company cash payment; (ii)&#160;withholding cash from an Award settled in cash; (iii)&#160;withholding from amounts otherwise payable by the Company to the Participant, including but not limited to additional withholding on the Participant&#8217;s salary or wages, or from proceeds from the sale of Common Stock issued pursuant to an Award; (iv)&#160;delivery of shares of Common Stock, including shares retained from the Award creating the tax obligation, valued at their Fair Market Value; <i style="font-style:italic;">provided, however</i>, except as otherwise provided by the Board, that the total tax withholding where stock is being used to satisfy such tax obligations cannot exceed the Company&#8217;s maximum statutory withholding obligations (based on maximum statutory withholding rates for federal and state tax purposes, including payroll taxes, that are applicable to such supplemental taxable income), and <i style="font-style:italic;">provided, further</i>, shares surrendered to satisfy tax withholding requirements cannot be subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements; or (v)&#160;by such other method as determined by the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment of Award</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Board may amend, modify or terminate any outstanding Award, including but not limited to, substituting therefor another Award of the same or a different type, changing the date of exercise or settlement, and converting an Incentive Stock Option to a Nonstatutory Stock Option. The Participant&#8217;s consent to such action shall be required unless (A)&#160;the Board determines that the action, taking into account any related action, would not materially and adversely affect the Participant&#8217;s rights under the Plan, (B)&#160;the change is permitted under Section&#160;<b style="font-weight:bold;">&#8206;</b>8 hereof, or (C)&#160;the change is to ensure that an Option intended to qualify as an Incentive Stock Option qualifies as such.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Board may, without stockholder approval, amend any outstanding Award granted under the Plan to provide an exercise price per share that is lower than the then-current exercise price per share of such outstanding Award. The Board may also, without stockholder approval, cancel any outstanding award (whether or not granted under the Plan) and grant in substitution therefor new Awards under the Plan covering the same or a different number of shares of Common Stock and having an exercise price per share lower than the then-current exercise price per share of the cancelled award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conditions on Delivery of Stock</u>. The Company will not be obligated to deliver any shares of Common Stock pursuant to the Plan or to remove restrictions from shares previously delivered under the Plan until (i)&#160;all conditions of the Award have been met or removed to the satisfaction of the Company, (ii)&#160;in the opinion of the Company&#8217;s counsel, all other legal matters in connection with the issuance and delivery of such shares have been satisfied, including any applicable securities laws and any applicable stock exchange or stock market rules&#160;and regulations, and (iii)&#160;the Participant has executed and delivered to the Company such representations or agreements as the Company may consider appropriate to satisfy the requirements of any applicable laws, rules&#160;or regulations. The inability of the Company to obtain authority from any regulatory body having jurisdiction, which authority is determined by the Board to be necessary to the lawful issuance and sale of any securities hereunder, shall relieve the Company of any liability in respect of the failure to issue or sell such shares at to which such requisite authority shall not have been obtained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acceleration</u>. The Board may at any time provide that any Award shall become immediately exercisable in full or in part, free of some or all restrictions or conditions, or otherwise realizable in full or in part, as the case may be.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">10.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Right To Employment or Other Status</u>. No person shall have any claim or right to be granted an Award, and the grant of an Award shall not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant free from any liability or claim under the Plan, except as expressly provided in the applicable Award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Rights As Stockholder</u>. Subject to the provisions of the applicable Award, no Participant or Designated Beneficiary shall have any rights as a stockholder with respect to any shares of Common Stock to be distributed with respect to an Award until becoming the record holder of such shares. Notwithstanding any other provision of the Plan, unless otherwise determined by the Board or required by any applicable laws, the Company shall not be required to deliver to any Participant certificates evidencing shares of Common Stock issued in connection with any Award and instead such shares of Common Stock may be recorded in the books of the Company (or, as applicable, its transfer agent or stock plan administrator). The Company may place legends on any stock certificates issued under the Plan deemed necessary or appropriate by the Board in order to comply with applicable laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date and Term of Plan</u>. The Plan shall become effective on the date on which it is adopted by the Board (the &#8220;<b style="font-weight:bold;">Effective Date</b>&#8221;). No Awards shall be granted under the Plan after the expiration of 10 years from the earlier of (i)&#160;the Effective Date or (ii)&#160;the date the Plan was approved by the Company&#8217;s stockholders, but Awards previously granted may extend beyond that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment of Plan</u>. The Board may amend, suspend or terminate the Plan or any portion thereof at any time; <i style="font-style:italic;">provided that</i> if at any time the approval of a Company stockholder is required as to any modification or amendment under Section&#160;422 of the Code or any successor provision with respect to Incentive Stock Options or pursuant to any other applicable law or regulation, the Board may not effect such modification or amendment without stockholder approval. Unless otherwise specified in the amendment, any amendment to the Plan adopted in accordance with this Section&#160;<b style="font-weight:bold;">&#8206;</b>10(d)&#160;shall apply to, and be binding on the holders of, all Awards outstanding under the Plan at the time the amendment is adopted, <i style="font-style:italic;">provided</i> the Board determines that such amendment does not materially and adversely affect the rights of Participants under the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authorization of Sub-Plans</u>. The Board may from time to time establish one or more sub-plans under the Plan for purposes of satisfying applicable blue sky, securities or tax laws of various jurisdictions. The Board shall establish such sub-plans by adopting supplements to this Plan containing (i)&#160;such limitations on the Board&#8217;s discretion under the Plan as the Board deems necessary or desirable or (ii)&#160;such additional terms and conditions not otherwise inconsistent with the Plan as the Board shall deem necessary or desirable. All supplements adopted by the Board shall be deemed to be part of the Plan, but each supplement shall apply only to Participants within the affected jurisdiction and the Company shall not be required to provide copies of any supplement to Participants in any jurisdiction which is not the subject of such supplement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Code Section&#160;409A</u>. Unless otherwise expressly provided for in an Award, the Plan and Award will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section&#160;409A of the Code, and, to the extent not so exempt, in compliance with Section&#160;409A of the Code. If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section&#160;409A of the Code, the Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section&#160;409A(a)(1)&#160;of the Code, and to the extent an Award is silent on terms necessary for compliance, such terms as deemed necessary by the Board in its sole discretion are hereby incorporated by reference into the Award. Without limiting the generality of the foregoing, if shares of Common Stock are publicly traded, and if a Participant holding an Award that constitutes &#8220;deferred compensation&#8221; under Section&#160;409A of the Code is a &#8220;specified employee&#8221; for purposes of Section&#160;409A of the Code, no distribution or payment of any amount that is due because of a &#8220;separation from service&#8221; (as defined in Section&#160;409A of the Code without regard to alternative definitions thereunder) will be issued or paid before the date that is six months following the date of such Participant&#8217;s &#8220;separation from service&#8221; or, if earlier, the date of the Participant&#8217;s death, unless such distribution or payment can be made in a manner that complies with Section&#160;409A of the Code, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the balance paid thereafter on the original schedule. The Company shall have no liability to a Participant, or any other party, if an Award that is intended to be exempt from, or compliant with, Section&#160;409A of the Code is not so exempt or compliant or for any other action taken by the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u>. The provisions of the Plan and all Awards made hereunder shall be governed by and interpreted in accordance with the laws of the State of Delaware, excluding choice-of-law principles of the law of such state that would require the application of the laws of a jurisdiction other than such state.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Data Privacy</u>. As a condition of receipt of any Award, each Participant explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of personal data as described in this paragraph by and among, as applicable, the Company and its subsidiaries and affiliates for the exclusive purpose of implementing, administering and managing the Participant&#8217;s participation in the Plan. The Company and its subsidiaries and affiliates may hold certain personal information about a Participant, including but not limited to, the Participant&#8217;s name, home address and telephone number, date of birth, social security or insurance number or other identification number, salary, nationality, job title(s), any shares of stock held in the Company or any of its subsidiaries and affiliates, details of all Awards, in each case, for the purpose of implementing, managing and administering the Plan and Awards (the &#8220;<b style="font-weight:bold;">Data</b>&#8221;). The Company and its subsidiaries and affiliates may transfer the Data amongst themselves as necessary for the purpose of implementation, administration and management of a Participant&#8217;s participation in the Plan, and the Company and its subsidiaries and affiliates may each further transfer the Data to any third parties assisting the Company in the implementation, administration and management of the Plan. These recipients may be located in the Participant&#8217;s country, or elsewhere, and the Participant&#8217;s country may have different data privacy laws and protections than the recipients&#8217; country. Through acceptance of an Award, each Participant authorizes such recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing the Participant&#8217;s participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom the Company or the Participant may elect to deposit any shares of Common Stock. The Data related to a Participant will be held only as long as is necessary to implement, administer, and manage the Participant&#8217;s participation in the Plan. A Participant may, at any time, view the Data held by the Company with respect to such Participant, request additional information about the storage and processing of the Data with respect to such Participant, recommend any necessary corrections to the Data with respect to the Participant or refuse or withdraw the consents herein in writing, in any case without cost, by contacting his or her local human resources representative. The Company may cancel Participant&#8217;s ability to participate in the Plan and, in the Board&#8217;s discretion, the Participant may forfeit any outstanding Awards if the Participant refuses or withdraws his or her consents as described herein. For more information on the consequences of refusal to consent or withdrawal of consent, Participants may contact their local human resources representative.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restrictions on Shares; Clawback Provisions</u>. Shares of Common Stock acquired in respect of Awards shall be subject to such terms and conditions as the Board shall determine, including, without limitation, restrictions on the transferability of shares of Common Stock, the right of the Company to repurchase shares of Common Stock, the right of the Company to require that shares of Common Stock be transferred in the event of certain transactions, tag-along rights, bring-along rights, redemption and co-sale rights and voting requirements. Such terms and conditions may be additional to those contained in the Plan and may, as determined by the Board, be contained in the applicable Award agreement or in an exercise notice, stockholders&#8217; agreement or in such other agreement as the Board shall determine, in each case in a form determined by the Board. The issuance of such shares of Common Stock shall be conditioned on the Participant&#8217;s consent to such terms and conditions and the Participant&#8217;s entering into such agreement or agreements. All Awards (including any proceeds, gains or other economic benefit actually or constructively received by Participant upon any receipt or exercise of any Award or upon the receipt or resale of any shares of Common Stock underlying the Award) shall be subject to the provisions of any clawback policy implemented by the Company, including, without limitation, any clawback policy adopted to comply with the requirements of the Dodd-Frank Wall Street Reform and Consumer Protection Act and any rules&#160;or regulations promulgated thereunder, to the extent set forth in such clawback policy and/or in the applicable Award agreement.</p><p style="display:none;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2024 EQUITY INCENTIVE PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CALIFORNIA SUPPLEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to Section&#160;<b style="font-weight:bold;">&#8206;</b>10(e)&#160;of the Plan, the Board has adopted this supplement for purposes of satisfying the requirements of Section&#160;25102(o)&#160;of the California Corporations Code:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any Awards granted under the Plan to a Participant who is a resident of the State of California on the date of grant (a &#8220;<b style="font-weight:bold;">California Participant</b>&#8221;) shall be subject to the following additional limitations, terms and conditions:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Limitations on Options</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Maximum Duration of Options</u>. No Options granted to California Participants shall have a term in excess of 10 years measured from the Option grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Minimum Exercise Period Following Termination</u>. Unless a California Participant&#8217;s employment is terminated for cause (as defined by applicable law, the terms of any contract of employment between the Company and such Participant, or in the instrument evidencing the grant of such Participant&#8217;s Option), in the event of termination of employment of such Participant, such Participant shall have the right to exercise an Option, to the extent that he or she was otherwise entitled to exercise such Option on the date employment terminated, as follows: (i)&#160;at least six months from the date of termination, if termination was caused by such Participant&#8217;s death or &#8220;permanent and total disability&#8221; (within the meaning of Section&#160;22(e)(3)&#160;of the Code) and (ii)&#160;at least 30 days from the date of termination, if termination was caused other than by such Participant&#8217;s death or &#8220;permanent and total disability&#8221; (within the meaning of Section&#160;22(e)(3)&#160;of the Code).</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Limitations for Other Stock-Based Awards</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The terms of all Awards granted to a California Participant under Section&#160;<b style="font-weight:bold;">&#8206;</b>7 of the Plan shall comply, to the extent applicable, with Section&#160;260.140.41 or Section&#160;260.140.42 of the California Regulations.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Requirement to Provide Information to California Participants</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent required by Section&#160;260.140.46 of the California Regulations, the Company shall provide to each California Participant and to each California Participant who acquires Common Stock pursuant to the Plan, not less frequently than annually, copies of annual financial statements (which need not be audited). The Company shall not be required to provide such statements to key employees whose duties in connection with the Company assure their access to equivalent information.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Limitations on Timing of Awards</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No Award granted to a California Participant shall become exercisable, vested or realizable, as applicable to such Award, unless the Plan has been approved by the holders of a majority of the Company&#8217;s outstanding voting securities within 12 months before or after the date the Plan was adopted by the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Restriction Regarding Recapitalizations, Stock Splits, Etc</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For purposes of Section&#160;<b style="font-weight:bold;">&#8206;</b>8 of the Plan, in the event of a stock split, reverse stock split, stock dividend, recapitalization, combination, reclassification or other distribution of the Company&#8217;s securities, the number of securities allocated to each California Participant must be adjusted proportionately and without the receipt by the Company of any consideration from any California Participant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2024 EQUITY INCENTIVE PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">STOCK OPTION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[INCENTIVE STOCK OPTION // NONSTATUTORY STOCK OPTION]</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Grant of Option</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This Stock Option Agreement (this &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;) evidences the following grant by Jade Biosciences,&#160;Inc., a Delaware corporation (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;), of an option (this &#8220;<b style="font-weight:bold;">Option</b>&#8221;) to purchase, in whole or in part, on the terms provided herein and in the Jade Biosciences,&#160;Inc. 2024 Equity Incentive Plan (as amended from time to time, the &#8220;<b style="font-weight:bold;">Plan</b>&#8221;), the shares of Common Stock set forth below:</p><div style="padding-left:35.5pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:93%;"><tr><td style="vertical-align:top;width:31%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:1pt 4.9pt 1pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Participant:</b></p></td><td style="vertical-align:top;width:68.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:1pt 4.9pt 1pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[<font style="font-family:'Symbol';">&#183;</font>]</p></td></tr><tr><td style="vertical-align:top;width:31%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:1pt 4.9pt 1pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Grant Date:</b></p></td><td style="vertical-align:top;width:68.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:1pt 4.9pt 1pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[<font style="font-family:'Symbol';">&#183;</font>]</p></td></tr><tr><td style="vertical-align:top;width:31%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:1pt 4.9pt 1pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Shares of Common Stock Subject to the Option:</b></p></td><td style="vertical-align:top;width:68.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:1pt 4.9pt 1pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[<font style="font-family:'Symbol';">&#183;</font>] (the &#8220;<b style="font-weight:bold;">Shares</b>&#8221;)</p></td></tr><tr><td style="vertical-align:top;width:31%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:1pt 4.9pt 1pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exercise Price per Share:</b></p></td><td style="vertical-align:top;width:68.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:1pt 4.9pt 1pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$[<font style="font-family:'Symbol';">&#183;</font>]</p></td></tr><tr><td style="vertical-align:top;width:31%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:1pt 4.9pt 1pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Expiration Date:</b></p></td><td style="vertical-align:top;width:68.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:1pt 4.9pt 1pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">11:59 p.m.&#160;ET on [<font style="font-family:'Symbol';">&#183;</font>]<sup style="font-size:7.5pt;vertical-align:top;">1</sup></p></td></tr><tr><td style="vertical-align:top;width:31%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:1pt 4.9pt 1pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Vesting Commencement Date:</b></p></td><td style="vertical-align:top;width:68.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:1pt 4.9pt 1pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[<font style="font-family:'Symbol';">&#183;</font>]</p></td></tr><tr><td style="vertical-align:top;width:31%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:1pt 4.9pt 1pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Vesting Schedule:</b></p></td><td style="vertical-align:top;width:68.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:1pt 4.9pt 1pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">This Option will become exercisable (&#8220;<b style="font-weight:bold;">vest</b>&#8221;) in accordance with the following schedule, subject to the Participant&#8217;s continued employment with or service to the Company through each vesting date: [<font style="font-family:'Symbol';">&#183;</font>].</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This Option is subject to the terms of the Plan, which are incorporated into this Agreement by reference. A copy of the Plan has been furnished to the Participant with the Option. Capitalized terms used but not otherwise defined herein shall have the meanings set forth in the Plan. Except as otherwise indicated by the context, Participant shall be deemed to include any person who acquires the right to exercise this Option validly under its terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[<font style="font-style:italic;font-weight:bold;">Include if granted to employee and is an ISO: </font>This Option is intended to qualify as an &#8220;incentive stock option&#8221; under Section&#160;422 of the Code. However, the Company does not represent or warrant that this Option qualifies as such. The Participant should consult with his or her own tax advisors regarding the tax effects of this Option and the requirements necessary to obtain favorable income tax treatment under Section&#160;422 of the Code, including the holding period requirements. If the Participant disposes (whether by sale, gift, transfer or otherwise) any Shares acquired upon exercise of this Option within the one-year period beginning on the exercise date or within the two-year period beginning on the Grant Date, the Participant shall notify the Company within 30 days after such disposition. To the extent that the aggregate Fair Market Value (determined as of the Grant Date) of the Shares with respect to which the Option (plus all other incentive stock options held by the Participant) are exercisable for the first time by the Participant during any calendar year (under all plans of the Company and its affiliates) exceeds $100,000, the Option or portions thereof that exceed such limit (according to the order in which they were granted) will be treated as Nonstatutory Stock Options. In addition, to the extent any portion of this Option does not qualify as an &#8220;incentive stock option,&#8221; such portion shall be deemed to be a Nonstatutory Stock Option.][<font style="font-style:italic;font-weight:bold;">Include if granted to non-employee or to employee and is an NSO:</font> This Option is not intended to be an incentive stock option under Section&#160;422 of the Code and will be interpreted accordingly.]</p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">1 </sup>Enter date that is 10 years from the Grant Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vesting Schedule</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This Option will vest in accordance with the Vesting Schedule set forth in Section&#160;1 above. In determining the number of vested Shares at the time of exercise, the number of Shares shall be rounded down to the nearest whole Share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[In the event of a Change in Control, all of the Participant&#8217;s then unvested Shares shall automatically accelerate and become fully vested, subject to the Participant&#8217;s continued employment with or service to the Company through such Change in Control.]<sup style="font-size:7.5pt;vertical-align:top;">2</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The right of exercise shall be cumulative so that to the extent this Option is not exercised in any period to the maximum extent permissible it shall continue to be exercisable, in whole or in part, with respect to all Shares for which it is vested and unexercised until the earlier of the Expiration Date or the termination of this Option under Section&#160;<b style="font-weight:bold;">&#8206;</b>3 hereof or the Plan.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise of Option</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Form&#160;of Exercise</u>. Each election to exercise this Option shall be accompanied by a completed Notice of Stock Option Exercise in the form attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</u> and signed by the Participant, and where applicable, a signed and completed Consent of Spouse or Domestic Partner in the form attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;B</u>, and received by the Company at its principal office, accompanied by this Agreement, and payment of the Exercise Price in full in the manner provided in the Plan. The Participant may purchase less than the number of Shares covered hereby; <i style="font-style:italic;">provided that</i> no partial exercise of this Option may be for any fractional Share or for fewer than 100 whole Shares. Subject to applicable law and as a condition to the exercise of this Option and the issuance of any Common Stock hereunder, the Participant agrees to become party to any stockholders&#8217; agreement, voting agreement, drag along agreement, right of first refusal and co-sale agreement, or any other agreement approved by the Board and creating obligations of or among any stockholder of the Company, as the Company may request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Continuous Relationship with the Company Required</u>. Except as otherwise provided in this Section&#160;<b style="font-weight:bold;">&#8206;</b>3, this Option may not be exercised unless the Participant, at the time this Option is exercised, is, and has been at all times since the Grant Date, in continued employment with or providing service to the Company or any of its subsidiaries (an &#8220;<b style="font-weight:bold;">Eligible Participant</b>&#8221;). The date on which the Participant ceases to be an Eligible Participant shall be referred to as the &#8220;<b style="font-weight:bold;">Termination Date</b>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Relationship with the Company</u>. If the Participant ceases to be an Eligible Participant for any reason, then, except as provided in Sections 3(d)&#160;and 3(e)&#160;below, the right to exercise this Option shall terminate three months after the Termination Date (but in no event after the Expiration Date); provided that this Option shall be exercisable only to the extent that the Participant was entitled to exercise this Option on the Termination Date. Notwithstanding the foregoing, if the Participant, prior to the Expiration Date, violates any non-competition, non-solicitation, non-disparagement or confidentiality provisions of any agreement between the Participant and the Company or its subsidiary, the right to exercise this Option shall terminate immediately upon such violation.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">2 </sup>To be included for non-employee director awards only.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise Period Upon Death or Disability</u>. If the Participant dies or becomes disabled (within the meaning of Section&#160;22(e)(3)&#160;of the Code) prior to the Expiration Date while he or she is an Eligible Participant and the Company has not terminated such relationship for Cause (as defined below), this Option shall be exercisable by the Participant (or, in the case of death, by the Participant&#8217;s Designated Beneficiary) within the period of one year following the Termination Date (but in no event after the Expiration Date); provided that this Option shall be exercisable only to the extent that this Option was exercisable by the Participant on the Termination Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination for Cause</u>. If, prior to the Expiration Date, the Participant&#8217;s employment or service is terminated by the Company for Cause, the right to exercise this Option shall terminate immediately upon the Termination Date. If prior to the Expiration Date, the Participant is given notice by the Company of the termination of the Participant&#8217;s employment or service by the Company for Cause, and the Termination Date is subsequent to the date of delivery of such notice, the right to exercise this Option shall be suspended from the time of the delivery of such notice until the earlier of (i)&#160;such time as it is determined or otherwise agreed that the Participant&#8217;s employment or service shall not be terminated for Cause as provided in such notice or (ii)&#160;the Termination Date (in which case the right to exercise this Option shall, pursuant to the preceding sentence, terminate upon the Termination Date). If the Participant is party to an employment or severance contract or agreement or offer letter (excluding any non-competition agreement) with the Company that contains a definition of &#8220;cause&#8221; for termination, &#8220;<b style="font-weight:bold;">Cause</b>&#8221; shall have the meaning ascribed to such term in such agreement or offer letter. Otherwise, &#8220;<b style="font-weight:bold;">Cause</b>&#8221; shall mean (A)&#160;the Participant&#8217;s dishonest statements or acts with respect to the Company or any affiliate of the Company, or any current or prospective customers, suppliers, vendors or other third parties with which such entity does business that results in or is reasonably anticipated to result in material harm to the Company; (B)&#160;the Participant&#8217;s conviction or plea of no contest to (1)&#160;a felony or (2)&#160;any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (C)&#160;the Participant&#8217;s failure to perform in all material respects the Participant&#8217;s assigned duties and responsibilities; (D)&#160;the Participant&#8217;s gross negligence, willful misconduct that results in or is reasonably anticipated to result in harm to the Company; or (E)&#160;the Participant&#8217;s violation of any material provision of any agreement(s)&#160;between the Participant and the Company or its subsidiary or any Company policies including, without limitation, agreements relating to non-competition, non-solicitation, non-disparagement, non-disclosure and/or assignment of inventions or policies related to ethics or workplace conduct.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Right of First Refusal</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Proposed Transfer</u>. If the Participant proposes to sell, assign, transfer, pledge, hypothecate or otherwise dispose of, by operation of law or otherwise (collectively, &#8220;<b style="font-weight:bold;">transfer</b>&#8221;) any Shares acquired upon exercise of this Option, then the Participant shall first give written notice of the proposed transfer (the &#8220;<b style="font-weight:bold;">Transfer Notice</b>&#8221;) to the Company. The Transfer Notice shall name the proposed transferee and state the number of such Shares the Participant proposes to transfer (the &#8220;<b style="font-weight:bold;">Offered Shares</b>&#8221;), the price per Offered Share and all other material terms and conditions of the transfer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Right to Purchase</u>. For 30 days following its receipt of such Transfer Notice, the Company shall have the option to purchase all or part of the Offered Shares at the price and upon the terms set forth in the Transfer Notice. In the event the Company elects to purchase all or part of the Offered Shares, it shall give written notice of such election to the Participant within such 30-day period. Within 10&#160;days after the Participant&#8217;s receipt of such notice, the Participant shall tender to the Company at its principal offices the certificate or certificates, if any, representing the Offered Shares to be purchased by the Company, duly endorsed in blank by the Participant or with duly endorsed stock powers attached thereto, all in a form suitable for transfer of the Offered Shares to the Company. Promptly following receipt of such certificate or certificates, the Company shall deliver or mail to the Participant a check in payment of the purchase price for such Offered Shares; <i style="font-style:italic;">provided that</i> if the terms of payment set forth in the Transfer Notice were other than cash against delivery, the Company may pay for the Offered Shares on the same terms and conditions as were set forth in the Transfer Notice; and <i style="font-style:italic;">provided further</i> that any delay in making such payment shall not invalidate the Company&#8217;s exercise of its option to purchase the Offered Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shares Not Purchased By Company</u>. If the Company does not elect to acquire all of the Offered Shares, the Participant may, within the 30-day period following the expiration of the option granted to the Company under Section&#160;4(b)&#160;above, transfer the Offered Shares which the Company has not elected to acquire to the proposed transferee; <i style="font-style:italic;">provided that</i> such transfer shall not be on terms and conditions more favorable to the transferee than those contained in the Transfer Notice. Notwithstanding any of the above, all Offered Shares transferred pursuant to this Section&#160;<b style="font-weight:bold;">&#8206;</b>4 shall remain subject to the right of first refusal set forth in this Section&#160;<b style="font-weight:bold;">&#8206;</b>4 and such transferee shall, as a condition to such transfer, deliver to the Company a written instrument confirming that such transferee shall be bound by all of the terms and conditions of this Section&#160;<b style="font-weight:bold;">&#8206;</b>4.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consequences of Non-Delivery</u>. After the time at which the Offered Shares are required to be delivered to the Company for transfer to the Company pursuant to Section&#160;4(b)&#160;above, the Company shall not pay any dividend to the Participant on account of such Offered Shares or permit the Participant to exercise any of the privileges or rights of a stockholder with respect to such Offered Shares, but shall, insofar as permitted by law, treat the Company as the owner of such Offered Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exempt Transactions</u>. The following transactions shall be exempt from the provisions of this Section&#160;<b style="font-weight:bold;">&#8206;</b>4:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any transfer of Shares to or for the benefit of any spouse, child or grandchild of the Participant, or to a trust for their benefit;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any transfer pursuant to an effective registration statement filed by the Company under the Securities Act of 1933, as amended (the &#8220;<b style="font-weight:bold;">Securities Act</b>&#8221;); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the sale of all or substantially all of the outstanding shares of capital stock of the Company (including pursuant to a merger or consolidation);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">provided, however</i>, that in the case of a transfer pursuant to clause (i)&#160;above, such Shares shall remain subject to the right of first refusal set forth in this Section&#160;<b style="font-weight:bold;">&#8206;</b>4 and such transferee shall, as a condition to such transfer, deliver to the Company a written instrument confirming that such transferee shall be bound by all of the terms and conditions of this Section&#160;<b style="font-weight:bold;">&#8206;</b>4.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment of Company Right</u>. The Company may assign its rights to purchase Offered Shares in any particular transaction under this Section&#160;<b style="font-weight:bold;">&#8206;</b>4 to one or more persons or entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</u>. The provisions of this Section&#160;<b style="font-weight:bold;">&#8206;</b>4 shall terminate upon the earlier of the following events:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the closing of the sale of shares of Common Stock in an underwritten public offering pursuant to an effective registration statement filed by the Company under the Securities Act or any other transaction that results in the shares of Common Stock (or any equity securities substituted therefore) being listed on an established stock exchange; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a Change in Control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Obligation to Recognize Invalid Transfer</u>. The Company shall not be required (i)&#160;to transfer on its books any of the Shares which shall have been sold or transferred in violation of any of the provisions set forth in this Section&#160;<b style="font-weight:bold;">&#8206;</b>4, or (ii)&#160;to treat as owner of such Shares or to pay dividends to any transferee to whom any such Shares shall have been so sold or transferred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Legends</u>. Any certificate representing Shares or notice of issuance of uncertificated stock evidencing the issuance of Shares shall bear a legend substantially in the following form (in addition to, or in combination with, any legend required by applicable federal and state securities laws and agreements relating to the transfer of the Company securities) until the Company&#8217;s right of first refusal has terminated in accordance with Section&#160;4(g):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">&#8220;The shares [represented by this certificate][referenced herein] are subject to a right of first refusal in favor of the Company, as provided in a certain stock option agreement with the Company.&#8221;</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement in Connection with Initial Public Offering</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Participant agrees, in connection with the initial underwritten public offering of the Common Stock pursuant to a registration statement under the Securities Act, (a)&#160;not to (i)&#160;offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any other securities of the Company or (ii)&#160;enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of shares of Common Stock or other securities of the Company, whether any transaction described in clause (i)&#160;or (ii)&#160;is to be settled by delivery of securities, in cash or otherwise, for a period specified by the representative of the underwriters of Common Stock or other securities of the Company not to exceed 180 days following the effective date of any registration statement of the Company filed under the Securities Act (or such other period as may be requested by the Company or the underwriters to accommodate regulatory restrictions on (A)&#160;the publication or other distribution of research reports and (B)&#160;analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule&#160;2241 or any successor provisions or amendments thereto), and (b)&#160;to execute any agreement reflecting clause (a)&#160;above as may be requested by the Company or the managing underwriters at the time of such offering. The Company may impose stop-transfer instructions with respect to the shares of Common Stock or other securities subject to the foregoing restriction until the end of the &#8220;lock-up&#8221; period.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Matters</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Withholding</u>. No Shares will be issued pursuant to the exercise of this Option unless and until the Company satisfies all applicable federal, state, and local or other income and employment tax withholding obligations as described in the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disqualifying Disposition</u>. If this Option is intended to qualify as an &#8220;incentive stock option&#8221; under Section&#160;422 of the Code and if the Participant disposes of Shares acquired upon exercise of this Option within two years from the Grant Date or one year after such Shares were acquired pursuant to exercise of this Option, the Participant shall notify the Company in writing of such disposition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nontransferability of Option</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This Option may not be sold, assigned, transferred, pledged or otherwise encumbered by the Participant, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the lifetime of the Participant, this Option shall be exercisable only by the Participant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Participant agrees that the Participant will not transfer any Shares issued pursuant to the exercise of this Option unless the transferee, as a condition to such transfer, delivers to the Company a written instrument confirming that such transferee shall be bound by all of the terms and conditions of Section&#160;<b style="font-weight:bold;">&#8206;</b>4 and Section&#160;<b style="font-weight:bold;">&#8206;</b>5; <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">that</i> such a written confirmation shall not be required with respect to (i)&#160;Section&#160;<b style="font-weight:bold;">&#8206;</b>4 after such provision has terminated in accordance with Section&#160;<b style="font-weight:bold;">&#8206;</b>4(g)&#160;or (ii)&#160;Section&#160;<b style="font-weight:bold;">&#8206;</b>5 after the completion of the lock-up period in connection with the Company&#8217;s initial underwritten public offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[<i style="font-style:italic;">Signature Page&#160;Follows</i>]</p><p style="display:none;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the Company has caused this Option to be executed by its duly authorized officer.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Jade Biosciences,&#160;Inc.</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:42%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:42%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[Signature Page&#160;&#8211; Stock Option Agreement]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PARTICIPANT&#8217;S ACCEPTANCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The undersigned hereby accepts the foregoing Option and agrees to the terms and conditions thereof. The undersigned hereby acknowledges receipt of a copy of the Plan.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">PARTICIPANT:</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address:</p></td><td style="vertical-align:top;width:42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Email:</p></td><td style="vertical-align:top;width:42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[Signature Page&#160;&#8211; Stock Option Agreement]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT&#160;A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTICE OF STOCK OPTION EXERCISE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Date:_______________<sup style="font-size:7.5pt;vertical-align:top;">3</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Jade Biosciences,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:38.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:11.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:38.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:11.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:38.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Attention: Treasurer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Dear Sir or Madam:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">I am the holder of an Option granted to me under the Jade Biosciences,&#160;Inc. 2024 Equity Incentive Plan (as the same may be amended and restated from time to time, the &#8220;<b style="font-weight:bold;">Plan</b>&#8221;) on [_______________]<sup style="font-size:7.5pt;vertical-align:top;">4 </sup>for the purchase of [__________]<sup style="font-size:7.5pt;vertical-align:top;">5</sup> shares of Common Stock of the Company at an exercise price of $[__________]<sup style="font-size:7.5pt;vertical-align:top;">6</sup> per share. Capitalized terms used but not defined herein shall have the meanings set forth under the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">I hereby exercise my option to purchase [__________]<sup style="font-size:7.5pt;vertical-align:top;">7</sup> shares of Common Stock (the &#8220;<b style="font-weight:bold;">Shares</b>&#8221;), for which I have enclosed [__________]<sup style="font-size:7.5pt;vertical-align:top;">8</sup> in the amount of [__________]<sup style="font-size:7.5pt;vertical-align:top;">9</sup>. Please register the Shares as follows:</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;" align="center"><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Name(s):<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </u><sup style="font-size:7.5pt;vertical-align:top;">10</sup></p></td><td style="vertical-align:bottom;width:48.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Address:<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</u></p></td><td style="vertical-align:bottom;width:48.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">______________________________</p></td><td style="vertical-align:bottom;width:48.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Email:&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</u></p></td><td style="vertical-align:bottom;width:48.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Tax I.D. #:<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </u><sup style="font-size:7.5pt;vertical-align:top;">11</sup></p></td><td style="vertical-align:bottom;width:48.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">3 </sup>Enter the date of exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">4 </sup>Enter the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">5 </sup>Enter the total number of shares of Common Stock for which the option was <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">granted</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">6 </sup>Enter the option exercise price per share of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">7 </sup>Enter the number of shares of Common Stock <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">to be purchased upon exercise</b> of all or part of the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">8 </sup>Enter &#8220;cash&#8221;, &#8220;personal check&#8221; or if permitted by the Option or Plan, &#8220;stock certificates No. XXXX and XXXX&#8221; or &#8220;notice of issuance of uncertificated stock No. XXXX and XXXX&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">9 </sup>Enter the dollar amount (price per share of Common Stock times the number of shares of Common Stock to be purchased), or the number of shares tendered. Fair market value of shares tendered, together with cash or check, must cover the purchase price of the shares issued upon exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">10 </sup>Enter name(s) to appear on stock certificate or notice of issuance of uncertified stock: (a) Your name only; (b) Your name and other name (i.e., John Doe and Jane Doe, Joint Tenants With Right of Survivorship); or (c) a Child&#8217;s name, with you as custodian (i.e., Jane Doe, Custodian for Tommy Doe). Note: There may be income and/or gift tax consequences of registering shares in a Child&#8217;s name.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">11 </sup>Social Security Number of Holder(s).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[Signature Page&#160;&#8211; Notice of Stock Option Exercise]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:34.55pt;margin:0pt 0pt 12pt 0pt;">I represent, warrant and covenant as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;I am purchasing the Shares for my own account for investment only, and not with a view to, or for sale in connection with, any distribution of the Shares in violation of the Securities Act of 1933, as amended (the &#8220;<b style="font-weight:bold;">Securities Act</b>&#8221;), or any rule&#160;or regulation under the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;I have had such opportunity as I have deemed adequate to obtain from representatives of the Company such information as is necessary to permit me to evaluate the merits and risks of my investment in the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;I have sufficient experience in business, financial and investment matters to be able to evaluate the risks involved in the purchase of the Shares and to make an informed investment decision with respect to such purchase.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;I can afford a complete loss of the value of the Shares and am able to bear the economic risk of holding such Shares for an indefinite period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;I understand that (a)&#160;the Shares have not been registered under the Securities Act and are &#8220;restricted securities&#8221; within the meaning of Rule&#160;144 under the Securities Act, (b)&#160;the Shares cannot be sold, transferred or otherwise disposed of unless they are subsequently registered under the Securities Act or an exemption from registration is then available; (c)&#160;in any event, the exemption from registration under Rule&#160;144 will not be available for at least one year and even then will not be available unless a public market then exists for the Common Stock, adequate information concerning the Company is then available to the public, and other terms and conditions of Rule&#160;144 are complied with; and (d)&#160;there is now no registration statement on file with the Securities and Exchange Commission with respect to any stock of the Company and the Company has no obligation, and has not made any representations regarding any current intention, to register the Shares under the Securities Act.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.9%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Very truly yours,</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(Signature)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[Signature Page&#160;&#8211; Notice of Stock Option Exercise]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT&#160;B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CONSENT OF SPOUSE OR DOMESTIC PARTNER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">I, _________________________________________________________________, spouse or registered domestic partner of _____________________________________________________________, have read and approve the Stock Option Agreement dated _______________, _____ (the &#8220;<b style="font-weight:bold;">Stock Option Agreement</b>&#8221;), between my spouse or registered domestic partner and Jade Biosciences,&#160;Inc. In consideration of granting of the right to my spouse or registered domestic partner to purchase shares of common stock of Jade Biosciences,&#160;Inc. set forth in the Stock Option Agreement,&#160;I hereby appoint my spouse or registered domestic partner as my attorney-in-fact in respect to the exercise of any rights under the Stock Option Agreement and agree to be bound by the provisions of the Stock Option Agreement insofar as I may have any rights in said Stock Option Agreement or any options or shares issued pursuant thereto under the community property laws or similar laws relating to marital property in effect in the state of our residence as of the date of the signing of the foregoing Stock Option Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Dated:_______________, ______</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Signature of Spouse or Registered Domestic Partner</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>5
<FILENAME>avte-20240930xex10d10.htm
<DESCRIPTION>EXHIBIT 10.10
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 12/3/2024 12:41:33 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.10</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RESTRICTED STOCK NOTICE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Jade Biosciences,&#160;Inc., a Delaware corporation (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u>&#8221;), hereby grants to Purchaser (as defined below) the number of Shares (as defined below) of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Common Stock</u>&#8221;) set forth below, upon the terms and subject to the conditions set forth in the Restricted Stock Purchase Agreement attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</u> (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restricted Stock Purchase Agreement</u>&#8221;), which is incorporated by reference in this Restricted Stock Notice (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice</u>&#8221;). The issuance and sale of the Shares shall be effective as of the Date of Grant, set forth below.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Purchaser:</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[<font style="font-family:'Symbol';">&#183;</font>] (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchaser</u>&#8221;)</p></td></tr><tr><td style="vertical-align:top;width:28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Date of Grant:</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[<font style="font-family:'Symbol';">&#183;</font>]</p></td></tr><tr><td style="vertical-align:top;width:28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Vesting Commencement Date: </b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[<font style="font-family:'Symbol';">&#183;</font>] (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vesting Commencement Date</u>&#8221;)</p></td></tr><tr><td style="vertical-align:bottom;width:28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Number of Shares:</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[<font style="font-family:'Symbol';">&#183;</font>] (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shares</u>&#8221;)</p></td></tr><tr><td style="vertical-align:top;width:28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Vesting Schedule:</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Shares shall vest according to the following schedule (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vesting Schedule</u>&#8221;): [<font style="font-family:'Symbol';">&#183;</font>]</p></td></tr><tr><td style="vertical-align:top;width:28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Acceleration:</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[<font style="font-family:'Symbol';">&#183;</font>]</p></td></tr><tr><td style="vertical-align:top;width:28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Forfeiture</b>:</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Shares shall be subject to forfeiture in accordance with Section&#160;&#8206;7.2 of the Restricted Stock Purchase Agreement.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">By Purchaser&#8217;s signature below, Purchaser agrees to be bound by the terms and conditions of the Restricted Stock Purchase Agreement and this Notice. Purchaser has reviewed the Restricted Stock Purchase Agreement and this Notice in their entirety and has had an opportunity to obtain the advice of counsel prior to executing this Notice and the Restricted Stock Purchase Agreement. To the extent the Shares are issued in uncertificated form, Purchaser also acknowledges and agrees that the Restricted Stock Purchase Agreement constitutes the notice required by Section&#160;151(f)&#160;of the DGCL (as defined in the Restricted Stock Purchase Agreement).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES,&#160;INC.:</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PURCHASER:</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">[</b><b style="font-family:'Symbol';font-weight:bold;">&#183;</b><b style="font-weight:bold;">]</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td style="vertical-align:top;width:39.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Print Name:</p></td><td style="vertical-align:top;width:39.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:42%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:39.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:39.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Address:</p></td><td style="vertical-align:top;width:42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:39.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:42%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Address:</p></td><td style="vertical-align:top;width:39.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Email:</p></td><td style="vertical-align:top;width:42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURE PAGE TO JADE BIOSCIENCES, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RESTRICTED STOCK NOTICE AND RESTRICTED STOCK PURCHASE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT&#160;A</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TO RESTRICTED STOCK NOTICE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RESTRICTED STOCK PURCHASE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Restricted Stock Notice (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice</u>&#8221;) to which this Restricted Stock Purchase Agreement (this &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;) is attached, Jade Biosciences,&#160;Inc., a Delaware corporation (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u>&#8221;), has granted to Purchaser (as defined in the Notice) the Shares (as defined in the Notice), upon the terms and subject to the conditions of this Agreement and the Notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Defined Terms</u>. Capitalized terms not specifically defined herein shall have the meanings specified in the Notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Grant of Restricted Stock</u>. In consideration of Purchaser&#8217;s agreement to provide Services, and for other good and valuable consideration, effective as of the Date of Grant set forth in the Notice, the Company grants to Purchaser the Shares upon the terms and conditions set forth in the Notice and this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Issuance and Sale of Stock</u>. The issuance of the Shares shall be effective upon the Date of Grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment for Shares</u>. The Purchaser shall pay the Company a purchase price of $0.0001 per Share, in cash, as consideration for the Company&#8217;s agreement to issue and sell the Shares to Purchaser.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delivery of Certificates; Book Entry Form</u>. The Company shall issue to Purchaser one or more certificates (which may be issued by electronic or other means) in the name of Purchaser for that number of Shares granted to Purchaser. Purchaser agrees that the Shares shall be subject to the forfeiture provisions in Section&#160;<b style="font-weight:bold;">&#8206;</b>7 and the other restrictions set forth in this Agreement (collectively, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restrictions</u>&#8221;). To the extent the Shares will be issued in uncertificated form, the Shares shall be recorded in the name of Purchaser in the books and records of the Company&#8217;s transfer agent with appropriate notations regarding the Restrictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stockholder Rights</u>. Subject to Sections <b style="font-weight:bold;">&#8206;</b>8 and <b style="font-weight:bold;">&#8206;</b>11, following issuance of the Shares to Purchaser and until the occurrence of a Forfeiture (as defined below), Purchaser (or any successor in interest) shall have all the rights of a holder of Common Stock (including voting and dividend rights, as applicable) with respect to the Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Forfeiture</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">7.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vesting Schedule</u>. The Shares shall vest according to the Vesting Schedule set forth in the Notice. Any Shares that, as of any given time, have not vested pursuant to the Vesting Schedule are referred to herein as &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Unvested Shares</u>&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">7.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Forfeiture</u>. Except as otherwise set forth in the Notice, Purchaser agrees that in the event of the voluntary or involuntary termination of Purchaser&#8217;s continuous performance of services to the Company or any of its subsidiaries, affiliates, successors or assigns (whether as an employee, consultant, advisor, director and/or officer) (any of the foregoing, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Services</u>&#8221;) for any reason or no reason (including death or disability), with or without cause, such that Purchaser ceases to be providing Services to the Company (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Service</u>&#8221;), any then-Unvested Shares shall automatically be forfeited by Purchaser on the date of such Termination of Service without any consideration therefor and without any further action by the Company, and such Unvested Shares shall thereafter be cancelled by the Company and shall no longer be outstanding (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Forfeiture</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limitations on Transfer</u>. In addition to any other limitation on transfer pursuant to applicable securities laws, Purchaser shall not sell, assign, transfer, pledge, hypothecate or otherwise dispose of, directly or indirectly, by operation of law or otherwise (any of the foregoing, a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer</u>&#8221;) any Unvested Shares. After any Unvested Shares have vested pursuant to the Vesting Schedule, Purchaser shall not Transfer any interest in such Shares except in compliance with the provisions herein, in the Company&#8217;s Bylaws and applicable securities laws. Furthermore, the Shares shall be subject to a right of first refusal in favor of the Company or its assignees as set forth in Section&#160;<b style="font-weight:bold;">&#8206;</b>14. Notwithstanding the foregoing, Purchaser may, subject to compliance with the transfer restrictions set forth in the Company&#8217;s Bylaws, transfer Unvested Shares (i)&#160;to or for the benefit of any spouse, children, parents, uncles, aunts, siblings, grandchildren and any other relatives approved by the Board of Directors (collectively, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Approved Relatives</u>&#8221;) or to a trust established solely for the benefit of Purchaser and/or Approved Relatives, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u> that such Shares shall remain subject to this Agreement and such permitted transferee shall, as a condition to such transfer, deliver to the Company a written instrument confirming that such transferee shall be bound by all of the terms and conditions of this Agreement or (ii)&#160;subject to Section&#160;<b style="font-weight:bold;">&#8206;</b>12.3 below, as part of the sale of all or substantially all of the shares of capital stock of the Company (including pursuant to a merger or consolidation). The Company shall not be required (a)&#160;to transfer on its books any of the Shares that have been sold or otherwise transferred in violation of any of the provisions of this Agreement or the provisions of the Company&#8217;s Bylaws or (b)&#160;to treat as owner of such Shares or to accord the right to vote or pay dividends to any purchaser or other transferee to whom any such Shares shall have been so sold or transferred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Investment Representations</u>. Purchaser represents, warrants and covenants to the Company as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">9.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchase for Own Account</u>. Purchaser is purchasing the Shares for Purchaser&#8217;s own account for investment only, and not with a view to, or for sale in connection with, any distribution of the Shares in violation of the Securities Act of 1933, as amended (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Securities Act</u>&#8221;), or any rule&#160;or regulation under the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">9.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosure of Information</u>. Purchaser is aware of the Company&#8217;s business affairs and financial condition and has acquired sufficient information about the Company to permit Purchaser to evaluate the merits and risks of Purchaser&#8217;s investment in the Company and to reach an informed and knowledgeable decision to acquire the Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">9.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Public Market</u>. Purchaser understands that the Shares have not been registered under the Securities Act by reason of a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of Purchaser&#8217;s investment intent as expressed herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">9.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restricted Securities</u>. Purchaser understands that the Shares are &#8220;restricted securities&#8221; under applicable U.S. federal and state securities laws and that, pursuant to these laws, the Shares must be held indefinitely unless they are subsequently registered under the Securities Act or an exemption from such registration is available. Purchaser further acknowledges and understands that the Company is under no obligation to register or qualify the Shares for resale. Purchaser further acknowledges that if an exemption from registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the Shares, and requirements relating to the Company which are outside of Purchaser&#8217;s control, and which the Company is under no obligation and may not be able to satisfy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">9.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Economic Risk</u>. Purchaser can afford a complete loss of the value of the Shares and is able to bear the economic risk of holding such Shares for an indefinite period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">9.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accredited Investor</u>. To the extent Purchaser is not a director or executive officer of the Company, by Purchaser&#8217;s execution of this Agreement, such Purchaser hereby represents that (1)&#160;Purchaser is an &#8220;accredited investor&#8221; as that term is defined in Rule&#160;501 of Regulation D promulgated by the Securities and Exchange Commission (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SEC</u>&#8221;) under the Securities Act and (2)&#160;Purchaser has either (i)&#160;preexisting personal or business relationships with the Company or any of its officers, directors or controlling persons, or (ii)&#160;the capacity to protect his or her own interests in connection with the purchase of the Shares by virtue of the business or financial expertise of himself or herself or of professional advisors to Purchaser who are unaffiliated with and who are not compensated by the Company or any of its affiliates, directly or indirectly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">9.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Consequences</u>. Purchaser understands that Purchaser may suffer adverse tax consequences as a result of the grant and issuance of the Shares to Purchaser and Purchaser&#8217;s holding or disposition of the Shares. Purchaser represents that Purchaser has consulted any tax consultants Purchaser deems advisable in connection with the grant, issuance, holding and disposition of the Shares (or has knowingly chosen not to consult a tax advisor) and that Purchaser is not relying on the Company or its employees, officers, directors, attorneys or accountants for any tax advice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">9.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certain Encumbrances</u>. Purchaser acknowledges that the Shares will be subject to certain encumbrances, including, but not limited to, limitations on transfer and vesting pursuant to the Vesting Schedule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">9.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchaser Address</u>. If Purchaser is an individual, then Purchaser resides in the state or province identified in the address of Purchaser set forth on the signature page&#160;hereto; if Purchaser is a partnership, corporation, limited liability company or other entity, then the office or offices of Purchaser in which its investment decision was made is located at the address or addresses of Purchaser set forth on the signature page&#160;hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">9.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Withholding</u>. Purchaser acknowledges and agrees that the Company has the right to deduct from amounts otherwise due to Purchaser (including, for the avoidance of doubt, the Shares) any federal, state or local taxes of any kind required by law to be withheld with respect to the issuance of the Shares to Purchaser and/or the vesting of the Unvested Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">9.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Bad Actor Disqualifying Event</u>. No &#8220;bad actor&#8221; disqualifying event described in Rule&#160;506(d)(1)(i)-(viii)&#160;of the Securities Act (a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disqualification Event</u>&#8221;) is applicable to Purchaser or any of its Rule&#160;506(d)&#160;Related Parties, except, if applicable, for a Disqualification Event as to which Rule&#160;506(d)(2)(ii)&#160;or (iii)&#160;or (d)(3)&#160;is applicable. For purposes of this Agreement, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rule&#160;506(d)&#160;Related Party</u>&#8221; shall mean any individual, corporation, partnership, trust, limited liability company, association or other entity that is a beneficial owner of Purchaser&#8217;s securities for purposes of Rule&#160;506(d)&#160;of the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Certificate Legends</u>. The stock certificate (whether in electronic or other form) evidencing the Shares issued hereunder shall be endorsed with the following legends:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">10.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISPOSITION MAY&#160;BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">10.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A RIGHT OF FIRST REFUSAL IN FAVOR OF THE COMPANY AND/OR ITS ASSIGNEE(S)&#160;AND TRANSFER RESTRICTIONS AS PROVIDED IN THE RESTRICTED STOCK PURCHASE AGREEMENT BETWEEN THE PURCHASER AND THE COMPANY. SUCH RIGHT OF FIRST REFUSAL AND TRANSFER RESTRICTIONS ARE BINDING UPON TRANSFEREES OF THESE SECURITIES. A COPY OF THE RESTRICTED STOCK PURCHASE AGREEMENT OF THE COMPANY MAY&#160;BE OBTAINED UPON WRITTEN REQUEST TO THE COMPANY.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">10.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Legends</u>. Any other notations required by any applicable federal or state securities laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company may be authorized from time to time pursuant to its certificate of incorporation to issue more than one class or series of stock. In such case and at any time or from time to time thereafter the Company will furnish without charge to Purchaser upon request the powers, designations, preferences and relative participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent the Shares are issued in uncertificated form, (i)&#160;this Section&#160;&#8206;10 provides Purchaser with notice that the Shares are subject to the aforementioned restrictions in satisfaction of the notice requirement set forth in Section&#160;151(f)&#160;of the General Corporation Law of the State of Delaware (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DGCL</u>&#8221;) and (ii)&#160;the recording of the Shares in the books and records of the Company shall be accompanied by the legends included in this Section&#160;&#8206;10.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lock-Up Period</u>. Purchaser shall not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any Shares (or other securities of the Company) or enter into any swap, hedging or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any Shares (or other securities of the Company) held by Purchaser (other than those included in the applicable Registration Statement (as defined below)) for a period specified by the representative of the underwriters of Common Stock (or other securities) of the Company not to exceed 180 days following the effective date of any registration statement of the Company filed under the Securities Act (each a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Registration Statement</u>&#8221;) (or such other period as may be requested by the Company or the underwriters to accommodate regulatory restrictions on (i)&#160;the publication or other distribution of research reports and (ii)&#160;analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule&#160;2241, or any successor provisions or amendments thereto) (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lock-Up Period</u>&#8221;); <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that nothing contained in this Section&#160;<b style="font-weight:bold;">&#8206;</b>11 shall prevent a Forfeiture during the Lock-Up Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Purchaser agrees to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriter that are consistent with the foregoing or that are necessary to give further effect thereto. In addition, if requested by the Company or the representative of the underwriters of Common Stock (or other securities) of the Company, Purchaser shall provide, within ten days of such request, such information as may be required by the Company or such representative in connection with the completion of any public offering of the Company&#8217;s securities pursuant to a registration statement filed under the Securities Act. The obligations described in this Section&#160;<b style="font-weight:bold;">&#8206;</b>11 shall not apply to a registration relating solely to employee benefit plans on Form&#160;S-1 or Form&#160;S-8 or similar forms that may be promulgated in the future, or a registration relating solely to a SEC Rule&#160;145 transaction on Form&#160;S-4 or similar forms that may be promulgated in the future. The Company may impose stop-transfer instructions with respect to the shares of Common Stock (or other securities) subject to the foregoing restriction until the end of the Lock-Up Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjustment for Stock Split, Stock Dividend,&#160;etc.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">12.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Split; Stock Dividends</u>. All references to the number of Shares in this Agreement shall be appropriately adjusted to reflect any stock split, reverse stock split or stock dividend or other similar change in the Common Stock that may be made by the Company after the date of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">12.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subject to Vesting Schedule</u>. In the event of the declaration of a stock dividend, stock split or stock combination, a recapitalization or a similar transaction affecting the Common Stock without receipt of consideration, any new, substituted or additional securities that by reason of such transaction are distributed with respect to any Unvested Shares or into which such Unvested Shares thereby become convertible shall immediately be subject to the Vesting Schedule, Right of First Refusal (as defined below) and forfeiture provisions (and shall be released at the same rate as such Unvested Shares are, or would have been, released under this Agreement as set forth in Section&#160;&#8206;7). Appropriate adjustments to reflect the distribution of such securities shall be made to the number and/or class of the Unvested Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">12.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger or Consolidation</u>. Upon the occurrence of any merger or consolidation of the Company with or into another entity as a result of which all of the Common Stock is converted into or exchanged for the right to receive cash, securities or other property or any exchange of all of the Common Stock for cash, securities or other property pursuant to a share exchange transaction, the rights of the Company hereunder shall inure to the benefit of the Company&#8217;s successor and shall apply to the cash, securities or other property which the Shares were converted into or exchanged for pursuant to such transaction in the same manner and to the same extent as they applied to the Shares under this Agreement. If, in connection with such a transaction, a portion of the cash, securities and/or other property received upon the conversion or exchange of the Shares is to be placed into escrow to secure indemnification or similar obligations, the mix between the vested and unvested portion of such cash, securities and/or other property that is placed into escrow shall be the same as the mix between the vested and unvested portion of such cash, securities and/or other property that is not subject to escrow.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;83(b)&#160;Election</u>. Purchaser hereby acknowledges that he has been informed that, with respect to the purchase of Unvested Shares, that unless an election is filed by Purchaser with the Internal Revenue Service and, if necessary, the proper state taxing authorities, <b style="font-weight:bold;">within 30 days</b> after the Date of Grant, electing pursuant to Section&#160;83(b)&#160;of the Internal Revenue Code of 1986, as amended (and similar state tax provisions if applicable) to be taxed currently on any difference between the purchase price of the Shares and the fair market value of the Shares on the date of purchase (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Election</u>&#8221;), there will be a recognition of taxable income to Purchaser, measured by the excess, if any, of the fair market value of the Shares, at the time the Unvested Shares vest over the purchase price for the Shares. Purchaser represents that Purchaser has consulted any tax consultant(s)&#160;or advisor(s)&#160;Purchaser deems advisable in connection with the purchase of the Shares or the filing of the Election under Section&#160;83(b)&#160;and similar tax provisions. Purchaser is relying solely on such advisors and not on any statements or representations of the Company or any of its agents. Purchaser understands that Purchaser (and not the Company) shall be responsible for Purchaser&#8217;s own income tax liability that may arise as a result of the grant or vesting of the Shares contemplated by this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PURCHASER ACKNOWLEDGES THAT IT IS PURCHASER&#8217;S SOLE RESPONSIBILITY AND NOT THE COMPANY&#8217;S TO FILE TIMELY THE ELECTION UNDER SECTION&#160;83(b), EVEN IF PURCHASER REQUESTS THE COMPANY OR ITS REPRESENTATIVE TO MAKE THIS FILING ON PURCHASER&#8217;S BEHALF.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right of First Refusal</u>. Before any Shares held by Purchaser or any transferee of Purchaser (either being sometimes referred to herein as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Holder</u>&#8221;) may be sold or otherwise transferred (including transfer by gift or operation of law), the Company shall first, to the extent the Company&#8217;s approval is required by any applicable provisions of the Company&#8217;s Bylaws, have the right to approve such sale or transfer, in full or in part, and shall then have the right to purchase all or any part of the Shares proposed to be sold or transferred, in each case, in its sole and absolute discretion (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right of First Refusal</u>&#8221;). If the Holder would like to sell or transfer any Shares, the Holder must provide the Company or its assignee(s)&#160;with a Transfer Notice (as defined below) requesting approval to sell or transfer the Shares and offering the Company or its assignee(s)&#160;a Right of First Refusal on the same terms and conditions set forth in this Section&#160;<b style="font-weight:bold;">&#8206;</b>14. The Company may either (1)&#160;exercise its Right of First Refusal in full or in part and purchase such Shares pursuant to this Section&#160;<b style="font-weight:bold;">&#8206;</b>14, (2)&#160;decline to exercise its Right of First Refusal in full or in part and permit the transfer of such Shares to the Proposed Transferee (as defined below) in full or in part or (3)&#160;decline to exercise its Right of First Refusal in full or in part and, to the extent the Company&#8217;s approval is required by any applicable provisions in the Company&#8217;s Bylaws, decline the request to sell or transfer the Shares in full or in part.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">14.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Proposed Transfer</u>. The Holder of the Shares shall deliver to the Company a written notice (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer Notice</u>&#8221;) stating: (A)&#160;the Holder&#8217;s intention to sell or otherwise transfer such Shares; (B)&#160;the name of each proposed purchaser or other transferee (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proposed Transferee</u>&#8221;); (C)&#160;the number of Shares to be sold or transferred to each Proposed Transferee; (D)&#160;the terms and conditions of each proposed sale or transfer, including (without limitation) the purchase price for such Shares (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer Purchase Price</u>&#8221;); and (E)&#160;the Holder&#8217;s offer to the Company or its assignee(s)&#160;to purchase the Shares at the Transfer Purchase Price and upon the same terms (or terms that are no less favorable to the Company).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">14.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise of Right of First Refusal</u>. At any time within 30 days after receipt of the Transfer Notice, the Company and/or its assignee(s)&#160;shall deliver a written notice to the Holder indicating whether the Company and/or its assignee(s)&#160;elect to permit or reject the proposed sale or transfer, in full or in part, and/or elect to accept or decline the offer to purchase any or all of the Shares proposed to be sold or transferred to any one or more of the Proposed Transferees, at the Transfer Purchase Price, provided that if the Transfer Purchase Price consists of no legal consideration (as, for example, in the case of a transfer by gift), the purchase price will be the fair market value of the Shares as determined in good faith by the Company. If the Transfer Purchase Price includes consideration other than cash, the cash equivalent value of the non-cash consideration shall be determined by the Company in good faith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">14.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment</u>. Payment of the Transfer Purchase Price shall be made, at the election of the Company or its assignee(s), in cash (by check), by cancellation of all or a portion of any outstanding indebtedness, or by any combination thereof within 60 days after receipt of the Transfer Notice or in the manner and at the times set forth in the Transfer Notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">14.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Holder&#8217;s Right to Transfer</u>. If any of the Shares proposed in the Transfer Notice to be sold or transferred to a given Proposed Transferee are both (A)&#160;not purchased by the Company and/or its assignee(s)&#160;as provided in this Section&#160;&#8206;14 and (B)&#160;approved by the Company to be sold or transferred, then the Holder may sell or otherwise transfer any such Shares to the applicable Proposed Transferee at the Transfer Purchase Price or at a higher price, provided that such sale or other transfer is consummated within 120 days after the date of the Transfer Notice; provided that any such sale or other transfer is also effected in accordance with the Company&#8217;s Bylaws and any applicable laws and the Proposed Transferee agrees in writing that the Company&#8217;s Bylaws and the provisions of this Agreement, including Section&#160;&#8206;8, shall continue to apply to the Shares in the hands of such Proposed Transferee. The Company, in consultation with its legal counsel, may require the Holder to provide an opinion of counsel evidencing compliance with applicable laws. If the Shares described in the Transfer Notice are not transferred to the Proposed Transferee within such period, or if the Holder proposes to change the price or other terms to make them more favorable to the Proposed Transferee, a new Transfer Notice shall be given to the Company, and the Company and/or its assignees shall again have the right to approve such transfer and be offered the Right of First Refusal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">14.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exception for Certain Family Transfers</u>. Anything to the contrary contained in this Section&#160;&#8206;14 notwithstanding, the transfer of any or all of the Shares during Holder&#8217;s lifetime or on Holder&#8217;s death by will or intestacy to Holder&#8217;s Approved Relatives or a trust for the benefit of Holder or Holder&#8217;s Approved Relatives shall be exempt from the provisions of this Section&#160;&#8206;14. In such case, the transferee or other recipient shall receive and hold the Shares so transferred subject to the Company&#8217;s Bylaws and the provisions of this Agreement, including Section&#160;&#8206;8, and there shall be no further transfer of such Shares except in accordance with the terms of Section&#160;&#8206;8 and the Company&#8217;s Bylaws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">14.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment</u>. The right of the Company to purchase any part of the Shares may be assigned in whole or in part to any holder or holders of capital stock of the Company or other persons or organizations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">15.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General Provisions</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">15.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u>. This Agreement and any controversy arising out of or relating to this Agreement shall be governed by and construed in accordance with internal laws of the State of Delaware, without regard to conflict of law principles that would result in the application of any law other than the laws of the State of Delaware.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">15.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</u>. This Agreement and the Notice set forth the entire agreement between the parties with respect to the purchase of the Shares by Purchaser and supersede all prior agreements and understandings relating to the subject matter of this Agreement and the Notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">15.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice</u>. Any notice, demand or request required or permitted to be given by either the Company or Purchaser pursuant to the terms of this Agreement shall be in writing and shall be deemed given when delivered personally or deposited in the U.S. mail, as certified or registered mail, with postage prepaid, and addressed to the parties at the addresses of the parties set forth in the Notice or such other address as a party may request by notifying the other in writing or when delivered by facsimile telecommunication or electronic mail to the electronic mail address set forth in the Notice or such other electronic mail address as a party may request by notifying the other in writing. Subject to the limitations set forth in Section&#160;232 of the DGCL, Purchaser acknowledges that the Company may deliver any notice to Purchaser under the DGCL or the Company&#8217;s certificate of incorporation or bylaws by electronic transmission (as defined in the DGCL) pursuant to Section&#160;232 of the DGCL (or any successor thereto) at the electronic mail address for Purchaser set forth in the Notice, as updated from time to time by notice to the Company, or as on the books of the Company, unless Purchaser notifies the Company in writing or by electronic transmission of an objection to receiving notice by electronic mail. Purchaser agrees to promptly notify the Company of any change in its electronic mail address, and the failure to do so shall not affect the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">15.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors and Assigns</u>. The rights and benefits of the Company under this Agreement shall be transferable to any one or more persons or entities by the Company, and all covenants and agreements hereunder shall inure to the benefit of, and be enforceable by the Company&#8217;s successors and assigns. The rights and obligations of Purchaser under this Agreement may only be assigned with the prior written consent of the Company and any purported transfer otherwise shall be null and void.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">15.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment; Enforcement of Rights</u>. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in writing signed by the parties to this Agreement. Either party&#8217;s failure to enforce any provision or provisions of this Agreement shall not in any way be construed as a waiver of any such provision or provisions, nor prevent that party thereafter from enforcing each and every other provision of this Agreement. The rights granted both parties herein are cumulative and shall not constitute a waiver of either party&#8217;s right to assert all other legal remedies available to it under the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">15.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cooperation</u>. Purchaser agrees upon request to execute any further documents or instruments necessary or desirable to carry out the purposes or intent of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">15.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u>. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">15.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Electronic and Facsimile Signatures</u>. Any signature page&#160;delivered electronically or by facsimile (including without limitation transmission by .pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">www.docusign.com</u>) shall be binding to the same extent as an original signature page, with regard to any agreement subject to the terms hereof or any amendment thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">15.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u>. If one or more provisions of this Agreement are held to be unenforceable under applicable law by a tribunal of competent jurisdiction, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (i)&#160;such provision shall be excluded from this Agreement, (ii)&#160;the balance of the Agreement shall be interpreted as if such provision were so excluded and (iii)&#160;the balance of the Agreement shall be enforceable in accordance with its terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">15.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Attorney&#8217;s Fees</u>. If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable attorneys&#8217; fees, costs, and disbursements in addition to any other relief to which such party may be entitled. The Company and Purchaser shall bear their own expenses and legal fees incurred on their behalf with respect to this Agreement and the transactions contemplated hereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">15.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NO EMPLOYMENT GUARANTEE</u>. PURCHASER ACKNOWLEDGES AND AGREES THAT THE RELEASE OF SHARES PURSUANT TO THIS AGREEMENT IS EARNED ONLY BY CONTINUING SERVICE AS AN EMPLOYEE OF THE COMPANY. PURCHASER FURTHER ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED EMPLOYMENT OF SERVICE OR SERVICE (WHETHER OR NOT AS AN EMPLOYEE) FOR THE VESTING PERIOD OR ANY PERIOD AT ALL, AND SHALL NOT INTERFERE WITH PURCHASER&#8217;S RIGHT OR THE COMPANY&#8217;S RIGHT TO TERMINATE PURCHASER&#8217;S RELATIONSHIP WITH THE COMPANY AT ANY TIME, WITH OR WITHOUT CAUSE OR NOTICE IN ACCORDANCE WITH LAW.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">15.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cancellation of Shares</u>. From and after the occurrence of a Forfeiture, no person shall have any rights as a holder of the forfeited Shares, and such Shares shall be deemed forfeited in accordance with the applicable provisions hereof and the Company (or its assignees) shall be deemed the owner and holder of such Shares. Purchaser hereby surrenders and agrees to surrender any and all interest in or claims to any forfeited Shares following any Forfeiture.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">15.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchaser&#8217;s Acknowledgments</u>. Purchaser acknowledges that he or she: (i)&#160;has read this Agreement; (ii)&#160;has been represented in the preparation, negotiation, and execution of this Agreement by legal counsel of Purchaser&#8217;s own choice or has voluntarily declined to seek such counsel; (iii)&#160;understands the terms and consequences of this Agreement; (iv)&#160;is fully aware of the legal and binding effect of this Agreement; and (v)&#160;understands that the law firm of Gibson, Dunn&#160;&amp; Crutcher LLP is acting as counsel to the Company in connection with the transactions contemplated by the Agreement, and is not acting as counsel for Purchaser.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">15.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Titles and Subtitles</u>. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>6
<FILENAME>avte-20240930xex10d11.htm
<DESCRIPTION>EXHIBIT 10.11
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 12/3/2024 12:41:48 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.11</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">August&#160;20, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Tom Frohlich</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Re: Offer of Employment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Dear Tom:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On behalf of Jade Biosciences,&#160;Inc. (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u>&#8221;),&#160;I am very pleased to offer you a position as Chief Executive Officer of the Company (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CEO</u>&#8221;) and a member of the Company&#8217;s Board of Directors (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board</u>&#8221;) pursuant to this letter agreement (the &#8220;Agreement&#8221;), provided you accept such offer as indicated by your signature below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Your position as a member of the Board and as CEO of the Company will commence as of October&#160;3, 2024 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u>&#8221;). Should you not commence services by the Effective Date or if this Agreement is otherwise terminated on or prior to the Effective Date, you hereby agree that this Agreement shall be void <i style="font-style:italic;">ab initio</i> and of no force or effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As the Company does not presently have a Canadian entity, your employment will be administered by a Canadian PEO, Globalization Partners LLC. We will be providing you with an employment agreement to execute with Globalization Partners LLC and your execution of that employment agreement is a condition of accepting your employment with the Company. While Globalization Partners LLC will be the named employer for Canadian payroll and tax purposes, the Company will be your employer for all other purposes. The Company may incorporate a Canadian subsidiary, and upon that happening the Canadian subsidiary will become your employer &#8211; with the Company and the Canadian subsidiary being jointly and severally liable for all liabilities under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Positions</b>. As CEO, you will report to the Board, and you shall have all duties, authorities, and responsibilities customarily associated with a CEO role. This is a full-time employment position. You will be a member of the Board until, pursuant to the terms of the Company&#8217;s bylaws, your successor is elected and duly qualified or until your earlier death, disability, resignation or removal. Notwithstanding the foregoing, for so long as you serve as CEO of the Company while the ownership interests of the Company are privately held, you will also be a member of the Board. If at any time the Company, or any successor entity, is publicly traded while you serve as CEO of the Company, you will be nominated for shareholder approval to serve as a member of the Board. Following the Effective Date, you will be deemed to have resigned from the Board upon ceasing to serve as CEO for any reason unless the Board agrees otherwise. It is understood and agreed that, commencing as of the Effective Date you will not engage in any other employment, consulting or other business activities (whether full-time or part-time), except as a director of Nested Therapeutics,&#160;Inc. and Borealis Therapeutics, or as expressly authorized in writing by the Board. Notwithstanding the foregoing, you may engage in religious, charitable and other community activities so long as such activities do not unreasonably interfere or conflict with your obligations to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Base Salary</b>. Following the Effective Date, the Company will pay you an initial base salary of $600,000 USD per year, payable in accordance with the Company&#8217;s standard payroll schedule and subject to applicable deductions and withholdings. Your base salary will be subject to periodic review and potential increases in the Company&#8217;s discretion. Your base salary in effect at any given time is referred to herein as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Salary</u>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Annual Bonus</b>. Commencing as of the Effective Date, you will be eligible to receive an annual performance bonus targeted at 50% of your Base Salary. The target annual bonus in effect at any given time is referred to herein as &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Target Bonus</u>.&#8221; Your 2024 annual bonus will be prorated based on your period of employment following the Effective Date. The actual bonus amount is discretionary and may be subject to achievement of performance targets established by the Board for such year. To earn an annual bonus, you must be employed by the Company as of the payment date of such bonus. Any annual bonus will be paid no later than March&#160;15th of the calendar year following the calendar year to which such bonus relates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#160;Equity</b>. Subject to approval by the Board, as soon as practicable following the Effective Date, the Company will grant you stock options to purchase a number of shares of the Company&#8217;s common stock representing 5.0% of the Company&#8217;s fully-diluted equity (reflecting all outstanding convertible preferred stock, warrants, options and other equity interests that are convertible into or exercisable for common stock on an as-converted and as-exercised basis) (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fully Diluted</u>&#8221;) with a purchase price determined by the Board on the date of grant (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Initial Options</u>&#8221;). The Initial Options will vest as follows: (a)&#160;25% of the Initial Options will vest on the one-year anniversary of the Effective Date and (b)&#160;the balance of the Initial Options will vest thereafter in approximately equal monthly installments for the next 36 months so that you would be fully vested on the four-year anniversary of the Effective Date, provided that you continue to serve as the Company&#8217;s CEO from the Effective Date through each such vesting date. The Initial Options will be governed by the terms of the related Stock Option Agreement, the Equity Plan (as defined below) and the terms and conditions approved by the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, and subject to approval by the Board or a committee thereof, following the Effective Date, the Company will periodically grant you additional stock options to purchase shares of the Company&#8217;s common stock, at an exercise price as determined by the Board or a committee thereof (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Replenishment Options</u>&#8221;), in order to maintain your ownership at approximately 5.0% on a Fully-Diluted basis until the Company has raised an aggregate of $200,000,000; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that the Board shall have no obligation to grant you additional stock options thereafter. The Replenishment Options will vest in 48 approximately equal monthly installments commencing on the applicable date(s)&#160;of grant; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, that you continue providing services to the Company through each vesting date. The Replenishment Options will be governed by the terms of the related award agreements, the Equity Plan and the terms and conditions approved by the Board or a committee thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Benefits/Paid Time Off. </b>Commencing as of the Effective Date, you will be eligible, subject to the terms of the applicable plans and programs, to participate in the employee benefits and insurance programs generally made available to the Company&#8217;s full-time employees in Canada. Details of such benefits programs, including applicable employee contributions and waiting periods, if applicable, will be made available to you when such benefit(s)&#160;become available. You will be entitled to paid time off consistent with the terms of the Company&#8217;s paid time off policy, as in effect from time to time. The Company reserves the right to modify, limit, amend or replace any of its benefits plans or programs at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Board Meetings; Expenses; Indemnification</b>. You will be expected to attend scheduled Board meetings in person whenever you are able and permitted by applicable health regulations and to participate by telephone if you are not able to attend in person. The Company will reimburse you for reasonable travel expenses in connection with attending Board meetings and for performing services as CEO in accordance with the policies and procedures then in effect and established by the Company for its executives. The Company will indemnify you for your service as a member of the Board in accordance with the Company&#8217;s bylaws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#160;Location</b>. Your primary work location will be remotely in Vancouver, Canada, provided that you may be required to engage in reasonable travel for business, consistent with the Company&#8217;s business needs. You may change your remote work location with prior written notice to and approval from the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Page 2 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#160;Indefinite Term Employment; Date of Termination</b>. Your employment with the Company will be indefinite until terminated in accordance with the terms of this Agreement. Your last day of employment for any reason is referred to herein as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Date of Termination</u>.&#8221; In the event that you elect to end your employment with the Company, the Company requires you to provide at least 30 days&#8217; advance written notice to the Company; and in the event that the Company terminates you without Cause, you shall be given at least 30 days advance written notice by the Company. Notwithstanding the foregoing, the Company may unilaterally accelerate the Date of Termination, and such acceleration shall not result in a termination by the Company without Cause for purposes of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To the extent applicable, you shall be deemed to have resigned from all officer and Board member positions that you hold with the Company or any of its respective subsidiaries and affiliates upon the termination of your employment for any reason. You shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Accrued Obligations</b>. In the event of the ending of your employment for any reason, the Company shall pay you (i)&#160;your Base Salary and, if applicable, any accrued but unused vacation, through the Date of Termination, (ii)&#160;the amount of any documented expenses properly incurred by you on behalf of the Company prior to any such termination and not yet reimbursed, and (iii)&#160;your statutory obligations (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accrued Obligations</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Severance Pay and Benefits Outside of the Change in Control Period</b>. In the event that the Company terminates your employment without Cause (and not as a result of your death or Disability) outside of the Change in Control Period, then, in addition to the Accrued Obligations, and subject to your execution of a separation agreement and release in a form acceptable to the Company, which shall include a general release of claims against the Company and all related persons and entities and a reaffirmation of the Continuing Obligations (as defined below) and shall provide that if you breach the Continuing Obligations, all payments of the following severance pay and benefits shall immediately cease (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation Agreement and Release</u>&#8221;):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Company shall pay you an amount equal to 12 months of your Base Salary (inclusive of your statutory entitlement) plus 15% to account for lost benefits over the reasonable notice period, payable in a lump sum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Company shall pay you any bonus earned but unpaid for the year immediately preceding the year in which the Date of Termination occurs, payable at the time such bonuses are paid to other Company employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding anything to the contrary in any applicable equity-based award agreement or plan, an additional 30% of the unvested portion of your then outstanding equity-based awards subject to time-based vesting (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Time-Based Equity Awards</u>&#8221;) shall immediately accelerate and become vested or nonforfeitable as of the later of (i)&#160;the Date of Termination or (ii)&#160;the effective date of the Separation Agreement and Release (such later date being the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accelerated Vesting Date</u>&#8221;); provided that no such acceleration of vesting shall occur if the Date of Termination precedes the one-year anniversary of the Effective Date; and provided further that any termination or forfeiture of the unvested portion of such Time-Based Equity Awards that would otherwise occur on the Date of Termination in the absence of this Agreement will be delayed until the effective date of the Separation Agreement and Release and will only occur if the vesting pursuant to this subsection does not occur due to the absence of the Separation Agreement and Release becoming fully effective within the time period set forth therein. Notwithstanding the foregoing, no additional vesting of the Time-Based Equity Awards shall occur during the period between the Date of Termination and the Accelerated Vesting Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Page 3 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Severance Pay and Benefits Within the Change in Control Period</b>. In the event that the Company terminates your employment without Cause (and not as a result of your death or Disability) or you resign for Good Reason, in each case within the Change in Control Period, then, in addition to you being entitled to the Accrued Obligations, and subject to your execution of the Separation Agreement and Release and it becoming fully effective, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;You will receive the severance pay and benefits set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;10(a)</u>&#160;and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10(b)</u>&#160;above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding anything to the contrary in any applicable equity-based award agreement or plan, the unvested portion of your Time-Based Equity Awards shall immediately accelerate and become vested or nonforfeitable as of the Accelerated Vesting Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the avoidance of doubt, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;10</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;11</u> of this Agreement are mutually exclusive and in no event shall you be entitled to payments or benefits pursuant to both <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;10</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;11</u> of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Continuing Obligations</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#160;<b style="font-weight:bold;">Restrictive Covenant Agreement</b>. As a condition of your employment, you are required to enter into an Invention Assignment, Non-Disclosure, and Business Protection Agreement (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Covenant Agreement</u>&#8221;), which must be signed prior to the Effective Date and is attached at Appendix B. For purposes of this Agreement, the obligations in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;12</u> and those that arise in the Covenant Agreement and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Continuing Obligations</u>.&#8221; You are advised to discuss the Covenant Agreement with a lawyer of your choice, and you have had an adequate opportunity to do so prior to executing this Agreement or the Covenant Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<b style="font-weight:bold;">Third Party Agreements and Rights</b>. You hereby confirm that you are not bound by the terms of any agreement with any previous employer or other party which would prevent you from performing your obligations hereunder. You represent to the Company that your execution of this Agreement, your employment with the Company and the performance of your proposed duties for the Company will not violate any obligations you may have to any such previous employer or other party. In your work for the Company, you will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party, and you will not bring to the premises of the Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such previous employment or other party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#160;<b style="font-weight:bold;">Litigation and Regulatory Cooperation</b>. You shall cooperate fully with the Company in (i)&#160;the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while you were engaged or employed by the Company, and (ii)&#160;the investigation, whether internal or external, of any matters about which the Company believes you may have knowledge or information. Your full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being reasonably available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after your engagement and employment, you also shall cooperate fully with the Company in connection with any investigation or review of any federal, provincial or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while you were employed by the Company. The Company shall reimburse you for any reasonable out-of-pocket expenses, including fees and costs for an independent lawyer of your choice hired by you, incurred in connection with your performance of obligations pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;12(c).</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Page 4 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<b style="font-weight:bold;">Relief</b>. You agree that it would be difficult to measure any damages caused to the Company which might result from your breach of any of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, you agree that if you breach, or propose to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to seek an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Withholding; Tax Effect</b>. All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or the Board related to tax liabilities arising from your compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Recoupment</b>. Amounts paid or payable under this Agreement shall be subject to the provisions of any applicable clawback or recoupment policies or procedures adopted by the Company, which clawback or recoupment policies may provide for forfeiture and/or recoupment of amounts paid or payable under this Agreement. No forfeiture or recoupment under such policies or procedures will give rise to a right to resign for Good Reason under this Agreement or any other agreement between you and the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">15.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Interpretation and Enforcement</b>. This Agreement, together with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</u>, the Covenant Agreement, and any award agreement between you and the Company, constitute the complete agreement between you and the Company, contains all of the terms of your employment with the Company and supersedes any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. The terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or arising out of, related to, or in any way connected with this Agreement, your employment with the Company or any other relationship between you and the Company (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disputes</u>&#8221;) will be governed by the laws of British Columbia, excluding laws relating to conflicts or choice of law and excluding Disputes arising in connection with any equity incentive plan, which shall be governed by the terms of the applicable equity incentive plan. You and the Company submit to the exclusive personal jurisdiction of the courts located in the Province of British Columbia in connection with any Dispute or any claim related to any Dispute, except for Disputes arising under any equity incentive plan, which shall be governed by the terms of the applicable equity incentive plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">16.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Assignment</b>. Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement without your consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets; provided further, that if you remain employed or become employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then you shall not be entitled to any payments, benefits or vesting pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;10</u> or pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;11</u> of this Agreement solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon you and the Company, and each of your and its respective successors, executors, administrators, heirs and permitted assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Page 5 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">17.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Waiver; Amendment</b>. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. This Agreement may be amended or modified only by a written instrument signed by you and by a duly authorized representative of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">18.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Enforceability</b>. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">19.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Conditions</b>. You must submit satisfactory proof of your identity and provide documentation of your legal authorization to work in Canada on or prior to the Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">20.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Prior employment agreements</b>. It is the policy of the Company not to solicit or accept proprietary information and/or trade secrets of other companies or third parties. If you have or have had access to trade secrets or other confidential, proprietary information from your former employer or another third party, the use of such information in performing your duties at the Company is prohibited. This may include, but is not limited to, confidential or proprietary information in the form of documents, magnetic media, software, customer lists, and business plans or strategies. In making this employment offer, the Company relies on your representation that you will not bring with you to the Company or use in the performance of your responsibilities at the Company any materials, documents or work product of a former employer or other third party that are not generally available to the public, unless you have obtained written authorization from such former employer or third party for their possession and use and have provided the Company with a copy of same. Also in making this employment offer, the Company has reviewed your prior employment agreement and agrees that: (a)&#160;you are not currently a party to any agreement that would restrict your ability to accept this offer or to perform services for the Company; (b)&#160;you are not subject to any noncompetition or non-solicitation agreement or other restrictive covenants that might restrict your employment by the Company as contemplated by this offer; and (c)&#160;you have the full right, power and authority to execute and deliver the Agreement and to perform all of your obligations thereunder. In the event that your prior employer commences any proceedings against you in relation to your acceptance of this employment offer and/or your employment by the Company, the Company will fully indemnify you including paying for your legal fees incurred in defending yourself against such proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">21.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Other Terms</b>. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of your employment to the extent necessary to effectuate the terms contained herein. The headings and other captions in this Agreement are for convenience and reference only and shall not be used in interpreting, construing or enforcing any of the provisions of this Agreement. This Agreement may be executed in separate counterparts. When both counterparts are signed, they shall be treated together as one and the same document. PDF copies of signed counterparts shall be equally effective as originals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">22.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Currency</b>. All amounts in this Agreement are expressed in US Dollars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Page 6 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">I look forward to working with you to make the Company a great success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Sincerely,</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ Tomas Kiselak</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Name: Tomas Kiselak</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Title: Director</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accepted and acknowledged:</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ Tom Frohlich</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Tom Frohlich</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">8/20/2024</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Page 7 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cause</u>&#8221; shall mean (i)&#160;your dishonest statements or acts with respect to the Company or any affiliate of the Company, or any current or prospective customers, suppliers, vendors or other third parties with which such entity does business that results in or is reasonably anticipated to result in material harm to the Company; (ii)&#160;your conviction or plea of no contest to: (A)&#160;an indictable offence or (B)&#160;any offence involving moral turpitude, deceit, dishonesty or fraud; (iii)&#160;your failure to perform in all material respects your assigned duties and responsibilities to the reasonable satisfaction of the Board, which failure continues, in the reasonable judgment of the Board, for 30 days after written notice given to you describing such failure; (iv)&#160;your gross negligence, willful misconduct that results in or is reasonably anticipated to result in material harm to the Company; or (v)&#160;your violation of any material provision of any agreement(s)&#160;between you and the Company or any written Company policies including, without limitation, agreements relating to non-solicitation, non-disclosure and/or assignment of inventions or policies related to ethics or workplace conduct.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Control</u>&#8221; shall have the meaning set forth in the Equity Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Control Period</u>&#8221; shall mean the 12-month period beginning on the consummation of the first event constituting a Change in Control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Code</u>&#8221; means the Internal Revenue Code of 1986, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disability</u>&#8221; shall mean a permanent and total disability as defined in Section&#160;22(e)(3)&#160;of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equity Plan</u>&#8221; shall mean the Company&#8217;s 2024 Equity Incentive Plan or any successor plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Reason</u>&#8221; shall mean that you have complied with the Good Reason Process (hereinafter defined) following the occurrence, without your written consent, of any of the following events: (i)&#160;a material diminution in your base salary or Target Bonus except for across-the-board salary and target bonus reductions of no more than 10% based on the Company&#8217;s financial performance similarly affecting all or substantially all senior management employees of the Company; (ii)&#160;a material change in the geographic location at which you are required to provide services to the Company or a requirement that you change your remote location to a location other than your then-current residence; (iii)&#160;a material reduction in your duties, authority or responsibilities; (iv)&#160;the failure of the Company to obtain the assumption of this Agreement by a successor; or (v)&#160;the material breach of this Agreement (or any other agreements with you) by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Reason Process</u>&#8221; shall mean that (i)&#160;you reasonably determine in good faith that a &#8220;Good Reason&#8221; condition has occurred; (ii)&#160;you notify the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii)&#160;you cooperate in good faith with the Company&#8217;s efforts, for a period not less than 30 days following such notice (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cure Period</u>&#8221;), to remedy the condition; (iv)&#160;notwithstanding such efforts, the Good Reason condition continues to exist; and (v)&#160;you terminate your employment within 60 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Page 8 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">APPENDIX B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">INVENTION ASSIGNMENT, NON-DISCLOSURE,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AND BUSINESS PROTECTION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THIS INVENTION ASSIGNMENT, NON-DISCLOSURE, AND BUSINESS PROTECTION AGREEMENT</b> (the &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;) is made by and between Jade Biosciences,&#160;Inc., a Delaware corporation with an office at 221 Crescent Street, Suite&#160;105, Waltham, MA 02453 (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;), and Tom Frohlich (&#8220;<b style="font-weight:bold;">Employee</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company and Employee agree as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Condition of Employment</b><b style="font-weight:bold;">.</b> Employee acknowledges that protection of the Company&#8217;s proprietary and confidential information is critical to the survival and success of the Company&#8217;s business because of the nature of the Company&#8217;s business. This Agreement is intended to protect the Company&#8217;s business (including that of its subsidiaries and affiliates) without unreasonably restricting Employee&#8217;s ability to work elsewhere if his/her employment with the Company ends. This Agreement will become effective on the date of Employee&#8217;s signature below. Employee&#8217;s obligations under this Agreement will continue even after his/her employment with the Company has ended, whether in circumstances of voluntary or involuntary termination of employment, and regardless of whether additional severance compensation is paid by the Company. Employee acknowledges and agrees that Employee has been provided at least ten (10) days to review this Agreement. Employee has been advised, and hereby is advised in writing, to discuss this Agreement with an attorney of Employee&#8217;s choice and that Employee has had an adequate opportunity to do so prior to executing this Agreement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proprietary and Confidential Information</b><b style="font-weight:bold;">.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Employee agrees that all non-public information and know-how, whether or not in writing, of a private, secret or confidential nature (whether or not marked as confidential), relating to the Company&#8217;s (including its subsidiaries&#8217; and affiliates&#8217;) actual or anticipated business, products, interests, customers, business partners, strategies, research and development or financial affairs (collectively, &#8220;<b style="font-weight:bold;">Proprietary Information</b>&#8221;) encountered by Employee in the course of or as a result of his/her relationship with the Company is and shall be the confidential information of the Company and, as between Employee and Company, the exclusive property of the Company. By way of illustration, but not limitation, Proprietary Information may include discoveries, inventions, ideas, products, product improvements, prototypes, beta versions, product enhancements, processes, methods, techniques, formulas, compositions, compounds, negotiation strategies and positions, projects, developments, plans (including business and marketing plans), research data, clinical data, financial data (including sales costs, profits, pricing methods), personnel data, computer programs (including software used pursuant to a license agreement), software source code, customer, prospect and supplier lists, and contacts at or knowledge of customers or prospective customers of the Company, and shall include Developments, as defined below. Employee will not disclose any Proprietary Information to any person or entity other than employees of the Company or use the same for any purposes (other than in the proper performance of his/her duties as an employee of the Company) without written approval by an officer of the Company, either during or after his/her employment with the Company, unless and until such Proprietary Information has become public knowledge through voluntary public disclosure by someone who had the right to make such a disclosure. While employed by the Company, Employee will use Employee&#8217;s best efforts to prevent unauthorized use, manipulation, publication or disclosure of any of the Company&#8217;s Proprietary Information.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Page 9 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Employee agrees that all files, documents, letters, memoranda, reports, records, data, sketches, drawings, models, passwords, laboratory notebooks, program listings, computer equipment or devices, computer programs or other written, photographic, or other tangible or intangible material containing Proprietary Information, whether created by Employee or others, which shall come into his/her custody or possession, shall be and are the exclusive property of the Company (or any person or entity designated by the Company) to be used by Employee only in the performance of his/her duties for the Company and shall not be copied or removed from the Company&#8217;s premises except in the reasonable pursuit of the business of the Company. All such materials or copies of such materials and all tangible property of the Company in the custody or possession of Employee shall be delivered to the Company, upon the earlier of (a) a request by the Company or (b) termination of his/her employment. After such delivery, Employee shall not retain any such materials or copies of such materials, including but not limited to electronic copies, or any such tangible property. For purposes of clarity, Employee agrees to disclose to the Company, upon the earlier of a request by the Company or termination of his/her employment, all passwords necessary or desirable to obtain access to, or that would assist in obtaining access to, any information of the Company which Employee has password-protected on any computer equipment, network or system.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Employee agrees that his/her obligation not to disclose or to use information and materials of the types set forth in paragraphs 2.1 and 2.2 above, and his/her obligation to return materials and tangible property, set forth in paragraph 2.2 above, also extends to such types of information, materials and tangible property encountered by Employee in the course of or as a result of his/her relationship with the Company or customers of the Company or suppliers to the Company or other third parties who may have disclosed or entrusted such information and materials to the Company or to Employee.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">However, in the event that Employee (a) is required, by court or administrative or regulatory order, or any governmental regulator with jurisdiction over Employee, to disclose any portion of the Proprietary Information or (b) is asked to or seeks to enter into evidence or otherwise voluntarily disclose in any administrative, judicial, quasi-judicial or arbitral proceeding, any portion of the Proprietary Information, Employee shall provide the Company with prompt written notice of any such request or requirement prior to the disclosure of Proprietary Information, so the Company may, at the Company&#8217;s expense, seek a protective order or other appropriate remedy to prohibit or to limit such disclosure. If, in the absence of a protective order, Employee is nonetheless compelled to disclose any Proprietary Information, Employee shall as soon as practicable thereafter advise the Company of the Proprietary Information so disclosed and the persons to whom it was so disclosed, and thereafter, may disclose only such portions of the Proprietary Information that are legally required to be disclosed.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Page 10 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">In addition, this Agreement does not prohibit Employee from participating in or cooperating with any government investigation or proceeding, nor does this Agreement restrict Employee from disclosing Proprietary Information to government agencies in a reasonable manner when permitted by applicable provincial or federal &#8220;whistleblower&#8221; or other laws.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Developments</b><b style="font-weight:bold;">.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">3.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Employee will, except as expressly provided in paragraph 3.5, make full and prompt disclosure to the Company of: all discoveries, inventions, improvements, enhancements, processes, methods, techniques, developments, software, and works of authorship, whether patentable or not:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">which have been created, made, conceived or reduced to practice by Employee or under his/her direction or jointly with others prior to the date hereof and which are potentially competitive with, or relate directly or indirectly to, the Company&#8217;s (including its subsidiaries&#8217; and affiliates&#8217;) actual or anticipated business, products, interests or research and development,</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">which are created, made, conceived or reduced to practice by him/her or under his/her direction or jointly with others during his/her employment by the Company, whether or not during normal working hours or on the premises of the Company, or</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">which are created, made, conceived or reduced to practice by him/her or under his/her direction or jointly with others using or based on knowledge of the Company&#8217;s tools, devices, equipment or Proprietary Information (all of which are collectively referred to in this Agreement as &#8220;<b style="font-weight:bold;">Developments</b>&#8221;).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">3.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Employee agrees to assign and does hereby irrevocably assign to the Company (or any person or entity designated by the Company) all his/her right, title and interest in and to all Developments and all related patents, patent applications, copyrights and copyright applications. However, this paragraph 3.2 shall not apply to Prior Inventions (as hereinafter defined) or Developments described in clauses 3.1(b) and 3.1(c) above which are not potentially competitive with, and do not relate directly or indirectly to, the Company&#8217;s (including its subsidiaries&#8217; and affiliates&#8217;) actual or anticipated business, products, interests or research and development at the time such Development is created, made, conceived or reduced to practice, and which are made and conceived by Employee not during normal working hours, not on the Company&#8217;s premises and not using or based on knowledge of the Company&#8217;s tools, devices, equipment or Proprietary Information. Employee understands that, to the extent this Agreement shall be construed in accordance with the laws of any jurisdiction which precludes a requirement in an employee agreement to assign certain classes of inventions made by an employee, this paragraph 3.2 shall be interpreted not to apply to any invention which a court rules and/or the Company agrees falls within such classes. Employee also hereby waives all claims to moral rights in any Developments. To the extent any Development (in whole or in part) is not assignable to the Company by law, Employee hereby grants to the Company an exclusive, perpetual, irrevocable, worldwide, sublicensable and fully transferrable right and license to use such Development in any manner without limitation.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">3.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Any copyrightable work prepared in whole or in part by Employee in the course of Employee&#8217;s work for the Company shall be deemed a &#8220;work made for hire&#8221; under copyright laws, and the Company shall own all rights therein. To the extent that any such copyrightable work is not deemed a &#8220;work made for hire,&#8221; Employee hereby irrevocably assigns and agrees to assign to the Company, from the moment of creation, all right, title and interest, including without limitation, copyright in and to such copyrightable work.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Page 11 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">3.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">All discoveries, inventions, improvements, enhancements, processes, methods, techniques, developments, software, and works of authorship, whether patentable or not, arising in the one year period after the termination or cessation of such employment for any reason which (a) are potentially competitive with, or relate directly or indirectly to, the Company&#8217;s (including its subsidiaries&#8217; and affiliates&#8217;) actual or anticipated business, products, interests or research and development, and (b) relate to any patent, copyright, trade secret, or other intellectual property right, worked on by Employee while Employee is employed by the Company, shall be presumed to have been created, made, conceived or reduced to practice during Employee&#8217;s employment with the Company and shall therefore be deemed a Development; <i style="font-style:italic;">provided, however</i>, that Employee may overcome the presumption with respect to the period of one year after the termination or cessation of employment by proving that such creation, making, conception or reduction to practice occurred exclusively following employment with the Company and without use of, and not based on knowledge of, the Company&#8217;s tools, devices, equipment or Proprietary Information.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">3.5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">To preclude any possible uncertainty concerning the ownership of Developments, Employee agrees to provide to the Company a complete written list of any Developments that Employee considers to be his/her property or the property of a third party and that Employee and the Company agree shall be excluded from the scope of this Agreement (&#8220;<b style="font-weight:bold;">Prior Inventions</b>&#8221;). If disclosure of any Prior Invention would cause Employee to violate any prior confidentiality agreement, Employee understands that Employee is not to fully describe such Prior Inventions, but is only to disclose a cursory name for each such invention, a listing of the party(ies) to whom it belongs and the fact that full disclosure as to such invention has not been made for that reason. Employee shall also list all patents and patent applications in which Employee is named as an inventor, other than those which have been assigned to the Company. If no such disclosure is provided on or before the start of Employee&#8217;s employment by the Company, Employee represents that there are no Prior Inventions.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">3.6</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Employee agrees to cooperate fully with the Company (or any person or entity designated by the Company), both during and after his/her employment with the Company, with respect to the procurement, maintenance and enforcement of copyrights, patents and other intellectual property rights (both in the Canada and foreign countries) relating to Developments. Employee shall sign all papers, including, without limitation, copyright applications, patent applications, declarations, oaths, formal assignments, assignments of priority rights, and powers of attorney, which the Company (or any person or entity designated by the Company) may deem necessary or desirable in order to protect its rights and interests in any Development. Employee will not seek additional compensation or reimbursement from the Company for time spent complying with these obligations. Employee further agrees that if the Company (or any person or entity designated by the Company) is unable, after reasonable effort, to secure the signature of Employee on any such papers, the Company and its duly authorized officers and designees shall be entitled to execute any such papers as the agent and the attorney-in-fact of Employee, and Employee hereby irrevocably designates and appoints the Company and its duly authorized officers and designees as his/her agent and attorney-in-fact to execute any such papers on his/her behalf, and to take any and all actions as may be deemed necessary or desirable in order to protect the Company&#8217;s or its designees&#8217; rights and interests in any Development, under the conditions described in this sentence.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Page 12 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Solicitation</b>. While Employee is employed by the Company and for a period of one (1) year after the termination or cessation of such employment for any reason (the &#8220;<b style="font-weight:bold;">Non-Solicitation Period</b>&#8221;), Employee will not directly or indirectly:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">4.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Either alone or in association with others, solicit, divert or take away, or attempt to divert or take away, the business or patronage of any of the clients, customers, or business partners of the Company that were contacted, solicited, or served by Employee directly or the Company during the 12-month period prior to the termination or cessation of Employee&#8217;s employment with the Company; or</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">4.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Either alone or in association with others (a) solicit, induce or attempt to induce, any employee or independent contractor of the Company to terminate his or her employment or other engagement with the Company, or (b) hire, or recruit or attempt to hire, or engage or attempt to engage as an independent contractor, any person who was employed or otherwise engaged by the Company at any time during the term of Employee&#8217;s employment with the Company; <i style="font-style:italic;">provided</i>, that this clause (b) shall not apply to the recruitment or hiring or other engagement of any individual whose employment or other engagement with the Company has been terminated for a period of six months or longer. However, this paragraph 4.2 shall not apply to (x) general advertising or solicitation not specifically targeted at the Company, its employees or independent contractors, (y) Employee serving as a reference, upon request, for any employee or independent contractor of the Company, and (z) actions taken by any person or entity with which Employee is associated if Employee is not personally involved in any manner in the hiring, recruitment, solicitation or engagement of any such individual (including but not limited to identifying any such individual for hiring, recruitment, solicitation or engagement).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">4.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">So that the Company may enjoy the full benefit of the covenants contained in this paragraph 4, Employee further agrees that the Non-Solicitation Period shall be tolled, and shall not run, during the period of any breach by Employee of such covenants.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Parties; Other Agreements</b><b style="font-weight:bold;">.</b> Employee represents that, except as Employee has disclosed in writing to the Company, Employee is not bound by the terms of any agreement with any previous employer or other party to refrain from using or disclosing any trade secret or confidential or proprietary information in the course of his/her employment with the Company, to refrain from competing, directly or indirectly, with the business of such previous employer or any other party or to refrain from soliciting employees, customers or suppliers of such previous employer or other party. Employee further represents that his/her performance of all the terms of this Agreement and the performance of his/her duties as an employee of the Company do not and will not conflict with or breach any agreement with any prior employer or other party to which Employee is a party (including without limitation any nondisclosure or non-competition agreement), and that Employee has not and will not disclose to the Company, bring onto the Company&#8217;s premises, or use or induce the Company to use, any confidential or proprietary information or material belonging to any previous employer or others.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Page 13 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Federal Government Obligations</b><b style="font-weight:bold;">.</b> Employee acknowledges that the Company from time to time may have agreements with other persons or with the federal governments of Canada or the United States, or agencies and regulatory authorities thereof, which impose obligations or restrictions on the Company regarding inventions made during the course of work under such agreements or regarding the confidential nature of such work. Employee agrees to be bound by all such obligations and restrictions that are made known to Employee and to take all action necessary to discharge the obligations binding the Company under such agreements.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous</b><b style="font-weight:bold;">.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">7.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equitable Remedies</u>. The restrictions contained in this Agreement are necessary for the protection of the business and goodwill of the Company and are considered by Employee to be reasonable for such purpose. Employee agrees that any breach of this Agreement is likely to cause the Company substantial and irrevocable damage that is difficult to measure. Therefore, in the event of any such breach or threatened breach, Employee agrees that the Company, in addition to such other remedies which may be available, shall have the right to obtain an injunction from a court restraining such a breach or threatened breach and the right to specific performance of the provisions of this Agreement, without having to post bond, and Employee hereby waives the adequacy of monetary damages or other remedy at law as a defense to such relief.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">7.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosure of this Agreement</u>. Employee hereby authorizes the Company to notify others, including but not limited to customers of the Company and any of Employee&#8217;s future employers or prospective business associates, of the terms and existence of this Agreement and Employee&#8217;s continuing obligations to the Company pursuant to this Agreement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">7.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Employment Contract and No License</u>. Employee acknowledges that this Agreement does not constitute a contract of employment and does not imply that the Company will continue his/her employment for any period of time. Employee further acknowledges that no license to any of the Company&#8217;s trademarks, patents, copyrights or other proprietary rights is either granted or implied by Employee&#8217;s access to and utilization of the Proprietary Information or Developments.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">7.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors and Assigns</u>. This Agreement is binding on Employee and his/her heirs, executors and administrators, and is for the benefit of the Company and its successors and assigns. The Company may designate affiliates and/or subsidiaries of the Company to have the same rights as the Company under this Agreement, and any obligation owed to the Company under this Agreement shall be owed to such an affiliate or subsidiary in the same manner as they are owed to the Company.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">7.5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interpretation</u>. If any restriction set forth in paragraphs 3 or 4 is found by any court of competent jurisdiction to be unenforceable because it extends for too long a period of time or over too great a scope of activities or in too broad a geographic area, it shall be interpreted to extend only over the maximum period of time, scope of activities or geographic area as to which it may be enforceable.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">7.6</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u>. In case any provision of this Agreement shall be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Page 14 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">7.7</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waivers</u>. No delay or omission by the Company in exercising any right under this Agreement will operate as a waiver of that or any other right. A waiver or consent given by the Company on any one occasion is effective only in that instance and will not be construed as a bar to or waiver of any right on any other occasion.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">7.8</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u>. This Agreement is deemed to be made in the Province of British Columbia, and will be governed by and construed and interpreted in accordance with the laws of the Province of British Columbia and the laws of Canada applicable therein, without regard to conflict of laws principles that would require the application of the laws of another jurisdiction.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">7.9</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement; Amendment</u>. This Agreement supersedes all prior agreements, written or oral, between Employee and the Company relating to the subject matter of this Agreement. This Agreement may not be modified, changed or discharged in whole or in part, except by an agreement in writing signed by Employee and the Company. Employee agrees that any change or changes in his/her duties, salary or compensation after the signing of this Agreement shall not affect the validity or scope of this Agreement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">7.10</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Captions</u>. The captions of the sections and paragraphs of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section or paragraph of this Agreement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">7.11</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Review by Counsel</u>. Employee acknowledges that he/she had the right to consult with legal counsel before signing this Agreement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[Signature page&#160;follows]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Page 15 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">EMPLOYEE ACKNOWLEDGES THAT HE/SHE HAS CAREFULLY READ THIS AGREEMENT, THAT EMPLOYEE HAD THE RIGHT TO CONSULT WITH COUNSEL BEFORE SIGNING BELOW, AND THAT EMPLOYEE WAS PROVIDED WITH THIS AGREEMENT ON THE EARLIER OF THE SUBMISSION OF A FORMAL OFFER OF EMPLOYMENT OR TEN BUSINESS DAYS BEFORE COMMENCEMENT OF EMPLOYMENT. EMPLOYEE UNDERSTANDS AND AGREES TO ALL OF THE PROVISIONS IN THIS AGREEMENT.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES,&#160;INC.</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">TOM FROHLICH</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ Tomas Kiselak</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By: </p></td><td style="vertical-align:top;width:44%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ Tom Frohlich</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:44%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Tomas Kiselak</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">8/20/2024</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:44%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">8/20/2024</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>7
<FILENAME>avte-20240930xex10d12.htm
<DESCRIPTION>EXHIBIT 10.12
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 12/3/2024 12:41:47 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.12</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">August&#160;29, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Jonathan Quick</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Re: Offer of Employment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Dear Jonathan:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On behalf of Jade Biosciences,&#160;Inc. (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u>&#8221;),&#160;I am very pleased to offer you a position as Senior Vice President, Finance of the Company (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Role</u>&#8221;) pursuant to this letter agreement (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;), provided you accept such offer as indicated by your signature below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Your employment with the Company in the Role will commence as of September&#160;23, 2024 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u>&#8221;). Should you not commence services by the Effective Date or if this Agreement is otherwise terminated on or prior to the Effective Date, you hereby agree that this Agreement shall be void <i style="font-style:italic;">ab initio</i> and of no force or effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Position</b>. While serving in the Role, you will initially report to the Company&#8217;s Chief Executive Officer (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CEO</u>&#8221;) or such other person as the CEO may designate, and have such duties, authorities, and responsibilities as are customarily associated with the Role. This is a full-time employment position. It is understood and agreed that, commencing as of the Effective Date you will not engage in any other employment, consulting or other business activities (whether full-time or part-time). Notwithstanding the foregoing, you may engage in religious, charitable and other community activities so long as such activities do not unreasonably interfere or conflict with your obligations to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Base Salary</b>. The Company will pay you an initial base salary of $320,000 per year, payable in accordance with the Company&#8217;s standard payroll schedule and subject to applicable deductions and withholdings. Your base salary will be subject to periodic review and potential adjustment in the Company&#8217;s discretion. Your base salary in effect at any given time is referred to herein as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Salary</u>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Annual Bonus</b>. Commencing as of the Effective Date, you will be eligible to receive an annual performance bonus targeted at 35% of your Base Salary. The target annual bonus in effect at any given time is referred to herein as &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Target Bonus</u>.&#8221; Your 2024 annual bonus will be prorated based on your period of employment following the Effective Date. The actual bonus amount is discretionary and may be subject to achievement of performance targets established by the Company for such year. To earn an annual bonus, you must be employed by the Company as of the payment date of such bonus. Any annual bonus will be paid no later than March&#160;15th of the calendar year following the calendar year to which such bonus relates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Equity. </b>Subject to approval by the Board of Directors of the Company (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board</u>&#8221;) or the Compensation Committee of the Board (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Committee</u>&#8221;), it is anticipated that the Company will grant you stock options to purchase 132,786 shares of the Company&#8217;s common stock (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Options</u>&#8221;) as soon as practicable following the Effective Date, with an exercise price per share equal to the fair market value of a share of the Company&#8217;s common stock on the date of grant (as determined by the Board or the Committee in its sole discretion). The Options will vest over a four-year period following the Effective Date, with 25% of the Options vesting on the first anniversary of the Effective Date, and the remainder vesting in 36 equal monthly installments on each monthly anniversary thereafter, in each case, subject to your continued service with the Company through the applicable vesting dates. The Options will be governed by the terms of the related award agreement, the Company&#8217;s Amended and Restated 2024 Equity Incentive Plan (as amended from time to time and including any successor plan, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equity Plan</u>&#8221;) and the terms and conditions approved by the Board or the Committee. In addition to the Options, you may be eligible to receive such future equity grants as the Board or the Committee may deem appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Benefits/Paid Time Off. </b>Commencing as of the Effective Date, you will be eligible, subject to the terms of the applicable plans and programs, to participate in the employee benefits and insurance programs generally made available to the Company&#8217;s full-time employees. Details of such benefits programs, including applicable employee contributions and waiting periods, if applicable, will be made available to you when such benefit(s)&#160;become available. You will be entitled to paid time off consistent with the terms of the Company&#8217;s paid time off policy, as in effect from time to time. The Company reserves the right to modify, limit, amend or cancel any of its benefits plans or programs at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Expense Reimbursement. </b>The Company will reimburse you for all reasonable and necessary expenses incurred by you in connection with performing your duties as an employee of the Company and that are pre-approved by the Company, provided that you comply with any Company policy or practice on submitting, accounting for and documenting such expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Location</b>. Your primary work location will be remotely in Massachusetts, provided that you may be required to engage in reasonable travel for business, consistent with the Company&#8217;s business needs. You may change your remote work location with prior written notice to and approval from the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;At-Will Employment; Date of Termination</b>. At all times, your employment with the Company is &#8220;at will,&#8221; meaning you or the Company may terminate it at any time for any or no reason, subject to the terms of this Agreement. Although your job duties, title, reporting structure, compensation and benefits, as well as the Company&#8217;s benefit plans and personnel policies and procedures, may change from time to time (subject to the terms of this Agreement), the &#8220;at will&#8221; nature of your employment may only be changed in an express written agreement signed by you and an authorized officer of the Company. Your last day of employment for any reason is referred to herein as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Date of Termination</u>.&#8221; In the event that you elect to end your employment with the Company, the Company requires you to provide at least 30 days&#8217; advance written notice to the Company. Notwithstanding the foregoing, the Company may unilaterally accelerate the Date of Termination, and such acceleration shall not result in a termination by the Company without Cause for purposes of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To the extent applicable, you shall be deemed to have resigned from all officer and board member positions that you hold with the Company or any of its respective subsidiaries and affiliates upon the termination of your employment for any reason. You shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Accrued Obligations</b>. In the event of the ending of your employment for any reason, the Company shall pay you (i)&#160;your Base Salary and, if applicable, any accrued but unused vacation, through the Date of Termination, and (ii)&#160;the amount of any documented expenses properly incurred by you on behalf of the Company prior to any such termination and not yet reimbursed. (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accrued Obligations</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Severance Pay and Benefits Outside of the Change in Control Period</b>. In the event that the Company terminates your employment without Cause (and not as a result of your death or Disability) outside of the Change in Control Period (as such capitalized terms are defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</u>), then, in addition to the Accrued Obligations, and subject to (i)&#160;your execution and non-revocation of a separation agreement and release in a form acceptable to the Company, which shall include a general release of claims against the Company and all related persons and entities and a reaffirmation of the Continuing Obligations (as defined below) and shall provide that if you breach the Continuing Obligations, all payments of the following severance pay and benefits shall immediately cease (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation Agreement and Release</u>&#8221;), and (ii)&#160;the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven-day revocation period:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Company shall pay you an amount equal to six months of your Base Salary, payable in substantially equal installments over the six-month period following the Date of Termination in accordance with the Company&#8217;s regular payroll practices beginning on the Company&#8217;s first regularly scheduled payroll date following the date that is 60 days after the Date of Termination; provided, however, that the first installment shall include any amounts that would have been paid following the Date of Termination had such installments commenced on the first regularly scheduled payroll date following the Date of Termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Company shall pay you any bonus earned but unpaid for the year immediately preceding the year in which the Date of Termination occurs, payable at the time such bonuses are paid to other Company employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject to your copayment of premium amounts at the applicable active employees&#8217; rate and your proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COBRA</u>&#8221;), the Company shall pay to the group health plan provider(s), the COBRA provider or you a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to you if you had remained employed by the Company until the earliest of (A)&#160;the six-month anniversary of the Date of Termination; (B)&#160;your eligibility for group health plan benefits under any other employer&#8217;s group health plan; or (C)&#160;the cessation of your continuation rights under COBRA; provided, however, that if the Company reasonably determines that it cannot pay such amounts to the group health plan provider(s)&#160;or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section&#160;2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to you for the time period specified above. Such payments, if to you, shall be subject to tax-related deductions and withholdings and paid on the Company&#8217;s regular payroll dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Severance Pay and Benefits Within the Change in Control Period</b>. In the event that the Company terminates your employment without Cause (and not as a result of your death or Disability) or you resign for Good Reason, in each case within the Change in Control Period, then, in addition to you being entitled to the Accrued Obligations, and subject to your execution and non-revocation of the Separation Agreement and Release and it becoming fully effective, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven-day revocation period:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;You will receive the severance pay and benefits set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;10</u> above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding anything to the contrary in any applicable equity-based award agreement or plan, the unvested portion of your then outstanding equity-based awards subject to time-based vesting shall immediately accelerate and become vested or nonforfeitable as of the later of (i)&#160;the Date of Termination or (ii)&#160;the effective date of the Separation Agreement and Release.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the avoidance of doubt, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;10</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;11</u> of this Agreement are mutually exclusive and in no event shall you be entitled to payments or benefits pursuant to both <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;10</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;11</u> of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Continuing Obligations</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<b style="font-weight:bold;">Restrictive Covenant Agreement</b>. As a condition of your employment, you are required to enter into an Invention Assignment, Non-Disclosure, and Business Protection Agreement (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Covenant Agreement</u>&#8221;), which must be signed prior to the Effective Date. For purposes of this Agreement, the obligations in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;12</u> and those that arise in the Covenant Agreement and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Continuing Obligations</u>.&#8221; You are advised to discuss the Covenant Agreement with an attorney of your choice, and you have had an adequate opportunity to do so prior to executing this Agreement or the Covenant Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<b style="font-weight:bold;">Third Party Agreements and Rights</b>. You hereby confirm that you are not bound by the terms of any agreement with any previous employer or other party which would prevent you from performing your obligations hereunder. You represent to the Company that your execution of this Agreement, your employment with the Company and the performance of your proposed duties for the Company will not violate any obligations you may have to any such previous employer or other party. In your work for the Company, you will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party, and you will not bring to the premises of the Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such previous employment or other party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<b style="font-weight:bold;">Litigation and Regulatory Cooperation</b>. You shall cooperate fully with the Company in (i)&#160;the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while you were engaged or employed by the Company, and (ii)&#160;the investigation, whether internal or external, of any matters about which the Company believes you may have knowledge or information. Your full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being reasonably available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after your engagement and employment, you also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while you were employed by the Company. The Company shall reimburse you for any reasonable out-of-pocket expenses, including fees and costs for an independent attorney of your choice hired by you, incurred in connection with your performance of obligations pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;12(c).</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<b style="font-weight:bold;">Relief</b>. You agree that it would be difficult to measure any damages caused to the Company which might result from your breach of any of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, you agree that if you breach, or propose to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to seek an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Golden Parachute Taxes</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<b style="font-weight:bold;">Best After-Tax Result</b>. In the event that any payment or benefit received or to be received by you pursuant to this Agreement or otherwise (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payments</u>&#8221;) would (i)&#160;constitute a &#8220;parachute payment&#8221; within the meaning of Section&#160;280G of the Code and (ii)&#160;but for this subsection (a), be subject to the excise tax imposed by Section&#160;4999 of the Code, any successor provisions, or any comparable federal, state, local or foreign excise tax (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excise Tax</u>&#8221;), then, subject to the provisions of Section&#160;14, such Payments shall be either (A)&#160;provided in full pursuant to the terms of this Agreement or any other applicable agreement, or (B)&#160;provided as to such lesser extent which would result in the Payments being $1.00 less than the amount at which any portion of the Payments would be subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state, local and foreign income, employment and other taxes and the Excise Tax (including, without limitation, any interest or penalties on such taxes), results in the receipt, on an after-tax basis, of the greatest amount of payments and benefits provided for hereunder or otherwise, notwithstanding that all or some portion of such Payments may be subject to the Excise Tax. Unless the Company and you otherwise agree in writing, any determination required under this Section&#160;shall be made by independent tax counsel designated by the Company and reasonably acceptable to you (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Independent Tax Counsel</u>&#8221;), whose determination shall be conclusive and binding upon you and the Company for all purposes. For purposes of making the calculations required under this Section,&#160;Independent Tax Counsel may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code; provided that Independent Tax Counsel shall assume that you pay all taxes at the highest marginal rate. The Company and you shall furnish to Independent Tax Counsel such information and documents as Independent Tax Counsel may reasonably request in order to make a determination under this Section. The Company shall bear all costs that Independent Tax Counsel may reasonably incur in connection with any calculations contemplated by this Section. In the event that <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;13(a)(ii)(B)</u>&#160;above applies, then based on the information provided to you and the Company by Independent Tax Counsel, the cutback described hereunder will apply as to compensation not subject to Section&#160;409A of the Code prior to compensation subject to Section&#160;409A of the Code and will otherwise apply on a reverse chronological basis from payments latest in time. If the Internal Revenue Service (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IRS</u>&#8221;) determines that any Payment is subject to the Excise Tax, then <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;13(b)</u>&#160;hereof shall apply, and the enforcement of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;13(b)</u>&#160;shall be the exclusive remedy to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<b style="font-weight:bold;">Adjustments</b>. If, notwithstanding any reduction described in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;13(a)</u>&#160;hereof (or in the absence of any such reduction), the IRS determines that you are liable for the Excise Tax as a result of the receipt of one or more Payments, then you shall be obligated to surrender or pay back to the Company within one-hundred 120 days after a final IRS determination, an amount of such payments or benefits equal to the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Repayment Amount</u>.&#8221; The Repayment Amount with respect to such Payments shall be the smallest such amount, if any, as shall be required to be surrendered or paid to the Company so that your net proceeds with respect to such Payments (after taking into account the payment of the Excise Tax imposed on such Payments) shall be maximized. Notwithstanding the foregoing, the Repayment Amount with respect to such Payments shall be zero if a Repayment Amount of more than zero would not eliminate the Excise Tax imposed on such Payments or if a Repayment Amount of more than zero would not maximize the net amount received from the Payments. If the Excise Tax is not eliminated pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;13(b)</u>, you shall pay the Excise Tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Section&#160;409A</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section&#160;409A of the Code, the Company determines that you are a &#8220;specified employee&#8221; within the meaning of Section&#160;409A(a)(2)(B)(i)&#160;of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement or otherwise on account of your separation from service would be considered deferred compensation otherwise subject to the additional tax imposed pursuant to Section&#160;409A(a)&#160;of the Code as a result of the application of Section&#160;409A(a)(2)(B)(i)&#160;of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A)&#160;six months and one day after your separation from service, or (B)&#160;your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision (without interest), and the balance of the installments shall be payable in accordance with their original schedule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by you during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To the extent that any payment or benefit described in this Agreement constitutes &#8220;non-qualified deferred compensation&#8221; under Section&#160;409A of the Code, and to the extent that such payment or benefit is payable upon the termination of your employment, then such payments or benefits shall be payable only upon your &#8220;separation from service.&#8221; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section&#160;1.409A-l(h).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The parties intend that this Agreement will be administered in accordance with Section&#160;409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section&#160;409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section&#160;409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section&#160;1.409A-2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section&#160;409A of the Code and all related rules&#160;and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section&#160;409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">15.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Withholding; Tax Effect</b>. All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or the Board related to tax liabilities arising from your compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">16.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Recoupment</b>. Amounts paid or payable under this Agreement shall be subject to the provisions of any applicable clawback or recoupment policies or procedures adopted by the Company, which clawback or recoupment policies may provide for forfeiture and/or recoupment of amounts paid or payable under this Agreement, subject to applicable Massachusetts law. No forfeiture or recoupment under such policies or procedures will give rise to a right to resign for Good Reason under this Agreement or any other agreement between you and the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">17.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Interpretation and Enforcement</b>. This Agreement, together with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</u>, the Covenant Agreement, and any award agreement between you and the Company, constitute the complete agreement between you and the Company, contains all of the terms of your employment with the Company and supersedes any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. The terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or arising out of, related to, or in any way connected with this Agreement, your employment with the Company or any other relationship between you and the Company (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disputes</u>&#8221;) will be governed by federal law to the extent applicable and otherwise by Massachusetts law, excluding laws relating to conflicts or choice of law and excluding Disputes arising in connection with any equity incentive plan, which shall be governed by the terms of the applicable equity incentive plan. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in the Commonwealth of Massachusetts in connection with any Dispute or any claim related to any Dispute, except for Disputes arising under any equity incentive plan, which shall be governed by the terms of the applicable equity incentive plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">18.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Assignment</b>. Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement without your consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets; provided further, that if you remain employed or become employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then you shall not be entitled to any payments, benefits or vesting pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;10</u> or pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;11</u> of this Agreement solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon you and the Company, and each of your and its respective successors, executors, administrators, heirs and permitted assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">19.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Waiver; Amendment</b>. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. This Agreement may be amended or modified only by a written instrument signed by you and by a duly authorized representative of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">20.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Enforceability</b>. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">21.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Conditions</b>. You must submit satisfactory proof of your identity, successfully complete a criminal background check, which you hereby expressly authorize by your execution of this Agreement, and provide documentation of your legal authorization to work in the United States on or prior to the Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">22.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Employee Representations</b>. It is the policy of the Company not to solicit or accept proprietary information and/or trade secrets of other companies or third parties. If you have or have had access to trade secrets or other confidential, proprietary information from your former employer or another third party, the use of such information in performing your duties at the Company is prohibited. This may include, but is not limited to, confidential or proprietary information in the form of documents, magnetic media, software, customer lists, and business plans or strategies. In making this employment offer, the Company has relied on your representation that: (a)&#160;you are not currently a party to any agreement that would restrict your ability to accept this offer or to perform services for the Company; (b)&#160;you are not subject to any noncompetition or non-solicitation agreement or other restrictive covenants that might restrict your employment by the Company as contemplated by this offer; (c)&#160;you have the full right, power and authority to execute and deliver the Agreement and to perform all of your obligations thereunder; and (d)&#160;you will not bring with you to the Company or use in the performance of your responsibilities at the Company any materials, documents or work product of a former employer or other third party that are not generally available to the public, unless you have obtained written authorization from such former employer or third party for their possession and use and have provided the Company with a copy of same.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">23.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Other Terms</b>. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of your employment to the extent necessary to effectuate the terms contained herein. The headings and other captions in this Agreement are for convenience and reference only and shall not be used in interpreting, construing or enforcing any of the provisions of this Agreement. This Agreement may be executed in separate counterparts. When both counterparts are signed, they shall be treated together as one and the same document. PDF copies of signed counterparts shall be equally effective as originals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">I look forward to working with you to make the Company a great success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Sincerely,</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Tomas Kiselak</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Tomas Kiselak</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Director</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accepted and acknowledged:</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jonathan Quick</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jonathan Quick</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8/29/2024</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cause</u>&#8221; shall mean (i)&#160;your dishonest statements or acts with respect to the Company or any affiliate of the Company, or any current or prospective customers, suppliers, vendors or other third parties with which such entity does business that results in or is reasonably anticipated to result in material harm to the Company; (ii)&#160;your conviction or plea of no contest to: (A)&#160;a felony or (B)&#160;any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii)&#160;your failure to perform in all material respects your assigned duties and responsibilities, which failure continues for 30 days after written notice given to you describing such failure; (iv)&#160;your gross negligence, willful misconduct that results in or is reasonably anticipated to result in material harm to the Company; or (v)&#160;your violation of any material provision of any agreement(s)&#160;between you and the Company or any written Company policies including, without limitation, agreements relating to non-solicitation, non-disclosure and/or assignment of inventions or policies related to ethics or workplace conduct.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Control</u>&#8221; shall have the meaning set forth in the Equity Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Control Period</u>&#8221; shall mean the 12-month period beginning on the consummation of the first event constituting a Change in Control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Code</u>&#8221; means the Internal Revenue Code of 1986, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disability</u>&#8221; shall mean a permanent and total disability as defined in Section&#160;22(e)(3)&#160;of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Reason</u>&#8221; shall mean that you have complied with the Good Reason Process (hereinafter defined) following the occurrence, without your written consent, of any of the following events: (i)&#160;a material diminution in your base salary or Target Bonus except for across-the-board salary and target bonus reductions of no more than 10% based on the Company&#8217;s financial performance similarly affecting all or substantially all senior management employees of the Company; (ii)&#160;a material change in the geographic location at which you are required to provide services to the Company or a requirement that you change your remote location to a location other than your then-current residence; (iii)&#160;the failure of the Company to obtain the assumption of this Agreement by a successor; or (iv)&#160;the material breach of this Agreement (or any other agreements with you) by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Reason Process</u>&#8221; shall mean that (i)&#160;you reasonably determine in good faith that a &#8220;Good Reason&#8221; condition has occurred; (ii)&#160;you notify the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii)&#160;you cooperate in good faith with the Company&#8217;s efforts, for a period not less than 30 days following such notice (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cure Period</u>&#8221;), to remedy the condition; (iv)&#160;notwithstanding such efforts, the Good Reason condition continues to exist; and (v)&#160;you terminate your employment within 60 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>8
<FILENAME>avte-20240930xex10d13.htm
<DESCRIPTION>EXHIBIT 10.13
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 12/3/2024 12:41:49 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.13</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>July 31, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Andrew King</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Re: Offer of Employment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Dear Andrew:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>On behalf of Jade Biosciences, Inc. (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u>&#8221;), I am very pleased to offer you a position as Chief Scientific Officer of the Company (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Role</u>&#8221;) pursuant to this letter agreement (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;), provided you accept such offer as indicated by your signature below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Your employment with the Company in the Role will commence as of August 1, 2024 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u>&#8221;). Should you not commence services by the Effective Date or if this Agreement is otherwise terminated on or prior to the Effective Date, you hereby agree that this Agreement shall be void <i style="font-style:italic;">ab initio</i> and of no force or effect.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-weight:bold;min-width:46.8pt;white-space:nowrap;">1.</font><b style="font-weight:bold;">Position</b>. While serving in the Role, you will initially report to the Company&#8217;s Chief Executive Officer or such other person as the Board of Directors of the Company (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board</u>&#8221;) may designate, and have such duties, authorities, and responsibilities as are customarily associated with the Role. This is a full-time employment position. It is understood and agreed that, commencing as of the Effective Date you will not engage in any other employment, consulting or other business activities (whether full-time or part-time), except as a member of the scientific advisory board of Borealis Biosciences, or as otherwise expressly authorized in writing by the Company. Notwithstanding the foregoing, you may engage in religious, charitable and other community activities so long as such activities do not unreasonably interfere or conflict with your obligations to the Company.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8239;</font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></font><b style="font-weight:bold;">Base Salary</b>. Following the Effective Date, the Company will pay you an initial base salary of $470,000 per year, payable in accordance with the Company&#8217;s standard payroll schedule and subject to applicable deductions and withholdings. Your base salary will be subject to periodic review and potential adjustment in the Company&#8217;s discretion. Your base salary in effect at any given time is referred to herein as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Salary</u>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8239;</font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></font><b style="font-weight:bold;">Annual Bonus</b>. Commencing as of the Effective Date, you will be eligible to receive an annual performance bonus targeted at 35% of your Base Salary. The target annual bonus in effect at any given time is referred to herein as &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Target Bonus</u>.&#8221; Your 2024 annual bonus will be prorated based on your period of employment following the Effective Date. The actual bonus amount is discretionary and may be subject to achievement of performance targets established by the Company for such year. To earn an annual bonus, you must be employed by the Company as of the payment date of such bonus. Any annual bonus will be paid no later than March 15th of the calendar year following the calendar year to which such bonus relates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8239;</font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></font><b style="font-weight:bold;">Equity.</b> Subject to that certain Restricted Stock Notice and Restricted Stock Purchase Agreement, dated June 18, 2024, between you and the Company, and the terms and conditions approved by the Board, you were granted the ability to purchase 546,448 shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restricted Shares</u>&#8221;), at an aggregate purchase price of $54.64. You have also made an election under Section 83(b) of the Internal Revenue Code of 1986, as amended, in accordance with Treasury Regulation 1.83-2 with respect to the Restricted Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">In addition, and subject to approval by the Board or a committee thereof, following the Effective Date, the Company will periodically grant you additional stock options to purchase shares of the Company&#8217;s common stock, at an exercise price as determined by the Board or a committee thereof (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Replenishment Options</u>&#8221;), in order to maintain your ownership at approximately 2% of the Company&#8217;s fully-diluted equity (reflecting all outstanding convertible preferred stock, warrants, options and other equity interests that are convertible into or exercisable for common stock on an as-converted and as-exercised basis) until the Company has raised an aggregate of $200,000,000; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that the Board shall have no obligation to grant you additional stock options thereafter. The Replenishment Options will vest in 48 approximately equal monthly installments commencing on the applicable date(s) of grant; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, that you continue providing services to the Company through each vesting date. The Replenishment Options will be governed by the terms of the related award agreements, the Equity Plan and the terms and conditions approved by the Board or a committee thereof.&#8239;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8239;</font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.&#8239;</b></font><b style="font-weight:bold;">Benefits/Paid Time Off. </b>Commencing as of the Effective Date, you will be eligible, subject to the terms of the applicable plans and programs, to participate in the employee benefits and insurance programs generally made available to the Company&#8217;s full-time employees. Details of such benefits programs, including applicable employee contributions and waiting periods, if applicable, will be made available to you when such benefit(s) become available. You will be entitled to paid time off consistent with the terms of the Company&#8217;s paid time off policy, as in effect from time to time. The Company reserves the right to modify, limit, amend or cancel any of its benefits plans or programs at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8239;</font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.</b></font><b style="font-weight:bold;">Expense Reimbursement. </b>The Company will reimburse you for all reasonable and necessary expenses incurred by you in connection with performing your duties as an employee of the Company and that are pre-approved by the Company, provided that you comply with any Company policy or practice on submitting, accounting for and documenting such expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8239;</font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.</b></font><b style="font-weight:bold;">Location</b>. Your primary work location will be remotely in California, provided that you may be required to engage in reasonable travel for business, consistent with the Company&#8217;s business needs. You may change your remote work location with prior written notice to and approval from the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8239;</font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.</b></font><b style="font-weight:bold;">At-Will Employment; Date of Termination</b>. At all times, your employment with the Company is &#8220;at will,&#8221; meaning you or the Company may terminate it at any time for any or no reason, subject to the terms of this Agreement. Although your job duties, title, reporting structure, compensation and benefits, as well as the Company&#8217;s benefit plans and personnel policies and procedures, may change from time to time (subject to the terms of this Agreement), the &#8220;at will&#8221; nature of your employment may only be changed in an express written agreement signed by you and an authorized officer of the Company. Your last day of employment for any reason is referred to herein as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Date of Termination</u>.&#8221; In the event that you elect to end your employment with the Company, the Company requires you to provide at least 30 days&#8217; advance written notice to the Company; and in the event that the Company terminates you without Cause, you shall be given at least 30 days advance written notice by the Company. Notwithstanding the foregoing, the Company may unilaterally accelerate the Date of Termination, and such acceleration shall not result in a termination by the Company without Cause for purposes of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To the extent applicable, you shall be deemed to have resigned from all officer and board member positions that you hold with the Company or any of its respective subsidiaries and affiliates upon the termination of your employment for any reason. You shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.</b></font><b style="font-weight:bold;">Accrued Obligations</b>. In the event of the ending of your employment for any reason, the Company shall pay you (i) your Base Salary and, if applicable, any accrued but unused vacation, through the Date of Termination, and (ii) the amount of any documented expenses properly incurred by you on behalf of the Company prior to any such termination and not yet reimbursed. (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accrued Obligations</u>&#8221;).&#8239;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.</b></font><b style="font-weight:bold;">Severance Pay and Benefits Outside of the Change in Control Period</b>. In the event that the Company terminates your employment without Cause (and not as a result of your death or Disability) outside of the Change in Control Period (as such capitalized terms are defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</u>), then, in addition to the Accrued Obligations, and subject to (i) your execution and non-revocation of a separation agreement and release in a form acceptable to the Company, which shall include a general release of claims against the Company and all related persons and entities and a reaffirmation of the Continuing Obligations (as defined below) and shall provide that if you breach the Continuing Obligations, all payments of the following severance pay and benefits shall immediately cease (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation Agreement and Release</u>&#8221;), and (ii) the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven-day revocation period:&#8239;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:39.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>The Company shall pay you an amount equal to 12 months of your Base Salary, payable in substantially equal installments over the 12-month period following the Date of Termination in accordance with the Company&#8217;s regular payroll practices beginning on the Company&#8217;s first regularly scheduled payroll date following the date that is 60 days after the Date of Termination; provided, however, that the first installment shall include any amounts that would have been paid following the Date of Termination had such installments commenced on the first regularly scheduled payroll date following the Date of Termination.&#8239;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:39.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>The Company shall pay you any bonus earned but unpaid for the year immediately preceding the year in which the Date of Termination occurs, payable at the time such bonuses are paid to other Company employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:39.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Subject to your copayment of premium amounts at the applicable active employees&#8217; rate and your proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COBRA</u>&#8221;), the Company shall pay to the group health plan provider(s), the COBRA provider or you a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to you if you had remained employed by the Company until the earliest of (A) the 12-month anniversary of the Date of Termination; (B) your eligibility for group health plan benefits under any other employer&#8217;s group health plan; or (C) the cessation of your continuation rights under COBRA; provided, however, that if the Company reasonably determines that it cannot pay such amounts to the group health plan provider(s) or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to you for the time period specified above. Such payments, if to you, shall be subject to tax-related deductions and withholdings and paid on the Company&#8217;s regular payroll dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.</b></font><b style="font-weight:bold;">Severance Pay and Benefits Within the Change in Control Period</b>. In the event that the Company terminates your employment without Cause (and not as a result of your death or Disability) or you resign for Good Reason, in each case within the Change in Control Period, then, in addition to you being entitled to the Accrued Obligations, and subject to your execution and non-revocation of the Separation Agreement and Release and it becoming fully effective, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven-day revocation period:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:39.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>You will receive the severance pay and benefits set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</u> above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:39.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Notwithstanding anything to the contrary in any applicable equity-based award agreement or plan, the unvested portion of your then outstanding equity-based awards subject to time-based vesting shall immediately accelerate and become vested or nonforfeitable as of the later of (i) the Date of Termination or (ii) the effective date of the Separation Agreement and Release.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the avoidance of doubt, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11</u> of this Agreement are mutually exclusive and in no event shall you be entitled to payments or benefits pursuant to both <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11</u> of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8239;</font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.</b></font><b style="font-weight:bold;">Continuing Obligations</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:39.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8239;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><b style="font-weight:bold;">Restrictive Covenant Agreement</b>. As a condition of your employment, you are required to enter into an Invention Assignment, Non-Disclosure, and Business Protection Agreement (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Covenant Agreement</u>&#8221;), which must be signed prior to the Effective Date. For purposes of this Agreement, the obligations in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12</u> and those that arise in the Covenant Agreement and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Continuing Obligations</u>.&#8221; You are advised to discuss the Covenant Agreement with an attorney of your choice, and you have had an adequate opportunity to do so prior to executing this Agreement or the Covenant Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:39.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8239;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><b style="font-weight:bold;">Third Party Agreements and Rights</b>. You hereby confirm that you are not bound by the terms of any agreement with any previous employer or other party which would prevent you from performing your obligations hereunder. You represent to the Company that your execution of this Agreement, your employment with the Company and the performance of your proposed duties for the Company will not violate any obligations you may have to any such previous employer or other party. In your work for the Company, you will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party, and you will not bring to the premises of the Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such previous employment or other party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:39.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8239;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><b style="font-weight:bold;">Litigation and Regulatory Cooperation</b>. You shall cooperate fully with the Company in (i) the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while you were engaged or employed by the Company, and (ii) the investigation, whether internal or external, of any matters about which the Company believes you may have knowledge or information. Your full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being reasonably available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after your engagement and employment, you also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while you were employed by the Company. The Company shall reimburse you for any reasonable out-of-pocket expenses, including fees and costs for an independent attorney of your choice hired by you, incurred in connection with your performance of obligations pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12(c).</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:39.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><b style="font-weight:bold;">Relief</b>. You agree that it would be difficult to measure any damages caused to the Company which might result from your breach of any of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, you agree that if you breach, or propose to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to seek an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8239;</font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">13.</b></font><b style="font-weight:bold;">Golden Parachute Taxes</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:39.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8239;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><b style="font-weight:bold;">Best After-Tax Result</b>. In the event that any payment or benefit received or to be received by you pursuant to this Agreement or otherwise (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payments</u>&#8221;) would (i) constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code and (ii) but for this subsection (a), be subject to the excise tax imposed by Section 4999 of the Code, any successor provisions, or any comparable federal, state, local or foreign excise tax (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excise Tax</u>&#8221;), then, subject to the provisions of Section 14, such Payments shall be either (A) provided in full pursuant to the terms of this Agreement or any other applicable agreement, or (B) provided as to such lesser extent which would result in the Payments being $1.00 less than the amount at which any portion of the Payments would be subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state, local and foreign income, employment and other taxes and the Excise Tax (including, without limitation, any interest or penalties on such taxes), results in the receipt, on an after-tax basis, of the greatest amount of payments and benefits provided for hereunder or otherwise, notwithstanding that all or some portion of such Payments may be subject to the Excise Tax. Unless the Company and you otherwise agree in writing, any determination required under this Section shall be made by independent tax counsel designated by the Company and reasonably acceptable to you (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Independent Tax Counsel</u>&#8221;), whose determination shall be conclusive and binding upon you and the Company for all purposes. For purposes of making the calculations required under this Section, Independent Tax Counsel may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code; provided that Independent Tax Counsel shall assume that you pay all taxes at the highest marginal rate. The Company and you shall furnish to Independent Tax Counsel such information and documents as Independent Tax Counsel may reasonably request in order to make a determination under this Section. The Company shall bear all costs that Independent Tax Counsel may reasonably incur in connection with any calculations contemplated by this Section. In the event that <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13(a)(ii)(B)</u> above applies, then based on the information provided to you and the Company by Independent Tax Counsel, the cutback described hereunder will apply as to compensation not subject to Section 409A of the Code prior to compensation subject to Section 409A of the Code and will otherwise apply on a reverse chronological basis from payments latest in time. If the Internal Revenue Service (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IRS</u>&#8221;) determines that any Payment is subject to the Excise Tax, then <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13(b)</u> hereof shall apply, and the enforcement of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13(b)</u> shall be the exclusive remedy to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:39.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><b style="font-weight:bold;">Adjustments</b>. If, notwithstanding any reduction described in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13(a)</u> hereof (or in the absence of any such reduction), the IRS determines that you are liable for the Excise Tax as a result of the receipt of one or more Payments, then you shall be obligated to surrender or pay back to the Company within one-hundred 120 days after a final IRS determination, an amount of such payments or benefits equal to the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Repayment Amount</u>.&#8221; The Repayment Amount with respect to such Payments shall be the smallest such amount, if any, as shall be required to be surrendered or paid to the Company so that your net proceeds with respect to such Payments (after taking into account the payment of the Excise Tax imposed on such Payments) shall be maximized. Notwithstanding the foregoing, the Repayment Amount with respect to such Payments shall be zero if a Repayment Amount of more than zero would not eliminate the Excise Tax imposed on such Payments or if a Repayment Amount of more than zero would not maximize the net amount received from the Payments. If the Excise Tax is not eliminated pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13(b)</u>, you shall pay the Excise Tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">14.</b></font><b style="font-weight:bold;">Section 409A</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:39.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8239;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section 409A of the Code, the Company determines that you are a &#8220;specified employee&#8221; within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement or otherwise on account of your separation from service would be considered deferred compensation otherwise subject to the additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after your separation from service, or (B) your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision (without interest), and the balance of the installments shall be payable in accordance with their original schedule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:39.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8239;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by you during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:39.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>&#8239;To the extent that any payment or benefit described in this Agreement constitutes &#8220;non-qualified deferred compensation&#8221; under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the termination of your employment, then such payments or benefits shall be payable only upon your &#8220;separation from service.&#8221; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-l(h).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:39.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8239;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>&#8239;The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:39.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8239;</font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">15.</b></font><b style="font-weight:bold;">Withholding; Tax Effect</b>. All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or the Board related to tax liabilities arising from your compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8239;</font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">16.</b></font><b style="font-weight:bold;">Recoupment</b>. Amounts paid or payable under this Agreement shall be subject to the provisions of any applicable clawback or recoupment policies or procedures adopted by the Company, which clawback or recoupment policies may provide for forfeiture and/or recoupment of amounts paid or payable under this Agreement, subject to California law including, but not limited to, Labor Code section 221. No forfeiture or recoupment under such policies or procedures will give rise to a right to resign for Good Reason under this Agreement or any other agreement between you and the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8239;</font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">17.</b></font><b style="font-weight:bold;">Interpretation and Enforcement</b>. This Agreement, together with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</u>, the Covenant Agreement, and any award agreement between you and the Company, constitute the complete agreement between you and the Company, contains all of the terms of your employment with the Company and supersedes any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. The terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or arising out of, related to, or in any way connected with this Agreement, your employment with the Company or any other relationship between you and the Company (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disputes</u>&#8221;) will be governed by federal law to the extent applicable and otherwise by California law, excluding laws relating to conflicts or choice of law and excluding Disputes arising in connection with any equity incentive plan, which shall be governed by the terms of the applicable equity incentive plan. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in the State of California in connection with any Dispute or any claim related to any Dispute, except for Disputes arising under any equity incentive plan, which shall be governed by the terms of the applicable equity incentive plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8239;</font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">18.</b></font><b style="font-weight:bold;">Assignment</b>. Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement without your consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets; provided further, that if you remain employed or become employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then you shall not be entitled to any payments, benefits or vesting pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</u> or pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11</u> of this Agreement solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon you and the Company, and each of your and its respective successors, executors, administrators, heirs and permitted assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">19.</b></font><b style="font-weight:bold;">Waiver; Amendment</b>. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. This Agreement may be amended or modified only by a written instrument signed by you and by a duly authorized representative of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8239;</font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">20.</b></font><b style="font-weight:bold;">Enforceability</b>. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8239;</font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">21.</b></font><b style="font-weight:bold;">Conditions</b>. You must submit satisfactory proof of your identity, successfully complete a criminal background check, which you hereby expressly authorize by your execution of this Agreement, and provide documentation of your legal authorization to work in the United States on or prior to the Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8239;</font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">22.</b></font><b style="font-weight:bold;">Employee Representations</b>. It is the policy of the Company not to solicit or accept proprietary information and/or trade secrets of other companies or third parties. If you have or have had access to trade secrets or other confidential, proprietary information from your former employer or another third party, the use of such information in performing your duties at the Company is prohibited. This may include, but is not limited to, confidential or proprietary information in the form of documents, magnetic media, software, customer lists, and business plans or strategies. In making this employment offer, the Company has relied on your representation that: (a) you are not currently a party to any agreement that would restrict your ability to accept this offer or to perform services for the Company; (b) you are not subject to any noncompetition or non-solicitation agreement or other restrictive covenants that might restrict your employment by the Company as contemplated by this offer; (c) you have the full right, power and authority to execute and deliver the Agreement and to perform all of your obligations thereunder; and (d) you will not bring with you to the Company or use in the performance of your responsibilities at the Company any materials, documents or work product of a former employer or other third party that are not generally available to the public, unless you have obtained written authorization from such former employer or third party for their possession and use and have provided the Company with a copy of same.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8239;</font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">23.</b></font><b style="font-weight:bold;">Other Terms</b>. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of your employment to the extent necessary to effectuate the terms contained herein. The headings and other captions in this Agreement are for convenience and reference only and shall not be used in interpreting, construing or enforcing any of the provisions of this Agreement. This Agreement may be executed in separate counterparts. When both counterparts are signed, they shall be treated together as one and the same document. PDF copies of signed counterparts shall be equally effective as originals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">I look forward to working with you to make the Company a great success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Sincerely,</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="white-space:pre-wrap;">&#8239;</font>/s/ Peter Harwin</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:44.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Peter Harwin</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Director</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accepted and acknowledged:</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ Andrew King</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Andrew King</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">7/31/2024</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8239;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cause</u>&#8221; shall mean (i) your dishonest statements or acts with respect to the Company or any affiliate of the Company, or any current or prospective customers, suppliers, vendors or other third parties with which such entity does business that results in or is reasonably anticipated to result in material harm to the Company; (ii) your conviction or plea of no contest to: (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) your failure to perform in all material respects your assigned duties and responsibilities, which failure continues for 30 days after written notice given to you describing such failure; (iv) your gross negligence, willful misconduct that results in or is reasonably anticipated to result in material harm to the Company; or (v) your violation of any material provision of any agreement(s) between you and the Company or any written Company policies including, without limitation, agreements relating to non-solicitation, non-disclosure and/or assignment of inventions or policies related to ethics or workplace conduct.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8239;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Control</u>&#8221; shall have the meaning set forth in the Equity Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8239;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Control Period</u>&#8221; shall mean the 12-month period beginning on the consummation of the first event constituting a Change in Control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8239;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Code</u>&#8221; means the Internal Revenue Code of 1986, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8239;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disability</u>&#8221; shall mean a permanent and total disability as defined in Section 22(e)(3) of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8239;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equity Plan</u>&#8221; shall mean the Company&#8217;s 2024 Equity Incentive Plan or any successor plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8239;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.&#8239;</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Reason</u>&#8221; shall mean that you have complied with the Good Reason Process (hereinafter defined) following the occurrence, without your written consent, of any of the following events: (i) a material diminution in your base salary or Target Bonus except for across-the-board salary and target bonus reductions of no more than 10% based on the Company&#8217;s financial performance similarly affecting all or substantially all senior management employees of the Company; (ii) a material change in the geographic location at which you are required to provide services to the Company or a requirement that you change your remote location to a location other than your then-current residence; (iii) the failure of the Company to obtain the assumption of this Agreement by a successor; or (iv) the material breach of this Agreement (or any other agreements with you) by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8239;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.&#8239;</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Reason Process</u>&#8221; shall mean that (i) you reasonably determine in good faith that a &#8220;Good Reason&#8221; condition has occurred; (ii) you notify the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii) you cooperate in good faith with the Company&#8217;s efforts, for a period not less than 30 days following such notice (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cure Period</u>&#8221;), to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and (v) you terminate your employment within 60 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>9
<FILENAME>avte-20240930xex10d14.htm
<DESCRIPTION>EXHIBIT 10.14
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 12/3/2024 12:41:49 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.14</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;September 3, 2024</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Hetal Kocinsky</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Re: Offer of Employment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Dear Hetal:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>On behalf of Jade Biosciences, Inc. (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u>&#8221;), I am very pleased to offer you a position as Chief Medical Officer of the Company (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Role</u>&#8221;) pursuant to this letter agreement (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;), provided you accept such offer as indicated by your signature below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Your employment with the Company in the Role will commence as of September 9, 2024 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u>&#8221;). Should you not commence services by the Effective Date or if this Agreement is otherwise terminated on or prior to the Effective Date, you hereby agree that this Agreement shall be void <i style="font-style:italic;">ab initio</i> and of no force or effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Position</b>. While serving in the Role, you will initially report to the Company&#8217;s Chief Scientific Officer (CSO) or such other person holding a senior management position equal to or higher than the CSO as the Board of Directors (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board</u>&#8221;) may designate, and have such duties, authorities, and responsibilities as are customarily associated with the Role. This is a full-time employment position. It is understood and agreed that, commencing as of the Effective Date you will not engage in any other employment, consulting or other business activities (whether full-time or part-time). Notwithstanding the foregoing, you may engage in religious, charitable and other community activities so long as such activities do not unreasonably interfere or conflict with your obligations to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Base Salary</b>. The Company will pay you an initial base salary of $450,000 per year, payable in accordance with the Company&#8217;s standard payroll schedule and subject to applicable deductions and withholdings. Subject to your right to terminate your employment hereunder for Good Reason (as defined in Appendix A hereto), your base salary will be subject to periodic review and potential adjustment in the Company&#8217;s discretion. Your base salary in effect at any given time is referred to herein as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Salary</u>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Annual Bonus</b>. Commencing as of the Effective Date, you will be eligible to receive an annual performance bonus targeted at 40% of your Base Salary. The target annual bonus in effect at any given time is referred to herein as &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Target Bonus</u>.&#8221; Your 2024 annual bonus will be prorated based on your period of employment following the Effective Date. The actual bonus amount is discretionary and may be subject to achievement of performance targets established by the Company for such year. Subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</u>, to earn an annual bonus, you must be employed by the Company as of the payment date of such bonus. Any annual bonus will be paid no later than March 15<sup style="font-size:7.5pt;vertical-align:top;">th</sup> of the calendar year following the calendar year to which such bonus relates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Equity.</b> Subject to approval by the Board or the Compensation Committee of the Board (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Committee</u>&#8221;), it is anticipated that the Company will grant you stock options to purchase 295,081 shares of the Company&#8217;s common stock (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Options</u>&#8221;) as soon as practicable following the Effective Date, with an exercise price per share equal to the fair market value of a share of the Company&#8217;s common stock on the date of grant (as determined by the Board or the Committee in its sole discretion). The Options will vest over a four-year period following the Effective Date, with 25% of the Options vesting on the first anniversary of the Effective Date, and the remainder vesting in 36 equal monthly installments on each monthly anniversary thereafter, in each case, subject to your continued service with the Company through the applicable vesting dates. The Options will be governed by the terms of the related award agreement, the Company&#8217;s 2024 Equity Incentive Plan (as amended from time to time and including any successor plan, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equity Plan</u>&#8221;) and the terms and conditions approved by the Board or the Committee. In addition to the Options, you may be eligible to receive such future equity grants as the Board or the Committee may deem appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Benefits/Paid Time Off. </b>Commencing as of the Effective Date, you will be eligible, subject to the terms of the applicable plans and programs, to participate in the employee benefits and insurance programs (a) generally made available to the Company&#8217;s full-time employees, and (b) specifically made available to the Company&#8217;s senior management. Details of such benefits programs, including applicable employee contributions and waiting periods, if applicable, will be made available to you when such benefit(s) become available. You will be entitled to paid time off consistent with the terms of the Company&#8217;s paid time off policy, as in effect from time to time. The Company reserves the right to modify, limit, amend or cancel any of its benefits plans or programs at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Expense Reimbursement. </b>The Company will reimburse you for all reasonable and necessary expenses incurred by you in connection with performing your duties as an employee of the Company and that are pre-approved by the Company, provided that you comply with any Company policy or practice on submitting, accounting for and documenting such expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Location</b>. Your primary work location will be remotely in Connecticut, provided that you may be required to engage in reasonable travel for business, consistent with the Company&#8217;s business needs. You may change your remote work location with prior written notice to and approval from the Company, which approval shall not be unreasonably withheld, conditioned, or delayed..</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;At-Will Employment; Date of Termination</b>. At all times, your employment with the Company is &#8220;at will,&#8221; meaning you or the Company may terminate it at any time for any or no reason, subject to the terms of this Agreement. Although your job duties, title, reporting structure, compensation and benefits, as well as the Company&#8217;s benefit plans and personnel policies and procedures, may change from time to time (subject to the terms of this Agreement), the &#8220;at will&#8221; nature of your employment may only be changed in an express written agreement signed by you and an authorized officer of the Company. Your last day of employment for any reason is referred to herein as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Date of Termination</u>.&#8221; In the event that you elect to end your employment with the Company, the Company requires you to provide at least 30 days&#8217; advance written notice to the Company. Notwithstanding the foregoing, the Company may unilaterally accelerate the Date of Termination, and such acceleration shall not result in a termination by the Company without Cause for purposes of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>To the extent applicable, you shall be deemed to have resigned from all officer and board member positions that you hold with the Company or any of its respective subsidiaries and affiliates upon the termination of your employment for any reason. You shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Accrued Obligations</b>. In the event of the ending of your employment for any reason, the Company shall pay you (i) your Base Salary and, if applicable, any accrued but unused vacation, through the Date of Termination, and (ii) the amount of any documented expenses properly incurred by you on behalf of the Company prior to any such termination and not yet reimbursed. (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accrued Obligations</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Severance Pay and Benefits Outside of the Change in Control Period</b>. In the event that the Company terminates your employment without Cause (and not as a result of your death or Disability) outside of the Change in Control Period (as such capitalized terms are defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</u>), then, in addition to the Accrued Obligations, and subject to (i) your execution and non-revocation of a separation agreement and release in a form acceptable to the Company, which shall include a general release of claims against the Company and all related persons and entities and a reaffirmation of the Continuing Obligations (as defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12</u> below) and shall provide that if you breach the Continuing Obligations, all payments of the following severance pay and benefits shall immediately cease (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation Agreement and Release</u>&#8221;), and (ii) the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven-day revocation period:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;&#8239;</font>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Company shall pay you an amount equal to 12 months of your Base Salary, payable in substantially equal installments over the 12-month period following the Date of Termination in accordance with the Company&#8217;s regular payroll practices beginning on the Company&#8217;s first regularly scheduled payroll date following the date that is 60 days after the Date of Termination; provided, however, that the first installment shall include any amounts that would have been paid following the Date of Termination had such installments commenced on the first regularly scheduled payroll date following the Date of Termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Company shall pay you any bonus earned but unpaid for the year immediately preceding the year in which the Date of Termination occurs, payable at the time such bonuses are paid to other Company employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject to your copayment of premium amounts at the applicable active employees&#8217; rate and your proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COBRA</u>&#8221;), the Company shall pay to the group health plan provider(s), the COBRA provider or you a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to you if you had remained employed by the Company until the earliest of (A) the 12-month anniversary of the Date of Termination; (B) your eligibility for group health plan benefits under any other employer&#8217;s group health plan; or (C) the cessation of your continuation rights under COBRA; provided, however, that if the Company reasonably determines that it cannot pay such amounts to the group health plan provider(s) or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to you for the time period specified above. Such payments, if to you, shall be subject to tax-related deductions and withholdings and paid on the Company&#8217;s regular payroll dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Severance Pay and Benefits Within the Change in Control Period</b>. In the event that the Company terminates your employment without Cause (and not as a result of your death or Disability) or you terminate your employment for Good Reason, in each case within the Change in Control Period, then, in addition to you being entitled to the Accrued Obligations, and subject to your execution and non-revocation of the Separation Agreement and Release and it becoming fully effective, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven-day revocation period:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;You will receive the severance pay and benefits set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</u> above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding anything to the contrary in any applicable equity-based award agreement or plan, the unvested portion of your then outstanding equity-based awards subject to time-based vesting shall immediately accelerate and become vested or nonforfeitable as of the later of (i) the Date of Termination or (ii) the effective date of the Separation Agreement and Release.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>For the avoidance of doubt, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11</u> of this Agreement are mutually exclusive and in no event shall you be entitled to payments, benefits, or vesting pursuant to both <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11</u> of this Agreement. For the further avoidance of doubt, no provision of this Agreement pertaining to the assignment of this Agreement, including without limitation <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 18</u> below, shall limit or deprive you of the payments, benefits, or vesting to which you are entitled under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11</u> of this Agreement. Specifically, if you remain employed or become employed by the Company, any purchaser or other counterparty of the Company, or any of their respective affiliates in connection with any transaction(s) pursuant to which the Company hereafter effects a reorganization, consolidation, merger, or transfer of all or substantially all of the Company&#8217;s properties or assets, then you shall remain entitled to any and all payments, benefits or vesting pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</u> or pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11</u> of this Agreement upon a subsequent qualifying termination of employment, notwithstanding any such transaction(s).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Continuing Obligations</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<b style="font-weight:bold;">Restrictive Covenant Agreement</b>. As a condition of your employment, you are required to enter into an Invention Assignment, Non-Disclosure, and Business Protection Agreement (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Covenant Agreement</u>&#8221;), which must be signed prior to the Effective Date. For purposes of this Agreement, the obligations in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12</u> and those that arise in the Covenant Agreement and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Continuing Obligations</u>.&#8221; You are advised to discuss the Covenant Agreement with an attorney of your choice, and you have had an adequate opportunity to do so prior to executing this Agreement or the Covenant Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<b style="font-weight:bold;">Third Party Agreements and Rights</b>. You hereby confirm that you are not bound by the terms of any agreement with any previous employer or other party which would prevent you from performing your obligations hereunder. You represent to the Company that your execution of this Agreement, your employment with the Company and the performance of your proposed duties for the Company will not violate any obligations you may have to any such previous employer or other party. In your work for the Company, you will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party, and you will not bring to the premises of the Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such previous employment or other party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<b style="font-weight:bold;">Litigation and Regulatory Cooperation</b>. You shall provide your reasonable cooperation to the Company in (i) the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while you were engaged or employed by the Company, and (ii) the investigation, whether internal or external, of any matters about which the Company reasonably believes you may have knowledge or information. Your reasonable cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being reasonably available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company, all at mutually convenient times. During and after your engagement and employment, you also shall provide your reasonable cooperation to the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while you were employed by the Company. The Company shall bear all costs that you may reasonably incur in connection with any of your obligations contemplated by thus <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12(c)</u>. Specifically, the Company shall pay directly or reimburse you for any reasonable out-of-pocket expenses, including fees and costs for an independent attorney of your choice hired by you, incurred in connection with your performance of obligations pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12(c).</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<b style="font-weight:bold;">Relief</b>. You agree that it would be difficult to measure any damages caused to the Company which might result from your breach of any of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, you agree that if you breach, or propose to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to seek an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Golden Parachute Taxes</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<b style="font-weight:bold;">Best After-Tax Result</b>. In the event that any payment or benefit received or to be received by you pursuant to this Agreement or otherwise (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payments</u>&#8221;) would (i) constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code and (ii) but for this subsection (a), be subject to the excise tax imposed by Section 4999 of the Code, any successor provisions, or any comparable federal, state, local or foreign excise tax (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excise Tax</u>&#8221;), then, subject to the provisions of Section 14, such Payments shall be either (A) provided in full pursuant to the terms of this Agreement or any other applicable agreement, or (B) provided as to such lesser extent which would result in the Payments being $1.00 less than the amount at which any portion of the Payments would be subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state, local and foreign income, employment and other taxes and the Excise Tax (including, without limitation, any interest or penalties on such taxes), results in the receipt, on an after-tax basis, of the greatest amount of payments and benefits provided for hereunder or otherwise, notwithstanding that all or some portion of such Payments may be subject to the Excise Tax. Unless the Company and you otherwise agree in writing, any determination required under this Section shall be made by independent tax counsel designated by the Company and reasonably acceptable to you (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Independent Tax Counsel</u>&#8221;), whose determination shall be conclusive and binding upon you and the Company for all purposes. For purposes of making the calculations required under this Section, Independent Tax Counsel may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code; provided that Independent Tax Counsel shall assume that you pay all taxes at the highest marginal rate. The Company and you shall furnish to Independent Tax Counsel such information and documents as Independent Tax Counsel may reasonably request in order to make a determination under this Section. The Company shall bear all costs that Independent Tax Counsel may reasonably incur in connection with any calculations contemplated by this Section. In the event that <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13(a)(ii)(B)</u> above applies, then based on the information provided to you and the Company by Independent Tax Counsel, the cutback described hereunder will apply as to compensation not subject to Section 409A of the Code prior to compensation subject to Section 409A of the Code and will otherwise apply on a reverse chronological basis from payments latest in time. If the Internal Revenue Service (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IRS</u>&#8221;) determines that any Payment is subject to the Excise Tax, then <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13(b)</u> hereof shall apply, and the enforcement of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13(b)</u> shall be the exclusive remedy to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<b style="font-weight:bold;">Adjustments</b>. If, notwithstanding any reduction described in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13(a)</u> hereof (or in the absence of any such reduction), the IRS determines that you are liable for the Excise Tax as a result of the receipt of one or more Payments, then you shall be obligated to surrender or pay back to the Company within one-hundred 120 days after a final IRS determination, an amount of such payments or benefits equal to the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Repayment Amount</u>.&#8221; The Repayment Amount with respect to such Payments shall be the smallest such amount, if any, as shall be required to be surrendered or paid to the Company so that your net proceeds with respect to such Payments (after taking into account the payment of the Excise Tax imposed on such Payments) shall be maximized. Notwithstanding the foregoing, the Repayment Amount with respect to such Payments shall be zero if a Repayment Amount of more than zero would not eliminate the Excise Tax imposed on such Payments or if a Repayment Amount of more than zero would not maximize the net amount received from the Payments. If the Excise Tax is not eliminated pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13(b)</u>, you shall pay the Excise Tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Section 409A</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section 409A of the Code, the Company determines that you are a &#8220;specified employee&#8221; within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement or otherwise on account of your separation from service would be considered deferred compensation otherwise subject to the additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after your separation from service, or (B) your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision (without interest), and the balance of the installments shall be payable in accordance with their original schedule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by you during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To the extent that any payment or benefit described in this Agreement constitutes &#8220;non-qualified deferred compensation&#8221; under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the termination of your employment, then such payments or benefits shall be payable only upon your &#8220;separation from service.&#8221; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-l(h).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">15.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Withholding; Tax Effect</b>. All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law. You hereby acknowledge that, except with respect to the Company&#8217;s obligations expressly set forth in this Agreement, (a) the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and (b) you will not make any claim against the Company or the Board related to tax liabilities arising from your compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">16.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Recoupment</b>. Amounts paid or payable under this Agreement shall be subject to the provisions of any applicable clawback or recoupment policies or procedures adopted by the Company, which clawback or recoupment policies may provide for forfeiture and/or recoupment of amounts paid or payable under this Agreement, subject to applicable Connecticut law. No forfeiture or recoupment under such policies or procedures will give rise to a right to resign for Good Reason under this Agreement or any other agreement between you and the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">17.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Interpretation and Enforcement</b>. This Agreement, together with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</u>, the Covenant Agreement, and any award agreement between you and the Company, constitute the complete agreement between you and the Company, contains all of the terms of your employment with the Company and supersedes any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. The terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or arising out of, related to, or in any way connected with this Agreement, your employment with the Company or any other relationship between you and the Company (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disputes</u>&#8221;) will be governed by federal law to the extent applicable and otherwise by Connecticut law, excluding laws relating to conflicts or choice of law and excluding Disputes arising in connection with any equity incentive plan, which shall be governed by the terms of the applicable equity incentive plan. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in the State of Connecticut in connection with any Dispute or any claim related to any Dispute, except for Disputes arising under any equity incentive plan, which shall be governed by the terms of the applicable equity incentive plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">18.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Assignment</b>. Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement without your consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets; provided further, that if you remain employed or become employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then you shall not be entitled to any payments, benefits or vesting pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</u> or pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11</u> of this Agreement solely as a result of such transaction; however, you will remain eligible for such payments, benefits or vesting in the event of a subsequent qualifying termination of employment. This Agreement shall inure to the benefit of and be binding upon you and the Company, and each of your and its respective successors, executors, administrators, heirs and permitted assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">19.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Waiver; Amendment</b>. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. This Agreement may be amended or modified only by a written instrument signed by you and by a duly authorized representative of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">20.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Enforceability</b>. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law in accordance with the original intent of the parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">21.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Conditions</b>. You must submit satisfactory proof of your identity, successfully complete a criminal background check, which you hereby expressly authorize by your execution of this Agreement, and provide documentation of your legal authorization to work in the United States on or prior to the Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">22.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Employee Representations</b>. It is the policy of the Company not to solicit or accept proprietary information and/or trade secrets of other companies or third parties. If you have or have had access to trade secrets or other confidential, proprietary information from your former employer or another third party, the use of such information in performing your duties at the Company is prohibited. This may include, but is not limited to, confidential or proprietary information in the form of documents, magnetic media, software, customer lists, and business plans or strategies. In making this employment offer, the Company has relied on your representation that: (a) you are not currently a party to any agreement that would restrict your ability to accept this offer or to perform services for the Company; (b) you are not subject to any noncompetition or non-solicitation agreement or other restrictive covenants that might restrict your employment by the Company as contemplated by this offer; (c) you have the full right, power and authority to execute and deliver the Agreement and to perform all of your obligations thereunder; and (d) you will not bring with you to the Company or use in the performance of your responsibilities at the Company any materials, documents or work product of a former employer or other third party that are not generally available to the public, unless you have obtained written authorization from such former employer or third party for their possession and use and have provided the Company with a copy of same.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">23.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Other Terms</b>. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of your employment to the extent necessary to effectuate the terms contained herein. The headings and other captions in this Agreement are for convenience and reference only and shall not be used in interpreting, construing or enforcing any of the provisions of this Agreement. This Agreement may be executed in separate counterparts. When both counterparts are signed, they shall be treated together as one and the same document. PDF copies of signed counterparts shall be equally effective as originals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>I look forward to working with you to make the Company a great success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>Sincerely,</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td colspan="3" style="vertical-align:bottom;width:55.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Tomas Kiselak</p></td><td style="vertical-align:bottom;width:44.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tomas Kiselak</p></td><td style="vertical-align:bottom;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:55.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accepted and acknowledged:</p></td><td style="vertical-align:bottom;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:55.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:55.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Hetal Kocinsky</p></td><td style="vertical-align:bottom;width:44.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:55.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hetal Kocinsky</p></td><td style="vertical-align:bottom;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:55.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:bottom;width:49.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">9/3/2024</p></td><td style="vertical-align:bottom;width:44.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cause</u>&#8221; shall mean (i) your dishonest statements or acts with respect to the Company or any affiliate of the Company, or any current or prospective customers, suppliers, vendors or other third parties with which such entity does business that results in or is reasonably anticipated to result in material harm to the Company; (ii) your conviction or plea of no contest to: (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) your failure to perform in all material respects your assigned duties and responsibilities, which failure continues uncured for 30 days after written notice given to you describing such failure; (iv) your gross negligence or willful misconduct that results in or is reasonably anticipated to result in material harm to the Company; or (v) your violation of any material provision of any agreement(s) between you and the Company or any written Company policies including, without limitation, agreements relating to non-solicitation, non-disclosure and/or assignment of inventions or policies related to ethics or workplace conduct.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Control</u>&#8221; shall have the meaning set forth in the Equity Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Control Period</u>&#8221; shall mean the 12-month period beginning on the consummation of the first event constituting a Change in Control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Code</u>&#8221; means the Internal Revenue Code of 1986, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disability</u>&#8221; shall mean a permanent and total disability as defined in Section 22(e)(3) of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Reason</u>&#8221; shall mean that you have complied with the Good Reason Process (hereinafter defined) following the occurrence, without your written consent, of any of the following events: (i) any material diminution in your base salary or Target Bonus except for across-the-board salary and target bonus reductions of no more than 10% based on the Company&#8217;s financial performance similarly affecting all or substantially all senior management employees of the Company; (ii) a material change in the geographic location at which you are required to provide services to the Company or a requirement that you change your remote location to a location other than your then-current residence; (iii) the failure of the Company to obtain the assumption of this Agreement, and all of the Company&#8217;s obligations hereunder, by a successor; or (iv) the material breach of this Agreement (or any other agreements with you) by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Reason Process</u>&#8221; shall mean that (i) you reasonably determine in good faith that a &#8220;Good Reason&#8221; condition has occurred; (ii) you notify the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii) you cooperate in good faith with the Company&#8217;s good faith and commercially reasonable efforts, for a period not less than 30 days immediately following such notice (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cure Period</u>&#8221;), to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and (v) you terminate your employment within 60 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>10
<FILENAME>avte-20240930xex10d15.htm
<DESCRIPTION>EXHIBIT 10.15
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 12/3/2024 12:41:59 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.15</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>October&#8239;16, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;Elizabeth Balta</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;Re: Offer of Employment</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;Dear Elizabeth:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;On behalf of Jade Biosciences,&#8239;Inc. (the &#8220;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u>&#8221;),&#8239;I am very pleased to offer you a position as General Counsel and Corporate Secretary of the Company (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Role</u>&#8221;) pursuant to this letter agreement (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;), provided you accept such offer as indicated by your signature below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;Your employment with the Company in the Role will commence as of October&#8239;22, 2024 (the &#8220;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u>&#8221;). Should you not commence services by the Effective Date or if this Agreement is otherwise terminated on or prior to the Effective Date, you hereby agree that this Agreement shall be void <i style="font-style:italic;">ab initio</i> and of no force or effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Position</b>. While serving in the Role, you will report to the Company&#8217;s Chief Executive Officer (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CEO</u>&#8221;) , and have such duties, authorities, and responsibilities as are customarily associated with the Role. This is a full-time employment position. It is understood and agreed that, commencing as of the Effective Date you will not engage in any other employment, consulting or other business activities (whether full-time or part-time). Notwithstanding the foregoing, you may engage in religious, charitable and other community activities so long as such activities do not unreasonably interfere or conflict with your obligations to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Base Salary</b>. The Company will pay you an initial base salary of $400,000.00 per year, payable in accordance with the Company&#8217;s standard payroll schedule and subject to applicable deductions and withholdings. Your base salary will be subject to periodic review and potential adjustment in the Company&#8217;s discretion. Your base salary in effect at any given time is referred to herein as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Salary</u>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Annual Bonus</b>. Commencing as of the Effective Date, you will be eligible to receive an annual performance bonus targeted at 35% of your Base Salary. The target annual bonus in effect at any given time is referred to herein as &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Target Bonus</u>.&#8221; Your 2024 annual bonus will be prorated based on your period of employment following the Effective Date. The actual bonus amount is discretionary and may be subject to achievement of performance targets established by the Company for such year. To earn an annual bonus, you must be employed by the Company as of the payment date of such bonus. Any annual bonus will be paid no later than March&#8239;15th of the calendar year following the calendar year to which such bonus relates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Equity.</b> Subject to approval by the Board of Directors of the Company (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board</u>&#8221;) or the Compensation Committee of the Board (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Committee</u>&#8221;), it is anticipated that the Company will grant you stock options to purchase 221,311 shares of the Company&#8217;s common stock (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Options</u>&#8221;) as soon as practicable following the Effective Date, with an exercise price per share equal to the fair market value of a share of the Company&#8217;s common stock on the date of grant (as determined by the Board or the Committee in its sole discretion). The Options will vest over a four-year period following the Effective Date, with 25% of the Options vesting on the first anniversary of the Effective Date, and the remainder vesting in 36 equal monthly installments on each monthly anniversary thereafter, in each case, subject to your continued service with the Company through the applicable vesting dates. The Options will be governed by the terms of the related award agreement, the Company&#8217;s 2024 Equity Incentive Plan (as amended from time to time and including any successor plan, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equity Plan</u>&#8221;) and the terms and conditions approved by the Board or the Committee. In addition to the Options, you may be eligible to receive such future equity grants as the Board or the Committee may deem appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Benefits/Paid Time Off. </b>Commencing as of the Effective Date, you will be eligible, subject to the terms of the applicable plans and programs, to participate in the employee benefits and insurance programs generally made available to the Company&#8217;s full-time employees. Details of such benefits programs, including applicable employee contributions and waiting periods, if applicable, will be made available to you when such benefit(s)&#8239;become available. You will be entitled to paid time off consistent with the terms of the Company&#8217;s paid time off policy, as in effect from time to time. The Company reserves the right to modify, limit, amend or cancel any of its benefits plans or programs at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Expense Reimbursement. </b>The Company will reimburse you for all reasonable and necessary expenses incurred by you in connection with performing your duties as an employee of the Company and that are pre-approved by the Company, provided that you comply with any Company policy or practice on submitting, accounting for and documenting such expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Location</b>. Your primary work location will be remotely in Washington, provided that you may be required to engage in reasonable travel for business, consistent with the Company&#8217;s business needs. You may change your remote work location with prior written notice to and approval from the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;At-Will Employment; Date of Termination</b>. At all times, your employment with the Company is &#8220;at will,&#8221; meaning you or the Company may terminate it at any time for any or no reason, subject to the terms of this Agreement. Although your job duties, title, reporting structure, compensation and benefits, as well as the Company&#8217;s benefit plans and personnel policies and procedures, may change from time to time (subject to the terms of this Agreement), the &#8220;at will&#8221; nature of your employment may only be changed in an express written agreement signed by you and an authorized officer of the Company. Your last day of employment for any reason is referred to herein as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Date of Termination</u>.&#8221; In the event that you elect to end your employment with the Company, the Company requires you to provide at least 30 days&#8217; advance written notice to the Company. Notwithstanding the foregoing, the Company may unilaterally accelerate the Date of Termination, and such acceleration shall not result in a termination by the Company without Cause for purposes of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;To the extent applicable, you shall be deemed to have resigned from all officer and board member positions that you hold with the Company or any of its respective subsidiaries and affiliates upon the termination of your employment for any reason. You shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Accrued Obligations</b>. In the event of the ending of your employment for any reason, the Company shall pay you (i)&#8239;your Base Salary and, if applicable, any accrued but unused vacation, through the Date of Termination, and (ii)&#8239;the amount of any documented expenses properly incurred by you on behalf of the Company prior to any such termination and not yet reimbursed. (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accrued Obligations</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Severance Pay and Benefits Outside of the Change in Control Period</b>. In the event that the Company terminates your employment without Cause (and not as a result of your death or Disability) outside of the Change in Control Period (as such capitalized terms are defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</u>), then, in addition to the Accrued Obligations, and subject to (i)&#8239;your execution and non-revocation of a separation agreement and release in a form acceptable to the Company, which shall include a general release of claims against the Company and all related persons and entities and a reaffirmation of the Continuing Obligations (as defined below) and shall provide that if you breach the Continuing Obligations, all payments of the following severance pay and benefits shall immediately cease (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation Agreement and Release</u>&#8221;), and (ii)&#8239;the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven-day revocation period:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Company shall pay you an amount equal to six months of your Base Salary, payable in substantially equal installments over the six-month period following the Date of Termination in accordance with the Company&#8217;s regular payroll practices beginning on the Company&#8217;s first regularly scheduled payroll date following the date that is 60 days after the Date of Termination; provided, however, that the first installment shall include any amounts that would have been paid following the Date of Termination had such installments commenced on the first regularly scheduled payroll date following the Date of Termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Company shall pay you any bonus earned but unpaid for the year immediately preceding the year in which the Date of Termination occurs, payable at the time such bonuses are paid to other Company employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject to your copayment of premium amounts at the applicable active employees&#8217; rate and your proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COBRA</u>&#8221;), the Company shall pay to the group health plan provider(s), the COBRA provider or you a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to you if you had remained employed by the Company until the earliest of (A)&#8239;the six-month anniversary of the Date of Termination; (B)&#8239;your eligibility for group health plan benefits under any other employer&#8217;s group health plan; or (C)&#8239;the cessation of your continuation rights under COBRA; provided, however, that if the Company reasonably determines that it cannot pay such amounts to the group health plan provider(s)&#8239;or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section&#8239;2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to you for the time period specified above. Such payments, if to you, shall be subject to tax-related deductions and withholdings and paid on the Company&#8217;s regular payroll dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Severance Pay and Benefits Within the Change in Control Period</b>. In the event that the Company terminates your employment without Cause (and not as a result of your death or Disability) or you resign for Good Reason, in each case within the Change in Control Period, then, in addition to you being entitled to the Accrued Obligations, and subject to your execution and non-revocation of the Separation Agreement and Release and it becoming fully effective, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven-day revocation period:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;You will receive the severance pay and benefits set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;10</u> above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding anything to the contrary in any applicable equity-based award agreement or plan, the unvested portion of your then outstanding equity-based awards subject to time-based vesting shall immediately accelerate and become vested or nonforfeitable as of the later of (i)&#8239;the Date of Termination or (ii)&#8239;the effective date of the Separation Agreement and Release.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the avoidance of doubt, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;10</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;11</u> of this Agreement are mutually exclusive and in no event shall you be entitled to payments or benefits pursuant to both <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;10</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;11</u> of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Continuing Obligations</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<b style="font-weight:bold;">Restrictive Covenant Agreement</b>. As a condition of your employment, you are required to enter into an Invention Assignment, Non-Disclosure, and Business Protection Agreement (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Covenant Agreement</u>&#8221;), which must be signed prior to the Effective Date. For purposes of this Agreement, the obligations in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;12</u> and those that arise in the Covenant Agreement and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Continuing Obligations</u>.&#8221; You are advised to discuss the Covenant Agreement with an attorney of your choice, and you have had an adequate opportunity to do so prior to executing this Agreement or the Covenant Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<b style="font-weight:bold;">Third Party Agreements and Rights</b>. You hereby confirm that you are not bound by the terms of any agreement with any previous employer or other party which would prevent you from performing your obligations hereunder. You represent to the Company that your execution of this Agreement, your employment with the Company and the performance of your proposed duties for the Company will not violate any obligations you may have to any such previous employer or other party. In your work for the Company, you will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party, and you will not bring to the premises of the Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such previous employment or other party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<b style="font-weight:bold;">Litigation and Regulatory Cooperation</b>. You shall cooperate fully with the Company in (i)&#8239;the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while you were engaged or employed by the Company, and (ii)&#8239;the investigation, whether internal or external, of any matters about which the Company believes you may have knowledge or information. Your full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being reasonably available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after your engagement and employment, you also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while you were employed by the Company. The Company shall reimburse you for any reasonable out-of-pocket expenses, including fees and costs for an independent attorney of your choice hired by you, incurred in connection with your performance of obligations pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;12(c).</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<b style="font-weight:bold;">Relief</b>. You agree that it would be difficult to measure any damages caused to the Company which might result from your breach of any of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, you agree that if you breach, or propose to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to seek an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Golden Parachute Taxes</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<b style="font-weight:bold;">Best After-Tax Result</b>. In the event that any payment or benefit received or to be received by you pursuant to this Agreement or otherwise (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payments</u>&#8221;) would (i)&#8239;constitute a &#8220;parachute payment&#8221; within the meaning of Section&#8239;280G of the Code and (ii)&#8239;but for this subsection (a), be subject to the excise tax imposed by Section&#8239;4999 of the Code, any successor provisions, or any comparable federal, state, local or foreign excise tax (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excise Tax</u>&#8221;), then, subject to the provisions of Section&#8239;14, such Payments shall be either (A)&#8239;provided in full pursuant to the terms of this Agreement or any other applicable agreement, or (B)&#8239;provided as to such lesser extent which would result in the Payments being $1.00 less than the amount at which any portion of the Payments would be subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state, local and foreign income, employment and other taxes and the Excise Tax (including, without limitation, any interest or penalties on such taxes), results in the receipt, on an after-tax basis, of the greatest amount of payments and benefits provided for hereunder or otherwise, notwithstanding that all or some portion of such Payments may be subject to the Excise Tax. Unless the Company and you otherwise agree in writing, any determination required under this Section&#8239;shall be made by independent tax counsel designated by the Company and reasonably acceptable to you (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Independent Tax Counsel</u>&#8221;), whose determination shall be conclusive and binding upon you and the Company for all purposes. For purposes of making the calculations required under this Section,&#8239;Independent Tax Counsel may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code; provided that Independent Tax Counsel shall assume that you pay all taxes at the highest marginal rate. The Company and you shall furnish to Independent Tax Counsel such information and documents as Independent Tax Counsel may reasonably request in order to make a determination under this Section. The Company shall bear all costs that Independent Tax Counsel may reasonably incur in connection with any calculations contemplated by this Section. In the event that <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;13(a)(ii)(B)</u>&#8239;above applies, then based on the information provided to you and the Company by Independent Tax Counsel, the cutback described hereunder will apply as to compensation not subject to Section&#8239;409A of the Code prior to compensation subject to Section&#8239;409A of the Code and will otherwise apply on a reverse chronological basis from payments latest in time. If the Internal Revenue Service (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IRS</u>&#8221;) determines that any Payment is subject to the Excise Tax, then <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;13(b)</u>&#8239;hereof shall apply, and the enforcement of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;13(b)</u>&#8239;shall be the exclusive remedy to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<b style="font-weight:bold;">Adjustments</b>. If, notwithstanding any reduction described in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;13(a)</u>&#8239;hereof (or in the absence of any such reduction), the IRS determines that you are liable for the Excise Tax as a result of the receipt of one or more Payments, then you shall be obligated to surrender or pay back to the Company within one-hundred 120 days after a final IRS determination, an amount of such payments or benefits equal to the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Repayment Amount</u>.&#8221; The Repayment Amount with respect to such Payments shall be the smallest such amount, if any, as shall be required to be surrendered or paid to the Company so that your net proceeds with respect to such Payments (after taking into account the payment of the Excise Tax imposed on such Payments) shall be maximized. Notwithstanding the foregoing, the Repayment Amount with respect to such Payments shall be zero if a Repayment Amount of more than zero would not eliminate the Excise Tax imposed on such Payments or if a Repayment Amount of more than zero would not maximize the net amount received from the Payments. If the Excise Tax is not eliminated pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;13(b)</u>, you shall pay the Excise Tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Section&#8239;409A</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section&#8239;409A of the Code, the Company determines that you are a &#8220;specified employee&#8221; within the meaning of Section&#8239;409A(a)(2)(B)(i)&#8239;of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement or otherwise on account of your separation from service would be considered deferred compensation otherwise subject to the additional tax imposed pursuant to Section&#8239;409A(a)&#8239;of the Code as a result of the application of Section&#8239;409A(a)(2)(B)(i)&#8239;of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A)&#8239;six months and one day after your separation from service, or (B)&#8239;your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision (without interest), and the balance of the installments shall be payable in accordance with their original schedule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by you during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To the extent that any payment or benefit described in this Agreement constitutes &#8220;non-qualified deferred compensation&#8221; under Section&#8239;409A of the Code, and to the extent that such payment or benefit is payable upon the termination of your employment, then such payments or benefits shall be payable only upon your &#8220;separation from service.&#8221; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section&#8239;1.409A-l(h).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The parties intend that this Agreement will be administered in accordance with Section&#8239;409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section&#8239;409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section&#8239;409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section&#8239;1.409A-2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section&#8239;409A of the Code and all related rules&#8239;and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section&#8239;409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">15.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Withholding; Tax Effect</b>. All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or the Board related to tax liabilities arising from your compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">16.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Recoupment</b>. Amounts paid or payable under this Agreement shall be subject to the provisions of any applicable clawback or recoupment policies or procedures adopted by the Company, which clawback or recoupment policies may provide for forfeiture and/or recoupment of amounts paid or payable under this Agreement, subject to applicable Washington law. No forfeiture or recoupment under such policies or procedures will give rise to a right to resign for Good Reason under this Agreement or any other agreement between you and the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">17.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Interpretation and Enforcement</b>. This Agreement, together with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</u>, the Covenant Agreement, and any award agreement between you and the Company, constitute the complete agreement between you and the Company, contains all of the terms of your employment with the Company and supersedes any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. The terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or arising out of, related to, or in any way connected with this Agreement, your employment with the Company or any other relationship between you and the Company (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disputes</u>&#8221;) will be governed by federal law to the extent applicable and otherwise by Washington law, excluding laws relating to conflicts or choice of law and excluding Disputes arising in connection with any equity incentive plan, which shall be governed by the terms of the applicable equity incentive plan. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in the State of Washington in connection with any Dispute or any claim related to any Dispute, except for Disputes arising under any equity incentive plan, which shall be governed by the terms of the applicable equity incentive plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">18.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Assignment</b>. Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement without your consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets; provided further, that if you remain employed or become employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then you shall not be entitled to any payments, benefits or vesting pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;10</u> or pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#8239;11</u> of this Agreement solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon you and the Company, and each of your and its respective successors, executors, administrators, heirs and permitted assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">19.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Waiver; Amendment</b>. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. This Agreement may be amended or modified only by a written instrument signed by you and by a duly authorized representative of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">20.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Enforceability</b>. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">21.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Conditions</b>. You must submit satisfactory proof of your identity, successfully complete a criminal background check, which you hereby expressly authorize by your execution of this Agreement, and provide documentation of your legal authorization to work in the United States on or prior to the Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">22.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Employee Representations</b>. It is the policy of the Company not to solicit or accept proprietary information and/or trade secrets of other companies or third parties. If you have or have had access to trade secrets or other confidential, proprietary information from your former employer or another third party, the use of such information in performing your duties at the Company is prohibited. This may include, but is not limited to, confidential or proprietary information in the form of documents, magnetic media, software, customer lists, and business plans or strategies. In making this employment offer, the Company has relied on your representation that: (a)&#8239;you are not currently a party to any agreement that would restrict your ability to accept this offer or to perform services for the Company; (b)&#8239;you are not subject to any noncompetition or non-solicitation agreement or other restrictive covenants that might restrict your employment by the Company as contemplated by this offer; (c)&#8239;you have the full right, power and authority to execute and deliver the Agreement and to perform all of your obligations thereunder; and (d)&#8239;you will not bring with you to the Company or use in the performance of your responsibilities at the Company any materials, documents or work product of a former employer or other third party that are not generally available to the public, unless you have obtained written authorization from such former employer or third party for their possession and use and have provided the Company with a copy of same.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">23.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Other Terms</b>. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of your employment to the extent necessary to effectuate the terms contained herein. The headings and other captions in this Agreement are for convenience and reference only and shall not be used in interpreting, construing or enforcing any of the provisions of this Agreement. This Agreement may be executed in separate counterparts. When both counterparts are signed, they shall be treated together as one and the same document. PDF copies of signed counterparts shall be equally effective as originals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">I look forward to working with you to make the Company a great success.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td colspan="2" style="vertical-align:bottom;width:51.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sincerely,</p></td><td style="vertical-align:bottom;width:48.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:51.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:51.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Tom Frohlich</p></td><td style="vertical-align:bottom;width:48.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:44.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tom Frohlich</p></td><td style="vertical-align:bottom;width:48.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:44.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td><td style="vertical-align:bottom;width:48.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:51.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:51.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accepted and acknowledged:</p></td><td style="vertical-align:bottom;width:48.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:51.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:51.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Elizabeth Balta</p></td><td style="vertical-align:bottom;width:48.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:51.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Elizabeth Balta</p></td><td style="vertical-align:bottom;width:48.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:51.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:bottom;width:44.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10/21/2024</p></td><td style="vertical-align:bottom;width:48.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cause</u>&#8221; shall mean (i)&#8239;your dishonest statements or acts with respect to the Company or any affiliate of the Company, or any current or prospective customers, suppliers, vendors or other third parties with which such entity does business that results in or is reasonably anticipated to result in material harm to the Company; (ii)&#8239;your conviction or plea of no contest to: (A)&#8239;a felony or (B)&#8239;any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii)&#8239;your failure to perform in all material respects your assigned duties and responsibilities, which failure continues for 30 days after written notice given to you describing such failure; (iv)&#8239;your gross negligence, willful misconduct that results in or is reasonably anticipated to result in material harm to the Company; or (v)&#8239;your violation of any material provision of any agreement(s)&#8239;between you and the Company or any written Company policies including, without limitation, agreements relating to non-solicitation, non-disclosure and/or assignment of inventions or policies related to ethics or workplace conduct.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Control</u>&#8221; shall have the meaning set forth in the Equity Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Control Period</u>&#8221; shall mean the 12-month period beginning on the consummation of the first event constituting a Change in Control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Code</u>&#8221; means the Internal Revenue Code of 1986, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disability</u>&#8221; shall mean a permanent and total disability as defined in Section&#8239;22(e)(3)&#8239;of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Reason</u>&#8221; shall mean that you have complied with the Good Reason Process (hereinafter defined) following the occurrence, without your written consent, of any of the following events: (i)&#8239;a material diminution in your base salary or Target Bonus except for across-the-board salary and target bonus reductions of no more than 10% based on the Company&#8217;s financial performance similarly affecting all or substantially all senior management employees of the Company; (ii)&#8239;a material change in the geographic location at which you are required to provide services to the Company or a requirement that you change your remote location to a location other than your then-current residence; (iii)&#8239;the failure of the Company to obtain the assumption of this Agreement by a successor; or (iv)&#8239;the material breach of this Agreement (or any other agreements with you) by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Reason Process</u>&#8221; shall mean that (i)&#8239;you reasonably determine in good faith that a &#8220;Good Reason&#8221; condition has occurred; (ii)&#8239;you notify the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii)&#8239;you cooperate in good faith with the Company&#8217;s efforts, for a period not less than 30 days following such notice (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cure Period</u>&#8221;), to remedy the condition; (iv)&#8239;notwithstanding such efforts, the Good Reason condition continues to exist; and (v)&#8239;you terminate your employment within 60 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>11
<FILENAME>avte-20240930xex10d16.htm
<DESCRIPTION>EXHIBIT 10.16
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 12/3/2024 12:41:59 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.16</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">ANTIBODY DISCOVERY AND OPTION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">THIS ANTIBODY DISCOVERY AND OPTION AGREEMENT</b> (&#8220;<b style="font-weight:bold;">Agreement</b>&#8221;) is entered into and effective as of July 24, 2024 (the &#8220;<b style="font-weight:bold;">Effective Date</b>&#8221;), by and among Paragon Therapeutics, Inc., a Delaware corporation (&#8220;<b style="font-weight:bold;">Paragon</b>&#8221;), Parade Biosciences Holding, LLC, a Delaware limited liability company (&#8220;<b style="font-weight:bold;">Parade</b>&#8221;) and Jade Biosciences, Inc., a Delaware corporation (&#8220;<b style="font-weight:bold;">Jade</b>&#8221;). Paragon, Parade and Jade are also referred to herein individually as a &#8220;<b style="font-weight:bold;">Party</b>&#8221;, or collectively as the &#8220;<b style="font-weight:bold;">Parties</b>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">&#8239;&#8239;<b style="font-weight:bold;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">WHEREAS</b>, Paragon has developed a proprietary platform technology for the discovery and development of antibodies against therapeutically relevant targets;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">WHEREAS</b>, Jade desires to engage Paragon to perform, and Paragon is willing to perform, certain research activities to discover, generate, identify, and characterize one or more monospecific antibody candidates directed to certain mutually agreed therapeutic targets of interest to Jade; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">WHEREAS, </b>Jade will have an exclusive option to enter into separate license agreements with Paragon to develop, manufacture and commercialize the resulting antibodies with respect to a given therapeutic target, all on the terms and subject to the conditions set forth in this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">NOW THEREFORE, </b>in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#8239;<b style="font-weight:bold;">ARTICLE 1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DEFINED TERMS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">1.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Achievement of Development Candidate</b>&#8221; means the first to occur of: (a)&#8239;nomination by Jade&#8217;s Board of Directors of a Jade Product as a &#8220;Development Candidate&#8221;; and (b)&#8239;the&#8239;initiation by or on behalf of Jade or its Affiliate or sublicensee of a toxicology study with respect to a Jade Product that employs applicable then-current good laboratory practice standards, the results of which are intended to be submitted as part of an IND.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">1.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Active Research Program</b>&#8221; shall have the meaning set forth in Section&#8239;5.2(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">&#8239;</b><b style="font-weight:bold;">1.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Actual Annual Costs</b>&#8221; shall have the meaning set forth in Section&#8239;5.2(c).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">&#8239;</b><b style="font-weight:bold;">1.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Affiliate</b>&#8221; shall mean any entity controlled by, controlling, or under common control with a Party hereto. For the purpose of this definition, &#8220;control&#8221; (including, with correlative meaning, the terms &#8220;controlled by&#8221; or &#8220;under common control&#8221;) means the direct or indirect ownership of more than fifty percent (50%) of the voting interest in, or more than fifty percent (50%) in the equity of, or the right to appoint more than fifty percent (50%) of the directors or management of, such corporation or other business entity. Notwithstanding the foregoing, (a)&#8239;with respect to either Party, Affiliates of such Party do not include [***] or its Affiliates other than such Party and its subsidiaries, (b) [***], and (c) [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">1.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Agreement</b>&#8221; shall have the meaning provided in the first paragraph of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">1.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Antibody</b>&#8221; shall mean any molecule, including [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">1.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Antibody Production Activities</b>&#8221; shall have the meaning provided in Section&#8239;2.1(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">1.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Applicable Law</b>&#8221; shall mean any national, supra-national, federal, state or local laws, rules, guidances and regulations, in each case, as applicable to the subject matter and the party at issue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">1.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">APRIL</b>&#8221; means a proliferation-inducing ligand, also known as tumor necrosis factor ligand superfamily member 13 (TNFSF13).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">1.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Background IP</b>&#8221; shall mean all Patents and Know-How Controlled by a Party (a) as of the Effective Date, or (b) that otherwise arise outside of and independently of this Agreement. Paragon&#8217;s Background IP includes the Paragon Platform Technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">1.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Bankruptcy Code</b>&#8221; shall have the meaning set forth in Section 9.5.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">1.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Bankruptcy Event</b>&#8221; shall have the meaning set forth in Section 9.5.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">1.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Budget</b>&#8221; shall mean the agreed budget for the activities set forth in the applicable Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">1.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Business Day</b>&#8221; shall mean any day other than Saturday, Sunday, or other national holidays in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">1.15&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Calendar Quarter</b>&#8221; shall mean the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30, and December 31.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">1.16&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Calendar Year</b>&#8221; shall mean each successive period of twelve (12) months commencing on January 1 and ending on December 31.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">1.17&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">CMC Activities</b>&#8221; shall have the meaning provided in Section 5.2(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">1.18&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">CMC Rate</b>&#8221; shall have the meaning provided in Section 5.2(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">1.19&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Commercialize</b>&#8221; or &#8220;<b style="font-weight:bold;">Commercializing</b>&#8221; shall mean to market, promote, distribute, offer for sale, sell, have sold, import, have imported, export, have exported or otherwise commercialize an Antibody or product, including a Project Antibody, Derived Antibody, Product, Multispecific Antibody, or Multispecific Product, as applicable. When used as a noun, &#8220;Commercialization&#8221; means any and all activities involved in Commercializing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.20&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Confidential Information</b>&#8221; of a Party shall mean any and all non-public scientific, business, regulatory, or technical information that is disclosed or made available by or on behalf of one Party (the &#8220;<b style="font-weight:bold;">Disclosing Party</b>&#8221;) to any other Party (a &#8220;<b style="font-weight:bold;">Receiving Party</b>&#8221;) in connection with this Agreement, whether in writing, orally, visually or otherwise. Notwithstanding any provision of this Agreement to the contrary, all Project Antibody Inventions and Project Antibody Technology shall be the Confidential Information of all Parties, and each Party shall be deemed as both the &#8220;Disclosing Party&#8221; and the &#8220;Receiving Party&#8221; with respect thereto; <i style="font-style:italic;">provided, that</i> if Jade does not exercise its Option or the Parties do not enter into a License Agreement in accordance with this Agreement, then the Project Antibody Inventions and Project Antibody Technology shall thereafter be the Confidential Information of Paragon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.21&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Control</b>&#8221; (including any variations such as &#8220;<b style="font-weight:bold;">Controlled</b>&#8221; and &#8220;<b style="font-weight:bold;">Controlling</b>&#8221;) shall mean, with respect to any technology or Intellectual Property Rights, possession by a Party and the ability (whether by ownership, license or otherwise) to grant a license or a sublicense of or under such Technology or Intellectual Property Rights without violating the terms of any agreement or other arrangement with any Third Party or requiring a payment. Notwithstanding the foregoing, a Party and its Affiliates shall not be deemed to &#8220;Control&#8221; any technology or Intellectual Property Rights that (a) prior to the consummation of a Change of Control of such Party, is owned or in-licensed, or (b)&#8239;after the consummation of a Change of Control of such Party, becomes owned or in-licensed (to the extent such technology or Intellectual Property Rights are developed outside of the scope of the activities conducted hereunder and without use of or reference to any technology or Intellectual Property Rights Controlled by such Party or any Affiliate of such Party immediately before such Change of Control, or any Confidential Information of the other Party), in each case ((a) or (b)), by a Third Party that becomes an Affiliate of such Party after the Effective Date as a result of such Change of Control or an assignee of such Party after the Effective Date as the result of an assignment of this Agreement in connection with a Change of Control unless prior to the consummation of such Change of Control or assignment, such Party or any of its Affiliates also Controlled such technology or Intellectual Property Rights. &#8220;<b style="font-weight:bold;">Change of Control</b>&#8221; means, with respect to any entity, any of the following: (a) the sale or disposition of all or substantially all of the assets of such entity or its direct or indirect controlling Affiliate to a Third Party; or (b) (i) the acquisition by a Third Party, alone or together with any of its Affiliates, other than an employee benefit plan (or related trust) sponsored or maintained by such entity or any of its Affiliates, of more than fifty percent (50%) of the then-outstanding shares of voting capital stock of such entity or its direct or indirect parent entity that holds, directly or indirectly, beneficial ownership of more than fifty percent (50%) of the then-outstanding shares of voting capital stock of such entity (a &#8220;Parent Entity&#8221;), or (ii) the acquisition, merger or consolidation of such entity or its Parent Entity with or into another entity, other than, in the case of clause (i) or (ii), an acquisition or a merger or consolidation of such entity or its Parent Entity in which the holders of shares of voting capital stock of such entity or its Parent Entity, as the case may be, immediately prior to such acquisition, merger or consolidation will beneficially own, directly or indirectly, at least fifty percent (50%) of the shares of voting capital stock of the acquiring Third Party or the surviving corporation in such acquisition, merger or consolidation, as the case may be, immediately after such acquisition, merger or consolidation, and in each case of (a) or (b), whether through a single transaction or a series of related transactions, but excluding any and all bona fide financing transactions or internal reorganizations for tax purposes (including the change of place of incorporation or domicile of such entity).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.22&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Cost Advance</b>&#8221; shall have the meaning set forth in Section 5.2(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.23&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Cover</b>&#8221; or &#8220;<b style="font-weight:bold;">Covering</b>&#8221; shall mean, with respect to a Patent, that, in the absence of a license granted under, or ownership of, such Patent, the making, using, selling, importation, or exportation of such product would infringe a valid and unexpired claim of such Patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.24&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Deliverables</b>&#8221; shall have the meaning set forth in Section 2.1(c)(i).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.25&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Derived Antibody</b>&#8221; shall mean any Antibody that (a)&#8239;is derived from or constitutes a modification of a Project Antibody, including [***], and (b)&#8239;[***]. For avoidance of doubt, any Antibody that [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.26&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </b>&#8220;<b style="font-weight:bold;">Derived Antibody Patent</b>&#8221; shall mean any Patent that Covers the composition of matter of, or any method of specifically making or using, any Derived Antibody.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.27&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Develop</b>&#8221; or &#8220;<b style="font-weight:bold;">Developing</b>&#8221; shall mean to discover, evaluate, test, research or otherwise develop an Antibody or product, including a Project Antibody, Derived Antibody, Product, Multispecific Antibody, or Multispecific Product, as applicable. When used as a noun, &#8220;<b style="font-weight:bold;">Development</b>&#8221; means any and all activities involved in Developing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.28&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Development Costs</b>&#8221; shall mean (a) [***] (such amounts, the &#8220;<b style="font-weight:bold;">Third Party Costs</b>&#8221;), and (b) [***] (such development fees, the &#8220;<b style="font-weight:bold;">Development Fees</b>&#8221;, and the development fees to be paid in any given Calendar Year during the Research Program, the &#8220;<b style="font-weight:bold;">Annual Development Fees</b>&#8221;); in each case ((a) and (b)) to the extent consistent with the applicable Research Plan (including [***]).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.29&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Directed To</b>&#8221; shall mean, with regard to an Antibody or product, that such Antibody or product is developed or designed to (a) [***], and (b) [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.30&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Dispute</b>&#8221; shall have the meaning provided in Section 11.7.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.31&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Effective Date</b>&#8221; shall have the meaning provided in the first paragraph of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.32&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Election Notice</b>&#8221; shall have the meaning provided in Section 4.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.33&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Equity Grant</b>&#8221; shall have the meaning provided in Section&#8239;5.8.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.34&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">FDA</b>&#8221; means the United States Food and Drug Administration, or a successor federal agency thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.35&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Field</b>&#8221; shall mean the prophylaxis, palliation, treatment and diagnosis of human disease and disorders in all therapeutic areas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.36&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Final Deliverable</b>&#8221; shall, on a Research Program-by-Research Program basis, have the meaning provided in the applicable Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.37&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Parade</b>&#8221; shall have the meaning provided in the first paragraph of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.38&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Indemnified Party</b>&#8221; shall have the meaning provided in Section 10.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.39&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Indemnifying Party</b>&#8221; shall have the meaning provided in Section 10.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.40&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Intellectual Property Rights</b>&#8221; shall mean any and all proprietary rights provided under (a) patent law, including any Patents; (b) copyright law; or (c) any other applicable statutory provision or common law principle, including trade secret law, that may provide a right in Know-How, or the expression or use thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.41&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Jade</b>&#8221; shall have the meaning provided in the first paragraph of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.42&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Jade Indemnitee</b>&#8221; shall have the meaning provided in Section 10.2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.43&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Jade Multispecific Antibody</b>&#8221; means any Multispecific Antibody that is Developed, Manufactured, Commercialized, or otherwise exploited by Jade, its Affiliates, or sublicensees (other than Paragon and its Affiliates and other licensees).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.44&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Jade Multispecific Product</b>&#8221; means any product that comprises or contains any Jade Multispecific Antibody.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.45&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Jade Product</b>&#8221; means, individually or collectively, as applicable, Project Antibodies, Derived Antibodies, Products, Jade Multispecific Antibodies, and Jade Multispecific Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.46&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">JDC</b>&#8221; shall have the meaning provided in Section 3.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.47&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Know-How</b>&#8221; shall mean all technical information and know-how in any tangible or intangible form, including (a) inventions, discoveries, trade secrets, data, specifications, instructions, processes, formulae, materials (including cell lines, vectors, plasmids, nucleic acids and the like), methods, protocols, expertise and any other technology, including the applicability of any of the foregoing to formulations, compositions or products or to their manufacture, development, registration, use or marketing or to methods of assaying or testing them or processes for their manufacture, formulations containing them or compositions incorporating or comprising them, and (b) all data, instructions, processes, formulae, strategies, and expertise, whether biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical, analytical, or otherwise and whether related to safety, quality control, manufacturing or other disciplines. Notwithstanding the foregoing, Know-How excludes Patent claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.48&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">License Agreement</b>&#8221; shall have the meaning set forth in Section 4.4(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.49&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">License Template</b>&#8221; shall have the meaning set forth in Section 4.4(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.50&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Losses</b>&#8221; shall have the meaning provided in Section 10.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.51&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">MAA</b>&#8221; means (a) a New Drug Application in the United States, as defined in the United States Federal Food, Drug and Cosmetics Act, and applicable regulations promulgated thereunder by the FDA, (b) a Biologics License Application in the United States, as defined in the United States Public Health Service Act, or (c) any application filed with any Regulatory Authority in a country other than the United States that is equivalent to either of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.52&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Manufacture</b>&#8221; or &#8220;<b style="font-weight:bold;">Manufacturing</b>&#8221; shall mean to make, produce, manufacture, process, fill, finish, package, label, perform quality assurance testing, release, ship or store an Antibody or product, including a Project Antibody, Derived Antibody, Product, Multispecific Antibody, or Multispecific Product or any component thereof, as applicable. When used as a noun, &#8220;Manufacture&#8221; or &#8220;Manufacturing&#8221; means any and all activities involved in Manufacturing an Antibody or product, including a Project Antibody, Derived Antibody, Product, Multispecific Antibody, or Multispecific Product or any component thereof, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.53&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Milestone</b>&#8221; shall have the meaning provided in Section 5.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.54&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Milestone Payment</b>&#8221; shall have the meaning provided in Section 5.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.55&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Multispecific Antibody</b>&#8221; means any Antibody that is comprised of (a) [***], and (b) [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.56&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Multispecific Product</b>&#8221; means any product that comprises or contains any Multispecific Antibody.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.57&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Notice of Dispute</b>&#8221; shall have the meaning provided in Section 11.7(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.58&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Option</b>&#8221; shall have the meaning provided in Section&#8239;4.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.59&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Option Period</b>&#8221; shall have the meaning provided in Section&#8239;4.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.60&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Paragon</b>&#8221; shall have the meaning provided in the first paragraph of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.61&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Paragon Indemnitee</b>&#8221; shall have the meaning provided in Section 10.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.62&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Paragon Platform Know-How</b>&#8221; shall mean (a) Know-How Controlled by Paragon or its Affiliates prior to or during the Term relating to antibody discovery and development, (b) all methods, materials and other Know-How used in the foregoing Controlled by Paragon or its Affiliates, and (c) platforms embodying, components, component steps and other portions of any of the foregoing in (a) or (b) Controlled by Paragon or its Affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.63&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Paragon Platform Know-How Improvement</b>&#8221; shall mean all Know-How developed or discovered through or as a result of the activities performed by or on behalf of Paragon under a Research Program that constitutes an improvement, enhancement, modification, substitution, or alteration to the Paragon Platform Technology; <i style="font-style:italic;">provided, however</i>, to the extent any of the Know-How developed or discovered under a Research Program specifically and solely relates to a Project Antibody, such Know-How will be considered Project Antibody Technology and not Paragon Platform Know-How Improvements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.64&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Paragon Platform Patents</b>&#8221; shall mean all Patents that Paragon or its Affiliates Control prior to or during the Term that Cover Paragon Platform Know-How or Paragon Platform Know-How Improvements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.65&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Paragon Platform Technology</b>&#8221; shall mean Paragon Platform Know-How, Paragon Platform Know-How Improvements, and Paragon Platform Patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.66&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Party</b>&#8221; or &#8220;<b style="font-weight:bold;">Parties</b>&#8221; shall have the meaning provided in the first paragraph of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.67&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Patents</b>&#8221; shall mean (a) unexpired patents and patent applications, (b) any and all divisionals, continuations, continuations-in-part, reissues, renewals, substitutions, registrations, re-examinations, revalidations, extensions, supplementary protection certificates and the like of any such patents and patent applications, and (c) any and all foreign equivalents of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.68&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Phase I Trial</b>&#8221; means a human clinical trial in any country of the type described in 21 C.F.R. &#167;312.21(a), or the foreign equivalent thereof, regardless of where such clinical trial is conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.69&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Phase II Trial</b>&#8221; means a human clinical trial in any country of the type described in 21 C.F.R. &#167;312.21(b), or the foreign equivalent thereof, regardless of where such clinical trial is conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.70&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Phase III Trial</b>&#8221; means a human clinical trial in any country of the type described in 21 C.F.R. &#167;312.21(c), or the foreign equivalent thereof, regardless of where such clinical trial is conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.71&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Pre-Effective Date Development Costs</b>&#8221; shall have the meaning provided in Section 5.2(d).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.72&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Product</b>&#8221; shall mean any product that comprises or contains any Project Antibody or any Derived Antibody thereof, other than as part of a Multispecific Antibody or a Multispecific Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.73&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Project Antibody</b>&#8221; shall mean any and all Antibodies that are Directed To a particular Selected Target and that are discovered, generated, identified or characterized by Paragon in the course of performing the applicable Research Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.74&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Project Antibody Invention</b>&#8221; shall mean (a) any invention or discovery, whether or not patentable, that was discovered or reduced to practice by or on behalf of Paragon under the Research Program that constitutes the composition of matter of, or any method of specifically making or using, any Project Antibody, and (b) all Intellectual Property Rights therein that are Controlled by Paragon or its Affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.75&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Project Antibody Patents</b>&#8221; shall mean all Patents that Cover the composition of matter of, or any method of specifically making or using, any Project Antibody, that are in each case Controlled by Paragon or its Affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.76&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Project Antibody Samples</b>&#8221; shall have the meaning provided in Section&#8239;2.1(c)(i).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.77&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Project Antibody Selection Criteria</b>&#8221; shall mean those criteria agreed to by the Parties in the applicable Research Plan that establish that a Project Antibody is suitable for clinical testing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.78&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Project Antibody Technology</b>&#8221; shall mean (a) the Project Antibody Inventions, (b) the Project Antibody Patents, (c) the Sequence Information and Results, and (d) all Intellectual Property Rights therein that are Controlled by Paragon and its Affiliates. For clarity, if the Parties execute a License Agreement with respect to a particular Research Program and the Research Term for such Research Program continues following execution of such License Agreement, any Project Antibody Technology first conceived, reduced to practice or otherwise generated following the execution of the License Agreement shall be licensed to Jade under such License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.79&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Regulatory Approval</b>&#8221; means all clearances, approvals (including approval of an MAA as well as any applicable pricing and/or reimbursement approvals), licenses, registrations or authorizations of any Regulatory Authority necessary to commercially distribute, sell and market a pharmaceutical or biologic product in a country or territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.80&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Regulatory Authority</b>&#8221; means any supranational, multinational, federal, national, state, provincial or local regulatory agency, department, bureau or other governmental entity with authority over the clinical development, manufacture, marketing or sale of a pharmaceutical or biologic product in a country or region, including the FDA in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.81&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Representatives</b>&#8221; of a Party shall mean such Party&#8217;s and its Affiliates&#8217; officers, directors, employees, contractors, subcontractors, agents and consultants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.82&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Research Plan</b>&#8221; shall have the meaning set forth in Section 2.1(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.83&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Research Program</b>&#8221; shall mean a research program agreed to by the Parties to identify Project Antibodies with activity against one Selected Target and to perform such additional activities with respect to such Selected Target as set forth in the applicable Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.84&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Research Term</b>&#8221; shall mean, on a Research Program-by-Research Program basis, the period of time beginning on the agreement by the Parties on the Research Plan and continuing until completion of the activities under the Research Plan for such Research Program or such other date mutually agreed upon by the Parties; <i style="font-style:italic;">provided, that</i> (a) if Jade does not exercise its Option in accordance with Section 4.3 prior to expiration of the applicable Option Period, then upon such expiration the Research Term shall automatically terminate and Paragon shall have no obligation to perform any activities under the applicable Research Plan thereafter, or (b) if Jade exercises its Option during the Option Period in accordance with Section 4.3 but the Parties are unable to finalize and execute a License Agreement during the thirty (30) day period referenced in Section 4.4(b), then upon the expiration of such period the Research Term shall automatically terminate and Paragon shall have no obligation to perform any activities under the applicable Research Plan thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.85&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Results</b>&#8221; shall mean the data, results, analysis, conclusions, outcomes, information, documentation, and reports that are generated by or on behalf of Paragon in performance of a Research Program, excluding Project Antibodies, Project Antibody Inventions, Project Antibody Patents, and the Sequence Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.86&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Selected Target</b>&#8221; shall have the meaning set forth in Section 2.1(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.87&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Sequence Information</b>&#8221; shall mean electronic files containing all Project Antibody sequences generated under a given Research Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.88&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Shares</b>&#8221; shall mean shares of common stock, par value $0.0001, of Jade.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.89&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Target</b>&#8221; shall mean a protein molecule that (a) [***], and (b) [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.90&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Term</b>&#8221; shall have the meaning provided in Section 9.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.91&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Territory</b>&#8221; shall mean worldwide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.92&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Third Party</b>&#8221; shall mean any person or entity other than Paragon, Parade or Jade or an Affiliate of any of Paragon, Parade or Jade.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.93&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Third Party Claim</b>&#8221; shall have the meaning provided in Section 10.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.94&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>&#8220;<b style="font-weight:bold;">Valid Claim</b>&#8221; means, with respect to particular Patent in a particular country, (a) a claim of an issued and unexpired patent (including the term of any patent term extension, supplemental protection certificate, renewal or other similar extension) in such country within such Patent that has not been abandoned or revoked, or held unpatentable, invalid or unenforceable in a final decision of a court or other governmental authority of competent jurisdiction from which no appeal may be taken, or has been taken before the expiry of the permitted time period, and that has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination, disclaimer or otherwise, or (b) a claim within a patent application in such country within such Patent that has not been pending more than seven (7) years from the earliest priority date of such claim and which claim has not been cancelled, withdrawn or abandoned or finally rejected by an administrative agency action from which no appeal can be taken.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CONDUCT OF RESEARCH PROGRAM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Research Program.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Target Selection</b>. The Parties intend to initiate one or more Research Programs, each focused on a particular Target (each, a &#8220;<b style="font-weight:bold;">Selected Target</b>&#8221;). No more than one (1) Selected Target will be included in any Research Program, unless the Parties otherwise agree in writing (e.g., in the case of a Research Program seeking to develop a [***]). As of the Effective Date, the Parties have agreed to the Selected Targets listed on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u>. Additional Targets may be added to the Selected Targets by mutual written agreement of the Parties, it being understood that each Party may accept or reject a new Selected Target in its sole discretion and no Party shall be obligated under this Agreement to agree to any further Selected Targets. The Parties acknowledge that, prior to any agreement with respect to a Selected Target and a Research Plan, it is intended that the Parties may initiate, from time-to-time, &#8220;proof-of-concept&#8221; studies [***] at no up-front Research Initiation Fee (as defined below) to Jade; <i style="font-style:italic;">provided, that</i> the costs of any such &#8220;proof-of-concept&#8221; studies may be recaptured by Paragon within the specified Research Plan and associated fees, in each case, as agreed by the Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Research Plan. </b>No later than [***] after the Effective Date (or in the case of any Selected Target added after the Effective Date, no later than forty-five (45) days after the Parties&#8217; written agreement on such additional Selected Target), the Parties will agree on a research plan, to the extent a research plan has not been previously agreed upon, for the applicable Selected Target that will include design, modeling, synthesis, evaluation, and other mutually agreed activities (&#8220;<b style="font-weight:bold;">Research Plan</b>&#8221;). For clarity, if at the end of such [***] period (or any extension thereof mutually agreed in writing) (i) the Parties have not agreed on a Research Plan, or (ii) Jade has not paid Paragon the Research Initiation Fee, the applicable Target shall cease to be a Selected Target and Paragon shall have no obligations with respect thereto. Once the Parties agree on a Research Plan and Jade pays the Research Initiation Fee for a Research Program, Paragon and Parade shall conduct research under such Research Program during the applicable Research Term in an effort to (1)&#8239;produce Project Antibodies against the applicable Selected Target for further Development, Manufacture and Commercialization (&#8220;<b style="font-weight:bold;">Antibody Production Activities</b>&#8221;), and (2) perform such other Development and Manufacturing activities with respect to the Project Antibodies as set forth in the Research Plan (which other activities, for clarity, may be performed following Jade&#8217;s exercise of the Option or execution of a License Agreement). The Parties may amend the Research Plan upon mutual written agreement. Paragon and Parade will use [***] to conduct and complete the activities set forth in such Research Plan on the timelines set forth in such Research Plan and in compliance with the Budget.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">(c)</b>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<b style="font-weight:bold;">Deliverables; Project Antibody Samples.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:126pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Following completion of the Antibody Production Activities set forth in the Research Plan for a Research Program, Paragon and Parade will deliver to Jade a data package that includes Sequence Information for all then-existing Project Antibodies and Results (the &#8220;<b style="font-weight:bold;">Deliverables</b>&#8221;). Additionally, upon request by Jade, and at [***] cost and expense, Paragon and Parade shall provide to Jade samples of proteins corresponding to such Project Antibodies that have been expressed in accordance with the Research Plan (&#8220;<b style="font-weight:bold;">Project Antibody Samples</b>&#8221;) to enable Jade to evaluate the Option. Following completion of a Research Program, Paragon shall deliver to Jade the Final Deliverable for such Research Program, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:126pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;</font>(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;During the Option Period with respect to each Research Program, Jade will review the Deliverables and Project Antibody Samples for such Research Program to determine whether [***] Project Antibody meets the Project Antibody Selection Criteria. If Jade determines that [***] Project Antibody meets the Project Antibody Selection Criteria, then Jade shall so notify Paragon in writing prior to the end of the Option Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Conduct of Research Program. </b>During the Research Term, Paragon and Parade shall (i) perform the activities assigned to it under the applicable Research Plan in a professional, diligent and good scientific manner, in compliance with all Applicable Law, and in compliance with the applicable Research Plans; (ii) ensure that its Representatives and subcontractors diligently perform the applicable Research Program in a manner in accordance with generally accepted industry practices by appropriately trained personnel who are experienced in the relevant fields and in compliance with Applicable Law; (iii) keep Jade fully informed regarding the progress and results of the Research Program; (iv) [***] provide Jade with any additional information regarding the Research Program that Jade reasonably requests; (v)&#8239;participate in teleconference(s) at a time(s) agreed upon by the Parties to provide an update to Jade on the performance of the Research Program; and (vi) give Jade [***] notice with respect to information known or believed by Paragon and Parade to be likely to materially impede or otherwise adversely affect the performance of the Research Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">2.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subcontractors. </b>Paragon and Parade may perform the activities under a Research Program through one or more subcontractors; <i style="font-style:italic;">provided, that</i> Paragon and Parade shall at all times be fully responsible for the compliance of such subcontractors with this Agreement and for the performance of their obligations under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">2.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Research Books and Records; Audit</b>. Paragon shall maintain complete and accurate records related to the activities performed by Paragon under a Research Program. All such books and records shall be retained by Paragon and Parade until the later of: (a) [***] after the end of the applicable stage of research; and (b) such longer period as may be required by Applicable Law. Upon Jade&#8217;s request and at [***] expense, Paragon shall provide copies of such records or such records shall be made available for Jade&#8217;s reasonable review, audit and inspection upon reasonable notice and with reasonable frequency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">GOVERNANCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Joint Development Committee</b>. The Parties will establish a single Joint Development Committee (the &#8220;<b style="font-weight:bold;">JDC</b>&#8221;) to oversee and coordinate the activities under all Research Programs in accordance with the remainder of this Article 3. The JDC shall be comprised of two (2) employees from Jade and two (2) employees from Paragon, with each Party designating one (1) such employee as its JDC co-chairperson. Subject to the foregoing, each Party shall appoint its respective Representatives to the JDC from time to time, and may change its Representatives, in its sole discretion, effective upon notice to the other Parties designating such change. Representatives from each Party shall have appropriate technical credentials, experience and knowledge pertaining to and ongoing familiarity with the activities to be performed under the Research Programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">3.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;JDC Meetings</b>. The JDC shall meet in accordance with a schedule established by mutual written agreement of the Parties no less frequently than once every three (3) months until, on a Research Program-by-Research Program basis, the end of the period specified in Section 3.5. The JDC may meet by means of teleconference, videoconference or other similar means, as jointly determined by the Parties. As appropriate, additional employees or consultants may from time to time attend the JDC meetings as nonvoting observers; <i style="font-style:italic;">provided, that</i> any such consultant shall agree in writing to comply with the confidentiality obligations under this Agreement; and <i style="font-style:italic;">provided, further that</i> no Third Party personnel may attend unless otherwise agreed by all Parties. Each Party shall bear its own expenses related to the attendance of the JDC meetings by its representatives. Each Party may also call for special meetings to resolve particular matters requested by such Party. Paragon shall be responsible for keeping minutes of each JDC meeting that record in writing all decisions made, action items assigned or completed and other appropriate matters. Paragon shall send meeting minutes to all members of the JDC within [***] after a meeting for review. Each member shall have [***] from receipt in which to comment on and to approve/provide comments to the minutes (such approval not to be unreasonably withheld, conditioned or delayed). If a member, within such time period, does not notify the drafting Party that s/he does not approve of the minutes, the minutes shall be deemed to have been approved by such member.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">3.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;JDC Functions</b>. The JDC&#8217;s responsibilities are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>Developing, reviewing, overseeing and coordinating the activities under each Research Plan;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>Periodically reviewing the progress of activities under each Research Plan;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>Updating or modifying each Research Plan; <i style="font-style:italic;">provided, that</i> such update or modification does not obligate any Party to perform any task or expend any resources outside of or beyond its obligations under the applicable Budget;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>Reviewing performance against the Budget and timeline for each Research Program periodically (at least [***]), and periodically meeting to review and (subject to mutual approval of the Parties), approving any discovery project Budget deviation where such deviation is greater than [***] percent ([***]%);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>Reviewing the reconciliation of Actual Annual Costs against the Cost Advance at the end of each Calendar Year for each Research Program; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>Determining whether the Project Antibody Selection Criteria for a Research Program are not achievable for any reason and therefore such Research Program no longer warrants further research.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">3.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;JDC Decision Making and Disputes</b>. The JDC will endeavor to make decisions by consensus, with each of Jade and Paragon having one vote. If consensus is not reached by the Parties&#8217; Representatives pursuant to such vote, then disputes relating to: (a) the reconciliation of Actual Annual Costs against the Cost Advance, as set forth in Section&#8239;5.2(c), will be resolved in accordance with Section 11.7; (b) technical or scientific decisions in the course of operationalizing each Research Program, including the nature of activities to be performed by Paragon and Parade thereunder, shall be finally decided by [***]; and (c) the Budget for any Research Program, and all other matters not covered by clauses (a) or (b), shall be finally decided by [***]. For clarity, and notwithstanding the creation of the JDC, each Party shall retain the rights, powers and discretion granted to it hereunder, and the JDC shall not be delegated or vested with such rights, powers or discretion unless such delegation or vesting is expressly provided herein, or the Parties expressly so agree in writing. The JDC shall not have the power to amend, waive or modify any term of this Agreement, and no decision of the JDC shall be in contravention of any terms and conditions of this Agreement. It is understood and agreed that issues to be formally decided by the JDC are limited to those specific issues that are expressly provided in this Agreement to be decided by the JDC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">3.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Disbandment</b>. The JDC shall remain in effect from the date on which it is established in accordance with Section 3.1 until, on a Research Program-by-Research Program basis, the expiration of the applicable Research Term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OPTION; LICENSE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Grant of Option.</b> Subject to the terms and conditions of this Agreement, on a Research Program-by-Research Program basis, Paragon hereby grants to Jade, during the Term and subject to delivery of the Election Notice in accordance with Section 4.3, an exclusive option (&#8220;<b style="font-weight:bold;">Option</b>&#8221;) to be granted an exclusive license under the Project Antibody Technology for the applicable Research Program to Develop, Manufacture and Commercialize Project Antibodies, Derived Antibodies and Products in the Field in the Territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">4.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Limited License Grant During Option Period.</b> Subject to the terms and conditions of this Agreement, on a Research Program-by-Research Program basis, and effective only during the Term, Paragon hereby grants to Jade a limited, exclusive, royalty-free license, without the right to sublicense, under the Project Antibody Technology arising from such Research Program solely to evaluate the Option and for the purpose of allowing Jade to determine whether to exercise the Option with respect to such Research Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Option Exercise.</b> On a Research Program-by-Research Program basis, Jade may, in its sole discretion, exercise the Option by delivering written notice of such exercise to Paragon (&#8220;<b style="font-weight:bold;">Election Notice</b>&#8221;) at any time during the period beginning on the initiation of activities under such Research Program and ending [***] following Jade&#8217;s receipt of the Deliverables for such Research Program, or such longer period as agreed upon by the Parties (&#8220;<b style="font-weight:bold;">Option Period</b>&#8221;). If Jade fails to exercise an Option in accordance with this Section 4.3 prior to expiration of the applicable Option Period, then, upon such expiration, such Option shall terminate and be of no further force or effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">4.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;License Template; Execution After Option Exercise.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>Within [***] of the Effective Date, the Parties shall negotiate [***] and use [***] to agree upon a form of agreement template (&#8220;<b style="font-weight:bold;">License Template</b>&#8221;) to be used in connection with Jade&#8217;s exercise of its Option, which will be consistent with the economic and other terms set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u>, and upon mutual agreement by the Parties on the form of such License Template, will be attached to this Agreement and replace the terms on the existing <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u>. If the Parties are unable to reach agreement on the definitive terms of the License Template within such [***] period, the matter will be resolved in accordance with Section 11.7 unless the Parties mutually agree to resolve the matter otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>Within [***] of Jade&#8217;s exercise of its Option with respect to a Research Program as set forth in Section 4.3, subject to any extension as mutually agreed by the Parties, the Parties shall use [***] to finalize and execute a definitive written agreement consistent with the License Template (the &#8220;<b style="font-weight:bold;">License Agreement</b>&#8221;) with respect to such Research Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 5</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PAYMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">5.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Research Initiation Fee</b>. Jade shall pay to Paragon, on a Research Program-by-Research Program basis, a one-time nonrefundable, non-creditable fee of One Million Two Hundred Fifty Thousand Dollars ($1,250,000) (the &#8220;<b style="font-weight:bold;">Research Initiation Fee</b>&#8221;) no later than thirty (30) days following finalization of the Research Plan for such Research Program. For clarity, the Research Initiation Fee is nonrefundable, non-creditable, and separate from any Development Costs (including the Pre-Effective Date Development Costs) or Cost Advance paid or owing with respect to a particular Research Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">5.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Development Costs</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>The monthly rate for the Development Fees (the &#8220;<b style="font-weight:bold;">Monthly Rate</b>&#8221;) shall be determined and charged on a Research Program-by-Research Program and calendar month-by-calendar month basis based on, with respect to any particular calendar month, the total number of Research Programs being conducted under this Agreement and each other similar Antibody Discovery and Option Agreement between Paragon and Parade, on the one hand, and Jade or any Affiliate of Jade, on the other hand (each such Research Program, an &#8220;<b style="font-weight:bold;">Active Research Program</b>&#8221;). For the period beginning on the Effective Date and continuing through December 31, 2024, the Monthly Rate for each Active Research Program in a particular calendar month shall be [***]. If a Research Plan requires Paragon to perform certain chemistry, manufacturing, and control activities (&#8220;<b style="font-weight:bold;">CMC Activities</b>&#8221;) in furtherance of the Research Program, then the Monthly Rate for such Research Program that would otherwise apply shall be [***]. Paragon shall have the right to adjust the Monthly Rate and the CMC Rate on an annual basis to account for inflation and other increases in costs by providing written notice thereof to Jade at least [***] prior to the commencement of each [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>On a quarterly basis, Jade will advance to Paragon any Development Costs contemplated in the Budget, including [***], and any [***] reasonably expected to be incurred by Paragon in the performance of the Research Program during the upcoming [***] in accordance with the Research Plan and Budget (less any pre-payments for Third Party Costs from earlier [***] that Paragon reasonably anticipates will be carried over to such upcoming [***]) (the &#8220;<b style="font-weight:bold;">Cost Advance</b>&#8221;). On a quarterly basis, Paragon will deliver an invoice to Jade for the Cost Advance, and Jade will pay the Cost Advance within [***] after receipt of Paragon&#8217;s invoice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>Within [***] after the end of each Calendar Year, Paragon will calculate and provide to Jade a written reconciliation of its actually-incurred Third Party Costs (incurred in a manner consistent with the Budget) for the prior Calendar Year (&#8220;<b style="font-weight:bold;">Actual Annual Costs</b>&#8221;) against that portion of the Cost Advance for such Third Party Costs for that Calendar Year, including reasonable documentation of such Actual Annual Costs. The form of such reconciliation shall be subject to JDC review and approval. If the amounts paid for anticipated Third Party Costs in the Cost Advance exceeds the Actual Annual Costs, then Paragon will credit such excess payment against Development Costs contemplated in the Budget and reasonably expected to be incurred by Paragon in the performance of the Research Program during any upcoming Calendar Year and Jade will deduct such amount from its next quarterly Cost Advance. If the Cost Advance is less than the Actual Annual Costs, then Paragon will invoice Jade for the difference and Jade will pay such amount together with its next quarterly Cost Advance. If no further amounts will be owed to Paragon hereunder, Paragon will refund such amount. For clarity, the above reconciliation will not apply to Annual Development Fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>Notwithstanding Sections 5.2(a), 5.2(b) and 5.2(c) to the contrary, the Parties acknowledge that Paragon has incurred (i)&#8239;approximately $5,611,515.00 in Development Costs through June 30, 2024, and (ii) certain additional Development Costs between July 1, 2024 and the Effective Date, as a result of work performed by Paragon at risk on the Research Program for APRIL (the costs described in (i) and (ii), the &#8220;<b style="font-weight:bold;">Pre-Effective Date Development Costs</b>&#8221;). Jade shall reimburse Paragon for the Pre-Effective Date Development Costs within [***] after Jade&#8217;s receipt of a written invoice that details the Pre-Effective Date Development Costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">5.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Milestones</b>. On a Research Program-by-Research Program basis, Jade shall make the following one-time non-refundable and non-creditable milestone payments to Paragon (or to such other designee(s), as designated by Paragon) as set forth below (each payment, a &#8220;<b style="font-weight:bold;">Milestone Payment</b>&#8221;), based on the achievement of the corresponding milestone set forth below (each, a &#8220;<b style="font-weight:bold;">Milestone</b>&#8221;) by Jade, its Affiliates, or its sublicensees with respect to the first Jade Product to achieve such Milestone. Jade shall, within [***] after it or its Affiliates achieve a Milestone, or within [***] after it learns that its or its Affiliate&#8217;s sublicensee has achieved a Milestone, notify Paragon of the achievement of such Milestone [***]. Following receipt of such notice, Paragon shall invoice Jade for such Milestone Payment, which invoice shall specify the bank account information into which such Milestone Payment should be paid. Jade shall make such Milestone Payment to Paragon or Paragon&#8217;s designee within [***] after receipt of Paragon&#8217;s invoice. Each Milestone Payment shall be paid no more than once, and Jade&#8217;s total Milestone Payments hereunder (together with any such Milestone Payments achieved and payable pursuant to a subsequently executed License Agreement for such Research Program) shall not exceed Twenty-Two Million Dollars ($22,000,000) for each Research Program. For avoidance of doubt, upon achievement of any Milestone, all prior unachieved Milestones shall be deemed thereby achieved and, if the Milestone Payment for any such prior Milestone has not previously been paid, it shall thereupon also be paid at the same time that the Milestone Payment for such subsequent achieved Milestone is paid. The Parties acknowledge and agree that once a License Agreement for a Research Program has been executed and is effective, any Milestone set forth in this Agreement that (a) has not yet been achieved, and (b) is duplicated in such License Agreement, together with the corresponding Milestone Payment, shall no longer be achievable and payable under the terms of this Agreement and shall only be achievable and payable under the terms of the License Agreement. Additionally, for the avoidance of doubt, if a Milestone is achieved and paid by Jade pursuant to this Agreement for a certain Research Program, then there shall be no Milestone Payment due for the achievement of such Milestone under a subsequently executed License Agreement for such Research Program, notwithstanding the inclusion of the same Milestone in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u> hereto or in such License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:82.8pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:23.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">Regulatory/Development Milestones</b></p></td><td style="vertical-align:bottom;width:23.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">[***]</p></td><td style="vertical-align:bottom;width:23.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">$[***]</p></td></tr><tr><td style="vertical-align:bottom;width:76.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">[***]</p></td><td style="vertical-align:bottom;width:23.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">$[***]</p></td></tr><tr><td style="vertical-align:bottom;width:76.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">[***]</p></td><td style="vertical-align:bottom;width:23.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">$[***]</p></td></tr><tr><td style="vertical-align:bottom;width:76.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">[***]</p></td><td style="vertical-align:bottom;width:23.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">$[***]</p></td></tr><tr><td style="vertical-align:bottom;width:76.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">[***]</p></td><td style="vertical-align:bottom;width:23.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">$[***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">5.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Financial Records.</b> Paragon shall keep complete and accurate books of account and records in sufficient detail to enable the Development Costs and Milestones payable under this Agreement to be determined. Such books and records shall be kept at the principal place of business of Paragon, for at least [***] following the end of the [***] to which such books and records pertain, and Jade shall be entitled to inspect such books and records at Paragon&#8217;s offices upon Jade&#8217;s reasonable request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">5.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Manner and Method of Payment</b>. All cash payment amounts hereunder are expressed in U.S. dollars (USD) unless otherwise specified. Each payment shall be made by electronic funds transfer in immediately available funds to a bank and account designated in writing by Paragon, unless otherwise specified in writing by Paragon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">5.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tax</b>. Each Party shall be responsible for paying its own respective taxes in connection with any activities that it performs and any payments that it receives under this Agreement. The Parties will commit [***] to provide each other with any tax forms that may be reasonably necessary in order for any Party to not pay or withhold tax or to pay or withhold tax at a reduced rate under an applicable income tax treaty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">5.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Late Payments</b>. In the event that any cash payment due for any undisputed amount under this Agreement is not made when due, then the cash payment shall accrue interest from the date due at a per annum rate equal to [***] above the then-current per annum prime rate reported by the <i style="font-style:italic;">Wall Street Journal</i> (U.S., Western Edition) or, if lower, the maximum legal annual interest rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">5.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Equity Grants</b>. Except as expressly agreed otherwise by the Parties in writing, upon completion of each of the Calendar Years ending December 31, 2025 and December 31, 2026, Jade will grant to Parade a warrant to purchase a number of Shares equal to 1.00% of the outstanding Shares as of the date of the grant, on a fully-diluted basis (assuming the exercise or conversion of any convertible non-voting preferred stock, stock options, pre-funded warrants or similar instruments), with an exercise price equal to the fair market value of the underlying Shares on the date of the grant as determined by the board of directors of Jade (each grant, an &#8220;<b style="font-weight:bold;">Equity Grant</b>&#8221;); <i style="font-style:italic;">provided, that</i> if Jade undergoes an initial public offering or a reverse merger transaction the rights and obligations of this Section 5.8 shall continue and Parade shall be entitled to warrants from the ultimate public company parent to purchase a number of shares of such parent equal to 1.00% of the outstanding shares of the parent as of the date of the grant, on a fully-diluted basis (assuming the exercise or conversion of any convertible non-voting preferred stock, stock options, pre-funded warrants or similar instruments), as applicable. Such warrants will be exercisable for a period of ten (10) years following the date of the grant. Each Equity Grant shall be effected on the last Business Day of each applicable Calendar Year and the corresponding grant date shall be such date. If the Term ends prior to the end of a Calendar Year, the Equity Grant for such Calendar Year shall be pro-rated for such Calendar Year and such Equity Grant shall be effected within five (5) Business Days of the end of the Term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 6</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INTELLECTUAL PROPERTY RIGHTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">6.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Ownership.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Background IP</b>. As between the Parties, each Party will retain all right, title and interest in and to all of its Background IP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Project Antibody Technology.</b> Subject to the rights and licenses granted to Jade in this Agreement, as between the Parties, Paragon or its Affiliates shall own all right, title and interest in and to all Project Antibody Technology, irrespective of inventorship. Jade agrees to assign and hereby assigns to Paragon all of Jade&#8217;s right, title and interest in and to the Project Antibody Technology, including any and all Intellectual Property Rights therein. Jade shall execute and deliver, and shall cause its Affiliates to execute and deliver, such additional documents, instruments, conveyances and assurances and take any such further actions as may be reasonably required to ensure that all right, title and interest in the Project Antibody Technology is effectively assigned to and held by Paragon. Jade and its Affiliates shall cause all of its and their employees who, in each case, generated, conceived of or created any Project Antibody Technology to assign without additional consideration all ownership rights in such Project Antibody Technology to Paragon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">6.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Patent Prosecution, Maintenance and Enforcement &#8211; Project Antibody Patents.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>Prior to execution of the License Agreement, Paragon shall have the sole right, but not the obligation, to prepare, file, prosecute, maintain or enforce any Project Antibody Patents at Paragon&#8217;s sole expense, and Jade shall reasonably cooperate and assist Paragon in such preparation, filing, prosecution, maintenance and enforcement, at Paragon&#8217;s request. Following execution of the License Agreement, (i) with respect to Project Antibody Patents that have been filed prior to the execution of the License Agreement, the Parties&#8217; respective rights relating to the preparation, filing, prosecution, maintenance and enforcement of such Project Antibody Patents shall be as set forth therein and Jade shall reimburse Paragon for any costs and expenses actually incurred by Paragon in the prosecution and maintenance of any such Project Antibody Patents in accordance with the terms of the License Agreement, and (ii) with respect to Project Antibody Patents that have not been filed prior to the execution of the License Agreement, (1) Paragon, at its sole expense, shall have the sole right, but not the obligation, to prepare, file, prosecute, maintain and enforce such Product Antibody Patents until the date on which the Final Deliverable for such Research Program is delivered to Jade, and during such period Paragon shall provide Jade with drafts of all proposed filings to any patent office with respect to such Project Antibody Patents in reasonably adequate time before submission of such filings for Jade&#8217;s review and comment, and (2) following the date on which the Final Deliverable for such Research Program is delivered to Jade, the Parties&#8217; respective rights relating to the preparation, filing, prosecution, maintenance and enforcement of such Project Antibody Patents shall be as set forth therein and Jade shall reimburse Paragon for any costs and expenses actually incurred by Paragon in the prosecution and maintenance of any such Project Antibody Patents in accordance with the terms of the License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>Jade covenants and agrees that it will not file or prosecute any Patents Covering any Project Antibody or Derived Antibody (including without limitation any Project Antibody Inventions) during the Term of this Agreement except as permitted under a License Agreement executed by all Parties with respect to a given Research Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">6.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Defense of Claims Brought by Third Parties.</b> If a Party becomes aware of any actual or potential claim that the Development, Manufacture or Commercialization of any Project Antibody, Derived Antibody, Product, Multispecific Antibody or Multispecific Product infringes or in the future will infringe the Intellectual Property Rights of any Third Party, such Party will [***] notify the other Parties. In any such instance, the Parties will [***] thereafter meet (which may be through the JDC) to discuss [***] regarding the best response to such notice. Certain additional rights and obligations of the Parties with respect to any such claim will be set forth in the applicable License Agreement (to the extent applicable).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">6.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No Implied Licenses.</b> Except as expressly set forth herein, no right or license under any Patents, Know-How or Intellectual Property Right of any Party is granted or shall be granted by implication hereunder. All such rights or licenses are or shall be granted only as expressly provided in this Agreement or the applicable License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 7</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PROTECTION OF CONFIDENTIAL INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Confidentiality.</b> Except to the extent expressly authorized by this Agreement, the Receiving Party agrees that, during the Term and for [***] thereafter, it shall keep confidential and shall not publish or otherwise disclose to any Third Party, and shall not use for any purpose other than as expressly provided for in this Agreement, any Confidential Information of the Disclosing Party. The Receiving Party may disclose Confidential Information of the Disclosing Party to those of the Receiving Party&#8217;s Representatives who have a need for such information; <i style="font-style:italic;">provided, that</i> the Receiving Party shall advise such Representatives of the confidential nature thereof, shall ensure that each such Representative is bound in writing by obligations of confidentiality and non-use at least as stringent as those contained in this Agreement, and shall be responsible for the compliance of its Representatives with the terms of this Agreement. The Receiving Party shall use at least the same standard of care as it uses to protect proprietary or confidential information of its own (but in no event less than reasonable care) to ensure that its Representatives do not disclose or make any unauthorized use of the Confidential Information of the Disclosing Party. The Receiving Party shall [***] notify the Disclosing Party upon discovery of any unauthorized use or disclosure of the Confidential Information of the Disclosing Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Exceptions.</b> The Receiving Party&#8217;s obligations under Section 7.1 shall not apply to any Confidential Information of the Disclosing Party that the Receiving Party can prove by competent evidence: (a) is now, or hereafter becomes, through no act or failure to act on the part of the Receiving Party in breach of this Agreement, generally known or available; (b) is known by the Receiving Party at the time of receiving such information from the Disclosing Party; (c) is hereafter furnished to the Receiving Party by a Third Party, as a matter of right and without restriction on disclosure; or (d) is independently discovered or developed by the Receiving Party, without the aid, use or application of any Confidential Information of the Disclosing Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Authorized Disclosure.</b> Notwithstanding the provisions of this Article 7, the Receiving Party may disclose Confidential Information, without violating its obligations under this Agreement, to the extent the disclosure is:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>required by a valid order of a court or other governmental body of competent jurisdiction or as otherwise required by Applicable Law, rule, regulation (including securities laws and regulations), government requirement, or as may be required in connection with any filings made with, or by the disclosure policies of, a stock exchange; <i style="font-style:italic;">provided, that</i> the Receiving Party shall give reasonable prior written notice to the Disclosing Party of such required disclosure and, at [***] request and expense, shall cooperate with the Disclosing Party&#8217;s efforts to contest such requirement, to obtain a protective order requiring that the Confidential Information so disclosed be used only for the purposes for which the order was issued or the law, rule or regulation required, or to obtain other confidential treatment of such Confidential Information; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>reasonably necessary to file or prosecute patent applications, prosecute or defend litigation or otherwise establish rights or enforce obligations under this Agreement, in each case, in accordance with this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">7.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No Requirement to Disclose Paragon Platform Technology.</b> Notwithstanding anything to the contrary in this Agreement, Paragon will not be required to disclose any of the Paragon Platform Technology to Jade other than as required to be included in the Deliverables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">7.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Use of Names.</b> No Party shall use any other Party&#8217;s name or trademarks in any advertising, sales, or promotional material or in any publication without the prior written consent of such other Party or Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">7.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Confidentiality of this Agreement.</b> This Agreement and its terms are considered Confidential Information of all Parties, and each Party shall keep confidential and shall not publish or otherwise disclose the terms of this Agreement without the prior written consent of the applicable other Party, except as expressly permitted by Section 7.3 or Section 7.7, and except that any Parties may disclose this Agreement and its terms to actual or potential investors, lenders, and strategic partners in connection with due diligence or similar investigations by such Third Parties or in confidential financing documents; <i style="font-style:italic;">provided</i>, in each case, that any such Third Party agrees to be bound by obligations of confidentiality and non-use at least as restrictive as those set forth in this Article 7 (<i style="font-style:italic;">provided, that</i> the confidentiality term applicable to such Third Party may be shorter so long as it is commercially reasonable).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">7.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Publicity.</b> Except to the extent required by Applicable Law or the rules of any stock exchange or listing agency, no Party shall issue a press release announcing that they have entered into an Antibody discovery partnership, without the other Parties&#8217; prior written consent, which shall not be unreasonably withheld.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#8239;<b style="font-weight:bold;">ARTICLE 8</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REPRESENTATIONS, WARRANTIES AND COVENANTS; DISCLAIMER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Mutual Representations and Warranties.</b> Each Party represents and warrants to each other that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not and will not conflict with any agreement, instrument, or understanding, oral or written, to which it is or may become a party or by which it may be or become bound.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Paragon Representations, Warrants and Covenants</b>. Paragon hereby represents, warrants and covenants to Jade that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>it will perform its activities under a Research Program with due care and in accordance with (i) Applicable Law, (ii) the terms and conditions contained herein and the applicable Research Plan, and (iii) generally prevailing industry standards;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>neither it nor any of its Affiliates have entered or will enter, directly or indirectly, into any contract or any other transaction with any Third Party or Affiliate that conflicts or derogates from its undertakings under this Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>it has the unencumbered right to the Paragon Platform Technology and the right, power and authority to use the Paragon Platform Technology in performance of the Research Plans and the performance of its obligations under this Agreement, in each case in accordance with the terms hereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>each Representative employed or engaged by Paragon or its Affiliate to conduct the activities under a Research Program has assigned and has executed an agreement assigning its entire right, title and interest in and to Project Antibody Technology to Paragon;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>there are no claims, actions, or proceedings pending or threatened, nor are there any formal inquiries initiated or written notices received that may lead to the institution of any such legal proceedings, in each case (or in aggregate) against Paragon or its properties, assets or business, which would, individually or in the aggregate, have a material adverse effect on, or materially prevent, Paragon&#8217;s ability to perform under this Agreement or to grant the Option or other rights granted to Jade under this Agreement; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>none of Paragon, its Representatives, or any other person used by Paragon in the performance of the Agreement has been or is (i) debarred, convicted, or is subject to a pending debarment or conviction, pursuant to section 306 of the United States Federal Food Drug and Cosmetic Act, 21 U.S.C. &#167; 335a, (ii) listed by any government or regulatory agencies as ineligible to participate in any Federal healthcare programs (as that term is defined in 42 U.S.C. 1320a-7b(f)) or government procurement or non-procurement programs, or excluded, debarred, suspended or otherwise made ineligible to participate in any such program, or (iii) convicted of a criminal offense related to the provision of healthcare items or services, or is subject to any such pending action. Paragon agrees to inform Jade [***] if Paragon or any person who is performing activities on its behalf under the Agreement is subject to the foregoing, or if any action, suit, claim, investigation, or proceeding relating to the foregoing is pending or threatened.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">8.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Disclaimer.</b> EXCEPT AS EXPRESSLY SET FORTH HEREIN, EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, DURABILITY, MERCHANTABLE QUALITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 9</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TERM AND TERMINATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Term.</b> The term of this Agreement (&#8220;<b style="font-weight:bold;">Term</b>&#8221;) shall commence on the Effective Date and, subject to earlier termination in accordance with this Article 9, shall continue on a Research Program-by-Research Program basis until the later of: (a)&#8239;the expiration of the Option Period if Jade does not exercise the Option in accordance with Section 4.3; (b) if Jade exercises its Option during the Option Period in accordance with Section 4.3 but the Parties are unable to finalize and execute a License Agreement during the thirty (30) day period referenced in Section&#8239;4.4(b), the expiration of such thirty (30) day period; or (c) the expiration of the applicable Research Term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">9.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Termination of Agreement for Material Breach.</b> Each Party shall have the right to terminate this Agreement or a Research Program upon thirty (30) days&#8217; prior written notice to the other Parties upon or after the material breach of any provision of this Agreement by any other Party if the breaching Party has not cured such breach by the end of such thirty (30) day period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">9.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Termination for Convenience.</b> Jade shall have the right to terminate this Agreement or any Research Program for any reason or no reason upon thirty (30) days&#8217; prior written notice to Paragon; <i style="font-style:italic;">provided, that</i> Jade will pay Paragon any unpaid fees due for Development Costs accrued prior to such effective termination date, as well as any non-cancellable obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program, as evidenced by Paragon&#8217;s records.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">9.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Termination for Delay</b>. Paragon shall have the right to terminate this Agreement or a Research Program immediately upon written notice to Jade if, as a result any action or failure to act by Jade or its Affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed for a period of four (4) consecutive months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">9.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Termination for a Bankruptcy Event. </b>Each Party will have the right to terminate this Agreement in the event of a Bankruptcy Event with respect to any other Party. &#8220;<b style="font-weight:bold;">Bankruptcy Event&#8221; </b>means the occurrence of any of the following: (a) the institution of any bankruptcy, receivership, insolvency, reorganization or other similar proceedings by or against a Party under any bankruptcy, insolvency, or other similar law now or hereinafter in effect, including any section or chapter of the United States Bankruptcy Code, as amended, or under any similar laws or statutes of the United States or any state thereof (the &#8220;<b style="font-weight:bold;">Bankruptcy Code</b>&#8221;), where in the case of involuntary proceedings, such proceedings have not been dismissed or discharged within [***] after they are instituted, (b) the insolvency or making of an assignment for the benefit of creditors or the admittance by a Party of any involuntary debts as they mature, (c) the institution of any reorganization, arrangement or other readjustment of debt plan of a Party not involving the Bankruptcy Code, (d) the appointment of a receiver for all or substantially all of a Party&#8217;s assets, or (e) any corporate action taken by the board of directors of a Party in furtherance of any of the foregoing actions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">9.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Disposal of Confidential Information.</b> In the event this Agreement expires or this Agreement or any Research Program is terminated and the Parties have not entered into a License Agreement with respect to an expired or terminated Research Program, each Party shall return to the applicable other Party all Confidential Information of such other Party (including all copies thereof) in such Party&#8217;s possession related to any expired or terminated Research Program; <i style="font-style:italic;">provided, however</i>, that each Party may retain one copy of such other Party&#8217;s Confidential Information in such Party&#8217;s secure archives for the sole purpose of monitoring compliance with its obligations hereunder or Applicable Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">9.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Accrued Rights; Survival.</b> The expiration or termination of this Agreement for any reason shall not release any Party from any liability or obligation that, at the time of such expiration or termination, has already accrued to any other Party or that is attributable to a period prior to such expiration or termination, nor will expiration or any termination of this Agreement preclude any Party from pursuing all rights and remedies it may have under this Agreement, or at law or in equity, with respect to breach of this Agreement. In the event of expiration or any termination of this Agreement, the following provisions of this Agreement shall survive such expiration or termination in accordance with their respective terms and conditions: Article 5, Article 7, Article 10 and Article 11, as well as Sections 2.3, 6.1(a), 6.2(a), 6.4, 9.3, 9.6 and 9.7.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#8239;<b style="font-weight:bold;">ARTICLE 10</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INDEMNIFICATION; LIMITATION OF LIABILITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">10.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;By Jade.</b> Jade hereby agrees to defend, indemnify, and hold harmless Paragon, its Affiliates, including Parade, and its or their Representatives (each, a &#8220;<b style="font-weight:bold;">Paragon Indemnitee</b>&#8221;) from and against any and all losses, damages, liabilities, expenses, and costs, including reasonable legal expense and attorneys&#8217; fees (collectively, &#8220;<b style="font-weight:bold;">Losses</b>&#8221;), to which any Paragon Indemnitee may become subject as a result of any claim, demand, action, or other proceeding by any Third Party (&#8220;<b style="font-weight:bold;">Third Party Claim</b>&#8221;) to the extent such Losses result from: (a)&#8239;the negligence or willful misconduct of any Jade Indemnitee in the performance of this Agreement; or (b) the material breach by any Jade Indemnitee of this Agreement; except, in each case, to the extent such Losses result from the negligence or willful misconduct of any Paragon Indemnitee or the material breach by Paragon of this Agreement, or where such Losses are subject to indemnification pursuant to Section 10.2 below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">10.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;By Paragon.</b> Paragon hereby agrees to defend, indemnify, and hold harmless Jade, its Affiliates and their Representatives (each, an &#8220;<b style="font-weight:bold;">Jade Indemnitee</b>&#8221;) from and against any and all Losses to which any Jade Indemnitee may become subject as a result of any Third Party Claim to the extent such Losses result from: (a) the negligence or willful misconduct of any Paragon Indemnitee in the performance of this Agreement; or (b) the material breach by any Paragon Indemnitee of this Agreement; except, in each case, to the extent such Losses result from the negligence or willful misconduct of any Jade Indemnitee, the material breach by Jade of this Agreement, or where such Losses are subject to indemnification pursuant to Section 10.1 above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">10.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indemnification Procedure. </b>In connection with any Third Party Claim for which a Party (the &#8220;<b style="font-weight:bold;">Indemnified Party</b>&#8221;) seeks indemnification from another Party (the &#8220;<b style="font-weight:bold;">Indemnifying Party</b>&#8221;) pursuant to this Agreement, the Indemnified Party will: (a) give the Indemnifying Party [***] notice of the Third Party Claim; <i style="font-style:italic;">provided, however, </i>that failure to provide such notice will not relieve the Indemnifying Party from its liability or obligation hereunder, except to the extent of any material prejudice as a direct result of such failure; (b) cooperate with the Indemnifying Party, at the Indemnifying Party&#8217;s expense, in connection with the defense and settlement of the Third Party Claim; and (c) permit the Indemnifying Party to control the defense and settlement of the Third Party Claim; <i style="font-style:italic;">provided, however, </i>that the Indemnifying Party may not settle the Third Party Claim without the Indemnified Party&#8217;s prior written consent, which will not be unreasonably withheld or delayed, in the event that such settlement materially adversely impacts the Indemnified Party&#8217;s rights or obligations. Further, the Indemnified Party will have the right to participate (but not control) and be represented in any suit or action by advisory counsel of its selection and at its own expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">10.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Limitation of Liability.</b> EXCEPT FOR LIABILITY FOR BREACH OF ARTICLE 7 OR FOR INDEMNIFICATION CLAIMS UNDER ARTICLE 10, IN NO EVENT SHALL ANY PARTY BE ENTITLED TO RECOVER FROM ANY OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT, EVEN IF SUCH OTHER PARTY HAD NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 11</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MISCELLANEOUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Independent Contractor Relationship.</b> Each of Paragon&#8217;s and Parade&#8217;s relationship with Jade is that of an independent contractor, and nothing in this Agreement should be construed to create a partnership, joint venture or employer-employee relationship. No Party is an agent of any other Party or authorized to make any representation, contract or commitment on behalf of any other Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Force Majeure. </b>No Party will be charged with any liability for delay or failure in performance of an obligation under this Agreement (other than any obligation to pay monies when due) to the extent such delay or failure is due to a cause beyond the reasonable control of the affected Party, such as war, riots, labor disturbances, epidemic, pandemic, fire, explosion, and compliance in good faith with any Applicable Law. The Party affected will give [***] notice to the other Parties of the nature of the cause of any material delay or failure to perform, its anticipated duration and any action being taken to avoid or minimize the effect. The Party affected will use its diligent efforts to avoid or remove such causes of delay or failure to perform and to mitigate the effect of such occurrence, and will continue performance in accordance with the terms of this Agreement whenever such causes are removed. The Party affected will give [***] notice to the other Parties of such resumed performance. If any such failure or delay in a Party&#8217;s performance hereunder continues for more than [***], any of the other Parties may terminate this Agreement upon written notice to the affected Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Entire Agreement; Amendment.</b> This Agreement, together with all Exhibits attached hereto, constitutes the final, complete, and exclusive agreement of the Parties with respect to the subject matter hereof and supersedes all prior and contemporaneous understandings and agreements, relating to its subject matter. This Agreement (including its Exhibits) may not be changed, modified, amended, or supplemented except by a written instrument signed by all Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Non-Waiver.</b> The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance. Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Severability.</b> Should one or more of the provisions of this Agreement become void or unenforceable as a matter of Applicable Law, then this Agreement shall be construed as if such provision were not contained herein and the remainder of this Agreement shall be in full force and effect, and the Parties will use their best efforts to substitute for the invalid or unenforceable provision a valid and enforceable provision which conforms as nearly as possible with the original intent of the Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Assignment.</b> Neither this Agreement nor any rights or obligations hereunder may be assigned by any Party without the prior written consent of the other Parties (which consent shall not be unreasonably withheld); <i style="font-style:italic;">provided, however</i>, that any Party may assign this Agreement and its rights and obligations hereunder without the other Parties&#8217; consent to its successor to all or substantially all of the business of such Party to which this Agreement relates, whether by merger, sale of stock, sale of assets or otherwise. The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties, and the name of a Party appearing herein will be deemed to include the name of such Party&#8217;s successors and permitted assigns to the extent necessary to carry out the intent of this section. Any assignment not in accordance with this Agreement shall be void.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Dispute Resolution.</b> The Parties recognize that a <i style="font-style:italic;">bona fide </i>dispute as to certain matters may arise from time to time during the Term relating to any Party&#8217;s rights or obligations hereunder or otherwise relating to the validity, enforceability or performance of this Agreement, including disputes relating to alleged breach or termination of this Agreement but excluding any disputes relating to Article 7 (Confidentiality) hereof or disputes relating to the determination of the validity, scope, infringement, enforceability, inventorship or ownership of the Parties&#8217; respective Intellectual Property Rights (hereinafter, a &#8220;<b style="font-weight:bold;">Dispute</b>&#8221;). In the event of the occurrence of any Dispute, the Parties will follow the following procedures in an attempt to resolve the dispute or disagreement:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>The Party claiming that such a Dispute exists will give notice in writing (a &#8220;<b style="font-weight:bold;">Notice of Dispute</b>&#8221;) to the other Parties of the nature of the Dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>The Dispute will be referred to the then Chief Executive Officer or Chief Operating Officer of Paragon and the then Chief Executive Officer or President of Jade who will meet no later than [***] following the initial receipt of the Notice of Dispute and use reasonable endeavors to resolve the Dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>If, within [***] of initial receipt of the Notice of Dispute, the Dispute has not been resolved, or if, for any reason, the meeting described in Section 11.7(b) hereof has not been held within [***] of initial receipt of the Notice of Dispute, then the Parties agree that such Dispute will be finally resolved through binding arbitration to be administered by JAMS pursuant to its Comprehensive Arbitration Rules and Procedures and in accordance with the Expedited Procedures in those Rules, as specifically modified by the provisions of this Section&#8239;11.7(c). The arbitration will be conducted by a panel of three arbitrators. Within [***] after the initiation of the arbitration, each Party will nominate one person to act as arbitrator, and the two arbitrators so named will then jointly appoint the third arbitrator within [***] of their appointment, who will serve as chairman of the panel. All three arbitrators must be independent Third Parties having at least [***] of dispute resolution experience (which may include judicial experience) or legal or business experience in the biotech or pharmaceutical industry. If any Party fails to nominate its arbitrator, or if the arbitrators selected by the Parties cannot agree on a person to be named as chairman within such [***]-day period, JAMS will make the necessary appointments for such arbitrator(s) or the chairman. Once appointed by a Party, such Party will have no <i style="font-style:italic;">ex parte </i>communication with its appointed arbitrator. The place of arbitration will be in Boston, Massachusetts or such other venue as the Parties may mutually agree. The arbitration proceedings and all communications with respect thereto will be in English. Any written evidence originally in another language will be submitted in English translation accompanied by the original or a true copy thereof. The arbitrators have the power to decide all matters in Dispute, including any questions of whether or not such matters are subject to arbitration hereunder. The arbitration will be governed by the Federal Arbitration Act, 9 U.S.C. &#167;&#167;1 <i style="font-style:italic;">et seq., </i>and judgment upon the award rendered by the arbitrators may be entered in any court having competent jurisdiction thereof. The existence, content and results of any arbitration proceedings pursuant to this Section 11.7 will be deemed the Confidential Information of all Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>Notwithstanding any provision of this Agreement to the contrary, any Party may immediately initiate litigation in any court of competent jurisdiction seeking any remedy at law or in equity, including the issuance of a preliminary, temporary or permanent injunction, to preserve or enforce its rights under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:82.8pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b>The Parties agree that any disputes relating to Article 7 (Confidentiality) hereof or disputes relating to the determination of the validity, scope, infringement, enforceability, inventorship or ownership of the Parties&#8217; respective Intellectual Property Rights shall be subject to the exclusive jurisdiction of the state and federal courts in New York, New York and each Party hereby submits to such jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">11.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Governing Law.</b> This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts without reference to conflicts of laws principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8239;<b style="font-weight:bold;">11.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notices.</b> Any notice to be given under this Agreement must be in writing and delivered either in person, by internationally recognized express courier, by email, or by facsimile, to the Party to be notified at its address(es) given below, or at any address such Party has previously designated by prior written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the earliest of: (a) the date of actual receipt; (b) if delivered by express courier, the next Business Day the express courier regularly makes deliveries; or (c) if delivered by email, upon the date upon which the receipt of such email is confirmed by return email. Together with any notice provided by a Party to any other Party in accordance with this Section 11.9, the Party shall send a copy of such notice by email to such other Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:60%;"><tr><td style="vertical-align:bottom;width:48.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If to Paragon or Parade:</p></td><td style="vertical-align:bottom;width:51.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Paragon Therapeutics, Inc.</p></td></tr><tr><td style="vertical-align:bottom;width:48.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:51.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">221 Crescent Street</p></td></tr><tr><td style="vertical-align:bottom;width:48.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:51.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Building 23, Suite 105</p></td></tr><tr><td style="vertical-align:bottom;width:48.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:51.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Waltham, MA 02453</p></td></tr><tr><td style="vertical-align:bottom;width:48.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:51.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attn: [***]</p></td></tr><tr><td style="vertical-align:bottom;width:48.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:51.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If to Jade:</p></td><td style="vertical-align:bottom;width:51.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jade Biosciences, Inc.</p></td></tr><tr><td style="vertical-align:bottom;width:48.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:51.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">221 Crescent Street</p></td></tr><tr><td style="vertical-align:bottom;width:48.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:51.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Building 23, Suite 105</p></td></tr><tr><td style="vertical-align:bottom;width:48.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:51.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Waltham MA 02453</p></td></tr><tr><td style="vertical-align:bottom;width:48.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:51.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attn: [***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Interpretation.</b> Except where the context expressly requires otherwise, (a)&#8239;the use of any gender herein shall be deemed to encompass references to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b)&#8239;the words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without limitation&#8221;, (c)&#8239;the word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall&#8221;, (d)&#8239;any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (e) any reference herein to any person or entity shall be construed to include such person&#8217;s or entity&#8217;s successors and assigns, (f) the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) all references herein to Sections or Exhibits shall be construed to refer to Sections or Exhibits of this Agreement, and references to this Agreement include all Exhibits hereto, (h) the word &#8220;notice&#8221; means notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement, (i) provisions that require that a Party, the Parties or any committee hereunder &#8220;agree,&#8221; &#8220;consent&#8221; or &#8220;approve&#8221; or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and instant messaging), (j) references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof, and (k) the term &#8220;or&#8221; shall be interpreted in the inclusive sense commonly associated with the term &#8220;or&#8221;. The headings of clauses contained in this Agreement preceding the text of the sections, subsections and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement or have any effect on its interpretation or construction. Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against any Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist. This Agreement has been prepared in the English language, and the English language shall control its interpretation. In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral, or other communications between the Parties regarding this Agreement shall be in the English language. To the extent there is any inconsistency or conflict between the terms and conditions of this Agreement and any Research Plan, the terms and conditions of this Agreement will prevail.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No Third-Party Rights.</b> The provisions of this Agreement are for the exclusive benefit of the Parties and their successors and permitted assigns, and no other person shall have any right or claim against any Party by reason of these provisions or be entitled to enforce any of these provisions against any Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Counterparts.</b> This Agreement may be executed in counterparts, each of which shall be deemed an original document, and all of which, together with this writing, shall be deemed one instrument. This Agreement may be executed by facsimile or PDF signatures, which signatures shall have the same force and effect as original signatures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Expenses</b>. Each Party shall pay its own costs, charges and expenses incurred in connection with the negotiation, preparation, and completion of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Binding Effect</b>. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal representatives, successors and permitted assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.15&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Construction</b>. The Parties hereto acknowledge and agree that: (a) each Party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; (b) the rule of construction to the effect that any ambiguities are resolved against the drafting Party shall not be employed in the interpretation of this Agreement; and (c) the terms and provisions of this Agreement shall be construed fairly as to all Parties hereto and not in a favor of or against any Party, regardless of which Party was generally responsible for the preparation of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.16&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Cumulative Remedies</b>. No remedy referred to in this Agreement is intended to be exclusive unless explicitly stated to be so, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">[Remainder of page left intentionally blank; signature page follows.]</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF,</b> the Parties hereto have executed this Antibody Discovery and Option Agreement on the Effective Date.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:43.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PARAGON THERAPEUTICS, INC.&#8239;</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES, INC.</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:42.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ K. Evan Thompson</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:43.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ K. Evan Thompson&#8239;</p></td></tr><tr><td style="vertical-align:bottom;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">K. Evan Thompson</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">K. Evan Thompson&#8239;</p></td></tr><tr><td style="vertical-align:bottom;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COO</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Secretary and Vice President of Corporate Development&#8239;</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PARADE BIOSCIENCES HOLDING, LLC&#8239;</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:42.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ K. Evan Thompson</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">K. Evan Thompson</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8239;<font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">&#8239;[Signature Page to Antibody Discovery and Option Agreement]</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>12
<FILENAME>avte-20240930xex10d17.htm
<DESCRIPTION>EXHIBIT 10.17
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 12/3/2024 12:42:00 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.17</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I)&#160;IS NOT MATERIAL AND (II)&#160;WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AMENDMENT NO. 1 TO ANTIBODY DISCOVERY AND OPTION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THIS AMENDMENT NO.&#160;1 TO ANTIBODY DISCOVERY AND OPTION AGREEMENT</b> (this &#8220;<b style="font-weight:bold;">Amendment</b>&#8221;) is entered into and effective as of September&#160;27, 2024 (the &#8220;<b style="font-weight:bold;">Amendment Effective Date</b>&#8221;), by and between Paragon Therapeutics,&#160;Inc., a Delaware corporation (&#8220;<b style="font-weight:bold;">Paragon</b>&#8221;), Parade Biosciences Holding, LLC, a Delaware limited liability company (&#8220;<b style="font-weight:bold;">Parade</b>&#8221;) and Jade Biosciences,&#160;Inc., a Delaware corporation (&#8220;<b style="font-weight:bold;">Jade</b>&#8221;), and amends that certain Antibody Discovery and Option Agreement, dated as of July&#160;24, 2024, by and between Paragon, Parade and Jade (the &#8220;<b style="font-weight:bold;">Option Agreement</b>&#8221;). Paragon, Parade and Jade are also referred to herein individually as a &#8220;<b style="font-weight:bold;">Party</b>,&#8221; or collectively as the &#8220;<b style="font-weight:bold;">Parties</b>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, pursuant to the Option Agreement, Jade engaged Paragon to identify, evaluate and develop one or more antibody candidates directed to certain therapeutic targets, and Paragon granted to Jade an exclusive option on a target-by-target basis to enter into one or more separate license agreements to develop, manufacture and commercialize the resulting antibodies in the Field in the Territory;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, the Parties desire to initiate (i)&#160;a new Research Program focusing on the [***] target, and (ii)&#160;a new Research Program focusing on the [***] target; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, the Parties desire to amend certain terms under the Option Agreement and otherwise ratify the Option Agreement as it relates to the two (2)&#160;new Research Programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW THEREFORE</b>, in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u>. Capitalized terms used herein which are not otherwise defined shall have the meanings ascribed to such terms in the Option Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendments to Option Agreement</u>.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The following definition is hereby added to Article 1 of the Option Agreement:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.95</b></font>&#8220;<b style="font-weight:bold;">Pre-Amendment Effective Date Development Costs</b>&#8221; shall have the meaning provided in Section&#160;5.2(e).</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Section 5.2 of the Option Agreement is hereby amended by adding the following new Section 5.2(e) immediately following the existing Section 5.2(d):</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 72pt;"><b style="font-weight:bold;">(e)</b><font style="display:inline-block;width:24.9pt;"></font>Notwithstanding Sections 5.2(a), 5.2(b)&#160;and 5.2(c)&#160;to the contrary, the Parties acknowledge that Paragon has incurred (i)&#160; Development Costs through the Amendment Effective Date as a result of work performed by Paragon at risk on the Research Program for [***], and (ii)&#160; Development Costs through the Amendment Effective Date as a result of work performed by Paragon at risk on the Research Program for [***] (the costs described in (i)&#160;and (ii), the &#8220;<b style="font-weight:bold;">Pre-Amendment Effective Date Development Costs</b>&#8221;). Jade shall reimburse Paragon for the Pre-Amendment Effective Date Development Costs within [***] days after Jade&#8217;s receipt of a written invoice that details the Pre-Amendment Effective Date Development Costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I)&#160;IS NOT MATERIAL AND (II)&#160;WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Parties have agreed to the Selected Targets attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u>, which hereby replaces the Exhibit A attached to the Option Agreement in its entirety.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Application of the Option Agreement</u>. The Parties acknowledge and agree that:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">in accordance with Section 2.1(b) of the Option Agreement, no later than forty-five (45) days after the Amendment Effective Date, the Parties will agree on a Research Plan, to the extent a research plan has not been previously agreed upon, for each of the two (2) new Research Programs for [***] and [***], respectively; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">in accordance with Section 5.1 of the Option Agreement, Jade shall pay to Paragon the Research Initiation Fee of One Million Dollars ($1,000,000) for each of the two (2) new Research Programs for [***] and [***] no later than [***] following finalization of the Research Plan for the applicable new Research Program.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ratification of the Option Agreement</u>. This Amendment is made by the Parties in accordance with Section 11.3 of the Option Agreement. Except as expressly set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2</u> above, the Option Agreement shall remain unmodified and in full force and effect. The execution, delivery and effectiveness of this Amendment shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of the Parties to the Option Agreement, nor constitute a waiver of any provision of the Option Agreement. In the event of a conflict between the terms of this Amendment and the Option Agreement, the terms of this Amendment shall control.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous</u>. This Amendment, together with the Exhibit attached hereto and the Option Agreement, constitutes the entire agreement and understanding between the Parties with respect to the subject matter hereof and supersedes all negotiations, representations, prior discussions and preliminary agreements between the Parties relating to the subject matter of this Amendment and the Option Agreement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">6.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u>. This Amendment may be executed in counterparts, each of which shall be deemed an original document, and all of which, together with this writing, shall be deemed one instrument. This Amendment may be executed by facsimile or PDF signatures, which signatures shall have the same force and effect as original signatures.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">[Remainder of page&#160;left intentionally blank; signature page&#160;follows]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I)&#160;IS NOT MATERIAL AND (II)&#160;WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the Parties hereto have executed this Amendment No.&#160;1 to Antibody Discovery and Option Agreement on the Amendment Effective Date.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td colspan="2" style="vertical-align:bottom;width:52.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PARAGON THERAPEUTICS, INC.</b></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES, INC.</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:52.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ K. Evan Thompson</p></td><td style="vertical-align:bottom;width:2.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.76%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:38.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Tomas Kiselak</p></td></tr><tr><td style="vertical-align:bottom;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:45.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">K. Evan Thompson</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tomas Kiselak</p></td></tr><tr><td style="vertical-align:bottom;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:45.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Operating Officer</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:52.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PARADE BIOSCIENCES HOLDING, LLC</b></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:52.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ K. Evan Thompson</p></td><td style="vertical-align:bottom;width:2.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:44.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:45.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">K. Evan Thompson</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:45.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">[Signature Page&#160;to Amendment No.&#160;1 to Antibody Discovery and Option Agreement]</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>13
<FILENAME>avte-20240930xex10d18.htm
<DESCRIPTION>EXHIBIT 10.18
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 12/3/2024 12:42:01 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.18</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BIOLOGICS MASTER SERVICES AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This Biologics Master Services Agreement (this &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;) is dated and effective as of July 3, 2024 (the &#8220;<b style="font-weight:bold;">Effective Date</b>&#8221;) and is between <b style="font-weight:bold;">Jade BioSciences, Inc., </b>a Delaware corporation, with an office at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453 (&#8220;<b style="font-weight:bold;">Client</b>&#8221;) and <b style="font-weight:bold;">WuXi Biologics (Hong Kong) Limited</b>, with its registered address at Flat/RM826, 8/F Ocean Centre Harbour City, 5 Canton Road TST, Hong Kong (&#8220;<b style="font-weight:bold;">Provider</b>&#8221;), each of Client and Provider being a &#8220;<b style="font-weight:bold;">Party,</b>&#8221; and collectively the &#8220;<b style="font-weight:bold;">Parties</b>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A.</font></font>Client discovers and develops biologics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">B.</font></font>Provider coordinates the biologics development and manufacturing services, including those provided by certain affiliated operating companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">C.</font></font>The Parties desire that Provider or its Affiliates provide services to Client on a project-by-project basis. The services for each project (the &#8220;<b style="font-weight:bold;">Services</b>&#8221;) will be provided pursuant to a separate and distinct contract (a &#8220;<b style="font-weight:bold;">Work Order</b>&#8221;) that incorporates certain terms of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Parties therefore agree as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">DEFINITIONS</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#8220;<b style="font-weight:bold;">Affiliate</b>&#8221; of a Person means any other Person that directly or indirectly Controls, is controlled by, or is under common Control with, the Person.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#8220;<b style="font-weight:bold;">Applicable Law</b>&#8221; means all applicable laws, regulations and current Good Manufacturing Practice (cGMP) and other official guidelines and directives of any Authority relevant to the Services performed under this Agreement, and the supply, use, marketing or sale of the Product.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">&#8220;Authority&#8221;</b> means any government regulatory authority responsible for granting approvals for the performance of Services under this Agreement or for issuing regulations pertaining to the Manufacture and/or use of Product in the intended country of use, including the FDA.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#8220;<b style="font-weight:bold;">Cell Line</b>&#8221; means the cell line that has been developed to produce a Product.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#8220;<b style="font-weight:bold;">Certificate of Analysis</b>&#8221; means a certificate of analysis for testing of Specifications of a Product in a form agreed to by the Parties.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.6</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#8220;<b style="font-weight:bold;">Certificate of Compliance</b>&#8221; means a document issued by WuXi Biologics attesting that a Product Batch has been manufactured in compliance with cGMP (as applicable) and that Manufacturing Batch records have been reviewed and approved by WuXi Biologics&#8217; Quality Assurance.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.7</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#8220;<b style="font-weight:bold;">Certificate of Testing</b>&#8221; means a certificate for testing of selected Specifications of a Product in a form agreed by both Parties, for the selected testing performed by WuXi Biologics.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.8</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#8220;<b style="font-weight:bold;">Confidential Information</b>&#8221; of a Party (the &#8220;<b style="font-weight:bold;">Disclosing Party</b>&#8221;) means all information and materials disclosed by or on behalf of the Party to the other Party (the &#8220;<b style="font-weight:bold;">Receiving Party</b>&#8221;) or its Related Persons (as defined below) in connection with this Agreement that is reasonably considered to be confidential and is not generally available to the public, and permits the Disclosing Party to obtain a business advantage over any third party(ies) that do not know or use such information. The Confidential Information of both Parties includes the existence, terms and objectives of this Agreement, and the nature of any dispute and the outcome of any arbitration proceedings arising out of or in connection with this Agreement. &#160;All data and information developed by either party relating specifically to the Products, including Cell Line validation data generated by Provider under Work Orders, constitutes Client&#8217;s Confidential Information. &#160;Confidential Information excludes:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">information that at the time of disclosure to Receiving Party is in the public domain (through no act or omission of Receiving Party);</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">information that was known by Receiving Party prior to receipt from Disclosing Party (as proven by Receiving Party&#8217;s written records);</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">information that is disclosed to Receiving Party by a third party without an obligation of confidentiality and having the legal right to do so (as proven by Receiving Party&#8217;s written records); and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">information that is independently developed by Receiving Party without any benefit of, and not being derived or arising from, Confidential Information.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.9</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#8220;<b style="font-weight:bold;">Control</b>&#8221; over a Person means (a) owning 50% or more of the voting securities or other ownership interests of the Person or (b) having the power to direct the management or policies of the Person.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.10</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#8220;<b style="font-weight:bold;">Facility</b>&#8221; means the facility(ies) of Provider identified in the applicable Work Order.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.11</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#8220;<b style="font-weight:bold;">FDA</b>&#8221; means the United States Food and Drug Administration, and any successor agency having substantially the same functions.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.12</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#8220;<b style="font-weight:bold;">Intellectual Property</b>&#8221; means patents and patent applications, trademarks and applications, trade names, service marks, domain names, copyrights and copyright applications and registrations, schematics, industrial models, inventions, know-how, trade secrets, computer software programs and other intangible proprietary information including Confidential Information.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.13</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#8220;<b style="font-weight:bold;">Person</b>&#8221; means an individual, a corporation, a partnership, an association, a trust or other entity or organization, including a government or political subdivision or an agency thereof.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.14</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#8220;<b style="font-weight:bold;">Product</b>&#8221; means the drug substance, drug product, or a part or derivative of the drug substance or drug product, that is manufactured through the Services or to be produced by a Cell Line.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.15</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#8220;<b style="font-weight:bold;">Specifications</b>&#8221; means the list of tests, references to any analytical procedures and appropriate acceptance criteria which are numerical limits, ranges or other criteria for tests described in order to establish a set of criteria to which Product at any stage of Manufacture should conform to be considered acceptable for its intended use that are provided by or approved by Client, as such specifications are amended or supplemented from time to time by Client in writing.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">SERVICES</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Work Orders.</b> Provider shall provide the Services to Client pursuant to each Work Order that is entered into during the term of this Agreement. The preferred form of Work Order is provided in <b style="font-weight:bold;">Exhibit A</b>. Each Work Order will automatically incorporate the terms of this Agreement and be a separate and distinct agreement. If there is a contradiction between a provision of this Agreement and a Work Order, then the provision in this Agreement will take precedence unless the Work Order specifically states that it takes precedence over such named provision, in which case such precedence shall be limited in application to the Services under such Work Order.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Manufacturing. </b>Both Parties will comply with the manufacturing terms in <b style="font-weight:bold;">Exhibit B</b>.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Affiliates</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;text-align:justify;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;text-align:justify;">Provider may delegate or subcontract the Services, or any part thereof, to an Affiliate of Provider listed on Exhibit C for the provision of Services described. If the Services are provided by an Affiliate, then references to Provider in this Agreement will be deemed to be references to the Affiliate with the necessary</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">modifications. Provider shall be liable for the performance of the Affiliate to the same extent as if the performance was that of Provider.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">An Affiliate of a Party may enter into a Work Order instead of the Party. If a Work Order is entered into by an Affiliate, then references to the Party in this Agreement will be deemed to be references to the Affiliate with the necessary modifications. The Party shall be liable for the performance of the Affiliate to the same extent as if the performance was that of the Party.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">CONTRACT PRICE; PAYMENT</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Contract Price:</b> Client shall pay Provider the undisputed fees in the amount and manner provided in the applicable Work Order (the &#8220;<b style="font-weight:bold;">Contract Price</b>&#8221;). The Contract Price may be charged in accordance with a lump-sum or other pricing structure as agreed by the Parties. The Contract Price will include [***].</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Expenses.</b> Client shall reimburse Provider for reasonable and documented expenses that are (a) authorized by Client, (b) described in the applicable Work Order, or (c) described in this Agreement, including Sections [***].</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Milestones. </b>If a Work Order includes a payment for completion of a project stage or other milestone, then Provider shall notify Client [***] after the milestone is achieved. Client will be deemed to have agreed that the milestone was achieved unless it notifies Provider otherwise within [***] of receiving such notice. Each milestone payment is designed to reflect the fair value of the corresponding Services, and is not dependent on any other milestone unless otherwise specified in the Work Order.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Payment.</b> Client shall pay undisputed amounts in each of Provider&#8217;s invoices within [***] of receipt by wire transfer to the account designated by Provider. All payments made under this Agreement and any Work Order will be made [***]. The Contract Price is exclusive of, and Client shall pay, any applicable taxes (other than taxes on Provider&#8217;s income) and other fees of any nature imposed by or under the authority of any government authority. Client may withhold any payment that the Client disputes [***] provided that Client informs Provider of such dispute within the original time for payment, in which case the Parties will meet to resolve the dispute [***].</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">No Clawbacks.</b> Other than as agreed by the parties, under this Agreement or an applicable Work Order, the Contract Price and other payments under this Agreement and any applicable Work Order are non-cancelable and non-refundable, provided that Provider shall refund any pre-payments made for Services not performed.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.6</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Payment Default.</b> In the event of an overdue undisputed amount (a &#8220;<b style="font-weight:bold;">Payment Default</b>&#8221;), interest of [***]% will accrue [***] on the overdue payment as of the date of the Payment Default. If the Payment Default is not rectified within [***] after Client&#8217;s receipt of notice of such Payment Default, then it will be deemed an incurable material breach of the applicable Work Order, and Provider may terminate the Work Order pursuant to Section 11.3(b).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.7</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Annual Review. </b>At [***], each Party to a Work Order may propose a prospective adjustment of the Contract Price to reflect documented changes in pricing factors including foreign exchange fluctuation, cost reductions and efficiency increases, inflation or deflation and changes in the price of raw materials. The Parties shall negotiate [***] with the aim of identifying a mutually acceptable amendment of the Work Order.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">PROVISION OF SERVICES</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Specifications.</b> Provider shall provide all the Services at the Facility or other facilities agreed by both parties and in accordance with the Specifications of the applicable Work Order.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Qualifications.</b> Provider shall ensure that the persons that provide the Services (the &#8220;<b style="font-weight:bold;">Personnel</b>&#8221;) (a) have the appropriate skills, training and experience and (b) are bound by confidentiality obligations consistent with the terms of this Agreement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Compliance.</b> Provider shall provide the Services in compliance with Applicable Law and applicable Good Practice (&#8220;<b style="font-weight:bold;">GxP</b>&#8221;) guidelines in all material respects.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">On-Site Monitoring.</b> Representatives of Client may, [***], visit the facilities where the Services are provided and consult informally during such visits with appropriate Personnel in order to monitor the Services. The representatives will be bound by rules applicable to the facilities and may, [***], be prohibited from entering or only given limited access to certain areas within the facilities. Provider may require that Client or the representatives execute an agreement that regulates the representatives&#8217; conduct during its visit. Client shall be responsible for all expenses incurred in connection with such visits [***], and all its personnel must be subject to the same level of confidentiality as in this Agreement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Regulatory Inspections.</b> Provider will permit visits and/or inspections by regulatory Authorities of any country as required by Applicable Law, and will permit Client or its agents to be present and participate in any visit or inspection by such regulatory Authority of the Facility (to the extent it relates in any way to any Product) or the manufacturing process. Provider will give as much advance notice as possible to Client</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">of any such visit &#160;or inspection. Provider will provide Client with a redacted (only to protect confidential information of Provider&#8217;s other customers and remove the contents not related to the Client&#39;s project ) copy of any report or other written communication received from such Authority in connection with such visit or inspection, and any written communication received from any regulatory Authority relating to the Product, the Facility (if it relates to or affects the development and/or manufacture of Product) or the manufacturing process, within [***] after receipt, and will consult with, and unless legally prohibited by regulatory Authorities, seek approval from, Client before responding to each such communication if time permits. Provider will provide Client with a copy of its final responses within [***] after submission. [***].</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">4.6</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Facility.</b> Provider will not change the location of such Facility or use any additional facility for the performance of manufacturing Services under this Agreement without at least [***] prior written notice to, and prior written consent from, Client, which consent will not be unreasonably withheld or delayed (it being understood and agreed that Client may withhold consent pending satisfactory completion of a quality assurance audit and/or regulatory impact assessment of the new location or additional facility, as the case may be). Provider will maintain, [***], the Facility and all Equipment required for the Manufacture of Product in a state of repair and operating efficiency consistent with the requirements of cGMP (if applicable) and all Applicable Law. Provider will be responsible for performing all validation of the Facility, Equipment and cleaning and maintenance processes employed in the Manufacturing Process in accordance with cGMP (if applicable), Provider&#8217;s SOPs, the applicable Quality Agreement (if any), and Applicable Law. Provider will be responsible for obtaining, [***], any Facility or other licenses or permits, and any regulatory and government approvals necessary for the performance of Services by Provider under this Agreement. [***], Provider will provide Client with copies of all such approvals, and Client will have the right to use any and all information contained in such approvals in connection with regulatory approval and/or commercial development of Product.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">SOURCING OF MATERIAL</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">5.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Materials.</b> Provider shall, [***], purchase all materials necessary for the Services (the &#8220;<b style="font-weight:bold;">Materials</b>&#8221;). If a Material is not commercially available, then Client may elect to (a) supply, [***], the Material to Provider; or (b) amend the applicable Work Order to permit the use of a commercially available substitute. Provider shall perform the market research and propose a list of vendors in compliance with Applicable Law and applicable GxP in all material respects, [***]. Provider shall take the inventory risk of the selected materials, such as the damages to pass through materials caused by improper storage or pollutions, [***].</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;text-align:justify;">5.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Client Materials.</b> If a Material is to be supplied by Client (a &#8220;<b style="font-weight:bold;">Client Material</b>&#8221;), then Client &#160;shall provide the Client Material [***] and provide such information as may be required</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">by Provider or Applicable Law concerning the stability, storage and safety requirements of the Client Material. Provider shall ensure that the Client Material will be (a) used solely for the purpose of providing the Services, (b) only distributed to Personnel on a need-to-know basis for the provision of the Services and (c) preserved and protected in a manner consistent with the specifications of the applicable Work Order and any relevant standard operating procedures or other instructions provided by Client. &#160;Client will at all times retain title to and ownership of the Client Materials, Product, any intermediates and components of Client Materials or Product, and any work in process at each and every stage of the Manufacturing Process. Provider will provide within the Facility an area or areas where the Client Materials, Product, any intermediates and components of Client Materials or Product, and any work in process are segregated and stored in accordance with the Specifications and cGMP (if applicable), and in such a way as to be able at all times during the period of the Agreement or applicable Work Order to clearly distinguish such materials from products and materials belonging to Provider, or held by it for a third party&#39;s account. Provider will ensure that Client Materials (which are under Provider&#8217;s control), Product, any intermediates and components of Product, and any work in process are free and clear of any liens or encumbrances arising from disputes with any third party. Provider will at all times during the period of the Agreement or applicable Work Order take such measures as are required to protect the Client Materials, Product, any intermediates and components of any Client Materials or Product, and any work in process from loss, damage and theft at all stages of the Manufacturing Process. Client agrees that it is responsible to insure such items against theft, damage or loss and under no circumstances shall Provider be liable for loss or damage to any such items. The foregoing agreement does not limit the Provider&#8217;s liability for Client Materials&#8217;(for clarity, such Client Materials should be specified in the applicable Work Orders) loss or damage solely resulting from Provider&#8217;s gross negligence or willful misconduct while the Services are being performed or while such Client Materials are in the Provider&#8217;s care. Provider will [***] notify Client if at any time it believes any Product or Client Materials, or any intermediates and components of any Client Materials or Product, or any work in process have been damaged, lost or stolen.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">5.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Unused Client Materials and Other Materials.</b> Provider shall, [***], return, destroy or otherwise dispose of unused Client Materials [***] after the earlier of (a) completion of the Services for which the Client Materials were provided, (b) termination of the applicable Work Order, or (c) receipt of written instructions from Client pertaining to its disposition. Provider may dispose of other unused Materials at its sole discretion upon [***] prior written notice to Client, and Client may elect during the [***] period to have the Client Materials transferred to Client.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">RECORDS</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:34.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;text-align:justify;">6.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Storage for Records. </b>All materials, data and documentation obtained or generated by Provider in the course of providing the Services, including all computerized records and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">files (&#8220;<b style="font-weight:bold;">Records</b>&#8221;), will be maintained in a secure area in accordance with industry standards and Applicable Law, [***]. While it is the Parties&#8217; intent that Provider shall retain ownership of any Provider IP or Provider Confidential Information contained in the Records, the Records with exclusion of the Provider IP and Provider Confidential Information are the sole and exclusive property of Client and Client shall be able to use the Records, unencumbered, for purposes related to the Product.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">6.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Retention of Records. </b>Upon termination of the applicable Work Order, Provider shall, at Client&#8217;s option, (a) destroy the Records, (b) deliver the Records to Client, or (c) retain the Records for [***] and then destroy the Records. If the Records are to be destroyed, then Provider shall give [***] notice to Client, and Client may elect during the [***] period to have the Records transferred to Client. Notwithstanding the foregoing, the Records may be retained solely to the extent as required by Applicable Law or as otherwise necessary for regulatory or insurance purposes.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">6.3</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Storage for Product. </b>All the Products shall be stored in Provider&#8217;s facilities for [***] after Provider&#8217;s issuance of a Certificate of Compliance with 1) a Certificate of Analysis (if full lot release testing is performed by Provider) or 2) a Certificate of Testing (if Client requests only selected lot release testing to be performed by Provider), as applicable, and a monthly storage fee for Products shall be charged after the [***] period. Client agrees that the commercial value and/or cost of replacement or remanufacture of any Products provided to Provider for storage is a matter that, as between Client and Provider, is within the sole and exclusive knowledge of Client. &#160;Client agrees that it is responsible to insure such items against damage or loss and shall purchase appropriate insurance to cover its Products stored in Provider&#8217;s facilities. &#160;[***]. Transportation of Product by Provider on behalf of Client shall be made at the sole risk and expense of Client, notwithstanding the use of any INCOTERMS delivery term on any waybill or other documentation relating to the transportation. Provider shall not be liable for the actions or omission of any delivery services or carriers or freight forwarders.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">INTELLECTUAL PROPERTY</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">7.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Ownership</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Except as otherwise provided in this Agreement, (i) Provider has no ownership rights in any Intellectual Property that is owned by Client, or licensed by any third party to Client, or any of its Affiliates, including Product, (&#8220;<b style="font-weight:bold;">Client IP</b>&#8221;) and (ii) Client has no ownership rights in any Intellectual Property that is owned by Provider, or licensed by any third party to Provider, or any of its Affiliates (<b style="font-weight:bold;">&#8220;Provider IP</b>&#8221;).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;text-align:justify;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;text-align:justify;">Provider shall ensure that each of the Personnel vests in Provider, or its applicable Affiliate, any and all rights that such person(s) might otherwise have in the</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Intellectual Property created or developed in connection with the provision of the Services, and all Intellectual Property relating to such inventions (excluding moral rights) (&#8220;<b style="font-weight:bold;">Project IP</b>&#8221;). Improvements, modifications, and derivatives of Client IP constitute Project IP. Provider hereby assigns and shall assign (and require its Affiliates to assign) all right, title and interest in Project IP to Client. Client will, [***], have sole control of filing and prosecuting applications for, and maintenance and enforcement of, patents for Project IP. Provider shall, [***], use [***] to assist Client to obtain, maintain and enforce the Project IP. Client shall use [***] to [***] notify Provider of any patents granted for Project IP. Provider will be responsible for all payments to be made to Personnel of Provider and its Affiliates in accordance with any Applicable Law requiring remuneration for inventions. For the avoidance of doubt, Provider has no right to file, prosecute, maintain, protect, defend, or enforce Intellectual Property claiming that covers any Product.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Notwithstanding the foregoing, Intellectual Property created or developed in connection with the provision of the Services (i) that relates solely to Provider IP, (ii) that relates to experimental methods independent of Client IP and Project IP, or (iii) that relates to manufacturing processes generally, in each case without reliance or reference to Client IP or Project IP (collectively, &#8220;<b style="font-weight:bold;">Manufacturing Improvements</b>&#8221;) is Provider IP and not Project IP.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">7.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">General Licenses</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Provider acknowledges and agrees that it does not acquire a license or any other right to Client IP except for the limited purpose of carrying out its duties and obligations under this Agreement and that such limited, non-exclusive, license will expire upon the completion of such duties and obligations or the termination or expiration of this Agreement, whichever is the first to occur.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Provider hereby grants and shall ensure that each applicable Affiliate will grant and hereby does grant, to Client and its applicable Affiliates a non-exclusive, perpetual, irrevocable, royalty-free, non-transferable(except in the case of Section 14.2) and sublicensable (through multiple tiers) license to Client and its Affiliates to use Provider IP solely to develop, Manufacture, have Manufactured, distribute, offer for sale, sell, and otherwise dispose of Product. Provider may, at its discretion, grant to Client the right to use Manufacturing Improvements under mutually satisfactory terms to be negotiated.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">7.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Additional Licenses</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.25pt 54pt;">In the provision of Services under this Agreement, Provider may recommend to incorporate into the process or deliverables some specific Provider IP that needs an</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">additional license. Prior to incorporation of such IP into the process and deliverables, Provider shall submit to Client a written list of such IP, describing it in reasonable detail. Within [***] of Client&#8217;s receipt of the information noted in the preceding sentence, Client will notify Provider of its decision as to whether to incorporate such IP into the process or deliverables. Provider shall not incorporate such IP into the process or deliverables without Client&#8217;s express written consent. For any specific Provider IP included in the process or deliverables for which Provider has failed to notify Client and/or for which Client has not expressly consented to the inclusion thereof, Client&#8217;s rights to such IP shall be the same as Client&#8217;s rights in the process or deliverables. If Client agrees that some specific Provider IP may be incorporated in the process or deliverables or may be necessary for Client&#8217;s full utilization of the deliverables, both parties shall discuss [***] regarding such license required.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">7.4</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">[***] <b style="font-weight:bold;">License. </b>If Client agrees to use Provider&#8217;s [***] for the manufacture of Product, then Client shall purchase from Provider a worldwide, fully paid-up, sublicensable (through multiple tiers), non-exclusive license to research, develop, make, have made, and commercialize the Product (the &#8220;<b style="font-weight:bold;">License</b>&#8221;). The terms of the License to Provider&#8217;s [***], including license fees and potential royalties, will be separately negotiated as a separate definitive agreement (&#8220;<b style="font-weight:bold;">License Agreement</b>&#8221;).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">8.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">REPRESENTATIONS AND WARRANTIES</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">8.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Mutual.</b> Each Party represents and warrants that (a) it validly exists under the laws of the jurisdiction in which it was organized, (b) it has the full power, right and authority to execute and deliver this Agreement and to perform its obligations under this Agreement, (c) this Agreement once executed will constitute a legal, valid and binding agreement enforceable against it and (d) its performance of this Agreement will not conflict with any obligations it may have to any other person.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">8.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Infringement. </b>Client represents and warrants that, to the best of its knowledge, the use of Client Intellectual Property and Client Materials in the performance of Services in accordance with this Agreement will not infringe the Intellectual Property rights of any third party.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;text-align:justify;">8.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Provider Representations and Warranties.</b> Provider represents and warrants to Client that (i) neither it nor any of the Personnel involved in the Services has been debarred, or, to the best of its knowledge, is under consideration for debarment, by the United States Food and Drug Administration from working in or providing services to any pharmaceutical or biotechnology company pursuant to the Generic Drug Enforcement Act of 1992 or any other governmental authority pursuant to analogous laws; (ii) to the best of its knowledge, the Provider IP will not violate the intellectual property rights of any third party and it will [***] notify Client in writing should it become aware of any</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">claims asserting such violation; and (iii) at the time of delivery to Client, the Product Manufactured under this Agreement will have been Manufactured in accordance with cGMP (if applicable) and all other Applicable Law, the Manufacturing Process, the applicable Quality Agreement, and Specifications.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">8.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Compliance with Law. </b>Each Party represents and warrants that it shall, and shall ensure that each of its Affiliate will, comply with all Applicable Law in connection with performance of this Agreement and any Work Orders. Each Party shall [***] notify the other Party upon becoming aware of a breach of this Section. Breach of this Section with respect to the U.S. Foreign Corrupt Practices Act or any other applicable anti-bribery law will be deemed an incurable material breach for purposes of Section 11.3(b).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">9.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">INDEMNIFICATION; LIMITATION ON LIABILITY; INSURANCE</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">9.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Third Party Claims Against Client.</b> Provider shall defend, indemnify and hold Client and its Affiliates and its directors, officers, employees, agents and consultants and legal, financial, accounting and other advisors (&#8220;<b style="font-weight:bold;">Related Persons</b>&#8221;) harmless from and against any and all liabilities and damages (including reasonable attorneys&#8217; fees) (&#8220;<b style="font-weight:bold;">Losses</b>&#8221;) resulting from any third party claims, demands, suits or proceedings (&#8220;<b style="font-weight:bold;">Claims</b>&#8221;) to the extent arising out of or relating to (a) its performance of the Services, (b) a material breach of this Agreement by Provider, (c) a material violation of Applicable Law by Provider or any of its Related Persons, or (d) the gross negligence, recklessness or willful misconduct of Provider or any of its Related Persons during the course of activities carried out in connection with this Agreement (except to the extent that such Losses are within the scope of the indemnification obligation of Client under Section 9.2). The indemnification obligations set forth in this Section 9.1 do not apply to the extent that the Loss arises in whole or in part from the gross negligence, recklessness or willful misconduct of Client or any of its Related Persons or Client&#8217;s material breach of this Agreement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;text-align:justify;">9.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Third Party Claims Against Provider.</b> Client shall defend, indemnify and hold Provider and its Related Persons harmless from and against any and all Losses resulting from any Claims to the extent arising out of or relating to (a) Client&#8217;s use of Project IP or deliverables produced in accordance with this Agreement and the written instructions of Client that were provided or produced under a Work Order (including use of any license under Provider IP), or Provider&#8217;s appropriate or proper use of Client Materials or Client IP provided by Client for use in the Services or due to compliance to any written instructions provided by Client for use in the Services; (b) a material breach of this Agreement by Client , (c) a material violation of Applicable Law by Client or any of its Related Persons, (d) the gross negligence, recklessness or willful misconduct of Client or any of its Related Persons during the course of activities carried out in connection with this Agreement, or (e) development or manufacture, use, handling, storage, or other disposition of Products by or on behalf of Client or any of its Affiliates, sublicensees,</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">agents or contractors (except by Provider), including Claims and threatened Claims based on product liability, bodily injury, risk of bodily injury, death or property damage or the failure to comply with any Applicable Law; except to the extent that such Losses are within the scope of the indemnification obligation of Provider under Section 9.1;. &#160;The indemnification obligations set forth in this Section 9.2 do not apply to the extent that the Loss arises in whole or in part from the negligence, recklessness or willful misconduct of Provider or any of its Related Persons, or Provider&#8217;s material breach of this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">9.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Intellectual Property Claims</b>. Client shall defend, indemnify and hold Provider and its Related Persons harmless from and against Losses resulting from Claims to the extent arising out of or related to infringement of any third party Intellectual Property rights in connection with the Services or the Product and where the infringement would not have occurred but for Provider&#8217;s reliance upon Client&#8217;s written requirements, specifications and Client IP. To the extent Claims that are based on Provider IP independent of the Services or Product under this Agreement or Provider&#8217;s breach of this Agreement, Client shall not be required to defend, indemnify, and hold Provider and its Related Persons harmless from those Losses. Provider shall defend, indemnify and hold Client and its Related Persons harmless from and against Losses resulting from Claims to the extent arising out of or related to infringement of any Intellectual Property rights related to the Services and that are based on Provider IP.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">9.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Defense</b>. Each Party shall notify the other Party within [***] upon learning of a Claim that is subject to indemnification pursuant to Sections 9.1, 9.2, or 9.3 (but failure to notify shall not relieve the indemnifying Party of its indemnification obligations unless such failure materially prejudices its ability to defend the claim). The indemnifying Party shall control, [***], the defense of the Claim [***] with counsel of its choice. The indemnified Party shall use [***] to cooperate in the defense at the indemnifying Party&#8217;s request and expense, and may participate in the Claim [***]. No compromise or settlement of any Claim may be made by the indemnifying Party without the indemnified Party&#8217;s written consent; provided that, if a settlement contains an absolute waiver of liability for the indemnified party, and each party has acted in compliance with the requirements of this Section 9.4, then the indemnified party&#8217;s consent will be deemed given.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">9.5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Limitations on Liability</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;text-align:justify;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;text-align:justify;">NEITHER PARTY WILL BE LIABLE UNDER ANY LEGAL THEORY (WHETHER TORT, CONTRACT OR OTHERWISE) FOR SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, HOWEVER CAUSED, EVEN IF THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, EXCEPT AS A RESULT</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">OF A BREACH OF THE CONFIDENTIALITY AND NON-USE OBLIGATIONS, OR FOR GROSS NEGLIGENCE OR WILLFUL MISCONDUCT. NOTHING IN THIS SECTION IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">[***].</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">9.6</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Insurance.</b> Each Party shall ensure that insurance coverage is carried and maintained with a financially sound and reputable insurer against loss from such risks and in such amounts as is sufficient to support its obligations under this Agreement. Each Party shall provide a copy of the applicable insurance policy if requested by the other Party.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">10.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">CONFIDENTIALITY AND PUBLICITY</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">10.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Confidentiality. </b>During the term of this Agreement and for [***] thereafter (other than with respect to trade secrets, which shall remain confidential for so long as they are protected under Applicable Law), the Receiving Party shall, and shall ensure that it, its Affiliates, and its Related Persons will, (a) maintain the Confidential Information of the Disclosing Party in confidence, (b) not use the Confidential Information of the Disclosing Party other than solely in connection with this Agreement and (c) not disclose the Confidential Information of the Disclosing Party to any third party other than (i) those of its Related Persons that have a need to know the Confidential Information in connection with the Services and are obligated to maintain the Confidential Information in confidence on terms at least as strict as those contained herein, and (ii) notify the Disclosing Party of any unauthorized disclosure of its Confidential Information [***] upon becoming aware of such disclosure. Notwithstanding the foregoing, Client may disclose the existence of this Agreement and Confidential Information of Provider confidentially in connection with a potential financing or acquisition or collaboration, provided, however, Client shall be liable for the acts and consequences of such disclosure.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">10.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Return of Confidential Information.</b> Upon termination of this Agreement, and if requested in writing by the Disclosing Party within [***] thereafter, the Receiving Party shall cause all Confidential Information of the Disclosing Party to be [***] destroyed or returned to the Disclosing Party; provided, however, that the Receiving Party may, subject to its obligations of confidentiality hereunder, retain (a) a single secure copy of any Confidential Information for legal archival purposes, and (b) electronic back-up files that have been created by routine archiving and back-up procedures need not be deleted.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">10.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Publicity.</b> Each Party shall not, and shall ensure that its Related Persons will not, use the name, symbols or marks of the other Party or any of its Affiliates in any advertising or</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">publicity material or make any form of representation or statement that would constitute an express or implied endorsement by the other Party or any of its Affiliates of any commercial product or service, without the other Party&#8217;s or Affiliate&#8217;s prior written consent.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">10.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Audits.</b> &#160;Provider and its Affiliates may have in the past provided, and may currently or in the future provide, services to other customers that are similar to the Services. Provider is absolutely committed to protecting Client&#8217;s Confidential Information and Intellectual Property, and shall not use such Confidential Information or Intellectual Property for the benefit of any person other than Client. In order to protect the Confidential Information of Client and the confidential information of other customers, Provider shall use [***] to ensure that other customers do not seek the disclosure of Confidential Information of Client, and Client hereby agrees it shall not seek the disclosure of confidential information of other customers of Provider. Notwithstanding the foregoing, if Client wishes to conduct an audit that relates to services provided to another customer for purposes of confirming that Client&#39;s Intellectual Property is adequately protected, then Provider shall use [***] to seek the other customer&#8217;s approval to waive confidentiality obligations to the extent necessary to allow Client to conduct the audit in a manner that does not involve disclosure of the other customer&#8217;s confidential information to Client. If another customer wishes to conduct an audit that relates to the Services for purposes of confirming that the other customer&#8217;s Intellectual Property is adequately protected, then Client shall discuss whether to waive Provider&#8217;s confidentiality obligations to Client to the extent necessary to allow the other customer to conduct the audit in a manner that does not involve disclosure of Client&#8217;s Confidential Information to the other customer. Such audits may involve an independent auditor designated by Provider and paid for by the person seeking the audit.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">11.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">TERM AND TERMINATION</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">11.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Agreement. </b>The term of this Agreement commences on the Effective Date and, unless earlier terminated pursuant to this Section 11, will expire on the later of (a) five (5) years from the Effective Date; or (b) the completion of Services under all Work Orders executed by the parties prior to the fifth anniversary of the Effective Date. The term of this Agreement may be extended by Client continuously for additional [***] periods upon written notice to Provider at least [***] prior to the expiration of the then-current term.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">11.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Client will have the right, in its sole discretion, to terminate this Agreement or Work Order (a) upon thirty (30) days&#8217; prior written notice to Provider; or (b) immediately upon written notice if Provider fails to obtain or maintain any material governmental licenses or approvals required in connection with the Services. Client shall pay off Provider for the Services rendered and the non-cancellable obligations occurred prior to the termination date; provided that Provider will use [***] to mitigate such non-cancellable obligations if applicable.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">11.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Work Orders. </b>Work Orders are subject to the terms of this Agreement and are not affected by the termination of this Agreement unless such Work Order is terminated together with the Agreement. The term of each Work Order commences on the date indicated in the Work Order and will, unless terminated earlier in accordance with this Agreement, terminate upon completion of the Services. Notwithstanding the foregoing, either Party may terminate a Work Order:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="white-space:pre-wrap;">at any time with six (6) months&#8217; advance notice to the other Party, provided, however,  Provider shall provide sufficient evidence to prove that there is reasonable cause to terminate the Work Order and discuss with Client [***] prior to the termination; provided further, if Provider terminates a Work Order pursuant to this clause 11.3(a), then no termination or cancellation fees shall be paid by Client, Provider shall continue to provide Services for the irrelative Work Orders; or</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>immediately upon notice to the other Party if</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font>a material breach of the Work Order by the other Party remains uncured thirty (30) days after notice of the material breach was received by such other Party; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</font></font>the other party files a petition in bankruptcy, or enters into an agreement with its creditors, or applies for or consents to the appointment of a receiver or trustee, or makes an assignment for the benefit of creditors, or becomes subject to involuntary proceedings under any bankruptcy or insolvency law (which proceedings remain undismissed for [***]); or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</font></font>a Force Majeure Event occurs that will, or continues to, prevent performance (in whole or substantial part) of this Agreement or any pending Work Order by the other party for a period of at least ninety (90) days. In the case of a Force Majeure Event relating solely to a pending Work Order, the right to terminate will be limited to such Work Order.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">11.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Survival. </b>Upon termination of this Agreement or a Work Order, all outstanding rights and obligations between the Parties arising out of or in connection with this Agreement or the Work Order, as the case may be, will [***] terminate, other than any obligations that (a) matured prior to the effective date of the termination or (b) by its nature are intended to survive, including Sections 2.1, 4.2, 4.3, 4.6, 6.1, 6.2, 11.4, 11.5 and Articles 1, 7-10, 12 and 14. Provider will, upon receipt of a termination notice from Client, [***] cease performance of the applicable Services and will take all reasonable steps to mitigate the out-of-pocket expenses incurred in connection therewith. Within [***] after the close-out of a Work Order, Provider will provide to Client a written itemized statement of all work performed by it in connection with the terminated Work Order, an itemized breakdown of the payments associated with that work, and a final invoice for that Work Order. If Client has</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">pre-paid to Provider more than the amount in a final invoice then Provider agrees to [***] refund that money to Client, or to credit the excess payment toward another existing or future Work Order, at the election of Client.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:14.4pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">11.5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Termination Fee.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">If a Work Order is terminated early by Client under Section 11. 2 or 11.3, then Client shall pay Provider for the Services rendered in accordance with the terms of this Agreement and all non-cancelable obligations in connection with the Services to the extent specified in the applicable Work Order; provided that Provider will use [***] to mitigate such non-cancellable obligations.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">If non-manufacturing Services, as specified in the applicable Work Order, are terminated by Provider due to Client&#8217;s material breach pursuant to Section 11.3(b), then Provider may charge Client a termination fee equal to [***] of the remaining value of such non-manufacturing Services within the Work Order as liquidated damages in connection with the redeployment of reserved Personnel and administrative overhead and costs.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">If manufacturing Services are terminated by Provider due to Client&#8217;s material uncured breach or at Client&#8217;s request, Client may be charged cancellation fees as specified in Section 12<i style="font-style:italic;">; </i>If manufacturing Services (manufacturing run(s) including non-GMP manufacturing, GMP manufacturing, and engineering run) are terminated by Provider due to a Client request to cancel or due to a termination of the applicable Work Order by Provider because of Client&#8217;s uncured material breach pursuant to Section 11.3(b), Client shall be charged cancellation fees as specified in Section 12 below. If Client requests to 1) postpone or reschedule, or 2) materially change the production scale or batch size of, a manufacturing run originally scheduled under an executed Work Order or Change Order and/or this Agreement, the same cancellation terms in Section 12 will apply,<i style="font-style:italic;"> provided that no cancellation fees will be charged in where such termination results from Provider&#8217;s breach of this Agreement, or its negligence or willful misconduct</i>.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">12.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">CANCELLATION TERMS FOR MANUFACTURING SERVICES</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">12.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Cancellation of non-GMP Drug Substance Manufacturing. </b>If a notice to cancel a non-GMP drug substance manufacturing batch in an executed Work Order and/or this Agreement is received, Provider will make [***] to find an alternative customer or project to fill the manufacturing slot. In the case where no alternative customer or project can be identified to fill the slot(s), charges for cancelling the related work under this Agreement (<b style="font-weight:bold;">&#8220;Cancellation Charge(s)&#8221;</b>) will be applied based on the following:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 28.95pt;"><font style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">[***] except the cost of raw materials purchased by Provider under the applicable Work Order for such non-GMP batch, if the cancellation notice is received [***] before the scheduled vial thaw;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">[***] of a non-GMP manufacturing batch fee plus the cost of raw materials purchased by Provider under the applicable Work Order for such non-GMP batch, if the cancellation notice is received [***] before the scheduled vial thaw;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">[***] of a non-GMP manufacturing batch fee plus the cost of raw materials purchased by Provider under the applicable Work Order for such non-GMP batch, if the cancellation notice is received [***] before the scheduled vial thaw;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">[***] of a non-GMP manufacturing batch fee plus the cost of raw materials purchased by Provider under the applicable Work Order for such non-GMP batch, if the cancellation notice is received [***] prior to the scheduled vial thaw.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">e)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">[***] of a non-GMP manufacturing batch fee plus the cost of raw materials purchased by Provider under the applicable Work Order for such non-GMP batch, if the cancellation notice is received [***]; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">f)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">[***] of a non-GMP batch fee plus the cost of raw materials purchased by Provider under the applicable Work Order for such non-GMP batch, if the cancellation notice is received [***].</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">12.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Cancellations for Drug Substance cGMP Manufacturing Run or Engineering Run. </b>If a notice to cancel a drug substance cGMP manufacturing run or an engineering run in an executed Work Order and/or this Agreement (as the case may be) is received, Provider will use [***] to find an alternative customer or project (but excluding any project under existing contract with Provider) for the manufacturing slot. In the case where no alterative customer or project can be identified to fill the slot(s), Cancellation Charge(s) will be applied based on the following:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">[***] except the cost of raw materials purchased by Provider under the applicable Work Order for purposes of such cGMP manufacturing run or engineering run, if the cancellation notice is received [***] before the scheduled vial thaw;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">[***] of the cGMP manufacturing run or engineering run batch fee plus the cost of raw materials purchased by Provider under the applicable Work Order for purposes of such cGMP manufacturing run or engineering run, if the cancellation notice is received [***] before the scheduled vial thaw;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">[***] of the cGMP manufacturing run or engineering run batch fee plus the cost of raw materials purchased by Provider under the applicable Work Order for purposes of such cGMP manufacturing run or engineering run, if the cancellation notice is received [***] before the scheduled vial thaw or anytime thereafter.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.04pt 28.95pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">12.3</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Cancellation for Drug Product cGMP Manufacturing Run or Engineering Run. </b>If a notice to cancel a cGMP drug product manufacturing run or an engineering run in an executed Work Order and/or this Agreement (as the case may be) is received, Provider will use [***] to find an alternative customer or project but excluding any project under existing contract with Provider) to fill the manufacturing slot(s). In the case where no alternative customer or project can be identified to fill the slot(s), Cancellation Charge(s) will be applied based on the following:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">[***], except the cost of raw materials purchased by Provider under the applicable Work Order for purposes of such cGMP manufacturing run or engineering run, if the cancellation notice is received [***] before the scheduled manufacturing run;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">[***] of the cGMP manufacturing run or engineering run batch fee plus the cost of raw materials purchased by Provider under the applicable Work Order for purposes of such cGMP manufacturing run or engineering run, if the cancellation notice is received [***] before the scheduled manufacturing run;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">[***] of the cGMP manufacturing run or engineering run batch fee plus the cost of raw materials purchased by Provider under the applicable Work Order for purposes of such cGMP manufacturing run or engineering run, if the cancellation notice is received [***] before the scheduled manufacturing run or anytime thereafter.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">13.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">SHIPPING</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">13.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">All materials to be provided by Provider to Client will be delivered FCA (carrier named by Client) (Incoterms 2020), including Product and other deliverables produced under a Work Order, returned Client Materials, returned Records and returned Confidential Information. For the avoidance of doubt, FCA (carrier named by Client) means Provider is responsible for handing over the materials, cleared for export, to a carrier named by Client. Client assumes risk at hand over and pays all costs as specified in Incoterms 2020.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">13.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">All materials to be provided by Client to Provider will be delivered DDP (site designated by Provider) (Incoterms 2020), including Client Materials. For the avoidance of doubt, DDP (site designated by Provider) means Client is responsible for delivery to and unloading at the site designated by Provider and pays all costs including import duties and taxes.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">14.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">MISCELLANEOUS</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">14.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Force Majeure. </b>&#8220;<b style="font-weight:bold;">Force Majeure</b>&#8221; means and includes such circumstances or occurrences which are beyond the reasonable control of the Party that materially prevent such Party from performing any of such Party&#8217;s obligations under this Agreement (other than the payment of money), and that are not caused by the Party&#8217;s</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">negligence, which may include, but not limited to, acts of God; pandemic(such as Covid-19), strikes and labour problems affecting an entire industry or region; lightning, fire, flood, washout, storm, or other actions of the elements; government actions, including embargos, sanctions, prohibitions; and war, civil disturbances or other imposition of sanctions by a governmental authority with jurisdiction over a Party. Neither Party shall be liable for non-fulfilment of its obligations or in breach under this Agreement if such non-fulfilment is due to Force Majeure for the duration of such Force Majeure. Each Party shall use [***] to mitigate adverse consequences in the event of such Force Majeure. &#160;A Party that is prevented from performing any of its obligations due to Force Majeure will [***] give notice to the other Party of the event and the obligations as to which performance is prevented or delayed. &#160;If a Force Majeure situation continues for more than [***], the unaffected Party may terminate any affected Work Order upon notice to the affected Party, without penalty or liability (including without limitation penalties described in Section 12).</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">14.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Assignment; Novation. </b>This Agreement may not be assigned by a Party without the prior written consent of the other Party; provided, however, that (i) a Party may assign this Agreement to any of its Affiliates with net worth or insurance commensurate with such Party&#8217;s obligations and sufficient capacity and personnel, without such consent, but with notice to the other Party; and (ii) Client may, without Provider&#8217;s consent, assign this Agreement (a) to a third party in connection with the transfer or sale of all or substantially all of its assets or the line of business or Product to which this Agreement relates; (b) to a successor entity or acquirer in the event of a merger, consolidation or change of control. Any purported assignment in violation of this Section is void. This Agreement binds the Parties&#8217; successors and assigns. &#160;Notwithstanding anything to the contrary in this Agreement, upon written notice from Client that Client has executed an exclusive license as to all or substantially all of the Client&#8217;s assets or Product to which one or more Work Orders relates, Provider shall, and hereby does (and Client, by providing such notice, also shall, and hereby does): (i) novate this Agreement and the applicable Work Orders to the Client&#8217;s exclusive licensee, on a form of novation agreement provided by Client and reasonably accepted by Provider (which acceptance shall not be unreasonably withheld, conditioned, or delayed) at the time of such novation; and (ii) enter into a new agreement that is an exact copy of this Agreement and includes only those Work Orders that are not subject to the novation in clause (i).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">14.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Notices.</b> All notices, requests, demands and other formal or legal communications required under this Agreement must be in writing and will be deemed to have been given or made and sufficient in all respects when delivered by reputable international courier to the following addresses:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36.5pt;text-align:justify;text-indent:-36.5pt;margin:0pt 0pt 0.25pt 28.19pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="padding-left:54pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.25pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.25pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.25pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.25pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:30.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:88.55pt;"><td style="vertical-align:top;width:69.59%;border-bottom:1px solid #d9d9d9;border-left:1px solid #f2f2f2;border-right:1px solid #f2f2f2;border-top:1px solid #d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">To Client:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.25pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.25pt;">Jade BioSciences, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.25pt;">221 Crescent Street, Building 23, Suite 105, Waltham, MA</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">02453</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.25pt;">Attn: [***]</p></td><td style="vertical-align:top;width:30.4%;border-bottom:1px solid #d9d9d9;border-left:1px solid #f2f2f2;border-right:1px solid #d9d9d9;border-top:1px solid #d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:29.75pt;"><td style="vertical-align:top;width:69.59%;border-bottom:1px solid #d9d9d9;border-left:1px solid #f2f2f2;border-right:1px solid #f2f2f2;border-top:1px solid #d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.25pt;">Email: [***]</p></td><td style="vertical-align:top;width:30.4%;border-bottom:1px solid #d9d9d9;border-left:1px solid #f2f2f2;border-right:1px solid #d9d9d9;border-top:1px solid #d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:111.55pt;"><td style="vertical-align:top;width:69.59%;border-bottom:1px solid #d9d9d9;border-left:1px solid #f2f2f2;border-right:1px solid #f2f2f2;border-top:1px solid #d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.25pt;"><font style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">To Provider:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36.25pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.25pt;">WuXi Biologics (Shanghai) Co., Ltd.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.25pt;">Area 301-A, Building No.2, 299 Fute Zhong Road</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.25pt;">China (Shanghai) Pilot Free Trade Zone</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.25pt;">Shanghai, China 200131</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.25pt;">Attn: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.25pt;">Email: [***] </p></td><td style="vertical-align:top;width:30.4%;border-bottom:1px solid #d9d9d9;border-left:1px solid #f2f2f2;border-right:1px solid #d9d9d9;border-top:1px solid #d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 28.95pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">14.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Independent Contractor.</b> The Parties are independent contractors, and nothing contained in this Agreement may be deemed or construed to create a partnership, joint venture, employment, franchise, agency, fiduciary or other relationship between the Parties.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">14.5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Non-Solicitation.</b> During the term of this Agreement and for [***] thereafter, Client shall not directly or indirectly induce or solicit (or authorize or assist in the taking of any such actions by any third party) any employee or consultant of Provider or any of its Affiliates that have provided Services under this Agreement to leave his or her employment or business association. Hiring advertisements and efforts not directed at a particular individual do not constitute a solicitation in violation of this Section 14.5.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">14.6</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Governing Law.</b> The laws of the State of New York, USA, without regard to any choice of law principle that would require the application of the law of another jurisdiction, govern all matters relating to this Agreement and the enforcement thereof. The parties expressly reject any application to this Agreement of (a) the United Nations Convention on Contracts for the International Sale of Goods; and (b) the 1974 Convention on the Limitation Period in the International Sale of Goods, as amended by that certain Protocol, done at Vienna on April 11, 1980.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">14.7</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Arbitration. </b>The Parties shall engage in [***] consultation to resolve any dispute arising out of or in connection with this Agreement. Such consultation will begin [***] after one Party has delivered to the other Party a request for consultation. If the dispute cannot</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">be resolved within [***] following the date on which the request for consultation is delivered, then either Party may submit the dispute to the JAMS International Arbitration Rules (&#8220;<b style="font-weight:bold;">Arbitration</b>&#8221;). The Arbitration tribunal will consist of three arbitrators. Within [***] after the commencement of the Arbitration, each Party shall select one person to act as arbitrator, each of whom must be a practicing or retired attorney or judge having at least [***] of litigation experience within the biopharmaceutical industry. &#160;The two arbitrators so selected shall select the chair within [***] of the commencement of the Arbitration, whom must a practicing or retired attorney or judge having at least [***] of litigation experience within the biopharmaceutical industry. If the arbitrators selected by the Parties are unable or fail to agree upon the third arbitrator within the allotted time, the third arbitrator shall be appointed by JAMS in accordance with the JAMS International Arbitration Rules. All arbitrators shall serve as neutral, independent and impartial arbitrators. The Arbitration shall be conducted in accordance with the expedited procedures set forth in the JAMS International Arbitration Rules. The place of arbitration will be New York City. The official language of the arbitration will be English. The arbitration proceedings will be confidential, and the arbitrator may issue appropriate protective orders to safeguard each Party&#8217;s Confidential Information. During the course of arbitration, the Parties shall continue to implement the terms of this Agreement including all Work Orders then in effect. The arbitral award will be final and binding upon the Parties, and the Party to the award may apply to a court of competent jurisdiction for enforcement of the award. Notwithstanding the foregoing, each Party has the right to institute an action in a court of proper jurisdiction for injunctive or other equitable relief pending a final decision by the arbitrator.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">14.8</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Entire Agreement; Non-Reliance. </b>This Agreement, together with each Work Order, contains the entire agreement between the Parties with respect to the subject matter of this Agreement. Prior agreements are hereby superseded. For the avoidance of doubt, prior confidentiality obligations are superseded to the extent that they cover Confidential Information. Each Party disclaims that it is relying on any representations or warranties other than those set forth in this Agreement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">14.9</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Amendment.</b> No modification or waiver of any term of this Agreement or any other form of amendment to this Agreement will be binding unless made expressly in writing and signed by both Parties.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">14.10</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">No Third Party Beneficiaries.</b> The provisions of this Agreement are for the sole benefit of the Parties.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">14.11</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Waiver. </b>The waiver by either Party of any breach of any term of this Agreement will not constitute a waiver of any other breach of the same or any other term. Failure or delay on the part of either Party to fully exercise any right under this Agreement will not constitute a waiver or otherwise affect in any way the same or any other right.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">14.12</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Severability.</b> If any provision in this Agreement is held to be invalid, illegal or unenforceable in any respect, then (a) the provision will be replaced by a valid and enforceable provision that achieves as far as possible the intention of the Parties and (b) all other provisions of this Agreement will remain in full force and effect as if the original agreement had been executed without the invalidated, illegal or unenforceable provision.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">14.13</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Independent Counsel</b><font style="white-space:pre-wrap;">.  Each Party has had the opportunity to consult independent counsel, and as such, this Agreement will not be construed to have been drafted by one Party or the other but will be construed as having been jointly drafted when interpreting its provisions.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">14.14</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Counterparts. </b>This Agreement may be executed in one or more counterparts, each of which will be deemed an original, but all of which together constitute one and the same instrument. Executed counterparts may be exchanged by facsimile or e-mail in PDF or similar electronic format.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[Signature page follows]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.25pt 0.55pt;">Thus, this Agreement was executed on the date stated in the introductory clause.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td colspan="2" style="vertical-align:bottom;width:44.31%;border-bottom:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">WuXi Biologics (Hong Kong) Limited</b></p></td><td style="vertical-align:top;width:3.98%;border-bottom:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:51.7%;border-bottom:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Jade BioSciences, Inc.</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:44.31%;border-left:1px solid #f2f2f2;border-top:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.98%;border-right:1px solid #f2f2f2;border-top:1px solid #f2f2f2;margin:0pt;padding:0pt 5.5pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:51.7%;border-left:1px solid #f2f2f2;border-right:1px solid #f2f2f2;border-top:1px solid #f2f2f2;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:44.31%;border-left:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.98%;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt 5.5pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:51.7%;border-left:1px solid #f2f2f2;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:44.31%;border-left:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.98%;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt 5.5pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:51.7%;border-left:1px solid #f2f2f2;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.8%;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:bottom;width:39.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Chris Chen</p></td><td style="vertical-align:top;width:3.98%;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt 5.5pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.8%;border-left:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:bottom;width:46.89%;border-bottom:1px solid #000000;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt 5.5pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Evan Thompson</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:44.31%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Chris Chen</p></td><td style="vertical-align:top;width:3.98%;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt 5.5pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:51.7%;border-left:1px solid #f2f2f2;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Evan Thompson</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:44.31%;border-bottom:1px solid #f2f2f2;border-left:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Director</p></td><td style="vertical-align:top;width:3.98%;border-bottom:1px solid #f2f2f2;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt 5.5pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:51.7%;border-bottom:1px solid #f2f2f2;border-left:1px solid #f2f2f2;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: President</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;padding-left:36.5pt;text-align:justify;text-indent:-36.5pt;margin:0pt 0pt 0.25pt 28.94pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit A&#8212;Form of Work Order</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WORK ORDER (NUMBER [</b><font style="font-family:Times New Roman;">&#9679;</font><b style="font-weight:bold;">])</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This work order is dated [<font style="font-family:Times New Roman;">&#9679;</font>] and is between Jade BioSciences, Inc. &#160;(&#8220;<b style="font-weight:bold;">Client</b>&#8221;) and [WuXi Biologics (Hong Kong) Limited](&#8220;<b style="font-weight:bold;">Provider</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The terms of the Biologics Master Services Agreement between Jade Therapeutics, Inc. and WuXi Biologics (Hong Kong) Limited, dated [<font style="font-family:Times New Roman;">&#9679;</font>] (the &#8220;<b style="font-weight:bold;">Master Services Agreement</b>&#8221;), are hereby incorporated by reference into this Work Order. Any modifications to the Master Services Agreement will be deemed to be references to this Work Order automatically. Each capitalized term used but not defined in this Work Order has the meaning given in the Master Services Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">SERVICES INFORMATION</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Title</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">[Project title]</i></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">[Description of the Services including deliverables and specifications]</i></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;text-align:justify;">1.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Tasks and Timeframe.</b> Provider shall complete the Services in accordance with the following schedule:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36.5pt;text-align:justify;text-indent:-36.5pt;margin:0pt 0pt 0.25pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.92%;"><tr><td style="vertical-align:bottom;width:5%;background:#d9d9d9;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.49%;background:#d9d9d9;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Task</b></p></td><td style="vertical-align:top;width:47.49%;background:#d9d9d9;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Completion Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">1</p></td><td style="vertical-align:bottom;width:47.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">2</p></td><td style="vertical-align:bottom;width:47.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">3</p></td><td style="vertical-align:bottom;width:47.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4</p></td><td style="vertical-align:bottom;width:47.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:22.64pt;margin-top:0pt;"><b style="font-weight:bold;">1.4 </b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:22.64pt;margin-top:0pt;"><b style="font-weight:bold;">Client Materials</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">[Description of the Client Materials to be provided by Client to Provider that are necessary to perform the Services]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.25pt 0pt;">1.4</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Reporting and Transfer of Data and Results</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">[Description of how data and results should be reported and transferred to Client, including electronic protocols for secure transmission of data and instructions for physical handling and shipping of materials if chemicals are being synthesized or other materials are to be transferred to Client]</i></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.6</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Additional Requirements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">[Any additional requirements such as additional obligations of the parties that do not appropriately fit into the task list and special handling of materials]</i></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">FEES; PAYMENT SCHEDULE</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">General Terms.</b> Expenses, milestones, payment and default and other general terms are provided in Section 3 of the Master Services Agreement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Contract Price and Upfront Payment. </b>The Contract Price will be USD [<font style="font-family:Times New Roman;">&#9679;</font>]. On signing of this Work Order, Client shall pay Provider [<font style="font-family:Times New Roman;">&#9679;</font>] % of the Contract Price as a non-refundable upfront payment.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">2.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">Milestones.</b> The table below lists milestones and related information.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36.5pt;text-align:justify;text-indent:-36.5pt;margin:0pt 0pt 0.25pt 28.94pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.92%;"><tr style="height:15pt;"><td style="vertical-align:top;width:5.38%;background:#d9d9d9;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:31.53%;background:#d9d9d9;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Milestone</b></p></td><td style="vertical-align:top;width:31.53%;background:#d9d9d9;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deliverable</b></p></td><td style="vertical-align:top;width:31.54%;background:#d9d9d9;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Milestone Payment</b></p></td></tr><tr style="height:59.1pt;"><td style="vertical-align:top;width:5.38%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1</p></td><td style="vertical-align:top;width:31.53%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">[Description including work required, criteria for achievement and timeline] </i></p></td><td style="vertical-align:top;width:31.53%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[<font style="font-family:Times New Roman;">&#9679;</font>] </p></td><td style="vertical-align:top;width:31.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[<font style="font-family:Times New Roman;">&#9679;</font>] </p></td></tr><tr style="height:15.35pt;"><td style="vertical-align:top;width:5.38%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></td><td style="vertical-align:top;width:31.53%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[<font style="font-family:Times New Roman;">&#9679;</font>]</p></td><td style="vertical-align:top;width:31.53%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[<font style="font-family:Times New Roman;">&#9679;</font>] </p></td><td style="vertical-align:top;width:31.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[<font style="font-family:Times New Roman;">&#9679;</font>] </p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">2.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Payment Instructions. </b>Unless an invoice provides otherwise, Client shall pay the invoice in USD by wire transfer to the account listed below (as may be amended from time to time):</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36.5pt;text-align:justify;text-indent:-36.5pt;margin:0pt 0pt 0.25pt 28.94pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.85%;"><tr style="height:12.85pt;"><td style="vertical-align:top;width:25.27%;background:#d9d9d9;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 5.25pt 0pt 5.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">[***]</p></td><td style="vertical-align:top;width:74.72%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 5.25pt 0pt 5.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">[***]</p></td></tr><tr style="height:12.95pt;"><td style="vertical-align:top;width:25.27%;background:#d9d9d9;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 5.25pt 0pt 5.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">[***]</p></td><td style="vertical-align:top;width:74.72%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 5.25pt 0pt 5.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">[***]</p></td></tr><tr style="height:24.95pt;"><td style="vertical-align:top;width:25.27%;background:#d9d9d9;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 5.25pt 0pt 5.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">[***]</p></td><td style="vertical-align:top;width:74.72%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 5.25pt 0pt 5.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">[***]</p></td></tr><tr style="height:13.1pt;"><td style="vertical-align:top;width:25.27%;background:#d9d9d9;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 5.25pt 0pt 5.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">[***]</p></td><td style="vertical-align:top;width:74.72%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 5.25pt 0pt 5.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">[***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.85%;"><tr style="height:25.1pt;"><td style="vertical-align:top;width:25.04%;background:#d9d9d9;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 5.25pt 0pt 5.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">[***]</p></td><td colspan="2" style="vertical-align:top;width:20.64%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 5.25pt 0pt 5.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">[***]</p></td><td colspan="4" style="vertical-align:top;width:25.83%;background:#d9d9d9;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 5.25pt 0pt 5.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:28.47%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 5.25pt 0pt 5.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.35pt;">[***]</p></td></tr><tr style="height:24.85pt;"><td style="vertical-align:top;width:25.04%;background:#d9d9d9;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 5.25pt 0pt 5.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">[***]</p></td><td style="vertical-align:top;width:7.73%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 5.25pt 0pt 5.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">[***]</p></td><td colspan="2" style="vertical-align:top;width:13.76%;background:#d9d9d9;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 5.25pt 0pt 5.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:9.13%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 5.25pt 0pt 5.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.35pt;">[***]</p></td><td style="vertical-align:top;width:14.26%;background:#d9d9d9;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 5.25pt 0pt 5.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td colspan="2" style="vertical-align:top;width:30.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 5.25pt 0pt 5.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.1pt;">[***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">COMMUNICATIONS</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">3.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">Technical Communications. </b>All technical communications required under this Work Order are to be sent via reputable international courier or email and addressed as follows:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36.5pt;text-align:justify;text-indent:-36.5pt;margin:0pt 0pt 0.25pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.92%;"><tr><td colspan="2" style="vertical-align:bottom;width:50%;border-left:1px solid #f2f2f2;border-right:1px solid #f2f2f2;border-top:1px solid #f2f2f2;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">If to Client:</b></p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-left:1px solid #f2f2f2;border-top:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">If to Provider:</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;border-left:1px solid #f2f2f2;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-left:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;border-left:1px solid #f2f2f2;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[<font style="font-family:Times New Roman;">&#9679;</font>]</p></td><td colspan="2" style="vertical-align:top;width:50%;border-left:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[<font style="font-family:Times New Roman;">&#9679;</font>]</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;border-left:1px solid #f2f2f2;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[<font style="font-family:Times New Roman;">&#9679;</font>]</p></td><td colspan="2" style="vertical-align:top;width:50%;border-left:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[<font style="font-family:Times New Roman;">&#9679;</font>]</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;border-left:1px solid #f2f2f2;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[<font style="font-family:Times New Roman;">&#9679;</font>]</p></td><td colspan="2" style="vertical-align:top;width:50%;border-left:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[<font style="font-family:Times New Roman;">&#9679;</font>]</p></td></tr><tr><td style="vertical-align:bottom;width:8.85%;border-left:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attn:</p></td><td style="vertical-align:bottom;width:41.14%;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[<font style="font-family:Times New Roman;">&#9679;</font>]</p></td><td style="vertical-align:bottom;width:8.86%;border-left:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attn:</p></td><td style="vertical-align:bottom;width:41.13%;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[<font style="font-family:Times New Roman;">&#9679;</font>]</p></td></tr><tr><td style="vertical-align:bottom;width:8.85%;border-left:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tel.:</p></td><td style="vertical-align:bottom;width:41.14%;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[<font style="font-family:Times New Roman;">&#9679;</font>]</p></td><td style="vertical-align:bottom;width:8.86%;border-left:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tel.:</p></td><td style="vertical-align:bottom;width:41.13%;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[<font style="font-family:Times New Roman;">&#9679;</font>]</p></td></tr><tr><td style="vertical-align:bottom;width:8.85%;border-bottom:1px solid #f2f2f2;border-left:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email:</p></td><td style="vertical-align:bottom;width:41.14%;border-bottom:1px solid #f2f2f2;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[<font style="font-family:Times New Roman;">&#9679;</font>]</p></td><td style="vertical-align:bottom;width:8.86%;border-bottom:1px solid #f2f2f2;border-left:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email:</p></td><td style="vertical-align:bottom;width:41.13%;border-bottom:1px solid #f2f2f2;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[<font style="font-family:Times New Roman;">&#9679;</font>]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Thus, this Work Order is executed on the date stated in the introductory clause.</p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.92%;"><tr><td colspan="2" style="vertical-align:bottom;width:47.81%;border-left:1px solid #f2f2f2;border-top:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Jade BioSciences, Inc.</b></p></td><td style="vertical-align:top;width:2.37%;border-right:1px solid #f2f2f2;border-top:1px solid #f2f2f2;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:49.81%;border-left:1px solid #f2f2f2;border-top:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">WuXi Biologics (Hong Kong) Limited</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:47.81%;border-left:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.37%;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.81%;border-left:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:47.81%;border-left:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.37%;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49.81%;border-left:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:47.81%;border-left:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.37%;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49.81%;border-left:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:47.81%;border-left:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.37%;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49.81%;border-left:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:38.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.37%;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.19%;border-left:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:40.61%;border-bottom:1px solid #000000;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:38.93%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.37%;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.19%;border-left:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40.61%;border-right:1px solid #f2f2f2;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:8.87%;border-bottom:1px solid #f2f2f2;border-left:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:38.93%;border-bottom:1px solid #f2f2f2;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.37%;border-bottom:1px solid #f2f2f2;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.19%;border-bottom:1px solid #f2f2f2;border-left:1px solid #f2f2f2;margin:0pt;padding:0pt 5.75pt 0pt 5.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40.61%;border-bottom:1px solid #f2f2f2;border-right:1px solid #f2f2f2;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit B&#8212;Manufacturing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Exhibit C:  Affiliates of Provider</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[***]</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>14
<FILENAME>avte-20240930xex10d19.htm
<DESCRIPTION>EXHIBIT 10.19
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 12/3/2024 12:42:11 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.19</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><i style="font-style:italic;">Confidential</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Execution Copy</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">LICENSE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">This License Agreement</b> (&#8220;<b style="font-weight:bold;">Agreement</b>&#8221;) is entered into and effective as of October 30, 2024 (the &#8220;<b style="font-weight:bold;">Effective Date</b>&#8221;), by and between Paragon Therapeutics, Inc., a Delaware corporation (&#8220;<b style="font-weight:bold;">Paragon</b>&#8221;), and Jade Biosciences, Inc., a Delaware corporation (&#8220;<b style="font-weight:bold;">Jade</b>&#8221;). &#160;Paragon and Jade are also referred to herein individually as a &#8220;<b style="font-weight:bold;">Party</b>,&#8221; or collectively as the &#8220;<b style="font-weight:bold;">Parties</b>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Recitals</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Whereas</b><font style="font-variant:small-caps;">,</font> Paragon has developed a proprietary platform technology for the discovery and development of antibodies against therapeutically relevant targets;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Whereas</b><font style="font-variant:small-caps;">,</font> pursuant to that certain Antibody Discovery and Option Agreement, dated as of July 24, 2024, by and among Paragon, Parade Biosciences Holding, LLC, and Jade, as amended by Amendment No. 1, dated as of September 27, 2024 (as such agreement may be further amended from time to time, the &#8220;<b style="font-weight:bold;">Option Agreement</b>&#8221;), Jade has engaged Paragon to identify, evaluate and develop one or more antibody candidates directed to certain therapeutic targets and has been granted an exclusive option to enter into one or more separate license agreements to develop, manufacture and commercialize the resulting antibodies with respect to a given target;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Whereas</b>, Jade has exercised such option with respect to the Licensed Target (as defined below), and the Parties desire to memorialize the exclusive license from Paragon to Jade with respect to such Licensed Target, all on the terms and subject to the conditions set forth in this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Now Therefore, </b>in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article&#160;I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DEFINITIONS.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following initially capitalized terms have the following meanings (and derivative forms of them shall be interpreted accordingly):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.1</font></font>&#8220;<b style="font-weight:bold;">Achievement of Development Candidate</b>&#8221; means the first to occur of: (a) nomination by Jade&#8217;s Board of Directors of a Licensed Antibody, Derived Antibody or Jade Multispecific Antibody as a &#8220;Development Candidate&#8221;; and (b) the initiation by or on behalf of Jade or its Affiliate or Sublicensee of a toxicology study with respect to a Licensed Antibody, Derived Antibody or Jade Multispecific Antibody that employs applicable then-current good laboratory practice standards, the results of which are intended to be submitted as part of an IND.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.2</font></font>&#8220;<b style="font-weight:bold;">Acquired Program</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.10(c)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.3</font></font>&#8220;<b style="font-weight:bold;">Acquiring Entity</b>&#8221; means, collectively, the Third Party referenced in the definition of Change of Control and such Third Party&#8217;s Affiliates, other than (a)&#160;the applicable Party in the definition of Change of Control, and (b)&#160;such Party&#8217;s Affiliates, determined immediately prior to the closing of such Change of Control ((a) and (b) collectively, the &#8220;<b style="font-weight:bold;">Pre-Existing Entities</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.4</font></font>&#8220;<b style="font-weight:bold;">Affiliate</b>&#8221; means any entity controlled by, controlling, or under common control with a Party hereto. &#160;For the purpose of this definition, &#8220;control&#8221; (including, with correlative meaning, the terms &#8220;controlled by&#8221; or &#8220;under common control&#8221;) means the direct or indirect ownership of more than fifty percent (50%) of the voting interest in, or more than fifty percent (50%) in the equity of, or the right to appoint more than fifty percent (50%) of the directors or management of, such corporation or other business entity. &#160;Notwithstanding the foregoing, (a) with respect to either Party, Affiliates of such Party do not include [***] or its Affiliates other than such Party and its subsidiaries, (b) Paragon and its Affiliates, on the one hand, and Jade and its subsidiaries, on the other hand, shall not be deemed to be Affiliates of each other, and (c) Affiliates of Paragon do not include new entities formed by or on behalf of Paragon for the sole <i style="font-style:italic;">bona fide</i> purpose of further developing, manufacturing, commercializing or otherwise exploiting Antibodies and Antibody products (excluding any Licensed Antibody Technology or Other Licensed Patents) using, among other sources, funds from Third Party investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.5</font></font>&#8220;<b style="font-weight:bold;">Agreement</b>&#8221; has the meaning set forth in the preamble.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.6</font></font>&#8220;[***]&#8221; means [***], a Delaware limited liability company with offices located at [***], or any permitted assignee of [***] under the terms of the [***] License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.7</font></font>&#8220;[***] <b style="font-weight:bold;">IP</b>&#8221; means the [***] Licensed Patents and the [***] Licensed Know-How.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.8</font></font>&#8220;[***] <b style="font-weight:bold;">License Agreement</b>&#8221; means that certain License Agreement, dated [***], between Paragon and [***], as amended by First Amendment to License Agreement dated [***], as such agreement may be amended or restated from time to time, subject to the terms of this Agreement. &#160;A copy of the [***] License Agreement as of the Effective Date is attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u>, which shall be updated from time to time in the event of any amendment to or restatement of the [***] License Agreement becoming effective or executed after the Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.9</font></font>&#8220;[***] <b style="font-weight:bold;">Licensed Know-How</b>&#8221; means the Know-How (as defined in the [***] License Agreement) that (a) is licensed by [***] to Paragon under Section 2.1(a)(ii) of the [***] License Agreement, and (b) is reasonably necessary or useful for the Development, Manufacture, Commercialization or other exploitation of the (i) Licensed Antibodies and Derived Antibodies that are &#8220;Partnered Antibodies&#8221; under the [***] License Agreement, and (ii) Products, Multispecific Antibodies and Multispecific Products that contain or comprise Licensed Antibodies and Derived Antibodies described in clause (i) of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 1.9</u>, in each case (i) and (ii) in the Field in the Territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.10</font></font>&#8220;[***] <b style="font-weight:bold;">Licensed Patents</b>&#8221; means the Patent Rights (as defined in the [***] License Agreement) that are (a) licensed by [***] to Paragon under Section 2.1(a)(ii) of the [***] License Agreement, and (b) reasonably necessary or useful for the Development, Manufacture,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Commercialization or other exploitation of the (i) Licensed Antibodies and Derived Antibodies that are &#8220;Partnered Antibodies&#8221; under the [***] License Agreement, and (ii) Products, Multispecific Antibodies and Multispecific Products that contain or comprise Licensed Antibodies and Derived Antibodies described in clause (i) of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.10</u>, in each case (i) and (ii) in the Field in the Territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.11</font></font>&#8220;<b style="font-weight:bold;">Antibody</b>&#8221; means any molecule, including [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.12</font></font>&#8220;<b style="font-weight:bold;">Applicable Law</b>&#8221; means any national, supra-national, federal, state or local laws, rules, guidances and regulations, in each case, as applicable to the subject matter and the Party at issue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.13</font></font>&#8220;<b style="font-weight:bold;">APRIL</b>&#8221; means a proliferation-inducing ligand, also known as tumor necrosis factor ligand superfamily member 13 (TNFSF13).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.14</font></font>&#8220;<b style="font-weight:bold;">Bankruptcy Code</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.4</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.15</font></font>&#8220;<b style="font-weight:bold;">Bankruptcy Event</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.4</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.16</font></font>&#8220;<b style="font-weight:bold;">Business Day</b>&#8221; means any day other than Saturday, Sunday or a national holiday in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.17</font></font>&#8220;<b style="font-weight:bold;">Calendar Quarter</b>&#8221; means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.18</font></font>&#8220;<b style="font-weight:bold;">Calendar Year</b>&#8221; means each successive period of twelve (12) months commencing on January 1 and ending on December 31.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.19</font></font>&#8220;<b style="font-weight:bold;">Change of Control</b>&#8221; means, with respect to any entity, any of the following: (a)&#160;the sale or disposition of all or substantially all of the assets of such entity or its direct or indirect controlling Affiliate to a Third Party; or (b) (i) the acquisition by a Third Party, alone or together with any of its Affiliates, other than an employee benefit plan (or related trust) sponsored or maintained by such entity or any of its Affiliates, of more than fifty percent (50%) of the then-outstanding shares of voting capital stock of such entity or its direct or indirect parent entity that holds, directly or indirectly, beneficial ownership of more than fifty percent (50%) of the then-outstanding shares of voting capital stock of such entity (a &#8220;<b style="font-weight:bold;">Parent Entity</b>&#8221;), or (ii) the acquisition, merger or consolidation of such entity or its Parent Entity with or into another entity, other than, in the case of clause (i) or (ii), an acquisition or a merger or consolidation of such entity or its Parent Entity in which the holders of shares of voting capital stock of such entity or its Parent Entity, as the case may be, immediately prior to such acquisition, merger or consolidation will beneficially own, directly or indirectly, at least fifty percent (50%) of the shares of voting capital stock of the acquiring Third Party or the surviving corporation in such acquisition, merger or consolidation, as the case may be, immediately after such acquisition, merger or consolidation, and in each case of (a) or (b), whether through a single transaction or a series of related transactions, but excluding any and all bona fide financing transactions or internal reorganizations for tax purposes (including the change of place of incorporation or domicile of such entity).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.20</font></font>&#8220;<b style="font-weight:bold;">COC Program</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.10(b)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.21</font></font>&#8220;<b style="font-weight:bold;">Claim</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.3</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.22</font></font>&#8220;<b style="font-weight:bold;">Combination Product</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.68</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.23</font></font>&#8220;<b style="font-weight:bold;">Commercialize</b>&#8221; or &#8220;<b style="font-weight:bold;">Commercializing</b>&#8221; means to market, promote, distribute, offer for sale, sell, have sold, import, have imported, export, have exported or otherwise commercialize an Antibody or product, including any Licensed Antibody, Derived Antibody, Product, Multispecific Antibody or Multispecific Product, as applicable. &#160;When used as a noun, &#8220;<b style="font-weight:bold;">Commercialization</b>&#8221; means any and all activities involved in Commercializing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.24</font></font>&#8220;<b style="font-weight:bold;">Commercially Reasonable Efforts</b>&#8221; means the level of effort and resources commonly applied by a similarly situated biopharmaceutical company to carry out a particular task or obligation with respect to a pharmaceutical or biologic compound, product or therapy owned by it, or to which it has exclusive rights, which is of similar market potential at a similar stage in its development or product life, taking into account issues of safety and efficacy, product profile, the competitiveness of other products in development and in the marketplace, supply chain management considerations, the proprietary position of the compound, product or therapy (including with respect to patent or regulatory exclusivity), the regulatory structure involved, the profitability of the applicable compound, product or therapy (including pricing and reimbursement status achieved), and other relevant technical, legal, scientific or medical factors. &#160;For clarity, the &#8220;<b style="font-weight:bold;">Commercially Reasonable Efforts</b>&#8221; of a Party under this Agreement will be determined on a product-by-product and country-by-country basis within the Territory, and it is anticipated that the level of effort for different indications and countries may differ and may change over time, reflecting changes in the status of the compound, product or therapy and the indications and the country or countries involved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.25</font></font>&#8220;<b style="font-weight:bold;">Confidential Information</b>&#8221; of a Party means any and all non-public scientific, business, regulatory or technical information that is disclosed or made available by or on behalf of one Party (the &#8220;<b style="font-weight:bold;">Disclosing Party</b>&#8221;) to the other Party (the &#8220;<b style="font-weight:bold;">Receiving Party</b>&#8221;) in connection with this Agreement, whether in writing, orally, visually or otherwise. &#160;Notwithstanding any provision of this Agreement to the contrary, all Licensed Antibody Inventions and Licensed Antibody Technology shall be the Confidential Information of Jade; provided that in the event of any termination of this Agreement the Licensed Antibody Inventions and Licensed Antibody Technology shall be the Confidential Information of Paragon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.26</font></font>&#8220;<b style="font-weight:bold;">Control</b>&#8221; (including any variations such as &#8220;<b style="font-weight:bold;">Controlled</b>&#8221;) means, with respect to any technology (including Know-How) or other Intellectual Property Rights, possession by a Party or one of its Affiliates of the ability (whether by ownership, license or otherwise) to grant a license or a sublicense of or under such technology or Intellectual Property Rights without violating the terms of any agreement or other arrangement with any Third Party; <i style="font-style:italic;">provided, that</i> if following the Effective Date (a)&#160;Paragon would Control any Patent that would be included in the Licensed Antibody Patents or Other Licensed Patents but for an obligation to pay royalties or other consideration for the Development, Manufacture, Commercialization or other exploitation of a Jade Product in the Territory in connection with a grant to Jade of a license under such Patent, and (b)&#160;Jade, pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.7</u>, agrees in writing to reimburse Paragon for all such royalties or other consideration, then such Patents shall be deemed Controlled by Paragon. &#160;Notwithstanding the foregoing, a Party and its Affiliates shall not be deemed to &#8220;Control&#8221; any technology or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Intellectual Property Rights that (i) prior to the consummation of a Change of Control of such Party is owned or in-licensed, or (ii)&#160;after the consummation of a Change of Control of such Party, becomes owned or in-licensed (to the extent such technology or Intellectual Property Rights are developed outside of the scope of the activities conducted hereunder and without use of or reference to any technology or Intellectual Property Rights Controlled by such Party or any Affiliate of such Party immediately before such Change of Control, or any Confidential Information of the other Party), in each case ((i) or (ii)), by a Third Party that becomes an Affiliate of such Party after the Effective Date as a result of such Change of Control or an assignee of such Party after the Effective Date as the result of an assignment of this Agreement in connection with a Change of Control unless prior to the consummation of such Change of Control or assignment, such Party or any of its Affiliates also Controlled such technology or Intellectual Property Rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.27</font></font>&#8220;<b style="font-weight:bold;">Cover</b>&#8221; or &#8220;<b style="font-weight:bold;">Covering</b>&#8221; means, with respect to a particular product, any Patent, that, in the absence of a license granted under, or ownership of, such Patent, the making, using, selling, importation, or exportation of such product would infringe a valid and unexpired claim of such Patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.28</font></font>&#8220;<b style="font-weight:bold;">CREATE Act</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.2(f)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.29</font></font>&#8220;<b style="font-weight:bold;">Derived Antibody</b>&#8221; means any Antibody that is created by or on behalf of Jade (but not by Paragon under the Option Agreement), its Affiliates or its or their licensees and: (a) is derived from or constitutes a modification of a Licensed Antibody, including [***], and (b) [***]. &#160;For avoidance of doubt, any Antibody that [***] will be deemed a Derived Antibody, irrespective of origin. &#160;Notwithstanding the foregoing, a Derived Antibody shall not include (i) [***], or (ii) [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.30</font></font>&#8220;<b style="font-weight:bold;">Designated Multispecific Antibody</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5(b)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.31</font></font>&#8220;<b style="font-weight:bold;">Develop</b>&#8221; or &#8220;<b style="font-weight:bold;">Developing</b>&#8221; means to discover, evaluate, test, research or otherwise develop an Antibody or product, including a Licensed Antibody, Derived Antibody, Product, Multispecific Antibody or Multispecific Product, as applicable. &#160;When used as a noun, &#8220;<b style="font-weight:bold;">Development</b>&#8221; means any and all activities involved in Developing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.32</font></font>&#8220;<b style="font-weight:bold;">Directed To</b>&#8221; means, with regard to an Antibody or product, that such Antibody or product is developed or designed to (a) [***], and (b) [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.33</font></font>&#8220;<b style="font-weight:bold;">Disclosing Party</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 1.25</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.34</font></font>&#8220;<b style="font-weight:bold;">Dispute</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.7</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.35</font></font>&#8220;<b style="font-weight:bold;">Dollar</b>&#8221; means a U.S. dollar, and &#8220;$&#8221; shall be interpreted accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.36</font></font>&#8220;<b style="font-weight:bold;">Effective Date</b>&#8221; has the meaning set forth in the preamble.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.37</font></font>&#8220;<b style="font-weight:bold;">Exclusivity Period</b>&#8221; means the period commencing on the Effective Date and continuing until the [***] anniversary of the Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.38</font></font>&#8220;<b style="font-weight:bold;">FDA</b>&#8221; means the United States Food and Drug Administration, or a successor federal agency thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.39</font></font>&#8220;<b style="font-weight:bold;">Field</b>&#8221; means the prophylaxis, palliation, treatment and diagnosis of human disease and disorders in all therapeutic areas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.40</font></font>&#8220;<b style="font-weight:bold;">First Commercial Sale</b>&#8221; means the first sale of a Jade Product by Jade, or one of its Affiliates or its or their Sublicensees, to a Third Party after receipt of all Regulatory Approvals required to market and sell the Jade Product have been obtained in the country in the Territory in which such Jade Product is sold. &#160;Sales for purposes of testing the Jade Product and sample purposes shall not be deemed a First Commercial Sale. &#160;Furthermore, for purposes of clarity, the term &#8220;First Commercial Sale&#8221; as used in this Agreement shall not include: &#160;(a) [***]; (b) [***]; or (c) [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.41</font></font>&#8220;<b style="font-weight:bold;">Force Majeure</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.2</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.42</font></font>&#8220;<b style="font-weight:bold;">IND</b>&#8221; means an investigational new drug application or equivalent application that is required to commence clinical trials for a product in the Territory and filed with the applicable Regulatory Authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.43</font></font>&#8220;<b style="font-weight:bold;">Indemnified Party</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.3</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.44</font></font>&#8220;<b style="font-weight:bold;">Indemnifying Party</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.3</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.45</font></font>&#8220;<b style="font-weight:bold;">Intellectual Property Rights</b>&#8221; means any and all proprietary rights provided under (a) patent law, including any Patents; (b) copyright law; or (c) any other applicable statutory provision or common law principle, including trade secret law, that may provide a right in Know-How, or the expression or use thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.46</font></font>&#8220;<b style="font-weight:bold;">Jade</b>&#8221; has the meaning set forth in the preamble.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.47</font></font>&#8220;<b style="font-weight:bold;">Jade Antibody Patents</b>&#8221; means all Patents that Cover the composition of matter of, or any method of specifically making or using, any Licensed Antibody or Derived Antibody, that in each case are owned or otherwise controlled by Jade or its Affiliates or Sublicensees as of the Effective Date or during the Term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.48</font></font>&#8220;<b style="font-weight:bold;">Jade Indemnitees</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.2</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.49</font></font>&#8220;<b style="font-weight:bold;">Jade Intellectual Property</b>&#8221; means any Patents, Know-How or other Intellectual Property Rights that are (a) necessary for, and actually used (or held for use) by Jade or its Affiliates as of the effective date of termination of this Agreement in the Development, Manufacturing, Commercialization or other exploitation of Jade Products, and (b) Controlled by Jade or its Affiliates as of the effective date of termination of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.50</font></font>&#8220;<b style="font-weight:bold;">Jade Multispecific Antibody</b>&#8221; means any Multispecific Antibody that is being Developed, Manufactured, Commercialized or otherwise exploited by Jade, its Affiliate or Sublicensee, excluding in each case, and subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.6</u>, any Paragon Multispecific Antibody.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.51</font></font>&#8220;<b style="font-weight:bold;">Jade Multispecific Product</b>&#8221; means any product that comprises or contains any Jade Multispecific Antibody.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.52</font></font>&#8220;<b style="font-weight:bold;">Jade Product</b>&#8221; means, individually or collectively, as applicable, Licensed Antibodies, Derived Antibodies, Products, Jade Multispecific Antibodies and Jade Multispecific Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.53</font></font>&#8220;<b style="font-weight:bold;">Know-How</b>&#8221; means all technical information and know-how in any tangible or intangible form, including (a) inventions, discoveries, trade secrets, data, specifications, instructions, processes, formulae, materials (including cell lines, vectors, plasmids, nucleic acids and the like), methods, protocols, expertise and any other technology, including the applicability of any of the foregoing to formulations, compositions or products or to their manufacture, development, registration, use or marketing or to methods of assaying or testing them or processes for their manufacture, formulations containing them or compositions incorporating or comprising them, and (b) all data, instructions, processes, formulae, strategies, and expertise, whether biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical, analytical, or otherwise and whether related to safety, quality control, manufacturing or other disciplines. &#160;Notwithstanding the foregoing, Know-How excludes Patent claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.54</font></font>&#8220;<b style="font-weight:bold;">Licensed Antibody</b>&#8221; means any and all Antibodies that are Directed To the Licensed Target and that are discovered, generated, identified or characterized by or on behalf of Paragon in the course of performing the Research Program, including [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.55</font></font>&#8220;<b style="font-weight:bold;">Licensed Antibody Invention</b>&#8221; means (a) any invention or discovery, whether or not patentable, that was discovered or reduced to practice by or on behalf of Paragon under the Research Program and that constitutes the composition of matter of, or any method of specifically making or using, any Licensed Antibody, and (b) all Intellectual Property Rights in the foregoing, that in each case is Controlled by Paragon or its Affiliates as of the Effective Date or during the Term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.56</font></font>&#8220;<b style="font-weight:bold;">Licensed Antibody Patents</b>&#8221; means all Patents that Cover the composition of matter of, or any method of specifically making or using, any Licensed Antibody, that in each case are Controlled by Paragon or its Affiliates as of the Effective Date or during the Term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.57</font></font>&#8220;<b style="font-weight:bold;">Licensed Antibody Technology</b>&#8221; means (a) the Licensed Antibody Invention, (b)&#160;the Licensed Antibody Patents, (c)&#160;the Sequence Information, (d)&#160;the Results, and (e)&#160;all Intellectual Property Rights in the foregoing Controlled by Paragon or its Affiliates as of the Effective Date or during the Term. &#160;For clarity, the Licensed Antibody Technology shall exclude [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.58</font></font>&#8220;<b style="font-weight:bold;">Licensed Component(s)</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.68</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.59</font></font>&#8220;<b style="font-weight:bold;">Licensed Target</b>&#8221; means APRIL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.60</font></font>&#8220;<b style="font-weight:bold;">Losses</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.61</font></font>&#8220;<b style="font-weight:bold;">MAA</b>&#8221; means (a) a New Drug Application in the United States, as defined in the United States Federal Food, Drug and Cosmetics Act, and applicable regulations promulgated</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">thereunder by the FDA, (b) a Biologics License Application in the United States, as defined in the United States Public Health Service Act, or (c) any application filed with any Regulatory Authority in a country other than the United States that is equivalent to either of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.62</font></font>&#8220;<b style="font-weight:bold;">Major Market Country</b>&#8221; means any of the following: [***], [***], [***], [***], [***] and [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.63</font></font>&#8220;<b style="font-weight:bold;">Manufacture</b>&#8221; or &#8220;<b style="font-weight:bold;">Manufacturing</b>&#8221; means to make, produce, manufacture, process, fill, finish, package, label, perform quality assurance testing, release, ship or store an Antibody or product, including any Licensed Antibody, Derived Antibody, Product, Multispecific Antibody or Multispecific Product, as applicable, or any component thereof. &#160;When used as a noun, &#8220;Manufacture&#8221; or &#8220;Manufacturing&#8221; means any and all activities involved in Manufacturing an Antibody or product, including any Licensed Antibody, Derived Antibody, Product, Multispecific Antibody or Multispecific Product, as applicable, or any component thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.64</font></font>&#8220;<b style="font-weight:bold;">Milestone</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.1</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.65</font></font>&#8220;<b style="font-weight:bold;">Milestone Payment</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.1</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.66</font></font>&#8220;<b style="font-weight:bold;">Multispecific Antibody</b>&#8221; means any Antibody that is comprised of (a) [***], and (b) [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.67</font></font>&#8220;<b style="font-weight:bold;">Multispecific Product</b>&#8221; means any product that comprises or contains any Multispecific Antibody.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.68</font></font>&#8220;<b style="font-weight:bold;">Net Sales</b>&#8221; means the gross amounts received for the Jade Product by Jade, its Affiliates and Sublicensees for sales or other commercial disposition of such Jade Product in the Territory to unrelated Third Parties, less the following, in each case related specifically to the Jade Product and actually incurred, paid or accrued by Jade, its Affiliates or Sublicensees and not otherwise recovered by or reimbursed to Jade, its Affiliates or Sublicensees;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>[***];</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>[***];</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>[***];</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>[***];</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>[***]; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font>[***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net Sales will include [***]. &#160;Net Sales will be calculated only once for the first <i style="font-style:italic;">bona fide</i> arm&#8217;s length sale of the Jade Product by Jade, its Affiliates or its Sublicensees to a Third Party, and will not include sales between or among [***]. &#160;Net Sales shall not include any amounts invoiced for [***] (i) [***], (ii) [***], or (iii) [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net Sales shall be determined from the books and records of Jade<i style="font-style:italic;">, </i>Affiliates of Jade or any Sublicensee maintained in accordance with U.S. generally accepted accounting principles (GAAP) consistently applied. &#160;Jade further agrees in determining Net Sales, it (or its applicable Affiliate or Sublicensee) will use Jade&#8217;s (or such Affiliate&#8217;s or Sublicensee&#8217;s) then current standard procedures and methodology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If a Jade Product is sold as a Combination Product (as defined below), the Net Sales of such Combination Product for the purpose of calculating royalties and sales-based milestones owed under this Agreement for sales of such Combination Product, shall be determined as follows: [***]. &#160;If any Other Component in the Combination Product is not sold separately, Net Sales shall be calculated by [***]. &#160;If both the Licensed Component(s) and any of the Other Components are not sold separately, the adjustment to Net Sales shall be determined by the Parties [***] to reasonably reflect [***] of such Combination Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For purposes of this definition, &#8220;<b style="font-weight:bold;">Combination Product</b>&#8221; means any pharmaceutical product that contains two (2) or more active ingredients, including (A) one (1) or more Licensed Antibodies, Derived Antibodies or Multispecific Antibodies (the &#8220;<b style="font-weight:bold;">Licensed Component</b>&#8221;), and (B) one (1) or more active pharmaceutical or biological ingredients that are not (x) a Licensed Antibody, Derived Antibody or Multispecific Antibody, or (y) an Antibody owned or controlled by Paragon or its Affiliate, the rights to which have been licensed to Jade or its Affiliate under a separate agreement (&#8220;<b style="font-weight:bold;">Other Component(s)</b>&#8221;), either as a [***], [***] or [***], and [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.69</font></font>&#8220;<b style="font-weight:bold;">Notice of Dispute</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.7(a)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.70</font></font>&#8220;<b style="font-weight:bold;">Option Agreement</b>&#8221; has the meaning set forth in the preamble.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.71</font></font>&#8220;<b style="font-weight:bold;">Other Component(s)</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.68</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.72</font></font>&#8220;<b style="font-weight:bold;">Other Licensed Patents</b>&#8221; means any Patents other than Licensed Antibody Patents Controlled by Paragon or its Affiliates as of the Effective Date or during the Term that (a) include a claim that expressly recites the sequence of a Licensed Antibody or Derived Antibody, and (b) are necessary to Develop, Manufacture or Commercialize Licensed Antibodies or Derived Antibodies in the Field in the Territory. &#160;Notwithstanding the foregoing, the Other Licensed Patents shall not include (i) Paragon Multispecific Patents, (ii) the Paragon Platform Patents (as defined in the Option Agreement), (iii) the [***] Licensed Patents, or (iv) any Patents that Cover (x) [***], or (y) [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.73</font></font>&#8220;<b style="font-weight:bold;">Paragon</b>&#8221; has the meaning set forth in the preamble.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.74</font></font>&#8220;<b style="font-weight:bold;">Paragon</b><b style="font-weight:bold;"> Indemnitee</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.75</font></font>&#8220;<b style="font-weight:bold;">Paragon Multispecific Antibody</b>&#8221; means a Multispecific Antibody that is Developed, Manufactured, Commercialized or otherwise exploited by Paragon or its Affiliate or licensee (other than Jade and its Affiliates and Sublicensees).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.76</font></font>&#8220;<b style="font-weight:bold;">Paragon Multispecific Patents</b>&#8221; means those Patents owned or otherwise controlled by Paragon or its Affiliates during the Term that Cover the composition of matter of, or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">any method of specifically making or using, a Paragon Multispecific Antibody, in each case excluding the Licensed Antibody Patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.77</font></font>&#8220;<b style="font-weight:bold;">Paragon Patents</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.2(c)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.78</font></font>&#8220;<b style="font-weight:bold;">Paragon </b><b style="font-weight:bold;">Third Party Agreement</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.7</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.79</font></font>&#8220;<b style="font-weight:bold;">Parent Entity</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.19</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.80</font></font>&#8220;<b style="font-weight:bold;">Party</b>&#8221; has the meaning set forth in the Preamble.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.81</font></font>&#8220;<b style="font-weight:bold;">Patent Challenge</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.3(a)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.82</font></font>&#8220;<b style="font-weight:bold;">Patent Infringement</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.3(a)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.83</font></font>&#8220;<b style="font-weight:bold;">Patents</b>&#8221; means (a) unexpired patents and patent applications, (b) any and all divisionals, continuations, continuations-in-part, reissues, renewals, substitutions, registrations, re-examinations, revalidations, extensions, supplementary protection certificates and the like of any such patents and patent applications, and (c) any and all foreign equivalents of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.84</font></font>&#8220;<b style="font-weight:bold;">Phase I Trial</b>&#8221; means a human clinical trial in any country of the type described in 21 C.F.R. &#167;312.21(a), or the foreign equivalent thereof, regardless of where such clinical trial is conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.85</font></font>&#8220;<b style="font-weight:bold;">Phase II Trial</b>&#8221; means a human clinical trial in any country of the type described in 21 C.F.R. &#167;312.21(b), or the foreign equivalent thereof, regardless of where such clinical trial is conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.86</font></font>&#8220;<b style="font-weight:bold;">Phase III Trial</b>&#8221; means a human clinical trial in any country of the type described in 21 C.F.R. &#167;312.21(c), or the foreign equivalent thereof, regardless of where such clinical trial is conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.87</font></font>&#8220;<b style="font-weight:bold;">Pre-Existing Entities</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.3</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.88</font></font>&#8220;<b style="font-weight:bold;">Product</b>&#8221; means any product that comprises or contains any Licensed Antibody or Derived Antibody other than as part of a Multispecific Antibody or a Multispecific Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.89</font></font>&#8220;<b style="font-weight:bold;">Prosecute</b>&#8221; or &#8220;<b style="font-weight:bold;">prosecution</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.2(a)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.90</font></font>&#8220;<b style="font-weight:bold;">Receiving Party</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 1.25</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.91</font></font>&#8220;<b style="font-weight:bold;">Regulatory Approval</b>&#8221; means all clearances, approvals (including approval of an MAA as well as any applicable pricing and/or reimbursement approvals), licenses, registrations or authorizations of any Regulatory Authority necessary to commercially distribute, sell and market a pharmaceutical or biologic product in a country or territory under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.92</font></font>&#8220;<b style="font-weight:bold;">Regulatory Authority</b>&#8221; means any supranational, multinational, federal, national, state, provincial or local regulatory agency, department, bureau or other governmental entity with authority over the clinical development, manufacture marketing or sale of a pharmaceutical or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">biologic product in a country or region, including the FDA in the United States and the EMA in Europe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.93</font></font>&#8220;<b style="font-weight:bold;">Reimbursement Obligation</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.7</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.94</font></font>&#8220;<b style="font-weight:bold;">Remaining Recovery</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.3(f)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.95</font></font>&#8220;<b style="font-weight:bold;">Representatives</b>&#8221; of a Party means such Party&#8217;s officers, directors, employees, contractors, subcontractors, agents and consultants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.96</font></font>&#8220;<b style="font-weight:bold;">Research Program</b>&#8221; means the Research Program (as defined in the Option Agreement) conducted by the Parties pursuant to the Option Agreement with respect to the Licensed Target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.97</font></font>&#8220;<b style="font-weight:bold;">Results</b>&#8221; means all data, results, analysis, conclusions, outcomes, information, documentation and reports that are generated by or on behalf of Paragon in performance of the Research Program, in each case excluding Licensed Antibody Inventions, Licensed Antibody Patents, Sequence Information and Licensed Antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.98</font></font>&#8220;<b style="font-weight:bold;">Reversion Products</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.6(c)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.99</font></font>&#8220;<b style="font-weight:bold;">ROFN Information</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.6(a)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.100</font></font>&#8220;<b style="font-weight:bold;">ROFN Negotiation Period</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.6(c)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.101</font></font>&#8220;<b style="font-weight:bold;">ROFN Period</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.6(a)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.102</font></font>&#8220;<b style="font-weight:bold;">Royalty Payments</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.3(a)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.103</font></font>&#8220;<b style="font-weight:bold;">Royalty Term</b>&#8221; means, on a Jade Product-by-Jade Product and country-by-country basis, the period commencing on First Commercial Sale of the applicable Jade Product in the applicable country in the Territory and ending, with respect to the particular Jade Product and country at issue on the latest of the following dates: (a) the twelfth (12th) anniversary of the date of First Commercial Sale of such Jade Product in such country; or (b)&#160;the expiration of the last-to-expire Valid Claim of a Licensed Antibody Patent or a Jade Antibody Patent Covering the Manufacture, use or sale of such Jade Product in the country at issue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.104</font></font>&#8220;<b style="font-weight:bold;">Sequence Information</b>&#8221; means electronic files of Paragon containing all Licensed Antibody sequences generated under the Research Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.105</font></font>&#8220;<b style="font-weight:bold;">Sublicensee</b>&#8221; means any Affiliate of Jade or any Third Party that receives a grant of a sublicense of, or other authorization or permission granted under, the licenses and rights granted to Jade in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1</u>, either directly from Jade or through multiple tiers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.106</font></font>&#8220;<b style="font-weight:bold;">Target</b>&#8221; means a protein molecule that (a) is chemically distinct from other molecules, and (b) wherein a binding entity derives recognized therapeutic value from binding to such molecule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.107</font></font>&#8220;<b style="font-weight:bold;">Term</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.1</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.108</font></font>&#8220;<b style="font-weight:bold;">Territory</b>&#8221; means worldwide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.109</font></font>&#8220;<b style="font-weight:bold;">Third Party</b>&#8221; means any person or entity other than Paragon or Jade or an Affiliate of either Paragon or Jade.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.110</font></font>&#8220;<b style="font-weight:bold;">Third Party Claim</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.111</font></font>&#8220;<b style="font-weight:bold;">US</b>&#8221; or &#8220;<b style="font-weight:bold;">United States</b>&#8221; means the United States of America and its possessions and territories, including Puerto Rico.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.112</font></font>&#8220;<b style="font-weight:bold;">Valid Claim</b>&#8221; means, with respect to particular Patent in a particular country, (a) a claim of an issued and unexpired patent (including the term of any patent term extension, supplemental protection certificate, renewal or other similar extension) in such country within such Patent that has not been abandoned or revoked, or held unpatentable, invalid or unenforceable in a final decision of a court or other governmental authority of competent jurisdiction from which no appeal may be taken, or has been taken before the expiry of the permitted time period, and that has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination, disclaimer or otherwise, or (b) a claim within a patent application in such country within such Patent that has not been pending more than seven (7) years from the earliest priority date of such claim and which claim has not been cancelled, withdrawn or abandoned or finally rejected by an administrative agency action from which no appeal can be taken.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article&#160;II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">LICENSES; TECHNOLOGY TRANSFER; MULTISPECIFIC ANTIBODIES.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.1</font></font><b style="font-weight:bold;">License Grants from Paragon</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Subject to the terms of this Agreement, Paragon hereby grants to Jade a royalty-bearing, exclusive (even as to Paragon and its Affiliates, subject to Paragon&#8217;s retained rights under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.3</u>) license, including the right to sublicense through multiple tiers (subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2</u>), under the Licensed Antibody Technology to use, make, have made, sell, offer for sale, have sold, import, export and otherwise exploit Licensed Antibodies, Derived Antibodies and/or Products in the Field in the Territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Subject to the terms of this Agreement, including <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.6</u>, Paragon hereby grants to Jade a royalty-bearing, non-exclusive right and license, including the right to sublicense through multiple tiers (subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2</u>), under the Licensed Antibody Technology to use, make, have made, sell, offer for sale, have sold, import, export and otherwise exploit Multispecific Antibodies and Multispecific Products in the Field in the Territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Subject to the terms of this Agreement, Paragon hereby grants to Jade a royalty-bearing, non-exclusive license, including the right to sublicense through multiple tiers (subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2</u>), under the Other Licensed Patents to Develop, Manufacture,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Commercialize or otherwise exploit Licensed Antibodies, Derived Antibodies and Products in the Field in the Territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>Subject to the terms of this Agreement, Paragon hereby grants to Jade a non-exclusive sublicense, including the right to further sublicense through multiple tiers (subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.2</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.8</u>), under the [***] IP to make, or have made, use, offer for sale, sell, import, research, develop, manufacture and commercialize (i) Licensed Antibodies and Derived Antibodies that are &#8220;Partnered Antibodies&#8221; under the [***] License Agreement, and (ii) Products, Multispecific Antibodies and Multispecific Products that contain or comprise Licensed Antibodies or Derived Antibodies described in clause (i), in each case (i)-(ii), in the Field in the Territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>Notwithstanding anything to the contrary set forth in this Agreement, the foregoing license rights do not include any rights to (i) [***], or (ii) [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.2</font></font><b style="font-weight:bold;">Sublicenses</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.2(b)</u>, Jade shall have the right to grant sublicenses under the rights granted to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1</u> to its Affiliates and Third Parties; <i style="font-style:italic;">provided, that</i> (i)&#160;each such sublicense shall be granted in writing and the relevant sublicense agreement shall be consistent with all relevant terms, conditions and restrictions of this Agreement, (ii)&#160;Jade will provide Paragon with a true and complete copy of each sublicense agreement and any amendments thereto within [***] days following execution thereof (which sublicense agreement and amendments may be redacted except to the extent necessary for Paragon to determine Jade&#8217;s compliance with this Agreement), and (iii)&#160;Jade shall remain responsible for all of its payments and other performance obligations due under this Agreement, notwithstanding any license or sublicense that it may grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>If any sublicense granted by Jade includes a further sublicense by Jade of the license granted in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1(d)</u>, then the following terms and conditions shall apply:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(i)<font style="display:inline-block;width:26.56pt;"></font>each sublicense shall be subject and subordinate to the [***] License Agreement and shall contain provisions consistent with the terms and conditions of the [***] License Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(ii)<font style="display:inline-block;width:23.78pt;"></font>except as to sublicenses to Affiliates, subcontractors and service providers, Jade shall as soon as reasonably practicable provide Paragon with (or, at the request of Paragon, provide directly to [***]) a copy of any executed sublicense agreement (which copy may be redacted to remove financial and other provisions that are not necessary to monitor compliance with this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.2(b)</u> or Section 3.4 of the [***] License Agreement); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(iii)<font style="display:inline-block;width:21pt;"></font>each such sublicense agreement shall contain a requirement that the Sublicensee comply with the confidentiality and non-use restrictions at least as stringent as those set forth in the [***] License Agreement with respect to ATX Confidential Information (as defined in the [***] License Agreement).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.3</font></font><b style="font-weight:bold;">No Implied Licenses; Reservation of Rights</b>. &#160;Except as expressly set forth herein, no right or license under any Patents, Know-How or Intellectual Property Right of either Party is granted or shall be granted by implication hereunder. &#160;All such rights or licenses are or shall be</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">granted only as expressly provided in this Agreement, and each Party reserves to itself all rights not expressly granted under this Agreement. &#160;Notwithstanding anything to the contrary under this Agreement, Paragon retains rights under the Licensed Antibody Technology to perform its obligations and exercise its rights under this Agreement and the Option Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.4</font></font><b style="font-weight:bold;">Information Transfer and Support to Jade</b>. &#160;Within [***] days after the Effective Date, Paragon shall provide Jade with the Results and Sequence Information in existence as of the Effective Date not already provided to Jade under the Option Agreement. &#160;Additionally, on a continuing basis during the term of the Research Program, within [***] days after additional Results or Sequence Information come into existence or are identified by Paragon, Paragon shall disclose and transfer such additional Results and Sequence Information to Jade. &#160;Each Party shall bear all costs and expenses incurred by such Party in connection with the disclosure and transfer of any Results and Sequence Information as set forth above. &#160;During the first [***] days after completion of the Research Program, in the event Jade makes any reasonable request for assistance in order to understand the Licensed Antibody Technology or use the Licensed Antibody Technology to continue the uninterrupted Development of the Licensed Antibodies, Paragon shall provide up to [***] month (approximately [***] hours) of such assistance, at [***] cost and expense at the then applicable [***] Rate (as defined in the Option Agreement) under the Option Agreement. &#160;Paragon shall consider and discuss [***] any additional requests for assistance made by Jade, which assistance may be provided upon mutual agreement of the Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.5</font></font><b style="font-weight:bold;">Paragon&#8217;s Rights with Respect to Multispecific Antibodies</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Subject to the terms of this Agreement, including <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5(b)</u> below and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.6</u>, Paragon reserves and retains the non-exclusive right under the Licensed Antibody Technology to Develop, Manufacture, Commercialize and otherwise exploit Multispecific Antibodies and Multispecific Products in the Field in the Territory. &#160;If Paragon exercises such right, then Paragon shall pay royalties to Jade in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IV</u>, <i style="font-style:italic;">mutatis mutandis</i>, with respect to any Multispecific Antibodies and Multispecific Products that are Commercialized by Paragon or its Affiliates or sublicensees (other than Jade and its Affiliates and Sublicensees) in the Field in the Territory, <i style="font-style:italic;">provided, that </i>references to Jade Antibody Patents in clause (b) of the Royalty Term definition and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.6</u> shall be disregarded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Jade has designated [***] Licensed Antibody or Derived Antibody as its lead compound and [***] Licensed Antibody or Derived Antibody as its backup compound, as set forth on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit C</u> (each such designated Licensed Antibody or Derived Antibody, a &#8220;<b style="font-weight:bold;">Designated Multispecific Antibody</b>&#8221;). &#160;From and after receipt of Jade&#8217;s notice, Paragon&#8217;s rights under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5(a)</u> shall expressly exclude the right to Develop, Manufacture, Commercialize or otherwise exploit (i) Multispecific Antibodies that have identical sequence identity within their variable regions as a Designated Multispecific Antibody, or (ii)&#160;Multispecific Products that comprise or contain any Multispecific Antibody referenced in clause (i). For the avoidance of doubt, if Paragon engages in Development or Manufacture of a Multispecific Antibody that meets the criteria of clause (i) or (ii) above <i style="font-style:italic;">before </i>Jade designates such Multispecific Antibody as a Designated Multispecific Antibody, then Paragon shall not be in breach of this Agreement, <i style="font-style:italic;">provided that</i>, Paragon ceases all such Development or Manufacture within [***] days following receipt of Jade&#8217;s written notice of designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.6</font></font><b style="font-weight:bold;">Right of First Negotiation</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Commencing on the Effective Date and continuing until the [***] anniversary thereof (the &#8220;<b style="font-weight:bold;">ROFN Period</b>&#8221;), Paragon will promptly notify Jade in writing if (i) Paragon has developed a descriptive research plan with respect to the Development of a Multispecific Antibody or a plan to license or grant rights in a Multispecific Antibody to a Third Party, or (ii) Paragon enters into [***] negotiations pursuant to an offer to or from any Third Party relating to the foregoing. &#160;Together with such notice, Paragon will provide to Jade all material information and research plans developed by Paragon with respect to such Multispecific Antibody (the &#8220;<b style="font-weight:bold;">ROFN Information</b>&#8221;), including existing drafts of any proposed filings to any patent office prepared by or on behalf of Paragon, or copies of any actual filings to any patent office made by or behalf of Paragon, in each case with respect to Paragon Multispecific Patents that Cover such Multispecific Antibody. &#160;Jade will have [***] days from receipt of the ROFN Information to deliver a written notice to Paragon of Jade&#8217;s desire to engage in negotiations for an agreement concerning the Development, or exclusive license or grant of rights to, such Multispecific Antibody.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>If Jade does not provide such written notice to Paragon of its interest to engage in such negotiations within such [***] day period, then (i) Paragon shall be free to enter into an agreement with a Third Party with respect to the grant of a license or other rights to such Multispecific Antibody and corresponding Multispecific Products without further obligation to Jade under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.6</u>, and (ii) Jade&#8217;s license under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1(b)</u> shall automatically exclude any right to Develop, Manufacture, Commercialize or otherwise exploit the identical Multispecific Antibodies Developed by or on behalf of Paragon and corresponding Multispecific Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>If Jade does provide Paragon such written notice within such [***] day period, the Parties will negotiate [***] on an exclusive basis for a period of up to [***] months from the date of Jade&#8217;s notice (&#8220;<b style="font-weight:bold;">ROFN Negotiation Period</b>&#8221;), an agreement for the Development, or exclusive license or grant of rights to, such Multispecific Antibody and corresponding Multispecific Products. &#160;Prior to and during the ROFN Negotiation Period, Paragon shall not enter into an agreement with respect to such Multispecific Antibody with any Third Party that will prevent Paragon from entering into an agreement with Jade for the Development, or exclusive license or grant of rights to, such Multispecific Antibody and corresponding Multispecific Products. &#160;Unless and until the Parties have entered into an agreement with respect to such Multispecific Antibody and corresponding Multispecific Products, Jade shall have no rights or license with respect to such Multispecific Antibody and corresponding Multispecific Products except as otherwise expressly provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1</u>. &#160;In the event that the Parties have not entered into an agreement with respect to such Multispecific Antibody and corresponding Multispecific Products prior to the expiration of the ROFN Negotiation Period, then (i) Paragon shall be free to enter into an agreement with a Third Party with respect to the grant of a license or other rights to such Multispecific Antibody and corresponding Multispecific Products without further obligation to Jade under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.6</u>, and (ii) Jade&#8217;s license under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1(b)</u> shall automatically exclude any right to Develop, Manufacture, Commercialize or otherwise exploit the identical Multispecific Antibodies Developed by or on behalf of Paragon and corresponding Multispecific Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.7</font></font><b style="font-weight:bold;">Third Party In-Licenses</b>. &#160;Jade acknowledges and agrees that (a) Paragon may enter into additional in-license agreements after the Effective Date and the Patents licensed to Paragon under such in-license agreements may be included within the Licensed Antibody Patents or Other Licensed Patents licensed to Jade under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1</u> if Jade agrees in writing to reimburse Paragon for royalties or other consideration due under such in-license agreement for the Development, Manufacture, Commercialization or other exploitation of a Product in the Territory in connection with a grant to Jade of a sublicense under such Patents (the &#8220;<b style="font-weight:bold;">Reimbursement Obligation</b>&#8221;), (b) if such Patents are sublicensed to Jade under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1</u>, then the licenses and rights to be granted by Paragon to Jade under this Agreement shall be subject to and limited by the terms of the corresponding in-license agreement(s) entered into by Paragon or its Affiliate (each, a &#8220;<b style="font-weight:bold;">Paragon Third Party Agreement</b>&#8221;), and (c)&#160;Jade shall comply with the terms of the Paragon Third Party Agreements to the extent applicable to Jade as a sublicensee and relevant to the licenses and rights granted by Paragon to Jade under this Agreement. &#160;In the event of any conflict between the terms of this Agreement and any Paragon Third Party Agreement, the terms of such Paragon Third Party Agreement shall control to the extent necessary for the Parties to maintain compliance with such Paragon Third Party Agreement. &#160;Jade shall comply with the Reimbursement Obligation by paying to Paragon any amounts subject to the Reimbursement Obligation at least [***] Business Days prior to the date when such amounts are payable by Paragon to the counterparty licensor under the applicable Paragon Third Party Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.8</font></font>[***] <b style="font-weight:bold;">License Agreement</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><b style="font-weight:bold;">Applicability of the </b>[***] <b style="font-weight:bold;">License Agreement</b>. &#160;The Parties acknowledge and agree that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(i)<font style="display:inline-block;width:26.56pt;"></font>the [***] IP will be licensed by [***] to Paragon under the [***] License Agreement and sublicensed by Paragon to Jade under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1(d)</u> of this Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(ii)<font style="display:inline-block;width:23.78pt;"></font>Jade agrees to be bound by the terms and conditions of the [***] License Agreement applicable to sublicensees to the extent of the sublicenses granted hereunder; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(iii)<font style="display:inline-block;width:21pt;"></font>in the event of any conflict between the terms of this Agreement and the terms of the [***] License Agreement that are applicable to Jade, the terms of the [***] License Agreement shall control to the extent necessary to maintain compliance with the terms of the [***] License Agreement, and Jade shall not be in breach of this Agreement to the extent that it is complying with any such conflicting and controlling terms of the [***] License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><b style="font-weight:bold;">Required Disclosures under the </b>[***] <b style="font-weight:bold;">License Agreement</b>. &#160;Notwithstanding anything else herein to the contrary, Jade hereby consents to Paragon: (i)&#160;providing a copy of this Agreement to [***] (which copy may be redacted to remove financial and other provisions that are not necessary for [***] to monitor compliance Section 3.4 of the [***] License Agreement); and (ii)&#160;disclosing to [***] any Confidential Information of Jade that is expressly and specifically required to be disclosed to [***] under the terms of the [***] License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><b style="font-weight:bold;">Payments Under </b>[***] <b style="font-weight:bold;">License Agreement</b>. &#160;As between the Parties, Jade shall be solely responsible for the following payments due to [***] under the [***] License Agreement:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(i)<font style="display:inline-block;width:26.56pt;"></font>any annual Partnered Antibody Program Fees (as defined in the [***] License Agreement) (other than the initial Partnered Antibody Program Fees) that become due under Section 4.4 of the [***] License Agreement due to Paragon&#8217;s activities under this Agreement or activities conducted by or on behalf of Jade, its Affiliates and Sublicensees under this Agreement, in each case with respect to the Jade Products; provided, that (a) any such payments, together with the initial Partnered Antibody Program Fees relating to this Agreement paid by Jade, shall be creditable under Section 4.4 of the [***] License Agreement against amounts also payable by Jade under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.8(c)(ii)</u> with respect to this Agreement (b) shall only be payable until the First Commercial Sale (as defined in the [***] License Agreement) of a Jade Product that constitutes a &#8220;Product&#8221; under the [***] License Agreement; and (c) shall only be payable once (and, as applicable, on an annual basis thereafter) per Partnered Antibody Program (as defined in the [***] License Agreement), irrespective of the number of Selection Notices (as defined in the [***] License Agreement) provided by Paragon or deemed provided by Paragon;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(ii)<font style="display:inline-block;width:23.78pt;"></font>the Development Milestone (as defined in the [***] License Agreement) payments under Section 4.5 of the [***] License Agreement, subject to any credits under Section 4.4 of the [***] License Agreement, to the extent payable due to achievement of the applicable Development Milestone (as defined in the [***] License Agreement) by Jade, its Affiliates or Sublicensees with respect to a Jade Product under this Agreement that is also a Product as defined in the [***] License Agreement; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(iii)<font style="display:inline-block;width:21pt;"></font>the Commercial Payments (as defined in the [***] License Agreement) under Section 4.6 of the [***] License Agreement to the extent payable with respect to a Jade Product under this Agreement that is also a Product as defined in the [***] License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Unless directed otherwise by Paragon, (x) Jade shall, on behalf of Paragon, make all such payments directly to [***] in accordance with the terms of the [***] License Agreement and shall [***] provide written confirmation of such payments to Paragon, (y) Jade shall deliver to Paragon (1) notice of the successful completion of each Development Milestone (as defined in the [***] License Agreement) by Jade, its Affiliates or Sublicensees with respect to a Jade Product under this Agreement that is also a Product as defined in the [***] License Agreement, which notice shall be provided within [***] days of such successful completion, and (2) notice of the First Commercial Sale (as defined in the [***] License Agreement) of each Jade Product under this Agreement that is also a Product as defined in the [***] License Agreement, which notice shall be provided within [***] days of such occurrence, and (z) Jade shall comply with Sections 5.1 and 5.2 of the [***] License Agreement to the extent applicable to the payments for which Jade is responsible. &#160;Any payments due by Jade under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.8(c)</u> shall be subject to any reductions pursuant to Section 4.9 of the [***] License Agreement. &#160;Paragon shall promptly provide to Jade a copy of any invoice received from [***] under Section 4.10 of the [***] License Agreement that is relevant to the payments for which Jade is responsible (or direct [***] to provide such invoices directly to Jade). &#160;Jade shall have the right to exercise and fund on behalf of Paragon the buyout rights under Section 4.11 of the [***] License Agreement for each Jade Product under this</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Agreement that is also a Product as defined in the [***] License Agreement in lieu of Jade&#8217;s ongoing payments with respect to clauses (ii) and (iii) above. &#160;For clarity, the payments set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.8(c)</u> are in addition to the amounts payable to Paragon under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IV</u>. &#160;Jade shall not be responsible for any payments under the [***] License Agreement other than those payments set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.8(c)</u> and the payments to be reimbursed by Jade under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.1</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><b style="font-weight:bold;">Covenants by Jade</b>. Jade hereby covenants and agrees that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(i)<font style="display:inline-block;width:26.56pt;"></font>On or before [***] of each year during the Term, Jade shall deliver to Paragon a written report for its activities under this Agreement meeting the reporting requirements set forth in Section 5.3 of the [***] License Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(ii)<font style="display:inline-block;width:23.78pt;"></font>Jade shall cure any breach of the [***] License Agreement caused by Jade, its Affiliates or Sublicensees within [***] days of written notice thereof, and shall provide Paragon with written notice of such cure upon completion thereof; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(iii)<font style="display:inline-block;width:21pt;"></font>Except as expressly required under this Agreement solely with respect to the [***] License Agreement, or for matters falling outside of this Agreement, Jade shall not communicate directly with [***] without Paragon&#8217;s prior written consent, which consent may be withheld in Paragon&#8217;s sole discretion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><b style="font-weight:bold;">Covenants by Paragon</b>. &#160;Paragon hereby covenants and agrees that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(i)<font style="display:inline-block;width:26.56pt;"></font>During the Term, Paragon shall maintain (to the extent within Paragon&#8217;s control) in full force and effect the [***] License Agreement including by faithfully, fully and timely performing its obligations pursuant to the [***] License Agreement (provided, that Paragon shall not be responsible for any breach or termination of the [***] License Agreement caused by any action or inaction of Jade, its Affiliates or Sublicensees, including a breach of this Agreement or the [***] License Agreement), and shall not terminate, in whole or in part, the [***] License Agreement to the extent relating to this Agreement without the prior written consent of Jade;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(ii)<font style="display:inline-block;width:23.78pt;"></font>Paragon shall, within the relevant time period required under the [***] License Agreement, cure (or shall use [***] to cause any sublicensee of Paragon under the [***] License Agreement other than Jade to promptly cure) any breach of the [***] License Agreement caused by any action or omission of Paragon or its Affiliates or other sublicensees;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(iii)<font style="display:inline-block;width:21pt;"></font>Paragon shall not modify or amend the [***] License Agreement in any manner that (x) is reasonably expected to adversely affect Jade&#8217;s rights (including the Development, Manufacture, Commercialization or exploitation of the Jade Products in the Field in the Territory under this Agreement) under this Agreement in any material respect, (y) increases Jade&#8217;s obligations under this Agreement in any material respect, or (z) increases the costs and payments of any kind under the [***] License Agreement for which Jade is or will be responsible (whether to Paragon or [***]) under this Agreement, in each case without the prior written consent of Jade, which consent may be withheld in Jade&#8217;s sole discretion and any such amendment or modification in breach of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.8(e)(iii)</u> shall have no effect on Jade&#8217;s rights under the terms of this Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(iv)<font style="display:inline-block;width:21.56pt;"></font>Paragon shall provide to Jade a copy of any amendment to or restatement of the [***] License Agreement promptly following execution thereof; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(v)<font style="display:inline-block;width:24.34pt;"></font>Paragon shall promptly provide to Jade a copy of any written notice of alleged breach, default or termination delivered by [***] under the [***] License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.9</font></font><b style="font-weight:bold;">Use of Licensed Antibody Technology and Paragon&#8217;s Confidential Information. &#160;</b>Notwithstanding any provision of this Agreement to the contrary, Jade shall have no right or license to use the Licensed Antibody Technology, the Other Licensed Patents, the [***] IP or any other Intellectual Property Rights or Antibodies owned or controlled by Paragon or Paragon&#8217;s Confidential Information to discover, generate, identify or characterize any Antibodies or Antibody based products other than the Jade Products (except as may be agreed under other definitive agreements entered into between Paragon and its Affiliates and Jade).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.10</font></font><b style="font-weight:bold;">Exclusivity</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Subject to the terms of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.10</u>, to the maximum extent permissible under Applicable Law, during the Exclusivity Period, Paragon shall not, and shall ensure that its Affiliates do not, directly or indirectly, conduct any activity, either on its own or with, for the benefit of, or sponsored by, any Third Party, including granting any license to any Third Party that would permit such Third Party, to develop, manufacture, commercialize or otherwise exploit any monospecific Antibody that is Directed To the Licensed Target in the Field. &#160;It will not be a violation of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.10(a)</u> if Paragon or its Affiliate, directly or through a Third Party, (i)&#160;conducts screening activities solely for the purposes of ensuring compliance with this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.10(a)</u>, (ii) conducts activities in accordance with the terms of this Agreement, the Option Agreement or any other written agreement between the Parties, or (iii) conducts activities with the prior written consent of Jade.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Notwithstanding anything herein to the contrary, if a Change of Control occurs with respect to Paragon or its Parent Entity, and the Acquiring Entity (or any of such Acquiring Entity&#8217;s successors or assigns, other than the relevant Pre-Existing Entities) as of the Change of Control has a program or product (or rights thereto) that would otherwise violate <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.10(a)</u> (each, a &#8220;<b style="font-weight:bold;">COC Program</b>&#8221;), then (i) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.10(a)</u> shall not apply with respect to such COC Program, and (ii) such Acquiring Entity will be permitted to continue such COC Program after such Change of Control and such continuation will not constitute a violation of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.10(a)</u>, provided, that the Licensed Antibody Technology and Confidential Information of Paragon and Jade relating to the Jade Products is not used in the COC Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Notwithstanding anything herein to the contrary, if Paragon or its Parent Entity (i) acquires a Third Party entity that has a program or product (or rights thereto) that would otherwise violate <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.10(a)</u>, or (ii) acquires asset(s) from a Third Party entity that would otherwise violate <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.10(a)</u> (each, an &#8220;<b style="font-weight:bold;">Acquired Program</b>&#8221;), then (1) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.10(a)</u> shall not apply with respect to such Acquired Program, and (2) Paragon or its Parent Entity will be permitted to continue such Acquired Program after such acquisition and such continuation will not constitute a violation of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.10(a)</u>, provided, that the Licensed Antibody Technology and Confidential Information of Paragon and Jade relating to the Jade Products is not used in the Acquired Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article&#160;III</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DEVELOPMENT, MANUFACTURING &amp; COMMERCIALIZATION.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.1</font></font><b style="font-weight:bold;">Jade Responsibilities</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>As between the Parties, Jade shall be solely responsible for all aspects of the Development, Manufacturing, and Commercialization of the Jade Products in the Field in the Territory during the Term, including distribution, product positioning, product strategy, product branding, core messaging, marketing, promotion, detailing activities and all decisions relating to the setting of prices in the Territory; invoicing and booking sales, and establishing all terms of sale, and all regulatory activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>As between the Parties, Jade shall be solely responsible for selection, registration and maintenance of all trademarks associated with the Jade Products in the Field in the Territory. &#160;As between the Parties, Jade shall solely own such trademarks in the Territory and pay all relevant costs thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.2</font></font><b style="font-weight:bold;">Regulatory</b>. &#160;As between the Parties, Jade shall control the regulatory strategy, regulatory filings, regulatory activities (including clinical trials for Jade Products) and communication with each Regulatory Authority for the Jade Products in the Field in the Territory. &#160;Jade shall have the right to reference any relevant data included in the Licensed Antibody Technology for the purposes of regulatory filings and safety reporting for the Jade Products, including all nonclinical data, pre-approval and post-approval clinical use data, and regulatory data with respect thereto. &#160;Jade or its designee shall be the party to file an application to each applicable Regulatory Authority in the Territory for, and to obtain and maintain, in its own name, the Regulatory Approval of the Jade Products in each country in the Territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.3</font></font><b style="font-weight:bold;">Diligence; Reporting</b>. &#160;Jade shall use Commercially Reasonable Efforts (a) to Develop and seek Regulatory Approval for at least one Jade Product in the Field in the United States and at least one other Major Market Country, and (b) upon receipt of Regulatory Approval for a given Jade Product in a given country, to Commercialize such Jade Product in such country, in each case ((a) or (b)) either by itself or through its Affiliates or Sublicensees or its or their respective contractors. &#160;Additionally, on or before [***] of each year during the Term, Jade shall deliver to Paragon a report summarizing its material development efforts with respect to any Jade Products, including a summary of current and anticipated preclinical and clinical activities, a summary of the status of any regulatory filings and anticipated regulatory filings, and achievement of any Milestones, during the preceding [***]. &#160;For the avoidance of doubt, if Jade determines, in its sole discretion, that it is inconsistent with the use of Commercially Reasonable Efforts to pursue Commercialization of a Jade Product in any country (other than the United States), it will not be considered a material breach of this Agreement to cease Development or Commercialization of such Jade Product with respect to such country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article&#160;IV</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FINANCIAL TERMS.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.1</font></font><b style="font-weight:bold;">Reimbursement of Payments to </b>[***]. &#160;Within [***] days of the Effective Date, Jade shall make a one-time, non-refundable and non-creditable payment to Paragon in the amount of [***] to reimburse Paragon for the sublicense fees under Section 4.7 of the [***] License Agreement paid by Paragon to [***] with respect to this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.2</font></font><b style="font-weight:bold;">Milestone Payments</b>. &#160;Jade shall make the following one-time payments to Paragon (or to such other designee(s), as requested by Paragon) (each payment, a &#8220;<b style="font-weight:bold;">Milestone Payment</b>&#8221;), based on the achievement of the corresponding milestone (each, a &#8220;<b style="font-weight:bold;">Milestone</b>&#8221;) by Jade, its Affiliates, or its Sublicensees with respect to the first Jade Product to achieve such Milestone. &#160;Jade shall, within [***] days after it or its Affiliates achieve such Milestone or within [***] days after it learns that its or its Affiliate&#8217;s Sublicensee has achieved such Milestone, make the corresponding Milestone Payment to Paragon or Paragon&#8217;s designee(s). &#160;Each Milestone Payment shall be paid no more than once, and Jade&#8217;s total Milestone Payments hereunder shall not exceed Twenty-Two Million Dollars ($22,000,000). &#160;For avoidance of doubt, upon achievement of any Milestone, all prior unachieved Milestones shall be deemed thereby achieved and, if the Milestone Payment for any such prior Milestone has not previously been paid under this Agreement or pursuant to Section 5.3 of the Option Agreement, it shall thereupon also be paid at the same time that the Milestone Payment for such subsequent achieved Milestone is paid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;" align="center"><tr><td style="vertical-align:top;width:7.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 6pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:52%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Milestone</b></p></td><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Milestone Payment</b></p></td></tr><tr><td style="vertical-align:top;width:7.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 6pt 0pt;"><b style="font-weight:bold;">#1</b></p></td><td style="vertical-align:top;width:52%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 6pt 0pt;">Achievement of Development Candidate</p></td><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 6pt 0pt;">One Million Five Hundred Thousand Dollars ($1,500,000)</p></td></tr><tr><td style="vertical-align:top;width:7.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 6pt 0pt;"><b style="font-weight:bold;">#2</b></p></td><td style="vertical-align:top;width:52%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 6pt 0pt;">First dosing of a human patient in a Phase I Trial of a Jade Product</p></td><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 6pt 0pt;">Two Million Five Hundred Thousand Dollars ($2,500,000)</p></td></tr><tr><td style="vertical-align:top;width:7.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 6pt 0pt;"><b style="font-weight:bold;">#3</b></p></td><td style="vertical-align:top;width:52%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 6pt 0pt;">First dosing of a human patient in a Phase II Trial of a Jade Product</p></td><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 6pt 0pt;">Three Million ($3,000,000)</p></td></tr><tr><td style="vertical-align:top;width:7.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 6pt 0pt;"><b style="font-weight:bold;">#4</b></p></td><td style="vertical-align:top;width:52%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 6pt 0pt;">First dosing of a human patient in a Phase III Trial of a Jade Product</p></td><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 6pt 0pt;">Five Million Dollars ($5,000,000)</p></td></tr><tr><td style="vertical-align:top;width:7.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 6pt 0pt;"><b style="font-weight:bold;">#5</b></p></td><td style="vertical-align:top;width:52%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 6pt 0pt;">Receipt of Regulatory Approval from the FDA of a Jade Product</p></td><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 6pt 0pt;">Ten Million Dollars ($10,000,000)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.3</font></font><b style="font-weight:bold;">Royalties</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><b style="font-weight:bold;">Royalty Rate for Products</b>. Subject to the terms of this Section 4.3, during the applicable Royalty Term (which shall be measured on a country-by-country and Product-by-Product basis), Jade shall pay tiered royalties to Paragon (or to such other designee(s), as requested by Paragon) as set forth in the table below on Annual Net Sales of all Products sold by Jade, its Affiliates or its Sublicensees in the Field in the Territory (together with any royalties payable under</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Section 4.3(b), the &#8220;<b style="font-weight:bold;">Royalty Payments</b>&#8221;). &#160;For clarity, any Net Sales of Product made in a given country after the expiration of the Royalty Term for such Product in such country will not be royalty-bearing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:79.92%;" align="center"><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Annual Net Sales of the Products in a Given Calendar Year</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Royalty Rate</b></p></th></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Portion of Annual Net Sales of the Products in a given Calendar Year above $[***] but up to and including $[***]</p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">[***]%</p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Portion of Annual Net Sales of the Products in a given Calendar Year of more than $[***], up to and including $[***]</p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">[***]%</p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Portion of Annual Net Sales of the Products in a given Calendar Year of more than $[***]</p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">[***]%</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><b style="font-weight:bold;">Royalty Rate for Jade Multispecific Products</b>. During the applicable Royalty Term (which shall be measured on a country-by-country and Jade Multispecific Product-by-Jade Multispecific Product basis), Jade shall pay royalties to Paragon (or to such other designee(s), as requested by Paragon) equal to [***] percent ([***]%) of Net Sales of all Jade Multispecific Products sold by Jade, its Affiliates or its Sublicensees in the Field in the Territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><b style="font-weight:bold;">Combination Products</b>. If any Jade Product contains (a) a combination of more than one Licensed Antibody, Derived Antibody and/or Multispecific Antibody, or (b) a combination of (i) one or more Licensed Antibodies, Derived Antibodies or Multispecific Antibodies, and (ii)&#160;one or more other Antibodies owned or Controlled by Paragon or its Affiliates, the rights to which have been licensed to Jade or its Affiliates under a separate agreement, then, in each case (a) or (b) unless otherwise agreed by the Parties, the royalty rate for the Royalty Payments payable to Paragon with respect to such Jade Product (x) shall be determined in accordance with the Royalty Rate chart set forth in Section 4.3(a) if such Jade Product does not contain a Multispecific Antibody, and (y) shall be determined in accordance with Section 4.3(b) if such Jade Product contains a Multispecific Antibody.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><b style="font-weight:bold;">Royalty Reductions for No Valid Claim</b>. &#160;If, during any Calendar Quarter during the Royalty Term for a particular Jade Product in a particular country, no Valid Claim of a Licensed Antibody Patent Covers the Manufacture or Commercialization of such Jade Product in such country, then the applicable royalty rate for the Royalty Payments set forth in this Section 4.3 for such Calendar Quarter shall be reduced by [***] percent ([***]%).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.4</font></font><b style="font-weight:bold;">Payment Reports</b>. &#160;Within [***] days after the end of the [***], Jade shall provide to Paragon a written report, on a [***] basis, stating the [***]; the [***], including [***]; and [***], including [***]. &#160;All Royalty Payments described in such written report shall be made by Jade at the same time it submits such written report to Paragon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.5</font></font><b style="font-weight:bold;">Payment Method</b>. &#160;All payments due under this Agreement to Paragon shall be made in U.S. Dollars by bank wire transfer in funds to an account designated by Paragon from time to time reasonably in advance of any payment due date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.6</font></font><b style="font-weight:bold;">Taxes</b>. &#160;The Parties agree to cooperate with one another and use reasonable efforts to minimize obligations for any and all income or other taxes required by Applicable Law to be withheld or deducted from any Royalty Payments, Milestone Payments or other payments made by Jade to Paragon or its designee(s) under this Agreement, including by completing all procedural steps, and taking all reasonable measures, to ensure that any withholding tax is reduced or eliminated to the extent permitted under Applicable Law, including income tax treaty provisions and related procedures for claiming treaty relief. &#160;To the extent that Jade is required to deduct and withhold taxes on any payment to Paragon or its designee(s), Jade shall: (i) deduct such taxes from such payment to Paragon or its designee(s), (ii) pay the amounts of such taxes to the proper government authority in a timely manner, and (iii) promptly submit to Paragon an official tax certificate or other available evidence of such withholding sufficient to enable Paragon or its designee(s) to claim such payment of taxes. &#160;For the avoidance of doubt, Jade&#8217;s remittance of such withheld amounts to the appropriate governmental authority, together with payment to Paragon or its designee(s) of the remaining amount owed, shall constitute full satisfaction of the applicable payment due to Paragon. &#160;Jade shall provide Paragon with reasonable assistance in order to allow Paragon or its designee(s) to recover, as permitted by Applicable Law, withholding taxes, value added taxes or similar obligations resulting from payments made hereunder or to obtain the benefit of any present or future treaty against double taxation which may apply to such payments. &#160;Paragon shall promptly provide Jade with any requested tax forms that may be reasonably necessary in order for Jade to not withhold tax or to withhold tax at a reduced rate under an applicable bilateral tax income treaty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.7</font></font><b style="font-weight:bold;">Foreign Exchange</b>. &#160;If any currency conversion shall be required in connection with the calculation of amounts payable hereunder, such conversion shall be made using the exchange rates reported on the [***] Business Day prior the payment due date for the purchase and sale of Dollars, as reported by the <i style="font-style:italic;">Wall Street Journal (East Coast Edition)</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.8</font></font><b style="font-weight:bold;">Late Payments</b>. &#160;Any amount owed by Jade to Paragon under this Agreement that is not paid within the applicable time period set forth herein will accrue interest at the per annum rate of [***] percentage point above the then-applicable United States prime rate as quoted in the <i style="font-style:italic;">Wall Street Journal (East Coast Edition)</i> (or if it no longer exists, a similarly authoritative source), calculated on a [***] basis, or, if lower, the highest rate permitted under Applicable Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.9</font></font><b style="font-weight:bold;">Blocked Currency</b>. &#160;If by Applicable Law of a country in which Net Sales occurred, conversion of funds into Dollars or transfer of funds from such country to the United States is restricted, forbidden or delayed for more than [***] days, then Jade can elect, at its sole discretion, that the amounts accrued in such country and owed by Jade to Paragon under this Agreement shall be paid to Paragon in such country in local currency by deposit in a local bank designated by Paragon, unless the Parties otherwise agree in writing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.10</font></font><b style="font-weight:bold;">Records; Inspection</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Jade shall, and shall cause its applicable Affiliates to, create and keep complete and accurate records of its sales and other dispositions of all Jade Products, including all records that are reasonably necessary for the purposes of calculating all payments due under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Upon reasonable advance written notice to Jade, Paragon shall have the right to retain a nationally recognized (in the US) independent certified public accounting firm to perform on behalf of Paragon an audit, conducted in accordance with U.S. generally accepted accounting principles (GAAP), of such books and records of Jade or its applicable Affiliates as may be reasonably necessary to verify the accuracy of any reports provided pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.3(d)</u> hereunder for any Calendar Quarter ending not more than [***] calendar months prior to the date of such request. &#160;Such audits shall not occur more frequently than [***] in each Calendar Year and shall not be conducted more than [***] with respect to any reporting period, in each case other than for cause. &#160;All information disclosed or observed during any audit pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.10</u> shall be the Confidential Information of Jade, and Paragon shall cause the accounting firm to retain all such information as Confidential Information, including, if requested by Jade, by requiring such accounting firm to enter into a customary confidentiality agreement with Jade prior to the initiation of any such audit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Upon completion of any audit hereunder, the accounting firm shall provide both Jade and Paragon a written report disclosing whether the reports submitted by Jade are correct or incorrect, whether the amounts paid are correct or incorrect, and in each case, the specific details concerning any discrepancies. &#160;No other information regarding Jade&#8217;s records shall be provided to Paragon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>Paragon shall bear its internal expenses and the out-of-pocket costs for engaging such accounting firm in connection with performing such audits; <i style="font-style:italic;">provided, however</i>, that if any such audit uncovers an underpayment by Jade that exceeds [***] percent ([***]%) of the total owed for such payment or payment period, as applicable, then Jade shall reimburse Paragon or its designee(s) for the amounts actually paid to such accounting firm for performing such audit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>If such accounting firm concludes that Jade has in aggregate underpaid amounts owed to Paragon during the audited period, Jade shall pay Paragon or its designee(s) the amount of the discrepancy within [***] days of the date Paragon delivers to Jade such accounting firm&#8217;s written report and an invoice for such amounts. &#160;If such accounting firm concludes that Jade has in aggregate overpaid amounts owed to Paragon during the audited period, then Jade may, at its election, either credit such overpaid amount against any future payment obligation to Paragon or require Paragon to refund such amounts within [***] days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article&#160;V</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INTELLECTUAL PROPERTY.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.1</font></font><b style="font-weight:bold;">Ownership</b>. &#160;As between the Parties, each Party will own and retain all right, title and interest in and to all Intellectual Property Rights owned or controlled by such Party as of the Effective Date or that come into the ownership or control of such Party during the Term outside the scope of this Agreement. &#160;Other than rights granted to Jade under this Agreement with respect</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to the Licensed Antibody Technology, the Other Licensed Patents and the [***] IP, nothing in this Agreement shall affect Paragon&#8217;s rights in any Patents, Know-How or other Intellectual Property Rights owned or controlled by Paragon or its Affiliates, now or in the future. &#160;Other than rights granted to Paragon under this Agreement with respect to the Jade Intellectual Property, nothing in this Agreement shall affect Jade&#8217;s rights in any Patents, Know-How or other Intellectual Property Rights owned or controlled by Jade or its Affiliates, now or in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.2</font></font><b style="font-weight:bold;">Patent Prosecution</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><b style="font-weight:bold;">Prosecution Generally</b>. &#160;For the purpose of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;V</u>, &#8220;<b style="font-weight:bold;">prosecute</b>&#8221; and &#8220;<b style="font-weight:bold;">prosecution</b>&#8221; shall include any patent interference, opposition, pre-issuance Third Party submission, <i style="font-style:italic;">ex parte</i> re-examination, post-grant review, <i style="font-style:italic;">inter partes</i> review or other similar proceeding, appeals or petitions to any board of appeals in a patent office, appeals to any court for any patent office decisions, reissue proceedings and applications for patent term extensions and the like.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><b style="font-weight:bold;">Prosecution of Licensed Antibody Patents</b>. &#160;As between the Parties, (1)&#160;with respect to any Licensed Antibody Patents that have been filed as of the Effective Date, Jade shall be solely responsible for, and have sole discretion over, preparing, filing, prosecuting and maintaining such Licensed Antibody Patents, in each case, at Jade&#8217;s sole expense, and (2)&#160;with respect to any Licensed Antibody Patents that are filed after the Effective Date, (x)&#160;Paragon shall be solely responsible for, and have sole discretion over, preparing, filing, prosecuting and maintaining such Licensed Antibody Patents until the date on which the Final Deliverable (as defined in the Option Agreement) for the Research Program is delivered to Jade and (y) following the date on which the Final Deliverable for the Research Program is delivered to Jade, then Jade shall be solely responsible for, and have sole discretion over, preparing, filing, prosecuting and maintaining such Licensed Antibody Patents, in each case, at Jade&#8217;s sole expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(i)<font style="display:inline-block;width:26.56pt;"></font><b style="font-weight:bold;">Coordination</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(A)<font style="display:inline-block;width:22.12pt;"></font>With respect to any Licensed Antibody Patents for which Jade has the right to prepare, file, prosecute and maintain, Jade shall provide Paragon with copies of all material correspondence from and to any patent office relating to such Licensed Antibody Patents, and Jade shall provide Paragon with drafts of all proposed filings to any patent office with respect to such Licensed Antibody Patents in reasonably adequate time before submission of such filings for Paragon&#8217;s review and comment. &#160;Jade will take into consideration Paragon&#8217;s reasonable comments prior to submitting such filings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(B)<font style="display:inline-block;width:22.67pt;"></font>With respect to any Licensed Antibody Patents for which Paragon has the right to prepare, file, prosecute and maintain, Paragon shall provide Jade with copies of all material correspondence from and to any patent office relating to such Licensed Antibody Patents, and Paragon shall provide Jade with drafts of all proposed filings to any patent office with respect to such Licensed Antibody Patents in reasonably adequate time before submission of such filings for Jade&#8217;s review and comment. &#160;Paragon will take into consideration Jade&#8217;s reasonable comments prior to submitting such filings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(ii)<font style="display:inline-block;width:23.78pt;"></font><b style="font-weight:bold;">Backup Right to Prosecute</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(A)<font style="display:inline-block;width:22.12pt;"></font>Jade shall notify Paragon of any decision not to prepare or file, or to abandon, cease prosecution or not maintain any Licensed Antibody Patent anywhere in the Territory. &#160;Jade shall provide such notice at least [***] days prior to any filing or payment due date, or any other due date that requires action, in connection with such Licensed Antibody Patent. &#160;In such event, Paragon shall have a backup right, but not the obligation, to prepare, file, or continue prosecution or maintenance of, such Licensed Antibody Patent, at Paragon&#8217;s expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(B)<font style="display:inline-block;width:22.67pt;"></font>Paragon shall notify Jade of any decision not to prepare or file, or to abandon, cease prosecution or not maintain any Licensed Antibody Patent anywhere in the Territory. &#160;Paragon shall provide such notice at least [***] days prior to any filing or payment due date, or any other due date that requires action, in connection with such Licensed Antibody Patent. &#160;In such event, Jade shall have a backup right, but not the obligation, to prepare, file, or continue prosecution or maintenance of, such Licensed Antibody Patent, at Jade&#8217;s expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(iii)<font style="display:inline-block;width:21pt;"></font><b style="font-weight:bold;">Cooperation in Patent Prosecution</b>. &#160;Each Party shall cooperate with the other Party in the preparation, filing, prosecution and maintenance of Licensed Antibody Patents, including in each case by providing the prosecuting Party with data and other information as appropriate and executing all necessary affidavits, assignments and other paperwork.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><b style="font-weight:bold;">Prosecution by Paragon</b>. &#160;Except with respect to Licensed Antibody Patents (which are addressed in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.2(b)</u>), Paragon shall be solely responsible for, and have sole discretion over, preparing, filing, prosecuting and maintaining any Patents (including the Other Licensed Patents and Paragon Multispecific Patents) that it owns or otherwise controls (the &#8220;<b style="font-weight:bold;">Paragon Patents</b>&#8221;). &#160;Paragon&#8217;s prosecution of any Paragon Patents shall be at Paragon&#8217;s sole expense. &#160;Notwithstanding the foregoing, in prosecuting any Paragon Multispecific Patents, Paragon hereby agrees that during the Term, neither Paragon nor any of its Affiliates or licensees will file, or assist any Third Party in filing, any Patent that includes a claim that expressly recites the sequence of a Licensed Antibody or Derived Antibody other than as part of a Paragon Multispecific Antibody.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><b style="font-weight:bold;">Patent Prosecution Costs Prior to the Effective Date</b>. &#160;Jade shall promptly reimburse Paragon for any actual costs and expenses reasonably incurred by Paragon that are related to the prosecution of any Licensed Antibody Patents prior to the Effective Date that have not been reimbursed by Jade under the Option Agreement. &#160; Jade will promptly reimburse Paragon for any future prosecution costs and expenses incurred by Paragon with respect to the Licensed Antibody Patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>[***] <b style="font-weight:bold;">Licensed Patents</b>. &#160;The Parties acknowledge and agree that Paragon has no right under the [***] License Agreement to file, prosecute or maintain the [***] Licensed Patents, and Jade has no right under this Agreement to file, prosecute or maintain the [***] Licensed Patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><b style="color:#333333;font-weight:bold;">CREATE Act</b>. &#160;Notwithstanding anything to the contrary in this Agreement, each Party will have the right to invoke the Cooperative Research and Technology Enhancement Act of 2004, 35 U.S.C. &#167; 103(c)(2)-(c)(3) (the &#8220;<b style="font-weight:bold;">CREATE Act</b>&#8221;) when exercising its rights under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;V</u> of this Agreement, without the prior written consent of the other Party. &#160;Where such Party intends to invoke the CREATE Act, it will notify the other Party and the other</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Party will cooperate and coordinate its activities with such Party with respect to any submissions, filings or other activities in support thereof. &#160;The Parties acknowledge and agree that this Agreement is a joint research agreement (JRA) as defined in the CREATE Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font><b style="font-weight:bold;">Disclosure of Jade Antibody Patents</b>. &#160;Upon the request of Paragon, Jade shall deliver to Paragon a list of the then-existing Jade Antibody Patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.3</font></font><b style="font-weight:bold;">Patent Enforcement and Defense</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><b style="font-weight:bold;">Notice of Patent Infringement and Patent Challenge</b>. &#160;Each Party shall give the other Party notice of any known or suspected infringement by a Third Party (&#8220;<b style="font-weight:bold;">Patent Infringement</b>&#8221;) of any Licensed Antibody Patent and any known or suspected challenge by a Third Party against the validity or enforceability (&#8220;<b style="font-weight:bold;">Patent Challenge</b>&#8221;) of any Licensed Antibody Patent within [***] days after such Patent Infringement or Patent Challenge comes to such Party&#8217;s attention.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><b style="font-weight:bold;">Jade&#8217;s First Right to Enforce or Defend</b>. &#160;Jade shall have the first right, but not the obligation, to bring and control any legal action, including by declaratory judgment action, patent litigation or similar proceeding, in connection with any Patent Infringement or Patent Challenge with respect to the Licensed Antibody Patents in the Territory at its own expense and discretion as it reasonably determines appropriate. &#160;Jade shall keep Paragon informed and reasonably consult with Paragon in the course of such legal action. &#160;Paragon shall have the right to be represented in any such legal action by counsel of its choice at its own expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><b style="font-weight:bold;">Paragon&#8217;s First Right to Enforce or Defend</b>. &#160;Paragon shall have the sole right, but not the obligation, to bring and control any legal action, including by declaratory judgment action, patent litigation or similar proceeding, in connection with any Patent Infringement or Patent Challenge with respect to the Paragon Patents in the Territory at its own expense and discretion as it reasonably determines appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><b style="font-weight:bold;">Settlement</b>. &#160;In connection with any such legal action or proceeding, Jade shall not enter into any settlement admitting the invalidity or unenforceability of Licensed Antibody Patents without the prior written consent of Paragon (such consent not to be unreasonably conditioned, withheld, or delayed).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><b style="font-weight:bold;">Paragon&#8217;s Backup Right to Enforce or Defend</b>. &#160;If Jade does not initiate a legal action for Patent Infringement or Patent Challenge with respect to any Licensed Antibody Patent within [***] days after a notice of such Patent Infringement or Patent Challenge under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.3(a)</u>, then Paragon shall have a backup right, but not the obligation, to initiate such legal action at its own expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><b style="font-weight:bold;">Allocation of Recoveries</b>. &#160;Any recoveries resulting from such legal action initiated by Jade or Paragon hereunder relating to Patent Infringement or Patent Challenge of the Licensed Antibody Patnets, including pursuant to a settlement, shall be applied as follows: (i) first to reimburse the [***] of each of the Parties in such action; and (ii) second, any amounts remaining after paying the amounts due each Party under clause (i) (the &#8220;<b style="font-weight:bold;">Remaining Recovery</b>&#8221;) shall be allocated as follows: (1) [***]; or (2) [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font><b style="font-weight:bold;">Cooperation with Patent Enforcement</b>. &#160;At the request of the enforcing Party (and at the requesting Party&#8217;s expense), the other Party shall reasonably cooperate and provide any information or assistance in connection with any legal action under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.3</u>, including executing reasonably appropriate documents, cooperating in discovery and, if required by Applicable Law, joining as a party to the legal action at its own expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</font></font>[***] <b style="font-weight:bold;">Licensed Patents</b>. &#160;The Parties acknowledge and agree that Paragon has no right under the [***] License Agreement to enforce the [***] Licensed Patents, and Jade has no right under this Agreement to enforce the [***] Licensed Patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.4</font></font><b style="font-weight:bold;">Third Party Patent Proceedings</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><b style="font-weight:bold;">Jade&#8217;s Right to Challenge Third Party Patents</b>. &#160;Jade shall have the sole and exclusive right, but not the obligation, to bring and control any legal action to challenge any Patents controlled by a Third Party, including by declaratory judgment action, patent interference, opposition, pre-issuance submission, <i style="font-style:italic;">ex parte</i> re-examination, post-grant review, <i style="font-style:italic;">inter partes</i> review, patent litigation or similar proceeding, in each case that are necessary or useful to Develop, Manufacture, Commercialize or otherwise exploit any Jade Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><b style="font-weight:bold;">Cooperation by Paragon</b>. &#160;At the request of Jade, Paragon shall cooperate and provide any information or assistance in connection with any legal action under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.4</u>, including executing reasonably appropriate documents, cooperating in discovery and, if required by Applicable Law, joining as a party to the action at Jade&#8217;s cost and expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.5</font></font><b style="font-weight:bold;">Common Interest Agreement</b>. &#160;At the request of either Party to conduct the activities under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;V</u>, the Parties shall cooperate [***] to enter into a customary common-interest agreement intended to preserve attorney-client privilege with respect to disclosures and communications by or on behalf of either Party or its Affiliates in connection with such activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article&#160;VI</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">PROTECTION OF CONFIDENTIAL INFORMATION.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.1</font></font><b style="font-weight:bold;">Confidentiality</b>. &#160;Except to the extent expressly authorized by this Agreement, the Receiving Party agrees that, during the Term and for [***] years thereafter, it shall keep confidential and shall not publish or otherwise disclose to any Third Party, and shall not use for any purpose other than as expressly provided for in this Agreement, any Confidential Information of the Disclosing Party. &#160;The Receiving Party may disclose Confidential Information of the Disclosing Party to those of the Receiving Party&#8217;s Representatives who have a need for such information, <i style="font-style:italic;">provided, that</i> the Receiving Party shall advise such Representatives of the confidential nature thereof, shall ensure that each such Representative is bound in writing by obligations of confidentiality and non-use at least as stringent as those contained in this Agreement, and shall be responsible for the compliance of its Representatives with the terms of this Agreement. &#160;The Receiving Party shall use at least the same standard of care as it uses to protect proprietary or confidential information of its own (but in no event less than reasonable care) to ensure that its Representatives do not disclose or make any unauthorized use of the Confidential Information of the Disclosing Party. &#160;The Receiving Party shall promptly notify the Disclosing Party upon</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">discovery of any unauthorized use or disclosure of the Confidential Information of the Disclosing Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.2</font></font><b style="font-weight:bold;">Exceptions</b>. &#160;The Receiving Party&#8217;s obligations under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.1</u> shall not apply to any Confidential Information of the Disclosing Party that the Receiving Party can prove by competent evidence: (a) is now, or hereafter becomes, through no act or failure to act on the part of the Receiving Party in breach of this Agreement, generally known or available; (b) is known by the Receiving Party at the time of receiving such information from the Disclosing Party; (c) is hereafter furnished to the Receiving Party by a Third Party, as a matter of right and without restriction on disclosure; or (d) is independently discovered or developed by the Receiving Party, without the aid, use or application of any Confidential Information of the Disclosing Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.3</font></font><b style="font-weight:bold;">Authorized Disclosure</b>. &#160;Notwithstanding the provisions of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VI</u>, the Receiving Party may disclose Confidential Information, without violating its obligations under this Agreement, to the extent the disclosure is:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>required by a valid order of a court or other governmental body of competent jurisdiction or as otherwise required by Applicable Law, rule, regulation (including securities laws and regulations), government requirement, or as may be required in connection with any filings made with, or by the disclosure policies of, a stock exchange, <i style="font-style:italic;">provided, that</i> the Receiving Party shall give reasonable prior written notice to the Disclosing Party of such required disclosure and, at the [***] request and expense, shall cooperate with the Disclosing Party&#8217;s efforts to contest such requirement, to obtain a protective order requiring that the Confidential Information so disclosed be used only for the purposes for which the order was issued or the law, rule or regulation required, or to obtain other confidential treatment of such Confidential Information; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>reasonably necessary to file or prosecute patent applications, prosecute or defend litigation or otherwise establish rights or enforce obligations under this Agreement, or obtain or maintain approval to conduct clinical trials or Regulatory Approvals, in each case, in accordance with this Agreement; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>under appropriate confidentiality provisions substantially equivalent to those in this Agreement (but of shorter duration if customary in the case of subclause (ii)): (i) in connection with the performance of its obligations or as reasonably necessary or useful in the exercise of its rights under this Agreement, including the right to grant licenses or sublicenses as permitted hereunder and the right to Develop, Manufacture, Commercialize and otherwise exploit Antibodies and products to which it has rights hereunder, or (ii) to actual or bona fide potential licensees, acquirers, merger partners, assignees, collaborators, investment bankers, investors or lenders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.4</font></font><b style="font-weight:bold;">Confidentiality of this Agreement</b>. &#160;This Agreement and its terms are considered Confidential Information of both Parties, and each Party shall keep confidential and shall not publish or otherwise disclose the terms of this Agreement without the prior written consent of the other Party, except as expressly permitted by <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.3</u>, and except that both Parties may disclose this Agreement and its terms to its legal, financial and investment banking advisors; <i style="font-style:italic;">bona fide</i> potential and actual investors, acquirers, merger partners, assignees, collaborators, investment bankers, lenders, licensees, sublicensees or strategic partners in connection with license or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">partnering transactions, due diligence or similar investigations by such Third Parties or in confidential financing documents; and counsel or other advisors for the foregoing; <i style="font-style:italic;">provided</i>, in each case, that any such Third Party agrees to be bound by obligations of confidentiality and non-use at least as restrictive as those set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VI</u> (<i style="font-style:italic;">provided, that</i> the confidentiality term applicable to such Third Party may be shorter so long as it is commercially reasonable).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.5</font></font><b style="font-weight:bold;">Publicity</b>. &#160;Neither Party will generate or allow any publicity regarding this Agreement or the transactions contemplated hereunder without the other Party first approving such press release or publication in writing, except for any public disclosure by or on behalf of a Party that is, in the opinion of such Party&#8217;s counsel, required by Applicable Law or the rules of a stock exchange on which the securities of such Party are listed (or to which an application for listing has been submitted) and except that a Party may, once a press release or other public written statement is approved in writing by both Parties, make subsequent public disclosure of the information contained in such press release or other public written statement without the further approval of the other Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.6</font></font><b style="font-weight:bold;">Return of Confidential Information</b>. &#160;Promptly after the termination or expiration of this Agreement for any reason, each Party will return to the other Party or destroy, as such other Party will direct, all tangible manifestations of such other Party&#8217;s Confidential Information at that time in the possession of the receiving Party, subject to the receiving Party&#8217;s right to maintain one copy of such tangible manifestations of such other Party&#8217;s Confidential Information solely for purposes of monitoring its compliance with this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article&#160;VII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REPRESENTATIONS AND WARRANTIES.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.1</font></font><b style="font-weight:bold;">Mutual Representations</b>. &#160;Each Party represents and warrants to the other Party that: &#160;(a) it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof; (b) it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder; and (c) this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not and will not conflict with any agreement, instrument, or understanding, oral or written, to which it is or may become a party or by which it may be or become bound.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.2</font></font><b style="font-weight:bold;">Representations of Paragon</b>. &#160;Paragon hereby represents and warrants to Jade as of the Effective Date that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Paragon has set forth, in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</u>, a complete and accurate list of all the Licensed Antibody Patents existing as of the Effective Date (including title, all inventors, owners, assignees, filing date, grant date, expiration date and status);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Paragon has properly filed, prosecuted and maintained the Licensed Antibody Patents existing as of the Effective Date;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Paragon has complied with all duties of disclosure and has not engaged in any inequitable conduct with respect to all Licensed Antibody Patents existing as of the Effective Date;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>all Licensed Antibody Patents listed in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</u> that have been issued as of the Effective Date are in full force and effect and are, to Paragon&#8217;s knowledge, valid and enforceable;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>other than the Licensed Antibody Patents listed in&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</u>, as of the Effective Date neither Paragon nor any of its Affiliates own or have any rights in, to or under any Patents Covering any Licensed Antibody, or their composition, or any method of specifically manufacturing such Antibodies;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font>there are no judgments against or awards or settlements against Paragon or any of its Affiliates, and there are no claims, actions, or proceedings pending or, to Paragon&#8217;s knowledge, threatened, nor to Paragon&#8217;s knowledge are there any formal inquiries initiated or written notices received that are reasonably likely to lead to the institution of any such legal proceedings, in each case (i) relating to any Licensed Antibodies or Licensed Antibody Technology or alleging that any Third Party has any right to or under any Licensed Antibodies or Licensed Antibody Technology that would conflict with the rights granted in this Agreement; or (ii) alleging that any Licensed Antibody Patent is unpatentable, invalid, unenforceable or infringed;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font>all of Paragon&#8217;s and its Affiliates&#8217; employees, officers, subcontractors and consultants: (i) have assigned, or are under contractual obligations to assign, to Paragon all inventions conceived, reduced to practice or otherwise related to the Licensed Antibodies or Licensed Antibody Technology; (ii) to Paragon&#8217;s knowledge, have no obligations under agreements or Applicable Law to assign any interest in any such inventions to any Third Party; and (iii) have existing obligations under agreements or Applicable Law to maintain as confidential Paragon&#8217;s Confidential Information as well as confidential information of other parties (including of Jade and its Affiliates);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</font></font>none of Paragon, its Representatives, or any other person used by Paragon in the performance of this Agreement has been or is (i) debarred, convicted, or is subject to a pending debarment or conviction, pursuant to section 306 of the United States Food Drug and Cosmetic Act, 21 U.S.C. &#167; 335a, (ii) listed by any government or regulatory agencies as ineligible to participate in any government healthcare programs or government procurement or non-procurement programs (as that term is defined in 42 U.S.C. 1320a-7b(f)), or excluded, debarred, suspended or otherwise made ineligible to participate in any such program, or (iii) convicted of a criminal offense related to the provision of healthcare items or services, or is subject to any such pending action. &#160;Paragon agrees to inform Jade in writing promptly if Paragon or any person who is performing activities on its behalf under the Agreement is subject to the foregoing, or if any action, suit, claim, investigation, or proceeding relating to the foregoing is pending or threatened;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font>no funding, facilities, or personnel of any governmental authority or any public or private educational or research institutions were used to develop or create any Licensed Antibody Technology, and neither Paragon nor any of its Affiliates has entered into a government</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">funding relationship that would result in rights to any Jade Products residing in the U.S. Government, the National Institutes of Health, or other agency, and the licenses granted hereunder are not subject to overriding obligations to the U.S. Government as set forth in Public Law 96-517 (35 U.S.C. &#167;&#167;&#160;200-204), or any similar obligations under the laws of any other country in the Territory; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</font></font>(i)&#160;the version of the [***] License Agreement attached to this Agreement as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u> is a true, correct and complete copy of the [***] License Agreement as of the Effective Date, (ii)&#160;Paragon has not received a notice of breach, default or termination from [***] under the [***] License Agreement, nor has Paragon delivered a notice of breach, default or termination to [***] under the [***] License Agreement, and (iii)&#160;to the knowledge of Paragon, the [***] License Agreement is in full force and effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(k)</font></font>Subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;V</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;10.6</u>, during the Term, Paragon will not grant a Third Party any license or other right in the Licensed Antibody Technology that would conflict with the rights and licenses granted to Jade hereunder with respect to such Licensed Antibody Technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.3</font></font><b style="font-weight:bold;">DISCLAIMER OF WARRANTIES</b>. &#160;EXCEPT AS EXPRESSLY SET FORTH HEREIN, EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, DURABILITY, MERCHANTABLE QUALITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article&#160;VIII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TERM; TERMINATION.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.1</font></font><b style="font-weight:bold;">Term</b>. &#160;The term of this Agreement shall commence on the Effective Date and shall expire on a country-by-country and Jade Product-by-Jade Product basis on the expiration of the Royalty Term for such Jade Product in such country, in each case, unless earlier terminated by a Party as set forth below in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VIII </u>(the &#8220;<b style="font-weight:bold;">Term</b>&#8221;). &#160;Upon expiration (but not termination) of the Agreement, the licenses granted in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1</u> shall survive and become royalty-free, fully paid-up, perpetual and irrevocable with respect to the applicable Jade Product in the applicable country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.2</font></font><b style="font-weight:bold;">Termination by Jade</b>. &#160;Jade shall have the right to terminate this Agreement in its entirety or on a country-by-country or Jade Product-by-Jade Product basis for any or no reason upon sixty (60) days&#8217; prior written notice to Paragon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.3</font></font><b style="font-weight:bold;">Material Breach</b>. &#160;Either Party may terminate this Agreement in its entirety for the material breach of this Agreement by the other Party, if such material breach remains uncured ninety (90) days (or thirty (30) days with respect to (a) any failure to make any payments owing to a Party hereunder, or (b) any material breach of this Agreement by Jade that also constitutes a breach of the [***] License Agreement) following notice from the non-breaching Party to the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">breaching Party specifying such breach, <i style="font-style:italic;">provided, that</i>, in the event of a dispute regarding the existence or cure of a material breach, no termination shall become effective until such dispute is finally resolved pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.7</u> in favor of the non-breaching Party and the breaching Party fails to cure such material breach within ninety (90) days thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.4</font></font><b style="font-weight:bold;">Insolvency</b>. &#160;Each Party will have the right to terminate this Agreement in the event of a Bankruptcy Event with respect to the other Party. &#160;&#8220;<b style="font-weight:bold;">Bankruptcy Event&#8221; </b>means the occurrence of any of the following: (a) the institution of any bankruptcy, receivership, insolvency, reorganization or other similar proceedings by or against a Party under any bankruptcy, insolvency, or other similar law now or hereinafter in effect, including any section or chapter of the United States Bankruptcy Code, as amended or under any similar laws or statutes of the United States or any state thereof (the &#8220;<b style="font-weight:bold;">Bankruptcy Code</b>&#8221;), where in the case of involuntary proceedings such proceedings have not been dismissed or discharged within [***] days after they are instituted, (b) the insolvency or making of an assignment for the benefit of creditors or the admittance by a Party of any involuntary debts as they mature, (c) the institution of any reorganization, arrangement or other readjustment of debt plan of a Party not involving the Bankruptcy Code, (d)&#160;appointment of a receiver for all or substantially all of a Party&#8217;s assets, or (e) any corporate action taken by the board of directors of a Party in furtherance of any of the foregoing actions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.5</font></font><b style="font-weight:bold;">Termination of </b>[***] <b style="font-weight:bold;">License Agreement</b>. &#160;In the event the [***] License Agreement is terminated in its entirety, this Agreement shall remain in full force and effect, provided that Jade is not in material breach of the terms of this Agreement, and agrees to be bound to [***] as a licensor under the terms and conditions of the [***] License Agreement. &#160;Jade shall have the option, in its sole discretion, to promptly enter into an appropriate agreement with [***] pursuant to Section 10.6(b) of the [***] License Agreement and the Parties will promptly enter into an amendment to this Agreement to effectuate the foregoing, including directing that all payments owed by Jade under the [***] License Agreement as of the effective date of termination of the [***] License Agreement shall be paid directly to [***] and, which for clarity, will not in the aggregate result in Jade owing any more, for any given payment, to [***] and Paragon than it otherwise would have owed if the [***] License Agreement was not terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.6</font></font><b style="font-weight:bold;">Effect of Termination of this Agreement</b>. &#160;If this Agreement terminates for any reason (excluding expiration under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.1</u>), whether with respect to a particular Jade Product, particular country or in its entirety, then the following shall apply:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>All licenses and other rights granted by Paragon to Jade under this Agreement with respect to the terminated Jade Product(s) and terminated country(ies) shall terminate, except as required for Jade, its Affiliates and/or its Sublicensees to perform any of its obligations that survive termination, including to continue to complete or wind down any ongoing clinical trials for any Jade Product, as may be required by Applicable Law or ethical principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>No later than [***] days after the effective date of such termination, each Party shall return or cause to be returned to the other Party, or destroy, all Confidential Information received from the other Party and all copies thereof related to the terminated Jade Product(s) in the terminated country(ies); <i style="font-style:italic;">provided, however</i>, that each Party may retain any Confidential Information reasonably necessary for such Party&#8217;s ongoing obligations and rights under this Agreement which do not terminate, and each Party may keep one (1) copy of Confidential</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Information received from the other Party in its confidential files for record purposes and such copy shall remain subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VI</u> of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Upon Paragon&#8217;s written request to Jade, Paragon and Jade shall [***] discuss [***], for a period of up to [***] days following such written request, terms and conditions under which Jade may be willing to grant to Paragon [***], [***] license under the Jade Intellectual Property to Develop, Manufacture, Commercialize and otherwise exploit the terminated Jade Products in the Field in the terminated countries that were the subject of any Development, Manufacturing or Commercialization activities performed by Jade or its Affiliates under this Agreement prior to such termination (&#8220;<b style="font-weight:bold;">Reversion Products</b>&#8221;), as well as the potential transfer of materials, ongoing clinical trials and applicable regulatory filings and relevant data generated by Jade with respect to the Reversion Products and necessary for the Development, Manufacture, Commercialization or other exploitation of such Reversion Products, such agreement to include commercially reasonable financial and other terms (including the granting of a right of reference and the exchange of pharmacovigilance information, as applicable), which terms shall take into consideration Jade&#8217;s contributions made in the Development, Manufacture, Commercialization and other exploitation of the Reversion Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.7</font></font><b style="font-weight:bold;">Survival of Sublicenses</b>. &#160;Upon termination of this Agreement, at the written request of any Sublicensee who is not then in breach of its sublicense agreement, such sublicense agreement will survive such termination of this Agreement, and Paragon will negotiate [***] the terms and conditions of a direct license with such Sublicensee that is consistent with the terms of this Agreement (as adjusted for the scope of license, products, field of use and other provisions of the original sublicense). &#160;For clarity, Paragon shall have no obligation with respect to any Sublicensee that is greater than or in addition to the obligations of Paragon to Jade under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.8</font></font><b style="font-weight:bold;">Accrued Rights; Survival</b>. &#160;The expiration or termination of this Agreement for any reason shall not release either Party from any liability or obligation that, at the time of such expiration or termination, has already accrued to the other Party or that is attributable to a period prior to such expiration or termination, nor will expiration or any termination of this Agreement preclude either Party from pursuing all rights and remedies it may have under this Agreement, or at law or in equity, with respect to breach of this Agreement. &#160;In the event of expiration or any termination of this Agreement, the following provisions of this Agreement shall survive such expiration or termination in accordance with their respective terms and conditions: &#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;I</u> (Definitions); <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1</u> (License Grants from Paragon) (upon expiration (but not termination) of this Agreement as set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.1</u> (Term)); <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2</u> (Sublicenses) (with respect to any payments or other performance obligations prior to conversion (if any) to a direct license pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.7</u>); <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.3</u> (No Implied Licenses; Reservation of Rights); <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 4.1 </u>(Reimbursement of Payments to [***]) to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.3</u> (Royalties) (with respect to any outstanding payment obligations that have accrued prior to the date of termination or expiration); <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.3(d)</u> (Payment Reports) (with respect any Royalty Payments that have accrued prior to the date of termination or expiration); <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.5</u> (Payment Method) to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.9</u> (Blocked Currency) (for the duration of any outstanding payment obligations under this Agreement); <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.10</u> (Records; Inspection) (for the duration set forth therein); <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1</u> (Ownership); <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.3</u> (Disclaimer of Warranties); <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VI</u> (Protection of Confidential Information) (for the duration set forth therein); <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.6</u> (Effect of Termination of this Agreement); <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.7</u> (Survival of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Sublicenses); <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.8</u> (Accrued Rights; Survival); <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IX</u> (Indemnification); and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;X</u> (Miscellaneous).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article&#160;IX</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INDEMNIFICATION.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.1</font></font><b style="font-weight:bold;">By Jade</b>. &#160;Jade hereby agrees to defend, indemnify and hold harmless Paragon, its Affiliates and its or their Representatives (each, an &#8220;<b style="font-weight:bold;">Paragon Indemnitee</b>&#8221;) from and against any and all losses, damages, liabilities, expenses and costs, including reasonable legal expense and attorneys&#8217; fees (collectively, &#8220;<b style="font-weight:bold;">Losses</b>&#8221;), to which any Paragon Indemnitee may become subject as a result of any claim, demand, action, or other proceeding by any Third Party (&#8220;<b style="font-weight:bold;">Third Party Claim</b>&#8221;) to the extent such Losses result from: (a) the gross negligence, recklessness or willful misconduct of any Jade Indemnitee in the performance of this Agreement; (b) Jade&#8217;s breach of any of its representations, warranties or covenants under this Agreement; (c) Jade&#8217;s Development, Manufacture, Commercialization or other exploitation of Jade Products (but, for clarity, excluding any activities conducted by Paragon under this Agreement or the Option Agreement); or (d) any breach of the [***] License Agreement that is caused by the actions or omissions of Jade or its Affiliates or Sublicensees, in each case ((a) to (d)), except in each case to the extent that any such Losses are indemnifiable by Paragon under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.2</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.2</font></font><b style="font-weight:bold;">By Paragon</b>. &#160;Paragon hereby agrees to defend, indemnify, and hold harmless Jade, its Affiliates, and its or their Representatives (each, an &#8220;<b style="font-weight:bold;">Jade Indemnitee</b>&#8221;) from and against any and all Losses to which any Jade Indemnitee may become subject as a result of any Third Party Claim to the extent such Losses result from: (a) the gross negligence, recklessness or willful misconduct of any Paragon Indemnitee in the performance of this Agreement; or (b) Paragon&#8217;s breach of any of its representations, warranties or covenants under this Agreement; in each case ((a) to (b)), except in each case to the extent that any such Losses are indemnifiable by Jade under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.3</font></font><b style="font-weight:bold;">Indemnification</b><b style="font-weight:bold;"> Procedures</b>. &#160;The Party claiming indemnity under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IX</u> (the &#8220;<b style="font-weight:bold;">Indemnified Party</b>&#8221;) will give written notice to the Party from whom indemnity is being sought (the &#8220;<b style="font-weight:bold;">Indemnifying Party</b>&#8221;) promptly after learning of the Third Party Claim for which indemnity is being sought (&#8220;<b style="font-weight:bold;">Claim</b>&#8221;). &#160;The Indemnifying Party&#8217;s obligation to defend, indemnify and hold harmless pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.2</u>, as applicable, will be reduced to the extent the Indemnified Party&#8217;s delay in providing notification pursuant to the previous sentence results in material prejudice to the Indemnifying Party; <i style="font-style:italic;">provided, however,</i> that the failure by an Indemnified Party to give such notice or otherwise meet its obligations under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.3</u> will not relieve the Indemnifying Party of its indemnification obligation under this Agreement. &#160;At its option, the Indemnifying Party may assume the defense and have exclusive control, at its own expense, of any Claim for which indemnity is being sought by giving written notice to the Indemnified Party within [***] days after receipt of the notice of the Claim, <i style="font-style:italic;">provided, that</i> (a) it agrees to indemnify the Indemnified Party from and against all Losses the Indemnified Party may suffer arising out of the Claim; (b) the Claim involves only money damages and does not seek an injunction or other equitable relief against the Indemnified Party; and (c) the Indemnifying Party conducts the defense of the Claim diligently. &#160;The Indemnified Party will provide the Indemnifying Party with reasonable assistance, at the Indemnifying Party&#8217;s expense, in connection with the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">defense. &#160;The Indemnified Party may participate in and monitor such defense with counsel of its own choosing at its sole expense; <i style="font-style:italic;">provided, however, </i>the Indemnifying Party will have the right to assume and conduct the defense of the Claim with counsel of its choice. &#160;The Indemnifying Party will not settle any Claim without the prior written consent of the Indemnified Party, not to be unreasonably withheld, unless the settlement involves only the payment of money. &#160;The Indemnified Party will not settle any such Claim without the prior written consent of the Indemnifying Party. &#160;If the Indemnifying Party does not assume and conduct the defense of the Claim as provided above, (i) the Indemnified Party may defend against, and consent to the entry of any judgment or enter into any settlement with respect to the Claim in any manner the Indemnified Party may deem reasonably appropriate (and the Indemnified Party need not consult with, or obtain any consent from, the Indemnifying Party in connection therewith), and (ii) the Indemnified Party reserves any right it may have under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IX</u> to obtain indemnification from the Indemnifying Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.4</font></font><b style="font-weight:bold;">Limitation of Liability</b>. &#160;EXCEPT FOR LIABILITY FOR BREACH OF <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">Article&#160;VI</u><font style="text-transform:uppercase;">,</font> FRAUD OR WILLFUL MISCONDUCT OR FOR INDEMNIFICATION CLAIMS UNDER THIS <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">Article&#160;IX</u>, IN NO EVENT SHALL EITHER PARTY BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT, EVEN IF THE OTHER PARTY HAD NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.5</font></font><b style="font-weight:bold;">Insurance</b>. &#160;Jade shall maintain at its expense insurance coverage consistent with normal business practices and adequate to cover the risks associated with its performance of any activities hereunder, and Jade acknowledges and agrees that the maintenance of such insurance coverage shall not relieve Jade of its obligations under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article&#160;X</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MISCELLANEOUS.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.1</font></font><b style="font-weight:bold;">Independent</b><b style="font-weight:bold;"> Contractor Relationship</b>. &#160;Paragon&#8217;s relationship with Jade is that of an independent contractor, and nothing in this Agreement should be construed to create a partnership, joint venture, or employer-employee relationship. &#160;Neither Party is an agent of the other Party or authorized to make any representation, contract, or commitment on behalf of the other Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.2</font></font><b style="font-weight:bold;">Force Majeure</b>. &#160;Neither Party will be charged with any liability for delay or failure in performance of an obligation under this Agreement (other than any obligation to pay monies when due) to the extent such delay or failure is due to a cause beyond the reasonable control of the affected Party, such as war, riots, labor disturbances, epidemic, pandemic, fire, explosion, and compliance in good faith with any Applicable Law (in each case, a &#8220;<b style="font-weight:bold;">Force Majeure</b>&#8221;). &#160;The Party affected by a Force Majeure will give prompt written notice to the other Party of the nature of the cause of any material delay or failure to perform, its anticipated duration and any action being taken to avoid or minimize the effect. &#160;The Party affected will use its diligent efforts to avoid or remove such causes of delay or failure to perform and to mitigate the effect of such occurrence, and will continue performance in accordance with the terms of this Agreement whenever such</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">causes are removed. &#160;The Party affected will give prompt written notice to the other Party of such resumed performance. &#160;If any such failure or delay in a Party&#8217;s performance hereunder continues for more than [***] days, the other Party may terminate this Agreement upon written notice to the affected Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.3</font></font><b style="font-weight:bold;">Entire Agreement; Amendment</b>. &#160;This Agreement, together with all Exhibits attached hereto, constitutes the final, complete, and exclusive agreement of the Parties with respect to the subject matter hereof and supersedes all prior and contemporaneous understandings and agreements, relating to its subject matter. &#160;This Agreement (including its Exhibits) may not be changed, modified, amended, or supplemented except by a written instrument signed by both Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.4</font></font><b style="font-weight:bold;">Non-Waiver</b>. &#160;The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance. &#160;Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.5</font></font><b style="font-weight:bold;">Severability</b>. &#160;Should one or more of the provisions of this Agreement become void or unenforceable as a matter of Applicable Law, then this Agreement shall be construed as if such provision were not contained herein and the remainder of this Agreement shall be in full force and effect, and the Parties will use their best efforts to substitute for the invalid or unenforceable provision a valid and enforceable provision which conforms as nearly as possible with the original intent of the Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.6</font></font><b style="font-weight:bold;">Assignment</b>. &#160;Neither this Agreement nor any rights or obligations hereunder may be assigned by either Party without the prior written consent of the other Party (which consent shall not be unreasonably withheld); <i style="font-style:italic;">provided, however</i>, that (a) Paragon may assign to an Affiliate or a Third Party its rights to receive some or all of the payments payable hereunder together with the right to receive Confidential Information of Jade, subject to compliance with commercially reasonable confidentiality and non-use obligations; and (b)&#160;either Party may assign this Agreement without the other Party&#8217;s consent to (i) its Affiliates or (ii) its successor to all or substantially all of the business of such Party to which this Agreement relates, whether by merger, sale of stock, sale of assets or otherwise. &#160;The assigning Party shall provide the other Party with prompt written notice of any such assignment. &#160;Except for an assignment pursuant to clause (a) above, the rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties, and the name of a Party appearing herein will be deemed to include the name of such Party&#8217;s successors and permitted assigns to the extent necessary to carry out the intent of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;10.6</u>. &#160;Any assignment not in accordance with this Agreement shall be void.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.7</font></font><b style="font-weight:bold;">Dispute</b><b style="font-weight:bold;"> Resolution</b>. &#160;The Parties recognize that a <i style="font-style:italic;">bona fide </i>dispute as to certain matters may arise from time to time during the Term relating to either Party&#8217;s rights or obligations hereunder or otherwise relating to the validity, enforceability or performance of this Agreement, including disputes relating to alleged breach or termination of this Agreement but excluding any disputes relating to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VI </u>or disputes relating to the determination of the validity, scope,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">infringement, enforceability, inventorship or ownership of the Parties&#8217; respective Intellectual Property Rights (hereinafter, a &#8220;<b style="font-weight:bold;">Dispute</b>&#8221;). &#160;In the event of the occurrence of any Dispute, the Parties will follow the following procedures in an attempt to resolve the dispute or disagreement:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>The Party claiming that such a Dispute exists will give notice in writing (a &#8220;<b style="font-weight:bold;">Notice of Dispute</b>&#8221;) to the other Party of the nature of the Dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>The Dispute will be referred to the then Chief Executive Officer of Paragon (or such individual&#8217;s designee) and the then Chief Executive Officer of Jade (or such individual&#8217;s designee) who will meet no later than [***] days following the initial receipt of the Notice of Dispute and use reasonable endeavors to resolve the Dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>If, within [***] days of initial receipt of the Notice of Dispute, the Dispute has not been resolved, or if, for any reason, the meeting described in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.7(b)</u> hereof has not been held within [***] days of initial receipt of the Notice of Dispute, then the Parties agree that such Dispute will be finally resolved through binding arbitration to be administered by JAMS pursuant to its Comprehensive Arbitration Rules and Procedures and in accordance with the Expedited Procedures in those Rules, as specifically modified by the provisions of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;10.7(c)</u>. &#160;The arbitration will be conducted by a panel of three arbitrators. &#160;Within [***] days after the initiation of the arbitration, each Party will nominate one person to act as arbitrator, and the two arbitrators so named will then jointly appoint the third arbitrator within [***] days of their appointment, who will serve as chairman of the panel. &#160;All three arbitrators must be independent Third Parties having at least [***] years of dispute resolution experience (which may include judicial experience) or legal or business experience in the biotech or pharmaceutical industry. &#160;If either Party fails to nominate its arbitrator, or if the arbitrators selected by the Parties cannot agree on a person to be named as chairman within such [***]-day period, JAMS will make the necessary appointments for such arbitrator(s) or the chairman. &#160;Once appointed by a Party, such Party will have no <i style="font-style:italic;">ex parte </i>communication with its appointed arbitrator. &#160;The place of arbitration will be in Boston, Massachusetts or such other venue as the Parties may mutually agree. &#160;The arbitration proceedings and all communications with respect thereto will be in English. &#160;Any written evidence originally in another language will be submitted in English translation accompanied by the original or a true copy thereof. &#160;The arbitrators have the power to decide all matters in Dispute, including any questions of whether or not such matters are subject to arbitration hereunder. &#160;The arbitration will be governed by the Federal Arbitration Act, 9 U.S.C. &#167;&#167;1 <i style="font-style:italic;">et seq., </i>and judgment upon the award rendered by the arbitrators may be entered in any court having competent jurisdiction thereof. &#160;The existence, content and results of any arbitration proceedings pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.7</u> will be deemed the Confidential Information of both Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>Notwithstanding any provision of this Agreement to the contrary, either Party may immediately initiate litigation in any court of competent jurisdiction seeking any remedy at law or in equity, including the issuance of a preliminary, temporary or permanent injunction, to preserve or enforce its rights under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>The Parties agree that any disputes relating to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VI </u>or disputes relating to the determination of the validity, scope, infringement, enforceability, inventorship or ownership of the Parties&#8217; respective Intellectual Property Rights shall be subject to the exclusive jurisdiction</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of the state and federal courts in Boston, Massachusetts and each Party hereby submits to such jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.8</font></font><b style="font-weight:bold;">Governing</b><b style="font-weight:bold;"> Law</b>. &#160;This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts without reference to conflicts of laws principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.9</font></font><b style="font-weight:bold;">Notices</b>. &#160;Any notice to be given under this Agreement must be in writing and delivered either in person, by internationally recognized express courier, by email, or by facsimile, to the Party to be notified at its address(es) given below, or at any address such Party has previously designated by prior written notice to the other. &#160;Notice shall be deemed sufficiently given for all purposes upon the earliest of: (a) the date of actual receipt; (b) if delivered by express courier, the next Business Day the express courier regularly makes deliveries; or (c) if delivered by email, upon the date upon which the receipt of such email is confirmed by return email. &#160;Together with any notice provided by a Party to the other Party in accordance with this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.9</u>, the Party shall send a copy of such notice by email to the other Party.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">If to Paragon:</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Paragon Therapeutics, Inc. </p></td></tr><tr><td style="vertical-align:bottom;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 31pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">221 Crescent Street</p></td></tr><tr><td style="vertical-align:bottom;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Building 23, Suite 105</p></td></tr><tr><td style="vertical-align:bottom;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Waltham, MA 02453</p></td></tr><tr><td style="vertical-align:bottom;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attn: Chief Operating Officer</p></td></tr><tr><td style="vertical-align:bottom;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: [***]</p></td></tr><tr><td style="vertical-align:bottom;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">If to Jade:</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jade Biosciences, Inc.</p></td></tr><tr><td style="vertical-align:bottom;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">221 Crescent Street</p></td></tr><tr><td style="vertical-align:bottom;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Building 23, Suite 105</p></td></tr><tr><td style="vertical-align:bottom;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Waltham, MA 02453</p></td></tr><tr><td style="vertical-align:bottom;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attn: Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: [***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.10</font></font><b style="font-weight:bold;">Interpretation</b>. &#160;Except where the context expressly requires otherwise, (a)&#160;the use of any gender herein shall be deemed to encompass references to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b)&#160;the words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without limitation&#8221;, (c)&#160;the word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall&#8221;, (d)&#160;any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (e) any reference herein to any person or entity shall be construed to include such person&#8217;s or entity&#8217;s successors and assigns, (f) the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) all references herein to Sections or Exhibits shall be construed to refer to Sections or Exhibits of this Agreement, and references to this Agreement include all Exhibits hereto, (h) the word &#8220;notice&#8221; means notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement, (i) provisions that require that a</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Party, the Parties or any committee hereunder &#8220;agree,&#8221; &#8220;consent&#8221; or &#8220;approve&#8221; or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and instant messaging), (j) references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof, and (k) the term &#8220;or&#8221; shall be interpreted in the inclusive sense commonly associated with the term &#8220;or.&#8221; &#160;The headings of clauses contained in this Agreement preceding the text of the sections, subsections and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement or have any effect on its interpretation or construction. &#160;Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist. &#160;This Agreement has been prepared in the English language, and the English language shall control its interpretation. &#160;In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral, or other communications between the Parties regarding this Agreement shall be in the English language. &#160;To the extent there is any inconsistency or conflict between the terms and conditions of this Agreement and any exhibit, the terms and conditions of this Agreement will prevail.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.11</font></font><b style="font-weight:bold;">No </b><b style="font-weight:bold;">Third</b><b style="font-weight:bold;">-Party Rights</b>. &#160;The provisions of this Agreement are for the exclusive benefit of the Parties and their successors and permitted assigns, and no other person shall have any right or claim against any Party by reason of these provisions or be entitled to enforce any of these provisions against any Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.12</font></font><b style="font-weight:bold;">Counterparts</b>. &#160;This Agreement may be executed in counterparts, each of which shall be deemed an original document, and all of which, together with this writing, shall be deemed one instrument. &#160;This Agreement may be executed by facsimile or PDF signatures, which signatures shall have the same force and effect as original signatures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.13</font></font><b style="font-weight:bold;">Expenses</b>. &#160;Each Party shall pay its own costs, charges and expenses incurred in connection with the negotiation, preparation and completion of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.14</font></font><b style="font-weight:bold;">Binding</b><b style="font-weight:bold;"> Effect</b>. &#160;This Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal representatives, successors and permitted assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.15</font></font><b style="font-weight:bold;">Construction</b>. &#160;The Parties hereto acknowledge and agree that: (a) each Party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; (b) the rule of construction to the effect that any ambiguities are resolved against the drafting Party shall not be employed in the interpretation of this Agreement; and (c) the terms and provisions of this Agreement shall be construed fairly as to all Parties hereto and not in a favor of or against any Party, regardless of which Party was generally responsible for the preparation of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.16</font></font><b style="font-weight:bold;">Cumulative</b><b style="font-weight:bold;"> Remedies</b>. &#160;No remedy referred to in this Agreement is intended to be exclusive unless explicitly stated to be so, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.17</font></font><b style="font-weight:bold;">Performance by Affiliates</b>. &#160;A Party may perform some or all of its obligations under this Agreement through Affiliate(s) or may exercise some or all of its rights under this Agreement through Affiliates, subject to the terms of this Agreement. &#160;However, each Party shall remain responsible and be guarantor of the performance by its Affiliates and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance as if such Party were performing such obligations itself, and references to a Party in this Agreement shall be deemed to also reference such Affiliate. &#160;In particular and without limitation, all Affiliates of a Party that receive Confidential Information of the other Party pursuant to this Agreement shall be governed and bound by all obligations set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VI</u><i style="font-style:italic;">, </i>and shall be subject to the intellectual property provisions of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;V</u> as if they were the original Party to this Agreement (and be deemed included in the actual Party to this Agreement for purposes of all intellectual property-related definitions). &#160;A Party and its Affiliates shall be jointly and severally liable for their performance under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[<i style="font-style:italic;">Remainder of Page Left Intentionally Blank; Signature Page Follows</i>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the Parties have by duly authorized persons executed this Agreement as of the Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:4.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PARAGON THERAPEUTICS, INC.</b></p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">JADE BIOSCIENCES, INC.</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:bottom;width:44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Evan Thompson</p></td><td style="vertical-align:bottom;width:2.03%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.96%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:bottom;width:44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Tom Frohlich</p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: </p></td><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Evan Thompson</p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: </p></td><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tom Frohlich</p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: </p></td><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Operating Officer</p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: </p></td><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">[SIGNATURE PAGE TO LICENSE AGREEMENT]</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">LIST OF LICENSED ANTIBODY PATENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">EXHIBIT A</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***] <b style="font-weight:bold;">LICENSE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">[EXHIBIT B TO LICENSE AGREEMENT]</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT C</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DESIGNATED MULTISPECIFIC ANTIBODIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">[EXHIBIT C TO LICENSE AGREEMENT]</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>15
<FILENAME>avte-20240930xex10d20.htm
<DESCRIPTION>EXHIBIT 10.20
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 12/3/2024 12:42:11 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.20</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">DISCLOSED.<br><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CELL LINE LICENSE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This Cell Line License Agreement (&#8220;Agreement&#8221;), effective as of October 22, 2024 (&#8220;EFFECTIVE DATE&#8221;), is entered and made by and between <b style="font-weight:bold;">WuXi Biologics Ireland Limited</b>, having an address at Dundalk Science &amp; Technology Park, Mullagharlin, Dundalk, Co Louth A91 X56F, Ireland (collectively, &#8220;<b style="font-weight:bold;">WuXi Biologics</b>&#8221;) and <b style="font-weight:bold;">Jade BioSciences, Inc., </b>a Delaware corporation, with an office at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453 (&#8220;Licensee&#8221;). WuXi Biologics and Licensee may be referred to herein individually as a &#8220;Party&#8221; and collectively as the &#8220;Parties.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Parties agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:33.1pt;text-indent:-33.1pt;margin:0pt 0pt 12pt 5.75pt;"><font style="display:inline-block;text-indent:0pt;width:32.55pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">&#8220;Affiliate&#8221; </b>of a person means any other person that directly or indirectly Controls, is Controlled by, or is under common Control with, the person.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">&#8220;Client Product&#8221; </b>means the [***] of interest to Licensee, which is designated by the Licensee to be produced by the Licensed Cell Line. Each different Client Product covered under this Agreement shall be specified in Appendix I. An amendment to this Agreement is required for each new Client Product produced by the Licensed Cell Line.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#8220;<b style="font-weight:bold;">Confidential Information</b>&#8221; of a Party (the &#8220;<b style="font-weight:bold;">Disclosing Party</b>&#8221;) means all non- public scientific, technical, financial regulatory or business information and materials disclosed by or on behalf of the Disclosing Party to the other Party (the &#8220;<b style="font-weight:bold;">Receiving Party</b>&#8221;) or its Related Persons (defined below) in connection with this Agreement. Confidential information shall be identified as confidential in writing or, if disclosed verbally or by observation, summarized in writing and submitted to the Receiving Party within [***] days of the oral or visual disclosure thereof; provided, however, information need not be labeled or marked &#8220;confidential&#8221; to be deemed Confidential Information hereunder, if under the circumstances it is, or should be, understood to be confidential. The Confidential Information of both Parties includes the existence, terms and objectives of this Agreement, and the nature of any dispute and the outcome of any arbitration</p></td></tr></table><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">DISCLOSED.<br><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 71.3pt;">proceedings arising out of or in connection with this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#8220;<b style="font-weight:bold;">Construct</b>&#8221; means a [***] developed by WuXi Biologics that is used for delivering genetic code and for transfecting and/or transforming the Host Cell Line for purposes of creating the Licensed Cell Line.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">&#8220;Control</b>&#8221; over an entity means (a) owning 50% or more of the voting securities or other ownership interests of such entity or (b) having the power to direct the management or policies of such entity.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.6</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">&#8220;Drug Product&#8221; </b>means the final dosage form which contains Client Product, in association with other active or inactive ingredients.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.7</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">&#8220;Drug Substance&#8221; </b>means bulk Client Product, which has not yet been packaged into its final dosage form.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:34.55pt;text-align:justify;text-indent:-34.55pt;margin:0pt 0pt 12pt 37.45pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:34.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.8</font></font><font style="display:inline-block;width:4.65pt;"></font><b style="font-weight:bold;">&#8220;Host Cell Line&#8221; </b>means the proprietary host cell line developed by WuXi Biologics, and designated by WuXi Biologics as the [***], that is used to make the Licensed Cell Line.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.9</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">&#8220;Licensed Cell Line&#8221; </b>means a transformed or transfected (using WuXi Biologics&#8217; Construct(s)) version of the Host Cell Line that produces the Client Product.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.10</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">&#8220;Licensed Know-How&#8221; </b>means any know-how and non-public information owned or controlled by WuXi Biologics that is used or incorporated in the Process, and that is necessary or useful to operate the Process as further described in the Technology Transfer Package. The word &#8220;control&#8221; when used in connection with Licensed Know-How includes both exclusively and non-exclusively licensed know-how and non-public information, as well a right of WuXi Biologics to transfer such know-how and non-public information to Licensee. As used in this definition &#8220;know-how&#8221; means all confidential and proprietary commercial, technical, scientific and other know-how and information, trade secrets, knowledge, technology, methods, processes, practices, formulae, instructions, skills, techniques, procedures, experiences, ideas, technical assistance, designs, drawings, assembly procedures, computer programs, specifications, data and results (including biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, preclinical, clinical, safety, manufacturing and quality control data and know-how, and including study</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">DISCLOSED.<br><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 71.3pt;">designs and protocols).</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.11</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#8220;<b style="font-weight:bold;">Marketing Authorization Approval</b>&#8221; means, with respect to a country or extra-national territory, any and all approvals (including a New Drug Application or Biologics License Application approved by the FDA), licenses, registrations or authorizations of any Regulatory Authority necessary in order to commercially distribute, sell or market a product in such country or some or all of such extra- national territory, including any pricing or reimbursement approvals.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.12</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">&#8220;Materials&#8221; </b>means the biological materials, including the Licensed Cell Line, provided to Licensee pursuant to the license granted under this Agreement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.13</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">&#8220;Media and Feeds&#8221; </b>means any proprietary media and feeds used in the Process.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.14</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#8220;<b style="font-weight:bold;">Net Sales</b>&#8221; means the amount earned and recognized as revenue by Licensee and its Affiliates or sublicensees for bona fide sales of Client Product to a third-party ([***]), less:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:71.3pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">[***];</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:71.3pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">[***];</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:71.3pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">[***];</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:71.3pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">[***];</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:71.3pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">[***];</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:71.3pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">[***]; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:71.3pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">[***].</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 71.3pt;">Net Sales will not include [***]. Such amounts will be determined from the books and records of [***], maintained in accordance with GAAP consistently applied.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.15</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">&#8220;Process&#8221; </b>means a process for manufacture of Client Product utilizing Licensed Know-How, Materials and Media and Feeds as described in the Technology Transfer Package.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.16</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#8220;<b style="font-weight:bold;">Regulatory Authority</b>&#8221; means any applicable supranational, national, regional, state or local regulatory agency, department, bureau, commission, council, or other government entity involved in regulating development of and granting regulatory approval for a pharmaceutical product, including the FDA and EMA.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">DISCLOSED.<br><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.17</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">&#8220;Related Persons&#8221; </b>means a Party&#8217;s Affiliates and their respective directors, officers, employees and agents.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.18</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#8220;<b style="font-weight:bold;">Research Cell Bank</b>&#8221; is a [***].</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.19</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">&#8220;Technology Transfer Package&#8221; </b>means all information and data describing the Process, together with all Licensed Know-How, Materials and Media and Feeds necessary or useful for the development and manufacture of Client Product using the Licensed Cell Line and/or the Process.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.20</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">&#8220;Third Party&#8221; </b>means any person other than the Parties to this Agreement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.21</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">&#8220;Third Party Manufacturer&#8221; </b>means (i) a Third Party whose primary business is contract manufacturing, or (ii) a Third Party who has a contractual arrangement with Licensee or with a sublicensee of Licensee that includes manufacturing of Client Product and/or Drug Product by such Third Party for Licensee or such sublicensee.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:33.1pt;text-indent:-33.1pt;margin:0pt 0pt 12pt 5.75pt;"><font style="display:inline-block;text-indent:0pt;width:32.4pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">License</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">WuXi Biologics hereby grants to Licensee and its Affiliates a non-exclusive, worldwide license, with the right to grant sublicenses as provided in Section 2.3, to the Licensed Know-How and the Licensed Cell Line, Materials, and Media and Feeds, for the purpose of conducting the Process, including the following licensed activities:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:98.65pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;text-align:justify;">i.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;text-align:justify;">to make, have made, import, sell and otherwise use Client Product; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:95.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">ii.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">to make, have made, use, sell, have sold, offer for sale, import, keep and otherwise deal in and further commercialize Drug Substance and Drug Product for any and all purposes.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Licensee or its Affiliates may contract with a Third Party Manufacturer for the limited purpose of developing and manufacturing Client Product on behalf of the Licensee or its Affiliates, provided that, such Third Party Manufacturers are bound by the contract to comply with the confidentiality and use terms of this Agreement, and that the Licensee or its Affiliates will remain liable for any Third Party Manufacturers&#8217; breach of this Agreement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">DISCLOSED.<br><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:71.1pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:32.85pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;text-align:justify;">2.2.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;text-align:justify;">For the benefit of doubt, a Third Party Manufacturer cannot manufacture Client Product, Drug Substance or Drug Product utilizing the Licensed Cell Line and Licensed Know-How without first being contracted with a Licensee, its Affiliates or sublicensee.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:71.3pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:32.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.2.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">A Third Party Manufacturer that has been granted a sublicense cannot grant, issue or transfer a sublicense to another Third Party.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Subject to the terms and conditions of this Agreement, Licensee shall have the right to grant sublicenses to a Third Party for the rights granted to Licensee under this Agreement. Each sublicense agreement shall be in writing and provided that the applicable sublicensee is bound by all applicable terms and conditions of this Agreement, and Licensee or its Affiliates shall remain liable for any sublicensee&#8217;s breach of this Agreement. Licensee shall inform WuXi Biologics in writing any and all such sublicenses. [***]. Licensee will notify WuXi Biologics in writing of any sublicense agreement with a sublicensee within [***] calendar days of the execution of such agreement. Any sublicense granted by Licensee to any rights licensed to it hereunder will terminate [***] upon the termination of the license by WuXi Biologics under the terms of this Agreement; provided, that such sublicensed rights will not terminate if, as of the effective date of such termination, a sublicensee is not in material default of its obligations under its sublicense agreement, and within [***] days of such termination, the sublicensee agrees in writing to be bound directly to WuXi Biologics under a license agreement substantially similar to this Agreement with respect to the rights sublicensed hereunder.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Except as expressly provided in this Agreement, nothing in this Agreement shall be deemed to have granted Licensee (by implication, estoppel or otherwise) any right, title, license or other interest in or with respect to any intellectual property, Know-How or information owned or controlled by WuXi Biologics.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:33.1pt;text-align:justify;text-indent:-33.1pt;margin:0pt 0pt 12pt 38.15pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:31pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.5</font></font>Invoicing of License fees will commence from [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:33.1pt;text-indent:-33.1pt;margin:0pt 0pt 12pt 5.75pt;"><font style="display:inline-block;text-indent:0pt;width:32.4pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer of Materials and Licensed Know-How</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 40.3pt;">WuXi Biologics shall notify Licensee in writing within [***] business days following the date on which WuXi Biologics completes transfection of the Host Cell Line to generate the Licensed Cell Line. Thereafter, [***] upon written request and the completion of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">DISCLOSED.<br><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 40.3pt;">due payment by Licensee (and in any event within [***] days following designation of a Third Party Manufacturer), WuXi Biologics shall disclose, make available, and conduct a full transfer, and shall cause its Affiliates to disclose, make available, and conduct a full transfer to Licensee, its Affiliates, or any one or more of its Third Party Manufacturers designated by Licensee, all Materials and Licensed Know-How, that is necessary or reasonably useful for Licensee and Third Party Manufacturers to solely develop and manufacture the Client Product. &#160;The Parties shall agree to a schedule for such transfer of the Materials and Licensed Know-How. WuXi Biologics will provide [***] assistance to enable such Third Party Manufacturer to manufacture Client Product, provided, however, it is the Third Party Manufacturer&#8217;s full responsibility to manufacture such Client Product after the transfer, WuXi Biologics will not be responsible for the Third Party Manufacturer&#8217;s success or failure to manufacture any Client Products. Initiation of such technology transfer will be determined by Licensee. WuXi Biologics will be reimbursed for such activities by Licensee on [***] rate. WuXi Biologics will provide [***] requested ongoing technical support if requested by Licensee with such support reimbursed on a [***] rate basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:33.1pt;text-indent:-33.1pt;margin:0pt 0pt 12pt 5.75pt;"><font style="display:inline-block;text-indent:0pt;width:32.4pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">License Fee</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 38.15pt;">As consideration for the license granted in Section 2 of this Agreement, and the representation and warranty set forth in Section 10 of this Agreement, Licensee agrees to pay WuXi Biologics a fixed non-creditable, non-refundable license fee of USD 150,000 for the Licensed Cell Line used in Client Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:33.1pt;text-indent:-33.1pt;margin:0pt 0pt 12pt 5.75pt;"><font style="display:inline-block;text-indent:0pt;width:32.4pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cell Line Royalties.</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">5.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">If Licensee manufactures all of its commercial supplies of the applicable Drug Substance using manufacturing facilities other than WuXi Biologics&#8217; or its Affiliates&#8217; manufacturing facilities, Licensee shall pay to WuXi Biologics a Royalty of [***] on the applicable Drug Product&#8217;s global Net Sales sold by Licensee, its Affiliates, or sublicensees, paid to WuXi Biologics [***]. If Licensee manufactures part of its commercial supplies of the applicable Drug Substance using WuXi Biologics&#8217; or its Affiliates&#8217; manufacturing facilities, the Royalty shall be reduced accordingly on a [***] basis, depending on [***]. If Licensee manufactures all of its commercial supplies of the applicable Drug Substance by WuXi Biologics or its Affiliates, no Royalty is applicable and no Royalty payment shall be due hereunder.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">5.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Licensee, or its sublicensee or assignee may, at any time, pay to WuXi Biologics, on a</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">DISCLOSED.<br><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 69.1pt;">Drug Product-by-Drug Product basis, a fixed non-creditable, non-refundable royalty buyout payment as set forth below. Once WuXi Biologics has received the royalty buyout payment from Licensee, or its sublicensee or assignee, future royalty obligations with respect to such Drug Product will be extinguished. No royalty payments already paid shall be creditable to royalty buyout payments and no previously accrued obligations will be affected.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:93.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">5.2.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">For the first Drug Product whose royalty obligations Licensee elects to buy out, Licensee shall pay to WuXi Biologics a buyout payment of [***].</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:93.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">5.2.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">For the second, and all subsequent, Drug Product(s) whose royalty obligations Licensee elects to buy out, Licensee shall pay to WuXi Biologics a buyout payment of [***] per Drug Product.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:93.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">5.2.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">For clarity, all buyout payments are based upon the order in which client makes the election to buy out the Drug Product royalty obligations, and are irrespective of the order in which such Drug Product(s) and/or its/their associated cell line(s) was/were developed, or when its/their associated program(s) entered IND. E.g., if Licensee elected to first buy out the royalty obligations corresponding to the second Drug Product developed under this Agreement, the buyout payment would be in the amount under Section 5.2.1.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:33.1pt;text-indent:-33.1pt;margin:0pt 0pt 12pt 5.75pt;"><font style="display:inline-block;text-indent:0pt;width:32.4pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment Terms</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 38.15pt;">Licensee shall pay WuXi Biologics&#8217; undisputed invoice(s) within [***] days of receipt by Licensee. Such payments will be made by wire transfer to the account designated by WuXi Biologics. Invoices must be submitted, and payment must be made, [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:33.1pt;text-indent:-33.1pt;margin:0pt 0pt 12pt 5.75pt;"><font style="display:inline-block;text-indent:0pt;width:32.4pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Bank Account Details</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 38.15pt;">Unless the Parties otherwise mutually agree in writing, and such mutual agreement is set forth in a particular invoice, Licensee shall pay each invoice by wire transfer to the account designated by WuXi Biologics. With respect to Net Sales invoiced in U.S. dollars, the Net Sales and the amounts due hereunder will be expressed in U.S. dollars. With respect to Net Sales invoiced in a currency other than U.S. dollars, payments will be calculated based on standard methodologies employed by Licensee or its Affiliates or sublicensees for consolidation purposes for the [***] for which remittance is made for Royalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">DISCLOSED.<br><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:33.1pt;text-indent:-33.1pt;margin:0pt 0pt 12pt 5.75pt;"><font style="display:inline-block;text-indent:0pt;width:32.55pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restriction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 38.15pt;">Licensee agrees that no attempt will be made by or on behalf of Licensee to modify or reverse engineer the Licensed Cell Line or attempt to reverse engineer, recreate or assemble the Construct(s). Licensee shall only use the Licensed Cell Line in the way as permitted by this Agreement and shall not use or have used the Licensed Cell Line for any purpose other than as provided hereunder, including operating the Process, the manufacture of Client Product, Drug Substance and Drug Product, and for other purposes reasonably related to securing Marketing Authorization Approval for the Client Product and/or Drug Product. Licensee shall not transfer the Licensed Cell Line to any Third Party except to a permitted sublicensee, as described in Section 2.2 above, permitted Third Party Manufacturer, or an assignee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:33.1pt;text-indent:-33.1pt;margin:0pt 0pt 12pt 5.75pt;"><font style="display:inline-block;text-indent:0pt;width:32.55pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnity</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.3pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">9.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensee</u> agrees to indemnify, hold harmless and defend WuXi Biologics, its Affiliates, and their respective directors, officers, employees and agents harmless (collectively, &#8220;WuXi Indemnitees&#8221;) from and against any and all liabilities and damages (including reasonable attorneys&#8217; fees) resulting from any and all claims from any Third Party (&#8220;Claims&#8221;) to the extent arising from the use of the Licensed Cell Line, Client Product, Drug Substance or Drug Product by Licensee; except to the extent WuXi Biologics is obligated to indemnify Licensee in accordance with Section 9.2 of this Agreement, and provided further that Licensee shall have no obligation to indemnify any such Claims that arise from WuXi Biologics&#8217; (i) negligence or intentional misconduct in connection with the Licensed Cell Line (ii) material breach of this Agreement (including the representations and warranties set forth in Section 10); or (iii) Host Cell Line components of the Licensed Cell Line or any Media and Feeds.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:22.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">9.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">WuXi Biologics will indemnify Licensee, its Affiliates, its sublicensees and their respective directors, officers, employees and agents, and their respective successors, heirs and assigns (collectively, &#8220;Licensee Indemnitees&#8221;), and defend and hold each of them harmless, from and against any and all Losses in connection with any and all Third-Party Claims against Licensee Indemnitees to the extent arising from or occurring as a result of: (i) the breach by WuXi Biologics of any provision of this Agreement; or (ii) any negligence or willful misconduct on the part of any</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">DISCLOSED.<br><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 58.3pt;">WuXi Indemnitee in connection with the Host Cell Line components of the Licensed Cell Line, except in each case to the extent Licensee is obligated to indemnify WuXi Biologics in accordance with Section 9.1 of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 58.3pt;">Each party must notify the other party within [***] days of receipt of any claims made for which the other party might be liable hereunder. The indemnifying party will have the sole right to defend, negotiate, and settle such claims. The indemnified party will be entitled to participate in the defense of such matter and to employ counsel at its expense to assist in such defense. No compromise or settlement of any Claim may be made by the indemnifying Party without the indemnified Party&#8217;s written consent; provided, however, that the indemnifying party will have final decision-making authority regarding all aspects of the defense of any claim. The party seeking indemnification will provide the indemnifying party with such information and assistance as the indemnifying party may reasonably request, at the expense of the indemnifying party.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:22.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">9.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Limitation of Liability. NEITHER PARTY WILL BE LIABLE UNDER ANY LEGAL THEORY (WHETHER TORT, CONTRACT OR OTHERWISE) FOR SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, HOWEVER CAUSED, EVEN IF THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, EXCEPT AS A RESULT OF A BREACH OF THE CONFIDENTIALITY AND NON-USE OBLIGATIONS IN SECTION 11. NOTHING IN THIS SECTION 9.4 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:33.1pt;text-indent:-33.1pt;margin:0pt 0pt 12pt 5.75pt;"><font style="display:inline-block;text-indent:0pt;width:32.55pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 38.15pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:33.85pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.1</font></font>WuXi Biologics represents and warrants that: (i) it is a corporation duly organized validly existing and in good standing under the laws of the Republic of Ireland; (ii) the execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on the part of WuXi Biologics; (iii) the performance of WuXi Biologics&#8217; obligations under this Agreement will not conflict with its charter documents or result in a material breach of any agreements, contracts or other arrangements to which it is a party; (iv) WuXi Biologics will not before the termination of this Agreement enter into any agreements, contracts or other arrangements that would be materially</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">DISCLOSED.<br><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 38.15pt;">inconsistent with its obligations under this Agreement; (v) WuXi Biologics has sufficient facilities, experienced personnel and other capabilities reasonably suited to enable it to perform its obligations under this Agreement; (vi) WuXi Biologics has the right to grant the licenses or sublicenses, as the case may be, therefor granted under this Agreement; (vii) WuXi Biologics is the sole and exclusive owner of the Licensed Know-how and Licensed Cell Line, or otherwise has the right to license the Licensed Know-how and Licensed Cell Line and grant rights to Licensee as set forth in this Agreement and during the Term of the Agreement, (viii) to the best of its knowledge WuXi Biologics is and will remain entitled to grant to Licensee the licenses and rights specified or contemplated by this Agreement, and to the Licensed Know-How , (ix) as of the Effective Date, neither WuXi Biologics nor any of its Affiliates has received any notice challenging WuXi Biologics&#8217; ownership or right to use the Licensed Know-How in relation to the Licensed Cell Line and, Host Cell Line component of the Licensed Cell Line, (x) to the best of WuXi Biologics&#8217;s knowledge, there are no valid grounds for any claim against WuXi Biologics or any of its Affiliates except for any claims caused by Licensee&#8217;s DNA sequence related to the Client Product incorporated into the Licensed Cell Line.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 38.15pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.2</font></font>Licensee represents and warrants that: (i) it is a corporation duly organized validly existing and in good standing under the laws of the Commonwealth of Massachusetts; (ii) the execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on the part of Licensee; (iii) the performance of Licensee&#8217;s obligations under this Agreement will not conflict with its charter documents or result in a material breach of any agreements, contracts or other arrangements to which it is a party; (iv) Licensee has sufficient facilities, experienced personnel and other capabilities reasonably suited to enable it to perform its obligations under this Agreement; and (v) Licensee will not before the termination of this Agreement enter into any agreements, contracts or other arrangements that would be materially inconsistent with its obligations under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 38.15pt;"><font style="display:inline-block;text-indent:0pt;width:43.9pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.3</font></font>Disclaimer of Warranties. OTHER THAN AS PROVIDED IN THIS AGREEMENT, THE LICENSED KNOW-HOW, AND LICENSED CELL LINES ARE PROVIDED AND LICENSED TO LICENSEE &#8220;AS IS&#8221;, THE PARTIES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT THERETO OR TO THE PRODUCTS, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSEVALIDITY OF THE RIGHTS LICENSED HEREUNDER, OR NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">DISCLOSED.<br><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:33.1pt;text-indent:-33.1pt;margin:0pt 0pt 12pt 5.75pt;"><font style="display:inline-block;text-indent:0pt;width:32.55pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 38.15pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.1</font></font>Subject to the exceptions listed below, during the term of this Agreement and for [***] years thereafter, the Receiving Party shall, and shall ensure that its Related Persons will, (a) maintain the Disclosing Party&#8217;s Confidential Information in confidence, (b) not use such Confidential Information other than in connection with this Agreement, and (c) not disclose such Confidential Information to any Third Party other than (i) those of its Related Persons that have a need to know such Confidential Information in connection with the Activities conducted pursuant to the Agreement and are obligated to maintain such Confidential Information in confidence and (ii) to the extent required by applicable law or judicial order, or to the extent reasonably necessary to prosecute or defend litigation or arbitration in relation to this Agreement, and, in either case, only after the Receiving Party gives the Disclosing Party [***] advance written notice of such requirement and [***] with the Disclosing Party&#8217;s efforts to limit or avoid such disclosure, to seek a protective order or secure confidential treatment of the Confidential Information, and/or to seek any other remedies available to the Disclosing Party at law or in equity. Notwithstanding the foregoing, the existence of this Agreement and its non-technical terms may be disclosed confidentially in connection with a potential financing, collaboration or acquisition or in discussion with a potential acquirer of Client Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 38.15pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.2</font></font>The Receiving Party&#8217;s obligations set forth in Section 11.1 do not apply to Confidential Information if (a) the information is public knowledge or becomes public knowledge after disclosure through no act or omission of the Receiving Party or any of its Related Persons, (b) the information can be shown by the Receiving Party to have been lawfully in its possession prior to disclosure, (c) the information was rightfully received on a non-confidential basis from a Third Party that was not obligated to maintain the information in confidence, or (d) the Receiving Party can show that equivalent information was developed independently by the Receiving Party without reference to the Disclosing Party&#8217; Confidential Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 38.15pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.3</font></font>Licensee may disclose the Confidential Information of WuXi Biologics to a Third Party for the purpose of exercising Licensee&#8217;s license rights hereunder (including disclosure to potential Third Party sublicensees), provided that Licensee shall, prior to such disclosure, ensure that each Third Party to which disclosure is to be made is made</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">DISCLOSED.<br><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 38.15pt;">aware of the obligations contained in this Agreement and agrees to be subject to obligations of confidentiality and non-use no less onerous than those contained in this Agreement. Any breaches of the obligations of confidentiality and non-use contained in this Agreement by such Third Party shall be treated as a breach of such obligations by Licensee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 38.15pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.4</font></font>Notwithstanding anything to the contrary in this Agreement, a Party may disclose this Agreement and its terms, and material developments or material information generated under this Agreement, in securities filings with the U.S. Securities and Exchange Commission (or equivalent foreign agency) and any rules of stock exchanges where the Parties may be listed to the extent required by applicable law after complying with the procedure set forth in this Section 11.4. In such event, unless otherwise required to comply with applicable law, the Party seeking such disclosure will prepare a draft confidential treatment request and proposed redacted version of this Agreement to request confidential treatment for this Agreement, and the other Party will [***] give its input in a [***] in order to allow the Party seeking disclosure to file its request within the timelines proscribed by applicable laws and regulations. The Party seeking such disclosure shall exercise [***] to obtain confidential treatment of this Agreement from the U.S. Securities and Exchange Commission (or equivalent foreign agency) as represented by the redacted version reviewed by the other Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 38.15pt;"><font style="display:inline-block;text-indent:0pt;width:43.9pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.5</font></font>The provisions of this Section 11 shall survive termination or expiry of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:33.1pt;text-indent:-33.1pt;margin:0pt 0pt 12pt 5.75pt;"><font style="display:inline-block;text-indent:0pt;width:32.55pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:43.9pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">12.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Voluntary Termination by Licensee</u>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 38.15pt;">Licensee shall have the right to terminate this Agreement upon at least six (6) months prior written notice to WuXi Biologics, and upon payment of all undisputed amounts due to WuXi Biologics through such termination effective date.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:43.9pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">12.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination for Default</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 38.3pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.75pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nonpayment</u>. In the event Licensee fails to pay any undisputed amounts due and payable to WuXi Biologics hereunder, and fails to make such payments within thirty</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 38.3pt;">(30) days after receiving written notice of such failure, WuXi Biologics may terminate</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">DISCLOSED.<br><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 38.15pt;">this Agreement [***] upon written notice to Licensee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 38.15pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.9pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Material Breach</u>. In the event Licensee commits a material breach of its obligation under this Agreement and fails to cure that breach within sixty (60) days after receiving written notice thereof, WuXi Biologics may terminate this Agreement [***] upon written notice to Licensee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 38.15pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination Upon Bankruptcy</u>. If either Party makes an assignment for the benefit of creditors, appoints or suffers appointment of a receiver or trustee over all or substantially all of its property, files a petition or commences a proceeding under any bankruptcy or insolvency act in any state or country or has any such petition or application filed against it which is not discharged within [***] days of the filing thereof, then the other Party may thereafter terminate this Agreement effective [***] upon written notice to such Party. All rights and licenses granted under or pursuant to this Agreement by WuXi Biologics are, and will otherwise be deemed to be, for purposes of the relevant provisions of the Bankruptcy and Insolvency Act, R.S.C. 1985, c. B-3 (&#8220;BIA&#8221;), including Sections 65.11(7), 65.13(9), 72.1 and 246.1 of the BIA; and the relevant provisions of the Companies&#8217; Creditors Arrangement Act, R.S.C. 1985, c. C-36 (&#8220;CCAA&#8221;), including Sections 32(6) and 36(8) of the CCAA (the BIA and CCAA being referred to collectively as the &#8220;Insolvency Legislation&#8221;), a grant of a &#8220;right to use&#8221; &#8220;intellectual property&#8221; as used in the Insolvency Legislation. The Parties agree that Licensee and its Affiliates and sublicensees, as licensees of such rights under this Agreement, will retain and may fully exercise all of their rights and elections under the Insolvency Legislation subject to the payment of amounts provided for herein. Without limiting Licensee&#8217;s rights under the Insolvency Legislation, if WuXi Biologics becomes insolvent or makes an assignment for the benefit of its creditors or there is filed by or against it any bankruptcy, receivership, reorganization or similar proceeding pursuant to or under the Insolvency Legislation or otherwise, Licensee will be entitled to a copy of any and all information specified in the Technology Transfer Package unless WuXi Biologics, or its trustee or receiver, elects within [***] days to continue to perform all of its obligations under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 38.15pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12.4</font></font>Expiration or termination of this Agreement for any reason will not relieve either party of any obligation accruing prior to such expiration or termination, including section 5 (Cell Line Royalties) shall survive termination or expiry of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">DISCLOSED.<br><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:33.1pt;text-indent:-33.1pt;margin:0pt 0pt 12pt 5.75pt;"><font style="display:inline-block;text-indent:0pt;width:32.6pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">13.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 38.15pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment</u>. This Agreement may not be assigned or otherwise transferred by either Party (subject to Licensee&#8217;s right to sublicense its rights hereunder) without the prior written consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed; <i style="font-style:italic;">provided, however</i>, that a Party may, without such consent, assign this Agreement in its entirety (a) to an Affiliate, or (b) to a Third Party in connection with a merger, acquisition, consolidation or a sale involving all or substantially all of the assets or business of such Party. Any attempted assignment or transfer in violation of this Section 13.1 shall be void.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 38.15pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Assistance</u>. WuXi Biologics will provide assistance to Licensee, and any sublicensee, in respect of Licensee&#8217;s or such sublicensee&#8217;s regulatory filing activities for the Client Product and/or Drug Product, at Licensee&#8217;s or such sublicensee&#8217;s reasonable cost and expense on [***] rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 3.79pt 38.3pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u>. The laws of the State of New York, USA, without regard to any choice of law principle that would require the application of the law of another jurisdiction, govern all matters relating to this Agreement and the enforcement thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 38.15pt;">The parties expressly reject any application to this Agreement of (a) the United Nations Convention on Contracts for the International Sale of Goods; and (b) the 1974 Convention on the Limitation Period in the International Sale of Goods, as amended by that certain Protocol, done at Vienna on April 11, 1980.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 38.15pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.4</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Arbitration.</u> The parties shall engage in good faith consultation to resolve any dispute arising out of or in connection with this agreement. Such consultation will begin [***] after one party has delivered to the other party a request for consultation. If the dispute cannot be resolved [***] days following the date on which the request for consultation is delivered, then either party may submit the dispute to JAMS International Arbitration Rules (&#8220;Arbitration&#8221;). The Arbitration tribunal will consist of three arbitrators. Within [***] days after the commencement of the Arbitration, each Party shall select one person to act as arbitrator, each of whom must be a practicing or retired attorney or judge have at least [***] years of litigation experience within the biopharmaceutical industry. The two arbitrators so selected shall select the chair within [***] days of the commencement of the Arbitration, whom must a practicing or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">DISCLOSED.<br><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 38.15pt;">retired attorney or judge have at least [***] years of litigation experience within the biopharmaceutical industry. If the arbitrators selected by the Parties are unable or fail to agree upon the third arbitrator within the allotted time, the third arbitrator shall be appointed by JAMS in accordance with the JAMS International Arbitration Rules. All arbitrators shall serve as neutral, independent and impartial arbitrators. (ii) The Arbitration shall be conducted in accordance with the expedited procedures set forth in the JAMS International Arbitration Rules. The place of arbitration will be Manhattan, New York. The official language of the arbitration will be English. The arbitration proceedings will be confidential, and the arbitrator may issue appropriate protective orders to safeguard each party&#8217;s Confidential Information. During the course of arbitration, the parties shall continue to implement the terms of this agreement. The arbitral award will be final and binding upon the parties, and the party to the award may apply to a court of competent jurisdiction for enforcement of the award. Notwithstanding the foregoing, each party has the right to institute an action in a court of proper jurisdiction for injunctive or other equitable relief pending a final decision by the arbitrator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 38.15pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.5</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u>. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may be executed by facsimile, .pdf or other electronically transmitted signatures and such signatures shall be deemed to bind each Party hereto as if they were the original signatures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">DISCLOSED.<br><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 5.75pt;">IN WITNESS WHEREOF, the Parties hereto have caused this AGREEMENT to be duly executed as of the Effective Date set forth above.</p><div style="padding-left:4.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:95.89%;"><tr><td colspan="2" style="vertical-align:bottom;width:49.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a name="_Hlk183599200"></a><b style="font-weight:bold;">WuXi Biologics Ireland Limited</b></p></td><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Jade BioSciences, Inc.</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:40.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Chris Chen</p></td><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:40.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Tom Frohlich</p></td></tr><tr><td style="vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: </p></td><td style="vertical-align:bottom;width:40.58%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chris Chen</p></td><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: </p></td><td style="vertical-align:bottom;width:40.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tom Frohlich</p></td></tr><tr style="height:13.05pt;"><td style="vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16 of 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>16
<FILENAME>avte-20240930xex23d1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 12/3/2024 12:42:11 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We hereby consent to the use in this Registration Statement on Form S-4 of Aerovate Therapeutics, Inc. of our report dated December&#160;2, 2024 relating to the financial statements of Jade Biosciences, Inc., which appears in this Registration Statement. We also consent to the reference to us under the heading &#8220;Experts&#8221; in such Registration Statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.25pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ PricewaterhouseCoopers LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Boston, Massachusetts</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 2, 2024</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>17
<FILENAME>avte-20240930xex23d2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 12/3/2024 12:42:13 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 23.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We consent to the use of our report dated March 25, 2024, with respect to the consolidated financial statements of Aerovate Therapeutics, Inc., included herein, and to the reference to our firm under the heading &quot;Experts&quot; in the prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">/s/ KPMG LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">San Diego, California<br>December 2, 2024</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.3
<SEQUENCE>18
<FILENAME>avte-20240930xex23d3.htm
<DESCRIPTION>EXHIBIT 23.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 12/3/2024 12:42:21 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;23.3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consent of Lucid Capital Markets, LLC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 2, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Board of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Aerovate Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">930 Winter Street, Suite M-500</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Waltham, MA 02451</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Re: Registration Statement on&#160;Form&#160;S-4&#160;of&#160;Aerovate Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Members of the Board:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We hereby consent to the inclusion of our opinion letter, dated October 30, 2024, to the Board of Directors of Aerovate Therapeutics, Inc. (&#8220;AVTE&#8221;) as Annex F to, and to the reference thereto under the headings &#8220;Prospectus Summary &#8212; Opinion of Lucid for Aerovate&#8217;s Board of Directors,&#8221; &#8220;The Merger &#8212; Background of the Merger,&#8221; &#8220;The Merger &#8212; Aerovate&#8217;s Reasons for the Merger,&#8221; and &#8220;The Merger &#8212; Opinion of Aerovate&#8217;s Financial Advisor&#8221; in the proxy statement/prospectus relating to the proposed merger involving AVTE and Jade Biosciences, Inc. (&#8220;Jade&#8221;), which such proxy statement/prospectus forms a part of AVTE&#8217;s and Jade&#8217;s Registration Statement on Form S-4 (the &#8220;Registration Statement&#8221;) to be filed on the date hereof, which this consent is filed as an exhibit thereto. In giving the foregoing consent, we do not admit (1) that we come within the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the rules and regulations of the Securities and Exchange Commission (the &#8220;Commission&#8221;) promulgated thereunder, or (2) that we are experts with respect to any part of the Registration Statement within the meaning of the term &#8220;experts&#8221; as used in the Securities Act and the rules and regulations of the Commission promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:4pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Very truly yours,</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr style="height:4pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Lucid Capital Markets</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LUCID CAPITAL MARKETS, LLC</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">LUCID CAPITAL MARKETS, LLC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">570 Lexington Ave, 40th Floor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">New York NY 10022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#010101" size="1" style="background-color:#010101;color:#010101;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0pt;" align="left"></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>19
<FILENAME>avte-20240930xex99d1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 12/3/2024 12:42:22 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.7pt;text-align:right;text-indent:-0.7pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consent to be Named as a Director</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:-0.7pt;margin:0pt 0pt 12pt 0pt;">Aerovate Therapeutics, Inc. is filing a Registration Statement on Form S-4 (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined company following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement and any amendments thereto.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sincerely,</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eric Dobmeier</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Eric Dobmeier</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 2, 2024</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>20
<FILENAME>avte-20240930xex99d2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 12/3/2024 12:42:22 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.7pt;text-align:right;text-indent:-0.7pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 99.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consent to be Named as a Director</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:-0.7pt;margin:0pt 0pt 12pt 0pt;">Aerovate Therapeutics, Inc. is filing a Registration Statement on Form S-4 (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined company following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement and any amendments thereto.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sincerely,</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Tomas Kiselak</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Tomas Kiselak</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 2, 2024</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>21
<FILENAME>avte-20240930xex99d3.htm
<DESCRIPTION>EXHIBIT 99.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 12/3/2024 12:42:25 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.7pt;text-align:right;text-indent:-0.7pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 99.3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consent to be Named as a Director</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:-0.7pt;margin:0pt 0pt 12pt 0pt;">Aerovate Therapeutics, Inc. is filing a Registration Statement on Form S-4 (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined company following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement and any amendments thereto.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sincerely,</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Chris Cain</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Chris Cain</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 2, 2024</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>22
<FILENAME>avte-20240930xex99d4.htm
<DESCRIPTION>EXHIBIT 99.4
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 12/3/2024 12:42:34 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.7pt;text-align:right;text-indent:-0.7pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 99.4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consent to be Named as a Director</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:-0.7pt;margin:0pt 0pt 12pt 0pt;">Aerovate Therapeutics, Inc. is filing a Registration Statement on Form S-4 (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined company following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement and any amendments thereto.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sincerely,</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Lawrence Klein</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Lawrence Klein</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 2, 2024</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.5
<SEQUENCE>23
<FILENAME>avte-20240930xex99d5.htm
<DESCRIPTION>EXHIBIT 99.5
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 12/3/2024 12:42:34 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-align:right;text-indent:-0.5pt;margin:0pt;"><b style="font-weight:bold;">Exhibit 99.5</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consent to be Named as a Director</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:-0.7pt;margin:0pt 0pt 12pt 0pt;">Aerovate Therapeutics, Inc. is filing a Registration Statement on Form S-4 (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined company following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement and any amendments thereto.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sincerely,</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Tom Frohlich</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Tom Frohlich</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 2, 2024</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.6
<SEQUENCE>24
<FILENAME>avte-20240930xex99d6.htm
<DESCRIPTION>EXHIBIT 99.6
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 12/3/2024 12:42:34 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.7pt;text-align:right;text-indent:-0.7pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 99.6</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consent to be Named as a Director</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:-0.7pt;margin:0pt 0pt 12pt 0pt;">Aerovate Therapeutics, Inc. is filing a Registration Statement on Form S-4 (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined company following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement and any amendments thereto.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sincerely,</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Erin Lavelle</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Erin Lavelle</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 2, 2024</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>25
<FILENAME>avte-20240930xexfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 12/3/2024 12:42:37 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 107</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Calculation of Filing Fee Tables</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Form S-4</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Form Type)</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">AEROVATE THERAPEUTICS, INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Exact Name of Registrant as Specified in its Charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Table 1 - Newly Registered and Carry Forward Securities</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:9.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:91.65pt;"><td style="vertical-align:bottom;width:7.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:91.65pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:91.65pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Security<br>Type</p></div></div></td><td style="vertical-align:bottom;width:6.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:91.65pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Security<br>Class Title</p></div></div></td><td style="vertical-align:bottom;width:7.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:91.65pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Fee<br>Calculation<br>or Carry<br>Forward<br>Rule</p></div></div></td><td style="vertical-align:bottom;width:12.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:91.65pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Amount<br>Registered</p></div></div></td><td style="vertical-align:bottom;width:6.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:91.65pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Proposed<br>Maximum<br>Offering<br>Price Per<br>Unit</p></div></div></td><td style="vertical-align:bottom;width:10%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:91.65pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Maximum<br>Aggregate<br>Offering Price</p></div></div></td><td style="vertical-align:bottom;width:9.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:91.65pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Fee Rate</p></div></div></td><td style="vertical-align:bottom;width:8.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:91.65pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Amount of<br>Registration Fee</p></div></div></td><td style="vertical-align:bottom;width:5.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:91.65pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Carry<br>Forward<br>Form<br>Type</p></div></div></td><td style="vertical-align:bottom;width:5.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:91.65pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Carry<br>Forward<br>File<br>Number</p></div></div></td><td style="vertical-align:bottom;width:5.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:91.65pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Carry<br>Forward<br>Initial<br>effective<br>date</p></div></div></td><td style="vertical-align:bottom;width:8.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:91.65pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Filing Fee<br>Previously<br>Paid In<br>Connection<br>with Unsold<br>Securities to<br>be Carried<br>Forward</p></div></div></td></tr><tr style="height:13pt;"><td colspan="13" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Newly Registered Securities</p></div></div></td></tr><tr style="height:57.35pt;"><td style="vertical-align:middle;width:7.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:57.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Fees to Be Paid</p></div></div></td><td style="vertical-align:middle;width:5.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:57.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Equity</p></div></div></td><td style="vertical-align:middle;width:6.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:57.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Common Stock, $0.0001 par value per share</p></div></div></td><td style="vertical-align:middle;width:7.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:57.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Other</p></div></div></td><td style="vertical-align:middle;width:12.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:57.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">1,826,967,326 (1)</p></div></div></td><td style="vertical-align:middle;width:6.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:57.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(2)</p></div></div></td><td style="vertical-align:middle;width:10%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:57.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">$60,898.92 (2)</p></div></div></td><td style="vertical-align:middle;width:9.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:57.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">$0.00015310</p></div></div></td><td style="vertical-align:middle;width:8.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:57.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">$9.33</p></div></div></td><td style="vertical-align:middle;width:5.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:57.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:5.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:57.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:5.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:57.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:8.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:57.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:35.5pt;"><td style="vertical-align:middle;width:7.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:35.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Fees Previously Paid</p></div></div></td><td style="vertical-align:middle;width:5.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:35.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#8212;</p></div></div></td><td style="vertical-align:middle;width:6.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:35.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#8212;</p></div></div></td><td style="vertical-align:middle;width:7.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:35.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#8212;</p></div></div></td><td style="vertical-align:middle;width:12.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:35.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#8212;</p></div></div></td><td style="vertical-align:middle;width:6.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:35.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#8212;</p></div></div></td><td style="vertical-align:middle;width:10%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:35.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#8212;</p></div></div></td><td style="vertical-align:middle;width:9.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:35.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:8.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:35.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#8212;</p></div></div></td><td style="vertical-align:middle;width:5.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:35.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:5.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:35.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:5.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:35.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:8.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:35.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:13pt;"><td colspan="13" style="vertical-align:middle;width:100%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Carry Forward Securities</p></div></div></td></tr><tr style="height:35.5pt;"><td style="vertical-align:middle;width:7.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:35.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Carry Forward Securities</p></div></div></td><td style="vertical-align:middle;width:5.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:35.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#8212;</p></div></div></td><td style="vertical-align:middle;width:6.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:35.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#8212;</p></div></div></td><td style="vertical-align:middle;width:7.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:35.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#8212;</p></div></div></td><td style="vertical-align:middle;width:12.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:35.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#8212;</p></div></div></td><td style="vertical-align:middle;width:6.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:35.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:10%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:35.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#8212;</p></div></div></td><td style="vertical-align:middle;width:9.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:35.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:8.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:35.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:5.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:35.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#8212;</p></div></div></td><td style="vertical-align:middle;width:5.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:35.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#8212;</p></div></div></td><td style="vertical-align:middle;width:5.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:35.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#8212;</p></div></div></td><td style="vertical-align:middle;width:8.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:35.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#8212;</p></div></div></td></tr><tr style="height:13pt;"><td style="vertical-align:middle;width:7.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="4" style="vertical-align:middle;width:32.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">Total Offering Amounts</p></div></div></td><td style="vertical-align:middle;width:6.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:10%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">$60,898.92 (2)</p></div></div></td><td style="vertical-align:middle;width:9.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#8212;</p></div></div></td><td style="vertical-align:middle;width:8.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">$9.33</p></div></div></td><td style="vertical-align:middle;width:5.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:5.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:5.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:8.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:13pt;"><td style="vertical-align:middle;width:7.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="4" style="vertical-align:middle;width:32.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">Total Fees Previously Paid</p></div></div></td><td style="vertical-align:middle;width:6.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:10%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:9.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:8.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#8212;</p></div></div></td><td style="vertical-align:middle;width:5.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:5.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:5.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:8.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:13pt;"><td style="vertical-align:middle;width:7.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="4" style="vertical-align:middle;width:32.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">Total Fee Offsets</p></div></div></td><td style="vertical-align:middle;width:6.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:10%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:9.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:8.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#8212;</p></div></div></td><td style="vertical-align:middle;width:5.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:5.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:5.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:8.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:13pt;"><td style="vertical-align:middle;width:7.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="4" style="vertical-align:middle;width:32.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">Net Fee Due</p></div></div></td><td style="vertical-align:middle;width:6.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:10%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:9.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:8.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">$9.33</p></div></div></td><td style="vertical-align:middle;width:5.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:5.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:5.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:8.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:13pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Relates to common stock, $0.0001 par value per share, of Aerovate Therapeutics, Inc., a Delaware corporation (&#8220;Aerovate&#8221;), issuable to holders of common stock, $0.0001 par value per share, of Jade Biosciences, Inc., a Delaware corporation (&#8220;Jade&#8221;), in the proposed merger of Caribbean Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Aerovate, with and into Jade, with Jade surviving the merger, and as part of the same overall transaction, Jade will merge with and into Caribbean Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of Aerovate, with Caribbean Merger Sub II, LLC continuing as a wholly owned subsidiary of Aerovate and the surviving corporation of the merger. The amount of common stock of Aerovate to be registered includes the estimated maximum number of shares of common stock of Aerovate that are expected to be issued (or become issuable) pursuant to the merger, without taking into account the effect of a reverse stock split of common stock of Aerovate, assuming an estimated pre-split exchange ratio (which is subject to adjustment prior to the closing of the merger) of approximately 21.4388 shares of common stock of Aerovate for each outstanding share of common stock of Jade.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Estimated solely for purposes of calculating the registration fee in accordance with Rule 457(f)(2) of the U.S. Securities Act of 1933, as amended. Jade is a private company, no market exists for its securities, and it has an accumulated capital deficit. Therefore, the proposed maximum aggregate offering price for the shares expected to be issued pursuant to the merger is one-third of the aggregate par value of the Jade securities expected to be exchanged in the proposed merger.</font></td></tr></table><div style="margin-top:12pt;"></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>26
<FILENAME>avte-20240930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/3/2024 12:42:26 AM-->
<!--Modified on: 12/3/2024 12:42:26 AM-->
<xsd:schema targetNamespace="http://aerovatetx.com/20240930" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:avte="http://aerovatetx.com/20240930" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:attributeFormDefault="unqualified" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>100100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails">
        <link:definition>140902 - Disclosure - INCOME TAXES - SUMMARY OF COMPONENTS OF NET DEFERRED TAX ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails" id="DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails">
        <link:definition>140903 - Disclosure - INCOME TAXES - SUMMARY OF RECONCILIATION OF FEDERAL INCOME TAX RATE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" id="StatementCondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>200100 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
        <link:definition>200200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" id="StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>200400 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss" id="DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss">
        <link:definition>240301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF FAIR VALUE INSTRUMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss" id="DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss">
        <link:definition>240303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailss" id="DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailss">
        <link:definition>240401 - Disclosure - BALANCE SHEET COMPONENTS - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetailss" id="DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetailss">
        <link:definition>240402 - Disclosure - BALANCE SHEET COMPONENTS - SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailss" id="DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailss">
        <link:definition>240502 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailsCalc2" id="DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailsCalc2">
        <link:definition>240502 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES (Details) (Calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfRentExpensesDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfRentExpensesDetails">
        <link:definition>240504 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF RENT EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>140101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails">
        <link:definition>140201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>140203 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails" id="DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails">
        <link:definition>140301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF FAIR VALUE INSTRUMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails" id="DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails">
        <link:definition>140302 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT TERM INVESTMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails" id="DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails">
        <link:definition>140303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>140501 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails" id="DisclosureStockholdersEquityDetails">
        <link:definition>140601 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails" id="DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails">
        <link:definition>140602 - Disclosure - STOCKHOLDERS' EQUITY - SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails" id="DisclosureShareBasedCompensationDetails">
        <link:definition>140701 - Disclosure - SHARE-BASED COMPENSATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails" id="DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails">
        <link:definition>140703 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF UNVESTED RESTRICTED STOCK UNIT ACTIVITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails" id="DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails">
        <link:definition>140704 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF FAIR VALUE OF STOCK OPTIONS ASSUMPTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails" id="DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails">
        <link:definition>140705 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION GRANTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails" id="DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails">
        <link:definition>140706 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY TYPE OF AWARDS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureRelatedPartyTransactionsDetails" id="DisclosureRelatedPartyTransactionsDetails">
        <link:definition>140801 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>140901 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" id="StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited">
        <link:definition>200300 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureOrganizationAndNatureOfOperationsDetails" id="DisclosureOrganizationAndNatureOfOperationsDetails">
        <link:definition>240101 - Disclosure - ORGANIZATION AND NATURE OF OPERATIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetailss" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetailss">
        <link:definition>240201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF NET LOSS PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetailss" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetailss">
        <link:definition>240202 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss" id="DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss">
        <link:definition>240302 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT TERM INVESTMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsWorkforceReductionPlanDetails" id="DisclosureBalanceSheetComponentsWorkforceReductionPlanDetails">
        <link:definition>240403 - Disclosure - BALANCE SHEET COMPONENTS - WORKFORCE REDUCTION PLAN (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetailss" id="DisclosureCommitmentsAndContingenciesDetailss">
        <link:definition>240501 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss" id="DisclosureStockholdersEquityDetailss">
        <link:definition>240601 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetailss" id="DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetailss">
        <link:definition>240602 - Disclosure - STOCKHOLDERS' EQUITY - SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails" id="DisclosureStockBasedCompensationDetails">
        <link:definition>240701 - Disclosure - STOCK-BASED COMPENSATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails" id="DisclosureStockBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails">
        <link:definition>240703 - Disclosure - STOCK-BASED COMPENSATION - SCHEDULE OF UNVESTED RESTRICTED STOCK UNIT ACTIVITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails">
        <link:definition>240704 - Disclosure - STOCK-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails" id="DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails">
        <link:definition>240705 - Disclosure - STOCK-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY TYPE OF AWARDS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureSubsequentEventDetails" id="DisclosureSubsequentEventDetails">
        <link:definition>240801 - Disclosure - SUBSEQUENT EVENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DocumentCover" id="DocumentCover">
        <link:definition>100090 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>110101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies" id="DisclosureBasisOfPresentationAndSignificantAccountingPolicies">
        <link:definition>110201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstruments" id="DisclosureFairValueOfFinancialInstruments">
        <link:definition>110301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponents" id="DisclosureBalanceSheetComponents">
        <link:definition>110401 - Disclosure - BALANCE SHEET COMPONENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>110501 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>110601 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensation" id="DisclosureShareBasedCompensation">
        <link:definition>110701 - Disclosure - SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>110801 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>110901 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies">
        <link:definition>120202 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables">
        <link:definition>130203 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsTables" id="DisclosureFairValueOfFinancialInstrumentsTables">
        <link:definition>130303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsTables" id="DisclosureBalanceSheetComponentsTables">
        <link:definition>130403 - Disclosure - BALANCE SHEET COMPONENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>130503 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>130603 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationTables" id="DisclosureShareBasedCompensationTables">
        <link:definition>130703 - Disclosure - SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>130903 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails">
        <link:definition>140202 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF NET LOSS PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>140401 - Disclosure - BALANCE SHEET COMPONENTS - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" id="DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails">
        <link:definition>140402 - Disclosure - BALANCE SHEET COMPONENTS - SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails">
        <link:definition>140502 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails" id="DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails">
        <link:definition>140702 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF OPTION ACTIVITY UNDER 2021 PLAN AND 2018 PLAN (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetails">
        <link:definition>140904 - Disclosure - INCOME TAXES - SUMMARY OF GROSS UNRECOGNIZED TAX BENEFITS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" id="StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>200105 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureOrganizationAndNatureOfOperations" id="DisclosureOrganizationAndNatureOfOperations">
        <link:definition>210101 - Disclosure - ORGANIZATION AND NATURE OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciess" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciess">
        <link:definition>210201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentss" id="DisclosureFairValueOfFinancialInstrumentss">
        <link:definition>210301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentss" id="DisclosureBalanceSheetComponentss">
        <link:definition>210401 - Disclosure - BALANCE SHEET COMPONENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciess" id="DisclosureCommitmentsAndContingenciess">
        <link:definition>210501 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquitys" id="DisclosureStockholdersEquitys">
        <link:definition>210601 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>210701 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureSubsequentEvent" id="DisclosureSubsequentEvent">
        <link:definition>210801 - Disclosure - SUBSEQUENT EVENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPoliciess" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPoliciess">
        <link:definition>220202 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTabless" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTabless">
        <link:definition>230203 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsTabless" id="DisclosureFairValueOfFinancialInstrumentsTabless">
        <link:definition>230303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsTabless" id="DisclosureBalanceSheetComponentsTabless">
        <link:definition>230403 - Disclosure - BALANCE SHEET COMPONENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesTabless" id="DisclosureCommitmentsAndContingenciesTabless">
        <link:definition>230503 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityTabless" id="DisclosureStockholdersEquityTabless">
        <link:definition>230603 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>230703 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowDetails">
        <link:definition>240503 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF SUPPLEMENTAL CASH FLOW (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails" id="DisclosureStockBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails">
        <link:definition>240702 - Disclosure - STOCK-BASED COMPENSATION - SCHEDULE OF OPTION ACTIVITY UNDER 2021 PLAN AND 2018 PLAN (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="avte-20240930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="avte-20240930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="avte-20240930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="avte-20240930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://aerovatetx.com/20231231/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xsd:element name="SeriesARedeemableConvertiblePreferredStockMember" id="avte_SeriesARedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesSeedRedeemableConvertiblePreferredStockMember" id="avte_SeriesSeedRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="WalthamLeaseMember" id="avte_WalthamLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FosterCityLeaseMember" id="avte_FosterCityLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RaCapitalHealthcareFundL.pMember" id="avte_RaCapitalHealthcareFundL.pMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TwentyTwentyOneStockOptionAndIncentivePlanMember" id="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TwentyEighteenStockOptionAndIncentivePlanMember" id="avte_TwentyEighteenStockOptionAndIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember" id="avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedLiabilitiesAndOtherLiabilitiesCurrent" id="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet" id="avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="DeferredOfferingCostsIncludedInAccountsPayable" id="avte_DeferredOfferingCostsIncludedInAccountsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock" id="avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PrepaidResearchAndDevelopment" id="avte_PrepaidResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="LeaseIncreaseInRentPercentage" id="avte_LeaseIncreaseInRentPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IncreaseDecreaseInOperatingLeaseAssetAndLiability" id="avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock" id="avte_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedResearchAndDevelopmentCurrent" id="avte_AccruedResearchAndDevelopmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="DebtSecuritiesAvailableForSaleMaturityTerm" id="avte_DebtSecuritiesAvailableForSaleMaturityTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" id="avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfComponentsOfOperatingLeasesTableTextBlock" id="avte_ScheduleOfComponentsOfOperatingLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfVotesForEachShareOfCommonStock" id="avte_NumberOfVotesForEachShareOfCommonStock" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="BofaSecuritiesInc.Member" id="avte_BofaSecuritiesInc.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShortTermInvestmentPolicyTextBlock" id="avte_ShortTermInvestmentPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" id="avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConvertiblePreferredStockPolicyTextBlock" id="avte_ConvertiblePreferredStockPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MilestoneAxis" id="avte_MilestoneAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MilestoneDomain" id="avte_MilestoneDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CapitalStockSharesAuthorized" id="avte_CapitalStockSharesAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ServicesAgreementWithCarnotLlcMember" id="avte_ServicesAgreementWithCarnotLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RelatedPartyTransactionTerm" id="avte_RelatedPartyTransactionTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NoticeToTerminateAgreementPeriod" id="avte_NoticeToTerminateAgreementPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MaterialBreachCorrectionPeriod" id="avte_MaterialBreachCorrectionPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" id="avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" id="avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram" id="avte_ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="IncreaseRentalAmount" id="avte_IncreaseRentalAmount" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PurchaseAgreementCashProceedsToBeReceivedUponClosingOfMerger" id="avte_PurchaseAgreementCashProceedsToBeReceivedUponClosingOfMerger" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="MergerAgreementTerminationFeesPayable" id="avte_MergerAgreementTerminationFeesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="MergerAgreementTerminationFeesReceivable" id="avte_MergerAgreementTerminationFeesReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="JadeMember" id="avte_JadeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MergerAgreementSharesToBeIssuedDenominatorForCalculation" id="avte_MergerAgreementSharesToBeIssuedDenominatorForCalculation" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="MergerAgreementSecuritiesCapitalAmountReservedForFutureIssuance" id="avte_MergerAgreementSecuritiesCapitalAmountReservedForFutureIssuance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>27
<FILENAME>avte-20240930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/3/2024 12:42:26 AM-->
<!--Modified on: 12/3/2024 12:42:26 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#StatementConsolidatedBalanceSheets" roleURI="http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#StatementCondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" roleURI="http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss" roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss" roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailss" roleURI="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetailss" roleURI="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailss" roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailsCalc2" roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailsCalc2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureCommitmentsAndContingenciesScheduleOfRentExpensesDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfRentExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="avte-20240930.xsd#StatementConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstruments" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureFairValueOfFinancialInstruments" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponents" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBalanceSheetComponents" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingencies" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureCommitmentsAndContingencies" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquity" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockholdersEquity" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensation" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureShareBasedCompensation" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsTables" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureFairValueOfFinancialInstrumentsTables" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureCommitmentsAndContingenciesTables" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityTables" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockholdersEquityTables" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationTables" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureShareBasedCompensationTables" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureShareBasedCompensationDetails" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsWorkforceReductionPlanDetails" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBalanceSheetComponentsWorkforceReductionPlanDetails" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="avte-20240930.xsd#StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciess" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciess" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentss" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureFairValueOfFinancialInstrumentss" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciess" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureCommitmentsAndContingenciess" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquitys" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockholdersEquitys" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensation" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockBasedCompensation" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTabless" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTabless" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsTabless" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureFairValueOfFinancialInstrumentsTabless" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesTabless" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureCommitmentsAndContingenciesTabless" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityTabless" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockholdersEquityTabless" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationTables" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockBasedCompensationTables" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetailss" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetailss" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetailss" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetailss" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockBasedCompensationDetails" />
  <calculationLink xlink:role="http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="100100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638687833443194989" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638687833443194989" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638687833443194989" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638687833443194989" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638687833443194989" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_638687833443194989" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638687833443194989" xlink:to="us-gaap_ShortTermInvestments_638687833443194989" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638687833443204989" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638687833443194989" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638687833443204989" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638687833443204989" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638687833443204989" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638687833443204989" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638687833443204989" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638687833443204989" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638687833443204989" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638687833443204989" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638687833443204989" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638687833443214976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638687833443204989" xlink:to="us-gaap_PreferredStockValue_638687833443214976" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638687833443214976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638687833443204989" xlink:to="us-gaap_CommonStockValue_638687833443214976" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638687833443214976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638687833443204989" xlink:to="us-gaap_AdditionalPaidInCapital_638687833443214976" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638687833443214976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638687833443204989" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638687833443214976" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638687833443214976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638687833443204989" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638687833443214976" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638687833443214976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638687833443214976" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638687833443214976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638687833443214976" xlink:to="us-gaap_LiabilitiesCurrent_638687833443214976" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638687833443224972" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638687833443214976" xlink:to="us-gaap_AccountsPayableCurrent_638687833443224972" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent_638687833443224972" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638687833443214976" xlink:to="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent_638687833443224972" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638687833443224972" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638687833443214976" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638687833443224972" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities_638687833443224972" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638687833443214976" xlink:to="us-gaap_OtherLiabilities_638687833443224972" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638687833443395001" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638687833443214976" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638687833443395001" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638687833443404999" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638687833443404999" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="100200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638687833443404999" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_638687833443404999" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesTradingUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss_638687833443404999" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss_638687833443404999" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638687833443414991" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638687833443414991" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638687833443414991" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638687833443414991" xlink:to="us-gaap_OperatingIncomeLoss_638687833443414991" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638687833443414991" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638687833443414991" xlink:to="us-gaap_OperatingExpenses_638687833443414991" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638687833443414991" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638687833443414991" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638687833443414991" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638687833443414991" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638687833443414991" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638687833443414991" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638687833443414991" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638687833443414991" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638687833443414991" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_638687833443414991" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638687833443414991" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_638687833443414991" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638687833443424981" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638687833443414991" xlink:to="us-gaap_OtherNonoperatingExpense_638687833443424981" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638687833443424981" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638687833443424981" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="100400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638687833443424981" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638687833443424981" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638687833443424981" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638687833443424981" xlink:to="us-gaap_NetIncomeLoss_638687833443424981" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638687833443424981" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638687833443424981" xlink:to="us-gaap_ShareBasedCompensation_638687833443424981" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638687833443434981" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638687833443424981" xlink:to="us-gaap_Depreciation_638687833443434981" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet" xlink:label="avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet_638687833443434981" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638687833443424981" xlink:to="avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet_638687833443434981" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638687833443434981" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638687833443424981" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638687833443434981" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638687833443434981" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638687833443424981" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638687833443434981" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638687833443434981" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638687833443424981" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638687833443434981" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638687833443434981" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638687833443424981" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638687833443434981" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability" xlink:label="avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability_638687833443444992" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638687833443424981" xlink:to="avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability_638687833443444992" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_638687833443444992" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638687833443424981" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_638687833443444992" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638687833443444992" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638687833443444992" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_638687833443444992" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638687833443444992" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_638687833443444992" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_638687833443444992" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638687833443444992" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_638687833443444992" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638687833443444992" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638687833443444992" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638687833443444992" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638687833443444992" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638687833443444992" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638687833443454982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638687833443444992" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638687833443454982" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638687833443454982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638687833443444992" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638687833443454982" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_638687833443454982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638687833443444992" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_638687833443454982" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638687833443454982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638687833443444992" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638687833443454982" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="140902 - Disclosure - INCOME TAXES - SUMMARY OF COMPONENTS OF NET DEFERRED TAX ASSETS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638687833443464985" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_638687833443464985" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638687833443464985" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638687833443464985" xlink:to="us-gaap_DeferredTaxAssetsGross_638687833443464985" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638687833443464985" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638687833443464985" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638687833443464985" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638687833443464985" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638687833443464985" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638687833443464985" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638687833443464985" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638687833443464985" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638687833443464985" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638687833443464985" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638687833443464985" xlink:to="us-gaap_DeferredTaxAssetsOther_638687833443464985" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_638687833443475200" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638687833443464985" xlink:to="avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_638687833443475200" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638687833443475200" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638687833443464985" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638687833443475200" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities_638687833443475200" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilities_638687833443475200" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_638687833443475200" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities_638687833443475200" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_638687833443475200" order="1" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails" xlink:type="extended" xlink:title="140903 - Disclosure - INCOME TAXES - SUMMARY OF RECONCILIATION OF FEDERAL INCOME TAX RATE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638687833443484990" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638687833443484990" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638687833443484990" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638687833443484990" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_638687833443484990" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_638687833443484990" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_638687833443484990" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_638687833443484990" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" xlink:label="avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits_638687833443484990" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits_638687833443484990" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638687833443484990" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638687833443484990" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" xlink:title="200100 - Statement - Condensed Consolidated Balance Sheets (Unaudited)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638687833443494986" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_638687833443494986" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638687833443494986" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638687833443494986" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638687833443494986" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_638687833443494986" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638687833443494986" xlink:to="us-gaap_ShortTermInvestments_638687833443494986" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638687833443494986" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638687833443494986" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638687833443494986" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638687833443494986" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638687833443494986" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638687833443494986" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638687833443494986" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638687833443504999" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638687833443504999" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638687833443504999" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638687833443504999" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638687833443504999" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638687833443504999" xlink:to="us-gaap_LiabilitiesCurrent_638687833443504999" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638687833443504999" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638687833443504999" xlink:to="us-gaap_AccountsPayableCurrent_638687833443504999" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent_638687833443504999" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638687833443504999" xlink:to="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent_638687833443504999" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638687833443504999" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638687833443504999" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638687833443504999" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638687833443514987" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638687833443504999" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638687833443514987" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities_638687833443514987" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638687833443504999" xlink:to="us-gaap_OtherLiabilities_638687833443514987" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638687833443514987" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638687833443514987" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638687833443514987" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638687833443514987" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638687833443514987" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638687833443514987" xlink:to="us-gaap_PreferredStockValue_638687833443514987" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638687833443514987" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638687833443514987" xlink:to="us-gaap_CommonStockValue_638687833443514987" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638687833443524983" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638687833443514987" xlink:to="us-gaap_AdditionalPaidInCapital_638687833443524983" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638687833443524983" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638687833443514987" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638687833443524983" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638687833443524983" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638687833443514987" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638687833443524983" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="extended" xlink:title="200200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638687833443524983" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ProfitLoss_638687833443524983" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638687833443524983" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss_638687833443524983" xlink:to="us-gaap_OperatingIncomeLoss_638687833443524983" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638687833443534987" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638687833443524983" xlink:to="us-gaap_OperatingExpenses_638687833443534987" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638687833443534987" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638687833443534987" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638687833443534987" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638687833443534987" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638687833443534987" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638687833443534987" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638687833443534987" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss_638687833443524983" xlink:to="us-gaap_NonoperatingIncomeExpense_638687833443534987" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_638687833443534987" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638687833443534987" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_638687833443534987" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638687833443534987" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638687833443534987" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638687833443534987" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesTradingUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss_638687833443544996" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss_638687833443544996" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" xlink:title="200400 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638687833443544996" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638687833443544996" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638687833443544996" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638687833443544996" xlink:to="us-gaap_NetIncomeLoss_638687833443544996" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638687833443544996" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638687833443544996" xlink:to="us-gaap_ShareBasedCompensation_638687833443544996" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638687833443544996" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638687833443544996" xlink:to="us-gaap_Depreciation_638687833443544996" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet" xlink:label="avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet_638687833443544996" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638687833443544996" xlink:to="avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet_638687833443544996" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638687833443554991" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638687833443544996" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638687833443554991" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638687833443554991" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638687833443544996" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638687833443554991" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638687833443554991" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638687833443544996" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638687833443554991" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638687833443554991" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638687833443544996" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638687833443554991" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability" xlink:label="avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability_638687833443554991" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638687833443544996" xlink:to="avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability_638687833443554991" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_638687833443565003" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638687833443544996" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_638687833443565003" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638687833443565003" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638687833443565003" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_638687833443565003" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638687833443565003" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_638687833443565003" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_638687833443565003" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638687833443565003" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_638687833443565003" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638687833443565003" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638687833443565003" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638687833443565003" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638687833443565003" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638687833443565003" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638687833443565003" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638687833443565003" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638687833443565003" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_638687833443574990" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638687833443565003" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_638687833443574990" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638687833443574990" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638687833443565003" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638687833443574990" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638687833443574990" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638687833443565003" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638687833443574990" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss" xlink:type="extended" xlink:title="240301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF FAIR VALUE INSTRUMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_638687833443574990" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsFairValueDisclosure" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_638687833443574990" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_638687833443584993" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsFairValueDisclosure" xlink:to="us-gaap_ShortTermInvestments_638687833443584993" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss" xlink:type="extended" xlink:title="240303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="DebtSecuritiesAvailableForSaleUnrealizedLossPosition" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_638687833443584993" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_638687833443584993" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_638687833443584993" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_638687833443584993" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_638687833443595017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_638687833443595017" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_638687833443595017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_638687833443595017" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailss" xlink:type="extended" xlink:title="240401 - Disclosure - BALANCE SHEET COMPONENTS - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638687833443595017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_638687833443595017" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_638687833443595017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_638687833443595017" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_PrepaidResearchAndDevelopment" xlink:label="avte_PrepaidResearchAndDevelopment_638687833443595017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="avte_PrepaidResearchAndDevelopment_638687833443595017" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetailss" xlink:type="extended" xlink:title="240402 - Disclosure - BALANCE SHEET COMPONENTS - SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="AccruedLiabilitiesAndOtherLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_AccruedResearchAndDevelopmentCurrent" xlink:label="avte_AccruedResearchAndDevelopmentCurrent_638687833443604996" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="avte_AccruedResearchAndDevelopmentCurrent_638687833443604996" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638687833443604996" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638687833443604996" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638687833443604996" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638687833443604996" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailss" xlink:type="extended" xlink:title="240502 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638687833443604996" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638687833443604996" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_638687833443615027" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_638687833443615027" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638687833443615027" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638687833443615027" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638687833443615027" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638687833443615027" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638687833443615027" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638687833443615027" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailsCalc2" xlink:type="extended" xlink:title="240502 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES (Details) (Calc 2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638687833443624997" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638687833443624997" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638687833443624997" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability_638687833443624997" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfRentExpensesDetails" xlink:type="extended" xlink:title="240504 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF RENT EXPENSES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="LeaseCost" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638687833443624997" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LeaseCost" xlink:to="us-gaap_OperatingLeaseCost_638687833443624997" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost_638687833443624997" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_638687833443624997" order="2" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>28
<FILENAME>avte-20240930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/3/2024 12:42:26 AM-->
<!--Modified on: 12/3/2024 12:42:26 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockholdersEquityDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureShareBasedCompensationDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureRelatedPartyTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureIncomeTaxesDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" roleURI="http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureOrganizationAndNatureOfOperationsDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureOrganizationAndNatureOfOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetailss" roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss" roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss" roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss" roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureCommitmentsAndContingenciesDetailss" roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockholdersEquityDetailss" roleURI="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetailss" roleURI="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockBasedCompensationDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureSubsequentEventDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureSubsequentEventDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" />
  <link:roleRef roleURI="http://aerovatetx.com/20231231/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStandardAndCustomAxisDomainDefaults" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://aerovatetx.com/20231231/role/DisclosureStandardAndCustomAxisDomainDefaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_MilestoneAxis" xlink:label="MilestoneAxis" xlink:title="MilestoneAxis" />
    <link:loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_MilestoneDomain" xlink:label="MilestoneDomain" xlink:title="MilestoneDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MilestoneAxis" xlink:to="MilestoneDomain" xlink:title="definition: MilestoneAxis to MilestoneDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="CashAndCashEquivalentsAxis" xlink:title="CashAndCashEquivalentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CashAndCashEquivalentsAxis" xlink:to="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="definition: CashAndCashEquivalentsAxis to RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="InvestmentTypeAxis" xlink:title="InvestmentTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="InvestmentTypeCategorizationMember" xlink:title="InvestmentTypeCategorizationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="InvestmentTypeAxis" xlink:to="InvestmentTypeCategorizationMember" xlink:title="definition: InvestmentTypeAxis to InvestmentTypeCategorizationMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="LeaseContractualTermAxis" xlink:title="LeaseContractualTermAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="LeaseContractualTermDomain" xlink:title="LeaseContractualTermDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LeaseContractualTermAxis" xlink:to="LeaseContractualTermDomain" xlink:title="definition: LeaseContractualTermAxis to LeaseContractualTermDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain" xlink:title="definition: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="TaxCreditCarryforwardAxis" xlink:title="TaxCreditCarryforwardAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TaxCreditCarryforwardAxis" xlink:to="TaxCreditCarryforwardNameDomain" xlink:title="definition: TaxCreditCarryforwardAxis to TaxCreditCarryforwardNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" use="optional" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="OtherAssetsNoncurrent" xlink:title="definition: AssetsAbstract to OtherAssetsNoncurrent" use="optional" priority="0" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="ShortTermInvestments" xlink:title="ShortTermInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="ShortTermInvestments" xlink:title="definition: AssetsAbstract to ShortTermInvestments" use="optional" priority="0" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="InvestmentTypeCategorizationMember" xlink:title="InvestmentTypeCategorizationMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="ShortTermInvestmentsMember" xlink:title="ShortTermInvestmentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentTypeCategorizationMember" xlink:to="ShortTermInvestmentsMember" xlink:title="definition: InvestmentTypeCategorizationMember to ShortTermInvestmentsMember" use="optional" priority="0" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="100300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesTradingUnrealizedLoss" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesTradingUnrealizedGain" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedGain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="140101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_BofaSecuritiesInc.Member" xlink:label="avte_BofaSecuritiesInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="avte_BofaSecuritiesInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram" xlink:label="avte_ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="avte_ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="140201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="140203 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails" xlink:type="extended" xlink:title="140301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF FAIR VALUE INSTRUMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShortTermInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails" xlink:type="extended" xlink:title="140302 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT TERM INVESTMENT (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_DebtSecuritiesAvailableForSaleMaturityTerm" xlink:label="avte_DebtSecuritiesAvailableForSaleMaturityTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="avte_DebtSecuritiesAvailableForSaleMaturityTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails" xlink:type="extended" xlink:title="140303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="140501 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_WalthamLeaseMember" xlink:label="avte_WalthamLeaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="avte_WalthamLeaseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_FosterCityLeaseMember" xlink:label="avte_FosterCityLeaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="avte_FosterCityLeaseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfLand" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_IncreaseRentalAmount" xlink:label="avte_IncreaseRentalAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="avte_IncreaseRentalAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForRent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_LeaseIncreaseInRentPercentage" xlink:label="avte_LeaseIncreaseInRentPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="avte_LeaseIncreaseInRentPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="140601 - Disclosure - STOCKHOLDERS' EQUITY (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_SeriesSeedRedeemableConvertiblePreferredStockMember" xlink:label="avte_SeriesSeedRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="avte_SeriesSeedRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="avte_SeriesARedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="avte_SeriesARedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_RaCapitalHealthcareFundL.pMember" xlink:label="avte_RaCapitalHealthcareFundL.pMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="avte_RaCapitalHealthcareFundL.pMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_CapitalStockSharesAuthorized" xlink:label="avte_CapitalStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="avte_CapitalStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_NumberOfVotesForEachShareOfCommonStock" xlink:label="avte_NumberOfVotesForEachShareOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="avte_NumberOfVotesForEachShareOfCommonStock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails" xlink:type="extended" xlink:title="140602 - Disclosure - STOCKHOLDERS' EQUITY - SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails" xlink:type="extended" xlink:title="140701 - Disclosure - SHARE-BASED COMPENSATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_TwentyTwentyOneStockOptionAndIncentivePlanMember" xlink:label="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_TwentyEighteenStockOptionAndIncentivePlanMember" xlink:label="avte_TwentyEighteenStockOptionAndIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="avte_TwentyEighteenStockOptionAndIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember" xlink:label="avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails" xlink:type="extended" xlink:title="140703 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF UNVESTED RESTRICTED STOCK UNIT ACTIVITY (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails" xlink:type="extended" xlink:title="140704 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF FAIR VALUE OF STOCK OPTIONS ASSUMPTIONS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails" xlink:type="extended" xlink:title="140705 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION GRANTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails" xlink:type="extended" xlink:title="140706 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY TYPE OF AWARDS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="140801 - Disclosure - RELATED PARTY TRANSACTIONS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_ServicesAgreementWithCarnotLlcMember" xlink:label="avte_ServicesAgreementWithCarnotLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="avte_ServicesAgreementWithCarnotLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_RelatedPartyTransactionTerm" xlink:label="avte_RelatedPartyTransactionTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="avte_RelatedPartyTransactionTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_NoticeToTerminateAgreementPeriod" xlink:label="avte_NoticeToTerminateAgreementPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="avte_NoticeToTerminateAgreementPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_MaterialBreachCorrectionPeriod" xlink:label="avte_MaterialBreachCorrectionPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="avte_MaterialBreachCorrectionPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="140901 - Disclosure - INCOME TAXES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:type="extended" xlink:title="200300 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesTradingUnrealizedLoss" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesTradingUnrealizedGain" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedGain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureOrganizationAndNatureOfOperationsDetails" xlink:type="extended" xlink:title="240101 - Disclosure - ORGANIZATION AND NATURE OF OPERATIONS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_BofaSecuritiesInc.Member" xlink:label="avte_BofaSecuritiesInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="avte_BofaSecuritiesInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash" xlink:label="us-gaap_DividendsCommonStockCash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_DividendsCommonStockCash" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram" xlink:label="avte_ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="avte_ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetailss" xlink:type="extended" xlink:title="240202 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss" xlink:type="extended" xlink:title="240301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF FAIR VALUE INSTRUMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShortTermInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss" xlink:type="extended" xlink:title="240302 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT TERM INVESTMENT (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_DebtSecuritiesAvailableForSaleMaturityTerm" xlink:label="avte_DebtSecuritiesAvailableForSaleMaturityTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="avte_DebtSecuritiesAvailableForSaleMaturityTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss" xlink:type="extended" xlink:title="240303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetailss" xlink:type="extended" xlink:title="240501 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_WalthamLeaseMember" xlink:label="avte_WalthamLeaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="avte_WalthamLeaseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_FosterCityLeaseMember" xlink:label="avte_FosterCityLeaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="avte_FosterCityLeaseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfLand" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_IncreaseRentalAmount" xlink:label="avte_IncreaseRentalAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="avte_IncreaseRentalAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForRent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_LeaseIncreaseInRentPercentage" xlink:label="avte_LeaseIncreaseInRentPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="avte_LeaseIncreaseInRentPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss" xlink:type="extended" xlink:title="240601 - Disclosure - STOCKHOLDERS' EQUITY (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_SeriesSeedRedeemableConvertiblePreferredStockMember" xlink:label="avte_SeriesSeedRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="avte_SeriesSeedRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="avte_SeriesARedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="avte_SeriesARedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_RaCapitalHealthcareFundL.pMember" xlink:label="avte_RaCapitalHealthcareFundL.pMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="avte_RaCapitalHealthcareFundL.pMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_CapitalStockSharesAuthorized" xlink:label="avte_CapitalStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="avte_CapitalStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_NumberOfVotesForEachShareOfCommonStock" xlink:label="avte_NumberOfVotesForEachShareOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="avte_NumberOfVotesForEachShareOfCommonStock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetailss" xlink:type="extended" xlink:title="240602 - Disclosure - STOCKHOLDERS' EQUITY - SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails" xlink:type="extended" xlink:title="240701 - Disclosure - STOCK-BASED COMPENSATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_TwentyTwentyOneStockOptionAndIncentivePlanMember" xlink:label="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_TwentyEighteenStockOptionAndIncentivePlanMember" xlink:label="avte_TwentyEighteenStockOptionAndIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="avte_TwentyEighteenStockOptionAndIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember" xlink:label="avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails" xlink:type="extended" xlink:title="240703 - Disclosure - STOCK-BASED COMPENSATION - SCHEDULE OF UNVESTED RESTRICTED STOCK UNIT ACTIVITY (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="240704 - Disclosure - STOCK-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails" xlink:type="extended" xlink:title="240705 - Disclosure - STOCK-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY TYPE OF AWARDS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureSubsequentEventDetails" xlink:type="extended" xlink:title="240801 - Disclosure - SUBSEQUENT EVENT (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_JadeMember" xlink:label="avte_JadeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="avte_JadeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash" xlink:label="us-gaap_DividendsCommonStockCash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DividendsCommonStockCash" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_PurchaseAgreementCashProceedsToBeReceivedUponClosingOfMerger" xlink:label="avte_PurchaseAgreementCashProceedsToBeReceivedUponClosingOfMerger" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="avte_PurchaseAgreementCashProceedsToBeReceivedUponClosingOfMerger" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_MergerAgreementTerminationFeesPayable" xlink:label="avte_MergerAgreementTerminationFeesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="avte_MergerAgreementTerminationFeesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_MergerAgreementTerminationFeesReceivable" xlink:label="avte_MergerAgreementTerminationFeesReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="avte_MergerAgreementTerminationFeesReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_MergerAgreementSharesToBeIssuedDenominatorForCalculation" xlink:label="avte_MergerAgreementSharesToBeIssuedDenominatorForCalculation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="avte_MergerAgreementSharesToBeIssuedDenominatorForCalculation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_MergerAgreementSecuritiesCapitalAmountReservedForFutureIssuance" xlink:label="avte_MergerAgreementSecuritiesCapitalAmountReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="avte_MergerAgreementSecuritiesCapitalAmountReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>29
<FILENAME>avte-20240930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/3/2024 12:42:26 AM-->
<!--Modified on: 12/3/2024 12:42:26 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cover [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Balance Sheets (Unaudited)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other long-term assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Default Label]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued liabilities and other liabilities current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accrued and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities, net of current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 5)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of September 30, 2024 and December 31, 2023, respectively; no shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.0001 par value; 150,000,000 shares authorized at September 30, 2024 and December 31, 2023, respectively; 28,867,711 and 27,762,703 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive (loss) income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive gain</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance, value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance, value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expense:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expense:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expense:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss before income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss before income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total tax provision</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive loss:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesTradingUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Trading, Unrealized Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized (loss) gain on securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain (loss) on securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average shares of common stock outstanding, basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average shares of common stock outstanding, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common stock outstanding, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average shares of common stock outstanding, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common stock outstanding, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AOCI Attributable to Parent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive (Loss) Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Gain/(Loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesTradingUnrealizedLoss" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesTradingUnrealizedLoss" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Trading, Unrealized Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized loss on investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized loss on investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesTradingUnrealizedGain" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesTradingUnrealizedGain" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedGain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Trading, Unrealized Gain</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain on investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock in connection with ATM, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock in connection with ATM, net, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of restricted stock units, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock under ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock under ESPP, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Statements of Cash Flows (Unaudited)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flow from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization expense</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet" xlink:label="avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet" xlink:to="avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of discounts and amortization of premiums on investments, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of discounts and amortization of premiums on investments, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Noncurrent Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other long-term assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other liabilities</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability" xlink:label="avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability" xlink:to="avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease asset and liability, net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Operating Lease Asset And Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease assets and liabilities, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flow from investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Short-Term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturities of short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flow from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sale of common stock in connection with ATM, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sale of common stock in connection with ATM, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock under ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock upon exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at the beginning of the year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of noncash investing and financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use asset obtained in exchange for operating lease liability</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_DeferredOfferingCostsIncludedInAccountsPayable" xlink:label="avte_DeferredOfferingCostsIncludedInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_DeferredOfferingCostsIncludedInAccountsPayable" xlink:to="avte_DeferredOfferingCostsIncludedInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_DeferredOfferingCostsIncludedInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred offering costs included in accounts payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_DeferredOfferingCostsIncludedInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred offering costs included in accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ORGANIZATION AND NATURE OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ORGANIZATION AND NATURE OF OPERATIONS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FAIR VALUE OF FINANCIAL INSTRUMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FAIR VALUE OF FINANCIAL INSTRUMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BALANCE SHEET COMPONENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Balance Sheet Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BALANCE SHEET COMPONENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCKHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCK-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCK-BASED COMPENSATION</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHARE-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_ShortTermInvestmentPolicyTextBlock" xlink:label="avte_ShortTermInvestmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_ShortTermInvestmentPolicyTextBlock" xlink:to="avte_ShortTermInvestmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_ShortTermInvestmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investment [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_ShortTermInvestmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Investments [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_ShortTermInvestmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:label="avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:to="avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expenses and Other Current Assets [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expenses and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Long-lived Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_ConvertiblePreferredStockPolicyTextBlock" xlink:label="avte_ConvertiblePreferredStockPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_ConvertiblePreferredStockPolicyTextBlock" xlink:to="avte_ConvertiblePreferredStockPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_ConvertiblePreferredStockPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_ConvertiblePreferredStockPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation Related Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently Issued and Recently Adopted Accounting Pronouncements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently Issued and Recently Adopted Accounting Pronouncements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently Issued Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SCHEDULE OF NET LOSS PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SCHEDULE OF FAIR VALUE INSTRUMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SCHEDULE OF SHORT TERM INVESTMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock" xlink:label="avte_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock" xlink:to="avte_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Prepaid Expenses And Other Current Asset [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_ScheduleOfComponentsOfOperatingLeasesTableTextBlock" xlink:label="avte_ScheduleOfComponentsOfOperatingLeasesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_ScheduleOfComponentsOfOperatingLeasesTableTextBlock" xlink:to="avte_ScheduleOfComponentsOfOperatingLeasesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_ScheduleOfComponentsOfOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of components of operating leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_ScheduleOfComponentsOfOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Components of Operating Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_ScheduleOfComponentsOfOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SCHEDULE OF COMPONENTS OF OPERATING LEASES</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock" xlink:label="avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock" xlink:to="avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of common stock shares reserved on and as converted basis for future issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SCHEDULE OF OPTION ACTIVITY UNDER 2021 PLAN AND 2018 PLAN</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SCHEDULE OF UNVESTED STOCK UNIT ACTIVITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SCHEDULE OF UNVESTED RESTRICTED STOCK UNIT ACTIVITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SCHEDULE OF FAIR VALUE OF STOCK OPTIONS ASSUMPTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF COMPONENTS OF NET DEFERRED TAX ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF RECONCILIATION OF FEDERAL INCOME TAX RATE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF GROSS UNRECOGNIZED TAX BENEFITS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_BofaSecuritiesInc.Member" xlink:label="avte_BofaSecuritiesInc.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_BofaSecuritiesInc.Member" xlink:to="avte_BofaSecuritiesInc.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_BofaSecuritiesInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to BofA Securities, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_BofaSecuritiesInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BofA Securities, Inc. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_BofaSecuritiesInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BofA Securities, Inc.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate amount of shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Number of Shares Issued in Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares sold</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram" xlink:label="avte_ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram" xlink:to="avte_ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the value of the common stock remaining which can be sold from time to time under the ATM ("At-the-Market") Program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of Remaining Common Stock Available For Sale Under ATM Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of remaining common stock available for sale under ATM Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avte_ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of remaining common stock available for sale Under ATM Program</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents and short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements are amortized over the remaining life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment, Long-Lived Asset, Held-for-Use</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss available to common stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to common stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options to purchase common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units (RSUs) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested restricted stock units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock awards and units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Paper [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial paper</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">US Treasury Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. Treasury bills</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate debt securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">US Government Agencies Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agency bond</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money Market Funds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total fair value of assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Fair Value, off-Balance-Sheet Risks [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, off-Balance-Sheet Risks, Disclosure Information</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_DebtSecuritiesAvailableForSaleMaturityTerm" xlink:label="avte_DebtSecuritiesAvailableForSaleMaturityTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_DebtSecuritiesAvailableForSaleMaturityTerm" xlink:to="avte_DebtSecuritiesAvailableForSaleMaturityTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_DebtSecuritiesAvailableForSaleMaturityTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturity term for debt securities classified as available for sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_DebtSecuritiesAvailableForSaleMaturityTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities Available For Sale Maturity Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_DebtSecuritiesAvailableForSaleMaturityTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturity term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross unrealized gains</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross unrealized loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross unrealized losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Noncurrent, Statement of Financial Position [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Unrealized Loss Position</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investments, Less than 12 months, Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investments, Less than 12 months, Unrealized Losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investments, 12 months or Greater, Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investments, 12 months or Greater, Unrealized Losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Unrealized Loss Position</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investments, Total Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investments, Total Unrealized Losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_PrepaidResearchAndDevelopment" xlink:label="avte_PrepaidResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_PrepaidResearchAndDevelopment" xlink:to="avte_PrepaidResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_PrepaidResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_PrepaidResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current assets</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_AccruedResearchAndDevelopmentCurrent" xlink:label="avte_AccruedResearchAndDevelopmentCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_AccruedResearchAndDevelopmentCurrent" xlink:to="avte_AccruedResearchAndDevelopmentCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_AccruedResearchAndDevelopmentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_AccruedResearchAndDevelopmentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Research and Development Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_AccruedResearchAndDevelopmentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued payroll and other employee benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Contractual Term [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Contractual Term [Domain]</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_WalthamLeaseMember" xlink:label="avte_WalthamLeaseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_WalthamLeaseMember" xlink:to="avte_WalthamLeaseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_WalthamLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Waltham Lease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_WalthamLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Waltham Lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_WalthamLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Waltham Lease</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_FosterCityLeaseMember" xlink:label="avte_FosterCityLeaseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_FosterCityLeaseMember" xlink:to="avte_FosterCityLeaseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_FosterCityLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foster City Lease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_FosterCityLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foster City Lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_FosterCityLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foster City Lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of land</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of land</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease term</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_IncreaseRentalAmount" xlink:label="avte_IncreaseRentalAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_IncreaseRentalAmount" xlink:to="avte_IncreaseRentalAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_IncreaseRentalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in rent square foot value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_IncreaseRentalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Rental Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_IncreaseRentalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase of rental value for square foot</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, option to extend</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Renewal term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment for rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment for rent</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_LeaseIncreaseInRentPercentage" xlink:label="avte_LeaseIncreaseInRentPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_LeaseIncreaseInRentPercentage" xlink:to="avte_LeaseIncreaseInRentPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_LeaseIncreaseInRentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease increase in rent percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_LeaseIncreaseInRentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease rent percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_LeaseIncreaseInRentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease rent percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of net minimum lease payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of net minimum lease payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating lease expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Amount representing interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average remaining lease term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average incremental borrowing rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_SeriesSeedRedeemableConvertiblePreferredStockMember" xlink:label="avte_SeriesSeedRedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_SeriesSeedRedeemableConvertiblePreferredStockMember" xlink:to="avte_SeriesSeedRedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_SeriesSeedRedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series Seed Redeemable Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_SeriesSeedRedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series Seed Redeemable Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_SeriesSeedRedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series Seed Redeemable Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="avte_SeriesARedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_SeriesARedeemableConvertiblePreferredStockMember" xlink:to="avte_SeriesARedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_SeriesARedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Redeemable Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_SeriesARedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Redeemable Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_SeriesARedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Redeemable Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_RaCapitalHealthcareFundL.pMember" xlink:label="avte_RaCapitalHealthcareFundL.pMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_RaCapitalHealthcareFundL.pMember" xlink:to="avte_RaCapitalHealthcareFundL.pMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_RaCapitalHealthcareFundL.pMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RA Capital Healthcare Fund, L.P [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_RaCapitalHealthcareFundL.pMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RA Capital Healthcare Fund, L.P</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_RaCapitalHealthcareFundL.pMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RA Capital Healthcare Fund, L.P</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_CapitalStockSharesAuthorized" xlink:label="avte_CapitalStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_CapitalStockSharesAuthorized" xlink:to="avte_CapitalStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_CapitalStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital stock shares authorized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_CapitalStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital stock shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_CapitalStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital stock shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity shares, value per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity, par value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of stock shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of stock shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_NumberOfVotesForEachShareOfCommonStock" xlink:label="avte_NumberOfVotesForEachShareOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_NumberOfVotesForEachShareOfCommonStock" xlink:to="avte_NumberOfVotesForEachShareOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_NumberOfVotesForEachShareOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to number of votes for each share of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_NumberOfVotesForEachShareOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Votes For Each Share Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_NumberOfVotesForEachShareOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of votes for each share of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee stock purchase plan awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock reserved for future issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_TwentyTwentyOneStockOptionAndIncentivePlanMember" xlink:label="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember" xlink:to="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Stock Option and Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Stock Option and Incentive Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Plan</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_TwentyEighteenStockOptionAndIncentivePlanMember" xlink:label="avte_TwentyEighteenStockOptionAndIncentivePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_TwentyEighteenStockOptionAndIncentivePlanMember" xlink:to="avte_TwentyEighteenStockOptionAndIncentivePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_TwentyEighteenStockOptionAndIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2018 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_TwentyEighteenStockOptionAndIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2018 Plan</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember" xlink:label="avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember" xlink:to="avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Plan and 2018 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Plan and 2018 Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage on total number of shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of additional shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock available for issuance, awards granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of units, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock units award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock option grants per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of common stock purchase price</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Duration of offering period for share-based compensation arrangement by share-based payment award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award, Offering Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount percentage on marker price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized stock based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized stock-based compensation weighted-average period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock options granted and outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Outstanding, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Outstanding, beginning balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Exercise Price Outstanding, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Exercise Price Outstanding, beginning balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted- Average Remaining Contractual Term, Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value Outstanding, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value Outstanding, beginning balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Exercise Price, Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Exercise Price, Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options, Cancelled/Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options, Cancelled/Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Exercise Price, Cancelled/Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options, Vested and exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Exercise Price, Vested and exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted- Average Remaining Contractual Term, Vested and exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, Vested and exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options, Vested and expected to vest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Exercise Price, Vested and expected to vest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted- Average Remaining Contractual Term, Vested and expected to vest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, Vested and expected to vest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of units, Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of units, beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Grant date fair value, Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Grant date fair value, beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Grant date fair value, Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of units, Vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of units, Vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Grant date fair value, Vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate, maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Domain]</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_ServicesAgreementWithCarnotLlcMember" xlink:label="avte_ServicesAgreementWithCarnotLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_ServicesAgreementWithCarnotLlcMember" xlink:to="avte_ServicesAgreementWithCarnotLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_ServicesAgreementWithCarnotLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to service agreement with Carnot LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_ServicesAgreementWithCarnotLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Service agreement with carnot LLC</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_ServicesAgreementWithCarnotLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Service agreement with Carnot LLC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_RelatedPartyTransactionTerm" xlink:label="avte_RelatedPartyTransactionTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_RelatedPartyTransactionTerm" xlink:to="avte_RelatedPartyTransactionTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_RelatedPartyTransactionTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of related party transaction for service agreement , in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_RelatedPartyTransactionTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of service agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_RelatedPartyTransactionTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of service agreement</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_NoticeToTerminateAgreementPeriod" xlink:label="avte_NoticeToTerminateAgreementPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_NoticeToTerminateAgreementPeriod" xlink:to="avte_NoticeToTerminateAgreementPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_NoticeToTerminateAgreementPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of days in which notice to terminate an agreement must be given.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_NoticeToTerminateAgreementPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notice To Terminate Agreement Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_NoticeToTerminateAgreementPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination notice period</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_MaterialBreachCorrectionPeriod" xlink:label="avte_MaterialBreachCorrectionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_MaterialBreachCorrectionPeriod" xlink:to="avte_MaterialBreachCorrectionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_MaterialBreachCorrectionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of days in which material breach must be corrected or agreement will be terminated.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_MaterialBreachCorrectionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Material Breach Correction Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_MaterialBreachCorrectionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Material breach correction period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses from transactions with related party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount payable to related parties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic Tax Authority [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic Tax Authority</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local Jurisdiction</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Tax Credit Carryforward [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Tax Credit Carryforward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NOL carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NOL carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research credit carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:to="avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Capitalized Research and Development Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized R&amp;D</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets (liabilities)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. Federal statutory income tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. Federal statutory income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent and other differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent and other differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" xlink:label="avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" xlink:to="avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation Research and Development Credits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development credits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance of unrecognized tax benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance of unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions based on tax positions related to the current year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions based on tax positions related to the current year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions based on tax positions related to the prior year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment in accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUBSEQUENT EVENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUBSEQUENT EVENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SCHEDULE OF SUPPLEMENTAL CASH FLOW</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SCHEDULE OF OPERATING LEASE EXPENSE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash" xlink:label="us-gaap_DividendsCommonStockCash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStockCash" xlink:to="us-gaap_DividendsCommonStockCash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsCommonStockCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends, Common Stock, Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsCommonStockCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash dividend</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Allowance for Credit Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for credit loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Current, Statement of Financial Position [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Restructuring and Related Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Cost and Reserve [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Cost and Reserve</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of individuals terminated or notified of their upcoming termination</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of number of individuals terminated or notified of their upcoming termination</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:label="us-gaap_RestructuringAndRelatedCostIncurredCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="us-gaap_RestructuringAndRelatedCostIncurredCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostIncurredCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring and Related Cost, Incurred Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostIncurredCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incurred costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="us-gaap_PaymentsForRestructuring_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for Restructuring</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Severance benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities associated with the Workforce Reduction Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseImpairmentLoss" xlink:to="us-gaap_OperatingLeaseImpairmentLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Impairment Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid included in operating cash flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total rent expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock available for issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of units, forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of units, forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Grant date fair value, Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">All Entities [Member]</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_JadeMember" xlink:label="avte_JadeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_JadeMember" xlink:to="avte_JadeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_JadeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Jade.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_JadeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Jade [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_JadeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Jade</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUBSEQUENT EVENT</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_PurchaseAgreementCashProceedsToBeReceivedUponClosingOfMerger" xlink:label="avte_PurchaseAgreementCashProceedsToBeReceivedUponClosingOfMerger" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_PurchaseAgreementCashProceedsToBeReceivedUponClosingOfMerger" xlink:to="avte_PurchaseAgreementCashProceedsToBeReceivedUponClosingOfMerger_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_PurchaseAgreementCashProceedsToBeReceivedUponClosingOfMerger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow to be received for concurrent investment upon closing of merger in purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_PurchaseAgreementCashProceedsToBeReceivedUponClosingOfMerger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Agreement, Cash Proceeds To Be received, Upon Closing Of Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_PurchaseAgreementCashProceedsToBeReceivedUponClosingOfMerger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash proceeds to be received upon closing of merger</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_MergerAgreementTerminationFeesPayable" xlink:label="avte_MergerAgreementTerminationFeesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_MergerAgreementTerminationFeesPayable" xlink:to="avte_MergerAgreementTerminationFeesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_MergerAgreementTerminationFeesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination fees to be paid upon termination of merger agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_MergerAgreementTerminationFeesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Merger Agreement, Termination Fees Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_MergerAgreementTerminationFeesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination fees payable</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_MergerAgreementTerminationFeesReceivable" xlink:label="avte_MergerAgreementTerminationFeesReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_MergerAgreementTerminationFeesReceivable" xlink:to="avte_MergerAgreementTerminationFeesReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_MergerAgreementTerminationFeesReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination fees to be received upon termination of merger agreement by other party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_MergerAgreementTerminationFeesReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Merger Agreement, Termination Fees Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_MergerAgreementTerminationFeesReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination fees receivable</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_MergerAgreementSharesToBeIssuedDenominatorForCalculation" xlink:label="avte_MergerAgreementSharesToBeIssuedDenominatorForCalculation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_MergerAgreementSharesToBeIssuedDenominatorForCalculation" xlink:to="avte_MergerAgreementSharesToBeIssuedDenominatorForCalculation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_MergerAgreementSharesToBeIssuedDenominatorForCalculation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Refers shares to be issued in denominator for calculation under merger agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_MergerAgreementSharesToBeIssuedDenominatorForCalculation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Merger Agreement, Shares to be Issued, Denominator for Calculation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_MergerAgreementSharesToBeIssuedDenominatorForCalculation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares to be issued in denominator for calculation</label>
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_MergerAgreementSecuritiesCapitalAmountReservedForFutureIssuance" xlink:label="avte_MergerAgreementSecuritiesCapitalAmountReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avte_MergerAgreementSecuritiesCapitalAmountReservedForFutureIssuance" xlink:to="avte_MergerAgreementSecuritiesCapitalAmountReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avte_MergerAgreementSecuritiesCapitalAmountReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents securities issued for aggregate purchase price under merger agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avte_MergerAgreementSecuritiesCapitalAmountReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Merger Agreement, Securities, Capital Amount Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avte_MergerAgreementSecuritiesCapitalAmountReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate purchase price under merger agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>30
<FILENAME>avte-20240930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/3/2024 12:42:26 AM-->
<!--Modified on: 12/3/2024 12:42:26 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DocumentCover" roleURI="http://aerovatetx.com/20231231/role/DocumentCover" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#StatementConsolidatedBalanceSheets" roleURI="http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://aerovatetx.com/20231231/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPolicies" roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureFairValueOfFinancialInstruments" roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBalanceSheetComponents" roleURI="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockholdersEquity" roleURI="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureShareBasedCompensation" roleURI="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureRelatedPartyTransactions" roleURI="http://aerovatetx.com/20231231/role/DisclosureRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureIncomeTaxes" roleURI="http://aerovatetx.com/20231231/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureFairValueOfFinancialInstrumentsTables" roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBalanceSheetComponentsTables" roleURI="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockholdersEquityTables" roleURI="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureShareBasedCompensationTables" roleURI="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureIncomeTaxesTables" roleURI="http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockholdersEquityDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureShareBasedCompensationDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureRelatedPartyTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureIncomeTaxesDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureIncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#StatementCondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" roleURI="http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" roleURI="http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureOrganizationAndNatureOfOperations" roleURI="http://aerovatetx.com/20231231/role/DisclosureOrganizationAndNatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciess" roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciess" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureFairValueOfFinancialInstrumentss" roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBalanceSheetComponentss" roleURI="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureCommitmentsAndContingenciess" roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciess" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockholdersEquitys" roleURI="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquitys" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockBasedCompensation" roleURI="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureSubsequentEvent" roleURI="http://aerovatetx.com/20231231/role/DisclosureSubsequentEvent" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPoliciess" roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPoliciess" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTabless" roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTabless" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureFairValueOfFinancialInstrumentsTabless" roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsTabless" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBalanceSheetComponentsTabless" roleURI="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsTabless" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureCommitmentsAndContingenciesTabless" roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesTabless" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockholdersEquityTabless" roleURI="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityTabless" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockBasedCompensationTables" roleURI="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureOrganizationAndNatureOfOperationsDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureOrganizationAndNatureOfOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetailss" roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetailss" roleURI="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss" roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss" roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss" roleURI="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailss" roleURI="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetailss" roleURI="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureBalanceSheetComponentsWorkforceReductionPlanDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsWorkforceReductionPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureCommitmentsAndContingenciesDetailss" roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailss" roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureCommitmentsAndContingenciesScheduleOfRentExpensesDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfRentExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockholdersEquityDetailss" roleURI="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetailss" roleURI="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockBasedCompensationDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="avte-20240930.xsd#DisclosureSubsequentEventDetails" roleURI="http://aerovatetx.com/20231231/role/DisclosureSubsequentEventDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DocumentCover" xlink:type="extended" xlink:title="100090 - Document - Cover" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638687833444665065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638687833444665065" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638687833444687313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638687833444687313" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638687833444687313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_638687833444687313" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638687833444687313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_638687833444687313" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638687833444687313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638687833444687313" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_638687833444687313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_638687833444687313" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638687833444695059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638687833444695059" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638687833444695059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638687833444695059" order="8" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="100100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638687833444695059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638687833444695059" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638687833444695059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638687833444695059" xlink:to="us-gaap_AssetsCurrentAbstract_638687833444695059" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638687833444695059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638687833444695059" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638687833444695059" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_638687833444695059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638687833444695059" xlink:to="us-gaap_ShortTermInvestments_638687833444695059" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638687833444695059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638687833444695059" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638687833444695059" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638687833444695059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638687833444695059" xlink:to="us-gaap_AssetsCurrent_638687833444695059" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638687833444705057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638687833444695059" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638687833444705057" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638687833444705057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638687833444695059" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638687833444705057" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638687833444705057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638687833444695059" xlink:to="us-gaap_OtherAssetsNoncurrent_638687833444705057" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638687833444705057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638687833444695059" xlink:to="us-gaap_Assets_638687833444705057" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638687833444705057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638687833444705057" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638687833444705057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638687833444705057" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638687833444705057" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638687833444705057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638687833444705057" xlink:to="us-gaap_AccountsPayableCurrent_638687833444705057" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent_638687833444705057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638687833444705057" xlink:to="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent_638687833444705057" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638687833444705057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638687833444705057" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638687833444705057" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638687833444715046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638687833444705057" xlink:to="us-gaap_LiabilitiesCurrent_638687833444715046" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638687833444715046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638687833444705057" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638687833444715046" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities_638687833444715046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638687833444705057" xlink:to="us-gaap_OtherLiabilities_638687833444715046" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638687833444715046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638687833444705057" xlink:to="us-gaap_Liabilities_638687833444715046" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638687833444715046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638687833444705057" xlink:to="us-gaap_CommitmentsAndContingencies_638687833444715046" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638687833444725073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638687833444705057" xlink:to="us-gaap_StockholdersEquityAbstract_638687833444725073" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638687833444725073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638687833444725073" xlink:to="us-gaap_PreferredStockValue_638687833444725073" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638687833444735192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638687833444725073" xlink:to="us-gaap_CommonStockValue_638687833444735192" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638687833444745367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638687833444725073" xlink:to="us-gaap_AdditionalPaidInCapital_638687833444745367" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638687833444745367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638687833444725073" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638687833444745367" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638687833444745367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638687833444725073" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638687833444745367" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638687833444745367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638687833444725073" xlink:to="us-gaap_StockholdersEquity_638687833444745367" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638687833444745367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638687833444705057" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638687833444745367" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="100105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638687833444755069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638687833444755069" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638687833444755069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638687833444755069" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638687833444755069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_638687833444755069" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638687833444755069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_638687833444755069" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638687833444755069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638687833444755069" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638687833444765059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638687833444765059" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638687833444765059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638687833444765059" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638687833444765059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638687833444765059" order="8" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="100200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638687833444765059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638687833444765059" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638687833444765059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638687833444765059" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638687833444765059" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638687833444765059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638687833444765059" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638687833444765059" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638687833444765059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638687833444765059" xlink:to="us-gaap_OperatingExpenses_638687833444765059" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638687833444775063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638687833444775063" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638687833444775063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638687833444775063" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_638687833444775063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638687833444775063" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_638687833444775063" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638687833444775063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638687833444775063" xlink:to="us-gaap_OtherNonoperatingExpense_638687833444775063" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638687833444775063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638687833444775063" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638687833444775063" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638687833444775063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638687833444775063" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638687833444775063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638687833444775063" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638687833444775063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss_638687833444775063" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_638687833444785313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_638687833444785313" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638687833444785313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_638687833444785313" xlink:to="us-gaap_NetIncomeLoss_638687833444785313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_638687833444785313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_638687833444785313" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_638687833444785313" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesTradingUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss_638687833444855100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_638687833444785313" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss_638687833444855100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638687833444865085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_638687833444785313" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638687833444865085" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638687833444865085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic_638687833444865085" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638687833444865085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_638687833444865085" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638687833444865085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638687833444865085" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638687833444865085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638687833444865085" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="100300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638687833444875124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638687833444875124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638687833444875124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638687833444875124" xlink:to="us-gaap_StatementEquityComponentsAxis_638687833444875124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638687833444875124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638687833444875124" xlink:to="us-gaap_CommonStockMember_638687833444875124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638687833444875124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638687833444875124" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638687833444875124" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638687833444875124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638687833444875124" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638687833444875124" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638687833444875124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638687833444875124" xlink:to="us-gaap_RetainedEarningsMember_638687833444875124" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638687833444885073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638687833444875124" xlink:to="us-gaap_EquityComponentDomain_638687833444885073" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638687833444885073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638687833444875124" xlink:to="us-gaap_StatementLineItems_638687833444885073" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638687833444885073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638687833444885073" xlink:to="us-gaap_SharesOutstanding_638687833444885073" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638687833444885073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638687833444885073" xlink:to="us-gaap_StockholdersEquity_638687833444885073" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesTradingUnrealizedLoss" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedLoss_638687833444885073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638687833444885073" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedLoss_638687833444885073" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesTradingUnrealizedGain" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGain_638687833444885073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638687833444885073" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedGain_638687833444885073" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638687833444885073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638687833444885073" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638687833444885073" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638687833444885073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638687833444885073" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638687833444885073" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638687833444895065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_638687833444885073" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638687833444895065" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_638687833444895065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638687833444885073" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_638687833444895065" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_638687833444895065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_638687833444895065" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_638687833444895065" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638687833444895065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638687833444885073" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638687833444895065" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638687833444895065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638687833444895065" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638687833444895065" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638687833444895065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638687833444885073" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638687833444895065" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638687833444895065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638687833444895065" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638687833444895065" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638687833444905065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638687833444885073" xlink:to="us-gaap_NetIncomeLoss_638687833444905065" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638687833444905065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638687833444885073" xlink:to="us-gaap_SharesOutstanding_638687833444905065" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638687833444905065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638687833444885073" xlink:to="us-gaap_StockholdersEquity_638687833444905065" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="100400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638687833444905065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638687833444905065" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638687833444915073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638687833444905065" xlink:to="us-gaap_NetIncomeLoss_638687833444915073" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638687833444915073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638687833444905065" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638687833444915073" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638687833444915073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638687833444915073" xlink:to="us-gaap_ShareBasedCompensation_638687833444915073" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638687833444915073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638687833444915073" xlink:to="us-gaap_Depreciation_638687833444915073" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet" xlink:label="avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet_638687833444915073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638687833444915073" xlink:to="avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet_638687833444915073" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638687833444915073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638687833444915073" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638687833444915073" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638687833444915073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638687833444915073" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638687833444915073" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638687833444915073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638687833444915073" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638687833444915073" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638687833444915073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638687833444915073" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638687833444915073" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638687833444925070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638687833444915073" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638687833444925070" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability" xlink:label="avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability_638687833444925070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638687833444915073" xlink:to="avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability_638687833444925070" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_638687833444925070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638687833444915073" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_638687833444925070" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638687833444925070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638687833444915073" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638687833444925070" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638687833444925070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638687833444925070" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_638687833444925070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638687833444925070" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_638687833444925070" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_638687833444925070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638687833444925070" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_638687833444925070" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638687833444925070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638687833444925070" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638687833444925070" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638687833444935069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638687833444925070" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638687833444935069" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638687833444935069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638687833444935069" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638687833444935069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638687833444935069" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638687833444935069" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638687833444935069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638687833444935069" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638687833444935069" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_638687833444935069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638687833444935069" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_638687833444935069" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638687833444935069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638687833444935069" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638687833444935069" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638687833444935069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638687833444935069" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638687833444935069" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638687833444945059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638687833444945059" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638687833444945059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638687833444945059" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6386878334449450591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6386878334449450591" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638687833444945059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638687833444945059" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638687833444945059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638687833444945059" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638687833444945059" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_DeferredOfferingCostsIncludedInAccountsPayable" xlink:label="avte_DeferredOfferingCostsIncludedInAccountsPayable_638687833444945059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638687833444945059" xlink:to="avte_DeferredOfferingCostsIncludedInAccountsPayable_638687833444945059" order="2" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="110101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638687833444955059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638687833444955059" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies" xlink:type="extended" xlink:title="110201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638687833444955059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638687833444955059" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstruments" xlink:type="extended" xlink:title="110301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638687833444965069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638687833444965069" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponents" xlink:type="extended" xlink:title="110401 - Disclosure - BALANCE SHEET COMPONENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_638687833444965069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_638687833444965069" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="110501 - Disclosure - COMMITMENTS AND CONTINGENCIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638687833444965069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638687833444965069" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="110601 - Disclosure - STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638687833444975067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638687833444975067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensation" xlink:type="extended" xlink:title="110701 - Disclosure - SHARE-BASED COMPENSATION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638687833444975067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638687833444975067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="110801 - Disclosure - RELATED PARTY TRANSACTIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638687833444996764" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638687833444996764" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="110901 - Disclosure - INCOME TAXES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638687833444996764" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638687833444996764" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="120202 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638687833445005084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638687833445005084" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638687833445005084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638687833445005084" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638687833445005084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638687833445005084" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_ShortTermInvestmentPolicyTextBlock" xlink:label="avte_ShortTermInvestmentPolicyTextBlock_638687833445005084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="avte_ShortTermInvestmentPolicyTextBlock_638687833445005084" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638687833445005084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638687833445005084" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638687833445005084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638687833445005084" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638687833445005084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638687833445005084" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:label="avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_638687833445005084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_638687833445005084" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638687833445005084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638687833445005084" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638687833445005084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638687833445005084" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638687833445015067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638687833445015067" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_ConvertiblePreferredStockPolicyTextBlock" xlink:label="avte_ConvertiblePreferredStockPolicyTextBlock_638687833445015067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="avte_ConvertiblePreferredStockPolicyTextBlock_638687833445015067" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638687833445015067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638687833445015067" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_638687833445015067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_638687833445015067" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638687833445015067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638687833445015067" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_638687833445015067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_638687833445015067" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638687833445015067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638687833445015067" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638687833445015067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638687833445015067" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="130203 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638687833445025065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638687833445025065" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638687833445025065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638687833445025065" order="2" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsTables" xlink:type="extended" xlink:title="130303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638687833445025065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638687833445025065" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_638687833445025065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_638687833445025065" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_638687833445035072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_638687833445035072" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsTables" xlink:type="extended" xlink:title="130403 - Disclosure - BALANCE SHEET COMPONENTS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock" xlink:label="avte_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock_638687833445035072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="avte_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock_638687833445035072" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638687833445035072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638687833445035072" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="130503 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638687833445045084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638687833445045084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_ScheduleOfComponentsOfOperatingLeasesTableTextBlock" xlink:label="avte_ScheduleOfComponentsOfOperatingLeasesTableTextBlock_638687833445045084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="avte_ScheduleOfComponentsOfOperatingLeasesTableTextBlock_638687833445045084" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="130603 - Disclosure - STOCKHOLDERS' EQUITY (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock" xlink:label="avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock_638687833445045084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock_638687833445045084" order="1" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationTables" xlink:type="extended" xlink:title="130703 - Disclosure - SHARE-BASED COMPENSATION (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638687833445045084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638687833445045084" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_638687833445055072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_638687833445055072" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638687833445055072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638687833445055072" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638687833445055072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638687833445055072" order="4" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="130903 - Disclosure - INCOME TAXES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638687833445055072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638687833445055072" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638687833445055072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638687833445055072" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_638687833445055072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_638687833445055072" order="3" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="140101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638687833445065077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638687833445065077" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638687833445065077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638687833445065077" xlink:to="srt_CounterpartyNameAxis_638687833445065077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638687833445065077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638687833445065077" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638687833445065077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_BofaSecuritiesInc.Member" xlink:label="avte_BofaSecuritiesInc.Member_638687833445065077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638687833445065077" xlink:to="avte_BofaSecuritiesInc.Member_638687833445065077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638687833445065077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638687833445065077" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638687833445065077" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638687833445065077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638687833445065077" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638687833445065077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638687833445065077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638687833445065077" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638687833445065077" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638687833445065077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638687833445065077" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638687833445065077" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram" xlink:label="avte_ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram_638687833445065077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638687833445065077" xlink:to="avte_ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram_638687833445065077" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_638687833445075069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638687833445065077" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_638687833445075069" order="5" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="140201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638687833445075069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable_638687833445075069" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638687833445075069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638687833445075069" xlink:to="srt_RangeAxis_638687833445075069" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638687833445075069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638687833445075069" xlink:to="srt_RangeMember_638687833445075069" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638687833445075069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638687833445075069" xlink:to="srt_MinimumMember_638687833445075069" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638687833445075069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638687833445075069" xlink:to="srt_MaximumMember_638687833445075069" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638687833445075069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638687833445075069" xlink:to="us-gaap_StatementLineItems_638687833445075069" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638687833445085078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638687833445075069" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638687833445085078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_638687833445085078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638687833445075069" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_638687833445085078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638687833445085078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638687833445075069" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638687833445085078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638687833445085078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638687833445075069" xlink:to="us-gaap_NumberOfOperatingSegments_638687833445085078" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails" xlink:type="extended" xlink:title="140202 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF NET LOSS PER SHARE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638687833445085078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLoss_638687833445085078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638687833445095088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638687833445095088" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638687833445095088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638687833445095088" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638687833445095088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638687833445095088" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638687833445095088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerShareBasic_638687833445095088" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638687833445095088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_638687833445095088" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="140203 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638687833445095088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638687833445095088" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638687833445095088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638687833445095088" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638687833445095088" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638687833445095088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638687833445095088" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638687833445095088" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638687833445105073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638687833445095088" xlink:to="us-gaap_EmployeeStockOptionMember_638687833445105073" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638687833445105073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638687833445095088" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638687833445105073" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638687833445105073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638687833445095088" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638687833445105073" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638687833445105073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638687833445105073" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638687833445105073" order="1" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails" xlink:type="extended" xlink:title="140301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF FAIR VALUE INSTRUMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638687833445105073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638687833445105073" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638687833445105073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638687833445105073" xlink:to="us-gaap_FinancialInstrumentAxis_638687833445105073" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445105073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638687833445105073" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445105073" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_638687833445105073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445105073" xlink:to="us-gaap_CommercialPaperMember_638687833445105073" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember_638687833445115071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445105073" xlink:to="us-gaap_USTreasurySecuritiesMember_638687833445115071" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_638687833445115071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445105073" xlink:to="us-gaap_CorporateDebtSecuritiesMember_638687833445115071" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638687833445115071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445105073" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638687833445115071" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_638687833445115071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638687833445105073" xlink:to="us-gaap_CashAndCashEquivalentsAxis_638687833445115071" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638687833445115071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_638687833445115071" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638687833445115071" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_638687833445115071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638687833445115071" xlink:to="us-gaap_MoneyMarketFundsMember_638687833445115071" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_638687833445115071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638687833445115071" xlink:to="us-gaap_CommercialPaperMember_638687833445115071" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638687833445115071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638687833445105073" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638687833445115071" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638687833445115071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638687833445115071" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638687833445115071" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638687833445125070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638687833445115071" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638687833445125070" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638687833445125070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638687833445105073" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638687833445125070" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638687833445125070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638687833445125070" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638687833445125070" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638687833445125070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638687833445125070" xlink:to="us-gaap_FairValueInputsLevel1Member_638687833445125070" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_638687833445125070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638687833445125070" xlink:to="us-gaap_FairValueInputsLevel2Member_638687833445125070" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638687833445125070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638687833445105073" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638687833445125070" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_638687833445125070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638687833445125070" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_638687833445125070" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_638687833445135080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638687833445125070" xlink:to="us-gaap_ShortTermInvestments_638687833445135080" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_638687833445135080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638687833445125070" xlink:to="us-gaap_AssetsFairValueDisclosure_638687833445135080" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails" xlink:type="extended" xlink:title="140302 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT TERM INVESTMENT (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_638687833445135080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_638687833445135080" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638687833445135080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_638687833445135080" xlink:to="srt_RangeAxis_638687833445135080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638687833445135080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638687833445135080" xlink:to="srt_RangeMember_638687833445135080" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638687833445145089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638687833445135080" xlink:to="srt_MaximumMember_638687833445145089" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638687833445145089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_638687833445135080" xlink:to="us-gaap_FinancialInstrumentAxis_638687833445145089" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445145089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638687833445145089" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445145089" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_638687833445145089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445145089" xlink:to="us-gaap_CorporateDebtSecuritiesMember_638687833445145089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_638687833445145089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445145089" xlink:to="us-gaap_CommercialPaperMember_638687833445145089" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember_638687833445145089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445145089" xlink:to="us-gaap_USTreasurySecuritiesMember_638687833445145089" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638687833445145089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445145089" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638687833445145089" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638687833445145089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_638687833445135080" xlink:to="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638687833445145089" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_DebtSecuritiesAvailableForSaleMaturityTerm" xlink:label="avte_DebtSecuritiesAvailableForSaleMaturityTerm_638687833445145089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638687833445145089" xlink:to="avte_DebtSecuritiesAvailableForSaleMaturityTerm_638687833445145089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_638687833445155073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638687833445145089" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_638687833445155073" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_638687833445155073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638687833445145089" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_638687833445155073" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638687833445155073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638687833445145089" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638687833445155073" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638687833445155073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638687833445145089" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638687833445155073" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent_638687833445155073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638687833445145089" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent_638687833445155073" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList_638687833445155073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638687833445145089" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList_638687833445155073" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails" xlink:type="extended" xlink:title="140303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_638687833445165074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_638687833445165074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638687833445165074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_638687833445165074" xlink:to="us-gaap_FinancialInstrumentAxis_638687833445165074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445165074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638687833445165074" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445165074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_638687833445165074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445165074" xlink:to="us-gaap_CommercialPaperMember_638687833445165074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638687833445165074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445165074" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638687833445165074" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember_638687833445165074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445165074" xlink:to="us-gaap_USTreasurySecuritiesMember_638687833445165074" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_638687833445165074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445165074" xlink:to="us-gaap_CorporateDebtSecuritiesMember_638687833445165074" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_638687833445165074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_638687833445165074" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_638687833445165074" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_638687833445165074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_638687833445165074" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_638687833445165074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_638687833445175073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_638687833445165074" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_638687833445175073" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_638687833445175073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_638687833445165074" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_638687833445175073" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_638687833445175073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_638687833445165074" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_638687833445175073" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_638687833445175073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_638687833445165074" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_638687833445175073" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_638687833445175073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_638687833445165074" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_638687833445175073" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="140401 - Disclosure - BALANCE SHEET COMPONENTS - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638687833445185084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent_638687833445185084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_PrepaidResearchAndDevelopment" xlink:label="avte_PrepaidResearchAndDevelopment_638687833445185084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="avte_PrepaidResearchAndDevelopment_638687833445185084" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_638687833445185084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_638687833445185084" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638687833445185084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638687833445185084" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="140402 - Disclosure - BALANCE SHEET COMPONENTS - SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_AccruedResearchAndDevelopmentCurrent" xlink:label="avte_AccruedResearchAndDevelopmentCurrent_638687833445185084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="avte_AccruedResearchAndDevelopmentCurrent_638687833445185084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638687833445185084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638687833445185084" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638687833445185084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638687833445185084" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent_638687833445195078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent_638687833445195078" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="140501 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638687833445195078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638687833445195078" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_638687833445195078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638687833445195078" xlink:to="us-gaap_LeaseContractualTermAxis_638687833445195078" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_638687833445195078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis_638687833445195078" xlink:to="us-gaap_LeaseContractualTermDomain_638687833445195078" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_WalthamLeaseMember" xlink:label="avte_WalthamLeaseMember_638687833445195078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_638687833445195078" xlink:to="avte_WalthamLeaseMember_638687833445195078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_FosterCityLeaseMember" xlink:label="avte_FosterCityLeaseMember_638687833445195078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_638687833445195078" xlink:to="avte_FosterCityLeaseMember_638687833445195078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_638687833445195078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638687833445195078" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_638687833445195078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand_638687833445195078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638687833445195078" xlink:to="us-gaap_AreaOfLand_638687833445195078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_638687833445205079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638687833445195078" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_638687833445205079" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_IncreaseRentalAmount" xlink:label="avte_IncreaseRentalAmount_638687833445205079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638687833445195078" xlink:to="avte_IncreaseRentalAmount_638687833445205079" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638687833445205079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638687833445195078" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638687833445205079" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_638687833445205079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638687833445195078" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_638687833445205079" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent_638687833445205079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638687833445195078" xlink:to="us-gaap_PaymentsForRent_638687833445205079" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_LeaseIncreaseInRentPercentage" xlink:label="avte_LeaseIncreaseInRentPercentage_638687833445205079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638687833445195078" xlink:to="avte_LeaseIncreaseInRentPercentage_638687833445205079" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638687833445205079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638687833445195078" xlink:to="us-gaap_OperatingLeaseLiability_638687833445205079" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638687833445205079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638687833445195078" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638687833445205079" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_638687833445205079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638687833445195078" xlink:to="us-gaap_OperatingLeaseExpense_638687833445205079" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails" xlink:type="extended" xlink:title="140502 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638687833445215072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638687833445215072" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638687833445215072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638687833445215072" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638687833445215072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638687833445215072" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638687833445215072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638687833445215072" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638687833445215072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability_638687833445215072" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_638687833445225079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_638687833445225079" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638687833445225079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract_638687833445225079" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638687833445225079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638687833445225079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract_638687833445225079" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638687833445225079" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638687833445225079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638687833445225079" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638687833445225079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638687833445225079" order="8" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="140601 - Disclosure - STOCKHOLDERS' EQUITY (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638687833445225079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_638687833445225079" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638687833445225079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638687833445225079" xlink:to="us-gaap_StatementEquityComponentsAxis_638687833445225079" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638687833445225079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638687833445225079" xlink:to="us-gaap_EquityComponentDomain_638687833445225079" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_SeriesSeedRedeemableConvertiblePreferredStockMember" xlink:label="avte_SeriesSeedRedeemableConvertiblePreferredStockMember_638687833445235081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638687833445225079" xlink:to="avte_SeriesSeedRedeemableConvertiblePreferredStockMember_638687833445235081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="avte_SeriesARedeemableConvertiblePreferredStockMember_638687833445235081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638687833445225079" xlink:to="avte_SeriesARedeemableConvertiblePreferredStockMember_638687833445235081" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638687833445235081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638687833445225079" xlink:to="srt_CounterpartyNameAxis_638687833445235081" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638687833445235081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638687833445235081" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638687833445235081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_RaCapitalHealthcareFundL.pMember" xlink:label="avte_RaCapitalHealthcareFundL.pMember_638687833445235081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638687833445235081" xlink:to="avte_RaCapitalHealthcareFundL.pMember_638687833445235081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638687833445235081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638687833445225079" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638687833445235081" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638687833445235081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638687833445235081" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638687833445235081" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_638687833445235081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638687833445235081" xlink:to="us-gaap_IPOMember_638687833445235081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638687833445245090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638687833445225079" xlink:to="us-gaap_ClassOfStockLineItems_638687833445245090" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_CapitalStockSharesAuthorized" xlink:label="avte_CapitalStockSharesAuthorized_638687833445245090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638687833445245090" xlink:to="avte_CapitalStockSharesAuthorized_638687833445245090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638687833445245090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638687833445245090" xlink:to="us-gaap_CommonStockSharesAuthorized_638687833445245090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638687833445245090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638687833445245090" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638687833445245090" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638687833445245090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638687833445245090" xlink:to="us-gaap_PreferredStockSharesAuthorized_638687833445245090" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638687833445245090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638687833445245090" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638687833445245090" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_638687833445245090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638687833445245090" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_638687833445245090" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_638687833445245090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638687833445245090" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_638687833445245090" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1_638687833445255076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638687833445245090" xlink:to="us-gaap_ConversionOfStockSharesIssued1_638687833445255076" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638687833445255076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638687833445245090" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638687833445255076" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638687833445255076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638687833445245090" xlink:to="us-gaap_SharePrice_638687833445255076" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_NumberOfVotesForEachShareOfCommonStock" xlink:label="avte_NumberOfVotesForEachShareOfCommonStock_638687833445255076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638687833445245090" xlink:to="avte_NumberOfVotesForEachShareOfCommonStock_638687833445255076" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails" xlink:type="extended" xlink:title="140602 - Disclosure - STOCKHOLDERS' EQUITY - SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638687833445255076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638687833445255076" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638687833445255076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638687833445255076" xlink:to="us-gaap_AwardTypeAxis_638687833445255076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833445265078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638687833445255076" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833445265078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638687833445265078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833445265078" xlink:to="us-gaap_CommonStockMember_638687833445265078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638687833445265078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833445265078" xlink:to="us-gaap_EmployeeStockOptionMember_638687833445265078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638687833445265078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833445265078" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638687833445265078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember_638687833445265078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833445265078" xlink:to="us-gaap_StockCompensationPlanMember_638687833445265078" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638687833445265078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638687833445255076" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638687833445265078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638687833445265078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638687833445265078" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638687833445265078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails" xlink:type="extended" xlink:title="140701 - Disclosure - SHARE-BASED COMPENSATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833445275092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833445275092" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638687833445275092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833445275092" xlink:to="us-gaap_AwardTypeAxis_638687833445275092" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833445275092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638687833445275092" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833445275092" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638687833445275092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833445275092" xlink:to="us-gaap_EmployeeStockOptionMember_638687833445275092" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638687833445275092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833445275092" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638687833445275092" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember_638687833445275092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833445275092" xlink:to="us-gaap_StockCompensationPlanMember_638687833445275092" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638687833445275092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833445275092" xlink:to="srt_RangeAxis_638687833445275092" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638687833445275092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638687833445275092" xlink:to="srt_RangeMember_638687833445275092" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638687833445275092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638687833445275092" xlink:to="srt_MinimumMember_638687833445275092" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638687833445285081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638687833445275092" xlink:to="srt_MaximumMember_638687833445285081" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638687833445285081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833445275092" xlink:to="us-gaap_PlanNameAxis_638687833445285081" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638687833445285081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638687833445285081" xlink:to="us-gaap_PlanNameDomain_638687833445285081" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_TwentyTwentyOneStockOptionAndIncentivePlanMember" xlink:label="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_638687833445285081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638687833445285081" xlink:to="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_638687833445285081" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_TwentyEighteenStockOptionAndIncentivePlanMember" xlink:label="avte_TwentyEighteenStockOptionAndIncentivePlanMember_638687833445285081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638687833445285081" xlink:to="avte_TwentyEighteenStockOptionAndIncentivePlanMember_638687833445285081" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember" xlink:label="avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_638687833445285081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638687833445285081" xlink:to="avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_638687833445285081" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445285081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833445275092" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445285081" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_638687833445285081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445285081" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_638687833445285081" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638687833445295091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445285081" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638687833445295091" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638687833445295091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445285081" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638687833445295091" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638687833445295091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445285081" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638687833445295091" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638687833445295091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445285081" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638687833445295091" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638687833445295091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445285081" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638687833445295091" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638687833445295091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445285081" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638687833445295091" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638687833445305093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445285081" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638687833445305093" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_638687833445305093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445285081" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_638687833445305093" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_638687833445305093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445285081" xlink:to="avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_638687833445305093" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_638687833445305093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445285081" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_638687833445305093" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638687833445305093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445285081" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638687833445305093" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638687833445305093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445285081" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638687833445305093" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638687833445315077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445285081" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638687833445315077" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638687833445315077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445285081" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638687833445315077" order="15" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails" xlink:type="extended" xlink:title="140702 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF OPTION ACTIVITY UNDER 2021 PLAN AND 2018 PLAN (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638687833445315077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638687833445315077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638687833445325089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638687833445325089" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638687833445325089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638687833445325089" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638687833445325089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638687833445325089" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638687833445325089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638687833445325089" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638687833445325089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638687833445325089" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638687833445325089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638687833445325089" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638687833445325089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638687833445325089" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_638687833445325089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_638687833445325089" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_638687833445325089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_638687833445325089" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638687833445325089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638687833445325089" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638687833445335078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638687833445335078" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638687833445335078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638687833445335078" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_638687833445335078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_638687833445335078" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_638687833445335078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_638687833445335078" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_638687833445335078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_638687833445335078" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_638687833445335078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_638687833445335078" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638687833445335078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638687833445335078" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638687833445335078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638687833445335078" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638687833445345078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638687833445345078" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_638687833445345078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_638687833445345078" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails" xlink:type="extended" xlink:title="140703 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF UNVESTED RESTRICTED STOCK UNIT ACTIVITY (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833445345078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833445345078" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638687833445345078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833445345078" xlink:to="us-gaap_AwardTypeAxis_638687833445345078" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833445345078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638687833445345078" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833445345078" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638687833445355084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833445345078" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638687833445355084" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445355084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833445345078" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445355084" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638687833445355084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445355084" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638687833445355084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638687833445355084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445355084" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638687833445355084" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638687833445355084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445355084" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638687833445355084" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638687833445355084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445355084" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638687833445355084" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638687833445355084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445355084" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638687833445355084" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638687833445355084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445355084" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638687833445355084" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6386878334453550841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445355084" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6386878334453550841" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6386878334453550841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445355084" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6386878334453550841" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails" xlink:type="extended" xlink:title="140704 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF FAIR VALUE OF STOCK OPTIONS ASSUMPTIONS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833445365082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833445365082" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638687833445365082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833445365082" xlink:to="srt_RangeAxis_638687833445365082" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638687833445365082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638687833445365082" xlink:to="srt_RangeMember_638687833445365082" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638687833445365082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638687833445365082" xlink:to="srt_MinimumMember_638687833445365082" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638687833445365082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638687833445365082" xlink:to="srt_MaximumMember_638687833445365082" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445365082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833445365082" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445365082" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638687833445365082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445365082" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638687833445365082" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638687833445375086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445365082" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638687833445375086" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638687833445375086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445365082" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638687833445375086" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638687833445375086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445365082" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638687833445375086" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638687833445375086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445365082" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638687833445375086" order="5" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails" xlink:type="extended" xlink:title="140705 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION GRANTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638687833445375086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638687833445375086" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638687833445375086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638687833445375086" xlink:to="us-gaap_IncomeStatementLocationAxis_638687833445375086" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638687833445375086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638687833445375086" xlink:to="us-gaap_IncomeStatementLocationDomain_638687833445375086" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638687833445385084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638687833445375086" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638687833445385084" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638687833445385084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638687833445375086" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638687833445385084" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638687833445385084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638687833445375086" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638687833445385084" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638687833445385084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638687833445385084" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638687833445385084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails" xlink:type="extended" xlink:title="140706 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY TYPE OF AWARDS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833445385084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833445385084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638687833445385084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833445385084" xlink:to="us-gaap_AwardTypeAxis_638687833445385084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833445385084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638687833445385084" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833445385084" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638687833445395094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833445385084" xlink:to="us-gaap_EmployeeStockOptionMember_638687833445395094" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember_638687833445395094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833445385084" xlink:to="us-gaap_StockCompensationPlanMember_638687833445395094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638687833445395094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833445385084" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638687833445395094" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445395094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833445385084" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445395094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638687833445395094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833445395094" xlink:to="us-gaap_ShareBasedCompensation_638687833445395094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="140801 - Disclosure - RELATED PARTY TRANSACTIONS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638687833445405103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638687833445405103" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_638687833445405103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638687833445405103" xlink:to="us-gaap_RelatedPartyTransactionAxis_638687833445405103" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_638687833445405103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_638687833445405103" xlink:to="us-gaap_RelatedPartyTransactionDomain_638687833445405103" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_ServicesAgreementWithCarnotLlcMember" xlink:label="avte_ServicesAgreementWithCarnotLlcMember_638687833445405103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_638687833445405103" xlink:to="avte_ServicesAgreementWithCarnotLlcMember_638687833445405103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638687833445405103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638687833445405103" xlink:to="srt_RangeAxis_638687833445405103" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638687833445405103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638687833445405103" xlink:to="srt_RangeMember_638687833445405103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638687833445405103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638687833445405103" xlink:to="srt_MaximumMember_638687833445405103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638687833445405103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638687833445405103" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638687833445405103" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_RelatedPartyTransactionTerm" xlink:label="avte_RelatedPartyTransactionTerm_638687833445405103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638687833445405103" xlink:to="avte_RelatedPartyTransactionTerm_638687833445405103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_NoticeToTerminateAgreementPeriod" xlink:label="avte_NoticeToTerminateAgreementPeriod_638687833445405103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638687833445405103" xlink:to="avte_NoticeToTerminateAgreementPeriod_638687833445405103" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_MaterialBreachCorrectionPeriod" xlink:label="avte_MaterialBreachCorrectionPeriod_638687833445415090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638687833445405103" xlink:to="avte_MaterialBreachCorrectionPeriod_638687833445415090" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses_638687833445415090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638687833445405103" xlink:to="us-gaap_OperatingCostsAndExpenses_638687833445415090" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_638687833445415090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638687833445405103" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_638687833445415090" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="140901 - Disclosure - INCOME TAXES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638687833445415090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638687833445415090" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638687833445415090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638687833445415090" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638687833445415090" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638687833445415090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638687833445415090" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638687833445415090" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638687833445415090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638687833445415090" xlink:to="us-gaap_DomesticCountryMember_638687833445415090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_638687833445425096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638687833445415090" xlink:to="us-gaap_StateAndLocalJurisdictionMember_638687833445425096" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_638687833445425096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638687833445415090" xlink:to="us-gaap_TaxCreditCarryforwardAxis_638687833445425096" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_638687833445425096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_638687833445425096" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_638687833445425096" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember_638687833445425096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_638687833445425096" xlink:to="us-gaap_ResearchMember_638687833445425096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638687833445425096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638687833445415090" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638687833445425096" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638687833445425096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638687833445425096" xlink:to="us-gaap_OperatingLossCarryforwards_638687833445425096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638687833445425096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638687833445425096" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638687833445425096" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="140902 - Disclosure - INCOME TAXES - SUMMARY OF COMPONENTS OF NET DEFERRED TAX ASSETS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638687833445435092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638687833445435092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638687833445435092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638687833445435092" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_638687833445435092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_638687833445435092" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638687833445435092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638687833445435092" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638687833445435092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther_638687833445435092" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638687833445435092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross_638687833445435092" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638687833445435092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638687833445435092" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638687833445435092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet_638687833445435092" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_638687833445435092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_638687833445435092" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities_638687833445435092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilities_638687833445435092" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_638687833445445085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_638687833445445085" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails" xlink:type="extended" xlink:title="140903 - Disclosure - INCOME TAXES - SUMMARY OF RECONCILIATION OF FEDERAL INCOME TAX RATE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638687833445445085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638687833445445085" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638687833445445085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638687833445445085" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_638687833445445085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_638687833445445085" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_638687833445445085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_638687833445445085" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits" xlink:label="avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits_638687833445445085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits_638687833445445085" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638687833445455109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638687833445455109" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638687833445455109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638687833445455109" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended" xlink:title="140904 - Disclosure - INCOME TAXES - SUMMARY OF GROSS UNRECOGNIZED TAX BENEFITS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638687833445455109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_638687833445455109" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_638687833445465102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_638687833445465102" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_638687833445465102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_638687833445465102" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638687833445465102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_638687833445465102" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" xlink:title="200100 - Statement - Condensed Consolidated Balance Sheets (Unaudited)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638687833445465102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638687833445465102" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638687833445465102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638687833445465102" xlink:to="us-gaap_AssetsCurrentAbstract_638687833445465102" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638687833445465102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638687833445465102" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638687833445465102" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_638687833445465102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638687833445465102" xlink:to="us-gaap_ShortTermInvestments_638687833445465102" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638687833445465102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638687833445465102" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638687833445465102" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638687833445475095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638687833445465102" xlink:to="us-gaap_AssetsCurrent_638687833445475095" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638687833445475095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638687833445465102" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638687833445475095" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638687833445475095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638687833445465102" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638687833445475095" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638687833445475095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638687833445465102" xlink:to="us-gaap_OtherAssetsNoncurrent_638687833445475095" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638687833445475095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638687833445465102" xlink:to="us-gaap_Assets_638687833445475095" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638687833445475095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638687833445475095" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638687833445475095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638687833445475095" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638687833445475095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638687833445475095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638687833445475095" xlink:to="us-gaap_AccountsPayableCurrent_638687833445475095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent_638687833445475095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638687833445475095" xlink:to="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent_638687833445475095" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638687833445485089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638687833445475095" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638687833445485089" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638687833445485089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638687833445475095" xlink:to="us-gaap_LiabilitiesCurrent_638687833445485089" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638687833445485089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638687833445475095" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638687833445485089" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities_638687833445485089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638687833445475095" xlink:to="us-gaap_OtherLiabilities_638687833445485089" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638687833445485089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638687833445475095" xlink:to="us-gaap_Liabilities_638687833445485089" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638687833445495152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638687833445475095" xlink:to="us-gaap_CommitmentsAndContingencies_638687833445495152" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638687833445495152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638687833445475095" xlink:to="us-gaap_StockholdersEquityAbstract_638687833445495152" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638687833445495152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638687833445495152" xlink:to="us-gaap_PreferredStockValue_638687833445495152" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638687833445495152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638687833445495152" xlink:to="us-gaap_CommonStockValue_638687833445495152" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638687833445495152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638687833445495152" xlink:to="us-gaap_AdditionalPaidInCapital_638687833445495152" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638687833445505110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638687833445495152" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638687833445505110" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638687833445505110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638687833445495152" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638687833445505110" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638687833445505110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638687833445495152" xlink:to="us-gaap_StockholdersEquity_638687833445505110" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638687833445505110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638687833445475095" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638687833445505110" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" xlink:title="200105 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638687833445515104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638687833445515104" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638687833445515104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638687833445515104" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638687833445515104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_638687833445515104" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638687833445525112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_638687833445525112" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638687833445525112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638687833445525112" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638687833445525112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638687833445525112" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638687833445525112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638687833445525112" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638687833445525112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638687833445525112" order="8" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="extended" xlink:title="200200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638687833445535108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638687833445535108" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638687833445535108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638687833445535108" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638687833445535108" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638687833445605110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638687833445535108" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638687833445605110" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638687833445605110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638687833445535108" xlink:to="us-gaap_OperatingExpenses_638687833445605110" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638687833445605110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638687833445605110" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638687833445605110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638687833445605110" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_638687833445615139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638687833445605110" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_638687833445615139" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638687833445615139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638687833445605110" xlink:to="us-gaap_OtherNonoperatingExpense_638687833445615139" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638687833445615139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638687833445605110" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638687833445615139" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638687833445615139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638687833445605110" xlink:to="us-gaap_NonoperatingIncomeExpense_638687833445615139" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638687833445615139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638687833445615139" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638687833445615139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638687833445615139" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638687833445615139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss_638687833445615139" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_638687833445625113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_638687833445625113" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638687833445625113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_638687833445625113" xlink:to="us-gaap_ProfitLoss_638687833445625113" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_638687833445625113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_638687833445625113" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_638687833445625113" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesTradingUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss_638687833445625113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_638687833445625113" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss_638687833445625113" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638687833445625113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_638687833445625113" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638687833445625113" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638687833445625113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic_638687833445625113" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638687833445625113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_638687833445625113" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638687833445625113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638687833445625113" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638687833445635097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638687833445635097" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:type="extended" xlink:title="200300 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638687833445635097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638687833445635097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638687833445635097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638687833445635097" xlink:to="us-gaap_StatementEquityComponentsAxis_638687833445635097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638687833445635097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638687833445635097" xlink:to="us-gaap_CommonStockMember_638687833445635097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638687833445635097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638687833445635097" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638687833445635097" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638687833445635097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638687833445635097" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638687833445635097" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638687833445645106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638687833445635097" xlink:to="us-gaap_RetainedEarningsMember_638687833445645106" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638687833445645106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638687833445635097" xlink:to="us-gaap_EquityComponentDomain_638687833445645106" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638687833445645106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638687833445635097" xlink:to="us-gaap_StatementLineItems_638687833445645106" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638687833445645106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638687833445645106" xlink:to="us-gaap_SharesOutstanding_638687833445645106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638687833445645106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638687833445645106" xlink:to="us-gaap_StockholdersEquity_638687833445645106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesTradingUnrealizedLoss" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedLoss_638687833445645106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638687833445645106" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedLoss_638687833445645106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesTradingUnrealizedGain" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGain_638687833445645106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638687833445645106" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedGain_638687833445645106" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638687833445645106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638687833445645106" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638687833445645106" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638687833445645106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_638687833445645106" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638687833445645106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638687833445655098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638687833445645106" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638687833445655098" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638687833445655098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638687833445655098" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638687833445655098" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638687833445655098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638687833445645106" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638687833445655098" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638687833445655098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638687833445655098" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638687833445655098" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_638687833445655098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638687833445645106" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_638687833445655098" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_638687833445655098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_638687833445655098" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_638687833445655098" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638687833445655098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638687833445645106" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638687833445655098" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638687833445665096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638687833445645106" xlink:to="us-gaap_NetIncomeLoss_638687833445665096" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638687833445665096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638687833445645106" xlink:to="us-gaap_SharesOutstanding_638687833445665096" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638687833445665096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638687833445645106" xlink:to="us-gaap_StockholdersEquity_638687833445665096" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" xlink:title="200400 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638687833445665096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638687833445665096" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638687833445665096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638687833445665096" xlink:to="us-gaap_NetIncomeLoss_638687833445665096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638687833445665096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638687833445665096" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638687833445665096" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638687833445675105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638687833445665096" xlink:to="us-gaap_ShareBasedCompensation_638687833445675105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638687833445675105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638687833445665096" xlink:to="us-gaap_Depreciation_638687833445675105" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet" xlink:label="avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet_638687833445675105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638687833445665096" xlink:to="avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet_638687833445675105" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638687833445675105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638687833445665096" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638687833445675105" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638687833445675105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638687833445675105" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638687833445675105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638687833445675105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638687833445675105" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638687833445675105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638687833445675105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638687833445675105" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638687833445675105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638687833445675105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638687833445675105" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638687833445675105" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability" xlink:label="avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability_638687833445675105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638687833445675105" xlink:to="avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability_638687833445675105" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_638687833445685097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638687833445675105" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_638687833445685097" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638687833445685097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638687833445675105" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638687833445685097" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638687833445685097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638687833445685097" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_638687833445685097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638687833445685097" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_638687833445685097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_638687833445685097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638687833445685097" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_638687833445685097" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638687833445685097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638687833445685097" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638687833445685097" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638687833445685097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638687833445685097" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638687833445685097" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638687833445685097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638687833445685097" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638687833445695096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638687833445685097" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638687833445695096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638687833445695096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638687833445685097" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638687833445695096" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_638687833445695096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638687833445685097" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_638687833445695096" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638687833445695096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638687833445685097" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638687833445695096" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638687833445695096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638687833445685097" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638687833445695096" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638687833445695096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638687833445695096" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638687833445705112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638687833445705112" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6386878334457051121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6386878334457051121" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638687833445705112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638687833445705112" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638687833445705112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638687833445705112" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638687833445705112" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_DeferredOfferingCostsIncludedInAccountsPayable" xlink:label="avte_DeferredOfferingCostsIncludedInAccountsPayable_638687833445705112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638687833445705112" xlink:to="avte_DeferredOfferingCostsIncludedInAccountsPayable_638687833445705112" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638687833445705112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638687833445705112" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638687833445705112" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureOrganizationAndNatureOfOperations" xlink:type="extended" xlink:title="210101 - Disclosure - ORGANIZATION AND NATURE OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638687833445715101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638687833445715101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciess" xlink:type="extended" xlink:title="210201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638687833445715101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638687833445715101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentss" xlink:type="extended" xlink:title="210301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638687833445725111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638687833445725111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentss" xlink:type="extended" xlink:title="210401 - Disclosure - BALANCE SHEET COMPONENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_638687833445725111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_638687833445725111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciess" xlink:type="extended" xlink:title="210501 - Disclosure - COMMITMENTS AND CONTINGENCIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638687833445735105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638687833445735105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquitys" xlink:type="extended" xlink:title="210601 - Disclosure - STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638687833445735105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638687833445735105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="210701 - Disclosure - STOCK-BASED COMPENSATION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638687833445745103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638687833445745103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureSubsequentEvent" xlink:type="extended" xlink:title="210801 - Disclosure - SUBSEQUENT EVENT" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638687833445745103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638687833445745103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPoliciess" xlink:type="extended" xlink:title="220202 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638687833445755106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638687833445755106" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638687833445755106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638687833445755106" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638687833445755106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638687833445755106" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638687833445755106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638687833445755106" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTabless" xlink:type="extended" xlink:title="230203 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638687833445755106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638687833445755106" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638687833445755106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638687833445755106" order="2" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsTabless" xlink:type="extended" xlink:title="230303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638687833445765109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638687833445765109" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_638687833445765109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_638687833445765109" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_638687833445765109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_638687833445765109" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsTabless" xlink:type="extended" xlink:title="230403 - Disclosure - BALANCE SHEET COMPONENTS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock" xlink:label="avte_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock_638687833445775109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="avte_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock_638687833445775109" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638687833445775109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638687833445775109" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesTabless" xlink:type="extended" xlink:title="230503 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638687833445775109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638687833445775109" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_ScheduleOfComponentsOfOperatingLeasesTableTextBlock" xlink:label="avte_ScheduleOfComponentsOfOperatingLeasesTableTextBlock_638687833445785129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="avte_ScheduleOfComponentsOfOperatingLeasesTableTextBlock_638687833445785129" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_638687833445785129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_638687833445785129" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638687833445785129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_638687833445785129" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityTabless" xlink:type="extended" xlink:title="230603 - Disclosure - STOCKHOLDERS' EQUITY (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock" xlink:label="avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock_638687833445785129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock_638687833445785129" order="1" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="230703 - Disclosure - STOCK-BASED COMPENSATION (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638687833445795112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638687833445795112" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_638687833445795112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_638687833445795112" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638687833445795112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638687833445795112" order="3" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureOrganizationAndNatureOfOperationsDetails" xlink:type="extended" xlink:title="240101 - Disclosure - ORGANIZATION AND NATURE OF OPERATIONS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638687833445795112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638687833445795112" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638687833445795112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638687833445795112" xlink:to="srt_CounterpartyNameAxis_638687833445795112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638687833445805120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638687833445795112" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638687833445805120" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_BofaSecuritiesInc.Member" xlink:label="avte_BofaSecuritiesInc.Member_638687833445805120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638687833445805120" xlink:to="avte_BofaSecuritiesInc.Member_638687833445805120" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638687833445805120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638687833445795112" xlink:to="us-gaap_SubsequentEventTypeAxis_638687833445805120" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638687833445805120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638687833445805120" xlink:to="us-gaap_SubsequentEventTypeDomain_638687833445805120" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638687833445805120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638687833445805120" xlink:to="us-gaap_SubsequentEventMember_638687833445805120" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638687833445805120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638687833445795112" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638687833445805120" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash" xlink:label="us-gaap_DividendsCommonStockCash_638687833445805120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638687833445805120" xlink:to="us-gaap_DividendsCommonStockCash_638687833445805120" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638687833445805120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638687833445805120" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638687833445805120" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638687833445805120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638687833445805120" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638687833445805120" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638687833445805120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638687833445805120" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638687833445805120" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram" xlink:label="avte_ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram_638687833445815106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638687833445805120" xlink:to="avte_ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram_638687833445815106" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_638687833445815106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638687833445805120" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_638687833445815106" order="6" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetailss" xlink:type="extended" xlink:title="240201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF NET LOSS PER SHARE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638687833445815106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLoss_638687833445815106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638687833445815106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638687833445815106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638687833445815106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638687833445815106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638687833445815106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638687833445815106" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638687833445825111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerShareBasic_638687833445825111" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638687833445825111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_638687833445825111" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetailss" xlink:type="extended" xlink:title="240202 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638687833445825111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638687833445825111" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638687833445825111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638687833445825111" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638687833445825111" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638687833445825111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638687833445825111" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638687833445825111" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638687833445825111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638687833445825111" xlink:to="us-gaap_EmployeeStockOptionMember_638687833445825111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638687833445825111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638687833445825111" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638687833445825111" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638687833445825111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638687833445825111" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638687833445825111" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638687833445835109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638687833445825111" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638687833445835109" order="1" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss" xlink:type="extended" xlink:title="240301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF FAIR VALUE INSTRUMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638687833445835109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638687833445835109" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638687833445835109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638687833445835109" xlink:to="us-gaap_FinancialInstrumentAxis_638687833445835109" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445835109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638687833445835109" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445835109" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638687833445835109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445835109" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638687833445835109" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_638687833445835109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445835109" xlink:to="us-gaap_CorporateDebtSecuritiesMember_638687833445835109" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_638687833445835109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445835109" xlink:to="us-gaap_CommercialPaperMember_638687833445835109" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember_638687833445845111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445835109" xlink:to="us-gaap_USTreasurySecuritiesMember_638687833445845111" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_638687833445845111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638687833445835109" xlink:to="us-gaap_CashAndCashEquivalentsAxis_638687833445845111" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638687833445845111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_638687833445845111" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638687833445845111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_638687833445845111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638687833445845111" xlink:to="us-gaap_MoneyMarketFundsMember_638687833445845111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_638687833445845111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638687833445845111" xlink:to="us-gaap_CommercialPaperMember_638687833445845111" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638687833445845111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638687833445835109" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638687833445845111" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638687833445845111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638687833445845111" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638687833445845111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638687833445845111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638687833445845111" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638687833445845111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638687833445845111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638687833445835109" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638687833445845111" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638687833445855106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638687833445845111" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638687833445855106" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638687833445855106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638687833445855106" xlink:to="us-gaap_FairValueInputsLevel1Member_638687833445855106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_638687833445855106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638687833445855106" xlink:to="us-gaap_FairValueInputsLevel2Member_638687833445855106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638687833445855106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638687833445855106" xlink:to="us-gaap_FairValueInputsLevel3Member_638687833445855106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638687833445855106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638687833445835109" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638687833445855106" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_638687833445855106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638687833445855106" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_638687833445855106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_638687833445855106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638687833445855106" xlink:to="us-gaap_ShortTermInvestments_638687833445855106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_638687833445865108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638687833445855106" xlink:to="us-gaap_AssetsFairValueDisclosure_638687833445865108" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss" xlink:type="extended" xlink:title="240302 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT TERM INVESTMENT (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_638687833445865108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_638687833445865108" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638687833445865108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_638687833445865108" xlink:to="srt_RangeAxis_638687833445865108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638687833445865108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638687833445865108" xlink:to="srt_RangeMember_638687833445865108" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638687833445865108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638687833445865108" xlink:to="srt_MaximumMember_638687833445865108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638687833445865108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_638687833445865108" xlink:to="us-gaap_FinancialInstrumentAxis_638687833445865108" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445865108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638687833445865108" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445865108" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638687833445875177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445865108" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638687833445875177" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_638687833445875177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445865108" xlink:to="us-gaap_CommercialPaperMember_638687833445875177" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember_638687833445875177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445865108" xlink:to="us-gaap_USTreasurySecuritiesMember_638687833445875177" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_638687833445875177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445865108" xlink:to="us-gaap_CorporateDebtSecuritiesMember_638687833445875177" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638687833445875177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_638687833445865108" xlink:to="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638687833445875177" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_DebtSecuritiesAvailableForSaleMaturityTerm" xlink:label="avte_DebtSecuritiesAvailableForSaleMaturityTerm_638687833445875177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638687833445875177" xlink:to="avte_DebtSecuritiesAvailableForSaleMaturityTerm_638687833445875177" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_638687833445875177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638687833445875177" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_638687833445875177" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_638687833445875177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638687833445875177" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_638687833445875177" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638687833445885108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638687833445875177" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638687833445885108" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638687833445885108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638687833445875177" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638687833445885108" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_638687833445885108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638687833445875177" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_638687833445885108" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent_638687833445885108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638687833445875177" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent_638687833445885108" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent_638687833445885108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638687833445875177" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent_638687833445885108" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList_638687833445885108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638687833445875177" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList_638687833445885108" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList_638687833445885108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_638687833445875177" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList_638687833445885108" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss" xlink:type="extended" xlink:title="240303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_638687833445895109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_638687833445895109" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638687833445895109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_638687833445895109" xlink:to="us-gaap_FinancialInstrumentAxis_638687833445895109" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445895109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638687833445895109" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445895109" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_638687833445895109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445895109" xlink:to="us-gaap_CommercialPaperMember_638687833445895109" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638687833445895109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445895109" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638687833445895109" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember_638687833445895109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445895109" xlink:to="us-gaap_USTreasurySecuritiesMember_638687833445895109" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_638687833445895109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638687833445895109" xlink:to="us-gaap_CorporateDebtSecuritiesMember_638687833445895109" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_638687833445905123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_638687833445895109" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_638687833445905123" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_638687833445905123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_638687833445905123" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_638687833445905123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_638687833445905123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_638687833445905123" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_638687833445905123" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_638687833445905123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_638687833445905123" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_638687833445905123" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_638687833445905123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_638687833445905123" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_638687833445905123" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_638687833445905123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_638687833445905123" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_638687833445905123" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_638687833445905123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_638687833445905123" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_638687833445905123" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailss" xlink:type="extended" xlink:title="240401 - Disclosure - BALANCE SHEET COMPONENTS - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638687833445915115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent_638687833445915115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_638687833445915115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_638687833445915115" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_PrepaidResearchAndDevelopment" xlink:label="avte_PrepaidResearchAndDevelopment_638687833445915115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="avte_PrepaidResearchAndDevelopment_638687833445915115" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638687833445915115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638687833445915115" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetailss" xlink:type="extended" xlink:title="240402 - Disclosure - BALANCE SHEET COMPONENTS - SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_AccruedResearchAndDevelopmentCurrent" xlink:label="avte_AccruedResearchAndDevelopmentCurrent_638687833445915115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="avte_AccruedResearchAndDevelopmentCurrent_638687833445915115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638687833445915115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638687833445915115" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638687833445915115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638687833445915115" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent_638687833445925117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent_638687833445925117" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsWorkforceReductionPlanDetails" xlink:type="extended" xlink:title="240403 - Disclosure - BALANCE SHEET COMPONENTS - WORKFORCE REDUCTION PLAN (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_638687833445925117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_638687833445925117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_638687833445925117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_638687833445925117" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:label="us-gaap_RestructuringAndRelatedCostIncurredCost_638687833445925117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_RestructuringAndRelatedCostIncurredCost_638687833445925117" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring_638687833445925117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PaymentsForRestructuring_638687833445925117" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_638687833445925117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_638687833445925117" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetailss" xlink:type="extended" xlink:title="240501 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638687833445935124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638687833445935124" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_638687833445935124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638687833445935124" xlink:to="us-gaap_LeaseContractualTermAxis_638687833445935124" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_638687833445935124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis_638687833445935124" xlink:to="us-gaap_LeaseContractualTermDomain_638687833445935124" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_WalthamLeaseMember" xlink:label="avte_WalthamLeaseMember_638687833445935124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_638687833445935124" xlink:to="avte_WalthamLeaseMember_638687833445935124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_FosterCityLeaseMember" xlink:label="avte_FosterCityLeaseMember_638687833445935124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_638687833445935124" xlink:to="avte_FosterCityLeaseMember_638687833445935124" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_638687833445935124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638687833445935124" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_638687833445935124" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand_638687833445935124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638687833445935124" xlink:to="us-gaap_AreaOfLand_638687833445935124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_638687833445945128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638687833445935124" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_638687833445945128" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638687833445945128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638687833445935124" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638687833445945128" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_638687833445945128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638687833445935124" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_638687833445945128" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_IncreaseRentalAmount" xlink:label="avte_IncreaseRentalAmount_638687833445945128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638687833445935124" xlink:to="avte_IncreaseRentalAmount_638687833445945128" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent_638687833445945128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638687833445935124" xlink:to="us-gaap_PaymentsForRent_638687833445945128" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_LeaseIncreaseInRentPercentage" xlink:label="avte_LeaseIncreaseInRentPercentage_638687833445945128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638687833445935124" xlink:to="avte_LeaseIncreaseInRentPercentage_638687833445945128" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_638687833445945128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638687833445935124" xlink:to="us-gaap_OperatingLeaseImpairmentLoss_638687833445945128" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_638687833445945128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638687833445935124" xlink:to="us-gaap_OperatingLeaseExpense_638687833445945128" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailss" xlink:type="extended" xlink:title="240502 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_638687833445955114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_638687833445955114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638687833445955114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638687833445955114" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638687833445955114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638687833445955114" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638687833445955114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638687833445955114" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638687833445955114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638687833445955114" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638687833445955114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability_638687833445955114" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_638687833445955114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_638687833445955114" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638687833445965120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract_638687833445955114" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638687833445965120" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638687833445965120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract_638687833445955114" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638687833445965120" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638687833445965120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract_638687833445955114" xlink:to="us-gaap_OperatingLeaseLiability_638687833445965120" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638687833445965120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638687833445965120" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638687833445965120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638687833445965120" order="9" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowDetails" xlink:type="extended" xlink:title="240503 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF SUPPLEMENTAL CASH FLOW (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638687833445975118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasePayments_638687833445975118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfRentExpensesDetails" xlink:type="extended" xlink:title="240504 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF RENT EXPENSES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638687833445975118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseCost_638687833445975118" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost_638687833445975118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ShortTermLeaseCost_638687833445975118" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_638687833445975118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCost_638687833445975118" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss" xlink:type="extended" xlink:title="240601 - Disclosure - STOCKHOLDERS' EQUITY (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638687833445975118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_638687833445975118" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638687833445985119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638687833445975118" xlink:to="us-gaap_StatementEquityComponentsAxis_638687833445985119" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638687833445985119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638687833445985119" xlink:to="us-gaap_EquityComponentDomain_638687833445985119" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_SeriesSeedRedeemableConvertiblePreferredStockMember" xlink:label="avte_SeriesSeedRedeemableConvertiblePreferredStockMember_638687833445985119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638687833445985119" xlink:to="avte_SeriesSeedRedeemableConvertiblePreferredStockMember_638687833445985119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="avte_SeriesARedeemableConvertiblePreferredStockMember_638687833445985119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638687833445985119" xlink:to="avte_SeriesARedeemableConvertiblePreferredStockMember_638687833445985119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638687833445985119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638687833445975118" xlink:to="srt_CounterpartyNameAxis_638687833445985119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638687833445985119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638687833445985119" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638687833445985119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_RaCapitalHealthcareFundL.pMember" xlink:label="avte_RaCapitalHealthcareFundL.pMember_638687833445985119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638687833445985119" xlink:to="avte_RaCapitalHealthcareFundL.pMember_638687833445985119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638687833445985119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638687833445975118" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638687833445985119" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638687833445985119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638687833445985119" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638687833445985119" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_638687833445985119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638687833445985119" xlink:to="us-gaap_IPOMember_638687833445985119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638687833445995114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638687833445975118" xlink:to="us-gaap_ClassOfStockLineItems_638687833445995114" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_CapitalStockSharesAuthorized" xlink:label="avte_CapitalStockSharesAuthorized_638687833445995114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638687833445995114" xlink:to="avte_CapitalStockSharesAuthorized_638687833445995114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638687833445995114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638687833445995114" xlink:to="us-gaap_CommonStockSharesAuthorized_638687833445995114" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638687833445995114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638687833445995114" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638687833445995114" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638687833445995114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638687833445995114" xlink:to="us-gaap_PreferredStockSharesAuthorized_638687833445995114" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638687833445995114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638687833445995114" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638687833445995114" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_638687833445995114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638687833445995114" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_638687833445995114" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_638687833445995114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638687833445995114" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_638687833445995114" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1_638687833446005112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638687833445995114" xlink:to="us-gaap_ConversionOfStockSharesIssued1_638687833446005112" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638687833446005112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638687833445995114" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638687833446005112" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638687833446005112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638687833445995114" xlink:to="us-gaap_SharePrice_638687833446005112" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_NumberOfVotesForEachShareOfCommonStock" xlink:label="avte_NumberOfVotesForEachShareOfCommonStock_638687833446005112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638687833445995114" xlink:to="avte_NumberOfVotesForEachShareOfCommonStock_638687833446005112" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetailss" xlink:type="extended" xlink:title="240602 - Disclosure - STOCKHOLDERS' EQUITY - SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638687833446015135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638687833446015135" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638687833446015135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638687833446015135" xlink:to="us-gaap_AwardTypeAxis_638687833446015135" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833446015135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638687833446015135" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833446015135" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638687833446015135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833446015135" xlink:to="us-gaap_CommonStockMember_638687833446015135" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638687833446015135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833446015135" xlink:to="us-gaap_EmployeeStockOptionMember_638687833446015135" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638687833446015135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833446015135" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638687833446015135" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember_638687833446015135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833446015135" xlink:to="us-gaap_StockCompensationPlanMember_638687833446015135" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638687833446015135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638687833446015135" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638687833446015135" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638687833446015135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638687833446015135" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638687833446015135" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails" xlink:type="extended" xlink:title="240701 - Disclosure - STOCK-BASED COMPENSATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833446025121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833446025121" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638687833446025121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833446025121" xlink:to="us-gaap_AwardTypeAxis_638687833446025121" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833446025121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638687833446025121" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833446025121" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638687833446025121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833446025121" xlink:to="us-gaap_EmployeeStockOptionMember_638687833446025121" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638687833446025121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833446025121" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638687833446025121" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember_638687833446025121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833446025121" xlink:to="us-gaap_StockCompensationPlanMember_638687833446025121" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638687833446025121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833446025121" xlink:to="srt_RangeAxis_638687833446025121" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638687833446025121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638687833446025121" xlink:to="srt_RangeMember_638687833446025121" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638687833446035122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638687833446025121" xlink:to="srt_MinimumMember_638687833446035122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638687833446035122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638687833446025121" xlink:to="srt_MaximumMember_638687833446035122" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638687833446035122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833446025121" xlink:to="us-gaap_PlanNameAxis_638687833446035122" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638687833446035122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638687833446035122" xlink:to="us-gaap_PlanNameDomain_638687833446035122" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_TwentyTwentyOneStockOptionAndIncentivePlanMember" xlink:label="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_638687833446035122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638687833446035122" xlink:to="avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_638687833446035122" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_TwentyEighteenStockOptionAndIncentivePlanMember" xlink:label="avte_TwentyEighteenStockOptionAndIncentivePlanMember_638687833446035122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638687833446035122" xlink:to="avte_TwentyEighteenStockOptionAndIncentivePlanMember_638687833446035122" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember" xlink:label="avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_638687833446035122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638687833446035122" xlink:to="avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_638687833446035122" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446035122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833446025121" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446035122" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638687833446045117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446035122" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638687833446045117" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_638687833446045117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446035122" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_638687833446045117" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638687833446045117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446035122" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638687833446045117" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638687833446045117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446035122" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638687833446045117" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638687833446045117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446035122" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638687833446045117" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638687833446045117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446035122" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638687833446045117" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638687833446045117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446035122" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638687833446045117" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638687833446045117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446035122" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638687833446045117" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_638687833446055115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446035122" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_638687833446055115" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_638687833446055115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446035122" xlink:to="avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_638687833446055115" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_638687833446055115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446035122" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_638687833446055115" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638687833446055115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446035122" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638687833446055115" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638687833446055115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446035122" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638687833446055115" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638687833446055115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446035122" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638687833446055115" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638687833446065117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446035122" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638687833446065117" order="15" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails" xlink:type="extended" xlink:title="240702 - Disclosure - STOCK-BASED COMPENSATION - SCHEDULE OF OPTION ACTIVITY UNDER 2021 PLAN AND 2018 PLAN (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638687833446065117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638687833446065117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638687833446065117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638687833446065117" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638687833446065117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638687833446065117" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638687833446075127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638687833446075127" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638687833446075127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638687833446075127" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638687833446075127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638687833446075127" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638687833446075127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638687833446075127" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638687833446075127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638687833446075127" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_638687833446075127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_638687833446075127" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_638687833446075127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_638687833446075127" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638687833446075127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638687833446075127" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638687833446075127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638687833446075127" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638687833446085117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638687833446085117" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_638687833446085117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_638687833446085117" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_638687833446085117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_638687833446085117" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_638687833446085117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_638687833446085117" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_638687833446085117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_638687833446085117" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638687833446085117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638687833446085117" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638687833446095132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638687833446095132" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638687833446095132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638687833446095132" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_638687833446095132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_638687833446095132" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails" xlink:type="extended" xlink:title="240703 - Disclosure - STOCK-BASED COMPENSATION - SCHEDULE OF UNVESTED RESTRICTED STOCK UNIT ACTIVITY (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833446095132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833446095132" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638687833446105144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833446095132" xlink:to="us-gaap_AwardTypeAxis_638687833446105144" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833446105144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638687833446105144" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833446105144" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638687833446105144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833446105144" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638687833446105144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446105144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833446095132" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446105144" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638687833446105144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446105144" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638687833446105144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638687833446105144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446105144" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638687833446105144" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638687833446105144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446105144" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638687833446105144" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638687833446105144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446105144" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638687833446105144" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638687833446105144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446105144" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638687833446105144" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638687833446115131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446105144" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638687833446115131" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638687833446115131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446105144" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638687833446115131" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638687833446115131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446105144" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638687833446115131" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638687833446115131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446105144" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638687833446115131" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638687833446115131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446105144" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638687833446115131" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="240704 - Disclosure - STOCK-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638687833446125131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638687833446125131" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638687833446125131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638687833446125131" xlink:to="us-gaap_IncomeStatementLocationAxis_638687833446125131" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638687833446125131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638687833446125131" xlink:to="us-gaap_IncomeStatementLocationDomain_638687833446125131" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638687833446125131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638687833446125131" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638687833446125131" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638687833446125131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638687833446125131" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638687833446125131" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638687833446125131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638687833446125131" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638687833446125131" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638687833446125131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638687833446125131" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638687833446125131" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails" xlink:type="extended" xlink:title="240705 - Disclosure - STOCK-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY TYPE OF AWARDS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833446135126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833446135126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638687833446135126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833446135126" xlink:to="us-gaap_AwardTypeAxis_638687833446135126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833446135126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638687833446135126" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833446135126" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638687833446135126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833446135126" xlink:to="us-gaap_EmployeeStockOptionMember_638687833446135126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember_638687833446135126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833446135126" xlink:to="us-gaap_StockCompensationPlanMember_638687833446135126" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638687833446135126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638687833446135126" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638687833446135126" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446135126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638687833446135126" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446135126" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638687833446135126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638687833446135126" xlink:to="us-gaap_ShareBasedCompensation_638687833446135126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aerovatetx.com/20231231/role/DisclosureSubsequentEventDetails" xlink:type="extended" xlink:title="240801 - Disclosure - SUBSEQUENT EVENT (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638687833446145123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_638687833446145123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638687833446145123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638687833446145123" xlink:to="us-gaap_SubsequentEventTypeAxis_638687833446145123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638687833446145123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638687833446145123" xlink:to="us-gaap_SubsequentEventTypeDomain_638687833446145123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638687833446145123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638687833446145123" xlink:to="us-gaap_SubsequentEventMember_638687833446145123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638687833446145123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638687833446145123" xlink:to="dei_LegalEntityAxis_638687833446145123" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638687833446145123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638687833446145123" xlink:to="dei_EntityDomain_638687833446145123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_JadeMember" xlink:label="avte_JadeMember_638687833446145123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638687833446145123" xlink:to="avte_JadeMember_638687833446145123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638687833446145123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638687833446145123" xlink:to="us-gaap_SubsequentEventLineItems_638687833446145123" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash" xlink:label="us-gaap_DividendsCommonStockCash_638687833446145123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638687833446145123" xlink:to="us-gaap_DividendsCommonStockCash_638687833446145123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_PurchaseAgreementCashProceedsToBeReceivedUponClosingOfMerger" xlink:label="avte_PurchaseAgreementCashProceedsToBeReceivedUponClosingOfMerger_638687833446155125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638687833446145123" xlink:to="avte_PurchaseAgreementCashProceedsToBeReceivedUponClosingOfMerger_638687833446155125" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_MergerAgreementTerminationFeesPayable" xlink:label="avte_MergerAgreementTerminationFeesPayable_638687833446155125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638687833446145123" xlink:to="avte_MergerAgreementTerminationFeesPayable_638687833446155125" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_MergerAgreementTerminationFeesReceivable" xlink:label="avte_MergerAgreementTerminationFeesReceivable_638687833446155125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638687833446145123" xlink:to="avte_MergerAgreementTerminationFeesReceivable_638687833446155125" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638687833446155125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638687833446145123" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638687833446155125" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638687833446155125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638687833446145123" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638687833446155125" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_MergerAgreementSharesToBeIssuedDenominatorForCalculation" xlink:label="avte_MergerAgreementSharesToBeIssuedDenominatorForCalculation_638687833446155125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638687833446145123" xlink:to="avte_MergerAgreementSharesToBeIssuedDenominatorForCalculation_638687833446155125" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="avte-20240930.xsd#avte_MergerAgreementSecuritiesCapitalAmountReservedForFutureIssuance" xlink:label="avte_MergerAgreementSecuritiesCapitalAmountReservedForFutureIssuance_638687833446155125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638687833446145123" xlink:to="avte_MergerAgreementSecuritiesCapitalAmountReservedForFutureIssuance_638687833446155125" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable_638687833446155125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638687833446145123" xlink:to="us-gaap_ConvertibleNotesPayable_638687833446155125" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>avte-20240930xs4007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 avte-20240930xs4007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !2 6H# 2(  A$! Q$!_\0
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M]T]-$N_D>->+)9/ '@?X,:OK-O+!8Z#) -3=4+&U#6^S<X'8$\^E>H:)\>O
M'B/5;73-,\5:;?:A=-LAMXI"7D;K@#%=S<64=Y \,\<<L3C#)(NY2/<&LRU\
M%Z'8W$5Q;Z/803Q'<DD=NJLI]00.*F52-1>^M=?\RH8>K0E^ZDK.U[KLDM->
MR/'H_%NF_#[]IGQ&=?G_ +,@\1:;91Z9<S*1%<2QLZM&&Z;OF'!I/'7BK3_A
MQ^T5IFO>(9O[.T._T5K./4)%/DK,LF[8[#H2.F:]OOM%LM3\G[7:07/E-O0R
MQAMC>HST-+J&C6>JPF&]M8;N(\[)D##\C3]M&Z;72S_+03PL^5QC):2YEIYW
ML_O/(O&G[4/@?3_#E[+H6LV?B76BOEV6D6;&22ZF;Y43 '0D\GL*QOV@9--.
ME>"+KQ39WFF6(N5^TZOID[1R:3(T?7<H^YG*FO:+/P9HFGW*7-MI%A;W"?<E
MCMU5E^A K1NM-@OX'AN88YX7^]'(H96^H-*-2$))P3T\Q5,/6KTY0JR6MK::
M:._>_P"*\M3Y'UMOA-8:/?7*?&3Q!<RQ1,Z0VVKN\KMCY550O))P *Z+P9;_
M !DN/!^A2S+ 9GL(&<W4:B4L8USO&.&SU]\U]"1>!O#\,JR)HFGJZG*L+9 0
M?RK9V,/2M_K6EFN;U.:.72YKN?+_ (;_ (W;)****X#W HHHH **** "D/;Z
MT44 1OU3_/:DAHHIK9CZ$U%%%(04444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5'+V_&BBD]A,X_P"']C;65UXH-O;Q0&;6)993$@7>Y1,L
MV.I/J:[,445T5_XC^7Y')A/X*^?YL6BBBL#L"BBB@ HHHH **** "BBB@ HH
%HH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>avte-20240930xs4008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 avte-20240930xs4008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !E 0P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]3F?RT!/T
MKS_XL?&SPO\ !_2/MNOWNV608@LH?FGF/HJ_U/%:'Q8^(%A\+O >J^([\J8[
M./,<9.#+(>$4?4X%?E5XY\;ZO\1_$]YK^MSM/?7+$C<<K$G9%'8 5U4*'M7=
M['R.?YZLHIJ%-7J2V\O-_H?0GB_]O[QCJ5TP\-Z-IVB6H;*M> W$SK_M<@#]
M:Y5/VV/BT]SO_M:P"Y_U8L%V_P"/ZUX0&(XS5N%. #WYKUHT*>W*?C]?B'-)
MWJ.NUZ:+\#Z&M/VWOBCYT;22Z1*BD90V6-P],AN*[71?V\_$J._]I^%].NE.
M-GV6=XB/KNW5\K6R9(K6M8N>:Z%A*,MXGE/BW.*#O&NWZV?YGV_X:_;<\)ZD
M FK:7?Z.Q; 8*)4]R2O3GVKU[PI\7/"/C8*FCZY:7,S=(/,VR?\ ?)YK\U[:
MWW#I^E=KX,TMM/&J:]A6_LV#9$V<$SR_*@!'H,FL*N7TK7BVF?293Q]F-2JJ
M6(IQG'J]FDE=OMLNQ^D:3!AG(93T(.<U,,8%?G[X0^+'C7P0($T_69;FV4JJ
MVEX?-1N>@SR,_P!:^@_"O[5NCW6H/I_B"V?2I8W\K[6HW0E@!G)ZCG->94P=
M2&L=5Y'Z/EW%V7XY6JWI2VM+;7L]OOL?0%%9^E:M:ZS917=E<Q75M(,K+"P9
M3^(J['D#D\UPGVZ:DKIW0^BBB@8445YS\5/C_P" _@Q=V-OXQ\00Z)+?(SVZ
MRJQ\Q5.#C -5&+D[15V!Z-17!_"WXU^#?C/:7]UX.UJ'6K>QE$-P\*L!&Y&0
M#D#M7=CI2:<7:2LP%HHHI %%%% !1110 444AZ&@!:*XCXH?%_PI\'=*MM2\
M7:Q%HUC<R^1%-,I(9\9QP#VJM\*OCEX+^- U"3P=KL&MQZ>RI<&%6'ELP)7.
M0.N#5<LN7GMH!Z!1114@%%%% !1110!\9_\ !1#Q--;Z%X4\/)E8;R>2[E&.
M&$8 49^KY_"OB,< >M?8?_!1>-CK/@>383%Y5TN_MG*<?6OCUN1Q7O856I*Q
M^!\53E/-:BD]DDON%0;FJ_" 2:HQ#]X*OVO4]Z[([GP^(=HV-6T3FMBUBSS6
M9:<XXK9M .!FNV!\O7;N;.GQ;563'/W0O][/05Z=XHTH^%M$T7PN0OVO:-2U
M#VE<?(GX+V]ZB^"?A>&[NKOQ3K"@>'O#Z_:&+<":;&4CZCOBLS4-8N-?U6^U
M>^.;B\E:9P3]T'HOX"N6I-RG9=#Z[ 8987 *K-6E5T7^%;O_ +>=DO),N^&;
M ->RW[#-MI4)O)<C(W_=B4_5C^E9$ELWDN6 :1\DYYW,3_B:[C5; ^'/"&FZ
M7("NH:P1JEZ.A2$96&(CUR"U9_A[34O-7$L\8>SL8FNY\<?*O0?BV*PYKGKS
MP=G&AUZ^LK?E&U_.Y'H7CW7_ (6ZY$-&NF^S6:I%/83,3%,>K@CL<D\BOLOX
M:?$/3/B3X;AU?3&94),<UO(,/!(/O(P]1GKW%?"%V[7#23.,R2LTC'W)S7HO
M[,GC&3PO\4ETQGQ8:U&8G5CP)5&48#UZ@UABJ*J0<UNCZ#AK/:N"QT<)5E>E
M4=DG]E]+>71KYGVP#D4M0Q.6[5-7@'[N%?FA_P %<0#XI^'^?^?.?_T,5^E]
M?FA_P5Q_Y&CX?_\ 7G<?^ABO3RW_ 'J'S_(F6QV/_!(X*/ WQ!*CKJ=O_P"B
M:^_<BO@+_@D=_P B+X__ .PG!_Z*KZ:_:<_:.L/V9_!MCXBU'2+O68+J\6S$
M%I(J,I*EMQ+=N*G'1<\9.,=V_P!!K8]CS2U\!_\ #W'PF./^$!US\+F#_&E_
MX>X>$_\ H0=<_P# F'_&I_L_%?R,+H^^Z3-?!-K_ ,%;/!\ES$L_@;7((68!
MY1-"Q4=SC/-?4/P4_:/\$?'_ $R6\\(:K]IDMR!=65PABN+<GIN0_P QD>]8
MU<-7HJ]2#0TTSU:BD+ =ZX/XI_&SP;\%])_M+QAK]KH]NW$:R?-+*?1$7+,?
MH*YTG)VBM0.\SF@]*^&_$G_!5_X>Z9=K'I'AG7=:@P=T[+' ,YXP&.2._:LG
M_A[CX3/_ #(6M@?]?$/^-=JP.)DKJ#%=&O\ \%7\?\*<\+Y'']K_ /LAKE/^
M"1 4:/\ $G'7[5:9/_ 'KQC]L+]MK1/VE_ ^DZ%IOAK4='DLKS[49;N6-E8;
M<8PIKV;_ ()$\:/\2CT_TJS_ /0'KTYTIT<N<:BL[_J2FG+0_1"BN4^(_P 2
MO#WPI\-W/B#Q1JD&DZ1;@!YYB>6/15 Y8GL!7R!XA_X*P^ =.U22'2/"NNZO
M:*/EN6,<&X^RL<X^M>+2H5:_\.-RKI;GW517P)_P]P\*=_ .N8_Z^8?\:0_\
M%</"AZ> =<'_ &\0_P"-='U#%?R,+KN??>:6O _@+^V=\._V@KXZ9HE]/I^N
M"/S#I>I1>5*RCJ4()5L>QKWD$9."/?%<4XRIOEFK,9\^_ME?"NX^(?PHDN-/
MA^T:KHLOVV)%R6= /WB@=R5Y%?FX#D="/4>E?M!/&)$((R.A!'45\ ?M=?LV
M-X(OY_&?AJS9] N'+WUO$,_9)"?O@=D/Z&O1PM91]QGYGQ;DT\0OK]!7:5I+
MR[_+KY'S!$VUABM"VX/%9RD8!!]_PJ_;L=PR,5ZT7J?C%>-XFW:'IZUV?@+P
MEJ?CSQ'9:'I,32W5RW+ ?+$@(W.WL*Y;PKH>I>*M:M-*TFU>]O[E]D44?\R>
MP'<U]?2V.C?LB_#5F1X;[XA:W%Y:NW)7U*CM&GZG%55KNG:,?B>QME&2+'RE
MBL6^7#T]9/O;[*\V<O\ &76M-\*:?IGPST"3-EIRB749UZSSGG!/UY/X"L7X
M6^%X_%OB+?>?+HFE(;W4)?X0J\A/J<5Y=IDM]K>K+%&)+_4KZ7"G[SRR,>I]
MZ]R^(;0?"GP-8^ ;20/K6H!;W69T/([B//U[5G*'LTJ:^)_TV>MAL4LRKU<S
MKQY:%.R2Z::0IKUW?E?N<MK_ (HE\4>(-1UJ8[#<REHUQQ'$  BCT  _6MK5
M(_\ A&OAY:QRX74?$$@E*_Q);)]W\":P_AMX6;Q[XQLM)!*V*+]IOY>@C@7K
MSZGH*3XC>,E\8^,KZ]@PMA!_HEG'_=B3@8^I!-2U[W*NG](J-:4<+/&5'[TV
MXKS;UF_DG;UEY&#<OQUSFE\$2D?$KPMM/S#48<8_WA67=W?78-S^AKOOV8O"
M4OC'XLVETT>^RTA3=S,PR-V,(/SY_"MI>Y3E*78\; J6-S/#T**U<T_DG=_<
MC[QC'-25'$WRC)Y-25\F?U<%?FC_ ,%<?^1H^'__ %YW'_H8K]+J_-'_ (*X
M_P#(T_#_ /Z\Y_\ T,5ZF6_[U'Y_D3+8['_@D=_R(OQ _P"PG!_Z*KZQ^.OP
M"\,?M"^&K70?%0NVT^VNENT%G-Y;;P"!DX/&":^3O^"1W_(B_$#_ +"<'_HJ
MONGQ%XCTOPGI%QJNLZA;Z7IMLNZ:ZNI!'&@]R:C'MQQ<G'>_Z(:V/ED?\$O_
M (,?\\]<_P# _P#^QH_X=?\ P8_YYZY_X'?_ &-=A>_M]_ RQF:(^.8;DJ2I
M,%K,R\>AV<_A4'_#PCX%C_F<#_X!3?\ Q-)/&RU7-^(:'E?Q-_X)?_#X^#=1
MD\)WNJ:=KD4326[W4_GQN0"=C+@=?6OA#]F7X@ZM\&OVAO#-[;F2%SJ2:7?6
M^2HEBDD\MU8=\$Y&>X%?J$?^"@WP*9AGQCW[V4W_ ,37Y33:M::Y^T-!J=A*
M+BQN_$\<\,H& R-<J0<'IP:]G ^WG3J4\0G:W4AVZ'[E^-?%5EX+\(:MX@U%
M_+L--M)+N=C_ '$4L:_#OX@>/?%_[4GQ>%Y-YVHZKJMU]GTVQ!RMO&S?)&H[
M #&3]37ZA_\ !17Q)-X=_9/\1)#'O.HR6UBS;B"BO(N3^0Q^-?#W_!-#PO!X
M@_:7MKJ>!)H]*T^:Z3=_"YPJD?3-<V7I4:%3$M:K8<MTCZ)^%/\ P2L\,6ND
M03>/-;OM1U.2/,MKIS"*&)CS@-@DXZ5WP_X)??!E>=NN9_Z_O_L:^N50+G'>
MG5Y<\7B)N[FRK(_*[]NK]D#P%^SU\/=%UKPHNH"]N[_[-)]KN?,79MSP,#G-
M>@_\$B_^0)\2>_\ I-G_ .@/76_\%8/^2.>%_P#L,?\ LAKDO^"1/_('^)0_
MZ>K/_P! >O5E.53+KS=W<FVIP/\ P53^)=_JOQ3T+P4KNFE:58K?O$&PLDTK
M, Q'?:JXY_O&K_[&/[!/ACXS?#5/&GC6]O7@OY&6RL;)_**(IP79B#G)S@5Y
MA_P4KD+?M5:R".%TVT7Z_(3_ %K]#/V4OB!X1T;]GCP#:W?B71+*YCTN,20R
MW\,;JV3U4L"#55JDZ&!I*D[<VX)7;N<.?^"7WP8_YYZY_P"!_P#]C6=X@_X)
M=_">XTFZ339]:L=0:,B"X:[#JC8X)7:,C-?47_"U?!1_YG#0?_!G#_\ %5F>
M(OC9X"\/Z+>:G=^,=#6VM(FED*:A$[8 S@ ,23]!7CK$XBZM-EV/PXL;W5/@
MU\5H9[>9X=6\-ZKP\+;2QBDP1GT8 @_6OWOTR5M1TVTNB=IFB23!]P#_ %K\
M#/%^H/\ $7XHZK>:="6;6M7=K:,=299<(/QR*_?+1(7M=%T^"0_O(K>-&QTR
M% ->OFRO[)R7O-:_@1'JD+KEE+J&F2P0W+6=RRYBGC_@<=#CN,]J\_\ "'Q)
MM/$NI:AX,\4V]M9>*[>,K<Z=*/W5Y$>!+%GAT8=1U'0UZ@8PPPPSBO*OCE\$
M;+XLZ7%)#.VE>)=/_>:;JUN2LD+]0I(ZJ3C(KP(VO9F&(]HH\U)7:Z=_+U['
MS/\ M"_L5WNEW<VN_#JT:]T^0[Y]#4YEA)/+0Y/S+S]T\CMFO(O!G[-/Q*\6
M:O#8KX8O-*B8_O+S4D,4,0]23R3["O:=&_; \;?!_6)_"WQ)T'^U+VR8I]KA
M(CE=>S>C@\<BK/BO_@H6)],>/P]X8DBOG! EOY 8T]\#DUZD98A+E2OYGY=B
M\)P[7JRKU:CIO[4-M>UK?EH=_8Z!X'_8T\#2:E/(NK^*KJ,1B1N)KI_[D8_Y
M9Q@]?UKY#\9_$/5?B+XEN==UR<37<Q"K$N=D"?PQH.P'\ZYGQ3XZUKQ]KTVL
M:Y?2ZAJ$[<;LX4=E1>P]A7U'^S]^S7%H=@/'GQ%1;*PLXOM=MIUQP$ Y$DH_
MDOKBNB'+ADZE1WDSY[%2K\2U(Y=E\/9X:&_:W>7GV1=^$/@BS^"O@:;XE^+X
MU&I20_\ $IT^7[Z%A\IQ_>;(^@KPK5/%.H>*==N]3NRUWJ6H3%F4 DEF. JC
M\ABMGX[?'&X^+OB</ 7MO#UD2EE:DX#>LK#U/8=A7I'[-/PQM;"PN/B9XN7[
M+HNF(TMI',O$A _UG/H>%]2:WC+V476J_$_ZL>7B*"S?$TLERM\N'I:REW?V
MIO\ 0U?$ZK\ _@TNBED_X3/Q9^\NW4X>WAQR!_L@';]2:\".I!(U5 0 ,#-6
M_B7\2+OXF>,[_7KQV"3-LMH2>(81]U1Z>I]S7+?:R!C-=="'+&\]6]6?*9]F
M"Q6)5'":4::Y8^BW?K)ZLTI[UY&_B=SPJKU)[ 8K[Y_9L^%Y^&OP^MUNXPNM
MZD!=WO'W"1\L?T5?U)KYP_9-^#S>-_$R^*=4MLZ-I<@-NCCY;B<<@^X7K]:^
MZ8TVDFO)Q^(O^ZCMU/U?@#('AJ;S3$+WIZ1\EU?SZ>7J$:8Y)S4E(6 XHR*\
M0_9 ) K\T/\ @K<ZMXN^'\??[%<-G_@8K]*KB>."-WDD6-$!9G8X"CU)K\;?
M^"@'QMM/C)\<)H=)NQ=Z)H,/V""1<%7D!S*RGN,_RKULKBY8F+70F6Q]-?\
M!)(E/ 7C]B#@ZG ,_P#;*O'/^"F_QJOO%GQ@3P%;73IH7AV)'N+='8++=R+N
MW.. 2J%<?[QKZ-_X);>!KOPW\"M2UR]62-=?U-YX$<8!BC41AA]6#5\+_MUJ
MW_#6'Q%!Y/VB$Y'_ %[15Z6'C"KF,Y;V_P" A/2)ZM^S/_P3HO\ XY> [7Q;
MK_BE_#>FWZEK&VM;4332(#C>Q8@ 'L,5[$?^"0_A\\_\+*U?_P %L/\ \57U
M/^RA<07'[.?P]>!TD7^R81N3ID#!_6O6P1@5Y=7,,3*H[3:&DC\_A_P2'\/
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>avte-20240930xs4014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 avte-20240930xs4014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &N MH# 2(  A$! Q$!_\0
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MG_Z"%U_WT*/["?\ Z"%U_P!]"@#7HK(_L)_^@A=?]]"C^PG_ .@A=?\ ?0H
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MA0!KT5D?V$__ $$+K_OH4G]AO_S_ -U_WU0!L45D?V$__/\ W7_?0H_L)_\
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MLC^PG_Z"-U_WT*/["?\ Z"-U_P!]"@#7HK(_L)_^@A=?]]"C^PG_ .@A=?\
M?0H UZ*R/["?_H(77_?0H_L)_P#H(77_ 'T* ->BLC^PG_Z"%U_WT*/["?\
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MI7GOQ2U:\TZ335M+EX"^_=L/7IBO0G[5\[_M?:3XJU;PMIUKX/N?LVI><S2
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MT$KG\Q4]KIDEM,':]FF&,;7Z5H44 %%%% 'G?Q\U36]%^$WB&^\.V\EWK$,
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT+IWC$P:=K.S3=8;"J^<13GVS]T^QKFE1G"/M*#O'KY'#@LXJT:BP^*7+/\
M!^A]UV6I6^H0K+;R+*C<AE.15K=SC%?/NBZ_>Z%<"2TG*]S&QRK#Z5Z=X<^(
M=GJ[)#=,+.[_ +K'Y6_&G3Q$9Z/1GVU'$PJZ/1G:T5&LF[G(Q3ZZSL%HHHH
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M\13J:)ZG4T4Q7# '(IU=)TBT444 %%%% !1110 4444 %%%% !1110 4444
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MF<'<6+C).<FO3J* ///%7P7T7QG?:-?:J]P^H:-N.G7ULY@N+;<NU@KJ0=I
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MO?\ H+3_ /?"UKT4 9/]D7G_ $%9O^_:T?V3>?\ 05F_[]K6M10!D_V1>?\
M06F_[]K2?V1>?]!:;_OVM:]% &1_9%Y_T%9O^_:T?V3>_P#05G_[X6M>B@#(
M_LB\_P"@M-_WPM+_ &1>?]!:;_OA:UJ* ,G^R+S_ *"TW_?"T?V1>?\ 06F_
M[X6M:B@#(_LF]_Z"L_\ WPM']DWO_05G_P"^%K7HH R/[)O?^@K/_P!\+1_9
M-[_T%9_^^%K7HH R/[(O/^@K-_W[6C^R;S_H*S_]\+6O10!D?V3>_P#05G_[
MX6C^R+S_ *"LW_?M:UZ* ,G^R+S_ *"T_P#WPM+_ &3>?]!6;_OVM:M% &3_
M &3>?]!6?_OA:/[(O?\ H+3?]^UK6HH R/[)O?\ H*S_ /?"T?V3>_\ 05G_
M .^%K7HH RO[)O/^@K-_W[6C^R;S_H*S?]^UK5HH R3I-X?^8K/_ -\+2'1[
MMEP=3F(]T6M>BC<#DKWX=V6HS>;<2%I/[RQJI_2JQ^%>F?WY/RKMJ*S=.#Z&
M;IP>K1Q ^%>F=WD_*AOA7II'$CCZK7;T4O90["]E#L>>7?PK7'^CRPOZ"9"/
MY5BW'P\U:V)\O3[2?WCF8'\C7KAZ4W9]?SJ71AV,Y8>G+H>$ZKX4N4C/V[PT
MLL?0ED,@KSW5OA%X#U.Z,UWX-L$F/4Q;HL_4"OKAU)Q@U3NM'L[]"+FUAFS_
M 'T!-3R5(_!*QPU<MI5=TGZI'QIK7P+\)B -H_A/1O. X6]DFQGZJ>*Y;[?X
MX^&JO)IGPXTJYMUX(T_49YU(]=C'-?:FH?#+1[U#Y<36CGHT3<#\*Y'5OA=J
M-AE[21;Q!V^Z]+VE>'QI21Y-7*91UHOE]$O\CY M_P!K_4=/OO*UKP1;1*.L
M4<TD4@/_  /BNAL?VP/#$Q_TGPO>VW&24=7 _7FO7O$'@^RO28=9T:&< =+J
M '!]B17)W7P3\#7>?,\.62,?XHP5I/$X:6DZ=CPW0S2E+W:R:\XV_(Y+4/VO
M_"-O'_H?AV_O7(XW$0C]3FJ^G?MA^'9R/MOA:[MAW,,JR ?AD5V-G\"_ UBP
M=- MG;.?WQ+X_,XJ>^^#/@O4O]=X;LE8]XE*']*/;X/;D9/)FS?-[2/I;_@&
M79?M1_#V\&',UF3P?M%L_'XBO5?A[\9-/UVQ671=22YT='VN;8Y:,_0C(^AK
MQS4/V9?!-UEHK6ZLV/>"X/'X&O&=9T+Q/^SGXP34K!WN=(F;"R8_=S)G[D@[
M-Z&M(1H5G:A*TNS#^T<QP#53$13AU<>A^CUMK=E=(K)XG'S#.&V*?Q!J\C+(
MN5\0AAZ@H:^9/A]\0M(^(>D"_L'"R@ 36S_?B;T(_K75C&WT_&N26)G3?+..
MI]?2S)58*<=4_,]RV?\ 4P?JE/CMY)7VIKK.W]U=A->%8W'C(Q[FGQS/"X>.
M1HW!SN5B#2^N_P!TV6/UMRGO']EW9_YBLW_?"T?V3>?]!:;_ +]K7FVA_$N_
ML-L=VOVV$=\X<?CWKT#0_&6F:X,03A9N\4G!KLIUX5-F=U.O"ILRS_9-Y_T%
MI_\ OA:/[)O?^@K/_P!\+6J&! P<TN:W.@R?[)O?^@K/_P!\+1_9-[_T%9_^
M^%K6W4WS!GH:0&7_ &3>?]!:?_OA:GM=/N+>4/)?RSKC[C*,5>W<XQ^- =6Z
M$4P%'2EHHH \O^*7PWL[_P .^+;W3M 77]8U>WBAN+*6\:!;I8C\J[@?D.">
M1U-?-D5O\$O"E]:6GQ \":]\/;UY419]3GF>T,F?E G1BIYKZ6_:)\07WA7X
M/>(M5T^XN[.:UB5VN;*6..:*/<-[(9/ER%R0*\B\#>%?@#XGM--\2:AXYTSQ
MU=W 6:*[\2ZY',^X]/W+, C ]MH- SZ=TTPFSMS;,&MO+7RF!SE<#'Z8J[5:
MT$8CC6';Y00;-GW=O;&.V*LT""BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT1>3(.#M7C&37RKKTO@!?&T_A#Q%\3_B#X@T>"Z2SU.:1LZ6)21B":94P,G
M(S]:!H^W=$F6YTRTF01^7) CJ(>8P"H(VGT]..E:%4]-MX+2RMH;556VCC5(
M@IR @   _#%7*!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%(&!HSS
M0 M%)FC.: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"@G)_W[6@#5HK*_LR^_P"@F_\ W[%']F7W_03?_OV* -6BLK^S+[_H)O\
M]^Q1_9=]_P!!-_\ OV* -2EK*_LN^_Z";_\ ?M:/[,OO^@F__?L4 :M%97]F
M7W_03?\ []BC^R[[_H)O_P!^UH U*6LK^R[W_H)R?]^UH_LN^_Z";_\ ?M:
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M$W_[]B@#5I*R_P"S+[_H)O\ ]^Q1_9=[_P!!.3_OVM &K165_9=]_P!!-_\
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M. +Y<V^=5;<2,_=8]*U_BIKU_INGZ5IVE3"UU'6+U+&*Z*[O)!R68 ]P <4
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M#[L<>>F3U- '9[^/2C=7EW@O4;W2/''B;0!JD^M:+86<5R+JZ8/);3L6S"7
M&[Y0&]1FN'^'7B[3M7T[1+O5?&>MQZA=-N?C;:>87.(]^W'H,9H ^B@<TM0V
MYRIZ?A4U !1110 4444 %%%% !1110 W=1Y@/>N7\>:=>W^FH+;6O[!M4<-=
MW2J"_E#J%)X7/K7 >"O%#V/B;Q%#INMS^)_"]A8&YDN9W#M!. 28PX SD#..
MU 'L^\9HWCU'YUXC;V'B;5OA[-XY3Q%=PZPUL^IV]BNW[(L:@N(63&3E1@G.
M>:]'\.>,;37O#VEZF2(C>VL5R8^NW>@;'X9H ZFBBB@ HHHH **** "BBB@
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MWT+PSI&FRD/+9V<-N[*."40*2/RKK"@)SWI<4 +1110 4444 %%%% !1110
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MY^#_ (5^(FB66E:[IBW-K8LK6;1.\,MLP& 8Y$(9>,=#S0,^3?%?A7Q#X6^
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110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>avte-20240930xs4015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 avte-20240930xs4015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &F W0# 2(  A$! Q$!_\0
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M>_\ /[=?]_F_QH_M.]_Y_;G_ +_-_C56B@9:_M.]_P"?ZZ_[_-_C2?VG??\
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MO\:]5_9RO;J7QEK DNIY -%NR \A/.T5Y%BO5_V;?^1TUC_L!W?_ *"*!'F
MU.^P?]-N1R?^6S?XT?VE??\ /[<G_MNW^-5A]W\:* +/]I7W_/[=#_MLW^-'
M]I7I_P"7ZY_[^M_C5:B@"U_:EZ/^7ZY_[_-_C2?VG??\_MS_ -_F_P :J[US
MC<,_6G8H L_VI??\_MU_W^;_ !H_M6^_Y_KK_O\ -_C5;^=&* +/]J7O_/\
M77_?YO\ &D_M.]_Y_KK_ +_-_C5:B@"S_:=[_P _UU_W^;_&C^T[[_G^N?\
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MIWLFG:JFFV8@9$#[T#*TF1VSSCK7)_&/08?#'Q(U;3(&WQ0K#@A OWHD;H
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M@ 98^O6@# I***!A75?"G_DI_A3_ +"4'_H8KE:ZGX5?\E/\*?\ 82A_]"%
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MW&CZ(^WJ*K3WR6[[65CQGBH_[5B_NO\ E7G'Z&7:*I?VK%_=?\J/[5B_NO\
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MV3_XJ@#\^,CU'YT?B*_0?_AF?X:_]"M;?]_)/_BJ/^&:/AM_T*]M_P!_)/\
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MGB:4HI.V][Z*W8_+GC^\*./[P_.OU&_X9%^$W_0H6O\ W]E_^*H_X9%^$O\
MT)]M_P!_9?\ XJM_KD.S/$_U*QW_ #\A][_R/R^MKJ2RN8[FWG>WN(F#QRQ.
M5=&'(((Z&MB;QYXDN;Q+N;Q%J<UTDK3K,]VY99&&&<'/!(X)K]*?^&1?A-_T
M*%M_W]E_^*H_X9%^$W_0H6W_ ']E_P#BJEXNF]T:1X.S&"M&K%?.7^1^:,7C
M'78=#ET5-=U%-'DD,K:>MVX@9B<[BF<9SSTIUKXUU^PU9M5MM>U"WU-T\IKR
M.Z=963&-I;.2,<8-?I9_PR+\)O\ H4+;_O[+_P#%4?\ #(OPF_Z%"V_[^R__
M !5'UJGV*_U0S/3]]'3;67^1^?&F?&[Q3I/AC5-*@U6[%UJ%S%<R:Q]LD6[4
M(I4('!SM()[UG6WQ'N;'P!J7A>VM+>$ZI<"?4=4W,UQ= '*HV3@ ')XZU^C'
M_#(GPFQ_R)]K_P!_9?\ XJC_ (9$^$O_ $)]K_W]E_\ BJGZQ2[&_P#JMFS2
M3K1T36[V>_3KU/R[W+V88IA89ZBOU'_X9%^$W_0H6W_?V7_XJC_AD3X2_P#0
MGVW_ ']D_P#BJOZY#LSB_P!2L<_^7D?O?^1^7/XC\Z3(]1^=?J/_ ,,B?";_
M *%"V_[^R_\ Q5)_PR'\)>WA"V_[^R__ !5/ZY#LP_U*QW_/R/WO_(\#_8[/
M_%K;[O\ \3:;_P!%Q45]3>%O@MX0\%:<]CHNCP6-H\IF:)2Y!<@ GEO11^5%
M<<JT&V[,^_P.55<-AH49M7BK:/\ X!T6I_Z__@-5,U;U+_7_ / ?ZU3KD1]2
M+FC\>*2I+?!N(P0&!;H1FAH!FV3@%3N(Z4#.[!XQUK\GX?B?X[TW0?BIX4@\
M0ZO-+XYUG5!I-V;J1FT\6=Q(9UC?/R#9MX!%>J>$OVH_B#H/PVT.QT?7M&TZ
M'PCX"TWQ%>?\)&#+=>(6FW92)RV<#;MW#)W$4@/T-VMC(X /))IN<CWK\X?V
MA?VG+^]^+MIXQTR_U_3(O 5GI%T-'TZ":2RNWN&5]0BNF3Y%\N%_X^F*_1C3
M=1M-:TZTU*PE6XL;V%+FWE0Y5XW4,I!^AIH":EQZTAX- .*8%C3P#>1_C_(U
MMUBZ?_Q^1_C_ "-;52 V1MJ,0,D#.*^2OA[^U]K?B+XBV>E7IT>ZM)Y[K[5I
MUI8WD-SIUI"6#73SR#RI$4JH;:>K@"OK290\3J>A&#7FD_P'\+3Z5H%@8[A?
M[$N)9K6992)"LN_S8G;'S1N'(*GV]* .*T_]MKP'K>DW-WI5KK&KW*7D-G;Z
M;86@FN;LRAS%)&JMC8WEL,L01W JS+^UGH$445Y::?J^N)>QP_9-+TW36:\$
MC*[,C@L "OEMGTQWK9\(_LV>%_!PM!:W&H3)8WT=]9K-(N("B.J1C:HRH$C#
M!R>G-6="^ /@_P .ZQ:7-J]TE[!EXDDN<GD."<=2/WK?I0!+/^T;X0E\(#7=
M*N9-<D-I#>_V58 ->I'* 4+QL1LZC)8@"N5M/VS_  1?1Z--;Z?KT]K?0+<W
M%U'8%H=-C,[0$W#AL+B52OR[O7I71Z]^S?X.U[P%8>%/LTMK;V*PI%?6Y5;H
M^3_J][E?GQCHP(K(TK]FOP)X&\*7>F_:+R'3[BV2SEFN[KJ!<M.,G  )DD/X
M'% #1^U/H.JW3VMI:ZGI96XMO*O-4T]UM[NWDN1!YL3!N5W$\]L9(Q6?K7[8
M.E1Z;)-HWA?7M0G:ZMTLXY[3R5U"VDG$37,#,?F0$]\$Y!Q@UA>!?V8W\.>)
MM1U+QKXACN=)FFMK?2-.BN&6*$)<^?&B[_[SX&P9SS72+^SMX%TJ:XTV3Q#J
M4=U-Y4>G07&I#S-/191*D=N#T&Y>ASP,=*!@/VT_A[)J?B&R@DO[M](60J;6
M 2?;&C<1RI"H;<65SMPP7/49'-31?M?^$I+_ ,.Z<VE:[!JVL7$UNVGSV02:
MS,4@CD,H+ '!8<(6;!SBGZ?^SOX#T;5M<CCU"XA2[87$FEFY0):M))YI=.-P
MW.K'DGOBIO$O[-W@SXC113RWM]/IT]_)JDT5O<*T-S([!CR02.5&"I!]Z T*
MUQ^U=X>T+5UTW4K/5;QA<^7<7^GZ>QM;&)KCR$>=BV5!? R,^N*]S5]Q%>7'
M]GKPF\6JP$7FS5!&)QYYY"3^>N../G_2O4@@&/:@0ZBBB@ HJIJFI6^D64EW
M=SQVMM$-TDTS!409ZDGI4BSEDW<$8SD=#0.Q/4,L_E$YZ 9I/-;:#Q2.VX#/
M?MB@1\^1?M#>(Y?$.BZG<'PMI'@_5]5;2[&SU*^>+4;H++Y;3(V/+SNY$9Y(
M[YJ]!^VI\/[V?7HK(:EJ$FF/LC2UMQ(]]^]$1,*AL_ZP[<,%/?IS6Y=?LW>&
M;O7ENS>ZM'I+7JZD_A]+DBQ:Y5PXDV8R/F ; (!/:HM$_9D\):!=WS6LE^MG
M<727<-CYBB*U<2^;B/"[L;NQ)P.!0!DZE^VAX"T:VT%M034K&[U-YDFL+FW$
M=QIXBF,$C3H6XQ("N%W$]1Q5[6OVK-!TC1M5U9/#WB&^TVPO6LC=0VB+'.4!
M,CQL[@%5"\DXR>!FK6L_LR^%-4UNTU9);^ROX;JXN))X)%)G6:8S/$^Y3\N\
MDC&",GFHO&W[+GA'QSI6G:?=3:E:1V-W=7<3VTX!S<?ZY2&4C!['&1V- ]#H
MOA%\6X_BL^LW5I$@TF"2%K&=00TT,D2R!F!Z'YNE>CUP_P -/A=HGPJTU['1
M%N!;NL2$W$N\XC0(O/\ N@5V)E;L,^U B>BJ-EJUOJ<3RV=Q%=1*[1L\3!@&
M4X9>.X(Z5:60L/ZT 244U23G-.H *0G\*6JMW/Y,$SE@H12V[&<<=<4 2F4@
M]J#*1V_2OB?3?C-XF\-0ZU?CQ;<^)-5O=/O+JR>VFBN]/8(XS*(542P&)#DH
MV<[2":NZQ\4;WP+>:IINE^/]6\2B[TB/4(=5GGMI[9G\R/?(FSYHE 8C##'/
MM0!]E^:W&%SUYH$K$_=KY^^/DLNO>&/#FM>'O'>I:6?[3LM-F_L*[B,<@GE1
M7W\-\VUCCTK,M=1U2Q^/FCZ!H/Q!OM>-A*$UNROI8?LT%MY3;8L !GN6;:V1
MT .:!V/I/S6QT!H\XYQ@5\U>.?CSXK\-^+O$^E^'].L-0;3VN;N;^U+EE58(
M+=)66,*.&;<0,USUE^T!XOM&U^>]CMKGP_?:E=Q:=,)RMW;%((I@G3&P!BH[
M]Z L?6WG-SE12B4D<C!KXS\/_M*>*+/2-3LM5NK#58;F;4C9RV5W_P 3"U^S
MW"C$Z@85"K[0<=AZU<TS]I'Q5X?M+FYUB;3M3U$SSVMNPN/)M(-]]';Q-<<?
M*$#@LWH* L?8:-N&:=7R;>?M7^,X8;F.ST70+Z30Q-)K%U#>.T$Z1R(I-LP'
M)(?OT((KZLLKD7EG!.!@2HK@'MD9H$34444 %(V<'%!. 341E.<>M 'SO#\<
MO'^G"]\6:CIV@W'@2#7'TB6VM6E34((_/\A9MS'8^&*DJ .#P:[34?VD/#]G
MHTE];Z=JVI2"RCOX[2UMAYDB22,BC+,%4Y0YW$ >M4[?]FGP_!KTFH7>L:W?
M:5]O?5%T*YNLV,=PS%]^P $X;+ $X!KGU_9)\":_H]Q]GUG6;N*>6.2UNA?B
M5;41N[(D8(*E07;@@_F*!Z'1_"W]HG3OBKJ5[=:;$(/#D6E)J"W-P"DR,))$
ME1UY'RF,\C(/8FN?TO\ ;:\!Z[8:C/IEMJ^ISVTT,=M9V5JLL]\DKE(I(E5N
MA8$8;:PXR,5U_P +_@/X2^&FFS6^B>?>6EQ;/:2M=3^<)(VD=W!([[G;^7:J
M'A']FCPMX,5([2?49;>"ZAN;.&65<6HB8LD:84$KD\YR3CK0!SFO_M@:/]DT
MAO#^CZG>M=7%E'>W-U:/';:9Y\XC\NY?/R28WD#D<#)Y%2:Q^U]I<=D'TCPK
MK]]<R7UI!:PSVGD?;K6:X$!N8"QPR GC."25XP<U?G_9J\#3:_!&E_J4,B-%
M>W.DPWN([TQS&2*2:/JP#DCL", ]*0_LU^#]+CFM)]9U=)KR2*/3#/?_ #V(
MBE$Z16V1P Z@XYX&.E :&9H'[8V@1^']6O/%&G7VBSV!G,;FW*P7X2Y: "W=
MC\S;@H.<#)/:FVW[7&E>(+[2;G255-!N[;S)IIXBT\-PMSY+P%5;&1_>!(Y'
M)%=)KW[/O@?5]-L]$OY9Q((;B.T5[D><"\_VAY$!'+!^<X(QQ5.T^!'@&YFL
MM+EU:?4=4L(V@.ZZ03R$2"9BR*!R"RYP.!B@-#I?A3\>]#^+DNIQ:=I^K:5+
M8QQ7)CUBT-NTUO)NV31\G*DHP]>*Z'X=^+KGQKX?_M::WCMH)[F5;8(2=\*N
M55CGN<$_E7.Z+X(\(>%X]5N+34?+5M-32+F5[L'RH(2PZ]F!EY/N*[;0-(M/
M#NC:?IE@FVRM(5AA&<_*HP.>_2@1KT5"LC%\'^534 ,D;8N?2OG<?M">(I-?
MTK5)G\+:/X-U'6&TBSM]5O7BO[O;+Y3RHV-@;=G$9Y('49KZ)<!AR,UY)J'[
M-?AJ^\0->F^U6'2I+U=2ET&*ZQ8R7*N'$FS&1\P#8! )'2@"MHW[2>AVO@F]
MUCQ+<6UEJ5M/? :5:-YES/#;W+PAXXB=S9V _4UBZI^V5X/LM:70&@O;'7WM
M!(;:^C5!;7+Q>9%;3 ,6#LNT\ J-PR0:[Q_@AX6/ABZT-[0O%<33SFZ;:;E3
M-,TSA9,9 WL>/2L#7?@#X-7QA>>++J\N--^VJJ7L/G(EO<2B,1)(Q89#[=HX
M(!P.*!F/X/\ VP/"&O\ B32O#%T\D6OW5L&D\A=\ NO*\UK9>2Y8*"<[=O&,
MYXJM-^VQX+M=*U"YN-+UNVOK2\BLO[+EMD$[M(I9&SOV*"JDX9@1C&,UMZ?^
MRWX/TC5[B\M)+^"VN+5[>:P28"-RT1B:3(7<'VGJ#UYQ6)I?[&G@W1?#FJZ3
M::EK*)J*Q)<3&:-BT<8*JFTIMQ@D=,]^M :&WK?[6W@+P]XUTSPU?W5Q;7=W
M;PW$LLD85+/SDWQ)*"=P9EYX! [FJOA#]J"R\4^(O%)ET74=(\-Z)H<.LK<W
M]JZ7%S&\DP\R-!G=&5B!&.<DY%6;']EKP5I&LZ7=V*7EI!96,.GR6*RAXKN.
M)-D?FEE+$A3C@C/'I6AX.^ GAWP VMW-OJFKRMJ%@FFF:]O2PM+5&D9(XB1A
M ID;D\\C- B#PI^U!X3\4:)I>K-!J&E6&HK=-#-?0J$'D1^:P+*Q&2@+*,\[
M2.HQ6!J7[8>@O8>+/[$T'6=2U#0=);4G@EMQ$'81B3RCEMRG:RG)&#S@G%8^
MH?LJZ%J?AF'PQX?U59=+G\00ZKK]W<2;[IVBP?+CV *I=1L;CE';UKL?%G[/
M'@W5_$NK^+=<O+P&;3YK,B2X6.&TBDCV2%& !'R] 20#VH SY/VQO VG>(H]
M!U4W>GZJEBES=Q-&&^RW#0"<VC@-GS0A[ KGC.:KVW[8?AG52;:+1_$&E7+F
M2)9]3TMDABF\@W$2.0W62(%U ],$@D5>3]G'P6GB#[9+JMZUSJMF()X9+E/^
M)@ZP+$;@Y7<TFQ5R5.#C.*W]3_9X\*:LN+C[:V;J*\XG(_>1VAM%[?\ /,_G
MS0,=X#^/&E>.O$:Z)9:=JTCB#>-7^P.NGRRJJM)$LIZ.NX<''?!.#7IL;[P3
MQCVKSGP9\#-$\#>*7U?2]0U5(?+*II3WA-HCE0KRB/\ O$*.3[XQFO1T0(,"
M@0CN5. *\3T[XH?$'Q9KE]J_A_0]%D\%Z?JDFF30WETT=].(WV33HWW$"MNP
MC<L%ZC(KVUE#=:\IU/\ 9S\.ZCXKGU47VKVUA=7:W]WH=M>%+&YN00?,=!SR
M0"0" 2.10!AW'[8'@VTCOY9M-U^.WB*BPE.FMC5@9E@)M>?GQ(Z@YQP<]*JQ
M?MF^$7B</H7B>&[R(HK.33")9Y_-,+PQC=\S)(-K=N>I%;5E^R[X2M-2:[>Z
MU:ZCBGCGL;:>[+1:?MG2<K N/E#.BYZ\<5D_$3]ES2O%,=B^E:E>:3>P7[73
M72SG>B/<&>78>S;SP3P*!Z&;>_MG>'-'N+Z[U"TN+?2X[6W$%H\?EWYOFEFC
MFM71V"JT?DG/..O)XJ_=?MG^"EDM!8:9XAUJ"ZA@=+G3M.,L7F3*S0PDY^^^
MQQZ CDXYJ[?_ +)7@FZTPQ^;J,=^ DAU1K@/<><LDDC3DL""[--)N)&#GH,5
MJ:3\%?![Z?%>V]W<W4"S6EV;I;D%6>U1T1B0,?QMG']* T,:R_;+^'=]XGT'
M1$N[J.XU9(L22Q!5MI9,^7#*-VX.Q!' (!ZD5EV_[9.E:ZNC_P!A>$_$-P^H
MZA:VZ1WMG]G9[:<L%ND!;YD!4^_%:&E_L^_#OPKJ^D^(;359;*V"CAKJ,P7I
M 9E9F(Y(!)^4@8'/2M&X^!_@>*S\/%-5N;,V<-I'IMU'>@,R6Y+QD$\-D,<G
MN#0#,O\ :/\ CMK7PK\0>$M)TJ;3;$:RER\E[J-C=7H7R@F%6.W!;G=U/ Q6
ME??M+:/X+\0^'?#GBJ"ZBOM36*-M8M[8K8&=X]X50S>9@@'G:0#P2*] O?!V
MF:MXNTCQ,_F-?Z;;S6]NR/\ NRDNW<2.^=HQ7G_B/]E?P;XL^(Q\9WTFHM>M
M=PWTEH)P('FC78K$$;L;>-N<>U BG-^U1:WG_"/2:7X1\026NJ:U%IK3WMF;
M=!;NCN+M"QP\>U"WK@'(IT?[7WA.73IKI-&\2$OY;Z9 =,99-6AD;9'-; GY
MD)Q][!P0<8-:VG?LVZ#IVG6UE_:^N7$5G?Q7UH+B^+BV6,%1 @(P(BC,I'<'
MK4/A[]E[PIH%S!.+O5K[[(\7V!+R\,BV,,;;D@B]$! X.3@ 9H X3X[_ +4.
MO_#3QY%I-C;Z?:6T>C6^JO:ZA8W5Q/</))(AA#P I#C8/F?C)]*^D="U%M8T
M6POFB$+7,"3&,.'"EE!QN'!Z]:\[^(7P$TWX@>)Y-;EU[6]'EN;%-.O;?3+D
M1Q7<"L[!7!4_\]&&00<&O1=&TBUT#2+/3;&(0V=I$L$,8.=J*, ?D* +M%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!D:GQ<#_=_K53%:%];233!
MD7(QCFJYL)_[@_,4T!6I58JP(.".A]*G%C/_ '/U%+]@F'\'ZC_&F!Q$/P>\
M!6VSR?"&D1[)+F92+89#W'%PWUDR=WK56_\ @1\-M57PZM[X$T&\7PXBQ:/Y
M]DC&Q0'(2/(^Z",@'C->@_89S_!^H_QI/L$PZ1_J/\:D#E[3X=^%K'3]?L(/
M#NGQV/B"2275[<0#9?O(NQS*/XLK@<]JUM%T6P\.Z/9Z5I=I'8:;9Q+!;6L(
MPD,:C"JH] *TQ83_ -P#\1_C1]AG'\ _,?XT 5R/SHXJQ]@G_N#\Q_C1_9\_
M]P?F/\: #3C_ *9'^/\ (UM5E6EI+#<HS)A1G)!]OK6K0 USA2:^;?VHK7QW
M_P )/X,OO!SZY=6UN[^=I.ELT,$\I=-K2RJ<C"[AAPR$$YYQ7TI2!0.PH ^0
M]6U'Q[XMG^(NAZ+XEU>.W\-0MY%[IC?:9II[ED<P=1DP('7@@C?D<@5R4?A/
MXK7&C:5KEIIWB&R\6PZ!>:=9W$]X\RE?.1MTBM@[VCW[-^2"!SFON"RTNSTX
M2BUM8;82N9)/*0+O<]6..I]ZL;%]!0!\1Z3X-^,.K>#+"(>(O&$,-JM[<690
MM;W <&(11S;V9I!N\TC>>02.F*]*T7P_\0M+^$WBK29)]7U#4H-<7^RY[^02
MW,EH7B=OF/503(!GH.*^DM@]!2[1Z"@#XRO?A'\0M:_LRTU/4_%-_:ZG?65[
MJ#W-V&-A(FH'+6Y_Y98@QT[<]:H^,? 7C^]LM&AUJW\6:KI>D7YS=:?,O]HF
MWCFN%C=9.I?RS'ENI!]:^VB@/84%%/84#/BV_P# 7Q*URV\-7OB6'7[N;3)-
M-GB-M,%F_P"7E<S[<>8ZJT/F=LY/<U,FG?%R#Q!I8)\5KKR"T&GF"5%TA+/8
M/M2W*#@RD[\$_-RFTCFOLW:,YQS1M'I0!X)^SOX9\:>$]:O(O$6J:]JEE?:;
M;73MKEQYYCO"SB5$/\("[?E'%>^4FT>@I:!!1110!PWQMM=9O?A=X@@\/+,^
MLO !;+!C>6WKG&>.F:^<+_P%\6D-QK$.O>+Y+YYI[Q;+[8/LZNFH8AC"=D^S
MECM[]\D5]CD ]:-H]* /B^'X?_%^Q6TU-/$'C";47MH+^2UFO08!>&[=&C*?
MW!;E?DZ< ]:T8[/XI^/I].T:Z'BWP]80C3[#4[V*X$,DS+/.;AXV!SM*&(%^
MN,8KZ_VCT%&T>E SXRATKXO6^LZ!%<3^+IM5MY+>+2IHYT^P^2MP1.;\?QL8
MAU;GH1@TWPE/\7/#6I>(Y[F'Q5KEA:ZQ#=R7,[E9KB(2,'AB@)(QM*_ZLA2!
MT%?9Q13V%+M'I0!\(6^O_%#4?&LMI)=>,+?7;*PM+Z&T%PHL[,27-V9/M@_B
MS"J8'/3CFM'X9V7Q'\?Z1IA@U/QO#H.J75A_:M[>7NV5W\R4SM;..4@,?E@X
M]L<Y-?;'V"V\^6;R(_.E4)))L&YU&< GN!D_G3K>VBM(4BAB2*)!A41< #V%
M CXIT_P_\:I=3^(B:AKWB*R9H)TC%I:M*FT2CR#;LSXSY60VP!CDG.0*KPP?
M&)= ^'%S]F\5&:RNY(VTO[7+_I4?FJ5FGF/S+\A8;)0PQU.>:^XL#THVCG@<
MT ?''BK3/BL+^VWCQ4@$MX^C+HDJ1Q)>&^D*M>C^.+R3'MW<8W=R*[SX0>%O
M'^B?$BQU37=4UV\M-4M]1&IVU_<>99P.DT?V7RD_Y9_*9,8ZCKT%?1>T>@HV
MCT% #(B2#GUJ2D  Z4M !32BGJ*=10!SND?#OPMX?UJ_UC3/#NEZ?JM__P ?
M=Y;6B1RS^N]@,M^-5+#X1^"-*M=5MK+PCHMI;ZMG[?%#81*ET#U$@"X8>QKK
M:* .7\/?"WP?X2TM]-T7POI.EZ>]P+IK6ULXXXS,,8DV@8W# P>O%0_\*C\$
M_P#"6+XH_P"$3T<>(UD\T:L+*/[3OQC=YF-V<<9S7744 9,OA+1)[B>>72+&
M2>=6661[="T@8;6#'&3D#!SU%,/@S0&C$9T33S&':0(;9,!F 5CC'4@ 9] *
MV:* .;M?AKX2L;Z^O+?PSI,%W?(([J>.RC#SJ&W!7.,L,\\]Z>?AYX79-04^
M'=+*Z@'6\!M(\7 ?&\/Q\P.!G/7 KH:* ,"Q^'_AC3-,ATZT\/:7;6$,)MH[
M:*TC6-(B<E H& I/./7FMU$6- J@*JC  Z 4ZB@ HHHH K:B\L6GW3P1M+.L
M3&.-2 6;!P 3P,FOASP-H?QC\3:SJUC>OXTT#1-4>R:Y>6^=YX)1<$7'E3/R
MH\O&=@"XZ"ONRD"@=A0!\$Z_XQ\9^$_%WA_P]K/B/Q3_ ,)(MQI]II-O;7:[
M);8W9$[7B=9&:,+\Y!. .1S78Q:9\6(?%.@I)_PE,>H)<6RZ?]ED1=+CMC,?
MM8O%_B8Q[L$\CY=N*^MI_#VEW.J0ZE-I]K+J,*E8[IXE,J#T#8R*O;%]!0!\
M&:'X%^+/A:;P5H^BW'B71M$L;J=5$@DN6^T&[8NTQW@-$T1&TOD<GC-==K/@
M?XJ6&@W][;^(/%RWFL6NI-?QK-YZVS)>C[*L$8(,>82PRA#$'.<BOL8 #M2!
M%!SM% 'QYI'A_P"*OB;P_P"';*^'B/08Y[:QM+RXM[W-VL0OB97\TC>&,.,Y
MY /KS72^(M&^)UI\)=$L;"?6+C7;*;5(1=2,KW1B$,ZVKNQZMGR\-USC-?3V
MP#L*-@]!0.Y\9:C\&/'MQJ:6$FL^+KBUTZ":\LM7DO@;P73V8+1^=UV&8?=Z
M9R.E9?C?PC\2=0\6V.N7MAXJ-W ;A+2ZT%TBDCEDMK+9YGK$94E+#ID-GBON
M'8N ,# I=H]!0(^,-9\"_$67Q'%KM_:ZW/XB.E:Q8V\MC(!;),\D#1[D'R[6
M EP2.H%-UC2?B_/JOB=+"X\7V^M30W27EP)D%@(RRBU-BO19%&<D>^[/%?:.
MT>E&T>E SR_X(>'M<\)1^)]&U6]U34].M-68:3=ZS/Y\[VS11M_K#RPWE\9^
MG2O4:3 ]*6@0E&*6B@"*7@C '-? MUKGB7Q]\1=6\*6^I>(-<UK??S:Q9R72
MRZ:C1W<(M3 @_P!643/''(/4Y-??Q /49K/L?#NEZ9>75W::=:VMU=',\T,2
MJ\I]6(&3^- 'R/J=[\5];T=[>YLO&-EI=A;6EIJ[6<JI>W8%Q*9GM&SG=M,.
M6'.T'%6=7M/B@_B'P[):OXU^T)%9?V0TT\?V95$G^D_VD%X=S'Z\^G-?7VQ?
M04NT>@H'<^.+>S^)O_".>(5N6\>'4I+R,Z\5N(]KIYK;_P"R^Z Q[<!<#;C^
M*JM_\-?B)\0?!FI6.N7?C$:5!H%ZVF69OS#<SN;DBW2Y*'YYA#ZGGC.37VAL
M7T%&T>@H"Y\;76D?$&T_L=)H?'$6@K,_V*+0YE2\%R%B$!N2WWH@!)D-E2<Y
MJ;6]-^*UQXL\5>1_PE#ZG)%?+,7E5M):U,?^BK;)T$H;&2.<[L\5]A[%]!1L
M7T% CY/^'7A;QU=?M"Z7JGB>UU^YN+*6^^U75Q(ITF*!DQ:BV4?=;9@-@9+;
MLU]8@4@0+T %.H 3%+110 4A -+10 FT4FT'M3J* (;I6-K,$SOV-MQZXKY
MC\#?%*[A.K3W_B2.\L6T^"WTM;@"TFBDDD6\,D/1_D*Y)Z<$<U]BTFT>E SX
MMT[X8_$CPWX5M_#UF=<U'2KFSCDGM=0E65(9&MKA)(4_N)DQ#:.,X]ZRM!\
M?$>^^',OAVVM/%T.BMIPM)+76KA3<K<_8W641,.5B+; H'&>E?<X4#M2;1Z"
M@#XMTS1_B;8ZKI4&E1^-+>:VM;.'2DGG7^SX].6U03)<J>6N/-$OS-EON8(%
M?2_P3\-W_AOX>:7#J]]J>H:M,GVB[EU>X,TXE;EER>@'0*.!7>;1Z4!0"<#&
M>M A-H]*7 I:* $  I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^"=S?G3O,<_Q'/UJ,<#TH_6C<"SI[L;M 6)'/!/L:V:Q=/\ ^/R/\?Y&MJD
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M$&GV5U";LP))I1EDUQXID6*$;/E4NK8W)QT(SS7T)\./B1XM\1_%;4_!NJ+
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MNAAG# 9XW9QVKE-/^$?P7O?#DM_8Z/82Z5K$R'SH2_S,)#MV8.4 8MTP!DT
M0^'OVJ$\2W]J;3PO=-HR6J7&I:C]JC_T,OYAC4)G,F5CR2O3('-6?@M^U+IW
MQA;Q R:#J&DVVEVPOH[B9=R3P$L,@XX?Y>5]QS7367P+^'FE7^BZC;^'K*WF
MT>V%M9L&(6.$$D C.& W'!.<9-:'@OX7>#?A[+J!T#3;?3CJI!F02%A(.?E"
ML2 O)X''6@#SRT_:AU"^T&RN8? ]U_:>L720:)8M?P@7L;1M()&?.(\(C$@\
MYP!FLH?MB7-]<VT.E^ =0OV+1VMU_ID2"WO&>2,0Y)PP#Q,-XXQ@UWP_9Y^&
MT>DZAH@\.6D=IJ$XNI8ED8/Y@S@H<Y7&3]W'4U8;X?\ PV\'V%N[6&F:;:6T
MEM#&S2!561"?)4\_>R[=>23WH&>6S?ME2:KI%Q=6/A.ZM;2*TMS<:A+<Q,+2
MYN$?RT\O.9 '0@D=N:@\.?MK6[:DFC7?A^^U&XMK)C=ZE:KMB-TEN9F7;CY4
M.-H;/4CC'-=7X*^ 'PLU/7+_ ,9:?%;:O974<<-I!T@M%B#QL%&><L7.6'!S
MBMR/X6?"P>-Y473+)-?.E[I(5D8*;0CR?,(SM/'R[NM '"P_MI?V;#)>>)?
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M-/BO2M LOM\,,>J6\>FVR^3J#E8H(Y7:Y1>W(8<XR:^MS&I.2.:7RUSG:,T
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M>@HVCT%+10 W8O/ Y]J=110 4444 %%%% !1110 444F: %HI,T9H 6BDHH
M6BBDS0 M%)2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%)F@!:*3-+0 4444 %%)FB@!:*3-% "T444 %%%% !1110 4444 %%%%
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M.F2VUFY->]Q>-O#]QK!T>+Q!I,FKEGC_ +.6ZC:XW+]Y#'G=D=P1Q6NY+D9
MZ]ACT% %K3_^/R/\?Y&MJL2P_P"/V/\ '^5;= !1110 4FX>HI&&166UK?17
MQG-XK6O4PF/E1[&L*M1T[6BW=]+:>;NUIZ7+C%2OK8OW%[;VD7F33QQ1YQN=
MPHSZ9-(;^V6=(3<1"9QN6,N-S#U KE)6BU+0!Y%N]V#)*@DC0%HR2><-^55(
MM%O5VQ&PQ=.T#QW(P1$J@97/4=#P/6OGJF;5E*/LJ?-%I.ZN]U>UTNNR>W=]
M#T(X2%GS2LU?L=U)/'"NZ21$&0,LP%1'4+7SI(OM,0EC&YTWC*CU([5ROB'1
MM<ODMS_HUTL4L;B,;EPP<'=[X ID>A2W-^89;1HOWLKRW/&'5N@![]N#Z5=7
M,\4JOLX4&EI:]];^B:7W[+7="AAJ3AS2GWV.QCNH9@A25'#C<NU@<CU%2UQV
MGV&HZ=?PF* O [-_K,952V3],Y)_&NP%>K@L3/$P;J0<6OZT.6M3C3?NNZ%H
MHHKT#G"BBB@ JCJLUW!&K6ELMRV?F5GV\>U7J0UG4@YP<4[>:M^MT5%J+NU<
MR!=2R7$ E4VX:%V:/()4\5E?:L/(BW;-;%TW3*V=J\YR>QX%;\VEV\NH1WQC
M_P!(1"@;/8^U8]WXW\-:?XAC\/W.KV,.L3\I8O(!(V1D<>X&17CU,+5J/WYV
ML]/-6MKLE=[I?([:3YM*<&]+NRVL]7UV[DB7$S:3,H+!2&"71Z 9X/K^-4EN
M/W(22X:*%2W[Y),J[8!&#_2FGXK>#!I][=?\))IIM+.407#B9=L;G.%/UP<>
MN*L+X]\*NVEPKK6GM_:2B2R42J1,#T*U$\)*=OWM[*W]:[?B;J%6-[T7OV?:
M_;MK^(]I;N)4FD<GS(P2@X*CC/Y?UJS>:R(;"&9"(S(Q4>9R. >_X5'X@\;>
M'O#%U:6VKZK::?<79VPQW#A2_./RS6$/BEI.I>&]4U/2;>XUI=.NVLGM;:/+
MM,K!<#/ '.=W0#-;?5YT^:,*NK7KKW(C3J55&?LG:^^RUT6NVYLVNJ7-U%=3
M!@6^S;TB7D[L'I5."^G6%?+N/,.Y'+*VX=#D?7VKF-.^//A^>SM[R[AN-,MI
M;:>9)IT&QGA)$D*D9!?N /O9XKT#P]>_VQHUE>FRDL#<Q+,;:=0'CR,X8=CS
M7.L'.JHKVUVK]^OS-JU.IA;NK2LKV^XP[_5[B.X25=5M=/BGNK=4^V<*Z,2/
M+3)'SMVKL(<X.:S]6\/V.M1VZ7UG%=+;S)/$KKPDB'*L/<5H1*5SGC/:O8P]
M*5*GRR=W=N_J[GE5)*<KI6)****Z3,0L%."0/J:@6_MGN6MUN(C.HRT8<;@/
MI5#7[J*V%J)7V;[A #SSS7.:C83:EJ%XD-@]HZ+(()50 2.RD%F;T]J\/&YA
M+#RY*4>9W2MUU5_E\]]NIVT<.JBO-V7]??\ (ZY-5LI(S*EW T>[9N$@(SZ9
M]:LB5&9@'4E3@@'H?>N&L_#\T]E<>9;3*J ; ZJLCG;AEXXQZ&M"Q34K"/4(
MI4PBQNXG'5FQP<_YQBN?#YGB)\KK46D^JOY_=>QI4PU-7Y)W:_X!U#3QH5#2
M*I8X4%AR?:G;U/<?G7G$-MJ%[9VD[IJ$L"LCEMX\W?M8,5/9>16C%;ZW]HM]
MYN3<;X]K!AY(C_B#CN<9_2L:6>3J6?L)6=K?U^7?R-)X%1T]HK_U_3.WW#U%
M1RW4,) DE1">@9@,UQWB)-<#PB)99)5PPDMCM0_,."I]O6J%['?P7R7%Q]I6
M42%&=V!C.7&T(.WRT8C.Y4I2BJ$O=MJUIKO\U]WF*G@E-)N:U/09+B*+&^1$
MSTW,!FD>ZAC#EYHU"#<^Y@-H]3Z5S&O6LMW?W480R,UHOD+ZD/EP/<_+52\L
M+_7))TCM6MH;LQQR&X7("(,G(]">*Z*^9U:<I0ITG)K1+77?RLM5'Y23,X8:
M$DG*=OZ7Z7^:.ONM0M;)%>XN(H48X5I'"@GVS44^KV-M.L,MY;Q3-@K&\@#'
M/3C-<E!8W5IY+:AIS:AY<)M0%4,!@\$ ] 1CGVIM]X<OKHW$L4)@C$$*?90J
MMN !RH8\@CIFN2IFN+<.:E1N^UG=*S>NRUV5G?R;T-8X6C>TIZ=]+;_?_70[
ME)HW)"NK$'! /0T^N?T8-_:U_L#)!LB7:W9\'/XXQ6^.@KZ/#5G7I\[5M6ON
M;7Z'GU(<DK)]OR ]*H7DC)<6H5L*6(;Z;35\]*H7.E0W=U;W$L>Z6 DHV3QG
MVIUU.4;4][KRTNK]^@J;BG[QQL^H/'=ZC';:F7CD@;,CN3Y3[@"6 'R=<"I;
M6:Z>QBFAN,QV\VSY9"ZS-N!&TGJ#TQ[UVOV9!OQ$OS?>^4?-]:58%10BQJJ@
MY  X!]:^<CDU7G<I5>^U]+N^FKZZGH/&1LDH?U]QS5EX@==*O7$;R7%NI=BW
M(+$G(]L>GI567Q3<1VD)%W8L69R;H9\HX .P?[1S^E=?Y2H6P@7<>>.OUK)U
M74[72Y(8)+0O$Q!W*@V*2<#\?I5XG#XBC23GB.5)6O9]_)]M&]UO?<5.I3G-
MI4[W=]_(Q'\1:G<1O(OE0Q.6B1=IWHWE%]WYCI1%XEO5LA(UQ;^5F.'[1(IV
MJ2N2[']*TQXKLC+<JD#.L(+LZ@<X."?4=:DF\06$1O8# 66V5"P"#:Y)P /7
MDBO/LG>7UWOW[/SVT;T^3.CR]CV[?UU,_2==NKJ]DD\EKE2B@B)@%P&8;QGL
M0,U1B\;7$EU/%') T6S>DK# C^;&6&>@]\&NX2)0H*(%&   ,8'I319Q+NQ"
M@W=?E'->E++L;R0C#$M6NWIO?Y_G?RL<RQ%#F;=/TU.4\+ZQ+<&\>>99Q'%Y
M@E0DJWS-T'IQ5&T\6W>HW$"+<PQQBYBS* ,,C9^4\\?_ %Z[.'2X;:\FN8X\
M2RJJ,>P4= !^)J9;.$# A11G)&T=:SCEF-=*G3=>W+>^_O=M;K_/I<IXFAS2
MDJ=[VMY=R=>M.IH&*=7U2/+$Z5%<7D%I"TLTT<4:_>=V  ^I-/D.%YKEY)XK
M^PNC' UYMN6'RH&:,X^\ W4BN#%XKZNK1MS-.WR_K_AC>E2]IOL=$VHVJ21(
MUQ$'E&8U+C+_ $]:<EY!('*S1G8VQL,.&]#[UPT.FS16VFV,^FR!45=]RL89
ML!CM7/8XY-7+C1+K3[MI;.%I(T*X#X.3R0<=\9//O[5XL,UQ,ES^QTTOO=75
M]FM;=].QVO"TD[<^ORMO^IV>X8SD8^M-CFCE7<CJZ],J<BN,UN74)M7MX(S<
MI-]F#K' V$67=C+>HJI;:?J]LDR0I=Q+N8S#<,$%\_NO0XS6E3.91K.G&C)I
M7U2_KYBC@TX*3FE<] W#/44A=0,E@!ZYKE+"+6$T^9U\PPJ7\J*X.9RN.!N^
MN>M9,-MK3VT\<ZWWV0RY"*_[S!0\9)SC=55,XE34/W$O>3Z;?\#SW\B8X-._
M[Q:?U_7YG?17,4X)CD20#J58'%/+JI + $] 37&^'Y+N/0M2C17DN(AL2-2
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MS1J.[ ' _.OF70/&.IOI]ZMYKLGEW8M9-4NK:[+_ -G1M<;)1)D?N7P<<8P
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M.M^$/#^E:5?6%O:Q:GIUS<75ZD\*2,5DC^1>N 6QU!H^J4?Y?Q?^8?V_F/\
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MG#_ADOQ!_P!%C\7?]_%H_P"&2_$'_18_%O\ W\6OH^HWDV,!CWH^J4>WXO\
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M=_W\6OHXG I V31]4H]OQ?\ F/\ UAS'_GXO_ 8?_(GSD/V2]?\ ^BQ^+O\
MOZM!_9+U_P#Z+'XN_P"_JU]'TUFVT?5*/;\7_F+_ %@S'_GXO_ 8?_(GSE_P
MR7X@_P"BQ^+?^_BT?\,E^(/^BQ^+O^_BU]&JV1TI0<T?5*/;\7_F'^L&8_\
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M_P#P%'_Q5'_#//Q/'_->-;_\!1_\56WMJG_/M_>O\SS?[.P?_0;#_P !J?\
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M^*I>VJ?\^W]Z_P Q_P!FX'_H.A_X#4_^0/I+-&:^;?\ AG7XK?\ 1==9_P#
M8?\ Q5'_  SK\5O^BZ:Q_P" H_\ BJ/;5/\ GV_O7^8?V;@?^@Z'_@-3_P"0
M/I+(I"BDY(YKYN_X9T^*Q_YKKK/_ ("C_P"*H_X9U^*P_P":ZZQ_X"C_ .*H
M]M4_Y]O[U_F']FX'_H.A_P" U/\ Y ^D=J^@I1@# KYN_P"&=?BO_P!%TUC_
M ,!1_P#%4G_#.OQ6_P"BZZS_ . H_P#BJ/;5/^?;^]?YA_9N!_Z#H?\ @-3_
M .0/I+-&:^;?^&=?BM_T776?_ 8?_%4?\,Z_%;_HNFL?^ H_^*H]M4_Y]O[U
M_F']FX'_ *#H?^ U/_D#Z2S1FOFW_AG;XK_]%TU?_P !1_\ %4?\,Z_%;_HN
MNL_^ P_^*H]M4_Y]O[U_F']FX'_H.A_X#4_^0/I+-+7S9_PSK\5A_P UUUG_
M ,!A_P#%4?\ #.WQ7'_-==8/UM1_\53]M4_Y]O[U_F']FX'_ *#H?^ U/_D#
MZ2S1FOFW_AG;XKGK\==8_"U'_P 51_PSK\5O^BZZQ_X"C_XJE[:I_P ^W]Z_
MS#^S<#_T'0_\!J?_ "!])9HS7S;_ ,,Z_%;_ *+KK/\ X##_ .*H_P"&=?BM
M_P!%UUC_ ,!1_P#%4>VJ?\^W]Z_S#^S<#_T'0_\  :G_ ,@?26:0HI/05\W?
M\,Z_%;_HNFL?^ H_^*H_X9U^*W_1=-8_\!1_\51[:I_S[?WK_,/[-P/_ $'0
M_P# :G_R!](;%]*=FOFW_AG3XK_]%UUG_P !1_\ %4?\,Z_%;_HNFL?^ H_^
M*I^VJ?\ /M_>O\P_LW _]!T/_ :G_P @?26:*^;?^&=?BM_T736/_ 4?_%4?
M\,Z_%;_HNNL?^ H_^*I>VJ?\^W]Z_P P_LW _P#0=#_P&I_\@?2=)FOF[_AG
M;XK_ /1==8_&U'_Q5)_PSM\5SU^.NL?A:C_XJG[:I_S[?WK_ ##^S<#_ -!T
M/_ :G_R!])T5\V?\,Z_%;/\ R776?_ 4?_%4?\,[?%?G'QUUD_\ ;J/_ (JC
MVU3_ )]O[U_F']FX+_H.A_X#4_\ D#Z2S1FOFW_AG7XK?]%UUC_P%'_Q5'_#
M.OQ6_P"BZZS_ . P_P#BJ7MJG_/M_>O\P_LW _\ 0=#_ ,!J?_('TEFC-?-O
M_#.OQ6_Z+KK/_@,/_BJ/^&=?BM_T776?_ 8?_%4>VJ?\^W]Z_P P_LW _P#0
M=#_P&I_\@?26:#@C!KYM_P"&=?BM_P!%TUC_ ,!1_P#%4?\ #.OQ6_Z+KK'_
M ("C_P"*H]M4_P"?;^]?YA_9N!_Z#H?^ U/_ ) ^D0JCL*4 #IQ7S=_PSK\5
MO^BZ:S_X"C_XJC_AG7XK?]%TUC_P%'_Q5'MJG_/M_>O\P_LW _\ 0=#_ ,!J
M?_('TCFC-?-O_#.OQ6_Z+KK/_@,/_BJ/^&=?BM_T776?_ 8?_%4>VJ?\^W]Z
M_P P_LW _P#0=#_P&I_\@?26:,U\W?\ #.OQ6_Z+IK'_ ("C_P"*H_X9U^*W
M_1=-8_\  4?_ !5'MJG_ #[?WK_,/[-P/_0=#_P&I_\ ('TCFEKYL_X9U^*W
M_1==9_\  8?_ !5)_P ,[_%?/_)=M9_\!1_\51[:I_S[?WK_ ##^S<#_ -!T
M/_ :G_R!])YHS7S;_P ,Z_%;_HNNL_\ @,/_ (JC_AG7XK?]%UUC_P !1_\
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M,6HQW\ =&5#MB\H(Y0AB,9((-:>H? R.Z\"Z'X<@NX;2/3XIXVV1%D8R*0V
MQ)QECU-:GQ@UV>7X6:U=:#?%;Z*2&..:W=ODD\Y 0=O/?G%<B_Q7\7:'BSU"
M&POKMM3ET2&X@MWC62X^1HY"NXX7:S9&>JUO*-&G)IQW1Y="IF6)HQE&HKJ3
MT>CNHK7:VS_,V=3^!$&I7^HO]MCM;:\F:0Q00A2@-BMKQCH<KNKG-%_9OO\
MP_I5K+8W^FKK5I="6-Y[>2:WF3R6AQ(KL<MM<D$="*Q7_:$\5V]OJTT(TS6Y
MX%O$-E:6[H]@89_*225BQ#*PR<<=![U?L?B;X^\6Z!!!!=:9IMTUAJ-U+J$$
M!G\T0^6(_+"OA6)<YY/W>*Q<L,WI%W/05+-Z,+2JQ4=%KY)[JUVK>6O2ZU.I
MOO@5/JEU/'<ZI"EA<(GF+;6XCD#BV>!MN. /G! [8Q570_@+?+J=EJ.M7^GW
M4]GY,*0VMD(X6BB1E0E?[_S]>V.*Y'PM\</&,FN:%I6RSO[(6,!EGF^2>\W0
M[FF0[LG:1C&#G!R13[[XS_$'1O"D5U=RZ*UW/966I>>EL\:Q13*Q:(*S_.XV
MC^(=:.?#OWN5B>&S:+]C[2.J26U[/3MIY]=NITNC_ #4/#OBC1=6L-5M[8:?
M;HDQ@A*R7;(A55<9*E>GS8W #%>RZ%)>#3+<ZGY2WQ4><(,[-WMFO +[XR:O
M#/+=6L]IH\%\;-GU74[>9XH UJ9,-%N^4LPVC!&,\Y.*M:)\7_&VHZKI=[-!
MI]MHTE]96-S:&VD$[^=&2TRN3\JC (!!XZFMJ=6E3?+!/4XL7@<PQ<5.NXNR
MW>C[VV[O_AE8^AP0>E+533+VWU&SCNK25)[>4;DDC.58>U6Z](^0::=F%<YJ
MN@W-W=W/DW216UUM$Z,F6X_NGW%='6!XFOYK#[.\*AFS(><X!$;$9QUY%>7F
M,:+H.5=-Q36S:>NG3R;.C#N:J6I[O_AQUUHOV@:CME %U"(AQ]W (S50>'IK
M75YKZ"5$W GRP"/,;;C+?EU%9-WJ&J2SPB9P[6Q:8QVX9!+A-P7KZTMMXKU*
M2R#R&V@5G %P5)5,C." ?PKY>>-R^=7]Y3E%IW3\U=OK9:R>[MWT/35'$1C[
MLDTU;]/GL:?BJPO;J*UDM81-<('0J0"HW#!.#56V\%M'<":1T(,?S#G*OLV\
M<XQ43:S>QZA<L91<#?$T4"J1@>622#W!/K2VWB/4[QHX(9+9WDD4?:!$VU,J
MS%2,]1@5G.IEU?$NK6C*4F]%IO'W;K7K9==-+V+C'$TZ:A!I*V_D]?P_JY>D
M\);D55F5<1+'@)P2$*Y_6JMSX.N[JY@DDO5V1A0%"$8PNW ]J-/\47LNIV45
MPL20S(,B-26W8.2>>!Q6KK>M/IT-O<PA9K:7Y,J,_,?NGZ9KJ5/*L30E5Y6H
MQ>NK7;6U]E<RYL73FHW5VM!UUH?VJULH3(!]G#*21URA7^N:HVOA683K+<SQ
MSLJE0!'@#Y-H_P :H7?B'4"\T+NBOEHC!&A$BC;GS <],T-XKNX;&.*+8UV%
M8,'4G&"H4G\ZSJ8K*ZE1RJ0?N_BU9)6OJU;;??0J-+%1C:+6OZZ[D<?AK4%U
M!+:-1';1 L+IE!.XH%X[_A6EHOA.?3K\W<URLCM('*J/1-M4)_$^K623>8D,
M[*75?+C(P58#=R>F#T]JZ#PUJ-UJ>G-+=K'O#E0T1R&7L:G 4<MJ8E4X*;FF
MY*][+IT=MMOQ'B*F)A3<I-6>FG4V5^Z*=2+]T4M?>'A!13)IDMX9)9&"1QJ6
M9CT ')-5M/UBSU6R@N[2=;BVG19(I4Y5U(R"/PI7'9VOT+3_ '3VKS7Q]\75
M\$:__9YT6ZU&WAM%OKV[A=0MM 7V%B#RQ'7 [ UZ,\JL-H/S'I7FOC/X7^&/
M$OC?3O$GB*595CCBL;>TDD*1O+YF]0V"/,R<?(P(X'%8U>?E_=[GH8'ZM[;_
M &I-QL]%NW]Z_P OR.;UW]I>VT2*-W\/7TPN;J>&T2([WN8H6*R2@*#CD< ]
M:O77[0UK#+/<1:!?3Z,CO;QWX=5WSI#YK1[#R, [<GN#75ZO\*/"NMV4%K<6
M!1+6>6>-K>YEAD1I&+2#>C!MK$G*YQ[5R4W[/>F7WQ&G\27]ZLVGR;F338HV
MC4DQ",[R'PWRC[P4,>,DXKEDL2GH[GLTJF33C[\)1:3[N^NEK/>V]]-_*U?4
M_P!HH:3X;EO[SP[-;7\%P89;":ZC#A1&LNY2/OY1AP!P>M2K^T?8I,9Y=#O8
M=!$/F'4RRXW^1Y^S9U^Z",^M=!JWPA\"^.85N;K3//WLS"6*XEA=OD$;*2K
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M8226+VUU;*643P,<CY@05*L,@@YKFKGX9_#FWO;#PR\)CU,F2^C5+V=;J0'
M=WE#;V4X .XD' KAJ>VN^622/I<+++N2*KTI2DM7R]K.]]5UUOVTN0:A\<TC
MNYYO[-NK71[2]%J]Z^T^>WDB5E"=5PK <]ZM:/\ &];S4K73=1T&[TO4+F1/
M*@DD1PT+Q2R)+N''_+)@1U%=9+\/?#5Q'(LFF121S7;7K*S,5>4QB,MC/.5
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MO$G@S5=:L[.&YT^WN&@GCE1(M\B2 <D\?>P<DUHCXG^"[EM2']O::[:<A^V
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M*"-0B(O 51T%:-J*LCS:%.IBY^UJJT>SZ]M.B6^NK?DBQ@>E+116)[H4444
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M4=VE8JFP@+9,$?\ WR*L(,*!C%.HHC",=D#;>X44458@HHHH **** "BBB@
MHHHH BDC64$,H8>A'!J,6<(((@3/^Z*LT5#A&3NT.[16:SA8Y,"$GJ2H)J5$
MV  # '&,8J2BA0BG=(+MA1115B"FOT'&:=10!R=[H%U=?:XX@JL+G[1'))N
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MFVLSZ=J!M$5Y"NY!;/+N/XKCZ&J6B?%GQ1K$^GZ>-/L8Y=219+74YXI(;?\
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MQAEG@>$31J%P9,C.U?4YX^M3:<5<"2;PAH]QYGF:?;OYDB3-NC'+H,(WU
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M@^(=>M-,TMWOFN%9Q(BD84#*N >JMS@CTJY1J[NX'=HFS/.<FGTU6W9]J=6
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M8*O8#YL =#71V7[/7ARQUV+54N;]Y8722*)Y4V@K(D@!.W)&Z)>IX&<5:O\
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+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>avte-20240930xs4016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 avte-20240930xs4016.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &F W8# 2(  A$! Q$!_\0
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M** "BBB@ HHI,T +1110 444F: %HI*6@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#Y,_P""D>BKXE^"6D:09'B%]XAL8/,0X*EI,!L^
MQP:Y[QYX_F\;?LEZ?X-4W5MJVL-/H%P[_-*D=JK/,[]QO2(C/^V*]J_:D^$6
MM?&3PAHFEZ'/:PW-EK=IJ,ANV*J8XGW, 1WQTKC+3]F76[/XO^//$?\ :5M-
MH6KZ7<II=HS'=!>W$025V'0+\BX(YP30!S_[/?Q<U/0+;X$?#RVM+5M'UCPW
M-<2W+EC/&82P0*<XQ\HSFK^I_M;:]I]KXOM8M#L[O7+?Q3'X8T*&,N(Y'D7(
MDG.>B\D[>H%5HOV=?B%X&@^$NO\ AE]$U3Q-X/TR?2[O3-0F>*VG27=\Z2*"
M05+=,<U1LOV3O&]UX;\27VHZSIT/B^;Q1'XITM[;<;=9%7!@DR,[<97<.>]
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\+0:C=^'?"L92SLK@SJ%#9.'D"'!< 9%?;XZ4 +1110 4444 %%%% !1110
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M\*O^@)XR_P#!!/\ X4?\/0OA5_T!/&7_ (3\_P#A0!]@L P(-</\3?@MX/\
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M_P#"@#["I,U\?#_@J%\*_P#H">,__"?G_P *#_P5"^%7_0$\9?\ A/S_ .%
M'V#FC('>OCW_ (>A?"K_ * GC+_PGY_\*!_P5"^% 8&72?%\$?\ %++H,ZJH
M]2<< 4 ?85+7.^ /'VB?$WPEIOB7PY?QZEHVH1"6"YB.0P/\B.XK;N[R*Q@D
MFGD6*&-2[R.<*J@9))[ 4 39'K1FODK6?^"F?PBTO5KJSM(_$6N0V\AB^VZ5
MI$L]N[#KM<#!JE_P]"^%7_0$\9?^$_/_ (4 ?86:,U\>_P##T+X5?] 3QE_X
M3\_^%'_#T+X5?] 3QE_X3\_^% 'V%FC-?'O_  ]"^%7_ $!/&7_A/S_X4?\
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MAM^\6<'*GN"*J6G[)W@FR\*Z3H40O1%8:PFNO=FX)N+N\7GS)G/WB>]>3?\
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MW\/RC&.>IJ'P]^R!X6T77=9UVZUC7=:U_6M&FT/4M4U&],DUU;NRL-W&,IM
M4@#BO-?^'H7PJ_Z GC+_ ,)^?_"C_AZ%\*O^@)XR_P#"?G_PH ]QU3]GGPSJ
MWPPT'P)/)>?V-HLEO+;,LV)286W)N;OS5GXJ? O1/BG_ &5=SWE_H>OZ02=.
MUW2)_(O+4,,.JO@\,,@@@]:\%_X>A?"K_H">,O\ PGY_\*/^'H7PJ_Z GC+_
M ,)^?_"@#V71_P!F+P=I?PV\3^#Y5N]2A\3J_P#;6I7DV^\OG88,CR>H[8Z5
M7TK]E/P3I&N_#G5HENVN_ EH]GI6^;*E74J3(/XCR>:\B_X>A_"K_H">,O\
MP03_ .%'_#T/X5?] 3QE_P"""?\ PH ^P5&#[8I<CUKX]_X>A?"K_H">,O\
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MWR*0VD./]4G_ 'R*FHH @%I#_P \8_\ OD4OV6'_ )Y)_P!\BIJ* (OLL/\
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MC;<K#U!%<4Z<J;M)#+%%%%9@%%%% !1110 444A.,4 %&0*8TRA"Q("CDDG
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MJMNIU9GJA1110 4444 %%%% !1110 4444 %(3B@G%1SSI!$TDCA$49))X%
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M:V)"D/!'KFEH- '4_#"\-MXDDAS^[G7[OTKVWP+KS>$?B7X8UB,E5AN@LO\
MM*3C%>&_#6V:X\5&1>5A3+'ZUZK= M<V(7ES<IM _P!X5A45[IC/U&MYUEB1
MUX#C</H>:EW<5G6,3/H=LBMY;FW4;@,D':.:\L3X0^/! B?\+BUHN+W[3O\
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M*XJR_=L^VRB3CCZ5N]OP9]%!L4;JP_&.D7^N^';RPTS6)M OYT*1:E;1)))
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M)JUUP.?(CZ'\:=T%C%\ >'7U_5X[R166PMCG<1PS>E>LWMP+>TFFZ!$X7O\
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MY5>71+QC@A5J_9:#% PDF<ROZ=A0H28E"3Z#-!L"B&YD&UF^Z#6OBDR!@ 8
MI>>F>:Z8QY58ZXQY589,_EQ.WH*]'\&61LM!MU;[S L?QKA-&TMM<U-(4'[B
M(YE?L?:O5(8UB154851@5V8>-VY'=AH:N9)1117>>B%%%% !6?J^DVFMZ;<V
M-Y ES:SJ4DC<9!!K0INT4 ?"7QE_9KUKX9WMQJOAV%]7\-RN7>W49EMN_ [B
MO(;:]AN251ML@ZQ/PZ_45^I+0HZE64,#P01UKR3X@_LP^"?'\CSR6;:5?,23
M<V&$9C[CO7ITL996J?>*Q\+X(QFC)'_UZ^A=7_8<UBVE8Z)XKB,(/RI>1%F_
M,5D)^Q?X],F&\0Z8JY^]Y1KL6)I-7YA'B(RW3-5S>(TRP0*]Y=N=JP0#>Q/;
M@5],:%^PU)+,K>(O%#SQ#DI8)L)]LFO<_A[\"?!WPX"/I>EH]XO_ "]W #RG
M\:SGC*<5[NH6/ /@-^RY>ZK?6_B7QM%Y,$1#VNE^_8O7UY;Q1P1I'&BHBC:J
MJ. /:I!& >*<% KR:E2565Y#M8 ,4M%%9#"BBB@ HHHH :4!.:\3_:$_9XM/
MBM;+J>FNNG^);13Y4ZC E']U_6O;J:4!]:N,Y0?-$#\P-?TK5?!VIR:;XCL)
M-,O$;'F.,1/[AJKI\X#(P=3W%?I/XM\!:#XWLC:ZUID%_%CCS%RR_0]J\ \4
M_L/:-<RO-X<UNZTR0Y(AG/F1"O5AC(/X]";'RP.1G!Q3MQZ#]:]PNOV+/',+
M%;;Q)ILJ#^]$1_2I[#]B3Q9<D?;_ !18Q1GJ(H6S^%;_ %BE_,(\#DFCM8]T
MTBQ+ZN:Z3P#\-/$OQ8U!;/0[*6WL-P$^I3(55!_L^M?4?@K]C/P?X<N8[K5I
MKC7KA2"4N6_=9]EKW72M&L=$LX[2PM8[.VC&%CA7: *YJF,2TIH=CD?A)\)M
M(^$OAQ--TY-\[?-<73??E;N?I7> =Z0(%-.KRFW)W904444@"BBB@ I",TM%
M &3XD\.V'BC2+G2M2MENK*Y0I(CC/XU\+_%_]GO7/A+?37>E02ZQX7D8LFQ2
MTEOST(':OOQD#'FHI;>*5&C=!(C#!5AD8^E;TJTJ3TV$?ES;74-T/W<@9^\9
MX8>Q%38QP?RK[>\??LI^!_'$S7"VLFBWCY)FL#LR?4BO(M4_8>U^VD/]C^*[
M=X1]U;J$EL>YKUHXNE):Z"L?/V2.F:4Y(R>GJ:]MC_8O\>.^)/$.F(F>6$1/
M]*Z?P_\ L-QR2J_B/Q-+<J#]RQ7RP?Q-4\322^(1\R13M=W26EA#)J%Y(VU8
M+==QS[XZ5]-_ ']EVZ@U"V\4>-45KB,A[33<96/T+>IKW7P#\%_"7PWA0:/I
M<27('S74J[I6^IKNA&._/UK@K8MS7+#1%6%5%50   !@ 4ZBBO/&%%%% !11
M10 4R105I](1F@#Y^_:)_9N3XB,?$'A]DLO$D*X(Z+<@=F]Z^.]4M;[PWJ4F
MFZ[92:7?Q':RRJ0C>X/>OU$* ]:Y?QK\-/#?C^R-OK>E07HQA9&7YU^C=:[J
M.*E37++5":/SA4;AN!!]Q1^9KZ@\3?L-Z;)(\OAS7[K3W;GR;O\ >(OTQ7'S
M_L6>.XGQ!XCTV5.Q:(@UZ$<32EU%8\///K3)IXK90TTBQCMN/6O?]/\ V(O%
M-RX_M+Q391Q=Q!"=WYUZCX(_8[\%^%YTN-0^T:_=+@G[8V8P?84I8JE%:.X6
M/EWX;?"+Q+\7]06'3K:73M&# 3ZC,A7Y>X4'K7W=\-OAMI'PQ\-6^CZ1 $C1
M<RS$?/*W<L:Z33],M=+M([:T@2WMXQA8XEVJ!5G:*\NM7E6\D-*PJC %+2 8
M&*6N884444 %%%% "=:SO$&@6?B/2;BPO8A+!*I4@]O<5I44T[$RC&<7&2NF
M?)'CCX?:G\.[UED1[K2&8^5=(,E!Z-7/Q.LR[T<.I[BOL^^LK>_M9(+F%)H7
M&&1UR"*\E\5?L[:7J,TEUHUT^E3MSY7WH3^%=]/$)Z3/S_'</U*<G/":KL]U
MZ'AA_6@5V>H_!'QAIKE$$&H+V:(;:IQ_"?QI(X7^R1%VW,<BNGVD.Y\Z\%BX
MOE=*5_3_ ".9(]!449ENKE+6RA:\O'X6*,9P?>O4-&_9VUG4&5M6U2.UMS]Z
M*!/G_.O7?!GPWT3P3"%L+<-.1\UQ* 9#^-93Q$(_#J>KA<CQ>(E^]7)'SW^2
M_P SE_@]\*/^$0A.JZIB;6;@<^D*_P!T5ZDG3ZTH'%+7FRDYN[/T3"X6E@Z2
MHTE9(****DZPHHHH **** $P*\:^.7P6'C6+^V-' AUVW7@ 8$Z_W3[U[-3=
MM--Q=T85Z$,1!TZBT9^?S/+;7DEG?0M8ZA$VUX)1@Y]1[54U?0;+7(]EW""P
MZ.O#5]K>/OA'X=^(,7_$RM ET%PMY!\LB_C7B.O?LM>(=,=VT+6H;NU'*Q7,
M9\SZ9KKC5B]SXO$93B*3]Q<R_$^;;CX8_,?L]\44]F&<4R#X8LS8GOMR^BBO
M:Y/@EX_BD*?V2LO/WP<"M32?V<_'&KOBXFM=+C[^8NXUISQ[GFK+ZTG94F>3
M:;H6F>&H244*W>23[WX5W_PY^%.K_%.]1O+ET[0$8&6YD4JTH]%^M>T>#?V7
M]!T*:.[UBXEUN[')27B$'V6O9;2SALK=(((DAA085$7  ]A6,ZO1'O83)G=2
MQ&B[+]2CX9\.6/A;1[;3=/A$-K @4 #K[GWK5* T!<4ZN4^MC%122.>\=^#+
M#QYX1U+0-0,D=I>Q&)GA;:Z>C*>Q!Y%<G\&_$^HW5M?>&=?C-MKFAR?9]LLZ
MR27-OTBN#CGY@.>.H->E2G"9SCW->4?%;P[?:)JUE\0?#6G6MWKVF((+V.>X
M\A;BP)S*"QXR@^<$_P!TCO04>LBEK+T37+7Q#IMIJ.G74%Y8W*"2*>WD#HZG
MN&'!_"M,4 +1110!%N.37CWQ6GC^*/B!/AI:6^EZOIA*OXLM[U2YM[-XV,:J
M!T>0C@]0 37:_$WQ_9?#CPS-JEY(JRR.MM9Q&-I#+<2';&NU?F(W$$XYP">U
M5/A1X&NO!_A\S:U<VVI^*-0;[1JVJ6]MY(N9,G;D>BJ=H^E '@/PB_X)\^$O
M@/\ M&Q?$CP9=R6.EFSFMVT.0;E1G7&Y&ZX]C7UO%]V@1@CGOZ4Y5"C Z4 &
M!6#XG\,1Z["&0^5=)]R3^AK?I,5,HJ2LR914U9GC]U#/ILYAO(S$XXW8^4^X
MI!R,]?QKU>^TZVU"+R[F%)%/9JY:]^',+$O97+P'^Z_*UP2P\E\.IYT\/*/P
MZG(X-'-;LG@35D^[=0N/I2Q^ M5<_O+J%%]A6?LY_P IC[*I_*S!8A%RQ"CU
M)J73M.N]<G\FT0JA/SS-T ]JZZP^'UI RR74KW+_ -TG"UU%K:16D2QPQK&@
MZ*HK6&'D_B-X8:3^+0IZ%HD&AV2V\0R>KN>K&M.DQ2UWI)*R/12459!1113&
M%%%% !1110 AJ)W8.P S4U02,!)CO]: .-\&?%72/''BOQ7X?L%G6^\-W*VE
MZ94PA=AD;3W&*P!^T=X0BMO'-Q=3S6<'@^^_LZ_>:,C?-C*K&!RQ/ 'N:^?_
M  )X6^(_B#]H/XWMX&\=V'A&WCUB(7$5YHJ7QE8Q\$,S#'TKE/!&B:1-I7QM
MT#XH>*)/MUYXTM[1?$.G6OV?%\4_=2A%R$ <=^* /I+PS^U'I^J>*-)T/7O"
MGB'P5)JQV:?=:[:B*&YDZ^6K G#$<@'%;WQ#^/FE>!M?3P[8Z5JGBWQ/Y0N)
M-'T.'SIH(3TDDR0%!XP"<GM7D'B'6_BK\#+KP]=?$;4-!^*/@NXU*SL1?)IX
ML]0L9Y&$<<BH-RR<D$G(/7 K;_9E$L?QI^/T.K$?\)(?$$,A)^]]@:-C9X[X
MV4 >K?"?XSZ)\6(K^*Q2YTW6--<1:CHVH1^7=6;GH'7T(Y!'%>@UY_H/B_P9
M/\5=?\.Z8(#XR@M8KK4S#;G<(VXC$D@&,_[.<XKOQWH 6BBB@ HHHH ****
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MEK'&I5PDDJ%I2S;BQ!!('O0!]8_$+]H;PY\-M?U32=42[:YT[1SK<QACW+Y
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M?27OB33=-U2=;G4_#VEZU-;:5J$@(+&>V7Y7WX ;U KV%- LX=&72H(A!8+
M+588^-L07:%!^G>N)^*WQKTSX62Z1IRZ=>^(?$NKNR:=H>EJ&N+C:,NW)"JJ
M@'YF(':N:E_:DTFR\%)JM_X:UW3]>EU%M)@\+W%OMOKBZ7^"/G:ZX.=X.W'>
M@#J-/^!GA'2/A3=?#E;![GPI=02V\MK=2&1BDF2WS'G.3D'L0*XZ7]CKP(-
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M0JC R?I5RB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI:VS]FBSUVC^52TU,!0!V%.KYX^Z"BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M] "*-HQ2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH 1C@5\^?&+]B/X:_'/QQ/XJ\31ZLVJSPQP.;2^,4>U%VKA
M=IP<5]"4F!6D*DZ;YH.S ^1_^'8'P4_YY:__ .#/_P"PI/\ AV!\%/\ GEX@
M_P#!G_\ 85]=45O]<Q'_ #\8K(^1?^'8'P4_YY>(/_!G_P#84?\ #L#X*?\
M/+Q!_P"#/_["OKJBCZYB/^?C"R/D7_AV!\%/^>7B#_P9_P#V%+_PZ_\ @K_S
MQ\0?^#/_ .PKZYHH^N8C_GX_O"R/D;_AU_\ !7_GCX@_\&?_ -A1_P .O_@K
M_P \?$'_ (,__L*^N:*/KF(_Y^/[PLCY%_X=@?!3_GEX@_\ !G_]A1_P[ ^"
MG_/+Q!_X,_\ ["OKJBCZYB/^?C^\+(^1?^'8'P4_YY>(/_!G_P#84?\ #L#X
M*?\ /+Q!_P"#/_["OKG-+1]<Q'_/QA9'R+_P[ ^"G_/+Q!_X,_\ ["C_ (=@
M?!3_ )Y>(/\ P9__ &%?75%'US$?\_']X61\B_\ #L#X*?\ /+Q!_P"#/_["
MC_AV!\%/^>7B#_P9_P#V%?75%'US$?\ /Q_>%D?(W_#K_P""O_/'Q!_X,_\
M["D_X=@?!3_GEX@_\&?_ -A7US1FCZYB/^?C^\+(^1O^'8'P4_YY>(/_  9_
M_84?\.P/@I_SR\0?^#/_ .PKZYS1FCZYB/\ GXPLCY&_X=@?!3_GEX@_\&?_
M -A1_P .P/@I_P \O$'_ (,__L*^N<T9H^N8C_GXPLCY&_X=@?!3_GEX@_\
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M\%/^>7B#_P &?_V%'_#L#X*?\\O$'_@S_P#L*^N<TM'US$?\_&%D?(O_  [
M^"G_ #R\0?\ @S_^PI?^'7_P5_YX^(/_  9__85]<T4?7,1_S\?WA9'R+_P[
M ^"G_/+Q!_X,_P#["C_AV!\%/^>7B#_P9_\ V%?75%'US$?\_&%D?(O_  [
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'_N%W?\ \:K\9[49/(K<L^@J7DV'75_A_D/F/V$3]O/X'R?=\9G_ ,%EW_\
M&JL)^W)\%I/N^+R?^X;=#_VG7Y'V?:MRR[5#RF@NK_#_ "'S'ZMI^VO\')?N
M^+<_]P^Y_P#C=6XOVP?A+-@IXI)_[<;G_P"-U^6MEC*UU>E\XK"6645U?X?Y
M#3/TMB_:I^&,^-GB3=G_ *<I_P#XBKL7[2/P\F *:_G_ +=)_P#XBOSUTGHO
MUKL]*_AKFE@*2ZL+GW)%\>? ]QCR]:W?]NTO_P 15V+XP>$YN4U7=_VPD_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZI 6BDW49% "T4F11N% "T4F11G% "T4WS!Q33,HZY% $E%-5@W2G4 %%%%
M!1110 444TN%/)H =13#(%QD<&E#^U #J*8)5/>CS!^/I0 ^BF>:,XH$@- #
MZ*8) <X[4>:N <]: 'T4PR#''/TI!,IZ'/TH DHJ/S1Q[\#ZTIE4'!('UH ?
M13/,%'F#&>U #Z*9YHI/.7UH DHIAE //YT"0$4 /HIGFK@GTI0X)ZT .HJ/
MSESC-'G*<8.<]* )**9Y@SCO1YBXSGB@!]%,,J^N30) W3GZ4 /HI@E4C(Y%
M E7!]J 'T5&9D&,GK3MXQQ0 ZBH_.0#E@*7S!S@Y([9H ?13!(#T^M+Y@]>:
M '45'YH]_P J#,@_B'YT 244SS5R!D9I/.7GGIUH DHI@D!H,BCN,^E #Z*C
M\Y<9R,>N>*43*<<]>W>@!]%,\U<4"4,,CD4 /HJ/SE_/I2B53C'4T /HJ,3*
M>_XT^@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXL?"6@_$*RU.VM1ICZ]>&-] FA4JWEQD%65R=_U7% &AH7[8.H?$?POX&MO
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M2EU4K(!W *GL:O?LY?%SX@_&S3[?Q/JOAW0]!\'W<<BP)'=RR:@TB/MR5V[
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M*3D?*2F<-7!_#G]G#QGIGQ0E\86/A+P_\,3!ID]O)I^F7K7-MJMP_P!QIHP
M JGG\:=X%_9R\62?&WPIXPE\%:!\-5T>2>;4[SP]J#2'6PZ%1"\0 "KN(?)Z
M=* #X<?M&36O@/0=%\#^";&V\5^)=<U*UT_37NY?L48ADS+<S2G+@<Y( )]*
MW=<_:P\1_#[PEX]A\5>%K,>.O!Z6]S/I^F74CV=];S.%22"1P&'<88 \5S_A
M+]F/XA> =%\):_I9TRZ\6^&=9U.[32Y9]MO>6MVW*>9CY&P!SCBG>*_V;_B-
M\3-'^)?B37(],T[Q;XIM[*QM-(@N=\%I!;R!OFEQ\S'GM0!W_@SX\>.(?C+X
M>\&^./#6D:=8^*M.EU'1;S2+MY7B,:[VBN5=1A]N3E,CCK7T0M>&:Y\(=?U#
MXZ_"GQ9"+7^RO#>F7-I?AI,2!WB*+L&.1D]:]S'2@!:*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH 0]#7P5_P %$_\ D>O"G_8.F_\ 1@K[U/2O@G_@HG_R/7A3_L'3?^C!73AO
MXJ/D.+/^115]8_\ I2/2? 7_ "(V@?\ 7C%_Z"*W2<>QK$\!1-_P@_A_"G'V
M&+M_LBMMXG/\!)^E?(U/CEZLFE_#CZ(\F_:3\6-H?@1=(MGF_M'79UL8TMD+
MR^63F1E502?EST]:Y'X2^(M-\,_&F?0]*LK_ $[P]KMA&]LE]8RVV;R)0'V[
MP,EEYX_NU['?> (-3\=Z;XHN9;B2XTVW>&UM2!Y4;/\ >D]=V.*;XX^'\/CD
MZ,]Q/<6=WI-ZE]:W5N 71AU7G^%AD&O1IUZ4:2HO9IW?F]M+:VLOQ.V,DH\I
MXK\"/%GB+2/"/B2RTGP7>Z_ ?$.I%;N&[@BBW%P"I5V#<'KQ67=^&-9^%]W\
M+X9=._M367U6\O7TVPE5%1I06\M&8A<+GUQ7OW@#X>VWP]TF]L+&6>XCO-0N
M-2=I@ 5>5@S*,=@12^)/A[;^)_$?AW6+B:>*?1)7F@CC&5<LN"&S6SQM-UYR
M27*[]]=&E?7SZ6*=1.6VAY;H.HWWQ3_:"LK^[TV7PK-X-LWCGTZ^='N;MILA
M67:2#$!CG.,XKC2/^+0^+O\ L=IO_1XKWKQ%\,H->\:Z'XIAN[K2]8TM6B\V
MV Q<P'K#(#U7^58]U\"[&;PEJ^@Q:A?6\>HZH^K&Y55+Q2LX;"@C& 1WIPQ5
M%<O1+ETUTLVWZ[W^=@YDST.W(^SQ<C&Q?Y5Y_P#&WQ/J?AOPUI\&CW/V'4-7
MU&'38[W 8VPD;#. >-V.E:OAKP/X@T34TN+_ ,8ZEKELJE?L=S:Q(A]#E1GB
MM'QCX)LO'.@3:5J4<JQ,RR1S0G;)#(IRKH>Q!KS:;ITZL7)\T5_6S,K*,CQ;
M6]+NOA1\3CJO]M:IXDCMO#EW<1)K,_GRAUP2-^ =A/\ #CBL70_'NM06?AWQ
M!8ZQXPUS7[VYA.I:9?V,HTJ2"9@'$*E L6P,"K \[3QS7KFC_!86^OMK.M:]
MJ7B:Z:RDT]EO454,#C!7"CK[]ZCT[X&I:OIEI<^(M8OO#>FW"W%GH<Q BC93
ME SCYG53R ?05Z?UJA;WWS-+5VWWTV\_+O?0W4EK=G!6MKXGUW3/B%XD;QOK
M=K+H>J7::79P7 %NB1'<4FCQ^]7L!G@5GWGQ7N/'7B'3[#4]0\2:'I4>CV][
M(OA.&07,T\H/WI$5BL:X.%QSGVKH_"GP7UK5;_QI_:VJZMHVDZGK<\TFEP!/
M+O(">&W<L@(X.*[G6/A)#+J-GJ>@:E>^$]3MK5;'[1IZJXD@7[J,C<''8]15
MRKT(3:E9OHUTT7E^2?WC<HJ5F>1-XX\9ZGX7\)6DNK:AI=X_B2;2FU%X#;SW
MUF -DKQD?*Y4_7(S5S7?&FO_  OG\>:+::YJ&LQVHM!IUUK4HN9[5YW",2Y
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M X%:&VBB@! H%+CFBB@!-@HVC.:** ,S4]"T[5KFSN+VRM[N>QF\ZUDFC#-
M^,;D)Z''&16C&@VCM110 _:,TFT8QTHHH -HQCM0$ HHH -@]Z H%%% "X]Z
M ,444 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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77BMMN[/WZG3A2@J=-62V0^BBBD:'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>avte-20240930xs4017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 avte-20240930xs4017.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (< O$# 2(  A$! Q$!_\0
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MP""#VK;\7_'K7M.\<:UX7T;1=/GN[;6=/TFWN+V=UC87-LTS2.%&?E*XP.M
MCWC(]:-P]17RSXD^/OC'Q9X'U>#0=-T[3]6T_3KJXU.Y:XD C,<S0@VV!G)*
ME@6Z=*]#^&.N:H/B!/IES?37UE>:#9:JJ2MN,$S+MDY[!B,X]<T >R44@Z"E
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!,BEKRO6
MOCOIVB_'SPS\+'TZYDU/7=+N-4BO5(\F-(2<JW.<G!Z#%:MA\1;Z?XC>(/#]
MYI,=CI.F645VFKO>1D2EC\RF/[R!>NX\4 =]2US.E_$;PUKD*R:?KVF7J,'8
M-!=(XPGWCP>@[TVQ^)/AK4M)NM3M?$&EW.G6K^7/=172-'$V<89LX!R: .HH
MKGK3QWH%_:ZE<P:UI\]MIK%;R6*Y4K;$#)WG/R\<\UY]X._:8\,^,OB3XT\*
M6S"*'PO:6U[/K$LR?9)HYE# HV>P/.?2@#V*BLS0/$6F^)].CO\ 2K^VU&RE
M^Y<6DHD1OH16G0 4444 )TID[JD3$L% &<DTYAE2*XKXE:E)9^'_ +-%)MGN
MV\D-Z+U;]*X\9B8X2A.M+:*;-J5-UIJ"ZGF?Q U&'Q%XMBO;&5HTLT")+CAG
M!SD#TJ#5O&6J^(-)NM'O7CN(Y"A>YV8D Z[1CCJ.M5=0M186^5.<# _I3])T
MTM 'ES\PSCW[U_/U7'XJK7JR3Y?:7YDMG?3;TT_(_4*>&H1HT^97Y-N][W+&
ME>,M5\,Z0NF6+0QP[RRW+)EX\]0>U)X2U5?#GC)M8O9'G2<,LTF.5+?Q8]*;
M?:7N@<(<KC[IJGIL(OX65VZ#!%1#&XNG5HIS;5.W*GMIY>GS%+#4)TZEE;G^
M)]7<^C+2\CN(HW1U99 &4KT(]:Q_%'@BQ\4ZKH&I7$D\%]HEY]LM)[9@K E"
MCQMP<HZL0P[X'I7/?"S47>RETV9P\MFXV,>IC/(KT05_0& Q4<;AH5XZ<RV[
M/JOO/S/$47AZLJ;Z'GTOP'\"SQQ))X=MV$5K>649+/N2"Z<R7"!MV<.Q)/ID
MXQ3&^ _@XZO'J8TN6.=4C0QQ7<R0R;$\M&>,-M=E3Y0S G%>BT5Z!S'!CX)^
M#?[-73SHD7V,6!TL1>8^/LQ;?Y?WNFXYSU]ZKI\!?!<7B9=?322NH"X2[Q]H
ME,!N$4(DQA+;"Z@8#$<5Z)10!YMJW[/?@;6=)TO3)]&:.QTVVEL;>*VNIH2+
M:3!DA=E<%XV(!*L2.*OV_P %_!]K!/!%HD2Q7#6CRKO?YFME"VY^]_   /7O
MFNZHH XGPM\(?#7@S6YM5TBSFMKJ7>-C74KPQ!SN<1Q,Q1 QY.T"JNI? [P=
MJWBT^)+G2&DU1IX[J0_:91%+-&,1R/$&V,R]B0<=:] I* /-K;]GCP':G6 N
MA+)%JMM)97$$L\KQ+!(V^2.)2V(59P&PFWD ]A4VA? 7P9X?G^TVVE/+>M>0
MZB]W=74L\TEU$A2.5G=B2P4D<\>U>AYHR,]: /,=8_9Q\!ZY;I;W&C/';@S;
MX[:[FA\T2OOD1RC@LC-SM/&:Z+PU\.=+\*Z]J>KVGGO=WT<-N3*X(BAB7;'$
MGHH]\G-=9FC(]:  =*6DR*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** /AW]I'XE:#\(?V\OACXK\333VNB6WA6_ADN(;=Y0'=F51
M\H/4UYS\8;N/QGX__:'UO3KZ:PTO4O FF7EO?&)U$L1?=M.!D;AP?2OT5N?#
MVGW[K)>6-M>.J[0T\*N0/;(KE/B9\'-$^*/@G5?#&HB6RL]1B6&2>P(AF55.
M5 8#H,=#Q0,_.KX;WG@O3?AE\6?';^&=+>UGT>RLXO"6AZCNND4!5EE=DYC1
MVP6QV'-<A<10-\*_VEH]-33QIMSH'A^:*'0+26*S#?:4!$889=@.&<=2":_0
MGX3_ +(GAKX7>*KKQ(^I7WB'6IK(:=]HU!(PJVX.=FQ%"GH.2":]A7PKIB1-
M$MA:K$RA6B$"!6 Z C'0>E [GYF_%+PE#X:L_P!JK2/#^F2V6F_V'X0G>SLH
MW"LF$:X8 =?E+;CUZYJO<Z/X'\2ZQ^T+%HTUQHG@2[T[0I;6^TK3Y)8D*[26
M\K@M%N!WX[9K]/AH%ING8V\1:==DI,2Y< 8 ;CD8[&DA\-Z?;QND=G;QHZ"-
MD2% I3'W2 .1[4"N?-/[ &O66K^"_%D%AX?T_2X;/5O*;4M&$B:?JK; 3/!&
M_P!P= 5'&:^JZJ:?IEMI<(AM+>*V@7[L4*!%'T XJW0(**** &R'"$UYI\3G
MW:II,>> CR8]^E>ER?<:O,OBFNW4])DR,;'3^1KYOB!M9?4MY?FCU,LM]:C?
MS_)G >(%+F%,\,RC]:UE01IM4<"LG7?E:VD[*ZD_G6JK#;UK\/IKWY?(_19?
M!$.O%9.F((]0NHEZ9)^E:O<5EZ?SJ5XXZ#C-.HES1%'X9>AV7PX<IXQG7^&2
MT#$>X;C^=>M+7DOPW4GQC.W\*V0'YM7K!02(5.>?2OVCAF[RZ/J_S/S_ #;_
M 'I^B'YHS61=Z%+(Q>#4+BV<]-IR/R-8U[;>,; ;K&[L-24?\LKJ,QD_\"%?
M5GCG89I:\SF^*NK^'2W_  DOA#4;:%>MWIN+J/'J0/F%;/A+XP>#_'%Q]GT;
M7[2XNQULW?RYU]BC8/Z4 =G12$@=>*,@T +4<S;%SUY J2HY!N!&=OO0!XSI
M?Q]D?Q#XI34K:RL]#T"_DL9Y4DD>YXD2)'V[=N&=QT/%;&N?'WP]IMY>Z?;R
M23ZC:Q32RAH6\J,13&"0LPZ?."!ZUJZE\(M$U'PSXBT1VF6WUR[DOIY4;YUF
M9UD#*?9U4@>U8<OP2\+:-I5^;Z^NF6_B:WNKJYG^:5I;DS$D_P!XR.?SQ0,V
M]$^,WAS7M=N]+@N);>6V>2-IKJ/RHG:-@KA7/!P2*Y?6/V@(='M[Z::UAC%K
M/(C"27:/*298VE+= H#9_"NFT[X.>';2\^U/;M<$RW$IBG;>A:9P[G!]P,>E
M5M3^!'AC6!,EW'+-%,7,D+/\CJTJR%2.XR@X]* (+#]H7PAJ6MZ9I,-W(;O4
M1'Y):$A<R M$&/;<%)'MCUKTY&+*"1BO+]$^ &@^&]?LM3TZYO(#;A0T.\,D
MH3/EALC.$#;1CL *]/C3:@&<^] A]%%% !1110 4444 %%%% !1110 4444
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MBCPY>K=Z7> E<C:\;#AD=?X6!X(KKQR*U-T[ZH6BBB@84444 %%%% !1110
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M\!9YUAAD<\;5S@U3T:'R[1I7^_*=S9JSJ7AO6Y(899M+NHK(M^\^7+G'JHY
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M2[C5_%'QC\2%M:M+#QCI>J6<%Q<1O'83-:R+Y*V\F<,=N[.,8K8ZS]93=0A
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_#CQS_PG&FW<DMHUA?6-Y+975JQR8Y$/7/H001]:["@04444 %%%% !1110
M4444 %%%% !1110 4444 %(3B@G%4[R\V/' G,LO0>@[F@"X&!SBEJDDOEWW
MD?\ 3/(JX.E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,?
MI7E_Q/MRFM:;=$$!U>(GWZBO4),[>!7-^-M ?7M&GCB %S&1+"2/XAV_$<5X
MN;X:6+P=2G#XK:>JU.[!5E0Q$9O8\;U^W,MDSKR5.>*O6THGACD4Y!4'-,CE
M6XB9'&UP2C1MP5;T-4M'D-H\MG+E'5B4!'WE]J_"7%PJ>J_$_2%+FA:^WY&J
M>WO65: 7&K7,O\,>%JUJ%\EK:E@1YAX1>Y-1:; +.SW2,%8_/(3T_.IDN:2C
MT6K!/EBVC;\/VCWWBG3(T^;RW,[?0#_$U[%:ABQ+ @XK@?A?I$AEN-7F3"SC
MR[<$<[!U;\37I Z"OV;AO"O#X)3DK.;O\NGX'P6:UU6Q%H[)6.!^-_A&_P#&
MGPYU#3])VG5(Y(+RV1^%DDAE654)[;B@&?>O-?B+\*O&OQ!\11W'V71([.9X
M+BWU*96CU+1B,&2-&3B7D'&3CFOHC%&VOK#QCYKA^ 7B@N^ES3:8-(L3J,UC
M>HK"ZN)+F,J%F&, +N))!.:=J'P-\8KXDLVM9=*;2);S1;V\FDW^<AL2FY$4
M<'=LR"3QFOI+:*3;[T#N?.6G_!+QA]MCL;W^QHM&T[5-8U:TO+<.;JXDO/M(
M2.08PJJ+DEB,[M@XK'C_ &:=<MO$6GW7DV&JV;V^FI=BZN9H_(EM(E3*1K@2
M XR-Q&#ZU]2[<]3^5!3)H"YY]\(O#&J:'#K^HZS MKJ>LZG+>R01MN$:<+&N
M?7:N3]:]#IH7!SFG4""BBB@ HHHH **** "BBB@ HHHH **** "BBD)Q0!7O
M[V+3[66XG<)%&NYF/I5#0HI;H-J%R-LLWW$_N)V'UK%O[D^+?$PTV'Y]*TXA
M[QQTDFZK%^'4_6NP0 +P,"@5S'U&X^S>(=-':573\>M;(KF/&TK6DVBW0.U8
M[Q58^S<5TXH&+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'5B:ZD_L_?#P_P#,M1'_ +;R?XUT<D8NTGJ.QZ=_PE&D?]!2S_[_ *_XT?\
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MO./^$;B_[_R?XTG_  S]\.R2!X;B)]//D_QHY*?=_<O\P/4/^$HTC_H*6?\
MW_7_ !H_X2C2/^@I9_\ ?]?\:\P_X9]^'><'PW&/K/)_C1_PS[\._P#H6XO^
M_P#)_C1RTN[_  _S'8]/_P"$HTC_ *"EG_W_ %_QH_X2C2/^@I9_]_U_QKS
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M.UBLK>."!!'%&H1$48  ' KA/@UX"G\(>%C+JK_:/$.IR&]U*<]6E;G;]%'
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M'7_09G_\ )__ (BNXVI_SQA_[]K_ (4$1@9\F'_OVO\ A1:'9_?_ , #A_\
MAJ7X=?\ 09G_ / "?_XBC_AJ7X=?]!F?_P  )_\ XBNW_=GI%%_WZ7_"@",C
M/E0CZQK_ (46AV?W_P#  XC_ (:E^'7_ $&9_P#P G_^(I#^U)\.C_S&9O\
MP G_ /B*[@JO_/&'I_SS6C"?\\H3_P!LE_PI6AV?W_\   X9OVI/AVO_ #&I
MP/\ L'S_ /Q%=-X,^,'A+Q_.8-#URWO+E1EK9MT<P'^XP!-:F$)_U,/_ '[7
M_"N&^*'PTL/&6C37=G#'IOB:Q4W.GZI:J(Y4E4;@I(ZJ<8(-'+"_8+'K,;AU
M!!!^E.KC?A#XQ?QY\.M$UN9!'<W4'[]1VE4E'_\ 'E-=E6-FFTQ!1110 444
M4 %%%% !4%TVR"1CV!-3U2U=Q%IMTQ/ C/\ *LZCY8-^145=HBT5MUA"3U(S
M6AM!K.T-3]@MMPY\M3^E:0I4E:"'/XV9TH&G2;XH'<2R?.5.=I/?%7PP)[9I
M7&1Q6/%(FB/%#+)-(MS,0C.,A"?X2?3TJF^75[$[FPR;@!5'4-*BN\-@QS#D
M2IPPJZ) <#(S3L42BIJS$G8P#J-QI "7Z%XL\748R/\ @0[5LP7,=PBO&ZNK
M<@J>M+/$)%P1N'IVK"GT&:RE:XTN3R)&Y:!^8G_P-8>_2VU7X_\ !-?=GOH_
MP.A# G ZTZL&Q\2(]PMM?1FQO.@C?[K^ZMWK92=)" &!)K6G5C45XLB47'<E
MHI*6M20HHHH **** "BBB@ HHHH ***:[8''6@".YG2VC:21@B*"S,QP !UK
MY_\ A\)/CI\5;KQRX\WP;X>=[#08V'%Q<9Q-=?0?=4_C6C\??$U[XMU'2_A;
MX;N/+U;7E\S5+J,\V&F@_O7)[,WW5^I]*];\(^&-/\'>'[#1-*MA::;8PK!!
M$O90/Y]S4[LS^)VZ(V$X&.>/6G4@&*6J- HHHH :_3->(>#YO[&_:E\>:<00
MNI:797Z>Y7*-_2O<,5XCXJQHO[5G@^Z(VQZKH%U8D_WG202#]#4LSGT9X-\(
M]$^,\OBOXN>&/AKXG\)>&=!TOQC>[FU6QENKU&F"R950=FW!R,^]>G)^SI\:
M-?PWB;]HK6(P?O0^'-#MK$>X#Y8U]!:7X8TC1;[4;VQT^"SN]0E$U[/ @5[E
M]NT-(1]XXXYZ5?N+ZVLH&FGN(X(1UDE8*H_$U1H?/#_L1>'M:V_\)3X[^(7B
MT8^9-3\12+&?^ QA?YUK:5^PS\#M(D61? 5I>R+SOU&XGNR?KYKL#6AXV_:]
M^&?@VZ^Q)KO_  D&JDX73=!A:]G+>F(P<?C6-%\6OB]\1H<^#?ALOAJRDQLU
M/QE<"%@/7[.F7/YB@#TW0O@]X!\+A#I'@W0=-V  -;:?#&0/J%S3?%/Q2\$>
M SY>JZWI]E.HP+2-@\Y] (TRQ_*O.XOV?_%_C:)3\1_B/J6HQDY;3/#:C3[4
M>Q89=Q]37I/@SX.>#? $")HF@6=K*O)NG3S9V/J9'RQ/XT <[:?%_6/%:G_A
M$O!.J7L)^Y?ZOBPM_J-WSL/PJY#X4\<^(6$FO^*(M*MCUL= BVGZ&9\M^0KT
M<( <\TN* .7T7X<:!HLHF2Q^T77>YO',\A/KEL_I73K&J+@# ]!2TM "8ILP
M_=/_ +II],DY1AC/;%(#Q?\ 9Z(_X5]=#//]K7@QC_IH:](Q7CFCZU>? ?4]
M6T;7=,O+CPQ<WDEYI^K6,)F">8<M'(J\@@]ZVQ^T5X)(_P!?J7_@NE_^)KLF
MG.3<5H!Z1CZBO![CP3XNM/B%=2>'- N_#]I=7EQ-J9%_'-I%] Z$":.,G?%=
MLVT':H&0220:Z_\ X:*\%?\ /?4?_!=+_P#$T?\ #1/@G_GMJ/\ X+I?_B:S
M]G+LQW/+Y/A#XM34+9U\/W UY[&PAM_$0OEV6+Q;O-,AW;CP?0[LUS4WPX\0
M>$-'A?7M+UC4FN-8TZWO8!Y$<.HN)9&=DV2$R$J1\SE0?NFO=?\ AHKP3_SV
MU$_]PZ7_  I#^T1X)(P9M1/UTZ7_ .)H]G+L.YY;+\#?&>J6>KW-I!-HUZ/#
MMU9Z%!+?[O[/>6]E<6QPQ!?[.X3S#PH?;G S20? K6]3TV&(Z/?C3T&I30V6
MJ206OD2R01I#LAA=E0;U8CD\Y;C.*]4_X:)\%?\ /?4?3_D'2_\ Q-'_  T5
MX*_Y[ZC_ ."Z7_"CV<NPKG#6WPJ\:QWZ3?9G0M+ \SK> %]M@8F).?F_><?K
M6'IO[/\ XAT>>TO+311'>6[:5+&_VXY62-B;HY+=QPQ[CUKU7_AHGP2/^6VH
M_P#@NE_PH_X:*\%9_P!?J1_[ATO_ ,31[.78+GBMK\&?&L]QJ%WJ7A*>XTZ;
M4=,OKG1HY((XY#!/*UP(%$K,_P CKAY&#2>PXKU%O 6OS?L_:_H+6CVM]-+=
M7.G:0TGF26UJ;CS8;0L"06V#;@$@;@,\5L_\-%>"O^>^I?\ @OF_PH_X:)\$
M_P#/?4@?;3Y?\*7LY=F%S"U#X9:GX@^,5GXC@L1;>$[RS35+F.60)/'J21-'
M$C)U'ROSV!2N7O?AKXIT?PEX=AM?#>J1^)K2QE@@U?0=2ACD@E,S.L-S&YV2
MVY!!)(;'(QGFO13^T7X))R9M2/\ W#YO\*3_ (:)\$G_ );ZE_X+YO\ "G[.
M78+G!:5\.?'VA^*YY[5;^+6K[6EU*;6HKY1I0M6C EA:WW EMV $VD\ A@*-
M$^!WB:PE\6V/B*&PUG0]2TB!9+G13)%J%[?)<23^:#(Y42AV#'=\I^10, BN
M^_X:)\$_\]M1_P#!?-_A1_PT5X)[3:B/^X?-_A1[.78+GG6E_#;Q:Z:K>:BF
MJW6J>*/$&ERQS:AY7VFRM[0;FGF6']W%N 8!%YZ9))KZ1?#.QSU->9_\-$^"
ML?Z_4A_W#Y?\*/\ AHKP2/\ EOJ7_@OF_P *%3EV$>E$<UYE^TEQ\'-5[?Z3
M:]O^FRU(/VBO!7_/?4O_  72_P#Q-<]XGUVZ^/KV'AGPWIM]%X?%Y%<ZKJ][
M 84$2-N$<8;EF8U<%*$E)K1:@?0GR^H_.BF[/^F)_,?XT5S77<=RU1112$%%
M%% !1110 4AZ4M(>E 'B7PK)/C_XJ_\ 8:C_ /1=>E<YKS7X4_\ (_?%4_\
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MI'&+R*>W68/C=G.&! QT//-=W_GK5DA39/\ 43_]<G_]!-.ILW^HFQU\I_\
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M9M1Z0Z[=K_[4J$_L.?#]#NM=2\661_Z8^(;K^KFJ<O[9C>'8_P#BL/A1X_\
M"_.&G.D_:H1[[HB<C\*Z3P[^V=\'_$+K&/&EGITQZQ:JCV;*??S0M4!CG]BW
MP_&I%OXX\>VW_7/Q!+Q^=4;C]CIK"&XFLOBE\0S<;2(]VL*S#V#%,C->ZZ'X
M_P##?B6$2Z3K^FZE'C.ZUNDD'Z&M+4]0CLM.GO'DQ! C2R..<*H))_(5G.*E
M&S*BW%W1\YZ7^R[XGEL(I5^-?Q)TR1A\T$U_$Y0^GW.15C_AF/Q\IQ;?M">-
ME8<CSE@D_P#9:]+\*>*])\<>'[3Q[H;7EY93V[&!4!3ST!(Y0]^#@UVNCWXU
M*UAN5WJDJ!U5P0P]B/6HC4M+V<GK^:[C<=.9;'@#?LX_%J-?W'[0_B $=YM*
MMW_PKRO]J+X6?%3PI\&=2N]>^,4_BK2!<6L<VEOH4$33AIE 'F*<CKV%?<I&
M:CGMH;E-DT22IG.UU!'Y5N04?#L8CT#3(\8"VL0QGT05:NK..YC*.@="""K#
M(.?:K 4*, 8 HQ2:NK <+>^"[O1&:Y\,SBS8GY]/F)-M+]/[A]Q4WAWQS!<W
MYL-4B?1=54;?LMT0!)_M1MT85V+K]W'XUD:]X;L?$-GY%]:K<(#E=XP5/JI'
M(/N*\R6&G0?/AG;^Z_A^76+\UIY,ZU6516K*_GU_X/\ 6IJ17*2-@-D^A&*E
M#!NE>>&/7_ [942:_HPZ(2/M,"^Q_C'ZUT_AWQ3I^OP>;9W(DP/FC;AT/HR]
M0:NCBU.7LZBY9=G^G=>9$Z+BN:+NNZ_7L;U%1+.K'AATS4@.:]$YQ::QQ2FL
M7QCXHL?!?AZ^UO4[A;;3K&)IYI&_N@=![GH/K0!Y?^T=\1;O2-+L?!WARX*>
M+_$F^&WE1=QL;4#]_=$#G"*#CU; %=#^S\/"8^$_A\>"KQ=1\-B K;WBHRF=
M@Q$DC!@#N+AB<C.37+_ #PQ?>(;_ %7XG^)8 NN>(,?V?#(/FL-/'^JB /W2
M1\S>YKP3X2_L]_\ "4?%/XK_  Z\2^*/%UGX/\-ZLMUI/AK2]0>RL)[.\W3C
M>\>'D^<N"NX ?C27<A:OF9],_$?]ISX7_"J46WB+QOI5IJ#$JNG6\OVF[9O0
M01;G_,5YTO[3OQ$^(K"+X7_!S6[JU?[NO>,B-(LR/[RQMF5Q] *]4^&G[/7P
MV^$*AO"'@O2-$N,8-W#;!KAL]<S-ES^)KT,1J#G'/K3+/FYO@;\8?B-^]\??
M%F70[23[^B>![<6J*#_#]H?,C?D*Z[P!^R3\,? ;K=P^&HM6U7.YM3UMVOKE
MCZ[Y"<'Z8KV3%+0!7M["WM(UCAA2&-?NH@VJ/H!4^*6B@!,5YU^T)HQU[X+>
M-K)%W.^DSR >Z+O'ZK7HU9OB#3%UC1=1L3TNK:2 _1E(_K2>Q,ES)HY_X.:W
M_P )+\+/">J[MQN],MY2?<QC/ZUV->,?L?WIN?V?_#=N[$S6!GL9 >JF.9T
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MB6:*12DD;@,K*>""#P1CM[U\Q:Y\(O%?[-6MWOBSX1POJOA.XE,^L> Y)/D
MZM+8D_ZM^IV=#0!]2 Y%+7!_"/XS>&?C3X9&L>'+TRA&\JZLIU\NXM)1]Z.5
M#RK UW:\@4 ,FXB8^U<-XZYUCPA#C._4@Y_X#&:[B<$Q,*XGQ.5N?'/@^$?>
M1[B;'T3%>;C[.C9]7'_TI'5AFU4NNS_)G91*!*Q]:L%0>H%0Q@\''K4]>@CF
M8T1J.@_6L;7/!'AWQ.&&KZ#INJ;@03>6D<I(^K UMT50CPK7_P!B;X,ZX[RK
MX*MM+N6;=]HTF:6U<'U&Q@!^5>6?'#]FB;X5_";Q1K?A+XC^.;);.QD,>E27
MQO8Y<C;Y8#@D Y[5]D5'- D\9210Z'JK#(- 'GWP+\,-X2^"O@K2&39):Z7
MK#IM)3)S^)K?OGDT&[NM8N+N8Z>D"J]L%W!2#]\?AUKI BJH & .PJ"[@\Z(
MH,$'@@]Q6%2',KK<J+MN%I>)>11R1-O1U#JP[@X(/ZU9KG/.N-"U"[N+ZZAC
MT8I&( 1@Q/G:5^AXK>BG64*5;.>1[U4)\VCT:_J_HP:L2T445J2%)BEHH KW
M$9D:/"Y&>3Z5R^O>!K?4K@7UF6TO5EY%W;\%CZ..C"NPII45SUJ%.O'EJ*Z_
MK;L7"<J;O$X*#Q9?^'IHK?Q/;")6.Q=0MQF%O][^Z?K796^H02V\<L<JRQL/
ME9#D'\:6^LH[V'RY$61&!#*ZY!_"N+F\&7WAF4W'AJ81PL2TFFW#$PM_NGJI
MK@?M\)T<X_\ DR_S_/U.C]W6W]U_A_P/R.X^U(V0K9_#I7S]XU$W[0'Q7@\(
MVLOF>"_#,R7.N,/NW=SUCM\]PO4UI_%'XU77ASPW_9NDV$D/CO59AI^FZ;./
MO2MQY@/=%&6)]J[CX-_#NW^%_@NUT@2?:;]LW%_=G[UQ</S(Y/UZ>U=U.M"O
M'F@]#AJ1DI^S:VW.XM[=($"(H6,*%51T '04"UC5B0H#'&2!R?K3T<-G':GU
MTEB=*6BB@ HHHH **** "F'[_MBGTQSR,=: /$_V9RFE'XDZ$#C^S/%MXJ)Z
M1R;)%_#YC7MPKP?X7.-'_:<^+^B]$O8--U>-?]Z(HY_,"O>!C''2ICL1!W0M
M%%%46%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "%0>U(J!>@IU%
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MI&P!M+IAMIY&<5Y>/7,J<>\H_P"9V8;1S?:+_*Q[0H  I:0=!2UZAQA1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^U>FECT,=*6D%+6AT!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $4_
MW!]17$_#_,FN>+91T;4RO_?* 5V\I^3CU_K7%?#-A+'K<XZ3ZK<$?@0*\RL[
MXJBO5_@=5/2C4^7YG<T445Z9RA1110 4444 %%%% !1110 5#<*-@/85-3'4
M/]*EZH#R_P")GB^Y\"P1_P!DV0S<;GFD\GY%8\!BP[Y[5VW@_6AKWA[3K[.Y
MIX%8XZ9Z']15Z[T^*XB,;PK-&P(*.,@U'IFE0:-9I;VD2V\*D[8TX S7ETL/
MB(8R=5U+TVK*-MGW7KJ=DZM*5",%"TT_BONB]<7$=O&6D8*H&23P /6N'G^.
M7P_M]0^PR>,-'6YSMV?:UP#Z9SC]:^0OV^?CWK-MXBA^'FB7\MA9K;^?JDEN
M^UIMWW8LCD#')]<U\GVEK$EG NQ<;.A&?T[UZ<I<I]/EW#DL9AUB*L^52V5K
MOYG[065]#>Q++!*LT3J&61""K#L01P15A6#=*_/+]BWXT:OX:\?V'@B\OI;C
MP_JRO':PS-D6LX!9=A/16Y!'TK]"H5( )X..@JDTU<^>S# SR^NZ$W?L^Z):
M***9YH4444 %%%% $%Q&'/3/%<7JO@$M?MJ.D3G2=0&"#%_JY/4.O0UW=,<9
M!'M7+7P].NK5%?\ ->:>Z9K3J2IN\7_7FNIP]AXWETB[2R\2VO\ 9MQ(=JW:
M\VTI]F_A^AKLX[F-E# Y4\@CD$52U/2HM2MV@N(8[B%AAHY "#7(R>'-8\'A
MI-#F-[9#YFTRZDX4?],G_A^AXKCYJ^%^)<\._P!I>JZKTU\C:U.KM[LOP?\
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MJQ\CT]<Y]J=3(\XYI]>^?1A1110 4444 %%%% !1110 4444 %%%% !1110
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M5 8>_I6K9\RV[F)IA9=9L[O&5?4KF,,.X(P/_0:FU3,^J7UQCY8;RWCS]/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI,T %&14,UW';@M(P11U
M9FP!7D'QX^/L?PHALK:QM%U'4[U3)&KMB-$!^\2.O-7"$JLE""NV!ZSJ>KVF
MCVSW-Y<1VT"?>DF<*H_$UY7\:/CS:?#WPG9:CH_D:O=:C*T-H4D#1 J 6+$>
MF1Q7SO\ %+XA^(/CYX3L+RRTZ<0:3*T6HV%KEU+N 8Y,=2, CV-;'[/WP1_X
M3[PUK]CXD2XLM/9XIK&,Y26.3G,J ]B,*?6O3C@X4J?M:\MGJAD&N?&+Q9\=
MO &K:+#8*M]9E+N=-/S_ *1 #@KMZYR0?<"OG?QM8:KX:T*#5)-,N(83<B!)
MIXBJJWH<U]W?"+X;Z1\']=NX+?SIIKE_LL]U.03S\T>/0$<?458^.GPVMO'_
M (;U[0)HQ_I]LUQ;'NLR^GZ&M5C51<J="-D]CBQE*5;#SIP=FUH_/H>&?L<Z
M9HNL16OC*<M)J-O<-9RVQ^Y:N1@./7/3\:^F_$^@Q6>N1W5G#%!=7*^8CQH%
M+3Q?,!D?WEW"OB+]B?6W\,?$;Q%X1UHBVCO8C#.LC8V3(V W/0]*^X[B6[U'
M0XE:,OJVE7<;.%'+;6 R/4%"37!6J5)SYYN]U^!EEN)>*PZG/XEH_5:,M>(Y
MK?4](TS54&Z'S%W9_N2#8RGZ9_2HFE>Y\)WMG(3]KTUPO/\ $%(*M^(JZVA+
M%%J.F/*J6=R6F@7^-&/+ #T!Y_&I?-L'GM;B-1-]N'V<N#P<#^(>O&*Y+VT/
M2N4K*V95U&PVEK?4+<W$)QPK%?F7\^:M:1ILUA-IUVQ2+?;K;W*,<%F'W2/?
MM4']ORHL$91;>6"\%M,@'!4_=(]CQ5/6I)M/EN[>5R\<%Q#?0EN3LW@,/P)I
MZB+D=II^F:7;NT[R/I-PP+Q\,"[<J?8AQ4UU>6VG_P!K6RVP\R(?; C\K(3_
M !?@15#Q;;?9;RZ9,K'J-JQ('3S8OF4_BN1^%3>*$\R"QU$#Y9HC!(1W5UR/
MUQ0D,LWNJW-O>%,JL5U9M+$PX(D"Y/-1_:;B-]#O/.9H[F,V\H)XW$95OKD8
M_&H=3877A;3+Q1EX-A./0C:U1/,LOP_2=F53:$2AF. OEOW/TS0D!';%H/#>
M@:GG]Y:W*B1C_<=BC_S'Y4OV<GPIJ;@#S;6^EF4]\J^:S=-\3:+J'PSUJ0:I
M:O9VHFWSI*"L7S$J3Z<XQ6+X'^,GA/7/"7B*X75%*6PDN;A7&UMC*/F /7G^
M=:<DU>RV8'8V<2ZCI?B,1@?O9"X_[X!%?"?[5S"_^+WA+D 2ZA!T]2ZU]-?#
M+]H;POJ>GZW'*;BT>VMS<!9P,S(JX.WWZ<5\C_%#Q%/\0?&OA_5['3I&2PU)
M;DP@Y8PJP8_D!6M7"UG"I:.Q[F35H4L5>H[:,_0;P6_GZL6;YMNGPH<^N6S4
M'@T?\3FSA/6UANU'L#.,5X9\+/VFHI_&%Q;:GIHM;":%Q!*CDLNS<X#>N>1Q
M5/X;_M.37GQ+5;_38K?2[]Y8HS$29(BS;@3Z\@?G6\L'77/[NR/%D[NY]!::
MO_%60P=H[RYE_- ?ZFEN &\5?9^TE\LA'T2OGCPM^U!<WOQ6B>YT^&'1;JX>
M(;,^9&IPH?WZ#CWH7]J">;XL)(^FQ#1!=^1D$^:!G9O_ *XH>"K)_#TN2?1>
MO?/KES;]?/>U5AZ@,2?Y4GC)G74;D1\-)IOD@_[TZK_6O M:_:FA_P"%HHL6
ME[]#BN4B:<L?,;&5W@?CG%:OCG]I_1K3XC1V:6,MQIEI+'!<W8?KMD#$J.XS
MC\JCZK65O=Z7#8]T\3-_9MW8&+Y!!:SA1[!0!_2H9[<:/8>'(\#,)+G/^X2?
MU->8?%#]H/POI7C6VT8O-<^0HCN+J$ QQ[RI_'@<UO?$WXP>%M)U32["75HE
MGF3<H3Y@JN,*6(Z @UC[&I[ONO4#K(TD@T'2Y2Q$UU>K,YSV))Q^52'5KMO#
M]SJ8E=6N+Q1$H_A3>% 'U S^-4/&?B32]/M-'MCJ%K"[(7A5Y0"_R84C\ZU-
M91=-\.Z5 ,;8Y8F/N$!<_P#H-8\KLGW DN]:9X=<O?+C>WLAY$>X<LX&7Y],
MD#\*P/B5JUO9>&[H00[9X;0+&5X5#)\H'UP36E=VIMO <$##$MV4+GN6D?<W
M\ZX#XD7H:RT]-W_(2O'O&]HHAA!^E8U;*#?R,*\^2DVO3[]"/X2:'#=>)9IF
MD5!8+'#$A_BP,L1^)KTK4M'N+R&[G^6>2]GB3Y#D)"&'?\,UR'P@TUK'PCJF
MMW P]P)&3/8<UU?AIY9)+2$R,EK86H:10>'D89Y^@I48N,-R,)'EI+SU^\3Q
M!.]Q<:A=;2MMI=LT<)/\4[K@D?0''XU)K86'3M-T)&V?NE>?_9AC&3^9&*72
M]8EU6TTNTFB2YEO0\\VX8"1!N"1[\ ?2IS_9^I6][=EC!/>L;$2.=Q."5 4>
MF>:UO;?H=)!97)T;P?\ : G^E7;%T4==[GY<?08JIX/\.:=!=7>K26UNT\1\
MH7;1C?\ +]YMV,]<UJ7NES/+"^X26FGVY$4:<EY0N 3]!5 Q,FDZ=HD>Z.6Y
M7S+EL?<CZMGZ]*KF=FNY1X=J7[,.G>/O&=]J-MJ$FF6-VQNI;5(]VT,QP%/;
M(Y]LUX[\;? 6L:-\2=1L(K2ZN[&(I;Z88E:01P*B[(UQT*\9]^:^U](OH]&\
M/7VJF/+W$A,,0'+<[8T'Y"HO"&GL=4N[BX*O):_(\AZ-</\ /,?P^5?PKT*6
M.J4Y7>J2LD(^<6_:3\3_  MT/1/#$NF)=ZO8VR?;9+YR&&[YD3CN%(Y-?0WP
M[^+VD^,O ]CX@NIHM+$[&)XKB4#;(.H!/6O-_B%\#M(^,?C0ZA]HETZXE&UI
M;< B2).-Y]R> ?05XU^T%\+KOP1J^F:7I45S>:#!;JL*1Y<K*3\Q8#^)NM:Q
MIX?$\D(^[)ZMB/NF"ZBN8A)$ZR(1D,IR"/8U)FOC'P9\<M;^"'@/3]'U+2YK
M_4[B1[B"WO9"GD6Y.%SWR3D@>E?1/P=^+MC\6/"TNIQPFQN+:7R;F!VR$;&1
M@^ASQ7!5PU2DN9KW;VN!Z-13$D5P"#P1FG9KF 6BBB@ HHHH **** "BBB@
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M;2&,R[9=?=3L!P6Z=,D"@#WK=1NKQJ+]F709D5T\5^,65@""-<?!'Y5@>/\
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M">&/^3U/&/\ V)]E_P"E+U[V:\#\,?\ )ZGC'_L3['_TI>@#WVBBB@ HHHH
M*0C/6EHH JRZ=;RS+,T,33)]V1D!9?H:\'\0_LA:#KGC:\UTZA<16MW.US-I
MZXVER<D ]E)YQ7T%28]ZUIU9TFW3=K@?G==>%O&*?$ZX2:RODO[6[+M-M;RT
MB4Y!!Z;-HXKUZW_:E;QAXOT[1FTP6^ER3K;Q7(;,FX_*)"O3Z#WKZHO]+@U&
MUG@FC5DF0QOD<E2,$5\WZK^R18>$8-8UW1KZ]U"]MHI)M.L&50$DZ@Y'+$<X
MKTUBJ5=6K1LTK(9['XBOK+3=-31;=P% S.D1R^S/W>/XG.!^)J95E\/:3+>.
MBRZS>%8XX@> QX6-?91R?H:^)_@_K6J>&/'Z^)-52^CT[3@\NIS3HQSD$*AW
M<%RQX'^%?0/@'XX6GQP\8MI*6L^B3)$6A5Y0Y:/'[QE( Q(1@>R[NM8UL'*E
M>SYHK=@>JZ-))';!EG,>DV"DR3$?\?4G5S_NYJV/(U"V6=!';:M>P$1!R253
MU [<51\3WD4"Q:/;1C[-"%\V&/J_]R$>['D^V3WITMK)HUB7=Q)KFH'RPP/$
M6>H7T517GON%A+Z-[>S.G1QR6NE64?\ I-R>&E_V%^O<^]3:4(?#FF2ZG>1E
M;NYP$@3E@/X(D%26FH6UY:2),ADT>T"@WLK']\X/\([C/?N:BUK3[I9ENQ*U
MSJ$[B"R15/EVH/5_J!GFEY"//O%GP;T[XS:PUQKJR07%HNQ[FT;!4]1 O8A1
MR3ZDU\X_&VVN_AAXO_X1S1;JYT_1+2-7MS%*1YKD?.[$=6SQ[#%?9]]?1:)9
M#1M+<1O#'NN;I_F%LG4NWJY["J&E^#=)OM/.HZW86\L"KNACOD5_*3KO;/\
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M*]T=^5VRL!_Q\1CI(/\ :7O[46 GT)[74[*71;K,UK(I:U=SAMF?N^SH?Q&
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M;6__ ,70!V5)7'?\+F^'_P#T//AO_P &UO\ _%T?\+F^'_\ T//AO_P;6_\
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MOA__ -#SX;_\&UO_ /%T =E17&_\+F^'_P#T//AO_P &UO\ _%T?\+F^'_\
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M ^M;&PA\,V U+4%'GH@B@MH^1%GHB^K$]3WS5;29K^]O+HVX07DK?Z5>-RD
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M56'UF%E?HA'TU14<4HE0,,$$9!'0BI*\H HHHH **** "BBB@ HHHH ****
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MMUYH )3+*5XR3VJAXRUGP7XEL-4TR+QWX;@MV%ZUO?$3>?>&XDC8I/\ )]U
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MN^U2ZFDUN>Y5$5;Y498U1B5X Y8%C\QYKTN"'R(PH.<4"):X3XZ?\D;\9?\
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ME?\ "KM% %'^P]/_ .?&V_[\K_A4UM86]IGR8(H0>OEH%S^56** $ Q2T44
M%%%% ",<"O'O#1V_M4^-@2 7\,:6R@GD@3W0)'MGBO8&&17DOQ5\">(K;Q;I
M'Q \$);77B;3K>33[O2KR3RHM5L682>1YF#Y4BN-T;XQDD-P: /7*0UXG%^T
M?JR)LNO@_P#$*&Y7Y9$CTV*5 PZ[767##/0CK3_^&D;[_HDGQ%_\%"?_ !R@
M#LOC+?7VE_#G6[K3-371;V&#<FH/"\JPC<-Q(168<9&X*=N<XXKYUN_C!\0;
M?0=!U+1HM6U#3)+274I9)XA<M/#ITKM=Q)((T)^TPO$(F*AB4/&<UZN?VC[T
M]?A'\1/_  3I_P#'*/\ AH^]_P"B1_$7_P %"?\ QR@9Y3K.K^)773[C7[^_
ML6L]4T&YN[Z"V\DN\L4C2)(53YE5F1,'ICMFK&H>(-5\=>%KVSG\0ZS<^(QJ
MMM_:.D_82$TIQ<X7RF,8 &S!QE@?O5Z;_P -'7O_ $2/XB?^"=/_ (Y2_P##
M1]Z?^:1_$7_P4)_\<H SI-0\3W_[//C(S37=UK%O]MM4GG39/) CD;CP,GR]
MW('-3?#[QM8>'M?U>(;(= EBTBRT:2WM&9)I);?Y5WHI)&X8W'A>Y%67_:-O
M'5E/PB^(A!&"#HZ<_P#D2H;/]H*XL;=8(?A!\0XH4&%C31D55'8 "3 % '*_
M KXI:_/J&JW?C37&D2.&*.^TQ[2X>73]1DN#$(P! H1""J[ 7Z%\@'->V-XN
MTOQIX1\32:/<?;!9?:M/GVHRE)XU(=,,!D@D<C@YXK@S^T=?'C_A4GQ%'O\
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M 2#D5]I:?8PZ=906L"[8(8UBC7T51@#\A7HXNI&C#ZO1NOYEY@6%Z4ZBBO(
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MN9"N"3D$<5]$4F!Z5K2JSHU%4ANAG@OP"^$_BSX2:/J2W3V4\UU.'-JKL4
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(* "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>avte-20240930xs4018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 avte-20240930xs4018.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '\ M@# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*V^$'BSQ!!92;%U*P13!.,?>7VKTSX._$J\^*7@U=<OO"^I>$9VN)(/[-U4
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M9/JESI+^E]:L@_,9%>D:1\=O 6NHK67BO290>@-VBG\B<TW6O@1X"\0J1?\
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MY-IW?I7PBOP\\2:C+X(T_P"&'Q+\(ZSX:TG4&UC0--UE]MY #N'DD Y902V
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M1DXKY(T'XB?%OXFW47C_ ,$_!;P3)IE[N_LS6-:U%8M2E@!*AW*QDKG!^7/
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M%QM9I&Z;MI.%'.<5TGQ(T35=.\ ZG;>!["WM]6N-J*(0L6 3AF!Z9 SBN/\
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MX&O4U;S]L?Q=XTF:+P%\.KZ_4G"7-VIV_D!_6FCP7^T;\4TW:KX@M/!E@_\
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MM:QKUSXM\9Z](LFJ:Y>($,FT82-$'"(O.!7KK@%"",C'2@1\?ZK\>OV=M?\
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M21,0Z'!R,UX)\;/'KZWX5E\)S^&-2\/:5?3QVDNNZE;@6EH@<?.NW."<?+G
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MW,<8TK6<;H]0M1M;/;..M=>UMH7Q)T6"_M;B.Y@E3=#=0-\WXX_E6'!JFL^
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M%%% !2'I2TAZ4F!\_?ML\?"&R/\ U'+#_P!'"O?;88@3Z5X!^VPP;X06>/\
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MU= ) XR#R.U<33B[,^HA.-2*E!W3):*0<@4M(T"BBB@ HHHH **** "BBB@
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M-,X5$'J2>*Y_PQ\4_"?C.]DL]%U^RU"ZC&XPQ2?/CN0#C(]Q0!U=%(&!Z4M
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MD"O#I?\ A-OV5-48@3>(_ ,K\M_%#SP/]AOT-?2'@+Q]H?Q#T6/4]&O%NH7
M#QMP\;8Y5E[&LG",O)G)C\K=&*KTI<U-[27Y/L_)EGPUXKLO$D!$<GEW ^]
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MV'!YQWQ7P_\ #7]KKX9ZO87&B_%F)-4\2:1<2Q+KS>'YI(+^,.=DBGRMRMC
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M[? SP]J^LZ]J>K*VHG2-4DL;:"8#9\AX=AW-?6\I#(PSCWKQ#]F9<CQW@?\
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MT?\ P%67YGF?@_\ 9V\#^$$1K718IKA.1-<_O&SZ\UZ-;Z?#:QB.*-44= H
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M.T>:)Y-5N#))(1N MD7<S#ZY !]Z .O(!8#@DGI[5XQ\9?V>;'QM)_;.AO\
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M\;1::NH\LSVTK.&4AE)S&, U]E:M:KJ>F7=HS%!/$T19>J[EQG]:^$M<\/\
MQ0^&5I\-/"+?#B_\2Z;X)UHW=MJVB2(RWMMA]NY204D^;D'B@:/:/V7_  QX
M(\%^/?'VA:=%XG;QO92PQZC>>,+PW=W<VN#]G>*3H8<9Q@#GK7TG7@7P-\)^
M,=;^)?B/XF^-M(C\,W>J6D.G:=H:2B66WMHR26F8<;V+=!TKWV@04444 (>!
M2%J4UB>*;?7+BP \/W-E:WV\'S+Z-G39W&%YS0!F_%+Q>_@CP3J&JPQ">\0+
M%;1-T>9R%0'VR0?PKS?2_AYX6U"2&+Q%XUO=1\9S /+/%K3P212<'9'$C *!
MTQM-'QLT/Q/>?!_5$\07EI<20W<$YETJ)T\N%7&\X/.1G-6/%W@+X>VGP;U&
MXBM+"WM8K!KBWU-"/.$P3*.)/O%MV._-,#8^+NJZC/J/A+P9I%]/I]QKUPZ7
M%]$W[^*UB3=(5/9FX&?<USOC3PBOP5L;'Q1X9O\ 4XH8+J*+4+*[O)+B*ZA=
M@I9@Y.&&<Y%9\U_?Z;=_!/Q7K[.A-LUC?SS'&R2: !&?TR1S]:ZW]HC4H;GP
M-%HT$BR:AJ]Y!;V\*G+-EP20/0 9S2 ]5MIA/$DBG*.H9?H1FI<U7L(3;V=O
M$3DQQJA_ 8JGJ^AMJDD;+?W-IL!&(&P&^M %+1/^1IUW_ME_Z":Z'UKE?"ED
M=/UW6H3-)<%?*_>2G+'Y>]=70 5!.^Q6.<?K4]1M'DY'KFF!\[_M$>#/B=K^
MO64_@^_E721%AK>WN/)<2=R3W%>3CX6_'H_\O6IG'KJ?_P!>OM\P@G)Y[\]J
M#%G/J:[(8IPCR\J^X^/QO#5''5Y5YUJD6^BE9'YX?$WP3\2-"TBVO/&CWMQI
MHFVQO/=><D;GU&>/J:X+2+.]U+5K2VTQ9)=1DD40+ <.'[$$=/K7Z>ZEX?L]
M8L);*]MXKNUE4J\4RAE8?2N?\,?"#PGX.OFO-(T.TL[IN/-1/F ] 3TKMAF%
MH-..I\;C. '6Q<:M+$/DTOS:R^3_ "['R=_PK#X\9'^EZF1[:E2CX7_'LR#9
M>:DC _*6U+@'U/-?;Z0A#GO2O$&&.V<US?79?RK[CZ5<(8=6_P!HJ_\ @?\
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MJ]A);RM!JES]LG/FD.LW9T/\)&*J:-\%-#TG6;#6)+C4=2U>R=FBO;ZZ:20
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MY?PKM:* $50O2EHHH Y[1?\ D:-=_P"V7_H-=#7/:)_R-&N_]LO_ $&N@]:
M%HHI* %I*R=6\4Z9HCJE[=) [<A3DDU0_P"%AZ 0,ZBH_P" M_A4.<5HV0YQ
M3LV=+TI P.<$5POB'XF65K9YTN=+RY8X (("CU.1S7/Z-\4M1CO$&H>7+;,<
M,50*5]^*QEB*<9<K9A+$TXRY;GK8.:.E<PGQ#T$#_D)(3_N&G#XA:#D Z@G/
MJIK7VD.YK[6'<Z)YDC5F=@BJ,EF. ![U#9ZE:Z@C/:W,-R@."T,@< ^F17E7
MQ]2\O-#T2[CM;K4_#<-ZD^KVNG$F6:VQUP.64'!(':J_@#2?!&M>(K/7O &M
MP620J4O],L_E6=".!)$V"C _Q8K3<U/85NX6F>$2H9D +QAAN4'H2.V:=%<1
MSH'CD61&Y#*P(-<9HFJ:9<_$[Q+80::8-3M[6U>YOMV1.K!BBX[;:\J^#WQ%
MUWPW\']&NAX3NK[0M/CE%UJ'VE%E=1*Y9XHNKJH(Y)&<' H ^B_QH.#7 >(/
MBFL$ND6?AW36\0ZGJL NH(4F6*..' /F2.<[1SCI5:#XP+'X4\2ZAJ&D3:?J
MWAY2U]I;RACTW*4<<,K#H<4 >CJH7I@4N?<5Y2GQHU*TM=/UC5_!]WI7A>],
M2C4'N4>6W\S 5Y8ARJ$D#()]Q4VL?&66U\>7'A'2_#=UK&JQ+%+NBF5(A$W5
MV8_= _7M0!ZAD>M+7E^H?%G57O-5'A[PI/KVGZ2Q2]NQ=)%N=1ETA4@[RO?D
M>E2Z[\:[+3='\*ZEI^EWFMP^(I?)MHK4 2AMA8 J?<8//')H ]*)P*A-Y L;
MR&>/RTSN<L,+CKD]JXCPI\1;W5/%4_AO7M!;0=7%K]M@1;I;B.6+=M/S ##
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M7U#BC%'*/^VJZVIP7_;B/F!?V>OBC/S/\0G4]]A>D/[,'CJ;)F^(UU[[=_\
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M1C]"*+R["^JY;)^[B6O6#_1GJ/Q7^,N@?"RRAEU*1I[FX!$%I!@O)ZGV'O7
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M>IKX<\&V^L6D$)OS?V]N7D'5'?:P..O!KU/2+"UT^RCAM84@0 <+_/WKXO\
MVG/^%B3:\$UZ%F\/B7-C]@!,6>Q;'.[Z]Z]R_9Q;Q^WAT_\ "7H/L>T?8O/X
MN2/]H>GUK**CSO0^IQ63T\/EM+&*I%RDW=)ZZ[?=U/;E.5[_ (TZF(V>,8-/
MK4^6"BBB@ I#S2T4 (!BC%+10 F*,4M% "8H Q2T4 %-V#.>].HH 3'%)L&*
M=2&@#.UO2[34=,N8+NWCN83&<QS*&4X'H:\?_91TZUB\%:I*EO&DIU.X3>J
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M#TWC_0+;C_IBO^%70,4M,\[VD_YF<7\0? T_BRWLI=-U&31]7TZ;[1:7:99
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MS1FN=_XJC_J%?E)1_P 51_U"ORDH Z+-&17._P#%4>NE#_OY2X\4>NE?^1*
M.AR*,USV/%'KI7_D2C'BCUTK_P B4 =#FC-<[_Q5'KI?Y24?\51_U"_RDH Z
M+-'%<[_Q5'_4+_*2E_XJCUTO\I* .AS1D5SV/%'KI7_D2C'BCUTK_P B4 =#
MFC-<[_Q5'_4*_*2G;?%'KI7_ )$H Z#-&:YW_BJ/^H5_Y$I<>*/72O\ R)0!
MT.:,US^WQ1ZZ5_Y$HQXG_P"H7^4E '09HS7._P#%4?\ 4*_*2C_BJ/\ J%?E
M)0!T6:,USH_X2@G_ )A7_D2G;?%'KI7_ )$H Z#-&:YXKXH'?2O_ ")0!XH]
M=+_*2@#H<T9KGC_PE '_ #"_RDI/^*H]=*'X24 =%FC-<]CQ1ZZ5_P"1* /%
M![Z5_P"1* .AS1FN>(\4#OI1_P"_E)_Q5'_4+_*2@#HLT9KG?^*H_P"H7^4E
M'_%4>NE#_OY0!T6:,USO_%4>NE?^1*/^*H]=*_\ (E '19HS7/8\4>NE?^1*
M3_BJ/72ORDH Z+-&:YW_ (JC_J%?E)2_\51ZZ5_Y$H Z'-&:Y['BCUTK_P B
M4NWQ1ZZ5_P"1* .@S1FN?V^*/72O_(E&WQ1ZZ5_Y$H Z#-&:YW_BJ/\ J%?^
M1*=M\4>NE?\ D2@#H,T9KGL>*/72O_(E&/%'KI?_ )$H Z'-&:YW_BJ/72_R
MDI<>*/72O_(E '0YHS7/8\4>NE?^1*,>*/72O_(E '0YHS7/ >*#WTK_ ,B4
MNWQ1ZZ5_Y$H Z#-%<_M\4#OI7_D2B@#H:*** "BBB@ HHHH *3%+10!SGCOP
M58>/?#\FDWXD6)F62.:%MLD,BG*NI[$&N&N?A3XQU6S?2[_X@7,FD.ABD\FT
M1+B1#P5+]LCC(KURB@#@M<^$^D:MX.TWP];"33(M*,;:=<6Y_>VLB#"LI[GK
MGUR:R++X3:MJFKZ?=^+O$TOB"#3Y!-;6:P"&,R#H[X^\17JE% #5Z4M+10 E
M+137.!GL* '45Q?B3XP>#_".HFPUC7[.QO54.T#,69 >A?:#M_'%=38:E;ZG
M:0W5I-'<VTRAXYHG#*ZGH01UH MT444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 444AZ4 +15#5=8L]$T^>^U"YBL[.!2\L\[A$0#N2:YWPS\6_"/C*_:QT7
M7;6^O%7?]G4E'9>Y4, 2/IF@#L:*0'@4M !1110 4444 %%%% !1110 445@
M^*_&^A>"K/[5KNK6FE0=FN90I;Z#J?PH WJ*I:5JMKK5A;WUE,MQ:7$:RQ2K
MT=2,@BL'Q7\4O"O@F[CM=;UNVL+F1=ZP.2SE?7:H) ]Z .KHK-T'Q!I_B73H
MK_2[N&^L91F.X@<,K?Y]*T: %HHHH **** "BBB@ HHHH **** "BBB@ HI#
MTK#\3>-=$\&6)O-<U6UTFW[/=2A=V.H4=3^% &[16=HNM67B+2;74M.N%N[&
MY020SIG#J>A&:S/%7C_0?!$,<NO:G;Z9'*V(_.8[G/LH!)_*@#I**PO"_C71
M?&MBUYHFHPZE;*YC:2$GY6'4$'D&B@#=HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *I:U>'3M(OKL $P0/*,C^ZI/]*NU5U*U6^L+FVDXCFB:-OHPQ_6
M@#S#]GO0+5_AA::I<P1W&H:X7OKVXE4,TQ=B0&..0!A<>E1_!*'_ (1_Q/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#G>R [6;W(->HVL*0QJB*%5> !P !T% $]%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>avte-20240930xs4019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 avte-20240930xs4019.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &# @L# 2(  A$! Q$!_\0
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MS4'OC;W"_+'*V[E&P063.* /TE-Y$9#'YJ>8/X XW#ZBD>>&)O+DD17;HK,
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MHHE'F,V<GV-?!7_!0IV3XG>&]K$?\2H]/^NK5]\*0"<8KX&_X*%_\E0\-?\
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M?^8E9?\ ?+U[-10!XS_PI/5O^@E9?]\-2-\$M5P<ZE9<]]KU[-BF;#GDY]*
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M=(\/:[XOUO6]*75]-M]%CC(N(2<'#.ZA2 ,\X% 'T")%..>M+O7&<\5\^_\
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M9$VJ3YK#('I7I/QSA\&?$?\ 9ETG1_@MJDFJ:5X$UJPU#48='MW%S]G19 S
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7*?$SX<:-\5O!]_X:U^&2;3;P#=Y+[)(V4@JZ-SM92 0>Q KJZ2@#,TC2QI
M&CV-@D]Q=+:0) +B[D\R:3:H&YV_B8XR3W.:L!2Q)P>OI_6K=+0!7"'ID_7W
MIC ^8  2>]6Z3% %=QA1N!(!STHP6YQ@^O2K&*,4 5_FZ\\<\CO2A6*YP<GU
MJ>@T 8?B+14\0:3/8R3SVAD'RW-N^V2)AT93ZBO/+;X1R:HDUQ'X[U2YFO 8
M-5GAE^6YC&/DC 8^2PP &!) +#O7>>-5U&;PAK*Z5/#:ZE]DE^SRW*%XT?:<
M%@.2/I7P[^SK\8O&'PB_94\.W,S6/B77_$VN'1O#UDJ/&1<.TI9YW).Y1L)X
M]A6,Z,*CO)'?A\=B,+%PI2LGY)_FOGZI/=(^K1\&;N+RVB\9:M'-8C;I3%MR
MV<?]UUSB;NN3CY<"J&H_##3-+GL])U#QWJ=M:ZC(66QGO DMS=CG>C$YQWV
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDT4"L/*C.0O4>HQ6L'-_$K'#7A1@U[&;DO-6_5GKU%(.12UH<H4444 %%%%
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MW_7_ !I!K^F?]!*T_P"_Z_XT :-%9_\ ;^F?]!*T_P"_Z?XT?V_IG_02M/\
MO^G^- &A16?_ &_IG_02M/\ O^G^-']OZ9_T$K3_ +_I_C0!H45G_P!OZ9_T
M$K3_ +_I_C1_;^F?]!*T_P"_Z?XT :%%9LOB'2T1F.I6F "3B=>GYUYM_P -
M0^ 02#J<N0<?ZK_Z] 'K1&:^7_&UEXK^"?[2>O\ Q T;P9JGC3PYXMTF&VNX
M-#C$EU;WL"JB,RDC]V8T SZGVKT<?M0^ #_S$I?^_7_UZC;]ISP S$_VE-SZ
M1?\ UZ .(^!7ASQ'\(_!WB?Q9X@\,W]YXB\7:Z^J3Z-IBB6:T23:B(W('RA<
MD]J[S]I3P_JGC/\ 9\\>:/I%A+?:KJ&C306UG$/GD=EX0#UKAOC!^V+X;\%?
M#_4-8\/3K?ZI \0C@N4(1@TBJV<'L":Z^T_:>\!M#$\NH2"1D4MMCX!(Y[T
M=!\!]%O_  U\'O!>EZI:/8ZC9Z7!#<6TGWHG"\J?>O0Z\C7]ISX?KS_:4I_[
M9_\ UZ=_PU%X _Z"4O\ WZ_^O0!ZU17G_A+XW>$_&VH3VFEZB&FBB\YO/Q&-
MN0.I/7)KKUU_3<<ZA:?A.O\ C0!HTC?=-4?[>TW_ *"-I_W_ %_QI&U[3<'_
M (F-I_W_ %_QH \0^  S\>/VA<\_\3S3_P#T@CKW[%?.OP$U>QB^.?[0$C7E
MNBR:Y8%6,R@-_H,?3GFO>_[?TW_H(VG_ '_3_&@#0HJA_;VFC_F(VG_?]?\
M&FMXATT8QJ%I_P!_U_QH T:*AAG68@HP=2,AE.01ZBIJ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@!*I:E;K+874;@-&\3 @]QBKU5[_P#X])_^N;?R- 'R%=_LE_!O
M4+J:YN?AYI,UQ,Y>21VFRS$\D_O*A_X9 ^"W_1.-'_[ZF_\ CE>P"BK \?\
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MORI+[D%%%%2;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !5>^_P"/.?\ ZYM_(U8J"^_X\I_^
MN;?R- 'C8HH%%4 4444P"BBB@ /2L+Q3_J[?_>/\JW3TK"\4_P"KM_\ >/\
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M]<EXF^$_Q0^&/QD\3^-_A1;^'M?M/%<41U+2?$5U):"WN(EVK+'*BN6!'52
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M\.>(-7\1S2^*M7B/A_Q%+80A44B582C M[G- 'WNOY=L&G4KR&5V<]22<4E
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M^QOOOY1UZF:\L^!HSJ'Q,_['"^_E'0!ZF!@4M%% #H_]8G^\/YU]10_ZI/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_G7.G1+\#_CRG_[YKJ/ -A<V=U=F>!X04&-ZXSS28';444AJ0!NE> _LI_\
M(=^-?_8^ZA_*.M[]J/XD>-/A=\'=4\0> M"7Q)XEMYHDAT]HFD#JS88[5(/
MK\\/A1^U'^T_X&\0:W]G^#3>5XFU]]5OGFL)\1/,RAPOS<* .] S]<**CB.2
M<G-24""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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$0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>avte-20240930xs4020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 avte-20240930xs4020.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (Z X4# 2(  A$! Q$!_\0
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M5>'_ -I'X;^*]:U;2=(\8Z7J&HZ5')-=P0S9,:1Y\Q@>C!<')&<5CO\ M?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXW4?_"<M* /I;<!W%&X'N*^:?^&>/C?_ -'':C_X3EI1_P ,\_&__HX[4?\
MPG+2@#Z6W =Q2;U]17S2?V>?CA_T<;J'_A.6E'_#/'QP_P"CCM0_\)RTH ^E
MP0>]&1ZU\TC]GGXX?]'':C_X3EI1_P ,\_&__HXW4?\ PG+2@#Z6R/449'J*
M^:?^&>?C?_T<;J/_ (3EI2?\,\_'#_HX[4?_  G;2@#Z7W#U%)N'K7S3_P ,
M\_'#_HX[4/\ PG;3_&N"^.O@SXX_!7X5ZYXR7X]WVK-IHAQ9OH-K&)/,FCCY
M89QC?G\* /M,.#WI<CU%?,EM^S_\;[FVBF'[1FHKYBA\?\([:\9&?6I/^&>?
MCA_T<=J'_A.VE SZ7R/449'J*^:?^&>?C?\ ]'&ZC_X3EI1_PSS\;_\ HXW4
M?_"<M*!'TMD>M&1ZU\T_\,\_'#_HX[4?_"<M*/\ AGGXX?\ 1QVH_P#A.6E
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDND380O7HQKTH=!7+.BZ4N6<;,ZJ3HU5ST[- *6BBD=(5X+^W/\ \FL>-O\
M=M/_ $K@KWJO!?VY_P#DUGQM]+/_ -+(* /;])_Y!=G_ -<4_P#015NJFD_\
M@NS_ .N*?^@BK= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!QOQ%^+'AKX5KHS^)+XZ
M?%JU\FG6LAC9E,S D!B/NCCJ>*T4\;Z3)XPD\,+.6UB.R74##M./)+E V>G4
M5Y1^TSX>L/%NM?#/0]2C$MCJ.M2VLR8!^5K649'H1P0>Q KP_0?&MWX!\;_$
M&R\9W.KQ7G@OP2+"YU/3.+NZM_M#_9[B!FX#E&7YCP&!)X% T?9GB?QGH_@W
M3TOM9O!8VCRI LCHS9=SA5P 3R:L>'/$NF^+-$M=7TFY%YIUTN^&95(#KG&<
M$ _G7PA%XG\1>%[/XK:)'J#Z/!;>"XM433[7Q#+JTEK=F?89GN&^[,RXW"/Y
M>E=OXJU[Q':^*;7X8VNKZA$?'LNCWUE=1W+_ &BVM N[4VB?/R +!C';SSZT
M!8^QDN4<97./7%<K\2_BEH7PHT.VU77GN1!<WL.GP16=NT\TT\I*QQJBC))(
MKY,\(^(?&>M^/U\0W%[;:1JZ>++BQNIK[Q0XQ:K,R)8_V=LV ; I4CYB3NSS
M7JG[9<LLO@[P"+74TT.[/CO11'JDL2R):MYS8E*L0&"]<$XH$>I_#OXS>&_B
M9>WUAI;WEKJEBJR7&G:G9R6MPB-]V38X!*D@C(S7<&9=V,'/TKYF^#4EY:?M
M(Z]!K'BJW^(NJ3Z%'Y>N6,$=LFGPK+_Q[R0QY0%R=P?=N.,8P*M_%!;3QE\<
M-3\.^+_$.H>'/#FG>'DU'2A::DU@LMPTC+-=>8I&]X (PJME1N)*G- 'T89E
M)(&21Z5QNN?&+POX<D\5QWUZ\3^&+>WNM3Q&Q\F.8$QD>N=IZ5\H?$36_$GB
M/Q?JMK::X+ZUTC0;&?1-=O?$[:0,LAW:@8D3;.S,H#9^7' 49S5OQY<W-QIW
M[14]W<0W-V_A?P^TD\'*._E299?4$\T#L?:<-['-$DB9*.H8''8C(K-\7^+M
M+\#>&M1U[6+@6NF6$+3SRXR0!V [L20 .I) KY4^(>L3^#?BJ/$>I:K<:WHD
M$NGQ*FB^(&M;[0PRJODM9$[+B.0D,W!?'TKUK]J&7/@GPK<3 ?V"GBK1Y=7$
M@^3[']I7.\'MYABS0!N^-OVA/"G@*>TMM0&IW-]/9C4)+*PT^2XFM;<_\M9E
M0'8H]^>#Z5!XA_:3\$^'U\.F.YO=;.OV4FH:>-&LI+LRVZ;=TF$&0!O7KZUQ
M?@'7])\%?M ?&%/%%[;Z5<7QL[ZRFOW""6R2#:VQF/*J^[(![]*YC1/%OA#_
M (7O\*]7T."'PUX7N/"VMM:Q7,8M$VFYMSN53@ ,<N/4'- 'O6E_&#PMKG@2
M;Q=IU^]]HT"MYK06[O-&ZG#1M$!O#@\%2,TGAWXP^%O$OPV3QY#J'V7PRT$E
MRUU>(8C&B$JY93R""",=:\U^!E]9ZE\2_BOXIT^>(>#;V\MDM[PG]Q<3QQ;9
MI48\$?=4GIE:Y;X2>%=+^*_[&LGAJ768M/AF-V7O497%JZWDDB,XSC;E5)!Z
MB@1[/X!^.?ACXB:PVE6!O['4S;B[@M=5LGM9+FW/_+:(./G7D<CD9Y KOVG4
M,$YR?:ODRWUGQWXJ^/?A(W5[X;UO4?#^DWET]EX99Q%*70+'YUP_^K\QA\L?
M08).:TOA[\3_ (G2?&CQ\FM>!X[73H3IK7R2>(HY8](B\AR9(UV_/N +$+CI
MS0!Z_P"+/CUX/\%RZE#J-]*;JQN(K0VMM TLTUQ(-R11(O+OCG Z#K5"/]I;
MP,W@/6/%;7EU#::/=)8ZC8RVCI>VEP[*J120$;@S%UQV.>#7A6B31:3\1OAC
MX[\3E8](\17NIW4=U<J%2WN9L+:[R>%)B3 )_O8K8_:-\8^"=?\  WQ';PY#
M;MJ=CJN@1:WK,$0$5Q(+N,QQF8<2-&G7KM#@&@#W3P-\;O"OQ N[ZRL;FYL]
M3L$$MSI^JVKVEQ'&?^6A20#*_P"T,BLKPQ^TCX+\7:]9:993WR1ZA*\&FZE<
MV4D5EJ$BYW)!,PVN>&QTS@XS7$>.M?\ #OBSX]^$7TJ[M+^+1=.U"7Q%=Q,)
M(8;%XP!',XXP2"=I]":R_#MU;?'C4O#6H6\FF^'/ .@SB]\-:/'-&E[J4Z(R
M0W!C!_<0*&)CC'S-@,V!@4 >G2?M'>"D\4_V)]KNB/M@TTZH+5S8"[_YX&XQ
MMWYXQG&>,YXKTQI%3!;//M7Q-?ZKI\G[$VK^%89XE\8O?-IHT\D"Z?4#?AE^
M7[Q8\-N]!G-=K\2_B%\5=*^-7@"QL? J36:3:C%:0CQ%'$NK(MMP\B[?W>W&
M\!L\T#/H#Q7\1M \%WEM;ZO?"S,UO/=F1A\D4,*AI)'/\*@$<^O%<KX)_:.\
M&>.]5_L^SFO["ZELVU"T35+&2U%];*/FEMRX'F* 03CG!!QBO!_C<=0^(WAO
MXC^(+O3 T6@VEAIMS80'SFC5;B.>^C1E #@+@$CLIKV3Q3\1/A]K\_AJVM&L
M_$6M7ME<SZ3-8(MPUK%]G;?,7'^J0K\N>,E@,4"+/A/]J7P%XOU33;&WNK^Q
M.J2&+3KG4M/EMK:\<9^6*5AM9C@X&>>U7/%O[1O@SP7XBO='O9[ZXETX1MJ=
MU964D]OIH<97[1(H(C)'..PY.!7SI/XBT?6/V*/"OA2PO+>]\8ZA':P:586[
MA[E;H7@8. .4V %BW& *]&\>>(]/\?ZSXE^''A2?2/#^F//Y7B_Q%,\<9\]T
M7?;P)D>;<% H:1N$&T<G@ SU#Q?\<M"\&731W6G:[>VZVZW9OM.TR2XMO**[
MMWF+\N .374>#/&>F^//"6E>)-(>232M3MTNK9Y8S&S1L,JQ4\C(P:\?^.3?
M:O"7A7X2^'[F2&X\5M'ICR0R'?;Z3$H-U(&'<Q#RP3U,E=WK.H^*_"NNZ)HG
MAOP3;:CX4$,<4NH#5([;["B_*$6 KE@% Q@T".B\'>.=)\=65S=:5,\BVUU)
M9S1RH4DBEC;#*RGD?U'-=%7BWP;*M\7?BX]CC^RCJ5L&QT-U]G7SOQ^[FO::
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"GK&J6
M^B:7=:A=%Q;6T;2R&-"[;0,G"@$D^PKE?A]\7O#7Q*\%3^*](N98M%@DFCFF
MOH6MVB,1(D+JW*@8)YKL+J6&"W>2X=8X4&YG<X50.Y-?''AEI?$G[(WQAL=!
MG6[U%M7UB016L@:1H_M&YL '/S(&QZT >^^#?VA_"'C?68-,L6U&VN+R![K3
MFOK"2"/4H4&6>W9AB0 $'UP0<8YJI'^TMX7&MZ5I=WIOB+3;C4[L6-H]]H\T
M4<LISA0Q'H"<^E<5XZ\2:'XRU;X%6WA>^M;^[_MN'48X[)P6CL8[243.<?=0
M;E4CCD@8K8TAD^+7[15YJ"M]HT#P%";*VYRC:E,!YK_6./"Y_P!HT#/=D.Y<
M^M.IL:A4 &,#TIU @HHHH *3-+7)>.-:\5Z.]H?#7AB'Q&),^<)=22T\KTQN
M4[LT +\0?B7HGPTTZVN]8DG9[J<6MK:6<#3W%S,1D)'&O+' )]@*PM+^//AS
M6O#6IZO96VKSR:9.MM>Z4NG2?;[=VQ@-!C=T(.>F.]>-_'#7/%?BC5_ &C:I
MIUO\,O$4VL--I?B=[]+R&R\N(E\KA4=Y 3&(WX.2<\5?^ 6J?\(AXQ^*Z>*/
M$%OXGU#3C#J.H^-(L1Q3P>6Q$31KE(C$JG*H2,$'J:!GK/@3XY>'OB!XJO/#
M=A!JMCK%I:+?2VNJ6$ELPA9]BM\WJ0?R/I5CQ_\ &30/AYJ5IIEY%J.IZM=1
M-<1Z=I%C)=3^2IPTA51PH/&3WZ9KA?V>;<CPMXA^+'B0#3;_ ,9W!U>1KMMI
ML],1=ME"W8;80'/3YI&S6IX]\76WBN=-%\*?$NQ\%:]);I?K?-8P79GM6! *
M"8A2N<'()_6@1M:A^T#X,L_!>A^)[>_FU2PUTA-,ATZW>:XNWYRB1 ;MR[6W
M XQ@YKH/A_\ $?1/B7H[ZCHEQ)(D4KV]Q;W$313VTJ_>CEC;E&'H?PKYC^%_
MAV[N/AA\._$OA^^T72M=\)WNIZ;%+K,\AT_6T>5UGN4D^^#,P,JL 0"6&,5W
MG[*3ZQK/B/XG^(]3O[+4(=3UA%AGTN%H[-S%"B.8<\NH8;?,/+%2: /HFBBB
M@!KG%?)?Q3U&SU/X@>*YK*ZANX5C2-I('#J'6+#+D=P>"*^M'[5\+P>$-2\#
MZWXYL-55$N9M0N+Q%1PP\N4,R<CV/X5Z^5_Q_E^J/%S7^ O7]&:FD_\ ()L?
M^N"?^@BK.>>U5])_Y!-E_P!<$_\ 015@]:^I9\M!7B=A\%^?BKIY_P"G.?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "![#_KWC_\ 015V@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<.LL)YVE?&[;Y6!M0,[<X 4\U[#>^(;/3KVTM+B>.*>[<QVZ.X#2L!DA1W.
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MJ6B_\@:P_P"O>/\ ]!%7: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4-Y9! *!^M?0G@GP'H7P[T"VT3P[IT.E:7;Y,=O!G&2<EF))+,>Y8DGUK>*
M^Q]10!X?^RKX6U+PEX-U>SFTB]T'P^VJ33:%INJ ?;(;1@I/G8)P3)O(#$L
M1FN2\)Z>?"NOZSX>UOX<ZIX@UVZ\4R:E::TED&M7C>421W371XC,2<;2<Y4
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M](T^T"D?N;>583)&OLVYOSKT?PY^T#=>+/B=K'AC2?"LMYINCZFVEW^I)J4
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M.A]<T <%X_TWQYX.\/>%_#EYXWOY8-2\60V-OK-JWEZB;)XY&\N9]N"P8?>
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MXGX+>++CQS\+?#6O7@'VN^LHY)L=/,QAOU%=M0 4444 %%%% !1110 4444
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M'_7O'_Z"*O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<\?6FF91W'KUH DHJE9:Q9:E]H^RW4-S]GE,$WE.&\N0=5..A&1Q5KS% S0
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M: -<O]9L;71R@=;Z2X40L#T*MG!SVQUJUH/B/3/%.F0ZCI%_;ZE8S F.XMI
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M;[_P4W7_ ,;H_P"&Q?A;_P!!B^_\%-U_\;KY-W-_>/YT;F_O'\Z/J=/^G_P
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M<1,$<;%A RR @2?-G'/->PM\#/!SZ3I6F2:6);'3--ETFVA=R0MM(H5D/KD
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M>I10PW,VXG>L0(08[8W&J%U\-=$NXO$J/#(O_"1;?[19)"#)B,1C![?* .*
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MD=&:3RR?E))%>M:/\;/&MS\0[BUGO+F32SKM_IJQ7.D1Q6*1Q*2@CN0=S2Y
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M#^5>7C=%'Y_H>M@'\7R_4\B_X0KXT?\ 12] _P#"8/\ \?H_X0KXT?\ 12]
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M% " 8I:** "BBB@ HHHH **** "BBB@!,44M% !1110 4444 %%%% !1110
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MP[O\1_V95_E7X'T;_P *:\!_]"=H?_@OB_\ B:/^%-> _P#H3M#_ /!?%_\
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M9P%12Q9V PH(!QGKBO+/A1XQT>]_:9^.,=AJMC=W4\.B_9X(KE&:9HK682
M'G:>&].]>075SX\T'XK^"]=\0_#V_E\2:IXCGF>1=1@*21"WD2.&+^ZJ(=W/
M4Y[T ?=0Z4M1P,7A1B,$C)!J2@ HHHH ***Y7QI=^+K9K7_A%]/TV_!SY_\
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MN*\=_P"&=9?^BC>,?_!@/_B:/^&=9?\ HHWC'_P8#_XFF2>Q9]Q1GW%>._\
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MHWBO7O EUHG@K5I42/6X[^.X%L'?8C31* RJ6P"1G&>10!]"T5XQXT^..O\
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MIG_7K%_Z *T*SO#W_( TS_KVB_\ 0!6C0 4444 %%%% !1110 4444 %%%%
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MX2^*;W3/#.I1^%+"]TV2UOY;61;F]*7*/.5MRN_8@'7J3G%=-IWB5OCU\6/
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MZM7_ )']Q]%]>PO_ #]C]Z.1G_U4G^Z?Y5Z]X$^'GA;4?"FE7%WX:T:ZN)8
M\DLVGPN[G'4L5R3[FN,F^%/BGRG'V>S^[VG/^%>N^"-+N-'\-Z?8W2A;BWB5
M'VG(R.N#7KY;0J4ZDG.+6G;S/G,[Q-&M2@J<TW?H_(YKQ7\!_!WBFTLX1HEC
MI4EI>PWT5QIMG##*'B?<HW!,X.,&O1 "%]Z44M?1GQH5X'^W9_R:EX\_ZY6W
M_I5#7OE>!_MV?\FI>//^N5M_Z50T >U^'O\ D :9_P!>T7_H K1K.\/?\@#3
M/^O:+_T 5HT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=",Y%25#:(([:-!T50O/L*FH **** "F-(JG!/-/KF/%_@:W\8-;&;4=2L#
M21_9]TT&[/\ >V]: ,WXGWWC&&PL+3P5;V3:C>W"PS7]^"T-C#@EI60$%SP
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M\FJ>//\ KA;_ /I3%0![1X=_Y .F?]>L7_H K1K.\._\@'3/^O6+_P! %:-
MPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH :4!!'8U6BTJT@NY+J.VACN9.))DC =Q[MU
M-6Z* &[:7%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 V1!(I5N0:C6UC4DA1D]ZFHH C2!4&%XI&MT;J*
MEHH 11M %+110 4444 %%%% "8I-M.HH ;M]>:-M.HH :%QWI0,'-+10 444
M4 %%%% !1110 4444 >(_$7]E;1/B)XVO/$LVO:OIMW=QQQRQ6C1^6=@('WE
M)'7UKE[?]ACPW:^;Y7BO7T,LAE?#Q?,QZG[GM7TM10!YY\'O@UIWP;T[4;/3
M[^\U'[=<?:9I[TJ7+;0H V@#&!7$?MU?\FJ>//\ KC;_ /I3%7O5>#?MT_\
M)JGCS_KA;_\ I3%0![1X=_Y .F?]>L7_ * *T:SO#O\ R =,_P"O6+_T 5HT
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0? 3P%J.H^!-"O;ZYT>WDFN)[%&>1RHR6)&2: /83\<OAW_T//A[_P &</\
M\52_\+R^'?\ T//A[_P9P_\ Q59 _9@^$N/^2=>'/_!?'_A1_P ,P?"7_HG7
MAS_P7Q_X4 :__"\OAW_T//A[_P &</\ \50?CC\/0H/_  F_A_!.,_VE#_\
M%5D?\,P?"7_HG7AS_P %\?\ A7@_AGX$?#JY_;,\<:%)X*T1]'MO"FG7$-DU
MDGE1R-/*&<#& Q& ?PH ^CO^%Y?#S_H>?#W_ (,X?_BJ7_A>7P[_ .AY\/?^
M#.'_ .*K(_X9A^$O_1.O#G_@OC_PH_X9@^$O_1.O#G_@OC_PH U_^%Y?#O\
MZ'GP]_X,X?\ XJO$?VTOBUX*U_\ 9F\;6&G>+=%OKR6& );VU_%)(V+B(G"A
MLG@$UZO_ ,,P_"7_ *)UX=_\%\?^%>)_ME_ /X<>$_V;?&.JZ/X)T33=1MTM
MO*NK:Q19$W742G! SR"10,]UT/XV_#Z#1=/1_&_AY62WC5@=3AX.T?[57O\
MA>7P[_Z'GP]_X,X?_BJYO1_V9OA//I=G*WP[\.LTD*,Q_L^/DE0<]*N_\,P?
M"7_HG7AS_P %\?\ A0(U_P#A>7P[_P"AY\/?^#.'_P"*I#\<_AW_ -#SX>_\
M&</_ ,563_PS!\)?^B=>'/\ P7Q_X4A_9A^$H''PZ\.?^"^/_"@#9_X7A\/
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M_P!$Z\.?^"^/_"@#7_X7E\._^AY\/?\ @SA_^*H_X7E\._\ H>?#W_@SA_\
MBJR/^&8/A+_T3KPY_P""^/\ PH_X9@^$O_1.O#G_ (+X_P#"@#:M_C7X!NYX
MX(/&F@332L$CBCU&(L[$X  W<DY%=C#*)D##@5\C?MG_  )^'?@S]FCQOK6B
M>"]%TG5;.&W>WO+.S6.:)C<Q#*L!D'&>E?5?ATYT+33US;1\^OR"@#2HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0VEND,,4<42#"HB!54>@ Z45-10 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-\D[%8@F/O,S?+@=R*N?#WXJ67Q$:_@BTO5]$U"Q*?:;#6;)K:5 X)1N>&!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M36Z"A/J!\X^ /"45WX*\1^#O^$*\0Z#/K%A,E[XAU]XI9;R=E*[Y'5V).3D
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M1:5'J436]]>R3:C+;N,-$9Y&EV'W 8"O4J0#%+2;;;;$%%%%( HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
$@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>avte-20240930xs4021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 avte-20240930xs4021.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &H V<# 2(  A$! Q$!_\0
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MF_;?-(*8\G[OEX/UKI?^%$^*\X_X7+XN_P"_5G_\9H ]GR*,BO&?^%$>+/\
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M_P!^K/\ ^,T >S9%&17C/_"B/%G_ $67Q=_WZL__ (S1_P *(\6?]%E\7?\
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MB?P]'KFF-XBCB$\ND+>QF[C0@$,T6=P&".<8YKYPN?V9-4T7XG_#:ST=(I/
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M3=D5[\B;% %*1F@B45-.,E=,^2=6\22_"W4KJ6_O->OK&&[>QCN+C3XX98<
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M,%95=0X5Q@@$9Y':OBBZ_8^\;:!H]YI>F0>$_&,GB/0H='U'5=?>6.32)$W
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MR4XJ4=F<;3B[,7;BC;3J;OJA!MI-IQVI=WM^M&[V_6@!0.:6F[O;]:-WM^M
M#J*;NYZ5DZMXPT/0+A(-3UBPTZ9QE([JZ2-F'L&()H V**I7&M6%IGS[RWAP
M@D/F2JN%) #<GID@9]ZLM.B1F1F"H!N+$\ >N: )**IV6KV6H_\ 'K=P7/RA
MSY,@?Y3T/!Z'M4L-[!<O*D4T<CPMLD5&!*-C.#Z'!H GHIH?/;]:-XS_ %H
M=14$-[!<&412QR&)ML@5@2A]#Z&BVO8+R!)X)4FA<962-@RL/4$<&@">BFAP
M?_KU NI6SW0MA/$;DH9!#O&\H#@MCTR0,^] %FBL?4?&&AZ/>QV=_K%C97DF
M-EO<7*([9.!A2<G)J_/J-M:K&TT\4(D8(A=P-S'H!ZD^E %FBLC6?%VB>'9(
MTU75K'37D!9%N[E(BX'4@,1G&156Y^(/ABRC@DN/$.E01SIYL327L:B1/[RY
M/(Z\B@#H:*J6>J6NHQB2TN(KJ(@,'AD#C!&0<CU'-6Z "BBB@ HHHH ****
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M0:BR[+&1V8_,,1O(H/5&1N]?=WB#X4^#/%VHIJ&N^$]"UJ_C 1+O4=,@N)5
MY #NI( K=M-'L=.O+JZM[.WM[F[*FXFBB57F*C:N\@9; X&>@XH ^$9-=O?V
MA?CCX'UO0_#?A?Q/?S?#F5KVP\5H9(+::/4A%,% 4_O%E5D/'05T6H?#C6-7
M_:#\2:;HW@3P#K#:?X=TE)[#6X,VUEGSOEME"'"DY[#H*^PK'PKH^F7?VJRT
MRQM+K:Z>=;VR1OM=][C< #AG^8CN>3S5N/2[6WOIKQ+>%+R9%CEN!&HDD5?N
MAF R0,G /K0%SQ73(/\ A#OVEM+TC2[>*TT_5_"Y>]LK4;8()+:14B*J.%^5
MBH]@/2O>*Y/2OA]8:;XXUGQ69);G5=2@AM-TF-L$$>2(T [%B6)/.?I75;O3
M&*!#J*8'SZ4NX^U #J*;N_.E!S0 M%%(3B@!:*:6/&,&C<?:@!U%-R3Z44 ?
MGMI?A'QYX%T>SNH/$GPLUO0OA/?7T?VB\L]3N&MY9Y&<F41J1YD8EYV9VG.2
M,5]N>"]<U/5OA[I>HZO>:/-JEU9K*]WHC.UC([ E6A,AW%3QC<>:^=? GBOQ
M/\*QJWPC\):#X=\?7EG<WDD-['XCMEEC2:9Y";^V.9=Z^9AB =P Z9KTS3?@
MMJ_A_P#9YT3P+IVIZ<-9TN*%EU#4[0SVR2I()&81[@=H)(7G@ >E SPWX1VM
MPGC;0_\ A+? 'Q#O?%7]L;IO$$OB6W:Q+><=DK0)>#]V!C]V(S@<8-?;JG)S
MVK\XOACHGAU/C?H\KZAX5DN++Q%:1/J$7@Z>W6XGF:1XC#.92!YC1.BR%<%\
M 5^CJ^M ,=67XBU@Z%I%[?BRN]0%K"TQMK&+S9Y=HSMC3(W,>PS6I2,H84"/
MCGX\7GA#XIV$#'PIJUY\3?$&F2V&A>'O$Y-B=%3<5;49EW$6Z1E@WF EW*JJ
M#)XXOXE:+;Z?I_Q+U'6-5_M?XB>%%T.U\,ZE+,1<,PCA'F0+GGS9#(6 SG)!
MKZY\<_ #X>_$O51J?BGPGINN:@(A!]INXMS[!T7.>E79O@UX(N=7T+5)O"VF
M3:CH<2P:;<R6ZL]JBC"JA/8=O3M0!U5C(YLXFEXD,:EOKCG]<U\OW/BKQAXD
M_;'^&,/B?P(WA"RL]-\0KI]Z=8@O?[17%H"VR,9BP I^;^]CL:^JL5X3\2N/
MVMO@H!T_LGQ%_P"@6= T>[#H*6D'2EH$%%%% !1110 A&:1D!%.I* .#\8_"
M33?$4);3YY?#FH-<BZ>^TT!9)6SD[O[V>]>;^-K!X(M5C^)OAJVU;PQ:%%M-
M?M3NN<$<LP7Y@0>/P[U]"8&:9-;Q7$;1RQI*C##*ZY!'N#0!\^^#O 7BCPS>
MV-W\//&D.L>%Y)$,^DZX68Q1DC.U@,@XZ< U[AK<VEV^DSRZN]LFG!?WK7A4
M1 'CG=Q7/W/P\MM'U36]?\.*EKX@O;+[-&)F)M0R\J3&.G.,D5@>*?%5DEO9
M^$O&NCRZC'>V EO[R"W;[$&!&1GMSS0)J^C)-$^ _P /K'Q9!XMT;2;>UO@K
M -8R%8) PZE =IX]JSOC/H&I>']"BUGP;X677-8AN%9K:*?R76/G<Z#NPX&!
MZ]^E<Y:_"+5O#4"ZO\)_%^[3W^==*O9?/M']E/\ #6AH_P"T9)X;OX='^)/A
M^Y\+7SD(E^J&2SF;..&'3]:4DI_&KG%+!TO9RA27)?JDM^^UKG&?#'XZW&MZ
MO_PB]M_:&@>)[FX:?^S-?@8R.1\TB)(?EP0#Q\N.HKVZ;QY?Z-"9-8T"XMHD
MY>>)@Z*.YKJEL+"]N(-1-M;RW"K^ZN3&I=5(_A;&0"*Y?XJ^%_$/BOPL]GX9
M\0?\([J8D61;@PB5)%&<HP/8U#IW?N2:]=?^"<U.AB,-1=YN;6UDE?Y-VOZ-
M(#XO\*:Q;/;7)2&.5A(\=Q&5#'J&R./QK7MH--NK^>^M-0_TB6W$'[N8%5 Y
M!"^M>'^$[7XCIX^T^R\>>"K#5T,+V<?B;2)0JPQD=7C)]AVSZ5U5_P#".[T#
M1]#MM+UJ-Q!?A]2U#5C^]EMF8DHA& &R5 /M0XU8Z73_ *^8J.+K5(N?(].Z
M:?3H_7I=>9Z3!I^J6::9##J27$<+'[7)<QYDF7'&W'0T3:OJMA;7\\^EF<13
M!;>*T<,\L9Q\Q!Z'VKRO4]=O?!&E^*-8UE]5\.:)HDR)%=R.+K[9&2H#HB\C
MEL<UU]KK/B*.:*W@U'3-2N'A6X6W=O+G,9Z,4/('O4N<E\47\M3JCBXR?*T[
M_CNUMOT=M#L/[>MQJ/V%A(EP(/M#!D.T+_O=,U+9ZO:7]O#/;W$<L,QQ&X;A
MS[5S#>+=6LP1J'AV<KC!>V.\8JJ/%OA:Y-BEW;O826DGFPI+"4$;>HQ1[:'5
MV]=#?V]/J[>NAWN<GK3JY")K"^M=2_LO7O+GO6#"4S!O*/\ LJ>E;&-334(V
M2:&6P6#!4C]XTOKGIBM%)/8U4D]F:]%84>MZA;V5B]YI<ANIYO+DCMSO$0R<
M,3Z8 _.IAXGL"VH!Y_(6P(%Q)*I55X]3UJBC7HJ*.XCE"%)%8.NY<-U'J*DS
M0 M%)G-+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y9\5_V@-*^$NJ
MV>GWVAZ]JTUS$9@^DV0F1%SC!8L.?:O4Z3:/2FFEN85HU)PM2EROO:_X'E7P
MI_:$TKXM:Y=Z78Z#K^DS6]O]H,FK60AC9=P7 8,WS9;H<<5L?%7XO6'PDTRT
MO=0TK5]66ZE,21:3:B9U(&26R0 *[W:!VHVBG=7O;0R5.NJ3@ZGO=[?I<\4\
M#_M4Z'X\\4V6A6OACQ3I]Q=DA+B_TX)"I S\S!SCIUQ7HWC_ ,=VOP[\*W>N
MWEG?7]O;;=T&G0^;,V2!\JY'KW(KI2H(P11M'I0VKZ(*=.O&G*,ZEY/9VM;Y
M7U/*OA5^T)I?Q;UN[TNPT'Q!I$]O!]H,FK60BC9=P4@,&;GGH<< ^AKS']H>
M_P#&O_"R(4AD\:S^"H+)&*_#6:#^T;6Z+'+74+D.\97&W9D<'(-?484#H*\R
M^(7P!T'Q[XB&OC4-8\/:X85MIK_0[UK:2XA!R(Y,9# 9.#C(S2;3V1K1A4A&
MU67,^]K?@?./B?X\ZS_PKB"XT#Q5J/BO5!X9AOX=?LQ_9T=^5U-("GV1U/DS
MD?(SEL AAM';LO$_[:UU\-K+5-(\8^$8=&\;6=Y8VUO9+JAGL+B*[CE>*=KE
M(=Z*HMYPZ^42"@V[@P->B:C^RCX OM%_LD6=W;Z?_90TC9#=L#Y/V@7#-NZ[
MVE&XMG))-10_LG>"ET6_M)9M8NM4O+R&_.OSW[MJ,4L(*P;)OX1&K. H&,.V
M<Y-(Z#A/#?[8WB'Q_'X;L/"/@*TU77]7EU&W=;G6'MK&%K18V,BS-;[Y(G$@
MVD1@YX(')"K^VW-)I]QJY\$R6NA:3HLNKZ_/<ZDOGV#QRR0/;1QHC"9_.CVA
MMRK@Y)'2M;Q-^RBNK^*?!;V?B#68-+T:'43=:C_:4G]IO/<B,!UEP1C"$%>@
M'05W6C?LW>!=&TV]T^WTMGTV^T==$N+2:5G62W#,Y)SSO+.S%LY).:!'BVB?
MM[7&J:+K4J^#;;4-8M(K2YMK33-4E:WD6>=8?)EGFMHQ'.A=20JNA!)#<59\
M4_M ^*M<N/#NGWVF-X-UW2/'\&AZS9:;J(NH;NWDTRXN5"S>6I*L-F05!#)W
M%>GV/[+OAB#2KBQOM5\0:W'));M&^J:F\[01PR"2.-,\!0RKDD$G')K4U/\
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MSV\<;+'&P0@9EWC@E17":E^V3XTUOX=IJ*^!;3PQ=^(/#-YK?AVZ.LBZ(,&
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M]N)?#VHYPUIJL1A93Z9/%=3X^\ >'OC#X0?1]8!O-*N&69)+68J0R\JZLO\
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M,J02GK[4L.MV,]M%<)=0M#+)Y2/NX9LXP/?- &A124M !1110 4444 %%%%
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M$=F<%1M% ['T+I?[4M@WB2_AU>SBTGPY FHRPZN\^[SX[6ZCM@RH!SYDC.%
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M!=0RY_N.#5K</6M4T]C5-/86BDS1FF,6BDR*6@ HHHH **** "BBB@ HHHH
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M%8,0 DCH#U!#'TH$;/PO_9LM_ARG@:S.J-J.F^%+:Y^RV[0! ]W/(S23X'
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M0?-CZ >E T?4@Z4M(.@I:!!1110 4444 %%%% !1110 4444 %%%% !1110
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MBUAK^S*B4VU@SID@$8;(SP12M=VL5/$1I0C5G62B]GWUOOZ:?B=*OQV\/_\
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MJ(=*6D'04M @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'N7@9'M67KJ:/=I!8ZLMI-%>2>5%;W85EF?!;:%;J< G\#0,^ ]%\)7?Q.^
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MROA#3)O MEKLWAB^N]*EU6\U6.*4,+=252W@D4$"61U()R-J GN* /K<.K'
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M?\:7->'_ /"4_M"?]$]\#_\ A3W'_P B4?\ "5?M"?\ 1/? _P#X4]Q_\B4
M>X9I' 92*\0_X2K]H3_HGO@?_P *>X_^1*0^*?VA,?\ )/? _P#X4]Q_\B4
M;_BK]FGX;>-M$TK2-7\-)/I^E7$MW90Q7<\!@FE.9'5HW#9.3SGC/%=;\/\
MX>Z#\,O#\6A^'+.2QTN)VD2&2XEG(9CDG?(S-^M>%_8_VB?^%G?\);_PB7@[
M[/\ V0-,&E?\)/<^5O\ .,GG?\>N,X.WIGBNI_X2K]H0?\T]\#_^%/<?_(E
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M#'@[XR6%E9>,-'&KVUE<?:K=?M$L)BEP5WAHW4YP3WKAO^$J_:$_Z)[X'_\
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M*+GR[(0P^6P3_13]\_-QC\:Z[_A*OVA/^B>^!_\ PI[C_P"1* /<,T$UX?\
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M9"XB&;4\(#@=JZT>*_VA,?\ )/? _P#X4]Q_\B4 >XTAY'6O#_\ A*_VA/\
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M"PO?%GAJTUB[L>(9I=RMMSDHQ4C>A/)1LJ?2N-_X2K]H3_HGO@?_ ,*>X_\
MD2F2>*/VA&4C_A7G@@\'IXHN/_D2@#2UK]DOX5^(?%MUXGN_"Y_MNZ>*2:ZM
MM0NH/,,0"QY6.55PH  &,#TKT]==TNVUB'0C>P)JK6QN8[)I!YK0JP4N%ZD
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M .1%]3J]U_X%'_,ZC<*-PKEO[<U__H!C_O\ 4?VSXC/318\>\M']KT/Y)_\
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MI_-$.G-;Q9:HJ(7,1Z2(?^!"G"13T(/T-;*47LR+-#Z*3<*3=3N(=129HS3
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,C!K&U_P=HWB::PFU/3X;R:QF$]L\@YB?U!K84Y-+6A[)Q/Q$FT_4X8_#?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4M8-V]YHDEY>DW.J1RR(([.% 3$.AQZCN:V8IUD. PW#[RYY4]<&@"6BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y._:+L=9?XK&[O;C
MQ]'X2?1?L]F/ LIDW:AO;<)XQG;\NW!/RGD$\5J_LA:7\0?"NF:_I/B2#5/[
M+M-/L'M4U=HRRZ@T<C7,4+(!F$#[/VP':0#(%=O=?L??!^\NI[F;P-9///(T
MLC^=,"S,<D_?]2:S/VAKY/@C^SX;?PG=-X1L+:XL].2]M%$C:?;2SI')(F\-
MRJ,Q!(..O:@>Y\R^'?%WC*Q^+_A":_N]/TXZSXCMKB+0+#PM%%,TKW$MO?*D
MY3.^%%C9Y3R8W8YZ5^B"\<5^=?A/XQRQ_$'3IK#XP:]XJU.R\=67A[2]*NID
M:#4M&F9$EEEB6)5DDQ(Y\_A@4'H:_111B@0ZLWQ#IUUJ^C7MG9W\NE7,\+QQ
MWL"JTD#$8#J&!!(Z\C%:5% 'R)\<?V0_'OCCPMJ4NG?$V]UK7SHK:3#'J]E
M%E5I \F64 1EL $A>0H%:'CSX#?$+4W\8>&+,6&KZ%XX_L]M4U^YG\F>T>%(
MTG80@$,7$8( ( )-?518 XHW"@"O:6WD6T<6.$4*/? Q7S%J/PPTOX??MB_"
MZ\TZ^UB[EU;3?$,DZ:GJ4MU'&0+1L1*Y(C&6/"XXP*^I:\)^)?\ R=O\%/\
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M_9C41?+$4NA#]G#JQ&$] .E &EN![T YK!@\+R6=C8VEKJ=Y#';2F5G=P[S
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M6L*'7[PVNGR2:1<I+<R^7)$I!\@<_,WM3IO$;0#5&;3[O99 $$)GS^,_)ZT
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M[!/B+_T"SH&>[#H*6D'2EH$%%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"]BN;5_NS*<*W&>">O%(#5HK)?Q5I,6J1:;)?0QZA*K/%;.VUY%50S,H/W@
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M9D2VCC,KRD_*J@9)^F!6;%XVT.>:QABU*&66^B$]LD9W&6,D#<,=N1S32;V
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MG_\ 73^L5 /&?"'P5U#3?AQXT\/W=MI%I-KML]O'%:!G@4_9_*$C@@9)(W'
M_6L#6OV<-4D,\]C/IOG3W<[F-PRI$CQQI%(N!]^'82@& -W!%?02W*G/.<<<
M$4C748QEP"3@ GJ?2I5::;: ^?\ PE^S7J'AK4-"U W=B]]8S6LMQ=+O\V8I
M=7,LK;B.6=)HT.>NS!X K-\0?"37O&/Q&\06ATM8-.F:61M:NBRFZ1Y;=A;\
M'E%$3 =N>@YS]*"9"!@YR.*9%<Q3.P1E9EZX(./KCI3^L3OS ?,/B'X >*K/
MQ3<ZI!9Z9K>GS:BC+I32&."6'S"R>8H3 5%^7G?[ #BM6W_9@U*VTEDGU"WU
M:_8QB6\>5X9YXEM5B$)D )V*ZC ((*JN037T?^'X4@8=^*/K,P/']:^#^NZ]
M\'=)\-2:C96FN64R2+<6T?DPJF61TP@'6&1UX !;!P*Y&S_9=UBTM&8:W!'J
M[11PC5U9S<1@),C%6ZC(DCXSSM^E?1V\9QGFD657;:#R!DBDJ\XJR ^:;+]E
M_7)-%>&?4[:SNA9S00>5(S+;RLL:^8@"*J[A&V2%S\_.3G/6Q_"[6_#_ ,"=
M<\.K&FH:E=R331V,<Q\E!(X/DJ0JA4Z\*H W' KVHR  9Z=>*;)(J1[FX'J:
M'7G+5C/GMO@1XKFLWM8;C3;"SOY(9YK1)I/+T]8I)7$$(  93YN,\8*G@YJE
MIW[-7B%)+62.^T_0A%$D @TYI-L15 AE0X'SL1N/3D#G/-?1XNXV8*&&XC<!
MGJ/6E2X1QN#94\[ATI_6)B/F_5?V=O$^I:!HMA:_V/HWV9OWL=E+(%#A8E\_
M)4G<WE,2%VD[^6)W$H/V:_$$%G;11RZ3Y<(\A+7<ZQ1DQ^6+E0!Q(I^<<=6;
MD'FOI$W"#//X>E/W# /7-'MYVL!\W7_[,^LQ:+,EO=6=YJ++O,LLC*)I_-D9
M9959'67"O@JP.>0".#7=?%+X6ZQXT\):+IZ-IFH75K:O;7-O>*T=K([P^69E
M50<%#EE';L0>:]760-T.10SA>IJ76DVFWL!\^67[/FOV6OV5Q-=:;J4*WJW*
MSW+/YEBJ3&0^2,'F0'#=.@ZBM3QS\ ]2\2ZQJ^IV=[:6UU>W<TIE)<.]NUM%
M&+=B/X"\9R.F&SUKVS[0F[ /)YH6[C<95@P)QE2#3]O.]P/&OAQ\(=5\#ZEX
MAU*XCL%;5; Q1Q6.=UHP9RL,9(&4 88Z<]A7)^#?V>=:O/#FDG4H[#0I8].$
M/V"%WE6*X^S>7]I.0,S%CECR>.I/-?2$MS'$F]W5(Q_$QP*<CAAE>A%'MYZO
MN!\Z?\,UZQJ$\UR]QIVCV]\S17FD64DA@6&.-# L9P-K&=&D<@#(D(Y.<T7_
M &9_$Y@E1M1L)YX40M?,S&?5 +A)O(GW*PV )M&0PX7(QQ7TYG/TI"X'T]:K
MZS4[@>0^(/A%J-_\%=,\*K)'>:I9>6ZM-<GRRZEB-Q9&#J-V-C+M(&,#BO.X
M?V?_ !AK<VM23S6>F7"73EKJ'*-JZ[81L=,,JPYC;:I# 9^Z.<_4+2!!EN!Z
MGM2[@0#QSSFIC7G&]@/GC1/V>O$&DQ74$MU8WLESIXABU"XGE:XL#Y;H8(B
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61110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>avte-20240930xs4022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 avte-20240930xs4022.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (X X4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "D/2EI&^Z: /RL_:4U"ZA^/OCF.*ZF
MC7^T3\J2$#[B>AKS;^U;X=+^Y_[_ #?XUZ%^TO\ \G ^.O\ L(G_ -%I7F7I
M7T5)>Y'T/YIS.36.KV?VY?FRU_:M]G_C^NO^_P"W^- U6^_Y_KK_ +_M_C56
M@5K9'F<\NY;.KWH'-]<_C.W^-!U:\QG[==#_ +;M_C7U5^SOX$TR[^#D^N^'
M?".D>._&9NVBN;#5KE8_)B'W=H(QS^&?6N=\8:'I6L_&OP/8Z?X$G^'_ (AN
MYQ'J&GZQ:K+ITK\8>-5;]XO4'&.U<?MES-6V/I_[%JK#TZ[J?';2SZNWQ;-]
MU<^=CJU[Q_I]UST_?-S^M+_:U\/^7ZZ_[_-_C7U1X+^%]AX@TKXZ:;J(T.TU
M&RN$CBU66#R+:R Y=T')10 3@5Y3XS_9YN]&T+0]<\+Z[:>-]$U:Y%E%=V$3
M1,EP3@(R,21D]_S%5&M%NST,J^3XJE3C5A[R=[[75I..U[O;IHKGEIU6^8<7
MUU_W^;_&D.J7^.+^Y_[^M_C7MFL_LKRV5MJUGIOC/2M9\8:1;?:[[PY!$ZNB
M@ LJ2'AV48R, ^M1Z'^S7877P^T#QEK?C_3?#6DZME0+RV=G23. H ;YNF2>
M *OVU.U[G/\ V/F'/R<FMK_%&UKI/6]M&]5NNIXNNJ7_ 'O[G_OZW^-/_M:]
M_P"?ZZ_[_-_C7M>F_LEZW<_%27P7=ZS:VP>P;4K/5HXC)!=0CH0,C'OR<>]9
M^F?LZVNN^(M1M-+\;Z=>:#HUK]HUKQ ;>1+>Q?)'E $YD<[<C& 0/7%+VM/N
M']DX];P>[6ZO=;Z7Z=7M;6YY$=6OLX^WW7_?YO\ &E&JWHZ7MT/^VS?XUZOJ
MG[.5Q;>(?"<&G>(K76O#7B2X%M::]:P,%1_XE>(G(8>F:Z&Y_9%(O_$.B6'C
MW2-2\6Z-$]R^B10.'>$="7)P&(QE0#C(R>:/:T^XXY1F$F[0V=MUVOIKKIJK
M7OT/!AJ][N/^G77'I,W^--_M6^/_ "_W)'KYS?XU[U<^%].'[-G@#4(]/M(M
M8N?$OV:2\DA#,PWD!7(Y91W%:_BG]FV_\;_%_P 9Z2=8T71)]$L(+MWMK$V]
MFP91_#O.S Y)R:E5XWU.B638EP3IOF;4=-OBBY=7T2/G :M?X_X_[G_OZW^-
M U:^'6^NO^_S?XU[E<_LL6$&A:9XD3XEZ$_@ZZ<P3:RT+J8Y]VT1I'U<DY[C
M 4DX K U3]G+4="^*_\ PAFI>(-)L+<V_P!M76KJ7RX7M\9W!2<EO]D'MZ5:
MJTWU.:>59A3LY0W:6Z>^VSV??8\L_M:^.1]ONA[F9O\ &D75;TC_ (_[DCVF
M;_&O6_%7P%A\)Z'H'B[1O$]AXQ\,7>I)927$$#0%)-X&THV<@\\_3VKU?XP?
MLUZ)XH^+$NGZ;XKT'PMJ=]:1-IGA\0-NG*IR6*X"$D' Y)ZXJ?;4[KL;QR7&
MRC)V]Y..EUJI7LT[V>UE9ZMGR;_:U_\ \_UU^,S?XTJZK?=[VY_[_-_C4FOZ
M)>^&-;O](U&#[-J%A,UO/%G.UU.#@]QZ&J.36ZL]CP).<).,F[HM'5K['_']
M=?\ ?YO\:1M5OMN/MMU^,S>OUJK2'[O^?6G9$\TNY]-_MD7EQ /AHT5Q-&S:
M I)5R"3GO7SC_:U\?^7ZY_[^M_C7T3^V;_J_AE_V+Z?SKYK(P*YZ'P+^NI]#
MG[:S"I9](_\ I*+7]JWW_/\ W/\ W];_ !H&K7O_ #_77_?YO\:J"E(%=%D?
M/\TNY;_M>][7MU_W^;_&@ZM?$?\ ']=?C,W^-5!P:6BP<TNY8&J7P!/V^YQ_
MUV;_ !H.L7N/^/\ NO\ O\?\:M^&-:B\.^(M/U.>P@U2*UE$C65S_JI@/X6]
MJ^T/ WBOPO=_"_5?B!XT^&/AGPWH48VZ8D<6Z>_D_P!E67[I/ /L>PKGJ5'3
MM[MSW<MR^.8<R=;D<==4WHMVWLCXC_M:]+8^WW(([><V?YT[^UKW_G_NO^_[
M?XU[1JOA^[\4_ .Z\3VFGZ/;0WWB+[/#8VM@?M:.[';&LV[[O;;M_&MBS_8[
M:3Q#IGAF[^(&BVGBZXC6>YT7RG>2!",\.#AV']WC/)!(YI^U@OBT#^R,74<?
MJ]Y)I.^B^*]MWN[;;^1\_P#]JWW_ #_W/_?UO\:#J]ZHYOKH?]MF_P :]/T#
MX%6-]J'BI=<\<Z3X:TS0KTV#7-TA>:X?=@,D*MNV].?KZ&O0OA9\"8_ 7[2/
MAS0-<DL?$VCZA827EO,(B8IXRF58HV<'O^-*5:"O85#*<96E!25HR:5[IVN[
M:I.]KKT/FXZM?$X%]=?]_F_QH_M>](_X_P"YQT_US?XUZQXV^"!\%: OB37]
M5BT;4-4U&0:5X=:V+32P^;@2/R-B8YP1TV]S7M7@WX8VZ_M*+HFN:=H>I))X
M6-S'#::?Y%N'.S:Q1F;Y^>6]^U2Z\4KI'10R7$U:G).7*[Q73[5[7UNMMK7/
MCW^U;X?\O]S_ -_6_P :/[6OS_R_W/X3-_C7KGB#]G$VG@O6-?\ #WC#2?%L
MNBN1JUC8(RM:^NUC_K /7 'I5_PE^S#9^*8=*LU^(VB0^*=3M&O+7188VGRH
M&<-*IVJV >,=O:K]M32NV<BRG'RFJ:AJU?XEKTT=[-WTMO?H>*_VK? ?\?UT
M#_UV;_&C^UK[C-_<_P#?YO\ &O7/!'[. \2^#-;\2:SXML?"UEHM^UC>FYMV
ME";3@L"IRQSP !^-=O<_!?X>67[-^H:U;>+[&]O3J+(FNFPE7>5 VVJH3E<]
M<_[53*M!:&M+)\95@YNT5RN2O)7:7E>_Z'S8VJWV/^/^Y_[^M_C31JM]_P _
M]U_W^8?UJJ?I@]Q1758\'F?<MC5;[_G_ +G_ +_-_C1_:U]_S_71_P"V[?XU
M4HHL@YWW+9U6](_X_P"Y_P"_K?XTAU6^ YOKGZ>:W^-5:&Y7\*5D)SEW/L/Q
M7=SC]DSX92+/*)&E?+!SD\OU->+?VA=?\_4__?QO\:]E\6_\FD?"_P#Z[/\
MS>O$J^<G\3]3^F<N_P!RH_X8_DBQ_:%U_P _4_\ W\;_ !H_M"Z_Y^I_^_C?
MXU7HJ#T"Q_:%U_S]3_\ ?QO\:7^T;H?\O4__ '\;_&JU% %G^T;L_P#+U/\
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M'&B+XDL;<7%SH\F8]@QG;YI.TM[?TH \K_M"Z_Y^I_\ OXW^-']H77_/U/\
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M5RO6[F'UE/\ C5>O;OV;-(L]0L_&UU<:!;^(KJQL4FM;*XB\S>^3P  3S[4
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MY?@-=R^-?#>C0ZU;7>D^($:2QUN"-C&X52Q!0G(/'0GO0!YI_:%U_P _4_\
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M_"H?&O\ T*VI_P#@.:3_ (5#XV_Z%;5/^_!H Y*D_$5UW_"H?&W_ $*VI_\
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M; 1PR''RL7Z!N]?=6P4;!0!\6?!SPSXQ\87F@7/AO^V?AG>1_#K3](_M35M
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MP\66'AWPUITUKJ]KX(M8CJME+-;QJDXA=&W@&-D<!2P#Y&>17W6$Q1MYSWH
M^ O#'P_U/X>0>#_B"?!WCO7O"ECKU]>WNG:Y%#>:U(L\"Q1WGV2)4V+E<&/!
M< [CZ5[S^QEIFH:9X4\?SZAX8O?!XU/QOJ>HVFDZA!Y,D5O+Y31G:.,$<\<
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MEBAB2&->B1J% _ 4 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPHI<@UC^+/$UMX-\,ZAK=Y#=7%K8PF:2*R@::9@!R$1>6/L*\47]MGP5P?\
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MB#.2N2JR[L8S61\*/ _BCXS^&](\+>%]/U#X=^'8_%NJ^(KF_P#LT<R63Q3
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M>+?C5JPN_$7A77;G4XFT2ZAOIK>SNU6UC',:L%=&8%"W7KZ5U?\ P\E^#?\
MSU\1?^"2;_"E3_@I#\'II$2-_$;R.0JJNB3$L3T XHY7V']:H/3VB^]'K/[-
MK%/@SX;M)/"-SX&N+*#[)/H=S"8_(E0E7*9^^C$%E?\ B# UZ97SZO[;7@IA
MD>&_'9'J/"UU_P#$UV?PN_:"T#XN:Q=Z=I&D^(]/FMHA,[ZSH\UG&P)QA6<
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M#.H^'H6N]:NKR#0;J2*32X7@Q:I<3QMQ(P #8."V1SCG9_X>2_!O_GKXB_\
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M .T[N ?05R'[/_[1'BIOBUX2T[QK\6O%?AGQ7?77DZWX:\::'LL9F)P(K9E
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MPY>C_(_+=/N+10GW%HK[M;'\./=A2'I3B,4T]#3$?IE\(O\ DF7AC_KPB_\
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M9\:]#Q,=\:]!:***\\\TDMO^/J#_ *Z+_.OHB#_5K_NBOG>V_P"/J#_KHO\
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MF3^I%L%%%% PKP;QE_R-FJ_]=S_(5[S7@WC+_D;-5_Z[G^0KS\;\"]3S,?\
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M:***YSF.R^%/_(RS_P#7LW_H0KUT=*\B^%/_ ",L_P#U[-_Z$*]='2O:P?\
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MU]%5\9B_X\_4_L'A7_D287_"@KYQ_;T&?@6__80@_P#0J^CJ^</V]#CX%O\
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M9\:]#Q,=\:]!:***\\\TDMO^/J#_ *Z+_.OHB#_5K_NBOG>V_P"/J#_KHO\
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MB@ HHHH **** "BBB@ HHKSWXX_&[0/V?_!*>*?$L5Y)I9O8+)C91"1T:5B
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M%/-=POQ5T[X(>)_B&/B+:3>&]5\<>%]'N=(L8+1Y$FN(]/\ L\UC"5!S(DO
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M*\*_#2R\,^,/$GB=KF6_UC7'C$MQ, #%!&,1P)C^!<L?<L: .QHHHH ****
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MQ>JM?YDM+112-@HHHH 3%%+10 E&*6B@ HHHH **** "BBB@ HHHH *2EHH
M*2EHH 3%&*6DH *,5RGQ'^(=C\-?"UUK6H!I5C(CAMXO]9<2MPD:CN2:U/"N
MJWNLZ#87FHV)TR]GB626S9MQA8\[2>Y%.SM<Q56#J.DGJE<V****1L)2T44
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<UX_\:6GP_\
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MI)U0*,$;.<@&N[U+X6V%U\4_V0/!GBG5--^(&F165V!>Q R6M] LFZ(8?EE
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MTVG2??;ZTVJ PM:\!^'?$FL:7J^K:)I^I:II3F2PO;JW5YK1CU,;'E32>(_
M?AWQA=Z7=ZYHEAK%SI<QN+"6]MUE:UEX^>,D?*W Y'I7G/QY_:K\%?LZ:OX?
MT[Q:FIF?75D-I_9UKYY9DX"[0<EF)  '<U@^+?VU?!'@KPUX7U'4=(\3G5_$
M5LUW9^&(=*=]56!6*M++ .47*DC/44M /4_%GP=\#>/]3M]2\3>$-$U[4+<
M17>H6$<TB8.1AF&:O7?P\\,7NL:1JT_A_3)=4T=#'IMVUJOF62GJ(FQE!]*\
MSN_VQOA;:?"&W^(_]N2RZ%<7(L(;6&W+7KW9_P"780]?,&.14OP8_:R\$?&_
M7-2T+3X]7\.>)-/A-S<Z-XCL6L[A81UDPW\-(#T2V^&WA2QO]?O[?PWID%]K
MZE-7N8[55?4 <_+,<?..3U]35"Y^"O@"]\(VWA6?P7H4WAJV<R0Z2]A&UM$Y
M/++&1@'/I7B]W_P41^$-KXE?3Q<:W<:+#=?8IO%,.F2-I44^=H1IOK[=Z3QM
M\;?$ME^VS\*/ ^DZM%)X,\0Z+/?7$$:*XN"$=D</UQPO2@+'NVC?##PCX;U1
M]2TKPQI&F:A):+8/<V=FD;O;J,+$2!R@ Q@U!H_PA\$>'-+UC3]+\(:)I]AK
M&3J-K;V"+%=GG_6J!ANIZUP?@3]K#P9\1/AIXW\=:7%J4>C>#[F>UU%)H5$K
M/"H9O+ )R,$8SBO!?VB_^"A;^%/#WPHU+P-I&JRV'BZ>"\N+N?3C*QLC)AH8
M<'!G.UAM]"*>@'U9HWP.^'GAN339-)\$:!ITVF3-/8O;6$:-;2L,%T(&02."
M:U_#GP_\->$&U0Z%H6GZ.=5F-SJ'V*W6(W4I!!>3 ^9L$\GU->*^%/CF?$_[
M4?\ PCJ>(M0M-,G\+1ZTOAF_TQ85M@PW;Y)B=P<#JA'%9MS_ ,%$_A!;^(Y+
M$7.MSZ)%<_8Y?%46ER-I239QL,WKGV[T: >U#X,^ 5\+3^&!X-T/_A')YC<2
M:5]@C-LTIZN4QC=[U+H/PD\%>%=5L]3T;PEHVD:E9VYL[>ZLK*.*2&$\F-64
M9V\GCWKSOXJ_MB_#SX.^--&\,ZY+J5Q>ZQI_]I6$FEVIN4N$/W(T"\L[GA0!
MWZUM? +]ICP;^T7::P?#?]H6.IZ/-Y&H:1J]L;>[MFR0"R>AP?IWH ]7Z "E
M HVT#TI@= GW13J:GW13JD HHHH **** "BBB@ HHHH *Y_Q-XXT7PC)IL6L
M7R6!U*Y6SM6E!VO*WW5W8P">V2,]*Z"L+Q?X.TWQQX<OM$U: 7%C>1E'7NOH
MRGLP/(/8BFM]3*KS\C]E;FZ7V/+_  Y"?BS\6M1UZ9_.\.>%IFL--BYV2WG_
M "VF]#L^X/?->U@8.:YWP#X$T[X=^%['0M,#_9+4-AYFW22,22S,>Y)/6NDJ
MI.[T.?"494H7J?'+5^K_ $6R\D%%%%0=H4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% "$9KX:\37NL^!/VLOBM\1M':[O(/#T.C0:SI,;9CGTV6)
M_.D"_P!^(JKC Y 85]R^M</HGPKTK0O'?BWQ7$LL]_XGBMX;Z&8AHML*,B@+
MCN&.?6@#Y)\'?%[6+ >*=*\ ZC90:IX^^+%[I]AKMW ;FWM+<VB3O.J9 =]D
M>$4G!)YKWSX&>.O%O_">>,_AUXVU2U\2ZOX<2UN8?$%I:"T^UP3J2HDA4E4D
M4J<[>",56L?V-? FE^ M4\)V*W]C876NOXCM;BVN#'<:;>D *]NX^Z% P!SP
M2*[?X0_!31_A#::C]BNK_5]5U.43ZAK&K3>==73@87<W8 <!1P* /DKXK^//
MB#\8/ _B+Q<-?TZQ\"67C:/P_#X6_L_$YCMK^.(W)N<[O-:16.S&W:1WS4OQ
M#_:L^(V@?$"]U;1-;;6O#.G>([;2KG2].\-9T=;>2Y6!O,U20JYG&[I$K*&
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M 4444 %%%% !1110 4444 %%%% !1110 4444 )2T44 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <\_^L?Z
MFDR:<_$C_4TG JP$R:7^&D/S4'@8H 2BBB@!5IU,HS0 X@4 "FT9I6 4]:4
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M5*JE6J)KFV3Z)=_-[_<N@M%%%0=X4444 %%%% !1110 4444 %%%% !1110
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M@G:,]3@'CVK13=K'DSR^$INHY?:3^2Z>C;;/CVQ\-WR>*7T75M1UJ/Q VO\
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M4D2-<NPC;+!?<J6IK<G$2E"FYQZ:_=O^ NE?%C3-7^)NI^"HHYQ?V%N)WNF
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MN$AC2<J$,@7!*CH,UZF&R-T,3#$73LVWIU;J:^MIK_P'T..KCE.G*GKJK?\
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M444 %%%% !1110 4444 %%)FB@!:*3-+0 4444 %%)FC- "T4F:6@ HI*,T
M+124M !1110 4444 %%%% !1110 444AH 6BDS2T %%)FEH ***3- "T4F:6
M@ HHI-U "T44W=0 ZBDS2T %%%% !1110 4444 <^_WW^M-)X-*_WW^M( *L
M#Y6_:9_:A^(WPM^-'A'X<_#KP7IGB_5_$%A)=QQ7UP86RA.0&W!0,#/)JO\
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M'3;^)KZ<_&C%%@!10>6%%'?U-%@.@7[HIU-3[HIU( HHHH 0J#UI-@]*=10
MW8*3RUQC%/HH :5!%(R!AQ3Z3% 'G_ASX(^&/"VN1ZG86\ZRP,[VUO+<N\%J
MSYW&*,G"9R>GJ:[\1C&"*7%+3;;W,J=*G27+3BDO(;L'''2D\M1V_.GT4C4J
M)IT$5Q)-'$J2RX+N!RV.F35@Q@T^B@5D-V+Z4% 13J*!C=@I0,4M% !1110
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M9G9548]3ST&30Z<T[6 [2BO,/AG\8T^)_B'Q)9Z=831Z5IT5G-9ZD^-ETEQ
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M.220O(XP>1G/%4Z-1:V ]8HKA_ 7Q2TGXB->16(N+6\M C36=T$$J(XW1O\
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M]3U>PO=.\0:I87&F1KH<&B02RH;L2@RB4(, [<'Y^-H..:VHIRFDG8#J;/\
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MH-Z/')NY=3N(5@NV>/-_<QW8NF(XX)8;=HX -9GB32?&7Q \!#5-7TR[FO\
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M@':JE 5//3G(K'T'X"7'C2-]2\7>);9_$^J70OM+FDMK>['V=;:.!AY3+Y;
MH%/ ^4X.<DUB6'P.\2Z9X;T:ZMQ=_P!M2:9-<2:;) ,0L%?9$TH.<LK(GE=,
MYKHEU?Q#JOA/P=-=_:3J\7BJ--'FN[/[)=2V*JOG-)#@%% \Y2,#*JA[C-/F
MM:$[_P!?D!Z9XU\)^'O#OPNTW1M9UMM*TG3[BS<7T@52SQ3+(H(  &XIC '&
M>*X.]L/ 1TNPU#2OB.FDW]QK5[?:=JL)CE/FS-^^A$9&U@-P'(R.*](^(WBJ
M2Y^$>O:WX<LGU^\%E(UA;);%W>?[B$1E<G:QST[&O(O&OPSC\!:=X<L-"MM=
M.OZ9I/V72KFRA$ME=7A<-)Y^%.TNP+LS[5(SS7/2NU9NVK [OP_^S;HFAF![
M'5+U8DU'3]3"/M;<]K&RC)_V]Y+?I6[>?!>";X?CPQ;ZU=V934/[2BU"-$,D
M<HG\X84C:0&XP>U<=\>-$\2Z]-X1ALTU7;'INJ2WJ:0[JGVE;9# '*?]-,[1
MW(KSRYAUSPSJFDVNOR^(E\(7,5I=ZFJO,]S+=-:EI"N/G($@RZIPIQG JHJ<
MTI<^N_W >@ZY^RQ;:O$;VY\573:U.]S+J6IS64$OV@S*BLR(X*PLJQ(JLG(
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MW #9Y52:]E\=W_@^Z-CX)\0/!&_B998K6R(*&X,8!?:1T89!!X.17!Z3\,_
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MPMT+6-9U'6=3N_#4BS7M]9ZM<+=6DAD;>TCH4W.<G@DDC@=.*QC&,6U);[:
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M&0-ASC).\Y/KDUH>'_A9HFC>.[_Q+IWB'6!?ZK/_ &A=6)OU:&;<H"@H5W;
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EWO1125:4G9^OZ@?2\1R,@YYJ2BBN( HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>avte-20240930xs4023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 avte-20240930xs4023.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &C X # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BD)Q32] KCLTF^H6DIA>JL3S$YEIOF>]5R])O
MIZ"NRQYE'F57\RCS*!7+ EYIXDJIYE.\P4:!S%K?3@0:K!Z<'Q2L5S%BBHED
MJ0$&D5<6BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;X-?]% T?_OZ?\*/^&QO@U_T4#1_^_I_PH]A5_D?W,+H]FHKQG_AL;X-?]%
MTC_OZ?\ "C_AL?X,C_FH&D?]_3_A1["K_(_N871[-17C'_#8_P &?^B@:/\
M]_3_ (4?\-C_  9_Z*!I'_?T_P"%'L*O\C^YA='L]%>,?\-C_!G_ **!H_\
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M_P"%-_X:U^$'_0_Z3_W\/^%'L*O\K^YD:GL/F4>97CI_:V^$/_0_:3_W\/\
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M36?X@US3O#&BW^KZI=)9:=90M/<7#YVQHHRS''/2LX8R:486O;^OU"Q^=0^
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M1110 4444 >=?M!WOV#X,>,9^/DTZ3.[T.!_6OS#T?2P+VZ2]DE,L_[R.$G
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M%^U+XB^(?A?X7:M?MH>ER>)=5O+*ZMI&</(D387R!W;US[54:%24>=+3^O\
M(/(^JP,TNWM7C@_:U^%:ZA%9-XPLEN7O'L2C9&R96VE6.,+SQSUK<\9_M!>
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MO1%$.L4?\.!\[?0=OK65)(T_& B#HG^/J:4*\SF21MSGJY_E4BQE\;0<$X!
MSGV KD;<CU4E CV*H!/WNP[UJ:1X<GUA3/,XL[!>7F;I]!ZFMC1O"6)8?M4,
MEQ<RL!#I\0W22,>F['3Z"OKGX/?LJ$_9-=\>PK(R$/;>'T_U<8[&4CJ?]G\Z
M;Y:2O4^XZ,%A<3FE3V>$6BWF]EZ=V>6_!3]GK5?B3#%+;1R>&_!^?WNHR+BX
MO1W$0]/]KI7VGX)\"Z%\.] BT?P_81V%F@^8J,R2M_>=NK&MI42)$C1%BCC
M5(T&%4=@!Z4N<8[UPU*DJKU/U?+,IPV54[4E>3WD]V2;J-WO46ZC=]*RL>U<
MEW>]&ZHMWTI0YI#N2AL4]7J ,33E:@=R<-3PU5P:>#2L6F60]2*U5@YJ56J3
M1,L*U2AJK@T]6H+3+"FI%-0 T]6J35,G%2*:A!J13S2+3)Q3U-1*:>IH-$3*
M<&I0:@!J1#4FB)E.*E0U"#4BM18T3)J*13Q2U!84444 %%%% !1110 4444
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MD7&O>,=5\6Q3W/\ :OBBYU6&PM;YUL[FV+(T GA!VL5*G@^U-5Z-KVM;R]-
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M(WFKZY"-&\6>&WTF[\8I#)J%F;B4-FX\OY7167< ><=:^D?A]?>(_ GQ[F\
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MHNE6"PP86>7Y(U'&T=S6K/,D$+R.V(HQDGT KSO4]3-]<R7LF0K';%'CD+V
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M>_URU73]'G%M?S1MO%O*2 $;;G#?,..V:U-"O)=9T'3[F0F.6[M$D8H?NLR
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M;7M,UFZTD2ZGINGR:5:S^<X\NV==K1X#8.0,9()]Z?H/P;\'^'/A\_@>RT6
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M*YPS36D661)(T&<J=I KV)+D2@MD?C\*CQ=>KC*GQ3D[>A!J]]]E@$28$TG
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MGRW^8-ECG+,6 .XG/%-\;?"'PC\1=,LK#Q#H4%_:V/%IAFB>  8PCH0P&,#
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M,U$RU1BR!QBHG'-3,*8131DT5G7I7AWPN7/[3/QE_P"N>F?^BFKW5QR*\/\
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MPCNWI_P_^1HHGT)X@^/7@#PG%I,FK^*M/L4U2!;JT\V0YDA;[LI 'RH<_>;
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M3?%6G7\\ZZ/8VS06#VLJ!#"957>S#:&$A7/;I6CAAK:/\?ZT$=)^S7\1-?\
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M_P R)H?_ ("+7I+FHF:KYY_S/[S)MGG!_9X^&.?^1$T/_P  UJ-OV>OAD/\
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M&PJRPJ,IFJ,VBNR9 KPWX5KC]ISXT_\ 7/2__135[N8\FO#/A6,_M0?&D?\
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M3'DF_P#)V[>GW.,TGAI:6:WM\RCZC\K_ &C1Y.>YKXSUSXZ?$?Q#K/CN_P!
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M88#]L>/! \WS0-Q^\,#%=_U96O=_=Z;:Z[BN?6P^).C?\+"_X0M9B==_L_\
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M45(O%,0<U*!Q2-$.09J513%6I5&*3+0HZ4M%%26%%%% !1110 4444 %%%%
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M&3QS;VF[*6FE!@OHS'_Z]?:42@\5^>_[7FM_VE\4/%#C[MNT-DOX#)KJPO\
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M6D R:D5:#1#U6GT@&!2U!:"BBB@84444 %%%% !1110 4444 %%%% !1110
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M0.;1W +!2?0=!V-6L'-N236GKVN%S[ZLO&.CZEJ.H6%IJ=I<WNG@&\ACE#&
M'IOQ]W\:GT'Q'IWB?3X[_2+Z#4;%V91<6[AT8J<$ CT(Q7YQ_!#P9XQOM6_:
M->S\=W%B;1KF.Z86J,;I]K'>23\O (P/6K/P[^)WC#]G_P#8HT?7-/\ $+7=
MWXBU)=/TR&6T#C2P7?S'4#F1CC('K6TL$MH2N[I?>KBN?I/N IDC@*37P_\
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MP0_Z)WI/Y/\ _%4?\,2_!#_HG>D_D_\ \57N-%'UBM_._O861X=_PQ+\$/\
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MR,]J^S\48S4PKU*;;B]]Q61\X?$W]D:'Q]?>&]<TWQSK?A7QGI.F)I,_B2Q
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M,B"!98B5V]LM7UG\4O\ @GSKES(K>$/$4=_8J^Y;'4/W;H2,$AAP16K\.?\
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MI7*L,"D4X+BEHI#$ Q2T44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-*@TZB@")HZ8
M4YJ?'-&VG<FQ5*<TW8,U:*4WRZJ]R6BL4'I2;*L&.DV^U!-BN4H$>:G*4!":
M L0>73@E3>72^7B@+$(3FG!*E"4\)2*2(@G-/6/FGA:=2N58:% I:6BD4%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 A'%-Q110)A1113ZDA3L444,I!C%+112&%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
F444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>avte-20240930xs4024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 avte-20240930xs4024.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &S XX# 2(  A$! Q$!_\0
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M*,+WW$"O9+;6-/NKI[:"^MIKA,[H8YE9UQUR <U^8?PC\>ZU\-?^":OBC5-
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MX7_%GXF?%KX/^(4^$W_"$^$_#TB0PZ99RJ[6L(D5F:0# 4'MQG@D]:['Q?\
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MX"/S_P#&G_!-3PG:? >>?0M,U*;XD1:1%)M-Z6CEO!&ID4)C&"VX 5R?Q#^
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MC'_@GI8_#NXTV32O&=C>-J$-A=,$+LDSD(6Z#<CG'OBN%O\ P#\>/VBA\,/
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M484444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !2$X&:6FN-R,/4=J &_:$QU[XI^1
M7C'Q-^&'Q!\5>((KWPSXU_L"P6 1&T=&X<$Y;(ZYXZUR(^!7QCQS\45_[X>N
MF%&$E=U$OO/ KYCBJ524(82<TNJ<+/[Y)GTKFC(KYJ_X41\8O^BHK_W[?_&@
M_ GXQ?\ 14E_[]O5^PA_S\7X_P"1C_:F-_Z 9_?#_P"2/I7(HR*^:O\ A1'Q
MB_Z*DO\ WP] ^!'QB_Z*DO\ WP]'L(?\_%^/^0?VIC?^@&?WP_\ DCZ5R*-P
MKYJ_X43\8O\ HJ2_]^WH_P"%$_&(?\U27_OV_P#C1["'_/Q?C_D']J8W_H!G
M]\/_ )(^DWD5!ECBG*P89!S7BGPT^%GQ$\+^)EO?$GC@:]IOELALQ&P#,>A)
M)XQ7LL$90D'./4US3BHNR=SV<)7J8BGSU:3IOL[7_!M$]%(*6H.P**** "BB
MB@ HHHH *2EHH **** "BBB@!!2T44 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4E+10 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(&.T$#@+NSBJ.G?LQ^4^I7NK^)C>W]Y<V5Q)/::?%:QE;67S$W1IPSL>&?\
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M9>@_ +4=/T2Z\.:CXUU#5/"O]GRZ99Z7Y"1&&%P0"\@YE9!PI..G.:IN+>B
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0D4"EI#)S\O"G Y)JOX+_:$T_P :^+K+P_#X8\2Z9/>V;:C;W6IV<<,$ML"
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MDK#N?,.J?L\^(!\-/#7AF*UT#6)M,DO6:YO#+!-:R3W$DJ3031_,"H<97HQ
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M'ID=Z^=K#]G_ .(NJWMUJ&I:$+?4Y?">JZ+>7]_K@NY;Z\G6+RV5!\D,/R,
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M$T*YLM7N;O5Y[F&[MF>29O*ABN)&:184/^K+!@"1SQZ4[_A"OC;_ -%-\/\
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M.\.>#M-\*SZG-8(ZR:G=O>W3R,6,DK8!.3Z   =@*\W_ .$)^-O_ $4[P_\
M^$P?_C]'_"$_&W_HIWA__P )@_\ Q^CE7= ._:E_Y)_HW_8Q:9_Z/%>QBO O
M$?P7^)_C==-L_$?Q&TB[TJUU"WOY8+3P_P"3)(8G#A0_G'&<=<5[XGW1QCVI
MR:Y8Q3[_ * .HHHK, HHHH **** &[<"D"C.2*?12L@$P,YI:**+ %%%% %:
M[L+>]:%IX4E:%O,C9D#%&_O#/0^]3*@7H/SI]%%D W;2CBEHHL FVDV\YQ3J
M*+( INT9SWIU%%@&E03S1M IU%*R :% I<"EHIV ;M .0.:"H'0<FG446 KP
MV4$$TDR1*LLF \@4;FQTR>^.?SJ?:/I2T4K(! ,4$9I:*=@$Z48I:*+ ,,8+
M9[T;!G-/HI60",H/6C:*6BG9 -V@<4N :6BBR 3%&!2T46 3&**6B@!*6BBF
M A% &!BEHH KO9PO<),T2-,@(60J"RYZX/;-3!<#CBG44K -VXZ4ZBBBP!3=
MM.HHL P1A<XI64%<4ZBERH"M;V,-M*\D<2K(^-[@?,V!@9/>K-%%.R0"8%!%
M+119 )MH Q2T460#70.,'I1M&<TZBAI, JM=6<-V4\Z)9-AW+N4':?4>]6:*
M+ -50 /:C:"<TZBE9 )MI-M.HIV ;M&:4 "EHHL 4444P"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHI6
M ****+ %%%%%@"BBBBP!11118 HHHHL 44446 ****8!1110 45%YM'FT#LR
M6BHO-H\V@+,EHJ+S:/-H"S):*B\VCS: LR6BHO-H\V@+,EHJ+S:/-H"S):*B
M\VCS: LR6BHO-H\V@+,EHJ+S:/-H"S):*B\VCS: LR6BHO-H\V@+,EHJ+S:/
M-H"S'NX3K0KAJ\H_:@O?$>G? SQ?J7A;Q WAG5=.L);P7R6RSOL1"S(NX@*6
MQC?SMZX->2>,?'_Q+B^'?P\_X1N[U*Z;6?#+M=2V6G_:;EKMK;<DIE887#<X
M!#$D$9Z5:@VKWZV ^L]P]:-P]:^:O&G[0'B;X;^#?A=IVGZ,OBKQ;XET^6:1
M]8N?[.1!:VZ2W#294XD.<!?6N"\4?M^ZAH.@>&[]?!]BEQJVFOK;6MYK'E[;
M0/M6*)O+_>7#<G;@#BJC1J2UBA'VED"C<*^1O%W[:NLZ/J^MMI/@F+4- T;^
MP9KR^NM2\B<0ZFH\L+#L.9%)/?&%[9KU[X]?&'4?@]I/A^?3]%C\07NL:K#I
M,5M+>?9@&DR Q?:>^.U2Z<TTK;_U^HSUK</6E# U\I_"O]L76_&_B;PU9ZWX
M/M=#TO6K35BE[#JGGLMSIY GRFP8B(("DG.<]J\<^%'[0'CW5O!WQ>N-8\63
MSW&H:%)XC\/M'-N?3XS+(@C3^[M 4X]Q6T<-4;::M_P]A'Z'[AZTM?./[,GQ
MW\0>/-8NO!OBK1ELM6TO0]/U2+4([[[3]NAF0?/)\J[)-W.!D<^W/T3YM8SA
M*G+ED.Q+147FT>;4!9DM%1>;1YM 69+147FT>;0%F2T5%YM'FT!9DM%1>;1Y
MM 69+147FT>;0%F2T5%YM'FT!9DM%1>;1YM 69+147FT>;0%F2T5%YM'FT!9
MDM%1>;1YM 69+147FT>;0%F2T5%YM'FT!9DM%1>;1YM 69+147FT>;0%F2T5
M%YM'FT!9DM%1>;1YM 69+147FT>;0%F2T5%YM'FT!9DM%1>;1YM 69+147FT
M>;0%F2T5%YM'FT!9DM%1>;0)J LR3(%&X>M>3?M1?$/6?A7\!?&/BSP_)''J
M^EVJ36S3()$#&5%.5/7AC7+:G^UCI'A'Q#HNAZYHVNOYT=C'?:[#9#^SK:XN
M8T:--Y8%\EADH&"YQUJU3G)7BKB/H+(HW#UKY8\4_M7WFK?&3PGX4\)V=[;Z
M2?$,VDZOJM[:+]EN1' SNL$F[(92.20.*Z[X3?M<^$?BQXWA\-Z=::Q92WL5
MQ<:3>ZA J0:K%"^V5X2&)&#GAPI(&:;IU(J[0'O.:-PKPCXN_M9^&O@[XKO=
M!U72->OY;.TAOKNZTVU62&U@DD\L2.2P( 8C@#)SQ7,^-/VLS=_!3Q]K_A73
M;_2_%&@:BNAPZ=KL"K(+R1D$+;5)#*1(K 9SQSBB-.I*S2T8SZ=!!'6@'-?&
M=M^U9XYB^&GPHU>>T%YKVH>()]%\0Z?86:R2SO"&#I"A8!6) [U](?!GXL:3
M\:/ %AXLT6.[M[*[:2,VU\@2>"2-RCHX!(R"O8FB=*<-9+01WM%1>;1YM9CL
MR6BHO-H\V@+,EHJ+S:/-H"S):*B\VCS: LR6BHO-H\V@+,EHJ+S:/-H"S):*
MB\VCS: LR6BHO-H\V@+,EHJ+S:/-H"S):*B\VCS: LR6BHO-H\V@+,EHJ+S:
M/-H"S):*B\VCS: LR'?1OJ+)HR:>AT6)=]&^HLFC)HT%RDN^C?4631DT:#L2
M[Z-]19-&31H%B7?1OJ+)HR:- L3;J-Q]*@Y]:.?6D+E)M]&^HLFC)IARDN^C
M?4631DT6'8EWTNZH<FDY]:!6)M]&^HLFC)I!RDVZDWU#SZTN33#E)=]&^HLF
MD)- 6,/XA^$XOB'X$U_PS-<-9PZO92V3SQC+('4J6 /<9J3P1X93P7X/T?0D
ME-TFFV<5FDK#!<(H4,1Z\5K[A2[O<4;JW07*?+_[</PH\6?%(^ H?#VAOK.G
MZ?<7=Q?"$1LZ,T:K&-KLI()W9PP]P:K:3^S!XE^(WACPEKGB'5D\!>-+'3VT
MJ\BT.WB>(V>[Y456!6.0 #E>F37U0V",D=/6C: >./7%:*K-04%I8GEU/!?$
M_P"R/IOB1_&;'7[R'_A)3H9<E5=H!IF?+P3]XOGYB:]!^*WPF@^*R>&UO+^6
MQ_L75K?5T,2@^:\1R$.>@-=T.G%+4<\]+O;_ "L5R(^:_P#ABFSAT#3M/M?%
MM[;RV-OK=O%<+"F[&I$>8?J@''K3YOV&/!NGQ6R^&YW\-L=#FT2_:UC!^WB1
M%4S29_C!7/'K7TC15^VJ_P P<B/'/@C^SE%\(/%FM^(9_$E[XEO[^QM=+@:[
MC6,6UK N$0!>I)QD^PKVC?4./?%+DU#E*3O)ZCY4B7?1OJ+)HR:6@<I-NI-]
M0\^M+DT@Y27?1OJ+)HR:>@[$V^C=4.3ZT9/K2%RDVZC?4'/K2Y/K0'*2[Z-]
M19-&33T'8EWT;ZBR:,FC0+$N^C?4.ZER:- L2[Z-]19-&31H*Q+OH\S-<D_C
MJUB>Y9[*]6TMYO(DNQ'F-&S@D\YQ[XK7CUN":_NK, B2V"&0GI\P)'/X4:#<
M))7:_K^F:Q?'I1OS5-KB)(_,,J^4!G>2,?G2R3I$I9Y552.#GK3T(+9?%+NR
M.E95AJ<.H6$=Y$["%@2-XY !Y)K-TOQ?;:K=1*EM=0PS@FWN)4PDP'<'/'MF
MEH7R2UTVW.FWT%\5F:?JUKJD!G@E_=!BI)XP0<'^56C-&)/+\Q2V,XSS1H3:
MSLRSOHWU46YC=BJR*6'4 C(^M'VR ;OWR?+U^8<4:!9EO?1OJ -N (.0>AIV
M33L.Q+OHWU%DT9-(.4FW'THW5!SZTM(.4FWT;JAR:3GUIZ!RDV^C?4631DT:
M#L3;J-U0Y/K1D^M N4EWTNZH<FDY]: L3[CZ4F^H>?6ER:0<I-N- 8U!SZTF
MX^M <IY+^U#\+_%OQF^'4W@[PWJ6G:79:JZPZK/?QL["W#*W[H#^+*]Z\B\?
M?LC>-O&/Q#O-0;Q!I=YH,=WID^E&^\TSZ?#;!!)!$H.Q=Y3<7P2>!7UP6 ')
MSFCC.*UA4G"W*3RIGRWI_P"RGXLL/BA::A_;6F2>$K3Q+=:]'"4873BX@:-T
M)Z<%N*D_9N_9.UGX*^-K6^OG\.S:;I<-Q!;7ME9L-0O?-8D/*['"[5;;A>N*
M^H <D8(_&D/#]<'VJG6J27*WIM_7WBY5<^<OCM^S!KGQ3\6^,M6L-5LK2+6]
M"M-*A2=6)1XKE969L=00,5SWB7]CC7/%>JZQ;7FNPVWA_6/'">)KT6<CQW)M
MDMA&D2L.C;\MGM@5]84A%"KSC%13T7_ _P A\B/D:V_8W\4^$[J!/#'B"SEL
M-+\3MXATM=89YI!NA*LDK=6)?G=[U[;^S5\)[[X*?">P\.:I>Q7^J&XN;V[F
MMP1%YLTK.0N>< $#\*], QWHY]:4JM2:Y9/3^O\ ,:@EL3;Z-]19-&360^4E
MWT;ZBR?6N=\7^/=#\"1V\VMZG;Z<EPWEPF9N7;(' ]LC)[9IJ+;LC*K.%&#G
M4:275Z(Z??1OJK;SB>%)%=71P&#*<@@]"#4F[WI6-%9JY/NI-]0Y/K2Y- ^4
MEWT;ZBR:,FC0=B7?1OJ+)HR:- L2[Z-]19-&30*Q+OHWU%DT9-&@[$N^C?46
M31DT:!8EWT;ZBR:3<11H%B;?1OJ')-+DT:!8EWT;ZBR:,FC0+$N^C?4631DT
M:!8BR/6DW^],S29]JBYM8EW>]&[WJ&@<4786)MWO1O\ >HB<T@HN%B7?[TN[
MWJ(GVH!Q1<+$N[WHW>]1$YI*+A8EW^]+O]ZB!]J0T7"Q-N]Z-WO40.*0\T7"
MQ-N]Z3?[U%2Y]J+A8ES[T;O>HMU&ZBX6)=WO1N]ZAI<@T7"Q*6QWI-_O5.^D
M*VTTBH9#&"P0'&2!TKPSX&_%SQ?XW\9ZAI_B.QAM[![>2>S,<7ELH60K@G//
M_P!:ANUCKH8.KB*56M3MRT[7UUU[+KL>_P"_WHW9(YQ42GY5XXQ0<'MS1<X[
M'RY\3?VA_&FC?&*Z\,Z(EI#;PS1V\5M?Q!#<.0,G>3]TD\'V-=[X&_:/TKQ!
MXJ'AC5[&;0M9),*^;,LD$D@'*JP_2O0O$_@#PWXS"_VWHMGJ,BJ5661!YBY]
M&ZBO%]8^ _@SX+6UWXS;5-5>"T!1+:18Y@-QQCE03Z9X(]:7O)^1]?3JY3C<
M-&A*BX55&T>7[4^C;7?K=/R93^*'[2>K:?\ $*;PMI,MMH6G6LGV>[U;4$+D
M$]9% [#(QZUSGP#F\=7OQ=^U+?:IK&@1F1+F_OO,2"5/X656[GJ!Z5W/PUU#
MX9_'GQ!/?3>$H(_$.FQH66[.[? .$?@A6QTP1D>]>_Q1I! D2*JH@PJJ  ![
M"EJW>YKB<;1RZC+ 1PO+4<5&?-9Z_P R:UUO=:VM;0L;AZTN[WJ'K2@XJKL^
M+L2Y]Z,^]1;J-U%QV)=WO2;_ 'J*ES[47"Q+N]Z-WO4-%%PL3;O>C=[U%GVJ
M"\O8+"!I[J:.WA7[TDC!0/Q-%PL7-_O0&SWJG97L&H6T=Q;2I/"XRLD;!E(]
MCWJ?/M1<5B7/O1GWJ+=1NHN.Q+GWHS[U%NHW47"Q*6]Z-WO46?:C=[47"Q+N
M]Z-WO4-+NI!8FW#U%-W^]1[J,^U.X6)-_O06_&H\^U)1<5CS&]@#V.J6Z/?O
M?->O)'8I&QBE(?(5N,;3W.:V-8@GDOM7D>%Q$S6AG" G,8!WXQU]\5V^X_0>
M@I.P'8>E!T2JN3O;^M/\CSQ(8DO/,,$A\,FZ8B(H^T'R^&V]=F[]:9"L4;PO
MJ4$YTD^>;561FV@M\O Y'&<9KT?<<YI <=.#WHN'M7V\M_ZU[F%X3'E>&K-/
M*96$9Q$_!/)^4YK!TF6-;ZRM],CO(8II"MUIMRA*0(<YPQZ8[8-=WWS2DYZT
M&:EK)M;_ -?UU/-[31[>X32+%;=U1-2F^U* R\!6*[O8\"ECM)D\0R":9XKM
M+XF)4MV9VC!^4!\XV8XKT?-)T&.WUHN7[65V_P"M?Z_!'FNGF:76H94MWMW=
M;I9H8XG&SY#@.Y^\2>E6['PU;%M(#VCD2Z8[S!\X,@48W>X.<9KT#/X\YYHS
MG.>?K0$JKEHM/Z9G^%BX\.Z<LH<2"(9W]?QK5S[U%GFC=1<Q:NVR7/O1GWJ+
M=1NHN%B7=[TF_P!ZBI<^U%PL2[O>C/O4(XI=U%PL2Y]Z-WO46Z@G-%PL2[O>
MC=[U#2@XHN%B7/O06QWJ(L?2@MUHN%B3?[\4!\]Z\F^/GC3Q1X,TC1V\(Q12
M:I?W+0[IHA( JH6VA20,G'7VKJ?AMXCN/&/@'P]K]]"D%[?VJRRQQC"ENA('
M;.,X]ZU]G)04^C/)IYC1J8R6!2?/%7VT^3[ZJ_J=@6P.M<E\5/%MSX*\":SJ
M]E!)<WEK;F2-(DWD$\!B.ZC.374Y]1S37171@P# C!5@",>GTJ(M)IM7.W$4
MI5*4H0ERMIV?9]SY2\"?M-^+(M"O]:U^SM=;TN%UC+6LJ0SQL?5,\K[XKUZ7
MX_Z%??"[4?&&D))>&T7;)I[8$L4O'RN.PYSD=J9XY_9V\$^-HU>33_[%NE8O
M]JTI%B9B>NY<$-7F_B+Q9X)_9YN(O!LNF7GB.(VV;F.X$8*I*V2=P4;\X^[V
M&.:].U&N_P!W%\W;R^\_-H/-LEC*./Q$?8\ME-ZOG>VED_E[VV_;SWQ-\8?%
M7Q.\/2R'69K:_@G"Q:)HL$F^5&_C=UYP*^E/V>K/Q+IOPYL;?Q0LR7JNYA%R
MQ:80DY429/WN3QZ8K6^&_ACP;I&DQZEX1T>SLK348UD$T"?.Z^C$Y;CTS79C
MBL:]>,H^SA&RO\_0]K),EKT*JQ^*Q#J3<;:7Y6KW3UW\K)(FR/6C(]:BW4;J
MX+GW%B7=[T;_ 'J(G-(*+A8EW^]&_P!ZCS[49]J+A8EW9[UXM^T_X+3Q'X5L
MM6CTM]:NM&E,OV*/.987&)!QSD  C'I7LF[VKA_C%XR?P/X*O-0MYX8-0EVV
MMD9_N><YP#^'7GCBMJ,I*I%QW/'S>C1JX&K#$?#;79[:IZZ.SV3W9P?@SXPP
M?#_X1^'[CQ?;W=O?2[K:TLTC_?2QJ<*<'&!@C)-7OAQ\=K_QW\2]4\-3:*MI
M#:0&59X9?."$8PLCCY1D$=#UK ^%/@>7XD^"KH?$"&#Q'##?L;.[WD&0#AF#
M)C<I.?0&O=-$T'3?#E@EGI=C;Z?:JH18K>,(, <9QU_'-=%5THN4;7?X+T/G
M<LI9CB8T*JJ\M%*.C7O2LK/FZ:O5-/;[S30C;][.><T_</6H1[4NZN&Y]REH
M2[O>C/O4-+NHN.Q+GWHW>]1;J2BX6)MWO06]ZA'%+N]J+A8DW^]&[WJ,GVI!
M1<+$P;WHW>]19]J"<T7"Q+N]Z7</6H0<4;J+BL2[AZT;O>HMU&ZBX[$N[WHW
M>]0GFBB["Q-N]Z,^]1;J7-%PL1Y]Z,C^]4>!1@4C:Q)_P(49']ZH\"C H"Q)
M_P "HR/[U18'K1@4!RDN1_>HR/[U1X%&!0'*29'K1D>M1\4<4!8DR/[U'']Z
MH\"DP* L2Y']ZE_&HL"CB@5B3(]:,C^]4?%&!0.Q)D?WJ,C^]4>!1@4!RDAQ
MCK6)XO\ %VF^!O#]UK.KS-!8V^ SHNXDGH !6M@5B^+O"FF>.?#]UHNL0-<6
M%P062-BC9'((([@T>A4%!5(^UORW5[;VZV\SSB;]J'P:L>G-+%JL%CJ08)<R
MV;*N0=N0>X^E<Q\*? 6G_#_XE7ES?^,+6Z>[1XM.LY)"KN';><9/.,XX[UUU
MI^S/X!A%BDMA?W*V;;HH[G4)9$ZYP5)QC/88%<;\>?@F-1UO_A,M/M)]4@M8
M0MQHUJYBERH^26%AW7@E>^*+/=GUF&GESG+"86I.$*B:;DHN]G[J6NE]F[I>
MA]'IT )P<=.XXIW7^+BO)/V>/%OBKQ/X%>;Q3:RI<07!AMKJ=/+DNHO[S+U!
M4_+G S7JHQP/2C=7/EZ]"6&K2HS:;B[::HF^A%<_XX\(6GCKPGJ.AWQ/V>Z3
M 9/O*PY4C\<5M9 /)_6@G@]OI1N8Q<H24X.S6J]3X8^'WC>3P)\3?#5C8Z4+
M#4;&1M'U9"=SWJM)\K,/X2!SGOQ7W<ZA&(]#6$/#.D#6I=8.DV/]JR*%:]\A
M?-8 Y'..H]:7Q+XKTWPCH\^J:K=1VEE",R2L>GMCN?:A+E/<S7'PS6M3G2I.
M,K6>MW)MW_-V76UET-L$>OZTO']ZN)\"?%7PW\1[=Y-#U!99$)WVTR[)E .-
MQ0\@>AKL, T'C5*-2C-TZL7&2Z-69+_P*C(_O4S(I.*".4DR/6C/O^M1'ZFD
MW<\'- K$_P"-(>!]ZHMV>E!ZC/8YH$U97)-PQP<FO'?VJ?L[?#)%O+F>VLC?
M0K.\"Y.S/-8_Q\^)GCGP;XBT&R\.6QBTZY4O<WR6)NBK[\;<?3G Y]ZYSPAX
MM\;>/-<\0Z+XHTL^(/"@MY)/])TLVJEEY7 /.?;/XT;Z'TV!RZK1C3S*4H\D
M?>MS>\TG:RTM?LGKUM8[W]E.>";X4)%:W,US:6U_<0P/.,'8&RH_(@_B:]AS
M[U\[_ [X\^')MOAQ=#7POI43F*UO =MO))G[KY^Y(W)P2?TKZ"0Y .>O.?6C
M0X<VH5J.-J.K!PYFVKVZ^:TOWMU)MWO^M Y[U'^-'XT'D\I)^-&1_>J/ ]:,
M"@.4DR/[U'']ZH\"DP* Y27_ (%1_P "J+ ]:,#UH#E)?^!4?\"J+ ]:,#UH
M#E)<C^]1_P "%1X%&!0'*29']ZC(]:CP*.* Y20'/>CIWJ/\:.#0'*29']ZC
M(_O5'@48% K$G_ J,X[U%@>M+P.] ^4DR/6CC^]4?%)@4!8F_&DR/6H^/6C
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M32Y*&OO W4['HS?M%V0^"%E\2GTNX6QGNEM_L7FY=%,YAWYQGMNQC/:M:?\
M:0^&]O8Z5>3>*81;:EN\B7[/,=H640LTOR9B42,J%GVC) KG%^ >H0_ G3_
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MIVD\+Z;(TPE$A:'.X20^1)GG^*(;#[ 5U-E:Q:?:06MM$D%M!&L,448PL:*
MJJ/0  #\*PJ3IR24%9FU.$U\3+6*,>]1Y-&37,;V)-OO0!4>\BD\PT:A8E*T
M;:CW$T;R* L2;:6HMQ-&31J%B3;1MJ/)HR:-0L2;:-M1[B*0R$ DG  R23@
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M?\$^HQ>)==J*V1N>(?A)J7AP2R3:KI%W:V]TUE=W-E=&5+2< X63Y<C.T@$
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MHX+L0N/FIVO_ +5OBR/7DM='T#13:31CRC>32%U<Z6U^<[>"H",GJ<BO7?\
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M'XZU:.U@XCM;N;[5 H] DFX ?2OD,1P[=MT)_)_YG1&OW/W&Y]J.>PR?:OR
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MI%:>62&3,<BQG#.8\_,%SUP<5R8\2ZPS1LVLZAG.4<W4G7;LR#NZ[<+_ +H
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M<GS,^WKP4:+<5HD4_C _AZ3P%?V7B?4QI=C= (LX!,F\'*E%'4^U>7#Q_:_
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M\QVJOF-EN3[**\_'UG0P\YK>Q<(N4E%=3].+6UBLH(H($6*"*-8XXU& J@8
M%>;_ !V^(H\$^%TM+&Y6/Q'JS?9=-C_VR<%R?X0,]3QFLKQ!^U1X'T2R-Q:7
M4VM'S/*,=C$3@XSDL> ,8KS_ ,<^'[7]IN/3/$&@:FVER6D+QM'J0"HJ[OF(
M(/!%?E<8N[;/L\#ELJ5:G5S"$H4K[M/=*Z5M][7*O[,=EXQMOB9KUIJ&HW%Y
MH]DC+>S-(9();HXQY;GJ0.I%>O?M ^/5\#> ;LK<O::CJ(^Q6;HN<2-P6SV
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MQJCQG#168/RQ$CH9",D>@'K7YQ-\W '2NJ^*GQ$U+XK>/M9\4ZK(9+O49S(
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MPU&5:IM%-OY'7&3/3IZ]:4?.!V^E>)?LQ6/B\Z%JVJ>*KJ\D-_.KVT-ZQ+J
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M4^$WA35[MY?-N+/4+@1R+/9WOES%8X?)&P_W3'\K8&#P>N*UM0BW=/\ X/\
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MGA61-TG_ (^[5\[D5^A9?2]EAH+J]?O/E<3/GJR8E%%%>B<P5Z#\#_C=XE^
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M-C^1_P!5S7XL#/KTYK]*_P#@F3XL.K?"3Q'H$C9?2-5\Z,$\B.=,C ]-R/\
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MZP"(JLFX[A\N!@ ;0,C(JX5:O-%2CHPLCRZB@]<T5Z!(4444 %%%% !1110
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M((3[Y ZD#N0.*ER4=P,&BI[ZRGTV[:UN8F@N%57:)QA@&4,IQ[@@_C4*(9)
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MX3ELF<]?$4YTW&+U/Q,(HVFOTB_X=(V9_P"9^G_\ E_QH/\ P20LQ_S/\_\
MX!#_ !K['^U,-_-^9X7*S\W=I]*-I]*_2'_ATA9_]#]/_P" 2_XT?\.D+/\
MZ'Z?_P  E_QH_M3#?S?@PY6?F]@T8-?I#_PZ0L_^A^G_ / )?\:/^'2%G_T/
MT_\ X!#_ !I_VIAOYOS_ ,@Y6?F]M-&#7Z1?\.D+/_H?Y_\ P"7_ !I/^'2%
MG_T/\_\ X!#_ !I?VIAOYOP8<K/S>P:-I]*_2'_ATA9_]#]/_P" 2_XTO_#I
M"S_Z'^?_ , E_P :/[4PW\WX,.5GYN[31@U^D7_#I"S_ .A_G_\  )?\:/\
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MU?Q3X5U35YVF?2OLMO>74=H(;58U6 V9$? 7D>;C&>=W-?6/_#HZT_Z*!/\
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M#_&D_P"'2%G_ -#_ #_^ 0_QH_M3#?S?G_D'*S\WL&C!K](?^'2%G_T/T_\
MX!#_ !H_X=(V?_0_3_\ @$O^-']J8;^;\_\ (.5GYO8-&#7Z1?\ #H^S_P"A
M_F_\ A_C2?\ #I&S_P"A^G_\ E_QH_M3#?S?G_D'*S\WMIHVGTK](O\ ATA9
M_P#0_P __@$O^-'_  Z/L_\ H?YO_ (?XTO[4PW\WX,.5GYNX-*H((K](/\
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M1_PZ0TO_ *'Z\_\  )/\:/[4PW?\PY6?FQM/I1@^E?I1_P .CM+_ .A_O/\
MP#3_ !I/^'2&E_\ 0_WG_@$G^-+^U,-W_,.5GYL;3Z4;3Z5^E'_#H[2_^A_O
M/_ -?\:3_AT?I?\ T/\ >?\ @$O^-/\ M3#=_P PY6?FQM/I1M/I7Z4?\.CM
M+_Z'^\_\ U_QH_X='Z7_ -#_ '?_ (!I_C1_:F&[_F'*S\U]I]*-I]*_2?\
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M5GYK[3[TOS'&<X'3)Z?YYK])_P#AT=I?_0_WG_@&O^-'_#H[2_\ H?[S_P
MU_QH_M3#=_S_ ,@Y6?FOM/I1M/I7Z4?\.CM+_P"A_O/_  #7_&D_X='Z7_T/
M]Y_X!+_C1_:F&[_F'*S\V-I]*-I]*_2C_AT=I?\ T/\ >?\ @&O^-'_#H[2_
M^A_O/_ -?\:?]J8;O^8<K/S7VGTHVGTK]*/^'1VE_P#0_P!Y_P" :_XT?\.C
M]+_Z'^[_ / -/\:/[4PW?\PY6?FO@^E&#Z&OTH_X='Z7_P!#_=_^ 2?XT?\
M#H_3/^A_N_\ P#3_ !I?VIAN_P"8^5GYK[3Z4;3Z5^E'_#H_2_\ HH%Y_P"
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MTNYT]%%%:'@"44M% "4M%% !1110 4444 %%%% !1110 4444 %)TI:0]#0
MF\4%P*\O^,/CS5O \NF36,]I#9.97O'F"O*L:*I!2,L"P&3NP<C(X-<)J7Q[
MURTMIM3@N--GM9C<+#8JI$MLL13$LASG:RL3R!CBA)O4=CZ++@4;Q7SOX\^/
MFM:3J5W%H\EI<6EO?SP&>&,3@K'903<G<  'E(8CH/I4^J?&;Q#9Z#J^JC4M
M$BFM@T*:3N#3*Z[/W@.?F4[R1G QCFBT@L?008&FO,L?WCBN2\$>)Y=4@L[:
M[N5O+R2U:Z>>)45,>9MV85C\PZ'''O7E'QX^*FJ>&O'>BPZ5)>O9:*B:CJL=
MG#O0Q/((RLQ[*$WN/]VFDV["/H-YTC7+' />G%P*^:/$7QRU&+Q;I=^^I:;:
M:'%+J\7V'S2TQ^SQE8VG4<X9AN&.Q7UJ"/\ :<\0-9LSVNCV\UE%=SW N;C;
M]H$#+\D>"0'96Z9.#@=Z?*V.Q]/;Q3'N$C^\<5\QR_M ^)M!N-2M"MKJMU=>
M(;^WLPY""U@@ACE$+Y8 ,V\@$GH&/.*V-'^+NM>,?'OA%#/::;83WMS;3:5'
M,&N<I"&S)SRI)X(] :FS"Q]""YC8C#=:?O%?.]SXV\5>'OB?XJ2V:VU,76O6
M>CVEM<2NL=I +!KIW"C@N<'ZD^E1Z;^T/X@UBYL[2SM=+DN=4>$VS+*66S5Y
M'0I.!SY@V9QQG)]*$F.Q]%M*J*6/ '>FBX1FV@\UXW\)?B_K7CGQ#%IFKV5E
M;_:]'&KP_8Y"VQ1<- RMGKDKN!'3.*\Q\*_&#7M/\1>(+K7);N73M,N-4.D1
M+( -1EBDPT;GL(UP0O7&3VI\KN*Q]:/*J+DGBD$Z%MH//6O'O#GQ*U+Q?X=\
M;6UQ>V-E?:+"JIK5D3)9YEM_-5QUR8\X8"LCX!^+IG.L:9=ZC=:IJ%G:17DA
M6\2]@E#*<R0R#D;R/]6PXI:B/>BX% <&OF"W^/WBOQ=9:;-:)9:+;S:KIC"Y
MF=<>3-</&]NZ[BP.%4[R #\PZBN^^*_QFN_A_P")M(TZT6UNS,\;W,$AVN(G
ME6,,&) '+9P,D^E/E=[#L>O?:H\XW<T&YC'\5>.Z=XHU#_A07B76'OY#JD$6
MJO'=DY9#%),$/_ 0%'X5Y3\./B-JUCY:7E[<7=O-;Z5*MO)J:W3&25@))/,3
M[N3_ ,LS22N(^N6F53@GFE$BMT.:^5_%OQJU3Q59:;IUS?0:1;7]_IL[76F7
M6Q[:VDO/)>WF<_<<C!SQT;TK5T'XN:]H6NZIH&F3V_B/2;-KVY@U>[GWO)!!
M"KF,%>'(8[=U.S ^E-X]Z P-?.>K_M/3P(/)_LVVC:2SC^VO(9HXY)K22X*$
M*>23&$'/&XDUT?P[^,>O:YXUMM!\26ECI5Q<VJS0PV[^:7;8KM\RDXQNQM8#
MID$YHL]P/9VG1203@BD^T1CJ<?7BO#OBMJ,]Q\1+;3M&\4S0>(E^RR1V:SI'
M:Z=#YG[R2=2?WC2J"B)UX!&.M<I:>,KE+FUU5_&,MG=ZG<:E!JMM-.C)I<,3
M.$<1G[A0*O)Z[OI2L.Q]-_:H_4G\*D1Q(H9>0:^9X]0O1\(OB%JT/B:^M]'2
M 7&DR7%\ANXBD>6:1\_*)'P0AYQQWQ7T7H-RMYHMC.LJ3"6!'\R-@RL2HR01
MP:+ 7Z***!!1110 4444 %%%% "44M% "44M% "48I:* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DQ2T4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+"BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>avte-20240930xs4025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 avte-20240930xs4025.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %3 9(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** &2
M?=XKP/XKWOCS0;/Q5XHNO&<'A/2M,4_V'IMM;13C4'"_*L^\%BSO\@5,8SFO
M?)"<<5\[>(/ WQ&U#XJW_B2^\/Z/XEL;.0+H-K<Z@T<-J@'^L:+:092<_,<X
M'2@">Q\2^.?BUXSN/#UGK$G@1="T2PO=5^R6Z37#ZA=(9%AS("!$BJ<@#))Z
MUD>'?BGXT^)8\.^$K758M UM[F_@UG6+:!7<I:N$+0*^55G)4\@@<XKK-6\*
M>.O"WQ#U'QGX7TW3]2E\0Z;;6VK:7=7)C$%U &$4L;X^9=KLI&,_*#6#I/P3
M\7> +?P]X@T22QU7Q1;7%[<:I:3N8X;@73;Y$C?!VE2!@D<XH Z_X3>.=4MM
M>\?>$O%.J+J5WX0FMW.LR1K#Y]K<0F6-I N%WJ%<$@ ' XK37]I?X5'C_A87
MAW_P81_XUF?#OX67]Q)X^UGQE%;QZMXT:**\L;*0M%;VL4/DQ1AR!EMK.2?5
MO:O)E_X)<? !%Q_PC5W_ .!ST#/HKPE\5_!_C^YN+?PUXETS79K= \R6%RLK
M1J> 2 >!76J.*_.;_@GWX'T?X<_MA_'KPSH5M]FTC3(8K>VC8[BJ"3@$]Z_1
MD4 +1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *3'M2T4 )BC%+10 4C=*6D/2@#X%_8T_P"3\/VCOK'_ .C!7WT.E? G[&?_
M "?A^T=]8_\ T8*^^QTH&Q:***!!1110 4444 %%%% !1110 QY!&N>M-\\9
M _"LKQ9I3ZWX?OK".>2WEGB*1RQ-M9&QP0?K7BOP[37?B1JMW#K5Y>VEIHEJ
M=*D$$Q1IK@G#29'<#%<%?$.E)12O<WA3YTY-VL>_/.$[9^E*LRM7S-H>F75G
MX4\>ZFNM:I+<Z9//9V_FW;,JH.A(_O>]=]\!K>.?1GU /K;7$D:++_:TA9&.
M,[HP>U84<:ZL^1QL7.AR1<KGK^<TM,3J?2GUZJU.4****8!1110 44F<49S0
M M%%)D4 +12;AZT;AZT +129HR* %HI,BC(H 6BDR*,@T +129!I: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ I#TI:0]* /@7]C3_ )/Q_:.^L?\
MZ,%??0Z5\"_L:'/[>/[1_P!8_P#T8*^^ATH&Q:***!!1110 4444 %%%% !2
M=*6F.2#@=Z &RC(Z?I7*>#/!47A*ZUJ2.YDN6U.\:\;>H 0G^$5%XS^(>G^"
M;BT@O4N9I;E7:);>/>2%&3FJ/ASXNZ-XHOY+:U-S$R6GVX//'L62+H2I]N]>
M=4KT%/ED]3HC3J\O,EH,A^$]O;Z!XETK[?,8]<GDGDD*#,1;L!5OX?\ @;4/
M!R&&Z\176LVJQK'##.BJ(@.XQ7 ^"_C+KFNZ9XHFOH[:WN+:V:^TT!<!H,D
MGUZ5T'ASXWZ?<Z#+<ZIY]I<V=DEY<EH=JNK<;HQWYXKBI5\*Y*:T[7-Y4Z]G
M%ZGJL>W)VX/K@U)7->"?&5MXRLI[B""YM7B<(\5U$4<9&0?<$=ZZ6O:ISC4B
MI1V9PM.+LPHHHK0044A8#%4KW58+(X>3+=D7EC2;2W NY_&F/*L2EG(11U+'
M K"EUB\N3B)!;)W9OF?\!T%5'@$K;IF>X;UD.<?05Q5,73AMJ=$:,I&Q/X@M
M(SA&:X;TA7=^O2JDFO7#',-KM']Z5OZ"H4C5 ,  >@XI<#TKAEC9/96-U0BM
MP;4+^7K,D0_V$S_.HMUQ(3NNYB/0' J;'&/TI, =JPEB:CZFBI070A\@D\S2
MGZN:/LW^V_\ WV:F_"EK-UIOJ5R1[%<P,O264?1S3A]H3E;R< =B<U-UI,4*
MM4747LX/H"ZA?1_\M4EQV=,?RJQ'K\B#]_:-@?Q1'=^G6JY%&VNB&+J1W)=&
M#V-:TU>UNONS*K'^"0[6_(U=W"N7F@CE_P!8BO\ 7K^=+!<75GQ!*60=(IN1
M^!ZUVT\9%Z2T.>5!K5'3YS2UEV>M17+".3,$W]UNA^AK2#CUKT(R4E=',TUH
MQU%)2U0@HHHH **** $W#Z4;J\H\9:Y\4M3\33:+X.T?2-(TN%%,OB77Y'E5
MV89VP6\>"VW."S,!GM7/2M\<_!2FY_M7PK\1$!WOI7V=M+NW4=1"X9D)]F'X
MT >\9&<450T>[EO].M;J6WEM7FA21K>8C?$2 2C8XR,X.*PM3^*'AG1_&^F^
M$KS5XX?$.I*S6MB58M(%&3R!@<#N: .MHKB_'GQ@\(_#:6UA\0:NEE<W2M)%
M;I$\LK(OWGV(I8*.[$8IVM_%[PAX>\+V7B"^URW32;[;]DGCS(;@L,@1JH+,
M?8#B@#LJ0]*P/!GCK0_'^AIJV@ZA'J-@SM'YB J5=3AD92 58>A -;K-\O%
M'P/^QH,?MX?M'?6/_P!&"OOH=*^!?V-.?V\?VCOK'_Z,%??0Z4#8M%%% @HH
MHH **** "BBB@ J.3)!QQ[T\TA!QVI._0#S?XA^#]1\2^(=&O;18_L]M!<1R
M%VP077"@#ZUP]O\ "SQ1I]EF&.!KE/#K:8G[S&)F?)[=-I)_"O?0@)SCGWI=
MGL*\RK@*=63D^IUPQ,X)170^?H?@7K/AV2$6-\^I1S:5)8SK=. (FQ\H3C[N
M<U9TOX;^)I$O6O;'3QY>CQZ;#!+)OCG(.3N]!VKW5D)&-N#ZBE"8[<>F*S_L
MVBG>**^MU&CS[X-^&=;\-Z?J,6J#[/;23*UG8F?SC;H%P1O[@GH.U>C4B+MZ
M#'M2&0"O2I4U1@H+H<LY.<G)CB<57NK^&TCWRN%7]3]*JZGK*6A\J,>;<D<)
MV'N?2L<1O++YL[>;*>Y& /I65;$1I+7<NG3<R:ZU.XOC^ZS;PGO_ !G_  J*
M.W6/E1R>I/)/XU*%'X4OTKQ:E>=5^\=\:<8;";><TI'%+17.:7$ P,4M%% @
MHHHH **** "BBB@ IK2;>G6G5$Y*@D#-)[ <BGQ4T5]?_L4"]^W^9LV?9'V]
M<9S_ '?>M+Q7XTTWP7:1W6J&=(')&Z&$R!<#JV.@^M<\9(Q\9,>8F3I7 SSG
M=Z>M7OBO_P DU\1$8XM#U'N*XU4DU)WU6QLXQO'31FWH>M6OBK3%O;:.9+=B
M0OGQ&-N.^#_.MBRU22P(6<F2WZ"0]4^OJ*H:."NFV0R"/L\?'_ !5PI[?4'I
M7IT*\Z:O<YJD%4.CBD$B@@Y!Y!'0BI*YO3;TZ;<"%CFV<X4G^!O3Z&NB4@CB
MOHJ=15(W1YDHN+LQU%%%:DA1110!Y5^TC_:T?PKO7T=YTE2YMVN!:2B*>2W$
MBF5(V)'S%00!WKP.X\$>(_&]S!\03H^L6'BO4O$-I;^'//D8'2--C(WM,@.
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M7!BJ_LHZ;F]*',[O8X#X>ZYXBUG4=835GL6@L;EK23[.C!WE !W9)Z<UZ'G
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M8760@# W<;>*] 3[HI:*B$%!614IN;NPHHHJR HHHH **** "BBB@ HQ110
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M-]<):VX(4R2' R>E %O/S4RYB,]M-$#C>A49Z#(QFJ&E>)=*U]Y%TZ^AO#&
M7$39V_6M.@6YX[X/^!-[X6\56>KR:M;W$<$C.8EC(8@]LU[;HUP+?5H220LH
M*'^E4\9ZT;A&RO\ W&!S]#0*QWE%-5MR@^HS3J!!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!YG^T)K.FZ-\-;S^T]!A\2Q74\-G%I=PP$4\TD@6,.3T7<1D^U?+OABZ
METK5+'5KOX.>"-%LM,\1Q:/?WD=RYETV3> LI&. 25P?]H9KZD_:"OO#5E\+
M]2;Q59W6HZ8\D4:6UB#]HDG+@1",CH^_&#VKP67P[9>,_B#IVH7_ ,,/B)IL
M5U=VLE]:-.BZ?<RQ$>7/=1[CO*X!)[X&:!H^P4((&/TI],&!CC%/H$%%%% !
M2,>*.E>;_&7X^^#/@'I%EJOC;56TJPO)S;PR"%I-S@9QA0>U 'Q[^RL,?MM_
MM+>YA7\YA7UG>>.?#VGWDMI=:Q:0W,;;7B:3#*?0BOC+]B'Q?I7C[]K'X_\
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M*J:7_P @ZV_ZYBK=! 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 >+_M;O+%\$]4,4T-D
M?M-L#J$_2R'FKF<9/)3[P^E<OX7BU[^U='+?'[2=7@\V+=:J+;==+D?*,-G+
M>W/->O\ Q4TR\U;P7?6MAX<TWQ9<R;=NDZNZI;3\C.\LI QUZ5\[7EKK'P\U
M/0-3USX"^ M%TQ]3MK:75K2ZA9K$NX59<"('AB!D=R* N?7 [=S3J8I! QT[
M4^@ HHHH *Y_Q5X%T'QO;0V_B#2+/6;>%_,CCO(A(JMZ@'O704C=* /SI_9"
MTJST7]LK]HZPL+:.SL;<0+%;PKM2-1.O ':OML#CK7QK^R3'YW[</[2Z8SE$
M/Y2"OLE'#(&'0B@L4]>/PKE]1^)_AG1M4ET^ZU)8;V%]DD90G#>E=0QVJ6[
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M4444 %(>12TAZ4 ? ?[&R[OV\?VCP>0?+!_[^"OL*6$VUQ+"1C8Y'X=J^/\
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MF#W[$^1Y98E>,X''M7NZ=* ,TZ@ HHHH **** "BBB@ HHHH **** "BBB@
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MMJUV+HV\1N0,"8H-X'UZT@)UZTZD Q2T %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4AXI:0T <[XT
M^(.@?#RPAO?$.J6^EVTTRP1R7#8WNQ "@=2<D5-XE\9Z5X-T>35-;OH-.L(\
M9FF; )/0 =6)[ <UYW^U9;03_!367EACE>*6V*,R@E#Y\?()Z&LOXN10W'Q=
M^#EOJ"AM.-W<NB.,HUP(/DR#P2!DB@#U;PAXXT7QYI/]I:%J,&I66XH9(CRC
M#JK \J?8@=:WCRM?/7AF2_L/V@?C<OAV".:1=(TR<6_2)K_RIMH/;+*%S^%>
M,I\6?VURH_XMCX:'L93_ /%4 9_[&?\ R?A^T=]8_P#T8*^^QTK\X?\ @G;?
M^(=3_:V^.5UXMLX-/\336\3:A:6QS'%+YO*K[=*_1X&@; C-96J:#%>GS8SY
M,_\ > X;ZBM:D(S0(XN\TR]MX95:W9P8V4&/D'((%?-W@[X/>*],\9Z=?7.D
MM';PW/F.P<$A<GG%?8N*,4 <C!HUY<R;3'Y*'JTA_D*W]-T>#3D^0%I3]Z1N
MIJ_M%&,4  & !Z4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!RWQ ^&N@?$[24TSQ#:R7=DKB3RDF>,$]L[2,TS6/A=X<U[PO9:!?V37.GV1
M5K8R2L98F7HRR9W!O?.:ZRB@#F_!GP_T/P#:7-OHMH;<74IGN)7=I)9WQC<[
ML26., 9/ KA?VD/B-X_^&W@./5/AUX+;QSKANDB;345B1&>K_+SQ7KU-8 "@
M#\=_@1\;OC-X6_:/^*WB'PS\*G\0>+]6V_VSH860G3?FR.!SU]:^D!^UW^U=
MC_DW&;\(Y_\ &C]C=)$_;N_:->1'56,95F4@']YV/>OOA1Q0-GP1_P -=_M7
M?]&XS_\ ?J?_ !H_X:[_ &KO^C<I_P#OU/\ XU]\8HQ0!\#_ /#7?[5W_1N4
M_P#WYG_QI/\ AKO]J_\ Z-QF_P"_4_\ C7WU28H ^!O^&N_VKO\ HW&;_OW/
M_C1_PUW^U?\ ]&XS?]^I_P#&OOG%&!0!\#?\-=_M7_\ 1N,W_?J?_&C_ (:[
M_:N_Z-PG_P"_<_\ C7WSBC H _.P_MX?M(KXL'AAO@-&/$36_P!K73,3><8<
MXW[<],UM?\-=_M7_ /1N,W_?J?\ QKU>4EO^"A=L>=O_  A[#../]97U%B@#
MX&_X:[_:N_Z-QF_[]S_XT?\ #7?[5_\ T;C-_P!^I_\ &OOG%% 'P/\ \-=_
MM7?]&Y3_ /?F?_&D_P"&N_VKO^C<I_\ OS/_ (U]]4F,4 ? _P#PUW^U=_T;
MC/\ ]^I_\:/^&N_VKO\ HW&?_OU/_C7WS28H"Y\#_P##77[5W_1N,_\ WZG_
M ,:/^&NOVK_^C<)S_P!LIQ_6OOFB@#\ZM;_;P_:1\.:SH^DZI\!DL-3UB1H=
M.M9A,)+IU&65!GD@$5N?\-=_M7?]&XS?]^I_\:]6_:>)/[2_[-P ) UB]/3I
M^Z2OJ(=* N? Q_:[_:N_Z-QF_P"_4_\ C1_PUW^U=_T;C-_W[G_QK[YQ1B@#
MX'_X:Z_:N_Z-QG_[\S_XT?\ #7?[5W_1N,__ 'ZG_P :^^:3% 'P-_PUW^U?
M_P!&XS?]^I_\:7_AKO\ :N_Z-QF_[]3_ .-??&*,"@#X&_X:[_:O_P"C<9O^
M_4_^-+_PUW^U=_T;C/\ ]^I_\:^^,4M 'YX>*/VYOVE_!.A7FMZ_\ AI.D6:
M;[B]N4G6.(9P"3GU('XU>L/VR?VI]3L;>\M?V=WN+:XC66*6..8JZ,,A@<],
M$?G7T!^WJ"?V2?B( &)^PKPHR3^]2O5/A,/^+8>$>,$:3:@_]^5H ^,O^&N_
MVK_^C<9O^_4_^- _:[_:N_Z-QF_[]3_XU]\XHQ0!\#']KO\ :N[?LXS?]^I_
M\:/^&N_VK_\ HW&;_OU/_C7WSBC% 7/@;_AKO]J__HW&;_OU/_C1_P -=_M7
M_P#1N,W_ 'ZG_P :^^<48H ^!O\ AKO]J_\ Z-PF_P"_4_\ C1_PUY^U=_T;
MA-_WZG_QK[YQ1B@+GYW>+?VZ_P!I3P'X>O==\0_ -='T>R3S+B\NUF2.,>YS
M7V=\ ?B7=_%[X0^%O%]]:Q6-UJ]DMU);P$E$)[ GM7FG_!0L[OV1/B*@#%OL
M0^Z,_P 8K?\ V*%*_LL?#=6!4C28L@\'O0#/;Z***!"T444 %%%% !1110 4
MUU#+@]*=7G_Q]UF\T#X.>*[ZPF:VNX[-E29#ADW$*2#V(#&@#I-+AT$ZE?2Z
M:FG_ &_(%T]KL\TG/&\KS^=;8KYF\5>#=%^$.J_!C5?"MG'IU]>:Y;Z+>21D
M[KVVN()#+YI_Y:,"H<,V<$&OIA>E #J*** "BBB@ HHHH *KW5Y#8Q&6XF2"
M)>KRL%4?4FK%>4_M,^&]-\1_!GQ0=2M$O!9V,MS KDCRY0IVL,$<CWH ]"DL
M-+AO?[7D@MH[I8MIOF50PCZXW]E_&K5CJ-MJ,*S6MS%=0O\ =DA<.I^A'%>"
M_$9/[;T;X-^';R5SI&K3VXOHMQ"W"I;AQ&V.H+#D=ZT/ NDVG@;]H_Q+X>T.
M..QT*]\/6^JOIUN-L$%R)VBW(@X3<O7'7% 'NE%(.E+0 4444 %%%% !44\\
M=O$TDDBQ1J,L[D */4FI*X#XP>&=!\1^&HW\4ZI)IWA[3IQ>WD?G>7#<*O2.
M4]TS_#WXH Z@0:/XA:SU(+9ZB;9BUM=KLE\L]RC#..G:K=EJMGJ._P"QW<%U
MY;;7\B0/M/H<'@U\C:WIMQ:>%/'?B3P_9W?A#P3XFN=+TRPL4!MRZ&54GO!'
MQY(=6VC&"0-QZUZ'J?A?2OA3\<?AY;>%;*+2;;5K>XL;ZUM5VI/'&FY'<=V!
M'WCR<T ?00Y%+35^Z*=0 4444 %%%% !3&8#J>M/JCJUK#?6<UK.SI'-&8V,
M;%6 (P<$<CZT 5;N71?$D5UID\EEJ<8^6XM&990/9UYQ^-3P:AIUI<QZ9'<V
MT5RB?)9K(H<(!QA,YQCVKY;30X/!7QU\$VUMX'?P'IEH]W!:ZO'="<ZZYC)6
M"0J21GEP9"3D8%9FG>%]/U;]E.[^(UTH_P"$ZDDNM:.O*Q%TMPETX1%?.50*
MH38.,=LF@#[&4DGUIU9N@7DFH:-I]U,,33V\<K@#&&*@G]36E0 4444 %%%%
M !2'BEJ"ZD6.-F=@JJ,LS= /6@"IJ]CINKP-8ZE%;74%P-IM[D!EDQSC:>M1
MV\NC^'DM-.BEL].5ALMK0.L>1Z(O'Z5\A:A\1-+^(OQ=\$^/9=?M(](C\1C2
M]"L_M01EM%24374B;NLTB@+D<(J_WJZWP_X+T;XL6GQEUCQ/$E[J*W]U8VMU
M-GS--AABS%Y)ZQD'Y\KC)H ^I-_L:*^<_AI\:O$UY\./"EQ<V;7ES+I-I)+<
MR(Q:5S"I+DYY).3^-% ['T=1110(**** "BBB@ K,\2:):>)="OM)U"$7%C>
MQ-!-&3C*L,&M.B@#R#PI\!_[#\0:/J>J^*-5\20Z&CKH]EJ"ILLRR[=Y*C,C
MA?E#-T_&O74Z4M+0 4444 %%%% !1110 5Q/Q9\ 7'Q-\(7?AZ+7+O0(;L%)
M[BSC1W>,@ADPW0'UKMJ* /+KWX+QZO\ #[2/#NHZ[?76H:.R2V&N!$2Y@D08
M1@!\O XQW%7OAU\*T\$:IJNLW^L7?B3Q%JBQQW.J7RJCF),[(U5>%49)]R:]
M#HH 0=*6BB@ HHHH **** $KSKXP_"4?%W2=,LI-;O-$^P7BWJM:HLBR,OW0
MZ-PP!YP:]&HH \LMO@W>:CX<UK0O%GBW4?%UAJ42QJMS#' ;8@Y#1E /F!P1
MZ%13_ _P9;PWXDAUW6O$FH^+-2M;<VME+J"(@MHSU "CEC@98\UZA10 U.%%
M.HHH **** "BBB@ K*\1Z)!XCT>\TRY\P6]W"T+M"Y1P#QE6'(/O6K10!Y!X
M?^!$UAKNCW^M^+]7\3V^BL9--L[]4"0.05#,5&9&"G )JA<_LUV4LT^GKXBU
M2+P5/>F_?PLH3[/YA?S&4/\ >$9?YMG3GWKVZB@".*,1@*H"HHP .PJ2BB@
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44 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>avte-20240930xs4026.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 avte-20240930xs4026.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $* J4# 2(  A$! Q$!_\0
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MIIMY<0_9K>YEL9)(X7O@H$4<CCY4/.<]CZ4/\-4S;21ZG/;W$ E DAB1 5D
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>1Z=KHT<VNFM+/IJ7OVS39FDW#(4K*6));)R#]:]74\4 +129HS0 M%)FC-
M"T4F:6@ HI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG(_L]/YFO4*\^2L['Z;0J>VI1J6M=)_>%%%%2;A1110 4444 %%%% !1110
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MX2Y1'!,+$9PWIQ4.B>+M&\1RS1Z9J=O?/"<2+"X8CW]Q[CB@#9HHHH ****
M"BBB@"*;H:_+G]JO_DX3Q?\ ]=8__0!7ZCS#Y37Y<_M4_P#)P?C#/_/:/_T
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MT$&_[]FC_A<?A;_H(-_W[- ';T5Q'_"X_"W_ #_-_P!^C1_PN/PM_P _[?\
M?LT =E*?E-?ES^U5_P G"^,/^NT?_H K]$9/C%X6*G_3V_[]FOSD_:5U*WUC
MXZ^*[NU?S()9D*/C&?D%=V$^)GP7&/\ N4/\2_)GFG:DX%&#2#GK7JGXX+G-
M+28Q10 F<>]*#FC(':C.?:@ VTO2D(-&<4##J<4-Q1@&D(S0(=2;_:@4AQF@
M!0<FEI!BEH *BF_U+_0U+44W^I?Z&CJ)GZK_ +-?_)$/!_\ UX)_6O3J\Q_9
MJ_Y(?X/_ .O%/ZUZ=7S\_C9_2F"_W6E_A7Y!1114':%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !112!LG% "T444 %%%% !1110 4AI:0T ?.GQ
MK _X3F;_ *Y)7!GK7>?&O_D>)?\ KDE<&>M42]Q,48I:*90F*,4M% "8HQ2T
M4 )BC%+10 F*,4M% "8HQ2T4 )BEHHH :W2OECXPC/Q+USVD7_T$5]4U\J_%
M\_\ %S-=_P!]/_0:[,+\;]#\^XR_W6'K_F<B<BBD&?6@YKU#\@%I#0O!YZ4I
MP>G2@!#WI ,@TZDH <2.>],/-*>E Z4 !H'2CK0!B@ /2C%#'I2T )@>M'XT
MA%&.10 ZHIO]2_T-2GO44W^I?Z&@'L?JO^S7_P D0\'_ /7@G]:].KS']FO_
M )(AX/\ ^O!/ZUZ=7S\_C9_2>"_W:G_A7Y!1114':%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% "'I7+>-;[5M-TJ6^TZ[L[6&UC>:X>\1F&U1GC'
M>NI/2L#QGX7'BW28].DN&AM#/'+<(H_UR*=QC/L2!GZ4 +X$U/4]9\)Z9?ZQ
M;QVNHW,(EEABSA,\@<^Q&?>M^HX4V1A<8QQBI* "BBB@ HHHH *0TM(: /G3
MXU_\CQ+_ -<DK@SUKO/C7_R/,W_7%:X,U1/4****904444 %%%% !1110 44
M44 %%%% !1110 AZ5\K_ !?'_%S-<_WU_P#017U0>U?*_P 7SCXEZY_UT7_T
M$5V83XF?GW&7^ZP]3D**/4TF<FO4/R 7K28_.EHH ;W[T=#TH!QVIQ.>^: $
M+Y'2A>E+10 F[%&<TM(5)H *6D Q2#[U "YH[BE/WC2#I0 IZ?K4<_\ JG[<
M&I*CG_U+?0T=0/U5_9J_Y(?X/_Z\5_F:]/KS']FK_DA_@_\ Z\4_K7IU?/S^
M-G])X+_=:7^%?D%%%%0=H4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !12,P4$DX'O35=3T_"@!]%%% !1110 4444 %>?\
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M9:?;PV=I$,+#$  * - =*6F^8G]Y?SH\Q/[R_G0 ZBF>:G]]?SI?,3^\OYT
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M_P!YO^^C2>8_]YO^^C24?B*8"^8_]YO^^C1YC_WF_P"^C24?@: %\Q_[S?\
M?1H\Q_[S?]]&D_ T?@: %\Q_[S?]]&CS'_O-_P!]&D_ T?@: %\Q_P"\W_?1
MI=[?WV_.FT?B* '>8_\ ?;\Z3S'_ +S?]]&DS10 OF/_ 'F_[Z-'F/\ WF_[
MZ-)^!H_ T +YC_WF_P"^C7->)3NOTR<G9W^M=)^!KFO$G%^F?[G]: ,RBC-&
M: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "D/:ES2=Q0!S6N_\
M?Y_W15"K^N#_ $X_[M9] D+1110,**** "BBB@ HHHH **** "BBB@ HHHH
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ML^+'_0*LC_V^+_A0/V+?BP.FDV7_ (&+_A7Z6;2:-AH^M3\@_P!4<O[R^_\
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:*** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>avte-20240930xs4027.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 avte-20240930xs4027.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %6 X # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "H
MY_\ 4R?[IJ2H[C_42?[IH _/#]O-V7XSZ<%9@/[&A_\ 1CU\YF5Q_&WYU]%_
MMZ_\EGT[_L#0_P#HQZ^<A7NT?X<3^?\ /O\ D95O7]$.$S_WV_,TGG.?XV_,
MT45L> +YLG]]OS-'FO\ WV_,TE)0 [SG_OM_WT:/.?\ OM_WT:2D(S0+4=YS
MC^)CGW-'F2?WV_[ZIO2EH 7S7_OM^9H\Y_[[?F:8SJ@^9@,^II0P.<$''7VH
M'J.\Y_[[?]]&CSG_ +[?]]&D[9[4A8#J0/K0&H[SG_OM_P!]&CSG_OM^9IH(
M(R#03@4"U'><_P#?;_OHT"9\_?;\S31CK1UH#4>9'Z[V/XFD\Y_[[?\ ?1IN
M2.!0.] 7'><_]]O^^C1YTG9V_,TE% [B^<YZNWYFCS7_ +[?F:2DS0*XX3.#
M]YOS->\?L3RN_P >;+<6(^QS=?H*\%&#D5[O^Q,<_'JR_P"O.;^0K*K\#/<R
M2_\ :-#_ !'Z4'[HKYX_;I)7X#WA4X/V^WZ?[QKZ';[HKYX_;I_Y()>_]?UO
M_P"A&O&H_P 1'[9F_P#R+ZW^%GYU>=)Q\[=/6D\QS_&WYFF-U'TI37O'\[IC
MO-?^^WYFCSG_ +[?F:9DX'%*/4T!J.\Y_P"^WYFCSG_OM_WT:;FC.: NQWG/
M_?;_ +Z-'G/_ 'V_,TP\4$X7.,^U 78_SG_OM_WT:!.P/WV_,U[$? GAC4_A
MOI>I:#8G4[Q9+1-1OA>$2V5Q)*%9+BW/2!@<+(AZ]ZM^(O@39SZ5<'3YX[+6
M[:\U!6MRKM#/%!*B (Q/R8#=\DUS^WAU/=63XF4.>%GHGIY]N[]#Q/SI.SM^
M9I/.?^^WYFO9-5_9KNM#O6AO/$5M%'!87E[=/]F)>(6X0N @;)5@XVMQG:>*
MA?\ 9SN4U"UL!XC@:\O-1-C9Q"U8F91&LIDSG"_(P^4\YXI^VAW,WD^/3LZ?
MXKK\SR'S7/\ $WYFCSW/\;?F:]BC_9RFDUY]-D\300HUU9V4$OV8N7EN5<QA
MU5CY9!C(;)-1CX/VM_HNE/9I''<7>DV]Q-/.S-MGDNFA+( < 8 X-#K4^XUE
M&,5^>-OFNGHSR+SG'.YC^)I!/)GB1OSKU;7/@$VBZ+>:@GB2"X-K$)FA-HZ9
M07/V=SG)^Z^" !DC\*UK3X :=IMQ>1ZKK$DEG-I+WEI>FS>*2"19EB)>$G)&
M3D XX(R!3=:"Z@LHQO-RN%NNZ^77R/$_,D;^,_G1YS_WV_[Z-:7BKP]<>$?%
M&IZ'<R1SSV$YA=X^C8[@=JR\UJG=71Y$XRA)PEHUN.\Y_P"^W_?1H\Y_[[?F
M:2DID:CO-?\ OM^9H\Y_[[?]]&D!YIIH"X_S7_OM^9H\U_[[?F::">E+0%R6
MUE?[?9_.W^OC[_[0K]E+7_4Q?[H_E7XTVO\ Q_6?_7>/_P!"%?LM:_ZF+_='
M\J\W&;Q/U'@K:O\ ]N_J0ZL<6$__ %S?_P!!-?CA<3.+BX^=O]<_?_:-?L?K
M'_(/G_ZYO_Z":_&ZX_X^;C_KL_\ Z$:,']HKC7X:/_;W_MH@F<G[[?F:#(X'
MWV_,TW% Z5Z1^6W'"5\??;\S1YK_ -]OS-(>12=* N.\Z3^^WYT>=)_?;\Z2
MDH$.\U_[[?F:#.Y&-[?F::"=V<5ZM\)/!GA?Q9X6U;[3:'5?%$4[&#3!>?9I
M'M1%DR6^1MED#]4/\/2LYS4%=G7A<//%5/9P=GY_UN>5B9R?OM^9I3-(1]]O
MS->R:!\'M)U71B]_.FG2S:79W-O=0([B.6:Y\HF1,\D]., 55@_9OU:3PY-J
M<VKVEO*MW<6RV[+A9!#<>0Q#EA\Q.2J@<@=:CVT.YWO*,99.$>;2^C7XW/)/
M.?\ OM^9H\Y_[[?F:]=O?V?$L;VZ$GBF$65I;WD]Q=_8F^0VTBHZ!,Y.2PP:
M5OV;-0CL= F?7;9)-6:V#1M%@QI.A>-T^;,F !NX&"PI^VI]R5E..;:5/;S7
M^9Y#YS@_?;\S2^:[9.]OS->QZ;\%M/M+>]^T7JZI*PTV6RN=C11[9[@Q.'3.
M>QJ,_ %;F*\O9=?@TN(7%^%MUM7E"QVURD+D,#ZR+@'GKFI]O IY3B]E&[ZZ
MK36W73?S/'Q*_/SM^=)YSC^-O^^J]4/P'GCM/%$AU=9KC0)G6:%;5Q')&CJI
M/F] Q#9"C/O57XT?#"P\"W=S?Z->_:-';59M+^SNC![>6.*.0@L?O@B3J/?T
MJU4BWRHQGEN*ITG6G&R7FO/7\-3S;SG_ +[?F:3SG_OM_P!]&DXYQS02:U/+
MN.\Z3^^WYFE$K_\ /1OS-,%+0.XOFO\ WV_,T><_]]O^^C3<G\*6@!?-?^^W
MYFCS7_OM^9IM("1FI>P7/T=_878O\!K0L23]MGZ_45[]/]W\&KP#]A;_ )(-
M:?\ 7[/_ #%>_P _W#_NFO#J_P 21_0V4?\ (NH?X5^1^<'[;3LOQYO &8?Z
M#;]#[&O!O.?^^WYFO=_VVO\ DO5[_P!>%O\ R->#5[%'^'$_%<Z_Y&%?_$QW
MG/\ WV_[Z-'FO_?;\S331TK8\.X[S7_OM^9H\U_[[?F:2B@6HOFO_?;\S1YK
M_P!]OS--)/2DR10,<T[*,F0@>N:3[0W!\UL'ISUKN?@L+$>/;>74=&FURUA@
MED:"W@\]HCM.)C'_ !JGWB/:O58O 8'B34KB]@L&MFUSPZRP6-J([:Z@GD;Y
MRC?,A8 Y08&2:QE449<I[>%RN>*I*K&75K;LK_U_GH?.8E<G[[?F:/.DQ]]O
MS-?1+? CPKJ.L7&JW-[=Z5I$XGE:VF?#Q.+MH1M*H3MQR%Q[9KG!\%= E\+7
M=S'>7\E_%975]'<\+"5AO4@V,I&0S*^>O!%+VT3:61XN/5=]^FGYW_SL>,^:
M_P#?;\S09F ),C<?[1KWV7X%>#H]5\51R:GJ%K;:7?'2H&N'W223"-GWA40[
MAP %XXY)J7PK\'/#EIJ/A6__ -,N[E+_ $8W5O<,K03I=B0LNW'&"G>I]O J
M.18MM)M=>O;?\F?/8N&)QYC>_-.\Y^TC?G7N>G_"K2=>T[2I=1DO!:BTO;E8
M;,(C!EOO* !QR,'O1>_!'P]I^IV<FW59M),5TUW)+.D8@:*Y$*R.^#A#D?*
M220*KVT2/[$Q3U@TUI^-O\SPOSWSCS#D>]+YTG=V_,U]!Z_\'-!MO#5_HP2X
M74-(N=8:#4H]J^:MN8RJS#'/#8%?/LD$UN?+N8)+:=<;HI4*,/J#S50J*IL<
M.-P%; N*J.]UT[]A!*Y_C;\S0)G!^^Q_$TE&,UJ>8.,LA_C;\Z3S7[NWYTP<
M4Z@+L7S7_OM^9H\U\_?;\S244!=BF20'[[?F:^B/V#W9OC=? N2/[(F[_P"V
ME?.U?0_[!O\ R7"__P"P/-_Z&E<]?^&SW\A_Y&=#U_1GZ,T445XA_0(5'<?Z
MB3_=-25%<_\ 'O)_NF@#\[_V].?C1IW_ &!H?_1CU\YXP37T9^WH?^+SZ9_V
M!8?_ $8]?.>,YKW:/\.)_/V??\C*MZ_HA:*0#%%;'@ :,8% .:6@!!TI:0G%
M*.: "C^$T@YZ4M UJ>W?!FX\.:%\*-7UOQ);:=)9IK\5K*UWI8O)IXC 2T$;
M'F,G .[M6KI7PST#QKJ'A/S=(N;329]/AW26<B0^69KED1I6()9@,  #G')%
M>!&]N3ISZ>+F5;%Y1.UN&/EEP,!L>N.,UI:=XSUW1V4V6LWMJ%B$(\J4C" Y
M"@=@#S7/*G+647J?24,SH*%.E7IWC%6]=;_=HM/6YZ=JGP>T72_"UFWE:U=:
MK>O>8U"$(;2U2"^-L%F3&>5&[.[@D#&*ZNY^$O@_PAK.MP00WNM+'I5VEQ;3
M?.^^,H%DA<H '.3T!QZUX(_B[7)=,GTYM8OC83RM/);&8['<G)8CU)Y/J:GD
M\?>)I;J&Z?7]0:XAB\F.1IV+*G]T'TX'Y5#IU'U-89AE\)<ZH:^[T6EM_6^^
MOH>SS_L^^'(+G6K19=5>8WE[;VLZR)LL5M[..X'G_+\Q8R;?X<;:^=H7,D:L
MPP2,D5M#Q=KHCU"/^VKXIJ+F2\43L!<,1@E_4XX^E9(&#[5K3C*-^9GE8[$8
M:OR_5Z?):]]OE_7G;9"#OQ2_RI.^:7K6QY09HS01SQTHQB@!:*** $/2D"\4
MZC/% #?NFO>/V)3GX]61_P"G2;^0KP?G/2O>?V)>?CS9?]>DW\A657^'(]O(
M_P#D94/\1^DY^Z*^>/VZ^?@->^U];_\ H1KZ'/W17SQ^W5_R0:]_Z_[?^9KQ
MJ/\ $1^VYQ_R+ZW^%GYT$?RIH_.E8]/I2=A7O'\[CJ3K2TG6@ Q0,'H*7--'
M% "]:&0,N&Z&DQDT<T =M'\8/$<?AZ/2%-@L82&![U;11=S0Q2"2*&24<M&&
M .._>K$WQO\ %,UG?P%[%6O99II+M+4+/&9G#R"-\_*"5''I7! XI)/NG/3'
M-9>SB^AW_P!H8I*WM'][V_KJ>L:3\:]2M[_4M7UG0+&9+O2KRQC>VL%BBN+B
M<+F6<_\ +7[@R,_2N?O_ (T>*-1U6VU*2ZMEN+>\>^C6.W"H'9!&5V]-FP ;
M?2O1?&EOXHTCX *=:M3?VNK1VAA,(C%KI-O&W[OH<^=(>N.BGGK3/AUX:\*S
M_#[2[N_T;3]1OIX;J:22XD(?='/&B*<$<88\=ZYTXI<SB?1NCC*M14(UFO=4
MW?1[VZ7OT:[>IYY:_&3Q%87_ -HLH]-T_;>6M\EO9V8CACEMPPBVJ#T^=LY/
M.:2'XK>*M/M+1!Y2P)!';PM);8#1QS&9,$]?G).:]HU#X0Z%=>&+V'2/#UO<
M7>H7DVG6=UY<DDD-P;H)YF\'8L$<!=LL1\R]Z36[CPSX^^'>IB,132Z7=W=G
MX?LW(5'MX(HDWY&/G*JSJ.A+4N>#?PG2\OQRTGB=;76KU\ORZ=5W/'U^.7BU
M'#I<VB.I#!EMP2I%R+D'G_IH ?IQ5AOCUXF>\2X^R:.%$<L1M!8@P,LLOFR;
MESR2XSG.:Z/X^^%-#\(Z5H,.FZ&NG7%Q(96NXXI5#0>6OEH[M\ID.6+;?:O%
MS\O2MXQA-7Y3PL96QV"JNC.LV]+V?S_4Z;Q3XUE\86%L+ZRMQJ@N[B[N=1CB
M5)+@R$$*<=EP0 >F:YK&*6DQCM6R5E9'C5*LZKYIN[_X%A:0]11UHS3,A:**
M* "BBDSF@"2V_P"/ZS_Z^(__ $(5^RUK_J8O]T?RK\:;;_C^L_\ KO'_ .A"
MOV6M?]3%_NC^5>;C-XGZCP3MB/\ MW]2'5_^/"?_ *YO_P"@FOQON#_I%P/^
MFS_^A&OV0UC_ )!\_P#US?\ ]!-?C=<#-U<8_P">K_\ H1HP?VBN--J'_;W_
M +:1DY%*.!2J *3'/M7I'Y8 /%#=*0]:4B@ '2CV[4"EH *ZWPA\5-=\#Z9+
M8::+"6)IS=PO>6BS26DY38986/*MMX]*Y$<TG0TFD]&;4:U2A+GI2L_([O2/
MC/XCT4P;!IUVD-O%:B*\M!*C)')YJ$@GE@_S;J=I_P 6M<E6WM;R&UU-%O'N
MC<?8U:[C5Y?.FCB?^!6<$\<^X%<%WS7NG[-L_ABUN=D^L0Z?XCO6N()(KNS:
M14M!$3^[<?*I9N23S@8'6L9QC%7L>S@*V)Q5:-#VW*N[?X:[^AR7C+XXZSXC
MU35FM(K33]*ODN;<6BVX!$4[AI"Q!YD)4?-5$?&;Q &TEQ'I9O-.\D)?&R3[
M3.(4*1++)U8*IP ,>_2MSX(^&M U/5]?74X;36+>VELXK9KHF)&$ETL;N 2#
M]PGKTKTW0_AOX2U?6898/#]C)MTJYGD@ DDA4Q:D\)=E4ERYA48QU.#Q64I0
MAIRGI8>AF&/7ME7LWYOO;HK=-+=#Q.#XJ>*Q;J8FB:"%+:,NMKN"K#(98LGM
MAR<^HI6^-'B=[:6V,]IY,INRR_9P<FYF2:;OT+QJ1Z#BO;/!@T#PT][X>U&%
M]'T;5;"^U34XD'[^"V+JD$>UN0VP$X//S9K/F^'N@:7X=\:W\OAJSNI-.U&]
M@C$$<DPV"")[/R"F1L^<LY;UZ\4O:0V<39X#'64X8CH[ZO3KZ_EK?L>77_QS
M\3ZC:7UO.NFL+P2K)-]D'FJLK!W56SP-R@TM]\:]6U^8'6]/TN]@4W,WD16:
MQK+<31",SOURZA5P?:O/$^X#NW<=:7J:Z53@MD?-/,L8]ZC?J[B(NQ0N<X'6
MG4E+6AYM@HH/(HH ,]>*2EH[^U "?A0>AI:0=#]*E[ ?HW^PJ0?@-:?]?L_\
MQ7O\_P!W\&KY^_84_P"2"V?_ %^S_P Q7T#<?=_!J\2M_$D?T/E'_(NH?X5^
M1^;O[;?_ "7J]_Z\+?\ D:\' XKWG]MH_P#%^KW_ *\+?^1KP>O7H_PXGXKG
M7^_U_P#$PIK4ZBMCP@I*6DH ,X/3-*6'I0>*3/MF@"WI6K7V@ZE;ZAIEY/I]
M];MOBN;:0HZ'V(K4G\>^);F\N;N77]0DN+J>*ZGE><LTLT1S$['N5)./2L"@
M9!J7%/<UC5G!<L9-+U?H=MH'CGX@Z]XQMY](\0:S>>(Y8FMH9(KD^:8N24S_
M '>IYZ=:M^+_ !GXUT+0K/P5JC7>B1609Y[=96!O=\OFAY.2'^;D$<&JOP5U
MFQ\/_$6UO-0NHK* VMQ"LER2(#(Z$*DI'(0YY(KJ/B/XBT/4OC%X)NHKW3KG
M3;"/3X+\V3,UC 8WS(D989,8'KG-9-+G6G0^@I2G/".JZ[4G*UG+HVOGZZ['
MGUI\1/$UA=:I<VWB/4K:;5%(OY(K@@W.>"7/?.3S5GP[KWC'7]7L],T;5=1N
M;T^4\,,<V"OV=6:-LGIY:[B#V&:]VOO%GA3Q,T>G6YTG4[F:X4PV<4(!F<:@
M=@^5<X\K''I2_%V]A\$Z?J&IL;>'4+NQ.BZ3/%Y8EG,DQ-Y<E$'RA8E6(9YZ
MUESI.W+J>@LME&/M'B6X1WM?SOK=I-].[:ON>"WOB/Q7X<O)=+NM4O[*YM-T
M#6_FD&+<PD91]6PWUIMC\2O%EA,9[7Q+J<,KI)&TD<Y&Y9&W.#ZAF )]^:^E
M)]6\+>/?B%#<^'9+)Q;QWBW3[0[B39&5O!N7!#<J >!7S[\98;NW^)6MI>:=
M'I4GF*8[2-E*QQE04P5XY'/%5"2F[-'%CL)4P=/V].NY1O96OV[WMY&?+\1_
M%EQ97ME+XDU%[2]D:6Z@\\[9W8@L6'?)49^E9WB/Q#?>*M9N-4U*7SKR?;O8
M<#Y0%'Z 5F#J:6NA12V1\]4KU:JM.;?JV_ZZB-TI<XI",T9]:HP#/M0*.M+0
M 4444 %?0_[!G_);[_\ [!$W_H:5\[]\5]$_L'#_ (OA>_\ 8'F_]#2N>O\
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MK<.S%_J;C?YX_C_D?F?D'N*3@="*_3#_ (8W^%?_ $+"_P#@0_\ C1_PQO\
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MP_U-QO\ /'[W_D?F?G%)GW%?IE_PQO\ "O\ Z%A?_ A_\:/^&-_A7_T+"_\
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M_P!"PO\ X$/_ (TO_#&_PL'3PPO_ ($/_C2^M4WHT:4^$<PI352%6*:ZIO\
MR/S;U75[O7-5NM2U&Y>\OKMS)/<2X+.QZDUL^'_B7XE\*:*=)TC5WL[$&0QJ
ML:%XC(H638Y&5W  'GM7Z%_\,<?"S_H6$_\  A_\:3_AC?X6=_#"_P#@0_\
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M\"'_ ,:%BJ?9A_J?CK<OM(V]7_D?F?N]:,CU%?IA_P ,;_"O_H6%_P# A_\
M&C_AC?X5_P#0L+_X$/\ XT_K<.S)_P!3<;_/'\?\C\S\CU%(3FOTQ'[&_P *
MQ_S+"_\ @0_^-'_#''PL_P"A87_P(?\ QH^MP[,/]3<;_/'\?\C\S\Y]!1D#
MN*_3#_ACCX6?]"PO_@0_^-'_  QO\*^_AA?_  (?_&CZW#LP_P!3<;_/'[W_
M )'YGY'J*,CU%?I?_P ,;_"O_H6%_P# A_\ &C_AC?X5_P#0L)_X$/\ XT?6
MX=F'^IN-_GC^/^1^9_?(KZ(_8-;_ (OC>C/)TB8#_OM*^J?^&./A9_T+"_\
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M^(-2NO$GBG3-2FU<75X]S%<NFGS7*.(F)2/R)(T5=@7"L5.<U#XFNK[X4?\
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M\"3I.-;V3K.%U&53M@\K:>.#_>/^UWH ZFBBB@ HHHH **** "BBB@ HHHH
M**** "N);_DL$7_8(;_T8*[:N);_ )+!%_V"&_\ 1@H [:BBB@ HHHH ****
M "BBB@ HHHH **** $;[IQUQVKFOA^D4>@NL26<:?;+GY;!BT>?.?)R?XB<E
MO?-=(XRC?2N;\ 2I-H+LDJ3#[9<C<D/E $2MD;?8\9[]>] '34444 %%%% !
M1110 4444 %%%% !1110!YWX]_Y*7\._^OB\_P#1%>B5YWX]_P"2E_#O_KXO
M/_1%>B4 %%%% !1110 4444 %%%% !1110 4444 <;X1BB7Q/XK:.+3XV-XG
MF&S8F1SY8YFST;Z=J[*N/\)3)+XF\4A)TE:.\561;?RBGR X+?Q_7\*["@ H
MHHH **** "BBB@ HHHH **** "N"_P":ZM_V+@_]*C7>UP7_ #75O^Q<'_I4
M: .]HHHH **** "BBB@ HHHH **** "BBB@!#7'?"V*&/PVWD1:=#']JN/DT
MMBT.?-;)R23NSU]\UV#=JX_X77,=UX=>2*XCN4^U3C?%;&W7(E8$;/;&,]^M
M '94444 %%%% !1110 45Y#XP_:B\"^#/$-UH4]W?:MK5I@7=AHFGS7TEKD9
M_>^6I"G'8G/M77?#?XK>&/BSI,NH^&-6CU*WAD\J9 K1RPOC[LD; ,A]B* .
MPHHHH :[;5)K@KSXNVR^-#X;T[1M4UJ>&6.&\O+*)3;V;MCB1BPR0""0H. 1
MFN\ESY;8Y/:OE7Q%\(?$MEX\\37&D:/?2ZMJNOV^JZ;XCCOMMO8PAXS,LD>X
M$_*K*5"G=N% 'JUM^T5H-SKZ69L=1ATF:]ETZV\02P@6%Q<Q[@Z(^<\,KJ&(
MVDJ<&H-*_:3\/7[&6\LM3T739;:XO++5+^WVV][#",RM$023A1NP0"1R*\S'
MPI\677A'1OA=_8<EMI>DZW/>'Q"]PABEM#/+/"5 .\2'S%1E(X(;DC%5=;^$
MWC3XD>#O#G@V]T(Z"OAW3KV!]2FN$,-U,\#10B,+D[#G+%@,#C%!1[=X!^--
MCXYUF/2I-&U?P_>SV8U"TBU>W$1N[?(!>/!/3<N5."-PXJUJV3\9/#Y[?V3=
M_P#H<5><IK.J77CSPUXT\8Z+)X*TSPYID]F[7<RRBXNKCRU*H(\_(HC)W'&=
MPXKHM(^(.@>-_C)HPT;5(K]X-)NS(L:N"H,D6/O 4"/75?+8[?6G"N$L-=OS
M\9-5T5IR=-BT:WNTAQTE::16;/T4<5T.H^*]/TO6;'2KF\AAU"^#&VMG/SS!
M?O;1[4[&2FFKLVZ0G![4U&W"N/\ BOX@OO"O@36]7TX1F^LK5YX?.&4+#U'I
M2'*2A%R?0[('-+67H%S+<:19S7#(;B2&-Y"HP-Q4$X'IFKQFX8]E[T[#335R
M:BHXI1( <CZ4\TBA:*IRZE;PW<5J]Q$ES*"8X6<!W ZD#J0,U.)<D8(QZYH$
M2T4@.>]+0,:V0.*YKP/+-(-8\Z6]EQ?RA?MJ!2J\8"8ZIZ'ZUTK]*Y3P6)K=
M-8WP/"7OY6 >X\[<./F']T?[/:@#K:*K+<Y( 9?SJP#D4 +1110 A.*3=SBJ
M>L-*NFW1A8+*L3,A(R 0../K7-?"3Q%J'BGP!HFJZFT3WMW!YDIA38N=Q' _
M"@AS2ER=?Z_S.SHHHH+"O.K3XS6>J>+[G1=.TG4]0M+.9K>[UJ&)1902*,NK
M.2"=O ) (!.*]%KY"M?@7XFT_6]0TJUTF_MKZ[\0W=_)XG74,VWV"=F9XO*W
M9SAMNW;C(SF@:/8-(_:3\/:GJ,,<]GJ6E:;=P7-S8:OJ$'EVM]' I>5HSDGA
M SC<!E02*9IW[3'A^>QNKK4M,U;0HTL/[3M%U&V"-?VQ(4/" 3N)++\IP?F'
M KS2\^&GC3QMX8\)^#+O0!H<7AFPO[:759IT>&YD>REM(/)"_-AO-WMD# &*
M9XC^''C?XF?V'?3^&SH5YX6T=;:*"YN$*7]T'B8JA4G$9$9P6Q]X<<4 >X^
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M+_2D^-Q_XIO2O^PU8?\ H]:/C<P'PC\6 \_\2^7BEV"IO5]%^ITUC_R+-O\
M]>*?^@5S'P1_Y)1I'^Y+_P"C7KI[,_\ %-P =K-!C_MG7,?!#_DE&D_[LO\
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M .GVO31N/U*M37N/B?8?(3X=U,GHQ\V#_&LK'J>V:W@_Z]&ST34R/[.N^?\
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M,98O]:W.XD_,>I'8YKL37'?"VXCN?#9>.>"X7[5<#?;VQ@3(E;C:>X[GOUH
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MJX*^E$/Q:1SGY=&=OE&3Q(* N-M&S\9=:_[ EJ?_ "-+47BK_DIW@[_=N?\
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MBG5J:A1110 4444 %%%% !1110 4444 <;X2A1?$_BIDALHF:\4L]M.9'?\
M=CF4$_(WL,<5V(X%<=X1>-_%'BH+-;R,EXH988#&RGRQPY_C/O78CI0 M%%%
M $4O)'8>]8OAP?:OMNHGK=2$)GM&F57^1/XU)XJG:+33'&2)KAA F.N6X)_
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M5Y)%YMW86_V>:[@OKZV:*WNH8>97B?\ B"CGUQS0!ZC7":P<?&3P]_V";O\
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M@AO_ $8*3 JVB_\ %ZM;[G^P[7_T=+47BP?\7+\&G_9N?_0!4UG_ ,EJUO\
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MWX;\10>#]-U"%X(--TMGBU6X4JRW-Q.#CR4;!"#J5RV< 5]#D9I-@H ^2(?
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M1VMV+Y'+'',,R-D_19#7$^'/VDK;4/BWKJ6FD3ZA:WP2TT]()%629H\X)+$
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M7%N[DE%%%44%%%% !1110 4444 %<$!_Q?5O^Q;'_I4:[VN#'_)=6_[%L?\
MI4: ,S1[;[5\3?',.,B:VMHSGIRCBKGP9N1<?#S203ND@C:#\48K_2F^%_\
MDK'C+VBM#^C56^#K?8=#U73W.U[+6+R$ #D#S"P_]"HMJ>C5LZ3[KE_])?\
MP#TU>5&>#BEI%^Z*6@\X**** "BFLX169C@#FJT.H0SR;$?+ X(H MT444 %
M%%% #6&1TS7)?#2:2?0F:2>]N3]HG'FW]N().)&XVCL.@/<<UUK' KE/AO'/
M#H3K.EW&WVB8@7LXFDQYC8^8=L=!V&!0!UE4]0?9M)VA0"2S<8_^M5EY%C R
M< \5PGQ@U.;_ (1E-'L9"NI:[*-,@8=4$@/F2?\  8PYS]*#2G3]K-0[E3X4
M0)K[:SXO<$G6+@K:[NJVD1*1<=MV&?\ X$*]&B38/051T+2H=%TRWLK= D%O
M&L48QT51@#\A6B*;*JS]I-R6W3TZ?@%+112,0I,4M% !1110 4444 %%%% !
M7":Q_P EE\/?]@F[_P#1D5=W7":Q_P EE\/?]@F[_P#1D5 T=T*6D%+0(***
M* "BBB@ HHHH **** "BBB@!&Z5RW@.$0C6\0VT.[496(M9S*&Z?,Q).UCW4
M=*ZD]*Y7P%)')_;?E/:N!J,H;[+&4 /&0V>K>IH ZNBBB@ HHHH **** "BB
MB@ HHHH **** "N'D_Y+!%_V"&_]&"NW/2N(?_DK\7_8(;_T:*3 KV__ "6'
M6CW_ +%M/_1TM=W$ 8Q7 VI+_&C6D'3^Q+4_^1I:[Z _)BM)=#EP_P +]7^9
MROC[PI=>+(-/M[>Y%F+74+>_,FP/O\I]VS!/&?6O-_V@G&GK97LI\L26EU:M
MGIRJL/U%>['%>+_M1IY'@:WO /\ 47B GT#_ "_UK2B_?C$XLQ@J>'JU5O9-
M_+^F>F:3,LNB64J\H;=2#[;*P/@QQ\,/#^>GD'I_OM70V,$IT:)(P-QMU"%C
M\H^4 9%4?AUX;N_"O@[3=(OI(YI[6,HTD0PK?,3Q^=9Z)6.U*7/%VZ?Y'+_#
MM(-5T[QG:D[XIM6O(G./X6&#7+_ &^N+[5)S,J*L6D6MN&#98F-Y(SN&./NU
M[<+58\[$5"3D[1C->(?!&-K'XB_$:R8%/LM[LC'3".[2#_T(UO%\T9M?UJ>;
M5@J-?#1;ZM?@W^29V^J<_&71<?\ 0'NO_1L=.^()/]J>$?\ L,)_Z"U1ZB<?
M&/1">/\ B3W77_KK'4OQ _Y"WA$?]1A/_06K*.DH^ATU':%3_$OT. ^+4!T_
M5_&"%=JZEI-I<L?5HKE4S^3"O8?%G_(IZR.WV.;G_@+5Y-^T<Z60TJ[+^6L\
M4UC(3P#\\<BC\T->K^*F$GA#60O_ #YS?^@&M&[PB_ZZ&5)VK5X=DOQN_P!3
MS&S<Z9X=^%.L ;O(N8+)AV5+B(QD_P#?6TUT_P ('">&=2SQOU?4, _]=WK
MU&QEO/V=+9X/EGL].@OH7_NM"5ER/^^*U_@G=G4/!UY<.$Q+JM[-&8^A5IF(
M/Y&IDO<;\S*D[8N$>\;_ )+]$6_ !_XKCQQ_U^Q?^B5KT2O.O <<T/C;QFTM
MM-%'+>Q-'+(A"2#R@"5/?D&O1*SGO]WY'IX;^&_67YL6BBBH.H**** "BBB@
M HHHH **** /._'O_)2_AW_U\7G_ *(KIYO^1NB_Z\V_]#%<QX]_Y*7\._\
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MQ^%,Z:?N4Y3ZO1?K^&GS.MA5@"2,9[5+2#BEI',%%%% !1110 4444 %%%%
M",<5X]X]N]?\6?%>T\%Z7XDN_#%C%I+:K-=Z>B&XEE,NR-07# (-I+#'S9QF
MO8&Z5Y_\0OA-'XWU.UU:TUK4?#FMVT+VJZCIK*)&MW(+1,&!!&1D'J#0 OP&
M\::C\0?A5X?US53&VI3QR0W3Q+M1Y8I7B9P.P8QEL=!FIM7.?C+X?_[!-W_Z
M,BJ[IWA.3P/X*T_0/"-O;6\-A&D$"7;,5V#EBQ')8DDD]R37*V7_  D'_"Y-
M#_MH6 7^R;OR_L98G_61=<T#/5Q2TU>!UIU @HHHH **2C- "T444 %%%% !
M1110 AKF? \IE&LYN+FXVZA*H^TVWD[.GRK_ 'E'9N]=,2,5S?@L.O\ :^\7
M2DWTA'VJ429'&"F.B^@H Z6BBB@ HHHH **3-+0 4444 %%%% "'I7A/Q!U;
MQ1XD^(FOZ%I?B6Y\-6GA_1%U6-K%8R]S<.7VB7>K?NQLY48SFO=J\T\??!.T
M\<:U_:L.L:CX?U":V-A>RZ<ZC[9:DDF)]P..IPPY&30!O?"KQ1<^-?AYX=UV
M\1([K4;&&YE2/[JNRY.WVSTJE=2"+XO1L02!H[=.O^M%:#:%J'AGP_INF>%8
M;&W@M$6!8;HML2)1A0,=ZY33X-<N/BJRZNUFDAT=A&;(MQF09)S18"II'CC1
M;G]H76M*2\1K_P#L>"(1>LB2.SH#_>"NIQ[UZU:G*G@CG\Z\.L_V3?#UCXGA
M\01:QJ_]JQW'VG[09AN+YR<G'0]/H:]QMD:,,&.23FMZO)IR.YX^7?7.6HL9
M!1]YM6=]'M?S1,:\:_:DU.RL?A=JJWL@1G,0MT_BDE#A@H'K@&O937FOQB^#
M]E\4=.83IOOK>,BS9Y66-'.,D@=>*FDU&I&4MDS7,Z=:K@ZM/#I.;32OMJ=+
MX"\5Z?XK\+Z9?Z=*9[::!6#XZ'&"I]P>*Z0-D9KB_AM\-[#X;:.;#38C#%(1
M+(IE9U\P@;MN>@XKM(UVH!4RMS/EV.O#>U]C#VZ2G97MM?RV*]U>1VL3RRD)
M&@+,[' 4 9))[  9KY?^&GQST/5/CYXGBB7R-.UQHXK2X=@!++$,!OHXSCZ>
M]?3]S9K<H\<BB2-@59&&0P/4$5C6G@?1+61)(]%TZ.2,@HR6J J1T(..*TIS
MC!24E>YY^.PN)Q%6C.A445"5W=7OI:U[JVC9SFHN'^,>B<9']BW1S_VUCKI-
M7\+6VO3V,UZC.;&<7-N4E*X<=SCKP>AJM=^#FN/&-GXA%S(L]K:2V:P CRV5
MV#$GOGY174A<1X/7&*RO:UCOA3=Y\ZT;_1'AO[5<=HWPP@NKF1(Q::K:3*9,
M?,/- < =_E)/X5Z=K=[;7O@G4Y[=U>"2PD>-U^Z5,9((]L&N+^,'P'3XOSZ?
M]LUNYL+2S4[+:! 5+G^,Y[XXKH/ 'PT3P5X)7PS/?RZS9H&C4W2@'RB/]7QV
M%;MQ]E%7UN>13ABEF%:3II4Y124KK5J^Z[:_AYD7@9K.;X3:5;7CJMK)I0$Q
M?A1&4PQ)[#!-<3^RMK=GJ?PP@L;:[%W=6%W/#.PX."Y*/]"N,5W_ (F^&UCX
MA\%2>&!)+I>F21B%A8ML;RQUC'^R1P?:N,^"_P #-*^'NHRZQI<VI6SR&2VE
MM+J=71U5R%8[1CMD>F:%*'LY1;U;T%4H8I8[#U(03A&+4G?77EV7DX_<V>O1
M6C1R [B<=>>M6\\T9I:YCZ$**** "BBDSF@!:*** "BBB@#R;XEZGJ_B#XE^
M&_ VF:U=^';:[LKG4[V^L HN'2-D18HV92$RSY)P>!BM+X&>*M3\3^$;Z'6K
MH:AJVBZO?:+<WRQ",71MYF02[1PI90I('&[.*T/B)\,U\<SZ=?6NKWOA[6M.
M+_9=3T_;YJ*XPZ%6!5E.!P>X!J3PWX(?X?>"XM%\-%9)86>03:BY=IY7<O)+
M*PY9V9F8GU- &;X\/_%R_AW_ -=[S_T2*CE\=K_PG'E?92(D)M#\WS'YOO8^
MO:L;7!XB;XH^ ?[:&GB+SKS9]DWDY\D=<UZ@VA6#7?VK['";KKYI0;OK652,
MI6Y78SJ1D[<KL<#X[U+6K?Q+:FR@E,4/,+)'N!)X/-3>-/&%W964%K/IK0RS
M$.3*P*_+@\8]Z]%6,J.N/:H+O3K6]55GMXIP.0)%!Q6<J4O>Y9;F;IR][EEN
M<=J_C1I/!JWUO$AEN?W3QL^1%D$'.*IZ+XRU:X\)RS0:8TDMNIC26,CRP !@
MX)R36QXQ\&C5]."6$,4%PK#D?+N7T.*G\"^';OP]I307;JTC3&0(IR$![5G:
MJZEKZ6,^6K[6U]+;^9SWP_\ %LZQ3Q:F## S;DE,14;R<D$]!6_X?UG3;O7-
M72WNHI))I%9 IY8! #CUP?2NCN+5+B%XF4;7!4C'8UQ>E?"V#3-0%Q]MG*KG
M8(SL(S[U?+4CRI:EJ-2'*EJ94WC6ZM_&S));JL"$VY !+!,_>KHM8\5:2-3T
MEC?1;4D9V.>@*D#/XU@Q^!=63Q8E[]I#6ZR[O.9\N5]#6UK_ ,.+77]4^VF=
MX"P =$ P<5$?:I/UZF</;6EIUZ]B7QIKEC9:?&LDZAI71T51DL P)/%7=4\0
MV"^')+TSC[--'B.3'WB>@JAJ?PUTS4H(HP'MC$,;HSRWUS5'Q!\/?^)#':::
M[[XBK;9)#L;&<\=C5/VJYG;H:2=7WG;H;FAZ]I\NAQ72W*&WBB59'Z;2HYSW
MJIX,UJSN-%,<,PDDMW=Y$'!4%F(^O%9GA_X=HNA3V^HQQBYF8D/&<E!VJUI7
MPWM]'CN"EY.9I!@.C;,#T([TTZKY78475?*VNAF^'/'D$^N7V^UG"7#[T\L;
MR-HQC YK,O?%TFH^.;8-:D6\<PA$;<.V#PQ';!.<59\!>&;VP\57C3 )':EH
MB3@^9D Y'M]:](&GVIF$_P!GA,W_ #T*#=^=3&%2<5=VU)C&I."YG;4GC' [
M5)30!QQ[4N:[#L%HHHH **3(]:6@ HHHH :V<<5XKXSO/$_C?XE^)= T;Q1=
M>%;/PSH]M>H;2*-FNKR<S%#+O!S"BPX*#&XN>?EKVL]*\U^(/P7@\<Z]_:UO
MKFJ>';V:T_LZ]ETN0(;VTW%O*?(.""S;7&&7<V.M &U\'_&-Q\0/AAX:\17<
M2PW>H64<TZ1_=\S&&*^Q()'L:HR,%^.3D]O#@Z?]?1K6&A7OACPWIND^%;>R
MM;:RC2WB@N-VQ(E7"@8YSP*Y+P\-:/QMN!K8L]__  CJ[/L>XC'VD]=U RAX
M&\>Z!JGQJ\9:?::G%<7@B@7R5]4#!P#WQD9K'\2?$CPSH/[3&D6UY?&TN&T=
M[&222,K$LC2!XU+GCD!N>@]:]7T_P'H>DZ[?:S9:5:6^I7V//NHXP'?'O4]_
MX2TW5762^T^TO91&T7F7$*NWEDY9<D=#CI18]6.)PL:C?+)Q<.7=)WLE?9Z>
M7XFC!J4$L*NC%T(R&7IBIC=Q!0Q;;D9KQ/QE^S_J5WJ^D3^$O$=UX8LK>X\V
MXLH9&,)[[D4\ ]L=*M_$+X.>+?$OA:YL+'QW>BXD*G$L2QJP# X+)AAZ\4G<
ME87#2Y'[=+FWNG=:VULFO/<]C-RB]<],]*:+R-@2,G R>*\KU/X5>+KOPO-I
MT?Q!U'[6UMY(E:"-<MMQU R,^O6F>$?A1XOT/PS9V-UX_OI+F&+8S+ CC/IN
M;DX]Z5WV,_J]#D<O;*]]K2^_8]3^W1LF<, 1QD=:\>^'GQ6\,:I\6O&VGP:D
M!>22P"-)$*>;Y<81]A/WL-VZT[P%\'_&GA^PO8M2\>WD[RW,DJ;8ED 4GU?D
M9]!P*I>$_P!GF]L_&7B;4O$FJ6_B'3=4*,MM/;*&9@.)"1]UAT&TC(ZT]>QW
MTZ."HPKQJ5E+1<O+??F7>.OWK]3V\7J$CY7'N5I?ML6#R21V'6O%5^!GB?3_
M !]%J6E>-]0LM 2 HEC*YG,1_NKNX*\9R>14OB[X.>--8UKP_=6/CZ\BALKG
MS9@8E0[<=0J\,3R,-QS0WY'+]5P[DDL0K-7VEH^VWZGLGVZ+&>>N,8H^VQE
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M#$R]R,4 <!I'Q<EU[3K:^LO!?B66UN$$D4GDP#(/0D>=Q5#PMXNU'25U/?\
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M#TWBC^PX;>18FL=6M=0D+_Q)$^X@>YKJH\8XH X=OB%JX&3X#UX =26MN/\
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M)P"#VKT 9R*YKX>Z')X:\*66E7$B2SVYD+.G0[I&8?HPKILT +1110 4444
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M9G^"?C#J/C#XP:IH-O96T?A**U=K+4#N\ZZFCDV3,,G'EACM!QR0>U;WQ?\
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M_L^ZIJ&L7^GVVNVMKX(U35XM:OM/%F/M9F25)=J2@\*7C4Y/S#G% 'NE%%%
M@HHHH **** "BBB@ HHHH 3%+110 4444 %%%% !24M% !28I:* $[TM%% "
M8I:** "BBB@!*6BB@!*,<TM% !1110 4444 %%%% !1110 F/:EHHH 2EHHH
M **** $HI:* "D(S2T4 %)2T4 (12T44 %%%% "48I:* $Q1BEHH **** "B
MBB@ HHHH *2EHH **** "BBB@ HHHH 3&*6BB@!,44M% "4M%% "4M%% !11
M10 4444 %%%% !1110 4444 %%%% "8I:** $HI:* "DI:* "BBB@ I*6B@
MI*6B@!*6BB@!**6B@!,>U+110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!24M>??';XRZ7\!/AS?>,M9MKJ\T^S>-)(;-0TA+L%& ?<T >@9HKQ#1_P!J
M_P ):Y\4]&\#6@N7O=2T0:ZM^P MH82H<*[$\-M.:[6U^.?@"\T,ZQ#XPT>3
M3!.;4W2W:[!* 3LSGK@$X[T =UFEKP_QU^UWX \$VVK.-5&L7&FZ7#K#P6!5
M_-MI95B5D;.#RP)]!S7J?A'QEH_C;3I;[1-4M=7M8YGMWFM)0ZK(IPRG'0B@
M#=HI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%% CZ%%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>avte-20240930xs4028.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 avte-20240930xs4028.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &Y Y8# 2(  A$! Q$!_\0
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MB68RN'8!1P2 !7*7_P 0]=^*WB'XMKX#\57RQ:7I5A>Z2D.459TW/(@4C.)
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M]M-V5>F#UZU5O/V=_%M]X*\%3:MY'B74?#VIWES_ &)?7CX:RG0KY N.IDC
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M HHHH **** $S036"NGZU_PE\MVVI0MH#6P1-/$.)%FSR^_/3':LA="\8_\
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MYYW$ FJ3A9"?-?0\MM?$/B#5?%-W%:FTT[PP?AL]S'IT<\SFW1DDP5!."^X
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MVNC^(;/PE\-;'2;O6M;T-?#*WMWHVC:L+?4UE?85G7=R\*_,@0' )'M7T)\
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MRQ(>F=NX@'BF6?A[1O$OQ&TKP]8>9<?#QO&CQZ=#'*_D.GV!FN(8VSS"9,#
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M8-PHR*\AD_9E\-RRR2-K?BS<[%CCQ#<@#)SQ\U)_PS%X:_Z#?BW_ ,**Y_\
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M8G!MY#ET(Z8-<'_PS%X:_P"@WXM_\**Y_P#BJ/\ AF+PU_T&_%O_ (4-S_\
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M/O\ AF+PU_T&_%O_ (45S_\ %4?\,Q>&O^@WXM_\*&Y_^*I^[W%SXG_GVO\
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M5,;'J1@<$UY[_P ,R>&?^@WXM_\ "AN?_BJ=_P ,Q^&1_P QOQ;_ .%#<_\
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M (JC3N'/BO\ GVO_  +_ .U/70<#G]**\GMOV:_#EK*776O%9.-OS>(+D_\
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M W?*RX!#KAL@'-;OPD^!_A7X(Z%=:5X5M;F"WNYOM%P][>S7<LSXQDO*S'H
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M 23CJQ]*]:H$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%_QUM/".GZ_JFL:/K'@X:]=PZG>/<M]N2Z2,W"EB2OFK*05&%_=C KZ57I0
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M_9;U"_'AWQ1H%WJ-SK%MX<UZZTNRO[R0R2RP(V4#.?O%<[<_[/->UT %%%%
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M9=WE?:-@V^9MSCGKS7J0&!BO _\ AL;P]_T(WQ$_\)>>E_X;&\/?]"-\1/\
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MQVH?"3PKJ7BVP\22Z+;'5;*WGMHI%C"H8Y0!(&0##9 QR/6O-_\ AL;P\?\
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M;P]_T(WQ$_\ "7G_ ,: L>^4G6O!/^&QO#W_ $(WQ$_\)>?_ !H_X;&\/?\
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M4 %%%% !2,-PP:6B@#QG7?V7/#7B#Q]/XCGU77H[*YO8M3N_#<-Z%TNZO(P
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M*** $-<+\4_A#HOQ8LK*'4Y+^PN[&4S66J:1=M:WEJQ&&,<J\C(X([BN[I*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+;<\^E?EB=?^"NI:G;W^K']H&XUL2PG5?$^HW,UO-HPE($$\VUQ&B/N!4JK
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M **** "BBB@ HHHH **** "BBB@ HHHH **** $I:** "BBB@ HHHH ****
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MX7O\7/\ HWO6/_"CL?\ &C_A>_Q<_P"C>]8_\*.Q_P :/83\O_ H_P"8'O\
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MSXB?]@B7^E '>?#_ /Y$7PY_V#;;_P!%+6_6!\/_ /D1?#G_ &#;;_T4M;]
M!1110 4444 %%%% !1110 4444 %%>:_'3XP/\&?"MGJT.A3^([J\OX=/@L+
M>X6%GDD.%^9N!S7%'X\?%L'_ )-ZUC\/$=C_ (UM&E.:YE:WJE^; ]_HKP#_
M (7O\7/^C>]8_P#"CL?\:/\ A>_Q<_Z-[UC_ ,*.Q_QJO83\O_ H_P"8'O\
M17@'_"^/BY_T;UK'_A1V/^-'_"^/BY_T;UK'_A1V/^-'L)^7_@4?\P/?Z*\
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M "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4E+7%?&/5M/T#X9>(M0U36KKP[86UH\DFIV/,UN!_$@/5O04 2?$SX
MK>%OA#X9GU[Q7K$&CZ;%CYY3EW)( "(.6.2.!6MX0\6:;XW\/6.MZ1.UQIUX
MF^*1D9#CT*L,@\$8-?G=XIM]3_:/M+?5=:77?%VC^&Y&T^YO=)L(XM6MH90&
M_?V;[E9BN")(CNY/%?HCX-M[2R\+Z5!8+,MG';1B(7((EV[1C>#SN]<\YS0,
MVZ***!!1110 5Y)^UK_R;9\1/^P1+_2O6Z\D_:U_Y-L^(G_8(E_I0!WGP_\
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MFU0OWG0L<X[FK/[0OPEU[7_A?X5T[PW;KK=SX9O;*[.GRNL/V]( !MR/E4\
M@=,UA&%)N*YM]_(#K?@S\<[+XP0ZS&FCZAX?U;1K@6]]IFIJ%EB+*&4_*2,$
M&N*B_:KOX?B?I?@O4_AMX@TFZU S21W$[1,JVT1^>X958L$ YSCG-'P/\'^,
MO FNWNL:[X>6;5?&^J3ZCJ\\%POEZ1&L>(8O5R<8X[DU%X0^%_C"\N_C#XRU
M&)-+\;^(99M-T!IF$@LM/A39;8(X&]LNP[G&:TY:,92VMTUZ_P!7 U?A)^U?
MH?Q=\:1:!9Z+JNFK>VLM[IE[>1IY5]!&^QW7:Q*\]F J+]NG_DU#XA?]>T'_
M *50UP7[(WP$\3_#[QK>:]J_A^/PM:#3(["2T>Z%W+>7(;=)<AO^6:L<D*,=
M:[W]NG_DU#X@Y_Y]H/\ TJAJ^6G'%05/:Z_,#V_1_P#D%6?_ %Q3_P!!%7*I
MZ1_R"K/_ *XI_P"@BKE>> 4444 %%%% !1110 444F: %KG-:\1R+<C3=+B6
M[U-QT/\ JX1_><]OIWJQ9^)(M2U>2SLXFN(801-=+_JU8?P@]S]*N:?H]KI?
MF?9H1&97+NW4L3ZF@!-%LI[&QCBNKI[V<<M,^.2>< >@[5H444 %%%% !111
M0 4444 %%%% !1110 4AZ&EI#T- 'B/[9WB'1_#'[-GC._U[PL/&FEB&&*71
M3<FW$QDF2-&:4#,:HS*Y<<J%)[5X+^Q)\*/$'P_^(5Y?WWPWTC1+*]LW_P")
MZOC0Z[=#+!A'&I^ZC'DD=>YKU+]LKQ79VWA&?PMK$/A&^TG6+)G33O%&IM9)
M=3Q7,#!<K@[ A=B0?O*HZ&O%_P!B70/#>F_&&6;2_"?PXT2[_L^4?:/"GB">
M]NL9&1Y;L1M/<XH&??J?=%.I%Z"EH$%,:5$959U#-T!/)^E8'C_QSIWPY\,7
M.NZK'=RV5N5#K8VSW$IR<#"("37RS\=K/1OB)KEG<^%M0\0ZK\3_ !%!:7'A
MJTCN)K9?#< QONI8P0L:-ABPE!+GY0* /L4RH&"EU#$9 SS3LU\/^-7G)\7_
M !(?5]0@\;Z+XWM]$L46]<1PV8,">3Y .TB4.[G*DG/!XK[;!P@(&#_*@#Q?
MXC?\G4_!W_L%Z]_Z!;5[:.E?,VJ>,]0\2_MB?#VPO/"VJ:##I=CKT5O?7P7R
MM07$"[XL$G& #SC@BOID4 +1110 4444 %-<95OH:=10!\E:-XQ\5?!?XV?%
MRZ?X5>,O%%AX@U2UNK.]T.TCDA9$ME0_,SKWST]*['_AJGQ!_P!$&^)?_@O@
M_P#CM?0E%=3JPEK*";TZOHK=P/GO_AJKQ!_T07XE_P#@O@_^.T?\-4^(/^B#
M?$S_ ,%\'_QVOH2BI]I2_P"?:^]_Y@?/?_#5/B#_ *(-\2__  7P?_':/^&J
MO$'_ $07XE_^"^#_ ..U]"44>TI?\^U][_S ^>_^&J?$'_1!?B7_ ."^#_X[
M1_PU3X@_Z(+\2_\ P7P?_':^A**/:4O^?:^]_P"8'SW_ ,-4^(#_ ,T%^)?_
M (+X/_CM9_P+N_$7C/\ :(\<^--2\#>(/!NEWNCV-G NOVZQ/(\;/NQM9AW'
M>OI2BG[6*BU&%K^; ****Y@"BBD)Q0 9 K#\3C4KF."STY3&;@E9;SC]PG<@
M=R>@IGB37);5HK#3U$VJW Q$AZ1CN[>@'ZUIZ3926.GV\$MP]U)&N'FD^\Y[
MF@!-)TJWT>QBM;5/+B0<#J2>Y)[FKHZ4M% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7,?$;PU=>,/!&LZ+9W5M
M97-[;/!'/>V:W<*EACYX6(#KV()Z5T],EQL.: /C?P-X4_:/^#T!\,^$/AK\
M(;32Y)=[:OIUY=6ENS'@R26^"^[V4D#H*^F/A=I?C'2O#$,?CK7+#7_$+R/)
M-<:79?9;6)2?EBC4DLP7IN8Y/4XZ5\(>)/VV/B3H/QG\3Z*][;)J"7,FGZ1X
M-_LQS(Q2Y1$<OC+&2(LP(.T 5^C.GR/+8V\DB>7*Z*S)_=)'(_"@;+-%%-<D
M*<<T"&RSQP(SR2+&B]68X IK7MNL(F,\0A/20N-OYU\[_%OXB_#SXA^%M9MO
M'%AXATS0- U",SVEY;O:Q:Q,&98[>/O.K-@[1UX[5X]H/P^L'O?A]X1\;6L&
MF?#[5M0U/4H_#<E^7MK3"*8+61]W4#<^S. 2<=* /NU'610RL&4\@@Y!KR7]
MK4_\8V?$3_L$2_TJA^R)<O<?!>RC6XDN["UOKVUL)I7+EK6.XD6'#'DC8  ?
M05SW[:GBOQ!I7P=\7Z78^$KG5=)NM(D^TZO%<QI':\@?,A.YN.>* /;? '_(
MB^'?^P;;?^BEK?KG_  QX'\/="/[.ML'_MDM=!0 4444 %%%% !1110 4444
M %%%% '@W[7^C:YJG@/0)]"T#4/$=QIVO6=])8Z9'YD[QQOEMHR*J?\ #5/B
M#_H@WQ+_ /!=!_\ ':^A**WC4BHJ,HWMZ@?/?_#5/B#_ *(-\3/_  7P?_':
M/^&J?$'_ $0;XF?^"^#_ ..U]"44_:4O^?:^]_Y@?/?_  U3X@_Z(-\3/_!?
M!_\ ':/^&J?$'_1!OB9_X+X/_CM?0E%'M*7_ #[7WO\ S ^>_P#AJGQ!_P!$
M%^)?_@O@_P#CM'_#57B#_H@OQ+_\%\'_ ,=KZ$HH]I2_Y]K[W_F!\]_\-4^(
M/^B"_$O_ ,%\'_QVO.?VB/BUXP^,WP:\2^#-+^"/Q"L+_58XHX;B\T^(0H5F
M1\L5D)QA#VK[*HJHU:<)*2AJO-@5-*1XM-M4=2KK$BD'J"%'%6Z**Y0"BBB@
M HHHH **3-075REI!)-(?W<:EVQR< 4 22S) C/(RHB\EF. *Q-=TV[UY8(8
M;T6VFN";AH<^;(O]U6[ ]S6;%8W7C.19[^-K71P<Q69X:?\ VG]O:NMBB6%%
M1%"JH  '0"@"'3].M]+M8K:UA6""-0JQKT%6J** "BBB@ HHHH **** "BBB
M@ HHHH **** "D-+24 > ?MI)8^'O@9X@\8'PEI?BO6M%@7[&=3LQ<I:))+&
MDLY7!)6-29& ZB.O OV(?B;8>+?B=:Z3H]MX8\1R6^FWW]K>(_#VCBS$+K<;
M;<DJ H66/H@R>.:^I_VG/$WB'P?\&]9U?PU<2V&HV\EL9+Z"R^VR6ML;B,7$
MRP8/FE8C(=H'-?/G[)WB[XA:S\7I[ZYAGLO WBB"^U.VT,Z/'90Z7;1RB.T<
M%5!\R4;BRMD\Y]*!GVP.@I:1>@I:!"$9%>2>,/V6OA]XW\9:AXKU/3+K^W[]
M8DN;NVOIH3*L:[8P0K#@#M[UZY10!YO<?L^^!KOQK;^*YM"ADUR )B=F8J[(
M-J.ZYVLZ@ !B,BO157 P>:?10!XC\1O^3J?@[_V"]>_] MJ]M'2O$OB-_P G
M4_!W_L%Z]_Z!;5[:.E Q:***!!1110 4444 %%%% !1110 4444 %%%% !11
M10 444A.*  G%4KW5K6PEMXYY0CSOLB7!)8_Y[TNK:G%I.GS7<NXQQC)"+N8
M^P'K6-X>TBXNKIM:U- M]*,0P'D6T?91_M'N: -+3="@T^]N[M2\MQ<-EI)3
ME@.RCT ]*TP,"@# I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ ICX92*?7&?%U[F'X<ZY)9Q:Y/<QVY=(
MO#3*NH.1SMA+<;CTYH _/"]\376O?%_Q->>,?&/Q<T76K77IK>S_ .$=\+L]
M@;59,1".0Q%\8X)X'4C@U^G&G$&QMB&=P8U(:088\=3[\U^=UW?>*M7\6O<_
M9?VHM/DGN5G;3HM3M%@A5G'&SJ(Q]>E?HE89%C;[O,W>6N?-.7SC^+W]: +-
M(>0:6B@#F/'7PU\-?$NPM['Q1HMIKEG;3"YA@O(PZQR@$!U]&&3S[UB#X!?#
M\>&G\/'PEIC:*\WVEK-H<H9>F_GH:]"HH H:'HECX<TNVTW3+2&PL+9!'#;V
MZ!$C4=  .@KS/]K7_DVSXB?]@B7^E>MUY)^UK_R;9\1/^P1+_2@#O/A__P B
M+X<_[!MM_P"BEK?K ^'_ /R(OAS_ +!MM_Z*6M^@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I,T$XK*U'Q%:V%[
M;V9#SW<Y^6*%=S ?WCZ#ZT +KFOVN@P"2<EY9#MA@CYDE;T45#H":I-'/<:I
MLC:8YCM$Y$*XZ$_Q'UJ>/P_:KJ[ZF5>6[90JO(V[RU]%'\.?:M2@! .,4M%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 444AZ4 >4?M.Z=XDU7X+:
M];>%9+N+5&,!<Z?.L%S]F$R&X$,C_*KF(. 3P"17R_\ L@^&/%&F_M"ZFBZM
MXB\2>&M)MKNWN-7U'6TO;&9FD!MC$$8_/Y9PP/0J:]<_;IT_XD>-OA9/X%\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMGI7)_$_X/:5\3=#NK![R]T"XG>-VU+1V2.X)0$*K[D99$P<%'5E([5WU&*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"BEK?K ^'_ /R(OAS_ +!MM_Z*6M^@ HHI* %HHHH **** "BBB@ HHHH
M**** "BBB@ HI#TIDDJQ(SN0JJ,DL< "@![':,USTWB1KO5UT_2X5O&C8"[G
M8XB@'<9[M[#IWJ>]'_"4:8JV&H&""1L/-"/F91P0I[?6KVE:5;:/91VMI$(8
M4'"KW]SZD]S0 ^.SAAEDF2)$FE/SR*N"WID]ZX[4;?4- \3ZEJ4>B2:Y!?Q1
M1H;=T$D+("-C!V V'.<C/)/'-=T5S2;!2:N=%&LZ+;M=-6:U[I]&GNCR?QCX
M.\4#X$:_H.@")?$E];31VZ1S>5';F5R2JN>R*Q ]<5R_C_X7:IH7@KP%IWAK
MX>^&OB!IWA^+[-<Z'JSQPS &(+YEM-("BMN!W!A\P/%?0&P8QVH\M?2A:&=2
MI*K-U);MW/G[P'\%O$GAC]EWQ'X,N5LDU[5HM3FM]*LYC]CT\W+N\=I$[#_5
MQ[PN<8SG'&*YFW_9QU."ZB9?#^DK%'\.3X=CP8P5OS'@J!C[I.?GKZGVC&.U
M)Y:^E,@_,?XFVM[\,/"?C?X=W^F>'M<\2>(=$T>!H[F[QJ%E/''%&L$$)CW7
M:Y7<A@)",S%]N,U^F.G*8[&"-@0R1JK ]<X%1SZ)I]U?VU]-96\U[; B"YDB
M5I(@>NUB,KGVJZJA1@4 +1110(**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ I#T-+10!\N?MJ_!7XD_%JR\-2^#==BCT/39)7UGPS/J$NGIJZG;
ML4W$?*%<'C@'/6O-_P!@_P ,W/PL^)7C;P[XB^%.H>"M8U>?^T--O%VWUFEJ
ML:JT(O58Y8L"VT\\U[C^VOX4OOB%^S=XN\,Z,MI=:Q>QPO;V5U<B!IQ'/'(Z
MQL2,2;4;:>@8C.:^'/#_ .SQ=>*_&,&O_#'X6Z_\.&TP6<<4>J:V[W)NA.F^
M>-?-;,?EAPY;(;(P!0,_5L-G'/%.J&V#K!$)"&D"@,P'4XY-34"$)P*J:AJU
MGI%L;B^NH;. ,J&6XD$:;F8*HR2!DL0 .Y('>LCX@>*;OP;X7N=5L?#^I^)[
MF$J%TW1PAN)<G'RAV5>/<U\3_M5^/O$'C#5=.O/$'@'QMI?AOP_>:/>:5;1Z
M?OBN-0DN8C)+<.C%28T8PQQ\@R.QS]V@#[?G\;:#;>((-!FUS38M=GC\V+2W
MNXQ<R)_>6(MN*^X%;2-N%? WC6+PYYWC*:\@LA\8IO'MI+8.8Q_:JVI\@P",
MXWK&(]X(4XX?/>OO7!" #KW H \7^(W_ "=3\'?^P7KW_H%M7MHZ5\QZB/'0
M_;%^'_\ PE;Z VC&RU[^Q1I F^T"+%OQ<>9\N[;M^YQG-?38S0!Q7Q5\=:KX
M&T.VFT+PQ?>+=9O;I+.UL+1A'&K,&)DGE((BB4*27(/.T8R:XO2/VF=+'PI\
M2^+?$FES^'KWPW=RZ;J6E><MPWVM I$4+IQ)OW+MP <G!'%:_P"T._Q(/@7[
M+\,+""ZU^]NH[>>ZEN(XGLK4Y\R:+S/E:4# 0-P"03D#!\=MOV9O$_BCP-H-
MO8--\+[WP_+=W"6%TUMK9U6ZFCP;VXE)'[]F+'>>06R,8& #J[G]JC4M0T/P
MI)X7\!WWB'7=:T9O$$VE?;$@%G9JVU@9"N&E)R%3 R1U%>I:/\8?"VI?#32/
M'4^KV^D^&]2MX;A+S4I%A2+S" J.Q.U6#':1GJ*^>_"'P<^+OPATCP?JFE6>
MF^,=>M_#DNA7UI/<QV7D2&4R0R!N5=%W$,!\QKL]=_9]U6#]E_PM\.+1;75]
M1T^?39+PRL%AF\N[CGN"-PY7._ /)XH&=_IG[27PNUJ[TRUL?'WA^ZN-3F:W
MLXH[^,M-(IP4 SG.>QZ]JTF^-_@%?&<OA(^,M%_X2>.9+=M(^VQ_:?-?.U-F
M<EN#\HY'?%>#^,_V<?$6KW7Q,NK'2=--QKGBK2=5LI3)&KM;VWE[R3_"5VG
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ML_050, BG4U/NCZ4Z@0A 88/-5K_ $NSU2W^SWEM%=0;E?RYD#+N4@J<'N"
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M: LQ]@* /RY\2>(O"GP6^(6B)X&^*VK+%X%U&:TM="\0^'I)[>"1ODDB6:,
MDD="<FOTV^%WQ)T'XL^"M,\2>'-2CU/3;H$":-2N)%.'0J<%2&!!!K\W;_QG
MX6UG5-3T33_BSXHL/A[KFNC6+G0Y/AS=/J D>99&C2\*_*A8#YNJC@"OT#_9
M_P#A#;_!KP7-I5OJ,FJO?ZC<ZM-<R1>42\\A?:$YP%! _"@H]0I",C!I:*"1
MAB5NHS5.?0=-NK*2SFT^UFLY#N>WDA5HV.<Y*D8)SS5^B@!D<21(J(H1%& J
MC  ]*\F_:U_Y-L^(G_8(E_I7KE>2?M:_\FV?$3_L$2_TH [SX?\ _(B^'?\
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M1E$-M'=Z.\;2,3C@'GOZ5]7V4RW-M%,H(610PR,'!&1FORN\G7_V>_B1]O\
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M;2 F:&?!V,N!M*%<=\YH ]<HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO<('213V(.015VB@#A8_@5\.HG1T\#>'D="&5AIL0((Z'[M=O'&(D55&U5X
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MEPJ*H+'/!/>O50,4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCSQG)=^'/%6I?$75]<M=3\.ZIX?2<Z#'N\H3-+E_+1!M<.L^25QC)H ^J?\
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M10 4444 %%%% !1110!SWBKP'H7C5[!M;TNVU(V,XN+<SH&\N0="/\*WE3:
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!.M)L'H*=10
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M11H1_&3PL1I33:A]C34^+9KM#%N.UF*L&&5.%/!QTK9NO'>@V3W:3ZO90M:
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MV'<&=U15;3]0M]4M4N;6:.YMWSMEB8,K8.#@CKR#5FL!!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !37^Z:=36^Z: /G/QY\'?'.O?$;5]1L=;BAL+DB2
M(&Z,;21!5!M64+NP2&^;=@;NF:SO#'PR\=-%/##8+HMK-JB.UO/J4A%E%!>/
M+MC.W]ZLB. I& "N",5J>./"GB0?%#4-7T;1Y[R_=T-M)>)NB0"(@213JP*8
M/6)@035.WOOBIIL-X8+?6KJRDM9X;47"1M<B[:*,[FXP(Q()-I_GQ7HQE)I)
M-=/ZW'8SM1_9[\?0Z0EI;ZU#>6=ND,D5JUY)YIED4?;/G92NW>H*;E. S< X
MIFE_ #XC66HV<[:U;%WECD>2&[.ZV=2NZ7<8]S%E&WY<$]^*ZY].\>6VH65Q
M<W6N3M<7=V[);&+9$XFQ;JRD<0F+.>Y."37,)%\719ZC-=3ZGYL<X?[+;Q@>
M=)E_DC?'R)]SG!'K34YM?$@1T'A3X':OX9\8>$=7N4L[N#3%A-R&O'9Q.;:2
M*><;^I)\OZA>V*TOCGX3U.^U>V\064<FH64%JL$VGV>]IKL>:&,?R D(0.2,
M].E=)XWMKF]^%NLQOHVIZQ=RD%]+6<J\CDKE ZX_=@]<=5#>M>+GX6Z[96]J
MD&FZK>R[8IK:[AS#]D0-(UQ;Q@MF,'(51W&*S@W.7-)[:"+GA3X,^.KG2=(\
M3OJ5KIFOZ6]N=*T>Z.]/)20L\4LY4R*9%DD4A?\ 8STX[?XJ_";7O%6LZSJ>
MEWD27$RV:P0-/M\V*-G,\)# JN_<O)!!QS7FLWPTO-1TG3;5O#NKZ<;Z\>:2
M2!',>B*#$0(DW?-,VP?O3P"7/U]#^+WA?Q7<_%/3==T'3IKV&+1YM/=DDVJO
MG2*K'&>2J_/_ ,!JVWSKWEU_K<#C[KX >.+R2W$MW9W5W'!(T6KS:@_F6X:(
MHMNJA1D9_CXX-=#9_"SQK=^(;?4]2@L;J"XGGD%L^JS;=,+2!C(-@'FLR*8R
MHP <=5S7"ZWX2^*=KI=MX7TRUU:+1X;,VK""7&44;@ZOU#%QCJ3SCI75^&M%
M^(?@JULY+1=8N-/><W5W:RE971?MLGRH#R,PLK$9YZ\8Q52<K7YD!F:?\ /'
M&E:3IUG!)9)!;*D$=NFH2+':.%"BY7Y1D@@D)C^*O2?A'\,-:\"ZS-=ZCJ$5
MPMQ9%+IEN7D,LXF=A(0W^PRC/X=JG^"UAXSFDO;_ ,97%^LXAA2"UF*"-<J2
MYPHY;..<UY#J'@_Q_P")KVXO;**:6]M4U!=5MI)#&+_%U&ZV@8$;/,B7 8=N
M.YJ'*4VX2D@-KP)\$?&.D^,],US7GLKV"SO$GEC_ +0+*9LS*]Q$NP;1L>/A
MB6.#DCBND\>?!#5_$OC+6=5TJXTR"RDMQ?6!FW%TU9<!)7P"-F% )R3R>*H:
MKX#U_6/A=XNT^TTB6VEU+Q%!>6=C= X2UVVW#*#]U0C J#_":YRQT'XG^$+E
M+/3;>6PM(+J:5A;)_HAD+@Y1>3Y/E]B1ALTTY2?,I)/8#LM ^ .N:'XF\!:R
M-9LV31 PN+/[-N$;R12?:'AD+9S+*X)R < <\8.##\#/&VI>)]4FU2ZMSI=W
M<L\T0OW"7"^8SH0BH",*0#N9CD>F*S=+U#XG:MI-A>VTNO2Z%<PI+<R,D:WS
M79AD(\H8^6W\WR<C'KVS5K4/"OQ-NM2L=:OK[6(M107,+K9%6MX088]N(AU!
M;S!NY(IWDGK) ;W@'X/>*=!\?Z+J>KFTOX]/$C-J37KO*J-"(UMUC(Z C.XG
MD>])XZ^!>NZUXQ\1ZKI=[I=K$\8U'05FW*]MJK"-9I'X^ZRQ(,CGYWXJ;P7>
MZVGBW3I=6AU*QSID,>I1^89&:X^T8MRQVCJF=W PN,U8^,7A*\\5>/M'CL]-
MOX)$M0XUV$LRV[*Y*PQ@'",QP7<C[@ YK-2FIZOH,Q?#_P $=>\+>,=)U"$V
M5S:V7ES+*+PHOF+&PDC:,K\\C.Q(E)&U>QKMOB%HGB/Q!XV\.21:+:ZKX=TX
M"ZEM_MZPR?;=V$:0%#O2,9=0,9?!/W17C-S\-]7EABMSX6U2SMKA8())/FD6
MUN57]_=A WS.Q^ZWJ<]J]4^'/A>^TKXJ:UJ$.E7NG:1/IGD2FZ)S)="7=YF=
MQ\PNI+;CC;PHISWYF[Z?UU$>81_#OQPGB.#18(Y[G4X8F+Z_-/.ML(_)(%NI
M(VN-QSGU)R.*T-'^ 'CVRF^UR:C;;-CPQZ=-?%B%=9 CF1(U&Z(N"JA=O+=\
M&J/A[X=>/](TO3;?^R+M#I-_<ZM:E9\L\LTDHVG)_A&& /'SCCBJEEX*^)WB
MSQ!92ZZNO):I<P0PS1S>7LB%Q'(SL/4#?AB.W2M[OI) :UI^S_XZTR+4UM38
MPS333SW,T5^[-JBRF(B-E9=J%!&YRP()8<<M6EH_[/WB..+3;K6FM=5O+&[M
M9;99M0=S'#'*[,H;8%W!67HH!VXX&*L/<_%V"RCLECU%KQA$R7(CC(6-8KA7
M#''WB_D'WSGUKN?'%EK.C?"C2(5N+V\N!<69U665@TQB+@S9('0'T[5C*I--
M*ZU&4/BY\.M>\4>(;Z[T=;&>SUG06\/W+W,YB:S!E9_/ VD2* Q&W@Y YYKG
M8/V9Y+[PWKJ7NKM)J,FHWMUIL1GW6</F2%D9E"@[BIPP)(&XUQ7B3X6^-G\)
MR:;9Z9>W-I<V^I7*JLN]H)9)H_W>TGE74;U'^\.]=U?Z1K!\ _\ "-Z1H=X[
M7UT&-[%8K8B)U=&&Z-6X4KN^;VQ3UBHQC-;B)]8^&'BSQW?Z5>7(TWP3]D:1
M?,T642W"GR/+$A8IM<;L83 PHZYK0U'X8^()/@YX1\/6UG9K<Z.\7V[2HKYU
MM[U$5T*B8C=@L5DPPZK@^M<+X*^'?B?27T>VU_39[?P]H]W=W\LLDS-O6=)?
M,!YR0H[?[8Q7HOPZFU"[^$D]KJPU2\UB/24$]M&Y24HROY*QMU$ACV[CG.ZH
MFW&UFFD,\JO?V=?'-Y]@MI+G3)+&VABC:$:@RP3(@4K#M\O<2&4_,6QTP,UZ
M3\$OA_XJ\&>(];O?$-U!]ENH(XRD5Z)4:99'/F*NU=H*E1\Q9B0>>E>81?"_
M7VT.)K?1-1C-RKFWTX!E32KLE-CC+9)"J=TG=LUI:/\ #Z]:Y_M._P##&J-I
ML=VL>I:$X=Y+V,13!;B1BW[V0RLK'' 7;UQ6TVY1:<E]W_! [3PQ\+_%F@?$
M+2M5>6WN+97G:[GN;PS*(FDE94ACVAD?#KD[BIQR,BN<\0_ WQOKWCJ[U6Y:
MSNM-74(KQ('O65)PDZN@"[,JRJ&Y9CSP *ZQM(\1:!X+^%AOK2^U.\TB>-]1
M2U!>1%\EU 89^;!*@_2K_@27QK/\0[F755OETN03-*MP%%NJY7[.(AUW;=V[
M.:QYY*\TU_3 I^/_ (<Z_J7C:[UC1-/TY3<0H)KBXOWVWL:1,OV&: @IAV8?
M..@![UR]G\#-;U.WTM[V&SL;FZNG'B-9KQ9?M-LRJ2(@B *NY%"H>B]R:QKO
MPAX\\>:=:16<0M;_ $.YO-5O;BYE=#<:MYY$"J!V2%01_#B1?2H-;\">*/$$
MNLR1>&;];K5UE:ZCO?EFM5D5>(KA6_>+D8$;#Y<<&M(W5ES+^OF![#\'/ >J
M_#RUO$U3['?7E[=,'NK63'DVL:[+9#D98A  ?0DGFO,]=_9_\6:S+J6NG4-/
MU'6-;N)_[3TN5PMND#LIB19E7<YC$46 W )<CK75>#/"GBRRTWXCVVIVMP\T
MVGQV>G3[^;H+:%%9>>&R0#[C-<WX9^#GC'PEHGARXT^\;3KV[BLK34+32H_*
M2.*.-F9I-Q.9"Y"EASCZU";C)RYE<13M?@=\0&U&[N[LVES8LZM/HXU1XXKW
M[X&&2,&,*&4Y8LQV]N*Z:\^$?BY_$MOJ,GV/4K3[03':2:G/$MDY6VVW"L!N
MDV^3(NTD'YE.?F85S%H/C#]E:6^EU-VBN8V-I!&%,TN?G59-IVQ],<%>O-7]
M#M?C#JM[+;ZO<WMG%-=QI>M;*@\M?-DSY+$8"^4(\XSS@YSFKDYO[2&<_??!
MGX@:?=11W2-XD2XOW5V2_,4<A(D*W4NQ1MQN48)8DC'3%>C^'?A%K>E?"GQM
MX9GDM)]6UE9O+O3,2L[R1!=\G&5YX[]*\UM].^,.DRSSPQ:Q_:%W-'<S2,P>
M-I!'&NT+C"@X?(X&:M:9H?Q/T&R>*"+7(K01MEXS')<M<[',?S,,F+S"N?8C
MMFG/F:^)"'3?#;Q=XI\9ZGHUO!<Z;:N;JWU/Q)>>8!<P231LB1PNNQBL:F-<
M9&WGC)%:=]^SQXO^QZK:V^HZ;,]G8S6>B7DK&(M'*^YXID1<*F"P&W./EJ?7
MK+X@1:/J,^OSW<S7$-TIA7;Y,-RCQ?9##M&1EVDYR<@#/2O3[LR:I\+]526W
MU'5;TVSQ7%M;R&*::;: \<;<8!;(!]*B56<;6:_,9B?%+X5W_C;3_"2:;?6U
MM-:L=.U!Y)2!)ITR*MTB8!W.=B[0>.3FN!U#]G[7X-(O;>":QO$BU!H;"WAO
M&MY(; +((8S,5)!5I6W+W50,USD_PM\2G1T^Q:3?I/=P.=/@B#1IH]\;F)RR
M9.541+]_N0WK6M;_  \N+OP_XBN!X:UBPNKR3R[2P=&E-NZ[]EQ(6?\ >RN3
MRW\((]*J-X124M/Z\Q&WXP^"WBRZM+46]U:W,MO9VMO!$ET+>V$R(ZL\D3(5
M>,;E.T%6XR"#6I\:_A=XW\?:AH+:3>VT,$%HD<\D-VUN8I_,0NXRK$J4# !<
M-G&3BJWQB\%Z[XDT;X=K-97#&RCG74?L\ O?*9H JY1B-WS=ST-<W;V_Q@L'
MTVQLX-0M$M],CL7"L)44"T&) S<;_-!SDD@Y'3%*#;2DI*ZN!<G^!?Q$;6+"
M\FU^.^$<ODK_ *61]G@C<>3(-R$E]@(;;R2>N*9JWP&\;QMH2Z3?Q6SVRK--
M=17S>9'<BY+R2$,K%PT7RA5VY9<,=N*L^*=)^)^CVNI_V7>ZU>LMUY=H69'Q
M&L(9"0JY;,F02?QXJ[\!?"7B_2/'^H:GXE365:ZT^;S/MEQOMA.UR7(1.@^5
MAC_@0I\\E'FYEH!PVE_#+QKXG2>6PM[G0;6 P0RVNH7#Q-J,PC=7NP)5.PAR
M&P!GG@DBO8OBMX#\0>*O#.B6.FSP7]U9Q/'<0SWKP!Y6B")/N49)C;+X(R>W
M->9KX7UG6]>TB_U2RNY[FVEU&/4Y#IPO0+@W*F,;&8!5\H)M8=OQIDGP^\=^
M'M9DU[2M')NKB?4([5K5-MU&\HVPO<,3AH5SNQV*BB3YFFY+09Z1X;^"US:_
M#GQIH>HW%K/J&NWDEV+Y6)$DODQ*LSY'#>9&6(YQD5SGAWX ^(;?5=.O9=:L
M;>>:UDNM6N+0M(W]JMD+-&I #*JLPYQT%;?PP\$>)? G@_Q7X-OH6NK=(3<:
M9>6\K.LGFQGS8P6^8,)@[^G[WCBN.L/A9XS\ ^&=,OM.DDM[NZM(;>_LM"AV
M2)MCRK$,2&?S,!F],U"E*\ESK41T4OP9\4Z)\()?"NFZA9W=S_;/VMA$GV;S
MK0REF122R^8V=V7#+G.0>M8%E\ O'D>@VIEUN&+78DCA-TM]*^(5BD5H]VT<
M'<@SCMG' JC?Z)\5M4N[!+\:K=SPWUA?3/!((8861QF,*!\Z\Y8@\@'(K?\
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M%HHHJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDV#-.HH 0 #I2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
..4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>avte-20240930xs4042.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 avte-20240930xs4042.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !" 4D# 2(  A$! Q$!_\0
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MR._X*]Z'#I?QT\%ZU#E;F]TAD?'_ $QF&T_^1#7SW_PT%XP_Y[3_ )FO>?\
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M=?H7\8M-^).IZ-:Q_#36= T75!-FXF\0V,MU$8\=%6-E(;/<U\4?'W_@G_\
M'?\ :4U^SU7QM\3O"5R]E ;:VMK/2[B""%&.6PH).6/4DD\#TITFE--L*J<H
MV1]_^"B/^$0T3_KQ@_\ 1:UM @U\L?#7X9?M0^";;P]I6H_$CP)K>BZ<(;>8
MSZ'<?:YK=, CS X&_8,!B.N"<U]2(>#VYK)K70T1Q/QS8#X->-\G'_$FN_\
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M_I7_ $2>_P#_  >1_P#QJK6E_P#!9GPY->1IJ7PQUBTM"?GEM=4AG=1Z[&1
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MGL?@=<^']+6[F4:;9A0[  0)QS]*C_L#3/\ H'6G_?A?\***]M'D!_8&F?\
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M"OY(MPSY;[E&Y?0XXR***TG\;(C\*#3T6+]N6Z=%"/<>"8S,RC!D*W1"EO7
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BMH]E+;::;H^8;&(O@QP[L^6N.-JX%?JUBBBM*OQ&<=C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>avte-20240930xs4043.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 avte-20240930xs4043.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  R 2@# 2(  A$! Q$!_\0
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M[/5[:,PD7"%XIXSGY6 ((QD\B@#3TRTUB'4=3CO+XW5@ZQFSE\M%EC/S;PV
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MK7PZFN-:T75-'.GZ/=:<-Q\N!MLI(PR$ CY,<>O)JWXL\(:GX@U[0M1AN[6
M:5(9ECDC9O,<[<@D$8'R\4 =I7(_$2[UFSTJV?0KL6]]).(E1XU=9<J3@Y'!
M^7M6GI-CJL6I7MSJ5Y#+%*B)!;VZLJ1 ;BS$DG).1S[5#XHTC4=7?3C8SV\
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M$&E4E0",$D Y/!KEM"\&Z]H7AJQT*'5+6.WMY 6NHHG69H_,WLHYP"<D9]*
M&ZWKFJ6WQ1T71HK]H].O8))I(O*0D%0QP&(S@[:Z+QAX@7PIX:U#56C\W[-'
MN6/H&8D!03Z$D5BZSX0U/4/'&G^(+>\M8UL8FABMY8V)8,"&)8'@_-Q@5=/A
M>YUG3-9L]?NTNH]1.U8K=2BP(%  7)/S9&[/K0!F::/$^I^$-.U.'51)J5R(
MKIK<P1+ 8V(8QKQN!"G@ECS^A4VB>&?$>DZ;;Z.^K6S:=;A8TNHH66Z,:D83
MDE0<?+N].V>:*8':T445(&7KNN0Z!9+<317$X9UB2*UC,DC,>@"CKTJJ/%<
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M3&RC:ZY5@2!D$>E:]8WA*QN=*\,:78W:HEQ:6L=NWEON4E5"[@<#@XSTK9I
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M^;-9LJ3C8R[6() Y SP.U96FZ3>7/C.\UVXA:SA-E'90Q.P9G =G+L!PO+8
MR?6F^'=/U&W\7^([VYLF@M+XPF&0RJQ^1-AR <C/6@!T?Q'T*:XCA2>Y9I)A
M;HPLYMC.6V@!]FW[W&<UU-<W$JZQXC"1@"PTG@*O1KEA^7R(?S?VKI* "BBB
MD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 Q5" *H"J!P!P*?110 4444 %%%% !1110 4444 1Q1I&&V*%W,6.T8
9R<]:DHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>avte-20240930xs4044.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 avte-20240930xs4044.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  A 1@# 2(  A$! Q$!_\0
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MMVOE_P 4?MF"R/A/PMX;\-MJ_P 2]7BAENO#D<HVZ3&P!<W$@X3:.U1_$_\
M;>L=(\;VWP]^'>B/\0?'TJ9GM;"0?9K(XY,LO0 4 ?4E<I\2/BEX5^$?A_\
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M:]6(('3UKX$^('[:FE_M#?%+4/&?CO3;_5O _AJ4-H/@ZV.R&YDS\LEPQX[
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>avte-20240930xs4045.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 avte-20240930xs4045.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  !  @# 2(  A$! Q$!_\0
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1OQ#_ .PEJ7_I'%1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>avte-20240930xs4046.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 avte-20240930xs4046.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  !  <# 2(  A$! Q$!_\0
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/I?\ U]3_ /IPHHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076997408000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AEROVATE THERAPEUTICS,&#160;INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001798749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076947179840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 31,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">57,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">90,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">90,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">8,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other liabilities</a></td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of September 30, 2024 and December 31, 2023, respectively; no shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 150,000,000 shares authorized at September 30, 2024 and December 31, 2023, respectively; 28,867,711 and 27,762,703 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">307,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="nump">224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(466)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(227,622)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(163,424)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(87,903)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">80,493<span></span>
</td>
<td class="nump">$ 94,398<span></span>
</td>
<td class="nump">$ 90,904<span></span>
</td>
<td class="nump">109,456<span></span>
</td>
<td class="nump">$ 125,723<span></span>
</td>
<td class="nump">$ 141,926<span></span>
</td>
<td class="nump">$ 113,095<span></span>
</td>
<td class="nump">126,743<span></span>
</td>
<td class="nump">$ 172,418<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 90,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076948349936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Aug. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Condensed Consolidated Balance Sheets (Unaudited)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">28,867,711<span></span>
</td>
<td class="nump">27,762,703<span></span>
</td>
<td class="nump">24,722,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">28,867,711<span></span>
</td>
<td class="nump">27,762,703<span></span>
</td>
<td class="nump">24,722,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076948324224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 10,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,656<span></span>
</td>
<td class="nump">$ 46,406<span></span>
</td>
<td class="nump">$ 64,219<span></span>
</td>
<td class="nump">$ 38,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">7,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,537<span></span>
</td>
<td class="nump">12,937<span></span>
</td>
<td class="nump">17,190<span></span>
</td>
<td class="nump">14,615<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">17,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,193<span></span>
</td>
<td class="nump">59,343<span></span>
</td>
<td class="nump">81,409<span></span>
</td>
<td class="nump">53,237<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(17,410)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,368)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68,193)<span></span>
</td>
<td class="num">(59,343)<span></span>
</td>
<td class="num">(81,409)<span></span>
</td>
<td class="num">(53,237)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">1,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,014<span></span>
</td>
<td class="nump">4,236<span></span>
</td>
<td class="nump">5,945<span></span>
</td>
<td class="nump">1,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">5,944<span></span>
</td>
<td class="nump">1,751<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,465)<span></span>
</td>
<td class="num">(51,486)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(16,237)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,563)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,198)<span></span>
</td>
<td class="num">(55,108)<span></span>
</td>
<td class="num">(75,521)<span></span>
</td>
<td class="num">(51,511)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(16,237)<span></span>
</td>
<td class="num">$ (24,775)<span></span>
</td>
<td class="num">$ (23,186)<span></span>
</td>
<td class="num">(19,563)<span></span>
</td>
<td class="num">$ (19,025)<span></span>
</td>
<td class="num">$ (16,520)<span></span>
</td>
<td class="num">(64,198)<span></span>
</td>
<td class="num">(55,108)<span></span>
</td>
<td class="num">(75,521)<span></span>
</td>
<td class="num">(51,511)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingUnrealizedGainLoss', window );">Unrealized gain (loss) on securities</a></td>
<td class="nump">307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="nump">703<span></span>
</td>
<td class="num">(407)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (15,930)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (19,585)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (64,211)<span></span>
</td>
<td class="num">$ (54,865)<span></span>
</td>
<td class="num">$ (74,818)<span></span>
</td>
<td class="num">$ (51,918)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.25)<span></span>
</td>
<td class="num">$ (2.13)<span></span>
</td>
<td class="num">$ (2.87)<span></span>
</td>
<td class="num">$ (2.10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.25)<span></span>
</td>
<td class="num">$ (2.13)<span></span>
</td>
<td class="num">$ (2.87)<span></span>
</td>
<td class="num">$ (2.10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares of common stock outstanding, basic</a></td>
<td class="nump">28,863,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,640,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,572,338<span></span>
</td>
<td class="nump">25,872,118<span></span>
</td>
<td class="nump">26,331,630<span></span>
</td>
<td class="nump">24,472,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares of common stock outstanding, diluted</a></td>
<td class="nump">28,863,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,640,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,572,338<span></span>
</td>
<td class="nump">25,872,118<span></span>
</td>
<td class="nump">26,331,630<span></span>
</td>
<td class="nump">24,472,104<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesTradingUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesTradingUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076945088976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="nump">24,410,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 208,867<span></span>
</td>
<td class="num">$ (59)<span></span>
</td>
<td class="num">$ (36,392)<span></span>
</td>
<td class="nump">$ 172,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingUnrealizedLoss', window );">Unrealized loss on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(407)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(407)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">298,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under ESPP, shares</a></td>
<td class="nump">13,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,511)<span></span>
</td>
<td class="num">(51,511)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2022</a></td>
<td class="nump">24,722,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">215,110<span></span>
</td>
<td class="num">(466)<span></span>
</td>
<td class="num">(87,903)<span></span>
</td>
<td class="nump">126,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingUnrealizedGain', window );">Unrealized gain on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">93,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,520)<span></span>
</td>
<td class="num">(16,520)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2023</a></td>
<td class="nump">24,816,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2023</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">217,717<span></span>
</td>
<td class="num">(201)<span></span>
</td>
<td class="num">(104,423)<span></span>
</td>
<td class="nump">113,095<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2022</a></td>
<td class="nump">24,722,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">215,110<span></span>
</td>
<td class="num">(466)<span></span>
</td>
<td class="num">(87,903)<span></span>
</td>
<td class="nump">126,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,108)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2023</a></td>
<td class="nump">27,653,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2023</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">268,926<span></span>
</td>
<td class="num">(195)<span></span>
</td>
<td class="num">(143,011)<span></span>
</td>
<td class="nump">125,723<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2022</a></td>
<td class="nump">24,722,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">215,110<span></span>
</td>
<td class="num">(466)<span></span>
</td>
<td class="num">(87,903)<span></span>
</td>
<td class="nump">126,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingUnrealizedGain', window );">Unrealized gain on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with ATM, net</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">44,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with ATM, net, shares</a></td>
<td class="nump">2,662,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units, shares</a></td>
<td class="nump">9,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">338,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under ESPP, shares</a></td>
<td class="nump">28,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,521)<span></span>
</td>
<td class="num">(75,521)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2023</a></td>
<td class="nump">27,762,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2023</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">272,640<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="num">(163,424)<span></span>
</td>
<td class="nump">109,456<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2023</a></td>
<td class="nump">24,816,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2023</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">217,717<span></span>
</td>
<td class="num">(201)<span></span>
</td>
<td class="num">(104,423)<span></span>
</td>
<td class="nump">113,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingUnrealizedLoss', window );">Unrealized loss on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with ATM, net</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">44,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with ATM, net, shares</a></td>
<td class="nump">2,662,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units, shares</a></td>
<td class="nump">815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">106,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under ESPP, shares</a></td>
<td class="nump">13,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,025)<span></span>
</td>
<td class="num">(19,025)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2023</a></td>
<td class="nump">27,601,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2023</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">265,594<span></span>
</td>
<td class="num">(223)<span></span>
</td>
<td class="num">(123,448)<span></span>
</td>
<td class="nump">141,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingUnrealizedGain', window );">Unrealized gain on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units, shares</a></td>
<td class="nump">5,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">46,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,563)<span></span>
</td>
<td class="num">(19,563)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2023</a></td>
<td class="nump">27,653,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2023</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">268,926<span></span>
</td>
<td class="num">(195)<span></span>
</td>
<td class="num">(143,011)<span></span>
</td>
<td class="nump">125,723<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2023</a></td>
<td class="nump">27,762,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2023</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">272,640<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="num">(163,424)<span></span>
</td>
<td class="nump">109,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingUnrealizedLoss', window );">Unrealized loss on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(270)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(270)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units, shares</a></td>
<td class="nump">2,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">133,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,186)<span></span>
</td>
<td class="num">(23,186)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2024</a></td>
<td class="nump">27,898,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2024</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">277,544<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="num">(186,610)<span></span>
</td>
<td class="nump">90,904<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2023</a></td>
<td class="nump">27,762,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2023</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">272,640<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="num">(163,424)<span></span>
</td>
<td class="nump">$ 109,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (64,198)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2024</a></td>
<td class="nump">28,867,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2024</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">307,888<span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="num">(227,622)<span></span>
</td>
<td class="nump">80,493<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2024</a></td>
<td class="nump">27,898,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2024</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">277,544<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="num">(186,610)<span></span>
</td>
<td class="nump">90,904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingUnrealizedLoss', window );">Unrealized loss on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with ATM, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with ATM, net, shares</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units, shares</a></td>
<td class="nump">2,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">119,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under ESPP, shares</a></td>
<td class="nump">34,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,775)<span></span>
</td>
<td class="num">(24,775)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2024</a></td>
<td class="nump">28,854,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2024</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">305,863<span></span>
</td>
<td class="num">(83)<span></span>
</td>
<td class="num">(211,385)<span></span>
</td>
<td class="nump">94,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingUnrealizedGain', window );">Unrealized gain on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">12,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,237)<span></span>
</td>
<td class="num">(16,237)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2024</a></td>
<td class="nump">28,867,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2024</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 307,888<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
<td class="num">$ (227,622)<span></span>
</td>
<td class="nump">$ 80,493<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesTradingUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesTradingUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesTradingUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesTradingUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076942893424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flow from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (64,198)<span></span>
</td>
<td class="num">$ (55,108)<span></span>
</td>
<td class="num">$ (75,521)<span></span>
</td>
<td class="num">$ (51,511)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">10,068<span></span>
</td>
<td class="nump">8,655<span></span>
</td>
<td class="nump">11,906<span></span>
</td>
<td class="nump">5,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization expense</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet', window );">Accretion of discounts and amortization of premiums on investments, net</a></td>
<td class="num">(1,912)<span></span>
</td>
<td class="num">(2,118)<span></span>
</td>
<td class="num">(3,057)<span></span>
</td>
<td class="num">(910)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(82)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
<td class="nump">483<span></span>
</td>
<td class="nump">4,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="nump">789<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="num">(110)<span></span>
</td>
<td class="num">(1,872)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,488)<span></span>
</td>
<td class="nump">880<span></span>
</td>
<td class="num">(164)<span></span>
</td>
<td class="nump">1,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other liabilities</a></td>
<td class="num">(4,152)<span></span>
</td>
<td class="nump">5,948<span></span>
</td>
<td class="nump">9,999<span></span>
</td>
<td class="nump">3,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability', window );">Operating lease assets and liabilities, net</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">332<span></span>
</td>
<td class="num">(114)<span></span>
</td>
<td class="num">(384)<span></span>
</td>
<td class="num">(133)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(60,149)<span></span>
</td>
<td class="num">(41,978)<span></span>
</td>
<td class="num">(56,778)<span></span>
</td>
<td class="num">(39,122)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flow from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(19,683)<span></span>
</td>
<td class="num">(96,194)<span></span>
</td>
<td class="num">(123,982)<span></span>
</td>
<td class="num">(147,623)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Maturities of short-term investments</a></td>
<td class="nump">62,583<span></span>
</td>
<td class="nump">102,500<span></span>
</td>
<td class="nump">136,000<span></span>
</td>
<td class="nump">154,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="num">(142)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">42,900<span></span>
</td>
<td class="nump">6,228<span></span>
</td>
<td class="nump">11,876<span></span>
</td>
<td class="nump">6,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flow from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock in connection with ATM, net</a></td>
<td class="nump">23,635<span></span>
</td>
<td class="nump">44,888<span></span>
</td>
<td class="nump">44,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments for offering costs</a></td>
<td class="num">(307)<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="num">(371)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from issuance of common stock under ESPP</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="nump">356<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock upon exercise of stock options</a></td>
<td class="nump">1,237<span></span>
</td>
<td class="nump">651<span></span>
</td>
<td class="nump">986<span></span>
</td>
<td class="nump">617<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">24,873<span></span>
</td>
<td class="nump">45,533<span></span>
</td>
<td class="nump">45,996<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">7,624<span></span>
</td>
<td class="nump">9,783<span></span>
</td>
<td class="nump">1,094<span></span>
</td>
<td class="num">(31,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at the beginning of the year</a></td>
<td class="nump">23,491<span></span>
</td>
<td class="nump">22,397<span></span>
</td>
<td class="nump">22,397<span></span>
</td>
<td class="nump">54,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at the end of the period</a></td>
<td class="nump">31,115<span></span>
</td>
<td class="nump">32,180<span></span>
</td>
<td class="nump">$ 23,491<span></span>
</td>
<td class="nump">22,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for operating lease liability</a></td>
<td class="nump">$ 206<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_DeferredOfferingCostsIncludedInAccountsPayable', window );">Deferred offering costs included in accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion of discounts and amortization of premiums on investments, net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_DeferredOfferingCostsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_DeferredOfferingCostsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease asset and liability, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076944332736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>ORGANIZATION AND NATURE OF OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">(1)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">ORGANIZATION AND NATURE OF OPERATIONS</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Organization and Nature of Operations</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate Therapeutics Inc. (&#8220;Aerovate&#8221; or the &#8220;Company&#8221;) was incorporated in the state of Delaware in July 2018, and is headquartered in Waltham, Massachusetts. The Company has a wholly owned subsidiary, Aerovate Securities Corporation. The Company is a biopharmaceutical company. The Company&#8217;s initial focus was on advancing AV-101, the Company&#8217;s dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (&#8220;PAH&#8221;). However, in June 2024, the Company announced negative results from the Phase 2b portion of its global Phase 2b/Phase 3 trial of AV-101 in adults with PAH, and, as a result, the Company decided to halt enrollment and shut down the Phase 3 portion of the Phase 2b/Phase 3 trial as well as the long-term extension study. In June 2024, the Company announced a corporate restructuring and in July 2024, the Company engaged Wedbush PacGrow as the Company&#8217;s exclusive strategic financial advisor to assist in the process of exploring strategic alternatives, including but not limited to an acquisition, merger, reverse merger, business combination, liquidation or other transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 30, 2024, the Company entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), by and among the Company, Caribbean Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (&#8220;Merger Sub I&#8221;), Caribbean Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of the Company (&#8220;Merger Sub II&#8221; and together with Merger Sub I, the &#8220;Merger Subs&#8221;), and Jade Biosciences, Inc., a Delaware corporation (&#8220;Jade&#8221;), pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, among other things, Merger Sub I will merge with and into Jade, with Jade surviving the merger as the surviving corporation (the &#8220;First Merger&#8221;), and as part of the same overall transaction, Jade will merge with and into Merger Sub II, with Merger Sub II continuing as a wholly owned subsidiary of the Company and the surviving corporation of the merger (the &#8220;Second Merger&#8221; and together with the First Merger, the &#8220;Merger&#8221;). In addition, in connection with the closing of the Merger (the &#8220;Closing&#8221;), the Company expects to declare a cash dividend to its pre-Merger stockholders of approximately $65.0 million in the aggregate (the &#8220;Cash Dividend&#8221;), provided such amount is subject to adjustment as set forth in the Merger Agreement. The Merger was approved by the Company&#8217;s board of directors (the &#8220;Board&#8221;), and the Board resolved to recommend approval of the Merger Agreement to the Company&#8217;s stockholders. The Closing is subject to approval by the stockholders of the Company and Jade as well as other customary closing conditions, including the effectiveness of a registration statement filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) in connection with the transaction. If the Merger is completed, the business of Jade will continue as the business of the combined company.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">At-the-Market Offering </span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 5, 2023, the Company entered into an ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement (the &#8220;Sales Agreement&#8221;) with BofA Securities, Inc., or the Agent, pursuant to which the Company can sell, from time to time, at its option, up to an aggregate of $75.0 million of shares of its common stock, through the Agent, as its sales agent. As of September 30,&#160;2024, 3,462,721 shares have been sold under the Sales Agreement, generating $67.9 million of net proceeds after deducting commissions to the Agent and other offering costs. As of the date of this Quarterly Report on Form 10-Q, up to $6.0 million of shares of the Company&#8217;s common stock remain available for sale from time to time under the Sales Agreement. </p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity and Management Plans</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since inception, the Company has devoted substantially all of its resources to research and development activities, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations and has not realized revenues from its planned principal operations. The Company has incurred losses and negative cash flows from operations since inception. As of September&#160;30,&#160;2024, the Company had cash and cash equivalents and short-term investments of $88.7 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management believes that the Company&#8217;s current cash and cash equivalents and short-term investments will provide sufficient funds to enable the Company to meet its obligations for at least twelve&#160;months from the filing date of this report while it explores strategic alternatives.</p><span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Organization and Nature of Operations</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate Therapeutics&#160;Inc. (&#8220;Aerovate&#8221; or the &#8220;Company&#8221;) was incorporated in the state of Delaware in July&#160;2018, and is headquartered in Waltham, Massachusetts. The Company has a wholly owned subsidiary, Aerovate Securities Corporation. The Company is a clinical-stage biopharmaceutical company that is focused on the development of drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. The Company&#8217;s initial focus is on advancing AV-101, the Company&#8217;s dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (&#8220;PAH&#8221;). The Company initiated a global Phase 2b/Phase 3 trial of AV-101 in adults with PAH in December&#160;2021 and announced in November 2023 completion of enrollment of the Phase 2b portion of this trial and enrollment of the first patient in the Phase 3 portion of this trial. </p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">At-the-Market Offering</span><span style="font-style:italic;"> </span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 5, 2023, the Company entered into an ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement, or the Sales Agreement, with BofA Securities, Inc., or the Agent, pursuant to which the Company can sell, from time to time, at its option, up to an aggregate of $75.0 million of shares of its common stock, through the Agent, as its sales agent. As of December 31, 2023, 2,662,721 shares have been sold under the Sales Agreement, generating approximately $44.3 million of net proceeds after deducting commissions to the sales agent and other offering costs, and up to $30.0 million of shares of the Company&#8217;s common stock remain available for sale from time to time under the Sales Agreement. </p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Liquidity and Management Plans</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since inception, the Company has devoted substantially all of its resources to research and development activities, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations and has not realized revenues from its planned principal operations. The Company has incurred losses and negative cash flows from operations since inception. In addition, the Company expects to incur substantial operating losses for the next several&#160;years as it continues its research and development activities. As of December&#160;31, 2023, the Company had cash and cash equivalents and short-term investments of $122.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management plans to continue to incur substantial costs in order to conduct research and development activities and additional capital will be needed to undertake these activities. The Company intends to raise such capital through debt or equity financings or other arrangements to fund operations. Management believes that the Company&#8217;s current cash and cash equivalents and short-term investments will provide sufficient funds to enable the Company to meet its obligations for at least twelve&#160;months from the filing date of this report.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076950664352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">(2)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements as of September&#160;30,&#160;2024 and for the three and nine months ended September&#160;30,&#160;2024 and 2023 have been prepared in conformity with generally accepted accounting principles (&#8220;GAAP&#8221;) in the United States of America for interim financial information and pursuant to Article&#160;10 of Regulation S-X of the Securities Act of 1933, as amended (the Securities Act). Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include only normal and recurring adjustments that the Company believes are necessary to fairly state the Company&#8217;s financial position and the results of its operations and cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The results for the three and nine months ended September&#160;30,&#160;2024 are not necessarily indicative of the results expected for the full fiscal&#160;year or any subsequent interim period. The condensed consolidated balance sheet as of December&#160;31,&#160;2023 has been derived from the audited financial statements at that date but does not include all disclosures required by GAAP for complete financial statements. Because all of the disclosures required by GAAP for complete financial statements are not included herein, these unaudited condensed consolidated financial statements and the notes accompanying them should be read in conjunction with the Company&#8217;s audited financial statements for the&#160;year ended December&#160;31,&#160;2023. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the Company&#8217;s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. Accounting estimates and management judgements reflected in the consolidated financial statements include: normal recurring accruals, including the accrual for research and development expenses, stock-based compensation, fair value of investments, and operating lease right-of-use assets and lease liabilities. Estimates and assumptions are reviewed quarterly. Any revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Net Loss Per Share</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company&#8217;s potentially dilutive securities have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes the Company&#8217;s net loss per share (in thousands, except share and per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,237)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,563)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (64,198)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (55,108)</p></td></tr><tr><td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,237)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,563)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (64,198)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (55,108)</p></td></tr><tr><td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Weighted-average common stock outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,863,327</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,640,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,572,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,872,118</p></td></tr><tr><td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.56)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.71)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.25)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.13)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:61.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,714,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,236,832</p></td></tr><tr><td style="vertical-align:top;width:61.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,754</p></td></tr><tr><td style="vertical-align:bottom;width:61.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,714,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,262,586</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(d)</span></span><span style="font-style:italic;font-weight:bold;">Recently Issued and Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In November 2023, the FASB issued ASU 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280)</i>: Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments&#8217; significant expenses on an interim and annual basis. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Entities must adopt the changes to the segment reporting guidance on a retrospective basis, and early adoption is permitted. The Company does not anticipate this ASU to materially impact our consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In December 2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740)</i>: Improvements to Income Tax Disclosures, which expands disclosures in an entity&#8217;s income tax rate reconciliation table and regarding cash taxes paid both in the U.S. and foreign jurisdictions. The standard is effective for fiscal years beginning after December 15, 2024, and interim periods in fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact the adoption of this standard may have on its consolidated financial statements and related disclosures, and does not anticipate this ASU to materially impact our consolidated financial statements and related disclosures.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(2)</b></span>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Basis of Presentation</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include the Company&#8217;s wholly owned subsidiary, Aerovate Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Use of Estimates</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The preparation of the Company&#8217;s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. Accounting estimates and management judgements reflected in the consolidated financial statements include: normal recurring accruals, including the accrual for research and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">development expenses, stock-based compensation, fair value of investments, and operating lease right-of-use assets and lease liabilities. Estimates and assumptions are reviewed quarterly. Any revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Cash and Cash Equivalents</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents include cash in readily available checking accounts, money market funds and commercial paper. The Company considers all highly liquid investments with an original maturity of three&#160;months or less from the date of purchase to be cash equivalents.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(d)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Short-term Investments</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Short-term investments consist of corporate debt securities, commercial paper and U.S. Treasury bills, classified as available-for-sale securities and have maturities of greater than three&#160;months. The Company has classified all of its available-for-sale investment securities as current assets on the consolidated balance sheets because these are considered highly liquid securities and are available for use in current operations. The Company carries these securities at fair value and reports unrealized gains and losses as a separate component of accumulated other comprehensive loss. The cost of debt securities is adjusted for amortization of purchase premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income in the consolidated statements of operations and comprehensive loss. Realized gains and losses on sales of securities are determined using the specific identification method and recorded in other income (expense), net in the consolidated statement of operations and comprehensive loss.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(e)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Concentration of Credit Risk</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains cash, cash equivalents and short-term investments with various high credit quality banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has not experienced any losses on deposits since inception.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(f)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Comprehensive Loss</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Comprehensive loss consists of net loss and unrealized gains or losses on available-for-sale investments. The Company displays comprehensive loss and its components as part of the consolidated statements of operations and comprehensive loss.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(g)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Fair Value Measurements</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">Level 1: Observable inputs such as quoted prices in active markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying amounts of prepaid expenses and other current assets, accounts payable, accrued liabilities and other current liabilities are reasonable estimates of their fair value due to the short-term nature of these accounts.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(h)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Prepaid Expenses and Other Current Assets</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any expenses paid prior to the related services rendered are recorded as prepaid expenses. Such prepaid expenses are expensed in the period the expense is incurred. If the expense is for a service covering multiple periods, it is expensed from the date the services begin and over the period of the service rendered (or contract service period if services rendered dates are not defined).</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(i)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Property and Equipment, Net</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property and equipment, which consist of leasehold improvements, furniture and fixtures, research equipment, computers and construction-in-progress are stated at cost less accumulated depreciation or accumulated amortization. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets, which ranges from <span style="-sec-ix-hidden:Hidden_n34-iiJT30mFenREfVs5IQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to <span style="-sec-ix-hidden:Hidden_g3-e0FT-IE2Xj7oAU60QZg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five&#160;years</span></span>. Leasehold improvements are amortized over the remaining life of the lease for leasehold improvements at the time the asset is placed into service.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(j)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Impairment of Long-lived Assets</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying value of long-lived assets, including property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. Through December&#160;31, 2023, there has been no such impairment losses recorded by the Company.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(k)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Leases</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the commencement date of a lease, the Company recognizes lease liabilities which represent its obligation to make lease payments, and right-of-use assets (&#8220;ROU assets&#8221;) which represent its right to use the underlying asset during the lease term. The lease liability is measured at the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the lease commencement date. The ROU asset is measured at cost, which includes the initial measurement of the lease liability and initial direct costs incurred by the Company and excludes lease incentives. ROU assets are recorded in operating lease ROU assets and lease liabilities are recorded in operating lease liabilities, current and noncurrent in the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected not to separate lease and non-lease components and not recognize lease liabilities and ROU assets for short-term leases with terms of twelve&#160;months or less.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(l)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Convertible Preferred Stock</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company records convertible preferred stock at fair value on the dates of issuance, net of issuance costs. Upon the occurrence of certain events that are outside the Company&#8217;s control, including a deemed liquidation event, holders of the convertible preferred stock can cause redemption for cash. Therefore, convertible preferred stock is classified outside of stockholders&#8217; deficit on the balance sheets as events triggering the liquidation preferences are not solely within the Company&#8217;s control. The carrying values of the convertible preferred stock are adjusted to their liquidation preferences if and when it becomes probable that such a liquidation event will occur.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(m)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Research and Development Expenses</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and other benefits of research and development personnel, including associated share-based compensation, costs related to research activities, preclinical studies, clinical trial, drug manufacturing and allocated overhead and facility-related expenses. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, as they are incurred, based </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(n)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Stock-Based Compensation</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Stock-based compensation expense represents the cost of the grant-date fair value of employee, officer, director, and non-employee stock option grants and restricted stock units, estimated in accordance with the applicable accounting guidance, recognized using the straight-line method over the vesting period for service-based options and using the graded vesting method for performance-based options. The vesting period generally approximates the expected service period of the awards. Forfeitures are recognized and accounted for as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The fair value of stock options is estimated using a Black-Scholes option pricing model on the date of grant. This method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#8217;s common stock, expected dividend yield, and a risk-free interest rate. Options and awards granted during the&#160;year have a maximum contractual term of ten&#160;years. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the average of the contractual term of the stock option and its weighted-average vesting period. The expected volatility of stock options is based upon the historical volatility of a number of publicly traded companies in similar stages of clinical development. The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future. The risk-free interest rates used are based on the U.S. Department of Treasury (&#8220;U.S. Treasury&#8221;) yield in effect at the time of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term of the stock options.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(o)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Income Taxes</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Income taxes are accounted for using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss ("NOL") and tax credit carryforwards. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="white-space:pre-wrap;">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.  The company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.  The company recognizes interest and penalties related to unrecognized tax benefits within income tax expense.  Any accrued interest and penalties are included within the related tax liability.</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(p)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Segment Reporting</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one operating segment.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(q)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Net Loss Per Share</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company&#8217;s potentially dilutive securities, which include convertible preferred stock prior to the conversion of such shares to common stock and outstanding stock options under the Company&#8217;s equity incentive plan, have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The following table summarizes the Company&#8217;s net loss per share:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75,521)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,511)</p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75,521)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,511)</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Weighted-average common stock outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,331,630</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,472,104</p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.87)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.10)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:61.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,230,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,110,219</p></td></tr><tr><td style="vertical-align:top;width:61.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,881</p></td></tr><tr><td style="vertical-align:bottom;width:61.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,252,312</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,139,100</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(r)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Recently Issued Accounting Pronouncements</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In December 2023, the FASB issued ASU No. 2023-09, "Improvements to Income Tax Disclosures." ASU 2023-09 requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024 and for private businesses for annual periods beginning after December 15, 2025, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its financial statement disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In June 2022, the FASB issued ASU No. 2022-03, Fair Value Measurement (Topic 820) - Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard will be effective for the Company on January 1, 2024, and is not expected to have an impact on the Company&#8217;s financial position or results of operations upon adoption.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076944122176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE OF FINANCIAL INSTRUMENTS</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">(3)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">FAIR VALUE OF FINANCIAL INSTRUMENTS</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following tables summarize the Company&#8217;s financial assets measured at fair value on a recurring basis and their respective input levels based on the fair value hierarchy (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for&#160;Identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level&#160;3)</b></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,926</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,926</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,537</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total fair value of assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,880</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,343</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,537</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for&#160;Identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level&#160;3)</b></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_NvvtqfTNDUi3pAQbMuV3Iw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_W5lZ48FLCEy_u2gCz_QeZg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_EIT7Ft-M4U2oTXvtr5qvPQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_XpL8HTw1KUeUXBHbhjlt2w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_lN0AgyYwBUGSBPvHUXVvCA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_ATiC6JEvSUm2xAjs-Qle-w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,386</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_FAR9X24s2UOjJM_mFfQemw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,386</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden__tPLOVORX06K05WNcJNPHQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_hGln6qJd7kWjTm5e4HDgWA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_sBbWTO6GDUu9JQZjdyFFlw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,945</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_Ib6YuqwgvUOu1jkJDvoCZQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,945</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_HN51f_bDUkShpzdYGLsCOw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98,948</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_sNomPq10ZESk15LyPnEosQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total fair value of assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 118,735</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,149</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_YNU4YHIeWEuPQ_VjMX_kCQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash Equivalents and Short-Term Investments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial assets measured at fair value on a recurring basis consist of the Company&#8217;s cash equivalents and short-term investments. Cash equivalents consisted of money market funds and commercial paper, and short-term investments consisted of U.S. Treasury bills, agency bonds, corporate debt securities, and commercial paper. The Company obtains pricing information from its investment manager and generally determines the fair value of investment securities using standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following tables summarize the Company&#8217;s short-term investments (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Maturity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 139</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,866</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,926</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,058</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Maturity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,386</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,945</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 98,711</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (23)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 98,948</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following tables summarize the Company&#8217;s short-term investments with unrealized losses for less than 12 months and 12 months or greater (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:35.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="16" style="vertical-align:bottom;white-space:nowrap;width:62.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">12 months or Greater</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Unrealized</b></p></td></tr><tr style="height:10.35pt;"><td style="vertical-align:bottom;width:35.88%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></div></div></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:35.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:35.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,760</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:35.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 488</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,007</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:35.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,986</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (23)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company did not hold any short-term investments in a loss position as of September 30, 2024. The Company considers whether unrealized losses have resulted from a credit loss or other factors. The unrealized losses on the Company&#8217;s short-term investments as of December&#160;31,&#160;2023, were caused by fluctuations in market value and interest rates as a result of the economic environment and not credit risk. As of September&#160;30,&#160;2024 and December&#160;31,&#160;2023, no allowance for credit losses was recorded. During the nine months ended September&#160;30,&#160;2024, the Company did not recognize any impairment losses related to its short-term investments. It is neither management&#8217;s intention to sell nor is it more likely than not that the Company will be required to sell these investments prior to recovery of their cost basis or recovery of fair value. Unrealized gains and losses are included in accumulated other comprehensive gain (loss). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Accrued interest receivable is written off through net realized investment gains (losses) at the time the issuer of the bond defaults or is expected to default on payment. Accrued interest receivable related to short-term investments was $0.3 million as of September&#160;30,&#160;2024 and $0.6 million as of December&#160;31,&#160;2023. </p><span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">(3)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">FAIR VALUE OF FINANCIAL INSTRUMENTS</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The following tables summarize the Company&#8217;s financial assets measured at fair value on a recurring basis and their respective input levels based on the fair value hierarchy (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:normal;width:41.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for&#160;Identical</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level&#160;3)</b></p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,255</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,255</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Commercial Paper</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,386</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,386</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,945</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,945</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98,948</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,586</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total fair value of assets</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 118,735</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,149</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,586</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:41.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">for&#160;Identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(level&#160;3)</b></p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55,577</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55,577</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Agency Bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 106,823</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 79,982</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total fair value of assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 125,259</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 79,982</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash Equivalents and Short-Term Investments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial assets measured at fair value on a recurring basis consist of the Company&#8217;s cash equivalents and short-term investments. Cash equivalents consisted of cash, money market funds and commercial paper, and short-term investments consisted of U.S. Treasury bills, agency bonds, corporate debt securities and commercial paper. The Company obtains pricing information from its investment manager and generally determines the fair value of investment securities using standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following tables summarize the Company&#8217;s short-term investments (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maturity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,386</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,945</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98,711</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98,948</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maturity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,645</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (84)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,577</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (267)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,536</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (133)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 107,289</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (484)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 106,823</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following tables summarize the Company&#8217;s short-term investments with unrealized losses for less than 12 months and 12 months or greater:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:65.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.56%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.58%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">12 months or Greater</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.03%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Unrealized</b></p></td></tr><tr><td style="vertical-align:bottom;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,760</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 488</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,007</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,986</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:32.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:67.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.01%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.32%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">12 months or Greater</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Unrealized</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:32.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,928</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (84)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,928</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (84)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,971</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,833</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (261)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (267)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:32.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,964</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (133)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,964</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (133)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (223)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,833</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (261)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (484)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company considers whether unrealized losses have resulted from a credit loss or other factors. The unrealized losses on the Company&#8217;s available-for-sale securities as of December&#160;31, 2023 were caused by fluctuations in market value and interest rates as a result of the economic environment and not credit risk. The Company concluded that an allowance for credit losses was unnecessary as of December&#160;31, 2023. It is neither management&#8217;s intention to sell nor is it more likely than not that the Company will be required to sell these investments prior to recovery of their cost basis or recovery of fair value. Unrealized gains and losses are included in accumulated other comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Accrued interest receivable is written off through net realized investment gains (losses) at the time the issuer of the bond defaults or is expected to default on payment. Accrued interest receivable related to short-term investments was $0.6 million and $0.3 million as of December&#160;31, 2023 and December 31, 2022, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076995737392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>BALANCE SHEET COMPONENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">BALANCE SHEET COMPONENTS</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">(4)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">BALANCE SHEET COMPONENTS</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Prepaid Expenses and Other Current Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Prepaid expenses and other current assets consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,875</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Accrued and Other Current Liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In June 2024, following the Company&#8217;s decision to halt further development of AV-101, the Company announced its plan to terminate nearly all of its workforce in the coming months (the &#8220;Workforce Reduction Plan&#8221;). As of September 30, 2024, 46 individuals, or approximately 90% of the Company&#8217;s workforce, have been terminated. The affected individuals have been and will be provided severance benefits, including cash severance payments. Each affected individual&#8217;s eligibility for severance benefits is contingent upon entering into a separation agreement, which includes a general release of claims against the Company. In connection with the Workforce Reduction Plan, the Company incurred costs (in consideration of releases) of approximately $6.4 million, which are primarily one-time severance benefits, during the nine months ended September 30, 2024. The Company has paid approximately $2.4 million of severance benefits, and liabilities associated with the Workforce Reduction Plan were approximately $4.0 million as of September 30, 2024. The Company estimates that the remaining liabilities will be paid in the fourth quarter of 2024 and first quarter of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Accrued and other current liabilities consisted of the following (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,704</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,363</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued payroll and other employee benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 292</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total accrued and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,948</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,821</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">(4)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">BALANCE SHEET COMPONENTS</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Prepaid Expenses and Other Current Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Prepaid expenses and other current assets consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:62.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,503</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Prepaid research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 478</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Total prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accrued and Other Current Liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Accrued and other current liabilities consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued research and development</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,363</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,751</p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued payroll and other employee benefits</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,368</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,691</p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,090</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 380</p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total accrued and other current liabilities</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,821</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,822</p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076995750720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">(5)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">COMMITMENTS AND CONTINGENCIES</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2021, the Company entered into a lease agreement (the &#8220;Waltham Lease&#8221;) for approximately 5,000 square feet of office space in Waltham, Massachusetts for the Company&#8217;s corporate headquarters. The Waltham Lease has a term of <span style="-sec-ix-hidden:Hidden_QkmZslh310SYGgzTas8QSQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">thirty-nine&#160;months</span></span> (&#8220;Lease Term&#8221;), unless extended or earlier terminated. The Company had the option to extend the Waltham Lease for one additional period of three&#160;years. The Lease Term has an initial abatement period, and the initial base rent payable is approximately $18,000 per&#160;month following the abatement period. The initial base rent payable will increase by approximately 2% per&#160;year over the Lease Term. The Waltham Lease commencement date was September&#160;1, 2021. In January 2024, the Company entered into the First Amendment to the Waltham Lease resulting in the lease expiring on December 31, 2025, and an increase of $1.00 per rentable square foot during the additional lease term. In obtaining this lease extension, the Company no longer has the option to extend the Waltham Lease for one additional period of three years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2022, the Company entered into a lease agreement (the &#8220;Foster City Lease&#8221;) for approximately 3,500 square feet of office space in Foster City, California. The Foster City Lease has a term of <span style="-sec-ix-hidden:Hidden_5dOxBlntyUCTd-8nElVMiw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">thirty-nine&#160;months</span></span>, unless extended or earlier terminated. The Company has the option to extend the Foster City Lease for an additional period of <span style="-sec-ix-hidden:Hidden_mWsXBWWQvkivgmOrUGyQhg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one&#160;year</span></span>. The base rent payable under the Foster City Lease is $22,600 per&#160;month and will be subject to annual increase of 3% on each anniversary. Following the Company&#8217;s Workforce Reduction Plan, the Company terminated all employees in the Foster City office and vacated the premises in September 2024. As a result, the Company impaired the related right-of-use asset of approximately $0.3 million, and recognized a loss on impairment in its general and administrative operating expenses during the three months ended September 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of September&#160;30,&#160;2024, the future minimum annual lease payments under the operating leases were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:74.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:25.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 12.25pt;"><b style="font-weight:bold;">Total Minimum</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:25.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 12.25pt;"><b style="font-weight:bold;">Lease Payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 242</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total operating lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 558</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less: Amount representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (18)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Present value of net minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Company&#8217;s leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the lease commencement date. The components of operating leases as of September&#160;30,&#160;2024 and as of December&#160;31,&#160;2023 were as follows (in thousands except lease term and discount rate):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 459</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average incremental borrowing rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Supplemental cash flow information related to cash paid for amounts included in the measurement of operating lease liabilities was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:75.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine months </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">ended </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:75.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid included in operating cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 323</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Rent expense was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:40.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 343</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:40.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 165</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:40.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total rent expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">(5)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">COMMITMENTS AND CONTINGENCIES</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2021, the Company entered into a lease agreement (the &#8220;Waltham Lease&#8221;) for approximately 5,000 square feet of office space in Waltham, Massachusetts for the Company&#8217;s corporate headquarters. The Waltham Lease has a term of thirty-nine months (&#8220;Lease Term&#8221;), unless extended or earlier terminated. The Company has the option to extend the Waltham Lease for one additional period of three&#160;years. The Lease Term had an initial abatement period, and the initial base rent payable is approximately $18,000 per&#160;month following the abatement period. The initial base rent payable will increase by approximately 2% per&#160;year over the Lease Term. The Waltham Lease commencement date was September&#160;1, 2021. In January 2024, the Company entered into the First Amendment to the Waltham Lease resulting in the lease expiring on December 31, 2025, and an increase of $1.00 per rentable square foot during the additional lease term. In obtaining this lease extension, the Company no longer has the option to extend the Waltham Lease for one additional period of three years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April 2022, the Company entered into a lease agreement (the &#8220;Foster City Lease&#8221;) for approximately 3,500 square feet of office space in Foster City, California. The Foster City Lease has a term of thirty-nine months, unless extended or earlier terminated. The Company has the option to extend the Foster City Lease for on additional period of one year. The base rent payable under the Lease Term will be $22,600 per month and will be subject to annual increase of 3% on each anniversary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the consolidated balance sheet includes an operating lease right-of-use asset of $0.6 million and operating lease liability of $0.7 million. The total operating lease expense was $0.4 million for both of the years ended December 31, 2023 and 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the future minimum annual lease payments under the operating leases were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:24.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 12.25pt;"><b style="font-weight:bold;">Total Minimum</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:24.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 12.25pt;"><b style="font-weight:bold;">Lease Payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 466</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 242</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total operating lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 708</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Amount representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Present value of net minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The components of operating leases for the years ended December 31, 2023 and December 31, 2022 were as follows (in thousands except lease term and discount rate):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Operating lease liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 705</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average incremental borrowing rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Legal Proceedings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company may from time to time be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings during the years ended December 31, 2023 and 2022, and no material legal proceedings are currently pending or, to the best of its knowledge, threatened.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076944118096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">(6)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">STOCKHOLDERS&#8217; EQUITY</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July&#160;2, 2021, the Company&#8217;s certificate of amendment to its certificate of incorporation became effective, which provided 150,000,000 authorized shares of common stock with a par value of $0.0001 per share and 10,000,000 authorized shares of undesignated preferred stock with a par value of $0.0001 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The holders of the common stock are entitled to one vote for each share of common stock held at all meetings of stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of September&#160;30,&#160;2024, the Company had reserved the following shares of common stock for future issuance:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:72.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common stock options granted and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,714,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:72.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares reserved for issuance under the 2021 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,982,105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:72.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reserved for future ESPP issuances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 401,218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,097,427</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">(6)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">STOCKHOLDERS&#8217; EQUITY</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Company&#8217;s Amended and Restated Certificates of Incorporation dated August&#160;3, 2020, the Company had a total of 94,052,154 shares of capital stock authorized for issuance, consisting of 50,000,000 shares of common stock, par value of $0.0001 per share, and 44,052,154 shares of convertible preferred stock, par value of $0.0001 per share. Shares of authorized convertible preferred stock were designated as 4,000,000 shares of Series&#160;Seed redeemable convertible preferred stock and 40,052,154 shares of Series&#160;A redeemable convertible preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July&#160;2, 2021, the Company&#8217;s certificate of amendment to its certificate of incorporation became effective, which provided 150,000,000 authorized shares of common stock with a par value of $0.0001 per share and 10,000,000 authorized shares of undesignated preferred stock with a par value of $0.0001 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2018, the Company issued 241,467 shares of common stock to RA Capital Healthcare Fund,&#160;L.P. at a price of $0.0012 per share. On July&#160;2, 2021, in conjunction with the Company&#8217;s initial public offering, or IPO, the Company issued 9,984,463 shares of its common stock and all outstanding shares of the Company&#8217;s redeemable convertible preferred stock were converted into 14,182,854 shares of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The holders of the common stock are entitled to one vote for each share of common stock held at all meetings of stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the Company had reserved the following shares of common stock for future issuance:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options granted and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,230,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Shares reserved for issuance under the 2021 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 604,363</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Reserved for vesting of outstanding restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Reserved for future ESPP issuances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 435,252</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,291,927</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076944114384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">(7)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">STOCK-BASED COMPENSATION</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Stock Option Plan</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s 2021 Stock Option and Incentive Plan (the &#8220;2021 Plan&#8221;) was adopted by the Company&#8217;s board of directors and approved by the Company&#8217;s stockholders in June&#160;2021 and became effective as of June&#160;29, 2021. Upon the effectiveness of the 2021 Plan, the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) was terminated and no further grants may be made thereunder. The Company&#8217;s 2021 Plan allows for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, stock bonuses, restricted stock, stock units and other forms of awards including cash awards to its officers, directors, employees, consultants and advisors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30,&#160;2024, a total of 5,675,841 shares of the Company&#8217;s common stock were authorized for issuance with respect to awards granted under the 2021 Plan, of which 2,982,105 shares remain available for issuance. The share limit will automatically increase on the first trading day in January&#160;of each&#160;year (commencing with 2022) by an amount equal to the lesser of (1)&#160;4% of the total number of outstanding shares of the Company&#8217;s common stock on the last trading day in December&#160;in the prior&#160;year, or (2)&#160;such lesser number as determined by the Company&#8217;s board of directors. Since adoption, the number of shares available under the 2021 Plan pursuant to the annual increases totaled 3,075,841 shares through January 1, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any shares subject to awards granted under the 2021 Plan or the 2018 Plan that are not paid, delivered or exercised before they expire or are canceled or terminated, or otherwise fail to vest, as well as shares used to pay the purchase or exercise price of such awards or related tax withholding obligations, will become available for new award grants under the 2021 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30,&#160;2024, 2,753,788 and 960,316 options had been granted under the 2021 Plan and 2018 Plan, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The options that are granted under the 2021 Plan and the 2018 Plan are exercisable at various dates as determined upon grant and terminate within 10&#160;years of the date of grant. The vesting period generally occurs over <span style="-sec-ix-hidden:Hidden_OXhRKVDiBU-X90wrZ-v3BA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to four&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes the option activity under the 2021 Plan and 2018 Plan for the nine months ended September&#160;30,&#160;2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual&#160;Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,230,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,489,191</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (265,482)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cancelled/Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,739,949)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,714,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and exercisable at September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,791,181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant date fair value of stock option grants was $14.92 per share for the nine months ended September&#160;30,&#160;2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30,&#160;2024, there was approximately $9.4 million of total unrecognized stock-based compensation expense related to unvested stock options granted under the 2021 Plan and 2018 Plan, which is expected to be recognized over a weighted-average period of approximately 1.9&#160;years.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) was adopted by the Company&#8217;s board of directors and stockholders in June 2021 and became effective upon the consummation of the IPO. A total of 230,000 shares of the Company&#8217;s common stock was initially available for issuance under the ESPP. The share limit will automatically increase on the first trading day in January of each year (commencing with 2022) by an amount equal to the lesser of (1) 1% of the total number of outstanding shares of the Company&#8217;s common stock on the last trading day in December in the prior year, or (2) such lesser number as determined by the Company&#8217;s board of directors. The number of shares available under the 2021 Plan increased by 247,229 shares effective January 1, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">2023 as determined by the Company&#8217;s board of directors. The ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 15% of their eligible compensation, subject to any plan limitations. The ESPP provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last trading day of the offering period. As of September&#160;30,&#160;2024, 76,011 shares had been issued under the ESPP, and 401,218 shares authorized under the ESPP Plan were available for issuance.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Stock Units</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of September&#160;30,&#160;2024, 31,881 restricted stock units had been awarded under the 2021 Plan. A summary of the status of and changes in unvested restricted stock unit activity under the Company&#8217;s equity award plans for the nine months ended September&#160;30,&#160;2024 was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:59.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average&#160;Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date&#160;Fair&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per&#160;Unit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,492)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,476)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units as of September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation of restricted stock units is based on the fair value of the Company&#8217;s common stock on the date of grant and recognized over the vesting period. The vesting period generally occurs over <span style="-sec-ix-hidden:Hidden_Sk9GO9o6hE2czOoGU9-uIA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to four&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30,&#160;2024, the Company had no unrecognized stock-based compensation expense related to its unvested restricted stock units.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(d)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation Expense</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations and comprehensive loss as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 458</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,817</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,987</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,798</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,545</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,237</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,068</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,655</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Stock-based compensation expense by type of award included within the consolidated statements of operations and comprehensive income (loss) was as follows: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,140</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,890</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,369</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock awards and units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 151</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee stock purchase plan awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,237</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,068</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,655</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">(7)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">SHARE-BASED COMPENSATION</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Stock Option Plan</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s 2021 Stock Option and Incentive Plan (the &#8220;2021 Plan&#8221;) was adopted by the Company&#8217;s board of directors and approved by the Company&#8217;s stockholders in June&#160;2021 and became effective as of June&#160;29, 2021. Upon the effectiveness of the 2021 Plan, the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) was terminated and no further grants may be made thereunder. The Company&#8217;s 2021 Plan allows for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, stock bonuses, restricted stock, stock units and other forms of awards including cash awards to its officers, directors, employees, consultants and advisors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, a total of 4,565,333 shares of the Company&#8217;s common stock were authorized for issuance with respect to awards granted under the 2021 Plan. The share limit will automatically increase on the first trading day in January&#160;of each&#160;year (commencing with 2022) by an amount equal to the lesser of (1)&#160;4% of the total number of outstanding shares of the Company&#8217;s common stock on the last trading day in December&#160;in the prior&#160;year, or (2)&#160;such lesser number as determined by the Company&#8217;s board of directors. Since adoption, the annual increases have accumulated to a total of 3,075,841 shares through January 1, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any shares subject to awards granted under the 2021 Plan or the 2018 Plan that are not paid, delivered or exercised before they expire or are canceled or terminated, or otherwise fail to vest, as well as shares used to pay the purchase or exercise price of such awards or related tax withholding obligations, will become available for new award grants under the 2021 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, 3,931,887 options had been granted under the 2021 Plan, with 604,363 shares authorized under the 2021 Plan available for future issuance. As of December 31, 2023, a total of 1,298,457 options had been granted and were outstanding under the 2018 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The options that are granted under the 2021 Plan and the 2018 Plan are exercisable at various dates as determined upon grant and terminate within 10&#160;years of the date of grant. The vesting period generally occurs over <span style="-sec-ix-hidden:Hidden_VYoFbHUwRE-bLITQC63xcQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to four&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the option activity under the 2021 Plan and 2018 Plan for the&#160;year ended December&#160;31, 2023:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual&#160;Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and expected to vest at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,110,219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 82,490</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,546,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (338,987)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cancelled/Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (86,889)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,230,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 49,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and exercisable at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,157,378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11.24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 25,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and expected to vest at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,230,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 49,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant date fair value of stock option grants was $15.69&#160;and $10.48 per share for the years ended December 31,&#160;2023 and December 31, 2022, respectively. All exercisable options are vested and all outstanding options are vested or expected to vest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023 there was approximately $29.1 million of unrecognized stock-based compensation expense related to nonvested stock-based compensation arrangements granted under the 2021 Plan and 2018 Plan, which is expected to be recognized over a weighted-average period of 2.3&#160;years.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Employee Stock Purchase Plan</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) was adopted by the Company&#8217;s board of directors and stockholders in June&#160;2021 and became effective upon the consummation of the IPO. A total of 230,000 shares of the Company&#8217;s common stock is initially available for issuance under the ESPP. The share limit will automatically increase on the first trading day in January&#160;of each&#160;year (commencing with 2022) by an amount equal to the lesser of (1)&#160;1% of the total number of outstanding shares of the Company&#8217;s common stock on the last trading day in December&#160;in the prior&#160;year, or (2)&#160;such lesser number as determined by the Company&#8217;s board of directors. The number of shares available under the 2021 Plan increased by 247,229 shares effective January 1, 2023 as determined by the Company&#8217;s board of directors. The ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 15% of their eligible compensation, subject to any plan limitations. The ESPP provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last trading day of the offering period. As of December&#160;31, 2023, 41,977 shares had been issued under the ESPP, and 435,252 shares authorized under the ESPP Plan were available for issuance.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Restricted Stock Units</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, 31,881 restricted stock units had been awarded under the 2021 Plan. A summary of the status of and changes in unvested restricted stock unit activity under the Company&#8217;s equity award plans for the year ended December 31, 2023, was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:65.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average&#160;Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date&#160;Fair&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per&#160;Unit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,881</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,913)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation of restricted stock units is based on the fair value of the Company&#8217;s common stock on the date of grant and recognized over the vesting period. The vesting period generally occurs over <span style="-sec-ix-hidden:Hidden_eUKRKJ4iNkSfQy8r2Vg3Mg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to four years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31,&#160;2023, the Company had unrecognized stock-based compensation expense related to its unvested restricted stock units of $0.9 million, which is expected to be recognized over the remaining weighted-average vesting period of&#160;2.4&#160;years. </p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(d)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Stock-Based Compensation Expense</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company estimated the fair value of stock options using the Black-Scholes valuation model. The Company accounts for any forfeitures of options when they occur. Previously recognized compensation expense for an award is reversed in the period that the award is forfeited. The fair value of stock options was estimated using the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:26.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.3 - 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.5 - 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">73.9 - 91.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">73.5 - 76.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.5 - 4.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.6 - 4.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Expected dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense recognized for stock option grants has been reported in the statements of operations and comprehensive loss as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,621</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,129</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,285</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense by type of award included within the consolidated statements of operations and comprehensive (loss) income was as follows: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:11.7pt;"><td style="vertical-align:bottom;width:61.03%;margin:0pt;padding:0pt;"><div style="height:11.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:11.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></div></div></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:11.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:11.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.5pt;"><td style="vertical-align:bottom;width:61.03%;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:61.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,494</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Employee stock purchase plan awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 211</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock awards and units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 201</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 33.1pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076944111392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">(8)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">RELATED PARTY TRANSACTIONS</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Services Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2018, the Company entered into a services agreement (&#8220;Services Agreement&#8221;) with Carnot, LLC (&#8220;Carnot&#8221;), an entity owned and controlled by RA Capital Management,&#160;L.P. under which Carnot provides research and other services to the Company. RA Capital Management,&#160;L.P. is a related party due to its equity ownership of the Company. The Company pays Carnot for services performed and costs incurred. The Services Agreement is for a term of two years. The Company may terminate the Services Agreement by giving 30&#160;days&#8217; prior notice and either party can terminate the services agreement for a material breach, if not cured within 30&#160;days following notice by the nonbreaching party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July&#160;2019, the Services Agreement with Carnot was amended whereby research and other services are now performed by Carnot Pharma, LLC (&#8220;Carnot Pharma&#8221;), an entity owned and controlled by RA Capital Management,&#160;L.P., and the term was updated to the later of (i)&#160;two&#160;years from July&#160;15, 2019 and (ii)&#160;completion of services under the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Expenses incurred by the Company under the Services Agreement with Carnot Pharma totaled $0 and less than $0.1 million for the&#160;years ended December&#160;31, 2023 and December&#160;31, 2022, respectively, and are presented in the statement of operations and comprehensive loss as research and development and general and administrative expenses. No amount was due to Carnot Pharma, LLC as of December 31, 2023 and December 31, 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076950570256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">(9)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">INCOME TAXES</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant components of the Company&#8217;s net deferred tax assets are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred income tax assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">NOL carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,199</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,781</p></td></tr><tr><td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,153</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,601</p></td></tr><tr><td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized R&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 19,404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,490</p></td></tr><tr><td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 923</p></td></tr><tr><td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,117</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 790</p></td></tr><tr><td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 43,802</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 23,585</p></td></tr><tr><td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (43,596)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23,283)</p></td></tr><tr><td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 206</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 302</p></td></tr><tr><td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred income tax liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (206)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (302)</p></td></tr><tr><td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (206)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (302)</p></td></tr><tr><td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net deferred tax assets (liabilities)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_LfTcQM9iZEGlLfhH4tvpYg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years&#160;ended&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Federal statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,831)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,829)</p></td></tr><tr><td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,389)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,828)</p></td></tr><tr><td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent and other differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 563</p></td></tr><tr><td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,049</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (787)</p></td></tr><tr><td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,676)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (757)</p></td></tr><tr><td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,487</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,663</p></td></tr><tr><td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company had federal NOL carryforwards available of $64.8 million and $46.9 million as of December&#160;31, 2023 and December&#160;31, 2022, respectively, before consideration of limitations under Section&#160;382 of the Internal Revenue Code or Section&#160;382, as further described below. The NOL generated from 2018 onwards of $64.8 million will carryforward indefinitely and be available to offset up to 80% of future taxable income each&#160;year. Additionally, the Company had state NOL carryforwards available of $44.1 million and $30.5 million as of December&#160;31, 2023 and December&#160;31, 2022, respectively. The state NOLs may be used to offset future taxable income and will begin to expire in 2038. At December 31, 2023 the Company had federal and state research and development credit carryforwards available of $6.0 million and $1.3 million, respectively. The federal credit carryforwards will begin to expire in 2038, unless previously utilized. The Massachusetts credit carryforwards will begin expiring in 2036, unless previously utilized. The California credits carry forward indefinitely. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has established a full valuation allowance for its deferred tax assets due to uncertainties that preclude it from determining that it is more likely than not that the Company will be able to generate sufficient taxable income to realize such assets. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred since inception. Such objective evidence limits the ability to consider other subjective evidence such as the Company&#8217;s projections for future growth. Based on this evaluation, as of December&#160;31, 2023 and December&#160;31, 2022, a valuation allowance of $43.6 million and $23.3 million, respectively, has been recorded against all of the Company&#8217;s net deferred tax assets, as the Company has determined that none of the Company&#8217;s balance of net deferred tax assets is more likely than not to be realized. The amount of the deferred tax assets considered realizable, however, could be adjusted in the future if objective negative evidence in the form of cumulative losses is no longer present and additional weight may be given to subjective evidence, such as estimates of future taxable income during carryforward periods and the Company&#8217;s projections for growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The future utilization of the Company&#8217;s NOL and tax credit carryforwards to offset future taxable income may be subject to a substantial annual limitation as a result of changes in ownership by stockholders that hold 5% or more of the Company&#8217;s common stock. An assessment of such ownership changes under Section&#160;382 and 383 was not completed through December&#160;31, 2023. Utilization of our net operating loss and income tax credit carryforwards may be subject to a substantial annual limitation due to ownership changes that may have occurred or that could occur in the future. These ownership changes may limit the amount of the net operating loss and income tax credit carryover that can be utilized annually to offset future taxable income. The Company will examine the impact of any potential ownership changes in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the activity related to the Company&#8217;s gross unrecognized tax benefits at the beginning and end of the&#160;years ended December&#160;31, 2023 and December&#160;31, 2022 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years&#160;ended&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance of unrecognized tax benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 529</p></td></tr><tr><td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additions based on tax positions related to the current year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,127</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 461</p></td></tr><tr><td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additions based on tax positions related to the prior year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td></tr><tr><td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance of unrecognized tax benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,214</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 993</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unrecognized tax benefit amounts are reflected in the determination of the Company&#8217;s deferred tax assets. If recognized, none of these amounts would affect the Company&#8217;s effective tax rate, since it would be offset by an equal corresponding adjustment in the deferred tax asset valuation allowance. The Company does not foresee material changes to its liability for uncertain tax benefits within the next twelve&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to taxation in the United States and various states. The Company&#8217;s Federal and state returns are subject to examination, due to the carryforward of unutilized net operating losses and research and development credits.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076947032080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements as of September&#160;30,&#160;2024 and for the three and nine months ended September&#160;30,&#160;2024 and 2023 have been prepared in conformity with generally accepted accounting principles (&#8220;GAAP&#8221;) in the United States of America for interim financial information and pursuant to Article&#160;10 of Regulation S-X of the Securities Act of 1933, as amended (the Securities Act). Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include only normal and recurring adjustments that the Company believes are necessary to fairly state the Company&#8217;s financial position and the results of its operations and cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The results for the three and nine months ended September&#160;30,&#160;2024 are not necessarily indicative of the results expected for the full fiscal&#160;year or any subsequent interim period. The condensed consolidated balance sheet as of December&#160;31,&#160;2023 has been derived from the audited financial statements at that date but does not include all disclosures required by GAAP for complete financial statements. Because all of the disclosures required by GAAP for complete financial statements are not included herein, these unaudited condensed consolidated financial statements and the notes accompanying them should be read in conjunction with the Company&#8217;s audited financial statements for the&#160;year ended December&#160;31,&#160;2023. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Basis of Presentation</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include the Company&#8217;s wholly owned subsidiary, Aerovate Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the Company&#8217;s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. Accounting estimates and management judgements reflected in the consolidated financial statements include: normal recurring accruals, including the accrual for research and development expenses, stock-based compensation, fair value of investments, and operating lease right-of-use assets and lease liabilities. Estimates and assumptions are reviewed quarterly. Any revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</p><span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Use of Estimates</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The preparation of the Company&#8217;s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. Accounting estimates and management judgements reflected in the consolidated financial statements include: normal recurring accruals, including the accrual for research and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">development expenses, stock-based compensation, fair value of investments, and operating lease right-of-use assets and lease liabilities. Estimates and assumptions are reviewed quarterly. Any revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Cash and Cash Equivalents</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents include cash in readily available checking accounts, money market funds and commercial paper. The Company considers all highly liquid investments with an original maturity of three&#160;months or less from the date of purchase to be cash equivalents.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_ShortTermInvestmentPolicyTextBlock', window );">Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(d)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Short-term Investments</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Short-term investments consist of corporate debt securities, commercial paper and U.S. Treasury bills, classified as available-for-sale securities and have maturities of greater than three&#160;months. The Company has classified all of its available-for-sale investment securities as current assets on the consolidated balance sheets because these are considered highly liquid securities and are available for use in current operations. The Company carries these securities at fair value and reports unrealized gains and losses as a separate component of accumulated other comprehensive loss. The cost of debt securities is adjusted for amortization of purchase premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income in the consolidated statements of operations and comprehensive loss. Realized gains and losses on sales of securities are determined using the specific identification method and recorded in other income (expense), net in the consolidated statement of operations and comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(e)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Concentration of Credit Risk</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains cash, cash equivalents and short-term investments with various high credit quality banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has not experienced any losses on deposits since inception.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(f)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Comprehensive Loss</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Comprehensive loss consists of net loss and unrealized gains or losses on available-for-sale investments. The Company displays comprehensive loss and its components as part of the consolidated statements of operations and comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(g)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Fair Value Measurements</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">Level 1: Observable inputs such as quoted prices in active markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying amounts of prepaid expenses and other current assets, accounts payable, accrued liabilities and other current liabilities are reasonable estimates of their fair value due to the short-term nature of these accounts.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(h)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Prepaid Expenses and Other Current Assets</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any expenses paid prior to the related services rendered are recorded as prepaid expenses. Such prepaid expenses are expensed in the period the expense is incurred. If the expense is for a service covering multiple periods, it is expensed from the date the services begin and over the period of the service rendered (or contract service period if services rendered dates are not defined).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(i)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Property and Equipment, Net</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property and equipment, which consist of leasehold improvements, furniture and fixtures, research equipment, computers and construction-in-progress are stated at cost less accumulated depreciation or accumulated amortization. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets, which ranges from <span style="-sec-ix-hidden:Hidden_n34-iiJT30mFenREfVs5IQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to <span style="-sec-ix-hidden:Hidden_g3-e0FT-IE2Xj7oAU60QZg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five&#160;years</span></span>. Leasehold improvements are amortized over the remaining life of the lease for leasehold improvements at the time the asset is placed into service.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(j)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Impairment of Long-lived Assets</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying value of long-lived assets, including property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. Through December&#160;31, 2023, there has been no such impairment losses recorded by the Company.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(k)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Leases</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the commencement date of a lease, the Company recognizes lease liabilities which represent its obligation to make lease payments, and right-of-use assets (&#8220;ROU assets&#8221;) which represent its right to use the underlying asset during the lease term. The lease liability is measured at the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the lease commencement date. The ROU asset is measured at cost, which includes the initial measurement of the lease liability and initial direct costs incurred by the Company and excludes lease incentives. ROU assets are recorded in operating lease ROU assets and lease liabilities are recorded in operating lease liabilities, current and noncurrent in the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected not to separate lease and non-lease components and not recognize lease liabilities and ROU assets for short-term leases with terms of twelve&#160;months or less.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_ConvertiblePreferredStockPolicyTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(l)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Convertible Preferred Stock</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company records convertible preferred stock at fair value on the dates of issuance, net of issuance costs. Upon the occurrence of certain events that are outside the Company&#8217;s control, including a deemed liquidation event, holders of the convertible preferred stock can cause redemption for cash. Therefore, convertible preferred stock is classified outside of stockholders&#8217; deficit on the balance sheets as events triggering the liquidation preferences are not solely within the Company&#8217;s control. The carrying values of the convertible preferred stock are adjusted to their liquidation preferences if and when it becomes probable that such a liquidation event will occur.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(m)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Research and Development Expenses</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and other benefits of research and development personnel, including associated share-based compensation, costs related to research activities, preclinical studies, clinical trial, drug manufacturing and allocated overhead and facility-related expenses. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, as they are incurred, based </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(n)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Stock-Based Compensation</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Stock-based compensation expense represents the cost of the grant-date fair value of employee, officer, director, and non-employee stock option grants and restricted stock units, estimated in accordance with the applicable accounting guidance, recognized using the straight-line method over the vesting period for service-based options and using the graded vesting method for performance-based options. The vesting period generally approximates the expected service period of the awards. Forfeitures are recognized and accounted for as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The fair value of stock options is estimated using a Black-Scholes option pricing model on the date of grant. This method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#8217;s common stock, expected dividend yield, and a risk-free interest rate. Options and awards granted during the&#160;year have a maximum contractual term of ten&#160;years. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the average of the contractual term of the stock option and its weighted-average vesting period. The expected volatility of stock options is based upon the historical volatility of a number of publicly traded companies in similar stages of clinical development. The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future. The risk-free interest rates used are based on the U.S. Department of Treasury (&#8220;U.S. Treasury&#8221;) yield in effect at the time of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term of the stock options.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(o)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Income Taxes</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Income taxes are accounted for using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss ("NOL") and tax credit carryforwards. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="white-space:pre-wrap;">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.  The company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.  The company recognizes interest and penalties related to unrecognized tax benefits within income tax expense.  Any accrued interest and penalties are included within the related tax liability.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(p)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Segment Reporting</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one operating segment.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Net Loss Per Share</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company&#8217;s potentially dilutive securities have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes the Company&#8217;s net loss per share (in thousands, except share and per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,237)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,563)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (64,198)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (55,108)</p></td></tr><tr><td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,237)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,563)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (64,198)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (55,108)</p></td></tr><tr><td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Weighted-average common stock outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,863,327</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,640,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,572,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,872,118</p></td></tr><tr><td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.56)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.71)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.25)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.13)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:61.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,714,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,236,832</p></td></tr><tr><td style="vertical-align:top;width:61.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,754</p></td></tr><tr><td style="vertical-align:bottom;width:61.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,714,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,262,586</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(q)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Net Loss Per Share</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company&#8217;s potentially dilutive securities, which include convertible preferred stock prior to the conversion of such shares to common stock and outstanding stock options under the Company&#8217;s equity incentive plan, have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The following table summarizes the Company&#8217;s net loss per share:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75,521)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,511)</p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75,521)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,511)</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Weighted-average common stock outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,331,630</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,472,104</p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.87)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.10)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:61.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,230,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,110,219</p></td></tr><tr><td style="vertical-align:top;width:61.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,881</p></td></tr><tr><td style="vertical-align:bottom;width:61.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,252,312</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,139,100</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(d)</span></span><span style="font-style:italic;font-weight:bold;">Recently Issued and Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In November 2023, the FASB issued ASU 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280)</i>: Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments&#8217; significant expenses on an interim and annual basis. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Entities must adopt the changes to the segment reporting guidance on a retrospective basis, and early adoption is permitted. The Company does not anticipate this ASU to materially impact our consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In December 2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740)</i>: Improvements to Income Tax Disclosures, which expands disclosures in an entity&#8217;s income tax rate reconciliation table and regarding cash taxes paid both in the U.S. and foreign jurisdictions. The standard is effective for fiscal years beginning after December 15, 2024, and interim periods in fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact the adoption of this standard may have on its consolidated financial statements and related disclosures, and does not anticipate this ASU to materially impact our consolidated financial statements and related disclosures.</p><span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(r)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Recently Issued Accounting Pronouncements</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In December 2023, the FASB issued ASU No. 2023-09, "Improvements to Income Tax Disclosures." ASU 2023-09 requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024 and for private businesses for annual periods beginning after December 15, 2025, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its financial statement disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In June 2022, the FASB issued ASU No. 2022-03, Fair Value Measurement (Topic 820) - Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard will be effective for the Company on January 1, 2024, and is not expected to have an impact on the Company&#8217;s financial position or results of operations upon adoption.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_ConvertiblePreferredStockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_ConvertiblePreferredStockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other current assets [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_ShortTermInvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term investment [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_ShortTermInvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076944973904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">SCHEDULE OF NET LOSS PER SHARE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes the Company&#8217;s net loss per share (in thousands, except share and per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,237)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,563)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (64,198)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (55,108)</p></td></tr><tr><td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,237)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,563)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (64,198)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (55,108)</p></td></tr><tr><td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Weighted-average common stock outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,863,327</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,640,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,572,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,872,118</p></td></tr><tr><td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.56)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.71)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.25)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.13)</p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The following table summarizes the Company&#8217;s net loss per share:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75,521)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,511)</p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75,521)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,511)</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Weighted-average common stock outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,331,630</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,472,104</p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.87)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.10)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:61.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,714,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,236,832</p></td></tr><tr><td style="vertical-align:top;width:61.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,754</p></td></tr><tr><td style="vertical-align:bottom;width:61.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,714,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,262,586</p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:61.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,230,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,110,219</p></td></tr><tr><td style="vertical-align:top;width:61.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,881</p></td></tr><tr><td style="vertical-align:bottom;width:61.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,252,312</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,139,100</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076995472208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">SCHEDULE OF FAIR VALUE INSTRUMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following tables summarize the Company&#8217;s financial assets measured at fair value on a recurring basis and their respective input levels based on the fair value hierarchy (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for&#160;Identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level&#160;3)</b></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,926</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,926</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,537</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total fair value of assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,880</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,343</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,537</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for&#160;Identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level&#160;3)</b></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_NvvtqfTNDUi3pAQbMuV3Iw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_W5lZ48FLCEy_u2gCz_QeZg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_EIT7Ft-M4U2oTXvtr5qvPQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_XpL8HTw1KUeUXBHbhjlt2w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_lN0AgyYwBUGSBPvHUXVvCA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_ATiC6JEvSUm2xAjs-Qle-w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,386</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_FAR9X24s2UOjJM_mFfQemw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,386</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden__tPLOVORX06K05WNcJNPHQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_hGln6qJd7kWjTm5e4HDgWA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_sBbWTO6GDUu9JQZjdyFFlw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,945</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_Ib6YuqwgvUOu1jkJDvoCZQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,945</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_HN51f_bDUkShpzdYGLsCOw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98,948</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_sNomPq10ZESk15LyPnEosQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total fair value of assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 118,735</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,149</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_YNU4YHIeWEuPQ_VjMX_kCQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The following tables summarize the Company&#8217;s financial assets measured at fair value on a recurring basis and their respective input levels based on the fair value hierarchy (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:normal;width:41.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for&#160;Identical</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level&#160;3)</b></p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,255</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,255</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Commercial Paper</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,386</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,386</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,945</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,945</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98,948</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,586</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total fair value of assets</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 118,735</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,149</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,586</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:41.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">for&#160;Identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(level&#160;3)</b></p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55,577</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55,577</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Agency Bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 106,823</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 79,982</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total fair value of assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 125,259</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 79,982</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">SCHEDULE OF SHORT TERM INVESTMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following tables summarize the Company&#8217;s short-term investments (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Maturity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 139</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,866</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,926</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,058</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Maturity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,386</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,945</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 98,711</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (23)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 98,948</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following tables summarize the Company&#8217;s short-term investments (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maturity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,386</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,945</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98,711</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98,948</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maturity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,645</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (84)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,577</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (267)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,536</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (133)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 107,289</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (484)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 106,823</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following tables summarize the Company&#8217;s short-term investments with unrealized losses for less than 12 months and 12 months or greater (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:35.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="16" style="vertical-align:bottom;white-space:nowrap;width:62.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">12 months or Greater</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Unrealized</b></p></td></tr><tr style="height:10.35pt;"><td style="vertical-align:bottom;width:35.88%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></div></div></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:35.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:35.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,760</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:35.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 488</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,007</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:35.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,986</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (23)</p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:65.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.56%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.58%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">12 months or Greater</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.03%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Unrealized</b></p></td></tr><tr><td style="vertical-align:bottom;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,760</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 488</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,007</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,986</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:32.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:67.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.01%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.32%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">12 months or Greater</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Unrealized</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:32.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,928</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (84)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,928</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (84)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,971</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,833</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (261)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (267)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:32.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,964</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (133)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,964</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (133)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (223)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,833</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (261)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (484)</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076944548240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>BALANCE SHEET COMPONENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock', window );">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Prepaid expenses and other current assets consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,875</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Prepaid expenses and other current assets consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:62.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,503</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Prepaid research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 478</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Total prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Accrued and other current liabilities consisted of the following (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,704</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,363</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued payroll and other employee benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 292</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total accrued and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,948</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,821</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Accrued and other current liabilities consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued research and development</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,363</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,751</p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued payroll and other employee benefits</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,368</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,691</p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,090</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 380</p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total accrued and other current liabilities</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,821</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,822</p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076949979248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of September&#160;30,&#160;2024, the future minimum annual lease payments under the operating leases were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:74.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:25.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 12.25pt;"><b style="font-weight:bold;">Total Minimum</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:25.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 12.25pt;"><b style="font-weight:bold;">Lease Payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 242</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total operating lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 558</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less: Amount representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (18)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Present value of net minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the future minimum annual lease payments under the operating leases were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:24.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 12.25pt;"><b style="font-weight:bold;">Total Minimum</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:24.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 12.25pt;"><b style="font-weight:bold;">Lease Payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 466</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 242</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total operating lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 708</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Amount representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Present value of net minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_ScheduleOfComponentsOfOperatingLeasesTableTextBlock', window );">SCHEDULE OF COMPONENTS OF OPERATING LEASES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Company&#8217;s leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the lease commencement date. The components of operating leases as of September&#160;30,&#160;2024 and as of December&#160;31,&#160;2023 were as follows (in thousands except lease term and discount rate):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 459</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average incremental borrowing rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The components of operating leases for the years ended December 31, 2023 and December 31, 2022 were as follows (in thousands except lease term and discount rate):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Operating lease liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 705</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average incremental borrowing rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_ScheduleOfComponentsOfOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_ScheduleOfComponentsOfOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076943275856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock', window );">SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of September&#160;30,&#160;2024, the Company had reserved the following shares of common stock for future issuance:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:72.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common stock options granted and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,714,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:72.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares reserved for issuance under the 2021 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,982,105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:72.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reserved for future ESPP issuances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 401,218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,097,427</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the Company had reserved the following shares of common stock for future issuance:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options granted and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,230,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Shares reserved for issuance under the 2021 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 604,363</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Reserved for vesting of outstanding restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Reserved for future ESPP issuances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 435,252</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,291,927</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of common stock shares reserved on and as converted basis for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076950563776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF OPTION ACTIVITY UNDER 2021 PLAN AND 2018 PLAN</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual&#160;Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,230,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,489,191</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (265,482)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cancelled/Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,739,949)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,714,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and exercisable at September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,791,181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the option activity under the 2021 Plan and 2018 Plan for the&#160;year ended December&#160;31, 2023:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual&#160;Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and expected to vest at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,110,219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 82,490</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,546,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (338,987)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cancelled/Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (86,889)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,230,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 49,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and exercisable at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,157,378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11.24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 25,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and expected to vest at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,230,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 49,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">SCHEDULE OF UNVESTED RESTRICTED STOCK UNIT ACTIVITY</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:59.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average&#160;Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date&#160;Fair&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per&#160;Unit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,492)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,476)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units as of September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:65.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average&#160;Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date&#160;Fair&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per&#160;Unit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,881</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,913)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">SCHEDULE OF FAIR VALUE OF STOCK OPTIONS ASSUMPTIONS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:26.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.3 - 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.5 - 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">73.9 - 91.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">73.5 - 76.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.5 - 4.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.6 - 4.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Expected dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations and comprehensive loss as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 458</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,817</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,987</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,798</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,545</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,237</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,068</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,655</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Stock-based compensation expense by type of award included within the consolidated statements of operations and comprehensive income (loss) was as follows: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,140</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,890</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,369</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock awards and units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 151</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee stock purchase plan awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,237</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,068</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,655</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense recognized for stock option grants has been reported in the statements of operations and comprehensive loss as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,621</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,129</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,285</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense by type of award included within the consolidated statements of operations and comprehensive (loss) income was as follows: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:11.7pt;"><td style="vertical-align:bottom;width:61.03%;margin:0pt;padding:0pt;"><div style="height:11.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:11.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></div></div></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:11.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:11.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.5pt;"><td style="vertical-align:bottom;width:61.03%;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:61.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,494</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Employee stock purchase plan awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 211</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock awards and units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 201</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 33.1pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076950504480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">SUMMARY OF COMPONENTS OF NET DEFERRED TAX ASSETS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant components of the Company&#8217;s net deferred tax assets are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred income tax assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">NOL carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,199</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,781</p></td></tr><tr><td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,153</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,601</p></td></tr><tr><td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized R&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 19,404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,490</p></td></tr><tr><td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 923</p></td></tr><tr><td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,117</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 790</p></td></tr><tr><td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 43,802</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 23,585</p></td></tr><tr><td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (43,596)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23,283)</p></td></tr><tr><td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 206</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 302</p></td></tr><tr><td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred income tax liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (206)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (302)</p></td></tr><tr><td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (206)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (302)</p></td></tr><tr><td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net deferred tax assets (liabilities)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_LfTcQM9iZEGlLfhH4tvpYg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">SUMMARY OF RECONCILIATION OF FEDERAL INCOME TAX RATE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years&#160;ended&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Federal statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,831)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,829)</p></td></tr><tr><td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,389)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,828)</p></td></tr><tr><td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent and other differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 563</p></td></tr><tr><td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,049</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (787)</p></td></tr><tr><td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,676)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (757)</p></td></tr><tr><td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,487</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,663</p></td></tr><tr><td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">SUMMARY OF GROSS UNRECOGNIZED TAX BENEFITS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the activity related to the Company&#8217;s gross unrecognized tax benefits at the beginning and end of the&#160;years ended December&#160;31, 2023 and December&#160;31, 2022 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years&#160;ended&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance of unrecognized tax benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 529</p></td></tr><tr><td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additions based on tax positions related to the current year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,127</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 461</p></td></tr><tr><td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additions based on tax positions related to the prior year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td></tr><tr><td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance of unrecognized tax benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,214</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 993</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076946689232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 05, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,635<span></span>
</td>
<td class="nump">$ 44,888<span></span>
</td>
<td class="nump">$ 44,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=avte_BofaSecuritiesInc.Member', window );">BofA Securities, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate amount of shares</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,462,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,662,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram', window );">Value of remaining common stock available for sale Under ATM Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the value of the common stock remaining which can be sold from time to time under the ATM ("At-the-Market") Program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=avte_BofaSecuritiesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=avte_BofaSecuritiesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076950559296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment losses | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Leasehold improvements are amortized over the remaining life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Leasehold improvements are amortized over the remaining life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076941317824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF NET LOSS PER SHARE (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (16,237)<span></span>
</td>
<td class="num">$ (24,775)<span></span>
</td>
<td class="num">$ (23,186)<span></span>
</td>
<td class="num">$ (19,563)<span></span>
</td>
<td class="num">$ (19,025)<span></span>
</td>
<td class="num">$ (16,520)<span></span>
</td>
<td class="num">$ (64,198)<span></span>
</td>
<td class="num">$ (55,108)<span></span>
</td>
<td class="num">$ (75,521)<span></span>
</td>
<td class="num">$ (51,511)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common stockholders</a></td>
<td class="num">$ (16,237)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (19,563)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (64,198)<span></span>
</td>
<td class="num">$ (55,108)<span></span>
</td>
<td class="num">$ (75,521)<span></span>
</td>
<td class="num">$ (51,511)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common stock outstanding, basic</a></td>
<td class="nump">28,863,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,640,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,572,338<span></span>
</td>
<td class="nump">25,872,118<span></span>
</td>
<td class="nump">26,331,630<span></span>
</td>
<td class="nump">24,472,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common stock outstanding, diluted</a></td>
<td class="nump">28,863,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,640,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,572,338<span></span>
</td>
<td class="nump">25,872,118<span></span>
</td>
<td class="nump">26,331,630<span></span>
</td>
<td class="nump">24,472,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.25)<span></span>
</td>
<td class="num">$ (2.13)<span></span>
</td>
<td class="num">$ (2.87)<span></span>
</td>
<td class="num">$ (2.10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.25)<span></span>
</td>
<td class="num">$ (2.13)<span></span>
</td>
<td class="num">$ (2.87)<span></span>
</td>
<td class="num">$ (2.10)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076944311776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">3,714,104<span></span>
</td>
<td class="nump">5,262,586<span></span>
</td>
<td class="nump">5,252,312<span></span>
</td>
<td class="nump">4,139,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">3,714,104<span></span>
</td>
<td class="nump">5,236,832<span></span>
</td>
<td class="nump">5,230,344<span></span>
</td>
<td class="nump">4,110,219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,754<span></span>
</td>
<td class="nump">21,968<span></span>
</td>
<td class="nump">28,881<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076944620240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF FAIR VALUE INSTRUMENTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">$ 57,615<span></span>
</td>
<td class="nump">$ 98,948<span></span>
</td>
<td class="nump">$ 106,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="nump">28,265<span></span>
</td>
<td class="nump">19,787<span></span>
</td>
<td class="nump">18,436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">57,615<span></span>
</td>
<td class="nump">98,948<span></span>
</td>
<td class="nump">106,823<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="nump">85,880<span></span>
</td>
<td class="nump">118,735<span></span>
</td>
<td class="nump">125,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="nump">28,265<span></span>
</td>
<td class="nump">19,787<span></span>
</td>
<td class="nump">18,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">9,078<span></span>
</td>
<td class="nump">10,362<span></span>
</td>
<td class="nump">26,841<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="nump">37,343<span></span>
</td>
<td class="nump">30,149<span></span>
</td>
<td class="nump">45,277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">48,537<span></span>
</td>
<td class="nump">88,586<span></span>
</td>
<td class="nump">79,982<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="nump">48,537<span></span>
</td>
<td class="nump">88,586<span></span>
</td>
<td class="nump">79,982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="nump">28,265<span></span>
</td>
<td class="nump">19,787<span></span>
</td>
<td class="nump">18,436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="nump">28,265<span></span>
</td>
<td class="nump">19,787<span></span>
</td>
<td class="nump">18,436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">9,443<span></span>
</td>
<td class="nump">38,386<span></span>
</td>
<td class="nump">55,577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">9,443<span></span>
</td>
<td class="nump">38,386<span></span>
</td>
<td class="nump">55,577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury bills | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">9,078<span></span>
</td>
<td class="nump">10,362<span></span>
</td>
<td class="nump">26,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury bills | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">9,078<span></span>
</td>
<td class="nump">10,362<span></span>
</td>
<td class="nump">26,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury bills | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">11,926<span></span>
</td>
<td class="nump">7,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">11,926<span></span>
</td>
<td class="nump">7,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies Debt Securities [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">27,168<span></span>
</td>
<td class="nump">42,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies Debt Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies Debt Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">$ 27,168<span></span>
</td>
<td class="nump">42,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies Debt Securities [Member] | Commercial paper | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,255<span></span>
</td>
<td class="nump">24,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies Debt Securities [Member] | Commercial paper | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,255<span></span>
</td>
<td class="nump">$ 24,405<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076943352992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT TERM INVESTMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Amortized cost</a></td>
<td class="nump">$ 57,391<span></span>
</td>
<td class="nump">$ 98,711<span></span>
</td>
<td class="nump">$ 107,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="num">(484)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">57,615<span></span>
</td>
<td class="nump">98,948<span></span>
</td>
<td class="nump">106,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent', window );">Accrued interest receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList', window );">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other long-term assets<span></span>
</td>
<td class="text">Other long-term assets<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Amortized cost</a></td>
<td class="nump">11,866<span></span>
</td>
<td class="nump">$ 7,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">11,926<span></span>
</td>
<td class="nump">7,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Amortized cost</a></td>
<td class="nump">9,438<span></span>
</td>
<td class="nump">38,362<span></span>
</td>
<td class="nump">$ 55,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">9,443<span></span>
</td>
<td class="nump">38,386<span></span>
</td>
<td class="nump">55,577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Amortized cost</a></td>
<td class="nump">9,058<span></span>
</td>
<td class="nump">10,334<span></span>
</td>
<td class="nump">27,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(267)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">9,078<span></span>
</td>
<td class="nump">10,362<span></span>
</td>
<td class="nump">26,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Amortized cost</a></td>
<td class="nump">27,029<span></span>
</td>
<td class="nump">42,090<span></span>
</td>
<td class="nump">24,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(133)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">$ 27,168<span></span>
</td>
<td class="nump">$ 42,255<span></span>
</td>
<td class="nump">$ 24,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_DebtSecuritiesAvailableForSaleMaturityTerm', window );">Maturity term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_DebtSecuritiesAvailableForSaleMaturityTerm', window );">Maturity term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | U.S. Treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_DebtSecuritiesAvailableForSaleMaturityTerm', window );">Maturity term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | US Government Agencies Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_DebtSecuritiesAvailableForSaleMaturityTerm', window );">Maturity term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_DebtSecuritiesAvailableForSaleMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity term for debt securities classified as available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_DebtSecuritiesAvailableForSaleMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes accrued interest, after allowance for credit loss, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076947169056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Short-term investments, Less than 12 months, Fair Value</a></td>
<td class="nump">$ 13,400<span></span>
</td>
<td class="nump">$ 59,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Short-term investments, Less than 12 months, Unrealized Losses</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(223)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Short-term investments, 12 months or Greater, Fair Value</a></td>
<td class="nump">7,586<span></span>
</td>
<td class="nump">24,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Short-term investments, 12 months or Greater, Unrealized Losses</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(261)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Short-term investments, Total Fair Value</a></td>
<td class="nump">20,986<span></span>
</td>
<td class="nump">84,696<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Short-term investments, Total Unrealized Losses</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(484)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Short-term investments, Less than 12 months, Fair Value</a></td>
<td class="nump">6,042<span></span>
</td>
<td class="nump">34,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Short-term investments, Less than 12 months, Unrealized Losses</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Short-term investments, Total Fair Value</a></td>
<td class="nump">6,042<span></span>
</td>
<td class="nump">34,928<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Short-term investments, Total Unrealized Losses</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Short-term investments, Less than 12 months, Fair Value</a></td>
<td class="nump">3,760<span></span>
</td>
<td class="nump">22,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Short-term investments, Less than 12 months, Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(133)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Short-term investments, 12 months or Greater, Fair Value</a></td>
<td class="nump">6,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Short-term investments, 12 months or Greater, Unrealized Losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Short-term investments, Total Fair Value</a></td>
<td class="nump">10,339<span></span>
</td>
<td class="nump">22,964<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Short-term investments, Total Unrealized Losses</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(133)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Short-term investments, Less than 12 months, Fair Value</a></td>
<td class="nump">488<span></span>
</td>
<td class="nump">1,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Short-term investments, Less than 12 months, Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Short-term investments, 12 months or Greater, Fair Value</a></td>
<td class="nump">1,007<span></span>
</td>
<td class="nump">24,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Short-term investments, 12 months or Greater, Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(261)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Short-term investments, Total Fair Value</a></td>
<td class="nump">1,495<span></span>
</td>
<td class="nump">26,804<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Short-term investments, Total Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">$ (267)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Short-term investments, Less than 12 months, Fair Value</a></td>
<td class="nump">3,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Short-term investments, Less than 12 months, Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Short-term investments, Total Fair Value</a></td>
<td class="nump">3,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Short-term investments, Total Unrealized Losses</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076950030832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>BALANCE SHEET COMPONENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 993<span></span>
</td>
<td class="nump">$ 1,168<span></span>
</td>
<td class="nump">$ 1,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_PrepaidResearchAndDevelopment', window );">Prepaid research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="nump">478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other current assets</a></td>
<td class="nump">882<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 1,875<span></span>
</td>
<td class="nump">$ 1,793<span></span>
</td>
<td class="nump">$ 2,276<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_PrepaidResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_PrepaidResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076949960480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES - (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>BALANCE SHEET COMPONENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_AccruedResearchAndDevelopmentCurrent', window );">Accrued research and development</a></td>
<td class="nump">$ 4,704<span></span>
</td>
<td class="nump">$ 9,363<span></span>
</td>
<td class="nump">$ 2,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and other employee benefits</a></td>
<td class="nump">3,952<span></span>
</td>
<td class="nump">4,368<span></span>
</td>
<td class="nump">1,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">292<span></span>
</td>
<td class="nump">1,090<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Total accrued and other current liabilities</a></td>
<td class="nump">$ 8,948<span></span>
</td>
<td class="nump">$ 14,821<span></span>
</td>
<td class="nump">$ 4,822<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076948194944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675,000<span></span>
</td>
<td class="nump">$ 1,090,000<span></span>
</td>
<td class="nump">$ 540,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">614,000<span></span>
</td>
<td class="nump">1,003,000<span></span>
</td>
<td class="nump">$ 259,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Total operating lease expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=avte_WalthamLeaseMember', window );">Waltham Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">39 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_IncreaseRentalAmount', window );">Increase Rental Amount | $ / shares</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lease, option to extend</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payment for rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_LeaseIncreaseInRentPercentage', window );">Lease rent percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=avte_FosterCityLeaseMember', window );">Foster City Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">39 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payment for rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_LeaseIncreaseInRentPercentage', window );">Lease rent percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_IncreaseRentalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in rent square foot value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_IncreaseRentalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_LeaseIncreaseInRentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease increase in rent percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_LeaseIncreaseInRentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=avte_WalthamLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=avte_WalthamLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=avte_FosterCityLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=avte_FosterCityLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076950638224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 242<span></span>
</td>
<td class="nump">$ 466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">558<span></span>
</td>
<td class="nump">708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Amount representing interest</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of net minimum lease payments</a></td>
<td class="nump">540<span></span>
</td>
<td class="nump">675<span></span>
</td>
<td class="nump">$ 1,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current</a></td>
<td class="nump">459<span></span>
</td>
<td class="nump">420<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current</a></td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">$ 255<span></span>
</td>
<td class="nump">$ 705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average incremental borrowing rate</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076944922384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 03, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_CapitalStockSharesAuthorized', window );">Capital stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,052,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,052,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock shares issued</a></td>
<td class="nump">14,182,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_NumberOfVotesForEachShareOfCommonStock', window );">Number of votes for each share of common stock | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">9,984,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=avte_RaCapitalHealthcareFundL.pMember', window );">RA Capital Healthcare Fund, L.P</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=avte_SeriesSeedRedeemableConvertiblePreferredStockMember', window );">Series Seed Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=avte_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,052,154<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_CapitalStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital stock shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_CapitalStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_NumberOfVotesForEachShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to number of votes for each share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_NumberOfVotesForEachShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=avte_RaCapitalHealthcareFundL.pMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=avte_RaCapitalHealthcareFundL.pMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=avte_SeriesSeedRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=avte_SeriesSeedRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=avte_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=avte_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076947068448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE (Details) - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">7,097,427<span></span>
</td>
<td class="nump">6,291,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">3,714,104<span></span>
</td>
<td class="nump">5,230,344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">2,982,105<span></span>
</td>
<td class="nump">604,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,968<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Employee stock purchase plan awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">401,218<span></span>
</td>
<td class="nump">435,252<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076947372320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">30 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,489,191<span></span>
</td>
<td class="nump">1,546,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Stock option grants per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.92<span></span>
</td>
<td class="nump">$ 15.69<span></span>
</td>
<td class="nump">$ 10.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avte_TwentyTwentyOneStockOptionAndIncentivePlanMember', window );">2021 Stock Option and Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage on total number of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,675,841<span></span>
</td>
<td class="nump">4,565,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,565,333<span></span>
</td>
<td class="nump">3,075,841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock available for issuance, awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,075,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | 2021 Stock Option and Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">604,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">604,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock available for issuance, awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,753,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,931,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | 2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock available for issuance, awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">960,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,298,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | 2021 Plan and 2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Minimum | 2021 Plan and 2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vested term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Maximum [Member] | 2021 Plan and 2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vested term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | 2021 Stock Option and Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,881<span></span>
</td>
<td class="nump">31,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vested term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vested term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Share-Based Payment Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage on total number of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000<span></span>
</td>
<td class="nump">401,218<span></span>
</td>
<td class="nump">435,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="nump">247,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of common stock purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">Offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate', window );">Discount percentage on marker price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,011<span></span>
</td>
<td class="nump">41,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Duration of offering period for share-based compensation arrangement by share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on offering date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avte_TwentyTwentyOneStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avte_TwentyTwentyOneStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avte_TwentyEighteenStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avte_TwentyEighteenStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076941416048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - SCHEDULE OF OPTION ACTIVITY UNDER 2021 PLAN AND 2018 PLAN (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, beginning balance</a></td>
<td class="nump">5,230,344<span></span>
</td>
<td class="nump">4,110,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Outstanding, beginning balance</a></td>
<td class="nump">$ 13.66<span></span>
</td>
<td class="nump">$ 9.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">4 years 11 months 23 days<span></span>
</td>
<td class="text">8 years 1 month 28 days<span></span>
</td>
<td class="text">8 years 5 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, beginning balance</a></td>
<td class="nump">$ 49,728<span></span>
</td>
<td class="nump">$ 82,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="nump">1,489,191<span></span>
</td>
<td class="nump">1,546,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Granted</a></td>
<td class="nump">$ 19.70<span></span>
</td>
<td class="nump">$ 22.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Exercised</a></td>
<td class="num">(265,482)<span></span>
</td>
<td class="num">(338,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Exercised</a></td>
<td class="nump">$ 4.67<span></span>
</td>
<td class="nump">$ 2.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options, Cancelled/Forfeited</a></td>
<td class="num">(2,739,949)<span></span>
</td>
<td class="num">(86,889)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Cancelled/Forfeited</a></td>
<td class="nump">$ 18.84<span></span>
</td>
<td class="nump">$ 9.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, ending balance</a></td>
<td class="nump">3,714,104<span></span>
</td>
<td class="nump">5,230,344<span></span>
</td>
<td class="nump">4,110,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Outstanding, ending balance</a></td>
<td class="nump">$ 12.91<span></span>
</td>
<td class="nump">$ 13.66<span></span>
</td>
<td class="nump">$ 9.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, ending balance</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 49,728<span></span>
</td>
<td class="nump">$ 82,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options, Vested and exercisable</a></td>
<td class="nump">2,791,181<span></span>
</td>
<td class="nump">2,157,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Vested and exercisable</a></td>
<td class="nump">$ 12.06<span></span>
</td>
<td class="nump">$ 11.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Vested and exercisable</a></td>
<td class="text">3 years 11 months 12 days<span></span>
</td>
<td class="text">7 years 9 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and exercisable</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 25,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,230,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 1 month 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076998897104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - SCHEDULE OF UNVESTED RESTRICTED STOCK UNIT ACTIVITY (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of units, beginning</a></td>
<td class="nump">21,968<span></span>
</td>
<td class="nump">28,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date fair value, beginning</a></td>
<td class="nump">$ 22.26<span></span>
</td>
<td class="nump">$ 21.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of units, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date fair value, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of units, Vested</a></td>
<td class="num">(5,492)<span></span>
</td>
<td class="num">(9,913)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date fair value, Vested</a></td>
<td class="nump">$ 21.30<span></span>
</td>
<td class="nump">$ 21.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of units, Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date fair value, Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076942847952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - SCHEDULE OF FAIR VALUE OF STOCK OPTIONS ASSUMPTIONS (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">73.90%<span></span>
</td>
<td class="nump">73.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">91.50%<span></span>
</td>
<td class="nump">76.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076946572256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION GRANTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,003<span></span>
</td>
<td class="nump">$ 3,237<span></span>
</td>
<td class="nump">$ 10,068<span></span>
</td>
<td class="nump">$ 8,655<span></span>
</td>
<td class="nump">$ 11,906<span></span>
</td>
<td class="nump">$ 5,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">458<span></span>
</td>
<td class="nump">1,817<span></span>
</td>
<td class="nump">4,987<span></span>
</td>
<td class="nump">4,798<span></span>
</td>
<td class="nump">6,621<span></span>
</td>
<td class="nump">2,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,545<span></span>
</td>
<td class="nump">$ 1,420<span></span>
</td>
<td class="nump">$ 5,081<span></span>
</td>
<td class="nump">$ 3,857<span></span>
</td>
<td class="nump">$ 5,285<span></span>
</td>
<td class="nump">$ 3,347<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076944630608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY TYPE OF AWARDS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,003<span></span>
</td>
<td class="nump">$ 3,237<span></span>
</td>
<td class="nump">$ 10,068<span></span>
</td>
<td class="nump">$ 8,655<span></span>
</td>
<td class="nump">$ 11,906<span></span>
</td>
<td class="nump">$ 5,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,014<span></span>
</td>
<td class="nump">3,140<span></span>
</td>
<td class="nump">9,890<span></span>
</td>
<td class="nump">8,369<span></span>
</td>
<td class="nump">11,494<span></span>
</td>
<td class="nump">5,316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Employee stock purchase plan awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="num">$ (11)<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock awards and units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">$ 116<span></span>
</td>
<td class="nump">$ 151<span></span>
</td>
<td class="nump">$ 201<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076944254640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - Service agreement with Carnot LLC - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_RelatedPartyTransactionTerm', window );">Term of service agreement</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_NoticeToTerminateAgreementPeriod', window );">Termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_MaterialBreachCorrectionPeriod', window );">Material breach correction period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Expenses from transactions with related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Amount payable to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=avte_ServicesAgreementWithCarnotLlcMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Expenses from transactions with related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_MaterialBreachCorrectionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of days in which material breach must be corrected or agreement will be terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_MaterialBreachCorrectionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_NoticeToTerminateAgreementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of days in which notice to terminate an agreement must be given.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_NoticeToTerminateAgreementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_RelatedPartyTransactionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of related party transaction for service agreement , in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_RelatedPartyTransactionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=avte_ServicesAgreementWithCarnotLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=avte_ServicesAgreementWithCarnotLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076945198576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets valuation allowance</a></td>
<td class="nump">$ 43,596<span></span>
</td>
<td class="nump">$ 23,283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">64,800<span></span>
</td>
<td class="nump">46,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 44,100<span></span>
</td>
<td class="nump">30,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076950615040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - SUMMARY OF COMPONENTS OF NET DEFERRED TAX ASSETS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 16,199<span></span>
</td>
<td class="nump">$ 11,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research credit carryforwards</a></td>
<td class="nump">5,153<span></span>
</td>
<td class="nump">1,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts', window );">Capitalized R&amp;D</a></td>
<td class="nump">19,404<span></span>
</td>
<td class="nump">8,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">1,929<span></span>
</td>
<td class="nump">923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,117<span></span>
</td>
<td class="nump">790<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">43,802<span></span>
</td>
<td class="nump">23,585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(43,596)<span></span>
</td>
<td class="num">(23,283)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(206)<span></span>
</td>
<td class="num">(302)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">$ (206)<span></span>
</td>
<td class="num">(302)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets (liabilities)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076944135056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - SUMMARY OF RECONCILIATION OF FEDERAL INCOME TAX RATE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. Federal statutory income tax rate</a></td>
<td class="num">$ (15,831)<span></span>
</td>
<td class="num">$ (10,829)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="num">(3,389)<span></span>
</td>
<td class="num">(2,828)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Permanent and other differences</a></td>
<td class="nump">416<span></span>
</td>
<td class="nump">563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Stock-based compensation</a></td>
<td class="nump">1,049<span></span>
</td>
<td class="num">(787)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits', window );">Research and development credits</a></td>
<td class="num">(2,676)<span></span>
</td>
<td class="num">(757)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">20,487<span></span>
</td>
<td class="nump">14,663<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total tax provision</a></td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Research and Development Credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480887/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076992891632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - SUMMARY OF GROSS UNRECOGNIZED TAX BENEFITS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance of unrecognized tax benefits</a></td>
<td class="nump">$ 993<span></span>
</td>
<td class="nump">$ 529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
<td class="nump">1,127<span></span>
</td>
<td class="nump">461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions based on tax positions related to the prior year</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance of unrecognized tax benefits</a></td>
<td class="nump">$ 2,214<span></span>
</td>
<td class="nump">$ 993<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076946811712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 31,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">57,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">90,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">90,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">8,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other liabilities</a></td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of September 30, 2024 and December 31, 2023, respectively; no shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 150,000,000 shares authorized at September 30, 2024 and December 31, 2023, respectively; 28,867,711 and 27,762,703 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">307,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive gain</a></td>
<td class="nump">224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(466)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(227,622)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(163,424)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(87,903)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">80,493<span></span>
</td>
<td class="nump">$ 94,398<span></span>
</td>
<td class="nump">$ 90,904<span></span>
</td>
<td class="nump">109,456<span></span>
</td>
<td class="nump">$ 125,723<span></span>
</td>
<td class="nump">$ 141,926<span></span>
</td>
<td class="nump">$ 113,095<span></span>
</td>
<td class="nump">126,743<span></span>
</td>
<td class="nump">$ 172,418<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 90,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076943630272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Aug. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Condensed Consolidated Balance Sheets (Unaudited)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">28,867,711<span></span>
</td>
<td class="nump">27,762,703<span></span>
</td>
<td class="nump">24,722,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">28,867,711<span></span>
</td>
<td class="nump">27,762,703<span></span>
</td>
<td class="nump">24,722,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076944719296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 10,328<span></span>
</td>
<td class="nump">$ 16,884<span></span>
</td>
<td class="nump">$ 51,656<span></span>
</td>
<td class="nump">$ 46,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">7,082<span></span>
</td>
<td class="nump">4,484<span></span>
</td>
<td class="nump">16,537<span></span>
</td>
<td class="nump">12,937<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">17,410<span></span>
</td>
<td class="nump">21,368<span></span>
</td>
<td class="nump">68,193<span></span>
</td>
<td class="nump">59,343<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(17,410)<span></span>
</td>
<td class="num">(21,368)<span></span>
</td>
<td class="num">(68,193)<span></span>
</td>
<td class="num">(59,343)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">1,183<span></span>
</td>
<td class="nump">1,804<span></span>
</td>
<td class="nump">4,014<span></span>
</td>
<td class="nump">4,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense:</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">1,173<span></span>
</td>
<td class="nump">1,805<span></span>
</td>
<td class="nump">3,995<span></span>
</td>
<td class="nump">4,235<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(16,237)<span></span>
</td>
<td class="num">(19,563)<span></span>
</td>
<td class="num">(64,198)<span></span>
</td>
<td class="num">(55,108)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(16,237)<span></span>
</td>
<td class="num">(19,563)<span></span>
</td>
<td class="num">(64,198)<span></span>
</td>
<td class="num">(55,108)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingUnrealizedGainLoss', window );">Unrealized (loss) gain on securities</a></td>
<td class="nump">307<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (15,930)<span></span>
</td>
<td class="num">$ (19,585)<span></span>
</td>
<td class="num">$ (64,211)<span></span>
</td>
<td class="num">$ (54,865)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="num">$ (0.71)<span></span>
</td>
<td class="num">$ (2.25)<span></span>
</td>
<td class="num">$ (2.13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="num">$ (0.71)<span></span>
</td>
<td class="num">$ (2.25)<span></span>
</td>
<td class="num">$ (2.13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares of common stock outstanding, basic</a></td>
<td class="nump">28,863,327<span></span>
</td>
<td class="nump">27,640,542<span></span>
</td>
<td class="nump">28,572,338<span></span>
</td>
<td class="nump">25,872,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares of common stock outstanding, diluted</a></td>
<td class="nump">28,863,327<span></span>
</td>
<td class="nump">27,640,542<span></span>
</td>
<td class="nump">28,572,338<span></span>
</td>
<td class="nump">25,872,118<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesTradingUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesTradingUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076946274784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Gain/(Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="nump">24,410,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 208,867<span></span>
</td>
<td class="num">$ (59)<span></span>
</td>
<td class="num">$ (36,392)<span></span>
</td>
<td class="nump">$ 172,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingUnrealizedLoss', window );">Unrealized loss on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">298,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under ESPP, shares</a></td>
<td class="nump">13,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,511)<span></span>
</td>
<td class="num">(51,511)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2022</a></td>
<td class="nump">24,722,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">215,110<span></span>
</td>
<td class="num">(466)<span></span>
</td>
<td class="num">(87,903)<span></span>
</td>
<td class="nump">126,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingUnrealizedGain', window );">Unrealized gain on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">93,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,520)<span></span>
</td>
<td class="num">(16,520)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2023</a></td>
<td class="nump">24,816,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2023</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">217,717<span></span>
</td>
<td class="num">(201)<span></span>
</td>
<td class="num">(104,423)<span></span>
</td>
<td class="nump">113,095<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2022</a></td>
<td class="nump">24,722,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">215,110<span></span>
</td>
<td class="num">(466)<span></span>
</td>
<td class="num">(87,903)<span></span>
</td>
<td class="nump">126,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,108)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2023</a></td>
<td class="nump">27,653,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2023</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">268,926<span></span>
</td>
<td class="num">(195)<span></span>
</td>
<td class="num">(143,011)<span></span>
</td>
<td class="nump">125,723<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2022</a></td>
<td class="nump">24,722,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">215,110<span></span>
</td>
<td class="num">(466)<span></span>
</td>
<td class="num">(87,903)<span></span>
</td>
<td class="nump">126,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingUnrealizedGain', window );">Unrealized gain on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with ATM, net</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">44,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with ATM, net, shares</a></td>
<td class="nump">2,662,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">338,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under ESPP, shares</a></td>
<td class="nump">28,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units, shares</a></td>
<td class="nump">9,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,521)<span></span>
</td>
<td class="num">(75,521)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2023</a></td>
<td class="nump">27,762,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2023</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">272,640<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="num">(163,424)<span></span>
</td>
<td class="nump">109,456<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2023</a></td>
<td class="nump">24,816,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2023</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">217,717<span></span>
</td>
<td class="num">(201)<span></span>
</td>
<td class="num">(104,423)<span></span>
</td>
<td class="nump">113,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingUnrealizedLoss', window );">Unrealized loss on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with ATM, net</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">44,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with ATM, net, shares</a></td>
<td class="nump">2,662,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">106,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under ESPP, shares</a></td>
<td class="nump">13,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units, shares</a></td>
<td class="nump">815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,025)<span></span>
</td>
<td class="num">(19,025)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2023</a></td>
<td class="nump">27,601,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2023</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">265,594<span></span>
</td>
<td class="num">(223)<span></span>
</td>
<td class="num">(123,448)<span></span>
</td>
<td class="nump">141,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingUnrealizedGain', window );">Unrealized gain on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">46,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units, shares</a></td>
<td class="nump">5,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,563)<span></span>
</td>
<td class="num">(19,563)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2023</a></td>
<td class="nump">27,653,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2023</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">268,926<span></span>
</td>
<td class="num">(195)<span></span>
</td>
<td class="num">(143,011)<span></span>
</td>
<td class="nump">125,723<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2023</a></td>
<td class="nump">27,762,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2023</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">272,640<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="num">(163,424)<span></span>
</td>
<td class="nump">109,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingUnrealizedLoss', window );">Unrealized loss on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">133,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units, shares</a></td>
<td class="nump">2,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,186)<span></span>
</td>
<td class="num">(23,186)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2024</a></td>
<td class="nump">27,898,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2024</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">277,544<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="num">(186,610)<span></span>
</td>
<td class="nump">90,904<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2023</a></td>
<td class="nump">27,762,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2023</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">272,640<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="num">(163,424)<span></span>
</td>
<td class="nump">$ 109,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (64,198)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2024</a></td>
<td class="nump">28,867,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2024</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">307,888<span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="num">(227,622)<span></span>
</td>
<td class="nump">80,493<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2024</a></td>
<td class="nump">27,898,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2024</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">277,544<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="num">(186,610)<span></span>
</td>
<td class="nump">90,904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingUnrealizedLoss', window );">Unrealized loss on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with ATM, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with ATM, net, shares</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">119,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under ESPP, shares</a></td>
<td class="nump">34,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units, shares</a></td>
<td class="nump">2,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,775)<span></span>
</td>
<td class="num">(24,775)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2024</a></td>
<td class="nump">28,854,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2024</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">305,863<span></span>
</td>
<td class="num">(83)<span></span>
</td>
<td class="num">(211,385)<span></span>
</td>
<td class="nump">94,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingUnrealizedGain', window );">Unrealized gain on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">12,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,237)<span></span>
</td>
<td class="num">(16,237)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2024</a></td>
<td class="nump">28,867,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2024</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 307,888<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
<td class="num">$ (227,622)<span></span>
</td>
<td class="nump">$ 80,493<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesTradingUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesTradingUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesTradingUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesTradingUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076944531456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flow from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (55,108)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">8,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization expense</a></td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet', window );">Accretion of discounts and amortization of premiums on investments, net</a></td>
<td class="num">(2,118)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(128)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">5,948<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability', window );">Operating lease assets and liabilities, net</a></td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(114)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(41,978)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flow from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(96,194)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Maturities of short-term investments</a></td>
<td class="nump">102,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">6,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flow from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock in connection with ATM, net</a></td>
<td class="nump">44,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments for offering costs</a></td>
<td class="num">(234)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from issuance of common stock under ESPP</a></td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock upon exercise of stock options</a></td>
<td class="nump">651<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">45,533<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">9,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at the beginning of the year</a></td>
<td class="nump">22,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at the end of the period</a></td>
<td class="nump">32,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for operating lease liability</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment in accounts payable and accrued liabilities</a></td>
<td class="nump">$ 64<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion of discounts and amortization of premiums on investments, net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease asset and liability, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076950536592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND NATURE OF OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>ORGANIZATION AND NATURE OF OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND NATURE OF OPERATIONS</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">(1)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">ORGANIZATION AND NATURE OF OPERATIONS</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Organization and Nature of Operations</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate Therapeutics Inc. (&#8220;Aerovate&#8221; or the &#8220;Company&#8221;) was incorporated in the state of Delaware in July 2018, and is headquartered in Waltham, Massachusetts. The Company has a wholly owned subsidiary, Aerovate Securities Corporation. The Company is a biopharmaceutical company. The Company&#8217;s initial focus was on advancing AV-101, the Company&#8217;s dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (&#8220;PAH&#8221;). However, in June 2024, the Company announced negative results from the Phase 2b portion of its global Phase 2b/Phase 3 trial of AV-101 in adults with PAH, and, as a result, the Company decided to halt enrollment and shut down the Phase 3 portion of the Phase 2b/Phase 3 trial as well as the long-term extension study. In June 2024, the Company announced a corporate restructuring and in July 2024, the Company engaged Wedbush PacGrow as the Company&#8217;s exclusive strategic financial advisor to assist in the process of exploring strategic alternatives, including but not limited to an acquisition, merger, reverse merger, business combination, liquidation or other transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 30, 2024, the Company entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), by and among the Company, Caribbean Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (&#8220;Merger Sub I&#8221;), Caribbean Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of the Company (&#8220;Merger Sub II&#8221; and together with Merger Sub I, the &#8220;Merger Subs&#8221;), and Jade Biosciences, Inc., a Delaware corporation (&#8220;Jade&#8221;), pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, among other things, Merger Sub I will merge with and into Jade, with Jade surviving the merger as the surviving corporation (the &#8220;First Merger&#8221;), and as part of the same overall transaction, Jade will merge with and into Merger Sub II, with Merger Sub II continuing as a wholly owned subsidiary of the Company and the surviving corporation of the merger (the &#8220;Second Merger&#8221; and together with the First Merger, the &#8220;Merger&#8221;). In addition, in connection with the closing of the Merger (the &#8220;Closing&#8221;), the Company expects to declare a cash dividend to its pre-Merger stockholders of approximately $65.0 million in the aggregate (the &#8220;Cash Dividend&#8221;), provided such amount is subject to adjustment as set forth in the Merger Agreement. The Merger was approved by the Company&#8217;s board of directors (the &#8220;Board&#8221;), and the Board resolved to recommend approval of the Merger Agreement to the Company&#8217;s stockholders. The Closing is subject to approval by the stockholders of the Company and Jade as well as other customary closing conditions, including the effectiveness of a registration statement filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) in connection with the transaction. If the Merger is completed, the business of Jade will continue as the business of the combined company.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">At-the-Market Offering </span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 5, 2023, the Company entered into an ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement (the &#8220;Sales Agreement&#8221;) with BofA Securities, Inc., or the Agent, pursuant to which the Company can sell, from time to time, at its option, up to an aggregate of $75.0 million of shares of its common stock, through the Agent, as its sales agent. As of September 30,&#160;2024, 3,462,721 shares have been sold under the Sales Agreement, generating $67.9 million of net proceeds after deducting commissions to the Agent and other offering costs. As of the date of this Quarterly Report on Form 10-Q, up to $6.0 million of shares of the Company&#8217;s common stock remain available for sale from time to time under the Sales Agreement. </p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity and Management Plans</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since inception, the Company has devoted substantially all of its resources to research and development activities, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations and has not realized revenues from its planned principal operations. The Company has incurred losses and negative cash flows from operations since inception. As of September&#160;30,&#160;2024, the Company had cash and cash equivalents and short-term investments of $88.7 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management believes that the Company&#8217;s current cash and cash equivalents and short-term investments will provide sufficient funds to enable the Company to meet its obligations for at least twelve&#160;months from the filing date of this report while it explores strategic alternatives.</p><span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Organization and Nature of Operations</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Aerovate Therapeutics&#160;Inc. (&#8220;Aerovate&#8221; or the &#8220;Company&#8221;) was incorporated in the state of Delaware in July&#160;2018, and is headquartered in Waltham, Massachusetts. The Company has a wholly owned subsidiary, Aerovate Securities Corporation. The Company is a clinical-stage biopharmaceutical company that is focused on the development of drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. The Company&#8217;s initial focus is on advancing AV-101, the Company&#8217;s dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (&#8220;PAH&#8221;). The Company initiated a global Phase 2b/Phase 3 trial of AV-101 in adults with PAH in December&#160;2021 and announced in November 2023 completion of enrollment of the Phase 2b portion of this trial and enrollment of the first patient in the Phase 3 portion of this trial. </p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">At-the-Market Offering</span><span style="font-style:italic;"> </span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 5, 2023, the Company entered into an ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement, or the Sales Agreement, with BofA Securities, Inc., or the Agent, pursuant to which the Company can sell, from time to time, at its option, up to an aggregate of $75.0 million of shares of its common stock, through the Agent, as its sales agent. As of December 31, 2023, 2,662,721 shares have been sold under the Sales Agreement, generating approximately $44.3 million of net proceeds after deducting commissions to the sales agent and other offering costs, and up to $30.0 million of shares of the Company&#8217;s common stock remain available for sale from time to time under the Sales Agreement. </p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Liquidity and Management Plans</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since inception, the Company has devoted substantially all of its resources to research and development activities, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations and has not realized revenues from its planned principal operations. The Company has incurred losses and negative cash flows from operations since inception. In addition, the Company expects to incur substantial operating losses for the next several&#160;years as it continues its research and development activities. As of December&#160;31, 2023, the Company had cash and cash equivalents and short-term investments of $122.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management plans to continue to incur substantial costs in order to conduct research and development activities and additional capital will be needed to undertake these activities. The Company intends to raise such capital through debt or equity financings or other arrangements to fund operations. Management believes that the Company&#8217;s current cash and cash equivalents and short-term investments will provide sufficient funds to enable the Company to meet its obligations for at least twelve&#160;months from the filing date of this report.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076998808240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">(2)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements as of September&#160;30,&#160;2024 and for the three and nine months ended September&#160;30,&#160;2024 and 2023 have been prepared in conformity with generally accepted accounting principles (&#8220;GAAP&#8221;) in the United States of America for interim financial information and pursuant to Article&#160;10 of Regulation S-X of the Securities Act of 1933, as amended (the Securities Act). Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include only normal and recurring adjustments that the Company believes are necessary to fairly state the Company&#8217;s financial position and the results of its operations and cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The results for the three and nine months ended September&#160;30,&#160;2024 are not necessarily indicative of the results expected for the full fiscal&#160;year or any subsequent interim period. The condensed consolidated balance sheet as of December&#160;31,&#160;2023 has been derived from the audited financial statements at that date but does not include all disclosures required by GAAP for complete financial statements. Because all of the disclosures required by GAAP for complete financial statements are not included herein, these unaudited condensed consolidated financial statements and the notes accompanying them should be read in conjunction with the Company&#8217;s audited financial statements for the&#160;year ended December&#160;31,&#160;2023. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the Company&#8217;s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. Accounting estimates and management judgements reflected in the consolidated financial statements include: normal recurring accruals, including the accrual for research and development expenses, stock-based compensation, fair value of investments, and operating lease right-of-use assets and lease liabilities. Estimates and assumptions are reviewed quarterly. Any revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Net Loss Per Share</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company&#8217;s potentially dilutive securities have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes the Company&#8217;s net loss per share (in thousands, except share and per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,237)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,563)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (64,198)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (55,108)</p></td></tr><tr><td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,237)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,563)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (64,198)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (55,108)</p></td></tr><tr><td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Weighted-average common stock outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,863,327</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,640,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,572,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,872,118</p></td></tr><tr><td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.56)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.71)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.25)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.13)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:61.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,714,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,236,832</p></td></tr><tr><td style="vertical-align:top;width:61.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,754</p></td></tr><tr><td style="vertical-align:bottom;width:61.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,714,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,262,586</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(d)</span></span><span style="font-style:italic;font-weight:bold;">Recently Issued and Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In November 2023, the FASB issued ASU 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280)</i>: Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments&#8217; significant expenses on an interim and annual basis. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Entities must adopt the changes to the segment reporting guidance on a retrospective basis, and early adoption is permitted. The Company does not anticipate this ASU to materially impact our consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In December 2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740)</i>: Improvements to Income Tax Disclosures, which expands disclosures in an entity&#8217;s income tax rate reconciliation table and regarding cash taxes paid both in the U.S. and foreign jurisdictions. The standard is effective for fiscal years beginning after December 15, 2024, and interim periods in fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact the adoption of this standard may have on its consolidated financial statements and related disclosures, and does not anticipate this ASU to materially impact our consolidated financial statements and related disclosures.</p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(2)</b></span>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Basis of Presentation</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include the Company&#8217;s wholly owned subsidiary, Aerovate Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Use of Estimates</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The preparation of the Company&#8217;s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. Accounting estimates and management judgements reflected in the consolidated financial statements include: normal recurring accruals, including the accrual for research and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">development expenses, stock-based compensation, fair value of investments, and operating lease right-of-use assets and lease liabilities. Estimates and assumptions are reviewed quarterly. Any revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Cash and Cash Equivalents</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents include cash in readily available checking accounts, money market funds and commercial paper. The Company considers all highly liquid investments with an original maturity of three&#160;months or less from the date of purchase to be cash equivalents.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(d)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Short-term Investments</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Short-term investments consist of corporate debt securities, commercial paper and U.S. Treasury bills, classified as available-for-sale securities and have maturities of greater than three&#160;months. The Company has classified all of its available-for-sale investment securities as current assets on the consolidated balance sheets because these are considered highly liquid securities and are available for use in current operations. The Company carries these securities at fair value and reports unrealized gains and losses as a separate component of accumulated other comprehensive loss. The cost of debt securities is adjusted for amortization of purchase premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income in the consolidated statements of operations and comprehensive loss. Realized gains and losses on sales of securities are determined using the specific identification method and recorded in other income (expense), net in the consolidated statement of operations and comprehensive loss.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(e)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Concentration of Credit Risk</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains cash, cash equivalents and short-term investments with various high credit quality banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has not experienced any losses on deposits since inception.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(f)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Comprehensive Loss</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Comprehensive loss consists of net loss and unrealized gains or losses on available-for-sale investments. The Company displays comprehensive loss and its components as part of the consolidated statements of operations and comprehensive loss.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(g)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Fair Value Measurements</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">Level 1: Observable inputs such as quoted prices in active markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying amounts of prepaid expenses and other current assets, accounts payable, accrued liabilities and other current liabilities are reasonable estimates of their fair value due to the short-term nature of these accounts.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(h)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Prepaid Expenses and Other Current Assets</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any expenses paid prior to the related services rendered are recorded as prepaid expenses. Such prepaid expenses are expensed in the period the expense is incurred. If the expense is for a service covering multiple periods, it is expensed from the date the services begin and over the period of the service rendered (or contract service period if services rendered dates are not defined).</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(i)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Property and Equipment, Net</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property and equipment, which consist of leasehold improvements, furniture and fixtures, research equipment, computers and construction-in-progress are stated at cost less accumulated depreciation or accumulated amortization. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets, which ranges from <span style="-sec-ix-hidden:Hidden_n34-iiJT30mFenREfVs5IQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to <span style="-sec-ix-hidden:Hidden_g3-e0FT-IE2Xj7oAU60QZg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five&#160;years</span></span>. Leasehold improvements are amortized over the remaining life of the lease for leasehold improvements at the time the asset is placed into service.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(j)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Impairment of Long-lived Assets</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying value of long-lived assets, including property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. Through December&#160;31, 2023, there has been no such impairment losses recorded by the Company.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(k)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Leases</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the commencement date of a lease, the Company recognizes lease liabilities which represent its obligation to make lease payments, and right-of-use assets (&#8220;ROU assets&#8221;) which represent its right to use the underlying asset during the lease term. The lease liability is measured at the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the lease commencement date. The ROU asset is measured at cost, which includes the initial measurement of the lease liability and initial direct costs incurred by the Company and excludes lease incentives. ROU assets are recorded in operating lease ROU assets and lease liabilities are recorded in operating lease liabilities, current and noncurrent in the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected not to separate lease and non-lease components and not recognize lease liabilities and ROU assets for short-term leases with terms of twelve&#160;months or less.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(l)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Convertible Preferred Stock</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company records convertible preferred stock at fair value on the dates of issuance, net of issuance costs. Upon the occurrence of certain events that are outside the Company&#8217;s control, including a deemed liquidation event, holders of the convertible preferred stock can cause redemption for cash. Therefore, convertible preferred stock is classified outside of stockholders&#8217; deficit on the balance sheets as events triggering the liquidation preferences are not solely within the Company&#8217;s control. The carrying values of the convertible preferred stock are adjusted to their liquidation preferences if and when it becomes probable that such a liquidation event will occur.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(m)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Research and Development Expenses</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and other benefits of research and development personnel, including associated share-based compensation, costs related to research activities, preclinical studies, clinical trial, drug manufacturing and allocated overhead and facility-related expenses. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, as they are incurred, based </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(n)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Stock-Based Compensation</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Stock-based compensation expense represents the cost of the grant-date fair value of employee, officer, director, and non-employee stock option grants and restricted stock units, estimated in accordance with the applicable accounting guidance, recognized using the straight-line method over the vesting period for service-based options and using the graded vesting method for performance-based options. The vesting period generally approximates the expected service period of the awards. Forfeitures are recognized and accounted for as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The fair value of stock options is estimated using a Black-Scholes option pricing model on the date of grant. This method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#8217;s common stock, expected dividend yield, and a risk-free interest rate. Options and awards granted during the&#160;year have a maximum contractual term of ten&#160;years. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the average of the contractual term of the stock option and its weighted-average vesting period. The expected volatility of stock options is based upon the historical volatility of a number of publicly traded companies in similar stages of clinical development. The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future. The risk-free interest rates used are based on the U.S. Department of Treasury (&#8220;U.S. Treasury&#8221;) yield in effect at the time of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term of the stock options.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(o)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Income Taxes</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Income taxes are accounted for using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss ("NOL") and tax credit carryforwards. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="white-space:pre-wrap;">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.  The company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.  The company recognizes interest and penalties related to unrecognized tax benefits within income tax expense.  Any accrued interest and penalties are included within the related tax liability.</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(p)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Segment Reporting</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one operating segment.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(q)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Net Loss Per Share</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company&#8217;s potentially dilutive securities, which include convertible preferred stock prior to the conversion of such shares to common stock and outstanding stock options under the Company&#8217;s equity incentive plan, have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The following table summarizes the Company&#8217;s net loss per share:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75,521)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,511)</p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75,521)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,511)</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Weighted-average common stock outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,331,630</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,472,104</p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.87)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.10)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:61.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,230,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,110,219</p></td></tr><tr><td style="vertical-align:top;width:61.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,881</p></td></tr><tr><td style="vertical-align:bottom;width:61.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,252,312</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,139,100</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(r)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Recently Issued Accounting Pronouncements</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In December 2023, the FASB issued ASU No. 2023-09, "Improvements to Income Tax Disclosures." ASU 2023-09 requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024 and for private businesses for annual periods beginning after December 15, 2025, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its financial statement disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In June 2022, the FASB issued ASU No. 2022-03, Fair Value Measurement (Topic 820) - Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard will be effective for the Company on January 1, 2024, and is not expected to have an impact on the Company&#8217;s financial position or results of operations upon adoption.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076996013648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE OF FINANCIAL INSTRUMENTS</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">(3)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">FAIR VALUE OF FINANCIAL INSTRUMENTS</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following tables summarize the Company&#8217;s financial assets measured at fair value on a recurring basis and their respective input levels based on the fair value hierarchy (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for&#160;Identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level&#160;3)</b></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,926</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,926</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,537</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total fair value of assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,880</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,343</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,537</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for&#160;Identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level&#160;3)</b></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_NvvtqfTNDUi3pAQbMuV3Iw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_W5lZ48FLCEy_u2gCz_QeZg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_EIT7Ft-M4U2oTXvtr5qvPQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_XpL8HTw1KUeUXBHbhjlt2w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_lN0AgyYwBUGSBPvHUXVvCA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_ATiC6JEvSUm2xAjs-Qle-w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,386</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_FAR9X24s2UOjJM_mFfQemw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,386</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden__tPLOVORX06K05WNcJNPHQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_hGln6qJd7kWjTm5e4HDgWA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_sBbWTO6GDUu9JQZjdyFFlw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,945</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_Ib6YuqwgvUOu1jkJDvoCZQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,945</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_HN51f_bDUkShpzdYGLsCOw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98,948</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_sNomPq10ZESk15LyPnEosQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total fair value of assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 118,735</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,149</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_YNU4YHIeWEuPQ_VjMX_kCQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash Equivalents and Short-Term Investments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial assets measured at fair value on a recurring basis consist of the Company&#8217;s cash equivalents and short-term investments. Cash equivalents consisted of money market funds and commercial paper, and short-term investments consisted of U.S. Treasury bills, agency bonds, corporate debt securities, and commercial paper. The Company obtains pricing information from its investment manager and generally determines the fair value of investment securities using standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following tables summarize the Company&#8217;s short-term investments (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Maturity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 139</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,866</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,926</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,058</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Maturity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,386</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,945</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 98,711</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (23)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 98,948</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following tables summarize the Company&#8217;s short-term investments with unrealized losses for less than 12 months and 12 months or greater (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:35.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="16" style="vertical-align:bottom;white-space:nowrap;width:62.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">12 months or Greater</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Unrealized</b></p></td></tr><tr style="height:10.35pt;"><td style="vertical-align:bottom;width:35.88%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></div></div></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:35.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:35.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,760</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:35.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 488</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,007</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:35.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,986</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (23)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company did not hold any short-term investments in a loss position as of September 30, 2024. The Company considers whether unrealized losses have resulted from a credit loss or other factors. The unrealized losses on the Company&#8217;s short-term investments as of December&#160;31,&#160;2023, were caused by fluctuations in market value and interest rates as a result of the economic environment and not credit risk. As of September&#160;30,&#160;2024 and December&#160;31,&#160;2023, no allowance for credit losses was recorded. During the nine months ended September&#160;30,&#160;2024, the Company did not recognize any impairment losses related to its short-term investments. It is neither management&#8217;s intention to sell nor is it more likely than not that the Company will be required to sell these investments prior to recovery of their cost basis or recovery of fair value. Unrealized gains and losses are included in accumulated other comprehensive gain (loss). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Accrued interest receivable is written off through net realized investment gains (losses) at the time the issuer of the bond defaults or is expected to default on payment. Accrued interest receivable related to short-term investments was $0.3 million as of September&#160;30,&#160;2024 and $0.6 million as of December&#160;31,&#160;2023. </p><span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">(3)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">FAIR VALUE OF FINANCIAL INSTRUMENTS</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The following tables summarize the Company&#8217;s financial assets measured at fair value on a recurring basis and their respective input levels based on the fair value hierarchy (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:normal;width:41.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for&#160;Identical</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level&#160;3)</b></p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,255</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,255</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Commercial Paper</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,386</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,386</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,945</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,945</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98,948</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,586</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total fair value of assets</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 118,735</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,149</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,586</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:41.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">for&#160;Identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(level&#160;3)</b></p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55,577</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55,577</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Agency Bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 106,823</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 79,982</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total fair value of assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 125,259</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 79,982</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash Equivalents and Short-Term Investments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial assets measured at fair value on a recurring basis consist of the Company&#8217;s cash equivalents and short-term investments. Cash equivalents consisted of cash, money market funds and commercial paper, and short-term investments consisted of U.S. Treasury bills, agency bonds, corporate debt securities and commercial paper. The Company obtains pricing information from its investment manager and generally determines the fair value of investment securities using standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following tables summarize the Company&#8217;s short-term investments (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maturity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,386</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,945</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98,711</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98,948</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maturity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,645</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (84)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,577</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (267)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,536</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (133)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 107,289</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (484)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 106,823</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following tables summarize the Company&#8217;s short-term investments with unrealized losses for less than 12 months and 12 months or greater:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:65.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.56%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.58%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">12 months or Greater</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.03%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Unrealized</b></p></td></tr><tr><td style="vertical-align:bottom;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,760</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 488</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,007</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,986</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:32.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:67.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.01%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.32%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">12 months or Greater</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Unrealized</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:32.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,928</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (84)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,928</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (84)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,971</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,833</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (261)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (267)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:32.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,964</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (133)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,964</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (133)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (223)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,833</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (261)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (484)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company considers whether unrealized losses have resulted from a credit loss or other factors. The unrealized losses on the Company&#8217;s available-for-sale securities as of December&#160;31, 2023 were caused by fluctuations in market value and interest rates as a result of the economic environment and not credit risk. The Company concluded that an allowance for credit losses was unnecessary as of December&#160;31, 2023. It is neither management&#8217;s intention to sell nor is it more likely than not that the Company will be required to sell these investments prior to recovery of their cost basis or recovery of fair value. Unrealized gains and losses are included in accumulated other comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Accrued interest receivable is written off through net realized investment gains (losses) at the time the issuer of the bond defaults or is expected to default on payment. Accrued interest receivable related to short-term investments was $0.6 million and $0.3 million as of December&#160;31, 2023 and December 31, 2022, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076950600224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>BALANCE SHEET COMPONENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">BALANCE SHEET COMPONENTS</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">(4)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">BALANCE SHEET COMPONENTS</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Prepaid Expenses and Other Current Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Prepaid expenses and other current assets consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,875</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Accrued and Other Current Liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In June 2024, following the Company&#8217;s decision to halt further development of AV-101, the Company announced its plan to terminate nearly all of its workforce in the coming months (the &#8220;Workforce Reduction Plan&#8221;). As of September 30, 2024, 46 individuals, or approximately 90% of the Company&#8217;s workforce, have been terminated. The affected individuals have been and will be provided severance benefits, including cash severance payments. Each affected individual&#8217;s eligibility for severance benefits is contingent upon entering into a separation agreement, which includes a general release of claims against the Company. In connection with the Workforce Reduction Plan, the Company incurred costs (in consideration of releases) of approximately $6.4 million, which are primarily one-time severance benefits, during the nine months ended September 30, 2024. The Company has paid approximately $2.4 million of severance benefits, and liabilities associated with the Workforce Reduction Plan were approximately $4.0 million as of September 30, 2024. The Company estimates that the remaining liabilities will be paid in the fourth quarter of 2024 and first quarter of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Accrued and other current liabilities consisted of the following (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,704</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,363</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued payroll and other employee benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 292</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total accrued and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,948</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,821</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">(4)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">BALANCE SHEET COMPONENTS</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Prepaid Expenses and Other Current Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Prepaid expenses and other current assets consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:62.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,503</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Prepaid research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 478</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Total prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accrued and Other Current Liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Accrued and other current liabilities consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued research and development</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,363</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,751</p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued payroll and other employee benefits</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,368</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,691</p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,090</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 380</p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total accrued and other current liabilities</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,821</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,822</p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076950591248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">(5)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">COMMITMENTS AND CONTINGENCIES</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2021, the Company entered into a lease agreement (the &#8220;Waltham Lease&#8221;) for approximately 5,000 square feet of office space in Waltham, Massachusetts for the Company&#8217;s corporate headquarters. The Waltham Lease has a term of <span style="-sec-ix-hidden:Hidden_QkmZslh310SYGgzTas8QSQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">thirty-nine&#160;months</span></span> (&#8220;Lease Term&#8221;), unless extended or earlier terminated. The Company had the option to extend the Waltham Lease for one additional period of three&#160;years. The Lease Term has an initial abatement period, and the initial base rent payable is approximately $18,000 per&#160;month following the abatement period. The initial base rent payable will increase by approximately 2% per&#160;year over the Lease Term. The Waltham Lease commencement date was September&#160;1, 2021. In January 2024, the Company entered into the First Amendment to the Waltham Lease resulting in the lease expiring on December 31, 2025, and an increase of $1.00 per rentable square foot during the additional lease term. In obtaining this lease extension, the Company no longer has the option to extend the Waltham Lease for one additional period of three years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2022, the Company entered into a lease agreement (the &#8220;Foster City Lease&#8221;) for approximately 3,500 square feet of office space in Foster City, California. The Foster City Lease has a term of <span style="-sec-ix-hidden:Hidden_5dOxBlntyUCTd-8nElVMiw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">thirty-nine&#160;months</span></span>, unless extended or earlier terminated. The Company has the option to extend the Foster City Lease for an additional period of <span style="-sec-ix-hidden:Hidden_mWsXBWWQvkivgmOrUGyQhg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one&#160;year</span></span>. The base rent payable under the Foster City Lease is $22,600 per&#160;month and will be subject to annual increase of 3% on each anniversary. Following the Company&#8217;s Workforce Reduction Plan, the Company terminated all employees in the Foster City office and vacated the premises in September 2024. As a result, the Company impaired the related right-of-use asset of approximately $0.3 million, and recognized a loss on impairment in its general and administrative operating expenses during the three months ended September 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of September&#160;30,&#160;2024, the future minimum annual lease payments under the operating leases were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:74.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:25.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 12.25pt;"><b style="font-weight:bold;">Total Minimum</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:25.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 12.25pt;"><b style="font-weight:bold;">Lease Payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 242</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total operating lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 558</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less: Amount representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (18)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Present value of net minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Company&#8217;s leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the lease commencement date. The components of operating leases as of September&#160;30,&#160;2024 and as of December&#160;31,&#160;2023 were as follows (in thousands except lease term and discount rate):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 459</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average incremental borrowing rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Supplemental cash flow information related to cash paid for amounts included in the measurement of operating lease liabilities was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:75.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine months </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">ended </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:75.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid included in operating cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 323</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Rent expense was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:40.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 343</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:40.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 165</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:40.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total rent expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">(5)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">COMMITMENTS AND CONTINGENCIES</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2021, the Company entered into a lease agreement (the &#8220;Waltham Lease&#8221;) for approximately 5,000 square feet of office space in Waltham, Massachusetts for the Company&#8217;s corporate headquarters. The Waltham Lease has a term of thirty-nine months (&#8220;Lease Term&#8221;), unless extended or earlier terminated. The Company has the option to extend the Waltham Lease for one additional period of three&#160;years. The Lease Term had an initial abatement period, and the initial base rent payable is approximately $18,000 per&#160;month following the abatement period. The initial base rent payable will increase by approximately 2% per&#160;year over the Lease Term. The Waltham Lease commencement date was September&#160;1, 2021. In January 2024, the Company entered into the First Amendment to the Waltham Lease resulting in the lease expiring on December 31, 2025, and an increase of $1.00 per rentable square foot during the additional lease term. In obtaining this lease extension, the Company no longer has the option to extend the Waltham Lease for one additional period of three years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April 2022, the Company entered into a lease agreement (the &#8220;Foster City Lease&#8221;) for approximately 3,500 square feet of office space in Foster City, California. The Foster City Lease has a term of thirty-nine months, unless extended or earlier terminated. The Company has the option to extend the Foster City Lease for on additional period of one year. The base rent payable under the Lease Term will be $22,600 per month and will be subject to annual increase of 3% on each anniversary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the consolidated balance sheet includes an operating lease right-of-use asset of $0.6 million and operating lease liability of $0.7 million. The total operating lease expense was $0.4 million for both of the years ended December 31, 2023 and 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the future minimum annual lease payments under the operating leases were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:24.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 12.25pt;"><b style="font-weight:bold;">Total Minimum</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:24.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 12.25pt;"><b style="font-weight:bold;">Lease Payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 466</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 242</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total operating lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 708</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Amount representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Present value of net minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The components of operating leases for the years ended December 31, 2023 and December 31, 2022 were as follows (in thousands except lease term and discount rate):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Operating lease liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 705</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average incremental borrowing rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Legal Proceedings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company may from time to time be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings during the years ended December 31, 2023 and 2022, and no material legal proceedings are currently pending or, to the best of its knowledge, threatened.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076944121408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">(6)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">STOCKHOLDERS&#8217; EQUITY</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July&#160;2, 2021, the Company&#8217;s certificate of amendment to its certificate of incorporation became effective, which provided 150,000,000 authorized shares of common stock with a par value of $0.0001 per share and 10,000,000 authorized shares of undesignated preferred stock with a par value of $0.0001 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The holders of the common stock are entitled to one vote for each share of common stock held at all meetings of stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of September&#160;30,&#160;2024, the Company had reserved the following shares of common stock for future issuance:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:72.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common stock options granted and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,714,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:72.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares reserved for issuance under the 2021 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,982,105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:72.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reserved for future ESPP issuances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 401,218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,097,427</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">(6)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">STOCKHOLDERS&#8217; EQUITY</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Company&#8217;s Amended and Restated Certificates of Incorporation dated August&#160;3, 2020, the Company had a total of 94,052,154 shares of capital stock authorized for issuance, consisting of 50,000,000 shares of common stock, par value of $0.0001 per share, and 44,052,154 shares of convertible preferred stock, par value of $0.0001 per share. Shares of authorized convertible preferred stock were designated as 4,000,000 shares of Series&#160;Seed redeemable convertible preferred stock and 40,052,154 shares of Series&#160;A redeemable convertible preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July&#160;2, 2021, the Company&#8217;s certificate of amendment to its certificate of incorporation became effective, which provided 150,000,000 authorized shares of common stock with a par value of $0.0001 per share and 10,000,000 authorized shares of undesignated preferred stock with a par value of $0.0001 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2018, the Company issued 241,467 shares of common stock to RA Capital Healthcare Fund,&#160;L.P. at a price of $0.0012 per share. On July&#160;2, 2021, in conjunction with the Company&#8217;s initial public offering, or IPO, the Company issued 9,984,463 shares of its common stock and all outstanding shares of the Company&#8217;s redeemable convertible preferred stock were converted into 14,182,854 shares of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The holders of the common stock are entitled to one vote for each share of common stock held at all meetings of stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the Company had reserved the following shares of common stock for future issuance:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options granted and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,230,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Shares reserved for issuance under the 2021 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 604,363</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Reserved for vesting of outstanding restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Reserved for future ESPP issuances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 435,252</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,291,927</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076950682288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">(7)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">STOCK-BASED COMPENSATION</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Stock Option Plan</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s 2021 Stock Option and Incentive Plan (the &#8220;2021 Plan&#8221;) was adopted by the Company&#8217;s board of directors and approved by the Company&#8217;s stockholders in June&#160;2021 and became effective as of June&#160;29, 2021. Upon the effectiveness of the 2021 Plan, the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) was terminated and no further grants may be made thereunder. The Company&#8217;s 2021 Plan allows for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, stock bonuses, restricted stock, stock units and other forms of awards including cash awards to its officers, directors, employees, consultants and advisors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30,&#160;2024, a total of 5,675,841 shares of the Company&#8217;s common stock were authorized for issuance with respect to awards granted under the 2021 Plan, of which 2,982,105 shares remain available for issuance. The share limit will automatically increase on the first trading day in January&#160;of each&#160;year (commencing with 2022) by an amount equal to the lesser of (1)&#160;4% of the total number of outstanding shares of the Company&#8217;s common stock on the last trading day in December&#160;in the prior&#160;year, or (2)&#160;such lesser number as determined by the Company&#8217;s board of directors. Since adoption, the number of shares available under the 2021 Plan pursuant to the annual increases totaled 3,075,841 shares through January 1, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any shares subject to awards granted under the 2021 Plan or the 2018 Plan that are not paid, delivered or exercised before they expire or are canceled or terminated, or otherwise fail to vest, as well as shares used to pay the purchase or exercise price of such awards or related tax withholding obligations, will become available for new award grants under the 2021 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30,&#160;2024, 2,753,788 and 960,316 options had been granted under the 2021 Plan and 2018 Plan, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The options that are granted under the 2021 Plan and the 2018 Plan are exercisable at various dates as determined upon grant and terminate within 10&#160;years of the date of grant. The vesting period generally occurs over <span style="-sec-ix-hidden:Hidden_OXhRKVDiBU-X90wrZ-v3BA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to four&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes the option activity under the 2021 Plan and 2018 Plan for the nine months ended September&#160;30,&#160;2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual&#160;Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,230,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,489,191</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (265,482)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cancelled/Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,739,949)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,714,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and exercisable at September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,791,181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant date fair value of stock option grants was $14.92 per share for the nine months ended September&#160;30,&#160;2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30,&#160;2024, there was approximately $9.4 million of total unrecognized stock-based compensation expense related to unvested stock options granted under the 2021 Plan and 2018 Plan, which is expected to be recognized over a weighted-average period of approximately 1.9&#160;years.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) was adopted by the Company&#8217;s board of directors and stockholders in June 2021 and became effective upon the consummation of the IPO. A total of 230,000 shares of the Company&#8217;s common stock was initially available for issuance under the ESPP. The share limit will automatically increase on the first trading day in January of each year (commencing with 2022) by an amount equal to the lesser of (1) 1% of the total number of outstanding shares of the Company&#8217;s common stock on the last trading day in December in the prior year, or (2) such lesser number as determined by the Company&#8217;s board of directors. The number of shares available under the 2021 Plan increased by 247,229 shares effective January 1, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">2023 as determined by the Company&#8217;s board of directors. The ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 15% of their eligible compensation, subject to any plan limitations. The ESPP provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last trading day of the offering period. As of September&#160;30,&#160;2024, 76,011 shares had been issued under the ESPP, and 401,218 shares authorized under the ESPP Plan were available for issuance.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Stock Units</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of September&#160;30,&#160;2024, 31,881 restricted stock units had been awarded under the 2021 Plan. A summary of the status of and changes in unvested restricted stock unit activity under the Company&#8217;s equity award plans for the nine months ended September&#160;30,&#160;2024 was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:59.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average&#160;Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date&#160;Fair&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per&#160;Unit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,492)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,476)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units as of September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation of restricted stock units is based on the fair value of the Company&#8217;s common stock on the date of grant and recognized over the vesting period. The vesting period generally occurs over <span style="-sec-ix-hidden:Hidden_Sk9GO9o6hE2czOoGU9-uIA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to four&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30,&#160;2024, the Company had no unrecognized stock-based compensation expense related to its unvested restricted stock units.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(d)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation Expense</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations and comprehensive loss as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 458</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,817</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,987</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,798</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,545</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,237</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,068</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,655</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Stock-based compensation expense by type of award included within the consolidated statements of operations and comprehensive income (loss) was as follows: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,140</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,890</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,369</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock awards and units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 151</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee stock purchase plan awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,237</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,068</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,655</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">(7)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">SHARE-BASED COMPENSATION</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Stock Option Plan</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s 2021 Stock Option and Incentive Plan (the &#8220;2021 Plan&#8221;) was adopted by the Company&#8217;s board of directors and approved by the Company&#8217;s stockholders in June&#160;2021 and became effective as of June&#160;29, 2021. Upon the effectiveness of the 2021 Plan, the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) was terminated and no further grants may be made thereunder. The Company&#8217;s 2021 Plan allows for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, stock bonuses, restricted stock, stock units and other forms of awards including cash awards to its officers, directors, employees, consultants and advisors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, a total of 4,565,333 shares of the Company&#8217;s common stock were authorized for issuance with respect to awards granted under the 2021 Plan. The share limit will automatically increase on the first trading day in January&#160;of each&#160;year (commencing with 2022) by an amount equal to the lesser of (1)&#160;4% of the total number of outstanding shares of the Company&#8217;s common stock on the last trading day in December&#160;in the prior&#160;year, or (2)&#160;such lesser number as determined by the Company&#8217;s board of directors. Since adoption, the annual increases have accumulated to a total of 3,075,841 shares through January 1, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any shares subject to awards granted under the 2021 Plan or the 2018 Plan that are not paid, delivered or exercised before they expire or are canceled or terminated, or otherwise fail to vest, as well as shares used to pay the purchase or exercise price of such awards or related tax withholding obligations, will become available for new award grants under the 2021 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, 3,931,887 options had been granted under the 2021 Plan, with 604,363 shares authorized under the 2021 Plan available for future issuance. As of December 31, 2023, a total of 1,298,457 options had been granted and were outstanding under the 2018 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The options that are granted under the 2021 Plan and the 2018 Plan are exercisable at various dates as determined upon grant and terminate within 10&#160;years of the date of grant. The vesting period generally occurs over <span style="-sec-ix-hidden:Hidden_VYoFbHUwRE-bLITQC63xcQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to four&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the option activity under the 2021 Plan and 2018 Plan for the&#160;year ended December&#160;31, 2023:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual&#160;Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and expected to vest at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,110,219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 82,490</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,546,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (338,987)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cancelled/Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (86,889)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,230,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 49,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and exercisable at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,157,378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11.24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 25,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and expected to vest at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,230,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 49,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant date fair value of stock option grants was $15.69&#160;and $10.48 per share for the years ended December 31,&#160;2023 and December 31, 2022, respectively. All exercisable options are vested and all outstanding options are vested or expected to vest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023 there was approximately $29.1 million of unrecognized stock-based compensation expense related to nonvested stock-based compensation arrangements granted under the 2021 Plan and 2018 Plan, which is expected to be recognized over a weighted-average period of 2.3&#160;years.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Employee Stock Purchase Plan</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) was adopted by the Company&#8217;s board of directors and stockholders in June&#160;2021 and became effective upon the consummation of the IPO. A total of 230,000 shares of the Company&#8217;s common stock is initially available for issuance under the ESPP. The share limit will automatically increase on the first trading day in January&#160;of each&#160;year (commencing with 2022) by an amount equal to the lesser of (1)&#160;1% of the total number of outstanding shares of the Company&#8217;s common stock on the last trading day in December&#160;in the prior&#160;year, or (2)&#160;such lesser number as determined by the Company&#8217;s board of directors. The number of shares available under the 2021 Plan increased by 247,229 shares effective January 1, 2023 as determined by the Company&#8217;s board of directors. The ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 15% of their eligible compensation, subject to any plan limitations. The ESPP provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last trading day of the offering period. As of December&#160;31, 2023, 41,977 shares had been issued under the ESPP, and 435,252 shares authorized under the ESPP Plan were available for issuance.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Restricted Stock Units</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, 31,881 restricted stock units had been awarded under the 2021 Plan. A summary of the status of and changes in unvested restricted stock unit activity under the Company&#8217;s equity award plans for the year ended December 31, 2023, was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:65.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average&#160;Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date&#160;Fair&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per&#160;Unit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,881</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,913)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation of restricted stock units is based on the fair value of the Company&#8217;s common stock on the date of grant and recognized over the vesting period. The vesting period generally occurs over <span style="-sec-ix-hidden:Hidden_eUKRKJ4iNkSfQy8r2Vg3Mg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to four years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31,&#160;2023, the Company had unrecognized stock-based compensation expense related to its unvested restricted stock units of $0.9 million, which is expected to be recognized over the remaining weighted-average vesting period of&#160;2.4&#160;years. </p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(d)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Stock-Based Compensation Expense</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company estimated the fair value of stock options using the Black-Scholes valuation model. The Company accounts for any forfeitures of options when they occur. Previously recognized compensation expense for an award is reversed in the period that the award is forfeited. The fair value of stock options was estimated using the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:26.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.3 - 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.5 - 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">73.9 - 91.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">73.5 - 76.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.5 - 4.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.6 - 4.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Expected dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense recognized for stock option grants has been reported in the statements of operations and comprehensive loss as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,621</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,129</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,285</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense by type of award included within the consolidated statements of operations and comprehensive (loss) income was as follows: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:11.7pt;"><td style="vertical-align:bottom;width:61.03%;margin:0pt;padding:0pt;"><div style="height:11.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:11.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></div></div></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:11.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:11.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.5pt;"><td style="vertical-align:bottom;width:61.03%;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:61.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,494</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Employee stock purchase plan awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 211</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock awards and units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 201</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 33.1pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076943316848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENT</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">(8)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">SUBSEQUENT EVENT</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 30, 2024, the Company formed wholly-owned subsidiaries, Merger Sub I, a Delaware shell corporation, and Merger Sub II, a Delaware limited liability company, each formed solely for the purpose of merging with Jade in connection with the proposed Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June 2024, the Company announced a corporate restructuring, and in July 2024, announced that it initiated a process to evaluate strategic alternatives. After a comprehensive review of strategic alternatives, including identifying and reviewing potential candidates for a strategic transaction, on October 30, 2024, the Company entered into the Merger Agreement, by and among the Company, Merger Sub I, Merger Sub II, and Jade, pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, among other things, Merger Sub I will merge with and into Jade, with Jade surviving the first merger as the surviving corporation, and as part of the same overall transaction, Jade will merge with and into Merger Sub II, with Merger Sub II continuing as a wholly owned subsidiary of the Company and the surviving corporation of the second merger. In addition, in connection with the Closing, the Company expects to declare the Cash Dividend to its pre-Merger stockholders of approximately $65.0 million in the aggregate, provided such amount is subject to adjustment as set forth in the Merger Agreement. The Merger was approved by the Board, and the Board resolved to recommend approval of the Merger Agreement to the Company&#8217;s stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger is expected to close in the first half of 2025. The Closing is subject to approval by the stockholders of the Company and Jade as well as other customary closing conditions, including the effectiveness of a registration statement filed with the SEC in connection with the Merger and the approval of The Nasdaq Stock Market LLC of the listing of shares of the Company&#8217;s common stock to be issued in connection with the Merger and (4) an executed Purchase Agreement for the Concurrent Investment (each as defined below) in full force and effect evidencing cash proceeds of not less than $80.0 million to be received by the combined company immediately prior to or following the Closing. If the Company is unable to satisfy certain closing conditions or if other mutual closing conditions are not satisfied, Jade will not be obligated to complete the Merger. The Merger Agreement contains certain termination rights of each of the Company and Jade. Upon termination of the Merger Agreement under specified circumstances, the Company may be required to pay Jade a termination fee of $2,340,000, and in certain other circumstances, Jade may be required to pay the Company a termination fee of $5,250,000. If the Merger is completed, the business of Jade will continue as the business of the combined company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger (the &#8220;Effective Time&#8221;), (a) each then-outstanding share of Jade&#8217;s common stock, par value $0.0001 per share, will be converted into the right to receive a number of shares of the Company&#8217;s common stock, based on a ratio calculated in accordance with the Merger Agreement (the &#8220;Exchange Ratio&#8221;), provided that any unvested restricted shares of Jade common stock will be subject to the same terms and conditions (including, without limitation, vesting and repurchase provisions) that are otherwise applicable to such unvested shares as of immediately prior to the Effective Time, (b) each then-outstanding share of Jade&#8217;s preferred stock, par value $0.0001 per share, will be converted into the right to receive a number of shares of the Company&#8217;s newly authorized convertible preferred stock, par value $0.0001 per share, equal to (x) the Exchange Ratio divided by (y) 1,000, (c) each then-outstanding option to purchase Jade common stock will be assumed by the Company, subject to adjustment as set forth in the Merger Agreement and (d) each then-outstanding warrant to purchase shares of Jade common stock or Jade preferred stock will be assumed by the Company, subject to adjust as set forth in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 30, 2024, Jade entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain existing Jade stockholders and new investors (the &#8220;Investors&#8221;). Pursuant to the Purchase Agreement, and subject to the terms and conditions thereof, Jade agreed to sell, and the Investors agreed to purchase, immediately prior to the consummation of the Merger, shares of Jade common stock and pre-funded warrants (together, the &#8220;Securities&#8221;) for an aggregate purchase price of approximately $300.0 million (collectively, the &#8220;Concurrent Investment&#8221;), which reflects the conversion of the previously issued $95 million of convertible notes. The consummation of the transactions contemplated by such agreements is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement and in the Purchase Agreement. Shares of Jade Common Stock and pre-funded warrants issued pursuant to this financing transaction will be converted into shares of common stock of the Company and pre-funded warrants to acquire shares of common stock of the Company, in accordance with the Exchange Ratio and the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that the Company does not complete the transaction with Jade, the Company may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of the Company.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076944101264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements as of September&#160;30,&#160;2024 and for the three and nine months ended September&#160;30,&#160;2024 and 2023 have been prepared in conformity with generally accepted accounting principles (&#8220;GAAP&#8221;) in the United States of America for interim financial information and pursuant to Article&#160;10 of Regulation S-X of the Securities Act of 1933, as amended (the Securities Act). Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include only normal and recurring adjustments that the Company believes are necessary to fairly state the Company&#8217;s financial position and the results of its operations and cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The results for the three and nine months ended September&#160;30,&#160;2024 are not necessarily indicative of the results expected for the full fiscal&#160;year or any subsequent interim period. The condensed consolidated balance sheet as of December&#160;31,&#160;2023 has been derived from the audited financial statements at that date but does not include all disclosures required by GAAP for complete financial statements. Because all of the disclosures required by GAAP for complete financial statements are not included herein, these unaudited condensed consolidated financial statements and the notes accompanying them should be read in conjunction with the Company&#8217;s audited financial statements for the&#160;year ended December&#160;31,&#160;2023. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Basis of Presentation</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include the Company&#8217;s wholly owned subsidiary, Aerovate Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the Company&#8217;s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. Accounting estimates and management judgements reflected in the consolidated financial statements include: normal recurring accruals, including the accrual for research and development expenses, stock-based compensation, fair value of investments, and operating lease right-of-use assets and lease liabilities. Estimates and assumptions are reviewed quarterly. Any revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</p><span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Use of Estimates</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The preparation of the Company&#8217;s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. Accounting estimates and management judgements reflected in the consolidated financial statements include: normal recurring accruals, including the accrual for research and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">development expenses, stock-based compensation, fair value of investments, and operating lease right-of-use assets and lease liabilities. Estimates and assumptions are reviewed quarterly. Any revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Net Loss Per Share</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company&#8217;s potentially dilutive securities have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes the Company&#8217;s net loss per share (in thousands, except share and per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,237)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,563)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (64,198)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (55,108)</p></td></tr><tr><td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,237)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,563)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (64,198)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (55,108)</p></td></tr><tr><td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Weighted-average common stock outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,863,327</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,640,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,572,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,872,118</p></td></tr><tr><td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.56)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.71)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.25)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.13)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:61.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,714,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,236,832</p></td></tr><tr><td style="vertical-align:top;width:61.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,754</p></td></tr><tr><td style="vertical-align:bottom;width:61.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,714,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,262,586</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(q)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Net Loss Per Share</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company&#8217;s potentially dilutive securities, which include convertible preferred stock prior to the conversion of such shares to common stock and outstanding stock options under the Company&#8217;s equity incentive plan, have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The following table summarizes the Company&#8217;s net loss per share:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75,521)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,511)</p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75,521)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,511)</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Weighted-average common stock outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,331,630</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,472,104</p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.87)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.10)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:61.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,230,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,110,219</p></td></tr><tr><td style="vertical-align:top;width:61.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,881</p></td></tr><tr><td style="vertical-align:bottom;width:61.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,252,312</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,139,100</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued and Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(d)</span></span><span style="font-style:italic;font-weight:bold;">Recently Issued and Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In November 2023, the FASB issued ASU 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280)</i>: Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments&#8217; significant expenses on an interim and annual basis. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Entities must adopt the changes to the segment reporting guidance on a retrospective basis, and early adoption is permitted. The Company does not anticipate this ASU to materially impact our consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In December 2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740)</i>: Improvements to Income Tax Disclosures, which expands disclosures in an entity&#8217;s income tax rate reconciliation table and regarding cash taxes paid both in the U.S. and foreign jurisdictions. The standard is effective for fiscal years beginning after December 15, 2024, and interim periods in fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact the adoption of this standard may have on its consolidated financial statements and related disclosures, and does not anticipate this ASU to materially impact our consolidated financial statements and related disclosures.</p><span></span>
</td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">(r)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;">Recently Issued Accounting Pronouncements</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In December 2023, the FASB issued ASU No. 2023-09, "Improvements to Income Tax Disclosures." ASU 2023-09 requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024 and for private businesses for annual periods beginning after December 15, 2025, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its financial statement disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In June 2022, the FASB issued ASU No. 2022-03, Fair Value Measurement (Topic 820) - Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard will be effective for the Company on January 1, 2024, and is not expected to have an impact on the Company&#8217;s financial position or results of operations upon adoption.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076944556976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">SCHEDULE OF NET LOSS PER SHARE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes the Company&#8217;s net loss per share (in thousands, except share and per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,237)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,563)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (64,198)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (55,108)</p></td></tr><tr><td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,237)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,563)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (64,198)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (55,108)</p></td></tr><tr><td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Weighted-average common stock outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,863,327</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,640,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,572,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,872,118</p></td></tr><tr><td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.56)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.71)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.25)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.13)</p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The following table summarizes the Company&#8217;s net loss per share:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75,521)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,511)</p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75,521)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,511)</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Weighted-average common stock outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,331,630</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,472,104</p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.87)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.10)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:61.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,714,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,236,832</p></td></tr><tr><td style="vertical-align:top;width:61.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,754</p></td></tr><tr><td style="vertical-align:bottom;width:61.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,714,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,262,586</p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:61.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,230,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,110,219</p></td></tr><tr><td style="vertical-align:top;width:61.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,881</p></td></tr><tr><td style="vertical-align:bottom;width:61.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,252,312</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,139,100</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076944138960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">SCHEDULE OF FAIR VALUE INSTRUMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following tables summarize the Company&#8217;s financial assets measured at fair value on a recurring basis and their respective input levels based on the fair value hierarchy (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for&#160;Identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level&#160;3)</b></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,926</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,926</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,537</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total fair value of assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,880</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,343</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,537</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for&#160;Identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level&#160;3)</b></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_NvvtqfTNDUi3pAQbMuV3Iw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_W5lZ48FLCEy_u2gCz_QeZg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_EIT7Ft-M4U2oTXvtr5qvPQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_XpL8HTw1KUeUXBHbhjlt2w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_lN0AgyYwBUGSBPvHUXVvCA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_ATiC6JEvSUm2xAjs-Qle-w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,386</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_FAR9X24s2UOjJM_mFfQemw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,386</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden__tPLOVORX06K05WNcJNPHQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_hGln6qJd7kWjTm5e4HDgWA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_sBbWTO6GDUu9JQZjdyFFlw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,945</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_Ib6YuqwgvUOu1jkJDvoCZQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,945</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_HN51f_bDUkShpzdYGLsCOw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98,948</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_sNomPq10ZESk15LyPnEosQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total fair value of assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 118,735</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,149</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_YNU4YHIeWEuPQ_VjMX_kCQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The following tables summarize the Company&#8217;s financial assets measured at fair value on a recurring basis and their respective input levels based on the fair value hierarchy (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:normal;width:41.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for&#160;Identical</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level&#160;3)</b></p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,255</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,255</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Commercial Paper</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,386</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,386</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,945</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,945</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98,948</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,586</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total fair value of assets</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 118,735</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,149</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,586</p></td><td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:41.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">for&#160;Identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(level&#160;3)</b></p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55,577</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55,577</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Agency Bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 106,823</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 79,982</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total fair value of assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 125,259</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 79,982</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">SCHEDULE OF SHORT TERM INVESTMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following tables summarize the Company&#8217;s short-term investments (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Maturity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 139</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,866</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,926</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,058</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Maturity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,386</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,945</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 98,711</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (23)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 98,948</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following tables summarize the Company&#8217;s short-term investments (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maturity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,386</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,945</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98,711</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98,948</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maturity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,645</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (84)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,577</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1&#160;year&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (267)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;years&#160;or&#160;less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,536</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (133)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 107,289</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (484)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 106,823</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following tables summarize the Company&#8217;s short-term investments with unrealized losses for less than 12 months and 12 months or greater (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:35.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="16" style="vertical-align:bottom;white-space:nowrap;width:62.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">12 months or Greater</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Unrealized</b></p></td></tr><tr style="height:10.35pt;"><td style="vertical-align:bottom;width:35.88%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></div></div></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:35.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:35.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,760</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:35.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 488</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,007</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:35.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,986</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (23)</p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:65.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.56%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.58%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">12 months or Greater</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.03%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Unrealized</b></p></td></tr><tr><td style="vertical-align:bottom;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,760</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 488</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,007</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,986</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:32.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:67.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.01%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.32%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">12 months or Greater</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Unrealized</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:32.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,928</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (84)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,928</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (84)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,971</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,833</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (261)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (267)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:32.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,964</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (133)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,964</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (133)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (223)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,833</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (261)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (484)</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076950568592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>BALANCE SHEET COMPONENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock', window );">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Prepaid expenses and other current assets consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,875</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Prepaid expenses and other current assets consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:62.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,503</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Prepaid research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 478</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Total prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Accrued and other current liabilities consisted of the following (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,704</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,363</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued payroll and other employee benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 292</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total accrued and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,948</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,821</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Accrued and other current liabilities consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued research and development</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,363</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,751</p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued payroll and other employee benefits</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,368</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,691</p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,090</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 380</p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total accrued and other current liabilities</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,821</p></td><td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.09%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:13.12%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,822</p></td><td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076943728640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of September&#160;30,&#160;2024, the future minimum annual lease payments under the operating leases were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:74.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:25.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 12.25pt;"><b style="font-weight:bold;">Total Minimum</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:25.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 12.25pt;"><b style="font-weight:bold;">Lease Payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 242</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total operating lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 558</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less: Amount representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (18)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Present value of net minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the future minimum annual lease payments under the operating leases were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:24.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 12.25pt;"><b style="font-weight:bold;">Total Minimum</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:24.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 12.25pt;"><b style="font-weight:bold;">Lease Payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 466</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 242</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total operating lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 708</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Amount representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Present value of net minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_ScheduleOfComponentsOfOperatingLeasesTableTextBlock', window );">SCHEDULE OF COMPONENTS OF OPERATING LEASES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Company&#8217;s leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the lease commencement date. The components of operating leases as of September&#160;30,&#160;2024 and as of December&#160;31,&#160;2023 were as follows (in thousands except lease term and discount rate):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 459</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average incremental borrowing rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The components of operating leases for the years ended December 31, 2023 and December 31, 2022 were as follows (in thousands except lease term and discount rate):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Operating lease liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 705</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average incremental borrowing rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">SCHEDULE OF SUPPLEMENTAL CASH FLOW</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Supplemental cash flow information related to cash paid for amounts included in the measurement of operating lease liabilities was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:75.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine months </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">ended </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:75.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid included in operating cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 323</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">SCHEDULE OF OPERATING LEASE EXPENSE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Rent expense was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:40.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 343</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:40.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 165</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:40.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total rent expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_ScheduleOfComponentsOfOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_ScheduleOfComponentsOfOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076950670208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock', window );">SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of September&#160;30,&#160;2024, the Company had reserved the following shares of common stock for future issuance:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:72.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common stock options granted and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,714,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:72.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares reserved for issuance under the 2021 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,982,105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:72.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reserved for future ESPP issuances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 401,218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,097,427</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the Company had reserved the following shares of common stock for future issuance:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options granted and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,230,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Shares reserved for issuance under the 2021 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 604,363</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Reserved for vesting of outstanding restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:74.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Reserved for future ESPP issuances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 435,252</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,291,927</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of common stock shares reserved on and as converted basis for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076950573712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF OPTION ACTIVITY UNDER 2021 PLAN AND 2018 PLAN</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual&#160;Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,230,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,489,191</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (265,482)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cancelled/Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,739,949)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,714,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and exercisable at September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,791,181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the option activity under the 2021 Plan and 2018 Plan for the&#160;year ended December&#160;31, 2023:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual&#160;Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and expected to vest at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,110,219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 82,490</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,546,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (338,987)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cancelled/Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (86,889)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,230,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 49,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and exercisable at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,157,378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11.24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 25,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and expected to vest at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,230,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 49,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">SCHEDULE OF UNVESTED RESTRICTED STOCK UNIT ACTIVITY</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:59.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average&#160;Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date&#160;Fair&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per&#160;Unit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,492)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,476)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units as of September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:65.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average&#160;Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date&#160;Fair&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per&#160;Unit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,881</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,913)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:65.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations and comprehensive loss as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 458</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,817</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,987</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,798</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,545</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,237</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,068</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,655</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Stock-based compensation expense by type of award included within the consolidated statements of operations and comprehensive income (loss) was as follows: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,140</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,890</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,369</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock awards and units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 151</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee stock purchase plan awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,237</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,068</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,655</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense recognized for stock option grants has been reported in the statements of operations and comprehensive loss as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:62.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,621</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,129</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,285</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense by type of award included within the consolidated statements of operations and comprehensive (loss) income was as follows: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:11.7pt;"><td style="vertical-align:bottom;width:61.03%;margin:0pt;padding:0pt;"><div style="height:11.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:11.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></div></div></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:11.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:11.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.5pt;"><td style="vertical-align:bottom;width:61.03%;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:61.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,494</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Employee stock purchase plan awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 211</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock awards and units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 201</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 33.1pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076946921120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND NATURE OF OPERATIONS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 30, 2024</div></th>
<th class="th"><div>Apr. 05, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,635<span></span>
</td>
<td class="nump">$ 44,888<span></span>
</td>
<td class="nump">$ 44,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividend</a></td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=avte_BofaSecuritiesInc.Member', window );">BofA Securities, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate amount of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,462,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,662,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram', window );">Value of remaining common stock available for sale under ATM Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the value of the common stock remaining which can be sold from time to time under the ATM ("At-the-Market") Program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=avte_BofaSecuritiesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=avte_BofaSecuritiesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076850234240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF NET LOSS PER SHARE (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (16,237)<span></span>
</td>
<td class="num">$ (24,775)<span></span>
</td>
<td class="num">$ (23,186)<span></span>
</td>
<td class="num">$ (19,563)<span></span>
</td>
<td class="num">$ (19,025)<span></span>
</td>
<td class="num">$ (16,520)<span></span>
</td>
<td class="num">$ (64,198)<span></span>
</td>
<td class="num">$ (55,108)<span></span>
</td>
<td class="num">$ (75,521)<span></span>
</td>
<td class="num">$ (51,511)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (16,237)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (19,563)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (64,198)<span></span>
</td>
<td class="num">$ (55,108)<span></span>
</td>
<td class="num">$ (75,521)<span></span>
</td>
<td class="num">$ (51,511)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common stock outstanding, basic</a></td>
<td class="nump">28,863,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,640,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,572,338<span></span>
</td>
<td class="nump">25,872,118<span></span>
</td>
<td class="nump">26,331,630<span></span>
</td>
<td class="nump">24,472,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common stock outstanding, diluted</a></td>
<td class="nump">28,863,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,640,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,572,338<span></span>
</td>
<td class="nump">25,872,118<span></span>
</td>
<td class="nump">26,331,630<span></span>
</td>
<td class="nump">24,472,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.25)<span></span>
</td>
<td class="num">$ (2.13)<span></span>
</td>
<td class="num">$ (2.87)<span></span>
</td>
<td class="num">$ (2.10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.25)<span></span>
</td>
<td class="num">$ (2.13)<span></span>
</td>
<td class="num">$ (2.87)<span></span>
</td>
<td class="num">$ (2.10)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076944273344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">3,714,104<span></span>
</td>
<td class="nump">5,262,586<span></span>
</td>
<td class="nump">5,252,312<span></span>
</td>
<td class="nump">4,139,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">3,714,104<span></span>
</td>
<td class="nump">5,236,832<span></span>
</td>
<td class="nump">5,230,344<span></span>
</td>
<td class="nump">4,110,219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,754<span></span>
</td>
<td class="nump">21,968<span></span>
</td>
<td class="nump">28,881<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076947424544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF FAIR VALUE INSTRUMENTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">$ 57,615<span></span>
</td>
<td class="nump">$ 98,948<span></span>
</td>
<td class="nump">$ 106,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="nump">28,265<span></span>
</td>
<td class="nump">19,787<span></span>
</td>
<td class="nump">18,436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">57,615<span></span>
</td>
<td class="nump">98,948<span></span>
</td>
<td class="nump">106,823<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="nump">85,880<span></span>
</td>
<td class="nump">118,735<span></span>
</td>
<td class="nump">125,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="nump">28,265<span></span>
</td>
<td class="nump">19,787<span></span>
</td>
<td class="nump">18,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">9,078<span></span>
</td>
<td class="nump">10,362<span></span>
</td>
<td class="nump">26,841<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="nump">37,343<span></span>
</td>
<td class="nump">30,149<span></span>
</td>
<td class="nump">45,277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">48,537<span></span>
</td>
<td class="nump">88,586<span></span>
</td>
<td class="nump">79,982<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="nump">48,537<span></span>
</td>
<td class="nump">88,586<span></span>
</td>
<td class="nump">79,982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="nump">28,265<span></span>
</td>
<td class="nump">19,787<span></span>
</td>
<td class="nump">18,436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Recurring | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="nump">28,265<span></span>
</td>
<td class="nump">19,787<span></span>
</td>
<td class="nump">18,436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Recurring | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Recurring | Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency bond | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">27,168<span></span>
</td>
<td class="nump">42,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency bond | Fair Value, Recurring | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency bond | Fair Value, Recurring | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">27,168<span></span>
</td>
<td class="nump">42,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency bond | Fair Value, Recurring | Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency bond | Commercial paper | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,255<span></span>
</td>
<td class="nump">24,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency bond | Commercial paper | Fair Value, Recurring | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,255<span></span>
</td>
<td class="nump">24,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">11,926<span></span>
</td>
<td class="nump">7,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Fair Value, Recurring | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Fair Value, Recurring | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">11,926<span></span>
</td>
<td class="nump">7,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Fair Value, Recurring | Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">9,443<span></span>
</td>
<td class="nump">38,386<span></span>
</td>
<td class="nump">55,577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">9,443<span></span>
</td>
<td class="nump">38,386<span></span>
</td>
<td class="nump">55,577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring | Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury bills | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">9,078<span></span>
</td>
<td class="nump">10,362<span></span>
</td>
<td class="nump">26,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury bills | Fair Value, Recurring | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">$ 9,078<span></span>
</td>
<td class="nump">10,362<span></span>
</td>
<td class="nump">$ 26,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury bills | Fair Value, Recurring | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury bills | Fair Value, Recurring | Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076947241520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT TERM INVESTMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Amortized cost</a></td>
<td class="nump">$ 57,391<span></span>
</td>
<td class="nump">$ 98,711<span></span>
</td>
<td class="nump">$ 107,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="num">(484)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">57,615<span></span>
</td>
<td class="nump">98,948<span></span>
</td>
<td class="nump">106,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent', window );">Accrued interest receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent', window );">Accrued interest receivable</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList', window );">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Short-term investments<span></span>
</td>
<td class="text">Short-term investments<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList', window );">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other long-term assets<span></span>
</td>
<td class="text">Other long-term assets<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Amortized cost</a></td>
<td class="nump">$ 27,029<span></span>
</td>
<td class="nump">$ 42,090<span></span>
</td>
<td class="nump">$ 24,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(133)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">27,168<span></span>
</td>
<td class="nump">42,255<span></span>
</td>
<td class="nump">24,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Amortized cost</a></td>
<td class="nump">9,438<span></span>
</td>
<td class="nump">38,362<span></span>
</td>
<td class="nump">55,645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">9,443<span></span>
</td>
<td class="nump">38,386<span></span>
</td>
<td class="nump">55,577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Amortized cost</a></td>
<td class="nump">9,058<span></span>
</td>
<td class="nump">10,334<span></span>
</td>
<td class="nump">27,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(267)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">9,078<span></span>
</td>
<td class="nump">10,362<span></span>
</td>
<td class="nump">$ 26,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Amortized cost</a></td>
<td class="nump">11,866<span></span>
</td>
<td class="nump">7,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">$ 11,926<span></span>
</td>
<td class="nump">$ 7,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Agency bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_DebtSecuritiesAvailableForSaleMaturityTerm', window );">Maturity term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_DebtSecuritiesAvailableForSaleMaturityTerm', window );">Maturity term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | U.S. Treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_DebtSecuritiesAvailableForSaleMaturityTerm', window );">Maturity term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_DebtSecuritiesAvailableForSaleMaturityTerm', window );">Maturity term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_DebtSecuritiesAvailableForSaleMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity term for debt securities classified as available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_DebtSecuritiesAvailableForSaleMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes accrued interest, after allowance for credit loss, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes accrued interest, after allowance for credit loss, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076947469264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Short-term investments, Less than 12 months, Fair Value</a></td>
<td class="nump">$ 13,400<span></span>
</td>
<td class="nump">$ 59,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Short-term investments, Less than 12 months, Unrealized Losses</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(223)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Short-term investments, 12 months or Greater, Fair Value</a></td>
<td class="nump">7,586<span></span>
</td>
<td class="nump">24,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Short-term investments, 12 months or Greater, Unrealized Losses</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(261)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Short-term investments, Total Fair Value</a></td>
<td class="nump">20,986<span></span>
</td>
<td class="nump">84,696<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Short-term investments, Total Unrealized Losses</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(484)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Short-term investments, Less than 12 months, Fair Value</a></td>
<td class="nump">6,042<span></span>
</td>
<td class="nump">34,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Short-term investments, Less than 12 months, Unrealized Losses</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Short-term investments, Total Fair Value</a></td>
<td class="nump">6,042<span></span>
</td>
<td class="nump">34,928<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Short-term investments, Total Unrealized Losses</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Short-term investments, Less than 12 months, Fair Value</a></td>
<td class="nump">3,760<span></span>
</td>
<td class="nump">22,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Short-term investments, Less than 12 months, Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(133)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Short-term investments, 12 months or Greater, Fair Value</a></td>
<td class="nump">6,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Short-term investments, 12 months or Greater, Unrealized Losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Short-term investments, Total Fair Value</a></td>
<td class="nump">10,339<span></span>
</td>
<td class="nump">22,964<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Short-term investments, Total Unrealized Losses</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(133)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Short-term investments, Less than 12 months, Fair Value</a></td>
<td class="nump">488<span></span>
</td>
<td class="nump">1,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Short-term investments, Less than 12 months, Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Short-term investments, 12 months or Greater, Fair Value</a></td>
<td class="nump">1,007<span></span>
</td>
<td class="nump">24,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Short-term investments, 12 months or Greater, Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(261)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Short-term investments, Total Fair Value</a></td>
<td class="nump">1,495<span></span>
</td>
<td class="nump">26,804<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Short-term investments, Total Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">$ (267)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Short-term investments, Less than 12 months, Fair Value</a></td>
<td class="nump">3,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Short-term investments, Less than 12 months, Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Short-term investments, Total Fair Value</a></td>
<td class="nump">3,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Short-term investments, Total Unrealized Losses</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076944091824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>BALANCE SHEET COMPONENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 993<span></span>
</td>
<td class="nump">$ 1,168<span></span>
</td>
<td class="nump">$ 1,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other current assets</a></td>
<td class="nump">882<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_PrepaidResearchAndDevelopment', window );">Prepaid research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="nump">478<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 1,875<span></span>
</td>
<td class="nump">$ 1,793<span></span>
</td>
<td class="nump">$ 2,276<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_PrepaidResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_PrepaidResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076944000288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES - (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>BALANCE SHEET COMPONENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_AccruedResearchAndDevelopmentCurrent', window );">Accrued research and development</a></td>
<td class="nump">$ 4,704<span></span>
</td>
<td class="nump">$ 9,363<span></span>
</td>
<td class="nump">$ 2,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and other employee benefits</a></td>
<td class="nump">3,952<span></span>
</td>
<td class="nump">4,368<span></span>
</td>
<td class="nump">1,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">292<span></span>
</td>
<td class="nump">1,090<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Total accrued and other current liabilities</a></td>
<td class="nump">$ 8,948<span></span>
</td>
<td class="nump">$ 14,821<span></span>
</td>
<td class="nump">$ 4,822<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076945198528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - WORKFORCE REDUCTION PLAN (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>individual</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>BALANCE SHEET COMPONENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate', window );">Number of individuals terminated or notified of their upcoming termination | individual</a></td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent', window );">Percentage of number of individuals terminated or notified of their upcoming termination</a></td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Incurred costs</a></td>
<td class="nump">$ 6.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Severance benefits</a></td>
<td class="nump">2.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1', window );">Liabilities associated with the Workforce Reduction Plan</a></td>
<td class="nump">$ 4.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected cost remaining for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated as of the balance sheet date since inception of the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the total number of positions eliminated as of the balance sheet date since inception of the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076947128864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Total operating lease expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=avte_WalthamLeaseMember', window );">Waltham Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">39 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lease, option to extend</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_IncreaseRentalAmount', window );">Increase of rental value for square foot | $ / shares</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payment for rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_LeaseIncreaseInRentPercentage', window );">Lease rent percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=avte_FosterCityLeaseMember', window );">Foster City Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">39 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payment for rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_LeaseIncreaseInRentPercentage', window );">Lease rent percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment of right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_IncreaseRentalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in rent square foot value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_IncreaseRentalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_LeaseIncreaseInRentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease increase in rent percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_LeaseIncreaseInRentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=avte_WalthamLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=avte_WalthamLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=avte_FosterCityLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=avte_FosterCityLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076952482512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2024</a></td>
<td class="nump">$ 316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">$ 466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">558<span></span>
</td>
<td class="nump">708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Amount representing interest</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of net minimum lease payments</a></td>
<td class="nump">540<span></span>
</td>
<td class="nump">675<span></span>
</td>
<td class="nump">$ 1,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current</a></td>
<td class="nump">459<span></span>
</td>
<td class="nump">420<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="nump">705<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of net minimum lease payments</a></td>
<td class="nump">$ 540<span></span>
</td>
<td class="nump">$ 675<span></span>
</td>
<td class="nump">$ 1,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average incremental borrowing rate</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076944502256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - SCHEDULE OF SUPPLEMENTAL CASH FLOW (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid included in operating cash flows</a></td>
<td class="nump">$ 380<span></span>
</td>
<td class="nump">$ 323<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076950546960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - SCHEDULE OF RENT EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease</a></td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
<td class="nump">$ 343<span></span>
</td>
<td class="nump">$ 332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total rent expense</a></td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
<td class="nump">$ 508<span></span>
</td>
<td class="nump">$ 332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076947305264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 03, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_CapitalStockSharesAuthorized', window );">Capital stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,052,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,052,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock shares issued</a></td>
<td class="nump">14,182,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_NumberOfVotesForEachShareOfCommonStock', window );">Number of votes for each share of common stock | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">9,984,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=avte_RaCapitalHealthcareFundL.pMember', window );">RA Capital Healthcare Fund, L.P</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=avte_SeriesSeedRedeemableConvertiblePreferredStockMember', window );">Series Seed Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=avte_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,052,154<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_CapitalStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital stock shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_CapitalStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_NumberOfVotesForEachShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to number of votes for each share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_NumberOfVotesForEachShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=avte_RaCapitalHealthcareFundL.pMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=avte_RaCapitalHealthcareFundL.pMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=avte_SeriesSeedRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=avte_SeriesSeedRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=avte_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=avte_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076944989552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE (Details) - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">7,097,427<span></span>
</td>
<td class="nump">6,291,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">3,714,104<span></span>
</td>
<td class="nump">5,230,344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">2,982,105<span></span>
</td>
<td class="nump">604,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,968<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Employee stock purchase plan awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">401,218<span></span>
</td>
<td class="nump">435,252<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076944787584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">30 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Stock option grants per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.92<span></span>
</td>
<td class="nump">$ 15.69<span></span>
</td>
<td class="nump">$ 10.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avte_TwentyTwentyOneStockOptionAndIncentivePlanMember', window );">2021 Stock Option and Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,982,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage on total number of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,675,841<span></span>
</td>
<td class="nump">4,565,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,565,333<span></span>
</td>
<td class="nump">3,075,841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock available for issuance, awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,075,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2021 Stock Option and Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">604,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">604,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock available for issuance, awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,753,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock available for issuance, awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">960,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2021 Plan and 2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Minimum | 2021 Plan and 2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vested term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Maximum | 2021 Plan and 2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vested term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units | 2021 Stock Option and Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,881<span></span>
</td>
<td class="nump">31,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vested term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vested term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Employee stock purchase plan awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage on total number of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000<span></span>
</td>
<td class="nump">401,218<span></span>
</td>
<td class="nump">435,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="nump">247,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of common stock purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">Offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate', window );">Discount percentage on marker price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,011<span></span>
</td>
<td class="nump">41,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Duration of offering period for share-based compensation arrangement by share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on offering date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avte_TwentyTwentyOneStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avte_TwentyTwentyOneStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avte_TwentyEighteenStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avte_TwentyEighteenStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076941132992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - SCHEDULE OF OPTION ACTIVITY UNDER 2021 PLAN AND 2018 PLAN (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, beginning balance</a></td>
<td class="nump">5,230,344<span></span>
</td>
<td class="nump">4,110,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Outstanding, beginning balance</a></td>
<td class="nump">$ 13.66<span></span>
</td>
<td class="nump">$ 9.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">4 years 11 months 23 days<span></span>
</td>
<td class="text">8 years 1 month 28 days<span></span>
</td>
<td class="text">8 years 5 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, beginning balance</a></td>
<td class="nump">$ 49,728<span></span>
</td>
<td class="nump">$ 82,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="nump">1,489,191<span></span>
</td>
<td class="nump">1,546,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Granted</a></td>
<td class="nump">$ 19.70<span></span>
</td>
<td class="nump">$ 22.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Exercised</a></td>
<td class="num">(265,482)<span></span>
</td>
<td class="num">(338,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Exercised</a></td>
<td class="nump">$ 4.67<span></span>
</td>
<td class="nump">$ 2.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options, Cancelled/Forfeited</a></td>
<td class="num">(2,739,949)<span></span>
</td>
<td class="num">(86,889)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Cancelled/Forfeited</a></td>
<td class="nump">$ 18.84<span></span>
</td>
<td class="nump">$ 9.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, ending balance</a></td>
<td class="nump">3,714,104<span></span>
</td>
<td class="nump">5,230,344<span></span>
</td>
<td class="nump">4,110,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Outstanding, ending balance</a></td>
<td class="nump">$ 12.91<span></span>
</td>
<td class="nump">$ 13.66<span></span>
</td>
<td class="nump">$ 9.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, ending balance</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 49,728<span></span>
</td>
<td class="nump">$ 82,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options, Vested and exercisable</a></td>
<td class="nump">2,791,181<span></span>
</td>
<td class="nump">2,157,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Vested and exercisable</a></td>
<td class="nump">$ 12.06<span></span>
</td>
<td class="nump">$ 11.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Vested and exercisable</a></td>
<td class="text">3 years 11 months 12 days<span></span>
</td>
<td class="text">7 years 9 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and exercisable</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 25,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,230,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 1 month 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076947164576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - SCHEDULE OF UNVESTED RESTRICTED STOCK UNIT ACTIVITY (Details) - Unvested restricted stock units - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of units, beginning</a></td>
<td class="nump">21,968<span></span>
</td>
<td class="nump">28,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date fair value, beginning</a></td>
<td class="nump">$ 22.26<span></span>
</td>
<td class="nump">$ 21.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of units, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date fair value, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of units, Vested</a></td>
<td class="num">(5,492)<span></span>
</td>
<td class="num">(9,913)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date fair value, Vested</a></td>
<td class="nump">$ 21.30<span></span>
</td>
<td class="nump">$ 21.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of units, forfeited</a></td>
<td class="num">(16,476)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date fair value, Forfeited</a></td>
<td class="nump">$ 22.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of units, Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date fair value, Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076952031968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,003<span></span>
</td>
<td class="nump">$ 3,237<span></span>
</td>
<td class="nump">$ 10,068<span></span>
</td>
<td class="nump">$ 8,655<span></span>
</td>
<td class="nump">$ 11,906<span></span>
</td>
<td class="nump">$ 5,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">458<span></span>
</td>
<td class="nump">1,817<span></span>
</td>
<td class="nump">4,987<span></span>
</td>
<td class="nump">4,798<span></span>
</td>
<td class="nump">6,621<span></span>
</td>
<td class="nump">2,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,545<span></span>
</td>
<td class="nump">$ 1,420<span></span>
</td>
<td class="nump">$ 5,081<span></span>
</td>
<td class="nump">$ 3,857<span></span>
</td>
<td class="nump">$ 5,285<span></span>
</td>
<td class="nump">$ 3,347<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076944869232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY TYPE OF AWARDS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,003<span></span>
</td>
<td class="nump">$ 3,237<span></span>
</td>
<td class="nump">$ 10,068<span></span>
</td>
<td class="nump">$ 8,655<span></span>
</td>
<td class="nump">$ 11,906<span></span>
</td>
<td class="nump">$ 5,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,014<span></span>
</td>
<td class="nump">3,140<span></span>
</td>
<td class="nump">9,890<span></span>
</td>
<td class="nump">8,369<span></span>
</td>
<td class="nump">11,494<span></span>
</td>
<td class="nump">5,316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Employee stock purchase plan awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="num">$ (11)<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock awards and units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">$ 116<span></span>
</td>
<td class="nump">$ 151<span></span>
</td>
<td class="nump">$ 201<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46076947369728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Oct. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Aug. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividend</a></td>
<td class="nump">$ 65,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_PurchaseAgreementCashProceedsToBeReceivedUponClosingOfMerger', window );">Cash proceeds to be received upon closing of merger</a></td>
<td class="nump">80,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_MergerAgreementTerminationFeesPayable', window );">Termination fees payable</a></td>
<td class="nump">2,340,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_MergerAgreementTerminationFeesReceivable', window );">Termination fees receivable</a></td>
<td class="nump">$ 5,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_MergerAgreementSharesToBeIssuedDenominatorForCalculation', window );">Shares to be issued in denominator for calculation</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Jade</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avte_MergerAgreementSecuritiesCapitalAmountReservedForFutureIssuance', window );">Aggregate purchase price under merger agreement</a></td>
<td class="nump">$ 300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes</a></td>
<td class="nump">$ 95,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_MergerAgreementSecuritiesCapitalAmountReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents securities issued for aggregate purchase price under merger agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_MergerAgreementSecuritiesCapitalAmountReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_MergerAgreementSharesToBeIssuedDenominatorForCalculation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers shares to be issued in denominator for calculation under merger agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_MergerAgreementSharesToBeIssuedDenominatorForCalculation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_MergerAgreementTerminationFeesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination fees to be paid upon termination of merger agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_MergerAgreementTerminationFeesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_MergerAgreementTerminationFeesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination fees to be received upon termination of merger agreement by other party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_MergerAgreementTerminationFeesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avte_PurchaseAgreementCashProceedsToBeReceivedUponClosingOfMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow to be received for concurrent investment upon closing of merger in purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avte_PurchaseAgreementCashProceedsToBeReceivedUponClosingOfMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avte_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avte_JadeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avte_JadeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>142
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MLQS TMF1?$\D9^\E9RLE]S7-<_*6I:L/V:4)*#>[,?@5I#?E8)?J#1/F 1.
M!(<YIH\)"X )0(H#S"#) 6:0YB!:N^B<O>@<]552L> 9B9-INN+D4YWE/H-7
M2@[FE1(F;( )\S!A0TR8CPD+,&$A)FR$"1LCP4[6EKM?6ZXRH8=)P06UJ)<7
MM*;<9NE '2E!])6C7+I6,&$>$+ZCR;4JYH@^)BQHAF]H5 H_!(R8+E\<-8U,
MUS"E# [M+5V#\S?5#K>Q-:7*=AF\SMQ@XE8#+LW<J+0!*LU#I0U1:3XJ+4"E
MA:BT44T[K5"EM0#9V&[+6CAJZ=!SKMJ.:AIP/5 @/KE\5H]TL<PQ:1XP 6G_
M#E$']%%I ;C_I7(W!(VDK O8B+1KR%(#]I9MTA:ML8/6F%)KC[P@R_*2[3M_
M2S/^44,7T4_X+H$:=W$6QJ0-4&D>*FV(2O-1:0$J+42EC6K::88U#4NN2B [
MDQJ.U;) #OTWJFQ#])ZS=!M77T 1Z^.?EP=J(PZ5-D"E>:BT(2K-1Z4%J+00
ME3:J:2?G#DM>&DT;UG)?F1[:9U3=/_LX;X"+P !.>A:3;XSWU4-<+&_4GADX
M!]>T=+E"06V;H=(": Z605U'+E( .].DFB,7*H"=;9JL415#/&K2MF+ET$"C
MIO(V7S]=B7DORB\$;GDE/_A*$;,5U$>E#5!I'BIMB$KS46D!*BU$I8U0:6,L
MVND:.W0,J;IEJ$SLS8X1G-BM1O_\BAFV+15M ]!.IXYT!O/ <:%D#/"HJS%I
M7!^TLTPF73T'T+A@ @7LP 0*V($)%.(I$NBA-T?M,_HDTS/3*&:WJ8]*&Z#2
M/%3:$)7FH]("5%J(2ANATL98M-.5=FA(4F5/IO<MR7BTC/_+9V0>Q0GY5"ZS
MST1<1N9\NLGB(FZY@'0:2U_7&OD5M>^(2O. "5PQ)B=JU(XB*BV )D#EICA@
MQ!HM<<#(UG0YUP/#&5I+/YP>FG94W;5KELJ@VES@1&BZ>N,V,FKS#I7F@7-P
M3<>4-8?:P4.E!= <RN\E4EEV@)UI./+=L!%D9QL.=63Q03SJ'MF=/CMQ:.<Q
M=3MO?UMY+>J-?!%E_/?RR:EX"JFP9CG'46A?3$L[_B?MBKXZ@$LEB4KSX G9
M<G<#=5 ?E19 4V!?Y$HZA,WD=#F"S1SIO#9NH;6(\=!/8^I^&B3&6;S<%."3
M1O<U[4(YHC;:4&D>/*&F'%&;;:BT )H")$?0K"E'T*PI1YC6(L=#RXVI6VY_
M5H^)\ME5M.59-.<[2>8D?2NOS%9EB5BDTQ\DW11Y$26S.)FKDF>S\<$<Q])U
M)E>-ZK NEBAJLPV:A6T9FFG(I2/JN#XJ+0"/A6DS79?O&$"6IF.+,[Y\SP"R
M%$>76G*1-H8L#4,PC[[+="K90Q.,J9M@_Y=D52D6:$FTB!:U!89*\Z!9M(@6
MM;V%2@O 8P&+%FHDP:(%+%M$"UC"HNT>/22]XMF\>HX_%_K;),7NN:_]UOUO
M!=Q53\A+V^_IM4^![0&]#J'M(WH]WCVL?1AV]X,%#U$VCY.<+/F;"$&<4D4A
MG>U^ V#WIDC7U:/;W].B2%?5RP6/9CPK#<3G;VE:?+PI!]C_$D/O?U!+ P04
M    " !H,X-9I%Q!+J(/  #EGP  &    'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;,5=:W/<MA7]*QPUTR8SV8AX$"!323/VDIBXC6,WDMOI1V9%2SO>A[I+
M26E_?<G56E@ =R\7ZZLX'V+)OC@ >0@"Y^ "/'M<KCZM;YNF37Z?SQ;K\Y/;
MMKW[\?1T/;EMYO7ZA^5=L^C^Y>-R-:_;[M?5S>GZ;M74UYM"\]DI3U-U.J^G
MBY.+L\W?O5]=G"WOV]ETT;Q?)>O[^;Q>_?=U,UL^GI^PD\]_\>OTYK;M_^+T
MXNRNOFDNF_;#W?M5]]OI,\KU=-XLUM/E(EDU'\]/7K$?3:'[ IN(?TZ;Q_7.
MSTE_*;\MEY_Z7]Y<GY^D?8N:63-I>XBZ^^.A&3>S68_4M>,_6]"3YSK[@KL_
M?T8WFXOO+N:W>MV,E[-_3:_;V_.3_"2Y;C[6][/VU^7C3\WV@K(>;[*<K3?_
M3QZ?8K4X22;WZW8YWQ;N6C"?+I[^K'_?WHB= FQ? ;XMP+T"7.\I(+8%A%=
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MF!2ME,"J/>?^32>U!P:J=&FQJE_BJC_&OL:AH@D)9;U(A9^I3%IG18IFAJ[
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MPQZ+Q9)7F;U6J_<BZ/.<Z$4J,^Y?MO)[7^SU6%09J_)P&!+DLO!_^5VP0^O
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M%B2+<A#A;%AAD<"IQ0*4ANB1C:W("*X1<Q)P&*^%(PNCYJ9@D^(YM)4>' P
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MN0G7*]  (SC(-9C;=OOH<0P50>]JUFML.& _/:\C3S+=H0"1A13SIXJD?IL
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M9BLMML$#K[E\0WNULMC!HU43\=KGP^TD!9._WFY H*@\S3<'4,4:;,TFR2G
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MS1AT*$L.D?;GGX91%)Q\H\+.:$9^01JW%IZ\)= _"<USK1XX]!(F%J3?#H(
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MXW9R4X"Z+Q%\;>*V2&Y ,]<WZ\[B<578P?S^'X5902\:P\36!,<'G[F&2K@
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MZS"-!/ <\6)U@QLLORF?_Q]02P,$%     @ :#.#6?'G76X1!0  T!   !D
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MD5%LS0#J7TM*WNK#3%#_$V/Z)U!+ P04    " !H,X-9#1>J.4@.   V2
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M%,9A"9M'$5*60KP.?3"$.Y0N9"N%9+65+\*\ ,)R01(/Q!V=&Y%4D),@(5(
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M\O=&(2EGFP0I02M$/BAD+7LW>8S,8N2?Y!"'F"YAATI$J"!L*EQ:A5LD\M]
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ML3$ET^+JSEKQW2!6J.$1#OHH%HF0X>M(C@"C@5D/FC*&6L=ZGA.6:+%-TI1
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MC6+^!H$6:B?IQ01$Y/@T.0-Q.D\O3Z;)9SH1*G>5@EJH3*8_Q-QS<7;J/[9
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M&(KE,B$8/"X0X'Q#(?+:C;B@^R-D\B=02P,$%     @ :#.#60D5!9;#"
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M^#$*.#\50J<#LT#VAT3C/U!+ P04    " !H,X-9M=D.DV0#  !H"0  &0
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MU+X:] S@S;W>="2K]-6X91(O6MU,\2E$N7) ^XXQ>>RH";K'U?1/4$L#!!0
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M,!&LW<<:]CHL271C?Q2F[ML=0W;%+O;K)XWYFJ$ECR"JD580:HE%:!/^S7)
M%4,\W4<>H7A &[B>,M534%=$$[7+@KID#:(LU2_AB9B\S=K@>_V=I[[S5(>G
MI!#H0D5P= _-7;Q%$+@D-C2"_9KG^3H0FJ=;==KRB&;Y>QK:TY9M.9IAM)V-
M$-UK^U</;9FFI_F>VV:<!DGTTI;G:)[7P5F^[I"VC;^<TG?U?FH_S%KMN8B&
M;5<S7:^U3(QULE^!JW?P&K%!^@!;?AX#_WJC/:&=785V]I-#NYO+V\EL#H'M
M%'ZF%V-95/$N]%S,JY"O*ZCKG^3;D=V.%Y37/%GJ7'+06QIF!TAB]WN3A"*O
M:M=PLK*EUGU?  (B<F =!0=("A<?X?:1@C1'?-D%2:SYC@>G#9Y,]J>_\WQ9
MQZ1[]?7V$HU'$)/XM9B$8-W<TTG-A[&C6:Y3&TATVWOF9CJB@L?+^O%Q2]=]
M_QU/+X8G@H@'Y(PEGG"=CG=X,N$6:8>YQ*J?_@Y+$)IBLX$EW(6E+HC6Z__2
M,_90:GA(#QTZ%1TZ3Z;#MZ.+*;H=O;]1M8((B^QWAD:SV<V'HMQ%A[V3/#?S
M[U_Q2X=E?\IP=](.=UOXD.=1J^QQ-:FN/AEXU2(G6S?1,7)T#"6[++6$[GE$
M11C)&-V%1 &&^1A&_R1K4LAU5&TG-PWSC\?+C#$4 I@EG% FO:T8;.D>C 74
MJ[)9DZOF"R ?"""\;V"T@UY[P.56X'*?#*Y#[TAH\H<L3[I0]1GMTG^.Y;-H
M@!8\3EF24Y7SR% D@4@V8PN^2B C"E1N0Z,(L;\VTM!T2[,@1VMPNSO&Y MO
MRC-I'!7J0BXEP*0Q2X1R2YX"!Q91LHQTY%P96\O'X7N&(IXK]RW2L?Q1M/SM
M\Z7Y6F*E_D;YZ,ZZ!+/V]7?X@5624U6JP G.3;/%6MDI8/<LXJDT8SV@LQN9
MM^9AM]XKX_)&W:UEZK^R!$XB4MII$$,R!61*Y=-Z.Y:%;*$CY]8LTF9^6S,Z
M0EU3\^S]4N9<P,0U'H8[Q*S530ALZPN'3,=H$+>G.79[09_%\-T#$@\IDS!4
MH 6$+J*-/*5M*-8E7!< 31Z% 2VNE2=C%W3Q&'(]B>%7:$OK0/X_0ZXZB/+1
M)&^>,[8:YXPMHU;W-<\W&L=L.OL$=_KXMB^)1Q[%IA'[' H<*HRVLTI<2Y2J
M-KMVP\1IQ!\8*Z=.-^"8 #24JJ>?8B&/Y8\P[GC,:^.V(\G%YG[8U_&6KECA
M9:^(O(8"M)+AXO_6)?&L6*81PSR!N1W-(;AQJ)CLH?X,;K8UTO%>8VJF=9AO
M,03"1OUAP):YVW^,3TLB+6GU:_'IEQ_R(9(#XUJ^U3"N62.7+R$2@MLWJM.
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M:&5E=',O<VAE970R-"YX;6RU6&N/VC@4_2M7V6K52BUY\IA90,J0S!2I/#1
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MA(N*6S5#C$24Y (QOR&$OW6D@>(B9_@O4$L#!!0    ( &@S@UG!M@>UWP(
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MB^ X?T&2GU"RSYYKOQ!*29@=[K#']D\I@'W_2@A]/TD#E&^I^O\"4$L#!!0
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M@A@\S,DR]>-)>MJCK+]9J[UQT;?S==_@EKZYX(;$=)Z"BWB")P+_H=Q?AQ*
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M.N6F#:R+,GF'/DJ8"U!=KD#W5CYRG-8I8C1U32,RBEJL1H;+6EVN:_=52;I
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MT9-CDB[.4@W9K'Y$FP;'Q 67(RZGY&8]FW<STUAINZ5^<%SOORMQ9[(7R_6
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MCD)WY'OS1Q]-[E$P]8/A@X?\WX$_#OT0#<<>FLQ&_A2Y\^E4,- P#'W!N_2
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M5*)1/SMNJ,/A$/,MC014?@,PX[$&S<:3\U8RD&P?GT"63,)Y)K[<P1F5<!4
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MW7Q+]:WI(-YW\!76 G_/XPMDXQ<(V]A!/R(+91LJ6%9_G.NA'GB=WU^@H5,
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M&FE]#2SP$A4)GY'-#2X%J00CDC#U#39EK*&!J&"<I"589)#&V?87_2PW8@\
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M6("$A4@80\(X"*;)T[;4K*!EK")O15K4AD5S+%69)WDT(XO5_%YV_).'ESG
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M%!FR( Q*XRB:+C)E#MAF=Z"QDE/UX+N7:;:7-IK\EYPZ!V<N26NI0AT%*"V
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MTQ8D.,.!Y^_T!Z&V!I3&431=4,K6< ZL2CAQQKGH#Y8SS>;>(=0/@=(HE!9
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MD"?+BX[=(?=)GB?S\L>IB"8B+0Z0OW](DOSE0Y'@.4F_E<4>_0]02P,$%
M  @ :#.#60ZOF0JP!0  <1T  !D   !X;"]W;W)K<VAE971S+W-H965T,S@N
M>&ULM5EK3^,X%/TK5G>TFI&@B9U'$Q8JE::SH!UH18'1?C2M::/)HVN[,//O
MUWDT:1+7A$SA XV=>X_O/7:N3^+SUYC^8&M"./@9!A&[Z*TYWYQI&ENL28A9
M/]Z02-QYCFF(N6C2E<8VE.!EZA0&&M)U6PNQ'_6&YVG?C [/XRT/_(C,*&#;
M,,3TUR4)XM>+'NSM.N[\U9HG'=KP?(-79$[XPV9&14LK4)9^2"+FQQ&@Y/FB
M-X)G'C(3A]3BT2>O;.\:)*D\Q?&/I'&]O.CI240D( N>0&#Q\T+&) @2)!''
M?SEHKQ@S<=R_WJ%_39,7R3QA1L9Q\-U?\O5%S^F!)7G&VX#?Q:]7)$_(2O 6
M<<#2_^ UM]5[8+%E/ YS9Q%!Z$?9+_Z9$['G@.P##BAW0'4'ZX"#D3L8;1W,
MW"&E6LM227GP,,?#<QJ_ II8"[3D(B4S]1;I^U$R[W-.Q5U?^/'A_&IT-SF]
M',TG'AA/;V:3V_GH_GIZ"T[!?'PU\1Z^3<#T*YC.TL[1^/[Z\?K^7_!PZTWN
M -(1!+-O(W'CUA,MZ&2MSQ[AV _8%X'R,/? YT]?P">@ ;;&E##@1^ A\CD[
M$9WB^GX=;QF.ENQ<XR*C)"YMD4=_F46/#D3O@ILXXFL&)M&2+"7^8[4_1 H
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M@I>$)@;B_G,<\UTC&: X91W^#U!+ P04    " !H,X-9#.$9 8H#  #<"P
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ME%:M9#7A9*>ZL17AHK=3PZUHOX%* [&_)H2_3.0!34,?_ ]02P,$%     @
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MF!GFT*?)CS@2JZ[1,E $"[Q)Q)3N;B$7U%!X<YIP_8MV>:QEH/F&"TKR9,F
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MTXACM2QN!9__6/%BP:KZ7\WJ&/%DWJ$ :>B,0=%N0-$FH&A34+0$%"T%1<M
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M'Q4C+=>[:G4F[*C*_UXO7B@<-5-0,>E=Y#C'KD>BF7,\]3. "J/(/T<M;52
MPR \1ZULE!_Z;H<ZDQRTDH-!R;^R0F5?5BFFB2J,J9 Z&X\,$EUSA2=3F+H1
M,33;(-^W)-L@I=B;&I(!%(E/4&>2PU9R."CY$Y=*,+=6'20XM"<P];%K*+91
M!'NAD0M+&Q5&./8,R38JB#W?@R5/6\G30<G5WK(I>?XB6VU!D-RI-?@-I!>
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M!.9Q?FH9IXP;H%[3#5!GNP%X-4+;/BE:08JFJ=!L0HT;H%[1#5##;H ZTPV
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M=]1,@;A1YAJ!4!!G3&1NRP<"<RE.O0#*C861GWT<XYG;M7' T%&)%&V: ]]
MB-U7X:1%ZH$B;5J,\9#_8<8#7E(P7T"R@7MV(VF)!2F:QNMOLV5LA_R+V XY
M8#OPW'O%A%<NN N1N@ZD:)H*S:;9N XY[CJ$+)]QJ.!>YRMU'KN97U/2,@M2
M-#UT!S8EQFS(<;,!6S[CEP930&HXD*(5N>^9C%CJ)8'IX3B;!F,2Y&&)!P%I
M)#E@$<!I)'@=@AD@M0E(T305FLVFL0GRL*\SG)]&L@=&E\] ")1& L3Y:21
M$)Q& @1":23C9E%5[;1LR]OK^_*N^K'<WBV[B7I5?>RNB[_M\WNVR[O%X9>V
MOK^YZE: O]1M6Z]W/RZJ<EYM^X#NWS_6=?OYEW&'_U1O/^W*N/T_4$L#!!0
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M+W=O<FMS:&5E=',O<VAE970U,RYX;6SM6FMOV[8:_BN$-PPIX-BQD[8Y;1+
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MKT; 5GEEVTF/RK^NDA 0.<8; &I9D:@R=_V#G\@)*N[* T(%J*,L:3<DH"&
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MNA'%'$!Z2AL5U$S*D48X/2]69!D630$B>!-D+,BS:!55+G7(4&"(OD"UA\V
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M)<NR4:T!H4;5DK(?"[Q7&&@X/>Y]018,\ U_3Y(=4BV-LW]NO6/V\]#SP.)
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M7=.?V&Z@*QP [Q<6[*/\P W"M_]?_0]02P,$%     @ :#.#68SS<WYS"P
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MK8A#;IA@D-WG^ (\NR6+)(]5KG-;S8@R32_B ;2M/ 78 ):@H&BXM"1G<W7
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M R72/U!5?*ALK7_C:98IE:WTGTM&P23A!!A?9)G:?. &VU\)._D_4$L#!!0
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MC03P'/%B=8,;++\IG_\?4$L#!!0    ( &@S@UGQYUUN$04  - 0   9
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M;,T ZE]+2M[JPTQ0_Q-C^B=02P,$%     @ :#.#69ETAJ)##@  -D@  !D
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MP7E4N?*&UQK9"&CWN,;=$4F:NM&JPM(]9V3)X!&ZHW5MB:*R1.4,R<]!*,O
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MO*K^-(23!3EEZ0Q6)<ZYF^7GV^7]/S[?__Z)W?^)_U<S!ZJT-HMK"K>!PN(
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MK'E *E=5")Y!W:S(3<&595:S<6YEG H6=E#.C9@7J>LX.?H'MN!T$Q$7N;0
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MO^H?G0[^V_^.3B^&P[[PWJ)YJK48SQ=&W/ETSI_SU6&=KG>/SKT(:1B%^2<
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M(0D; /W3.*;K"IN@^++]\']02P,$%     @ :#.#6=TG C/> P   @\  !D
M  !X;"]W;W)K<VAE971S+W-H965T-C0N>&ULW5=MC]HX$/XK5EI5K11M7H&P
M!:0 J19I%Q!A[^ZK20:(FL0YVRR[_[YV@!!(EM(KTNGN"_'8GL?SC!\/FLZ6
MT.]L#<#1:Q*GK*NL.<_N-8T%:T@PNR,9I&)E26B"N3#I2F,9!1SF3DFLF;K>
MU!(<I4JOD\]-::]#-CR.4IA2Q#9)@NE;'V*R[2J&<IB81:LUEQ-:KY/A%?C
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M4Z?S\M2!UJ=0-(E",]G7):J#JE%Y(&L2CT 3)'^@99G\Z;K8P1;&3K.:]>/
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M6E>&5Y9]O)QHD16]<RVTZ<3%,#%/'TH;8/9C(?1A8@FJQS3X!5!+ P04
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M7I"_*_/\_48U4)[A'OT'4$L#!!0    ( &@S@UGO-86_-P0  .L0   9
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M"?FM9)Q/ W#SY19\ 20&LPW=<10O><L44HW*R5QDF3^DF=L7,I_B[3UPK+^
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M3Z[)Y0:C)68J0#Y?42K>;M3Q-?]_H_,_4$L#!!0    ( &@S@UE%=GYP?P(
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MX_J3S)25W4@Y$#0OGMLG*N3C77S&LH$#I@!R?4ZIV Q4@+HE]/X 4$L#!!0
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M+(R8A05 9]"ISV53GTMM?3ZP9,N%>A9'[$L>R6^&UY 6VG<E 0GS(&$^)(Q
MPH++DXO?U:XD'+M]+K9[*L+\DM6C^^H"E.:!TGQ0&@&E!37-=+9U#BP3YXEE
M3KICHC3CU&-IY\$CRK+\_*VB9G;F*=>9XNF!5.MZ:UOO76](F@]*(Z"T (K6
M505N58&UJO@S3^Z8*!2QXU))8<T%8C3<5-(HCH<'RV-U#RD\G;-*T;;3^^X!
M2?-J6D?%1XN"IT,(:)\"*%JW[JT]Y6CMC?F;F_=GJPCJ2H'2/%":#THCH+0
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M^+FV*P:U74%I'BC-!Z414%H 1>O*I+5=L=YV_=Y9"-)O7(#2/%":#THCH+0
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M4<"V88CISVL2Q*]7/=C;==SYJS5/.K3AY0:OR)SPA\V,BI96H"S]D$3,CR-
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M-#$0]Y_CF.\:R0#%*>OP?U!+ P04    " !H,X-9:#I:7[4#  "5#0  &0
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M W;_&6/Z=L$=U.>XT_\ 4$L#!!0    ( &@S@UFMM(BMDP0  ,H;   9
M>&PO=V]R:W-H965T<R]S:&5E=#@W+GAM;+V9:V_B.!2&_XJ5':UFI*6)<P.Z
M@ 3D,J/=3E%I=W8^NL&%J$F<L4UI__TZEZ;D0J;=L?H%$O.^C^V3DY-@3PZ$
MWK,=QAP\QE'"ILJ.\_1<55FPPS%B9R3%B?CECM 8<7%*MRI+*4:;W!1'JJYI
MMAJC,%%FD[QM16<3LN=1F. 5!6P?QX@^+7!$#E,%*L\-5^%VQ[,&=39)T1:O
M,;])5U2<J15E$\8X82%) ,5W4V4.SWUH9(9<\4^(#^SH&&13N27D/COYLIDJ
M6C8B'.& 9P@DOA[P$D=11A+C^%%"E:K/S'A\_$SW\LF+R=PBAI<D^A9N^&ZJ
MC!2PP7=H'_$K<OB,RPE9&2\@$<L_P:'4:@H(]HR3N#2+$<1A4GRCQS(01P;!
MZ3;HI4%O&LP3!J,T&*_MP2P-YFM[L$J#U338)PQV:;!?V\.P- SSBU5$-[\T
M#N)H-J'D &BF%K3L(+^^N5M<D3#)4G'-J?@U%#X^6U]?+O\:+.9KUP'+RXN5
M^W4]O_YR^14,P'KYV75N_G;!I0=.RMQ_LV,7++Z#Z^^K7#O_-K]RUN"C@SD*
M(_9)H&[6#OCXX1/X ,($7._(GJ%DPR8J%S/(QJ$&Y6@7Q6CU$Z,UP 5)^(X!
M-]G@38??Z?>/?^;W^OU0[P&H(O15_/7G^"_T7N(:IV? T/X NJ:;'0-:OMYN
M=,7CUWIW?ZUWK]_NX$#8X4F[_WJ[WG,IC.I6,'*><6HV.T3Q8"'JV@8L22R*
M/4-YN9Q3BI(M%@68@]LG<*Q;H:>\>7Y M"N?%D679G>7V7/FG*4HP%-%/$@8
MI@]8F?W^&[2U/[MR02;,D0ES9<(\F3!?$JR646:5468??;;F)+@?W.:9$AQG
M%'[,CG%7PA1$*R=F[Q$/,_%6(>Z.A^-$:(L,W1C614Y;!,7[R:BN<MNJD6U9
M=9'7@8)CS:ZK_+;*,H<OHEH(K2J$UL]#"$B:A:WS@=%K?^L-)A/FR(2Y,F&>
M3)@O"5;+#KO*#OO]2[8M,Z-DPAR9,%<FS),)\R7!:ADUK#)J*+UD%T2[5K*A
MV2C9;9$!3:U1LMNB\6C<$+EMT<BPQXV*W19!:(X;@_+;*LN )RKVJ(K@J#>"
M;IQ&Y ECP/+2G>YIL!/A!&F$Q#_/[*;KK..]T+?>=3)ACDR8*Q/FR83YDF"U
MG!E7.3-^_SH^EIE1,F&.3)@K$^;)A/F28+6,@MK+PH8FO9*7R.-7V &$C4I>
MBHZKIMEX878Z-+;>J.,=&F@TW[P[1'IS1'Y_;_7X'2T,P=[X76'&:1AP$;ZB
MDA>U&Z!D _9)R+N7;WJ9;[WII-(<J317*LV32O-ET>J9H[]DCO[^U;SL4U9F
MR:0Y4FFN5)HGE>;+HM4SZV6%#O8NU_R_FBYU":ZDU18Y]&;Q;VL@M)O5OT-D
MP6;U;XO$7XMF]6^+QJ-&]5>/=@AB3+?YY@\3,=PGO%C/JEJK#:9YOJW2:%_
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M1AS!'( '#(DB^Q[<>Q^%Z_=4N/G?X/ /4$L#!!0    ( &@S@UF7BKL<P
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M:T61M:+(6E%DK?ZGK#_&\?"/XY=GVIMV>,[/EK^3W/P"4$L! A0#%     @
M:#.#60=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " !H,X-9+6! B>X    K @  $0
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M965T-"YX;6Q02P$"% ,4    " !H,X-9I%Q!+J(/  #EGP  &
M    @(&M(   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @
M:#.#63ECH,=%"   [BD  !@              ("!A3   'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;%!+ 0(4 Q0    ( &@S@UFVI#$:-PH  &@@   8
M          " @0 Y  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M    " !H,X-9_$%**[T;   '8   &               @(%M0P  >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ :#.#68SS<WYS"P  ,4P
M !@              ("!8%\  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+
M 0(4 Q0    ( &@S@UG>24G"FP4  +<3   9              " @0EK  !X
M;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ :#.#6:'G\H+O
M!P  7QX  !D              ("!VW   'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q02P$"% ,4    " !H,X-9\>==;A$%  #0$   &0
M@($!>0  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( &@S
M@UD-%ZHY2 X  #9(   9              " @4E^  !X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L! A0#%     @ :#.#65*Q:#]4!   IPH  !D
M         ("!R(P  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M    " !H,X-9A<%/@Y\)  #D'   &0              @(%3D0  >&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( &@S@UG27'V]71T  .MM
M   9              " @2F;  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L! A0#%     @ :#.#6:-QQ(+[!   %!$  !D              ("!O;@
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !H,X-9"14%
MEL,(  #E/@  &0              @('OO0  >&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+ 0(4 Q0    ( &@S@UG=)P(SW@,   (/   9
M  " @>G&  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @
M:#.#67DM'B2A!   G!   !D              ("!_LH  'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"% ,4    " !H,X-9M=D.DV0#  !H"0  &0
M            @('6SP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4
M Q0    ( &@S@UEP\$65DP<  #LA   9              " @7'3  !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ :#.#6>*.<90[!0
M@0X  !D              ("!.]L  'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6Q02P$"% ,4    " !H,X-9<<XYP!($  #4$0  &0              @(&M
MX   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( &@S@UG!
MM@>UWP(  -<'   9              " @?;D  !X;"]W;W)K<VAE971S+W-H
M965T,C4N>&UL4$L! A0#%     @ :#.#6>_K'R38!   L1H  !D
M     ("!#.@  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &@S@UE6UZM^Y@(  *\(   9              "
M@0<( 0!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ :#.#
M6:(J"03^ @  D@@  !D              ("!) L! 'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"% ,4    " !H,X-9BWTU \\%  #V+@  &0
M        @(%9#@$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0
M   ( &@S@UGKF/G] P0   $/   9              " @5\4 0!X;"]W;W)K
M<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ :#.#60DG='7X!0  ?C0
M !D              ("!F1@! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q0
M2P$"% ,4    " !H,X-9I(52YIH#  #X#P  &0              @('('@$
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( &@S@UF/P:/M
MVPL  '>0   9              " @9DB 0!X;"]W;W)K<VAE971S+W-H965T
M,S<N>&UL4$L! A0#%     @ :#.#60ZOF0JP!0  <1T  !D
M ("!JRX! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " !H
M,X-9#.$9 8H#  #<"P  &0              @(&2- $ >&PO=V]R:W-H965T
M<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( &@S@UD.AFWL@0,  /0-   9
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M970T-"YX;6Q02P$"% ,4    " !H,X-99UQB\'T#  #9"P  &0
M    @('I3 $ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (
M &@S@UE[\=+,;0,  +P)   9              " @9U0 0!X;"]W;W)K<VAE
M971S+W-H965T-#8N>&UL4$L! A0#%     @ :#.#64L,ZG[O @  $0@  !D
M             ("!050! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"
M% ,4    " !H,X-9V*59Y@4)  #R30  &0              @(%G5P$ >&PO
M=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( &@S@UGM=,LQ>@,
M &81   9              " @:-@ 0!X;"]W;W)K<VAE971S+W-H965T-#DN
M>&UL4$L! A0#%     @ :#.#65*%/P."!0  :!H  !D              ("!
M5&0! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " !H,X-9
MVAX)#J0/  #QGP  &0              @($-:@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4Q+GAM;%!+ 0(4 Q0    ( &@S@UG-G&27U@4  ,H6   9
M      " @>AY 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%
M  @ :#.#64]T5:4Q"@  /"   !D              ("!]7\! 'AL+W=O<FMS
M:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " !H,X-9_$%**[T;   '8
M&0              @(%=B@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+
M 0(4 Q0    ( &@S@UF,\W-^<PL  #%,   9              " @5&F 0!X
M;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ :#.#6=Y)2<*;
M!0  MQ,  !D              ("!^[$! 'AL+W=O<FMS:&5E=',O<VAE970U
M-BYX;6Q02P$"% ,4    " !H,X-9H>?R@N\'  !?'@  &0
M@('-MP$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( &@S
M@UGQYUUN$04  - 0   9              " @?._ 0!X;"]W;W)K<VAE971S
M+W-H965T-3@N>&UL4$L! A0#%     @ :#.#69ETAJ)##@  -D@  !D
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M=#8S+GAM;%!+ 0(4 Q0    ( &@S@UG=)P(SW@,   (/   9
M  " @8_X 0!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @
M:#.#61X'9C.1!0  $Q8  !D              ("!I/P! 'AL+W=O<FMS:&5E
M=',O<VAE970V-2YX;6Q02P$"% ,4    " !H,X-9M=D.DV0#  !H"0  &0
M            @(%L @( >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4
M Q0    ( &@S@UE<9 J&_08  -X>   9              " @0<& @!X;"]W
M;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ :#.#62JO!!.(!
M21H  !D              ("!.PT" 'AL+W=O<FMS:&5E=',O<VAE970V."YX
M;6Q02P$"% ,4    " !H,X-92']]<MH$  "T&@  &0              @('Z
M$0( >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( &@S@UF'
M%K!+T@,  *T0   9              " @0L7 @!X;"]W;W)K<VAE971S+W-H
M965T-S N>&UL4$L! A0#%     @ :#.#600M$S,F"@  0'4  !D
M     ("!%!L" 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &@S@UER"!&NZP(  %@'   9              "
M@>(Y @!X;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%     @ :#.#
M63KOA:.M!0  SRT  !D              ("!!#T" 'AL+W=O<FMS:&5E=',O
M<VAE970W-RYX;6Q02P$"% ,4    " !H,X-9[S6%OS<$  #K$   &0
M        @('H0@( >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0
M   ( &@S@UE%=GYP?P(  .4%   9              " @59' @!X;"]W;W)K
M<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @ :#.#61D^<0OO @  '@H
M !D              ("!#$H" 'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6Q0
M2P$"% ,4    " !H,X-9"2=T=?@%  !^-   &0              @($R30(
M>&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    ( &@S@UFDA5+F
MF@,  /@/   9              " @6%3 @!X;"]W;W)K<VAE971S+W-H965T
M.#(N>&UL4$L! A0#%     @ :#.#64N^]8YJ"P  (XL  !D
M ("!,E<" 'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6Q02P$"% ,4    " !H
M,X-92OWS;:H%  !Q'0  &0              @('38@( >&PO=V]R:W-H965T
M<R]S:&5E=#@T+GAM;%!+ 0(4 Q0    ( &@S@UEH.EI?M0,  )4-   9
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M;',O+G)E;'-02P$"% ,4    " !H,X-94#YJ[.,%  !=.@  #P
M    @ %$?P( >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ :#.#6<,EV4B4
M @  WS,  !H              ( !5(4" 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ :#.#68V<RZLT @  5C(  !,
M ( !((@" %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     &  8 !7&@  A8H"
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>272</ContextCount>
  <ElementCount>282</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>40</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100090 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DocumentCover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>110101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>110201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstruments</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>110401 - Disclosure - BALANCE SHEET COMPONENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponents</Role>
      <ShortName>BALANCE SHEET COMPONENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>110501 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>110601 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureStockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>110701 - Disclosure - SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensation</Role>
      <ShortName>SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>110801 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>110901 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureIncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>120202 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>130203 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>130303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsTables</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstruments</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>130403 - Disclosure - BALANCE SHEET COMPONENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>BALANCE SHEET COMPONENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponents</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>130503 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>130603 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aerovatetx.com/20231231/role/DisclosureStockholdersEquity</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>130703 - Disclosure - SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationTables</Role>
      <ShortName>SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>130903 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aerovatetx.com/20231231/role/DisclosureIncomeTaxes</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>140101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aerovatetx.com/20231231/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>140201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>140202 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF NET LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF NET LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>140203 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>140301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF FAIR VALUE INSTRUMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF FAIR VALUE INSTRUMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>140302 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT TERM INVESTMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT TERM INVESTMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>140303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>140401 - Disclosure - BALANCE SHEET COMPONENTS - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>140402 - Disclosure - BALANCE SHEET COMPONENTS - SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>140501 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>140502 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>140601 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>140602 - Disclosure - STOCKHOLDERS' EQUITY - SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>140701 - Disclosure - SHARE-BASED COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>140702 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF OPTION ACTIVITY UNDER 2021 PLAN AND 2018 PLAN (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - SCHEDULE OF OPTION ACTIVITY UNDER 2021 PLAN AND 2018 PLAN (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>140703 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF UNVESTED RESTRICTED STOCK UNIT ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - SCHEDULE OF UNVESTED RESTRICTED STOCK UNIT ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>140704 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF FAIR VALUE OF STOCK OPTIONS ASSUMPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - SCHEDULE OF FAIR VALUE OF STOCK OPTIONS ASSUMPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>140705 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION GRANTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION GRANTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>140706 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY TYPE OF AWARDS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY TYPE OF AWARDS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>140801 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureRelatedPartyTransactionsDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aerovatetx.com/20231231/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>140901 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>140902 - Disclosure - INCOME TAXES - SUMMARY OF COMPONENTS OF NET DEFERRED TAX ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails</Role>
      <ShortName>INCOME TAXES - SUMMARY OF COMPONENTS OF NET DEFERRED TAX ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>140903 - Disclosure - INCOME TAXES - SUMMARY OF RECONCILIATION OF FEDERAL INCOME TAX RATE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails</Role>
      <ShortName>INCOME TAXES - SUMMARY OF RECONCILIATION OF FEDERAL INCOME TAX RATE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>140904 - Disclosure - INCOME TAXES - SUMMARY OF GROSS UNRECOGNIZED TAX BENEFITS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>INCOME TAXES - SUMMARY OF GROSS UNRECOGNIZED TAX BENEFITS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>200100 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>200105 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>200200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>200300 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>200400 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>210101 - Disclosure - ORGANIZATION AND NATURE OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureOrganizationAndNatureOfOperations</Role>
      <ShortName>ORGANIZATION AND NATURE OF OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>210201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciess</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>210301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentss</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>210401 - Disclosure - BALANCE SHEET COMPONENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentss</Role>
      <ShortName>BALANCE SHEET COMPONENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>210501 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciess</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>210601 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureStockholdersEquitys</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>210701 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>210801 - Disclosure - SUBSEQUENT EVENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureSubsequentEvent</Role>
      <ShortName>SUBSEQUENT EVENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>220202 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPoliciess</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>230203 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTabless</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>230303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsTabless</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstruments</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>230403 - Disclosure - BALANCE SHEET COMPONENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsTabless</Role>
      <ShortName>BALANCE SHEET COMPONENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponents</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>230503 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesTabless</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>230603 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityTabless</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aerovatetx.com/20231231/role/DisclosureStockholdersEquity</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>230703 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>240101 - Disclosure - ORGANIZATION AND NATURE OF OPERATIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureOrganizationAndNatureOfOperationsDetails</Role>
      <ShortName>ORGANIZATION AND NATURE OF OPERATIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aerovatetx.com/20231231/role/DisclosureOrganizationAndNatureOfOperations</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>240201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF NET LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetailss</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF NET LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>240202 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetailss</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>240301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF FAIR VALUE INSTRUMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF FAIR VALUE INSTRUMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>240302 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT TERM INVESTMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT TERM INVESTMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>240303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>240401 - Disclosure - BALANCE SHEET COMPONENTS - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailss</Role>
      <ShortName>BALANCE SHEET COMPONENTS - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>240402 - Disclosure - BALANCE SHEET COMPONENTS - SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetailss</Role>
      <ShortName>BALANCE SHEET COMPONENTS - SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>240403 - Disclosure - BALANCE SHEET COMPONENTS - WORKFORCE REDUCTION PLAN (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsWorkforceReductionPlanDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - WORKFORCE REDUCTION PLAN (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>240501 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetailss</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>240502 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailss</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>240503 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF SUPPLEMENTAL CASH FLOW (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - SCHEDULE OF SUPPLEMENTAL CASH FLOW (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>240504 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF RENT EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfRentExpensesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - SCHEDULE OF RENT EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>240601 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>240602 - Disclosure - STOCKHOLDERS' EQUITY - SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetailss</Role>
      <ShortName>STOCKHOLDERS' EQUITY - SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>240701 - Disclosure - STOCK-BASED COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>240702 - Disclosure - STOCK-BASED COMPENSATION - SCHEDULE OF OPTION ACTIVITY UNDER 2021 PLAN AND 2018 PLAN (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - SCHEDULE OF OPTION ACTIVITY UNDER 2021 PLAN AND 2018 PLAN (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>240703 - Disclosure - STOCK-BASED COMPENSATION - SCHEDULE OF UNVESTED RESTRICTED STOCK UNIT ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - SCHEDULE OF UNVESTED RESTRICTED STOCK UNIT ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>240704 - Disclosure - STOCK-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>240705 - Disclosure - STOCK-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY TYPE OF AWARDS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY TYPE OF AWARDS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="avte-20240930xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>240801 - Disclosure - SUBSEQUENT EVENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com/20231231/role/DisclosureSubsequentEventDetails</Role>
      <ShortName>SUBSEQUENT EVENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aerovatetx.com/20231231/role/DisclosureSubsequentEvent</ParentRole>
      <Position>88</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>avte-20240930.xsd</File>
    <File>avte-20240930_cal.xml</File>
    <File>avte-20240930_def.xml</File>
    <File>avte-20240930_lab.xml</File>
    <File>avte-20240930_pre.xml</File>
    <File doctype="S-4" isDefinitelyFs="true" isUsgaap="true" original="avte-20240930xs4.htm">avte-20240930xs4.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>avte-20240930xs4007.jpg</File>
    <File>avte-20240930xs4008.jpg</File>
    <File>avte-20240930xs4014.jpg</File>
    <File>avte-20240930xs4015.jpg</File>
    <File>avte-20240930xs4016.jpg</File>
    <File>avte-20240930xs4017.jpg</File>
    <File>avte-20240930xs4018.jpg</File>
    <File>avte-20240930xs4019.jpg</File>
    <File>avte-20240930xs4020.jpg</File>
    <File>avte-20240930xs4021.jpg</File>
    <File>avte-20240930xs4022.jpg</File>
    <File>avte-20240930xs4023.jpg</File>
    <File>avte-20240930xs4024.jpg</File>
    <File>avte-20240930xs4025.jpg</File>
    <File>avte-20240930xs4026.jpg</File>
    <File>avte-20240930xs4027.jpg</File>
    <File>avte-20240930xs4028.jpg</File>
    <File>avte-20240930xs4042.jpg</File>
    <File>avte-20240930xs4043.jpg</File>
    <File>avte-20240930xs4044.jpg</File>
    <File>avte-20240930xs4045.jpg</File>
    <File>avte-20240930xs4046.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1156">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>149
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "avte-20240930xs4.htm": {
   "nsprefix": "avte",
   "nsuri": "http://aerovatetx.com/20240930",
   "dts": {
    "schema": {
     "local": [
      "avte-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "avte-20240930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "avte-20240930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "avte-20240930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "avte-20240930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "avte-20240930xs4.htm"
     ]
    }
   },
   "keyStandard": 253,
   "keyCustom": 29,
   "axisStandard": 18,
   "axisCustom": 0,
   "memberStandard": 25,
   "memberCustom": 11,
   "hidden": {
    "total": 38,
    "http://fasb.org/us-gaap/2023": 36,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 272,
   "entityCount": 1,
   "segmentCount": 40,
   "elementCount": 412,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 1156,
    "http://xbrl.sec.gov/dei/2023": 8
   },
   "report": {
    "R1": {
     "role": "http://aerovatetx.com/20231231/role/DocumentCover",
     "longName": "100090 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets",
     "longName": "100100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R3": {
     "role": "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "100200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "longName": "100300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8NQImWg4J0qy7AIOsD5XtA",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R6": {
     "role": "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "100400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:Depreciation",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies",
     "longName": "110101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies",
     "longName": "110201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstruments",
     "longName": "110301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R10": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponents",
     "longName": "110401 - Disclosure - BALANCE SHEET COMPONENTS",
     "shortName": "BALANCE SHEET COMPONENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R11": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingencies",
     "longName": "110501 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R12": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquity",
     "longName": "110601 - Disclosure - STOCKHOLDERS' EQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R13": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensation",
     "longName": "110701 - Disclosure - SHARE-BASED COMPENSATION",
     "shortName": "SHARE-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R14": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureRelatedPartyTransactions",
     "longName": "110801 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxes",
     "longName": "110901 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies",
     "longName": "120202 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "unique": true
     }
    },
    "R17": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables",
     "longName": "130203 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R18": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsTables",
     "longName": "130303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R19": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsTables",
     "longName": "130403 - Disclosure - BALANCE SHEET COMPONENTS (Tables)",
     "shortName": "BALANCE SHEET COMPONENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "avte:ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R20": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesTables",
     "longName": "130503 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R21": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityTables",
     "longName": "130603 - Disclosure - STOCKHOLDERS' EQUITY (Tables)",
     "shortName": "STOCKHOLDERS' EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "avte:ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R22": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationTables",
     "longName": "130703 - Disclosure - SHARE-BASED COMPENSATION (Tables)",
     "shortName": "SHARE-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "unique": true
     }
    },
    "R23": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesTables",
     "longName": "130903 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
     "longName": "140101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R25": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails",
     "longName": "140201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails",
     "longName": "140202 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF NET LOSS PER SHARE (Details)",
     "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF NET LOSS PER SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R27": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails",
     "longName": "140203 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE (Details)",
     "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R28": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
     "longName": "140301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF FAIR VALUE INSTRUMENTS (Details)",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF FAIR VALUE INSTRUMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R29": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
     "longName": "140302 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT TERM INVESTMENT (Details)",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT TERM INVESTMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R30": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails",
     "longName": "140303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES (Details)",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R31": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "longName": "140401 - Disclosure - BALANCE SHEET COMPONENTS - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "avte:ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R32": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails",
     "longName": "140402 - Disclosure - BALANCE SHEET COMPONENTS - SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES - (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES - (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q",
      "name": "avte:AccruedResearchAndDevelopmentCurrent",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R33": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetails",
     "longName": "140501 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA",
      "name": "us-gaap:OperatingLeaseLiability",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "avte:ScheduleOfComponentsOfOperatingLeasesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R34": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails",
     "longName": "140502 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R35": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails",
     "longName": "140601 - Disclosure - STOCKHOLDERS' EQUITY (Details)",
     "shortName": "STOCKHOLDERS' EQUITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "As_Of_8_3_2020_EcWWeWov-0O5egWgb1IO4Q",
      "name": "avte:CapitalStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R36": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails",
     "longName": "140602 - Disclosure - STOCKHOLDERS' EQUITY - SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "avte:ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R37": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
     "longName": "140701 - Disclosure - SHARE-BASED COMPENSATION (Details)",
     "shortName": "SHARE-BASED COMPENSATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_oV0DwhFiqUeSjADTrzXG4A",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails",
     "longName": "140702 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF OPTION ACTIVITY UNDER 2021 PLAN AND 2018 PLAN (Details)",
     "shortName": "SHARE-BASED COMPENSATION - SCHEDULE OF OPTION ACTIVITY UNDER 2021 PLAN AND 2018 PLAN (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails",
     "longName": "140703 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF UNVESTED RESTRICTED STOCK UNIT ACTIVITY (Details)",
     "shortName": "SHARE-BASED COMPENSATION - SCHEDULE OF UNVESTED RESTRICTED STOCK UNIT ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Gy-ZvYruXkinoI8nJEgktA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R40": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails",
     "longName": "140704 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF FAIR VALUE OF STOCK OPTIONS ASSUMPTIONS (Details)",
     "shortName": "SHARE-BASED COMPENSATION - SCHEDULE OF FAIR VALUE OF STOCK OPTIONS ASSUMPTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails",
     "longName": "140705 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION GRANTS (Details)",
     "shortName": "SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION GRANTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R42": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails",
     "longName": "140706 - Disclosure - SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY TYPE OF AWARDS (Details)",
     "shortName": "SHARE-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY TYPE OF AWARDS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R43": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureRelatedPartyTransactionsDetails",
     "longName": "140801 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2019_To_7_31_2019_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_n2CK4UQgq0-A1CPzs_pKqg",
      "name": "avte:RelatedPartyTransactionTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2019_To_7_31_2019_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_n2CK4UQgq0-A1CPzs_pKqg",
      "name": "avte:RelatedPartyTransactionTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesDetails",
     "longName": "140901 - Disclosure - INCOME TAXES (Details)",
     "shortName": "INCOME TAXES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_LI5YHiUWtUqb-dWGgEgt2Q",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails",
     "longName": "140902 - Disclosure - INCOME TAXES - SUMMARY OF COMPONENTS OF NET DEFERRED TAX ASSETS (Details)",
     "shortName": "INCOME TAXES - SUMMARY OF COMPONENTS OF NET DEFERRED TAX ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails",
     "longName": "140903 - Disclosure - INCOME TAXES - SUMMARY OF RECONCILIATION OF FEDERAL INCOME TAX RATE (Details)",
     "shortName": "INCOME TAXES - SUMMARY OF RECONCILIATION OF FEDERAL INCOME TAX RATE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetails",
     "longName": "140904 - Disclosure - INCOME TAXES - SUMMARY OF GROSS UNRECOGNIZED TAX BENEFITS (Details)",
     "shortName": "INCOME TAXES - SUMMARY OF GROSS UNRECOGNIZED TAX BENEFITS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2021_3SZLVaYF3Uaoxk9Z6taH9Q",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
     "longName": "200100 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Uncategorized",
     "order": "48",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "longName": "200105 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Cover",
     "order": "49",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R50": {
     "role": "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
     "longName": "200200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "50",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw",
      "name": "us-gaap:NonoperatingIncomeExpense",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
     "longName": "200300 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "51",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8NQImWg4J0qy7AIOsD5XtA",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R52": {
     "role": "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
     "longName": "200400 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "52",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA",
      "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndNatureOfOperations",
     "longName": "210101 - Disclosure - ORGANIZATION AND NATURE OF OPERATIONS",
     "shortName": "ORGANIZATION AND NATURE OF OPERATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "53",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R54": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciess",
     "longName": "210201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "54",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R55": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentss",
     "longName": "210301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "55",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R56": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentss",
     "longName": "210401 - Disclosure - BALANCE SHEET COMPONENTS",
     "shortName": "BALANCE SHEET COMPONENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "56",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R57": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciess",
     "longName": "210501 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "57",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R58": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquitys",
     "longName": "210601 - Disclosure - STOCKHOLDERS' EQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "58",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R59": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensation",
     "longName": "210701 - Disclosure - STOCK-BASED COMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "59",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R60": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureSubsequentEvent",
     "longName": "210801 - Disclosure - SUBSEQUENT EVENT",
     "shortName": "SUBSEQUENT EVENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "60",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPoliciess",
     "longName": "220202 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "61",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R62": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTabless",
     "longName": "230203 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "62",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R63": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsTabless",
     "longName": "230303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "63",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R64": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsTabless",
     "longName": "230403 - Disclosure - BALANCE SHEET COMPONENTS (Tables)",
     "shortName": "BALANCE SHEET COMPONENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "64",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "avte:ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R65": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesTabless",
     "longName": "230503 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "65",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityTabless",
     "longName": "230603 - Disclosure - STOCKHOLDERS' EQUITY (Tables)",
     "shortName": "STOCKHOLDERS' EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "66",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "avte:ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R67": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationTables",
     "longName": "230703 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "67",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R68": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndNatureOfOperationsDetails",
     "longName": "240101 - Disclosure - ORGANIZATION AND NATURE OF OPERATIONS (Details)",
     "shortName": "ORGANIZATION AND NATURE OF OPERATIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R69": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetailss",
     "longName": "240201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF NET LOSS PER SHARE (Details)",
     "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF NET LOSS PER SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R70": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetailss",
     "longName": "240202 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE (Details)",
     "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R71": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss",
     "longName": "240301 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF FAIR VALUE INSTRUMENTS (Details)",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF FAIR VALUE INSTRUMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R72": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss",
     "longName": "240302 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT TERM INVESTMENT (Details)",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT TERM INVESTMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss",
     "longName": "240303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES (Details)",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS - SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R74": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailss",
     "longName": "240401 - Disclosure - BALANCE SHEET COMPONENTS - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "avte:ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R75": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetailss",
     "longName": "240402 - Disclosure - BALANCE SHEET COMPONENTS - SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES - (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES - (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q",
      "name": "avte:AccruedResearchAndDevelopmentCurrent",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R76": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsWorkforceReductionPlanDetails",
     "longName": "240403 - Disclosure - BALANCE SHEET COMPONENTS - WORKFORCE REDUCTION PLAN (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - WORKFORCE REDUCTION PLAN (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate",
      "unitRef": "Unit_Standard_individual_HQaf273bdUKcqMGv_RJZsw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate",
      "unitRef": "Unit_Standard_individual_HQaf273bdUKcqMGv_RJZsw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetailss",
     "longName": "240501 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "us-gaap:OperatingLeaseExpense",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_PLHhQPxnDkGS0X1B4pdMdQ",
      "name": "us-gaap:OperatingLeaseImpairmentLoss",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailss",
     "longName": "240502 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowDetails",
     "longName": "240503 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF SUPPLEMENTAL CASH FLOW (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - SCHEDULE OF SUPPLEMENTAL CASH FLOW (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfRentExpensesDetails",
     "longName": "240504 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF RENT EXPENSES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - SCHEDULE OF RENT EXPENSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss",
     "longName": "240601 - Disclosure - STOCKHOLDERS' EQUITY (Details)",
     "shortName": "STOCKHOLDERS' EQUITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "As_Of_8_3_2020_EcWWeWov-0O5egWgb1IO4Q",
      "name": "avte:CapitalStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R82": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetailss",
     "longName": "240602 - Disclosure - STOCKHOLDERS' EQUITY - SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "avte:ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R83": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails",
     "longName": "240701 - Disclosure - STOCK-BASED COMPENSATION (Details)",
     "shortName": "STOCK-BASED COMPENSATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_rO2RmIvkokKdeJv-xbshfQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails",
     "longName": "240702 - Disclosure - STOCK-BASED COMPENSATION - SCHEDULE OF OPTION ACTIVITY UNDER 2021 PLAN AND 2018 PLAN (Details)",
     "shortName": "STOCK-BASED COMPENSATION - SCHEDULE OF OPTION ACTIVITY UNDER 2021 PLAN AND 2018 PLAN (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R85": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails",
     "longName": "240703 - Disclosure - STOCK-BASED COMPENSATION - SCHEDULE OF UNVESTED RESTRICTED STOCK UNIT ACTIVITY (Details)",
     "shortName": "STOCK-BASED COMPENSATION - SCHEDULE OF UNVESTED RESTRICTED STOCK UNIT ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Gy-ZvYruXkinoI8nJEgktA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mQCZMz_2oEWLJpuw7OHgvw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
      "unitRef": "Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails",
     "longName": "240704 - Disclosure - STOCK-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)",
     "shortName": "STOCK-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R87": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails",
     "longName": "240705 - Disclosure - STOCK-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY TYPE OF AWARDS (Details)",
     "shortName": "STOCK-BASED COMPENSATION - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE BY TYPE OF AWARDS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R88": {
     "role": "http://aerovatetx.com/20231231/role/DisclosureSubsequentEventDetails",
     "longName": "240801 - Disclosure - SUBSEQUENT EVENT (Details)",
     "shortName": "SUBSEQUENT EVENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_30_2024_To_10_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_RPVQa3dXU0OggwPnCBtwgg",
      "name": "avte:PurchaseAgreementCashProceedsToBeReceivedUponClosingOfMerger",
      "unitRef": "Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avte-20240930xs4.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r596"
     ]
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Related Parties",
        "terseLabel": "Amount payable to related parties",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r714"
     ]
    },
    "avte_AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion of discounts and amortization of premiums on investments, net",
        "label": "Accretion of discounts and amortization of premiums on investments, net"
       }
      }
     },
     "auth_ref": []
    },
    "avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetailss",
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued liabilities and other liabilities current.",
        "label": "Accrued and other current liabilities",
        "totalLabel": "Total accrued and other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "avte_AccruedResearchAndDevelopmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "AccruedResearchAndDevelopmentCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetailss": {
       "parentTag": "avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Research and Development Current",
        "terseLabel": "Accrued research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive (loss) income",
        "terseLabel": "Accumulated other comprehensive gain",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r78",
      "r135",
      "r466",
      "r483",
      "r484"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income",
        "verboseLabel": "Accumulated Other Comprehensive Gain/(Loss)",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r10",
      "r26",
      "r374",
      "r377",
      "r413",
      "r479",
      "r480",
      "r626",
      "r627",
      "r628",
      "r633",
      "r634",
      "r635"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r596",
      "r720"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r499",
      "r633",
      "r634",
      "r635",
      "r696",
      "r721"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r302"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "verboseLabel": "Stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r339"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DocumentCover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails",
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails",
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails",
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails",
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfLand",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of land",
        "terseLabel": "Area of land",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Default Label]",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r131",
      "r153",
      "r183",
      "r192",
      "r194",
      "r229",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r367",
      "r371",
      "r391",
      "r462",
      "r523",
      "r596",
      "r608",
      "r662",
      "r663",
      "r704"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r137",
      "r153",
      "r229",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r367",
      "r371",
      "r391",
      "r596",
      "r662",
      "r663",
      "r704"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total fair value of assets",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized loss",
        "negatedTerseLabel": "Gross unrealized losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]",
        "terseLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r581"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Estimated fair value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r237",
      "r456",
      "r639"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330"
     ]
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "BALANCE SHEET COMPONENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies",
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies",
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "avte_BofaSecuritiesInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "BofaSecuritiesInc.Member",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndNatureOfOperationsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to BofA Securities, Inc.",
        "label": "BofA Securities, Inc. [Member]",
        "terseLabel": "BofA Securities, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment in accounts payable and accrued liabilities",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "avte_CapitalStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "CapitalStockSharesAuthorized",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital stock shares authorized.",
        "label": "Capital stock shares authorized",
        "terseLabel": "Capital stock shares authorized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r129",
      "r570"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndNatureOfOperationsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents and short-term investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents at the end of the period",
        "periodStartLabel": "Cash and cash equivalents at the beginning of the year",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r87",
      "r151"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r87"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Total cash equivalents",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r716"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of noncash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r182",
      "r276",
      "r277",
      "r278",
      "r280",
      "r283",
      "r288",
      "r290",
      "r489",
      "r490",
      "r491",
      "r492",
      "r584",
      "r611",
      "r631"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r602",
      "r603",
      "r604",
      "r605"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Note 5)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r66",
      "r463",
      "r510"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingencies",
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r257",
      "r258",
      "r567",
      "r661"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetailss",
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r599",
      "r600",
      "r602",
      "r603",
      "r604",
      "r605",
      "r633",
      "r634",
      "r696",
      "r718",
      "r721"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss",
      "http://aerovatetx.com/20231231/role/DisclosureSubsequentEventDetails",
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "verboseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss",
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "verboseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r511"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r72",
      "r511",
      "r529",
      "r721",
      "r722"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.0001 par value; 150,000,000 shares authorized at September 30, 2024 and December 31, 2023, respectively; 28,867,711 and 27,762,703 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r465",
      "r596"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r139",
      "r141",
      "r146",
      "r457",
      "r475"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r119"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of stock shares issued",
        "terseLabel": "Conversion of stock shares issued",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureSubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable",
        "terseLabel": "Convertible notes",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r107",
      "r715"
     ]
    },
    "avte_ConvertiblePreferredStockPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "ConvertiblePreferredStockPolicyTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred stock [Policy Text Block]",
        "label": "Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r587",
      "r717"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndNatureOfOperationsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r272",
      "r278",
      "r419",
      "r572",
      "r574"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent",
     "crdr": "debit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Current",
        "terseLabel": "Accrued interest receivable",
        "documentation": "Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r237",
      "r238"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes accrued interest, after allowance for credit loss, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Accrued interest receivable",
        "documentation": "Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r237",
      "r238"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes accrued interest, after allowance for credit loss, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "crdr": "credit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit loss",
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r237",
      "r246",
      "r247"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss",
        "terseLabel": "Amortized cost",
        "documentation": "Amortized cost, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Short-term investments, 12 months or Greater, Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r243",
      "r581"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedLabel": "Short-term investments, 12 months or Greater, Unrealized Losses",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r243"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Short-term investments, Less than 12 months, Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r243",
      "r581"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Short-term investments, Less than 12 months, Unrealized Losses",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r243"
     ]
    },
    "avte_DebtSecuritiesAvailableForSaleMaturityTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "DebtSecuritiesAvailableForSaleMaturityTerm",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity term for debt securities classified as available for sale.",
        "label": "Debt Securities Available For Sale Maturity Term",
        "terseLabel": "Maturity term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsTables",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF SHORT TERM INVESTMENTS",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "totalLabel": "Short-term investments, Total Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r241",
      "r581"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Short-term investments, Total Unrealized Losses",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r242"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r581"
     ]
    },
    "us-gaap_DebtSecuritiesTradingUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesTradingUnrealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Trading, Unrealized Gain",
        "terseLabel": "Unrealized gain on investments",
        "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in net income (trading)."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_DebtSecuritiesTradingUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesTradingUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Trading, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized (loss) gain on securities",
        "verboseLabel": "Unrealized gain (loss) on securities",
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in net income (trading)."
       }
      }
     },
     "auth_ref": [
      "r640",
      "r654"
     ]
    },
    "us-gaap_DebtSecuritiesTradingUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesTradingUnrealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Trading, Unrealized Loss",
        "negatedTerseLabel": "Unrealized loss on investments",
        "terseLabel": "Unrealized loss on investments",
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in net income (trading)."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "avte_DeferredOfferingCostsIncludedInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "DeferredOfferingCostsIncludedInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred offering costs included in accounts payable.",
        "label": "Deferred offering costs included in accounts payable"
       }
      }
     },
     "auth_ref": []
    },
    "avte_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.",
        "label": "Deferred Tax Assets, Capitalized Research and Development Costs",
        "terseLabel": "Capitalized R&amp;D"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets (liabilities)",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NOL carryforwards",
        "terseLabel": "NOL carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r695"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "verboseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r695"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research credit carryforwards",
        "terseLabel": "Research credit carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r695"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r695"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets valuation allowance",
        "negatedLabel": "Less: valuation allowance",
        "terseLabel": "Deferred tax assets valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r694"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r695"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r41"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensation",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION",
        "verboseLabel": "SHARE-BASED COMPENSATION",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r304",
      "r332",
      "r333",
      "r335",
      "r589"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsCommonStockCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsCommonStockCash",
     "crdr": "debit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndNatureOfOperationsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureSubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends, Common Stock, Cash",
        "terseLabel": "Cash dividend",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DocumentCover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails",
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetailss",
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share, basic and diluted",
        "terseLabel": "Net loss per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r170",
      "r173",
      "r176",
      "r177",
      "r178",
      "r180",
      "r382",
      "r383",
      "r458",
      "r476",
      "r576"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails",
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetailss",
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r173",
      "r176",
      "r177",
      "r178",
      "r180",
      "r382",
      "r383",
      "r458",
      "r476",
      "r576"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies",
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36"
     ]
    },
    "avte_EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation Research and Development Credits.",
        "label": "Research and development credits",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation.",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r692"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetailss": {
       "parentTag": "avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued payroll and other employee benefits",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized stock based compensation",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized stock-based compensation weighted-average period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails",
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetailss",
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options",
        "verboseLabel": "Options to purchase common stock",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DocumentCover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureSubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Entities [Member]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DocumentCover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DocumentCover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DocumentCover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DocumentCover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DocumentCover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss",
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r125",
      "r143",
      "r144",
      "r145",
      "r157",
      "r158",
      "r159",
      "r161",
      "r167",
      "r169",
      "r181",
      "r230",
      "r231",
      "r291",
      "r336",
      "r337",
      "r338",
      "r359",
      "r360",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r381",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r413",
      "r479",
      "r480",
      "r481",
      "r499",
      "r553"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386",
      "r389"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386",
      "r389"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r386",
      "r427",
      "r428",
      "r429",
      "r582",
      "r583",
      "r585",
      "r586",
      "r587"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r390"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE OF FINANCIAL INSTRUMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstruments",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE OF FINANCIAL INSTRUMENTS",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r293",
      "r298",
      "r386",
      "r427",
      "r585",
      "r586",
      "r587"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r293",
      "r298",
      "r386",
      "r428",
      "r582",
      "r583",
      "r585",
      "r586",
      "r587"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r386",
      "r429",
      "r582",
      "r583",
      "r585",
      "r586",
      "r587"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r427",
      "r428",
      "r429",
      "r582",
      "r583",
      "r585",
      "r586",
      "r587"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r390"
     ]
    },
    "us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOffBalanceSheetRisksDisclosureInformationLineItems",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]",
        "terseLabel": "Fair Value, off-Balance-Sheet Risks, Disclosure Information",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r239",
      "r244",
      "r245",
      "r274",
      "r288",
      "r379",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r474",
      "r581",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r653",
      "r655",
      "r656",
      "r657"
     ]
    },
    "avte_FosterCityLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "FosterCityLeaseMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foster City Lease [Member]",
        "label": "Foster City Lease",
        "terseLabel": "Foster City Lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r533"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "terseLabel": "IPO",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment losses",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r40",
      "r92"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r93"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Net loss before income taxes",
        "totalLabel": "Net loss before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r79",
      "r111",
      "r183",
      "r191",
      "r193",
      "r195",
      "r459",
      "r471",
      "r578"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r253",
      "r538"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r538"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r342",
      "r348",
      "r352",
      "r357",
      "r361",
      "r363",
      "r364",
      "r365",
      "r494"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails",
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for income taxes",
        "totalLabel": "Total tax provision",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r124",
      "r168",
      "r169",
      "r184",
      "r346",
      "r362",
      "r477"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r344",
      "r345",
      "r352",
      "r353",
      "r356",
      "r358",
      "r488"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent and other differences",
        "terseLabel": "Permanent and other differences",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S. Federal statutory income tax rate",
        "terseLabel": "U.S. Federal statutory income tax rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State taxes",
        "terseLabel": "State taxes",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued and other liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "avte_IncreaseDecreaseInOperatingLeaseAssetAndLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "IncreaseDecreaseInOperatingLeaseAssetAndLiability",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease asset and liability, net.",
        "label": "Increase Decrease In Operating Lease Asset And Liability",
        "terseLabel": "Operating lease assets and liabilities, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other long-term assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "avte_IncreaseRentalAmount": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "IncreaseRentalAmount",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in rent square foot value.",
        "label": "Increase Rental Amount",
        "terseLabel": "Increase of rental value for square foot"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "The net amount of nonoperating interest income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "avte_JadeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "JadeMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureSubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Jade.",
        "label": "Jade [Member]",
        "terseLabel": "Jade"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfRentExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfRentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Total rent expense",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r595"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "SCHEDULE OF OPERATING LEASE EXPENSE",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "avte_LeaseIncreaseInRentPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "LeaseIncreaseInRentPercentage",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease increase in rent percentage.",
        "label": "Lease rent percentage",
        "terseLabel": "Lease rent percentage"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureSubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Lease, option to extend",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesTables",
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "SCHEDULE OF FUTURE MINIMUM ANNUAL LEASE PAYMENTS FOR OPERATING LEASES",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailsCalc2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total operating lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailss": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2022",
        "terseLabel": "2025",
        "verboseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailss": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailss": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Amount representing interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease term",
        "terseLabel": "Operating lease term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r153",
      "r229",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r368",
      "r371",
      "r372",
      "r391",
      "r509",
      "r577",
      "r608",
      "r662",
      "r704",
      "r705"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r108",
      "r468",
      "r596",
      "r632",
      "r658",
      "r697"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r128",
      "r153",
      "r229",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r368",
      "r371",
      "r372",
      "r391",
      "r596",
      "r662",
      "r704",
      "r705"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "avte_MaterialBreachCorrectionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "MaterialBreachCorrectionPeriod",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of days in which material breach must be corrected or agreement will be terminated.",
        "label": "Material Breach Correction Period",
        "terseLabel": "Material breach correction period"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss",
      "http://aerovatetx.com/20231231/role/DisclosureRelatedPartyTransactionsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r299",
      "r454",
      "r478",
      "r501",
      "r502",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r568",
      "r569",
      "r580",
      "r584",
      "r588",
      "r597",
      "r664",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711"
     ]
    },
    "avte_MergerAgreementSecuritiesCapitalAmountReservedForFutureIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "MergerAgreementSecuritiesCapitalAmountReservedForFutureIssuance",
     "crdr": "debit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureSubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents securities issued for aggregate purchase price under merger agreement.",
        "label": "Merger Agreement, Securities, Capital Amount Reserved for Future Issuance",
        "terseLabel": "Aggregate purchase price under merger agreement"
       }
      }
     },
     "auth_ref": []
    },
    "avte_MergerAgreementSharesToBeIssuedDenominatorForCalculation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "MergerAgreementSharesToBeIssuedDenominatorForCalculation",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureSubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers shares to be issued in denominator for calculation under merger agreement.",
        "label": "Merger Agreement, Shares to be Issued, Denominator for Calculation",
        "terseLabel": "Shares to be issued in denominator for calculation"
       }
      }
     },
     "auth_ref": []
    },
    "avte_MergerAgreementTerminationFeesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "MergerAgreementTerminationFeesPayable",
     "crdr": "credit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureSubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination fees to be paid upon termination of merger agreement.",
        "label": "Merger Agreement, Termination Fees Payable",
        "terseLabel": "Termination fees payable"
       }
      }
     },
     "auth_ref": []
    },
    "avte_MergerAgreementTerminationFeesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "MergerAgreementTerminationFeesReceivable",
     "crdr": "debit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureSubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination fees to be received upon termination of merger agreement by other party.",
        "label": "Merger Agreement, Termination Fees Receivable",
        "terseLabel": "Termination fees receivable"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r299",
      "r454",
      "r478",
      "r501",
      "r502",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r568",
      "r569",
      "r580",
      "r584",
      "r588",
      "r597",
      "r664",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flow from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flow from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88",
      "r89"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flow from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails",
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetailss",
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent",
        "verboseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r89",
      "r112",
      "r126",
      "r138",
      "r140",
      "r145",
      "r153",
      "r160",
      "r162",
      "r163",
      "r164",
      "r165",
      "r168",
      "r169",
      "r174",
      "r183",
      "r191",
      "r193",
      "r195",
      "r229",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r383",
      "r391",
      "r473",
      "r531",
      "r551",
      "r552",
      "r578",
      "r606",
      "r662"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails",
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss available to common stockholders",
        "terseLabel": "Net loss attributable to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r162",
      "r163",
      "r164",
      "r165",
      "r170",
      "r171",
      "r175",
      "r178",
      "r183",
      "r191",
      "r193",
      "r195",
      "r578"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies",
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Issued and Recently Adopted Accounting Pronouncements",
        "terseLabel": "Recently Issued and Recently Adopted Accounting Pronouncements",
        "verboseLabel": "Recently Issued Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationTables",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF UNVESTED STOCK UNIT ACTIVITY",
        "terseLabel": "SCHEDULE OF UNVESTED RESTRICTED STOCK UNIT ACTIVITY",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "avte_NoticeToTerminateAgreementPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "NoticeToTerminateAgreementPeriod",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of days in which notice to terminate an agreement must be given.",
        "label": "Notice To Terminate Agreement Period",
        "terseLabel": "Termination notice period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "avte_NumberOfVotesForEachShareOfCommonStock": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "NumberOfVotesForEachShareOfCommonStock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to number of votes for each share of common stock.",
        "label": "Number Of Votes For Each Share Of Common Stock",
        "terseLabel": "Number of votes for each share of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Expenses from transactions with related party",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r191",
      "r193",
      "r195",
      "r578"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfRentExpensesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfRentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r595"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total operating lease expenses",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Impairment of right-of-use asset",
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of net minimum lease payments",
        "totalLabel": "Present value of net minimum lease payments",
        "verboseLabel": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityAbstract",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailss": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailss",
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities",
        "verboseLabel": "Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailss": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailss",
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities, net of current portion",
        "verboseLabel": "Non-current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid included in operating cash flows",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r408"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average incremental borrowing rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r595"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumAnnualLeasePaymentsForOperatingLeasesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average remaining lease term (in years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r595"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforwards",
        "terseLabel": "Operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION AND NATURE OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndNatureOfOperations",
      "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "ORGANIZATION AND NATURE OF OPERATIONS",
        "verboseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r104",
      "r485",
      "r486"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetailss": {
       "parentTag": "avte_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other long-term assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other liabilities",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r461",
      "r505",
      "r506",
      "r608",
      "r719"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Expense",
        "negatedLabel": "Other expense:",
        "terseLabel": "Other expense:",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense:",
        "totalLabel": "Total other income",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailss": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r659"
     ]
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for rent",
        "terseLabel": "Payment for rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsWorkforceReductionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Restructuring",
        "terseLabel": "Severance benefits",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r629"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payments for offering costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Short-Term Investments",
        "negatedLabel": "Purchases of short-term investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss",
      "http://aerovatetx.com/20231231/role/DisclosureSubsequentEventDetails",
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "terseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r276"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss",
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r511"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r276"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r511",
      "r529",
      "r721",
      "r722"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of September 30, 2024 and December 31, 2023, respectively; no shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r464",
      "r596"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailss",
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailss": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r248",
      "r249",
      "r571"
     ]
    },
    "avte_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses and other current assets [Policy Text Block]",
        "label": "Prepaid Expenses and Other Current Assets [Policy Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "avte_PrepaidResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "PrepaidResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailss": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid research and development.",
        "label": "Prepaid research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndNatureOfOperationsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of common stock in connection with ATM, net",
        "terseLabel": "Proceeds from sale of common stock in connection with ATM, net",
        "verboseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Proceeds from issuance of common stock under ESPP",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r14"
     ]
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturities of short-term investments",
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r14"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss",
        "totalLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r138",
      "r140",
      "r149",
      "r153",
      "r160",
      "r168",
      "r169",
      "r183",
      "r191",
      "r193",
      "r195",
      "r229",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r366",
      "r369",
      "r370",
      "r383",
      "r391",
      "r459",
      "r472",
      "r498",
      "r531",
      "r551",
      "r552",
      "r578",
      "r593",
      "r594",
      "r607",
      "r628",
      "r662"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r460",
      "r470",
      "r596"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r120",
      "r123",
      "r469"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Leasehold improvements are amortized over the remaining life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "avte_PurchaseAgreementCashProceedsToBeReceivedUponClosingOfMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "PurchaseAgreementCashProceedsToBeReceivedUponClosingOfMerger",
     "crdr": "debit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureSubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow to be received for concurrent investment upon closing of merger in purchase agreement.",
        "label": "Purchase Agreement, Cash Proceeds To Be received, Upon Closing Of Merger",
        "terseLabel": "Cash proceeds to be received upon closing of merger"
       }
      }
     },
     "auth_ref": []
    },
    "avte_RaCapitalHealthcareFundL.pMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "RaCapitalHealthcareFundL.pMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RA Capital Healthcare Fund, L.P [Member]",
        "label": "RA Capital Healthcare Fund, L.P",
        "terseLabel": "RA Capital Healthcare Fund, L.P"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss",
      "http://aerovatetx.com/20231231/role/DisclosureRelatedPartyTransactionsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r292",
      "r299",
      "r327",
      "r328",
      "r329",
      "r430",
      "r454",
      "r478",
      "r501",
      "r502",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r568",
      "r569",
      "r580",
      "r584",
      "r588",
      "r597",
      "r600",
      "r660",
      "r664",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss",
      "http://aerovatetx.com/20231231/role/DisclosureRelatedPartyTransactionsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r292",
      "r299",
      "r327",
      "r328",
      "r329",
      "r430",
      "r454",
      "r478",
      "r501",
      "r502",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r568",
      "r569",
      "r580",
      "r584",
      "r588",
      "r597",
      "r600",
      "r660",
      "r664",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r418",
      "r703"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r535",
      "r538"
     ]
    },
    "avte_RelatedPartyTransactionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "RelatedPartyTransactionTerm",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of related party transaction for service agreement , in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Term of service agreement",
        "terseLabel": "Term of service agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r415",
      "r416",
      "r418",
      "r420",
      "r495",
      "r496",
      "r497",
      "r536",
      "r537",
      "r538",
      "r557",
      "r559"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndNatureOfOperationsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r272",
      "r278",
      "r419",
      "r573",
      "r574"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r341",
      "r712"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails",
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetailss",
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested restricted stock units",
        "verboseLabel": "Restricted stock awards and units",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostExpectedCostRemaining1",
     "crdr": "debit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsWorkforceReductionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities associated with the Workforce Reduction Plan",
        "documentation": "Amount of expected cost remaining for the specified restructuring cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "crdr": "debit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsWorkforceReductionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Incurred Cost",
        "terseLabel": "Incurred costs",
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r254",
      "r255",
      "r256"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsWorkforceReductionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date",
        "terseLabel": "Number of individuals terminated or notified of their upcoming termination",
        "documentation": "The number of positions eliminated as of the balance sheet date since inception of the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsWorkforceReductionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date Percent",
        "terseLabel": "Percentage of number of individuals terminated or notified of their upcoming termination",
        "documentation": "Percentage of the total number of positions eliminated as of the balance sheet date since inception of the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r99",
      "r467",
      "r482",
      "r484",
      "r493",
      "r512",
      "r596"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r157",
      "r158",
      "r159",
      "r161",
      "r167",
      "r169",
      "r230",
      "r231",
      "r336",
      "r337",
      "r338",
      "r359",
      "r360",
      "r373",
      "r375",
      "r376",
      "r378",
      "r381",
      "r479",
      "r481",
      "r499",
      "r721"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use asset obtained in exchange for operating lease liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r595"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndNatureOfOperationsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Aggregate amount of shares",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndNatureOfOperationsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares sold",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsTables",
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ACCRUED AND OTHER CURRENT LIABILITIES",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails",
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables",
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF SUPPLEMENTAL CASH FLOW",
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented."
       }
      }
     },
     "auth_ref": []
    },
    "avte_ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityTables",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of common stock shares reserved on and as converted basis for future issuance.",
        "label": "SCHEDULE OF COMMON STOCK SHARES RESERVED FOR ON AND AS-CONVERTED BASIS, FOR FUTURE ISSUANCE"
       }
      }
     },
     "auth_ref": []
    },
    "avte_ScheduleOfComponentsOfOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "ScheduleOfComponentsOfOperatingLeasesTableTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesTables",
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of components of operating leases.",
        "label": "Schedule of Components of Operating Leases [Table Text Block]",
        "terseLabel": "SCHEDULE OF COMPONENTS OF OPERATING LEASES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF COMPONENTS OF NET DEFERRED TAX ASSETS",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables",
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF NET LOSS PER SHARE",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF RECONCILIATION OF FEDERAL INCOME TAX RATE",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedForStockOptionGrantsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationTables",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsTables",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FAIR VALUE INSTRUMENTS",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386"
     ]
    },
    "us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueOffBalanceSheetRisksTable",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, off-Balance-Sheet Risks [Table]",
        "documentation": "Schedule detailing the information required and determined to be disclosed regarding the fair value of financial assets and financial liabilities, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r105"
     ]
    },
    "avte_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsTables",
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentsTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]",
        "label": "Schedule of Prepaid Expenses And Other Current Asset [Table Text Block]",
        "terseLabel": "SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r534",
      "r535",
      "r538"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationTables",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF OPTION ACTIVITY UNDER 2021 PLAN AND 2018 PLAN",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r52"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FAIR VALUE OF STOCK OPTIONS ASSUMPTIONS",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r97",
      "r98",
      "r99",
      "r132",
      "r133",
      "r134",
      "r182",
      "r276",
      "r277",
      "r278",
      "r280",
      "r283",
      "r288",
      "r290",
      "r489",
      "r490",
      "r491",
      "r492",
      "r584",
      "r611",
      "r631"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF GROSS UNRECOGNIZED TAX BENEFITS",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r592",
      "r693"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r196",
      "r579"
     ]
    },
    "avte_SeriesARedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "SeriesARedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Redeemable Convertible Preferred Stock [Member]",
        "label": "Series A Redeemable Convertible Preferred Stock",
        "terseLabel": "Series A Redeemable Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "avte_SeriesSeedRedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "SeriesSeedRedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series Seed Redeemable Convertible Preferred Stock [Member]",
        "label": "Series Seed Redeemable Convertible Preferred Stock",
        "terseLabel": "Series Seed Redeemable Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "avte_ServicesAgreementWithCarnotLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "ServicesAgreementWithCarnotLlcMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to service agreement with Carnot LLC.",
        "label": "Service agreement with carnot LLC",
        "terseLabel": "Service agreement with Carnot LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails",
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested term",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discount percentage on marker price",
        "documentation": "Discount rate from fair value on offering date that participants pay for shares."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of units, forfeited",
        "negatedLabel": "Number of units, forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant date fair value, Forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of units, Granted",
        "verboseLabel": "Restricted stock units award",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant date fair value, Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of units, Ending",
        "periodStartLabel": "Number of units, beginning",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant date fair value, Ending",
        "periodStartLabel": "Weighted Average Grant date fair value, beginning",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of units, Vested",
        "negatedLabel": "Number of units, Vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant date fair value, Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock available for issuance",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "avte_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Duration of offering period for share-based compensation arrangement by share-based payment award.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Offering Period",
        "terseLabel": "Offering period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options, Cancelled/Forfeited",
        "negatedLabel": "Options, Cancelled/Forfeited",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-Average Exercise Price, Cancelled/Forfeited",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Granted",
        "verboseLabel": "Options granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option grants per share",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value Outstanding, ending balance",
        "periodStartLabel": "Aggregate Intrinsic Value Outstanding, beginning balance",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock options granted and outstanding",
        "periodEndLabel": "Options Outstanding, ending balance",
        "periodStartLabel": "Options Outstanding, beginning balance",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r309"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price Outstanding, ending balance",
        "periodStartLabel": "Weighted-Average Exercise Price Outstanding, beginning balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r309"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Vested and exercisable",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "periodEndLabel": "Options, Vested and exercisable",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price, Vested and exercisable",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Vested and expected to vest",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "periodEndLabel": "Options, Vested and expected to vest",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price, Vested and expected to vest",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage on total number of shares outstanding",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
        "terseLabel": "Common stock available for issuance, awards granted",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfUnvestedRestrictedStockUnitActivityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price",
        "terseLabel": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration period",
        "terseLabel": "Expiration period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted- Average Remaining Contractual Term, Outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted- Average Remaining Contractual Term, Vested and exercisable",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted- Average Remaining Contractual Term, Vested and expected to vest",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of common stock purchase price",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "avte_ShortTermInvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "ShortTermInvestmentPolicyTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term investment [Policy Text Block]",
        "label": "Short-term Investments [Policy Text Block]",
        "terseLabel": "Short-term Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss",
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term investments",
        "terseLabel": "Total short-term investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r624"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfRentExpensesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesScheduleOfRentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term lease",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r595"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss",
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r24",
      "r125",
      "r143",
      "r144",
      "r145",
      "r157",
      "r158",
      "r159",
      "r161",
      "r167",
      "r169",
      "r181",
      "r230",
      "r231",
      "r291",
      "r336",
      "r337",
      "r338",
      "r359",
      "r360",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r381",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r413",
      "r479",
      "r480",
      "r481",
      "r499",
      "r553"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r181",
      "r455",
      "r487",
      "r500",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r511",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r530",
      "r532",
      "r533",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r553",
      "r601"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Cash Flows (Unaudited)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Balance Sheets (Unaudited)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r181",
      "r455",
      "r487",
      "r500",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r511",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r530",
      "r532",
      "r533",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r553",
      "r601"
     ]
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseByTypeOfAwardsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Member]",
        "terseLabel": "Employee stock purchase plan awards",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued",
        "verboseLabel": "Issuance of common stock under ESPP, shares",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r71",
      "r72",
      "r99"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss",
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued",
        "terseLabel": "Issuance of common stock in connection with ATM, net, shares",
        "verboseLabel": "Number of shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r71",
      "r72",
      "r99",
      "r489",
      "r553",
      "r565"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted stock units, shares",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r71",
      "r72",
      "r99"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationScheduleOfOptionActivityUnder2021PlanAnd2018PlanDetails",
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options Exercised",
        "verboseLabel": "Issuance of common stock upon exercise of stock options (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r71",
      "r72",
      "r99",
      "r313"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under ESPP",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r71",
      "r72",
      "r99"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock in connection with ATM, net",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r71",
      "r72",
      "r99",
      "r499",
      "r553",
      "r565",
      "r607"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted stock units",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r99"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r24",
      "r99"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r75",
      "r76",
      "r91",
      "r513",
      "r529",
      "r554",
      "r555",
      "r596",
      "r608",
      "r632",
      "r658",
      "r697",
      "r721"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquity",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquitys"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY",
        "verboseLabel": "STOCKHOLDERS' EQUITY",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r152",
      "r275",
      "r277",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r291",
      "r380",
      "r556",
      "r558",
      "r566"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureSubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "SUBSEQUENT EVENT",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r422"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndNatureOfOperationsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureSubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r422"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureSubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r422"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndNatureOfOperationsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureSubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r422"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndNatureOfOperationsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureSubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r422"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureSubsequentEvent"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENT",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r423"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndNatureOfOperationsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "documentation": "Different names of stock transactions and the different attributes of each transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndNatureOfOperationsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForOnAndAsConvertedBasisForFutureIssuanceDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Sale of Stock",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponents",
      "http://aerovatetx.com/20231231/role/DisclosureBalanceSheetComponentss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "BALANCE SHEET COMPONENTS",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary equity shares, value per share",
        "verboseLabel": "Temporary equity, par value",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r42"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockholdersEquityDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary equity, shares authorized",
        "verboseLabel": "Temporary equity, shares authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r274",
      "r288",
      "r379",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r474",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r653",
      "r655",
      "r656",
      "r657"
     ]
    },
    "avte_TwentyEighteenStockOptionAndIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "TwentyEighteenStockOptionAndIncentivePlanMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Plan [Member]",
        "label": "2018 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Plan and 2018 Plan [Member]",
        "label": "2021 Plan and 2018 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "avte_TwentyTwentyOneStockOptionAndIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "TwentyTwentyOneStockOptionAndIncentivePlanMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureShareBasedCompensationDetails",
      "http://aerovatetx.com/20231231/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Stock Option and Incentive Plan [Member]",
        "label": "2021 Stock Option and Incentive Plan",
        "terseLabel": "2021 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "Agency bond",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r585",
      "r713"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueInstrumentsDetailss",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentDetailss",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsWithUnrealizedLossesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury bills",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r585",
      "r587",
      "r713"
     ]
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsTables",
      "http://aerovatetx.com/20231231/role/DisclosureFairValueOfFinancialInstrumentsTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF SHORT-TERM INVESTMENTS WITH UNREALIZED LOSSES",
        "documentation": "Tabular disclosure of unrealized gains and losses on investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance of unrecognized tax benefits",
        "periodStartLabel": "Beginning balance of unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r349"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions based on tax positions related to the current year",
        "terseLabel": "Additions based on tax positions related to the current year",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureIncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to the prior year",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies",
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r39",
      "r117",
      "r118",
      "r121",
      "r122"
     ]
    },
    "avte_ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram",
     "crdr": "credit",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndNatureOfOperationsDetails",
      "http://aerovatetx.com/20231231/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the value of the common stock remaining which can be sold from time to time under the ATM (\"At-the-Market\") Program.",
        "label": "Value of Remaining Common Stock Available For Sale Under ATM Program",
        "terseLabel": "Value of remaining common stock available for sale under ATM Program",
        "verboseLabel": "Value of remaining common stock available for sale Under ATM Program"
       }
      }
     },
     "auth_ref": []
    },
    "avte_WalthamLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aerovatetx.com/20240930",
     "localname": "WalthamLeaseMember",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://aerovatetx.com/20231231/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Waltham Lease [Member]",
        "label": "Waltham Lease",
        "terseLabel": "Waltham Lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails",
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetailss",
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares of common stock outstanding, diluted",
        "verboseLabel": "Weighted-average common stock outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r178"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetails",
      "http://aerovatetx.com/20231231/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfNetLossPerShareDetailss",
      "http://aerovatetx.com/20231231/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://aerovatetx.com/20231231/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average shares of common stock outstanding, basic and diluted",
        "terseLabel": "Weighted-average shares of common stock outstanding, basic",
        "verboseLabel": "Weighted-average common stock outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r178"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(27)",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b),(f(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2A"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-3A"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//210/tableOfContent"
  },
  "r622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-14"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479365/842-20-25-6"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>150
<FILENAME>0001104659-24-124782-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-24-124782-xbrl.zip
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MHC*R':=?M;6P??+7F!8=(Q24N''H$4#:VC4FT(?UU[:U.99<T)F5A7#+)C,
M4;$K:>L0>BQO>J 1LC>$GYY=[TO-B-#[/W2I1/Z@2XU7U? 63VY?M>T/XC1Y
M4S\'*:&Z4!%,PND8V_RL L2<=>N& S&KZ'D@*LQ9 & '$(#QJS[A9141XRI0
M,R:$3NM$X<W+:(#V+2BTK1=DNQ]TK> 23J@!>J'Z2A:@7)CY5:#BRT8Q(Q\
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M:*7LSC$+QUGM$%8[< !,@H,Y9XHR6#Z6Q[OH])<_@U>IXH;$F]%3!UWF^F<
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M^;N3^"P'-W,C<9Z[W5ZOZ>LGY3JUY0@D4((>:#-3W*((CHRSTI*RI!&&KUJ
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M!X8H:9W$%=.)8BC"$\"!2=_)P7[$TWO!C6;Q?$*FQD<OH08<(/.L3K(R!G
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M!#W09J:X11$<&9_O"*;GHB5E22,,7[4 Z0A'2/[*K4!$F]$ ' T!&]$6E1K
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M@]7(+[.O$2T$/W.MOVF\D^-># ?C*Z%< WEF<B68$4RWTJA-2(7C,)5,1J8
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MY8?A:+@<*K1.Y=-L^9D LU4M,V\A6VO3\Q4FUHLI_>=6@Y?N\V!RF*8P.ZL
M)U5E\V)8'PC-D;\,$$T(FUKO]+$NQBK 6)T_9QU)0\")XE8Z'Y1S\ EHND[(
M[A8YC;)U2=$Q-O%FNY%-<ZL:WK7)\$#6HV7'[U-FGL3OCB=Q,FV/A\$>)IVA
M^]/)<CCYIDSZ_JP<.Z6R6J[FBC0>3H;CU9@4GZSDD312Y(4BS>0__$8>IW-I
M.E/F,FW&_W@*2V@:,D2(DPPS1&!P=$!$O%K=J<,%"9L0;5F^(>,5)6YLYFT.
MC@'*"G L$7F9W /T,H3XFZ.-BND)87I\PR'0_4'<JR+JPFPP+K(VL5B-98*L
M6F'$^0?HK(A*A_*T?+,*FI6@E0M2CA2F 5[TX3!T@#RW% QJ2\X)WJB.I@"2
M/PGX@1)"FLF2$]9GPY2YMCAM0)-8 K236.URJ4_H[)S.DDGZB1(L=?Y9.X'@
M9V7JP8.=]&5%C125-_1?>3P<7EOQ\=DAZX:S\W,RL7XZ$TVV&>8\<,["W*E-
M,O-]VK5P^A"?.;I%9@YOAVQW..44 FBD3WI)],C*[WYO=(@R2.,7A#0P#VCG
MCSPNX0#-Y^Z*3QHVQP5/!!M!PHL9Q)]O?)D%0_Y?_P]02P,$%     @ :3.#
M67/(=D@;/0  SOH# !4   !A=G1E+3(P,C0P.3,P7V1E9BYX;6SM?6MSVSB6
MZ/>MNO]!-_MA]E:MD]CIGNGNFIXM6I83[<JB1H]D,E^F:!*RN*%(#4@ZUOSZ
M"X"41(D "%(D<>BH:B9MFWB=!PX.S@M__J^7M==[1CAT __W-]=OW[_I(=\.
M'-=_^OU-'"VO?GGS7W_Y/__VY_][=?6WV^FHYP1VO$9^U+,QLB+D]+Z[T:HW
M#S8;R^\]((Q=S^O=8M=Y0KW>]?NWO[Q]__;7GWM75W]A8]Q:(>D3^#TVV,W;
MZ]V'?CI<X/_6N[YY]^'=S?N;G\A/O_UT\]O-'WO&PZ[A UG;TBULZ;G^M]_H
M/X]DQAX!T@]_>PG=W]^LHFCSV[MWW[]_?_O]P]L /Y'^[Z_?_>UA-+-7:&U=
MN7X86;Z-WO1(^]]"]L=18%L1PU"F^\LC]G8#?'BWGTO8@OYVM6MV1?]T=7US
M]>'Z[4OHO$F72#\K3+)K_I)KG\)T_>NOO[YC7_=-R4!.M&^;'??G=\G';%-7
MLHH]AO[R;[W>GW'@H2E:]MALOT7;#?K]3>BN-QY=)?O;"J/E[V^LYXA"??/3
M^U\_O*<P__LL(B2GS-0/_##P7(=RP/Z/H;F<18'];15X#N'/P3]C-]J^Z='I
M%M/A?GD6PL$SZ1*]O+6#-66&#]?D?^]HNW>59F!(4"+"NS,1<.>&MA>$,48F
M?K)\]U^,R0S?F<7KM86W9'WNDT_8W;;\R+#M(/8CLC$G!!+;1>$=BBS7"TOB
MI*Y)=:")B ^74&V"44CHMU]XDT@Z9\J.H(@*/B?V$.D51*23:WG>]L[UXLA]
M1C-DQ]B-2+-Q$ U]VXL=Y S]ON79L<>&-Y>L+7+&*!H%83A!>+:R,-* ^:8A
MT4'0>\O%GRTO)D#=NSZ1NP2H(9' F)W#&9#W#3-?SZ5!/9.#1MML%>!HCO!Z
MZ#^C,*)?6\.:;.ZN(2W\0C3!A4_T.,_]%W+H_CE?^C:W(!WH[0?KM9NLC4@R
MHI-0V474[1J.*96A=8"<5[#.A50R(@P #TQ)B1+XK 4[1\(I.<KP,W+N VS2
MP\P(":7([8L<.>RT(W^_CR,RZC ,8ZIBUX^L1E:G!?%TS>P^20#9(#]D1_C9
M")./"@?0 QT73.(AAY OPJ[-;CB$I@O?)1H247SJV',U+@$B"C/'#%NXN:'?
M0X/P^3KYL6D,EE@!1 2R->>^#U[HCV1R.R!*^[^89,E ]Q%;-:BH;2RM<RB_
MW<[)I.;2^&YA1R^*!4O1@=(I\J@!:&+A:#LG% XMNY;-73BN#F#)#3=8H[GU
M<KYRR1NJ/9"R1CR'<I2C;LU;^%;LN*39&8;#,^8$8$H<6U1C,Y?F!F&K%FY7
MG^!B_R)H>$4&,.A6"8D12J\)##KBQ'8HK4:P#J)-9G2"9P8#:P=KTA &QE!T
M-JRR(6& V("U";@Q3"?JZ[>&R4>% VB[UK :EP 1A=+K?-/(4YN\<VBKV2#3
MP%*TH#1^#-$_8W)8#YYK\+N*ABL+&EO]#K[3M2RM\)%UC<.K)\O:)(M R%F_
M&[R0.U?H/GIHX!/-++D.C]PP"M\4HHF.'NX"LW)S4(C?(2\*Z5_HA"%%Z0>&
M3CJUTLJ5F<OR'<(:5'V*PRA8&R]N>!>L+9=(_J45>RK@R#>2P@09>"QL[T!*
M?\Q"1<F)PK7U%L4XV-#_,!R^(^?W\EW:_MUWEQSZ5[Z%<? =835JG+**A_%^
M/#KA5?H+ ?/ZEZOKZZL;%LKW[Z=S*4.RG\GUHW>.N][/MB+KQ';\B*[(7RF'
M!7XU$#+!?C0 \6>V7N[HYR]Z/]B5PTA;XXKS0]>P7#;2U1JM'ZLR"'^MQ^.>
MOU#+\VI<'ANM5F(G.[@9:N_&SBR8_,TEBA43M/ZWHUD1%<<.L\/NY6(3PI N
M9K<<+["/UN#1R.$ 5Y;U]"\'49_^X1\'\[1GA3LC-%W9;A[/>D3>[V\*VT5N
M1'$B:?>N?>BRB[@[DATI6.(&*3R\!D> '+C&P,<@$8[>#98R]QG<O\3!6H4*
M@0),AR7_UA..V(N"'F^D."0C!,RU:9$-'V!R1/W^YEH+>>_08W0P7G&X5MP@
M106O@79 QM8:<;FUJ!D7J&PS?9PKH42@#%B6<?,#4HX5#P2);T5>WMMM]@N'
MG\MW3#%7IJ-FA' Y7]R  Z!^;J] IT !R"S_JT]!]P5OZ!IW1/Z.1O_RCP>7
M7"^CP$<<5N9^2^$\^5;_>K@\)OAZNB;]W,5'75 $099[CH:@#)+K"DE>[I64
MQ-9.+5%DI=0O(U%496U/E55^6PV0GBR$RZ?2-BED@C8 -%<I60(UZ+@*+&]@
MRMF" 1OG[Q!'&8J3WP[4)K_\8VKY3SRYF/O[[H [_+W-%3X<63&R:SS^DEWE
M0]9"H>?\S2$QD*WZZ%S==67'9K:+;H[ITP@=A#?T#*>:+8=Y9$UV%UIND[98
M"FUB;*^L$!E/&*5A<<?K$:A_)?OMM4+E?OJ854JTH#KP6:[FS9'HA<IC0U((
MF,.)^IXX>X#[+47)R3<=J@PW -K F$H:%FMRNSVTF5A;=KNERSZLW7<FGN4+
M-TN34^P4IT:FT+<%^3P3M(++[#8]6@?=G\W,#VDK4T^KZ[@6WLZLO<.9I]<7
MM=NQIKB=#N@.:Z $,)>9JSI_\RIWV,&KT$&CVE](M: "S$?ZOV@&MGT41H:V
M&3)A!X(3KJ!59B-P6\& B\_]1>W$L,'@=1E9 G7X3AF<,RQC;_%PNB\K^VOY
MS$:^A=U 9JKAM3DUT1RW:0N*=-*%'VZ0S:I%\?FVJ-T.&G$[ *89+AD"=>BX
M9IGLH(QGQ8-!DL0[E8G#MKQ/*0:./VE<-I=+I6HH'&6<B]^@8/E9WLL.0%D.
MLOIK^!'17DZSJ@8O24K5/4$(5?SC*$VJ&EC8=_VG?3K5[98_ .]>W/Q,NUMV
MDS.!H9%PFZDVEV(+QE9L@V>"TA@[NC$WMT(J.HI7!DF8<#*Z.(*@H%6*9&$K
M#7"Q6]L289J'-4/XV;4)#?D);%0'#OF?N)NUB:%3#-8[M#XA4,0O0:-8S&YV
MP4KH1JUW!9 V==\*5S1FE/R'NC*?+4_@^2YNN',!21IJ"?[9)3?Q%\;_*]\Q
M6<-0>]?1.4-I]"85<T%0*Z*.W$S"R1-GTSF30MJ3^RSJV^T#LFAT-Q4?]Y@9
M8VQ>Y%Z)'KL#6*6'3MAYJ^*>L25ZG,(NZZ'Q1"Q!S* *_$>'7O%D=',I30)T
M#^U__.0B3&BPVH[0,_+DVTBA4WXG23L!V4QA?I'*VZJPKV2#2?J"V&HJ!!?L
M-E6T"/:=9&;1UI/,"&D3'HI["'Q-X@8IRG@-M /2MR+T%."TM!17553OP 64
MWT'?/I'0*:@ ;'8CY(>F3*\R)"1.'Y&]B6@1%VS946QYM+0-A]^+FJ7X$3<#
M AKWQ"AN* %/_UE02)N@!(A9#A<-3/E<-B D_DXJ*^[=;KMW9K@BO;#E7N1)
M6L*!D<OK2FWE<.KG>!52!>5@/9;LPN$3$2\=%A+W"[*AU%/HU'/F0"3)%861
M*;65PZF?^U5(%92#52&#CI<R!SQL;%]5UXBC%='"N+FC\D9'DC#?" 10$CDO
M;B8$3#]_%U D4 8N+]-/!SV(<]Y@D'B9K*^/D>-&?0OC[3+ +)@YS\Z%[79>
M.'$[*- )(PD46\L@A1%'4$RLH"RT69X7#L\\@T7#-L7](;+?/@7/[QSD)JQ!
M?CAP!/F%7-R>+&_@1WR!+?BZOZ*=?&U\M<ED_)14SJ==)NK1)YV71SXV ^GJ
MCV^)1R.PW-*CGG)&^O.[$Z!'Y-?SJP]5*R*G(8@J#%$4&H\ANTB?ADQQ/^X"
MI$X^:A#;9K1".%G'./#M&&-R'SJ!0=HF!470ILE=P2M&E@9W\9$>J(%R%(1U
M-!+=&((13G;(!KM,#_G]S7O=B1><:M<G])4UV:?%\9I HZX"('+B\@=0H.W-
MQ36@FZFY !<WE#!X&[X/,9N7H)6 ]4OZ/WA3B#:%P \B$WMB+8&K(*@7(JSV
M@+5$"TDQ=?W^_8?W[WM7AXP/\G/?',_,T?#.F _N>K,Y^<_#8#R?]<Q[\IO9
M_Y]/YNAN,)W]H3?XZV(X__I&O:[NCLG:K3LSMQX/12?332-J]$[/$A5*XRCV
MV0%0[Q[FUH8],']V3\O13_>Q(B0G^ZY=RJB4\BEHVPPE\C5O%<E05+JG !JM
MU)C2"MX^<G8) -QSL*AQ0_0X/MWDQ)"71PJ*8=!*!<-QW&3FB>6R!Z,V;F1Y
M4F(4]&F3)C=GTJ0 %+VDL>UX'3.7![N\47 P6E%)\9P^VR<GDWK_-DGVX5R2
MJ8.EE7R95V>D9.*T:Y,</YU)#L[RM:+]X!PGLG9(?BS4N3(-FT$\J\.N>*+G
M5LU5KE+UZP3127'UW^S C\C58."QIK^_"='3.K$6I=^]($3.[V\B'+>O'+/W
ME\PX"FGM=7(*BHB3;P?@6%&D4G[MA_OEM?;M(;I3YK9'OB& 8T)UH^07#X<&
MM"3V(75UCBW*),>O^ F(HM03P.FA1B4E:#I#MH_BRZ12SS;)]G.#9$N@@4,V
MP_G?.+7^S0.!OL]$]N-I4;<I(J(C=".4I*^B"2) .>FS\K0!RR807I*:GK9-
MAOGC.0S3/"K@<!L[>>BSD<BY(SO$?TJ6S-8Y1M_9%[%&JM2W3;K_Z>Q3N!@>
M\,1+%+J*U,MU!F"R*L6D"A3-P0B>I S4DS<\67W.,8K,Y7V E\BE#\!6V:IJ
MP[;)!K\TM8O50 7/#?M7@6MFAS+C A<+99"C+#%>"?LP!+%O)EM8.'A!V';#
M@V>VA/00C-,F>_S:E+@0P :>P FWUD!AZ4# )8 4?.4MWU468"@8K#=>L$4)
M*B9IF7Y:R[#"/I>,U2HCO&]JLTL !$_MA%>%$%12 V2C =_ZA7ROO/UE2(##
M%40'21R)$E/L29M6*7B6$^EDX858__.[^D/?#F_PFOC)\M/0/5HH+EZO+;PU
MES/WR7>7KFWYD6';] $4RDF!Y]HNRKQKG\&O*!KNI_?7[Z][5[W#G.07<_K1
M& __;LR'YKAGC.]ZL\7#@S']RN+AAA_'P_MAWQC/>T:_;R[&\^'X8V]BCH;]
MX6#6^X]T^O\'-DAN7X#?Q(GWXP%%J\!)XB#)YCO4X+_=YAOOFDE#[&J=HH;=
M??Y+3>)F<,+O&B L%0UBT.L7PPV]1U6RK]XXOB*.W-&D^EM0I0@E>)OS-EA:
M!S\/.3/><N-8"MIJ5&TJ\1/%?0%(>C56WNLJN0-?**[YG?3%O2A!<Z1>UBH#
M.QA!<X"/Y@VX3II%.$4V<I^18_J9T@@B=B@W!H3(F_)\4@Y&.)>/[ M),<4-
M^87=G9([U; <?16&@!#5<PYY%4"$0]T)#FR$G)#6P:=+M7R;P)$)HA205*$?
MA+B?TG14@*LVX@GT'&;B,)=31 $EM\S,Y,8SN>C1D^(^P!2B!;E@8B-:DU4_
M86O-TX3.&0U"") R!<^&%LZFI/6M3RMD^XY"!G*5 2"$[93>IF4 U&Q1NK5"
M-S27$W(6D/7L#4LUVI-N\O:D6V,V9,F4D^E@-AC/,X:ESEN3-*5<5GRM_>0;
M'-N-,'7R9,7MFUR$K\KGONHWFW#?D<^MLW4</A!TK..U$(LGWW4;1?(4WZ'Q
M9*'M(])ZD2/R^+O&JVD1(H\7>LF)NN1$B:^$Y#2)MM0-&A%5A>I8&[JZ18B6
ML3=REZ)35ZDG!.N-$B65H(%S:1BN-Y:+Z?K,Y2CPGT;4JI24YOF$/(?<>LBZ
M!813[ O!,J-$.D5XX!"/GVY@8$P%.H7C=GMH,K&V]$\L/''PLG$30V(2UB 2
MI/6-#\&LHY[W6 _,<!AE9UPT-\Q^[#_-DI-#&!8B;@_!NJ,6(2*&H7MW^YF]
M0DY,K1R3@%SH(Y=H'MN[_ .B 8V*84^4TIPDSZ85!ESZ0"EKBVA<,@V8V3U3
M6MID\*$^D\%5;];_-+A;C :LNSDGO8?&:/2U=S<<+>;#SX/>;-!?3(=SVGIL
MSGO#<7^TN!O<D1]Z\T^#7M\8]1>C9$8R!.M&OHX'\][(G,UZD\&T-_MD3 <=
M,$_LZ7OFP[-2\T;-D[2< =G:B]:MS C'I-,(ZQUE3C:)1[U9N>5>\%;O!J-"
M5TO/=*NC16_AM6S4;Q+\+RV)(VD/(%):^6WT0 DBS478CC*P%@2EX72V**C%
M)NT#P-Y0A4(%4 $4ELK2I,CJ5]_PVFR%=6/HZ%Y;\S'?/0OEF7 ;:WHG:X;Y
M=F.#E3KU\&!-6-)\?=^_P&HN[UW?\FUR&1_Z1.[&S+QPV&C[AIFO)6_<'_).
M^GMC..U]-D8+=F^^'XZ-<9_<F\FE>#:?+I)ZR,=WZTR/;"/PE^(]_M)2\;XS
M<JU'UV-<D[Z)ZY@T%C+&-$6+-!@'/M[]RLPLLOMPC>.W*\DX;">YQ@I;@[F"
MUD[HK- 1@J]5&6*!G4N$60 2*PM$ .$+%%H=/N1_DMXRZYT"QHVT@/.S=*\7
M?.U%6&F2.:TV139782%63EL -\XF6/ZTABL'<JV46\SFF,FO[4'?D9)/U@&
M=M@T#67@:]Z">!-@HAP>UPTLV(K2/@#\XLUO22D&-&_-C\$SPCX[0YZ0GX30
M*A-7O3L UW?SVU85&=HCY D&3D/ Q:JSK$/[VK- )C>J/<LP ,3FRU\B_Z^*
M)N$J0\)0D(M9G&\NK@*Q5OH_!#[:/ECX&XKN8]^14U;4&(!67 <?9TDJ E5
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MEH4 SOTI <0D>HA%E5X&$94&YG(G'J2[2=X1@&6Z\M:20U8; 05GS-"W:8
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M0FO*)_W ?T8XHBG?$](788P<QDQB7T.E80"X=Z0LME?!*T'7&+&,&BA59@P
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MZ"G!@E9J$@4_(E?%*#5.+P@9PNEL(:5H01\ 7K"VJ%J "7CA9KG;JTK,V0A
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M'G/QL-Q@ O_\.Z'U-OG7]+/W$*(3#7U:F=!]1D(=L>(8 &YX8GVO(DR-$6=
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M)Y>#$22!QS'%3?I<1)A8B8?EZ*LP!(1 Q'/(JP B'.I.<& CY(3W!'ZZ5)H
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M85$G2)*^*:XIP@&<_,(2F83Z<P8;M$!)R5DQF;"]^%8&]QX-AYA!4<RJN#T
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M+%OX?$J=,^A[OJ=^/*D;%=3T_.Y5'Y!#7838$0K#^<KRKV\>2,M5-7]H^4D
MJ!5:F;$\QKIBGRT+62:LI+(__NPY :A#G6+'' )?"W?N #3Q*/"?A.I8W9,
MT-] \U\>8Z^5X=H0AX5S @AM[!0[=E8<\L&KT9$!(C02X+6CZRQ2AYA2'!E
M4"5 !BHO<IKU:5,CN9MXJ.F+! PM>UMJ.>_TS_D7/?OFP\,P=3 ;XSOR^W@^
M''\<C/O#+OB6J?J,T B1B>]0:&.744;F-);V:%<\L$50@E+VC2V/QB-(W,'B
MYF#\P0KDR&Y/,41:Q39O65*_K:P##"]L$:L54:4.IZH@'?:+Y44K:\UFY5KJ
MA:T >$B+666?O<J#H %TW@=AA'"?G%<%&!4T!& _+(%4 1":Q0=/"(X*$OH+
M>VGS+2C"<RQ").= ]QP!!M$3S>7(\AT!\;(-0&R@TA3+0@#G I4 8A(]Q*):
M+X.(2@-SN1,/TMTD[PC -%UY:\DA@TW  =$[R W%1N;23.1"P,*(19NKY!@
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MU27KNHNQZS\1?G(#)UGO&'UGG\3>;[7.$,)-U*_/BD !HB%=V@2[MC#((M,
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MCV$&02'I;1/F/9''7#PL-YC!/_].:+U-_C7][#V$Z$1#G]:]<Y^14$>L. :
M&YY8WZL(4V/$&;A/JP@A_PS:E!@"P#5-B30E0&I^VY"9:Z/568,"N(Z5VUA5
M@(1M(A6=I86.SQH&UN<<K0TK@ISX<U68[GE/*Z-T%P:>9HQE'NGZ2/J*2B8W
M-QV $Z4A]FP,9<"R5*K >"B:;"[-. HCRW=<_RF)#$PN>'5SHM*4 $Y(8-RH
MA+97P)$GNZXHF;B!>;H0EZ95$H+,;CX;.,-QW&3I;;&>;$8 -2> ,J$,:Z^
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M+:"<N)&]V@=&AK(471RL*+LPG=\2MX^6:'=R5>VT&5ZO+!.VP54T09,$0'1
M_K_W[]Z_?_^!["R?O "+_R0?W@_81_ _$FPL'W:Y]N'&\^U_PC9' !/;.?LY
MZ/:)I=\_O!\0_MH#X/,M74:??N"?_C @K/N.+D/[A3J'_R2N%Y.T@R#9-=F'
M\+P#O&]!K%"1MJEDQG,KXRFG&>Y@*M+K-%=)M\$;1H62-LE*/+<L@/Y0&D&J
M+OZ?Y.,?!W_\]_\8_,>'#[S]1_;GOW\<_,?['RXIJH:K%:_M9#D/EKT:NS?6
MSF8SEX)?M[@U[ABKT#)SKBB_*=Z(JQ)8^=!!0I? />(KVR5+0=K0X;?]=N]
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MQ[-;^F<M\49$A;R-UI.NSB]"$/H*?[=26*EZP0B%KAW=_-PQ'+'+0O&D">X
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MH"%A&PGP**'2.Q"1T473?1$[9F7ZE'A4UP/JMB__L;=].M]X?KB@_C9U0JG
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MG35)^1C<@ Q.9&EJEYRYDS2-WLR9ZFND&C",W-ZQ?+(ZOA[!)@'+A#_\RTM
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MUXFK16YT^>V*5^(FT6HN22WVPENW/'LS<LJE _7YY0=/O#;0\960]K6+7E:
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M%$$R$HM6N:@W($<1,2[PF;!T;$0[XDI\NJ3V"XAU&<@Y#]F  !N+J7<S'KS
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M%]5J*J%>>3ZZ(AV0< -W?M:>O^5"0<H:1G?G0H^X7!X8$UY (EYCFS*9Q.
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MV%L+<DKPNT!,K:.U\B)PPH,P<.#/,J8.TT=7J[PC\U[!0GSD7+)60AM\+A0
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MF$5[T5*-9%?<85%'_W0\R/3#&PBUI&]0SBSE]?S,EG!]SH=\ 4Z$LS*S0(O
M",8C/@M]]WM8G9ZNDTN](\?>LD$^A'0'(HE]MO!NB]]CT46[1YC1U(*%H*)*
MN">HTU@]/1%Y.A@/B! %ANU$&'*4AM_I%_+ 1?1;4T^SX+#ET5:VR[>,]Y83
M$"9\Q(^PB83KA?;:AK_7<&_?]LE^M_2V8/RXH5KI81Q(^$#93UNXIJR9Q1O
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MCX!:T5Z%>%V37L]@6U4[#3NU0<([#C&(*>N9R0;GGH]+I3O?7E*4Z-VU]7)
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ML\]0ZINJ@(3,'%R0.7:\/?P H)^#=J#BHE.(0Q5 <7U7%; ^^UX0H/VVW=0
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M]E9D?9P4U4D9;)V/-?'Q1!-0FN@^\#""A=A;W%4GX6Y6JKX>1 3?O5V!]W\
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M%FA(>/1_:'?CS7*0YW!(Y(1^@!8Z_0^)DMG/!\._.QMTI]E\7[Y8[C.80L?
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M[B*VNN 9?5X)OAZ 2</$2$E2]0OKN)#1/NPWQZ%9+OT->J,+=A!079J1YZ+
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MEJ@WU.5<?D7E-,REGPS]%I-8D:7Z8#*F/AJ\_UTYM16#_51_= FUM\S87L5
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MRR/;L</M%"Z3XLE?M%'F[D!:#9^@&CZ>$;/E0:R[6\&!0N1B261ZU($+T^5
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M&;CH(178;V.UMET;28W2AM-UFU,K)?!'^2<&9;5;1%Q%]HI.1&<UL4W3(9N
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M[YXW<*/KKT80@)"T1"K6F&J<*JE8%J84AJ7L8NLN6FRYX!GM-<G*K'\,;_Q
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M>S0XAQ)3\+KQER_0_AO//L##XUC6OK>V;#>#)\QU4TC=MKN=J[84\G!I,DV
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MAF:YQ55$MT?]I2:ER2RKG"ZY-7&J379!*\U',P,^6@L"](C$"H UXB.<ZM^
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M,BKV,+  LQ<+/5FP"5\\W_[/X>PAZ8S1RJNF7G;E'#E>W$+J/[2]]=IS65C
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MP?\SIU_-?I0%=X3OQ1FS#[WQZ*LYG<-_OS=F@]G_PC_'V70'L]G"&/7,RQT
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M6VP!)C.&&><J]F99E&;XE/JJQG,2[>V^N._'$:XW9#4%]@R';86H8/ 6AK'
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M FVN^O(RY;#M=>& :AX $D)+%%C21N'NA8=A?UI\3-$8@OW!:9]5S*JU#M'
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M. RTJRO=/9=C&;5N74-27@(@-CP X@F*P/O-503.HFFD#0O 4H9BA3".&=Q
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M:YU(XL/&DD2Y\0(/*F&.$Z\J*>*U>!N%H(F3)IPXO \UV%R[(MB<@M$ &(6
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MP47\C,I(C7R$N<Z_X6NPGBOD/S!MT0SEB&^X6K@W*.W<ME0:6'=6MC >^K-
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MFR&&O5_ +A?,Y.%25AI(MQ)N"$2<D5WZX'X"GSK:G]?%=GR2]^/%O=R/O:(
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M?*)RC;R7)MW9V_!OL#N@9L+@;@81A7; ]GTTGH$OFV$O,[&6KG<F69KJ AY
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M*_M1EWX1SYV8"P?B[W05 )%585B.F9*8SH*#%IQ; (3N0M %X=WQ?&1DZ4_
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M%'BK^F 8NIVR'?WUT3HQHWMJUZ*J;RZ%CS2C<4GUYYR>XYD)N]&;++C$#+X
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M;-GTGT/OSQ]MP4=)2I"MJX,4(IWGI"OS@F58UX8=P02YNLX.(1^T-VVW$/_
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MYOM#K_Q6Z/5Y4,?E"G^Q$+G12],M_4&3G8RRZ8HC4WZ_7 "SX=B/Q$G9W><
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MGD\EI$%IH$0)^YZ#_G3ND=R\'<-\J]P\7QBPMC^J!G;3;PG')#]1F-KW$#E
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M4-M\S/%3JE9FEM16&E;\[2$<Q \$#6Q8CQ[QZ7K3QG(L)>]:](-12.:-F<)
M06M00@WGL18K(D&WPQA[I A2>_'H^:O$0/59]F2(:S_.G2\NF,,ZA.:%+(T1
M9(W1W'S1U!60:FYROLP)Z,U)7Z>_2M:BIA)8VO?\CO<N_?$)V:'3OF7HSDMM
MWG_ZG#@2_58M)*EHX\S8;185L<U.6'H:\3(R$UH1+ :19.$> 5W1'8:NX&7G
M<_5J5)PBT:02^;S3J]3N>>G'*W^'F,,9FPVM2LZI2/-:)%]VTPB"DG; EGN4
M3&0+ +QDR;%$<'(R>^F8A<,Y.)"NC*4T#KRN[SOTFK\BJY\2.A773H![XLUL
M.;P))J D?EC06TJ*B6&/Q@2)\'[:@.,(-<8I8<_06#L^2;JH5#8C0R->EW=H
M(E<C[8F,2XF3WN"[E).?M(L@O:)I)G5E:&_T?\ V@@ =>H]XZ*]3/],2_H%Z
M(FJ%95"[BJ'._:_C8D_RBX0N',5R??])SJ*.RH<JW3*<JR[L%1/<D\:W#3YP
MU%#?8S\7TG&.J!OQ418Y4&!K(TK3M= ^?^W._E,W-6WB< 1T-/  4'B!?L<Q
M [KM$_WLRD&(7F-A<J7O+WR-VP-Z"])%V-_'(#WNLWN/MQ[B.=ETSL6]2-(Z
M-1?#C!)60.J[/^2<;B;G].U#SNDAY_3R^*:NZ!MX1K^+=-,KUP/H2O]#)+S?
M%=@S/%E31W@\K@ G@N(C81Y?(G9%PJ7OD*9U")ML0I_K"7 0#L3F%R1[\-T8
M)CC!*(%/*?4G4X5L#H-+CR?9_/RD(S%N%HM"-QL2:W7EC8XK-]4%_>G:!C:)
M"M>1D 0!PO ];]85<J@RR4W%&G5LHP;[,V:!CP?\KKWAL44<8973[:1K?XM*
M?%%/[U<N:A,0;!)PL]9#VC0)HDT$$$=9BTH3(GY4&+B!'FER* !0D!'C'9X"
MY"F6T.7*AN7!= *)W/(X71%#ITG"@@Q& C)+MR? )\"NYXO];N5_0 644:8G
MB[#6PIM[J&L%ET6VBQ& NY#_'!":N-MG\K(]E\QQR9M'(3PQ5:6KNN.@6X3=
MYHW:[?>!&W30#$=S'9K;/9+<MQ,Y>$74W@<_92PO1=6J#J+;W^(WHSK0Z/*B
M<6$4MMT-UTOHD#^?HGU'C!(A] SP0/J7?Y3I?!*2FR*^IE05(/H-UH!)[U5T
M;RE7(P];=3DV$J_7#^SQ3>+[+FCVZBNQVLAEQLE7"7:=;'5VJ<(-3G*5M/>)
M-A,KH@IWVP\N@^( 0SJ!(.D4WP?&QZ?W$O:8XU=%\]W*&E)JYU.VX<U[^BMF
M\'R58FEFFDT 7\PW!R)C'"5*WR9))2S,+"A^[*;R2-";_$UEZ6R(Y7IK$S<P
MTF>E^4>':'-260CSE%M;:*8\-WG\'@F(VVD&26_!V%82E 0->[(@U-3XBX.P
M30<#4FQJC5H;SNYB\7*%C2>5_/W))LH_FBUJ%E$'U[PI0RRWS?&U@9ZA&W=<
M/K?Q]N6XTD\"8FF:#N;B>C\HMX+34!N-N07B4^1RY-.\^P:H6.R<\RG=1-2>
M-U3XO'9]/OBR-%QQ@)38+_<6-WJ5P;VL*C^GT%U#E2)H@KCZ[!ZON\O6G*K1
M(GK[.[^5GT'L;SAXWAP:5AWA?>3+J9EWV+_&24##V+4@,J_YXDE:/A5'3U7!
M6,889@5^JBJ\L;L.!2G^4(2D9'SGWQ7K?:>B@[JE>-"XS?>7S(1J/3D2(<+:
MOUKHNOQ\ N86N!2L?!W-HT+YWIRDTD; 1BGJ/$S'LY4C)691-V2X/2=<Y @+
MXP:@:V_@ #&^ ?/52HZ:*F?F/M<>UP6LY(+/.#"]J4PI3C:S)1YY?5@<0/U
MT0+OD4C0MPYNC!46EB^ODU9D;T%<J@;OMEY'8/OD(54UI:(8L%1J I+208;]
MEVQ&KZAQ!'TFNM(^/1KCSORU,_IH%Q<UFTGPJ)WA2K"?FI4&Z9^)LPJC>\3K
MF7C?KI#C(6I],U'KIP]1ZX>H]<OCF[I>_.> 4WM&J3&&@!$XG9(N=^4ZYT1^
MQ* E0YL?!5(D84)U ?UC1G<G1LY<A)4K4+D,@QLJ!UDD1A"[/J$+>K54EPE\
M!1P"W],\ (4M:LU.'TEAA; -##+"4*[.:/(+]5=ZTOTO8OK0J&CB8292T&4Q
M].DD.M6##> .N [/-;&/WOTB<O0UW17HU#D##<>#$ZX-M;?Z_L)XTO<4(.NF
M[M1&W/=N%8$^23B2$9:;X-QM#4UM[1KHH1<"P2ZI=(-B'.[M@3>XLT)N>P7+
MJ%X-BY@=_-)58Z%!Z+#79]Q[@?"#W():'*9/X51_P>J37HEH?<F%T'R>?JSC
M-Z=OY:'9&Q[? N+Y.55E&6XA57%<9@PU>6-:8PR?::K;2ZU'BZ7O*?/?U#7@
M[Y,":5K\NU"?QP?BO(_25<\YA$"^Q XN\W)IN#XPT\0#</4A0;<0>!);MVQU
M@J.D6_T+'D?\%RM7M/KXCQV)_(R# =D.K7-=:)N%^R@#3,ZDYP?0Z:"=<[E/
MF^VYL(Y<ZXLV-#=;&739=?%H*Y.3=[JI!<G]&*90EPE\2F'LBB)QRE\9(.G,
MB<"23E(D@R:[ /XOT$D9;W42180>(9K\06=-..)*K[U4:U<&KOTEM[\0A"F1
M!&R:P<XNS&K;/MU]8?!;V>&TS5#B0G/,H,G-VM("11<H]%+"4=-8%:?6X*F!
MI)YP!2S93O!/.X"N@Z$X6"FX%D!&?"7G=]R3;SU?"#TWU.TSY"ZF%3 A#>*=
M<7MC_/7>,MN43_40%+@WFB S].@(>FMIXDY(*?IE+QFV\>\=S+PP>=S9YK:8
MCBS!GX *:W#?$ W>1:OI)<NZNN1;*.#9=),W;(5LF6^C))LN,MFBWQ"-7+YC
ML-7A.I*[V-W[J1V?W9!V#("=K E_E) 4BH:JA\SF&YQ(JB>8CN-&B&\<-.@G
M3'#_ RR2'*NT@<_%RMC 1"7A+G%'%1;5@=(SVR]!BZ?-L^4KP1F)C01%A#DS
M:DRYZ;C[:AQF'FV NSX\"U<K2P@*\V!8?B*QR,N%%%BFK4+H?'%2E!4)E7+4
MS1RTRS^E6#D/ESG14*0BEKJA*S$8F@W^2^,;@1":$:"5M#PF5^F)\I8H)4RU
M%3,4-D>W-FK\FL&97\37[?#5'7AG44 CHFP.E]IL0NDB*G9-OE"6*[H#DHMI
MXOO7-T@,[B_%53%&UJ!\7(I.XEJ?*.%F)R$NBWI9,,WC>/G. *(YUK[+>6Q"
MYH9?:^Z+BDN+^J3HV\R^& :='U$Z+GU(IA253%W5M\GFK</]H5/'5ZE85X:-
M8MEWY]N)X%327Z-R!?HW,IG<)(2!WK:EGG&4 _?UIJ#G-Q6B4G@?V!GX^>!2
M1+(=1 5]XXS;D+E*NIFF,>)^QVW/+B4J?<UL(3 >LIQZ')J.%T-MHKD]4Z8D
M9UA>1R"FY,]2+(KE0PH#YJXA8M3)TJ.I#4%(13G)BJ;KZ!4R3D"0&CCU7GHX
M&%4QF2RFG^"?O0XNYOZ1:36$?H7#XNW"Z>Y&PSD\J?-MJ3#NEBDXQT_I<%R4
M5X 8^FHZ/FM^X]T9HE\67>FQZ?!FZMBGN@BW6S\ ,=UH>N&[A_3"0WKAY<G1
M#<ENB4U)HM,U(:8P),W6RH;K0'IL&HKDEL['9:YKK!(K2YQO$H#@S%'E1EGJ
M.0=ENDJ[E92:Y1/YDCXQ0@_'3FAT@R';FH4#31D5_+WZ5PFNCBP+C4O3Y-T2
M;6'$VY3Z.D9\0= )CNVPU\CE3K:^>E&3U CEDD""3:"L2F3+N&F1+;*%<E[]
M4@B)GX\V4<PJ+'9 ITKV/Q@WDMFYE[;-R4W=@OC&9\P#*B5=T" !#\ZY@Y&*
M0*VPV?7,FY)\)P&6DH@%&96-4#0TRQMJ;RNS(+BS?*'S+RZFL Y),_T5M:N-
M5:YHY"O0TST7@$7E$"O2.CKF-S>L<HE 0BV7",Q/%>'_?F[)?W(LO_EBBOO)
M%#=U TQ/A$HK"O9)QD%E$::^#X%2,>N>743'&7L]*4_#H0Q"S\D8+%.W?%]7
M@CQR2!C):"*#\&PT8ZNSF"&TL$H\[99N%I :*9+K_DH'1#7R5SL0=Q(ETT$;
M/VBX86.R<6(AUXF?1??V9E%M;IB2..R"<S\ 6#'5X(H!0?#OQ5NX#V$!IE[+
M)=F&<W0)CK44$L<XUO&B')SJV+(<+'F-YO@L@+Y,X"U@%[<FITIG!<>\GK67
M"N^>R8%1:]R"$AQ$235/W5TT&.:CS27?4<^9-E6 "#(IPCV<K";MDUI0$5O)
MACOO3:^P"2,IIYEOXHGOB& @:+QW5P47*;TB(NH;<1>EB'<<ZJ&$2VFV-$4'
MZLU$<R6O@PL7SC)JE^C/*LY[TJFH6&L;IV"Q)ED.B9R#06O5AEM=I!A 4'^C
MU42;W,>SV@!Z0PN%%>31"OA>"%&4'.Z#,U)?2D5P ._V5Z-PVJ   EY(BT(O
M-11V48)H@QLV6E_O=\:8A44TH][]#0X#N]]!CP9&N'QG[.X,#()@UUDH:TB/
MGH#::X1K!RX/>$BUW'D!9PHK0LC4&Y,* YD@%:O"%'-=87Z@CS'/<3Z\16+B
MX@5!KKFK(YP?FZHUKL9&63,RFW@>PK4&Y$)M+;S"&52=W+=+;XNPJU*\"#(_
M5R3L+?C;]U0?WA2::_K'!R(JWK!H7;J[7[XQ:HC:#B2&G*5>B?TP?WHH4F5[
M7T O<9<4\7+,J7. ")RED=2S%-0:P=Q::!7N"1>5J%:^8'>DN K9QU]!D&L!
MR /AP=@H&&T)]:9BT1-D.:8N7 4!N5242V\ZP;UF^]RAPH@IL6UO-P6!1!)Q
MV;@KS::.5'@WG !023\37E8M5SFXS[EVC")"I)0B]/"6P!6+4,Z W0Z5]E%7
M/ E>2!QD']]^[R^.F;D@4_*J$!_\A]S<Z*U,'%HZ F\TO/J[CBT]>X@M_3YB
M2^^SLJ[I2BHJZQ%GKV\L4/(UT?>,G^K\V9UIM<^8,T>@R@G- +>>'OWS-T@Y
MV%+&'G6<RQR U_JIE=6G[B_Q%+!#0?@324;&7]6F#,$L%[/#\,RV#?P/I5AI
M8<?^_,W)-UYB8 (T5Z4L$IA8'OWVR#.IG(CCU5?R!XO,':6P%6X&IR*4;EKJ
MP9B']C [A\=L]O^,!3[]PE*A+6AIUUG.G4[W5\EE7,PA$>M?(AB*HAU3ZT=0
MJJ</]+I/*SS'ZH#3[*UI-,8%'\CQ;[K"!W+M8H6O*+ D"!=1JTAQ^D"9?],5
M/I#KOMIY?ZTK19G)_^E,_F XW&=#[W='JBM7=<>+PL3F+]-!3[Z]9T?^V>')
M\\.3HY,GOV7V.23OWT6P[LGT'J*3_W)T\OE#=/*W$)U,Z?S+<E9WU! YO>5;
M>#>O_:;*EH9_W%5_W1N\>C=JKI,D#G8QAGO\N)S#V$5=$3P\EA7YS+'"?K@^
M%OI(IV'4$9.4U(2;\[C2P=U4[^KY77&&Q<(LNAP&_WH!U*\;.Y:5-MJZSAIJ
M],+TL33<$%J!K^R@Y'5T,1DV6"9P0]@<DYN5:T$+M\6Y+'JV4,VRM]ZSZ$9"
MUQETX1KI8&EPGG$'JIIK%@CJYS1 G:ILILN:M\T#EU+FWMA"(UVH#_2B+JF>
M?DEMKFW7K$Q+Y3,% K>WDT N&FG6J*Z@F253<R7X40D#MI@B [@5"E$%E8$[
M)!!E3HI[*%&:EAVX:C@W."[35)W4ECQ.KF)P:?^J;K&9$EO<*P??(RAXN$HN
M >#Q<!47\2) D0 Q*SV'0XOYV@E55,RZ$K<,(72ZO+TU6B.5DME<F+KT^>VX
MXF)82NM+8O:LN\%R2^NMG!*W8^[C"%!C>UVO;Z=.6EK[=3H3^@28)R]K&X$D
MI U]>)E]Y5NQ_12B=DT-YS'WE26K4N4,9P2TV%D>ZG;J">]46C-ZIJGHGO"F
M+H>2V]<W.5SM'N"KSMYQ(^O'7;:OWDXIRTY)D7TDA-T-NA0W_OBDA]>L87<8
M^[QR>%^V6RZC.AH'*LUM2!ZH@2I*LL$4=D;.F\+\WR$YZR(Q@Y!H7 <\N"2-
M<-R .L?/GSTE@$+IT-K9[M\4=M7N=O^ML;ZE9?3X*&ID4%6HN6R!(H5_#,E0
MZ!F5@ID>$.7)R9Y^M/=XB&>_,X+=%'+3[@@6 0UM%'ARXP(I) 9.#6 E.H$J
M^HA(1V##[7$5'YN&0LY'/<QOP>,5.R]JP.]! 4R<E>4O5G:CD"RUI\&]4<%&
M*[##HW.%Y#0N7D&9655B'2*8,^= 5="HK^NJLS$.A<K1#-V'5^U/"6Y,'B%N
MY6>F]$P34-?8#0AW,QT?_3&]\5*,/-S>X^_.+-U;5N5D3$;UOQ8F#>\JU])E
M1-IA4X\_[ WV@<"3:LXEANYN#MMSS&)')MJBW&L=_.U<U_-&K<#88Q00JKMM
MHWX8K#^,KPMSO2V^X'S$6W0/A.IV'$E>+*7.RQK!S-TK"1'+_RMJX6(LN84&
M[A?W$N&R"N2?Q!UJTX;D>$:(I$!ERMQ8YN_L':ETI48VWX#.WH%W5L@H<[NX
MJ?N8[N8;@>BROM3K4:_Z?6=2[*8@N.Z%%',R:)LTB^,AL>OHL6+Q4$27+W-Q
MO(-+BE[F7N#Q71.D\5X @7SC6=KP$+7:)V9B$([N\WB)X75R_<Y3\<6WC$&>
MMW^P'T& ;QBRI;_T/MR4EV!ZAKZ(G;#,=)8P-?M(2*;R(8(@LFD6$B.X<PBJ
M-R@3!L8]WHU9^TM28[#>.$#1OQR4@U%N#S83*,1,J W%V%8:1Z)8@R^FUZ-H
M7Q%]P^4:B+3NQ%M8EK_2S_%73JB#FZ<772X2#3-)?NVKP04 03KGN.U#6/W@
MWS&Q@1@M=YC9^%?3&!<U</$568S#:5VLX8]%NRQ?_G]02P,$%     @ :3.#
M65YCB!+4,0  ;R4! !D   !A=G1E+3(P,C0P.3,P>&5X,3!D,3,N:'1M[7UK
M<]M&EO9?P9N=O"-54=35CBQY4B5?9L:S,XG+5BJU'YM D^P8!+AH0!+SZ_?<
M^@(0I*C$EBR96SNQ31*-OIP^U^><\_+_[>V]+::J2'66_//R/_].LC)M9KJH
MD[32JH9/KTT]32[+^5P5R7]T59D\3UY5)IOH)#D\&#X?'AX]&Q[L[?WX$L9Z
M+0^5Q5ER>+1_O']T<'0"?SL[.3P[>9%<_"?9^>7R]2[]^LW/KR__Y_U;?NW[
M7U[]^]WKY+N]_?U?CU_O[[^Y?,-?G P/#I/+2A76U*8L5+Z___:G[Y+OIG4]
M/]O?O[Z^'EX?#\MJLG_Y87]:S_*3_;PLK1YF=?;=CR_Q$_BO5MF/+V>Z5DDZ
M5975]=^^^^7R[WNG\(O:U+G^\>6^^Y-_.RJSQ8\O,W.5V'J1Z[]]-U/5Q!1[
M=3D_.SZ8U^?PY#Y\W?G-S=ZUR>KIV>'!P??G<Y5EIICLY7I<GST;GIZ&CRHS
MF?K/2E[:6:5S59LKC6-'HZ:Y5M79J*RGY]T7]#TY=\^-RZ+>&ZN9R1=G?[TT
M,VV3G_1U\J&<J>*O _X$_K2Z,N._GM.OK?E=P]"PO%K?U'LJ-Q,8'.=ZSNL_
M@^\2_-_A$?\%WSAJO?%:T]I&99[!EV]OIF9D:J24P^.7^R/8M?D7F.-OC:W-
M>+%NEOBP>^WUU-1ZS\Y5JL_FE=Z[KM0<?O/__^OTZ/C%^<M]_.V/_VKR17)\
M.$B0AA_/M"^*K(*Y_#>0V>.9] =]EOP\'NLJ*<?)V]D\+Q?(A![/ M[ '4UX
MZ\\>SZQ_+I*1GJI\C-O^+Y7IY)4I;6HTR ,[2-X5Z3#9J:<ZP<>.#LY?-FYX
MFEBFT[)2R('VTC(OJ[/_.J#_.^]^FYM"GS5%IBO\V]+7-.:9+7.#+.-U.0-9
MLWBYW]!LCP[/=V$JB9HE5[I:)'-@AQ9$3%W"I)%B%F63J,3QPD39Y/74Z''R
M$=<!6V92)"V3,G'A:N0-][^T#V6NXW4E\Z:RC8)3@]744V.37-<U3%1-*JU)
M#-_['"_<J]L',*_**Y/!OM-VIZD&LK--.I5#@%TW1692DOZC!?ZJ2BS0K:J;
M2@.5Y>7U\/%<C/_!Z6O/AU@)BDG'%/1//%#X$E2BM)S-\-K@3@"97303F%8B
MTN/^3_$MG$J**D'R!HXD/LIA\G%:-CD?9%'68>:PTU=P32R>'\ZW/4925HD9
M,Y5Z&DG@'Z"8Z.K:6)T Y<Y,(0H@_GY>&?@OT79WN &]'Y[4\#8B=_B1JKOC
M6^!..9!/<E6:+'EI6L3#2S8UT$$*:U8C.!9D B_WS8^)*C(\B*),QF65TO0U
MS8#),%*P_A0ABEX(ZEE=SLZB3TCKB_Z-FN,*RJ6/X/K @L]Z*#8S=IZKQ9DI
M\.#W1GF9?CI?TK5@YT4W/'D^/(518D(O2B'SPZ%0^%JM[;TP4U38ALFO4Y,+
M=123F/+Y#(G\:>/AJ!9)I>=E5;M#E_N"Q'?XP[ECS6]O=-H0*7C.7 DW06)*
MYKJRS,IQC%>EJN@LWY@*SJ^L[(,S<II2BY//U"+)-',\V!BDOJF"!=*J,E@L
M"E35U-.R,O(/^$FE[;P$TV9D<OH4EZR 7Z9 &4!^8&S!Y;"V3$VPQ=SN#Y-+
MO"OP_RH9-WF^5P.AQDS+B<1A\HXN*BT.QBTS>C==NHQNW< Q 3Q@Y;>WPP#\
M82/7T,5$@0D(U( 'P,<6WHT#%K;):QP0SI:_'S46MM;"A'%47O#.]533EV$)
MR#A45=,_0/+H&Q(VN#/)3,]&08[;(.%5=F5L">K!R!'+JQ)LT1R6W5)I2A)5
M@67I&Y !UN(V\]G\#EL"B[K&4X*Y"RL40ALF/Y4U'H*M80?Q>_P2^(N>E/ O
MO@]("6%WP#0S$U,V\&XT/8%9C> R$7.B9>/&-W!Y%O&FV#+)2SX*HI_HJZRD
M[6\*6!W<$1@-A1%P7I#"M'6P\6/@AR*S2 Z7(Y@#D;'MW,MAGQ'KV16*T&#H
M/K3@[F6#T7#(<)=8:8LC=@;\4^N(!%!15C.5MSBR?-15*SI,]\N\6WCXT9#-
M[=NY_2O0IY./*E?5@AG^W\L<U#5'WEVY'3->8@=SM6"ML'!B(!GAD):&Q+OX
MEY,?#@; =)&Q)PLPE0;X$-T$9" I<-D,?5!+>I:7&W3A\&;#<Q5,#^[^5&>-
M7"7;C'Z#.2)QJ_D<J)^&!FVU29GJ\4<X]A16#.NRPX0TO'B:M)21CL>"V9H2
ME%JXQ%<&3@='F9<U\AQ8H\J0@%D+*GHG#12;5II9\-+[X!G61Q+0>G O)[#%
M, YR0.!:E88+7;&=@UJ2\>+P7N5<3!K-CT,1=U^%(K_E!W?B!\<;\X.+HFB
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M-DT<&'R@*:SJB@4_U)S_'>-ONP?0M0X\BA3M7)&P#NE!2B.AB6\K2,&*O"L
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M]GR>!/TY2:<Z_>3<>8L 9M W**9L++M$M-W2*\Q? U!-7$VX-NR>+YP;5CF
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MV35\05]=+S@"'0-(D)@SWA@X>Y#?!K^5HA2AD8$J@=[G=#_'^):DA0TS*/R
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MWJO,>9OIU[FII^BVPYN(KY+ZQX3%K7MA1@;HKDXB)(\W02!PN0VHBXUXOCP
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M04Z-#=Z, ,!NR9TOVXZJ)%>WIWKQ94KN $SOQ9]'NBUP>>"3!H,S7;O"(1$
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MEE(2$'Q7FW8X9, XE-1E$0U+47Q%7\[YQ%:^,^M6RZ="ZS/>!TBY$UA1F)?
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M\-J8?DP0FVF+JLG8!;LBL4$/OV4]A*(/YE)G\&<5\0--2;0?R!1B(%K9<*S
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M.,R@J"#J6OQ]YL/2$W"'+U%R3(+6Y$E$N];G7!2;1"+QJB^ITX=<\ZG6%:?
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M[B_QE+':7Q@"]X@LK"KE ]#5=<H&]$E")&:#F$2T%SB;_5+!.N2A^&1EM$M
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MKTAL'$[K8@U_+-IE^>K_ U!+ P04    " !I,X-9GH'T8@1U   &( , &0
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M C9B.2\4-ZLNOJ8Q*UI5W<#IW-WKO9;7XZ@.U&2:%3/HPW0*3Z.M!UJ6[\!
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MN5YFYS:!XG+MDM >\Z4>>X9Y+E?]3^4\G%S41P*V^=[R,+@>*WHG7'I=IK7
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MC"H\.VZT(AX_W=!-D[92;W>G".7?T'I;J7/V!+HPR=-1JI).YN.M/!=/U\F
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M=KK*F'/K:@IJK&- #-O0&J*2I=+GULM$';.(9JP1(9PT!&A&]!R-:T";1DK
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M\J)':I/&6N2+CRA=RN^;-ZBPEXB'_%$N PPM.F>D5@&'IUT>"^^4\^7Y>YH
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M]$IP@ $# CK3%1;@(I>4@]?D4(=J\PM^8Q1O?M1C.5EJA=T=J0H=F*H3Z#.
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M39I0A1Z)&/FJO#?NM@LG.BA1O%J/RK;Q0O+9EU^B#W!2).1_"[V<(VCYE%V
MRE04I%08+<BV3D<@S*O#F5MX\7L*\]^Z /O^LXU3;.,4VSC%UMHIMG<_3K&/
M1;[S>X29?!96;;0?FV9'D?D*]'G61;@ :=>46<P+PIAE0]]#5BI%9Z*2:B]3
MC;-Y$%Q3/V RC5+!2#LO$PYA0CS;DQI/&^H</[;W%HIA78\++C*/!AKT6 );
M&,/)*T[C+$SA9];<] ^[P2%\)Z]IY7I*T*F1A.)V8[EG5!2<3D6N/ZV_C"H!
M?=MGB'Y ^#KD$S5V4*AS[)WWF71[0JC;ZL18H-6<MS8-8GUTQWO)N3]75(7=
M<0F?LX>'*)5%E1=5;B%B7)!)V@3#<@>VX!E%SV46D2JH5;&D1@.^5_P]/Q/R
M#X],3K1(U;4JE8EI]A8V 3,J2CD99<XB8U&D H;49M9I)36]G15ES% &C V1
M[MXQ0BD;F%>A3J1)<RJ[V!T6VXN(*S/RBWNOX"@UUN@H"$E?P=80E1A=YCPE
M8BXVMF8!*XUHB)&1OZ.,KX_,WTLFWJ'):6>)_RA[;$LV=+V6WG"\8_M*53Q3
M2,&"V.K9\E7-?;MXRTQWY9P%"] )V]^2:V:;BWWACK1'0Z/-G>R7_N&XL9ZQ
M[I0QR>)8516?DHM2ZBDK7LC_C4_#G-,\8*U&<]8>E0I@@Q?F9J+*2T115%'&
M"4Q8$-I^M(4&#*$+.V#F=+QEYO9Z,LTNXU6%Y((9XHAJ$2NP=2P#PR^UI>QY
M@MJOMCM5'DT\+0;.2]@J\+VR,VHW;H+M2UC+X;PG]_:^5,&;FN0[8'.%5R/=
M0Z>>J[LOI95F_&"EPN&<8*Z&.6R-W?'%TV=]-K=[22W$5&(\?,Y4562-31R^
M<(04J; N<W:YXO*_8>L8PEX38$8I@;42>0'K:3&6A((9XL.='7JHURK!V:(.
MAD*!_SILCTCNXSEGS!:T& 7E9Y9:RJ4V63R=II1?9TY3@P=<"$]V,U.DIY7?
MT"Q35(I'\O1N2L!$R!77(M#L-KV/->EOP9:;O@M-WM9^,0XM=&]EG%ZG%>X@
M5'$Q)2CA"&= .NJ/#+/QYT@T@E%#'-UK">2U-AJ]CSO9?2>PFBDC!^M\GW+9
MEIEDL 9;#N?/LME((L4NNK6; %GWDB;)K6%7:>/<QVX:)*.&*[9ST .J)HP,
M+17QXO (B]CS+!@?XZ;>H?L/SI<-5E!F%*]X#9",]/1P!?+*B6.(@]_:A,'6
M<K+RT>"2>Z3F%J$ON?L!SX_'7KSPPHZ*T1F(D+>T!4W(=CL:IVH4#+YJ4KM/
MHQ%,">W1_-,G D7CI)J?;#T2K;?<]*A36(^T,>+-S'DY+KAA$Z5061"V91MZ
M<A8Z:QTID2(0C=/4;"(=":(F-947#T87?W2%JD]K9W@8N=G 7'_X>?_YQJ._
M\>AO//JK]NBO2?75DU'H4R$2U>)R)T#H;NV&L)M8%V7OEPIOH[#%L2+Y@7 @
M<:6W*B[3H4=?'Z#MA\E"HMA[3Z=4DV]J=>YIOJ2I.AI8^SRG>'XV,[V"2V$3
MO1P;7T54#M.Z-+BK(9,\YE@[3JB<?SO\<.[EGJ%;YZB8P.J%UA LX-!YR%F3
M2<KMJ=6]Y]2WQIX,ODZ195)YUU.< HF)Z&E$#(+6"*7987=T<%[3*?;XKOUB
M C0G\3;[>MP^&\P;9X6*@P_17$K<4CC ^@[0#W:#WWOY-W6M3;?:@'V/QX0E
MR4@"BT%7O!1K$^9C]*>;%UK'3WU=N T)JH*<.8(6(M$@2&8VT\R6HG=A/I6]
ML2-^[.EVR#!#JWEAO3IR!L3C*$6KVD0+<(!V@T-Z<VN(@@GL*NQVMR!4F]8E
MY&,D?376'(6+36.T(58:!P<E&I5$]*X=IQ,"+[%/BS+X4B&6X,NHL""S312V
MHJC['$GP&J9%K=C,GV(*.1Q*\,J8'.M<]=P@J"0%,4HSTA#-[!&JQIDLKHGG
MSCY-%25167G5PQ!'.6X-O(HI4& E8:AD>MW1E[FCM4YCMF.+!H2\5%EC1L0L
MIT%K)YTSP8SC8I/-M'*KVM;,"/IUN\$G'"VY4Z\-%R+93DX#)7VQMTE]I7 >
M.YL0LMOD.G76LL.;]]G6\<J=9I&X GJ6,(S+VZ*J<;%]B*#/\;C!C#UF!+9L
M:E<*$7U2M]M%JDV:FNO+TG1TMPJ7J5=G]GL]:,.@&&3EMF^07V9I-9;HJH0*
M-*^]">MD#,V3).(LRB\;4#7-<ZIF*'Y9^T2N")\),C-&_%:4.QNDB1A10!4#
M;DPT5_,AY7<6)=:D&G)1<N)?B-%)*!3KY Z$]YNCR>=X_F>#I1]E/];N>2JB
M( >5?D0K4]X=;^,,G+]K<_50VTU=G]0]D*A0ZH]^G53^[]Y-LHIYJ?_<Y2Q6
MG''8:RXM=I$6^37R^):XQY6V&=Y>R/$C2[(H[,!-6>M=$&=+D</\SZ9,JR05
MPF!W;LBAPO!4 LE)S(:3E2OM'9LGKIW4<5=7Z00,X'6+V!?O"<VVYD7>05O#
MU:_!BC?B1L3!PAD,Y2QLA>G<D@JZBG>0I;J<JB]'R-7=+T-(4J!;0W1VLWZ>
M.KMZ296I4%IDI\4T^8S*WF(K!9Y9:E\[S*PBKOT_FURXD2C-7['F@%DA[(AV
MPXM]8;3U$:6'JA%_T:_G_QV##!;CXQ<CMLAD3^IUB+66DG'!2,X%6BYT;J$P
M_5&47T+S%Z,SK)8N!$1\VE:&F-)]T>,)1FJQN2$F^>H^9/47.H11DI@ M@-)
MM]/GGM>"]Q;TSQSKD"LZC.1,FDR*_)JJ:N-WOI*G@0FFI)R078S@+.<#DIXU
M!>F-TVGVF& R2T[>C_<Q>>QDJ'C:#JG8D\[$P/F"I34G?\O:>":B@S.:P%EQ
M19J.AC;F8M.$..FHUI>\Q8A?0F+5B*;'4Z.B-9IB+!$N1VQ71D;5$(VOF I]
M6!HH P\9<H")7 )"41$E"3YN2U7;T@TB7=-4K:0M\26N)8/.&FC&55HT589U
M+!"K$(GI<V/%N5WMLS$"+RI5U6"< VQ/-,ZY-;K$A% P5U:GY)J6%1[KEK<K
M(5?!"/T#C745F1J0=MB'L^Y(LB'XM0[>:EOX.))2=/ZE\-Q+Q%FBBP4LR$H_
M%YIC*BMVWL9S9)I/+>7D'@'M*->SQ6RS> _FZN$"!5.3GR3<X/0C:+U^&HL5
M38UU<G&I/9S#\X ECNK[8^B(D9#B8G&^R&?AEO?JOIJCX.&R2C?AH1]^WG^Q
M"0]MPD.;\-""\)!SIR<LI'_\$-"$_-</^!5<S SL>OVP'"+S;C2MU&O]ASNQ
M^!!9)=@8<4/X8LF"[PHEB0.^:B>+9J"@O8Z:NA"A>\$R5Y?PO\3L7JHD'ZS(
M#Z]#N>$9K!JSU-R7:?*,[YU8AZQ\(Z=\)P$5B(Z!H4%/ZF39MC_?VWVY]\!M
MUZV^P%)24W)N5R&86O&N;?T3&OY'/07?<L@][@G:W]\+CD #PUTR.*]!N:XW
M,_,H9N9MDV;D$-L_"(/S!HZE8._I\\WD/(K)^1U] %A?Z,-A\'3_V?.#S;P\
MBGDYK.O\-0<F-S/R*&;D6WNV!I/'"MIOZZ*3$;3U;5I4,6$1-OK88YJ<C3[V
M6&=FHX\]XLD1?6RCCCVN:9FOCCTAEXSV.#V W_J.I$2/(3QW(W'HT[L&WS#F
M74ZQ^*?-Y!PPJ137%-$($8S=2*B&@F;_;+@4K,Z0#%OUGQR6OTO")NG<X'9@
M"JE+<D*+594-G5*T6^)W&'N#]\ASG#QD>0<%VD&,B9ZCY_%N[O$T:S *OX6/
MN,*0"C+G8ST_F^R$EUT795+IY#"Y7S*^PM;7E7Q/K?)^@B;IWWI:-=1)@@Z&
M>%QBQ4QYB XG9X9?V;3 (MQU8^U-6=9YJ<>D:F!U%:9A3U24Z\"I\!$*+M%]
M*CW)OMT@F0@(HD:$#F+0 Y$C.N%O"G*ZN:^&F\S4+TN*F+]I"XA'S,%I80(6
M8=SHDH^%F[NIPH91S:-3\U)^#<)[RT4'$HJ)>7H87"A0V$@SXE7N,RNF.$E,
M=18$XE+15)!G[B_*GMJ6!^N1DZ&0%PHBEY!,=6H"A>V9U7+.!"9TCZ!<*GNO
M^::5:B\)]M"8T7;060+<GO8*8$A/C_P;W*2Y@P@MZ8D8TL08>D2<0P5R O5W
MAT:C6VD&HZH875=$2EC/-)^P&:P^:B!N*73N<IM+K-I]Q@ZU*?@)@V7X"F]H
M6^\]/4G?C)1T-[=.KZ0PK$N6J#D2M\;;G37)(6$]^+B.J[X4US;RU<UA('12
MLNUP&.E6\(.J4'-IX*8[Q>&,,F&HX+BXH1KQ,,C"H<@%K?NKU6ZEVV[*!,'*
MY%#1G $"\G8QTI('PSS+6+7+9NO+J-"F$.I1D2^E$_K;PEY-?5+.#X3X2;\H
M4RO<:5)[US$$*Z49' *(R1#KE!/#0.5PA.B!<YZ6J9KSU[E-"=+6$DK.VY2V
M_'1_M4-P 'X3,9J )%15!'K$)6XL?VZWI(ZH6'4#,^1&*AMFZ&+<A:DM&3&4
M+]3,&<[&FLJBJO6JNN',Q;R0'<ZBKYU]TJ#337838>OU+FYI6^8TT[Z?*@]]
MX26""$(]O479.0I3K>\PX(NS9C2"KZ)21#&!O(CXJ"KB-*HU#_7<QS,^>JPB
MACHC%C9CEEW+&=5E.L=:T,H 7DG!TLJ,;"HA\=3H'88(43":5D;3<67(3(G]
M&I1.;"965,^8(AO>?*5RSC5A6"$K2_:,X3Z:I2\45X;A3;;2?KXY4B*H3KUP
M&/.>G'K:9* YX\I&DZ],ANEEDS*>%#.@<Z'WH&\Z0\1D;/DL]/F)W#ET:QW*
MAI&6#J:3L/^I5^G>DU/J"%$BLTH920MG3*:EFS=CAKVTJCN4KHC7HL0Z:!$,
MF)4KG1>ALR>LWMK^1;JG"<&[(TG4%&BK\?*4L< =6N]0B09#<UJ&BYUS:I+I
MG!'9?L* DH+*(D?2\**,,J>L;&M/'ZKZ6K52_V M1J5(\%S6L[X.([3*Y?&A
ME<R<_)1651 G(DCI3&2(()1>&_KJ???(JJ8(/U.5BDJ4 VA#>)LG4&H" O(0
M$K;!6-T[QNKE!F.UP5AM,%:K3L'_5H_4G6O9?"PX47>'3VQ.O[ 48PLY0E$9
MTJ28-C&C17MG$EI,3>:;6.=TS1I=<)W-<3[DC";$U+-X7%'%R(YBPO#BJ#+)
M(97?F5)R]-(ZTUXQS14ZZ[VC\X;'DTYPHW3<N;#,$6S^J!E!?ZO>1 ^=[$C\
M/JR,Q<X]D@5OU,*VZ8+IY3I157N0K-ZD;VM7." Q[#(-RS,QO=YZJ#H*9+O%
M;IX!@?V.WP6< X#$!+J<J/W&%43CUVO3S*(7S'3,WKM&(G/GRA8#KA):H;3L
M<I4K%VZ/=7YT0=&XJ%!$N/I0)94G^&Y42YNRU!+5K9>;J\M"V!="L07D@RF^
MH_HI_-9H$N[,E?Y6R#X&)(T\%?-2M&Y%8MK=S1WKCQD8W))=5XJLZL7[_1I-
MR)TYNX\<PUQ/AQU-\<R NIT7UW >72I;^82<89P6Y.0J:OI>7;L7,YC4M6+&
M:;TVQ,BVEM?BTQPN8/L<#>-TV(AE2VF\BN_C]"-*\&F87]?U.)@D3=X#3?)J
MY/HA2F6Y:?292EE$)2CTMDZTYX*0\G*.#\EW?+3[8JMCWZ+_/:[G490*);=P
M&;<G3'SA5%=IA&QR$I3I\9.P]9X)V;'K);F&YU_",BLU<<\4#7+$ZFOERMG?
MUGH_NS/]]U$S:5@C#\[PD$_U^?*QT%GN+I%AU_N7LH\'@U#BK;$*:Y-GPA:3
MI7%:&T^]7%@5(;.^1JX"$]L6::XC<1CYJ6E+M<[S.4?H^J!4#7:U9Y1CNYK"
MGZX5V27,Z)GE_W/FLO.CM1Z@92W\T#H)=)A%^9<W5C'B"SD^6^W^WUX\ *:Q
M9]'L=0[ZG>]<6"R3G2[<8>#P47]1_\^KC?]GX__9^'_6V?]S0I6P/P[.SX/?
M?QV<#3Z]"\E4K[L:)NEWQO3E4PBVY6&1$-%VC&P-K%Q^FC*7DCVC)+9 NAT>
M>\>1)LG%L7UTJ89Z[=5F.Y/G[_&(+@GBVWUUL C#YXB5\W@<QA&<9?JDT)]I
MY;WF[0O!!3=N*[)?THOUI=&0B/+4O>PQ\_%[SH6W/0WEO\M#)Y_M[S[?C/H#
MC#J<5]*AU8YX=YCQ)+VO@_1Q"#EL+?L;(7_PK>5@]^#99MB_W["[>'\XV4'+
M!#5@_X<EL?\'"T_7^QB!19K4Z>'9X2^?4+D=G!V>#CY?G!R!'GOR\?^U=SXK
M" )!&'^5?8#0N@01!+5*6:*!T:U#E)"0*!52;U]#FR 1J_EOI^9B5X?]?C8S
MSC=R[341\,BK<O@ <C]6FPX0UF!VA^_7M[B*GN1 Z_55"G0^-DPVL5R/6Z;#
M37&*V3"Q*;=RNTJK,BT1#09Q?AM>0?N4K#ZIPY=W*^RZ?>;SH@X4_X"]^ H#
ME,&>O9I'C4:AGW6VT)B9;&%92A3&9W@Q\[/(5)"/*B*E9_ZFO);2A $/V,XV
M+&ZHEY7J-=PG8=LRMM\)159X-: 4A%"N8$ - Y7<=0E$'.)H@43/W\&XAGBY
ML ;;7.;S?SPZP9;YB\\,/_&/41P*!]E'7!%4;+7M&<!*$8+"K<KU20@D*FV'
M9=LH;.;:AN5,.\RV.:*>&&GVAS1+C]7_EJB:B3JUQ8@<(H?Z3L0%<?%GK9^T
MDB<BT!-1QYY ]98"5CH_[:4VAB78&.##?/EF:C>*&0?*P]*0C:"L9R")@KW,
M,J## 3Y^#I?P.+H#4$L#!!0    ( &DS@UD5N7^![@X  (YJ   9    879T
M92TR,#(T,#DS,'AE>#$P9#$W+FAT;>U=>W/:N!;_*KK9NW>3'=Y)VBQD,T/
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M>8L%GDN'+>H\T(#G;.8EGODYL3.>@WK+V/JS+U ,05*/>@J4*C =]9?-,Z(
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M'MA;P?TOM< 6[3^T9/[EII/_ U!+ P04    " !I,X-9WCGFM4-A  !P5P,
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M<5X*Q*%"F>%8;3782UWDO^"/]6N#,!M%8OP^C*,PEEN]*/&_V<.A"L+_#N,
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M*M*L #F#TQ/PVI$ (I+,)4!^ 0V"S0J#IP+?/9]D^)JDW[SSM")Y>,=@0*4
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ME7VV:C>)HV$V)'PT,J<[1"BT'M;@4\<M)V$]PD8"M7TLLLFDM89W+<J[UBB
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M%Z2!N<Z[#UMJW.VI#IOC'(EF9.P7PQZ%3O!YX%%8)HG;9W"$.'8:C^WMJ&[
M\LX7K6H^3;@OW)F1%V+B)58BPA(N$C[SH,M$FQ0E&#]G6YZ>A!GU<[T=Q$RR
M>[B)>CF%Q<K&5F'FA!%@S2'3&%M%N<0>V#<".3._T\P"YHZS4A%ZW-,8[DR8
MPCESKU9=<&I.T(67IA]C((^'4RF$Y6LY]1HC]3<)16_,H0:)@K&AS&B=V>"2
M.KZH#'M6-UX]MD$0@Y%(64_ 5T\<D>IVV:M!N:NEK&RSNC*E!\ V%U%NR'YB
MQF#V9.C*NP%]2*I6MTCS_2+RAF&F\ZKADD<U:?$< C6X/O1C>K)^5?@3M8I)
M+@%?5N\=:_HNCB+R9FX32@D2%(>-$/8PLY-!O9KM-VUF'GUIU#C5.T/1GQXV
ME>,S"%IX*#07$$21C)L$BX7]ZZM4-;6XN^I+3#KYY$4 FF.\L/D\\*!B%FG<
M0K!!$*5E4)5P,%&4*16_F/*^*O@HJA@A ^.AX>#F'3BWO,]7VA_42B/O3EK%
M,6Q*:! -:[39L+T6!HC.UW!4<F)<NNTEUZ H_083G7CU827QCUI/E?O"BK[:
M'>L8<AH"624^[:>\!P7P@MDY)F6GX#( 7(8>+ U!C<)Z@D9QK=U)C2^I= !E
M>S1>[^6%0=^L6=CVLGMT?GF\INV"]]NO7Z]<_./-BX5KEQ7_N%)>)63+EQ)-
M6H5LW;%#LZ@MY\)!7U?\N*<23N#GH.ZA5\3%K=7J&=B!Z6RO40D[(U1CT +?
MCBCN*4\,W]^$,)88PGC;A#":$$83PFA"& N&,/J(H3\?PH*2*6[ NP0D#ZV$
M1>R_[E/W&/0!U[A8PSB N;'7F?SP64V"J<D_^4I^ _8-65C;NL";\F?S*2#$
MY']W7.[*%<"/G5PHZYW_>637]YQ,R\?$.:C=:-G_X+4IY/72Q+%?YN *3GV;
M4*YRLCX8N46CN7,^#)?%:@=:%=Q=^YY5CJDSW2)FQR>V@6MQ&C.'@;)J#9*3
M'KK"ZN2J.2;>K!2HT>)ZY*7$ZZ3HUU$DOZ#Q.[\-7W58F!!!62$WXMHR=#1H
M_X5#K=SI)P+"3YV+9IG9QE/ D3;K(23N,KF&4G-J7F(@2_7/Z/(E#"-*3^-%
MR6N:N%"=>.F'7)+U;Y98:_1[9TF.7(;XIA[+N*1=;F12AA3G4FY?MWQ^9MT_
M>3/MOBIN7J>5=<[%@JH217.4QD7QM#?U#;I 5\IM\3BK54L<8[5:8B@K95L9
MN9V(%%CP-M;M)]_F9 N3#'%[?96E>X2D0@%?^N"HDD6[LSGY3"<6T1AS'3 H
MW"]@<A%7\DIJ"B(I2(LZ2QD$L<QI*DW=K1GV6OT01U4<!&\H?)IQ+H9)L*U[
MG<+@J'TC57.5S%I%^!!F*!_@N/HHI',<UL[K;H*EM]AF8[41/?88F!(4;OUD
M2E,X>SF5HPBNHHZ/IK)2S&L%;ZPL#"N(3=/5T\>>6>COX"F*G%;=D_F=+',S
M;36LA;^P<AAJE"[,:XEDP/D1M:D?CPABUD0O5=*HR:VWD*)*+HL) 5@+17[J
M\JSFN1QZ\KJ#$(H:K":W:]DI5.9D.,6PBS"QOJ5Z&LJ@KA[JN&D#*2-<@P[&
MF;5S+926$S),I\O#49^<'9V#,?CY2HM^1M_6S;_NQ+B'5H=)TG']6-42\]Q9
MW$02E:KJK'09%BJ^@.]0A=!Z=F9.F8Z#("6+- VQQA_^WD^)P>%8=X("L(T<
M?%H9\G;5O/>++^'D[+I[>MH]NO[2.?4N+L\ONI?7OZ^G>W_52.?MFA=BG6OG
MQ9.3 _F$EDP.=23VHGL-MN:JDT/W.R+;NY:747MJ^M=NA)NE6 .- ?.>2I<7
M^;\-.-I)G ,I2,3^IT0H=B:QWI+1KYQ6NXDISJ:/*\EP%3N<6G,RQDBGWP==
M Y-H['"0R9*9R^&H=(P3%]B5TH9#6+'Z>CGK==(A[UFQ\VSMFKV-F0M3B[?\
M@DZ)8W/''Q\IW>B]U"U?8)(S\OGM%C5ELOTM&8&6;M\R"(REW\:08<M!%U#7
M@D8G*X1123>R36](^FK):\@7Q=90$Z1=8I#V71.D;8*T39"V"=+.&Z1]NTOK
MK-=AL"=3+A7T% &[U(-3SZS"*H&JZU]B>U-46?(M1X= R2$'&2EVPR056L1L
MSJ?=72A4PXKRXYU@R?\M5\*U8."@+,/AR0*["6\GT-M/+JA(C!$5O')PR^&#
M%4@]0LR"?;<=;?R)M\$ C8Q+7E'HL!B GMHLA6E+U75Q"9#JK,?"6;W<#MQ8
M-6(F=Y<$+;G+5"$,+@C?J;"A8"<PD$X'H"2\RGM-5(\Z&SV*O&T81=:NU'[+
M0^1E3%U7_MS)37&3B=$+Q[Q-+3@S93V(PMACF"\=[+??J'WUY@V.A] 9UTG=
M+]V+[%[3$[Y)!74WFSKQ:9A3PFZNSMYP<DZZ58LE7"<?GWO:-1D+.+=*<(Q)
M!<\FE<.",N;PAO4I%J9O2=O[J'V*MTD8Z(!#D!2]O#5AM1EL*,S+:)GSERT+
M9$V5 &'&=U_&08N+F?@0IG"*2(1#=K2*G)W&3D7$,D/\ZVQ?S.]#\%?>AW!/
MG/@)10JY(U1[!@9P+0//ELG;8BO>>1!13ZE'$;GS(V\H\T$2X'T,)*(B*N"R
MDN6K.([B#IP,$-8-6XO_"E]QIFN$,$"P3K*Z".I0XTK"$!P%I+A4'WA\;,?Y
MR_PAS?$W0$F/N*$C#CH?T)$]-UO^.8Z/,)O(),+@A<4<&U_Q0AGV;U<J4><>
M+_ G)E3O5$$E-L[@G\097.HIO@E#9R6>;!ES-D6HPF<55FA'IO%34KC4Z!@E
M"Y/L<-;13]W?QP*(P  G-6!%IDBU585I(F2WB:L%Z>7T*^UW4J-C&#C>,C'V
MEIDLUY5_'^$2J-Q*I1!896@TSI09J#4X:6HICV<EK;D.=*IBDQ1+YPS3?IAF
MK/+Z?O'$;1U_CHOV8O[8Q2^:LA/) K'-Q G_;)W35;60P=_23]5@=#GITY9U
M];3I43<09K%4;@AH1B.)&ALH*VDJ;Q.5QI,F8Q'EXRU$/.!KI9,'\?L-=;MU
M^8[(%"*NZE6^W][EJ$I6]/@.TD0V#"X?%HF/,(LEY&)R=4\GE^':RVCSV0I+
MJ04JW;)E S\K8]CZ!#A$B3H#JEV_KQ-]!"XZDY13BK>_KMS5Y)+9=9\M7=99
M5G2VU%F5JYG Z)VNGREV9UI2.XC=W!V3+5#3XCIHE+1%E;15*O.^1TGKE CJ
M<^AIS^5*Y(B4KO@XB2?-MYD8^RWG"E$%WY"14#&KS4] 1T@Y,TUE7&G, \;$
MQV0I7"^:@<,2M<EA#<12$40*V>T2G<D_6X#IH DP-0&F)L#4!)@6K *T.G\H
M[0[U)H2W<'B\;7V=7$PR?([.E!R_6@+$;85L74L8_ R-9*T&)SP3'W0_2J$G
MY=6T7<'"G%R$4=O[:G<N,HY!D_!LH8<P7'5980=V<EG+-\('N>4*4D3LRY8=
MKJD+59 2"9(L4_"\L*2[@23[NB(6I^Y613S69B8_9"#CNZSL!IC *3Y>:7S#
M 0I"NJH3S9R\9>]5_4M+,!@GIM&'<^)<?1>J254 E+]RLKER/=EHK*=9UB72
MC&C?<;LE1KFJYZY271*S9R9//=?==N$]];^:O4ZJ%JO)^9^NVZ@J+.LD[]W+
M)-6_<NNM*A.FDI,B!RWF/TXYGGL%D?%P'U:#?X;63Y%IZ!\$14R9^MD]P^:=
MK@IKZC^7FZJ^OPZYZDP9,U=RJ@4%KF?R4KCVOZ%9'E@[&NN;]KDPZI5:& >J
M#N5'DD8!4 *P;+P/&$ .@ZUBU)K3G5%Q0]K>#=USH54Z+(;BF_948%"YI1'B
M5'D3;+M=LS9_KPNUF6XFQ+5R8QH<Q=-R;O4;:^?:ZH7TI7*2CI)<E9JSOXB:
M$NHH>B:!10!O@@TL?154+F:^PGAS&(<Y=4<N.T0ML+S2IGR^?-<?C>7<PU_>
MK5HIS+U 5A>7W2NP5L@4N"*]_VOG\K(#EDYW3?&MWK3?KIA(>K?F)3"?R<'*
M,(A=]+Q?"$Y.4[WFF<'=B91=]J21(:8 & [4E0^XFOP>9GGIX )&+^X,8_VC
M2,,L"-DA#LH9JZ3PZSNLP4AO1(S@50Q'$+*22E$B5,!&R1WF8;/'F,)RIMLM
MI3-0_HYM&M5&QQ+3] <MB_LB:BV"/*B,@W#S^GU6YUJ5$2>X6VV+-X1>"K95
MX.+8JC0B!JY6Y:G<4]+;"#9I:I6^>A/M.'5[T"3N@P3*R^0I>TTA@R(PYD%B
MQ28Y)WT=)<(*WOE5RFYX0$5DW,=XBVK*B%??%,-/O_4M;23V)+L3D&1-V+QE
M5QKKZ'=M(I2%WE'"<&JK;4IGR5HD^?K;$:JUT7A3$F_9&E59D38 >7,YEE%[
M\^[%XDK+PGLT1M"EOA!6LX*O?"M"604/GGI[K/@G2L]P$PR!D)M@Y$"TIM+-
MK4@*X]LDNBU=&N8V# AT@2!W>B*E:"[F+,^^GJ$6=]3O([ S:FD8EGT]QN_Y
M$E.2RE5. >>/NLOR<5K<>)U@"*9*ENL!T&A$2&[R)E)"2(E=:>KXE20:#>!%
M0,0%43D^VPLQXW80)U%RPYV8Z;DB10"17*^),K1"GR?0M?*P.SZM=>?@8-?-
MQ"E;V6*[5J,VV .+6,!+DR(C?>50Y4S>R^-L!Y3A.K=A@OF0RHEF,9W1O4Q'
MA?AG0*_'Y%>D_61\>D)?]]$M)NZ$P?%HZLF6&.[;V6[B?4V\KXGW-?&^!>-]
M5!""_64RU.6TYY_E \SO4!?9@ZQ1F#[44 /K5@PB3UGY;WL\[?RM^F30LADZ
MJ0?.#^;L9V]JUEB,5E%#I[:<N;_A/3MTW>9/30!D8<MS?ZTMSRKV&Q 5&Z#S
MNI["W$!>3D\>K8)&J,I 2G0>*[<)_*Y2<U93C#/;(Z.;.%G]@-JV#XUGYZAT
M>$GX9O$CE(1-NAQYBXPVYZ$HUS %\%*54=KV/M1^SK-5S:6U#ONE?44!:(D%
MF$=)FA8C+&E!_"U4R3O<KJ=4F:W+B^8-:!-A#]D1:,<FEA'@TG'5& TI* Y:
M-K=6<W: ;^ULV)WVWD:OB4DLT\=_L&8QB9.SX^[GLY./)T>DKQQZIR>@T;#N
M O__]*3SX>3TY/KW0]!JKKY<=LZ.NDV@8CE\^6#- Q779#(SVSQB):NC_.BF
M:\]$*R=3R(MECL,863!5#L"0,S+L]4=!F$I,.,\H11ZX)OY-@A!)QI+J^V^,
ME$*O2A'EIJQ!103Z(=:/A_A7U>51UY\KGAN ^0POF!<FGE'$V4?DEC"B9R4R
M+02YAHEWQT:JT9WR='4/ V1B7:D);ENY8 *.+XWEV,#!8\![3@R"TR13*=IF
MBI6F>%4_"&O.F!$ )(8(U5E! 9N4DWDHBVS.C6+Z<%Y>@69632DQEPL;5:4.
M&@/'MVH",M7^O6)"^$UJ"0X"%L:6K!\9LX P;UUUI-(!V0+#JI !E^8&FS2_
M:F-!;&+F?T/"B%4Z5$V;0;MD?^:K;)3MLE<-:A2W3%,,UAEP*5M=<;.S-;I\
MQCV;LIR-:8A0PVT063\9F?/0]UI9%%8HS I$L+&D]9"#]J[* )G^X\S+)!7M
M44,%5]<"1NH%"9<#CD83J-\&FO>4(&>!T#B <3= , H","""YTOPF#-3JYM]
M8I.Y;?>2[#IJ:"L8!CEXL2CALL(@,T2NYA<L=)U\LADB=P(8I$JM\TDQQ1=J
MY(F:Y:+,OG)#"E/GIJ$'JFFD(_+)3.MQ75.A*^N;+):WF-B&T]=123Y^#[,P
M87<UMF2VA?"L<]/<KM"PALV6W8[%K-4&P.87CK!GHQ/(==JQEJ7-9J(&U))L
M/_QM-62%^U<H7&WC 5!!H=J-F7_LPT4DL1IJ44$\#Z=M/5H&S\7/ERJ!6760
MFSH+4\/$#^WB4=ASS,N,@XC@3106?,L""2][@5JIIAEN7%*/;3X=T-1DEJ*"
MW42TEAG1VFDB6DU$JXEH-1&M12O8V,M!347B/*42_,S8;FX3E%(E49H8:S^$
M?153BVSZM"<0 CJ)E7Z3&[_$&(MJ E@4C/1'D8Y;W.P"!$7EXP!&')0*"RBH
M9:\/RA\5852DI<8QG@8U=^@]M1%J=+"J&;ISJ)N%/,88W5VN,?I4KH-Z[7-.
M6W25+<^5<_.N$JC#0W)3ZU(V2X=>^SF,S7H#<Q'C4BH,AS+1MB[U:V9^ZA1P
M0-NFLM,#*%:*59NZ(+=\\QUEC2&/H.0  EZBIG1%KD% W6MIH/DH/EFQCK6]
MIJH8%9ILY@3V[2Q?A!:]=O9,;R0R)^2K1ARXU;$.,&%UZ7K9M8D0=6N:QF%:
M+D&IID6F<1]AZE1HK/5@(LL'B*'#Y#51E3Q_K&(U*'DF]58ZGIJC,X!ETPY^
M';V/*R<#UCM+Y!@O I=LUB143$FEN+,!"XAOH6H=$T53%T*D>4]W)\F*WA\J
M5Z*J>-DYPDK-RE!;:Z&R16H,R%AO@YAGJ66J695,!'FHO)6.@D@P?SQ=I27-
MTOJ*F.XT::'Z35IAPFK<5/X!NC;51V#4D17HDF&QCPA770EW6+/@Z2J$; -5
MS97N?=U;#O_)N\>;R\EC20%?1WH=_B"!F53"*C)P7N,@5?L)\@L&-W)>J!36
MR<E:THE:-MHM\#1B]YC+\?UP9(ULS1V;O))!D&+O.=* 0;?.(X>O\?,*)H
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M9ED!3VZ>3*1E..2(&.>1&+\/8U+#>U'B?V-A$Y)#_[VEH[Z;_/FCYLC_Q(&
M>Z1#$1W:8DQ]I&J'U8[1?R;,ZZFW >AGB=K=C&KWM=O3L+*G4_H,.->Z)JF&
MRZ301>E3-\ZJZ\3C(BQU0&K(ZION!/(73,AFS8(4!NLMASJCLSG&B6.LGF-Y
M0%STQ"GBPAN!AJ(+B7HB_H9-$_TQH?Z1H8*)M!0]YVP U785@9D1! ^.-E3]
MPE0_1<7H&#R;FUJJZP=?@W:3&^ Y?;3T<)Z"\BJYR0(F@C$27(:QPJ'NA5')
MVW!?SOW!*SB'MTE4Q#EZM^V.6LIM#E*U7##GRF08N8Q];@&YP65_]B]5\1\,
M$&;#,$,L3U-;N-E0XPQJG&0K'[&GO?=9_"$Q#MV]);) #Z'*0&*%7(&PHU!%
M0D(M1M*C=JNR#1O@&P@ U6H*7R.I;]88("KE#V/3J'U/8V7JIN#3*F!!A*M#
M$C'L-_*T \73*%F(PC5"=2FI7:3IQ:.J'_%VU4RE53JQ79U*0PU&B$#'N2T5
M2ZI))%S<IE_O1,*K I3,6Q&Q07]_A1?= (?8J 5VD1N+5*$:4^=&RY'>D_F=
M5*B8%RJP.(FC?']!KV+GS@RR\O)P:%'%4I6_7U^ EIVF1YF[=CX-L@ZN>>8V
MX&[$T 0WR2>@HX:N^H^!&F #*-]B&H2\'""Y.,I)UPUW6]K='PQN[B[BYNXC
M;NY^>P__>-/RWN!G;_ S)#3Z\S7M; <O#LIA^/[MULXV?+5+7^SLM]W 1XL5
M6A*9(R4_[7DK14J!7;-QPOOF2]S0FLZ.%EJ'4XA,>YY3,C;5NQO[#@3T*'/B
M+L0JBWPKZ6^-0.S(7,/39MPN>3+D1'8C$D3;^VK7"[(Z2.>/Q;Q;BI9<&G5#
M0=K *E.H1-E:*Y=#*E N,\9Q-/C5'8ZG=H.URG!*WRAINX$<0K7&IT!"D-P9
M'\](C!E1%I27Q _IQVI REA/OW&F)>.]1*2DT,DE*EO+8N.8*Z<S,D761*V6
M&;5ZW42MFJA5$[5:ZZC5B]0NI7*+O(!VEM(PX;1\UHL8=XOS<%TF[Z:%J_1Z
M&(A).)7]0C>+&":Q')>BC0PAS/8EFU=E/V&&L)8W\.6=2 .36DU & J40A5_
M."),C1$ID6?2@)=J.NRWGR"$\+*YM*BZK9"E<%^NK*4A?I2R/2-/]B7NTHFK
MX%4"@!AY&UM)A6XW,3@(;Q>I&[WY=?GYF+PT1^)2;5SOGJ GE<+H9*/)7*-[
MP'[<1'_51JB,2UIJ>;DU3Y$4U6"5+HI5NE+AP]HIPHW"$R_;V;)MRI1')O9\
M]-8BF]>ZC':MAFIL?$^7]9JN,AQYZVU6ZZ.H:G$ RY.E)6<;MWT)U^7?!5=#
M,:$K:XL=LKC(6Q$5)934]$VP>QK:D<G,B\)_%V% J^76BE.O,O -.8J2L;8K
ML4HYO36 %K&,F$\$L (0PRD'^S!-<R!%H/"<LCQ[VNSDG^-.KCY^,-S)*:3X
M\#NFPVHZ)$>)\I6'%7B3 Y;6D^JB!351[BIW,+=V]R^ALX'L\0]S6*D/"SP$
MFR.<L<P-]_.TB#>R3<MWAI?UT^<+]^<MK^8C:O$3PXY+J8?:G&,7A=X"W4@)
M-6E:OM6G74QZ3*<P1^<5/<EI#Y.%=/J,%F*,53RXAYP6_"Y*[FSOD5HWZ1X[
MFQX84_D(# R&R\K\@0R*B&-ONYMVQRUX>WS#;CX%?8!OR(!CT&][(D=<3+@@
ML/P65QVZ!PU/A3=H B&FL7I/8 )P9:F*M;DP[A&_UN2,O$JJD,0<',G$4+H[
MPVJ;NQND(E&OV-9L.J[H6'%2L^LZ^*+/A2)/,E7:EDU!W(%0U?<LT)P1W>?H
M>C9M:>L;T>*5:ZI;EED(N;MFA9!'G;.C[NDI.X:P&/**FB-\[IQ]^=@YNOYR
MB:T/KKJ7_S@YZEXU%9(S-G^!CD_WD=#."]+0LI9Q9'.]I&_D\W%:@%3G\#I%
MM2UFSX%',NC+I"LE8X49(< 1,C."*RY8FE!U4ZU@J!4$G(+(*4+5 !$!"AF[
MN!\2HCY8[\"E8U;)32$]]U77B2-]BH -JA/,HB1W8_S,^N/DWD%A)U!J<%T]
M26S[-3@PJ$0M)54X@T;)'IT=K-O+4ORJM@?PQLQ#1<FSNWWHG.T1O0[>3%_N
M'.(1;AH1Q^D\0=FSEI.4$8L "?DYLQ3Q?[OOV@>OI^2OV$NUPRLXU)SQJR:,
M]J PVILFC-:$T9HPVEJ'T1IWT]R^G-7W /,UQN#@*%?8$1D[*<6=,>TS=$*
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MTZ\2(\P#_(NB!LX=3,>\5A=BFR2"ODJ3G1/YNI2-]\K\2<JE!&&0H0"-X&=
M-DH:SCICG$\%'+X\\HFC5<#L) *M!O'ZC*M-Y]E1@7%UX!Q!@GC[^('N&]4;
M*X9 Z9&L$^&"L>-GEDP98O,]<8L8>9>LTIK6"&H3$$Q[F\IZ)[8-X>:I018H
M#PPRS'S2:C-=$RW@\)IR)(VQ<X\<51WIJF\S?T?LB74UQ6B+V!H 26@@HX (
M/R!5%QEGJ;ML:M<]I2^4[45XLA:?(1M,]<H&-GEGK4/K<40]F,[J)Z/QE-Y"
MQLN6Q-@:>)!DE=VU'5)6KVN<HME"9$T1=26 4VQB!,M02/;66B$YHRN?47S#
MZ_!=X(Y NC-$"P@>9J<BV"Q*2:\GKA;)&Q&1E"]B.$J6X?C3,#4Q\PHQ#V%F
ME$S-G)99=&"%^.20\ZL'XA;]Q,")T2R)N0%\(*LJ F:R4SM:C"SGZ&.&9\M
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M7?H%UM4G,57;!R+'N(?"*E5U^GF:!(6?)^G8\R-19++]$T14]M^VW^W\J/&
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M[A_ CW;B>/<6P3,Q-GP HG_ 'QHF"_"XP%0I$-R(P8Y"C:O$N%5.RG$0?+1
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MS\8S",.3?!U]@7_J6-PUOB*5F.9J3/1*&!2E+PN]$60]5Y%@C5RLCX5_R!-
MD4\]-"V;_5FXQ;-P [B2V[XG.$^1U:5AYSA[HVGRI."%S(F<U-G( \/9,W!5
M$PJ,WOX@ >9A+.G(PQ072 ZF\W#(?G,=PA&"F[:%:08S@SRNE;NXG/(38NXO
MX&>5-"HWLR1!J]_X$KFSK]OOR]S>J7CSI.)]]6*#_)CFR8FP!D]C5%R#X#HN
MN(&*:WMWL2 1A46>84Q2GSZ>(K,TZV4>DNZ!16QRW9RG"%XS^W@I&8ZIT\8;
M=PF49K<]XM%%6K^U57"SBG6J6_PWF#;+0>YHP%(\URNI+2JI#6!R+<"('=^I
M)-I]Z1I F;=B10-!T[-Y^W4)ZL+I+>,,01>5[]H2K?.T5,1;B!3]X)W.%:J3
M2[&AP3PL$,VC(0\F2TE@ASJ^P%AK8KSM:&TQ7-C<_<!T:'#5!"DU:N(!3W$N
M"!'V8?X>6S(]FK[28[I:]BHT2>BQ7(.W$98ZY6>(*NBH,%O7S XX.FAJB&DE
M> X/)+*<,$SKD $I$6(-B\<.4WP+NX5!Q.B*V)NL2B*'7G.AZW!)+_&W1")/
M[&?&/6AJ%LT=TTD*1HG7,:%'7">.S/M%D&>+,*&8@9D>OQ/$5BO^0V:5DWA)
MH]*L[:P*18!TLP^ZBY8=1VKX;6M\H=R7Q^T:=*^A\T-D#L+*.Q+"PCE?<2C&
M?_%(Z_!PH!>Z;67($TG=ER_LV2(,?%;%X&[5!\IJ%(9:+S0) [O(_D3IR4.U
MLJPIKBSO<Z3;R9&^['.D3RE'VBW+2X] 9H>)=VLLQZ IJMG,4;Q-GF.?=A1#
M:A2-([#-GJ9S,& WUAF6A&CM)PR8X$BU/P=\'1XY3 R%<]:T!+"8W/;F0W!@
M'"D#WAK!IQ:C9<+DV.ZIHJYDR#C%APFJ.VU65,8\,8S9+:;8;4/SE; SY8+H
M=%IM^"OBX+J&U*RI@[':L <N\R9JON5NO1S<P0]*3U$/PT9BIA<0<RT=@^YB
MJ>+<!S?A6,*]S6:*RWVXXKU+T^)#>G;P/2SOEN?%M=H9S=%4:8+QVZ4[:\F+
MF!$,6E:]:6=3R:8C+&MN@=Y/W**?N$F)#88U-TJQPN_:<JLM/J";F#$93NL\
ML$-B$,+AL""5Y9G,NJ<B:3O2'"X >^ ;TYR1^$KVH% +8P*7_L&Y6C%%B:C.
M_&WVA0[6LC\3IV-\41@8-H*+N25<E<(/J;7+"#$PSI8O>Q;3[0KU)L5!EV?'
M5V?!\2,%FP2O]@]WQH^YU\[W*2D;5!+5813M6 6_MQ><R2-P",IV*G=R]W<P
M>D&>IO%?'4:@>CM;M&IJP2NN.> @1IQK-<B4&>\TK6(D@R>.3P')EW%9T;$<
MS+((\PJ.J=L"(ZFQKUCJ,B9C<3*)X77&M!UXKRBKAJ+#_;EALB.;^2,G.VQ!
MJ\2Y4[9)UFH,@KFRD]]HRF:=>TV]CZ:AI:FFRI>>86;;;8 V@,>?*C0P:?NT
M(Y4>I<[6H/E7=X"9_^&E: /HL01V-[!<3TU?C%9<H&Y[;SN&@T&IBA*SLH6B
M(G$/SZ=;B:^ Y/N^<'Q.Z'PC!)^=YWZO;'&O; #"/M5=[*^R;G=M@DU?*4S4
M+L=TO)./T_(U6R,FCI53=_1)R@%VM%9:K8M>++8G%AN@K)?@.A[/N1LP1J<_
M<+<J+1L@@$%:YE7Y2(F\#IYSSK(7DBT*R0;0N-,L2=KH6,+@]_TO^^ VXM=\
M#,CM_EU?>%L'^GYIM[BT&P"*_.1%W^WKH9=P@UC_F<7 !Y^)$*F];D/(DGQ:
MI+8$%B&GP1I,*[RH@G\E#N5UF*9P:<ZD]VW=<_JZ\RUA*E[UF(JGA*GXL139
M!OF=]Z?'[9K+8V\,WF<99^M.\VH2'$>S.,4:3YO\"S5%'/Q;J*L#D,UTM* J
M#>R"W!]9VUOI#?(SQ.W?<4KEV7RZ2,)O,8*#P7B,-< 0DS.F0BV*PTE*_-%P
M!DTK>",,\2E$C_#7!2D:@CFB!<KE.503B/"<L$<H;+/I^0;Y NX@:.&ZP9<P
M:>F 3BDBNI2I^QJPW>$B8&!M-V2\EG7[8N#>R%=7)^438$^.12SS4I,#7MK2
MG>,Y0J[#!-N3(<$61\.D[),HS!7+FS].JAT?8G/%;"B<>IH[3:K"V@#(TOX/
MXW,^6+F@BG4=#<:Y8_8IPSR%IIDJ# S=^S6-,IS-$V6O;X/1AD'K*IG\(;>D
M1IJ\0>/A7HDB@N"U:]AZ2X//+3BH37/AH:0:F<!W,@H3ASRR,4AF5ASU$<GM
M;_4-DCKOLWRD@H_A'ZK*'V^DZ;"/-&U95#;(:9Q?G+9EI:0OO)2+@,Y(8;@1
MFG^2&=.5'JB1KY%#N/2^T0 /5V.+'PSZ%^:4ZC#+/$:U3H4/-@52U\JH/+&\
M/M+EBU[MN'M05.4T0QW8"]46A6J#C,@Y#'^6QN-818\Y)=)S6VU?6C;(B&AI
M63SR#%HO+ML7EPUR(\M0\,L!%BY)"C/*V()P1A6B:2NT)TEX4Z>/DCH[-GNQ
MW3G=!*\TYB]A^[G,U!Y11&9!)Y13'9\+<0_^'&L,TE$\]_NXE3FZ$(4:Y4J&
M0Z<J4FG(L+&F@H8 6T'7 0\TX;#Z-L^ESI=;I7(L)AOW KQ% =X@ X2>89_W
M>>B%VR#O0RY]O?2Z1>6 JM$EN;1C3YCR1A/96'8FZ;V'A1=2%S138,)2?PT-
M2R/V#:["X'W,R-TV-CO\OHF#TU07MMH+J^5,%9[+J.=6JG&Y==X2VW'#.1@_
M:,U)$7BIRG4T!*SY62^^6Q3?#:+]M*)B;)6P=H_2RN(0T\]]<&#K$K-!UD D
MIL7>:C>T1.L-C#&R&B=)X+62MQW>00 9XQ+2ST /4J@2FZA,L57QF.V:W27J
MRJHG9=13)'6KRZE^Y.SM(+X@);P&]84;#2XL?O-D%96[\3OTVV=[V^?5!AD7
M6L_;:S/L_NE JNM@VE"A:C[5^&"/B"7RQ;%^MHL\6CFKE4K5SO6!TZNCUDN8
M6L9RZ^![)E31I2.OA54EM35A[1/7XV*VA(MYW>-B>ES,]ZJX-\B?M2CN%M)]
MJ[=UZH(4-?IX>5RPKX0^51C+94O.@_ZHWN**;Y &<^VSEMH>Y):]CB-#A3G*
MR):%C9HL:O5B@X9?'B/JH>:7TV?6'NR6C)AKE=NNT#_O96>+LK-!MDL[.^V1
MH';665S2K_B[*3A)B)A"4J$PG<1#;I>);2#E+_R1&Q:FHG7#.#HPA98D4F[,
M&+\+RW!@0TGR"]!'1-3-?X'R0H<+?XV/JI(09!B&J3@YZU!-CA!G@XL)EUXK
MXL@>8%^U8A9CM\>T@@,.T5XC^--0,"?Q5[4[D, 6/Z[,8/\4U.4!O,!8$&0V
M=&Y9;[QPN)/W-43B7@=2J6M'NU3>1%[1";L53K5=$1ABGQ@Y?QU6P\AU^^"^
M#MZQ8A9+QA])5 [Q2/R"-"AP7Q?Z&PL)FLFC>;8UM6+]R>[(]?'AWL![%Z>7
M'3].#A_] ^MIHBBR-*RP^O2R\-)*7%6S4)8L6#/\(XOZ")[$_Y). /8KN,Q^
M6V;?8N<[OVT _KTH^%]A&B8+^=1S8XB>2T9@^@QF0LX_"/X)"AH%0R*9 V=F
M97Y8P'#+Q'.2Y!69$DQ @_TB56C"3J*MZ57P-E7P!BGD1BA\>2+0.5M-Z,DI
M[O6Y5J]@K@5H:"[6.A?=[HE*D9,3_\GL:P1[P+T(\@VR![/QKW:*$^V]6EAB
MSI1SL-MP,VHYO-0%\](-L4$WTHO?%L5O@Y3T$DKPIB#B^8W":,YP:8]- K6P
M&A8^1? EIZ/9LF1VX+!PY(_I">$T8TTX1XF#T2P3-TN@4Q<L*^0N!<[=)Z[\
M8VIIJ%CVBJ.:F_FMN,ZZJ-]\66RU3U_=YR;;(&W>27[]B#*P7=G67AP?MSAN
M  98UN6A7>G?TCQB8(G+EW*]#Q!H9*_[HOY9$:K687R%2R+GDDMB1M5I)Z7)
M?-=5M7<BQ5T]EE9HHB&F>&\";7T[;  N,.MU@@HVA5?9*78?,<*@;U%Z!W*S
M <2@YF8U->?QY\OS#_TJ;6^57F^0R?Y /6,>Y78.?MX_Z#?RED5D@YS9Q^.6
M6G+R=6F$7#KN5 B)=>%5FE,J)5)CMUBS5HHNU>58DC[@FZ)1<Y(58+?'HP*Y
MB@4S9/'7T@:.(J;8IKA*)ABOZ=$!VT$'O.G1 4\)'= MRZ7MDS$D9H?@_>GQ
M@.,VP6^2$"BTZ;Z%W?Z9FSO^584)'"Q?5'Z-H2W:XDZ]A5MWZ-0)XE=MQ8&4
M;K.=03GC- W;GJ^!5TZ18YD%*N;X7"WMU!] 6SR -DCA?PS_0$I7I@4XX>5M
M3P.8E9.6;>\TK6;W?^A(Z1W-;2_S!MEV!_.X 6FQA^!MY2V>A5^5[C.L!GYN
M5I*E U0S"?YO&A=3)$T9?85#91 DX5!A(I/3-R8=&19%E1/ENV2#!]23FO"4
MW'D#STOL\+,"^7%[V/'.Z(]-7'2D_7I31K8",;*S6,V%\M9B;5ID[]??U\3U
M&F1[&F2#9/%'L!%@NZ6/E!GC9>_/;EU*-LCI&BD)/H>+.GE[+RU/65HV2$ZN
M4^71[((CB&'*.O8L[_>PPAOD^[8/!^^1X'>^SALDLBY E1.[6SLUWB3/"EB^
M&?J7!9/64>LH(5UH9\JKYT=A7WM%U/CK@ACEG&;/AJX-I]Z!++1PT]49D\"-
MJ5*-C[14>X3GI)Z6GOM;ZP6J?^?!'Z3]98/4SE1F@J%=Y82'FX<QH9+"T2BO
M.@O.6BK)X78(>+)H3YA= 3DQFLFTS(YT/_#;;GIT?YOIS>&3WDQP+/E[B6G_
M^OG=UOP.^_F]T_D=]?-[I_,;]?-[I_.K6N<73\U^CK<UQ^.V.;YC@[Q[.HTE
MRGU =3].KZ-H[9JA ALNP0[1:,%E*58K8MQ9FZ=,[/Q+[+T,3TQ<PKA&\-AA
MEH8!-I+_Y5G\:Q#F,S2"#]X<%6 ZII-R:GBA5[9W!2'H67MU%FCV=NDEW.:C
M;!4/57E#1,XY6MZFZJ$Q!\WFI11(%F,=H\?Q2(QUSNHXO4UM8U/=Y_0N&IW^
MT$"!MSU0X,< "M1W)!&<,U6-;K.,RF.895_9[T-/+^?B26+'6ZJ@!@%J)E>_
MC UU#NYW1\\$LS!.+?D[M\&B3!Q!!*B9%M=OH0\+7ZNY;I>%77A TQAFQB+8
M^<OQ\>==*HV)"X1B)X(]4(86GH8Q9I;V($0>'H)1ZY?'&YJY035)7$:H&QVT
M4A<GRRYK1RP_Q<<8K8RWX'Z2^H?F*_\&^F-"HJ<!^>ND<F %L&DE93>C*A=?
MG LA"'#]8$?@>:/[@/#P<Z[Q))L--?N1OF#' 94,59+=[#*@W,JDCJ&T_5H?
ME$*L3[SZ<J#BXN79(DQ*79-/A]/>,,2 Q$RG"^#^-X9/M,8IY<1YNL<P:-TT
M82$!F^*=?_J=<Q'T)Q(Y [[6,:&V=X0AX1%)TUBH>8C%BTACT+)K'6,"#O?Z
M<U$%^6!]%_QMB[K95*B-L*#"F-:!4*5WA-(Q$\C-<H4B8"0)<<G1#K_"KB-@
MS QAG^9JC&4.\MV2V7\P47]?[R4QC4608R[I6"5XV?)"'2%JK_:Z'K&6('5Y
MDP4[A[M4[4[H!"[E@(V0JRCF6A2'E^!XE_J![!S87ZQ(A=',J3O?[>#:;E:"
MX+S[KJ13?FL.4EZK-B696^/NOK.M D;AW?FVNUI#ZLYW7+"]N=CU00R:G]-G
MY>PJNN%-(Z3&(/K<QL2V0$GT "5PVKB!**S0;$0^OF@#[JPR^[7M[5=_P.P+
M:H[TMH>LTL;XH,=8W4D.9(.BC(N,:HA!"SWZ;K44E^[SW]N4F#<;%(A\FM.*
M&%.GY[=^Z$7<H(1CJ0I_//N^+^"[,Z'9 ';-0F,,H.Z:?,L/[(+N.\N<[Z+:
MF$TW)M"2^" 3^/ 7TC&!W(51K*DO"EU@3:WP5B1=-WP6:"8:0F,POH2]U>-N
MQ5MXY*UM=G/+<Q@2RX48V-^Q 018D=S(>F?U96R)J&+(M)UVU=:G8^A4/#*Z
M[C.XD(2(UK?=:59^U$^0W8'$8&TCY/KH)%![O>L)ET/X@,:Y$])=]%"J[:N,
M#2#\(A:]C?#0:[<!>-I9NZ77.8T&'J41T9<-WX$\;0"S7L[@W6)&W$:2_N?I
MT;M,#?S )!9V'!N& BIXXM^"\]OMA6V+PK8!2GNIW=*&]\04@#%:;^N8TVVB
MMIJAJW%2];GG[>2>?^YSSS]&[GDM#K=;&DC4D-&V)\92@JY>RV]1RV]0J6&\
MSJ9>?SSFYZO]0X*D]A;H5L5E@X(/+2ZWNC0.6FV#0/>]2M?A_IM>M+8L6AOD
MT4!6,']Z!@?$(VUJK&/I!S_W\K)=>7F[019MO>;7%&'MPV+;7[D-4F?2#> $
MP^4JG3S2F->K_1=]OGS[\K)!UDSDY3P=8V3@$5L2O<C<B<ALE#7I"%-A/K-*
MU;=YC*6R<PE78?!16MD[!&F%T+4Y_#K8V0J[Q(<)=<I!V'-E&^<X?\($[LWA
MA$+VHK@H*L3R@7VC;NB7137DC@'\2[=G#OVYI[Z%NE4I?7 -ZQ/I/V%]P)GF
M?Q<5C)>V!.9,L5^0R.((F]!0'R/E]Q?2G8 (U'GK!%!N=N1/ F9#05H<IK>B
M)WB[RPVP2>IIBD&8\^ *&U.U90:F%8PQ&,$T$&:SQ.MT<RW#]\>+6B[F""$N
M1GD\Y!STX4%PLO]^_Y)SYF^.7AP<[A\>P-ZBW+$6!%]&-*,3B7N81U1;#T^X
MP8]9&NNCH9Y.B+5542]/6Y2G35)/+$_W+%##7J"^"X':)+TD G7/$C7J)>J[
MD*A-0ME@-YU]B[F%((61XD=*PZX#22]Z5V'+8K-)2'L+[%0K 1U=)"=((GH'
M#)/LYLZL?W<_=5<_ELAL$JK.LT*-:J4>*Y+JSN6W\1J8OGM/MO5!C&V+V<\;
M1+@OB3 -I6&]6/?]UA7M'[[JA67+PK)!4-UE[Y^#DKENM:F3)"!4"I;U8W1'
MKO0Z5^L/.5 4?#P^QN/J!OM9AX7;1  +\.% '#%C=/3,99V;22B);P]&MP#[
MZM$N.N6XV\"_]"?C[G8$7GF I?U+%DC\!R;YL,+RSH+&BF7Y3' ?+JE7-4>\
MW^D FU%KAL"V\O1>W+<H[AOD!-JDH]V$*ZHYB#O)%K;(GJ%!9?\<<X^<06 _
M*DJJ$4;113H+%A>82/A';I\:3E0Z6F#S<S3DN/<Y2+X**\M+.4'48DK!V210
ME-B6=AM&H"VN43N67C=UAU'?;Z*N>85:1+M'06X'!7GPO(=!_A@PR%O/ CRR
MD%;"'I+2T*>]%8].MYQ]I O.*FP6VI\86SPQ-D@)7GJFR:<AO%WX>+VP'I2V
M?:'9((UVJ9 4"T7ADOF5'ZD7ALB#<>^T;UMB-DB472JLBT:3#P\T+_Y,YAI#
M8MD\I8P"?6!9R,9C<)1R<).B.(?%S?"?:C9/LH52 C+(0_F\J(;>WVB32C(?
MB=? T@U[B/UV)6*#3-<EB$.8XTKGV20/9^U<^?6K5BK[MLFG.J_7'$ZZ*F1"
ML+:?LA\"DCI'IB^YJ-9?N!><+0K.!@DM:47?'L:)PC+$6(KI5A\FBR)F#0%&
MJL"#LJH<93/B3W0[WD?9J)JQCLI2(96<P\'E\'4QTV-I^@G =4,U#9,QJC%=
M!@!R*?W;0B%]:!/ESLJ@9MKD/+U&/YG&WEDS- B^:)J)<_M6]!HM7!"]%&]1
MBC?(KUTJ,)L*AV3O<>9D@[?[K_LBH^U+S ;IM<M/[R_<G?TXY>40Y*7/DVU;
M7@Z>;Y(H0X&Y4).LC(7.$P:118]7;GH]LWVYV21GAG+SV&6EUS';EY5-$D[$
M9KW0#2X?IQ'#P+*7?1G*G4C-)D%GD1ID,FGX<0-TJGS*]KWA8J_1-TX2$?B=
MSDD,0_+UB.R+]!<GPU/*Q<-=WU/O$LOB0X3@VC]STO=MK?&<K_7C&DWS<%B*
M^/$&K9$$S(G&R(:>-]O@Z9L2!5%1*1PO%:=@[J1L-)Q'3U<5[ZARAZ"^-RH9
MPQ-W#@[+*1:FI#$Z&*$% T?$/S3NGH36KH ,[^6Q$9IK9[C+^PGO215#H6:=
MX>$6Y5Z9[7$M4? WK- )3H@@L8/\4.K8"-='3Z]_0RPW.KOTT6VFCHT,G*QO
M9UO#^MSV"F";"F"#!$);I*(9T%'(MY]G:3P*QK&T/- Q%@&:$L@F25K$2G-N
M%D[,1D-6FL&87B*V*1$;) @<DK..EL>60\WOU>)R:E"<3CJJ8JT$+&TJ<.+"
M/$!HL02-XL&L\.,Y]H0H*#1#/]=R,Y!:009L<7B0R?+U99H8__[M8>(A- 3Y
MG"-)%MPF1\]5.<VS:C)EJ,\<-&89PP'1"_XV!7^#/ @G%=H*?:AL%61IEH$>
MK'#!#/5P$8RF:B:<5!$5=V#G&5QNEFK]F\+R"%.Y#D$XAC%S^ KV*B)$/G4B
MSB8I,1OB/<(Y@:>"ZS !:X3NK7\(@DYGK7Y*W]YL6^"J@QY<]93 53^8^ML@
MFU=W 1]9T.!M3_&[?3'9(%UF?.SF07F3Y4D$+]5[=5M=I TR5(XEWE$W" 8G
M&]EB>CBU?P[UK;7N?:M?S-O:E?VR;W'9#S;(,[D.&$5Z'J4^[]G:[T)<-D@O
M_?YE@_I0#TG>#A7SP>:@+HYG\':CT-"J@^D'CCM!@!B++F=*K+PFA)\KE8.#
M<QF/LEY6MBDK&Z27G/!Q2YZ@'F)WPNL2.B9WU_E8 L$#\J)UXQXNZ*/ <$2"
M46?"<LL *=:.!.Q2CR=7T$=*,U!Y!%1)!_^48;ZRL:@BAD6 89H;[=9#\/3.
M^C-Y20H+H)[%'CO4JC$<PFMDPC6?J^OL*W8O@']/L<5/E?*@,9>!@D\L6D1I
MG2H,QXX493EH[L9Q2L57(^+WXD@:#"4O.\JYG!*N,3$#*!KB'U4>%U',<T"A
M!.XNF6:85U'PPUFXP):L9?A5I3S4L."7H8_@GTA,$IBD@TEK4+BNI/ ;"*KD
M?092;%*?&-@YM.8X'; S8IZA,-)WR' ,G3.B(VC"75:G)!O8V^<>R?] \B9&
MXF01PQ9RL<T6?,Y9)VY&2N94H:[A\YTWN\$"7.'"=LR&OY(8,TISF"A:*9T8
M$B87'"#.'J\0_^T];(2H1NQ8P#LPRL,;,L8\J2/!H398?RB-Q$6&APA[6'.=
MZ[62<D%JG]HE&/ T(QAWI(_]L$R;]NW6470;>)VTP$3&.]CV*D<\)_SJ&-5.
MHJ37\3F10S^Z\?_TZX?SD[.++V=?CH*KLY._7GSZ\.DO_PBN+H\OOKP_NSP*
M/O[^X>K\R^>SD_/WYR?!\<75^6^?3L_/ONS?W?O\@.<CA?#=TW&5-L7!7S#Q
M('O;Z:ITCV;+F\,GO2P$&'&7Y4LU_,-)Z..Q;UMMFS*"@?%1,>8.FF_""Z43
M1*%T@5_L#4$=$UR X-\%ZL0=TMPA7:UOT^P,1&4N>BARF2F7R17F1I5)4''>
M\YYS4D3CM*L39O4J41H9)Q),7JX]0Q7L.&]ZS^]P2.\P<!+'S43SE1I-4ZR4
M)?:%"E]U!H?5@%MGSV"]F7IA@%5,<)>Q(!;D FQ=#Y,SPT(#% /\+ZUWH[74
MRJW0A75" \MO:?#8*XMM*8OAALK"[HS[AE%RVGAM997"/:W"XJV,(MOO]:WM
M]5;V,]G<[?1G_3Z_KWT^NB^CP-]G3VQW=;0+[FAP/.@A!EN"&!SV$(.G!#'H
M%F:_'WA;L])U+,K^F+GO8R:ZHV/&/U7LJ=%YL(RKG,/3C_: X1B;G#(DK0_Q
M]+>-,XZ;SI]_QOE@0Y$BV\96) NR;BJR :FMQ%R0R@--@>;3GW'I@+O1=^+=
MMGU-5[9L;5/:+OD8S..F*O<NTGF7^HOI.)0C?(0VC&$(6ET,-C)EA5F8,-[,
M*\PDPZUOUF05QD\]WO-1$F*Q ,Q-K>P>/MG#\0YZM79/:DW5U-I%5F(:H2A#
MSF&$Z0(S'A.MYYC+)5_4.Y?Y2L]KLZ)-91W_BC+*7K!Z4Y2WDV_@&;A?2)PY
M31/K/_OD[_:"VX=K!+=M)4#1![/O*YC]((<U!<PP $6&28&-[_AP]*P/KN&P
MMD?A'$/- HRX?!B@J-1@\!"\SNUXREF(%)Q,1\$OL;?N?-NX!,D9'1$7^G4<
M87H53\%?GL6_HH[BQ]#!18E:QQCCF1LJ,P\P S=P;@D#,<^42M2U/Y%!:&B/
MS!V0("LN2D.%A!^;GY+%250Z45P:& T8*&7.J?U6<Q0U*@^>EODF3I) 7M&8
MJORLH,PK8]& 45GB>.:4Z9?W;ADZM=]"]F7X*YIQ" $M7U@(29VSK1*!T^B4
M3ZIO0C>ONYL$.YQY[GZ(?8" %<!("BFW#=:TFAO#G- ;I4/*C*:=?E.X)E(X
MD2!?)/<F:4/O'!-C$$V'/X^[QK3R9I,7+B<^/H+"X/HA5@&?B5_!BQ'V2>JS
M;;31IR@RO(]P6,(:M'$[8SBJ<5*;DS:KN0=8:EG21)%0]EK\SK(,Y[IQG9E]
MK0; ^9-Z-+)[L*:HQ9735^D"WMI-'DJ;DON+AP,,*JW5/K/K*X1^6A?Q5D H
MS>+=_4G;P?.W2\4--/?M$L<2=?AZ_Y4(%:]L7>D9+:V];)P!^'>61PA!4EH!
M=3AG?#G=0WM6I(<9$5G7_#;$4)MGD9..AQP]IJE?8^Y?[+]YZ\T]JW1.P[O&
M!_Q9R\([9),\Q2J_AJOU(8<4E(ZNACL6648)_ER%19:&PP0[ZB &2C</:#D<
M=[)\@/7K?);_LQ). +EF8'YD:C]AG+1$A#J34Q3U!!]\*FH_Z.00I!_43SFX
M(QPT&=AG".YB#GCG.+&B9$(*Z'1YO0EF68KN=/M9]Y V*)Y?.EGQ8O_E+4*^
M>X0O_J@D?0U1/VC1,5V&CZ\N0A(]D+"9@2'B+#FUV[RR"ZM"X*?C&%\"HU,E
M4V1@ !*C,9[E"/=*8#_0EL./TPFI+)2F#'5?O6UYEY*K@X*/K_[OX,09A$>.
MV,(FVK7D?3A@>^& %VN$ RZRX!R5A3(TEN! (7U#?FV(1R[)#:1H0< [^\RH
M;_4-F8>+Q(T?<24T&K3B9F(K"UEQ-GU14QI>S?])LYN]OV8W>-DY&$4)\E)4
M($J?D<$>RUXN^2YNB1)\&EO/%,WCNI<&AE<\L\!?'!0]7+_#,5Q..U.\7#O(
M@K2K<\\^.;JEY.B+/CGZ8R1'S<9,03-X:D*'7]JBS$3P%&IZ<LK-Y-=L%(*7
MK9(Q!TQXOZ+U8V_K<8G4VR;)CE\Y%-[NGVN#D>&?A8_^7 70)"$!BABX(0%Z
M[6^88@(%B5_6[NP.PT2<ZMS:_0&ZO0/TY1H'J&OO7%&A IUO$9AM<P*@26;8
M/3[_WHB<D7KA]BWC,1K*X :<4A63ECH^B[0?(K$^L0*%LYL?V\92C3FY;^1^
MPA>A<3+]9]&."A-0=Y&S375BVT$6U25/'Z@1^[!8F"(L<[BCXK3"/4;D<4%4
MY?4RKW;R[F9PD:<H- \Q;TV^1<M+(P<YO#F\@'UW#-O!V<[6ZCAF,\%X>?Y<
M4[D1&L>TY?32DLG0,HK.N9<)-*:3U6_:O @YECC*BE(K@SG;(7$ZJO*<1VG[
M-E#&-4M3<:B,&,B ==[:#-GTMKMEI.@:&",N'((KJ@=]:I=M3/QVC761D+)#
M5==*R$X!7&1;9Z'"I#W7KAMGW?K?%&,M,&I"GBQEJDD&,Q9&TN.W*UZL,RO4
M2@I:Q)4OKM(8S9F\FN.Y<FH;I.D7;$7WM&_7:FX"!NBD8\"!VA1^BV'J%1Q?
M_-4TJ_)BUQ2+V9>GV 1?@U+B"HF.6E <SV%1Y*LO<5^OU-3A]OWMOQH%M"+1
M=2AY55'(0RE?8'>(K&=17U#$:.CPZ$ *T[RO*3YB%%$UAV?/*O(,K <M:R&Y
MG_X0W-XA^&J-0[!>(<,>(VNF2QLLZ(*J](GH1U%5]3"%$CI6^$K'"H>@:&\>
M#&56*]HP/@CG8MGRQUEL*])8W15HQ6 '/J3TOBH71+V?6_9/[8P43H!$,D6U
M\PUT-,/J8V4QD!C*',%L1S8"?2\KZ5<$_XT7<CD8 ,X3N%.!YPHZA07" 9K,
M!WB@;0RS0WO36UC7YD3KI 9H\%*]\/>.P^+#$--&M:+X&_9'N\N7_+99\2$2
M 4Y*KL"29,)7O<SU#CDN$'"X:\Q AXR:K9"8C<U[WM^Z'LL&"F&Y<S4)P::,
M^L/GSO+G)"I3LD +&#,1!7M) $='-I&F%#Q"84_ *R4G P.$)#P;W 1#C&"*
MZ]L,?(\GNZ=4_-FW:3P$37Y"XKAC4T3.#*WT6C#^E=A]3NU]6[682R>VJX^#
M]UCU3L <\N^(]7=>:G9@8^FE&>A<&Z:P-=(/51IMS0GN1B#[W48*N1-8#06W
MRGG<6N*!\-;.HT&81*YUP %;96OB;/FH-!0D<.LX#Z[#/!8O>,+!0<25W+J"
M!ES+K[\<]BU8;TH42^:QZX!#QUP4?PWHO1^\S]C6":^S.-*MV**L&J(IZ1@3
MZ22<4"S#=Z)S=ZZ9^J9C"#3LF5*,/0M&<(C!3@B) \>,QZ"+*7!QRP$G=#=X
ML)%^,CM/+)Z.@:RZ%BV6$M.[X"1@/@$>T6)_KW8H&]BB-5)'*J2LE<YH+9GG
M9:"]KCV.8$<XX66OTRK+'("$]N3$VTJ.O>R38T\I.?9#!8M>KQ$L,ME\;I7B
MM%#KXT!W&@<Z\;KUM"2 !(JH4S85_"MQ4#MNUQL#Z\:O-V][MCMP<'@<,)_-
M$5^'9\W8 &P-WA[L"CSK30TF^15TV"&YH!2ES>F-=&5? .N6MO8+JL7T.^T/
MZIU#=X$?.HAL+IT02Y?P6UT&3 ;?.3RNMA3*&DDE%GA2MHHG.[7;PF^L'*92
MT@C_1B8XMM/]1AVLX&QFVY1N:>O^*ILH"BO0O)#14+/D_4H"4]Z:()<@F5^)
MV]U7ERK8&7<7QHEWU-=AF;FUGFRU][K9=<.:E >D[DXY'%F%(9G,,S@:8)P8
M3TDGA0[Y"'T@=T>'J]0\S)>V)AZP33V/E;EWR%"FI7?6B1#X<<LMO7K*^O3I
M::T9_)KL 0UGZN^T;)ZU3-CZ$7)97!,19<RQ#BFN4YMS+KU(4$& L-=,1F>D
M=>,23<F<KF!' =_7D_TQ4U7;E _VFE9YJA.2SBZF^6\P>MBM"L\VA8F#I5/2
M'T)W6$_!+E>F&,.C50PMQU*YB4G-@O+![+ G,*S 7*EQ>3V-)!OZ4G+0W(/$
M! 7'(&5\;XQZD#[VA$]*J5QEVW:T.)V1'"GD2*ZMC5WJ:])9G'/1$6FO#J<>
M'Y]5I:D]L<BB!G;C@5#@DE(QM>O>_O>!H??=V$GGG*1XH *7*"RE\8\.%)EZ
MYC\5*$*IL%&@SI#1J7MH=APS*\M&K\;NC)3*4V/UDI(V57:K0M(8!CZ"M3+3
MYS"MNG.V,9QJS*8I-^,$ 6G@3!QF8LU#W!*^#7:VT_":JB@=93F6".%='-&K
M;P(-7T%"9C; (A>'UO%:=2@/P4V7'0HK&K5\@+0UUA.#F^%1^N&T?/1<<G_:
M'TV2^*@F^_<T444A=._:B]0"3N8EO1,%E?_,;*XZKF81O"Y.<('_=_+HP-:Z
M>:=""Q[Z(=H:FO2_"\XSM4?>DIDM<&_+QBSJMO*[W@ZW<^_V!EYOX/4&7I]\
M63GY\JI/OO3)E^_2-3G<?[-&\L4]U\[3/5WSZ5:G<*!W]#7-;A(5301>1B>D
MA!2QO8]650C3=L]2B_M&H:Y7/'=7NIC")AV\3#0$Q@D"\1E"IVK[W04T+I0<
MD8.M:('4Z">!%NY@RW7'X!RT#V&G8>J#5X87PDF*$'- /!M6>6%]4'0'+#33
MV"8:ML_V@R6CZ9S3=K^B\W T?;[Y<7(X&J,MU$=7 Y/85M2B.XSKV:]W&G>&
MKE=L]9R!GC%ZR4_&IO+=600RQF/_$0CHM(-X#++AL+BT-5#GODM.7;3#EE0W
M'X]KW 0.'8JXSDD\B^4^-32YJMDL;>*T4^SZ/L02+"QCXU9%N>F[N!K.O$T]
M2 &&ZJA)]%1G5_#>;>G]BQH[E5.(8U)GA2>\2E)FFOPKZUR^-1>NU:&3;!32
M1< C$(I4WB@1F8YZ $/]M?3%!_XM=)%:]P\<SHL\2Y:2>KD.*#&\QHQ6J].;
MW/Y0[VAK7^LN?8#3/@\7HF>M@8Z4:-A#K'#WQ](;&0H.CL_]5A6PT0OP"##%
MYCFZ%*J[P2W-=6#R(%0\,!22*E\8>.]5N*_F].8L1]1B39<D."*Y?*[Z&JJM
M66:U5LR\\"OUGO(T5Q_'OS-,S-+%.)8M0^ZN/@=P039>2 V_<#2;8VE;0YOL
M["?"LV8!1.>?.<@]5-:R'NKBUX:9?RO7FF.#=9Z-]QYOBH3PJGZ</A7F-M<'
M8<-R2"49GCFX%J==S5CRBI]\\T#NX_+%:>/(T/L\'>ZP>!L&7,.,[5H$4ZO6
M-%T'J]]E->-NF3&WZJ/8BG<,NML1]K7Q:!;56,AAR<8SZ3GI$LO3K:E^Y<42
MRY*Y?)#]P7UG.*);G'OBT8N"4T.)X1+U;.,([R034@G\A"G0ZL1"DH64SB$8
MBM&NHQQ>[RP5-><%Z<Z&8+(ISOP6=TDKB8Z8.:!;"";7I75TJI2$KT1<*\L=
MT<DG*.@%V;DNJQ39 Y(=D<;((@%\1FDNE\@^R8K#?>_D'SO3\KK/M#S53,M3
M/X/J(+!;XI'""?\[.R);.'.."\_N$P_2P[8,J0VF(@WHT]67'L>W8:S'%$"+
M3NQ0@T_$):7P79H2R6B](=-"$U8%[XE^874.6X^J@>  R'5P^S-V^4 ;*F(L
MLSD9?;2^O/5HU:M8K\)&UNOKF,(,K3%^A _:2]!CJT9E.S2!'8%;>"<ZF!.7
MEC#@:Y$ :U##45#CG\!THS')M>#"=UX-RQKS72N/\69D'L:1):6RC3O@9G%)
M3M'::Q-.D#2FM&'<I,C<..X#12M,6S50:Q01P+!%<W&\V<%T&,\)$7L.;3S:
MHORXJL_F!(,O8=+*0=:YC2C-YXJ$+ER'68S+B@3/]%/C*U9NH7:DDS\=[X&U
M)3!8(8>POO! $+BB-1A^2T5P9!7L(@AWF=RM\?ZP7W)9 DR.BW2EU6S(7'Y?
M5"+"=T'HW?5TE,$;^HFW"+^/VKY]*H&K>L7?QSA119FEZ\FF.3?K:N#5K?$*
M+X^Z$)72O-%M^F10"V-HR94C /1L#&_IDN,Y$9T_/P%&-S9IB[R3H,&AY._H
MUN-(^W6D(2U48.71/9W8'[ZDHT*-+;G.2M4%Z_6M(<!6N7J(A;SCN%GWD@EN
MG=M\*)=_S>6)W?FVZ]C<@XY:4"0WM9P<UN"NMQ!IXTM;.>!JF\[P%;H415>?
M4(,()W[BC\6:C/!2"_>E3"VGDY;9.=AU.$ X$C_".-&X2FH$L&3N/6UEHRE+
M94:,J6B.T";5BI[_UFD36,IA?8ZW8D_1>CSJ.<E&1'7,9+<X$?_RQ-&%:XA*
M*X)7^P=T[:O]P_5TFY_CP"_,ED!7F5^"N0<*UY$VCCC5<#L>M&_&/Q@0_RV%
M*%R2NYK1 39'-6IR"MA#XN?;XJ"M9,"&MJ'!%^ U1XK3ZPSE@DK)D<F,JIO<
MT(,=R,'SE3)6M#X^AFJUI<263Z*+;7S;JT66T?H:&^^TVP(G:C;6-(S^**%C
M3)&V0OWQ-\-J@04>'F>:,Q,'M\T$ONBR'=['KK<4NW[3QZZ?4NRZ6YBW=R3B
MUTFLJD;I;99R,VVCKNI&#'/;%<)JI[N3^L3\R,$'UX&QQ[1S]F[-=MX/>B!1
MUX74E =H7:UC8MK9:(" 'HHXN$7%"\"@T0;6M05N1RYY(6+L+O%H5TS0(ZZS
M0*\O\-;HP6.7+Z6"M0=9;"O!%:V3X$)BH31$R1!!X%25#W'0E]1*B)Y('NE3
MRJ1-Q"8J1 WB;"VPK8M#,X#\UX-;'&S+FY0KZATTEI*(V_(X2(ZJ'\0_93Y/
MTTVRIEVT<?EJ_\4/TG#6=26Y0<["PXEU*^P1GL+16J&(AH=;IS5B\KR!$[UI
M[4K;)%YE5!J^ +5#<8(N<L^G$P)MZS%I4#WM%4N<^&Y+,';&*Y!!#_Y_%I9$
MP#<.&=P'[AB6R;6Q]-8L EB"695BETFG.S -@9^IJ_?KJ5DN^'#"=(43/Y$_
M-9@+[S$5(O_Z??"E"=Z4JVW3\?[@AZ':^#"4-7*A&X:Q\L<X&$_K!Y\?+S+H
MWQT_+B?*LR[C KNEKA;C"GX/6W;$@15%1<2W.&":_Q$F?AS"(_ >X"_1?]C.
MA7E,%KI!(]4NUGHTNM&R90_;J6$76EG VUP(?1CE%/>/4X_GY/:S2;@FI?@6
M?CYR$9.WG5HN26;8C9_.EKHVN^YYAF^J7T01 N1FBIJ*!A=@D=I@C7CM$L"&
MUJ_DJK3I5#T'3\62\21JX%:XVT H#%ZS@C6.S"6'(1D6.Z;Q,3+KF] HB9K
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M:5_AZ*C?V3T_2&@X:].?'%L[.>HSWA/);2N'^W.?PWT*.5Q_H=MDN5OITVW
M%D@+W+7OJCFH/H2F-&JZSL_Q-+@;R^W/O,!/OYZ>_>WLPZ?/'\\NK@;!Q^.+
MW]\?GUS]?GE^\9?@?X6S^1&8GA\_GEV>G!]_./]_CJ_./UWLW]VK_(!IB1=8
M1+9R5H+4_:4&4:%.C:5Y4N\5W%5^XD^Q'E+7/[*N3&2E WX(>G,@]D #A+@^
MZ+!1^67#]K F91X/*R;]T*Z&5K8T#/TA7 A6.*:']2?#G'TC#,SG*I@A2^^$
M_@:)^$I58'3Q+./;1ZH,XZ064B8\'96@C83\MV[6@-= ?\*;SW,B0:B_X9'P
M(VAJ[&&6?<5_%V&"BT/8_ (9\^*"7#A\GFT3$R9"\X$?YVI2P>-QVNP@^PUU
M9Y'6/[6A"LT^-\!UBTE"M<= 91U8UV+P. %\'2D43?)%LQ%F1R(;;%]C2ZU!
M@BI#QV0;.3'.(!H;59"V(H@2G640K@"M>@C ]L[:P[5(W+5:6),#U[0?H("[
MT2U6F3H?CDDY%H-V)>0BUT=P(;5V+1'%S>PRGOCN2HL 70\8ZS).@B3;MPF.
MJW*:(66#2>IML V6<L_D:JR(2TE(?T2LH[ ,;6_$SKZ(CG_<EG5LSAZ'"\*Q
M*A=.^7'KRWF51A1-2,W$XO#P\%)[X1P=>6&JAP>7]A-S-<*J^!?<2,T,BM[2
MCZMP[,Z;.HF@1 H3-<K1>\QY0'GS#%]0$>TG0PPT^HE6U"&1:EW<AJJ!"9%,
M4Q9D0ZI_,UH3_I_0]1HDD(8SZ;OAWEM/0I=!PMA\I-3(F\_O]=CV]-B+-?38
M*6R2"6[&(UA+V1R-?JNVXLJ:GW"$7>JJ&VJ7"K\MB W9]JGFK:?4UU8Y(0M8
MMYU#\CV/(*I-S_R>4G/'+Z6!P7F_YW3FQ_"/#/\7#4X8+XF;Q"B'NUR93A1?
M<\J;=PXLF,37*FV,27\^TC>&M_7[;].A7O^9A"OE-UZAR@[.&<;&A[N[&I S
M7.!>4TC&91$:M]3VB\Y@O1;G@</2RSF)$;QE84XJTPH7T4'9MJDBA"*BJ&:P
MT>)_Z:)54V84.>R+2F2GP9.8+I:H9[DW);^9G$\WA2S![I^3)0?:VFAD.O[,
M'^80'?AW(O<"Q*LRA4T=!XK[F+83FZ[QV6[Q;H9ILO"08#A01>]%D^\2*!$1
M$?@RD39<HZP:E@/3<1=\*(*/<YTLS7*M0FD0.,V$8 ;18"Y,13,]H"HD-;M\
M=V--))8:JW8W-&SN%NH*Q1J_SC_O;6;DE?8A5;H7,%P26KE9UCUIA'5J'J\G
M3%_K0)M;M#73(2/O@^);"HH?/N^#XGU0?,6@^-\>:TS\_?G%\05&O(.KL\N/
M7_J ]S:-UY=K!;S];L:4$;5T<*:GC3Y-_]Y&?D0X;"I\14/IE."QCG'#--EH
M7>XA;\$ 7<(]<&!!3=')B,<\?N2TX)#*:-<>$O.5^03QJ8:XP!#6F6NU8^IT
MDA_;YB66>/7-K65ZTBS$:3UJ27^ZVV@\G"/V),1WG1B2I1W7<MOA>9$4XEK;
MBDLMD6UTZ80,TD:,+CSB2,(.6EIA0<0;\&RORFJ7(2WZCJN"(!MOX4-;N(9*
MN(1;^C^,LIRCN&3^SBP3^SI 3#,&]]E=K&@#[2HM96FGZ29V<[_9BVEBP=-K
MGMQ<-D-_XF@<1K3$90OM1_MM=4%&QVW0$M#M$<7[\VYK$,#.NS*BC)\6U1XW
ML++F+TQCE6NPY7IYGB-P>F;.0N_%]'TL#SLJK!3[.'*-2TK];FPK57/O,BO!
M%6CN'MMGUT$R85D>UG+<P!6+O:N;#'^8H X]A<T4YD6P\^^'AP,P*/'_=UW7
MJ\WMHOC!,L=N$'"9<$S][<TT6\?/OK"TM2F%=LM<2PU^8MX>S?G2G$S<+(&>
M8R_"I<6W!H?R.LZJ@OH'J93GMJO+5AO9ND.^6"]O(%>-7X*&SE."#,1Z$07<
M5(2@GTA)&;Q3^^M(WX%A@5H)_?C&K*'KBK=^/*?3BBX:>3EL&&A'AQV&$4K?
MO%#O]#_<X>&CQ9U!"Q_C-\BPX7HQ855FOA-#G[@^7D O!_X"V;LP_C*'_X_,
M&R@TN,-$Y@#<'OGUF_V??S:.C7A1!_-O 2'< NU^R?<TF,YO>62=7Z.KU?S2
MF71QC\C4?;5_\$HL7O[G/3@WK^6!K]LM[,91M*KC7D8KK<2KPWX=NM9A97M@
MK1E_^;R?\3\UXZX5:&?^&:F>[UG]/+XI_[>#M:7[!]8GM;8*S;D^]HTZ-XY\
M@K"F",SI7I5L1ZX_I<J8X>\Q\/)7L$TQU'\U!:,5#7YKG!\,7HEMWJN3.U4G
MA[TZ62U[TYQ8;H,6987 $L-@6L$-P64I8\VR&'R>8G[J/+BB3%8C7];KENT(
MN>OBWZ9;#GO=<C^ZY46O6^Y#M_3*Y:Z5RS17UG39^?<7)G#8*Y [52 O>P5R
M+PJDUR!W+.9DDC13$*]Z17(_BN15KT@V5227M\!FD<6!,+NGQ[W^N#,+1*4M
MZN/@>9?^>$;))XVWVS:*<<.L6 ^5V@;69!V<_V6V").^'OC.ZX%76(1%<(GL
M-9CXULAVQOTLY3JUR*\7'G3<+?21VR-$'QMH8%<+ S:8J1#)0PF*$VIH\]YP
ML:?QV<14S>/!CS7@91@6,8*&'#@25B2"*.'-<BU6VX ?A8TVLS )]&9#E60W
M./+C-$4RZ0NX[ O6\NI*3E-G!)I\:3O$!NYG>:7T3IE-N \)X8.H(,"\LNX+
M3+B*'B2^)9#X00\2?PH@\68;<\N-A$IL9\B\5ROA^[1F<W&2&N;7VFT<-ZJG
M)+0ZFU';H48=ER#J2NKJ-H]SCUK!TZL&K]11W>45L;"N #4+:P$+>#>5)-\5
M,NG-S_L_'W9BDZ9M,B"';=T0Z/;7?ESGH773+>>E:SE0J73=*=P-@[_07CF!
M"](HS(-_@#@[;O2T7[D[6+FUBE)<R])?F76"2/W\^SOG,]9#\SFPVCZ9-/=)
M$ ZS:Q7\.Z.WAU495'.N;HV<<E;^>KVP5+]8W9N%IO,_-@NE]A-[![L +K2X
M?I;V0;\3^IWP_4SL'>Z$7MKO5-I_W!#X4X^^ULGCUHN^4DCS8Y64L6D.Y =D
M3^\HS-K]8+RR^]NN8.Q6H[#P(?*(Z6IAK,]'E, .;ZU=U%^-\.N2F=QR1+9/
M7=Q9@X/EK4ZRV5#W*/4WR?FXP=1#A$-AG#(?%&X#^V/O^,-ZD0;%VR XA?>Z
M=DG?8-,\PSI'3\+L]<R>U'P0=EB0&EIZ9OU1Q/]3>YCT@&Q]5*S)0[&/ 4<=
MW=OS+FOK:BD]3YI=+>N5R88HC[8RZQ9BT*,JSD2/7S>=;581<XUG&!1J'B*C
MH&T[Q5T&ZN13AGL*?@D;NG#:+$C_RN'"YS*D(8H*S+4J=<.DIAQ7YT<<I=3*
ML^.)SLZW7;="5LB-HJ[&7)Y2Q[Z>I9]#<B/.\*YQ&_E/E*E"=PY@XKM.2:/%
M7ZP\0C_>W?YTLU>ZGMJKO*VIO&@C>T'A.A$3,8KZ11;\+423^"0)XYG+V' ^
M-IE9U(C&[/\_%8BE\EC4&BF%D&@=XU&5A'D+Z9SSI6&12[V!,.*FR9?)?7I!
M X%#47 -MNV@N 9#5H/$CGJ6U$RCU?1"+<GK)[=M@J4Q?V;3Y;@B;HOLNI'2
MLTEN#V7R<HTMHXOZF4K2HS-ILN\X*3?0JBZ;C6_@VD;KEE]0=T!DGL$!6]L2
M8D4;>4 L?GJWT1='[OUMO$F^0\7>_IUA3(2Q-$093.I1'@]9^Y/4^B-S' -\
M(S&#FP0)U/9T."/VOI:[V'?OR>BVA3,X['$&3PEG\$/IY%<;Z.2/JIQFD<=6
MSN$#T625:B>(<?2NK\Q X_V^_V7?H%!!N0W#]"M8ONC>$<4?DA2E ;*E%1SI
M)PL92= X%A'ZP0>!$!-C3,;_S34+*5%&A]&UX>\'"TM3K>'8L3R[/_:W)V*O
MUQ"QJ_";\@[[*^LPLAO)S=XRL-/0,B3?"#WG,&6?&4]?Y*#-+>>LLIRSX%[%
M,VKP/83Y"JTI3LW,I4\'$MO.; _PH,0Q48@KYF[EM4[L>.,A#V6*@:8,XV-H
MZ<+%W(\0;EX_[P=MK%/FD68O>6=]L[VO$X=KW7*N"3)<</]L56I2>K"'P/:M
M\C"!%5%SB4B4X5=]@3.)$HTLB*;:[1Z/+T>O#@M(5E+X#2F6M&$- U4)S#EO
M4,&C*J?%/37P:V]P;\<N2X+W+F%0,(]DRW%3%^;%3X2GF5])\;*.T)^A4?&O
MX+)8C8UL>:.AMZ%YCIW5IH;QTN\^,B\J,I&EGO)8NCZN)?J.XDER7V[=0?<C
M:6$VKM5N25TP"41K2"$+XW3Q/67*86)@NH,).F\IW3IT&?Q#TI&@&F'GIRHW
ML2F\/0QJCBW>V:STK&?T\,8Q>GRT-B/,-(VQ@8"S?<+K,$YX(Z+U+4J7;5-'
M;HJ*[B0OK5CJEH@[J@'R5KWY0ML?7WL5WFN/"2Y7*(IA8W2XH?7$RE12CX9Y
MCE$R9SZ1"US/*&X2%^R[TFIJOP5&$L8I;4%A^;S!1H^FYX?N2#FNL 4,Z+ "
M77 '9.AXT>ZQYEC^35Y([1K5HFMF^V.C[X*G)\;!1TS3'B*)Y"VKE*L13A+E
M">R.;VC105V+H*ZY#A,8.=B2RFPYL*QA2V/XPM7AL.$QXH7M.' /^?K3DOEQ
M(D.:4N!<#56JQK'AWIO#?83*;EQ16$,41SC!P%I)HI.0(I+&)Q17G6%C'>IS
MJ@.1>@!ZJGV[QVPI/>VT$A87;K(IN*F0W5AX&?$Y0\^2215V8P^Y#08OB\E'
MP5@P%.GJ+)D [R/4X49=TZ$JD=_4E21PVY Y73:ZUL<T.;VMM#U;Z<T:MA+H
M-O@[#<Z^C:@ENA] 9,9\:F<PPI,_Q:A=[)K>YHR+$;P,:G]D>_D0;6>88)S0
M</*+%M2Q>+.K!J:%;N,1M/VJ0D=/E(R4Q*R0D(3E=.6HRV]X/>8/3L.%L%)R
MKQK?0G=[]HRHY)B[\R2DP,63D.2D/$;R#[_$WJ3RLL2@P.,1S.K?<>A?0+(5
M6 -9E:<@\CMGV!CD),/_/>-N%[N_/(OOL_KIR4O^VS4D_P.N?QO3\3&:\?;4
M;+.<VSU38KT5PE/D'16BW-IQRC3)\)Y9Y(2>I6L[H?7!*<TK/"-!5X(*U^&Y
M.>G3M)JQ@C6\W1)M#F%+S+,8C3*">%*YTE2E>\ZS_8XUL"]FO(U0PO]99:7M
M=+4]^:;,?SS&F&*:!4D&6Q?,^6]@"7"W$SZ(X1C2E@\%9X(";CM28)YJ#:)!
M#%Y8%;M$P;W!@$ 5@@.?PAKCI-%K+7<.^IVWO9WW\QH[[S=\(UB3$SE8:F=.
MTS>F7)+3JHL-)@?V,:(S*AJXYP?\B",]L"4R$Q5"?:]C0>8*ZS+IAXB5[N\7
M<NFP'REZY0/<N$,*0+.S#DN&OKK.OA.@P*87)$%%BF0$WU!GR$$@/-GM+7)<
M?XQU0E3/>]%YM9:6\OFM_:X WIWA;U@G["*GSW]X1*0HC,K>'G]-0;;6^-E
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MX2$QBW!4-.^U$Z_^+<KK.]II^*_&URQ'5 ]B:_G9BT" (X+KJE^=N*U.T36
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MP_"N&*U,.0F1W332%(SAPG;K<#EGBOG?CH\0:?X#-&FK8O>HE]R[0N&XDHL
M") WPMEA.-) ;"*OT;>*_JS@;',]?^BDT8OG?=+H*26-?B1-5(=AN9J(PPPJ
M$E,9HSB5CL/Z(%FAK$,*_0D(E^E$ M/PSRHNN6Y5X'D-#G*X[R/18C^X+-0[
M,2Q?&0F]/YQU%=BV[133%XARIYV$^0(8+;G4C#JET#]=Q-890MML3T(3K3-\
MD .!_=/OK"_:B^"=]5=P^"666SM&&EE 'L[@[Y*^U.832<&F$F^7X)!#U2/5
M@DPL@1%Y!DC&''#080F/%/"$..RY4W=SD@:2<8MS4NF&XD]&,%/E-",Z ]3)
M\1BQTPGFOS3@T^0;+:2S%_D[:VM 9!W,4I@9WL;"]"?$1;L)\XAA8H;\WUZ@
M!:Q+O@8:Y&N?,DK"F*)F&@/C]<E!I# 'XK+\-OU83K&N0U$OFC3+EUY-3Y=Q
MI N.?J+?2G4M1%FEVRTTBGD*2=B0$R2<C@ZR.HF_*JX[!HO2%+KB[,1EY9:*
M.CT>G/>ML48BY-OMZ="VQP3ZT]1/3B-[1@VHB:G9J?'MD!%E-GQCKV_R2'K,
M358E42WN:3#>!7O_;2PL1P:(W1QV9].8&%'J7"J"1^- -TL:N'V2N+1$MPJ-
M>F5R9\SU:,+9F*9M 2KX6JL5Y*L (2G9@F)$&7PYHL 15D' W7+0#XA.$^):
M[):"<4\NBN#CBB-,7/^%FU*Z>\B/"<KO9 -P,]$O7+7B1*\T4(:W.F)*P(/0
MG'JHK$8U/E;:IK:T?8,M<V1*#Y9H.7K7-&NI6C*Y!'I0#?=B7E=\(R$-=+LV
M.N_=).0RO5?T=!OG:/V!V JJPD<KUE^[._%>!#<*.:EJ-ZB1&TF^2N"13JQ2
M-Q1ORN+_W]ZW]K:-9&G_%6* !62 2=NY=)(.=@!9EA/M:\M>R9Z>QF(_4!)E
MLT.1&I*RH_WU;YU;74CJUJ/(3L(/T^-((EE5/'7J7)^GB31^.Z#\!.H7;%KV
M&N0H;1GRNU,Z +!K<RKF*K&8EKJ>2MD\77 %^CY'13$)1T&&/:)*;!XBX&7V
M^6NK*"/01@?^7LKH^!)"D[9XD'(NBW]]_*O8W[?*?% C'A9H5)^GRL0]RQ8$
MN]U)<V7U1F.O#34IKTZ\VY?#EQU*]R@E^/KUV\ G1<!^!?1\JP6Q^J=-XRL2
M2T*U<$1]54HVE#A$7!V*DC^.X$B4G6[=Y3X,XN(>8<24 :*.XAGN5^L78)<L
M,EU'")6W]D?ZJE:0<R$,5*A"_C:<2I'8FU<RP9/7KXZ#%^]&RNH\\JDF"/8C
MO +S7I O&\%+'>6*_=X;)\<%:3@J:>52ZZC?-7?+9Q%4)L'AA+SQ9<VM,]/P
M<VN1U"N=L>6;/8 A6"<Z>A0L0?6<NJ;XF306:2.K6D\CET73LE'-6P+P_Z)<
MMH \BK%M,6>=2T&E*0EP4MVE,B1=[TW3(B-5(-OS!>3 T5:7QA(-*N\8[(ZU
MZMR61BO&O&6M-QIW;QHWJFA<;[K@"@+E3T/V(V*Y)3%*B)79U0S0AZ0K.]RR
M77S7T0/L.;"'4 *H, &4>)"A&:%='3BE,V[Y!V!AZN=$78HO?X4Y;RPB\A>W
M#U^ RL>,">H>5.5F6DW*:4\IIY,FY?0CI9Q6"S/K#M;I:C_?1W/;KR?62CBW
MV)_G$]"FH\#FG&C"R/UH'"ESP/NDMR5!&?5%E?18?5"JYS,>O[[5I@3&SE+'
MD4R/N802K'YR## 5]CD'#\UH,"5?L&9@GEW* 8.G7@WT8C[\^N+MR3NO]?JM
M:[Z9_QY_?'5\_.+5\9LC;=)*,U<=X(0IUS/&+_0S% 870%.)HR_6')K[.C3_
M+!V:ZA2E%PB+KH3!KN5>1;,5%$4PUL!V;E7B@?K.."/@G6)^"KI O");A.#J
M9)FDF71%D)21KYW4BGP"N2>E\C1.PNK8J,W43$B%8.9/ U 88/Y9[0$((4B#
MV$AH1J%=>)H\F8M!=WND>DU;/U '/E@J2%F84++MT:Y;3L0AK$\!-IP]>]O-
M7TJ[>6BT_Q/1?.![/CSESLDQ-/Q 7K"$ZF\(AW1A,E7A!6Z#+A (Z29_/I(H
M/1"MRHCN&/X/$+&I=(!+):O;EVA7;:"#O>[A347S_BJ:=T'5/.L-.Q?MWF5W
M ,PBID/%Z8?X9Z=[?>.UAU[WG]#5,KSXPQMV;[SSJ\'-9^]S=]#M]7VOV^Y\
M]J[;@YL_K)_)[:$!Y@]L@FE?7%B/@8?"-_^OUS_SY3KO:N#U+J\O>EWU6:_?
MN;@]Z_4_>3>?NZ4KS[K#WB?U:#7ZSF?U<?NT=]&[^</WSFX'^F_SY477^^_;
M-GUZWKOIPZ/4'+PV#KO7N;UH#[SKV\'UU;#K>_VK_HM>_WR@'MV][/9OX($P
MA%[_IGMQT>W<J%MYUX.KZRY,>=#[]/EF2+_I#<[HCMVA#W-I#WI#F,#YX.I2
M/:QS=3L8=FG\:C3]3[YW.VQ_ZL)/;P;MLZZZ:[NCQH-]0L^MM6F'WJQGVYQU
MTQU<?O3@O[U^PYRS=PWT?J=^+#C?RHCE&)2NI@<$.',V(["-I+9N2T,K87$Z
M_BP0Q^S%:/E"?#1-H,MN+WQG_]L;!7F4RU/*W;"A6K.E\G271+NCN5R<.TC'
M-3^R#+6Q2)"R(PR4I1 ::U= 8_E0MUW:40@X D\)CM'K>6"BM& %(##VZOCC
M5J\7?WOR\4A>\RUT:5F+VM($J,;F/Y*E+A$B50R00U45"F35*P>Z/E]D#PAC
M H HU*65D6R\F*IQ^^A ++UY$$U>+.8^Q''G(6:W,9FI7+V'E+*M9;,)X<M-
M,K8L6Z6O6<H:4VI_BFR7YK ;RUD=441M$QVP+MW16[_2WTAI(4B69V$AL!NU
M^DQ]M84ZD\9]3 YR%12U3.;15_6 UJ_'1]XD6.H2CU7HR.R1--*V/VG;Q7"_
M5,("@+7>*89-''O=AJ*!!M*MI4N I&9R\U6$%8+?[< *1@QA4+XZ"Z%\! *G
MD(>>>(EZ(R!I'UC2"(]%^;'PX6OYL*P+H:<:"_\,\8;FIYH'2RY>>92J.RF2
M<W%"1W2/K>:'FX=*V.(<\8)UF#MP+EP9/SI2"PK /S FWCB:>P,R\W23$K%<
MV"2]]I3T>M4DO7Z.I%=Y'U%A^E(7HDMD>5=(-PUB1?QZ6(H"!PN &MCH75Q:
M)PB 8T9B"LIZ!B+A3DQ;. O19@RU'Z/.\RBFH<OCX.2&"AB$@%/F*,3K[8JF
M@YJ_)\<OWU'*(E'J^"'-1 _6*35)^Y4_!SU.C :P7+4'!QP!0'!8/B\*S4_4
M6!_[LSYV05KN)2B#R7BY C@%X]2[V;FEC78:)%^RQ;P8+[WN@\"0E9TC&W:,
M![&-4UJ^-SNG'DQF%@9)3C>']OLLY%)%+E^A BD^U8DZ;$6WP$@_Q)<<6P;I
M>,0-X=6#;Q@=QJ5 T)EGN[&"8/>D<T-,'%/S;S_1?D;EIG'P"&QG0G:FWLB4
MD&!8"=DH\9@&#S7US/@^F#.S5[5LTEK73CH)B0MLIHL#S4BM@3" <: +"*JW
ME61\08*#V#/>UA&(TJ#L8(3O/6)#20G&/TH>TE@I80#;M]=?BA7U!US975#1
MJMKULRC/F:,LRM5297?<#ZN>0$8B*C"-N;;D-D.V+-79 R8J"Q2_/V9BY2)H
MI$Z&JG -PX;*-4S":80[9ZQ,[$@ Z3%", 'L0JRXM<)*+*3V5"?AJ,@)C#5$
M&QG!^PETIU;"7=E5;QN03>YT\2GGG\)@ OI4V%O@*9[2CHF-&@EKB$-YD!.U
M(DJM"6=S@_D\C1)]OT!O+O)MXYC)"RS*!^YK"$JX:FHAPX)JZUHA>08&/(GJ
M*+U"^1B:<V^4,I,OX=/A(IM)8*H8X1&#.ITA197<-M4<7?L[NG:!;[7#-.K=
M@#J@G;GVJHIO9Y][/?OPVE!/8 5Y2]ZW7Q_N)N]Y91V";\C3T5>ELN2<=U2]
MI[N23X J)VIPGG7Q!9([4OQ5*W1S0V[UF40:'FG-:JP+C*5STBB\1(!SB!I5
MK1-^3LS95&]MH9@%B4,)H[M:R':@<=A6LV70_@J*=U-U#9NR@MZ-1LZJ<<"Q
MAU=5ZXL &PU?WH(/-+N2VYR\I&1,(QT\S 0Z*$N B[>Q(L:J"S)>!@+VP*?N
MAEAW&\VQ#K%L'A]U3K)T  $:89>!+AZK(SXB.DZN6I"@]=T=^$_H1DD](LZ$
M8B48HDGA\)%H)5"V)3)[WWF@+HW MF\X W4+ M4RH%#A>D7K9_?(!5%FBS8Z
M>G\Z>A<H6TKI@33>E(5S%9U+KQ+"TZ\Q+Z'5JL/^J^PQ*P/U!!3([RF/1'8H
M6DL5N!-NFEF M6R'\WW["RL%4'.HA(GKM? V1K;E!E_NF^'+M>/89"HUZ56Y
MC]IJD9,RJCK>KEKOU[(E;-%HY013;GW- M)2I]81OW[]K<T'I&'8IYQ-\LO]
M&NK&OX"8J4^'-@N-A>)I-7HX)=MPB$FNU#IT'$HR(KB,DD5(?W/M*V2@(@3I
M?*2^L30A8[K,WB<[W=TJ-6REM3CS:@_BS93]D(PC]>A#6ND_^OXHH]CU4P^:
M^!BOI<X[KC%6"$/;%IX*VQ9#CX/]@51\9,?2IZ9ET,E<.9CDZA8KNYAUK;3.
MX]@0P&@\8X7*',Q#B524FA77[%HVCU9LW&U977SO7ID[RB&F&#;N.VN58">H
MU0BX W/-7&NX!W6=B^M)RW:T]SOR":]F(F0[<9*Z-E>%0@V&BP1JT(K<.CG2
M=?#VP)N<V9YR9J^;G-G/D3/;7JNQ15DBJ8K9K,[ QIT8^@$LOZ.:M_G2#6'D
M3UK73[1.%1^B.>"_&3@DEOB5 4*DD$B8T=GH-1T.NBR39(?M@B@?+_*<_L5A
M ; W(T(B6\Q-2 !-",O7 5DL/=2O#U=QZP(>2S@"MADA>L'&*75=6.@S/"!Z
MM/1>F'@,WJ:GE&X<AP1H<XUXO53L\=?9<M?8$;E8$>=1&$]6FA1DH$##1TBX
M6GI[<MR:!T<!ETL'W4VMOCU(!G@Q6 ;L"%@1*O88+#^BUB2@6C/I%[$#4ZUM
M,CV#4'K_9"W<9(^%08.H$9K#D^K9*:LE$5/("ZQP,M#.,\Z#!>Q!0-EL^X1Q
M^,!0V8%F S-K4N?156? [?2V_04_7/%V2N)3RBFR].AH"JYR]9$^?1'8\4IR
MT<)59'0EFE7&8<1-UG()IW$'22Z+$\-H(ZOEQU2K!%D-O=?4F]\'2LF,E7E[
M%\687+%@@RC+J%_'D40@Z?'L[$*E&(9FA=67%@%>A$5&!OMBQ#@(C%^R\VJ;
M^9>7N_X%-S'&_<48W^T08QQB)((8S$PDPR&"P0.L$AXO)4Q(&9>/-5:B5HA$
MX%_0VX&8G)(MDY3!+(?^L4TR@GNQ[BN*JDM I:(Q5R1WW$;"\"Y%T$0^P-9E
M<@*.]^M3#O47/M:>)?/_T3[+"QVZ6I-U0C B2A)SY F/(V5 XN;G6_N:$Q[X
M".!H@X,_MTY(FZ!&:.F4@D'@(+. N@/AW,Y0R+)8>2@'L:T:F"V]79GW'<*D
M<%"#XK'@/T@+,P[*94S=)OS7*(G]*8GW.RB)]GB< 4KT .,8'SU1&N6&);L[
M*%N_#<O)"$,#+XR,#I4HNF34V!M0O '/<R.8('A:#15JB?3)OG)0/F&'QE":
M 8!1-,=ZKCZ1ZZ"@LU%H;+7Y[=IL:YZ98!!7^K+T;V!NZQ=LKM0.&A_5A<%D
M+J8,P<TT+<H =X;XC4RAA!NZ;F,1TD>!%5&T6Q&"'G.6[H9?52I>6P2@?K7C
M+/U2CJ:LRVHJ QS5OUH":ZBO"D1WYLE).+ZL](7,[/"^.C,PGP$D'8T%8I]/
MT>#5DBSQ)^)L0J%CA7WDM1;;-[&5 48<F)JG2#IZ+<BM'AU^95_1TRV;2ZUD
MW?%JBATR@RUIT".M4U3K(, -9/NZ17AX1Z2L2K;+DY5.OZ?*Z<.O^FM:]7[J
M]9BF@T5;G6J#$/ 1M6*BP^[ 0\R]-R]/J+5T$$:SD7I!H93X78L@2)#GZ&#O
M[8TL''7[1BN%-5T40OTG@EO-?A+J,9^W6FA!\=<6X]@<O(>6&#5Q9/B N?/Z
M _"KTEB5%8#I2S.T>57?W7S?NI.]1)Z#0TK:!QK *5C1:KTZ5'RN-%A+?*+)
MPK2@;R-T=1;/X1?VY)BW$*8*E+[I)61XX!E:F9LY&0LJ3C_TB-_* 7F%3'CW
MT?S0(W@G6N<,>),"9=1C:/)WHH[D7/!3I5!:UUE:2$/ :K+Q9_EJWQ/ DM?:
MLL+L\.-[)]:1CDXUN>T]Y;;?-+GMGR.W;;L6!]_ [VD#KXH</8GF[OV3!M53
M%\\2Y&QB&^M@0'?.>'@XE^IT"^,X2,)TD1]]QV!7L+[/$^JJUS_K7O9[Y[U.
M W2U]UCRAYV KDY78,(P3;CINIF$TQ :*2+>K518>)]B+T,V0\PHAY##+<^E
MPENA<"N1=7@M:D0/DJUZ)R4WP8JC")WV20E.3TQ/:F*J(.,TSP&Y?A+,U$FF
M_I (-N+9*T_/5$:/T[S([3I@*[-,?%O\<[JY.EBS)#00-5-8N)925C&%,^.E
MO]7L+G"$;HV 6G]*'Q-A7GGZ7!."#?M2,($]4=S(PHX9TRZHJ[ E1C@93"#+
ML"\P5XB-X[E5L8-]00<>Y[P9=K/5=L%X,<)OXFQEH/#J3/NR,GV44"7AG=IJ
MD(7'CN4O(&D)2!M'[J>+V)LIG<W4K#Q7KG'1*[0-T\M'['-ULN\FOF[5CV>6
M]"+5W*-V@8C?Y2%,,#!;Y^E^Q-Y5YR%[*9MPJVT@YNN[[4ZFO40(.;@PAE?.
M+?NOK81AS^D*^^ <?P2:52?4K+H5"(W)R ;"R8,M6!QU@UE"U[)D&E:4ZZA/
M['+_,N<=RE$* SO2[03.+UQYU,1PMF!2)S0;*+CU*XMT4%/N T6JF]3K_H[+
M7>#43O7+MT],#5Z^\=#T:T[-NHX6?]]G9DD?;G]@\CYP3J"R<MWN^*F<#8<\
M#VH.S>V.! ;H*E>,?HN#H5Y[C?:MO:QZC@.KKI-&=>U7=>V"S5=RL]'G6O=[
M,";&X439(7FYL(3V,)J3Q,=">VIIR_73Q1.VA6#1"Q*R5G*4(A:%0(=W#<ID
MH=< 5>?CO?J/680("-.PRCM=0"'IS@-::CPJ9T2ZIY]:T2#@E7#-*CRAJE[!
M_".EO69PVPRL8LG;PE =M6G L@J"MO,@GRH%3M-A#06Z^BD>_DK3KYO"888I
MP%Y!31SKJ'WS!K0@ZQ<P"95*@U.#NO $\E%T@+/<>!9FX4.4+J 0)"'D.#J(
M<P>U0_WJ3^5)F+U0%8&=NP)]: ND0PQ+CAA/$_W0Z@2QZT%7&0E;BT/T&(9%
MI=GWT.K)G'R4.=.($UD81R&CBE073\R)R-78]G:J+<?D3=GFB3-:R8IG@,T6
MY/EB1J/ S<FA#.;E5>YB#FN,%>AIC.5\>./'1"(?OAA VRN<$>)FP ?U>K7Z
MKE<A56&#V+PP,'_"V0/_ZE"L8U=P1;0UH\(AUA1M53^ZJO%L&<VU5\#*YXOI
M%*G%HAQ5^*)P!OY1(V[1PA(*%1)RQH!"DH1+B6#ALR=I2#7<R@W^ CLF2OY<
M)!H>C2,&4$/(O2%*_*9ZQ+7#9*)FQMFJ$2 VL'-'?.Q)>),(#75U9-6=%_8+
M)L0:>!>KGL:U'3H !W!C.>*'Z3+3-0>1%E<E1V-@JZ2ED;+#)IFYIV3FVR:9
M^7,D,WF_K]_7H.@J[,H34%\ !<A0LJPX<"M"$V!.3+)RT(SOTQ15)!\^"+K%
MVWEW(\,#';]2P]2"@_(9*57($%)8J?#J)J$FH(ZE]0:S,0SRL"CBT#I2X99P
M.I!U9H/>0R\+ER+6*G"?:GX19V*16+@)<,O[,)YHJ@]L;,$',^JI?=C@@Z6*
M:TIGSQ;JO#09?-=_<49FG1Q8I=J%U ?A+J\MR U<73!*'Y"8\&C-Z4V>C)R?
MOCPE#XTE'1+T$5E'REJ^DP"Z \BVM->]KO52CG\&B%<G5[9V7.',1LBP8>=:
MTL)8O30) ?]>+1K, <)N,!+*"XTT(H?,#^R=E4:E>[QB.17<ZTB3'ZY:U0R+
M?=&:60HY7'V3Q)/%%8#VE9:C;)=K@((:B6V"77L+=NT"!7T1S:S<V(5T*=40
MR '7VD6/B=GP7Z<#9(V[.C^$K&U;S$%ECLZJK[G4YS7RS@?MVS/@</N]=W%Q
M?GOA7?:&G:O^V6WG!CZ%Z9:*,3RFQKM5'P^ -V[XG):!]B(0\'G]*Z_[#Z#
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M=%0KLWY'ND!PMG$7$RY_9 9!D5Q\!FD"M6WO*8%7[>5%E.(1*:Y"6K''B"/
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M6 OAV%:?E&/&^!J]/@):6&2%*$YX<R%F8_Y<9%&NE)]!5G#?$SJP5*^/58=
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M1RA^- G#)HK3*,W'6 3*08OO1I :#?;,Y:L)2S3"U80E&OGZ+N6K"4LTHG6
ML$2EN[41LT;,OGE8XA=,GDO1Y#-9RZ8X:C_T2\<[\2\583;/0B(&<K@?"6KN
M$4HF=:\"E-5P%0U6-?UK$4&?K,9J\J&$AZZ'2RS^D#ML\A$$MW+)$.!$)=B"
ME>>FIBZW\*.@-@I:6>@^%EK<PE#5 K0R8@'7W-Y&B)O'"Z@=1;K7!Z@^4=LV
M#XY\@W8(OWI,LTDN<!9\.6-4^*6/<_X<!^5\I48DW]4,:B3X*%8+\7T6J!GQ
M3:3,,-9<G7H$K7%IK.::.*X\TZ&HTCUJ.4#ES<(@D;(V9CCAMC_[KG@G\_ )
M/QQ;",(I-JA053ZRK5A%D5B!9B-P:9AT ?GR)NF8/BE+AP/!2\ 3W!! '9I;
MWE9=7,4LT^#N#K*[ SRFV[M;=J<=-M(0+C@UZG'3:2! _;E]SYS C">:"A=:
M7A'!40DSS1<$#Z$OEM;*\5+P [GWE;B1(UU057ZQ(N0$58S7:$ ,?>TJ-$3&
M0%2#F1YYE0U XRG+/_78U4B_[D'45R!##MX12K^@P#% C/,4,,CKIX.KH=OM
M3$TF\ L#E21R)6@$4_UV:D'(::1J<G='6(EH*1FSU%S"AHNE"10VC*WVFAKH
M.>HTM#5;95;T\ASV!B%M:-T?5;8DE<[)XL,VSNL@><I=I#:  1;43XXLM'09
M!=TH]P6Q%30N4&4_!#&#B%*AHD;T=7I[F=0AQI+2NKI:H@^W\!*P(8D/%.Y.
M:MID]M0F\Z%ID_DYVF08><!NV6>,&N)X+$(;@)K5")ZBOJ@1_I!WO7R:FE^C
M$@BM+[!Q(OHB=>#.'BX?TQKX.]/:!+OF6"<)0(LFA[#PF4736'>+PX+P[FA,
M$Z"/6S".M#G%6RY*9_@"ZXSI28@FK51GG@=J2>_@)/[SJ*2F$8Y9!A@#;4"V
M( H-JA^GGE>8$34TJM.,*Z&-)1+Q*53(,;3!0@4PDQ>$MU=8AH6&2=#(0PCU
M(&:/@<Q>,4SS?,3V_D)G"K15RNM-LXKI&(F+0'TS!/4B;8TYDCF/L5<&.0%<
MXN7J[5\:09.V_/LPH Y[Z&*.B;S+D"I4B5?G4&"O6Y71)Q$'@,]BQ$67?Q#4
M,]3H9L'\/M>D1$A]J38=##9/8^BSGA*GRD.8$"H*=8^1@V%,,YJI/C&9 T(3
ML; %4D\+@Z8W_$2X!,F4B1PWS!-JEVQ!+6G2MS(;17<+(JQ&W+&$07KQD\I"
M$6=*LO1=%'W[?09W 6P"I_M<7999?:^(0Q'ISA$&9#!BBS-"RC7RQP(>Y))H
M)V2$2V+$B?)B1=<6M*0@0)4:FEH_(VR"UR&H'L;U*W_#\Q1RT.K"6OB6H/]I
MY_+2(+$X*Z^)]+83:(C=)%0B"H>+63/Y'D+99&D"-*)I%E!'#VF DGTT"HO'
ML(2AI;9ID+%8K^0*J9NVZ1[A+A=$ <"M3HS!B TDY.KC)8L7MJHY(R$^2NZ4
MH^6I8UP1+L^0C%1_EVL1O0(ZCZ#KI8GZ[#'JLPOK=C_U-C99(DC5QE^](*U
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M.O]WFIBAC*3W89+$0%T5Q<^96/D'O15X8Y2VIFG^^BO'QZ&_<5T<51?&7$Y
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MHV\F72>-O B]7*J+U\["=ZV&6QI95SD%N]EP![H6E@+Q91+BMTEM_@J&ULC
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M3?',;PIP^VD#<&,UX1U9/"3='K^FA.[OI'0F#TP@/(.Y:<P77.IGV5,*=ZW
MZOM@N%28!>Y\\DXU)=-MHKUIHSZF'-1@Z;V.81N'%7-0'Y:TP-(/X:V$"EJV
ML@Z9MI014QS_BP6"GO@CL06V6%?IP^!:16FXED-B5V683W7;<00/(_>NP5^%
MN"M17IC76PA=AJ;)E/!#.)A7P8]HL@V/DZ)?"AP+Z(?0VVJ "(%M>-4,&,0M
M>3_ .$Z+.C'1/"D>YGMH=9S1>%]VAH>D=>IL2,DQJ+7E#I .6W6W A&.+U[B
M0EF&66)FS/YQZ$U+Q+5>\<C8*>1:4X^M^R.H."+1T%ZU6&U:/(Q-N4&*AU+F
MQ>8B-1YN4\V8X7/'E'Q!-=LZUB6&[3 _C#<X\4L]_ OWGA#DIT$4RL4P:SB=
M#;*<(F-SZG_(_W!H!K@HD@7E;O]+^+&";"T#L( ',>SML0C:*J4+V&?E=!I+
MM;S8KY47@^P& ]3\H_)8Q.)N\K*DYY")JOM&X;F+5+%XWQ_*PS*XX1Q+8B%)
M01O[=\61W!5H[C"X?UC(.^ZV5=JA I\>/85CDC6R7U?(-%1YXI +7N-TNZ#
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M-.MW43D@489/+,SW3;]HB'47W&XG,]VL&]5.@T4QO?#%D/L87HSL2ZB>)'E
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M6QDA],S8FF'RQ?U[9UY9YV,,5_XEWA8QQYA6'>W:#S%F,@9V+3 ZKW?!O=+
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MIID4%%,@7O%(R/)RLD:JANL\\6Y;\XRFZ^3YF#U<>7\T!MU/T%YA0)#T;+9
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MNK!JHEB8Y//P./X_HR#*&G'BMT4R'V7G+8<P)4>S=MS(>9X*G!H53#))!)?
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MVP]Q@\C>I'9M*%^^&<HT=(]N8*;7.Z!(Z4&7XI";,YQ4WW7C*55[6"L&BZ"
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M2<//N-U!T@V?%X:*8[I,&:Y$"L_\^Q?UX;GT8<$EUJIT)SKFD@V$Y.5@+\&
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MK?O^K-/WIFR2/"J(/W9)K2(7!,<?2?C^,JFC;Y.F(*@9#-2O]7P_[\RW3%T
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M KJ73J?IV(:FR#.'@T: %'0$-B#&;1([$09R30^#V%'[T177&CHRWXBA$,5
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MJJ!4UVD%2X1:RVB4QDK_X%!?D.;TU:<:M!O\_0P$[FU4*B1%][JK$F8!WTQ
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MR]6+-BYMM89O%[BMZQL@#5HGKI4(K19A5AJ3NX RK_N7PH],@*@EL2TN27%
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ML&FM775<41 R;F@E$#/<V3M6O9;W0&. LXI5<W/FO2W;Y#7K;&)J(,V=#6;
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M1@C[8BW$?F.&3D8:)[?@)*4%< . G,RW9<Y<RBN!^YHTJ[D ,OMEXJ@>-V,
MJRUY2Y8N*GBFI#>.0# U><-J#&/ B-5[;7B%Y=YMTU%#& JYQRQ/<M]*0H@
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M/Y): =OUM*_]"5^[4""_0O&[XTX/P9V^5O:$9*D9E+ A#-1KJ#&ON8T&>FH
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M\BRR5'1,Q\1I]*)PRL,K6"-,X9!)KCW!8  L/V/4IFP>.IYT'T00J/-),EU
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M?J?'%QGS$X5:5&6>RH!,&KU1M 77+RA.Q#A%CG8+F@)A# T)5+"AWL ZWO"
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ML0V&$4\<B2*Y1_%DH@L<TZ3(9BM?V/NR'OYDV<4UL)MT@)<%":HHU52!X#^
M+PH0_J27P!??'L!KYZ6OJ[#T3F7)O8?CZ'E51=1GK')X0^Q<CH:ZH.QYN/<R
M]\Q<?PXUG%=\ 2IGMW&)VY_= "^-8,2%AC, KRGT?VK@TL2[$W4;O,!32 _
M:^@0\,5J4B&CAN?96WC'\(S#,.A?$0 ?-#Q*P>W_U*DN0!*=.L4G^ AO,>)
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MH,59(*X0EZ,A?D @TA TH*(C5).&24VZ%-%#H:_KI.&:A[&D_%1A&^:9H=N
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M/E)Y!W_V8=0-@Y[4!?%$9IZ;0V?K<[^=@VW!8FC,'#?9CT:9AD,6G&8IM8(
MBA^!+I%/@82WG5%^TLANENC6Y(<4KS9">:"ZYJDTU$;++AJY3)M5^2CFN_OM
MN*>A/FC0WD.WR)599,_WW0"!#] *S0E-QG^$*T\P^9UNA'Y!G8PR5-@,2PE"
M$[U'E&_2M1LG8H''6#16#T.^VAGE9M?*I'<0>.WNFHZU.*S=YMD<L=B2KIY6
M7.S+ 2074[BLOC.PILX*_(%*$ <6@^I-I<O".-XS2RLX"2U\R=@#K.B9WD)9
MF#&H9L(RA0?:#&'ZC#5*=XS/.\7!NUS^+)?:JTVT(S;J&!W+XF'!ZM85)YFW
M*I2ZIRN9 1.VRNU.(5=3.9<NSTRHTSP;7XM1J4K15C:O;7@OXM2?S-V>U;KA
M8>(ZCIRZF.-S9&?7(SM_>!AG]^J99[D&(6%L)LLPMEUN>H(1XRK _ :2@A5J
M.&>#AKGM=:Q9(F"E^XJ6K .KL;H%%$,T)A3\&[#]**@3N4=82%-7@XPYFI5#
M!V[=.W/ZN]6GE['Y;:K.V-CRC-.+3Y_.1J/A\+DLXVE9T\KSONU<:K2>ZFTP
M^>[""B35E;1^4(\9/2["< I5PE'B/3,RP9#C3"O2<L=SL=-+:BN)#,EZ07.$
MM)%:W"7Q:$%I8HZ(L05OS$HZ/A ']9!;)IQJ!OK]P":K^9F^S9[A/*A2;'WV
MJA:&80[L:L72]3.NZ*N"0O/$NKVH2>GA$!J6BU4R+#$<N"%AO5<\EM(FOIG7
M+R)#<4FQ3'P1,;Y8R <TKA@SH;9CQBQ=>[@M-".)]G4NS<*X_*8HON.$*ZBK
MYE3I6#+<-G:)T[22#*+AA2%9#LZ[O+6"SC$/ZE2E\2RK2\FD%OA%TUG#K4#/
M*>O&NQ3GC\6%L.O=MVN;PS[69_F[5@JQ@_X;JG!SI,;8JCXROD&V5DE0U(DN
MY?9)5C0(42#MZ8A791-&7["UPJI5&5Z9SI1?X%.)X!M5R<5EHZ*  $J\9H1
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MP5^'#A; 5R0\U<$U&^PV#NQ0O0)_MU3T<K,/99UCT+TTJ]G8>.JT(R@0+2/
MR'W9HNN>L6P.X:S/T7:M<+EI;FT[6R.3JCFE9=+:B691@^]!Q1=IVV;U?>6V
MUWB_,0YO,GR*F*SC4Z"4%R&&)JJIC5 +-;F7B?XOOOW6K[@ZA"K2C+&:CF8;
ML]/KT^&NE3-;%\NVDR JT\Y?M%K^FS"$Z6HS 3,VI5I0[A_0*4 69.?,-G&
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MBUZZ,%'Q3-C?DVNGCSN$UQNF$AO!9=PWZ(7K4GDEG<C@=AIQ:HIZ>4=MTJ=
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MDR>?AN<?X/^C!ZF/O#,[OB\'=B7H@JYG"G3L*5G> ZYJ]HLOS+4-!U7SJF>
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MN>OGHN:6RU^%-7=KL]\!4$L#!!0    ( &DS@UEDKJBE6P0  "H4   8
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M?).[?BYN[KG\95ASNS;_ U!+ P04    " !I,X-934/"1F$$   A%   &
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MB:;K(^Z<)>N@\UKTM_SFC*5RYY_8*FO\CN+]8*JR%.#?:X HO,ZB564K#:2
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M^B=%4"'XUZ\0^8N.88GRYE+O[I+<-WESL:(#WH4>1U#1)XH*Q_>O9H$YE06
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M8:/82LM)#N_$B9GYC$_I9.*CO0@7E<OI5H1B<IGJ%FB^JLC/LSFM/4?9;O.
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M]_W<P< U()$X'P^JV<F'0EUE3% MM<C/"W1%!E\ #^>S(.A@6!OUZ.&&WK/
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MAJAB)@XD!C5L&#K\:.UE.C8OZT!D(,-D?6#Y\!O%E+C6SM4<CD^T<:LBA8;
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M%+- +KG#U%1^M;M9I83*-%)(2<IBFF\P %AC.A)8L[M#WR;N.D%@,#*;2^?
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M<HT-'%I0R7K-B&^_T<<=3GP\/CW"PDU\>IR' 4'DIQR;=3E$9HTI,'7WAP&
MEP(K#?KV"WRRW7)4<XI1P$6X:BIF"Z/B*'CG"00"G^=Q]('6MZ,U99AC SX)
M'(1H4ETDZJE$LZ5D1\4AKE2ENE@(7.P= (B>9.,#E^_!I:8!$UU0X^'D_+NK
ML7IGEG%PA9F83'W&Q\UBXX''@W@\P+XOC</]-?%/"##!LY"UF$P_Q[3IV"04
MZIH1K16XE#0 :+Q!@!F8'O6K0/+,"+.JYOE^3K!A!K2<J_I$,4/]X+W6/A
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M1$&/!P#Z<3+*AT%8B$4$\IO'FP_+-@:GA1PASJOR0/\E '36PPMA;V3=7PO
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M!^=Y?V'6)_@8K2[:?[I!T&?5V\XI$AZLN'U6U?"R'C5.$UA;1D- (VL"8/_
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M]C"X__Z?L[92;)U\Z5-"N8@: +P/=5K!7;7^Q:LS?F'YB6$L]D2%UELJ-O!
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ME>3<K5R&OZ$*F75H"R!3T<BNO+P2G6MM5M6!%SQVRU#>#)ZPA*O"?G/X5D_
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MM!][KH=,V'2VX& XASB-[KU[_.E IN5(?#_\\M2+XD1/G]Y%DX+O@LJ9Y0A
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M=2!&.0G1DXHJUC!-4M2E?,<;JY]3P2*0.LXA""GX$%$FG1,K6L^<$BJS"K5
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M 5_*OL&-RM2%N3.4:2>%DD+2)G@&0L0?K1N8VFD4CGSJQG$\BCQLI8:]Z;K
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M&R[$ZN8<*J("_W]P*#V'*C6-2X"Q)C@*S%B2RG6QMK-^>*,?C*R?\<;]-.(
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M2*7L0P )&;D?$,5[FDV(%!U'I3/A2RFT#EI)E P0..!.<G2YF15\*"^,;<Z
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MB?KE^2V&[Q+A!2GLA_7.(9+Q&(J-=I/WE,S($$8>Z!\H-QVZB\1[ZS_ODE^
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M&Q#^E"[\EHF*636SC[!4C]=7X>_K3*1;#8VN)XVRO44)?)0^0D@(H>ER RT
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M-[ WDKA\YZ'1SYNK]*2K1 T>-=PST#AV0$<'2!I9_33V$-V8-0#7F6K\9):
M"FH6V#Y>()DV%AI!3BXAXV3$P(V-2U,OUCAOTTTCG9-'PH9:4=JZ)^7 22D7
M&2X*V0VE4*=.]RU=9@I**K>DD>1I3CS'+W#:8[1H:#99EK[.E*NL(([#C&DX
MAMTR4?;, ).H:8P<1')>N#;MQ9H[OMP=]X:V471H$G=.1%*[&Q9%!E<P6M^P
MB@=JGY_D4\2C0KU\I6(G[S&;4VGT0?$4RW6FZF)KK%)\2Y\<J\\FZZUWCY7U
M[V<*^QGJ^,M*^K6P04VSK;W5VMZ;:;F=R7*P>]E>'$UK;1 XN'%C6>1#14TY
MOL=U\TR,*G]:$5+!_'C(<,W1(R0[%;-(*]$^;;H46*H2K6).,A,7CEZ/[H#,
M>+"2A["2AH? :RDS@8?$-^B6?/(.,(2?6A;E"*FQPS[P(H4C3KG,< 7O,#"A
MI9-<',N=K$B%[LM+%8TL?,18/,$G;)5L2?,DXQ1/3.\24P;?8NQM/<$L(=JZ
M:>G@^@+=,?(:ROROFIO(30X*VHD7Y^@CUCDB^O2'SD#B@N2MY"@/\6Y<R]):
M)=TXR8(,S-"+2,&8L:8FSWK!/.N#)L^ZR;-N\JR;/.NGN<AO2)VL:A"4*;<U
MKO*]52'*=-E3GC448J\YN9,3N9Z:%K1I/3*W;IQ)VLHD8JEMC$*^WKZ0945Q
M.D:1^JR%^B]UL*>B-MZQUU[1(9[5N<CC[ S=V>=EE#I6J<9 #9S+K@?$O1@*
MXJX_M>V=W2WJ!J'(IW:4+#V^<J0]N[U'(ZTK*?32R22,$K.?3QTU[*R(&H[E
M">?*"Q70S3N)[J-;JQG%"+)U&M43Q.42Q?>6+/TM-@$XFM,"@"DBUP> #'#2
MRU2Q<BPWULDVE@R9<CT%/$S=N] $T#45,]]6C-!1F:7N2R<#;3/;-Y$/H[:T
MDLP^+"C&QV2 C*91IA85)FM9=<>D%UR]VSN'K>TY^UU=MOR"6UX#Z&/LNE$'
M&[>VR;[9_L4Z6-=;?@[S__!U\A9N>1&2CW._\#IG-3_YEHDY@BM3A8]K3R<&
M5=@Y"#B6[-I816YA%DD1PD*HH]\P0]4MHR!QI,]FX@L7"S)B@7@X.@\-R9/^
M@O_E#(N)PHTQ'U+ ;G8&\5;_,(]XQ]A&^BE;@B10@7(),<[.)\$1$Q@R'IWK
MQ90%@@4@U15+7!A2OB@FF*/1-9US\8P.+*6>2WF\"O[(]C]]'AH)#85V/5E+
M"D;A @.5/+W8%,6UK:IN9(O@=/$,%7K08JVEC*9F:O8%M#F%FB1_I?F)F5Z!
M<!ZZ69DMX8^DF\568ZE3I+HS\=UC[)!R]?W<_FIFO[;J,UT4S:P,!A77;4C5
MHXN"-X*<7Z1MG UJ8>+YUO;A5A:S,X( 0D.3)&N,H-1+^UGKR;SDOA9W#%^*
M7UTSD.]\<XQ1&K;W5E41>QP&V875#EW)VZ7B(@,QTSK%Q=:Z/GJAN;>?O !<
M^1D:>F%.!.!H-5M*<_D'=<*N$0K9V+G:69.CSNF09<\D[#"R6:J(E/D8LM\:
MF#6"(I.%J'QSC1Y#C)T[5I&&?%><G2W=%$=WTB$&(&)9)FCR/4; $??8,QR5
M:[[./QWMJ3&,U\*" ^P(Y"L<GFR5&;,'*<H5NG/N[PK[<\\Z(ZTX5G(P=';_
M_^Q]:Y/;QM'N7V'EY)Q*JJ"U;K;E..>MDB4YUIO8UBLI29U/+I  EXA!@,%E
MU\RO/]/7Z0$&)'<EBRL+'^)H=TE@+CT]?7GZ:>#OF>AMN1@K7^')D;)HE*R
MWFB9)\:5@9MW0(9T@K5Z=DJMM]/G3JOA5[T;[Q8R?[;$6OHB\2(79F/0QRG;
M^G:/0,GF@]NHP8?GKJOOWC+I1-DW:_T:P$R\;L*98&,NTH='11 5)'T6 8V-
MO5>$(-Z/@Z)=0IUCJ6.CYSBB31/0#_!=#-!U&_>I-DX-SCQI\'*;QQ2ZU6"D
M3 2>4EQ<+HACAT./["8OE4GHU,4<KR5&_\">0+T/_V]G_[HO^1Y^_.#S.8EU
M:A+KR9S$FI-8<Q)K3F*=W+C^>]^P\EO%HG@CZ#TWHK_A!>_1,0Q8S 'VA$6V
M2->8 E$FU(]3V\P?ZJL<"!S%@4NH#05<=[('2B7.MS&$:=Q%V3N; 2BQ1^UN
M6P!JP.,UI$8&DH^F376S]6-?31 BWKAT@=;1'1?1TB#'*]((@?"G?5>'DH^_
M";7G2%CA-Z%DABC+ 0*2= 9_X]&#BR_T-IA6)Z89X@#T^+X/P3&Y_\')C@KW
M (\YA'K6 NE\>/'YH_]]AR8AW>J'_SUQ8L$..C/KP9?GW\%)<^>$Y7AZ.6^I
MW=+'D";ZJ'?T;=&5@SU%".MM%=-!4^0#[?Z- YLO-)OS(V=SU/J[XX)NIPIL
M?=1UZD^;(G,6  K[DX?W'WU]^G0.:*R[MK7O9;Z_Y>T+M-/'O'NWTTB_]MP"
M8^_+BX<#Z_L>_2I8@;?U=O%M4V^<'MI\XL+)NN7,=^/CKS[Q;2 =\4%G]&Q3
MY.O%Z,Y%K^\Y>WV_P;/_WW65=ANWE__3%ZN?/W&QNQNG_]$7G_@VG.'TO\DK
M2$7_ TI_7C4YU(]!$IW2%I1#>@NE>GV3_Q:UP-,J:]SS_XK9J&_^\?V;9/%J
M<_'\XA,7Q+NA#QY__HEOP]FL@3>K L CSA!0<^#_I-O=UXOO@$.@7D/?XSQM
MH,H?K 3/HO,;5!'?Y8"I_FN]*JKVYWVR^'Y6#W=#/7S^X!/?AK.IA^_S#,8D
MNN$W>.A?0,O.9=YM%M^D99<FB_^>3_T=.?6//_%M.,.I_TM>Y8T[[\^8& @N
M_6=ULZL;@KVOH-%)L_\-ZH';]1UZP>UF-'XR)S#ND :9LQ9W7-W,B8D7C?.\
MGM?+;5Y 9<!L?-P1U?'Y'*$\@\N1%K_Y;,2S35.T3G  ]?XL+:HY#'EW#OWC
M^Y_X-ISAT/^&C_I;]^!V\=?".5+IG'>\"P?\T9-/?!OF _X^#_C?TNLFA^3I
M7\M\OLGOTD%__/ 3WX;YH+]G+[U:_"V]RDO ;'_2@G5'SO>7G_@VW)WS+9S;
M'Z2@P$;@3US4L]8@_OWBS<7BVSS#I,K+:E5O\\7;]!<H=D4"[S3&%0]5(4/*
MED?G8M!\VDK_6N*RR*#3?2E5\"TW6NZ@FB43<K@_%].)%"I_I)E*%="3AP\>
M?KVXQ5K]^;/BOQKFG%LL<S<%9)Z&GA)VZ>@[!;;U^&6_0*9KP+!\YGY&3HV>
MJ<-\&U1X!3)[&>J(?_=N!L)A;BG'D2\"#, QM1SQ6=O==0^G!^VI716O69/7
MS65:%?_!I\N<@(^&EWJ;IQ63+;RA5:?Y/?KBR1_2/]*_M6(SRR\63]NVWX8U
MK]""@V<!_"LIK?EWU))+&#6($P%)%ZA]U:J^=./*%TB_7C>+LFY;(GXBUAZF
M=.(6 N89 5\7_NIB\:8 @QF^&/Y%J*KTO<1FYI]N"<FF.*J8GB7L F:9=YC!
MGOE6JMISG>-*K%GZ"I*^SDG?*I0^MWOQ<4^^U,DT,)\MMD#63J<GSTQ/:/GT
MB0,83 C4Q!TXB V<Q&3R)"Y..X0?B'_K_2GL'_*K-$L7K_/,?:[MI+U!3($_
M^>I,"OS-+97:.VAX0X=YP50G"Q$N$+KA>LGGWT4,XUL1B*4>7&TR(%U-)O;Q
M#'IZ8B1']/9  9ZLN^-O^W4T5OQ=R)")9'_OH,CNEKQ=L%"<7YF]+MJ?%]^F
MQ.8044H/'Y]))WU31WEX@:+"V&!7:0.,<XO&30,NV+9>%4A(+(R!A>_(QN05
M]$LWB+[M@*+SPFWD CPCDC5[<WK"2R0!<^>"O0FO%MAH K)X.$W+7 @O@%(4
M3!'0"U4/Q!P@%C1.Z(P$-!PK9LN 85%;566B9@K4/=L.P[%X?@U\XI_N*"OE
M:YSNZ[ 7C/)_> ?L_!W9YK:+=[4EV[>^G9@<+60DSIQ4[9&W5BAFH&R'#BIP
MPH#%SJ?34':F557WSKW YF8_.K6GC#F/'A!C3L+4_6+VEW0^TPS8+H$9,Z6F
M9B,FXWK0;IDL?;P-ZIW<#8FJH\2T7Y2/PHNPU3(T:G2*(\M7(+=B:#GY_#G'
M5LK4B"M*53=W-YV/V2V.&1A!+\23?@W"ZFU$[U][&G!H[H9-/8%9VG8+/$E(
MP5[NQF_,\AU:W<!H.3Q>/[B'/DO;C3!+"JDBG!FD7#_P[BC;>$+=1O4.#VS2
MX5O@5!*;[^*RR=..^,]+,"L:9X64/9BFJ7ZM*[83/6.NW<Q;)TE.RJ</ZLSV
M>)SM\:N9[7%F>YS9'C\NML?9 IDMD$,6"#:-J X9#LX-&#>OL.3)!SL8D:&-
MO)3:,Q3[H]0E<S(;G]X9-VCF8'LD:J 1#>PG^OCX>X]V38J]20FD[9LN%L8;
MJI?(7.T^V.;:PZF-=)QC&V9V#.9C^7[\[V'DBW-:137NHKA+]VBDCWK=\4FU
MW8JQBS!*[R9MMMQDPAS]L4LAYV[==S!$[3$-O_<^M]+><KQM/@CS0;C%07@#
MT?YQ1'K<;FS D8QN8X'=9=JN#=ML^+X"60'=P$!EXSWDMKII9T&=!?46@CJ!
M/A"!#7XKB0OG^I:0!$R='5+EZZ(;F4/46+WML<Q;&S)!\[2FW10[)\ E=69R
MO^:&', EWA0(?R8[J^+,G7Z=GOTU#.XNR_K]6=3OIJB'?7^+EL*5/@,W"@!:
M2P)D7R+L$))#C /T&[N8EL5Q4 ==_H>T&!24^$CR<)3BSJ%!'*8VN#7AFUU9
M='-V;CZ )SOM#<L/MUT$^=%[I:A6#8(W8FTBHJ?2.<#4M:FLJ\M[X#;,9M L
MFN]9-+/<B&59_+LO,H!U3+0SB::/9J-E%LSW+Y@E<"IB>ST54788)X42%":T
M)>?D)S=^9_3A;]^4$1-O-EGFXW<S]]B ]MI^M<K;=MV7[*FV_79+S1R-FWJ7
MM?TL;W=5WF[LHR[KM$%B71]#9)L%FII2'^FV1WQ8T;9UZ1MBDR7#".V7%;6C
M=G/'7!"!XWS+Y16"::[2HD3A75/Y3-<42X[CU!/N<U"'0Y"=Q29/K]PB"@BH
M*[8,<,<AF'$!\N<ZAVZM;6P\& \EX!$WS5YBU@XZT64X1M^TNN6, 7:VALAI
M6:2(SRWR.70ZG]5WNALV*43JL0-]9H-#DE9RP@UU$CF N3"^B9']5;[3LP@=
MI+$C<,Y5) 4+-@ELCR<97R%/DG;%[O^=P.=T*C&S=;$(+RTP'A?I:E/D5YAJ
MVZ8%=K:&PJFULYT(I3Z?@?D,O.L9J+";=M:O0-L*/$'4<-X@>AE[:8/(TQ>Z
MQ252Q()]#M4-B$1PXHX)!7X8?J>=7>A91M^##=_DSKIH<BWB<2+)3C"HV#5W
M+P$-;7'XV&+>^@#>% (-O@)=CC]!"++%D@-(U9;E;]^EAC3AI^E.SX?OA,/W
MPNGS11%X-0+$P03SJR:_)[AYZAV$$*#&NMD)?10-(CF_;;]LNY0J=VYREB5"
M1K:2G.PF+= \,P_-ZG[ICO#2R0L^(I5JOMH;95C(>UDC1+!V[VK DV+: ^>[
M]17IA)J>3^Z-C/!ZXQ8&_!9PZZ!:(J9'\$F@=I9HZ:WHR&$U4^*6PMV.>)E^
MYKZ?0R5VA7"JBNP\*+>5@SDZY[_RMC-Y0^8;O,!M?MFD6ZQ]8@R6MPLX KG(
MU]"T?/;(YIO^-E(G!R\%2"ODZK'9B#O2E_EB6=1=OMI4;E"7>ZVF17!)2BP&
M>68<M@VPZC88HR 5 7%V\+Q:%&Q!#WY-1U2,6??&#FN*H3"P N,5'MKX" X:
MN3JR#FH&&1)LGG.:%6VMDFWZ,R@Z!(85*\!7PA><,&+Y,)0<(4^!>R)ZJ>XT
M!O#'LOC9J8]-76<<A5G)7ZZ*C\$_G$WO.WX@S<5:[CD,"%+($4"1.* ,>OK\
MQ;W[]Q_X0Z'Q1!\DR89'2(.'?,G$P_4'9/@48WPNM#M::/?P_EQH-Q?:S85V
M<Z'=7;S YRO[U"O;"4J18VD];O^R%N^9K$5W#U Y?=- 81SEUQBG7309EN@@
MLY0GHD';TSZ+/O\J;=)+8'4;%.7]2+D14PIO/PVC@'^[D?X!?/ MF!,9Y2R9
MX4D^.GP0DRG]T4<AV.!8_ VGE?N/7IS->X[&$#1O0T5\@XT!@H'HOF!P@0(P
M-_@61F"0-M%$8:SCP\57P'J87Z)2<89=X9PJ<'G>T= ZOSZ:7?R[JIY> NU<
M1KRG7C9)]DI2%2"FNS)E;=5VD%VZ1'7DPX@"&'#6Z#6Y(%#0PE$KR\C'?%OH
M4)@2%76T04VZ,^EFF%X2 L@=6GBJ,P?FC-5\ZYXHUJ],O J!*O*#C: 6U55=
M7B%+7)E7E]V&RF!!+)T&O\K!^T4_FB $K26_8P8L^#Q>I<!KU>!UXG8:N DY
M#&6(J)Q9ZZR QBV*N\*%$(_<;>->[QKHZ<LUC6>[,26@'(0%9#(:E-=00A@>
M]-,;AA7\+0C'O<C)0&G[W:YNH [NLG<&-80)I:1>R(19DT@&>^4>#IBFW,;T
M"<]ADQ=UB]HG4#11YC+W&= ]0#M68G+ FPF>]PS4FA4?$R,)!_7;3U).,VQ^
MFJG+V?"XL89Y1H'S<F]HV>&J!T1]130<SYW 78/*</\'W'T=,>/FR 'H%&3%
M,<X#Q+PQ\+[RB]MW\??=F]23F03]@S>V*HG;''AUJ?^R&#?+O7N(TTN@P(I6
M.! HMT L9E57W.O2GW.LM@([2^B=9PMG/DVW.TW?Y$1;^<YR2ZD[YO_H&R06
M(=F%[!>FSAMB_EL0K<XB!>[JMHN^.M%OH>2KE;]G AVB)UFG5VX@(-O_<J8#
M)N36==-O%YQS\Y<[YN#)/G/_7T$*GP:S7V!\KAV,=56FQ19@!9B?;.CRVC5%
MW1R^Q3Z-&_Q'Y0_PM7=08D>UR!/U>/,%/ZNDTU(<$4[0DPL\P12 <[[JM!#!
M^6KN;):Y9_R*/3UX"%9N-/7.4';/%46S6+^S6(\L2G]#'2TG4)[IL)!@+AZ8
M1?-7$<T@/$NX21,B62M$-,!Q(MZSY\X()P*WH:(&$2C>G$/4I0=OSV(]B_5M
MZ@T JZ+A.M_?QC0-FS8JQ@QQB2GM!%WLS(<*8%!EI, 2O1:LE S1RD!9ZL0Z
M("YR)VA=]AAD)$: KH/GM/W2.53&ZCY,Q"*OAPM$@J#SN9G/S6TB;+43R&+5
ML;]/'(BHN].&N@ATUWD^$2,32 #D_-F6B7[FV[1HL(IXCEW-<OJ^S194O\NF
M3JF]64/JGRV5OO5.'U;30[X)_@$5+4YK(NQBPN=4%Q(S?'G6>L;%0U4T;+D7
MU16<)+@ =OGP01 O@PP39@5]-"JKT6)* 0Q#.7#^'.86HXQ=U-G"S0#X2/FE
MB*.Y"\&I&W03>XM(&>X2!N3 2#O,/R/[JNE?*PT^N(^MLT&9D>PVC>=L@S5H
M_7:D%>W#QZ<TP8S0T )8<>%N?K=/4!K!=0(-T DQ2P(V-T&[H!;H$"W RJT
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MMHI>=' W$M+46!(W!L?%)S+4Y8>7\=#QN=[4!]7I5%MPCHMA@S'W8T2[#M5
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MP(X\K2HP EYC<!ML-, K,\;V_KV_>B_6631I27_8.RVU(/S'\WR%M0(<<'^
M4:='@D1WHZ;Z><6;OLF=^4AU'3#H%[^L-M"A!7E/BQ:M,,$:OGGQ+,#2];M,
M]AX&_C\]8E/<-K[FPO[AX/^'ZF-2;%';Y@<EZ#C8YT1H^#\QV@=[_<Q=&-^Z
M [WX'@3'8+R/X+LASG.$7O9W__7HT1=RFQQ4!J<BQ06A.!V3\V0)[[B..+^S
MQZ^B=+SD[+QGQ?X^282_=>X.DP/ZK@CHX\5Z*L"4=C68'A20YE" .XI@HR>:
M\,K&F;,'DCFCIDBB',L]ZQHLD(.?"+@W"FW4 V#GA+LBKI9U7.2CPO5#6:P4
M_5CW8?$6ARFMN-:-@F8^U#W]XV0^4@>+U@C&PL. S:!-&.V7!?2A@B7N#\CB
MF$2I.G[$[=.ZM6[7!5VB5(Z:R%O>],O%RP36%KTT4-LU[#$$W3.,)KG++FWV
M=GT3NM>QDI(-B8K'3Z/4 ;L'-%?.0\:20?>2$Q[N8=KZU0$&&_[X;=&TG08B
M?2J,+AU?XQ8;HYWY2QYL\#NGED7E^4%@;E*+^]X0AIR^=@'F_51!=YA-E0CA
M>*>2P.7G,BZN(^&BI=$14UL*HQ1>,="&N\%2D!8CN;]TV*\<(AC"4A,Z\PF)
M!GP:"U^9 R<B4W D=U A"]0SJ'="*ARK*H9JXG"NTO ZL07*YB?M$J\>\.9L
M<KRL0*"AYSQ;G0B8U9'[$6O-G#D)-U^:3-K.I179:-IOJ-L;2C_B0,/18PD]
M<U&-P_H0+.*X=]#URY>J6T%*+:8CH 7RZ(V1ZE#:UW-E4X<B:QB@Y/JR(U^Q
M?=X3HY(6UV9%V_0[#D=5%*-:8?E?L ENM3$$@G??Z-W^JK%-QJ=E=?2 V!46
M+Y#P <2_F^&E+>EMDMU(<-ZW5$=QFAB&X4%U.KOIB>H)C2LXP" 7]3[/\0HV
MP5*X3&OW";QT?F&0@7[X8O&"_PE? &U75U*\@DP%J[Y,P=9VYGH)G;I8W9:T
M?V%9^D)R'DM&H/@Q#7K.V=TC1X6K?^H2&;PMQL&\X];K2@)V?*N#5O(102C)
M?H&L-*DF[4&)D5KHI@5]QMP_G9K,\'?:6<N&3?4]L,:0YZ8,>?Y+"B,VWPY>
M8!Y U 4-DTD0VSY8X[R.X*U2_QM8H;IABA551,"?F.=8LLQ^&'U/!40':.?<
MAD^Y@#(!]UUX">I(&RBOU\G1IYVZ*_&*8UB,:-3;R<5U#CF"]@;V(B4+:2B<
M %5D$[5X7^E=8Z5>>X>ZO7.BN13?B#)W0^/<WWSV&:.EBVKU#Y3[O[%K @NG
M[OQKF$+ P$)945@42]=PTJ;(#@Z>3@F3<1)>LJJ2BY&D,&*/ZN[T][J#7(?7
M$\5I6/.'3]<..ZD2: +9#K!S<'D^YK/E:YA1C]O[*876\NR\SLO3SMC:+Q0*
M ,_'L^4#9!.,.,D$&B&2 /2:&HJY.O&'CH;4OA%9&M^2PUK! 9,+@1\.H$4'
MP@;( *?$MJGGA2!T -=:>X# PP<7CQ\]>7(4?@%1%XQ-X0<G05>+^Q?W'SZ8
M>N(;N$G;Q=,ATFKJZ2- %C&[@\&[EXLVG'DBJ=DMUVI"W M">'L!H!3;K;/2
M4^[;B%%2BQ/)?Y&T)8_?>;'N!:T7G&F^WX3JV@TD YE7@O5^]/CB_O\69>EA
M'MZ;.K81F&]%V_M>YIPHUE' KL/?!'J/4T8[&FR3[R"C#7GF8,A?/+YXK$.^
M"61G:JB!G7*S#3IAA1]<?/%K+7 $/0.@VAT[Q9KR)HXRA 9!<S0<:<3&]ZJ_
MM1 A\NBAY)%;R5:+W]_'' 1Z@.#*'GA6T7(*X/?WHZI!O3FYX9"F3$'/HW5B
M<>)XB6W@JB(UW$%YA8"?F9'E )Z:&8JV8*VS?G,F$R2_H!YNBE3G8TF&/YZ3
MX7,R_.XGPS^\S5;MV9%K;Q0FM]?"5)<7;\V;8-Y %7*N<*3R)LE HD4?$W7K
MW@,")ZW!$6, _(3!)S=8"U&RIB-!^$5:V,,\Y  8C$R;W$29:-2O0-_:1+_<
M!8SD%N1#<#JV: X;U'C'H<_*D8%-"H47EW57H 6+85/W]SU8M>YD%BW0(XQW
M]&+QQMVW&/HY=:EOL-*<T;D["^UN^=!;LTMXJ^5[&W/Q%#=)]@WXC#CC>^0;
MVR  :IN[[/);QLGX+K.A<Q(W14C52 %]"/I@#H(6EHBLL/^3BHW4ASG["RVQ
M8S0EGM N_MY)#GX(NN7NJ;$WJ7-@WW2Q,"E;)L2E'$NJ_1VN458YIV*#"N<-
M 'PS<A68'=@PNL0M4%P=7IH$ /< <>#H+,!QQURE9Y8<@S..3"2KN50C^BJ>
M9^!2Z0A8:HP\30B$3UQ9SD\O(Q!>8K)(<)(\6HDR<) 5X<LW7;K7,YH+HJ]!
M?DVBD2%2(#A#1](B'+R2@!I5:G5,O#WT)9'B%;MK9L,EOZLZ+8*P&"Z/WX>\
M0*FV\704(@'!!ZI\G><AU U;A' V"U6 N]&W<K?Z4S"^1#'D39CN(%-AHN+"
M"+=2S^Y]:Y+8HE,WKO\:\<+!71?3&@%5G@D&4,A)LC\(R/O3W.UZ;F)VT,,L
M)DB?@2Z:CZ&FRR%=6B 48%4TJWX+-B V"3(7$2=T;#\@J/D@>1V=;'?@?O_P
MXM%C7QHFRF#R2?X81)_V^<7#S^5I<__)^4C<XDB@^W+8!Z.4,2'K_$TDO ]Y
MV&!U[C Y2^+M)-'">0ZQ>S/F!#NY-^17L9'%UA+UA&E-RM^9J$4+B*XROX0?
MJZ#1@M.FB*ZS!/T, &(?#NLDP?=:% ?MEH^MZ>/+D^Y#\57B'/\CRU;*(!'M
M0> 1P<.I*;K"M((GC9GH*X,>PY0%/83(K0NL[%0OLLE\ASUQK]PNQ\: @9YD
ML2_R,B,L(Y 34CBZT62].#)WU2_AW32PQO#@"%HT"O<='#"MXSUO@.%%],P-
M0RI#HFNROZKL -/.")QPI'JF&0=R)L)&QFXTB%A6).^(+YUP.3&&V 8[C][2
MT89$6-N<(M*18P615E03,=PB@N^X#>5H+/PIU#%/'CYX^#4V1@@%^MG$H$YH
MC?#@\5>G\'Q&'- )R*[IC3(^>0<:><4@Q]I@:GR4;W5XM2FX02 M<XKOX&UU
M)_78V]%=[^&9> EWF[J_W-@05PC'LR$8C2D=HFYSRL@=T&8/B<%<TV/:]@0A
MJNV'U82@SROI$)4LJN$M6,DUZ.2X7CK+4"RE6$B*-&B34[NYJ56C\)T$^TP
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MC3\>MH0.\C.PNZLN'U8J0X*T+V,-N::IAR";!'%CIPDR#T;&UPZL=M[6$*8
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MZWV1H)Z#('] O>UG.[%GHQ@G?&NZ=<2"VWI:13UT>>+7I+TB2\K%X)F''!K
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M-'U&EEK?<%9@);<6F-2%NWN<$J\KC.UCG+WH>KUDU4J$#",@_UN\47'YP*)
MV4"@%3\6/E<3*_M=50@#PP>C[GZ6DO",V<5B%(8I\E#$R84X+EK&.J$K6]G/
M]?B9H-WQ=";AGZEX)G8VE%#E;E$'V"Y9//K)1E)BPQBKE$Z(-." /:T 9N"+
M4A.;LQ>'F.P4J*W&@NVF9S)*T(?#RJP 31G-V.<1S@GV,V)"@ K77@.+%TI*
M9*Q*SYYS0VO")WQ$Q1S#\'-ORW$L(&2ADI9?[ TF]K2P&9^P8*8HI(,0;71R
M!Z<R*M0>,2/IUDW4S!G(TQ!S%>"L1H"I)$!KK0 U5I:J%@6H8F=H .V:9$#"
M<IMBSAM8OG;D?0%W+F5 @N2<>*-L/NCF*"^K-H0PIEKL N7N$N&."MT/MS<1
M< PREFZ!>5JH8?G'A78<IS@T$U91/#K33V$RO'/7297O6]ZJQ3H'-%^85UJC
MN=IQX9],G).4*@)EB77@%XM7NEB8>YY:&]_1!\[+DBD-_N6T*I& R^V/7/88
M6@)FJ7P=LB?9D-&RA#:CA_ B:ZHGO44E?+02&9TQN*JQU0EF; ^<$KLK008I
MT&UT+SD-U[*[9:TT6Z ZFN<A+I5;XLBBB7;CWK HM(;LYV2[;6A Z:40I$*5
M7QP#,<X*<HYJ2@X?3J3V<P*>L81P]V&=[DZ:H0'2;R\8)A)UR-]CFD;O\EC
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MW=#D MDPP.P#JS8DT=05%*Y6#5U079&W),8K)5U..NROU^:K)K>G[-!"P@\
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M/VP[#!T+?CH]<%PJB(\Z7BE9P9-T]K$5 *MV%^F553O.P5TH0Z,.NW)+(@-
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M3&Q=TF3N*L'.X!%OU]?O;R:;2JD..OZL (\APCH!L-#/?B\]R'S3D7*;N;$
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ME'A)A%-".O!&I2"]GM0%%CC<:(YWRLN:RE,6D89&4F4S% FBLLI3-Q:HU;)
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M'MBM%KWMRA&T*^8,O<5F,QU\5<((Q@0<&9CHT\)&[)GFA".9I:<P6-=[N 4
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M='J!B6&$)0QXF:3<#!$&F$&JZP%2G9,Y1 *_;NH+H?I&ZG)]3"@#NK[J!P-
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MM,.7]$ UD:2!E%L44.[C!)[5757D.X9E$5K.N[],D--Q<3L^CK,B[&>V30[
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MXH#6QR)Z<5I,("8'WP:C) L7=39-<CH=N69(2F)#/M+2B;AJZ9\)[!,.JMP
ML1?6COM<&#L9A&3J=\:<D5![2"]_\N@R%T@\5CA.,J3A>PW]=5C:Z$LJ1/I"
M22>O!KZ,QKT-AT!E5,2.?6BUW'+TMIS8RG?C"A.O<7Q XF';BMMM@:SF#+)T
M#Q#D<1?+6.[%461T0_XV[3(R\6BX\*]'<ITS'H-$5OO@'R%OC<$D]+MR6D&;
M8HYZ@0:9HM@EXK/JW 7J!9IW#WN;AOTW7,[6@7MJM*X+S5\&=QG=1DK)O"'O
M[1,7; B7'Z_EN#)J70OQ>*!;@7XQ'.AZG_\G4.*YAH:^G:'D]J9/GV3!!Z'_
M09V1\GKZV\^^?/J[RR]6P3#L-+-CZ@DN&857(--$::MURD!0V&OHE^5D4?@_
M]O_8:8UY<S "*#>,MB7LFN*J7!G/H9*A$XG]VZH;I8#)QI1O(M,O;4UA+4[&
M'[X'":?+7*%/83P^DXX"Z]8^4%; %MF2=U"9P<X$<=ZO+9R&Y&'\CE."U&NE
M4ZZS&5W$>SO3&5-M1X!^(13*5NNJV9>D+F,KB@CE? N<#[Z56"!YUFR)T\Y5
M)A<*BQ"@1D=#4X)REUOL6(]H3,1B< >,^KF1UP?>=X_5V*5!.5G2MNFZB[7,
MQDA9MIOH8M9A&MDU0]\Q1V<)0:(W#^;?9F6I(TSY+V+.T#R?Y\U>JQ]A)\(/
M75=;WCFM;\"N3H4SBJBW$BE;\*B&(\Y(SAQ9HF-+4I)5MU]]M%WT\MQ#HH7S
M+5\451XX_MJL]%RH&0VN^_GSD8\IWM$WM="]XMGA-_XH"[YZIG"FGSPKPNX6
MP]ZN1[]\\:/S"@FODQ-D XX+8*DI&\;.PNZ(\\<Q-3V,+#)=).;;;:M'=3I-
M#)C3 52,EG!1"=I4GW?&D/:-_-,HQ=C0;:H#M7N,6E^('VK'BD4@R"E)+\5:
MT\Q'-^F<['HPKJR;9-=^8AF<,J9H_:LRG. -8#&8L4N-U,N?+GZZ?'VISCSG
M&[[6O$+*<JN?.DQVO  B?84'9^:T<(>_#+NC@)X_9=!S:?>(5T\5L^A1%??I
M090MP,%RK"NR!-.FF*KSQ3]H:D(GAXJU5NEPBN6Y[&ER4_\Y3#_]M*19<YPT
MTQ0:A:2-.%1)"U(#[W^0)HM:&B1@#,GXMV649<K1_RPD-'K-N$30/N0^D)8Y
M>6OA?K-?&@3 AHB22_"J4+,%!(+ O4MVUUP6B2]1):?5!'^*7#Q2@F.7DY)?
M>TV9:Z[3%TI<SP'9G<Q53M0@V@FMA:Q>)^5C?=+HAK2)%T1['$"XITMEB?#,
MG3CE^ 7)\K13Q..BKP8:\OQG:<<GM?M+MZ/LO^",BT:L-+Q@'O.</6DQ-$>_
MOC]);+FDHDF.4-TM0%PDQUN9A<TV_/5V^S*YJ5?$SU2#O)!;1.(#0H1#06&;
M=#C-F-*@V*X 9\1AK\J/A?.Q=TR-M19A4U,)B'"*H5HP1B,0GE4579SJIO/3
MV"WE1MM@>U9;KI$NW0AVH0X:NJ*6_!!<8:7'R0_:]A?A[:A,_XV+*;\BX7?K
M2/^VI8/"E(>SQ,1;DRI^(B(A5L9#_CVD%VA\A"C.?XCCWK.G,.*KKKYJJ8"!
M#GBNGT2$]MW*=0GY&^((PZKTUW&X=!OU)/&YJZQ)Z8G;@A)ZK+]BF6C]%YZ2
M]3BB)/O)1/+BGLZ<!]'E8'\61)EQ_69<.K>)RX62J,(+4)C,6Q*D\R"S&H[R
M=*$DYK-%FLZBQS,@'6K-NAIUO?&#<2>D>WY7AS6M/H-Q\!BP@J8=8.8\DZ;$
MSL4*9,JHB1H32G*<ZO'%O1,)O3'$#H-<#5=#UT<&6Y;VK]K\GQ5)PF(V\]O\
MQK)QL>4GR5ZX(BYV58E9#^+I+73KH>)/[8LDQC[A%"2 G^OA]@]\=5H?CKU4
M<%04RL)9\(0P23"N3Q:N+E??DV=8EPD-T%/>% 09]',<Y[XO%15[]>J'YZN_
MJ4?RJFS"_MKQ#!%)""$H!SIH=8U^@OU\K5DWVDV]5OKS'TKQO$%-2VQ]WN>=
M7,5TM["L-<T;-VS_N@PN-X7K\GK\=JPTI@\DPM1-\HL?*:25A*[CUG7J)<ZO
M2NEACS],&^PR1]"+DBS>,TDD4A,/@AY)&[);C&1P.,;&$B?3B$'<:LU>3=]&
M#TM:J.2?3]LN"(M)6T=EL-_. :(NN%1#?R+WRDWO'..+909Y(_IJ=L&TQ;PI
M<AA5..?MYAJ]]$Z!=$>:<:/,-_/XZ5Q4:WW6.A=I^#+(KC1(=GAT%8U"BI)B
M6OHE\B85 Y]SQH6@<%608U^DB*!BVW"NT6V"],_Q0LEWTE9);L!-2C^ C=E<
M2YV?LK%!,2+T(45%Q&A!KS5'<@""J7Q#_U^F-ZE+:"-1<)SIY,X!<<@<M0VS
M<,J IZZJ)8RK+HFHUSP=R0&H]'Z:,27BY*N&J:'A-W\HI>RGYU+VN93][U+*
M?B=Z+6AG=2MHDB1QQ^YF_6^U_,Y+""IH/^RN<F7T>Z4^F _*1FZ>AF>OOGGU
M[3BW-3+P?PO!P(Q]IU\R*E,W3F,E'N-2836IVG(6A'KXN(Z\F:V9\2TYC!4;
M3D$7E9TOB0!1^I+Q-5>6 :HONYZ_^=WE[ZQH174#U+Z^^,]84]V2VZLN>'@B
M#PB 9C)>AF,X%VX*G\MEE^,IB,0,((>C$5#2/%O\?> &N%L([&*[V4R1<=;S
MOFV@0N7TT5#1<6?7Z/5<D\,MDU8S8TE+>+YQWH#; !+PX'4IKHOF!N/D CRP
MV!8JPT7'6V=@5Q^EI0L*GSY.L+AB4C(;S8^1)V/1+C7-3 DH>S>(MGPA$4M[
M)<D#XGW4$6:7EZ]:<9MM"$,[,A@I&FN$*5.$4;RW&[5:Z(^D/$S7 *9-@V<K
M*N*EK(-31NH5FB&; ;0G'5#MM7:+#>5/^)ZQ].TF5"5+[$\GP<3E/'/"H(6D
M,]+Y[M0+=PV]K?:X3R%[9<KS_M!ECC:\I@D)5_34A.8./;L<#\Y-^R@14P2&
M&(**H-1G(51WLT=M]EI:44I&B9(#F25[/45;'<U:XMMQ)M/I/X58.(5Z0C)T
M'>3E='58&T04LP4B_PL@>C[:H7XW@!Y^*J8^',D6EHT&]FC(.AJX8/W!6EIN
M/:+.7X;](:B.ME]]/[2KKW0Y7M-'PX&G9,)Z?/KDZ:=) N$OWW_UFO[HT^5!
MK\A?NSTE\5HW_W;K@[S\6<[CLXU43'3 3*M<Z/PV_)$M\[L03++-NJ<.A1-S
M*G3-KHP>]*4'AG3[4PT#/S>ZM$<;?[-YL^+R= _%1=$?N@ZH_;V1&;2)6-+[
M"T]].) <G)^\QZ^-??"'RS]\<6?X@UNE+SLA?B)&SJN2LAH<0*HASE\SJ+<^
M2 /2]GD+!.BP:!]5'[/KQC,;':59#+ET&^0DWT77#NU84^+,OL%(8EV3,W%%
MS13F^]&5?O/T\M//OEBMQ;\4FKLOPZW?Z=[;9(1M6VU)+]<UQIGSUGY78$I;
MD%<98*]: %7]YM7W> K_&/SSV=>4VAIF@##P^9NG]E(TH$.SRC7X2.@ %>6Z
M]X3'ZBBCJE'&]V*8P(^JM[<_!+6C4H>$ID_RL&A4+Z#^@!TP"*CY9@?01RW@
MM4,X7'QE6937+Y_;?%V9UYT_2V_SW7#[63(GZ+K<\=QR4U^$@TEI=*I\ES_3
MU'@7PHHG3RRLX!Q\3/A^]J2_YC1]Q]#V'FQXI0S9R^*< D<="#._5\<-6)F%
ME,:"T@#<>[D7.ER$/-K.N*0*K8\GU8GL24F2;M2!JUT_BWI3^1#=LTAB]TQU
M>.;_.9VD8F@XU\!=S$6[:(B5B:5.(K-QRN U1U]\"C]_\KDJR]=YN\Z#*W.Q
M^O[G77F,?LR33^$/CW]WYF,["_*O(LCDJSBAE<E;#M&UE4W:*5^Q(GXN'LZS
M#=IFZ.+?&V[;5PUU*\86_E'[^(IZ1U9MHW":1IXB-V_\P?*Q%C4L^38:-[DY
M!AFP*UAAR+'@4,L6<\.=#]3Y0-V#X-!DL*D)/NFF<<XE)@=(\A+>FBASXV23
M.WL%H,/YI\B,5?OY2W <NVE:JM\UR-SOCA9K2J#SG:6_[ R]"*[7$ %@GH6S
M<Z29H_#(7]M]GB=\6#_$?,/WEF_06"FZ<N>3=#Y)]^%83(>29'"+FC\C@DPR
M_U*D$IRK!#/^[L_'\2EAJ]$A2"M\EZ7+Y$@ T_74LZ:WS^TX684]"5S4MH7(
M8C-P =T]YY=TS<=\))Z<3\3C/!'CJ'EN;.^ZV;$'1&F =56+.R3S96\;3F7,
M2V:<3J*K4/LHQDSRG1*77=''!(/2YIOKH7>\:.1'.B0+FT_ACIR]Y8"6 GSY
M\XNF*"Z^;O/Z#0Z?GUU-'I0 &>P5FNVVVA 0UB.G0YVM)=(,2D\9PY*R/?*V
M+K'H2T+,J 1R)LNH4-,.[6]>]U2&H)'>L-R9D?>!:DAY]XQPU4E2_-!3RLUE
M@?XQ$*(3,LYW2)I>JB.0)B?18Y0\K^K2F+I>#T&?**47#X!X[?U)^#=:DP:>
M#&>4ZF&7MUEZ,]'7Q;U<,1ZO8\F6O!"PS74Q%X[0!'/V9E+(J[8N65Q*FFHY
MM7:93#K(0:/>79MJBMEYY)[#ZQ2"07 BJU]],'0F7WQZ[N(Z=W']NW1QW:%F
M%>Z/F5=%,XK:7+H6]J73"5 '[U;QP^035Y.UYUPS/O)=J0RVN21Q4*_P*);S
M-\KG'H7_Q(5##^@IW'WE8YB:\"9Y-!YYHL9'DVE3 ZV#A610T!?.$?6!>%0*
M!K)$_HTNB!2< -&2>]4Q^:[FU:QI1L9K,+)ZJDYC)+[L$%#^3OPI+<',7=V*
ME0#MLT_9M!F6"HHS1X[3*FEBL5I+8IA+F;0(7Q4G0@!%U6=HI$5Z>9W&1;.\
M9PB,W)X/?4%<)/2+!]N(I]"A_CYIE2J8O:*QNE+33M\G&Y5[L9!8TM%>V</(
M'"UPG2<%JUM__G (RU$/.&RYM(R9#MI>\=S.[BB@Z*G "@G@CCN2>N ZI+UK
MV40R:4V4.$#IE$?-;=;<9=^CB"$^\"D24Y+AE/MTJ=G&@94H.\MRV\T\K8X#
M(H^$B31DU_&HMDZ;QQ5#0EQ(Q_MQ0YAE).I1D0GY<!F:, *C6GIREU'1A=X(
MHW4)=8VZYN\?%U@S1025M1$_!+3&,F0\UC?!68OPL>_Q]%<-TCR]$,M^6[TI
M27%EO^1K)=VU4'38.+=9\P:00V[!A%%EO( :90P.LP1G&%&<7L EIL:Q]$RS
MY#BXSE8I@\98]T>0U#GYQ+/N@%SOUN=-V<5BJ6^$4-R72C!>25-3A,<N1MJ,
M)$U^W A%&3]N4)9P.J[V<AA5;>\706G_;;+CVN'P@7EFV?U<,T,&*$!$]U"N
MVDMJ&44TYX )^$B'C\8'^?86%GHCSLKP;X^\[K<U!XY4VXW2H34W"=8TJ:E*
MX"NFWN%>>)\PL9WORTFOS$(*+>4N_I>U)\3N!#:%DY9&W\Y^6VI\5KVSOX=I
M"\[7R^1CDM _G^[''7?]*IW#2M)X()0@A%O=]0J#E\B.DCS1+@L=.[^N3O-/
M.(\RX]'(^2O/Z6HOY&JK&0(H^M)W!!'0"G"GW(B2WZ7@OF4D?U NV@U\TOHK
MGU'74 T(&-/ +0NF_)'0A2$E"MP\4OFY3*(>B GP#LOOCJG+8<N5^&#G1^WR
M4(\(.>)-$X(H\K"'OM.!-)0J$H]V)/6<Y=5?%XRK4C4&[_[2J#UIH52WZ9YR
M6V=7*AFX(]M!$PO*?N':[(J$-]V!IHG47$Y33FM"0N<!#,VO?Z1I><*[9%G[
MF'6Q8=L7J^?A.O1Z+^"U?*\N5C9611RN<T;:\84HX6 4/9H<@:?('K:8/:;Z
MB%/2<WY@'.R89$/"\^\[+0S)K=%EFRMP&$_R@*-V<&ZO4DLBOV'B$B0C"39/
MGJ5;6V+?]["=XD9[[%H1'!1= A8/1)6XO"Y2Y9@G3U,2QP5OT U-C:;'@QQ1
M9=$37R#305/U834\X4T=9 C9T^Z!-=K2:\=R$E(!B5,);EGU*^\1$S+Y@O/_
MA##$#5IBT"_S&8 X,V84(FDL5@3E*V6JH4W9;:R&-#F_,QZ<])>R)Q=3/+2K
MX %#Z='QR8A:#)$;?O*WO"OR?W DR* 3A?$GC>&2QRDP[[T:U+Z!-U#W>; 6
MBOL0&9F=GSG!NJ14@ ()*04'0T@)5X.,QEV>%/2X^#R[6I>"ND3 9T[T\T3X
M\SUM'@R*' /V&!<.PNJ[H&;HT3+YGEO]\32L)SJ947 \)SI>C!ET)5R'(=O(
M;W6#@SQ2$9[[@I%L50;IMQ,<<A-"DLU-'R$#3[_%B1 ?&TX?L;33-B?T6)A2
M#O+ \P)L?WF;.%7A!O4J @<4KM5_$=O%JZ![AYS;E<;!4SHDD0YVML0@# V-
MU-UZ9D[32:7X5G?.?($)8]SQQQ*X0ZXH0K)P']2[M*7?^%+[_/"M3"/%O&20
MH;U"#5W\-9K;\9@19_]?E!LWW?^9P%9FTKGE4TAT[>\(34:0#+[ 5S^_7/VY
MN2EQP&Y T?-.HRU5OYB E<Z Y03L;5OTH=3@/SO7X,\U^',-/N;\I+0XIZC?
MJ;9SN?J1V!>OJ_)MXA] JTW4,'UJY$1EMVFK-5U92J)ID97( !0O0?DHR&$1
M#@W&11RGR=^]JJ)9^V#2P,+!;@)[#(*%" ND'!Z<!!P]K"#N%JEOY3WE@M)Y
MFCAH&7116+BRA/*/W]M #>'#[,@QT^%EJK7FL8>8$8]W>>WPHA$;ZSIQ/5+
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M^JJ1QR"*^RLF>GH7-@HF+>]'A!0S\R7*2Y&24&!<B7BBF+F<ABFSNS%09-+
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M!I.UC4 2,A+9OF$HCVX&IX-=(73G0$'-?2$"\YRBEXTMIA2/B8S=;6C80=[
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MDI]DE6#E\/5=TDKL2/#X#>[0.4F6*CZ-\0?(7V+_&+89H-"H3".W0@3R>KZ
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MO/6>M][/VGHFTA-Q!>08Z[^&L!K=@";=U&TTB>_HK'*H.!M((#^>=^?S[OR
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M)Z*S&BR 0]JLLQ$M1'J\L<"^8,25"4\D753QO9,[P^ZP4=)DQ9],KWEM1UY
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MYD':RI?ME^R-TV3WS/WPR4@]F7JXZ;PBU>,5P#Q\XL^OWWJ5=H<VY\SAH=W
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M@?H1@IGZL2,3K57!;WY<?<L?Y^R)U@)CQOGLHUXQ WJ'MG;T3T(BL&B!J"I
M*H0Y3D5HZZB&3><=C[DEI^+H?S0^L2I)CRS[2II[$(NZ1?*I3UXHQ9?=/]GY
M!'[ Q(E/T/6=OMB4V&JG&5'"@2F;C^<B5\-7G4 )^UQHWFXVUIWNN ;7L6B?
M2,XQ$084S$/W-Q%'I@:*]K;=1?HT2;(C:S?>L,!LM;JMB=!"6('4>G$Y7P]R
M^(:Q+#2WO6J)C4W[=Z(,X7P_4<Z,"SW.1 E"*M>57NIAP+,LS'J@*AKC(B@9
MIP0J!6:C:-NDL6=FML1?&<^TVL6X00I9Q'*4=(D)5FJ>QGVD-/X"_L]*1I$8
M,CN'2?BQT4A+'%%B6@@&LY4T+URI]36#7\8#[[42)4EP0&\.,JU9M@YV.?G
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MY#9U%FDP\F0'#2J$8);T,/)0?=HC&8,?>NFRFC@8%O"V=[Z'_$)@:4UFB)"
MH& <P]0QMS=JIC_;6**8[I3)*M5#82K=2]K)4+?<\)13TARBHE%(C(]COP93
MT";AF =CDL4I1\E=N0TI0U-+<0;:^WZV$>O:-SUNP7'/. D4$V^<V+YQ1-FS
MM/6B&VNA\8E5; ..27HBX<.EZ<%>3!CC>(*5P6:^"6C-BN:H'Q)O3O^9(;O>
M062F@YJ),LH B[39SY71$EGXD;W@CUK1_7 < X"LU"H)^5)V/*BNW22P9.2+
ME-7O#+<99^"R4?IHWY$+,GO^76'Z4&'FKIGPQS5AU(T+*&R2PR2\672+<J.$
M-G>&\W(-@\Q4>Y1P)*LI/9:4U&+"\5UO?!BO[+TH K/%2]2X/E%^\%R[BQDW
M^%&?RIG@ZJLIY/ET ]V6MA4CGD5O8TLSU&-Y=]JAFZEJ,48A>]!*5#40C*T%
MU^]&37VS0B\C/Y4&.[J8OQS*)FS(_TQ)IRW6;#:%*#,8[7"E:P6 (\P:8)DI
M?IJ*U)M&XY^A44:7KG?<?)-HA(25LZ<KG,>RJ1?992MI<=^)$1.U^6*TW3G'
M14^)J.+1V7.KT?XW*7PPG7ZP?\%X@HZF@C?4;X.A7(W]S37E^-8J\(EHJW$H
M<3:]/$JH>I)"#(J$Q .4SQI60>^=S,K/V 247UM-G.&H&SKO[#U2KQE!DTMK
M*,B@:-6=,DDVG^'D1F\ER4IR D=3EDYEK21@&6:#^>""^T76?*1\^W6_VTBW
MFCWHUU)%_ORYBOQ<17ZN(IO1OUB]$_=0P#L<.E+J?W>,X;,']Z0$B%F%2MIJ
M'((^%:-4$F)*$\$^KQ\5HYHPG3O'MIA']#>^[V);#Y+LB'A=3>/V*TFMKXI9
M:[@>(&=L)E73H#?(V<"\8(J0?DYSM4WU4OP=:@;:"OGD4PLOB*UO4?:5;D*F
M?]8PI/A@G].&[J9UZ!0SP/.I=3=DZ8*-:#:7DD@B//^ TO9:.:=)93,[8;\B
MAP3QW\AL\/<-5FD(0R#6CMNC9-_U;G6QU(M!R)C\%6M"6* -OJL':RRE0-"3
M"P)]C/'(\!"S%?PKYI/!I]D-IZ=FY'^< '_!"7#-$&%IHY@*=>JPQV0^ I'!
M:@.=;]2Z.M2DM=:86UC>@S[A*MY=DHF7 "FAII,TL?G;[O,R8O;/FLYE?!\K
M.-1&M$_ 2^;K$))?# &X,S*?NHTZ+FUU%!U"($PEPHVQQ_N^Y,(7R^YFZ2Q$
M+2<G@=1T"&=-J!@Q79+Y2J$,E?+0.M)9I0SG0-)(E#]]F3;L*MXQ[[%"30#9
MP'!%ODQI8\-4OHU" F4[^LE""3+\/OG#5[-/K7<UD2M"T?S3E\#Z[CLC@O2'
M]F5,-W)X'&;^Y3RE^9(L,Y?C*949DYOCR[.3J7Z /L-&-X.\342)4KKGI:^=
M2H,*#8:N]5E\QV6 B4!A+&47MP5G,CBR\AZ^&P]O 67;CEDG!62%[4UF<>IO
M<&IEG=,\63"(M&25 'Z(BL6^+HJ/!NFG7SE?1HR[="Q9WB3E^J>0.XIJKWJU
MTK^0&8P5%414EJATO7*<7YN@[-[?&Z8O/7"V\>*8N*O,WS^:+HC8I@3IX2\E
M/D2K(9(/\K5U1LQYD=PKZ 8=F@C&C]E1:\:)/:[BDP@.Y]3(>] ([MD.-/Y%
M+%E*I2UK?2V,V;PGJ>)([[4?E"^HT0!-_1*-]&4V8")=&6,OF2"?RL^_(>21
M8)(PXT\9\Y5UJ)$U[ZXLHZY]N51%J9(:BD#N%8DO%7J3A_>^E&\WE#6K=-=I
MGVX5\ZNZE,PGH\\;W&5[*J+Q/YP&-/?=HYF(*AHKF+*=CHZQH>M-^JE<KCP3
MM;&\XPVQ>>TVDVM3KWF[G&36Z =GB=#BS<,\[6!4\5T$C]\GJ_&)CTR"5^4U
M8IAHG\-2=HP!3G5[SV@5-B1Y/ FEDS9FS[9@E>[!#]UF54JD:6V;NO<K/T2B
MIF'R:U\&$U]*))7]Z"QFH#N\'5DJ 8P.CF3"5<.]L.=PV#6YDJ&>V,4YE.[+
MO<H;+Q](338_X#RF6S)+2 *0+1E=YLV&%S.F_;%T_8_WGVS!L%@9RS;5D!+G
M%DU V5C-#<,2J;6UR"4U_0BSS HC'M6]'@YA"Y)'L/8..'MBT0?WD/!9P=T2
M,%:P-]?+?S.U+[DW@BUT1R ;=A;/E]Z]1S"W7F9U^F78J_\<S?CWML3I1[ZF
M;?O6>0?J8I_#</V[WWTDANOING&=9HZI>LDU%H_XJ7H+)]E<G$P$84^YA4VN
M1G#<E+OQC'-L;LGXX, ZR+D13=F#\JX[E,[]\M*GZ,&?SCV:>6-V(W[H]&;-
MF<8KM#*D_)%AS1M.*$L2.5CQS0YW'P#.%$V& U*YUG A%0J&D*EHKNN_ATN8
MAAI5)]!\3\#(/$GJXF@Z%KZ+1YIWXN/@ NSJ_1YNN#W<O]OZNME35E><(A%*
MEK;0H=ZT?;T6$2_Y=NE6Y9'0[@H+0%X%!\W8::TC.?>[?BYW]4$+I1U;\\<M
M]G!1E-T.>:-0B0<Q@6PH,$9YZU9_NK=])?]UW//21J:Z2&["\H13S J;C_Q4
M#9S/V28\=FQ+=N'"&+D&Y !E=(*F^B>3AG=&:9X4 =WX_%;]Q1OLR?V">\EW
M7C0+/UZ\N]"NZDI:JN%=],P("R,=7E?\CD%TB5CYZ4#",-1\TH9A7BJ]Y:CG
MV_KF_$2JJB-.+NMRO%$<^_="*/%.<OMJG3#('P94,XZKKXG8#4;I8O5:%Z''
MFF#_:EPG?Z+UQ6T1//5!#8-SYA7]<IKY,EC$]7NKKO,Y5$D:PG:-S:@=!@)[
MI-(1<-%A7 -1Z.U_-97X+YXK\<^5^.=*/'5%D;LC(IW])JI1<8^W="32"8>C
M)&"I>K=+B1$]<2I 2=$=$M05M=,T&6CTGG"-:P;=,>$/:QGUM(==NNP/F153
MJ%>PYPP (_.>9GJ5ZE%)E !H$B6N59P10YAU]1KEZB0/82BH^ 600H6;DM^*
M^28I;LX^=A>]^\479\JQHP&BXS"">^-K8[@[.LALB"JE?$ZNG:T0)GW?B.KW
MZA7;[B\^^^(+(_12'-^8<G/*_1+^<?7Y_PR_N:;8F[8")95%* VW1ACX$1W]
MF1,:X]'P2?Y%&M8/X1&O#Y+P^U_???4.@VIV+7. 6[/UK?!8NVPV1Z+84D ]
MJW^HB%-S$9D?N9TL!I"B'VZKF_H(!;*>7G>8A!)S+TV0E"9'27L;#B1[$\?P
M(QP@QQ^,M#+2.!Z]@71%D+N@YWW^NX<]+6SNL16.\.21G&R"SQ",X15@>2V^
M29]'+L\<$L2)85>JFB_W]:'77UQSGLHV5OO.FM27J^O^KC%-2!%&+Z V&;\P
M<M.-4I3>A""" :\QJ\/FA[8X4$%Q]R6J>D@ZG'1D8H,]'!,TM9;2.W@]67(O
M>1<]V*?MT@MLV(;.!+FGM4>YMV%OBE5K,N7(#"+\=&C9%)3JF6,OPY1M6T<#
M[)'73R#?X.?&U?_C-*53LCP?J)$ 8/^WO@W;GW@=!'R<DU'S;L?/2[O(J(4Y
MX]BG]-KARNCV[7*U5(V1"\OH1S]F_"9C3NA+RDY(V62'#%M2_RBL'VZQM9):
M82'=S[51EB1B?5+Q $6JL^UT@@]*8Y *::F*$['@AUET>.VF0^6 BO)6+LFT
MSR)F.:?.XET:*5R.J.R?/@=B#ASEQ7S]L5QQ8_,"S_0>8YV79UCXP=HAMCO&
MXQ+^L;NF0#G')L0=\ ,WLQ1,*6W4W:Z_T[?,3YY7GO/$M>,Q&#B !FU$/O7S
MM\,(D#6SA5E?Q2)!PX-S[LJJPQJR3]RH<B,ZUW?6]7A-I7%/C1;F:E+5:(;T
M0RMV!X/!6R2X2215(0F'W?$%< 3-AI$1<G4[ >_RX\^*V%V>G>KS"94%>=<B
M8,J5M?>->'6N,?"I,!%CJJ\;EL[H^NX%"H_!57EQ&1P1/>7S?V0"[5'F?!1V
MO3>O'79#9_V-W%67=?>>'5(WV>IFT[(DX$XBOD"P@]+(C32'HA""OPBA@0Z=
MQC'&>S$;A29&9PX\ACSU_7NE Z(GO MK&_YS]7^H^_2X^BJ,F\[8M^28L1OY
M^6<5.=5?\I;ZD_ &?M\0;A39OE%[4%84^!P X..^19ZXE69[[J+,+YF0\,_!
M//]%W3L;HMXK3 0".Y,]A[ZI;@0;2#37(B2CF3=>@"Q0, K5[(&4C7.T[W%X
M2O4)J\*5Q<+/5/D#%=IIC#=BK&TG<7UW;-RB9I^(R53-#T//21HM7W7':"%1
MZXR.08:03'N34 ?2 RV5.'T.-9VK2 Z]*@]^?H*XI3K\#PIUN,UZ3(I)7<%H
M9Q(!'V!(TKOB/'D=O@?J5;OY?_X'R<?^"2W\_T7_\[_H"_]%&=/=?[T-4?/_
MX S/$U:X?>.)9MX*T<P3UK?%;C1Q)0D#*>B]Z^!:M,'Q(,+J>F*U#]0K&=Y:
M,]PCZ9>N236&:=B^"ZMXV0QLG[YD^_1;^*1M]R)8P37O(RA<,4,US>6KK[]Y
M\=EGGXOWLP4QT6)!F?FQQ:D U@ZX.1X8/[1*_BR;U3%6Z:?@VTHB0R 0QJ@F
MN!-CC3/<@I.;"UL]6(#ZJGG\JY3]/DCG /X-T=3+V :OBRGT1^0PCRD54@*4
M6?<W1UD@0<$9"1,P7E'G30L8;^NAO@H_]1UG:%[I)SPHDNF BL(5"R<K85=,
M.F#P#Y%:,@W&F,B%5PK$>J3;JW7 6->(I0\IHJLF($%12", #RPI2,5-:,IS
ML@.=3(<V82_(F?"]<A@SDIQ[D!3&A4(]#BTC&9GY@/F,E:!XOM^1^T 2)5?/
MFUL VRU$8D&9'3FZ&\O[)0>.)URW -?,:!!ZLE=_Y:_';2'XXB@=G=Z&%"^0
MQ%S##V.)E?+6H5F&V@G=F;N=HE0HV:]CIBS37<<:*OE*"-Q7 TR"_,AKT&MO
M 8*Q!!;][MP"FG-*6P<H#^!N&178ITF(^QZU"6&_DN20=_%B]>KM]V_^R@9U
MWW?]>B>"T%-[V6\R-O3D40#P DL0#H+4&5@N99K(K<ND,2D-DL(0]TW8:1OL
MF\-H.8+R+T<;_I<D*UA(1<CAX7#<#/A)09OI>B !2MKVM+9W_;#;F.5AW1QM
M>FMC:CJJ4^DHMO4M@O"(E(VCD-DA"'M3DSA6LM$S8^D@ ,6!!R>_9;")[F3)
M7+"QB*W7V^1B1;O)@KD0 *482FJ(Z"1XH=D T:VY\>RPX8J2[JF$4>ULX:"T
MQ".8?_"P1_9?R#9P.%3*?K]<,5TZNYT&JD33>G"787MS\6XXJSHC4FV*BRGG
MG"F7O(C6\E[+GI6^5BI)Q2:;30<E2UOB "Z=U/AT[CK%#&;WBCH+*G7@E ?C
M^[C*F5ED-P-^?SKXK;[A-AA4NO1SR.?LL@3G,5D$3JBE^FU5W/=30MR#4],/
ME^V&%*\N@?7YM4B=__[+YR+_<Y'_GZ7(_Z&YM_*%0*FN;;]K>PJ2P'2U"M.\
M W+X:B:__#%"2.>Q+0>(J76U7_6>GN93$(<TFP5'L&#08ZE+D]TZ^LL&[B=>
MB5,\V>OI5VN"(&Y\2UCJ7-Q'W,6=]:UP8!)[_@&D6L*:XZZ3*OS>@!N9^_$N
M&P-*Y-57O?MXR(@3Y9:4$(*P#4;T4L,BHNDVF-E-+>Q%<[),J[(*JQ^\*807
M%GX90%.]4 V<TXJ5565BA281/'4B;&-\GQKJM=0)SM",XUQP&N22\/4<-TYA
M=Z8I.MDMLEFB&[T0RD7>)Q6D0HWU@!V-.62^/QD)HU*V5-T.IXXF7[R! <ZH
M*-'6FWWP$E&4@JX]_.TRNH#<H<NAKS>Y2N6/[][^\%U!3#OQB6*;GU*Z@=>+
MV?,%B0#7E1RC3+;3^3V($[$(K/ 2]PY #A3#@<W(38)5*A,V@>8G:5)SGA/W
MYAZ&\3"O]Z'"57/TISW(I3WTW11EF07QOU;6!1,*2)W&4G2?S-92;"_PBL$@
M-^'[84(.Y_+WL3ET:>]>R\(CYW5N "LB-*HAJ:Q!NBJY_"Z-0,GML-6D;1:O
M(5: ,?!B:M)\2B\"PN$\T_<BC1<3864?[9JK?@)=ID2_DB6CNN[83).4PTF[
M>$_ L-&=3MUC5A(>'7$5JG*93C"(ZO4#O'*9<G$JQY=JS:\V7$1.!!V9(A7:
MD M+S!F.N7]N 9B(ME)&\R#">&5C(Q3.:G.RBT2(WD%S0J^U/>SXA(RL*J$O
M,RRF)1^)QEXS'@ --,U['^+&A(U0GD2B-4G;SLY#A'50[*@"X1F1>[1^AXY_
M*Y@<4M1X<=W?5?G/S+/"";LYB%GE[&/;N?E5?XY=@4A.5*V:UE("RF -VY]H
MF9W@LD;@9?2+W++ENT\I?1F)/<"IS[Y2L&;:5)ZQ9#I&;.8S%)&WN V9?QF.
MEO">NZZ+PG'+X!=.EJ^'C K.6YA5-G>Y[Q#Y&B6I0R8MX5YD&M!/;7OD:9>%
M-5,Z'KY*_/U!:,$#.WK2L3_<$/]&LOFXN89Q$WLE)*0NI; =YSSPA=V@!HHM
M!^J;!K)(*A5N^/.MOQ8<EZ>'$IE2;N5?3,0;_B;3#$FITB,[NH(+1SBJP+XF
MW^0&GYN>TB#-QK:$TE&)FLSFM@U_MVX?-QXU924_,57K2]1#_(KZI(Z0('$-
M4]@7P%=XG-6;$YV3\W[*@9&ZAK.OK%B1KUA99RDW15@+K4?G+/15OD)>BL"F
M=F0>5',/)5E$)*I%/O#MQ$J$"R91#QOGE\E"#8=1SJ=V][LK/*%5KTU<(5Q+
M+=&+(XZ@IN[!!(PX3/#?RTK\=Y$&"]<G:R<Y.@KIW\K/2WK^X]9;W#5P%[U5
MEOGD9CA3U63R<^:NFO_&XIH+5RVGS^HQN9VRY*.X6G1_)X4V+:QY)PK&FM"\
MXR14N^2>O,")!8NZ:XUV3+-D+F!(+-*1O++'VQL/0.YWY@4B]"7&YKF8J+>K
M<*%@N%3ZSV_.>!;T"GT<#^6O-1,,MCE5G-5&>0GPMEV]%Z^>LP-7Q'D@;+UJ
MBF#;>B9MQ37>+>Z*RT-+?704LQ!UVE57N#U$(H7A3KSE<JWYRV8VW4I%-D-5
MO-D"4_$CSMDO!:?XX%[L!'%:V(-QU\<,D9AIKA6;8^$)H;,,4U6<42>,0,6Q
M9J/9QP>_S.,B KX2HN*4[-X!^6VN8@YMT]M]F]9BO9ZLM#(7; ?04O-$$7U)
M5.DS&2O.1+$Y]BY.5FH7*'3E%@^.Y@&LD<8=J11^LX$5::'C<QEWI4^&K7;E
M4FHW\$70*)CEFX#] $Z6UW S+<'&C4UY).<X;G*7:<"2,=J/!ZSY$(]3UJCA
MG &UFE"PT#'<QWS'U4X@'F%\L$1A[MKQNE$HMU96D9II#$+-H83+HNE4GSVL
M-$36KA9BCQNDN159!IDA]3V7!RA,"L48F3MS.$-V4-B/2%H%UZR^H3-.WF]_
M&-922KM"4\ 0@Z/[51O"@QP[=N(8Q;'BO94XQF!(EW[L1I+CY$38U:!ZK<LD
MN.RYZ^/5/O?D*/R<I0)1^J":87<B8[KK[VSX#!;M5C$L1)_R8>CTM'/NREHD
M0$86\Y;+#0AR-\0W%4NU><#PW;UR^J1,EO;,NF1LGV*7T5I<ABW0=REAP592
M@L)D+H<Y14[>3_CQ$%*;(J&-(>,^/AK_0<H!F R:616#(M"S025H^*+!))B)
MIC/RH@2]L76E_1>Q#'0> JGG.@GU/;175PVKOJCPH5QS.B ;9-B.X4I0&D0Y
M2ZP*=4=NGYKZ?HB5BJY<</+D7O=5AH26P(5:2/L(HX:@%211J\%EVW<6=#+J
M_-=2N/_M<^'^N7#_SU*X7W;CK4E$(8G16Y\948 .E\")!0L[;Z#HCAY59@1?
M6T),T8?EWEL"^LZ9F2)'&'BT8R'_"ZY1\7]\:5=]?,^>F_(E8CC?RAE!NN%'
MY2+91.R=OT0T]W+:3DO;6]=QUDDY#Y54*%P XV31NC%Q^?F@)!LW2P!B2$#?
MJ(^RI5R_OR_NJ3C/&Y12M,0RREHB"5]!RG<!KYP!Y--83#R:F8O;R-<*]]9B
MJL+*E*4<B>:)9U7@X$P*A9>&/N&A.P<OH#J3P D66HSN\4&LIF<'Q3D92SO$
MGFD>R,31]#SB2^M4][LIKNN3^Q&H$9E<;3B.@N(SUP1$&29!1S,[3L99/%L"
M[F/]6QC,FGT*)P[?=O8?6SV7E4<RRZM*W2<>S@AMIZQU^$'*+S,),KT ;8N9
M B8/>XSM;[=)>567(FN=L^?"GQ"$>'^OVZ=&YJY&'S!5.-#A89IV/\<-]8T,
MAEIZ9ZUX\]$RNZ>F'^(H8U/'J:V)V%7?-=TI#W%J-4I\ JV@,V/OS .2V=3\
MQ[T#;,4:0+I8$(HL:X0R^ZJ[H\.S. $73T$+6+BTD@ Z'Y]'E46$N$,AY<%U
M<M-(QC+!<VF6U]N\!(LPMW!I5PP2(>WX8<%DJ:)9_8I"S!D& :@>Z]Y*,TI)
M]D.R" 8]I/R#+TL16R)R?=V,.YTI?B1?\8V_7\@49VBBE64O(^Z)6IUM'TM,
M&<SP5;B;Y?KWNR%I6F744X+R]I</)WW>"&T!;M,JF8"8*^F%UB51X 4X1GAQ
M)?.%! OC!!<]$S&AFC3=SN "H(I@JZW>A$]:-=#PX;XQV]>5]O5$P6TQ"%O2
M%1:6^UI4^-8,NG"2GI?A0^-"0FD3+'!?AJ*Y\>7.3A/OT-(LI$F=8?_1\S9^
MJ7;'G-U*"^4.#CJNHEB.J=VP+=KT7*8GU@Z=87A%X)S");>Q6N6]R+5TM2UY
M/KC&+L-ZZE\C&0>UT+?"R17^P\2ZO;AQ,H3X<XW[D;'>\6:L9OYMR9;+QVLO
MO#(SD"A/2'_TT!^%"+3V@O)4)8X]HJ26*PBHHFZ\57'=6CZ2L?RZ'4FX53C/
M!^)BNFRFNT:KF#-$X>R2'IJK>M@L-^EYZM&2MQ-]XD\(24H;4E3"PE<^_;>T
MC"TWLX!_G1<]>["#"Z14]J:/!23P^-)QP6U\^TL8;W13Y[TU&6S'H)3(;)=#
ML*T;J>IM"/XTH[QW)1Y]GY<9.:Y&+R/4%_#N/E21EC$7&;I]N/2LZ"L.6E9P
M<_M2PDNZ4,+"7[<<#;(+1O^%PK5E$>AO"L'+27?H0<RK!)*EEN-^J3"69R^'
MSLWVH065ZDUI9N"EK2RB!B$ZLY%&%[Y)/:HW:5_8[ =%LWKRU("Q@<P#HH0'
M4+[@RE(?1*@#_K8E"F3<N\4^ZB=.OY/3%$O(DR"4!;DLA3!%:R'])7_*9'A.
M=[HL$1W-";-KKT@@!S\G@<J;'M)%,+2VI2B>!$I@.6&T"V\YKNL;:^V\;'MG
M_,+/',:)$%+!?M0W[69W#*YFO[M-&'L(9=7>[(*O,QPK@=LG/1K!^1$7>'<4
MJN'LF(<SM"&+$;O@489-E0#5"7I8IWR4S5.\0#CRVOM[1LM.QE"CEU(1?Y[V
MS!<1$]$MH/:0*][<W$"1M)2?,;+XVGBG5",P*:1>TN< !4C0_9S%5$NJ&#'!
M00D[3KG!93G4(/?)'RV3\KI$ F8MJ3,IH<*'7?2TU?LB@+ES*^QRD>EFZI\L
M&\C9[M*>%R/R27-Q=5$5+5"? @9GF.=/PX02 &G*9E)]# (OX+K7):B< IZ6
MS86VWX5DW.=N7#S<TWM+"$,$)-,4K[+<1ZZOHCOTOE$6\Z[9B409AN49,,,!
M*.BCZ;' <5.'7I,?[5;8$K!AT&!52;==C/ VIH+C^]!<+U3XLQ)]ZG2)Z:$6
M*?8-'!02B<HPS4T(HQ !OV]\[],[:3,XV93MDC5C,&>U_9XD\YG!\:<E$QD'
MPS 9!W=&:[R9I<MH;N7N3SFD%%5B$7=ARQI=C0@'S1RJEN"$$3TMLG#6>43/
MF"%)'^B'N(+ 4%.L0(J3OR"4X'6V?M'I]F2R;..;HK]8Y,)QE#?W<3O\T&L[
MU,PP\/?D@D'@OF0)G<=B/@@3+*3L#2D.F'M.X$G^6HKYOWLNYC\7\Y^+^>)7
ML,DEC[!_KPA6 X/&]DS7;3EF;D0B(XP_DZ?(WJR!2<4LC5**<WWX)RQ;=(']
MO8/D=<D/0MZCV: @6\<6YGGO,A=%-LV:R<SK*7=E9Y4:G@8 5)=]S+83+DCV
M F@6N<=I&@Z->V:\^7F^N%%[=^3>Y"WN9,\D%OD-P2]%5RO7FSG*C[F?B?T<
ME>)B,^;@JRYYF.1:I>DD>5IP5KA]V?4EV#38/54*A<^<_-@1(L0 W.=@I6O^
M+3  -(N3;A*Q/+L#6M!X<\:^Q.1I"T.GSXP']*\.&7:!QQ46]+\/I)A)9=\W
MTG!3H^4F 4"XV"L)(=;0[9-L$KZ,Y_+>7G3^HV^4 0;:,?'7$9B0UCW#HT5Z
M6X*9>,JT08W:1@#J3<J9B2XO&L3###]2"M@:L!<#-]>2=9;KKUT83HJ-R=0Y
MPINF</%CO;'3)"%GAD:VF/CQKR)QJ6[D6KMFC L[>-,A$ALE+(C&R5([U)+M
M,\G&!!:%SIGGP.@+JM(Q-G3,2=;3Y:9A3;O@=7?]7=@GS:UTL@U'$W^E=\/K
MNU?A1]:R)-STN/#-A"-"R*C93(QIWUA\VSC[,"Q5EC*0FTN36-SRA%(3#X(I
M;>O9H#T=BF(L^#/AURDXM\2#6AV</,K=7%W'4J?]B#79$[VRU]YV;X( CI])
M>W,8H?HR<GX7H]R0D205&#:=#'9Y_(;Y>4_:0LZ)&4;PUA+^+*?Q(O_CO#M'
M&VC,"4$-B+V04MZU6 E,TN*-$$:HP*MOMR\WLM-E8-D'=L_"+7[=WKB$?L$D
MT>3N.R:O[YT;M17XH)IC!-RT5:B^,Z*ZCRQOKY0R:13&.H#<!Q&S,2TS6H!N
M@@"%,(A#;5"V-7=N^MP$!7/7]6[+.0LW->ED<.UL)\3A7#X?O+R&"*XCB=<=
M\V'SO91@OI*+D#)N=C'Y(:63%AM+_!3GX B'D>(R+N8V6+/'O;;VH R^C(85
M5L.E&9FHG?ZB/;_'^)YHL.XZY?! '_U]N1Y;1<[*>1.]".L_=3BUH0 =66CK
MAIOE>3(6&YXM94R7 P1".)'F6M\WBKX(SY^.-X4TFO%AZ'L\Y5+1C+CW5"^A
MY*_STIU1P>>TO@M0X65^7\MMEM-%C\X-_3%GZY,8?0J.4I_^Z3]^)E>O*.5#
M $ITY=^+]>2;Y^=T^<Q1F#.$J .&5@DJU A>V21%..C;9=QJ 1IA=,14<)E1
MC<:_WP_2T- CJ?U$IF57,DF)3EG]5=LD3S@F$03G2=J$; W"\(S#Z5,NMXP+
M,*G?SUYBO@$_E38%1OY'J@+/%E=E03!- ]V-W+GJ9>?%O5&.B:0UDR-C*R9F
MOR WJ';#,J[7'HS[O;Z"5EM>'8!'>['Z3ZE79@>#H]47I\]&-1NQ@;@,B @'
M**TY\'VR=B5IIF>J=\U#5!U.<CQ@+0&#2]J__R$(T5\ DZ @ ^$-)]_U;NC!
MS45].? HB"U3:'=48,HU\!KL9QH7V'DX"C6JDH0A!M4:]XL'(;:4V[[9+#L*
M>0#PN%?3*]$LW.\YD%_&%W .TE&*93.7TEB1Z\?JRE*^B],JG=*C94FY)2%M
MU"UC6R]6WZ;.M^=28N*$[CBK-;I!0F/(B5K*G\)FF<QV,.US_(P$V!OGG<<6
M,/XC)S@Z+03:FT^]FH1T3BDUDA*_1Y/AZ-R7"J;T=8.QN#]<^)Q<RA^Q?'P\
MLBK2GF$2V@X69^)732I[\PUO4(DR0_NI\T#_02X%_[KVEKG7>K631 2'@H/D
MZ1N(>A7.L99=;<])SO<DT*9:YALR]%R?TQ29G,/*1(K W:G@KR0@A,CYLA5#
MX)3:+6(>*(#;*(((/T#S2NCU:/HYC*!_&_M@447NRGLR:O=TV?D@A4/>AGU\
M('8Y6OKJQ-I7A<4'^.'T!EABC$,&+ML!Z09XE 9Y)J&%YR! ="0<PC9K0N0>
M&3I]ZN)4LGI6\+\/Y18Q2)PFX^08>U<)EH2GU_:^P24=Y\R6$P?LW\:D!2NM
M96:=(W(OP?-KJ7'_RW.-^[G&_5SCIEQC7@V+Y4DK?:.7PZ%FI;KJ>YFHF:.I
M66W78B\"V;.MNI\Q XETYB=>>FZ61E_WPTT_2)*7>,3#R]\VFXBM>OCM B\H
M\S""(]D/37^K7.1YH"@9UNF:BF6<%81HSWVJUT-S<YC$:5C":RU)'3,KJO40
MS!L#1L;IIL2B<+@Y7^I(1)42%%X"Y= =H>V0NLWP+JROZ^X>H<*%)JIBOQ0W
M7\_;J^9M>O&B7$%F6 5Y$G9&O64??).>OD.?:N3[FI77'0)_5]\MT,]'-R 3
M"\+\;%K $:ZUT'MH4LX>E5^/O8]M"$:B#U"4NDW)=)\ D%[G*[:ON5P:IJ[/
M&Y#B-"S/K8?Z:.FYP1$FO,_(9;)5I%-N5G]MZNOCBW=[.I*OJ(JTKE=OT.,R
MKEZ%*?N$/D1S^L5G+Y//K@&2^>+SEY]:"$?%>HE94M2I5KOH[ SP:ISFG&=-
M2!:0D< I"V.93$';6Q83JUJ#&^?8WO*OI'(/3*#'K[^R]Y>YIO=SS'<>?[V.
MIR(] G$=E8IN;1N"U0QN5/5-+S,V:O26=_6Q/ M>!6]3H?5V2ZE+9CT UDGK
M[PH\EE*X+M +PR*O@E'M#E*_RZBQ#7P] V-89I.3]YQ'=!VD'G"QC>-2: +7
M^*7R5" O ,M@HHRG.)'S\"%X_@L%/(&1]8;>&BT8OI*5G*/X"4JS-'<5'TRD
MQ%",Y7_DY#V(D:4!U>IBJU>C</(RE$V0/B@F,O5U)'.Q;J&AX8*"<58X'><O
M/OO\RVK! L"# 'Z! 0Z*4,.-Y'7@0&=!_W/:170(#T*YEY7Q^[Z? 3*Y+NS*
M$[^AM9G9:\7NS,S@5(7+!&49; A!"?&@7DS]"PR*1?X8^-<2/7V=+$6$[A$/
M]0'=-^<N3)P!;6Z\9RJ$5J4\'6A([]SJI$5^ZS9- #9W8L7/6F^GG5>87*N?
MM-2[0"^O>"DVZYN/9M=/6? SC79JGK-N_U^,&C&CK5B],M-$B$RNSF,8E]07
M34Y_/U+."B6::,;<+3%S K8G_:=(\DZ;F;DE-OT-K+]<RL$WRMU^YQAI?759
M9> IX)O<K!C-KK;9:!IZEI8ODZJ&;UVV+-X@RY=DMN42I5K'^@!D;=SQ%ZL?
M+]X1,\\-V8;5:P:!A4?@G_D_P^-?W=PTNL@TIC\)D.YU.ZP/!.L\[(#YP,8P
M 2B',=RNYM7N^K9N=ZP#Y<1*Z8E["B&49?:NJ=^#Y7^Z;AR$2PT,D]ZX)X2Y
M/&@--5YX,IFBVDH&;QHS'J7YIDRG)3SBC^UR /$__OW5/KCQ%5O]-]WZ8G4;
M9K;N^FV[^N-OVG__1#S.,QY"'S=/E#"S3'9'I6]8>'PHMSVQ[1= 0C:Q4::6
M^I/6>I)7[$5)XR7ES-T!NFQ!?!QW#)X2?I&+-PI/I,VP(^\D_ R[1=BCK./I
MMC=9$CB/ZD)P+>>+?PE33T$QG4VOIBL:6F;K2^^".CRYN.K&WY)F)SNL,G'X
M1C1([LM4AXB)<]D9R2C9-^9EAY:#S+N5] T&2*"B1*L8-^'0Q%%['FVO.SQ=
M-]WR-.T/X7W$V:RE47$UOF]!>ZJ;F9U,81;>6&WEU B$'(F:$."Q[B$_$8[P
MH:.N0:['3P[P<6GR<FP3-&A%OJ,HJ6QS0[0 ?;VA_Y%NV%S=^:-MT'E>0\<N
M8_*_7/RY1-:Y0)Z4NBKH5[7 H=3K4#$=KJ+!2;-)&K!ASL"D)/;I#+L .^(R
M;L$R:$&/<XNZKJ.18.TO%21.QY1C8"K6*P@].C\E%D07=CCH4@2*QXX:@A<Q
MW(GTOKYN5.>2T!M< %4B/5Y1O6$Z0$'$\4SQV>H_(<+A3\"!8#ZF*U7I7EV1
M,>B\MA;[">R#T-0>NC!7E)/!>:(J@L)Y/L"K2MO7U<.<9V:4<S,!?9UX4E(N
M?BHNRMP]L-'_K\/NJ"'.%[^-)H4P-E2W)&KSA(R>\BAA 977BV9G )0=-:](
M%"!MS(JU2S-&?!.$77UU@)">13B[L-@'RL32[B9AGQ[:<\D&C_P\4X'<!I[-
MUZ]<*ODJ*L'?H)JK#>=ZS!;*RA)?0+ &P%@S$F,E.GV5MNV+IYRS5V&["A@N
MV.7VNN^#_>AJY7B2P8?)X.V_Y[R8CG@566=!9(3LO:+(7-ILWBO%Q]2)N!4<
MHU[%-B]6?VYZFAK&4%"J6 _"8IJT[4Q8/?KZ'RO=-B0,E=%/_#FIM3QO-C\D
M;U\SB)%A:3W#SF$X#EW#9^3S:A6.R9?L6= 75'1BWSM9S0-H#*!N50]F(%)I
M2EB_VWX]2\G$IGOX9M_\N/JV00:/)S_A1?1Y+-]X"1()]W@DF[XY$$"C[N)X
MPC_2[MXUOL%%FY7"RX6]Q/E?*/-R!]2>L#DWR5<X5RSE#_INFCS7! ?^-!O$
MN#)YU5^-%/OOGPODSP7R?Y8"^4- D F\[(2@>F8%^"I*<-.Y/'-D71GG/.<Y
MP7ETP%Q5VIE#D%_UXUC.:)QV)R5M=9+/+/,D4\)-QQ"Z+!B;%-811HM<!IR1
MDONL^;A@MJ4C0@@_T9T=5EB!G?>5W@LYN-@G-BMAE!;3<%^\>$ZT2KOFB?IJ
MHA1^Q"/0P.EIXMWD]\0<Q&\/Y;0V//1(!"H<J#H"1X,%3(/(R_(DNIRZ$D(A
MBW[=WS58 .R?V6LN\:?'#J;(!+05-"'H=UKCW59JI5A7\%>G6].SV(O.'B$V
M2'W;4_JGYCUU[P@JD1?G)1S]&KIA/E$,P'<FI<UG@+LJTE*>'G\&JH\L4&NK
MA:#Z-GCA%*YH=8]*_9M^?8!'%PN(E*EO&A-)<.25?JNUE'3AU$CT_6MC1M?X
MJ2"!OF2RHE0W0@OB'.V0'2CL/M5[&)MD5(\+/7@+!?!VG7C_6P#.PP72W(79
MX?\*Q^# )WBK*&5=&Y[I9$;QF3XY%K^QVMF\4"W*:9>T@NTF+0 #B2-A3[90
MP,V0O0B_.$[<H:K,&+MVVX"$.J$'61Z(Q!?VD_IR^M.G-HS*BG//;[[D'@]0
MVL:@-2SOWI$I/7S]WSHQ2]U/2B5[L6(X,$J(!H8.M]C-R%QB;<?]!E"@E;8
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MTP3995+WTR2R1+'6V9)PV/["_IO]/'<W=M QXW+V#1XJ:\FB7H73EF89_$5
M(Y0],30@.^,<0IG,]$)Z8V3?;.8J2*+IT6UW="V$1U%SP)BA*5!G:"\/5E0@
M<0L">$Q);SN])R!A]H+L@W+M>A0R MQ$J%8PG%#_B7T:Q;2&1_2[VPB(*TC-
MZ\81:%J2=JF2=XJB5W.*P.27Y%=*%A3B,JP8E/#K*86KG[.P&Y+S&?DD6 TH
MR@==K/[JV/5%,L]S5Q)5?AB=9&4=E'IN)G+)HM]X,P&:AV;HQ-VJ5@FFF_[!
MSF0CM.^$X#-M'SF> [EXOY:*_+\^5^2?*_+_+!7Y9?<D":]+C<^MM%@N4-*E
MJ=.TA5@]1FT?SN@N;FI 8N<-\U*)A;:W\D(O7+;*'JE=H+DJ+MM8&#13>#L0
MD<KIYQ+T$:DEJE;""?M9?3A/J^VZ2%WR!.@9!?3AA"Q3[CZ6)6YVE/D#T#$F
M83+NL+DSV+%*2U&0W'<0 _8::V7RQSFCO9/<DP01#M(I<6;OJ G]EK7HGI9B
MCELY%VA9$&G^V>K,2S'HLTSS+QP+OF7WG].HEG +4_+?AWK24M=<ZJ]8/EKD
M=A.:Q94]-M(%4^'MD2O\LBMEIV@YD>KC-"H1>9Y3![ :>@X+X+Q6&!OE9^MV
MPS$(T-4L+I94D2+B5'@:PK>^^(S37D< =6%/0(!6#\$P!<L-"X(2I1:]"4^
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M-9_)!+KLILT@7EFQ,G,A@#0#174J9..%@?C1:[^GN8YYN)8HEV6/L#TKNKA
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M\?4R1IA3]^)+)WL$181:&7&L)^&0-YO0FTKEE?S&*]*BZP\W5-.IH?A%_M%
MW'K&(,89NJ2 $ G2.%]_>0CW1<=4?%0@L'-%U?DC<T0$]]$Q):1)HIEJ)'F"
MO$ "ZEM]_\VW[Y!VU^REEAC.+%:I2,]$I>!96K=>[1M]O]75H:4VO9OKXTCT
MR=T*KQ^30_O]H3->[5W-L^0/Z2Z2]X19H9PD(#+HHE-.!%T5<I8I$24\3Z1V
M<-UON%>6FTI)6XHEG1Q[/:8S#&JO)8ZI[W?C!5(0Y]>&F??>_+=T49* N/W
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MZUE*_-/<QW3%_E5TX#307H,>(5^4K:,061CK8E1CFN3%BEH7Q8NUB? L*$Q
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M[\6^:/0%1 !;5.=U>4[DANYGRZS!1LG0[@$;)@MA,;9S@D#&"O]C >U&I04
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MG%D)L20X2EP8278ZK4Z L]VZ.$[%.T_$XL1V\T,&. %)'XQHG-'V2'!,O"(
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MK60EF9$2L5$J 6@[PA6\]IMA"8]9BK) BLBI+TY!_6!ZTPE_.Z<S;V9AD-<
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MVI)GTXM# S;M3=-]S.!5XD9;5NI4Z3W9\1@=K?5[:.1-ON!F'PL$+6S'<<2
MSPV5,X^_U]DHP6M'GT[BY'0YM"/#AZC#(PY6.)O -H*%3H8[C%8[$/)!6+YN
MS'^*F>Z.&V<O,%07"19=G(W%A]RV ;4/SWGF?,W6%[D8(D<JJ4 >]07Z!<QU
MYM=&EFEF^+G]\_ A8R#(7@04+7T_$1_I*M"9J#A\J66/K8UH&IX>MKO3*/3
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M/'9=Y-!I#3&O>#K=E/O[M:5U/;?O@N3*<DEMI]O<^#9:IUQ*30)<3&[^!2L
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MWRR?K()&,8T;S"R:\WP&:NM.<7Z5Q62I4XQ>/"1FI?H, %63-8Y8RZ6@GIH
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MS,\!M0\ ><I^K\3H)ET_157=T(TZ6?.G3NMQ_[B\S)=GW!>(#15T4ZH<>[)
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M-N%FK$A3Z^[5!3BOW!-L77=4_L2&@%/8,S"G\WE'-KK[ ;C83;YQ#3$\G2S
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MTZQU5V-77614J^RGQ OL-JS*\YG?@[+XF)?%F9-4O)\[8H; FO^^Y6E&=5H
M\27Y+BV:;GU%AK\18A*4$[T4MQ]5^E>^V1J#E2&S:X.I%5[,X+9W.%:VZT^;
M;$%D!W773,7"RI89YA#$Y'(G<4D5R[UR:['L-\V%H9Q@LFT74-.T1"^*2$:O
M11",NS]CZ3"S1!Q&HC%#BHHX"R@%EH-!A^,0R\\83:DQU128;'!!QAZRQE5*
M=AVBDMI\U?)5MLI+0%UUF5 0K-;)';\U7DK9YF.CL"RFH#A@\^R;,:$.CT]:
MYP*U=^D#CWG;(C0%7"]0MT^&[FE&5[DUVG"=Q;YVBK.9J?=]-1T3;BN 5B!
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M/@+UBX(*HE/Z(^7S-J>& :#J<3D4YH2P/:?K!4/-9GC?[-.2'1-1,S]T)QJ
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M(*1W;&7<JSRD+-]1#]2HBY173O&6Z):R&$?"0 2G^JWK3R<AL'R5Z[#J.%$
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M&J.'_[QB18;>NT&1XZ^P$< U_4)!YH/A*HU0,'$1V_1>\^@&'^- M2^!W]Y
MHR K@E@S:HW#&F*7W"FVK2D#)*OXIW$@93C[G#(:9NR7,$%PO\8A]C$(BHQ#
MXR_ ^J>F*JJ]"/U,?RA^\ =D:X1C09I",OZNFZ/<0.\D(6*%,A$H-2P@XE8U
M>AE7Z\=]4GN@W*=J;XQ098/D&EL68O?= K#7.)1>ZH2ZMB5"_ DS0B[%3*#$
M!QH18E$R3@KF9#[3\YJ%3V!P,05;@!YGY/1@T6T6ZFFUK,32'^I;UM'&_U%
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M,@&O!$/)?/FN]WN[OE[DO%A_/DJ%2N+!2CPU+8*:H!\!>,C^#:W(9$HQY5X
M<Z(>/P![I3FD<4C:'EZ0N9C9X=B@LMS$TZ2GR=DT^99\V#IU3A+CA$,=FM9
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M9#K6]?H)),]Q2#MR*M%UCHC>-71=E.)TRCDF+&_\(4;5:'\QN412B?8VN+,
M5P8+VYG![)M0=\/LH!JZOV!>]NN7).ZK5]42D)A?@]%AQU=09!7I1\'E[(H
MSFY5EKF#I:#"SA++Y0X2<)%[TP)4$=;$0"3*SK,WW\A?*A01R\TI4]T0Z_*I
M\C_@Q,R5AT25,N#%5$^UFO[JNNHTDA>FH/':!#0A;2&=0XY-KY*\JV9X!9+H
MYMR@1U.Z*=F@D'Y?\36F&)#R 3B_H,TKW5/QF[H47G10 </.@DF1(:T2ME!R
M26+4:L1)N!UDLM$^D8"2S[,H$3Q. FP[LESG_! RW[1>+563ZH+UB_JKXL1"
M!V!5E52^5E'_L/00@HW$8,4AGYKKU>649HH!)%%RJ10D&TG)$K0D+]0@%'8>
MBHW$Y0M%*N)4Q(?Y;'H[,$ O)[,V(>8C'V+V(68?8J[C6Q*_2,L%JV)'8C/9
M#$:!*M2S(@O%=,"%B)*IR#+T4>^1K3&(W$Q.R$U2FC0F2:F7872+<G!FP-)6
MBO'%XOY%E9IF$5:B8"4C](E4D#MC_?VP<&J_7O-494_)$WK;E">D[](RE,Y?
M78S'DL-73'>]?+U*;0+#3.M)0BY)1TI=\*T#45)(5(=P_T2&U<"^R^W PRLQ
M>>D_QA>#2T>8/+I[+B[#]E=.:_HYEF("<OW2V:_\K6U!B&:'Y4NR3I.;>'%.
M97<'I!M]8(4'#-CDO7;#N(#):XEE!.23<T;_^N.SN"O2)]RPS/M[HLNKM/L0
M=>S.2*;]='TZ9JW;LS;H;CCSXD%1%\G1D-Q^4UG/2^53[]VBI%I&JK(_BCR,
MPG\C'I:[ GCJ^>'>D;E1'5/! FI%H</TI"_@.V)^F>340@*'>T?$_IM*JW[>
M.S[L[ND[BD$[Y$$)5"/JH&%=(D!;_/!Y?\\:]B6-JT>3ZV\()<*[!($5EB.W
M]56GUIO0<?.\USOIGIA08TRH>>I5',&!PTS.JA*&?/'\J#S@<?=P]G!/=!':
M8##/+$SX"P4A\5%6['\C7\I76;$?6"(_6QX<HD*V+I=Y5TNRRK!<0!B-: 0O
M)$#WQV]?,X7+C8D-)S!.Q*0G<Y<5>2)X?1'SG7$R1(_4($RF@NU.V) 76-I9
MAC/ 5!&#B""H0;Q%5G=\9K<2'GU/O(J*?>'*@PD<4" H+\MY>!ID.#)O85(+
MUH9][\?!,!(+A!E8N9K=X$PE<RK7(\W-#B*1THQZK8Y.D?,Z!&^^2H$ =UNL
M^%%F#P9Z"NG16'H,3RK'-JJQF)J7 IN);CMX(4KM""PEF)1M^_T23U1,@_KO
MB@?@/&"EV# CSG+8+]D7-).;_=,-[9%+XE_%Z))RR:Q2YU$XE@Y#W-4Y='9J
MY*" B81D3"$!,X7V4T.])HW*8O8)-QH=0?;V*<X,N^C$]HBY2MK4-_0;)'%@
MR0Z0PKD>136>@7/TP)F^(-MQ:YQ-DTO.@?+$4I!392M4Q^_I9G7I9HJEKI\3
MP7W0A8Z* *!(>/KQ]#.;?J[#$9@0OX9)-D3<:,]W/-W,03?_#O.4>5+QI#*3
M5 1K29G7;#S9W(ULSMF 0;\R!K+)4XRGF-D4DT!Q(2\FGMEXTKDCJOO'\W>>
M:CS5W)%J;F/OLO%4<T>J>0?.?V]P>ZJY$]7\%4HF/:_Q5',GJOD;_S=+@T_A
MF <7,[G-.F3L'ON,79^QN_H9NYX%>Q:L6/#MA'O_IZ>;N]+-YR2=7H7#X*])
M!)/R-.-I9B;-?$L3*//B1>;M2T\Z=R*='U=A.@K^RM))$@NNXV,NGFSF(9O?
MA$)_^W-%N<V>IYH5I9HPG;*?P3<G,;N%<E:RC\L/75B!;HMI"B@(A'#/*/<W
MA,K',:$@9K((G^\(!@O0WE2Z0;_'T@5XZR#GHQ@A,J)0_$ "QFC8_*E./Y8%
M0S'@C\0[6&0A+A#6_LO*ATXP">,BHU96B/,)_X#7BN$('=)-7 > %#%KJH.?
ME<T<7&%A?=WJ(8TZOP'8D.?[^U8U"LSA^='^<5?CQJDJ4ZATO\8B&2S3BINV
M%2I<]O=.NST]IJH<F#7=;O#W3!71] ]_R0J76O#\C[N'XES%'O(=Z2-"GJ X
M1_ENBFOY[$U^)8BVF+Z1R'X\!1=6&'&-BW+\%"^3">T(@L\;CT75)(F?QG:)
M$2.,&JJ3<T:P2)0Z0F+ES@M3DR2.RI0JBJ/9LXX[C(,8T.Z1_')5U/92)=-#
MB42IP/#@\,BJS,F3X/GQP6GWP%#+#ZC+DZ@]F5--9.JJ&()9-&";EFNN5J#(
M9Q;EZEJ>.TA/FM21>+FD+7".#<G[YGC4H%[&=:?A)XX+K.H!@T](_)Q*;U>J
MYJ5H60I0+7UJZ)E&.-SO'A[\V<8R*0DJB_5;@P,&[CA*;EY=A2.Q9_KO'9"-
MK\BE>R/V:*8W57_/!ED"59KZ"CZ&G]6Y[]W^<9EH3MHJ)'$4X VA0E%7JP>A
M?]+?VW]MUT7:WOR2+E Z#=*66I2,[M$RC\A2YJJGM3VGU*H']@^ZO9Z_1OX:
M^6LTYRG)(]G;]T>R[".98>%ZMO84IX/VMNOQ:+LY4F^3>JARTTU_0L\W86.H
MN'OSR3UXRRH0>$;-KG%HN$KW>P*8!1P<K5\O@KDW;0>V30"K)<Y7=4O(J*S^
M=T'[(Q641GJ1$WODS6G,-;GS=GT$I)QT2XCG(>0B=A*XSE^>]9_==W=.NWO+
M9S5SDT[-9KW3KAC<GKM>RCL^],L@W7USQV<008;>]N+YYY?N*<X6#15[WB1B
MO?K3<,CY>*S.#QVW3WEX3@H/>C2.N_V2IW>'/G)/M-E%_NS-P>[A;O\@<"3J
M(EA ==L>>V?F7?.\>L6#;=BY2>?Q1<:=-FAF_9&GD3OM@F6@K1HWF9\DGB_H
M;H 5M&H7PY*(Z!>VS95])VVW=8MZQP?=?F6;[B%SUDV&'._V]G?[^XOF#ZM"
M_$\F,%9EP>T@/OYT'^B+6\/U/<"QM5(L>O_DH%OE4XLQ"]:-:Q_M]@X?@6MO
MNE9W3\U_5?:@ GCCCWV!ROQ&+?D^>OR:R('#D^[1-FKJI[N]@]U^U4CQNMRZ
M:NHMV>[^<+VBOK:*^N%I]\0KZN17VMOMB__K>95MRS3UEI(43P)>:]\ZK?W@
MZ&B;U?:%"X#MH?N54]N;8?K\V7JM?6VU]@/!7[W63GNQV^MYI7W[E/89R!6>
M#+SBOGV*^T%_,7)AW81 ?[=WY!7W35+<9P ^^ /VVOO::N_[W3VOO"N'R_%N
MO[H;7FO;;.6]&0??4X#7V[=/;S_:ZQYLH]Y^@A'7A?/_[:'[E=/;V\"+_>EZ
MI7U=E?;#_M%BBHXV0&L_VNV=>JU]^[3VEKZ<G@2\VKYU:OO1_LEVNMN% .A[
MM7V3U/:VKN[^=+W:OJYJ>_^T[]5VS;4/O-:^?5K[V90@NC\G$0<$[S3X@?A@
M29I[6O#J^_:J[_VCO>U4WZ'0Z6"W=^HUO(W1W\_9@$4\SYFO3/6:^T9H[KV]
M$Y\FHS7W_M$C\.NMUEW6075OZNCIS]^KZUNGKO<.#[8S2:8/ &)>6]\@;?VO
M27[E4V2\QKY9&OO!H5?8C<*^M]NK NMXA6VS%?:_\7^S-/@4CGEPX2M2O=+N
ME?:#WG;ZV ]W3QY! &P/V:^<SO[NFD>)SX_Q.OM&Z>S[O<.F_)A=[!_]!*T*
MRW.<\X"6VH3[+&;1;19FT"'<-.0N!E$XC&XAP6(D_JZVY%[@V4O!U#MI7<2O
M+!,3@>;J>1;PGU,Q'C O[#8_39,QS[(P$6L)_E6,+K'E.7Q30./U8!S&+!Z&
MXLMLF'(>PV=94J2"]^&O1DQ0B!@?&ZN+'X^HTSHL.,BO6!YD5RSE01:*50JM
M> "CBO<%0_$Q$QN6AAGX/N!I;,E^$^9788R-V =A,G4J_P,Q?)'EZ:WJ29^I
M33>SA/G >?3ZP52=1$XG82;V(N5CGJ;8LAY:O\/;@+C$;9A]COC#WNN7W> =
M&U[!N^#QV<\%5VP4L"#BXG^&8NM",54>R+5REHI'LIQ=<B2GH;@JN.01!Y$S
MU:<R3H:%/$UX+HS'$9M,L(G]+G1A#R>3(A;[#0RI&[PO4O&K=)*D7.W9,(FA
M$UW*8+) $$Q3<4Q;E&++>+-;*8<T(3CX(<NN@@&+&(@^04E""P6F%CP_W O$
M^49B$IT ^1%\"D>)APH[UCM^#:\2YQA.\=7V6+!BZ+8:/-_?TR,%@GA@B;FX
M!O"#\R@!BNP&9U%^E1275_BM/4USI@.Q9S?!#1>4A[LU3E*YMC 3(T^+=)H(
MFNT$<1)S.D+QMS68V(Y1F(H3%:=B;8JDTN[3W&-@,<-ADL(>1X+H!7=D%LN!
MY:<\*Z(<_\P*08W,7J;X69SDL%HNEB&(Y(H#I0!9#8I<T$Z6 S&&\74278M)
MPZ,1_PDDDH4CGB)5T357G"$C^DGQ@$?A6&PYZD% QU?B*B<I#B\YR[_*MQ,^
M3Z8X,I!3B0?(->E;76DY:_78'8I[E(*&<?4H374;^S;V#XQ<E>RU!RJ^.]/_
M</HU:\-M1TI>V7#,6H,4BGW4%"[Y#G4;9F/QYE<LNF&WF5SFR4FWK]M:OM+M
MNO9A.H?=DY,_!^:?L!V5C9NPGSO6CCDF#SVE/D*50GTVH^7Q8YQ!2:#M6]H,
M"Z[$=?_+LS_]^'I>4AQH$/BWT,>$\(B<QI7RHV=O?N!]!K8BO@7"UEH%>V.=
M9CW%T<QHSW9Z>UTS6[EIYD-WLRN[2%^**S-\ ;\(_BOHXY,O2_OK')-CJ](+
MZ:.&X1_U6"P]P[!/Y+]=B&X(EIF+B\]U+]/@&IJ&"JXB>/- *29#XNUB?LGP
M=\$Y0F IXO.OPSP9\)1:C.[O=<3N")L0QYU#X +_?X6'B5JLOH_4_D[<Q8A-
M,_Y*_>/U K9%-YHUCH(=U?P;)[$3L=NDR%^-PY]\9)^/NM%$X*Y?1%D4\-VN
M_45-A];[SK]LVP #G&'@5,R:__S3Z='QZ>NRV52R?9I-D0<M8,Z+?S8XYU$$
MY>G"C(^22SOP5C%[/-UXNM%TDPU#3RF>4F93RDB(K]S)P?7DXLFEB5S.HW R
M\-3BJ64^:DE:NX5[TO&DTT0Z'S]\K@U=>9KQ---$,U_3XO<&M!=/-IYLFLCF
M6YK\SW=/-IYL[D8VW_EE$169)QQ/.'<CG(OI;=J )>S)QI--8Q"HN9_O\LEF
MSU/-:E+-_RM2!LDIS;3BA%OU"2(?T"'9)\\"FC-H!EDJX8308IIB=P.>WW >
M!S&_Q#AC\+S7ZW>MS(UX)#[J[HM=P@^Z,O=$D*?X-63!3/@H%&?8_B((SS[O
MBY%/]<B0R#%?NDTW^#N&%.'7_<-?LL+=<-S"X^[AM)25!A=)7;>:=+]G;_(K
M<>[%] W%)*<\A?R ,*)L*GC9\4)?1J^A5UHODZD2,PY*Y?R(G\8!!)F+"'-O
M6)"R^!)'*8WP1P$ </*88;,Q*>O%X#:@&P@Y*#S+PPF. ^DZUK&'0!$Y9?:P
M7"7LO.P$@@,,KX(;E@5L.DV3G_BX.+/G^Z=[W9Y^/D^"Y\<'A]UC]0E$>L-,
MIK10BAFL&N?TFY@C)JA  I?8&?SF,T\OQ3_/+E/.,64**.AP[TB0HAIR^6F#
M=T@5O(/0H6D=B==+ZH+<@R$E-S@)"Y EYF8KX"=.AD$UP0 ^(:Y]2LD$>:KF
MI:A9RIW9V?PG_6[ON"T[UN*?UN"0(3:.DAN5$*K^W@&1\HHR9F[$'LU,5M'?
MLT&61$7.]25\C'R)EJ17))N3^B1=:Q3@#G/F*UO)4@]-1S\Y6N(163I0];2V
M[Y3DD?3\D2S]2-HUVH-N:]J_9VR+.I_9U6/.W9$B1XI099A/?P9BGX2"I#(R
M'[%@HY+::W2$&A/&U1A(,;@-OK )U[K!(OA[TW[D" XI=*XX7]*>U.P"J<+5
M_U9V1.PG4,Y?GO6?W7=W#KNG+=OS1.32F(0\QV:]T[8 ;L_\M&;MZ?P/_3)(
M=]_<\1E0X#F][<7SSR_=4[Q+<:BZV]7Z6'E^:'P_Y>$]2C%IBX]S4=Q@PTNL
M:[2I52.:^<GA^:+J%%%EF7L?Y/O7I+*QU]GO'W:K%=CW8"_KQBZJD?M@T?QB
M52[#8S&'C5K?@^R6%;O4O5ZO6X5"6XS.L&[WO"FKR^L$"]0)-FK)]U,'UH0Y
M')^</A @<DWEO5N?XB6\E_#K*^'W]\7Q>/F.>]&2H^)%O!?Q6RCB]_O'B]'^
MUXT5S*C]\3+?R_SUE?G]?J][[&4^[D5+^827^5[F;Z',[^\=+,8B6#=6T 97
MX@6^%_CK*_![!R>+B<QM@,#'D@)OVGLQO^5BOK=W_,#V(6LJYJL@,%ZX>^&^
MOL)]_]0;\W(K6HO:O9SW<GX+Y?Q14[^!S9;R-<B 7LQ[,;^^8A[+OGWGD%=[
MB^@<\IZ%Z41P\WSG5\'85Z.5R.OM[!Z2A3];VH=,4WX=)D4FOAO020UN\9WZ
M!(.<LTF 32?BF%XBIOA-3/I2;*23E#U/+Q)#&6O3$N'4MT3P+1%LD('M;(DP
MBY.;9D(KT-4FV.IN,[Y[A4<L6WGLJ;-I<LD]TIVGF[O2C5!\0P_DZ^GFSG#S
MEV#1>=AP3S8>-MR3S3;#^.YYJEE-JODM3$-$$YV/<%8?G'5^1_"=T%J?(Q:&
M"]+:[QXL J2UU]U3PU0A6N=?SH9@MC:\;$,P6WO=OCYK0&SM=8\,"7F\UI7#
M:SUY.%YKKWMZX&$-5P()M#D-8*E'Y,%!/5[K:A[)K&0+S]F>YH#N"MA*#,T#
MMKH,W@.V-NS.4;?76SJY>,#6N^B3JX:]N?!LSY98W:+8P88G07O$UF:E94,A
M6_N=@W[_H;7>LZRAU608CXOP_!0[LFSFL%'K>YCELE*7>B$XS$L3>8\/S>SU
M E\/]C@JP=HPB 5@.J^GU&])L?%2WTO]-9;ZI_V#[I&7^;@7[4D*7NQ[L;^-
M8O^T=_10G(CU%/IM^=A>ZGNIO\92O\727VQ-^'J7@)NLHI0/.7"1X/-_LLGT
M]1FD%\49&V(]W-.5>I=G3VEH4.K,;SBER9G2NIRGDZRC$KS$H#!_S&Z+QY"7
MB8E>D#RFJZC9-0LC./Z.2H3K[0>3),L#6+]X^H]"T-[X%A+6)I06EEO[  ]9
MA8RS:KQE^AJD1[(@@KK#(8M'X8CE7#W,61K=[F0YHZ2Z813&.,2(7_,HF>I*
M]G$R+&2AGUQ@Q":TPEW(Q HGDR+F =[;N:JYVP^\H2)TJA]R=N6!Y:$\R,7Y
M0_[?LFM$.RM=)&I3'LYL1,^)[])@+!Y(4@E8,$R*2'PI9C&D"R%I6>?*XJ:8
M\6 8S(\4&TPT*QZZI?I2CC.B9,J12L]U+F13RF_3X;X(XV%48%+HN,C%*4":
M)1=[) ABRFYQ.U]BA:H8RR:T3F">A)'Q(G$F,T2A ):/.D1[#))0(T&*JI!V
M.>S+K;)MO7+()F@K56IM2Q9UWTZ?G3N)NB5YVDW(K:1/M\_=ITS?)V6Z<KJ/
MGS:]?]0W6<TR<;K?DC@-LP%9T#M^G3TL>7H-X$+Z>QXNQ,.%>+B0A5H,JUB,
MH#;R =4(^SV?L+L22>Y-[HJ^3WI?]A&UNI/Z_@+Y"^0OD+] :WLZ_@*MS1'1
M@OUY+/L\VAG:GF=H*U@#M[_\BJ9[%\"A1SAXR_)%U;_U5[GX;<XBK3E*X>ZY
M.6V4\OCU'W>J?9NY5S\P:N')QI/-G?;J;/A'$:8\W0;"66ZQ;2O9K'ZE[4>*
M!='V-)7=KEK-+.H"*U;ZN.BDN*/=?F^W?["X1+C^EN>']N]"-$]4)CH_.7Q+
MDYQCS]N?GB0\20!)_'=R%6=)+.4;Q+X"^9&GD'MGTZZ>8'GZFGKP@*S:M5A0
M/N[)X=X#>ZJV1UQ74Y<XV.TM7)=8%;)_&BFQ*JL%9Q)D9CU.K80_UN4=J[C8
M17KK#_9>,GNC%O> Z,1*R=K]PP6(V@VH=MW?[>U[2_[QS;95V8!G;SZ^_QR\
M+;@_\:TY\2_)-1/+R8*S#_[4%VM\;]1Z[V-WKXFX/]U&R[J_VSOTEO5FF&!G
MH?@@6VQ#>G^<2SO.#Q=_\^?H#>@U-J![G;V]10C5#;"A>[N]$V]#;Y-%=<ZB
MVVF6@#C.^?#*G_S6G+RWI;TMO>6V='\KP]0GNZ>[_7VOM&^ \?7VX_D['\O<
MM%-]%X7!IS"*;OUI>L-ZC0WK?N? &]9*YA[L]OM>S]X:Z^ISF":+=G&O\(+]
MB;_Y$ +FIS]P;TIOHRE]L+>(-+1U$^N]_FYOMU]M'.?U]/6SNKY^__CAX^?/
MRA,>0Q68M\ VX60O6)R,0W^4WIA>8V,:H'R])0UIWOV]18O<[=8[5UOQ?O;F
M>S+BR>-YN5=X[?[PWYQ-+KDOM/9&]58:U8?;:%/W=_N'WJ;>#,OK&S1 2AZK
M :4_V.6%-W@Z_-V?I+>HU]BB[G46 U.R 4;UX>[Q;J_:"=VKV9MJ5D'I](_4
METYOSXFK=&]_Y-Z6WD9;>K^WG;G>)[N]:K=SKZBOG\EUGL3CJ( VL\&G<,R#
MBV&(/6?]X6[ X9X-(VA7[!TEWKS>%/.Z[VUK65/=/UJT#-YN/72U%?%G;][R
M*(Q#UB'(Z(_QL.L/?VL._YQ'_)+'/#A/TFF28@=M?_S>YMY*F[NY_&L7.T4_
M_H'->42/WF3;GA,]!?]^%>9BEX>UK85XFERSG ?0SJ7"19;:%/PL9M%M)JR5
M9&SU!?_.!6%G//C,TTN>UK<'7R!U2G6L=]*ZCD_%,!P%*;\.^0T?!?D5#\9A
MS.)AR*(@Y^DDZP1Y@I^+06$9\,\P'D/'>9A[<,.R8%H,Q"E%MP&[9F$$A-N!
MM4=@AF?2#(>7X/HGM/[<6G\P$F/%EP'<9'C=?[.X8.DMZ0?]O=Y)\"+E8YZF
M,,4D$&^$60"9BFM4TX*]9:OQH=[KE]V@9NEY(L@MF*9\$A83>-.095?!2*@K
M8CQZ-V?#JR!GT VM$[ H$;.^"?.K(!'/I\$?!8MS0;/04E$L-$^%F=H%HU5,
MQEYP1VSA,"J ,>&+1T#(.#1LYQ ;]8GA4PYK'2=1E-QDKQZ1L/?F(^R[;?6F
M-[WO'?H.G2O1S]:W'%[9(VI7WD[\!?(7R%^@>U^@?2^!_ 7R%\@WO5^C\VAE
M:%ZE?IK3N6/3>SB6=6DN/+/][SE:U\%;87)O3%OJ._K@F_M2+\P/?[)!7<PO
MBO0ZO!;SHUTZ3R9BEVXWBWAF[=9RR6F_C0&M&SE]0V^IIZ4'TY)X%C[\R[/^
MLWMN6.]H?01;#259G>S?*B>UVJY!^Z._#-+=-S-_-4Y2&L^FV=_X53B,^$)?
M](7G-%XREA>#95?N4S/O5=V$9CY4,[V9S[QX3J^:3$#7ZAV_SEZZ%_@N63RH
M6ZU8K^>%I_CL[?:.=_M[OG/" B/?)ZO7'7M^BOA1_/7OW\\ 2RI[C#3=K::,
M_;MPE)6CC+^%<<Y2YF3Z!B^^L&S$_G@5_.W'][.7FT,J*E$DZ)UT3P]G;8X=
M_]R[@_7_T'2BI<JB^2GG^8+NSYTD\A/=GWD2CN:B(2&,J] 1=]57UE#_.%V\
M^K$JE/\TNL:JK/;9F__E/X-O5RR=B'D6N 9?"O(8\<.G/M??PE2H@PV"_[>/
MWS\N5O"ORL)]Q<\CAHQ6*MWWZ,&"=P/*?4YW][TGX"D\ :NR <_>?$V+WYD'
MJ'Q*8W]5-N#9F[/OY^CGF:+&9@3ZV:\?OVZ0);\$&;_IZ[V/D;XUFL"ZB?V3
MW5Y_T9V3MX?:5\L ?Q^F?!S=BK&+]''\]ZNRUFTSP?^77?.W3!QG:@3U_Y[]
M]G9=+6_M7^^?=H]6P[^^58M?"\M]KNUY]J97%5Y;:+X?87L);[UOC_7^@^=)
M' Z]_;ZE]OMOW[\*4]TRW,4'&V2XKX"47"G#?@7V8UT-_WD5B8?UJ5I'Z_\
MVD#Z^/MFF/\_V$TVOHUO1R,/Q[AI#H"O\3")D^NF]+NO7W[\G_<%>%_ UOL"
M'IY#MP&^@'U [O2Q_*WR!ER(YV,?S-]69\ E_[\&U>#LP[L-\@KX<+X/Y_MP
M?JOH/_06_:98]/^SWX<4+7^6&V#!_S69B$\N;X//?!0.PYA;,OK]Q__SYKLW
MW[?>?.\_K/'&YICOC^"5WVHU=N7-]T_OOOP_;[QOI_'^0<P5)@^JGM$)/GS_
M]M<-,MQ70%*NE&&_ ONQKH;_O+& _A9:_[T#;_UOBO7_<3(IXN22QS_]<6Z
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MQ1>7H6TH_OC'YPUK#K%L@M@ 0_!DZ^S 0]DLU]N!&V$'GDU3[OI)?6!P$ZW
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M("0J? ^6 2D%Y\N\@0BE]^\2F*T02.;>GV5X@X1J0SL'3HQZ "LXN@UI^ L
M)P4=WX(NO[CCG01!FJ$6C4<^'N(N*OH(0/R(%V:*D.J)7 $":#ID<O05%+K
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M&*3I@. )/_3I%\9T(>NF((T/%HOTP)Z'+7HQ:E>T@_IH3FE>PY.2WJKV1J#
M]Q9W*0<<1B Y<O1< VF<EA!WCC90VM-@Z OM\@620CFXA9Z$TY*IH,_[P^OW
M!9Z'A03@MA\-F<;0Y"' S=@(6]134:?PKTRA7,JOY+3" 4#_-W$36M.5D\UV
M&2(\NR6;U&)]8]3C/YXC6;+)6&'7MO"J;9$-^DT[)>IHZE2*4%CDT':T)Z]W
ML* 8RQ=@FQ*#$<K(.B>I0I#[(-$K FE7W$FP\"IT5#:L#F5J+.)IS6%="Q(#
M2D>[NS[8)6QLJRC82-O1-0?Q1+$ZRCJ_P@U2CD +,&0@1X,N,3X_;1BU+';2
MWLZ0DUB(E$3+0G<!!-( O"AC_=X HL'MUB@'U)+=34(,'-ZX)/JW/F8AR<0H
M0[*,+2D2BSL.PGAHBFH!06 2&45@"=3$';0#W_(]68B@=$-JMT*XO S&;P22
MO\_FN26X4;ID Z/#8M 5\ *-28?0U5MMO$[3?:AKQ1WN3AW%.@:3L/"B\._/
MX,ALK_^A5SU)PO-O !EDFV=L!CV*&6<1]]^ZS@N4B=8%<4M9+4 )2 E7U)^9
MDR)$S(:]S\#G0!2Y%CQ\N+\][RXHB7"1.$$;%BY!.@ \A':LL#I9$S)K@12*
M5-[J]?B(H/8+8"/447A\Y6^AIT]40&&K,<()'2A* \540[$O;E%*:PPX0.4U
M<7'7E?51AD>5$0 []NFQJ!&3SK9O9(*LR=%Q%+O5,ZA-0+/E^!I8;<!04:&8
ME-QQ)=X X+TX"O@]>@%?6UCVHKX6IX!07%>[YSX?B\*G74GQPO1N@='U!IJP
M05AG=@PDI'@@U*&-T"!@6%XX M17@8-:K"W"M(4(^DV>/Q.BG.SVV_1)?Z<5
M^3/].+3OT$+#XH)-:SD ^U0Y$21?X8??P$@HX$-\]7/\@+BEG*N^GB+!)GB>
M6*<=!6\:Q-HUQF=U"L< X H! ,J5U,="LY^_&7591ZS/(7JSYXOKCVK'P))Q
M[*%)AU33*^$/,B%PE=,8#&4,6Z.9G6*L_Y9"G2P:&.<F]C-Q;9!G2-9%K.T*
M-MZVHFTV@ $)0,1H]Z/K)/*^"9U7<B#F8/-(9VPH_"J^T2]Q'[!+'QT-X!V=
MMLG2L 31FW;1V&"Z&Y1Q$0TY;KYUHE[/HH3"ZG6QKL__!6.K'M!UI@0/B*TH
M5S%7RO/E?<7)YEEDF#1A[K#C]02K=*BC>%MOK6TDY:"K(-JG_.(#%P3+#N -
MD#,9%O/T9X.4W&"%DCEQK'*E22W&N$#1244,+, Q.9FK[&244 :BX*SLC<B,
MO]1 >[EC=CGG[\N88@0 W4^ 5(0YXV#OR/?V=_</,7R->3WO)B*-+4%5!B:_
MACQ 7!$ ]'1 5GE'RDQ.[.PBQ:H8X2CP0S:168Q,XE:@#&)819&8RH#E2PS]
MW_53TG1IIB+'R;@1X!$^DQT4NNE(R@DZ"(@[8%G=E8".1#E/8R8'71C2B_)
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M?5KE#,S>.!W:+. S82I) )Q*T<AI'$J*W*/Z/U:CR%@4K57$ZD2HQY]'/FL
MI0N)^J&GUQZ-K\>GPK.@FW::)E23B5O^E.H[(O$5Z+,3FQ M@\ )^L0F?'Y!
M<7BYTRO)U >=# Y293'1V;[ ]]YIG)+/HM+<R<T]694\CYB#%P"P^?#IJ?+Z
M+NV55<T3L^T7JA"XQJM;V8_.JR3EH$ME+RI7[/(T'=A^[#[!_MW[!/N9I9FH
M=$"7KRT,TC@6PUR^UO^P.?@%,*8*WV$0,. HHQ,Y%&61NF%#^L0)[(W']? 3
M%0KF&%Z1Z7WI<"&;"_>K9G[YJK,[M>/."CE:ZP.U9SW@,%W[JO_>P0+BUQR]
MO@,PS0P<JZMIG6"EZ.9I7!:/$ZR,@8A,8+6S_[(N5H^G&5RTR@.JRJW<Q0_V
MIG2.7[186GHLO>KL3>W6;=$T1S3-;EIMDG0+OA+;;2B8%H"RTMASNGJ8A<AZ
MWI?^0PR[PM>D?RHKJU/?6WY%-N*CW&6N"@?4>Y!"^9_HIC[TNO!&[ERR2\,?
MVG7N.&/@Z<1%/\!XF3;^L;YB?IR\3&UH3].BJ_AUR:AD>@OO_JX/F\#_^UM>
M#L=UX$O*[CNJ%)4T'@47:.C9>_;SUMXV0+4<_C##+2$#N?[VW+AE,UACL:2^
M=_#"?[&W/T<ZWY\3G:_ Q!(,9-K!M+>_?[SRO2_]^0RQ:U7&$G4R8V/^X0O_
M\/!XCJQRT,PJNB':\A.__UAVJ9OE;:I/]/[LVK7.WBLYF%F(=I]R2>,Q?VM8
MCE[=>2$UV^\?=79-F622)M) W\,HF[?K[5;ED?S?^\7X3.7ELUD3DQ#]TSOL
MCQ^7YXQ#TX"B&4,$V+Z8Q(++N>=33#.K=']E<XUE#.QZ=#<E%U P7@?!)R_Q
M)9,]225@Y %QCHZS(_&H,8E0SP/D5N6U]^'#J;>EXN?F9[I]DDJ&N*B+:QJP
M6VG !02X0D;YR)DO1-^C3[VC,65!*:E0_80"^FF,Z?P[24T1MVDA36;=_2J,
M<DQ^ZA:K7 9EQI7F!(@H&7^W25!BXJT'MGG*N1I5@T&U6@EWNE?/1ODTJ+W_
MT@PX^$+#KN.=8(Z% (71_X'4[?3VK_U:;@R+/[J8&H'W$)@H20KPT)W_%@X8
M)ABOL]/'.F<[#2M^;0^X\,>L8W:!"9E81 ,KI^VFKR@AS"_TJ4=D6-0J3%+5
M+0;X22*LX3)%&5AX :9U9XS%'871RD-+'NZOMCQ4AOE48:C)UO6_.MY516D>
MD+LTR4BNKM7=NBI/3!E2P'LT-+5F5"#!E8_UXE23ZF49U .>  ;,OLK"NQ5Q
M*3%CAU^8_&=(%9/7?7L7.B>:.8V0NJU34+7E_M%?<:U?RUAE#O</*$5[I%B:
MF[VL#M48^24O0,)Q88&N:CYXX;2Q$BM1G\8,;EJ%/I87;1]+V\<RYSZ61^A:
M:163I9@.5ELQ*3?X7HK)BH[<7RM1*&6V4G+*Z.91QO1T.NVDO"GS0A4>/:U2
M6[Z:UW=9VH\CA0ZJSSH!'.Z<13&/S_AB^A\66@K[Q1HQ0I5I6-'NQ1)KH>TF
MC*XL[J1,F"FJ662]:DB*<^ :V=-30.>J$8W=&?1YI=V^K$M-&\K,FIUF;&X*
MV1<<"' JL*1K*]KVIC+]V(:KHE7CUD3ZH$6M2)<)75";UV@G1&0BGPL0(V8D
MB)H(XH#@(>_8G_8.Y"6$? # \3UPVJ*8ET&G.A-13OTVUI  @)PBL)_V=W<]
M(*@8R0\[K*I*/')/ <YE7"AD6:,.&$_WP//W()#FIN0@#/.>[E=3+J7=M&@C
MN-[C;\&1ZJN'0]@=&R/Z-[S%H<S0]!0XQZ<<:H*W?F\ XL78_+FLU?1TVL_#
M8N&RXV):)?;$88FZWCQ4Y')O:J$^R:Y4T;'"U(@GTQ<:ZPAT1P70MJOV,A'^
M67),)>?>C5Y,*@_.=?Y-#1^[1*H<:^ $+AE(5WV?6 UPE[H!#LMQO7,>!W21
M($5BZ\"76"257&4&L$#W0%"AF1'@6 MJ5C28P2E)N;<EJ#R7YTN:21BL_?6_
MZ[TMVV,5_M]SMFH/N@R?=JL.5Y7XFXDD#(<'GCWW) T("638\6;0J(M#/5RN
M0"+AGD;I)=A]"2]7\3UZX=LHS=$H ZI1\RK@M!U=YDN-#G'L]D]$A2*1L-9-
MILFZ27C6:XV=DRZHQG]*:7OS_!&WX<EM*)E6LXYD()N:2W1/3G.7]H16';9K
MF^:?3AU5JG>KR==TRPRS*) &>2PVD!U0E<-WK,JG2Y"E+>@V_NU#*[JKRSD.
MCSJO7BVP G6\[%3[A&M7?OHX]_FT%<)/@:+IT9ZI=QVV#-0R4,M ][^QJ\7'
MX@7:(AFF%6BM0%L!%+46P3)CIV6@E4%1:Q$L!SY:BV )L// 7@45O5F9%M5/
M8B#GU(DYI0OSB1I3&YH5%MF9NKMP.IA?6^J<FD]_IZN?YMK/JO)Y<UWS%QFK
M36[]9;MECQGL$:0Q"M"_/]M_]KVL<K#2K/)/^DO3]0E>(*,GU,R)(,]5\F2N
MBW[!1(S;8_[8_+GU4\M.K;:YYQ"$.1'@;^K"P<>CZDI=S&GU5NNT6N?>6F=.
M-/?X:JM!WZP,BX\IKME^X5A*?]EF7DP@-;?LLQFKM;G9<Q16R]3=_@@WU=]+
MC2\UG2P80&M%(W/282V]; B]M#*EI9%6ILP+6-]APBWAP*&I+3O7Z<#3;2=S
MY9<5'SGT [4"CSY9R#MP>KK5?.P6;0_*4*_$<7X@P=M2X;(8%RLD2J:JBCW_
M\.61?[BWV^J))1$X/ZV7"-GMO'HQ[_C9JMECOZ:)H$OM_[N,@J]>Z\+,4] N
MUX#(A\A>HUU;<OANT;SNYYTIZ5ORWR3R7V-IN'>P[[\\?M&2PWI*0S)L6ZFG
M[.'-BTE.GI"^%GYG&V*8$F( /=^B>2F##4\FL%>$5G<[!RVIKKU$.C@X\E^\
MF*^IN5:(;F72$E'K7N=@?QX6XQH$4G^1>.?S/](@2O*O(]_[.&\#<HD=J#9^
MT(:3-CA^T$936_)OI>&]R6'_U9&_>SQ?7V;=R6&%I&$;3=WL:.IY'/VOZ,JB
M[[T5<2%\[]<VE+H!@8O'4/)KA>AE#5QL6N%H2\6MN (C='_//]A;EX#ZZ@NH
M-2LMW>L<;D1IZ?U[M#^ER<ZY'N5_ID?YKVF?]B*[*-?\U&N-ZJ5T[Y^&F-<:
MKQM)S*W<VAA4MW)K)4^]"='(+ J\L[0[D)',UL3;:]WZ-GZSDDY^&X5LJ;@5
M5W;]W.%+_^AP7:*0&R2N-K3:\W N&>T5B6U. \4UO#7W_A'E,A9?U]=); N;
M%JVVUYT<ECJ"T)9YMN3?2L.6'%IIV$K#>9'_!L1<3_M9E'NG(DI:QW;=(QAM
MJ&I%(QAMP+6EXE9<M8ANQ=7ZB*O-C,5^$'>93 +I_2.64=*.,&WC#VW\H8T_
MM/&'EOQ;:=B20RL-6VFXT='8\PR,X@_B5L:Q;/W>-L"QX8AN QPM%2]Q2\8Z
M"*B7!_[+E[LMUA8M;=:LI[[ANJ;GA>C&<EY;B:-$[O2Y:WVOL__RQXECWD@E
M:.Q-$*+\%/[[=50 1(.F-OR/(A$W<@"6I/<NC>/T#A#J%7WI?939C=LA-4?\
M*MMU[WCJ:4YR+Y1YD$5=&7I@M.*V<AG@I?=>((;XO_ %@AF4Q-^BR>>^QS$C
M0M?^WANO*V$["7X/KQG"4__YE[T7NV_V7QUZ:0^>B7)OF*7?1O Z4="2S^'O
M? @;*W/?$W&,O_M5A)*TULLW< H]WL 32>A)<SM]JFZG]T0FX6-< @Y4I+"'
M(!U(VN#,9VE3TCM-!]T(X0'_ )2-O'*8,LA.XS2'XW2>A@*[S@M<8OL0#0 C
MB#?:]H=(,,_XW@40Q"")X$CT-9WU(LG+3"2!-$,AGIP"+V G(.-H2X 6A&94
MVVG:!5FESI3)?Y> KM#KCNBW <I6^B7B"QX-TFR89M41NZ-8W.6:7GSZK]<7
MN0=[DQE1/;RV_DIQDTDBO-R[BXJ^)T70I_6+.JEI(NEXUWV92_M)H-G;"-[6
M2[/F<SV4AG&A3(H\35 &$SDGN>2?QPK3$?P-4"@S/IL7I$FB&)I.@G0K^&]8
M#;882(DJQNMF:0F$! <049(7N.,!0IE?J'F@!\_"/P1]/R*N@F7N )+P()U:
MG:K#D.[*.)*WL"?]S'2,$<ARQ+2O,5=]1.><@BG<#)Q5YKG(1DA,HB@RW"\^
ME\D"SN7]NP1QU8L -D. *"TZ$:.L^<+H5O\7_F/,YUB*#&V-OK$'P2!\#!4=
M$*%J#MH_K!2T'GRS_[*^T_^PMUJ%D':4T:_NZ[;.H%3P/ID<-W*G"UC_NB-Z
M\.;7(KX3HUP=\_BXLW_X5W4/^&MSY_<!;N>H<WS\5Z_Z)X)C#' #\6W'@I@3
M>N&G]$=DF^C/0+XBNE]G,A;(%+BVM>ICX* FLPXL"2R\?B9[?W_VE^O/IY--
M@B3-!B)V3 +UT;.?KXF#@?Y/X5ND7F,&B)\M;#93'.^,8;:SM]NI=JN 5GWH
M GL,BOPEV*;!%O["^R]OGY[<KL'709,3,^,7\D<3EG\$UKB?;GD'HDD =^=!
MF>=1)<3&9 C)%:4*;8%#!V%[ 9\CB=8L+#Q@+YE9]HYWH@63[PT!=3D:5M(Q
ML(JHB.]K75TW+,Q6DW+<I^MW4AUGSLX_JYW?PS#;.SR^AV&V!-8/('S 6U:8
MUK;GHJR;J[+[IT2-R00$XG3 T >US$:/L2['R8;)$K0U:,B0L$@:'']\]O[T
M@^]M1=O>U*".4KGOH@P4^GFOAX0'!@4>S]<OA"UZ%[ R&-4#_$2;"<HR8JN)
M/B/RAXT745(BC8#F%-Y='XS]D2X!2>_0/L[+;AZ%$6IA.-R)!(9";8]K$OV7
MV6UTBRO8JE^!@?>J]H9/;$71-N,4WC<46:%_F0NPWU-PKM$? $6?Y,JNT88&
M6.FQM->^D@AVM;@R!2<>W ;/A8* \QEPBW9QJA,!XL#:;GSA$O"'VC_H',"/
MM*SDD_#/,B^0[!;'*R?3B-6X6A4+Y2YO61R5RP(%'B!,N;3CO+6EB8HL>_A-
MLI.6!8BUA(SAO$^6;4_3_&"0(I.EP5=X,@GBLOI5WORS*,_+RJ>F[[]D<D=Y
MBG#*!#@:_K7M;<EOM07)/07_&U@^1@TQ++.\%(DY:OTXRE_0JX#"RY$.S8+;
M3.6PIB@+0!M%HX!I 608FT*.36,)'Q#AXQM(J^/K0&-(Q(+PDG+0A9?"8:MC
M&]9VCB[1R-9[/?\6]$4"W'6)U.9M.>&&00I0#M$RC^O1A_DJ1W<7]U%Y!Y-5
MGE?IO&W?DD_W(26@@9XDW^R*J>D)D5^A^[OQ? 5,+G,^[DG]," D^Q& @$(M
M" OUP@A-77KEG@]^QRSZ\:<2$!BE(+K(_Z?5_$DJD@7%1.4*:)N.MW2H8Q*
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M>'+U%J F]AX'%;N%);$5_G3;!-UU/NTUP9@RL":Z2Y%8C.S&8IC+U_H?;^9
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MP-(SCV-?9N:J)3@PJJV"QAC?DW991QC!8IF:TB"S(9HG"H4G>KY%]>RD7^O
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M:N;$$A^)5 P>ORFA:19[[E\7%9%2$ GWPQ@SW-"$\GDKB^\T(:^*K PP#[3
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MPC1W@]_C E5?%;S5U$?F43C4%'60CAK?@OLF3K _8*.<D76JKEWK8IKDF;N
MXG:6BLPGTS=VQ53T58>-]EI$Q<K-QQ_@X;EU4METL:"APQAT1C[#F\3-=7]F
MC95)NKYLDZYMTG7YDZZ/;9*ZMY07WN'K755/-.P,.MX6ON-?:?;5.\68 [H
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M>0]WC>9U[;N'>=!6\;?3:!E?H/786"S]D05EU? @6>%BQ4AH! :7RCC.V<E
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MO4/FA%4>="7V?B.Q],8)^S.NQTY#I'EQ%@6JL#1+T?.)^:WLF5[QZ!4LIX$
M^34-9JV6][Q\8&K1DR7>X0D+QR>?(#+-I9Y0L-/OQK!*S?;($_D3DIK'-7X4
MCE!"$B9DQV?RJ=/#?(TL)UU=2-VV!&XKTK 1W2B5.*V681:,<B:Q"Y%/K%^-
M-,L/R":S&JKQ/$6^+<>:1GG^Y07\LC!M( J%O6848^WQ[D6RZYE#2U+/SAY"
M!T-J6'^"'Q]>NKG+FDYHD-WIC!H?S@VJAUW+1&LY1>RZ]GT1,@P'-'?)?-#G
MVX,F$AX'FFR,/*#3+;!?JV&2K*R*6LK6:,JI!V*L"AOX<\9BR]CI96-G,[86
MSUEA7],$OS&T6P#8!JOO30J%K>(:>S%^56.">W=_3\]A[3_.C-O[7FVAQAC,
M$?0 C=P_J0QEH*84DAG28KSL#%&YBCT0V0):/ UT3O A$.?C6JHI3<]/IZ@?
M2V&2PMJLS6<5#KZG-7#SJHZEA3M;^J/!U6A39JA1J%^D8S2XLD%1GTG7(]LJ
MR1ZL'%1>I**,WM'!<_FVIAIJ6V]7[LJJV/]^;UR/:6KEG\%K"QF?+%!.; /;
M+_<_?/G/I5S5350*<2?X .[4BJ,E3P[R++WO-C47<K86RYY'6SZO:/_YU#J2
MX/<,?L:_VIU"$>>Z,5O8=E:$?TT+_,OYKV_/+BZ#\W?!/T[>G@6GYQ\^G'\,
M+J_.3_\9G%_P+S]=G+T[N[@X>RN_O_SE_+=?WP8?SZ^"R[./;X/W'X.K7\[>
MR]5\S>G9Q=7[=^]/3Z[.+H/?/EZ]_Q6O^7_!Q=GIV?M_G04GP:]G5U=G%_CF
MJXN3CY<?WE]=G?P:O+LX_X!7!F?_]_27DX]_ARO_?O;Q*OCW^ZM?X$675Q>_
MG5Z]/_]X&;R#X>&%E[_!T#Z^Y4?UC& #C-6WQG-&+7[.I8J^K/IH'9:LS2'F
MZX-(ZW(H]_/RKL^3;8P(?LG%D7M8^B9P@Q79M2$7AB/HI&"#BBR(4LP"YOW%
M\RKY&F0P6?:^F,:C V-<.$4J"K61\\>K?!J\*_(;T C@P)[>%+!W3R/LT7@&
M3F+P-A]-58*F.UP(=_X3W,<T^A(&OT9W!9G4_TRID!$^!V[(X/>WZ%O1N:,*
MGH>IPL.KVT-K?_*:-(:7,#+%$"9TY,Z3]E[D\TZIO/>,K#-<WW-=WOL/,$<H
M%O'?=:+//G/7I<K0=?H7>N*?4'IBDCWN",7R@9%9)")#QRF+"_CJ?R:Z/7CC
M[9?CA(I!8<GD]=)?.IK.W@2_J(CF^ (.FJ@8,SO:6P4KE<]8Y']1*$G_S,=@
M%WZY[WS%!Q5CM;]^/B\Y)OE&"DS-GZ.TBAKW_5UE8.JFP6E>9R V=,=I#B9D
MP0?5N("W%O<;H,2HGZ".@5,HI:O!H.-RXW7OL[%\3(.+]/OI-J>V21=.8F!D
M2ISC8!V/_1$GWHCA2N,DB4G:VIX9/ LO=#M#_9SD)8K;&&Q?OAMF8D<*EMUF
M);H(>D'LF]R!#,:.>#,'XV+"]*#IRAJECCJ%=\68?'!<SJ%T5[L_FQSGWI#C
M''*<FY_C_-;:V@N4H%:X-7$:R>H]+-Q,CIB%291N#M#JB]PM@'02B9Q)^T29
MM$N=2>.6N?W4-#_\;4L/&ORO? KJ*W5B](0^?0NS>R==@LF+^KT& RP6S):-
M;?@ .RE*MU0+G'&^T)XD35H)PQ-$-/B#GP]>OMI]]7H3\LV-8=(TVH&NSR^X
MZO)Z,<,,UC"<I#4($MQ\;QUV9_QW9ORN"(;Z>9?U*'A/%[J_>!\&!,Q#FYP"
MWE*@&VJP'L>Z^(\3PB>YR"F=X*WN9\IEJ@Q1@#%9R34_-_#;<N#T'CBM&MUJ
MM1F>%]=1IJ%Z1$.:WZ''003* MBS5T^1*J78+/;10<@V5,CBVA>O06H&J5DL
M-8CP3>(DPC#V(#&#Q"R6&%?'1*E-#@[2,TC/8NFQ:'Y$'6" QH*^.MLK<L:8
M0:>6#&T0MD'8%@O;;<YI=,$G3(2SKZMZG4M3L<[GEI,\-H[*_<(B0<R,D9MJ
MA$@"Y<, +V>*Z$0_**7AJQ0-X>RMAGWHQXR4H#JX],BMPG3N,B,:Y'V0]\7R
MK@Q6WY8-(OR<DA)(]RCM=FPOTW8Z%G^+1&PLJTSXT.8=E_ONB (-X19$PA;=
MJHSENL](""E)@ECW-+J#GZX1+IOAGQ C)E%""?7@;I6+^>GCRF1YA=#SC:9(
MIZ3H/1PH\)X14< ;_F&Y5)(L6,BE*GJXZ 7SC1K_E2$N)"EBNO-^V'G#SEN\
M\SH$34V0>[MLEQG";C(PQR33^"!3S^@U[]W?/= B__;OI[\ZA<2VB\$719AS
MW%"#L ["ND0XTJL8'F1FD)G%,F/I\DUQ6\F5 TW]9O,Q%C<\25)"8 I*^O+L
MU/AVT7A<%]C"BQ 3$WR?]!++I"2'3!5L+C"$&@:1?8#(ZI8+TC*(;#YU.\C/
M(#_+R8_3&G$0F$%@EG "$(///5'0QQR$9A":Q4)3*#BA,- (W\L4-]17%>-_
M@P0-$K2$!&']>XJUO;4C28/H#*+S$!-9!U@'N1GD9KEPYRU\8RPQR[8<^16,
MNO\6UV<GQ(YG8"?4(B7B:+OIUQJK222]3[G@<1#004 ?8E5=8Y>\O+CGC&^"
M*:$025BFB;#T.WR=@U -0K5,0$!=LX6%])0(].9T#$[^($&#!"US;D9?!U#W
M(##+"XSN"\^!@0BF7<L/-])4F9HD%3>?'R1JD*@E)"J[38I<0VX&932(SM*B
MT\ST<OF<P!B1(%7(!#68;(Y4/8?B\/VA.'PH#M_\XO!!00\*VF0"RIK K\-Y
M/HC+0S!=47R;E)IV2R-+)VH /@R"M!2@5&#Z#F&"(.Q3QO+?)#,!0D>329)B
M(YU!M ;16D*T9D5RB^A0(JV-JB@HU;C&^D%JTK9!(C1(T(9*4#\^V60QF9@5
MB0#]LJ@Y_33[Y,[SR8PT[,E,L/NQ%K*=!40Z4<$=**;2R@YGJPP#[)603!)I
MC"!97MV+ZPN(1ZKB:^&4IKI&K 4#(_06J1F=!B9$=.Q"O:O%0](]$MU5T*P]
M6,LYI8>,HC)A5CHYA.3A3M-M*2_.1R#HNK:LZYE5KLM#W;&';G\X=PHJ\%9+
MPFEM *?B:7ZK,NS'^P9]7^YI,0E^KLLDPYX5GY3MJ;AN2E@S\4B.JGD4;R*D
M@NWN-026!"=N6XUQW,+%J/28R-/H+L0[ZXRZ@A@V5M.Q\*[ !V:Z]"\,8EN6
M!:]+\ICVO (+&:MY63&XS18ZR]6E<R3>4L._4F9$CXHT4=2Y(<<]L)"K5O<L
M  .]H^K2^6B/%M?9AN.HQEY,5>DC+9"OJBY9F6%W$BH*-53NRM2LT4Y@*6*\
MQD@+$F4\9T(55VI]26U^(TJVUP7WST3>7&XS .IW%I5(\8:F(59FXD-(UQC4
MB$[1BY&(38%L"Q<N%964OM$4>K^WL2<[@2]B:9G[<N9L:%.."DX/BA>+H'G)
M()$/E<BD,@=!XUA@F3131S ?+/II"^FZ"-3V!QMN,VTX;I6!=L9X7-3PWU+A
MIH1=0_(4W3-F3+JJ!I0E_:)8PKB%18)@GU%-L@O;7=N#FE/?$%H2CR_71P;2
M#)H<6=UJ'?50#+)N^JQ*;U[='LE_FO<DIS4K^S H[%NB89;H2\XDEGH3HJZ2
MY' 9^NU.J6 _K= :<!^VO5$>][#7-G2OE8J:)B-':QA<<TOW&9GYOLS#ED+&
M5I0P+*PCY@7TF0K+]LHE[MJWDKTV?T_<>SNBO]T*MIS6M/'LP[F]U3L[.N8S
M$Y@RO[NX_$TZ"S8:RVQS4V^^)S1M@%$7Z'XA[I9O?915/>;#Y+?<"TCSG9)4
MX=XC%B1J5LCEBK0A)[IY\?PY^Q-N[&$K/X@/QMBA(&37:-AIMO@<Y8MH:P/A
M66$CU['Q3%<&9KHGYWH.TWT(MBY:[.U.Y'VD,#Z++^X!'APV:T)DN);N5D+X
M6\<>"9'.4Q1,)1C@]68/I:6CWK2A=91 8XW$6&YW:6]W<F_WB!>V_L[VM=W=
MW=WE9C]%M[]SX_*>(]-# _0G5"B#I?#P_"'&X+@EE;AO?,@YYZ(T[]4M6JU.
M,+\1YB;^+?6QNF=[PE #XI]_S^&? 1;OUX4.$C3N&F1VD-EE,/QPA($IJ8QB
MGX%ZS3.1.4HLP7%6DR%[74=H]2DEAENL1J T2;US)\&BR.^4/.]-XW*\V/7T
MT"Q%<2W?>/ZI-NW4UQG&:$F^F:=PFE2#+A[D>CFYUOT'(FID <($RK5L-.?T
M0ZI2C&=[XZ(T&L?( ,]=B#DUU&3;S#9<FQ> !)LQ!A<J#+"ITRA-RIN&;M?A
M5\OL&C*8G0X2]+FNA6O(Z;D@@YM*=U$986G S)V11JHBC)R>]2FW+7=>@H]&
M@U.Z4?E3VHCDXJV8;$+IYL30%[E3&(_RPC1P;;&Z'>Z^/C'6=1ZK-R:$-<JS
MNO3TPZS(X>->H&U(45]K^L$],NJ01^/T:I&N*O*.N^B:[,H(;KL/6;> [0G6
M8!A,\+'*3J(YH3$HK\!L9.L48V#3.I/ /[Y;&IZ&;AQWB8C4&W^@)9JW'!XH
MA*B'6TQE59&GSK! [,1_(:U)C3UI^;$3WU+OA9]O$M:N)H@6;#FK3/RP*#HT
MG]&(&"%9;K >-<D2;:G+54PHJ_,D;L\;:FF,76VM962ZRE#6Y#K/XV 2H2&#
M@X2#IT:N6I/,@ 62)V_+!$N;.[,QO<][YE#K@P%J/4"M!ZCU8&\]&WNKX9\:
MO>WUC*HK2E%U9<AAX^A0T6#@#P*W6.#<J(J1-B(:(V.#DC;$' 7_ 4LA*QOI
MF@0,IML<K?][-W7C&&^6&5M(A!*TI] -IM0'7IDF*FL1?K*%U''SGU"P!U%>
MBG7H"TBI-O;1L[C-OS0D&ROE5<I.TQOBCZ6_:]\,,PY3*^'.CC"]A44SXX,*
M5=4%/ 9$%!GZI U$D4]Q8[1>.TZC9/H&G";,DU!&KE+"2H/<MS6[NP08LB@H
M%U"@P3JX4>!/3(-#7B0X@Z5V6]$'LC]/O#$HTXM2<IVNFT)Q51Q329Z8TV ]
MRIP_P,]FVNPD;+]IAE:EV?"8LSS61986PP%W,!\7R8CS!9XG^W)O?\_U9&&@
MG+'43BJXRMNL,=:5Q<'1>&T&=)BO)!^2NFRX(D#+3ZX=6,C@<Y#C2&$,QT7U
MM?!XC-XVSMY453=YW! (6M!!&0[*L!.>CFHF[%=-,T'N4K0.= 9L;X4<D3X5
M#6Q;;)SJ1R!Z ':A&]FBUQ>E'H#D8PLG("<@!!U20B1?PKG&DB);/X* A."-
MZUQB= VW7E-L!2Y*:QX>W5Q*A&T6)7%0T]937Y.RXNRSU"X&LSS%YN-2092I
M.VS LR[M@3.E\LFV;=\3YSP'4S*A/$7@4DJ9MK(6+)M;'&T#YH7AN]8J86<'
M"CU&<(3DJ42E=%*-= ;XJ8F:!)A0EFAN%$MH#Y]_5^39=9SC]([NEQ&-/Z&2
M&ER11Z Q8050BB81PHESA$?"+^YN0%RQ"ZFW)VS5!=:7&'W 1V9I LG$^T?@
MSIA38>4@C8,T+HE"($03^:=YQ/4^-K'K2ETC12$Q]6;2P)2H#O(WR-^R>%G$
M<EV#L%'\;X*)&HG"4+5)9T2F$87II''VK 37">PIO''"B@/<>Q#?90Q<DPK%
MK',>)Y-[C<ER[5KT94/WS#=P:S'1&1==FHRPN;EAV \XK4$L'Y1?$=QQ:)/V
M)(<<GO--S9G!*A!&GSQ,@T_0:E3Z\Y4=A8.#: ZB^>#4GXF4H%;496(Z)V-.
M=HUU]=I]A$YJQ92)-)&QC3L:;Y>4#]H8W<D?JN^$^1J[(VVF<%KO(3LXK6C[
M\.[CHR&T>M\/0U.<'%Y#/SC;#_]PF^2I'##VM)%=V4*@^<.@C_)B)<,>'?;H
M:N"0@N*[5HAJPT+X:(SU$RIV _JS MS'9);J@!QO><[O(WY1T@'.#4[TDN*S
M<5T,H8Q!:I=+C+)% K(H@@7B-Y;H?Y'?@T86R6+Y%@1H&0@* &XJKEFX.X*]
MC2)[+G6N2Q )Q8$/.3H&:1VD=:G$*IH3+BG."L268W8E)CR"FP@,?)')N"<\
MXO Y]4CZ)LGR[B#*&RS*6&M9YNFM4W^#\A7GKJTZR0MUC1FUAW. [<_6R0'V
M,:_0ZC=E\=['>)E+AU4H<6TGRWA#7>ROHVO#EU9&J7(BGC8(RC'.A-,_\.&*
MD.Z%B]S),U5)6:R'GMQ*=M0.N!^B0>[=/U(Z]B\8!4CX:^+\+M,)3<R-@[=C
M*G&W; + ,-A(,H"<#44=K;6K001'4@ A80%._O;/A;"3T%54R.$PD<C\+&#V
M</D*0'?FA:[<[>3C<?+J$YWVO<V36+,LQ'D]JAI,)/U,"J0$7121+>39#H-Z
M)L B2?\K9(1KI_H=/6SB*Y97*G3+':(9:.^OR=2K,9>GC^X%+=5ZV$<X*DZC
M$FZO^B>&J(80F0#K\N/N*EG9YFPTV%N&RFE5;&8ZFW_I\NHOS2QEUAJ6'R:$
MSE%#,H5B_X<@FJ));]:-;&R%R^%0X3)4N&Q^A<NWYK#\9C2%^(P-)BETN GM
M8;$>7L*GG2U_>M9"3UCOUTA6.#B3&^I,/E>RPM;3'D!8N J>0E0MFP5:&;;8
MAFZQ#2$VFT=HQLW1VF1F ZG8GVAK#YOY8;G:?E2C:]^'P;?F*&T&>P,MYTW@
MQ!2NX*'O'_V7OLT>BV0M-\Y4)]37(-'I-(;OX"*$EJKXIZ7H4_5;.TI*>LYN
M=T0\X(>0K19.Y9!]^<QX7I@:+V+K-C&?/$,^HO+!C$+;;U;-R_KF*<2LZRI+
M>H(4_ G5\&!A?0^E_+WH()\=&>0@Y!LJY)M !CD(ZB"H2]88;1B]B\EP+JY%
M^A-*^2#7WY_\H,_D?2CCP=;)-M.;; 3U@4=!L/6S#&W57 3NW*W+J_FV_ ?Z
M"Y\#]\%P$F^HQOI>W >>RAH.V$%X-ZE4W:GM[:E9E^S'@T08_KA!4CP(\88*
M\7?!:AL061+_GQ\X!FU"T)\_YMDE&6K,__>#(,)6B.M^9!-@&-@+=V3KZ_%[
MUMNXF="H/3A9RS,X4FE^%W;<'@D3(R]Q4FA/%5._7J[#PGDRPHDC,CB1\I/"
M=F/K:D!J<T..,!GD@LL;XR ;D@S![90]&$79%_KS!'1=-B:*P/@V*>GF"+1+
MD:G[,M2&0)2YM/O.E=?:-7$;9<-;D,H1'![&9W'FMK^7JL9<I/?<)$#_-,"6
M!KWJ&P>L.%"2DRJ1@BIL\0XC!.%1&1[9T36UB8]K;M@PB<9)FE0Z>8F*N,X$
M?! BK(G@%2"1QBE#4<U ZL<Z8<C\#">8)&!H:O )[(B\1/.Y\'[_/L-$PKS0
M_G, @A\-0/ !"+[Y0/#A8!@.!DVP5Q<9=FY"/9V!A3DC)Q%. 4SX,LZLF3-(
MJD9"C2%X&5-'\^5DC=!-"!R7*K/5G .#\ [":\AZ=)UJG)3CFKM><=NHZQS-
M' OK<L2UBQ]G$,U!-%<;R,!"6$Q_J2S.BU):(7"M3-PK<EZ5D,>>-&!N!TE\
M+)Q>C6MV^%KT8MA2D:'PE12/$:XRYWHV%UC/>5JWSL1V;&P<[5<6.SY(Z""A
MBR6T1;V%V>]Q7J>QK0NE?BF8/QM+E0(X8?$C[,HA#S&(Y!(BR6Y02AU:*3GV
M#?(/:^**.<ET5Z"._:'[ DU5A%PQ+5.9X^L8UH,S@^Z@B*%3DN3"?[%^"_\Y
M(7?0>I1^PZ.G/&DJL ^*0NK":,E/2E(RP[0$DERB1C!T4O)'&@?_62RNW*81
MME>BB;Q,*;Z!4AV?"O5"2M2"=YQ)T%"H=L6*%&[8LH4LKU3YG2A0EI,?_;4+
M!,C-TH2Z!;)1V-0'.$2\!5VEB\_Q+P5<0:6GCB/7$".Z6Z,8Z9&=TH%/RV -
M;Z)TXF*C7#2E;A)0=HM1QU-Z^J]T/6F!S#W9Z.)))V0G9\,:U/+-6,U\F0S;
M=#U,IA0:<BB?DM#C:;+04BKQ=PJ+;"$SWF+@<HTB@G)[HZ3<F65/T+D/F]L=
M%,MU"@&#F]I*MZC2$][EIC%L*8>63G"A<//7=1N3FGEZBT?N'SI;.-@[2_;1
MZZE7CN"*ZVCZH.IE5T9M843(Y4*EZ;3N_JE0;L%U5P%TQ?W\Y)#00[!JOZ/
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MM9BP;!J%%F8R)BX6'2:&V53I1)(YSI)/E:"GN>\I!X\+;$<SJN-K@@2#=<#
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M,'R8<(6HVFY3>Y#!00:7,662<ND*5H:C6*(;86&V<6?'_;,^X<FXXAIXF+^
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M.V6YXL(P"1+FON,I"[T,GV#5 '6%.2FT9I;(@IC=<Z2&X93XUQ$W*')(M,Q
MZ-2MRH;9U?=(V88@RH[=3WL/XQV3Q$E>&*OB\4[&&HW>YO!1;RD$TVN6>(WM
M:EGTI4I9/S_M!-?LA@Q=F](2&?U&O^\62+&*'VK<-/!P_<Z=O[8]%F.H3?'%
M_E;X]."-)N1]DJ'0']9Y8NT=;QR[62KC9+K+A))08$E)6>IMM-RZK6^+F)@'
MQ2X0L_C0V,<2_B):QIC:%=2SW[!" ''1W&=0\=C#^RD8#(&D/@2:Z6]Y:QPO
MSM>CYZIK3,7S$3CR+"H"."'J.:Y'^^YUF:I>6<EW$(&'5ZHL'Q9;SQ0V43I^
M\KU'JSLATHZC>D&(AO#-=(*@QQXG)9[ S/P[@D'H.)9>3+-J?$#9^(ZGUUHG
M VI/."Q-O[8''O:TV9;3"#,<3T5A'S+Q+QF^(G-UN+\UENIC>9=YA6T_S2VG
MT2?X-;I[/EC,_2&7/N32-S^7OM9<\(53"]IC@ZXO3[PHH.ZU)##),C_9M/A4
M7>P;MCGPI83V)YH7:KMNU JI %0I:30KU4_Z'V]6L+HON&6]]ZLJGQ$DB@;Q
M(HWNP<[^:9)\5;$K9EHQL4!@L_@J;B@)7(H?_N+^P:>T?]+XL80>\T.BO$D&
M8.1O[FZ22KV +3Y&O7!71+,WSG!D,\FP__?_>GW\\O4;;GAO1^E?-(>3_TD?
ML*3^6F1?@"6>**3R7BQTS<HQ[,$B@&'Q=)'_>5I/@U&"\<UD7FZ&/::X%E;U
M(BF_<-5/K%*IT>J]EVJI='&<)&#KJBX4]74W"AI7Y2\H67\A45S#MAAVQ7/?
M%6! P)V:R5V$&M.F-RJ=!==DD&(RGMH84_].CM)YH5:B"4DK72Z,+V\1K> U
M]$Q[%S<'D)U"$2O#%[_3+^2>"6=$;T^FG:V5[WYNON_-.V#(%0O&.4*@%4JI
M8=42/YFO3): @& S+;.HY*89W86K:7Z *2>O[C9/D>S%7<66^II$8X3XXM]8
M_=B&5*7K\7W+6L^EC2J*D%L&7UT':ZJ,UXB]ZR$"<PJAG5J=OZ?Y"(%Y4?%%
M54Z.J+R?PK?J%-')OZ[.+)>&?@$WJ;!I73K!N-^N/G.$*8<Y51OP <U7THDE
M,"99:V?#W?AT7:FAZ7SF,"[QIZXK1*0#R?JS9>(+I$8(=6$Y?#J628=<0CZF
M:A3"#?'N"FDB[[V6QM+OGH@];(\?V'!9*8B<.XG2&^A0H2.LPE/-5+@R(,HE
MWH=.C36/I56$[>(HF2G&\$I@PM[-WK4>[Q3<1WHF1%8:,7>.]+,447"("C;@
MW6Y1O&2JK$AB>ZKH5G53>43!CX<[N[N.'FP;6%3K:LB9;&Q3%!D'4N+H'B-I
M:JP,>D8HMD+80E3S8H+<90\:E0"*X$SGB![K4^;20R53J-(Q;N16YB-5<3FY
M-P+EZB1I72*U7LX.6],N\#BF)(QIBP'UUM \92;YNBB,[/.E>!PEB\!**"?,
MB:8RZV?B\J=-7;ZF.3O/3'A0BU(_WL#D4$S,D'@%G9-8>]"%X:QIA>L%S51@
M&QF95!W2X&G$QD+V(KX$!9DJ.S&?;-V9%H059B>ZEBPN\=!%TFR,'L-Y#0-O
M\!&&71ED!OCVS@0AW6SL=.DDA<OBY[4V-+VP!6=G'].4M&;\80/LE4^&^$?7
MI,;P+[&QWXN-O3Z3Y1QV&FR_:4?3RNY]/TXY-%\%/^[O'!]8C0Z'2";> Q-[
M]1F<J%D%#:FX\2#S3%"_O@0-$].+"[9 /:YD@1$^AGSW<0#''.$OX=2(74.$
MI2"!LS9-B-7/S#0#1,5VQL0#B UR"Y+_+22"N#'\)^-PT8/B%B*$7S CI>92
M9<D,D0A,ZH/@5#E*M6,<P)DC['PP%/')4/E9Q 8,_ /L26QB*&7*693>(V B
MPH,)3*OFC,4Y32E,<E*)]:;M?WSI+7&/% [J27J.H=9043%V6B;"L#MF 587
M)F^Q>^)X)CC6G/Q'(Q/(Z%BV5Y:O(*Q.QYO7%A]%T&'! 1TD7BWS<4+5Q2:I
MU TL=J"]<X!,>A?,C4(MZS:NR\"VNCO#;P&[+$Y [8/U*];?G&/".QZG[ 19
M0[ '&X('#QQY(&J4R"L3^,:H\![.=G;$Q1&37!/#)8QQ3Y,O\,RD&-=3-&VQ
M;PR<H+=1D?!QJNAP158;+!<II%=B5 W1Z"'NUHJ[>5)K]VI_I-CP//<'I;E6
MW[47#8 RKMFY[ -\+04/&I'?TS>(-QL4<AYD?Y-E?YFT2NO\LK1].B3,ADPI
M-1?:6$.$MI@T:,:H'M-@D-9!6K^+M'JVBNYZ[*I;VP&Y,\DQ".H@J$\R*9CI
M/"&K6@C/<VRWAYW$?:IB?,B/>QAK;4=8(X<:<F2BEVPC<X@EUB&X-_#\?J%]
M#@BU@P&A-B#4-A^A-B Y!O6_G/J/QC<86B,# _6^J?SAU%I;W3MIJ:638Z&D
MX<IZ,DG&&$7%820YA?FH8J0O.]S-%"\A^ZXDCSF!GAL$Y*JY4//K5W74>42Q
M_]Q$]H@BL%'USU5\[7Y0W7=U+4/HM!V91+J@#\ODX 8WRU3X7(GM:(+;PF .
MZB4IV_27R\T.=J[!C#A%E5OA<_DKQ=;!.A\1XXD9)TW3G*@[1;-A\F4DDEQ*
M_L>TIK$<Z9SHO8;#G6<=WL8UP?EX7!M>%!B DFGOW#@[P3M.F4U-6CE-8/_%
M35?!SZ;HXN,HIB=2,[")5[;'T,*XO4#LGN@'>!7K\^),FY 3*\"A2F91*B5X
MQG#=.(3TO'0O"$S*R4S0NRG,O<KK4I B*'H+::VRN+,M]DH:[2VN=UR0Q94,
M;N0S GRGL6$2'!5=RFA"A97PK8+FY:K@'S;.Y2O@W9$P>\-C*M\)541 D0)3
MQ$Y',DF@1?<Z1&':+B!'!*?3NHK: VJBY54G+I&O=XH*'U4$:"E).*=ET- K
M*E'<F=-DLP,',"?<0QXS0S1G4<)'5@;S5Y:(\P&C8X?+WC2?A;<FAIX,8Y*Z
MO9JQTG3W/#[WPNYCU6\+2@@3N2TT?=TQ&:RJ2KJFX]S!:UV1?83:",WAW!H2
MYH +;9T9+B)W3EN($O55C#AILP[Z'%$.8IV:#N^&O(B'.$NCK'3T)Q]L+?H0
MUTYRF:>6AITX$T!A#8$ CI3+;"!K!Z9M,D;J8AP"59\X6"XYELZ^ROXX&6_&
M\9G#O-5".7AFJAVZ]"HNAQD^E3[BWTYM=6RYO@/V?:,1KL?CX?8M64&=T1+
MZCD4"#XGDN!3^JQA QFT6V[>>V$?T7YP<1.]SWXLC8;?_Y,@P\M-[*,*:*.*
M3VOR%Z-RX13<^(T?>:O2^% (0)OB?<M:-(]>8SAJF^N,W353^/TR%46,FR-F
M1G"<!3S;!9[[V7#,/X2;(M+6CU?:;BC7F9D=PR%4B>!S%<6(NXR-83J6HF/2
M\5AI30>)HJZAZ.'<93"<FV2&\P-_KKR'K@MJ@C7CR*R'Z%\T>:@'K./I+#.)
M_=I&SQ0<(LQZ,1>[@_)*X%730Z>C,^M-LU$30< F* K7ANJ4$D9XG(J&YC_A
M0IFE04([.$_I1-(2J!R-WA**<B?XQ5KLU/VU4RH,U6]9@Z&5";39>SP/I_V&
M!7+'"0E^!"';V@] EI-1GG]Y <\ G:*CI.5VX]%-\>OCJ9SI,U&S,7H<-5&0
M@CUEX.19B57[@CW$2YG>R%2Y($L9\OIVCSAH#;E!4\9$F\[>K^%CTK8#@V)D
MYE[%K0N,M>6:?LZ8MDK=/SV_9L"5.QW26@R;QRD=FS&=&'JGH[W\.\)+9CCJ
MG&4CM@TC3QY5J7X([HWLOBTC8(D)=0(%%&5OA 8[YIJ?,)L1)@8$P(CX33W[
MH0=KU#PLWDA&]HOX96V=%LRUMRY=35$R>Q=:F^!F545^SUU2FB)N%H<:8-N;
M^+OIGJZK)4S+[;A1:M >5:4$ZF+8K/FWZ_WP("NTB[MN?;9D)Z]@8U_V])/M
M#.9Y:P[;1+@KGT0=Z ")[SEP$3G.6&N'H+0@ZRPU6:4V'*G20<$YMZ&$<YR7
M;(:FL%/GEYS]+\OR%+9X#85Z:]'9X%/M- X&5F@TK)#W,7'RS:)[C1 G;CZ<
M3X5>+AJ^'#/F7N3R2CV3''OEKS $L!3[<:-"'+HU:^2N#H;I$I@*&UP=2]F+
MB533+QNM;B5/+AYI[)B^PC*S+!O98CMR)WAG^! *=9W3V,02"!M116^8I)SA
MHZ+ C8Z-G$;N,?)?UZ5?9);E7/U!46\D^6I*+84W^)%"[.Z9AY%[@ZD8-O[X
MM>8UE$&9E0;M=YMS/X)8MZLWZIVRIZ5##JFWE!:<2LJW_%@7_C+)G@^%SN$
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M<)M"//#L2I!( 82@9$VE!^=(;ELMXZ]E Q?&;MB^3X@E<NM&A9SKRLE9,CX
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MELR[0V,-?C@6K/&<F83,VS2SY$!!- N&SL0Z-,]VE$,#@M<MC8T9Y>DE\.E
MCXZT %*IT:.@QN?Q'M4>$XM^7 ?18OZ(H4#T XJ9TNT"$ <)G>H ZOKP<.MN
MHXYCPUGO2GKF<7T&/C-+\RR]=NH%O$AP<:$V&YAT>!G&,=V#5VCG&X*'>HU
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M6VAA+GNQH(T!= .+R.4V4W%H2TEB@OTVK)CL,0D_!/9N6<[;6D[&5@ '-0@
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M,TUGX>K^.W%OB6?S/]R<X0$.4$G;;.QPHY=ACQJF&L*MYH SQ9@Q!"Z/<5T
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M@XZQ(L^-<9XN6L 2]MSU;LPH^ID!.<EUF9'/"$M<MK.&8$V.MWZ>(T4$M[?
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M)[B/Y62NT7HW"1X /X;DM_G9W)BOF6T,@EVV]I;C*#Y9]^(OC-77Y@T5#6]
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M5T!&8ER7>8OY=DO$#+X8#-8XN?09EVJVGZ%?0!\Y.@6=7U BU_V0W,L<65O
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M\,I^>9Y77M!)XT%E-S/P8/0&/"6*;0,-&MQ7<[RL7>GR4"X<H LX.Y&#P"J
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M'PK*OB0'MLM&*9$E,Z#:/EIZX6[3]4#UCGS-5I?.U911?5,:T#YSGA28[()
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M&=F*F%#+>;IH83NNP84$@,,-L0LV-X S"7!F$G0#\RPV.F*>76!6%T1QGJ%
M(D('Z=7'I/^)HS;'XL+2F+E'D=FZX"*TOU%(F^J=CZP5$Q.X=^KEW"U7=;X
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M?49^S[FC'0:R6ZR -%^HVMS&CY/%*BN &8>*J<QS':^$U7=O(+ /_-B)\"O
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M*XJ4M0JS4\D!&@2%I9'7$4^M RVV";RK%I 2DO#5):"^)6EQ]*UA]402;K9
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M]ZXMS]T!RU69$=UL < G6'AJ8Q!I%9%%V U.D^H8;9[5IA?0L)5A1).VO*T
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MI;;EMZ$8=J\MAFV+8=MBV+5:Z!S(G"08,^$ %$9A/?")&_00F)$CTOEH.4@
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M#I$VN?/BSEOG;=^^7S9)-+'<K?(K49.B,5VRKBYBD($T?4:4JOJ;+-?F$GZ
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M)';WL#.7V@ZF2RS3KD%P&R377.V*7%#\[4@XNS+)MNV;@AI-=[K;.%<:E]R
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M;3</G")VQE[A>'_RL/5%J>G3DNF*@4)V04V?[?SD;55MZ:I,!:-P".5M,<I
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MMXI*^#;<S^B^>F,%<9642Q<J/<ND6P?J 5(.Q: (8#3TBW[_[._)*CU[_+J
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M3HCERX(?*D.D#RCNOK<=<0#7>9GS\'>#+0DFX^ S^H+1K(27B'L/O&DXG4"
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MZ=QD@;MQHQ&TW_*I'U>C[<G:VAPS,;5.,97<^OL_0U/./2<XOK7]]) G2M]
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MIVUQ8O5( (LJ)CR.V&E%,7D#@O ?:$<CVPT/HWMN8_'AF>U[2&GHUIDQ<)&
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M&2WJ1Y IXM;5>!E,LR4UWUU44FR.[ %'::6C#DN6+BEY@5(_"]-C< "'8U=
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M<L%D^PLR@<.>_UVNMP_E=RDD?\WT36C2I@=+)VA.S/48E7\3I.0^&VZYH7C
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M'*.W*]]+I*"[@<#AU3SGX280ST.#19;.TO,R+4<&Q3YVL=MEN37%&V_#,5+
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M3@1]F-=K3-EBM9\U,Z G9DT]1U^Z#,NZA9.%ZG!NZ+,XUBQ",K]/)O\2%LL
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M?E/V;D=-R"YUSX0C=HQT9ND,5MX_[@[A@8U0IG\V*,WN\$]?Q>+:L#2EZJ/
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M3[-?TF:3;^M/1>K_LBCAAFJ*3_5\U*,OT_D*:\,_S3N.=8F2J"G""SC4F.*
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M#.CIV3=T3GT$Z"/;31%>XOCLZ0</^I6)M0CF[PU']-V_Y111A0U#%_8/GEA
MNJ:>X:!%ITKG)HW(YQ6\+8?G$08ZWX"O:,H#0^"F4>-&;FX(GJV90,*54NYO
MAR02=- )UI$21 ",_25HHJ,E7$[:1UX"^FVZ)G;'=,M@ .D#=Y-WB6F6JD<(
M J.J%?BQZ;&=V IU'2C[.VS?KA3AMD2@P=R$,,=CJMHV(DP/0_'@;BNQ<LM
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M]#.Z?HP]^ 'J0RQTE<9%;W0&KUDS:C\BC@?N7%513TQ#5/89>8.Y.),X' [
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M@[<4NWYLZD:>V_A%4X_4VJ  USAU3QR#.-#SQR+K==U+(K[)%S6LV3^X54^
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M%_=U-#@ LS7[&H(^%(6.]H[TC9^.<S3W+.C8'@V[)L]]+6.RK;JS3HE:'1%
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MY$NAEF1E'L]^)(RWM2UB]<>C<=FSPK]6M"NN21,F4>;4 89;YD0O$1;Q<(7
M,RZQF!2YG@M,8Z*)!(M?]\U"IDP70T< >-]0,F8^'+"B)U%S+$F$)%I50U07
M<?/:1&*L^-$D,SDG 9&Q@M(K]/<\1H!7 ;@/BYDWEQA#)V\A=(VUY,6-%Y!<
MV!RF%3I73' @,1-UP@RK-,]I1MB?NZ+NW9D(*OB/H$]*C"\:&4@$OM?;L49Q
MOI#O$BE94VY!3Z&7&43!FN32Y(7M8,H>@,<EG"U8P$K"H\R27H06L7AG-T2*
MXZC!2RSWX&UO,8\*7E">A2%0$J'-_8MX1-'94>H.$(&F+RR'V^2ZP^AM<\K(
MF1F\PU7*X\%@:(LDP&42AC(6')@^.:):;9M7#<S0DDO#%LDNX4;]HS!H$)M<
M8K*4- B$F&%_30RMYZA)N,MQD\2[J,;5';E\?\FWD26&IY VACTF ;2)+E0/
M;#B!226J_1.LOP]27,G12\B.+8NWZ#JR*(*+!HN]0(1XNLR[+1UX."]D529:
M([ULN.A_2TJBQ65F%XZ(:K@>NL07$C^=,Q\I*XN%=R LP[]37I$5:U%2:X1E
MX*EE<4#C,]Q!CF7 AU[ /^.SB)K:2SDI3M91>3:EHDC>3!W)F+96T:I=/[TR
MII,CN:5)I1<]DEN<%2!.*>D(IN@GJ!A(+QS/5GIC</B*^X_#K#3U>M..LU*#
MBRTC?:'J%(<M8XRF6G133]%NI['2W*7SXI,-VK)K4&T*,Y$:+"!:V#PN<-E*
M/159WHS.I!_<T?&[$%0HAT6Y"H&(MC''EI9.?\LQDNLZW&9&Y]!Z8R%<<AK*
M);(_&)2T]B I^Y(D0=@>VGBEUS7V+F3_,0NH \4A>.Z$2:_,^6 MG@<0+MY=
MC+3;@$SZ8N'3MQP/RNF0() .4["7,!QH'/?+R%_5@]1P IG)[0;M,*+ONWXO
MX:BT/:76&FT)=4>2PAYZD!"82L#$!*-NM.^![@-6Y]7E^4]>S.!FSW.V,V##
MRQQN_)P"D>T0)J?/_=/LE[39Y%NXV%X698O0*V$;FJ_2LDN/8?8<.I+OP4 ;
M]]4F-XE;UZ"%D"X,C/% >Y\PO$"B!2TS+JK7 ?_$[LMMYWCU4$? MSNPH\!\
M3.V[OO\*6]\\+HP7TY3:57U-C%RH1PHBZ7Q;9!7HW65?F2CFW[U\XP)LW":4
MLD/7M",8&=,E/K9)%VV\$^GL^1%%/-U^+&J\7Q(-7G*U8?N68G/.+H,SB!U5
M)8;9CE QR'9Y1- ,Q$75188G3",ZVL:,+C#=(PO%8%0?TV5&[1CN/RR6/$)F
MG3)=K_EJ$;FH)3[/ Y9P*@J6KEZ6KL$.2_@1$T_(:CK+4AR,EZI<!9(X 7-L
MQ8*-CQ7FU:98H_W$*7WE+&-!$G"*K2MVL<R*RS4*!HT+4SQR->57=7FE-N5(
MR7JE]G/7]F_39/837%KHP22SO\*7J:N;9!19O\!?X10GOB-?\/SD>[B^-)+(
MYT,,T$S,]"GWSQK]<4,ASD_-)\Z/3909>Z@!HK\H^097E7HWZNO6>AP5\A#L
MMEN9?1H5S\>Q)DE;YDT 4;GVN%F0I3 J#-^W"]CWG:'P'[VG>X%9M>V]#(G_
M.$(D\F!_O_CX?@E"U8WF\8:H-*1?J)TN)A2>;6 _."VGIF+"=>'1Y.!?J/;(
M0SWG'/3 W W1"'J-R2QF["@SNMT;SFCA%))&A),+ON2\#YZ'H#R)4+KO."8@
M!1;3*5U6.G[(L=46S:RE@,(EJ#W"<F'K)DHGH4%,_E;!RR4Z8RJ($]IA4N@F
MN1USA!TW>+\EX[.""A8H2.,>3^UE"1>@SXY!VWLVJQV8>VRM6KPBVI-A:[8\
MM#YFOFB^0X<Y[VT [H@B14XM28<W&EKR^X.DWWVY+ 21@DCTAOD?Y($58EGN
M"H^U[\R_\HQYKX4Q[R,?^$^*'?OY"G&F^?6= L4X> SG_(KEFVS31:=89;!D
M<HH-Q5Z*CR%I^,0R<:@>&-DD5(PH37.Y4KS1TN;YVZE2#2E2E*%0K3VF)C+6
M-52[:)%C=9R1 ";M!*8<IP'QO]8YW) 9!0UZ(0L<-7!6(D:E</R=; ]'>X,7
M 5?,&$P<V2!Y.5RGRS:)6FR3Z>J(; )U2,09Z'X?"D GUS 9NL>(WNQ+?3>#
MW=R",IL?A<KUS:#O;IB$D"9'#3QI[A(Y^O7B]2\_!]Q\WVS8Q&$=Q7+#T6.#
M21 N0RB8V47@AS,\44K[9'O9#O=#]".A)G&?3=KUZ2'M>DB['M*NK.NHOD#@
M2]S)=:/:[5I;P+(6J#F\0KT!J9(/5!M:5XK3S)KTVO6.,]7!74+1,"+C7E^K
MM?78I0#CB,I)W7*^K*DD&HKO*SE!(,$"#+D@-:1K3L:7$:'FS8"\2:&FR*S:
M2GS1H<BXTI"UI*0O7,9+X'V7:2.7R7"B-0%E;J'-27TG"L9*8=H-MS_.&,M5
M'=WP#"D-D&0'1\30"H\KIW:\GZ'LMW@+Z?9Y+K>-M),X/?- OYGV^9A>1(5^
MPB[>)?@13G>Q[M=6Z93.?CV^.)8I"Y$U+;WUC)4D<?9W6 (2S80YUJW2:WJ^
M4=>,X0K[I279-\&F<="%+O+$@0@6A[.3"0*[5/LJO +Y;5M.IMTH>A9]30>?
MHOEYC38M'-%BHP@S0FYQ0W&9Y%ALW../9R]QW@2_EA,6F184DV6W20R2 E&'
M:HK0 FJH**P$]U? "7-G>@1U7Z4E#G[/6&*>?2:7KBM'!6COE^>/]C$U,O&]
M4[[($<"0("A<8J=!R)38O*\\\>!O$QS4,Q8M(9%D&*=MT(X?)C=^(TA'O&MI
M(*9.R[" 9BA2'1J%C[$ELG@YMGV2I[.7WV)1C9JBI<!/%@A8)F6&]B"R<\=B
MA<8 G*>6L/ T0J[4U.NMQ3 CQ9\DJZE[)W$2R;+YTVFKY;POQ=<8R7MSV;L<
MG@M<##G5FH*NN5#_'X^_75$O)*D3(]1]13PU6C>YSWZ_H^*3I;4QMN8>\&RL
MX<,,QLW7CRW1KQ750EUT7'+(=1K,KT.E"WV')2YZA.)O#^YL&8DMDH]([QV*
MQ*-;'OB-7P]I;B+_43HA;>&LU K#+( P$,'/SDX>/4[L('0IN?^;&G]6A'>2
MJ@F7%*ZU_R1T0*<[/ZH%^FP*!W\F&^G5Z]D;:O%PIS$@Q]'ON#NLPHXJ:4@;
M8Z=TN=,[ZMP"]UZ3XU>U4DZ"K#L W@4HHZM4WS,9/Y5*'D/XJ$]Q//N>2WF3
M^-7T:WN[9%40+X)XL,Y%M"0YCS&G*- EL2(+=+GV' DE:['$:*Y=X03]MBPR
M%EE49<.0*T]!P6>UA%T]_"N[PD85$DDA^H& \6%*^K8&N2D4+C1Z8Q4952TF
M8#G$/3&4T#%*]@;/,'5Q<AS&",^Q&GSW%"XV(QT>WH(1-HN2"5@G+_FX3TQ3
MWNL6A&,O>]8Q%*FV8MA3OA)'($0/-^]> $N%YQ).#I.RMYJ9$O4,7\X-P/@:
MN*Y@C*MBPU4ZP["H2[.Z"LY"6[H4W!8I\$6X+F-T$^0-Y50"KP!>YI=]2OT-
ML++4SH0$87$S;1\Y)#<0"01/B%*G@OGPFH++W-)NXH?"%0]GBXN*T,]3P"]?
M(,.OI]A5-".C.<.:PR[W)H4$::>[WH@=8IO*77"X(R5E@Z(SNOGM+:_>()#A
M)6,)8Q,;/VFM\94(A-VS.U(0-S:P>OKPUOVK[E?.Y=M(EWQ/W5]>2">_-YHF
MN[ND*S>(^PE<N]#3\/1Q5/F^2K/9V2/J)\C=ATT]@N)%0Y_"1.#44-;]]>KX
MFV,4]!_Q?[,<95Q\:+1QJDO8TFP?6%Q.KO2D[ZCT#N>RR6E"#/EAP2..' PJ
MX=FB,DN&NU#GQ.8RK21C:=+'F3F8+H\ZDDRG] F_+?!3I;T#10R7.2DY5(D<
M_9(Z<=34HH/FL-*2DPG'>]2@;EJ=Q5</AYV0:.@N$1V6HAK<BXC' *^$X=.U
M9#\90TQ[+4 CO(>XG6R4T@+OZN^\8'BQU:P4<_2>%<:YK!>]4%0;,CSQ^!N.
MBX T$3X&!Z?0#2>>-)2.Q 4_6<'!5&8-,K4X>@"#_'LMAE278V?:2#":_!J<
M!JQ27;Q%+,^#1=JRU'(_RB,FTR:#I&K#1?KHY/3!6Z7\@/]>Y6G9\0^1K!27
M<)Y7.36L)"##%Y3?X9Y.=5WR(;&YVV09+8]CTJF'0=,3!'(OI(WBN"K"+4/N
M$ ZL#@Z>WC!N_5QEB0D"D_ S=PS##3+)5R)LCUA@ENQ^%$[V\PK1<!1&TA'/
MUJ1S2-(QA\:F%J&6M;JDS;&&5^RA#HMDG:&,(#6)H1'03C+SC0 2\B)J0'F7
MA\BA$JRX&H]W7Y196 ["++2,)2"SW )$H<-R*-SQIXFDYSY>?M\%1/T;AK#?
M107NRV_.7;;:8^E[\*H;877K9LL<?>)2\A#TD[)&!4<%!VTR*!#!<!88N"$
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M".J@4@;IA\'&9U'92P1XP$8S$1OCR.F@*RZ#,"%+/W7%$"AR?3K@0>!<:NI
M[:P2#;^8#X4G7E<F</OM>-;/W'41?X]-/>9Y7LEZY)E;#=L#.^Z7-<-*B/*1
MG NUD.-F3MKX\"1J?!A:=;D^;G@ $[7IO; KID0CA-+<2^LXV^+=CH>312:[
M.U5JK%L-*TKV?Y@"*:KH/69!TF0M5@/[18@*Q'^]$^4#AY[%E?916F5.1Z^X
M54Q#,6'+Q$X(NQ?QZ4B.8EZBL""J/@JRY"'$TIDO9L6(1M3*)\?1RV2)3I7^
M"78>HF*:V0H;KR&,J'6>D4\96_WAQ$UQB]JU^/A1@\Y*0L92SQN\5!=3=@5N
MC%2JJVC39?<,G1I>(V&$.1JQ"E1"KF#D9<I$EAF:.AZ!!%4ZUZV"'-'A[Q<I
MZA'41L1?MN;&9%F^(.#F7:GFKUDALG?"6#20N*!UB6(X0%_$NXX%**YFO2:P
M410KC84J++OU_%%<X*!7MUQIT]BIZ?BI6$J^NI;;PDT5S Y(3JEM::A%%2$.
MT5>=D+NI=(JBZ,QCE82N681Q5'/^88ON[<V(5:R-ACLNWP0=YV,EXZ6,+MSI
MN/0H&CY88MI&"XM2)U.:1MUW)3>WQ%@I+$D!)UP"Y5UL#7'!*O94IE].W(0:
M"*B;^"+[J>YPL@9&[\9F5F57*YIID_HX; !FU.!O")A$#82'-,LGERM$A[E6
M7'6'A2$,)KSD&*#FM>XD)AS=C9JXU%M&:JZ8]3F$T4CS[=SZ<-KW)/Z^%*XD
MJJ03RVP16AQK>7N<,*/VCZ(1.'("QE7'AFV*A YL;+VA[L]@GO&G5,(U_(5B
M1//V5E6GW&U.3C"5I,,FSD.<,Y@0]J7(_3O?.3J>,G<,G[-+*.^.CH8)&JX%
M6F:"UR@")3'IB_P=GC?^>MB(78><8;4<F]9#$K7V)D7I-: &L@,\<KQ!^)<]
MT^4NG%(#RL+%(6E1E$[.K)&',^YU2\J:%?271A$CNBGV)LF8PW'I_':-;)B;
ME:M:**;'FA&4_YI,"NJI@S8'%L&9]4WWBR9(_4&/P_"_Q2)D/51R+8QX)./R
MZHC59%(-J:YF=57@J9/-N%G1AAW@'U#3@W",]$?,9M5<Y2#L=- QY"G8>W''
MT3E5L ,W?):T])UUW)W@=8]&AE8,-67$%6/8M7Y-]9A\O*]J7;V\'#N1EHP,
M4_NR$C5*W\XI]](*H+W@JI"5#69 5,Y]"_-W*4I[+-N^Y (E1!!G;[[]\<(U
M4*(,NO;6&JA#., 4760R)\:!G?,#J-9:MI03J9=<8I!6B!!-!=6/ZV$->'&S
M*#:%\/8AJC/UUP:/CR39 *T(>TVO?'>N -&G%5KGR R/BF^^Y7&(+BA8^'!9
M$[GKL#&TAN?H=RSEESU6%F!Y\[9%EGE.]?>5=?LN":***UX&DD&QO\([%)L/
M]T?7%%RUX\&PDG!/#%\4H/&^^Q(N$V*3UJ'(K2Z=[T(.J/A)HH&" %?3[J(2
M)K/S%.M0K7$9-#JS>R%PMU1C.Y<C"@)'B041]S=KTNM(M@)USG)DN2*U3NBM
M$M1,G(AEXTM[^[)_6E""!^1F#<*\6/1-U!V<W\PM1EOQ)/#9I-*'D1]6=-[R
M5IR,&U44I!UJ/@5Q";T*XQM#(=+0/]X9KS1&/[%?1!P2TRFD3.QU.ZT;JVT9
MI,0ZP@,-UOISRW"^QN&?JU"]<9+RNZ<X*\7J=+'[BX)D>H#C1<1N0= O:7Q!
MYSIT%XF;K&"Q9TK V$$C;-=]Q?,'F 4RK0NBX^3C_-PLZ2AT2XJ*@Q0P3(5>
M!74@3(2(@*I\Y*N)R5V+EY.:!W%;)O:\K0&39@JX!]- ?N'N80"<65CKNNV\
M1A.SC1%Q%MY7;<QI)2+V\!>SE5:9&@0[K%ACVF*P^H1<WL%S8Z56J).E?E5W
MQX+V<6*: 2N!_XOSR*V&,H3X'N<!YL6:'F"%HF::1.Z!N4SPGX3,T^9#7@RU
M123?B_W<]962=JZAI13?2]8CTA"AKN.SC1PE4O STA30EU%J5]M8FEED^@I;
M3_?5(O8*/,GDWJ<S-&.:%NVSR;2?'C+MATS[(=,N^8@U6J9VXA5]IA"M>M&C
M!M+8OKO%>G#UI2FV%)+[%GJ1%CR>O8AOCNGH)RDMLN)=H]),:LX80U=P!W8*
M/1K0?V&40WQ!)9%9&>Z2@,N3)E54\5V@.[>FGMK''H[(KJ0KY1U0^K%=T#2!
MBQ+#GV#0%TJ>1AEUU(V\0KS0X7[?LYI4TKYK-2TGZJ.FA)"$:YN06_#T,@()
MX*\H>>D;_7*#,TJ3XOU>Y6804[=R7F78D]1AN73B@[ZO[(ZR=S!]/3AG*VVY
M[W =Q0/"K^XH//'+E!NUSW7:!5L5<+1D[#ZB[W0\^R'%;X%=1YW>M]+IZ@I=
M_1+APQP)L$?'WGY$AJ"&Y97VGT3+0.A#,+4"'S2:=J*8&K%=U@)?V9$58GS'
M=/N[G:!!/JM*-X.S:3DZ.# RS68D/KF,C$OQXUST["L^9X4U IMP("?0I8Z:
MTSV7XC!?T89%#XTB#!IYB"W<Z*^"E^9PCAB9X,;3%T/,AF"]M-*4N*&(R90W
M<6A]=RB_BXRC6 (KIS$DTA0?5Q]P30)J1W5>J#@R&)[BQ>4<N1HRN/W2\M#9
MX""GMY'3)4:,D]EURE0HG"0BG8E4AB2Z<8?GH98^B-E!S&ZC#I=]&[284M!*
MBD:]B A"1_P_FXU/-*C9X;^7\!=;JIGG1"+8*_4BL $I[]@P]'X0W8/HWJIC
MD81Q\^(?U'FN(9!!Q1%<S4F/9%O(OBFSN28P 24J^5_FNQUD\""#MVJDS-6%
M6;YH\IQ*RIM-W7"70ZW52R_A,W'@LGR>-IS!1*D#OX64(UF-TH1=6)00G:G^
MST$:#])XNSZ<W)MX76>6 Q>EQJDK ID1[$;2Y18H4! V8I4T2J@1NZN(NN$@
MBP=9O%VS'2]+BB(HD80SF7V3I\WL^Z#H7C-BOE%')R&4(Z5_\U0QU!S8B: O
M#-^7HF]QEEQD:1SS&A./8,SJ'HGTR4&B[Z=$%]7?^RJ$+M6 #)'.17%5$&7"
MHB$NM!+])Y#PXI[T?_F ^/ZBK-O<)9C:.%Z6^*K)?7 )HUM!H)X43E(YY1K1
MJW6%/, K2JT1QB%"?<3X(Z&6FVB5R[3@C8N"#Q+U$\7ZH@8TC!ZJ_5P8W0';
M3 <Q1RTE^\H(J.FR_RG=G$CSB-I'L+EE>LVZS"?.X&VK8EX8!CI:NGJY/*)Q
M$/SR>/9R.F7 8*DHMX+K:\F"::B-IC:8"I<X=081I\1; :,]#O%XDGU*\XV%
M?_9:<8M<H:8 =L0^7S)IF!4>&T))VBFU85\Q-:1(=8.=#]%J X,&*96+Y3)O
M-#"+0B;$/(IS<CS@7F:P#<!B-5A_P="LUT3%W-18<T<XS9*1ASMFC&/*KZ1@
MH]WQ6(:\8I5PDZ?=6@GKUWA6#&Y:,&\W5AL7S:)?<^6"0U]:^8>>67GN*KW"
MW"Y:@V%LO(A%@W0\A:2&]>6#9R:S57V-F:[$\C51TM35TT7W<VU5-02P&4JT
MG+G"PN2?#[3OZP*4/XPK%>C2FQSDC"CT7DMHXEMV\*[@8/VN:+\I=?[UZQ>O
M0/?B[E)9.!A"\X82\+ECX0$Y6UV#P'J.K% ZXP[C"E:"& 1I 2C>(EV?Y[8L
MB71_)LK-ACSBAE$'=-0YXTJT1D=V_AI;Q/'K@T!2"0I6>TCV%;Z#&&E2[ K#
M:*72BY4!3Q$Q:J%$>-@0+HS\]RI^C*2(U2\!3:SZWO&RSU$#6I@?"\'R%">'
M5#6LXS@;.L^[ZUQ(JL9K:(Y>6&C'((<U.FTPU_6>3?Q%FU#A@?$]MBM,HP=>
MI+3<=CX/D0Q(] 1S-^3-PF"Q0'MGK[R@<$5GO"!1#438-4V#CZ?F>IEQM0+S
MS W8UHI.FL 0W$-)V:08C+58NG:5CH[,8N>*HO*^1,2T@>H)H>.X)=VABC@_
MC46S(WEC"E!$B(*CU&OIDV[PQ+;. \B22C.4.H)1%2V</N3@%3 %XLFMXM[!
M)*(1:?&48[KVR7^*N?(_,.U//\0W6%V-8K<84,.J,>J"-AX\VHL6Z&5)H^)V
MM^DW:);9K52+("NHME4HDRHU!.QF^VQ FV<'T.8!M'D ;:H>L^)3"XCNK&F1
M#E$3NCPNHN1K&F\+\X'(3;:;8H$U *E !B/PNI"/3]"O144%7"CZ3GS)054:
MNY)(3ZY=E;%(G>OP^7=$CMJ3:=YZ#]P9<XEG89)W"V/!?#M1X\=>RH"-HV[S
MB$9ZU3=9R=>5@46C?F)[S4Z["=N.2Q@IK%<W1//1=Y%W]JJ:72 Q#%(C,>'*
MV<G9:2CQ$ONPNZZG;$-/S<3A09PF@_RO7)5MQ-Y@S)!Q)9I5K,T''L'P7G*?
MQXM?AQ+LX:5#SP!)#JOH"P[Z"4AEE@4_EJS^.P*)_FK]X&@4R9!,@TZ4O\G]
M74SL)SM8#;E)UK+N9=^W.2YXX&^2VG+'CS ^SDA9RD7@3' Z</U?559\G+B8
MD);@[A\T,52[+JW;P<A/SZ)Q*V*,AEQ7KO3F-L,^GGVC9-!@#)^>'>%3I8B%
M81;F@^(.6 R=0G#4+HR.FJB@E#YB,!SUUPH'=\*\#8EU,;*P^I8:KV)AK^K2
M\$3]H8O9\XG7TV92S]#<0#K']'3*@\JT:%K_B7_&DW0D .MR1##?CLF5]W$^
MXXP+[B88W$[VGPGCKDZT'D2WQ++PK3K001T81J8=J06+?,S..]Y&BC0SYV['
MW=+HMC=6)=/(2/4%#Q77>_!@=;^= &)E.+6T1A6>,#]7FB'1.[%@%)U6 $KC
M9'+86"!1+7/<D[_!]4[RO2U&-N^,6'K"Z0G%\8/C%A^)</J4 <V?+H*5[)!^
ME@K^MKW57!536Z$IYLT77Q$L%59X\WS:M9D^CNB_^:FER+P/H^,C;R'X]Q^<
M'F3D/F(:P@?%%[RFX#>&Q8UXU)A?8\QMDL"/]=>GSR:8TGP90:<=Z:J:8\58
MM0('G I7X#E['R3EQ'79:Y//SO-GF*Y9IE<<&$TI/-\7G;U%;Q-;//D1+@V;
M$<OAK69>M"TS!<<>%%<RUD=G.\8Z^133&X4?'[5PYUYXKOGVH[,C>J@H(0N7
MV4SQFV^E+*@8!UDB,SD0H[7<[@?[Q-+%^.=>-QT,KD<C@RN=90U,:FQTB9TD
M:9U^0_<=ZMFSD]/GPM,_,2I[#@7NEJ6R?3%=HLV-0S:!&JU3@AD*-U&Y@E84
M!UO<WPGC5]^9/IN(3Z"K09>/N ^;/(/3VE!XAVYN?_)%'GZMJ,O3!2IJS$G8
M3R*;  3+:$3 YFE'!(84K1&LYM151S<GG0>.'Z+<%?08$<?H=1+@["MG^>3D
MPHBBBE[1P(V\4"(:]Y)$HUJJY",2 6U@8CR;1FT:EDWH^B<(O#EN)-(L-^O?
M&CS*%17PYVVG-RLWPZ3.]-PS^*[C^]3I@!Q 7XN?M_XV06="F&%=/=_0_/US
M7V[UE)\^"Z<\U$2C1"Z,?X2Y419@E%,KOH&79-E;X16A^'L<<H_["^1Q53?O
M7D4_6A:R5:K1+T/^EYAOEJ!P-/'4I)L<]/_"W7\X%A_JG_U<S;[)%Y$CF8!2
MPO__!:A9 J)0C^*<8ZROO[^(J-7Q;R]^_NNK;XY CV$GM!PG5I:>;*/%I2Z$
MC<VY#P,"3Z*((14-6K[>*/E13<%/GJ*QJG I6IL'_Q,6Q/*?1$HS"N?J;;(S
MSJ$'M&_-!$F]?SG!B#OPED)N7 :&]C>-IL440<=ZW (EZK&,[9FQKM$Z,%<5
MZ=Q+:G0$?^()$"$8>#ER6_#Q&.@6R?LG/#PA3LU'"4OP0W V2#!W*3,^;VE9
M,/[/1T,)^N2=R2#ZD>AQ2Q==-&RA!E;R 1]*P5-&#L;=W40MU4_V+;G'<)BO
MI?%TM11:CS>Y5KJ>\\3@V)S-'HC6?/7F7#3E%\+,Y*:'A[E,1:@Y'$-J:ED3
MM0-EF"2QX<Z+.)-67 L_@&%AH2=2^<F7V1C'$-SGDTU^S9?;+W"YS;Y%ZEX4
MS=^;(^;5A.&06(,OXG,+KFR"7GK>2'&R\LCC-JAU+'1?);L0_8:[3RZ+J_S(
M>0URK><Z:>NH34C]UE_[!#W0UD8IWW7PHQ!/HC"F^WZ)8=@L=,L:M- 1M<N6
M<HKQ(R7WLB?8L(A>.K1<3LL%U]SC.&H4C+1<!D]2L[ /3L7LYY!M)_Y3ZOX:
M(D4< 5IJCQZ4Y@=S^2:3&^HWW#P#(5LT5%:VK'<>G+G7.1I2>Q^S-VY -XYG
M8.3F[C>:;?2MJH4T6W=YG;XKUOV:7>HKYR7*:M,[)-T*EUL#0V<O1[=I#RTL
MREF1,:<Y]:=S_CJW#,"E AL>+0-AT.KJCEU:V]G@>86%TR@>$EEBZ.#1GDA=
M:-IB;T=; H0#LZGR)D=^**U7-=HXMO&11!W&3.U/B5+'AD4Q_A%*C@K;'6B,
M[^]4>-P$0<6V1,(DI>Z3N,ZU, 8_I0T//9*&,=O!BFGK,T>1*:U4^8N;HHD2
M +(P166\U\>S[Q5:1( L%TI5\YZZ7^HKY_DBY:QQ(NLD-(-83B_N9?X. P_P
MI4@4O"I0<DAJC\[U0J[JWEMET8-9GXGYZ78WR].LY*+-T;=M1>+5,*6I^E)Q
MR]<X</<49?*-F#1]][Z+>BVTW\1ZC#$^[4_VV22M'QZ2UH>D]2%I_7?04&VF
M# 78#AO]PFF+Q.H<'%&N65/!TUGG&-8JVK7<I,K56G/5)%':(Z*SNE17'>VJ
M)E])NVOX424WC^CP.+)$6YW.BNP__PWU]]=XZ< S_X><-2[R^)\71@CS;RP>
MGX%)SLZFJU+Y0=';839W1^DXG-]KSL10M",M77/; ;^=DQ57:>BH&BE6PYAU
M\N(E,*3EB<Z_3[DYA4>]*XE^QSSN568742S8A<MS;JW;)R.!YR) 05H-<:PI
M-\$?AJ\RYZCR>&R0.; @7#2!N EV;S0QBF,+9,=_BF9X7G7%T5^*Q5N\=$C(
M>[#WU*D]_\N%.K5?13][F99P0EZP;8;NL/[BY8OS^!<L4N!&@\U(0O0:[%^-
M=^-,D)H*(YCR)_&M3Y\_?V(/_?[5Z_/@71./DKC(LN")#4Q(ECIL7)7V:-G-
MB:P;[3MX/\AL0Q$T7*4[C&#"PEHI1#M=KX#MPY6U.M<&QV26(YL347EQ.K@H
M2VYMTM94V"!TH8N\N*)_UHB7%<:73;IEBK%UCT(E.7^$A6"0*F& (7P,IC(9
MP,DL+V14$D!K!!<0XS/5'>TQJZ FIF_!HK_I\C5!,O/F"D.;P:'3WEN^\[7V
MD]WNJ1<6CX<=YC"KD%7R<>!Y4X/ENN492V>X:DLKC@/$G@SB0N$&33["#%W\
M!ZP&7"2<:U$?<A/KIIAL#1>"X*=5ICW9! PC,!I=P<:J"4@J>%!.'3$*"@GQ
M!<^DQ5GL/]:S*_"Y-/T/DTG8IR)OK6\VM0>BNE6K<HI^!9&P30>)1%*PD*G$
M/1#6UORRD(B@/-N#R\+3C: 5_\\U>@O@'NZI8&3MSDLA9F]8V3ERI&JJ!$&Y
MU/%=BU0Z- +LG,@A:_.%4-W.N1IR2R- 3B.8,.QA?2U'R52I!NHH$3@X+<IE
MB_7P& E%R+VK>O=6!R96+Z/T=H!AT>*Z]A:);KV<5#L^^-_R/!\\730P*3@9
MO!_;65:3/\0-N[;:_M@6=";T_[*&Q^1]6D(Q3%S]473X2KA9J2 5NTWY?AE1
M6Q67MU(^LXD-'3B=T5!<F=?P31':B[-:@=O?N8CO]<90-T0E>8S;X4L9&RW#
MT2A*SL 'T #($L;^VPY<WT00 I?,=:A9@J ,K"F!=GFA;%U*JWDTWQ[A_V(6
M#Q']FLN#3_MU+Z#QD#22M<#8(&H1:449ET.=RUU!/ O4+C[,D ZT\O:C&H)9
MX?U1YMFEJ8!6KOVXJ0I;X4&3%%W4>5LZ :PE$I+*]_"<W\V]^F)<E[<D,T5"
M2'CE#Q-O8*Y(/P+Z,;)=4BZ5"_JV\IN @,4]97,1XT5<!\(_A>^T79G/.4(/
M*PF""_IYK5U-$KOOIZ_[<)NVMH\3-SYJ#/R,+O9FAL$A"9S,<_T0 UHR9^Z&
M85TM)^S:)<AXM"P(F-K-SI$$W"HO+A%!@J75E_ T+ :,;K]01NJ>%<QUG[AC
M/>V1.JW4D%+<J[KD9A*HF+@LD(^>E@-U&+!F_&^PL#&%F')Z;S5L2A7)!N9B
M=D_Z>/:K5P2#2%S*#Y$4&8Y16IG:@=!SAA=284 VS3A.K*,\D79/;U2E]GEQ
M5QA7LL)#55UPK73E[-B)/I%K=+_<Y^_H>J8^;"UVLLT9K$*+0;:?VQ#IDJ(;
MX\5VTQ17;.\$>ER0_+IIM4D#I9IYL<E#&)/NNS>!-=,10_%O5J[NH3PGU;8>
MD, RSRN\7PM[?7VOU3$#LEZ<HZ0T0@,[)0 ,GVC)BPMLPK[<WFK$1_V-R:W3
M;DE+2LC!$V/X@]8L(P/S0FORS/<2<VX12ML*!-9JIA?^HV;SGYU*0?EQ)@G.
M:H=F(5>9@6J9@P6 !AZ-@TFZK@JK6&8H!2;>P]O?ZX5]91D5?A\MT61^Y2Y]
MVU^/P512G6#%X;/7? VULXN^:E?8E?"<B$*EV%&C'0-_R3;5MF]Z=XFF3QL1
MQ!XEIG&MYIX/VH_T*\0<\[^*3#W8%ZNB!'&MS#0>QR]4]\2=ZH+KDG#](G:.
MH#H9HEN3%-$+R@WP*/75G';[=[A-OK*!S2[806XM!O+BQXN +Q@V!Y?J35UA
MBY52R&,I"TG>+:F2E)M Q3?=,J>K$>T/IU6M?MYW9$I;;,J9DK]3]42J0 X$
M#HAY%!22SI\*70#\!C]#6@5JE\$?IA4<X%7>37YZM"ZR:["(6SWKZ8*<]57=
M;C"8&=>6<(Y^56RD(@5IV5D$<-6I_1MUSR7,MQ$#A%8<Q7I-F#FT;?"H@'2A
MCPKG]VMP<:M*X*1_!A$%(U'@N 2?>IC,7J#C53<5N$7GH.W6<_C]U^@'G)X]
M?1;DW'UM, 80L,M<&*[A=D$OSJ@0Y"[Y&>S2<) 0\HG^0X"/13CG6Q[!WZ_\
MFQ*>A9#G3T=I-:Y'.D2ZC+BX*F)H<"%!E'59J!>+U5LADZ?.V]GN5 ; H8*4
M+B)/E,%/H/."WW*P'4RCA19/>./3+4M7,%9',YH!K[!>L(B4.\;^-2%HSKSY
MW 8V<KJQ0;FV$T#C@/H?:Z@@-A[1#**.Y1K?K3DLMINAI;!&BA2M<MGF^: #
MC#"71*V*QE'CA-V<)!AYW#>(2Z8;=EO=P[)TG5Y2@ICSQ /^OS#D(W1 0&XG
M?0V-M9A:Q)=ZE>TJD^@G9!)U7/;35]S.#;X6Q>,3QU=84^$/(O4^F]SQHT/N
M^) [/N2..3YL/='@^KM4K5=S*<R5!&!#G4155T=!,^,MT%[6#<?L? 0&73-0
M&'7%'VA[KIZ 7Z+7X-U]I^V6,>B1>!X(M*>*SFR+V:)'Z[94-E3*\?6.>)\Z
M?]I]L#/+_ W<^*_1T5UL_^<"_&;489]/CAE'/Y/AT\KH%.XTE_Q3#PX6FL-D
M;E@F,1D:'JU<6A(O+LM<'%60(C#WI)0HD1:GVA>5I&?)/>(H7,S/;67FA*RC
M^,*P&WJPP?EF/%)#/^J]/@UBK71*XZSH%"F;?QE_BXJ)YM1IADU1Q<2Q3<5?
MXG%%SLA&-I>_1@LX&@'E3=9YE#B8'M6.]:8%1JQV6;=4-RH.?1<Z+@V6+$0A
MI]9:>M%:5F^7D28>HO^+U,ZF35>1FQ U J9H#ODG6E AZ )S*<,0?LD7JPK]
M6L[<? N+5*\%$?Y"G2G^7>(<%M C6L5OT:0B:D;92G^I5O<F,=GC!TWMLM>F
MN#[BFLN&JXU&)*984,!_EL:\^$S_1;K)8$Q@3Y+ES:V(4D%TYB&W/:1H\. (
MXX3PWIH^8-! D6..>4,\!\8?H.YTE-BCV+G)$OV;PIO##+HV:=*H.[G5&&CC
M@+1>&\BH(\T@M=:Y8VJEB:."VXS_KR*^NG)I]OUP78YGWVHN((3>]_@*'$2<
MR!@ZQV9@RR=3QCP9[GRVU*S'__HR[I\>KF Z9&9.>Q$JEE$A(IFX'.A*?=&J
M95%GOH4:1U:M\LIJ@LE#_";'LZ?9#3E7^.OO>[@EQD&4[[\/011<DKSKRI&5
MP L8VPIPM+FX*0F9&=J-D)GA8D513]QFEBA%]PC(A%BX?F"(-I+!1#+!E7P8
M**O(T^=J:@+#,CCI'QP@Y)H"*7?;)163_*UW<0U_B^""ZQ7\?SQ4"[*+_YIJ
M!SMCQ_CE1:*23QXW7RNA;%GN(K)96^U I@_ Q"^A^>%K>"NU7;XATQ$;[DX\
M;.K>($6::_MO8128]16\I^&0,J7'-;5.T?I9RA40'"/@T.[P!%_P1<;QI<=6
M/Z$)(+E1?VG0HW^!$7_.:6$L)RY/B]JU.G<ZQ*"T'"P<:(:/K:5X.;*K%=G
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M6 R+)M2#@F@';M[N]Y#'1DO$2552R?EDI%,KQ@+W'ZZ\*!+*"0WHQJQJBOE
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MHD($@'E/$0&Z]G>T70<)U0;F@*7:K*\$GH]XD+UG)C!96Y9HVZ/K!34O"+C
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MWF@F)&;8X#*!@@@/)S4$@ 8([OKLAG%K,?5!%_-;D 6((/F6=C7.8%W5/*N
MS( I&FIBS\,R]'XQA5IMJN^QPP<QA7(VF$>[JL"V:59S0!O,"H#D0QR(^\,L
M"KOO2^>.T-O;X7<-$PV"6CH_:K2C:&K3,>[^@"B&$8*>;NT@NYB4HPRR*V'N
MF(21%PO;RT=.6C0LU=75B4%.:K;%]%Z0B26Z3%@;+HWP3//=C&[5+G0/SB1)
M@&M;3HENDH@)JSF2A;</C7_@#Y-M$9#216DWJ8L8UV$FN\EH;29BJ-Q$>K>A
MX3LLJ5,&K,S^E)%IP3((V>EH'!SY0N>@@\X($'11;S(MAC2GPK",7,UKO0UZ
MAXWL(0!7-  5CE6*E=0 Z=U[+BUKD$_AS^MZ^HO1?S5E$U0L82LL"'&<"D"=
M=%P0Y KU;6 ^/IV6OL*.8#SX%XJCKSW2JE>HD0,XU2HY',@69D-DX@'6(1"0
MT@0@>!S4Q7S,^A]WBN$0,5"4,T2&\P2&8<8JC,Q8F(,4LUQ8=I5- L1\9%!,
M$XP'0H=\!I*1N:W)P7A,D:2NLE5-S0M9('P""0%GDZY7CPV/GM.EL_!H^<G$
MY<-5I&2Y21<CW-?*JV8QU\4D55HV#;P[&7(:D<+Q>+G/*'YLSA3LF7WM#=4>
M83<D%LR!V4EM?P2UXZE@U_,&!B@[*6LT$-AK4>'847"$7"1J$5?<927=2&DY
M!RRTV;H>UM09$2LP3HP83L;9YY@X0PN'Z:TY.98YS-T"(Z2O$=@3G)API(,=
MB"DN+=,+B23<WKFAIS+]3NT(I+JU/Z+".\&WEG5;W!@OBV+0>,<$N"PRZ"=#
M>M<6#U+PKKBC]=>PPK;,9,)B9[(;<"DK:B1SVK"@JZM*P/C&T #X+5EO2K\'
MR))R\#%-)_@-ZCU6FN)/\J].*5B1A_*K<QZYB^&_(%\.!6<SJN2F1%!]E96#
M'4#NFB%^5XZ0K/[RYN+5,M@$D7Y=GH(Z)RP!*R"')C>*3D,J/!V$7)5$,:LM
MB"W8$[]7)/C*/]FP7EH2HGJ64EY=IS(0WX+3=3X*<,NAP+9K-\@IGCZ%0F,E
M'D-A40^:#LFOJK,=)SKE=")Z/,B(@T-FCG(@K50O(SK>^M)0[MMW*T=U"J53
M73B_U/T7M(#0W.@O.)LI ;.!VX\9\P0-IY!A,_A1Z2WK'9$G2*L!2^'3Q/75
MH$QN)/'HCHR[73V\L;-FLG^#^QL3MSR&56+S-7BRPGW[(N%8ZFI*0IE+1N;[
MQC+%IX6G-I2,=@6#,\(FB$J,: #PS3[KE4QIBH+APNM$"\:0XI/$:WL/5E<:
MYFLKM%)H3@05 S^-D]O6J":AJAW"<J1MX;^0B1*?C:#103 O0^JKAG@W@'([
MVL3YTC,V-I[<(D>X&V^*<O1Z@?)]"'G4PTT>=9-'_5[RJ/=3:56ZV-#K,QQ,
MA;Z=&.FH *F_PZ.UD*U"EQOD4'I0?Y$+82$G?5C3<SN01?=D#"'HRI1PB=:P
MI9W0^A2/ 49!"'IA&^5E@8:*JC53A-9^?I-D6ZNRC3(-)N5KOULU0MU$'*P^
MY4.^DV(XQ2AQR+IC0&,]-B$](F;;@,&83 N%Y!K=/)M@0X+<)/<%)[LPDP.%
M8-.Q,;-YFR@]@";-> )1#S!P??,"H 8)_?NN==OPTM.ZT"961EO$&#T##;F)
M1%:LU4KQO8P*S2I.<73<9#=711=.O/?'4 "26L/W?Z2S &)(3#?KZ1NG RT4
MC!0)OAHZ.!@^81@@GP>JQ)*AQLBL'UV0!'P@\IIW^&03UKWX\,[W4#2*7CLD
M/N HF.'BPT'TZ7<*4E01/GA>RY[)!MU.%Q"=:X(>HV>*/:?=;]1&QW70BBME
M:6K@>V!^8G:6N/\PGV'K (!.N**3R,_5I@#;Z\)/Q)IX,!T'\$PQ='.Q<P5Z
M*B$>+GKA=5:E_ND^"==C)491="TL:)_FMU>0YCQJG&J_0F>4WZE\%(XGUYRU
M+XYP@YUIYY.?[VYD7,QPM)"CH-Z_AOIM2(<;CB_^E]=ID+^?<&IX3.G"5'5G
M$X3TU:H8OUX53 =;4I$\QN,;@8X.>#*S'C!) 4:#J:@'%/H=9> H:6M 4^3@
M-AMK2R?B5 $S1&9=$^^$ICG6&@9Z>(6.2S,2Q%1S"W!'I8\BY/5TFO;*:=61
ML@MS]LC0CB'\UM6TC@90>AN^F*/@6>K5!UQ)HRP%\IJ"PKW&:3(^$*92S*/X
MCJX0R'-N'$M#PHL^)$>+"XO\ZP4X-G"N*NB"G6HKJXDV<' F[G3=Z+;R!L<+
M]T#*T!SL[>T_>7;X!( S@]\>/GE^A+_U4=QHZ^79=O2ZB)X>G#Q1,IU@HS!-
M0!?1;YX"%;;Z-X@)AJOXEF."$M<(9BHW8T=X\;=7;TTP'NL:&B(V1ZSPPJ<9
M-C[BOE6ZNXJ21Z%A9F)D>+'<]GW%_V[6,Y,0JWI&ZU2N6PH\TI[>^@+-,8:/
M!EA"#'8+P)@-FG04G9O3AFP3 ]M'U#YZC7AW1Z7*G411H@CA(C>,7K0M,.(W
M*3,#=?]O<]D$LVN4FRT$]>T*H@?;7(JZ+6LYF 2XTK8+YQB 5-<T4XL"@=EZ
M2=V_LBE7@V2B[^ZLR/H-""HX< EE>4G5[)VEH,MXG)9X)P1KT[VC3#H%U7YH
M)8<AM*;",[JSD?N8B+&9Y6BKXOXLW 8>:R!!;H9KF="Z2$8<"O1HDH;9=;6T
M?R;9(7EWRG<0J%'H.O%1YZHPLX$2U6?;FJ]H_Z!NKCQW,L0!86-H5KF/)1!7
M=3< 6#XR+.JUI2*7YI"G^1!([(WH:J+(F;:^XSEFR\:G&DSP\I:, V*](I<I
MJ\V%ZS8WKP E#$-H-,,D.S0H$[K^C+AZ<'QRD^&"LDXC#:#O0!Q]1EVD"\F,
MYG8GS%H(1@%XCWTZ'D.>W%9V*)&\L_#[WO^[&+\]\RWT5:LP^;:D).E-> KS
MERARLTZ9[/U&V;(7%2MS$O 5/!:V1*95$WO9KP:F).'1%;GO3G,Y'=SG8H(Z
MO41VM:3TP"%S*C\LRLR<-[VU,M+) P!3]F4#C6V250I;X R!8#$<[HP29XUZ
M20%.^=%\806\!J6%:SD,@E*"+ZQP%]M%I3@J+5N@O!@0F+3'$A%_  )0@']+
MIN).7>Q0+ <R7V:@*'W8K(?IL1TL$_>4FJ*%_!-ML_I_9X48#0)'Y4."8?KP
MMI/;??7UA9H$72<,.4 &-4C$F?B53P=!^T+FKGW%W)>C#MI!HFI8$T5).,H\
MW:YSNG4U:ROV0@4V1Y211:_&5\J2Y=(-V"4F* -7 7_X,$5[?<GDN_>XRI"!
M6GT,<;W0MH<FAXR<982#=;<QK=ZT[%]QV;<7*["G/#LY6E98*E@::) /?QAB
M6\(4BX- U"(>=^!P-S@&17F9Y&J3WF35%:-+54!GZ\?EI!\"'5CMB'05EW B
M2W\@D=H\^K5C7 VGB-=CE*B&'KLE&Q67X+VZ_\\O.06-E]*'/W:DZ04' ,/"
MM#\!<;'.  &R/?4=4(5K:9J=0@K^S*?@__06P;<SR\(6J\ LZJ7U#8I@Z'7Y
M\D\49'\78LD>'&I2<:246(.TW"EXU\"I>"AC2T?#'7. ^L4@Y7+27-&?_7M8
MS_B/616@W\%2"4,6RW<J.ZYS;2TR"?#BEV"TSZ>41&]<0Y-NPP[ %G+D@X."
M."TE)A7O[Q&JUW&F(M#/X+_=3T59X>F('P[CZ=$F);Q)"7\O*>'Y^EUN\9A*
MTC#/.*#HRS2XVP.3KNHR&QN!L,_30F*66@4,3U>G$ZN^I Q,BMVZ0TIJQ/)'
MQ%(DV].7?]D&ACF&YHI01Y*9E*L1^8)=J%P9+UO>-D%KL/=!-NMHAM7]HP(0
M]R-(K12$ R7-O*T8 CV .EIZJ71+_26@?=BVY-PLCQS#J5RJ.^9MT\>I:9TZ
MIZR8P:NOLNK)%=)AJF<;W(/6M(N[*W4[(HNWW8S-&#=;X(1;Q*(<%%.::Q[O
M:\S$-R[L\+:/;2#V+A>VY/H:M9YU>[1-T2W3R;26T4(>-A8?!5IT,B")@TZ,
MT*W2;)7X511J7;6T-]K^&C9;Y00/QEEYSD1LAB.^H8 C]WHZ @>$H6NX0M0'
MM8!GF%I9N3T+_&T3=@_X]'YA37/JQ-ZY'GO.[9XJ#TKSCQ[_+2EWD ()G1$A
MD0/M90$9J>1$V-N\(PQ5%QK%(,#,@IJ]C0>%Z#U =B5#1W(1&+KFHQ-*6A:2
M#=)G J8U<YH8W.X>\VU16%WGTGP*X7B:L GD\(=#J-L$>!X+XE4SQMC /)<@
M-B/41/"4G&N"U!&#H9A',J@U_-<W0_:Y$X:S_,U]H"@/2G2* $5#9\S*$SGS
MB"VP'A;8G\\J;OH'7+^-33+XW4NL$@;W/J.>_ *#DG@K50%:\'V>JAS-EATT
M12"X$INGG!";5WS6._#[X'0ZTRH755$@B3-^/P0-ONUI0Z@^-:QPM,,H,AX"
M-8,"BZMD-*2@[23!E Q-A*T$S9Y3+,6V#+:V=I!.$)&<^XQ@3_NI%PAWK3BU
M03'OZ6@BC7HX?GU-B?U$.!Q/UT2JD/* J@JEQC?YE(VG8SC*XP[,0_++4*L@
M SBZ;FOIL+_K !/_ R?P!@-GE&%9<4X%XT-@\X]F=T?_A\_4'IA^PKC[ 1F&
M2;,  R&%@H*T!"@?XJ@:S"<2X(Z?<0I6DCPS+VX(B:/Q/+JE,2T'DM/N#@><
MRVQ@*PK>ED5=]*&S)VPB;X6$3+@*ZX<\4G_'2O BREJYD4'D'_+[](OW9Z=2
M)T@=3 -OON-6X'GI[%(G]H4Z+87P DM?8/BODO"C*ZR <?/SO5,Z,X 0Q3P'
MKR&031+K-O1)L=&QY1/E$-QQQF QYNK3Q(UL6&WCY4D=UJ Q) [M&VHU%-7>
M!H(1V(TN0'\HB(49H<T*!D816:_"3]8JFF@S0COI@,(-0L6HX # /R5EQ.H8
M%DI,A=@CLC&=&*3;1RE&@;M?P/K$MSN(!=>L1-#>%2DC69%P$)%D-P$-[Q:>
M<#H;W@AA/K3*L+RXSVD@V\E. ?.:!7E243V"OMAR%&#Y*F$I*0%#![Q@&L,N
MIPHC*KWV\)*2GG![1402$)Y3_\%$+/D-Y%WC!0?FF+L8^S6K 1]UQXP[HP2\
M2*^Q<9"N87>.Z>(FX'%1.@G1)F!%-EG?MJC1N'G#T@WPIB@_5LULZQ5&_C5L
M'[<[I(;MSURGD%C%UN1Q,'K!.!CPZ&G-F0V6IP!+5AF# R8!N1W4Y3T8/R3%
M:9.#H?))Q69V9WE(YRHXS9!#!<C/0<BSL"KYUH$:G2)ECG?:[3G*_=>T5YHS
M(RJ>.5^%O<8J,@"5Q6<PM)!X70(SS0R2;G#=SZ9:34B/@OC?9.A"-)Z9 ,=B
M-N':1 [O,,"!;RT$:L+2:KT[KH2'4:KD,#4_&V:K]@X"WB'W>?-W2?WKQ5NF
M'B--@UKAXWV%(#A28T7_*-/A*.5,YX<_?"H3RIB9N"?HAKQT\K7K; K(.LU4
M,]C!<SVF!Y;5FF"H,J<M13_ ZT0,5$F?=7OL01WCAVVPZ)\^>7IT' M4#T'G
MJM7 &*;[,9I7TE@-M5)?F4'\GLQL G8+M2@8BUI4?AA33RR6TLL7((J70$(R
MYP_'T9_0.QF=C@&D/0'!/ZVRI",?>?=F7KEPJ<N2V[.SOI*1IMFX-^5,#A:F
MD\EG2FSX1RH+<EN W@XXK$B9AN]OXJOY&HCY:&>_G;U5@^@.S;ORT=0I#RJB
M=%*334:I%4?R/(LRN\RT_,Z9\Z/$\PS_GH[<*GS,5A7OHJ(#]*);?=XAJ!1Z
MZW.6PU*V^)(RMRE.F5ZR9(*6O91P7[/IMB4GBVKC;1D2QWJ-9&E?,O<C6]"@
M>0W!C2;?TAD4?2R:?#CMI<>;7.(FE[C))<[;!XX^V7WH%:-!$(["CE+--+XU
MQ6.GD'MQ#TATAU850="1Y& Q*A<.=%4X"S'$8Y0"S_>_G?KZ3KZW7DO"YG?"
MM[ &YSOGL@%HG9/+J;O41IYLZ?=7[WRI*/2@P*/@YFQW_HM"+^5A=AE7=-N=
M=?0K!*ZI[R:A@N5!2JTV;$VZA:0@&*P#$95 !4H!UL@']=XZ]L5=2_O/GSV/
MML[J*[\'[0]:RW?_^?,]^@+>KAEF+!1W=PNO5DB.LMDG<*/; G;;AB*^+D;7
M5%U\[>X^[E!+1EW9]786T$L,6KH,B1:]9/OGC&T^M\LJ/N?Z1BRFJV*#GLDK
M2BMIG9/V:[R#(@NG+46^H^A,9BO-1.UWG<,=JFE5D6UXPN])":@3_U8M\#[M
M7^5\%AJ"_0ZK]KP!][81#</G873@@_,,Y>2<G_UN&J%D1N3UA7_K@-NT)\<[
M^((8#$XUF6M]9[=4N/?.TQX1O4'7.91=J8W\ 513HQNGJ#RT#^;]@T@:ML#4
MU!*I+VD3Q[6-9HOC1PL P(?]M@JQ+!CX+ AX, E=0EQ+[MSO4"B&'DLAE,:"
M,@:>B7%Y/13NKYFM]%=34LDW8X=[89M#H\I"C!4^:XX;*.RZ?[F)_34MLVJ@
M6#3*6NK? MWQ&*"J;,,!9&#Q,<$#5J5+YT))3[&XF05_FFN5>4O<)))HUS3F
M9#JMH EW0A1@EC+O:NI,_FEB&KU ,X/,J%1VD;IN>71!>(49FJ62(W\Y'*D=
MB _[T"&59Y@N*IW--A>P8-Y\XOS::4*-;4PC D/7A7R/(OS:EK-<$&RH:)&S
M]Z_Y5WH)%YT/4>B]U@-.&P] -QK;TOI8@46)&X11A282YRU=8^ 1"N-9KZE^
M1]UO(2'E-;^_>WEFM3:L+Z9,Z2PAA&%?O^73^'-AR#ON'NJGR[$V7WH :H_M
M0>#1@1P@:QA)ET9PV5F5VY%'T&J".\TCF),@&\2RZYI$X(9V"JSC&P+HAY(Z
MFBBE5ME<#@2T,("&&F@;X+:=Z ^DV4@:A"S$;@^[84BK*)TF8K9Q#H7T%,/@
MP^JFGI2W@:<J\U]A3LP+==0KBV2 1 *X&=5/.*H:U;8XLNAT@A,[2B95^I/\
M\/,2_(D=YUC5Q?@G&*#\JBXF6-^-@]@9);-B6O\TS#ZE ^O8B"M,+DA=NO\-
M&FXI+,0/3^P?V!$_.-P?NC/S1>/'GA*WJQPNP!UP(__9J:TZW7$N2Q\\T1NG
MU'XVPV'WC8?]___'\Y.GSW_^^Y-Z8$<9?BAPKY8X@3MZS ;?!)OM\%3&8O'*
M<>$4B6?X)J:IM$F@U4Q6AL?T9_7U8$&>P*8^02G82.1&(E4B06[LU<#5>]"@
MCRGT)I*)-7_IMC7<[PAB Q?'M*(2(OE2PQZ)@] SE64I4_HPE&7 V(A-72S?
MEJ&LDQV.\_!\$6$KNX'E:\3X]7&;$[,Y,7<[,1E;?!S>MU76T&WD\8-(3 U#
M)?L8-F) QBX(YJEP@JIY?)GA'XBL3PO#AUK$W19BH9JIW*H3M4P*C<705@=H
M-9HUN$Z]HT>P3NJ,P#GZ&8[<&IV'O6]R'#8'X,X'0$)P3A2908!XV#!I?O)S
MX 8Z^3S'# &(W)FB&X9.GS3T(4N/]1A_=;\PI&KB+Y/.]Q_ V@<.+,'MY.69
M:2*X6)P2G0A%X^? B=>K)"O'B8+[XH6"5X\47@>WBK 6=!Q@K@+[S5>!B=\(
M#A-'ED(CK^'9<,T83E!"%,0N3IV#[L9E?G$]^7)<6RF$KRP0BO]"K2R>(QIW
MZ;P66 5=O."FY]VADB?&902: 6008.JVKIE]>\'79.VJ%CHH510@'>HY$[NF
M%;:2(%4[)I0UV4FJ9HYCGO8/4J&JD]%DT73I-_?%?0+#1XDV#OCF[@J/L*H;
MNK00<<42Y@3PNPV5[+4:$291$%?:]D@MUU*&YLNDJ0&1"C]8GPW3M-IX&QN!
MO9NQ!0*'+@2FA[#Q#&!ATQ'6^T 5D4>@;]RB6N%<3;%!"1FJ.!?52Z&LRTLQ
M]KSUH1-4,U:0(H9X%92YR4B(]H&I;-L(S!NQWHCU??0PFNQ.>I",%(QCUJ-5
M4 >+EK33GL#C+'H8K/.MBMOLC-=;,5GE O][G83TVWBV&QG]_-!H%S FXY\I
MXIN/F&+*ED.;3.3M*>DHC-\(7GZ9H?T0BCM/-L6=F^+.[Z6X\QX^ZZE>@\W8
M3A)4!(5>+0=^;DJH/R!0_KYAY>2.]X$/4,'M&?*$!!RA%G-D86A97T%Y>WF%
MDZV42BE\4824NME(^5TBXRM*Y)_:^:/K5AG(85.T^DY [Z#*KE7_*&'+TW?O
M?_.,%)6OI!+6ME8XQM94=.-;;TN#@K*Y;*$;2WW&POD'/Q'?'S1 E0$D\W:C
M=NPEPN=1_X!IN [#1$_FH6U3E$X"4(TA>-I!+D?+659\\9DB?5(#9$6 I,T,
M=\ M3* 3C-AC&>I+P+FLHZUT]W*W40.TL&FFY@AR49KCM;TB&7Q#YUXT O!-
M#*CA4I$6VW(S9WL:-6E0:E,R\063YY2-.E V4.C0L]@[*9;:795@W(.P>K?:
MWL39-K9SRW9N1=H,#KZ4>K48N>&+;N>@([7J:*PBEB#BC(E1L0!X@UYR=<&Q
M$/S-PF+*CM($%O\G<Q3P]YD2W0C_4H0_A0I+O'?0 AJD8Z@:+9E(G*,7#8J.
M>\JGE--7G606 %)A2]0?6GI'\JE@@\+4@%%]C*HDJ_IE*L%[NC4A D0%RH6V
M7M]W-3-_"2[3(/C*K5^-QB\8U_^D4*$U6&GK5[/:/AP:&G">"\G[/!Y0@%N0
M]M7$#OX4M(=U8UZ[+Q^MR+!;#"<5+DUP1E<+(64W:#&R _/S:?6#W22X>ZTK
M9'K6+ _#C/T)[@ $*)"%?JIEWPH!2SIRVG8F6R1='$R&YZJ;3*@01;GS&V/!
M8'\[M+=L[_J6!/PX3RRPC%EA>%CV^J:(^EGI+!WHR^L_]GKP!V@;? MK0%U^
M$5.DU.L96BL&J_=""N=E;_]GK(@Z^)G_5:6-BD&.5EB.)"GVZ*5.!'_VN%.:
M!H10S:=T/+&"GU7^6%G^JO!HJ;LO3GXSNJ .?56, EBC.=1,'1&/XJ-[E1.#
M..IE!8S$#8FB81 ^"!OFV G8_CZM\LU9ZSQKB#2YL'?8-,UYV;9XJ^%)-&<H
M&]HSC&7F99H,9@'?D-P++6*W\+%X(G-_+'/@VD!RJ1:%'(=K@@!M<WIL[R>U
M'Y\Y7%E .X3OXQ[%M!*VH 1/*42@%<<9^P'QKD3_12#( L:A[8?F1<C^8(L
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MVR IUW?P-&/(ROU F"?.7I]B>W(Z4/HTN#P6+*6L3\OV'<\1+;]%L?:(HOO
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MY93O'X1_,.?@X'#I_;_?BU0L#I8_RBG?.]Z]1N9R*TQ]<'#P+8+4#U$0'D<
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M,ZY22Q9++(>$(:S)'S')QNR1RXC:#@-22AW+S4E=)J08+=-0DO:I(D[-N/;
MF3JE.&C"\>P<!O5YR@JCV-N!WA3;DE52%*C\)U:@?8QX@XWTHM!I5X!I'4IJ
M2%<$!V[2J0^P6JI FB3_D>HUCNY8AK$L*:]P+'+Z0I/5D#\]!](5+12MYA42
MA259SQMIY9NOA,^H=/IX\K6/AGSM(5][R->^?7+H2RI#?#.!C<:G[4930E_
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MR!88#<\6"I^;!;\6^16LQCEK>Z0KUYNT&G!3@L4EHYOQZ$07=33 WT"_ BD
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M6%Q=YNFE&@>O\E(/J%SS/.J7TL6^J6YG59'K(G,^?N%0T8::Z1$M3F#\$DC
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M'C[\W!QMC:(U[GXY\*+=:R>^=S Z/CJ];_&Y+0L[J%>?(#[[4X$?6H#NW[<
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M!QR)6S=MWR8YNQZ<Y^G0E/TKUVE-YO71^.EMX7O>WS0U<]!JAV;M0[/VS^/
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M<(Q<5IZ*/%(J+OG+2#3\.DW7-26 KB0BD>0P!5S-%V!MU.F*QX/6M'P::*[
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M\J'415G#J4[F\*4RJ@9C0/I&9*<@%%_*<ID7P+;H$X[%T5N&4R4P,6HZ10?
MI<I(GP$ZA!'ZG8D]"[#F=P37B3#_^#Q@+S!&LM#=O,R7=>J(^)!!G"H>-;P?
MQA2M1NY'YV$ZW4F3J=(O'3;*L%%N*9+G2<&.DVX#<V2V _H0LQI](76AK5/K
M,+:H9P,/#CQX2Q[D@5FX(62VJ7%D(J/!E\,9@X<ZWM>@7)65TL;@P( # ]Y9
M6Q##JB.H([A9B&NK32/^2<46<4L.]=\S<@I?5,8GP3AY?X+H+.,D<K!YO8T
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M= R-%L,^H1,T[ 9+5SH*$?=D&'3Z:MS.V?+.OG @U[*2H=$HSB60/XT&:$
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M0.;.641)-3CYMWF*W<O9\+E 4-$IW ++]5L=SU@+Q5^>Z>[L?_UALB$!YJ4
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MS;S%I\=X-C;Y<LRYE19;)NEPH<F6M\428P^;'86RS;*>+?,>!+8+W4YF@X$
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MP&-C"Q,/<AJP.+BVA'_!BG:CF;0KQ7R>_YE!.W*L40F82BT3'.=&8+HE95^
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M%C#94O0O2T;R;7',Y>+5V#CJ<O$ 86S)M:C P3JZY\<86O_MAIQ/1'NRB\>
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MB"$8JL('5OG1]4/N%7D#J'KX_/E"=RKC!64?N?)!5]Z@IIX4/R5]#LE9<EN
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MA3G@XTN<11'_ZI,;#F9AJ(SU<\\9O\C>H;_'XG&AD@GP,U^3:,]-'("P571
M2RW9P7MM/>U%=,C,]T2$4P5Q(S\G1O7:5+P-2\Z:Q9><;2<\G$]#-TSZ7V P
M%V)Q<BBS;,$T'PZRM-'G&0 &PDP(WL&YH*X4H=?\YX@.XVSL0AETIF&&PB
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M0R3$G1!WDA8CI(40=U,1]Z..?79V2@#M?B'NC Z4$'="W"F,0(C[;F,&)G
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M%/I^,&3!B?@P9](?5NB/W:'UMSK^;S])LGD&0]EDJK *7HB +*)I%#@>?T[
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M(KZV9DRKRRLH/[&MZM>U2ULO-JUL/3WM79P]9P#9+K5\FN;#.[7DAKFTX1X
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MLSP);_&R3A/@-E-"6T>5C_DR7#K4EM'\Y%,1K0D0AC[(I^Q"",& 3S)FYS5
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MP##& M )_@297M[)/Y9H9K1'A]??$-\["HY%K[X$*1[V5-!T$*(2!9R)AEO
MWN0UK2R3E@+>DRB5]V/M+T_J7R;G](I3A_>F\CWU>,.9#H-MY$M'FQ5.&L1
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MLO *8 1B;](/SESZ@4L_V/WT@T>VX#YC[:T0")O)$^2>1S]+'H"2F'%A48
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MFI:SR_]+:?F-0G3$"^'2+AOXP4!$V+ +[,_8!)8V>9VG7]'31'8KNC*+IAU
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M%5')@<PL%TDE8C5@JM!G?0IB,\Q),X7>JN7@;DO!#?Y0JV=!NS-.XWDU;S2
MHJ1T;HDYP3@C1A"#_(Y2G&00E6IV8#96&TVKL16.P1A\A)])AF&C9H2L:6S
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MK4EZ%S^X$4Z$8SO!^"5HDPZ#94(,[*V&@$*(I'=D@RHP[+4&:$KQ;)JN-*,
MEK4)G85]*R09F\>\]),-NCY9Q3<CJ]OHU3F0IT5&<<A)Y\?';'3'N 9\Z ..
M='CEF#6Y1@#\$WD^K5''7F/K,?@=A4@Z>EN#!:=@Z[ZC_PH4,>&)79DVBL=Y
M!OL<TO_9R#?QK,%V4T1J!_HDVM:)-(Q*/9CYAZ1,@7CV,C.9F.A>@_+#;7 ?
M1W"2L4SF+V[^Y]Q7\4 SDIZB'HSYXG;VE/,5=9J=[Y9\)[__M0L:+"0+XAY_
M7>(&.NG]^^4_C4I^P1RPE^#?8&5!_2N^7E'V5U]^-JB0 #^"VC31@W#-G/33
M0\W5'&<;)(JSJ-^_94B;?^E']AJ'%KR%SE<<P?TOB",^^6T!OSXR^1(NNIVH
MP*]>\9=W0A:!_L-<&"R]=>PC=U:-<%=7^16F$7Z::W]7ERV:2689O9;25KQ4
M&\'2;7UIQ'Q*W#?-LO%=>NM(FH$JY[J$8,,PT-0#:0)*53-Q!ASLT8-C;8I*
M##P\"HBMY:E*AV6 E@:I7&%,U^O(-P >68*\*QL=19)':WU?PP*T,B C8!LZ
M9$Q-$4( Z@T7!(,D=<:-2<=294F?P6)A5E@N#M*)K#(U#JRFHQ^]I+Y%,$8G
M1!\2A<RXNJD3 GZ1D#$'W*FB:7J$.]' :H.9O98,0^H,+(.8X*'PHB"DF/]]
MQ-[VZICE97=;W+.[_0Z8_\#?/B5MW0*V6^%S;WA1!A6*^5B/^KD'[1.[BN7]
MCK%[&<)K_NRF\SO:;3[^?NYIO@+8\K/S87,%:;MC*UPISYPQ>'0@<9<2R),,
MRF,0*\0B(.Q]@H+,&N]>2,@9I1C53:A/UNA3_ZOG(,%Z4*'(*M@EN6M)BK$>
M^TM:=:ZCP%T'+>55H*BT%I!^;T]F2\-&<Y(GS 88\/Y7-"/J;X##F7X;FA$]
M8P_TZX$$:L;1A:_CB',9H*AI4A<4I24K*-P<L'_= MUERP1X_-PU414-^0^B
MA#SH.9@,8.*R"5Y,?L(LQGOT:OQ(]&H')I%DU5&LI_"#'<G%3[ESC;(01%5D
MK.FFK6=!KGR70?AR&.B@P6L7HL($4\24BS6J0+"%-[Z9*A(4DWIQ0;.Z'?]?
MTZQ^8$I>9>K_Z:P*OU((UZO %UZ&P+_DW$4\GEW$WDHTF L-8YBK1Y<+BQG;
M43Q 88!4@5+0:7-S0,& J-PORP'1T)0EA;H,YWQE*X&D"%P!Y;N!7-14+T'S
M D9AC6D^"5JK/W"=O:H$JBFGF!JHIARHI#@OQ%[>4@@UDT\S)8Y$,_D]OKEB
M2LS=O=Q8EQ5;Q0@>7V]%'X'5V4PADLXD(NGXR\E!>*/OC@&:BN3N2Z55?AL;
M"3\Z#I>3COS&@1I,\N+;ILJ!W'3PL@-C[82W.?R)NZK._<0UJ3+V:@=Z%#_[
M8?NU\-879_>%W^Z\5_E-?,NEF581239\64O_,U=@((H0\WE^@45'. \@%-=N
M)M1^]]M\1S\9'%R]<^:-/<@> \%5L7,7U@_'^K!;!M9>[UP"97J.[PMNZ+(&
M?VE9RVP#'B?7()V!"H+<!S?[$6(#3Y">ET9M6O$)9,UA<![/AF[E1LH[>7C*
MVZM8A4A"$/%,\P8;%NXF"&V)'.'<1K8[V(T('8@W\&#JL'DP(42RV>1;&)#V
M4P4&I/TM0^[;+_>E#YO[-MZOO38<[J-]$W>X%1NRWQO8+W/8[)=.1S+"F\H%
M7 <\E8S$A1WPWV+6^(TQ%WJ<./^&P=-"E!'R_AMX/WO8O"]DDV#YTV^Q_*RG
M$YI^VHDG5+[[94#6JN1P.? /BK5"ZQ\ 6MH="0Z7 9-B))/)OD4#LDX/$8X=
MS_\4_)<(,@,>8+W&RLQZ,L*+:[TU)R-NU^?&,Y%$<J.8R>%:YT0Y\ACXDIED
MR+A[KNK?]W[XVV$NJ1W%ZA+#F_R'CQU=;K--)U7#?8^O"9M-S8&N6?T!AS+*
M26U@FE=89-<GK[QEJ/3*TDW/VAU  ;00%D"'!=!;+H#VG@<4[/+BK9=$2YS<
M_?=+*Y[.=*1XLM=*9#MB*]%-BZUVNQUOD7B6B&)<%(2X^(6AACU1K97*^5(U
M=U4' ER>5ZX*Q5J]<GJ1*Q1;B40RD<C8PW<LC6X5MCCGC?9:C?/EIPLWYP6<
MJYQR"/H_W]N,]EN$VFX 0(\MO@"TO()][;N>O_PLLDW4*6Z.<ECG(O?0&"LS
MJO2[$6H3>F#%M2F6W7C+$M"IP%H_5L:TMI0*/ T#2QB>9@"'9-+JJ._PF1;5
M6&!I-%@Y3,;UL>Z&]'KS6AM\#-@,WJ,3<!.P](9Z3<885#O8''E/*&WX<&([
M0,2D^\?FP(>*H4IWU37N0NH26$9?TFDMXKK-;SJL8Y>!L]525'.2 1I>16>)
M[=RS@5Y?LBT9,FW5L-:30_A^O*$V?)O>M+CLEE @HHHTTRSS1T]^(EVO"G',
M$&-BO\_H.:_[Y;OWAQ7])]X+_S:.#_^?_V13Z>S?KWB!ZWVS/UK AM:*V.4<
MR%#H(PGIOXWYP;BYO_1.QS_DH<_*0\M=94)F"IGI=6:B/L4Z?>2D,I;Z%;D=
MBO[&(0%BM!7Q>,AG0> SJK18+ZL(I^EV?RL\G=+#FGP)'2V[U54$'&0-R_V8
M.]>>,?=K50%E'Z)KDYYBA+5ATY,E7O8Z;;'UC.J+JUWV$>R67BR$_'#/]V25
MVRICN@C6/')/3W3PN*:D=LC\5(-N*<1@[JA=XUDOYNUCFQ %Z/-^(_8!44U?
M/A^Z6(_OPZNW++\)J]'9*4TZ<62UPRT[F2\\D.2D:+$XGV50V5E]YWP4-P E
M0T\A &AT<->!U3Z]N@)B>&1*0*%)OCF .<Q5;Z>(0B[%Q4F=1PO4WEO;#=3=
M3/-RB$#GE=3M3TN3S=ZR8@Y4&X1[:M<YZ[LH**RF=P$'6']+XSY+Q[C/3I>/
M+8ID^,'794;JD\7"85C=_&U <XMB>4:APQ#3I,+9I4&2![X_FQ;IRF)@IBUB
M7&.!,U%K**0+#R(F/&E]:0R1;(=:)*23I<KFC :]H()G#N<RBT?#=(0;9YK*
M!L-;ARZG32 49:&ZK;#80ZK)2JA5:>3$XL0.5^EI'<K,GO/8]/.K0N<YW[=,
M5%I/O8ROWFKY,P:H,L>ZC 1@(?\UT;$?!H)#^;>JDVA>T0R$\5160:FP/(1G
M+73YJ(7:SND),1G)"-E(*NW=>%D6A_4,^V(5CV08ULAF#8X%Y0;&^L@+Z+MX
M7K0P.RRF1W14''4*@*PZ9Y)60\BJTQ=3#6[&!-ZF(%&\VFO5.@&[]$M0L=&>
MI>)1DJFDZQ)J6RHT5%$.-*6+KA1E#0GL&$,-"$4'E 1Q<+Z>*K']9&.:*NU$
MM4(PF$AXB_NIS5]D162=SG<[I7(B:T9')F"[#/N,24GMQ(#THL#EX3W(TNX1
M+?=HJ1CWG2T5>&"6.VQ3((WLRO]$,OZ68_D>=*1@E7:V%G.^'994]B6*L86:
M/TM,O_'E<9?3N/B-/V=KZ@Y@;G,WYH1NIQ^JQZ7QO!\-;@\8W-FJ<3Y'T<7\
MP78KIH"G5S<*/ ZW.U1J@U*SS-WTZ_#U,XV)Z44FS:QN@^AY"[K;;]^KVFU;
MS)!*@:#2:YT\0S(%@DRA,!T"E4)A.@@RO=+!-Z32%JD4S&;WKQ3YT(&9-ZSZ
MH!N(^Y?\[BJG0^@H'G DA(SP 8R0>:4<Y]4*G&(M7RPW<F?S:IN =Y3/+%']
MI?6QW()_;:$6#X7W*(2WW+P^*=88BU=.MR; (>F#3_K*J7T"YSQ7*]8/17=_
M'.E#'1\*^E$(^I8%/"1Y\$E>:3;JC5RY4"J?A8H]5.RAE!^EE)\4R\734KZ4
MN[KZ%:KWD/"A?O^3^\]938A3ISY^PKHLN<LY1SMWS YOO6[VU< ^=UW$4W!S
M5N$J=^5B;:MZ8AW.3%U2X2%]7C 3F#S>\K_;PHA])?5^V>B/G$;@CT+('R%_
M? A_)!,'R1_;V =8<6^[C0EZUN C>>)=5YUO<(B$_N*<=UZ!S.1?6!Y[9I_:
MH&6Y=B'LMH.8%<C>GY?SD?YKT+ALWU@)N2'DAD7[<ZC<$,P4UG;MR)>?IY*L
MC^CUMPN7"'.^FR@<[!C6^"6+A&"F:=L57P$8EI8Y)T07SV!JX[^=&Z.M\3&D
M5_QX.9)LRF)#&7K,PEO4%_<U=WJ1Y43:!A/__WB2J2'17R%Z.AU+I+9M6X)"
M[R\__]I6ANSCK>6V+4I5TJ6^IN+Y/J 7L6#)WO-FN[8DXC=NRZ8D4![,_A3-
M'M"P+8.#'9MW86]"SCAPSLC&4IFC#GAV9:<.T2CYCT [%Y_B#6B[MDGQK=ND
MH'!4Z.E^G+4):1Y8FN_"C@2%W&%P\[9MEX*OH5O1;>A6L1NZ_3AJ+_3(_<Y]
M+SPD^"=;>/!"BL^WA^+>7,!^>,5:-K01=ZIK P7[[(4^X*?Q 6E///& "\1=
M-H^_RN7LH7GWK<_&#J]C:"?\\+%AP0?QP]'&$F\S&Q>:*M'.NC>6W!D>M<L8
M9JH#8UWVRA<'8G "RC1[M$&?@6L^8^B24[LZ@'(),T2XD]OK>H2K#F*%G>_9
M)\+]D0-WC('[-[=E2;P(.2L<;J04TOR-WHL8$^*'&PB%^R/OM"?G!.]ZN]0Z
MLFH,9Q'NVF-+CL*##8XB"*B3&D8V86031C;!XIK/&-D4%?E9:A-SP)U(BBE%
MN(L=F*+/:'>"H"_V9V2.3C<< SN$FS/[MA5'%\@4=;G#%;3VB,A$WXWQ"..8
M(+ND81P39*L34*8)XY@ VJ;#-D3Y@2X;IC;&.SGSDJPN;- <GE\;',L3!(T1
M1C*!L2E!8(<PDMFWM3BZ2*8!,!C<I6P011KN>E]_ZUU=PB IR/[N!M9K=[U?
M0M8X<-;828>8 '/%\1[&?YM%NI*F.I[(YRX5LA30[,HR)<-^8\?A(F\@9D(\
M%4D)XC%$3.DP8EK-#IMCZ,O/_WL,L=)..2&,E9Q='Y6[DB9$44CHKH;N:KC=
M$PQ#$U"F";=[ IC "YH%@IESBL(1MRV,9K>%H=UBNO/>,? _#DDZYKX*/#>&
M$9IJ?/,&1'\8 J7"$.BP?5Z_L1+Y2"J3BJ3Y^ $2]$ ,3Q"H;6,HP\<PI#VX
M"(:EO7PZ_;LIM17R\Y^N//GSR6+SZ9P[;SS?.!IQ!'\[FC(F9,GH[[%FR*:L
M >*)(J%B=O"#BO2+#[BYL8W:K&G?Y^"\<?RTXG5TZEB*./9)3,9XYW8>((E*
M7"1QDF5J',^AO_#/=YC8^9?BR86"W2P!$"C2V" _G#^<5]*G7S27E-O0&*QG
MCLQN&<*]E4A<)A&-TY?9>V_07!'#X&B#!N&OV!H.]A++PS =A4@Z2N)@@:FV
MKC7\]TV)"8]F9:N(QVVE,8?T?S;B;<\:;#87*6_T2;2M$VD8E7HP\P])F4HS
MPUYF)A,3W1NH?KCWG<01G&0LD_F+F_\YYW4/-"/I*>K!F,_78D\Y7U%UZ7RW
M)'M^^=T%#19,6=P31$K<0">]?[_\IU')+U@V]A+\&^1.'TF*KY^@_=67GPTJ
M]UJ/R\.O0.'Y_4W23P\U5W.<UUY&_?J1(6W^I1_9:Q0BZ(_.5QS!_2\GTB>_
M+>#71R:?DZS;OBE^]8J^_7A=EZ5.]-[TRXMA(]M)7^?,!!-F8%9#-DP#&7>^
M[<L9 TDG],L+[,C<T48C#=^A=8:<;!@6I;LUAN\ZF@I4-(!)7GY%%<2+Z#KI
MLCO.N %1G$A*F7'M&3>_X\:^V";F^0I6/R$TWI)A.L,<@8!Q@"#0;#K7T_27
MG[:_X@;P?)<HI"^9  >8[_D0<T#PWB?"C;4IO!)^FV@FH>'>\D]=V0#)H,(N
M09AH0)2H@YP @'15LKH\-TTII/\VX"6ZV=,468MQ)Z0C6?":-8#*N%" 4S8-
MHO1P,@ )>V$C4!XT,+"T"<*&H,ZAD4T.[Y)C4>M(FG&J9G(ZF6A#@D;2=)!!
MB:=RBFL\4P+7!0MA XV/0?0;60$H8**C2/+(X-I$)1 CRY+":5,5.&(@CQ'F
M-2#%\.8)K@\/Z?#$6-)-%1?1\\PA&PL3&MPUI3A=]5D5>X)S7Q%&X.3YR+,J
M_4KX^UN,RQF,21!K(S)J8P3OF^.L&N&J!&_>.Y?T*1 .,>6KOJ%X:Q- %<Q+
MF68@3<B&I& B0)GB%0Z/O TH!^]KT6Y8G8$]?X0C3QT"I@Y@1ZA R2*LR+SJ
MC!L#;519TF>P#I@25H*#="*KC$2@M73D"QA.)'BG35)X R,HPP PJ]RU),7@
M%)DQK0&Z@.=.))VN DP 5]"!HR-<W0+=SB5 2W!W.!MJH($V )U <%\YQPG9
MA)A9+I;U^7"AX?$9'O' #8_3C/U%N^.(D7UU3<SY WF-F0+Z,ZA+KJU)>A??
MXJ;J(FBH<$*46OC!*U^1!>&B':$G$EZ.HXW&!DP5,N,;F#'^V9BQ2V+V?U>P
M(O4<;$\E$K+5^]DJ<=ALE4RD(HE$QL-4:&MUN8/6TO8F?!R&6@A&Q2.I1-SS
MU NN.#/N1._(S#?5QNC9&<S5F\K@J:*C G^9 W J4CR[[@L=/8[F!>@+NN ;
M,R,/O$Q9,&33M[!I\K#9U"[#VIA-/R]SK$A8O\8;J3WSQMM!]K+&5_D;TQCO
MRA.@;GEGKB "4SMSIS+Q")_BWZ9&X7'G^8]7I[,W:=.@W MP #GR>)@C#W/D
MP<^12YS<_?=+*Y/IB$)"%%HD24@KT1;3K7:"%UI9L9T2>JEL)YF,?V&(8$]4
M:Z5ROE3-7=4!W9?GE:M"L5:OG#;.B_G*]4FI7"S ?ZNYLOW0CB70X0=T+QQ^
M:/NF]-^OY$+/><'G*J<<+(!S5L"Q)?SZYWN;T7^+J[!K>^CNZ N+D%>PL'UM
MU)>?198XFV)"C#/&I"/WT!M1:":5="-4Q?? C=&F:'ADM8><3O.I:'<P.:QA
M-LWW"UA!4Y)50A/%U#",=>UI!G" ZXUIQ._P&2<S+8/K:K!R3-OVL0R)]'KP
MM9/(@V&8ANYB2A?,*K&MF#$&]0YF1MX32AL^G-@>( $? E!@#K@.N'2P?!]*
M=-*7='K/XTMIY+PV:E.\P1^@-69N3MUOQ$<CTI4!E4 E9H<Q\V.-[*GL=UT3
MG0;D$IC\$863^2=K!G):IV-1CP1^B8"Z$).XG!\4PYLYN3OV\2D0446::9;Y
MHR<_D:Y7#SF6B_&\W\?V5!%\^>[]8<59GO?"OXVBAO_SGVPJG?W[%;]YO3?[
M1PO8T,#1%#DK ^0TW2X-Q$Q[KP=.%]UVLHL$0:EHF"XB3RCI+%^4([HVD>QM
M)^H)@Z2W">7#1<' UX\TG; -F^1?;Q*2N:_WSH@M9.9/QLPNFS*.E-S,^CJ^
M"UDL9+$_9#%5PAW7I2+LM1R':C- 7+<BVQ(R71"8CKKEKUA+EQF[OHMB5YT(
M<,\ Q-8SGR\5X+*$8-=1LZCWPQWUDU6^MHPE,N UCYP(1>IT@"\E//N-J2Z*
M-MU2B,'R738BZ\6\72P#08M.QCHQ,+YW4G*:OEPF0=\&X\:>D&8M/>8E)#&N
M":O3684#!22R.FJ0U8YB=6F)PLS-^&%I!O!SAZUC7KB $-*:AADMOJ&[=O 5
M?<Q-+-KE'2O6 H],";"5Y)N-9@H7YL&W4Q0B3^*RI<ZC!3RV,H\(R&7!1HRK
MNRG+S4,A.K^DKE_FVP'A  I/+0SH:5!E$+FJ7:<<9DX+","0&M2U78MM+-ZB
MP:RE.S55L(:Q9=I!&0,"3 3F(Z0^60P+887S]P(G6!3C,PHGQLVF3JC;#:OU
M0OIGTR*-66#/;%>,:VBN]^[2PO'BW2^&H#T5TNTS!]^PV@\VZTMCB-D[U$ A
M 2T5,8/A/6CDF</D3/_0A 0N!J>?8FH:E]^A:VP3"+I94L*),NA#3JT.,Z@R
M2VTS>TB+F2BW>RJ:Z.=7Y966OC&N7*9Y;'^Y![8PA6Y;S!'[ D';DL$"^S7;
M @N.B9>-G!+(]?D%FH'H W_":'_Z1@*R=.0QI9P;^:U(Y;A%B,[>2#2O: :^
M[U1602_#7ZQ42[6PPHU6?ZTCRUPIKEDK%2BO5_86-1&Q7^]B9G$+A<WA;*3@
MNL!01'L6T+;+325=!YRPTD 7!:\,QG4 '[9?4$IO%_6>[WGC'9IWD64<-4B-
MEHU95%4,>M13'[>"CK,"3>]+JOQ,^?9MRUC2?_N1]M)2JL\K>JY,V;[## M/
M;8\-4.'-$XYU6=,=N;0S?FA O.N'Q:,ZT;4G><2>$F(I-^VR&MT=:8RY9(>5
M5W,0]Q73Q5S/ BF-=F7%HJI<,F3C&U/ZF"<%@!SPG5U23U7MZ[!F,['$SH'U
M6#0GRTOSJTR$/=J!V6ED>T4>R0SHR+(!+1.3RTO&P*:8H_;:A"K31W0D8*K_
M\K$YK4?S"F&:L%6QNGRN:8V-)Z$;O!B&^M#X7_Y%E4ZW"  J^KX".B5$[49L
MA].;[+-#7/^[4\D8SX'0*("MB*OUY\L <TS'=N>V:U'RT??N*10B>V,!"2)K
MK)@7N*0#[F ;/2-*&1W=>N:R,GJ#<O%0;(X$S'[3Q*0Y1]" , 7? RND<,6G
MSD!20??44)_XPPAFGIA=ICX*F\3VD"-S _RZ"V4SJ:VU;)I5($ #RV?O\//4
M4TU$YN5,'JG.]77"V&,J&78XYVSD+"]ACG%&,)?G_)03A5@BGO'6=KG\Z%.G
MJ,>I;:4#5U=-?,4E\S%>%-:]L@YJ$QEYZ4C%FM<O# ,Y==7='_DEC*IS%"V@
M;TH/6V#--R7M2IWQ,OTLRF<2S"F/+87.,9$4:[XR],3](B2D/3+DE-"YBU@>
MG_%)G+,7Y*H$>."_O%\QL%6OXWFO3]]]L!S_V<&WJ\$HPU,7Z05]-)<U1Q=(
M_;Y.3Z^@9'<(Z1I<3]=&3/=(RAJ6<G<3T'_B%ATH.QQXP;D\F(J01%@1$E:$
M;+DBQ'L(7:"UA3NH$?EPS[FITL->*Y((S!0ZIWY<D[*T_0C*KO-=8VKC1-:,
MCHSM(8T(4^(EM1,#-2X*7![>@Z(+Q@<L+QC[$TM6J.<IQNW#0.P1@4]&N#M)
M 9=@%.&N<QS8@&0\]M8==H:.%*S2IAK2OL.8R\<P>'[?SRWT&Q\]E\F)WRR<
M@=4=P-S. BQ_OUD#G-=:.WA8S?-^S&/VP)%RBOB<SU',SO]@6FL*>'I587CV
M*MRA4MO0T$COA$E]_6]B8GJ123.K&WMYWC+>O)V(QV;]<:N5;$BEP%-)B&53
M(9D"3Z90F Z!2J$P'0290O_AXZCTUNZ&>^C;M6;5F3>L>J?*_6.7O%29_E&-
MZ%Y6G9\""2$C?  C9%Y*DMF3O'A.HUC+%\N-W%G1/8,1\%:%F26JO[0^EEOP
MKRW4XJ'P'H7PEIO7)\4:8_'*Z=8$."1]\$E?.65DKY_G:L7ZH>CNCR-]J.-#
M03\*0=^R@(<D#S[)*\U&O9$K%TKELU"QAXH]E/*CE/*38KEX6LJ7<E=7OT+U
M'A(^U.]_H-_MFA#GO._X"<^PR%W.*?':,3N\XWZAEP/[W'41>Z7,686KW)6+
MM:WJB74X,W5)A8?T><%,8/)XR_]N"R-,:^R9C?[(:03^*(3\$?+'A_#'2SHW
MP/RQC7V %;?XV9B@1[H_DB?>>[?=:^?OZ2].%ZP5R,1N,SIW1D_6ZNQ4@7TX
M:=M!3* N8/U(_S5H7/;"I6?[05/('B%[!/K"U3]9=S"37']J:3Y%\FL_MYQ^
M1+E1\&3\Z"C]<K>EO9/YI9O7?2=I^(]+=>_]8M1M!!"AY@ZF2[<_9;X'- 13
MOQ\[/VRB\H/%#$&U OOFE#\V#*$5.$ZO+O3?/PNE0_\]]-^#J+G?D>,O^/K>
M%MV^MQ6[[^V/HW;T0E?_L[OZG]2Y#[/U8;8^] %#;__@*>TVAXN+KY'==GW=
MCD^?*A18A9Y%A(2QP:>)#3ZKNQ=F^H.#E_USQR$8CV#QS8OVY&6,A7L&811Q
M6+YE$)3DWCW(D-*?*U#XL#V#EQ$2!@5'IK;W;8(#HLF#Y<Y]5GX('?\#3"1M
M8##VK61"/S_T_D(_/[B4/@2]'RKY,"KX-$I^WP8[('H_6+[>9^6'0[ .P>*4
MPS 8^U8R851PB+YB<*S#YS0%H=X/" \<AI(_+(T>1@6!]0*#H_>#Y>N%_+#7
MO>%@,4,@MXOWS2:AGW^(WE]P]/WG5.[[\//3H9^_0J>_A)X]("1TZX],I^_;
M/@=$S0?+D_NL_' (29]@<<IAY('VK62.,0C(*0I'W-80FMT:@G:,Z,[[1\#_
M.,3\F/O*C>%W336^':"7&!Q#\3FM0F@" L(#AZ'O]ZK<OYM26R$__^G*DS^?
M+.;!HWW;@N<;;/A-/\+? ];"1X@)63+Z>ZP9LBEK0$"B2*BA'?SP_%^(!P]P
M<^,8M?G;;ASNO''\M.)U=.I8BCB&2DS&>.=>""")2EPD<9)E:AS/\3CO=YC8
M^9?BR86"M3 '"!1I;) ?SA_.*^G3+]I-RK4O,T=FMPSAWH<A+I/HR\__NXJW
M]P;-%3$,SAR \ I_Q=9P<% :K7AXQL.W'85(.MJ/P0)O;UT)^B]<$1,>*\%6
M%8\G%R']GXU$S+,&6]I$RJ)]$FWK1!I&I1[,_$-2IM+,L)>9R<1$]PJ6'VY_
M_SB"DXQE,G]Q\S_G(N>!9B0]13T8\_E^["GG*Z:Y[>^65(!?C>R"!@MF.>[9
M7)"X@4YZ_W[Y3Z.27V K]A+\&\1?'TF*K\>9_=67GPVJ?K0>EX=?@<+S"TPD
M+]^MYCBOJ8OZU31#VOQ+/[+7Z&508YVO.(+[7TZD3WY;P*^/3#ZGG4W(OGI%
M[4N<W/WW2RN52F;2B7:BE>QTI59"B'=;4B8KMDBWG<JF>IE$*BU^88A@3UP5
MSW)7U[E&HUBKM^*99#KC_+YC87-(CTK,(?U+=_U00#D;4O?*GRT":4=$PM(5
M1&>:UIW**E?5M0Y>C7-U5>6F,@1)8PDTK3765%"WA)O *KN@\9#Q<D37)I))
M4.<)Z;\-KJ.-1AKRL=898DA%=-+EVC-X4#:XL:X]S> W>& $('R'S\88XBS+
MB&UQD7^LK6T6$]M9/BUE^%:;Q).M!)_(MC)\HMO*IKI904QDD_%VS\=BQ?MJ
ML=:HM])\(I7(!).[;!@_CJ\6H6L !W4@AL8+7H /NEQ/5B6U(TO*G#$,+VMQ
M\ 0X0 2B](X183=AE=1.#"-S&%8@'3)J$YW]$!<BH'S$. WBX0\Q0O_J:3I'
MI,X 'P 69F-GH H-3F9,;4ZU*'Z!(;ZL=3D"B^FN>7F$&T@3PK4)4>'QCF+A
M4 "2P+MP-ON5.NG+AJE+J,WF:\-?0;7)L&8RERF=C#7=1/ NJ]=G*'D1#O$Y
M)A2I]KNH,(VMMB)W.*G3 6ML@O8$#.HC6.=X#/#C9Z(89(KPV$ Q'+AS@3,[
MT'1;@ U)[M(7(#K)$ZS>I#CQO!X?EBR0>/BP33E]61DAGZQCC0NI2[@363,Z
M,@$T&A'.PQ!U,C:]1.,IT1)T&1>62C@AX_D&.0.18I.]IVNCA5%?@<3P2B#B
M-PZB /?UG/MFEP<HX5?H.6ZNZ#RL8VB^)UVF\+/$5X@%@'%!9$Q)5C$[A612
M)%4R-7T&JEF7^B > X[92Z 7 +D:0:Z2EI@2Q)'X7EFUB)WGTO %\%V'Z"I^
MU25&1Y?;#,*R9MJB(^"CYAH*?4,J5'6Y0Z9XP]I LPR2US3,G3'&EM2W\G8?
M_ "5>Q/_V@S+N-=]7R#M3*?-IS.];(OTDD(KD6BG6ID,Z;8ZF52\FTFW^:04
M]]F9N_-BK?BKTLSGRJ>E<N&Z4BN6RJ>5&O@,I4JY)? )/I4.IOFAH', .P?
M<P@]A^!S'OCW9YI<BP,B;%CM!Q!8A\]EM8=.-VH!X'6=/%JR/M='.*+XU(%0
MM$^X'#QE6P'D.[U+A=I$53R5S4$$N%4A*,>J)2D1[M&2=$"H,J,/=2Q=9S*!
MP@]RNZ!*6'9:P[=Y8>+PS12,>C$/^A\@US45,PO*C&E_Y[<1*!%;D7!3T@9?
M&V&3S+F"67+I %Z0')H)GQ+P!N&_"^"QY<ZAF8,;60.O;!@6Z@/$Q0*\_K4
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M>F? !C&W/!GC2JI;01-A-=VCL;>.TK)E0['ML,[*;WSE/M1DH&:FU@)/9W3
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M'=/X<0@>\\XUSF'PW^XV0@Y0EX1,%S+=G@S881#N.&-!]T!/BADS[.?@MLG
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M^\[FQ)6T[>_OKU#-/EMU3CW@E42>L\]4R2 P)@<9["\J(34@HP *I%__=I!
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M)OYTIN0O.Q0&Y4N_<O)O+J94@/IXOS1YO.MHCN&>ZP=SP#]_USWX.!7^M0<
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MI]<-:[SI2&*V6#;K_47VL0?%#QP:6]AB*F3]AMA3Q<$P?^=>+TOIS!H/C;%
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M>&ALL[9]O_)0:[0YL7([$3:+J3Z?FQ,T-+99@_EZ]C#-K]ML39  UY_J(F_
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M^"MEZ&/=4BR5EJ%?3K(;K?*E!$H)]#((E$(TGVK-GP.B>8-TP2 7EY@0KF(
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M^(B?U_[-QB8H3E(-?(U7V'F#-#DB#$EX3+,!:7X6I!(8X:VTN.+>9EP[3"Y
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M-+Q=(N&SEX?I^%HH))Q0ZQ@TJY&ROZ3<>W)[.//7MV:K_HW<K(B70#IMX@G
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M<GXA1F5 /LR.?L[+LMRG?+MDH@%K!G=!$#@MDH>--(#%X'#VW$$)Y,K(]KW
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M1O)BYMH[VR1"QM;NM3\E\M6\O3A'N7?--S]\>&N*[U3O,$M$WDV9LD/*_?4
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M6R+%GK>__.=O\6W<-5E1<5I1!_PA7^?_EL?1GZ^Y_G+M(-]=.W#F$4-O:>T
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M,6\#*\S:5<RSN^$5-Q$9SQHV4R";^0 .ZH$:/=9HN):CHS)^N-T[,G[NB@;
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M.Z;S\,?Q[K\=(2#F],+\HF'PY5=%>[O.ZZX1O$TZ\+>LK?8_@Q_[=TDS1;
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M;,F'!5ZBW0YP,DL,^PT?JE!"'>%PF5&7P6@/+.[A9$S87'$YAPH9O8WDL)8
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M[9^%:6M =']:RBR0X97RIL^G[P4QV/)=1_D': !1JH^MZ[S=,E\T_/IN^7=
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MF)4$L2@Y?<[?K&?SI6YA(J.^JEF8MA7II^Q:( _>5N;[@D3"RE$^J4:T-QM
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M#D@3LU.>YDQ2SU<]IK8WRP!/50J<D0NZ"FP_&$D9P5@G=DJ8RR_^"AJIP9/
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M3>7QHB:7*^)T^A#*A6F[0A7D2> .1EA96LL73;G"L)UJB5V)!8PMHG&I!7(
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M(O[KG0+(Q*/L?>MIH'4?G/Q+0+. <4*QX=%+'$\1AKHZ@G],FEZBOS[V_LT
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M$_#3D<PFQ5F95<O@TD9[:4E.-6TQ$SCR[.U)ARKIN<[$XNU8+%:WET.VVVG
MD6=OU\QTJT>T,P:7L[,;A:JWY171@"0Y>_M62PBK F^02J1"Z\UZ76>[Z89
MGX\<K(9+J5C8=/%NLT;+DZRSR @HF_9LY#0_U(MBFZ+P4F)A3C>KA<KJ?B6^
MXY&)"$WW-L;2@&\O5)<<LVKFMA.O:M?!2($5<2DV2DA"G"3&4&Z@S(AB/"$D
MQB))L&R")D9G-"AH8CQ=Y^4V!\Q:,Y<P"],!]!DN2,J"I[FN6). ,I^L5L26
MCU-U]J*DU&NUZ6H:+^A*2QLN9H3%4A']HJ1H3$SH- <2AX-(7B^MQHI$21<E
MI<"H>(^(9U9\NCK=;.DQ6QK0SB5)B6<;/;-C5GE.-"R6K[,$VR :ER2E4ETT
M; %ZNUQ7L-:+#"XG6]V+DH([D1P?J=12N#WB<SQ5GHJQE7-)4O*13&- #O-E
MCF%[M:;&$P:;25Z2E"27+VJ961GP=K^D1(3-JCVJ3"Y)2FY-#:;DE%]PS&"E
M14I]R5:%BY(R6@NY4;]7*.&Y:FM;5V=QL4 G#R3ER+$[VB4SMN%B.V2H;W:T
M]4,CA$\7\J(JU'">U)E%24D+J=S(.=T+6_9BH;I&MZBF1!7M<:TI %9&-B5H
MP]EP;VG#-Z9475)\OW4HK*% I6H)+HZWDGR1H%(\L13A)@[@+KB #[?@!@KG
M[SJG.UCU(Q*2KJKBP@2_=S_XH8K?.,+AYS/3$88_FY[N(OM-PAGNKX<-STYV
MB4=W&<W0?_??U,7(?' FF$J6D]4TA[7R'-?&TK5*O5;EJNW6$U&&*\[4?=!O
M&0J=+)W/_2!X-+--2QYOGO'YZP98B/((XZ#?H+FN%K22:JY+E?:L,RP)?1'+
MJQ1P*WT25Q;XW9*F8&2KH#;V)[6;4U(;N3/R)^3.IXV(>JY;%&V.X^1 UOAT
MIA_)V[V8WK8;9[KUZ:&5'9G!(9E]S]4GL^B2V0N\F*YCZWEY8QV9SU#DL;]E
M%"?1;1-^V?SGM\N1UZ'$P<09.)^I)RUS<1UQ>:CMI5L%8^NW:%OZ[@,W_.A]
MXFN>-^8@].F/09_X]R3QOSPXVLW+?Q_AJ>SSQ3/<)S!DE'FVYLI(7EUX.(HK
MC"&Q=G;F[O<(0KG?0^AP*Q$'TNC?A1]D_.VZO-#T/WGF_N_BT-15VP+_[M1^
MUS_<6^+GM4DG7F](_P<N9/_?#X7#8U'RGESPT==]\1E#?A0CR"C^;/6RD!&?
MQ @B%L43(2<"P F(32$C@L (B$W/GH^'C BQZ8=Q G^AU'#(B+<QXO6)=Z_S
M'CYOU>P;5GU34_WJ]U(NMKB_&A&@YXH^_'^_R%_O14,Z2MRVJ#G["H(,CUYR
M&*7Y]>?LF&I7S6)X)8%X=C/X7!TX6_Y=Y.&V%:"#+0\O[4E?"2#"_>#^^\'9
M,; GK>?_O0VNW[%ZPT?U',7#OPK(WY/+9Y?ROQJ7R:\"W4]P^<V%KP_1]@X5
M>XX.*.)1\N2()N)]=+30TW.9JR%OH H6?<J.X\6H[[WNJV0!>(&48#7]_=P<
MH%?=PGQ+"L#QD6[ZY.+?XZ5^NA>O=XK%[IJW>=8>F+4ZD6B@BR\QU+"38&[2
MUMO;1N\MNG=1V0#45@M5-IA9.Z]5V;JRX"36X7I<-[>860.6$=8V4ED&J2R-
MWR31_G/<V>OHYSNLIP";2@8P@6A(4_<*RPBL@*HOT VXK^"T!@1T/Z$3V;US
MQ5\ZB_IFX'LU>\F]">>K6M/7M*0VRCSJV04$SL82.9;&QRG<+N!R<5R3ZMM(
M4J"0T12+T[<SF;ZY%+]TM/TM%OG35/5J=M*[5#6V;;27&VD[4G*R/%W8W76>
M':,D#&@L4?&;>#??W%3Z&H&FVH6[OF&PZ?K!IGM7=0X&F >0,('!_ZN'MES5
M?JVS/)SJ^<:$XVR\NZK)FW%,CU";B4 C4XVD\3"Z]0G1K7NK0H@10<>(J\?2
MWH01JX;(L UA7%32VV&F87,SD=DX$".@C4@F;N+.?7,;,6@&X4Z2,<:=15NW
M1!5;O#9'+(RTO<E(O'<QKYL==MQ[88&!ZQN?5N[R3[U$V*=QF^L[^?R$7^O<
MIIW;U$@Z6VO'48J[>W893]SD(.0'!>+N+O"A)G\YP^M]FCPKK5LSIF]I"DF.
MR?BJM[36#-)D9($]D/&;%!K]<C;8CZN?>#RMTQS_"U=^T<]/UFEX+!QW7G.A
M+(ON"F5T)>UQ23>O9[(OP>!/[6 >3U1<V+ 1CNF59):+:%I1->.4396<^U=<
M.*3ML1&M/J[I:U=;<&<34<6-;OM?NF;]!>('UE_P-KHH3C^GU)^;5@CW.75O
MZL6>S6CZOFF%P>8+^6/S;H/-%VA=/Y\"&#(F!+*0+R&0!9TO(9 %E#%X](>6
M9?H4MKPCS?=9I^5N1+AMUN\;-M:;9T6>D^26":.'$$E'R=LR_^U+_^QL_\\4
MA(^HPADU/J<81"@M[]S&;E\:XF9(&FXA@4..H&\A :XY\$;0^&BAB5 JOJE4
M?*@P1;AO7#XL^0)Y".?DVIV273NI\PPZ[GK]^ 4Q^91]E;Q7@OIS9'CW'9;S
MX%004^\/E_I5KJ"Y666^6E[.*GOZVHI5%\=&9, Q"BGF.FRGP@[-PL0KGI%X
MB#'7NX 6ZG>HWS]*OZ^;-?I._:Z+)<L9;X9;A6'6H)FGN'YJZ5?:(!_B]'ES
M^Z]BY-U$E]]AQ'T=BVTA;@Q=50_N-X'Y0M4W &!#H(&Q_/X\@>#&$3\1R7_6
MFE\\8?Q^B'[UI '.U[^FUT;WX.KDTXC>UF*EY7;=*RDURZ(-(.#]3,3Q*G=0
MT&*[7D& 4*F#I-1';TG#)0P-&3XU#]050,M";Q U,^*_)L2 @%MU'\& L@K:
M<X/F;7ZS(*1EI2+%&ZND5Q*$>& 2H57W(T-S;D) Z)_?W#^_=]+[RV<<-W7B
M[[W\(&T'MRD-<IY*\_1>H,2FN4E6;F;X=%O.C5/E7E5(.EYY$.(!3URO0$B(
M$"%"A AQ=X/QS0BQ9 IFONC,%&XCJ+.A&,FWMCV_.$B,O0D^_"A;,<B&X6&U
M$/$U^8UAL. C.\%+6?G^ )2:&*Q-X9K'/H$F0I"VAIN< !]L";O:!:_:)7)@
M,9/Q1'ZBM(@N14C#61+/)_U2)-0#2]XDJ!!B13#5),2*@&'%34Z3WXL5IFZR
M5+%&XKC(<V:!)/+#/M_PBIT@J"!#F_+)TB<W+VOQ?&:57S9BYYHAR_&U2SFI
MV1+0&BZ'.6$'F6^2"D0#R=CTA 0Q]*I;I+X]>0N5I';2M1>M;(2(G<[^OXX2
M]_9.-JH>HAN_=QAXL"X_89!T=6,"(EY>H#B&K_XMJHZX,7?5/M@HN2^.]7N/
MHX@2&!UEV;^PQQ\1/<Z(B0J3')#LR$'QOG5<>L3_[(7D1)\O".M)(LK<B"TG
M&AY[9,+_B=C40-#[W^U:^NGB/#XH'=Z3]C^"CI9;[44?8VG=+=OR6(I'/)3.
M9^72I6*$@-#SJ*X>&1\_/";_&5V]/T)HE?Y&([#_Q4CWF_^<4/R(<4>^IO="
M[Z,G'K]CB^CN"D(,!SA(C,<"&$EQ@2+A3\-XC!+&B1@@<7I(LO'$+X\0XFX?
MD6?#;HQ:Y65>;MA;1DDDK)380 6)3D>:9C&;[Y9'!3PG%2OB=MP>5JR&0)Z/
MU)L5)0^WUXW"V(.I4>WI"5M -Y[PTY%)/KW-S'E5P'-:>3LFQ"G18='=1_)T
MY*K33I?U=%%21'FZ7K'M6'TR0>=M9\\<Y5.K!MU9*TI7+SG]9;8R9,B&0)^/
MC!"Z&2-!Q\3G16J0=O0-L:R@/?1L)#]TV.3463)X+6X9?,8PE'AB(L3/1]9
MILDU2_,N%^ED-Y)3M[<S#HT\7I$PI.GX$! ):%X0C$#!:4!>L4-H9]"4R++X
MB!J=\2I",].&9!?K_+)CT&JY.,4GN0DJ'74ZLDD/QO%IK V4$MLI<-+&L%71
M@2/ITY%V":=GW5Q-PEMI3:UM#35G0KJ2YRLK#BJK,I?N KZTG)ERN]]JKZ@)
M''GV=K&I-X1:U2YRD1''C+CT,#GF'#CR[.VJI)/S43ZF\6 )5K1<4<OJY**D
MU)=:A;&2];P"[.FL90J&F),N\K^ZID$NPR1Z"E.E:X-FC>[@U$7^5\IE@Y#Y
MWHCO KQ>[S7GF6X7E?4^6Q%1VD[H3"PF*NE*=5TG++&42:&19RN*Y&:5?HD9
M#_D2.RXV9GTY#OJ32S)5: \*>:HG]?C6@&N48WUN(]L796K=[PECV4HJO,CC
M>4=:C.M< XVD3D=R>;4V,;>S!L^,'"G6DV>%&D CX_[(6]<B2^OSN6RA"Y'(
MG$40#*$,:!*T93.R*:FZ:1L7ZI')DQ$^Y.UN@E^N<6".(^EJ*Y<\JT?VNDI>
M^TWUUTMA1&0>N+'$)TL]LK>R<L]R?"Y8A0>[L??NO^E_+EGQP9E@NE:I%-H5
MKMIN8<EJ!DO7JNU"-<=5TP6N=2]KW"LR1^Z-C(*&)>V);5K>,0R4;N+!+2,'
MA1=:"AO,-17!"),U2\=$#)H')L#$B0$ $FSL;S06F;TD_F]75*VI.,?*:(S[
M&?'O/\@#Q,3%PM#7T.VS@+IYK6=J+L>60*^M6E\0*P(.] Z8I$>5::'3N.2:
MLKYV$H*O?X([#Z1VZ$6VJ+:!,4^N95- /J?@S]8=5'%3DX6%V=B,EB6=4UJ9
M+M=)\..,)4\.7=I"-?N&HY$DM'AKXS)<S]YIQ3TUKXJ&(:"=,6.TIEN^%*F.
M'#LVBZT5Y]<?^@%:TF<N*V8N;=$ V!@ "YET^G@L2Q  D*)"[F#^>AZPBFB:
MHC2U36!9IDO^ WXBMA#Q?U'=0&.A0Y0#V!2((_1HR&<SBK7AV"-&8E/1A(R'
M?YVCUSZ#FC?GPP'A(R:0?H]L Y49,8%V2ODR,$T :@N <%R;N ]'KZV-=_,X
MX ,GM3HS<BV:?(D?]L1DDJ#+8O+7'VLJ&]8FHLD:P.;P:U/SU,G$_O9%WZ,4
M>L-.[A^@6*MP%ABD#H"J.,(@(Z!MK<K <(DI:^A^E4?PG;(A4B-FZ0M7,:#&
M>=]V/SSF"N+K:W8P5O"Y 7>P*[ F(\I=.C](T%R$%B?J.#MJ+NK.L4X,=1W"
MA.;N4Z_@"[=&]2LU"=3&-7?=;9US5WW (FT^&E2RQ7)1 3Q#I=>6Z<RA1/S1
M-7#&$[0!H,>@@O3P$WWTM<6V"33@>&\_(,B ;4SD>JNJX34VEJELNDRIG')E
M%B*SA^4;*&UG$NO)VZ.X0I%#)W 00"#-T*'<$$JEB^P>[1[<XSDD?KL10_15
M]YAN(6Y<&T0V3P#^?ZX<>_QL87[$>_PMA9K%C6OK976C>1BG/(1\P,\61=GA
M%PK35W0E-LNOLEKCUQ^"O8SYBUW!#!=_#FJ[(HZ<\LKC[=-\<F15A7^6#)?[
MP\W[MN4%-%J%R"IGB=WM<,"#;A;OMROL*C9,!H5KK]NEW<BS^^""3Y."AAA7
M!P8*D(D3L&=AA#Q4O2W3V5H]-<7)<GQH./::F[7AMGT>9?[KD7](&3%4)\OE
MW*/^7=IP)>@W(#QT63M"6[0#]X466%@'%52@F8;(&,6@!5<4-;A_;] 'U#/6
M&_I#5C9,"TO"1X_<Q_L?'T_  *:M(@#"W K"P+?ZP'HA&^A3*!R[<BY8S)L(
M[0&%BR2^@$'4?0$(,O)*'@$/!J;0MC$%BR\.33;>8'BF)[=R]F1K)\FGY,IW
MSBC7.?/EBGJ_7-7U$9>(J_.BTLISCBX18EKM'EE_Y&NE:B=02)Q$-3G7[2?P
M(-O1BBFEN)TI\VZWSLP&)#V+0!@GHD^@@:O1GN?GFX.Z#H7$-O:@\+C[>5RS
M7"F#4J(/+1&"@SL.0O:.IW"G->'X8[G1=$S5H;-JW,(D^22^73!)QI"-5[-)
M;!Q?]X@-/>!;PXA*]PO$,B,UKFF37($X6XU(:'JUU,?)A$IS4J3-I-LWLDG4
M<:Q%E!=]BJM-A0CNS-3I$$Q\FP2[;([<J,[]*[S>A2&K"+G(=_N[61W*B(&E
M96MS)Y^7$F*X=QK[.@'Q9HPF?"@C9F[EK/%>W,2[=7[24_-LMF'<SNUMV)1=
M*[>*%C_/I516*H_)=1'J3>R!?H?;>\"$!PSE(<%I:K+H[:MG''JK,WM; M_(
MGV7JY)9*5T957A0UB>KIQ?1XY+S&G[V^TWK. :0;<-C[$#'(_+@,BE2Z6>@H
M-C/C-HGEBIZ-S,EJ[>T2+B1>=M#.C7<;LN/4>/0L^B&XG<-%"?YM#[A57X?V
M\QC >XIAKI5N+;W$<WFNGF62M_2Y].TJFZ'[DRRWL9Q*-MZ,J243;DL0^9FG
MK"S/W4(6[8[$ICV< <DUF$4-FMOJD:%[,]_I'@RXK?M443/)'I?(CWB98",@
M6YZN^2:"_PON$Z0D$-V:3IH,?2<3.CEWLAB2)F+S61%+9$#$/ ,"-6)!U\$0
M0$+]52'T0JF9HFT+2HIJC]Q^B! E?<SP30OW9#NBCR,VLC-05Z=7.$Z?<M.3
M?DL2P#$2HC75QKP)W#95>SE@#L1 PC.QJ=ZS)WB+S&U:D@"RXQG42CQZWIH*
M@^Q5$17<J^(G!-Q=%M]\?;KM+KMM+E*L:D9*$A7OK_@TEZW(U7J].)LG$<7B
M3U+,VTTL][[]*>'\+IUN<.%F&PAQ@%\'EP<7>FFVKO"FB,M-)M.-$%63*DZN
M1$:_5=I%(DYGE-JV\YD&3DY;\\8T']^T)M VNO'Z7WN ?//U%ZCJO%,OMN,*
M6;" TYK'$O3*04)$7;@D^90>(AL.W1':]9QR?3O,LQA/(T,Q5VL1UZ/8I[0
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MB,MP]:9LNJG/7XFB.SR%DC'7M=?35*N I)IP<)-/6ZMII] L%OCXY-<?&G_
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M@MPBJ >")1_8Y^-=%_V3 _;=:4=%ETK\&PB[61X+%60]?(QLJ9#SK^=[1X=
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M9R1N7#@4H7%O^$F?<"4H(<G[!97]Q?Y&JP":A+[A3A.5^OT'82W"CCE*BL4
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M&3\;.5N".!XW%RM\DYQ&Q$4DWUO,49GQLY&;>**TB60S T5.4H81T9,#O="
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M(U>H$/1\7./[P\.+$81@:$@H\E<3^1<\X*!UX>BZOX%1Y%IM2KXS;U_PUGX
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M= 60T@+Z\3M1 ^%YL1[S92GW*PT%_-KS+$Y06/R9P_:\;[T?'I <SW-X%7T
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MA(81Q>/N.:TE*GT4:E_LG?7RARJL=GJ=-'M"BT 2QMBF&TH"IS7@FD7:S!'
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MF &Z2!8=4[55.=H@_J,EUJ-(8X2\7L.=:?%EY9'=?D9HQQ1@;[Z .0] O(O
MO0V\)>=JH:I,N<0,(SBA(B>3<EIO\B@%-YYQY'C7.=IT_I-EZ*/ /P14%Y(@
M^T5VKK^._W<C\+W9>-)S%$U RN)ZT]K@E0V1\XB ^O4/AD5;VE$-AZB&0^CW
MQ<] !$9]4YGV1],JZW1(9UY%60%3%$@$L)A#,+DMC[MA?FUP7#+>$6(>N#-A
MO)^O!\S$6"^+9*T\4U.;U8)!,X-!QH7HAQOQ&!&(4'>T"1_BT)#_(L='L*-]
MG,!WWZ\N4W&A\P9A;'I(O,:+A(]>@=L74JW)=GW<$=8?>8JS3:E1*JY(&Z%,
M4RXE%"V7<<!<D?0.+9#Q%!YDN<^(-KXF5GZGM!%2Q@P7;00;=?HA;?0T*;6A
M,VH)V0S6A7HNJQ>GED<;NP,4]+$2\_FB31%M?*W$PYW21D@9,R2T<9$8U0]I
MH[])M+II?ICD*#23KIJFF$D-%4@;_F$.# VFTF"4D?.=:@]W2AOA;'FX6"/8
MD-8/60,9;+2:.^$D)-%)ZI,IFZZ1FR9D#>]@"1&GJ6"\C2C=*?0QK;WD16PA
MFS%K(IAR/#82+%6, 23$)%5S;%F*MCGO--TIL*(0X=K9^/8\D%57JB3[LP#$
MA,7;7&EDT<DFQ5%]M9UWE*W#8,R9 U;8-^8"5C!UT(E60S;;\!73$+3'LP#R
M/ LT<J-<K[$=J+-VNCT;2J;C+HM@%J!AI.KNNB/K,]</.X0'\R+R1%(G-GHB
M 9('R04+K(9&Q(T_B<H%RHUFIBTS6(M((OE$N3^NZ4[9V'I40%V&&R_:'5_@
MQ@\ZQ.?&Y'&@(4J/>YCTN,!*CCPV-_XT]!@H-\[&:[><;O5X=C-KM-U*OJ&8
M,Q=202I@;KQ&=WR!&S_H$,B-P)L[544SRAA\D(S!H"JT1-3XD_AJH-284XMF
M>SA+IV;M@K1>L.LE8J *9 (86+V[_O@"-W[4(SXYGLB>CD2-'C.?LB=#5I&E
MA ":)RBR'W^V8L88*AW-X8E;VQ!G,<.Q+;@Q YX69'#Z7O8I'BP'\P(225=O
M?R!I^[MIIU%L-J0\V2TB&50K=W%58RS2/7,H%_G&M+.G!<9GA9HS'\EF?>Q-
M05;]A0OVT_/;.8A?4(FAE,BV$;4_UC=(VU@O<PR/ICX/=-]JW^QFYJ,N^E[O
M>!,T':<I/(YCITX]!W4,.F+>T"9E75G!Z^KM#QOS?CM0?$GF=:5UN]PSMPDD
M,TJDIDBU5BEB"N263\/HM]HWWV#>#WK'8]YDG"*0.$D<GS,/@GDCG_>&,X$O
M(#!W]?:'AGE_&H:^)/.JT[S1X^=I<K:<]XU5+I7(IITFY)9/@_2WVC??8-X/
M>F?G\Y))+([CQ_+:P?B\43+US293!Z]_>/7FAXUXOQWCOB3Q4@5T+B+9@3UK
MNV-Z+/'ZJC[QG+K/MP!NM7.^P;P?=8]'O62<!M2+HI>AWCM,2/]?6P#D$ #V
MIXYEJ^/-8=?\[%W/_F:B#/!@OGDQ]=53O'__5FWP Q%\VY;EF"#"\@F"O@&#
M&],-&SS=-@ B!4<"UB+%5'A3=0[1!IIB@4_ O[P-5P%^/59U01=500// 1_,
MP3M83\!&S]G&\W6UI%H+3=A _,C_T51=3DP\+/_^^#$_?7MXJZ]:KJ2N]O\%
M_]D_6=1DP83XG>Q>[WD"A/?>3YG(OP.9YEX;%$;L4?H,T5P"0]^^_7\=OOX+
MI21$0S/,W_O)^J!=NQ' /(Y1Y,3(E(590AB#1_\6-%?86+MV)E-/SPGUOY_G
M>]@1,> U *\I=O!OV"%'O3D7UHF#/GNU54>__.U-[]X'AJ5"COUMRAJ87E8R
MO.NK^WE#8AN+WQCZ!$N2S,&?NP81Z%.2#&B0WO F_C(D_R?$)B:<$?^[4\^<
M,F.? G0XUVG^;5W_?7<?_?JG YD3[C9FX 0+\/QLI\*AK7YHI5Z7)L!0O+SM
MKEM?/GP]%D==[7\))C'Q+WA%[']BF/?+O]\,PJM1?+4%ZS_0_^B=V^^'1?!F
M9IZF4F222(YX"4FE>$(",S,]0D6>'E,B0J7&$CF"FR6P(X*G[YAOS2]#.WKU
MR-VPC0Q- E\RLFFL  ''.A/@E"QD!\S_5MQWRXNZ""AYY ^>W]+,GLTS!V3>
M?F9P8]R2)5F>"Q=K[&?M>W[AV.$;QUY>&1IL&^Z+3\ /9-."'(LF_Q][W]JD
MJ):T^_W\"J/G?4_,Q"E[N(,]>W8$(MX5$?'VA4!<('*3FZB__@!6=U<UU;=J
M+;5<$S&]JZUL7+DR\\E<N9+,_Y1X/TZQ]PO[;\+)/^7/[O-?;_BEIEN*5EX<
MIE%G^% ".PVDJI/'T"7523$X"M]P-:]QTX]&N*"6-$%JJ%(!%*80M(:G]D?@
MBHXQ.L)0"PQG%H]ZJ7X.J(G9?MWR<',D.RX%=-9:K#I]4<$4%/F6%.WMJW0'
M"619%48[9##<S)9K4<$5^EO*Q7)4!T2C$\F<JDZC7COQ9)!1%A\ZC=Q96ZJ.
M%"3>U15DN^$YOI>34M^2"GI+7Q'D4+2<C=D*C62K3D-6(;*X_SDE4N\);FNT
M0V702) EWNNMQ%U&65BI-*NU]VI;7B#F4*/]]G(Q'Y)&2EE<*;68.UXYF,7I
MUQLRXPO5*3O-2?%O2>U%W=]L.R-1QKQ-"R%W(2TTDXRTP-0JZI$5QE)X2]+M
MQGI[$/N#0Z*01:;ZG3ABM7G \3'=:>^F=MT<L&)*27Q+V9Y6 W-7/E3YN*&Y
M4VP<3ETC>V:!_2HUI?G)8>/R$L.P4];I<F)HI)1%]I?:@B"(,5Z1N;5?EUD1
M854Z>VB1_6Y/!)6N:5&\*CM4IU:=EQO+G+3 /M_9H1P I(=P8U$?;H4IT:ZS
M"J44OK_?\%JDI[E;?@*T6FL3FQLN%%/* OM4MU=.2$5B$;!H$-+NT,*86I)2
M%M@GZ+T=CEUTCP OF>N$R+61F9%2%MG'@\F$6W28F2RH#IXTM*TULW+2 OO2
M3O?([:Q"6&IY,C\87:<CNMGW%]F?>^S$67>WJH6AY;4QM@!O]EF%+K(_X+A%
M-*G1K*4V.RMQ3]J^M1-3RJ*>C#NH,V[W55FUF#IQT'UJFWX]K9#?4E8BI>%)
MRZ2-=#0Q:G&+]GJ$9<]DOJ4, K5UJ(M+(/N!LAGW*=XZE+-UHH7=GR1!<\+O
MI"XB4?A8B+">O-Z("E-DB:3KXH%P#--REE37JC<V06^84186VJ[T9DO>EC;(
MOK*LCI<=I)>0&26*%D"J+W!]->'7B+^;'0ZN&?OZA,U("RMU#-2O+&W10\H.
M12 M%?<FJ9E4BBNMS!2)V+A=$NG8\H!PIUO#IC+*PDJWG$"'+0 DGE-[*X/C
M@# A,\K"EM8'%+$D[7)BE;5P0DHD[WIX1EGDR9T[_-86$QEIK)EA4*X/FQ.<
MS4@+/*U[ ^0P0@<RWYFF!X&!G-2==DY:4'Z[4T^8ECYTK+V CCFI[^L]7TQ5
MO\B_O-18PN\-2$MERL-A[<#@0#$RTH+V<6K*P'B\7%A8>[AS.LBAML_*09#B
M7AUZ>ZMZP-<1$F_VHZ%4._2Z24Y:W(+:'NV02:0+\J3E@2X86H<XW=>,MK '
MVW#'1L# *!F;[-K[^IKSZ6SN.UID3!55?KL:UPA+\N;U)?#[HK7,20N,18W(
M<%L5O\(["DUMRP>@J-D;3&B1,:!6&GJ=ZI*RKVRJ1.H .>^X@((6V MJNJV.
MVFTK+B?;AF8NVIM:3EK<@RXO[QO!\##BX]U@J%&NN!ZDJHUB1;XP=] =CJO-
M#5(.DV$*0E%_T3<RTL)NA7-DP4GCL(,X"W0H-7K]CAWG3RUJ3-D(+6Y$DSRV
M"ZJ3V @$4A(STB)>]OGJ7@MF@Z$EZ/BJ.TKDJK))<MH"8 (IZN\%>^4A)BFU
M?=<8$V4L7VT1,<M<$U7+Q'PB@P3ER#YJA!TE70->W(3=N#(?* ,:LWQTW@ S
MS0"+D9&1%H1;WR$S)1@V.-ZIZJW : YH;9IDI 7AHO%HVK#[FP4/2+3;;T>K
M^8;+%U 0;OD0ES6:FI5Y,QJW>%IL>0,L7T!1:>?&L&[7]@J"E(U>=3G"!BOW
MD$] +_"5[L]TK$3RP?+7XUTC)LSRNFYDI(7%&G6$]=FAY"/.JBVH:LOR%DI.
M6E2O@X#UQJNFE\AJ;[+F>3N69?I(6UBM,;,$>3Y-4(3:S@C&P QIEBD-65RM
MWO7GP&Q5IP@'-AV"HIS5/'5<*6G1'\5H=Q<SL<_[J[@E3E5W+F?&0+YD#.N9
MP5G+W9#'1,Z9BRMJ"HXK**X61:*D8\U5DU<78[=,D,ERL\[[[Q:CG'8-(:LM
MG;"$G;M.H5FLTTQ.6EAM:Q..29&N3N08FPOT(1R0 7;LZEM8[;3+,4T+5#K6
M9$(2;1;#AQTD[_]=7&W4WG7[7.MPL+AQ9SU#-H-6<&SE5EBMCXE)\X D%61B
M6_YR-A_NZ_6<M+#:;MM,MZH\;%C<9%9-YJ*W/A!L1EI0V[FKSUE3:^S3[1(C
MP##4^M#/FT(5&:-%DMWA^FYF^2$VI]*55]N#_+%%QO:#-2^T5\*6[TPV"SDP
MZ\W=]OC< M2H!V."L2-RP:M('_-K232LH/D[485-&$O=:6>XE@9\1Y) L])J
M+J1!_HI ,30:^4UY5.GLD$F[D6R9T.*]0_[4PGY9X:SAA%U=D1O.<C[1IE5.
MJ!Y?/"AL@K9M WY1J91E=8)[U=7(%[9V_MCB)BS*#736;;?62-P0^<;,/0C-
M#!=?B#JHT:3%(W47R [!;(RNM/&$;EY966",];KH=K=&YBE^5=N*#[@AH><7
MT@7&^OZ(/-3 :,K'<L+4D=I!-L/\!J6@"$834[J;UF0H8VU30L4R2FMTOH#B
M'JP[%:%>I[B#7&;5 6-TM_AZGYXC7X@F@C36".6P'"&<0S3\*CJPRE9.6M@M
MO]4W9O1^)2/ ;U*+LC_955+9IJ0%C6'J@<6LM;F+<$W#B2Q4\:9<_M2B<YK/
M\7!1;C,J[P^'(]XX>!.=/=(6#S.(+A\FNZG+JX.I#)ICML'Y;$Y;<$Y:+]A*
MS+@3\<*.]WLK;#^14@>)O1!Y1%R5WX9JNV(U/%EP]XWF*E@8&6E!N'Q3EWNM
M+H/*9=KU6HR,UE9<3EH0[JR)&.MR<& LSI8)VCVD-CS-20O"'<[6$R[&Q@.$
M*N\\21JUD;K$9J1%I24G\K1?;XX0Q/3C^L0+='\>I;0O1!Z379W%F$,GW:H@
MLEP,!SK1RDD+B^TM.S%6K7?7%FAN(BGQR%6EEI,6U6NY]G5FWQCNK$:U,55F
M71$7*T9.6UCM-*8;EJ1MNW)Y.R'3.-"846'ZW!="A$W7YAH#Z>#*TF):&9GD
M@&@Y8D9:D(*@]E'>JVX-V>PUFFV#B\-MS\A("XPEU36".I-#4P9UG7&%68NV
M.TE&^L)Y9:4K(Z]&+I".$*&2O-2-V2Q_;)$Q7ZI1[:$P4.7.7!IK"QSW\$KZ
MW!=BA-1.J,F@5Q_+<9U;#,@Y.1N9;$9:8*R-._&RY[H$STV;P[9"1FXK4Z\7
MPHG](CJ08T3H\]2BQ8>5)=Y$M_E3"^I5K5HMHK7N<+P_VLXG]A2=;9.<M+@'
M(19$J+Q!'3DFF!@=Z+;;&J6T+T03I--N#-7T<,US?C*5V?H&D5$Q(RWLEKLE
M\/ZDAD^M&&^Y"\+N<9:?DQ:P@UQ[\DC&5IJ,6:Y,["P=#\;Y HK8T2)'NT:[
MKC$(M5[LHD'%)B=<_M@B=JA+A&:FB6[)#A*/^"YO]S;'U7[!CORV]<NMS[%4
M0_-L6]V$X-/G'YZF$+/+DL>+DNPF0#M>-3R[/E#CR'M^=Y!_\BS?7TSW%^_%
MHN#SPAZ_$#UF*']Z79X_!:<_TC]\G?C)5<23YWOI,W7;2SXG/#__O9Q=NW\Z
MWG$EZ3[]]([I\;[OV26&N@B]K-;@S'=++UZ#'@E?=[%YBII4*(B+"X+^R$!!
M7(,@H$5 04!!? --%2B(*Q $M @H""B(Y]"$0$%<@R"@14!!0$' J.D*!0$M
M @H""N*I()B/! D%<06"@!9Q/8)@H""N0! P:KH202 ?D1\V0X>"^#U!_+S1
MYN_=D+X=U_1O<'U6;_@.6?[9K=_;OU8$Y0Y9/I>J_]"S0U5_GW*_0Y9_=BL!
M5?U]ROT.68:H?I]ROT.6?Y8UA:K^/N7^L]S@.V09HOHO9,!N:1-@]NGRR$87
M./Y1;Y[/S3\7MY-FNB]Q0I:O@.6W<517Q?(=2OD.67Z;%-)5L?SV#OB%!MN:
M9V?\Y,,+7\=&Y2-VWF& ]"]$C3_L:JAIL1/;:C[/[B3AQ1W:YQVR_#;YCZMB
M^?U TAMD,%Y_DBV U#LZW\/3_)U8[GL[S5]Y=NX.'? =L@S/][<:<Z31XGF]
MZQ\?@]+E9&6EJGTKIR!X?LT%)T0K$-R*S.X07ZZ/97ARO6$P.N_)]4_!:.1%
M)W,@\$!Z_9S>D$&^YD#ZQ6*)UUHLRGPDT?_]9K(DNMF5\ODR;S%8\D]-FO,<
MQW./&Y0/O[F56..T&O!^(_^!:B[++?=FQ7J?87]JEIL K( ;FEL 9?=<=LQY
MW>D=7CG"^#:7W O3WV"T"Z/=:S7/DXU,/]ZQW' 4>YR8?>-H6_SS+%'/#8N9
MS8=00C'_RI'DAL7,J1OS=(FF=ROGFS?GAFJZ__YGUPNSL;)0UC\_]-RPK&M
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M*@"XP.E@P,Q##=,D@Q?T^- ?#:4HKIWY7,_&KA3YG7#+J[(ZGP[V'863D\R
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M]1E&C1M'C7LO.GT%&[342#V["JT(&E\?^NM:NR5X?JYYK;"1L#,5H9 J4KS
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M6<!I#@!;+40W<R/65@/:B;]VP#+Z:-M^8Y(/Z!JW("4'C5G;?=<#D94=?3
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M]/7ACG]^U-HR_K14'8D\0PICCGYF*+48JT!K8Y./Z7>MS813F1V]D@A*)N#
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MR!"$! \$<!$#='>TR:H@P_-"G C>@JH4#0.N?'VXRM]NC4%P.K2@93\0(SV
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M]UNH);K!5++5E OT@T-/<J].^S +^VMWYL +#2HK VR)P!ZBT4O,&P68Y0E
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MV:U;C>'":]?26>W[,$.L&0.;&VF+B4_WBHUL&513>0YAQNG7^1@S,&9\W5*
M+[63>2]6C8NTU>[-/2<QFS>:YU@*$"==E&.KP5;S=5;3LRNI8GM!E44@]C+%
MP6AL>/19(EF_LIIK*S<X4R$0KC^X)[KQ5L.[(OLRPM-X<PI6<ZSF6,VQFF,U
MOT,UO_14GC"R'"_F 6=*Z.8<N-X4I_)P*N];X@];8KZ,)!SRNGB5.V_("ZL<
M5CFL<ECE[E3EKBTJ_FH3'J>AM#DQL/#V.QS^OJ+P]V57NWQ-:<JVL6[*IJ++
M1LET/<=';?<Z$X6"!>5F!E\@>]:!FP,#3T#]Z1[\*^JP/S2\BEA9Q7A?GZ;)
MRFP]HDN_7Q\7K'/;<)E;>EGE'JEP>:)7H_PR3\[XNC9+QDNQ)\#["XEB4%5<
MG'Z@$PF\DP7'M*XUIO6EU0!&C>2T57^1$0M"IC$OBKW./,M=8C4 MDMLES=B
ME]=4#TN?NA[VRYT.;UTK2\,"+T^FB>*@T$RO&XK</+73T6<:U4[V2<A.9DOO
MN3XPRKPRY)#3D<9.!P:W^P&W#S@=7%O/LD_\7!"G])(;N[&F 6*W4H)XMLA*
MUII.@8,0E+!E&]V?CO-_./]W^Y[-][HA+U;60$86/4WS \%VUKVX..U.4ZOE
M,)^.%T\>Z)@;TG.7>9X\B3/#8VI<JB;-FYI$Q5&@@TD],"D6;^7!N8MS@\('
M/((\UTKWZ+A+B_7Q4U6:YH=-,+U(CP!;#;::FYU*KSY(<'QV7OJY?/))5F;\
MJI.34@,^7BX,3A\1&"9G@]I4+D[*,E=>-6+TL-?GT.R<QK,SQIE+P9D/S,Z2
MUZC4._56CV3+9*);4YYJC>)%;K2]\N((\5%X)-I. (0K IJ1@6LDKKU&XHO7
M^A<=^[O]Y;\H;,SS(.^0>I)C5FGNS?FZ*'A49U!2)>?D,8!:(T&-9#U>XK/B
MDURE6SDE[S8E*A$< 40^,"R-\PXWEG?X8E\$0\JUG!WT!2AERV5V-!9*-=+W
MQMG9,^NW\YF3KX7(L5CFGFJC"KFBGC/TLUJ5RZJ&4(K%*(51ZNI1Z@.+J%'!
M,-G9DYJ<=,?M:0+$BSFMBRNML+EA<SN%N;F90;==9PLYT4\_-9_'ZBJ?-RXR
MHW!=-0:.;3FR!Z"_,/ (=^M=X&*#3\4DSGPB]TD#%%=SVOCM1RNVYGJT4))F
M<LN^[:YUL3S)D_E.DHWQI=^_<.2#2X'>9*Q.E9;4);N+V9A-5\UT"9T_RJ*
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MQ;\1&$K\14Z2[UI $@DL^."5M(G5M]=+=D%,[(9;&SIDAGF^.'A,B\4L!<V
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MH?G#[2QZUP07[OS??)?1X2**O]@DX7;L0+(<-[:!3XS]MV,"*J0QCFW@1]N
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M,/[J3!3%S6F.!*8?'@C/NN"!&<.2]%UF5>0'13U/\=E-B=T4R%[55GD42X,
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M8(GS;;^0!TATNB3[KR?M05=$('^'K[<G[SLW9DI@(@'1T%>L#$?9%7#19SP
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M^I1P^&1TH5P];CT?5EX*Y7N)7!+5>GWI9SL@,S"Z4$CDQ-V4%]O3!^Q=EHB
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M9W?YVF'**9Z-&I+D)MD+4DS*\V.Q*\RQ;X"?(@:4.4GV+1<RNQ@)>5_(?#)
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M4T&5U 0)_Y6%KHG,^Z_;2FFQP:LC;VDA@]?]"HQ**F] !F$&#%N ^7:N_$\
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M.2%89IX@U@/Z2<:%S:\ZQ*H76@UC^I:(!5Z'0TD-%1BH3M@Q+;#Q:QKGOD_
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MV#&J2.VN4<*I(@JR@E/%SE#%LF3%7MN8T^5V$3O#=$,L(IM*EY9WMLB0:,8
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M-:R7M'K60J!Z-#;?-'L3X+$@/4PO@5I95*:[9A"2%UU*0JAA<CIPL;\=\@*
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M<ASRK<($0XC99<<VPIQ.OPGQXBPKSNHMV_06YK$XV^:[S8_I4[+YA/CF>)6
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M72U(_4R#@!H9V*3?)*:0$EF7@&UIR+'VZ':(,5+ &"W#:6K$YXP=.Z^YNJ8
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M0$&CZHI)9(N>=$"AP\,3/#P1B?#$%S,=N5@AMZ=G&=A":!!2MH4F@4MT-!C
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M_*=1R'B)(+AU0@-C? ,05(_8Z%V3@>V=PG-OLURV"^W7E('.!=3,^ [D47F
M^@1_:Z/><$_\P_LWSPFTJ"CWMR4,#'0-,!@P2RP 0DT#N#T[*@84?,I"P8B;
MKR=J">&(@"* ;X\,@ZF)0]/I",46^$PJ\ +K8@RT2-G'I.8=D";H5AUE1-<P
MJ<B!MZNHD0SZ8&1 )#)/F-"_31:RD#444"B/"2Y5:.)Y2.RLZ)@42W97MNE#
MOK)3A8"]*\CP&9_@[KSE;QU>?*K[**84O\Q5@-AHN^\BK1A;4Y.X),BZ1N C
M&64.-) [,?8B%&UMAUI?<_;FKL]E?$R:F/ ,W0&!C[>T!/H$C](109A,H;BD
M/$17!/A!-0(DC"J![E$!X0>/ *JTJ%ID)@4\S'*4[D(@PTK@=S!0K+:C@7YC
MN\']XN9M!/Z&V*-($,FPR9"R%U#/@YZ=F#2>4D7"]O2_=V_0 &@%"4"@SB9%
M(LI&72AV3,(('*^L:C*5:Y?$[(!>_ADPS=RO_.M]$P=>7U%LHPD_>I%)$&R.
MB8>&J7X#IT?IQC PBC6X5.'W02J#Q&;+"ZA":KS!EBPD"I=C1S(P@^F9=HJA
M,[('%0IR$:@ 2,.ER.DEQH22;*K-)H%-N;_5G*9P^C8P78KOXPTNY>DNO- >
MB;'OJ&D"B[%5W6%=DN%QHZZ!M&2,=$*W9:DM%54#K-W'JH<08-&A.F0YPPDB
MW5WV9^%_I)K #6P;8?0R*VG1FN># &  AFL(!)YAX.LBS[KSJ:N&,V!:@>=,
MUD'?.?,[<!EN,+Q=E#M,MRW8:>@QGI\ ^P$I8W0(I1_Z.KPE")68,$.NW@*I
MP%300&!DY=_OW3F[= I0Q1U^85L!&U:7^P2)->#-A#P>A&Q@V1/43S_RW0<A
MF7I/\I_2!AHS1AY<W16KF(9PD]'P1%0(:'E;09  .INJ[G;V![SZC[YENB[T
MHR\E->8@>#X;U1[]B?MC$[GORF@-K3W%L5 BN%(>5]E2,3E.M0V2EV>X4ZT%
MI@FQF(T(]$]G#6F,2A@11\9Z+S(U2F K6+T':(,G>S0<),(Y/%OV;\+E3'CF
MI^H.+"8R*"JK*[.HA2M9J.UOX3P&F@YB9CR[RII_&?9IF*AG^CNF9+$8$6^=
M%""VB*6 4$!D ))&OWQ<N]T=//5 C0^,/K@#H)A5(N@.YJ)P#9/5^-096A%!
M2]N3Z^3%)7TJZMZ7WI2J?JIO *D&6"46^[E&8-6E0'>*JL\/=*A%#+-/[O2:
MO\2$*(H26A'LB;%E0B"XJJ)P9>CQ.X,VV'IC=2&J6?"DJ5M\_?L6D%NJ?VY6
MPL8"( ?;U$Q[BXX0Q Z-?# C+:"?90 "J'9X!_@8QL!3T>C!XK, GVVB4@/0
MM3OG<4!HL_3UL!3P+!6;B1]_)1-6@1L8D;Q'<1,>\"'1IEOPB,<U_WQ;HX\P
MLZD7&MCU7+.D3SZZ^PT)J<H\2PS'MKGEAK[6(R]$<8+VQJSEM-AF1.V(\H/M
M?\*N].FN[^I'SJQ92S#T:!EOIRJ+8HX!GC $4:1-'D0C26#_4Z13MX.^=B+6
M@F15=:^K>M?Y[#*AH'E^49@18#$H0=LL3 96$GA5;!R>3P:?>1SU;V W:I_5
M"WC/@$TQO_ZO3**0%G,3P>1YG:$EX55B.DNOFEU>C!)\Q\0)?0.OCX_A.G0O
M]-5@HOZ5$F>*$WXR]*A>7<-?A<ST)2SVP)X)KQZJAF/!TUS)V)KXY&_W# IB
M*B@5K_!7#U-H5=(%48;%D!2X^,P'<#5:B'@30NWCJ'#%1) V\9X9JEFD%]X5
M0ZP T&Q-0D!SI+/\EE&!F_3_L &S%G.)-ABTF5.Q00ER3NE'5X;M- E([0'.
MHV#28P8F;I$DW@8\ (\>:'!OA^@8RM'&,R&'NDX]E)I-_7B$/K@/JB+['@H-
M!1T7BU7?\-_F(HBTR(L@>!$$+X+@11"+BB"BEZ ^-EQ7!RS!S6:B@PFW+N:1
MT?FCAM>HRZ)(+&Y.PW^NV1J(+J)B(T-D56I#6^!'F1--)'? <.W T]S0-\NZ
M8,C/EEE<'<]\@GIL&L[\"'PH[T;#B(0%$3L&"PI2"%(]B>\<$0TT*E@8=M<W
M<3"</0GQSZNGI)MCQDY"*-(;%Q23ABW^K@QF)JB$*?//;8VR^;P1L\M:9 C&
M1A#J:#/ #[!-C*^!B6: C4VHQ2ZWAJZ?0$$72#^Z5X-AVS'E/DT@T)0?#>NB
M/V++[;9W8\G+>#>]PA)P16A[B1@E HH[EG&+N0X$]J["KUV[AIE,@<34$+<P
M&!BF[=4'4_?2S]())6]N%]PXR:_0Q89S8\$\^KQ* [I=,#?A558@.?Q^OI<E
M3V>RNY:;-7:S8FZ6E*;%+.*]:.[J6)4T<TQF4I7POA9&-5BBQ\OKLHAVVY0!
M:@Y-&26$,C H)FSF,=B</5-VF*1]  0V1D[]E"M*!IUF@.!>,\P2+J!QE].
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MH8+,6[Q;D3-+Q'-('\=!6HQ4O5J1B>9$&"*$FH$Z!"HM-'F,13. 6A:4L13
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MMD"9%DB*EC%9SGH@1X_:9<N3 8%D]H.^2!**DG"!N%E.'Y:CLLB65(064TF
M?!49F42=^NI6O@9:.7N40L])=E8B59&:JM^M-XX!<6(95%4Y_W*(I0S@ZN-(
M!\SF7=6#9D'*1!IZP1@(.^#H/NT%>^K<RB(KCOIV:.--,R)3 UA/JT/C+)%W
M\'M4"U'4+4V%FK=;RGUJ=\MY+@^R@@Q?U>62K:T;H['X]]([*;.F<J!2[@$G
M^O"XB(9P(#/'0N>G<^*&24FJ5MK;:0QVB0$;A,1B[ 0IDS65SH9#JYC]3>(.
ML[5( (73PN.A?XPJ"[D22@DX38C5KA-C,-?-^Q?QJ5^E0 UT7 HOO5* ^4R)
MHWG^K82Y:L"-O4:X:6:NK#\8_UV;DO?4=Z1SCJ@/C<HU-\C%Z4TDP P#*^K.
M"3E5Q)FZR03DB:*<#O1/"*NMT7L4-3^"C)?\H-E%D?2'C<FH]1AF\6/3Q3A/
M=2,^;5";5Q7K;G7@N>L"SR[P[ +/+O"\J<!SP"[MA&1[*6UZ(+,'##4K#DQJ
M S)JBH*H7I2%("1YWR8!R;8%]64-_LQAGWG* 0KU<ULJC?,4*S5^%'V$<XZ>
MQ0,XB5(OHDFN1!U6;U9_F4>UWX)P,TK''$$Y6TBB^&1E1"=)J:Y$*L[$FA?H
M^B9X9'6% ZL<K$0PY4VEL+7R70":.AC\4RM]GK4C[-24/<3&:%,5S]:A="0E
MQ-RX(+5_91_^(]' :@'Q9V'3$^;VT*[V0C&-\^SC*/@AAS:>:YG$?* <H+>B
M[N_^:G_QK".L(^S_?__CY/#HY-.26/LZ)M'0EE>40[\@!BH/$ VFZ7Q2,\35
M7_]O'G/\+_"EFIE'402F<\M9$: *RL7)3$.6VA60MUX)N%I,WN&@PT&%@]V9
M./BUQMW?:]<9[-1&8>]/&UT_M-C7!5;*GTO0F/K/@; (13(;?UOU)6HD0&6"
MO"YYQPU%+%_<!*#5 <V:%F-'PYW;,_MQDL0#-5UA,+5_I.0OR%?1:)+;=Q37
M"(KKS:2XW^I:4H&2JKR>40\0.&/<C.*B#SY%):;6(U:H@PJ3L30CB+1WR-)\
ME"XTATSL;A@!>53'\5!B\PN:FY%'U)U25TJ "IG=Q4-J9:MS3#0=%@KG C*9
M;7B2M# F[T8<?V57^-QV>CIK9\%T:P9TJS8*5_>,>\1T;+L"#;<#=UI<+.8_
MZ8K](/&T_1)BEU/LU3#&@4"(,R8CJEHA+%7F4Q5A)J7FZE_^]=5TD=0ARCFI
M0R(2X52-YIF-A?5:. Q@<OPZNI,:@%9ZENG4008/DP,%"&6*_8>P%5$1>R_R
MCZQ0>DL'20;:984!BI :?632CKLHGYO*9$MB;)6B:V/S08AI32:P8L!+?513
M*@FD<*^8<B 1W60!8!P\K'_;]CZ;*]/FDTW(,TPIWCR5GV"C:<MRLVR_N<!%
M8\4RI%);M/>:ZND]J]7'+&@AW)B( =5G%;"F LMJHV;[@JI1MGG-0>?U/\9,
M/M"'3'Y@)32GNX+,:1QAQXA __%%KO)3U#*T+'4/ILU1XKN)Q *3QY0%"EG@
MQ9G0$S4.(^H"@23'E"-2_):_Y103C >JY=(@RW5##-49(HU#Y&-%1J:FQPI;
MYL1Y<HOK;DL<&AG*\:14GGDGHST[]W$!A#>:@S*_5;8"#9Y-CCE&A)DYDZP&
M_!F@KZ0F''YH>S];EQ[[+'RXD'K!Y:E-%/.QF*N&LC4CGFP)T?G'TEH^CTR@
M7*6"WY-8,W?)B[:I;AENFYBLW70D?NH>3&!EC*73<82HAYVW%P "2"8>4R4W
MG[^QO+3>9A@1X!NK)(UAGD6:#4UN*[0(U4"':!AKC[D9G*19AS/O]C+6R:)5
M#0?T&&J(QVJ9B6C-@1"USALFF', "NXD+.11I1L4M5HANU2-UAK(X9":F%!7
M9=#(TL)HQLD.F/OA*U% &:'Y1'%IJ\&S\'[JUMM08X-KB0E/5@($X:.MQ]L-
M/<I*B_=>: ES"??DG;.,^*+7*L]7F;]7S;FY3Z3W7K9O::P,]K]AP5'M3&CX
MM=:-U0 4X&&9WX878HB@<,R66?H@&.6)!CXU2J=J"FEE_VC==N95ZJ)V5)9$
MJF<NV5[GS*,Q"V6I2 %TSN]!I9^U.@KU:VBTO3.52JYX3UW?7;HEE<N!7FWE
MK: 2W_?*0 #01-*P^*H8?VPN2E5?$6$:EV@D-E*3FXQ16SRM;*LM&7>X'ND2
ME6!I96.CPP+,!3FV)?ESSW!69.];K^4L(DIYQAPH*\5_J7' 7>2*61AX)Z"2
M_Z\L,(V27K695M]30WG_=SO'\;.5XX@14AH.2%E_6.^5Y( *C9$&3!4JCYZ3
MX"KI>B9],\V Z175 2JYE1/NK:3.HAN6[M)9)->5<T_Q>N-(/B%SM*B\X;Y*
MI:X,5)TTO_Q+E[2LDI:*?3]RG3AKISJBY8C)(BIU*"EY=WQ]Y^85Y61F;>V?
M??]J1A$H&E0/EL$[Y^E?BZ=K0]@L$-JMHEXG?79YVP@K]2O)53JVU3&TQ%]B
MD*NWZNQ68G!]Y"RY=YBIBJ)W%#+),>9I#TO#NS0DOE9:\IC[&/""/%+.@FS+
M )&FV<&_RR.UO/\&CH";MZ?V\L]*,W,ESRC;ZHR>GLOH<1D]+J/'9?1L*J-'
M&;*#0K+Q[' )I@WGVJ*/33OHREJQLKPJ!28HDUL>RE:[RD$[ &MBGR07&U+:
M;.$N5ZKM$1AU*OE%10;(O6R:T:IZ&@JQ\M*J%,9D))>:!+>-_E@N51CH'EU6
M->RH6-%J[C@T?<I)W XKK>HL:,!2P!."]$[K@0K"K<>"R/1J+^K"T7<XG6!T
M,IP6F]?:CU6!+B:3,"C @--Y"^7N(4[^*'DSAB8T1R:6;M*I/!RJ]D3U'#==
MWU4%LOJX?L$BM=Y^2TX*O"T:E,ZV6Z4]G09[M7;P#YF6M%]L#E 4X!?0":):
MA%'PK1NC&?T!:$17*_&IUV?AGU0MPC5F,N#'JI>DN4Z!%TKWR8'\.?>H(CMZ
MJ9I5382G0W:<NFS-UK)+082V-LQUEW%?WVC)_LPJ.,0C,53+XZAHYNR7O02U
MD1B:?KA(SJHIMWHSS#!#ZKV=']EX=W:%IMDVV!^!TG%U+J(.7W(H4U?%+[:'
MMM \WG0MW/=Y,"VL5AMS"]MVR8.FX9UB98D,Q@/L!#2TJ,]JOU"W7&HV6@N]
M?B+1-O@@CG*R@>?UK&AYV-XHGDILI!3)45 T7#"3%U3]$_"+(3:,4%8HXCLE
MO\KH%AC=4%6_4A7M"G;SAL(ZEW$$:C" E%, JMR/AA;&)(,M<:L[8A3%1N1=
MY!DH^ @&;H)HY2I6FR'6,AB4\[G4-;%<0T9"P[!1+0:3.OO4ACV?B HN98AC
MS.50-T*<S5:)RU/,)5!!)B\$&U<FJM39ZGBI%M<<W+R@57L#MBB11!87(UAQ
MX3W X1"8"#I,+][#^G?"1 (WCQ6@83;5N]+>GHB3L\DMH_!:76.>!2%Y$Y43
M5##M3.'F:+ D=UR7T; DS1 *LPH5F\I-_V%-^3DM3_DY5YBV49;ZC_E3B PE
MZ$8+1>L%U%B?S][T;(_JNTF_3#4#M"N;J6RYJ5=]9C66PXV?Q:KK$W<*:X@3
M64WOL!HQ6]VI2BEP.CA'%>:ZF-I,4O%#$8S3ELZ\"YCSDG2<WTW/ECO>/.<B
M363P;> Q"U0M,CC$;"+,C#V)U2AIJE1/##_KD4M6%R6MEVH;@%X74,DUQ6VH
M%W*L^R18$1K^FGX)>A]&&_52S*&H""0?5SHLF*?*VG=1)QC/*D\N 6<82S49
MA*"D"FN+2V.XF 029+':8&E5RS<J3:6FW@2>#BA3 =MWX5LT9#^!0:XZF(#T
MT94FJ74J:N];6TEM:*G2C<+,RNDK%W'/082JHM5I;"\)2J'8XX[<9Q8G; PC
M,$E9Z?Q&:CJTJ;#J<3%)TQD 1Z6/<<H/-4PH:HRH31M>>3 )E#N?DTG%-(G#
MT-+JK02R>,5%C$UL&]3%.@WHJ'/+@P!4,XE) 4J,*B<!6]N<#,3][*R\:,.\
MU3'5Y>&\CG+7_'8)^<R%4H6T6C4VLEG-R*)F(&AAJ$$KB]^@>9N*#>>I]H2@
M,$>*V*-X-V=(LTN-.?*?>9 &F>6]((W/#)"P)S_C _K-2C'4[-6,K^#SK'1>
M4'KWBC,_Y90S4!L-SE'%DS#DTG/*$Z^V1BAT]K+:7#^]@=EL$*AS?XF3D0PX
M 8CBM[Y.4Z?#$]^><DJ;9LT5Q]30B#+34,GRX913A7F* B<.H&/2:J/F)P%Y
M2HPM,I8\K-+(,0/(V=R&DTO8XC%BWM@YUJOFW59M\,.,*5 \^V,A\95G<##V
MZ"CA]ZO3(AZ\$@9M)FJK4GM22C>R^;PZ#S$AU@L,1;0*%M!2ZI!-+]KLADLP
M6;8&A+/'FG!NO-T*Q'B2YU1E\.[4][HM*FW6XC _AP+.<^7?Q31@C+:PM]51
MVKZ+TKHHK8O2NBCMIJ*TI6JW2EA,BQ*4?187YIZ_&"@ID@9U8(0$=GDDF9D]
M5N+U)BEJ5JYHI<UL931634)L7K>?O5?3<5H9NV98 L,2>,YTD("ZR*IR)7=9
MQ1S,_; ZK=61K]],JUR^-/@ FU&+K HO'D=6*K'!"AU**%<R7$G=+,:V="H>
M;VZ$YNQ.5&8HJ#WR!TX)UK>;E@4[/X4M*%(U;3&S33?5:S>.K-2M>Y'@"#B[
MX,:\TC+N?"P<H[0_#B+B=&(.SX#2J '(H4OK]*CYJ9-@-8/2U]']G5IMOU!?
MMB=4DYUEU1+IUJ_%">=T"+3K(_@[J1O0$H"#<>&%HI]2W1PGKIO4>*^82<:)
MY(E)$^>K+F$-^Z<L35TQ3E5;27IM(L%*B*HH].W?Y]^M?LL/U!>< M0V!N@V
M(]@3JR#A%+@YWAM7U@$G5!-+%6)'B(Z\67H+;U(_I!32HH1661=EXZ/,%TJW
MRL]3"GZE3$*%AE3)B[:Z# )31277Q##2J4E2RCE9(U[RXY40?":@=<C$[-9
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M &@/GN>=:; 4CB ,N#$7UO)3E)I8P!LP"TX53B/\00TSV11W\4,!ZMP4XE5
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MK)O+ 1A9U2H'!^V#@[_8L9P*X5CN>&M]=$]CU\R/=\$0<,C\O8=\Y"-'T!X
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M0S6Z=Q#?2\^/HS3 B:<J@%A68' :NYK=BI'((,*LH- 3Y,C!'_QT<M#>YY?
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MATMSP9FPM;R!#.,'%>_/T),1T4O@"M(<U"&SS!"4*_1V)*"_!8DL;0X0(I6
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M<(6&YT93KX0DB9=RF@4S"T.,-.0VS(D/+=CM!YH]&.8X01>Q&UZA5C&\%#B
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MG:MC)/OUCE!\DV3^1L8L$<TWN'+J:0Q@79K]EJD'U&W^W=^O8] .9B7X.UW
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M4S]#W.[N=XY4%K;$Y'\OA:L-1B#4H\PDN:KDV@P8$8W%Q0<7][(9!IA?G7K
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MP?4\B'KZ7DF9&/Z>HR2'PZ:R]"!=U2S\_CT?WI+$T[R8N)BB904WJV8//HD
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M3UF^0U )6LH9,@D2$TJCP_;V]^![[?1_;[F0J?]B15,%A(%WV<_S@Q\^T:8
M(J4[*;W."DKC@<SIKP&GO/=6SD:^U,?SH=SXDC(L-&8NQD?D*O!$#<LP' V?
MD^T\4C^"_XETNTSFBS9$E1\-$RLPHR5!=9;"D9AG47A!6EQ:--3],TO=+3%_
M:0*;US9C'E%2U0B5;]7%49^$WL]\39V4+:S"[8 KHG_&1_81<B/2>!"JZ'1J
M]_TT*5N TOH%<[*W+ .)[X7 5+"!*B0+6^N1MU*_DV \EL. V\C2\>M +@5
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MK?'P)NQ_V_UU;/&OMOAW66O\ ZLGC:@%M/,UC?I#%G.+B[7%Q:O=3NVPT8O
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M#NC.G0+$<P?7,8A8OE!\->7QZEB([#2>$DXACOIL'/-S]<$\!3Q9B:NXD[X
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MP*G\\+,)A1 H#U06Y$1M)T7U"%^!OXO'@>KR!RJY4GE%CNJ)E\4\0?H$"4/
M*,I."5US[T7X/(8)Z5/$%Z;LEIB'!-3LW;^"OWU5,LDA)&%@&@!O&X5I[.O=
MN-/.5PDLK=.HQP'P$R](4?[D5*V[A(^=K(Q&DR)<Y.*@:GA5CX."!QH!.9.-
M6_--F$IO =X;IRP@%'@:>OUA6SI[0M*\4#0^$%I+K.:L/W1B' 2+YXVX%08"
M#=HHQIU'FA;[M_T]H/N.,X9'T,7M*G&2"[%JJM O,I26VC>L"*^]>N[[*3)O
M&GX+D+CT8FPGC4<AOMK!'9)Q@$>(83YNV(/DJ96$R/$DF!.DHYZP)PDT\?*
ME+;K-F H7ST+A!QU+\52 'X 2C );O%IBH>5(I,ZGJ\1'_ (F:5HJ1NF29S
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M [41=/8X05L:T4ZZ8NCQ\BDX6(@OPD]0E@#]8G"2"I.HU(FZNV"UT\-<CK(
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M#67_M;YLCH;%Y715P#%1#+M2MQTP(^*X\!<UQ1M3>ROF([JD>F(=(("+J1/
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M5Y-E041(!J[(AS $OW14+J4F:U6!YQ/6YBGC%1T2<6&H04ME4E!,:P:@T\
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MXN9*!M4=-JXV<,RP-KS8L*%')B"HD7>'C]X8'"9HMXE]?WLH#K@I2!=2M9Q
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M< 8]RLN)U<:[I!P6S16[YL6U;)_$[(_$[ Y9?4#QFPWF]J. +"*0$= 5(LI
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MT-*[]@EIN,XN6"@J" #;=F;3P8R;_)-"F='9](^VX6Z$CYFSDV*XW&GRWNH
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M<(;#WL9F.'H;( :+&/TQGY<])/1V;-2_(F70RZ89W16 B#P#*EKOF4ZBKK[
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M\*$YHD\WYB*]2G!64I&RC'P=;INC? %1E-/;.&_S*4=]S(<3.AK8@Q@S(=L
M,R-FGC,%3<;Y"XAD'SWNK'7W*;GN+V=G'_SB)%55%Q*&<HC@/.:FG.0N]\2\
M4:):1S]/6;6E?!*G+4!/Y620YPY6^ZD18]7JHCX>VWG4LRI57:!CB'Y_;+(8
MZ=+SLO%&YQJGZM=(CTD'E[!#2PV+F?1R!&PS&U@DVBVCM6$".:F/C[FZC(..
M.QEI<W^]R11A381:SJ>L:DI@42^N.?C7'M)I(QN17YOT.E(:)E^D8AR^PI(>
MX&8[@YO)VX&?[C;:95ZUP#VMKQ(/PLMS0W* N(6"%%J%[VQ@2=\;,T^6^UN<
MS K)K6'FV@@^JG$8W!3;[[L^*R\MB_AB2NQX(9.Z!D"'9I#U((>DZX+RU7J$
M^-U^YK@G?>W, <0E$^>,N(NV+],"[X[;VW"&3;5XL1I;]?1 ^G*[Y-Z..%]>
ML<OHO$ W0SO.Y'V/9.-;P]B-/(*XZ\RR9H)-^"!YPW[JR=-'B7O)^!_S)=J0
MUQG,.5A7Z/NP)B=K/OR!JE0U>?SN\Q9,2M5*_!!R2>7H]\FR&J/QB?J_7Q)7
MSI/]T?;ZC74#R'=\[>S9M@(HXDN>ODA>/'N>/#\YN6%ZCX@:G?U][<'F;QPS
M74W>-*TD!%V0$))8B%-#5QL^J9E5_D9"1\(U-[HQ?WJ)Q$C3T-EX)'F_K)Y+
M6D= <>C-XBI1B^[7ND?<8SOGF,.O47]\51\:C<B[AOIXE%C#P&<H5%-_LCOL
M%DON=@4K8"0I6=TPDW0ITAN!5R=S&4FSH)BL.3Y<Y7%R^NS9!N]HB#;(,Z$B
M;Q3>BW[_]X4T_@8MELT>P-QFX+(?A?15=QL%VZ,S%'/%USA:=[O.7EVWP'!8
M=R?SH2:ZA^BZTK$[S]FA=C[$3OKJW&D7#*=/]7BM4T[0(HUF'G-<E5/JVA^[
MS[):G/NL)4>Q+2TBD4[U4&+D5I;<(T[97,(18BTX!+MP>(1*BA%+M:X;^G$&
MZ/IWC:8[/:#I#FBZ[Q%-=^_2SR9ANLJ('(<#TQ#D6ON]ILNY\B+!:!H>)%3<
M-PNMA_)4"W_HJ]"T(/,JKO0BN382NVK=C''WF*:I$T08-7LV$U!:37EB$M/A
MV+VR\C1*JY<]/WQY(1RV'?];SQ'WB@4QI0M!XF%*E8+,1WSS&U]V$BI-]FJ;
M+)/N&;7!$35:^60;K<MO\OBO]/$Y1%F@XXY%O;WGJ%32[M'<B:D53/Z"?L82
M^+?.DZ+TC Z%A7V$GEJ\/E\$I\&GE+[8=(-Z4 0_L\F$^(EXP+0,*?ESX>[N
M@5_K [M+NE6KWF6E_Q# %-J376! 7<J^\3;QU EF%.&YB"B?O'"W9S:8_*JG
MMG+SPT,E%&XF-^)]S8)*^@LI&5A&487J-HO^FV]BL[@(@J#?#69)DM.!>5(K
MFJ^.N7#Q1BN;MW@==;:0UD:T  %1Z!^26+5T5?B6E?B1PPLE81LOC,$S7Q1,
M=43#Y:A1@U+Z./X1-36YPV*:#-VKTV1KB>,M,ZZ\EF7=-G:1F^;[JD>7Z]&-
M-\]7S OOHVZ3A Z=IT,D3!@Q!>T\SI@SC.=_OM!_ZWN1\J!Z,B/13Z(P7<4_
M&%= C,$S4MX0B;)OO7@/H+S[+WG<E.5C0J*0RX_S?9WDW803#_1E5*1K9(_:
M;/0?SN5^=(*#D3^<A-4>72+=-#-E/N\B[(QY50&[(N% 7S\]E-+N<EU-MEU7
MZQ-3UH(#N]:T!ILM"TYYM0BH:,54M\I*\F^6-@O&U:=.8G!-H>C S'V[0M&.
MB+GMJ>+[['<4F^H4W-R) 7R2!-4#9>7"65U?)?8/:'!_%A6%H[6':^X64'VC
M11?@[$GB8NWG/, JW41:&+9':=\]$KN* /TA<W^G4.N[QEB'ZL#W@+)NOCW,
M&A/R0P"MS^"&F$S-JJ@S2+5O[!_3*Z89-[N;6(G)JV$@'09^[3<\U;C(2B!W
M2NDH-[Y?<S=[/5Z1KFMGA.QE-)4?K,U7#,$[ND40VDY^@%6@RR^$)8?OD(SF
MV7PLN0Z]!SF*R[+WVS\J]^_1)1=0S.]O'C4-6L(,_[M^'<4&Y]W8?59%V&@#
MA 0A+_;HTNB\*@%01:3W [1E0F%,T;"'BL'>N($*B$Z4!S P[#VZ;E%!ODQ?
MG%5)<"$OHRVSS -HL_(B-0!%GB1#UJJS F$3N7[NP>-US'*5&')+.1U,#'!%
M+7/HO$&,G7$?#J<5N >!EG-YGIZ+]3(NW3:RE"11@,MPWJ(TIM*T\FY+4SI
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M?\[M&]*0T>ZC94Y%K-?.:TPB&K7A155"SS)V-9B/6<,@HMQ7@Q@&5IZ*1,K
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MU-_=^EZ2S#%HML,";Z@[U&>8F8F!NSQ9S2_D:"40/W\'^7=J+QUCE8HVT<F
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MN?1ER_%ZZ.HRB]I<FW<T^!X&;TATSM<Y!3QYTZP[FXK5E$ZD,MQ4,@FILCR
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MH9; 36PS51VY$HPL^8=0(KR"]K6>/79<Y ?KGMHWUO'MZ-J\7T ,F]KF&@'
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M( >N>'9Z<G'J/;GC>OM&ZVUQ4S@$]0[HLD)_U)3P1P)8M&!_NM71I#GC*?
MWGZ>IA5C,[EII]@@4-E=+@1=N'C#K6:(<E>;)?'I)QN35@O_;!NV*-\$BJT3
MVZ.!L1$.=<+UPV#\XN;"Y8[+\S:79WEC/PXP?*N$?'(LDEF?C4Y:SK4,L#XZ
M2X5MB24E^IA"H"'"IBUJGJ^>VA.2S^&0--=$4K_D=;/B#F/HX(&I:S43N37;
M4-_6"A'P>8/^A!O@S)T!0"UW@FE.6(0DHU-GPT:[-3IP=BE'E$172>$BQ$S
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M$9UNVN.0NUKE0%B/W5LQ)PY)AQ$=]V3)M=R<$BAP+,7,A^I_'5MF;WEJUOI
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MR8B?=C+B3&/>-SH,S^#;Q*X2A% 0'U6IZ6YD[5<[Y^@O3G?@.2\K7D>D$B%
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MORHU]0_C2[!C-MQ0AMJ,4C.X]51]&YZMI3)O%)N&);VQ]7'CGPBV",:2R\3
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M,Q[9@-V L"-KNR*V=(ILF=G[L+5>/:"=M=?6RC058OO^$+HN^#=T6YS1)M9
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M4FK"K#9RF$;_Y4[AV/F!'?4"#)^E0V=!."C*"R K"%$ 9E]8!3.'IE,,((&
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M&=(?#FI(GSTY._D?09P7B7;Z.R\-$TFVLZK%Z2(E2J-<[D'E+KH8%VO2M-,
MY'R'F(?E4:0U/64B:5!D"KUH[#PX :9IB_:"$.@48R")?@"?A<:^O;<-RXV/
MD*JZ'2#I=K8)<&?"#*"3+,AF^#DCMYMMQY/Y._?=T!3 RQ+H +9Y04L(>D3
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ML\NAT5<.ZV&H>'E^[%>]4;_J^4B8<0?>29\:ZK%)]6!-JN\UBMP&@U$^_SW
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M+7,O,_\2,:I&Y=;=YXP_R&JP],[V*N];M9B@SS*U ?G6PI(XA>A!1:WL#5'
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M-WPN3%HHJ1A63+.8C<?8M5U [5-$/]0^5 2[>^]$9_C5[EF2Y=\PN:3<8R+
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MUU)18_#1?KA5"9X#<*&S5(>!]>$GP@Y:L5L-,QF)\Y>C)X0K.AXS>%-7;)M
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MVML 6U&;Y\RT(@CPW?IPHAR[\9$]AE>PPW"3%R[5CFDMZ]+O<+&#]A30BKL
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M/J^%G"''D;[.'"=#YCT=U$]@H>K894MW"98TM5K3V("A\$*[M'*2<;0H8C<
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MC*O;G<JJ##QL^%$5LTIK2"<=%3>5:4;MOLG:0 ]_9&PN8L3PY7><J6MVP)U
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M[)\,X-+#OUH)<NQ&?46*< RU'!+I*/&K^!>6I4W CVONZ1C>-\1^$R@M-[C
M)48Z- .%7FE^NC,4- 'M2)E3);Q6AF[#T6?B6K@A!WZ$#:WH5%HU0\Z+C#)
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M1)_>PX_G%]')KQ_/SGX[>_<I^MO9Q[.?_SLZ__CQ[!_O3T]^?OO?T1\GY_^
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M38#'@7RX'V)W*YT*JG!W.+4\*%NZ'4=;B& @+%L3WF >R(*&!89$^94K(N?
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M16O.C[DW[AVM 0W'FJL2*!HIN[JJ;3\W^@^:,/O_V?L2WK:Q+-V_0@33[]D
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MB>]]//!@]_:W'^6K'X)1)*&]7^%H$/KS]=/$TE&=)UT:JV!@=04JAI%F!@"
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M51%<5:08&//VRV;7K7K\+<'BG^!XGH88XZ?$F<\TR\I!M7WYJBYR(#G4JHN
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M%)JI36VDVUJ#K];J5#L@MS99L!JS6>D6#8W^K#9_;D@Z+R>*5S]$=+IY5#T
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M"E*75\-M5#7Z[H*16=R%<TM,X_?E*U+ZP6<KY--$L5:,6T.^[&=4U-,!H3(
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MDC@3JW_848,QHU,52I<4LQM?)Q5(.^L8[D]H$,$-MKSB:6&N&<V1%4Y.LQ(
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MU"R(Z5O;F'4 95]#?B-.;TS].-H,57\1=7M<^R.K(U(Z8=@,B8*W,N%IH%2
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M,B -!;I-!,E"#5J'@^33:D0KO8TCB?IT6_/;25 PWS JB!VO)##HYO% \%
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MYC%X;M4QX^-*<G5.>,O5&CTY9!VBTQAYGMS&147EZV'X0?E ,X\GKIV1'CB
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M4L1DCUW  +"&(/($W\\7:WZFNN"<HU<S6MQ9.2DPXH1:#RD+IM62J=,I=!5
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MHXTK.YFYXH 5O22 8./ !AT(3_IJ%L%9D@.]LDX .6^<ALQ^=VN!=(9=R>?
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M?_;P$<5;$1A;7(=?' ;\V[V#[#6.-NRLV)T6M(G1Y%A)[?R:F64G"\_\Y -
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M'FD'>+NF_!834,)NEK.=AVQ:VFQ/MVM27CB'U%2#;'A,G,#0?;\-[UJ-6]\
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M#.%P3,>!=LX02E21[TSU([LA^(1DP]I2K'?TFS9E![O9">2'.853W$KTKAY
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M.HT<UU?,+URYA<K,@+GL@:EZ$:*)RN4(3<DHS<^_M?*(@I-GVVM P1I0L(J
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M#JCM<9-5TR9U9T<0,IB>H/YM0>2EBQD=H*V>$#U&K<I*4!0EET1'U;D5T(+
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M#<P"$)/>O5? /\\]ZX)0]BB^AN!TV-)SE,!%T";U-E4*5CG.XM"DPYKL&KL
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M!F];>E$[979#V]$FA?4,I[=&J\ B+XG=?>F$YT#[5'HHVN@5D^\AJ+IF4"%
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M,!#<@?45/1ZM/"5MWV5I4?]L(/EMN9J4[.%QB=IOBS8\IQV9= ,L\Z\IL=_
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MPJ7)]L9<6_V980DXK;I1GS>%;G6B-H=8$6@[U'P,B7S+0"O;6&2V(()#;9-
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MAV!%S@&1G&,F-4LZ)B0;^#0NR@K#$0D]$BB/>4G/=S5@A/M;P1\9?V$F -&
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M':1W""NHOE.4M^JYK)YB"1002,S!.VH0% GDO,3TO04Z7PV%FPLL06GM&R3
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MJH+["HR)J7J+CH?Z2:E0.!#KM^KE4)L=85"D5WD*OS+H* )"D4]D#(XBJ*4
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MIW:N>1G#;;C@6!"HPUI14<>&<TJPN^AF[K,GB)61)VG"OV [^,J70\ZB533
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MI%7V*IVR&[O3*#M/*-Y\NTF$8H3B_*"XKI\9E104UR44YQ:</0<4ZUJVZ
M<#Z@K&\"E"]6066MAK \"98K",L(R_L/R[G%P\\'R^\ET"\(M16$VAV!6@.A
M%J%V_Z$VM[R#F5![Z[G%!&DO5>$^TO1Z?>8&$@+O/,<V!PM"KC$5<A%QMPIQ
MJXBXB+C[C[@?4T!Y>IW4V),U$Z!%"55J=L'X8(?!S.*J:RO+C#B]53A]ACB-
M.+W_.)U?PLTLX,T N121!=HM6P#_#(T0.P*UF\_E0:A%J/UPJ,VO:F*+N;;G
M<T2,A=4F#;HI-]L7SXV"90R[6AE!=4= M8Z0AY"7%^3Q__5Z0T">7BV7DS9*
MN06!W3 :L#@4/UW2[4RBPUA$ZUQV@+O+'Z11*9,_7#N4.=J;C -;=P^F]#)H
M^FR4/ UIVV'\?\M^R?[D/Q*F=!CU@3.ZBE3C?L(5(%.%(N7RK]-98E'I;6K7
M8-U03%).F.3ZNFC(60U'_Y?T\-O4?'[RO<BUB@I>5//CU+RZDK9TP>-/K-CV
M&7TNT@Y_]3EU7ND@4/.LUTNZ$?=5/D\:*,-*D&JI7O^5#'^%]1A;S!Y]*Z:6
M3"%*$?HYG\N[XH]\,23UF1?8<**>0Q0VG.?P[,Q3Q;YP5#_7M=+9AK9E%*C*
M::1232$??C8G,?]L=GX 2@0+7)-_"V$_8U0[FR[%*H+0-1RM6L;AA]GE'UM7
M^24_$,QCN(+\G?,0W'GRJ<<?INA$TTI5.>_4<#);J:6."S4$^=&4%\8;-;ZG
MXG%JE06W)G0M>WMSFG9H/V#G\2_I70-*4&.&F9MR:3/+1:/0RZZ5^"0SF_')
M""Z%T10=.O B=5-V+J$?#S5>-C6+M;2 GR&YI18R]79(@.\XWFLL(<1_%U\Y
M3)]+KG_EZSJ3X9+O:3OPG"ADGX#WYL7#%42$48EI:8;FCYI78DH?#JLVJ9]?
M\,0=W,X=7$A$WO F*D$D@ZS)?A[ /@Y5W3PP=2^6,#\ P^7Z<(7ZHU9L)_ER
MJM:E7M->8175Q-N>8_%'*:7Y'Z=M9,J1Q4&^W/"B;8(UE2JFI!&M_T:X"&);
M)+8T[!'KWD90%VQO.'=]"R.-;O+G^I9G IL>$+%=LL#T;9$UEEW2@W7Q--#%
M@RZ>3;MXJM5ZI08U3,K\P^IIV&O+DB:5BJ;*,.7JXR%);<ND-"]U(^K'U7FG
M%#!9W-VCRCW=-$L;=?K\DX^=HZ8SF.CVT<K%?R[L]_E!X^IYJDL!NL8SN%G!
M%JB(FQO'3:-1T:JZKI<US:B53S_2'=[W;4?!HW2'Z\OAX[?("@!?6.A[I"FD
MO1WTBJ=60Y9%T1$?L_BH(3XB/FX:'^6O>@745+T2RY65,F?>G.7*BX<?<7DH
MT2R&[TP2D!RM'"Q1$]$!<PW%L5V61!6 IRIV0DY@NJ//K1^$#S/JYQ%/2IUL
MK>9, \TAH%8%GE:6.UV^>)T+TF)FY-NAG6W)LZ/GBUH./%ZRQXN.QPL>+SD=
M+P8<+]7&T&PQK!Z=7S!^GZH0>("Y>^9(.\84-$T';597L6;PT7IA=T#N["=O
MT=RI#[=AW'HOJ9XC*GIU)PP9N35FUK42"NJ(I/D9,LIUK=XX96^ZEJ,APPY"
MT80H:@>V95.?2X8")F<AX )X!XRT$-Y=N&Y$G6E@M[C(^(/R+<@T#M@)DT1^
M2%=!I$.D6PSI1FOOZY7\)+ZFYP8BS[%#[GS;9*\<5/RN%P6LZ7E]J!ER<W-7
M(+9KL3[C/_BEOLB4Y !ED7[4=FR34-/T(C?D>\)10]9"W>D2^WFB!6J8B!:K
MHD5N19-3:/'][L=O2V+#+.$% 2(-$!4$" 2(%0$BM_*]*8"XB4S;(DW:MT.N
M@'"]X9F%($TTD;\S_&W\#1E\OQA\?>218J??/,]ZM5TNI7LFM"7E1Z\P'#B1
MQ0];_D7&3E MI=/G#Y['JLACR&-S\)C=AJ"AR\AU550\[?4_D:8?A69W#I[3
MD>=BGC/0#+9O+$>7DQQCL?27UO5OMQ</?]Q?M1ZU*E3B6:[>QIWWRED1U$B^
M.+[+!BF6Y,P;\(6C8>0S @51T#:=8LI& YER;YDR)V6RT?@0V_25;YODTFOW
MF,V9/_0(?](+@S@$FE2]GL>T5(![VXSXS*4]MN.=8/,$#C13(W"L"AP?8:9^
MX \*R'<[8 Y]1N#('SC0?(W L2IP?(3YNMGU[8 T*=?R$35R1PT#40-18T74
MR*V16MKI15]EX-YWAR%R? 1R5!$Y$#E61([<&H)E%17RU?>ZCFUV$3?RQXTS
MQ W$C15Q([<&55G+J,O%CA?F. QQ(V?<T,I:Z?JVA="Q7]"Q//\>?;YV(36>
M_/O+_0VY=H.0@C9PZ9D1Y$]B=$#"-JWF-V0;9)M);/- WSS7ZPW(U5O(W$ T
MY#*[K$>1C\;YJ'EQ@WR$?"1?\=JUN5#*[S?9>=]GHBW!D+FF<A<?NQDY,N__
MQG:?VY#TC[PVQFN75U^1UY#7YCRS+EG'=FUDJAE,=7/Q!9D*F6I.IKJA;>8@
M/[W#3W?W5\A/R$_O\M.=S\!^B!+?^\R$40C(2*D\(3XU<D>?&+F&<L+4%/W)
M+VE("131*8G2.C0,96I0FN^@Q!FTL*3\$_&E\D(0P.N]X;;%^:NV\_QU\!R5
MMY>MPUB0EY>-<S64K?C*&!%-?N?N1YUJ]+C,P.2RIWL!I]I%JD_B<KOIYKXE
MK<%ZBW3JG=IA.FEY^3;A<>+5I3,6TZ!>+963SM*NY[*$7 @TUR5E4H;WIGM
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MB*3\YN-X[O8J$HV($88^N[8)]E??=DV[3YU)?C=[M?&>(*4>)*QO7E8^+/)
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M.SO/.9ZS?/P" @(<W()"Y_B%>/D%^/_]"!W#Z1Y&)C8F)C9^3G9._O]GH;4
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M'MQ->Y$DW"!3FVADJ)&!M\ZZ\LG!:R"_(7IVM*^G_:1290,EM#[#3;;,U]E
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MHU9@5C0S94N.NU==<VWGY-7SHE].WYXIN[@94KS,\6J^IK83,KFJ7S>H#JM
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M_A@ 2G*:*[&R=%[;AO.(G[&R]-3)_P%02P,$%     @ :3.#67IEXA%[:@
M='X  !<   !A=G1E+3(P,C0P.3,P>',T,#$T+FIP9]2[!UR4R[(O^I$1) <E
M2Y8L.0B,BF3)2@XB$D>2Y#@@@F0$! 0DYSB2,T@6 <DY#B 99 !AA&'F@6NO
MM=<Y9^U]]S[WG7O?^V;J]_NZN_[=5=75H7IZT-/H98!414%9 <# ! ",RP^
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MU'8<REA*'BDZA:OZ4QTI(?(*/:W;E\C+EA$5 J$U?D*H#GN"O?409<>T,>=
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M23L?0+K:\'YX3#7S.;O(O&.KNME^9,X8W=;%,])*Z3_<Z!'YB-:]JDIMDHX
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M)]&4>8WT(J.2,$URO(;B=(J+S&,_Q\Y%]M9)>WYI@4+/Y];Z8P+P=2.BIH1
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MPHOV-#!W;(6>QEG0KWZ()YZ[T9O"W)K:R(@&9$O*3!4\6%:W+4&K[8W.\RN
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MR?U4]Q//0:YRU<LMCISN:[X:R]\W&MTC@32PD'MSD*0M,Q817CJSYG%;<"1
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MK99G;_*,#":GKNN(7U@DJ[Q- H9R)2."YKL,4($3)I(1XP7YRKV3U"+!P,6
M@0C2A(&6\:6(DZS>=9'CY!3':J&0O??R"%4Y>0?/#"H?U,<,E'NC$C)KS3%K
M76+8PVET0C%KE-%!;*R=Y&C;NU"T;7:Y )72Z,]44864"+)C#_?P(0X_#+=G
MGM#R%)Q[QRF9[$#5IK XR^YB+E<4=;!4.RP$AK'V?"4WC\T(C\Y=BXDJS?=#
M1K=(1[XZ=-D0?)(FQ*D3PUG5.@!Y(1J!-_WR5C-W!L^',%Y6<LK ,&+C<SX4
M_I,/BY3.LG#WW]9QW6[+!!:X2[K7Q8518H:>^;9B@8^D^UKC6AAUX@+<R""
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M1X??(UF45V^&G7F3,*_3E,9]2S57Z8TYEWL)R[F)@LD29?8R:T7CCAW%BU@
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M[K+Y <G*R#Q8^O[(JB1:%-RHC05$:NK.T'%8("S#OPM,H87^B<NSHT,MS(V
M2?0Q^B[H=5$O%&45'9*^SV<,G1D#H[Z0;/8A1C#!=D^P@#UN"IC/I3E&HL+
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M/ZHP3V=<K0]KZZ^SJL/W9/F1Z.TX+G1E8%L@MMNP<+LRP'D@X@-P,58)Q?J
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M&SLJ1R38M\I+L, W\PI*75JTV:&A]1"I<5:8XV?IDRO7-6KQA-.61, !NI3
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MZ8V)9 +<Q!1A_3_5AD5>YB#3FBP1\(P7(X0&G0O9S.3Z0@7.@IK!)RP\7X2
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M@E/="LEN879BL1M9'S8"D?1P^\U6_*8I/U#*G],N>@3)-'7J6C&T-+;.0):
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M\OXQ%?OF^L; V5!"UX1O>J4#WF0-#L+"1W*]&>2=M><\)\5%B@P)Q[':4E0
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M<W.&J!*5X6AK8K539R!M0#MC%F#S)ZE_J\RN<X8[E^MVA;9D@D65?&;/OJ\
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MBYN/*2^\M:?>E.Y5#VV'D1JID3E)#SZ;B2EJBEQIU[5\?]1<.'_SX?MT;"H
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M8K,O)8 0:YTQBL-B&R_7WK;1#34\Q;:GD4O&5=C%(S12.0K'8,IST[/&MVA
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MZNAQ3;%(4^$+\$NI:]5U,1LJK$(I2R^T?3M8/H1U4*.N+F36(37FO=& B]"
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M0+!U2)#>9FA8/=:.&Q)+N$?'.RPX&H]5!4V6XD&)('A?^W@7]&:MG:0L5WS
MSI41+)\B&=\)#P9:Z=@N*U!/$"FH@A+KEE79FPT/G*8$";0L">X=:U76&.F
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M*.V>#8WCA]\G%%LX5 B9F?BJ&:%TOUBC[%J?XN)8RKL^!-F;9+HX&(IX3\%
M2?>D,K3,".]DK%]]-'_3;ONU[O545X6HV.=EUV+[R6,+48]V&Y[;YW0Y%^B5
MKOO35CV),U;T[. @4F -%2Y:-4[F[64N:,@R2N0W],M"W&WQ<J%\:A,/$]:N
M:-_:_/#NP8PN;3!^FBSQ4)(E M@R$:I;7H 2IDAXJ.)@3RIG]42W8H=H?"Y\
M,=+&IV23-U^]OCKN3+5'H#S:<L'VYI&<K3;A_2&C.YK%M7IO6M^[LI0^#_G
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MA92V%\OQ%5N]*$5M"T4NT%NMMC1ZQP7/EUHUFFTQY2K9>DN*6Z_"[+*4,U"
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MUCR8O>N &G9/Y>NHB]ZL6T8-44EM'M08&1!-M7%J\CY-M_[C=K(]W:N.,49
MD>.WP5:3BA2UF[D>:S61* 9*Y+Y56'_ =9"@>I#:QE.C\PD1D".S->IE\DFU
MR/E9\=3.B<;K0\^LK):1-5:G'<RX?9( ;C*,,2OQZ!N1/WY4ZZL2WZ^]ZWL?
M+9G3WD"\G$I2M'#I$C*>Z542AA&#,YLN[ XV%L]Z>MX\2=!E5?\[^\8.5('3
MZ>.GX&(K!MACIB-8J=BMOK1)DDE_RMV2Q-G&H:9N.((>/Y_U0M["FAX5'(XQ
MM>2Z[& J31FF3H!MV%V9 +_7!A]R# DZ/1:A_U0%+?)8!S[M1?]H7WV&UT:+
M\PFS,M'3/NXHWI6!FSH+96U3FPZ20&$WNAC6[^2)8]ZHJJI1_77^R!%KJ?6W
M5%LF<0G=)!$H="!:N"0R5_)[^]0$_9\Q=OOX4>Z6<W:-/N\P *'O1D1E67'Z
MZ1$KA<!05YF:.L2@O6;5S'G!VX!VI2,A38;I,"*]((YU8TCX<>!@=74Q09W(
M$PQ#\#U T]7WI.I6<BU\/:*V!@3VEP,]%G[: N*18WD7;\ZAX.=$=5.&O\_
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MHZ=%I^0SMY\V_)O(L@/ESB!#[8/=65247<2$\<SK1M57T>2O&06P$P\MEAD
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MN,IS=<)]ECE%E#^H,#2MMFZ?_.U;A"SDF:99'=/4ZAW4FOR$[R-23[$ST.)
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M]*OF?'"^!X3NW()!"DU_/-8R+RA/C^^@&UX(,[8#9!XY"D43_H5 /TW]*Z?
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MV+;R6VUMR=TA-@*)9#.%5=G89(QO$NND_KX3STP5LG[@YS9SP^P+NSN@F'2
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M/)'\1;4] !EG0OP=QT6E\D6J7QD0K"/'GJ0"]92S2%+FEI_+L3UVR^GKI/7
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MZ#6<^<"BVD@(;/?.@^]W2_SDMBO^3&8\O?\D;"UPYZ";UO)8Z;%XGYLZM;R
M:\J4@RFV#E2OKP;A8"EB;OJUXVQI7XS0B6/+=%613 B\FB;Y>K(FW=H]*]KY
M8" >,* IN=;@^,?GFRJ7?#+3\".U1]042IA>$93AF%.N!:3OA7RCLNTVSG[T
M1@4A09*'=HLWD <8$)BWZD!I6C:\D%Z^J_"V=I8U'ARIKA;ZH[F% U=\X!&4
M)[Q1 )%2/%I@,R$92M55J*$V]6"(9U1E6T _XP''/< 907:IY'O3W=*P1ST
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M_L^W%AM'V<,#V87_P<A9!L41=0UZ"$X(!()[PN >W"$$#^X,! \,[B[!W88
MP4.0P5T&=W=W&=P9- 3=O-]76[6[55OU_3A_NKINW>J^?<[S=)^^)7-Y7A;
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MDTK@%=3JH'L7N;6"^[JOY/,Z-43^ZQB$<EI0$Y:H:@^((5Q;Z!#1\=H*P)N
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M_P^0> H?9=E*=6QNA.':1S!LKJ$1V5L%R>J=WI#UO59UD$1@T@B),'?CY=#
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M>YFZIP+>NI^$Z;CHGO$2T[[O"VR8(<M>_$38<?J?K:I&AHX6QV4-WNGAWP7
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MEJ<^MW^FH^TP<#*X:>Q40IOOOYWCJ.=3_/F9;B>3NVB8(HPE*8GLZ21NC45
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M;:R?Q9)WLHV NA;%1,#C:9&:/3I_1]&IRZ]Q,NGZ8L[P#)[9G9Q#@^9WED:
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M>"*P]%9S[E%A<@>0Q9>155L^1V%-09.B.XIB+^9S,8.XB:\90F EUP$9@C>
M-C]_6!;QYRHET,H"PHNR#7*!#NZ[ >">HQ[%(;R OR8P26\ (0#?$-0>##>
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MCNEZ\B[ZMK)S["C:T=DN2:&Q_"63#Y^ <2>M>FXW3X@VX;YJ']#K@GCW\Z\
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M9+&]T/<3Z'\);OL^M9/Q#-B8"G;RZGX9>;Q2<9[T>$R5?5;!54XLR\7.?42
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M!$1Z#0J*2E-Z#XCT)M)K5#JA2 ^]22^A" @JO;?0D="[B/02J2%!>DN0$B'
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M^-K .LBJJ'78E&S0:XT+5:>L)SJRC?>'V"X+W(!D/9QZ 2O>I'=#:=UC^3S
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MZ>&]17,NV!N;[3@%^59R#,CD_AC=)=L.,7."A9LJX>]AP.S*E1"AJ[S+0B!
M0*DYZT*)WJO4ZXY"D[CUG):WU6\Y8,$-,^P[,0^F;8LW.*KC:"RRYVI'$*+E
M;"OFFPBQXX5*$M,/76L^4-*S^1;# 7#]C9I2:),FOA03?[?'",=>C/Z0NHSS
M0"1.'NY>4WE[EY$S&NP_(?#2R\G&FC2F S>DVSS3T 9^V?9AV-L=F[=D;_TF
M= _Y1!7TRET.F".I5$A?4V@"?LZHX'[WQZ<(RADF)L+6ZFL\U<6++Z07K6\N
M 6/77?[^69BF39]DYKG,!G$LOA1GJHI7R#%V.)W0.D;ZIE:E,S9I#J\MJ'%J
MG%E':'JN*=T%0$?5_JP?_[H$)(/1&FX@M/!8QV&CY!^X =9N.I#>WP>W.M)<
M":3>".2;RA^ONGOQPER<KQ_DE;-"*M%%2W0J_-"&Z[9G'_F]!?D!-A_X:':,
MI!"!O?D9WD]W:D7V =Z[#+P%E_F5+-+W_<6M'X*!AB19AFSV''A-^Z)+0(^X
ML.1:V_$HJY I-&&W@4E]ZV5 ^H]G('% EN!35[G1,1?ASW>(2"<S?^"48QRE
MV=!MVA;3MJ8!/)J-R7M;@;GW%7D'8'(4_A*B51U4_.V/_*7JIAH&QG8)ZI;6
MA78F_NW6BW-# !\^RS0E=B/+9*.F:\VZ^4L"X4'V03<@S&S(2&F0/5IXAI<@
MY%[6L)"FR\CU>I_C+?'=G-I00X#G6@@PSP*(Y".HYAEM-6:(-B56]CZ(?,!H
M18-G;K>RDA GWX+"81?7-QLOJ/";V'6YR0=9DZI!D=V_=UZ92=W+6#7P[J%)
M(83[P(*%%7!7.B+47ZIJ:^[+2+1[$.9A<V/,\0N&6^F@^S6DXA;/#G.HQE#2
MH4(A6<$GI98!VUGGV[^[/*Y.4,(K'*QW%M4IRX^S'@FO7( &R;6--\S[/?*(
MVIU^\88S3?_MGWL9/^^HL!\=CW8Q29MS=W=0!G5[.S9F\9N^,%=ZD&35FU]E
MK/HJX)T=<?-_!#+Q1WSZRBX('13B":=S*!7:G--O,=-HW$8\SS_+;Z[H(")8
M8?=[0>$S2Z!)9Q,0Y:C-2;\]$J+,?,VL>D>)$O+Q'$Z)FAT84+[XK'WQGF<-
M3+ZXN'E!WH%_5KS(*Q;(-;7#/$+Z1_>,?^T>WP_(=M3*!]8@WV#9.CP3;O3Y
M>8[_=6!LJP3=E"1D8=B^\1C$+X=K9.$<6[^/ +- U]7Q0>CR-C_39GJ$=2-*
M4"=EZ*D^\58O57_[#;R[CY,]]I,6-KZMO:ZRKP2*-(X0N&7GG*A9IGA3MZ'8
M2X>9@P@F?5@1N_MPW1A/CLON8>>J39L8ZEGBK+T8'?^DXP?;63[H^]BZB'K6
MPQJ7>!,3#%+==:$_F'D\QI9<8CV:RZK7=_SY\_43>&K[[1SL)6  %6L!K$=D
MLG%K8*MB>'=6O]H:,>SL)XO1Q*4,$K;[.VRIJ& Q[0_Q$'L,G[K>U Y?*[TG
M5<UYK5S=2)-+S<^((>H84O=#H>%[P<LT8[:9,0<$8Q-MMRW_DGQ[4^0M0=<_
MANL"D;O2 3C=;I-+0)QP1^0%/U*68\C/\QR&@6CZSLS-3*A86T<\(_]!%N=T
MJRN=B_X8WE;)/7V5WG%N5Q<V?IV3%QO+OZ&7/?@'JTSB/*KUB'J8\. \KY4;
MEXV^*,:@*(=YTY@A6NGOU#[9A.>15//LW5#T!%+(<FYVT+92%.++58QU-:=>
M#M[Y:@X+[O-A:Z;#474#+@%D%Q1V%U+!9-("5?8G"*UVVO $)E77ZY-!G5'/
M@^;H#+N\>3 "$2 R?PZ$1=M*RL,0S]*F]\+&*[7QB>:"?#M(RNV#QZ]SB09Y
MJ1P 9TW](.IZEVL*MQ&]$YTIMF]B2-/%K](M5H/=RJW%^0%I6X]7CSRXP\)V
MP5FRU%.>NR[+19'H8;!.%FH'1;TVUNN%A G,[O8(1M&_\I:L@G)/(,R)^R0O
M ;$[_M18_0;U6-@=.UE.1- =QE7KCS^-L@5YJZ6J=\:XVS4! 7/6?.'28LBF
M2J7O">%L=*DAMXL3Y;<S"4MX/X;>[!@@5>7%O8TE ,ZB',>MBT@^1O:IPDUZ
MWK;86ALIMJB1O7^R^\A0!G)HJI!VL*Y<F_(R<N<TK#L"\T#B%IXE6.;/,,#'
M,%S $B^PTK6\O;GC*/VX<JBINQ';KY_WD6?0E3CK(_?:*]\#GAE@+[._9#VS
MZ=)\5:$D$V>](!$/QU:7[[(OLAN,U8'-.V\O>T"6=VFZQ4;A/T)-M6DLYE,;
M&A)+>TPE&'T8VB5MVM4N :&N_M8X$.P2X'0N9(IS;O:NW#(\%J,?EED(1Q0#
M*,.P.53S\I^9H[ZKOW[GGN  5K PQX6]G!(IY?4G+U N59!MYXI9-ZYF-!>D
M,ZNK.[8Y*Y/1!%CC#3 N,9> N_O2*A,+W!'2(*XT>E$QT55Z2+7K@P$05&!1
M]PAN!;LNOP,1Z%EB:\#NA5L6SNV=R52HWTV7L.G<TG;SG2FKFKX6+(U:X>[?
ME5K^P?RT9:)!QOG$"$'O96"B]US5*C%NA21FG<!SIO$3(BL\Z<\'AYKVLM^<
M%GF]HGFQV$ ]X+4E)LAY36E9\!TDZKSNP4P.3KG[IK24DZ5W)14U?#9WJ@A:
M.7O,SI9(3[S!HP6* -/*/O)7Q'K5X9C\A?(VV6G; K1F1GN0-&;JGN\L[9!^
M*K$U>L_$F88!O@/=\!A?PROE>&WS@G><WFI20"/TF=LG5D>W2,ZM(L0E0!R-
M>.W^&0?^A")WIND#WFIGQ"O)<)KB6K-G,\,/V^G&G9._BP"=DN@/,.@O@2]5
M7L:.^!Q7U:%'8#@6C/9.?Z9%-L?,PW%I?7>7H!S^(ES#T7LW.M&DA<^L<!)Z
M3BD?8:*3DD]NH3?D]R1UUH)O?E_V7.N0E/;S*;('D5W)5C^Y)EQ0#_C._+;D
M70M\T*NIUK5Z51=+<G>7)W7$:P#Y'NH!$=2\_W4L[KP$A"8Z<ZZ6!GJBPZ==
MA#MV'S>:+?J$OZCPMJ)&AL4 SBR'.>ZJ$+-IJ]W^.D"<23C 1L;P$XR776[A
M14\%J/''*BX-1BO8HG2O1'5W)Y)5SC1(!MN[I%!:?C=5]M0]<+5S<:7V,HQU
M(_/'QXM.G--%AI,-O\FJ(UK)O)JW<JCL</!D5PZH>=.M!W#-C[WHPS<%HF#B
M=Q)K[<_Q\M@F[?.\*^*))>A7;!7W&F1Q(6IJO]:T)5/M;#BM]CK$4"[)#7Z3
M&(3+3C/T!C'*<OOK."ETMO/A\C<DZS8R9=9B*^=_%J75]!>:<27GVJN+8GJO
MCK9#HB-8K\ <2T\V1<.YKNKTW=TJCUW6;7=&RX5VN10;TG+;!E_1V#+%RDT#
MW_<LK;$E:78]M]DJB)@(V[];!E;Z@=93I+UDLD,K#_"O!TM?6*F2)9HO6R>F
M<CLO)/JNM9_C/2\!]QDB@W: I!?!CXCS_E'WEBP)J@[0/: EZL>KHVTBE^$T
MT$\6DYP9(@+4"Y4S.1,:QB:*C-?USL=WC9S.I*#L:SW]QX:9.E..!%L/%Y$H
M 2Y!KN34_I? YH1\-@I?3UHB]!+5>;(T)UK&5FV*7R2;#E_JX2^:88D)<'-Z
M/M,W< OW@L #>$KUQA1%<PFPS:;TUYG9:=C<%X%30I-'.%W8F]!?E#1E<3G2
M'RU>K.:/BLMTPG7S@L7_JM9[HU4,ZZ[64C?&\66]_?,":LOD_:Z[7\"S2T!:
MRH^%%J^U%L0_%Z&GM,1P]^QR8X+>-P I(*6\"/U3QPR.#_V_/-&1]QL.*YG9
M6-3KJAL6&H^3>)_=D(K29V22P=/E*@)<EX!X<"[>I2^0&T?Q6?"+0B^,-1/V
MZ1YTH>"MR%QQR$%(MLGRH< L3:<):>SNT490P]Z;VA:QT\!PGU)5T?1B,YH4
MOK::/Y:.G\,LYJ]>%T072&?7P4A@\41GWQ&9VT3>3K#H1N=D,!D)UB(.R.Y_
MA5$$?K=@')=6+MKVS8Z2-E]1CQ<A;#-*FU8-EW1!!.1Y73MN+;LBVJIB )B+
MA_[<8[*\4.\S3HL( Z-5]4^F0ZH:# ;NN=\U2<I_.+=%50FIG7]HI;%&5[JK
M3+$8X;@R!W5]RK;G/J1[[^F>&],\^_Z!\XFRVK'O(^*>0^ LL"M3!AZ5? G0
MP8E%[S4L"FJR8RX!O<Q3R*9G)I+HO.CY<Y.L5N\J9&?V#8(8=KO7I+$AK\>=
M;:\48FW[;E)KXG'"#/5M<=)<LGSN-F^/OXMU13K6Y.L<WCDW>8@'+,@G ^_A
MM76Q:]6ULADEW6-:U=\L XJK&-THH&GP,]N-8TED=,6.-!M&TV&T&UD[NXV(
MCT?4&TBQL)RN=@%%:>\"?AE<-)^]W&AL%QWWY\NQR\R.]60#:\7J-SGQWHO=
MJ3K3"/\9?.V(LQ(@UI5=VYZZ'*"LF34TD$TMP+OSM,;>!!;#SUUK17Q-[#VA
MXN.*?85$QQM81&U.A'VKLDQX*V9;;;)@I@AB3F]^=F(T\%G.366EIAQ1O.N3
M:S_7MMV''G8^ZY;T'/UY1$4__Z+R#>2A5^.>-YUNUVLRUM\6XR5;SP9S%LSG
MOK-IUFG2EG]/JKL76;(IQ^H(NEF_3R$0WT!Q;9$;*:WQ:4\)SC/L(EW.D):+
M+'D%6$QH17Z7!9XG21MB.NB@#B@C;.KH>V$^*L/&Z3P(BNZ+R??1P8\JX_8S
M8>?*F7J/;3;"(\T,I=!4L:=9Y=AL75Q6Z9GR<!&^=D*]]!YV:M*$;''%?;7;
MLI\@"CA::U_"PN**P>&^+C'^!J\G"LWY!!HX6WU>HL6:1W/6@L5'60,'LV[C
M1J-%^-YJ*O1F<A_7&$S7GY,;IXT,Z?)TBMTIOLOJ7W!"MRW)'FZ/7N1':DXN
M__5?H$@$.71@B/E1I\XA_#X6M*MHO<)F,<TO#<3P4<EWQ*C'@\ =C=<FUKB8
MEE2X^LF86#J'#<9 D'@&$Z3'QBIVIKD(#]9K.:/\A/E4DNKHO,;M$.S>K,!.
M])IH5XY]\SCD?$+;7R_GETV["+:XOX/% <AT%:P!KK\FUO P# 7=+J&AQWB^
M-X*Q+B%&=;TRX,,_UAG7\"*&F?Q9T3^O/8S5].X]]?JTC+J[/88W.3 U]SKN
M7]0P>!*90:EE9LD73K+,_HAXPT?'.BX?\+V'A#I1N1!*A]S17U:>:N"NF2+H
MY]DA"@>;V[%+257#3H5F=< ETD;=^O)+P)W]S$DDR$'S+K(_$WBE)_*VLOBG
M&N)%94RF-N5OVTQGVR?6W;FQ5!"HKV!T7G7(QV/28>0O5>D@2S?)KYA5B"DW
M2JUP7!MA,OW2^Q@D](C#/:4/X&T )"9P%T!/5'#AX6%&6W,&,1[DXI4%CYWH
MLC/6G*@IA;*.XE!U0:%<V(?PY>.&MHO^:<^'TU4TNRYK+!$?U%2<<YR)0RQ2
M^'/91I(>3-?'WI>^852HD-A9)4_:80G.OJ#'-Y5N==SVS&;8ZJCW.-6.V2EN
M@?J+",^$BD$__WGW\1LJHI.]=8QT4I;['";+#H6;3#LWD,R8JL\(GJ9'WIM^
MH/GDP.DKS9 CY<R'.Y4MT_*[AK_.4UIO>A85%HY-P^D\'F#WO[B62'T_AG!_
M)!;S&L5Y#M#-0'GZO;6QV1HXP]CP=ICD9N@5S[R^!"#>DRSL9FNXF[F$=#BP
M:#-#Z'54EU'4&PCZ?-84^R6.]BO\; DSH5+_ S\ /_[T-Y1)17.SIJ'5IOTU
M2HR_PG5"4G2%6XPCQ(DEX&3C($@ E1%RAS.("F(@2S\%E^UZ@VGY^,'(;$1K
M^N5?\")^"C@665UBQR-7(*A8A$V2*&*_6!TG93RV1,R,KL@-\]"Q9:,]V98#
M6N>[O RPG_K6?UWVWW]Z@_!O79UM P05_)M<@L'X3GW''47AQC3?\,;BNUV/
MXZ*7DZSBDB7COPM*(44$=E:6>Y91#%"K^<5+@!6TZ") 75?'XVS)'NR7ZH)F
MVN&9MJ\-Z#]]29H*'3KVP=KVWG1<G:Z$<XDBI$]O*_$4:9C\:#'7DFPD)6VP
M" H)I$UJ)4)<99^Y"^VPB^2?<1\)\*6@4>UTY+:%SID1?EL/NQ\OR[Q1#;W0
MCO3EK_-T9<\M[QU_.%9#KX.0K[<.ILO&B@V<YISG/,!ZI>(D GGQ!N8W&]07
MG]N_23:71%M3Y_$H=AF0)OI<Z<C(&)#U* FT:KVWR5O'070NH<6/,E\TU]8?
M9V:Z\.(39_+BP+.GQ"45^Y2!WV2O8:=GFKRRYYE3E]H*U?.W#9FSBA\,;26I
M]LATN71P,!&=AI@']07%S6EW?S*7E-AU;OCBKIO^;;+>7$;!; D4D+,,D$I^
MQY/D,I>B4HW5'ZFI@+J8CXM\F+J12AK)OUOCX^V%<A-_Y_6-A7.-E+@9$_QD
MX6+@XO8G9>QJ\(RT,04RLC?): N[7?<PIW&_QZ2^9\WN67]/)W',+)9A9V 9
M%(%("/?+F5TRU<P[+S"N:'+>RD,WJ2?Z_DJ0X0G%AYRI+FYEW[RX%Q"I-2U-
MOK)XH],BR&:KIC@K20A0=^^5_M3A-V[2L&$/8)U++]4=/*JO@[I2I%(1_GI2
MP"FO3DFN_54#0HA2<C5:F*A\97_6M#OH3JMR"62X#)K>XXVH4*>LR&*9>3")
MGJ938MA]]%E%[H'[AG:E;W9XJU 15$RN9EP8HK(CW,+X7O1XW-;13I(H"Z+U
M]/GOF>S_+(_">@+SIRXD*&/3BM%M-A)<DR)DK1DS3+>=#270D5JIWXTO1MLI
MZG"7@$A_>_;L>SC2R,/^"4=^9J]['&\2#/-%Q1=\ND0V/[PDC5R\^&9!DMY3
M;2_JMNTK-.^0SMQ655ZXY6:*FC?3"O*U_!)H;<!*MQD#TSQ/"&2S9P;%>)1#
M1< UT$RRE:F5%)TDPA_J,/*XK!=]P0_E!^^W3<0 L$ZVQR^P!LT^A19F#A;<
MIMM\PO8,AHG;KP9$*VT3_6/7@#AL?O'PB'@5#-VQL[_<$<X<D>2-WC8=\CEL
M$SACG]+TF+C>N 0F82]VE<X\&)TK'L@L"L>YH&$1 [WV@<QX;V/U]2D1E26N
M(65JNW2/,&+>9S'>.V<KBR;[*UI-:!:JJ$&<;G?UIFK0PQK>ZM89[^O'42&Q
MH07N,8"=5O4S(!38Y[N6&_!@/UIX44SOB[,GB,K>=VIFSB"7@Z,F:S;0$!7,
M,G7KF':,%SV>KA9Z[WIH)Y\!(W[^CGFN_*EW%3>FJ;]-"&V%4/J,\-R/\E<O
M;WGX)7?3@1FS8C?4Q/6D+#C0AL.KR@$\EZ):BWWET'3!C/0X]S57K/\H+>#J
MTGB*V0P*E?5"+*]#I5R7@B7C0<NV[SU@X6)@2H.N/?_'GB2-!W.+*E9ODZV:
M?OB,:,GOR%5)@G]N=X;)8:LR"LWQL!X!=+GHI*,GW]5Y/'$X5^=LQY7A QUR
MKS^I,L2X[#[S+".PX0)&8B&E4*'^4]H9B&>1@RM\CF]"=<6\A\G X)72LDK5
MP+$=;JUEQ<D0\\%D\0RL7( OPW1_$PSYU5D2_M(2SG7A0200";+2CLRB;30U
MY_]^.JD-,X@UC1ETL7K:X\G((?AX@T7BS<)O<YMHK')W(! /KR0HUE3;^>M7
MS"G;>KNWIMJ-_7KC>PTZN!]B$:((@,J6G[%":?205?N:R*B*PT]#J%V6#O+9
M;2&%?+/1Q!\')F'U:1ST1_?;&I?ZI8PL8^BH%9G?Z^D$ QB)Z9QC *O20=C)
MGB!:?S'/''R3<CVR/C9\[AB91$J\J*TOBVEGQZX3:&3!(:CZIK +#H+P](L+
MYH8.BJ#\K;MO(= HC@_N)YV'TL@-T]NA3XB8- NH/_^6NYN@Z&;!C(<4X2W[
M A_B> 5'72N@H2J9>W[1Y-=5D(ZN>8?Z@.P11#/_F\CH!RJC9QK7%<]+;3\'
M5-T^]8F]$":R5KK.I\CV0S>H/)7K$N 94IS>=:7M8/'M#!M9LM,$4,G6^.B#
MD3"HP([&J]KK'VY;!Y_U9*5.?9QW)EHK(KV?%BQ-[_)SLM/57A98.U%%4$3/
M"JO8-#:UCXOX.#D7-J4I<';QE@_UFT?/0=<JC"X&4%0>L%M@J+>Z)EBY.@OO
M8+#_IG2(=BY@Y*E5XSMW:NEUY,.V[U<A>.8RR])Y"< F.&1JY;O"H:%.!@<3
MQR=&,Y[&_)XWYV;D'[0ZO4,]BV>":GU.,M_R?S*6AT]LES1:OP2\#_?8W\E]
MG-':P>FUX[CY^:1JY.J%+:B?)YVU]HVBIT[(*&DI'VMW=\\;E7D.$R:H>U].
MAH"?6_\X+NQNFFMW:P=;T.#O/?PJS>GB66SJ\/M!7U_*HG0U;^X[*T47Q.@T
M#$>3>8AX1-PGK7_V$"_0%_BD?29K&SRQ,O7%>EKX"Z=A&E)[ZHMKQ-<0K5DJ
M +!0:B"H-OM]JVOE@D.2@P4G]LOB8IDQ.*B;KT*]N)"@TJ+C3">>XI"<+Q,-
MM\\+EG8[.=;'^WD[.*5H9$Y,GC&<$;UN:/9\48]:<P+N.J][6T"F#^,%*1@T
MZJL;KSOMYAE9WG9[7M(Y>*K__;^S(>)_;404BO?W7$?(2C45GP@!TX)E&?!!
MN-"5+F0'>^LSVV5SOU[)_F),FZ)PJ?"GF]Q-+:F=8'[[#T[!C_LUWE^C5/0$
MU5T"NH*H"8+X.O07;KWZYF24%CZ(_9-L66):$\-#;YLXU;'JQ3'VT/94++A'
MDP5]>$HXY:M/E&TN&2RS2/_0^ ?%$C4JW[ELJ%L3O=FU8T?\.P&%ULNZA45%
MR0*A151Q<VGYGCZNMTV4P]<_G;'H1OC<-%.C^1YN)#:\]G1^1#/ I9 @AAM)
M<G<2:4I8:\(ZM7^L5EZ>]?#SL8(YWGO.TCG_<_TK*[+VO>,!5>/C<IK76/?L
MD9!L (%KBB" 1H5*1H9):V/#^B2+8ZNLVD+>NI":T:6NVE"'N5G.E;G)NOUD
M<^_S&XG'*O3NGM$N^@NV(^);=5W10_$R)ACPL[O*2K,LLC[$3PK.#,?Z&%EO
M)R44);[H=<MGW+"C_DT:><&U!;Y[P:R(1: Z91^/M\KSQYU:Y+L'%<DT1&1M
MW]3L]B9Z^*K3<HB; QD-%4"WM<[9OO>_#M_L8!&)AVBW-<2LO$C;TAM;>2KN
M(FXF&*6A7B_^<E:&5.24F;J:-BQD1"@3S%<M>91CAX_L"J)JU;;'#2FUI_<@
M"@RH"=JX!V=F@W88D<8TQEY=^GY1"1(>#_%EY$(#>.C=0!;9.ML3S^5;)'S_
M5K^L,"_X_D?_P<U,/!A]TL\#(X$$L1-D2$-$KG*$+9/T:/C*1/$$+U=SZ)ZW
M>=[C7W(&"S>>B$D0DV1-GVC$J  \CZJTN\"W#\&12 N.EG&G@M  K_,CGHD#
M!I34.89H0Z:$>*UC]O=R1]0% \$,&Y%:9FPV>",#>RZ\'?]*/-:T<O"KU[.;
MDO0L"-M"G_N$1^E=S-HQTJ28CX'/4"CP%L-]"IYN;QHVH%XHYKGA2>[MEZ&,
M$;\9+4D^WSJG?_94HHN].S7_+?2ZDM1+T@0[((6T9[X#LT=CH&S:0%=C&G5G
M^Y78:LQ\04Z/XH,3,W#+=,KPK&6'^\(CI,6P[H98[QC9._A\?9Q37Q^!AQH;
MT,-5R5,=%U P4/_XVY_!SFVP7P6O#R=J*8OZPLP6]3 D6QQJNZP<,WG\L!W_
MIF3Q,4YQ+<3S;;QT^]L!KI@+,XVE&+)7\F46=_!?2O GZ*/TGD?M0'RY*HYX
MDZ)PRY!ASG+>R'ZO>H>?^]U=:Z[;/E;)% '2-,2 U[I,9L13G\<X?W=<K>5;
M36!W-E6K8A'!?OIH4?)B22J>9M>MZ'V61D@O!OU!894B-S1R<<RS:JB[@TI:
MQPGW2:4UI2>SPNL9P6#FZ,97/\.??!8+9.M\<3Z.4*JQ4^1\GI@$J7BQH(1U
MO]R [PV-Q_9)H>7?NHK'./[&!T6#WYD].6^7TA(=K.^"G=- -+(TD+G("!'P
M7;RW1FNSTW,9 >7T5\_*GW\OS%.TC._UJG ALVL$T738PZ]#ASJS;D[[,^5"
M'?H/V&QUI@ZCA;.;?+X9\%A'*!I\N-&3UD4,L'W8WD!=+8.5>7Q-5KZ+&U5(
M+.MSGB?L9"N/AV-7,-95L=[PC2P6L:<.!@CK%C/S_I1'UXPPX(SCI&\OM476
M4>PL)N<YPG R_+P*=B!!6(:\:V[%;.A8/+/'N*41JN$B4\$KW6G)_4!M[QV9
MR1E'K[(\$BZ,>CSXBV;4A,2?*F"9W(41[X+1JD.WL6":HAJ>H<>+>LJA"S^X
M/GGD#M?3'Y1]7Q2C)P^&'L(]S].D1<KQ?OU@FK5IX?)A29:A,\/&Y"WZ>!L=
M)^;D]T==)*S>=(>/XV%OH?MJEM+^K6,D95T1BI(9C-V'?;+_^\:ONN<EK]@$
M5I#=H+L.2[33!&VTDR2?HD"Z^KCU%*$H^6[-7H*(HW7-(*L^.&*.K@EV";!W
MXAFPN(T-+%U&W=Z4U)B1C.\O+)1-0QZH_G"MH"P;8=AW[I?HAVRM&0YVBG-_
M]BZ@;AY!9_L"_B!74K/*E\$PBQOXO$S*7(P A3W">B2E5#E_KF%QM3AS?L(Z
M7-[6++C8CLM6AF>T74JQ@N ,ODY0J,:NP_RET/OD6RD5Y47YQMO>]+6*U0L]
ME+=S>#R57NY(WCI[VCV[PLGV:&XW5'XSSO<E::=D=D\OSC!4]C[$@FFL_1'$
M-_Z'24"R0[NHX*?8>O4"=U;1@R=#X4P/8E;@(H>@G5+TL&G/:4??P+3P4)N$
M0"O8U=W!.=>N%T>KH9(!%/S,KLQJV)+J1L5Z7-Q;(8L;)K:JUU&\=NNYJ[J^
M)PO>8_YQ57&B\FTUXX_'M(!%;=V&"<<"1,L7CM!G:=[BUUI=>CN8CB@,;)NP
MA^R*)5*:OU9N!TP9BF!&Z<S]Y:9O']0IYG?W.>V&=*:<%Y5)S.7*=5/&2!)9
M%+(*JOU>^+-@\'8/K;Q_=\_T7'-HB[EP>#XKIY%T4[^CCF,[HVY[+1M7;GPC
M9E>5CQJ#:.#:^]5;GZTS@0K,+ELPJ=[]THF$H$?C32+2G\AC>*PS43DM85PP
M+[J^=5JKIQPEUC+R&Q")B?<S)1N%<96*FSSYFP$">O4SO/F(NB_<(?WZB6N5
MZR*_M<.E=;V7^53,3--2U)(Z)OBBOVD?I[7'3'BJ!UATL[38DR1^S_T0<^ P
MX9&=="3NJ/'LZ5K"ZMSCQQ#BBD=Y,8#_+YC2IH4BKJ=7"S,I'_(]-JS=K3@Q
MO\%W!=LL4[ZVSP0.<H#^UO^Z%44"V8W9ZE'(]#V4)G@:JL5"O',_E]64*++H
M*%T[U0WFEHETWU3)H=Z#). &H@I"^C/LT%9OSF:57\K\50EQ8,#1WN%"9+(^
MW6[L4_, "T,. 4+1SFF1<M9"IW^EO'E8U6^AE65^'@GO_YYITAM/*3GEK*['
M)^1VMM4^*R8<JFWMN/ =2;G*5.09C>;^,DR&F5T+^%-ZV/8JB,KBP70=4 #4
M%@GBN?6JV"E&MSWN*"\WY)788\8^;_!UZ1>G@;GNZ%G4T^RE>9K3F&4GY_R.
M^H0UFH^_S(*E_/1.G7#C!/4",'PIYN5'MM]]KM.1TLPRK&R&:K4![)&3VUI%
M_?-)IE,V7RRHC_^IV/#_BXWXP27  *7V)X) C>$S$ENB:81LW?AE.!(H/3F2
MBB/5@=D;5=&JLOME'2V^#SQ33LKH0XCM_$CI7SF??M@:N(:&BY /1:X6)%[0
M;>^TI'ZX!-Q-!#W!G451%.5Z$U,429!UP6VRU@='T2R*M(:*">_R[3A^V4KK
MJ$G:5F_9$3?AW3TF-FE,4[+OX0F0O+;K6</*2V<:4,+V%[RGLZ':UZ^<UVP[
M3_J\ MDG*9M6V!YV6A5= @3-@LA8D13*WS_),%.[EY/ "BOKCNWJD'87^GPB
M3VF)?NJ6K\,0_Z?;D_XO9M0(PW1_1VQONF] >X-#2Q4O;(340P8RY9J9@"';
MNV=7\'+\Z]SW13*1=RGO/R2EJCE4L#Z8^N/+E S-3Z74:2;QJA(;" 2Z/YKF
M2PEBS"!UW;8H71D%+$+O7Y@.,5IL/_^P[ZF3UL0-1YOMO%)V)8/^5&=QA8&[
MV^8\:9'"VK'PYWI<:&'H@>3WG%*"5(PKIF71M--+,JQ^9K5B3>;Y^:11LK_,
M5%(-VQ1O6W15@PZK%E7NR.M3O491&HAAJ:WC3=Y 'U)%NHDY?XF,GP&-^[]
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M2G\%7_S?VGOOL*:VK6\T@(I2+11!(2H(* +2.T&1)@(BTDM$D&($I$<(!$5
M:1$4$!"B("+21*KT#DJ3WDM"+X&$$A:0<H-[G_/N<][SO>>[7[U_W.=)GF2M
MC/F;8XPYZLQ:R2:#TV55):_K&28R5)"1];9$I"T7JJF&E38MQA5<;TD%A1:O
M5,*>#R 4/DWNZ#_=TY:Q&%_6HA/[M3-?@>*#,S?P'QJL$8;G#S40N=W?NU3<
M=ZEP*)SOO>3TDKF#%K+XI> J#D-/5Z#%_#D!&#),MW=+[%2C!\PM.OM'IN6N
MN_?GL6?RPL<J&9W7([[5%B]$@IN36TH\V-!^7(4/^,(^?-('P:S>VM_^S*.J
MU=,V'Y=A(>IM&X"CW/+3KB8)XAF?!PFN3!VILL^!FQD&PXH>^@?E?*P_$=.[
MOHJ7U(VEVS54F8G*AW7X2&>0M,BI) _LI2KICXNC"4]S1S6RVC.M=B_:O2EW
MGE4D+X#NI6EZ)B"+J:"(K>[3<)A-'ZYX[#1"D>6K2_(M.: H6"<J[GCJ#Q9/
MW2X/Z[ D@H9I+P4,A-03+G[O+6DO=Q?7TT[2:-&UR?JZ^V7F>GJB]%K%+JVS
M9CY6]"K]F9>.:*^@Y;_;=![&/RB96(C<,K^B<>:'Q 7S4I^)JON%J-WYFF%:
M)/6CM%NBHZK<[0EGH(5Q8XV\>KN#_)XGB&-/=VZ&#'!LICV/\A]2NU#L?,?K
M56\EY,[61>\>F>U$->>R*#7_!>?N%;/L0G*]04%7F?S_L2WTF,.(74(D40"
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MGJ3!3_V3&BY!_I$[LR$9Q_^0\\R_D_-=3[+:]Q=4$#KJMQ+_O: \&2MO4;O
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MD)Y109@[!4UHMC)]#0CQQ\$_QC*-O:?%[-ZRL]MD4; =!V.Y,*I8>"D O>]
MHS5FYUU<@U>U44'YKA3.F<&)PRYC6XNB\EHB9JKZ*A:9$+T"DD=MPZ?()JY3
M9\7:2'=1"[8>H!91K?''J@_Y9,+\!3US7_"8*Z6%&KC\1%Z>DZEL+7YUO.G#
M<LG C?I?5Q>U8%RY#(OI$>K_IW;DS/Y,?17)*^YL]V1_/"0;RN:"9DH,L?GR
M)JJP;P-*)1[^63SYBR>[-.[NYUD[9@WD?!OPYYV1O:[V<"TX!F)"N3PC:YMG
MD_9%B]4C.>MB3L6AHE<#D(CR3BN 1LD^F2]MHM#IUW=*80*:G0\QGC=LJ62U
MCH&A^H]NBE8HGS3FN^0BQ>@OSVYY3XSCC8,QG?/'<55GVH,.9M;@Q'^YIY!6
M+GVE>>7];W[LEB69RXQZ_:OK)H>B7:5NG:B0-&5DW,A^N,A>6F4Z2=^'=!-3
MVC<FF%;;9[?F6126E15"S^F]&?YD**W,?$^^O4\V$E]0QW^^IT:6=)_04N:>
MI9D/=[0J#D4 .%>K.TE)]D<W.$T8+B8*>G/.[77CA#&=?EAZ8'D3$_IF\K)N
MW)+P:_-RF)$27>$HBUWP>8/QZ1D^T7C" NY8/D(=?ZOB\';Q<;W W.[\Y2%\
MG&"_N(/PF<3T+PRA1G4%0C*71[0&>X0#@KC$2KS&@J3@]B:#^6JLI&O]'TN^
M#PI5EO;Z).46?*BXYL'1/E>D<JOQ2KEPVD!GT)"<+1/-<.<(1RRJ=/,U\\EY
M8ZLN6=EEF[Y1$DGS(653KD_0C<B81#0["?P%>&AS><JR=UU"K.1HQO>DOM6R
MXU_M+KBNU;FJ#70C3(!P#X(55N@[MKU2YY&XCP5I5VSZ8BP;:#HMP+1_\6[4
MD-Q/*BCY?G7L.F]\65A^K0,TK+')OROKX[D!]P[(R&#D8^C:PF.74^ \Q 16
M86NQ).!-;X&X#ZNJU0EKFR:!V-:*, 722M90T.6)E2DFDN+TDROG(H8T*]*6
ME9M]I6X^:-%@>WLZ_TR9&WR^0J3OL6%*):EIHCL]5T45 PV98JTY"QMM#7,E
M6>3"2[%ZK?*>.B]AL+,I)^Q'U2<-=(5_F7TE70.L/@)EK;4<*CYJ*)?\'UG5
M\0FI'Y?]G_LFU,^&ZCYQ\+N%LPT1$*IYA$>W!@3*U_N;A:D88T0E>%Q&Q<9L
M720\?,2*$Z):Q9-0ZRU-]'?W/*PL43CC "SX!% Z8XFO2?D,!#2M<(\5GQ!M
M/NM^FE[Q_*L'L8E\2'I6CY_13D*#>RN! T-+BT;+_NSUZ/"*Q"8)!MOE9+?4
MLTHQK[_HY@-6.@,9%5Q%HV.5K9=5W,9,;XG>*SO$.TN2P"\T3!6S/W-;]W9G
M'X,KF_;YY 1HR7E):\KF=I?-LQEV57LJ#=0&(\]Z*Z.CU;AAJ<(W\,B0+3[P
MG;+2K[$[@JB+Q2E1FU_91=L 'N&HX/=>MJYYE%\2L/="H=,%;!: L#ZE1_^.
ME_OC'6-#)3G[CCC/$P$B)*^;5W/G7-VS;$J0620%Z3&2-EZO/L.$@ QU*U9E
M:%1R2[63)YJ]="!P%MG*CNM8J"Q689MN7K/YX"DE>D8'CPSV_H"7UT;7^U9$
M#T5MS;XVJ4G#JD\7=_,OXA_G;2QL%"@-UKHHNUK:^%F$U/G+)D;+5LH550WY
M%;<Q!%],$'4Z+!!?5^\1)W5S>E 4$5BK5-:H/),QZH:7_69EI>406';M@8L4
MY5WAT@WGP8==5!#R]6:@*^6:M[_\RQI^0&/:[ZF;[,HZ>S-VK%JC2=[2]9W2
M\[BC>3C7\9Q37U&IU88WM]%G2'(]:B*DVT,J)AX?FWT^P?WJ]C0G8D)\$ F_
MVJ]\_=)\MDA9Y&A5G*=TL.B"3JUS_T QSEV7 'U^!6'X?FH9E3,VHCH^N&ZO
M' =MCV?SE7M\=SN/3X-8V%\"/KNLU)'&V6L0^F7Q%8 TPH\XR0UQQ7X^ROEC
MZDS^P/FG;0(K-SX/NA&';-R7%D8QWOY"\7BG^IH+!/E&EVU5B1L]V\SD>TNC
MM>$RJ?=%B]/H,Q,>;,QZIH73W!H>7D]A(R ;D1%^R=#0/))J (;OSB"K&G;2
MR2E94<AYY,&XC@K+K)=U$'I?LQD3#6LPACO5)SN^_ CW)90<^NIBZ>*V<.Y9
M[_@K00%&.BU0Z\VZ8F#@B1,&^H*7=\GW$^2T=:.7S-RP:H[VI5>'0-.S[[S,
M>$WR4S96%@[4Z]?<"<:@&U"G'D+8"JJD14L28ME)=Q/6.N%#ZR=_U+K<JS&U
M<E-5_&*$X.VM$2') EXY@(:!E8WIS%U*_>!,]/#\'0W!*7DF.8>T*3'[AY!B
MTEZI;"3ZF(LGL+H4^;'VI8-O8,_E)W:=10S@E#E2)?EI"RP=.$5@6Y@.;ZCE
M7?&"*5GGY5N0$V_UFGJGS;F]C9<^73_!U>^T^X*G[4-+[KEDH&#*C_Q0K/LJ
M,*\BR=C,Y]97/WB_NY%XAUGO\>G"Q'8ZR^N&BHZ'A@X5?]/IK51.[6HJ.C6.
MWG !-?L_1@G>U16S).^-?5L4/3FV;CJ1>,U ,R4A5=/-8I O*\_-PA-VC*[L
M0;^91:9'Q.QJN:B-8X)TB'41KS*K(+[6<K4X?Z!E28!.W]?R]GY)O61J3.S
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MW.:MO<M>V\WFAN&FSI[BCF31W(.*^Y)7>_G97CC7 &2N*FLC1Q)^<U0*$B!
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MA7L E""!+6CJ%&V>5.K;JF5MQI"EUKH:]?O66>LKRM-4P\P0K%\4L-4"Q,?
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M9B$V>W%MU<_>89?!Z\N[UU,\>:[<3?)!BD#IQM)H=),M3X]W&VG1#J'IXZ/
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M4/N%+/[)X,$,M/SU%,L*+Z2"7G82&<DJM4"/IEX6^QS4X^9OR.,PRCD[-.X
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ME'WM\__G/^=?9+B>),_,FGO-RLP]6<'-X)8!-U45510!!(0   '^#X"; [P
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M !7H,3SY5<2G\^=JH"LL;-7L'0Y =84\Q(84XMMS#'15"2.ZV3D(Z:L!7N,
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MI]:8$:JC\:L!Y=E2Z"9EA8%B4L<#"U1:[W-T_?);?^V9N,3H]Y"OUM;$TL4
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M:3E."_L(16PVA6?%PDR1A/ \PVC7LTXEV#)YERFOH.NC+S_O"XA^&7*6E]F
M[_A]_OKV<?^3YQ&%[[':#" Q] V ;#^4M$L$QX[<REAMM9UYB+6L7+@!]$J]
M\WWD;^)HED8-6IFWS"_H=_/GQ'A@8U==P&N/F@:C-MNAEK?-_<':[="45[MP
MO886,?O4RH[;RL%7'JN)I*?]OA;<V6K-GRR_0X/4@Q411 X%UNG*KC^V2UQ(
M[I/? ?Q]NFP7(XX9FQDL'-[8:=DC:4+M3]8KW1S_:&-RX&?YXNL$SA,%J9ZA
MC9GKE9Y06L?N[_:]W91[%K>[IYLZ2<3-0JTMR8(-7WVN(!-LMP?;?&1D*^PZ
M.M'S]4T8WZCQ:@SV4# [R9\#:Z)*/R'58<TK]^EH^D6+XM-N*44N:P1A<.T8
MA*_,5J?3EQ@:&06F_?=:_VN.49I6'H-/]FQ2!=1;V[2):5"6L EP%TV;2$/U
M=/?Q^JR[&JOJ.K_XZF 4S[BWCI^OY:%D?H=1;O)1$?X^L3.Z#/+\^BN>!?=D
MNF@"HK=>*<BCD_(B?$;SSYK6\Q[%><JN9S6UO<M\8SC3DIZ*'9/<TNIW8K@,
M>MVJV,EGSW;< ]G 0WGF=ZW3I8Z*P)!SZ8(D-PJDAQ.\6ST;5B+(+JL+K_'\
M/QC+G8>[ZLH B,S?K$6/@O:Y)1H\2(YJ)!LQ&-"B4"R++?"?63F\6QZ+,3O:
M_C4OR=HQI;IFGU@M+!N\5HIU(RH0Q!=5.=7Y?U-]S=D:^<*CY\]A7W@Q&Z"V
M!=?4<Z$J>U;T2^LH^=?[1=P2<N5@!"79DQ797)Y%WO;A4K!CWBZ1].57F-NC
M&G\N5&QN-(ZH*_HZ+H36'[9:;,&/7(EI; =KR@<(HIE-XWFX&5+6;]L 3AC%
M-JZR+MU^:FR[/..(^"BJ8.8CT399415 ,!.N]<MRP0__VK*O&SWP;Y IT?0/
M9(8NTNU:-F_C<J"QH?N)W?@(BW=E?[@;GDN_;TQ^M9T%\AT&;9@KX1Z?C<[!
M\>HK83>  X[NR[NUTSWG-P#*?<O/E@VM"ZCC'\8(/#?X!O UZ]K"X$[,L:&6
M]6D7[R03$'D#^++WN+!)_MD_M2VP=VU:"#=66&<RU"'7;R#0,/+>"6QU#@%M
M@T)UCP,M26[M=[->KG=5EI)\#*7L!(38^ZNN42;),XP6U,;B64>K'4SLRJZ;
M JS+*)N*#[T<=/ &>\OVRT!8#GP2V*#ZH4F3;+TL'BTS2JJVQBIV#FNC?=IL
MO,1RCT7WXB._WUP+@:5&S$=O,VT.RZ/S$8(6U$1Z:OI[<E_2@%H:;--Z:]/(
MRYWY *+E\0A-'KN/W@2[%@WK+MH[EQ*'L_ODRM'PK[7Y#_4V&T27GB1V+J*Y
M3L!_!C3+3X3*,I/*$13*4YJL P7KK-*]AQKTYV)5GB)2LAC@,*JVV-G%ZGMC
M$@DGE=(_NX=_W.[RF[02QR:KD+1^-.]3D9,T'-\1U7MO<="I-@QOY3]G_<>I
M-;#@_P^+ES=HF>+ZNM;6CP0LHHU5E(7A6B>5:>H&C5<AF7Y.H9L=6L#KL^)0
M$T+,&,X:Q=T>@$BFWY<^W,]NOWZ%,9Z;I7\FY/O^@!A@< . Y3-C1U>A,9_Z
MV.C2@^Z^)]J:T,A6[SMJ4*'<@&VQJI;H(S&?KG/+G9!#+>E_]DPA5.?N!Y0(
MTU6VX/VI[TY+E .;NB721X4NKXXM,R^5D&2(F6C4=J_:-\?NG:RTKMDF5M$%
M,1,-U:51%.]&%*MR8%R+E:IL('S3K;>;S1S'@GUONQXL$6>:;N2CKL_U:*0>
M]%3U/..8 %T[9<Y@V#C3V*Y^Q9N^/K'W*(OI\X:TR! HI8;TXX;];H#!V_HI
M-^%8-[S=7Q@P9AO[C\E+CX5-=+)3YHF--C$L%)IQL%D#OFSJ[@.2SZI5-/KB
M52H<7;-+2#JJOA6E_QAB][(D5PK!)': /B]1^(.>4TK5+IJ&,:E*7)BB,+^6
M0.#.=\H=K[H7,&:$C!LU_H.!O56MNO:[+!)9T^[IU$Y[O$UXU8J0/N MG'JU
M?^_H.E%WF5JIP[RWZ[RSH>B%I_GO8>CO^8#9KSDT4WG\9Z1<O /RVB)\9(1W
MJ>_?QH6YRWU;5G9NE.<4&=3_#6Y#>^]DV C29A(EQ D%](ZK98D];B%3YE9F
MHOUAPBNN_F^0QY+<SP'KR6A7T?I%.>E>R\#\*FDX";R,L[3)2G]?;OIR@6K5
MRG220.J:?_N:?'B=_TO5 55I>XHGPU>"9XM:)0'/AJ#/%BH0UH6+"-<R0^2H
MAHM6__@?F,AL05K+WO8'X&\XE$?#JO68$*LO*UA4TK4F",L]U2!>]I0:K-OA
M+V3E;XL$V9.)C\$F,&^F+-;'E>G&O"/_O_)H^0]QSXY$+-! N3O^S'3AXJ#:
MQU2F<C@4C4&:<?YDJ-DDYD15&QL]_KF[W"UV9DXVL$R*74+Q] 7:?T!79JZV
MHIC[H>JICZZ1.JZ]EA?^%(M\"8<;8\0[O_'RR.G.*D-Q\*6-P??6)*GE(Y$D
M6/C7;<+D5UFP@0=LU4&"N4FUUL%^]W]_-#7C2HJ8*I>BN^A'PE>[$X\D5FYC
M.0V1N0.Q;B7[U$XJP<\G#S'Q+&/\:JU(!D%V5]"'+,P-8*Y]+3^Q@\X6$7I_
MI^UI:E;_<0Q/W/*D66.0O;J.Z"+>$_>'I$?;_ZNO?%T]RB*^TDE\%V-2G;9T
MQG1:_;5%-5769_'KAD%=;1C(;C0J[]%8J!._9JC9N%OC-<?>55^BK2R],'/F
M[^&3Y9<A9YI4@E2RKHQTYUC&V^_)=%Y7#?E>'\U5.)*, $)L\!-L=VX D1ZH
M&T!?<\J 5=U,[SY]SCLUUT<$.PAT#;GA,K"9N(<_.4[^CJ:I*I3:OTS!KJU>
M_PHNFG(U2WGUP^/H#H3*,8BMP#6#BI_+E7((09Y 05IWH$A(M<<_5B+DL%!_
M$>+U(9V9>B.C7=!P+S93Z3;)$"<A&QHS>""*^$M*V2S]7?>L'ZU$UVB(A@<\
M/3[EV1RJC2-^#=X1GC5]$P2,-]D, S["?.%R^P8B1I?H6TCR<U;M(CCI&ANO
MM3IX_^JBL.MGCXL7Y1S^?@!%' UHX/W=+'4.2R?Z9@T<>TNF]=+9SZT6RS@0
M*TX*V6BB'#*QM+PDG,G:64[N&PK)"PL,G%81RW[%=T#Y:JAXR5(:IW;][?#)
M#>#VKDGM!X1IY>$KQX?\OB(NI #3P'.0R*"S(?%?P2FUOD(#$8.G/I/-=?U=
M)'&=Y5[7\+:>-68W:R^)HA$Q"N:?I:PW4=96>T90 ^:;[,]Z6@3!&&3E5H_,
M!^]891I'KV5ALU=O  FX@/7X)4NENJECX2YXV>^7:<,Q*RSW@V@F456@#UUW
M4$&XUQ-6T/JNB:/5UI'^WT-#G(KX!B[T$,]^UGY *(]TQ9,<;:#5<LA8"$$]
MB@?#,G^@[L]UDAG&+>'V_%K<;+LO>3X:UDW9H7X=Y[(]=<31TQKD^126DF/?
MVD/4Y3G3;9=,OX!=N6(G"Q 4LKLCP<DS1#4;:6?1BF!$TRWAC*\SCI)C5KLF
MT$8?#-TCQ)9N&TFS+_Y(:AWP>%[P(0$Q(E/:?5^F-M:RR2YS+5Z039-B],K*
MY3EE8WD*1D MYUWG:1[_NC#KLA9B-'$^/SX!9&5<4XTF01"[+[')6Y8J!R<C
M+.>"U-J1JM$&$WA3\,+C5/JVA9;7+!NI\F5Q6%@?)A4+1G0L,S&X"7[VF\&0
M]ZOX=B\/=H&)ZOA$O#3;;P"99U+2-9N&>T>C:?AH>!?M=:W0$82S=K3"4><&
MX.2(+%H@,8K97%Q0.=;0UXH"-OEV5OEG5LDJ.;K)%8^/<+G8E9@\?3D7CFB1
M\<#""R#"6((U%P;8)3[3@V#/TMG:S4NBYR*.7"QR\'4 C@_:4QMNP8@<:']:
M0$Z]9)%M-@#7:N%HEWY*W,)8O2T+%'SQ%9=\>VF4;^R?@^06L;W+IL.FE@=2
MFR0NG'J=]W/()3WYSA-#P2M4NWCQMFBU^B9S[C]Z3$GN&I\  5R8FG-8/@#R
ML RBGG0BP^" :/W2[WS<QF6K_];C0%-FT!(@RU,+403O5I?&_TGESF.T=/9L
MH$E5[>*[0%J,!V69HNB2O-:)#[U"B]5+>PH<W1M3%U2]Q)=$'ZHG'  " V>Z
MBJ[,%HQP<N-H_[-ND$EW@!586/PN0[J"G>".IRAV>B41>+M#JG9Y=U+ENR-<
M9(&6>VKUB6-86,1N7N-QS$I#?G0-CF#MD+NO*U<NH4N_\Q>NOV/99N7Z "$_
MG>4O2>K8OWP9D]US VCRC:W$BNO/^ 393[J>K<=A'!9^]Y]"[=<I)Z A#/@)
M"Q9LLI>?LX$F]];RTR\EX\PFHM/O,6>UH B,U00G5M0[967XNMKG.W:Y#<DD
MWG3[!N#WR1A(<0.PC1]J3 Q!:$\72J::JCDZ"_:0)B@\^I+7E48=137@*ECM
M3; $X4?!>_+$X$"UB2;O/*R]C7/)BR_[C7E-,SRQ9QE3?W(D^/5"B$)^<YO?
M -+!ZW_A#]BP$E^,:FJ:JF3+I\@:T/'^3M 9]M WJ2/'IX8"1. _BJ<7QG@Z
MGF_WW3Z5=R):BSC!VVL$;37Z\XGE%+VNB36C'%_?HZ!P_)%L@B5>7^EW8X:A
M>-Y$[1NT3=I-EIP\#"?B921+$ 'VY[6>URJA0@]UUKLI'"U8&L('EN4,3$F.
MW$K:E$[%[1UTC@!2YU5YEJ:+FXZGM\Y4^T=,KWA^7'[BM#+^J/ %;1VW)G][
ME^=*ZTWGPHEIH<G#<P)!"Y_UT7DV6'\^)4XJN+QWS"*X.G*DD5,FD_A.<!)X
MZ@9@G\SH8#+XOBSOS^&+>HT3BZKBAS&?4EKR9H\M!#4D?&*V<H "WMWJ>=X%
M?%]*N!OCY,+<[PCJ3J*#Y R TG^VF%MB^;<4.=JV)]FSFEG8T%WS;#%[O.+*
M(O3_FXX%(OI^A&"BG63D@GQ%E :]^:Q-&&*A0K*>,<S:+Q\'2% -YT4\VZX6
M_%>1@K;<C"H!+X%*/E2\>NQT?U\2+X,-MG--[!$'L[%%1.5>+9HFA6O0M(+B
MH1*8-%4.^V?H_5U]IF?M1<ETD24)I;OZ)J ?N/CP/9E8KECUZM\OBILG"M2L
MWDV;4_*I%M"=N1VP%C:7H63ZVGYYN97."6:ZJ\@.NO2'?"6]E$2X'5RMAL:9
MR!=Y53M@#"Y;H3;1IHH;HP0NO?4^G.PL/ER&O7\U3U^P.L8'FU:^H&EWCI&\
M*YB[X2XY+%#^^F=:>\3^#K@R2[]PB@,2*0N]DF%5\?*+=^&96U"_ 9CF5V3_
MV',B"'8E_V:;P!BU2X0ZH=3;Q<)_S1L>6M;XSX\:CE=[V];-U+C82-LTIS)1
M?B%Z]3$TWM5=U<-"&)DKJU:.TYAD_QXTT]7><B(,;6 =@U)?9/X='W*!5M D
M2]T)3*)RW]4P4+_LT&/5N.-5FZ[<OFECU_.]YRRFZ7_$<[9=@]8[E 9!35J)
M5JBFW8GMJ$&-[ZT.J;_[JKCTG\G\W-BNEKX!8/2F&BGIE=S\OIG^+*C*\\]C
MA\Q$&MGZGBV%RU4NR@8C.7O.+YOR6IZ4XZ>.R@^J(-"'(2JV.UH$^Z:U%6.I
MOEN:P;]51X#,SK*FZ_ETL)H]:?V#F;8<JA';394)E1A#&2+I^U[]OEDK!]OK
MEM00&>1,YZ,-G;UTC)5,I2F<*P8:<A#%M$$PA*DM:Y)*O^KQ,%<I"/E#-<?0
M/!EE.?S$09MLA$!W?/'(0:E/?*KHMC:^*1E>6D!'F/%X%(@D/OA99(83:!M'
M_Y2'?\O>=7W4VFR5]^)7.YWVN7G+/EP"#J'$>GSUE]&<\KXRM90[0JC996U3
MG!00TO&,B<@:ZJW&?X?R,N=P%]FS3F"N]VZQ1.RYWS,<#UW7\0![G+]3KZCB
M AVD_\HOU?3\T_0J[I5N8'M,P:H6I9&_GF4Z,S-9T&/7!T9&BO<5C%^OY<G=
M<]@C_TM$Z)D6/B3M"2Y_22&] 8CP@;.9LO9U6Z")\Z;J9[G/;P#W%Z(&UPR;
M!*E=+$[U>S^K'192R80&J[V[8#$0,DQ;8!MP2RQ\5RD[GKRL7'9=H'!DG69Z
M8=<HJ]6@FZ'D2FHF_GC0?3RK91YLL=?L)ZD"PI[Z6]R?$W@M1EP^X)1;\IF^
MSF%\)+!*P/4![?PSWYY;6@7 B;)LY0WFM'DO4/B3Z[X,-8[8:'?]^FO^TQ5$
M;13WQ-_\QE7$M^(TDR&ZX:XH"]])B"U5!?O1J/&;PORYW)_-;T0DEX)7C^>I
MSTV;K\N].U4P1],"1?!W43U9<K]C2):ZIVQR#/0%)M#RV0^S$P-C?>+E4>-<
M] ]JVLD@7[G\V('/<VX ?"-()XGTDN+86T"'B85/B['JH=S5$1Z.\D5BS*'R
M:P=D,A%AJ.TCO.S$G).!I.>.O'Z=L #U$V+0GOX;(C9\6J7][^8C*\?(#..&
M]@%]-/\7&,5J N4U4>FTN'Q%L$=R.O.P_^G9#0 ]$YE78C7FB"I)AV'@L=:C
MEZVW9/)76G&.CSKKZ:$Q,T8W  TJ-<90=-)+F-[6%/D-@&D0DSVB\+[%U!&7
M,ML0@8NTA!=+2DH3DHU>+J2SO;=Z-KK>6S)UY%QD#OX#=5OJJY24_57\3J$B
MY<"EZ=$I%2+O'LA=P)->X!2+Y+48'B/WWZ3V)U-NUCDU)WD'",H+57":CER=
MQ E6:GXDR;,E/)?Z4>&]'PSZ.685NT4UR*SEPM(Y( UMN?>7 =DO6,P..F4X
MN&QW.(8<K_3\U,'&,>_0,_3>+TG&Q#I;L<<MSVID_4;:W/.HS8Z5MYJQ>T[Y
M[)2+*R3,8&0FVPOC8BMHS*8^]SRB_>@V0.J2?,)D03XV^-MB%?G8H",UK-$^
M0-L?F/2X"__.Z_.4K'"Q?]E@W;*%8S/462CK\4;6(RMZVFWBZZUK_GSL.#+H
M.39VG8R[U=A%F#W62MSD?E5/-FD9)R/!LYICY;I@<9/Q=U_NCQMIRF8>'*U"
M$7_X<KPR:P_1=UM-*\M:S#!Q7#*A%3BPPQ_MU-2@N^?RKMAV9.&TF]4X1.K[
M_#TJ^B4#5R@%+M7T:MJR'WA+5F=5^ .UF;*,^>+RDNHC=%HL2$#Q=<_>8AZX
M=8(5I[F^S_#6]! ^ZOF7A7NS"._P+^ <09?9;T,1RSSM[_ [O92_I]?JFUH-
MQ=LZT5(BTZQ&/\^Z<32(T0@+=I1A;R=G/YM \V2-2N*]PI[F7>.'01DI^HP$
M?S5D3K 8/Q0K<:6%S=9&%3_PBSUB;Y\XBLCX\H(3['E+)@KTP3K%4@4\[RV"
M)1)\X)^Z?5C_*"/M\5 P3A2D^ EK>&O-+<SBWCB.M])RP5C-3>*Z"BDXE9KA
M_T[*\B/;K1]_@O>;C;+HBJ3THSO.#*1'M,A"ID)(4)8QB/'5O+UYM14;!@8=
MYSB[@UNC3(<YAC5WH]P5@298Z(_0[Z,QP#X0. LSYWR&H>%*2;5)^[$8=VLG
MT*YC$D^M]4 9Q5K#V3D5'7=G35^),UVP_2AMQ[!9="+Z?8F!IG9>K/DBY<3]
MW@3XL#3\,/V2O@7#OW;<-&^2+[1E+3]H#X24#P"(Y< K9\<Q>6P=DT^R8=\6
M3$LK;IN9E/3]2N:H(WQ+<YQ<'= D@G;DVF;F)M91%N4RU/Z!=)RK4O@O.]SD
M?QK%(P!:FS?BYH.N9"][:'WLG&]9**(0B(-0TH??F^L;S57U.O6XG YCQF]=
M]25U3/=25SXBX6\FKMH+["Q-=CZ7S*!:4,@/5,OA2^Z#I^$<L*>.R/->7Y.D
MY VG<Y.$ZGL%:@0O2,.,ZMDR60S_W !HNQYB(Q#;'PZ$!1IW^QYH5-,7O0-G
MZ![=2M+PX00D6YL"&\Y[@%BM#HG:66R*D$ CQK^T/F'S4=)K+SZ"V01>=.WK
M9\]TRP[!P_;?F(A:4?']^:P=MRH=ZF;Y5HP_M^<^P=T BA4H2 _W<SX&_ZC-
MQ;F\^X8%/X]X\TFC)8K&DUVM+.9;92 +?&F%I(MY%TB,7F@1Q.V6MOX=##Y2
MA*>GJLD*JD = WEIR--FU T@"GUXVV'P,KC!S)1M7^PR)*K):%KY5R[)G%R2
M@"VO >Q/#FNV"4@^.BID4-HNODH9C. =5BM?6)3(:1X\,FEEI)#SFD35EN*T
MOO;;UZCZV)-KFYO5?DE^<$=0UE*$";ALWMO%<1V+AB('^]RH_%5-..9E9A/$
MJQ(3/W&^E92C?'65M&[:J:H4:R)VV9SFQ_Q,9]CEK9B<XG--=X,*7:_M[$[X
MJFWZN@4_11DHUN':(*%I7:H:+<>I,:WM&OW;? Z_$6'->VE_5IYEV(K,/<SY
M<%VKZ=[Q-T7JDD+7^?8=U&E-DKZ<?#->3,^Z@W]B/0R0N[6-JH L$.?-K$O0
M!+<$Y[3(LE"NLW58M0J[4+[:Y.>WTY]R?IH.G1(<Z>-AX:>[R#C=JG9\X#Q#
MXPAWUA7$[+MY)K@;1R]QKC0I7G?S"5!]-@UXVT$_R<Y"!_).MN[7FRG.UDH_
M6C849F&XO_+<]%.#/SGHMN,>QX9O5DAFR4+[ZQ/Y3^X_.B B0HL5F(?]FCX!
M+F4W +"I8-TI!]"9!%?UX0; L*JLC7*!SKD)98K5[SVM>LDJ.]ME"XK;"*&3
MC*/Y'3ZH0["9Q4GXP<_0+!E.RR4V<E3IY>:OQU=O;MQ8+[(:>WOC5.>Z=%UR
M[%AVR^'(^NE)N/^BBGY7*R/.B54S$A[9.-S/Y/^4)OGYTZ87IP+=E!.^MGH.
M+PJ^K JG7X]./N$B].W_BEQ^7[%]G@[EX[*^'K1*Q@UNJF,\(;P5+00C35WI
MMG(GM5DCDQ#-PCT@.;J"J,()XUOH<EK\M<I2E$^K[%F_%1:(X/F 'KWK'[?F
MH\SKS-7:8LAL:OWX(DPN .]3QC5]T/S6]ZF'4%$)-D&%^-A&"'0<I@SAN3(4
MZ<9VK@DI4._=]T8+-9W!8<+SS+V7>?G5@[PMC4%@+W=Z=W$QOM7#\]U^2#)*
MJ4\/IXBJC48'L4JKJ-]3<]5@WTS@ZTG>N ,V)#/N+2FJ/[*9+E"G"TR:%S]C
M[G';WNO/WEHHZXV6;W6>8KL'1$DU?$ W11VJUHDG&$9!!*Y+"_,'&.CG\[($
MG;DC^ZB+4H<;O,*66S<\WN"9\9.?+"#J^MV35M")XV6C(E%JFY@&5\++$^)M
MTV%B<Z^K=L[^3^VM9_19W2@#)6*'8R%;W!APS]$5X$87G-^8,?P0^*(V3U;P
M2MML&6<0>^2-?3?N6L/VL$'>QLF]X/J20F['<CX\H$N *[FT[XFBWX8-S=;[
MW.P;0,UC?[Z?.#DAM3.+SM/]C*?7D/,F [:OHCP7NOX_<WV84X#WN+,W(O!G
M>]TS'60FUQ4%?S5N83Q]1K=2W":'XS!0M#YMF1B18U";%.IX_6!R_8FOH[7@
M0*:C@+O94O1^LT)?^9%X\J^BO::TSN6,>\G>*/%0NZ59QB[%.U5KJG7:Q&?E
M]M '<M'1G#]^<[6.7GW(GX)_@6A??\4)E_C/+*@(2XQ^+)2)+U<0'>RHP/FS
MS)SWK22PT4_X: KUFIL\RK-9+)!_^PU!:I04%F%T]2#ON U-4)7(%:$XL2GP
M FY8*9Z#X<H)T7\X7;, .Y?^DC9=(TS[H@BKYZ]-/$6.EU :".&:.+O29)O=
MHZ]K?^BOOPGH_AG)>5JM:<N@B3Q* PS,;L8FMRB8W0!V))+YOP?_2#TVL8\V
MZSQ!! 4]W%!M\?Q#9)FO\1%$^@.;5FDZY^^ZHT@QM]9(QF1!1Y[_&&A&8V+H
M6[KPPUT!1KWT62@H/>5<\K2&8%UY!RPH)QDZ] IUS#S_..I^2%JBZ6/)$Y%:
M^5>:M5K=ST$?LE@D+1YEV:5H&PFX]T5CZ\3Z0K@[^77'CX0?MN=OYJG/K6M]
MW.!Z&!T*DQB"L$^:#/9*ET+=1<YOJVA@6."&:V7I:H(/Q<1,9DVB4A37-M[E
MA82G,;; /$52-HL[T%=]*,)C#X]R<Q=^EY*%)^Z?<'IMJREGQ,!$M>K(Z->3
MWEPN^6V&^==?K)E F8PE$^A8'U--H0F'U"W3L=.1EK=<BBU<04CBB3+0W&5:
MY^&<->%YE?.+)#^:\#=WV#*WFCJA.]X?C<URF7MN  YW\6F^_>.JYD<A9L%$
M?&41.*DR11^_2C47U\D^2('O>.(-0'C997;4;*;D*$-\F.R(VL01LZ'\P--"
MNX7P^HZVJ)BCM&\LV\YFJZ789OTYY][<Y=FW+5]PJVJTDV4#12[BF&G%Z>G\
MARS;Q 7F"A==N04ET1]Z"YSYSO DG N2OKX(HC;ES-'8UEX?4]+UQ<K@H^KM
MPH-$C[%:IO.M+OB$<-%XAUSPMR\GY]0TY J>BX>)Q!M\PB2.!S[J[?'AM8]J
MAT[8$MUO +*#R M#9.WS=.D2*?.]U._/Y3W<YK7Z;@!DWG(T,.K=6+_*V06>
M!9LN3T;7BY1G1[1)FL'WD,?KF$\(88)9;/B>0V.]#&,>?ZS" OO>+3GP"/XA
MA&)"7A0[M@=TR'C=\MG%T>4'Q\M/B=N+>;?.Z!"6C0R]^]V$3I=V&27*7@%?
M>UPK254S^'E!HF]!L6TS]671?2?/Y0_RJF.N2LG*:ZRH7^QS4'W\Y4F"D> &
M(X!$$,\9/(D_I=8X6E (?/UZ7;4E?!GS/$^Y]9G9^4\I]D##<1!QB- LS@C9
MV);CGLT<[PC)_L+ZG:H^)6+'J]]='_:FN#7KW W\?F=*CUK9G426*LL7_.7.
M_]PM_C\1J15[)B-)R01:P7[W<DC=;5L^<D2@G]QR;^8?Q?-"G/_R(YMF3>/2
MK*-];F93V\5-50-9I$P0/#5D8@4HT4VR=VF7MB;SY6O2UJ*Y>OE78T@_U[<J
MFPT*%;6MCOF5WCS^Z[(GR8<[Q<W!?B\Y!M:V?HLN#2C:^OSX8?N3T(_QV"*1
MA3NETO2E",]U(5[8#*(,'3\ZDSI:0_[4_5YPAZ0%"..6:Z4#KY[W9(9(^-/[
M31^['FS6MYP<".5DN'RPJ:%$;I<$CA[L(_$K/=)WCN(K!0RA;1_R('&&WI;"
MO[3MV\[1([[-0Q#6*@U.I0T%HC-MHGU?$#] IF#URF!:]-5G\P=\,X'R15(K
M[Y>))[OH2V8^9F^F8_2V%C6(MC*)R$,U(+ ]<$G;>YS<^MV2,/H3+Q]J85PC
MU/IJ=O"J^I2RVAQ^ACV2\&=B*>DJ#>/:"9U>9.>6!.JD'.M],P,#Y^">RA@7
M)<U6T<4B]Y)7:[_R]E0Y.G:G/F]L\[3$X)3<[EP??AB_[X)FQ"5+!$DN)W83
MO.;UJU@P_BD0)'RV']9@'_DN@9YX+,EIJ+YY,JV*8P0V9+(WP:1U-);D7B5-
MGH.7,)88+U^:O4M;TO0C2#W>#G]7]1FHYIY-K0L VXV!8R$A#W!*$Q#[ HTG
MY3Z;8)F?8S;*//:#D_F]70580<3^*+V_J>*#SQ^[BCF#6)\;><3:O;C# E35
M^F)@/Z 5K0UYCE0I6V.^ 61.43EZ\<@0A'Z#W "^K_)B)$ZU#JI1U-LP288N
MMIF^],OT%-]T*!FW2F\J%0W0UFHH=.ZC 2J^O&IIWM B.K*4!AC:H!^Z,8R#
M;P1GN=G7=]>KMTJ.EIE?"//[^-L2\@,' 5=Q\6:*!4Y"7P]C2TUG50N(J2G[
M6,91W'LP]?'H&*$C^C\_.4^V<R])%CYS!48O7,")40R(P6@A><;^VEV:_JKE
M0;$?[+J&SA\@/5?OX?NO<J4T:_2[HML"@8D<#H^2,'2+4!+QI#_=8L M/E#,
M@\@T:-37F5K7HL;&E[^TGD0#5#D0*)C+L]K,#K4K)7#^?7F:%2.8_75^N?'P
M_;:\L08"8@586T["@RU9LF)_^/HV;,E+H;XE7Z]Y8BL.P\CSZ1CZL,A UAXH
M0CRYW%X4GIHLH0J6$5V\!/6O/.@0NP'<K88HTR&G\I;]WU&9YN<LWO=,H&2G
M6_IY:!$<?/5Z82^?1*@_,KNG>E[6/69;)NT-=)B=<_)]Q*%1_MU0VT._/GE6
M%&MW[-=L6(4WQQ5U*Y&BM*B\]6.0'[&;V6H6FC+2\GM-[NHUCQ$4Q?I;GOV3
M7O*0_XQ8RB"CU(66^=RQX>,UAU/^TR=G5.N!;H/Y3/X1:_DQC6YHN.].0W#S
MW-,.=_J+'H+]*0,&6"S.$9%\QQ\*:WL!-XG,^)BA(KC99>MN3)MW(#78%)R&
MO &LCD;B'Y@N*1?..DN::0K",FT\KB>TW)SVS@[_XM^Z0Y6 2U6AW:+N\B,%
MK1H RT3ZTYPW1:_R#D7S[^$XL!+KQPR.;(+?Z>'2$@D8"Y/X38>)@.GI<??
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MF)TF2+DY_#;\YO.G3"R\#: 9_GHF?9GNW.(,\>"KIH8V>WM;P_B%@?,:R3L
MH5]E*099FX-(=&^"/#DFG$@WH!8(\]CR.6&<8L(UJ#W$URP-T[]Z:Y[SW.T;
M.@(=.]-Q#0%RV3.J/2O@NNG)L!:V&*TWI T$6C>F+1#9G@Q*.):?_::?5V-0
M:!,W%)C,Q.#6X+0NML78Y/?&,-T< ^L%BY%/K7G6LTP]ITR8N41*$A>2UI4W
M;L\S+*O^N-S*4>SK[[>\YKL*QW=,.T!G5P<YX[/._=&T^FV199?^DBY'Q2%O
M>RZL[!</W9'#KW\*9AT5L^@-O4<=I%V&M1R;9'M%^$PDBA^##F#7./8V>WHT
M;A<"ZZ\+97 :D;(OHX,U_:V+.6A2?.UFW@C\!/\>5^/G>//YJ/N*&(=F@80/
MTX]*'%E3^N+ /+>[)^8"S7LZSK?*QL^G?$"9@;UK*H1&_-)OQW&_H9&?X#_D
M&#\8JZ@XH/Q*8;SI-!0;Q/>2*,!A=;G*H">@M/*HG!5<TZG<RZZ1[U=CL_N>
MUST.HWK:=5/T,>F-Z*+QZQ=A^+)_/P/1OWCZ=KCK8E^\3],TZ,N.P\70H"^
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MU]R<>ABZE7UB<ZKSF&M#AR?1@W4F 9-[>#A-[OT/@J1W/1A*>W-OOKO3)9@
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MG8$KD*GZ0,*QC^HDLW6U5!I7N'DB3XW@P8"E:#&EW!V@2W#M2":W514.6?V
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MR)^4Q*I!@N=4SY&#QAC3.X!:7>4H7$+O$>>7'Q5//BRSUXNSB__N<;J6OLF
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M'*!;YP[P?H-KLGKR1^^7%,["L$L^9.Y4.[>P5*-ZZR)N]D.-7. $YH5::G=
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MQL(#Q=UU;BJ((BXOY?%]%0#3'N6'F>[,:\%U"'\]?BSPFY1:SW3M(>,H^U;
M O+'^]H 12:P6DU;G51VXQ?KZ'\VV]DOIN;^+?/G?Y!;L9PP/"OAS,[&&S-V
MN[9$,0H!=3#S70FJG\,4I\QPE%="CL>AG1L8Z!W@]4C8'0#EX'0'Z!G%LU(Q
M]KKF<PJ_ YP ,?<FW.D[P+4)"ZJQC>6>-QVOME\S@.X :'>L66UCI__:"V<R
MPUI(NEB.? -?W@&J9/KN *JFK<^O;?[3'!'A&"]D>(CY3:6_8;%8E+N !>?G
M/:1:7LDK-AL:8M7PQ>A/PT)R+-IC_]7S^__A0L2WCEU3-S3)"F>H#,=.W64F
MS(&UY3,.Q"P@3/=VUW>Z$3."NB:Y8/87NP.$V$-O^>IJ6:BVF5_4V\<PO*N>
M*M>MH]OCTW$GVO[*2:7]-?N0QAKO5R80!8OD"61;@CC/+LVK/%PWR)=O:<AY
M=U2=^4EN4];H4NG53<ZU!)0X:Y579@.\+_JFSKX@ZC''MZY'(^=?5EAZ6V'=
M:83TMU'%AA*DZ:5>(<-:8L_-HT,PB)ZYY5\WX!7WO)ZYUJF*')M"D]Z/YO6+
M;1L?9J-ESVFBLPJE$##\6K2+5FD>"%2*O0MB>.0O9";"*Z^4&<$6/"?SQG K
M:J?[5/I8M_8[[-")+Z9!WH<;6F JQ@5@8@/KX(%]T2S!]\P?*(].ZAVW;?H=
M3%0IC!JQ#?6'TRX .([<@OJ*UDS_(HDTB$07;,_8]]"L!-R]@K^8(S(KEF]\
MCW?&DNF.-%W2%)>6N_5<V=1Y/%U^ORE\$E=+ALA2S;$Y"[CG"Q!P+ZO;M[*R
M>*N$ $JH]WEAG^.<R5>ORU@+TE4']QG07\+ +=DEBZ5:8X)?A@KMUQS,RK]D
MQ9(R;V=&UHS/R89W]/1-1=O\&.":_.:&9E=C<WE0OQIE)=HM(5-V]-7JQA=4
M7%?EDK?D4.W-*Y\W7F("$I G02$9+*L/5RC <D^1V]2),Y GEBDOC0ZULV[>
MJR]^NP-0^.$7Y&!,24@5SWTCZ4X04L&+<9F[-XU86VU1VR:4/YM<U??G&T:P
M;A)E6'=V*^SJTBH*CVP%.EF&6]/7(]^BL 5V KAW?_.1;X@DBAF2A>G&KY/M
M$/F_NWIGNVPY57N</<O#3/N>.^IY7;?-R!]E)N\^:>Y1J-4A<\>J$UXZ">7N
MR^U#Z9%KM?+3QW6_+5C=\>(;M]/VNL=US4^_&8)SR4ZFJ!AUOFB]['AH238:
MF=B2_7]] O1C++M.=Q!>.?&\HOU@&[>_-0H6N@\3)GIM2&U4L-BLF"MB(T"M
M@_4Q8$R7MK'-H/131^#8DNPXT&^5H)W V\*TO@VA]Y?>1'3VB]]GXP,%QVA?
MINQU9$OSF15JNGEUF46E;!F2ZMGTRDB%JEOPC6Z%?*]HGD7@.!:K>\6[SBQ<
M(,@-R4V04-2/^X.JVTMV;M%LAO:E\UI%0,#N/J9B#ZAKFZ(OOP^C( [QY-"1
M5&$@;M?&(&J,M#O'SRCG$E,.?](QU^2!=NO"=28>BKW=>AA?&GBPK:0@$RTE
MICV>/<'O:-HUD,@EXO ,O"B9? =0KI/&5Y:-(#&%FXZ/WP$TIBQ#GZF9J(>A
M$Z+\3D_9,6 $52M]0(J*HWG=FRF;:.&Z7&.\CAWIF]U>7^Y'L38A79?^>JE"
MP^9/$J60GSZS5UK,,Q<6SW6FK=6*"4:9>([)J\V[A+!EQLJV%#7\/&MJFEU:
MD%"Z>EA$X^D6W=K,7(:U4]3&)3)$N*W7/D?_,=_P%6%_Y?J\2V+_3N9/6S40
MEK+W9PSYV<I..5-LIHQ?*"<IK R==,V)22H&1B-&6&IAL4G:C>,'UPQE%VD$
M3E=OFXS_ZCH*71O\=94)6IN&^>M@-O/]'5"#&,7AQV6G$GSL?O;?496:;$E'
M-A):BU_.2I=K6#J<*+9,7T[R7ROD!X2KB&X\YG6B)'/NB_=D#*9A4O<]*>DC
M87'01X*M3N7D46JKN-_1(UWD]C("D;>@0?M/A/K] C$52.R@]9!F)B'$4AML
M["1*G>1MW<2>N0$O[Z@2I?W8>W<JD?(RT7B.EXKQW2$$C'94[WT!+\P$3!V,
MQDNY6YOX?C%QV>96_G-<!KM?%F(>AV.K=%MHPGF?J-9@1MI!,LGKR[7UUU\D
M66ZBFS1OD_M,JR7Q 06E!E"[^U@*M$D]B\CD7;&L6%%T,94FV1NRQRDHP^X6
MXY#'B9:*J?[;]N=OQ^ZU80=3Z7Q=Y ":M[O.E^D$]5"HAZ"?)FW>8HDRH>',
M>$UF$FO=-VNOWZ%X9F>Z'95@_$;DT=//E74Z[P(0<X]WAV4.)])*UEAFG3$E
M(L_7T*^[G(H7EC1%6J<B&KX ,8G26^F3/A&D^YX+N&M'Z]C&?>'MMB:^2P0&
M(LWI6-Y&N_MEHSXN"G7+0U]T%%PK\C<)B95WL$K* B6]6R!IL$C^]NH<5&$4
M<X)+L0(EL;4MWY-(M1*W3&#5DQ< (';F).'>P2U@AXBJTP!3;%3KVR+9FC18
M].6M((&VTXOV8;'2XM] *LZ,*8$KWEF61TM;B;M'"\!10S9C-=MOY""AIIKG
MLH)5;LD/_>@W\'IAI+9&"IN1(B"0N'GDLFK+U(/'CV/G-O<9/&/Z-K37,_$\
M1SY:+U^[HMWG_M#S+HP^:8';^\TXE/]1'/>L$_*O +L)_I7O7/'=")H\G7<*
M=E% A;]'*9W%M#9,LB>;'G1VF,70OTX<I%[+]/W[17I(=A7:,7N-70[>05PN
M2!;\':H5-><17J^L-UCK?]A;-K^0(N'J%@T0+].DN7XU"7R"\NH\IZY?TH-!
M"064>$9]]O;_.GX\L-+R[K<VDSRMH.C*8KJV0#YV9SBC=Z?W'\GK<;--V1M7
M1H2FO((U_\67XXZ^&L6[9[_XV/KUJ+#252D6!C7SU5DCQ<KZL.['9N3&/@>)
M XS"Q5Z"9A\O#-:30G1KH;.!3$+*:;]W-P7[O*,=]LAI)T=X7)D2PEAQCGYA
M2U^(A*/4^BX/8V7X9Y;L?(?@/:V'H=;-] IIU>4A-XU:BA><;C]C&ED9P]>H
M3@)'B;!*J%IDW@KT9.QI-?89XZ_)2$3[4Z,W;X(.H2>O$6Z1J[>2T/[_;AAE
M?[<*NTXZ)+H#S$B2W%##QQ%"J,E[0M:&0MR$E-]3$R.$^K^I;OM.&8[M(W\C
M3#L$=;"S@5SNI'?\VK113U56R%X"3*S5.TM\^>2SF>*1.-Y&)_'WD>;,Y+5;
MNLVS(O2O/:!(P1U@:_<G8-=].23PX81#(H$3GBUI9PA^PG;5B[AKSW)HYT\4
M^ ;?B/.6 'FO-.U+L"EKL0;N /_)C->;1M/%'WZI=%;8FHV!JD^$[-E_J=TZ
M*^D KA+C8DEL]_@JN(*IW7=;;5;CHMQW'ZGWG&[$^3@YD9_Z,..]QUY(Q %\
MP,AVW0&(@%[Y?"6YMLPLDSQT [S=1N[FM-$V=/*9>5F^<[($U^2XT%6*492O
MA6;4'> +3!JM&+*V%4BYW108*DQ=R(1/X!?%H4BS9)<;;I"/9Y?Q0-IM%/$#
MT]?1QC;)/MH77@8TS,4X\HOSYF=^//<\YX2H4+W-"4;-+"CW ]WD]OP^!C)B
M'/AR>2CD4?-+=*8L3QR>+&^PXJ0R^ ;)RQHUVJ^ L4S BP9%H2?/FNO>^WR@
M=X>RFJD>US.NG SYQ$:M@"GG, -,KZ1$8[6+P1JIJ1'X#U!O2MA_9LI;23S(
M18M]EF&U-WW6&':DUKC'Q^\N[WQI/(+3DO D:3_08+%1*[@YS%4!X)M2M>(4
M?DD5G5J_Q("Z*<]0:U/Y6Q7!1J+C.76(T6,FL.J[9FMBEES;(X.B18[YHP*9
MO8=W.RNWTPJ38+M:O)^GF]Y3GQ,N6S70?RYO@J;S$#4&<?G'_%0RBNMN$HNY
MEN",/E4WW06K?#_0O1VHJ%Q\<\R?\'=P@Y26$Y],GD54'<MB>Q75W"$E?P?X
M_.YUQQ:TYI]5MKUW/^5C%E2DK4\O=)V%YI[Z@(6\PSM,@>T-FE7R2&FA3A;(
MCS*>]VK2^Z6KGHW,9F9BCKT;K)9HT'DF#B8$Y_2LH%"F4@24.FE^7-CL4$B!
M?Y.UO@B7,9M79J208YZ%K&2%UR,0=5H8MZYQDUE*FI?E7Y_F\(D]6ZV/CE4P
M@8;)/(ZA2^],(\47=#-_]$_3TPWN]O#;Y\L_%[9\B=OSO5UW=6O\KM2JA!%>
M D^_O.IX$ZRHD!$L9[Z#]:#)A']U.<9RLER$8&1_OCG*YR3"/.UH.\_":3VY
M>9F\;B$CZ&($(9%-XC(1R.)-H%<3>S#29<K25)<D]32LEUJQHZ,#&R]>:?5=
M5A@S 3[HEDR: /LV@^V?X!]N^^=#' J\M^^2-[.E'[\K&K_0V^1? W15X4KX
M/7?!^9!4'F_;U&*U/3Q0;.JDJ+JM'I$S\?G<3<'1)FV>T$%_$$!'L$^^22>M
MZ"(7Y]^,ZNLJY4Q^AMH,3S2PC.2RH!80ZAXG92?,<16SM( ;CUV3H*[ E:!%
MV:Y,YF:XC3O%:RL"KA<]M);\UGIX"_2H92)O]IXYQZJ?2Z+??\[OIBZC8OM%
M+A*J)-^@"0HXQ0>"YL-=TCIK42RQ[D,O_-2Q%:=/OB,ET^V_?1\3>91Y!_@3
MRBLX__I"\14^5E"W!]NGF4NE=RB2(&$'2?NK92),X/0PY3+'^.RKXJ@=C;DT
MQ&I1L.-JK.TU5P[0];F[565$V#W1/$(,T1]^N@;[Y=GIG1OA11RV2+DYN:<1
M?ZOY;5T=_SN=<,W3I59F<7V%D?[PEK '^?B6V^XR8/%D8DOR(?XH58,@N[ID
MQ19X+&_.6<HZ2!IZ2Z5_KRVV=,9D4>!_ D_I^@4,YUZ.%>1"5]KX;Y\U_7Q.
M-I 5:DIP!\A1>W,'Z/ '7ZO[Z/>"/U^"NVZ8=Y'\GSY^0"U_<1>FT5$HZ'T2
MKO-)PS+8&X&_4N'<;:6\@FA'X*%'+5:6H]OWZ&1O@VVQBU$'!<SUV=N7GVUU
MN >]#ZA4^K5V&!Y>6?^\1Y,F<*R_K%>>W1ERI_-OH"4GCJ;UNYF0T4D6(L7[
M=]'L#C INGP'4"AW_^SRJLE+SE_S2LY?-GQ%MS#5:55WDI<'SH0\?N_3__TW
M^\>GOQCT,55+37&S[4B-[ZM91"-B,1X-^QL^Z,*HB\<)22P2VHBD7YQ+;?F3
M[H,.BHNY375A!^2N%@W1DIN(A_J]R\PR.)AV74QR"7A[#M(RSI=,J,\5&KM(
M)?>B"R/7(;(W5D[X5CK49A"17GJ$O0T"18W0V*FY?=2UF+]JG Q3LY+NLXZ/
MO:&N,%:!Y$M45GX#\5BJ%-L1SGK0;1F<>M[@>#O=P_*<E.*X^R)+AU[E D]E
M[FQ%22VEU\C3]\R;0?8+/.[BPE=/ DI7S:/.HQPW7Q1=#=ULBFSJ%KS0&-=K
M^V5K3  E-^CC D74;ED*UCY[6;B'E="GT[C)A#:47%P\*Z"$N'U$*0CMUXTG
M5/%L3NNQ>. Y<XW:4RS:%>[-PWNV3.K2?!D?4=X!&(NJV(^H2E\T-J?Y*><T
M3C_@T4E-6@]BUL#;C3V-_26/\R,NC&=HZ"+6OC%(@])MF]%^^^3:'MD>'?@
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M\JGR$K&;A-@[M6N0ME/4>6^BU+7.,MS7K.]\ZI1$0H(]=Y72N+X6?.(G8:=
MP;E)YXMTSLC%:."&)CO0=/S.TWN!!.,IOP'2[A0D]% :"GJ2[:@1JGP)K7A=
MK$P<J:J/>XUZ;OM^%4<L %'N3Z^9XD")DJGDC1Y+U[$R_73M;I/GW?YQJY69
M@O@;I2H.>G>1;(#LC)"%OQ+/,]*&_P%02P,$%     @ :3.#62P,969_PP
M+]$  !<   !A=G1E+3(P,C0P.3,P>',T,#$X+FIP9[2\!UA3W;8V&J1WZ9U0
MI8FH@'0"(EVDB4B-BE(%1'J-@O0F(J (!.FH$)$.@=!1D5XBG21(+PDU0$@N
M?GOO;^_OG/W?>\Z^S[]@/I0YUYCC'6..NA:0?I(6 .>-] SU &3G  "RLP\
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M>^16@JUVV[G,+QK_[4WHLE]B4J*5TD;7R?*9!Z%3]>C!;C4@.PGP:+[=!^5
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M5ZOTGM?;S6S<1V:Z,/THM#I1.C2<WK^_)N#J]6J5:=;6S<X4>)[,%%820 =
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M.XJOWTMNI1K%*#''6Q<J]!\;Q:AT/M/^JBC\1+N]7WLJB'FSF@002^DC=@8
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M8%?])<;N16?SZ/]#VWL&-!EM;[Y14)0B(B"=J#1I(KT'%.G2I3=ITJ0)2(!
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M>ILOJMGP=")/\.!)&GO9@B#>E]\YH.Q%'T[XAZI0D=[^Q5BG<GEM]V@W3?B
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M:.&S(C---V]R"_,_^9QAAI1EU+K/X-\)WA@#:[QF>5L4D7G@0<2]$S-5@="
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MMX@B%"M%AO+UVU;%&/Z5S]#[1[TA)CIV16;7</%?:P2@4\&7 .V<!NN9Q?8
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M-:N[1:;V_Z!.]-GB_QIN,BE'(C/K$H%JM'G+U7[P"IK958@WQN8^Q^?GE\U
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M^>,3J[^Y,N%+M<,W=#%^\40@7A:'Q(INLC\<]IDG,<3LT,XA6E;5W;A&^U3
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M_E'[CH%GW_8#*"'PVTILGI^A,DLT[0<RB_42YX6'8^)^/E7C@A73=QB?\34
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M"H[[X3!Z7]<@G<Z%>V-RSZ!NU E4G4>/5-4.,[(RI[D;0LZ9(+27@!Q7]"6
M0&J&<TW_C*A+\3?AU"OVLQL&B&A!-LAV$R[JUN?!CFC'.()ACG_,%U=F]\R"
MA6WG!S4./^XUD)'1T07 D?"/"R1X36]_KZ5+ ,7F GO:$=^<>,PSRH\!CFQ>
M:7NS!?Q_6N]!;,9!W LN=Q? 9!T+E.;*1J9RS]Y6"JQN?$:RKK"B7)<W$6IR
MPJ7].=VL,XUF&I->_2=FKPM?@Z8[K\MQX)KQW1Z8=\AVU!EZ% YA\0.[';=P
MX[@2E]>O@X[(%\'9JW%Y/A62OV'WVNS:J*R>+5/=.__=Z+;]4<P[746=0SY
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MC7_<Y/U6A7S)=C#I\/F7_2+.MO-FJ((7X:; 12SE6\"62-%&SL5#F_R1)SL
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M_TP@RM-Z."';"Z<>X T*$\@F1A>TF6_#(#BF?NW/X/,;")T6=C%6$?F%;_N
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M,7Z=;:O ]VUJ?4XH@D"\$E"PX.:&.LG(#0"+0[K"]P%6SDG>K[[  ?"4A/I
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M^T:4\..3=SZ5=[YVN )]!&.4C-/3?2IZ-NJS(U\BF[?S_*:V*.U7+="JNAL
M]M9DG6'8MX*J@T?2@E^"F4:"W@8U=6Q*%N-,,C;%;? R:S$7^_()R6+L7EY
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MA)6V5-22/Q&T8BQ5:A]0%'P+!J [#5#68:=7?OJW9A)<G3G4?9?*0+X>,6_
MN^G5^%*_S#Q& Y@X[PT:9*"<:5-T@5U9J/B9.&FF_,[M>'=L-PH83CQOH@M9
M)/3*,T .-"*/8>U9&;!8^<Z&@DYEEI8DX@'86C)?DK@URQ:>[P:P0' J4++Y
MUO*,D$YZKYZNFN="CU_%WXSDCO+GA7-:Z")3<LTA'I&A,[,9I4P0Y6\X8GS'
MHW=D3ZHT<'!N!V,VFKTKO2 \BMM?'<Z^Y73ZH]6CSF"?./_!>$BKW6:2\G?F
MV=2^&P!0'9%-2/]TV7L_7YA$=4,)GTJ14)$"^EKSG0R=8^?J0JQ%_S)HEND+
M4[2<\!VES_23/HD.5"?];AV2R/6!R!)T[0#M>CI^'?@;9WW.(^?AGPL?KZ4+
M? N!!7Q*'S)Y<'T93K".!L,/K=%!L$N3M[U]#,0S]2)O9,^4'"BXWM+YOX-N
M< 4HK4';_(61IP.?BE;LA+ON*^HW"T^59NXMWIG& "FJ@>]/V(UJ/>[$6U#,
MNFT4M(2-5;H8$5!IR/-(Q$K=_8:V+_;V.<@-UT[6RM"MGW[SDLJ1L()9BV&M
M6%R]WGF9MR[#"/U%PK>R,=_6S6 ;*2=]-O-U['[?!T=NQ_AS!6\6T6TS%9(F
MO;=EL%AN8_RKO*+YY8^7A=Z?AC"J &<S8)M94(7)3KK\X)G'>E9&->24\PD3
M?5U.?!,YDMH/$77ZM.A-@>%V0KE0"LKH63M3*'8Q!L\X__^M0\Q_E[ I[L3<
M,_PWUTX33LJY*;W#CGO3K>?+Z^S;/2&PP!]6C8$@[6-B'E8<<7AC[ IL\[U3
M??%K2F&2CW%4F3""5CRMP9KW/H*]]FX8=63CAP,)5>'(NH#G<POU^P,ILPPZ
MW#25&\]3/=W>=4ON!#%@Y)(N83,7]@SWF\.,+C],0>I&-#]R]G[OXM#)9)78
MK*+HLC>K78GE:". D"]S!1$;&;S=<")<YJ_(W.KD^:!$=)1'15O#EB,IW)]-
M4479TT&6VMNP=7$8A2F8@K6.I=YU/Z9?H7_&%=BF>]^BSU0$;>91:,? .%..
M4<PQ7E2T=W]3^V!R@3^3O1)_L7DWRQYT39JA3N%]O J-9/PP9]MX!DV4<Y3!
MIGXI@XN(ASWEW391W&?8"J18[O-)\<OPAJNM_PRAR@%IQX94KKJ"&*=B=29G
M\J;V$]$>D5@7J[H0G9UKNZ"W5\EOB6X =0>C =5*]WS_8P"]H7G;0*;Z:6YN
M4E6![VZ-KE_0M HB90O^&G[;9K])@\4()](W(U RAP5!:R]XX?$F[+<&K@90
M+IW?^!"CR]"BO_X8C-+Q_5M9+M:A2J_KI_$7H8%:FC< "L6K9YULK#A?A_(>
M-:^@2Z5W*'\K*V)TP:<$F/P<HFB!M\V'Z%))]RI,I/*_E!ZA_F<EV@WH/.B+
M&\#01ZSQMS%0R7CR6TH?/V:C=(*FN8^2@L4X;M$%P8MO ,6W0+C_ G3]/(<H
M_+;JOPA2_)W@O7\07/D[P?^8"[L!X,M*W "LKK4T@F"L]-*WTKF%DOLO4#3_
M T**T1M O^9N >CRM\I?H/ZP3Q?%;WPF<9O[[T5E]I>H_@F\WZWS[T^IMR1,
M_LJEFTC\[VOX"V\1!*58^>D&D,B*D_-/=+>EC;W_*:B-&*AT8_]?DLAC8+D5
MS2UA@#MUGN!?F&\ &E7#+Z3_(3. ^ZO;%_'H%_@W@,^W7_RG^KVKHH !?T,1
M)>G>.?P"L.6F8)\EC?R(=0/@N7U6_R//7+2R#/T#FQ&W7__\N!_8\;<??V3H
M'4].='%+N?/?MIS9W[N0W/6U!E#^GQWK%OT?N?R-^)_L?PCF+Y)5?Z#4*MA_
MN;6"\JYS;SM%YS^[(=UMU=5_EY[6_G_@)\@IZJ_F5UCY1Z,1_N\>]%^X]V-@
M/9WL/'I,=9N;^D]NO/[>7*E_?PMP%\T3'+/XA\3_-1,+'K+R5ZNT^O\-.V"+
M7][MTE]#_ _Q*,#6OT868_NSC>B6)8[4#8_WEWZ2',ALD):BM!':\)TPRK6R
MJ/I.DWUVJ!3OC,.*2B?ZG=N3A"WSY.]USYL207@J9T.(1^VN48#5^K$/%PH5
MJ_O"O;,]JGR<K /S'OW-5_OE$3SE1<V[V<;I0S5HU3*[](YL+_@AF0K\KL!O
MW-E9>T 8/^/687R;O&\!.6!F6^46R6-.<J@(]1XKUK0^)5P]A@&$C/OJ(!@;
M.#IPJB,N\_-5 D/H64@CJM]#B.931Y'M_9G\B<6%E[F(=!;"RJ)<7(\< O=_
MXS/P_RPI^6I@3^@(FIB//9_:[)CF,J^M?:?R0^* A)AH+7W3GQ_EU"/%UVE/
M3VE2W]&FNW+F\9@^M5FCBU0J+8=H($K&F[P.\)_=T6K*OT97#5Q0OB^_GJG<
MF4W7H4_?T"CH""G!L.+X1A44V#6TS(2VGW[\X6+K0O.#O&QB.N8].[ _B+R-
M?36C:=^CW7&^9T-^^9LHQWJ 9S$SR!>PLU6^!.RC"8ITWZHZ:6UR*K>BCH,#
M"2NN ]@5@O]M<,F_DMSD-XPJPH2L.^7)L?$,Q#TC<,R#U>37#KF'="C <>+5
M/%>]%9SS"51KJO+!P< Z;L)H6F_)EH(]?[^I]+@_":'K[OR7CC2ZB@C,AOBM
MP8N;/1PL]H*=H.=:<,+?WAR:_B2/J,"ATL+V(<OZFVEBGSM1@*7_*41$J>$,
M;*HN>O<;%H_,44S\08GT9.6,R8L9IW(N2#Y<]*O-PE8O>#98HO?,;YS3#!9:
M6.*&ZT43UF1Z<0;7)9RB-)>QB).A,O;5"<+-O0%\"+I5O8@E6+#8"VT-T]6M
M*6VTW(\)+2;DK'&6JSMH_.6JT:]@0>CG&-W-[?FX>.;$YP,//%K"77CK+$$9
MC._B-4THNR6%-9HR^JXYIO>9OV7T><&].=^:U"A":/:BG?>4_MQ%W[$HX&3<
M5OE_%.CI?TQ_]GQ?I9@UL(=CW_] ?MC*!#S*(1 (2XD"H#KC1QQ:LH/-] %H
M*X]X]&>?[!T<!RG-U(:EY3;?6>%]%CB8R-:4>.H0<K"?W.?9J*&:+UDXFV8@
MLG3N<U<G<S/JU(G!+ITK$?8C4D(6T#QI]8@:84,X+!?D(R,!,IV!782%P*1I
MEQ?0%K"S=W0/H&[]3ZK*>QV'$XV8PGG+&D7- ?.L.%N7;",CY60D(8_8+::8
M!,W3:.Y.Z"I0* !.R"_^2T!"]CAT=?ZO%33(+&MG='G#1F WA&R$V#7\AT1,
M''MU)0Y".%K@"J=;K+X ,51K-C>&2T#W<GTQ%^ LLBOSH(.$[=9J-((] TK/
MC0=M8>>,MX'RO4D/^\2NK@87N 5IPUM;IIW>AY ;_#8'UK"62F.WZ1?MFH%.
M8J5FUH5](3'$BX,<+T-I'>^NN8U#T\R\S^71[Q#WGZE3+2X9HOU>MMIPN'/7
M?F]83S@60(-YAG[K%Y%C+6" ]9=J!? K+_5&>^[[=HW+;[_@/.E/P K[I/_-
M8FJV/; Y'L\;^ASE3WH#,&^5\/P5^[%K N\$0"QRH:_6SOK?Q&E,B!D'^.KS
M(_9I>K60HT6"ZY_:IU/.W.I4!=[\M'[SW3A.3%\UCCT&G0>_G349'G28R"[=
M7R-=Z&**S:S]*.$LDG-/&M"Y%NNMTGF!'<1O:@0#11CJCL5+Z)8;;[5D1_DK
MG@W6-31,0?S/:AKB@_GZGEJN(5WM6Z^^^.M:%&.$)MR]T\WV[PN-D.ZP/;+\
MY>K]G0XJN5KAIX86K$3G*:!P7;=1ICN@8L,=[ <V!R2_NU]+(27,@R798=!8
M"6F$BOB/V =DUA+\GP\=-AN/6,(<X<]/!P/=Y%U6\).<2- W@(% OJA)>WI:
M;2-[^^=9_+3&5!_#,FPW@2+ =G*L/8'_:6+]8&GQYW@&8\HH?IJADD5"U1)'
M#F);*Q0GW>,_SY;_9TG+XKC@;UL^3-ZSSY_N4*MK*,@6]D(H6O:CF"/=,A\%
M2[](__<!-9^R<2(^8E!E-X V?JT)&1)FDCYEI1GEW7J9P@P1?.9NZK%+[*+;
M>N/(PZ6,[=)VZ["T_@=6'Q8OWUV_W*J4GC>>KM/ 578B?_XQ5B.K5>>>PVS"
M(NNK-\KD=/L>N-:HDJV<.[BZ #P 5C#@:_;_K07L?TBSSNUJ;#-RKXRW4V.3
M[K[[#3Y(!]12+ H#/A<H T0>4S'8,K>^9]'QT:3OV*E]G5W@3W\#P#U$$>7"
M CS-B.R$H<*S@3P3"WTM?DL_)\FS:)LAE>9:ZLY,#D29,]QQ-%<W@#AI^_N@
M5W73CKD3_MQP3O'>1'G<O6I5%T9;:PZL[GGL*LDM^OAQ&5EZFZ$J)G3NY;,Y
M?TD49U7HR1)0!Q4?M1F^;S9'(X:-DIOZF?@Y5',[J^X&0! XD46'TN]U(O-N
M6%X^FFL3O-^[,R\_[<>USQS&S]3W?4=F]41T!%O2+GWT08==XU6SA+3/U^W
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MEGM'1%XU./49BR&F>?;WY&B^LNJ: N@ 0%D9LHG_;TL,ULW<_P)02P,$%
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MSSM6)) M\KN"VW"O'6E=836<MX'=G:?++52@$\S%<VCZA4!>&.A>M H,36Y
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M5H-RTN)L")1\,;FUBI8F7NMGDI\C_J[O0"]HO\2!:%\H^EV.F^J:/@OOF3V
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M4K6D5(LWU>"YU<J'HS7 >AR7GW%/1]:1>,:P)4H.P-U!UE!;/D6/8BAX\?A
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MVX(!^%0/X[(KVF^P">D@J%^ZC!#0L LO<2!_0?N-['\&+/#_%;+_ /8W7#"
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M3,]+[!4O2SU^AS@)JE[ W;P21ZI[!;>/;'^0Q_F4[VS'^2Y-$=_@ ^80V[U
M^?-Q_&.="ZP(7?&=B--^=92"VU+K]%8'S#'24<JXW-0:&3FGKS[LP+SK:)G
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MM:I#K> ;?=T^;(P1YX@*..BM*VJ4'[.S?$O0YL$\2W.L=E-X-H8;]X<QLJJ
M-H(U/SQZS!9^*ZKGK_W%6,/\L)%X866'+6J=&7=3.\\R,K[KB49I6+M$B:N:
M+TMC$)$HLA+(T&L@4+8>*3&?8?--9::7=4^@ F&)F5:*S^1/='7EF+>@,*X>
M+@RK:[THT5,O0ACMLZN1(?[O%)GP[78-2FRH*$QOB#$/>.\XS4N@],V72Y6^
M[6]>'7\S-IAG?V"7>Z^+,OV;+W<D[6-=Z_U.7UFA<D(=X<]WU>PA;*OGD%.Z
M,C2P!9-=M=42+S?0FFY5-IQW+K=]J/\DN/G'*5;!15419"G]L/6,3J3\_)P6
M#3"6IQNZ<_"V4GGS,\H?7<@NLFCGDZ**A%F<4U&MZ;ZZ(B7Z>GM$(R45*OEF
MHD]TWQ]AL^0T]VNA</*M8?F)&Y-NMB'5B:]55N,%\T/5EW"\XB]'S"8Q@Q^3
MV^1(-5M8Z<4[>1-'T"V&WPZG$1MY^/EFVQ-< .M+P8BB5T'&__\NG:MDP*/+
MR#)XF^'$8-R^NE_DEA%\5S<:0QI7M5MQ:8]Z?9Z[^EPO^C/,IG9Z9LUPL++,
M5S!O&+>;*MA?VIJ0U APHTZ5#1.>,7?G:*V+@MVKZ3E]YBD/W7!4/QXP,]0=
M%_QBP79S+>H)]GM=4X4GM:/;GYH;ZV-@D]3\[*-?GBD>L2.X&4U0 4NM1!R1
MFU<WQ]YT0Y_7]NQNL!V$;U1Q9N3X2TAP9TQ=^"ZU$A":EVS!W-_S>8;N>*BR
MIE[M:DDK/QY),!E;&F/4CK^:$SZ,^C:EI+L?2 KG33.?]Q?F*I'&ZI%@C3A<
M'1>V?]FO6Z&C6\:S2Z/2SBQ_\YV .F(O1DH6ON3T1L.A5^]<\M35-V+)8G]F
M>(<3UU]TO?"BFT!5BJ1 ^E[MQ\_36WKA'B_<J'^6?)P6)F%F9&(BW\6_X,+<
MH7K_;_-G@+9&W*0(SW=J9?8$_WMT_,\;PU2)^H0]>]9_W+_H!@QRBF8V:SU<
M5)EHG=21ET<Q<MU^66\^]9;\> P7@=9YTBW>^YZ7L!$UC+-YM]!%2/-/1W\"
MX;N,C_B%^P@PXD?O/Y&5>&447-K%XJ,O("76E\B.H[P\ZL^KK5LJ0FA[.&?K
M2MV!%?C2J5/F(U6R5W#-6^]=A]MUZHO"@U268W=^]3.[FN>&2*]%/V^3L14C
MC)D]+.)UR&F*4B4JXK',S<7%0U)AB/SZC.TZSX%<#5BZ\3S6<,*^>H,3NZNJ
MEM#?LW?-%*,\%0U8?V'LR6"8Q4 #\IF%:,">6[P_252P6-82C]TKQ\<%P12O
M$@E/%\\0Q/K\555'20F\' &YX!O"\D"*A%X>0SJ@#(AG-C[>2*P5$]_/8W67
MDA$[;U5CM"'WUHX'K,W#X2L9O=?U.Z))BA -*/PQI&R]E:J9%\ZKPRRI,67/
MS_]Z*!E;*\D.4U/&G^&4LB_V//)47PL1P@&*RJ"XE\4\Y8MW*=DB-FF?_Z*3
M^JXJ-^MSG5&2]\'^@YH" VX9807_^16!V2&)LLE4X-4<EFQE;[3?_Q?6>WIR
MW!4(W^N DH:,:55-E"UTU3[D9I:#S[O/^NDO(E$,;2CZ@DT9ELLL'U-;.#.>
M&L*OQCL7-FML-<]Z6N+ &Z_TU$D%ZZ1I</2^&%:I=WF75H@1:;<T#;-0%\V!
MECUQA^FCR1,*>7:7HF^5C63RK$;9B[*!5]0H1U]OWYQI31'NB6<-X_P./QOK
MX_1WRS^R"1!([%Q'GG;P5A>+ #*VAQ$-X*$<N[3!>C-*(]D39HLS/'MN//&"
MG^\[Q &A[*Y#9MP#5VP^YJAP_B@IU7R4Q_E#4^5.O:0>0@W&Q\;%&CJ;*CX]
MAND?Z$;""9J\+#E%]JXD46Q+H#!8&D-2J;T'22X5KXU#]?FT_:NDN1BC&PP/
M&)<Y45I+$8-(SNWE10B5J:+PF>]$$B]%AU7US$:ISNZTS(I0V _/,.G3G=&
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M:W*903MSI36BI!6YQR[P$\/% V^N?IFNK1A"13/6 V(2D25!M79)A(9*B1>
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MLS';#OCA@@PW0117W*@"K8Q;BS,S_:_JFCE/:"E[::;SE:3(3YYE?#3Z":4
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M1)W99X^:R=XM>23W\.EY$Q[=\6<)ULXA8K!-QW'_X^$2X2W)D<A4;S UA9G
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M1S:'K!,_T&X>*G?GDCHP/7;$^R]EU?](3NGZ(Z;SGZ%[I^&'FQ7(L5..U"W
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MO2D=NO(<'L5)0SZ46)K )F04K%[ETY/#A@J"<H=8I^FC</SN;\?/+6NX.*3
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M/SL7#T.)Y17 <R-*\_'MA47UE:O@@8OGD_QZ!XKVAEM<,BH+&[K:A^I55;>
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M2@E[S]\P,S+H#FH=NUGV:PQ= RSPBD7W4&LA"N0!2AM'])AGC7.GRW'D3 )
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M XB0'KO2!NE<J9RUTZ*+GID.YL.$+FP?;>1; 1ZZ8)IUP8^=+."/8@>REBO
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MAK:'5_=8M<^<>O#PO_7?A,I<NLB&'WTW2CTC=)RCYW%UG=@/A0S@WH@2_T
M8D'S7B"B6#L2 /@$SH%GYN4? *[_#@ T[PO_CPE$^KY'USX1WVL#_T?_/PZO
M^:EL8Y%=!'?Y 1\Y+S@G !!TSC\ 4U#N&KKTK_#_:3P#<?B?E*/;!.#OK3,X
M!_S\! '8_(MZ%=CQFI_<@VWJ^OCY2@*0<08YPV>L:OX3%8A(1@7>9/!7\JVJ
M-*'2B>FY8N:[DK"</H5)A(FOWE'G1UH&3W2$,4)P5!41.*U28^WLA6(K,P5F
M#IJ:&T*_HT?M.AZM;$B?,JY;6LJJ@S*V?']0HOT[# 8[$#18HMY2%U<A -U/
M"0#Z%/R?6C B>E&_1LS18RL=L: C_2-&G" C 0#E$8 WMU<USUG*R @ =0@!
M&-C]X:YQG6P@_C5>"G12Y$N)9Z8D /'C\&Y6= X^RC*8.*"+ *P>_S3.82%9
M[4"%^CL0@.SD3#CB%AQ[#D*%XOZQ[L=VO0^ ;:.L^N-/;_P;,")F5/_4,%/U
M/$:7,HZ(Z[],TN-OCG5!AS\9?=6XWVI4 $N=5GK>[U,JM<CXLT8**IGD=GM8
M#B"%\ AOM^H:20&O\OX/D;MO4 V)L@!!SY/^\Y=A$@EUT?]W$0WTK5--_]L?
MH$FH!HOEDR)M2TUU' -<>-9S!ZV3J-]+WB\HKDZG.IU"0L.Q-:LM\>%@!G]5
M)$PTZ9>+V&R!F;=+R95!@'F^3'"OY*:$AY-PD1Q6>N66!)&(7N$$X#6V YL*
M1NC &/%O]H@LO8"&HZ4/T>?EK3;$O[#4QT^ T5@"@-#$22_'=&P9$HF/(G9T
M5YXN*'3T[N*'2G E*.5@,$4K!7SCT2BQUXJ= #"K$N>XJXG3FP/Q=-0@"0 2
MNKF,A8YPVH-0T5L$ ,LIA'UR[[Q&\>EI[RD,E9_(RW'IY<8>.DR 9&(NOJRG
M!:=YGF)T8K02<)D T$ [X4="#G"L>#0!B,S!L\P$$8"M_YC+"@SOL<!^PX>Z
M@ @ &0AWG0"$M:"3SVGFP'@*,%;ON- ;'M%1XT0 ;N(8B8+USVM%@NH+>B#4
M6#^,#;H^*P_KICU1D16U,. !M>=^*>CZG)*.0I,\OK\&LN>]R@=>^W<"-,)C
MX5RM1N@<1%S#RK<T]@<3?%.7I*&-^SQS2HFY*?-Q+PU L2#3<&]L.,;%:MTJ
M^-@R' 7OG'"8O@1^(Z7AU1";$OO&1*!P!#5U@#6P).Z?+ 4U M#E;X73\3^P
M_1-$H']\:=9?(E>RAZN?8[&##[@]7O"O2VLD+@UN-XE_@@7]V:NI*- Y]1P(
M3_N'Y,2-%"J] CYEK@7CV/L(0._,R#)J)E"2.).9)@'H'""2%HPHQ]D2 **G
M30""X_$L 4X\RTC0;!W\0R#E*!B5WTK<7W?_74ZLL :!Y/^$Z!D!H/=>%3]E
MK87CZ."H'#S70;_5D3!Q:BS''ZF9SEK$7SG_9/"'E61_L=(>;_-OM)>"_S/"
MT,T#++2#$SY:ED, 5JR)Z(/^%5_E.H8#-.//N8ZO'61;H'^E&^A?$3XYPW,=
M_D'H[S*G]V_H'A'1?8>[?CJIT-'T=_X0==J-"A(",)J619R]71PO&/^?^'+^
MS\LMGB$ ]>(QSLX;C7!:1PJYL UJ;T'W9>Z_B1S<;NH/7]3AW9]00O\GMFAG
M+]7GY?Q8K-Z#1ES2;__TGCNPSJO9)\,C>")J?' U>64S6.]#<M?IU>JW76$9
M;*J4?.=SN]T7MA]EA\TOL#SV4E5GT;_^7V4>6 F\BGLV'LB]^,/8W'3'M+TJ
ML%K+)6]KVL730\ Q]I<+#^M+22V> !W-'-Q+5'D;>^A:34O*0$2Y76T-H^O6
M%RF]FL'$U[<Y=6,_QV4WNL7K8DVMN&#ZV@?,5EC*/EZ=[FW+:Q'%9B2_4D37
M[4\8?I*R-N_);5MJNI4NX*RGVKFV4W&C%O-JR#V-@3/[>Q33/*8"U6]3#-Q4
M%DJ>'H:,2-&=R>ZA?9Y#)/RK;[?R2NQF/'C2%AOF'>,YXNP[T_\V(.EK-R/-
MKGSL4'S/CT"^'2Z+D12O;6[#+S2M; <W[ABW]L29-7(66W*-:\;[^R 8Z<4:
MBH966*?KMDKIZ]9"]C!ZZB3W4\WW':;O=G+_8O_S0@S#'HYSSX'E'SZIG1 W
MW D0VYJU*'ZMV'0W3'AP,XP[WK3,#TVI78NN1*7X?#)S$3WV#+TJ($7-%[-R
MM-@8''=\^+LKEA1$ VM8O8BR2,^0C<Z9^2J846C5S,@WP.PJG*CR1<[9SZ[N
M0,S3[CS[V2>SL*410R+K/7PG!FROP,9"D0'3?,PJO,=9L%#I-*[A\[+R4IWO
MSR$UEKW/4T6(KD8!*L.IU0W!4-+*[HSP^^S9YR\*BCD^H,;)8N&2._)O?@<J
MH_+JPUV$6^Y$X>1Z4Q3#)%I3E )-"Y#7I:/AW+!RX8-+VY8\TZU*I2;SCKYQ
M>84+UQ;;BD\LK1*<6Q]6QW:NR.P-*%VG!3EC)Y ,"2NB?$[RM2,\3>G"[NM7
MO!;YWUA2RGWAGE&9*+Y9I2@+,<6"D5*I8@76R%C-7M_6*MCI\L"+6;-9'=B7
MJ[.BWP/O"G!VQ;[;&+YSYTY%3@?TTXG4R&Q/7X.>I79![8OYVQ:J5V*1D-I>
MSA &#99T!Z:M="GTQH<5,+53X+4IP6=YCF,GR8PT[+:<9*'<[Q*%3>DMEY!+
M2[9O+Z21]7,\K>174@YKOXZMEM(!]2RS2'60.ND4P1Y9T6IZ^U=9U$TR67QZ
M0],5*9>0?"U9J2;89+E6/.II8S-:?2IML3V^!&:E77G1TLGT?8G'YD?]>VPR
MA2H]%"2Y?*]5*8,<>.); I>I7=J?+L;L'<2;TA^IOC[@[/_I/5"NI+2[&G$,
MM:+#N<9;M4R5*1I(8ZHN5(5-/$[D,7CDPZ_+)S,[+T+[.Y(L:QB:/N9_Q:48
M9H40K' OW-E\C*:,*:^-U5CWI%;3L=&9/;O#V1DO(28Q09GN0 OR(  .=_D/
M:2N28^</^Y4\# 2RU1<*7E1$2M.>*8&ZQK'* =6.9:L*N[1,)4[59L;SJMP.
M9T)O>;Z'N,]]"M/Q _VT+;?8!5&))6[JXZ?C>DS:JQN:]-=-63Z^H;+:F*,D
M\Y8C#:HJ@Y\]AAGI=$R-N\CV@F?EU5>-EW<C<[]BV'Z)D;F^9P $;%;)I'='
M+?L\''F^/Q)XK<X0UQI&F07*\Z=&*D1K$,TN#GML%F^$4:_L\!*3-:?\Z]CP
M+W-@7_^?SB<!T)V*"-/^!MLSF9W3I&!;F4]E YDI97L779-F<9E>A?O?!GF1
M054[U $L;]Z\^*'PZ$[742F$ WNFA9(-*S_>>^1E(3_CEB)PW?P7@I)L(>I$
MS:H9M1P:R+CK#:=KA7CZE"TZ8#QV(B\<-="RZ%RE+C>/[;_CE;P8<XM3#MDT
M/T@ JO&\_@_K:F9JH677?KYJ"1VK5=BN0-:]7U@9VFBZ0A?"&<-;U$(F=2&^
M]M4([[9I191T&BFGU9GF_?NYS88QH7I\UU[X\I*4_2C/25/30"1S#FY!U^*C
M9!R+8//(5D:D<:LH=WR.W?Y:<]>MGD"DH3FKEO+V4PV27<N$LQN[F(8E7K1@
MM(M-4D6VDQVU3?4D%]$M>-OJR,=6(ZO :DR:HF"F7$NRL)/!Y2^>M8 MDKY\
MZ A%%%I_,FB#C210!QHJ+2YSG&A ^*>K6F^<:<"@O7.QPQE*]16(<PT%H<G,
MFNFC;5&;ECI(F]25\.&<1NXX20IH)\[>7APG'!^A(UW;,.,+ZJ4-L#)_S?'M
MBW2B-G?*W)VG58BJK; VM[YE=D7&5>$MJ3+JLE:](NTLJZ7RO +G-*E!.B4;
M][0PM5#:R=4"%I*JE8XY>+?E[=9QOC.9FFRQ&@+ UQ)KK9,X1[N_HLY/GYLP
MR$F.*0_[O<H;:8\VT$&1E?V">F/&%[JNU+@[=TL;>EY*J*TTI"1#5Z2**C[+
MALU@7F'U5N",.TG-#=$;S>/K4=/]>B))=SF3M.S>@7:ZKU:>5,WP[(X'WH"5
MW*L\+PYD-#/?F3;\S3:=VCW"TD!5QIE(]<8O6-'M3K\O)E/$VU+J/,M?867D
MHN6V*+1DYW"[LJP_?TXY[=I7QS&FMX>2<10D<IQRY,B6<_Y>&2[,.^NB[=]Z
MB]N_*Z_UM7W7O"'BG/4A^(@OZJ0'61J" $<JNI5N+2F-U8+W2CQ;)E_Y8=_\
M?JW[B6DOAXZV)HCE!KD]:Q]4'M(;'PJO-@H^NB[J/"VL+0K>2Y:5353W9OVV
M$/;K06$_8&LP4KA%5)QFL(;^4[<0J8\'!TMJW T7Y]2Y;[1KV2:I1$0I)$+6
MJ"N40C %*//3E3J#HC2>BKB/[?QGY"':LJKU'*'],N\:K<'>BG9-0UZ;O4OR
MZ.4W.-&R^>U3UY*"/L\*\[PWL=+-DB5J#MJWR&]YVP^<76T2#^E@\V="9,S6
M=%MR3HM:MZ,9/CX?$\-=U3,]V]L6F^%5\_@=GM+!T37L0,N;518X&<@R6K<8
MV+TS8'G&&^*.L8 8AS](,KNL)1,2_D&U$XCY_-2[;)G#WP-%/)8$QD57XG71
MO#DE*JX_2U]=-O"6FEXAM2.!S;Y6?O["HQ_:WWH!;=^US."OB>["Z968F-U7
M5!?HF'7=^<U.XS)*'@=JNV+]*XA28%HVV-_6$^6- /= @ 7M7*+EQ;1?RR0P
M,[=61.,H8_G,UH0S0LSH978OXY+:#UTVI:]GF&C4&UZFL>-O6@?2&E/[O,,]
M#ZMJ?<1=A1Z>)%"YO_T2TB)'QIVZ'<B#>S >>,TQV4C>;8XO_:N'HY]U )F:
MAZ,<\'%=[?<C*J6N'0;AS3;P(]1R=P8O[N9D?YM+,=;2P5-;2WHCA6OY[(&7
M%I?F6Y[(#FCA)B='604YE)=_.I#?WQ0-[OFF(VQ>V3Y9*C*^@5G/J6]T$(T:
M1C>'=$ E\S4I'3>CR/W8XY3%L&Z(]?&><JMH/A'[R?R4Y-\OS'H?WV[Z22M?
MN*_5R3H,,\#$HP8BQ3<KT^>-1]W4WZ=^J.5:2KM6LF2:N3#>S>&_PN ^DZX.
M,QKPT]$>2+^,34#F5[O<G;_;,NYL6U4?\W5\WM2\S]V7O_,;?6^&.X_O0(RR
M!/9R?URJ5[!H192G=NRETU_">PK.N\\8W\XZ<MM_6WZ;]8CZ"!G\8Q+EO:>.
M8&1?V*J2;J_)TBR_I2.X:S)A6__Z/$) 1)^IMFH > MQGL0+GN<I"B/2O/4G
MUANFQ45KDXV/+?0'(#ZE1YM/J4SRR("5URK#"LCV@'?]7+)Q8%OQ<#BC_YWB
M>:= A<GY!W'#<U_>C/_X0C^I_\5=<.%$FTMCK6K@V5)+!H^_*NIW;P83-K[3
MRQ03B@#3S"U)-T2X[9<_?[UQNK+RC4XBD?&A\ ,_U.THTH%B[,QJ7?QKFR:?
M5FFDB[;.ZQ\67XJW4\U&'*[.MS9\E$/X*'^8AO'W8WB54''Q2*4[KOP3QV8V
M+?5FA0_U.7[8:OU)98B##K8K$( ^ WL$XQM3J?QK:/.HAO&["UTY9J%^(0D3
MWTFN4'9\A$:>Y]@V5:&/D@R-DN0#VN+#N,R,7>LTJ^ZGV (<=]_R= >1KHYZ
M9VI.]6\#9SVHC;=+&A+O8F;ZY<LP'0%(S&1.6W--78"!6HV+KUF3OH6BEAOM
M)<SJVLV]7Y=\.3WF&O:EDR9Q1MX%L'B]1@@=..+81MD%7:^9*I=]JW-\S<4\
MB<^>,]-+N1+Z@>S.^6W59A7WYO:[6'LT9:^E #HP"G\IT>+N")[I<NO\;L/W
M3A_?X!BY5QQ>EU]<+C+M0"B1,K(X@LBEZ1_MZJ:>/:ZW;7/WNQG9VCB;_(*2
MDK(I4R3 ,IGZ2G>E@&>YGPH:DXQD9(&V\[[6XI^J]8+4SD-XN_7Z]>_A?_%J
M:+Z =AV[^"%KP;5BR5#[G*T+X>%NJ9>])O.9M*B:ZTDU3]PWZ H'<F05C4SR
M!MW 3O4R.Y'>4,1CBZ>:7P]\:BYMMM_"8C(UF\;^*0<26NKL1KG-XGIOZ/SS
M)&>2=&#M_,)+*_K F]L@EMJ2/;4'VH-7JUO].+,[ZJ$^ANK]@1IKI%3\TC.+
M0SQM+=^$;]X+\;C-#5"^A';#[:Q8ME+7B3Y18ZFTMJC62&2YT*R+_*!_=2$9
M*G";[W!/A3=XA3%&7J@WGAE6<&\\$2\\PJ!-9U02X(!!M$[:Q;Z#77@?ZNIX
M2@#ZP?0P-R31QF?V]KZ"9F@4@)K!LNU)]+39O,AHJ"@Y=Z-^C83R2HP=P!TS
MXB1^.-7+>AOT9)^G4Y7KI=I%33_C WB]TB]/M/E<F!J)EP)%X6EG_-50&+S5
M):=T_G3[!$\.&JV+#0G\8>+[Q5<61PS2CTA^ZVYKZW7V(33XR6/>.CWXN^O5
M9,5E@6V>+8,CV">.YE$>FT3;SUS*+$!FCU**I*G8"=,L&MNW_G/;#>IV65MD
M_$5AIDUBX(<NK/=J?^BJ>+A0?R!/]=3QXJT%I6I5ZZ<''OS">\^K/G/;?SXU
M2L,]CT>&1QX%"-]O0@6TY^4O6 GOU)^*91?_(JH;_N^9C&DH!O ;D&G6F3 6
MZ7(;T1!]<'S.8$6_-?>HI'!):6&"/[_/RY'I[JL?[+SGA3SQ!BC* 0L0DC+Z
M&$2GEKO;+-/PS"%Y8A[*Y3?/Q%SUY([B2]7.W:Z2=&5L3SZ6UGSBE?WX<:R'
M84>8=L3/(S.VIH3G=XN'.U^95X)B7RS7[!6-MS)5^!N@371NZZ/]!RS;'.-Q
M/L9O^G(%3@5(M B XUPU_MJLOS)ZH/> ;M>W(\[U%<>^%*=Z0D/+&0M[I53Q
M66C7 %^0E\TE*KE,S>S=CLM2&0PP,\VIBJ,].]I%2XC@@)H,G2=G[N;U*]PA
M05I"  /4'C'3V\:/M$SQ\,S[]-&N-J7,3<3MV:V%N8=MU@F,-WTH1U]3523C
M*)&[/UJM4=_Z J]/S6UV>WF?8J(+L.%ZYS^:@C^*?AZ7 .AW8K*&25:GV_Q6
MPG*@R/AH$*NB5L[7!EY02TMM;4-3],=RP; +)FF7<^C>MH1[9CIC3J]G!].[
M"O>!'77\'K5C1='\VJ_W;WC2BDHI31776_*ML2PHV)!%8>JWK03QXW!*:8IP
M9$><P+28<ZF85 ND9G96I\Z53KBN=S=.XWZ?O<%*8,PR(\[!M^([&B7'@V5I
MS#S^J?S>*"S@Z<1TE4L3NCZ+ #S%@H]DRO)WC9,Z?BDL$X ?RHSG'%,BA<='
ML@ '<<2K[,*$6W_%<:73B[J>2<;R/.HZT,=!E$P)C>O_ULB:@KP%KZP8*'UX
MP7':*-)G5/JB%F=PF*:3X4WP)7QS1K8E"P%(,-/<Q)L3IQR]X+2Y8!0&\\;X
M)VWVG-KT($'1JY=,>\\NX8 FE1?*EA]R" #=KO@YBQL' 5CIA*.ECVBM5Z^A
M;_^HV;\^TEC!0P#"/)/Q4;(Q<-13\)_KQS1; I =NPK"<3#B!5.$JNP7]#+<
M+17^!8P4O$?^&P%0O]P/QMX"X70 /[: /GZ9,3SKZC)JN)H C&F@X_%TE 2
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MH.2Q[@6_ /GI,4Z^^B@6.[%O7!?(TW-7FXI-C8AKI#./E252KN^;ZV<S,X%
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MH="EH,G<Z*6DBE"\$V#ZWXF%?;,]2S%IVD";CF+CL?X7FDK]36X 0B;=Z2^
M+?!!"VE/VW6,6JETC!_?D=K^F8JP[])EV-NY]?)R'>"KQ+H!8F@7MX3-]"\I
MHI;R$+-2ERMHOSA^6RA==HB"+8[A]7ZAPN-\HU8-,%FMT OH&ZA\11K/9[EP
M1R+M-#$9MX;6?=(U;L?BG(=Q'E' *464C4[SK9ZLC8R_Q\75M]$E'3.G["4
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MVK)G)4 CP*A'WF5OGK(I_>+^UT;R]%:CD=OPXG<=7Z$3_JSH' 0^'A$K.4P
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M'UOKB!)8IY9DJY#U[N=W 2-@$QK#/3-Z]O*6^@5?=Y5]_Y9L2R=EVO-X:=H
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MI\/Y,].I%TJ1-A.KUXN-7N*:["Y$6))(41V?_HLB4Z8XS];$V5!&0<YOU1*
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M?%"_\70( H LX<=SAB/$SYDK&. K[6"B,\,9\@_53'KX?QK1"W<1C[:DF2$
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M*-OUNUHR-3-CM?G,&B*8&$?"M.99G2LKREY('VV3UE>C4Q89 ;-J>I' <-3
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MT]# QY^D@2Y'EK759;46-"C!>-CB6@Z;0AU(Y2Y],?XCYE^S_:__5^/3ZJH
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M2]AF>+_,MCE#ED3J+V'E[ !FQ8YVD:.#J]4J5R5RG2J47)R<G#[;>]0>]!%
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MZ>_^E53941\YJCK2+?_ZF3?D *-S+8U6ZV\*%&ONUJKGB+:N3W][7$7Z;79
ME'[\\(1Z:RX-90^VRJ;9 S*88*^NQE\C@V8.O=ZW>>W#-^P_^@Z9>E]R>6Q2
M3^)ZQ 'X@G_0W^7CL_5P!0:TCWYG5]>LWD#-KB$S8;#L%Q9W]BN!"NB(DE'"
M!Y;19J H@%JQ6ODN+!HCG*C!]\WG?7$7C9#C$5ZF8,I=6-W>"R9ZK&JHQL;/
MC[SPR%\Y]<^2^?^^Q1'?D5[=OUQ;]OZ],KO[6\_>*?<NV54@?_A0/VZ:5C .
M/MT7*OE&Q1<8VVT%IO.-'_2 VI; %GW?'E\-G&_N'=173*9[,"V+U[";U3=_
M)TI/2(@I%4P#G%>'9@E-\Z#F^D0('7S<=VFV?2:63,U>+6;O-Y-L<HF"ZWQP
M]@GH*I%3\(.Y\+-N!M\00]_"69 2>.MYZ+=:T[S0\"<ZL@+#%WP0?)#2VHVA
M 5+E")H4_9/*#%T,-3G,]:AP./>KRFJ6KAOG616^!3R1219.I9QSJ:G^(X1G
MDM+'3A6B.],0=2K9TOS,;&<NII('$-)J5,J9X<=^=MP=Z242I+?DD+R*S/<*
M4-/]S!MS$]]#PU/_2P._H,L()]HS )KE87&-%%2?PP@B=: F8,A;8Z]1.7&#
M30;P,Z4@S8&QQ-8DS=+G&Q#"\3C9AT5H&FWT0LZ2<AFZ^"W2Z^P\26H2QN+5
M4)M^(*I6^/B8<J7#QGP_DHCC@3-!8"1E)S##@A+EU=_=[T)A%D\,DOW3X*35
M=RZ)ZF?L2']GF(5P? .JYXPMBOH:SN+=OWFDVQ\8%SR&RZ9M"?&R]OTV]Z9K
MXNC]I(OEE-?S!UY-'6F4<IQ?XY-@<J,=>+^78M9+<NZ1(;(/"')  M/RPR7S
MN[ 0J TLZ60GV>F9T4+I@^*D"!Q52CQ^0(:;\=4MX$!M;9G,HKEF[.PFG;=\
MV>'<>U-+\(%'?'UJ 99M[8L<#CZB8VH],&*=915')!CCMG9@B!AQ\*[\ZQO2
M4R;6Q/"S)HH_8DS^G;)[]M/,J:J_4CT;'4K(181<=;BLWAJ;,E2R[;!^_=J)
M_S>*/:.60F+$[@-$)O_YR(_>'U%ORGRL<"" :PO)>[G!!.I#7!TB_UR>KNX1
MG=^1Y]K"XMA:+-CB-#5!N-QU]9_)K'WLLIH.9%%>4UAD@ =L2-\"(KV*9CQ7
M[[<K5^[J>%$TT4\C\%W.+#=[!M_+"3#+%_YS[UI)2_'+_W"I&'_ H?'L.W-L
MP7DS%<_Y26Z<>H:UL0X^U>&C&5J<OV]![-F]%[!/78331!&?A+BMT[7U1=@&
M+U0UI#8+D+> >-5&)_LB])9RA$I'6T:_$P':,.[O3-QRT-;FD47^.Y&&:*'7
MCO95E1];O\U@YIG?D7\$6;HG_OF#YV7JWWKJ..1Y'=;0Z<LFM.6Y5*L1(TAW
MB-/3[]N,X5-@"&0+N>F$[P&9C 9G+S3DS?K\OF-_5,7W95-TZ#L6O5IA0<G-
M#.1+Y&XEE/UZI=N[+YGGQ 0//'3(G&F.:HC5,C?-U#(*49T24OGE!\E)/Y"E
M'DH(R8AY0Q!/$3BY0C[G3/W[' &D='@.-7&H9336*=*AFT9?_V1G1T/A1!-G
M02YBY>'&W[2,(5]'1]KJ;@%G_9]/L]@F0<YBQ&?+)K^Q;#:B<HUQY>^YVY(
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MD<O]:6I^0?A"#/>!6S+DW53%RS-NA2#H8F&B==C!?LQC+<B[==ESI0 9/,/
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MDY:]<(5Q5/;N3E':X.:],5BN&]=PQO/Q6?9.8VD3=P?UW3YHIM0Q[4O<X<.
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MO_4%XNV,^ZORUL>T%K62YE'FX/-U?MZ(+<4Q.^II<ND1T %[B0X<Z&6X!^"
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MT>S%RV_=\IP4;>)K84H),ZK0X4!_+U&[R@H@E=T<YD:TPMHM-U>G6S28PY#
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M<3 E_Z5IJ]@Z$5%073M10=,*L9N?W7"E\5;;A@;-<,4A4\"&& 4WQ&Z O)<
M*#,\%,>ZW4J,[E3TCFH0DSU@]A!+4F8ORSSMM1_(OM]]R>[O3YNKQ?8U,:&1
M=%FMSQ',=]D33-7(0K,$YN[/.&TN$C!P3I[/I@,P*E<_&I>_M5^ 7XRG24MO
M[?1#.ZI_P _25W1OCKR%C,$S 1\K? 5V@7E\N421E^92)J>].:&!JWYCM3-!
MG$3\W<^W52?H[^R]]Y%244\>>$1&W0R4F%Y=SW&A<9%W$:BX_E:1SFBL PBD
M#&DZFVVP9T;\>F#CQ>BY:[!**"L+1#-/"$.(]R7-8J357+RV35/QFB?BV#><
MY7O2 :4_1^=J<YS$FCUE.CNQ[7]N5D'8#A+YMCD8NV(QN%5?6JP(Z.LH0$_)
M GK%;[G^7#L(L3&;T-R&W$:+ICJ*155]5,KJ&>GHU/AM2% MYUDVDU$S8ES2
M:Y8X>P]XPB?R,L#@,X]P_3YULK2[2^ ;S8A,[Z1?^+B\ R(YJ'O 10V*OS?!
M_]WX647F:%5 U4U&W&9"Z-$KHT[%P?580_@%[W31T_+4FF/O=I=51S.=DOP)
MQ?7@:-SN=+$I,#E'Y4A98&Z@K(S2:ZIJ[)/+,RX7*;_9'RM":&G)[9C#J+#B
M5. 4B /ROMVH\1X0\ZU(S2[-+Q\_'H(JSPAF:&<KP9CIS&U/FW@NBQX>5'.>
M&/G\*'FHXY9Z&+LA/+9(@8BL";8'N50N/6I-,T_8J$_6:A''%;^DG'2QTE3_
MVC.D7,T^-C)@,N=\*/>I_7AQ 7/:*P1<V]E"Z1QP&"2J3'.>CE>GZ(@]3+U9
MD":T*%W%?IKC"9!#$FG<D3+9^)X-WP/JC>:[=8I@2:[,GL$'IUF'33(6BTJ3
M_")20V\,X&\N*50+O*>U]'\0M^.:LJ]"\;L_MY@X[-X#ENM3L2_4AJUXE/S
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M"7UO*>9G7R3H,#*?5RKM 0(N25Z2;#HZL9K2J,87W!\B>31 +P6@^QBL Q3
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M ]3[-1Y.*<Q9*;S /KX&3"BBE'%T9YR74=;A)HH#DF];Y7$T'3!*7-19\#4
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M'*'A51$?^E6Q6"+D\Y> %XK%F@>08KD,1*K4<$P%_=V-7_WZN0E7#K@9-$O
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MBDR+@?PW'(&@RT?P3&IXYN*3<U%. 981;S*CC8_O_.&5/_7E2L@-MM[0B8]
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M6<.AKTG"MNG$0MT-8_8FJ%P,S*S=TT<0ATN*4?UVD(-&'I>0O[^D=?RQN#S
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M_O?VVT,#6GF665^T58=86U JB(*3=ZS+/(43>YCV;OQ8)WO %3!/U7#;F:Y
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M5Q=V"7V4,N:0H4/NP^#&UZR?J W'$\0K*T2K,X0*@(DK'3#BE!'F;K,D]>9
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M)DB%9+L5J;@^[V-D9R<;0D5?!Z!\$)WV1T;S=ZRE5D[BVFW.L<S211(P'?P
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MTH 1:<C^297Y#K&KB>12E2$N/IO\5_\@>M#41'YMY E7)%%QI7X^PTII^%8
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M55Z[$4F\N=LAH9#Y+)@G3_QW%O\.33SS'9OZJHD-<XW<DGP:(X_>V^ ZVNV
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M@-GZ/UBY9#CM,9JU%'K,SPQQJ!A]& UEM08"[%/L,_PR?JZL2%=I<;? QW0
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M,Q6$+T$.;X$,30/\^*WMYU0_$40*?(J_T>R.CE0WG?3>:@3BZ5'1JZ@/&7T
M,"3B^Y.<CH;5^HGIKM&73GE N !Y<96>Y4 X;)(E[!W3Y^TO#3Z,!.H[1O8I
MV[FXEEGGO/+Z<0=5JT,>([FU/V&*+C;,S#)G3[FI74747,X3GJO^/USUGK7_
M+/>MY>OZ%8V7J20J')HYM,1)A$Z OY.&]UF-"QFZ68L&/\6:SE:UO4I_T=FT
MY.XE_F7^H4%KS7+%12@I&B__9Q!!IQP\F%=:\LVMN99((]+@%:D%M+8E O6\
M]ZCA>[F,"G(2T?A/"&BEY<G;,(E?VSRWB$LKC5DU01>%%U;"WY\22>,_G/9
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M 7UFX21F26LI4+'&1'Z)->7S5V+7_Q*I"U;TNI)%)R4,F3R<'.:**GVCC%)
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M95O#Q)#7#.#[3@Q,[D1=:Y>D_9*NMZ?DB%=CMF)C 0,(H:*INS,$<_IH,P-
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M =RS"UO28?L5PKU08C%4W^0W]<67,B_U:?2'S]CUZ?C Z8^49*K]1AUTQO<
M<4$=E76>:K]-1ZVVKE&98#,LPU-;A6ELC63=0G3>A'[HG%)UAPO\5MAHTJ_
M[FHO:G,=D0:_T[=UWEU'OQ!Q?VV.,]Y];N7I:$B6V.>@Y^RR.IJ:@9 I@LXS
MXWET;02E!OPKP=$(4C9MDK_VAH+QG%Z=\/Z!9 ![9:%,BVW#MC?W;3-=/+^[
MB)K8M\+&'MNL=>)6[ES!F(Y?/@5^I1]S-?+FU)%'E9! MF.G)^HV%E86X?TM
MHDBNY _.-<DQJGR^IA AM]VH)^EIZP=BXQ"?[]W(<P6U$BY;YV!N7_OL\Z*
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M)96;XP<FOZATHD\^);#+;*[?8CH63']2<9<IP+4P#IH^;/WX"HQRH#O]7=R
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M]L/EO[!P?*_=Z,1AS$2Y_95P](5DZL)T,V?/W$)$ZM:K>*?,3O5(?1EA4?-
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M%>KD7[09';KIM-PX_N[.T*E;(LBZCX=6,E:.[>7X8V)DQ ;E*$VA^0A(9]"
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M:4QNYW.],$(SG56 =]JDRXB/J/H/^N_I>GG].N9I:>+RZ/ ="<WC9CJ3GAS
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M5NW<8V6\GK)O+UVSRTIB??SIV);(P:Q2N^71%9_;C[Q#'W069X]:IYTSLFA
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MH=;WYX?;(V<T6''MH05[TCD::\K?=Z#5+FQW?$-8V[?A*1_Q<*_!Q-.%26C
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MFA@NZGB'00#EAPEZ;VG/3/U^S80Q(_D; N6H\M,!4?=O[XLO7FTW;+21[_=
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M)ZPL@\Z+K[FPB&C6>ZY>&M"A-@8).@%T1V*M[NH.9SD^@KR)LBCN%(+7@'8
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M3#I7@:49L;1"U2=N\DCQ*?BY8ZV_43\Y[?5>I0M#>T";X785KP.ED#JK.K&
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M&PO(,5< *7T\Q^CUC3FN@*T1P7 F_G*]L!\*$VMF\:XG>VZWK?8H/>SF7Z^
MGT4+BB=T<N<6I'$EO+7)PGR\1O$0)069?7N<,F.36RU\A91OMGQZ5B+]]K#9
M-YBL(3=1G38/Y]S)601.JQS2H_IQOBFN[;!I\7OXI)5ZD)GQS,[O4N$YWIH?
MGRCBQ >>F51,:^LXP/]D%Y>*T9L*=/P?].;Q#[DKGTV9>@^D_C7N+H,/17G%
MRV3P.$X-4XTL#X=ZE&'EGF/T8LJPQ8;<EDY^=,*C=USI;;$ZOB0L^]FHVJC3
M::/V 1#%GD[VJ=(BY3;,XMY*U G\S0)."]E#;NUDBFC^F1XQ7.TM6F-;0+8@
M1:/YA&.<X,%I%2ML$$B\VRW>C6[.AY=-P'_<F/G.0[D3[\IQ3_LZ[Z6VLPRK
M>5WJ7(S(S7(=!Y&\=]2&M7K_"KL"<)'.<EF<$_G5 "GW++CBO.=F?S_?]R&G
MXQENE5V3E.)A>$$-I5'7*'6E.OGQ**E!UV;K-6=4O:[-&>-?GTL-EOP_A;<
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MDI,ZBG<U6> WL?J85A1\L#,!]K0ULY?)/^H4AGAS(#WZ1YQGNJY57,RMF"0
M6EL@"<P45@MP&%Z-$L.X(35B<-R9.O;\<+O3'?>U='6E2FZO^)!<7S@YE@^M
M/Z( &^*0&+)8"%.21Q^L#N1SYCR*71PX*T(V?^$H%I$.O_LK1JFK2M:<Z4TV
MX%OC99&*./85*,9/A:\%G=A9"I']*IVZ]U#G_1Q\P_[&73N!.PP#LB3:NTWZ
M"%NK3B<HT(<Q?H4_;)!$VT5=B$5ZJTGS53:XSE*8UIXTOB 7KH3JA 47D$E
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M]<-Q\=&BWP,;*M6M^6#%6)%43/D0-366J=\?'NU6-S:7D<>4(^KO?UGD\(7
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MC;\"7'^9:?%T',%DY6<N;1\9?^I2A>2_C@#26"''?VAF1$49L0#M^SJ:7K$
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MF97:OW$^(%@L5:&FW]/#F^:+(4J)(MA0>Z<W<<=*'OZOFR/\"R6E!@JE!II
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M]-9=@21,4D_G5AI"N9S.KJX"27:^FH-VW^O_BIO4/0.X'?]Q.8G3-'__X74
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MF&1!_(QA8BQQJD]*K8ZC9_S;5!G\W?D9$T9@V52AXX:V,=T,4H1B*_%Z<5/
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MS3K%==4&W[BLF*IE3)::FM_UX;)UJ=^=(NIEB43G?RGIQ?'J,X?2*C]?1P_
M3>:9I+<3<JU39':A&^R,ND??6NI_%3E]$"=T;LNDFWV_K6618CR[>\RXOH'9
MZ9>Q[AS=IW>>/)6CG[,P0]["J<B1WF?8=^,'6(5BU4H(SYLL4\UWS2VI_MU)
MHIV*KP.0\5P?UAI/H9"8@'V<(9-$M;[L\$RCR1<ZP![NIX'1UY38)Q-UVEH^
M_\X#XTO],P&[<'SI&A38 BRJ, #LJ2W(= ;QR>W(,FA<:0;\]?':[T>F'/4V
MA:4+U[+/6E77C.<XAZVNOCT@QDA\P/OXCO2M%Y0"$WAEB=6MPX2LM#Y<[>M0
MA^/O2+-\D[,L!R:F-ZY]C?^F"LNX-][(4LD)NV[QTU[A>>1'_&KM"&^7@1=I
M<X;5.S\H;%1U'RYX+2?%]_OW69\/)J_SAGE<^AY6!^.%WZX9)P[O?D@"T@F;
MW>I F%E'?)7PF_N&+0OR"2(EYR(=<Z+%^F+ R+ENX4O2J!;OG_8T0[V2S;1[
MZZK>O0])5X:5%WN\&0]<KNR \-JZ .JQ4[V_9]!GH!-HZJ."8F^*^JFA&!.5
MO3&!+%I1Z%>X/0\CYEGO9<,!*9KQ$82G4SST:^+PX5;W8U6O\MT&6?XRPSPZ
MA=]7@[N$.T9F+_\*@KU6E/?UI7,*IQWX%QV<#1=4W1P3ZY 70=[O5%XD72<E
M##%)']5?_VSA7I$!0-0-,0FK\(<0S?<(<*+]6K2N(=B6^[<]Z[ 9/X%$DYM)
MPX'BE07$' U&*L674W_RN-8TSGIY.D=UE$QA0(4]-VX7BP3L2B0<Q<=*\V\W
MP1H.JE$"ZI-GC.&+M..YHP<__UJA#E/1T:SC7QSN&Q9W]@YXG9[W"26@RE:2
MLS_? BQY<*^;N\7QX\ 5+4Y$TWMIG_!6ZVM<]Y&<C?/5A_B<XW>10#*$=DWY
M<QN; W<11K^G23.")Z]>_1?WOMUB)]NR--^YZI%1P!-,Y$H\@QG(LXT!42[4
M'/MT;=\GT5 =OI_D=M4@A>,,@4;< H!+U/:,M<H]I/>P'D@Z/1V(Q(?1UWY2
MO*/,BG7SQ4/WM+Z;X*\AH5[7GV]HYK'"U^GNAAXJ63*/(6FK3D\<P$S7:ZIB
M XZ72D^#I"/S%U05M0![FH4?X]6H_CEP\33G4NN.)F3JX'_&FB)O\MQ0#[HT
MJNM3U!G)O!^;#3Z68#'V%DE<#_0F)"<VHX/+T(V$)?9:(T]%LI&I+T92WBAI
MLK8SC[R]R&\31YG+Z?JF8[@9R-,^1/RY,;&<)CD(]HPY$\6/=QC5F.U+DFQ[
MFEZ\@4ZZ>)T56S\2_\E/Q"_KE3^EWH1',59V]A8P1S$\(FM(/3X\7UNQ]AK7
M5W;87!37 N&-U-1L#EE]D3\V:R+'.',V7RL_D.=9;NC-0A>G#/-%P\H4<X'C
M9G\2^\G44PQ87F]E..<EZ>5]%P^^MVZ75J1=YZ8]L**6Z^ #'=@I6VA;X-[V
M6T.%R[>TH$;BN-SG",-JRS$?A<;SHQ;"9XD=-R%3%L)EWR2<5=B=*WU[GP$9
M>.J:6Y#ZX4[[7((+1+Y@E4!;55"X!*[G!K5<PD3PNWN]XHC1$A2^:B.J?)$R
MM"A5-_B)9/-S*S+9F*"1OT\?R>Z9,B716:6)S<+^9ID3':=_F4SW&I60:  M
M:1C#/0I3?J$0D5@9#_Q(2<TBD'Y33\4AU(6NR;\B/KQGSZQS]*<<21?/X0RO
M'/$ 6<PY5&$<*^0"]D#)HZ7P8/ZV4M)48)U#F4437EB'[%H).].^Y%:%;V!$
MBX+52BS'VOL)&PJT,\!,7B FP_.<26=Z3\N!4L19F:S_1>T7*U8;W4AJ6M5=
ML0-EB:JUU/<Q^UL51UNEB;M+7F"*.49VR.M.B1$*B*,QV\19F?[8T2>[A#H6
M2Q!N(6G*DF.[X6?Z=\HX&9-N.(K Y58=4-D0?A?Z4F GWCF-L,78=_+;CZ<J
M1OQ:57.1]Y?7J*$UV)4,B[&+O+'P#T/6.YQN9VTC@U>(^LR1E#HIMJ4.I^5K
MS6X?,V@)QGS?RUF>IZZ+M5J3J_FK4(ME2U77<]<'_/=Z?'CV+RH,[6\!I)(O
M<A989QWS_!IJ9J=-.K=76!I=!UQYB<+-"!EFH);S!*4ZP*GC)3DO5KY^M_LU
M/9S$-0]Z778RB'YH_C#,_,;+J%]<1,A=T8!QJKA25AB6?KE=!8(_#:#N\[!$
M[ZD<'ED[(X]B51HDU%T^C[P]A[ZJK@KIHH&C4VIS%]27#P1Z:)I4<3V?:M!7
MN[:];5,KX::2"/OPF!!:Z.01[4NX%B:_^*GX,*I4];F2AE&81QJKRU=J!8N8
MQP1#5L1OZ#)%FV%-!]<F31=.=4D5OJ8+P)D7)_J1&W <KD(-RF[$%)J2QC:^
MQ&'<%*A7V_W1NN%E$&_,\>=,P^!E9[<XT, G\$=_EG?(;P&,;>81Z$MD2Q9R
M6J4QQH02E.32 %1@I%H8=HFZC!K_T-#ZJZDA-%KU4P<K52\A-6.!*JBXPTVJ
MFZ\1R/3<FN%+3)1VS_LD#56'?=@N--#8<.FO+G_#2R62N62)G3$-B<H%KDM&
M":#TT\EU3*;'\BV@6B6-(=S#:Y56;$:MO7=#QH6&SHIOX"11PH+A[+>?('*A
M"U+6.0M>0#=Z7/-H7RENQ)@Q&KRAXF[=:.80Z5[.BNFI$1WR#SCI>XRWH/44
M,.^2M*,]/\_U1/457C)9-1'_.[&*3.LDN +I_O<3)3730!*NY+39?N[KUWXM
M@DICTC@7J.W@5Z^%9M;;FL!B16F+/#"Q9U35OSJ#6AXKB_58VJ=]ZKP%=,-M
MPO5:84V36 EO)V^OPG1M]V@!SGXZ2S(.XD<_Z1Z!]A]Z?ZG*C_Y*KP#HPL71
M"4E(@QGM[I6D#[! KFX!1/6+&EX-Q@<GU5N!]RH*ZS'O<_LD^>68+V94R<J(
M_US'2^V-VN?6./VH]_WPBD,P3U7B.+]M_?DRS9;0$J7"RK638E468?J5CFVP
M6"KMD\Z4+K<E?$:U[1&UY0#^F6<K#R998C>RE1JC==[$NNZS?*HR=RTHJ>CO
M5M,JW&)(NYZ[N;]C3B$X9+[J6+1<G)=A/FT<N;@3]%C"4OU-D613Y..$;0?T
M9Q2EVI0@J-4(F*H^OM*<\M?$7"TA[]O'@L_L5*QT_IQ=3C\G_+B1"'E,&/@U
MVV3AY*&'1)E[/+^@5[&E;OO-[G7VS46I^6,_%I<50RPAN$3#\D$(J$"5KH&F
M+0V!CH8,_8KN?83S6(78;5YO/L&7@10=QDSY+2^@M2[)I.%TZB;+KA&RM;KY
M8]FWV=<WXO5K[)5RBRIW5,TW_3=[66Z;]Z7*WO>VR8RUX*U@SOSUS#EF57,^
MDS65":CLYM%&T#GV;P410E-@) RK@UWB7"[IZ<VVXT?K#4-)<Q%KH-]$N4JJ
M'"&;LX17C5#'ZSSW9O6C+]7JWC;TZ\*I:$K23;G-"_O7+">T5)*?N#,\V5)9
MWT=QB.Z_V4%D)FY$ 7T*SW=]+%&/?I /P<K3DG--36+_RH\7>^M/*KDJC]4(
MRD3X.%:+1*8H7>$:X5V,'Q8U>:@,$HQIM&\5LN)D+2.&%]E#NL"D<6 /T^>5
M6/- <7@X>]10FMZ77/_T_;%[5S"%B?M\PR"9'G''?.M)V]9CJ[%E5(ATR8N#
M$%/CPYNA^@_>S%2+P;+SQ_>8TAP2F2M!>J]W"6?.;P%/$1K<(#C+'COJP?<4
MOL6V//MZG=A^9SMM6F*[Y[4A[6QY23T^K#+6)T*^!#=3 N"F'?PLJ??9Z4CH
M=W<HH='NK$@8M^V3/1KRK9B/R1;Q&B 0'U6P1J?H]^P%"D#&\K/9VALA8 KW
M*@^- 5NZ5<$@T([8R*/.1]W4U"2WFPA6ZS_]1)5#W@KWF7QA.FP@"Z1'EJFL
MX;[7EKHX=8HP[[@6*?*3'SUSHMYCH K>>5=4T$4\GB<>4Y[>=B0FX8F==TG8
M,Q9WK"W<<^E_$7I6<:S40U^Q:7B_:E]%DN9"WV#\9I(QKC?=FN4NEEVIX/!5
M#2TY.7QNN@2:7;9.;"3F)[P()$IS#!$NR8/DFA,NS,W_&OTB8+1-P[F#$K^(
M,C1).E&O$E]V&S$R&_(B<U,KF;G[D)^-SMGN5TS.@';C"_;;F';$BV)R_G)9
M&R-\V5LI/8>A! ^98I.<V3?[=XP1/FE&BT9S%BT-N"O*R&)J+O\F_5 _KD B
M$^RGN+6.-(OJ,?@*[0RGG/T4LB[7X\)9EK;]:N':S:RM(SQVXS5$'')\<G.Q
M< NH0:3&EW&)%Y8<O7JQLW0$2TU7;D[16%T3FZB%H>?4/78=%0.=)+-,])_T
M,U%S5!+B(,BVG2S25E94\[R3CI0J'_),Z*?M^+SU-'(*VZJM?[ST=IQ3K22<
M-:QW;2?#HZ1N>C]CFW?:6-!G7H3(B>Z-;N?)YD5LG-Q!!F)0>Z1,0R$K46,&
MJVE<+)A76'->?WS5ENCM1WYANP\=K_5I=3<*8,_3="-ONCE^$R^VD4XNO]=-
MD3(^DR?*-Q_&R6M9!1!(=!NKEG3]U',3C!B]J(]VWIBH7(D-3Y2(VNS6>S(_
MJRY51O)X]UG_?<$WN84=P_/.H0V/^1;K_@BD-?J,Y6@H+[CH.^6M@V%@%J#1
M=4]XAWR!D([&;K:F*656:O6.DS>NWBW WGM-Q26;+P.OK]*A];"")-=XX!W&
MUCGX U/QB+R&,Y\BB!:(H$R!W@((MAM_V:]!!I5^]*48!C:?5_?YU(^60GBZ
M'U#-TE*_L*V)#>.5-F\BE346+;Z9K]!YNA&LH=AZ>!J5?&!S*!,J?0L(N?S"
M/+F^,&ON"VM8<++Z^S51('N@]E!2L6!VH:!\-C-?Y-V-D0+K;N50S $@(^E
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ML;T;'1)S7%59]SSF+J"5DZ2 7Z>_\DO5Y_Y A,I=3(SC4L>5,F?]E)QU,Q6
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MDNR?L(^F3@41ZN==3)93-Y/WL= HYY1L35P,=;S.C6//6%<P*78[MGCLI^E
MD8);-T;XX8%M3.C'["M-AK%7#[?^Y.Y:=:8=B3:RM+3_NS]N*Y];M'@C:S8Q
M*U<98>;%*;JO(OJL_$Y+Q7R87Z1.K,R<^*O7-S1>.55^ZYWAO4?YF!W;3Z0T
MU:Y&;W,F47MNW*:Y3K\<'&[8HWR8*!HI,8ZD3BHBL3NNWFEF#;S$&(0YKF2I
MD<T7&8;+'PE:_*<*4(@1Q[C37K94!)IO5M+6H.3^%"]7$ ]RW&PPDP>5"$+N
MG*CQ:SFDOV!EFYC)=4#DJ4>9V0C\<"8J%V (D(7/+@[XD\6VF+@'7B0^9;D\
M!M<86QO_A#?43#G4^%OZSKUH18 "-Y'IZ1219<+(M=:(0>+]M>4-(^;X52#D
MAZFITI6_S-N RD$.=G_D)MA(KZ*&$ZKB<%"UV%XD5\MV%.R; EE&B/7/,TA<
M^8!^/3'X_"^46UP9+4Z?-7Z\R1#JC)"YU3_B7PK9_2!P0Z-!]H(D]:F6G\CY
M]>GI)"LXT=L]V#>MT,>O2R/1I*HJ="I?UH:*D'='RS=?ZY_L#[Y;YMY;R*_R
M%Y":D.UV>L\V$.0X;G"8K)A1P%! @]*"O,^Z]+U9]S<[EI7VNMJV$0V7R,^
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M<3=W[9&@\LO#E.PD>+ZR;;UXC2#-40G ]E?'B">-$9#H!8S36 _48^8KRF6
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M:_48C;T][[1ZD&;]6\C.)^,4:<PH,LBB//,[K)F!@TI=$REY6)=DJ_#ZYUR
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MJGN@\VJJ0@<7WH1R1]/^^?R4T#0WQ,SEJ7I>+0D5WR\ P;3AGQ\V ;6C;MH
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MI\JUJ%;6C^E^"4],RL>225[@Z1Q5V2-^DMN6=A<A'4;I0FA#Q7,JG:ZD1RI
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M_/%9>GM,P&+*]OY4$%F%S3:_^F7H'+_ ]@+;$E=O-+.+0LHOX]"Z'1$\5MY
M1HGM$AY)*7#E+IA:H,<%+TCY*,^]]*4J"/G]IX"UBOZT2? S]AOY3!_8O_)\
MMYUE^E)<G0PB5W'#XR0]<%?[%V#:T0-7=5J_W(4_IU&/NDD"$S_X9+.S/,]R
ML5OX#V#=-_\"R""[Z0(=("#&.2O;RUSS%U>;OS:QK^[>HUT.H22T83Y)OD']
M_8QTZ0$KNH [6[SR6K:WLFF_IB[^S4@I]=@#K7S2/UM-SK8'SVX4Y0\MA4ZZ
M)4JP?%@#]7:,> %!3LD!Y9HHC)1*4+Q^+*0=SHG#\?9,W147]P6YVODLDI11
M!Y+ZK?.RU2:PP<)0Q,Q8F4TIA_ZA5[$/'B76VYR>23PHM;]+AOB.0S_;HL-,
M:2Y4<Z#?W-1X(V<\@X@6/VWLU>!CP",YNS\@EIE^Z9V]9)]##>77"WP71A!&
MI:P1Q%KND#'Q&Q(8]PDAJ-A^P/VFG[1*JF1>=TX+%'G 0HZ6BZ\)"%9.D(\S
M,.>:![MOQK[S<QQ0@BX3/8AF?6ES(O7G*XYI7\H]#E9>13TO67V4OW0E3FX\
MD&M(2/69D7W&^R<R43\RS!:.;B8(@NR;[-'R2;UT;;32C.L'1/A7/[<[4M7I
M_57T)5?&Z8D8\54FRQHGAY)V.]TIG1@JBN)"!+==@U5[%D3GJYW)JXW?6"]1
MF 1F11%;6VL;?:&RRF?N=?PM57OUN=NA:HS8_#G68LM57;G[AZO8;XCL^\'
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M<L<(D=OQD2/4KP]]#"&D4$QXO!OD*7A]'VY<#&,8*7C P?47D!;NF\7A8_M
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MF6?J6ZWC=/U(6,B3K2)2A2TS"Z6F14$Q=5!7/+CQ6/!X,EODG8%-#2?)XQX
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M67OV['GFG9EW9E__NEX&W%534E4"X-T" /!N?H#K><!S /ZM6W__-^OVS9^
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M(% =%'^B59&\4SXFLE/7]]-JH]YF[Z/XSWJ2?\3>P9C=NPP2G=L"\([KZ-:
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MCYC_R7TMPR;NO_$,D/T?*V7K0AR"FL+'=H_!<;!N"RS3-2 O./\:L#2!H^U
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ML8TTFO4\\(P'^9XA+]W;,:(75.LA3Y6!QC)5<1:H8>49[N^KSO#"D/YOA,O
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MAR\O4?%=Q9K\?J^ 32[9P\V,SI3>5)&D8B@GNN)+/K[(*&*(5[ZQJ6&_XT!
MYSB?1O&MW9$R;.?Y%#)KHXAR=8'YX$QW'%+0;@9-G.AECXLQ'D3U1^W*&.08
M;5\X=?V>-5?BC%'<)\)YE5(X;&AM10VJ/N;V["TVG2Q8-O CU[VC>']'6[+$
M4M1L6/;'PX&%4D+[@.PZ_#J=4(M[I:V),=#XF H.M*''8%S2-J'_O1LJ8SU\
MO^$?7W#V17A2@_-5;))@D.V1['95<C"GD&2L.J<*PH!N6]%>L83!X')RBU,'
MO%+XZHG&A]@M[C;-9+=7Z '[[[+J2N@D+PC=$UD]\+!FO+;C)[N'&U_ I3'V
M!D'9Q_%ZO-) +L@9RSGS^37@E"BPHT8I K9U>GD-4&-K0_28/YAH%<@UW\ZH
M6S.4"FQUM,RV[DJ@9%N[ &]HA00)80IP(\RPL%9ISSF#.+"XBVAORUN'0KM/
M7RE1%/Y>HO-*'TK'/U@L!!5]^K2!<<RGW$-3EJKZM75PEUR$%OMFJD[<V5G0
M_3D6:-UH@+-N>M0NBY5IG)Y0B>UCMIP+K>^-YKY-L]52&&2PU4R#R=CQG/BM
M<:OAP#K-\"UESN".F69ZGHEQP?3T]JB(2\.ZY&_*EYL5GGI#O^L<L:M,*[?R
M^8WU#3,7K@'IY\#R(7;70J(G2O*LH0<9Q*(HF]U5])$Y"APG<D!IWYQOGTW9
M]-'X$_]YP&.6\$>;R9^^L1\/!RX2 ]82ZC8-\I\(K2==\.MDO3G*$I]^Y"]R
M]C+HIK8-+QX[GY4[!EAF%B_\L\.^U<2UC:\?T+;EHRV=?'!6N'2@O5^X</!L
M7RMK?']8@2V+.3@E0B2WE._;#4O 960HLAOS3E1&E(?.W?AQZ>1V<DC,HYQ;
M_S]T9Y]V^U"+%.LEQX&90D!!-R>KAW:-E*FYS6E6_IF[!>LJZ^.1[QX_>::W
MLTQ])/_,%$5IZB^,.T&GD09S^Z(?7[R"=@G19KOM)*IE'2,(KHK97/"'ECMB
MO)WXH1RE3[:U>>[6V#5 &AN_'W.2*BV?SMF7=,^I*C>-!F2E)_7H"Q/P>A<_
M)(/+:SI\>,&[^?J>NAM$#', F8+*HX>,ID2B[K=_Q;CENQCQ[T]/SYDI;:E"
M1'^MOE40W]]K;NWOA]>:(U9O>LKY+K!_?\3)ZE7\52Y]$5+IDT6#Y2>Z/&OW
MYYLR0O *S^?DC^<6P8<=6')%CWVBROS4CSQW>&8()?+W=)C( OK0(6"9=_[,
MY^(O,=W%ONH&Z'N)D9XLQ%"-DAW_H%@;SA^'Y^XJIV4<6D\'SW7T41]'Z/04
MT#X)6&YT_RH=KL8A?P$3J85:_##Z8#'33,I 2(5L=QR^\"1$G6QMEYW-]J*V
M;J;P&B!P1 I_71-\\,RU6Q1-& ^RTZ+%='?"[T+%+1 8!]U)WF/(GHKH" 5I
M> PG=:DJY0\_E\QU+T>+XLJAOH[:TR(4[JP;=Q=NA/J95/$EGN#JM*RBHK/^
M_==SBQB)0<<LRQIQM@^!NI6QQ:8755F/MC0B5B1GW*6:-YGTLCUBSD._@6H/
M8N7$%^VD(,&U%6PCN@F]B)/8SZ\* RQ[*JB5B<S*?5)Y&8]U)88]KP%59L,G
MF]]^K4\FY4^"ZNL@<G?>#ZZ#YJV^WY%]MK?WZF=82>]W?U$G61?<<]G=K_@B
MSG=:&5;$>Q.CQ)9HZA#$OE+]"E1V&=0.[HL[;'8#B]_ZZ(C6]G;FOLH(7JKZ
M_K23H4-@$I^/.\K<7_G(S_R(=RWIP,G\48;";L^NU>OX< !;UFBQ1EFNZ86#
M:P$_@*M=$E6T]W.N(4I&UL/'!SE8J^&AG3!RR=Q9"=2?>/O^?<KW'C]GAE!V
M@!-AB*O#* X(U</DHEDTQV5,*"-K73#R=266\;SC-F9*/V<\2A=4=KU!"[\M
M=+*H0K.FU$D-F8>-^ /QR+M>%B:%"I1FQ:2X(F+E*+"Z-P-^]TC$A7F5:$)2
MP/*@C*K8QQW>\?I<]K3U)&O#RQ@\D&?<,E@5[7):B@9V ^_:"[AY((F<R@4,
MZ5#SIFU]93YX7A!A3\L"7OG?=/WRPWI=DYMK"?ERE8M/1)J44\>,Z+5:\;8@
M3QW@M5H]86/M[+[Y:J.M<HM,*,TRV8H?/KIJ_"ZY<1Q/XT+K[AE<O'_.UE6&
M25S]O!0B"HN>^QF?,W\GX4PE(5#736:LFVQZOGW"C9G:NX]"D)&M:+KP32EH
M9P+[[:+&E3:S\PR187%5(*/N@GK>PR84YPOIF9$*_*'SRLPVW?&TH727\&?8
M07B?JT%BVP.L&::?.PX!96ZV"0,UL*B9><]AZOIGW[S[_(681OK38!_C7<%L
M8?7MHQDGF6M Y7*@X'321Y(5'"E6/F4%?C/.4&!*3>0MY(KL.=-F3=S[V3E-
M\7\[ZR4Z@C,QH:N4B5[7 #K?GTO?FJTC^1.7-XP.,@W]H#M;K1V"^;%O;CTM
MZ]L8>>CVJE37W6VOD6V'*_>V4#]MBE+RX.>H'_ARLH3^64_9@<:82R1723'6
M\JK(&AT^Z4V9WYEC##$RT7QHMYNFT;W6[;3TOC.3-<Z";K?C7CNW XRBHA:Q
MNS-"89L&?KFR^@I][^>O97;R$E:2SO6DZ#]M ,D*3@4U^XR%J)/AKLQ-LJ30
M7FCALLM<=R^09M<SD1+CWO\BI0_<7)];)%9T/_-2>*!&92V@0/-A=[2. ?%E
M9[7K$TBTW$-,F4!4.U5GR?,OO@$Z,!I5._>O*H<F2WE]:M]OU1LP>1R*WX\T
MU;NHG6RRLCK"W_:MY/CDPQ')U*>_F1&$A#S& %?I&T^-(6%8FKPM[Z 'TZ(:
MFM9I%ZH%=?4A3/6MY:0N-M8<)$2WRM4OU3"G6C2VBT2A"J,S?8C*WW]\AA\F
M7\7=KF.@,E,.;7FCX%[$S1[#QERX&Q&HGF%\B B!W'3OS*:8!@6TP>?XABBH
M8#%?_(^Y5RXUIF5]U<H/"#D_[,F$:%)6^%=X?.>G7G]]T]&I$-#J//L7$6F.
MI6@/^9$1M[^B%\$=?<4_$J4H@5&D6KCY>3WI=')A4>=%C-$IJ8+"@]RQ+IB]
M<JP.^L,&\7K]V!L]>GA1/AV!%K;N/47YLY'Z9Y6EC'[@U*0CIOW YP_R2O5-
MQ]/&YDX7EO+ OR^'>H!,6$ID-+1"O9?9J77I:&B$[!J0O#8-CO/4(L,&H BF
M4K_DN@22E;4O'BYT,W("O=J490/+#B\<*IXLCF:^<W%9& JE8GM]QO?+ $8*
M54(+!,OHL97DV=\<0V,K*M1B<GK!4_?\Q=N\U0EVIU;YM"+R^SI,/Y2\=;T&
M--N/F$%@!F?WP+$RTH&HU=[F^.Q<YU$9/48!9#_)4K?011D9ZXS@Z@AE;..=
M$D?\(48VYZ55+4A7.P*=882;O 805N X?(/&0$B>L56QN8U4H(#0HZ%BMK*S
MT3,FNB.Y%/?ZL%?J[!G3SYB)I86RX3B$\<FC2:,89Z&E$Y#83_<M2TRO"<5Y
M2=O;:T"&+#S+^S*1KZ8CD.M4NM'//.'S1Y\[;<I:S;':U<&&>FN#1R8:"ZPP
MXC.Z;M^6[FO K_3=4F$K.6/AJXD%&(D6X8[#&_=IAH*K&'=\&BPYEI]'2M>S
M:'?-*J:(S(K /&WGH.$<@2&<A51K]7.A$IIEN"O4U^W$)YRB/S?6-4F<;+&L
MHD#&EY^)>H.4I7YR=IXCWII&L 9^$7 YC804(UH[K( )SU?$(^Y$EYKZ9> R
M&:]679US6'DNO_Y9@OLC^]^<0^H2?UR!@AM#YR=P/WJ&%A._758N\6<;>\J]
ML^@U?'_2^U(+7T:?PA?!Z1C4]("8TCAX^"4V)GA8]ZDE-7/Y1KF*7^E/^Z1A
M+OG[I=5U1N^G5+6,:ST&WS>5[D]QU,G?[S66M!Q8V&9(3E/J-?19J>P7^1S)
M9/<B^\2@H-]#Y>&P--,1P[CF$\ODXOS)/^>%%BH#S8@L_3]3FF(E4Y@2\9?U
M%;TO$_7':O1X]#.YS)5*QN)UE/OU##E<1IA*;/_$-3/@K])]AZIC*G*@W*,L
M>C/\]35K)K,OY#/6V^A@%:Y++!VV%=Q(7LHBX[ IJ,Z#%1Y:Z>1;_B*-V-,3
M1!Q49R7^)H+K^J.P!L4L+6?[UP!WJEF=@""ZF<BN[S4M8T F.-J +(\_'AA4
M,^L=!%L_RX0QM@MO7P.HLP-M>LZ LQ<$'^WX:J,&#W,8)02NSK8&MR"2&%#_
M#YE[%*E%]#&^V4K9WLOO?JB08MCJJE:UJ,5CV3,UGKV=,$+V!=EP?-$ZKM13
M&G4Z?K1VMT5:)<CF_=$NS[378[V"K8DQ>+9V1M\;'H,?:^OF[G')EX\513J.
MBXIR6[XX,&2\+"S?9Q)GK<XV:%.EF['%<;9-KZW\*,J0*>&*_UJ0X-J^424C
MN7Q^TD^MU4S*'F0Q5G#*EOHG7Z,^4?/RH?W79[&'2=]>WDR[.Q.Y)&DM_L#'
M'U>>CJ4+//'8O@R<[WC0UKMY&I35IP[A6N3L>_FQ7\9BL4.UG<(A(S%:C@YC
MHC=E\73I]Z]\E8K)A)C^W^\H5R&?LEFJX"N(!$\72I/V!\E>T2/88^CATDM/
MQ%0FBT1M"XL#(X,C?14O5>*I/@"4ZH>YB-%\#"Q&W:&H( )7R-)4-V1? P([
MA!;=E"["&D1<$ ^OW-?F>UE*^29;BDF3]V_Z[.<M&=YHQ9"U;W$Z&5%/198G
MZ=Q-)QH")N_7:"YD&#X6,K#WKU,@EQ"S(Q=RM>LL!?S6ZQXU&.S6FVHJIBO9
MGA2:X![F$S3^G#7Y@8]61^6-(JTVWG^';JM3,&8+!4S6WM142]^B;K&@IZB-
MLMQMP>C:*\UQ$^FH$;3R [HWY\PS7]+P11SW"</L.JJ#,FU0XGH8'U"4"X)?
M]#%NQ@NA%F.38<6S7I.+3#64F+&3N#D1OT]= RPKM'KU-#Q6@%'"D-_M:1=J
MG/5)Y!6M=VMX@O8?.E. FV0#P&.9_:O/'&>4I^VY%LYF+ G#[3NJZRISFGM.
M<5RM7Z<JO:3-++0Z8A88?YEVWHTV>BR1],JCR02P476B-4MQU"OH.[[:DRW7
M/.T%IY$OZN><G;B?P&-=\W&(_I?\D[&4^($%5W=WWPN)KSHIJJW:571@R- 0
M]MWY_N6I[J2,JE?9HF]L_XQ4ZF)^GGHNE5-AMQ-!*^_W[3&E@G?/^3551^KL
MS8)&Y.XWM(V?M-&LD&5HQ=Z?T%/OF$Q(HAVUI^*^J)[>G==)K]+#@!LW,BSQ
M*X!&)4LHR!H/&^M2C7?-%WMFI:8<K/*4(_25B_4T<T1-L7$_U(OQ9<0S9O'[
MVODT7Q.;*23IYJ"T&'5@)P+0B_QX8G<RW' S9@9Z!S],W4@M?-OIN]T#AIH&
MVAX!BE/MAMT'XY;YVZFZO="D$/2KR8)7=4YDMO&.' 06VC\67TNN81=X;E'.
MCFAI44+EQO9%7SE70#DWXF38 YLLH_.MH,#T"%F>F888NFZ*QP&O*@2N' DC
M,<JG7C.MW&[Y=E50M<DUE&:BQZ:QK>"L(BV">=.J=8;G2)7H)\D>2^3M23G&
MJT]U F1#A7:"4/G)^6_-BCOFOWS]I?6C)S9MC"R;]-J-4C^^+Y=DO+U,<N;Z
M+<NG@!>OUP0A7G$-(+B"_*!D23QUJM,*GPXBQ?V&#]9/,QA=O@[V$2;&+F1Z
MO!/N<TB:[K 8&GZNC!:/+&^%>7SQA9BU!9SOKHR_=LC;8T]Q^)W2_H),XC9^
M@G#,A;IOX8ZF1$S2%$CNG1\^[N?T.%0*$XD4F]X4].T[W#YT@-_W,6%*HBVM
M#'HMYG-2>A3T\ZS>A^U^^RC4K>0/<WV):!AZP42A/$FT_ %[(I-$VDV%$2,(
MD+,=$96;"[P&5( &*.'+5RGW&U%GL7PG$!K9Q885DRCNMDDGD3\5;R&/0Q\9
MT>X-]O.J<HLN*:-"&'&<ZJN4>X_)1G(KHT^?,\[1"KH(RWJ,J!T_<%-MM8XV
M+.%;.KEBEP2&+5%R8/10!TJH @9$<>^7OK&*R6*J@J&:M>!OETN%KN:\5]FB
M#@?4F!1=%#R1'PMT6+&2+Y]5?$,W\"G5VR])^NY;]RQJ(>F5MG(Q.[)WN@:6
M!>N!1FQ6J-5EL714=R]8JC(I0'RV8-S)\^-N(1-5P</WEQ=I;WLRRM!:RU9+
MB3(.R&L _1_<0S:VF=H OPJ.Y$ I:<Q+][NJ5 //E&\'HG]*;)E_+6<IY-^6
M+3]O.B@&2ML!JV5'(JT"(>KHO6,Y0>:%Z0;Z#K<WM!7-VP\3-A@B[[.)'TXF
MA*NPJ!R4>5P*+XT4VNH"V>R%??,U9BA:YZ:F2M5JU(;J\N_2SR7M+0-\=X8#
M<B3S15VH=+:7EM^A+*_2X*HUX_NUE R__[0_FA!PWG<Z";9.X5%VO2P,43%"
M3DCTL\?IMS-<I3\8D]%#'M L8?(.P&BZ!(17A3W#N,E#"^T,!PMGAK=9+Z(^
M=L4=(SQ_/Y;I7(HQ7_S2'-R#84&&F1.C;>*]!DZ(^0O0LKO@:H6Q</KU!T9=
M)3AVMZR,_<<MX=P?"=ZNK>U_"Z0-#F:BM7Y/^E_J).'GH%&?CM<8P54FS+G(
MEG#+Z#+,&-L]=OQ5P#GY5/5E#>Y00O7;TU/3!'?IF1WN^%9APC@9[G+;AB<(
M\JORM#7QM]^?@8([L3R'#:_&!7:=G3UW<M[,>'[Z%/0F9%U5[WSU3MN/NC)5
MV9$>J&*ACGZN@1U]ELOL J@?D=N[[<V38Z\[3U4]VQ% NFG+LZ U7L-E*ZKN
M-)U.S-/CP]$W.S?U"Y.N$MG?3I4FD3GX^<.'-]/B]PQ;BY#947->GZ<&/PBK
M;(!X7>^,*SE,?&8L;H*,8GZWTU8QDGS,2.4SS%1/FU\:&0.U_#B]!LS.KWX>
MZ:2,$IL[^'%Q)\=PPJ1&!YX"XBT%M1;!ORC[GP+G(I<7X!&BC#)FR%Q6'/4,
MRTCL +"EX?/Y$UEJS?RQ&LACTRZ^?<:]);)\"OCB";91]"1]-P"MU-UK?.^L
M$\$TT"!EL.9TE2(R/$#(/73[C##U#,'O- Z_:<TNH&WCPT]''O>T0(S=<:^\
MCP/8&$1K@]@GS+O6<,?D:)4KWS]!;?&NQGW9/XK<'1O?[7FQ6OH@K#&YJ ,=
M#'@UH(T"\WY@T:IBEO5EY'['ZEC;3A2:_&-K VXL1K:F^]"T-\%M!Q< SN=D
M'MU4_J9$Y_Y#_^M4:OGI[C5@,!KY^=FVF-O6F9!C2SATR"%X,A'B+BO+4X**
MC/,2 &!*1WJ8+:XR+GZ^'E>2.Y!A S6NAFZ9OW'>F':][RBU8LL*_ 'V<G+/
MV LQ4[BUH$0BQ29_HK=KGS-EY*[2A:C]-I/ %5M?4C1[#4C!CDQJ173</5Z*
MSJ;X.N/9=_5[)_H-R)^)</'YL>@X2 V[>Y41)*J*RNR+M?/CH23?3B:J-!BY
MB/R#P'C*35T 60?=2(9HRI.:(PTUG^,//&AW;V-0@K91;CE&2A9E+4\Y?:E-
M/KH&<(]:>/:"4]J,@HB+'VZ*ALANT164CAM\NF/?FJJRF62HF:JK>>(N;\!Y
M8)A@1_>04=3XN6$AZT;9 ,\+=Y62QZ75S$WLPP9>99)?]-P]%%)T9?P*C(9U
M1MZJS)7W:3R+G2O2?"QLFW87K7=_I:R/7/,S@?P8M:>H5':JF7U]3>46CF6"
M>_)$NG&WG%UW1*0(_X^L5ITZ6+0YIO5S4GE%G>H "=X0S3O"$M&CR+Z#N5R1
MT\QG*)&\@,.7>@Y4<>4VN4;"G7*(4>]AOX,^ESEN?4S(N&W&W73-T?F0X/IA
M[X[%#XG-\-T$+3KD140-15@B>9-Z["[T8(SC7N17MM2MT:Z"INVK_O7S)7HU
MC>7#-L@K6'HZ?.%W2R",+<&R;9([H$W-W2Q6T/JMGPQ\,N.H+:"'06JAVR_Q
MLG  3V[[DA)=+"JK:Z9F(V<AX=+!PP;Y1=&5^64K7:IB(&1*.#C-HBOGA*NN
MQ&#D=T1_#Q*5E.L_]7E]JCW<:-6.32)78;^?)$:X9<NL***5:4.E9N']O!:G
MTC.YV.W ':WN=L:087&N386G9X01Z;.!#.?3[65E\[9?R3$"<<HD7G)+:HNI
M! 3#PL-]UM0E A81"U?KGS8;)IQ\6GCOLG\;V-J5U7!K;F^0JWWQ!$'WZ34]
M)Z%GAZG'2*'Z&XL*W[,>^@MON!U_48GF_.OJ!B;2@[T3T1/QT*![&)[3MR:R
M#OW4B*A6UZ$-Q2_S[]"_$@]>HUOJ5S'ZX)ZKCP))NY;G^,79'%2<C'P;I^:?
M9RU.-:\^BIHQF$_(P%:LI"S?WP^45I-YN1QR.SD1R?@P>&:ZO9/PWLY:V_/3
M/VDG&7P,G;LI$ER27CQ9/)3:A)!"OX8XD+- E)CTWMZ2<LA61\CBKX;TDX<S
M*5)T17Z#1E<0XFQ+/TMZ&G*=P8,\IPZQ8^6EL+'F=K.K+)BC@U;40+- 7 8Y
M3P^10K^WG!%_S<35]!7/UO FTTZV$J7]V@=3'[DA\MC\N**]1VH[AR?<"P=*
M!_Z1/FTL;5M&.TUB=C[ZDC>M<Z2[]J^B_6+Y0O)GIA]%)8WSR&.T;_II+WL#
M4:*;-IK^L=#KP*UODR8EWU8*:@=32Q5%;V7I317S"7G9IVJ [Q08KH2D<!&*
MU/:*7(1,D#S*"P[_+]\A_D5LL%RH.ZHAJIUSN_UV=5/JR96H^LN(!S0<+.]<
M=)+,@XW2LLG&'&7D?2I-MM+>[S"H40=,1A%;ZHS2;SLXE\SGCB@:JEY:9[;4
MM7B>G]T]1F2!'!,9S'R-!2)0B*@Z 7([?WB4W%#QPA;[)RR\YOLR (][0V>N
M_3WBWE5..S,FOS\]Z/:4#/=5\EQZA!=\#\3QRH^>.'TP6;8@AQLD!R.9#HVS
M+^*KPR:$]LJQ0/6;Y=C1&YD%F!ECM%:8R!*%Z.KO[5+VCOJFH=?/F)X_G2-^
M&(<?LW\,G].\^-[7_6(4>[_<MT6[;I3/*S,VVCD_/D[HL:0W!P%&5FK2!W(+
MZK=Z0 OQS>RMP7BH=<0J-(^+7/(16!U^+F*TXT[Z]O;.'5H*(0T7K B&H<*7
MQ[BCM:6MYA._#(]=[J.P^A=C/'<\DLXT?2L'OX=JM$ :L$_KV)9J=]GN:Y%U
M+E\#2"$8N/ZTR#5@#US]2I>RVB3BEWJ-6XLKNP 4G T5N2KRNL> 3(SX,LGK
M['4-H,*D&$T;_ES$[4MK/6%Q2"-XF(0A*QW(]<\.Y %WP@#M]['<\.[F_@C^
MVGO*1I%J4G)%-B4B5?,#(8;)DDE3ZLYF/73?[I0*[*ZNQ@I$9'!%^[D@@8Q#
M;(7%2_89U@C\PM8#-V%5UM'OM*V:P57OGKK[K7S^NK-@:']ULG,-P/]J'TB^
M3,DXM HC-;9O8);=#_5Z;)FNU0Y0)RVC8T_J9+5\NAQS_ORT ].V>HR)RV#H
M#CBME:.>@#6<Y#*-9&5&W'?$GW)W.T'D!N%AI:>#Z+&2]:,GL<AB\X(CS:1>
MCE:QI!9G==^%PQ]1$K>/S$4+@KK]87&M.JM &JQ&"UQ[^F1HTS<BL5B#S&UN
ME9C%PGDU(2>$YPE%O%3UA\58YP;<>^'/5\5!$B-E&)[EB*8\W^^;G1>4,0):
MIVDE;[L%7UC$5<D F]7=3+E2T!V]]>)P>D\8&5:E Q.-=!+HHK'7QB3;>HO&
M;R>FTJ'PN&4%EZXR]H]!O_)[Z^GE\%%7IV7YVT$,*'B,]>1>;J.0]&#18.TY
M;R$1/Y&S<!Q;*WBT@P9',><;N[P4VPI$FO!)R\.-JS(6F!Y0]50++0OO,1U7
MPAT4,N(X$%A0X2E=8KBG0'S[_<3NQ;LM*' ?D-IWJ/^L>IZE@T3+:D,Q@F/X
M]AZC =,F5YM//XB^U:$0,[)Z3+4#%H/_RF:N::EN4!";T[P&0(MVS.#1'9:!
MEKX,R*FE<"\6<IH5F[#[$52E2DSL+8J,O@5/Q.EDHVD/:'%#.#ZT7 ?:QC!%
M>QR9V>=/5PDG>U/0(US$;[1WV;2U6&GP]3#U>.<<T?4M1;D&-]*\=PV(;B?!
M<(.G^+./=-K&G3:R_>2.$[3I+3 SH$L#S&4/D#R(PG[N(.+UD9=$83#=$-XZ
MCPJ>LS_*#3/#@@KH! )QP%F,5G=SZEGP)BH[^?V<II/NVH)L,Z#(CL-YA<#?
MIQ\1";X&T,G1[@0Q3SB_J9OD#Y&A7L!?/U &:_]:PZ^]I>@J2@36J%T-^EPI
M_'X29%MA.+WO)*Z&$L5UE&S1N_W>&9LW4RI[_<J'J)OM86!.%LGQ-8 ,^FP"
M:K8L[4*W9;4OLA/[W(?YZ]PO$E6]/^Y$" :M"!!=JV#ISEQ'I%8$\U%OVAC,
M86YI")1NX9[T$3O !!:Z;^[]E36A;AM(T<Y$&;E$M(N]3[<TMQDRN!R0;I:G
MRGIO.*'; ]B5JJB>ZGX.Z\1ZX_]LY;PT0413AM:Q( CL_;7"6_5\,\P2:D3^
M+)LUO8X:2U"HX0 L3@[!YUE>A!IG&(R;83GHSB<RS2X]V3_AGUM-+TG_>',H
M'B31*ZYUE>VU PD#$6.YSJ8U I$"=W]MGU7'+YI6*1P*E[(&KK!:R$4TQHN?
M*DS+2!>W)UGD^K(=*>+& QI;54M>B5QDN<I\><ZBI)_?.*B]WOQZ-6:!5[C%
M'V9R#8"XVOL?X<8NW+'"4ZVVG@'P:KN+EBT^9TZSGT./$GTE^B@\8HY8!.8R
M(:BT$K2R/IHK5"XWUS9CJA[^YE[YX :ER(/R-VZ#YZ$V2[0.H)K^GG[4=--R
M//]E=V@7>&YLFJ,]ZX< P,Y0*2R'Y1GC-T<<'2@&9.W"N.V?'L?G)"#BD;>3
M\1->R=DS_&"$]KU,D*6BPGLPD:M'MA^==L(]R*<*& \"<[]D?KNCEC!:9$%
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MIC&]QP-(AQ"@@3+0\JF;*&S)KZ=Q=K.&E"?)OK1\>M@-[23!X*.6CJ/LW-Y
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M4;$_)W:S@#V>9+0&M0 S*WF]8>"9 16M]2/@U(8I$WK7SL4#^6^[9WXYTJO
M,_,.<' HT%?B.ER7_6L#?2)*G;1_48O6*UFY3=H8>.&DVAC[>:\+>Z3N%"Y\
M)>LY6'1@*Y'\:#:B7ZADS=0!1781B!3JM?LPJ3R-D;&Q+%ONL@K"8?[U?6V%
MWDT!SM+FL49YJ+3.'>%/B3:I #>$%PVNF^B>#.W-RSJ>,*F$GN"ZGX_5:UMK
MIWA-3%[?L_H)L.(1?ZN/7ASQ_,R:X1ZI@5#,N[2M8[J^ HNO&48VNL(]IW )
MB,M 0!WE-RP]9+J%JW,=(@'2:([_H_\];3;$\4AN"1>!\&'_X?Q+@M[>&B]J
M&T.PD4VSSAUF)R[U$\Q25&AJ_]YXX*G>?+\JB"2 ?;W-_$8%(X+DCJ;IS81'
M'AX*Z,^]L&ZHY6QV:/WW_J7RIMMY8=D?S2V%16)M1O*LBT,P(T;AMH%2"GV4
M0S !<XVV(U9KH#1,*_"M$9-W:NHGT;BLCJ'+FF;M55O@[@>3NLK.3._WS-N%
M=##43WRN:;;Y./BJYCW5UT^MY5N2EZ.NMZJ-W )U=P >XQMU+J]C6=' 01@C
M"O=0!PGO:0DK,2OWK)F>OE1NO:'8?,QC;0%'/7,L:'6M'*/Q_\OC*0>?1@&+
M"H;7XM%RQ=-9[V)FG$,UA\8#NZ4#1S^5(OQP?/QYV9R.31\@C2YZD/']8$*T
M_]'1"2>-[K1]S@2A1./[YU7R*IL/6AT$]C(I^_P(^I8Y9GS%BFW9/"IV?CRY
M;?N$76UBEI+@ZRX2U2J>3YHEJGRE8<J&>G01$=U]/^]H=27.43DP_RV92EH+
MMCLEP20B>8*#E*QB/O] @B^RD&-]V?2]@I?>4&AGI)N13"K47)>4OVE8-DZ6
M*DR$:E0K3RL]9_[!89XU!]SP5"Q@GKO+PY0U_$.TB5QKYNJ\G%#:LO0(D7@U
MEV#:V,M1&<L;!0RP8_K M<E7X='BLC&-_/>"IVW(?M]\]/RK!$>\?R5S*G[I
MEP_VQ-BHQ>.(")_V!><::^V_?PLODB(<:>3I?>;!!V#*,'^P2)1A7T)W[OH,
MW_#_3(A7R,B0%@4X/8ZC)ZA;B:8G%I"@U+BB&;*Q.P+0_$R58N^Z X!L,4'(
MY3Q@;!%GW6N";-$C2QN^OB&FUS.':;_XBDS=;X?O #LLG4*NL&^<&V-S_MPO
M=])NSF]9=1!MZ 07-WLN&L;%J//WJ7[9(MXP!+J#=4@7A,<V&?NO<B53;Q)E
M%0F9GVHH;/!H&#%/>'^J0+\WZS=]N1U?S%$V"3-'$7WOD7SN=/+[V^WT.;;^
MWR"#T9 S@9'B^Z[S5QNGN->Z'>'E2@7+.*R.4@T:M^@;^E*8*0588 N!]>U;
MU2HL4/,\Q,I)P6Q4H#8=7WA*#;? M/K$BI>PV8*-D!=Z?+X\*!&C6&)MHK0/
MJYCJWUU'H;48[JQXW[CU-F>#-#:SCM!&:?909U'2V1FV]7;.,PBZGN/#N.R?
MEW5^YH[.+_V(&=+8@\KH]X]%T1[".4:1T4;NF VL7+G_> "!UBIK=-5915W:
M1@]U#W_FUQ$"I^47#L?<CQ8_S?QI:'PX826WM-GY.*?0*OB<XIICU<1<_K8>
M" ![ZO5QOO)_-TDJK1:?P8+_48_M8.DIW<9$)[!-;TU%J]N?"=$F I6<GJ_*
M9HN2E".,BY&0VL_U/F74U:RS:@$N\ V5FA6=+](C*R";N0[<^]4%#AS*WU[,
M\;[O)8)74RQ;4S=>M*>/!3J]G&//P=X!I$UUBE9>SC)FO5^]B=JM=-B<Y'Y^
MQ/W#NB\"%.LS4R0+X^B47D6AU2 TW)%?O7-[QB(]5@#^;XS0<5.F <2FI'85
M!G%A#/Z74PJ_@1D4UP9%MM/>V'1(F<T,GH>9V_/1QZBLBH)G01PGARH=198)
MCR]J6:7_:%\(W$-+]>4 FR]9.1RY;=+,7;!4[??\2/<.H+E=^?B:;FHXOC=@
M>);>J0LC/<Q]T&;<B'98J;Z(ANHYZ<ZZ_I$ZS@R2@9'?5N<70'5=*ZKJ":":
M(IM11*F/H&#7\F-:G3]>'PLU\RTJ8KZ79K!/\EB7#BJS1=4-*G.,ZAQ)1^+,
MX^$7)N5),E5_!4BXZ+C=>J@B!^*!)>7+,F:63X='^0# 8,2-WB#XA;_$'HAT
M&D++/UR UG_%\V?P&+<B=TWM F*H760PSQJ:^6_6.#^]KNK<1\;^#E"U[83R
MN(BW+FKYBR$5I=+C6=Q'/V&0P)?*@6)7I,#<MH9]NBCYQS5USM56"0V[1RO-
MBU[7U1CV8MCZXWE.: &=8<Q3."!>]^+BV/APZF],^^A(T>(J)2B_]/ ,9LA.
MSFA]O(AQH(GMWW9+_:I4I]=+47,'"-Z^97.CE2EY: 2M[B?I<V1=C/$FUCK6
M?SXJ"'6-2.0[$HY[0L6Z.!4M1K!"MESI"#\)GD2;TU7Z0?[693\?[DE;"+-J
M=8I%7V5=/YC5'GA>>>PG]EVW3ZN;^3$,&-UX?HG]8A^X1F!')- Q)3CLW.G,
M\UMZ!]<=.IR11G[C7[S.K&H>V#SO)W\T4+XG6F@HR^7P-.T,=@1-0;W$YAKV
M_ZT#D?BJHYZ)^J?;"6PMEGRU>8ZI#IZA"YZ*=1URS*_LA&D-%X3#OB,TD]O/
M[AF<XCKUW,[YN(^2P\:!K*85D%;*.^)#"0<7^9$AAR_<_W;0[I*@C]</>H2[
MB"WSS"^3&G6>M=_X=F94!<LB2X)!%J.<W.=.N)'^;Q0S@D9(!FWE]]0<+N.!
MJ1O^PJB.6A2E@1^D;P;&*/A1<,>1(J E&L-QG;EFC$XOCFZ^Y!(&OBK,MBZ;
MWB6<.$WWV+K,ENMWB/4^[K\)K8D2&,?P6,\V3)H!9%[2$FP\E'N$?=A\!!D6
MH"<QVI7_](O.;]AOURA)K4QB+PT*4W#!QMM3,)@*PI; J&L]D #"?<AKA17U
M/"#CT$1\_+ZMK89U/;,F:OLV"A?\0%4Y\FERG(S&BT,6*7$F8XI#[5/+7W@6
M:'.74\[I%6$NKI<.@U=R3O M#79'R9?T?YJVQ'(JV=Y"WB3V5><\8,I*DU"X
M'F</?Z"V/#8<I^H7:E!=VS3%%0I-D?6*!Q_!$#,E& &T2< ZI[\$GV0M=G'&
M\]3>^//\"%U1O%3\R$0,5_./FB.;41%M[3*9(0=K*-8OO2QT3>7YQ4!_OI_H
MNI^1NF7<\LMT%Y#X6UJO8W#!'>!Q!VU\6,Z#ZLGB3]=9VX<>)P^FOV#I\^-
M^%UH$22Q'%HO]L,Z^+"3;*@I72O#,UI"EP)+>HR8*0]Z[[>?66_OFD<?2E]D
M044S;%RM_T.T]K!.ST*5/HY-6INFS$./.;[V'RMAIJ-MY:M_.72I4<J_J%/H
M; $()"*JV<PPA[JB0JM7W608,#E53F'K*<"2SJJEIJ5^C^\V+S+>"S!D!AH6
M:MUS/KYW9L2KR7Z%?%:M1,U']Y3_A'?<3 68IZ595OHEPO!M?D+/_^\H#[$
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MD/6L2E\;Z\XE\N5K[6B?R&MK0L ^P 7SRI8D1KLC_3>E%I-(?=[F0[U=HC7
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MY<N>$ PE=,,8N-P$CNZD$3B.I=S].CY8[&E+AHW,[UKP"!S? DW^/#2>B<:
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M#3)C^9M_3\H%A?/BV 5M\VG(&\E[SJ9MS<R41VL^W %2WWSF29"4P"M53MT
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MUMG4DRZ<3P[MI2C657K<:'(#_V3$M>AO@X=;:XK9+UZ#]EOC$QOL< L&05P
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MN'?.[\DB#'%<Z'9*3$.\#Y%FZ 47M=10SM/Q'ZO>C;!BK5VS;\HV@@>'BHS
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M'"0*_X8MAT:<O,#;M!==Z@@%VKTMW<H6C.D.8&,29F/N?_"(>56V)SBU+L"
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MP(KM.&B7 =?]SXP3_SNT&/_?_'2#(GWYULW2J>Q7@$'^_T6F@'9>+>-M\ZX
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MDOH2D\PUY,PEF=Z&8D5T.BQ/37PW;3APS=X7KR[?_C\^E%-3]NA_Z""L_ K
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MR2 :C*\0)B]E/*J5L:[.!^M3)\L/%ZW-<A- [!N? J=LNN0;BR^5SE@%<EY
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M)7< 'X@H)^R;?1N'P:6&'K5SB26]=4NX[WH'3<?M7<\4QK(C]':NZ6NFY5H
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M"*!SH@7O9\P1P"(C$?_G>_5^1SGTL\;,-2HHW=#]M(CL7O:S#'5,%$Q%:H?
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M/3AC3$"?8WUN=9RT\CND_M'=UN @W9(/#CZGK05GF=B1*%4"'7 FY$63XZQ
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M_()2R_,P4=N("Z9->\O+O%8%[7T=^8V61U< 1R_:]4FF)5'IUD1\>L:4#T=
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MG/ _=XB!(A#[YXG\SX:28*Y_0!_R9E;U]]30T5> H6=_]"];Q_]3@Q(K4+1
MRTV<_C+D"O C#;6$9WI"'+AQ_6XH,>!_,OY70QOW/\^<)A0Y _ R+-W <\%@
M6L+UT2L M2H:UM"K3-1ZS14!I(#<!J[KH \(%%__Q:<$I1%.-#Y)O*>$@#*
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MWC>;:FW5Z/NZY/HU9>*FY8V_C7:.]ZSS1,KLX@.\7[NSKRL6,Y?V;V&K%K6
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MM@UD'6 AQ8X4A]#$:,1!/6FCSM-RXYS&LLS0S>#ZGZ*3A#ZR]'XK1P+Z366
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M_/,0.ZPFXAK 9CDOD"531I91:?1XCYL,"%Y3$AZY!GB<&^*$P;-\D(J4Q&O
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MIO%#=XD5M^1XPJ2N ?,Y"-+$$"Z<U:431K^^8''.B7WRSUNQK_U#X>Y,T8O
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M)F+X?I"P:N8* 6P5[:JA]['\.+E+3?36?B0FO><FX(<BBJJ5^MS]_7JM6QP
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M.?6V\31_Y;WIY?A=ZP6E[;L&=VH/?,+36.[J<SEZW?7]]J"0&R@<':Y R_.
MP3IHHD5HV;EWE :SU.<3GH.4I 7N,BVJ[OYR]7;,L^8.=A^]!1B'[UE5A9-6
M/4DQGMH;TIR9,?/E:V:Z!;0OQOUFS7RKYJ^W&JOMXNNN."+)S ?6N,Z[LBL
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MW)-@UH+1<OL&'8312R&V2A]?J\;3/+XW\\.NJ&&'-UG/- 7KLAO<@$M'GF;
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MUJ9S*/_B@FJ#[PV,U'<J((XYCB!Y4!4S?D<D" X\]A[.YV36RRG7NR?L9.S
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M?.O$6L58> C#BI?[BH$U?9O?\:Y:K:5<,E7HQ/8?<T[EB2(=E!H=SF\Z_][
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ME)N;/.'> GH]3Q5NS& $0+:Y"%B,7PTH7]F=V\UZJ-HA>5*DJUHZ%_4<<@6
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ML6;Y].ZG<.VC<J_!RMGUU>UO,-ZZM(4VYOSVE7A"#8.A\Z]$=2Y-7C. G?I
MQO'9F/8'^%IA0S].@>W>T4V=20%5Q^:/#BV(N,2VOR^!NP<?%\SD[R>XZ[-K
ME506C?A3W1:T^>5XR1.,Z!$Q&AF3X"][)9UKC+)D:"&1,7SSM-U@ERZZ>NZ+
M ^WU--Y0+?-E^RL/:-AJ1OXUU_FQ=W+#\*-10P8]EK?8GUNK*'O ?7X$V3>L
M*.=@.+HNB] A2>9+D+'OSY^/7_1Q'L4)XS&4\3'!/@"I[UXAD-D3Y:=9F/=U
MVH5&RB>R7SZ+*M%8+(H-#0)HXB?+%BV68$/3B6JENU[0B #'!_B"._JL3IY6
M$'%]66NW[YBV=I"9.#WK8%H]B6W&:\:9F_:GG$GKI7LU<::5J=E9$X3J)_;T
MCBU;EUXH?W7W L._6>0@R5LX./7T8W#.*)))^F/*-B:7FJ2*;'K!J*\(_AX(
M>O$>A ,DU)1_6YT;6)HW#@#<<.+'%S$ED*74BZI"/M5'_#]BSJ3_G&GQZ!T9
MW3&[9(]\CJ56':CX@E3^F(W@!:B@N)%47O5!X@E/-/RG :,_]*;9+VH>OODY
M^(XI'<"O) KPF2@VZAGJACVZS;\'?*'']Q]+.MY!3IFA(PLM)S[_]-^6HG.5
M7CUJ/*)71D/A/><WZH3#?DB2D/@!Z=+L'O :WTE%K;M-H+L=K4@FWI=,A6V;
MS?VKX*4+??XA%S?)$,.BE.$AQDS#%"A3_/3<^&I-LVZ],IQGV7!SKL]X^=O2
MS6?,^AHB^NZUGWZ?>/PRX=W:$'_2^=Z_\"GTG@G6=K.,$1NL\@>CJFN?(9VV
MD]H^6VY$U7])+,1* $8QF66M@$3*[42&N8H;9C3)S1L$X8VSOY"IL4+\ =R'
M>33,RC@FGL;F'A#Z+=T'OT(FM.)Q)/)6X]]%2_M=":%1Q5PXU?ZOO(S#!3IR
M*+4BUCO)0ZZ%'9,7O4U_E"I(JTV*DC*?X+A-8\^1"<7_JLR-M?.UE2>L*=)A
MV'A^U.>GL!Y0Y35YCE#J[)B65"I<PK2#>)G:^619XKX%3"_6;/YP9;\>^%8%
M:88]1<]""][G>%D93GXQ5E95X\R12FD1"+9WHA+Z_!?[T1\LQFF7[CX.T2Q@
M?A[PN][T+0W&(O<?HGZL^Y;1>+8^K35:?C[2D)RH.DU,P^*;F:O)YXVS$5_G
M;QTOO<#(D;"&\=/Y@S2 U##1E+*?2B;P&'&N>EO@%& 70"MXH7PA338CW%>Z
MR';YDZ25/Z"N>6?)G^SJ'H!LUU9!>X9:E/^[B'44MSGE%&J?QN$7C_WY_FP[
MUIPV=>!YB/]PRK5(J2D)D,@L[2+U(NH>L'_7YI%_-R:S7)EV+3.M>9LIM;?5
MGB?%6\&8<C?&B/$J]5FNZ!7GODF*36I1\:8BPV9JTH;.MO+NHY?H>[6$T[^^
MY9?8GDQW-"S\"YSS8%=^"O]WLXIFC3HSEB$:R7/$&_+,J$QAC?S2;TM#D^F?
M..O_QU\LZ_<]X,4V:K:6:T*V',II,R&1UV*FS7!,\$AATUSWQAWSW@TM@;P]
M3RZ,5!1*MHDC2/OU389]4V2=,W9)?Q#Q+,#6F>9&H!%U6/LLV7"ZP#9IU_B#
M-;DVXZ,4JVD0O=<I!_ (U=3&(T' \:+.I,7[U*[+NEGN4[A2:66>TX4C' 1:
M@7?J^:6LT:JHHS)#BX$^;<,.A0[C4B-_1[T,IJWO6+/I\O77U7NSR'?-J3MX
M'7UZ0, 1IVM0F]K\\SS::A9?7 U<O]?77^[F7F N5!LP?CDF'V8URITKE^$9
M0Q[NV:0O1-SUAD1W_8(A.:M^\D2L_>*TFTM!U,; P8(D$SO'QSCI)%\F$E8+
M0GZ4J:_Y^@1T2^=1A'O (Q:H,U]CE$J\OJHPP2MCP4!G]UE]L+"^O$Y=.G9P
M_.;@Z"06( @8>2U8*)(@QQKWX_&O?D]V*?[YKE%BSH6#.R&_VK5A%<8='YD?
M<SHM;8R?JIYQ[0]Q## U#8M=A@ATC2FG^',82J<4.0CL\2_9"Z\0W(WYO0UY
MFX:H:RO M\*->4_H%O-6GG-*MVS "W$30\#B]?T]QY-A60[O;,'WZQ9;V/TZ
M5ELW[#8-J8\]4I^^=@=%Q>7HZ9TR7,#RBS!Y.7UK[)65$)W4*/W&^+'</XQN
MMT%0)RLH W3Y@%E^9J?QZU:Q%UYO\!%$Y1[P5+ICA6NJ#B0^9Q*I9P!7G+P;
M%&ULX&_"O2C?XE]6HRC6##XK#3<=."'6\?(L0IH:RX>J)!WV>\WI1([6/A+F
MYM^  0BW&="&PT )!8F*MOVDFT]Z+&]X7$[0QW="1^3T+QAGW$'/EKUF5F?I
MY9NJ8PZ]"[B+3.KZ%CIW?KDSR\(^K=7C]493:T!UIHXD-6F, I*"CG2F#FWK
M.UM:R"-?U@;C:QV*X1\LL(T^C( WLY]MS0K%]< ?:.:A8+.5:Q4_ O>'*J-1
MB$>TXC:8QBKG0%="?[SC!28ZGV"@-JOWV8[/IQ:_*# %^=2(@Q^IPE.%MX.E
M>I^LOQ,&EMDU&EV>_\MI21[V]+K(B!H.DO=B\JQ,%;+3K&>#]];%EB!E*('2
MC^>XSZ+QM)HFZZD]B6C[:A,L]OT4JM<ZY0-LZ3%LY/'K%S4H1*_#ZW&(+..3
M[%E1%8F>!?,[;[$S&?9SV%^X";I1(BF/]'M1N%[<7',%1TW^(111M9KY9,..
M\:>"I519=X<8Q!@MTB,3WD$'?.[L@1QLXRW?H[B"1.ENQRWH)N,0\R4.5!I+
MX4* UQS^RT9%OZN+,.K]8SS52%P+&HIRE26'X7\D^E$![L<2/OK_,NX!P6T4
M:%5)F365"@DU-)/GA I+LC^B39-FI^%=&S)Q+JB($?8*%E,6FD1<4%HVH#T3
MK>Y,[[*0CA<DS>OUO?\>0"C]>JS,V'"GY>Z;]3[KY(;5\Q.NNPE2-B=9-HLL
M%S,@4@9*QS7KGO5XQR=]HB>@"+A"2Z'?X*0T#>+ELON5GW+WQO+5 !Y4^4KB
M=R=!&_-J (&I%[CGCKYVTEWBOZ#JFD ^P\8HX34E5L:8-N+'G#*R&,957L)%
M6><"+VVUZB#:#U)&@N'4FZW1^ J\3,>E?P'7>:P1?X38F6X1'Y;%H[G5228"
M@"240/*&\S+D[0MN*^-KFA8![V/*-Q%KAHR:,J[#F^=GI=(\M_EM%FOW #R#
MD;S%A7^<1(7)Q8[@YW_Z_8YW$5;VJ_L:EU_4#A4AGC#7R',O#- Y#VCTT1]_
M,EYUUH;4?+'\"\[A4X9M3WV<N$<_L5C*$3=/,-XE0WGM<]]/AXSE&U0DL*L3
MC+MBF!2[] "!JV^7,UU]4Z?@XUHM4$U?<9BG%<0.4UL)$4<C0@5;"8B$W%7?
M-Y@Z^OR UKQZU= ?^IE%:B"O"J[^"L:)\;Z6QZ#KC)T/C*4XM2.&>UJ2(X2H
M._EF';@/#FW"+:'8]JZZ\NJ 1\!_ZB\A0BA8M$<[K_Y<'0&WL?9DUM_JUN9/
M;=SI&U9! J/4C)(SZB00!I3YCTJG0_< HGD#$],>H;K]B%&F"/T3YJ@0)A#X
M%6>4W61-L+)F<+H'=9'6=28IR8'^NC &)%TK$RJX2 MBD0^:1-HM>V,;7V[T
MX6\>YP7M?UC?*@+> ^J=(QGGXN84Q@6U'02M_HC$*YJ:[(#\W1J#LAE92P9A
MIO> $!>,I3NENSGF_6E.@>S7.<U%7'\FSKIJT")TN/]IORA9H3^A%VWE"S<D
M2/)/ED=#(_V_+<3<G5<\_?ALYA01^/"I=MD2'$41-A;5]AQYX)U-?E3J,&Y6
MQ^'Z;/!;!-0B]1^NW0Z5:6%PP<,CZE=C:&#8VW!^CKZ=S]-X5'P.L*SP_J&/
M#?:A=1"L9QYHI[PHOJ#B=W"4(+*E;M%R.L^W&.$F%ZQJ+5Y62F4C(&B)GD[0
M_$SA05W"5O3Y96,]RY$C.['$)!;89;)-XCSSMJ2.?@'1@Z1D*5I;[)7Y/(GM
MKS42HXNWM5S262]R(%/@/[I"II4K)=L'_B>?4;A]#W@S]"_PSNZ;>5PF/SJD
M>GV,U)&.80ZV.5WO>TE8N_3)54D*<*HY3CQSL'GIVROCH(V\&1,@#=>\L&@&
MK_'V!CR[T4;;(,+:5(N'2G;!>$D_D6_,!B,G=-R[*JW3;QV>#HV0G5='!&W&
MA*&=_3Y$L)4"<J.T,X6A.&5LC(RNL;&[[,))J\()'D5,7XXYV+CV/4N+AUCA
M!<U3AU^*["LK-AMBU6:5?N9H_WM_I,#_B&;U^Y*;UH ;DS;!CU2=)NUF6_G7
MW6>#6SD#K/#T-Z!210Y*:^O/] 543PQ9D^QLDQQH:IV9T^/,KP<0*PDF2NF7
M-=;;K-YC4KX7Q6'=N7%1OH3:0VOU-^SK1%9=\-O,QNQ=TIW4BK2CD,/'/;#&
M)JD^JPG9B+C:>6$9]4X[7@R[3&B;K@,P[T:-#^-K1"DW^_K#ET/1/897?,*^
MQVWGL'K!:-N!7BH(Q97N04=1T:B(@H<=QS IU%;K/6R[4_*0AG3'E#ZH@]FK
M%EF_T(R"A0NID_R5I[Z6/EC3NP=XO^^^D8-4\C(4:39K0&"-LEYZ0+>+;3&I
M8BX%QQN/B8#57!F:4Z ],N"%X>[[Q]CF#F@)^C(V+4>0^AV^&'I,ZUNNJJ_:
MU/$3A$-A/S6*BYC("[%[QW'><M<AO[+"NG=P<$H%RF_4C^]S<'AQ%+<&?M[_
MO9G+ZU&'[&WNP[7]B3 N((\"#)WB PA]>FFX/E3UK<5Z4&;VF2\OW=EER3HL
MBDX$DWF)=HXX _GS77QN:[$-]P_/R$.1#6X3!/*WO_7UXYS];?TL_[)L.&WH
MBPW'R+['BC2F:(TDPF@KK\*K3"--=_KP3U62_!H-'1E%;C%.%/Z&*WN=_FP_
M7Y!F1(V"]'7,6I#7GFH)W5-RYI]YWE^^4M.0GI4V$>+0M<M)BYFQ:WWTU/]
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M&614,Y<K^4F--6LIY'>Z780R&ZQ(<C4W0O/=4SG%6(DR_KRWFDD<^:L^6<I
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MPE1'WP2][1B@]?#%2(=NJ8N!NNV]5,SV>NC-BV,5G>;I#DH@[]=L<BJ6\GN
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MA7T1E8.(9]0\O#/'7O^.>6;_M)UGYLCYB-G@<]#K)+ DUNF95&E$5+HG;#P
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M&A1<=^.Y;;6<M+8(V=<I7CI %?S5LJ*Z8>VWH3:T,=S,522'3IT^<CTY1OD
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M>%.3LS4A>@ WP62P31V]LLMR0%"QS\3;6=GH);\OJPH>3'EWPT2,*!SFB?(
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M ZAB7+560^@"O4P:K*#ML]S,[+#XH,PER<]X3WHT%BW64T*Z"K_>Q^:'[S6
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MNG?^*D2 \/>EAGZB-9JY+9:= 0*-[V,*^L2CONJ1Y5*%78AACVHOZH/.]0Y
MOA*ZDOE I#ABI=X-<5?RVQGO_B44"0\X"IIKTSHHN\\JT#$6,L$CGU(*)9KO
M6ZH.9N$@S2&4Y,AQ:VZ9IKR@WV-/1^;H@N'G%2.P>6MS4% &UQ[M@W5C[1,M
MMQ8WN@-O;-'7.YG3KZ!62C(!40NLOXJHEN/#':4B%WTM%P):PQG06+(YC8\R
MBF_&4S0;8EZCS2>>A'?1_M <\>)&]K^BO9I;%-!1Z?HF/8CG _?,&R$O<J_*
M$TK". I3Q%:"H0Q'&M7QTG,F?:WF'7,%KRULO5H.WSH%SH$^0UB US3HU/IS
M43/NT0P2M1G'-/W.3##C)J9QR;G:LB2Y5AD*9@ZM'O\[5-K[X136QFRA6B_Z
M8<XT<M6WU^Z>:.1V>_/"*4X+O-GAEYT"'@VV3@4R\66L,41.[/_J':0\(9Z-
M*[Q9$8W/\;3YCQG=:IO' @*VKC6KV<C_E#BX(PJ_S<[9^BK+PWAG*RQ6RMFL
M2\0+^3IG;+5BU=X:1EMP]6%QT_L7WA<+(+\.P)5G@.\G(W T3K4!36@Y* %Z
MZQ9H$*L )>\;5A4[HLE9N5#AL-M,!F),X2?=[X _CV-XU*>Z3W\.JE#I&+!J
MG@&2@>T(*]28?5-**=IOL6;0SJQ^>.F)TRD%'8M7EPO722"E#MA?'3AG'\**
MT9JFP04]V("39+;.?F'E$=A62EX(&U><U#H:;IVZAZ7(FZNW6-<><B9+TM*J
MAO4;&76:1Z"KP5WEGCC>H,RQ9"[Y<22>Y,&0P1\KWKQX72Q=6PK3-"ZCY3#%
M>L#.@(S1@;;.;*N=?B,5L;\>FAYTDOM$9"[MLGF8VOXK>1KM=^=W+IXOA"7V
M:3X*+T:8LHX_PS/6^#9ZB]9$FER:^$$(A:O/9W5X>7[YN!Z6!-V_<@;0C5]N
M#GC>\ZIRF$4W!JH[M&H6M*C4,<Y/#U"\.[R[<XVAG0'I=9J$L+5G\D9'R9O!
MI*$--&ATNG'U**O,%X,"+]P=5I6CIUU<VIGKS_J,( I.3[+JA[S?3^-IL(/]
M;C820YT=^A/W)RIU#FV0%FT+/WBH(4[O@("+M)=\DP=*X)18[9^.7\KR^013
M^PMY%T_$4D/&^IO?]*ELZ%W5>'@'/[/;K(-LHAS/F86T?DGSV_^,^56$T\I9
MYY!'I_\X--A%IO)NP<J9S*O*(H'Y[I+*:2]7FD?"R.%)RG/<*H/L]A%]U:]+
M9?J6OS.6XJ_58LHXFO,F].H$VQU=EXY>)[ ]_4KS1D@"X $1$&BLARB@ZE&8
MTY@$F-<ITL'59LKN>T6)+B]/ #,IL8PDR$*G0LS#(.P3S\RVRSSVBJSF[C-E
M5O)T'.7"+V$I_0LV-S;5D,%[TV5Z)FJO$2(NBTM^S!S:;&_DKERZ-7QGJ-(/
M1.V6TYS,A\E.KZA(2PUG#-DQ_CCK0RED<5..B1.S4L(#S(#!<M[,0*!8UH,@
MG ,F>4P9KSR7!!K2OA2L9'[+4'#O:K7D\5P#V6DZ>":+<3EXLTA$P[]B!P=5
MBWJKFC_Q<K(CT^S0+-/K:&$XQS\MN$U/0<IU=>37\Q"-5 1,8-RT>>97DL,L
M)>FDHOM\UY>?;]%,=N$J3T"['EUAP>-YR$YH5]RVG655==Q6$:=+C/("#,U>
MR=MRR)&X5*L&VL K]EV)<!56GE/5Y*@0%Z>^,9FM*L/;#GAXE.(9J:$R&\<H
MU/D]_X;_I9>^>\BRKF^?O[UQFJO?0J+P))&9B>7@Y^"9E#, F1."EM#I^LGF
M&3Q^<+-35>BERCM M4+[E:0YQ @3I,^U>^8,<%O^S<5O!C!UX5LS(3!J_L<=
M^Q>)>3P3%]_B>@8H??=-YV<%8^+*?+\+/61(;BOHZ/JH/Q=I\->\+H6#26;-
M'(96,7@&1O5 (WZZL:8\(+R@.RSM?H]8G^Z$?_0]DCM"D6)1(_UXM:^X6S,*
MF7 Z_J1<Z.W8F._3[AL9YF\KIR9 6, ;:8_AP9?FP[^FR\7]3?N+1+;IQU8^
MYJ,9ZT/Q;Q\X[>A1QBPJ2NIPD5;2Y,Y;AK3HE_89W0XZ!1<MMRWCZ%\][&]_
M.4NKK;_C4+MH/]5?E'!DN&<"@'-C3/PW(D^>],'B^)]TQCZGE(QSB+Y;J5Z^
M\O"&0NJ%\%?&)B<24U!7!)G3PC LJS)Y_&'K,F>;5<"$Q#&$]$09+X]%!<"-
MS+)Q:HL^]&7+#556/2 ,TPUU#X#@T3!E<5Y@BY3,L,<:/FQE2<*PE-=?5',Q
M6//0-'I_I^<8%-2,$<MS+<2)RP\(S#TTGAA3Y.U-_@E)01?:01*XJRKI>HZ#
MG&EU'Q1^<4:B4W! L7! ,0Z:?ZGU1^1Q;\J@ UDNG@(A;)(Z"=Q=)ESOSG]\
M0.D?K])!CDY N*U.W-5]QOHS @=!1DVO#VPN'UU'-GD[)9HO%:UX, ]_%/7D
MXV]CXYM<2*>/2'I&K0[:O9GJ67PQ+Y?WS053M^\,G+7!X0*SV_Y9E3H0K%@I
MQ6@@FU]HPH-.5X@PT'<T8W0-NM<9M5AB4/J>_>WZ/.*C#*,H)86;AG%M0%.H
MC=/H1A'[/6"O#XLRFZ4SA".ERF''!]CIN/H]HY[9NC^+$3KYI+Y91%/>YOQ9
M9H#KA<^P,,E++NSUW@/>OUADB=5$ D:QB87-].GA;66:(]L4,7#$&4";:%(W
MCO>64"KGU /Q2E4V:5"M4(N9* W"5QIE I>?AE"J=9P!DMP86D$V/%YQ*S.6
M75JQU0</Z5EG514<-^7AK_;8B ,*_GFTSLD"D&;=$U(87WA9C/RY<$ 2=:S9
M5Q4>.G7O#/!!=68X3#1TW+A?H<:<O?1+)W*MZ2M9LHUL1\)BL.4\N,6>NFL>
M' CB&EZ"[:QY)'6/LN>@@53'5(:;O"HZHI>6KTONB_BCU'PT@X)6X/"DR:8@
M[GQ CH)B F-4Z"\ZB5]"UF6Y+C55$CR- 2S^V=95M7:DW^#R.-77F;A# A4S
MJX::D'V9RKU!@?VJ(K-(^G[>/D5JBUO34,=QVN#9,X!OI+%;^%/?9\-.7;#;
M!W._KNZS<23876[L#&SK;JS8XO@&<(C_-0AZ,+6FOW'<M\JH'5/LP-[EX&G/
MM!6=I-+PV-8QTL,Y0QY7F&_-V2%;Z(?7 5M"=>WF>(M_7('G2;!SD/@FD[O7
M?8DFX]3QZVB@L/'(^OE&=]IZ;LW4,ERC*NX#5I\AGGOYT^:XSPOFU)AFDC ;
M"6_*->HIM$U\<MPR0_Q0+Z?P'\.QUQ-^<B/I>4;FE\>NW;WH^ (U:V43FL-7
M%U-!)_3YIK(S+T<7W[=/'=_$97+-]K^3R.B$G &8RE>7PG0JBQUMOGP34O@U
MQ%=6A!N)5'VY;[O'$JW3RC=&?NT>C@O!EZBEC+02VZ$I<8<M),MQ@&U#9$N^
M4<V44J0ICW@?\,148UR-,=M^8=4>?'T2/B)#J=61(BZO%2?+V,WS9G4CVAQ>
MH%NZ;6,E*YM#P2YFZP<2!X_1)_5>U@ULN/ \MP0E5;XG4T/*$+*#[P7W1^B_
MJ=>^$7)O<PC*NJ,A!,LGK7G;Y[4&$\BZ[W')C^;\OY;_<1GWB7K)/:DV")4Z
M7FIZO2!;ULWD_3(H4SA9:C@#?A\'8PT5X.>W'QU6K;PKE-88A\8L]U4[T.;U
M9*]IC[*$F;Q#QLV9^37G=YJX)GC[5T2=&.!->PK[IKKFQ,H^M3W,X_OQF?)D
M7=1F]Z #-YBKT-.%I=.]WGQ)3B(D8A\ @3EGX25[+2+;W$02W.?H!3M'7[5[
M>^PAP9$"URN;\M,81\@1CN[FB"*NGT<.."?DE1@@I=[DL[4:_GJ-KZV8\J?W
MY[#/8 KJ/_9U^@>GY7[A'\^3(UJUZL:&2G-M2@2[1#>;?QP+%MBLE*7<,)P<
M_^'\T*IL9"NCLBHQS-1%8M%C+[?.;'9^%G'3:#7K,/CMQ0;0,54T.-H3DZ^L
M.JKHW=ZA>LV8IKXNPVH56;BYT[N^\ JB.8N@'1O3 P44*=Y'!]B]IE9>\.D;
M P/0U';/=BYW7&^W!X<ZON@<>Z/-;N&0[5)1<9S3I$&/<VPYB"Q<S"K$B[M(
M)678^UN$M+,KL&X=!3++O?-^[H#6/^W'Y 3QPJUG"X'&_8G*9GGZ[:YD5SK&
MUBBN[3.#K^/I,,/!6W6R=V+0-_238R6T4]1JCM(CY/*C20O,2XKT'FH\G4/)
MHV:24LI( [+/O^ 9&">:Y_?S+8-( I_BJ4W>L]>A)FE&1R.D$MWP,%?_Q-6O
M,;7A)NP>STM!R^D12N!8#0]]G%FUS=V/M'$^N18+GQYJ#,7X]E4C&/#J&'3S
M*!^D1;^.$3(6G7P+].@-RI/^>/ )=1Z_+K!8+*9@C;O@E,2X'Z^1.;X6;S0!
M.?;JW/9?NMU9<^RK3Q/OX&(V(1Q_5'N QV6Q-H>/KNM6A*+FS)"T_87#U5H_
M0W'<I]"5(Y/.T(E/8GFFRM])JI$_ML<5YXT#L&9SUC6U X@R)W(&>"B7<C&L
MZXW2A&5TS64.&A[0R\L>U1;,PRT*:L:"@P1_[?NOS9;L;[@I[Z?=/]U C=9<
M+F4M6Z.^<86'Y,LKKD7W3O,"\]"1]><X9&M>_F-8EO6W! %*W5*O^)&8*Q#P
M@ZHW>A4_[E[7)2FC:GV!90WFQRMT1&Y4%/O]X7(@ME[!'>%8]M)KCH2JNF1D
M6S=)=GVOH_%'G@:!?F:/>*ZKN40\W@+.+UI9OXUXY_WR";4*57>=UY);F53X
MK]<IY?8R]Q]Y;[A)ZX6W>%/U[%N%K6P7I%:1@J<>05]#V\\ YC"O.L43"3?J
MU7'']IQ@'1"V6&/5^'L]=)>G>"$Q8S3%2'GWL>" IKR%C6AQT-$MPG7(G,8&
MVD?*^%,DS NB_:AK+2+/D5CAU=JI W?'"=<CD-=D'L\841E\@14),#M.CKY
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M5GO3PM]B!K.CG3-PD1-ZW0>I/4?0MH?-41,ZDCJLM+%S[E^?NWC54!1\GL\
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M>V"-,\ [58((HCF3]PRPXIUR!@#$XJT( \T(\9GFZ)2$$9&7PZN4>*DG:$+
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MT]YRM32I,J8P_"L8!YEX-QSM_9.UN,^[>\C[7D5 RUNH(B2&@6'AG>+BQG,
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MF-1O^11SE0RV2[4#D%@/@ZXAB=3Y3?OIW[0G%B"9(HU$:S@E*F?E^<@L7*3
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MU]V6IFJ0';J_33;AC*OL[=>&@D6.P,ZCY3@[3O'<BJUGVV4_#\P$G<=^)>8
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M 0R^*I!P4MMB% V^\-?+W/\9Q^W7?P!02P,$%     @ :3.#6>;*I\[_.0
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M8#[K7.?^RMGM?*.;AXX)VA%,N,U]="NHTC8G$I]24Q[X=[IG"8EO<W$&G?X
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MY[B.8K7G!2ZDT%ED6;*YZ-#/QRQU/F_K7DY-.U29\YQR=(EN(<IF[.M\8K%
MY7R'QX^ZZ0,V\IHS1N8;T)BRK7KJ#$K4XEM)L(W7,CD^.G5#=9R'1X/!==-*
M)P.IV)? 9&S;2X3GLF,67HPV5T%KH_J6?]2'OLH9<ZQU\(UBV#'6123VT3LI
MNLP'@2 ';C(@63)Y7B'_S<)_!K*GUGC%.^HEXK6?1:;<C(:&X@?I8J)?Z0:R
M$N"[2M?@Z.V9TG3'F]HE]EL5]TH;1RE8O2>W,7-!3R#MZ3WRO_E8>@F/FN1
MDQWNAA,2T#[=H#V!)8_+A728,T%O.SHN>2&9/]J>OC;:1LT3#36M\^L1$2<H
M>+^V9%M[KF>=ONP'UKM\OX=A->7  F^VE1_4YL*X*=SKB=R7*<S%=(BSA<GX
M9N\'2O=J*1\7ZCD%>=_/SK4[U295DVIQ;<"C?9F5.3&5]$^+#H\T"MZ6CQ6V
M>5Z2RS,X0FX$%)=^WVIJN6%1+._H<:T=X;@G8Y7(N&JWHSG[-1?MS2NXF5\]
MGA3VU4%FAUDQYR$H'QI:!'TRAKE[88I4C[.:WF4=8T71CAUQ@VOQK6ITWJMY
MW'7:$8S$77L=V;907M^%(1F%\QA!K:8DU6^9;7,'>%@X> A#!X5I7WXS4]ZA
M(]@86+WB/F_QIRWL$X8>:H\2VNB*(S8QF:G]\:U)+2]A[DNTD?ZCX@?/O-G6
M,((:$B!%S;]T_G +=*?>*WSKSKW+KO'&Q&"A>T2-3G2@HJ-,G /OBR0G$G1.
MWDTO75B"SM5%L8G3BV^>& 47?.7_6N_-)< :^DM.1+VWU4-<:VSD7Q(7$_6>
M3, $JH8,70S/F7YP1.C4H;S'LZKH%1U,]V@>Y[@<$0D<["P&H[:Q 'E-'-FV
M^.[Q5'9NE>J+<OPGC<%/:!4 : L9WYSN?K@Y\7@'?4'IY\4=&G\V%'5199];
MB3E7[H=$"59=,RH%Y=/[K621@.Q8\C]K)!SN(?BCBWL@&O=T_@$UI\,GY]=6
M%DJ-<KY4\5^.;,X](OA$?V3/@?>5%WYCP5Z:<:KF(36D7A/E$99_J[?4C?0U
MPTLR.04-\@^,%)LZVA?D2*L6D14ECWF'[M2X*"%N8S<'JP=9$<$(@0D@-UF4
MSF+0)Y02F%B6%_]+I?891K'Y#A*GV#+^ -KA[$7R>)?D_6MR.CW&D'VC&@V"
M=Y" I2=3]'MQ 67H-GV4%#RR5TUXZ%*#C4Q6XYN.M0+Q:Z(2&G"UZ?MJ]4)8
M1*U2"Y745EL "8=Z]:_0BUZ-JSQ6P7Q]9CS3YV2; U<TER*P!#<G&I @3OAK
M'[$J_4 HDQ?W:]E->>E(X#"3$GH#&1?AP82[<WY;O=J1^9=SKK$#QWN5#L/'
M;5\'+F8NN/%Z,JN_T9_ RDWL,M@F)<4*'99NV*B-3THV+Z8XW.RVYO]ZD-!:
M.F.;1>K'VC4E3IUH5?!]ILO9R@;7N(,81D3/H:MY!!!SO_SOO=-9A@M#4C20
MSIW.5 X^.J7.Q0;?E85:RM,Z11EOD9OHO]G$ C6@J/$3;]2GU,F>6ECW, E"
MD>> C76@(?9Q </[:%3M9,0)RW2M_PC"<:$2J=BKIR=<M;"@7J@4;]P>NJ"P
M"N#T"QUB@5T!9%KW=-MU=]AMB,BSA-7N2MN*S;/>A/A$WN.H#_UJK:K=2Z)8
M((@8.%9379G*S8-:H@-RS.T]ZXSNP[+4_;Q.8HJ8/72XY)@S(2B]G_Y<\]MM
M-8[#H3676D.G7:-H\W-5JV:>4"?)RX\/KMQP:2S*N7/'F?'"!6V9NA_.H#_R
MZD+$-;'VV[6L,,?*73TI/$9FJ9+%4&FJ+0S>9?%#IQ:IY?C<30&(XH!OF@%Q
M^^%E'E-HDS-"W*,'\,8"X1A6J'(S^IY(=[\TEP')=_]1\ 7K=*I50^B4V$=\
MXXFW_(]C?=;A94B%MH>1+4RY#C34@S9"QWE>Y'@>T57!\A#RGUWG$F@=*,^H
M<XOR4M%+U-VY.36^B><O.)RE!BH51+>"16$%5/B:)1S$)0! "G#@=6#P+YQ3
M>@*(:]7TNYM./J7.T8?EXG+W,\IK<=)9,+A]QSDNEF;T'Z$POJ!$[D=*FGO?
M&\HM_LJCJ?C"WC)A.801/X9 DGA9&L ,9S!,2-]VT)?F00HU0\),U77>,3V>
M^'R Q_UAEJ"(E?:XW%E-FAL)[H@+:^+^ON//-$(ZK5QJMB5NEX$9=5TPL6_@
MI8>[M)#;7_?! MWJ<<A%**@5!0YV/EDPVDYN@J+F9Y.2YQ'NAJR0[U;/IO:W
M;UCNF-,?,ZF>9%4@A0K*BNS$39-R!J5:Q/53ZQ-OGQKI:5?R7:C&^D[';3)?
MG[J][-RC:BK1Y<\6R;U(8W?JR6>/;%Z8DZ&_92W6SQJL?NK#G'1$2<]<R+XK
M5;0895SDO@453-[R9Y4V2/PF>7VKX4I%'HL,+;K%$.YE4%3M[GW=<,WQFJUR
MWC4K4JI)5S)R,U^]Q:!CAS+G]@7FB?)%O_F%3&<7 0YBDA;[;S)GB69J*,7E
M^@CWN.!%"E[S[J;%F >PFK>Y=54-;^F2*B Q&KC*1Z7F!' Q._'8J&5U4I'P
M%GV+HAAI$KU$C9'"8$KW"+PF!5K&$)G8ARL;NP0N2YE!/DZEV9"<0\,)#T=+
MNY&=7&72$7:$I^IY/H,7RT#Y\J%%J\^]X;[]&VARI=&?QS':VE-"!%7&Q05Q
M3]W$>[" 5$&L4+?,V7-W&*WT#=0MS%<,:"Q%;N)Z(2AZN3'AFW%]:D6,[*<O
M^G0D]9_.W/3AW+8T9K3H\94R?;TV5$Q8%&RFLZY>FJ9.A.-GI&Y6_..$SV[Q
M&62V>-NMMXVJ4=11=L5;TWSS,Z9/JN4D;;BV%61!H9#/X-M0U?(^E'FWCW_6
MNTUF9N6:>?[9?FWX-N4\S[>^Q+ [,EL]/@0=CM3DY%#>$<%S!X9+X06&Y[=F
MM5GFLOI9_<5%I"3T8]"/$:8T'6T,4&"TI6E"Q N1U-IBKSIG//]@<X8 Y98D
MNL>!&\W,A:Y>"GAC9--#UV),$",X41VG->G.7<8O87>ML>-=!YO-?A';<A@9
M]^2%ZKD"!-PY_#*%AN;4V<.*.<>_PXIMA<&+SI"-BU!#'I+>%N?1Q@@%QC&T
M$(L..%M<MQ="QT=M< ]6H&QC\S):6)7[RY(3HK&SB&T2'.E)GQ[;6HQ^@ %3
M/PP7W"5&#,O6('L2*4KY.W53'4(9J5[$O F*]1T1V$HG66D+@ZJ5#!?:-=5X
MT6A\[RM^Q!(J/$1DB"-)T3$D[E4N?7B2C[Q76Y<B*5*/>.-UTN:D7FF@*J#X
MRO2=&@L>1U[I\XQ61:K#X5BHP KX^@4;6OVS[=FK*<1):4% )WF1T1"IZY.4
M "XQ@O0O,T(S4&-D1CSRU'0L13&J5YI^NJ85=_%IQ304;.FTZYS[5DG5.U=#
M01:#!$$.9>+TK[1DJMW51B%)X.WL4^]/@A)UP U[1$ISS:N+XY4-*8X6.50?
MUJO,B'18-W70G9:T7\2_$"B;*8-%W6M2<].M#W4Y,7BN??@(Y.5&17M\Y7IR
MMWH Z7_KXO^?$+X4IS#'!IZ@I@PQ)5GGNZ(CRJLC@&#G=[/U6*1+>QY''F/0
MU7&S@@\QE<SO/2?@D0B9A&:@S^]_KS&Y#+*\Y??7_'65W7$%$JA\%IR5ASMT
M.-YLMCSXMGS]X./0_+Q+QH2F#+5*2'Q0I)V\6:3HR>\M"3OW!DGU<]T:GU+U
M .=<NW[?0L2@RYU@A.>OIZ74NVE(I3D%>=]N%68A-ER7C/>:,C?+/]K6KQ\9
M/WXP(UDMW=$"._7RZ*LU LBNSI'\KU[_8&?^/U!+ P04    " !I,X-9*0K\
M <4@  "%*P  %P   &%V=&4M,C R-# Y,S!X<S0P,C8N:G!GU7H'6%3)MNXF
M24[2Y- J(B"2!!00:)0ACY)4,JU(1B7GL$$&T49H@@(VDD%$!01!0$*+))6<
M%20GD9P;Z'!W.SK'N6_F?O>>=[Y[WMM0?%V[TEI_K5KK7]60/I+& 38]+5TM
M@((2 "B@'X T#&@ 5)24Y%_HH89^:>AH:*BI:1AH:0_0,3$P,3$R,#(RLQQD
M8V9A9V%D9.-B8^> <7)R,K%R\W#!> [".&'D22BHH#'4-/0T-/0P9D9FV/_X
M(;T!V.DH&"CSJ"B. )3L%%3L%*1&  [)24/Q[0&^/Q24D(P':.GH&1BA#N5L
M "4%%14E-159:J@U!&H'J-EI#AZ6/7N P^@J[1$/V,GP^"PZX7,E]9S&W:M'
MY6P];]$S<''S\/*)'!,5$S\NKW#JM**2LL8OFEK:.KIZ)A<O738U,[>X9F?O
MX.CD[.+E[>/KYQ\0&/%;Y.VH.W=1"8GW'R0EISS$9.?DYCW.?U+PM/1E6?FK
MBLJJUV\;&IN:6]Z]_]#3V]<_,/CQT]#$Y-3TS.S<E_FO:^L;FUO;.[C=/;)>
M%  5Q8_G+_5BA_2BI*:FHJ8EZT5!Z4?NP$Y-<UCVP,&S1K17/3B.G RG@YV+
MSRJIIQ>6,U[EM/7L9N Z*C\ALD96[9MF_SW%;OU3FOVAV#_T&@*8J"B@S:-B
M!Q  P20;)0;\3\O3G0JX75G2C>J:\I&*04[;'(Q(NFA,\Z5ZZB## USQDQ[/
M.X^>&VL52UVW5)BSD&X,"=W6<4#9]5%U>@FVEWYZP/5>:*D8JXCP]EG ;.E+
M'F@UB!^EJWEE/W3!J\FX)UC2+<?IY+RL"IHZW?G$6-#.;XGX=L!K@ 1P+"TF
MZZ!-;OV2L"M, G2,LQ@5IZC.W!%<52P8GO1YKFS=D>^3;S-D=N1$G,%Q,<NX
M-D[?1ZNZPL!4!"8L6*1W:)N^KE_MW1"W;*FXY,P]BLIUV [E\_>K/8PQ1ZRE
MIHQ>5Y8R%+AQ1#;R(SW3,V2I ;EA%/ .P2FT8M0;$YNAT%\='5EY6[+PB,H5
M@>4.NGJ\Z^7AR<>I 1ZLGPJ7[4L2=":"QC,U!6+5+JK,J:+S6%?[Y6X<#7RT
MO<-&KY[ $T]A#C"="@_O275=+7W;GA7+F'IG\;+9G*O:J?='0@9$BZT<PL[<
M2?6<HPYQA3?5'24!OR%_Y08=3_.ZIVK<6+"DO[@5P]5K]8IK)WZWY,!(A>)L
MF%*K]$'=R4[F,:LFQ+;P8T.K$M89BEN6Z<J!_6Y1MY<=^D;<I(N]M66CQ<N/
M24J\H&USO\#2L#ZE%B5PN2^=ML>NJZ@L@DHRIO-@=A7US@+N4@Q5 ]>H8*S=
MJZ392W&W-!N;SU=N=NH!4[.XR$+]X*XAI^W''#X>SASMWAH.AQ,::;ZHSP\\
M944-^OF=DK'\9/Z\]X[?6=7Z@VES-'$T,Z;IKE5(NOEXG5));%OI>\4S:-9#
MNYU3F(DMY&^>GUU!YY*:V(YAER-QA7.-T?V&<P(; V$GE^N.C'[!C!0VM96V
M"CT5M93@^M"("(YO;AM[DVD?#;<8*\5%!X&38XMW3A2VZ?INOV15?#A)5W42
MUGQ**")#PUJS)4(^M?7B;5>C(Y(Y9N,9NW8>\;M/%%J^C#&LR"-AIW)8'A=0
MO':-.EXXIU<Y>5JI7H#U0YBJ HL)=LK&;RHC6J,^<-@,=%"88*=7J1>SJ2U!
M;>K4C7=:S)63@*@]^%VW]M$LQ[F.B\>6&MW%J![@'DZ!+[[X^G:Y4&G7]MT8
M\O V<QB5J;[+^_7".73A#6QT:-/JNJHO)295Y+E;8QB]V;C "Z''KQD[6>=W
MMB6</9QA72="C>^RG>IOEJ&?/Y_1D,3-)]N#&=&\W81^?[;L!H]P?I<A+:O]
M&L?E&U>&K>=/S0N<+C&_L/J9V];N_!?#*][C D3.-/LUFWV+LDK_PBMFZ7TJ
M;LZR"3IY?G3QBF\HFCU#'XQVCM<JY%9AQ'[UD_LU6>BF;N.3:J.21=DF#R(=
MSDCZM@^C>7Y-K'[0Q=TK%9<O8=3]'ZR'KFYO93)8P!L+GDOYQ$C9[J4-I,Z^
ME^^IZRWWC31J:>_0W>0<\*=M2@X5<YU2X<JF8SCA=\KXH7"R1.(M]?DNE ($
MUBN^NC0OSE)&_2JFV J!!-XUK%IF^+M<7-!X*Y:NQ3=Q]&B)GDEK19@,Z@2+
M3J>2ZA>J@NI'&M0=VFU/S*[5T037KK9L=\,/AA[[B%/!&3UG[EO7V,:^.M#<
MMA&3HRKQU7S<,@4E,WZ+;F_P <YRVQ8'CH_!-"8%)31/#3V7ZFE!/&HO3U52
M1%CT2(FK76MKZFWJR!.-PA@9C&(O3=M9XU+-#7A:O01G<X>" TLM28#3+^/.
MW0UQ?**_VKT*M1X;%<9LLO+[EY* <^FC8P8EMY?-#Z7/8 +:KG+)Y+]0$O6;
M,,$VI/&=UQF5/XGOH1_Z9'^$-E'ILTF6TMR"Q5!4U&*Y;I)^2DV+F0W@A8XG
MKN(]S-,?SK6OV:X/\";M7'A5?K_AA@='^?OU^&/CO"R*S4I-UW#/6H;J"L:K
MHX>#(K(-G-U46U.U/_-ROA6V0[\.=1#PY>S'54_$%%6YE'P*\$T\WL 1\*;,
M4Q,^HM6BR(F(JN.U&')Z'9/TM,$P:(N]_5ZD6?V'YJHYITPFDS6_SNY%Z1M+
MF:]BMX/N7$T@7CL8SB: H'Y6TL'=FVA- B*W^&.0&B]K7E?L2S:NT0L))+Y4
M+75%KV6\?5?>^BPH^L"MD02_=+/\RT[3OIK6>"%^1FLP<O/]Y@V6C@^S\RM%
MA]&NG]_OY*IZJ?-M&FD"L']WN5]F2*&KKPF(2,(,*32AHHNR$*.0U=>$ 4;?
M2TJGD9:X4R8E2NS_LZ)G 8CEMO-FTF0GRCN$<:%^[<8 VNX1Q[+UWUF/<&DZ
M&M1DA4ML"19(T[%5.7Q,V<U0'%)UK5\Y9?EQ@6_EM_@$"7Z)L&0WM?DM7MV9
M5UM#CR;0$TU 4)MI7*=PB\"=Y2B6IV\>J$7UY!>+XDP#A-**8@2&Y@M/[+G8
M$%Z>?YC[^23L>=Y=D5)/UH%::P,84&;L<*^+LEL7(Z?.J'G,V0G(3D@*8Q#+
M_K<7OC;89<G!&&\)_H>2RSZN$@%3BOXS:9?N[]]RM3#6>^1^=@69C"BWNT+L
M2I>9)@%%Z# =(H5E=]Z2O6L&(LT!+=[P](/ H._H2&</%F<FQ$\",F<S2$"X
M+E$>?/MF]1,)2/E6%R<JX'!'!%O!,:WD5B/"ROZ7060_M]<D=M"<!'1&[I"
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M1<%5@P6;-"0"$9/1XR^]XP).(..,-#EIG?Z5'# JSW-4H:Z_;.2XY9+R<L<
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M-IO8;K!2/*?.FITZF[\SN)'39K B/:?. E5%=Y+_IBJ ;>2G4["6.J-+EQ
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M6(%V_Y<9U(V$Q'&FQD'//J@64_.T7DR>=;#40=\XG=DR=&OK*_?-/<<QI+*
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MD5-=HO#YQP7S(K,?FV9 0P#,\!\2 !JQ+<T(Z:0SD=R_7 1+^!A&?O+0/ )
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M2C"'[GSGW415W0<D6["(<!I#M=+5_WY-_2%E?1P!P%QNO0?]L@L]\JECCJ/
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M$'T24&8B"FN+Y<H],*+EZ/*U/Z-<<)Z+/ZU@,Y06I[.9IV]FT[Q0<JX_#"<
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M1^S ^#M;GC@W>>7E.BMF9U]D=J-7RY'0FQC_[ORSM-'J27&S0-P\1(MF<H
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M"( K[ +1OB)HN,7$71J<?U#'Q'/'5ER.:"Y-6K"RPK4-T 7LJN5+X'[L-$;
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M<6@+DLM0?!(>;F5VJ\;JH#MM#D4_<E?SJ#Q0"O*M4D_=DW[13@34E(25CP2
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MF*8] <EIVPFZ/59C5./J,5?&6A"+C=\?/#]!N."WANS']:@VAY1HYOCPSYM
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MN .<V737E5TPE0.:+_A*0067&'S34QK1&FVI;M> ODKDH]L,XC-AI$];^GL
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MB,C_\>Y=$)5><_RY]Z*+M(BR'V2^UDH/HT'B;&N@N0:HB0.W8)1KF@?K7-?
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MPOG=1>0Y4=ILLZ%6?=U" %QF]Y4LIJ:N:/M/8$1"+-_3TS/)0>[DNEO5D00
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MM"DD_4,L(;UFY'7EM6&05.&Z3W.)I8<U*C$[>KY\[[*63%3'C3W +Z0!9#O
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MHE.[WZG:2T7>M= IV##G&72G TY4PCG9PLKTI!]0?VT3/9.-]CV1@X\%3#Z
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MV(.2N,1D(OWH6G2<UK.X/]Z*>>E27J>O=?3+ KI;^#QB*8FQ#W$P4SCL"5Z
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M]P$]X=/#BK<I<"&SSEA,5BWHFJ\CS,HJF>W].7_H*NVWU1:S+WT-N-.JZJ7
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MV-R8A?ZF+2HO>G0.N)VH1Z9D);*FJP\9#1_QG#A]5/U9SX6UX5'HTU8!U]3
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M I[5BR *FD(^M+7NT[5$3@4K@9T*8(]UK"ESF-\Y=+"@+I6<NA/];L-"-_]
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M54U$X-K,1W9\K%H9(0:-B5PWU. 0=PBFM"+HX95'J5^^O;K1309L9" 5H2,
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M<(AK,;H$MQ?6_ 8S8.^"2!/L=ULS?[OJ6%O5;<8D[ ;^":E[V_H&AZ%!/D>
MUN^/0'3A'Y&*5]((D7EOFF#O5SQ!4,>#T#VA?'QIVJB*A(8IC&+[#B__53MO
M)V=NQS#(5]VK^<].M*^\5./_Z'P@"%'%W]W.S,._7&& 5B?CRY8+W+*K[XZ6
M)$=8GU%1K7'W'XO[#F <(_'-SUWS(_$V!V!;=O>ZTRH2#H;#D)W\W++Y\*;*
M3)^0\;FJ9@N]KBZRO T@+9%["702*>: /F04/F 1>N^Y_E5*SUDDMD>TT-/F
M@=;9ZF)+'MB3GE\L E;8_-O<^"4VK/"_O8N&;P)7$';7[X(ZM?)*N^\%W\]$
M(#XGWU;A15(W"FVW+1=K)H%7+YPMNQ[?RG4[6Y8;5^^8SFPR_7NHW-4QV^W"
M0ZHM9HTGP6)>9UR.I3%,W^LH6Z/:L_R83E-W^O"5*P/S4I(H5W 8].%^=K*=
MT(LD@FE;?.ZR;*S65YGRP=R S]'NDI+4;10\<:M<],&/T+5LG3<&'&*[&S^Q
M5E961J^WADFF>RR*+"""@15I+PH)Y.@O!"-QA /&[LD9GQL<!&6O?-X&M:_G
MC@GX<?-7Z_W3U-GK$">"[*]N0F&_P'X->C;EUHS4,9%<R_.96@^<RV,&605Z
M RR%?D][B=]7.AZMAD,T'C*T\?$$7T4&KKF..KY#:JY2!S-=0X^DMUZBU/":
M]3WCVSEU"I^,:1V1T4ZQ'UB[0C'D.BFG#_96?G3&H4]HXIXOS@CPU$@@(,9<
MK[EG7*^Q(I5L)!L;D50['6I=_KCHN16#9;RG]S':*Q7;:>-2:'3_ZMCNBHE9
MTTG.>"C(V_]LWT?8AYTN@/>8>G'$.8#72;=_F@QK>DSXA5=5C?_+7/HX\A9J
MCF=]1[#R$<<<Z ^[BAGH;+&-W\$>XLJJC=\#M-FP]+?J.3E6+X;-DY93X01^
M@_[<]FX7_F"WOE^&EV^L![TXY,9 XD$S-3KD_O%1P\CL6^>%,D]*!D9I<9#8
M:B1 23@'S]WDY>O_WNPP47L ;2PV.V4<R-NA%*NK)9PG4Z5S-48W78W4OI#]
MNW$+&48_,-)KT',#&QT5G8LG:0I_)3(^..S=8C72P\-CC^M)W<TMZE<.H0]Y
M$,+"?*_(EHFR6,=$''?#?EM0^>NY9,TAA]3^Y7-9ME]F[P=Q!PL(A+7B-AH9
MZ GJV/+L@'R33MZL<,$$J5%S97A77/I8-&W?2UP1ST.^-ZP]Q,^I0D-*VMA"
M]J$-*X/:XCKD0-WDN6\+FL*0F/'!^%MQ4U6H,=1N$"S ]_@P>J"LRV=G8< 2
MTW.[J#_U:_]D0_T62>SW]E)Y.V$U&A-2CY5@']6][<4_&[-=D'W@H>*=&2HE
MQ61JT4TNB_'@*^>+Q'(W3 'Q;[QG:WB%VW''1Y]U"[]LX(GZ4-+%(S\:VY['
M5>/'^<+^Q&R:+'9A+3Y3.]VNQ (BA:%K&1B_UM_)'G3VW$:1XP7OY\_ VD1N
M[J;I;0'H-5(N6,)PZ5ZINY3GP21-@"Y&*A\!KL@UZQ&$%DB1 ?I]XEA;[27'
MTWNL\RH7#]\@R6<17&T8'S/-)+--G+:;T_'5HC$KI,9%F<\G&^7#3IU,I&+M
M(E5W:X@W\8532!I>NX<HTT(P.$1(%&[[G(=RSO0 KT*KRS.G.)$7)2G;-96P
M4M-.-P [?0=R>$Y? 42D>N*%Y8PYJ\,8QWDVH.-)YC74H\EYG\Q[XU\=NN57
MNKQ><G @R$D4WXK=.Z2>9@1A$U,3?S=.U'N>=0:&'9WB.P*\X\8($YFV2-D/
M_'V"S'H*9ZGC<W 1"D+APZ"/Q&,N#IJNR9Q_8KA[=R ;=9,"Z:TZ9:";#A 4
M23WT+/3X;9M""0QHS=O'S07-@+]&X)Q=?!!M6>D#[L8V3ZNDS'=^_;!0Y221
MHT0BG8!KAV^A#.F$:\FM[M4/.S\@^RT$&3Q%OC2X".^/A\"_1#A_FMU0\-,;
MKKV"9/AME\S?C6. 9OS/%XEZ=ZI3J^RTV0-/*(GD02J:FF,7*]KNEE2FCIUG
MD\RU?D5V^B$YW<N+[3L_'N]KQ>*. &_8?SK&66%AS=/W",""E%!)GD$!$0&W
MAQ?M^RJ#A*;ZXZU.^X\4>NE3E4+E#E.1[%B$%7)8FE?EJV)G2!?R\?H^.+ZT
M4JQF=;=3@)'6+%21F1RD%JW=)C.3]E_@,7V>N@LB3)"5"T8MJN-#26R%)-&+
MQN\3)%(SJS$N7)L/LNTWSKH2S1/&::'90.%!X8X0PD:OPK$+#:8)[SSO9VA=
MKJE(:A"3H>DHA!>LD32!F9,#2X0AQVA<O*K",.<A*=2GZU'?@RB- (X90(%K
M O')!3T>I"BM? '4JS3C2&QB=C)[V?,U;IKB23K#?;P1EJ812+6.6"<H/W*7
M<+*.FES?X5Y"G T;4WH-?^!I$O&TK:JB]2.YS-(%R8N6E* G3@PN)$?^F4VD
M*NW$ .N-Q#&3"-J35+O\BC=>I8 ;_I%V_R8/\Z%7L?2).+F&ZLK \K(D'>!=
MOW$+#2>I*VN< J<57JH[!ZQ9PM)]/Q'I>\MXS:Y4(7' D&W>&UU/!/O+#]V_
M[HYQO'J>>M-Q-#"1G/:U@&W;C790A5QPR!$@YD\(G%,Y2*F:@8^9M2N/IH1\
M(PCSC\+N94 >6"Q?TQ6OM$Y#57*2(A!_'YO<1#*@+#F9EUXDQ[NJKL\#ECO9
MX>'I<5:2R^2]T(0?@%.)K,4]?L;J=Y0E_@V:GT3^.R9"*EUHO[-)W>*9G7>@
MC)<SQ+*B7@@5?0S7+J_R[I2'%\X%K?>[N[L(2N4Q<#]*?NG%8_2]MD>B-_89
MZ_AA: D0?H0=.[);@RR/;K;")N#EVK:025W-2?>#&[=.50@*OZ)7? Z$DUDO
MHH*)@#Y?3LCC$57L3N*H:Z=/BWY[OV(-3VE-L>CGYECCM['@+,2Q7W@HC6 '
M^^>1ZVY94OUVAK[?7O>R*><TIP('"$;O+!?WX6\5HI*]F=6<P4]K,N,Y[N6Q
MMD-%\$"T4\ 1P,F)87Q*9@BGYNR39Z7M_70Q@/'ZUQN?&Z5Y+AP#L#:@UB+1
MJ[#V2-PIV 1"V?7[Y[!#H6:8Z2#W?40$W+&@W"Q_/(__^2X#_Z/R+;/VJ;1&
M=^N KF/*QK2W^V_W_J/6:C8];<C*\%.RL3A,5)+!, #U,/([%EZ*(LFCY8HH
MNB8O=NUJ9 0@KH.M:[SN;C?'L3M,(J-#E_PD>^ *"7Y*<A@Q)/C @ #D9@GJ
MWYG\PNNK[5B^]KR;X=M<VEX[@AT?>000-L!Z$!N\]HC^#I9C"OJ7)$K4C@!*
M<<1O+#ZQ?UR7EYM^#?0P@.@I?+AY[D 0N-4!VH@QN*5ZZO!?%[P_X"%-*OLN
MYBVF4_NV41$V]0[F;NUJ@A9B8=/\V1E^9WZ^2^/+Z2- JM81 !J6% 8(7GT)
MZQ$\ M1=!UK_L?P%^W/'&(I50?/?WYCXYY]UK@.N_EPN^N?Y6&58R!C^6D^E
MXX]][PSJ4YSM)M4G48/O-D0!?]I [=OQOSP9L+CIIVNB&/[?EGT*_/;PN\?8
M]!E^_/+#8_\OYSHVS'HZ9$AS\8H_"0EJ .]YVXQ_WA[YUS@U0H/30].'XQY\
M^L2KJWU 4\-Y<]@T.\9]N#*A0)VC[<+FI<L"'PO78_TDE4[,1 J@IP-7H:!W
M8S[1-TMT8M2-:_B>F;S>_*PE&-=Q]J/$V! 50<JI^6H4K$1H81-ACA ZA,/F
MQE7X8:/\5DNJO--^++!&&O3T >4X;#$+?E@>@#T"$*]9T<-&9<>/ -?%G'HO
MRO95)(11G!V[XC>0FTXQKCYF>H[LQQQ IRSYN,+W'PZDN&=VX+:S3:<8.R\;
MYL8"2+8=U[X..#LFV]^G2C>NWJ>;X<?%<M*BK$S_F$.F@QCI CM9VJ\II$OZ
M_KY@QLO3?&7+?ZW_?6&N.UQJ3/D/W7+Z5*DO9V6$ <[]AT'B[^E--Q 5;)4=
M 5MD&UK+S((D-CM]4T@+0.W2C*"V:>QW^_K]PTG)>OJ_>,[Y_[>!$/R[TRTK
M+;4.3&$=%=_51]$U5+^?8D_P$6"3'^]";*B8WC\/]BU2(CL"\ L'@U:Y'8X
M&0F5B_^K_=\KG[=-9[@X["MM:@=B<]TX(9>XZYEQ7KD#M+S._7I@(+UA[[[E
M:X8;&*>ZDWB)VT-?A\1=KR40[9![;[M.BW[K7N<>KH&2A0%,_T/(_AFZ ]H1
M6"^W BLNR,@UO _ZVP[JU++DDJDYQ0GQ',$+"_[]2(E94!A2RQN#"J@[@YT.
MGPVH]ZH,?2+&U:3[(E0&)"_\8."FWGYZ[L=(HZ^BVL!7)P'[BI_YJO@RWN8(
MR+<C(J#W,2!F(%[;5Z@% [=O,^@EV+$%V+S+ZN-Z6FH8R,E%']7O&7$0I3?9
M"D"4:#-R7)"_/(-3Y9/ <1-U<V8V#I_O;!P>&ZLM<T6\WI$(V27*'!:K )>>
M+HZMOQ$/MD9<%>N&9VN!G5R='6O@<XY"5HGRELU>(P/A_[=!\_*M6P&0&S*N
MCO=$=T9Z-[,O9=O);K \F]0L^!2D92C8W:LGOBPU+J]\CMPW;-:I[@(>K(L/
MS<&S+1B%2; NLR&\';)9'FQ>2?.L)"OS.4&!J;)B\AT"TD+YH\9RPC)"LCY7
M!-XO3WW,P-@<;']&D07[L+47T@7PFF?5UAR"RW2)C]PJJ@[;;5T62J5)]J#C
M*2[Z5%(T\YQ:YJEK^O'_.FS$_..TS4&M<"\)6NAYG'H^*.0QMH#-_9+.V6*G
M8WIBN>1"_;+?3&K)UFW)RR=CAE]=%JM4VC>:#QTAGEPV3:DE%L!LN2.?:)\8
M@NKE3G0YR48(G593&C=7#SGPO_VA_N0A%_XNFO=J@R5;Y8 $P2@/\EF@='S9
MJ[IM-^U,U36/ZWSWR?'M'1NJO.4L!N8OWT>5 0J>GLCV]'O[& DSQL=9XY*;
MZBYA-_R53+S?@:MU[]>BB&UO+*>/!X0@M^\\:."\>MZAJIL.HO$"+HB/FYGV
M2SV!X\O)U4&G&.D@JP>EO 5O+S,UZR7$?GI_<=EX)B)&%?@D_S$R>9?4]<<]
M^2ZW[H7"LHP.7^V )PW0K"665GIY8I&':X&UDYV)L<9G/D)F1=L2SMRAW6LS
M,*]<R\&=G+V"5\2LG8 *8)0->:]J)KH7YYA=%XHOU 36/8XW]L+FA%%Z._F!
MYJYC%PX#'%#;MX</[T$HK.N)?)Q47&X?9XE5)+K]WS(3V7\L+E>UM519=L1,
M.S5*8]>)F]S<QD&6WJ''^ ]B(:S!:*=0(B.N;(/2'^,@;/+FLNTJ@LD0Z">/
M8#LL4.+. >_Y,@\I79])P&T$P842.+?;W:)+/B/.2N+&I40]-$XZ<RIN1:;/
MC7R& 53((-Z8X#6:O.7=BTL)ECP#PDEJX/L>AVG>MNG1_,P/\GBPFL'!=B>,
M%CB[ +Z)MVZI<43)Z&O5DPOGY=D>DY_1#OFD&<X/1-^C+O1H.0(PE$5SI3&D
MW)!GV&7+HR]^>,;'WY'?Z(X@?7XH=W26ZZ ^U2M[DG*S"I#I":%JV;LXG9R3
MJIBW/8AT&UAW/$7&LZFV9WH=<.^ 7F2(.5OY_& 9&0;$&$QXI-<P?7!\97K_
M>+FW[9*ET#\8(OU!WW46ZC]*2]($O4(O>2XB=<=JS*PE#JJ*<PI2$L(FW\)Y
MX1V_BIC5+,IX@Q^)XTY0LMWD"Y[.TCX"T$QC%@ZYAQ%'@$#>:/R(1E'>\+37
M$4!2F1B&9<!;'@'808M3.]&$<ZNPUNC?7]\'21!.@KY2H?HLR7XN-57\QU)]
M_YA8%9X_ OAK$.KW]D7J06AO@OD1(--[&(3-+/[1%OPVH?R"@,*>.P*\)K49
MUZ'$:5ZB..,1X.Q>/JFET+ FRE1A8;.M"!Q-6Q*IX8!>G3%#4:QPZ;QECV;M
M(LA9/KAA+$X+9:A9T>I+TEG*28+%D7\A.:G^Y[^SZ<DQ;_??WAH+5W\CI@MM
M??'2P[V#-Y^F>>ID#?X=5J"9R#ZD9C,D*BZ6[MGVN>#.-UV?H7J!19'A%/((
M20HO1LV^((L<C@)6V0_R$PMWDCXL6\WYPI8JB)+#=4 2S+R%TCKJ5NQ+8Y$1
M[@I/*E;%=6H+5*[-B,NQQIH(03WJ9896ZDB**U (N]7(QQRLR\9W&4?_1GHL
M,6QAP')>>O3QLZU['V+[V:PKQ-]P*IT\,.BT.@+<O;AF[9*H/[T! +MD+PA@
MP=I]KGJ!OJP#!$7!+=N$:JB^J?;30$'(T%/.5WYJESLX-BS2ES0_,%[)!=#[
M&>3^UT^(&QW'M:G&M8!.*!F\;W+(GNSPO"]ZA>[!5=[,>2_-IGB^P_Q:A!+^
MP"YKFL"+NUM1^F[9\NR 4(EKFE9?DT_ADF9K.U9MPI9\<UH#A94(0#[*@IBU
MJO#BQ*M@0A/:[DK<F-9AL9W34;1:[N\?9MR[[TT6=N@_$"8361Q)Z_S-_BYU
MPZTHJG)?6P([7N- %2+2[ 4C7  =M\ S-/BZ/ZK$![K8/5L.+'&_(/P6"8/$
M;5AELX6?JWBA$R#;AT3HC"[P3=IRB]Z6;.<GB4'#U&[YF5A.RKF8&_'*#1PR
M#2M ,BAS(41"&UO>'5VIV1_UA.W$7)B90??-9_E4YG,!/:=',OI4.8C,V,*X
MF91CG=?Z1#,&MFLN-^N;7;M\G?AP/ZY#9B&M'$%(MFG6.Z#0/A097ND @:V^
MR?:$I.U2)^[K4WG^KDR'J4@*_QLC5)[$U.-.ARSEJ!__U_S'8/V*XE61!#6D
MG?RRW+MH@(]:WB3RJM#0> <&IFK1LW]UI))I 48#V1I(O.\U#&)@'"6UW0Y<
M!DE?#2L_6"633R\B *28VL"Y$",WC(\ C5%M!-O?)^QK_YY6$"J"1'1XVK:3
M:1N1Q1TTJ_';RZ*T1.)QX-9_M[3M+O/F$: ^DWC/^Y!U!HBM)8K#^FI7@/A;
MWP]Z'S^RFX_WQVXUR=7QXX3KX6;:?:)7RKO&P;O//.V[<^F'.I2*EJXT#7J)
MP&9ND1A()3DC?[1G-]\XN[6/7\1_*2:IV'SFWSX;=_OAO^ER?W2Z7ERF5_O]
M5.2. ,^?0R_W(^\SO' 3\QIIUM JUJ[QW-B.9.)]3',M\=YC;\]+UB_7+.+2
M13_R9V&CUQBPR<U3Y[ ( K\*&0X4 ;7.,FW+-EW.N1(KDGM_E#%BY-(%9_^$
M"3TE3%TH?@!GI(T7PDX;X1**6?;83+U:C]<6?8[K% QGN85X4EI=Z+/233SI
M.R@+8W([%&D:"P[<@)['T*F/[2Z:F)=<ONH BA=]TMG@_%+/T99\ZIU@1L+M
M%_[QRM%9VIH*)TW_G]N&;-"DT[N< >!Z96\O50^I]HP0$O7&R(E-":!]]?(E
M&(?ON5$H-]XG'U]ZNS)I>:Q!/]P;ZAFG>/GZ]1Y.H4#/G-6=(X#0P*X?2?[/
M1Q-CX+:^0VET;J@(/FYLVXOM%1.A?O&=3L^=Y)!YQC+9F-BN@!'A]+:K8:NQ
M$?E9RF6$EQQB!\;+-#YN&59X\MO8RE"A_NPAZ7:W;YB@L7G^MM>6UQ^/LO"\
MW>'D?2HRH,)-N,4GA#>X/PMD:J$*9M+\LN IR ]X]RGT[FOR8C]:.<#31J1!
M/:K$)S41Q]#F)1SJ6M/#A <9E%7Z")L/.DV9Y?+3TE:(ME0Z3)%'N'%2P;TK
M0^K8C)>/ +2%2JQV;BII]W8;Q^0_A4X)40F$DM'A^XQ&\]7Y3(\ 1L<V@NHN
M0$"MI@'&BRI" S+@EHA/O283!5&G>-CJE>59%ZQ80/9P&G1B>'9OFL;@3ER.
MH!28/0EJWVOG_&G<^E*LAO#I-<!;EUL$ML-$,2(=OL3!48)I$LP@E#_NR3QJ
MIIHN=7ZR6IH*[^6*N("S63T"X,C-\.&S792*-.[8M(B=3N4'>\TZE[<$R@,U
M]B421]R-R"L&=-^>4XB4M_"92O>AP;G,ZB9B$QO'?(N=;3SR._(FVNSN/[J7
MWN$L&G"!3!"@W(%0@HW+-5EA$:X2IZYF+GMP593"5-Z T3.,CDD8AIWZV''9
M'(H*Y_9"V.Q& -03I]U8QVJ+9++I+X/?=O9!7_4M[O!@RM.VNY:9SB-+1F'T
M&E^ZJX'+BO:O8VL!!9<= 7@L%DT=LW(L[,[.=D1-@;/%: \^3O%S&"KKUGO"
M[6ZGSP)M=U P*SP0 K0E*.#>@TXA@=F0(!KN6EF1162#G0][HI*&(*O;ZC.1
M#B3[$4 X#2= ;)F4^-9A&8]U:E2(]JOCP(.;QLJW[+VB4JQYV-F?M"#;>#V5
M7BHP9'DBGA\!YK:(@K#1FJPC@+Q($IMN5D7ELM_>_KF,*K\_,N1E[[$^$S8N
M@FE"OIL-A8.@^RR3.4,5ZB!S,&R8]_@?CR+^WPPA,6<KCAT'D"K^$4;LZIWA
M0J3B?0?;3:V\T2V9C\!FOQTG-54FZ$T\'.WT0H4SS1)G64P9G=T2G6J0^$P3
MP$]O/!=U' RYVI+D%$E0MH8O,9>WID"2,3$Q+V=[\VD#2.7HVR0FV4=O-[JL
M<L@M:P1JD8EW5!]8=W)-IL8,P=^]HCP\3%XW?/"17S-J78]U7V!FW%M;@F9)
MWUBTTX:W[,&99]2)CGV1,ULU(TH+TK3C/S\%9A3K.XS:=$AC!*TR2FPCS'YM
MZU5Y%WXO1\9 !I)W_Z;V_^WCQ] CP($UK#UO!G7 M;UQR"4RW7/5DNRWJ;<S
MAIM$%I5[T+U9T%@74GX6Q&&;I.=7/LW\!7^S6<;"0,_VA61BB*;&Y_K8_+>'
M=%98JC5&&(X<XY[RWFY?5 *=HJW-]8H]_ZGI5Z'3IP;4*4\QW?#3A0AS("AK
M#F,)]POQH!9?Z;H*E![0?DHX^>Y'[.+@C2]3HV]4V38OI+Q_O7=OH==HR(J!
M2 LQ:TA"I@KT2]M).]PF3DE_]--M.74<<'9B[9MJ?1M)D!M#-":'UK8&/M,I
MPV89GBM)Y'5EVQ,O]+M.7N'A="@LC!&\&1'QW*7W:R*&JD69"MWC5ZADD6?.
MZ?H^DD_@B5QY ]03S &$% L 33<18; 2WLKF#1Y[%<&XELHDZ\G5KC)3AX(/
MR7<DIEQ%7:*^%A![42?<UF!H6*#K!MUX8:4+.GE<I#3GTPK#>#^ <B(Z7@_@
M/R#SXK[6QT*'O4UR.%X*U]TY2Z'PV2YSF0\X5 ;V=_+)MK=G,PX_]PAT7H""
M"Y-Q^&$#C4_+PDL8X!TP=&=7]*6T>)O7F"^,7_/U#KK[H &P<'E!&LJ A44@
M3Q1.K7!M!"<X&+7NO]^/0BBQT\PO,19 @B2,A#EFJV387ZBPXQLW-V89(LHY
MXK1QJ)!'R3J]7(^9:,146+XX/+_,/2[>5-4*UC6]^*JB\OO#ED;D1FCA-:MW
M! O<>]/CJ>$?EO*]P6+K;[P]N3R->M4/>$? 3,C=>Q<DQG.(.E<Q[(?>:D>
M+/V1XP<"4 H<J&F#:PH\A@J>Q9:G#P@4Q?:M!TY4)IZIU'K&333)YWF9R0NN
M/:R&S0VJG%X@^J0? ?IS[;_9M;$>UP,C/C,XD;J+.5:;(X"YP1% C?59WA)P
M\V3I$:#P_!$@/:S*$O)K,M]^[,=6U05N?B;6/N#Z,6'#P+GW")#_ N;9XY3C
M56R#T2P7L]16O)R$X5!CMI#8+[]/.+T'NE&5L[A;;?5FU_;:8R/QM<%BE6P_
MYNLEJ:VMEPL+4W>=.V_BYU*?4J6OF?XG CFS:&?'<%653^# !A*L@6U;_3*K
M>.C=V-2:9!S$D=6GTU')S'E6LR])7XHK\U*5\_]A[;WCFOJ6]>$(4I3>.T'I
M(J!4J:$H5:2I=(+2B8!2 X3>I#=!!>F]!I!>0@<1Z4TZ"2 UDDB+$.#E>^[I
MY]YSR_O[8_Y=:W_V7K/F>6:>F?TUG+\>*KJGB<GO!5)=W+($K\"D)R2TA1:N
MX$O4#FYLMU'U+K,Z:W9+K ^/YT_(5,<K.,/< E0MD Q"C5,[TYRY^W'R"5:M
M:$;34][HWCWS*LK.\.^) ;]*MB!7_/2E!6&/KVL_B]T$GA^S]K#U8O2=?WYW
M%E?6\2X+"Z=9#9NN>S2Q_VFVAV$I4TYACO)C1WV69YFJTDJZ_-O&G"#L2"9F
MLX=)]F<YQV+#\PW5RKC/BUINK^^]O2'Y:W0 HL"&XFNV=T<ZJ_;*PGLO 33*
MCF^0Y1H_^1K %)WW$3O&762L4LS5[V@W-PB"%/O$<JP*I^ZS$,I/?@93X:8W
M^:\>D!9H-,6%1<2L^?G3]C$>];Z>"R7P4522TW@GU_PUV;T+A5@@(25E!GT-
MD@>CI/&9_T",P>).6>)3\MIG+V$*U6V8AM*<GL+ON^-F*V"B7_5$O62(N[1O
M@J@>K$:?VN@1C/^9Z!B:VYIM.5XQ\T%3Z5C8,PQXS;YOJ!CW;$V4WA@:^K2^
MY7/[&)H[F?%APU.0N.S)J*[67B"R#'9UCA^RH< 79*N7@+7Z0UZ&J9UNTZ\W
MVF41T4N=O_<O6,M[@8?* ;R7@%4$U86<.EY2]RUH*Q3V^!+0!0/BO1!A><7S
M!G],M-@/_$$R&HB95N2Z!.118$4O 4280.P\"%G6]L<F3'^W";V?%O@ [;^/
M_],.Q?_9#B%X[;_MD."H?>$/;[_"^4"%2T#/4]P5BALFPKV_0L(X$ YMCR=K
MQ3+%7@(<$MAQDP88Z;?R;(7+6\=2KT4Z7&KD$]@4]YSM. 9\3PVB V;N"*LQ
M=F0 \J*%/A#\263+0E"-?R(I]&'U\^2[?I<;)JX/SKN]N;SY<XJ@*>9ITWG5
MDU,Z98OD#R,+K%L;<X"5CMM2!L;;QQCMUR<&:DT^!6<C?ND '7ZMQO&]E_7U
MNB(\[)0%6>M9/ZKBW]7]Y_J0?V?F [VN%!;0GB[6D1A[3V=;=[]7&'4%=/I2
M=V&$(M0X:/=[B*^1[N/W;)0.A&N!A%##XP2<PC7,:)@B*_Y6W<3Z>S^G4\^-
MZ<+6^ZN#O BRG\<&2EM"VPGA\^!8#SBY*C"^?H@BL%>4>U"R_[WML9GQN^PT
M@:GD;TQ%/V04GL@:=7/RG#<H\FR!6/"Z>>WH6J<;[GS9!5#IL_O?8@TV:-@1
M8OT:,?>N *+1UD@V]Y"U*T_4QM>MBL'S"75N3,ZKSX_H9WD$!R1(7WT>(! ?
MO-T?,_UA]2;$<J'BMK6\"MV$RIKK)E@.?X47,0<H8'A]ABN[,33R\9@$A8JX
M0N%&ZWQ?Q6.6-#GHV4C%=SEU2SFC! <0507G"?(D#.8,(?Z(.7L^):F@!:(8
M#+"<GR0M(C,!>NM)*WY;I7USQ8S0ZB;T8M6V\B&4RG^47'3QUG_FM7<B]Z+<
M3H!$>_EF42)[PJYPYU=\J4-I]?&H1Y'D/MQ6 *"R^0FZ%-5![0@F@8$+O^.T
M-I]-N-1%*4Z6][FSJD.^ ,7HFILVHP''*X# +S%_+=V<;N(!]U<#J3RXSV07
M2"[FA#W^\W[TU97ZB[@JIRS",?ZQ.@K57F]6KW9[?][XC\"/<@-L&PVQT:67
M  I#%-4IUPKM)0!C07()X(#G"E2N&=RY(Q:'WOE[SQ+_FV?]V7WM_^99YX6B
MOX\1)Q=7H.6O*]*!,. _%LS_LZ\A^ +_Y&I@%7WUNL(_1OPL7P*^465= OZ\
MXE]]M2ZPYQDT].*M:&\'GNF*J@] MK0$CM]U;,Z?K?P./ECY9U]MVSQ^BZN_
MBKLKQ&W:J\.BJPF]0F3GSQ_D1Z .=-^JA-NI#S$D?GI!Y71V)[IDNOB&H(!3
MVW<&B0)HW<)3SSN[M((D);?4&5RBA=[]K5/C\123D:#C]12-0&_6]Z_<7A,!
M-.\.$HA_^?JV+<TZ2(C.8M+E:".$V?510_IJ1D2DXJN8\VF7SA/)#(:XV=AU
MD_TUB 4[>Y\=U/$2,!_HZK3[,NK%HX=Z93D $B4! @[0D\8)],N&^G"K$,F;
M-7#EYR7_IMSR1S*7\]J9(V]")((8&MI/TFT*CCZJ9"0Z8YG:Z_MJRI/<GSQB
M=#TU3C,I:(<;3G#^-H#O.[01Y5F5DK\ M>YU,]MN7)E?YL8<Q]_M%6ED<QZ\
M0Q">IOA6#/H#47Q>+*^# I+@V68\ RG,M5^4+ R^LD&$#*%K31?8WO;U#A%3
MI3_GOC5/(GFPN9>)VG]K.MJWO5_U(FNH<UD@Y,RP86PD@>.=K$6=VULT.X,>
M;% -]75.?G,B./L594A:DN]-T^NW6!C6L^Z=IR& T)5^T\CH(P6QW;. \Y?:
M&:V0[5RQ"DC#/97J5<KEH]UW>B09BP&C".)6;&5'](^QW!3S(#Y^NY=57Z3R
M6S8ALD& EV)"X\]>W_,I'K_"!/]:ZJ']3RKG]QWRHO^;YD"-)P( ?@:MD^?U
MU6G+,AND!X@O[Z^G@3;;12I+^PJV#RR&F@:8!TE;/YQ=VS5>YIP0$:G*,)T:
M$S[,I^[T81P_UK\8_^E J*TSEC.Y[_)SJJV1B2(MV3"-L#9!24'H,?E-0&?A
MOVD*^C?V 6=[.]O<OF^V.1(YTLS[R73]Y/[">XTVB:\MH4DCW[7?-!W^" +)
MB\)T/.$P,%9R,Q9FC75_-%/IN5UYQ9&1')A6A>!ZD_O4\:HT,.L0*(?&ZNQV
M_R?EFH9;F5UQ&H[$S-BILP-PYJSW\IUIO.D)R/:\I.XW?[/)PI,8PSKC6\_?
M](_DW3_:!N<]9V&4.FL;7C;='):!K>':SQT(AF^MLYH*$'[ SO: *6#:U8TU
M6+48QRJ3A<<B+T)^W=MESZ'F\&>V.=@W#EUEZL$BBS%83-J'>:'AX[3/#FX1
MEAF_MR!C)3DW63FCK)'#(@LZD\*WJJL;E-FECK=HN/7' +(W#T#SLQ<ZGU'\
MYR&\%ZF[GNM_GS<4(&S#!5X";HO^K7BZ2XB\!.#?(M@O =7.C1?1IBO_^W>>
M(D$7_74*]@CRPL_53G746^;WRW#O>\!EQ=!=);(JR'$+.8'FH(^-W(L019O4
M=OJGL@1.*>H*_:6U4A]^R#U<5VG:TL4"3;- 5/-55:<?C=+0[^ZTQ;4.@1\!
M>[*=IG*N$\8:C/]WG:H:OGHD[P(F6[RC),$A\T>-X3:M,4^MK[D7CU2;GW]X
M'+&JRHTO^\&U2M?)8S1T":BEBI#7+[H8:TD7J42)TD(AF@VMC4W31QS.HJ_L
M[!+9K*G50*"TUYV'=R"S()=,$$H]#L&HNPH&X&[N]PG"N<R6M&9-(P;VM-G'
M!S=J$:R/4E5OS2L#T@\ZYD*1]K'RTF<J%# \#9!(GO<\XMA];OMTG2G1<O$G
MD>73V'@E$D>RK">:.?8+NR>/A&__RDL+_@M\_W_DHO_AGD1'ZU*,M>;F#Z*9
MN^R\MHBTN<MR7T+9UP\K='15G/WT&WPVU2=0YYMS4X&5*3768\';2I28I?,?
MGZ^?>-][*VS[VCG_Q<'OP&57N.D"(7UT+C$)X9AAR?^Y_E:R#A#1T=0?[#X=
M(]FX!,0CF/'&$XHRD.CJL":L5#%O)CRV"$O_1JG$Q< X7R.&>(E5T) UWAU<
M; K3I4AM<VO\>.=V.>CD+3-?A^@%#U2T!X)E D^TZ6*ED96?3I]M##D<?W8Z
MT/00^5F5K-Z2I5#\M2D.\/#9[H#6N<+XK,M[NSSP U(]GXX5-O5AW!'>@0#]
M%\[DPX^&7 +XYK!T%UU785WKJ.67[M^YT;MKRS#0)2")J2?[F*+A$C"N;784
M_"]2D/\%?/S8!Q"^925@=U,,DM(^_;--UY,W(OX'V4->$4^@[M.$Z?8S/>+^
M>N'#!AY'2T-SN>M4@K_UO%]Y<T_DC\%D&./8OEA4B=K*%;>D['\)S#ED<-><
M0([O6=<W7E?+E*;5/.+).G(+NC:1]C_[+H1?.QSA4?/P+G@()S\V/J98M<S)
MU%P N["H6<O%^E M:?1$W[AY0*\)SG.>'J" .T/9)XQDH$!T,(49B1Z'@[N*
MS*T^(HWD5HFZ2T=5:\=+&"AV=J]OS?E6O860:A0RQ$>2PDE-6\- Z.T&GTY.
M2K>5".7>VE5TO 3L"5;,XSZCI'*]BX8Q7S7V*MYFPL0++!Q/$RGBX T>*B]!
MR^QZXON>6X*.3#^C_VB:9-!:,ZVM:PV9\6NZU=+$HWP]N:RM:;=&<RB X?W:
M)8!%-*CMOGL%(JY\=_>:_C''S4FTD6Y*0II\[%J'Y"]1M*1]#G2H9YD7^R/N
MC2L$%<<ZTWT),*G'$GU+:ZD*=:#7IO=RS*S6E?[6%L(2OZS1!_#/.AU^YSUH
M<Z)7N5;JT2@FD/3.\Y9[LL+.]U>SW9PBSB"]&JQK E]B%Y:/BMUX_KO,N\JE
M^OS*YI!KG&YEV-8T<S=O7Z.EA]EW[;FP7W*HF''1[F=/81Q7EZWE%4W*,3-J
MB$\]X,P-7)/K6*!"_H)F:(_O24 K/)'YNL66FA(G-"\I[=0>T30L%=\T*X47
M,_Y[J46!=;#R X;D>;S;KO7C$+[,<>E%K>+UL$!2Q8)3/6*I7'F$R!3/I+"-
M4)'2&[_7D>?6@:.\H&^S1LX$9@^3U'*YGUU[ZL7 $![+"B-@@Z8Q1\I16Q'X
M2-H%,?Y?(O%?+#\QN<VS5(AP0):R$ 6^X>1KEU"I@UQZ\H,XGL* M*?]<U8\
M/48CA^H;/&KF@C1A8/;TR?NJ"L9 3**.=1DT_J!;S<\XK%&(;[3^6N_X8"HM
M71 E14"!8U*%KW\93Y93@=;U[&4 92 K;@YD!68!4BUOT>%=IXO')"G4SYZ<
MZ#B+T3#T(JR\>'S%!7B,YKRD5JSK&H/8?VN4?K)^P/F.(JWT1N>P,#>[('\A
M@8#3*3HBV%KR9Z$G1=P[H1:SF(_7W^2<6'>627/*88Z*PM(73V>R&>.XB"1)
M6I0)[8N #R11V;3RGLA]EFVC%OO>?;(5*/>C^NF\4)TIO,9X0[:?YWOJ5M+%
M!-$[E+SS;56^LR-7:'^EI^'T),+#E<5)5C$?<]S3RUK&827;EP>V:-/X8GW]
MMT.9M,A2GZH]"5\02*5B/V=*.+^I(96_,56UH.:>K:<"*7<(A8\1VJGG@N5/
M-Y3M16K&&;"VL4L.^%E<\9TH7.U#;S)%]KS-+Z]+0,UG-O\:\Q4TO 3W"QB6
M=;=Q7,*?<K=[OT#S/-?/S_^NM[[;M5]YQE\;.2MD<JC<< 'NJV#*2\"?KS4/
MAN!5]L!N*B2Z(/5BI+$+=#0("?BW.J>_60$_/:">:&GJ^>NVSRU]M.1U\:\!
M)9+.=K,/ZR QS=?U13D+LCHI-^=+=UC9.;F3)U H39U:BN[I)G4%Y1?H;26&
M0_^7)Y8=TM2=7.,AJ?&:RK1/5I8):R\!LDOQ#%%>>64B 3NQ-]WZ&;R"@QX
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M4Q[CZZI\:_)[YOV'X])$75A_[*C8)"4L&02&J^=4*MU_[H/4_O\WMA!@R//
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MH42='LE0=@.\"QP%8JQHDQ0-]?R>/W8XQ^MOWR.^0[N]75ZZ4*/3"\LUYWQ
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M>7=M*B7H3F-(@"(4C!))K5QRJ"P17HZK6W9,3XV=,7I#PI9G%_V,HF;VQW-
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M*90=V9(6F;LSGU;HX_?&FBFCTHERQ?YSA(<[_4.J=^&65.;!*4I?6P;0%FM
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MQC$],!PU87,Q-EE50?YY](!\+X7;E=TCQ[[E7UM/5PE 2&+,SVN$9[(+@$O
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MQ;*D7;MJ<H0'Z9,K\9Y5-P6&D@\*&BV*1(L)F;'M1DY]'TI.1,/';DI!^2\
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M^Q H6OD"",^]%("'/K\CU Z'.<3G@!.;7,ICYCB!OB^ SL.@1[%PEV&MN1>
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M,)59ORA,[H\%A8JQA.;9<7<)4IT-);XO5^UQHBUO1VVCCH'@*,;@&+ZYJ2S
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M\L_6)4_S^1[RC6W_A+\ =E4"IU1MD^#//_N/N@NVDPFV&2=Q*HZ<W_*+AG=
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MT'9HW"G&QW3U:%/O8":&[+RLUV'U6EQ.7/L28-&<:'4KVW^/&?=-DXXO61&
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MB8"G@*W_ZU3[_WJO=3G[/U!+ P04    " !I,X-9:A7-2O\=   2'P  %P
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MB B)R4G)R<E(R<@H**FI*"@AE&1D5/14$!I:.CHZ\CL,4'I:*#4M'>V_AX#
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M0[+J*8[M()\>,;[+'M/(DCSWHH@ #7^\/^C[!R"3_F6$T7<S=#4KW\4^@;M
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M$34WEXD6C#XLGD-UZ2Z<A>K^@?D&.3+QA.I*8L!PSC-L&NG;DQ-M; ):5@5
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MCKWH D>:/!A&.9]9?B";K2S9O>AYUTU.]Q]_?<PQ8QZ1DVC?\^Y68/1[^57
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M!G15B*42>7:MUY$I;U:$UA<=RTWM<)]UF7" QFC7C;-#.:\1_D'H'JG%,:Q
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MV:&[73FC%TFVU@[T]Z54>/"WS+S$--YIIJT,]!P6%9RC3>>QK+D?N<*<ISS
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M,#(T,#DS,%]C86PN>&UL4$L! A0#%     @ :3.#67/(=D@;/0  SOH# !4
M             ( !F2P  &%V=&4M,C R-# Y,S!?9&5F+GAM;%!+ 0(4 Q0
M   ( &DS@UFO F$:06   "E?!@ 5              "  >=I  !A=G1E+3(P
M,C0P.3,P7VQA8BYX;6Q02P$"% ,4    " !I,X-95L;8F7QQ  !O=@@ %0
M            @ %;R@  879T92TR,#(T,#DS,%]P<F4N>&UL4$L! A0#%
M  @ :3.#6>6)-VH=,@  7$,! !D              ( !"CP! &%V=&4M,C R
M-# Y,S!X97@Q,&0Q,"YH=&U02P$"% ,4    " !I,X-9IQC: W9'   5M@$
M&0              @ %>;@$ 879T92TR,#(T,#DS,'AE>#$P9#$Q+FAT;5!+
M 0(4 Q0    ( &DS@UG>F!R3!B\  $#S   9              "  0NV 0!A
M=G1E+3(P,C0P.3,P>&5X,3!D,3(N:'1M4$L! A0#%     @ :3.#65YCB!+4
M,0  ;R4! !D              ( !2.4! &%V=&4M,C R-# Y,S!X97@Q,&0Q
M,RYH=&U02P$"% ,4    " !I,X-9B@;*)6DQ  !"#@$ &0
M@ %3%P( 879T92TR,#(T,#DS,'AE>#$P9#$T+FAT;5!+ 0(4 Q0    ( &DS
M@UDC_5 WB2\  -OZ   9              "  ?-( @!A=G1E+3(P,C0P.3,P
M>&5X,3!D,34N:'1M4$L! A0#%     @ :3.#69Z!]&($=0  !B # !D
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M9#(P+FAT;5!+ 0(4 Q0    ( &DS@UE@_['()64  #.I @ 8
M  "  3X\! !A=G1E+3(P,C0P.3,P>&5X,3!D-RYH=&U02P$"% ,4    " !I
M,X-9:G,XK$X#  !."0  &               @ &9H00 879T92TR,#(T,#DS
M,'AE>#(S9#$N:'1M4$L! A0#%     @ :3.#69=P]_0< P  [P<  !@
M         ( !':4$ &%V=&4M,C R-# Y,S!X97@R,V0R+FAT;5!+ 0(4 Q0
M   ( &DS@UE]H#.BP 8  !4?   8              "  6^H! !A=G1E+3(P
M,C0P.3,P>&5X,C-D,RYH=&U02P$"% ,4    " !I,X-9UR"09392   5-@(
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M,RYH=&U02P$"% ,4    " !I,X-9//KNZ5X$   R%   &
M@ 'U0 4 879T92TR,#(T,#DS,'AE>#DY9#0N:'1M4$L! A0#%     @ :3.#
M64U#PD9A!   (10  !@              ( !B44% &%V=&4M,C R-# Y,S!X
M97@Y.60U+FAT;5!+ 0(4 Q0    ( &DS@UFZO3YT700  "X4   8
M      "  2!*!0!A=G1E+3(P,C0P.3,P>&5X.3ED-BYH=&U02P$"% ,4
M" !I,X-9+RQ=8J0+  "PX@  &               @ &S3@4 879T92TR,#(T
M,#DS,'AE>&9E97,N:'1M4$L! A0#%     @ :3.#63Z$,8\]W0X ,+R+ !0
M             ( !C5H% &%V=&4M,C R-# Y,S!X<S0N:'1M4$L! A0#%
M  @ :3.#62C[P>H3)P  &2@  !<              ( !_#<4 &%V=&4M,C R
M-# Y,S!X<S0P,#<N:G!G4$L! A0#%     @ :3.#67 0EX$$)@  ""<  !<
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M=&4M,C R-# Y,S!X<S0P,38N:G!G4$L! A0#%     @ :3.#6>0:FI,VU0
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M,C$N:G!G4$L! A0#%     @ :3.#61E?T(P?IP$ Y;8! !<
M ( !H=<: &%V=&4M,C R-# Y,S!X<S0P,C(N:G!G4$L! A0#%     @ :3.#
M6>CQ1;*=# $ +A4! !<              ( !]7X< &%V=&4M,C R-# Y,S!X
M<S0P,C,N:G!G4$L! A0#%     @ :3.#6<=6SV\S3 $ *U<! !<
M     ( !QXL= &%V=&4M,C R-# Y,S!X<S0P,C0N:G!G4$L! A0#%     @
M:3.#6>;*I\[_.0  7#\  !<              ( !+]@> &%V=&4M,C R-# Y
M,S!X<S0P,C4N:G!G4$L! A0#%     @ :3.#62D*_ '%(   A2L  !<
M         ( !8Q(? &%V=&4M,C R-# Y,S!X<S0P,C8N:G!G4$L! A0#%
M  @ :3.#6=VE;02OM0  ML,  !<              ( !73,? &%V=&4M,C R
M-# Y,S!X<S0P,C<N:G!G4$L! A0#%     @ :3.#6="=CC4G'0$ !C0! !<
M             ( !0>D? &%V=&4M,C R-# Y,S!X<S0P,C@N:G!G4$L! A0#
M%     @ :3.#66H5S4K_'0  $A\  !<              ( !G08A &%V=&4M
M,C R-# Y,S!X<S0P-#(N:G!G4$L! A0#%     @ :3.#6>NW)N!$%@  (!<
M !<              ( !T20A &%V=&4M,C R-# Y,S!X<S0P-#,N:G!G4$L!
M A0#%     @ :3.#6=DRB\Q!$@  *A,  !<              ( !2CLA &%V
M=&4M,C R-# Y,S!X<S0P-#0N:G!G4$L! A0#%     @ :3.#6>?%V?'$ 0
MAP(  !<              ( !P$TA &%V=&4M,C R-# Y,S!X<S0P-#4N:G!G
M4$L! A0#%     @ :3.#66S0[:S" 0  A0(  !<              ( !N4\A
M &%V=&4M,C R-# Y,S!X<S0P-#8N:G!G4$L%!@     T #0 % X  +!1(0
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>avte-20240930xs4_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:avte="http://aerovatetx.com/20240930"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="avte-20240930.xsd" xlink:type="simple"/>
    <context id="As_Of_8_3_2020_us-gaap_StatementEquityComponentsAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_c5TH3GCKvEGQuOxOnb7Lrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="As_Of_8_3_2020_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_lrXI44Ykp02VlKaxJ3Nieg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avte:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1mDefc7T6EyF8Qo5feNffg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mK0glKtp20-JMUhi6bQzgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SOdnYt1ZJUmGZUp4nkZ_Dg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eIQAEotTfU2ghqhEOp-9tQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_GUQQrLL2E0uGyzx6Fyxj_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2018_To_8_31_2018_srt_CounterpartyNameAxis_avte_RaCapitalHealthcareFundL.pMember_f26Wjuj0S0u8Hw2V4pgTMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avte:RaCapitalHealthcareFundL.pMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gOVZr7JYNEKGhCeqwxOmnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K4s3v6nxgU-obbx2d9aSOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OqpE3l_LB0G_beKE0PBP5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uXs3dXPjTUaFIqn7C-QEEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_70YqRRSkWEWlj8cmh1CBtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2AicAM6JCEOlEUXMi5ktng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_vPXXIZakVEKr1VLr1ptsQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_FsIjL_FCA0ypY_AxEKEtOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Y6cZV9QIL0C4SojMpiXIJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_lCewvdNJxkWfBMMcTCfUEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_V-lvpQAYG0u0LVvYzwbGTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CPH6za25g0uUfCifzsYkkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vnVV5804C0ScsiBOSJ6srg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Y99KaUn2oUW0_Rr118_mxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_qUiBx0SpzUGr9LR_aNTQUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_QLbiEq19A02perNXBXbTKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_r3UKbN8hp0mfWhezRkf1lQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_UqfaQqRd1U-rmSnO35M5GQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UCLAdEOov0OXILzRhTTw3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZE61xkcRkUCNaq4gU5yrWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FJ3Ctxrxc0CDo2XUQUe3QA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KPy_Azxvr0mBNfoqRZD5Ew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VpGpQUz2xki0YzMNgZlDQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_afA-gfdpa02BAMGQN_YZBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_HPAMtIcY9Eq1U2SHfyr_uw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_M2y81zs0L0Oc7hgVHJlBTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HWbpxkODu0WkRFHnGDEkSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_HyF9ifdj0Ui9zRFDa7dqYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_Ju0lA-npTUKKlfj1h0_hIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_a5ipJvXbekyb6Q7U_qk5JA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dcFzNA8x9Ui_AjpnWINDyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QECF8CV7f0Kgvhlc6flPyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZtSEQpTQBEWAhx3kbiC17g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_m_AT2h9P5EyXiFBYKZDj7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_VEufXZsdzEu6C4BySyFyBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_wvATQii3UU6_fDF_T6RfnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_s7LhYqe820KPsrH32hrUXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_gxzbNSquREapCV0wgG6K_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_9J-eqG0s9EqtvXrgFV1g6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_HTNjaqHx1UmoE5boQ95RMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_VbGf1ULGCUm2eW5RKvPgKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_B2h8T12AhEy09dFKjhebjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_Z4bGGvwZkEKAnVLtaP7k4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_RToG1KKrEU2I3goa1SB0fQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_cYlSXcLKKkmR--QmXRet5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_zGfui5LVXkSMPfb_dUdAhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_r3JexBQzmEy8wd3QhtRFlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_r9QjcP-Lg0ePFAB0AX5tPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_DbsTo893-0aN2-ZX2BZP2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_tzNK_fGEakm5HbGQ9zPcaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_PbzReIi7W0qZtcZBeUxt9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_xuDF7JacqEyVD_8bE4KGbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_paK6hjSIN0utjCqZ6uTFBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_Qsv0Icq8UEm3CaReRWRLpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_878tdSddu02PyGWA-g7TfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_ZI4VzLqXf0WVcsu5oJ_P-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_GLAldi10KUCn9sv4BDXzvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8Ja-oIvtvEOUSt1VbId_rw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_YfltLULy-Euim90Lqzh2Iw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_23DxYpsziUKkF0FV76-EIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_2EbSprzX4UmWm8yxfF94Hw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_dAN4ZtziuEiP3QwWp9yKPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_ywomA-WM5EmdfslLNmeoUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_NYTb6k4rLkCljLkmM_mSYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_14Q4SyHhfEip0yfmjiQBjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_SnzjzhUup0auURpf_CvbCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_8pnWeqBIpESIlttN4ujbaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__iWQPWvZwkOiM4XiYpOJ7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_geY3vwOu-UyPu9NwOyIAkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hMDvqIPNTkyi3vwRMi3AWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iFYHzpsOAk6upQL9o0JHJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HmDl-Xe2CkiW7tLgrbq_Fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uKGL0eef7kyr6Ltc79lK9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vWNBs-3fkEi8yguhaSbYeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bPKy-329i0a269T7iYdlfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8NQImWg4J0qy7AIOsD5XtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2018_srt_CounterpartyNameAxis_avte_RaCapitalHealthcareFundL.pMember_MybYzQoXkkeq-kvOFSYqcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avte:RaCapitalHealthcareFundL.pMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_wlI-MiSjLkiqAu8-lbQ9Sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyEighteenStockOptionAndIncentivePlanMember_5jF5V5Er3Eu8MevJLE47ZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_12_31_2023_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_xUfhDItNQkiJKYFlFdOMwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_i_a9v0UQS0KpP37FqkD36Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_s-aYJQaQfEO0AGSWXOYO6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_oV0DwhFiqUeSjADTrzXG4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyEighteenStockOptionAndIncentivePlanMember_J-NqcxMgNUSJ7I39_xVsUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_rO2RmIvkokKdeJv-xbshfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2024_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_Heb8BZ5jAUughxoa-nLBgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_p7xQ831-8k-rQnNZukmxqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_jOQSNYFMiE2CvUhNjVDLEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_ePMqutmojUyuoaStQiHwbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_1_1_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_7n9TuWQvlEKuoOSnaqxmoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_73e_CZGNZEyHg-KoZi_SKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_Ftq0AHVniEWCeuEfN5x_ZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_KY3AqSzTb0OwCTsNTj4W_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_7qar8kvNhkGFswXJGPAVXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_AM4SWxu1AEWvAgiUoTpxpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_gcSTyLkkmk2V2zzgD-_vtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_g2GESSwZAUiWFez9AGcUtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_ZBG0wBshS02tcTB4D_om6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_cbrxP5-YikuDmBVJrOS3Sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_teg0ACtMzkG-j6fB92sMEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_KBzCYJ3aOkiZwx3mZ7SYTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2flsdvnZxUqHPV0GQoL5Gw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_x6W-38r_4UO4O_0NkamyBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_kdwiV7iJm0yXiFQVoEPDqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YD6uCjdaok-GlOfcPMgZfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember__SKGl6wkOE-Kjnfpn0KZcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_R7ajYhISp021nisBN9RonQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tKrwYaxnJk285FLx0psBsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_wbLsz84n5UemDXpr6FCylA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mQCZMz_2oEWLJpuw7OHgvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_uPFIHMkymk27XMLFjHO_1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_dh_QB-NHhUST-PrSPEqJ1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_8Cexqi34OkyeCy4KU0ckUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_WbyCz7z-OUWYQdDXhY6H5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MM86-nEOIUC1fgZNk-MY1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_mxwv-vX1-EKBfodK731-kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mCr7TNm_z0awNKcONlrnIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nOSs2A7SvUChDUg7Gvgu0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_t77TAzlnOUGgpyEM6N3T8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_GhxOUzzS90-GzmvIc16b8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_8aHt_5B77EiYc-jzE1Txdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_5_2023_To_4_5_2023_srt_CounterpartyNameAxis_avte_BofaSecuritiesInc.Member_eXGnRQpI10OVMaKnBBIqeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avte:BofaSecuritiesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-05</startDate>
            <endDate>2023-04-05</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_W6CC4s96t0iIo9WxVs7plA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_nBfMkaz2rkyUUeyEAYEfkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_srt_CounterpartyNameAxis_avte_BofaSecuritiesInc.Member_fT8d84SKjEiyXJr9wvIUUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avte:BofaSecuritiesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_avte_BofaSecuritiesInc.Member_LeFPgJGk10aB82UXVdtuHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avte:BofaSecuritiesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_Omgdwr0yakip4mYX2MbLqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_LI5YHiUWtUqb-dWGgEgt2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_pWvY-k6LJEyAy3X_g6pRyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_WDqRejYbEUSzCLXwlEWRhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_hsfYMw1YQUiRxCSpEvhLOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_4mWrWAlR1U2qPGLn2vS_fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_PLHhQPxnDkGS0X1B4pdMdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">avte:FosterCityLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_Db-jvbls9U2OcKGqstWiEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avte:ServicesAgreementWithCarnotLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_GK_CqlKS30Gm2NvMdNBc3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avte:ServicesAgreementWithCarnotLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_j8k9mWHPuUaAW-sNf4hesg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nyimchTjV0KbghS9hcjUig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UlG_BWompUqeXJDTFYDksw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pv40wdBMdU2Z1HGOA_ocaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fB9Oej3iHEuLzftkJpBxOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Rr0GlkP2XEun1mQJs3HD0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aXw1Zj8XYkqQuwDSYY4ipw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KuqcIl38qk-Am_HOfAm4Iw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_1_31_2024_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_zn19noNKY029l5Ec-T6CTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">avte:WalthamLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_b5ksvgJaa02KO-43SndRnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_6Bs2-neN-U2EmecB-QIl0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_JDWj8X9B5Eu8UjEOpYq-Pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avte:TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_8CT_KtQnWUiGek0hhT0EXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_SfcoGV5hFkuKGuO_rvH3RA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_wy5Ete1m60Gp0JfLF-sD_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_g1st23sQ50KGJ_c8e9kcQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yYm-QanqNEuE0_c7yIDEKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_s-ZbaqOFEkqsqlAtFTXFQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_R1aNdniYp0yg5IJCGgDujA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_y1zASwVL00OvpCxcnCK7Yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rSCB_jEoQUWrJ9udMpqr1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_2_2021_To_7_2_2021_zM4kB7thfEaK38J25p-KHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="As_Of_7_2_2021_w8fg7T9i30-Tb8oR9Nn9Ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_WBdMq-xE_k6SSkWqaFUxDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_7LIRbHXsBEeM6CKDpiodeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_CommonStockMember_euLPHJw1sEmiJdRRSszShQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_4YcJ4RjRj0GB-mGnU1wJUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Gy-ZvYruXkinoI8nJEgktA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_aLb1VNRswEiUg0bp5BxGmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_CommonStockMember_YflOQXijzkee839-W5_-ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vFkjMAci2kCM1_635tV-aQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_n9o8wjs2y0evFtOumxNmtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_eQIO1TPDN0uO88FWDH85mA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_qTxFaY50VUaWw7Jr5uMTQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_C-UwaOvYgEmhc5KbjSNoaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_jXLEnvJsuU2DjT7WrX1onA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_F964c7FBf0qgpnkWSEYhwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AyHw9eprTkCuYHbb4OSTdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_e-zMRu88YEulFM6FDn839A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_3SZLVaYF3Uaoxk9Z6taH9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8yGurj7uGke-WnYhN4sOug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YzIcvZaeZUu6LSDu8bymCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_HnxnO2kja0uIhwuJkAHhcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_fyLg3XbfjUyiu8CJN34Bjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_PE43wqGHWU6QaYBuVIux_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_cMFhMcP0AE2-6VZ7iiNWxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_GL6agAj25k-cPwtptPUzow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_xThuN_5MDkqYF87Q3NeYSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__yohEd5oXkm5sOjdtwzPqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_dKc-asA1AkOzmsiFfkV83w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_d-MHPg2o6kmGhmn8RSNWEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_sWDh72OE6kSOPCSLEhKjBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Uy_OzIg220WOoPfwtTN9Cg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_alE2cQWlWUmYEMSvxQfOpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Lk-ps-R70EiQI3935QJvXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kHkV564Q4kqYbVZPXq-xpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Kcx7c1ohMECfaPSrYxC0Nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_sGvwx0X7s0WPUgXlH8FQrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">avte:FosterCityLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_psQydqKoEkSDWEV9UfDtig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">avte:WalthamLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ZpDGpfQ1TkilwLHCKcIxnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_3UmwRa-EAE-11acDMKDuHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_KH1NXBTyjkur0ov9ZtwkMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_shfv-0j6hE2RH9wjzcjK0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_VNugwlI_n0evghUr12SqYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_QNvV2K_cRECh_I59hVJgKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ChUwiv23hEy7LMz7LGvpuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_LZBhq8TBukyCmnM6XHK1BQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_pLhOme55706_ApNfgYI-eA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_z3LyNn-sk0-txThcBPD1Yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Cxy8Whj0fkC98fl4coAgEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_vfttyrGb-EW4_y-k4IU1OA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_h9FVlzwiVkmij0mSQNLnEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_SpjyK1AxVEqPXklSW5dc7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_DdnUA-mndEmQoBFn-wT6ng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_8Qb64bPhgUq_qlFXMzlYzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_tQTCT3FErESwh4_H6D13eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_eKXqES4MhEC5wSlAU18O1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_W3X1hUg8vke6Gh4fxUQQlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FLsOS9KJZUm-Ldlf9yt1hQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tfvBCfSvrEinR9S17WhtYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_gnY1UC1Lf0eSFvl6XWqbGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pzSeRKqRmUWfGQi3u9vQfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_FUDixdV2nkO01qprXRWNww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ImI5-uZhs02-PHLXTrl4zw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3YNubJsuwUyt1b4HmIVa7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_0RTLeeNjREWrXNlRldBizg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_RQUeGZjabU2LSVSR_5lP_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_G7iErj3me0qVgh1ge_DiqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_tdpGz56jqk6Dn9XNb5jQVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LKCmt_IMoEm2kACXc_PCig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_fjXbQ_EYZ0OduVaJ4JsVzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avte:ServicesAgreementWithCarnotLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_0tBp6f6PUUW7kvis6j685w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avte:ServicesAgreementWithCarnotLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_srt_CounterpartyNameAxis_avte_BofaSecuritiesInc.Member_IwOYf_4k8kOpNBRHvM5Rxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avte:BofaSecuritiesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_avte_BofaSecuritiesInc.Member_t15u6BZEqkaKnYEH9TOQCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avte:BofaSecuritiesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_l2cNv6JCfkyvIREeesp36w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_WvqE0K12M0iiC1AH3k88Tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_7_31_2019_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_n2CK4UQgq0-A1CPzs_pKqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avte:ServicesAgreementWithCarnotLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="Duration_10_30_2024_To_10_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_RPVQa3dXU0OggwPnCBtwgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-30</startDate>
            <endDate>2024-10-30</endDate>
        </period>
    </context>
    <context id="As_Of_10_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_UR7pUGE3y0avsGAAh5HJFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-30</instant>
        </period>
    </context>
    <context id="As_Of_10_30_2024_dei_LegalEntityAxis_avte_JadeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7tb7W4BvUUu3IUTHi97FXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avte:JadeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-30</instant>
        </period>
    </context>
    <context id="Duration_8_1_2018_To_8_31_2018_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_-N_0UjeZlUm9GQWNR1RVdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avte:ServicesAgreementWithCarnotLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_m3e0XkrsxkWOCq0GHEPF6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">avte:FosterCityLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_DaiW5HZ95E-5aglfFdRpPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">avte:WalthamLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_1_31_2024_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_PodE97lmJkSHEwoc1aClWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">avte:WalthamLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_0Iv5XCHgWUyuS-1MyqMPSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_SYM7muK7eU6UOC8tcjKjzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_BlyAQCATVkGjKh-kOfQdJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_O8QXwFu-kEqrEQwa9rKRJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_eZcGsEFbHEW38q44Yr6mVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_OlIabHctWUyzxlnqkr4bCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_rsRxqqwUvEm2inEelixs4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_zaDLiCFPqUqEufSLy6NbzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_qYrKRTeZrkCEoPKcnJyr4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_YQFimAiCRUGyikQapBgwVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_kql4M0ph3Umd2bhh5TV1nA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_8_3_2020_EcWWeWov-0O5egWgb1IO4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_Vote_68Fy5nhdn0WonvfwhauHwA">
        <measure>avte:Vote</measure>
    </unit>
    <unit id="Unit_Standard_sqft_5xtOY_aM_0eoVegCdMhIVQ">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_Standard_segment_bCa297tYP0mkIHafmd-9BQ">
        <measure>avte:segment</measure>
    </unit>
    <unit id="Unit_Standard_individual_HQaf273bdUKcqMGv_RJZsw">
        <measure>avte:individual</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      id="Hidden_D8P5g644MEqYiCcOi5fx2g"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      id="Hidden_KQ43XTa71UGoOuPuvoxvkQ"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      id="Hidden_UTi9VdCHy0yvkZrI7rz-4A">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      id="Hidden_ki9xJbPqnEiOMq8YpIJHoQ">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      id="Hidden_9AOUSbiMT0-FAEyAzmzKuA"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      id="Hidden_5-ruO4LtJES2K1msXUwd4g">http://fasb.org/us-gaap/2023#ShortTermInvestments</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      id="Hidden_hQmR02kie0SHXecfenEnnA">http://fasb.org/us-gaap/2023#ShortTermInvestments</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tc_uPlj5sCms0OGS1TNNkDgng_0_1">0001798749</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tc_ZaGaVv1mSEad3KsvZxbdcA_1_1">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      id="Hidden_ocCBIaD8DUywIpPD-inl4w"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      id="Hidden_uqoQ-VLEfEKQOnE0P46H4A"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_W6CC4s96t0iIo9WxVs7plA"
      id="Hidden_n34-iiJT30mFenREfVs5IQ">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_nBfMkaz2rkyUUeyEAYEfkw"
      id="Hidden_g3-e0FT-IE2Xj7oAU60QZg">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_x6W-38r_4UO4O_0NkamyBg"
      id="Hidden_VYoFbHUwRE-bLITQC63xcQ">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YD6uCjdaok-GlOfcPMgZfg"
      id="Hidden_eUKRKJ4iNkSfQy8r2Vg3Mg">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      id="Hidden_LfTcQM9iZEGlLfhH4tvpYg"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      id="Hidden_BTUAgG66VkC8uiBG5TgIww"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      id="Hidden_g-F-zaysXU2M6cBzvAutMw"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      id="Hidden_4JwO-qU5RkW6VPbwSIIzwQ"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_qTxFaY50VUaWw7Jr5uMTQQ"
      id="Hidden_NvvtqfTNDUi3pAQbMuV3Iw"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_eQIO1TPDN0uO88FWDH85mA"
      id="Hidden_W5lZ48FLCEy_u2gCz_QeZg"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_sWDh72OE6kSOPCSLEhKjBQ"
      id="Hidden_EIT7Ft-M4U2oTXvtr5qvPQ"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_d-MHPg2o6kmGhmn8RSNWEQ"
      id="Hidden_XpL8HTw1KUeUXBHbhjlt2w"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_Qsv0Icq8UEm3CaReRWRLpw"
      id="Hidden_lN0AgyYwBUGSBPvHUXVvCA"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_zGfui5LVXkSMPfb_dUdAhA"
      id="Hidden_ATiC6JEvSUm2xAjs-Qle-w"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_ZI4VzLqXf0WVcsu5oJ_P-A"
      id="Hidden_FAR9X24s2UOjJM_mFfQemw"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_r9QjcP-Lg0ePFAB0AX5tPg"
      id="Hidden__tPLOVORX06K05WNcJNPHQ"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_DbsTo893-0aN2-ZX2BZP2w"
      id="Hidden_hGln6qJd7kWjTm5e4HDgWA"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_cYlSXcLKKkmR--QmXRet5g"
      id="Hidden_sBbWTO6GDUu9JQZjdyFFlw"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_878tdSddu02PyGWA-g7TfA"
      id="Hidden_Ib6YuqwgvUOu1jkJDvoCZQ"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_r3JexBQzmEy8wd3QhtRFlg"
      id="Hidden_HN51f_bDUkShpzdYGLsCOw"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_d-MHPg2o6kmGhmn8RSNWEQ"
      id="Hidden_sNomPq10ZESk15LyPnEosQ"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_d-MHPg2o6kmGhmn8RSNWEQ"
      id="Hidden_YNU4YHIeWEuPQ_VjMX_kCQ"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_psQydqKoEkSDWEV9UfDtig"
      id="Hidden_QkmZslh310SYGgzTas8QSQ">P39M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_sGvwx0X7s0WPUgXlH8FQrg"
      id="Hidden_5dOxBlntyUCTd-8nElVMiw">P39M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_sGvwx0X7s0WPUgXlH8FQrg"
      id="Hidden_mWsXBWWQvkivgmOrUGyQhg">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_cbrxP5-YikuDmBVJrOS3Sw"
      id="Hidden_OXhRKVDiBU-X90wrZ-v3BA">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_KBzCYJ3aOkiZwx3mZ7SYTQ"
      id="Hidden_Sk9GO9o6hE2czOoGU9-uIA">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Narr_3KYIRfLgmk-7CbIjnUNFmQ">S-4</dei:DocumentType>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Narr_OVtRYY3e2E2B1suk5YAvfg">AEROVATE THERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tc_LizwkTAaCEWmu4PvpR-TDQ_1_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tc_8reE8S0-r0C8lyPF64GguQ_1_4">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tc_VBLyJ8t71UGrkboJOx3WBg_2_4">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Narr_iSFW0TBvkkW2QUA-JRG49Q">true</dei:EntityExTransitionPeriod>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_RBvDLJARpkyVI629bT_O3w_5_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">23491000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_w_M0NlG0qkqUWSHNs7lolw_5_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">22397000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_2I6dbzCp1E28FQ2CXHWbIQ_6_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">98948000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_SNbXbFRofE-etw4ACbY0gw_6_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">106823000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_G5rHKPs8KEaXQbRYvw7emA_7_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1793000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_26pd06G7pUyQu42gHsuTWA_7_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">2276000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_SZew7qlDTE21pr9CS6diBA_8_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">124232000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_GOqgEJbDtEKGokmIhijQfw_8_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">131496000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_AqKKDY-0Tky3iNM_jFWsaQ_9_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">288000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_4JZYNfiv3k6AJfPOttuMNQ_9_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">242000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_h8soSiCkUUWJhyfe3820Dw_10_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">614000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_9KQ8y2z-RkuQD7SnkJYWIg_10_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1003000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_NMPq4t4vAU-b1ZHtR_4Ghw_11_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">2284000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_HLNeZdJB3k6gFYMpeB51TA_11_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">2560000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_MV0AK4Dk7ky5K3oIz2baYA_12_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">127418000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_U6XIiiZHdEObLWOlWs6ogg_12_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">135301000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_e3IdSMaBh0iJDDemRmg5Sw_17_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">2396000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_qcOKE13jT02CekzznRqqvw_17_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">2575000</us-gaap:AccountsPayableCurrent>
    <avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_1K2KV7v5rkmwRfi7cpPDXg_18_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">14821000</avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_K95hKUGRAkiMXz8cqxGrTA_18_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">4822000</avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_Gs-xXUD7iEaKHCkQ1ckWOQ_19_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">420000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_6b0IrQReC0K1ew3IwO5GqA_19_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">385000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_w2v-8mJ16kWJ1fyKqhzOVA_20_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">17637000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_h8ahAS1PdkuJY8_KxpnlRw_20_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">7782000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_SAbXAi-kA0iYUk8Ie8anaw_21_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">255000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_20BMFTm-EkmmDiz2Y9mqWg_21_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">705000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilities
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_RBuh7EPNBU6aQMgVjmq0cA_22_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">70000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_qFsMFBRn4U-9CTfJPc8q9w_22_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">71000</us-gaap:OtherLiabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_zjvLiHkakUSRLYJjWXvvdQ_23_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">17962000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_Dx52aToRvk6yZMNALkKs7A_23_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">8558000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="INF"
      id="Narr_szf5J-nRaUiQ7t8URD_uQA"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="INF"
      id="Narr_DMQn_d65nUqSk8UH02_9vw"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="INF"
      id="Narr_0i4tRXuaG0iJpqgrQvrrAg"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="INF"
      id="Narr_c2_1D6PxeU23E4H55I7ocA"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="INF"
      id="Narr_hWRwdFxw8kC_orvD4O8xlg"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="INF"
      id="Narr_Ld1x0AtFjkKwSXWvKn4UQg"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="INF"
      id="Narr_g2e4IoSuW06sC8pj90RY0w"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="INF"
      id="Narr_NkZRpGpGFUixSsL_fmNS5w"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="INF"
      id="Narr_BgwSDfALt0mhQn2buc2wyw"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="INF"
      id="Narr_IQgLvzABWE24tfKZQBv28w"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="INF"
      id="Narr_9DicjN_tp0CAB6y3o7DJ0w"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="INF"
      id="Narr_UGCpdin1m0idpDxWLqd6bA"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="INF"
      id="Narr_RsTUsZqqoUK7Ze1HQIQehg"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">27762703</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="INF"
      id="Narr_idlN_PQOc0WoQFXIyyPp7g"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">27762703</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="INF"
      id="Narr_Yzsyis-9_UiIadiKW4jYBg"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">24722974</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="INF"
      id="Narr_WO-semx4sEO9ebCV5aYDQQ"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">24722974</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_yPrt11I0T0GsYdE35vG8uw_28_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_tGdrcV1JmUGZk4r4uGP4EQ_28_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_9RPFJlHX_0-F7gieNtKPYw_29_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">272640000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_LqsXhT5__0eZpgeKlUrSxg_29_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">215110000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_1QkhxlNxDkqopSyhAIhQzg_30_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">237000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_6k3rBlreR0O1SInhsyvaYA_30_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-466000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_zJJWFDXAmEmwiLxmRZxb8A_31_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-163424000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_fcURjK3t2k2BaNj-_yU3WQ_31_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-87903000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_X4yPXGV_rUuQDT761fXvxA_32_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">109456000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_Jv4dKwVRb0uGOHlhPjKC0w_32_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">126743000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_5hA0bfnWeEC1ix2_jr_PTA_33_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">127418000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_JV1yxVnPhE2HsAJ7q8q9VA_33_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">135301000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_Ujvm-tCR0UCKiZoSNQV6Qw_4_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">64219000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_-CB0Wjvrz0qjB21vBzk96A_4_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">38622000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_O1xySUlqREmXvEeuoQV1ng_5_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">17190000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_gt_JkRbPE021ahzzZBTtpw_5_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">14615000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_2hi58gNk3E6rIsnipS0eSA_6_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">81409000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_XXOAoKu9DEmWzyK0PKhNKA_6_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">53237000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_ojOfg7KOw0igdxqIdwgGCw_7_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-81409000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_yBDAw3-4wk6kgD68w5mWJA_7_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-53237000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_xwh4BI6lVkGNb2zDdSr0-w_9_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">5945000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_sChcVcmLrU6b_FudgpMI7Q_9_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1830000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_qqdrdxtZhUOtNBICcWs93g_10_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_4TVCClLNB02mLkwnRZnsdg_10_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">79000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_mgEb8Zt3VkmQ0r-RpjrW4A_11_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">5944000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_KaJlC7MdGkqEiaVrrhllHg_11_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1751000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_A6rk2WNWbkWYIrd8u9gFQA_12_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-75465000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_POFjsgs9lEql51QSasdLVQ_12_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-51486000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_wMyGAkbx-0mOz3EEwiCS6w_13_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">56000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_0xJpqFa-90OLayQ0C8zmDw_13_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">25000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_OcbVeE9vV0qHoHlFqD-s2g_14_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-75521000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_poDjjiKd5EabCP3QVfQlgA_14_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-51511000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_Fu1FM9TQJ0KfQGxCD9VClw_16_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-75521000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_d6_J7L87AEKwhX_7q53zXw_16_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-51511000</us-gaap:NetIncomeLoss>
    <us-gaap:DebtSecuritiesTradingUnrealizedGainLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_8IPzhIg12USMibxVnfOikg_18_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">703000</us-gaap:DebtSecuritiesTradingUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesTradingUnrealizedGainLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_8F5uaYj96kGrhI9k2YTJlw_18_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-407000</us-gaap:DebtSecuritiesTradingUnrealizedGainLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_gk0EhE6nr0-HCC8wX52CKQ_19_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-74818000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_GNgyQpybzkm_mwfPgRxovg_19_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-51918000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="2"
      id="Tc_S6k5mG-R20KpoYR_htN5yw_20_3"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">-2.87</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="2"
      id="Tc_S6k5mG-R20KpoYR_htN5yw_20_3_2"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">-2.87</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="2"
      id="Tc_FfeoVXijgEevX1DjuvuvMA_20_6"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">-2.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="2"
      id="Tc_FfeoVXijgEevX1DjuvuvMA_20_6_2"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">-2.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="0"
      id="Tc_VHOxdwU8x06_40T9HRVecQ_21_3"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">26331630</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="0"
      id="Tc_VHOxdwU8x06_40T9HRVecQ_21_3_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">26331630</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="0"
      id="Tc_GYvMaFgeqEOsybpvZYLLTQ_21_6"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">24472104</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="0"
      id="Tc_GYvMaFgeqEOsybpvZYLLTQ_21_6_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">24472104</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8NQImWg4J0qy7AIOsD5XtA"
      decimals="INF"
      id="Tc_wXMOhDjbqUmA6yhiKYSpiQ_6_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">24410393</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8NQImWg4J0qy7AIOsD5XtA"
      decimals="-3"
      id="Tc_dlxKmqFeP0mDrB3YYgTMlg_6_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_m_AT2h9P5EyXiFBYKZDj7Q"
      decimals="-3"
      id="Tc_LbrtTlv5f0CSZrQhRFn0MQ_6_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">208867000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_VEufXZsdzEu6C4BySyFyBQ"
      decimals="-3"
      id="Tc_AQWpD3FB-EWrVr0CCdSv7Q_6_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-59000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZtSEQpTQBEWAhx3kbiC17g"
      decimals="-3"
      id="Tc_g0Xyup21qUG3nnUtM2aP8Q_6_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-36392000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_3SZLVaYF3Uaoxk9Z6taH9Q"
      decimals="-3"
      id="Tc_UtoNkt5fUk29EoyeLZtRkQ_6_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">172418000</us-gaap:StockholdersEquity>
    <us-gaap:DebtSecuritiesTradingUnrealizedLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yYm-QanqNEuE0_c7yIDEKg"
      decimals="-3"
      id="Tc_DKqv2XF_Ukuv8dWcgvQ0UA_7_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">407000</us-gaap:DebtSecuritiesTradingUnrealizedLoss>
    <us-gaap:DebtSecuritiesTradingUnrealizedLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_mRp81Oz_kE2K6kcwN2l4bw_7_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">407000</us-gaap:DebtSecuritiesTradingUnrealizedLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LKCmt_IMoEm2kACXc_PCig"
      decimals="-3"
      id="Tc_jFOtTpec90qPPDShqJQSOQ_8_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">5476000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_a8kRPxNnxUynoYIeCEyirg_8_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">5476000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uXs3dXPjTUaFIqn7C-QEEg"
      decimals="INF"
      id="Tc_zz289nzbzU-lfdLytpyfZA_9_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">298712</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LKCmt_IMoEm2kACXc_PCig"
      decimals="-3"
      id="Tc_bqSZtXIqFUqSNV-79q4wEg_9_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">617000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_Ed-8lNVtckeLz3v2LLR9Ug_9_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">617000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uXs3dXPjTUaFIqn7C-QEEg"
      decimals="INF"
      id="Tc_-qosxU9nLkOKmTECry6ppA_10_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">13869</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LKCmt_IMoEm2kACXc_PCig"
      decimals="-3"
      id="Tc_wDexsXU3rUC0k-inrpWv8g_10_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">150000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_9dDa45UobU-Y66ac2R1fHw_10_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">150000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KuqcIl38qk-Am_HOfAm4Iw"
      decimals="-3"
      id="Tc_YcwHFZMTq0a4QXbWOGF01A_11_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-51511000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_axUC36_LJ0WQ88d8FwOnIQ_11_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-51511000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bPKy-329i0a269T7iYdlfQ"
      decimals="INF"
      id="Tc_l1SqB7wdM0ah7ziebxIbkQ_12_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">24722974</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bPKy-329i0a269T7iYdlfQ"
      decimals="-3"
      id="Tc_cGwaW2v6M0SVIyKXU86_Wg_12_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dcFzNA8x9Ui_AjpnWINDyw"
      decimals="-3"
      id="Tc_b6iJwNp-LUm2oWrrUPPKEg_12_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">215110000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QECF8CV7f0Kgvhlc6flPyA"
      decimals="-3"
      id="Tc_FQQWFSixYECMA24trtmQng_12_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-466000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_a5ipJvXbekyb6Q7U_qk5JA"
      decimals="-3"
      id="Tc_fZjd7LDgfUq-kn1cA5y4lg_12_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-87903000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_MNyO7QULU0m9tW8lG-cMzw_12_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">126743000</us-gaap:StockholdersEquity>
    <us-gaap:DebtSecuritiesTradingUnrealizedGain
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_y1zASwVL00OvpCxcnCK7Yw"
      decimals="-3"
      id="Tc_3jjz3N2hBkC-su3eOtbG-w_13_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">703000</us-gaap:DebtSecuritiesTradingUnrealizedGain>
    <us-gaap:DebtSecuritiesTradingUnrealizedGain
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_oNU0or-pWUm7mH44RDJQfg_13_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">703000</us-gaap:DebtSecuritiesTradingUnrealizedGain>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_RQUeGZjabU2LSVSR_5lP_g"
      decimals="-3"
      id="Tc_Szz2Flodg0GsaxW35vZn5w_14_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">11906000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_yjPYSCDsNEagYzMh7H-t_w_14_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">11906000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OqpE3l_LB0G_beKE0PBP5g"
      decimals="INF"
      id="Tc_isj_reVGGU-qMdZzC9m0OA_15_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">2662721</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OqpE3l_LB0G_beKE0PBP5g"
      decimals="-3"
      id="Tc_DfVZWzpvpUCArw7IV_EQIw_15_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_RQUeGZjabU2LSVSR_5lP_g"
      decimals="-3"
      id="Tc_tcVx5Lp2V0ertTlTINlUYg_15_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">44282000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_2_VeaVDchUqLvc-2DYmaKg_15_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">44283000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OqpE3l_LB0G_beKE0PBP5g"
      decimals="INF"
      id="Tc_-luRyUhS4UeIfKjlHKmrgw_16_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">9913</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OqpE3l_LB0G_beKE0PBP5g"
      decimals="INF"
      id="Tc_qsD3TVc360WQcxYw9fBytQ_17_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">338987</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_RQUeGZjabU2LSVSR_5lP_g"
      decimals="-3"
      id="Tc_4akXlDREm0az1kz07ovtoQ_17_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">986000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_UT_JNGYTtESp5K6cFoLX6Q_17_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">986000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OqpE3l_LB0G_beKE0PBP5g"
      decimals="INF"
      id="Tc_xrUtHzWSz0SSVu2olV9xhw_18_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">28108</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_RQUeGZjabU2LSVSR_5lP_g"
      decimals="-3"
      id="Tc_bOdSOQdirEm0pCTNetGAbQ_18_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">356000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_RTTqMPhE7UihoW1wfrC6zQ_18_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">356000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Rr0GlkP2XEun1mQJs3HD0A"
      decimals="-3"
      id="Tc_lZTNN_Iz6k6dAGODO1SvXQ_19_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-75521000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_OkQR4FTOLEOIA9MLtF5YKw_19_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-75521000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iFYHzpsOAk6upQL9o0JHJA"
      decimals="INF"
      id="Tc_bOhnFABIWESODoshFWttzQ_20_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">27762703</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iFYHzpsOAk6upQL9o0JHJA"
      decimals="-3"
      id="Tc_lIkUh-oDHkeHMFCDaKSFkw_20_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_r3UKbN8hp0mfWhezRkf1lQ"
      decimals="-3"
      id="Tc_kxngZ8SmJEKOXFIqywkjqA_20_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">272640000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_UqfaQqRd1U-rmSnO35M5GQ"
      decimals="-3"
      id="Tc_LcmWbDkrTk2dLMfHFxqqWg_20_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">237000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_QLbiEq19A02perNXBXbTKA"
      decimals="-3"
      id="Tc_tPJTCbK7SkqBPRi8qNf7mA_20_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-163424000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_Ayei7e0vUEmDNcjULGn5VQ_20_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">109456000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_oKA9eRZaj06waHDKtho40w_4_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-75521000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_-NAW2LSZEEKPFbT6vHg5Dg_4_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-51511000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_jZ_8F9AXQUS7w29A3pKHUw_6_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">11906000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_nDe2Swl3WUiGtuV48FOwDA_6_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">5476000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_gpwzc4NyBUa4nx2ntnjKaA_7_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">96000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_vqjyNWtfzkCaLgRnDKAf9g_7_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">68000</us-gaap:Depreciation>
    <avte:AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_jgM1H2xLskytLOKGT4ASBA_8_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-3057000</avte:AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet>
    <avte:AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_ip2UiANFeECNvdM3P3aikw_8_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-910000</avte:AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_IaqSE2_O_kCGgih5787X3A_10_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-483000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_J_2Q10vKRE-r6XIa1WW58g_10_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-4677000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_u3lt-Yk-VUaloUpzyVoFbQ_11_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">110000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_fSQ89zwqZ0abEx5Qa31sXw_11_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1872000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_bQOogcGGRU2pY15U4AG3ww_12_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-164000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_nA_oD7UHd0q--pAh4a3wJg_12_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1368000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_NtvJ_tF8ZEmxz4vTMz88qQ_13_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">9999000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_BpwObMfbFEKVRgmYCOaFgA_13_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3672000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <avte:IncreaseDecreaseInOperatingLeaseAssetAndLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_08iEXMoToUGbksdpqPwKfQ_14_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-26000</avte:IncreaseDecreaseInOperatingLeaseAssetAndLiability>
    <avte:IncreaseDecreaseInOperatingLeaseAssetAndLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_0VoaMjTBgkufsMInPLBFAQ_14_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">43000</avte:IncreaseDecreaseInOperatingLeaseAssetAndLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_mMDJi89_eUixqOtjAq-SCA_15_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-384000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_YOKcp3JtbkC1zRPSXupnNA_15_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-133000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_7_-MzsDwmU2EifSsC2Z85A_16_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-56778000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_fiin2ydNskO1UtJXyQ67hQ_16_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-39122000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_Vq9MbN85sEyZWhKFSok5Xg_19_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">123982000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_LxNofLzLU0W4d6ZVuuYNRw_19_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">147623000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_0chSRODKQUOj0DIyhog5Tg_20_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">136000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_-3WPVxbGtE6Gf4xq8-8t9w_20_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">154744000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_PewIcroWp0GCx_6m1uc74A_21_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">142000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_57yKWTPpf0Onxiokba4drQ_21_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">195000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_xe8Rqa-6DEWseA9WNbIQLA_22_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">11876000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc__gjDcmPBKEue38VT97myYA_22_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">6926000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_DWKVdqWdikGstGl2rVa-OQ_25_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">44888000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_Qta4hWJmwkGEZGYnYsD8ag_26_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">234000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_6Rku8GydRU67Sz0CO83_EQ_26_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">371000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_VSaEfrPIlESeI0_L5Kin4Q_27_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">356000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_xU0Gi6Q3zUa4GnfZCvBW6A_27_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">150000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_8sZbyod3EUqiAWs27F-Icw_28_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">986000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_3KF3xrFHKUyDJwtBAjnclg_28_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">617000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_VcIV3sEYN0O_HON0Fq-zTQ_29_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">45996000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_e0z01__Cl0Sye8RxQ7OUrQ_29_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">396000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_w5AQKLUjTE2ZHMuCcLqKhA_31_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1094000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_4tGmTCuH70-QWFkISYNvZw_31_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-31800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_UEPfRz1480Kvpn7ZwWNo2g_32_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">22397000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="As_Of_12_31_2021_3SZLVaYF3Uaoxk9Z6taH9Q"
      decimals="-3"
      id="Tc_skgz0J6XVUKUL5MUcNTwYw_32_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">54197000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_lZlDDBY78EePUUasZdzDMg_33_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">23491000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_T4mc7VFECUiEaFvuJzh9hg_33_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">22397000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_5TojZhOP0Ey4s5MC6v7X4g_36_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">765000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <avte:DeferredOfferingCostsIncludedInAccountsPayable
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_EzIcsk1aO0y94f9JvSnb7g_37_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">15000</avte:DeferredOfferingCostsIncludedInAccountsPayable>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_-fZQaktVdkKXsv2FNUJr5g">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;(1)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Organization and Nature of Operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Aerovate Therapeutics&#160;Inc. (&#x201c;Aerovate&#x201d; or the &#x201c;Company&#x201d;) was incorporated in the state of Delaware in July&#160;2018, and is headquartered in Waltham, Massachusetts. The Company has a wholly owned subsidiary, Aerovate Securities Corporation. The Company is a clinical-stage biopharmaceutical company that is focused on the development of drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. The Company&#x2019;s initial focus is on advancing AV-101, the Company&#x2019;s dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (&#x201c;PAH&#x201d;). The Company initiated a global Phase 2b/Phase 3 trial of AV-101 in adults with PAH in December&#160;2021 and announced in November 2023 completion of enrollment of the Phase 2b portion of this trial and enrollment of the first patient in the Phase 3 portion of this trial. &lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(b)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;At-the-Market Offering&lt;/span&gt;&lt;span style="font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 5, 2023, the Company entered into an ATM Equity Offering&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; Sales Agreement, or the Sales Agreement, with BofA Securities, Inc., or the Agent, pursuant to which the Company can sell, from time to time, at its option, up to an aggregate of $75.0 million of shares of its common stock, through the Agent, as its sales agent. As of December 31, 2023, 2,662,721 shares have been sold under the Sales Agreement, generating approximately $44.3 million of net proceeds after deducting commissions to the sales agent and other offering costs, and up to $30.0 million of shares of the Company&#x2019;s common stock remain available for sale from time to time under the Sales Agreement. &lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(c)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Liquidity and Management Plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Since inception, the Company has devoted substantially all of its resources to research and development activities, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations and has not realized revenues from its planned principal operations. The Company has incurred losses and negative cash flows from operations since inception. In addition, the Company expects to incur substantial operating losses for the next several&#160;years as it continues its research and development activities. As of December&#160;31, 2023, the Company had cash and cash equivalents and short-term investments of $122.4 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Management plans to continue to incur substantial costs in order to conduct research and development activities and additional capital will be needed to undertake these activities. The Company intends to raise such capital through debt or equity financings or other arrangements to fund operations. Management believes that the Company&#x2019;s current cash and cash equivalents and short-term investments will provide sufficient funds to enable the Company to meet its obligations for at least twelve&#160;months from the filing date of this report.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_4_5_2023_To_4_5_2023_srt_CounterpartyNameAxis_avte_BofaSecuritiesInc.Member_eXGnRQpI10OVMaKnBBIqeg"
      decimals="-5"
      id="Narr_25Q5FtFHPEqmqTTmswPRxw"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">75000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_avte_BofaSecuritiesInc.Member_LeFPgJGk10aB82UXVdtuHQ"
      decimals="INF"
      id="Narr_RHRszG05fEqU9YZAEBZqJQ"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">2662721</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_avte_BofaSecuritiesInc.Member_LeFPgJGk10aB82UXVdtuHQ"
      decimals="-5"
      id="Narr_tzsPsTwzAEuxmox9ypi9_Q"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">44300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <avte:ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_avte_BofaSecuritiesInc.Member_t15u6BZEqkaKnYEH9TOQCA"
      decimals="-5"
      id="Narr_yLtp3n5qwUCL0cXd4Wp5Dg"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">30000000.0</avte:ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-5"
      id="Narr_lhWJH51eekyZtmg3vteQ7A"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">122400000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_38vfvHgio0Oc-Pa-9c0bqw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(2)&lt;/b&gt;&lt;/span&gt;BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and include the Company&#x2019;s wholly owned subsidiary, Aerovate Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(b)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. Accounting estimates and management judgements reflected in the consolidated financial statements include: normal recurring accruals, including the accrual for research and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;development expenses, stock-based compensation, fair value of investments, and operating lease right-of-use assets and lease liabilities. Estimates and assumptions are reviewed quarterly. Any revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(c)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents include cash in readily available checking accounts, money market funds and commercial paper. The Company considers all highly liquid investments with an original maturity of three&#160;months or less from the date of purchase to be cash equivalents.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(d)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Short-term Investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Short-term investments consist of corporate debt securities, commercial paper and U.S. Treasury bills, classified as available-for-sale securities and have maturities of greater than three&#160;months. The Company has classified all of its available-for-sale investment securities as current assets on the consolidated balance sheets because these are considered highly liquid securities and are available for use in current operations. The Company carries these securities at fair value and reports unrealized gains and losses as a separate component of accumulated other comprehensive loss. The cost of debt securities is adjusted for amortization of purchase premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income in the consolidated statements of operations and comprehensive loss. Realized gains and losses on sales of securities are determined using the specific identification method and recorded in other income (expense), net in the consolidated statement of operations and comprehensive loss.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(e)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains cash, cash equivalents and short-term investments with various high credit quality banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has not experienced any losses on deposits since inception.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(f)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive loss consists of net loss and unrealized gains or losses on available-for-sale investments. The Company displays comprehensive loss and its components as part of the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(g)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"&gt;Level 1: Observable inputs such as quoted prices in active markets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"&gt;Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"&gt;Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying amounts of prepaid expenses and other current assets, accounts payable, accrued liabilities and other current liabilities are reasonable estimates of their fair value due to the short-term nature of these accounts.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(h)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Any expenses paid prior to the related services rendered are recorded as prepaid expenses. Such prepaid expenses are expensed in the period the expense is incurred. If the expense is for a service covering multiple periods, it is expensed from the date the services begin and over the period of the service rendered (or contract service period if services rendered dates are not defined).&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(i)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment, which consist of leasehold improvements, furniture and fixtures, research equipment, computers and construction-in-progress are stated at cost less accumulated depreciation or accumulated amortization. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets, which ranges from &lt;span style="-sec-ix-hidden:Hidden_n34-iiJT30mFenREfVs5IQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; to &lt;span style="-sec-ix-hidden:Hidden_g3-e0FT-IE2Xj7oAU60QZg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&#160;years&lt;/span&gt;&lt;/span&gt;. Leasehold improvements are amortized over the remaining life of the lease for leasehold improvements at the time the asset is placed into service.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(j)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Impairment of Long-lived Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying value of long-lived assets, including property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. Through December&#160;31, 2023, there has been no such impairment losses recorded by the Company.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(k)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;At the commencement date of a lease, the Company recognizes lease liabilities which represent its obligation to make lease payments, and right-of-use assets (&#x201c;ROU assets&#x201d;) which represent its right to use the underlying asset during the lease term. The lease liability is measured at the present value of lease payments over the lease term. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the lease commencement date. The ROU asset is measured at cost, which includes the initial measurement of the lease liability and initial direct costs incurred by the Company and excludes lease incentives. ROU assets are recorded in operating lease ROU assets and lease liabilities are recorded in operating lease liabilities, current and noncurrent in the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected not to separate lease and non-lease components and not recognize lease liabilities and ROU assets for short-term leases with terms of twelve&#160;months or less.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(l)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company records convertible preferred stock at fair value on the dates of issuance, net of issuance costs. Upon the occurrence of certain events that are outside the Company&#x2019;s control, including a deemed liquidation event, holders of the convertible preferred stock can cause redemption for cash. Therefore, convertible preferred stock is classified outside of stockholders&#x2019; deficit on the balance sheets as events triggering the liquidation preferences are not solely within the Company&#x2019;s control. The carrying values of the convertible preferred stock are adjusted to their liquidation preferences if and when it becomes probable that such a liquidation event will occur.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(m)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and other benefits of research and development personnel, including associated share-based compensation, costs related to research activities, preclinical studies, clinical trial, drug manufacturing and allocated overhead and facility-related expenses. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, as they are incurred, based &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(n)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;Stock-based compensation expense represents the cost of the grant-date fair value of employee, officer, director, and non-employee stock option grants and restricted stock units, estimated in accordance with the applicable accounting guidance, recognized using the straight-line method over the vesting period for service-based options and using the graded vesting method for performance-based options. The vesting period generally approximates the expected service period of the awards. Forfeitures are recognized and accounted for as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;The fair value of stock options is estimated using a Black-Scholes option pricing model on the date of grant. This method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#x2019;s common stock, expected dividend yield, and a risk-free interest rate. Options and awards granted during the&#160;year have a maximum contractual term of ten&#160;years. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the average of the contractual term of the stock option and its weighted-average vesting period. The expected volatility of stock options is based upon the historical volatility of a number of publicly traded companies in similar stages of clinical development. The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future. The risk-free interest rates used are based on the U.S. Department of Treasury (&#x201c;U.S. Treasury&#x201d;) yield in effect at the time of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term of the stock options.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(o)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;Income taxes are accounted for using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss ("NOL") and tax credit carryforwards. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.  The company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.  The company recognizes interest and penalties related to unrecognized tax benefits within income tax expense.  Any accrued interest and penalties are included within the related tax liability.&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(p)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one operating segment.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(q)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company&#x2019;s potentially dilutive securities, which include convertible preferred stock prior to the conversion of such shares to common stock and outstanding stock options under the Company&#x2019;s equity incentive plan, have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;The following table summarizes the Company&#x2019;s net loss per share:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (75,521)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (51,511)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss available to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (75,521)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (51,511)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Weighted-average common stock outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,331,630&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,472,104&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.87)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.10)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,230,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,110,219&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,968&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,881&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,252,312&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,139,100&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(r)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In December 2023, the FASB issued ASU No. 2023-09, "Improvements to Income Tax Disclosures." ASU 2023-09 requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024 and for private businesses for annual periods beginning after December 15, 2025, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its financial statement disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In June 2022, the FASB issued ASU No. 2022-03, Fair Value Measurement (Topic 820) - Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard will be effective for the Company on January 1, 2024, and is not expected to have an impact on the Company&#x2019;s financial position or results of operations upon adoption.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_LkkjwaXQY0K7Jvl3XBGdGg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and include the Company&#x2019;s wholly owned subsidiary, Aerovate Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_RLufNvdm7UiSEnCEv7pPFQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(b)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. Accounting estimates and management judgements reflected in the consolidated financial statements include: normal recurring accruals, including the accrual for research and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;development expenses, stock-based compensation, fair value of investments, and operating lease right-of-use assets and lease liabilities. Estimates and assumptions are reviewed quarterly. Any revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_Qv8OtQUJnkmnhi7PRwoNaw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(c)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents include cash in readily available checking accounts, money market funds and commercial paper. The Company considers all highly liquid investments with an original maturity of three&#160;months or less from the date of purchase to be cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <avte:ShortTermInvestmentPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_cLkEP-GitEGuXVPS3Ommqg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(d)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Short-term Investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Short-term investments consist of corporate debt securities, commercial paper and U.S. Treasury bills, classified as available-for-sale securities and have maturities of greater than three&#160;months. The Company has classified all of its available-for-sale investment securities as current assets on the consolidated balance sheets because these are considered highly liquid securities and are available for use in current operations. The Company carries these securities at fair value and reports unrealized gains and losses as a separate component of accumulated other comprehensive loss. The cost of debt securities is adjusted for amortization of purchase premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income in the consolidated statements of operations and comprehensive loss. Realized gains and losses on sales of securities are determined using the specific identification method and recorded in other income (expense), net in the consolidated statement of operations and comprehensive loss.&lt;/p&gt;</avte:ShortTermInvestmentPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_XyZQoenz3UKKeo8ljk0Nbg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(e)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains cash, cash equivalents and short-term investments with various high credit quality banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has not experienced any losses on deposits since inception.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_XCq1Z7SBQ0Ohr8NtAYsNtg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(f)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive loss consists of net loss and unrealized gains or losses on available-for-sale investments. The Company displays comprehensive loss and its components as part of the consolidated statements of operations and comprehensive loss.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_1cAWJ0Hz1kyIhDgXy5Aw7w">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(g)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"&gt;Level 1: Observable inputs such as quoted prices in active markets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"&gt;Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"&gt;Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying amounts of prepaid expenses and other current assets, accounts payable, accrued liabilities and other current liabilities are reasonable estimates of their fair value due to the short-term nature of these accounts.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <avte:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_Ut94TTsm-kKkjO3uqFmw-g">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(h)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Any expenses paid prior to the related services rendered are recorded as prepaid expenses. Such prepaid expenses are expensed in the period the expense is incurred. If the expense is for a service covering multiple periods, it is expensed from the date the services begin and over the period of the service rendered (or contract service period if services rendered dates are not defined).&lt;/p&gt;</avte:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_TQzxAUqQzUK5pbXB0i0i2A">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(i)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment, which consist of leasehold improvements, furniture and fixtures, research equipment, computers and construction-in-progress are stated at cost less accumulated depreciation or accumulated amortization. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets, which ranges from &lt;span style="-sec-ix-hidden:Hidden_n34-iiJT30mFenREfVs5IQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; to &lt;span style="-sec-ix-hidden:Hidden_g3-e0FT-IE2Xj7oAU60QZg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&#160;years&lt;/span&gt;&lt;/span&gt;. Leasehold improvements are amortized over the remaining life of the lease for leasehold improvements at the time the asset is placed into service.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_JKgXm5uZVEKvePH409ajSQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(j)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Impairment of Long-lived Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying value of long-lived assets, including property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. Through December&#160;31, 2023, there has been no such impairment losses recorded by the Company.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="0"
      id="Narr_Zd8-4msL_UmJnqM_bBUd7g"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_S8ro-uPMeUGET7Ef9Z-kXQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(k)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;At the commencement date of a lease, the Company recognizes lease liabilities which represent its obligation to make lease payments, and right-of-use assets (&#x201c;ROU assets&#x201d;) which represent its right to use the underlying asset during the lease term. The lease liability is measured at the present value of lease payments over the lease term. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the lease commencement date. The ROU asset is measured at cost, which includes the initial measurement of the lease liability and initial direct costs incurred by the Company and excludes lease incentives. ROU assets are recorded in operating lease ROU assets and lease liabilities are recorded in operating lease liabilities, current and noncurrent in the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected not to separate lease and non-lease components and not recognize lease liabilities and ROU assets for short-term leases with terms of twelve&#160;months or less.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <avte:ConvertiblePreferredStockPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_jfzrSjarw0i4TFw72amGuw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(l)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company records convertible preferred stock at fair value on the dates of issuance, net of issuance costs. Upon the occurrence of certain events that are outside the Company&#x2019;s control, including a deemed liquidation event, holders of the convertible preferred stock can cause redemption for cash. Therefore, convertible preferred stock is classified outside of stockholders&#x2019; deficit on the balance sheets as events triggering the liquidation preferences are not solely within the Company&#x2019;s control. The carrying values of the convertible preferred stock are adjusted to their liquidation preferences if and when it becomes probable that such a liquidation event will occur.&lt;/p&gt;</avte:ConvertiblePreferredStockPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb__UWTolqHr0KcgPvPV5IzVg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(m)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and other benefits of research and development personnel, including associated share-based compensation, costs related to research activities, preclinical studies, clinical trial, drug manufacturing and allocated overhead and facility-related expenses. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, as they are incurred, based &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_gBtrwPrSMkKmfHX8YlxoNw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(n)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;Stock-based compensation expense represents the cost of the grant-date fair value of employee, officer, director, and non-employee stock option grants and restricted stock units, estimated in accordance with the applicable accounting guidance, recognized using the straight-line method over the vesting period for service-based options and using the graded vesting method for performance-based options. The vesting period generally approximates the expected service period of the awards. Forfeitures are recognized and accounted for as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;The fair value of stock options is estimated using a Black-Scholes option pricing model on the date of grant. This method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#x2019;s common stock, expected dividend yield, and a risk-free interest rate. Options and awards granted during the&#160;year have a maximum contractual term of ten&#160;years. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the average of the contractual term of the stock option and its weighted-average vesting period. The expected volatility of stock options is based upon the historical volatility of a number of publicly traded companies in similar stages of clinical development. The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future. The risk-free interest rates used are based on the U.S. Department of Treasury (&#x201c;U.S. Treasury&#x201d;) yield in effect at the time of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term of the stock options.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_AM4SWxu1AEWvAgiUoTpxpw"
      id="Narr_qSgp_R6M2kabgRb9jrw80g">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_5Mkyw_rJuEqxP98Z3wigbQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(o)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;Income taxes are accounted for using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss ("NOL") and tax credit carryforwards. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.  The company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.  The company recognizes interest and penalties related to unrecognized tax benefits within income tax expense.  Any accrued interest and penalties are included within the related tax liability.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_-bGaCrGrJEC6sYW3cKVRng">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(p)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one operating segment.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="INF"
      id="Narr_R8oOol6R-kmHu6mMywB5-w"
      unitRef="Unit_Standard_segment_bCa297tYP0mkIHafmd-9BQ">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_btwWhBe4lkeZrcsDqjA8ug">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(q)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company&#x2019;s potentially dilutive securities, which include convertible preferred stock prior to the conversion of such shares to common stock and outstanding stock options under the Company&#x2019;s equity incentive plan, have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;The following table summarizes the Company&#x2019;s net loss per share:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (75,521)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (51,511)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss available to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (75,521)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (51,511)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Weighted-average common stock outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,331,630&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,472,104&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.87)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.10)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,230,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,110,219&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,968&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,881&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,252,312&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,139,100&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_UbUKyOWLRUWGCsMT_MIV0g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;The following table summarizes the Company&#x2019;s net loss per share:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (75,521)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (51,511)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss available to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (75,521)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (51,511)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Weighted-average common stock outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,331,630&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,472,104&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.87)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.10)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_f9YcFDCA8UKu3tQxjjzVVg_4_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-75521000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_yBYUWljb-0iS1QgIN-udVw_4_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-51511000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_qTDNrl4R6Umise87CpglyA_5_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-75521000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_wzPX4u1Km0uUH0pyFdIvog_5_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-51511000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="0"
      id="Tc_yKuShD-dGE6gPJGwS6B9Rg_8_3"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">26331630</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="0"
      id="Tc_yKuShD-dGE6gPJGwS6B9Rg_8_3_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">26331630</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="0"
      id="Tc_6TKnpAN-KkOu1sMvHkl-WA_8_6"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">24472104</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="0"
      id="Tc_6TKnpAN-KkOu1sMvHkl-WA_8_6_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">24472104</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="2"
      id="Tc_VoGYsGfdnk2Fsa0MJu-m4w_9_3"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">-2.87</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="2"
      id="Tc_VoGYsGfdnk2Fsa0MJu-m4w_9_3_2"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">-2.87</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="2"
      id="Tc_rzNPZ4biW0qwGGogK42-pA_9_6"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">-2.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="2"
      id="Tc_rzNPZ4biW0qwGGogK42-pA_9_6_2"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">-2.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_cW-v2ZSPjUqsYJY_hOlIwQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,230,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,110,219&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,968&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,881&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,252,312&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,139,100&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_KH1NXBTyjkur0ov9ZtwkMA"
      decimals="INF"
      id="Tc_WoHXhZASU0WNPEMT-zD67w_3_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">5230344</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ChUwiv23hEy7LMz7LGvpuQ"
      decimals="INF"
      id="Tc_j9NE5irV-EWU_r_jeOygRw_3_4"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">4110219</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_3UmwRa-EAE-11acDMKDuHQ"
      decimals="INF"
      id="Tc_mgEuD1n-ykS97sKtineEVA_4_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">21968</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_QNvV2K_cRECh_I59hVJgKg"
      decimals="INF"
      id="Tc_0et2HXJqyEmI6LbA3cK-nw_4_4"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">28881</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="INF"
      id="Tc_ds3uzUzxnE-8H6aX9MxltQ_5_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">5252312</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="INF"
      id="Tc_sjR7SWsW5UCUgcd1DgMacg_5_4"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">4139100</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_v-LPkOBQT0OMt8L-c2AAqA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(r)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In December 2023, the FASB issued ASU No. 2023-09, "Improvements to Income Tax Disclosures." ASU 2023-09 requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024 and for private businesses for annual periods beginning after December 15, 2025, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its financial statement disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In June 2022, the FASB issued ASU No. 2022-03, Fair Value Measurement (Topic 820) - Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard will be effective for the Company on January 1, 2024, and is not expected to have an impact on the Company&#x2019;s financial position or results of operations upon adoption.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_1X4MxkgG9EuvqB5vQGp4Xg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;(3)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;FAIR VALUE OF FINANCIAL INSTRUMENTS&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;The following tables summarize the Company&#x2019;s financial assets measured at fair value on a recurring basis and their respective input levels based on the fair value hierarchy (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:normal;width:41.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for&#160;Identical&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Agency bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Commercial Paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,386&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,386&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,945&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,945&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 98,948&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88,586&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total fair value of assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 118,735&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,149&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88,586&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:41.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for&#160;Identical&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,436&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,436&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,436&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,436&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55,577&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55,577&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Agency Bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,405&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,405&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 106,823&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 79,982&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total fair value of assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 125,259&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,277&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 79,982&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Cash Equivalents and Short-Term Investments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial assets measured at fair value on a recurring basis consist of the Company&#x2019;s cash equivalents and short-term investments. Cash equivalents consisted of cash, money market funds and commercial paper, and short-term investments consisted of U.S. Treasury bills, agency bonds, corporate debt securities and commercial paper. The Company obtains pricing information from its investment manager and generally determines the fair value of investment securities using standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following tables summarize the Company&#x2019;s short-term investments (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Maturity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Agency bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2&#160;years&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 179&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2&#160;years&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,386&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2&#160;years&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,334&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2&#160;years&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,925&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,945&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 98,711&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 260&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (23)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 98,948&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Maturity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;1&#160;year&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,645&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (84)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,577&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;1&#160;year&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,108&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (267)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Agency bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2&#160;years&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,536&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (133)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,405&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 107,289&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (484)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 106,823&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following tables summarize the Company&#x2019;s short-term investments with unrealized losses for less than 12 months and 12 months or greater:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:65.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.56%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Less than 12 months&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.58%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;12 months or Greater&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.03%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,042&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,042&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Agency bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,760&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,579&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,339&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 488&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,007&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,495&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,110&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,110&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,586&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,986&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (23)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:32.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:32.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:67.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:32.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.01%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Less than 12 months&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.32%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;12 months or Greater&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:32.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:32.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:32.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,928&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (84)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,928&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (84)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:32.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,971&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,833&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (261)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,804&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (267)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:32.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Agency bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,964&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (133)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,964&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (133)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,863&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (223)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,833&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (261)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,696&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (484)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company considers whether unrealized losses have resulted from a credit loss or other factors. The unrealized losses on the Company&#x2019;s available-for-sale securities as of December&#160;31, 2023 were caused by fluctuations in market value and interest rates as a result of the economic environment and not credit risk. The Company concluded that an allowance for credit losses was unnecessary as of December&#160;31, 2023. It is neither management&#x2019;s intention to sell nor is it more likely than not that the Company will be required to sell these investments prior to recovery of their cost basis or recovery of fair value. Unrealized gains and losses are included in accumulated other comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Accrued interest receivable is written off through net realized investment gains (losses) at the time the issuer of the bond defaults or is expected to default on payment. Accrued interest receivable related to short-term investments was $0.6 million and $0.3 million as of December&#160;31, 2023 and December 31, 2022, respectively.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_BmsCG8PFvUONZaPfiA1MDA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;The following tables summarize the Company&#x2019;s financial assets measured at fair value on a recurring basis and their respective input levels based on the fair value hierarchy (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:normal;width:41.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for&#160;Identical&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Agency bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Commercial Paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,386&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,386&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,945&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,945&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 98,948&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88,586&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total fair value of assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.34%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.91%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 118,735&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.56%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.6%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,149&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.1%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88,586&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.61%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:41.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for&#160;Identical&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,436&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,436&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,436&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,436&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55,577&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55,577&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Agency Bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,405&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,405&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 106,823&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 79,982&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total fair value of assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 125,259&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,277&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 79,982&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_jXLEnvJsuU2DjT7WrX1onA"
      decimals="-3"
      id="Tc_DxrMaF0580OYzeJsXL_UQA_9_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">19787000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_C-UwaOvYgEmhc5KbjSNoaA"
      decimals="-3"
      id="Tc_KEG1dv2KQEKCEwB6t3Y94w_9_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">19787000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_alE2cQWlWUmYEMSvxQfOpw"
      decimals="-3"
      id="Tc_Yb3621cLpkKHcwtI3LH7tw_10_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">19787000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Uy_OzIg220WOoPfwtTN9Cg"
      decimals="-3"
      id="Tc_O7A29qrBA0-iBSyUz4-I7A_10_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">19787000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_GLAldi10KUCn9sv4BDXzvw"
      decimals="-3"
      id="Tc_-L6Jd0UCNUWsmhrfc9Ti0g_13_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">42255000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_RToG1KKrEU2I3goa1SB0fQ"
      decimals="-3"
      id="Tc_7qEomVAd50qDKjA_SdxIvA_13_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">42255000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_2EbSprzX4UmWm8yxfF94Hw"
      decimals="-3"
      id="Tc_JXnIJ4F9V064BlxDchrEOQ_14_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">38386000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_xuDF7JacqEyVD_8bE4KGbQ"
      decimals="-3"
      id="Tc_zLXAZzqc0EemxpKmv5BM9Q_14_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">38386000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8Ja-oIvtvEOUSt1VbId_rw"
      decimals="-3"
      id="Tc_G_bdccPzY022dsv3sbwaCQ_15_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">10362000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_paK6hjSIN0utjCqZ6uTFBQ"
      decimals="-3"
      id="Tc_2yr8ziPWlUKOt6jrQjYGuA_15_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">10362000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_23DxYpsziUKkF0FV76-EIA"
      decimals="-3"
      id="Tc__IEGBw1hVUO_T4zvS71Zhw_16_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">7945000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_PbzReIi7W0qZtcZBeUxt9w"
      decimals="-3"
      id="Tc_pkAa9s5oUUOrJQJ9qPtgMQ_16_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">7945000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_alE2cQWlWUmYEMSvxQfOpw"
      decimals="-3"
      id="Tc_TMe69xbKYkq2qAKN53XGWQ_17_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">98948000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Uy_OzIg220WOoPfwtTN9Cg"
      decimals="-3"
      id="Tc_cCdI3QgCWU2VQA3_FqSbQw_17_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">10362000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_sWDh72OE6kSOPCSLEhKjBQ"
      decimals="-3"
      id="Tc_OBSorDHXNU66-KZN7TD1Rg_17_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">88586000</us-gaap:ShortTermInvestments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_alE2cQWlWUmYEMSvxQfOpw"
      decimals="-3"
      id="Tc_-cgE9VrXdEO19QTquLI3NA_19_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">118735000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Uy_OzIg220WOoPfwtTN9Cg"
      decimals="-3"
      id="Tc_sbxpcvwoWEiF1EudZa3nwQ_19_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">30149000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_sWDh72OE6kSOPCSLEhKjBQ"
      decimals="-3"
      id="Tc_AL8Z8PI6C0WCSUJawLkuxQ_19_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">88586000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AyHw9eprTkCuYHbb4OSTdg"
      decimals="-3"
      id="Tc_CqPJ8G_PMESPKWikpzm9Bw_9_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">18436000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_F964c7FBf0qgpnkWSEYhwg"
      decimals="-3"
      id="Tc_M_YIIzwiC0KGC49lMH6yww_9_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">18436000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Kcx7c1ohMECfaPSrYxC0Nw"
      decimals="-3"
      id="Tc_X4S3hHNVvEuOC79yOULZDQ_10_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">18436000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kHkV564Q4kqYbVZPXq-xpg"
      decimals="-3"
      id="Tc_TaQT90JxHE6aIrnHegbXfg_10_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">18436000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_8pnWeqBIpESIlttN4ujbaw"
      decimals="-3"
      id="Tc_VU8AFepDbkiYHZbMa-vp_Q_13_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">55577000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_ywomA-WM5EmdfslLNmeoUw"
      decimals="-3"
      id="Tc_wfIHz9-hsEuOrZ_CKvYjhA_13_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">55577000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_SnzjzhUup0auURpf_CvbCQ"
      decimals="-3"
      id="Tc_waVSP0GywUul6u12b8TeOw_14_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">26841000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_NYTb6k4rLkCljLkmM_mSYg"
      decimals="-3"
      id="Tc_pA_d1jpQCE2XafBo_7IF1g_14_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">26841000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_14Q4SyHhfEip0yfmjiQBjA"
      decimals="-3"
      id="Tc_li-kUJ6ADkq6dwNri2RtGA_15_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">24405000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_dAN4ZtziuEiP3QwWp9yKPg"
      decimals="-3"
      id="Tc_P8bN7nLNQUWdcExR9zMypQ_15_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">24405000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Kcx7c1ohMECfaPSrYxC0Nw"
      decimals="-3"
      id="Tc_mwfIdN0IGU2z0P1nVUnucQ_16_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">106823000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kHkV564Q4kqYbVZPXq-xpg"
      decimals="-3"
      id="Tc_kyfwgVpB7UiiTMSTp0p88w_16_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">26841000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Lk-ps-R70EiQI3935QJvXw"
      decimals="-3"
      id="Tc_JDZ33o79lkKPRF87lvcRMg_16_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">79982000</us-gaap:ShortTermInvestments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Kcx7c1ohMECfaPSrYxC0Nw"
      decimals="-3"
      id="Tc_Lw0uqm-zu0qWHMe3m4MMtA_18_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">125259000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kHkV564Q4kqYbVZPXq-xpg"
      decimals="-3"
      id="Tc_5ilFJ5rzeUepb3KrQJGc6Q_18_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">45277000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Lk-ps-R70EiQI3935QJvXw"
      decimals="-3"
      id="Tc_4dlGXXmGHUqhJJj5cad8Jw_18_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">79982000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_7zmf5Rc5iUWqMgowzPXv_Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following tables summarize the Company&#x2019;s short-term investments (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Maturity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Agency bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2&#160;years&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 179&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2&#160;years&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,386&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2&#160;years&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,334&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2&#160;years&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,925&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,945&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 98,711&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 260&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (23)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 98,948&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Maturity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;1&#160;year&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,645&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (84)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,577&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;1&#160;year&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,108&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (267)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Agency bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2&#160;years&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,536&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (133)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,405&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 107,289&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (484)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 106,823&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <avte:DebtSecuritiesAvailableForSaleMaturityTerm
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_OlIabHctWUyzxlnqkr4bCg"
      id="Narr_qWh5wPBlzUqE6U-KrqGOUA">P2Y</avte:DebtSecuritiesAvailableForSaleMaturityTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg"
      decimals="-3"
      id="Tc_qb6SxEx5cUe7r_K1FGOSiQ_5_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">42090000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg"
      decimals="-3"
      id="Tc_qEdGyfxvEUmDnTBJkRq9GA_5_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">179000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg"
      decimals="-3"
      id="Tc_KILFzGl-s0u9Zrj0ThTpJQ_5_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg"
      decimals="-3"
      id="Tc_99I-vZIk_E-cha0yjCS6pQ_5_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">42255000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <avte:DebtSecuritiesAvailableForSaleMaturityTerm
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_zaDLiCFPqUqEufSLy6NbzQ"
      id="Narr_ErP_oa1v-0i0y8GffgCQGA">P2Y</avte:DebtSecuritiesAvailableForSaleMaturityTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q"
      decimals="-3"
      id="Tc_EfS6sLc4aEyjDjePAFZqOA_6_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">38362000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q"
      decimals="-3"
      id="Tc_sBFymzb0zkeFoiTp-RvNIQ_6_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">29000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q"
      decimals="-3"
      id="Tc_p8AM9_u4g0Oh_ox52iLxgQ_6_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q"
      decimals="-3"
      id="Tc_9Dlb-2fLwkutcr9w4-tTsA_6_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">38386000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <avte:DebtSecuritiesAvailableForSaleMaturityTerm
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_eZcGsEFbHEW38q44Yr6mVw"
      id="Narr_7Od7ttfk5kqmvt_28wB3Mg">P2Y</avte:DebtSecuritiesAvailableForSaleMaturityTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w"
      decimals="-3"
      id="Tc_LKI4AAprjkGYatD95TqWng_7_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">10334000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w"
      decimals="-3"
      id="Tc_lGxrp_1nokSKEAmQD8hxOw_7_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">31000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w"
      decimals="-3"
      id="Tc_LSDIa5QddkeSHpy5MCx3Jw_7_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w"
      decimals="-3"
      id="Tc_zMyr3EjJCUqTuI2D2WChGw_7_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">10362000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <avte:DebtSecuritiesAvailableForSaleMaturityTerm
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_rsRxqqwUvEm2inEelixs4Q"
      id="Narr_44smtp7kaEGISHjAO6t_gA">P2Y</avte:DebtSecuritiesAvailableForSaleMaturityTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q"
      decimals="-3"
      id="Tc_jLqXUti2_0e0qHf3km_4CA_8_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">7925000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q"
      decimals="-3"
      id="Tc_LFUmRjfrjEijuzVVBahlaA_8_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q"
      decimals="-3"
      id="Tc_NOBTNIlWCk6fyyCwrNZWwg_8_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q"
      decimals="-3"
      id="Tc_YZNCXB47g06G6E5lwbJEEg_8_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">7945000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_FpEd-FRj4U2ayjsxfYX5vQ_9_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">98711000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_qTIiNbt9y0ez5q0bScJtsQ_9_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">260000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_JOvyiMgAUk6l_NSM5GgkVw_9_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_ebQxFMV3mEy1_zsPG43dfg_9_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">98948000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <avte:DebtSecuritiesAvailableForSaleMaturityTerm
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_kql4M0ph3Umd2bhh5TV1nA"
      id="Narr_P5DnjcqfJkabUjJtgVBh9g">P1Y</avte:DebtSecuritiesAvailableForSaleMaturityTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_GL6agAj25k-cPwtptPUzow"
      decimals="-3"
      id="Tc_Wfw4-3C78EuhNgA54cGhpQ_5_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">55645000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_GL6agAj25k-cPwtptPUzow"
      decimals="-3"
      id="Tc_83WQD_MKx0KtxVTuw7UXHg_5_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_GL6agAj25k-cPwtptPUzow"
      decimals="-3"
      id="Tc_4rQ5CBlWLE-A2BYjKv6XEw_5_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">84000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_GL6agAj25k-cPwtptPUzow"
      decimals="-3"
      id="Tc_OYPgV-HZWUisr3vEb7WG3Q_5_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">55577000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <avte:DebtSecuritiesAvailableForSaleMaturityTerm
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_qYrKRTeZrkCEoPKcnJyr4Q"
      id="Narr_502dxCHwZ0SJ434xdHbSmg">P1Y</avte:DebtSecuritiesAvailableForSaleMaturityTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8yGurj7uGke-WnYhN4sOug"
      decimals="-3"
      id="Tc_B9j5tx_RrU-Yf6X5I0ZxXQ_6_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">27108000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8yGurj7uGke-WnYhN4sOug"
      decimals="-3"
      id="Tc_ymDdXfohkUqOC1OEE_9XCQ_6_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">267000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8yGurj7uGke-WnYhN4sOug"
      decimals="-3"
      id="Tc_jQfoAKkfd0eLC05iIeAr1g_6_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">26841000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <avte:DebtSecuritiesAvailableForSaleMaturityTerm
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_YQFimAiCRUGyikQapBgwVA"
      id="Narr_uynXua4cekeuBfbcmVyFAA">P2Y</avte:DebtSecuritiesAvailableForSaleMaturityTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_cMFhMcP0AE2-6VZ7iiNWxQ"
      decimals="-3"
      id="Tc_fYZb0xqcv06OwADJwosCwQ_7_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">24536000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_cMFhMcP0AE2-6VZ7iiNWxQ"
      decimals="-3"
      id="Tc_glOINKHGtkCsqn5yCGtjpg_7_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_cMFhMcP0AE2-6VZ7iiNWxQ"
      decimals="-3"
      id="Tc_crBZpP90uU-mycrpXdB3Ig_7_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">133000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_cMFhMcP0AE2-6VZ7iiNWxQ"
      decimals="-3"
      id="Tc_6nzCZ07wjUmBvO5Nf4dAGg_7_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">24405000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_M3pQF0Aa9USfESjrA7IGAg_8_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">107289000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_Dc0n61eD0EmOaa4JYWmy6w_8_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_abAHTp6je06yRmhi7InSdA_8_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">484000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_QXPxXlyng0CQ6wvUff43xw_8_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">106823000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_7B4GRys0v0O5HbCct40i3g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:65.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.56%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Less than 12 months&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.58%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;12 months or Greater&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.03%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,042&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,042&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Agency bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,760&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,579&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,339&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 488&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,007&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,495&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,110&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,110&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,586&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,986&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (23)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:32.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:32.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:67.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:32.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.01%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Less than 12 months&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.32%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;12 months or Greater&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:32.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:32.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:32.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,928&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (84)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,928&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (84)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:32.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,971&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,833&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (261)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,804&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (267)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:32.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Agency bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,964&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (133)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,964&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (133)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,863&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (223)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,833&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (261)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,696&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (484)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q"
      decimals="-3"
      id="Tc_srC84Z44IEmbY5Ns0AlKVg_5_2"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">6042000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q"
      decimals="-3"
      id="Tc_mzoprdBmAkOgDFkkhRuuPw_5_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">5000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q"
      decimals="-3"
      id="Tc_3Q1MNZQqN0q64IkrvsmlDQ_5_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">6042000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q"
      decimals="-3"
      id="Tc_5WmhI20KKkSlSOXmFPww4g_5_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">5000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg"
      decimals="-3"
      id="Tc_ka4wTUKJt0KG9Y02NxieZg_6_2"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3760000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg"
      decimals="-3"
      id="Tc_YPNPCfmvrUySFvny6U_kFw_6_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">6000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg"
      decimals="-3"
      id="Tc_vXkUBUBFmk2_keCTO2HcyA_6_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">6579000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg"
      decimals="-3"
      id="Tc_z3gK1a5Xd0SKC6bKwUd2Hg_6_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">8000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg"
      decimals="-3"
      id="Tc_mk5zchBz30-D5yLiJz5TJA_6_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">10339000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg"
      decimals="-3"
      id="Tc_2gvKjt8Ofki1C_2El0_Q9Q_6_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">14000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w"
      decimals="-3"
      id="Tc_nC0juwXiUUOsdQnEfgLsXw_7_2"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">488000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w"
      decimals="-3"
      id="Tc_83waXynraEmKiKqrFBL5vA_7_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">2000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w"
      decimals="-3"
      id="Tc_z0SCzPUxDkaMjWQI8Ud5Fg_7_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1007000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w"
      decimals="-3"
      id="Tc_n6ekbLVzuU6D7eI_S9YrRg_7_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w"
      decimals="-3"
      id="Tc_2NvxHcy430KYEt9gWcNbcA_7_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1495000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w"
      decimals="-3"
      id="Tc_Fd9-ZHr2yEGFXWZRocyDHA_7_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q"
      decimals="-3"
      id="Tc_Q7Lv6hL13kuKuRtYyZcHyQ_8_2"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3110000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q"
      decimals="-3"
      id="Tc_AL4HjntIPkaoLFnD7pc-Fg_8_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q"
      decimals="-3"
      id="Tc_M9qA3ccbbUGovJLsQ7Q7LA_8_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3110000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q"
      decimals="-3"
      id="Tc_mIcWi7wqJ069aTY_UUWYXw_8_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_rx6ZnarNxEyV5MdGM5w8tg_9_2"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">13400000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_n1p6f4QxLEm1nxKC6q4OsQ_9_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">14000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_FzyZts9eD0W3FXaO_XewCA_9_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">7586000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_rArUMrNjRUaYUiTrSdznKQ_9_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">9000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_pRPI_A2l6UKPJ-ehFiwjXw_9_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">20986000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_IrZ62k-900KyCAj4HuUJBg_9_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">23000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_GL6agAj25k-cPwtptPUzow"
      decimals="-3"
      id="Tc_EcVXHIRdGUulbX8gms1mCg_5_2"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">34928000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_GL6agAj25k-cPwtptPUzow"
      decimals="-3"
      id="Tc_JfcRaSQ60kWROX96kvANmA_5_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">84000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_GL6agAj25k-cPwtptPUzow"
      decimals="-3"
      id="Tc_gDVzS4LD_kiVN8hRLkeYfg_5_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">34928000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_GL6agAj25k-cPwtptPUzow"
      decimals="-3"
      id="Tc_p0M5t44f30ejMu6BibsskA_5_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">84000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8yGurj7uGke-WnYhN4sOug"
      decimals="-3"
      id="Tc_nmL-gk-M_km13YAqMQyPCw_6_2"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1971000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8yGurj7uGke-WnYhN4sOug"
      decimals="-3"
      id="Tc_3rGW-3iPYEWTs5V9bbRWFQ_6_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">6000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8yGurj7uGke-WnYhN4sOug"
      decimals="-3"
      id="Tc_ptbw2Mo_CU6TcCGF3kzX-Q_6_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">24833000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8yGurj7uGke-WnYhN4sOug"
      decimals="-3"
      id="Tc_2N-KdxUsF0SezvPltcs3vQ_6_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">261000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8yGurj7uGke-WnYhN4sOug"
      decimals="-3"
      id="Tc_reSunN2_Pk6tYg2DNx95VQ_6_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">26804000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8yGurj7uGke-WnYhN4sOug"
      decimals="-3"
      id="Tc_u52Pil6NgEquQ31QByHHYA_6_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">267000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_cMFhMcP0AE2-6VZ7iiNWxQ"
      decimals="-3"
      id="Tc_-pmZXF3J_EW2W6Ku24nkZQ_7_2"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">22964000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_cMFhMcP0AE2-6VZ7iiNWxQ"
      decimals="-3"
      id="Tc_bjpSDVUsS024STJVdj6EHg_7_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">133000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_cMFhMcP0AE2-6VZ7iiNWxQ"
      decimals="-3"
      id="Tc_Eu9Wx3VR_UO27KAPCq6rNA_7_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">22964000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_cMFhMcP0AE2-6VZ7iiNWxQ"
      decimals="-3"
      id="Tc_HqKAXnd9fUKVlFa0YKFgpQ_7_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">133000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_8LdkeUzoGkmJZ0PaQi_VKQ_8_2"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">59863000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_mnY-0hTXn0Oqmd_CyhtI1Q_8_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">223000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_NdQJf3hfGkOby1wRvMkA_w_8_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">24833000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_LcXc55BxD0OgpBsqxws3lw_8_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">261000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_nqTkxAKNfkG1eMayLV_Iuw_8_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">84696000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_cUCKEwx0r0Gi72R3syeabg_8_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">484000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-5"
      id="Narr_xCXiuQbpEEWCn-usoY6mJg"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">600000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-5"
      id="Narr_aK3NSYkEfUSczntRY5Irvw"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">300000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_xmgvBO9E70SAUJ14BU1qag">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;(4)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;BALANCE SHEET COMPONENTS&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Prepaid Expenses and Other Current Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:62.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,168&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,503&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Prepaid research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 375&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 478&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Total prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,793&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,276&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accrued and Other Current Liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Accrued and other current liabilities consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:62.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,363&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,751&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued payroll and other employee benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,368&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,691&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total accrued and other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.09%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:13.12%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,821&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.09%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:13.12%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,822&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <avte:ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_45sf72ZinUCDY-HuX3oTuQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:62.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,168&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,503&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Prepaid research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 375&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 478&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Total prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,793&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,276&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</avte:ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_5X7PVJJWxUuU8uZsOP19Qw_3_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1168000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_PkpEc8wEXEWGpjtZ86_xuw_3_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1503000</us-gaap:PrepaidExpenseCurrent>
    <avte:PrepaidResearchAndDevelopment
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_F39G850fB0uI0iJfOcPz-A_4_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">375000</avte:PrepaidResearchAndDevelopment>
    <avte:PrepaidResearchAndDevelopment
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_3zQTqyczdkGiihpuWxH8fQ_4_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">478000</avte:PrepaidResearchAndDevelopment>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_bhoHQgEEu0WvOiyf3o-4yg_5_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">250000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_vQa68Q_fJkCzbDQuEja6yw_5_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">295000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_EYwHHgUxoEyTGyO25FOT7g_6_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1793000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_jKxSj6Ytnk22f27vXqtx6g_6_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">2276000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_y8-E6XKi8E-nnJls74u4Kw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Accrued and other current liabilities consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:62.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,363&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,751&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued payroll and other employee benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,368&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,691&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total accrued and other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.09%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:13.12%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,821&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.09%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:13.12%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,822&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <avte:AccruedResearchAndDevelopmentCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_tPafr-ZE6k2aGV8VM8bsIg_3_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">9363000</avte:AccruedResearchAndDevelopmentCurrent>
    <avte:AccruedResearchAndDevelopmentCurrent
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_PaKtwfybzk66xeRH4EYBqw_3_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">2751000</avte:AccruedResearchAndDevelopmentCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_Tn3KqzxXKkOtt5re_0YD-w_4_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">4368000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_LleTmr5UuUyp1cqMMc7QvA_4_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1691000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_k3hGgFiRDUCTiGfBLXN_Aw_5_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1090000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_q6IsHJwjkEy_ljba-HSzXw_5_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">380000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_Gepji09HgkS1W41cbjA0HA_6_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">14821000</avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_sos84JO200aUEsI21HbYUQ_6_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">4822000</avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_igd0bUuW9Uqx0esf-CNSGA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;(5)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;COMMITMENTS AND CONTINGENCIES&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In August&#160;2021, the Company entered into a lease agreement (the &#x201c;Waltham Lease&#x201d;) for approximately 5,000 square feet of office space in Waltham, Massachusetts for the Company&#x2019;s corporate headquarters. The Waltham Lease has a term of thirty-nine months (&#x201c;Lease Term&#x201d;), unless extended or earlier terminated. The Company has the option to extend the Waltham Lease for one additional period of three&#160;years. The Lease Term had an initial abatement period, and the initial base rent payable is approximately $18,000 per&#160;month following the abatement period. The initial base rent payable will increase by approximately 2% per&#160;year over the Lease Term. The Waltham Lease commencement date was September&#160;1, 2021. In January 2024, the Company entered into the First Amendment to the Waltham Lease resulting in the lease expiring on December 31, 2025, and an increase of $1.00 per rentable square foot during the additional lease term. In obtaining this lease extension, the Company no longer has the option to extend the Waltham Lease for one additional period of three years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In April 2022, the Company entered into a lease agreement (the &#x201c;Foster City Lease&#x201d;) for approximately 3,500 square feet of office space in Foster City, California. The Foster City Lease has a term of thirty-nine months, unless extended or earlier terminated. The Company has the option to extend the Foster City Lease for on additional period of one year. The base rent payable under the Lease Term will be $22,600 per month and will be subject to annual increase of 3% on each anniversary.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2023, the consolidated balance sheet includes an operating lease right-of-use asset of $0.6 million and operating lease liability of $0.7 million. The total operating lease expense was $0.4 million for both of the years ended December 31, 2023 and 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2023, the future minimum annual lease payments under the operating leases were as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:72.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;width:24.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 12.25pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Minimum&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;width:24.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 12.25pt;"&gt;&lt;b style="font-weight:bold;"&gt;Lease Payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 466&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 242&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total operating lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 708&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: Amount representing interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (33)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Present value of net minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 675&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of operating leases for the years ended December 31, 2023 and December 31, 2022 were as follows (in thousands except lease term and discount rate):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating lease liabilities:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.75%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 385&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 705&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 675&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average remaining lease term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average incremental borrowing rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Legal Proceedings&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company may from time to time be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings during the years ended December 31, 2023 and 2022, and no material legal proceedings are currently pending or, to the best of its knowledge, threatened.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfLand
      contextRef="As_Of_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_psQydqKoEkSDWEV9UfDtig"
      decimals="INF"
      id="Narr_RKmWDrShzUK-Ndwu3j3xkw"
      unitRef="Unit_Standard_sqft_5xtOY_aM_0eoVegCdMhIVQ">5000</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_psQydqKoEkSDWEV9UfDtig"
      id="Narr_EcSVj2xasUKUbXaAA15LaA">P39M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_DaiW5HZ95E-5aglfFdRpPw"
      id="Narr_nmdZMFJLJkeU64Cxtswmig">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_psQydqKoEkSDWEV9UfDtig"
      id="Narr_Z8QgiPSNn0O83DMyW6KLBA">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:PaymentsForRent
      contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_DaiW5HZ95E-5aglfFdRpPw"
      decimals="0"
      id="Narr_eUjpJiwUpk6Ykok3jHvFnQ"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">18000</us-gaap:PaymentsForRent>
    <avte:LeaseIncreaseInRentPercentage
      contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_DaiW5HZ95E-5aglfFdRpPw"
      decimals="INF"
      id="Narr_Zz6VztXlBEii7brwuxEjTw"
      unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA">0.02</avte:LeaseIncreaseInRentPercentage>
    <avte:IncreaseRentalAmount
      contextRef="Duration_1_1_2024_To_1_31_2024_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_PodE97lmJkSHEwoc1aClWg"
      decimals="2"
      id="Narr_FVnJBkJzjkmWWP6jZ25j-A"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">1.00</avte:IncreaseRentalAmount>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="Duration_1_1_2024_To_1_31_2024_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_PodE97lmJkSHEwoc1aClWg"
      id="Narr_u00xX1y5ZUSb-l5YI1qDcQ">false</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_1_31_2024_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_zn19noNKY029l5Ec-T6CTg"
      id="Narr_lf3S1LpY4EOh_-0wjlhbeg">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:AreaOfLand
      contextRef="As_Of_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_sGvwx0X7s0WPUgXlH8FQrg"
      decimals="INF"
      id="Narr_Qu4uOLSJtUmGBl8cLf2xJQ"
      unitRef="Unit_Standard_sqft_5xtOY_aM_0eoVegCdMhIVQ">3500</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_sGvwx0X7s0WPUgXlH8FQrg"
      id="Narr_6P2z4CMdNUaanc4XoJCfdw">P39M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_sGvwx0X7s0WPUgXlH8FQrg"
      id="Narr_4CRIVku6jEy9qv5jdsgvxQ">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:PaymentsForRent
      contextRef="Duration_4_1_2022_To_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_m3e0XkrsxkWOCq0GHEPF6A"
      decimals="0"
      id="Narr_ozvFD5YgFEytwMF7R3lKsg"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">22600</us-gaap:PaymentsForRent>
    <avte:LeaseIncreaseInRentPercentage
      contextRef="Duration_4_1_2022_To_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_m3e0XkrsxkWOCq0GHEPF6A"
      decimals="INF"
      id="Narr_MlDAXE9HdUi18-eFLhxURQ"
      unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA">0.03</avte:LeaseIncreaseInRentPercentage>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-5"
      id="Narr_c0D3hoXug0S2GySc_eFfjg"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-5"
      id="Narr_Ns-Kc47YvUCEFMiNPPJjmA"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-5"
      id="Narr_hj4lTuHDQ02hSmQhH7ySgw"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-5"
      id="Narr_I4NmVPJT7k2ItewSm395vw"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_udZFqz6MaUibo3VdXDSxDw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2023, the future minimum annual lease payments under the operating leases were as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:72.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;width:24.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 12.25pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Minimum&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;width:24.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 12.25pt;"&gt;&lt;b style="font-weight:bold;"&gt;Lease Payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 466&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 242&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total operating lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 708&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: Amount representing interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (33)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Present value of net minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 675&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_cPVElBsSPkqVyD0TPyv3Yw_3_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">466000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_FSsUzcsmMUihadiTXD8fjg_4_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">242000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_gsYUxuasdk6Jh9a4zxp7xA_5_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">708000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_UnV7jy89c06zCREPulETCQ_6_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">33000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_d7e24gdUTkKUeOG2g-V7jw_7_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">675000</us-gaap:OperatingLeaseLiability>
    <avte:ScheduleOfComponentsOfOperatingLeasesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Group_FNYtDpzYCkmqwlPDXCWnOA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of operating leases for the years ended December 31, 2023 and December 31, 2022 were as follows (in thousands except lease term and discount rate):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating lease liabilities:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.75%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 385&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 705&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 675&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average remaining lease term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average incremental borrowing rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</avte:ScheduleOfComponentsOfOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_ZZhgEI34IUWHeDCxZMh6Zw_3_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">420000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_6eB55Br9mEO7keU0tfM5pw_3_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">385000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_NpBDCpoMh0yb48r06MwALg_4_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">255000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_zww7-Hh4zk6oU0EnVNVCHA_4_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">705000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_uFGsbFEsR0GC7CQvbwDLUQ_5_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">675000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_do-0keK96k6jBOW6n-ff-A_5_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1090000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      id="Tc_bcsRlyvxE0WwL-sy7MQ1_Q_6_3">P1Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      id="Tc_b6vpDc6N-kmVKAw7mzCh0Q_6_6">P2Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="2"
      id="Tc_n8TMGfsEKEW3GqvSVDDwZQ_7_3"
      unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA">0.06</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="2"
      id="Tc_jTvq0CJtlkW2ovicUndl9Q_7_6"
      unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA">0.06</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_s3kWcgW5V0iSKSrPz2R-Ng">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;(6)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the Company&#x2019;s Amended and Restated Certificates of Incorporation dated August&#160;3, 2020, the Company had a total of 94,052,154 shares of capital stock authorized for issuance, consisting of 50,000,000 shares of common stock, par value of $0.0001 per share, and 44,052,154 shares of convertible preferred stock, par value of $0.0001 per share. Shares of authorized convertible preferred stock were designated as 4,000,000 shares of Series&#160;Seed redeemable convertible preferred stock and 40,052,154 shares of Series&#160;A redeemable convertible preferred stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On July&#160;2, 2021, the Company&#x2019;s certificate of amendment to its certificate of incorporation became effective, which provided 150,000,000 authorized shares of common stock with a par value of $0.0001 per share and 10,000,000 authorized shares of undesignated preferred stock with a par value of $0.0001 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In August&#160;2018, the Company issued 241,467 shares of common stock to RA Capital Healthcare Fund,&#160;L.P. at a price of $0.0012 per share. On July&#160;2, 2021, in conjunction with the Company&#x2019;s initial public offering, or IPO, the Company issued 9,984,463 shares of its common stock and all outstanding shares of the Company&#x2019;s redeemable convertible preferred stock were converted into 14,182,854 shares of the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The holders of the common stock are entitled to one vote for each share of common stock held at all meetings of stockholders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2023, the Company had reserved the following shares of common stock for future issuance:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock options granted and outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,230,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Shares reserved for issuance under the 2021 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 604,363&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Reserved for vesting of outstanding restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,968&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Reserved for future ESPP issuances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 435,252&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,291,927&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <avte:CapitalStockSharesAuthorized
      contextRef="As_Of_8_3_2020_EcWWeWov-0O5egWgb1IO4Q"
      decimals="INF"
      id="Narr_R8HfmHMhy0C1jCIGkMetPA"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">94052154</avte:CapitalStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_8_3_2020_EcWWeWov-0O5egWgb1IO4Q"
      decimals="INF"
      id="Narr_nMeAl9w0sUCtvhVIRJIU7g"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_8_3_2020_EcWWeWov-0O5egWgb1IO4Q"
      decimals="INF"
      id="Narr_o8VAbgA1aE-Fd3d_SvsWig"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_8_3_2020_EcWWeWov-0O5egWgb1IO4Q"
      decimals="INF"
      id="Narr_BFL9Z_WK_UKZatFI7nr_MQ"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">44052154</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_8_3_2020_EcWWeWov-0O5egWgb1IO4Q"
      decimals="INF"
      id="Narr_w3jN_xJ-ckm1Paw5pYxhcw"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_8_3_2020_us-gaap_StatementEquityComponentsAxis_avte_SeriesSeedRedeemableConvertiblePreferredStockMember_c5TH3GCKvEGQuOxOnb7Lrg"
      decimals="INF"
      id="Narr_tLR6HyjAXUimEequXNixyQ"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">4000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_8_3_2020_us-gaap_StatementEquityComponentsAxis_avte_SeriesARedeemableConvertiblePreferredStockMember_lrXI44Ykp02VlKaxJ3Nieg"
      decimals="INF"
      id="Narr_ohKL_LsTzEOcQ_d-brMBMw"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">40052154</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_7_2_2021_w8fg7T9i30-Tb8oR9Nn9Ag"
      decimals="INF"
      id="Narr_jEfBSHdSOUyQC201oTWFgA"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_7_2_2021_w8fg7T9i30-Tb8oR9Nn9Ag"
      decimals="INF"
      id="Narr_EyJwlFpSH0aiLEkQNoQV4Q"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_7_2_2021_w8fg7T9i30-Tb8oR9Nn9Ag"
      decimals="INF"
      id="Narr_AV1XlKCzTUa9HwEKZyzz6w"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_7_2_2021_w8fg7T9i30-Tb8oR9Nn9Ag"
      decimals="INF"
      id="Narr_orpQZTmOVk2F810F-uWDqA"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_1_2018_To_8_31_2018_srt_CounterpartyNameAxis_avte_RaCapitalHealthcareFundL.pMember_f26Wjuj0S0u8Hw2V4pgTMA"
      decimals="INF"
      id="Narr_xVUU7_5xWUydgKTxa6V2mw"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">241467</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_8_31_2018_srt_CounterpartyNameAxis_avte_RaCapitalHealthcareFundL.pMember_MybYzQoXkkeq-kvOFSYqcw"
      decimals="4"
      id="Narr_eZb1iwicPUOAxBYoHKZ9RQ"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">0.0012</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_GUQQrLL2E0uGyzx6Fyxj_A"
      decimals="INF"
      id="Narr_q9MioMtRcE69n1n0j-Wdsg"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">9984463</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="Duration_7_2_2021_To_7_2_2021_zM4kB7thfEaK38J25p-KHg"
      decimals="INF"
      id="Narr_epj0ilCDJkGUJfw7StfKdg"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">14182854</us-gaap:ConversionOfStockSharesIssued1>
    <avte:NumberOfVotesForEachShareOfCommonStock
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="INF"
      id="Narr_9WyjPO-s6EmTdJAhEKpY_A"
      unitRef="Unit_Standard_Vote_68Fy5nhdn0WonvfwhauHwA">1</avte:NumberOfVotesForEachShareOfCommonStock>
    <avte:ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_2LYnHAg15EeqUomqvlivTg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2023, the Company had reserved the following shares of common stock for future issuance:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock options granted and outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,230,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Shares reserved for issuance under the 2021 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 604,363&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Reserved for vesting of outstanding restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,968&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:74.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Reserved for future ESPP issuances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 435,252&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,291,927&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</avte:ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_CommonStockMember_YflOQXijzkee839-W5_-ag"
      decimals="INF"
      id="Tc_rTEzvjsgqEyKuuTNgQ0q9w_2_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">5230344</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_aLb1VNRswEiUg0bp5BxGmQ"
      decimals="INF"
      id="Tc_Xxo9bFkDZUa8XA626QVMDA_3_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">604363</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Gy-ZvYruXkinoI8nJEgktA"
      decimals="INF"
      id="Tc_7AKQ9P244kKvolr2WOZxZA_4_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">21968</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_4YcJ4RjRj0GB-mGnU1wJUA"
      decimals="INF"
      id="Tc_1o-D9-ovLEWBBY7ka8gYtg_5_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">435252</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="INF"
      id="Tc_nJjgTFhBZEefgXp4GZXh2g_6_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">6291927</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_D0OoZfwvGkO9Y7oSr4Gnqw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;(7)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;SHARE-BASED COMPENSATION&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Stock Option Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s 2021 Stock Option and Incentive Plan (the &#x201c;2021 Plan&#x201d;) was adopted by the Company&#x2019;s board of directors and approved by the Company&#x2019;s stockholders in June&#160;2021 and became effective as of June&#160;29, 2021. Upon the effectiveness of the 2021 Plan, the Company&#x2019;s 2018 Equity Incentive Plan (the &#x201c;2018 Plan&#x201d;) was terminated and no further grants may be made thereunder. The Company&#x2019;s 2021 Plan allows for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, stock bonuses, restricted stock, stock units and other forms of awards including cash awards to its officers, directors, employees, consultants and advisors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2023, a total of 4,565,333 shares of the Company&#x2019;s common stock were authorized for issuance with respect to awards granted under the 2021 Plan. The share limit will automatically increase on the first trading day in January&#160;of each&#160;year (commencing with 2022) by an amount equal to the lesser of (1)&#160;4% of the total number of outstanding shares of the Company&#x2019;s common stock on the last trading day in December&#160;in the prior&#160;year, or (2)&#160;such lesser number as determined by the Company&#x2019;s board of directors. Since adoption, the annual increases have accumulated to a total of 3,075,841 shares through January 1, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Any shares subject to awards granted under the 2021 Plan or the 2018 Plan that are not paid, delivered or exercised before they expire or are canceled or terminated, or otherwise fail to vest, as well as shares used to pay the purchase or exercise price of such awards or related tax withholding obligations, will become available for new award grants under the 2021 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2023, 3,931,887 options had been granted under the 2021 Plan, with 604,363 shares authorized under the 2021 Plan available for future issuance. As of December 31, 2023, a total of 1,298,457 options had been granted and were outstanding under the 2018 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The options that are granted under the 2021 Plan and the 2018 Plan are exercisable at various dates as determined upon grant and terminate within 10&#160;years of the date of grant. The vesting period generally occurs over &lt;span style="-sec-ix-hidden:Hidden_VYoFbHUwRE-bLITQC63xcQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; to four&#160;years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the option activity under the 2021 Plan and 2018 Plan for the&#160;year ended December&#160;31, 2023:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and expected to vest at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,110,219&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 9.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 8.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 82,490&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,546,001&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 22.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (338,987)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Cancelled/Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (86,889)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 9.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,230,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 13.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 8.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 49,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and exercisable at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,157,378&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 11.24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 7.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 25,152&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and expected to vest at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,230,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 13.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 8.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 49,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The weighted-average grant date fair value of stock option grants was $15.69&#160;and $10.48 per share for the years ended December 31,&#160;2023 and December 31, 2022, respectively. All exercisable options are vested and all outstanding options are vested or expected to vest.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2023 there was approximately $29.1 million of unrecognized stock-based compensation expense related to nonvested stock-based compensation arrangements granted under the 2021 Plan and 2018 Plan, which is expected to be recognized over a weighted-average period of 2.3&#160;years.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(b)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;) was adopted by the Company&#x2019;s board of directors and stockholders in June&#160;2021 and became effective upon the consummation of the IPO. A total of 230,000 shares of the Company&#x2019;s common stock is initially available for issuance under the ESPP. The share limit will automatically increase on the first trading day in January&#160;of each&#160;year (commencing with 2022) by an amount equal to the lesser of (1)&#160;1% of the total number of outstanding shares of the Company&#x2019;s common stock on the last trading day in December&#160;in the prior&#160;year, or (2)&#160;such lesser number as determined by the Company&#x2019;s board of directors. The number of shares available under the 2021 Plan increased by 247,229 shares effective January 1, 2023 as determined by the Company&#x2019;s board of directors. The ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 15% of their eligible compensation, subject to any plan limitations. The ESPP provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#x2019;s common stock on the first trading day of the offering period or on the last trading day of the offering period. As of December&#160;31, 2023, 41,977 shares had been issued under the ESPP, and 435,252 shares authorized under the ESPP Plan were available for issuance.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(c)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023, 31,881 restricted stock units had been awarded under the 2021 Plan. A summary of the status of and changes in unvested restricted stock unit activity under the Company&#x2019;s equity award plans for the year ended December 31, 2023, was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:65.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&#160;Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&#160;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per&#160;Unit&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units as of December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,881&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24.58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,913)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,968&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22.26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation of restricted stock units is based on the fair value of the Company&#x2019;s common stock on the date of grant and recognized over the vesting period. The vesting period generally occurs over &lt;span style="-sec-ix-hidden:Hidden_eUKRKJ4iNkSfQy8r2Vg3Mg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; to four years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31,&#160;2023, the Company had unrecognized stock-based compensation expense related to its unvested restricted stock units of $0.9 million, which is expected to be recognized over the remaining weighted-average vesting period of&#160;2.4&#160;years. &lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;(d)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimated the fair value of stock options using the Black-Scholes valuation model. The Company accounts for any forfeitures of options when they occur. Previously recognized compensation expense for an award is reversed in the period that the award is forfeited. The fair value of stock options was estimated using the following assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:26.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.3 - 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.5 - 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;73.9 - 91.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;73.5 - 76.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3.5 - 4.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1.6 - 4.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Expected dividend&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation expense recognized for stock option grants has been reported in the statements of operations and comprehensive loss as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:62.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,621&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,129&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,285&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,347&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation expense by type of award included within the consolidated statements of operations and comprehensive (loss) income was as follows: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:61.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.7pt;"&gt;&lt;td style="vertical-align:bottom;width:61.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:11.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:11.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;div style="height:11.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:11.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.5pt;"&gt;&lt;td style="vertical-align:bottom;width:61.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,494&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,316&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Employee stock purchase plan awards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 211&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock awards and units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 201&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 98&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 33.1pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_jOQSNYFMiE2CvUhNjVDLEg"
      decimals="INF"
      id="Narr_XmSDkM79D0K_GXNTtg_0Wg"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">4565333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_s-aYJQaQfEO0AGSWXOYO6A"
      decimals="2"
      id="Narr_Nvmw1JsolUmnobgWGnMrGQ"
      unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="Duration_7_1_2021_To_12_31_2023_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_xUfhDItNQkiJKYFlFdOMwQ"
      decimals="INF"
      id="Narr_UGA8m4z1_EyDLgpr-kV6tQ"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">3075841</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_oV0DwhFiqUeSjADTrzXG4A"
      decimals="INF"
      id="Narr_U57znnm9n06ZjNPODjfrvw"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">3931887</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_p7xQ831-8k-rQnNZukmxqQ"
      decimals="INF"
      id="Narr_TDuWn3R78U6WqwPhgGOzkQ"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">604363</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyEighteenStockOptionAndIncentivePlanMember_J-NqcxMgNUSJ7I39_xVsUw"
      decimals="INF"
      id="Narr__9Gy__PfbEyYT0et6qrNmA"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">1298457</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_7qar8kvNhkGFswXJGPAVXQ"
      id="Narr_Tcs87ZG3tU6BJEokUPzyVA">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_kdwiV7iJm0yXiFQVoEPDqQ"
      id="Narr_c4ec9vV_JkuRNfzsaOyMYg">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_ZMa4aQ6DX0qT2GWUrYueVQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the option activity under the 2021 Plan and 2018 Plan for the&#160;year ended December&#160;31, 2023:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and expected to vest at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,110,219&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 9.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 8.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 82,490&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,546,001&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 22.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (338,987)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Cancelled/Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (86,889)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 9.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,230,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 13.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 8.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 49,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and exercisable at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,157,378&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 11.24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 7.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 25,152&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and expected to vest at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,230,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 13.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 8.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 49,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="INF"
      id="Tc_XP2aXFPZRkCbuA4_q5QTLg_6_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">4110219</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="INF"
      id="Tc_ADHR1d5IwEK_dEPxvfBQig_6_5"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">9.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      id="Tc_63VHaRkvp0qeXSg4w54YBg_6_7">P8Y5M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_OPWvITxza0eaCzzsdymVHw_6_10"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">82490000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="INF"
      id="Tc_nNznQThn2USeMMsgXw3N5A_7_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">1546001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="INF"
      id="Tc_IibEuLDBIkygjQq6N9bUGw_7_5"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">22.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="INF"
      id="Tc_025LnL7-GkKnHFNFl-6-6w_8_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">338987</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="INF"
      id="Tc_iCq9fivA906LY2iGS0g-2A_8_5"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">2.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="INF"
      id="Tc_U5IQmqczdki0dVtguZgTrg_9_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">86889</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="INF"
      id="Tc_mReBYi0ipUq-LrtD8aOeTQ_9_5"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">9.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="INF"
      id="Tc_vEfpxL-XPkCr7wfzjAIjMQ_10_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">5230344</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="INF"
      id="Tc_yVoT92rddEmvwliyrgU6_w_10_5"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">13.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tc_DP8R30CBjUaJLHM1clJheQ_10_7">P8Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_LMSr_i63b0KRmLB_3qUobQ_10_10"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">49728000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="INF"
      id="Tc_M2SaQSHiLkGPVEnODtW9vw_11_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">2157378</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="INF"
      id="Tc_6BmZHdxpr02q6c74LEOBLQ_11_5"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">11.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tc_KFEaKkYK_0KHai7S1SBeRQ_11_7">P7Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_UPM19WqSvEawWxpZ8zRcvg_11_10"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">25152000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="INF"
      id="Tc_nbdVPCdPfUeWHVS2tIpx3Q_12_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">5230344</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="INF"
      id="Tc_0OK0QhrwNUajnUqv5qdHlw_12_5"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">13.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tc_R8P3rSdTkUuP7Mko1RpHCw_12_7">P8Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_uLuqbLB1jkSmyrBxBcxPNg_12_10"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">49728000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="INF"
      id="Narr_BG6OxbHhQE-Jha056enx2g"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">15.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="INF"
      id="Narr_PrtSEfI2rUiHhjH4RJ_5hQ"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">10.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-5"
      id="Narr_WEjhd3Pw2E2yWcmGpQ_tWg"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">29100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Narr_gEy_E2_z1Eio4GntjIlhZQ">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_ePMqutmojUyuoaStQiHwbg"
      decimals="INF"
      id="Narr_ZIwwHdH3nUSxgdtLmTtZ9A"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">230000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_l2cNv6JCfkyvIREeesp36w"
      decimals="INF"
      id="Narr_aPaYGlWKQ02-0BTxH6BG6Q"
      unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA">0.01</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2023_To_1_1_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_7n9TuWQvlEKuoOSnaqxmoQ"
      decimals="INF"
      id="Narr_oeZg1Q77jkqKlX-bwHqeew"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">247229</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_WvqE0K12M0iiC1AH3k88Tw"
      decimals="2"
      id="Narr_8JsNlO6ac0-7W_JDN817oA"
      unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA">0.15</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <avte:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_l2cNv6JCfkyvIREeesp36w"
      id="Narr_QKN5FQlm_U-kl2OjkIwWyg">P6M</avte:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
      contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_WvqE0K12M0iiC1AH3k88Tw"
      decimals="2"
      id="Narr_0bu4m5E_SU6m50xzfGYymg"
      unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_l2cNv6JCfkyvIREeesp36w"
      decimals="INF"
      id="Narr__J-DmZA960ibPMjmMLJUtA"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">41977</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_4YcJ4RjRj0GB-mGnU1wJUA"
      decimals="INF"
      id="Narr_kixCkuxRmUuIboxPUIlkHA"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">435252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_ZBG0wBshS02tcTB4D_om6g"
      decimals="INF"
      id="Narr_HgZxHn9NUkaktWlCY7xTVw"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">31881</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_s3yQZVnwyEiI8be6QWlPYA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:65.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&#160;Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&#160;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per&#160;Unit&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units as of December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,881&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24.58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,913)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,968&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22.26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_gcSTyLkkmk2V2zzgD-_vtQ"
      decimals="INF"
      id="Tc_Tar4PfUJQESZ2xkGVmyjmg_5_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">28881</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_gcSTyLkkmk2V2zzgD-_vtQ"
      decimals="2"
      id="Tc_OWV6VDY8qk2zwgZK63Es4g_5_5"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">21.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_6Bs2-neN-U2EmecB-QIl0w"
      decimals="INF"
      id="Tc_qJF-YHg9xEm2eu775LObHg_6_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_6Bs2-neN-U2EmecB-QIl0w"
      decimals="2"
      id="Tc_vrhk5qEQe02Hw5pu44wMJg_6_5"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">24.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_6Bs2-neN-U2EmecB-QIl0w"
      decimals="INF"
      id="Tc_2SWOWm-Ss0CzxN4VgtzCcA_7_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">9913</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_6Bs2-neN-U2EmecB-QIl0w"
      decimals="2"
      id="Tc_HB0LX0TzaUaUa7fOVsbCSQ_7_5"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">21.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Gy-ZvYruXkinoI8nJEgktA"
      decimals="INF"
      id="Tc_sPgWRCfRvkq5W5NvhJP66w_9_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">21968</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Gy-ZvYruXkinoI8nJEgktA"
      decimals="2"
      id="Tc_L6WNRrObkEynBI0gd7YTwA_9_5"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">22.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember__SKGl6wkOE-Kjnfpn0KZcQ"
      id="Narr_ukVu46uvnU6dWhTCrbHXEw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Gy-ZvYruXkinoI8nJEgktA"
      decimals="-5"
      id="Narr_YCu7wgn0akqzx4r2pGFrzA"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_6Bs2-neN-U2EmecB-QIl0w"
      id="Narr__tN6jsIJN021mZXu2RmlAA">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_EPjzkmTE60O9Jmc6RjpZ0Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:26.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.3 - 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.5 - 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;73.9 - 91.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;73.5 - 76.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3.5 - 4.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1.6 - 4.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Expected dividend&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_73e_CZGNZEyHg-KoZi_SKw"
      id="Narr_j8XsE1Npo0WOr28-2zXPhw">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_AM4SWxu1AEWvAgiUoTpxpw"
      id="Narr_L6VRPmqud0GFZLuY66Fxgw">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_Ftq0AHVniEWCeuEfN5x_ZQ"
      id="Narr_eMPtYSDydkaHIUrW7ttyhA">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_KY3AqSzTb0OwCTsNTj4W_Q"
      id="Narr_kPKH3bRyskGjkp4ydAFAHw">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="3"
      id="Narr_7EWlQiMX00SZQZa87h2MJQ"
      unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA">0.739</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="3"
      id="Narr_ljhtmS9JI0a8mmB0YCodFA"
      unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA">0.915</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="3"
      id="Narr_ZElrqEbVK0mQsrgr2JKOqQ"
      unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA">0.735</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="3"
      id="Narr_M_uIDH3Vk0a2C-Ke6ZzbVg"
      unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA">0.765</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="3"
      id="Narr_ZnVR20eX3EOA-CB8nHJdLw"
      unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="3"
      id="Narr_J1Z5PUCdB0KYIa2LTLUljw"
      unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA">0.048</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="3"
      id="Narr_IHfOOm8z0kG7zsU5m0vlhQ"
      unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="3"
      id="Narr_2DQCyEWDDE-pZOUxBIOzrQ"
      unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_3WIBzCnin0Kyjrce05KlqQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation expense recognized for stock option grants has been reported in the statements of operations and comprehensive loss as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:62.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,621&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,129&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,285&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,347&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation expense by type of award included within the consolidated statements of operations and comprehensive (loss) income was as follows: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:61.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.7pt;"&gt;&lt;td style="vertical-align:bottom;width:61.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:11.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:11.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;div style="height:11.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:11.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.5pt;"&gt;&lt;td style="vertical-align:bottom;width:61.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:9.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,494&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,316&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Employee stock purchase plan awards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 211&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock awards and units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 201&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 98&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 33.1pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_SpjyK1AxVEqPXklSW5dc7w"
      decimals="-3"
      id="Tc_BBtyt0JVEEa6NhVnWjTA4A_3_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">6621000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_eKXqES4MhEC5wSlAU18O1g"
      decimals="-3"
      id="Tc_PA-SIoALQUWZ512nKwlUxw_3_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">2129000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_DdnUA-mndEmQoBFn-wT6ng"
      decimals="-3"
      id="Tc_-MJd4ad96k6X37gORpjMVg_4_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">5285000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_W3X1hUg8vke6Gh4fxUQQlQ"
      decimals="-3"
      id="Tc_aT1gq91-1E-Z_o5Btrd6uA_4_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3347000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_mK6An4mZPEKdwtSiEO6F3g_5_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">11906000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_0shW0IbKw0Kvuy86fMptuA_5_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">5476000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MM86-nEOIUC1fgZNk-MY1w"
      decimals="-3"
      id="Tc_7M2OqttB0kWZ381dfA9O3Q_3_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">11494000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_8aHt_5B77EiYc-jzE1Txdw"
      decimals="-3"
      id="Tc_pW-kYIx7rUiK_XGUXb7wpA_3_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">5316000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_l2cNv6JCfkyvIREeesp36w"
      decimals="-3"
      id="Tc_gPRbVGsSPU21BciBtoyfYA_4_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">211000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_t77TAzlnOUGgpyEM6N3T8w"
      decimals="-3"
      id="Tc_qE8j2X2LzkazEgDS8XF-WQ_4_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">62000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_6Bs2-neN-U2EmecB-QIl0w"
      decimals="-3"
      id="Tc_pkOFBAMwTUK0c3xsTWuwxg_5_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">201000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_GhxOUzzS90-GzmvIc16b8w"
      decimals="-3"
      id="Tc_DFadl7nCdkK5ZuiM4nxOsA_5_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">98000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_STD4afZKAEai-MsLu141Kg_6_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">11906000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_0us3wO33skSeHlJOoKsfMA_6_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">5476000</us-gaap:ShareBasedCompensation>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_stzsSI5-EEmAFuqirPwJ0w">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;(8)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;RELATED PARTY TRANSACTIONS&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Services Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In August&#160;2018, the Company entered into a services agreement (&#x201c;Services Agreement&#x201d;) with Carnot, LLC (&#x201c;Carnot&#x201d;), an entity owned and controlled by RA Capital Management,&#160;L.P. under which Carnot provides research and other services to the Company. RA Capital Management,&#160;L.P. is a related party due to its equity ownership of the Company. The Company pays Carnot for services performed and costs incurred. The Services Agreement is for a term of two years. The Company may terminate the Services Agreement by giving 30&#160;days&#x2019; prior notice and either party can terminate the services agreement for a material breach, if not cured within 30&#160;days following notice by the nonbreaching party.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In July&#160;2019, the Services Agreement with Carnot was amended whereby research and other services are now performed by Carnot Pharma, LLC (&#x201c;Carnot Pharma&#x201d;), an entity owned and controlled by RA Capital Management,&#160;L.P., and the term was updated to the later of (i)&#160;two&#160;years from July&#160;15, 2019 and (ii)&#160;completion of services under the agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Expenses incurred by the Company under the Services Agreement with Carnot Pharma totaled $0 and less than $0.1 million for the&#160;years ended December&#160;31, 2023 and December&#160;31, 2022, respectively, and are presented in the statement of operations and comprehensive loss as research and development and general and administrative expenses. No amount was due to Carnot Pharma, LLC as of December 31, 2023 and December 31, 2022.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <avte:RelatedPartyTransactionTerm
      contextRef="Duration_8_1_2018_To_8_31_2018_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_-N_0UjeZlUm9GQWNR1RVdQ"
      id="Narr_U0g5r8deXEeTc7dIMKnnWA">P2Y</avte:RelatedPartyTransactionTerm>
    <avte:NoticeToTerminateAgreementPeriod
      contextRef="Duration_8_1_2018_To_8_31_2018_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_-N_0UjeZlUm9GQWNR1RVdQ"
      id="Narr_2TskPhSK20OK0JjzVfIhdg">P30D</avte:NoticeToTerminateAgreementPeriod>
    <avte:MaterialBreachCorrectionPeriod
      contextRef="Duration_8_1_2018_To_8_31_2018_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_-N_0UjeZlUm9GQWNR1RVdQ"
      id="Narr_5255-t5O4Ea76eDwOkfL4g">P30D</avte:MaterialBreachCorrectionPeriod>
    <avte:RelatedPartyTransactionTerm
      contextRef="Duration_7_1_2019_To_7_31_2019_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_n2CK4UQgq0-A1CPzs_pKqg"
      id="Narr_rMiX0g8yvUCZpGVPqPfWbw">P2Y</avte:RelatedPartyTransactionTerm>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_Db-jvbls9U2OcKGqstWiEQ"
      decimals="-6"
      id="Narr_gGEIGJH3DU2nEoi0E0A0Iw"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">0</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_GK_CqlKS30Gm2NvMdNBc3A"
      decimals="-5"
      id="Narr_p06OEJLlPkaAKOiheuH6WA"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">100000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_0tBp6f6PUUW7kvis6j685w"
      decimals="0"
      id="Narr_CQIRRyg_XEWwI2nVSRbZVA"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">0</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionAxis_avte_ServicesAgreementWithCarnotLlcMember_fjXbQ_EYZ0OduVaJ4JsVzw"
      decimals="0"
      id="Narr_XLRmCI5TjkK4EToM2vRAVg"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">0</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_d_sS68pwv0-eIs1omF9KJA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;(9)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;INCOME TAXES&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant components of the Company&#x2019;s net deferred tax assets are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred income tax assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;NOL carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16,199&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 11,781&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research credit carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,153&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,601&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Capitalized R&amp;amp;D&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 19,404&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,490&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Stock based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,929&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 923&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,117&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 790&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 43,802&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 23,585&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (43,596)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (23,283)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 206&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 302&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred income tax liabilities:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (206)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (302)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (206)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (302)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net deferred tax assets (liabilities)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_LfTcQM9iZEGlLfhH4tvpYg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;A reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate is as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years&#160;ended&#160;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15,831)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,829)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,389)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,828)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Permanent and other differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 563&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,049&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (787)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,676)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (757)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,487&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,663&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total tax provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 56&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company had federal NOL carryforwards available of $64.8 million and $46.9 million as of December&#160;31, 2023 and December&#160;31, 2022, respectively, before consideration of limitations under Section&#160;382 of the Internal Revenue Code or Section&#160;382, as further described below. The NOL generated from 2018 onwards of $64.8 million will carryforward indefinitely and be available to offset up to 80% of future taxable income each&#160;year. Additionally, the Company had state NOL carryforwards available of $44.1 million and $30.5 million as of December&#160;31, 2023 and December&#160;31, 2022, respectively. The state NOLs may be used to offset future taxable income and will begin to expire in 2038. At December 31, 2023 the Company had federal and state research and development credit carryforwards available of $6.0 million and $1.3 million, respectively. The federal credit carryforwards will begin to expire in 2038, unless previously utilized. The Massachusetts credit carryforwards will begin expiring in 2036, unless previously utilized. The California credits carry forward indefinitely. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has established a full valuation allowance for its deferred tax assets due to uncertainties that preclude it from determining that it is more likely than not that the Company will be able to generate sufficient taxable income to realize such assets. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred since inception. Such objective evidence limits the ability to consider other subjective evidence such as the Company&#x2019;s projections for future growth. Based on this evaluation, as of December&#160;31, 2023 and December&#160;31, 2022, a valuation allowance of $43.6 million and $23.3 million, respectively, has been recorded against all of the Company&#x2019;s net deferred tax assets, as the Company has determined that none of the Company&#x2019;s balance of net deferred tax assets is more likely than not to be realized. The amount of the deferred tax assets considered realizable, however, could be adjusted in the future if objective negative evidence in the form of cumulative losses is no longer present and additional weight may be given to subjective evidence, such as estimates of future taxable income during carryforward periods and the Company&#x2019;s projections for growth.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The future utilization of the Company&#x2019;s NOL and tax credit carryforwards to offset future taxable income may be subject to a substantial annual limitation as a result of changes in ownership by stockholders that hold 5% or more of the Company&#x2019;s common stock. An assessment of such ownership changes under Section&#160;382 and 383 was not completed through December&#160;31, 2023. Utilization of our net operating loss and income tax credit carryforwards may be subject to a substantial annual limitation due to ownership changes that may have occurred or that could occur in the future. These ownership changes may limit the amount of the net operating loss and income tax credit carryover that can be utilized annually to offset future taxable income. The Company will examine the impact of any potential ownership changes in the future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the activity related to the Company&#x2019;s gross unrecognized tax benefits at the beginning and end of the&#160;years ended December&#160;31, 2023 and December&#160;31, 2022 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years&#160;ended&#160;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Beginning balance of unrecognized tax benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 529&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Additions based on tax positions related to the current year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,127&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 461&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Additions based on tax positions related to the prior year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Ending balance of unrecognized tax benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,214&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 993&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The unrecognized tax benefit amounts are reflected in the determination of the Company&#x2019;s deferred tax assets. If recognized, none of these amounts would affect the Company&#x2019;s effective tax rate, since it would be offset by an equal corresponding adjustment in the deferred tax asset valuation allowance. The Company does not foresee material changes to its liability for uncertain tax benefits within the next twelve&#160;months.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject to taxation in the United States and various states. The Company&#x2019;s Federal and state returns are subject to examination, due to the carryforward of unutilized net operating losses and research and development credits.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_r3CAOUC9Y026gWYOFgDmHQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant components of the Company&#x2019;s net deferred tax assets are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred income tax assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;NOL carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16,199&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 11,781&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research credit carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,153&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,601&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Capitalized R&amp;amp;D&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 19,404&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,490&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Stock based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,929&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 923&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,117&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 790&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 43,802&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 23,585&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (43,596)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (23,283)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 206&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 302&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred income tax liabilities:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (206)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (302)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (206)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (302)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net deferred tax assets (liabilities)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_LfTcQM9iZEGlLfhH4tvpYg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_g6MS-ePq90Cc80JE0WauzA_4_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">16199000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_CYjNdTLxkE2_jtxhz5tfPw_4_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">11781000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_TBSWKr0kLEK5w7msrfqkVQ_5_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">5153000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_9v-OGtGWeEOnJHgjmvy9wg_5_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1601000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <avte:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_8sNVWof4h0meP1fl6OaXrg_6_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">19404000</avte:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <avte:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_xX7fEm_zJEKkyS0mK0XeTQ_6_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">8490000</avte:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_XwuYkX0cJEiC7Y5fJq5Z-Q_7_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1929000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_YfEfD-qaIEWxmzc16dHrDg_7_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">923000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_v5JQFsG7RkWKo3GaJmSTqA_8_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1117000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_CI8hEyHXskeeX0Yb0XHUcA_8_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">790000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_UUZ6o_mCI0WvXxKv23glKQ_9_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">43802000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_9vlC9KuPCkSZf5_xPQHxCw_9_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">23585000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_-otI0kuSpUyhUj_H9wrMZg_10_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">43596000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_BDMVpDuBQUSKkzjvrdi3jQ_10_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">23283000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_pitMDR_uj0O1VBXQTyBkYA_11_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">206000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_GJqif0C5NkqNwxHWoih0Ug_11_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">302000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_hxrT_LhbSEW_BPCgWB1eew_13_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">206000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_lGiEp3oIYUKqXjhiQPHy8A_13_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">302000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_pmgg1Gcnx0uRJsPiDuFF6A_14_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">206000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_ECcGEtEd6UeOqw286pmlhw_14_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">302000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_N3ZC0VnDvE2ZJbmbzTFsIA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;A reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate is as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years&#160;ended&#160;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15,831)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,829)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,389)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,828)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Permanent and other differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 563&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,049&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (787)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,676)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (757)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,487&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,663&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total tax provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 56&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_syZQVvzyJ0q7SbUG-npsLg_3_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-15831000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_84ywc5-X1Uac1m5v1QYhXA_3_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-10829000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_IrYdWzBpIUGGa9Uqtc8lXA_4_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-3389000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_6-pFL5sozEi1eEVnllujUQ_4_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-2828000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_ruq5jlq3DkuJQIinRqrpjQ_5_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">416000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_UKS7jlqfeUScaRCtPpvEhQ_5_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">563000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_I1rZ-wpSgEqNljkMfRONOg_6_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1049000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_L3Mvx26pz0WCZgxhvQtHbg_6_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-787000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <avte:EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_8oqx6j6Zu0anchSMEAcoGg_7_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-2676000</avte:EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits>
    <avte:EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_K3p4q_SU3U-jxUIA5GONKw_7_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-757000</avte:EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_Oc_vbgoavkW8unmMhiu7BA_8_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">20487000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_Kg0lKWN1Wkm2Dn_kWuYoAQ_8_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">14663000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_CwV-lPB__USqVlM0kiCgUQ_9_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">56000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_C_JOX5-wBUCpoXab6yjp6w_9_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">25000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_LI5YHiUWtUqb-dWGgEgt2Q"
      decimals="-5"
      id="Narr_bszgC6BgRESokf5-X2h7PQ"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">64800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_4mWrWAlR1U2qPGLn2vS_fw"
      decimals="-5"
      id="Narr_Pym4galJ5kGNPL14vdj_iw"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">46900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_LI5YHiUWtUqb-dWGgEgt2Q"
      decimals="-5"
      id="Narr_nvKdOYKpCEu3VXaJha3tnA"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">64800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_Omgdwr0yakip4mYX2MbLqw"
      decimals="-5"
      id="Narr_Zy43YNnXUEKw0OWZ7laJyw"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">44100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_hsfYMw1YQUiRxCSpEvhLOA"
      decimals="-5"
      id="Narr_ezjtCCQY_0WUOpm87qP4bA"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">30500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_WDqRejYbEUSzCLXwlEWRhA"
      decimals="-5"
      id="Narr_TV1oDXWvtEiZaVcHN0Wctg"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">6000000.0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_pWvY-k6LJEyAy3X_g6pRyA"
      decimals="-5"
      id="Narr_LijB9pr5g0qITL3mU8s83w"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-5"
      id="Narr_qVzz_382-ECOM0oJVooSYg"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">43600000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-5"
      id="Narr_b-0S_U1LW0-xo3a7piqnLw"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">23300000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tb_4f4EYDXRt0GvLYUss4UTBA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the activity related to the Company&#x2019;s gross unrecognized tax benefits at the beginning and end of the&#160;years ended December&#160;31, 2023 and December&#160;31, 2022 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years&#160;ended&#160;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Beginning balance of unrecognized tax benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 529&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Additions based on tax positions related to the current year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,127&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 461&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Additions based on tax positions related to the prior year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Ending balance of unrecognized tax benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,214&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 993&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_ZyA9PdR2OUmc55f8WbDNrA_3_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">993000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021_3SZLVaYF3Uaoxk9Z6taH9Q"
      decimals="-3"
      id="Tc_r0oPjESInUWFrwfAKPs1Rw_3_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">529000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_mcZV1vrvZ06lmdJ92DOdIw_4_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1127000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_pq84eKESTEuxoM9EkDg4hg_4_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">461000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      decimals="-3"
      id="Tc_3kpvSMaK9Uy-ZHWi9dJNQA_5_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">94000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="Duration_1_1_2022_To_12_31_2022_poKjxMUsa0iR6DW-1Ns4Jg"
      decimals="-3"
      id="Tc_6i0tR0UooEyKunfFGO_MMg_5_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_Hfz-nUCHAE6nw8atST7vzw_6_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">2214000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_33SKx5N780mZRqQ0FMmATw_6_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">993000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_U1-xkhovVUiT4imA2mQsOw_5_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">31115000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_PniCWoxBi0y1TB5twaR_Ew_5_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">23491000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_gA6BdfNBmUON9qcBnzk_uA_6_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">57615000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_1-te3jFzb02YiiGNk0f1Ow_6_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">98948000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_YXsxTsvsh0O8Sn3Jutg6iw_7_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1875000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_L-D7NvmAPkSP2PxnFoCPzw_7_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1793000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_lZxwmobZv06ot9M0IWwGmw_8_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">90605000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_niP3S0UiPU-j0EnxqGuNjw_8_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">124232000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_nku0_SMr6EK_lZAWDn8NyA_9_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">14000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_olyTnucztkCAfSKE9_CASA_9_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">288000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_nsZZLSd3V0-nj8g0cVW-rw_10_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">259000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_ox3V_Xz0MkCZ5jyMRDoIMw_10_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">614000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_3zfS43y2xketxKnNPXx-zw_11_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">81000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_30_uSnBNi0yqpUwpxctKhA_11_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">2284000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_O38qPEbWoUa3XZ5was4OHQ_12_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">90959000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_Vm9FCHBCn0uejJRNrDboZg_12_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">127418000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_dHGczeoc-EOGK81Mbs9bHQ_17_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">908000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_C2nLYYUofkuMnAtt9MtJnQ_17_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">2396000</us-gaap:AccountsPayableCurrent>
    <avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_5GJ26KBqOU6FSXoFM1sLrg_18_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">8948000</avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_WGKPjlJ2uk6QzlVLwVi7_w_18_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">14821000</avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_71UBes5y8kSJYKT8t2QVXg_19_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">459000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_XgncqNkbZUagc15qTZ2nEw_19_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">420000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_EZ2ECcN040ax9cT6QtbtZw_20_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">10315000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_tWcYEExZCEKFuXXY7QyNdQ_20_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">17637000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_tBx7rWaR40-oft8Pg-38lw_21_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">81000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_N8VRLAZfBkWVGEbtZLfh7A_21_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">255000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilities
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_dNHCC4tuUUq9mzf5ew2IlA_22_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">70000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_eAL9YfX0f0G3KhAa-lQ7UA_22_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">70000</us-gaap:OtherLiabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_IbpLETYvwEq6R1NgNPEKfg_23_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">10466000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_ywIU3a6vCkKinHMqycUpJw_23_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">17962000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="INF"
      id="Narr_jY_nI_26nkSysj0V3HAECw"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="INF"
      id="Narr_HLtqTZR9HE6oeUTXYXEVzQ"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="INF"
      id="Narr_yo_jgxCoOEuMnEAzbkDdiQ"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="INF"
      id="Narr_E2bolh-Ud0GNPsZlpqagCw"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="INF"
      id="Narr_FwaNMmkAi0ioO8NP7s7q6g"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="INF"
      id="Narr_wHGaboHMaU-0HOpAVSecMA"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="INF"
      id="Narr_InL7bflLlkWc9zas7hS6NQ"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="INF"
      id="Narr_y9p4l7Punke8wv6gHWKjEg"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="INF"
      id="Narr_hJEurFtKvkO4iLxY6cKrqA"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="INF"
      id="Narr_zj-0kxLOt0mvHKhWavXswQ"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="INF"
      id="Narr_WFtiQQzsC0a8qxHiHV1Hiw"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="INF"
      id="Narr_Mi3KKEmvDkC7JV4i1hcrrA"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="INF"
      id="Narr_h3-4XNp3_EaK6Dfl5RmRgw"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">28867711</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="INF"
      id="Narr_uf6ZHvgXokmZj4nYHP4O2w"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">28867711</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="INF"
      id="Narr_Km4geJ7FWUaHqQTmyRhNdg"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">27762703</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="INF"
      id="Narr_5xcTZvP8TUisa2iwKEq2Lg"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">27762703</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_B1c45jSg_UiEO2cd2uzr0g_28_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_QcmHjubxe0GnlAV5IQYOAQ_28_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_Kk1PCKuIdEOB6qotd4p2eA_29_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">307888000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_PX1HI6FuMkmPT8KxlbmKew_29_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">272640000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_qVfrv0L7tE-oYtP82kkc5g_30_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">224000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_MG5aA7LnpUeeW65s3-WBbg_30_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">237000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_Gy01mKKxS0S0M5qaVhGamg_31_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-227622000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_EowEm8DZ70GH_pWRlZBWQQ_31_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-163424000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_LHXN0J3_2U6qCMk-WNIbsg_32_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">80493000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_gYNm0tlq7ESb5Hv7fmiwMA_32_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">109456000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_DeyMipcQ4UO9yvsFt55u3w_33_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">90959000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_M3bj7kSPMkmQwtn6-ylXxg_33_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">127418000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="-3"
      id="Tc_2rorMzQOEEGZb0f0hAjQFA_4_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">10328000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="-3"
      id="Tc_YecPPD4sIEG6VNGDygS7wA_4_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">16884000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_XyxBWoqYJkWlD6P7R_z5zw_4_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">51656000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_WHfNg1MjAkWvJBj1UOvYQA_4_12"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">46406000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="-3"
      id="Tc_5lm23t4uuECKig3z6YNhVA_5_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">7082000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="-3"
      id="Tc_OCcJ5HQyeUGMDTwlKB47og_5_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">4484000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_dQKyrj4Y-keH2VWeLzNDxw_5_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">16537000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_rVaRHHrtkUeHhpoUbLkQ-g_5_12"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">12937000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="-3"
      id="Tc_QeGK5ozf1Uag0YWvN9lRfA_6_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">17410000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="-3"
      id="Tc_6Yz8sLnk2ka1gnyVCYr9VQ_6_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">21368000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_qXXBq5PB1kulHRPHTFTXtw_6_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">68193000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_RKKjcO_Bt0Wxk9wZWkK5ig_6_12"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">59343000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="-3"
      id="Tc_7h6UPOpSkU66H24UV1dvAQ_7_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-17410000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="-3"
      id="Tc_rJr6GdlHFkOPmVXtnW167A_7_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-21368000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_0yimzPqUk0akMBiBLAMBAg_7_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-68193000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_8g1cddnlIUODEIeF2-lRuA_7_12"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-59343000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="-3"
      id="Tc_CD1kvMBum0qukXtr_jbiAg_9_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1183000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="-3"
      id="Tc_W5xWWvJzD0CLN398H0KpOQ_9_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1804000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_TM5j8T5qx0yqE62XDQM3NQ_9_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">4014000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_mGckEaz5d0G--tOMcfSAWA_9_12"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">4236000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="-3"
      id="Tc_BluXY8Aw4UuO7zcaP6cADw_10_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-10000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="-3"
      id="Tc_D8ztsjaGhUmUhMQ7Q1lczQ_10_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_0LC5QH5atUaZWI5UxapUfg_10_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-19000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_2nr7bmOuMEuwvI2rux3iTQ_10_12"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-1000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="-3"
      id="Tc_Cnp0p5kR8k61u5ibV2IQHg_11_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1173000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="-3"
      id="Tc_W46jL5g86EWBXyf8ewXB2w_11_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1805000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_k6A8yVT4SUqwIOFVxdS-eA_11_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3995000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_-U2fOaXnqkOH-4TZM4_tSw_11_12"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">4235000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="-3"
      id="Tc_mwl4pFy9oU2nbbQkanSX_g_12_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-16237000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="-3"
      id="Tc_8QMyekEzhE2BASY5Kd6XFQ_12_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-19563000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_bPjHmkr1IUawZC6ebEAwVQ_12_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-64198000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_0FI8niRdlUGELOnfsi0nUQ_12_12"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-55108000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="-3"
      id="Tc_XcYnNIY7rUqtUmTDrgv3Iw_14_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-16237000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="-3"
      id="Tc_SKStvn5dR0GYMB94XRXj2w_14_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-19563000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_xb9GSfedp0S8UYjFcJ5epA_14_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-64198000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_ZXTRTgbfIU-Wp3HBcO0_WQ_14_12"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-55108000</us-gaap:ProfitLoss>
    <us-gaap:DebtSecuritiesTradingUnrealizedGainLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="-3"
      id="Tc_7miHMgjU-k24UaLe77eBnQ_16_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">307000</us-gaap:DebtSecuritiesTradingUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesTradingUnrealizedGainLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="-3"
      id="Tc_WkfhWugla0KcxyRy3Ly4FQ_16_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-22000</us-gaap:DebtSecuritiesTradingUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesTradingUnrealizedGainLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_oOyLjXbjMEuT5umM1Ea2gg_16_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-13000</us-gaap:DebtSecuritiesTradingUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesTradingUnrealizedGainLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_r-fnKc5NKki9yvpA1CYYCw_16_12"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">243000</us-gaap:DebtSecuritiesTradingUnrealizedGainLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="-3"
      id="Tc_kyJPJIv5t06rreJ-glFCuw_17_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-15930000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="-3"
      id="Tc_Wld9y8CiJ0yYxHOFDnIjsw_17_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-19585000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_Xy-RVB_Z7U61CBMrrcC9Zg_17_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-64211000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_0YylNwhUd0-T7nhjEBN5yQ_17_12"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-54865000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="2"
      id="Tc_PFbFWPzYikSBSkZdruwqIQ_18_3"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">-0.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="2"
      id="Tc_PFbFWPzYikSBSkZdruwqIQ_18_3_2"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">-0.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="2"
      id="Tc_rCSeA2R470G-KXfNnuKozQ_18_6"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">-0.71</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="2"
      id="Tc_rCSeA2R470G-KXfNnuKozQ_18_6_2"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">-0.71</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="2"
      id="Tc_kfxwKBRW_EykPSwLGPgrkw_18_9"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">-2.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="2"
      id="Tc_kfxwKBRW_EykPSwLGPgrkw_18_9_2"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">-2.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="2"
      id="Tc_FiIrSZkB9kSHdxpExq0o1g_18_12"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">-2.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="2"
      id="Tc_FiIrSZkB9kSHdxpExq0o1g_18_12_2"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">-2.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="0"
      id="Tc__p6-Zd-DS0iXfny0SoxqFA_19_3"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">28863327</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="0"
      id="Tc__p6-Zd-DS0iXfny0SoxqFA_19_3_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">28863327</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="0"
      id="Tc_wdxSKWrz-0Cb-9j0MNLI2g_19_6"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">27640542</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="0"
      id="Tc_wdxSKWrz-0Cb-9j0MNLI2g_19_6_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">27640542</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="0"
      id="Tc_ijGoW_mB5kqmXovF9-DBuQ_19_9"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">28572338</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="0"
      id="Tc_ijGoW_mB5kqmXovF9-DBuQ_19_9_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">28572338</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="0"
      id="Tc_6H1mc0DYtkSwf8fd_nvOhg_19_12"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">25872118</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="0"
      id="Tc_6H1mc0DYtkSwf8fd_nvOhg_19_12_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">25872118</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iFYHzpsOAk6upQL9o0JHJA"
      decimals="INF"
      id="Tc_lgZUzVFwPka6Fh-eB6StLg_6_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">27762703</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iFYHzpsOAk6upQL9o0JHJA"
      decimals="-3"
      id="Tc_cQ3pRhm33UGFRLUZPSxvRw_6_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_r3UKbN8hp0mfWhezRkf1lQ"
      decimals="-3"
      id="Tc_NDRbrvtVSUiOV-eyuilepA_6_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">272640000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_UqfaQqRd1U-rmSnO35M5GQ"
      decimals="-3"
      id="Tc_0jd_3DmtAUGsfjSZhW_CSQ_6_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">237000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_QLbiEq19A02perNXBXbTKA"
      decimals="-3"
      id="Tc_-cWrWzSxTUGuKc3Tielrng_6_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-163424000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_FAf8CRMgaUisICnAUnrSZQ_6_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">109456000</us-gaap:StockholdersEquity>
    <us-gaap:DebtSecuritiesTradingUnrealizedLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_wy5Ete1m60Gp0JfLF-sD_Q"
      decimals="-3"
      id="Tc_x__rLLcLdECfUC8rFl93iw_7_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">270000</us-gaap:DebtSecuritiesTradingUnrealizedLoss>
    <us-gaap:DebtSecuritiesTradingUnrealizedLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_FUDixdV2nkO01qprXRWNww"
      decimals="-3"
      id="Tc_fWuMFRu_h0GGTtTN39c6DQ_7_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">270000</us-gaap:DebtSecuritiesTradingUnrealizedLoss>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SOdnYt1ZJUmGZUp4nkZ_Dg"
      decimals="INF"
      id="Tc_w4KkMJkTIEWbp3Ke08YGgg_8_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">133282</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pzSeRKqRmUWfGQi3u9vQfQ"
      decimals="-3"
      id="Tc_FVVP5ujeqUWHn8MqD6JSgg_8_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">704000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_3_31_2024_FUDixdV2nkO01qprXRWNww"
      decimals="-3"
      id="Tc_oD1ftKiaCkmEsewelFW56g_8_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">704000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SOdnYt1ZJUmGZUp4nkZ_Dg"
      decimals="INF"
      id="Tc__sYvtQeFgkK9W-Lszw9XEQ_9_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">2776</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pzSeRKqRmUWfGQi3u9vQfQ"
      decimals="-3"
      id="Tc_Zt6bQxrQkkesUqC_f0ZI4w_10_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">4200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_3_31_2024_FUDixdV2nkO01qprXRWNww"
      decimals="-3"
      id="Tc_azMg8rnUd0OmapXTTfg7jg_10_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">4200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UlG_BWompUqeXJDTFYDksw"
      decimals="-3"
      id="Tc_q04W7aIuykeqPfKyMQJ8Xw_11_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-23186000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_FUDixdV2nkO01qprXRWNww"
      decimals="-3"
      id="Tc_szFxPg70M0ytsDPRaw0jNg_11_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-23186000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hMDvqIPNTkyi3vwRMi3AWA"
      decimals="INF"
      id="Tc_CmelX3uT7Em7t7mvIi4tTQ_12_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">27898761</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hMDvqIPNTkyi3vwRMi3AWA"
      decimals="-3"
      id="Tc_AIVOqguwPES3iWQEZDRwyw_12_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vnVV5804C0ScsiBOSJ6srg"
      decimals="-3"
      id="Tc_yUpgQKE2CkClMnh_KXbw1Q_12_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">277544000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Y99KaUn2oUW0_Rr118_mxA"
      decimals="-3"
      id="Tc_w2TrMzUPTEuReLUglhNQHA_12_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-33000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CPH6za25g0uUfCifzsYkkw"
      decimals="-3"
      id="Tc__kWVVU5JQkiowvCk8I7S0Q_12_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-186610000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_qUiBx0SpzUGr9LR_aNTQUg"
      decimals="-3"
      id="Tc_-B7xH1I8akWHF_vyqbw6YQ_12_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">90904000</us-gaap:StockholdersEquity>
    <us-gaap:DebtSecuritiesTradingUnrealizedLoss
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_SfcoGV5hFkuKGuO_rvH3RA"
      decimals="-3"
      id="Tc_QO1rG9cp3kyOtxGmIQ3C4Q_13_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">50000</us-gaap:DebtSecuritiesTradingUnrealizedLoss>
    <us-gaap:DebtSecuritiesTradingUnrealizedLoss
      contextRef="Duration_4_1_2024_To_6_30_2024_gnY1UC1Lf0eSFvl6XWqbGQ"
      decimals="-3"
      id="Tc__5l8x85JlUaRnoLxiOZVjw_13_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">50000</us-gaap:DebtSecuritiesTradingUnrealizedLoss>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gOVZr7JYNEKGhCeqwxOmnQ"
      decimals="INF"
      id="Tc_qLOfWVZOr0Oc7IWZ3ZDW4w_14_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">800000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tfvBCfSvrEinR9S17WhtYg"
      decimals="-3"
      id="Tc_02SdIrRfS02h18NvEdS9pA_14_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">23635000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_4_1_2024_To_6_30_2024_gnY1UC1Lf0eSFvl6XWqbGQ"
      decimals="-3"
      id="Tc_rtrCEiy3F0Gpo8HJ3i9vZg_14_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">23635000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gOVZr7JYNEKGhCeqwxOmnQ"
      decimals="INF"
      id="Tc_bCH06vlDOE6rICSJapUFGw_15_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">119239</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tfvBCfSvrEinR9S17WhtYg"
      decimals="-3"
      id="Tc_C80A3kF-RUmVLnmXMy0vrw_15_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">511000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2024_To_6_30_2024_gnY1UC1Lf0eSFvl6XWqbGQ"
      decimals="-3"
      id="Tc_5vtlkb9CRkKnMUo-mfmkNg_15_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">511000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gOVZr7JYNEKGhCeqwxOmnQ"
      decimals="INF"
      id="Tc_OjmE5BqsQ0CSEvBBWG__-g_16_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">34034</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tfvBCfSvrEinR9S17WhtYg"
      decimals="-3"
      id="Tc_NdkJcl6Y2Ea-kkfxFZrLPA_16_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">308000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_4_1_2024_To_6_30_2024_gnY1UC1Lf0eSFvl6XWqbGQ"
      decimals="-3"
      id="Tc_cj8oZVc73UKjzD2gE6eMjg_16_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">308000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gOVZr7JYNEKGhCeqwxOmnQ"
      decimals="INF"
      id="Tc_iamRJV1_vkujNHSOowgqqA_17_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">2716</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tfvBCfSvrEinR9S17WhtYg"
      decimals="-3"
      id="Tc_MHBb7UmS60qXq19e3ESzQw_18_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3865000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2024_To_6_30_2024_gnY1UC1Lf0eSFvl6XWqbGQ"
      decimals="-3"
      id="Tc_wbwCGyztGkCzGlgwnNE3Vw_18_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3865000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nyimchTjV0KbghS9hcjUig"
      decimals="-3"
      id="Tc_4Bc8721pAEW5AYDETvA7QA_19_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-24775000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2024_To_6_30_2024_gnY1UC1Lf0eSFvl6XWqbGQ"
      decimals="-3"
      id="Tc_GqxTNvx0TkKYuGRmvG741w_19_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-24775000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_geY3vwOu-UyPu9NwOyIAkw"
      decimals="INF"
      id="Tc_G8Go8_usqkKYCdXxw4W-VA_20_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">28854750</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_geY3vwOu-UyPu9NwOyIAkw"
      decimals="-3"
      id="Tc_N7kFbsoq_kK4SDNCGnnLNg_20_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Y6cZV9QIL0C4SojMpiXIJg"
      decimals="-3"
      id="Tc_uMCRDQBE8kKGbJVP00ibWQ_20_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">305863000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_lCewvdNJxkWfBMMcTCfUEA"
      decimals="-3"
      id="Tc_6lkQ9-v95EOBsjEsPkRUbA_20_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-83000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_FsIjL_FCA0ypY_AxEKEtOA"
      decimals="-3"
      id="Tc_EO7m3lGTFUmunGHJe-AYqw_20_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-211385000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_V-lvpQAYG0u0LVvYzwbGTg"
      decimals="-3"
      id="Tc_uqkaEq62MEecPNvHb1x5Zg_20_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">94398000</us-gaap:StockholdersEquity>
    <us-gaap:DebtSecuritiesTradingUnrealizedGain
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_s-ZbaqOFEkqsqlAtFTXFQQ"
      decimals="-3"
      id="Tc_wV0a0MhSFECDk16nfcKF6w_21_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">307000</us-gaap:DebtSecuritiesTradingUnrealizedGain>
    <us-gaap:DebtSecuritiesTradingUnrealizedGain
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="-3"
      id="Tc_wQ7KEi79VkOrHzXjoefRaA_21_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">307000</us-gaap:DebtSecuritiesTradingUnrealizedGain>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1mDefc7T6EyF8Qo5feNffg"
      decimals="INF"
      id="Tc_l2ZzUrwUukKAgR530ycMbw_22_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">12961</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FLsOS9KJZUm-Ldlf9yt1hQ"
      decimals="-3"
      id="Tc_YvxgOxflxEmq6CvGHPMKDQ_22_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">22000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="-3"
      id="Tc__0g7WRAvjEqKTAVJCwIeng_22_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">22000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FLsOS9KJZUm-Ldlf9yt1hQ"
      decimals="-3"
      id="Tc_pa77q3qIJ0CHhvozHokvdw_23_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">2003000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="-3"
      id="Tc_XWLm4faWykSeZto8nLlgPw_23_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">2003000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_j8k9mWHPuUaAW-sNf4hesg"
      decimals="-3"
      id="Tc_SsEr_uDqM0-hfw0MD9SZ0Q_24_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-16237000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="-3"
      id="Tc_u5uyPPqZJEOybvSor04g1w_24_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-16237000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__iWQPWvZwkOiM4XiYpOJ7Q"
      decimals="INF"
      id="Tc_KuE6JWb4c0KvMhrpS1NAkw_25_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">28867711</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__iWQPWvZwkOiM4XiYpOJ7Q"
      decimals="-3"
      id="Tc_5s53vdM3YUWN-cOrArEdxA_25_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2AicAM6JCEOlEUXMi5ktng"
      decimals="-3"
      id="Tc__CjIxsKujU6gjh6CAJcQ7g_25_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">307888000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_vPXXIZakVEKr1VLr1ptsQg"
      decimals="-3"
      id="Tc_Cexm2fNI_0aMqktasJwN7w_25_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">224000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_70YqRRSkWEWlj8cmh1CBtA"
      decimals="-3"
      id="Tc_i73oVoa40Eue_64zzv5qjw_25_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-227622000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_L4J3edCl7kiV7kxG9o1bcw_25_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">80493000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bPKy-329i0a269T7iYdlfQ"
      decimals="INF"
      id="Tc_26CjU_r46U-ywbx_uOnwJQ_6_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">24722974</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bPKy-329i0a269T7iYdlfQ"
      decimals="-3"
      id="Tc_KD4RPcTdw0qFF1agC3DU9g_6_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dcFzNA8x9Ui_AjpnWINDyw"
      decimals="-3"
      id="Tc_A7wgAM2f606C774lXHH_Zg_6_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">215110000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QECF8CV7f0Kgvhlc6flPyA"
      decimals="-3"
      id="Tc_QteWIGgzwUi5EBosZUS3iA_6_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-466000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_a5ipJvXbekyb6Q7U_qk5JA"
      decimals="-3"
      id="Tc_c9RShHStj0Oz_tcc4f6MsA_6_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-87903000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_AunStqKsvEaUaZXPyK_CUw_6_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">126743000</us-gaap:StockholdersEquity>
    <us-gaap:DebtSecuritiesTradingUnrealizedGain
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rSCB_jEoQUWrJ9udMpqr1w"
      decimals="-3"
      id="Tc_ppChjoJ7hkqSXUF3PyqGqQ_7_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">265000</us-gaap:DebtSecuritiesTradingUnrealizedGain>
    <us-gaap:DebtSecuritiesTradingUnrealizedGain
      contextRef="Duration_1_1_2023_To_3_31_2023_tdpGz56jqk6Dn9XNb5jQVA"
      decimals="-3"
      id="Tc__lzlGv3YD0yGN_pxlO5SKg_7_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">265000</us-gaap:DebtSecuritiesTradingUnrealizedGain>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mK0glKtp20-JMUhi6bQzgA"
      decimals="INF"
      id="Tc_2RqRIQ4cmkSv1-2m5hUgdw_8_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">93966</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_G7iErj3me0qVgh1ge_DiqA"
      decimals="-3"
      id="Tc_z6KPfaCfv0WfJSM6csDK-Q_8_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">223000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_3_31_2023_tdpGz56jqk6Dn9XNb5jQVA"
      decimals="-3"
      id="Tc_ZiDe5JGFTE-xxeUmlKvlVQ_8_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">223000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_G7iErj3me0qVgh1ge_DiqA"
      decimals="-3"
      id="Tc_lQAlM8Q7T0qOtVeBDctsOg_9_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">2384000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_3_31_2023_tdpGz56jqk6Dn9XNb5jQVA"
      decimals="-3"
      id="Tc_uXYtah8rjE23yTD1ExKqEw_9_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">2384000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aXw1Zj8XYkqQuwDSYY4ipw"
      decimals="-3"
      id="Tc_zwAOPORKN0yaMafLK9ktqg_10_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-16520000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_tdpGz56jqk6Dn9XNb5jQVA"
      decimals="-3"
      id="Tc_cD0X646oVkOJzm_z_JSNJQ_10_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-16520000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vWNBs-3fkEi8yguhaSbYeg"
      decimals="INF"
      id="Tc_WWVAVP2ifk2PX3y9Cv3-Jw_11_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">24816940</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vWNBs-3fkEi8yguhaSbYeg"
      decimals="-3"
      id="Tc_-RaB64vP4EWOkboen83GzQ_11_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HWbpxkODu0WkRFHnGDEkSA"
      decimals="-3"
      id="Tc_1o0gi8VSxk2I6hvjKcNw-g_11_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">217717000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_HyF9ifdj0Ui9zRFDa7dqYg"
      decimals="-3"
      id="Tc_dH1F0mLtaUCop_imy5pRng_11_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-201000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_M2y81zs0L0Oc7hgVHJlBTA"
      decimals="-3"
      id="Tc_RKliB1m5JU6PX1e6_fXgkg_11_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-104423000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_Ju0lA-npTUKKlfj1h0_hIA"
      decimals="-3"
      id="Tc_UNYjWk10nk21q8Wt_VfUVg_11_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">113095000</us-gaap:StockholdersEquity>
    <us-gaap:DebtSecuritiesTradingUnrealizedLoss
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_g1st23sQ50KGJ_c8e9kcQg"
      decimals="-3"
      id="Tc_mL8QO2cguEyCdVCjeuOY9w_12_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">22000</us-gaap:DebtSecuritiesTradingUnrealizedLoss>
    <us-gaap:DebtSecuritiesTradingUnrealizedLoss
      contextRef="Duration_4_1_2023_To_6_30_2023_0RTLeeNjREWrXNlRldBizg"
      decimals="-3"
      id="Tc_Y4i81sf9_U6-9vmHSs5Xhg_12_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">22000</us-gaap:DebtSecuritiesTradingUnrealizedLoss>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K4s3v6nxgU-obbx2d9aSOQ"
      decimals="INF"
      id="Tc_y_lLILLFREOSqjAmp1L2GA_13_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">2662721</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K4s3v6nxgU-obbx2d9aSOQ"
      decimals="-3"
      id="Tc_r1ywNZufPEuhvyaSJt9QsA_13_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3YNubJsuwUyt1b4HmIVa7Q"
      decimals="-3"
      id="Tc_VyXls7xKe0Ceaa2c_pX_zw_13_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">44282000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_4_1_2023_To_6_30_2023_0RTLeeNjREWrXNlRldBizg"
      decimals="-3"
      id="Tc_kXyF5rL0Fk225FCvcZzhCg_13_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">44283000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K4s3v6nxgU-obbx2d9aSOQ"
      decimals="INF"
      id="Tc_Mk3DH5W180mzHcbazrpIMQ_14_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">106756</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3YNubJsuwUyt1b4HmIVa7Q"
      decimals="-3"
      id="Tc_pLDlRnZ0c0KNy5mEOuJZFg_14_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">333000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2023_To_6_30_2023_0RTLeeNjREWrXNlRldBizg"
      decimals="-3"
      id="Tc_AdCPnLOgXkmaJOaRzLqjCg_14_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">333000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K4s3v6nxgU-obbx2d9aSOQ"
      decimals="INF"
      id="Tc_IXot23xYX0OPXvHQZH-82w_15_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">13866</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3YNubJsuwUyt1b4HmIVa7Q"
      decimals="-3"
      id="Tc_zuGIY3fCEkibCObjrkMnBQ_15_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">228000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_4_1_2023_To_6_30_2023_0RTLeeNjREWrXNlRldBizg"
      decimals="-3"
      id="Tc_MyvhA47FB0yduYPNqfGg-A_15_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">228000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K4s3v6nxgU-obbx2d9aSOQ"
      decimals="INF"
      id="Tc_TE3nbg3WQ02k0d3Ltm-mJQ_16_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">815</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3YNubJsuwUyt1b4HmIVa7Q"
      decimals="-3"
      id="Tc_Y3l19lKGgESZyezKRUNPxw_17_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3034000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2023_To_6_30_2023_0RTLeeNjREWrXNlRldBizg"
      decimals="-3"
      id="Tc_Fa3Xf_e7T0yqycbie9OECg_17_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3034000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fB9Oej3iHEuLzftkJpBxOA"
      decimals="-3"
      id="Tc_XClkJSvLsEyXZiR_aULDgQ_18_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-19025000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2023_To_6_30_2023_0RTLeeNjREWrXNlRldBizg"
      decimals="-3"
      id="Tc_qVyXMPEkG0eY-z6fMYXRTw_18_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-19025000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uKGL0eef7kyr6Ltc79lK9A"
      decimals="INF"
      id="Tc_5J78XPTUA0KKbGxL_obWxQ_19_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">27601098</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uKGL0eef7kyr6Ltc79lK9A"
      decimals="-3"
      id="Tc_SHgleWoQmUuPuSjuoTPrLA_19_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VpGpQUz2xki0YzMNgZlDQw"
      decimals="-3"
      id="Tc_ClsL4e0EAk207zUqCsTYhw_19_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">265594000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_afA-gfdpa02BAMGQN_YZBQ"
      decimals="-3"
      id="Tc_zMGIiR7JO0KEL6KEyek_NA_19_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-223000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KPy_Azxvr0mBNfoqRZD5Ew"
      decimals="-3"
      id="Tc_VjUg43PmK02IWo-_I3oZqA_19_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-123448000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_HPAMtIcY9Eq1U2SHfyr_uw"
      decimals="-3"
      id="Tc_kiO17TBk00qbExTcYniB_w_19_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">141926000</us-gaap:StockholdersEquity>
    <us-gaap:DebtSecuritiesTradingUnrealizedGain
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_R1aNdniYp0yg5IJCGgDujA"
      decimals="-3"
      id="Tc_mDdRxX8TDk-M7B-clRFqXA_20_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">28000</us-gaap:DebtSecuritiesTradingUnrealizedGain>
    <us-gaap:DebtSecuritiesTradingUnrealizedGain
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="-3"
      id="Tc_Xaq8q4KfgEmFjg3G5ShEcA_20_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">28000</us-gaap:DebtSecuritiesTradingUnrealizedGain>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eIQAEotTfU2ghqhEOp-9tQ"
      decimals="INF"
      id="Tc_Dl1F9TYhxUSGtuqz1922YQ_21_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">46777</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ImI5-uZhs02-PHLXTrl4zw"
      decimals="-3"
      id="Tc_FLt95P4Ho0WROvs4RXAqBQ_21_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">95000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="-3"
      id="Tc_QKc09OVYNUmbKHKMrhVsgw_21_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">95000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eIQAEotTfU2ghqhEOp-9tQ"
      decimals="INF"
      id="Tc_JscBdlx1kUK1GIX09MfbsQ_22_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">5312</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ImI5-uZhs02-PHLXTrl4zw"
      decimals="-3"
      id="Tc_1-zJZk_ukUqLkAtCVzXyhw_23_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3237000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="-3"
      id="Tc_oa7Ks0PNU0SGvP_uzdGfaw_23_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3237000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pv40wdBMdU2Z1HGOA_ocaw"
      decimals="-3"
      id="Tc_B8xt0uovM0iaEuYBDFUh_Q_24_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-19563000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="-3"
      id="Tc_oP2KlMRgYUmR8XQqRjtzQQ_24_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-19563000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HmDl-Xe2CkiW7tLgrbq_Fg"
      decimals="INF"
      id="Tc_hcRKka8sRUSOEgYxSp_fCA_25_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">27653187</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HmDl-Xe2CkiW7tLgrbq_Fg"
      decimals="-3"
      id="Tc_dA6N0Nv6oUuRXASKlrkTbQ_25_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZE61xkcRkUCNaq4gU5yrWQ"
      decimals="-3"
      id="Tc_S2gT69xcr0-UzpbVWkuVIg_25_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">268926000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FJ3Ctxrxc0CDo2XUQUe3QA"
      decimals="-3"
      id="Tc_0jMWORoAyUuhupNCyuOS2Q_25_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-195000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UCLAdEOov0OXILzRhTTw3w"
      decimals="-3"
      id="Tc_gI4qR04LpES7C0MfkOXKtw_25_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-143011000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_e-zMRu88YEulFM6FDn839A"
      decimals="-3"
      id="Tc_j76AhuuuKUeSX2PnNPVt3Q_25_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">125723000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_SqqLDplXQEWR1kM3RiscRg_4_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-64198000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_XoFSDrCfS0K2gS3iUa8BXg_4_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-55108000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_b3_DWWHz70OmlXxOBM6DFw_6_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">10068000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_b2ug1va7Kk6FOqW1bzsICg_6_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">8655000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_UZupSwxS1ki2rNaGcB6TNg_7_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">274000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_6u56ZWMoCUuZcDnMTjEfEg_7_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">68000</us-gaap:Depreciation>
    <avte:AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_lny9i8EMM0u84tSnMcwBPQ_8_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-1912000</avte:AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet>
    <avte:AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_wXLFxkB0M0mYxastdf3nxg_8_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-2118000</avte:AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_c_06Pps3z025bQ7uFY7rjQ_10_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">82000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_UwIHUIvkT02H0XhVdzOhBQ_10_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">128000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_8U4vKg-XwkOAUaQXFYDHXw_11_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-789000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_-jrMh1p9fUqcmqmr_9iQuQ_11_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">70000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_8oDgq9-_8kGnwxc2NvUtVQ_12_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-1488000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_5NUeBzCDH0iygBkhuOghpA_12_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">880000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_q69qn_pL30SPYBBsZDMl3w_13_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-4152000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_bMrANz53iky5ciq8yf45cQ_13_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">5948000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <avte:IncreaseDecreaseInOperatingLeaseAssetAndLiability
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_LhjVMartlEmOXjtb31f_Gw_14_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">220000</avte:IncreaseDecreaseInOperatingLeaseAssetAndLiability>
    <avte:IncreaseDecreaseInOperatingLeaseAssetAndLiability
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_IuRW7OtQAEW5fonMW0mTRA_14_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">9000</avte:IncreaseDecreaseInOperatingLeaseAssetAndLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_7_IbIVcMekGZ7cpUEzlvjw_15_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">332000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_3Hxr-sIeJkaEZmU6eZOpJg_15_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-114000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_Ld9tr6tYJUeklHVFdqqAmw_16_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-60149000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_jXby8AlJNEa-TgpT6mfR3Q_16_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-41978000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_ohogI6p1o0OumIj4m9Xqbw_19_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">19683000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_A6KdyiVqZ0OL-FsT-AMhVw_19_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">96194000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_6ZomomRwaEa2KvFrDjW_cA_20_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">62583000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_5PTQS7364Eu5WmyL8-P7tA_20_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">102500000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_Egi13x0AqUmSqdls2ihuYw_21_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">78000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_MOIxRA3KcECVc1nSW_hzBg_22_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">42900000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_-KWpu_mMMEyjaznduh3gPQ_22_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">6228000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc__-BYFJ_g2UOkUesRfphulQ_25_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">23635000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_WONyAUeypkqrNCQZ5CamDQ_25_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">44888000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_8MtlZvkkG0qSc2ZOMfNRBA_26_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">307000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_PF_H_6afvU-q8uTsSLvlYA_26_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">234000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_P2l_M3R-nUelPpnk83lfkA_27_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">308000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc__Y6K9NB0nUieaeVqJ8FVjw_27_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">228000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_OSsSnvOY3kC2RNrjdsF-0A_28_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1237000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_vNbLyUUPakWroclQIU0Lew_28_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">651000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_mzMtoAoPUEytk4YLMSEtKg_29_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">24873000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_2w-14Kc4sUSwfLcrToMn3A_29_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">45533000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_mFdLP53gvUWJILIh8MfiPg_31_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">7624000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_uQG0L2E5PkSYSgW3yA1LOA_31_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">9783000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_oVtGMxCOt0Od-0M5oKNwAA_32_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">23491000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="As_Of_12_31_2022_P8Zsc2cSgEOfuzNTRStuDQ"
      decimals="-3"
      id="Tc_5pBLSG8H1ES3fTHD6PtJ9Q_32_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">22397000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_cFK9n2Frs0yJONQQ4P2l9Q_33_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">31115000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="As_Of_9_30_2023_e-zMRu88YEulFM6FDn839A"
      decimals="-3"
      id="Tc_N2sLNBY7tke8BydLdy5B6g_33_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">32180000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_dbT5RexU3kWKVKEUmPld0w_36_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">206000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_lBTrZfa0rEuijq81Gr4tUw_37_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">64000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tb_zujOrBdYI06EOELAYaoyRg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;ORGANIZATION AND NATURE OF OPERATIONS&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;(a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Organization and Nature of Operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Aerovate Therapeutics Inc. (&#x201c;Aerovate&#x201d; or the &#x201c;Company&#x201d;) was incorporated in the state of Delaware in July 2018, and is headquartered in Waltham, Massachusetts. The Company has a wholly owned subsidiary, Aerovate Securities Corporation. The Company is a biopharmaceutical company. The Company&#x2019;s initial focus was on advancing AV-101, the Company&#x2019;s dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (&#x201c;PAH&#x201d;). However, in June 2024, the Company announced negative results from the Phase 2b portion of its global Phase 2b/Phase 3 trial of AV-101 in adults with PAH, and, as a result, the Company decided to halt enrollment and shut down the Phase 3 portion of the Phase 2b/Phase 3 trial as well as the long-term extension study. In June 2024, the Company announced a corporate restructuring and in July 2024, the Company engaged Wedbush PacGrow as the Company&#x2019;s exclusive strategic financial advisor to assist in the process of exploring strategic alternatives, including but not limited to an acquisition, merger, reverse merger, business combination, liquidation or other transaction.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On October 30, 2024, the Company entered into an Agreement and Plan of Merger (the &#x201c;Merger Agreement&#x201d;), by and among the Company, Caribbean Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (&#x201c;Merger Sub I&#x201d;), Caribbean Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of the Company (&#x201c;Merger Sub II&#x201d; and together with Merger Sub I, the &#x201c;Merger Subs&#x201d;), and Jade Biosciences, Inc., a Delaware corporation (&#x201c;Jade&#x201d;), pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, among other things, Merger Sub I will merge with and into Jade, with Jade surviving the merger as the surviving corporation (the &#x201c;First Merger&#x201d;), and as part of the same overall transaction, Jade will merge with and into Merger Sub II, with Merger Sub II continuing as a wholly owned subsidiary of the Company and the surviving corporation of the merger (the &#x201c;Second Merger&#x201d; and together with the First Merger, the &#x201c;Merger&#x201d;). In addition, in connection with the closing of the Merger (the &#x201c;Closing&#x201d;), the Company expects to declare a cash dividend to its pre-Merger stockholders of approximately $65.0 million in the aggregate (the &#x201c;Cash Dividend&#x201d;), provided such amount is subject to adjustment as set forth in the Merger Agreement. The Merger was approved by the Company&#x2019;s board of directors (the &#x201c;Board&#x201d;), and the Board resolved to recommend approval of the Merger Agreement to the Company&#x2019;s stockholders. The Closing is subject to approval by the stockholders of the Company and Jade as well as other customary closing conditions, including the effectiveness of a registration statement filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) in connection with the transaction. If the Merger is completed, the business of Jade will continue as the business of the combined company.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;(b)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;At-the-Market Offering &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 5, 2023, the Company entered into an ATM Equity Offering&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with BofA Securities, Inc., or the Agent, pursuant to which the Company can sell, from time to time, at its option, up to an aggregate of $75.0 million of shares of its common stock, through the Agent, as its sales agent. As of September 30,&#160;2024, 3,462,721 shares have been sold under the Sales Agreement, generating $67.9 million of net proceeds after deducting commissions to the Agent and other offering costs. As of the date of this Quarterly Report on Form 10-Q, up to $6.0 million of shares of the Company&#x2019;s common stock remain available for sale from time to time under the Sales Agreement. &lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;(c)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Liquidity and Management Plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Since inception, the Company has devoted substantially all of its resources to research and development activities, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations and has not realized revenues from its planned principal operations. The Company has incurred losses and negative cash flows from operations since inception. As of September&#160;30,&#160;2024, the Company had cash and cash equivalents and short-term investments of $88.7 million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Management believes that the Company&#x2019;s current cash and cash equivalents and short-term investments will provide sufficient funds to enable the Company to meet its obligations for at least twelve&#160;months from the filing date of this report while it explores strategic alternatives.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:DividendsCommonStockCash
      contextRef="Duration_10_30_2024_To_10_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_RPVQa3dXU0OggwPnCBtwgg"
      decimals="-5"
      id="Narr_Lzx7Rhe5BUSSm3uxGQh6Jw"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">65000000.0</us-gaap:DividendsCommonStockCash>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_4_5_2023_To_4_5_2023_srt_CounterpartyNameAxis_avte_BofaSecuritiesInc.Member_eXGnRQpI10OVMaKnBBIqeg"
      decimals="-5"
      id="Narr_I5iiZJLdS0CqIBelce0_2g"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">75000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_CounterpartyNameAxis_avte_BofaSecuritiesInc.Member_fT8d84SKjEiyXJr9wvIUUw"
      decimals="INF"
      id="Narr_GbxUO2U9akavOoe8RGXiLw"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">3462721</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_CounterpartyNameAxis_avte_BofaSecuritiesInc.Member_fT8d84SKjEiyXJr9wvIUUw"
      decimals="-5"
      id="Narr_BumIMhUE30SjA2Z31dH-Lg"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">67900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <avte:ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram
      contextRef="As_Of_9_30_2024_srt_CounterpartyNameAxis_avte_BofaSecuritiesInc.Member_IwOYf_4k8kOpNBRHvM5Rxg"
      decimals="-5"
      id="Narr_Xn4X9U0ImEupPF_e0hf6qQ"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">6000000.0</avte:ValueOfRemainingCommonStockAvailableForSaleUnderAtmProgram>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-5"
      id="Narr_GsFQW6bRskmzApzgg-tEbw"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">88700000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tb_wV-NldgiKUy_eUUZnqXDqw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;(a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying unaudited condensed consolidated financial statements as of September&#160;30,&#160;2024 and for the three and nine months ended September&#160;30,&#160;2024 and 2023 have been prepared in conformity with generally accepted accounting principles (&#x201c;GAAP&#x201d;) in the United States of America for interim financial information and pursuant to Article&#160;10 of Regulation S-X of the Securities Act of 1933, as amended (the Securities Act). Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include only normal and recurring adjustments that the Company believes are necessary to fairly state the Company&#x2019;s financial position and the results of its operations and cash flows.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The results for the three and nine months ended September&#160;30,&#160;2024 are not necessarily indicative of the results expected for the full fiscal&#160;year or any subsequent interim period. The condensed consolidated balance sheet as of December&#160;31,&#160;2023 has been derived from the audited financial statements at that date but does not include all disclosures required by GAAP for complete financial statements. Because all of the disclosures required by GAAP for complete financial statements are not included herein, these unaudited condensed consolidated financial statements and the notes accompanying them should be read in conjunction with the Company&#x2019;s audited financial statements for the&#160;year ended December&#160;31,&#160;2023. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;(b)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. Accounting estimates and management judgements reflected in the consolidated financial statements include: normal recurring accruals, including the accrual for research and development expenses, stock-based compensation, fair value of investments, and operating lease right-of-use assets and lease liabilities. Estimates and assumptions are reviewed quarterly. Any revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;(c)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company&#x2019;s potentially dilutive securities have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following table summarizes the Company&#x2019;s net loss per share (in thousands, except share and per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (16,237)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19,563)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (64,198)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (55,108)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (16,237)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19,563)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (64,198)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (55,108)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Weighted-average common stock outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,863,327&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,640,542&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,572,338&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,872,118&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.56)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.71)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.25)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.13)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,714,104&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,236,832&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,754&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,714,104&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,262,586&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(d)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recently Issued and Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;i style="font-style:italic;"&gt;Segment Reporting (Topic 280)&lt;/i&gt;: Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments&#x2019; significant expenses on an interim and annual basis. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Entities must adopt the changes to the segment reporting guidance on a retrospective basis, and early adoption is permitted. The Company does not anticipate this ASU to materially impact our consolidated financial statements and related disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740)&lt;/i&gt;: Improvements to Income Tax Disclosures, which expands disclosures in an entity&#x2019;s income tax rate reconciliation table and regarding cash taxes paid both in the U.S. and foreign jurisdictions. The standard is effective for fiscal years beginning after December 15, 2024, and interim periods in fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact the adoption of this standard may have on its consolidated financial statements and related disclosures, and does not anticipate this ASU to materially impact our consolidated financial statements and related disclosures.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tb_BCR_htwfwkmfmtb2HHvgzg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;(a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying unaudited condensed consolidated financial statements as of September&#160;30,&#160;2024 and for the three and nine months ended September&#160;30,&#160;2024 and 2023 have been prepared in conformity with generally accepted accounting principles (&#x201c;GAAP&#x201d;) in the United States of America for interim financial information and pursuant to Article&#160;10 of Regulation S-X of the Securities Act of 1933, as amended (the Securities Act). Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include only normal and recurring adjustments that the Company believes are necessary to fairly state the Company&#x2019;s financial position and the results of its operations and cash flows.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The results for the three and nine months ended September&#160;30,&#160;2024 are not necessarily indicative of the results expected for the full fiscal&#160;year or any subsequent interim period. The condensed consolidated balance sheet as of December&#160;31,&#160;2023 has been derived from the audited financial statements at that date but does not include all disclosures required by GAAP for complete financial statements. Because all of the disclosures required by GAAP for complete financial statements are not included herein, these unaudited condensed consolidated financial statements and the notes accompanying them should be read in conjunction with the Company&#x2019;s audited financial statements for the&#160;year ended December&#160;31,&#160;2023. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tb__8b-AM4p10Gouw7MNRlYdg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;(b)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. Accounting estimates and management judgements reflected in the consolidated financial statements include: normal recurring accruals, including the accrual for research and development expenses, stock-based compensation, fair value of investments, and operating lease right-of-use assets and lease liabilities. Estimates and assumptions are reviewed quarterly. Any revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tb_C9pY79J1rECAk5mO9zgOrA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;(c)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company&#x2019;s potentially dilutive securities have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following table summarizes the Company&#x2019;s net loss per share (in thousands, except share and per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (16,237)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19,563)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (64,198)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (55,108)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (16,237)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19,563)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (64,198)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (55,108)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Weighted-average common stock outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,863,327&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,640,542&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,572,338&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,872,118&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.56)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.71)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.25)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.13)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,714,104&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,236,832&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,754&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,714,104&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,262,586&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tb_CKYVPL39J0yWu-xvaAkjbA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following table summarizes the Company&#x2019;s net loss per share (in thousands, except share and per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (16,237)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19,563)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (64,198)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (55,108)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (16,237)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19,563)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (64,198)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (55,108)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Weighted-average common stock outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,863,327&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,640,542&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,572,338&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,872,118&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.56)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.71)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.25)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.13)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="-3"
      id="Tc_-83OVHfMIkSwb-tdy1JqFQ_4_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-16237000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="-3"
      id="Tc_qixUwQnv-02L5rDwU7UoGw_4_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-19563000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_aN99tfUU-UOrspO3lVIKTQ_4_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-64198000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_bD_ZL9mbjUeheuxnf6VU5Q_4_12"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-55108000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="-3"
      id="Tc_mwgzOFmLx0uQXLw8_btDrQ_5_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-16237000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="-3"
      id="Tc_eDLW03SnZEaWnejqeRLr0w_5_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-19563000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_KsPFpfBlLUCTnzAjb7pVug_5_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-64198000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_jYu9KqWJWUqiisFa_f0RIQ_5_12"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-55108000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="0"
      id="Tc_Ibmunrc0ok2QIc7oFSZMmA_8_3"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">28863327</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="0"
      id="Tc_Ibmunrc0ok2QIc7oFSZMmA_8_3_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">28863327</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="0"
      id="Tc_lH_9GLLK0kWZfKq_eqiTFA_8_6"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">27640542</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="0"
      id="Tc_lH_9GLLK0kWZfKq_eqiTFA_8_6_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">27640542</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="0"
      id="Tc_sdFdOGJK2kilWqDWQgfnVQ_8_9"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">28572338</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="0"
      id="Tc_sdFdOGJK2kilWqDWQgfnVQ_8_9_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">28572338</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="0"
      id="Tc_lQgneF1lqkiWExX25ervXw_8_12"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">25872118</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="0"
      id="Tc_lQgneF1lqkiWExX25ervXw_8_12_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">25872118</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="2"
      id="Tc_70wLo5FSgUqSrC4lvGn84A_9_3"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">-0.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="2"
      id="Tc_70wLo5FSgUqSrC4lvGn84A_9_3_2"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">-0.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="2"
      id="Tc_mEjpmUOTv06joGt5hl9E-g_9_6"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">-0.71</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="2"
      id="Tc_mEjpmUOTv06joGt5hl9E-g_9_6_2"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">-0.71</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="2"
      id="Tc_rmOxV2zIKkeKaveib3fHHg_9_9"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">-2.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="2"
      id="Tc_rmOxV2zIKkeKaveib3fHHg_9_9_2"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">-2.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="2"
      id="Tc_b_R4Mz4450W5Q0OMVqw8Ng_9_12"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">-2.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="2"
      id="Tc_b_R4Mz4450W5Q0OMVqw8Ng_9_12_2"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">-2.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tb_Gc6r7TT1REmScK7ALpx_pQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,714,104&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,236,832&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,754&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,714,104&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,262,586&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ZpDGpfQ1TkilwLHCKcIxnw"
      decimals="0"
      id="Tc_clkRSW2KE0aPeJGXW1W0nw_3_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">3714104</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_VNugwlI_n0evghUr12SqYg"
      decimals="0"
      id="Tc_tEUfQ6MuHEyNS-BD-BGtdw_3_4"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">5236832</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_shfv-0j6hE2RH9wjzcjK0Q"
      decimals="0"
      id="Tc_4QgYzic0t0KJYMghZHKcpA_4_4"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">25754</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="0"
      id="Tc_UqQnY7D960KbdOTqv8F4nQ_5_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">3714104</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="0"
      id="Tc_aWIVjmOFsUyIiV83ac1zxA_5_4"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">5262586</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tb_oUY-DeqcN0exZqb8kk5Z2w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(d)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recently Issued and Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;i style="font-style:italic;"&gt;Segment Reporting (Topic 280)&lt;/i&gt;: Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments&#x2019; significant expenses on an interim and annual basis. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Entities must adopt the changes to the segment reporting guidance on a retrospective basis, and early adoption is permitted. The Company does not anticipate this ASU to materially impact our consolidated financial statements and related disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740)&lt;/i&gt;: Improvements to Income Tax Disclosures, which expands disclosures in an entity&#x2019;s income tax rate reconciliation table and regarding cash taxes paid both in the U.S. and foreign jurisdictions. The standard is effective for fiscal years beginning after December 15, 2024, and interim periods in fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact the adoption of this standard may have on its consolidated financial statements and related disclosures, and does not anticipate this ASU to materially impact our consolidated financial statements and related disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tb_QNEn0CbvC06PKqvZk-WZig">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;FAIR VALUE OF FINANCIAL INSTRUMENTS&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following tables summarize the Company&#x2019;s financial assets measured at fair value on a recurring basis and their respective input levels based on the fair value hierarchy (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for&#160;Identical&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Agency bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,168&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,168&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,926&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,926&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,443&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,443&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,078&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,078&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 57,615&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,078&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,537&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total fair value of assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85,880&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,343&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,537&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for&#160;Identical&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_NvvtqfTNDUi3pAQbMuV3Iw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_W5lZ48FLCEy_u2gCz_QeZg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_EIT7Ft-M4U2oTXvtr5qvPQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_XpL8HTw1KUeUXBHbhjlt2w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Agency bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_lN0AgyYwBUGSBPvHUXVvCA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_ATiC6JEvSUm2xAjs-Qle-w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,386&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_FAR9X24s2UOjJM_mFfQemw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,386&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden__tPLOVORX06K05WNcJNPHQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_hGln6qJd7kWjTm5e4HDgWA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_sBbWTO6GDUu9JQZjdyFFlw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,945&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_Ib6YuqwgvUOu1jkJDvoCZQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,945&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_HN51f_bDUkShpzdYGLsCOw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 98,948&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88,586&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_sNomPq10ZESk15LyPnEosQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total fair value of assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 118,735&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,149&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88,586&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_YNU4YHIeWEuPQ_VjMX_kCQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash Equivalents and Short-Term Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial assets measured at fair value on a recurring basis consist of the Company&#x2019;s cash equivalents and short-term investments. Cash equivalents consisted of money market funds and commercial paper, and short-term investments consisted of U.S. Treasury bills, agency bonds, corporate debt securities, and commercial paper. The Company obtains pricing information from its investment manager and generally determines the fair value of investment securities using standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following tables summarize the Company&#x2019;s short-term investments (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;September&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Maturity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Agency bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;1&#160;year&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 139&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,168&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;1&#160;year&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,866&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,926&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;1&#160;year&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,438&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,443&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;1&#160;year&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,058&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,078&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57,391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 224&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57,615&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Maturity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Agency bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2&#160;years&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 179&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2&#160;years&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 38,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 38,386&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2&#160;years&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,334&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2&#160;years&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,925&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,945&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 98,711&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 260&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (23)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 98,948&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following tables summarize the Company&#x2019;s short-term investments with unrealized losses for less than 12 months and 12 months or greater (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:35.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="16" style="vertical-align:bottom;white-space:nowrap;width:62.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Less than 12 months&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;12 months or Greater&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:10.35pt;"&gt;&lt;td style="vertical-align:bottom;width:35.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:35.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,042&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,042&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:35.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Agency bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,760&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,579&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,339&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:35.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 488&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,007&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,495&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:35.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,110&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,110&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,586&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,986&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (23)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company did not hold any short-term investments in a loss position as of September 30, 2024. The Company considers whether unrealized losses have resulted from a credit loss or other factors. The unrealized losses on the Company&#x2019;s short-term investments as of December&#160;31,&#160;2023, were caused by fluctuations in market value and interest rates as a result of the economic environment and not credit risk. As of September&#160;30,&#160;2024 and December&#160;31,&#160;2023, no allowance for credit losses was recorded. During the nine months ended September&#160;30,&#160;2024, the Company did not recognize any impairment losses related to its short-term investments. It is neither management&#x2019;s intention to sell nor is it more likely than not that the Company will be required to sell these investments prior to recovery of their cost basis or recovery of fair value. Unrealized gains and losses are included in accumulated other comprehensive gain (loss). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Accrued interest receivable is written off through net realized investment gains (losses) at the time the issuer of the bond defaults or is expected to default on payment. Accrued interest receivable related to short-term investments was $0.3 million as of September&#160;30,&#160;2024 and $0.6 million as of December&#160;31,&#160;2023. &lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tb_2iA16SK0Q0eJ6WbEbDA_pQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following tables summarize the Company&#x2019;s financial assets measured at fair value on a recurring basis and their respective input levels based on the fair value hierarchy (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for&#160;Identical&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Agency bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,168&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,168&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,926&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,926&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,443&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,443&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,078&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,078&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 57,615&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,078&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,537&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total fair value of assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85,880&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,343&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,537&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for&#160;Identical&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_NvvtqfTNDUi3pAQbMuV3Iw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_W5lZ48FLCEy_u2gCz_QeZg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_EIT7Ft-M4U2oTXvtr5qvPQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_XpL8HTw1KUeUXBHbhjlt2w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Agency bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_lN0AgyYwBUGSBPvHUXVvCA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_ATiC6JEvSUm2xAjs-Qle-w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,386&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_FAR9X24s2UOjJM_mFfQemw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,386&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden__tPLOVORX06K05WNcJNPHQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_hGln6qJd7kWjTm5e4HDgWA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_sBbWTO6GDUu9JQZjdyFFlw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,945&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_Ib6YuqwgvUOu1jkJDvoCZQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,945&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_HN51f_bDUkShpzdYGLsCOw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 98,948&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88,586&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_sNomPq10ZESk15LyPnEosQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total fair value of assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 118,735&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,149&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88,586&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_YNU4YHIeWEuPQ_VjMX_kCQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_n9o8wjs2y0evFtOumxNmtQ"
      decimals="-3"
      id="Tc_XJ7cW8Ews0G0BBNCB7sO-Q_9_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">28265000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vFkjMAci2kCM1_635tV-aQ"
      decimals="-3"
      id="Tc_UHLKNa_NLkmlQ2iSeqy7JQ_9_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">28265000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_dKc-asA1AkOzmsiFfkV83w"
      decimals="-3"
      id="Tc_P58JTbvshUaT7wmix8OqvQ_10_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">28265000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__yohEd5oXkm5sOjdtwzPqg"
      decimals="-3"
      id="Tc_DbOGJndPlUi3AnLK01D8AQ_10_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">28265000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_VbGf1ULGCUm2eW5RKvPgKw"
      decimals="-3"
      id="Tc_4VgjJJl5i0GS1G0Ra2k57g_13_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">27168000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_wvATQii3UU6_fDF_T6RfnA"
      decimals="-3"
      id="Tc_i0rY_QDKnUi6Jt_VIABbSg_13_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">27168000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_B2h8T12AhEy09dFKjhebjg"
      decimals="-3"
      id="Tc_PkXtU2Ppd0-QieGfV2fHgg_14_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">11926000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_s7LhYqe820KPsrH32hrUXg"
      decimals="-3"
      id="Tc_frxwcmNj6U6r5hnPfV-LUg_14_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">11926000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_Z4bGGvwZkEKAnVLtaP7k4g"
      decimals="-3"
      id="Tc__2OvlpBhsEGGX1KZWgbEoQ_15_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">9443000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_gxzbNSquREapCV0wgG6K_Q"
      decimals="-3"
      id="Tc_5606CG4fK0G2JGP7BgLF6w_15_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">9443000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_HTNjaqHx1UmoE5boQ95RMA"
      decimals="-3"
      id="Tc_C7CDfLJNrUWB2mJSZLSkCg_16_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">9078000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_9J-eqG0s9EqtvXrgFV1g6Q"
      decimals="-3"
      id="Tc_5AQe5K5Vv0a6R-8lbcbhXg_16_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">9078000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_dKc-asA1AkOzmsiFfkV83w"
      decimals="-3"
      id="Tc_dwChbX1On0-Q2FSOGqI4NA_17_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">57615000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__yohEd5oXkm5sOjdtwzPqg"
      decimals="-3"
      id="Tc_JTnpHQlQrk6-LO1PpT2jig_17_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">9078000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_xThuN_5MDkqYF87Q3NeYSw"
      decimals="-3"
      id="Tc_VxpMNzx0f02taNfQRyGfOQ_17_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">48537000</us-gaap:ShortTermInvestments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_dKc-asA1AkOzmsiFfkV83w"
      decimals="-3"
      id="Tc_-GMPtnK_q0KIMRkRaZAiGg_19_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">85880000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__yohEd5oXkm5sOjdtwzPqg"
      decimals="-3"
      id="Tc_su7AaOMYmEuh33FFU0vkfQ_19_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">37343000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_xThuN_5MDkqYF87Q3NeYSw"
      decimals="-3"
      id="Tc_9IDE2KQaTUSm4U_KGBlcig_19_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">48537000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_jXLEnvJsuU2DjT7WrX1onA"
      decimals="-3"
      id="Tc_jPe93QG4xk2YeASIMgTP3g_9_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">19787000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_C-UwaOvYgEmhc5KbjSNoaA"
      decimals="-3"
      id="Tc_maZMp6bDYEW2IJC6TAQ7bg_9_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">19787000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_alE2cQWlWUmYEMSvxQfOpw"
      decimals="-3"
      id="Tc_qUbcDrI3vEyXxS2spMBIEQ_10_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">19787000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Uy_OzIg220WOoPfwtTN9Cg"
      decimals="-3"
      id="Tc_UNlbpAhgwku2XHPCKeM8FA_10_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">19787000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_YfltLULy-Euim90Lqzh2Iw"
      decimals="-3"
      id="Tc_J2yhFxF0qEOgq74I-JeEuw_13_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">42255000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_tzNK_fGEakm5HbGQ9zPcaQ"
      decimals="-3"
      id="Tc_Y3PMVCJSCkqxtZOblKEcfA_13_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">42255000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_2EbSprzX4UmWm8yxfF94Hw"
      decimals="-3"
      id="Tc_vl_ZW3ZkJUqlt3NA8N_vQg_14_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">38386000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_xuDF7JacqEyVD_8bE4KGbQ"
      decimals="-3"
      id="Tc_Yf7qbNmaHkKaAKyP-2fXYA_14_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">38386000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_8Ja-oIvtvEOUSt1VbId_rw"
      decimals="-3"
      id="Tc_NP51hai4IECUJaM2RDcFsQ_15_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">10362000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_paK6hjSIN0utjCqZ6uTFBQ"
      decimals="-3"
      id="Tc_0jUKAJNhL0y1ZB2ZdMaKdg_15_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">10362000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_23DxYpsziUKkF0FV76-EIA"
      decimals="-3"
      id="Tc_XkjdmcR_W0Wwqj69Mn9IFA_16_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">7945000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_PbzReIi7W0qZtcZBeUxt9w"
      decimals="-3"
      id="Tc_F6K02D_9IUChiytFK5ut5A_16_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">7945000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_alE2cQWlWUmYEMSvxQfOpw"
      decimals="-3"
      id="Tc_GCNhMaEkXUW6RtOSkvYOvA_17_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">98948000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Uy_OzIg220WOoPfwtTN9Cg"
      decimals="-3"
      id="Tc_bfHRKCBrgU-X9npEQBdn-Q_17_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">10362000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_sWDh72OE6kSOPCSLEhKjBQ"
      decimals="-3"
      id="Tc_Fa1gbTqeokqn6Xj81dekbA_17_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">88586000</us-gaap:ShortTermInvestments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_alE2cQWlWUmYEMSvxQfOpw"
      decimals="-3"
      id="Tc_kWNFG8GnU0WOa1VXKK3I8Q_19_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">118735000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Uy_OzIg220WOoPfwtTN9Cg"
      decimals="-3"
      id="Tc_wwPK17YWEEmnKQgqUjK_MQ_19_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">30149000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_sWDh72OE6kSOPCSLEhKjBQ"
      decimals="-3"
      id="Tc__ESpP0RyLUejCyP-BSY9gA_19_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">88586000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tb_lqR8tqQis027ANr7IzdWcA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following tables summarize the Company&#x2019;s short-term investments (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;September&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Maturity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Agency bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;1&#160;year&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 139&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,168&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;1&#160;year&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,866&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,926&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;1&#160;year&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,438&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,443&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;1&#160;year&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,058&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,078&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57,391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 224&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57,615&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Maturity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Agency bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2&#160;years&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 179&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2&#160;years&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 38,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 38,386&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2&#160;years&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,334&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:40.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2&#160;years&#160;or&#160;less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,925&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,945&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 98,711&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 260&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (23)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 98,948&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <avte:DebtSecuritiesAvailableForSaleMaturityTerm
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_SYM7muK7eU6UOC8tcjKjzQ"
      id="Narr_n1OW6Jlmmk-NghNqgYzOuw">P1Y</avte:DebtSecuritiesAvailableForSaleMaturityTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_HnxnO2kja0uIhwuJkAHhcQ"
      decimals="-3"
      id="Tc_bCLtyLoY90WyHiZnDKN_5w_5_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">27029000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_HnxnO2kja0uIhwuJkAHhcQ"
      decimals="-3"
      id="Tc_jwUZChgA-0SIeQqT1_xG9Q_5_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">139000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_HnxnO2kja0uIhwuJkAHhcQ"
      decimals="-3"
      id="Tc_ApfLPC0oQ06oPbkAKsdjiQ_5_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">27168000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <avte:DebtSecuritiesAvailableForSaleMaturityTerm
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_BlyAQCATVkGjKh-kOfQdJA"
      id="Narr_6CyMu72eJUudOf5Q0MI56Q">P1Y</avte:DebtSecuritiesAvailableForSaleMaturityTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_fyLg3XbfjUyiu8CJN34Bjw"
      decimals="-3"
      id="Tc_9KY6ayS2j0CjeNrM9cR20Q_6_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">11866000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_fyLg3XbfjUyiu8CJN34Bjw"
      decimals="-3"
      id="Tc_DMslFoYA30mEz4dwqGOShw_6_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">60000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_fyLg3XbfjUyiu8CJN34Bjw"
      decimals="-3"
      id="Tc_k6iI8bFbR0e80IU-PP_3aQ_6_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">11926000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <avte:DebtSecuritiesAvailableForSaleMaturityTerm
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_O8QXwFu-kEqrEQwa9rKRJA"
      id="Narr_smUX_9rMAkSkoyCrE4Fo_A">P1Y</avte:DebtSecuritiesAvailableForSaleMaturityTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_PE43wqGHWU6QaYBuVIux_w"
      decimals="-3"
      id="Tc_Zdqbq7F74U2YIyjTCNehcA_7_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">9438000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_PE43wqGHWU6QaYBuVIux_w"
      decimals="-3"
      id="Tc_LBBsWI5HbUWDDgoOQ32f1g_7_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_PE43wqGHWU6QaYBuVIux_w"
      decimals="-3"
      id="Tc_ychviAjcQ0-OpcOXREyGMw_7_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">9443000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <avte:DebtSecuritiesAvailableForSaleMaturityTerm
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_0Iv5XCHgWUyuS-1MyqMPSg"
      id="Narr_7LnQILbJQUCtN2TlZrtRlg">P1Y</avte:DebtSecuritiesAvailableForSaleMaturityTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YzIcvZaeZUu6LSDu8bymCg"
      decimals="-3"
      id="Tc_uWKeuH7ozU-UcmQ-U2nMng_8_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">9058000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YzIcvZaeZUu6LSDu8bymCg"
      decimals="-3"
      id="Tc_lM-d2guyPUGPQbAw5AfJ7A_8_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">20000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_YzIcvZaeZUu6LSDu8bymCg"
      decimals="-3"
      id="Tc_4P5Rh-SS0kyYJKvoUpOjPg_8_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">9078000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_jUGRV-0OWUCMIQzZi9lyxQ_9_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">57391000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_PAsnbmTRFUuaPVRGbUwBLQ_9_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">224000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_A-7X70JI60imJ9dBGfefYw_9_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">57615000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <avte:DebtSecuritiesAvailableForSaleMaturityTerm
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_OlIabHctWUyzxlnqkr4bCg"
      id="Narr_iNbeKoUuqkqw8Cwqr48bzQ">P2Y</avte:DebtSecuritiesAvailableForSaleMaturityTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg"
      decimals="-3"
      id="Tc_rNW-LiD5BEqt8ZVCEGykXQ_5_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">42090000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg"
      decimals="-3"
      id="Tc_mcbuFVwaUUqHk-BsO5pCOg_5_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">179000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg"
      decimals="-3"
      id="Tc_oCq22AKR70iMo7joDKkLeQ_5_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg"
      decimals="-3"
      id="Tc_9MluHGanXU2027nqKtOclw_5_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">42255000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <avte:DebtSecuritiesAvailableForSaleMaturityTerm
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_zaDLiCFPqUqEufSLy6NbzQ"
      id="Narr_rZ8alhcEo02xwV2NVPOZFw">P2Y</avte:DebtSecuritiesAvailableForSaleMaturityTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q"
      decimals="-3"
      id="Tc_BN1SEA-P4E-_u4C58pOIFQ_6_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">38362000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q"
      decimals="-3"
      id="Tc_Fz69FDWz6UWgNNIuq7yECg_6_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">29000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q"
      decimals="-3"
      id="Tc_tL9m1ri700C47euDSnJ9tQ_6_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q"
      decimals="-3"
      id="Tc_kQDY6nVZrUaEkyh6vkhkaA_6_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">38386000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <avte:DebtSecuritiesAvailableForSaleMaturityTerm
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_eZcGsEFbHEW38q44Yr6mVw"
      id="Narr_5ABepR0m0UuGA2fUUzUZdg">P2Y</avte:DebtSecuritiesAvailableForSaleMaturityTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w"
      decimals="-3"
      id="Tc_1BYhyvL6PUKInFRmUQzhmQ_7_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">10334000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w"
      decimals="-3"
      id="Tc_H7nYcl0WDEaFP6_SmecSqA_7_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">31000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w"
      decimals="-3"
      id="Tc_xkSYqmel8US30oxMC-p29g_7_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w"
      decimals="-3"
      id="Tc_SwcekCmsckeIWEdkloqqxA_7_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">10362000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <avte:DebtSecuritiesAvailableForSaleMaturityTerm
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_rsRxqqwUvEm2inEelixs4Q"
      id="Narr_Z-6eQiK_vk2CZ6veKe-0yQ">P2Y</avte:DebtSecuritiesAvailableForSaleMaturityTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q"
      decimals="-3"
      id="Tc_ec7haCMKkU2G06-eayk3Zg_8_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">7925000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q"
      decimals="-3"
      id="Tc_eQZWSzcdS0eEqz26_785tw_8_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q"
      decimals="-3"
      id="Tc_oTeyw4i1tkWn-vTIEZ3PIA_8_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q"
      decimals="-3"
      id="Tc_yhoX6WYsykeE8NzqFO7Dww_8_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">7945000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_RHM1rPcSGk6hgV0mas10SQ_9_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">98711000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_XdG5aFsbKkmTqlkUGhgpOw_9_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">260000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_UyO1pZN1zkKFzbJptNVN3A_9_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_VoFfgUpy-UqIBzE64L1WJA_9_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">98948000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tb_-o5rfZk1XkuWDF2IHpE-Ag">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following tables summarize the Company&#x2019;s short-term investments with unrealized losses for less than 12 months and 12 months or greater (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:35.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="16" style="vertical-align:bottom;white-space:nowrap;width:62.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Less than 12 months&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;12 months or Greater&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:10.35pt;"&gt;&lt;td style="vertical-align:bottom;width:35.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10.35pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:35.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,042&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,042&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:35.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Agency bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,760&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,579&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,339&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:35.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S. Treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 488&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,007&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,495&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:35.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,110&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,110&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,586&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,986&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (23)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q"
      decimals="-3"
      id="Tc_4VjRe4U8I0GSEqQXPnvl7Q_5_2"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">6042000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q"
      decimals="-3"
      id="Tc_BRX6dmrBGkihrkDR6ttegQ_5_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">5000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q"
      decimals="-3"
      id="Tc_m1LgcfIlRUSX9n9OD2uEEw_5_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">6042000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_jFR_SYgZdUGGkRm6FQDb8Q"
      decimals="-3"
      id="Tc_mu5giqyuukibek5wrD3cZA_5_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">5000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg"
      decimals="-3"
      id="Tc_nNEcy53bP0yz0EeGx8xwtQ_6_2"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3760000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg"
      decimals="-3"
      id="Tc_pDHS4a7Ea0Gf3sOTbiyABQ_6_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">6000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg"
      decimals="-3"
      id="Tc_uXmOOrfFqEG87N7MsQzV2Q_6_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">6579000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg"
      decimals="-3"
      id="Tc_QtNrtK-zn0KuiGh0huSetw_6_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">8000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg"
      decimals="-3"
      id="Tc_lzkw6hR7oEaiyk_2OOf6ow_6_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">10339000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uw66FkJz4Ue9DAJQB5NlXg"
      decimals="-3"
      id="Tc_1jvegWfTlE-JQJjbSp3G1w_6_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">14000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w"
      decimals="-3"
      id="Tc_FCs4wo0FlUu_sx9OOcZnpA_7_2"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">488000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w"
      decimals="-3"
      id="Tc_ompod8u86EOEVCJqtfS-Ag_7_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">2000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w"
      decimals="-3"
      id="Tc_nrayLFYH60iFpIRyI_iuNw_7_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1007000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w"
      decimals="-3"
      id="Tc_u7HeWfQrukG78VS8y_Toaw_7_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w"
      decimals="-3"
      id="Tc_V550A5cw9EWiRXRdux1Wag_7_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1495000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-BD13nmS9U-USxwMVFU09w"
      decimals="-3"
      id="Tc_a-y35pfnD0ujtC1dB8F0cA_7_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q"
      decimals="-3"
      id="Tc_zHV6g1WacUasnKOFzAPvYA_8_2"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3110000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q"
      decimals="-3"
      id="Tc_O04xRo15LEKkyxM5Wd4CbA_8_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q"
      decimals="-3"
      id="Tc_Qk9tpraYjkit3VyIAUKtSg_8_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3110000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_EAiFHodKCESLIEvbG4EH3Q"
      decimals="-3"
      id="Tc_kGRMniySO0uPGcX5oyRQtg_8_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_KxK4hZvgFE2MdV1UWnh30Q_9_2"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">13400000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_GKdQr_BQ2k6SmcUEJjDK0w_9_5"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">14000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_sjZy20PohkGUU0oPzSL_fQ_9_8"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">7586000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_op8Kpv9vmUqeetedTiM6Kw_9_11"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">9000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_W3nhR8jUX0W80wMqdJrWEg_9_14"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">20986000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_Lj0IiH6jpUuRnPGas2uGIg_9_17"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">23000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-5"
      id="Narr_HdAtuSyXPEudnGGnz8FWtg"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-5"
      id="Narr_tsWu0jnHI0C9dWZpDHCzZw"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-5"
      id="Narr_cSjKq_PDHkG1QMS4heRCDA"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">300000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-5"
      id="Narr_VD2nP5PHDU-nIieVP1daQw"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">600000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tb_XHkF6_CyIEyG4VLrg_-09g">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(4)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;BALANCE SHEET COMPONENTS&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,168&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 882&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 375&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,875&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,793&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accrued and Other Current Liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In June 2024, following the Company&#x2019;s decision to halt further development of AV-101, the Company announced its plan to terminate nearly all of its workforce in the coming months (the &#x201c;Workforce Reduction Plan&#x201d;). As of September 30, 2024, 46 individuals, or approximately 90% of the Company&#x2019;s workforce, have been terminated. The affected individuals have been and will be provided severance benefits, including cash severance payments. Each affected individual&#x2019;s eligibility for severance benefits is contingent upon entering into a separation agreement, which includes a general release of claims against the Company. In connection with the Workforce Reduction Plan, the Company incurred costs (in consideration of releases) of approximately $6.4 million, which are primarily one-time severance benefits, during the nine months ended September 30, 2024. The Company has paid approximately $2.4 million of severance benefits, and liabilities associated with the Workforce Reduction Plan were approximately $4.0 million as of September 30, 2024. The Company estimates that the remaining liabilities will be paid in the fourth quarter of 2024 and first quarter of 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Accrued and other current liabilities consisted of the following (in thousands): &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,704&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,363&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued payroll and other employee benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,952&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,368&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 292&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total accrued and other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,948&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,821&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <avte:ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tb_yvhU98QzrUKFpcsED47RjQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,168&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 882&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 375&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,875&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,793&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</avte:ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_WtdNOssFL0eMwpS8D5RbcQ_3_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">993000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_XMHYlloyAEGDjfsu3LYqLg_3_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1168000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_siSTafRR8UO5cJTa2Hn8Fw_4_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">882000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_N4DgDKNLA0ySqqBuO3Gv2Q_4_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">250000</us-gaap:OtherPrepaidExpenseCurrent>
    <avte:PrepaidResearchAndDevelopment
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_ZZJ6fWCpJ0-zB346UppGtA_5_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">375000</avte:PrepaidResearchAndDevelopment>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_XMhswNrdS06HpqFGc-9gsw_6_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1875000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_2viuBaXVw06s1ru0fi0gig_6_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1793000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="INF"
      id="Narr_DeTW55_NFUeF5AxNT9F8Vw"
      unitRef="Unit_Standard_individual_HQaf273bdUKcqMGv_RJZsw">46</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="2"
      id="Narr_x1WEb4nYj0yLyvUM2zAWqw"
      unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA">0.90</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-5"
      id="Narr_--VigptL9kerjiuDsWiZuw"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">6400000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:PaymentsForRestructuring
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-5"
      id="Narr_zIZSkbhkI0KWYXMthNzKZA"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">2400000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-5"
      id="Narr_889EKeIOHES4kDUIOOaQtg"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">4000000.0</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tb_kfdcwHJbeE-Uug9FJiLf7g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Accrued and other current liabilities consisted of the following (in thousands): &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,704&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,363&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued payroll and other employee benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,952&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,368&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 292&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total accrued and other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,948&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,821&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <avte:AccruedResearchAndDevelopmentCurrent
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_ldSRX8Bu2UWyoWq1iGN1pA_3_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">4704000</avte:AccruedResearchAndDevelopmentCurrent>
    <avte:AccruedResearchAndDevelopmentCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_cqD18dqrz0yL0FpkAqkUhQ_3_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">9363000</avte:AccruedResearchAndDevelopmentCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_Eg3lgKCYcUyadTC02JrCVg_4_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3952000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_4Z2Bo3mGqUKG2fJzoJfsFg_4_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">4368000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_yvM1kZuMwEGf0FoCdWV-gQ_5_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">292000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_LwXVgy00ZEmRYWBuW1b0kA_5_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1090000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_WI97hcC79kCjzPTmDrnHRQ_6_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">8948000</avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_WybrY_gamkydfB9sqYEeKQ_6_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">14821000</avte:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tb_ObPN7_DoHE-MwiHdgwsiaw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(5)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In August&#160;2021, the Company entered into a lease agreement (the &#x201c;Waltham Lease&#x201d;) for approximately 5,000 square feet of office space in Waltham, Massachusetts for the Company&#x2019;s corporate headquarters. The Waltham Lease has a term of &lt;span style="-sec-ix-hidden:Hidden_QkmZslh310SYGgzTas8QSQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;thirty-nine&#160;months&lt;/span&gt;&lt;/span&gt; (&#x201c;Lease Term&#x201d;), unless extended or earlier terminated. The Company had the option to extend the Waltham Lease for one additional period of three&#160;years. The Lease Term has an initial abatement period, and the initial base rent payable is approximately $18,000 per&#160;month following the abatement period. The initial base rent payable will increase by approximately 2% per&#160;year over the Lease Term. The Waltham Lease commencement date was September&#160;1, 2021. In January 2024, the Company entered into the First Amendment to the Waltham Lease resulting in the lease expiring on December 31, 2025, and an increase of $1.00 per rentable square foot during the additional lease term. In obtaining this lease extension, the Company no longer has the option to extend the Waltham Lease for one additional period of three years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In April&#160;2022, the Company entered into a lease agreement (the &#x201c;Foster City Lease&#x201d;) for approximately 3,500 square feet of office space in Foster City, California. The Foster City Lease has a term of &lt;span style="-sec-ix-hidden:Hidden_5dOxBlntyUCTd-8nElVMiw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;thirty-nine&#160;months&lt;/span&gt;&lt;/span&gt;, unless extended or earlier terminated. The Company has the option to extend the Foster City Lease for an additional period of &lt;span style="-sec-ix-hidden:Hidden_mWsXBWWQvkivgmOrUGyQhg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&#160;year&lt;/span&gt;&lt;/span&gt;. The base rent payable under the Foster City Lease is $22,600 per&#160;month and will be subject to annual increase of 3% on each anniversary. Following the Company&#x2019;s Workforce Reduction Plan, the Company terminated all employees in the Foster City office and vacated the premises in September 2024. As a result, the Company impaired the related right-of-use asset of approximately $0.3 million, and recognized a loss on impairment in its general and administrative operating expenses during the three months ended September 30, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As of September&#160;30,&#160;2024, the future minimum annual lease payments under the operating leases were as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;width:25.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 12.25pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Minimum&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;width:25.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 12.25pt;"&gt;&lt;b style="font-weight:bold;"&gt;Lease Payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 316&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 242&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total operating lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 558&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: Amount representing interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (18)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Present value of net minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 540&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As the Company&#x2019;s leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the lease commencement date. The components of operating leases as of September&#160;30,&#160;2024 and as of December&#160;31,&#160;2023 were as follows (in thousands except lease term and discount rate):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 459&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 540&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 675&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average remaining lease term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average incremental borrowing rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Supplemental cash flow information related to cash paid for amounts included in the measurement of operating lease liabilities was as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:75.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine months &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;ended &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid included in operating cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 323&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Rent expense was as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:40.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine months ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:40.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 115&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 111&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 343&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 332&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:40.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 165&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:40.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total rent expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 115&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 111&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 508&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 332&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfLand
      contextRef="As_Of_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_psQydqKoEkSDWEV9UfDtig"
      decimals="INF"
      id="Narr_gI2toN_BXUezoarh3wgOwA"
      unitRef="Unit_Standard_sqft_5xtOY_aM_0eoVegCdMhIVQ">5000</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_DaiW5HZ95E-5aglfFdRpPw"
      id="Narr_TooBIjLKL0qdIv3zN1rVAQ">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_psQydqKoEkSDWEV9UfDtig"
      id="Narr_3tPJjY3F7ECF3pTovKx_og">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:PaymentsForRent
      contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_DaiW5HZ95E-5aglfFdRpPw"
      decimals="0"
      id="Narr_Cjq0W23PnkuRVKoSgpYeAw"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">18000</us-gaap:PaymentsForRent>
    <avte:LeaseIncreaseInRentPercentage
      contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_DaiW5HZ95E-5aglfFdRpPw"
      decimals="2"
      id="Narr_8QG2uUOb6Umg3XobpzWGFQ"
      unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA">0.02</avte:LeaseIncreaseInRentPercentage>
    <avte:IncreaseRentalAmount
      contextRef="Duration_1_1_2024_To_1_31_2024_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_PodE97lmJkSHEwoc1aClWg"
      decimals="2"
      id="Narr_eTX9joGoWUSKVvPaBHsrdA"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">1.00</avte:IncreaseRentalAmount>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="Duration_1_1_2024_To_1_31_2024_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_PodE97lmJkSHEwoc1aClWg"
      id="Narr_wBajvji9bkexXX57BDuKzg">false</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_1_31_2024_us-gaap_LeaseContractualTermAxis_avte_WalthamLeaseMember_zn19noNKY029l5Ec-T6CTg"
      id="Narr_wlXKgd69q0eWA9-hF9CzZg">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:AreaOfLand
      contextRef="As_Of_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_sGvwx0X7s0WPUgXlH8FQrg"
      decimals="INF"
      id="Narr_Ipc9MaYMPEC7zxDGQk6oMg"
      unitRef="Unit_Standard_sqft_5xtOY_aM_0eoVegCdMhIVQ">3500</us-gaap:AreaOfLand>
    <us-gaap:PaymentsForRent
      contextRef="Duration_4_1_2022_To_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_m3e0XkrsxkWOCq0GHEPF6A"
      decimals="0"
      id="Narr_Ot5tCFESrUqe68287PafJQ"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">22600</us-gaap:PaymentsForRent>
    <avte:LeaseIncreaseInRentPercentage
      contextRef="Duration_4_1_2022_To_4_30_2022_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_m3e0XkrsxkWOCq0GHEPF6A"
      decimals="2"
      id="Narr_8pfEfzKFVU--mmBpddH22g"
      unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA">0.03</avte:LeaseIncreaseInRentPercentage>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_LeaseContractualTermAxis_avte_FosterCityLeaseMember_PLHhQPxnDkGS0X1B4pdMdQ"
      decimals="-5"
      id="Narr_UXQW6xSsZkOuLUrxcyi7ew"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">300000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tb_7jV8Yg3X9kuTjKeLN8RXWA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As of September&#160;30,&#160;2024, the future minimum annual lease payments under the operating leases were as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;width:25.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 12.25pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Minimum&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;width:25.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 12.25pt;"&gt;&lt;b style="font-weight:bold;"&gt;Lease Payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 316&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 242&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total operating lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 558&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: Amount representing interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (18)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Present value of net minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 540&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_D6JHIuqFQUa2lJhIklwKjw_3_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">316000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_Eg-aw6w5mkmDk49DQetLsg_4_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">242000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_tds2CG4r_0-hty-BSaKpBQ_5_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">558000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_QSPJWaVSgES-ZjytZcZJiQ_6_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">18000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_-mywYTOxJ0GAgXXXmSr0Qg_7_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">540000</us-gaap:OperatingLeaseLiability>
    <avte:ScheduleOfComponentsOfOperatingLeasesTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tb_kk0-GeL1UEycfbZI278dvQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As the Company&#x2019;s leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the lease commencement date. The components of operating leases as of September&#160;30,&#160;2024 and as of December&#160;31,&#160;2023 were as follows (in thousands except lease term and discount rate):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 459&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 540&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 675&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average remaining lease term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average incremental borrowing rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</avte:ScheduleOfComponentsOfOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_kfzj4RVjMEOsUowcN25Pow_4_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">459000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_anoosM82ukmM_K3C1L6eJg_4_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">420000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_Q6_dvMMbF02DVqYHxh667g_5_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">81000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_O3138Ff7pUaQnVU2X4khCQ_5_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">255000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_6vf7zm_7J0eX60BPNFvpMA_6_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">540000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_7MzmJEdVx06xF_l68PnG6w_6_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">675000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      id="Tc_B0G_vPnFc0euHCv7jNnBaw_7_3">P1Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      id="Tc_FzmkPMcdLkeqEJML_qV-2A_7_6">P1Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="3"
      id="Tc_uoXxb0CaikWPwFCkpoiPeg_8_3"
      unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA">0.064</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="3"
      id="Tc_H65-VT3ErU-v3HO8XY8xAw_8_6"
      unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA">0.060</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tb_Z6DXDOgDCkaE_zkuNwM5Ug">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Supplemental cash flow information related to cash paid for amounts included in the measurement of operating lease liabilities was as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:75.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine months &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;ended &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid included in operating cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 323&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_fwfbKfqkg0yV2_D-jJpv3w_3_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">380000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_a3xfqkvOm0yoEwetSM_cdA_3_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">323000</us-gaap:OperatingLeasePayments>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tb_vqK3-j7uUE25tnG8kEAfGQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Rent expense was as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:40.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine months ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:40.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 115&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 111&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 343&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 332&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:40.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 165&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:40.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total rent expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 115&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 111&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 508&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 332&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="-3"
      id="Tc_4LbKVKGRoUyWdKRYGxyBZQ_3_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">115000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="-3"
      id="Tc_vVV6jjMkIEKHtymUQkCnFQ_3_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">111000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_hUpoY7eyW0Wb5b07Hok6Dg_3_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">343000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_bhVnzCddhkCiktD7VzOCJQ_3_12"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">332000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_w-oQjDcf9UGebKRJ2Xtl7g_4_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">165000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="-3"
      id="Tc_odLQYUFhGkOyyWFZMXrn7A_5_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">115000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="-3"
      id="Tc_PxquMY6HzEiMK45c0mnbvQ_5_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">111000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc__1ewlWoNPkOw91Ac3yL0HQ_5_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">508000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_Pg3hsvtLGEyvOLhQ3lRz4Q_5_12"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">332000</us-gaap:LeaseCost>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tb_Sxkp51P1sUSql_O5r4KSMw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(6)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On July&#160;2, 2021, the Company&#x2019;s certificate of amendment to its certificate of incorporation became effective, which provided 150,000,000 authorized shares of common stock with a par value of $0.0001 per share and 10,000,000 authorized shares of undesignated preferred stock with a par value of $0.0001 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The holders of the common stock are entitled to one vote for each share of common stock held at all meetings of stockholders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As of September&#160;30,&#160;2024, the Company had reserved the following shares of common stock for future issuance:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:72.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Common stock options granted and outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,714,104&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:72.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares reserved for issuance under the 2021 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,982,105&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:72.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Reserved for future ESPP issuances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 401,218&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,097,427&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_7_2_2021_w8fg7T9i30-Tb8oR9Nn9Ag"
      decimals="INF"
      id="Narr_ugdv3_MgAU6xHaqOx6nKuA"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_7_2_2021_w8fg7T9i30-Tb8oR9Nn9Ag"
      decimals="INF"
      id="Narr_6WjWALa19k6u1enAmkHFmA"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_7_2_2021_w8fg7T9i30-Tb8oR9Nn9Ag"
      decimals="INF"
      id="Narr_xmKmnrQV506Tt1wEHa-rAA"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_7_2_2021_w8fg7T9i30-Tb8oR9Nn9Ag"
      decimals="INF"
      id="Narr_uJJClbgXH0CsyGRtH-SWzA"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <avte:NumberOfVotesForEachShareOfCommonStock
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="INF"
      id="Narr_qRurA_robUiQJ77HKg3vxg"
      unitRef="Unit_Standard_Vote_68Fy5nhdn0WonvfwhauHwA">1</avte:NumberOfVotesForEachShareOfCommonStock>
    <avte:ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tb_v5_gFjN-gEmjk5fnbn5Fxg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As of September&#160;30,&#160;2024, the Company had reserved the following shares of common stock for future issuance:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:72.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Common stock options granted and outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,714,104&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:72.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares reserved for issuance under the 2021 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,982,105&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:72.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Reserved for future ESPP issuances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 401,218&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,097,427&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</avte:ScheduleOfCommonStockSharesReservedOnAndAsConvertedBasisForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_CommonStockMember_euLPHJw1sEmiJdRRSszShQ"
      decimals="INF"
      id="Tc_J6gkSh4JuUmCzCVc7jLFrQ_2_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">3714104</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_7LIRbHXsBEeM6CKDpiodeA"
      decimals="INF"
      id="Tc_xfh-GVciY0-eTKIcQ_F-yQ_3_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">2982105</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_WBdMq-xE_k6SSkWqaFUxDA"
      decimals="INF"
      id="Tc_iFD26ANvX0SfHfyY0le1MQ_4_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">401218</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="INF"
      id="Tc_XhnbpqeAoUmA6lHD5TkgeA_5_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">7097427</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tb_m18c7GVNZ0mgL-hlavwMpA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(7)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;STOCK-BASED COMPENSATION&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;(a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock Option Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s 2021 Stock Option and Incentive Plan (the &#x201c;2021 Plan&#x201d;) was adopted by the Company&#x2019;s board of directors and approved by the Company&#x2019;s stockholders in June&#160;2021 and became effective as of June&#160;29, 2021. Upon the effectiveness of the 2021 Plan, the Company&#x2019;s 2018 Equity Incentive Plan (the &#x201c;2018 Plan&#x201d;) was terminated and no further grants may be made thereunder. The Company&#x2019;s 2021 Plan allows for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, stock bonuses, restricted stock, stock units and other forms of awards including cash awards to its officers, directors, employees, consultants and advisors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of September&#160;30,&#160;2024, a total of 5,675,841 shares of the Company&#x2019;s common stock were authorized for issuance with respect to awards granted under the 2021 Plan, of which 2,982,105 shares remain available for issuance. The share limit will automatically increase on the first trading day in January&#160;of each&#160;year (commencing with 2022) by an amount equal to the lesser of (1)&#160;4% of the total number of outstanding shares of the Company&#x2019;s common stock on the last trading day in December&#160;in the prior&#160;year, or (2)&#160;such lesser number as determined by the Company&#x2019;s board of directors. Since adoption, the number of shares available under the 2021 Plan pursuant to the annual increases totaled 3,075,841 shares through January 1, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Any shares subject to awards granted under the 2021 Plan or the 2018 Plan that are not paid, delivered or exercised before they expire or are canceled or terminated, or otherwise fail to vest, as well as shares used to pay the purchase or exercise price of such awards or related tax withholding obligations, will become available for new award grants under the 2021 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of September&#160;30,&#160;2024, 2,753,788 and 960,316 options had been granted under the 2021 Plan and 2018 Plan, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The options that are granted under the 2021 Plan and the 2018 Plan are exercisable at various dates as determined upon grant and terminate within 10&#160;years of the date of grant. The vesting period generally occurs over &lt;span style="-sec-ix-hidden:Hidden_OXhRKVDiBU-X90wrZ-v3BA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; to four&#160;years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following table summarizes the option activity under the 2021 Plan and 2018 Plan for the nine months ended September&#160;30,&#160;2024:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,230,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 49,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,489,191&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (265,482)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Cancelled/Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,739,949)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,714,104&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.98&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and exercisable at September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,791,181&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The weighted-average grant date fair value of stock option grants was $14.92 per share for the nine months ended September&#160;30,&#160;2024. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of September&#160;30,&#160;2024, there was approximately $9.4 million of total unrecognized stock-based compensation expense related to unvested stock options granted under the 2021 Plan and 2018 Plan, which is expected to be recognized over a weighted-average period of approximately 1.9&#160;years.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;(b)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company&#x2019;s Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;) was adopted by the Company&#x2019;s board of directors and stockholders in June 2021 and became effective upon the consummation of the IPO. A total of 230,000 shares of the Company&#x2019;s common stock was initially available for issuance under the ESPP. The share limit will automatically increase on the first trading day in January of each year (commencing with 2022) by an amount equal to the lesser of (1) 1% of the total number of outstanding shares of the Company&#x2019;s common stock on the last trading day in December in the prior year, or (2) such lesser number as determined by the Company&#x2019;s board of directors. The number of shares available under the 2021 Plan increased by 247,229 shares effective January 1, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;2023 as determined by the Company&#x2019;s board of directors. The ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 15% of their eligible compensation, subject to any plan limitations. The ESPP provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#x2019;s common stock on the first trading day of the offering period or on the last trading day of the offering period. As of September&#160;30,&#160;2024, 76,011 shares had been issued under the ESPP, and 401,218 shares authorized under the ESPP Plan were available for issuance.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;(c)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As of September&#160;30,&#160;2024, 31,881 restricted stock units had been awarded under the 2021 Plan. A summary of the status of and changes in unvested restricted stock unit activity under the Company&#x2019;s equity award plans for the nine months ended September&#160;30,&#160;2024 was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:59.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&#160;Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&#160;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per&#160;Unit&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,968&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22.26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:59.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,492)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:59.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (16,476)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22.58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units as of September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation of restricted stock units is based on the fair value of the Company&#x2019;s common stock on the date of grant and recognized over the vesting period. The vesting period generally occurs over &lt;span style="-sec-ix-hidden:Hidden_Sk9GO9o6hE2czOoGU9-uIA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; to four&#160;years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of September&#160;30,&#160;2024, the Company had no unrecognized stock-based compensation expense related to its unvested restricted stock units.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;(d)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations and comprehensive loss as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:8pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 458&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,817&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,987&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,798&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,545&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,081&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,857&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,237&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,068&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,655&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Stock-based compensation expense by type of award included within the consolidated statements of operations and comprehensive income (loss) was as follows: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,014&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,140&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,890&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,369&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock awards and units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 116&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 151&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Employee stock purchase plan awards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 135&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,237&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,068&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,655&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_9_30_2024_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_rO2RmIvkokKdeJv-xbshfQ"
      decimals="INF"
      id="Narr_JCwH5uClcUeFDfs2kSRguA"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">5675841</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_9_30_2024_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_rO2RmIvkokKdeJv-xbshfQ"
      decimals="INF"
      id="Narr_k2O_xyxbD0iRL1IUIizYxw"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">2982105</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_i_a9v0UQS0KpP37FqkD36Q"
      decimals="2"
      id="Narr_JAWTmf4Qp06owiRzcrV8-g"
      unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_1_1_2024_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_Heb8BZ5jAUughxoa-nLBgw"
      decimals="INF"
      id="Narr_Fzz9JyWKjkGQVf-Y_brwzw"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">3075841</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_wlI-MiSjLkiqAu8-lbQ9Sw"
      decimals="INF"
      id="Narr_gxY1oU3lrky1kDDqM2tPLw"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">2753788</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyEighteenStockOptionAndIncentivePlanMember_5jF5V5Er3Eu8MevJLE47ZQ"
      decimals="INF"
      id="Narr_y1eGm46D60S8-zIW0SNNHg"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">960316</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_b5ksvgJaa02KO-43SndRnw"
      id="Narr_18Rqhml9Z0KZ4IQKaU5J2Q">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_teg0ACtMzkG-j6fB92sMEQ"
      id="Narr_8GwmBr2gPEqkj7EtmH3U2Q">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tb_hfsHRPMZDkeezoRHeKKieg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,230,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 49,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,489,191&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (265,482)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Cancelled/Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,739,949)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,714,104&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.98&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and exercisable at September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,791,181&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="INF"
      id="Tc_Tjtv4rvBf067c01LnlSbjA_6_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">5230344</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="2"
      id="Tc_w5mSZCMVNEW1ZMdwHuHbTw_6_5"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">13.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_UCIHal_O0U2o6pKkC_BGdw"
      id="Tc_uB_rBUzvSkabhpZy_6DbCg_6_7">P8Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2023_ZC4zaP9Uc0mYVaOK4tobdA"
      decimals="-3"
      id="Tc_GUrmtsTD40uVpv2Gh9mY8w_6_10"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">49728000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="INF"
      id="Tc_culh4LlooUSe0f6imFDOhw_7_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">1489191</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="2"
      id="Tc_EPGdqDOx9EW1eMeiszxm6g_7_5"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">19.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="INF"
      id="Tc_wO4EhHADx0SchscfJJzROA_8_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">265482</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="2"
      id="Tc_7s9FN4JRXkWKD34Ceu1mBA_8_5"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">4.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="INF"
      id="Tc_ec4ytAn26EeCDo5VTwshJA_9_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">2739949</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="2"
      id="Tc_9HXkxNg2Q0CRNV60o5Mthg_9_5"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">18.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="INF"
      id="Tc_uW80le0u30iE8GcIe1Hx6w_10_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">3714104</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="2"
      id="Tc_zu7FIFXX7EuaXA-exNCz2A_10_5"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">12.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tc_-WlEVE1MrUWpACE0I_SCtQ_10_7">P4Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_Q7ZnstyUNEG5ndoVbJNmhg_10_10"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">12000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="INF"
      id="Tc_vpBN1dG5WUaKJV8SD3uAJw_11_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">2791181</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="2"
      id="Tc_WJsUK9pNCU-NbuTofkeeKA_11_5"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">12.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tc_H8PudXhcHE6cKGwvueSvpA_11_7">P3Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="As_Of_9_30_2024_guipCEDWLEK-bVX3OTG49Q"
      decimals="-3"
      id="Tc_OmzmxRI6iUy7eZQwdHeYwQ_11_10"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">12000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="2"
      id="Narr_xf_QmrG82Uer7be98shqPQ"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">14.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_JDWj8X9B5Eu8UjEOpYq-Pg"
      decimals="-5"
      id="Narr_3pt1KrrenkWZIu-KGVbm-g"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">9400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneAndTwentyEighteenStockOptionAndIncentivePlanMember_b5ksvgJaa02KO-43SndRnw"
      id="Narr_DNDsmhIMr02iLf_eNj-yNw">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_ePMqutmojUyuoaStQiHwbg"
      decimals="INF"
      id="Narr_AYRrD__d-kinIZ1qK04trQ"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">230000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_WvqE0K12M0iiC1AH3k88Tw"
      decimals="2"
      id="Narr_9pPksjJnI0Ok7v4ljX6DFg"
      unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2023_To_1_1_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_7n9TuWQvlEKuoOSnaqxmoQ"
      decimals="INF"
      id="Narr_fJVs27PJHUC8RZt8JG9y7g"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">247229</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_WvqE0K12M0iiC1AH3k88Tw"
      decimals="2"
      id="Narr_hHBG__D2Zk2VA4Qim58yIg"
      unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA">0.15</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <avte:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
      contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_WvqE0K12M0iiC1AH3k88Tw"
      id="Narr_cz4CqsBpAEOlcHTDghFY2A">P6M</avte:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
      contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_WvqE0K12M0iiC1AH3k88Tw"
      decimals="2"
      id="Narr_SkyhFnZlSEuSXNgTmxIzOg"
      unitRef="Unit_Standard_pure_-vGtaWzbZUeWF0YTM8v3bA">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_wbLsz84n5UemDXpr6FCylA"
      decimals="INF"
      id="Narr_Ms-dPeFYP0aSeUT6EvkDWg"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">76011</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_WBdMq-xE_k6SSkWqaFUxDA"
      decimals="INF"
      id="Narr_N3MnwCRyD0e3lR-rUVOFCg"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">401218</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_avte_TwentyTwentyOneStockOptionAndIncentivePlanMember_g2GESSwZAUiWFez9AGcUtA"
      decimals="INF"
      id="Narr_EONAFbn0IEmcJUgm-ViksA"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">31881</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tb_qmyxEJQJ2U-sdNpidxJGsg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:59.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&#160;Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&#160;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per&#160;Unit&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,968&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22.26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:59.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,492)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:59.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (16,476)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22.58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:59.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units as of September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Gy-ZvYruXkinoI8nJEgktA"
      decimals="INF"
      id="Tc_SnvS8WMM6UiLZWnkQ9W7Nw_5_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">21968</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Gy-ZvYruXkinoI8nJEgktA"
      decimals="2"
      id="Tc_PbU3lNPL8UqLlpb4HMO93w_5_5"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">22.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mQCZMz_2oEWLJpuw7OHgvw"
      decimals="INF"
      id="Tc_AMHS9H1yJ0OwlmR6jiv3_A_7_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">5492</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mQCZMz_2oEWLJpuw7OHgvw"
      decimals="2"
      id="Tc_txqkyPN4F02kqiS44zTH1g_7_5"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">21.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mQCZMz_2oEWLJpuw7OHgvw"
      decimals="INF"
      id="Tc_YmWAbSDW20OCSWknLe3O0g_8_2"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">16476</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mQCZMz_2oEWLJpuw7OHgvw"
      decimals="2"
      id="Tc_t7AEdE0wqEGhR4C42aRDRw_8_5"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">22.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2flsdvnZxUqHPV0GQoL5Gw"
      id="Narr_fTUpH81mRESUBDnZGzBLUA">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_8CT_KtQnWUiGek0hhT0EXw"
      decimals="-3"
      id="Narr_Grcs81SeYkqrq4xQ0yAp9w"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tb_TjrgxOnufEqVoZOm-TQJXQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations and comprehensive loss as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:8pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 458&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,817&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,987&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,798&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,545&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,081&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,857&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,237&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,068&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,655&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Stock-based compensation expense by type of award included within the consolidated statements of operations and comprehensive income (loss) was as follows: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,014&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,140&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,890&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,369&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock awards and units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 116&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 151&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Employee stock purchase plan awards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 135&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:43.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,237&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,068&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,655&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_LZBhq8TBukyCmnM6XHK1BQ"
      decimals="-3"
      id="Tc_mWzYjHP77k6l_3vASF1TsA_3_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">458000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_vfttyrGb-EW4_y-k4IU1OA"
      decimals="-3"
      id="Tc_bbZOPDkx0UW1QEUhiaYNdQ_3_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1817000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_z3LyNn-sk0-txThcBPD1Yw"
      decimals="-3"
      id="Tc_0jN-qgSlmk65IfIvZsNGnA_3_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">4987000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_8Qb64bPhgUq_qlFXMzlYzQ"
      decimals="-3"
      id="Tc_0E1sHSo34Uqf7S2wcCaQ0A_3_12"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">4798000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_pLhOme55706_ApNfgYI-eA"
      decimals="-3"
      id="Tc_qCDV9ohnwEK3T9X3FFWniQ_4_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1545000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_h9FVlzwiVkmij0mSQNLnEg"
      decimals="-3"
      id="Tc_-nZwG0ApXkuZnd97ElPuGw_4_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">1420000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Cxy8Whj0fkC98fl4coAgEw"
      decimals="-3"
      id="Tc_VHXjou-Ap0enm9sY9u3Ung_4_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">5081000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_tQTCT3FErESwh4_H6D13eg"
      decimals="-3"
      id="Tc_LkvC_7xYVUG3oaFu41Hfdg_4_12"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3857000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="-3"
      id="Tc__NYcB_ImrkCgCu7ZeNP7qg_5_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">2003000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="-3"
      id="Tc_XGPyzea6okWdD9QCnsWZCg_5_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3237000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_P1doux7B90OzKuUG-aHp5Q_5_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">10068000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_mL-jPvhuZEW0xDO2I4UPPw_5_12"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">8655000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tKrwYaxnJk285FLx0psBsA"
      decimals="-3"
      id="Tc_LyC1_nuxQU2h2h5VtZtXtA_3_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">2014000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_WbyCz7z-OUWYQdDXhY6H5A"
      decimals="-3"
      id="Tc_D7JQ6wQlf0io_8dLJGnE0A_3_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3140000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_uPFIHMkymk27XMLFjHO_1A"
      decimals="-3"
      id="Tc_HllyPygRiEKv0uSXlXYhEQ_3_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">9890000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nOSs2A7SvUChDUg7Gvgu0A"
      decimals="-3"
      id="Tc_kRCw3eMvYEaeYjRGTDjvhg_3_12"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">8369000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_8Cexqi34OkyeCy4KU0ckUw"
      decimals="-3"
      id="Tc_hgp71p7A50S6M9O6cmJZMw_4_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">52000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mQCZMz_2oEWLJpuw7OHgvw"
      decimals="-3"
      id="Tc_sV6IKC8yCUiTwLPnIntjVg_4_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">116000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mCr7TNm_z0awNKcONlrnIg"
      decimals="-3"
      id="Tc_bsnof25z5kGLF7M4lSxB6g_4_12"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">151000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_R7ajYhISp021nisBN9RonQ"
      decimals="-3"
      id="Tc_a_JX-zR5TUSL8hLrmvuezg_5_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">-11000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_dh_QB-NHhUST-PrSPEqJ1w"
      decimals="-3"
      id="Tc_s-Xy5jXhQU6iHiPILvYQKw_5_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">45000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_wbLsz84n5UemDXpr6FCylA"
      decimals="-3"
      id="Tc_amtAZ4r4sk6NPYlqnuRdxg_5_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">62000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_mxwv-vX1-EKBfodK731-kg"
      decimals="-3"
      id="Tc_Oq4IivmSika1tERLhfwdqA_5_12"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">135000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_7_1_2024_To_9_30_2024_DSbl0LdfOEmW8LoQE76jaw"
      decimals="-3"
      id="Tc_uGCtqx4usECun1P-HXjCUg_6_3"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">2003000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_7_1_2023_To_9_30_2023_3cDqUBNe2ESSvGPLMm9ExQ"
      decimals="-3"
      id="Tc_2JJb3uJxC0WH98qZg2SuIw_6_6"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">3237000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      decimals="-3"
      id="Tc_zzi3jusWtkSaFmScINhbTg_6_9"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">10068000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_9_30_2023_93eIz5a0M0qnC6MKS9E7tA"
      decimals="-3"
      id="Tc_Bl-lP-XLnE6jaE-pCB4KpQ_6_12"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">8655000</us-gaap:ShareBasedCompensation>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_uIihoWrxvEq2hrOtMYs4BA"
      id="Tb_9cob3qmGoE6Z0jbCQcT8zA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(8)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;SUBSEQUENT EVENT&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On October 30, 2024, the Company formed wholly-owned subsidiaries, Merger Sub I, a Delaware shell corporation, and Merger Sub II, a Delaware limited liability company, each formed solely for the purpose of merging with Jade in connection with the proposed Merger.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2024, the Company announced a corporate restructuring, and in July 2024, announced that it initiated a process to evaluate strategic alternatives. After a comprehensive review of strategic alternatives, including identifying and reviewing potential candidates for a strategic transaction, on October 30, 2024, the Company entered into the Merger Agreement, by and among the Company, Merger Sub I, Merger Sub II, and Jade, pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, among other things, Merger Sub I will merge with and into Jade, with Jade surviving the first merger as the surviving corporation, and as part of the same overall transaction, Jade will merge with and into Merger Sub II, with Merger Sub II continuing as a wholly owned subsidiary of the Company and the surviving corporation of the second merger. In addition, in connection with the Closing, the Company expects to declare the Cash Dividend to its pre-Merger stockholders of approximately $65.0 million in the aggregate, provided such amount is subject to adjustment as set forth in the Merger Agreement. The Merger was approved by the Board, and the Board resolved to recommend approval of the Merger Agreement to the Company&#x2019;s stockholders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Merger is expected to close in the first half of 2025. The Closing is subject to approval by the stockholders of the Company and Jade as well as other customary closing conditions, including the effectiveness of a registration statement filed with the SEC in connection with the Merger and the approval of The Nasdaq Stock Market LLC of the listing of shares of the Company&#x2019;s common stock to be issued in connection with the Merger and (4) an executed Purchase Agreement for the Concurrent Investment (each as defined below) in full force and effect evidencing cash proceeds of not less than $80.0 million to be received by the combined company immediately prior to or following the Closing. If the Company is unable to satisfy certain closing conditions or if other mutual closing conditions are not satisfied, Jade will not be obligated to complete the Merger. The Merger Agreement contains certain termination rights of each of the Company and Jade. Upon termination of the Merger Agreement under specified circumstances, the Company may be required to pay Jade a termination fee of $2,340,000, and in certain other circumstances, Jade may be required to pay the Company a termination fee of $5,250,000. If the Merger is completed, the business of Jade will continue as the business of the combined company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger (the &#x201c;Effective Time&#x201d;), (a) each then-outstanding share of Jade&#x2019;s common stock, par value $0.0001 per share, will be converted into the right to receive a number of shares of the Company&#x2019;s common stock, based on a ratio calculated in accordance with the Merger Agreement (the &#x201c;Exchange Ratio&#x201d;), provided that any unvested restricted shares of Jade common stock will be subject to the same terms and conditions (including, without limitation, vesting and repurchase provisions) that are otherwise applicable to such unvested shares as of immediately prior to the Effective Time, (b) each then-outstanding share of Jade&#x2019;s preferred stock, par value $0.0001 per share, will be converted into the right to receive a number of shares of the Company&#x2019;s newly authorized convertible preferred stock, par value $0.0001 per share, equal to (x) the Exchange Ratio divided by (y) 1,000, (c) each then-outstanding option to purchase Jade common stock will be assumed by the Company, subject to adjustment as set forth in the Merger Agreement and (d) each then-outstanding warrant to purchase shares of Jade common stock or Jade preferred stock will be assumed by the Company, subject to adjust as set forth in the Merger Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On October 30, 2024, Jade entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with certain existing Jade stockholders and new investors (the &#x201c;Investors&#x201d;). Pursuant to the Purchase Agreement, and subject to the terms and conditions thereof, Jade agreed to sell, and the Investors agreed to purchase, immediately prior to the consummation of the Merger, shares of Jade common stock and pre-funded warrants (together, the &#x201c;Securities&#x201d;) for an aggregate purchase price of approximately $300.0 million (collectively, the &#x201c;Concurrent Investment&#x201d;), which reflects the conversion of the previously issued $95 million of convertible notes. The consummation of the transactions contemplated by such agreements is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement and in the Purchase Agreement. Shares of Jade Common Stock and pre-funded warrants issued pursuant to this financing transaction will be converted into shares of common stock of the Company and pre-funded warrants to acquire shares of common stock of the Company, in accordance with the Exchange Ratio and the Merger Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company&#x2019;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that the Company does not complete the transaction with Jade, the Company may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of the Company.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DividendsCommonStockCash
      contextRef="Duration_10_30_2024_To_10_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_RPVQa3dXU0OggwPnCBtwgg"
      decimals="-5"
      id="Narr_CPG_v-TcBUy5TwEzVUKo0w"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">65000000.0</us-gaap:DividendsCommonStockCash>
    <avte:PurchaseAgreementCashProceedsToBeReceivedUponClosingOfMerger
      contextRef="Duration_10_30_2024_To_10_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_RPVQa3dXU0OggwPnCBtwgg"
      decimals="-5"
      id="Narr_ASes0PTmykm9dX8UD0JUaQ"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">80000000.0</avte:PurchaseAgreementCashProceedsToBeReceivedUponClosingOfMerger>
    <avte:MergerAgreementTerminationFeesPayable
      contextRef="As_Of_10_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_UR7pUGE3y0avsGAAh5HJFA"
      decimals="0"
      id="Narr__0WfeEVkrU23R9d2bE5lPQ"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">2340000</avte:MergerAgreementTerminationFeesPayable>
    <avte:MergerAgreementTerminationFeesReceivable
      contextRef="As_Of_10_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_UR7pUGE3y0avsGAAh5HJFA"
      decimals="0"
      id="Narr_45K0p33lgE-sLgbVh-JG_w"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">5250000</avte:MergerAgreementTerminationFeesReceivable>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_10_30_2024_dei_LegalEntityAxis_avte_JadeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7tb7W4BvUUu3IUTHi97FXg"
      decimals="INF"
      id="Narr_dLu2AFnFDky1Wcx4p5yk3Q"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_10_30_2024_dei_LegalEntityAxis_avte_JadeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7tb7W4BvUUu3IUTHi97FXg"
      decimals="INF"
      id="Narr_VujdjkSaA0CmNCY50NgZFQ"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_10_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_UR7pUGE3y0avsGAAh5HJFA"
      decimals="INF"
      id="Narr_q68j6fOcckGhxnlzjp8Sjg"
      unitRef="Unit_Divide_USD_shares_tUJbs87Q6U6XiSGugzuA2A">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <avte:MergerAgreementSharesToBeIssuedDenominatorForCalculation
      contextRef="As_Of_10_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_UR7pUGE3y0avsGAAh5HJFA"
      decimals="INF"
      id="Narr_TdNWh4San0C3kxs1__1Gvg"
      unitRef="Unit_Standard_shares_PIQPdG5VI0C1lKV3ilAs5w">1000</avte:MergerAgreementSharesToBeIssuedDenominatorForCalculation>
    <avte:MergerAgreementSecuritiesCapitalAmountReservedForFutureIssuance
      contextRef="As_Of_10_30_2024_dei_LegalEntityAxis_avte_JadeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7tb7W4BvUUu3IUTHi97FXg"
      decimals="-5"
      id="Narr_HTbyhNV9DkK_Vx4-RdSejA"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">300000000.0</avte:MergerAgreementSecuritiesCapitalAmountReservedForFutureIssuance>
    <us-gaap:ConvertibleNotesPayable
      contextRef="As_Of_10_30_2024_dei_LegalEntityAxis_avte_JadeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7tb7W4BvUUu3IUTHi97FXg"
      decimals="-6"
      id="Narr_JDMpf4wrJUCeGpm6mA1afQ"
      unitRef="Unit_Standard_USD_sPDzklywcUKl3CL4B-_Etg">95000000</us-gaap:ConvertibleNotesPayable>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
